Page last updated: 2024-10-27

fluorouracil and Colorectal Cancer

fluorouracil has been researched along with Colorectal Cancer in 6297 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
"Although phase III studies have investigated the effect of adding bevacizumab to the 3-weekly capecitabine plus irinotecan (XELIRI) combination in the first-line treatment of metastatic colorectal cancer (mCRC), no phase III studies investigating the effects of adding bevacizumab to biweekly XELIRI have been published."10.27Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials. ( Alvarez Suarez, S; Blanco Codeidido, M; García Alfonso, P; López Martín, P; Martin, M; Mondejar Solis, R; Muñoz Martin, A; Tapia Rico, G, 2013)
"In DaVINCI, a randomised phase II trial, patients with advanced colorectal cancer were randomly allocated to: Combination therapy (FOLFIRI), irinotecan (180 mg/m(2) IV over 90 min, day 1), 5-fluorouracil (400mg/m(2) IV bolus and 2400 mg/m(2) by 46-hour infusion from day 1) and folinic acid (20mg/m(2) IV bolus, day 1), 2-weekly; or Single-agent, irinotecan (350 mg/m(2) IV over 90 min), 3-weekly."10.25Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. ( Boland, A; Brown, C; Buck, M; Clarke, SJ; Gebski, V; Goldstein, D; Jeffrey, GM; Lowenthal, RM; Ransom, DT; Simes, RJ; Tebbutt, NC; van Hazel, GA; Yip, S; Zalcberg, J, 2011)
"The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer."10.23A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. ( Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S, 2008)
"The aims of this multicentre, randomised phase III trial were to evaluate: (1) the role of levamisol (LEV); and (2) the role of folinic acid (FA), added to 5-fluorouracil (5FU) in the adjuvant treatment of colorectal cancer."10.21Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study. ( Adamo, V; Bianco, AR; Carlomagno, C; Cortesi, E; De Placido, S; De Vita, F; Farris, A; Ficorella, C; Gallo, C; Gebbia, N; Gemini, M; Iannace, C; Ianniello, GP; Lopez, M; Manzione, L; Palazzo, S; Palmeri, S; Paoletti, G; Perrone, F; Persico, G; Pistillucci, G, 2005)
"The French contribution to the development of 5-fluorouracil (5-FU) infusion in advanced colorectal cancer includes five randomized trials and specific researches on the 48-hour bimonthly regimen, chronotherapy, and individual dose adaptation."10.18The French experience with infusional 5-fluorouracil in advanced colorectal cancer. ( de Gramont, A; Krulik, M; Louvet, C, 1996)
"Fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab is the standard second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) who are refractory or intolerant to fluoropyrimidines and oxaliplatin."9.69Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer. ( Ando, M; Bando, H; Honda, K; Kadowaki, S; Kato, K; Masuishi, T; Matsubara, Y; Muro, K; Nakazawa, T; Narita, Y; Nozawa, K; Ogata, T; Tajika, M; Taniguchi, H, 2023)
"The PanaMa trial demonstrated significant benefit in progression-free survival with the addition of panitumumab (Pmab) to fluorouracil and folinic acid (FU/FA) as maintenance therapy following first-line induction therapy with FOLFOX/Pmab in patients with RAS wild-type metastatic colorectal cancer."9.69Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial. ( Alig, AHS; Ballhausen, A; Fruehauf, S; Goekkurt, E; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Karthaus, M; Kasper, S; König, AO; Kurreck, A; Meyer-Knees, JW; Modest, DP; Müller, L; Sommerhäuser, G; Stahler, A; Stintzing, S; Trarbach, T; von Weikersthal, LF, 2023)
"Combination irinotecan and cetuximab is approved for irinotecan-refractory metastatic colorectal cancer (mCRC)."9.51Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. ( Bekaii-Saab, T; Dakhil, SR; Faggen, M; Fuchs, CS; Heying, EN; Lipsyc-Sharf, M; Meyerhardt, JA; Ng, K; Noble, S; Ou, FS; Rubinson, DA; Schrag, D; Schuetz, SR; Stella, PJ; Weckstein, DJ; Wender, DB; Yurgelun, MB; Zemla, TJ, 2022)
" Patients with colorectal cancer scheduled to receive adjuvant chemotherapy with capecitabine plus oxaliplatin are enrolled, and topical hydrocortisone butyrate 0."9.51Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC s ( Ahiko, Y; Aikou, S; Boku, N; Furukawa, N; Iimura, Y; Ishibashi, M; Kuroda, S; Nojima, M; Shida, D; Tanabe, T, 2022)
"The randomised open-label phase III XELAVIRI trial failed to demonstrate non-inferiority of the sequential application of fluoropyrimidine plus bevacizumab followed by additional irinotecan at first progression (Arm A) versus initial combination of all agents (Arm B) for untreated metastatic colorectal cancer in the initial analysis of time-to-failure-of-strategy (TFS, 90% confidence boundary of 0."9.51First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI ( Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schwaner, I; Stahler, A; Stintzing, S, 2022)
"The XELAVIRI trial compared sequential (fluoropyrimidine and bevacizumab; irinotecan (Iri) at progression) versus initial combination therapy (fluoropyrimidine, bevacizumab, Iri) of treatment-naïve metastatic colorectal cancer (mCRC)."9.41Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). ( Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kumbrink, J; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schuster, V; Schwaner, I; Stahler, A; Stintzing, S, 2021)
" CASE REPORT We report the case of a patient who was diagnosed with stage IV colorectal cancer and who underwent chemotherapy with a high dose of 5-FU as part of the FOLFIRI (Folinic Acid, Fluorouracil, Irinotecan) treatment plan."9.41Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review. ( Gofir, A; Hutajulu, SH; Nugroho, DB; Yuwono, KA, 2023)
"Although 5‑fluorouracil (5‑FU)‑based chemotherapy is the major treatment for colorectal cancer, it has disadvantages such as systemic toxicity, lack of effectiveness and selectivity, and development of resistance."9.415‑Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review). ( Al Doghaither, HA; Al-Ghafari, AB; Alzahrani, SM; Pushparaj, PN, 2023)
" This article presents a systematic review of studies evaluating the efficacy and safety of chemotherapy regimens combining fluorouracil and standard or low-dose leucovorin in treating colorectal cancer."9.41High vs. low-dose leucovorin in regimens with fluorouracil in colorectal cancer therapy. ( Goněc, R; Juřica, J; Šuverová, P; Synek, S; Turjap, M, 2023)
" The trial TyRosine kinase Inhibitor for the treatment of Chemorefractory Colorectal Cancer (TRICC-C) trial evaluates the addition of nintedanib to mFOLFOX6 (fluorouracil, folinic acid and oxaliplatin) in patients with metastatic colorectal cancer (mCRC)."9.41Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111). ( Berger, AW; Büchner-Steudel, P; Decker, T; Ettrich, TJ; Güthle, M; Hannig, CV; Hebart, HF; Heinemann, V; Hermann, PC; Herrmann, T; Hoffmann, T; Hofheinz, RD; Perkhofer, L; Seufferlein, T, 2021)
"The aim was to explore the correlation between increasing doses of [6R]-5,10-methylenetetrahydrofolate (arfolitixorin) and plasma concentrations of deoxyuridine (dUr) in patients with metastatic colorectal cancer (mCRC), subjected to 5-fluorouracil (5-FU)-based chemotherapy."9.41Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin. ( Carlsson, G; Gustavsson, B; Odin, E; Taflin, H; Tell, R; Wettergren, Y, 2021)
"The multicenter, open-label, randomized, phase III EPIC study (EMR 062202-025) investigated cetuximab plus irinotecan versus irinotecan in patients with epidermal growth factor receptor-detectable metastatic colorectal cancer (mCRC) that progressed on first-line fluoropyrimidine- and oxaliplatin-based chemotherapy; we report the outcomes of patients with RAS-wild-type (wt) disease."9.41Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. ( Burris, H; Chen, W; Eng, C; Esser, R; Lenz, HJ; Middleton, G; Nippgen, J; Scheithauer, W; Sobrero, A, 2021)
"In patients with metastatic colorectal cancer (mCRC) refractory to standard therapies, S-1 plus raltitrexed showed a good objective response rate (ORR) and significant survival benefit in our previous study."9.41Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study. ( Bi, F; Cao, D; Chen, Y; Cheng, K; Gou, HF; Li, Q; Li, ZP; Liu, JY; Luo, DY; Qiu, M; Shen, YL; Wang, X; Yang, Y; Zhou, YW, 2021)
"The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC)."9.41Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III ( Baba, H; Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kotake, M; Morita, S; Nakamura, M; Ohori, H; Sakashita, A; Sato, A; Shimada, K; Takahashi, M; Takahashi, S; Takashima, A; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2021)
" Eligible patients aged ≥70 with unresectable metastatic, untreated, RAS/BRAF wildtype metastatic colorectal cancer will be randomised 1:1 to receive panitumumab alone or panitumumab plus infusional 5-fluorouracil."9.41MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). ( Bailey, L; Briscoe, K; Burge, M; Caird, S; Chantrill, L; Cuff, J; Espinoza, D; Francesconi, A; Karapetis, C; Ladwa, R; Pavlakis, N; Price, T; Segelov, E; Shannon, J; Siu, HWD; Sjoquist, K; Srivastav, R; Steer, C; Tebbutt, N; Thavaneswaran, S; Tie, J; Wilson, K; Wuttke, M; Yip, S, 2021)
"Both regorafenib and reduced-intensity FOLFOXIRI (riFOLFOXIRI) prolong survival in patients with metastatic colorectal cancer (mCRC)."9.34Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. ( Chang, SC; Chao, Y; Chen, WS; Cheng, HH; Huang, SC; Jiang, JK; Lan, YT; Lin, CC; Lin, HH; Tai, CC; Teng, HW; Wang, HS; Yang, SH, 2020)
"BACKGROUND The aim of this study was to perform an accurate exploration on the efficacy of oxaliplatin/5-fluorouracil/capecitabine-cetuximab combination therapy and its effects on K-Ras mutations in advanced colorectal cancer."9.34Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer. ( Chen, J; Chen, Z; Huang, J; Ma, X; Wei, L; Wen, J; Wu, D, 2020)
"Fluorouracil and leucovorin combined with oxaliplatin or irinotecan plus bevacizumab (Bmab) or cetuximab (Cmab) are now widely accepted treatment options as first-line or second-line chemotherapy for metastatic colorectal cancer (mCRC)."9.34Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial. ( Doi, S; Fujiwara, H; Kawamura, T; Mikami, R; Nakamoto, Y; Noda, M; Okumoto, T; Tokunaga, Y; Tomita, N, 2020)
" 130 male and 63 female eligible patients with metastatic colorectal cancer were randomized to receive chronomodulated Irinotecan with peak delivery rate at 1 of 6 clock hours staggered by 4 hours on day 1, then fixed-time chronomodulated Fluorouracil-Leucovorin-Oxaliplatin for 4 days, q3 weeks."9.34Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial. ( Adam, R; Ballesta, A; Bouchahda, M; Chollet, P; Focan, C; Garufi, C; Giacchetti, S; Huang, Q; Innominato, PF; Karaboué, A; Lévi, FA, 2020)
"We designed an open-label, noncomparative phase II study to assess the safety and efficacy of first-line treatment with trifluridine/tipiracil plus bevacizumab (TT-B) and capecitabine plus bevacizumab (C-B) in untreated patients with unresectable metastatic colorectal cancer (mCRC) who were not candidates for combination with cytotoxic chemotherapies."9.34Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study. ( Amellal, N; Argilés, G; Aubel, P; Borg, C; Danielewicz, I; Egorov, A; Falcone, A; Fedyanin, M; Garcia-Alfonso, P; Glynne-Jones, R; Kanehisa, A; Kroening, H; Moiseenko, V; Pfeiffer, P; Punt, CJA; Saunders, MP; Stroyakovskiy, D; Van Cutsem, E; Van de Wouw, AJ; Wasan, H, 2020)
"Chemo-embolisation with drug-eluting beads loaded with irinotecan (DEBIRI) increased survival as compared with intravenous irinotecan in chemorefractory patients with liver-dominant metastases from colorectal cancer (LMCRC)."9.34Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. ( Artru, P; Dahan, L; De La Fouchardière, C; Guimbaud, R; Jouve, JL; Lepage, C; Montérymard, C; Pellerin, O; Pernot, S; Raoul, JL; Sefrioui, D; Smith, D; Taieb, J; Tougeron, D, 2020)
"Cetuximab has been shown to be clinically active when given in combination with irinotecan in patients with irinotecan-refractory metastatic colorectal cancer (mCRC)."9.34Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). ( Baba, E; Boku, N; Denda, T; Esaki, T; Fujii, H; Goto, M; Hara, H; Hironaka, S; Hosokawa, A; Hyodo, I; Ishida, H; Kadowaki, S; Kishimoto, J; Koh, Y; Kuramochi, H; Makiyama, A; Matsumoto, S; Moriwaki, T; Muro, K; Nishina, T; Okuda, H; Otsu, S; Ozaki, Y; Sakai, D; Sakamoto, T; Sato, M; Satoh, T; Shimokawa, H; Shinozaki, K; Sugimoto, N; Tamagawa, H; Tamura, T; Taniguchi, H; Tokunaga, S; Tsuda, T; Tsuji, A; Tsushima, T; Yamazaki, K; Yasui, H, 2020)
"To evaluate the safety and tolerability of escalating doses of selinexor plus 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) in metastatic colorectal cancer (mCRC) patients."9.34Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL. ( Amberg, S; Bokemeyer, C; Kranich, AL; Mann, J; Nilsson, S; Papadimitriou, K; Rolfo, C; Stein, A; Theile, S, 2020)
"The addition of aflibercept (AFL) or ramucirumab (RAM) to folinic acid, fluorouracil, and irinotecan (FOLFIRI) prolongs overall survival and progression-free survival compared with FOLFIRI alone in patients with metastatic colorectal cancer (mCRC) as second-line therapy."9.34Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan. ( Kashiwa, M; Matsushita, R, 2020)
"Combination of chemotherapies (fluoropirimidines, oxaliplatin and irinotecan) with biologic drugs (bevacizumab, panitumumab, cetuximab) have improved clinical responses and survival of metastatic colorectal cancer (mCRC)."9.30Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol. ( Albino, V; Amore, A; Avallone, A; Belli, A; Botti, G; Capozzi, M; Casaretti, R; Cassata, A; Chiodini, P; D'Alterio, C; De Feo, G; De Stefano, A; Delrio, P; Di Marzo, M; Izzo, F; Napolitano, M; Nappi, A; Nasti, G; Normanno, N; Ottaiano, A; Pace, U; Palaia, R; Petrillo, A; Picone, C; Portella, L; Rachiglio, AM; Roma, C; Romano, C; Scala, S; Silvestro, L; Tafuto, S; Tamburini, M; Trotta, AM, 2019)
"Regorafenib is an oral multikinase inhibitor for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, irinotecan, oxaliplatin, monoclonal antibodies targeting vascular endothelial growth factor, and monoclonal antibodies targeting epidermal growth factor receptor."9.30Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial. ( Chang, TK; Chang, YT; Huang, CW; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yeh, YS, 2019)
"Background This phase I/II trial evaluated toxicity and antitumor activity of everolimus plus mFOLFOX6 + bevacizumab for first-line treatment of metastatic colorectal cancer (mCRC)."9.30Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. ( Boucher, KM; Garrido-Laguna, I; McGregor, K; Orgain, N; Sharma, S; Stenehjem, DD; Thorne, K; Wade, ML; Weis, J; Weldon Gilcrease, G; Whisenant, J, 2019)
" As hydrogen gas was recently reported to activate PGC‑1α, the present study investigated whether it restores exhausted CD8+ T cells to improve prognosis in patients with stage IV colorectal cancer."9.30Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis. ( Akagi, J; Baba, H, 2019)
"The study investigated the potential prophylactic effect of L-carnosine against acute oxaliplatin neurotoxicity in colorectal cancer patients with emphasis on the redox (Nrf-2, MDA), inflammatory (NF-κB, TNF-α), and apoptotic (caspase-3) parameters."9.30L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways. ( El Abhar, H; Saad, AS; Saleh, S; Schaalan, M; Yehia, R, 2019)
"The 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) regimen is the standard first-line treatment for metastatic colorectal cancer (mCRC), however, the optimal second-line regimen for KRAS wild-type mCRC patients is still investigational."9.30CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial. ( Bai, L; Bi, F; Chen, Y; Cheng, Y; He, X; Hu, X; Li, J; Li, Y; Liu, W; Liu, Y; Luo, Y; Ouyang, X; Qin, S; Shi, Y; Sun, G; Sun, Y; Wang, L; Wang, Z; Xu, J; Yao, Q; Zhang, Y; Zheng, R, 2019)
"Curcumin is a safe and tolerable adjunct to FOLFOX chemotherapy in patients with metastatic colorectal cancer."9.30Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. ( Barber, S; Brown, K; Foreman, N; Gescher, A; Griffin-Teall, N; Howells, LM; Irving, GRB; Iwuji, COO; Morgan, B; Patel, SR; Sidat, Z; Singh, R; Steward, WP; Thomas, AL; Walter, H, 2019)
" This is the first clinical trial assessing safety and tolerability of Genistein in combination with chemotherapy in metastatic colorectal cancer."9.30Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study. ( Ang, C; Dharmupari, S; Holcombe, RF; Moshier, E; Pintova, S; Zubizarreta, N, 2019)
"Chemotherapy-induced nausea and vomiting (CINV) causes significant morbidity among colorectal cancer patients, receiving fluorouracil, oxaliplatin, and leucovorin (FOLFOX) chemotherapy even with standard antiemetic prophylaxis."9.27Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer. ( Blanke, C; Bubalo, JS; Chen, E; Edwards, MS; Fisher, A; Herrington, JD; Lopez, CD; Palumbo, A; Takemoto, M; Williams, C; Willman, P, 2018)
"Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC)."9.27S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. ( Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, K; Kobayashi, Y; Komatsu, Y; Kotake, M; Miyamoto, Y; Morita, S; Nakamura, M; Ohori, H; Sato, A; Shimada, K; Shimodaira, H; Takahashi, S; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2018)
"To investigate the association between UDP-glucuronosyltransferase (UGT)1A polymorphisms and irinotecan-treatment efficacy in a Chinese population with metastatic colorectal cancer (mCRC)."9.27UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy. ( Chen, J; Feng, J; Huang, L; Liu, B; Peng, P; Qiu, H; Xie, C; Yu, Q; Yuan, X; Zang, A; Zhang, T, 2018)
"Regorafenib, a multikinase inhibitor that inhibits angiogenesis, growth, and proliferation, prolongs survival as monotherapy in patients with refractory colorectal cancer."9.27Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. ( Bekaii-Saab, TS; Cohn, AL; El-Rayes, BF; Fernando, NH; Goldberg, RM; Grogan, W; Horgan, AM; Ivanova, A; Kasbari, SS; Kim, RD; Leonard, G; McCaffrey, J; McDermott, R; Moore, DT; O'Neil, BH; O'Reilly, S; Olowokure, OO; Ryan, T; Sanoff, HK; Sherrill, GB; Yacoub, GH; Zamboni, W, 2018)
"Metformin may be a promising drug in protecting colorectal cancer patients against oxaliplatin-induced chronic peripheral sensory neuropathy."9.27Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study. ( El-Fatatry, BM; Hussien, FZ; Ibrahim, OM; Mostafa, TM, 2018)
"This randomized phase III trial compared hepatic arterial infusion (HAI) chemotherapy with 5-fluorouracil (5-FU) followed by uracil/tegafur (UFT) and leucovorin (LV) versus UFT/LV alone for patients with curatively resected liver metastases from colorectal cancer (CRC)."9.27A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundatio ( Aoyama, T; Asahara, T; Hirata, K; Kusano, M; Nakamori, S; Oba, K; Ohashi, Y; Okabayashi, K; Saji, S; Sakamoto, J; Tsuji, Y; Yoshikawa, T, 2018)
"This study examined the association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and survival of patients with colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)-based chemotherapy in Taiwan."9.24Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy. ( Chang, SN; Hsieh, LL; Lai, CY; Lin, YK; Sung, FC; Tang, R; Yeh, CC, 2017)
"Fluorouracil and folinic acid with irinotecan (FOLFIRI) plus bevacizumab (BV) is widely used as second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, oxaliplatin, and BV."9.24Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab. ( Ando, M; Araida, T; Hamano, M; Hayashi, K; Hirai, E; Itabashi, M; Kameoka, S; Kawakami, K; Kuramochi, H; Nakajima, G; Okuyama, R; Yokomizo, H; Yoshimatsu, K, 2017)
"There are no published cases about bullous pyoderma gangrenosum induced by leucovorin, fluorouracil and oxaliplatin (FOLFOX) chemotherapy."9.22Leukocytoclastic vasculitis presenting clinically as bullous pyoderma gangrenosum following leucovorin, fluorouracil and oxaliplatin chemotherapy: a rare case report and literature review. ( Abdollahimajd, F; Diab, R; Kaddah, A; Mirzaei, HR; Rakhshan, A, 2022)
"The purpose of this systematic review is to analyze the published data on the efficacy and safety of doses higher than 180 mg/m2 of irinotecan recommended in the drug's summary of product characteristics in  metastatic colorectal cancer patients with genotypes UGT1A1*1/*1 or *1/*28  who are treated with the FOLFIRI regimen."9.22Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review. ( García-Gil, S; Gutiérrez-Nicolás, F; Miarons, M; Riera, P, 2022)
"The efficacy of irinotecan as the adjunctive therapy to fluorouracil and leucovorin remains controversial in patients with colorectal cancer."9.22The efficacy of irinotecan supplementation for colorectal cancer: A meta-analysis of randomized controlled studies. ( Jiang, W; Liu, Q; Yang, D; Yang, SB, 2022)
"A multicenter, open-label, noncomparative, randomized phase II study (PEPCOL) was conducted to evaluate the efficacy and safety of the irinotecan or PEP02 (MM-398, nanoliposomal irinotecan) with leucovorin (LV)/5-fluorouracil (5-FU) combination as second-line treatment in patients with metastatic colorectal cancer (mCRC)."9.22PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. ( André, T; Arbaud, C; Bachet, JB; Bennamoun, M; Bonnetain, F; Brusquant, D; Chibaudel, B; de Gramont, A; Dupuis, O; Garcia, ML; Hammel, P; Khalil, A; Larsen, AK; Louvet, C; Maindrault-Gœbel, F; Tournigand, C; Wang, YW; Yeh, CG, 2016)
" This study was to evaluate the efficacy and safety of maintenance therapy with capecitabine versus observation following inductive chemotherapy in patients with metastatic colorectal cancer."9.22Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. ( Hu, XH; Jia, J; Li, YH; Lin, DR; Lin, YC; Luo, HY; Ma, D; Peng, JW; Wang, FH; Wang, W; Wang, ZQ; Xu, RH; Yuan, X; Zhang, DS, 2016)
" The present study was initiated to validate the use of therapeutic drug management (TDM) to personalize 5-fluorouracil (5-FU) dosing in patients with metastatic colorectal cancer treated in routine clinical practice."9.22Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice. ( Bertsch, T; Birkmann, J; Braess, J; Holdenrieder, S; Jaehde, U; Kraff, S; Kunzmann, V; Link, K; Miller, MC; Moritz, B; Mueller, L; Roessler, M; Salamone, SJ; Stoetzer, OJ; Suttmann, I; Wilhelm, M, 2016)
"Observational and preclinical studies have suggested that metformin has antitumor effects in solid tumors, including colorectal cancer (CRC)."9.22Phase 2 Trial of Metformin Combined With 5-Fluorouracil in Patients With Refractory Metastatic Colorectal Cancer. ( Alex, A; Bariani, G; Bezerra Neto, JE; Braghiroli, MI; Capareli, FC; Faria, LD; Hoff, PM; Lobo Dos Santos, JF; Miranda, VC; Riechelmann, RP; Sabbaga, J, 2016)
"The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer."9.22Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study. ( Ciftci, R; Iner-Koksal, U; Kaytan-Saglam, E; Namal, E; Okyar, A; Ordu, C; Pala-Kara, Z; Pilancı, KN; Saglam, S; Yucel, S, 2016)
" This randomized phase II study evaluated the antitumor activity and safety of icrucumab and ramucirumab each in combination with mFOLFOX-6 in patients with metastatic colorectal cancer after disease progression on first-line therapy with a fluoropyrimidine and irinotecan."9.22Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. ( Alcindor, T; Asmis, T; Bendell, J; Berry, S; Binder, P; Burkes, R; Chan, E; Chan, T; Gao, L; Gill, S; Jeyakumar, A; Kambhampati, SR; Kauh, J; Kudrik, F; Moore, M; Nasroulah, F; Ramdas, N; Rao, S; Rothenstein, J; Spratlin, J; Strevel, E; Tang, PA; Tang, S; Yang, L; Zbuk, K, 2016)
"The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint."9.20A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H, 2015)
"5-Fluorouracil (5-FU) is chemotherapeutic agent widely used for the treatment of colorectal cancer."9.20Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer. ( Chang, SW; Chen, TH; Huang, CC; Lee, H; Wu, DW, 2015)
"A UGT1A1 genotype-directed dose escalation of irinotecan (CPT-11) was performed in patients with metastatic colorectal cancer receiving first-line FOLFIRI chemotherapy."9.20A phase I study of UGT1A1 *28/*6 genotype-directed dosing of irinotecan (CPT-11) in Korean patients with metastatic colorectal cancer receiving FOLFIRI. ( Bae, KS; Hong, YS; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG, 2015)
"The aim of this study was to determine the recommended dose (RD) of a triweekly capecitabine, oxaliplatin, irinotecan, and bevacizumab (XELOXIRI/bevacizumab) regimen that was easier to administer than FOLFOXIRI/bevacizumab, using capecitabine instead of 5-fuorouracil (5-FU), in patients with metastatic colorectal cancer (mCRC)."9.20A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer. ( Furuhata, T; Hayashi, T; Hirakawa, M; Hirata, K; Iyama, S; Kato, J; Kawano, Y; Kobune, M; Miyanishi, K; Mizuguchi, T; Murase, K; Ohnuma, H; Okagawa, Y; Okita, K; Osuga, T; Sato, T; Sato, Y; Takada, K; Takahashi, M; Takimoto, R, 2015)
"The phase III CRYSTAL study demonstrated that addition of cetuximab to fluorouracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival, progression-free survival, and objective response in the first-line treatment of patients with KRAS codon 12/13 (exon 2) wild-type metastatic colorectal cancer (mCRC)."9.20Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. ( Beier, F; Ciardiello, F; Heinemann, V; Köhne, CH; Lenz, HJ; Melezínek, I; Rougier, P; Stroh, C; Tejpar, S; Van Cutsem, E; van Krieken, JH, 2015)
"This study was conducted to evaluate the efficacy and safety of the combination of capecitabine and oral leucovorin (LV) as a third-line chemotherapy for patients with metastatic colorectal cancer (CRC) showing resistance to irinotecan- and oxaliplatin-containing regimens."9.20A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer. ( Choi, DR; Choi, YK; Han, B; Kim, BC; Kim, HS; Kim, JB; Kim, JH; Kim, KY; Song, HH; Yoon, SN; Zang, DY, 2015)
"A dose-finding phase I/II trial that evaluated the maximum tolerated doses of a combination of three drugs with irinotecan, oxaliplatin and capecitabine (COI regimen) has been conducted in patients with metastatic colorectal cancer (mCRC)."9.20Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. ( Aitini, E; Bajetta, E; Barni, S; Bertolini, A; Ciarlo, A; Di Bartolomeo, M; Dotti, KF; Iacovelli, R; Maggi, C; Perrone, F; Pietrantonio, F; Verusio, C, 2015)
"The oral multikinase inhibitor regorafenib improves overall survival (OS) in patients with metastatic colorectal cancer (CRC) for which all standard treatments have failed."9.20Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. ( Argilés, G; Benson, A; Cascinu, S; Ciardiello, F; Grunert, J; Guillén Ponce, C; Köhne, CH; Luigi Garosi, V; Macpherson, IR; Rivera, F; Saunders, MP; Sobrero, A; Strumberg, D; Tabernero, J; Van Cutsem, E; Wagner, A; Zalcberg, J, 2015)
" We included patients older than 18 years with previously untreated metastatic colorectal cancer, with stable disease or better after induction treatment with six 3-weekly cycles of capecitabine, oxaliplatin, and bevacizumab (CAPOX-B), WHO performance status of 0 or 1, and adequate bone marrow, liver, and renal function."9.20Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. ( Braun, HJ; Cats, A; Creemers, GJ; de Jongh, FE; Derleyn, VA; Erdkamp, FL; Erjavec, Z; Haasjes, JG; Honkoop, AH; Jansen, RL; Koopman, M; Loosveld, OJ; May, A; Mol, L; Nieboer, P; Punt, CJ; Simkens, LH; ten Tije, AJ; Tol, J; van der Hoeven, JJ; van der Torren, AM; van Tinteren, H; Wals, J, 2015)
"This study is the first to combine daily oral curcumin with standard care FOLFOX-based (5-fluorouracil, folinic acid and oxaliplatin) chemotherapy in colorectal cancer patients with inoperable liver metastases: the CUFOX trial."9.20Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial. ( Berry, DP; Brown, K; Howells, LM; Irving, GR; Iwuji, CO; Morgan, B; Steward, WP; Thomas, A, 2015)
"The current study aimed to evaluate the short-term efficacy and safety of endostar plus irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) in treatment of advanced colorectal cancer (CRC)."9.20Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study. ( Hu, XL; Li, BL; Sun, HG; Zhang, Y; Zhao, XH; Zhou, CY, 2015)
"The aprepitant therapy was more effective than the control therapy for prevention of CINV in colorectal cancer patients receiving an oxaliplatin-based regimen."9.20Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ide, Y; Kudo, T; Miyake, Y; Mizushima, T; Mori, M; Morita, S; Nakata, K; Nezu, R; Nishimura, J; Ohno, Y; Sakai, D; Satoh, T; Sekimoto, M; Takemasa, I; Takemoto, H; Uemura, M; Yamamoto, H; Yasui, M, 2015)
"S-1, a novel oral prodrug of 5-fluorouracil (5-FU), and irinotecan with or without bevacizumab is known to be effective in metastatic colorectal cancer (mCRC)."9.20S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies. ( Goto, A; Ichikawa, Y; Iwasa, S; Kato, K; Matsumoto, H; Nagashima, K; Okita, NT; Shimada, Y; Yamada, Y; Yamaguchi, T; Yasui, H, 2015)
"This randomised, open-label, phase I/II study evaluated the efficacy and safety of nintedanib, an oral, triple angiokinase inhibitor, combined with chemotherapy, relative to bevacizumab plus chemotherapy as first-line therapy in patients with metastatic colorectal cancer (mCRC)."9.20A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. ( Bennouna, J; Bouché, O; Capdevila, J; Carrato, A; D'Haens, G; Dressler, H; Ducreux, M; Latini, L; Oum'Hamed, Z; Prenen, H; Sobrero, A; Staines, H; Studeny, M; Van Cutsem, E, 2015)
"The TRICOLORE trial is a multicenter, randomized, open-label, controlled phase III study which aims to evaluate the non-inferiority of combination therapy with S-1/irinotecan/bevacizumab (a 3-week regimen [SIRB] or 4-week regimen [IRIS/bevacizumab]) to oxaliplatin-based standard treatment (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) in patients with metastatic colorectal cancer who had not previously received chemotherapy."9.20Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. ( Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S, 2015)
"The purpose of this randomised phase III trial was to evaluate whether the addition of simvastatin, a synthetic 3-hydroxy-3methyglutaryl coenzyme A reductase inhibitor, to XELIRI/FOLFIRI chemotherapy regimens confers a clinical benefit to patients with previously treated metastatic colorectal cancer."9.20A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. ( Han, SW; Hong, YS; Hwang, IG; Jung, SH; Kang, HJ; Kang, WK; Kim, HS; Kim, ST; Kim, TW; Lee, J; Lee, JY; Lee, KH; Lim, HY; Lim, SH; Park, JO; Park, SH; Park, YS, 2015)
"The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen."9.19Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. ( Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA, 2014)
" We conducted a phase I study of dasatinib, capecitabine, oxaliplatin, and bevacizumab (CapeOx/bevacizumab), with an expansion cohort in metastatic colorectal cancer (CRC)."9.19Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. ( Arrowood, C; Blobe, GC; Brady, JC; Cohn, A; Haley, S; Hsu, SD; Hurwitz, HI; McCall, S; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Rushing, C; Starodub, A; Strickler, JH; Uronis, HE; Zafar, SY, 2014)
"Efatutazone, a novel oral highly-selective peroxisome proliferator-activated receptor gamma (PPARγ) agonist, has demonstrated some inhibitory effects on disease stabilization in patients with metastatic colorectal cancer (mCRC) enrolled in previous phase I studies."9.19Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. ( Hyodo, I; Komatsu, Y; Machida, N; Ohtsu, A; Onuma, H; Sasaki, T; Yachi, Y; Yamazaki, K; Yoshino, T; Yuki, S, 2014)
"We investigated the efficacy and safety of capecitabine and gemcitabin (GemCap) in heavily pre-treated, therapy-resistant metastatic colorectal cancer (mCRC) patients and the clinical importance of cell-free DNA (cfDNA) measurement."9.19Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study. ( Andersen, RF; Jakobsen, A; Pallisgaard, N; Ploen, J; Spindler, KL, 2014)
" This phase I study used radiolabeled huA33 in combination with capecitabine to target chemoradiation to metastatic colorectal cancer."9.19Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. ( Cavicchiolo, T; Chappell, B; Gill, S; Herbertson, RA; Hopkins, W; Lee, FT; Lee, ST; Murphy, R; O'Keefe, GJ; Poon, A; Saunder, T; Scott, AM; Scott, FE; Tebbutt, NC, 2014)
"Irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil administered every two weeks (FOLFIRI regimen) is active in patients with metastatic colorectal cancer."9.19Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients. ( Arai, T; Goto, A; Hamaguchi, T; Muro, K; Sasaki, Y; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2014)
" This study examined the efficacy and safety of combining bevacizumab and panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer (mCRC)."9.19Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer. ( Hu, AP; Li, SL; Liang, HL; Liu, JY, 2014)
"Data collected from 20 elderly patients (75-92 years old) with breast or colorectal cancer who received oral capecitabine were analyzed."9.19Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer. ( Daher Abdi, Z; Lavau-Denes, S; Leobon, S; Marquet, P; Martin, J; Prémaud, A; Rousseau, A; Sauvage, FL; Tubiana-Mathieu, N; Urien, S, 2014)
"We investigated the efficacy and safety of a new second-line chemotherapy of combining folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) with both panitumumab and bevacizumab to treat patients with metastatic colorectal cancer (mCRC)."9.19Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer. ( Fan, Z; Han, G; He, L; Qin, Z; Xie, S; Xu, W, 2014)
"The FOLFOXIRI regimen (irinotecan, oxaliplatin, fluorouracil [5-FU] and folinic acid [FA]) increased the response rate and overall survival compared to FOLFIRI in patients with metastatic colorectal cancer (mCRC)."9.19Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer. ( Ehninger, G; Folprecht, G; Hamann, S; Schütte, K; Stoehlmacher-Williams, J; Trarbach, T, 2014)
"To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer."9.19Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. ( Chen, C; Chen, G; Ding, P; Gu, Y; He, Y; Li, C; Li, W; Li, Y; Lu, Z; Luo, H; Pan, Z; Wan, D; Wang, F; Wang, Z; Wu, X; Xu, R; Yuan, Y; Zhao, M, 2014)
"Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival."9.19Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? ( André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014)
" A phase II study was conducted to determine the feasibility of a dose-intense two weekly schedule of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer (mCRC)."9.19Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study. ( Adams, J; Deva, S; Findlay, MP; Hinder, VA; Isaacs, R; Jackson, CG; O'Donnell, A; Perez, DJ; Robinson, BA; Sharples, K; Thompson, PI, 2014)
"We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of metastatic colorectal cancer."9.19S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, ST; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2014)
"The purpose of this phase II study was to evaluate the safety and efficacy of weekly irinotecan and capecitabine (wXELIRI) treatment in patients with metastatic colorectal cancer, specifically the rate of severe diarrhea."9.19Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients. ( Chen, Z; Guo, W; Li, J; Li, W; Liu, T; Shen, L; Xu, J; Zhang, W; Zhu, X, 2014)
"BACKGROUND/Aims: To determine the effect of the pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine."9.19The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study. ( Endo, I; Ichikawa, Y; Kunisaki, C; Osada, S; Ota, M; Shoichi, F; Suwa, H; Tanaka, K; Tatsumi, K; Watanabe, J; Watanabe, K, 2014)
"This randomized phase II trial investigated the efficacy and safety of capecitabine/oxaliplatin (CapOx) plus bevacizumab and dose-modified capecitabine/irinotecan (mCapIri) plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer (mCRC)."9.17Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. ( Arnold, D; Dietrich, G; Freier, W; Geißler, M; Graeven, U; Hegewisch-Becker, S; Hinke, A; Kubicka, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schmoll, HJ; Tannapfel, A, 2013)
"Metastatic colorectal cancer (mCRC) is commonly treated with 5-fluorouracil, folinic acid, and oxaliplatin or irinotecan."9.17Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. ( Boix, O; Ehrenberg, R; Fischer, R; Folprecht, G; Hacker, UT; Hamann, S; Köhne, CH; Kornacker, M; Krauss, J; Kuhlmann, J; Lettieri, J; Mross, KB; Schultheis, B; Strumberg, D, 2013)
"This randomized, double-blind, placebo-controlled, phase IIb study evaluated adding sorafenib to first-line modified FOLFOX6 (mFOLFOX6) for metastatic colorectal cancer (mCRC)."9.17Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. ( Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L, 2013)
" In this study, we determined the dose, efficacy, and tolerability of irinotecan according to UGT1A1 genotypes when combined with capecitabine in patients with metastatic colorectal cancer."9.17A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ( Bae, KS; Chang, HM; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG; Sym, SJ, 2013)
"In this multicenter, open-label, randomized phase 2 trial, the authors evaluated the vascular endothelial growth factor receptor inhibitor axitinib, bevacizumab, or both in combination with chemotherapy as first-line treatment of metastatic colorectal cancer (mCRC)."9.17Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study. ( Cartwright, TH; Cescon, TP; Cohn, AL; Edenfield, WJ; Hamm, JT; Infante, JR; Kim, S; Malik, IA; McGee, PJ; Rado, TA; Reid, TR; Richards, DA; Rosbrook, B; Tarazi, J, 2013)
"A novel combination of capecitabine, oxaliplatin, and bevacizumab was evaluated in colorectal cancer patients enrolled in a phase II clinical trial."9.17Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. ( Amara, A; Bulusu, A; Honeycutt, W; Hurwitz, HI; Liu, Y; Nixon, AB; Pang, H; Starr, MD; Wong, NS, 2013)
"To investigate the safety and efficacy of pemetrexed combined with chemotherapy as second or third line in patients with stage IV colorectal cancer (CRC)."9.17Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. ( Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; You, SX, 2013)
"The aim of this study was to evaluate 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET for early prediction of the standard anatomic response and survival outcomes in patients with metastatic colorectal cancer (mCRC) receiving leucovorin, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX)."9.173'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer. ( Hong, YS; Kim, HJ; Kim, HO; Kim, JS; Kim, KP; Kim, TW; Lee, JL; Lee, SJ; Moon, DH; Oh, SJ; Ryu, JS, 2013)
" This phase I/II trial assessed the safety and efficacy of capecitabine plus oxaliplatin (XELOX) plus bevacizumab and imatinib in the first-line treatment of patients with metastatic colorectal cancer."9.17Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. ( Arnold, D; Hacker, UT; Hallek, M; Hinke, A; Hochhaus, A; Hoehler, T; Hofheinz, R; Kanzler, S; Moehler, MH; Schimanski, C; Seufferlein, T; Siebler, J; von Wichert, G, 2013)
" This study investigated the effects of 5-fluorouracil (5-FU) chemotherapy on the levels of lipid peroxidation, reduced glutathione (GSH), glutathione peroxidase (GSH-Px), antioxidant vitamins, and elements in colorectal cancer patients."9.17Effects of 5-fluorouracil on oxidative stress and calcium levels in the blood of patients with newly diagnosed colorectal cancer. ( Koçer, M; Nazıroğlu, M, 2013)
"Twenty-nine unresectable colorectal cancer patients were stratified to either ≥70 or <60 years of age, where the disposition of capecitabine and its metabolites were compared."9.17Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030). ( Albain, KS; Blanke, CD; Coleman, D; Ely, B; Gold, PJ; Gotay, C; Lenz, HJ; Louie, SG; Raghavan, D; Shields, AF, 2013)
"The combination of bevacizumab and capecitabine is an effective and well-tolerated regimen for elderly patients with metastatic colorectal cancer."9.17Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. ( Andre, N; Cunningham, D; Jonker, D; Lang, I; Lorusso, V; Marcuello, E; Ocvirk, J; Osborne, S; Saunders, MP; Shin, DB; Waterkamp, D, 2013)
"The combination of oxaliplatin and oral capecitabine (XELOX) has shown to be an active regimen in metastatic colorectal cancer (MCRC)."9.17Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer. ( Alvarez, E; Campos, B; Candamio, S; Casal, J; Gallardo, E; Grande, C; Mel, JR; París Bouzas, L; Quintero, G; Villanueva, MJ, 2013)
"Current guidelines recommend treatment with capecitabine and bevacizumab for patients (pts) with non-resectable metastatic colorectal cancer (mCRC), although clinical data in this particular patient group are lacking."9.17Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial. ( Arnold, D; Behringer, D; Hegewisch-Becker, S; Kettner, E; Kirsch, A; Kretzschmar, A; Pflüger, KH; Stein, A; Wolff, T; Zimber, J, 2013)
"This study evaluated the activity of 2 schedules of erlotinib in combination with chemotherapy, and the prognostic significance of serum amphiregulin (AREG) and transforming growth factor alpha (TGFa) in metastatic colorectal cancer."9.17Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha. ( Ahuja, A; Chan, AT; Chan, C; Chan, SL; Dattatray, RD; Ho, WM; Hui, EP; King, AD; Lau, W; Ma, BB; Mo, F; Poon, A; To, KF; Wong, SC, 2013)
"The prognostic and predictive value of multiple serum biomarkers was evaluated using samples from a randomised phase III study (HORIZON II) investigating chemotherapy with or without cediranib in metastatic colorectal cancer (mCRC)."9.17Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy. ( Barry, ST; Hoff, PM; Jürgensmeier, JM; Morgan, SR; Pommier, AJ; Robertson, JD; Spencer, SK, 2013)
" This randomized, multicenter, parallel-group, open-label phase II trial compared axitinib with bevacizumab each in combination with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) for second-line treatment of metastatic colorectal cancer."9.17Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. ( Barone, C; Bendell, JC; Bloom, J; Kim, JG; Kim, S; Pastorelli, D; Pericay, C; Ricart, AD; Rosbrook, B; Sobrero, AF; Swieboda-Sadlej, A; Tarazi, J; Tournigand, C; Wainberg, ZA, 2013)
"It was the aim of this study to evaluate maintenance therapy with bevacizumab + capecitabine following induction with bevacizumab + capecitabine + oxaliplatin (XELOX) versus bevacizumab + XELOX until progression as first-line therapy in metastatic colorectal cancer (mCRC)."9.17Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial. ( Buyukberber, S; Buyukunal, E; Camci, C; Cevik, D; Dane, F; Kilickap, S; Ozdener, F; Sencan, O; Uslu, R; Yalcin, S; Yilmaz, U; Zengin, N, 2013)
"This study aims to determine the efficacy and tolerability of capecitabine (CAP) plus bevacizumab (BEV) as treatment for frontline metastatic colorectal cancer (mCRC) in frail and/or elderly patients."9.17A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer. ( Chan, D; Dichmann, R; Hecht, JR; Hu, EH; Liem, AK; Naeim, A; Patel, R; Tchekmedyian, NS; Wainberg, ZA; Wang, HJ; Ward, PR, 2013)
"This phase II trial investigated the efficacy of an induction regimen of bevacizumab, capecitabine plus oxaliplatin (XELOX) followed by maintenance therapy with bevacizumab plus erlotinib as first-line therapy in patients with metastatic colorectal cancer."9.17Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer. ( Alonso, V; Bustos, IA; Cirera, L; Dueñas, R; Falcó, E; García-Girón, C; Muñoz, A; Pericay, C; Rivera, F; Salud, A, 2013)
"The phase III CONFIRM clinical trials demonstrated that metastatic colorectal cancer patients with elevated serum lactate dehydrogenase (LDH) had improved outcome when the vascular endothelial growth factor receptor (VEGFR) inhibitor PTK/ZK (Vatalanib) was added to FOLFOX4 chemotherapy."9.17Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib). ( Azuma, M; Danenberg, KD; Danenberg, PV; Folprecht, G; Ladner, RD; Lebwohl, D; Lenz, HJ; Meinhardt, G; Sherrod, A; Shi, MM; Trarbach, T; Wilson, PM; Yang, D; Zhang, W, 2013)
"This randomized, multicenter phase II study involved 80 metastatic colorectal cancer patients aged 70 years and above (performance status [PS] 0-2) or 65 years and above (PS 2), randomly assigned to arm A (capecitabine 1250 mg/m twice daily on days 1-14) or arm B (capecitabine 1000 mg/m twice daily on days 1-14, oxaliplatin 100 mg/m on day 1 initially, 130 mg/m for subsequent cycles)."9.17Randomized phase II study of capecitabine with or without oxaliplatin as first-line treatment for elderly or fragile patients with metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group CO06-01. ( Ahn, JB; Hong, YS; Jung, KH; Kim, HJ; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, JL; Park, YS; Shim, BY; Zang, DY, 2013)
"To investigate the association of colonic methane, formed by methanogenic achaea, and pH with gastrointestinal symptoms during colorectal cancer chemotherapy."9.17Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer. ( Blom, M; Holma, R; Korpela, R; Osterlund, P; Poussa, T; Rautio, M; Sairanen, U; Saxelin, M, 2013)
"The objective of this study was to compare the pharmacokinetics and safety of two tablet formulations containing 500 mg of capecitabine (CAS number 154361-50-9) in patients with colon, colorectal or breast cancer."9.17Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer. ( Chachad, S; Malhotra, G; Naidu, R; Purandare, S, 2013)
"The combination of bevacizumab and bolus 5-fluorouracil, leucovorin and irinotecan is highly effective in patients with metastatic colorectal cancer (mCRC)."9.17Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu ( Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M, 2013)
"This double-blind, phase III study aimed to demonstrate that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in previously untreated metastatic colorectal cancer (mCRC)."9.17Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. ( Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA, 2013)
" We aimed at identifying novel genetic markers that would improve prediction of irinotecan toxicity and response in advanced colorectal cancer patients treated with folic acid (leucovorin), fluorouracil (5-FU), and irinotecan (camptosar)-based regimens."9.17Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. ( Bélanger, AS; Cecchin, E; Couture, F; Guillemette, C; Harvey, M; Innocenti, F; Jonker, D; Lévesque, E; Toffoli, G, 2013)
"To assess safety and efficacy of folinic acid, 5-fluorouracil, gemcitabine (FFG) and folinic acid, fluorouracil, oxaliplatin (FOLFOX4) regimens with added bevacizumab as first-line treatment in patients with advanced colorectal cancer (CRC)."9.16Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. ( Gill, JF; Hentschel, P; Higby, DJ; Khan, MQ; Leichman, CG; Madajewicz, S; Malik, SK; Nicol, SJ; Ritch, PS; Waterhouse, DM; Zhao, L, 2012)
"The aim of this study is to prospectively evaluate the efficacy of combination chemotherapy with every second week cetuximab and irinotecan in patients with pretreated metastatic colorectal cancer harboring wild-type KRAS."9.16Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ( Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S, 2012)
"We conducted a Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics (PK) of CKD-732 [6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate] in combination with capecitabine and oxaliplatin (XELOX) in nine metastatic colorectal cancer patients who had progressed on irinotecan-based chemotherapy."9.16A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. ( Ahn, JB; Chung, HC; Hong, YS; Kim, C; Kim, DH; Kim, HR; Kim, TW; Lee, YJ; Park, KS; Rha, SY; Roh, JK; Shin, SJ, 2012)
"The authors evaluated the influence of 5-fluorouracil (5-FU) on treatment tolerability in 81 colorectal cancer patients given adjuvant 5-FU intravenously plus folinic acid for 6 cycles."9.16Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer. ( Amadori, D; Amatori, F; Danesi, R; Del Tacca, M; Di Paolo, A; Flamini, E; Ibrahim, T; Mercatali, L; Ravaioli, E; Sacanna, E, 2012)
" The primary objectives of this study were to determine the maximum tolerated dose of vandetanib with capecitabine and oxaliplatin, without and with bevacizumab, for the first line treatment of metastatic colorectal cancer (mCRC), and to define the dose limiting toxicities."9.16A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. ( Cabebe, EC; Fisher, GA; Sikic, BI, 2012)
"This study was intended to ascertain the feasibility of a combination therapy with irinotecan by 24-h intravenous infusion (24-h CPT-11) and 5-fluorouracil (5-FU) for patients with metastatic colorectal cancer, to estimate the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD), to determine the recommended dose (RD) for the Phase II study, and to evaluate the efficacy of the combination therapy."9.16Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer. ( Gamo, M; Kambe, M; Kanamaru, R; Kikuchi, H; Ohashi, Y; Yoshioka, T, 2012)
" From August 2008 to December 2010, stage II and III colorectal cancer patients receiving capecitabine-based chemotherapy enrolled in the trial voluntarily."9.16Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. ( Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX, 2012)
"Patients with refractory metastatic colorectal cancer were randomized in a two-stage design to receive vorinostat at 800 or 1,400 mg/day once a day × 3, every 2 weeks."9.16A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. ( Fakih, MG; Groman, A; McMahon, J; Muindi, JR; Wilding, G, 2012)
" This phase 2 study assessed enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab as maintenance therapy for metastatic colorectal cancer (MCRC)."9.16A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer. ( Di Bartolomeo, M; Fuchs, M; Heinemann, V; Hossain, AM; Nicol, S; Stoffregen, C; Wolff, RA, 2012)
" This phase II study tested the efficacy and safety of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as first-line treatment for metastatic colorectal cancer patients."9.16A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. ( Burtness, B; Cohen, SJ; Denlinger, CS; Dotan, E; Lee, J; Meropol, NJ; Mintzer, D; Ruth, K; Sylvester, J; Tuttle, H; Zhu, F, 2012)
"Previous phase III studies raised concern about the safety of the combination of capecitabine and irinotecan in patients with metastatic colorectal cancer (mCRC)."9.16A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer. ( Chen, E; Feld, R; Knox, J; Krzyzanowska, MK; Liu, G; MacKay, H; Moore, MJ; Petronis, J; Renouf, DJ; Wang, L; Welch, S, 2012)
"Using the recommended doses obtained from our previous phase 1 trial of a modified Saltz chemotherapy regimen for metastatic colorectal cancer (weekly irinotecan and bolus 5-fluorouracil/l-leucovorin for 3 weeks every 28 days), we performed the present phase 2 trial to evaluate efficacy and toxicity."9.16Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients. ( Akashi, K; Baba, E; Esaki, T; Fujishima, H; Kusaba, H; Makiyama, A; Mitsugi, K; Nakano, S; Tanaka, R; Uchino, K, 2012)
"We previously reported a 35% overall response rate (ORR) with biweekly 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) plus irinotecan as first-line therapy in elderly patients with metastatic colorectal cancer (mCRC)."9.16Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. ( Alfaro, J; Aparicio, J; Aranda, E; Benavides, M; Cabrera, E; Campos, JM; Carrato, A; Dueñas, R; Etxeberría, A; Gil-Calle, S; Gómez, A; Gómez, MJ; González-Flores, E; Guasch, I; Marcuello, E; Massutí, B; Pericay, C; Queralt, B; Reina, JJ; Valladares-Ayerbes, M, 2012)
"The NORDIC-VII multicenter phase III trial investigated the efficacy of cetuximab when added to bolus fluorouracil/folinic acid and oxaliplatin (Nordic FLOX), administered continuously or intermittently, in previously untreated metastatic colorectal cancer (mCRC)."9.16Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. ( Birkemeyer, E; Christoffersen, T; Dahl, O; Dajani, O; Erdal, AB; Fokstuen, T; Glimelius, B; Guren, T; Hansen, F; Hofsli, E; Ikdahl, T; Johnsson, A; Keldsen, N; Kure, E; Pfeiffer, P; Pyrhonen, S; Sigurdsson, F; Skovlund, E; Sorbye, H; Starkhammar, H; Tveit, KM; Yilmaz, MK, 2012)
"To evaluate the safety and efficacy of combination chemotherapy with 5-fluorouracil (5-FU), leucovorin, irinotecan and oxaliplatin (FOLFOXIRI) in Japanese patients with advanced colorectal cancer."9.16A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28. ( Akiyama, Y; Araki, K; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Nagashima, F; Saji, S; Sasaki, Y; Sunakawa, Y; Yamamoto, W; Yamashita, K, 2012)
"To evaluate the maximum tolerated dose (MTD) and pharmacokinetic profile of a chronomodulated, dose-intensified regimen of capecitabine in combination with oxaliplatin (XELOX) in metastatic colorectal cancer (mCRC)."9.16Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. ( Chen, X; Choo, SP; Chowbay, B; Farid, M; Koo, WH; Ong, SY; Ramasamy, S; Tan, SH; Toh, HC, 2012)
"Patients with clinical T3/4 colorectal cancer were randomly assigned to receive the preoperative administration of tegafur suppositories (group A) or no preoperative treatment (group B)."9.16Usefulness of the preoperative administration of tegafur suppositories as alternative adjuvant chemotherapy for patients with resectable stage II or III colorectal cancer: a KODK4 multicenter randomized control trial. ( Hasegawa, H; Hisa, A; Kitagawa, Y; Ohishi, T; Okabayashi, K; Watanabe, M, 2012)
"Treatment for metastatic colorectal cancer (mCRC) commonly involves a fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevacizumab or an epidermal growth factor receptor monoclonal antibody."9.16Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. ( Allegra, C; Castan, R; Ferry, D; Lakomy, R; Macarulla, T; McKendrick, J; Moiseyenko, V; Polikoff, J; Prausová, J; Prenen, H; Ruff, P; Tabernero, J; Tellier, A; Van Cutsem, E; van Hazel, GA, 2012)
"To compare the efficacy of cediranib (a vascular endothelial growth factor receptor tyrosine kinase inhibitor [VEGFR TKI]) with that of bevacizumab (anti-VEGF-A monoclonal antibody) in combination with chemotherapy as first-line treatment for advanced metastatic colorectal cancer (mCRC)."9.16Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). ( Barker, P; Bodoky, G; Bondarenko, I; Cunningham, D; Karapetis, CS; Kocakova, I; Koski, SL; Mainwaring, P; Mookerjee, B; Robertson, J; Rougier, P; Salazar, R; Schmoll, HJ; Sobrero, A; Van Cutsem, E, 2012)
" HORIZON II [Cediranib (AZD2171, RECENTIN) in Addition to Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer] assessed infusional fluorouracil, leucovorin, and oxaliplatin/capecitabine and oxaliplatin (FOLFOX/CAPOX) with or without cediranib in patients with previously untreated metastatic colorectal cancer (mCRC)."9.16Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). ( Cheng, Y; Fielding, A; Hochhaus, A; Hoff, PM; Kim, TW; Koynov, KD; Kurteva, G; Li, J; Pestalozzi, BC; Pike, L; Pintér, T; Robertson, JD; Saunders, MP; Tebbutt, NC; van Eyll, B, 2012)
"Capecitabine plus oxaliplatin (CapeOX) is one of the reference doublet cytotoxic chemotherapy treatments for patients with metastatic colorectal cancer."9.16S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2012)
"The aim of this study was to investigate the value of the cyclin D1 isoforms D1a and D1b as prognostic factors and their relevance as predictors of response to adjuvant chemotherapy with 5-fluorouracil and levamisole (5-FU/LEV) in colorectal cancer (CRC)."9.16Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. ( Dahl, O; Elsaleh, H; Fluge, Ø; Knudsen, ES; Leh, S; Li, Z; Myklebust, MP; Myrvold, HE; Pestell, RG; Rui, H; Tran, TH; Tveit, KM; Vonen, B, 2012)
"Irinotecan and 5-fluorouracil (5-FU) are used to treat metastatic colorectal cancer."9.15Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. ( Berglund, A; Berglund, M; Byström, P; Fredriksson, LA; Garmo, H; Glimelius, B; Kohnke, H; Sørbye, H; Wadelius, M, 2011)
"A regimen consisting of 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) is widely used in France in the first-line treatment of metastatic colorectal cancer (MCRC)."9.15Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. ( Adenis, A; Bennouna, J; Bergougnoux, L; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Lledo, G; Rebischung, C; Ychou, M, 2011)
"To evaluate the efficacy and tolerability of systemic chemotherapy with irinotecan (CPT-11), UFT and leucovorin (LV) combined with hepatic arterial infusion (HAI) consisting of 5-fluorouracil (5-FU) in colorectal cancer patients with unresectable liver metastases."9.15Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases. ( Matsumoto, H; Mori, T; Takahashi, K; Yamaguchi, T; Yasutome, M, 2011)
"To evaluate the efficacy, safety and quality of life of a short course of oxaliplatin plus capecitabine (XELOX) followed by single-agent capecitabine in patients with previously untreated, inoperable, metastatic colorectal cancer."9.15Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. ( Allen, J; Bentley, D; Gollins, S; Lloyd, A; Morris, J; Saunders, MP; Soe, W; Swindell, R; Taylor, MB; Valle, J; Waddell, T, 2011)
"The primary aim of the high-dose 5-fluorouracil (5-FU) and leucovorin (LV; HDFL48) phase I study was to determine the maximum tolerated dose and dose-limiting toxicity of 5-FU and LV with modified tri-monthly 48-h continuous infusion of high-dose 5-FU/LV in patients with metastatic colorectal cancer."9.15Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. ( Chen, RR; Cheng, AL; Ho, YF; Lu, WC; Yeh, KH, 2011)
"This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin, levoforinate, and infusional 5-fluorouracil (FOLFOX4) as a second-line therapy for Japanese patients with unresectable advanced or metastatic colorectal cancer."9.15A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience. ( Emi, Y; Fujita, F; Hasegawa, H; Inomata, M; Kakeji, Y; Kitazono, M; Maehara, Y; Morikita, T; Ogata, Y; Oki, E; Sadanaga, N; Saeki, H; Samura, H; Shirabe, K; Shirouzu, K; Tanaka, T; Tokunaga, S; Yamamoto, M, 2011)
"This study was designed to determine the efficacy and tolerability of capecitabine, oxaliplatin and bevacizumab in combination with cetuximab as first-line therapy for advanced colorectal cancer."9.15A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. ( Aklilu, M; Ashton, J; Bendell, JC; Blobe, GC; Cushman, S; Fernando, NH; Hurwitz, HI; Morse, MA; Nixon, AB; Pang, H; Wong, NS, 2011)
"The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of cetuximab combined with capecitabine and irinotecan (CAPIRI) or capecitabine and oxaliplatin (CAPOX) in the first-line treatment of metastatic colorectal cancer (mCRC)."9.15Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Haberl, C; Hass, HG; Heinemann, V; Jung, A; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schalhorn, A; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF; Zellmann, K, 2011)
"The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease."9.15Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. ( Cascinu, S; Celik, I; Ciardiello, F; Cunningham, D; Folprecht, G; Köhne, CH; Láng, I; Maurel, J; Nowacki, MP; Rougier, P; Schlichting, M; Shchepotin, I; Tejpar, S; Van Cutsem, E; Zubel, A, 2011)
"The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and combination of capecitabine with oxaliplatin (CAPOX) plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC)."9.15Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K, 2011)
"This study was designed to determine the efficacy and tolerability of a novel 2-week regimen of capecitabine, oxaliplatin (OHP), and bevacizumab in patients with chemo-naive advanced colorectal cancer."9.15A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. ( Bendell, JC; Blobe, GC; Fernando, NH; Honeycutt, W; Hurwitz, HI; Morse, MA; Pang, H; Wong, NS, 2011)
" However, circadian chronomodulated chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin (chronoFLO4) offered no survival benefit as compared with the non-time-stipulated FOLFOX2, in an international randomized trial involving patients with previously untreated metastatic colorectal cancer (EORTC 05963)."9.15Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). ( Bjarnason, GA; Carvalho, C; Focan, C; Garufi, C; Giacchetti, S; Iacobelli, S; Innominato, PF; Karaboué, A; Lévi, F; Moreau, T; Smaaland, R; Tampellini, M; Tumolo, S, 2011)
"A week on/week off capecitabine schedule with oxaliplatin/bevacizumab was evaluated in patients with metastatic colorectal cancer (mCRC)."9.15A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer. ( Balaban, EP; Crandall, TL; Kane, P; Lembersky, BC; Pinkerton, RA; Potter, DM; Rajasenan, KK; Ramanathan, RK; Schmotzer, A; Sehgal, R; Zeh, H, 2011)
"The present study was done to establish a prognostic model for patients and trials using an oxaliplatin-based or irinotecan-based first-line chemotherapy in metastatic colorectal cancer."9.15Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. ( André, T; Artru, P; Bengrine-Lefevre, L; Bonnetain, F; Chibaudel, B; de Gramont, A; Desramé, J; Larsen, AK; Louvet, C; Teixeira, L; Tournigand, C, 2011)
"The AIO KRK 0110/ML22011 trial is a two-arm, multicenter, open-label randomized phase III trial comparing the efficacy and safety of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in the first-line treatment of metastatic colorectal cancer."9.15A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial. ( Aubele, P; Bangerter, M; Denzlinger, C; Freiberg-Richter, J; Giessen, C; Heinemann, V; Hinke, A; Kullmann, F; Mayerle, J; Modest, DP; Moosmann, N; Schulz, C; Sieber, M; Stintzing, S; Teschendorf, C; Vehling-Kaiser, U; von Weikersthal, LF, 2011)
"Efforts to improve efficacy and minimize toxicity have led to pharmacokinetic monitoring of plasma 5-Fluorouracil (5-FU) levels in colorectal cancer patients undergoing chemotherapy."9.15Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. ( Beachler, C; El-Deiry, WS; Finnberg, NK; Gingrich, R; Kline, CL; Liao, J; Scicchitano, A; Sheikh, HS; Sivik, J, 2011)
"This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin in combination with levofolinate and infusion 5-fluorouracil (FOLFOX4) as first-line therapy for Japanese patients with unresectable metastatic colorectal cancer."9.15A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience. ( Baba, H; Egashira, A; Emi, Y; Fujita, F; Hasegawa, H; Hayashi, N; Higashi, H; Inomata, M; Kakeji, Y; Kohakura, F; Kohnoe, S; Maehara, Y; Niwa, K; Ogata, Y; Ohga, T; Oki, E; Samura, H; Shirabe, K; Tokunaga, S; Toyama, T; Yamamoto, M, 2011)
"In a multicenter, double-blind phase II trial, we compared the efficacy and safety of perifosine plus capecitabine (P-CAP) with placebo plus capecitabine (CAP) in patients with metastatic colorectal cancer (mCRC) who had progressed after as many as two prior therapies."9.15Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. ( Bendell, JC; Campos, LT; Gardner, L; Hagenstad, C; Hermann, RC; Nemunaitis, J; Richards, DA; Sportelli, P; Vukelja, SJ, 2011)
"This study investigated the antitumour and chemosensitizing effects of celecoxib in the treatment of advanced colorectal cancer."9.15Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer. ( Chen, JM; Jin, CH; Li, RX; Liu, XM; Wang, AH; Wang, GP; Xing, LQ, 2011)
"Irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI) is accepted as a reference treatment for the first-line treatment of patients with metastatic colorectal cancer (MCRC)."9.14Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the ( Aranda, E; Benavides, M; Cámara, JC; Carrato, A; Constenla, M; Díaz-Rubio, E; Dueñas, R; Gomez, A; Marcuello, E; Martinez-Villacampa, M; Massutti, B; Navarro, M; Reboredo, M; Valladares, M, 2009)
"Oxaliplatin combined with either fluorouracil/leucovorin (OXAFAFU) or capecitabine (OXXEL) has a demonstrated activity in metastatic colorectal cancer patients."9.14Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. ( Barberis, G; Cannone, M; Comella, P; Condemi, G; Farris, A; Filippelli, G; Maiorino, L; Massidda, B; Natale, D; Palmeri, S, 2009)
"The combination of oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX-4) is still a reference regimen in advanced colorectal cancer; however, the addition of new biologic compounds represents a significant way forward."9.14An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. ( Anthoney, A; Bauer, J; Caponigro, F; Govaerts, AS; Lacombe, D; Marréaud, S; Milano, A; Twelves, C, 2009)
"Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatments for patients with metastatic colorectal cancer (mCRC)."9.14Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. ( Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J, 2009)
"This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients."9.14Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. ( Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P, 2009)
"5-Fluorouracil refractory metastatic colorectal cancer patients were intravenously treated with HA-Irinotecan (300 mg/m(2) irinotecan with 1,000 mg/m(2) HA) on day 1 of a 21-day cycle."9.14A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients. ( Brown, TJ; Cinc, E; Fox, RM; Gibbs, P; Jennens, R; Michael, M; Ng, R; Pho, M, 2009)
"Thirty-one patients with non-resectable, colorectal cancer (CRC) liver metastases received irinotecan 120 mg/m(2), followed by leucovorin (LV) 20 mg/m(2) and 5-fluorouracil (5-FU) 500 mg/m(2) administered by HAI every 2 weeks, plus UFT (tegafur-uracil) 200 mg/m(2)/day with LV 30 mg/day on days 1-22, followed by a 6-day rest."9.14Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer. ( Ariche, A; Baruch, NB; Brenner, B; Dinerman, M; Greif, F; Idelevich, E; Kashtan, H; Mavor, E; Miller, R; Shani, A; Susmalian, S, 2009)
"For the purpose of developing a longitudinal model to predict hand-and-foot syndrome (HFS) dynamics in patients receiving capecitabine, data from two large phase III studies were used."9.14A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. ( Cassidy, J; Dartois, C; Freyer, G; Girard, P; Hénin, E; Hoff, PM; Sirzen, F; Tod, M; Twelves, C; VanCutsem, E; You, B; Zuideveld, KP, 2009)
"This phase II study was conducted to determine the efficacy and safety of capecitabine and bevacizumab in untreated elderly metastatic colorectal cancer patients."9.14A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. ( Fakih, MG; Khushalani, N; Mashtare, T; Puthillath, A; Romano, K; Ross, ME; Steinbrenner, L; Wilding, G; Wisniewski, M, 2009)
"This study assessed radiotherapy combined with capecitabine and oxaliplatin in patients with primary, inextirpable colorectal adenocarcinoma."9.14Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study. ( Anderson, H; Berglund, K; Byström, P; Ekelund, M; Fernebro, E; Glimelius, B; Gunnlaugsson, A; Holm, T; Johnsson, A; Kjellén, E; Påhlman, L, 2009)
"This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer."9.14Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. ( Aparicio, J; Bokemeyer, C; Bondarenko, I; de Braud, F; Donea, S; Hartmann, JT; Koralewski, P; Loos, AH; Ludwig, H; Makhson, A; Schuch, G; Stroh, C; Zubel, A, 2009)
"Second-line irinotecan-based chemotherapy is commonly used in metastatic colorectal cancers after first-line oxaliplatin-based chemotherapy."9.14Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. ( André, T; Bengrine-Lefevre, L; Bidard, FC; Cervantes, A; de Gramont, A; Figer, A; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2009)
"This Simon 2-stage phase II trial was designed to document antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer (CRC)."9.14Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer. ( Grossbard, M; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Wasserman, C, 2009)
"This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer."9.14Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. ( Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009)
"Irinotecan-based chemotherapy regimens are 1 option for treatment of metastatic colorectal cancer (mCRC)."9.14Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. ( Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X, 2009)
"The present study aimed at investigating whether the simultaneous evaluation of pharmacokinetic, pharmacogenetic and demographic factors could improve prediction on toxicity and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil (5FU)/leucovorin therapy."9.14Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. ( Barile, C; Bolzonella, C; Bononi, A; Crepaldi, G; Ferrazzi, E; Frigo, AC; Gusella, M; Marinelli, R; Menon, D; Padrini, R; Pasini, F; Stievano, L; Toso, S, 2009)
"Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC)."9.14Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. ( Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E, 2009)
"Bevacizumab (BV) prolongs the survival of colorectal cancer patients when combined with irinotecan (CPT-11)-based regimens."9.14Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy. ( Hamaguchi, T; Hirashima, Y; Horita, Y; Kato, K; Nakajima, T; Shimada, Y; Yamada, Y, 2010)
"Studies indicate that adjuvant 5-fluorouracil (5-FU) with folinic acid (FA) in colorectal cancer patients with completely resectable liver-limited metastases (LMCRC) offers clinical benefit over surgery alone."9.14A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. ( Bokemeyer, C; Hohenberger, W; Kwok-Keung Choi, C; Maurel, J; Navarro, M; Rivera, F; Santoro, A; Shacham-Shmueli, E; Thezenas, S; Ychou, M, 2009)
"To evaluate the efficacy of bevacizumab in combination of irinotecan,fluorouracil and leucovorin for metastatic colorectal cancer treated by failed prior oxaliplatin -based regiment."9.14[Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer]. ( Chen, B; Chen, JZ; Cui, F; Luo, RC; Wan, C; Zheng, H, 2009)
"To evaluate the efficacy and safety of irinotecan combined with xeloda (CAPIRI regimen) in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin."9.14[Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin]. ( Bai, CM; Chen, SC; Cheng, YJ; Jia, N; Shao, YJ; Zhou, JF, 2009)
"The aim of the current study was the investigation of the value of bevacizumab+5-fluorouracil(5-FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options."9.14Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial. ( Caricato, M; Coppola, R; Gasparro, S; Rizzo, S; Russo, A; Santini, D; Spoto, C; Tonini, G; Valeri, S; Venditti, O; Vincenzi, B; Zobel, BB, 2009)
"Bevacizumab (Avastin) significantly improves overall survival (OS) and progression-free survival (PFS) when combined with first-line irinotecan (IFL) plus bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic colorectal cancer (CRC)."9.14Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. ( Ackland, S; Chiara, S; Clarke, S; Gapski, J; Langer, B; Mainwaring, P; Perez-Carrión, R; Sobrero, A; Young, S, 2009)
"To determine the efficacy and tolerability of capecitabine combined with oxaliplatin (CAPOX) or irinotecan (CAPIRI) as first-line treatment in patients with advanced/metastatic colorectal cancer aged > or =70 years."9.14Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. ( Bordonaro, R; Caputo, G; Cordio, S; Manzione, L; Novello, G; Reggiardo, G; Rosati, G, 2010)
"To determine the efficacy and tolerability of oral fluoropyrimidine S-1 plus irinotecan in patients with previously untreated advanced colorectal cancer."9.14Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. ( Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Watanabe, M; Yasuda, N, 2009)
"To assess the resectability rate of patients with initially unresectable liver-only metastases from colorectal cancer (CRC) after treatment with irinotecan/capecitabine."9.14A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer. ( Cai, J; Ji, X; Li, Q; Tucker, S; Wan, F; Wang, D; Zhao, R; Zhong, B; Zhu, J, 2010)
"We investigated the efficacy of fluorouracil (FU), leucovorin, irinotecan, and bevacizumab (FOLFIRI + B) in a phase II trial in patients previously untreated for metastatic colorectal cancer (mCRC), and changes during treatment in plasma cytokines and angiogenic factors (CAFs) as potential markers of treatment response and therapeutic resistance."9.14Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. ( Abbruzzese, JL; Adinin, R; Ellis, LM; Eng, C; Glover, KY; Heymach, JV; Hoff, PM; Kopetz, S; Lieu, C; Morris, JS; Overman, MJ; Tran, HT; Valero, V; Wen, S; Wolff, RA; Yan, S, 2010)
"The primary objective of this study was to determine the activity and safety profile of biweekly oxaliplatin combined with continuous oral capecitabine in the first-line treatment of metastatic colorectal cancer."9.14Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin. ( Bargagli, G; Bellan, C; Conca, R; Fiaschi, AI; Francini, E; Francini, G; Lazzi, S; Lorenzi, B; Martellucci, I; Pascucci, A; Petrioli, R, 2010)
" PATIENTS AND METHODS Patients undergoing first-line treatment for metastatic colorectal cancer (CRC) eligible for treatment with irinotecan plus infusional fluorouracil/leucovorin (FOLFIRI) were screened for the UGT1A1*28/*28 genotype and excluded from the study."9.14Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. ( Azzarello, G; Basso, U; Buonadonna, A; Cecchin, E; D'Andrea, M; De Mattia, E; De Paoli, P; Gasparini, G; Innocenti, F; Lo Re, G; Mini, E; Nobili, S; Pessa, S; Toffoli, G, 2010)
"We conducted a phase I/II clinical trial to determine the safety and feasibility of combining vorinostat with 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer (mCRC) and elevated intratumoral thymidylate synthase (TS)."9.14A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. ( Cole, S; Danenberg, KD; El-Khoueiry, A; Fazzone, W; Groshen, S; Iqbal, S; Kornacki, M; LaBonte, MJ; Ladner, RD; Lenz, HJ; Wilson, PM; Yang, D, 2010)
"This phase I/II study was conducted to assess the maximal tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of gefitinib in combination with capecitabine in patients with advanced colorectal cancer (aCRC)."9.14Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). ( Frieling, T; Graeven, U; Hegewisch-Becker, S; Lehnert, L; Reinacher-Schick, A; Schmiegel, W; Trarbach, T; Vanhoefer, U, 2010)
"A dose-finding study was performed to evaluate the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD) and the recommended dose (RD) of escalating the doses of capecitabine and fixed doses of irinotecan and oxaliplatin on a biweekly schedule for metastatic colorectal cancer patients (mCRC)."9.14Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. ( Bandres, E; Bitarte, N; Chopitea, A; Gacía-Foncillas, J; Patiño-Garcia, A; Ponz-Sarvise, M; Ramirez, N; Rodríguez, J; Viudez, A; Zarate, R, 2010)
"Combined therapy with irinotecan/fluorouracil/levoleucovorin (calcium levofolinate) [IFL] has lost its position as the standard regimen for metastatic colorectal cancer because its toxicity and effectiveness have become controversial."9.14Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies. ( Asaka, M; Fuse, N; Kato, T; Komatsu, Y; Kudo, M; Kunieda, Y; Miyagishima, T; Sakata, Y; Tateyama, M; Wakahama, O; Watanabe, M; Yuuki, S, 2010)
"The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based combination were assessed in a phase II, open, multicentre, uncontrolled study."9.14Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. ( Bolaños, M; Bosch, C; Castro-Carpeño, J; Escudero, P; Feliu, J; García-Girón, C; Gil, M; González-Barón, M; Llombart, A; López, R; Losa, F; Madroñal, C; Safont, MJ; Salud, A, 2010)
"A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association."9.14Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. ( Bruera, G; Calista, F; Cannita, K; De Galitiis, F; Ficorella, C; Gebbia, N; Guglielmi, F; Iacobelli, S; Lanfiuti Baldi, P; Mancini, M; Marchetti, P; Martella, F; Morelli, MF; Pelliccione, M; Porzio, G; Ricevuto, E; Russo, A; Santomaggio, A; Tudini, M, 2010)
"To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial."9.14Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010)
"A phase I multicentre trial was conducted to define the recommended dose of capecitabine in combination with oxaliplatin and irinotecan (OCX) in metastatic colorectal cancer."9.14Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). ( Cathomas, R; Köberle, D; Lanz, D; Popescu, R; Roth, A; Ruhstaller, T; Simcock, M; Uhlmann, C; von Moos, R; Widmer, L, 2010)
"The impact of thymidylate synthase (TYMS) and UDP-glucoronosyltransferase 1A (UGT1A) germline polymorphisms on the outcome of colorectal cancer (CRC) patients treated with irinotecan plus 5-fluorouracil (irinotecan/5FU) is still controversial."9.14UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. ( Abad, A; Aranda, E; Benavides, M; Carrato, A; Ginés, A; Layos, L; Manzano, JL; Marcuello, E; Martinez-Balibrea, E; Martínez-Cardús, A; Massutí, B; Moreno, V; Navarro, M; Valladares, M, 2010)
"Capecitabine has shown similar efficacy to 5-fluorouracil (5-FU); a regimen containing 2 weeks of capecitabine/oxaliplatin (CapOx) has demonstrated noninferiority to infusional 5-FU/oxaliplatin/leucovorin (FOLFOX) for the treatment of metastatic colorectal cancer (mCRC)."9.14A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. ( Eickhoff, JC; Holen, KD; Jumonville, A; Loconte, NK; Lubner, SJ; Mulkerin, DL; Schelman, W; Seo, S; Thomas, JP, 2010)
"The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 trial in patients with metastatic colorectal cancer."9.14Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. ( Amoroso, D; Andreuccetti, M; Ciarlo, A; Cortesi, E; Cremolini, C; Cupini, S; Del Monte, F; Falcone, A; Fontanini, G; Fornaro, L; Granetto, C; Loupakis, F; Lupi, C; Masi, G; Salvatore, L; Sensi, E, 2010)
"Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line chemotherapy for metastatic colorectal cancer."9.14Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K, 2010)
"To evaluate the efficacy and safety of bevacizumab plus capecitabine in treating metastatic colorectal cancer(mCRC)."9.14[Efficacy and safety of bevacizumab plus capecitabine for metastatic colorectal cancer]. ( Ai, B; Ding, L; Li, L; Wu, JY; Wu, XN; Zhao, YB; Zhou, MZ, 2010)
"This study reports the long-term follow-up of patients with metastatic colorectal cancer (CRC) participating in a randomised phase II study that compared the efficacy and toxicity of the combination of irinotecan (IRI), fluorouracil (FU) with leucovorin (LV) (arm A) versus sequential chemotherapy with IRI plus FU/LV followed by oxaliplatin (OXA) plus FU/LV (arm B) as first line therapy."9.14Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer. ( Aravantinos, G; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Linardou, H; Makatsoris, T; Papadimitriou, C; Papakostas, P; Papamichael, D; Pectasides, D; Pentheroudakis, G; Samelis, G; Skondra, M; Stavropoulos, M; Syrigos, KN; Varthalitis, I; Vourli, G; Xanthakis, I; Xiros, N, 2010)
"Fluorouracil (FU) is a cornerstone of colorectal cancer treatment; however, it has clinical and subclinical influence on the heart."9.14Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. ( Hasbak, P; Jensen, SA; Mortensen, J; Sørensen, JB, 2010)
"601 patients with advanced or metastatic colorectal cancer receiving first-, second-, or third-line irinotecan-based therapy were regularly analyzed for response and toxicity until the end of therapy."9.14Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study. ( Ababneh, Y; Fahlke, J; Galle, PR; Maintz, C; Moehler, M; Musch, R; Schimanski, CC; Schmidt, B; Siebler, J; Soeling, U; Verpoort, K, 2010)
"This phase I study was conducted to determine the maximum tolerated dose (MTD) of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) in patients with advanced colorectal cancer (CRC)."9.14Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. ( Carducci, M; Dancey, J; Donehower, RC; Hidalgo, M; Iacobuzio-Donahue, C; Jacene, H; Jimeno, A; Kahn, Y; Kulesza, P; Laheru, DA; Messersmith, WA; Rudek, MA; Spira, A; Zhao, M, 2010)
"The results indicate that the modified CAPOX regimen is safe and effective as salvage treatment in patients with advanced colorectal cancer who were previously treated with irinotecan-based frontline therapy."9.13Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study. ( Amarantidis, K; Ardavanis, A; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Polyzos, A; Souglakos, J; Tsousis, S; Vamvakas, L; Vardakis, N; Varthalitis, I; Ziras, N, 2008)
"To demonstrate the noninferiority of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX-4) as second-line therapy in patients with metastatic colorectal cancer after prior irinotecan-based chemotherapy."9.13Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. ( Bang, YJ; Butts, C; Cox, JV; Cunningham, D; Goel, R; Gollins, S; Laguerre, S; Navarro, M; Rothenberg, ML; Siu, LL, 2008)
"The aim of the study was to investigate the associations between UGT1A1(*)28 genotype and (1) response rates, (2) febrile neutropenia and (3) dose intensity in patients with metastatic colorectal cancer treated with irinotecan."9.13UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Punt, CJ; Van der Straaten, T, 2008)
" This randomized phase II trial investigates the feasibility and efficacy of gefitinib and 5-fluorouracil, folinic acid, irinotecan (FOLFIRI) in patients with metastatic colorectal cancer."9.13A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. ( Carnaghi, C; Comandone, A; Granetti, C; Lorusso, V; Mari, E; Oliva, C; Pressiani, T; Rimassa, L; Ronzoni, M; Santoro, A; Siena, S; Zuradelli, M, 2008)
"To determine the maximum tolerated dose (MTD), characterize the principal toxicities, and assess the pharmacokinetics of EKB-569, an oral selective irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with capecitabine in patients with advanced colorectal cancer."9.13A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. ( Abbas, R; Boni, J; Bukowski, R; Croghan, G; Donehower, R; Erlichman, C; Hidalgo, M; Jimeno, A; Laheru, D; Martins, P; Messersmith, W; Pelley, R; Rudek, M; Zacharchuk, C, 2008)
"To compare the time to deterioration in health-related quality of life (HRQoL) in patients with previously untreated metastatic colorectal cancer receiving a 5-fluorouracil (5-FU)-based chemotherapy regimen with or without the addition of bevacizumab (BV) in two randomized, placebo-controlled studies."9.13Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. ( Cella, D; Holmgren, E; Hurwitz, HI; Kabbinavar, FF; Wallace, JF; Yi, J; Yost, KJ, 2008)
" Progression-free survival (PFS) and toxicity were determined in 267 metastatic colorectal cancer (MCRC) patients who were treated with first-line capecitabine (CAP) plus irinotecan (CAPIRI), or CAP single agent in a prospective randomised phase III trial (CAIRO)."9.13GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Koopman, M; Kweekel, DM; Nortier, JW; Punt, CJ; Van der Straaten, T, 2008)
"We investigated the gefitinib, 5-fluorouracil (5-FU), leucovorin and oxaliplatin (IFOX) regimen as first-line therapy in patients with metastatic colorectal cancer."9.13A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. ( Cho, CD; Fisher, GA; Halsey, J; Kuo, T; Ramsey, M; Rouse, RV; Schwartz, E; Sikic, BI, 2008)
" Effects of the ABCC2 genotype on the pharmacokinetics (PK) of irinotecan and the metabolites were examined in Japanese patients with metastatic colorectal cancer receiving irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI)."9.13Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). ( Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Matsunaga, M; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W; Yamashita, K, 2008)
"This study was conducted to assess the tolerability and efficacy of a ternary bimonthly irinotecan (CPT-11) - oxaliplatin (OHP) - infusional 5-fluorouracil (5-FU)/folinic acid (FA) combination in advanced colorectal cancer patients who had received prior CPT-11 and/or OHP-based chemotherapy regimen."9.13Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. ( Checcacci, D; Del Buono, S; Filippelli, F; Mazzei, T; Mazzocchi, V; Mini, E; Nobili, S, 2008)
"XELIRI (capecitabine/irinotecan) is effective and well tolerated in metastatic colorectal cancer (mCRC)."9.13Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer. ( Asmar, L; Berger, M; Boehm, KA; Cartwright, T; Cohn, A; Hyman, W; Kuefler, P; Nugent, JE; Richards, D; Ruxer, RL; Vukelja, S, 2008)
"Since the combination of capecitabine and irinotecan has successfully been used as a first-line treatment in metastatic colorectal cancer (MCRC), we expected promising results when given as a second-line treatment to metastatic colorectal patients who had been pretreated with 5-Fluorouracil and Oxaliplatin."9.13The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. ( Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ, 2008)
" A Phase-II study was undertaken to determine the activity of a dose attenuated schedule of irinotecan, capecitabine, and the COX-2 inhibitor celecoxib in patients with advanced colorectal cancer."9.13Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. ( El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM, 2008)
"Patients with histologically proven primary colorectal cancer and bidimensionally measurable liver metastasis, not fully resectable based on technical inability to achieve R(0) resection, but potentially resectable after tumor reduction, were given FOLFIRINOX: oxaliplatin 85 mg/m(2), irinotecan 180 mg/m(2), leucovorin 400 mg/m(2), bolus fluorouracil 400 mg/m(2) and fluorouracil 46-h continuous IV infusion 2,400 mg/m(2), every 2 weeks for a maximum of 12 cycles."9.13Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. ( Delpero, JR; Desseigne, F; Guimbaud, R; Kramar, A; Mitry, E; Nordlinger, B; Portier, G; Quénet, F; Rivoire, M; Viret, F; Ychou, M, 2008)
"The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P)."9.13Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. ( Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ, 2008)
"The objectives of this phase I/II study were to determine the maximum tolerated dose (MTD), characterise the principal toxicities in the phase I part and assess the efficacy in the phase II part of gefitinib, an oral selective inhibitor of the epidermal growth factor receptor, in combination with capecitabine in patients with advanced colorectal cancer (CRC)."9.13Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer. ( Alonso, V; Bovio, H; Colomer, R; Cortés-Funes, H; Escudero, P; García-Carbonero, R; Grávalos, C; Jimeno, A; Juez, I; Sevilla, I; Vega-Villegas, ME, 2008)
"The aim of this study was to evaluate the effects of a combination of folinic acid, 5-fluorouracil (5FU) and irinotecan (FOLFIRI 1) administered every 2 weeks in a population of elderly subjects with advanced colorectal cancer."9.13Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. ( Badetti, JL; Berdah, JF; Chamorey, E; Codoul, JF; François, E; Hébert, C; Lesbats, G; Mari, V; Teissier, E, 2008)
"We evaluated the outcome of 140 patients aged > or = 70 years of age who received first-line treatment for metastatic colorectal cancer within the German phase III trial of FUFOX (5-fluorouracil/leucovorin/oxaliplatin) versus CAPOX (capecitabine/oxaliplatin)."9.13Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. ( Arkenau, HT; Englisch-Fritz, C; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T, 2008)
"Oxaliplatin in combination with capecitabine prolongs survival in patients with metastatic colorectal cancer (mCRC)."9.13Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. ( Balteskard, L; Berglund, A; Fokstuen, T; Ogreid, D; Pfeiffer, P; Ploen, J; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, K; Yilmaz, M, 2008)
"This two-part phase Ib/II study investigated the feasibility of administering cetuximab in combination with oxaliplatin and infusional 5-fluorouracil (5-FU)/folinic acid (FA) in a weekly schedule (AIO FUFOX protocol) as first-line treatment in patients with epidermal growth factor receptor-detectable advanced colorectal cancer."9.13Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. ( Arnold, D; Dittrich, C; Herrmann, T; Höhler, T; Lordick, F; Riemann, J; Schmoll, HJ; Seufferlein, T; Wöll, E; Zubel, A, 2008)
" For this purpose, 110 XELOX (capecitabine/oxaliplatin)- or FUOX (fluorouracil/oxaliplatin)-treated metastatic colorectal cancer patients were selected prospectively for genotyping."9.13Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. ( Abad, A; Aparicio, J; Aranda, E; Díaz-Rubio, E; García, T; Ginés, A; Gómez-España, A; Guino, E; Maestu, I; Manzano, JL; Martinez-Balibrea, E; Martínez-Cardús, A; Sastre, J, 2008)
"Oxaliplatin combined with 5-fluorouracil (5-FU), with or without leucovorin (LV), is effective and well tolerated for first-line therapy of advanced colorectal cancer (CRC)."9.13A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer. ( Bernard, SA; Bjarnason, GA; Braich, T; Desimone, P; Evars, JP; Hrushesky, WJ; Jolivet, J; Ramanathan, RK, 2008)
"Guidelines recommend combined doublet backbone chemotherapy based on 5-fluorouracil and oxaliplatin (OX) or irinotecan (IR) as the first-line treatment options for metastatic colorectal cancer."9.12Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis. ( Hui, F; Qi, X; Ren, T; Shen, Z; Wang, S; Xu, C; Zhang, Y; Zhao, Q, 2021)
"The antimetabolite, 5-Fluorouracil (5-FU), is the only chemotherapeutic drug to significantly improve 12-month survival rates of patients with Colorectal Cancer (CRC)."9.12Current Perspectives on the Role of Nrf2 in 5-Fluorouracil Resistance in Colorectal Cancer. ( Gong, J; Xu, H, 2021)
"The efficacy of oxaliplatin combined with capecitabine (XELOX) as second-line therapy in patients with advanced colorectal cancer (ACRC) resistant to irinotecan is not well established."9.12Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. ( Baltesgard, L; Ehrsson, H; Fokstuen, T; Glimelius, B; Mortensen, JP; Pfeiffer, P; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, KM; Wallin, I; Øgreid, D, 2006)
"A total of 630 patients with previously untreated metastatic colorectal cancer were randomised in a 2:1 fashion to receive bolus 5-fluorouracil (5-FU) and leucovorin (LV) plus either 3H1 (n = 422) or placebo (n = 208)."9.12Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. ( Bhatnagar, A; Bridgewater, J; Carmichael, J; Cassidy, J; Chong, G; Coleman, R; Cosgriff, TM; Coxon, F; Cunningham, D; Harper, PG; Hawkins, R; Jones, JJ; Moore, M; Northfelt, D; Redfern, CH; Sreedharan, S; Steward, W; Valone, F, 2006)
"We treated 74 patients with unresectable metastatic colorectal cancer (not selected for a neoadjuvant approach) with irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin (FOLFOXIRI and simplified FOLFOXIRI)."9.12Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. ( Allegrini, G; Brunetti, IM; Cerri, E; Cupini, S; Falcone, A; Filipponi, F; Goletti, O; Loupakis, F; Marcucci, L; Masi, G; Pfanner, E; Viti, M, 2006)
"Oxaliplatin and 5-fluorouracil (5-FU) act synergistically in colorectal cancer."9.12Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. ( Cho, HK; Chung, SJ; Kang, JH; Kim, DD; Kuh, HJ; Lee, ES; Lee, JW; Lee, KS; Park, JK; Shim, CK, 2006)
"Irinotecan or oxaliplatin combined with 5-fluorouracil (5-FU) +/- folinic acid (FA) has changed the treatment standards for metastatic colorectal cancer (CRC)."9.12Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients. ( Bas, C; Bella, S; Chacon, M; Coppola, F; Escobar, E; Hidalgo, J; Korbenfeld, E; Martin, C; Martinez, J; Reale, M; Richardet, E; Senna, S; Smilovich, AM; Wasserman, E, 2006)
"To compare the efficacy and toxicity of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOXIRI) vs irinotecan and 5-FU/LV (FOLFIRI) as first-line treatment of patients with metastatic colorectal cancer (MCC)."9.12FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog ( Androulakis, N; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Kalykaki, A; Kouroussis, Ch; Mavroudis, D; Polyzos, A; Samonis, G; Souglakos, J; Syrigos, K; Tsousis, S; Vamvakas, L; Ziras, N, 2006)
" We evaluated oral rubitecan (5 days on, 2 days rest per week) on a continuous schedule, in patients with advanced colorectal cancer (CRC), who progressed after 5-fluorouracil based chemotherapy."9.12Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy. ( Auber, M; Cai, C; Kiefer, G; Matin, K; Patel, H; Potter, D; Ramanathan, RK; Schmotzer, A; Stoller, R; Zamboni, W, 2006)
"The purpose of this study was to evaluate the safety and activity of fixed-dose capecitabine in patients with advanced colorectal cancer and to correlate pretreatment plasma concentrations of homocysteine and serum and red cell folate with toxicity."9.12A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. ( Beale, P; Clarke, SJ; Horvath, L; Ong, S; Rivory, L; Sharma, R, 2006)
"The purpose of this phase II trial was to determine the efficacy and safety of the XELOX (capecitabine/oxaliplatin) regimen as first-line therapy in the elderly patients with metastatic colorectal cancer (MCRC)."9.12XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. ( Bolaños, M; Casado, E; De Castro, J; de Mon, MA; Escudero, P; Feliu, J; Galán, A; González-Barón, M; Lopez-Gómez, L; Losa, F; Salud, A; Vicent, JM; Yubero, A, 2006)
"Determine the toxicity, tolerability, and pharmacokinetics of SU5416, a vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, coadministered with bolus 5-fluorouracil (5-FU), leucovorin, and irinotecan (IFL) in untreated patients with metastatic colorectal cancer."9.12Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. ( Berlin, JD; Cropp, GF; Donnelly, E; Fleischer, AC; Hande, KR; Hannah, AL; Lockhart, AC; Rothenberg, ML; Schaaf, LJ; Schumaker, RD, 2006)
"To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer."9.12Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX, 2006)
"In advanced colorectal cancer previously treated with oxaliplatin, efficacy of irinotecan-based chemotherapy is poor and the best regimen is not defined."9.12A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. ( André, T; Artru, P; de Gramont, A; Flesch, M; Landi, B; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Plantade, A, 2006)
"The purpose of this study was to evaluate the antitumor activity and toxicity of fixed sequences of capecitabine/oxaliplatin followed by capecitabine/irinotecan in patients with previously untreated metastatic colorectal cancer."9.12Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer. ( Alvarez, JV; Arcediano, A; Cassinello, J; Castro, IG; Colmenarejo, A; Filipovich, E; López, MJ; Marcos, F; Pujol, E; Segovia, F, 2006)
"To evaluate the efficacy and tolerance of the gemcitabine/oxaliplatin (GEMOX) combination as second-line chemotherapy for patients with advanced colorectal cancer (CRC) pretreated with an irinotecan (CPT-11)/5-fluorouracil (5-FU)/leucovorin (LV) regimen."9.12Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. ( Boukovinas, I; Christofillakis, C; Georgoulias, V; Potamianou, A; Syrigos, K; Tselepatiotis, E; Tsousis, S; Varthalitis, I; Ziras, N, 2006)
"To examine whether carbogen and nicotinamide increases 5-fluorouracil (5-FU) delivery to colorectal cancer metastases."9.12Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. ( Aboagye, EO; Gupta, N; Hoskin, PJ; Jones, T; Kötz, B; Osman, S; Phillips, R; Price, PM; Saleem, A; Vernon, C; Wasan, H, 2006)
"COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib."9.12Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? ( Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR, 2006)
"The aim of the study was to verify the efficacy and safety of the addition of celecoxib to FOLFIRI combination therapy in patients affected by advanced colorectal cancer."9.12FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). ( Colucci, G; Di Renzo, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Mallamaci, R; Pezzella, G; Romito, S, 2006)
"To evaluate the efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer."9.12[Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer]. ( Chen, JZ; Liao, WJ; Luo, RC; Zheng, H, 2006)
"We conducted two phase II trials evaluating the combination of 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) as first-line treatment in 74 metastatic colorectal cancer patients."9.12First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. ( Allegrini, G; Andreuccetti, M; Barbara, C; Brunetti, IM; Bursi, S; Cerri, E; Cupini, S; Falcone, A; Loupakis, F; Marcucci, L; Masi, G; Murr, R; Ricci, S, 2006)
"In a prospective study, 250 metastatic colorectal cancer patients were treated with irinotecan, fluorouracil, and leucovorin as first-line treatment."9.12The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. ( Biason, P; Boccalon, M; Bonura, S; Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Pangher, V; Errante, D; Frustaci, S; Gaion, F; Galligioni, E; Giusto, M; Medici, M; Pasetto, LM; Pessa, S; Russo, A; Sandri, P; Toffoli, G, 2006)
"LV5FU2 with high-dose leucovorin (LV), weekly infusional 5-fluorouracil (5FU) (AIO schedule) and raltitrexed have been demonstrated to be active agents in first-line treatment of colorectal cancer."9.12Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial. ( Bedenne, L; Berger, C; Bouche, O; Cassan, P; Ducreux, M; Dunant, A; Fournet, J; Leduc, B; Mousseau, M; Pignon, JP; Raoul, JL, 2006)
"Previously, we reported results of Intergroup N9741, which compared standard bolus fluorouracil (FU), leucovorin, plus irinotecan (IFL) with infused FU, leucovorin, plus oxaliplatin (FOLFOX4) and irinotecan plus oxaliplatin in patients with untreated metastatic colorectal cancer."9.12Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. ( Alberts, S; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2006)
"To provide bevacizumab (BV) -based therapy to patients with advanced colorectal cancers (CRC) who had exhausted standard chemotherapy options, and to evaluate the response to BV combined with fluorouracil (FU) and leucovorin (LV) in this patient population."9.12Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. ( Boron, M; Chen, HX; Grochow, L; Jaffe, C; Kaplan, RS; Mooney, M; Mosby, K; Rubinstein, L; Vena, D; Zwiebel, J, 2006)
" Capecitabine plus irinotecan appears to be a feasible first-line treatment for patients with advanced colorectal carcinoma."9.12Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. ( Akkermans-Vogelaar, JM; Antonini, NF; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Punt, CJ; Rodenburg, CJ; Vreugdenhil, G; Wals, J, 2006)
"Oxaliplatin (OXA) and irinotecan (IRI) are active drugs for metastatic colorectal cancer, their toxicity profiles are not overlapping, and both drugs have shown at least additivity with folinic acid-modulated 5-fluorouracil (5FU)."9.12Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. ( Casaretti, R; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Massidda, B; Palmeri, S; Putzu, C; Sandomenico, C, 2006)
"To evaluate the clinical activity and toxicity of capecitabine plus irinotecan as first-line therapy for patients with metastatic colorectal cancer (mCRC), and to describe the association of expression of thymidine phosphorylase (TP), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) with antitumor activity."9.12Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. ( Andria, M; Dhami, M; Diasio, RB; Godfrey, T; Gold, PJ; Kovatich, AJ; Lund, KA; Meropol, NJ; Mitchell, E; Schwarting, R, 2006)
"Until recently, fluorouracil (F) and leucovorin (L) had been considered the standard therapy for patients with colorectal cancer."9.12Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. ( Aabo, K; Bjerregaard, B; Eckhoff, L; Jakobsen, A; Mortensen, JP; Pfeiffer, P; Sandberg, E; Schønnemann, K, 2006)
"The aim of the study was to assess the impact of an eicosapentanoic acid-containing protein and energy dense oral nutritional supplement (EPA-ONS) on nutritional and inflammatory status, quality of life (QOL), plasma phospholipids (PPL) and cytokine profile, tolerance of irinotecan-containing chemotherapy and EPA-ONS in patients with advanced colorectal cancer (CRC) receiving chemotherapy."9.12Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. ( Beale, PJ; Childs, A; Clarke, SJ; Read, JA; Smith, N; Volker, DH, 2007)
"In this study, the maximum tolerated dose and toxicity profile of FOLFIRI (infusional fluorouracil [5-FU]/leucovorin/irinotecan) plus gefitinib (an oral inhibitor of the epidermal growth factor receptor) were evaluated as first-line therapy in patients with metastatic colorectal cancer."9.12Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. ( Battu, S; Blaszkowsky, L; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Meyerhardt, JA; Ryan, DP; Wolpin, BM; Zhu, AX, 2006)
"Oxaliplatin stop and go in combination with leucovorin and 5-fluorouracil has been successfully used in a previous study (OPTIMOX1) in metastatic colorectal cancer (MCR)."9.12Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. ( André, T; Bidard, FC; de Gramont, A; Fellague-Chebra, R; Flesch, M; Hebbar, M; Louvet, C; Mabro, M; Mineur, L; Postel Vinay, S; Tournigand, C, 2007)
"To characterize the efficacy and safety of palifermin in reducing the incidence of oral mucositis (OM) and diarrhea when administered to patients with metastatic colorectal cancer (CRC) receiving fluorouracil/leucovorin (FU/LV) chemotherapy."9.12Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. ( Abdi, E; Cesano, A; Chen, MG; Clarke, S; Davis, ID; Gayko, U; Gutheil, J; Rosen, LS; Schnell, FM; Zalcberg, J, 2006)
"This phase II randomised trial compares oxaliplatin plus protracted infusion of 5-fluorouracil (pviFOX) or oxaliplatin plus capecitabine (XELOX) in the first-line treatment of advanced colorectal cancer (ACRC)."9.12Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). ( Ballardini, P; Di Fabio, F; Gentile, AL; Giaquinta, S; Lelli, G; Martoni, AA; Mutri, V; Piana, E; Pinto, C; Rojas Llimpe, FL, 2006)
"To assess the toxicity and dose delivery of weekly bolus 5-fluorouracil (5-FU) at 425 mg/m(2) plus low-dose folinic acid (FA) for 24 weeks as adjuvant treatment for colorectal cancer."9.12Weekly fluorouracil at 425 mg/m(2) plus low-dose folinic acid for 24 weeks as adjuvant treatment for colorectal cancer: assessment of toxicity and delivery. ( Gollins, SW; Ramani, VS; Wong, H, 2006)
"Irinotecan at 180 mg/m2 combined with an infusional 5-fluorouracil/leucovorin (5-FU/LV) regimen (FOLFIRI) is a standard first line therapy for metastatic colorectal cancer (mCRC)."9.12Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer. ( Bressole, F; Chalbos, P; Debrigode, C; Desseigne, F; Duffour, J; Gourgou, S; Mineur, L; Pinguet, F; Poujol, S; Ychou, M, 2007)
"The purpose of this study was to compare the activity and toxicity of an irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) combination with a standard regimen of 5FU and LV, in patients with advanced colorectal carcinoma."9.12A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma. ( Andreadis, C; Gennatas, C; Michalaki, V; Mouratidou, D; Pafiti, A; Papaxoinis, G; Tsavaris, N, 2006)
"Several schedules of 5-fluorouracil (FU) and irinotecan (IRI) have been shown to improve overall survival in advanced colorectal cancer (CRC)."9.12Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial. ( Barone, C; Basso, M; Cassano, A; D'Argento, E; Di Leonardo, G; Landriscina, M; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N, 2007)
" This phase I/II dose-finding study evaluated gefitinib in combination with a 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI-AIO) regimen in patients with metastatic colorectal cancer."9.12Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO). ( Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J, 2006)
"To determine the maximum tolerated doses (MTD), toxicities, efficacy, and pharmacokinetics (PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and leucovorin (IFL) in patients with previously untreated advanced colorectal cancer."9.12Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. ( Clark, JW; D'Amato, F; Dancey, J; Earle, CC; Eder, JP; Enzinger, PC; Fuchs, CS; Kinsella, K; Mayer, RJ; Meyerhardt, JA; Michelini, A; Ogino, S; Ryan, DP; Stewart, CF; Supko, JG; Zhu, AX, 2007)
"This study was designed to measure the dihydrouracil (UH(2))/uracil (U) ratio in plasma as a surrogate marker for dihydropyrimidine dehydrogenase (DPD) activity and to investigate the relationships of the UH(2)/U ratios in plasma with the toxicities of 5-fluorouracil (5-FU)-based adjuvant chemotherapy and 5-FU plasma concentrations in colorectal cancer patients."9.12The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. ( Chen, G; Chen, YB; Li, S; Lu, ZH; Pan, ZZ; Wan, de S; Wang, GQ; Zhou, ZW, 2007)
"A phase II study was conducted to evaluate the toxicity and efficacy of irinotecan/5-fluorouracil/leucovorin (CPT-11/5-FU/LV (AIO schedule)) as salvage treatment in patients with metastatic colorectal cancer."9.12Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial. ( Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, C; Mavroudis, D; Pallis, A; Souglakos, J; Vardakis, N, 2007)
"Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without bevacizumab; or bevacizumab alone."9.12Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. ( Alberts, SR; Benson, AB; Catalano, PJ; Giantonio, BJ; Meropol, NJ; Mitchell, EP; O'Dwyer, PJ; Schwartz, MA, 2007)
"The objective of the present study was to evaluate the gene expression of the DNA mismatch repair gene MSH2 as a predictive marker in advanced colorectal cancer (CRC) treated with first-line capecitabine."9.12Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine. ( Danenberg, KD; Danenberg, PV; Jakobsen, A; Jensen, LH, 2007)
"To compare the use of capecitabine plus oxaliplatin (CAPOX) with infusional fluorouracil (FU)/folinic acid plus oxaliplatin (FUFOX) as first-line therapy for patients with metastatic colorectal cancer (MCRC)."9.12Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. ( Arkenau, HT; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T, 2007)
"The aim of this phase III trial was to compare the efficacy and safety of capecitabine plus oxaliplatin (XELOX) versus Spanish-based continuous-infusion high-dose fluorouracil (FU) plus oxaliplatin (FUOX) regimens as first-line therapy for metastatic colorectal cancer (MCRC)."9.12Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Tri ( Abad, A; Aparicio, J; Aranda, E; Carrato, A; Chaves, M; Díaz-Rubio, E; Gómez-España, A; González-Flores, E; Losa, F; Massutí, B; Maurel, J; Queralt, B; Reina, JJ; Rivera, F; Sastre, J; Tabernero, J, 2007)
"Individually, oxaliplatin and irinotecan have substantial activity in metastatic colorectal cancer (CRC) in combination with 5-fluorouracil/leucovorin."9.12Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. ( Ames, MM; Erlichman, C; Goetz, MP; Krook, JE; McWilliams, RR; Morlan, BW; Rowland, KM; Salim, M, 2007)
"We randomly assigned 820 patients with advanced colorectal cancer to receive either first-line treatment with capecitabine, second-line irinotecan, and third-line capecitabine plus oxaliplatin (sequential treatment; n=410) or first-line treatment capecitabine plus irinotecan and second-line capecitabine plus oxaliplatin (combination treatment; n=410)."9.12Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. ( Antonini, NF; Creemers, GM; Dalesio, O; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Loosveld, OJ; Mol, L; Punt, CJ; Rodenburg, CJ; Sinnige, HA; Slee, PHTJ; Tesselaar, ME; van Bochove, A; Vreugdenhil, G; Wals, J; Werter, MJ, 2007)
"To evaluate the efficacy, side-effects and quality of life in the advanced colorectal cancer patients treated by irinotecan plus fuorouracil and leucovorin with thalidomide or without thalidomide."9.12[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. ( Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ, 2007)
"This study was designed as a multicentre phase II trial to assess the efficacy and safety of gefitinib in association with capecitabine and oxaliplatin in patients with untreated metastatic colorectal cancer."9.12A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer. ( Cognetti, F; Di Costanzo, F; Ferraresi, V; Gabriele, A; Gamucci, T; Gasperoni, S; Gelibter, AJ; Giannarelli, D; Nuzzo, C; Pollera, CF; Signorelli, C; Zeuli, M, 2007)
"prospective, randomized, open-label trial in group of 204 patients with advanced colorectal cancer randomized to either chemotherapy with irinotecan+5-FU+leucovorin or supportive care alone (control group) between January 1999--January 2005 was performed."9.12Evaluation of adjuvant chemotherapy irinotecan + 5-fluorouracil + leucovorine in advanced colorectal cancer. ( Klek, S; Kulig, J; Popiela, T; Richter, P, 2007)
"Capecitabine results in superior response rate, improved safety, and improved convenience compared with 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (MCRC)."9.12Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. ( Bexon, A; Diamandidis, D; Eckhardt, SG; Javle, M; Justice, GR; Keiser, W; Lee, FC; Liebmann, JE; Lin, E; Patt, YZ; Salvatore, JR, 2007)
"To evaluate the maximum tolerated dose and dose-limiting toxicity (DLT) of 10-hydroxy-camptothecin (10-HCPT) in HFL regimen for the treatment of advanced colorectal cancer (CRC)."9.12[10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer]. ( Cai, RG; Chen, SS; Chu, DT; Wu, F; Zhang, HG, 2007)
"To assess activity and safety of an experimental combination of irinotecan and oxaliplatin (IRINOX) as first-line treatment in advanced colorectal cancer."9.12A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study ( Adenis, A; Bécouarn, Y; Boucher, E; Cany, L; Cvitkovic, F; Jacob, JH; Montoto-Grillot, C; Senesse, P; Thézenas, S; Ychou, M, 2007)
"A phase I/II study was performed to determine the safety and activity of a capecitabine plus oxaliplatin and irinotecan (COI) regimen using capecitabine concurrently with oxaliplatin and irinotecan in previously untreated patients with metastatic colorectal cancer."9.12Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. ( Bajetta, E; Bajetta, R; Celio, L; Colombo, A; Denaro, A; Di Bartolomeo, M; Dotti, K; Ferrario, E; Mancin, M; Pusceddu, S, 2007)
"To evaluate the efficacy and toxicity of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every 2 weeks on previously untreated advanced colorectal cancer patients in Chinese population."9.12A Phase II trial of oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX4) as first-line chemotherapy in advanced colorectal cancer: a China single-center experience. ( Bao, HY; Fang, WJ; Huang, S; Shen, P; Shi, GM; Xu, N; Yu, LF; Zhang, XC, 2007)
"Capecitabine and oxaliplatin are both synergistically active against metastatic colorectal cancer (MCRC)."9.12Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer. ( Benekli, M; Buyukberber, S; Coskun, U; Dikilitas, M; Er, O; Kaya, AO; Ozturk, B; Polat, M; Uner, A; Yamac, D; Yaman, E; Yildiz, R, 2007)
"We have evaluated the efficacy and safety of cetuximab plus FOLFIRI for irinotecan and oxaliplatin-refractory colorectal cancers."9.12A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer. ( Chang, HM; Kang, YK; Kim, MK; Kim, TW; Koo, DH; Lee, JL; Lee, JS; Lee, SS; Ryu, MH; Sym, SJ, 2007)
"This phase II study investigated the efficacy and safety of cetuximab combined with standard oxaliplatin-based chemotherapy (infusional fluorouracil, leucovorin, and oxaliplatin [FOLFOX-4]) in the first-line treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer (mCRC)."9.12Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. ( André, T; Casado, E; Cervantes, A; Ciardiello, F; de Gramont, A; Díaz-Rubio, E; Humblet, Y; Kisker, O; Soulié, P; Tabernero, J; Tortora, G; Valera, JS; Van Cutsem, E; Van Laethem, JL; Verslype, C, 2007)
"To evaluate the combination of bevacizumab with infusional 5-fluorouracil (5-FU), leucovorin (LV) and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (CRC) pretreated with combination regimens including irinotecan and oxaliplatin."9.12Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. ( Kim, HJ; Kim, SH; Kwon, HC; Lee, S; Oh, SY, 2007)
"This multicenter, randomized trial compared overall response rate between pemetrexed plus irinotecan (ALIRI) and leucovorin-modulated 5-fluorouracil plus irinotecan (FOLFIRI) in patients with advanced colorectal cancer."9.12A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer. ( Bazin, IS; Biakhov, MY; Blatter, J; Goldstein, D; Gorbounova, VA; Granov, DA; Hossain, AM; Kaiser, C; Ma, D; Underhill, C, 2007)
"Three agents with differing mechanisms of action are available for treatment of advanced colorectal cancer: fluorouracil, irinotecan, and oxaliplatin."9.11A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. ( Alberts, SR; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2004)
"This Nordic multicenter phase II study evaluated the efficacy and safety of oxaliplatin combined with the Nordic bolus schedule of fluorouracil (FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer."9.11Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. ( Berglund, A; Braendengen, M; Dahl, O; Fokstuen, T; Glimelius, B; Sørbye, H; Tveit, KM; Øgreid, D, 2004)
"The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first-line treatment in metastatic colorectal carcinoma (CRC)."9.11Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. ( Artale, S; Bajetta, E; Beretta, E; Biasco, G; Bonaglia, L; Bonetti, A; Buzzoni, R; Carreca, I; Cassata, A; Cortinovis, D; Di Bartolomeo, M; Ferrario, E; Frustaci, S; Iannelli, A; Lambiase, A; Mariani, L; Marini, G; Pinotti, G, 2004)
"The current study was designed to evaluate the antitumor activity and toxicity of capecitabine and oxaliplatin in previously untreated patients with advanced colorectal carcinoma."9.11Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. ( Marshall, JL; Meropol, NJ; Shields, AF; Zalupski, MM, 2004)
"The purpose is to determine the plasma pharmacokinetics, the maximum-tolerable dose and to preliminary evaluate the antitumor activity of irinotecan administered as a 7-day continuous infusion every 21 days in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed."9.11A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ( Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G, 2004)
"Our objective was to determine the maximum tolerated dose (MTD) of sequential raltitrexed (Tomudex) and 5-fluorouracil (5-FU) by bolus administration every 3 weeks in patients with advanced colorectal cancer (aCRC) and appendiceal adenocarcinoma."9.11Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer. ( Bertino, J; Dimery, I; Endres, S; Kelsen, DK; Kemeny, N; Saltz, L; Schwartz, GK; Tong, W; Welch, M, 2004)
"This phase II study evaluated a modified Japanese capecitabine regimen as first-line treatment for advanced/metastatic colorectal cancer."9.11A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. ( Kondo, Y; Nishisho, I; Sakamoto, J; Sakamoto, N; Takemiya, S, 2004)
"As single agents, irinotecan and oxaliplatin are active in colorectal cancer after fluorouracil (FU)-containing regimen failure."9.11Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients. ( Bajetta, E; Beretta, E; Buzzoni, R; Cortinovis, D; Di Bartolomeo, M; Dognini, G; Ferrario, E; Toffolatti, L, 2004)
"Irinotecan has proven anti-tumor activity as induction treatment in combination with 5-fluorouracil (5-FU) or as second-line treatment after 5-FU in patients with metastatic colorectal cancer."9.11Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. ( Batran, SA; Bokemeyer, C; Büchele, T; Haag, C; Hartmann, JT; Hofheinz, RD; Jäger, E; Kanz, L; Niederle, N; Oechsle, K; Pflüger, KH; Reis, HE; Wilke, HJ, 2004)
"Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (MCRC)."9.11XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. ( Brunet, R; Butts, C; Cassidy, J; Conroy, T; Debraud, F; Díaz-Rubio, E; Figer, A; Grossmann, J; Sawada, N; Schöffski, P; Sobrero, A; Tabernero, J; Twelves, C; Van Cutsem, E, 2004)
"Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of body weight every two weeks) and 411 to receive IFL plus placebo."9.11Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. ( Baron, A; Berlin, J; Cartwright, T; Fehrenbacher, L; Ferrara, N; Fyfe, G; Griffing, S; Hainsworth, J; Heim, W; Holmgren, E; Hurwitz, H; Kabbinavar, F; Novotny, W; Rogers, B; Ross, R, 2004)
"This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer."9.11Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004)
"Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer."9.11Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004)
"This study was designed to assess the safety and efficacy of capecitabine and mitomycin C (MMC) in previously untreated patients with advanced colorectal cancer (CRC)."9.11Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. ( Cunningham, D; Hill, ME; Norman, AR; Oates, J; Price, T; Rao, S; Ross, PJ; Shellito, P; Tebbutt, N, 2004)
"FOLFOX, a bimonthly combination of leucovorin, 5-fluorouracil and oxaliplatin, is active in metastatic colorectal cancer, but sometimes causes cumulative sensory neurotoxicity."9.11Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2004)
" In an effort to improve the therapeutic effect of a MAb-based regimen in colorectal carcinoma (CRC) patients, the effects of a combination of alpha-interferon (alpha-IFN), 5-fluorouracil (5-FU), granulocyte-macrophage colony-stimulating factor (GM-CSF) and mouse MAb17-1A was evaluated in 27 patients with metastatic disease."9.11Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. ( Frödin, JE; Liljefors, M; Mellstedt, H; Nilsson, B; Ragnhammar, P; Ullenhag, G, 2004)
"Bowel mucosal injury associated with 5-fluorouracil (5-FU) treatment might result in secondary lactose intolerance."9.11Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. ( Elomaa, I; Ikonen, M; Joensuu, H; Korpela, R; Ollus, A; Osterlund, P; Peuhkuri, K; Ruotsalainen, T, 2004)
"The aim of this study was to evaluate efficacy and safety of the combination chemotherapy with irinotecan plus capecitabine in patients with advanced colorectal adenocarcinoma."9.11First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. ( Baek, JH; Bang, SM; Cho, EK; Im, SA; Lee, JH; Oh, JH; Park, SH; Park, YS; Shin, DB, 2004)
"To evaluate the safety and efficacy of irinotecan (CPT-11) alternated with a weekly treatment for 4 weeks of oxaliplatin (L-OHP), high-dose leucovorin (LV) and a 48-hour 5-fluorouracil infusion (5-FU 48 h) as first-line chemotherapy for patients with advanced colorectal cancer (ACC)."9.11A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. ( Colarusso, D; Manzione, L; Pizza, C; Reggiardo, G; Rinaldi, A; Rosati, G; Tucci, A, 2004)
"The effectiveness of capecitabine, an oral fluoropyrimidine carbamate, is well documented in previously untreated metastatic colorectal cancer patients (overall response rate: 25%)."9.11Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. ( Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ, 2004)
" Patients with advanced, untreated, measurable colorectal cancer received sequential methotrexate (MTX) (days 1 and 15)-->l-OHP+FU (days 2 and 16) (200, 85 and 600 mg m(-2), respectively) followed by 3 weeks of CI FU (200 mg m(-2) day(-1)) given from day 29 to 50, modulated by weekly leucovorin (LV) (20 mg m(-2))."9.11Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. ( Barni, S; Belvedere, O; Beretta, GD; Frontini, L; Grossi, F; Guglielmi, A; Labianca, R; Pella, N; Puglisi, F; Sobrero, A; Zaniboni, A, 2004)
"Irinotecan (CPT-11) is an effective drug in patients with advanced colorectal cancer (CRC)."9.11Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. ( Balcells, M; Benavides, M; Carabantes, F; Cobo, M; García-Alfonso, P; Gil-Calle, S; Graupera, J; Muñoz-Martín, A; Pérez-Manga, G; Villar, E, 2004)
"This multicentre phase II study was designed to evaluate the antitumour activity and toxicity of bifractionated camptothecin (CPT-11) and 5-fluorouracil/ leucovorin (5-FU/LV) in the treatment of patients with metastatic colorectal cancer (MCC) who had been pretreated with 5-FU/LV-oxaliplatin (FOLFOX regimen)."9.11Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. ( Cesta, A; Lalli, A; Lullo, LD; Nuzzo, A; Rea, S; Recchia, F; Saggio, G, 2004)
"A combination of irinotecan 125 mg/m2, 5-fluorouracil (5-FU) 500 mg/m2, and leucovorin (LV) 20 mg/m2 (Saltz regimen; treatment on days 1, 8, 15, and 22 every 6 weeks) is widely used for the treatment of metastatic colorectal cancer."9.11Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. ( Arai, T; Goto, A; Hamaguchi, T; Hosokawa, A; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2004)
"In a previous phase I-II study we demonstrated that the FOLFOXIRI regimen [irinotecan 125-175 mg/m2 day 1, oxaliplatin 100 mg/m2 day 1, l-leucovorin (l-LV) 200 mg/m2 day 1, 5-fluorouracil (5-FU) 3800 mg/m2 as a 48-h chronomodulated continuous infusion starting on day 1, repeated every 2 weeks] has promising activity and efficacy in metastatic colorectal cancer."9.11First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. ( Allegrini, G; Andreuccetti, M; Brunetti, I; Cerri, E; Cupini, S; Falcone, A; Fontana, E; Marcucci, L; Masi, G; Ricci, S, 2004)
"The addition of oxaliplatin to fluorouracil (FU) and leucovorin (LV) improves the outcome of patients with colorectal cancer (CRC)."9.11Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. ( Benson, A; Brandt, DS; Burger, B; Garay, CA; Gupta, S; Gurtler, J; Hallman, D; Hochster, H; Kemeny, N; Kennedy, P; Polikoff, J; Shumaker, G; Wertheim, M, 2004)
"A weekly continuous 24-h infusion therapy with 5-fluorouracil (5-FU) preceded by a 2-h infusion of calcium folinate (CA-FA) was shown to be an effective first- and secondline treatment in advanced metastatic colorectal cancer."9.11Second-line treatment of advanced colorectal cancer with a weekly simultaneous 24-hour infusion of 5-fluorouracil and sodium-folinate: a multicentre phase II trial. ( Fritze, D; Kreuser, ED; Kuhfahl, J; Link, H; Pichlmeier, U; Schulte, F; Steinbrecher, C; Wagner, H; Wagner, T, 2004)
"The efficacy of combination therapy with irinotecan and capecitabine has been demonstrated for the first-line treatment of metastatic colorectal cancer (MCRC)."9.11Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study. ( Gnad-Vogt, U; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Pilz, L; Saussele, S; Wein, A, 2005)
"To determine the efficacy, impact on quality-of-life (QoL) and tolerability of two different irinotecan administration schedules in combination with capecitabine as first-line treatment of metastatic colorectal cancer."9.11A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. ( Bernhard, J; Borner, MM; Brauchli, P; Dietrich, D; Herrmann, R; Honegger, H; Koeberle, D; Lanz, D; Popescu, R; Rauch, D; Roth, AD; Saletti, P; Wernli, M, 2005)
"We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of protracted venous infusion (PVI) 5-fluorouracil (5-FU) against the standard bolus monthly regimen of 5-FU/leucovorin (LV) given for 6 months as adjuvant treatment in colorectal cancer (CRC)."9.11A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. ( Chau, I; Cunningham, D; Hickish, T; Hill, M; Iveson, T; Jodrell, D; Lofts, F; Norman, AR; Oates, JR; Ross, PJ; Tait, D; Webb, A, 2005)
"Capecitabine and irinotecan are commonly used in the treatment of metastatic colorectal cancer (CRC)."9.11UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. ( Andria, ML; Bever, J; Blanchard, RL; Carlini, LE; Gold, P; Hill, T; Meropol, NJ; Rogatko, A; Wang, H, 2005)
"Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC)."9.11Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. ( Hamm, JT; Hecht, JR; Kabbinavar, FF; Mass, R; McCleod, M; Nelson, B; Novotny, WF; Patel, T; Perrou, B; Schulz, J, 2005)
"Although irinotecan 350 mg m(-2) is a standard option for relapsed/refractory advanced colorectal cancer, there is some evidence that suggests that a higher dose may be more effective, with acceptable tolerability, following 5-fluorouracil (5-FU)."9.11Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. ( Bleiberg, H; Borner, M; Dirix, L; Gonzalez Baron, M; Gruia, G; Joosens, E; Morant, R; Roth, A; Sibaud, D; Van Belle, S; Van Cutsem, E; Van Laethem, JL, 2005)
"The objective of this study was to assess the efficacy and safety of two regimens of irinotecan, combined or alternated with bolus 5-fluorouracil (5-FU) and folinic acid (FA), and the Mayo Clinic regimen as first-line therapy for colorectal cancer (CRC)."9.11Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer. ( Artandi, M; Borner, M; Boussard, B; Carlsson, G; Espana, P; Graeven, U; Ridwelski, K; Rosales, AM; Schmiegel, W; Schölmerich, J, 2005)
"The aim of this study was to investigate the therapeutic value and safety of third-line treatment with mitomycin-C (MMC) and capecitabine (Xeloda) in patients with advanced colorectal cancer pretreated with combination regimens including 5-fluorouracil (5-FU), folinic acid (FA) and irinotecan (CPT-11) or 5-FU, FA and oxaliplatin (L-OHP)."9.11Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. ( Im, YH; Ji, SH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, SH; Lim, DH; Park, BB; Park, JO; Park, K; Park, KW; Park, YS, 2005)
"The combination of 5-fluorouracil (5-FU) plus leucovorin (LV) with oxaliplatin has become one of the standard treatments for advanced colorectal cancer (CRC)."9.11Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer. ( Abad, A; Antón, A; Aranda, E; Carrato, A; Cervantes, A; Diaz-Rubio, E; Guallar, JL; Manzano, JL; Marcuello, E; Martinez-Villacampa, M; Massutí, B; Navarro, M; Sastre, J, 2005)
"A phase I-II multicenter trial was conducted to define the maximal tolerated dose and describe the activity of an OCFL combination using oxaliplatin (OHP), irinotecan (CPT-11) and 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (CRC)."9.11Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. ( Allal, A; Bauer, J; Gervaz, P; Mentha, G; Morant, R; Philippe, M; Roth, AD; Ruhstaller, T; Seium, Y; Stupp, R; Trembleau, C, 2005)
"Irinotecan (IRI) and oxaliplatin (OXA) are effective in the treatment of colorectal cancer."9.11Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. ( Aravantinos, G; Bacoyiannis, C; Bamias, A; Basdanis, G; Chalkidou, S; Dimopoulos, M; Economopoulos, T; Fountzilas, G; Kalfarentzos, F; Kalofonos, HP; Karina, M; Kosmidis, P; Koutras, A; Papakostas, P; Pectasides, D; Samantas, E; Samelis, GF; Skarlos, D, 2005)
"To determine the tolerability of capecitabine in elderly patients with advanced colorectal cancer (CRC)."9.11Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. ( Bolaños, M; Casado, E; Escudero, P; Feliu, J; Gómez-Reina, MJ; González-Baron, M; Llosa, F; Lopez, R; Lopez-Gómez, L; Sanz-Lacalle, JJ; Vicent, JM; Yubero, A, 2005)
"Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA), a recombinant, humanized anti-vascular endothelial growth factor monoclonal antibody that inhibits tumor angiogenesis, has demonstrated survival benefit in patients with previously untreated metastatic colorectal cancer when combined with irinotecan/fluorouracil (FU)/leucovorin (LV; IFL)."9.11Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. ( Bergsland, E; Hambleton, J; Hurwitz, HI; Kabbinavar, FF; Mass, RD; Sarkar, S, 2005)
"Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma."9.11Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study. ( Casaretti, R; Cataldis, GD; Comella, P; Farris, A; Lucia, LD; Maiorino, L; Massidda, B; Natale, D; Palmeri, S; Tafuto, S, 2005)
"In a phase III trial, combining bevacizumab (BV)--a recombinant, humanized, monoclonal antibody targeting vascular endothelial growth factor--with irinotecan, bolus fluorouracil (FU), and leucovorin (LV; IFL) increased survival compared with IFL alone in first-line treatment of patients with metastatic colorectal cancer (CRC)."9.11Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. ( Berlin, J; Fehrenbacher, L; Hainsworth, JD; Hambleton, J; Heim, W; Holmgren, E; Hurwitz, HI; Kabbinavar, F; Novotny, WF, 2005)
"Irinotecan combined with continuous-infusion 5-fluorouracil (5FU) has been shown to be an effective and tolerable regimen in the treatment of metastatic colorectal cancer (MCRC)."9.11Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer. ( Asama, T; Ashida, T; Ayabe, T; Chisato, N; Ebisawa, Y; Kamiya, K; Kasai, S; Kohgo, Y; Kono, T; Tomita, I, 2005)
"Between July 2001 and September 2002, 49 eligible patients were enrolled in an open-label phase II study to assess the efficacy and safety of first-line treatment with capecitabine/irinotecan in metastatic colorectal cancer."9.11Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. ( Asmar, L; Boehm, KA; Cartwright, T; Encarnacion, C; Lopez, T; Vukelja, SJ, 2005)
"Seventy-two patients suffering from a metastatic colorectal cancer received, as first line treatment, a combination chronotherapy with 5-FU and folinic acid (infused from 10 pm to 10 am with a peak at 4 am, respectively at doses of 700 and 300 mg/m2 per day) and carboplatin (infused at the dose of 40 mg/m2 per day from 10 am to 10 pm with a peak at 4 pm)."9.11[Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study]. ( Biquet, JF; David, A; Delforge, M; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Materne, R; Moeneclaey, N; Weerts, J, 2005)
"Seventeen colorectal cancer patients received as first (12 cases) or second line (5 cases) treatment a combined chronotherapy with CPT 11 (infused at day 1 from 2 to 8 am; peak at 5 am), given with 5 FU (700 mg/m2 per day ; days 2-5) and folinic acid (300 mg/m2 per day, days 2-5) both infused from 10 pm to 10 am with a peak at 4 am, and carboplatin (40 mg/m3/day - days 2-5 ; infused from 10 am to 10 pm - peak at 4 pm)."9.11[Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer]. ( David, A; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N, 2005)
"The aim of this study was to determine in patients with previously untreated advanced colorectal cancer the maximum tolerated dose (MTD) and safety profile of irinotecan in combination with capecitabine, to identify a recommended dose and to determine the response rate and time to disease progression."9.11A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. ( Bakker, JM; Falk, S; Groenewegen, G; Kerr, DJ; Maughan, T; Nortier, JW; Punt, CJ; Rea, DW; Richel, DJ; Semiond, D; Smit, JM; Steven, N; Ten Bokkel Huinink, WW, 2005)
"To verify the effectiveness of oral 1-hexylcarbamoyl-5-fluorouracil (HCFU) in improving the surgical cure rate in advanced colorectal cancer, a multicenter randomized comparative study was conducted."9.11A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer. ( Kodaira, S; Kotake, K; Koyama, Y; Ohashi, Y, 2005)
"This study was designed to determine the effectiveness and tolerance of oxaliplatin, folinic acid (FA) and infusional 5-fluorouracil (5-FU) (FOLFOX-4) chemotherapy when used as a second-line treatment in patients with advanced colorectal cancer for whom an irinotecan-containing regimen failed."9.11Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience. ( Baek, JH; Bang, SM; Cho, EK; Han, SH; Lee, JH; Oh, JH; Park, SH; Shin, DB; Sung, JY, 2005)
" Glutamine may decrease chemotherapy-associated diarrhea."9.11A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. ( Ansari, R; Cheng, L; Helft, P; Juliar, B; Loehrer, P; Pan, CX; Pletcher, W; Seitz, D; Sweeney, C; Vinson, J, 2005)
"Protracted venous infusion 5-fluorouracil (5FU) combined with mitomycin C (MMC) has demonstrated significant activity against metastatic colorectal cancer."9.11Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. ( Chong, G; Cunningham, D; Dickson, JL; Hill, ME; Norman, AR; Oates, J; Price, TJ; Rao, S; Tebbutt, N, 2005)
"To investigate the gefitinib, fluorouracil (FU), leucovorin, and oxaliplatin regimen (IFOX) in previously treated patients with metastatic colorectal cancer."9.11Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. ( Advani, RH; Cho, CD; Fisher, GA; Ford, JM; Halsey, J; Kuo, T; Sikic, BI; Wakelee, HA, 2005)
"5-Fluorouracil remains a key drug in the treatment of colorectal cancer, and the development of a simple and effective test for selecting patients likely to benefit from postoperative adjuvant chemotherapy is an important objective."9.11Correlation between expression of orotate phosphoribosyl transferase and 5-fluorouracil sensitivity, as measured by apoptosis index in colorectal cancer tissue. ( Kamano, T; Kawai, K; Matsuda, M; Sakamoto, K; Watabe, S, 2005)
"The aim of the current study was to evaluate the activity and toxicity of a combination of oxaliplatin with bolus fluorouracil and leucovorin in colorectal cancer (CRC) patients pretreated for advanced disease with various schedules including continuous fluorouracil infusion."9.11Activity and toxicity of oxaliplatin and bolus fluorouracil plus leucovorin in pretreated colorectal cancer patients: a phase II study. ( Buccilli, A; Ciccarese, M; Ferraresi, V; Gabriele, A; Gamucci, T; Giampaolo, MA; Giannarelli, D; Mansueto, G, 2005)
"HLA-A2-positive patients with confirmed newly diagnosed metastatic colorectal cancer and elevated serum carcinoembryonic antigen (CEA) were randomized to receive three cycles of standard chemotherapy (irinotecan/high-dose 5-fluorouracil/leucovorin) and vaccinations with CEA-derived CAP-1 peptide admixed with different adjuvants [CAP-1/granulocyte macrophage colony-stimulating factor/interleukin-2 (IL-2), CAP-1/dSLIM/IL-2, and CAP-1/IL-2]."9.11Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. ( Anderson, KS; Ansén, S; Bohlen, H; Diehl, V; Geisen, C; Gracien, E; Jurkiewicz, E; Nadler, LM; Schmidt, M; Weihrauch, MR; Wittig, B; Wolf, J; Xia, Z, 2005)
"We examined patients with previously untreated metastatic colorectal cancer, who were enrolled into two phase I/II trials of combination chemotherapy (irinotecan, leucovorin, and 5-fluorouracil) and daily oral gefitinib."9.11Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. ( Brahmandam, M; Cantor, M; Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kinsella, K; Kulke, MH; Loda, M; Meyerhardt, JA; Michelini, AL; Namgyal, C; Ogino, S; Ryan, DP, 2005)
"A biweekly regimen of irinotecan 200 mg/m2 on day 1 and levo-leucovorin (LV) 250 mg/m2 plus 5-fluorouracil (5-FU) 850 mg/m2 via intravenous bolus on day 2 was assessed in 2 consecutive randomized trials in metastatic colorectal cancer (CRC)."9.11Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials. ( Buzzi, F; Comella, P; De Cataldis, G; De Lucia, L; Farris, A; Filippelli, G; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Natale, D; Palmeri, S; Roselli, M; Tafuto, S, 2005)
"We tested the hypothesis that the combination of trimetrexate (TMTX) and capecitabine (CAP) would be active in patients with previously treated metastatic colorectal cancer (CRC)."9.11A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer. ( Earle, M; Evans, T; Ferri, W; Friedland, D; Jacobs, SA; Matin, K; Pinkerton, R; Ramanathan, RK; Richards, T; Troetschel, M; Volkin, R; Wieand, S; Wong, MK, 2005)
"This randomised, open-label trial compared oral tegafur (FT)/leucovorin (LV) with the intravenous bolus 5-fluorouracil (5-FU)/LV as first-line chemotherapy for advanced colorectal cancer (CRC)."9.11Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer. ( Arcusa, A; Batiste-Alentorn, E; Boleda, M; Campos, JM; Cirera, L; de Mendizábal, EV; de Olaguer, JP; Escudero, P; Galan, A; Guasch, I; Losa, F; Manzano, H; Méndez, M; Nogué, M; Saigí, E; Salud, A; Vicente, P, 2005)
"Patients with liver-only metastases from colorectal cancer deemed not optimally resectable by a surgeon with expertise in liver surgery received fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)."9.11Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. ( Alberts, SR; Dakhil, SR; Donohue, JH; Goldberg, RM; Horvath, WL; Levitt, R; Mahoney, MR; Nair, S; Rowland, K; Sargent, DJ; Sternfeld, WC, 2005)
"com) and infusional 5-fluorouracil (5-FU) as second-line therapy in metastatic colorectal cancer (MCRC)."9.11Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. ( Gamucci, T; Gasparini, G; Gattuso, D; Longo, R; Mariani, L; Morabito, A; Sarmiento, R; Torino, F; Vitale, S, 2005)
"To assess the feasibility and activity of a combination schedule with irinotecan (CPT-11), oxaliplatin (L-OHP), brief infusional fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer (MCC) patients."9.11An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. ( Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L, 2005)
"To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with bolus and continuous infusion of 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFIRI regimen) as first-line treatment of elderly patients with metastatic colorectal cancer (MCC)."9.11Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. ( Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Milaki, G; Pallis, A; Souglakos, J; Xenidis, N, 2005)
"Pemetrexed and irinotecan have demonstrated antitumor activity as single agents in lung, pancreatic, breast, and colorectal cancer (CRC)."9.11Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer. ( Becker, K; Hochster, H; Hong, S; John, W; Kettner, E; Kroning, H; Lordick, F; Macdonald, J; Ramanathan, RK; Schmoll, HJ, 2005)
"Irinotecan and raltitrexed are active against advanced colorectal cancer, act through different mechanisms, and have non-overlapping toxicity profiles."9.10Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. ( Aparicio, J; de las Peñas, R; Farrés, J; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM; Yuste, AL, 2002)
"We evaluated the efficacy and safety of the weekly combination of etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer (ACC), previously treated with weekly LV + 5-FU."9.10Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer. ( Diamantis, T; Dimitrakopoulos, A; Gennatas, K; Kosmas, C; Paliaros, P; Papastratis, G; Tsavaris, N; Tsipras, H; Vadiaka, M, 2002)
"To determine the feasibility, recommended doses, plasma pharmacokinetics, and antitumor activity of a biweekly chemotherapy regimen with oxaliplatin (L-OHP), irinotecan (CPT-11), infusional fluorouracil (5-FU), and leucovorin (LV) in metastatic colorectal cancer patients."9.10Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. ( Allegrini, G; Brunetti, IM; Conte, P; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G; Pfanner, E, 2002)
"Overall results of this study indicate that the administration of clinically relevant single-agent doses of both capecitabine and oxaliplatin is feasible and seems to result in promising therapeutic activity in patients with advanced colorectal cancer."9.10Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer. ( Huber, H; Kornek, GV; Längle, F; Raderer, M; Scheithauer, W; Schmid, K; Schüll, B, 2002)
"To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)."9.10Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002)
"In the present study, we evaluated the efficacy and safety of the weekly combination of etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer (ACC), previously treated with weekly LV+5-FU."9.10Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer. ( Gennatas, K; Kosmas, C; Kouraklis, G; Margaris, E; Papastratis, G; Rokana, S; Skopelitis, E; Tsavaris, N; Vadiaka, M; Xila, V; Zografos, G, 2002)
"Irinotecan (CPT-11) has been shown to prolong survival and improve quality of life in comparison to best supportive care in colorectal cancer patients with pretreatment of bolus 5-fluorouracil (5-FU)."9.10Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study. ( Emig, M; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, R; Pilz, L; Queisser, W; Samel, S; Willeke, F, 2002)
"We investigated the activity of irinotecan given with a more convenient modified bimonthly de Gramont regimen of bolus and infusional 5-fluorouracil [IrMdG] in advanced or metastatic colorectal cancer in the first and second line setting."9.10Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. ( Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT, 2002)
"Most patients with colorectal cancer (CRC) who have failed initial 5-fluorouracil (5-FU) chemotherapy have worsening of disease-related symptoms (DRS) and quality of life (QOL)."9.10The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial. ( Feld, R; Fields, A; Goel, R; Hedley, D; Jolivet, J; Lee, IM; Maroun, J; Michael, M; Moore, MJ; Oza, A; Pintilie, M, 2002)
"This multicentre phase II study evaluated the efficacy and safety of irinotecan combined with the Nordic schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line therapy in patients with advanced colorectal cancer."9.10Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. ( Boussard, B; Frödin, JE; Glimelius, B; Kjaer, M; Linné, T; Oulid-Aïssa, D; Pfeiffer, P; Pyrhönen, S; Ristamäki, R; Skovsgaard, T; Tveit, KM, 2002)
"The efficacy and safety of preoperative chemotherapy with carmofur (HCFU) for colorectal cancer were evaluated in a randomized controlled study involving 63 institutes in the Kanto area."9.10[Neo-adjuvant chemotherapy with carmofur for colorectal cancer--a multi-institutional randomized controlled study]. ( Ishikawa, H; Iwasaki, Y; Kanazawa, K; Kitajima, M; Kodaira, S; Kotake, K; Koyama, Y; Miyata, M; Nagamachi, Y; Omoto, R; Shida, S; Tajima, Y; Tamakuma, S, 2002)
"The purpose of this study was to evaluate the efficacy and tolerance of the bimonthly administration of oxaliplatin in combination with high-dose leucovorin and infusional 5-fluorouracil (5-FU) (FOLFOX2 regimen) in patients with advanced colorectal cancer (ACC) who did not respond or whose disease progressed within 3 months after front-line treatment with CPT-11-containing regimens."9.10Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC). ( Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Panopoulos, C; Papadouris, S; Sarra, E; Souglakos, J; Vardakis, N, 2002)
"This phase II trial investigated the safety and efficacy of two doses of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, plus fluorouracil (FU)/leucovorin (LV) versus FU/LV alone in patients with metastatic colorectal cancer."9.10Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. ( Bergsland, E; Fehrenbacher, L; Griffing, S; Hurwitz, HI; Kabbinavar, F; Lieberman, G; Meropol, NJ; Novotny, WF, 2003)
"The effect of different dose intensities of 5-fluorouracil (5-FU) in advanced colorectal cancer was investigated."9.10Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. ( Berglund, A; Carlsson, G; Frödin, JE; Glimelius, B; Gustavsson, B; Hansen, F; Jakobsen, A; Kjaer, M; Madsen, EL; Poulsen, JP; Sandberg, E, 2002)
"The aim of this study was to investigate whether N-(phosphonacetyl)-L-aspartic acid (PALA) can enhance the activity of low-dose methotrexate (LD-MTX) modulated infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer."9.10High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. ( Baron, B; Bleiberg, H; Blijham, GH; Couvreur, ML; De Greve, J; Genicot, B; Jansen, RL; Kok, TC; Nortier, JW; Wagener, T; Wils, J, 2003)
"To evaluate the efficacy and safety of neoadjuvant treatment comprising weekly high-dose 5-fluorouracil (5-FU) as a 24-hour infusion, folinic acid (FA) and biweekly oxaliplatin (L-OHP), followed by metastatic resection in patients with primarily resectable liver metastases of colorectal cancer (CRC)."9.10Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. ( Baum, U; Brückl, W; Fuchs, F; Günther, K; Hahn, EG; Hanke, B; Hohenberger, W; Merkel, S; Ott, R; Papadopoulos, T; Reck, T; Riedel, C; Wein, A, 2003)
" We did a randomised trial to compare an intrahepatic arterial (IHA) fluorouracil and folinic acid regimen with the standard intravenous de Gramont fluorouracil and folinic acid regimen for patients with adenocarcinoma of the colon or rectum, with metastases confined to the liver."9.10Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. ( Buckels, J; Cain, D; Kerr, DJ; Ledermann, J; Mayer, D; McArdle, CS; Schlag, PM; Sherlock, DJ; Stephens, RJ; Taylor, I, 2003)
"This phase II study was designed to evaluate the efficacy and toxicities of oral doxifluridine plus leucovorin as a randomized trial with those of intravenous 5-fluorouracil (5-FU) plus leucovorin in previously untreated metastatic colorectal cancer (CRC)."9.10Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin. ( Ahn, JH; Kang, YK; Kim, JC; Kim, JG; Kim, TW; Kim, WK; Lee, JH; Lee, JS; Min, YJ; Yu, CS, 2003)
"To assess the relationship between systemic exposure to capecitabine metabolites and parameters of efficacy and safety in patients with advanced or metastatic colorectal cancer from two phase III studies."9.10Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. ( Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL, 2003)
"Capecitabine and oxaliplatin, two new agents with potential synergistic activity, have demonstrated promising antitumor efficacy in advanced colorectal cancer (ACC)."9.10Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. ( Depisch, D; Kornek, GV; Kovats, E; Lang, F; Lenauer, A; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B, 2003)
"Out of various high-dose 5-fluorouracil (5-FU) regimens given with or without folinic acid (FA), the optimal 5-FU schedule has still to be defined as treatment for metastatic colorectal cancer (CRC)."9.10Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study. ( Boehme, M; Galle, PR; Gutzler, F; Moehler, M; Raeth, U; Rudi, J; Steinmann, S; Stremmel, W, 2003)
"Because no consensus exists regarding recommendable dose levels for irinotecan, an intrapatient dose escalation phase I-II study was initiated in previously treated patients with colorectal cancer."9.10Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with Fluorouracil-based chemotherapy: a study to determine recommendable therapeutic dosage. ( Alvarez, E; Buesa, JM; Carrasco, J; Esteban, E; Fra, J; Jiménez Lacave, A; Muñiz, I; Sala, M; Viéitez, JM, 2003)
" In preclinical models, there appears to be additive or synergistic effects when combining 5-Fluorouracil (5-FU) with nonsteroidal anti-inflammatory agents (NSAIDs) for the treatment of colorectal neoplasms."9.10Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. ( Ashfaq, R; Becerra, CR; Frenkel, EP; Gaynor, RB, 2003)
"In North America, no effective therapy has been available for patients with progressive metastatic colorectal cancer after front-line treatment with irinotecan, bolus fluorouracil (FU), and leucovorin (IFL)."9.10Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. ( Berlin, JD; Bigelow, RH; Burger, BG; Garay, CA; Gupta, S; Haller, DG; Hart, LL; Le Bail, N; Marshall, JL; Oza, AM; Ramanathan, RK; Rothenberg, ML, 2003)
"Our results suggest that irinotecan and MMC combination therapy is effective and well tolerated in patients with fluoropyrimidine-resistant metastatic colorectal cancer."9.10Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. ( Ambo, T; Arai, Y; Denda, T; Hyodo, I; Ohtsu, A; Shirao, K; Yamada, Y, 2003)
"Irinotecan has shown activity in advanced colorectal cancer resistant to leucovorin and fluorouracil."9.10Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M, 2003)
"We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of 5-fluorouracil (5-FU) delivered by protracted intravenous infusion (PVI 5-FU) against the standard bolus regimen of 5-FU and folinic acid (5-FU/FA) given for 6 months as adjuvant treatment in colorectal cancer."9.10Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. ( Chau, I; Cunningham, D; Hickish, T; Hill, M; Iveson, T; Jodrell, D; Lofts, F; Norman, AR; Oates, J; Ross, PJ; Saini, A; Tait, D, 2003)
"In this multicenter phase II study the efficacy and safety of the alternating schedule of irinotecan (CPT-11) with bolus 5-fluorouracil (5-FU) and leucovorin (LV) were assessed as first-line chemotherapy in patients with metastatic colorectal cancer (CRC)."9.10A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer. ( Aparicio, J; Borrega, P; de la Puente, CG; Lorenzo, A; Moreno-Nogueira, JA; Pica, JM; Reina, JJ; Rueda, A; Salvador, J, 2003)
"Irinotecan (CPT-11) and raltitrexed are active against advanced colorectal cancer (ACC), act through different mechanisms, and have only partially overlapping toxicity profiles."9.10Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. ( Aparicio, J; Bosch, C; Busquier, I; Díaz, R; Fernández-Martos, C; Galán, A; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM, 2003)
"Three different therapeutic regimens of irinotecan (CPT-11) in combination with 5-fluorouracil (5-FU) and folinic acid (FA) were evaluated for efficacy and safety in the first-line therapy of advanced colorectal cancer."9.10A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. ( Boussard, B; Bouzid, K; Khalfallah, S; Padrik, P; Piko, B; Plate, S; Pshevloutsky, EM; Purkalne, G; Serafy, M; Tujakowski, J, 2003)
"To determine the activity of biweekly oxaliplatin, combined with weekly bolus fluorouracil (FU) and low-dose leucovorin (LV) chemotherapy (bFOL), as first-line therapy for patients with metastatic colorectal cancer."9.10Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. ( Chachoua, A; Escalon, J; Hochster, H; Muggia, F; Speyer, J; Zeleniuch-Jacquotte, A, 2003)
"The purpose of this study was to determine the efficacy and toxicity of oxaliplatin in combination with weekly bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with 5-FU-pretreated advanced colorectal cancer."9.10Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study. ( Changchien, CR; Chen, JS; Chiang, JM; Hsieh, PS; Tang, R; Yang, TS; Yeh, CY, 2003)
"This study was designed to evaluate the safety and tolerability of oxaliplatin combined with weekly boluses of 5-fluorouracil (5-FU) and low doses of leucovorin (LV) and to determine objective response, progression-free survival, and overall survival of patients with previously untreated advanced colorectal cancer."9.10Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer. ( Arcediano, A; Cassinello, J; Colmenarejo, A; Escudero, P; García, I; González del Val, R; Guillem, V; Marcos, F; Marfà, X; Oruezábal, MJ; Pérez-Carrión, R; Pujol, E; Salud, A; Valero, J, 2003)
"Capecitabine and oxaliplatin are both active anticancer agents in the treatment of patients with advanced colorectal cancer."9.10Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. ( Cognetti, F; Ferraresi, V; Gabriele, A; Gamucci, T; Giannarelli, D; Nardoni, C; Pino, MS; Zeuli, M, 2003)
"To define the maximum-tolerated dose (MTD) and to evaluate the dose-limiting toxicities (DLTs) of the combination of capecitabine and irinotecan in patients with metastatic colorectal cancer."9.10Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study. ( Achterrath, W; Frings, S; Harstrick, A; Rustum, YM; Schleucher, N; Seeber, S; Tewes, M; Vanhoefer, U; Wilke, HJ, 2003)
" irinotecan, 5-fluorouracil (5-FU) and leucovorin (LV) with hepatic arterial infusion (HAI) of pirarubicin in non-resectable liver metastases from colorectal cancer."9.10Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). ( Auroux, J; Aziza, T; Braud, AC; Bugat, R; Buyse, M; Cherqui, D; Dupuis, O; Fagniez, PL; Ganem, G; Guimbaud, R; Haddad, E; Kobeiter, H; Piedbois, P; Piolot, A; Tayar, C; Valleur, P; Zelek, L, 2003)
"To evaluate the toxicity and efficacy of a modified deGramont regimen of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin in patients with advanced colorectal cancer who have progressed on at least one but not more than two prior chemotherapy regimens."9.10A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. ( Catarius, KJ; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Mayer, RJ; Ryan, DP; Stuart, K; Winkelmann, J, 2003)
"The tolerance and efficacy of oxaliplatin and irinotecan for metastatic colorectal cancer are unknown in elderly patients."9.10Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. ( Aparicio, T; Artru, P; Belloc, J; Desramé, J; Dominguez, S; Etienney, I; Ezenfis, J; Lecomte, T; Locher, C; Mabro, M; Mitry, E; Montembault, S; Vayre, L, 2003)
"The combination of irinotecan (CPT-11), oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) is one of the possibilities to overcome chemoresistance in advanced colorectal cancer (ACRC) patients."9.10A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients. ( Bria, E; Garufi, C; Sperduti, I; Terzoli, E; Vanni, B; Zappalà, AM, 2003)
"We investigated the pharmacokinetics (PK), preliminary clinical results and toxicity of chronomodulated oxaliplatin (OHP) plus 5-fluorouracil (5-FU) without folinic acid (FA) in 13 patients with metastatic colorectal cancer."9.10Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer. ( Arpicco, S; Brusa, P; Bumma, C; Cattel, L; Infante, L; La Grotta, G; Passera, R, 2003)
" once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment."9.10Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003)
"This multicenter, open-label, phase II study was performed to assess the efficacy and toxicity of irinotecan 350 mg/m2 intravenously every 3 weeks in patients with advanced colorectal cancer (CRC) previously treated with 5-fluorouracil (5-FU)."9.10A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil. ( Arizcun, A; Cruz, JJ; de la Torre, A; Diz, P; Duarte, I; España, P; García López, MJ; García-Girón, C; Martínez del Prado, P; Méndez, M; Navalon, M; Pujol, E; Salut, A, 2003)
"This study combined oxaliplatin with the Nordic bolus schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer."9.10Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. ( Dahl, O; Sørbye, H, 2003)
") 5-fluorouracil (5-FU)/LV chemotherapy in metastatic colorectal cancer and to compare 5-FU exposure with these two treatment options."9.10Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ( Borner, MM; Caponigro, F; Comella, G; de Boer, RF; de Wit, R; Fumoleau, P; Greim, G; Martin, C; Peters, GJ; Schoffski, P; Sulkes, A; van der Born, K; Wanders, J, 2002)
"Twenty-two patients with unresectable liver metastases from colorectal cancer were treated with continuous HAI of 300 mg/m2 5-fluorouracil for 5 days a week and 6 mg/m2 cisplatin for 2 hours on 5 consecutive days a week."9.10Protracted hepatic arterial infusion with low-dose cisplatin plus 5-fluorouracil for unresectable liver metastases from colorectal cancer. ( Baba, H; Endo, K; Ikeda, Y; Kohnoe, S; Okamura, T; Tajima, T; Toh, Y; Yamamoto, M, 2002)
"The combination of CPT-11 with 5-fluorouracil (5-FU) in advanced colorectal cancer (ACC) represents an attractive approach."9.10Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. ( Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kandilis, K; Kouroussis, C; Mavroudis, D; Sarra, E; Souglakos, J; Vamvakas, L; Ziras, N, 2002)
"Hand-foot syndrome (HFS) has been previously reported as a side effect in 45-56% of patients treated with capecitabine."9.10Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. ( Abushullaih, S; Hoff, PM; Munsell, M; Saad, ED, 2002)
"The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-Fluorouracil (5-FU)+Leucovorin (LV)."9.10Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. ( Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M, 2002)
"Two randomised studies were performed with trimetrexate (TMTX) as a biochemical modulator of 5-fluorouracil (5-FU)/leucovorin (LV) in advanced colorectal cancer (ACC), one in Europe and one in the United States."9.10Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer. ( Blanke, CD; Hammershaimb, L; Punt, CJ; Zhang, J, 2002)
"To study tolerability and efficacy of an intensified chronomodulated schedule of fluorouracil (5-FU) and l-folinic acid (l-FA) as first-line treatment of metastatic colorectal cancer, 5-FU was given near individually determined dose-limiting toxicity in a multicenter phase II trial."9.10Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. ( Adenis, A; Chevalier, V; Chipponi, J; Chollet, P; Coudert, B; Curé, H; Focan, C; Kwiatkowski, F; Lévi, F; Niezgodzki, G; Perpoint, B; Pezet, D; Tubiana-Mathieu, N, 2002)
"Cimetidine has been shown to have beneficial effects in colorectal cancer patients."9.10Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. ( Imaeda, Y; Kobayashi, K; Matsumoto, S; Okamoto, T; Suzuki, H; Umemoto, S, 2002)
"To compare the efficacy and tolerability of eniluracil (EU)/fluorouracil (5-FU) with that of 5-FU/leucovorin (LV) as first-line therapy for patients with metastatic/advanced colorectal cancer."9.10Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. ( Ansari, RH; Bell, WN; Colwell, B; Levin, J; McGuirt, PV; Pazdur, R; Schilsky, RL; Thirlwell, MP; West, WH; White, RL; Wong, A; Yates, BB, 2002)
"To determine the efficacy and tolerability of combining oxaliplatin with capecitabine in the treatment of advanced nonpretreated and pretreated colorectal cancer."9.10Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. ( Borner, MM; Brauchli, P; Castiglione-Gertsch, M; Dietrich, D; Goldhirsch, A; Hanselmann, S; Herrmann, R; Honegger, H; Morant, R; Müller, S; Pestalozzi, BC; Roth, AD; Saletti, P; Stupp, R; Wernli, M, 2002)
"This phase II study was designed to evaluate the efficacy and toxicity of 3-h interval sequential methotrexate (MTX) and 5-fluorouracil (5-FU) with leucovorin (LV) rescue in the treatment of patients with metastatic colorectal cancer."9.10Effect of a 3-hour interval between methotrexate and 5-fluorouracil in the treatment of metastatic colorectal cancer. ( Hamaguchi, T; Haruyama, K; Matsumura, Y; Muro, K; Shimada, Y; Shirao, K; Sugano, K; Yamada, Y, 2002)
"5-fluorouracil remains the standard therapy for patients with advanced/metastatic colorectal cancer."9.10Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study. ( Blackstock, AW; Case, D; Higgs, V; Melin, SA; Savage, P; Tomlinson, SK; White, DR, 2002)
"A phase II trial investigated the activity and toxicity of a bolus administration schedule of oxaliplatin, fluorouracil (5-FU), and leucovorin (LV) therapy in patients with untreated advanced colorectal cancer."9.10Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. ( Amadori, D; Cruciani, G; Giovanis, P; Marangolo, M; Nicolini, M; Oliverio, G; Panzini, I; Pasquini, E; Ravaioli, A; Rossi, A; Tassinari, D; Turci, D; Zumaglini, F, 2002)
"To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with oxaliplatin (L-OHP) plus fluorouracil (5-FU)/leucovorin (LV) (de Gramont regimen) as first-line treatment of metastatic colorectal cancer (MCC)."9.10Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. ( Agelaki, S; Androulakis, N; Athanasiadis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, Ch; Mavroudis, D; Samonis, G; Souglakos, J; Tsetis, D; Vardakis, N, 2002)
"To evaluate the safety profile of capecitabine using data from a large, well-characterized population of patients with metastatic colorectal cancer treated in two phase II studies."9.10First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. ( Bajetta, E; Boyer, M; Bugat, R; Burger, U; Cassidy, J; Garin, A; Graeven, U; Hoff, P; Maroun, J; Marshall, J; McKendric, J; Osterwalder, B; Pérez-Manga, G; Rosso, R; Rougier, P; Schilsky, RL; Twelves, C; Van Cutsem, E, 2002)
"The aim of this multicenter prospective study was to evaluate the role of intratumoral parameters related to fluorouracil (FU) sensitivity in 103 metastatic colorectal cancer patients receiving FU-folinic acid."9.10Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. ( Bourgeon, A; Chamorey, E; Chazal, M; Delpero, JR; Etienne, MC; Formento, JL; Formento, P; Francoual, M; Laurent-Puig, P; Letoublon, C; Magné, N; Milano, G; Pezet, D; Renée, N; Rosty, C; Seitz, JF, 2002)
"To evaluate the activity and safety of an alternating schedule of irinotecan (CPT-11) with high-dose 5-fluorouracil (5-FU) given as a weekly 48-hour infusion in combination with leucovorin (LV) in the first-line treatment of metastatic colorectal cancer (MCRC) patients."9.10A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer. ( Manzione, L; Reggiardo, G; Rosati, G; Rossi, A, 2002)
"The combination of irinotecan plus 5-fluorouracil and folinic acid has clinical and survival benefits over 5-fluorouracil and folinic acid alone in the setting of first line treatment of metastatic colorectal cancer."9.10Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. ( Cunningham, D; Falk, S; Jackson, D, 2002)
"To determine the maximum-tolerated dose (MTD) of a weekly schedule of irinotecan (CPT-11), leucovorin (LV), and a 24-hour infusion of fluorouracil (5-FU24h) as first-line chemotherapy in advanced colorectal cancer and to assess preliminary data on the antitumor activity."9.09Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. ( Achterrath, W; Harstrick, A; Köhne, CH; Rustum, YM; Seeber, S; Vanhoefer, U; Wilke, H, 1999)
"The aim of this prospective study was to assess the efficacy, clinical benefit and safety of CPT-11 (irinotecan) in patients with stringently-defined 5-fluorouracil-resistant metastatic colorectal cancer (CRC)."9.09Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). ( Alexopoulos, CG; Blanc, C; Bleiberg, H; Blijham, GH; Cholet, P; Cote, C; Cunningham, D; Dirix, L; Fillet, G; Hérait, P; Levi, F; Panagos, G; Punt, CJ; Symann, M; Ten Bokkel Huinink, WW; Unger, C; Van Cutsem, E; Van Groeningen, C; Vannetzel, JM; Wils, J, 1999)
"In a prospective multicenter trial, 279 patients with metastatic colorectal cancer who had failed 5-fluorouracil therapy were randomized 2:1 to receive either best supportive care (BSC) plus treatment with the topoisomerase I inhibitor, irinotecan (CPT-11; Rhône-Poulenc Rorer, Antony, France), at a dose of 350 mg/m2 every 3 weeks or BSC alone."9.09A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. ( Cunningham, D; Glimelius, B, 1999)
"In a multicenter phase III trial, 267 patients with nonbulky metastatic colorectal cancer who had failed first-line 5-fluorouracil (5-FU) therapy were randomized to receive second-line treatment with either the new topoisomerase agent, irinotecan (Rhône-Poulenc Rorer, Antony, France), or a high-dose infusional 5-FU regimen."9.09Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group. ( Blijham, GH; Van Cutsem, E, 1999)
"Our objective was to establish the balance between costs and effects of treatment with Tomudex (raltitrexed) as an alternative to treatment with 5-fluorouracil (5-FU) plus leucovorin (LV) in patients with advanced colorectal cancer."9.09An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer. ( Byttebier, G; Groener, MG; Rutten, FF; van Hout, BA; van Ineveld, BM, 1999)
"The combination of 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (I-OHP) was shown to be both more active against metastatic colorectal carcinoma and better tolerated if the drug delivery rate was chronomodulated according to circadian rhythms rather than constant."9.09A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. ( Brienza, S; Chollet, P; Dogliotti, L; Focan, C; Le Rol, A; Letourneau, Y; Lévi, F; Llory, JF; Perpoint, B; Rotarski, M; Zidani, R, 1999)
"This multicenter phase II study was designed to assess the efficacy of the alternating schedule of tomudex with methotrexate (MTX)/5-fluorouracil (5-FU)/leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer."9.09A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. ( Agostinelli, R; Baldelli, AM; Barni, S; Cascinu, S; Catalano, G; Catalano, V; Frontini, L; Gasparini, G; Giuliodori, L; Labianca, R; Martignoni, G; Mattioli, R; Silva, RR, 1999)
"To evaluate the objective tumor response rates and toxicities of leucovorin (LV) plus fluorouracil (5-FU) cancer regimen combined with oxaliplatin (85 mg/m(2)) every 2 weeks on metastatic colorectal cancer patients with documented proof of progression while on bimonthly LV and 5-FU alone."9.09Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. ( André, T; Beerblock, K; Bensmaine, MA; Bouché, O; Carola, E; de Gramont, A; Desseigne, F; Dupont-André, G; François, E; Louvet, C; Lucas, V; Merrouche, Y; Morvan, F, 1999)
"To determine whether immunohistochemical thymidylate synthase (TS) quantitation predicts for clinical outcome in patients with advanced colorectal cancer treated by fluorouracil (FUra)-based chemotherapy."9.09Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. ( Antonelli, G; Aschele, C; Baldo, C; Casazza, S; Debernardis, D; Lionetto, R; Maley, F; Sobrero, A; Tunesi, G, 1999)
"Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs."9.09A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999)
"To study how adding oxaliplatin (l-OHP) to chronomodulated fluorouracil (5-FU)-leucovorin (LV) affected the objective response rate, as first-line treatment of metastatic colorectal cancer."9.09Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. ( Adam, R; Bertheaut-Cvitkovic, F; Chollet, P; Coudert, B; Faggiuolo, R; Focan, C; Giacchetti, S; Larregain-Fournier, D; Le Bail, N; Le Rol, A; Letourneau, Y; Lévi, F; Llory, JF; Misset, JL; Perpoint, B; Walter, S; Zidani, R, 2000)
"The potential of raltitrexed (Tomudex) in combination with 5-fluorouracil (5-FU) as treatment for advanced colorectal cancer has been investigated in two phase I clinical trials."9.09Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials. ( González Barón, M; Harstrick, A; Schwartz, GK, 1999)
"Thirty-seven colorectal cancer patients with grade 1-4 diarrhea (NCICTC) caused by chemotherapy with 5-FU-containing regimens, received oral loperamide at the initial dose of 4 mg followed by 4 mg every 8 h (total dose 16 mg/24 h)."9.09High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. ( Agostinelli, R; Amadori, D; Bichisao, E; Cascinu, S; Catalano, G; Catalano, V; Giordani, P; Luppi, G; Sansoni, E; Silingardi, V, 2000)
"CPT-11 (irinotecan) has shown activity in patients with advanced colorectal cancer resistant to leucovorin (LV) and 5-fluorouracil (5-FU)."9.09CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. ( André, T; Carola, E; Couteau, C; de Gramont, A; Gilles-Amar, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F, 1999)
"The aim of this study was to develop a phase II study gauging the contribution of a daily low-dose of carboplatin combined with 5-fluorouracil (5-FU) and folinic acid (FOL) in a chronotherapy schedule for advanced colorectal cancer patients."9.09Chronotherapy with 5-fluorouracil, folinic acid and carboplatin for metastatic colorectal cancer; an interesting therapeutic index in a phase II trial. ( Focan, C; Focan-Henrard, D; Kreutz, F; Moeneclaey, N, 2000)
"To evaluate in patients with advanced colorectal cancer (CRC) three treatment regimens of oral capecitabine in order to select the most appropriate regimen for testing in phase III."9.09Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. ( Allman, D; Burger, HU; Cassidy, J; Dalley, D; Dirix, L; Findlay, M; Kocha, W; Osterwalder, B; Pazdur, R; Schölmerich, J; Seitz, JF; Twelves, C; Van Cutsem, E; Verweij, J, 2000)
"Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil."9.09Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. ( Alakl, M; Awad, L; Carmichael, J; Cunningham, D; Douillard, JY; Gruia, G; Iveson, T; James, RD; Jandik, P; Karasek, P; Navarro, M; Roth, AD; Rougier, P, 2000)
"It has been shown that irinotecan is superior to infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer after 5-FU failure."9.09Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. ( Bellanger, A; Durand-Zaleski, I; Juhel, H; Levy-Piedbois, C; Piedbois, P; Schmitt, C, 2000)
"MF (protracted infusion 5-fluorouracil (5-FU), 300 mg/m2/24 hours plus bolus mitomycin, 7 mg/m2 every 6 weeks, maximum 4 doses), was recently shown in a randomised trial to be superior to protracted 5-FU alone, as first-line chemotherapy for metastatic colorectal cancer (Ross et al."9.09Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. ( Chester, JD; Dent, JT; Ride, E; Seymour, MT; Wilson, G, 2000)
" One hundred thirty-six patients with metastatic colorectal cancer who failed to respond to a 5-fluorouracil-based treatment received 714 cycles of irinotecan."9.09Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. ( Adenis, A; Burki, F; Douillard, JY; Dufour, P; Marty, M; Mignard, D; Mousseau, M; Rougier, P; Wendling, JL; Ychou, M, 2000)
"The purpose of this study was to evaluate the efficacy, toxicity, and safety of outpatient chemotherapy with weekly high-dose 5-fluorouracil (HD-5FU) in previously treated patients (pts) with metastatic colorectal cancer."9.09Phase II study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer. ( Cohen, Y; Lavrenkov, K; Mermershtain, W, 2000)
"The aim of this study was to clarify whether increased 5-fluorouracil (5-FU) uptake by tumor tissue following preoperative UFT administration is a prognostic factor after surgery in colorectal cancer patients."9.09Preoperative UFT administration for patients with advanced colorectal cancer--increased uptake of 5-fluorouracil by tumor tissue is a prognostic factor. ( Ayabe, H; Eida, K; Furukawa, M; Ino, M; Ishikawa, H; Kunisaki, T; Nakagoe, T; Nakamura, Y; Nogawa, T; Sawai, T; Tobinaga, K; Tsuji, T, 2000)
"We performed combination chemotherapy adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in 11 patients with gastric cancer and 7 with colorectal cancer."9.09[The effect of combination chemotherapy to adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in patients with gastric or colorectal cancer]. ( Iesato, H; Kamoshita, N; Kato, Y; Morishita, Y; Nagaoka, H; Ohwada, S; Ohya, T; Okabe, T; Takeyoshi, I; Yokomori, T, 2000)
"To evaluate the safety and efficacy of a five-day regimen of oral 5-fluorouracil (5-FU) plus eniluracil (776C85) in patients with metastatic colorectal cancer (CRC)."9.09A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. ( Bonny, T; Bukowski, R; Burris, H; Hochster, H; Hohneker, J; Levin, J; Mani, S; O'Rourke, M; Schilsky, RL; Wall, JG, 2000)
"We evaluated economic implications of treatment with irinotecan, following a RCT which demonstrated significantly increased survival at 1 year with irinotecan (45%) compared to infusional 5-fluorouracil (5-FU) (32%) in patients with metastatic colorectal cancer."9.09Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure. ( Blijham, G; Jolain, B; Rougier, P; Schmitt, C; Van Cutsem, E, 1999)
"To determine the efficacy of fluorouracil (5-FU) plus eniluracil when administered to patients with previously untreated metastatic colorectal cancer."9.09Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. ( Beck, T; Bell, WN; Chevlen, EM; Hochster, H; Hohneker, J; Levin, J; Lokich, J; Mani, S; McGuirt, C; O'Rourke, MA; Schilsky, RL; Weaver, CH; White, R, 2000)
"In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the standard North Central Cancer Treatment Group/Mayo Clinic 5-day bolus 5FU/LV regimen."9.09Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. ( Bonetti, A; Boni, C; Cassidy, J; Cervantes, A; Cortes-Funes, H; de Braud, F; de Gramont, A; Figer, A; Freyer, G; Hendler, D; Hmissi, A; Homerin, M; Le Bail, N; Louvet, C; Morvan, F; Papamichael, D; Seymour, M; Wilson, C, 2000)
"To analyse patients' travel and time costs associated with 2 alternative drug therapies for advanced colorectal cancer: raltitrexed and fluorouracil plus folinic acid (leucovorin) [5FU + FA]."9.09Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. ( Heyes, A; Palmer, MK; Sculpher, M, 2000)
"The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer."9.09Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. ( Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB, 2000)
"The purpose of this study was to determine the efficacy of twice weekly hypo-fractionated radiation therapy (RT) plus continuous infusion 5-fluorouracil for unresectable or locally advanced colorectal cancer with synchronous metastases."9.09Avoidance of colostomy placement in advanced colorectal cancer with twice weekly hypofractionated radiation plus continuous infusion 5-fluorouracil. ( Breslin, T; Janjan, NA; Lenzi, R; Rich, TA; Skibber, J, 2000)
"QUASAR is a large trial of adjuvant chemotherapy for colorectal cancer in which clinicians could choose to deliver a standard adjuvant cytotoxic chemotherapy regimen, 5-fluorouracil (5-FU) and L-folinic acid (L-FA), in either a once-weekly or a four-weekly schedule."9.09Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group. ( Barnwell, J; Gray, R; Kerr, DJ; McConkey, C, 2000)
"A phase II study was carried out to evaluate the efficacy and toxicity of a double biochemical modulation of 5-fluorouracil (5-FU) by methotrexate (MTX) and leucovorin (LV) in patients with advanced unresectable colorectal cancer."9.09Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer. ( Cizej, TE; Markovic, A; Plesnicar, A; Stabuc, B, 2000)
"The aim of this phase II study was to investigate the therapeutic value of second-line treatment with oxaliplatin, irinotecan (CPT-11) and mitomycin C (MMC) in patients with metastatic colorectal cancer pretreated with 5-fluorouracil (5-FU)-based chemotherapy."9.09Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer. ( Brodowicz, T; Hejna, M; Köstler, WJ; Raderer, M; Scheithauer, W; Tomek, S; Wiltschke, C; Zielinski, CC, 2000)
"Univariate and multivariate analyses were performed on data from 370 5-fluorouracil (5-FU)-resistant advanced colorectal cancer patients treated with oxaliplatin (Eloxatin)/5-FU+/-folinic acid (FA) to identify prognostic factors for oxaliplatin-based treatment."9.09Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients. ( Bleiberg, H; Bleuzen, P; Brienza, S; Cvitkovic, E; de Gramont, A; Ducreux, M; François, E; Gamelin, E; Lévi, F; Marty, M; Simon, J, 2000)
"Studies of bimonthly 48-hour regimens of high-dose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS)."9.09Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F; Molitor, JL; Tournigand, C, 2000)
"Irinotecan is a topoisomerase I inhibitor that prolongs survival in patients with colorectal cancer refractory to fluorouracil (5-FU) and leucovorin (LV)."9.09Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. ( Alakl, M; Awad, L; Douillard, JY; Elfring, GL; Gruia, G; Locker, PK; Miller, LL; Pirotta, N; Saltz, LB, 2001)
"The aim of the study was to evaluate the efficacy, tolerability and quality of life in 5-fluorouracil (5-FU) pretreated colorectal cancer patients after combined 5-FU and Ginkgo biloba extract GBE 761 ONC (i."9.09Phase II study of combined 5-fluorouracil/ Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancer. ( Häring, B; Hauns, B; Köhler, S; Mross, K; Unger, C, 2001)
"Irinotecan (CPT11) has established activity in the treatment of advanced colorectal cancer without cross-resistance with established 5-fluorouracil/folinic acid-based therapy."9.09Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer. ( Adam, R; Bismuth, H; Castaing, D; Coeffic, D; Durrani, AK; Gil-Delgado, MA; Guinet, F; Khayat, D, 2001)
"Sixty eligible patients who had previously untreated, measurable, metastatic colorectal carcinoma were treated with oral eniluracil 50 mg on Days 1-7, 5-FU 20 mg/m(2) on Days 2-6, and LV 50 mg on Days 2-6."9.09Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. ( Hollis, D; Mayer, RJ; Meropol, NJ; Niedzwiecki, D; Schilsky, RL, 2001)
"To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer."9.09Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. ( Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R, 2001)
"We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer."9.095-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001)
" 29 patients with peritoneal carcinomatosis of colorectal origin without evidence of distant metastases underwent cytoreductive surgery and intra-operative HIPEC with mitomycin-C (MMC), followed by systemic chemotherapy with 5-fluorouracil (5-FU)/leucovorin."9.09Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. ( Beijnen, JH; Boot, H; de Bree, E; Kaag, MM; van Coevorden, F; van Slooten, GW; Witkamp, AJ; Zoetmulder, FA, 2001)
"This phase II study examined a regimen (FOLFOX7) of leucovorin (LV), high-dose intensity oxaliplatin, and 5-fluorouracil (5-FU), as second-line therapy for metastatic colorectal cancer."9.09High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F, 2001)
"Patients with isolated hepatic metastases from colorectal cancer were treated every three weeks with increasing doses of oxaliplatin (4 hours; starting dose 25 mg/m2, escalation in steps of 25 mg/m2) in combination with folinic acid (1 hour, 200 mg/m2) and 5-fluorouracil (2 hour, 600 mg/m2)."9.09Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. ( Beckert, B; Beykirch, M; Braess, J; Goecke, E; Hiddemann, W; Kern, W; Lang, N; Schalhorn, A; Stein, J; Stemmler, J; Waggershauser, T, 2001)
"To identify the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of oxaliplatin (L-OHP) given on a weekly schedule including fixed doses of leucovorin (LV) and infusional 5-fluorouracil (5-FU), to define the toxicity profile of this regimen and to find preliminary evidence of its activity in pretreated patients with metastatic colorectal cancer (MCRC)."9.09Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. ( Manzione, L; Pizza, C; Rosati, G; Rossi, A; Tucci, A, 2001)
"Thirty-six patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding palliative chemotherapy with fluoropyrimidines leucovorin +/- irinotecan, participated in this study."9.09Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. ( Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Schuell, B; Ulrich-Pur, H, 2001)
"A multi-institutional study was performed to evaluate the appropriate duration of oral administration of Carmofur (1-hexylcarbamoyl-5-fluorouracil, HCFU), a 5-fluorouracil (5-FU) derivative, for postoperative adjuvant chemotherapy in patients with colorectal cancer undergoing curative operation."9.09Optimal duration of oral adjuvant chemotherapy with Carmofur in the colorectal cancer patients: the Kansai Carmofur Study Group trial III. ( Fujii, H; Kamigaki, T; Kuroda, Y; Nakamura, T; Ohno, M; Tabuchi, Y; Yamagishi, H, 2001)
"The primary objective of this trial was to determine the objective response of two regimens with CDDP administered every 2 weeks immediately before or after an 'optimal' 48-hour chronomodulated infusion of 5-fluorouracil (5-FU) modulated with leucovorin (LV) in metastatic colorectal cancer patients."9.095-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. ( Allegrini, G; Bocci, G; Brunetti, I; Conte, P; Danesi, R; Del Tacca, M; Falcone, A; Lencioni, M; Masi, G; Pfanner, E, 2001)
"To evaluate the efficacy and safety of oxaliplatin (L-OHP) in combination with leucovorin (LV)-modulated bolus plus infusional 5-fluorouracil (5-FU; de Gramont schedule) every 2 weeks in chemotherapy-naive patients with advanced colorectal cancer (CRC)."9.09Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study. ( Agelaki, A; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malamos, N; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N, 2001)
"Thirty-three metastatic colorectal cancer patients were randomized to receive a 60-minute infusion of irinotecan before or after a 48-hour infusion of 5-FU modulated by LV."9.09Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. ( Allegrini, G; Comis, S; Conte, P; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Lencioni, M; Masi, G; Pfanner, E, 2001)
"A statistical analysis was performed on the patient data collected from two compassionate-use programmes using oxaliplatin (Eloxatin(R)) + 5-fluorouracil (5-FU) +/- folinic acid (FA), to identify predictive factors for oxaliplatin-based salvage treatment in patients with 5-FU-resistant advanced colorectal cancer (ACRC)."9.09Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. ( Bensmaïne, MA; Bleiberg, H; Brienza, S; Cvitkovic, E; de Gramont, A; Ducreux, M; François, E; Gamelin, E; Lévi, F; Marty, M, 2001)
"To compare the efficacy and safety of orally administered capecitabine (Xeloda; Roche Laboratories, Inc, Nutley, NJ), a novel fluoropyrimidine carbamate designed to mimic continuous fluorouracil (5-FU) infusion but with preferential activation at the tumor site, with that of intravenous (IV) 5-FU plus leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer."9.09Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. ( Allman, D; Bajetta, E; Boyer, M; Bugat, R; Cassidy, J; Findlay, M; Frings, S; Harper, P; Jahn, M; McKendrick, J; Osterwalder, B; Perez-Manga, G; Rosso, R; Rougier, P; Schmiegel, WH; Seitz, JF; Thompson, P; Twelves, C; Van Cutsem, E; Vieitez, JM; Weitzel, C, 2001)
"A weekly continuous 24-hour infusion therapy with 5-fluorouracil (5-FU) and calcium - folinic acid (CA-FA) was shown to be an effective first-line treatment in advanced metastatic colorectal cancer."9.09Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer. ( Drees, M; Fritze, D; Hartung, G; Hehlmann, R; Hofheinz, RD; Kreuser, ED; Kühnel, J; Queisser, W; Riedel, C; Rost, A; Wein, A, 2001)
"38 patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding systemic chemotherapy with oxaliplatin in combination with 5-fluorouracil/leucovorin or the specific thymidilate synthase inhibitor raltitrexed were enrolled in this study."9.09Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. ( Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Pidlich, J; Raderer, M; Scheithauer, W; Ulrich-Pur, H, 2001)
"The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer."9.09Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001)
"Thirty-one patients with advanced colorectal cancer were treated with a regimen of epirubicin, cisplatin and continuous-infusion (c."9.09Epirubicin, cisplatin and continuous-infusion 5-fluorouracil (ECF regimen) in the treatment of advanced colorectal cancer. ( Caporale, A; Franchi, F; Gargano, L; Konstantatoy, E; Marcellini, M; Masciangelo, R; Menichetti, ET; Seminara, P, 2001)
"Capecitabine and oxaliplatin are both active anticancer agents in the treatment of patients with advanced colorectal cancer (ACRC)."9.09Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study. ( Carpi, A; Cherubini, R; Cognetti, F; Di Costanzo, E; Gasperoni, S; Moscetti, L; Paoloni, FP; Sdrobolini, A; Zeuli, M, 2001)
"Modulation of 5-fluorouracil (FUra) using leucovorin (LV) is a standard treatment approach in patients with metastatic colorectal cancer."9.08A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal cancer. ( Erlichman, C; Feld, R; Fine, S; Kaizer, L; Moore, MJ; Myers, R; Thiessen, JJ, 1995)
"A new modality of locoregional chemotherapy based on biochemical double modulation of 5-fluorouracil (FU) with both leucovorin (LV) and cisplatin (CDDP) against liver metastases of colorectal cancer was devised."9.08[A new modality of locoregional chemotherapy based on biochemical double modulation of 5-fluorouracil with both leucovorin and cisplatin against liver metastases of colorectal cancer]. ( Fukada, D; Kato, M; Kunieda, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H; Tsuji, K; Umemoto, T, 1995)
"The combination of 5-fluorouracil (5-FU) and folinic acid (FA) has demonstrated activity in colorectal cancer (CC)."9.085-Fluorouracil, folinic acid and cisplatin in advanced colorectal cancer: a pilot study. ( Bacoyiannis, C; Daliani, D; Katsikas, M; Kosmas, C; Kosmidis, P; Sakelaropoulos, N; Tentas, K; Tsavaris, N, 1995)
"Modulation of 5-fluorouracil (5-FU) is currently being investigated in advanced colorectal cancer."9.08Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin. ( Astone, A; Barone, C; Cassano, A; Corsi, DC; Fontana, T; Noviello, MR; Pozzo, C, 1995)
"The aim of this study was to investigate the effects of adding interferon alfa-2b (IFN) to protracted venous infusion fluorouracil (PVI 5-FU) from the start of treatment in patients with advanced colorectal cancer."9.08Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. ( Ahmed, F; Cunningham, D; Findlay, M; Hickish, T; Hill, M; Middleton, G; Nicolson, V; Norman, A; Watson, M; Webb, A, 1995)
"We have conducted a retrospective study of high-dose folinic acid and 5-fluorouracil in 96 patients with advanced colorectal cancer."9.08High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients. ( Adams, M; Hanna, CL; Mason, MD; Maughan, TS; McKinna, FE; Morrey, D; Williams, LB, 1995)
"To compare the efficacy and toxicity profiles of a combination of fluorouracil (5-FU) with recombinant human interferon alfa-2a (Roferon-A; Hoffman La-Roche AG, Basel, Switzerland) versus the combination of 5-FU with leucovorin (LV) in the treatment of advanced colorectal cancer."9.08Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group. ( , 1995)
"A clinical trial was conducted in order to evaluate the anti-tumor effect and toxicity of a continuous infusion of 5-fluorouracil (5-FU) for metastatic colorectal cancer."9.08Clinical trial of continuous infusion of 5-fluorouracil using an ambulatory pump for metastatic colorectal cancer. ( Kondo, H; Ohkura, H; Saito, D; Shimada, Y; Shirao, K; Sugano, K; Yamao, T; Yokota, T; Yoshida, S, 1995)
"A multicentral cooperative study was conducted to evaluate the clinical efficacy and toxicity of l-Leucovorin (l-LV) and 5-fluorouracil (5-FU) in advanced colorectal cancer."9.08[A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)]. ( Abe, T; Kikkawa, N; Konishi, K; Maehara, Y; Ota, J; Sowa, M; Taguchi, T; Takashima, S; Yabushita, K; Yasutomi, M, 1995)
"Trimetrexate (TMQ), a non-classical folate antagonist, was studied in a randomized controlled trial in patients with advanced colorectal cancer and without prior chemotherapy."9.08A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: a Southwest Oncology Group study. ( Brown, TD; Fleming, TR; Goodman, PJ; Macdonald, JS; O'Rourke, T; Pugh, RP, 1995)
"These results indicate that suramin is inactive in patients with metastatic colorectal cancer pretreated with fluoropyrimidines."9.08Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. ( Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995)
"No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy."9.08Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. ( André, AM; Bertino, JR; Conti, JA; Grossano, DD; Kemeny, NE; Saltz, LB, 1995)
"A Phase II study of combination treatment with 5-fluorouracil (5-FU), leucovorin (LV), and interferon alpha-2a (IFN) in patients with previously untreated metastatic colorectal cancer was previously reported by the authors."9.085-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. ( Buter, J; de Vries, EG; Mulder, NH; Sinnige, HA; Sleijfer, DT; van der Graaf, WT; Verschueren, RC; Willemse, PH, 1995)
"A total of 56 consecutive patients with metastatic colorectal cancer received treatment with 5-fluorouracil (5-FU) given at 425 mg/m2 by rapid intravenous infusion, immediately preceded by leucovorin (LV) given at 20 mg/m2, with cycles being repeated every 4 weeks."9.085-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study. ( Dale, J; Fried, G; Haim, N; Stein, M; Tsalik, M, 1995)
"Between September 1990 and August 1994, 11 patients (pts) with liver metastases (mets) from colorectal cancer were treated with continuous hepatic arterial infusion chemotherapy of 5-fluorouracil (FU) plus leucovorin (LV)."9.08[Continuous intraarterial infusion of 5-fluorouracil plus leucovorin for liver metastases from colorectal cancer]. ( Ban, K; Higashi, H; Imanari, T; Ishihara, S; Kitazaki, M; Masuda, K; Matsumoto, M; Noma, M; Ota, M; Shida, H, 1995)
"We undertook a multicenter phase II trial of 5-fluorouracil (5FU) + 1-leucovorin (1-LV) in previously untreated patients with metastatic colorectal cancer to determine the response rate, response duration, time to progression, survival, and toxicity."9.08A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. ( Erlichman, C; Fine, S; Gorg, C; Gustavsson, B; Hoffmann, W; Kerr, I; Preusser, P; Schmoll, HJ; Thuerlimann, B, 1996)
"This randomised clinical trial, involving patients with advanced colorectal cancer, was carried out to compare the effectiveness of accelerated folinic acid (FA) plus 5-fluorouracil (5-FU) with that of the conventional regimen of 5-FU alone."9.08Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care. ( Aquino, A; Botta, G; De Martino, A; Frediani, B; Lorenzi, M; Marsili, S; Marzocca, G; Palazzuoli, V; Petrioli, R; Tani, F, 1995)
"A joint study was performed by the Tokai HCFU study group, which included 41 institutions to study the usefulness of the concomitant therapy with Mitomycin C (MMC) and Carmofur (HCFU) as a postoperative adjuvant chemotherapy in patients with colorectal cancer who had curative resection."9.08Prospective adjuvant therapy with mitomycin C and carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group, the first study for colorectal cancer. ( Ito, K; Kato, T; Koike, A; Miura, K; Takagi, H; Yamaguchi, A, 1996)
"To determine the plasma pharmacokinetics and the maximum-tolerated dose (MTD) of intravenous (IV) azidothymidine (AZT) administered 90 to 120 minutes after fluorouracil (5-FU) and leucovorin and to preliminarily evaluate the antitumor activity of this combination in metastatic colorectal cancer."9.08Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. ( Brunetti, I; Conte, PF; Danesi, R; Dargenio, F; Del Tacca, M; Falcone, A; Nethersell, AB; Pfanner, E, 1996)
"Phase II studies of fluorouracil (5-FU) administered by protracted intravenous infusion have suggested an improved response rate and decreased toxicity profile when compared with 5-FU given by bolus injection in patients with metastatic colorectal cancer."9.08Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. ( Anderson, T; Benson, A; Haller, DG; Hansen, RM; Krzywda, B; Quebbeman, E; Ryan, L; Tormey, DC, 1996)
"We studied the effect of postoperative chemotherapy using 5-fluorouracil (5-FU) infusions and 1-hexylcarbamoyl-5-fluorouracil (HCFU) oral administration for curatively resected Stage II to IV colorectal cancer."9.08Postoperative chemotherapy for colorectal cancer by combining 5-fluorouracil infusion and 1-hexylcarbamoyl-5-fluorouracil administration after curative resection. ( Akiyoshi, T; Kakegawa, T; Maehara, Y; Ogawa, M; Sugimachi, K; Tomita, M, 1996)
"A phase II prospective trial was carried out to study the concept of 5-fluorouracil (5-FU) dose-intensity in patients with advanced colorectal cancer."9.08Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. ( Burtin, PC; Danquechin-Dorval, EM; Delva, RG; Dumesnil, YF; Gamelin, EC; Gesta, PH; Goudier, MJ; Larra, FG; Lortholary, AH; Maillart, PJ, 1996)
"We evaluated the role of low-dose alpha-2b interferon, added to chemotherapy, for advanced colorectal cancer; we randomized patients, to either a combination chemotherapy of 5-fluorouracil (5-FU) and high-dose folinic acid (HDFA) or the same regimen plus interferon."9.08Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2B interferon in advanced colorectal cancer. ( Di Lullo, L; Fabiani, F; Fanini, R; Lalli, A; Lombardo, M; Nuzzo, A; Peretti, G; Recchia, F; Torchio, P; Venturoni, L, 1996)
"A total of 26 patients with advanced colorectal cancer received 60 mg/m2 methotrexate i."9.08Multimodal biochemical modulation of 5-fluorouracil by leucovorin, methotrexate, and interferon alpha in patients with advanced colorectal cancer. ( Alessandroni, P; Casadei, V; Cascinu, S; Catalano, G; Del Ferro, E; Fedeli, A; Rossi, D, 1996)
"Methotrexate (MTX) has been described to modulate the activity of fluorouracil (5-FU) in patients with metastatic colorectal cancer."9.08Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study. ( Bleiberg, H; Blijham, G; Buset, M; Collette, L; Dalmark, M; de Greve, J; Lacave, A; Sahmoud, T; Selleslag, J; Wagener, T; Wils, J, 1996)
"To determine the effects of interferon alpha-2a (IFN alpha) on the efficacy and toxicity of fluorouracil (FUra) and leucovorin (LV) in patients with advanced colorectal cancer."9.08Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. ( Cunningham, D; Duffy, AM; Harper, PG; James, RD; Kerr, DJ; Ledermann, JA; McAdam, WA; Neoptolemos, JP; Nicholson, M; Perren, TJ; Seymour, MT; Slevin, ML; Stenning, SP; Stephens, RJ; Taylor, I, 1996)
"A phase II study was performed to evaluate the clinical and immunological effects of a regimen of fluorouracil (5-FU) and folinic acid (FA) combined with thymopentin (TP-5) and interleukin-2 (IL-2) in the treatment of patients with metastatic colorectal cancer."9.08Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: clinical and immunological effects. ( Ameglio, F; Di Lauro, L; Frasca, AM; Gandolfo, GM; Garaci, E; Lopez, M; Paoletti, G; Rasi, G; Santini, S; Vitelli, G, 1995)
"With the association of 5-fluorouracil (5-FU) and alpha-interferon (IFN), objective responses as high as 26 63% have been reported in untreated patients with advanced colorectal cancer."9.08A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. ( Acito, L; Bascioni, R; Bavosi, M; Carle, F; Cascinu, S; Cellerino, R; Del Papa, M; Francini, G; Giustini, L; Latini, L; Marcellini, M; Pancotti, A; Piga, A; Rossi, G, 1996)
"A phase I trial of 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN) was conducted in 15 advanced colorectal cancer patients refractory to a bolus regimen of 5-FU/LV."9.08A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. ( Cascinu, S; Catalano, G; Del Ferro, E; Ligi, M, 1996)
"To compare the efficacy and toxicity profiles of a combination of fluorouracil (5-FU) and recombinant human interferon alfa-2a ([IFN alpha 2a] Roferon-A; Hoffmann-LaRoche, Basel, Switzerland) versus 5-FU alone in the treatment of advanced colorectal cancer (ACC)."9.08Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. ( Buys, SS; Buyse, M; Einhorn, L; Figlin, R; Froimtchuk, MJ; Greco, FA; Man, A; Marshall, EM; Ritter, L; Schilsky, R; Schuchter, L; Schuller, J; Yap, AK; York, M, 1996)
"A joint study was performed by the Tokai HCFU study group, which included seven institutions, to examine the value of oral administration of Carmofur (HCFU), a 5-fluorouracil (5-FU) derivative, for postoperative adjuvant chemotherapy in patients with colorectal cancer undergoing curative resection."9.08Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: five-year follow-up. Tokai HCFU Study Group--third study on colorectal cancer. ( Baba, S; Ishii, M; Ito, K; Kato, T; Matsumoto, S; Miura, K; Takagi, H; Yamaguchi, A, 1996)
"5-Fluorouracil (5-FU) remains the most active therapeutic agent in advanced colorectal cancer."9.085-Fluorouracil continuous infusion in metastatic colorectal cancer. ( Ang, PT; Tan, EH, 1996)
"In a pilot study we treated 19 patients suffering from recurrent or locally advanced inoperable colorectal cancer, with concurrent hypofractionated radiotherapy (4-5 Gy/fraction, 2 fractions per week) and 5-fluorouracil bolus, 1 hour before RT at doses of 300 mg/m2."9.08Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study. ( Kapsoritakis, A; Kosma, L; Koukourakis, M; Mouder, N; Skarlatos, J; Yannakakis, D; Zambatis, C, 1996)
"Treatment using a combination of 5-fluorouracil (5-FU), interferon-alpha (IFN alpha-2a) and interleukin 2 (IL-2) has been shown to mediate disease regression in selected patients with advanced colorectal cancer."9.08Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer. ( Goey, SH; Gratama, JW; Mertelsmann, RH; Osterwalder, B; Primrose, JN; Stoter, G; Verweij, J; Ward, U, 1996)
"This multicenter study compared the therapeutic ratio of a monthly schedule of low-dose leucovorin (LV) and fluorouracil (5-FU) bolus with a bimonthly schedule of high-dose LV and 5-FU bolus plus continuous infusion in patients with advanced colorectal cancer."9.08Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. ( Bedenne, L; Bosset, JF; Bouché, O; de Gramont, A; Etienne, PL; François, E; Guillot, T; Louvet, C; Milan, C; Morvan, F; Rougier, P, 1997)
"To compare the efficacy and toxicity of fluorouracil (FU) and racemic leucovorin (d,l-LV) versus FU combined with the l-isomer of leucovorin (l-LV) in the treatment of advanced colorectal cancer."9.08Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. ( Burger, D; Depisch, D; Greiner, R; Karner, J; Kornek, G; Kovats, E; Marczell, A; Pidlich, J; Raderer, M; Rosen, H; Salem, G; Scheithauer, W; Schneeweiss, B, 1997)
"Although leucovorin (LV) + 5-fluorouracil (5-FU) is considered the treatment of choice for advanced colorectal cancer in most countries, the optimal schedule of this combination has not yet been established."9.08High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a 'GISCAD' phase III study. Italian Group for the Study of Digestive Tract Cancer. ( Arnoldi, E; Barni, S; Cascinu, S; Comella, G; Dallavalle, G; Duro, M; Fiorentini, G; Frontini, L; Gottardi, O; Labianca, R; Luporini, G; Martignoni, G; Oliani, C; Pancera, G; Pavanato, G; Piazza, E; Raina, A; Valsecchi, R; Zaniboni, A, 1997)
"Fourteen patients with 5-fluorouracil (5-FU) refractory, progressive colorectal cancer metastatic to liver and/or lung were treated with continuous oral trofosfamide, an alkylating agent structurally related to cyclophosphamide and ifosfamide."9.08Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil. ( Eberhardt, W; Harstrick, A; Klaassen, U; Korn, MW; Müller, C; Seeber, S; Strumberg, D; Wilke, H, 1997)
"Diarrhea is one of the dose-limiting toxicities for administration of fluorouracil (5FU) in patients with colorectal cancer and can result in severe morbidity and mortality."9.08Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study. ( Ardizzoia, A; Barni, S; Cascinu, S; Catalano, G; Cazzaniga, M; Del Ferro, E; Ghiandoni, G; Labianca, R; Ligi, M; Luporini, G; Pessi, MA; Rocchi, MB; Ugolini, G; Zamparelli, G, 1997)
"A three-arm randomized phase III trial in advanced colorectal cancer patients was designed to test whether substitution of an equivalent dose of (1) l-leucovorin or (2) oral leucovorin would more effectively potentiate fluorouracil (5-FU) than standard intravenous (I."9.08Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. ( Goldberg, RM; Hatfield, AK; Kahn, M; Knost, JA; Krook, JE; Maillard, JA; Moertel, CG; O'Connell, MJ; Sargent, DJ; Schaefer, PL; Tirona, MT; Wiesenfeld, M, 1997)
"The aim of this phase I study was to establish the maximum tolerated dose (MTD) of 5-fluorouracil (5-FU), administered as a 5-day chronomodulated infusion in combination with 1-folinic acid (FA) to ambulatory metastatic colorectal cancer patients."9.08A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer. ( Aschelter, AM; Franchi, F; Gallà, DA; Garufi, C; Giunta, S; Lévi, F; Narduzzi, C; Nisticò, C; Pace, R; Silecchia, GF; Terzoli, E, 1997)
"To determine whether high-dose infusional fluorouracil (FU) is effectively modulated by leucovorin (LV), interferon (IFN) alpha-2b, or both when given to patients with metastatic colorectal cancer."9.08Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. ( Andreesen, R; Bade, J; Dörken, B; Harstick, A; Hecker, H; Hiddemann, W; Horster, A; Käufer, C; Klaasen, U; Köhne, CH; Ohl, U; Schmoll, HJ; Schöffski, P; Schott, G; Schubert, U; Westerhausen, M; Wilke, H, 1998)
"The purpose of this study was to compare the objective response rate, duration of remission, and survival of 5-fluorouracil (5-FU) versus those of 5-FU plus levamisole in metastatic colorectal cancer using the same dose and schedule of these agents as in the North Central Cancer Treatment Group and intergroup studies of adjuvant therapy."9.08Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. ( Bandealy, MT; Einhorn, LH; Gonin, R; Loehrer, PJ; Monaco, F, 1998)
"Although the efficacy of 5-fluorouracil (5-FU) modulated by leucovorin is well established for advanced colorectal cancer, the question of the most effective regimen and optimal dose of leucovorin remains unanswered."9.08A prospective randomized study comparing high- and low-dose leucovorin combined with same-dose 5-fluorouracil in advanced colorectal cancer. ( Blanc, F; Bons-Rosset, F; Fabbro-Peray, P; Gouze, C; Heran, B; Marçais, O; Perney, P; Ribard, D; Veyrac, M; Ychou, M, 1998)
"From February 1995 through October 1996, 25 patients with metastatic colorectal cancer showing a clinical resistance to 5-fluorouracil (5-FU) entered this study."9.08Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. ( Aapro, MS; Biffi, R; Brienza, S; De Pas, T; deBraud, F; Munzone, E; Nolè, F, 1998)
"A wide variety of fluorouracil (FU)-plus-leucovorin (LV) dose schedules are in clinical use for the treatment of advanced colorectal cancer."9.08The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK). ( Bacchi, M; Borner, MM; Castiglione, M; Fey, MF; Goldhirsch, A; Hanselmann, S; Herrmann, R; Leyvraz, S; Morant, R; Pagani, O; Pestalozzi, B; Weber, W, 1998)
"5-Fluorouracil and leucovorin combination is the most commonly applied chemotherapy treatment for colorectal cancer patients, both in the adjuvant setting and for advanced disease."9.08A phase II trial of carboplatin, methotrexate and fluorouracil in fluorouracil-pretreated colorectal cancer. ( Botto, F; Ghio, E; Neri, E; Pensa, F; Pronzato, P; Tognoni, A; Vaira, F; Vigani, A, 1998)
"Patients with histologically confirmed advanced colorectal cancer were randomized to receive folinic acid (FA; 500 mg/mq in 2-hour intravenous infusion) and 5-fluorouracil (5FU; 600 mg/mq given as an intravenous bolus 1 hour after FA), beginning every week for 6 weeks, followed by a 2-week rest period, either without hydroxyurea (HU, arm A) or with HU (35 mg/kg per day) given orally in three administrations (every 8 hours) starting 6 hours after 5FU administration (arm B)."9.08High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research. ( Algeri, R; Angiona, S; Belsanti, V; Boni, C; Corgna, E; Di Costanzo, F; Figoli, F; Gasperoni, S; Luppi, G; Malacarne, P; Marzola, M; Passalacqua, R; Sdrobolini, A; Zironi, S, 1998)
"To compare raltitrexed (Tomudex; Zeneca Pharmaceuticals Ltd, Macclesfield, United Kingdom) a direct, specific thymidylate synthase (TS) inhibitor with fluorouracil (5-FU) plus high-dose leucovorin (LV) as first-line treatment for advanced colorectal cancer (ACC)."9.08Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. ( Cocconi, G; Cunningham, D; Francois, E; Gustavsson, B; Hietschold, SM; Kerr, D; Possinger, K; Van Cutsem, E; van Hazel, G, 1998)
"The objective of this multicenter study was to compare the efficacy and toxicity profiles of a combination of 5-fluorouracil (5-FU) given by bolus injection together with intravenous leucovorin (LV) versus high-dose 5-FU in continuous infusion (CI) in the treatment of advanced colorectal cancer."9.08Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. ( Antón-Torres, A; Aparicio, J; Aranda, E; Barneto, I; Carrato, A; Cervantes, A; Díaz-Rubio, E; García-Conde, J; López-Vega, JM; Massutí, T; Sastre, J; Tabernero, JM; Trés, A, 1998)
"Patients with proven metastatic colorectal cancer, which had progressed within 6 months of treatment with fluorouracil, were randomly assigned either 300-350 mg/m2 irinotecan every 3 weeks with supportive care or supportive care alone, in a 2:1 ratio."9.08Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. ( Awad, L; Cunningham, D; Heikkila, R; Herait, P; Hickish, TF; Jacques, C; James, RD; Johannesen, TB; Punt, CJ; Pyrhönen, S; Starkhammar, H; Topham, CA, 1998)
"In phase II trials, irinotecan is active in patients with advanced colorectal cancer, but the survival and clinical benefit of irinotecan compared with second-line fluorouracil by continuous infusion is not known."9.08Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. ( Awad, L; Bajetta, E; Bleiberg, H; Herait, P; Jacques, C; Labianca, R; Morant, R; Navarro, M; Niederle, N; Possinger, K; Rougier, P; Van Cutsem, E; Wils, J, 1998)
"Data from 12 metastatic colorectal cancer patients who were submitted to a pilot study with a multistep subcutaneous (sc) low dose recombinant interleukin-2 (rIL-2), 5-fluorouracil (5-FU) and leucovorin (LV) administration were compared with those from 13 historical controls who were comparable for the major prognostic indices."9.08A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study. ( Anselmi, L; Carpi, A; Ferrari, P; Nicolini, A; Sagripanti, A, 1998)
"The cumulative pharmacokinetic pattern of oxaliplatin, a new diamminecyclohexane platinum derivative, was studied in patients with metastatic colorectal cancer."9.08Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. ( Allain, P; Boisdron-Celle, M; Bouil, AL; Brienza, S; Cailleux, A; Cvitkovic, E; Delva, R; Gamelin, E; Krikorian, A; Larra, F; Robert, J; Turcant, A, 1997)
"We evaluated the pharmacokinetics of 5-fluorouracil (5-FU) combined with recombinant human interferon (IFN)-alpha 2a in 10 previously untreated patients with advanced colorectal carcinoma."9.08Pharmacokinetics of recombinant human interferon-alpha 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma. ( Kim, J; Koss-Twardy, SG; Passe, SM; Patel, IH; Pazdur, R; Satoh, H; Zhi, J, 1998)
"Raltitrexed (Tomudex) is currently licensed for first-line treatment of advanced colorectal cancer."9.08Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancer. ( Cunningham, D; Farrugia, DC; Norman, AR, 1998)
"This multicenter phase II study was designed to assess the efficacy of the alternating schedule of irinotecan (CPT-11) with bolus 5-fluorouracil (5-FU) and leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer (CRC)."9.08A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. ( Barone, C; Cognetti, F; Cote, C; Dirix, L; Filez, L; Garufi, C; Gruia, G; Humblet, Y; Pozzo, C; Starkhammar, H; Terzoli, E; Van Cutsem, E, 1998)
"FOLFOX2, a bimonthly regimen of high-dose leucovorin (LV), 48-hour continuous infusion of 5-fluorouracil (5-FU) (LV-5-FU) and oxaliplatin (100 mg/m2) produced a high response rate (46%; 95% confidence interval (95% CI): 31%-60%) in 5-FU pre-treated patients with metastatic colorectal cancer."9.08Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. ( André, T; de Gramont, A; Louvet, C; Raymond, E; Tournigand, C, 1998)
" 439 patients were entered into a phase III trial comparing a novel thymidylate synthase (TS) inhibitor Tomudex (raltitrexed, formerly ZD1694) with 5-FU and leucovorin (LV) for the treatment of advanced colorectal cancer."9.08Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. ( Kerr, D; Palmer, M; Seymour, L; Zalcberg, J, 1998)
"To compare two commonly used schedules of fluorouracil (5FU) and leucovorin in the treatment of patients with advanced metastatic colorectal cancer."9.07Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. ( Buroker, TR; Gerstner, JB; Gesme, DH; Kardinal, CG; Krook, JE; Levitt, R; Mailliard, JA; O'Connell, MJ; Schaefer, PL; Wieand, HS, 1994)
"Eighty-one patients with metastatic or locally advanced colorectal cancer were treated at four oncological centers in Denmark with a regimen consisting of 5-fluorouracil 400 mg/m2 and leucovorin 20 mg/m2 for 5 consecutive days every 4 weeks."9.07Metastatic or locally advanced colorectal cancer treated with 5-fluorouracil and low dose leucovorin. ( Andersen, LJ; Brunsgaard, NH; Jensen, BB; Mejlholm, I, 1994)
"Twenty-one patients with advanced, pretreated colorectal cancer in disease progression were entered in a phase II study to investigate the use of 5-fluorouracil (5FU) + leucovorin with subcutaneous Interleukin-2 + alpha interferon (alpha-IFN)."9.07A phase II study of advanced colorectal cancer patients treated with combination 5-fluorouracil plus leucovorin and subcutaneous interleukin-2 plus alpha interferon. ( Amadori, D; Fedriga, R; Flamini, E; Maltoni, R; Milandri, C; Pezzi, L; Riccobon, A; Ridolfi, R; Santoni, A; Velotti, F, 1994)
"In a previous phase II trial, circadian (chronomodulated) delivery of fluorouracil (5-FU), folinic acid (FA; leucovorin), and oxaliplatin (1-OHP; a new platinum complex with no renal and minor hematologic toxic effects) produced an objective response rate of 58% in 93 patients with metastatic colorectal cancer."9.07Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. ( Chollet, P; Dogliotti, L; Faggiuolo, R; Focan, C; Garufi, C; Itzhaki, M; Lévi, FA; Perpoint, B; Vannetzel, JM; Zidani, R, 1994)
"Interferon alpha (IFN-alpha) enhances the activity of 5-fluorouracil (5-FU) in the treatment of advanced colorectal cancer although the mechanism is not understood."9.07The effect of 5-fluorouracil and alpha interferon and 5-fluorouracil and leucovorin on cellular anti-tumour immune responses in patients with advanced colorectal cancer. ( Nichols, PH; Primrose, JN; Ramsden, CW; Ward, U, 1994)
"A total of 101 patients with advanced colorectal cancer in two consecutive Southern Italian Oncology Groups (GOIM) studies (8501 and 8801--arm A) were treated with a sequential combination of high dose methotrexate (HDMTX) and fluorouracil (FU)."9.07Sequential treatment with high-dose methotrexate and fluorouracil in advanced colorectal cancer. Experience of the Southern Italian Oncology Group (GOIM). ( Colucci, G; Giotta, F; Giuliani, F; Leo, S; Maiello, E; Pedicini, A; Pezzella, G; Prete, F; Romito, S; Valori, V, 1994)
"In an attempt to evaluate the feasibility of 5-fluorouracil (FU) treatment modulated by (R,S)-leucovorin (LV) and interferon alpha (IFN alpha) in patients with advanced colorectal cancer, we conducted a phase I trial with increasing doses of subcutaneous IFN alpha (3 x 1 x 10(6) U, 3 x 3 x 10(6) U, 3 x 3 x 10(6) U, 3 x 5 x 10(6) U and 3 x 10 x 10(6) U/week) and 500 mg/m2 LV i."9.07Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration. ( Djavanmard, MP; Gnant, MF; Jakesz, R; Locker, G; Mader, RM; Marosi, C; Rainer, H; Steger, GG, 1994)
"The management of patients with advanced colorectal cancer remains dependent on the optimal use of 5-Fluorouracil (5-FU)."9.07Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer. ( Carter, R; Cunningham, D; Evans, C; Findlay, M; Ford, H; Hill, A; Husband, J; Nicolson, M; Norman, A, 1994)
"Twenty-two patients with metastatic colorectal cancer entered a Phase I-II trial to assess the maximum tolerable dose of alpha-2B-interferon administered intramuscularly three times per week in combination with fixed doses of 5-fluorouracil (450 mg/m2 IV for 5 days, and, from day 28, weekly) and folinic acid (200 mg/m2 IV before 5-fluorouracil) and the efficacy of this combination."9.07Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients. ( Bertuccelli, M; Brunetti, I; Cianci, C; Conte, PF; Falcone, A; Ricci, S, 1994)
"5-Fluorouracil (5-FU), when combined with leucovorin (LV) or interferon-alpha (IFN-alpha), may result in improved response rates compared with 5-FU alone in patients with advanced colorectal cancer."9.07Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study. ( Burghouts, JT; Croles, JJ; de Mulder, PH; Kamm, Y; Punt, CJ; van Liessum, PA, 1993)
" The purpose of this study was to compare its therapeutic effect with a standard fluorouracil (FU) regimen in patients with locally advanced or metastatic colorectal cancer."9.07Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. ( Amadori, D; Bajetta, E; Calabresi, F; Colleoni, M; Comella, G; Lorusso, V; Marangolo, M; Rosso, R; Scanni, A; Sobrero, A, 1993)
"25 patients with metastatic colorectal cancer were entered into a phase II trial of combination chemoimmunotherapy using a sequential regimen of 5-fluorouracil (5-FU) and leucovorin and high-dose recombinant human interleukin-2 (rIL-2)."9.07Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2. ( Landry, JG; Ritchey, JL; Rosenberg, SA; Shlasko, E; White, DE; Yang, JC, 1993)
"A prospectively randomized trial was performed to determine whether the combination of fluorouracil (FU) plus leucovorin (FU-LV) administered orally is more effective than equitoxic FU for patients with metastatic colorectal cancer."9.07A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. ( Brenckman, WD; Bukowski, RM; Clendennin, NJ; Collier, MA; Guaspari, A; Laufman, LR; McKinnis, RA; Sullivan, BA, 1993)
"Biochemical modulation of bolus fluorouracil (5-FU) by addition of leucovorin to the treatment regimen has increased response in patients with disseminated colorectal cancer from fewer than 20% to more than 40%."9.07Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer. ( Groshen, S; Jeffers, S; Leichman, CG; Leichman, L; Rosen, PJ; Spears, CP, 1993)
"Thirty-one patients with hepatic metastases from colorectal carcinoma were treated with carboplatin (CBDCA), 55 mg/m2, given in a 4-hour intra-arterial infusion daily for 5 days, and 5-fluorouracil, 900 mg/m2, given in a 20-hour intra-arterial infusion daily for 5 days."9.07Intra-arterial hepatic treatment with carboplatin (CBDCA) and 5-fluorouracil (5-FU) in metastases from colorectal carcinoma. ( Abuchaibe, O; Bilbao, I; Hidalgo, OF; Pardo, F; Rebollo, J; Tangco, E; Vieitez, JM, 1993)
" This prospective phase II study evaluates the efficacy and toxicity of hepatic arterial infusion of 5-Fluorouracil (5-FU) via an implantable Infusaid pump in previously untreated patients with localised but unresectable hepatic metastases from colorectal cancer."9.07Continuous hepatic artery infusion of 5-fluorouracil for metastatic colorectal cancer localised to the liver. ( Boyle, FM; Levi, JA; Smith, RC, 1993)
"We have reported that 5-fluorouracil (5-FU) and folinic acid increased response rate and survival in patients with metastatic colorectal cancer."9.07Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. ( Erlichman, C; Fine, S; Gadalla, T; Steinberg, J; Wong, A, 1992)
"From January 31, 1986 to January 31, 1989, 184 eligible patients were enrolled in a randomized study of either infusional or bolus 5-fluorouracil (5-FU) for the treatment of metastatic measurable colorectal cancer."9.07Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer. ( Bogues, W; Cripps, IC; Fields, A; Maroun, J; McCormick, R; Pater, J; Shah, A; Temple, W; Weinerman, B; Wilson, K, 1992)
"Because of the different sites and mechanisms of biochemical interaction among 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN), we hypothesized that the concomitant use of IFN could increase the activity of the 5-FU/LV combination in colorectal cancer patients."9.07Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patients. ( Cascinu, S; Catalano, G; Fedeli, A; Fedeli, SL, 1992)
"15 untreated patients with advanced measurable colorectal cancer along with other 29 patients in progression after failing first line chemotherapy with fluoropyrimidines received 5-fluorouracil (5FU) 500 mg/m2 given as a weekly bolus at mid-infusion of leucovorin (LV), 500 mg/m2 administered intravenously over 2 h and interferon alpha 2b (IFN) 3 x 10(6) U given intramuscularly every other day."9.07Phase II study of 5-fluorouracil plus leucovorin and interferon alpha 2b in advanced colorectal cancer. ( Aschele, C; Bolli, E; Bruzzi, P; Gallo, L; Guglielmi, A; Mori, A; Nobile, MT; Parodi, GC; Sobrero, A; Tixi, L, 1992)
"A high rate of response to 5-fluorouracil (5FU) and alpha-interferon (alpha IFN) combination therapy has been reported in metastatic colorectal cancer patients."9.07Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study. ( Burghouts, JT; de Mulder, PH; Punt, CJ; Wagener, DJ, 1992)
"One hundred sixty consecutive patients with histologically confirmed colorectal cancer (advanced disease) without prior chemotherapy were entered in a randomized trial comparing 5-fluorouracil (5-FU) 1,000 mg/m2 intravenously per day for 5 consecutive days in continuous infusion versus cisplatin (CP) 100 mg/m2 on day 1 plus 5-FU as described on days 2 to 6."9.07A prospective randomized trial of continuous infusion 5-fluorouracil (5-FU) versus 5-FU plus cisplatin in patients with advanced colorectal cancer. A trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.). ( Antón, A; Aranda, E; Belón, J; Carrato, A; Cruz-Hernández, J; Díaz-Rubio, E; Jimeno, J; Martin, M; Massuti, B; Sánchez, J, 1992)
"Treatment results in advanced colorectal cancer have improved during the last decade since the incorporation of agents like folinic acid, PALA, or interferon as active biomodulation of 5-fluorouracil (5-FU), the most potent drug in this disease."9.07A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation. ( Köhne-Wömpner, CH; Poliwoda, H; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, HJ, 1992)
"Patients with advanced colorectal cancer were randomized to receive either fluorouracil (5-FU) 370 mg/m2 IV days 1 to 5 followed by weekly applications of 5-FU 600 mg/m2 or the same doses of 5-FU preceded by folinic acid 200 mg/m2."9.07Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer--preliminary results of a randomized trial. ( Günther, E; Hinrichs, HF; Hirschmann, WD; Koniczek, KH; Natt, F; Sondern, W; Steinke, B; Wagner, T; Wander, HE; Werdier, D, 1992)
"Several reports on fluorouracil (5-FU) and alfa interferon (IFN-alpha) combination therapy in patients with advanced colorectal cancer have been published."9.07Fluorouracil continuous infusion plus alfa interferon plus oral folinic acid in advanced colorectal cancer. ( Burghouts, JT; de Mulder, PH; Punt, CJ; Wagener, DJ, 1992)
"In a clinical phase II study, 23 patients with progressive metastatic colorectal cancer and failure after first-line chemotherapy with fluorouracil (5-FU) and folinic acid (FA) were treated with a 5-day continuous infusion of recombinant interleukin-2 (IL-2), 3 x 10(6) cetus U/m2/d, followed after a rest period of 2 days by 5-FU, 600 mg/m2/d, and FA, 300 mg/m2/d over an additional 3 days."9.07Interleukin-2 followed by fluorouracil and folinic acid in refractory colorectal cancer--results of a clinical phase II study. ( Hiddemann, W; Koch, O; Musch, E; Ottensmeier, C; Rückle, H; Ruelfs, C; van de Loo, J, 1992)
"One hundred eighty-one patients with measurable recurrent or metastatic colorectal cancer, who had not received prior chemotherapy, were randomized in a prospective controlled trial to receive 5-fluorouracil (5FU), 13."9.07Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). ( Bacchi, M; Bartolucci, R; Belsanti, V; Boni, C; Calabresi, F; Di Costanzo, F; Marzola, M; Sofra, M, 1992)
"5-Fluorouracil (5-FU) remains the most effective chemotherapeutic agent in the management of patients with metastatic colorectal cancer."9.07Treatment of advanced colorectal cancer by 5-fluorouracil-leucovorin combination with or without allopurinol: a prospective randomized study. ( Chaitchik, S; Inbar, M; Merimsky, O, 1991)
"To report a new syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia after treatment with N-phosphonacetyl-L-aspartate (PALA) and fluorouracil for metastatic colorectal cancer."9.07A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) ( Costa, P; Kemeny, N; Kurtz, RC; Martin, D; Murray, M; Niedzwiecki, D; Seiter, K; Urmacher, C, 1991)
"Hepatic intra-arterial (HIA) infusion of floxuridine (FUDR) via an implanted pump has shown promise in the treatment of colorectal cancer metastasized to the liver."9.07Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. ( Chase, JL; Grobman, BJ; Hohn, DC; Lewis, BJ; Mulvihill, SJ; Rayner, AA; Roh, M; Stagg, RJ; Venook, AP; Warren, RS, 1991)
"Effectiveness, toxicity and complications of 5-fluorouracil (FU) and mitomycin-C (MMC) treatment were analyzed in 30 patients with metastatic colorectal cancer confined to the liver."9.07Phase II study of intra-arterial fluorouracil and mitomycin-C for liver metastases of colorectal cancer. ( Largiadèr, F; Metzger, U; Röthlin, M; Weder, W, 1991)
"A phase I study of 5-fluorouracil 600 mg/m2/week and folinic acid 500 mg/m2/week on day 1 and cisplatin administered weekly on day 2 was carried out on 30 patients with metastatic colorectal carcinoma of which 20 patients were pretreated with 5-fluorouracil."9.07A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma. ( Creaven, P; Gebbia, N; Gebbia, V; Palmeri, S; Petrelli, N; Rausa, L; Russo, A; Rustum, Y, 1991)
"In a previous study (J Clin Oncol 7:1407-1417, 1989), we identified two dosage administration schedules of fluorouracil (5FU) combined with leucovorin that were superior to single-agent 5FU for the treatment of advanced colorectal cancer."9.07Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. ( Gerstner, JB; Kardinal, CG; Krook, JE; Levitt, R; Mailliard, JA; O'Connell, MJ; Poon, MA; Tschetter, LK; Wieand, HS, 1991)
"The importance of the interval between methotrexate (MTX) and fluorouracil (5-FU) was studied in 168 patients with previously untreated, measurable, advanced colorectal cancer."9.07The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. ( Bertino, JR; Capizzi, RL; Davis, CA; Durivage, HJ; Farber, LR; Katz, KH; Marsh, JC; Pasquale, DN; Richards, F; Rome, LS, 1991)
"Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection."9.06Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. ( Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Martin, JK; Nagorney, DM; O'Connell, MJ; Rubin, J; Tschetter, LK; Wieand, HS, 1990)
"Pursuant to a promising report suggesting that an allopurinol mouthwash could have a protective effect against 5-fluorouracil (5-FU)-induced stomatitis, the authors performed a randomized, placebo-controlled, double-blind, crossover study."9.06A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. ( Athmann, LM; Burnham, NL; Cianflone, SG; Cross, M; Dose, AM; Etzell, PS; Gainey, DK; Hagen, L; Loprinzi, CL; Therneau, TM, 1990)
"We have performed a prospective randomized controlled study of 5-fluorouracil (5FU) + leucovorin versus 5FU alone in patients with metastatic colorectal cancer."9.06Fluorouracil and leucovorin for metastatic colorectal cancer. ( Erlichman, C, 1990)
"A novel sequential administration schedule of PALA (N-phosphonoacetyl-L-aspartate) and thymidine to enhance the cytotoxic effect of 5-fluorouracil (5FU) was tested in 36 patients with advanced gastric cancer and 21 patients with advanced poorly differentiated (anaplastic) colorectal cancer."9.06A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer. ( Goldberg, RM; Krook, JE; Kugler, JW; Laurie, JA; Moertel, CG; O'Connell, MJ; Pfeifle, DM; Rubin, J; Wieand, HS; Windschitl, HE, 1990)
"A total of 21 untreated patients (5 males, 16 females; median age, 55 years; range, 28-72) with advanced measurable colorectal carcinoma were treated with an association of 5-fluorouracil (1000 mg/weekly) and alpha-2 interferon (three times a week s."9.06Alpha-2 interferon and 5-fluorouracil in advanced colorectal cancer. ( Aversa, SM; Daniele, O; Fiorentino, MV; Fornasiero, A; Ghiotto, C; Morandi, P, 1990)
"Four single-arm trials using methotrexate (M), 5-fluorouracil (5FU), and leucovorin (L) were sequentially performed in metastatic measurable colorectal cancer using different dosing and timing schedules for the three drugs."9.06Sequential methotrexate, 5-fluorouracil, and leucovorin in metastatic measurable colorectal cancer. Does it work? ( Cripps, C; Johnston, J; Maroun, J; Stewart, D; Weinerman, B, 1990)
"A prospective controlled randomized trial testing adjuvant postoperative combination chemotherapy (5-fluorouracil, lomustine (CCNU) and vincristine) versus no adjuvant therapy in patients operated on for Dukes' C colorectal cancer is reported."9.06Adjuvant chemotherapy with 5-fluorouracil, vincristine and CCNU for patients with Dukes' C colorectal cancer. The Swedish Gastrointestinal Tumour Adjuvant Therapy Group. ( Asklöf, G; Bergman, L; Domellöf, L; Hafström, L; Hansson, K; Kugelberg, C; Nilsson, T; Norryd, C; Rudenstam, CM; Wählby, L, 1990)
"The Mayo Clinic and the North Central Cancer Treatment Group (NCCTG) conducted a randomized clinical trial comparing five different combination chemotherapeutic regimens to single-agent 5-fluorouracil (5-FU), given by intravenous bolus technique (500 mg/m2 for 5 days) as a control, in the treatment of advanced colorectal cancer."9.06A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. ( O'Connell, MJ, 1989)
"Ninety-one patients with metastatic colorectal cancer were treated with continuous ambulatory 5-fluorouracil (5FU) infusion 250-300 mg/m2/day through a chronic indwelling central venous catheter."9.06Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: results in 91 patients. ( Anderson, T; Ausman, R; Beatty, P; Frick, J; Haas, C; Hansen, R; Quebbeman, E; Ritch, P; Schulte, W, 1989)
"5-Fluorouracil (5-FU) is an essential component of systemic chemotherapy for colorectal cancer (CRC) in the palliative and adjuvant settings."9.055-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. ( Buchler, T; Cervena, K; Veskrnova, V; Vodenkova, S; Vodicka, P; Vymetalkova, V, 2020)
"We performed the present systematic review and meta-analysis to evaluate the efficacy and safety for S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma (mCRC)."9.01Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis. ( Chen, J; Wang, J, 2019)
"5-Fluorouracil (5-Fu) is one of the most commonly prescribed antineoplastic agents against gastric and colorectal cancers."8.98Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis. ( Meng, F; Wang, Y; Xing, X; Zhang, L; Zhong, D, 2018)
"The clinical benefit of double-front-line therapy (including oxaliplatin or irinotecan or bevacizumab plus 5-fluorouracil (5FU) or capecitabine) compared to monotherapy (5FU or capecitabine) in elderly (> 70 years) patients with metastatic colorectal cancer (MCRC) is controversial."8.98Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients. ( Aparicio, T; Ghebriou, D; Guetz, GD; Landre, T; Maillard, E; Taleb, C; Zelek, L, 2018)
"Nowadays, systemic chemotherapy with intravenous (IV) 5-fluorouracil (5-FU) remains the most commonly prescribed treatment for metastatic colorectal cancers (CRC), in combination with other cytotoxic drugs."8.98Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis. ( Deng, Y; Wu, Z, 2018)
"The antiangiogenic monoclonal antibody aflibercept in association with fluorouracil and irinotecan improves the survival of patients with metastatic colorectal cancer (mCRC) treated previously with oxaliplatin-based therapy."8.93Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district. ( Ciuffreda, L; Fanchini, L; Mecca, C; Pinta, F; Ponzetti, A; Racca, P; Spadi, R; Zanini, M, 2016)
"Capecitabine is a tumor-activated oral fluoropyrimidine used in breast and colorectal cancer."8.91Hypertriglyceridemia and hyperglycemia induced by capecitabine: a report of two cases and review of the literature. ( Han, GH; Huang, JX, 2015)
"The relative efficacy and safety of first-line metastatic colorectal cancer (mCRC) treatment regimens, capecitabine with irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI), are not well defined."8.91Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI). ( Cao, J; Ding, HH; Ji, ZY; Jiang, T; Jin, JH; Song, WF; Wang, JJ; Wang, LW; Wu, WD, 2015)
"The National Institute for Health and Care Excellence (NICE) invited the manufacturer of aflibercept (Sanofi) to submit clinical and cost-effectiveness evidence for aflibercept in combination with irinotecan and fluorouracil-based therapy [irinotecan/5-fluorouracil/folinic acid (FOLFIRI)] for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy, as part of the Institute's Single Technology Appraisal process."8.91The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of ( Duarte, A; Duffy, S; Rodriguez-Lopez, R; Simmonds, M; Spackman, E; Wade, R; Woolacott, N, 2015)
"5-fluorouracil continues to be the cornerstone of treatment for colorectal cancer."8.90Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed. ( Avallone, A; Budillon, A; Di Gennaro, E; Iaffaioli, VR; Silvestro, L, 2014)
"An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer."8.90Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014)
"Oxaliplatin, irinotecan and 5-fluorouracil in combination with or without targeted therapies are well-documented treatment options for first- and second-line treatments of metastatic colorectal cancer."8.90A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. ( Jensen, BV; Larsen, FO; Nielsen, DL; Palshof, JA; Pfeiffer, P, 2014)
"Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based."8.89Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. ( Cool, M; Deboever, G; Hiltrop, N; Lambrecht, G, 2013)
"The aim of this pooled-analysis is to evaluate the benefit of capecitabine (C) versus standard intravenous 5-Fluorouracil (5-FU) as monochemotherapy or combination therapy in advanced colorectal cancer (CRC) in terms of safety and efficacy."8.885-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials. ( Barni, S; Cabiddu, M; Petrelli, F, 2012)
"To evaluate the benefit and safety of fluorouracil implants on colorectal cancer."8.88[Fluorouracil implants for colorectal cancer: a systematic review and meta-analysis]. ( Chen, JR; Huang, Y; Li, YL; Nie, YL; Zhang, MM, 2012)
"The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer."8.87Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011)
"We performed a computerized search using combinations of the following keywords: "metastatic colorectal cancer," "Xeloda," "chemotherapy," "capecitabine," or "5-fluorouracil."8.87Capecitabine-based chemotherapy for metastatic colorectal cancer. ( Fan, J; Ling, W; Ma, Y; Wang, H, 2011)
"We performed a meta-analysis to evaluate the efficacy and safety of Fluorouracil (FU)/Leucovorin (LV)/Oxaliplatin compared to FU/LV in treating advanced colorectal cancer."8.86A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer. ( Chen, ML; Dai, LH; Fang, CH; Liang, LS; Wang, XK, 2010)
"A meta-analysis of randomized controlled trials (RCT) was carried out to determine the efficacy and safety of capecitabine plus oxaliplatin (CAPOX) or fluorouracil plus oxaliplatin (FUOX) as first-line treatment for metastatic colorectal cancer (MCRC)."8.86Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis. ( Gao, P; Ma, B; Tian, JH; Yang, KH; Zhao, G, 2010)
", Nutley, NJ) is an orally administered fluoropyrimidine carbamate that serves as a prodrug of 5-fluorouracil (5-FU), an integral component of chemotherapy (CT) regimens for metastatic colorectal cancer (mCRC)."8.86Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer. ( Boehm, KA; Cartwright, T; McCollum, D, 2010)
"Capecitabine, an oral prodrug of 5-fluorouracil, is indicated for adjuvant treatment in patients with Dukes' C colon cancer and for subsequent lines in metastatic colorectal cancer."8.86Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer. ( Best, JH; Garrison, LP, 2010)
"Capecitabine is an oral fluoropyrimidine that is shown to have similar efficacy to 5-fluorouracil (5-FU) when used both alone and in combination with oxaliplatin in the treatment of colorectal cancer (CRC)."8.86Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer. ( Aliberti, C; Chiriatti, A; Fiorentini, G; Licitra, S; Montagnani, F, 2010)
"Literature searches from large publication databases (PubMed, ASCO, ASCO GI, ESMO) were performed to capture key data relevant to bevacizumab, irinotecan, and the treatment of colorectal cancer."8.86Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer. ( Heinemann, V; Hoff, PM, 2010)
"To compare clinical efficacy and toxicity of irinotecan combined with 5-fluorouracil and leucovorin with those of oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer."8.86Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis. ( Hou, SH; Li, YP; Liang, XB; Wang, LC; Yang, J; Zhang, X, 2010)
"Capecitabine (N -pentyloxycarbonyl-5-deoxy-5-fluorocytidine), an oral prodrug of 5-fluorouracil, has provided compelling efficacy data for the treatment of metastatic breast cancer and stage III or IV colorectal cancer, both as monotherapy and in combination regimens."8.85Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. ( Aprile, G; Mazzer, M; Moroso, S; Puglisi, F, 2009)
"Relevant studies were identified in PubMed, Ovid, Cochrane database and the American Society of Clinical Oncology abstracts using the following search terms: gemcitabine, fluorouracil, capecitabine and colorectal cancer."8.85Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512). ( Hoimes, C; Merl, M; Pham, T; Saif, MW, 2009)
" In this review, we summarized the current status of our knowledge about the effectiveness of curcumin when given in combination with current chemotherapeutics such as 5-fluorouracil, oxaliplatin, and gemcitabine in treatment of gastrointestinal cancers with particular reference to colorectal cancer."8.85Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview. ( Majumdar, AP; Patel, BB, 2009)
"Continuous-infusion 5-fluorouracil (5-FU)/leucovorin (LV) and oxaliplatin is a frequently used regimen in metastatic colorectal cancer."8.84Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer? ( Bennouna, J; Douillard, JY; Senellart, H, 2008)
"Six randomized phase II and III trials have investigated the role of oxaliplatin (OX) in combination with capecitabine (CAP) or infusional fluorouracil (FU) in metastatic colorectal cancer."8.84Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. ( Arkenau, HT; Arnold, D; Cassidy, J; Diaz-Rubio, E; Douillard, JY; Grothey, A; Hinke, A; Hochster, H; Martoni, A; Porschen, R; Schmiegel, W; Schmoll, HJ, 2008)
"5-fluorouracil (5FU)-based treatments remain the main chemotherapy for colorectal cancer."8.84Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer. ( Etienne-Grimaldi, MC; Formento, JL; Francoual, M; Milano, G, 2007)
"Based on improved safety and efficacy results, advanced colorectal cancer (CRC) treatment has recently shifted from intravenous bolus 5-fluorouracil (5-FU) monotherapy to standard combinations of prolonged intravenous 5-FU infusion with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI)."8.84Capecitabine plus oxaliplatin for the treatment of colorectal cancer. ( Carrato, A; Gallego-Plazas, J; Guillén-Ponce, C, 2008)
"Uncertainty exists about whether elderly patients benefit to the same extent as younger patients from combination therapy with irinotecan in the first-line treatment of metastatic colorectal cancer (CRC)."8.84Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. ( Douillard, JY; Folprecht, G; Hecker, H; Köhne, CH; Maughan, TS; Mitry, E; Rougier, P; Saltz, L; Schubert, U; Seymour, MT; Stephens, RJ; Van Cutsem, E, 2008)
"Capecitabine, an oral prodrug of fluorouracil (5FU), has shown efficacy in terms of progression-free and overall survival at least equivalent to standard folinic acid (leucovorin)-modulated intravenous 5FU bolus regimens in patients with metastatic colorectal cancer."8.84Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence. ( Avallone, A; Casaretti, R; Comella, P; Franco, L; Sandomenico, C, 2008)
"To evaluate three technologies for the management of advanced colorectal cancer: (1) first-line irinotecan combination [with 5-fluorouracil (5-FU)] or second-line monotherapy; (2) first- or second-line oxaliplatin combination (again, with 5-FU); and (3) raltitrexed, where 5-FU is inappropriate."8.84The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. ( Eggington, S; Hind, D; Ryan, A; Sutcliffe, P; Tappenden, P; Tumur, I, 2008)
"In a dozen years of development, irinotecan (CPT11) became one of major therapeutics in the taking care of the metastatic colorectal cancer (CCRM)."8.83[Irinotecan for the treatment of metastatic colorectal cancer]. ( Assenat, E; Duffour, J; Ychou, M, 2006)
"A combination of irinotecan (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is one of the standard treatments for advanced colorectal cancer patients."8.83[Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer]. ( Goto, A, 2006)
" A phase III randomized trial, Xeloda in Adjuvant Colorectal Cancer Treatment, demonstrated that treatment with single-agent capecitabine was equivalent to bolus 5-fluorouracil with leucovorin with respect to disease-free survival and overall survival, with significantly less diarrhea, stomatitis, neutropenia, nausea and vomiting, and alopecia."8.83Capecitabine: a new adjuvant option for colorectal cancer. ( Berg, DT, 2006)
"Oxaliplatin, fluorouracil, and leucovorin are commonly used to treat advanced and resected colorectal cancer."8.83Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. ( Andre, T; Bleiberg, H; de Gramont, A; Goldberg, RM; Green, E; Rothenberg, ML; Sargent, DJ; Tabah-Fisch, I; Tournigand, C, 2006)
"During the last decade, considerable progress has been made in the development of 5-fluorouracil/leucovorin (5-FU/LV) regimens that optimize antitumor efficacy while minimizing toxicity in the management of colorectal cancer."8.82Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer. ( de Gramont, A; Kuebler, JP, 2003)
"To evaluate the clinical and cost-effectiveness of capecitabine and tegafur with uracil (UFT/LV) as first-line treatments for patients with metastatic colorectal cancer, as compared with 5-fluorouracil/folinic acid (5-FU/FA) regimens."8.82Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. ( Brewer, N; Cowan, J; Kaltenthaler, E; Ward, S, 2003)
"Four phase III clinical trials comparing a fluorouracil-based regimen with the same regimen plus either CPT-11 or oxaliplatin in advanced colorectal cancer patients were reviewed."8.82Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11. ( Bleiberg, H; Buyse, M; Di Leo, A, 2004)
"Fluorouracil (FU)-leucovorin (LV), irinotecan, and oxaliplatin administered alone or in combination have proven effective in the treatment of advanced colorectal cancer (CRC)."8.82Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. ( Goldberg, RM; Grothey, A; Sargent, D; Schmoll, HJ, 2004)
"Comparative trials of capecitabine (Xeloda) versus 5-FU/LV in metastatic colorectal cancer have shown that hand-foot syndrome (HFS) was the only clinical adverse event occurring more frequently with capecitabine."8.82Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). ( Hoff, P; Lassere, Y, 2004)
"The modulation of fluorouracil (FU) by folinic acid (leucovorin [LV]) has been shown to be effective in terms of tumor response rate in patients with advanced colorectal cancer, but a meta-analysis of nine trials previously published by our group failed to demonstrate a statistically significant survival difference between FU and FU-LV."8.82Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. ( Braud, AC; Buyse, M; Carlson, RW; Michiels, S; O'Connell, M; Piedbois, P; Pignon, JP; Sargent, P; Thirion, P, 2004)
"Hand-foot syndrome is a localized cutaneous side effect associated with the administration of several chemotherapeutic agents, including the oralfluoropyrimidine capecitabine (Xeloda)."8.82Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. ( Blum, J; Scheithauer, W, 2004)
"New results presented at ASCO Conference in 2003 added further important data to our knowledge on successful use of irinotecan in colorectal cancer (CRC)."8.82[Recent results of irinotecan therapy in colorectal cancer]. ( Hitre, E; Láng, I, 2004)
"Variations of fluorouracil (5-FU) therapy have formed the backbone of chemotherapy for advanced colorectal cancer for many years."8.82Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics. ( Hwang, JJ, 2004)
"In 2002, the UK National Institute for Clinical Excellence (NICE) issued guidance on the use of irinotecan, oxaliplatin and raltitrexed in advanced colorectal cancer."8.82The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. ( Poston, GJ, 2005)
"Irinotecan is a cornerstone drug in the management of metastatic colorectal cancer, as demonstrated by several randomized studies proving a survival benefit for the first time."8.82Irinotecan-based regimens in the adjuvant therapy of colorectal cancer. ( Douillard, JY, 2005)
"Capecitabine is active against anthracycline- and taxane-pretreated metastatic breast cancer."8.82Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. ( Gauthier, AM; Hennessy, BT; Hortobagyi, G; Michaud, LB; Valero, V, 2005)
"We examined the cardiotoxicity in 153 patients treated with capecitabine and oxaliplatin in two prospective trials for advanced colorectal cancer."8.82The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). ( Cunningham, D; Ng, M; Norman, AR, 2005)
"For more than 40 years, 5-fluorouracil (5-FU) has been considered the most effective systemic agent for managing advanced colorectal cancer."8.82Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. ( Saif, MW, 2005)
"The combination of capecitabine (Xeloda) and oxaliplatin (Eloxatin), or XELOX, is an effective and safe approach to the treatment of advanced colorectal cancer, with the potential advantage of convenience over standard combination regimens."8.81Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? ( Twelves, C, 2002)
"In this review, the clinical rationale and update of the present clinical status of irinotecan in the treatment of colorectal cancer and future prospects of irinotecan-based combinations are discussed."8.81Irinotecan in the treatment of colorectal cancer: clinical overview. ( Achterrath, W; Cao, S; Harstrick, A; Rustum, YM; Seeber, S; Vanhoefer, U, 2001)
"Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) both have demonstrated single-agent activity in patients with colorectal cancer."8.81Capecitabine/irinotecan combination regimens in colorectal cancer. ( Kerr, DJ, 2002)
"The administration of fluorouracil (5-FU) by continuous intravenous infusion (CI) is an alternative to the bolus administration of 5-FU in patients with advanced colorectal cancer."8.80Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. ( Benedetti, J; Brufman, G; Buyse, M; Fryer, J; Hansen, R; Isacson, R; Laplanche, A; Leichman, C; Levy, E; Lokich, J; Macdonald, J; Pater, J; Piedbois, P; Pignon, J; Rougier, P; Ryan, L; Weinerman, B; Zee, B, 1998)
"5-Fluorouracil (5-FU) remains the agent of choice for the treatment of colorectal cancer."8.80Biomodulation of Fluorouracil in colorectal cancer. ( Ardalan, B; Franceschi, D; Jaime, M; Luis, R, 1998)
"Oxaliplatin was first introduced to the clinical setting as a combination therapy with 5-fluorouracil/folinic acid (5-FU/FA) in an attempt to improve the response rate obtained with 5-FU/FA against colorectal cancer."8.80Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. ( Bleiberg, H; de Gramont, A, 1998)
"The addition of leucovorin (LV) to 5-fluorouracil (5-FU) in advanced colorectal cancer has shown improved tumour response rates in many trials, but the optimal LV/5-FU regimen has yet to be determined."8.80A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). ( André, T; de Gramont, A; Krulik, M; Louvet, C; Tournigand, C, 1998)
"But fluorouracil (5-FU) and irinotecan (CPT-11 [Camptosar]) have shown activity in metastatic colorectal cancer and are approved for its treatment in the United States."8.80Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials. ( Erlichman, C; Goldberg, RM, 1998)
"Salvage treatment with 5-fluorouracil (5-FU) with or without leucovorin may induce responses in patients with advanced colorectal cancer whose disease progresses after adjuvant therapy with the same drugs."8.80Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer? ( Goldberg, RM, 1998)
"Therapeutic options after failure of 5-fluorouracil (5-FU) for the treatment of colorectal cancer include regional treatments, different 5-FU-based regimens, and different chemotherapy regimens."8.80Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure. ( Henderson, CA, 1998)
"Fluorouracil (5-FU) continuous infusion is superior to 5-FU bolus in patients with advanced colorectal cancer, but the survival difference between the two treatments is small and, therefore, the difference in toxicity profile is crucial in choosing a treatment for individual patients."8.80Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. ( Benedetti, J; Brufman, G; Buyse, M; Fryer, J; Hansen, R; Isacson, R; Laplanche, A; Leichman, C; Lévy, E; Lokich, J; Macdonald, J; Pater, J; Piedbois, P; Pignon, JP; Quinaux, E; Rougier, P; Ryan, L; Thirion, P; Weinerman, B; Zee, B, 1998)
"The final results of two very important randomized trials of irinotecan (Campto, Rhône-Poulenc Rorer, Antony, France) as second-line treatment for patients with advanced colorectal cancer are presented."8.80Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice. ( Cunningham, D, 1999)
"Irinotecan, also known as CPT-11, is a topoisomerase I inhibitor currently approved for use as a second-line agent in the treatment of advanced colorectal cancer."8.80The role of irinotecan in colorectal cancer. ( Saltz, LB, 1999)
"Two randomized phase III trials with irinotecan as second-line treatment of metastatic colorectal cancer have shown that irinotecan (CPT-11, Camptosar) significantly improves survival when compared with best supportive care or continuous infusion of fluorouracil (5-FU) after failure of 5-FU."8.80Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer. ( Douillard, JY, 2000)
"5-Fluorouracil (5-FU) is the most active single agent for treatment of advanced colorectal cancer, although objective responses occur in only 20% of patients, and there seems to be no impact on overall survival."8.79Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-alpha: an overview of clinical trials. ( Raderer, M; Scheithauer, W, 1995)
"Even though fluorouracil (5FU) remains the standard treatment of advanced colorectal cancer, almost 90% of patients treated with 5FU alone do not achieve an objective response to chemotherapy."8.79Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. ( , 1994)
"Possible prognostic variables for tumor response, time to progression (TTP), and survival in 141 patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy were analyzed."8.79Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy. ( Fountzilas, G; Gossios, K; Pavlidis, N; Skarlos, D; Svarna, E; Zisiadis, A, 1996)
"CPT-11 (Campto, irinotecan) is a new topoisomerase I inhibitor and one of very few new cytotoxic agents to demonstrate clinical activity in colorectal cancer since the introduction of 5-fluorouracil (5-FU) into clinical practice almost 40 years ago."8.79CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. ( Khayat, D; Saltz, L; Shimada, Y, 1996)
"Several modifications to the administration schedule of 5-fluorouracil (5-FU) alone or in combination with other agents have been investigated in advanced colorectal cancer."8.79Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: a critical review of comparative studies. ( Facendola, G; Labianca, R; Luporini, G; Pessi, A; Pirovano, M, 1996)
"All of the published adjuvant studies for colorectal cancer in which 5-FU (either as a single agent or in combination with other cytotoxics or levamisole) was compared to a no-treatment control group were ranked according to the total planned dose of 5-FU (assuming a body weight of 70 kg or a body surface area of 1."8.79The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer. ( Siderov, J; Simes, J; Zalcberg, JR, 1996)
"The rational of leucovorin modulation of 5-fluorouracil and the clinical results in colorectal cancer are reviewed with special emphasis on the monthly schedule of low dose leucovorin and 5FU bolus for 5 consecutive days (NCCTG-Mayo Clinic regimen) and the bimonthly schedule of high-dose leucovorin and 5FU bolus plus continuous infusion for two consecutive days (LV5FU2) which is now considered as a new standard."8.79[Modulation of 5-fluorouracil with folinic acid in advanced colorectal cancers. Groupe d'étude et de recherche sur les cancers de l'ovaire et digestifs (GERCOD)]. ( André, T; de Gramont, A; Krulik, M; Louvet, C; Molitor, JL; Raymond, E; Tournigand, C, 1997)
"A variety of 5-fluorouracil (5-FU)- based chemotherapy regimens have been investigated in colorectal cancer patients in randomized trials over the past decade."8.79Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin. ( Grem, JL, 1997)
"A meta-analysis was performed on nine randomized clinical trials that compared fluorouracil (5-FU) with 5-FU plus intravenous (IV) leucovorin (LV) for the treatment of advanced colorectal cancer."8.78Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. ( , 1992)
"Three clinical trials have been conducted with fluorouracil (5-FU) and recombinant interferon alfa-2a (rIFN-alpha 2a) in the treatment of advanced colorectal carcinoma."8.78Clinical trials of fluorouracil with alpha-interferon in advanced colorectal carcinomas. ( Bready, B; Moore, DF; Pazdur, R, 1991)
"Seventy-five previously untreated patients with measurable advanced colorectal cancer were treated with 5 fluorouracil 1,000 mg/m2 as a 24-hour intravenous (i."8.78120-hour 5-fluorouracil (5-FU) continuous infusion (CI) plus BCNU in advanced colorectal cancer. ( Aguilo, J; Asencio, F; Candel, MT; Delgado, F; García-Reinoso, J; Martínez-Abad, M; Sánchez, JJ; Sanchis, C; Viciano, V; Villar-Grimalt, A, 1991)
"5-Fluorouracil (5-FU) is a widely used chemotherapeutic agent for colorectal cancer (CRC) owing to its potent anticancer effects."8.315-Fluorouracil crystal-incorporated, pH-responsive, and release-modulating PLGA/Eudragit FS hybrid microparticles for local colorectal cancer-targeted chemotherapy. ( Bae, J; Hee Lee, E; Kim, H; Kim, J; Kim, MS; Kwak, D; Lee, J; Phyu Hlaing, S; Ryong Moon, H; Saparbayeva, A; Yoo, JW; Yoon, IS, 2023)
"5-Fluorouracil (5-FU) represents the cornerstone for colorectal cancer therapy."8.31Enhancement of the antitumor effect of 5-fluorouracil with modulation in drug transporters expression using PI3K inhibitors in colorectal cancer cells. ( Abo-Elfadl, MT; Abo-Zeid, MAM; El-Daly, SM; Hussein, J, 2023)
"As EIF3D is oncogenic in colorectal cancer (CRC) and is associated with multidrug resistance, this study aims to investigate whether and how EIF3D regulates resistance to 5-fluorouracil (5-Fu) in CRC."8.31EIF3D promotes resistance to 5-fluorouracil in colorectal cancer through upregulating RUVBL1. ( Du, W; Li, C; Liang, Z; Lu, K; Yang, C, 2023)
"5-Fluorouracil (5-Fu) is a first-line drug for colorectal cancer (CRC) therapy."8.31Thiol oxidative stress-dependent degradation of transglutaminase2 via protein S-glutathionylation sensitizes 5-fluorouracil therapy in 5-fluorouracil-resistant colorectal cancer cells. ( Chen, A; Chen, W; Chen, Z; Dai, W; Jiang, R; Li, X; Ling, Y; Ma, Y; Ni, M; Wu, J; Yao, Q; Zhou, Y, 2023)
" In this study, 5-fluorouracil (5FU) was loaded into ruthenium (Ru)-based nanocarrier (5FU-RuNPs) for the first time to eliminate the disadvantages of 5FU, and its cytotoxic and apoptotic effects on HCT116 colorectal cancer cells were compared with free 5FU."8.31The Novel 5-Fluorouracil Loaded Ruthenium-based Nanocarriers Enhanced Anticancer and Apoptotic Efficiency while Reducing Multidrug Resistance in Colorectal Cancer Cells. ( Bulut, H; Danişman-Kalindemirtaş, F; Kariper, İA; Özerkan, D, 2023)
"We evaluated the pharmacokinetics and pharmacodynamics/toxicodynamics of uracil-tegafur (UFT) after multiple administrations in colorectal cancer (CRC) model rats, and applied a pharmacometric approach to describe the time-course alterations of plasma 5-FU concentrations and tumor shrinkage."8.31A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model. ( Ito, Y; Kobuchi, S; Nakamura, T; Okamura, M; Tsuda, M, 2023)
"Encorafenib + cetuximab (E+C) is an effective therapeutic option in chemorefractory BRAFV600E metastatic colorectal cancer (mCRC)."8.31Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer. ( Altucci, L; Anderson, A; Ciardiello, D; Ciardiello, F; Coker, O; De Falco, V; Della Corte, CM; Famiglietti, V; Fowlkes, NW; Kanikarla, P; Kopetz, S; Lee, HM; Martinelli, E; Martini, G; Morris, V; Napolitano, S; Sorokin, A; Tabernero, J; Troiani, T; Villareal, OE; Woods, M, 2023)
"5-Fluorouracil (5-FU) is widely used for colorectal cancer (CRC) treatment; however, continuous treatment of CRC cells with 5-FU can result in acquired resistance, and the underlying mechanism of 5-FU resistance remains unclear."8.31Relationship between anticancer sensitivities and cellular respiration properties in 5-fluorouracil-resistant HCT116 human colorectal cancer cells. ( Kurasaka, C; Nishizawa, N; Ogino, Y; Sato, A; Uozumi, H, 2023)
"Insensitivity and resistance to 5-fluorouracil (5FU) remain as major hurdles for effective and durable 5FU-based chemotherapy in colorectal cancer (CRC) patients."8.31Targeting PTGES/PGE2 axis enhances sensitivity of colorectal cancer cells to 5-fluorouracil. ( Cao, L; Geng, L; Geng, S; Ren, X; Zhan, H, 2023)
"To date, oxaliplatin and irinotecan are used in combination with 5-flourouracil (5-FU) for metastatic colorectal cancer."8.31Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells. ( Bock, F; Cappel, ML; Frerker, B; Hildebrandt, G; Klautke, G; Kriesen, S; Manda, K, 2023)
"The gold standard drug for colorectal cancer (CRC) treatment, 5-Fluorouracil (5-FU), induces pharmacological tolerance in long-term management."8.31Dermatan Sulfate/Chitosan Nanoparticles Loaded with an Anti-Inflammatory Peptide Increase the Response of Human Colorectal Cancer Cells to 5-Fluorouracil. ( Barredo-Vacchelli, GR; Birocco, AM; Blachman, A; Calabrese, GC; Camperi, SA; Cenci, G; Curcio, S; Gianvincenzo, PD; Moya, S; Rodriguez, JA; Sosnik, A, 2023)
"In this study, we investigated the combined treatment of 5-fluorouracil (5-FU) and Anatolian propolis extract (PE) on colorectal cancer (CRC)using in vitro and in vivo studies."8.31Propolis Enhances 5-Fluorouracil Mediated Antitumor Efficacy and Reduces Side Effects in Colorectal Cancer: An in Vitro and in Vivo Study. ( Aydogdu, G; Durmus, E; Goren, AC; Guler, EM; Hekimoglu, ER; Kanimdan, E; Kocyigit, A; Oruc, HH; Ozman, Z; Yasar, O; Yenigun, VB, 2023)
"5-Fluorouracil (5-FU) is the first-line treatment for colorectal cancer (CRC) patients, but the development of acquired resistance to 5-FU remains a big challenge."8.31Targeting proteasomal deubiquitinases USP14 and UCHL5 with b-AP15 reduces 5-fluorouracil resistance in colorectal cancer cells. ( Chen, X; Ding, W; Jiang, LL; Liu, AC; Liu, BY; Liu, JB; Lou, EZ; Mao, Q; Meng, Y; Peng, GJ; Shi, XP; Tang, DL; Wang, JX; Wu, JZ; Zhang, HC; Zhou, H, 2023)
"We found that ABCA2 polymorphism was significantly associated with systemic exposure to capecitabine and capecitabine-induced neutropenia in Japanese patients with CRC."8.31A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer. ( Fujita, KI; Ishida, H; Kubota, Y; Matsumoto, N; Murase, R; Shibata, Y; Shimada, K, 2023)
" Here, we designed a composite liposomal nano-carrier co-loading 5-Fluorouracil (5-FU) with all-trans retinoic acid (ATRA) to assess anticancer efficacy of the combined drugs in colorectal cancer (CRC)."8.31In vitro co-delivery of 5-fluorouracil and all-trans retinoic acid by PEGylated liposomes for colorectal cancer treatment. ( Afshar, S; Amini, R; Azarifar, Z; Najafi, R; Tanzadehpanah, H, 2023)
"The efficacy of fluorouracil + oxaliplatin + irinotecan with bevacizumab (FOLFOXIRI + BV) has been verified for metastatic colorectal cancer (mCRC)."8.12Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice. ( Aoyama, T; Kazama, K; Numata, M; Oshima, T; Rino, Y; Sato, M; Sato, S; Shiozawa, M; Sugano, N; Tamagawa, H; Uchiyama, M; Yukawa, N, 2022)
"To evaluate the efficacy and safety of apatinib combined with FOLFIRI in the first-line treatment of advanced metastatic colorectal cancer (mCRC) and explore potential factors of efficacy."8.12Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer. ( Liu, H; Rong, X; Wang, J; Wang, Y; Yu, H; Zhao, J, 2022)
"Acquired resistance of 5-fluorouracil (5-FU) remains a clinical challenge in colorectal cancer (CRC), and efforts to develop targeted agents to reduce resistance have not yielded success."8.12ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer. ( Cheng, Z; Dong, S; Hu, S; Li, L; Li, S; Liang, S; Luo, L; Xu, Q; Zhang, G; Zhang, W; Zhang, X; Zhong, M; Zhu, J, 2022)
"Most patients affected with colorectal cancers (CRC) are treated with 5-fluorouracil (5-FU)-based chemotherapy but its efficacy is often hampered by resistance mechanisms linked to tumor heterogeneity."8.12CDX2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancer. ( Bersuder, E; Brigand, C; Chenard, MP; Delhorme, JB; Duluc, I; Freund, JN; Gross, I; Martin, E; Rohr, S; Terciolo, C; Vlami, O, 2022)
"Chemotherapy is used for recurrent and metastatic colorectal cancer, but the response rate of 5-fluorouracil (5-FU), the standard treatment for colorectal cancer, is low."8.12Effect of Thymidine Phosphorylase Gene Demethylation on Sensitivity to 5-Fluorouracil in Colorectal Cancer Cells. ( Akiyama, N; Eto, K; Koyama, M; Manome, Y; Osada, E, 2022)
"Our findings demonstrated that targeting RAS pathway using Valsartan interferes with cell-proliferation, induces apoptosis, reduces migration and synergistically interacts with 5-FU, supporting further studies on this new therapeutic approach for colorectal cancer."8.12Inhibition of angiotensin pathway via valsartan reduces tumor growth in models of colorectal cancer. ( Amerizadeh, F; Asgharzadeh, F; Avan, A; Ebrahimi, S; Fakhraei, M; Farshbaf, A; Ferns, GA; Giovannetti, E; Hassanian, SM; Khazaei, M; Mostafapour, A; Sabbaghzadeh, R, 2022)
"To compare the efficacy and safety of folinic acid, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab or aflibercept in metastatic colorectal cancer (mCRC) patients pretreated with oxaliplatin-based chemotherapy."8.12A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. ( Hong, JY; Jo, H; Kang, WK; Kim, H; Kim, ST; Lee, J; Lee, MS; Lee, YP; Lim, HY; Park, JO; Park, SH; Park, YS, 2022)
"The impact of activating transcription factor 4 (ATF4), differentially expressed in colorectal cancer (CRC), on 5-Fluorouracil (5-FU) chemoresistance has not been fully explained."8.12ATF4-mediated microRNA-145/HDAC4/p53 axis affects resistance of colorectal cancer cells to 5-fluorouracil by regulating autophagy. ( Chen, H; Hu, H; Ma, J; Xu, L; Zhang, Q; Zhao, L, 2022)
"The oral fluoropyrimidine S-1 has shown comparable efficacy to capecitabine in Asian and some Western studies on metastatic colorectal cancer."8.12Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer. ( Kwakman, JJM; Mol, L; Punt, CJA, 2022)
"The aim of this study was to improve the direct results of reconstructive surgery in patients operated on for complicated forms of colorectal cancer, by using 5-fluorouracil in the postoperative period."8.12The Effect of 5-Fluorouracil on the Adhesion Process in Patients Operated on for Colorectal Cancer. ( Irimbetov, S; Osombaev, M; Zhakipbekov, S, 2022)
"Clinically, 5-fluorouracil (5-Fu) is a first-line drug for the treatment of patients with colorectal cancer (CRC)."8.12Synergistic antitumor activity of 5-fluorouracil and atosiban against microsatellite stable colorectal cancer through restoring GATA3. ( Chen, M; Chen, Y; Guo, X; Li, J; Li, Z; Meng, F; Qiu, T; Wang, M; Wang, W; Xu, F; Yang, M; Zhang, H; Zhang, Q; Zhang, Y, 2022)
"Cancer patients treated with capecitabine and oxaliplatin (XELOX) often develop hand-foot syndrome (HFS) or palmar-plantar erythrodysesthesia."8.12Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. ( Al-Tassan, NA; Cheadle, JP; Escott-Price, V; Houlston, RS; Kaplan, R; Kerr, DJ; Kerr, R; Madi, A; Maughan, TS; Palles, C; Watts, K; Wills, C, 2022)
" In this study, we aimed to determine the changes of autophagy in the cellular model of acquired chemoresistance of colorectal cancer cell lines HCT116 and SW620, induced by 5-fluorouracil (5-FU) or oxaliplatin (OxaPt) treatment, and determine the susceptible factors for autophagy inhibition."8.12Differential effects of 5-fluorouracil and oxaliplatin on autophagy in chemoresistant colorectal cancer cells. ( Jonusiene, V; Kukcinaviciute, E; Sasnauskiene, A; Starkuviene, V; Zitkute, V, 2022)
"To date, 5-fluorouracil-based chemotherapy is very important for locally advanced or metastatic colorectal cancer (CRC)."8.12Targeting DCLK1 overcomes 5-fluorouracil resistance in colorectal cancer through inhibiting CCAR1/β-catenin pathway-mediated cancer stemness. ( Cheng, J; Jin, M; Lin, Z; Ren, J; Wang, L; Wu, G; Yang, K; Yu, D; Zhang, D; Zhang, T; Zhao, L; Zhou, P, 2022)
"Surgically resected colorectal cancer specimens from 89 patients were decellularized to produce patient-derived scaffold, which were seeded with HT29 cells, cultured for 3 weeks, and treated with 5-fluorouracil."8.125-fluorouracil treatment of patient-derived scaffolds from colorectal cancer reveal clinically critical information. ( Bexe Lindskog, E; Holdfeldt, A; Landberg, G; Salerno, S; Ståhlberg, A, 2022)
"Five-fluorouracil, folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) regimen is used as the first-line treatment for metastatic colorectal cancer (mCRC)."8.12Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study. ( Gao, L; Liu, X; Ma, X; Ou, K; Wang, Q; Yang, L; Zhang, H, 2022)
" Therefore, this study aimed to clarify the role of PYCR1 and its interaction with SLC25A10 in a chemotherapeutic agent 5-fluorouracil (5-FU)'s toxicity to colorectal cancer cells."8.12The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer. ( Mai, Z; Qiu, X; Song, Y; Xia, W; Yang, X; Ye, Y; Zhang, M; Zhou, B, 2022)
"a capecitabine and oxaliplatin drug combination regimen has shown a survival benefit in patients with advanced colorectal cancer, yet its administration represents an attractive option for low resource settings."8.12Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study. ( Begg, W; Kibudde, S, 2022)
"5-Fluorouracil (5-FU), a known cardiotoxin, is the backbone for the treatment of colorectal cancer."8.12Managing life-threatening 5-fluorouracil cardiotoxicity. ( Boldig, K; Ganguly, A; Kadakia, M; Rohatgi, A, 2022)
" Topoisomerase-I inhibitor irinotecan is used clinically to treat colorectal cancer (CRC), often in combination with 5-fluorouracil (5FU)."8.12ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer. ( Bagby, SM; Cadogan, EB; Davis, SL; Diamond, JR; Durant, ST; Hartman, SJ; Hughes, GD; Leal, AD; Lieu, CH; Messersmith, WA; Pitts, TM; Schlaepfer, M; Simmons, DM; Tse, T; Yacob, BW, 2022)
"We experienced 2 cases of Stage Ⅳ colorectal cancer obtained long-term survival by chemotherapy with only capecitabine."8.12[Two Cases of Stage Ⅳ Colorectal Cancer with Long-Term Survival following Single-Agent Chemotherapy with Capecitabine-A Case Reports]. ( Ando, K; Chiku, T; Fukuyama, M; Hashiba, H; Sano, W; Shinoda, K; Suda, K, 2022)
"The aim of this study was to investigate the antitumor effects of quercetin and luteolin combined with 5-Fluorouracil (5-FU) in HT-29 human colorectal cancer cells."8.12Quercetin and Luteolin Improve the Anticancer Effects of 5-Fluorouracil in Human Colorectal Adenocarcinoma ( Ağca, CA; Aşkın, H; Erdoğan, MK, 2022)
"Adjuvant chemotherapy with 5-fluorouracil (5-FU) does not improve survival of patients suffering from a form of colorectal cancer (CRC) characterized by high level of microsatellite instability (MSI-H)."8.02Casein Kinase-1-Alpha Inhibitor (D4476) Sensitizes Microsatellite Instable Colorectal Cancer Cells to 5-Fluorouracil via Authophagy Flux Inhibition. ( Behrouj, H; Dastghaib, S; Ghavami, S; Hudecki, J; Khazayel, S; Likus, W; Mokarram, P; Rezaie, S; Siri, M; Zamani, M; Łos, MJ, 2021)
"Although effective drugs have been developed, including 5-fluorouracil (5-FU), advanced colorectal cancer (CRC) shows low therapeutic sensitivity resulting from the development of 5-FU resistance."8.02Apigenin enhances apoptosis induction by 5-fluorouracil through regulation of thymidylate synthase in colorectal cancer cells. ( Choi, J; Hwang, S; Lim, W; Song, G; Song, J; Yang, C, 2021)
"5-Fluorouracil (5-FU) resistance has been long considered as an obstacle to the efficacy of chemotherapy in colorectal cancer (CRC)."8.02Syndecan-2, negatively regulated by miR-20b-5p, contributes to 5-fluorouracil resistance of colorectal cancer cells via the JNK/ERK signaling pathway. ( Hua, R; Li, X; Ni, Q; Tang, D; Wang, D; Yan, X; Zhang, Y; Zhu, J, 2021)
"Currently, 5-Fluorouracil (5-FU) based chemotherapy is the primary option for colorectal cancer after surgery, whereas chemotherapy resistance related mortality is observed in a large proportion of patients."8.02Anemoside B4 sensitizes human colorectal cancer to fluorouracil-based chemotherapy through src-mediated cell apoptosis. ( Duan, XW; He, X; Hou, XL; Li, HQ; Liao, GB; Liu, W; Tang, J; Wang, JX; Yan, HZ; Yu, SY, 2021)
"First-line regimens in the treatment of metastatic colorectal cancer (mCRC) combine a fluoropyrimidine with oxaliplatin (FOLFOX/XELOX) or irinotecan (FOLFIRI)."8.02Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens. ( Carneiro, BA; El-Deiry, WS; Marks, EI; Matera, R; Olszewski, AJ; Safran, H; Yakirevich, E, 2021)
" Herein, mesoporous silica nanoparticles, a supported lipid bilayer and cetuximab were integrated to fabricate a hybrid nanoplatform for effectively encapsulating and selectively delivering 5-fluorouracil (5-FU) against colorectal cancer (CRC) cells."8.02Cetuximab functionalization strategy for combining active targeting and antimigration capacities of a hybrid composite nanoplatform applied to deliver 5-fluorouracil: toward colorectal cancer treatment. ( Chen, R; Gu, Q; Huang, Y; Li, J; Peng, C; Peng, W; Shao, G; Sheng, Y; Sun, Y; Tan, Y; Wang, L; Wang, Y; Yang, P; Zhang, Q; Zhou, J, 2021)
"Recently the phase 3 BEACON trial showed that the combination of encorafenib, cetuximab, and binimetinib versus cetuximab and irinotecan/FOLFIRI improved overall survival in pre-treated patients with metastatic colorectal cancer (mCRC) with BRAF V600E mutation."8.02Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA. ( Ding, D; Hu, H; Huang, J; Li, S; Zhu, Y, 2021)
"The administration schedule of capecitabine for the treatment of metastatic colorectal cancer (mCRC) in clinical trials has been 14 days of drug with 7 days off in a 21 day cycle (14/7)."8.02Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review. ( Akce, M; Alese, O; Bryson, E; Davis, C; Draper, A; El-Rayes, B; Goyal, S; Hall, K; Patel, U; Sakach, E; Shaib, W; Szabo, S; Watson, M; Wu, C, 2021)
" Chemotherapy using 5-fluorouracil (5-FU) has been widely applied to treat colorectal cancer (CRC)."8.02Low curcumin concentration enhances the anticancer effect of 5-fluorouracil against colorectal cancer. ( Lin, J; Shao, Y; Song, F; Yang, X; Zheng, X, 2021)
"Combination therapy comprised of fluoropyrimidine plus irinotecan with an angiogenesis inhibitor is widely used as a second-line treatment for metastatic colorectal cancer (mCRC)."8.02Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor. ( Aoki, K; Hamano, T; Makishima, M; Oki, E; Sano, F; Yamanaka, T; Yamazaki, K; Yuki, S, 2021)
"5-Fluorouracil (5-FU) resistance is an urgent problem of colorectal cancer (CRC) chemotherapy that needs to be resolved."8.02LncRNA ENSG00000254615 Modulates Proliferation and 5-FU Resistance by Regulating p21 and Cyclin D1 in Colorectal Cancer. ( Deng, Y; Fu, Y; Huang, R; Li, J; Xie, X, 2021)
"5-Fluorouracil (5-FU)-based chemotherapy is the first-line treatment for colorectal cancer (CRC) but is hampered by chemoresistance."8.02The loss of SHMT2 mediates 5-fluorouracil chemoresistance in colorectal cancer by upregulating autophagy. ( Chen, C; Chen, J; Fan, G; Liu, X; Lu, H; Na, R; Peng, Z; Song, G; Tang, H; Wang, X; Wang, Y; Xiao, C; Yan, D; Zhuang, G, 2021)
"To evaluate the anti-cancer effects of OJe, its possible mechanisms of action were investigated in 5-fluorouracil (5-FU) resistant SNU-C5/5-FUR colorectal cancer cells."8.02Anti-cancer effects of the aqueous extract of Orostachys japonica A. Berger on 5-fluorouracil-resistant colorectal cancer via MAPK signalling pathways in vitro and in vivo. ( Kim, J; Kim, JW; Kim, SH; Mariappan, R; Moon, D; Yoon, SP, 2021)
"BACKGROUND The impact of therapeutic drug management (TDM) on reducing toxicity and improving efficacy in colorectal cancer (CRC) patients receiving fluorouracil-based chemotherapy is still unclear."8.02Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy. ( Chang, R; Chang, Y; Han, J; Qian, J; Shen, C; Zhao, H; Zhou, X, 2021)
"5-Fluorouracil (5-FU) is regarded as the first line treatment for colorectal cancer; however, its effectiveness is limited by drug resistance."8.02The combined effect of dichloroacetate and 3-bromopyruvate on glucose metabolism in colorectal cancer cell line, HT-29; the mitochondrial pathway apoptosis. ( Alboghobeish, S; Behmanesh, B; Khodayar, MJ; Mahdavinia, M; Nikravesh, H; Teimoori, A; Zeidooni, L, 2021)
"The study aimed to explore the efficacy of pharmacokinetic-based 5-fluorouracil dose management by plasma concentration test in advanced colorectal cancer treatment."7.96Pharmacokinetics-based Dose Management of 5-Fluorouracil Clinical Research in Advanced Colorectal Cancer Treatment. ( Deng, R; Guan, X; Shen, B; Shi, L; Wang, M; Yang, D; Zhu, W, 2020)
"For over 50 years, 5-Fluorouracil has played a critical role in the treatment of numerous malignancies, including colorectal cancer."7.96Optic neuritis induced by 5-fluorouracil chemotherapy: Case report and review of the literature. ( Gilbar, PJ; Grewal, GD; Holcombe, DJ; Raina, AJ, 2020)
"5-fluorouracil (5-FU) is widely used in chemotherapy for colorectal cancer (CRC), but a high rate of chemoresistance reduces its effectiveness in clinical treatment."7.96FoxO3 reverses 5-fluorouracil resistance in human colorectal cancer cells by inhibiting the Nrf2/TR1 signaling pathway. ( Du, Q; He, B; Liu, C; Liu, X; Mi, Q; Peng, S; Qu, X; Wang, J; Yang, Y; Yao, Z; Zhang, X; Zhang, Y; Zhao, S; Zhao, Y; Zhu, Y; Zou, J, 2020)
"FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), a 5-fluorouracil (5-FU)-based chemotherapy regimen, is one of most common therapeutic regimens for colorectal cancer."7.96Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer. ( Chang, CW; Chen, MJ; Chen, YJ; Chiang Chiau, JS; Chuang, WH; Lee, HC; Li, LH; Liu, CY; Shih, SC; Tsai, TH; Wang, HY; Wang, TE, 2020)
"5-Fluorouracil-based therapy remains the main approach in colorectal cancer, even though there are still some drawbacks, such as chemoresistance."7.96Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo. ( Achim, M; Banciu, M; Casian, T; Dragos, N; Drotar, DM; Licarete, E; Luput, L; Muntean, D; Patras, L; Porfire, A; Rauca, VF; Sesarman, A; Stejerean, I; Toma, VA; Tomuta, I; Vlase, L, 2020)
"The standard first- and second- line chemotherapy backbone regimens for metastatic colorectal cancer (mCRC) are 5-fluorouracil (5-FU)/capecitabine-based with addition of irinotecan or oxaliplatin."7.96Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme. ( Carter, AM; Iveson, T; Mullamitha, S; Shiu, KK; Spooner, C; Stevens, D, 2020)
"5-Fluorouracil (5-Fu) is used as a conventional chemotherapy drug in chemotherapy for patients with advanced colorectal cancer, but many patients still suffer from treatment failure due to 5-Fu resistance."7.96CXCL-13 Regulates Resistance to 5-Fluorouracil in Colorectal Cancer. ( Cao, G; Chen, E; Huang, X; Jin, D; Ju, Z; Luo, X; Song, Z; Wang, F; Xu, J; Zhang, G; Zhang, W; Zhou, W, 2020)
"When the 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy regimen is used to treat colorectal cancer (CRC), chemotherapy-induced peripheral neuropathy (CIPN) caused by oxaliplatin can substantially affect quality of life (QOL) in the CRC patients."7.96Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study. ( Chen, JL; Chou, PL; Hsu, HT; Huang, YY; Juan, CH; Lin, PC; Wu, LM, 2020)
" Casein kinase 2α (CK2α) is highly expressed in 5-fluorouracil (5FU)-resistant colorectal cancer (CRC) cells."7.96Casein Kinase 2α Enhances 5-Fluorouracil Resistance in Colorectal Cancer Cells by Inhibiting Endoplasmic Reticulum Stress. ( Han, YS; Kim, HJ; Lee, JH; Lee, SH, 2020)
"5-Fluorouracil (5-FU) is a chemotherapeutic drug widely used to treat colorectal cancer."7.96Comparative lipidomics of 5-Fluorouracil-sensitive and -resistant colorectal cancer cells reveals altered sphingomyelin and ceramide controlled by acid sphingomyelinase (SMPD1). ( Akao, Y; Bandu, R; Jung, JH; Kim, KP; Komura, K; Lee, HM; Lee, KY; Lee, MY; Taniguchi, K, 2020)
"To analyse the results of fluorouracil (5-FU) plasma concentration monitoring in patients with advanced colorectal cancer after 5-FU treatment, and to provide a reference for the application prospect of 5-FU plasma concentration monitoring technology."7.96A retrospective analysis of plasma concentration monitoring of fluorouracil in patients with advanced colorectal cancer. ( Bi, Y; He, G; Li, X; Liu, Q; Ma, J; Yang, Q; Zhang, C; Zhang, J, 2020)
" Herein we revealed a previously unrecognized mechanism of 5-fluorouracil (5-FU) resistance contributed by high SphK2-upregulated dihydropyrimidine dehydrogenase (DPD) in colorectal cancer (CRC), which is evidenced from human CRC specimens, animal models, and cancer cell lines."7.96SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression. ( Cui, SX; Guo, ZK; Luo, DD; Miao, RR; Qu, XJ; Shi, WN; Sun, SY; Wan, SB; Wang, WY; Wu, SH; Yu, XF; Zhang, YH, 2020)
"5-Fluorouracil (5-FU) is one of the most effective drugs for the treatment of colorectal cancer (CRC)."7.96Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins. ( Cai, J; Li, W; Liu, Y; Ma, L; Xu, Y; Yang, Y; Zhang, Y, 2020)
"The purpose of this study was to investigate the effect of metformin or the combination of metformin and 5-FU on the growth and metastasis of colorectal cancer (CRC)."7.96Metformin Inhibited Proliferation and Metastasis of Colorectal Cancer and presented a Synergistic Effect on 5-FU. ( Sang, J; Sun, Q; Tang, R; Yang, M, 2020)
"The AXEPT trial demonstrated that modified XELIRI (mXELIRI; capecitabine + irinotecan) was noninferior to standard treatment with FOLFIRI (fluorouracil + leucovorin + irinotecan), both ± bevacizumab, in the treatment of metastatic colorectal cancer (mCRC)."7.96Cost-effectiveness of Capecitabine + Irinotecan Versus Leucovorin + Fluorouracil + Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China. ( Li, Q; Liao, W; Wang, X; Wu, Q; Zhang, M; Zhang, P, 2020)
"Cancer stem cells (CSCs) from colorectal cancer (CRC), characterized by CD133 expression, have been associated with 5-fluorouracile (5-FU) chemoresistance."7.96MMR-proficient and MMR-deficient colorectal cancer cells: 5-Fluorouracil treatment response and correlation to CD133 and MGMT expression. ( Caba, O; Cabeza, L; Jimenez-Luna, C; Melguizo, C; Mesas, C; Oliver, JA; Ortiz, R; Perazzoli, G; Prados, J, 2020)
" In this perspective, we recently developed a multipurpose thermosensitive hydrogel based on reversible thermogelling properties of poloxamers P407 and P188, a bioadhesive excipient and antineoplastic effect of 5-fluorouracil (5-FU) for the local treatment of colorectal cancer (CRC) in ectopic CT26 murine models."7.96Thermosensitive hydrogels for local delivery of 5-fluorouracil as neoadjuvant or adjuvant therapy in colorectal cancer. ( Agapova, E; Al Sabbagh, C; Boudy, V; Kramerich, D; Mignet, N; Seguin, J, 2020)
"To investigate the influence of longan flower extract (LFE) on the sensitization of colorectal cancer (CRC) cells to 5-fluorouracil (5-FU) treatment, HT-29, Colo 320DM and SW480 cells were treated with LFE and 5-FU alone and in combination, and the cell viability was then assessed by trypan blue exclusion, the cell cycle by propidium iodide staining, the mitochondria membrane potential by rhodamine 123 staining, and the expression levels of associated genes by immunoblotting and quantitative real-time polymerase chain reaction."7.96Synergistic Effect of Combined Treatment with Longan Flower Extract and 5-Fluorouracil on Colorectal Cancer Cells. ( Chang, HL; Chang, HP; Chen, CH; Chen, SJ; Chou, JL; Chung, YC; Hsu, CP; Lin, CC, 2020)
"Despite new agent development and short-term benefits in patients with colorectal cancer (CRC), metastatic CRC cure rates have not improved due to high rates of 5-fluorouracil (5-FU)/leucovorin/oxaliplatin (FOLFOX)-resistance and a clinical therapeutic plateau."7.91ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells. ( Amin, S; Jaiswal, AS; Law, BK; Narayan, S; Ramisetti, S; Sharma, AK; Singh, P; Singh-Pillay, A, 2019)
"5-Fluorouracil (5-FU) is an important chemotherapeutic agent for the systemic treatment of colorectal cancer (CRC), but its effectiveness against CRC is limited by increased 5-FU resistance caused by the hypoxic tumor microenvironment."7.91Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer. ( Kim, CW; Kim, HG; Lee, DH; Lee, JS; Oh, ET; Park, HJ, 2019)
"The first-line chemotherapy of colorectal cancer (CRC), besides surgery, comprises administration of 5-Fluorouracil (5FU)."7.91Ganoderma Lucidum induces oxidative DNA damage and enhances the effect of 5-Fluorouracil in colorectal cancer in vitro and in vivo. ( Cumova, A; Galanova, N; Horak, J; Hucl, T; Kostovcikova, K; Kozics, K; Macinga, P; Opattova, A; Rejhova, A; Sliva, D; Turnovcova, K; Vodenkova, S; Vodicka, P; Vodickova, L, 2019)
"The high-budding group demonstrated resistance to 5-fluorouracil-based chemotherapy, whereas the low-budding group exhibited significant survival benefits from adjuvant chemotherapy in stage III colorectal cancer."7.91Differential Survival Benefits of 5-Fluorouracil-Based Adjuvant Chemotherapy for Patients With Microsatellite-Stable Stage III Colorectal Cancer According to the Tumor Budding Status: A Retrospective Analysis. ( Hase, K; Kajiwara, Y; Mochizuki, S; Okamoto, K; Shinto, E; Ueno, H; Yamadera, M; Yamamoto, J, 2019)
"In the present study, we aimed to determine the efficacy of trabectedin (TRAB) combined with oxaliplatinum (OXA)+5-fluorouracil (5-FU) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (PDOX) mouse model."7.91Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model. ( Bouvet, M; Han, Q; Hoffman, RM; Singh, SR; Sun, YU; Tan, Y; Ye, J; Zhao, M; Zhu, G, 2019)
"The aim of the present study was to determine the efficacy of trabectedin combined with FOLFIRI (irinotecan, leucovorin and 5-fluorouracil) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (iPDOX) mouse model."7.91Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model. ( Bouvet, M; Clary, B; Han, Q; Hoffman, RM; Singh, SR; Sun, YU; Tan, Y; Ye, J; Zhao, M; Zhu, G, 2019)
"The current study suggests that the identification of predictive signatures of fluorouracil (5-FU) response for stage II and III colorectal cancer (CRC) could be confounded by chemotherapy-irrelevant low relapse risk."7.91Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit. ( Ao, L; Cai, H; Guo, Y; Guo, Z; Li, N; Song, K; Song, X; Wang, X; Zhao, W; Zheng, W, 2019)
"Selected SNPs in the adenosine pathway could affect the clinical outcomes of patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab."7.91Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. ( Battaglin, F; Berger, MD; Cao, S; Cremolini, C; Falcone, A; Heinemann, V; Lenz, HJ; Lo, JH; Loupakis, F; Millstein, J; Naseem, M; Puccini, A; Soni, S; Stintzing, S; Tokunaga, R; Zhang, W, 2019)
"Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU."7.91Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. ( Chakrabarti, S; Eiring, R; Finnes, H; Grothey, A; Halfdanarson, T; Hartgers, M; Lobo, R; Mitchell, J; Okano, A; Sara, J, 2019)
"5-Fluorouracil (5-FU) represents the backbone of systemic therapy regimens of colorectal cancer."7.915-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer. ( Abdel-Rahman, O, 2019)
"Oral uracil-tegafur/leucovorin (UFT/LV) and intravenous 5-fluorouracil (FU)/LV are common adjuvant therapies for Stages II and III colorectal cancer."7.91Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan. ( Hsu, TC; Wang, CC, 2019)
"5-Fluorouracil (5-FU) has been established as the first-line chemotherapy for advanced colorectal cancer (CRC); however, acquired chemoresistance is often the cause of poor therapeutic response."7.91Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. ( Goel, A; Sakatani, A; Sonohara, F, 2019)
" We sought to characterize the effects of 5 fluorouracil (5FU) chemotherapy on colon inflammation and functional measures in colorectal cancer (CRC) and to further determine whether gut microbiota can influence this response."7.91Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota. ( Bader, JE; Carson, JA; Carson, M; Chatzistamou, I; Enos, RT; Kubinak, JL; Murphy, EA; Nagarkatti, M; Pena, MM; Sougiannis, AT; VanderVeen, BN; Velazquez, KT; Walla, M, 2019)
"The efficacy of Fluorouracil (FU) in the treatment of colorectal cancer (CRC) is greatly limited by drug resistance."7.91ABHD5 blunts the sensitivity of colorectal cancer to fluorouracil via promoting autophagic uracil yield. ( Chen, Y; Hao, J; Li, F; Li, J; Liang, H; Luo, X; Ou, J; Peng, Y; Sun, W; Wang, L; Wu, S; Xie, G; Xie, X; Yang, W; Zha, L; Zhang, Y; Zhao, Y; Zhou, Q, 2019)
"5-Fluorouracil (5-FU) is an anticancer drug that is most frequently used to treat colorectal cancer (CRC) patients, but unfortunately it shows limited efficacy."7.91Tacalcitol increases the sensitivity of colorectal cancer cells to 5-fluorouracil by downregulating the thymidylate synthase. ( Klopotowska, D; Kutner, A; Milczarek, M; Rossowska, J; Stachowicz, M; Wietrzyk, J, 2019)
"Colorectal cancer (CRC) is still the third most common cancer in the world with a limited prognosis due to the chemoresistance of CRC cells to 5-fluorouracil (5-FU)-based chemotherapy."7.91Long non-coding RNA PCAT6 targets miR-204 to modulate the chemoresistance of colorectal cancer cells to 5-fluorouracil-based treatment through HMGA2 signaling. ( Fan, D; He, H; Lei, M; Liang, Y; Shen, L; Wu, H; Zhou, Q; Zou, Q, 2019)
"5-Fluorouracil (5-FU) remains the gold standard of first-line treatment for colorectal cancer (CRC)."7.91Establishment and Characterization of 5-Fluorouracil-Resistant Human Colorectal Cancer Stem-Like Cells: Tumor Dynamics under Selection Pressure. ( Bulanin, D; Francipane, MG; Lagasse, E, 2019)
" 5-Fluorouracil is a clinically approved drug which has limited response rate in the realm of colorectal cancer amelioration, hence our study aims to improve its efficacy by aiming the simultaneous delivery of 5-Flurouracil and apigenin which is naturally occurring flavone abundantly present in fruit and vegetables through a single liposome to combat and control colorectal cancer effectively in-vitro and in-vivo."7.91Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer. ( Banerjee, S; Mandal, M; Sen, K, 2019)
"Only 10%-20% of colorectal cancer (CRC) patients observe effective responses to 5-fluorouracil (5-FU) based chemo-treatment."7.91Epigenetically Down-Regulated Acetyltransferase PCAF Increases the Resistance of Colorectal Cancer to 5-Fluorouracil. ( Fang, X; Fang, Z; Hu, W; Jin, Y; Liu, T; Miao, QR; Wang, X, 2019)
"Although DNA-mismatch-repair-deficient (dMMR) status and aberrant expression of miRNAs are both critically implicated in the pathogenesis of resistance to 5-fluorouracil (5-FU) in colorectal cancer (CRC), whether these two factors regulate tumor response to 5-FU in a coordinated manner remains unknown."7.91MicroRNA-552 deficiency mediates 5-fluorouracil resistance by targeting SMAD2 signaling in DNA-mismatch-repair-deficient colorectal cancer. ( Dai, ZJ; Guan, HT; Liu, D; Ma, YG; Yan, CY; Zhao, P; Zhao, Y, 2019)
" In the present study, the antitumor effects were investigated, and the possible underlying mechanisms of kaempferol combined with 5‑fluorouracil (5‑FU) in colorectal cancer cells were explored."7.91Synergistic effect of kaempferol and 5‑fluorouracil on the growth of colorectal cancer cells by regulating the PI3K/Akt signaling pathway. ( Chen, Y; Li, Q; Lin, J; Lin, S; Peng, J; Wei, L, 2019)
"We developed a molecular beacon targeting miR-141-3p, aberrantly increased in 5-fluorouracil-resistant colorectal cancer cells (R-CRCCs)."7.91Theragnosis by a miR-141-3p molecular beacon: simultaneous detection and sensitization of 5-fluorouracil resistant colorectal cancer cells through the activation of the TRIM13-associated apoptotic pathway. ( Heo, HJ; Jeong, SH; Jung, WY; Kim, S; Lee, YS; Moon, SU; Park, MG; Park, Y; Song, SK, 2019)
"To assess if CT texture analysis (TA) can serve as a biomarker of liver toxicity in patients with colorectal cancer treated with 5-fluorouracil (5-FU)-based chemotherapy."7.915-Fluorouracil induced liver toxicity in patients with colorectal cancer: role of computed tomography texture analysis as a potential biomarker. ( Alessandrino, F; Cruz, G; Meyerhardt, JA; Qin, L; Rosenthal, MH; Sahu, S; Shinagare, AB, 2019)
"5-Fluorouracil (5-FU)-based chemotherapy has always been the first-line treatment of colorectal cancer (CRC)."7.91The long non-coding RNA HOTAIRM1 suppresses cell progression via sponging endogenous miR-17-5p/ B-cell translocation gene 3 (BTG3) axis in 5-fluorouracil resistant colorectal cancer cells. ( Chen, J; Hou, J; Liu, C; Qin, A; Ren, T; Ren, W; Shan, F; Xiong, X, 2019)
"5-Fluorouracil (5-FU) as a chemotherapeutic drug is used to treat colorectal cancer (CRC)."7.88The Effect of miR-200c Inhibition on Chemosensitivity (5- FluoroUracil) in Colorectal Cancer. ( Dermani, FK; Heydari, K; Najafi, R; Saidijam, M; Shabab, N; Sharifi, MR; Soleimani Asl, S, 2018)
"Our objective was to evaluate the benefit of re-exposing patients with refractory metastatic colorectal cancer (mCRC) to a combination of oxaliplatin, irinotecan and 5-fluorouracil treatment."7.88Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients. ( Artioli, M; Braghiroli, MI; Braghiroli, OFM; Costa, FP; Fernandes, GDS; Girardi, DDM; Gumz, BP; Hoff, PM; Paterlini, ACCR; Teixeira, MC, 2018)
" The objective of this exploratory study was to examine the association of low skeletal muscle, commonly known as sarcopenia, on the pharmacokinetics (PKs) of 5-fluorouracil (5FU) in patients receiving FOLFOX for colorectal cancer."7.88The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. ( Choi, SK; Deal, AM; McLeod, HL; Muss, HB; O'Neil, B; Patel, JN; Sanoff, HK; Shachar, SS; Walko, CM; Weinberg, MS; Williams, GR, 2018)
" The prognostic role of TOPO-1 and CES-2 in patients with metastatic colorectal cancer (mCRC) who underwent irinotecan chemotherapy was largely unknown."7.88Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer. ( Guisheng, L; Haixin, H; Li, H; Shaojun, C, 2018)
"To investigate expression of cell cycle-related and expression-elevated protein in tumor (CREPT) in colorectal cancer (CRC) and determine its prognostic value in response to 5-fluorouracil (5-FU)."7.88Overexpression of CREPT confers colorectal cancer sensitivity to fluorouracil. ( Chang, ZJ; Ding, LD; Jia, BQ; Kuang, YS; Li, J; Liu, HY; Liu, SH; Wang, XN; Wang, Y; Wang, YY; Yang, L; Zhu, BT, 2018)
" In this study, we investigated the effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma (CRC) cells and its mechanism."7.88The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism. ( Jiang, GS; Liu, GW; Liu, YH; Ren, WD, 2018)
"Fluoropyrimidines, such as 5-fluorouracil (5-FU) and related prodrugs, are considered one of the most successful agents in the treatment of colorectal cancer, yet poor specificity and tumor cell resistance remain the major limiting bottlenecks."7.88DNA-based nanoscaffolds as vehicles for 5-fluoro-2'-deoxyuridine oligomers in colorectal cancer therapy. ( Aviñó, A; Eritja, R; Fàbrega, C; Jorge, AF; Pais, AACC, 2018)
"We aimed to evaluate the effect of potential regulatory variants in NLRC5 on overall survival and survival after 5-fluorouracil (5-FU)-based therapy of colorectal cancer (CRC) patients."7.88Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy. ( Catalano, C; da Silva Filho, MI; Försti, A; Hemminki, K; Jiraskova, K; Levy, M; Liska, V; Naccarati, A; Vodicka, P; Vodickova, L; Vycital, O; Vymetalkova, V; Weber, ANR, 2018)
"To investigate the effects of miR-519d on the 5-fluorouracil resistance in colorectal cancer cells and to explore the mechanism."7.88MiR-519d reduces the 5-fluorouracil resistance in colorectal cancer cells by down-regulating the expression of CCND1. ( Chi, YJ; Huang, R; Lin, JY, 2018)
"Chemotherapeutic 5-fluorouracil (5-FU) combined with oxaliplatin is often used as the standard treatment for colorectal cancer (CRC)."7.88Chrysin Attenuates Cell Viability of Human Colorectal Cancer Cells through Autophagy Induction Unlike 5-Fluorouracil/Oxaliplatin. ( Chen, CI; Chen, YJ; Cheng, KC; Chien, PH; Hsiang, YP; Hsu, YC; Lin, YM; Lu, CC; Pan, HL, 2018)
"BACKGROUND 5-Fluorouracil (5-FU)-based chemotherapy is a conventional therapeutic approach for the treatment of patients with colorectal cancer (CRC)."7.88miR-106a Reduces 5-Fluorouracil (5-FU) Sensitivity of Colorectal Cancer by Targeting Dual-Specificity Phosphatases 2 (DUSP2). ( Chen, X; Huo, Z; Liu, Z; Qin, Y; Tian, X, 2018)
"Capecitabine is a pro-drug of 5-fluorouracil (5-FU), and is an orally available chemotherapeutic used to treat colorectal cancer (CRC)."7.88Investigation into Enhancing Capecitabine Efficacy in Colorectal Cancer by Inhibiting Focal Adhesion Kinase Signaling. ( Baek, JH; Jeong, KY; Kim, HM; Lee, H; Park, MH; Sim, JJ, 2018)
" Median time from initial diagnosis of metastases to the start of regorafenib and treatment duration was 13."7.88Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial). ( Aranda, E; Benavides, M; Durán, G; Falcó, E; García-Alfonso, P; Gómez, A; López, R; López-Ladrón, A; Montagut, C; Muñoz, A; Rivera, F; Ruiz de Mena, I; Salgado, M; Sastre, J, 2018)
" Here, the role of PKM2 in the anticancer efficacy of 5-fluorouracil (5-FU) was evaluated in colorectal cancer (CRC)."7.88Enhancing 5-fluorouracil efficacy through suppression of PKM2 in colorectal cancer cells. ( Cao, Y; Jin, Y; Lin, Y; Pan, D; Wang, D; Zhang, Y; Zheng, C, 2018)
"To evaluate the safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (mFOLFOXIRI) for patients with advanced colorectal cancer (CRC)."7.88[Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer]. ( Cai, Y; Deng, R; Deng, Y; Hu, H; Li, J; Ling, J; Wu, Z; Yang, L; Zhang, J, 2018)
"Almost all colorectal cancer (CRC) cell lines are known to overexpress aspartate aminotransferase (GOT1), which potentially regulates the intracellular levels of reactive oxygen species (ROS) via the production of NADPH, and supports tumor growth."7.85Inhibition of GOT1 sensitizes colorectal cancer cells to 5-fluorouracil. ( Hong, C; Li, X; Zheng, J, 2017)
"Although 5-fluorouracil (5-FU) is known to interfere with the synthesis of ribonucleic acid and deoxyribonucleic acid, the mechanism underlying its therapeutic efficacy in colorectal cancer (CRC) has not been fully elucidated."7.855-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer. ( Cao, L; Du, C; Gu, J; Huang, D; Peng, Y; Wang, H; Yang, Y; Yao, Y; Zhao, Y; Zhu, WG, 2017)
"To evaluate whether the results of chemosensitivity testing were associated with prognosis of colorectal cancer patients after adjuvant 5-fluorouracil (FU)/ leucovorin chemotherapy."7.85Clinical Significance of 5-Fluorouracil Chemosensitivity Testing in Patients with Colorectal Cancer. ( Hong, KD; Ji, WB; Joung, SY; Kim, JS; Kim, YS; Lee, JH; Min, BW; Ryu, JS; Um, JW, 2017)
"5-Fluorouracil (5-FU) is a widely used chemotherapeutic drug in colorectal cancer."7.85Translational reprogramming of colorectal cancer cells induced by 5-fluorouracil through a miRNA-dependent mechanism. ( Auboeuf, D; Bash-Imam, Z; Catez, F; Dalla Venezia, N; David, A; Diaz, JJ; Dutertre, M; Lafôrets, F; Macari, F; Marcel, V; Mertani, HC; Pannequin, J; Pion, N; Polay Espinoza, M; Saurin, JC; Textoris, J; Thérizols, G; Vincent, A, 2017)
"Cardiotoxicity is a rare but challenging complication of 5-fluorouracil (5-FU) therapy."7.85Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer. ( Franck, C; Malfertheiner, P; Venerito, M, 2017)
"Preclinical evidence demonstrates that mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway inhibition increases sensitivity to 5-fluorouracil (5-FU) in colorectal cancer (CRC) cell lines and xenografts."7.85MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. ( Chen, Y; Fakih, M; Gong, J; Pillai, R; Shirasawa, S; Yang, L, 2017)
"Preoperative 5-fluorouracil- (5-FU-) based chemoradiotherapy is a standard treatment for locally advanced colorectal cancer (CRC)."7.85Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. ( Ai, YQ; Chen, ZT; Ju, YH; Li, WH; Li, YF; Liu, QY; Qin, JY; Wang, H; Xiong, W; Ye, Q, 2017)
"5-Fluorouracil (5-FU) has broadly been applied to treat colorectal cancer as one of the most effective chemotherapeutic agents."7.85Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model. ( Li, M; Liang, X; Liu, Z; Teng, N; Wang, X; Xie, W; Yang, Z; Zhang, Z, 2017)
" Our study focused on capecitabine during capecitabine plus oxaliplatin (XELOX) treatment as an adjuvant therapy for colorectal cancer."7.85Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer. ( Hama, T; Inoue, A; Kawakami, K; Kobayashi, K; Machida, Y; Suenaga, M; Sugisaki, T; Suzuki, K; Yamaguchi, K; Yamaguchi, T; Yokokawa, T, 2017)
" 5-Fluorouracil (5-FU) is the first-line chemotherapeutic agent for colorectal cancer; however, most patients develop resistance to 5-FU through various mechanisms."7.85Synergistic antitumor effect of 3-bromopyruvate and 5-fluorouracil against human colorectal cancer through cell cycle arrest and induction of apoptosis. ( Chong, D; Huo, Q; Liu, F; Liu, H; Ma, L; Zhang, P; Zhang, Z; Zhao, S; Zheng, H, 2017)
"5-Fluorouracil (5-FU) resistance or multidrug resistance (MDR) has become a major obstacle in clinical treatment of cancers including colorectal cancer (CRC)."7.85Scutellaria barbata D. Don inhibits 5-fluorouracil resistance in colorectal cancer by regulating PI3K/AKT pathway. ( Feng, J; Jin, Y; Lai, Z; Li, Q; Lin, J; Peng, J; Wei, L; Yan, Z; Yang, H, 2017)
"The aim of this study was to explore the effects of single agent treatments and combination of Blu9931 and 5-fluorouracil (5-FU) on the biological characteristics of colorectal cancer cells and its mechanism."7.85Combination of FGFR4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells. ( Han, C; Jiang, D; Li, J; Wang, M; Wang, X; Ye, Y; Zhao, C, 2017)
"Colorectal cancer (CRC) is one of the leading causes of cancer mortality and 5-Fluorouracil (5-FU) is the most common chemotherapy agent of CRC."7.85Effect of AICAR and 5-Fluorouracil on X-ray Repair, Cross-Complementing Group 1 Expression, and Consequent Cytotoxicity Regulation in Human HCT-116 Colorectal Cancer Cells. ( Chang, SF; Chen, CN; Huang, WS; Lee, KC; Lin, CT; Liu, JL, 2017)
"A 32-year-old female with stage IV colorectal cancer and metastasis to the liver experienced cardiotoxic reactions after treatment with 5-fluorouracil and its oral prodrug capecitabine even at two-thirds the recommended dose."7.85Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses. ( Ardalan, B; Cioffi, JH; Estes, DJ; Florou, V, 2017)
"5-fluorouracil (5-FU) is one of the major components of many standard regimens for chemotherapy of colorectal cancer (CRC) and some other malignancies."7.85The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells. ( Eftekhar, E; Jaberi, H; Mansouri, A; Naghibalhossaini, F; Shefaghat, M; Tatar, M, 2017)
"Metastatic colorectal cancer (mCRC) combined with hyperbilirubinemia is typically considered a contraindication to irinotecan-based therapy, a proven first-line treatment of mCRC."7.85Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment. ( Chen, CW; Huang, CW; Huang, MY; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, JY; Yeh, YS, 2017)
"We analyzed the results of previously treated patients with metastatic colorectal cancer (mCRC) who received regorafenib plus FOLFIRI with the irinotecan dose escalation on the basis of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping."7.85Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer. ( Cheng, TL; Hu, HM; Huang, CW; Ma, CJ; Tsai, HL; Wang, JY; Wu, IC; Yeh, YS, 2017)
"5-Fluorouracil (5-FU) is the most commonly used chemotherapeutic agent for colorectal cancer (CRC)."7.85FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10. ( Chen, C; Chen, J; Chen, L; Chen, Y; Chu, X; Dai, T; Geng, J; Huang, M; Liu, X; Mao, X; Ren, L; Wang, L; Wang, Q; Wang, R; Wang, Y; Xie, T; Xue, L; Yu, H; Zhang, K, 2017)
"This retrospective study enrolled 131 patients with stage III colorectal cancer who underwent curative resection: 72 received 5-fluorouracil-based adjuvant chemotherapy (chemotherapy group) and 59 did not (surgery-alone group)."7.85Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer. ( Kameyama, H; Kobayashi, T; Kosugi, SI; Okamura, T; Shimada, Y; Tajima, Y; Wakai, T; Yagi, R, 2017)
"High-dose 5-fluorouracil (5-FU) containing chemotherapy occasionally causes hyperammonemia and can be lethal."7.85Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. ( Funakoshi, T; Horimatsu, T; Matsubara, K; Matsubara, T; Miyamoto, S; Muto, M; Nakagawa, S; Nishikawa, Y; Yanagita, M; Yonezawa, A, 2017)
" Hypoxia reduces sensitivity to 5-fluorouracil (5-FU)-chemotherapy for colorectal cancer (CRC)."7.85Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance. ( Adam, J; Bishop, CL; Bundy, JG; Feakins, R; Gammon, L; Jalaly, A; Jeffery, R; Lewis, A; Lowe, R; McDonald, S; Nijhuis, A; Parker, A; Propper, D; Silver, A; Soga, T; Suraweera, N; Thaha, MA; Thompson, H, 2017)
"To evaluate the efficiency and safety of hepatic artery infusion chemotherapy (HAIC) using raltitrexed or 5-fluorouracil for colorectal cancer (CRC) liver metastasis (CRCLM)."7.85Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis. ( Chen, H; Gao, S; Guo, JH; Li, XT; Wang, XD; Zhang, HY; Zhang, PJ; Zhu, X, 2017)
"The purpose of this study was to evaluate both in vitro and in vivo anticancer activities against colorectal cancer (CRC) of electrospun polylactide (PLA) nanofibers loaded with 5-fluorouracil (5-Flu) and oxaliplatin."7.83Antitumor activity of electrospun polylactide nanofibers loaded with 5-fluorouracil and oxaliplatin against colorectal cancer. ( Jing, X; Liu, S; Liu, T; Wang, X; Zhang, J, 2016)
" This study evaluates the cost-effectiveness of UGT1A1 genotyping in patients with metastatic colorectal cancer undergoing irinotecan-based chemotherapy compared to no testing from the perspective of the German statutory health insurance."7.83The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance. ( Butzke, B; Giessen-Jung, C; Heinemann, V; Oduncu, FS; Pfeufer, A; Rogowski, WH; Severin, F; Stollenwerk, B, 2016)
"We evaluated the usefulness of the in vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) for prediction of clinical response to fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer."7.83In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer. ( Kang, J; Kim, IK; Kwon, HY; Lee, KY; Sohn, SK, 2016)
"5-Fluorouracil (5-FU) is one among the anti-cancer agents in FOLFORINOX treatment along with oxaliplatin and irinotecan for the treatment of colorectal cancer."7.835-Fluorouracil enteric-coated nanoparticles for improved apoptotic activity and therapeutic index in treating colorectal cancer. ( Kuppusamy, G; Praveen, TK; Satish Kumar, MN; Tummala, S; Wadhwani, A, 2016)
"5-Fluorouracil (5-FU), a cell cycle-specific antimetabolite, is one of the most commonly used chemotherapeutic agents for colorectal cancer (CRC)."7.83Smad4 sensitizes colorectal cancer to 5-fluorouracil through cell cycle arrest by inhibiting the PI3K/Akt/CDC2/survivin cascade. ( Chen, X; Dou, L; Leng, C; Luo, X; Wu, C; Zhang, B; Zhang, Z, 2016)
"Irinotecan (CPT-11)-induced neutropenia is associated with UDP-glucuronosyltransferase (UGT) 1A1*6 and *28 polymorphisms."7.83UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. ( Kusumi, T; Manabe, M; Miyata, Y; Mizunuma, N; Morita, Y; Taniguchi, F; Touyama, T, 2016)
"5-Fluorouracil (5-FU) is widely used in chemotherapy for treatment of colorectal cancer."7.835-Fluorouracil induces apoptosis of colorectal cancer cells. ( He, C; Li, CY; Liu, T; Wang, L; Zhang, JT; Zhou, WL, 2016)
"To evaluate the safety and efficacy of the combination therapy of fluorouracil, leucovorin and irinotecan (FOLFIRI) and aflibercept in Asian patients with metastatic colorectal cancer (mCRC), who had progressed after oxaliplatin-based chemotherapy."7.83Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer. ( Chong, DQ; Choo, SP; Chua, C; Imperial, M; Manalo, M; Ng, M; Tan, IB; Teo, P; Yong, G, 2016)
"Multidrug resistance (MDR), a phenomenon that often occurs with drug treatment and is characterized by relapse or attenuation of drug efficacy, is almost unavoidable in colorectal cancer (CRC) patients receiving 5-fluorouracil (5-FU)-based chemotherapy."7.83miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1. ( Bian, Z; Feng, Y; Hu, Y; Huang, Z; Li, M; Liu, H; Yao, S; Yin, Y; You, Q, 2016)
"A 69-year-old woman presented with arterial hypotension, pulmonary oedema and a severely depressed left ventricular ejection fraction (LVEF) of 25% only 3 days after having received her first treatment for colorectal cancer with 5-fluorouracil (5-FU)-based therapy."7.835-Fluorouracil-induced acute reversible heart failure not explained by coronary spasms, myocarditis or takotsubo: lessons from MRI. ( Dalsgaard, M; Fakhri, Y; Lav Madsen, P; Nielsen, D, 2016)
" In this study, we investigated the effect of NNMT on 5-fluorouracil (5-FU) sensitivity of colorectal cancer (CRC) cells, and the underlying mechanisms."7.83Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway. ( Li, F; Li, G; Liu, H; Ruan, Z; Wang, X; Wang, Y; Xie, X; Yu, H; Zhang, J; Zhou, Y, 2016)
"To analyze the efficacy of last line sorafenib treatment in colorectal cancer patients."7.83Last line therapy with sorafenib in colorectal cancer: A retrospective analysis. ( Becker, M; Galle, PR; Martchenko, K; Möhler, M; Schimanski, CC; Schmidtmann, I; Thole, V; Thomaidis, T; Wehler, TC, 2016)
" In this study, we demonstrated that anisomycin, a JNK activator, stimulates nuclear export of GATA-6 in a colorectal cancer cell line, DLD-1."7.83Anisomycin-induced GATA-6 degradation accompanying a decrease of proliferation of colorectal cancer cell. ( Horyozaki, A; Maeda, M; Ushijima, H, 2016)
"The development of chemoresistance to 5-fluorouracil (5-FU) is a major obstacle for sustained effective treatment of colorectal cancer (CRC), with the mechanisms being not fully understood."7.83Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine. ( Chen, X; Chen, Y; Hao, L; Hou, A; Li, Y; Liang, H; Luo, P; Miao, H; Ou, J; Ruan, Z; Shi, C; Wang, R; Zhang, X, 2016)
"5-fluorouracil (5-FU)-based chemotherapy is the main chemotherapeutic approach for colorectal cancer (CRC) treatment."7.83Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells. ( Cai, Z; Che, J; Chen, D; Chen, J; He, L; Huang, L; Iwamoto, A; Lan, P; Lin, M; Liu, H; Lou, Q; Qin, Q; Ren, D; Wang, H; Wang, J; Wang, L; Wen, C; Yang, X; Zhang, D, 2016)
"The purpose of this study was to compare health-related quality of life (HRQoL) and costs associated with 2 adjuvant chemotherapy regimens [capecitabine-based therapy versus 5-fluorouracil/leucovorin (5-FU/LV)-based therapy] in stage III colorectal cancer patients."7.81Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients. ( Chen, HC; Chen, HH; Chen, WT; Chou, YH; Fang, CY; Hsu, HH; Huang, CC; Lee, HC; Lin, BW; Lin, JK; Lin, PC; Tan, EC; Ting, WC; Yang, MC; Yeh, CH, 2015)
" However, the molecular mechanism as to how miR-203 modulates the chemosensitivity to 5-fluorouracil (5-FU) in colorectal cancer is poorly known."7.81miR-203 enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer. ( Gao, F; Li, T; Zhang, XP, 2015)
" In the present study, we analyzed the cytotoxicity of LA on colorectal cancer (CRC) cells differing in their p53 status and investigated a putative synergistic effect with the anticancer drug 5-fluorouracil (5-FU)."7.81Lipoic acid induces p53-independent cell death in colorectal cancer cells and potentiates the cytotoxicity of 5-fluorouracil. ( Dörsam, B; Fahrer, J; Göder, A; Kaina, B; Seiwert, N, 2015)
"An aptamer (Apt) conjugated hyaluronan/chitosan nanoparticles (HACSNPs) were prepared as carrier for targeted delivery of 5-fluorouracil (5FU) to mucin1 (MUC1) overexpressing colorectal adenocarcinomas."7.81Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas. ( Atyabi, F; Dinarvand, R; Esfandyari-Manesh, M; Ghasemi, Z; Mottaghitalab, F; Sayari, E, 2015)
"Thymidylate synthase (TYMS) is an important enzyme for 5-fluorouracil (5-FU) metabolism in metastatic colorectal cancer (mCRC) patients."7.81Thymidylate synthase expression in circulating tumor cells: a new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients. ( Abdallah, EA; Alves, VS; Araújo, DV; Buim, ME; Chinen, LT; Dettino, AL; Fanelli, MF; Gasparini Junior, JL; Machado Netto, MC; Mingues, NB; Ocea, LM; Rocha, BM; Romero, JV; Souza E Silva, V, 2015)
"We prospectively evaluated the feasibility of XELOX(oxaliplatin 130 mg/m/(2) on day 1 plus capecitabine 1,000 mg/m(2) twice daily on days 1 to 14 every 3 weeks) for adjuvant treatment in 15 patients with stage III/IV (Japanese classification) colorectal cancer and pathological curability A or B after D2-D3 lymph node dissection."7.81[A feasibility study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for Japanese patients with advanced colorectal cancer]. ( Higashino, K; Noura, S; Ohue, M; Sakai, D; Shingai, T; Sugimoto, N; Takeuchi, Y; Yagi, T; Yamamoto, S; Yano, M; Yoshinami, T, 2015)
" Herein, we investigated an alginate-based 3D scaffold for screening of 5-fluorouracil (5-FU) or/and curcumin on malignancy of colorectal cancer cells (CRC)."7.81Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer. ( Buhrmann, C; Goel, A; Kraehe, P; Popper, B; Shakibaei, M; Shayan, P, 2015)
"Preoperative 5-fluorouracil (5-FU)-based chemoradiotherapy is a standard treatment for locally advanced colorectal cancer (CRC)."7.81Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. ( Ai, YQ; Cui, JG; He, WJ; Hou, Y; Jiang, YX; Ju, YH; Li, WH; Li, YF; Liu, S; Liu, Y; Qin, JY; Wang, L; Wang, Y; Wu, XR; Xia, YX; Xiong, W, 2015)
"500 mg/m(2) uracil was administered orally to 12 subjects with stages II-III colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects with stage IV metastasized CRC, all treated with CAP containing therapy."7.81Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ( Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015)
" Overexpressing miR-197 could increase the sensitivity of colorectal cancer cells to 5-fluorouracil (5-FU)."7.81MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer. ( Bai, C; Chen, Y; Han, Q; Sun, Z; Zhao, L; Zhao, RC; Zhou, J; Zhou, N, 2015)
"There was performed a molecular genetic study of UGTlAl gene allelic variants polymorphism in patients with colorectal cancer who had had chemotherapy irinotecan-containing regimens FOLFIRI."7.81[The role of assessing UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity in the course of chemotherapy for colorectal cancer]. ( Abramova, NA; Dvadnenko, KV; Kit, OI; Vladimirova, LY; Vodolazhskiy, DI, 2015)
"This study aimed to investigate the association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and the prognosis of colorectal cancer (CRC) patients undergoing 5-fluorouracil (5-FU)-based chemotherapy in Taiwan."7.81Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and fluorouracil-based treatment in Taiwan colorectal cancer. ( Chang, LC; Chin, J; Hou, CF; Lin, TJ; Liu, WS; Su, SM; Wu, NC; Yang, JY, 2015)
" This gene codifies for the target enzyme of 5-fluorouracil (5-FU), the basic treatment in colorectal cancer."7.81Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS. ( Balboa-Beltrán, E; Barros, F; Carracedo, A; Duran, G; Lamas, MJ, 2015)
"We investigated the synergistic effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor plus radiation therapy, on the proliferation and survival of gastric cancer (GC) and colorectal cancer (CRC) cells."7.81Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor. ( Kang, WK; Kim, J; Lee, I; Lim, T, 2015)
"5-Fluorouracil (5-FU), a common chemotherapeutic agent used for the treatment of colorectal cancer (CRC), by itself has inadequate response rates; highlighting the need for novel and improved treatment regimens for these patients."7.81Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, Epithelial-to-mesenchymal transition and apoptosis in colorectal cancer. ( Buhrmann, C; Goel, A; Kraehe, P; Popper, B; Shakibaei, M; Shayan, P, 2015)
"5-Fluorouracil (5-Fu) has been widely used as a first-line drug for colorectal cancer (CRC) treatment but limited by drug resistance and severe toxicity."7.81Gypenosides Synergistically Enhances the Anti-Tumor Effect of 5-Fluorouracil on Colorectal Cancer In Vitro and In Vivo: A Role for Oxidative Stress-Mediated DNA Damage and p53 Activation. ( Fan, J; Kong, L; Liu, Q; Wang, P; Wang, X; Yang, Q; Yuan, W; Zhang, K, 2015)
" Aflibercept is used for the treatment of metastatic colorectal cancer (mCRC) in association with irinotecan."7.81Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients. ( Beltjens, F; Bengrine, L; Ghiringhelli, F; Ladoire, S; Vincent, J, 2015)
"The efficacy of 5-fluorouracil (5-FU)-based chemotherapy for colorectal cancer (CRC) widely varies among patients; therefore, it is difficult to accurately predict chemotherapeutic responses."7.81Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer. ( Bai, W; Wu, Y; Xi, Y; Zhang, P, 2015)
"Assessment of oxaliplatin-associated hepatotoxicity in patients receiving oxaliplatin, fluorouracil and leucovorin chemotherapy (FOLFOX) for colorectal cancer remains controversial."7.81Serum Type IV Collagen Concentration Correlates with Indocyanine Green Retention Rate and is an Indicator Of Hepatotoxicity In Patients Receiving FOLFOX for Colorectal Cancer. ( Fujino, S; Hosokawa, Y; Katsumata, K; Makino, H; Maruno, K; Mushiake, H; Sugiyama, Y; Watanabe, M, 2015)
"To evaluate the cost-effectiveness of the addition of bevacizumab to the irinotecan-fluorouracil (Douillard regimen-CPT-FUFA-) in first-line treatment of metastatic colorectal cancer in a single-institution population."7.80Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer. ( Albert-Mari, A; Jimenez-Torres, NV; Ruiz-Millo, O; Sendra-Garcia, A, 2014)
"TS mRNA expression levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer."7.80TS mRNA levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer. ( Guan, W; Hu, J; Liu, B; Qian, X; Shen, J; Wang, H; Wei, J; Xie, L; Yu, L; Zhang, Q, 2014)
"Although FOLFOX (infusional fluorouracil/leucovorin plus oxaliplatin) is established as a standard chemotherapeutic regimen, the long term efficacy of adjuvant XELOX (oral capecitabine plus intravenous oxaliplatin) in Asian colorectal cancer (CRC) patients remains anecdotal."7.80Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis. ( Chiu, J; Chu, KW; Epstein, RJ; Leung, R; Poon, J; Tang, V; Wong, H; Yau, T, 2014)
" However, it is still unknown the association of GOLPH3 expression with the prognosis of colorectal cancer (CRC) patients who received 5-fluorouracil (5-FU)-based adjuvant chemotherapy."7.80GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy. ( Chen, L; Cui, M; Di, J; Dong, B; Ji, J; Jiang, B; Liu, M; Ma, Y; Su, X; Wang, Z; Xing, J; Yang, H; Yao, Z; Zhang, C; Zhang, N, 2014)
"This study compared the clinical responses of patients with metastatic colorectal cancer (mCRC) with 5-fluorouracil/leucovorin with irinotecan (FOLFIRI) plus bevacizumab therapy either with or without uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping and irinotecan dose escalation."7.80Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinote ( Chang, SF; Hu, HM; Huang, CM; Huang, CW; Huang, ML; Huang, MY; Lu, CY; Tsai, HL; Wang, JY; Yu, FJ, 2014)
"Patients with colorectal tumors with microsatellite instability (MSI) have better prognoses than patients with tumors without MSI, but have a poor response to 5-fluorouracil–based chemotherapy."7.80Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy. ( Arzouk, H; Bengrine-Lefèvre, L; Biard, DS; Bouvier, AM; Buhard, O; Chapusot, C; Collura, A; Coquelle, A; De Thonel, A; Delarue, P; Dorard, C; Duval, A; Fléjou, JF; Garrido, C; Gaub, MP; Guilloux, A; Iacopetta, B; Lacoste, C; Lagrange, A; Lefèvre, JH; Lepage, C; Loh, M; Marcion, G; Marisa, L; Mews, A; Milano, G; Parc, Y; Platell, C; Saget, A; Seigneuric, R; Selves, J; Senet, P; Soong, R; Svrcek, M; Taieb, A; Tournigand, C; Wanherdrick, K; Zeps, N, 2014)
"Weekly cetuximab plus irinotecan-based regiments are standard first- and second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC)."7.80Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population. ( Bi, F; Cao, D; Chen, Y; Li, Q; Qiu, M, 2014)
"We retrospectively investigated the relationship between IVS14+1 G > A genotype of the dihydropyrimidine dehydrogenase (DPD) gene with plasma concentration of 5-fluorouracil (5-FU) as well as adverse reactions in 80 patients with locally advanced or metastatic colorectal cancer."7.80The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: ( Cai, X; Fang, JM; Gu, HL; Hu, J; Song, WF; Wang, LW; Xue, P; Yang, HY, 2014)
"Although 5-fluorouracil (5-FU) is an important drug for colorectal cancer (CRC) treatment, no useful biomarker is currently available to predict treatment response."7.80Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer. ( Fukui, T; Iida, T; Miyake, H; Miyoshi, N; Naitou, H; Ochiai, T; Ohno, K; Okumura, M; Sakamoto, M; Takahashi, M; Tokunaga, Y; Tsumura, H; Umeki, M, 2014)
"The effectiveness of 5-fluorouracil (5-FU)-based adjuvant chemotherapy is reported in patients with colorectal cancer (CRC), but the usefulness of 5-FU metabolic enzymes as predictive biomarkers of the efficacy of this chemotherapy remains unclear."7.80Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis. ( Hasegawa, H; Ishii, Y; Kitagawa, Y; Okabayashi, K; Shigeta, K, 2014)
" Therefore, we hypothesized that SNAI2 (Slug) may mediate 5-fluorouracil (5FU) chemotherapy resistance through inhibition of miR145 in colorectal cancer and thus represents a novel therapeutic target to enhance current colorectal cancer treatment strategies."7.80SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression. ( Camp, ER; Ethier, SP; Findlay, VJ; Hurst, K; Nogueira, LM; Quirk, D; Staveley O'Carroll, KF; Wang, C; Watson, DK, 2014)
"Recent observational studies showed that post-operative aspirin use reduces cancer relapse and death in the earliest stages of colorectal cancer."7.80Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients. ( Ali, R; Chan, ML; Chia, WK; Deng, YH; Ho, GF; Jian, X; Mehta, S; Segelov, E; Sharma, A; Soon, SS; Tan, CS; Toh, HC; Wee, HL, 2014)
"We tested the hypothesis that expression of microRNAs (miRNAs) in cancer tissue can predict effectiveness of bevacizumab added to capecitabine and oxaliplatin (CAPEOX) in patients with metastatic colorectal cancer (mCRC)."7.80Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab. ( Boisen, MK; Dehlendorff, C; Hansen, TF; Holländer, NH; Høgdall, EV; Jensen, BB; Jensen, BV; Johansen, JS; Keldsen, N; Larsen, JS; Linnemann, D; Nielsen, BS; Nielsen, SE; Osterlind, K; Pfeiffer, P; Qvortrup, C; Tarpgaard, LS, 2014)
"The triplet combination of fluorouracil, oxaliplatin and irinotecan for metastatic colorectal cancer improves efficacy at the cost of increased toxicity."7.80Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis. ( Brunner, S; Camenisch Gross, U; Cathomas, R; Freyholdt, T; Mey, U; von Moos, R, 2014)
"Effectiveness and toxicity of transcatheter arterial injection of irinotecan-eluting beads (DEBIRI) with and without concurrent capecitabine in pre-treated patients with metastatic colorectal cancer (CRC)."7.80Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer. ( Akinwande, O; Hayes, D; Martin, RC; Miller, A; O'Hara, R; Tomalty, D, 2014)
" Herein, we examined the effectiveness of a combination treatment regimen of 5-fluorouracil (5-FU) and curcumin in colorectal cancer (CRC) cells."7.79Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and Src protein kinase signaling pathways. ( Busch, F; Goel, A; Lueders, C; Mobasheri, A; Shakibaei, M; Shayan, P, 2013)
"First-line chemotherapeutic treatment of colorectal cancer (CRC) typically comprises oral (capecitabine) or intravenous 5-fluorouracil (5-FU) plus leucovorin (LV), in combination with oxaliplatin (XELOX or FOLFOX, respectively), although debate exists regarding the best course of treatment by modality in clinical practice."7.79Comparative effectiveness of 5-fluorouracil with and without oxaliplatin in the treatment of colorectal cancer in clinical practice. ( Clingan, PR; Dawber, JP; Eckermann, S; Healey, E; Ranson, M; Stillfried, GE, 2013)
" 5-fluorouracil (5-FU) has been a drug of choice for treatment of colorectal cancer (CRC)."7.79Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer. ( Kang, SB; Kim, DG; Kim, IH; Kim, SH; Kim, SL; Kim, SW; Lee, SO; Lee, ST; Trang, KT, 2013)
"We investigated the correlation between plasma ratio of dihydrouracil/uracil (UH2/Ura), a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase (DPD) activity, and 5-fluorouracil (5-FU) treatment efficacy in rats with colorectal cancer (CRC)."7.79Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013)
"We developed a pharmacokinetic/pharmacodynamic (PK/PD) model with the value of the plasma ratio of dihydrouracil (UH2)/uracil (Ura), which is a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase activity, determined before 5-fluorouracil (5-FU) treatment to simulate the growth of tumors after 5-FU treatment in rats with colorectal cancer (CRC)."7.79Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013)
"To investigate the use of liposomal irinotecan (Irinophore C™) plus or minus 5-fluorouracil (5-FU) for the treatment of colorectal cancer."7.79Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil. ( Allen, TM; Anantha, M; Bally, MB; Dos Santos, N; Harasym, N; Hare, JI; Neijzen, RW; Waterhouse, DN; Webb, MS, 2013)
"To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer."7.79Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW, 2013)
"This retrospective cohort study investigated the association between epidermal growth factor receptor (EGFR) polymorphisms and clinical outcomes in colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)-based chemotherapy."7.79Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy. ( Chiou, HY; Hsieh, LL; Lai, CY; Sung, FC; Tang, R; Wu, FY; Yeh, CC, 2013)
"The relationship between the plasma ratio of dihydrouracil/uracil (UH2/Ura) and hepatic dihydropyrimidine dehydrogenase (DPD) activity after repeated 5-fluorouracil (5-FU) treatment in rats with colorectal cancer (CRC) was investigated."7.79A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Nishimura, A; Okada, K; Shibata, N; Takada, K, 2013)
"The aim of this study was to determine the feasibility of S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with initially unresectable metastases from colorectal cancer."7.79Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013)
"To evaluate gemcitabine plus capecitabine as third-line or later-line therapy in patients with refractory advanced colorectal cancer (CRC) who maintain a good performance status (PS)."7.79Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: a retrospective study. ( Alonso, MÁ; Jorge, M; Mendez, JC; Montes, AF; Pellón, ML; Quintero, G; Ramos, M; Reboredo, M; Romero, C; Salgado, M; Valladares-Ayerbes, M; Varela, S, 2013)
"Mucinous colorectal cancer (CRC) exhibits distinct clinical and pathological features, including poorer response to fluorouracil (FU) compared with non-mucinous tumours."7.79Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil. ( Ardizzoni, A; Azzoni, C; Bottarelli, L; Campanini, N; Cascinu, S; Cunningham, D; Mandolesi, A; Negri, FV; Scartozzi, M; Silini, EM; Tinelli, C; Wotherspoon, A, 2013)
"In diabetic patients complicated with colorectal cancer (CRC), metformin treatment was reported to have diverse correlation with CRC-specific mortality."7.79Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. ( Gao, F; Guan, M; Xue, Y; Zhang, Q; Zhang, Y; Zheng, Z, 2013)
"We analyzed the clinical efficacy and safety of capecitabine plus oxaliplatin( XELOX) and bevacizumab( BV) as neoadjuvant chemotherapy, administered for the treatment of patients with resectable metastatic colorectal cancer between October 2009 and December 2012."7.79[Neoadjuvant chemotherapy with capecitabine plus oxaliplatin and bevacizumab for the treatment of patients with resectable metastatic colorectal cancer]. ( Egawa, T; Ito, Y; Kemmochi, T; Makino, H; Mihara, K; Mori, T; Nagashima, A; Ohkubo, Y; Yamamuro, W, 2013)
"Capecitabine is one of the most effective oral chemotherapeutic drugs for advanced or recurrent colorectal cancer and gastric cancer."7.79[Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy]. ( Amemori, K; Koike, C; Shigematsu, T; Shirai, M; Sunda, K; Takeda, K; Yamada, T; Yamagiwa, K, 2013)
"The drug fluorouracil (5-FU) is a widely used antimetabolite chemotherapy in the treatment of colorectal cancer."7.79Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer. ( Ally, AA; Asano, JK; Brown, CJ; Chan, SY; Cheng, GS; Cheung, PY; Chittaranjan, S; Gill, S; Griffith, M; Griffith, OL; Hou, YC; Lee, A; Luk, M; Marra, MA; Miao, L; Moore, R; Morin, GB; Morin, RD; Mwenifumbo, JC; Novik, K; Owen, D; Paul, JE; Pugh, TJ; Severson, T; Tai, IT; Tang, MJ; Taylor, G, 2013)
" We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), either alone or in combination with oxaliplatin (FOLFOX)."7.79Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. ( Andreu, M; Baiget, M; Bessa, X; Brea-Fernández, A; Bujanda, L; Candamio, S; Carracedo, A; Castells, A; Castellví-Bel, S; Cazier, JB; Cortejoso, L; Crous-Bou, M; Durán, G; Fernandez-Rozadilla, C; Gallardo, E; García, MI; González, D; Gonzalo, V; Guinó, E; Jover, R; Lamas, MJ; Llor, X; López, R; López-Fernández, LA; Moreno, V; Páez, D; Palles, C; Paré, L; Reñé, JM; Rodrigo, L; Ruiz-Ponte, C; Tomlinson, I; Xicola, R, 2013)
"The aim of the study was to analyse the prevalence and characteristics of secondary diabetes induced by 5-fluorouracil (5-FU) based chemotherapy in non-diabetic patients with colorectal cancer (CRC)."7.79Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study. ( Fang, J; Feng, JP; Li, M; Lin, M; Luo, M; Xie, T; Ye, DW; Yuan, XL; Zhou, Y; Zhu, YM, 2013)
"We initiated this preclinical study in order to analyze the impact of sorafenib single treatment versus combination treatment in human colorectal cancer."7.79Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy. ( Berger, MR; Galle, PR; Gockel, I; Graf, C; Hainz, M; Hamdi, S; Maderer, A; Moehler, M; Schimanski, CC; Schmidtmann, I; Theobald, M; Wehler, TC, 2013)
"To investigate the hepatic dihydropyrimidine dehydrogenase (DPD) activity in colorectal cancer (CRC), which is critically important to create a patient-specific dosing regimen, we performed 5-FU pharmacokinetic studies in 1,2-dimethylhydrazine-induced CRC model rats (CRC rats)."7.79Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats. ( Imoto, K; Ito, Y; Kobuchi, S; Okada, K; Takada, K, 2013)
"Five prognostic factors had been previously identified in patients with metastatic colorectal cancer (MCRC) who received irinotecan-based second-line chemotherapy."7.79Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. ( Fukushima, H; Komatsu, Y; Muro, K; Naito, Y; Shitara, K; Takano, T; Yamazaki, K; Yasui, H; Yuki, S, 2013)
"Resistance to 5-fluorouracil (5FU) poses a constant challenge to the management of colorectal cancer (CRC)."7.79Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy. ( Chan, EC; Cheah, PY; Ho, HK; Koh, PK; Mal, M; Phua, LC, 2013)
"The goal of the present study was to compare the efficacy of the combination of cetuximab and irinotecan to the combination of oxaliplatin and fluoropyrimidines as second-line chemotherapy in patients with irinotecan-refractory and oxaliplatin-naïve metastatic colorectal cancer (mCRC) harboring wild-type KRAS."7.79Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. ( Baek, JY; Hong, YS; Kim, HJ; Kim, JC; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, JL; Lim, SB; Park, JH; Park, SJ; Yu, CS, 2013)
"No standard treatment exists for patients with metastatic colorectal cancer who have progressed after treatment with 5-fluorouracil (5-FU), oxaliplatin, irinotecan and an anti-EGFR antibody."7.78Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer. ( Boisen, MK; Fromm, AL; Jensen, BV; Larsen, FO, 2012)
"In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin."7.78Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012)
" The aim of this study was to investigate the schedule-dependent effect of 5-fluorouracil (5-FU) and platinum derivatives (cisplatin or oxaliplatin) in colorectal cancer (CRC) cell lines, and to explore factors affecting it."7.78Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells. ( Fujita, M; Minegaki, T; Okumura, K; Takahashi, M; Takara, K; Yamamoto, K; Yokoyama, T, 2012)
"The efficacy of bevacizumab combined with infusional 5-fluorouracil/leucovorin (5-FU/LV) plus irinotecan (FOLFIRI) as the second-line treatment for metastatic colorectal cancer (mCRC) has not been fully clarified, although bevacizumab combined with infusional 5-FU/LV plus oxaliplatin (FOLFOX) in the second-line setting has demonstrated a survival benefit."7.78Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV stud ( Baba, E; Bando, H; Boku, N; Esaki, T; Fukunaga, M; Hyodo, I; Kato, S; Katsumata, K; Miyake, Y; Moriwaki, T; Ozeki, M; Satoh, T; Takashima, A; Yamashita, K; Yamazaki, K; Yoshida, S, 2012)
" We investigated the clinical significance of miR-10b and its involvement in chemotherapeutic resistance to 5-fluorouracil (5-FU), which is a key component of common chemotherapy regimens in colorectal cancer."7.78MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. ( Doki, Y; Ishii, H; Mimori, K; Mori, M; Nishida, N; Shibata, K; Sudo, T; Tanaka, F; Yamamoto, H; Yamashita, S, 2012)
" The aim of the present study was to analyse the possible predictive value of miRNA-126 in relation to first line capecitabine and oxaliplatin (XELOX) in patients with metastatic colorectal cancer (mCRC)."7.78The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. ( Hansen, TF; Jakobsen, A; Lindebjerg, J; Sørensen, FB, 2012)
" We analysed a cohort of 302 patients with colorectal cancer treated with 5-Fluorouracil (5-FU)."7.78Data-driven assessment of the association of polymorphisms in 5-Fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer. ( Afzal, S; Colding-Jørgensen, M; Jensen, SA; Mosekilde, E; Poulsen, HE; Rasmussen, CH; Sarac, SB; Thirstrup, S, 2012)
" Deficient mismatch repair, or microsatellite instability, is a potent marker for the ineffectiveness of 5-fluorouracil (5-FU) in colorectal cancer (CRC)."7.78FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer. ( Fujinaka, Y; Iimori, M; Kakeji, Y; Kitao, H; Maehara, Y; Morita, M; Nakanishi, R; Tokunaga, E; Yamashita, N, 2012)
" In this retrospective study, we assessed the efficacy of palonosetron versus granisetron for the incidence of CINV induced by mFOLFOX6 and FOLFIRI in patients with advanced colorectal cancer."7.78[Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey]. ( Hayakawa, Y; Muro, K; Noma, H; Okamoto, H; Sato, Y; Tatematsu, M, 2012)
"Five patients with primary colorectal adenocarcinoma or anal squamous cell carcinoma were started on a 2-weeks-on, 1-week-off capecitabine dosing regimen in addition to other chemotherapeutic agents and/or radiation."7.78Capecitabine-induced chest pain relieved by diltiazem. ( Ambrosy, AP; Fisher, GA; Kunz, PL; Witteles, RM, 2012)
"Radiosensitization by vorinostat under hypoxia was studied in four colorectal carcinoma cell lines and in one colorectal carcinoma xenograft model by analysis of clonogenic survival and tumor growth delay, respectively."7.78Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma. ( Flatmark, K; Fleten, KG; Furre, T; Hektoen, HH; Kristian, A; Ree, AH; Saelen, MG, 2012)
"To evaluate effects of UDP-glucuronosyltransferase1A1 (UGT1A1) and thymidylate synthetase (TS) gene polymorphisms on irinotecan in metastatic colorectal cancer (mCRC)."7.78UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. ( Jiao, SC; Liu, ZY; Shen, L; Wang, JW; Wang, Y; Xu, JM; Xu, N, 2012)
"The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using cytoreductive surgery prior to treatment with hyperthermic intraperitoneal chemotherapy with mitomycin C as part of a multidrug regimen."7.77Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. ( Chang, D; Mahteme, H; Stuart, OA; Sugarbaker, PH; Van der Speeten, K, 2011)
"Capecitabine plus oxaliplatin (CAPOX) is an established treatment option in colorectal cancer, but can be associated with severe toxicities."7.77Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. ( Baird, R; Barbachano, Y; Biondo, A; Chau, I; Chhaya, V; Cunningham, D; Karpathakis, A; McLachlan, J; Rahman, S, 2011)
"Irinotecan (CPT11) at 180 mg/m(2) with LV5FU2 for metastatic colorectal cancer (MCRC) has response rates (RRs) of 56 and 4% as first- and second-line treatments, respectively [1-2], and higher doses of CPT11 result in higher RRs."7.77Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients. ( Goubely, Y; Kirscher, S; Mineur, L; Molinari, N; Plat, F; Sabatier, R, 2011)
"A total of 152 patients with metastatic colorectal cancer who were treated with oxaliplatin and continuous infusion 5-fluorouracil were genotyped for 21 polymorphisms in 13 cancer-related genes by PCR."7.77Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. ( El-Khouiery, A; Gordon, MA; Iqbal, S; Labonte, M; Ladner, RD; Lenz, HJ; Lurje, G; Nagashima, F; Sherrod, A; Wilson, P; Yang, D; Zhang, W, 2011)
" In the present study, we evaluated the characteristics of paclitaxel (PTX) and 5-fluorouracil (5-FU) penetration and their effects on tissue penetration using MCLs of human colorectal cancer cells (DLD-1 and HT-29) grown in Transwell inserts."7.77Penetration of paclitaxel and 5-fluorouracil in multicellular layers of human colorectal cancer cells. ( Choi, MS; Kim, SH; Kuh, HJ, 2011)
"Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer."7.77A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. ( Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J, 2011)
"There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)."7.77Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011)
" In the present study, we aimed to investigate the antitumor effect of DCA combined with 5-Fluorouracil (5-FU) on colorectal cancer (CRC) cells."7.77Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. ( He, J; Li, J; Liang, H; Pan, F; Tong, J; Xie, G, 2011)
" We aimed to evaluate the effect of pretreatment serum metabolic profiles generated by (1)H NMR spectroscopy on toxicity in patients with inoperable colorectal cancer receiving single agent capecitabine."7.77Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. ( Backshall, A; Clarke, SJ; Keun, HC; Sharma, R, 2011)
"Germline DNA was available from 568 previously untreated patients with advanced colorectal cancer participating in the CAIRO2 trial, assigned to capecitabine, oxaliplatin, and bevacizumab ± cetuximab."7.77Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. ( Beijnen, JH; Burylo, AM; Cats, A; de Boer, A; Deenen, MJ; Doodeman, VD; Guchelaar, HJ; Punt, CJ; Schellens, JH; Smits, PH; Tol, J; Vincent, A, 2011)
"Thymidylate synthase (TS) expression levels appear to be related to response to 5-fluorouracil-(5-FU)-based chemotherapy in colorectal cancer (CRC) patients."7.77Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. ( Cianchi, F; Genuardi, M; Mazzei, T; Mini, E; Morganti, M; Napoli, C; Nobili, S; Papi, L; Putignano, AL; Tonelli, F; Valanzano, R; Vignoli, M, 2011)
"We have extensively assessed a biweekly regimen of irinotecan plus folinic acid and fluorouracil bolus (IRIFAFU) in metastatic colorectal cancer (MCRC)."7.77Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience. ( Barbato, E; Barberis, G; Comella, P; Condemi, G; Filippelli, G; Ionta, MT; Massidda, B; Natale, D; Palmeri, S; Putzu, C; Sandomenico, C; Tafuto, S; Vessia, G, 2011)
"The role of the calcium binding protein, Calbindin 2 (CALB2), in regulating the response of colorectal cancer (CRC) cells to 5-Fluorouracil (5-FU) was investigated."7.77Calbindin 2 (CALB2) regulates 5-fluorouracil sensitivity in colorectal cancer by modulating the intrinsic apoptotic pathway. ( Allen, WL; Johnston, L; Johnston, PG; Longley, DB; McCloskey, K; Proutski, I; Stevenson, L; Stewart, G; Wilson, PM, 2011)
"Infusional fluorouracil/leucovorin (FU/LV) plus irinotecan (FOLFIRI) is one of the standard first-line options for patients with metastatic colorectal cancer (mCRC)."7.77A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. ( Baiget, M; del Rio, E; Marcuello, E; Páez, D; Paré, L; Salazar, J; Sebio, A, 2011)
"We studied patterns of DNA damage signaling and cell cycle response to clinically-relevant (bolus) and high doses of 5-fluorouracil (5-FU) in three colorectal cancer cell lines with differing MMR and TP53 status in an attempt to better understand how 5-FU exerts its cytotoxicity."7.77DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status. ( Adamsen, BL; De Angelis, PM; Kravik, KL, 2011)
"FOLFOX (a combination of leucovorin, fluorouracil and oxaliplatin) has achieved substantial success in the treatment of colorectal cancer (CRC) patients."7.77Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. ( Eshima, K; Horie, H; Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Konishi, T; Matsuda, K; Muto, T; Nozawa, K; Watanabe, T; Yamamoto, Y, 2011)
"5-fluorouracil (5FU)-based chemotherapy is the standard treatment for advanced stage colorectal cancer (CRC) patients."7.77DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells. ( Carethers, JM; Iwaizumi, M; Tseng-Rogenski, S, 2011)
"For recurrent or metastatic colorectal cancer, a combination of leucovorin and fluorouracil with oxaliplatin (FOLFOX)is a standard first-line regimen."7.77[Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy]. ( Hasegawa, J; Hirota, M; Kim, Y; Nezu, R; Nishimura, J; Yoshida, Y, 2011)
"The purpose of this study was to investigate whether specific combinations of polymorphisms in 5-fluorouracil (5-FU) metabolism-related genes were associated with outcome in 5-FU-based adjuvant treatment of colorectal cancer."7.77The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer. ( Adleff, V; Afzal, S; Andersen, JT; Barile, C; Bertolaso, L; Brødbæk, K; Budai, B; Gusella, M; Hitre, E; Jensen, SA; Jimenez-Solem, E; Kralovánszky, J; Láng, I; Orosz, E; Padrini, R; Pasini, F; Petersen, M; Poulsen, HE; Vainer, B; Vogel, U, 2011)
" Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29%)."7.77Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. ( Balaban, EP; Bull, J; Frenkel, EP; Graham, M; Periman, P; Perkins, S; Pruitt, B; Ross, M; Ruud, C; Sheehan, RG, 1994)
"Failure rate of colorectal cancer after surgical resection remains around 50% and adjuvant treatments are clearly required."7.77Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU. ( Nordlinger, B; Rougier, P, 1993)
"To investigate the mechanism of enhancing apoptosis-inducing effects of 5-fluorouracil on human colorectal adenocarcinoma cells by stable transfection of extrinsic Fas-associated death domain protein (FADD) gene, both in vitro and in vivo."7.76Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells. ( Jiang, Y; Luo, H; Yin, A; Zhang, X, 2010)
"A retrospective analysis was conducted to compare the tolerability and efficacy of single-agent capecitabine and 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) in the first-line treatment of patients aged > or =65 years with metastatic colorectal cancer (mCRC)."7.76Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. ( Bodnar, L; Stec, R; Szczylik, C, 2010)
" We investigated whether p53 polymorphism and mutation were associated with in vitro sensitivity to 5-fluorouracil (5-FU) in patients with colorectal cancer."7.76Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer. ( Higashiguchi, T; Hotta, T; Iwahashi, M; Matsuda, K; Nasu, T; Oku, Y; Takifuji, K; Tominaga, T; Yamaue, H; Yokoyama, S, 2010)
"The purpose of the present study was to investigate polymorphisms related to the metabolism of fluoropyrimidine and oxaliplatin, thymidylate synthase (TS) and excision repair cross-complementing gene 1 (ERCC1) 118, in metastatic colorectal cancer patients treated with capecitabine and oxaliplatin (XELOX)."7.76EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. ( Andersen, RF; Jakobsen, A; Jensen, LH; Ploen, J; Spindler, KG, 2010)
" To test this we have addressed the hypothesis that histone deacetylase inhibitors SBHA and MS275 potentiate inhibitory effects of classical anti-colorectal cancer cytostatic, 5-fluorouracil (5-FU), on survival of colorectal cancer (CRC) cells in vitro."7.76MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells. ( Flis, K; Flis, S; Gnyszka, A; Spławiński, J, 2010)
"The in vitro chemosensitizing effect of triptolide (PG490) on the cytotoxicity of 5-fluorouracil (5-FU) was determined in three colorectal cancer (CRC) cell lines."7.76Triptolide simultaneously induces reactive oxygen species, inhibits NF-kappaB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines. ( Armesilla, AL; Cassidy, J; Darling, JL; Guo, X; Mathew, S; Wang, W; Xu, B, 2010)
"The aim was to evaluate the cost of capecitabine vs conventional combination chemotherapics such as 5-fluorouracil (5-FU) for the treatment of metastatic colorectal cancer (mCRC) in Italy."7.76Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients. ( Bianchessi, C; Bollina, R; Carteni, G; Cozzi, C; De Portu, S; Grimaldi, AM; Mantovani, LG; Ravaioli, A; Tamburini, E; Testa, TE, 2010)
"To explore the effect of PI3K p85alpha gene silencing on the 5-fluorouracil (5-FU)-induced apoptosis of colorectal cancer cells."7.76[PI3K p85alpha gene silencing by RNA interference promotes 5-fluorouracil-induced apoptosis of colorectal cancer LoVo cells]. ( Ma, YQ; Ni, L; Song, YG; Yang, H, 2010)
" The SFK inhibitor saracatinib (AZD0530) is currently in phase II trials in patients including those with colorectal cancer (CRC), where links between SFK activity and poor prognosis are particularly striking."7.76Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters. ( Bönisch, H; Bryce, RA; Dive, C; Ghattas, M; Green, TP; Hickinson, DM; Morrow, CJ; Smith, C, 2010)
"A hospital based cross-sectional retrospective study was conducted to determine the frequency of hand foot syndrome (HFS) with Capecitabine as a single agent and in combination with Oxaliplatin."7.76High frequency of hand foot syndrome with capecitabine. ( Azman, N; Haron, M; Kamil, M; Khalid, I; Yosuff, N, 2010)
"Resistance to 5-fluorouracil (5-FU) represents a major contributor to cancer-related mortality in advanced colorectal cancer patients."7.76Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy. ( Auman, JT; Deal, AM; Hoskins, JM; Hudson, ML; Ibrahim, JG; McLeod, HL; Meyers, MO; Muhale, F; O'Neil, BH; Thorne, LB; Walko, CM; Watson, RG; Yu, J, 2010)
"Although the 2009 edition of the Guidelines for Colorectal Cancer Therapy recommend capecitabine as a standard postoperative adjuvant chemotherapy for colorectal cancer therapy, a characteristic adverse event, hand-foot syndrome, develops at a high incidence, and appropriate management is necessary to continue therapy."7.76[Adverse events in patients treated with capecitabine as adjuvant chemotherapy after surgery for colorectal cancer--countermeasures against hand-foot syndrome]. ( Chiba, M; Fujimoto, H; Igawa, A; Iizawa, H; Ikeda, E; Inoue, K; Ishiyama, K; Kobayashi, Y; Matsuda, M; Mori, N; Saito, T; Sato, T; Sugawara, M; Suto, T; Suzuki, Y; Watanabe, T; Yabuki, H, 2010)
"Patients with locally advanced and metastatic colorectal cancer treated with capecitabine or 5-fluorouracil/leucovorin (5-FU/LV) as monotherapy or combination therapy with oxaliplatin from 2003-2006 were identified in the Thomson Reuters MarketScan® databases."7.76Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison. ( Cartwright, T; Chu, E; McKenna, EF; Schulman, KL, 2010)
"Combination of capecitabine and irinotecan (XELIRI regimen) is an active and well tolerated treatment for metastatic colorectal cancer (mCRC)."7.76Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. ( Alvarez-Suarez, S; García-Alfonso, P; Jerez-Gilarranz, Y; Khosravi, P; Martin, M; Muñoz-Martin, AJ; Riesco-Martinez, M, 2010)
"The combination regimen of mitomycin-C/5-FU/leucovorin showed marginal activity and tolerable toxicity profiles in heavily pretreated metastatic colorectal cancer patients."7.76Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. ( Choi, IK; Choi, YJ; Kang, EJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2010)
"This retrospective study evaluated the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil (5-FU) for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy."7.76Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis. ( Arai, Y; Aramaki, T; Boku, N; Inaba, Y; Kichikawa, K; Matsuoka, M; Nishiofuku, H; Otsuji, T; Sato, Y; Tanaka, T, 2010)
"In progressive colorectal cancer these treatment results can be regarded as a significant change in the natural history of the disease."7.76Folinic acid (FA) plus 5-fluorouracil (FU) in progressive advanced colorectal cancer. ( Freund, M; Poliwoda, H; Preusser, P; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, H, 1988)
"The aim of this study is to evaluate if mismatch repair (MMR) defective colorectal cancer has a different response to adjuvant 5-fluorouracil (5-FU) chemotherapy in a cohort of patients prospectively followed during 5 years."7.75The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. ( Alenda, C; Andreu, M; Balaguer, F; Bessa, X; Bujanda, L; Castells, A; Clofent, J; Cubiella, J; Jover, R; Llor, X; Morillas, JD; Nicolás-Pérez, D; Payá, A; Pons, E; Reñé, JM; Sempere, L; Xicola, RM; Zapater, P, 2009)
"Modifying the capecitabine dosing schedule from 14 days on, 7 days off (14/7) to 7 days on, 7 days off (7/7) may enable higher doses and improved antitumor efficacy in colorectal cancer xenografts."7.75In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models. ( Dugan, U; Heimbrook, D; Higgins, B; Kohles, J; Kolinsky, K; Packman, K; Shen, BQ; Zhang, YE; Zioncheck, TF, 2009)
"To investigate the synergistic effect of epidermal growth factor(EGF) and 5-fluorouracil for the treatment of human colorectal cancer in BALB/C nude mice subcutaneous xenografts model."7.75[Synergistic use of epidermal growth factor and 5-fluorouracil for the treatment of human colorectal cancer in BALB/C nude mice subcutaneous xenograft model]. ( Tao, KX; Wang, GB; Ye, L, 2009)
"Capecitabine, an oral alternative to 5-fluorouracil (5-FU) in patients with colorectal cancer (CRC), has equal clinical efficacy and a favorable safety profile; however, its use may be limited because of unit cost concerns."7.75Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. ( Chu, E; Schulman, KL; Song, X; Zelt, S, 2009)
"A total of 76 patients with recurrent or metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) combination chemotherapy were enrolled in the present study."7.75Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. ( Bae, SH; Chae, YS; Choi, GS; Jeon, SW; Jun, SH; Kang, BM; Kim, JG; Kum, Y; Lim, KH; Moon, JH; Park, IJ; Ryoo, HM; Sohn, SK, 2009)
"Panaxadiol enhanced the anti-cancer effects of 5-FU on human colorectal cancer cells through the regulation of cell cycle transition and the induction of apoptotic cells."7.75Panaxadiol, a purified ginseng component, enhances the anti-cancer effects of 5-fluorouracil in human colorectal cancer cells. ( Li, XL; Mehendale, SR; Sun, S; Wang, CZ; Wang, Q; Yuan, CS, 2009)
"The purpose of this study was to assess retrospectively the sequential treatment of hepatic arterial infusion (HAI) chemotherapy followed by systemic therapy using oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin, namely, FOLFOX, for patients with liver metastases from colorectal cancer."7.75Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer. ( Ozaki, T; Seki, H; Shiina, M, 2009)
"The correlations between adenomatous polyposis coli (APC) mutations and 5-fluorouracil (5-FU) adjuvant chemotherapy and colorectal cancer (CRC) patients' prognosis are not well known."7.75Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects. ( Chen, SP; Chen, YL; Chiu, SC; Harn, HJ; Kang, JC; Lin, PC; Lin, SZ; Pang, CY; Su, CC; Wu, CC, 2009)
"A combination of oxaliplatin(L-OHP), folinic acid and 5-fluorouracil(5-FU)(mFOLFOX6)has been widely administered to treat advanced or recurrent colorectal cancer."7.75[Effect of withdrawal of 5-fluorouracil bolus administration on recovery from neutropenia in colorectal cancer patients treated with mFOLFOX6 chemotherapy-comparison with total dosage reduction]. ( Chihara, S; Demizu, M; Iwakawa, S; Kimura, F; Maeda, C; Nakanishi, Y; Oosawa, M; Ueda, H; Yano, K, 2009)
"We designed a study protocol in 2005 and 16 patients with metastatic colorectal cancer were treated accordingly in the first line setting with XELIRI regimen (capecitabin, irinotecan) + bevacizumab."7.75[Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer]. ( Kocák, I; Kocáková, I; Nemecek, R; Rehák, Z; Standara, M; Svoboda, M, 2009)
" The aims of the present study were to compare, in vitro and in vivo, the antiangiogenic and antitumor activities of metronomic irinotecan (CPT-11), oxaliplatin (L-OHP) and 5-fluorouracil (5-FU) in colorectal cancer and to investigate the metronomic combination of these drugs."7.75Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. ( Alì, G; Allegrini, G; Bocci, G; Canu, B; Danesi, R; Del Tacca, M; Di Desidero, T; Emmenegger, U; Falcone, A; Fioravanti, A; Fontanini, G; Orlandi, P, 2009)
"To compare chemotherapy-related and total medical costs among patients with colorectal cancer (CRC) receiving capecitabine or 5-fluorouracil (5-FU) monotherapy after surgical resection."7.75Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer. ( Bendell, JC; Cartwright, T; Chu, E; Shi, N; Wei, W, 2009)
"To evaluate the efficacy and the safety of combined 5-Fluorouracil, irinotecan, bevacizumab and sirolimus in refractory advanced colorectal carcinoma."7.75Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study. ( Chauffert, B; Ghiringhelli, F; Guiu, B; Ladoire, S, 2009)
"5-Fluorouracil (5-FU) is considered to be the backbone of colorectal cancer (CRC) systemic therapy since the great majority of recommended regimens include its administration."7.75Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma. ( Garita, R; Michelin, OC; Okoshi, K; Paiva, BS; Paiva, CE, 2009)
"We describe the case of an HIV-positive 48-year-old male patient with metastatic colorectal cancer, treated with a bevacizumab, irinotecan, fluorouracil, and leucovorin regimen, with concomitant HAART."7.74Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer. ( Bearz, A; Berretta, M; Berretta, S; Fisichella, R; Lleshi, A; Nasti, G; Simonelli, C; Tirelli, U; Zanet, E, 2008)
"We investigated the association between thymidylate synthase (TS) germline polymorphisms and response to 5-fluorouracil-based chemotherapy in 80 patients with liver-only metastatic colorectal cancer (MCRC)."7.74Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. ( Alessandroni, P; Baldi, G; Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Fornaro, L; Giordani, P; Giustini, L; Graziano, F; Loupakis, F; Magnani, M; Maltese, P; Masi, G; Ruzzo, A; Santini, D; Tonini, G; Vincenzi, B, 2008)
" [Ann Oncol 2002;13:308-317] showed that four prognostic variables can be used to classify patients with metastatic colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)/leucovorin (LV) into three risk groups with different overall survival (OS)."7.74Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. ( Hurwitz, H; Irl, C; Kabbinavar, F; Zurlo, A, 2008)
"In this study, we investigated the efficacy and toxicity of fluorouracil(FU)+Leucovorin(LV)with oxaliplatin (FOLFOX)and irinotecan(FOLFIRI)for patients with advanced or metastatic colorectal cancer."7.74Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies. ( Adachi, K; Arimoto, Y; Kanamiya, Y; Nakamura, R; Nishio, K; Oba, H; Ohtani, H; Shintani, M; Yui, S, 2008)
"The modified irinotecan plus bolus 5-fluorouracil/L-leucovorin (IFL) regimen (irinotecan plus bolus 5-fluorouracil/L-leucovorin) used to be one of the standard treatments for metastatic colorectal cancer until approval of oxaliplatin in Japan."7.74Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan. ( Chin, K; Hatake, K; Matsusaka, S; Mizunuma, N; Muto, T; Oya, M; Shinozaki, E; Shouji, D; Suenaga, M; Yamaguchi, T, 2008)
"This retrospective study was performed to evaluate a survival benefit of the full administration of 5-fluorouracil (5-FU), irinotecan (CPT-11), and oxaliplatin (L-OHP) to patients with unresectable or recurrent colorectal cancer."7.74[The validity of full administration of 5-fluorouracil, irinotecan, and oxaliplatin to unresectable or recurrent colorectal cancer]. ( Inoue, N; Ishibashi, K; Ishida, H; Ishiguro, T; Matsuki, M; Mitsuhashi, T; Miyazaki, T; Okada, N; Okita, T; Sano, M; Yokoyama, M, 2008)
" To meet this demand, a nurse-/pharmacy-led clinic was established at the Beatson Oncology Centre in 2003 for the provision of oral capecitabine to metastatic colorectal cancer patients to provide a controlled and supportive environment."7.74A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: results of a prospective audit and retrospective survey of patient experiences. ( Branch, A; Cassidy, J; MacDonald, L; MacLeod, A; McDonald, A; Mohammed, N, 2007)
"The purpose of this study was to compare the activities of various enzymes, participating in the metabolism of 5-fluorouracil, between colorectal cancer and nontumor tissues and to investigate the association of the enzyme activities with clinicopathological backgrounds."7.74Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer. ( Fukushima, M; Matsusaka, S; Wakabayashi, I; Yamasaki, H, 2007)
"The aim of this study was to investigate the influence of combining thymidylate synthase (TS), X-ray cross complementing factor 1 (XRCC1) and uridine diphosphate glucoronosyltransferase (UGT1A1 *28) polymorphism genotypes in response rate and time to progression (TTP) in metastatic colorectal cancer patients treated with 5-fluorouracil (5-FU) plus irinotecan or oxaliplatin (OXA)."7.74Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxa ( Abad, A; Catot, S; Cirauqui, B; Manzano, JL; Martinez-Balibrea, E; Martinez-Cardus, A; Moran, T; Taron, M, 2007)
"Randomised trials have established the importance of oxaliplatin (O) and irinotecan (I) in advanced colorectal cancer (CRC)."7.74Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis. ( Adena, M; Damianovich, D; Tebbutt, NC, 2007)
"In patients with advanced colorectal cancer, leucovorin, fluorouracil, and irinotecan (FOLFIRI) is considered as one of the reference first-line treatments."7.74Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. ( Bareil, C; Bascoul-Mollevi, C; Bibeau, F; Chalbos, P; Conseiller, E; Copois, V; Del Rio, M; Fraslon, C; Granci, V; Kramar, A; Leblanc, B; Martineau, P; Molina, F; Pau, B; Salvetat, N; Ychou, M, 2007)
"This study explores the effect of 5-fluorouracil (5FU) exposure on mRNA levels of its target enzyme thymidylate synthase (TS) and the rate-limiting catabolic enzyme dihydropyrimidine dehydrogenase (DPD) in tumors of colorectal cancer patients."7.74Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer. ( Jansen, G; Mauritz, R; Peters, GJ; Pinedo, HM; Smid, K; van Groeningen, CJ, 2007)
"To evaluate the efficacy and safety of a regimen using Irinotecan, 5FU and Leucovorin for patients with advanced or recurrent colorectal cancer."7.74Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes. ( Iinuma, N; Ishizone, S; Koide, N; Maruta, F; Miyagawa, S; Nakayama, J; Yanagisawa, Y, 2007)
"Primary colorectal cancer tissue from 24 patients was investigated to evaluate the relationship between the mRNA expression level of several 5-fluorouracil (5-FU)-related metabolic enzymes (thymidylate synthase, TS; dihydropyrimidine dehydrogenase, DPD; and thymidine phosphorylase, TP) and chemosensitivity to two different 5-FU doses and duration (1: 5-FU concentration 1."7.74Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer. ( Abe, H; Endo, Y; Kurumi, Y; Mekata, E; Naitoh, H; Okumura, K; Shiomi, H; Tani, T, 2008)
"Cetuximab (Erbitux) in combination with irinotecan is the most promising combination in heavily pretreated patients with advanced colorectal cancer."7.74Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. ( Iversen, A; Jensen, BV; Nielsen, D; Pfeiffer, P; Vejlø, C; Yilmaz, M, 2007)
"The oxaliplatin/fluorouracil/leucovorin (FOL-FOX regimen) is an effective and generally well-tolerated regimen in Western clinical studies of advanced colorectal cancer."7.74Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience. ( Fukuoka, M; Nakagawa, K; Okamoto, I; Ozaki, T; Satoh, T; Shimizu, T; Tamura, K, 2007)
"The objectives of the present study were to evaluate the efficacy and safety of an outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as the first-line treatment for patients with advanced colorectal cancer."7.74Outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as first-line treatment for patients with metastatic or recurrent colorectal cancer. ( Ahn, BM; Baek, JH; Chae, YS; Cho, YY; Choi, GS; Jun, SH; Kim, JG; Kim, SN; Lee, IT; Lee, SJ; Moon, JH; Sohn, SK, 2007)
"Capecitabine is a fluoropyrimidine-based drug that offers physicians a more convenient treatment for advanced colorectal cancer (CRC), with manageable toxicity and antitumor activity comparable to that of continuous-infusion therapies with 5-fluorouracil (5-FU)."7.74DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. ( Danenberg, KD; Danenberg, PV; Jakobsen, A; Kuramochi, H; Lindebjerg, J; Nielsen, JN; Shimizu, D; Vallböhmer, D; Yang, DY, 2007)
"A combination of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) is one of the standard regimens for palliative and adjuvant chemotherapy for colorectal cancer."7.74Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer. ( Asaka, M; Doi, T; Fuse, N; Kojima, T; Muto, M; Ohtsu, A; Tahara, M; Takeuchi, S; Taku, K; Yoshida, S, 2007)
"Short-term infusion of 5-fluorouracil with leucovorin in combination with irinotecan or oxaliplatin has been considered as standard treatment for metastatic colorectal cancer."7.74Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. ( Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T, 2007)
"To investigate the mechanisms of drug resistance, a set of cell lines with different levels of sensitivity and possessing different mechanisms of resistance to 5-fluorouracil (5-FU) was established from a colorectal cancer cell line."7.74Swainsonine reduces 5-fluorouracil tolerance in the multistage resistance of colorectal cancer cell lines. ( Deguchi, K; Hamaguchi, J; Kamiyama, N; Kudo, T; Nakagawa, H; Nishimura, S; Oshima, T; Sato, Y; Sun, B; Takahashi, M; Todo, S, 2007)
"The addition of bevacizumab to 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) improved the time-to-progression (TTP) and overall survival (OS) in comparison to FOLFOX in the second-line treatment of metastatic colorectal cancer (MCRC)."7.745-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study. ( Bir, A; Fakih, MG; Lombardo, J; Tan, W; Wilding, GE, 2007)
"The clinical efficacy and safety of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer were studied retrospectively."7.74[Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer]. ( Hori, S; Hyodo, I; Iguchi, H; Imamine, S; Kajiwara, T; Kataoka, J; Moriwaki, T; Nasu, J; Nishina, T, 2007)
"The authors reported in a previous study that NK012, a 7-ethyl-10-hydroxy-camptothecin (SN-38)-releasing nano-system, exhibited high antitumor activity against human colorectal cancer xenografts."7.74Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil. ( Hamaguchi, T; Kano, Y; Kato, K; Koizumi, F; Matsumura, Y; Nakajima, TE; Shimada, Y; Shirao, K; Yamada, Y; Yasunaga, M, 2008)
"To evaluate the effect of thymidylate synthase (TYMS) and methylenetetrahydrofolate reductase (MTHFR) genotypes on toxicity in patients treated with capecitabine for advanced colorectal cancer and to determine the effect of these polymorphisms on the pretreatment levels of serum folate and plasma homocysteine."7.74Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. ( Clarke, SJ; Hoskins, JM; Liddle, C; London, R; Rivory, LP; Sharma, R; Zucknick, M, 2008)
"Low tumour expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) have been linked with improved outcome for colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)."7.74Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. ( Diasio, RB; Han, HC; Iacopetta, B; Joseph, D; Ng, SS; Salto-Tellez, M; Shah, N; Soo, RA; Soong, R; Tai, BC; Tan, WL; Zeps, N, 2008)
"Standard weekly cetuximab and irinotecan (CetIri) is an effective regimen in heavily pretreated patients with advanced colorectal cancer (ACRC)."7.74Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. ( Bjerregaard, J; Jensen, B; Nielsen, D; Pfeiffer, P; Qvortrup, C; Yilmaz, M, 2008)
"5-Fluorouracil (5-FU) is the most commonly used anticancer drug for colorectal cancer (CRC)."7.74Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy. ( Iinuma, H; Watanabe, T; Yamada, H, 2008)
"To evaluate 5-fluorouracil (5-FU) and 5-fluoro-5,6-dihydrouracil (5-FDHU) pharmacokinetics and disease-free survival (DFS) in colorectal cancer patients given 5-FU-based adjuvant chemotherapy within a nonrandomized, retrospective, pharmacokinetic study."7.745-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. ( Amatori, F; Bocci, G; Danesi, R; Del Tacca, M; Di Donato, S; Di Paolo, A; Falcone, A; Federici, F; Iannopollo, M; Lastella, M; Lencioni, M; Orlandini, C; Ricci, S, 2008)
"A combination of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) has become one of the global standard chemotherapy regimens for metastatic colorectal cancer."7.74Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer. ( Asaka, M; Doi, T; Fuse, N; Hamamoto, Y; Minashi, K; Muto, M; Ohtsu, A; Tahara, M; Yano, T; Yoshida, S, 2008)
"70 patients with advanced colorectal cancer were treated with irinotecan and 5-fluorouracil."7.74[Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients]. ( Bao, HY; Jiao, SC; Li, F; Li, J; Shen, L; Song, ST; Wang, JW; Wang, Y; Xu, JM; Xu, N; Yang, L; Zhang, JS, 2007)
"This study evaluated the effects of oral capecitabine on the quality of life (QOL) of Brazilian patients with metastatic colorectal cancer who received capecitabine (1000 or 1250 mg/m2 twice a day on days 1-14, every 3 weeks) in a prospective, multicenter, open-label, noncomparative study."7.74Evaluation of quality of life in patients with metastatic colorectal cancer treated with capecitabine. ( Cabral, S; Federico, MH; Filho, Ude P; Franke, FA; Gampel, O; Perdicaris, MR; Ribeiro, Rde A; Segalla, JG; Skare, NG; Van Eyll, B, 2008)
"Although 5-fluorouracil (5-FU)-based chemotherapy is commonly used in patients with advanced colorectal cancer (CRC), little data exist on the tolerability and benefit of therapy in elderly patients."7.735-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study. ( Buroker, TR; Cha, SS; D'Andre, S; Goldberg, RM; Kugler, JW; O'Connell, MJ; Poon, MA; Sargent, DJ, 2005)
"To determine whether the nonselective and relatively inexpensive nonsteroidal anti-inflammatory drug ibuprofen would be effective in inhibiting colorectal cancer and might improve mortality in a mouse model."7.73Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. ( Albert, A; Chang, AJ; Liu, TC; Sangha, S; Wolfe, MM; Yao, M; Zhou, W, 2005)
"To clarify the correlation between the expression level of thymidine phosphorylase (TP) and efficacy of doxifluridine (5'-DFUR) and 5-fluorouracil (5-FU), samples from 177 colorectal cancer patients who underwent curative resection were evaluated by immunohistochemical staining using a newly developed monoclonal antibody 1C6-203."7.73Thymidine phosphorylase expression and efficacy of adjuvant doxifluridine in advanced colorectal cancer patients. ( Hasegawa, R; Hasegawa, S; Koda, K; Miyazaki, M; Oda, K; Seike, K; Takiguchi, N, 2005)
"To investigate the prognostic value of thymidylate synthase (TS), topoisomerase-1 (Topo-1), and proliferating index Ki-67 in advanced colorectal cancer patients on irinotecan (CPT-11) in combination with fluorouracil treatment (5-Fu)."7.73[Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment]. ( Colucci, G; Giuliani, F; Maiello, E; Mangia, A; Montemurro, S; Paradiso, A; Simone, G; Xu, JM; Zhu, BD, 2005)
"Although several evidences have demonstrated a synergistic activity of 5-fluorouracil with irinotecan and oxaliplatin, thus explaining the use of this drug combination in the first-line treatment of advanced colorectal cancer, the need for the reintroduction of 5-FU in the second-line setting is more questionable."7.73The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. ( Barni, S; Berardi, R; Beretta, GD; Cascinu, S; Catalano, V; Gasparini, G; Graziano, F; Labianca, R; Scartozzi, M; Sobrero, A; Zaniboni, A, 2005)
"The aim of the study was to define the feasibility and efficacy of Xelox (capecitabine and oxaliplatin) administered through a new and original schedule in advanced pretreated colorectal cancer (CRC) patients."7.73Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. ( Caricato, M; Coppola, R; Di Seri, M; La Cesa, A; Rocci, L; Santini, D; Schiavon, G; Spalletta, B; Tonini, G; Vincenzi, B, 2005)
"The tumor-activated fluoropyrimidine capecitabine achieves response rates superior to those of bolus 5-fluorouracil/leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer (CRC), with favorable safety and fewer hospitalizations."7.73Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. ( Braud, Fd; Brunet, R; Butts, CA; Cassidy, J; Conroy, T; Diaz-Rubio, E; Figer, A; Grossmann, J; Schoffski, P; Sobrero, AF; Tabernero, JM; Twelves, CJ; Van Cutsem, EJ, 2005)
"We successfully treated four advanced colorectal cancers with irinotecan (CPT-11) plus 5-fluorouracil (5-FU) and l-leucovorin (l-LV) combination chemotherapy."7.73[Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy]. ( Aiba, M; Kamoshita, N; Makita, F; Morishita, Y; Nagashima, T; Ohwada, S; Takeyoshi, I; Tokiniwa, H, 2005)
"The present study aimed to prospectively investigate the influence of thymidylate synthase (TS) polymorphisms (5'-TSER, 3'-TSUTR) on the disease-free survival (DFS) and overall survival (OS) of patients with colorectal cancer (CRC) who were treated with adjuvant 5-fluorouracil (5-FU) therapy."7.73Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. ( Adleff, V; Budai, B; Czeglédi, F; Gyergyay, F; Hitre, E; Horváth, Z; Kásler, M; Kovács, T; Kralovánszky, J; Láng, I; Lövey, J; Orosz, Z, 2005)
"These results suggest that phospho-EGFR levels determine the sensitivity of colorectal cancer cells to gefitinib alone and that chemotherapy-mediated changes in phospho-EGFR levels determine the nature of interaction between gefitinib and chemotherapy."7.73Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. ( Galligan, L; Johnston, P; Karaiskou-McCaul, A; Kelly, D; Longley, D; Van Cutsem, E; Van Schaeybroeck, S, 2005)
"Fluorouracil-based chemotherapy, such as that with 5-fluorouracil (5-FU)/leucovorin, is standard as first-line chemotherapy for advanced colorectal cancer (CRC) in Japan."7.73In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer. ( Akiyama, T; Hirabayashi, Y; Hirai, T; Ikeda, M; Iki, K; Kubozoe, T; Matsumoto, H; Sadahira, Y; Tsunoda, T; Urakami, A; Yamamura, M; Yamashita, K, 2005)
"Irinotecan, in combination with 5-fluorouracil (5-FU) and a high dose of leucovorin (LV), known as FOLFIRI regimen, has shown activity in recurrent or metastatic colorectal cancer."7.73Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer. ( Byun, JH; Chang, SK; Choi, MG; Choi, SI; Hong, YS; Kang, JH; Lee, DS; Lee, KS; Lee, MA; Oh, ST; Shim, BY; Woo, IS, 2005)
"Some retrospective studies have shown a lack of benefit of 5-fluorouracil (5-FU) adjuvant chemotherapy in patients with mismatch repair (MMR) deficient colorectal cancer."7.73Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. ( Alenda, C; Andreu, M; Bessa, X; Bujanda, L; Castells, A; Clofent, J; Cubiella, J; Jover, R; Llor, X; Morillas, JD; Nicolás-Pérez, D; Payá, A; Piñol, V; Reñé, JM; Xicola, RM; Zapater, P, 2006)
"To report 2 cases of severe hypertriglyceridemia associated with the use of oral capecitabine."7.73Capecitabine-induced severe hypertriglyceridemia: report of two cases. ( Babaoglu, MO; Guler, N; Kurt, M; Shorbagi, A; Yasar, U, 2006)
"Resistance to apoptosis is one of the important determinants of resistance to 5-fluorouracil (5-FU) in colorectal cancer cells."7.73Overexpression of hRFI inhibits 5-fluorouracil-induced apoptosis in colorectal cancer cells via activation of NF-kappaB and upregulation of BCL-2 and BCL-XL. ( Kitayama, J; Konishi, T; Nagawa, H; Sasaki, S; Watanabe, T, 2006)
"We identified genes related to 5-fluorouracil (5-FU) sensitivity in colorectal cancer and utilized these genes for predicting the 5-FU sensitivity of liver metastases."7.73Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. ( Endo, I; Hayasizaki, Y; Ichikawa, Y; Ishikawa, T; Kunisaki, C; Matsuyama, R; Momiyama, N; Shimada, H; Shimizu, D; Suzuki, H; Togo, S, 2006)
" In this study, we evaluated the correlation between sensitivity to 5-fluorouracil (5-FU) and the mRNA expression level of several 5-FU-related metabolic enzymes [thymidylate synthase, dihydropyrimidine dehydrogenase (DPD), thymidylate phosphorylase (TP), orotate phosphoribosyl transferase, and uridine phosphorylase] in primary colorectal cancer and synchronous liver metastases from ten patients to investigate how colorectal cancer acquires 5-FU resistance during liver metastases."7.73Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer. ( Endo, Y; Kaizuka, M; Kurumi, Y; Mekata, E; Okumura, K; Shiomi, H; Tani, T, 2006)
"The purpose of this study was to analyze the value of germline and tumor thymidylate synthase (TS) genotyping as a prognostic marker in a series of colorectal cancer patients receiving adjuvant fluorouracil (FU) -based treatment."7.73Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. ( Capellá, G; Cuatrecases, M; de Oca, J; Dotor, E; Figueras, A; Germà, JR; Guinó, E; Martínez-Iniesta, M; Molleví, DG; Moreno, V; Navarro, M; Pareja, L; Peinado, MA; Serrano, T; Vilardell, F; Villanueva, A, 2006)
"Several variables associated to thymidylate synthase (TS), the biological target of 5-fluorouracil (5FU) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients."7.73Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil. ( Fernández-Contreras, ME; Gamallo, C; García de Paredes, ML; Gisbert, JP; Roda-Navarro, P; Sánchez-Hernández, JJ; Sánchez-Prudencio, S, 2006)
"To evaluate the regimen of 5-fluorouracil (5-FU) and mitomycin-C (MMC) in terms ofresponse rate and overall survival in advanced colorectal cancer."7.735-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer. ( Aphinives, P; Bhudhisawasdi, V; Sae-seow, O; Uttaravichien, T, 2006)
"We present two cases of multiple liver metastases from colorectal cancer, which did not respond to hepatic arterial infusion (HAI) using 5-fluorouracil (5-FU 1250 mg/body weekly) alone, but responded to HAI using 5-fluorouracil (5-FU 750 mg/body weekly) and l-leucovorin (l-LV 50 mg/body weekly) achieving a complete response (CR)."7.73[Two cases of multiple liver metastases from colorectal cancer which responded well to hepatic arterial infusion (HAI) using 5-fluorouracil and l-leucovorin]. ( Enomoto, M; Higuchi, T; Iida, S; Ishikawa, T; Kato, S; Sugihara, K; Uetake, H; Yasuno, M, 2006)
"The combination of irinotecan (CPT-11), bolus 5-fluorouracil (5-FU) and folinic acid (FA) (Saltz regimen) has recently been questioned as first-line chemotherapy for metastatic colorectal cancer after high early death rates due to gastrointestinal and thromboembolic events were reported in two US trials."7.72Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer. ( Adami, B; Baldus, M; Burg, H; Ehscheid, P; Galle, PR; Heike, M; Hoffmann, T; Hohl, H; Klein, O; Moehler, M; Schroeder, M; Schwindt, P; Zanke, C, 2003)
"The Mayo Clinic regimen of leucovorin 20 mg/m followed immediately by 5-fluorouracil 425 mg/m administered for 5 consecutive days every 4 weeks is commonly used in the treatment of colorectal cancer."7.72Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients. ( Bar-Sela, G; Beny, A; Haim, N; Tsalic, M; Visel, B, 2003)
"5-Fluorouracil (5-FU) is the major chemotherapeutic component for colorectal cancer (CRC) and other types of solid tumours."7.72Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. ( Cassidy, J; McLeod, HL; Wang, W, 2003)
"The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer."7.72Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003)
"The aim of this study was to investigate the influence of low dosage (131)I-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody C50 ((131)I-C50) on tumor growth and the therapeutic efficacy of combination of low dosage (131)I-C50 with chemotherapy using 5-fluorouracil (5-FU) on human colorectal cancer xenografts in nude mice."7.72[Influence of combination of low dosage 131I-labeled anti-carcinoembryonic antigen antibody C50 and 5-fluorouracil on tumor growth of colorectal cancer xenografts in nude mice]. ( Cai, SR; He, YL; Lin, ZJ; Zhan, WH; Zheng, CX, 2003)
"Loss of DNA mismatch repair (MMR) occurs in 10-15% of sporadic colorectal cancer, is usually caused by hMLH1 hypermethylation, and has been shown to confer resistance to various chemotherapeutic reagents, including 5-fluorouracil (5-FU)."7.72Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. ( Arnold, CN; Boland, CR; Goel, A, 2003)
"To predict the sensitivity of colorectal cancer to 5-fluorouracil (5-FU), we compared the gene expression of surgically obtained colorectal cancer specimens with chemosensitivity to 5-FU as detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) assay."7.72Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. ( Fukushima, M; Hasegawa, H; Kitajima, M; Kubota, T; Nishibori, H; Takechi, T; Wada, N; Watanabe, M; Yoshinare, K, 2003)
"To determine the efficacy of the combination of oxaliplatin and capecitabine in patients with advanced colorectal cancer."7.72Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience. ( Cunningham, D; Gillbanks, A; Harper-Wynne, C; Hill, M; Norman, AR; Sumpter, K, 2003)
"The aim of this analysis is to evaluate the effect of 5-fluorouracil (5-FU) rechallenge on subsequent response and survival in patients with advanced colorectal cancer (CRC)."7.72Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. ( Chau, I; Cunningham, D; Hill, M; Norman, AR; Ross, PJ; Yeoh, C, 2003)
"Fifty-two consecutive patients with advanced colorectal cancer who developed persistent diarrhea following chemotherapy with 5-fluorouracil despite dose reduction were treated with amifostine 800, 500 or 150 mg/m(2)."7.72Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study. ( Kosmas, C; Koufos, C; Margaris, H; Papalambros, E; Papantoniou, N; Retalis, G; Rokana, S; Tsavaris, N; Vadiaka, M; Zografos, G; Zonios, D, 2003)
" In this study, we assessed whether or not the TSER genotype is an efficacious marker for tumor sensitivity to 5-fluorouracil (5-FU)-based oral adjuvant chemotherapy for colorectal cancer."7.72Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. ( Fukuoka, H; Haseba, M; Hidaka, S; Komatsu, H; Nakagoe, T; Nanashima, A; Sawai, T; Shibasaki, S; Shindou, H; Tagawa, Y; Tsuji, T; Yamaguchi, H; Yano, H; Yasutake, T; Yoshinaga, M, 2003)
"We herein report the result of a prospective study to investigate the efficacy of cimetidine administration in conjunction with chemotherapy for stage IV colorectal cancer."7.72[Effect of cimetidine with chemotherapy on stage IV colorectal cancer]. ( Fujimoto, T; Hashimoto, M; Ishibashi, K; Iwasaki, K; Ogawa, K; Umehara, A; Yokomizo, H; Yoshida, K; Yoshimatsu, K, 2003)
"The level of the enzyme thymidylate synthase (TS) is known to inversely correlate with the clinical activity of 5-fluorouracil (FU) in advanced colorectal cancer patients."7.72Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer. ( Aschele, C; Belvedere, O; Cataldi, P; Di Loreto, C; Guglielmi, A; Puglisi, F; Sobrero, A, 2004)
"5-Fluorouracil improves mortality in stage III colorectal cancer patients."7.72Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. ( Arnold, CA; Behling, CA; Boland, CR; Cabrera, BL; Carethers, JM; Doctolero, RT; Goel, A; Miyai, K; Nguyen, L; Smith, EJ; Tajima, A, 2004)
" For practical reasons and for the convenience of the patient, we used XELOX (Xeloda 2000 mg/m2 orally on days 1-14 and oxaliplatin 130 mg/m2 as a 30-min infusion on day 1) in patients with advanced colorectal cancer resistant to irinotecan and 5-fluorouracil."7.72Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. ( Hahn, P; Jensen, HA; Pfeiffer, P, 2003)
" In this study, digital karyotyping was used to search for genomic alterations in liver metastases that were clinically resistant to 5-fluorouracil (5-FU)."7.72Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. ( Bardelli, A; Choti, M; Diaz, LA; Donehower, R; Galizia, G; Iacobuzio-Donahue, C; Kinzler, KW; Lengauer, C; Parmigiani, G; Romans, K; Saha, S; Shih, IeM; Velculescu, VE; Vogelstein, B; Wang, TL, 2004)
"5-Fluorouracil, a widely used drug in cancer treatment, is known to have cardiotoxic effects: chest pain with ECG changes, arrhythmias, arterial hypertension or hypotension, myocardial infarction, cardiogenic shock and sudden death have been described in the literature."7.72Management of patients with persistent chest pain and ST-segment elevation during 5-fluorouracil treatment: report about two cases. ( Alberti, A; Corrada, E; Ferrari, S; Mafrici, A; Marenna, B, 2003)
"Preclinical in vitro and in vivo studies have demonstrated synergistic interactions between 5-fluorouracil (5-FU) and type I and II IFNs against human colorectal cancer cells."7.72Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. ( Barsoum, J; Choi, EA; Fraker, DL; Lei, H; Maron, DJ; Mick, R; Spitz, FR; Wilson, JM; Yu, QC, 2004)
"To elucidate mechanisms of resistance to chemotherapies currently used in the first-line treatment of advanced colorectal cancer, we have developed a panel of HCT116 p53 wild-type (p53(+/+)) and null (p53(-/-)) isogenic colorectal cancer cell lines resistant to the antimetabolite 5-fluorouracil (5-FU), topoisomerase I inhibitor irinotecan (CPT-11), and DNA-damaging agent oxaliplatin."7.72Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. ( Aroori, S; Boyer, J; Carey, PD; Johnston, PG; Longley, DB; McCulla, A; McLean, EG; Wilson, P, 2004)
"To evaluate the efficacy and safety of capecitabine as first-line therapy in patients with advanced and recurrent colorectal cancer."7.72[First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer]. ( Feng, FY; Fu, Q; Guan, ZZ; Huang, JJ; Liu, DG; Ruan, QL; Shi, D; Sun, SR; Wei, YQ; Wu, G; Wu, WQ; Wu, XD; Xiong, HH; Yang, CY; Yu, BM; Yu, SY; Zhang, P; Zhao, Y; Zheng, S; Zhuang, W; Zou, LQ, 2004)
"Expression of thymidylate synthase (TS) and the 5-fluorouracil (5-FU) metabolic enzymes, including dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT), thymidine phosphorylase (TP), and uridine phosphorylase (UP), has been reported to be associated with the sensitivity to 5-FU-based chemotherapy in colorectal cancer."7.72Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis. ( Inokuchi, M; Shirota, Y; Sugihara, K; Tajima, M; Uetake, H; Yamada, H, 2004)
"5-Fluorouracil (5-FU) is the chemotherapeutic drug of choice for the treatment of metastatic colorectal cancer, but resistance to 5-FU remains a major obstacle to successful therapy."7.72Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. ( Beigi, M; Clausen, OP; de Angelis, PM; Fjell, B; Galteland, E; Haug, T; Kravik, KL; Reichelt, W; Stokke, T; Tunheim, SH, 2004)
"The aim of this study was to observe the effects of neoadjuvant therapy with irinotecan and 5-fluorouracil (5-FU)/folinic acid (FA) on the resection rate and survival of colorectal cancer patients with initially unresectable hepatic metastases."7.72Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. ( Barone, C; Basso, M; Cassano, A; Giuliante, F; Nuzzo, G; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N; Vellone, M, 2004)
"One hundred and thirty-eight stage II and III colorectal cancer patients were included to evaluate the prognostic significance of genetic markers (including mutations of the p53, K-ras genes, and microsatellite instability) on the response to 5-fluorouracil (FU)-based post-operative adjuvant therapies (PAT)."7.72p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. ( Changchien, CR; Chen, HH; Chen, JS; Fan, CW; Hsieh, LL; Tang, R; Tsao, KC; Wang, JY; Wu, CM, 2004)
"Capecitabine is an oral prodrug of 5-fluorouracil and has been studied for the treatment of colorectal cancer."7.72Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. ( Brouwers, JR; Jansman, FG; Postma, MJ; van Hartskamp, D; Willemse, PH, 2004)
"The purpose of this study was to examine the relation between tumoral expression of dihydropyrimidine dehydrogenase (DPD), the rate limiting enzyme of the degradation pathway 5-fluorouracil (5-FU), and the efficacy of 5-FU based chemotherapy for colorectal cancer."7.72[Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer]. ( Hashimoto, D; Inokuma, S; Ishida, H; Nakada, H; Ohsawa, T; Shirakawa, K; Yamada, H; Yokoyama, M, 2004)
"Ten cases of advanced and metastatic colorectal cancer treated with irinotecan plus fluorouracil and l-leucovorin systemic chemotherapy (CPT-11/5-FU/l-LV) were investigated."7.72[Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer]. ( Hidaka, K; Matsukura, S; Samejima, R; Tanaka, M, 2004)
"High expression of thymidylate synthase (TS) is allegedly associated with the chemoresistance to 5-fluorouracil (5-FU) in colorectal cancers."7.72Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to ( Inada, K; Kamoshida, S; Maruta, M; Matsuoka, H; Matsuyama, A; Shimomura, R; Shiogama, K; Tsutsumi, Y, 2004)
"To determine whether deleted in colon cancer (DCC) protein expression in colorectal cancer (CRC) metastases could predict outcome to palliative fluorouracil (FU)-based chemotherapy and to assess whether it is similar to that observed in the corresponding primary tumors."7.72Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy. ( Aschele, C; Bandelloni, R; Casazza, S; Debernardis, D; Gallo, L; Lonardi, S; Monfardini, S, 2004)
"The efficacy of a concomitant oxaliplatin/bolus 5-fluorouracil/leucovorin regimen in 123 heavily pretreated patients with advanced colorectal cancer was evaluated."7.72Compassionate-use oxaliplatin with bolus 5-fluorouracil/leucovorin in heavily pretreated patients with advanced colorectal cancer. ( Amin-Zimmerman, F; Glisson, SD; Hargis, JB; Hicks, RM; Kosfeld, RE; LaRocca, RV; Leaton, KE, 2004)
"We retrospectively evaluated the relevance of thymidylate synthase (TS) expression in normal colonic mucosa as a predictive factor of toxicity in colorectal cancer patients receiving adjuvant fluorouracil (5-FU)-based chemotherapy."7.72Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy. ( Borzomati, D; Caricato, M; Coppola, R; Grilli, C; La Cesa, A; Perrone, G; Rabitti, C; Santini, D; Tonini, G; Verzì, A; Vincenzi, B, 2004)
"This study was conducted to evaluate the prognostic significance of thymidylate synthase (TS) expression in the tumor tissue of patients with metastatic colorectal cancer (CRC) who received protracted venous infusions of 5-fluorouracil (5-FU)."7.72Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil. ( Araake, M; Hamaguchi, T; Hosokawa, A; Morita, H; Muro, K; Orita, H; Shimada, Y; Shirao, K; Yamada, Y, 2004)
"The 5 fluorouracil hepato-arterial infusion (5-FU HAI) therapy has a good effect on the liver metastases of colorectal cancer."7.72[The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer]. ( Ebuchi, M; Hasegawa, K; Kato, K; Koide, A; Maruyama, M; Maruyama, S; Ohbu, M; Takashima, I, 2004)
"5-fluorouracil (5-FU) is a chemotherapeutic agent widely used in the treatment of solid malignancies, especially in colorectal cancer."7.72Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature. ( Aparicio, J; Calderero, V; Díaz, R; Guerrero, A; Pellín, L; Segura, A, 2004)
"We investigated the immune profile of patients with resected Dukes' stage C colorectal cancer (CRC), receiving adjuvant therapy with edrecolomab (Mo17-1A) or first-line 5-fluorouracil (5-FU)-based chemotherapy."7.72The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study. ( Gouveris, P; Katsoulas, HL; Kosmas, C; Kosmas, N; Papalambros, E; Papantoniou, N; Rokana, S; Skopeliti, M; Tsavaris, NB; Tsitsilonis, OE, 2004)
"Combined infusion of 5-FU and mitomycin C by hepatic artery catheter port is an effective treatment for liver metastases from colorectal cancer."7.71Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer. ( Jiang, HC; Liu, LX; Piao, DX; Qi, SY; Wu, LF; Zhang, WH; Zhu, AL, 2002)
"TS levels were measured immunohistochemically on archival specimens of colorectal cancer metastases from 124 patients homogeneously treated in a series of clinical trials at our institutions with: (A) leucovorin (LV)-modulated infusional 5-FU (n = 48); (B) LV-modulated bolus 5-FU (n = 41); (C) methotrexate (MTX)-modulated bolus 5-FU (n = 35)."7.71Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. ( Aschele, C; Bandelloni, R; Barni, S; Cascinu, S; Catalano, V; Debernardis, D; Drudi, G; Gallo, L; Giordani, P; Lonardi, S; Maley, F; Monfardini, S; Turci, D, 2002)
"We evaluated the effect of hepatic arterial infusion chemotherapy with levofolinate (l-LV) and 5-fluorouracil (5-FU) for multiple liver metastases from colorectal cancer."7.71[Evaluation of hepatic arterial infusion chemotherapy with levofolinate (l-LV) and 5-fluorouracil (5-FU) for multiple liver metastases from colorectal cancer]. ( Ebisui, C; Fujimoto, T; Fukuchi, N; Izawa, H; Kanai, T; Sakita, I; Soma, I; Yoshida, T, 2002)
"LSMs for 5-fluorouracil and 5-fluoro-5,6-dihydrouracil therapeutic monitoring have been developed in 80 patients with colorectal cancer (training set) given 5-fluorouracil, 370 mg/m(2) per day as an intravenous bolus, plus leucovorin, 100 mg/m(2) per day, for 5 days every 4 weeks."7.71Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. ( Amadori, D; Cionini, L; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Ibrahim, T; Mini, E; Vannozzi, F, 2002)
"Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) exhibit single-agent activity in colorectal cancer, have nonoverlapping major toxicities, and exhibit a synergistic effect in tumor xenograft models."7.71Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. ( Kerr, D, 2002)
" We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib."7.71Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002)
"Irinotecan (CPT-11), oxaliplatin (OXA) and different folinic acid(FA) modulated 5-fluorouracil (5-FU) regimens are active as first-and second-line chemotherapy of metastatic colorectal cancer."7.71Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens. ( Galle, PR; Heike, M; Hildner, K; Hoffmann, T; Moehler, M; Siebler, J, 2002)
"5-Fluorouracil (5-FU), in association with leucovorin (LV), is the most used chemotherapy agent in the treatment of colorectal cancer."7.71Effect of chemotherapy with 5-fluorouracil on intestinal permeability and absorption in patients with advanced colorectal cancer. ( Barletta, E; Carratù, R; Daniele, B; De Magistris, L; De Vivo, R; Delrio, P; Palaia, R; Pignata, S; Secondulfo, M; Tambaro, R, 2001)
"There has been no standard therapy for patients with metastatic colorectal cancer who have failed to first-line fluorouracil-based treatment."7.71Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer. ( Kang, YK; Kim, HC; Kim, JC; Kim, SH; Kim, TW; Kim, WK; Lee, JH; Lee, JS; Lee, KH; Yu, CS, 2001)
"Irinotecan (CPT-11) has shown considerable activity in colorectal cancer, and its combination with 5-fluorouracil (5-FU) represents an attractive approach."7.71A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer. ( Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kotsakis, A; Koukourakis, M; Kouroussis, C; Mavroudis, D; Romanos, J; Souglakos, J; Vardakis, N, 2001)
"The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer."7.71A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001)
"The aim of this study is to clarify whether the expression of metallothionein (MT) is related with the malignant potential in primary colorectal cancer and/or synchronous liver metastasis."7.71Expression of metallothionein in colorectal cancers and synchronous liver metastases. ( Dhar, DK; Hishikawa, Y; Kimoto, T; Kohno, H; Koji, T; Kubota, H; Nagasue, N; Tachibana, M; Ueda, S, 2001)
"To identify the prognostically highest risk patients, DNA content and p53 nuclear or cytoplasmic accumulation, evaluated by monoclonal antibody DO7 and polyclonal antibody CM1, were determined in 94 surgically resected stage II (Dukes B2) colorectal cancers, treated or not with adjuvant 5-fluorouracil-based chemotherapy."7.71p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy. ( Benevolo, M; Brenna, A; Buglioni, S; Cosimelli, M; D'Agnano, I; D'Angelo, C; Mottolese, M; Perrone Donnorso, R; Vasselli, S; Zupi, G, 2001)
"High levels of thymidylate synthase (TS) expression have been associated with poor survival of colorectal cancer (CRC) patients to 5-fluorouracil (5-FU)-based chemotherapy."7.71A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. ( Elsaleh, H; Grieu, F; Iacopetta, B; Joseph, D, 2001)
"We investigated whether the efficacy of peroral doxifluridine and hepatic arterial 5-FU infusion on synchronous liver metastasis of colorectal cancer could be predicted based on the expression of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in the primary colorectal lesions."7.71[Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions]. ( Fujioka, M; Hashimoto, D; Hoshino, T; Inokuma, S; Ishida, H; Ishizuka, N; Matsumoto, Y; Miura, T; Murata, N; Nakada, H; Odaka, A; Ohsawa, T; Takeuchi, I; Yamada, H; Yokoyama, M, 2001)
"To test the hypotheses of whether the relative mRNA expression of the thymidylate synthase (TS) gene and the excision cross-complementing (ERCC1) gene are associated with response to and survival of fluorouracil (5-FU)/oxaliplatin chemotherapy in metastatic colorectal cancer."7.71ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. ( Brabender, J; Danenberg, KD; Danenberg, PV; Groshen, S; Lenz, HJ; Shirota, Y; Stoehlmacher, J; Tsao-Wei, DD; Uetake, H; Xiong, YP, 2001)
"The oral, tumour-selective fluoropyrimidine capecitabine represents a major new strategy for the treatment of colorectal cancer."7.71Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. ( Twelves, C, 2002)
"At increasing use of high-dose 5-fluorouracil-based chemotherapy for metastatic colorectal and gastric cancer complicated drug-induced colitis is observed more frequently."7.71[5-Fluorouracil-induced colitis--a review based upon consideration of 6 cases]. ( Hotz, J; Madisch, A; Marquard, F; Stolte, M; Wiedbrauck, F, 2002)
"The aim of this study was to evaluate the objective tumor response rates and toxicities in elderly patients (older than 70 years) with advanced colorectal cancer treated with 5-fluorouracil (5-FU) as a first-line palliative chemotherapy regimen."7.71Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-year experience. ( Broisin, L; Ferrero, JM; François, E; Guardiola, E; Magné, N; Namer, M; Ramaïoli, A, 2002)
"The aim of this study was to assess in patients with advanced colorectal cancer which factors were associated with short-term survival (6 months or less) and progression to first-line 5-fluorouracil (5-FU) chemotherapy."7.71Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens. ( Cellerino, R; Lippe, P; Massacesi, C; Piga, A; Pistilli, B; Rocchi, MB; Valeri, M, 2002)
"We investigated the relevance of mdm2 and p53 primary tumour expression to the clinical outcome of a consecutive series of advanced colorectal cancer patients treated with a 5-fluorouracil-based chemotherapy."7.71mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer. ( Costa, A; De Lena, M; Lacava, J; Leone, A; Paradiso, A; Ranieri, G; Silvestris, N; Simone, G; Vallejo, C, 2002)
"5-Fluorouracil (FUra) modulated by leucovorin (LV) is active in the treatment of colorectal cancer."7.70Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. ( Cao, S; Rustum, YM; Troutt, AB, 1998)
"Prior to the administration of 5-fluorouracil chemotherapy, the authors examined 14 colorectal carcinoma patients with unresectable liver metastases using a single PET scan and 18F-labeled fluorouracil (18F-FU)."7.7018F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. ( Dimitrakopoulou-Strauss, A; Gutzler, F; Moehler, M; Raeth, U; Strauss, LG; Stremmel, W, 1998)
"The purpose of this study was to investigate the side-effects experienced by patients with colorectal cancer receiving 5-fluorouracil + folinic acid chemotherapy."7.70Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. ( Dikken, C; Sitzia, J, 1998)
"The purpose of this work was to estimate the population pharmacokinetic parameters of 5-fluorouracil (5-FU) in patients with advanced colorectal cancer using circadian change kinetics."7.70Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. ( Astre, C; Bressolle, F; Duffour, J; Gomeni, R; Joulia, JM; Pinguet, F; Ychou, M, 1999)
"The comparative saliva/plasma pharmacokinetics of 5-fluorouracil (5-FU) were investigated in 21 patients with metastatic colorectal cancer receiving high-dose folinic acid (LV (leucovorin) 200 mg/m2) followed by 5-FU bolus (400 mg/m2) and continuous infusion (600, 750, 900 or 1200 mg/m2) on days 1 and 2."7.70Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid. ( Astre, C; Bressolle, F; Duffour, J; Joulia, JM; Pinguet, F; Ychou, M, 1999)
"In a recent multicentre, randomised, controlled, open-label study (Rougier and colleagues, Lancet 1998, 352, 1407-1412), irinotecan significantly increased survival without any deterioration in quality of life compared with best-estimated infusional 5-fluorouracil (5-FU) therapy in the setting of second-line treatment for metastatic colorectal cancer."7.70Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. ( Hickish, T; Iveson, TJ; Schmitt, C; Van Cutsem, E, 1999)
"5-fluorouracil (5-FU) is considered the standard antineoplastic drug of choice for metastatic colorectal cancer."7.70Changes in thymidylate synthase mRNA in blood leukocytes from patients with colorectal cancer after bolus administration of 5-fluorouracil. ( Ehrnrooth, E; Poulsen, JH; Sørensen, B; Sørensen, BS; von der Maase, H, 2000)
" In this study, we have determined the expression patterns of dUTPase in normal and neoplastic tissues and examined the association between dUTPase expression and response to 5-fluorouracil (5-FU)-based chemotherapy and overall survival in colorectal cancer."7.70dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. ( Caradonna, SJ; Groshen, S; Ladner, RD; Lenz, HJ; Lynch, FJ; Sherrod, A; Stoehlmacher, J; Xiong, YP, 2000)
"The basis for current clinical trials in the treatment of colorectal cancer with the combination of irinotecan (CPT-11) and 5-fluorouracil (FUra) with or without leucovorin (LV) is their proven activity as single agents, their different mechanisms of action, and lack of CPT-11 cross-resistance to previous FUra/LV treatment."7.70Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. ( Cao, S; Rustum, YM, 2000)
"The addition of oxaliplatin (L-OHP) to a 5-fluorouracil (5-FU)/ leucovorin (FA) regimen was retrospectively evaluated in 35 consecutive advanced colorectal cancer patients after progression of disease."7.70Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. ( Aschelter, AM; Bertheault-Cvitkovic, F; Brienza, S; Caterino, M; Cosimelli, M; Garufi, C; Giannarelli, D; Giunta, S; Lévi, F; Nisticò, C; Pugliese, P; Terzoli, E, 2000)
"The authors describe the retrospective analysis of treatment by 5-fluorouracil and interferon-a aof 34 patients with advanced colorectal cancer."7.70Retrospective evaluation of 5-fluorouracil-interferon-a aTreatment of advanced colorectal cancer patients. ( András, C; Antal, L; Csiki, Z; Gál, I; Szegedi, G; Takács, I, 2000)
"Thymidylate synthase (TS) expression in colorectal cancer metastases has been shown to predict for the clinical response to 5-fluorouracil."7.70Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. ( Aschele, C; Debernardis, D; Maley, F; Sobrero, A; Tunesi, G, 2000)
"We observed leukoencephalopathy in 1 patient, and progressive dementia in another, during the administration of 5-fluorouracil (5-FU) and levamisole."7.69Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases. ( Dobranowski, J; Fawcet, SE; Figueredo, AT; Molloy, DW; Paulseth, JE, 1995)
"One hundred and seven previously untreated patients with measurable metastatic colorectal cancer who were treated with 5-fluorouracil (5FU) and leucovorin (LV) in two different maximum doses and schedules were retrospectively analyzed."7.69A comparative study with two administration schedules of leucovorin and 5-fluorouracil in advanced colorectal cancer. ( Bacoyannis, C; Basdanis, G; Foutzilas, G; Karvounis, N; Kosmidis, P; Markantonakis, P; Mylonakis, N; Sobolos, K; Tsavaris, N; Zisiadis, A, 1995)
"The purpose of this study was to explore the mechanism of interaction between 5-FU and levamisole by investigating the effect of this combination on HLA class I gene expression in the colorectal cancer cell line WiDr."7.69Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line. ( AbdAlla, EE; Blair, GE; Johnston, D; Jones, RA; Sue-Ling, HM, 1995)
"To confirm our previous kinetic analysis of the mode of cell-killing action of 5-fluorouracil (5-FU), we carried out a flow cytometric analysis with human colorectal cancer DLD-1 cells."7.69Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells. ( Inaba, M; Mitsuhashi, J, 1994)
"We studied the effect of combined chemo-immunotherapy, 5-FU followed by thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2) at low doses, on liver metastases from colorectal cancer, induced by splenic injection of DHD/K12 cells (1,2-dimethylhydrazine-induced colon adenocarcinoma) in syngeneic BDIX rats."7.69Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. ( Garaci, E; Pierimarchi, P; Rasi, G; Silecchia, G; Sinibaldi-Vallebona, P; Sivilia, M; Spaziani, E; Tremiterra, S, 1994)
"The purpose of the study was to evaluate the efficacy of long-term continuous administration of 5-fluorouracil (5-FU) in ambulatory patients with colorectal cancer."7.69[Treatment of advanced colorectal cancer with long-term continuous infusion of 5-fluorouracil]. ( Ando, J; Kotake, K; Koyama, Y; Nasu, J; Ogata, Y; Ozawa, I, 1994)
"From September 1989 to September 1992, 17 patients (pts) with non-curative or recurrent colorectal cancer were treated with 5-fluorouracil (FU) plus leucovorin (LV) systemic therapy."7.69[5-Fluorouracil plus low-dose leucovorin in the treatment of advanced colorectal cancer]. ( Ban, K; Imanari, T; Machida, T; Masuda, K; Matsumoto, M; Noda, Y; Shida, H; Takei, Y; Yamamoto, T, 1994)
"In 16 advanced colorectal cancer patients with 5-fluorouracil-associated diarrhea, we evaluated the role of bacterial pathogens in the development of this adverse effect."7.69Have enteric infections a role in 5-fluorouracil-associated diarrhea? ( Cascinu, S; Catalano, G, 1995)
"Patients with colorectal cancer liver metastases were treated with fluorouracil (5FU) as a protracted venous infusion (300 mg/m2/d), with or without interferon-alpha 2b for two 10-week blocks separated by a 2-week break."7.69Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. ( Cronin, B; Cunningham, D; Findlay, M; Flower, M; Hickish, T; Husband, J; Iveson, A; Ott, R; Pratt, B; Young, H, 1996)
"Thirty-seven patients with advanced colorectal cancer were treated with fluorouracil (5-FU) and folinic acid (FA) (Jan 1990-Dec 1992)."7.69Advanced colorectal cancer treated with combined 5-fluorouracil and folinic acid: the experience within a surgical department. ( Carey, PD; Farrer, C; Gordon, A; Guillou, PJ; Monson, JR; Pearce, S; Sommers, SS, 1995)
"In this phase IB study, 24 patients with advanced colorectal cancer were treated with escalating doses of weekly chronomodulated 48 h infusions of 5-fluorouracil (5-FU) biochemically modulated by methotrexate 40 mg/m2 and (6S)-leucovorin 8 x 45 mg orally."7.69Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study. ( Kamm, YL; Punt, CJ; Wagener, DJ, 1997)
"The authors report a patient with colorectal carcinoma who developed neutropenic enterocolitis after treatment with 5-fluorouracil and leucovorin."7.69Neutropenic enterocolitis in a patient with colorectal carcinoma: unusual course after treatment with 5-fluorouracil and leucovorin--a case report. ( Blumgart, L; Kemeny, NE; Kronawitter, U, 1997)
"The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy."7.69Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. ( Barzacchi, C; Chiara, S; Di Somma, C; Meszaros, P; Nobile, MT; Rosso, R; Sanguineti, O; Vincenti, M, 1997)
"5-Fluorouracil (5-FU) has been an accepted effective against colorectal cancer, but combination regimens resulted in a lesser effect than 5-FU alone."7.695-Fluorouracil + cisplatin + mitomycin C is a relatively most effective combination against xenograft lines of human colorectal cancer. ( Imamura, M; Kawabata, K; Nio, Y, 1997)
"This study was conducted to investigate the activity and toxicity of 5fluorouracil folinic acid+mitomycin C combined with alpha 2b interferon in advanced colorectal cancer based upon recent studies suggesting a possible biochemical modulation of 5fluorouracil by interferon."7.68Mitomycin C, 5fluorouracil and folinic acid in combination with alpha 2b interferon for advanced colorectal cancer. ( Bascioni, R; Battelli, N; Battelli, T; Delprete, S; Manocchi, P; Mattioli, R; Mazzanti, P; Pilone, A; Rossini, S; Silva, RR, 1993)
"We studied the levamisole toxic effects in adjuvant therapy for colorectal cancer."7.68[Toxicity of levamisole in adjuvant chemotherapy for colorectal cancer]. ( Beerblock, K; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Navarro-Carola, E; Soubrane, D; Varette, C, 1993)
"Interferon (IFN) has been shown to enhance the cytotoxic effects of 5-fluorouracil (5FUra) in colorectal cancer, and clinical trials with this combination resulted in higher response rate with respect to 5FUra alone."7.68Cytokinetic effects of interferon in colorectal cancer tumors: implications in the design of the interferon/5-fluorouracil combinations. ( Acetoso, M; Bartolucci, M; Cascinu, S; Del Ferro, E; Fedeli, A; Foglietti, G; Grianti, C; Lungarotti, F; Olivieri, Q; Saba, V, 1993)
"5-Fluorouracil (5-FU) is the most widely used cytotoxic drug in oncology and the only one useful in the management of colorectal cancer - a leading cause of cancer death worldwide."7.68The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. ( Collins, DJ; Cunningham, D; Findlay, MP; Glaholm, J; Leach, MO; Mansi, JL; McCready, VR; Payne, GS, 1993)
"The efficacy of the protracted infusion of 5-fluorouracil (FU) 200 mg/m2/day admixed with leucovorin (LV) 20 mg/m2/day was assessed for the treatment of advanced colorectal and breast cancer patients."7.68Continuous intravenous infusion of leucovorin and 5-fluorouracil for the treatment of advanced colorectal and breast cancers. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JM; Tzeng, CH, 1993)
"In order to elucidate the effect of tumor vascularity on a various regimens concentration in tumor tissue, correlation among tegafur, 5-fluorouracil (5-FU), uracil concentrations in tissue and the microangiography were examined in 27 patients with colorectal cancer after preoperative administration of UFT (400 mg/day for 7 days)."7.68[Studies on tissue concentration of tegafur, 5-fluorouracil, uracil after UFT administration together with the study of microangiography of colorectal cancer]. ( Ishikawa, H; Kusano, H; Miyashita, K; Nakazaki, T; Ogawa, T; Shimizu, T; Shimoyama, T; Yasutake, T; Yoshida, A; Yoshida, K, 1993)
"Forty-one patients with metastatic colorectal cancer were treated every four weeks with methotrexate 25 mg/m2 i."7.68Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination. ( Cascinu, S; Catalano, G; Fedeli, A; Luzi Fedeli, S, 1992)
" UFT (400 mg/day in terms of tegafur) was given preoperatively for 1-6 days in 6 patients with gastric cancer and 13 with colorectal cancer."7.68[Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT]. ( Inaba, S; Kawai, K; Kondo, Y; Ogino, A; Tsuchiya, K; Ueda, Y; Umeda, T, 1992)
" In a literature review of all published data of folinic acid and 5-fluorouracil intravenous bolus therapy in colorectal cancer with comparable dose intensity, an attempt was made to characterize the possible differences of the variations of schedules used."7.68The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer. ( Bokemeyer, C; Poliwoda, H; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, HJ, 1992)
"The combination of folinic acid (FA) and 5-fluorouracil (5FU) is the most active systemic chemotherapy against advanced colorectal cancer."7.68High dose alpha-2b interferon + folinic acid in the modulation of 5-fluorouracil. A phase II study in advanced colorectal cancer with evidence of an unfavourable cost/benefit ratio. ( Dallavalle, G; Labianca, R; Luporini, A; Luporini, G; Pancera, G; Tedeschi, L, 1992)
"A cohort of 35 patients with advanced colorectal cancer, not previously exposed to chemotherapy, were included in a phase II study exploring the combination of interferon-alpha, 9 MU subcutaneously three times weekly, and 5-fluorouracil 750 mg/m2/day during 5 consecutive days in continuous intravenous infusion followed with weekly bolus injection of fluorouracil 750 mg/m2."7.68Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: activity in liver metastasis. ( Antón, A; Aranda, E; Blanco, E; Camps, C; Díaz Rubio, E; González Larriba, JL; Jimeno, J; Lízón, J; Massuti, B, 1992)
"Twenty-six patients with advanced colorectal cancer were treated with a combination based on multimodal biochemical modulation of 5-fluorouracil by means of high dose folinic acid, low-dose alpha-2b interferon and dipyridamole."7.68Fluorouracil, high-dose folinic acid, low-dose alpha-2b interferon and dipyridamole in the treatment of advanced colorectal cancer. A pilot study. ( Arcangeli, G; Bonera, F; Braga, M; Marini, G; Marpicati, P; Meriggi, F; Montini, E; Ragni, F; Simoncini, E; Zaniboni, A, 1991)
"18 patients with advanced colorectal cancer entered a phase I-II study of high-dose 48 h continuous infusion 5-fluorouracil (5-FU) for 6 weeks."7.68Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. ( Aranda, E; Barneto, I; Diaz-Rubio, E; Gonzalez-Larriba, J; Gonzalez-Mancha, R; Martin, M, 1990)
"Since there is no effective second line chemotherapy in colorectal cancer resistant to fluorouracil, this study was carried out to evaluate the therapeutic activity of the pineal hormone melatonin, which has appeared to have antineoplastic activity in some experimental conditions, in patients with metastatic colorectal carcinoma who did not respond to fluorouracil."7.68A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates. ( Archili, C; Barni, S; Crispino, S; Lissoni, P; Paolorossi, F; Tancini, G, 1990)
"Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical milieu at its site(s) of action."7.68Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. ( Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM, 1990)
"Thirty patients with advanced colorectal adenocarcinoma were treated by chemotherapy with an alternating regimen consisting of 5-fluorouracil (5-FU)-mitomycin C and 5-FU-dacarbazine at 3-week intervals."7.67Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study. ( Droz, JP; Herait, P; Kac, JL; Rougier, P; Theodore, C, 1989)
"Based on in vitro studies that have demonstrated synergy between recombinant alfa-2a-interferon (rIFN alpha-2a) and the fluoropyrimidine, fluorouracil (5FU), against two human colon cancer cell lines, a pilot clinical trial was initiated to determine the effects of the combination of 5FU and rIFN alpha-2a in patients with advanced, unresectable colorectal carcinoma."7.67Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. ( Goldman, M; Itri, L; Lyver, A; Rader, M; Schwartz, EL; Wadler, S; Weinberg, V; Wiernik, PH; Zimmerman, M, 1989)
"27 patients with advanced colorectal cancer were treated in a phase-II trial with high dose sequential methotrexate (MTX), 5-fluorouracil (5-FU), and folinic acid (FA)."7.67Sequential high dose methotrexate, 5-fluorouracil and folinic acid does not improve response rates in advanced colorectal cancer. ( Flechtner, H; Heim, ME; Queisser, W; Schuster, D; Worst, P, 1989)
"Favorable results have been reported for the treatment of advanced colorectal cancer with the combination of 5-fluorouracil (5-FU) and leucovorin (LV)."7.67Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. ( Peters, GJ; Pinedo, HM; van Groeningen, CJ, 1989)
"A total of 24 patients with advanced colorectal adenocarcinoma were entered into a phase I-II study of 5-fluorouracil (5-FU) and cisplatin, 21 of whom had previously received 5-FU."7.67Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma. ( Creaven, PJ; Herrera, L; Madejewicz, S; Mittelman, A; Petrelli, NJ; Plager, J; Rustum, Y; Soloman, J, 1989)
"Following the observation of antitumor activity for the combination of 5-fluorouracil (5-FU) and cisplatin in metastatic colorectal carcinoma, the combination of 5-FU and iproplatin was tested, also in colorectal carcinoma, in the hope of attaining equivalent activity without the nephrotoxicity observed with 5-FU/cisplatin."7.67Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma. ( Creaven, PJ; Herrera, L; Mittelman, A; Petrelli, NJ, 1989)
"An enhanced antineoplastic effect of 5-fluorouracil in patients with advanced colorectal cancer has been produced either by combination with folinic acid or administration by continuous infusion."7.67High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. ( Cady, J; De Gramont, A; Demuynck, B; Gonzalez-Canali, G; Grange, JD; Krulik, M; Lagadec, B; Loiseau, JP; Louvet, C; Maisani, JE, 1988)
" Safety endpoints were rates of any grade and grade 3/4 adverse events during maintenance therapy."7.30Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212 ( Alig, AHS; Caca, K; Fruehauf, S; Goekkurt, E; Graeven, U; Haas, S; Heinemann, V; Heinrich, K; Held, S; Karthaus, M; König, AO; Kretzschmar, A; Kurreck, A; Modest, DP; Mueller, L; Sommerhäuser, G; Stahler, A; Stintzing, S; Trarbach, T; von Weikersthal, LF, 2023)
"Mebendazole was well tolerated and its addition to bevacizumab and FOLFOX4 enhanced tumor response to treatment which was translated by significant improvement of overall response rate 12 weeks after intervention [10 % (2) versus 65% (13) for control and mebendazole groups, respectively; p = 0."7.11Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer. ( El-Azab, GA; El-Ghoneimy, RA; Hegazy, SK; Mostafa, MF; Zakaria, F, 2022)
"To overcome this problem, patients with colorectal cancer are treated with chemotherapy for a short time, followed by a less aggressive maintenance regimen of the chemotherapy drug 5-fluorouracil and the targeted therapy drug bevacizumab."7.01Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003. ( Cui, K; Gurary, EB; Kim, TW; Lerman, N; Taieb, J; Yoshino, T, 2021)
"Capecitabine (Cape) is an oral prodrug of the antimetabolite 5-fluorouracil."7.01Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer. ( Ali, A; Daily, KC; Dang, LH; George, TJ; Iqbal, A; Ivey, AM; Lee, JH; Ramnaraign, BH; Read, TE; Tan, SA; Terracina, KP; Wang, Y, 2021)
" In this phase II study, we prospectively analyzed the efficacy and safety of raltitrexed combined with S-1 (RS regimen) in the treatment of mCRC after the failure of conventional chemotherapy."7.01A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer. ( Chen, Z; Guo, W; Huang, M; Li, W; Qiu, L; Wang, C; Wang, Y; Yang, Y; Zhang, W; Zhang, X; Zhang, Z; Zhao, X; Zhu, X, 2021)
" Overall, grade 3 adverse events, such as leukopenia and neutropenia, were observed in two of three patients (66."6.90Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial. ( Emoto, S; Hata, K; Hiyoshi, M; Ishihara, S; Ishimaru, K; Kaneko, M; Kawai, K; Muro, K; Murono, K; Nagata, H; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Shuno, Y; Tanaka, T, 2019)
"Simvastatin 80 mg tablets were taken orally once daily every day during the period of chemotherapy."6.90A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. ( Ahn, JB; Han, SW; Kang, WK; Kim, ST; Kim, TW; Kim, Y; Lee, J; Lim, HY; Park, JO; Park, YS, 2019)
"Metastatic colorectal cancer (mCRC) has low survival rates."6.90A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. ( Beck, JT; Berlin, JD; Cubillo Gracian, A; Deming, DA; Elez Fernandez, E; Garcia-Alfonso, P; Gorbunova, V; Hofheinz, RD; Luo, Y; Mangel, L; Nechaeva, M; Ramanathan, RK; Sullivan, D; Torres, AH, 2019)
" As for the biomarkers, carcinoembryonic antigen and lactate dehydrogenase (LDH) smoothly declined immediately after the initial dosing in patients with a partial response or stable disease."6.90Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study). ( Hirata, K; Hotta, Y; Imasato, M; Ishibashi, K; Iwamoto, S; Maeda, H; Makiyama, A; Mishima, H; Morita, S; Morita, Y; Munemoto, Y; Nagasaka, T; Nagata, N; Sakamoto, J; Takemoto, H; Tanaka, C; Toyofuku, A; Yoshida, Y, 2019)
"For stage II/Dukes B colorectal cancer (CRC), clinical biomarkers are urgently required to direct therapeutic options."6.87Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer. ( Gray, R; Handley, K; Hutchins, GGA; Kerr, D; Magill, L; Quirke, P; Seymour, M; Southward, K; Tinkler-Hundal, E; Treanor, D; Wright, A, 2018)
" A prospective clinical trial was designed to evaluate the efficacy and safety of fluorouracil monotherapy combined with panitumumab administered to patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) intolerant to oxaliplatin and irinotecan."6.87A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial. ( Denda, T; Fukunaga, M; Kanda, M; Kataoka, M; Kim, HM; Mishima, H; Munemoto, Y; Nagata, N; Oba, K; Sakamoto, J; Takano, N; Takemoto, H; Tokunaga, Y, 2018)
"Many studies have determined colorectal cancer chemoresistance mechanisms such as drug efflux, cell cycle arrest, DNA damage repair, apoptosis, autophagy, vital enzymes, epigenetic, epithelial-mesenchymal transition, stem cells, and immune system suppression."6.82MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil. ( Gazouli, M; Lampropoulou, DI; Nemati, M; Pouya, FD; Rasmi, Y, 2022)
"Metastatic colorectal cancer (mCRC) frequently occurs in elderly patients."6.82Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). ( Adhoute, X; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Breysacher, G; Charneau, J; Chone, L; Cretin, J; Gargot, D; Gasmi, M; Jouve, JL; Khemissa, F; Lavau-Denes, S; Lecomte, T; Legoux, JL; Lepère, C; Locher, C; Maillard, E; Michel, P; Mitry, E; Phelip, JM; Provençal, J; Sobhani, I, 2016)
"Pharmacokinetically guided (PK-guided) versus body surface area-based 5-fluorouracil (5-FU) dosing results in higher response rates and better tolerability."6.79A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy. ( Atluri, PM; Chay, CH; Deal, AM; Ibrahim, JG; Inzerillo, JJ; McLeod, HL; O'Neil, BH; Olajide, OA; Patel, JN; Sherrill, GB; Walko, CM, 2014)
" The most commonly reported adverse events in the FOLFOX6 cohorts included decreased appetite, neutropenia, diarrhea, peripheral neuropathy, and vomiting."6.78An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer. ( Adams, LM; Botbyl, J; Brady, J; Chau, I; Corrie, P; Digumarti, R; Laubscher, KH; Mallath, M; Midgley, RS, 2013)
"Thirty-six metastatic colorectal cancer patients received every 2 weeks, as first- (17) or second-line (19) treatment a combined chronotherapy with CPT-11 (infused at day 1 from 2 to 8 a."6.78Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report ( Demolin, G; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N, 2013)
"Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) signalling with activity against all three VEGF receptors."6.78Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. ( Cunningham, D; D'Haens, G; Douillard, JY; Robertson, J; Stone, AM; Van Cutsem, E; Wong, RP, 2013)
"Cediranib is an oral, highly potent VEGF signaling inhibitor of all three VEGF receptors."6.77Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer. ( Boku, N; Mishima, H; Okamoto, W; Satoh, T; Shi, X; Shimamura, T; Yamaguchi, K; Yamazaki, K, 2012)
"Cediranib is an oral highly potent VEGF signalling inhibitor that inhibits all three VEGF receptors."6.77Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study. ( Amagai, K; Baba, H; Bando, H; Denda, T; Fukase, K; Hazama, S; Kato, T; Mishima, H; Muro, K; Shi, X; Skamoto, J; Yamaguchi, K, 2012)
"Fifty-two patients with advanced colorectal cancer were enrolled in an ancillary pharmacogenetic study of the phase II CETUFTIRI trial."6.77Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. ( Bennouna, J; Chatelut, E; Douillard, JY; El Hannani, C; Etienne-Grimaldi, MC; Faroux, R; Formento, JL; Francois, E; Francoual, M; Hennebelle, I; Jacob, JH; Milano, G, 2012)
"Leucovorin Sodium (LV/Na) has a high solubility, and is stable when given with continuous infusion of 5-FU."6.77A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer. ( Bleiberg, H; D'Haens, G; Deleu, I; Efira, A; Humblet, Y; Paesmans, M; Peeters, M; Rezaei Kalantari, H; Vandebroek, A; Vergauwe, P, 2012)
"Patients with metastatic colorectal cancer (mCRC) were randomized to XELOX plus bevacizumab using a standard triweekly cycle (Q3W) or a dose-dense biweekly cycle (Q2W) schedule."6.77A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). ( Cartwright, T; Hu, S; Hurwitz, H; Kwok, A; McKenna, E; Mitchell, EP; Patt, YZ, 2012)
" The most frequently observed adverse events reported with AZD6244 were acneiform dermatitis, diarrhoea, asthenia and peripheral oedema, compared with hand-foot syndrome, diarrhoea, nausea and abdominal pain with capecitabine."6.76A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. ( Adenis, A; Bennouna, J; Boer, K; Douillard, JY; Escudero, P; Kim, TY; Lang, I; Morris, CD; Pover, GM; Valladares-Ayerbes, M, 2011)
"8 or 45 μg/m(2) in combination with capecitabine-oxaliplatin (XELOX)."6.76Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies. ( Andretta, V; Bennicelli, E; Bordignon, C; Caprioni, F; Comandini, D; Fornarini, G; Guglielmi, A; Lambiase, A; Mammoliti, S; Mazzola, G; Pessino, A; Sciallero, S; Sobrero, AF, 2011)
" Although skin toxicities are the most common adverse events associated with EGFR inhibitors, the differences in efficacy and safety between pre-emptive and reactive skin treatment according to KRAS tumor status has not been reported."6.76The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. ( Iannotti, N; Lacouture, ME; Mitchell, EP; Pillai, MV; Piperdi, B; Shearer, H; Xu, F; Yassine, M, 2011)
"Patients with previously treated solid tumors received axitinib (starting dose 5 mg twice daily) combined with FOLFOX plus bevacizumab (1, 2, or 5 mg/kg, cohorts 1-3, respectively), FOLFIRI (cohort 4), or FOLFOX (cohort 5)."6.75A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. ( Abhyankar, V; Burgess, RE; Chen, Y; Infante, J; Kim, S; Robles, RL; Sharma, S; Tarazi, J; Tortorici, M; Trowbridge, RC, 2010)
"As a project of the Kanagawa Colorectal Cancer Study Group, we performed this study to analyze the efficacy and the safety of modified FOLFIRI (irinotecan: 150 mg/m2) therapy for Japanese patients with metastatic colorectal cancer."6.75[Modified FOLFIRI (l-LV, 5-fluorouracil and irinotecan) therapy for Japanese patients with metastatic colorectal cancer]. ( Akaike, M; Imada, T; Masuda, M; Matsukawa, H; Ozawa, Y; Rino, Y; Shiozawa, M; Shiraishi, R; Suzuki, H; Takahashi, M; Tamura, I; Yamamoto, N; Yamamoto, Y; Yukawa, N, 2010)
" This study aims to achieve an improved disease free survival for patients after resection or resection combined with RFA of colorectal liver metastases by adding the angiogenesis inhibitor bevacizumab to an adjuvant regimen of CAPOX."6.75A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. ( Bergman, AM; Dalesio, O; Rinkes, IH; Schouten, SB; Snoeren, N; Tollenaar, RA; van der Sijp, JR; van Hillegersberg, R; Verheul, HM; Voest, EE, 2010)
"Liver metastasectomies were performed in 26% of all pts and in 39% of pts with LM."6.75"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. ( Antonucci, A; Baldi, PL; Bruera, G; Cannita, K; De Galitiis, F; Ficorella, C; Mancini, M; Marchetti, P; Ricevuto, E; Santomaggio, A; Tudini, M, 2010)
"Tetrathiomolybdate (TM) is an oral copper chelator under development as an anti-angiogenic agent."6.74A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. ( Brewer, GJ; Gartner, EM; Griffith, KA; Henja, GF; Merajver, SD; Pan, Q; Zalupski, MM, 2009)
" Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation."6.74Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009)
"Cediranib is a highly potent and selective inhibitor of the 3 vascular endothelial growth factor receptors and has a halflife suitable for once-daily oral dosing."6.74Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. ( Botwood, NA; Robertson, JD; Rothenberg, ML; Schmoll, HJ, 2009)
"Cediranib is a potent oral inhibitor of the tyrosine kinase activity associated with all subtypes of vascular endothelial growth factor receptor."6.74Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer. ( Chen, E; Gauthier, I; Jonker, D; MacLean, M; Powers, J; Seymour, L; Wells, J, 2009)
"Vorinostat was given orally twice daily for 1 week every 2 weeks."6.74A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. ( Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Pendyala, L; Ross, ME; Rustum, YM; Toth, K; Zwiebel, JA, 2009)
" Patients exhibited high compliance in dosing administration."6.74Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. ( Akhmadullina, LI; Barker, NP; Davidenko, IS; Firsov, I; Gertner, JM; Gotovkin, EA; Kopp, MV; Kulikov, EP; Moiseyenko, VM; Peterson, DE; Rakovskaya, GN; Rodionova, I; Sherman, NZ; Shinkarev, SA; Tuleneva, T; Woon, CW; Yarosh, A, 2009)
"Irinotecan is a chemotherapeutic agent used in the treatment of CRC and has demonstrated synergistic potential when used with radiation."6.74Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. ( Bower, GD; Briggs, GM; George, J; Goldstein, D; Olver, IN; Pavlakis, N; Price, D; Rossleigh, MA; Tapner, MJ; Taylor, DJ; van Hazel, GA, 2009)
"The R0 secondary resection rate of metastases was greater in the FOLFOXIRI arm (6% v 15%; P = ."6.73Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor ( Allegrini, G; Andreuccetti, M; Barbara, C; Benedetti, G; Brunetti, I; Chiara, S; Cortesi, E; Crinò, L; Evangelista, W; Falcone, A; Fanchini, L; Fioretto, L; Granetto, C; Masi, G; Orlandini, C; Pfanner, E; Picone, V; Porcile, G; Ricci, S; Vitello, S, 2007)
"To evaluate the efficacy and the toxicity of front line FOLFOX4 combined with bevacizumab in patients with metastatsic CRC (mCRC)."6.73Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. ( Agelaki, S; Androulakis, N; Chatzidakis, A; Christophylakis, C; Diamandidou, E; Emmanouilides, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Kotsakis, A; Mavroudis, D; Sfakiotaki, G; Souglakos, J; Touroutoglou, N; Vamvakas, L, 2007)
" Administration of TroVax alongside chemotherapy was safe and well tolerated with no SAEs attributed to the vaccine and no enhancement of chemo-related toxicity."6.73Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. ( Carroll, MW; Chikoti, P; Drury, N; Griffiths, R; Harrop, R; Hawkins, RE; Kingsman, SM; Naylor, S; Redchenko, I; Shingler, W; Steven, N, 2008)
"Patients (n = 567) with metastatic colorectal cancer were randomly assigned to receive FLIRI or Lv5FU2-IRI."6.73A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. ( Albertsson, M; Balteskard, L; Berglund, A; Byström, P; Garmo, H; Glimelius, B; Heikkilä, R; Keldsen, N; Pfeiffer, P; Starkhammar, H; Sørbye, H; Tveit, K, 2008)
"The addition of cetuximab to capecitabine, oxaliplatin and bevacizumab in the first-line treatment of ACC appears to be safe and feasible."6.73A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. ( Antonini, NF; Cats, A; Creemers, GJ; Erdkamp, FL; Koopman, M; Mol, L; Punt, CJ; Rodenburg, CJ; Schrama, JG; Tol, J; Vos, AH, 2008)
"Patients with colorectal cancer (CRC) and liver metastases have a poor prognosis, but can benefit from perioperative chemotherapy and disease resection."6.73Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. ( Gruenberger, B; Gruenberger, T; Herbst, F; Scheithauer, W; Schueller, J; Tamandl, D; Zielinski, C, 2008)
"Individual FU dose adjustment based on pharmacokinetic monitoring resulted in significantly improved objective response rate, a trend to higher survival rate, and fewer grade 3/4 toxicities."6.73Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ( Boisdron-Celle, M; Delva, R; Dorval, E; Gamelin, E; Jacob, J; Merrouche, Y; Morel, A; Pezet, D; Piot, G; Raoul, JL, 2008)
"Gefitinib at a dose of 250 mg daily in combination with weekly 5-fluorouracil at 2,000 mg/m(2) or gefitinib at a dose of 500 mg daily with 5-fluorouracil at 1,600 mg/m(2) plus oxaliplatin has an acceptable safety profile."6.73Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO). ( Bokemeyer, C; Hartmann, JT; Höhler, T; Holtmann, M; Kröning, H; Pintoffl, JP, 2008)
"In patients with advanced colorectal cancer (ACRC), retrospective studies have shown that low expression levels of TS and DPD correlated with response to 5-FU."6.72Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. ( Dercksen, W; Giaccone, G; Noordhuis, P; Peters, GJ; Pinedo, HM; Smid, K; Smorenburg, CH; van Groeningen, CJ; van Riel, AM, 2006)
"Traditionally, metastatic colorectal cancer (MCRC) has been treated with intravenous (i."6.72A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. ( Gollins, S; Grieve, R; Samuel, L; Twelves, C, 2006)
"Thalidomide was escalated individually to 600 mg po QD as tolerated."6.72The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B, 2006)
" This PK model could be useful in identifying predictors for PK and pharmacodynamic variability to individualize dosing."6.72Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. ( Brouwers, JR; Jansman, FG; Kho, Y; Neef, C; Prins, NH, 2006)
"Patients with untreated advanced colorectal cancer were enrolled to this single arm phase II multi-center cooperative group trial of bevacizumab combined with IFL."6.72A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. ( Benson, AB; Catalano, PJ; Giantonio, BJ; Levy, DE; Meropol, NJ; O'dwyer, PJ, 2006)
" 5-FU pharmacokinetics was determined on day 2 of the first, third, and fifth cycles; type and the grade of adverse reactions were recorded on the next cycle."6.72Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. ( Barile, C; Bononi, A; Crepaldi, G; Ferrari, M; Ferrazzi, E; Grigoletto, F; Gusella, M; Menon, D; Padrini, R; Scapoli, D; Stievano, L; Toso, S, 2006)
"Patients with metastatic colorectal cancer (MCC) usually receive FOLFOX-4, or other oxaliplatin (L-HOP)-based regimens, until the occurrence of progressive disease, with an increase in the incidence of neurotoxicity which is correlated to the cumulative dose of L-HOP."6.72FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. ( Cioppa, T; Civitelli, S; Francini, E; Francini, G; Intrivici, C; Lorenzi, M; Marsili, S; Nettuno, R; Paolelli, L; Petrioli, R; Roviello, F; Tanzini, G, 2006)
"Patients aged 70 or more, with stage IV colorectal cancer, ECOG performance status not worse than 2."6.71First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study. ( Daniele, B; De Maio, E; Gallo, C; Iaffaioli, RV; Manzione, L; Ottaiano, A; Perrone, F; Pignata, S; Rosati, G; Rossi, A; Tambaro, R, 2003)
"Postoperative complications were reported in 14 patients (13 occurring within 30 days after resection) and severe complications in 5 cases (including two deaths after extended resection)."6.71Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies. ( Gassel, HJ; Gog, C; Hohenberger, W; Jauch, KW; Lehmann, U; Lorenz, M; Müller, HH; Padberg, W; Proschek, D; Ridwelski, K; Staib-Sebler, E; Vestweber, KH; Zamzow, K, 2003)
"The objective of this study was to develop a population pharmacokinetic model and validate it using a Bayesian approach for predicting, a priori and a posteriori, the individual volume of distribution (V(d)) and clearance (Cl) of 5-fluorouracil (5-FU) given as short-term intravenous infusion in weekly and multiple doses."6.71A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer. ( Almenar-Cubells, D; Climente-Martí, M; Jiménez-Torres, NV; Merino-Sanjuán, M, 2003)
"A prospective phase II study was performed to determine the feasibility, efficacy and safety of arterial hepatic infusion (HAI) using pirarubicin combined with intravenous chemotherapy."6.71Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer. ( Adenis, A; Baulieux, J; Colin, P; Couzigou, P; Douillard, JY; Ducreux, M; Fallik, D; Jacob, J; Mahjoubi, M; Mahjoubi, R; Rougier, P; Seitz, JF; Ychou, M, 2003)
"Median survival in advanced colorectal cancer patients treated with 5-fluoro-uracil (5FU) and leucovorin (LV) is between 12 and 18 months."6.71[Long term survival in metastatic colorectal cancer treated with leucovorin and 5-fluoro-uracil chemotherapy]. ( André, T; Artru, P; Carola, E; de Gramont, A; Krulik, M; Louvet, C; Mabro, M; Molitor, JL; Perez, N; Tournigand, C, 2004)
"Weekly treatment at these doses is convenient and well-tolerated for the large majority of patients, and achieves DI comparable with the 5 days a month QUASAR schedule and other more toxic standard regimens."6.71Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. ( Anthoney, DA; Crellin, AM; Messruther, J; Patel, K; Sebag-Montefiore, D; Seymour, MT, 2004)
"The purpose of our study was to determine the maximum-tolerated dose, dose-limiting toxicity, safety profile, and pharmacokinetics of the polyamine synthesis inhibitor SAM486A given in combination with 5-fluorouracil/leucovorin (5-FU/LV) in cancer patients."6.71Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer. ( Bootle, D; Bridgewater, J; Choi, L; de Bruijn, P; Eskens, FA; Ledermann, JA; Mueller, C; Planting, AS; Sklenar, I; Sparreboom, A; van Zuylen, L; Verweij, J, 2004)
"Topotecan has shown fewer side effects and higher efficacy when given as a continuous i."6.71Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer. ( Deckert, PM; Hütter, G; Keilholz, U; Szélenyi, H; Thiel, E, 2004)
" Pharmacokinetic studies were performed on cycle 1 and 2 to assess the best sequence and detect any interaction between the two drugs."6.71Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients. ( Adam, R; Bastian, G; Bismuth, H; Castaing, D; Gil-Delgado, MA; Guinet, F; Khayat, D; Rocher, MA; Spano, JP; Taillibert, S; Urien, S, 2004)
"Among 13 patients with advanced colorectal cancer, 10 required dose reductions of irinotecan and 5-FU because of dehydration, diarrhoea, and neutropenia, seven of whom required hospitalisation, three with neutropenic fever."6.71A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. ( Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML, 2005)
"Patients (n=38) with colorectal cancer received IFN-alpha 5 MU/m(2) SC on days 1-6; on days 2-6, LV 200 mg/m(2) IV was given with 5-FU at initial doses of 370-425 mg/m(2)/h."6.71A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel. ( Ernst, A; Grem, JL; Grogan, L; Grollman, F; Ismail, AS; Kao, V; Kirsch, IR; Parr, A; Quinn, MG; Wright, MA, 2005)
" This study was performed to determine the efficacy and safety of irinotecan (CPT-11) in combination with fluorouracil (FU) administered as a 48-hour continuous infusion twice a month in elderly patients."6.71Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. ( Abad, A; Antón, A; Aranda, E; Carrato, A; Díaz-Rubio, E; Gil, S; Maestu, I; Marcuello, E; Masutti, B; Maurel, J; Navarro, M; Sastre, J; Valladares, M; Vicent, JM, 2005)
" Studies of bimonthly regimens of high-dose leucovorin (LV) and 5-fluorouracil (5-FU) by continuous infusion combined with oxaliplatin (L-OHP) have shown encouraging response rates in patients not responding to a bimonthly LV/5-FU regimen."6.70Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. ( Atanackovic, D; Corovic, A; Gruber, Y; Hegewisch-Becker, S; Hossfeld, DK; Nierhaus, A; Pichlmeier, U, 2002)
" A phase II clinical trial of this combination using a continuous dosing schedule was carried out in patients with metastatic colorectal cancer."6.70Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. ( Benson, AB; Catalano, P; Cornfeld, MJ; Graham, DL; Huang, J; Marsh, JC; O'Dwyer, PJ, 2002)
" Therefore, we performed a study of PVI 5FU in 61 patients with advanced colorectal cancer to assess the variability (inter- and intra-subject) in 5FU Css associated with PVI 5FU (300 mg m(-2)day(-1)) and to attempt to correlate pharmacodynamic end-points (anti-tumour activity, toxicity) with 5FU Css as a prelude to 'exposure-guided' 5FU administration."6.705-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer. ( Aird, R; Bowman, A; Jodrell, DI; Knowles, G; McLean, C; Stewart, M; Wall, L, 2001)
"164 patients with advanced colorectal cancer were enrolled in this randomised, placebo-controlled, double-blind, multicenter phase III study."6.70Double-blind randomised placebo-controlled phase III study of an E. coli extract plus 5-fluorouracil versus 5-fluorouracil in patients with advanced colorectal cancer. ( Clemm, C; Clevert, HD; Häring, B; Hockertz, S; Kalousek, MB; Kruse, A; Schneider, B; Thumann, A; Unger, C; Weber, B, 2001)
"In palliative first-line treatment of colorectal cancer, the secondary resection of distant metastases after downstaging has constantly gained in importance."6.70Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. ( Baum, U; Becker, D; Bernatik, T; Brueckl, WM; Hahn, EG; Hänsler, J; Hohenberger, W; Köckerling, F; Martus, P; Ott, R; Reck, T; Riedel, C; Schneider, T; Wein, A, 2001)
"Trimetrexate (TMTX) is a biochemical modulator of 5-fluorouracil (5-FU) and leucovorin (LV)."6.70Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. ( Croles, JJ; Douma, J; Hammershaimb, L; Keizer, HJ; Lochs, H; Muller, EW; Punt, CJ; Schüller, J; Skovsgaard, T; Ten Napel, CH; Zhang, J, 2002)
"Furthermore, presence of lung metastases, a primary rectal cancer and presence of lymph node metastases all predicted a better outcome in the multivariate setting."6.70Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. ( Aranda, E; Baron, B; Blijham, G; Cunningham, D; Di Costanzo, F; Glimelius, B; Hecker, H; Köhne, CH; Micheel, S; Palmer, M; Pignatti, F; Rougier, P; Scheithauer, W; Schöffski, P; Wils, J, 2002)
" Eight episodes of grade 3 or 4 stomatitis were observed, and were responsible for dosage modifications of MTX and 5-FU."6.69Double modulation of 5-fluorouracil by methotrexate and high-dose L-leucovorin in advanced colorectal cancer. ( Acuña, JM; Acuña, LA; Amato, S; Barbieri, MR; Cuevas, MA; DeLena, M; Dominguez, ME; Lacava, JA; Langhi, MJ; Leone, BA; Lorusso, V; Machiavelli, MR; Ortiz, EH; Perez, JE; Rodriguez, R; Romero, AO; Sabatini, CL; Salvadori, MA; Vallejo, CT, 1998)
"Diarrhea was experienced by six of 10 patients, and only three patients were able to receive six weekly chemotherapy treatments without dose reduction or delay."6.69Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. ( Blumenson, LE; Creaven, PJ; Meropol, NJ, 1998)
"Only patients with colorectal cancer who had evidence of unresectable metastases confined to the liver were eligible."6.69Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. ( Bernath, AM; Bolton, JS; Burch, P; Colon-Otero, G; Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Nagorney, DM; O'Connell, MJ; Schroeder, G, 1998)
"203 patients with measurable advanced colorectal cancer were randomised to bolus 5-FU either as an injection for 2-4 min or as a short-term infusion lasting 10-20 min."6.69Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. ( Berglund, A; Brunsgaard, N; Gadeberg, C; Glimelius, B; Graf, W; Gustavsson, B; Hansen, P; Jakobsen, A; Kjaer, M; Lindberg, B; Lorentz, T; Påhlman, L; Sandberg, E; Sellström, H, 1998)
" Four episodes of grade 2 stomatitis were observed, causing dosage modifications."6.69Biomodulation with sequential intravenous IFN-alpha2b and 5-fluorouracil as second-line treatment in patients with advanced colorectal cancer. ( Amato, S; Barbieri, MR; Domínguez, ME; Lacava, JA; Langhi, MJ; Leone, BA; Machiavelli, MR; Marrone, N; Ortiz, EH; Pérez, JE; Rodríguez, R; Romero Acuña, JM; Romero Acuña, LA; Romero, AO; Vallejo, CT, 1998)
"All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)."6.69Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999)
"16 patients with advanced colorectal cancer were treated with 650 mg/m2/d fluorouracil as 5 day continuous infusion and randomized to receive either 20 mg/m2 or 100 mg/m2 calcium folinate as short infusion twice daily."6.69Pharmacokinetic and pharmacodynamic comparison of two doses of calcium folinate combined with continuous fluorouracil infusion in patients with advanced colorectal cancer. ( Jaehde, U; Kreuser, ED; Schunack, W; Streit, M; Stremetzne, S, 1999)
" To predict 5-FU catabolic deficiencies and toxic side effects, we conducted a prospective study of patients treated for advanced colorectal cancer by high-dose 5-FU."6.69Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. ( Boisdron-Celle, M; Delva, R; Gamelin, E; Genevieve, F; Guérin-Meyer, V; Ifrah, N; Larra, F; Lortholary, A; Robert, J, 1999)
"Recent advances in the management of colorectal cancer have improved the quality of life and the survival of patients treated with chemotherapy."6.69[Bimonthly 5-fluorouracil in elderly patients with metastatic colorectal cancer. Study of 50 patients]. ( Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M; Maindrault-Goebel, F, 1999)
"Six of 40 patients with metastatic colorectal cancer obtained an objective response (15%; 95% confidence interval, 6-30%)."6.69Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. ( Avallone, A; Blackie, R; Budillon, A; Caponigro, F; Cartenì, G; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lucia, L; De Vita, F; Gravina, A; McLeod, H; Morsman, J, 1999)
"In primary colorectal tumors, the concentration of 5-FU was on average 3."6.69Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. ( Banken, L; Cassidy, J; Dumont, E; Durston, S; Mori, K; Reigner, B; Roos, B; Schüller, J; Utoh, M; Weidekamm, E, 2000)
"Cimetidine has demonstrated a survival benefit in a randomized trial as adjuvant therapy for gastric cancer."6.68A randomized trial of cimetidine with 5-fluorouracil and folinic acid in metastatic colorectal cancer. ( Adams, WJ; Clingan, PR; Legge, J; Links, M; Morris, DL; O'Baugh, J; Phadke, K; Ross, WB, 1995)
"Site of metastases included liver (n = 16), lung (n = 7), abdomen (n = 2), pelvic recurrences (n = 2), cutaneous (n = 1)."6.68Cytarabine and cisplatin as salvage therapy in patients with metastatic colorectal cancer who failed 5-fluorouracil + folinic acid regimen. French Northern Oncology Group. ( Adenis, A; Bonneterre, J; Carlier, D; Darloy, F; Demaille, A; Pion, JM, 1995)
"Thirty-five patients with metastatic colorectal cancer were treated; 15 (41%) had received previous therapy, 22 (63%) had W."6.68A phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer. ( Adam, R; Bismuth, H; Caussanel, JP; Jasmin, C; Lévi, F; Metzger, G; Misset, JL; Smolensky, M; Soussan, A, 1995)
" These results show that there is no pharmacokinetic advantage to the use of 6S-LV rather than 6R,S-LV as a modulator of 5-FU."6.68A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma. ( Berghorn, E; Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, YM, 1995)
"Metastatic colorectal cancer is generally incurable."6.68Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer. ( Abbruzzese, JL; Brown, BW; Gross, HM; Jones, DV; Levin, B; Levy, LB; Pendergrass, KB; Pugh, RP; Wade, JL; Winn, RJ, 1995)
" The dosage was as follows: group A received FA i."6.68Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. ( Archimandritis, A; Bacoyiannis, C; Giannopoulos, A; Kalahanis, N; Karatzas, G; Kosmas, C; Kosmidis, P; Papachristodoulou, A; Papadimas, V; Polyzos, A; Sakelaropoulos, N; Tsavaris, N, 1996)
"To determine the most effective dose of leucovorin (folinic acid [FA]) within a weekly bolus fluorouracil (FU) schedule, we conducted a randomized multicenter trial to compare therapeutic effects and toxicity of high-dose FA versus low-dose FA combined with FU at equal doses in both treatment groups."6.68Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. ( Bernhard, G; Bernhard, H; Heike, M; Jäger, E; Klein, O; Knuth, A; Lautz, D; Meyer zum Büschenfelde, KH; Michaelis, J, 1996)
"Sixty-eight patients with advanced colorectal cancer received every 2 weeks hydroxyurea per os 1."6.68Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. ( Beerblock, K; Bennamoun, M; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Mal, F; Moreau, S; Soubrane, D; Varette, C; Zylberait, D, 1996)
"Ukrain is a new effective drug in the therapy of colorectal cancer."6.68Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer. ( Korsh, OB; Kravchenco, OB; Susak, YM; Yaremchuk, OY; Yatsyk, IM; Zemskov, VS, 1996)
"Residual metastases were surgically removed in 13 patients (26%)."6.68Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. ( Adam, R; Bertheault-Cvitkovic, F; Bismuth, H; Brienza, S; Brummer, PD; Ithzaki, M; Jami, A; Kunstlinger, F; Lévi, F; Misset, JL, 1996)
"Grade 4 leukopenia was observed in 1 case and grade 3 to 4 thrombocytopenia was observed in two cases, respectively."6.68The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD). ( Antón-Torres, A; Aranda, E; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Massutí, T, 1996)
"Chemotherapy pretreated patients with colorectal cancer seem to have a substantial survival benefit with this salvage protocol."6.68High-dose infusional 5-fluorouracil combination therapy of metastatic gastric and colorectal cancer. ( Hausamen, TU; Loeffler, TM, 1996)
"Colorectal carcinoma is one of the most common neoplasms in Western societies, being second only to lung cancer as a cause of death from malignancy."6.68First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer. ( Beuzeboc, P; Deffontaines, D; Diéras, V; Dorval, T; Garcia-Giralt, E; Jouve, M; Palangie, T; Pouillart, P; Scholl, S, 1996)
"These studies demonstrate that the present dose and schedule of AZT in combination with 5-FU + LV has significant activity in metastatic colorectal cancer and that the combination of 5-FU + LV with AZT increases the amount of DNA damage."6.68Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand break ( Allegrini, G; Andreuccetti, M; Antonuzzo, A; Brunetti, I; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Lencioni, M; Malvaldi, G; Pfanner, E, 1997)
"Doxifluridine (5-dFUR) is a fluoropyrimidine derivative, which is preferentially converted to 5-fluorouracil (5-FU) within tumour tissues."6.68Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. ( Artale, S; Bajetta, E; Bignami, P; Buzzoni, R; Del Vecchio, M; Di Bartolomeo, M; Magnani, E; Somma, L; Zunino, F, 1997)
"Two hundred patients with advanced colorectal cancer received PVI 5-FU 300 mg/m2/day for a maximum of 24 weeks and were randomised to PVI 5-FU alone or PVI 5-FU + MMC 10 mg/m2 (7 mg/m2 from June 1995) 6 weekly for 4 courses."6.68A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. ( Cunningham, D; Iveson, T; Massey, A; Norman, A; Oates, J; Padhani, A; Popescu, R; Prendiville, J; Ross, P; Watson, M; Webb, A, 1997)
"Sixteen patients with metastatic colorectal cancer have been treated with a regimen involving an 120 h continuous infusion of rIL-2, 18 x 10(6) iu m-2 day followed by three injections of 5FU 600 mg m-2 at weekly intervals."6.67A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer. ( Franks, CR; Hamblin, TJ; Oskam, R; Palmer, P; Sadullah, S; Stevenson, J; Williamson, P, 1993)
" in 15' x 5 days) every 4 weeks (Arm A), or to 5-FU alone at the same dosage (Arm B)."6.67Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer). ( Aitini, E; Barni, S; Beretta, A; Beretta, GD; Cesana, B; Comella, G; Cozzaglio, L; Cristoni, M; Labianca, R; Pancera, G, 1991)
"In 28 patients with advanced colorectal cancer, in progression under FA-5FU, we continued treatment with FA-5FU plus DIP."6.67Multimodal biochemical modulation of 5-fluorouracil activity in advanced colorectal cancer with allopurinol, folinic acid and dipyridamol. ( Antonopoulos, A; Bacoyannis, C; Beldecos, D; Karvounis, N; Kosmidis, P; Mylonacis, N; Tsavaris, N; Valilis, P; Zamanis, N; Zinelis, A, 1990)
"Thirty one gastric cancer pts."6.67[High-dose leucovorin and 5-fluorouracil in advanced gastric and colorectal cancer. High-Dose Leucovorin and 5-FU Study Group]. ( Akazawa, S; Matsuoka, T; Mukaiyama, T; Ogawa, M; Ota, K; Sakai, Y; Sakata, Y; Sasaki, T; Wakui, A; Yoshino, M, 1990)
"5-Fluorouracil (5-FU) has become one of the most widely employed antimetabolite chemotherapeutic agents in recent decades."6.66Recent Advances in Designing 5-Fluorouracil Delivery Systems: A Stepping Stone in the Safe Treatment of Colorectal Cancer. ( Entezar-Almahdi, E; Farjadian, F; Mohammadi-Samani, S; Tayebi, L, 2020)
"Sixty patients with advanced colorectal cancer were randomized between cisplatin (60 mg/mq i."6.66Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study. ( Cesana, B; Clerici, M; Labianca, R; Luporini, G; Montinari, F; Pancera, G, 1988)
"5-fluorouracil is a chemotherapeutic agent that plays an important role in the treatment of various cancers including head and neck and gastrointestinal malignancies."6.53Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review. ( Mahipal, A; Markey, KR; Saneeymehri, SS, 2016)
"To compare the efficacy and safety of two chemotherapeutic regimens, irinotecan monotherapy or irinotecan in combination with fluoropyrimidines, for patients with advanced CRC when administered in the first or second-line settings."6.53Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. ( Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N, 2016)
"Pharmacokinetic guided dosing of 5-fluorouracil chemotherapies to bring plasma 5-fluorouracil into a desired therapeutic range may lead to fewer side effects and better patient outcomes."6.53Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review. ( Clarke, A; Connock, M; Court, R; Freeman, K; Gurung, T; Saunders, MP; Sutcliffe, P; Taylor-Phillips, S; Uthman, OA, 2016)
" The risk of mortality, therapeutic efficacy, and adverse effect were meta-analyzed."6.53Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis. ( Chen, K; Gong, Y; Shen, Y; Zhang, Q; Zhou, T, 2016)
" Herein, we critically discuss the current data on the efficacy and safety profile of bevacizumab in combination with fluoropyrimidine-based chemotherapy for first-line and maintenance treatment of metastatic CRC and briefly comment on existing controversies and future perspectives."6.52Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer. ( Grapsa, D; Saif, MW; Syrigos, K, 2015)
"Capecitabine has previously been compared to 5-fluorouracil-either as a monotherapy or in combination with oxaliplatin, irinotecan, or biological drugs-and has been found to have comparable efficacy and safety profiles."6.50Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? ( Aguado, C; Díaz-Rubio, E; García-Paredes, B; Sastre, J; Sotelo, MJ, 2014)
"Capecitabine is an orally administered fluoropyrimidine carbamate that is absorbed intact from the gastrointestinal tract and becomes metabolically activated to 5-FU within the tumor."6.46Evolution of capecitabine dosing in colorectal cancer. ( Sun, W, 2010)
"Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration."6.46Update on capecitabine alone and in combination regimens in colorectal cancer patients. ( Azzariti, A; Cinieri, S; Colucci, G; De Vita, F; Lorusso, V; Maiello, E; Millaku, A; Numico, G; Petriella, D; Pisconti, S; Russo, A; Santini, D; Silvestris, N; Tommasi, S, 2010)
"Capecitabine is an oral prodrug of 5-fluorouracil."6.44Capecitabine in the treatment of colorectal cancer. ( Cassidy, J; Kelly, C, 2007)
"For instance, in patients with colorectal cancer, higher enzyme activity of topoisomerase-I seems to be predictive of a better response to irinotecan."6.43Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. ( Lentz, F; Pons, G; Rey, E; Tran, A; Tréluyer, JM, 2005)
"Irinotecan was first developed in patients refractory to fluorouracil."6.43Benefit-risk assessment of irinotecan in advanced colorectal cancer. ( Glimelius, B, 2005)
"Worldwide, colorectal cancer is a common cancer and a major cause of morbidity and mortality."6.43Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer. ( Jefford, M; Khamly, K; Michael, M; Zalcberg, J, 2005)
"Capecitabine is an oral fluoropyrimidine which is converted to 5-fluorouracil primarily in tumor tissue, and has the advantages of ease-of-administration, acceptable toxicity and significant antineoplastic activity."6.43Capecitabine in the treatment of colorectal cancer. ( Cassidy, J; O'Neill, VJ, 2005)
"The chemotherapy of metastatic colorectal cancer (CRC) has undergone a succession of refinements."6.42Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. ( Carnaghi, C; Comella, P; Díaz-Rubio, E; Douillard, JY; Santoro, A; Sobrero, A; Van Cutsem, E, 2003)
" The use of irinotecan together with raltitrexed is also being investigated, as is its combination with oxaliplatin."6.42Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers. ( Ducreux, M; Köhne, CH; Schwartz, GK; Vanhoefer, U, 2003)
" DPD-inhibiting oral fluoropyrimidines showing promise in early clinical studies included UFT (the 5-FU prodrug, tegafur, plus the DPD substrate, uracil), eniluracil (an irreversible DPD inhibitor that improves the oral bioavailability of 5-FU) and S-1 (tegafur plus a reversible DPD inhibitor, 5-chloro-2,4-dihydroxypyridine, and oxonic acid)."6.42Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer. ( Schmoll, HJ, 2003)
"Colorectal cancer is a leading cause of cancer death worldwide."6.42Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. ( Gill, S; Goldberg, RM, 2004)
"Colorectal cancer is the second leading cause of cancer death in the USA and fluoropyrimidines have been the mainstay of treatment for over 40 years."6.42Capecitabine: the new generation of fluoropyrimidines in colorectal cancer. ( Iqbal, S; Lenz, HJ, 2004)
"Capecitabine (Xeloda) is an oral prodrug that is enzymatically converted to fluorouracil (5-FU) within cancer cells."6.41Current status of capecitabine in the treatment of colorectal cancer. ( Rothenberg, ML, 2002)
"Capecitabine (Xeloda)(R) was developed as a tumour-selective fluoropyrimidine carbamate to achieve higher intratumoural 5-FU level and lower toxicity than 5-FU."6.41Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer. ( Di Costanzo, F; Gasperoni, S; Sdrobolini, A, 2000)
"Metastatic colorectal cancer remains incurable with available systemic therapeutic options."6.41Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer. ( Grivicich, I; Mans, DR; Peters, GJ; Schwartsmann, G, 2001)
"Unusual aspect of the development of oxaliplatin was that substantial evidence of its activity was gathered when used in combination with protracted infusion of 5FU combined with leucovorin, preceeding the formal demonstration of its single activity in this disease."6.41[Oxaliplatin in combination with 5-fluoro-uracil and folinic acid as treatment of metastatic colorectal cancer]. ( André, T; Gramont, AD; Louvet, C; Maindrault-Goebel, F, 2001)
"Capecitabine is an orally administered fluoropyrimidine which is selectively activated in tumour tissue to the active moiety fluorouracil and is cytotoxic through inhibition of DNA synthesis."6.41Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. ( Goa, KL; McGavin, JK, 2001)
"Trimetrexate is a nonclassical antifolate that has demonstrated antitumor activity against a number of malignancies, including those resistant to the classical antifolate methotrexate."6.40Trimetrexate: review and current clinical experience in advanced colorectal cancer. ( Blanke, CD; Messenger, M; Taplin, SC, 1997)
"Over the last 40 years the treatment of colorectal cancer has not achieved the same progress as treatment for other types of tumors."6.40Beyond 5-fluorouracil monochemotherapy in colorectal cancer--it is time. ( Franchi, F; Satta, F, 1997)
"In human colorectal cancer cell lines and various animal tumour model systems 5-fluoro-2'-deoxyuridine (FdUrd) is more effective than 5-fluorouracil (5-FU)."6.40Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. ( Ackland, SP; Peters, GJ; Rustum, YM; van Groeningen, CJ; van Laar, JA, 1998)
"Colorectal cancer is one of the most frequent cancers in the western world."6.405-Fluorouracil in colorectal cancer: rationale and clinical results of frequently used schedules. ( Kamm, YJ; Punt, CJ; Rietjens, IM; Wagener, DJ, 1998)
"Irinotecan or CPT11 is a topoisomerase 1 inhibitor."6.40[Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials]. ( Peeters, M; Van Cutsem, E, 1998)
"Irinotecan treated patients lived for significantly longer than those on 5FU: median time of survival was 10."6.40[Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials]. ( Ducreux, M; Mitry, E; Rougier, P, 1998)
"Tegafur/uracil has been commercially available in Japan since 1983 and examined extensively in various tumours."6.40Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil. ( Hoff, PM; Lassere, Y; Pazdur, R, 1999)
"Although phase III studies have investigated the effect of adding bevacizumab to the 3-weekly capecitabine plus irinotecan (XELIRI) combination in the first-line treatment of metastatic colorectal cancer (mCRC), no phase III studies investigating the effects of adding bevacizumab to biweekly XELIRI have been published."6.27Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials. ( Alvarez Suarez, S; Blanco Codeidido, M; García Alfonso, P; López Martín, P; Martin, M; Mondejar Solis, R; Muñoz Martin, A; Tapia Rico, G, 2013)
"In DaVINCI, a randomised phase II trial, patients with advanced colorectal cancer were randomly allocated to: Combination therapy (FOLFIRI), irinotecan (180 mg/m(2) IV over 90 min, day 1), 5-fluorouracil (400mg/m(2) IV bolus and 2400 mg/m(2) by 46-hour infusion from day 1) and folinic acid (20mg/m(2) IV bolus, day 1), 2-weekly; or Single-agent, irinotecan (350 mg/m(2) IV over 90 min), 3-weekly."6.25Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. ( Boland, A; Brown, C; Buck, M; Clarke, SJ; Gebski, V; Goldstein, D; Jeffrey, GM; Lowenthal, RM; Ransom, DT; Simes, RJ; Tebbutt, NC; van Hazel, GA; Yip, S; Zalcberg, J, 2011)
"The purpose of this study was to examine the efficacy of a combination treatment of sequential irinotecan and doxifluridine, an intermediate of capecitabine, evaluated by the response rate and safety in patients with metastatic colorectal cancer."6.23A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. ( Amano, M; Fukunaga, M; Ikeda, K; Ikeda, M; Ikenaga, M; Ishida, H; Kato, T; Mishima, H; Monden, M; Murata, K; Ohnishi, T; Ota, H; Sakamoto, J; Sekimoto, M; Tominaga, S, 2008)
"This study was conducted before the approval of oxaliplatin, cetuximab, and bevacizumab and was designed to evaluate a novel microtubule targeting agent, T138067, in patients with metastatic colorectal cancer (CRC) previously treated with irinotecan and 5-fluorouracil."6.23Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma. ( Bergsland, E; Berlin, JD; Lockhart, AC; Rosen, L; Rothenberg, M; Venook, A, 2008)
"The aims of this multicentre, randomised phase III trial were to evaluate: (1) the role of levamisol (LEV); and (2) the role of folinic acid (FA), added to 5-fluorouracil (5FU) in the adjuvant treatment of colorectal cancer."6.21Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study. ( Adamo, V; Bianco, AR; Carlomagno, C; Cortesi, E; De Placido, S; De Vita, F; Farris, A; Ficorella, C; Gallo, C; Gebbia, N; Gemini, M; Iannace, C; Ianniello, GP; Lopez, M; Manzione, L; Palazzo, S; Palmeri, S; Paoletti, G; Perrone, F; Persico, G; Pistillucci, G, 2005)
"The French contribution to the development of 5-fluorouracil (5-FU) infusion in advanced colorectal cancer includes five randomized trials and specific researches on the 48-hour bimonthly regimen, chronotherapy, and individual dose adaptation."6.18The French experience with infusional 5-fluorouracil in advanced colorectal cancer. ( de Gramont, A; Krulik, M; Louvet, C, 1996)
"17 patients with metastasizing colorectal cancer were treated in a phase II-study with systemic intravenous chemotherapy (Petrelli N, Proc ASCO 286, 1987) consisting of leucovorin 500 mg/m2 in a 2 hr infusion and 5-fluorouracil (5-FU) 600 mg/m2 bolus one hour after the commencement of the leucovorin infusion."6.16[5-Fluorouracil (5-FU)/leucovorin in comparison to other current chemotherapy protocols in metastasizing colorectal carcinoma]. ( Baur, M; Dittrich, C; Havelec, L; Mader, R; Marosi, C; Scheithauer, W; Schlappack, O, 1991)
"The purpose of this study was to evaluate the effectiveness of several new approaches designed to enhance the activity of fluorouracil (5-FU) in the management of advanced colorectal cancer."6.16Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. ( Cullinan, SA; Everson, LK; Krook, JE; Laurie, JA; Mailliard, JA; Moertel, CG; O'Connell, MJ; Poon, MA; Tschetter, LK; Wieand, HS, 1989)
"Xenografted patient-derived colon cancer tissues with MSI also show variable patterns of HDAC2 expression in mice."5.91The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil. ( Brachetti, C; Brenner, W; Kiweler, N; Krämer, OH; Linnebacher, M; Matschos, S; Mullins, C; Nguyen, A; Piée-Staffa, A; Roos, WP; Schneider, G; Schwarz, H, 2023)
"Colorectal cancer has risen to the third occurring cancer in the world."5.91The Gut Microbiota Metabolite Urolithin B Prevents Colorectal Carcinogenesis by Remodeling Microbiota and PD-L1/HLA-B. ( Chen, J; Chen, Q; Jin, S; Song, H; Song, X; Wang, L; Wang, Z; Xing, W; Yang, H; Zhao, W, 2023)
"Colorectal cancer (CRC) is the third most common cancer in the world, but current chemotherapy options are limited due to adverse effects and low oral bioavailability of drugs."5.91Development and cytotoxicity evaluation of multiple nanoemulsions for oral co-delivery of 5-fluorouracil and short chain triglycerides for colorectal cancer. ( Barreto, T; Branco, PC; Fukumori, C; Ishida, K; Lopes, LB, 2023)
"Blastocystis is an enteric protozoan parasite with extensive genetic variation and unclear pathogenicity."5.91Blastocystis sp. reduces the efficacy of 5-fluorouracil as a colorectal cancer chemotherapeutic treatment. ( Govind, SK; Jayalakshmi, P; Kumarasamy, V; Kuppusamy, UR, 2023)
"Conventional therapy for colorectal cancer often involves the use of 5-fluorouracil as a chemotherapeutic agent."5.91In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells. ( Dehelean, C; Ilia, I; Ionita, I; Macasoi, I; Pinzaru, I; Susan, M; Susan, R, 2023)
"Metformin is an old, inexpensive, and relatively safe anti-diabetic medication that can decrease the risk of several types of cancer in patients with diabetes."5.72The Emerging Role of Metformin in the Prevention and Treatment of Colorectal Cancer: A Game Changer for the Management of Colorectal Cancer. ( Ala, M, 2022)
"5-Fluorouracil is an anticancer drug with a short biological half-life."5.72The development of a novel oral 5-Fluorouracil in-situ gelling nanosuspension to potentiate the anticancer activity against colorectal cancer cells. ( Abdullah, S; Aldahlawi, A; El Hadad, S, 2022)
" The efficacy and adverse effects of maintenance treatment were compared between the two groups."5.72Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer. ( Cha, Y; Huang, W; Tian, Y; Xiong, H; Yuan, X; Zhang, H, 2022)
"Chemotherapy resistance of colorectal cancer stem cells (CRC-SCs) has become a major challenge in clinical treatment of cancer."5.72Methionine restriction enhances the chemotherapeutic sensitivity of colorectal cancer stem cells by miR-320d/c-Myc axis. ( Liu, C; Wang, JL; Wu, DZ; Xin, L; Yuan, YW, 2022)
"But its role in the development of colorectal cancer (CRC) cancer remains unknown."5.72FAM98A promotes resistance to 5-fluorouracil in colorectal cancer by suppressing ferroptosis. ( Deng, H; He, Z; Li, G; Mou, T; Shi, J; Sui, C; Sun, K; Wang, T; Wang, Y; Xu, Z; Yang, J; Zhang, P; Zhuang, B, 2022)
"Chemoresistance is a main obstacle for colorectal cancer treatment."5.72Stabilizing and upregulating Axin with tankyrase inhibitor reverses 5-fluorouracil chemoresistance and proliferation by targeting the WNT/caveolin-1 axis in colorectal cancer cells. ( Li, J; Liu, J; Liu, K; Luo, F, 2022)
"5-Fluorouracil (5-FU) has long been used as a standard first-line treatment for CRC patients."5.72Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer. ( Duan, T; Feng, J; Huang, X; Jin, W; Ke, K; Mei, R; Mou, Y; Shou, L; Sui, X; Sun, X; Wu, Q; Xie, T; Yu, S; Zhang, R; Zhu, Q, 2022)
" Data from experiments for 48 h showed that Bru, alone or in combination with 5-FU, is capable of causing an increase in the percentage of apoptotic cells in HT-29 cells compared to those of Erio alone or in combination with 5-FU."5.72Potential cancer treatment effects of brusatol or eriodictyol combined with 5-fluorouracil (5-FU) in colorectal cancer cell. ( Alper, M; Ardıl, B, 2022)
" However, during CRC treatment, long-term use of traditional chemotherapeutic drugs will reduce the sensitivity of chemotherapy."5.72A serum metabolomics study based on LC-MS: Chemosensitization effects of Rauvolfia vomitoria Afzel. combined with 5- fluorouracil on colorectal cancer mice. ( Kong, WR; Wang, JF; Wang, N; Wang, SQ; Wang, ZF; You, YL, 2022)
"On day 2 of re-treatment, serous retinal detachment recurred and treatment was discontinued."5.72[A Case of Serous Retinal Detachment after Encorafenib, Binimetinib, and Cetuximab Treatment for BRAF V600E Mutant Colorectal Cancer]. ( Ajihara, T; Fukuya, Y; Hanada, M; Koike, T; Kono, T; Miyata, R; Naritomi, T; Shiozawa, S; Yoshimatsu, K, 2022)
"Fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab is the standard second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) who are refractory or intolerant to fluoropyrimidines and oxaliplatin."5.69Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer. ( Ando, M; Bando, H; Honda, K; Kadowaki, S; Kato, K; Masuishi, T; Matsubara, Y; Muro, K; Nakazawa, T; Narita, Y; Nozawa, K; Ogata, T; Tajika, M; Taniguchi, H, 2023)
"AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of patients with metastatic colorectal cancer (mCRC), with a modest benefit among proficient mismatch repair (pMMR)."5.69An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer. ( Antoniotti, C; Bensi, M; Bergamo, F; Boccaccino, A; Boquet, I; Catteau, A; Conca, V; Cremolini, C; Galon, J; Giordano, M; Leonetti, S; McGregor, K; Morano, F; Murgioni, S; Nielsen, TJ; Papiani, G; Passardi, A; Pietrantonio, F; Ross, DT; Rossini, D; Salvatore, L; Schweitzer, BL; Seitz, R; Tamburini, E; Varga, MG, 2023)
"The phase Ia/b trials investigated the safety and tolerability and antitumor activities of suvemcitug for pretreated advanced solid tumors and in combination with FOLFIRI (leucovorin and fluorouracil plus irinotecan) in second-line treatment of metastatic colorectal cancer using a 3 + 3 dose-escalation design."5.69Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials. ( Cao, J; Ding, Y; Feng, X; Ji, D; Liu, L; Mao, C; Song, L; Song, W; Wu, Y; Xu, N; Zhang, J; Zhang, Y, 2023)
"In this prospective randomized crossover trial of systemic chemotherapy in patients with low-grade mucinous appendiceal adenocarcinoma, patients did not derive clinical benefit from fluorouracil-based chemotherapy, given there were no objective responses, no difference in OS when treatment was delayed 6 months, and no difference in the rate of tumor growth while receiving chemotherapy."5.69Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. ( Beaty, KA; Eng, C; Foo, WC; Fournier, K; Hornstein, N; Lano, E; Mansfield, P; Matamoros, A; Overman, MJ; Rafeeq, S; Raghav, KP; Scally, C; Scofield, LC; Shen, JP; Taggart, M; Tidwell, RS; Uppal, A; Yousef, AM; Zeineddine, FA; Zeineddine, MA, 2023)
"The PanaMa trial demonstrated significant benefit in progression-free survival with the addition of panitumumab (Pmab) to fluorouracil and folinic acid (FU/FA) as maintenance therapy following first-line induction therapy with FOLFOX/Pmab in patients with RAS wild-type metastatic colorectal cancer."5.69Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial. ( Alig, AHS; Ballhausen, A; Fruehauf, S; Goekkurt, E; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Karthaus, M; Kasper, S; König, AO; Kurreck, A; Meyer-Knees, JW; Modest, DP; Müller, L; Sommerhäuser, G; Stahler, A; Stintzing, S; Trarbach, T; von Weikersthal, LF, 2023)
"The outbreak of coronavirus disease 2019 (COVID-19) has affected the treatment of cancer patients, with particular regard to the management of both chemotherapy and side effects."5.62NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study. ( Caputo, V; Cicero, G; De Luca, R; Ferrera, G; Mistretta, O; Paci, R; Rosati, G; Volpe, C, 2021)
"Regorafenib, which has been approved as a salvage line for metastatic colorectal cancer, features many adverse events, and there are few cases in which the approved dose can be administered."5.62[A Case of Long-Term Survival after Administration of Regorafenib for Stage Ⅳ Colorectal Cancer]. ( Koike, T; Kono, T; Miyano, Y; Oyama, K; Shiozawa, S; Yokokawa, H; Yoshimatsu, K, 2021)
"Fatty liver is a side effect of chemotherapy that limits the ability to treat colorectal cancer (CRC) patients in the most effective way."5.62Alterations in hepatic fatty acids reveal depletion of total polyunsaturated fatty acids following irinotecan plus 5-fluorouracil treatment in an animal model of colorectal cancer. ( Bathe, O; Jacobs, R; Mazurak, VC; Monirujjaman, M; Nelson, R; Pant, A, 2021)
"Colorectal cancer is the second most common malignant tumor in China."5.62[Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil/leucovorin for colorectal cancer]. ( , 2021)
"Drug resistance in colorectal cancer is a great challenge in clinic."5.62MicroRNA-29b-3p promotes 5-fluorouracil resistance via suppressing TRAF5-mediated necroptosis in human colorectal cancer. ( Fang, Y; Liu, P; Shen, X; Wang, W; Wu, S; Zhang, H; Zhou, Y, 2021)
"Zotarolimus is a semi-synthetic derivative of rapamycin and an inhibitor of mammalian target of rapamycin (mTOR) signaling."5.62Anti-Cancer Effects of Zotarolimus Combined with 5-Fluorouracil Treatment in HCT-116 Colorectal Cancer-Bearing BALB/c Nude Mice. ( Chang, GR; Chen, CH; Kuo, CY; Liao, HJ; Lin, TC; Lin, WL; Tsai, MY; Wang, YC, 2021)
" Although curcumin is known to have anti-tumor, hepatoprotective, and hypoglycemic-like actions, its low water solubility, oral absorption, and bioavailability impede its therapeutic uses."5.62Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids. ( Abugomaa, A; Ayame, H; Elbadawy, M; Hayashi, K; Hayashi, SM; Hazama, S; Ishihara, Y; Kaneda, M; Nagano, H; Nakajima, M; Sasaki, K; Shibutani, M; Shinohara, Y; Suzuki, N; Takenouchi, H; Tsunedomi, R; Usui, T; Yamawaki, H, 2021)
"Developing new drugs for killing colorectal cancer (CRC) cells is urgently needed."5.56Toosendanin-induced apoptosis in colorectal cancer cells is associated with the κ-opioid receptor/β-catenin signaling axis. ( Chen, J; Chen, S; He, L; Huang, L; Li, W; Liu, H; Liu, R; Wang, F; Wang, H; Wen, C; Yang, X; Yu, WK; Zhou, Q, 2020)
" Chemotherapy-induced side effects were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE Version 5."5.56Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. ( Abdhaghighi, MJ; Jalali, H; Janbabaei, G; Negarandeh, R; Nosrati, A; Saghafi, F; Salehifar, E, 2020)
" We weekly applied the orofacial section of the Acute and Chronic Neuropathy Questionnaire of Common Toxicity Criteria for Adverse Events of the National Cancer Institute of the United States of America (Oxaliplatin-specific neurotoxicity scale)."5.56FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study. ( Costa, BA; da Rocha Filho, DR; de Albuquerque Ribeiro Gondinho, P; de Barros Silva, PG; Gifoni, MAC; Junior, RCPL; Lima, MVA; Lisboa, MRP; Vale, ML, 2020)
" Whether a patient who experienced a major cardiac side effect from 5-FU can be safely rechallenged with this drug is a clinical dilemma."5.565-Fluorouracil Rechallenge After Cardiotoxicity. ( Almnajam, M; Desai, A; Kim, AS; Mohammed, T; Patel, KN, 2020)
"Glycine has been shown to protect livers from CTx-induced injury and oxidative stress, and it reduces platelet aggregation and improves microperfusion."5.56Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury: A Colorectal Cancer Liver Metastasis Treatment Model in Rats. ( Bausys, A; Feldbacher, N; Hoefler, G; Kolb-Lenz, D; Leber, B; Maneikyte, J; Schemmer, P; Stiegler, P; Strupas, K, 2020)
" In the attempt to better define prechemotherapy baseline clinical and biomolecular predictors of drug toxicity, we trained and compared five ML algorithms starting from clinical, blood biochemistry, and genotype data derived from a previous phase Ib study aimed to define the maximum tolerated dose of irinotecan (FOLFIRI (folinic acid, fluorouracil, and irinotecan) plus bevacizumab regimen) in patients with metastatic colorectal cancer."5.51Machine Learning Application in a Phase I Clinical Trial Allows for the Identification of Clinical-Biomolecular Markers Significantly Associated With Toxicity. ( Bedon, L; Buonadonna, A; Cecchin, E; Dal Bo, M; Fabbiani, E; Polano, M; Toffoli, G, 2022)
"Aflibercept is an antiangiogenic drug against metastatic colorectal cancer (mCRC) combined with 5-fluorouracil/leucovorin/irinotecan (FOLFIRI); however, no antiangiogenic biomarker has yet been validated."5.51Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial. ( Aranda, E; Díaz, IA; Élez, E; García-Alfonso, P; Gómez-España, MA; Graña, B; Grávalos, C; Losa, F; Martínez de Castro, E; Ortiz-Morales, MJ; Polo, E; Riesco, MDC; Rodriguez-Ariza, A; Ruiz-Casado, A; Safont, MJ; Salgado, M; Salud, A; Tabernero, J; Toledano-Fonseca, M; Valladares-Ayerbes, M, 2022)
"Combination irinotecan and cetuximab is approved for irinotecan-refractory metastatic colorectal cancer (mCRC)."5.51Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial. ( Bekaii-Saab, T; Dakhil, SR; Faggen, M; Fuchs, CS; Heying, EN; Lipsyc-Sharf, M; Meyerhardt, JA; Ng, K; Noble, S; Ou, FS; Rubinson, DA; Schrag, D; Schuetz, SR; Stella, PJ; Weckstein, DJ; Wender, DB; Yurgelun, MB; Zemla, TJ, 2022)
"Cetuximab in combination with chemotherapy is a standard first-line treatment regimen for patients with metastatic colorectal cancer (mCRC) RAS wild-type (wt); however, the efficacy of cetuximab plus leucovorin, fluorouracil and oxaliplatin (FOLFOX) had never been demonstrated in a prospective, randomized, controlled phase III study."5.51[The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab]. ( Colombo, A; Porretto, CM; Rosati, G, 2022)
" Patients with colorectal cancer scheduled to receive adjuvant chemotherapy with capecitabine plus oxaliplatin are enrolled, and topical hydrocortisone butyrate 0."5.51Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC s ( Ahiko, Y; Aikou, S; Boku, N; Furukawa, N; Iimura, Y; Ishibashi, M; Kuroda, S; Nojima, M; Shida, D; Tanabe, T, 2022)
"Initial systemic therapy for patients with metastatic colorectal cancer (mCRC) is usually based on two- or three-drug chemotherapy regimens with fluoropyrimidine (5-fluorouracil (5-FU) or capecitabine), oxaliplatin and/or irinotecan, combined with either anti-VEGF (bevacizumab) or, for RAS wild-type (WT) tumors, anti-EGFR antibodies (panitumumab or cetuximab)."5.51Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line tre ( Dechow, T; Ettrich, TJ; Fruehauf, S; Fuchs, M; Heinemann, V; Hoyer, I; Kaiser, F; Karthaus, M; Kiani, A; König, A; Kurreck, A; Modest, DP; Müller, L; Quante, M; Reinacher-Schick, A; Roderburg, C; Schwaner, I; Sommerhäuser, G; Stahler, A; Stintzing, S; von Weikersthal, LF, 2022)
"The randomised open-label phase III XELAVIRI trial failed to demonstrate non-inferiority of the sequential application of fluoropyrimidine plus bevacizumab followed by additional irinotecan at first progression (Arm A) versus initial combination of all agents (Arm B) for untreated metastatic colorectal cancer in the initial analysis of time-to-failure-of-strategy (TFS, 90% confidence boundary of 0."5.51First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI ( Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schwaner, I; Stahler, A; Stintzing, S, 2022)
"This trial investigates the addition of panitumumab to chemotherapy with fluorouracil/folinic acid and oxaliplatin (FOLFOX) in a 2:1 randomised, controlled, open-label, phase II trial in RAS wild-type colorectal cancer patients with R0/1-resected liver metastases."5.51FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314). ( Fischer V Weikersthal, L; Fuchs, M; Heinemann, V; Held, S; Jacobasch, L; Jung, A; Junghanß, C; Kaczirek, K; Kaiser, F; Karthaus, M; Kasper, S; Keitel, V; Kiani, A; Lerchenmüller, C; Lorenzen, S; Modest, DP; Moosmann, N; Sent, D; Stintzing, S; Uhlig, J, 2022)
"The addition of aflibercept to the fluorouracil and irinotecan (FOLFIRI) regimen significantly improved clinical outcomes in patients with metastatic colorectal cancer (CRC) previously treated with oxaliplatin."5.51Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group. ( Acar, R; Akbas, S; Akinci, MB; Araz, M; Arslan, C; Artac, M; Bahceci, A; Bilgetekin, I; Bilici, A; Cakir, E; Celik, E; Cilbir, E; Cincin, I; Dede, DS; Demirkiran, A; Deniz, GI; Dogan, I; Erdem, D; Erdogan, AP; Eren, OO; Erol, C; Garbioglu, DB; Gulmez, A; Hacibekiroglu, I; Hamdard, J; Hizal, M; Inal, A; Kahraman, S; Kaya, AO; Koca, S; Kubilay, P; Kucukarda, A; Kut, E; Mandel, NM; Menekse, S; Nayir, E; Oksuzoglu, B; On, S; Oyman, A; Ozyukseler, DT; Paydas, S; Sakin, A; Sen, E; Sendur Mehmet, AN; Sevinc, A; Taskaynatan, H; Tastekin, D; Turhal, S; Uncu, D; Yalcin, B; Yildirim, ME, 2022)
"Platinum was readily detectable in skin biopsies more than 60 months post-completion of FOLFOX."5.51Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy. ( Cao, Y; Chang, Q; Chen, EX; Hedley, D; Ornatsky, O; Zhang, W, 2019)
"Chemotherapy is currently used to treat colorectal cancer (CRC), the most common cancer worldwide."5.51Identification of bioactive compounds in Lactobacillus paracasei subsp. paracasei NTU 101-fermented reconstituted skimmed milk and their anti-cancer effect in combination with 5-fluorouracil on colorectal cancer cells. ( Chang, CY; Pan, TM, 2019)
"Irinotecan (CPT-11) is a drug used against a wide range of tumor types."5.51Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer. ( Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019)
" Through univariate and multivariate logistic regression analyses, factors predicting the development of serious adverse events, fatal adverse events, and toxicity-related hospitalizations were determined."5.51Predictors of toxicity-related hospitalization in four randomized studies of 5-fluorouracil-based chemotherapy in metastatic colorectal cancer. ( Abdel-Rahman, O; Ahmed, O, 2019)
"Korean female patients with colorectal cancer who received 5-FU chemotherapy experienced more frequent adverse drug reactions including alopecia and leukopenia than male patients."5.51Sex-Dependent Adverse Drug Reactions to 5-Fluorouracil in Colorectal Cancer. ( Jung, J; Kim, KS; Kim, SY; Lee, E; Lee, S; Lim, H; Moon, A; Oh, S, 2019)
"Cancer stem cells (CSCs) residing in colorectal cancer tissues have tumorigenic capacity and contribute to chemotherapeutic resistance and disease relapse."5.51Combination of 5-fluorouracil and thymoquinone targets stem cell gene signature in colorectal cancer cells. ( Agaimy, A; Ballout, F; Çapci, A; Chanvorachote, P; El-Baba, C; Erlenbach-Wuensch, K; Gali-Muhtasib, H; Geppert, CI; Hartmann, A; Huebner, K; Klein, V; Muenzner, JK; Ndreshkjana, B; Roehe, AV; Schneider-Stock, R; Steinmann, S; Tsogoeva, SB, 2019)
"Irinotecan (CPT-11) is a drug used against a wide variety of tumors, which can cause severe toxicity, possibly leading to the delay or suspension of the cycle, with the consequent impact on the prognosis of survival."5.51Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters. ( Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019)
"Melatonin has antitumor activity via several mechanisms including its anti-proliferative and pro-apoptotic effects."5.48Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro. ( Bejarano, I; Espino, J; Pariente, JA; Pariente, R; Rodríguez, AB, 2018)
"Significant inter-individual variation in the sensitivity to 5-fluorouracil (5-FU) represents a major therapeutic hindrance either by impairing drug response or inducing adverse drug reactions (ADRs)."5.48DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer. ( Ahmed, MU; Apu, MNH; Chowdhury, SM; Hasnat, A; Islam, MR; Islam, MS; Nahar, Z; Nahid, NA; Shabnaz, S, 2018)
" Pretreatment with the pan-caspase inhibitor, z-VAD-FMK, attenuated the caspase-dependent apoptosis induced by circularly permuted tumor necrosis factor-related apoptosis-inducing ligand alone or combined with 5-fluorouracil."5.48Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480. ( Liang, X; Sun, T; Yang, S; Zhao, R; Zhu, T, 2018)
"Colorectal cancer is one of the most common malignancies both in men and women."5.48A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo. ( Chen, CQ; Ding, HW; Li, DD; Ren, TS; Wang, J; Wu, Q; Zhao, CH; Zhao, QC, 2018)
"Here, we show that colorectal cancers (CRCs) display negligible expression of OTC and, in subset of cases, ASS1 proteins."5.48Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes. ( Al-Aqbi, SS; Alexandrou, C; Andreadi, C; Blades, M; Boyle, W; Brown, K; Cheng, PN; Higgins, JA; Howells, LM; Karmokar, A; Luo, JL; Moore, DA; Murray, GI; Rufini, A; Thomas, A; Viskaduraki, M, 2018)
"Crocin was able to ameliorate the severe inflammation with mucosal ulcers and high-grade dysplastic crypts as detected by inflammation score, crypt loss, pathological changes and histology scores."5.48Crocin synergistically enhances the antiproliferative activity of 5-flurouracil through Wnt/PI3K pathway in a mouse model of colitis-associated colorectal cancer. ( Amerizadeh, F; Avan, A; Boroumand, N; Ferns, GA; Fiuji, H; Ghayour-Mobarhan, M; Hassanian, SM; Khazaei, M; Moradi-Marjaneh, R; Nosrati-Tirkani, A; Rahmani, F; Rezaei, N, 2018)
"Background Early relapse in colorectal cancer (CRC) after curative resection is mainly attributed to the key determinants such as tumor histology, stage, lymphovascular invasion, and the response to chemotherapy."5.48Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy. ( Ajaj, AR; Al-Hiary, R; Al-Yacoub, S; Kadi, T; Majdalawi, K; Mukred, R; Tantawi, D; Yousef, AM; Yousef, M; Zawiah, M, 2018)
"Colorectal cancer is one of the most frequently diagnosed cancers worldwide."5.48The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer. ( An, C; Li, H; Mushtaq, N; Shi, Y; Ullah, S; Xu, J; Yang, F; Yuan, L; Zhang, S, 2018)
"Isoliquiritigenin (ISL) is a natural flavonoid that exhibits anticancer properties in various carcinoma cell types."5.48Isoliquiritigenin-mediated p62/SQSTM1 induction regulates apoptotic potential through attenuation of caspase-8 activation in colorectal cancer cells. ( Jin, H; Lee, SH; Seo, GS, 2018)
"Curcumin has been reported to be an effective compound in the reversal of MDR in colorectal cancer cells."5.48Nrf2 is a key factor in the reversal effect of curcumin on multidrug resistance in the HCT‑8/5‑Fu human colorectal cancer cell line. ( Chen, YY; He, LJ; Jia, YW; Liu, DF; Liu, XP; Miao, DD; Shen, J; Ye, HZ; Zhang, C; Zhang, SP; Zhu, YB, 2018)
"Right-sided colorectal cancer (RSCRC) were associated with reduced overall response rate (ORR) (4."5.46The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. ( Antoniotti, C; Cascinu, S; Cremolini, C; Demurtas, L; Falcone, A; Gelsomino, F; Giampieri, R; Loretelli, C; Mandolesi, A; Masi, G; Meriggi, F; Pusceddu, V; Puzzoni, M; Scartozzi, M; Zaniboni, A; Ziranu, P, 2017)
"Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab."5.46Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. ( Bibeau, F; Del Rio, M; Emile, JF; Gongora, C; Martineau, P; Mollevi, C; Robert, J; Roger, P; Selves, J; Tubiana-Mathieu, N; Vie, N; Ychou, M, 2017)
"Capecitabine is an oral fluoropyrimidine, and administration of oxaliplatin does not necessarily require the insertion of a central venous access device (CVAD)."5.43Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer. ( André, T; Bonnet, I; Bouché, O; Boucher, E; Chibaudel, B; Dauba, J; Faroux, R; Garcia, ML; Guering-Meyer, V; Hug de Larauze, M; Lapeyre-Prost, A; Lièvre, A; Malka, D; Obled, S; Taieb, J; Ychou, M, 2016)
"Capecitabine is a chemotherapeutic agent used in the treatment of metastatic colon cancer and metastatic breast cancer."5.43Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy. ( Aladağ, E; Karakulak, UN; Maharjan, N; Övünç, K, 2016)
"Here we will show that, in a colorectal cancer patient cohort, both poor and ultra-rapid metabolizers have significantly increased the risk of developing severe toxicity (grade3-4)."5.43Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort. ( Borro, M; Botticelli, A; Gentile, G; La Torre, M; Lionetto, L; Marchetti, L; Marchetti, P; Mazzotti, E; Mazzuca, F; Simmaco, M, 2016)
" We evaluated treatment-related adverse events (AEs), progression-free survival (PFS) and overall survival (OS)."5.43Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer. ( Abdullah, NM; Sharial, MM; Yusof, MM; Zaatar, A, 2016)
"Treatment with lenalidomide reduced tumor vessel density (p = 0."5.43Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. ( Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L, 2016)
"Among the advanced colorectal cancer patients who received treatment with FOLFOX or FOLFIRI at Koyama Memorial Hospital, patients older than 65 years of age were selected in order to assess the effectiveness of aprepitant as an antiemetic supportive therapy."5.43[Study of the Efficacy of Aprepitant in FOLFOX/FOLFIRI for Elderly Patients with Advanced Colorectal Cancer]. ( Hanaka, J; Nakayama, H; Takahashi, M; Terashima, T, 2016)
"However, the expression of tmTNF-α in colorectal cancer (CRC) and its association with clinical outcome in CRC have remained unclear."5.43Molecular correlates and prognostic value of tmTNF-α expression in colorectal cancer of 5-Fluorouracil-Based Adjuvant Therapy. ( Huang, K; Li, N; Li, X; Liu, C; Ma, J; Ming, L; Ren, H; Sun, X; Wang, S; Xu, M, 2016)
"Most colorectal cancer (CRC) cell lines are identified to overexpress phosphoserine phosphatase (PSPH), which regulates the intracellular synthesis of serine and glycine, and supports tumor growth."5.43Inhibition of phosphoserine phosphatase enhances the anticancer efficacy of 5-fluorouracil in colorectal cancer. ( Li, X; Xun, Z; Yang, Y, 2016)
"Andrographolide is a natural diterpenoid from Andrographis paniculata which has anti-bacterial, anti-antiviral and anti-inflammation activities."5.43Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression. ( Fu, Z; Gao, J; Gu, Y; Guo, W; Li, L; Liu, W; Shu, Y; Sun, Y; Wang, W; Xu, Q, 2016)
"Capecitabine is an oral 5-fluorouracil (5-FU) pro-drug commonly used to treat colorectal carcinoma and other tumours."5.42A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. ( Carracedo, A; Castells, A; Castellvi-Bel, S; Domingo, E; Fernández-Rozadilla, C; Freeman-Mills, L; Gonzalez-Neira, A; Howarth, K; Johnstone, E; Jones, A; Julier, P; Kaur, K; Kerr, D; Kerr, R; Love, S; Martin, M; Pagnamenta, A; Palles, C; Pita, G; Rosmarin, D; Ruiz-Ponte, C; Scudder, C; Taylor, J; Tomlinson, I; Wang, H, 2015)
"Using the Tet-OFF system and a human colorectal cancer cell line, DLD-1, we first constructed an in vitro system in which TS expression is dynamically controllable."5.42Dynamic modulation of thymidylate synthase gene expression and fluorouracil sensitivity in human colorectal cancer cells. ( Fukushima, M; Hattori, H; Kawabata, R; Maehara, Y; Nakao, S; Oda, S; Taguchi, K; Uchida, J; Wakasa, K; Yamanaka, T, 2015)
"The role of MCTs in the survival of colorectal cancer (CRC) cells is scarce and poorly understood."5.42Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells. ( Amorim, R; Baltazar, F; Miranda-Gonçalves, V; Moyer, MP; Pereira, H; Pinheiro, C; Preto, A, 2015)
"However, the role of KLF8 in colorectal cancer remains unknown."5.42Suppression of KLF8 induces cell differentiation and sensitizes colorectal cancer to 5-fluorouracil. ( Bai, Y; Chen, C; Chen, Y; Cheng, T; Liu, S; Luo, X; Peng, Y; Shi, X; Wang, J; Wu, Y; Yan, Q; Zhang, M; Zhang, W; Zhang, Y; Zhao, J, 2015)
"Most liver metastases from colorectal cancer (CRC) are unresectable at diagnosis."5.42Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial. ( Artru, P; Chalabreysse, P; Desramé, J; Lledo, G; Marsot, J; Mithieux, F; Pellerin, O; Pernot, S; Taieb, J; Watkin, E, 2015)
"However, the potential role of GA in colorectal cancer and its ability to overcome the chemotherapeutic resistance in CRC cells have not been well studied."5.42Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells. ( Chen, J; Huang, L; Iwamoto, A; Li, W; Lin, M; Liu, H; Lu, B; Rutnam, ZJ; Wang, Z; Wen, C; Yang, X, 2015)
"Because the serum concentration of 5-FU fluctuates and displays various patterns, the dosage should not be based on body surface area."5.42Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer. ( Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Okumura, H; Tohyama, K; Tsuruta, A, 2015)
"We present 2 patients with metastatic colorectal cancer who had progressed despite treatment with first-line FOLFOX and second-line FOLFIRI combination chemotherapy regimens."5.42Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. ( El-Deiry, WS; Marks, EI; Scicchitano, A; Tan, C; Yang, Z; Zhang, J; Zhou, L, 2015)
"The XELAVIRI trial compared sequential (fluoropyrimidine and bevacizumab; irinotecan (Iri) at progression) versus initial combination therapy (fluoropyrimidine, bevacizumab, Iri) of treatment-naïve metastatic colorectal cancer (mCRC)."5.41Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). ( Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kumbrink, J; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schuster, V; Schwaner, I; Stahler, A; Stintzing, S, 2021)
" CASE REPORT We report the case of a patient who was diagnosed with stage IV colorectal cancer and who underwent chemotherapy with a high dose of 5-FU as part of the FOLFIRI (Folinic Acid, Fluorouracil, Irinotecan) treatment plan."5.41Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review. ( Gofir, A; Hutajulu, SH; Nugroho, DB; Yuwono, KA, 2023)
"Aflibercept; a decoy receptor for vascular endothelial growth factors (VEGFs) and placental growth factor (PLGF), in combination with FOLFIRI (leucovorin calcium, fluorouracil, irinotecan hydrochloride) chemotherapy regime, was FDA approved in 2012 as second-line salvage chemotherapy for metastatic colorectal cancer (mCRC)."5.41A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety. ( Chorawala, MR; Patel, RS; Thakur, A, 2023)
"Although 5‑fluorouracil (5‑FU)‑based chemotherapy is the major treatment for colorectal cancer, it has disadvantages such as systemic toxicity, lack of effectiveness and selectivity, and development of resistance."5.415‑Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review). ( Al Doghaither, HA; Al-Ghafari, AB; Alzahrani, SM; Pushparaj, PN, 2023)
" This article presents a systematic review of studies evaluating the efficacy and safety of chemotherapy regimens combining fluorouracil and standard or low-dose leucovorin in treating colorectal cancer."5.41High vs. low-dose leucovorin in regimens with fluorouracil in colorectal cancer therapy. ( Goněc, R; Juřica, J; Šuverová, P; Synek, S; Turjap, M, 2023)
" The trial TyRosine kinase Inhibitor for the treatment of Chemorefractory Colorectal Cancer (TRICC-C) trial evaluates the addition of nintedanib to mFOLFOX6 (fluorouracil, folinic acid and oxaliplatin) in patients with metastatic colorectal cancer (mCRC)."5.41Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111). ( Berger, AW; Büchner-Steudel, P; Decker, T; Ettrich, TJ; Güthle, M; Hannig, CV; Hebart, HF; Heinemann, V; Hermann, PC; Herrmann, T; Hoffmann, T; Hofheinz, RD; Perkhofer, L; Seufferlein, T, 2021)
"Irinotecan/5-fluorouracil (5-FU; FOLFIRI) or oxaliplatin/5-FU (FOLFOX), combined with bevacizumab or cetuximab, are approved, first-line treatments for metastatic colorectal cancer (mCRC)."5.41Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance). ( Auman, JT; Bertagnolli, MM; Blanke, CD; Casey, G; Etheridge, AS; Furukawa, Y; Howell, SD; Innocenti, F; Jiang, C; Kubo, M; Lenz, HJ; McLeod, HL; Ou, FS; Owzar, K; Parker, JS; Patil, SA; Plummer, SJ; Ratain, MJ; Sibley, AB; Venook, AP, 2021)
"The aim was to explore the correlation between increasing doses of [6R]-5,10-methylenetetrahydrofolate (arfolitixorin) and plasma concentrations of deoxyuridine (dUr) in patients with metastatic colorectal cancer (mCRC), subjected to 5-fluorouracil (5-FU)-based chemotherapy."5.41Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin. ( Carlsson, G; Gustavsson, B; Odin, E; Taflin, H; Tell, R; Wettergren, Y, 2021)
"The multicenter, open-label, randomized, phase III EPIC study (EMR 062202-025) investigated cetuximab plus irinotecan versus irinotecan in patients with epidermal growth factor receptor-detectable metastatic colorectal cancer (mCRC) that progressed on first-line fluoropyrimidine- and oxaliplatin-based chemotherapy; we report the outcomes of patients with RAS-wild-type (wt) disease."5.41Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. ( Burris, H; Chen, W; Eng, C; Esser, R; Lenz, HJ; Middleton, G; Nippgen, J; Scheithauer, W; Sobrero, A, 2021)
" We analyzed the differential impact of PPI use on capecitabine and fluorouracil using the data set from the AXEPT trial, a phase III randomized trial that demonstrated the noninferiority of mXELIRI (modified XELIRI: capecitabine plus irinotecan) to FOLFIRI (leucovorin, fluorouracil, and irinotecan), either with or without bevacizumab in patients with metastatic colorectal cancer."5.41Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT). ( Kang, J; Kim, SY; Kim, TW; Lee, JS; Morita, S; Muro, K; Park, YS; Sakamoto, J; Xu, RH, 2021)
"In patients with metastatic colorectal cancer (mCRC) refractory to standard therapies, S-1 plus raltitrexed showed a good objective response rate (ORR) and significant survival benefit in our previous study."5.41Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study. ( Bi, F; Cao, D; Chen, Y; Cheng, K; Gou, HF; Li, Q; Li, ZP; Liu, JY; Luo, DY; Qiu, M; Shen, YL; Wang, X; Yang, Y; Zhou, YW, 2021)
"The aim of the present study was to characterize the pharmacokinetics of irinotecan and its four main metabolites (SN-38, SN-38G, APC and NPC) in metastatic colorectal cancer patients treated with FOLFIRI and FOLFIRINOX regimens and to quantify and explain the inter-individual pharmacokinetic variability in this context."5.41Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen. ( Barbolosi, D; Deyme, L; Evrard, A; Gattacceca, F; Mbatchi, LC; Tubiana-Mathieu, N; Ychou, M, 2021)
"The purpose was to determine whether adding Pmab versus no Pmab to an adjuvant regimen of hepatic arterial infusion (HAI) of floxuridine (FUDR) plus systemic (SYS) leucovorin, fluorouracil, and irinotecan (FOLFIRI) improves 15-month recurrence-free survival for patients with RAS wild-type colorectal cancer."5.41A Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Therapy With or Without Panitumumab After Hepatic Resection of KRAS Wild-type Colorectal Cancer. ( Capanu, M; Chatila, WK; Chou, JF; Connell, LC; D'Angelica, MI; Jarnagin, WR; Kemeny, NE; Kingham, TP; Sanchez-Vega, F; Shi, H, 2021)
"Irinotecan, a topoisomerase inhibitor, is a common cytotoxic agent prescribed for metastatic colorectal cancer (mCRC) patients."5.41A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab. ( Chang, TK; Chen, PJ; Chen, YC; Cheng, TL; Chuang, KH; Huang, CW; Li, CC; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yin, TC, 2021)
"The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6)/capecitabine and oxaliplatin (CapeOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC)."5.41Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III ( Baba, H; Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, Y; Komatsu, Y; Kotake, M; Morita, S; Nakamura, M; Ohori, H; Sakashita, A; Sato, A; Shimada, K; Takahashi, M; Takahashi, S; Takashima, A; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2021)
"The phase III AXEPT study showed the noninferiority of modified capecitabine plus irinotecan (mXELIRI) with or without bevacizumab relative to fluorouracil, leucovorin, and irinotecan (FOLFIRI) with or without bevacizumab as a second-line treatment for metastatic colorectal cancer."5.41Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer. ( Ahn, JB; Bai, L; Cho, SH; Fang, WJ; Han, SW; Hong, YS; Iwasa, S; Kim, TW; Kotaka, M; Lee, KW; Matsuoka, H; Morita, S; Muro, K; Nakamura, M; Nishina, T; Park, YS; Sakamoto, J; Yamada, Y; Yuan, XL; Yuan, Y; Zhang, DS, 2021)
" Eligible patients aged ≥70 with unresectable metastatic, untreated, RAS/BRAF wildtype metastatic colorectal cancer will be randomised 1:1 to receive panitumumab alone or panitumumab plus infusional 5-fluorouracil."5.41MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). ( Bailey, L; Briscoe, K; Burge, M; Caird, S; Chantrill, L; Cuff, J; Espinoza, D; Francesconi, A; Karapetis, C; Ladwa, R; Pavlakis, N; Price, T; Segelov, E; Shannon, J; Siu, HWD; Sjoquist, K; Srivastav, R; Steer, C; Tebbutt, N; Thavaneswaran, S; Tie, J; Wilson, K; Wuttke, M; Yip, S, 2021)
"Berberine is an alkaloid isolated from the Chinese herbal medicine Huanglian, and has long been used as an antibiotic."5.40Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. ( Cai, Y; Huang, P; Jiang, W; Luo, R; Shi, Y; Sun, Y; Xia, Q, 2014)
"Gefitinib was cytostatic."5.40Gefitinib enhances the effects of combined radiotherapy and 5-fluorouracil in a colorectal cancer cell line. ( Aristei, C; Calzuola, M; Cecchini, D; Contavalli, P; Falzetti, F; Marini, V; Palumbo, I; Piattoni, S; Valentini, V; Vecchio, FM, 2014)
"We enrolled 234 patients with Stage III colorectal cancer who underwent curative resection."5.40Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status. ( Fukazawa, S; Hase, K; Hashiguchi, Y; Kubo, T; Naito, Y; Okamoto, K; Shikina, A; Shinto, E; Ueno, H; Yamamoto, J, 2014)
"Cinnamaldehyde is an active monomer isolated from the stem bark of Cinnamomum cassia, a traditional oriental medicinal herb, which is known to possess marked antitumor effects in vitro and in vivo."5.40Cinnamaldehyde/chemotherapeutic agents interaction and drug-metabolizing genes in colorectal cancer. ( Liu, SL; Qi, MH; Yu, C; Zou, X, 2014)
"5-Fluorouracil (5-FU) is a first line chemotherapeutic medication used in the treatment of gallbladder cancer; however, the efficacy is below satisfactory."5.40Icariin-mediated inhibition of NF-κB activity enhances the in vitro and in vivo antitumour effect of 5-fluorouracil in colorectal cancer. ( Cai, GX; Cai, SJ; Gu, WL; Guan, ZQ; Li, DW; Li, XX; Peng, JJ; Shi, DB; Xu, Y; Zheng, HT, 2014)
"0144) adverse effects in stage II/III patients."5.40Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens. ( Beachler, C; El-Deiry, WS; Harvey, HA; Kline, CL; Mackley, HB; McKenna, K; Messaris, E; Poritz, L; Schiccitano, A; Sheikh, H; Sivik, J; Staveley-O'Carroll, K; Stewart, D; Zhu, J, 2014)
"A total of 102 metastatic colorectal cancer patients treated with a oxaliplatin (XELOX) ±Bevacizumab combination were retrospectively evaluated."5.40Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy. ( Berk, V; Bozkurt, O; Duran, AO; Inanc, M; Karaca, H; Ozaslan, E; Ozkan, M, 2014)
"A primary challenge in identifying replicable pharmacogenomic markers from clinical genomewide association study (GWAS) trials in oncology is the difficulty in performing a second large clinical trial with the same drugs and dosage regimen."5.40Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses. ( Alba, E; Alonso, R; de la Torre-Montero, JC; Dolan, ME; González-Neira, A; Lopez-Fernandez, LA; Martín, M; Pita, G; Wheeler, HE, 2014)
"Colorectal cancer metastasis is a major cause of mortality worldwide, which may only be controlled with novel methods limiting tumor dissemination and chemoresistance."5.40Unbiased proteomic and transcript analyses reveal that stathmin-1 silencing inhibits colorectal cancer metastasis and sensitizes to 5-fluorouracil treatment. ( Chung, MC; Lim, TK; Tan, HT; Tan, XF; Wu, W, 2014)
"Sampling of saliva is a quick, noninvasive, safe and painless process that gives information about patients Ura and UH₂ levels prior to chemotherapeutical treatment."5.40Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2014)
" A randomized trial showed increased OS and decreased toxicity with PK-guided compared with BSA-based 5-FU dosing in patients with mCRC."5.40Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer. ( Ayer, T; Chen, Q; El-Rayes, BF; Flowers, CR; Goldstein, DA; Harvey, RD; Howard, DH; Lipscomb, J, 2014)
" All patients were genotyped for MTHFR 1298A>C and 677C>T polymorphisms and analysed in both cohorts separately for the association between the MTHFR genotype and incidence of grade 3-4 overall toxicity and specific adverse events, as well as efficacy parameters."5.39MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer. ( Gelderblom, H; Guchelaar, HJ; Punt, CJ; van Huis-Tanja, LH, 2013)
"5-fluorouracil (5-FU) has been widely used since the 1980s, and it remains the backbone of many chemotherapeutic combination regimens."5.39DMET™ (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity. ( Amadori, A; Boldrin, E; Rumiato, E; Saggioro, D, 2013)
" Clinical data demonstrated that there was higher correlation between DPD activity and toxic effects of 5-FU (p<0."5.39Evaluation of clinical value of single nucleotide polymorphisms of dihydropyrimidine dehydrogenase gene to predict 5-fluorouracil toxicity in 60 colorectal cancer patients in China. ( Lu, Z; Sun, B; Zhang, X, 2013)
"In 5-fluorouracil (5-FU)-treated patients, the tumour overexpression of SOX9 correlated with markedly poorer survival (HR=8."5.39Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients. ( Candy, PA; Colley, SM; Davidson, JA; Leedman, PJ; Phillips, MR; Redfern, AD; Stuart, LM; Wood, BA; Zeps, N, 2013)
" Pharmacogenotyping is therefore recommended to guide dosing of 5-FU and prevent neutropenia."5.39Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients. ( Bannur, Z; Fijeraid, H; Hamzah, S; Hasbullani, Z; Hashim, H; Md Nor, A; Ngow, H; Ramasamy, P; Salleh, MZ; Shia, JK; Sood, S; Teh, LK; Zailani, M; Zakaria, ZA, 2013)
"Elderly patients with metastatic colorectal cancer (mCRC) differ from the general population and are underrepresented in clinical trials."5.39Oxaliplapin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients. ( Aprile, G; Bearz, A; Berretta, M; Borsatti, E; Canzonieri, V; Ferrari, L; Fiorica, F; Fisichella, R; Foltran, L; Lestuzzi, C; Lleshi, A; Lutrino, S; Nasti, G; Talamini, R; Tirelli, U; Urbani, M, 2013)
"Capecitabine is a member of the fluoropyrimidine family of chemotherapeutic agents that selectively delivers 5-fluorouracil (5-FU) to tumors."5.38Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm. ( Rather, A; Shah, A; Shah, NR, 2012)
"Population-based studies of adverse events are scarce."5.38Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. ( Cen, P; Du, XL; Liu, C, 2012)
", Salt Lake City, UT) that measures plasma 5-FU concentration and reports an AUC in mg · h/L has been developed to optimize therapy using pharmacokinetic (PK) dosing."5.38Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. ( Grier, CE; Hamilton, SA; Haregewoin, A; Kaldate, RR; McLeod, HL, 2012)
" We also observed bioavailability of ursolic acid in the serum and tissue of animals."5.38Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine. ( Aggarwal, BB; Baladandayuthapani, V; Deorukhkar, A; Diagaradjane, P; Guha, S; Kannappan, R; Krishnan, S; Prasad, S; Reuter, S; Sung, B; Wei, C; Yadav, VR, 2012)
"Patients with CIMP-positive colorectal tumors do not benefit from 5-FU-based adjuvant chemotherapy."5.375-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. ( Alenda, C; Andreu, M; Balaguer, F; Bessa, X; Boland, CR; Bujanda, L; Castells, A; Clofent, J; Cubiella, J; Goel, A; Jover, R; Llor, X; Morillas, JD; Nguyen, TP; Nicolás-Pérez, D; Payá, A; Pérez-Carbonell, L; Reñé, JM; Rojas, E; Xicola, RM; Zapater, P, 2011)
"In metastatic colorectal cancer patients treated with mFolfox-6, the combination of haplotype XPD Lys751Gln-GSTP1 105Val seems to predict the risk of progression."5.37Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. ( Balboa, E; Barros, F; Bernardez, B; Carracedo, A; Duran, G; Gallardo, E; Lamas, MJ; Lopez, R; Touris, M; Vidal, Y, 2011)
" The drug combination elevated the plasma level of PHT in a patient on chemotherapy with capecitabine for colorectal cancer."5.37[A case of toxicity caused by drug interaction between capecitabine and phenytoin in patient with colorectal cancer]. ( Fukui, E; Kawahara, K; Sakurai, M; Ueda, R; Yamada, R, 2011)
"Acriflavine was active in cell spheroids, indicating good drug penetration and activity against hypoxic cells."5.37Novel activity of acriflavine against colorectal cancer tumor cells. ( Fayad, W; Felth, J; Fryknäs, M; Glimelius, B; Graf, W; Gullbo, J; Hassan, S; Larsson, R; Laryea, D; Linder, S; Mahteme, H; Nygren, P; Påhlman, L; Rickardson, L, 2011)
"Capecitabine is an oral fluoropyrimidine that was designed to allow selective activation in tumour tissues, thus reducing toxicity."5.36Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer. ( Ahmad, A; Gounaris, I, 2010)
"Here we adapted an orthotopic colorectal cancer model, in which HT-29 colorectal cancer cells form tumors in the rectal lining and metastasize to the para-aortic lymph nodes with high frequency."5.36Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging. ( Prewett, M; Steiner, P; Surguladze, D; Tonra, JR, 2010)
"Colorectal cancer is the most common form of malignancy in Taiwan and the third leading cause of death from cancer, preceded only by lung and hepatic cancers."5.36rTSbeta as a novel 5-fluorouracil resistance marker of colorectal cancer: a preliminary study. ( Chow, KC; Lin, YL, 2010)
"Capecitabine is an oral fluoropyrimidine which is transformed to 5-Fluorouracil inside tumor cells, where it achieves high drug concentrations."5.36Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect? ( Emiliani, A; Losanno, T; Manna, G; Seminara, P, 2010)
"We compared clinical outcome and pharmacokinetic (pK) parameters of a new pharmacokinetically-guided dosing strategy in two groups of patients (age < or >65 years) with metastatic colorectal cancer (mCRC)."5.36Clinical impact of intesified 5-Fluorouracil-based chemotherapy using a prospective pharmacokinetically-guided dosing approach: comparative study in elderly and non-elderly patients with metastatic colorectal cancer. ( Abderrahim, AG; Bressolle, F; Duffour, J; Pinguet, F; Poujol, S; Roca, L; Ychou, M, 2010)
"Colorectal cancer is (CRC) one of the commonest cancers and its therapy is still based on few drugs."5.365-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency. ( Bodmer, WF; Bracht, K; Liu, Y; Nicholls, AM, 2010)
"Colorectal cancer is one of the leading malignancies in the world."5.36Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer. ( Fu, ZX; Shen, W; Tu, JK; Wang, XH, 2010)
" Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment."5.35A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. ( Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E, 2009)
"Capecitabine is a chemotherapeutic prodrug that is metabolised to 5-fluorouracil."5.35Coronary spasm induced by capecitabine mimicks ST elevation myocardial infarction. ( Curzen, NP; Ferchow, L; Hobson, A; Scott, PA, 2008)
"Patients with colorectal cancer that had recurred, following surgery and adjuvant chemotherapy and underwent a second operation were included in the present study."5.35Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy. ( Agrogiannis, G; Arapogiannis, G; Gouveris, P; Kavantzas, N; Kopterides, P; Kosmas, C; Kyriakou, V; Lazaris, A; Papathomas, T; Patsouris, E; Tsavaris, N; Zorzos, H, 2009)
"Using HCT-116 human colorectal cancer cells, we compared the efficacy of WG and RG."5.35Asian ginseng enhances the anti-proliferative effect of 5-fluorouracil on human colorectal cancer: comparison between white and red ginseng. ( Aung, HH; Fishbein, AB; Li, XL; Mehendale, SR; Sun, S; Wang, CZ; Yuan, CS, 2009)
" Coadministration of S-1 changed the pharmacokinetic behavior of CPT-11 and its metabolites."5.35Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer. ( Hamada, A; Saito, H; Sasaki, Y; Tazoe, K; Yokoo, K, 2009)
" Grade 3 or 4 hematological toxicities were leukocytopenia in four patients, and neutropenia in 12 patients, while non-hematological toxicities such as nausea, anorexia and sensory neuropathy occurred in only one patient each adverse event."5.35The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer. ( Hattori, M; Honda, I; Kato, N; Kobayashi, D; Matsushita, H; Okochi, O; Tsuboi, K, 2009)
"To understand the mechanisms of the effects of combination treatments, we established animal models showing antitumor activity of bevacizumab as a monotherapy and in combination with capecitabine or capecitabine and oxaliplatin and measured thymidine phosphorylase (TP) and vascular endothelial growth factor (VEGF) levels."5.35Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models. ( Fujimoto-Ouchi, K; Mori, K; Yamashita, Y; Yanagisawa, M; Yorozu, K, 2009)
"Both regorafenib and reduced-intensity FOLFOXIRI (riFOLFOXIRI) prolong survival in patients with metastatic colorectal cancer (mCRC)."5.34Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. ( Chang, SC; Chao, Y; Chen, WS; Cheng, HH; Huang, SC; Jiang, JK; Lan, YT; Lin, CC; Lin, HH; Tai, CC; Teng, HW; Wang, HS; Yang, SH, 2020)
"Cetuximab plus leucovorin, fluorouracil and oxaliplatin (FOLFOX-4) is superior to FOLFOX-4 alone as a first-line treatment for patients with metastatic colorectal cancer with RAS wild-type (RAS wt mCRC), with significantly improved survival benefit by TAILOR, an open-label, randomised, multicentre, phase III trial."5.34Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial. ( Ding, H; Fang, L; Gao, P; Huang, L; Wang, H; Ye, W; Zhu, Z, 2020)
"The addition of oxaliplatin to the standard 6-month fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer has been reported to reduce the risk of relapse although it does not increase survival."5.34Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial. ( Banzi, M; Cardellino, GG; Cinieri, S; Ciuffreda, L; Corallo, S; Corsi, D; Galli, F; Labianca, R; Lonardi, S; Maiello, E; Mambrini, A; Marchetti, P; Mattioli, R; Petrelli, F; Pusceddu, V; Rimassa, L; Ronzoni, M; Rosati, G; Rulli, E; Sobrero, A; Zagonel, V; Zampino, M; Zaniboni, A, 2020)
"BACKGROUND The aim of this study was to perform an accurate exploration on the efficacy of oxaliplatin/5-fluorouracil/capecitabine-cetuximab combination therapy and its effects on K-Ras mutations in advanced colorectal cancer."5.34Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer. ( Chen, J; Chen, Z; Huang, J; Ma, X; Wei, L; Wen, J; Wu, D, 2020)
"Biweekly schedule of XELOX-2 (capecitabine plus oxaliplatin) showed interesting results in first-line therapy of patients with metastatic colorectal cancer (mCRC)."5.34Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802). ( Aieta, M; Bordonaro, R; Cinieri, S; Colucci, G; Cordio, S; Di Maggio, G; Di Maio, M; Febbraro, A; Giuliani, F; Latiano, TP; Maiello, E; Pisconti, S; Rinaldi, A; Rizzi, D; Rossi, A, 2020)
"Fluorouracil and leucovorin combined with oxaliplatin or irinotecan plus bevacizumab (Bmab) or cetuximab (Cmab) are now widely accepted treatment options as first-line or second-line chemotherapy for metastatic colorectal cancer (mCRC)."5.34Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial. ( Doi, S; Fujiwara, H; Kawamura, T; Mikami, R; Nakamoto, Y; Noda, M; Okumoto, T; Tokunaga, Y; Tomita, N, 2020)
" 130 male and 63 female eligible patients with metastatic colorectal cancer were randomized to receive chronomodulated Irinotecan with peak delivery rate at 1 of 6 clock hours staggered by 4 hours on day 1, then fixed-time chronomodulated Fluorouracil-Leucovorin-Oxaliplatin for 4 days, q3 weeks."5.34Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial. ( Adam, R; Ballesta, A; Bouchahda, M; Chollet, P; Focan, C; Garufi, C; Giacchetti, S; Huang, Q; Innominato, PF; Karaboué, A; Lévi, FA, 2020)
"We designed an open-label, noncomparative phase II study to assess the safety and efficacy of first-line treatment with trifluridine/tipiracil plus bevacizumab (TT-B) and capecitabine plus bevacizumab (C-B) in untreated patients with unresectable metastatic colorectal cancer (mCRC) who were not candidates for combination with cytotoxic chemotherapies."5.34Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study. ( Amellal, N; Argilés, G; Aubel, P; Borg, C; Danielewicz, I; Egorov, A; Falcone, A; Fedyanin, M; Garcia-Alfonso, P; Glynne-Jones, R; Kanehisa, A; Kroening, H; Moiseenko, V; Pfeiffer, P; Punt, CJA; Saunders, MP; Stroyakovskiy, D; Van Cutsem, E; Van de Wouw, AJ; Wasan, H, 2020)
"Chemo-embolisation with drug-eluting beads loaded with irinotecan (DEBIRI) increased survival as compared with intravenous irinotecan in chemorefractory patients with liver-dominant metastases from colorectal cancer (LMCRC)."5.34Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. ( Artru, P; Dahan, L; De La Fouchardière, C; Guimbaud, R; Jouve, JL; Lepage, C; Montérymard, C; Pellerin, O; Pernot, S; Raoul, JL; Sefrioui, D; Smith, D; Taieb, J; Tougeron, D, 2020)
"Cetuximab has been shown to be clinically active when given in combination with irinotecan in patients with irinotecan-refractory metastatic colorectal cancer (mCRC)."5.34Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). ( Baba, E; Boku, N; Denda, T; Esaki, T; Fujii, H; Goto, M; Hara, H; Hironaka, S; Hosokawa, A; Hyodo, I; Ishida, H; Kadowaki, S; Kishimoto, J; Koh, Y; Kuramochi, H; Makiyama, A; Matsumoto, S; Moriwaki, T; Muro, K; Nishina, T; Okuda, H; Otsu, S; Ozaki, Y; Sakai, D; Sakamoto, T; Sato, M; Satoh, T; Shimokawa, H; Shinozaki, K; Sugimoto, N; Tamagawa, H; Tamura, T; Taniguchi, H; Tokunaga, S; Tsuda, T; Tsuji, A; Tsushima, T; Yamazaki, K; Yasui, H, 2020)
"Twenty-eight colorectal cancer patients who received infusional 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) therapy were randomly and evenly assigned to the cystine and theanine group and the control group."5.34Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial. ( Abe, T; Akazawa, N; Hirashima, T; Ichikawa, H; Kakita, T; Kobayashi, M; Komura, T; Oikawa, M; Okada, T; Otake, S; Sato, R; Tsuchiya, T; Yazawa, T, 2020)
"To evaluate the safety and tolerability of escalating doses of selinexor plus 5-fluorouracil, leucovorin and oxaliplatin (mFOLFOX6) in metastatic colorectal cancer (mCRC) patients."5.34Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL. ( Amberg, S; Bokemeyer, C; Kranich, AL; Mann, J; Nilsson, S; Papadimitriou, K; Rolfo, C; Stein, A; Theile, S, 2020)
"The addition of aflibercept (AFL) or ramucirumab (RAM) to folinic acid, fluorouracil, and irinotecan (FOLFIRI) prolongs overall survival and progression-free survival compared with FOLFIRI alone in patients with metastatic colorectal cancer (mCRC) as second-line therapy."5.34Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan. ( Kashiwa, M; Matsushita, R, 2020)
"The phase III West Japan Oncology Group (WJOG) 4407G study showed noninferiority of folinic acid, bolus/continuous fluorouracil, and irinotecan plus bevacizumab to modified folinic acid, bolus/continuous fluorouracil, and oxaliplatin 6 plus bevacizumab in progression-free survival (PFS) as first-line chemotherapy for patients with metastatic colorectal cancer."5.34Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study. ( Hironaka, S; Hosokawa, A; Kusaba, H; Matsuda, C; Morita, S; Muro, K; Okamura, S; Shinozaki, K; Shirakawa, T; Tamura, T; Tsuda, M; Tsuda, T; Tsushima, T; Ueda, S; Yamashita, H; Yamazaki, K, 2020)
"FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) + aflibercept improves median overall survival (OS) and progression-free survival (PFS) in patients with previously treated metastatic colorectal cancer (mCRC)."5.34Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302). ( Aparicio, T; Caroli-Bosc, FX; Dahan, L; Desrame, J; Doat, S; Lapeyre-Prost, A; Le Malicot, K; Lecomte, T; Lepage, C; Marthey, L; Mary, F; Pernot, S; Sigrand, J; Taieb, J, 2020)
"In this phase 3, open-label trial, 307 patients with metastatic MSI-H-dMMR colorectal cancer who had not previously received treatment were randomly assigned, in a 1:1 ratio, to receive pembrolizumab at a dose of 200 mg every 3 weeks or chemotherapy (5-fluorouracil-based therapy with or without bevacizumab or cetuximab) every 2 weeks."5.34Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. ( André, T; Benavides, M; Bendell, J; de la Fouchardiere, C; Diaz, LA; Elez, E; Farooqui, MZH; Garcia-Carbonero, R; Gibbs, P; Jensen, BV; Jensen, LH; Kim, TW; Le, DT; Marinello, P; Punt, C; Rivera, F; Shiu, KK; Smith, D; Van Cutsem, E; Yang, P; Yoshino, T, 2020)
"5-Fluorouracil (5-FU) is a chemotherapeutic agent for the treatment of colorectal cancer that interferes with the growth of cancer cells."5.34Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells. ( Aung, HH; He, TC; Luo, X; Mehendale, S; Ni, M; Song, WX; Wang, CZ; Xie, JT; Yuan, CS; Zhang, B, 2007)
"Familial Mediterranean Fever is a chronic hereditary disease which is relatively prevalent in the Middle East and is associated with recurrent episodes of serosal, synovial or cutaneous inflammations."5.34Adjuvant chemotherapy with 5-fluorouracil in a patient with colorectal cancer and Familial Mediterranean Fever. ( Brenner, B; Purim, O; Sulkes, A, 2007)
"Although colorectal cancer has the third highest cancer mortality rate, the treatment remains far from optimized with patients showing variable responses to standard treatment."5.33Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer. ( Kidd, EA; Li, X; McLeod, HL; Shannon, WD; Watson, MA; Yu, J, 2005)
"Gene expression profiling of 3 colorectal cancer cell lines (DLD-1, HT-29 and NUGC-3) and the corresponding 5-FU-resistant sublines (DLD-1/FU, HT-29/FU and NUGC-3/5FU/L) showed 81 genes that were differentially expressed."5.33Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays. ( Danenberg, PV; Hayasizaki, Y; Ichikawa, Y; Ishikawa, T; Okazaki, Y; Shimada, H; Shimizu, D; Togo, S, 2005)
"Metastatic/advanced colorectal cancer is considered a resistant disease and oncologic emergencies secondary to advanced disease may be regarded with a nihilistic attitude."5.33Oncologic emergencies secondary to advanced colorectal cancer successfully treated with oxaliplatin/5-fluorouracil/leucovorin: report of three cases. ( Anselmi, E; Bertè, R; Bidin, L; Cavanna, L; Civardi, G; Lazzaro, A; Moroni, CF; Palladino, MA; Rodinò, C; Vallisa, D, 2005)
"However, standard treatment for Dukes C colorectal cancer patients currently involves the administration of 5-fluorouracil (5-FU)-based adjuvant chemotherapy after surgery."5.33SMAD4 levels and response to 5-fluorouracil in colorectal cancer. ( Aaltonen, LA; Alazzouzi, H; Alhopuro, P; Arango, D; Dávalos, V; Hemminki, A; Järvinen, H; Mecklin, JP; Salovaara, R; Sammalkorpi, H; Schwartz, S, 2005)
"Irinotecan (CPT11) is a prodrug activated in humans mainly by carboxylesterase 2 (CES2) generating the SN38 metabolite responsible for the drug efficacy and toxicity."5.33Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. ( Biason, P; Buonadonna, A; Cattarossi, G; Cecchin, E; Colussi, A; Corona, G; Frustaci, S; Masier, S; Toffoli, G, 2005)
"Capecitabine is an oral prodrug to 5-fluorouracil (5-FU)."5.33Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma. ( Hoeffding, LD; Jakobsen, A; Lindebjerg, J; Nielsen, JN, 2005)
"The subjects were 31 patients with colorectal cancer who underwent surgical excision between December 2003 and July 2004 at our department."5.33The relationship between 5-fluorouracil sensitivity and single nucleotide polymorphisms of the orotate phosphoribosyl transferase gene in colorectal cancer. ( Hata, M; Kamano, T; Kitajima, M; Maeda, T; Ochiai, T; Sakamoto, K; Takita, N, 2006)
"Capecitabine was approved for funding in the province of British Columbia in the spring of 2002 as an oral chemotherapeutic option for metastatic CRC."5.33Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis. ( Gill, S; Ho, C; Ng, K; O'Reilly, S, 2005)
"The treatment of metastatic colorectal cancer by chemotherapy alone was considered palliative and without the potential to cure patients unless patients were rendered resectable."5.33Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases. ( Kemeny, NE; Leonard, GD, 2006)
"Microsatellite instability is a recognised pathway of colorectal carcinogenesis responsible for about 15% of all sporadic colorectal cancers."5.335-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer. ( Kaufman, A; Ramanathan, P; Robinson, BG; Schnitzler, M; Warusavitarne, J, 2006)
" Our data suggest that GSTT1-null is associated with a greater probability of developing toxicity to 5-Fu/CPT-11/Lv treatments, indicating a potential application of this genetic analysis in predicting adverse effects of this regimen."5.33Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients. ( Aranda, E; Bandres, E; De la Haba, J; Garcia, F; García-Foncillas, J; Gómez, A; Huarriz, M; Morales, R; Romero, RZ, 2006)
"Median time to disease progression was 9."5.32Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. ( Aparicio, J; Calderero, V; Díaz, R; Gironés, R; López-Tendero, P; Pérez-Fidalgo, JA; Segura, A; Yuste, AL, 2003)
"These data in a heavily pretreated patient population confirm that oxaliplatin is safe when used as a single agent or with a variety of FU-based regimens as salvage therapy in patients with advanced colorectal cancer."5.32Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. ( Clark, JW; Gococo, KO; Haller, DG; Kardinal, CG; Kemeny, NE; Lenz, HJ; Mitchell, EP; Ramanathan, RK, 2003)
"Patients with liver metastases of colorectal cancer were treated with 5-FU (500/600 mg/m)+folinic acid with or without trimetrexate."5.3219F-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil. ( Heerschap, A; Kamm, YJ; van den Bergh, EJ; Wagener, DJ, 2004)
"Patients with stage III/IV colorectal cancer were treated by bolus intravenous (I."5.32Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. ( Chabner, BA; Charlat, O; Clark, JW; Kelly, P; Kreconus, E; Nesbitt, S; Puchalski, TA; Ryan, DP; Stanton, VP; Supko, JG; Zhu, AX, 2004)
"Catheter-related deep venous thrombosis is a complication that can occur in patients receiving chemotherapy."5.32Upper extremity deep venous thrombosis in patients with 5-fluorouracil-containing adjuvant chemotherapy--three case reports and a review. ( Albertsson, M; Tham, J, 2004)
" We have examined the effect of this CDO alone and in combination with a range of common chemotherapeutic agents in colorectal cancer cell lines."5.32The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines. ( Liu, WM; Propper, DJ; Scott, KA; Shahin, S, 2004)
"We evaluated the cytotoxic effect of ZD0473 administered alone or in combination with 5-Fluorouracil (5FU) or SN38 in a panel of sensitive and 5FU-resistant colorectal cell lines (HT29/HT29-5FUR and LoVo/LoVo-5FUR)."5.32Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines. ( Abad, A; Martinez-Balibrea, E; Plasencia, C; Taron, M, 2004)
"Objective responses in colorectal cancer patients were: 1st-line MdG (22 assessable): PR=36%, NC=32%, PD=32%."5.31A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. ( Cheeseman, SL; Chester, JD; Dent, JT; Joel, SP; Richards, FJ; Seymour, MT; Wilson, G, 2002)
" In order to evaluate the clinical relevance of SMAD4 deletion, gene copy alterations were determined by copy dosage using real-time quantitative PCR in 202 colorectal tumour biopsies from a previous randomised study of adjuvant chemotherapy."5.31SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer. ( Boulay, JL; Herrmann, R; Laffer, U; Lagrange, M; Lowy, A; Mild, G; Reuter, J; Rochlitz, C; Terracciano, L, 2002)
"Cerivastatin may allow successful 5FU therapy in chemoresistant patients."5.31Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. ( Cassidy, J; Collie-Duguid, E; Wang, W, 2002)
"Colorectal carcinoma is one of the most common malignancies in the western world, and although fluorouracil (5-FU) has been used in its treatment for almost 40 years, new agents with significant activity have been introduced recently."5.31The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. ( Antoine, EC; Bastian, G; Gil-Delgado, M; Khayat, D; Nizri, D, 2001)
"It has previously been shown that colorectal cancer patients who are homozygous for the triple tandem repeats (L/L) have significantly higher thymidylate synthase mRNA expression than those homozygous for the double repeat variant (S/S)."5.31Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. ( Groshen, S; Lenz, HJ; Park, DJ; Stoehlmacher, J; Tsao-Wei, D; Zhang, W, 2002)
"Fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (FOLFOX) plus panitumumab therapy is a commonly used first-line chemotherapy for metastatic colorectal cancer (mCRC)."5.30SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer. ( Fukunaga, M; Kato, T; Kotaka, M; Kuramochi, H; Kuroda, H; Kurosawa, S; Minagawa, N; Mishima, H; Miura, T; Miwa, K; Munemoto, Y; Nagata, N; Nakamura, M; Noura, S; Oba, K; Sakamoto, J; Satake, H; Takahashi, M; Takahashi, T; Touyama, T, 2019)
"Combination of chemotherapies (fluoropirimidines, oxaliplatin and irinotecan) with biologic drugs (bevacizumab, panitumumab, cetuximab) have improved clinical responses and survival of metastatic colorectal cancer (mCRC)."5.30Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol. ( Albino, V; Amore, A; Avallone, A; Belli, A; Botti, G; Capozzi, M; Casaretti, R; Cassata, A; Chiodini, P; D'Alterio, C; De Feo, G; De Stefano, A; Delrio, P; Di Marzo, M; Izzo, F; Napolitano, M; Nappi, A; Nasti, G; Normanno, N; Ottaiano, A; Pace, U; Palaia, R; Petrillo, A; Picone, C; Portella, L; Rachiglio, AM; Roma, C; Romano, C; Scala, S; Silvestro, L; Tafuto, S; Tamburini, M; Trotta, AM, 2019)
"Regorafenib is an oral multikinase inhibitor for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, irinotecan, oxaliplatin, monoclonal antibodies targeting vascular endothelial growth factor, and monoclonal antibodies targeting epidermal growth factor receptor."5.30Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial. ( Chang, TK; Chang, YT; Huang, CW; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yeh, YS, 2019)
"Background This phase I/II trial evaluated toxicity and antitumor activity of everolimus plus mFOLFOX6 + bevacizumab for first-line treatment of metastatic colorectal cancer (mCRC)."5.30Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. ( Boucher, KM; Garrido-Laguna, I; McGregor, K; Orgain, N; Sharma, S; Stenehjem, DD; Thorne, K; Wade, ML; Weis, J; Weldon Gilcrease, G; Whisenant, J, 2019)
" The main eligibility criterion was disease progression after bevacizumab plus fluorouracil with irinotecan or oxaliplatin in patients with wild-type KRAS exon 2 metastatic colorectal cancer."5.30Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. ( Adenis, A; Artru, P; Bennouna, J; Bertaut, A; Borel, C; Borg, C; Bouché, O; Conroy, T; Denis, MG; Deplanque, G; des Guetz, G; François, E; Ghiringhelli, F; Hebbar, M; Hiret, S; Seitz, JF; Stanbury, T, 2019)
" As hydrogen gas was recently reported to activate PGC‑1α, the present study investigated whether it restores exhausted CD8+ T cells to improve prognosis in patients with stage IV colorectal cancer."5.30Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis. ( Akagi, J; Baba, H, 2019)
"First-line treatment for metastatic colorectal cancer (mCRC) typically entails a biologic such as bevacizumab (BEV) with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI)."5.30Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). ( Bendell, J; Hochster, HS; Hurwitz, HI; Lee, JJ; Lenz, HJ; Nicholas, A; Palma, JF; Price, R; Reeves, JA; Scappaticci, F; Somer, B; Sommer, N; Tan, BR; Xiong, H, 2019)
"A phase II trial (planned n=58) using second-line therapy for metastatic colorectal cancer with either oxaliplatin-based (mFOLFOX6) or irinotecan-based (FOLFIRI) combination chemotherapy and 100 mg erlotinib daily on days 3-8 after each infusion (days 1 and 2) every 14 days."5.30A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer. ( Burt, A; Chen, EY; Donovan, J; Kampa-Schittenhelm, KM; Kearney, MR; Lopez, CD; Strother, J; Todd, K; Vaccaro, GM, 2019)
"The study investigated the potential prophylactic effect of L-carnosine against acute oxaliplatin neurotoxicity in colorectal cancer patients with emphasis on the redox (Nrf-2, MDA), inflammatory (NF-κB, TNF-α), and apoptotic (caspase-3) parameters."5.30L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways. ( El Abhar, H; Saad, AS; Saleh, S; Schaalan, M; Yehia, R, 2019)
"Aflibercept in combination with 5‑fluorouracil (5‑FU)/irinotecan improves overall survival in the second‑line therapy of patients with metastatic colorectal cancer (mCRC)."5.30Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study. ( André, T; Auby, D; Bachet, JB; Bonnetain, F; Chibaudel, B; Dauba, J; De Gramont, A; Deplanque, G; Desramé, J; Dubreuil, O; Garcia, ML; Hamed, NB; Larsen, AK; Lebrun-Ly, V; Lecaille, C; Lledo, G; Louvet, C; Meurisse, A; Tijeras-Raballand, A; Tournigand, C, 2019)
"The 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX) regimen is the standard first-line treatment for metastatic colorectal cancer (mCRC), however, the optimal second-line regimen for KRAS wild-type mCRC patients is still investigational."5.30CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial. ( Bai, L; Bi, F; Chen, Y; Cheng, Y; He, X; Hu, X; Li, J; Li, Y; Liu, W; Liu, Y; Luo, Y; Ouyang, X; Qin, S; Shi, Y; Sun, G; Sun, Y; Wang, L; Wang, Z; Xu, J; Yao, Q; Zhang, Y; Zheng, R, 2019)
"Curcumin is a safe and tolerable adjunct to FOLFOX chemotherapy in patients with metastatic colorectal cancer."5.30Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial. ( Barber, S; Brown, K; Foreman, N; Gescher, A; Griffin-Teall, N; Howells, LM; Irving, GRB; Iwuji, COO; Morgan, B; Patel, SR; Sidat, Z; Singh, R; Steward, WP; Thomas, AL; Walter, H, 2019)
" This is the first clinical trial assessing safety and tolerability of Genistein in combination with chemotherapy in metastatic colorectal cancer."5.30Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study. ( Ang, C; Dharmupari, S; Holcombe, RF; Moshier, E; Pintova, S; Zubizarreta, N, 2019)
"Data from a trial of first-line panitumumab plus FOLFIRI (folinic acid, infusional 5-fluorouracil and irinotecan) in metastatic colorectal cancer were retrospectively analysed to investigate the effects of primary tumour location and early tumour shrinkage on outcomes."5.30Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab. ( Berkhout, M; Gallego, J; Hofheinz, RD; Karthaus, M; Köhne, CH; Koukakis, R; Mineur, L; Thaler, J; Van den Eynde, M, 2019)
" The mean total dosage was 6."5.30[Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine]. ( Baba, H; Kohnoe, S; Matsuoka, H; Morita, M; Saito, T; Seo, Y; Taketomi, A; Tomoda, H, 1997)
"Forty-six disseminated colorectal cancer patients had measurable tumor biopsies for polymerase chain reaction (PCR)-based determination of TS mRNA pretreatment."5.30Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. ( Baranda, J; Boswell, W; Danenberg, K; Danenberg, PV; Groshen, S; Leichman, CG; Leichman, L; Lenz, HJ; Metzger, R; Tan, M, 1997)
" Gastrimmune immunisation may be a therapeutic option for the treatment of colorectal cancer in combination with 5-FU/leucovorin."5.30Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model. ( Clarke, PA; Grimes, S; Hardcastle, JD; Justin, TA; Michael, D; Morris, TM; Robinson, G; Watson, SA, 1998)
"When tegafur was injected, the concentration of 5-FU in cancer tissue or lymphnodes was significantly higher than in normal tissue."5.30[Concentrations of 5-fluorouracil (5-FU) in serum and tissues at venous injection of tegafur or 5-FU--clinical study on colorectal cancer]. ( Inamura, Y; Kanemitsu, T; Kojima, T; Miyashita, A; Naruse, T; Owa, Y; Suzumura, K, 1998)
"Capecitabine (Xeloda) is a rationally designed oral, tumor-selective fluoropyrimidine carbamate aimed at preferential conversion to 5-fluorouracil (5-FU) within the tumor."5.30Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ( Banken, L; Cassidy, J; Glynne-Jones, R; Goggin, T; Reigner, B; Roos, B; Schüller, J; Twelves, C; Utoh, M; Weidekamm, E, 1999)
"The outlook for patients with advanced colorectal cancer remains poor."5.29Pharmacokinetics of 5-fluorouracil in colorectal cancer patients receiving interferon. ( Patel, N; Perren, T; Pittman, K; Primrose, J; Selby, P; Slevin, M; Ward, U, 1993)
"Five cases of colorectal cancer with unresectable liver metastases treated from April 1992 to April 1993 in Osaka National Hospital were summarized in this paper."5.29[Continuous intra-hepatic-arterial infusion of low dose 5-fluorouracil for colorectal cancer patients with unresectable liver metastases]. ( Imamura, H; Kanoh, T; Kikkawa, N; Miyazaki, M; Nakayama, T; Tamaki, Y; Taniguchi, K; Tohno, K; Utsunomiya, T, 1993)
"The benefits from medical treatment in colorectal cancer are limited."5.28Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acid. ( Bajetta, E; Colleoni, M; de Braud, F; Nelli, P; Nolè, F; Zilembo, N, 1992)
"Twenty-five patients with pretreated advanced colorectal carcinoma were subjected to second-line chemotherapy with sequential high-dose methotrexate and 5-fluorouracil."5.28Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil. ( Airoma, G; Bianco, AR; Caponigro, F; Gridelli, C; Incoronato, P; Palmieri, G; Pepe, R, 1991)
" The dosage of raIFN-2a could not be further escalated above 12 x 10(6) IU."5.285-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study. ( Gebbia, V; Palmeri, S; Rausa, L, 1990)
"Aflibercept (ziv-aflibercept) significantly improves progression-free (PFS) and overall survival (OS) when added to 5-fluorouracil, leucovorin and irinotecan (FOLFIRI), compared with FOLFIRI alone, in patients with metastatic colorectal cancer previously treated with oxaliplatin-based therapy."5.27Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. ( Dochy, E; Lakomy, R; Macarulla, T; Magherini, E; Moiseyenko, VM; Papamichael, D; Prausova, J; Ruff, P; Soussan-Lazard, K; Van Cutsem, E; van Hazel, GA, 2018)
"Chemotherapy-induced nausea and vomiting (CINV) causes significant morbidity among colorectal cancer patients, receiving fluorouracil, oxaliplatin, and leucovorin (FOLFOX) chemotherapy even with standard antiemetic prophylaxis."5.27Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer. ( Blanke, C; Bubalo, JS; Chen, E; Edwards, MS; Fisher, A; Herrington, JD; Lopez, CD; Palumbo, A; Takemoto, M; Williams, C; Willman, P, 2018)
"The authors hypothesized that patients with metastatic colorectal cancer (mCRC) who had tumors with low thymidylate synthase (TS-L) expression would have a higher response rate to combined 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab (FOLFOX/Bev) than those with high TS (TS-H) expression and that combined irinotecan and oxaliplatin (IROX) plus bevacizumab (IROX/Bev) would be more effective than FOLFOX/Bev in those with TS-H tumors."5.27Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203). ( Benson, AB; Catalano, PJ; Cheema, PS; Chiorean, EG; Feng, Y; George, TJ; Grem, JL; Hall, MJ; Kauh, JS; Meropol, NJ; Mulcahy, MF; O'Dwyer, PJ; Saltzman, JN; Zangmeister, J, 2018)
"Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC)."5.27S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. ( Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, K; Kobayashi, Y; Komatsu, Y; Kotake, M; Miyamoto, Y; Morita, S; Nakamura, M; Ohori, H; Sato, A; Shimada, K; Shimodaira, H; Takahashi, S; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2018)
"The PANDA study is a prospective, open-label, multicenter, randomized phase II trial of first-line therapy with panitumumab in combination with dose-adjusted FOLFOX or with 5-fluorouracil monotherapy, in previously untreated elderly patients (≥70 years) with RAS and BRAF wild-type unresectable metastatic colorectal cancer."5.27The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. ( Arnoldi, E; Battaglin, F; Bergamo, F; Boni, L; Boscolo, G; Buggin, F; Cremolini, C; Lonardi, S; Loupakis, F; Lucchetti, J; Lutrino, ES; Morano, F; Passardi, A; Pella, N; Pietrantonio, F; Salvatore, L; Scartozzi, M; Schirripa, M; Tonini, G; Zagonel, V, 2018)
"The prospective, randomized, open-label FIRE-3/AIO KRK0306 trial evaluated the first-line therapy of patients with KRAS exon 2 wild-type metastatic colorectal cancer with fluorouracil, folinic acid and irinotecan plus either cetuximab or bevacizumab."5.27Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial. ( Baumann, AB; D'Anastasi, M; Heinemann, V; Hesse, N; Hofmann, FO; Holch, JW; Modest, DP; Reiser, MF; Ricard, I; Sommer, WH; Stintzing, S, 2018)
"FOLFOXIRI (Fluorouracil, folinate, oxaliplatin, and irinotecan) plus bevacizumab improved progression-free survival (PFS) and overall survival in patients with metastatic colorectal cancer (mCRC), compared with FOLFIRI (fluorouracil, folinate, and irinotecan) plus bevacizumab, but significantly increased the incidences of adverse events."5.27A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. ( Bando, H; Emi, Y; Iwamoto, S; Kagawa, Y; Kanazawa, A; Kato, T; Kotaka, M; Muro, K; Nakamura, M; Nakayama, G; Oki, E; Sakisaka, H; Taniguchi, H; Touyama, T; Tsuji, A; Yamaguchi, T; Yamanaka, T; Yamazaki, K; Yoshino, T, 2018)
"Aflibercept combined with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) as second-line treatment of metastatic colorectal cancer (mCRC) significantly improved survival compared with FOLFIRI alone in the pivotal VELOUR (aflibercept vs."5.27Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. ( Antoniotti, C; Aprile, G; Bordonaro, R; Ciuffreda, L; Di Bartolomeo, M; Di Costanzo, F; Fasola, G; Frassineti, GL; Iaffaioli, V; Leone, F; Maiello, E; Marchetti, P; Pastorino, A; Sobrero, A; Zaniboni, A; Zilocchi, C, 2018)
" Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine."5.273 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. ( Allan, K; Azzabi, A; Boyd, KA; Bridgewater, J; Briggs, A; Cassidy, J; Cunningham, D; Dhadda, AS; Ellis, R; Essapen, S; Falk, S; Farrugia, D; Glimelius, B; Gollins, S; Harkin, A; Harrison, M; Haydon, A; Hickish, T; Hollander, NH; Iveson, TJ; Kerr, RS; McQueen, J; Medley, L; Olesen, RK; Paul, J; Propper, D; Raouf, S; Rees, C; Saunders, MP; Scudder, C; Tabernero, J; Wasan, HS; Waterston, A; Weaver, A; Webb, A; Wilson, C, 2018)
"To investigate the association between UDP-glucuronosyltransferase (UGT)1A polymorphisms and irinotecan-treatment efficacy in a Chinese population with metastatic colorectal cancer (mCRC)."5.27UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy. ( Chen, J; Feng, J; Huang, L; Liu, B; Peng, P; Qiu, H; Xie, C; Yu, Q; Yuan, X; Zang, A; Zhang, T, 2018)
"Regorafenib, a multikinase inhibitor that inhibits angiogenesis, growth, and proliferation, prolongs survival as monotherapy in patients with refractory colorectal cancer."5.27Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. ( Bekaii-Saab, TS; Cohn, AL; El-Rayes, BF; Fernando, NH; Goldberg, RM; Grogan, W; Horgan, AM; Ivanova, A; Kasbari, SS; Kim, RD; Leonard, G; McCaffrey, J; McDermott, R; Moore, DT; O'Neil, BH; O'Reilly, S; Olowokure, OO; Ryan, T; Sanoff, HK; Sherrill, GB; Yacoub, GH; Zamboni, W, 2018)
"Irinotecan (CPT-11) in combination with 5-fluorouracil (5FU) is widely used in the treatment of colorectal cancer."5.27Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial. ( Bosman, F; Brauchli, P; Delorenzi, M; Dietrich, D; Fiocca, R; Klingbiel, D; Piessevaux, H; Roth, AD; Tejpar, S; Yan, P, 2018)
"Metformin may be a promising drug in protecting colorectal cancer patients against oxaliplatin-induced chronic peripheral sensory neuropathy."5.27Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study. ( El-Fatatry, BM; Hussien, FZ; Ibrahim, OM; Mostafa, TM, 2018)
"The efficacy and safety of the FOLFIRI (leucovorin, 5-fluorouracil, irinotecan, and oxaliplatin) regimen combined with aflibercept has not been studied in the first-line management of patients with metastatic colorectal cancer (mCRC)."5.27AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. ( Aravantinos, G; Bafaloukos, D; Efstratiou, I; Fountzilas, G; Goudopoulou, A; Kalogera-Fountzila, A; Kalogeropoulou, L; Karavasilis, V; Kentepozidis, N; Koliou, GA; Kotoula, V; Koumakis, G; Laschos, K; Pectasides, D; Pentheroudakis, G; Petraki, C; Poulios, C; Samantas, E; Sgouros, J; Souglakos, I; Tikas, I; Voutsina, A; Vrettou, E; Zarkavelis, G, 2018)
"This analysis investigated the cost-effectiveness of panitumumab plus mFOLFOX6 (oxaliplatin, 5-fluorouracil, and leucovorin) compared with bevacizumab plus mFOLFOX6 in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC)."5.27A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. ( Christodoulopoulou, A; Garawin, T; Graham, CN; Hechmati, G; Knox, HN; Sabatelli, L; Strickler, JH, 2018)
" We sought to generate a comprehensive inherited pharmacogenetic profile for oxaliplatin and 5FU/capecitabine therapy in advanced colorectal cancer (aCRC)."5.27Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy. ( Adams, RA; Cheadle, JP; Colley, JP; Fisher, D; Harris, R; Humphreys, V; Idziaszczyk, S; Kaplan, RS; Madi, A; Maughan, TS; Maynard, J; Meade, AM; Wasan, H, 2018)
"This randomized phase III trial compared hepatic arterial infusion (HAI) chemotherapy with 5-fluorouracil (5-FU) followed by uracil/tegafur (UFT) and leucovorin (LV) versus UFT/LV alone for patients with curatively resected liver metastases from colorectal cancer (CRC)."5.27A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundatio ( Aoyama, T; Asahara, T; Hirata, K; Kusano, M; Nakamori, S; Oba, K; Ohashi, Y; Okabayashi, K; Saji, S; Sakamoto, J; Tsuji, Y; Yoshikawa, T, 2018)
"Mitomycin C was given to 9 patients as a third-line regimen with resulting 5 NC for 2-4 months."5.27[Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C]. ( Farroukh, R; Gerlach, D; Hoffmann, W; Kress, M; Migeod, F; Seeber, S, 1988)
"To determine if the addition of cetuximab vs bevacizumab to the combination of leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen or the combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regimen is superior as first-line therapy in advanced or metastatic KRAS wild-type (wt) colorectal cancer."5.24Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. ( Atkins, JN; Benson, AB; Berry, S; Bertagnolli, MM; Blanke, C; El-Khoueiry, AB; Fruth, B; Goldberg, RM; Greene, C; Hochster, HS; Innocenti, F; Lenz, HJ; Mayer, RJ; Meyerhardt, JA; Mulkerin, DL; Niedzwiecki, D; O'Neil, BH; O'Reilly, EM; Polite, BN; Schilsky, RL; Schrag, D; Venook, AP; Watson, P, 2017)
"In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when added to FOLFOX [folinic acid, 5-fluorouracil, and oxaliplatin] or FOLFIRI [folinic acid, 5-fluorouracil, and irinotecan]."5.24First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). ( Abad, A; Aranda, E; Carrato, A; Dueñas, R; Escudero, P; Gallego, J; García-Paredes, B; Gómez, A; González, E; Grávalos, C; Longo-Muñoz, F; Losa, F; Manzano, JL; Massuti, B; Pericay, C; Rivera, F; Safont, MJ; Valladares-Ayerbes, M, 2017)
"The hepatic artery infusion (HAI) of irinotecan, oxaliplatin and 5-fluorouracil with intravenous cetuximab achieved outstanding efficacy in previously treated patients with initially unresectable liver metastases from colorectal cancer."5.24Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). ( Adam, R; Boige, V; Bouchahda, M; Carvalho, C; Desterke, C; Ducreux, M; Focan, C; Guimbaud, R; Hebbar, M; Innominato, P; Karaboué, A; Lemoine, A; Lévi, F; Milano, G; Saffroy, R; Smith, D; Taieb, J, 2017)
"The combination of hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin with intravenous cetuximab has safely achieved prolonged survival in colorectal cancer patients with extensive liver metastases and prior treatment."5.24Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study. ( Bouchahda, M; Chatelut, E; Etienne-Grimaldi, MC; Focan, C; Innominato, P; Karaboué, A; Lévi, F; Milano, G; Paintaud, G, 2017)
"This study examined the association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and survival of patients with colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)-based chemotherapy in Taiwan."5.24Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy. ( Chang, SN; Hsieh, LL; Lai, CY; Lin, YK; Sung, FC; Tang, R; Yeh, CC, 2017)
"To assess the cost-effectiveness of panitumumab in combination with mFOLFOX6 (oxaliplatin, 5-fluorouracil, and leucovorin) vs bevacizumab in combination with mFOLFOX6 as first-line treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC) in Spain."5.24Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. ( Gea, S; López-Martínez, N; Rivera, F; Valladares, M, 2017)
"Fluorouracil and folinic acid with irinotecan (FOLFIRI) plus bevacizumab (BV) is widely used as second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, oxaliplatin, and BV."5.24Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab. ( Ando, M; Araida, T; Hamano, M; Hayashi, K; Hirai, E; Itabashi, M; Kameoka, S; Kawakami, K; Kuramochi, H; Nakajima, G; Okuyama, R; Yokomizo, H; Yoshimatsu, K, 2017)
"In Japan, oxaliplatin (OXA)/5-fluorouracil (5-FU)/leucovorin (LV)-the mFOLFOX6 regimen-is the most frequently used first-line chemotherapy backbone for metastatic colorectal cancer."5.24mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design ( Kurosawa, S; Mishima, H; Nagata, N; Oba, K; Sakamoto, J, 2017)
"There are no published cases about bullous pyoderma gangrenosum induced by leucovorin, fluorouracil and oxaliplatin (FOLFOX) chemotherapy."5.22Leukocytoclastic vasculitis presenting clinically as bullous pyoderma gangrenosum following leucovorin, fluorouracil and oxaliplatin chemotherapy: a rare case report and literature review. ( Abdollahimajd, F; Diab, R; Kaddah, A; Mirzaei, HR; Rakhshan, A, 2022)
"Carmofur, 1-hexylcarbamoyl-5-fluorouracil (HCFU) is an antineoplastic drug, which has been in clinics in Japan since 1981 for the treatment of colorectal cancer."5.22Versatile use of Carmofur: A comprehensive review of its chemistry and pharmacology. ( Islam, MM; Mirza, SP, 2022)
"The purpose of this systematic review is to analyze the published data on the efficacy and safety of doses higher than 180 mg/m2 of irinotecan recommended in the drug's summary of product characteristics in  metastatic colorectal cancer patients with genotypes UGT1A1*1/*1 or *1/*28  who are treated with the FOLFIRI regimen."5.22Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review. ( García-Gil, S; Gutiérrez-Nicolás, F; Miarons, M; Riera, P, 2022)
"The efficacy of irinotecan as the adjunctive therapy to fluorouracil and leucovorin remains controversial in patients with colorectal cancer."5.22The efficacy of irinotecan supplementation for colorectal cancer: A meta-analysis of randomized controlled studies. ( Jiang, W; Liu, Q; Yang, D; Yang, SB, 2022)
"The purpose of this phase II study was to explore the efficacy and safety of an alternating regimen consisting of folinic acid, 5-fluorouracil (5-FU) and oxaliplatin (mFOLFOX6) plus bevacizumab, and folinic acid, 5-FU and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer."5.22Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). ( Akagi, Y; Emi, Y; Higashi, H; Ishikawa, H; Kusumoto, T; Maehara, Y; Matsuda, H; Miwa, K; Ogata, Y; Oki, E; Saeki, H; Samura, H; Sueyoshi, S; Tanaka, T; Tokunaga, S; Touyama, T, 2016)
"The aim of this multicenter, open-label, randomized phase II trial was to evaluate the efficacy of a dose-dense capecitabine and oxaliplatin (XELOX) regimen in patients with metastatic colorectal cancer (mCRC) for whom reintroduction of oxaliplatin had been planned as a third- or later-line regimen."5.22Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study). ( Bando, H; Fujii, A; Fukunaga, M; Hata, T; Honda, M; Ishibashi, K; Kobayashi, M; Matsuda, C; Mishima, H; Munemoto, Y; Nagata, N; Oba, K; Oshiro, M; Tanaka, C; Tokunaga, Y, 2016)
"Panitumumab plus infusional 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) significantly improved overall survival versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer (mCRC)."5.22Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer. ( Barber, B; Dong, J; Douillard, JY; Hechmati, G; Maglinte, GA; Wang, J, 2016)
"The HE6C/05 trial randomized 441 patients with stage II-III colorectal adenocarcinoma to adjuvant XELOX (capecitabine, oxaliplatin) or modified FOLFOX6 (5-fluorouracil, leucovorin, oxaliplatin)."5.22Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin. ( Cohen, SA; Fountzilas, G; Gkakou, C; Gourgioti, G; Grady, WM; Kalogeras, KT; Karavasilis, V; Kotoula, V; Papaxoinis, G; Pectasides, D; Pentheroudakis, G; Raptou, G; Wirtz, R; Wu, C; Yu, M, 2016)
"gov NCT00561470) was to investigate the treatment effect of adding aflibercept to second-line infusional 5-fluorouracil (5-FU), leucovorin and irinotecan (FOLFIRI) in patients with metastatic colorectal cancer (mCRC) who had failed any prior oxaliplatin-containing regimen."5.22Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing A ( Andria, M; Arnold, D; Cunningham, D; Dochy, E; Grávalos, C; Hoff, PM; Humblet, Y; Joulain, F; Kröning, H; Lakomý, R; Le-Guennec, S; Macarulla, T; McKendrick, J; Mitchell, E; Moiseyenko, VM; Prausová, J; Ruff, P; Schmoll, HJ; Tabernero, J; Ten Tije, AJ; Van Cutsem, E; van Hazel, G; Vishwanath, RL, 2016)
"The purpose of this study was to assess the efficacy and tolerance of induction chemotherapy combining LV5FU2 with increased doses of irinotecan adapted to UGT1A1 genotyping and cetuximab in untreated potentially resectable liver metastases of colorectal cancer."5.22High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT). ( Buc, E; Chatelut, E; De la Fouchardière, C; Mendoza, C; Mineur, L; Pezet, D; Phelip, JM; Quesada, JL; Rivoire, M; Roblin, X, 2016)
"A multicenter, open-label, noncomparative, randomized phase II study (PEPCOL) was conducted to evaluate the efficacy and safety of the irinotecan or PEP02 (MM-398, nanoliposomal irinotecan) with leucovorin (LV)/5-fluorouracil (5-FU) combination as second-line treatment in patients with metastatic colorectal cancer (mCRC)."5.22PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer. ( André, T; Arbaud, C; Bachet, JB; Bennamoun, M; Bonnetain, F; Brusquant, D; Chibaudel, B; de Gramont, A; Dupuis, O; Garcia, ML; Hammel, P; Khalil, A; Larsen, AK; Louvet, C; Maindrault-Gœbel, F; Tournigand, C; Wang, YW; Yeh, CG, 2016)
"SIRFLOX was a randomized, multicenter trial designed to assess the efficacy and safety of adding selective internal radiation therapy (SIRT) using yttrium-90 resin microspheres to standard fluorouracil, leucovorin, and oxaliplatin (FOLFOX)-based chemotherapy in patients with previously untreated metastatic colorectal cancer."5.22SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. ( Boucher, E; Bower, G; Cade, DN; Eliadis, P; Ferguson, T; Findlay, MP; Ganju, V; Gebski, V; Gibbs, P; Heinemann, V; Isaacs, R; Kröning, H; Moeslein, F; Peeters, M; Perez, D; Powell, A; Price, D; Ricke, J; Robinson, BA; Rodríguez, J; Shacham-Shmueli, E; Sharma, NK; Strickland, AH; Taieb, J; Thurston, K; Tichler, T; Van Buskirk, M; van Hazel, GA; Walpole, E; Wolf, I, 2016)
" This study was to evaluate the efficacy and safety of maintenance therapy with capecitabine versus observation following inductive chemotherapy in patients with metastatic colorectal cancer."5.22Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. ( Hu, XH; Jia, J; Li, YH; Lin, DR; Lin, YC; Luo, HY; Ma, D; Peng, JW; Wang, FH; Wang, W; Wang, ZQ; Xu, RH; Yuan, X; Zhang, DS, 2016)
"Patients with 5-fluorouracil-refractory metastatic colorectal cancer at the MD Anderson Cancer Center were offered screening in the Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC) program to identify eligibility for companion phase I or II clinical trials with a therapy targeted to an aberration detected in the patient, based on testing by immunohistochemistry, targeted gene sequencing panels, and CpG island methylation phenotype assays."5.22Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. ( Abbruzzese, J; Dasari, A; Eng, C; Fogelman, D; Hamilton, S; Kee, B; Kopetz, S; Liang, L; Maru, D; Mazard, T; Meric-Bernstam, F; Mills, GB; Morris, J; Morris, V; Overman, MJ; Raghav, K; Shaw, K; Shroff, R; Shureiqi, I; Vilar, E; Wolff, RA; Xiao, L, 2016)
" The present study was initiated to validate the use of therapeutic drug management (TDM) to personalize 5-fluorouracil (5-FU) dosing in patients with metastatic colorectal cancer treated in routine clinical practice."5.22Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice. ( Bertsch, T; Birkmann, J; Braess, J; Holdenrieder, S; Jaehde, U; Kraff, S; Kunzmann, V; Link, K; Miller, MC; Moritz, B; Mueller, L; Roessler, M; Salamone, SJ; Stoetzer, OJ; Suttmann, I; Wilhelm, M, 2016)
"Observational and preclinical studies have suggested that metformin has antitumor effects in solid tumors, including colorectal cancer (CRC)."5.22Phase 2 Trial of Metformin Combined With 5-Fluorouracil in Patients With Refractory Metastatic Colorectal Cancer. ( Alex, A; Bariani, G; Bezerra Neto, JE; Braghiroli, MI; Capareli, FC; Faria, LD; Hoff, PM; Lobo Dos Santos, JF; Miranda, VC; Riechelmann, RP; Sabbaga, J, 2016)
"The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer."5.22Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study. ( Ciftci, R; Iner-Koksal, U; Kaytan-Saglam, E; Namal, E; Okyar, A; Ordu, C; Pala-Kara, Z; Pilancı, KN; Saglam, S; Yucel, S, 2016)
"We previously showed that a sequential chemotherapy with dose-dense oxaliplatin (FOLFOX7) and irinotecan (FOLFIRI; irinotecan plus 5-fluorouracil/leucovorin) is not superior to FOLFOX4 in patients at advanced stage of colorectal cancer with liver metastases."5.22Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial. ( André, T; Bonnetain, F; Brusquant, D; Chibaudel, B; de Gramont, A; Garcia-Larnicol, ML; Hamidou, Z; Hebbar, M; Hug de Larauze, M; Louvet, C, 2016)
"It is now widely accepted that therapeutic antibodies targeting epidermal growth factor receptor (EGFR) can have efficacy in KRAS wild-type advanced colorectal cancer (CRC) patients."5.22TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer. ( Brünner, N; Christensen, IJ; Glimelius, B; Guren, TK; Ikdahl, T; Kure, EH; Moreira, JM; Nielsen, HJ; Noer, J; Nordgaard, C; Pfeiffer, P; Sorbye, H; Tarpgaard, LS; Tveit, KM; Ørum-Madsen, MS, 2016)
"FIRE-3 compared first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in patients with KRAS exon 2 wild-type metastatic colorectal cancer."5.22FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. ( Al-Batran, SE; Decker, T; Giessen-Jung, C; Heinemann, V; Heintges, T; Held, S; Jagenburg, A; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Lerch, MM; Lerchenmüller, C; Modest, DP; Moehler, M; Rossius, L; Scheithauer, W; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF, 2016)
"This randomized phase II trial compared panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) with bevacizumab plus FOLFIRI as second-line chemotherapy for wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and to explore the values of oncogenes in circulating tumor DNA (ctDNA) and serum proteins as predictive biomarkers."5.22Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G. ( Boku, N; Denda, T; Hyodo, I; Moriwaki, T; Muro, K; Nishina, T; Nishio, K; Okuda, H; Sakai, K; Shitara, K; Takano, T; Tokunaga, S; Tsuda, M; Yamanaka, T; Yamazaki, K; Yonesaka, K, 2016)
" This randomized phase II study evaluated the antitumor activity and safety of icrucumab and ramucirumab each in combination with mFOLFOX-6 in patients with metastatic colorectal cancer after disease progression on first-line therapy with a fluoropyrimidine and irinotecan."5.22Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy. ( Alcindor, T; Asmis, T; Bendell, J; Berry, S; Binder, P; Burkes, R; Chan, E; Chan, T; Gao, L; Gill, S; Jeyakumar, A; Kambhampati, SR; Kauh, J; Kudrik, F; Moore, M; Nasroulah, F; Ramdas, N; Rao, S; Rothenstein, J; Spratlin, J; Strevel, E; Tang, PA; Tang, S; Yang, L; Zbuk, K, 2016)
"A multicenter randomized trial was performed comparing oral tegafur/gimeracil/oteracil (S-1) and uracil-tegafur/ leucovorin (UFT/LV) as adjuvant therapy for stage III colorectal cancer."5.22Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer. ( Kaiho, T; Kobayashi, S; Koda, K; Kosugi, C; Maruyama, T; Matsubara, H; Miyauchi, H; Takiguchi, N, 2016)
"The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint."5.20A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H, 2015)
"5-Fluorouracil (5-FU) is chemotherapeutic agent widely used for the treatment of colorectal cancer."5.20Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer. ( Chang, SW; Chen, TH; Huang, CC; Lee, H; Wu, DW, 2015)
"Perioperative FOLFOX4 (oxaliplatin plus 5-fluorouracil/leucovorin) chemotherapy is the current standard in patients with resectable metastases from colorectal cancer (CRC)."5.20FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized ( André, T; Auby, D; Bonnetain, F; Brucker, P; Brusquant, D; Carola, E; Chibaudel, B; Dalban, C; de Gramont, A; Dutel, JL; Faroux, R; Flesch, M; Gayet, B; Hadengue, A; Hebbar, M; Khalil, A; Landi, B; Legoux, JL; Louvet, C; Mabro, M; Martin, P; Mineur, L; Paye, F; Pruvot, FR; Smith, D; Taieb, J; Truant, S; Vaillant, E; Ychou, M, 2015)
"A UGT1A1 genotype-directed dose escalation of irinotecan (CPT-11) was performed in patients with metastatic colorectal cancer receiving first-line FOLFIRI chemotherapy."5.20A phase I study of UGT1A1 *28/*6 genotype-directed dosing of irinotecan (CPT-11) in Korean patients with metastatic colorectal cancer receiving FOLFIRI. ( Bae, KS; Hong, YS; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG, 2015)
"The results for efficacy and safety over the time course of the VEGF Trap (aflibercept) with irinotecan in colorectal cancer after failure of oxaliplatin regimen trial were analysed based on data from 1226 patients randomised to receive FOLFIRI plus either aflibercept (n=612) or placebo (n=614)."5.20Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. ( Arnold, D; Bhargava, P; Chevalier, S; Cunningham, D; Ferry, DR; Hoff, PM; Lakomỳ, R; Macarulla, T; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Schmoll, HJ; Ten Tije, AJ; Van Cutsem, E; Van Hazel, GA; Vishwanath, RL, 2015)
"The aim of this study was to determine the recommended dose (RD) of a triweekly capecitabine, oxaliplatin, irinotecan, and bevacizumab (XELOXIRI/bevacizumab) regimen that was easier to administer than FOLFOXIRI/bevacizumab, using capecitabine instead of 5-fuorouracil (5-FU), in patients with metastatic colorectal cancer (mCRC)."5.20A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer. ( Furuhata, T; Hayashi, T; Hirakawa, M; Hirata, K; Iyama, S; Kato, J; Kawano, Y; Kobune, M; Miyanishi, K; Mizuguchi, T; Murase, K; Ohnuma, H; Okagawa, Y; Okita, K; Osuga, T; Sato, T; Sato, Y; Takada, K; Takahashi, M; Takimoto, R, 2015)
"The phase III CRYSTAL study demonstrated that addition of cetuximab to fluorouracil, leucovorin, and irinotecan (FOLFIRI) significantly improved overall survival, progression-free survival, and objective response in the first-line treatment of patients with KRAS codon 12/13 (exon 2) wild-type metastatic colorectal cancer (mCRC)."5.20Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. ( Beier, F; Ciardiello, F; Heinemann, V; Köhne, CH; Lenz, HJ; Melezínek, I; Rougier, P; Stroh, C; Tejpar, S; Van Cutsem, E; van Krieken, JH, 2015)
" We therefore conducted a multicenter randomized phase III trial to compare fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) with and without Goshajinkigan (GJG), a traditional Japanese herbal medicine (Kampo), to determine GJG's potential for reducing peripheral neuropathy in patients with colorectal cancer."5.20Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. ( Baba, H; Emi, Y; Higashijima, J; Ishida, H; Kakeji, Y; Kato, T; Kojima, H; Kon, M; Kono, T; Maehara, Y; Miyake, Y; Ogata, Y; Oki, E; Saeki, H; Sakaguchi, Y; Shirabe, K; Takahashi, K; Tomita, N; Yamanaka, T, 2015)
"This study was conducted to evaluate the efficacy and safety of the combination of capecitabine and oral leucovorin (LV) as a third-line chemotherapy for patients with metastatic colorectal cancer (CRC) showing resistance to irinotecan- and oxaliplatin-containing regimens."5.20A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer. ( Choi, DR; Choi, YK; Han, B; Kim, BC; Kim, HS; Kim, JB; Kim, JH; Kim, KY; Song, HH; Yoon, SN; Zang, DY, 2015)
"A dose-finding phase I/II trial that evaluated the maximum tolerated doses of a combination of three drugs with irinotecan, oxaliplatin and capecitabine (COI regimen) has been conducted in patients with metastatic colorectal cancer (mCRC)."5.20Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. ( Aitini, E; Bajetta, E; Barni, S; Bertolini, A; Ciarlo, A; Di Bartolomeo, M; Dotti, KF; Iacovelli, R; Maggi, C; Perrone, F; Pietrantonio, F; Verusio, C, 2015)
"The oral multikinase inhibitor regorafenib improves overall survival (OS) in patients with metastatic colorectal cancer (CRC) for which all standard treatments have failed."5.20Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. ( Argilés, G; Benson, A; Cascinu, S; Ciardiello, F; Grunert, J; Guillén Ponce, C; Köhne, CH; Luigi Garosi, V; Macpherson, IR; Rivera, F; Saunders, MP; Sobrero, A; Strumberg, D; Tabernero, J; Van Cutsem, E; Wagner, A; Zalcberg, J, 2015)
" We included patients older than 18 years with previously untreated metastatic colorectal cancer, with stable disease or better after induction treatment with six 3-weekly cycles of capecitabine, oxaliplatin, and bevacizumab (CAPOX-B), WHO performance status of 0 or 1, and adequate bone marrow, liver, and renal function."5.20Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. ( Braun, HJ; Cats, A; Creemers, GJ; de Jongh, FE; Derleyn, VA; Erdkamp, FL; Erjavec, Z; Haasjes, JG; Honkoop, AH; Jansen, RL; Koopman, M; Loosveld, OJ; May, A; Mol, L; Nieboer, P; Punt, CJ; Simkens, LH; ten Tije, AJ; Tol, J; van der Hoeven, JJ; van der Torren, AM; van Tinteren, H; Wals, J, 2015)
"This study is the first to combine daily oral curcumin with standard care FOLFOX-based (5-fluorouracil, folinic acid and oxaliplatin) chemotherapy in colorectal cancer patients with inoperable liver metastases: the CUFOX trial."5.20Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial. ( Berry, DP; Brown, K; Howells, LM; Irving, GR; Iwuji, CO; Morgan, B; Steward, WP; Thomas, A, 2015)
"The current study aimed to evaluate the short-term efficacy and safety of endostar plus irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) in treatment of advanced colorectal cancer (CRC)."5.20Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study. ( Hu, XL; Li, BL; Sun, HG; Zhang, Y; Zhao, XH; Zhou, CY, 2015)
" We assessed the efficacy and safety of ramucirumab versus placebo in combination with second-line FOLFIRI (leucovorin, fluorouracil, and irinotecan) for metastatic colorectal cancer in patients with disease progression during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine."5.20Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin ( Bodoky, G; Chang, SC; Ciuleanu, TE; Clingan, PR; Cohn, AL; Garcia-Alfonso, P; Garcia-Carbonero, R; Grothey, A; Kim, TW; Lonardi, S; Nasroulah, F; Obermannova, R; Portnoy, DC; Prausová, J; Simms, L; Tabernero, J; Van Cutsem, E; Yamazaki, K; Yoshino, T, 2015)
"The aprepitant therapy was more effective than the control therapy for prevention of CINV in colorectal cancer patients receiving an oxaliplatin-based regimen."5.20Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ide, Y; Kudo, T; Miyake, Y; Mizushima, T; Mori, M; Morita, S; Nakata, K; Nezu, R; Nishimura, J; Ohno, Y; Sakai, D; Satoh, T; Sekimoto, M; Takemasa, I; Takemoto, H; Uemura, M; Yamamoto, H; Yasui, M, 2015)
"The OPUS study demonstrated that addition of cetuximab to 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX4) significantly improved objective response and progression-free survival (PFS) in the first-line treatment of patients with KRAS exon 2 wild-type metastatic colorectal cancer (mCRC)."5.20FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. ( Beier, F; Bokemeyer, C; Ciardiello, F; Duecker, K; Heinemann, V; Klinkhardt, U; Köhne, CH; Lenz, HJ; Tejpar, S; van Krieken, JH, 2015)
"In vitro and pre-clinical studies have suggested that addition of the diet-derived agent curcumin may provide a suitable adjunct to enhance efficacy of chemotherapy in models of colorectal cancer."5.20Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. ( Berry, DP; Brown, K; Cai, H; Dennison, A; Garcea, G; Greaves, P; Griffin-Teal, N; Higgins, JA; Howells, LM; Irving, G; Iwuji, C; James, MI; Karmokar, A; Lloyd, DM; Metcalfe, M; Morgan, B; Patel, SR; Steward, WP; Thomas, A, 2015)
"S-1, a novel oral prodrug of 5-fluorouracil (5-FU), and irinotecan with or without bevacizumab is known to be effective in metastatic colorectal cancer (mCRC)."5.20S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies. ( Goto, A; Ichikawa, Y; Iwasa, S; Kato, K; Matsumoto, H; Nagashima, K; Okita, NT; Shimada, Y; Yamada, Y; Yamaguchi, T; Yasui, H, 2015)
"This randomised, open-label, phase I/II study evaluated the efficacy and safety of nintedanib, an oral, triple angiokinase inhibitor, combined with chemotherapy, relative to bevacizumab plus chemotherapy as first-line therapy in patients with metastatic colorectal cancer (mCRC)."5.20A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. ( Bennouna, J; Bouché, O; Capdevila, J; Carrato, A; D'Haens, G; Dressler, H; Ducreux, M; Latini, L; Oum'Hamed, Z; Prenen, H; Sobrero, A; Staines, H; Studeny, M; Van Cutsem, E, 2015)
"In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved progression-free survival of patients with metastatic colorectal cancer compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab."5.20FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. ( Allegrini, G; Antoniotti, C; Boni, L; Carlomagno, C; Cazzaniga, M; Chiara, S; Cremolini, C; D'Amico, M; Falcone, A; Fontanini, G; Granetto, C; Lonardi, S; Loupakis, F; Lupi, C; Mezi, S; Ronzoni, M; Sensi, E; Tomasello, G; Tonini, G; Zaniboni, A, 2015)
"We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter phase III study of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) versus FOLFIRI alone as second-line therapy in patients with metastatic colorectal cancer (mCRC; ClinicalTrials."5.20Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. ( André, T; Cervantes, A; Chan, E; Ciuleanu, TE; Ducreux, M; He, P; Hotko, Y; Jung, AS; Koukakis, R; Lordick, F; Oliner, KS; Patterson, SD; Peeters, M; Price, TJ; Punt, CJ; Roman, L; Sidhu, R; Sobrero, AF; Strickland, AH; Terwey, JH; Van Cutsem, E; Wilson, G; Yu, H, 2015)
"The TRICOLORE trial is a multicenter, randomized, open-label, controlled phase III study which aims to evaluate the non-inferiority of combination therapy with S-1/irinotecan/bevacizumab (a 3-week regimen [SIRB] or 4-week regimen [IRIS/bevacizumab]) to oxaliplatin-based standard treatment (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) in patients with metastatic colorectal cancer who had not previously received chemotherapy."5.20Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. ( Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S, 2015)
"The purpose of this randomised phase III trial was to evaluate whether the addition of simvastatin, a synthetic 3-hydroxy-3methyglutaryl coenzyme A reductase inhibitor, to XELIRI/FOLFIRI chemotherapy regimens confers a clinical benefit to patients with previously treated metastatic colorectal cancer."5.20A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. ( Han, SW; Hong, YS; Hwang, IG; Jung, SH; Kang, HJ; Kang, WK; Kim, HS; Kim, ST; Kim, TW; Lee, J; Lee, JY; Lee, KH; Lim, HY; Lim, SH; Park, JO; Park, SH; Park, YS, 2015)
"The conventional first-line chemotherapy for metastatic colorectal cancer (mCRC) consists of fluorouracil (5-FU) in combination with either oxaliplatin or irinotecan."5.19Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment. ( Guren, T; Ikdahl, T; Kjersem, JB; Kure, EH; Lingjaerde, OC; Tveit, KM, 2014)
"The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen."5.19Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. ( Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA, 2014)
" We conducted a phase I study of dasatinib, capecitabine, oxaliplatin, and bevacizumab (CapeOx/bevacizumab), with an expansion cohort in metastatic colorectal cancer (CRC)."5.19Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer. ( Arrowood, C; Blobe, GC; Brady, JC; Cohn, A; Haley, S; Hsu, SD; Hurwitz, HI; McCall, S; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Rushing, C; Starodub, A; Strickler, JH; Uronis, HE; Zafar, SY, 2014)
"Efatutazone, a novel oral highly-selective peroxisome proliferator-activated receptor gamma (PPARγ) agonist, has demonstrated some inhibitory effects on disease stabilization in patients with metastatic colorectal cancer (mCRC) enrolled in previous phase I studies."5.19Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. ( Hyodo, I; Komatsu, Y; Machida, N; Ohtsu, A; Onuma, H; Sasaki, T; Yachi, Y; Yamazaki, K; Yoshino, T; Yuki, S, 2014)
"We investigated the efficacy and safety of capecitabine and gemcitabin (GemCap) in heavily pre-treated, therapy-resistant metastatic colorectal cancer (mCRC) patients and the clinical importance of cell-free DNA (cfDNA) measurement."5.19Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study. ( Andersen, RF; Jakobsen, A; Pallisgaard, N; Ploen, J; Spindler, KL, 2014)
"Patients with colorectal cancer starting adjuvant or first-line treatment with a chemotherapy combination containing fluorouracil, capecitabine, and/or irinotecan were randomly assigned to receive octreotide LAR 30 mg intramuscularly every 4 weeks (experimental arm) or the physician's treatment of choice in case of diarrhea (control arm)."5.19Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial. ( Andrade, AC; Barrios, CH; Chinen, RN; Correa, M; Coutinho, AK; del Giglio, A; Dutra, C; Forones, NM; Hoff, PM; Passos, VQ; Portella, Mdo S; Saragiotto, DF; van Eyll, B, 2014)
" This phase I study used radiolabeled huA33 in combination with capecitabine to target chemoradiation to metastatic colorectal cancer."5.19Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine. ( Cavicchiolo, T; Chappell, B; Gill, S; Herbertson, RA; Hopkins, W; Lee, FT; Lee, ST; Murphy, R; O'Keefe, GJ; Poon, A; Saunder, T; Scott, AM; Scott, FE; Tebbutt, NC, 2014)
"To evaluate panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated wild-type (WT) KRAS exon 2 (codons 12 and 13) metastatic colorectal cancer (mCRC)."5.19PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal ( Canon, JL; Fasola, G; Go, WY; Hecht, JR; Karthaus, M; Oliner, KS; Rivera, F; Schwartzberg, LS; Yu, H, 2014)
"Irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil administered every two weeks (FOLFIRI regimen) is active in patients with metastatic colorectal cancer."5.19Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients. ( Arai, T; Goto, A; Hamaguchi, T; Muro, K; Sasaki, Y; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2014)
" This study examined the efficacy and safety of combining bevacizumab and panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer (mCRC)."5.19Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer. ( Hu, AP; Li, SL; Liang, HL; Liu, JY, 2014)
"Data collected from 20 elderly patients (75-92 years old) with breast or colorectal cancer who received oral capecitabine were analyzed."5.19Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer. ( Daher Abdi, Z; Lavau-Denes, S; Leobon, S; Marquet, P; Martin, J; Prémaud, A; Rousseau, A; Sauvage, FL; Tubiana-Mathieu, N; Urien, S, 2014)
" Three of six patients in cohort 2B-1 experienced grade 3 mucositis, and further study of the combination of everolimus, mFOLFOX6 and panitumumab was aborted."5.19A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. ( Bernard, S; Davies, JM; Dees, EC; Goldberg, RM; Ivanova, A; Keller, K; McRee, AJ; O'Neil, BH; Sanoff, HG, 2014)
"We investigated the efficacy and safety of a new second-line chemotherapy of combining folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) with both panitumumab and bevacizumab to treat patients with metastatic colorectal cancer (mCRC)."5.19Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer. ( Fan, Z; Han, G; He, L; Qin, Z; Xie, S; Xu, W, 2014)
"The FOLFOXIRI regimen (irinotecan, oxaliplatin, fluorouracil [5-FU] and folinic acid [FA]) increased the response rate and overall survival compared to FOLFIRI in patients with metastatic colorectal cancer (mCRC)."5.19Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer. ( Ehninger, G; Folprecht, G; Hamann, S; Schütte, K; Stoehlmacher-Williams, J; Trarbach, T, 2014)
"Cetuximab and bevacizumab have both been shown to improve outcomes in patients with metastatic colorectal cancer when added to chemotherapy regimens; however, their comparative effectiveness when partnered with first-line fluorouracil, folinic acid, and irinotecan (FOLFIRI) is unknown."5.19FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. ( Al-Batran, SE; Decker, T; Heinemann, V; Heintges, T; Hielscher, J; Höffkes, HG; Jung, A; Kahl, C; Kiani, A; Kirchner, T; Kullmann, F; Lerchenmüller, C; Lindig, RU; Link, H; Modest, DP; Moehler, M; Müller, S; Niederle, N; Rossius, L; Rost, A; Scheithauer, W; Scholz, M; Seipelt, G; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF, 2014)
" From August 2012 to August 2013, 34 patients with pathologically documented advanced colorectal cancer (T3/T4 with metastases or nodal status up to N3) and measurable metastatic disease, who required palliative chemotherapy based on the combination of 5-fluorouracil, oxaliplatin and irinotecan, were prospectively recruited in this study."5.19Association between chemotherapy and plasma adipokines in patients with colorectal cancer. ( Kasperczyk, S; Malinowska-Borowska, J; Nowak, P; Rogalska, A; Świętochowska, E; Słomian, G, 2014)
"To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer."5.19Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. ( Chen, C; Chen, G; Ding, P; Gu, Y; He, Y; Li, C; Li, W; Li, Y; Lu, Z; Luo, H; Pan, Z; Wan, D; Wang, F; Wang, Z; Wu, X; Xu, R; Yuan, Y; Zhao, M, 2014)
"Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival."5.19Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? ( André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014)
" A phase II study was conducted to determine the feasibility of a dose-intense two weekly schedule of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer (mCRC)."5.19Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study. ( Adams, J; Deva, S; Findlay, MP; Hinder, VA; Isaacs, R; Jackson, CG; O'Donnell, A; Perez, DJ; Robinson, BA; Sharples, K; Thompson, PI, 2014)
" The incidence of adverse events frequently associated with irinotecan and capecitabine were neutropenia (any grade, 55."5.19A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study). ( Goto, A; Hamamoto, Y; Morita, S; Nakajima, T; Nakayama, N; Nishina, T; Sakamoto, J; Shimada, K; Ura, T; Yamada, Y; Yamaguchi, T; Yamazaki, K, 2014)
"This phase II study aims to evaluate the efficacy and safety of biweekly cetuximab in combination with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) as first-line treatment of metastatic wild-type KRAS colorectal cancer."5.19Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). ( Alonso, V; Cirera, L; Fernandez-Plana, J; Mendez, M; Pericay, C; Quintero, G; Saigi, E; Salgado, M; Salud, A, 2014)
"We report updated progression-free survival (PFS) and overall survival (OS) data from a trial that compared capecitabine plus oxaliplatin (CapeOX) versus S-1 plus oxaliplatin (SOX) for the first-line treatment of metastatic colorectal cancer."5.19S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, ST; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2014)
"The purpose of this phase II study was to evaluate the safety and efficacy of weekly irinotecan and capecitabine (wXELIRI) treatment in patients with metastatic colorectal cancer, specifically the rate of severe diarrhea."5.19Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients. ( Chen, Z; Guo, W; Li, J; Li, W; Liu, T; Shen, L; Xu, J; Zhang, W; Zhu, X, 2014)
"BACKGROUND/Aims: To determine the effect of the pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine."5.19The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study. ( Endo, I; Ichikawa, Y; Kunisaki, C; Osada, S; Ota, M; Shoichi, F; Suwa, H; Tanaka, K; Tatsumi, K; Watanabe, J; Watanabe, K, 2014)
"Elderly patients with previously untreated metastatic colorectal cancer (mCRC) were randomly assigned to receive fluorouracil (FU) -based chemotherapy either alone or in combination with irinotecan (IRI) in the Fédération Francophone de Cancérologie Digestive (FFCD) 2001-02 study."5.17Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. ( Aparicio, T; Bouché, O; Breysacher, G; Charneau, J; Cretin, J; Gargot, D; Gasmi, M; Jouve, JL; Le Brun-Ly, V; Lecomte, T; Locher, C; Mitry, E; Ramdani, M; Seitz, JF; Stefani, L; Subtil, F; Teillet, L, 2013)
"This randomized phase II trial investigated the efficacy and safety of capecitabine/oxaliplatin (CapOx) plus bevacizumab and dose-modified capecitabine/irinotecan (mCapIri) plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer (mCRC)."5.17Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. ( Arnold, D; Dietrich, G; Freier, W; Geißler, M; Graeven, U; Hegewisch-Becker, S; Hinke, A; Kubicka, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schmoll, HJ; Tannapfel, A, 2013)
"Metastatic colorectal cancer (mCRC) is commonly treated with 5-fluorouracil, folinic acid, and oxaliplatin or irinotecan."5.17Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. ( Boix, O; Ehrenberg, R; Fischer, R; Folprecht, G; Hacker, UT; Hamann, S; Köhne, CH; Kornacker, M; Krauss, J; Kuhlmann, J; Lettieri, J; Mross, KB; Schultheis, B; Strumberg, D, 2013)
"The use of bevacizumab in combination with fluoropyrimidine-containing chemotherapy is a well-established first-line and second-line treatment for patients with metastatic colorectal cancer (mCRC)."5.17An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]. ( Burge, M; Clarke, S; Cordwell, C; Gibbs, P; Reece, W; Tebbutt, N, 2013)
"This randomized, double-blind, placebo-controlled, phase IIb study evaluated adding sorafenib to first-line modified FOLFOX6 (mFOLFOX6) for metastatic colorectal cancer (mCRC)."5.17Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. ( Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L, 2013)
"After resection of their primary tumors, patients with KRAS wild-type synchronous nonresectable liver-limited metastases from colorectal cancer were randomly assigned to receive chemotherapy (FOLFIRI [fluorouracil, leucovorin, and irinotecan] or mFOLFOX6 [modified fluorouracil, leucovorin, and oxaliplatin]) plus cetuximab (arm A) or chemotherapy alone (arm B)."5.17Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. ( Liu, TS; Qin, XY; Ren, L; Wei, Y; Xu, B; Xu, J; Ye, LC; Ye, QH; Yu, Y; Zai, SY; Zhu, DX, 2013)
" In this study, we determined the dose, efficacy, and tolerability of irinotecan according to UGT1A1 genotypes when combined with capecitabine in patients with metastatic colorectal cancer."5.17A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. ( Bae, KS; Chang, HM; Hong, YS; Kang, YK; Kim, HS; Kim, KP; Kim, TW; Lee, JL; Lee, JS; Shin, JG; Sym, SJ, 2013)
"In this multicenter, open-label, randomized phase 2 trial, the authors evaluated the vascular endothelial growth factor receptor inhibitor axitinib, bevacizumab, or both in combination with chemotherapy as first-line treatment of metastatic colorectal cancer (mCRC)."5.17Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study. ( Cartwright, TH; Cescon, TP; Cohn, AL; Edenfield, WJ; Hamm, JT; Infante, JR; Kim, S; Malik, IA; McGee, PJ; Rado, TA; Reid, TR; Richards, DA; Rosbrook, B; Tarazi, J, 2013)
"A novel combination of capecitabine, oxaliplatin, and bevacizumab was evaluated in colorectal cancer patients enrolled in a phase II clinical trial."5.17Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. ( Amara, A; Bulusu, A; Honeycutt, W; Hurwitz, HI; Liu, Y; Nixon, AB; Pang, H; Starr, MD; Wong, NS, 2013)
"To investigate the safety and efficacy of pemetrexed combined with chemotherapy as second or third line in patients with stage IV colorectal cancer (CRC)."5.17Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. ( Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; You, SX, 2013)
"Newly diagnosed K-RAS wild-type colorectal cancer patients with unresectable liver-only metastases were treated with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX6) plus cetuximab every 2 weeks for a maximum of 12 cycles."5.17Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. ( Baek, JY; Hong, YS; Ji, JH; Kang, HJ; Kim, KP; Kim, SY; Kim, TW; Lee, J; Park, SH; Park, YS; Shim, BY; Shin, SJ, 2013)
"The aim of this study was to evaluate 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET for early prediction of the standard anatomic response and survival outcomes in patients with metastatic colorectal cancer (mCRC) receiving leucovorin, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX)."5.173'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer. ( Hong, YS; Kim, HJ; Kim, HO; Kim, JS; Kim, KP; Kim, TW; Lee, JL; Lee, SJ; Moon, DH; Oh, SJ; Ryu, JS, 2013)
" This phase I/II trial assessed the safety and efficacy of capecitabine plus oxaliplatin (XELOX) plus bevacizumab and imatinib in the first-line treatment of patients with metastatic colorectal cancer."5.17Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. ( Arnold, D; Hacker, UT; Hallek, M; Hinke, A; Hochhaus, A; Hoehler, T; Hofheinz, R; Kanzler, S; Moehler, MH; Schimanski, C; Seufferlein, T; Siebler, J; von Wichert, G, 2013)
" This study investigated the effects of 5-fluorouracil (5-FU) chemotherapy on the levels of lipid peroxidation, reduced glutathione (GSH), glutathione peroxidase (GSH-Px), antioxidant vitamins, and elements in colorectal cancer patients."5.17Effects of 5-fluorouracil on oxidative stress and calcium levels in the blood of patients with newly diagnosed colorectal cancer. ( Koçer, M; Nazıroğlu, M, 2013)
"Twenty-nine unresectable colorectal cancer patients were stratified to either ≥70 or <60 years of age, where the disposition of capecitabine and its metabolites were compared."5.17Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030). ( Albain, KS; Blanke, CD; Coleman, D; Ely, B; Gold, PJ; Gotay, C; Lenz, HJ; Louie, SG; Raghavan, D; Shields, AF, 2013)
"The combination of bevacizumab and capecitabine is an effective and well-tolerated regimen for elderly patients with metastatic colorectal cancer."5.17Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. ( Andre, N; Cunningham, D; Jonker, D; Lang, I; Lorusso, V; Marcuello, E; Ocvirk, J; Osborne, S; Saunders, MP; Shin, DB; Waterkamp, D, 2013)
" We prospectively evaluated the impact of UGT1A genotypes and haplotypes on severe toxicity and efficacy in patients treated with fluorouracil, leucovorin, and irinotecan combination chemotherapy (FOLFIRI) for metastatic colorectal cancer (mCRC) from the two prospective multicenter phase II studies in Japan."5.17UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. ( Ando, H; Fujita, Y; Hamamoto, Y; Hazama, S; Hinoda, Y; Inoue, Y; Kanekiyo, S; Kato, T; Kobayashi, M; Mishima, H; Nagata, N; Nozawa, H; Oba, K; Oka, M; Okayama, N; Okuyama, Y; Sakamoto, J; Takahashi, K; Takemoto, H; Tsunedomi, R, 2013)
"The purpose of this multicenter phase II study was to evaluate the efficacy and safety of a combination of irinotecan, 5-fluorouracil (5-FU), and leucovorin (FOLFIRI) plus bevacizumab as first-line chemotherapy in Japanese patients with metastatic colorectal cancer."5.17FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. ( Akiyama, Y; Aoki, T; Fujii, M; Hagiwara, K; Hironaka, K; Kochi, M; Nakajima, T; Osuka, F; Takahashi, T; Takeuchi, M; Teranishi, F, 2013)
"The combination of oxaliplatin and oral capecitabine (XELOX) has shown to be an active regimen in metastatic colorectal cancer (MCRC)."5.17Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer. ( Alvarez, E; Campos, B; Candamio, S; Casal, J; Gallardo, E; Grande, C; Mel, JR; París Bouzas, L; Quintero, G; Villanueva, MJ, 2013)
"Current guidelines recommend treatment with capecitabine and bevacizumab for patients (pts) with non-resectable metastatic colorectal cancer (mCRC), although clinical data in this particular patient group are lacking."5.17Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial. ( Arnold, D; Behringer, D; Hegewisch-Becker, S; Kettner, E; Kirsch, A; Kretzschmar, A; Pflüger, KH; Stein, A; Wolff, T; Zimber, J, 2013)
"This study evaluated the activity of 2 schedules of erlotinib in combination with chemotherapy, and the prognostic significance of serum amphiregulin (AREG) and transforming growth factor alpha (TGFa) in metastatic colorectal cancer."5.17Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha. ( Ahuja, A; Chan, AT; Chan, C; Chan, SL; Dattatray, RD; Ho, WM; Hui, EP; King, AD; Lau, W; Ma, BB; Mo, F; Poon, A; To, KF; Wong, SC, 2013)
"Previous results of the EORTC intergroup trial 40983 showed that perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) increases progression-free survival (PFS) compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer."5.17Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. ( Bechstein, WO; Finch-Jones, M; Glimelius, B; Gruenberger, T; Jaeck, D; Mauer, M; Mirza, D; Nordlinger, B; Parks, RW; Poston, GJ; Primrose, JN; Rougier, P; Scheithauer, W; Schlag, PM; Sorbye, H; Tanis, E; Van Cutsem, E; Walpole, ET, 2013)
"The prognostic and predictive value of multiple serum biomarkers was evaluated using samples from a randomised phase III study (HORIZON II) investigating chemotherapy with or without cediranib in metastatic colorectal cancer (mCRC)."5.17Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy. ( Barry, ST; Hoff, PM; Jürgensmeier, JM; Morgan, SR; Pommier, AJ; Robertson, JD; Spencer, SK, 2013)
" This randomized, multicenter, parallel-group, open-label phase II trial compared axitinib with bevacizumab each in combination with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) or 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) for second-line treatment of metastatic colorectal cancer."5.17Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study. ( Barone, C; Bendell, JC; Bloom, J; Kim, JG; Kim, S; Pastorelli, D; Pericay, C; Ricart, AD; Rosbrook, B; Sobrero, AF; Swieboda-Sadlej, A; Tarazi, J; Tournigand, C; Wainberg, ZA, 2013)
"It was the aim of this study to evaluate maintenance therapy with bevacizumab + capecitabine following induction with bevacizumab + capecitabine + oxaliplatin (XELOX) versus bevacizumab + XELOX until progression as first-line therapy in metastatic colorectal cancer (mCRC)."5.17Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial. ( Buyukberber, S; Buyukunal, E; Camci, C; Cevik, D; Dane, F; Kilickap, S; Ozdener, F; Sencan, O; Uslu, R; Yalcin, S; Yilmaz, U; Zengin, N, 2013)
"This study aims to determine the efficacy and tolerability of capecitabine (CAP) plus bevacizumab (BEV) as treatment for frontline metastatic colorectal cancer (mCRC) in frail and/or elderly patients."5.17A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer. ( Chan, D; Dichmann, R; Hecht, JR; Hu, EH; Liem, AK; Naeim, A; Patel, R; Tchekmedyian, NS; Wainberg, ZA; Wang, HJ; Ward, PR, 2013)
"This phase II trial investigated the efficacy of an induction regimen of bevacizumab, capecitabine plus oxaliplatin (XELOX) followed by maintenance therapy with bevacizumab plus erlotinib as first-line therapy in patients with metastatic colorectal cancer."5.17Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer. ( Alonso, V; Bustos, IA; Cirera, L; Dueñas, R; Falcó, E; García-Girón, C; Muñoz, A; Pericay, C; Rivera, F; Salud, A, 2013)
" This investigation analyzed the value of Cet-ST for treatment efficacy in a randomized trial comparing cetuximab plus capecitabine/irinotecan to cetuximab plus capecitabine/oxaliplatin as first-line treatment of metastatic colorectal cancer."5.17Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu ( Giessen, C; Heinemann, V; Jung, A; Kapaun, C; Kirchner, T; Laubender, RP; Modest, DP; Moosmann, N; Neumann, J; Stintzing, S; Wollenberg, A, 2013)
"The phase III CONFIRM clinical trials demonstrated that metastatic colorectal cancer patients with elevated serum lactate dehydrogenase (LDH) had improved outcome when the vascular endothelial growth factor receptor (VEGFR) inhibitor PTK/ZK (Vatalanib) was added to FOLFOX4 chemotherapy."5.17Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib). ( Azuma, M; Danenberg, KD; Danenberg, PV; Folprecht, G; Ladner, RD; Lebwohl, D; Lenz, HJ; Meinhardt, G; Sherrod, A; Shi, MM; Trarbach, T; Wilson, PM; Yang, D; Zhang, W, 2013)
"This randomized, multicenter phase II study involved 80 metastatic colorectal cancer patients aged 70 years and above (performance status [PS] 0-2) or 65 years and above (PS 2), randomly assigned to arm A (capecitabine 1250 mg/m twice daily on days 1-14) or arm B (capecitabine 1000 mg/m twice daily on days 1-14, oxaliplatin 100 mg/m on day 1 initially, 130 mg/m for subsequent cycles)."5.17Randomized phase II study of capecitabine with or without oxaliplatin as first-line treatment for elderly or fragile patients with metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group CO06-01. ( Ahn, JB; Hong, YS; Jung, KH; Kim, HJ; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, JL; Park, YS; Shim, BY; Zang, DY, 2013)
"To investigate the association of colonic methane, formed by methanogenic achaea, and pH with gastrointestinal symptoms during colorectal cancer chemotherapy."5.17Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer. ( Blom, M; Holma, R; Korpela, R; Osterlund, P; Poussa, T; Rautio, M; Sairanen, U; Saxelin, M, 2013)
"The objective of this study was to compare the pharmacokinetics and safety of two tablet formulations containing 500 mg of capecitabine (CAS number 154361-50-9) in patients with colon, colorectal or breast cancer."5.17Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer. ( Chachad, S; Malhotra, G; Naidu, R; Purandare, S, 2013)
" The present study was an open-label, sequential-cohort, dose-escalation trial of intravenous aflibercept administered every 2 weeks in combination with 5-fluorouracil, levofolinate, and irinotecan (FOLFIRI) in patients with previously treated metastatic colorectal cancer (mCRC)."5.17A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. ( Asayama, M; Boku, N; Doi, T; Fujino, T; Machida, N; Ohtsu, A; Onozawa, Y; Yamaguchi, K; Yamazaki, K; Yoshino, T, 2013)
"The objective of this economic evaluation, which was based on patients from two randomized controlled clinical trials (NO16966 and NO16967), was to compare direct medical costs to the Australian health-care system of capecitabine plus oxaliplatin (XELOX) and bolus and/or infusional 5-fluorouracil (5-FU) plus folinic acid combined with oxaliplatin (modified [m] FOLFOX-6) in first-line and second-line treatment of advanced or metastatic colorectal cancer (mCRC)."5.17Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia. ( Gibbs, P; Hack, SP; Kerr, A; Price, T; Stokes, L; Todd, C; Tran, G, 2013)
"The combination of bevacizumab and bolus 5-fluorouracil, leucovorin and irinotecan is highly effective in patients with metastatic colorectal cancer (mCRC)."5.17Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu ( Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M, 2013)
"This double-blind, phase III study aimed to demonstrate that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in previously untreated metastatic colorectal cancer (mCRC)."5.17Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. ( Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA, 2013)
" We aimed at identifying novel genetic markers that would improve prediction of irinotecan toxicity and response in advanced colorectal cancer patients treated with folic acid (leucovorin), fluorouracil (5-FU), and irinotecan (camptosar)-based regimens."5.17Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens. ( Bélanger, AS; Cecchin, E; Couture, F; Guillemette, C; Harvey, M; Innocenti, F; Jonker, D; Lévesque, E; Toffoli, G, 2013)
"The optimal chemotherapeutic regimen suitable for metastatic colorectal cancer (mCRC) patients previously treated with 5-fluorouracil (5FU), oxaliplatin, irinotecan and biotherapies remains an unresolved issue."5.16Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies. ( Chauffert, B; Ghiringhelli, F; Guiu, B; Ladoire, S; Vincent, J, 2012)
"To assess safety and efficacy of folinic acid, 5-fluorouracil, gemcitabine (FFG) and folinic acid, fluorouracil, oxaliplatin (FOLFOX4) regimens with added bevacizumab as first-line treatment in patients with advanced colorectal cancer (CRC)."5.16Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. ( Gill, JF; Hentschel, P; Higby, DJ; Khan, MQ; Leichman, CG; Madajewicz, S; Malik, SK; Nicol, SJ; Ritch, PS; Waterhouse, DM; Zhao, L, 2012)
"The aim of this study is to prospectively evaluate the efficacy of combination chemotherapy with every second week cetuximab and irinotecan in patients with pretreated metastatic colorectal cancer harboring wild-type KRAS."5.16Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. ( Inaba, Y; Kato, M; Kawai, H; Komatsu, Y; Muro, K; Sato, Y; Shitara, K; Tajika, M; Takahari, D; Utsunomiya, S; Yamaura, H; Yamazaki, K; Yokota, T; Yoshida, M; Yuki, S, 2012)
"We conducted a Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics (PK) of CKD-732 [6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate] in combination with capecitabine and oxaliplatin (XELOX) in nine metastatic colorectal cancer patients who had progressed on irinotecan-based chemotherapy."5.16A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. ( Ahn, JB; Chung, HC; Hong, YS; Kim, C; Kim, DH; Kim, HR; Kim, TW; Lee, YJ; Park, KS; Rha, SY; Roh, JK; Shin, SJ, 2012)
"The authors evaluated the influence of 5-fluorouracil (5-FU) on treatment tolerability in 81 colorectal cancer patients given adjuvant 5-FU intravenously plus folinic acid for 6 cycles."5.16Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer. ( Amadori, D; Amatori, F; Danesi, R; Del Tacca, M; Di Paolo, A; Flamini, E; Ibrahim, T; Mercatali, L; Ravaioli, E; Sacanna, E, 2012)
" The primary objectives of this study were to determine the maximum tolerated dose of vandetanib with capecitabine and oxaliplatin, without and with bevacizumab, for the first line treatment of metastatic colorectal cancer (mCRC), and to define the dose limiting toxicities."5.16A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. ( Cabebe, EC; Fisher, GA; Sikic, BI, 2012)
" This prospective study was undertaken to examine the generation of oxidative stress, in 106 colorectal cancer patients, by 5-fluorouracil and oxaliplatin combination (FOLFOX) therapy as measured by urinary excretion of 8-oxo-7,8-dihydro-2-deoxyguanosine (8-oxodG) and 8-oxo-7,8-dihydro-guanosine (8-oxoGuo)."5.16Oxidative damage to guanine nucleosides following combination chemotherapy with 5-fluorouracil and oxaliplatin. ( Afzal, S; Henriksen, T; Jensen, SA; Poulsen, HE; Sørensen, JB; Weimann, A, 2012)
"This study was intended to ascertain the feasibility of a combination therapy with irinotecan by 24-h intravenous infusion (24-h CPT-11) and 5-fluorouracil (5-FU) for patients with metastatic colorectal cancer, to estimate the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD), to determine the recommended dose (RD) for the Phase II study, and to evaluate the efficacy of the combination therapy."5.16Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer. ( Gamo, M; Kambe, M; Kanamaru, R; Kikuchi, H; Ohashi, Y; Yoshioka, T, 2012)
" From August 2008 to December 2010, stage II and III colorectal cancer patients receiving capecitabine-based chemotherapy enrolled in the trial voluntarily."5.16Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. ( Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX, 2012)
"Patients with refractory metastatic colorectal cancer were randomized in a two-stage design to receive vorinostat at 800 or 1,400 mg/day once a day × 3, every 2 weeks."5.16A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. ( Fakih, MG; Groman, A; McMahon, J; Muindi, JR; Wilding, G, 2012)
"Molecular markers to predict response to 5-fluorouracil (FU)-based treatment of recurrent or metastasised colorectal cancer (mCRC) are not established."5.16Response prediction in metastasised colorectal cancer using intratumoural thymidylate synthase: results of a randomised multicentre trial. ( Danenberg, K; Danenberg, P; Goeb, R; Hebart, H; Henne-Bruns, D; Kornmann, M; Kron, M; Link, KH; Staib, L, 2012)
" This phase 2 study assessed enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab as maintenance therapy for metastatic colorectal cancer (MCRC)."5.16A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer. ( Di Bartolomeo, M; Fuchs, M; Heinemann, V; Hossain, AM; Nicol, S; Stoffregen, C; Wolff, RA, 2012)
"The AIO KRK-0306 trial compares the efficacy of infusional 5-fluorouracil, folinic acid, irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC)."5.16FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. ( Decker, T; Fischer von Weikersthal, L; Giessen, C; Heinemann, V; Heintges, T; Jäger, E; Jung, A; Kirchner, T; Modest, DP; Neumann, J; Scheithauer, W; Stintzing, S; Stoll, C; Vehling-Kaiser, U, 2012)
"The aim of this phase III trial was to compare the efficacy and safety of bevacizumab alone with those of bevacizumab and capecitabine plus oxaliplatin (XELOX) as maintenance treatment following induction chemotherapy with XELOX plus bevacizumab in the first-line treatment of patients with metastatic colorectal cancer (mCRC)."5.16First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. ( Abad, A; Antón, A; Aranda, E; Arrivi, A; Benavides, M; Cervantes, A; Díaz-Rubio, E; Dueñas, R; Escudero, P; Fernández-Martos, C; Gallén, M; Gómez-España, A; González, E; Lacasta, A; Llanos, M; López-Ladrón, A; Losa, F; Marcuello, E; Martínez de Prado, P; Massutí, B; Rivera, F; Safont, MJ; Sastre, J; Tabernero, JM; Valladares, M, 2012)
" This phase II study tested the efficacy and safety of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as first-line treatment for metastatic colorectal cancer patients."5.16A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. ( Burtness, B; Cohen, SJ; Denlinger, CS; Dotan, E; Lee, J; Meropol, NJ; Mintzer, D; Ruth, K; Sylvester, J; Tuttle, H; Zhu, F, 2012)
"Previous phase III studies raised concern about the safety of the combination of capecitabine and irinotecan in patients with metastatic colorectal cancer (mCRC)."5.16A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer. ( Chen, E; Feld, R; Knox, J; Krzyzanowska, MK; Liu, G; MacKay, H; Moore, MJ; Petronis, J; Renouf, DJ; Wang, L; Welch, S, 2012)
"Using the recommended doses obtained from our previous phase 1 trial of a modified Saltz chemotherapy regimen for metastatic colorectal cancer (weekly irinotecan and bolus 5-fluorouracil/l-leucovorin for 3 weeks every 28 days), we performed the present phase 2 trial to evaluate efficacy and toxicity."5.16Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients. ( Akashi, K; Baba, E; Esaki, T; Fujishima, H; Kusaba, H; Makiyama, A; Mitsugi, K; Nakano, S; Tanaka, R; Uchino, K, 2012)
"The addition of irinotecan to infusional 5 fluorouracil and leucovorin significantly improves the response rate and survival compared with 5 fluorouracil/leucovorin alone in metastatic colorectal cancer."5.16First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study. ( Assy, N; Basher, W; Chetver, L; Shnaider, J; Zidan, J, 2012)
"This phase I study evaluated sunitinib plus modified FOLFOX6 (mFOLFOX6: 5-fluorouracil, leucovorin and oxaliplatin) in Japanese patients with treatment-naïve metastatic colorectal cancer."5.16Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer. ( Boku, N; Hamaguchi, T; Hashigaki, S; Hirohashi, T; Kato, K; Lechuga, MJ; Li, Y; Ohtsu, A; Shibata, A; Shimada, Y; Yamazaki, K; Yasui, H; Yoshino, T, 2012)
"We previously reported a 35% overall response rate (ORR) with biweekly 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) plus irinotecan as first-line therapy in elderly patients with metastatic colorectal cancer (mCRC)."5.16Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. ( Alfaro, J; Aparicio, J; Aranda, E; Benavides, M; Cabrera, E; Campos, JM; Carrato, A; Dueñas, R; Etxeberría, A; Gil-Calle, S; Gómez, A; Gómez, MJ; González-Flores, E; Guasch, I; Marcuello, E; Massutí, B; Pericay, C; Queralt, B; Reina, JJ; Valladares-Ayerbes, M, 2012)
"The NORDIC-VII multicenter phase III trial investigated the efficacy of cetuximab when added to bolus fluorouracil/folinic acid and oxaliplatin (Nordic FLOX), administered continuously or intermittently, in previously untreated metastatic colorectal cancer (mCRC)."5.16Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. ( Birkemeyer, E; Christoffersen, T; Dahl, O; Dajani, O; Erdal, AB; Fokstuen, T; Glimelius, B; Guren, T; Hansen, F; Hofsli, E; Ikdahl, T; Johnsson, A; Keldsen, N; Kure, E; Pfeiffer, P; Pyrhonen, S; Sigurdsson, F; Skovlund, E; Sorbye, H; Starkhammar, H; Tveit, KM; Yilmaz, MK, 2012)
" Treatment consisted of first-line chronomodulated or conventional delivery of 5-fluorouracil, leucovorin and oxaliplatin for metastatic colorectal cancer."5.16Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. ( Bjarnason, GA; Coudert, B; Durando, X; Focan, C; Garufi, C; Giacchetti, S; Iacobelli, S; Innominato, PF; Lévi, FA; Mormont, MC; Tampellini, M; Waterhouse, J, 2012)
"To evaluate the safety and efficacy of combination chemotherapy with 5-fluorouracil (5-FU), leucovorin, irinotecan and oxaliplatin (FOLFOXIRI) in Japanese patients with advanced colorectal cancer."5.16A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28. ( Akiyama, Y; Araki, K; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Nagashima, F; Saji, S; Sasaki, Y; Sunakawa, Y; Yamamoto, W; Yamashita, K, 2012)
"The primary objective of this study is to evaluate the safety, tolerance, and pharmacokinetic profile of liver-directed therapy with drug-eluting beads irinotecan (DEBIRI) in combination with systemic modified FOLFOX in the treatment of unresectable liver metastases in chemotherapy-naive patients with colorectal cancer."5.16Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. ( Martin, RC; Metzger, T; Schreeder, M; Scoggins, CR; Sharma, V; Tatum, C; Tomalty, D, 2012)
"To evaluate the maximum tolerated dose (MTD) and pharmacokinetic profile of a chronomodulated, dose-intensified regimen of capecitabine in combination with oxaliplatin (XELOX) in metastatic colorectal cancer (mCRC)."5.16Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. ( Chen, X; Choo, SP; Chowbay, B; Farid, M; Koo, WH; Ong, SY; Ramasamy, S; Tan, SH; Toh, HC, 2012)
"Patients with clinical T3/4 colorectal cancer were randomly assigned to receive the preoperative administration of tegafur suppositories (group A) or no preoperative treatment (group B)."5.16Usefulness of the preoperative administration of tegafur suppositories as alternative adjuvant chemotherapy for patients with resectable stage II or III colorectal cancer: a KODK4 multicenter randomized control trial. ( Hasegawa, H; Hisa, A; Kitagawa, Y; Ohishi, T; Okabayashi, K; Watanabe, M, 2012)
"S-1 is effective in sequential combination with irinotecan (IRIS) in treating metastatic colorectal cancer."5.16Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients. ( Akiyama, S; Andoh, H; Gamoh, M; Ishioka, C; Kato, S; Maeda, S; Mori, T; Murakawa, Y; Ohori, H; Sasaki, Y; Shimodaira, H; Suzuki, T; Takahashi, S; Yamaguchi, T; Yoshioka, T, 2012)
"A total of 106 patients planned for palliative single-agent capecitabine (53 in each arm, 65%/35% colorectal/breast cancer) were randomised to receive either concomitant pyridoxine (50 mg po) or matching placebo three times daily."5.16A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications. ( Ahmad, A; Armstrong, G; Blesing, C; Bond, S; Bulusu, R; Corrie, PG; Daniel, F; Hardy, R; Hill, M; Lao-Sirieix, S; McAdam, K; Moody, AM; Osborne, M; Parashar, D; Wilson, CB; Wilson, G, 2012)
"Treatment for metastatic colorectal cancer (mCRC) commonly involves a fluoropyrimidine-based chemotherapy regimen such as infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) or fluorouracil, leucovorin, and oxaliplatin, often combined with bevacizumab or an epidermal growth factor receptor monoclonal antibody."5.16Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. ( Allegra, C; Castan, R; Ferry, D; Lakomy, R; Macarulla, T; McKendrick, J; Moiseyenko, V; Polikoff, J; Prausová, J; Prenen, H; Ruff, P; Tabernero, J; Tellier, A; Van Cutsem, E; van Hazel, GA, 2012)
"To compare the efficacy of cediranib (a vascular endothelial growth factor receptor tyrosine kinase inhibitor [VEGFR TKI]) with that of bevacizumab (anti-VEGF-A monoclonal antibody) in combination with chemotherapy as first-line treatment for advanced metastatic colorectal cancer (mCRC)."5.16Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). ( Barker, P; Bodoky, G; Bondarenko, I; Cunningham, D; Karapetis, CS; Kocakova, I; Koski, SL; Mainwaring, P; Mookerjee, B; Robertson, J; Rougier, P; Salazar, R; Schmoll, HJ; Sobrero, A; Van Cutsem, E, 2012)
" HORIZON II [Cediranib (AZD2171, RECENTIN) in Addition to Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer] assessed infusional fluorouracil, leucovorin, and oxaliplatin/capecitabine and oxaliplatin (FOLFOX/CAPOX) with or without cediranib in patients with previously untreated metastatic colorectal cancer (mCRC)."5.16Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II). ( Cheng, Y; Fielding, A; Hochhaus, A; Hoff, PM; Kim, TW; Koynov, KD; Kurteva, G; Li, J; Pestalozzi, BC; Pike, L; Pintér, T; Robertson, JD; Saunders, MP; Tebbutt, NC; van Eyll, B, 2012)
"Capecitabine plus oxaliplatin (CapeOX) is one of the reference doublet cytotoxic chemotherapy treatments for patients with metastatic colorectal cancer."5.16S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. ( Baek, JY; Cho, SH; Chung, IJ; Hong, YS; Jo, SJ; Kang, HJ; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, J; Lee, JW; Lee, KH; Lee, KW; Lim, HY; Park, YS; Shin, DB; Shin, SJ, 2012)
"The aim of this study was to investigate the value of the cyclin D1 isoforms D1a and D1b as prognostic factors and their relevance as predictors of response to adjuvant chemotherapy with 5-fluorouracil and levamisole (5-FU/LEV) in colorectal cancer (CRC)."5.16Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. ( Dahl, O; Elsaleh, H; Fluge, Ø; Knudsen, ES; Leh, S; Li, Z; Myklebust, MP; Myrvold, HE; Pestell, RG; Rui, H; Tran, TH; Tveit, KM; Vonen, B, 2012)
"In the MACRO study, patients with metastatic colorectal cancer (mCRC) were randomised to first-line treatment with 6 cycles of capecitabine and oxaliplatin (XELOX) plus bevacizumab followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression."5.16Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study. ( Aranda, E; Arrivi, A; Bando, I; Benavides, M; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Gómez-España, A; González, E; Manzano, JL; Marcuello, E; Martínez de Prado, P; Massutí, B; Montagut, C; Reboredo, M; Rivera, F; Safont, MJ; Sastre, J, 2012)
"Irinotecan and 5-fluorouracil (5-FU) are used to treat metastatic colorectal cancer."5.15Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. ( Berglund, A; Berglund, M; Byström, P; Fredriksson, LA; Garmo, H; Glimelius, B; Kohnke, H; Sørbye, H; Wadelius, M, 2011)
"A regimen consisting of 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) is widely used in France in the first-line treatment of metastatic colorectal cancer (MCRC)."5.15Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. ( Adenis, A; Bennouna, J; Bergougnoux, L; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Lledo, G; Rebischung, C; Ychou, M, 2011)
"To evaluate the efficacy and tolerability of systemic chemotherapy with irinotecan (CPT-11), UFT and leucovorin (LV) combined with hepatic arterial infusion (HAI) consisting of 5-fluorouracil (5-FU) in colorectal cancer patients with unresectable liver metastases."5.15Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases. ( Matsumoto, H; Mori, T; Takahashi, K; Yamaguchi, T; Yasutome, M, 2011)
"In view of a potential gain in anticancer activity in advanced colorectal cancer (ACRC), there has been considerable interest in using a higher than the approved standard dose of capecitabine (CCB) combined with oxaliplatin."5.15Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen. ( Czejka, M; Farkouh, A; Gruenberger, B; Scheithauer, W; Schueller, J, 2011)
"To evaluate the efficacy, safety and quality of life of a short course of oxaliplatin plus capecitabine (XELOX) followed by single-agent capecitabine in patients with previously untreated, inoperable, metastatic colorectal cancer."5.15Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. ( Allen, J; Bentley, D; Gollins, S; Lloyd, A; Morris, J; Saunders, MP; Soe, W; Swindell, R; Taylor, MB; Valle, J; Waddell, T, 2011)
"Infusional 5-fluorouracil and leucovorin with oxaliplatin is one of the standard regimens for patients with pretreated metastatic colorectal cancer, as well as for first-line chemotherapy."5.15A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer. ( Esaki, T; Fujii, H; Inaba, Y; Kato, K; Kusaba, H; Mizuno, T; Mizunuma, N; Muro, K; Shimada, Y; Shirao, K; Tsuji, Y; Yoshioka, A, 2011)
"This phase I/II study determined the recommended dose of FOLFIRI (irinotecan, infusional 5-fluorouracil and leucovorin) for Japanese patients with advanced colorectal cancer, and evaluated safety at the recommended dose in patients without the UDP-glucuronosyltransferase 1A1*28 allele which caused reduced enzyme expression."5.15Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer. ( Akiyama, Y; Ando, M; Ando, Y; Endo, H; Fujita, K; Kawara, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Yamamoto, W; Yamashita, K, 2011)
"The aim of the present trial was to evaluate whether an intermittent chemotherapy with levo-leucovorin + 5-fluorouracil (5-FU) + irinotecan (CPT-11) was at least as effective as the same regimen given continuously, both administered until progression, in patients affected with advanced colorectal cancer and not previously exposed to chemotherapy for metastatic disease."5.15Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. ( Aglietta, M; Barni, S; Beretta, GD; Corsi, D; Cortesi, E; Dapretto, E; Floriani, I; Fornarini, G; Isa, L; Labianca, R; Lonardi, S; Nicolella, D; Sobrero, A; Turci, D; Zaniboni, A, 2011)
"The primary aim of the high-dose 5-fluorouracil (5-FU) and leucovorin (LV; HDFL48) phase I study was to determine the maximum tolerated dose and dose-limiting toxicity of 5-FU and LV with modified tri-monthly 48-h continuous infusion of high-dose 5-FU/LV in patients with metastatic colorectal cancer."5.15Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. ( Chen, RR; Cheng, AL; Ho, YF; Lu, WC; Yeh, KH, 2011)
"This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin, levoforinate, and infusional 5-fluorouracil (FOLFOX4) as a second-line therapy for Japanese patients with unresectable advanced or metastatic colorectal cancer."5.15A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience. ( Emi, Y; Fujita, F; Hasegawa, H; Inomata, M; Kakeji, Y; Kitazono, M; Maehara, Y; Morikita, T; Ogata, Y; Oki, E; Sadanaga, N; Saeki, H; Samura, H; Shirabe, K; Shirouzu, K; Tanaka, T; Tokunaga, S; Yamamoto, M, 2011)
"The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status was predictive for outcome in patients receiving cetuximab plus FOLFOX-4 (oxaliplatin/5-fluorouracil/folinic acid) as first-line therapy for metastatic colorectal cancer (mCRC)."5.15Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. ( Bokemeyer, C; Bondarenko, I; Celik, I; de Braud, F; Hartmann, JT; Koralewski, P; Schlichting, M; Schuch, G; Zubel, A, 2011)
"This study was designed to determine the efficacy and tolerability of capecitabine, oxaliplatin and bevacizumab in combination with cetuximab as first-line therapy for advanced colorectal cancer."5.15A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. ( Aklilu, M; Ashton, J; Bendell, JC; Blobe, GC; Cushman, S; Fernando, NH; Hurwitz, HI; Morse, MA; Nixon, AB; Pang, H; Wong, NS, 2011)
"The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of cetuximab combined with capecitabine and irinotecan (CAPIRI) or capecitabine and oxaliplatin (CAPOX) in the first-line treatment of metastatic colorectal cancer (mCRC)."5.15Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Haberl, C; Hass, HG; Heinemann, V; Jung, A; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schalhorn, A; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF; Zellmann, K, 2011)
"0 mg/kg q2w, concomitantly with a combination of capecitabine and oxaliplatin (XELOX) and FOLFOX-4 (oxaliplatin in combination with infusional 5-FU/LV), respectively, in patients with metastatic colorectal cancer (mCRC)."5.15A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer. ( Abt, M; Burns, I; Chen, E; Goldstein, D; Major, P; McKendrick, J; Rittweger, K; Robinson, B; Zhi, J, 2011)
"To observe the effect of modified Sijunzi Decoction (SJZD) on immune function in patients with colorectal cancer undergoing chemotherapy (CM) with FOLFOX4 protocol (oxaliplatin + calcium folinate + 5-fluorouracil)."5.15[Immune enhancing effect of modified sijunzi decoction on patients with colorectal cancer undergoing chemotherapy]. ( Xiao, H; Yang, J, 2011)
"A combination of fluorouracil and leucovorin (5-FU/LV) with oxaliplatin (FOLFOX) is an established first-line therapy for metastatic colorectal cancer (mCRC)."5.15Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study. ( Fujiwara, M; Iwata, N; Kodera, Y; Koike, M; Nakao, A; Nakayama, G; Ohashi, N; Okuda, N; Tanaka, C; Watanabe, T; Yokoyama, H, 2011)
"The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease."5.15Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. ( Cascinu, S; Celik, I; Ciardiello, F; Cunningham, D; Folprecht, G; Köhne, CH; Láng, I; Maurel, J; Nowacki, MP; Rougier, P; Schlichting, M; Shchepotin, I; Tejpar, S; Van Cutsem, E; Zubel, A, 2011)
"A subgroup of patients from the CAIRO2 study (randomized phase III study on capecitabine, oxaliplatin, bevacizumab with or without cetuximab in first-line advanced colorectal cancer) that received capecitabine plus oxaliplatin (CAPOX) treatment in combination with bevacizumab was selected."5.15Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer. ( De Bruijn, MT; Hinrichs, J; Kranenburg, O; Punt, CJ; Raats, DA; Rinkes, IH; Teerenstra, S; Tol, J, 2011)
"We report updated overall survival (OS) data from study NO16966, which compared capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX4) as first-line therapy in metastatic colorectal cancer."5.15XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. ( Cassidy, J; Clarke, S; Díaz-Rubio, E; Figer, A; Gilberg, F; Koski, S; Rittweger, K; Saltz, L; Scheithauer, W; Wong, R, 2011)
"The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and combination of capecitabine with oxaliplatin (CAPOX) plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC)."5.15Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Fischer von Weikersthal, L; Giessen, C; Haberl, C; Hass, HG; Heinemann, V; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; Zellmann, K, 2011)
"This study was designed to determine the efficacy and tolerability of a novel 2-week regimen of capecitabine, oxaliplatin (OHP), and bevacizumab in patients with chemo-naive advanced colorectal cancer."5.15A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. ( Bendell, JC; Blobe, GC; Fernando, NH; Honeycutt, W; Hurwitz, HI; Morse, MA; Pang, H; Wong, NS, 2011)
" However, circadian chronomodulated chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin (chronoFLO4) offered no survival benefit as compared with the non-time-stipulated FOLFOX2, in an international randomized trial involving patients with previously untreated metastatic colorectal cancer (EORTC 05963)."5.15Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). ( Bjarnason, GA; Carvalho, C; Focan, C; Garufi, C; Giacchetti, S; Iacobelli, S; Innominato, PF; Karaboué, A; Lévi, F; Moreau, T; Smaaland, R; Tampellini, M; Tumolo, S, 2011)
"A week on/week off capecitabine schedule with oxaliplatin/bevacizumab was evaluated in patients with metastatic colorectal cancer (mCRC)."5.15A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer. ( Balaban, EP; Crandall, TL; Kane, P; Lembersky, BC; Pinkerton, RA; Potter, DM; Rajasenan, KK; Ramanathan, RK; Schmotzer, A; Sehgal, R; Zeh, H, 2011)
"The present study was done to establish a prognostic model for patients and trials using an oxaliplatin-based or irinotecan-based first-line chemotherapy in metastatic colorectal cancer."5.15Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. ( André, T; Artru, P; Bengrine-Lefevre, L; Bonnetain, F; Chibaudel, B; de Gramont, A; Desramé, J; Larsen, AK; Louvet, C; Teixeira, L; Tournigand, C, 2011)
"The AIO KRK 0110/ML22011 trial is a two-arm, multicenter, open-label randomized phase III trial comparing the efficacy and safety of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in the first-line treatment of metastatic colorectal cancer."5.15A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial. ( Aubele, P; Bangerter, M; Denzlinger, C; Freiberg-Richter, J; Giessen, C; Heinemann, V; Hinke, A; Kullmann, F; Mayerle, J; Modest, DP; Moosmann, N; Schulz, C; Sieber, M; Stintzing, S; Teschendorf, C; Vehling-Kaiser, U; von Weikersthal, LF, 2011)
"In this open-label, randomised, phase 3 trial, we randomly assigned patients (1:1 ratio) with advanced, measurable, non-resectable colorectal cancer and WHO performance status 0-2 to receive either first-line treatment with bolus (400 mg/m(2)) and infusional (2400 mg/m(2)) fluorouracil plus leucovorin (400 mg/m(2)) (simplified LV5FU2 regimen), second-line LV5FU2 plus oxaliplatin (100 mg/m(2)) (FOLFOX6), and third-line LV5FU2 plus irinotecan (180 mg/m(2)) (FOLFIRI) or first-line FOLFOX6 and second-line FOLFIRI."5.15Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial. ( Abbas, M; Auby, D; Azzedine, A; Bedenne, L; Bouché, O; Castaing, M; Denis, B; Ducreux, M; Etienne, PL; Gargot, D; Gasmi, M; Geoffroy, P; Lombard-Bohas, C; Malka, D; Mendiboure, J; Michel, P; Pignon, JP; Rougier, P; Texereau, P, 2011)
"Efforts to improve efficacy and minimize toxicity have led to pharmacokinetic monitoring of plasma 5-Fluorouracil (5-FU) levels in colorectal cancer patients undergoing chemotherapy."5.15Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. ( Beachler, C; El-Deiry, WS; Finnberg, NK; Gingrich, R; Kline, CL; Liao, J; Scicchitano, A; Sheikh, HS; Sivik, J, 2011)
"An ancillary phase II study was conducted to study interindividual variability in cetuximab pharmacokinetics and its influence on progression-free survival (PFS) in metastatic colorectal cancer patients cotreated with irinotecan and 5-fluorouracil."5.15Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ( Azzopardi, N; Boisdron-Celle, M; Gamelin, E; Gouilleux-Gruart, V; Lecomte, T; Morel, A; Paintaud, G; Piller, F; Ternant, D; Vignault-Desvignes, C; Watier, H, 2011)
"The efficacy and safety of bevacizumab with modified irinotecan, leucovorin bolus, and 5-fluorouracil intravenous infusion (mIFL) in the first-line treatment of metastatic colorectal cancer (mCRC) has not been well evaluated in randomized clinical trials in Chinese patients."5.15Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. ( Ba, Y; Feng, FY; Guan, ZZ; He, J; Liang, J; Luo, RC; Qi, C; Qin, SK; Shen, L; Wang, D; Wang, JJ; Wang, LW; Xu, JM; Xu, RH; Yu, SY, 2011)
"This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin in combination with levofolinate and infusion 5-fluorouracil (FOLFOX4) as first-line therapy for Japanese patients with unresectable metastatic colorectal cancer."5.15A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience. ( Baba, H; Egashira, A; Emi, Y; Fujita, F; Hasegawa, H; Hayashi, N; Higashi, H; Inomata, M; Kakeji, Y; Kohakura, F; Kohnoe, S; Maehara, Y; Niwa, K; Ogata, Y; Ohga, T; Oki, E; Samura, H; Shirabe, K; Tokunaga, S; Toyama, T; Yamamoto, M, 2011)
"In a multicenter, double-blind phase II trial, we compared the efficacy and safety of perifosine plus capecitabine (P-CAP) with placebo plus capecitabine (CAP) in patients with metastatic colorectal cancer (mCRC) who had progressed after as many as two prior therapies."5.15Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. ( Bendell, JC; Campos, LT; Gardner, L; Hagenstad, C; Hermann, RC; Nemunaitis, J; Richards, DA; Sportelli, P; Vukelja, SJ, 2011)
" We evaluated the efficacy and safety of cetuximab plus 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX), the ERBIRINOX regimen, as first-line treatment in patients with unresectable metastatic colorectal cancer (mCRC)."5.15Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. ( Assenat, E; Bibeau, F; Bleuse, JP; Crapez-Lopez, E; Desseigne, F; Kramar, A; Mineur, L; Portales, F; Samalin, E; Thezenas, S; Viret, F; Ychou, M, 2011)
"This study investigated the antitumour and chemosensitizing effects of celecoxib in the treatment of advanced colorectal cancer."5.15Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer. ( Chen, JM; Jin, CH; Li, RX; Liu, XM; Wang, AH; Wang, GP; Xing, LQ, 2011)
"To observe the efficacy, side effects and impact on the quality of life of Aidi Injection combined with leucovorin calcium/5-fluorouracil/oxaliplatin (FOLFOX4 regimen) in the treatment of advanced colorectal cancer patients."5.15A clinical study on safety and efficacy of Aidi injection combined with chemotherapy. ( Huang, XE; Li, CG; Li, Y; Tang, JH; Xu, HX, 2011)
"Irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI) is accepted as a reference treatment for the first-line treatment of patients with metastatic colorectal cancer (MCRC)."5.14Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the ( Aranda, E; Benavides, M; Cámara, JC; Carrato, A; Constenla, M; Díaz-Rubio, E; Dueñas, R; Gomez, A; Marcuello, E; Martinez-Villacampa, M; Massutti, B; Navarro, M; Reboredo, M; Valladares, M, 2009)
"Oxaliplatin combined with either fluorouracil/leucovorin (OXAFAFU) or capecitabine (OXXEL) has a demonstrated activity in metastatic colorectal cancer patients."5.14Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. ( Barberis, G; Cannone, M; Comella, P; Condemi, G; Farris, A; Filippelli, G; Maiorino, L; Massidda, B; Natale, D; Palmeri, S, 2009)
"The combination of oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX-4) is still a reference regimen in advanced colorectal cancer; however, the addition of new biologic compounds represents a significant way forward."5.14An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. ( Anthoney, A; Bauer, J; Caponigro, F; Govaerts, AS; Lacombe, D; Marréaud, S; Milano, A; Twelves, C, 2009)
"Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatments for patients with metastatic colorectal cancer (mCRC)."5.14Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. ( Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J, 2009)
"This study evaluated the maximum tolerated dose (MTD) and the dose limiting toxicity (DLT) of erlotinib when combined to irinotecan and capecitabine in pre-treated metastatic colorectal cancer patients."5.14Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. ( Bajetta, E; Bajetta, R; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Galassi, M; Gevorgyan, A; Mariani, L; Venturino, P, 2009)
"5-Fluorouracil refractory metastatic colorectal cancer patients were intravenously treated with HA-Irinotecan (300 mg/m(2) irinotecan with 1,000 mg/m(2) HA) on day 1 of a 21-day cycle."5.14A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients. ( Brown, TJ; Cinc, E; Fox, RM; Gibbs, P; Jennens, R; Michael, M; Ng, R; Pho, M, 2009)
"Thirty-one patients with non-resectable, colorectal cancer (CRC) liver metastases received irinotecan 120 mg/m(2), followed by leucovorin (LV) 20 mg/m(2) and 5-fluorouracil (5-FU) 500 mg/m(2) administered by HAI every 2 weeks, plus UFT (tegafur-uracil) 200 mg/m(2)/day with LV 30 mg/day on days 1-22, followed by a 6-day rest."5.14Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer. ( Ariche, A; Baruch, NB; Brenner, B; Dinerman, M; Greif, F; Idelevich, E; Kashtan, H; Mavor, E; Miller, R; Shani, A; Susmalian, S, 2009)
"For the purpose of developing a longitudinal model to predict hand-and-foot syndrome (HFS) dynamics in patients receiving capecitabine, data from two large phase III studies were used."5.14A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. ( Cassidy, J; Dartois, C; Freyer, G; Girard, P; Hénin, E; Hoff, PM; Sirzen, F; Tod, M; Twelves, C; VanCutsem, E; You, B; Zuideveld, KP, 2009)
"This phase II study was conducted to determine the efficacy and safety of capecitabine and bevacizumab in untreated elderly metastatic colorectal cancer patients."5.14A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. ( Fakih, MG; Khushalani, N; Mashtare, T; Puthillath, A; Romano, K; Ross, ME; Steinbrenner, L; Wilding, G; Wisniewski, M, 2009)
"A total of 91 ACC patients received capecitabine and oxaliplatin (CAPOX) as a part of a multicentre phase-III study of the Dutch Colorectal Cancer Group."5.14Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Nortier, JW; Punt, CJ; Van der Straaten, T, 2009)
"This study assessed radiotherapy combined with capecitabine and oxaliplatin in patients with primary, inextirpable colorectal adenocarcinoma."5.14Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study. ( Anderson, H; Berglund, K; Byström, P; Ekelund, M; Fernebro, E; Glimelius, B; Gunnlaugsson, A; Holm, T; Johnsson, A; Kjellén, E; Påhlman, L, 2009)
"This randomized study assessed whether the best overall response rate (ORR) of cetuximab combined with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) was superior to that of FOLFOX-4 alone as first-line treatment for metastatic colorectal cancer."5.14Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. ( Aparicio, J; Bokemeyer, C; Bondarenko, I; de Braud, F; Donea, S; Hartmann, JT; Koralewski, P; Loos, AH; Ludwig, H; Makhson, A; Schuch, G; Stroh, C; Zubel, A, 2009)
"Second-line irinotecan-based chemotherapy is commonly used in metastatic colorectal cancers after first-line oxaliplatin-based chemotherapy."5.14Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. ( André, T; Bengrine-Lefevre, L; Bidard, FC; Cervantes, A; de Gramont, A; Figer, A; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2009)
"We randomly assigned 755 patients with previously untreated metastatic colorectal cancer to capecitabine, oxaliplatin, and bevacizumab (CB regimen, 378 patients) or the same regimen plus weekly cetuximab (CBC regimen, 377 patients)."5.14Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. ( Antonini, NF; Cats, A; Creemers, GJ; Dalesio, O; Dijkstra, JR; Erdkamp, FL; Koopman, M; Mol, L; Punt, CJ; Richel, DJ; Rodenburg, CJ; Schrama, JG; Sinnige, HA; Tol, J; van Groeningen, CJ; van Krieken, JH; Vink-Börger, ME; Voest, EE; Vos, AH, 2009)
"This Simon 2-stage phase II trial was designed to document antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer (CRC)."5.14Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer. ( Grossbard, M; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Wasserman, C, 2009)
"An economic analysis (based on interim data from a long-term, randomised, multi-centre, controlled, clinical trial) to evaluate chemotherapy with XELOX (capecitabine/oxaliplatin) versus FOLFOX6 (5Fluorouracil/leucovorin/oxaliplatin) as an adjuvant treatment for high risk colorectal cancer patients in Greece."5.14XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis. ( Fountzilas, G; Fragoulakis, V; Maniadakis, N; Pectasides, D, 2009)
" This phase III randomized multicenter trial investigated the benefit of adding ED to fluorouracil (FU) based therapy in patients with stage III colorectal cancer."5.14Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer. ( Bernard, S; Cohen, A; Eisenberg, P; Fields, AL; Forster, J; Kardinal, C; Keller, A; Schulz, J; Schwartzberg, L; Wissel, P, 2009)
"Oxaliplatin is a promising drug for cancer therapy and the oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) regimen has become the standard adjuvant treatment for colorectal cancer."5.14Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. ( Airoldi, M; Cattel, L; Drescher, A; Jaehde, U; Milla, P; Weber, G, 2009)
"We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS gene in tumors and clinical response to cetuximab."5.14Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. ( Bodoky, G; Chang Chien, CR; D'Haens, G; Folprecht, G; Hitre, E; Köhne, CH; Lim, R; Makhson, A; Nippgen, J; Pintér, T; Roh, JK; Rougier, P; Ruff, P; Schlichting, M; Stroh, C; Tejpar, S; Van Cutsem, E; Zaluski, J, 2009)
"This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer."5.14Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. ( Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009)
"Irinotecan-based chemotherapy regimens are 1 option for treatment of metastatic colorectal cancer (mCRC)."5.14Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. ( Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X, 2009)
"The present study aimed at investigating whether the simultaneous evaluation of pharmacokinetic, pharmacogenetic and demographic factors could improve prediction on toxicity and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil (5FU)/leucovorin therapy."5.14Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. ( Barile, C; Bolzonella, C; Bononi, A; Crepaldi, G; Ferrazzi, E; Frigo, AC; Gusella, M; Marinelli, R; Menon, D; Padrini, R; Pasini, F; Stievano, L; Toso, S, 2009)
"Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC)."5.14Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. ( Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E, 2009)
"The purpose of the study was to evaluate the cost-effectiveness of capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX4) as first-line or second-line chemotherapy in patients with metastatic colorectal cancer."5.14Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. ( Fukuda, T; Shiroiwa, T; Tsutani, K, 2009)
"To identify new polymorphisms (single nucleotide polymorphisms, SNPs) in DNA repair pathways that are associated with efficacy and toxicity in patients receiving oxaliplatin and capecitabine for advanced colorectal cancer (ACC)."5.14Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Nortier, JW; Punt, CJ, 2009)
"Bevacizumab (BV) prolongs the survival of colorectal cancer patients when combined with irinotecan (CPT-11)-based regimens."5.14Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy. ( Hamaguchi, T; Hirashima, Y; Horita, Y; Kato, K; Nakajima, T; Shimada, Y; Yamada, Y, 2010)
"Studies indicate that adjuvant 5-fluorouracil (5-FU) with folinic acid (FA) in colorectal cancer patients with completely resectable liver-limited metastases (LMCRC) offers clinical benefit over surgery alone."5.14A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. ( Bokemeyer, C; Hohenberger, W; Kwok-Keung Choi, C; Maurel, J; Navarro, M; Rivera, F; Santoro, A; Shacham-Shmueli, E; Thezenas, S; Ychou, M, 2009)
"To evaluate the efficacy of bevacizumab in combination of irinotecan,fluorouracil and leucovorin for metastatic colorectal cancer treated by failed prior oxaliplatin -based regiment."5.14[Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer]. ( Chen, B; Chen, JZ; Cui, F; Luo, RC; Wan, C; Zheng, H, 2009)
"To evaluate the efficacy and safety of irinotecan combined with xeloda (CAPIRI regimen) in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin."5.14[Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin]. ( Bai, CM; Chen, SC; Cheng, YJ; Jia, N; Shao, YJ; Zhou, JF, 2009)
"The aim of the current study was the investigation of the value of bevacizumab+5-fluorouracil(5-FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options."5.14Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial. ( Caricato, M; Coppola, R; Gasparro, S; Rizzo, S; Russo, A; Santini, D; Spoto, C; Tonini, G; Valeri, S; Venditti, O; Vincenzi, B; Zobel, BB, 2009)
"Bevacizumab (Avastin) significantly improves overall survival (OS) and progression-free survival (PFS) when combined with first-line irinotecan (IFL) plus bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic colorectal cancer (CRC)."5.14Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. ( Ackland, S; Chiara, S; Clarke, S; Gapski, J; Langer, B; Mainwaring, P; Perez-Carrión, R; Sobrero, A; Young, S, 2009)
"In the present study, either modified IFL regimen (modified irinotecan, fluorouracil and leucovorin, mIFL) alone or in combination with bevacizumab was used to treat patients with metastatic colorectal cancer (CRC)."5.14Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin. ( Huang, YT; Liao, WJ; Luo, W; Ma, L; Shi, M; Wang, XN; Wen, Q, 2010)
"Combination chemotherapy with oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) has become a standard regimen for colorectal cancer."5.14Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients. ( Ikeguchi, M; Kanazawa, A; Katano, K; Kidani, A; Makino, M; Ozaki, N; Sugimoto, S; Takeda, H; Tanaka, T; Yoshimura, H, 2009)
"To determine the efficacy and tolerability of capecitabine combined with oxaliplatin (CAPOX) or irinotecan (CAPIRI) as first-line treatment in patients with advanced/metastatic colorectal cancer aged > or =70 years."5.14Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. ( Bordonaro, R; Caputo, G; Cordio, S; Manzione, L; Novello, G; Reggiardo, G; Rosati, G, 2010)
"A subgroup analysis of oxaliplatin (LOHP)+irinotecan (CPT-11)+5-fluorouracil (5FU) and leucovorin (LV) (FOLFOXIRI regimen) versus irinotecan+5FU/LV (FOLFIRI regimen) as first-line treatment of patients >65 years old with metastatic colorectal cancer is presented."5.14Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG). ( Athanasiadis, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Karampeazis, A; Kouroussis, Ch; Polyzos, A; Souglakos, J; Vamvakas, L; Ziras, N, 2010)
"To determine the efficacy and tolerability of oral fluoropyrimidine S-1 plus irinotecan in patients with previously untreated advanced colorectal cancer."5.14Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer. ( Kusano, M; Matsui, N; Nakao, K; Narita, K; Tsunoda, A; Watanabe, M; Yasuda, N, 2009)
"To assess the resectability rate of patients with initially unresectable liver-only metastases from colorectal cancer (CRC) after treatment with irinotecan/capecitabine."5.14A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer. ( Cai, J; Ji, X; Li, Q; Tucker, S; Wan, F; Wang, D; Zhao, R; Zhong, B; Zhu, J, 2010)
"This study compared chemotherapy discontinuation with maintenance therapy with leucovorin and fluorouracil after six cycles of folinic acid, fluorouracil, and oxaliplatin (FOLFOX) chemotherapy in the first-line treatment of metastatic colorectal cancer."5.14Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. ( Afchain, P; André, T; Artru, P; Bennamoun, M; Carola, E; Chibaudel, B; Colin, P; de Gramont, A; Dupuis, O; Flesch, M; Larsen, AK; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Mineur, L; Tournigand, C, 2009)
"A phase-III trial showed the non-inferiority of oral capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) in terms of efficacy in first-line treatment of metastatic colorectal cancer."5.14Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer. ( Adenis, A; Bennouna, J; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Llédo, G; Rebischung, C; Ychou, M, 2010)
"We investigated the efficacy of fluorouracil (FU), leucovorin, irinotecan, and bevacizumab (FOLFIRI + B) in a phase II trial in patients previously untreated for metastatic colorectal cancer (mCRC), and changes during treatment in plasma cytokines and angiogenic factors (CAFs) as potential markers of treatment response and therapeutic resistance."5.14Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. ( Abbruzzese, JL; Adinin, R; Ellis, LM; Eng, C; Glover, KY; Heymach, JV; Hoff, PM; Kopetz, S; Lieu, C; Morris, JS; Overman, MJ; Tran, HT; Valero, V; Wen, S; Wolff, RA; Yan, S, 2010)
"The primary objective of this study was to determine the activity and safety profile of biweekly oxaliplatin combined with continuous oral capecitabine in the first-line treatment of metastatic colorectal cancer."5.14Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin. ( Bargagli, G; Bellan, C; Conca, R; Fiaschi, AI; Francini, E; Francini, G; Lazzi, S; Lorenzi, B; Martellucci, I; Pascucci, A; Petrioli, R, 2010)
" PATIENTS AND METHODS Patients undergoing first-line treatment for metastatic colorectal cancer (CRC) eligible for treatment with irinotecan plus infusional fluorouracil/leucovorin (FOLFIRI) were screened for the UGT1A1*28/*28 genotype and excluded from the study."5.14Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. ( Azzarello, G; Basso, U; Buonadonna, A; Cecchin, E; D'Andrea, M; De Mattia, E; De Paoli, P; Gasparini, G; Innocenti, F; Lo Re, G; Mini, E; Nobili, S; Pessa, S; Toffoli, G, 2010)
" Oxaliplatin combined with capecitabine has demonstrated activity in advanced colorectal cancer."5.14Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI- ( Alberts, SR; Bolton, JS; Dentchev, T; Lai, LL; Mahoney, MR; Molina, R; Nagorney, DM; O'Connell, MJ; Roh, MS; Schwarz, RE; Smyrk, TC; Wagman, L; Weiland, TL, 2010)
"We conducted a phase I/II clinical trial to determine the safety and feasibility of combining vorinostat with 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer (mCRC) and elevated intratumoral thymidylate synthase (TS)."5.14A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. ( Cole, S; Danenberg, KD; El-Khoueiry, A; Fazzone, W; Groshen, S; Iqbal, S; Kornacki, M; LaBonte, MJ; Ladner, RD; Lenz, HJ; Wilson, PM; Yang, D, 2010)
"This phase I/II study was conducted to assess the maximal tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of gefitinib in combination with capecitabine in patients with advanced colorectal cancer (aCRC)."5.14Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). ( Frieling, T; Graeven, U; Hegewisch-Becker, S; Lehnert, L; Reinacher-Schick, A; Schmiegel, W; Trarbach, T; Vanhoefer, U, 2010)
"A dose-finding study was performed to evaluate the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD) and the recommended dose (RD) of escalating the doses of capecitabine and fixed doses of irinotecan and oxaliplatin on a biweekly schedule for metastatic colorectal cancer patients (mCRC)."5.14Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. ( Bandres, E; Bitarte, N; Chopitea, A; Gacía-Foncillas, J; Patiño-Garcia, A; Ponz-Sarvise, M; Ramirez, N; Rodríguez, J; Viudez, A; Zarate, R, 2010)
"Combined therapy with irinotecan/fluorouracil/levoleucovorin (calcium levofolinate) [IFL] has lost its position as the standard regimen for metastatic colorectal cancer because its toxicity and effectiveness have become controversial."5.14Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies. ( Asaka, M; Fuse, N; Kato, T; Komatsu, Y; Kudo, M; Kunieda, Y; Miyagishima, T; Sakata, Y; Tateyama, M; Wakahama, O; Watanabe, M; Yuuki, S, 2010)
"Adding irinotecan and/or oxaliplatin to every-2-week 5-fluorouracil (5-FU)/leucovorin (LV) prolongs survival in patients with colorectal cancer (CRC) but increases neutropenia frequency."5.14A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. ( Dreiling, L; Gollard, R; Hecht, JR; Heim, W; Malik, I; Mo, M; Patel, R; Pillai, M; Swan, F, 2010)
"This phase II trial evaluated the efficacy and safety of cetuximab combined with FOLFOX6 (leucovorin [LV] 5-fluorouracil [5-FU]/oxaliplatin) in the first-line treatment of patients with advanced or metastatic colorectal cancer."5.14A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. ( Badarinath, S; Boccia, RV; Cosgriff, TM; Dakhil, SR; Headley, DL, 2010)
"The aim was to investigate whether germline polymorphisms within candidate genes known or suspected to be involved in fluorouracil (FU), oxaliplatin, and irinotecan pathways were associated with toxicity and clinical outcome in patients with metastatic colorectal cancer (mCRC)."5.14Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. ( Barrois, M; Beaune, P; Boige, V; Bouché, O; Castaing, M; Ducreux, M; Laurent-Puig, P; Le Corre, D; Loriot, MA; Malka, D; Mendiboure, J; Miran, I; Mulot, C; Pignon, JP; Trégouët, DA, 2010)
"To compare the efficacy and toxicity of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin (5-Fu/LV) plus oxaliplatin (FOLFOX4) regimens as adjuvant chemotherapy for stage III colorectal cancer."5.14[Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer]. ( Fang, F; Li, DC; Lu, GC, 2010)
"Twenty-one patients with advanced colorectal cancer were treated with intravenous infusion of endostar (15 mg/day for 14 consecutive days) and irinotecan (250 mg/m(2), single dose on the first day), and oral administration of capecitabine (1."5.14[Short-term therapeutic effect and safety of endostar combined with XELIRI regimen in the treatment of advanced colorectal cancer]. ( Liao, WJ; Luo, RC; Shen, P; Shi, M; Wu, Wy, 2010)
"The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based combination were assessed in a phase II, open, multicentre, uncontrolled study."5.14Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. ( Bolaños, M; Bosch, C; Castro-Carpeño, J; Escudero, P; Feliu, J; García-Girón, C; Gil, M; González-Barón, M; Llombart, A; López, R; Losa, F; Madroñal, C; Safont, MJ; Salud, A, 2010)
"A weekly administration of alternating irinotecan or oxaliplatin associated to 5-Fluorouracil in advanced colorectal cancer was planned in order to evaluate a new schedule maintaining dose intensities of each drug as in double combinations and tolerability of the triplet association."5.14Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. ( Bruera, G; Calista, F; Cannita, K; De Galitiis, F; Ficorella, C; Gebbia, N; Guglielmi, F; Iacobelli, S; Lanfiuti Baldi, P; Mancini, M; Marchetti, P; Martella, F; Morelli, MF; Pelliccione, M; Porzio, G; Ricevuto, E; Russo, A; Santomaggio, A; Tudini, M, 2010)
"This Phase I study was designed to determine a safe combination dose of 5-fluorouracil (5-FU) and arsenic trioxide (ATO) to treat 5-FU-resistant relapsed/refractory colorectal cancer patients."5.14A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. ( Ardalan, B; Duncan, R; Fernandez, A; Ganjei-Azar, P; Gonzalez, M; Lee, K; Lima, M; Mezentsev, D; Podolsky, L; Ramos, Y; Reis, I; Subbarayan, PR, 2010)
"To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial."5.14Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010)
"A phase I multicentre trial was conducted to define the recommended dose of capecitabine in combination with oxaliplatin and irinotecan (OCX) in metastatic colorectal cancer."5.14Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03). ( Cathomas, R; Köberle, D; Lanz, D; Popescu, R; Roth, A; Ruhstaller, T; Simcock, M; Uhlmann, C; von Moos, R; Widmer, L, 2010)
"The impact of thymidylate synthase (TYMS) and UDP-glucoronosyltransferase 1A (UGT1A) germline polymorphisms on the outcome of colorectal cancer (CRC) patients treated with irinotecan plus 5-fluorouracil (irinotecan/5FU) is still controversial."5.14UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. ( Abad, A; Aranda, E; Benavides, M; Carrato, A; Ginés, A; Layos, L; Manzano, JL; Marcuello, E; Martinez-Balibrea, E; Martínez-Cardús, A; Massutí, B; Moreno, V; Navarro, M; Valladares, M, 2010)
"Capecitabine has shown similar efficacy to 5-fluorouracil (5-FU); a regimen containing 2 weeks of capecitabine/oxaliplatin (CapOx) has demonstrated noninferiority to infusional 5-FU/oxaliplatin/leucovorin (FOLFOX) for the treatment of metastatic colorectal cancer (mCRC)."5.14A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. ( Eickhoff, JC; Holen, KD; Jumonville, A; Loconte, NK; Lubner, SJ; Mulkerin, DL; Schelman, W; Seo, S; Thomas, JP, 2010)
"The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 trial in patients with metastatic colorectal cancer."5.14Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. ( Amoroso, D; Andreuccetti, M; Ciarlo, A; Cortesi, E; Cremolini, C; Cupini, S; Del Monte, F; Falcone, A; Fontanini, G; Fornaro, L; Granetto, C; Loupakis, F; Lupi, C; Masi, G; Salvatore, L; Sensi, E, 2010)
"Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line chemotherapy for metastatic colorectal cancer."5.14Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K, 2010)
"To evaluate the efficacy and safety of bevacizumab plus capecitabine in treating metastatic colorectal cancer(mCRC)."5.14[Efficacy and safety of bevacizumab plus capecitabine for metastatic colorectal cancer]. ( Ai, B; Ding, L; Li, L; Wu, JY; Wu, XN; Zhao, YB; Zhou, MZ, 2010)
"Patients with histologically confirmed breast cancer or colorectal cancer receiving single agent capecitabine started at 2000 to 2500 mg/m(2) daily from day 1 to 14 every 3 weeks were randomly assigned to receive 200 mg or 400 mg daily of pyridoxine for PPE prophylaxis."5.14Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia. ( Chalermchai, T; Sriuranpong, V; Suwanrusme, H; Tantiphlachiva, K; Voravud, N, 2010)
"Colorectal cancer (CRC) patients whose tumours have microsatellite instability (MSI) do not benefit from adjuvant 5-fluorouracil."5.14Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX. ( Bennamoun, M; Boisseau, A; Cucherousset, J; Des Guetz, G; Lagorce, C; Lecaille, C; Mariani, P; Morere, JF; Nicolas, P; Sastre, X; Schischmanoff, PO; Uzzan, B, 2010)
"This study reports the long-term follow-up of patients with metastatic colorectal cancer (CRC) participating in a randomised phase II study that compared the efficacy and toxicity of the combination of irinotecan (IRI), fluorouracil (FU) with leucovorin (LV) (arm A) versus sequential chemotherapy with IRI plus FU/LV followed by oxaliplatin (OXA) plus FU/LV (arm B) as first line therapy."5.14Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer. ( Aravantinos, G; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Linardou, H; Makatsoris, T; Papadimitriou, C; Papakostas, P; Papamichael, D; Pectasides, D; Pentheroudakis, G; Samelis, G; Skondra, M; Stavropoulos, M; Syrigos, KN; Varthalitis, I; Vourli, G; Xanthakis, I; Xiros, N, 2010)
"Fluorouracil (FU) is a cornerstone of colorectal cancer treatment; however, it has clinical and subclinical influence on the heart."5.14Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. ( Hasbak, P; Jensen, SA; Mortensen, J; Sørensen, JB, 2010)
"Colorectal cancer patients receiving FOLFOX-4 or capecitabine plus oxaliplatin were randomized to (Arm A) calcium gluconate 1g +15% magnesium sulphate 1g diluted in 100 mL of dextrose 5% or (Arm B) placebo."5.14Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. ( Chay, WY; Choo, SP; Gao, F; Koo, WH; Lo, YL; Ng, HC; Ong, SY; Tan, SH, 2010)
"601 patients with advanced or metastatic colorectal cancer receiving first-, second-, or third-line irinotecan-based therapy were regularly analyzed for response and toxicity until the end of therapy."5.14Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study. ( Ababneh, Y; Fahlke, J; Galle, PR; Maintz, C; Moehler, M; Musch, R; Schimanski, CC; Schmidt, B; Siebler, J; Soeling, U; Verpoort, K, 2010)
"This phase I study was conducted to determine the maximum tolerated dose (MTD) of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, with 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) in patients with advanced colorectal cancer (CRC)."5.14Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. ( Carducci, M; Dancey, J; Donehower, RC; Hidalgo, M; Iacobuzio-Donahue, C; Jacene, H; Jimeno, A; Kahn, Y; Kulesza, P; Laheru, DA; Messersmith, WA; Rudek, MA; Spira, A; Zhao, M, 2010)
"In a recent randomized study, we demonstrated that XELOX (oxaliplatin + oral capecitabine) was well tolerated and not inferior in terms of efficacy to the infusional FOLFOX-6 regimen in first-line treatment of metastatic colorectal cancer (mCRC)."5.14Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6. ( Bennouna, J; Conroy, T; Dominguez, S; Douillard, JY; Ducreux, M; Faroux, R; Florentin, V; Hebbar, M; Lledo, G; Perrocheau, G; Ychou, M, 2010)
"The results indicate that the modified CAPOX regimen is safe and effective as salvage treatment in patients with advanced colorectal cancer who were previously treated with irinotecan-based frontline therapy."5.13Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study. ( Amarantidis, K; Ardavanis, A; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Polyzos, A; Souglakos, J; Tsousis, S; Vamvakas, L; Vardakis, N; Varthalitis, I; Ziras, N, 2008)
"To demonstrate the noninferiority of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX-4) as second-line therapy in patients with metastatic colorectal cancer after prior irinotecan-based chemotherapy."5.13Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. ( Bang, YJ; Butts, C; Cox, JV; Cunningham, D; Goel, R; Gollins, S; Laguerre, S; Navarro, M; Rothenberg, ML; Siu, LL, 2008)
"The aim of the study was to investigate the associations between UGT1A1(*)28 genotype and (1) response rates, (2) febrile neutropenia and (3) dose intensity in patients with metastatic colorectal cancer treated with irinotecan."5.13UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Punt, CJ; Van der Straaten, T, 2008)
" This randomized phase II trial investigates the feasibility and efficacy of gefitinib and 5-fluorouracil, folinic acid, irinotecan (FOLFIRI) in patients with metastatic colorectal cancer."5.13A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. ( Carnaghi, C; Comandone, A; Granetti, C; Lorusso, V; Mari, E; Oliva, C; Pressiani, T; Rimassa, L; Ronzoni, M; Santoro, A; Siena, S; Zuradelli, M, 2008)
"Patients with metastatic colorectal cancer were treated with fluorouracil, leucovorin, and irinotecan and were also given ALVAC-CEA/B7."5.13Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. ( Benson, AB; Berinstein, NL; Caterini, J; Conry, RM; Cripps, C; Dalfen, R; Debenedette, M; Elias, I; Garett, C; Heim, WJ; Kaufman, HL; Kim-Schulze, S; Lenz, HJ; Marshall, J; Moore, M; Salha, D; Singh, D; Urba, WJ; Vogel, T; von Mehren, M; Yu, M, 2008)
"Stages I-III colorectal cancer patients (n = 753) were randomized to receive either surgery alone (control arm), surgery plus postoperative portal venous infusion of 5-FU 500 mg/m(2) plus heparin given for 24 hours for seven consecutive days plus mitomycin C 10 mg/m(2) given on the first day (arm 2), or surgery and the same chemotherapy regimen administered by peripheral venous route (arm 3)."5.13Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-term results of a randomized controlled trial. ( Aeberhard, P; Harder, F; Herrmann, R; Laffer, U; Lorenz, M; Maibach, R; Metzger, U; Zuber, M, 2008)
"To determine the maximum tolerated dose (MTD), characterize the principal toxicities, and assess the pharmacokinetics of EKB-569, an oral selective irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with capecitabine in patients with advanced colorectal cancer."5.13A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer. ( Abbas, R; Boni, J; Bukowski, R; Croghan, G; Donehower, R; Erlichman, C; Hidalgo, M; Jimeno, A; Laheru, D; Martins, P; Messersmith, W; Pelley, R; Rudek, M; Zacharchuk, C, 2008)
"To compare the time to deterioration in health-related quality of life (HRQoL) in patients with previously untreated metastatic colorectal cancer receiving a 5-fluorouracil (5-FU)-based chemotherapy regimen with or without the addition of bevacizumab (BV) in two randomized, placebo-controlled studies."5.13Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. ( Cella, D; Holmgren, E; Hurwitz, HI; Kabbinavar, FF; Wallace, JF; Yi, J; Yost, KJ, 2008)
" Progression-free survival (PFS) and toxicity were determined in 267 metastatic colorectal cancer (MCRC) patients who were treated with first-line capecitabine (CAP) plus irinotecan (CAPIRI), or CAP single agent in a prospective randomised phase III trial (CAIRO)."5.13GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. ( Antonini, NF; Gelderblom, H; Guchelaar, HJ; Koopman, M; Kweekel, DM; Nortier, JW; Punt, CJ; Van der Straaten, T, 2008)
"PURPOSE To determine whether irinotecan plus oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic colorectal cancer (CRC) previously treated with single-agent fluoropyrimidines."5.13Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. ( Bodoky, G; Garay, C; Habboubi, N; Haller, DG; Koralewski, PM; Miller, WH; Olivatto, LO; Rothenberg, ML; Wong, AO, 2008)
"To evaluate the antitumor activity and toxicity of 5-fluorouracil (FU)/leucovorin (LV) and capecitabine (C) given with either oxaliplatin (OX) or camptothecin (CPT-11) in the treatment of chemotherapy naive patients with metastatic colorectal cancer."5.13Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. ( Bisegna, R; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F, 2008)
"We investigated the gefitinib, 5-fluorouracil (5-FU), leucovorin and oxaliplatin (IFOX) regimen as first-line therapy in patients with metastatic colorectal cancer."5.13A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. ( Cho, CD; Fisher, GA; Halsey, J; Kuo, T; Ramsey, M; Rouse, RV; Schwartz, E; Sikic, BI, 2008)
" Effects of the ABCC2 genotype on the pharmacokinetics (PK) of irinotecan and the metabolites were examined in Japanese patients with metastatic colorectal cancer receiving irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI)."5.13Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). ( Akiyama, Y; Ando, Y; Araki, K; Endo, H; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Matsunaga, M; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Sasaki, Y; Sunakawa, Y; Tanaka, R; Yamamoto, W; Yamashita, K, 2008)
"This study was conducted to assess the tolerability and efficacy of a ternary bimonthly irinotecan (CPT-11) - oxaliplatin (OHP) - infusional 5-fluorouracil (5-FU)/folinic acid (FA) combination in advanced colorectal cancer patients who had received prior CPT-11 and/or OHP-based chemotherapy regimen."5.13Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. ( Checcacci, D; Del Buono, S; Filippelli, F; Mazzei, T; Mazzocchi, V; Mini, E; Nobili, S, 2008)
"XELIRI (capecitabine/irinotecan) is effective and well tolerated in metastatic colorectal cancer (mCRC)."5.13Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer. ( Asmar, L; Berger, M; Boehm, KA; Cartwright, T; Cohn, A; Hyman, W; Kuefler, P; Nugent, JE; Richards, D; Ruxer, RL; Vukelja, S, 2008)
"Since the combination of capecitabine and irinotecan has successfully been used as a first-line treatment in metastatic colorectal cancer (MCRC), we expected promising results when given as a second-line treatment to metastatic colorectal patients who had been pretreated with 5-Fluorouracil and Oxaliplatin."5.13The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. ( Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ, 2008)
" A Phase-II study was undertaken to determine the activity of a dose attenuated schedule of irinotecan, capecitabine, and the COX-2 inhibitor celecoxib in patients with advanced colorectal cancer."5.13Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. ( El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM, 2008)
"Patients with histologically proven primary colorectal cancer and bidimensionally measurable liver metastasis, not fully resectable based on technical inability to achieve R(0) resection, but potentially resectable after tumor reduction, were given FOLFIRINOX: oxaliplatin 85 mg/m(2), irinotecan 180 mg/m(2), leucovorin 400 mg/m(2), bolus fluorouracil 400 mg/m(2) and fluorouracil 46-h continuous IV infusion 2,400 mg/m(2), every 2 weeks for a maximum of 12 cycles."5.13Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. ( Delpero, JR; Desseigne, F; Guimbaud, R; Kramar, A; Mitry, E; Nordlinger, B; Portier, G; Quénet, F; Rivoire, M; Viret, F; Ychou, M, 2008)
"The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P)."5.13Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. ( Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ, 2008)
"A phase II trial was initiated to evaluate the efficacy and toxicity of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic colorectal cancer."5.13Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6. ( Au, GK; Chan, RT; Choi, CK; Ho, JW; Law, WL; Lui, L; Siu, S; Tung, SY, 2008)
"The objectives of this phase I/II study were to determine the maximum tolerated dose (MTD), characterise the principal toxicities in the phase I part and assess the efficacy in the phase II part of gefitinib, an oral selective inhibitor of the epidermal growth factor receptor, in combination with capecitabine in patients with advanced colorectal cancer (CRC)."5.13Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer. ( Alonso, V; Bovio, H; Colomer, R; Cortés-Funes, H; Escudero, P; García-Carbonero, R; Grávalos, C; Jimeno, A; Juez, I; Sevilla, I; Vega-Villegas, ME, 2008)
"The aim of this study was to evaluate the effects of a combination of folinic acid, 5-fluorouracil (5FU) and irinotecan (FOLFIRI 1) administered every 2 weeks in a population of elderly subjects with advanced colorectal cancer."5.13Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. ( Badetti, JL; Berdah, JF; Chamorey, E; Codoul, JF; François, E; Hébert, C; Lesbats, G; Mari, V; Teissier, E, 2008)
"We evaluated the outcome of 140 patients aged > or = 70 years of age who received first-line treatment for metastatic colorectal cancer within the German phase III trial of FUFOX (5-fluorouracil/leucovorin/oxaliplatin) versus CAPOX (capecitabine/oxaliplatin)."5.13Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. ( Arkenau, HT; Englisch-Fritz, C; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T, 2008)
"Oxaliplatin in combination with capecitabine prolongs survival in patients with metastatic colorectal cancer (mCRC)."5.13Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. ( Balteskard, L; Berglund, A; Fokstuen, T; Ogreid, D; Pfeiffer, P; Ploen, J; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, K; Yilmaz, M, 2008)
"Food and Drug Administration reviewed a single, open-label, multicenter trial in which 463 patients with epidermal growth factor receptor-expressing metastatic colorectal cancer who had progressed on or following treatment with a regimen containing a fluoropyrimidine, oxaliplatin, and irinotecan were randomized (1:1) to receive best supportive care (BSC) with or without panitumumab (6 mg/kg every other week) administered until disease progression or intolerable toxicity."5.13U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. ( Cordoba-Rodriguez, R; Fuchs, C; Giusti, RM; Hughes, M; Keegan, P; Koti, K; Men, AY; Pazdur, R; Pilaro, AM; Rothmann, M; Shastri, K; Weiss, KD; Zhao, H, 2008)
"To evaluate the efficacy and safety of bevacizumab when added to first-line oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or fluorouracil/folinic acid plus oxaliplatin [FOLFOX-4]) in patients with metastatic colorectal cancer (MCRC)."5.13Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. ( Cassidy, J; Clarke, S; Couture, F; Díaz-Rubio, E; Figer, A; Koski, S; Lichinitser, M; Rivera, F; Saltz, LB; Scheithauer, W; Sirzén, F; Wong, R; Yang, TS, 2008)
"This two-part phase Ib/II study investigated the feasibility of administering cetuximab in combination with oxaliplatin and infusional 5-fluorouracil (5-FU)/folinic acid (FA) in a weekly schedule (AIO FUFOX protocol) as first-line treatment in patients with epidermal growth factor receptor-detectable advanced colorectal cancer."5.13Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. ( Arnold, D; Dittrich, C; Herrmann, T; Höhler, T; Lordick, F; Riemann, J; Schmoll, HJ; Seufferlein, T; Wöll, E; Zubel, A, 2008)
" For this purpose, 110 XELOX (capecitabine/oxaliplatin)- or FUOX (fluorouracil/oxaliplatin)-treated metastatic colorectal cancer patients were selected prospectively for genotyping."5.13Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer. ( Abad, A; Aparicio, J; Aranda, E; Díaz-Rubio, E; García, T; Ginés, A; Gómez-España, A; Guino, E; Maestu, I; Manzano, JL; Martinez-Balibrea, E; Martínez-Cardús, A; Sastre, J, 2008)
"Oxaliplatin combined with 5-fluorouracil (5-FU), with or without leucovorin (LV), is effective and well tolerated for first-line therapy of advanced colorectal cancer (CRC)."5.13A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer. ( Bernard, SA; Bjarnason, GA; Braich, T; Desimone, P; Evars, JP; Hrushesky, WJ; Jolivet, J; Ramanathan, RK, 2008)
"TRIBE and TRIBE-2 studies demonstrated higher benefit from FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan)/bevacizumab compared with FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX/bevacizumab as an upfront option for metastatic colorectal cancer patients, with more toxicities."5.12Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO. ( Antonuzzo, A; Boccaccino, A; Borelli, B; Buonadonna, A; Caponnetto, S; Conca, V; Cremolini, C; Daniel, F; Falcone, A; Lonardi, S; Marmorino, F; Masi, G; Pietrantonio, F; Raimondi, A; Rossini, D; Santini, D; Sbrana, A; Tomasello, G; Zaniboni, A, 2021)
"Guidelines recommend combined doublet backbone chemotherapy based on 5-fluorouracil and oxaliplatin (OX) or irinotecan (IR) as the first-line treatment options for metastatic colorectal cancer."5.12Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis. ( Hui, F; Qi, X; Ren, T; Shen, Z; Wang, S; Xu, C; Zhang, Y; Zhao, Q, 2021)
"The antimetabolite, 5-Fluorouracil (5-FU), is the only chemotherapeutic drug to significantly improve 12-month survival rates of patients with Colorectal Cancer (CRC)."5.12Current Perspectives on the Role of Nrf2 in 5-Fluorouracil Resistance in Colorectal Cancer. ( Gong, J; Xu, H, 2021)
"Notwithstanding recent treatment advances in metastatic colorectal cancer (mCRC), chemotherapy with a combination of a fluoropyrimidine and a folate agent, often 5-fluorouracil (5-FU) and leucovorin, remains the backbone of treatment regimens for the majority of patients with mCRC."5.12Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. ( de Gramont, A; Glimelius, B; Marshall, J; Stintzing, S; Yoshino, T, 2021)
" In this review, we mainly focused on a multiple strategies by employing 5-Fluorouracil, curcumin, and lipids in Nano formulation for the possible treatment of colorectal cancer and its metastasis."5.12Multiple strategies with the synergistic approach for addressing colorectal cancer. ( Abdel-Daim, MM; Akhtar, MF; Akter, R; Albadrani, GM; Hari, B; Karthika, C; Najda, A; Rahman, MH; Sayed, AA, 2021)
"It is necessary to systematically evaluate the clinical efficacy and safety of bevacizumab (BEV) combined with 5-fluorouracil + leucovorin + oxaliplatin (FOLFOX) regimen in the treatment of advanced colorectal cancer."5.12The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: A systematic review and meta-analysis. ( Chen, D; Liu, W; Wang, X; You, J; Zhang, H; Zhang, S, 2021)
"Fluorouracil (5-FU) is widely used in the treatment of colorectal cancer."5.12Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? ( Altés, A; Baiget, M; Marcuello, E; Menoyo, A; Rio, ED, 2006)
"The efficacy of oxaliplatin combined with capecitabine (XELOX) as second-line therapy in patients with advanced colorectal cancer (ACRC) resistant to irinotecan is not well established."5.12Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. ( Baltesgard, L; Ehrsson, H; Fokstuen, T; Glimelius, B; Mortensen, JP; Pfeiffer, P; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, KM; Wallin, I; Øgreid, D, 2006)
"To investigate the safety/tolerability of the EGFR-antibody cetuximab when added to irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) for first-line treatment in patients with metastatic colorectal cancer (mCRC)."5.12Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. ( Folprecht, G; Köhne, CH; Lutz, MP; Nolting, A; Pollert, P; Schöffski, P; Seufferlein, T, 2006)
"A total of 630 patients with previously untreated metastatic colorectal cancer were randomised in a 2:1 fashion to receive bolus 5-fluorouracil (5-FU) and leucovorin (LV) plus either 3H1 (n = 422) or placebo (n = 208)."5.12Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. ( Bhatnagar, A; Bridgewater, J; Carmichael, J; Cassidy, J; Chong, G; Coleman, R; Cosgriff, TM; Coxon, F; Cunningham, D; Harper, PG; Hawkins, R; Jones, JJ; Moore, M; Northfelt, D; Redfern, CH; Sreedharan, S; Steward, W; Valone, F, 2006)
"We treated 74 patients with unresectable metastatic colorectal cancer (not selected for a neoadjuvant approach) with irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin (FOLFOXIRI and simplified FOLFOXIRI)."5.12Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. ( Allegrini, G; Brunetti, IM; Cerri, E; Cupini, S; Falcone, A; Filipponi, F; Goletti, O; Loupakis, F; Marcucci, L; Masi, G; Pfanner, E; Viti, M, 2006)
"Oxaliplatin and 5-fluorouracil (5-FU) act synergistically in colorectal cancer."5.12Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. ( Cho, HK; Chung, SJ; Kang, JH; Kim, DD; Kuh, HJ; Lee, ES; Lee, JW; Lee, KS; Park, JK; Shim, CK, 2006)
"In metastatic colorectal cancer, a combination of leucovorin (LV) and fluorouracil (FU) with oxaliplatin (FOLFOX) 4 is a standard first-line regimen."5.12OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. ( André, T; Buyse, M; Carola, E; Cervantes, A; Chirivella, I; de Gramont, A; Etienne, PL; Figer, A; Flesch, M; Lledo, G; Louvet, C; Mineur, L; Perez-Staub, N; Rivera, F; Tabah-Fisch, I; Tournigand, C, 2006)
"Irinotecan or oxaliplatin combined with 5-fluorouracil (5-FU) +/- folinic acid (FA) has changed the treatment standards for metastatic colorectal cancer (CRC)."5.12Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients. ( Bas, C; Bella, S; Chacon, M; Coppola, F; Escobar, E; Hidalgo, J; Korbenfeld, E; Martin, C; Martinez, J; Reale, M; Richardet, E; Senna, S; Smilovich, AM; Wasserman, E, 2006)
"To compare the efficacy and toxicity of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOXIRI) vs irinotecan and 5-FU/LV (FOLFIRI) as first-line treatment of patients with metastatic colorectal cancer (MCC)."5.12FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog ( Androulakis, N; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Kalykaki, A; Kouroussis, Ch; Mavroudis, D; Polyzos, A; Samonis, G; Souglakos, J; Syrigos, K; Tsousis, S; Vamvakas, L; Ziras, N, 2006)
" We evaluated oral rubitecan (5 days on, 2 days rest per week) on a continuous schedule, in patients with advanced colorectal cancer (CRC), who progressed after 5-fluorouracil based chemotherapy."5.12Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy. ( Auber, M; Cai, C; Kiefer, G; Matin, K; Patel, H; Potter, D; Ramanathan, RK; Schmotzer, A; Stoller, R; Zamboni, W, 2006)
"The purpose of this study was to evaluate the safety and activity of fixed-dose capecitabine in patients with advanced colorectal cancer and to correlate pretreatment plasma concentrations of homocysteine and serum and red cell folate with toxicity."5.12A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. ( Beale, P; Clarke, SJ; Horvath, L; Ong, S; Rivory, L; Sharma, R, 2006)
"The purpose of this phase II trial was to determine the efficacy and safety of the XELOX (capecitabine/oxaliplatin) regimen as first-line therapy in the elderly patients with metastatic colorectal cancer (MCRC)."5.12XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. ( Bolaños, M; Casado, E; De Castro, J; de Mon, MA; Escudero, P; Feliu, J; Galán, A; González-Barón, M; Lopez-Gómez, L; Losa, F; Salud, A; Vicent, JM; Yubero, A, 2006)
"Determine the toxicity, tolerability, and pharmacokinetics of SU5416, a vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, coadministered with bolus 5-fluorouracil (5-FU), leucovorin, and irinotecan (IFL) in untreated patients with metastatic colorectal cancer."5.12Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. ( Berlin, JD; Cropp, GF; Donnelly, E; Fleischer, AC; Hande, KR; Hannah, AL; Lockhart, AC; Rothenberg, ML; Schaaf, LJ; Schumaker, RD, 2006)
"To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer."5.12Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX, 2006)
"In advanced colorectal cancer previously treated with oxaliplatin, efficacy of irinotecan-based chemotherapy is poor and the best regimen is not defined."5.12A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. ( André, T; Artru, P; de Gramont, A; Flesch, M; Landi, B; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Plantade, A, 2006)
"The purpose of this study was to evaluate the antitumor activity and toxicity of fixed sequences of capecitabine/oxaliplatin followed by capecitabine/irinotecan in patients with previously untreated metastatic colorectal cancer."5.12Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer. ( Alvarez, JV; Arcediano, A; Cassinello, J; Castro, IG; Colmenarejo, A; Filipovich, E; López, MJ; Marcos, F; Pujol, E; Segovia, F, 2006)
"To evaluate the efficacy and tolerance of the gemcitabine/oxaliplatin (GEMOX) combination as second-line chemotherapy for patients with advanced colorectal cancer (CRC) pretreated with an irinotecan (CPT-11)/5-fluorouracil (5-FU)/leucovorin (LV) regimen."5.12Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. ( Boukovinas, I; Christofillakis, C; Georgoulias, V; Potamianou, A; Syrigos, K; Tselepatiotis, E; Tsousis, S; Varthalitis, I; Ziras, N, 2006)
"To examine whether carbogen and nicotinamide increases 5-fluorouracil (5-FU) delivery to colorectal cancer metastases."5.12Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. ( Aboagye, EO; Gupta, N; Hoskin, PJ; Jones, T; Kötz, B; Osman, S; Phillips, R; Price, PM; Saleem, A; Vernon, C; Wasan, H, 2006)
"Oxaliplatin (OXA), raltitrexed (RTX), 5-fluorouracil (FU) and folinic acid (FA) have shown activity in metastatic colorectal cancer, radioenhancing effect and synergism when combined."5.12Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study. ( Avallone, A; Budillon, A; Cascini, LG; Comella, P; Delrio, P; Guida, C; Lastoria, S; Marone, P; Morrica, B; Parisi, V; Petrillo, A; Tatangelo, F, 2006)
"COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib."5.12Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? ( Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR, 2006)
"The aim of the study was to verify the efficacy and safety of the addition of celecoxib to FOLFIRI combination therapy in patients affected by advanced colorectal cancer."5.12FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). ( Colucci, G; Di Renzo, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Mallamaci, R; Pezzella, G; Romito, S, 2006)
"The aim of the study was to evaluate the safety and efficacy of the raltitrexed/5-fluorouracil/levofolinic acid combination regimen as first-line chemotherapy for elderly patients with advanced/metastatic colorectal cancer."5.12Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas. ( Bordonaro, R; Borsellino, N; Callari, A; Caruso, M; Cicero, G; Ferraù, F; Gebbia, V; Tirrito, ML; Tralongo, P; Valenza, R; Verderame, F, 2006)
"To evaluate the efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer."5.12[Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer]. ( Chen, JZ; Liao, WJ; Luo, RC; Zheng, H, 2006)
"We conducted two phase II trials evaluating the combination of 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) as first-line treatment in 74 metastatic colorectal cancer patients."5.12First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. ( Allegrini, G; Andreuccetti, M; Barbara, C; Brunetti, IM; Bursi, S; Cerri, E; Cupini, S; Falcone, A; Loupakis, F; Marcucci, L; Masi, G; Murr, R; Ricci, S, 2006)
"The purpose of the study was to evaluate the influence of baseline haemoglobin level in predicting response to 5-fluorouracil (5FU)-based first-line chemotherapy in advanced colorectal cancer patients."5.12The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients. ( Aglietta, M; Alabiso, I; Alabiso, O; Berruti, A; Bitossi, R; Brizzi, MP; Dogliotti, L; Forti, L; Gorzegno, G; Harris, A; Magnino, A; Miraglia, S; Saini, A; Sculli, CM; Sperti, E; Tampellini, M, 2006)
"In a prospective study, 250 metastatic colorectal cancer patients were treated with irinotecan, fluorouracil, and leucovorin as first-line treatment."5.12The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. ( Biason, P; Boccalon, M; Bonura, S; Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Pangher, V; Errante, D; Frustaci, S; Gaion, F; Galligioni, E; Giusto, M; Medici, M; Pasetto, LM; Pessa, S; Russo, A; Sandri, P; Toffoli, G, 2006)
"LV5FU2 with high-dose leucovorin (LV), weekly infusional 5-fluorouracil (5FU) (AIO schedule) and raltitrexed have been demonstrated to be active agents in first-line treatment of colorectal cancer."5.12Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial. ( Bedenne, L; Berger, C; Bouche, O; Cassan, P; Ducreux, M; Dunant, A; Fournet, J; Leduc, B; Mousseau, M; Pignon, JP; Raoul, JL, 2006)
"We investigated whether the determination of orotate phosphoribosyltransferase (OPRT) and thymidylate synthase (TYMS) polymorphisms could predict the toxicity of 5-fluorouracil (5-FU) in colorectal cancer patients."5.12Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. ( Hirayama, R; Ichikawa, W; Sasaki, Y; Suto, K; Takahashi, T, 2006)
"Previously, we reported results of Intergroup N9741, which compared standard bolus fluorouracil (FU), leucovorin, plus irinotecan (IFL) with infused FU, leucovorin, plus oxaliplatin (FOLFOX4) and irinotecan plus oxaliplatin in patients with untreated metastatic colorectal cancer."5.12Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. ( Alberts, S; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2006)
"To provide bevacizumab (BV) -based therapy to patients with advanced colorectal cancers (CRC) who had exhausted standard chemotherapy options, and to evaluate the response to BV combined with fluorouracil (FU) and leucovorin (LV) in this patient population."5.12Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. ( Boron, M; Chen, HX; Grochow, L; Jaffe, C; Kaplan, RS; Mooney, M; Mosby, K; Rubinstein, L; Vena, D; Zwiebel, J, 2006)
" Capecitabine plus irinotecan appears to be a feasible first-line treatment for patients with advanced colorectal carcinoma."5.12Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study. ( Akkermans-Vogelaar, JM; Antonini, NF; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Punt, CJ; Rodenburg, CJ; Vreugdenhil, G; Wals, J, 2006)
"We determined whether hepatic intra-arterial infusion of 5-fluorouracil (5-FU) in patients with synchronous hepatic metastases from colorectal cancer, in whom the primary lesion was resectable but hepatic metastatic lesions were non-resectable helped improve survival time when administered on the basis of the results of the anticancer drug sensitivity test."5.12Repeated hepatic intra-arterial chemotherapy based on results of anticancer drug sensitivity test in patients with synchronous hepatic metastases from colorectal cancer. ( Isogai, A; Kubota, S; Matsuoka, H; Nagaya, M; Tsukikawa, S; Yanagi, Y, 2006)
"Oxaliplatin (OXA) and irinotecan (IRI) are active drugs for metastatic colorectal cancer, their toxicity profiles are not overlapping, and both drugs have shown at least additivity with folinic acid-modulated 5-fluorouracil (5FU)."5.12Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer. ( Casaretti, R; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Massidda, B; Palmeri, S; Putzu, C; Sandomenico, C, 2006)
"To evaluate the clinical activity and toxicity of capecitabine plus irinotecan as first-line therapy for patients with metastatic colorectal cancer (mCRC), and to describe the association of expression of thymidine phosphorylase (TP), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) with antitumor activity."5.12Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. ( Andria, M; Dhami, M; Diasio, RB; Godfrey, T; Gold, PJ; Kovatich, AJ; Lund, KA; Meropol, NJ; Mitchell, E; Schwarting, R, 2006)
"Until recently, fluorouracil (F) and leucovorin (L) had been considered the standard therapy for patients with colorectal cancer."5.12Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. ( Aabo, K; Bjerregaard, B; Eckhoff, L; Jakobsen, A; Mortensen, JP; Pfeiffer, P; Sandberg, E; Schønnemann, K, 2006)
"The aim of the study was to assess the impact of an eicosapentanoic acid-containing protein and energy dense oral nutritional supplement (EPA-ONS) on nutritional and inflammatory status, quality of life (QOL), plasma phospholipids (PPL) and cytokine profile, tolerance of irinotecan-containing chemotherapy and EPA-ONS in patients with advanced colorectal cancer (CRC) receiving chemotherapy."5.12Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. ( Beale, PJ; Childs, A; Clarke, SJ; Read, JA; Smith, N; Volker, DH, 2007)
"In this study, the maximum tolerated dose and toxicity profile of FOLFIRI (infusional fluorouracil [5-FU]/leucovorin/irinotecan) plus gefitinib (an oral inhibitor of the epidermal growth factor receptor) were evaluated as first-line therapy in patients with metastatic colorectal cancer."5.12Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. ( Battu, S; Blaszkowsky, L; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Meyerhardt, JA; Ryan, DP; Wolpin, BM; Zhu, AX, 2006)
"Oxaliplatin stop and go in combination with leucovorin and 5-fluorouracil has been successfully used in a previous study (OPTIMOX1) in metastatic colorectal cancer (MCR)."5.12Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. ( André, T; Bidard, FC; de Gramont, A; Fellague-Chebra, R; Flesch, M; Hebbar, M; Louvet, C; Mabro, M; Mineur, L; Postel Vinay, S; Tournigand, C, 2007)
"To characterize the efficacy and safety of palifermin in reducing the incidence of oral mucositis (OM) and diarrhea when administered to patients with metastatic colorectal cancer (CRC) receiving fluorouracil/leucovorin (FU/LV) chemotherapy."5.12Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. ( Abdi, E; Cesano, A; Chen, MG; Clarke, S; Davis, ID; Gayko, U; Gutheil, J; Rosen, LS; Schnell, FM; Zalcberg, J, 2006)
"In a multicenter trial, we randomly assigned 173 patients with completely resected (R0) hepatic metastases from colorectal cancer to surgery alone and observation (87 patients) or to surgery followed by 6 months of systemic adjuvant chemotherapy with a fluorouracil and folinic acid monthly regimen (86 patients)."5.12Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. ( Bedenne, L; Belghiti, J; Bosset, JF; Bouche, O; Bugat, R; Elias, D; Guimbaud, R; Lazorthes, F; Nordlinger, B; Piedbois, P; Portier, G; Rougier, P; Saric, J, 2006)
"This study provides strong arguments indicating that IPCH with oxaliplatin is better tolerated than EPIC with mitomycin C and 5-FU, and is twice as efficient in curing residual peritoneal carcinomatosis measuring less than 1 mm."5.12Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis. ( Benizri, E; Di Pietrantonio, D; Elias, D; Malka, D; Menegon, P; Raynard, B, 2007)
"This phase II randomised trial compares oxaliplatin plus protracted infusion of 5-fluorouracil (pviFOX) or oxaliplatin plus capecitabine (XELOX) in the first-line treatment of advanced colorectal cancer (ACRC)."5.12Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). ( Ballardini, P; Di Fabio, F; Gentile, AL; Giaquinta, S; Lelli, G; Martoni, AA; Mutri, V; Piana, E; Pinto, C; Rojas Llimpe, FL, 2006)
"To assess the toxicity and dose delivery of weekly bolus 5-fluorouracil (5-FU) at 425 mg/m(2) plus low-dose folinic acid (FA) for 24 weeks as adjuvant treatment for colorectal cancer."5.12Weekly fluorouracil at 425 mg/m(2) plus low-dose folinic acid for 24 weeks as adjuvant treatment for colorectal cancer: assessment of toxicity and delivery. ( Gollins, SW; Ramani, VS; Wong, H, 2006)
"Irinotecan at 180 mg/m2 combined with an infusional 5-fluorouracil/leucovorin (5-FU/LV) regimen (FOLFIRI) is a standard first line therapy for metastatic colorectal cancer (mCRC)."5.12Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer. ( Bressole, F; Chalbos, P; Debrigode, C; Desseigne, F; Duffour, J; Gourgou, S; Mineur, L; Pinguet, F; Poujol, S; Ychou, M, 2007)
"The purpose of this study was to compare the activity and toxicity of an irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) combination with a standard regimen of 5FU and LV, in patients with advanced colorectal carcinoma."5.12A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma. ( Andreadis, C; Gennatas, C; Michalaki, V; Mouratidou, D; Pafiti, A; Papaxoinis, G; Tsavaris, N, 2006)
"Several schedules of 5-fluorouracil (FU) and irinotecan (IRI) have been shown to improve overall survival in advanced colorectal cancer (CRC)."5.12Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial. ( Barone, C; Basso, M; Cassano, A; D'Argento, E; Di Leonardo, G; Landriscina, M; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N, 2007)
" This phase I/II dose-finding study evaluated gefitinib in combination with a 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI-AIO) regimen in patients with metastatic colorectal cancer."5.12Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO). ( Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J, 2006)
"To determine the maximum tolerated doses (MTD), toxicities, efficacy, and pharmacokinetics (PK) of gefitinib combined with irinotecan, 5-fluorouracil (5-FU) and leucovorin (IFL) in patients with previously untreated advanced colorectal cancer."5.12Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. ( Clark, JW; D'Amato, F; Dancey, J; Earle, CC; Eder, JP; Enzinger, PC; Fuchs, CS; Kinsella, K; Mayer, RJ; Meyerhardt, JA; Michelini, A; Ogino, S; Ryan, DP; Stewart, CF; Supko, JG; Zhu, AX, 2007)
"This open-label, phase IB study was undertaken to determine the safety/toxicity profile and recommended dose of oral once-daily PTK787/ZK 222584 (PTK/ZK) combined with oxaliplatin/5-fluorouracil (5-FU)/leucovorin (FOLFOX4) chemotherapy in patients with advanced colorectal cancer."5.12A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. ( Bartel, C; Henry, A; Laurent, D; Masson, E; Poethig, M; Steward, W; Thomas, AL; Trarbach, T; Vanhoefer, U; Wang, J; Wiedenmann, B, 2007)
" Infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) is a standard therapy for colorectal cancer."5.12Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. ( Bolling, C; Brennscheidt, U; Cassidy, J; Díaz-Rubio, E; Fettner, S; Feyereislova, A; Hanauske, AR; Jones, RJ; Rakhit, A; Sastre, J, 2007)
"This study was designed to measure the dihydrouracil (UH(2))/uracil (U) ratio in plasma as a surrogate marker for dihydropyrimidine dehydrogenase (DPD) activity and to investigate the relationships of the UH(2)/U ratios in plasma with the toxicities of 5-fluorouracil (5-FU)-based adjuvant chemotherapy and 5-FU plasma concentrations in colorectal cancer patients."5.12The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. ( Chen, G; Chen, YB; Li, S; Lu, ZH; Pan, ZZ; Wan, de S; Wang, GQ; Zhou, ZW, 2007)
"A phase II study was conducted to evaluate the toxicity and efficacy of irinotecan/5-fluorouracil/leucovorin (CPT-11/5-FU/LV (AIO schedule)) as salvage treatment in patients with metastatic colorectal cancer."5.12Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial. ( Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, C; Mavroudis, D; Pallis, A; Souglakos, J; Vardakis, N, 2007)
"We conducted a randomised phase II study to compare irinotecan monotherapy with irinotecan in combination with infusional 5-fluorouracil/folinic acid (5-FU/FA) regarding efficacy and safety of these regimens in second-line therapy after failed fluoropyrimidine therapy in patients with metastatic colorectal cancer (mCRC)."5.12A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. ( Arnold, D; Graeven, U; Heuer, T; Nusch, A; Porschen, R; Reinacher-Schick, A; Schmiegel, W, 2007)
"Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without bevacizumab; or bevacizumab alone."5.12Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. ( Alberts, SR; Benson, AB; Catalano, PJ; Giantonio, BJ; Meropol, NJ; Mitchell, EP; O'Dwyer, PJ; Schwartz, MA, 2007)
"Patients with previously untreated metastatic colorectal cancer were enrolled in a phase II trial of infusional 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), bevacizumab and erlotinib."5.12Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. ( Battu, S; Bhargava, P; Blaszkowsky, L; Earle, CC; Enzinger, P; Fuchs, CS; Lawrence, C; Mayer, RJ; Meyerhardt, JA; Ryan, DP; Stuart, K; Zhu, AX, 2007)
"The purpose of the present study was to evaluate the differences in the sequence of administration of 5-fluorouracil (5-FU)/leucovorin (LV) followed by irinotecan (CPT-11), or CPT-11 followed by 5-FU/LV in advanced colorectal cancer (ACC)."5.12Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study. ( Adoniou, E; Bacoyiannis, C; Felekouras, E; Gryniatsos, J; Kosmas, C; Papadoniou, N; Papalambros, E; Papastratis, G; Polyzos, A; Sigala, F; Skopelitis, H; Tsavaris, N; Zacharakis, M; Zografos, G, 2007)
"The objective of the present study was to evaluate the gene expression of the DNA mismatch repair gene MSH2 as a predictive marker in advanced colorectal cancer (CRC) treated with first-line capecitabine."5.12Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine. ( Danenberg, KD; Danenberg, PV; Jakobsen, A; Jensen, LH, 2007)
"To compare the use of capecitabine plus oxaliplatin (CAPOX) with infusional fluorouracil (FU)/folinic acid plus oxaliplatin (FUFOX) as first-line therapy for patients with metastatic colorectal cancer (MCRC)."5.12Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. ( Arkenau, HT; Freier, W; Graeven, U; Greil, R; Grothey, A; Hinke, A; Kretzschmar, A; Kubicka, S; Porschen, R; Schmiegel, W; Schmoll, HJ; Seufferlein, T, 2007)
"The aim of this phase III trial was to compare the efficacy and safety of capecitabine plus oxaliplatin (XELOX) versus Spanish-based continuous-infusion high-dose fluorouracil (FU) plus oxaliplatin (FUOX) regimens as first-line therapy for metastatic colorectal cancer (MCRC)."5.12Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Tri ( Abad, A; Aparicio, J; Aranda, E; Carrato, A; Chaves, M; Díaz-Rubio, E; Gómez-España, A; González-Flores, E; Losa, F; Massutí, B; Maurel, J; Queralt, B; Reina, JJ; Rivera, F; Sastre, J; Tabernero, J, 2007)
"Individually, oxaliplatin and irinotecan have substantial activity in metastatic colorectal cancer (CRC) in combination with 5-fluorouracil/leucovorin."5.12Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. ( Ames, MM; Erlichman, C; Goetz, MP; Krook, JE; McWilliams, RR; Morlan, BW; Rowland, KM; Salim, M, 2007)
"Gefitinib, an orally active inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, combined with chemotherapy, has shown efficacy as second-line treatment for advanced colorectal cancer (CRC)."5.12First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. ( Boselli, S; de Braud, F; Lorizzo, K; Magni, E; Martignetti, A; Massacesi, C; Santoro, L; Zampino, MG; Zaniboni, A; Zorzino, L, 2007)
"We randomly assigned 820 patients with advanced colorectal cancer to receive either first-line treatment with capecitabine, second-line irinotecan, and third-line capecitabine plus oxaliplatin (sequential treatment; n=410) or first-line treatment capecitabine plus irinotecan and second-line capecitabine plus oxaliplatin (combination treatment; n=410)."5.12Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. ( Antonini, NF; Creemers, GM; Dalesio, O; de Jong, RS; Douma, J; Erdkamp, FL; Honkoop, AH; Koopman, M; Loosveld, OJ; Mol, L; Punt, CJ; Rodenburg, CJ; Sinnige, HA; Slee, PHTJ; Tesselaar, ME; van Bochove, A; Vreugdenhil, G; Wals, J; Werter, MJ, 2007)
"To evaluate the efficacy, side-effects and quality of life in the advanced colorectal cancer patients treated by irinotecan plus fuorouracil and leucovorin with thalidomide or without thalidomide."5.12[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. ( Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ, 2007)
"This study was designed as a multicentre phase II trial to assess the efficacy and safety of gefitinib in association with capecitabine and oxaliplatin in patients with untreated metastatic colorectal cancer."5.12A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer. ( Cognetti, F; Di Costanzo, F; Ferraresi, V; Gabriele, A; Gamucci, T; Gasperoni, S; Gelibter, AJ; Giannarelli, D; Nuzzo, C; Pollera, CF; Signorelli, C; Zeuli, M, 2007)
"In the OPTIMOX1 trial, previously untreated patients with advanced colorectal cancer were randomly assigned to two different schedules of leucovorin, fluorouracil, and oxaliplatin that were administered until progression in the control arm or in a stop-and-go fashion in the experimental arm."5.12Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. ( Abrahantes, JC; André, T; Burzykowski, T; Buyse, M; Carola, E; Cervantes, A; Chirivella, I; de Gramont, A; Etienne, PL; Figer, A; Flesch, M; Lledo, G; Louvet, C; Mineur, L; Perez-Staub, N; Quinaux, E; Rivera, F; Tabah-Fisch, I; Tournigand, C, 2007)
"prospective, randomized, open-label trial in group of 204 patients with advanced colorectal cancer randomized to either chemotherapy with irinotecan+5-FU+leucovorin or supportive care alone (control group) between January 1999--January 2005 was performed."5.12Evaluation of adjuvant chemotherapy irinotecan + 5-fluorouracil + leucovorine in advanced colorectal cancer. ( Klek, S; Kulig, J; Popiela, T; Richter, P, 2007)
"The objective was to evaluate the efficacy and toxicity of leucovorin plus 5-fluorouracil combined with oxaliplatin (modified FOLFOX regimen) every 2 weeks on previously untreated advanced colorectal cancer patients in the Chinese population."5.12A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer. ( Qiu, F; Tang, XM; Tao, QS; Xiang, XJ; Xiong, JP; Xu, J; Yu, F; Zhang, L; Zhong, LX, 2007)
"An economic evaluation of the irinotecan, leucovorin, 5-fluorouracil (FOLFIRI) combination versus the irinotecan, oxaliplatin, leucovorin, 5-fluorouracil (FOLFOXIRI) regimen in patients with metastatic colorectal cancer was performed in the context of a randomised phase III study."5.12Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece. ( Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, A; Prezerakos, P, 2007)
"Capecitabine results in superior response rate, improved safety, and improved convenience compared with 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (MCRC)."5.12Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. ( Bexon, A; Diamandidis, D; Eckhardt, SG; Javle, M; Justice, GR; Keiser, W; Lee, FC; Liebmann, JE; Lin, E; Patt, YZ; Salvatore, JR, 2007)
"To evaluate the maximum tolerated dose and dose-limiting toxicity (DLT) of 10-hydroxy-camptothecin (10-HCPT) in HFL regimen for the treatment of advanced colorectal cancer (CRC)."5.12[10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer]. ( Cai, RG; Chen, SS; Chu, DT; Wu, F; Zhang, HG, 2007)
"To assess activity and safety of an experimental combination of irinotecan and oxaliplatin (IRINOX) as first-line treatment in advanced colorectal cancer."5.12A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study ( Adenis, A; Bécouarn, Y; Boucher, E; Cany, L; Cvitkovic, F; Jacob, JH; Montoto-Grillot, C; Senesse, P; Thézenas, S; Ychou, M, 2007)
"A phase I/II study was performed to determine the safety and activity of a capecitabine plus oxaliplatin and irinotecan (COI) regimen using capecitabine concurrently with oxaliplatin and irinotecan in previously untreated patients with metastatic colorectal cancer."5.12Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. ( Bajetta, E; Bajetta, R; Celio, L; Colombo, A; Denaro, A; Di Bartolomeo, M; Dotti, K; Ferrario, E; Mancin, M; Pusceddu, S, 2007)
"To evaluate the efficacy and toxicity of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every 2 weeks on previously untreated advanced colorectal cancer patients in Chinese population."5.12A Phase II trial of oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX4) as first-line chemotherapy in advanced colorectal cancer: a China single-center experience. ( Bao, HY; Fang, WJ; Huang, S; Shen, P; Shi, GM; Xu, N; Yu, LF; Zhang, XC, 2007)
"Capecitabine and oxaliplatin are both synergistically active against metastatic colorectal cancer (MCRC)."5.12Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer. ( Benekli, M; Buyukberber, S; Coskun, U; Dikilitas, M; Er, O; Kaya, AO; Ozturk, B; Polat, M; Uner, A; Yamac, D; Yaman, E; Yildiz, R, 2007)
"Two consecutive studies have evaluated the efficacy of oxaliplatin combined with the Nordic bolus schedule of 5-fluorouracil and folinic acid as first-line treatment in metastatic non-resectable colorectal cancer."5.12Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer. ( Berglund, A; Dahl, O; Glimelius, B; Ogreid, D; Sørbye, H; Tveit, KM; Wanderås, EH; Wentzel-Larsen, T, 2007)
"Tegafur is an oral fluorouracil prodrug used in the treatment of colorectal cancer."5.12A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule. ( Bennouna, J; Cardot, JM; Château, Y; Douillard, JY; Etienne-Grimaldi, MC; François, E; Gamelin, E; Milano, G; Renée, N, 2007)
"We have evaluated the efficacy and safety of cetuximab plus FOLFIRI for irinotecan and oxaliplatin-refractory colorectal cancers."5.12A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer. ( Chang, HM; Kang, YK; Kim, MK; Kim, TW; Koo, DH; Lee, JL; Lee, JS; Lee, SS; Ryu, MH; Sym, SJ, 2007)
"This phase III study compared the safety and efficacy of the following three different irinotecan-containing regimens in the first-line treatment of metastatic colorectal cancer: irinotecan plus infusional fluorouracil (FU)/leucovorin (LV) (FOLFIRI), irinotecan plus bolus FU/LV (mIFL), and irinotecan plus oral capecitabine (CapeIRI)."5.12Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. ( Barrueco, J; Fuchs, CS; Ganju, V; Jeffery, M; Marshall, J; Mitchell, E; Richards, D; Schulz, J; Soufi-Mahjoubi, R; Wang, B; Wierzbicki, R, 2007)
"Tissue samples from patients with pathologic ((p)) stage III colorectal cancer were tested for sensitivity to 5-fluorouracil (5-FU)."5.12An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer. ( Isogai, A; Kubota, S; Matsuoka, H; Nagaya, M; Tsukikawa, S; Watanabe, T, 2007)
"This phase II study investigated the efficacy and safety of cetuximab combined with standard oxaliplatin-based chemotherapy (infusional fluorouracil, leucovorin, and oxaliplatin [FOLFOX-4]) in the first-line treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer (mCRC)."5.12Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. ( André, T; Casado, E; Cervantes, A; Ciardiello, F; de Gramont, A; Díaz-Rubio, E; Humblet, Y; Kisker, O; Soulié, P; Tabernero, J; Tortora, G; Valera, JS; Van Cutsem, E; Van Laethem, JL; Verslype, C, 2007)
"1) To confirm the efficacy of irinotecan plus folinic acid/continuous 5-fluorouracil as bimonthly FOLFIRI regimen in metastatic colorectal cancer patients."5.12FOLFIRI chemotherapy for metastatic colorectal cancer patients. ( Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Sukthomya, V; Tonusin, A, 2007)
"To evaluate the combination of bevacizumab with infusional 5-fluorouracil (5-FU), leucovorin (LV) and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (CRC) pretreated with combination regimens including irinotecan and oxaliplatin."5.12Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. ( Kim, HJ; Kim, SH; Kwon, HC; Lee, S; Oh, SY, 2007)
"Chemotherapy with fluorouracil and folinic acid could improve survival of patients with stage II colorectal cancer, although the absolute improvements are small: assuming 5-year mortality without chemotherapy is 20%, the relative risk of death seen here translates into an absolute improvement in survival of 3."5.12Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. ( Barnwell, J; Gray, R; Hills, RK; Kerr, DJ; McConkey, C; Williams, NS, 2007)
"This multicenter, randomized trial compared overall response rate between pemetrexed plus irinotecan (ALIRI) and leucovorin-modulated 5-fluorouracil plus irinotecan (FOLFIRI) in patients with advanced colorectal cancer."5.12A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer. ( Bazin, IS; Biakhov, MY; Blatter, J; Goldstein, D; Gorbounova, VA; Granov, DA; Hossain, AM; Kaiser, C; Ma, D; Underhill, C, 2007)
"In metastatic colorectal cancer, phase III studies have demonstrated the superiority of fluorouracil (FU) with leucovorin (LV) in combination with irinotecan or oxaliplatin over FU + LV alone."5.11FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. ( Achille, E; André, T; Buyse, M; Colin, P; Couteau, C; de Gramont, A; Flesh, M; Ganem, G; Landi, B; Lledo, G; Louvet, C; Mery-Mignard, D; Quinaux, E; Tournigand, C, 2004)
"Three agents with differing mechanisms of action are available for treatment of advanced colorectal cancer: fluorouracil, irinotecan, and oxaliplatin."5.11A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. ( Alberts, SR; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2004)
"This Nordic multicenter phase II study evaluated the efficacy and safety of oxaliplatin combined with the Nordic bolus schedule of fluorouracil (FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer."5.11Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. ( Berglund, A; Braendengen, M; Dahl, O; Fokstuen, T; Glimelius, B; Sørbye, H; Tveit, KM; Øgreid, D, 2004)
"The aim of the current randomized Phase II study was to investigate the efficacy and safety of capecitabine combined with irinotecan as first-line treatment in metastatic colorectal carcinoma (CRC)."5.11Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. ( Artale, S; Bajetta, E; Beretta, E; Biasco, G; Bonaglia, L; Bonetti, A; Buzzoni, R; Carreca, I; Cassata, A; Cortinovis, D; Di Bartolomeo, M; Ferrario, E; Frustaci, S; Iannelli, A; Lambiase, A; Mariani, L; Marini, G; Pinotti, G, 2004)
" In all, 18 patients with peritoneal and/or local metastases from colorectal adenocarcinoma underwent debulking surgery followed by 5-fluorouracil (5-FU) 550 mg m(-2) day(-1) i."5.11Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. ( Berglund, A; Glimelius, B; Graf, W; Hansson, J; Mahteme, H; Nygren, P; Påhlman, L, 2004)
"The current study was designed to evaluate the antitumor activity and toxicity of capecitabine and oxaliplatin in previously untreated patients with advanced colorectal carcinoma."5.11Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. ( Marshall, JL; Meropol, NJ; Shields, AF; Zalupski, MM, 2004)
"The purpose is to determine the plasma pharmacokinetics, the maximum-tolerable dose and to preliminary evaluate the antitumor activity of irinotecan administered as a 7-day continuous infusion every 21 days in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed."5.11A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ( Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G, 2004)
"Our objective was to determine the maximum tolerated dose (MTD) of sequential raltitrexed (Tomudex) and 5-fluorouracil (5-FU) by bolus administration every 3 weeks in patients with advanced colorectal cancer (aCRC) and appendiceal adenocarcinoma."5.11Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer. ( Bertino, J; Dimery, I; Endres, S; Kelsen, DK; Kemeny, N; Saltz, L; Schwartz, GK; Tong, W; Welch, M, 2004)
"This study evaluates the efficacy of capecitabine using data from a large, well-characterised population of patients with metastatic colorectal cancer (mCRC) treated in two identically designed phase III studies."5.11Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. ( Bukowski, RM; Cunningham, D; Dufour, P; Graeven, U; Harper, P; Hoff, PM; Lokich, J; Madajewicz, S; Maroun, JA; Marshall, JL; Mitchell, EP; Perez-Manga, G; Rougier, P; Schilsky, RL; Schmiegel, W; Schoelmerich, J; Sobrero, A; Van Cutsem, E, 2004)
"The purpose of this report is to evaluate the efficacy and toxicity (Tx) of a double modulation of 5-fluorouracil (5-FU) by trimetrexate (TMTX) and leucovorin (LV) in patients with advanced recurrent (inoperable) or metastatic colorectal cancer (ACC)."5.11Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma. ( Bologna, F; Dominguez, ME; Lacava, JA; Leone, BA; Machiavelli, MR; Ortiz, EH; Pérez, JE; Romero, AO; Salum, G; Vallejo, CT, 2004)
"This phase II study evaluated a modified Japanese capecitabine regimen as first-line treatment for advanced/metastatic colorectal cancer."5.11A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer. ( Kondo, Y; Nishisho, I; Sakamoto, J; Sakamoto, N; Takemiya, S, 2004)
"Irinotecan (CPT-11) and bolus 5-fluorouracil (5-FU)/leucovorin (LV) administered weekly for 4 weeks every 42 days (Saltz regimen) is active but substantially toxic in patients with metastatic colorectal cancer (CRC)."5.11Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer. ( Baba, E; Fujishima, H; Harada, M; Kikuchi, I; Mitsugi, K; Miyanaga, O; Nakano, S; Ueda, A, 2004)
"As single agents, irinotecan and oxaliplatin are active in colorectal cancer after fluorouracil (FU)-containing regimen failure."5.11Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients. ( Bajetta, E; Beretta, E; Buzzoni, R; Cortinovis, D; Di Bartolomeo, M; Dognini, G; Ferrario, E; Toffolatti, L, 2004)
"Oxaliplatin (L-OHP), irinotecan (CPT-11) and 5-fluorouracil (5-FU) have shown their efficacy in metastatic colorectal cancer."5.11Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors. ( Abad, A; Antón, A; Carrato, A; Diaz-Rubio, E; Gallego, J; Manzano, JL; Marfa, X; Massutí, B; Yuste, AL, 2004)
"Irinotecan has proven anti-tumor activity as induction treatment in combination with 5-fluorouracil (5-FU) or as second-line treatment after 5-FU in patients with metastatic colorectal cancer."5.11Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. ( Batran, SA; Bokemeyer, C; Büchele, T; Haag, C; Hartmann, JT; Hofheinz, RD; Jäger, E; Kanz, L; Niederle, N; Oechsle, K; Pflüger, KH; Reis, HE; Wilke, HJ, 2004)
"Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (MCRC)."5.11XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. ( Brunet, R; Butts, C; Cassidy, J; Conroy, T; Debraud, F; Díaz-Rubio, E; Figer, A; Grossmann, J; Sawada, N; Schöffski, P; Sobrero, A; Tabernero, J; Twelves, C; Van Cutsem, E, 2004)
"Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan, bolus fluorouracil, and leucovorin (IFL) plus bevacizumab (5 mg per kilogram of body weight every two weeks) and 411 to receive IFL plus placebo."5.11Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. ( Baron, A; Berlin, J; Cartwright, T; Fehrenbacher, L; Ferrara, N; Fyfe, G; Griffing, S; Hainsworth, J; Heim, W; Holmgren, E; Hurwitz, H; Kabbinavar, F; Novotny, W; Rogers, B; Ross, R, 2004)
"While several studies have reported that thymidylate synthase (TS) tumour expression can be a reliable predictive marker of clinical response to 5-Fluorouracil (5-FU) for advanced colorectal cancer patients, only a few studies that searched for predictive factors of irinotecan (CPT-11) clinical response are available."5.11Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients. ( Chiriatti, A; Colucci, G; Giuliani, F; Maiello, E; Mangia, A; Montemurro, S; Paradiso, A; Simone, G; Xu, J; Zito, A, 2004)
"This phase II study examined bimonthly oxaliplatin (85 mg/m2) added to a continuous infusion of fluorouracil (3000 mg/m2 for 46 h following a 400 mg/m2 bolus), with leucovorin (LV) (150 mg/m2) administrated in a simplified way to patients with metastatic colorectal cancers (CRC) refractory or resistant to 5-fluorouracil (5-FU)."5.11Oxaliplatin added to simplified bimonthly low-dose leucovorin and 5-FU for pretreated advanced colorectal cancer is effective and not affected by different previous 5-FU regimens. ( Chao, TY; Chen, LT; Chen, PM; Chen, WS; Hsieh, RK; Liu, JH; Yang, TS, 2004)
"This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer."5.11Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004)
"Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer."5.11Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004)
"This study was designed to assess the safety and efficacy of capecitabine and mitomycin C (MMC) in previously untreated patients with advanced colorectal cancer (CRC)."5.11Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. ( Cunningham, D; Hill, ME; Norman, AR; Oates, J; Price, T; Rao, S; Ross, PJ; Shellito, P; Tebbutt, N, 2004)
"FOLFOX, a bimonthly combination of leucovorin, 5-fluorouracil and oxaliplatin, is active in metastatic colorectal cancer, but sometimes causes cumulative sensory neurotoxicity."5.11Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2004)
" In an effort to improve the therapeutic effect of a MAb-based regimen in colorectal carcinoma (CRC) patients, the effects of a combination of alpha-interferon (alpha-IFN), 5-fluorouracil (5-FU), granulocyte-macrophage colony-stimulating factor (GM-CSF) and mouse MAb17-1A was evaluated in 27 patients with metastatic disease."5.11Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma. ( Frödin, JE; Liljefors, M; Mellstedt, H; Nilsson, B; Ragnhammar, P; Ullenhag, G, 2004)
"Bowel mucosal injury associated with 5-fluorouracil (5-FU) treatment might result in secondary lactose intolerance."5.11Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. ( Elomaa, I; Ikonen, M; Joensuu, H; Korpela, R; Ollus, A; Osterlund, P; Peuhkuri, K; Ruotsalainen, T, 2004)
"The aim of this study was to evaluate efficacy and safety of the combination chemotherapy with irinotecan plus capecitabine in patients with advanced colorectal adenocarcinoma."5.11First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. ( Baek, JH; Bang, SM; Cho, EK; Im, SA; Lee, JH; Oh, JH; Park, SH; Park, YS; Shin, DB, 2004)
"To evaluate the safety and efficacy of irinotecan (CPT-11) alternated with a weekly treatment for 4 weeks of oxaliplatin (L-OHP), high-dose leucovorin (LV) and a 48-hour 5-fluorouracil infusion (5-FU 48 h) as first-line chemotherapy for patients with advanced colorectal cancer (ACC)."5.11A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. ( Colarusso, D; Manzione, L; Pizza, C; Reggiardo, G; Rinaldi, A; Rosati, G; Tucci, A, 2004)
"The effectiveness of capecitabine, an oral fluoropyrimidine carbamate, is well documented in previously untreated metastatic colorectal cancer patients (overall response rate: 25%)."5.11Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. ( Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ, 2004)
"We evaluated quantitative measurement series (MS) with 18F-FDG and PET and compared different quantification methods for prediction of individual survival in patients with metastatic colorectal cancer receiving chemotherapy with 5-fluorouracil, folinic acid, and oxaliplatin (FOLFOX)."5.11Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. ( Burger, C; Dimitrakopoulou-Strauss, A; Irngartinger, G; Rudi, J; Rühl, A; Strauss, LG; Stremmel, W, 2004)
"To compare the effect of 5-fluorouracil (5-FU) portal vein infusion (PVI) for 7 days after radical resection, with intraluminal chemotherapy during operation for eliminating liver metastasis and elevating long-term prognosis in colorectal cancer."5.11[Comparing the effect of adjuvant chemotherapy by portal vein infusion with intraluminal chemotherapy for colorectal cancer]. ( Chen, G; Ding, PR; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Wang, FL; Wu, XJ; Zhou, ZW, 2004)
" Patients with advanced, untreated, measurable colorectal cancer received sequential methotrexate (MTX) (days 1 and 15)-->l-OHP+FU (days 2 and 16) (200, 85 and 600 mg m(-2), respectively) followed by 3 weeks of CI FU (200 mg m(-2) day(-1)) given from day 29 to 50, modulated by weekly leucovorin (LV) (20 mg m(-2))."5.11Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil. ( Barni, S; Belvedere, O; Beretta, GD; Frontini, L; Grossi, F; Guglielmi, A; Labianca, R; Pella, N; Puglisi, F; Sobrero, A; Zaniboni, A, 2004)
"A phase II trial was designed to determine whether mistletoe extract can induce objective tumor response in patients with metastatic colorectal cancer resistant to 5-fluorouracil and leucovorin (5FU/LCV)-based chemotherapy."5.11Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy. ( Bar-Sela, G; Haim, N, 2004)
"Irinotecan (CPT-11) is an effective drug in patients with advanced colorectal cancer (CRC)."5.11Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. ( Balcells, M; Benavides, M; Carabantes, F; Cobo, M; García-Alfonso, P; Gil-Calle, S; Graupera, J; Muñoz-Martín, A; Pérez-Manga, G; Villar, E, 2004)
"This multicentre phase II study was designed to evaluate the antitumour activity and toxicity of bifractionated camptothecin (CPT-11) and 5-fluorouracil/ leucovorin (5-FU/LV) in the treatment of patients with metastatic colorectal cancer (MCC) who had been pretreated with 5-FU/LV-oxaliplatin (FOLFOX regimen)."5.11Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. ( Cesta, A; Lalli, A; Lullo, LD; Nuzzo, A; Rea, S; Recchia, F; Saggio, G, 2004)
"This phase I study was conducted to establish the dose-limiting toxicities and maximum-tolerated dose of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in combination with FOLFIRI, a standard regimen of irinotecan, leucovorin, and infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer."5.11Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities. ( Donehower, RC; Grouleff, P; Hidalgo, M; Kelley, SK; Laheru, DA; Lum, BL; Messersmith, WA; Ramies, DA; Rogers, T; Senzer, NN, 2004)
"The combination of irinotecan and a fluoropyrimidine has been widely accepted as a treatment for advanced colorectal carcinoma."5.11Gene expression profiles of colorectal carcinoma in response to neo-adjuvant chemotherapy. ( Hiro, J; Inoue, Y; Kobayashi, M; Kusunoki, M; Miki, C; Mori, K; Shirane, M; Tanaka, K; Yanagi, H, 2004)
"A combination of irinotecan 125 mg/m2, 5-fluorouracil (5-FU) 500 mg/m2, and leucovorin (LV) 20 mg/m2 (Saltz regimen; treatment on days 1, 8, 15, and 22 every 6 weeks) is widely used for the treatment of metastatic colorectal cancer."5.11Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. ( Arai, T; Goto, A; Hamaguchi, T; Hosokawa, A; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2004)
"In a previous phase I-II study we demonstrated that the FOLFOXIRI regimen [irinotecan 125-175 mg/m2 day 1, oxaliplatin 100 mg/m2 day 1, l-leucovorin (l-LV) 200 mg/m2 day 1, 5-fluorouracil (5-FU) 3800 mg/m2 as a 48-h chronomodulated continuous infusion starting on day 1, repeated every 2 weeks] has promising activity and efficacy in metastatic colorectal cancer."5.11First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. ( Allegrini, G; Andreuccetti, M; Brunetti, I; Cerri, E; Cupini, S; Falcone, A; Fontana, E; Marcucci, L; Masi, G; Ricci, S, 2004)
"The addition of oxaliplatin to fluorouracil (FU) and leucovorin (LV) improves the outcome of patients with colorectal cancer (CRC)."5.11Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. ( Benson, A; Brandt, DS; Burger, B; Garay, CA; Gupta, S; Gurtler, J; Hallman, D; Hochster, H; Kemeny, N; Kennedy, P; Polikoff, J; Shumaker, G; Wertheim, M, 2004)
"A weekly continuous 24-h infusion therapy with 5-fluorouracil (5-FU) preceded by a 2-h infusion of calcium folinate (CA-FA) was shown to be an effective first- and secondline treatment in advanced metastatic colorectal cancer."5.11Second-line treatment of advanced colorectal cancer with a weekly simultaneous 24-hour infusion of 5-fluorouracil and sodium-folinate: a multicentre phase II trial. ( Fritze, D; Kreuser, ED; Kuhfahl, J; Link, H; Pichlmeier, U; Schulte, F; Steinbrecher, C; Wagner, H; Wagner, T, 2004)
" Two clinical trials show that the addition of bevacizumab to a regimen of either fluorouracil plus leucovorin (FL) or FL combined with irinotecan (IFL), significantly improves response rate and time to tumour progression and increases overall survival for patients with advanced colorectal cancer (ACC)."5.11Bevacizumab for advanced colorectal cancer. ( Hadj Tahar, A, 2004)
"The efficacy of combination therapy with irinotecan and capecitabine has been demonstrated for the first-line treatment of metastatic colorectal cancer (MCRC)."5.11Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study. ( Gnad-Vogt, U; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Pilz, L; Saussele, S; Wein, A, 2005)
"To determine the efficacy, impact on quality-of-life (QoL) and tolerability of two different irinotecan administration schedules in combination with capecitabine as first-line treatment of metastatic colorectal cancer."5.11A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. ( Bernhard, J; Borner, MM; Brauchli, P; Dietrich, D; Herrmann, R; Honegger, H; Koeberle, D; Lanz, D; Popescu, R; Rauch, D; Roth, AD; Saletti, P; Wernli, M, 2005)
"Fluorouracil (5-FU), oxaliplatin and irinotecan combinations improve time to tumor progression (TTP), objective response and overall survival (OS) in patients with metastatic colorectal cancer (MCRC)."5.11Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. ( Alberts, SR; Delaunoit, T; Findlay, BP; Fuchs, C; Goldberg, RM; Green, E; Krook, J; Morton, RF; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2005)
"We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of protracted venous infusion (PVI) 5-fluorouracil (5-FU) against the standard bolus monthly regimen of 5-FU/leucovorin (LV) given for 6 months as adjuvant treatment in colorectal cancer (CRC)."5.11A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. ( Chau, I; Cunningham, D; Hickish, T; Hill, M; Iveson, T; Jodrell, D; Lofts, F; Norman, AR; Oates, JR; Ross, PJ; Tait, D; Webb, A, 2005)
"Capecitabine and irinotecan are commonly used in the treatment of metastatic colorectal cancer (CRC)."5.11UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. ( Andria, ML; Bever, J; Blanchard, RL; Carlini, LE; Gold, P; Hill, T; Meropol, NJ; Rogatko, A; Wang, H, 2005)
"Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, increases survival when combined with irinotecan-based chemotherapy in first-line treatment of metastatic colorectal cancer (CRC)."5.11Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. ( Hamm, JT; Hecht, JR; Kabbinavar, FF; Mass, R; McCleod, M; Nelson, B; Novotny, WF; Patel, T; Perrou, B; Schulz, J, 2005)
"Although irinotecan 350 mg m(-2) is a standard option for relapsed/refractory advanced colorectal cancer, there is some evidence that suggests that a higher dose may be more effective, with acceptable tolerability, following 5-fluorouracil (5-FU)."5.11Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study. ( Bleiberg, H; Borner, M; Dirix, L; Gonzalez Baron, M; Gruia, G; Joosens, E; Morant, R; Roth, A; Sibaud, D; Van Belle, S; Van Cutsem, E; Van Laethem, JL, 2005)
"The objective of this study was to assess the efficacy and safety of two regimens of irinotecan, combined or alternated with bolus 5-fluorouracil (5-FU) and folinic acid (FA), and the Mayo Clinic regimen as first-line therapy for colorectal cancer (CRC)."5.11Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer. ( Artandi, M; Borner, M; Boussard, B; Carlsson, G; Espana, P; Graeven, U; Ridwelski, K; Rosales, AM; Schmiegel, W; Schölmerich, J, 2005)
"The aim of this study was to investigate the therapeutic value and safety of third-line treatment with mitomycin-C (MMC) and capecitabine (Xeloda) in patients with advanced colorectal cancer pretreated with combination regimens including 5-fluorouracil (5-FU), folinic acid (FA) and irinotecan (CPT-11) or 5-FU, FA and oxaliplatin (L-OHP)."5.11Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. ( Im, YH; Ji, SH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, SH; Lim, DH; Park, BB; Park, JO; Park, K; Park, KW; Park, YS, 2005)
"The combination of 5-fluorouracil (5-FU) plus leucovorin (LV) with oxaliplatin has become one of the standard treatments for advanced colorectal cancer (CRC)."5.11Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer. ( Abad, A; Antón, A; Aranda, E; Carrato, A; Cervantes, A; Diaz-Rubio, E; Guallar, JL; Manzano, JL; Marcuello, E; Martinez-Villacampa, M; Massutí, B; Navarro, M; Sastre, J, 2005)
"A phase I-II multicenter trial was conducted to define the maximal tolerated dose and describe the activity of an OCFL combination using oxaliplatin (OHP), irinotecan (CPT-11) and 5-fluorouracil (FU)/leucovorin (LV) in metastatic colorectal cancer (CRC)."5.11Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. ( Allal, A; Bauer, J; Gervaz, P; Mentha, G; Morant, R; Philippe, M; Roth, AD; Ruhstaller, T; Seium, Y; Stupp, R; Trembleau, C, 2005)
"Although intravenous (IV) 5-fluorouracil (5-FU) and uracil/futraful (UFT) have comparable antitumour efficacy in the treatment of metastatic colorectal cancer (MCC), we wanted to assess which of these two regimens would be preferred by our patients."5.11Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience. ( del Giglio, A; Lima, AP, 2005)
"Irinotecan (IRI) and oxaliplatin (OXA) are effective in the treatment of colorectal cancer."5.11Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. ( Aravantinos, G; Bacoyiannis, C; Bamias, A; Basdanis, G; Chalkidou, S; Dimopoulos, M; Economopoulos, T; Fountzilas, G; Kalfarentzos, F; Kalofonos, HP; Karina, M; Kosmidis, P; Koutras, A; Papakostas, P; Pectasides, D; Samantas, E; Samelis, GF; Skarlos, D, 2005)
"To determine the tolerability of capecitabine in elderly patients with advanced colorectal cancer (CRC)."5.11Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. ( Bolaños, M; Casado, E; Escudero, P; Feliu, J; Gómez-Reina, MJ; González-Baron, M; Llosa, F; Lopez, R; Lopez-Gómez, L; Sanz-Lacalle, JJ; Vicent, JM; Yubero, A, 2005)
"Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA), a recombinant, humanized anti-vascular endothelial growth factor monoclonal antibody that inhibits tumor angiogenesis, has demonstrated survival benefit in patients with previously untreated metastatic colorectal cancer when combined with irinotecan/fluorouracil (FU)/leucovorin (LV; IFL)."5.11Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. ( Bergsland, E; Hambleton, J; Hurwitz, HI; Kabbinavar, FF; Mass, RD; Sarkar, S, 2005)
"Oxaliplatin 100 mg/m(2) iv on day 1, and capecitabine 1,000 mg/m(2) orally bid from day 1 (evening) to day 11 (morning) were administered every 2 weeks (OXXEL regimen) to 38 patients as first-line treatment for metastatic colorectal carcinoma."5.11Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study. ( Casaretti, R; Cataldis, GD; Comella, P; Farris, A; Lucia, LD; Maiorino, L; Massidda, B; Natale, D; Palmeri, S; Tafuto, S, 2005)
"In a phase III trial, combining bevacizumab (BV)--a recombinant, humanized, monoclonal antibody targeting vascular endothelial growth factor--with irinotecan, bolus fluorouracil (FU), and leucovorin (LV; IFL) increased survival compared with IFL alone in first-line treatment of patients with metastatic colorectal cancer (CRC)."5.11Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. ( Berlin, J; Fehrenbacher, L; Hainsworth, JD; Hambleton, J; Heim, W; Holmgren, E; Hurwitz, HI; Kabbinavar, F; Novotny, WF, 2005)
"Irinotecan combined with continuous-infusion 5-fluorouracil (5FU) has been shown to be an effective and tolerable regimen in the treatment of metastatic colorectal cancer (MCRC)."5.11Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer. ( Asama, T; Ashida, T; Ayabe, T; Chisato, N; Ebisawa, Y; Kamiya, K; Kasai, S; Kohgo, Y; Kono, T; Tomita, I, 2005)
"Between July 2001 and September 2002, 49 eligible patients were enrolled in an open-label phase II study to assess the efficacy and safety of first-line treatment with capecitabine/irinotecan in metastatic colorectal cancer."5.11Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. ( Asmar, L; Boehm, KA; Cartwright, T; Encarnacion, C; Lopez, T; Vukelja, SJ, 2005)
"Seventy-two patients suffering from a metastatic colorectal cancer received, as first line treatment, a combination chronotherapy with 5-FU and folinic acid (infused from 10 pm to 10 am with a peak at 4 am, respectively at doses of 700 and 300 mg/m2 per day) and carboplatin (infused at the dose of 40 mg/m2 per day from 10 am to 10 pm with a peak at 4 pm)."5.11[Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study]. ( Biquet, JF; David, A; Delforge, M; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Materne, R; Moeneclaey, N; Weerts, J, 2005)
"Seventeen colorectal cancer patients received as first (12 cases) or second line (5 cases) treatment a combined chronotherapy with CPT 11 (infused at day 1 from 2 to 8 am; peak at 5 am), given with 5 FU (700 mg/m2 per day ; days 2-5) and folinic acid (300 mg/m2 per day, days 2-5) both infused from 10 pm to 10 am with a peak at 4 am, and carboplatin (40 mg/m3/day - days 2-5 ; infused from 10 am to 10 pm - peak at 4 pm)."5.11[Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer]. ( David, A; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N, 2005)
"The aim of this study was to determine in patients with previously untreated advanced colorectal cancer the maximum tolerated dose (MTD) and safety profile of irinotecan in combination with capecitabine, to identify a recommended dose and to determine the response rate and time to disease progression."5.11A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. ( Bakker, JM; Falk, S; Groenewegen, G; Kerr, DJ; Maughan, T; Nortier, JW; Punt, CJ; Rea, DW; Richel, DJ; Semiond, D; Smit, JM; Steven, N; Ten Bokkel Huinink, WW, 2005)
"We performed this phase III study to compare the irinotecan, leucovorin (LV), and fluorouracil (FU) regimen (FOLFIRI) versus the oxaliplatin, LV, and FU regimen (FOLFOX4) in previously untreated patients with advanced colorectal cancer."5.11Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. ( Agostara, B; Borsellino, N; Brunetti, C; Carrozza, F; Cartenì, G; Caruso, M; Chiarenza, M; Colucci, G; Cordio, S; Cramarossa, A; Di Bisceglie, M; Di Seri, M; Durini, E; Filippelli, G; Fortunato, S; Gebbia, N; Gebbia, V; Giuliani, F; Guida, T; Leonardi, V; Lopez, M; Lorusso, V; Maiello, E; Mancarella, S; Manzione, L; Misino, A; Montemurro, S; Nettis, G; Paoletti, G; Pezzella, G; Pisconti, S; Romito, S; Rosati, G; Valdesi, M; Valerio, MR, 2005)
"To verify the effectiveness of oral 1-hexylcarbamoyl-5-fluorouracil (HCFU) in improving the surgical cure rate in advanced colorectal cancer, a multicenter randomized comparative study was conducted."5.11A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer. ( Kodaira, S; Kotake, K; Koyama, Y; Ohashi, Y, 2005)
"During surgery, 753 patients with stage II-III colorectal cancer were randomly assigned to systemic chemotherapy alone (379 with fluorouracil and folinic acid, and 374 with fluorouracil and levamisole), and 748 to postoperative regional chemotherapy with fluorouracil followed by systemic chemotherapy with fluorouracil and folinic acid (n=368) or with fluorouracil and levamisole (n=380)."5.11Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial. ( Arnaud, JP; Baila, L; Bedenne, L; Bleiberg, H; Bouché, O; Conroy, T; Debois, M; Grobost, O; Guimares dos Santos, J; Lacourt, J; Lasser, P; Mackiewickz, R; Morin, T; Nordlinger, B; Ollier, JC; Rougier, P; Seitz, JF; van Cutsem, E; Wals, J; Wils, J, 2005)
"l-leucovorin (LV)/5-fluorouracil (5FU) may play an important role, as an adjuvant chemotherapy, in improving the survival of patients with stage III colorectal cancer."5.11Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer. ( Arii, K; Higashiguchi, T; Hotta, T; Matsuda, K; Oku, Y; Takifuji, K; Tominaga, T; Yamaue, H; Yokoyama, S, 2005)
"This study was designed to determine the effectiveness and tolerance of oxaliplatin, folinic acid (FA) and infusional 5-fluorouracil (5-FU) (FOLFOX-4) chemotherapy when used as a second-line treatment in patients with advanced colorectal cancer for whom an irinotecan-containing regimen failed."5.11Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience. ( Baek, JH; Bang, SM; Cho, EK; Han, SH; Lee, JH; Oh, JH; Park, SH; Shin, DB; Sung, JY, 2005)
" Glutamine may decrease chemotherapy-associated diarrhea."5.11A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. ( Ansari, R; Cheng, L; Helft, P; Juliar, B; Loehrer, P; Pan, CX; Pletcher, W; Seitz, D; Sweeney, C; Vinson, J, 2005)
"Protracted venous infusion 5-fluorouracil (5FU) combined with mitomycin C (MMC) has demonstrated significant activity against metastatic colorectal cancer."5.11Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. ( Chong, G; Cunningham, D; Dickson, JL; Hill, ME; Norman, AR; Oates, J; Price, TJ; Rao, S; Tebbutt, N, 2005)
"Building on results from Southwest Oncology Group trial 8905, this trial was designed to compare low-dose continuous infusion (LDCI) of 5-fluorouracil (5-FU) versus intermittent high-dose infusion (HDI) of 5-FU in disseminated colorectal cancer (CRC) for evidence of survival advantage based on dose intensity."5.11Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study. ( Bearden Iii, JD; Benedetti, JK; Hochster, H; Leichman, CG; Lenz, HJ; Macdonald, JS; Shields, AF; Wade Iii, JL; Zalupski, MM, 2005)
"To investigate the gefitinib, fluorouracil (FU), leucovorin, and oxaliplatin regimen (IFOX) in previously treated patients with metastatic colorectal cancer."5.11Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. ( Advani, RH; Cho, CD; Fisher, GA; Ford, JM; Halsey, J; Kuo, T; Sikic, BI; Wakelee, HA, 2005)
"5-Fluorouracil remains a key drug in the treatment of colorectal cancer, and the development of a simple and effective test for selecting patients likely to benefit from postoperative adjuvant chemotherapy is an important objective."5.11Correlation between expression of orotate phosphoribosyl transferase and 5-fluorouracil sensitivity, as measured by apoptosis index in colorectal cancer tissue. ( Kamano, T; Kawai, K; Matsuda, M; Sakamoto, K; Watabe, S, 2005)
"The aim of the current study was to evaluate the activity and toxicity of a combination of oxaliplatin with bolus fluorouracil and leucovorin in colorectal cancer (CRC) patients pretreated for advanced disease with various schedules including continuous fluorouracil infusion."5.11Activity and toxicity of oxaliplatin and bolus fluorouracil plus leucovorin in pretreated colorectal cancer patients: a phase II study. ( Buccilli, A; Ciccarese, M; Ferraresi, V; Gabriele, A; Gamucci, T; Giampaolo, MA; Giannarelli, D; Mansueto, G, 2005)
"HLA-A2-positive patients with confirmed newly diagnosed metastatic colorectal cancer and elevated serum carcinoembryonic antigen (CEA) were randomized to receive three cycles of standard chemotherapy (irinotecan/high-dose 5-fluorouracil/leucovorin) and vaccinations with CEA-derived CAP-1 peptide admixed with different adjuvants [CAP-1/granulocyte macrophage colony-stimulating factor/interleukin-2 (IL-2), CAP-1/dSLIM/IL-2, and CAP-1/IL-2]."5.11Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. ( Anderson, KS; Ansén, S; Bohlen, H; Diehl, V; Geisen, C; Gracien, E; Jurkiewicz, E; Nadler, LM; Schmidt, M; Weihrauch, MR; Wittig, B; Wolf, J; Xia, Z, 2005)
"We examined patients with previously untreated metastatic colorectal cancer, who were enrolled into two phase I/II trials of combination chemotherapy (irinotecan, leucovorin, and 5-fluorouracil) and daily oral gefitinib."5.11Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer. ( Brahmandam, M; Cantor, M; Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kinsella, K; Kulke, MH; Loda, M; Meyerhardt, JA; Michelini, AL; Namgyal, C; Ogino, S; Ryan, DP, 2005)
"A detailed questionnaire was completed after each chemotherapy cycle for patients with metastatic colorectal cancer enrolled in a phase I trial of oxaliplatin and capecitabine."5.11Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. ( Fioravanti, S; Grem, JL; Harold, N; Leonard, GD; Quinn, MG; Schuler, B; Thomas, RR; Wright, MA, 2005)
"A biweekly regimen of irinotecan 200 mg/m2 on day 1 and levo-leucovorin (LV) 250 mg/m2 plus 5-fluorouracil (5-FU) 850 mg/m2 via intravenous bolus on day 2 was assessed in 2 consecutive randomized trials in metastatic colorectal cancer (CRC)."5.11Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials. ( Buzzi, F; Comella, P; De Cataldis, G; De Lucia, L; Farris, A; Filippelli, G; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Natale, D; Palmeri, S; Roselli, M; Tafuto, S, 2005)
"We tested the hypothesis that the combination of trimetrexate (TMTX) and capecitabine (CAP) would be active in patients with previously treated metastatic colorectal cancer (CRC)."5.11A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer. ( Earle, M; Evans, T; Ferri, W; Friedland, D; Jacobs, SA; Matin, K; Pinkerton, R; Ramanathan, RK; Richards, T; Troetschel, M; Volkin, R; Wieand, S; Wong, MK, 2005)
"This randomised, open-label trial compared oral tegafur (FT)/leucovorin (LV) with the intravenous bolus 5-fluorouracil (5-FU)/LV as first-line chemotherapy for advanced colorectal cancer (CRC)."5.11Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer. ( Arcusa, A; Batiste-Alentorn, E; Boleda, M; Campos, JM; Cirera, L; de Mendizábal, EV; de Olaguer, JP; Escudero, P; Galan, A; Guasch, I; Losa, F; Manzano, H; Méndez, M; Nogué, M; Saigí, E; Salud, A; Vicente, P, 2005)
"Patients with liver-only metastases from colorectal cancer deemed not optimally resectable by a surgeon with expertise in liver surgery received fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)."5.11Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. ( Alberts, SR; Dakhil, SR; Donohue, JH; Goldberg, RM; Horvath, WL; Levitt, R; Mahoney, MR; Nair, S; Rowland, K; Sargent, DJ; Sternfeld, WC, 2005)
"com) and infusional 5-fluorouracil (5-FU) as second-line therapy in metastatic colorectal cancer (MCRC)."5.11Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer. ( Gamucci, T; Gasparini, G; Gattuso, D; Longo, R; Mariani, L; Morabito, A; Sarmiento, R; Torino, F; Vitale, S, 2005)
"To assess the feasibility and activity of a combination schedule with irinotecan (CPT-11), oxaliplatin (L-OHP), brief infusional fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer (MCC) patients."5.11An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. ( Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L, 2005)
"To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with bolus and continuous infusion of 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFIRI regimen) as first-line treatment of elderly patients with metastatic colorectal cancer (MCC)."5.11Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. ( Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Milaki, G; Pallis, A; Souglakos, J; Xenidis, N, 2005)
"Pemetrexed and irinotecan have demonstrated antitumor activity as single agents in lung, pancreatic, breast, and colorectal cancer (CRC)."5.11Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer. ( Becker, K; Hochster, H; Hong, S; John, W; Kettner, E; Kroning, H; Lordick, F; Macdonald, J; Ramanathan, RK; Schmoll, HJ, 2005)
"5-fluorouracil (5-FU), irinotecan, and oxaliplatin are the most active drugs in advanced colorectal cancer (CRC), and survival is improved with patient exposure to all of them."5.11FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. ( Aparicio, J; Balcells, M; Busquier, I; Campos, JM; Fernandez-Martos, C; Llorca, C; Maestu, I; Perez-Enguix, D; Vincent, JM, 2005)
"Raltitrexed (Tomudex) is proven effective in metastatic colorectal cancer."5.10Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics. ( Balteskard, L; Edna, TH; Laino, R; Norum, J; Rønning, G; Wählby, L, 2002)
"Irinotecan and raltitrexed are active against advanced colorectal cancer, act through different mechanisms, and have non-overlapping toxicity profiles."5.10Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. ( Aparicio, J; de las Peñas, R; Farrés, J; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM; Yuste, AL, 2002)
"We evaluated the efficacy and safety of the weekly combination of etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer (ACC), previously treated with weekly LV + 5-FU."5.10Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer. ( Diamantis, T; Dimitrakopoulos, A; Gennatas, K; Kosmas, C; Paliaros, P; Papastratis, G; Tsavaris, N; Tsipras, H; Vadiaka, M, 2002)
"To determine the feasibility, recommended doses, plasma pharmacokinetics, and antitumor activity of a biweekly chemotherapy regimen with oxaliplatin (L-OHP), irinotecan (CPT-11), infusional fluorouracil (5-FU), and leucovorin (LV) in metastatic colorectal cancer patients."5.10Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. ( Allegrini, G; Brunetti, IM; Conte, P; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G; Pfanner, E, 2002)
"We have investigated the efficacy, safety and quality of life profiles of three therapeutic combinations [irinotecan + leucovorin (LV)/5-fluorouracil (5-FU), oxaliplatin + LV/5-FU and irinotecan +oxaliplatin] in patients with metastatic colorectal cancer after failure of a 5-FU-based regimen, or whose disease had progressed within 6 months of the end of treatment."5.10Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study. ( Bennouna, J; Ducreux, M; Hua, A; Lepille, D; Marre, A; Méry-Mignard, D; Mignot, L; Rougier, P, 2002)
"Overall results of this study indicate that the administration of clinically relevant single-agent doses of both capecitabine and oxaliplatin is feasible and seems to result in promising therapeutic activity in patients with advanced colorectal cancer."5.10Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer. ( Huber, H; Kornek, GV; Längle, F; Raderer, M; Scheithauer, W; Schmid, K; Schüll, B, 2002)
"To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)."5.10Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002)
"In the present study, we evaluated the efficacy and safety of the weekly combination of etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer (ACC), previously treated with weekly LV+5-FU."5.10Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer. ( Gennatas, K; Kosmas, C; Kouraklis, G; Margaris, E; Papastratis, G; Rokana, S; Skopelitis, E; Tsavaris, N; Vadiaka, M; Xila, V; Zografos, G, 2002)
"Irinotecan (CPT-11) has been shown to prolong survival and improve quality of life in comparison to best supportive care in colorectal cancer patients with pretreatment of bolus 5-fluorouracil (5-FU)."5.10Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study. ( Emig, M; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, R; Pilz, L; Queisser, W; Samel, S; Willeke, F, 2002)
"We investigated the activity of irinotecan given with a more convenient modified bimonthly de Gramont regimen of bolus and infusional 5-fluorouracil [IrMdG] in advanced or metastatic colorectal cancer in the first and second line setting."5.10Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. ( Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT, 2002)
"Most patients with colorectal cancer (CRC) who have failed initial 5-fluorouracil (5-FU) chemotherapy have worsening of disease-related symptoms (DRS) and quality of life (QOL)."5.10The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial. ( Feld, R; Fields, A; Goel, R; Hedley, D; Jolivet, J; Lee, IM; Maroun, J; Michael, M; Moore, MJ; Oza, A; Pintilie, M, 2002)
"The purpose of this study was to evaluate the efficacy and tolerance of a combination of irinotecan, oxaliplatin, and 5-fluorouracil (5-FU)/leucovorin in advanced colorectal cancer (ACC)."5.10Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. ( Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; García-Foncillas, J; Martín-Algarra, S; Martínez-Monge, R; Rebollo, J; Rodríguez, J, 2002)
"This multicentre phase II study evaluated the efficacy and safety of irinotecan combined with the Nordic schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line therapy in patients with advanced colorectal cancer."5.10Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. ( Boussard, B; Frödin, JE; Glimelius, B; Kjaer, M; Linné, T; Oulid-Aïssa, D; Pfeiffer, P; Pyrhönen, S; Ristamäki, R; Skovsgaard, T; Tveit, KM, 2002)
"Oxaliplatin (OXA) and irinotecan (IRI) are active drugs in first-line as well as second-line treatment of advanced colorectal cancer patients, their toxicity profiles are not overlapping, and both drugs have shown synergism with folinic acid-modulated 5-fluorouracil (5-FU)."5.10Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies. ( Avallone, A; Casaretti, R; Comella, G; Comella, P; De Rosa, V; Fiore, F; Izzo, F; Lapenta, L, 2002)
"The efficacy and safety of preoperative chemotherapy with carmofur (HCFU) for colorectal cancer were evaluated in a randomized controlled study involving 63 institutes in the Kanto area."5.10[Neo-adjuvant chemotherapy with carmofur for colorectal cancer--a multi-institutional randomized controlled study]. ( Ishikawa, H; Iwasaki, Y; Kanazawa, K; Kitajima, M; Kodaira, S; Kotake, K; Koyama, Y; Miyata, M; Nagamachi, Y; Omoto, R; Shida, S; Tajima, Y; Tamakuma, S, 2002)
"The purpose of this study was to evaluate the efficacy and tolerance of the bimonthly administration of oxaliplatin in combination with high-dose leucovorin and infusional 5-fluorouracil (5-FU) (FOLFOX2 regimen) in patients with advanced colorectal cancer (ACC) who did not respond or whose disease progressed within 3 months after front-line treatment with CPT-11-containing regimens."5.10Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC). ( Agelaki, S; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Mavroudis, D; Panopoulos, C; Papadouris, S; Sarra, E; Souglakos, J; Vardakis, N, 2002)
"This phase II trial investigated the safety and efficacy of two doses of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, plus fluorouracil (FU)/leucovorin (LV) versus FU/LV alone in patients with metastatic colorectal cancer."5.10Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. ( Bergsland, E; Fehrenbacher, L; Griffing, S; Hurwitz, HI; Kabbinavar, F; Lieberman, G; Meropol, NJ; Novotny, WF, 2003)
"The effect of different dose intensities of 5-fluorouracil (5-FU) in advanced colorectal cancer was investigated."5.10Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer. ( Berglund, A; Carlsson, G; Frödin, JE; Glimelius, B; Gustavsson, B; Hansen, F; Jakobsen, A; Kjaer, M; Madsen, EL; Poulsen, JP; Sandberg, E, 2002)
"The aim of this study was to investigate whether N-(phosphonacetyl)-L-aspartic acid (PALA) can enhance the activity of low-dose methotrexate (LD-MTX) modulated infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer."5.10High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. ( Baron, B; Bleiberg, H; Blijham, GH; Couvreur, ML; De Greve, J; Genicot, B; Jansen, RL; Kok, TC; Nortier, JW; Wagener, T; Wils, J, 2003)
"To evaluate the efficacy and safety of neoadjuvant treatment comprising weekly high-dose 5-fluorouracil (5-FU) as a 24-hour infusion, folinic acid (FA) and biweekly oxaliplatin (L-OHP), followed by metastatic resection in patients with primarily resectable liver metastases of colorectal cancer (CRC)."5.10Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. ( Baum, U; Brückl, W; Fuchs, F; Günther, K; Hahn, EG; Hanke, B; Hohenberger, W; Merkel, S; Ott, R; Papadopoulos, T; Reck, T; Riedel, C; Wein, A, 2003)
" We did a randomised trial to compare an intrahepatic arterial (IHA) fluorouracil and folinic acid regimen with the standard intravenous de Gramont fluorouracil and folinic acid regimen for patients with adenocarcinoma of the colon or rectum, with metastases confined to the liver."5.10Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. ( Buckels, J; Cain, D; Kerr, DJ; Ledermann, J; Mayer, D; McArdle, CS; Schlag, PM; Sherlock, DJ; Stephens, RJ; Taylor, I, 2003)
"This phase II study was designed to evaluate the efficacy and toxicities of oral doxifluridine plus leucovorin as a randomized trial with those of intravenous 5-fluorouracil (5-FU) plus leucovorin in previously untreated metastatic colorectal cancer (CRC)."5.10Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin. ( Ahn, JH; Kang, YK; Kim, JC; Kim, JG; Kim, TW; Kim, WK; Lee, JH; Lee, JS; Min, YJ; Yu, CS, 2003)
"To assess the relationship between systemic exposure to capecitabine metabolites and parameters of efficacy and safety in patients with advanced or metastatic colorectal cancer from two phase III studies."5.10Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. ( Blesch, KS; Burger, HU; Gieschke, R; Reigner, B; Steimer, JL, 2003)
"Capecitabine and oxaliplatin, two new agents with potential synergistic activity, have demonstrated promising antitumor efficacy in advanced colorectal cancer (ACC)."5.10Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. ( Depisch, D; Kornek, GV; Kovats, E; Lang, F; Lenauer, A; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B, 2003)
"Out of various high-dose 5-fluorouracil (5-FU) regimens given with or without folinic acid (FA), the optimal 5-FU schedule has still to be defined as treatment for metastatic colorectal cancer (CRC)."5.10Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study. ( Boehme, M; Galle, PR; Gutzler, F; Moehler, M; Raeth, U; Rudi, J; Steinmann, S; Stremmel, W, 2003)
"Because no consensus exists regarding recommendable dose levels for irinotecan, an intrapatient dose escalation phase I-II study was initiated in previously treated patients with colorectal cancer."5.10Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with Fluorouracil-based chemotherapy: a study to determine recommendable therapeutic dosage. ( Alvarez, E; Buesa, JM; Carrasco, J; Esteban, E; Fra, J; Jiménez Lacave, A; Muñiz, I; Sala, M; Viéitez, JM, 2003)
"The purpose of this study was to evaluate the prognostic value of quantitative dynamic FDG PET studies in patients with metastastic colorectal cancer receiving FOLFOX (fluorouracil, folinic acid and oxaliplatin) chemotherapy."5.10PET-FDG as predictor of therapy response in patients with colorectal carcinoma. ( Dimitrakopoulou-Strauss, A; Rudi, J; Strauss, LG, 2003)
"To test the activity of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in patients with colorectal cancer treated with adjuvant 5-fluorouracil (5-FU) plus leucovorin (LV) and suffering from mucositis."5.10Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature. ( Colarusso, D; Manzione, L; Rosati, G; Rossi, A, 2003)
" In preclinical models, there appears to be additive or synergistic effects when combining 5-Fluorouracil (5-FU) with nonsteroidal anti-inflammatory agents (NSAIDs) for the treatment of colorectal neoplasms."5.10Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. ( Ashfaq, R; Becerra, CR; Frenkel, EP; Gaynor, RB, 2003)
"In North America, no effective therapy has been available for patients with progressive metastatic colorectal cancer after front-line treatment with irinotecan, bolus fluorouracil (FU), and leucovorin (IFL)."5.10Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. ( Berlin, JD; Bigelow, RH; Burger, BG; Garay, CA; Gupta, S; Haller, DG; Hart, LL; Le Bail, N; Marshall, JL; Oza, AM; Ramanathan, RK; Rothenberg, ML, 2003)
"Our results suggest that irinotecan and MMC combination therapy is effective and well tolerated in patients with fluoropyrimidine-resistant metastatic colorectal cancer."5.10Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer. ( Ambo, T; Arai, Y; Denda, T; Hyodo, I; Ohtsu, A; Shirao, K; Yamada, Y, 2003)
"Irinotecan has shown activity in advanced colorectal cancer resistant to leucovorin and fluorouracil."5.10Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M, 2003)
"We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of 5-fluorouracil (5-FU) delivered by protracted intravenous infusion (PVI 5-FU) against the standard bolus regimen of 5-FU and folinic acid (5-FU/FA) given for 6 months as adjuvant treatment in colorectal cancer."5.10Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. ( Chau, I; Cunningham, D; Hickish, T; Hill, M; Iveson, T; Jodrell, D; Lofts, F; Norman, AR; Oates, J; Ross, PJ; Saini, A; Tait, D, 2003)
"In this multicenter phase II study the efficacy and safety of the alternating schedule of irinotecan (CPT-11) with bolus 5-fluorouracil (5-FU) and leucovorin (LV) were assessed as first-line chemotherapy in patients with metastatic colorectal cancer (CRC)."5.10A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer. ( Aparicio, J; Borrega, P; de la Puente, CG; Lorenzo, A; Moreno-Nogueira, JA; Pica, JM; Reina, JJ; Rueda, A; Salvador, J, 2003)
"Irinotecan (CPT-11) and raltitrexed are active against advanced colorectal cancer (ACC), act through different mechanisms, and have only partially overlapping toxicity profiles."5.10Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. ( Aparicio, J; Bosch, C; Busquier, I; Díaz, R; Fernández-Martos, C; Galán, A; Garcerá, S; Llorca, C; Maestu, I; Vicent, JM, 2003)
"Three different therapeutic regimens of irinotecan (CPT-11) in combination with 5-fluorouracil (5-FU) and folinic acid (FA) were evaluated for efficacy and safety in the first-line therapy of advanced colorectal cancer."5.10A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. ( Boussard, B; Bouzid, K; Khalfallah, S; Padrik, P; Piko, B; Plate, S; Pshevloutsky, EM; Purkalne, G; Serafy, M; Tujakowski, J, 2003)
"To determine the activity of biweekly oxaliplatin, combined with weekly bolus fluorouracil (FU) and low-dose leucovorin (LV) chemotherapy (bFOL), as first-line therapy for patients with metastatic colorectal cancer."5.10Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. ( Chachoua, A; Escalon, J; Hochster, H; Muggia, F; Speyer, J; Zeleniuch-Jacquotte, A, 2003)
"The aim of this phase II study was to investigate the tolerance and efficacy of a second-line irinotecan/mitomycin C combination in patients with advanced gastric or colorectal cancer, pretreated with 5-fluorouracil."5.10Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer. ( Bamias, A; Papamichael, D; Pavlidis, N; Syrigos, K, 2003)
"The purpose of this study was to determine the efficacy and toxicity of oxaliplatin in combination with weekly bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with 5-FU-pretreated advanced colorectal cancer."5.10Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study. ( Changchien, CR; Chen, JS; Chiang, JM; Hsieh, PS; Tang, R; Yang, TS; Yeh, CY, 2003)
"Although recent trials have raised concerns about the toxicity of raltitrexed monotherapy in patients with advanced colorectal cancer (aCRC), similar concerns have also been raised with other chemotherapy regimens in aCRC."5.10Lessons learned from raltitrexed--quality assurance, patient education and intensive supportive drugs to optimise tolerability. ( Garcia-Vargas, J; Thomas, RJ; Williams, M, 2003)
"This study was designed to evaluate the safety and tolerability of oxaliplatin combined with weekly boluses of 5-fluorouracil (5-FU) and low doses of leucovorin (LV) and to determine objective response, progression-free survival, and overall survival of patients with previously untreated advanced colorectal cancer."5.10Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer. ( Arcediano, A; Cassinello, J; Colmenarejo, A; Escudero, P; García, I; González del Val, R; Guillem, V; Marcos, F; Marfà, X; Oruezábal, MJ; Pérez-Carrión, R; Pujol, E; Salud, A; Valero, J, 2003)
"Capecitabine and oxaliplatin are both active anticancer agents in the treatment of patients with advanced colorectal cancer."5.10Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. ( Cognetti, F; Ferraresi, V; Gabriele, A; Gamucci, T; Giannarelli, D; Nardoni, C; Pino, MS; Zeuli, M, 2003)
"To define the maximum-tolerated dose (MTD) and to evaluate the dose-limiting toxicities (DLTs) of the combination of capecitabine and irinotecan in patients with metastatic colorectal cancer."5.10Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study. ( Achterrath, W; Frings, S; Harstrick, A; Rustum, YM; Schleucher, N; Seeber, S; Tewes, M; Vanhoefer, U; Wilke, HJ, 2003)
" irinotecan, 5-fluorouracil (5-FU) and leucovorin (LV) with hepatic arterial infusion (HAI) of pirarubicin in non-resectable liver metastases from colorectal cancer."5.10Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial). ( Auroux, J; Aziza, T; Braud, AC; Bugat, R; Buyse, M; Cherqui, D; Dupuis, O; Fagniez, PL; Ganem, G; Guimbaud, R; Haddad, E; Kobeiter, H; Piedbois, P; Piolot, A; Tayar, C; Valleur, P; Zelek, L, 2003)
"To evaluate the efficacy and safety of irinotecan as second-line treatment in patients with advanced colorectal cancer (ACC) failing or relapsing after 5-fluorouracil (5-FU) plus leucovorin (LV) standard chemotherapy."5.10Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. ( Dimitrakopoulos, A; Giannakakis, T; Gouveris, P; Karadima, D; Kosmas, C; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Rokana, S; Tsavaris, N; Tsipras, H; Vadiaka, M; Ziras, N, 2003)
"To evaluate the toxicity and efficacy of a modified deGramont regimen of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin in patients with advanced colorectal cancer who have progressed on at least one but not more than two prior chemotherapy regimens."5.10A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. ( Catarius, KJ; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Mayer, RJ; Ryan, DP; Stuart, K; Winkelmann, J, 2003)
"The tolerance and efficacy of oxaliplatin and irinotecan for metastatic colorectal cancer are unknown in elderly patients."5.10Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. ( Aparicio, T; Artru, P; Belloc, J; Desramé, J; Dominguez, S; Etienney, I; Ezenfis, J; Lecomte, T; Locher, C; Mabro, M; Mitry, E; Montembault, S; Vayre, L, 2003)
"The combination of irinotecan (CPT-11), oxaliplatin (L-OHP), 5-fluorouracil (5-FU) and folinic acid (FA) is one of the possibilities to overcome chemoresistance in advanced colorectal cancer (ACRC) patients."5.10A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients. ( Bria, E; Garufi, C; Sperduti, I; Terzoli, E; Vanni, B; Zappalà, AM, 2003)
"We investigated the pharmacokinetics (PK), preliminary clinical results and toxicity of chronomodulated oxaliplatin (OHP) plus 5-fluorouracil (5-FU) without folinic acid (FA) in 13 patients with metastatic colorectal cancer."5.10Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer. ( Arpicco, S; Brusa, P; Bumma, C; Cattel, L; Infante, L; La Grotta, G; Passera, R, 2003)
" once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment."5.10Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003)
"This multicenter, open-label, phase II study was performed to assess the efficacy and toxicity of irinotecan 350 mg/m2 intravenously every 3 weeks in patients with advanced colorectal cancer (CRC) previously treated with 5-fluorouracil (5-FU)."5.10A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil. ( Arizcun, A; Cruz, JJ; de la Torre, A; Diz, P; Duarte, I; España, P; García López, MJ; García-Girón, C; Martínez del Prado, P; Méndez, M; Navalon, M; Pujol, E; Salut, A, 2003)
"This study combined oxaliplatin with the Nordic bolus schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer."5.10Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. ( Dahl, O; Sørbye, H, 2003)
") 5-fluorouracil (5-FU)/LV chemotherapy in metastatic colorectal cancer and to compare 5-FU exposure with these two treatment options."5.10Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ( Borner, MM; Caponigro, F; Comella, G; de Boer, RF; de Wit, R; Fumoleau, P; Greim, G; Martin, C; Peters, GJ; Schoffski, P; Sulkes, A; van der Born, K; Wanders, J, 2002)
"Twenty-two patients with unresectable liver metastases from colorectal cancer were treated with continuous HAI of 300 mg/m2 5-fluorouracil for 5 days a week and 6 mg/m2 cisplatin for 2 hours on 5 consecutive days a week."5.10Protracted hepatic arterial infusion with low-dose cisplatin plus 5-fluorouracil for unresectable liver metastases from colorectal cancer. ( Baba, H; Endo, K; Ikeda, Y; Kohnoe, S; Okamura, T; Tajima, T; Toh, Y; Yamamoto, M, 2002)
"The combination of CPT-11 with 5-fluorouracil (5-FU) in advanced colorectal cancer (ACC) represents an attractive approach."5.10Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. ( Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kandilis, K; Kouroussis, C; Mavroudis, D; Sarra, E; Souglakos, J; Vamvakas, L; Ziras, N, 2002)
"Hand-foot syndrome (HFS) has been previously reported as a side effect in 45-56% of patients treated with capecitabine."5.10Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. ( Abushullaih, S; Hoff, PM; Munsell, M; Saad, ED, 2002)
"The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-Fluorouracil (5-FU)+Leucovorin (LV)."5.10Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. ( Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M, 2002)
"Two randomised studies were performed with trimetrexate (TMTX) as a biochemical modulator of 5-fluorouracil (5-FU)/leucovorin (LV) in advanced colorectal cancer (ACC), one in Europe and one in the United States."5.10Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer. ( Blanke, CD; Hammershaimb, L; Punt, CJ; Zhang, J, 2002)
"To study tolerability and efficacy of an intensified chronomodulated schedule of fluorouracil (5-FU) and l-folinic acid (l-FA) as first-line treatment of metastatic colorectal cancer, 5-FU was given near individually determined dose-limiting toxicity in a multicenter phase II trial."5.10Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. ( Adenis, A; Chevalier, V; Chipponi, J; Chollet, P; Coudert, B; Curé, H; Focan, C; Kwiatkowski, F; Lévi, F; Niezgodzki, G; Perpoint, B; Pezet, D; Tubiana-Mathieu, N, 2002)
"Cimetidine has been shown to have beneficial effects in colorectal cancer patients."5.10Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. ( Imaeda, Y; Kobayashi, K; Matsumoto, S; Okamoto, T; Suzuki, H; Umemoto, S, 2002)
"To compare the efficacy and tolerability of eniluracil (EU)/fluorouracil (5-FU) with that of 5-FU/leucovorin (LV) as first-line therapy for patients with metastatic/advanced colorectal cancer."5.10Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. ( Ansari, RH; Bell, WN; Colwell, B; Levin, J; McGuirt, PV; Pazdur, R; Schilsky, RL; Thirlwell, MP; West, WH; White, RL; Wong, A; Yates, BB, 2002)
"To determine the efficacy and tolerability of combining oxaliplatin with capecitabine in the treatment of advanced nonpretreated and pretreated colorectal cancer."5.10Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. ( Borner, MM; Brauchli, P; Castiglione-Gertsch, M; Dietrich, D; Goldhirsch, A; Hanselmann, S; Herrmann, R; Honegger, H; Morant, R; Müller, S; Pestalozzi, BC; Roth, AD; Saletti, P; Stupp, R; Wernli, M, 2002)
"This phase II study was designed to evaluate the efficacy and toxicity of 3-h interval sequential methotrexate (MTX) and 5-fluorouracil (5-FU) with leucovorin (LV) rescue in the treatment of patients with metastatic colorectal cancer."5.10Effect of a 3-hour interval between methotrexate and 5-fluorouracil in the treatment of metastatic colorectal cancer. ( Hamaguchi, T; Haruyama, K; Matsumura, Y; Muro, K; Shimada, Y; Shirao, K; Sugano, K; Yamada, Y, 2002)
"Results of recent trials comparing combination chemotherapy consisting of 5-fluorouracil (5-FU), folinic acid (FOL), and oxaliplatin, given either as flat (A) or chronomodulated (B) infusion for metastatic colorectal cancer, were subjected to pharmaco-economic evaluation."5.10Pharmaco-economic comparative evaluation of combination chronotherapy vs. standard chemotherapy for colorectal cancer. ( Focan, C, 2002)
"5-fluorouracil remains the standard therapy for patients with advanced/metastatic colorectal cancer."5.10Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study. ( Blackstock, AW; Case, D; Higgs, V; Melin, SA; Savage, P; Tomlinson, SK; White, DR, 2002)
"A phase II trial investigated the activity and toxicity of a bolus administration schedule of oxaliplatin, fluorouracil (5-FU), and leucovorin (LV) therapy in patients with untreated advanced colorectal cancer."5.10Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. ( Amadori, D; Cruciani, G; Giovanis, P; Marangolo, M; Nicolini, M; Oliverio, G; Panzini, I; Pasquini, E; Ravaioli, A; Rossi, A; Tassinari, D; Turci, D; Zumaglini, F, 2002)
"To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with oxaliplatin (L-OHP) plus fluorouracil (5-FU)/leucovorin (LV) (de Gramont regimen) as first-line treatment of metastatic colorectal cancer (MCC)."5.10Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. ( Agelaki, S; Androulakis, N; Athanasiadis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, Ch; Mavroudis, D; Samonis, G; Souglakos, J; Tsetis, D; Vardakis, N, 2002)
"To evaluate the safety profile of capecitabine using data from a large, well-characterized population of patients with metastatic colorectal cancer treated in two phase II studies."5.10First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. ( Bajetta, E; Boyer, M; Bugat, R; Burger, U; Cassidy, J; Garin, A; Graeven, U; Hoff, P; Maroun, J; Marshall, J; McKendric, J; Osterwalder, B; Pérez-Manga, G; Rosso, R; Rougier, P; Schilsky, RL; Twelves, C; Van Cutsem, E, 2002)
"The aim of this multicenter prospective study was to evaluate the role of intratumoral parameters related to fluorouracil (FU) sensitivity in 103 metastatic colorectal cancer patients receiving FU-folinic acid."5.10Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. ( Bourgeon, A; Chamorey, E; Chazal, M; Delpero, JR; Etienne, MC; Formento, JL; Formento, P; Francoual, M; Laurent-Puig, P; Letoublon, C; Magné, N; Milano, G; Pezet, D; Renée, N; Rosty, C; Seitz, JF, 2002)
"To evaluate the activity and safety of an alternating schedule of irinotecan (CPT-11) with high-dose 5-fluorouracil (5-FU) given as a weekly 48-hour infusion in combination with leucovorin (LV) in the first-line treatment of metastatic colorectal cancer (MCRC) patients."5.10A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer. ( Manzione, L; Reggiardo, G; Rosati, G; Rossi, A, 2002)
"The combination of irinotecan plus 5-fluorouracil and folinic acid has clinical and survival benefits over 5-fluorouracil and folinic acid alone in the setting of first line treatment of metastatic colorectal cancer."5.10Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. ( Cunningham, D; Falk, S; Jackson, D, 2002)
"To determine the maximum-tolerated dose (MTD) of a weekly schedule of irinotecan (CPT-11), leucovorin (LV), and a 24-hour infusion of fluorouracil (5-FU24h) as first-line chemotherapy in advanced colorectal cancer and to assess preliminary data on the antitumor activity."5.09Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. ( Achterrath, W; Harstrick, A; Köhne, CH; Rustum, YM; Seeber, S; Vanhoefer, U; Wilke, H, 1999)
"The aim of this prospective study was to assess the efficacy, clinical benefit and safety of CPT-11 (irinotecan) in patients with stringently-defined 5-fluorouracil-resistant metastatic colorectal cancer (CRC)."5.09Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). ( Alexopoulos, CG; Blanc, C; Bleiberg, H; Blijham, GH; Cholet, P; Cote, C; Cunningham, D; Dirix, L; Fillet, G; Hérait, P; Levi, F; Panagos, G; Punt, CJ; Symann, M; Ten Bokkel Huinink, WW; Unger, C; Van Cutsem, E; Van Groeningen, C; Vannetzel, JM; Wils, J, 1999)
"In a prospective multicenter trial, 279 patients with metastatic colorectal cancer who had failed 5-fluorouracil therapy were randomized 2:1 to receive either best supportive care (BSC) plus treatment with the topoisomerase I inhibitor, irinotecan (CPT-11; Rhône-Poulenc Rorer, Antony, France), at a dose of 350 mg/m2 every 3 weeks or BSC alone."5.09A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group. ( Cunningham, D; Glimelius, B, 1999)
"In a multicenter phase III trial, 267 patients with nonbulky metastatic colorectal cancer who had failed first-line 5-fluorouracil (5-FU) therapy were randomized to receive second-line treatment with either the new topoisomerase agent, irinotecan (Rhône-Poulenc Rorer, Antony, France), or a high-dose infusional 5-FU regimen."5.09Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group. ( Blijham, GH; Van Cutsem, E, 1999)
"Our objective was to establish the balance between costs and effects of treatment with Tomudex (raltitrexed) as an alternative to treatment with 5-fluorouracil (5-FU) plus leucovorin (LV) in patients with advanced colorectal cancer."5.09An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer. ( Byttebier, G; Groener, MG; Rutten, FF; van Hout, BA; van Ineveld, BM, 1999)
"Twenty-six patients with metastatic colorectal cancer were given cisplatin (CDDP) and dacarbazine (DTIC)."5.09Phase II study of cisplatin and dacarbazine for metastatic colorectal carcinoma resistant to 5-fluorouracil. ( Akbulut, H; Arican, A; Cay, F; Demirkazik, A; Dinçol, D; Içli, F; Karaoğuz, H, 1999)
"The combination of 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (I-OHP) was shown to be both more active against metastatic colorectal carcinoma and better tolerated if the drug delivery rate was chronomodulated according to circadian rhythms rather than constant."5.09A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. ( Brienza, S; Chollet, P; Dogliotti, L; Focan, C; Le Rol, A; Letourneau, Y; Lévi, F; Llory, JF; Perpoint, B; Rotarski, M; Zidani, R, 1999)
"Data from a multinational phase III trial were analyzed to evaluate the use of in- and outpatient services for 373 patients with metastatic colorectal cancer being administered uracil/tegafur (in a molar ratio of 4:1 [UFT]) plus oral calcium folinate (Orzel) (N = 188) vs 5-fluorouracil (5-FU) plus oral calcium folinate (N = 185)."5.09Impact of uracil/tegafur plus oral calcium folinate on resource utilization. ( Ollendorf, D, 1999)
"This study was designed to determine if histopathologic evaluation of patients with resectable colorectal cancer following preoperative chemotherapy with uracil and tegafur with a molar ratio of 4:1 (UFT) could predict chemosensitivity to postoperative fluoropyrimidines to prevent recurrence of disease."5.09Using preoperative UFT to predict sensitivity to fluoropyrimidines in colorectal cancer. ( Fujii, M, 1999)
"To determine the maximum tolerable doses (MTDs) of irinotecan (CPT-11) and 5-fluorouracil (5-FU) plus levofolinic acid (LFA) administered together every two weeks, to define the toxicity profile of this regimen, and to have a preliminary evidence of its activity in the first-line management of advanced colorectal cancer patients."5.09Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group. ( Avallone, A; Casaretti, R; Catalano, G; Comella, G; Comella, P; Comis, S; De Vita, F; Faranda, A; Gravina, A; Orditura, M; Petrillo, A, 1999)
"This multicenter phase II study was designed to assess the efficacy of the alternating schedule of tomudex with methotrexate (MTX)/5-fluorouracil (5-FU)/leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer."5.09A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. ( Agostinelli, R; Baldelli, AM; Barni, S; Cascinu, S; Catalano, G; Catalano, V; Frontini, L; Gasparini, G; Giuliodori, L; Labianca, R; Martignoni, G; Mattioli, R; Silva, RR, 1999)
"To evaluate the objective tumor response rates and toxicities of leucovorin (LV) plus fluorouracil (5-FU) cancer regimen combined with oxaliplatin (85 mg/m(2)) every 2 weeks on metastatic colorectal cancer patients with documented proof of progression while on bimonthly LV and 5-FU alone."5.09Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. ( André, T; Beerblock, K; Bensmaine, MA; Bouché, O; Carola, E; de Gramont, A; Desseigne, F; Dupont-André, G; François, E; Louvet, C; Lucas, V; Merrouche, Y; Morvan, F, 1999)
"To determine whether immunohistochemical thymidylate synthase (TS) quantitation predicts for clinical outcome in patients with advanced colorectal cancer treated by fluorouracil (FUra)-based chemotherapy."5.09Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. ( Antonelli, G; Aschele, C; Baldo, C; Casazza, S; Debernardis, D; Lionetto, R; Maley, F; Sobrero, A; Tunesi, G, 1999)
"Chemotherapy for 5-fluorouracil (5-FU)-resistant colorectal cancer is largely ineffective with new and innovative therapeutic strategies needed to benefit patients developing progressive disease while receiving 5-FU or 5-FU-based programs."5.09A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil. ( Anderson, N; Bern, M; Coco, F; Lokich, J; Moore, C, 1999)
"We randomly assigned 156 patients at the time of resection of hepatic metastases from colorectal cancer to receive six cycles of hepatic arterial infusion with floxuridine and dexamethasone plus intravenous fluorouracil, with or without leucovorin, or six weeks of similar systemic therapy alone."5.09Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. ( Bertino, JR; Blumgart, LH; Brennan, MF; Cohen, AM; Conti, JA; Fong, Y; Huang, Y; Kemeny, N; Shi, W; Stockman, J; Sullivan, D; Turnbull, AD, 1999)
"To study how adding oxaliplatin (l-OHP) to chronomodulated fluorouracil (5-FU)-leucovorin (LV) affected the objective response rate, as first-line treatment of metastatic colorectal cancer."5.09Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. ( Adam, R; Bertheaut-Cvitkovic, F; Chollet, P; Coudert, B; Faggiuolo, R; Focan, C; Giacchetti, S; Larregain-Fournier, D; Le Bail, N; Le Rol, A; Letourneau, Y; Lévi, F; Llory, JF; Misset, JL; Perpoint, B; Walter, S; Zidani, R, 2000)
"The potential of raltitrexed (Tomudex) in combination with 5-fluorouracil (5-FU) as treatment for advanced colorectal cancer has been investigated in two phase I clinical trials."5.09Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials. ( González Barón, M; Harstrick, A; Schwartz, GK, 1999)
"Thirty-seven colorectal cancer patients with grade 1-4 diarrhea (NCICTC) caused by chemotherapy with 5-FU-containing regimens, received oral loperamide at the initial dose of 4 mg followed by 4 mg every 8 h (total dose 16 mg/24 h)."5.09High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. ( Agostinelli, R; Amadori, D; Bichisao, E; Cascinu, S; Catalano, G; Catalano, V; Giordani, P; Luppi, G; Sansoni, E; Silingardi, V, 2000)
"CPT-11 (irinotecan) has shown activity in patients with advanced colorectal cancer resistant to leucovorin (LV) and 5-fluorouracil (5-FU)."5.09CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. ( André, T; Carola, E; Couteau, C; de Gramont, A; Gilles-Amar, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F, 1999)
"To investigate the pharmacokinetics of levamisole and a metabolite, p-hydroxylevamisole in patients with colorectal cancer treated with 5-fluorouracil (5-FU)."5.09Pharmacokinetics of levamisole in cancer patients treated with 5-fluorouracil. ( Connolly, M; Ding, C; Gwilt, P; Kremer, A; Tempero, M, 2000)
"The aim of this study was to develop a phase II study gauging the contribution of a daily low-dose of carboplatin combined with 5-fluorouracil (5-FU) and folinic acid (FOL) in a chronotherapy schedule for advanced colorectal cancer patients."5.09Chronotherapy with 5-fluorouracil, folinic acid and carboplatin for metastatic colorectal cancer; an interesting therapeutic index in a phase II trial. ( Focan, C; Focan-Henrard, D; Kreutz, F; Moeneclaey, N, 2000)
"To evaluate in patients with advanced colorectal cancer (CRC) three treatment regimens of oral capecitabine in order to select the most appropriate regimen for testing in phase III."5.09Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. ( Allman, D; Burger, HU; Cassidy, J; Dalley, D; Dirix, L; Findlay, M; Kocha, W; Osterwalder, B; Pazdur, R; Schölmerich, J; Seitz, JF; Twelves, C; Van Cutsem, E; Verweij, J, 2000)
"In patients with colorectal cancer, selective high 5-fluorouracil concentration in the cancer tissue could be achieved by a combination of 5'-deoxy-5-fluorouridine and local immunotherapy with a mixture of OK-432 and fibrinogen."5.09Selective augmentations of intratumoral 5-fluorouracil concentration by local immunotherapy with OK-432 and fibrinogen. ( Amano, M; Haba, A; Monden, M; Monden, T; Ohue, M; Sakita, I; Sekimoto, M; Tamaki, Y; Tomita, N, 2000)
"Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil."5.09Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. ( Alakl, M; Awad, L; Carmichael, J; Cunningham, D; Douillard, JY; Gruia, G; Iveson, T; James, RD; Jandik, P; Karasek, P; Navarro, M; Roth, AD; Rougier, P, 2000)
"It has been shown that irinotecan is superior to infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer after 5-FU failure."5.09Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. ( Bellanger, A; Durand-Zaleski, I; Juhel, H; Levy-Piedbois, C; Piedbois, P; Schmitt, C, 2000)
"Oxaliplatin is a novel platinum derivative, which, combined with 5-fluorouracil (5-FU), and folinic acid (FA), demonstrates synergistic activity in metastatic colorectal cancer (MCC)."5.09Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. ( Fountzilas, G; Janinis, J; Papagianopoulos, P; Papakostas, P; Samelis, G; Skarlos, D, 2000)
"MF (protracted infusion 5-fluorouracil (5-FU), 300 mg/m2/24 hours plus bolus mitomycin, 7 mg/m2 every 6 weeks, maximum 4 doses), was recently shown in a randomised trial to be superior to protracted 5-FU alone, as first-line chemotherapy for metastatic colorectal cancer (Ross et al."5.09Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer. ( Chester, JD; Dent, JT; Ride, E; Seymour, MT; Wilson, G, 2000)
" One hundred thirty-six patients with metastatic colorectal cancer who failed to respond to a 5-fluorouracil-based treatment received 714 cycles of irinotecan."5.09Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. ( Adenis, A; Burki, F; Douillard, JY; Dufour, P; Marty, M; Mignard, D; Mousseau, M; Rougier, P; Wendling, JL; Ychou, M, 2000)
"The purpose of this study was to evaluate the efficacy, toxicity, and safety of outpatient chemotherapy with weekly high-dose 5-fluorouracil (HD-5FU) in previously treated patients (pts) with metastatic colorectal cancer."5.09Phase II study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer. ( Cohen, Y; Lavrenkov, K; Mermershtain, W, 2000)
"The aim of this study was to clarify whether increased 5-fluorouracil (5-FU) uptake by tumor tissue following preoperative UFT administration is a prognostic factor after surgery in colorectal cancer patients."5.09Preoperative UFT administration for patients with advanced colorectal cancer--increased uptake of 5-fluorouracil by tumor tissue is a prognostic factor. ( Ayabe, H; Eida, K; Furukawa, M; Ino, M; Ishikawa, H; Kunisaki, T; Nakagoe, T; Nakamura, Y; Nogawa, T; Sawai, T; Tobinaga, K; Tsuji, T, 2000)
"We performed combination chemotherapy adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in 11 patients with gastric cancer and 7 with colorectal cancer."5.09[The effect of combination chemotherapy to adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in patients with gastric or colorectal cancer]. ( Iesato, H; Kamoshita, N; Kato, Y; Morishita, Y; Nagaoka, H; Ohwada, S; Ohya, T; Okabe, T; Takeyoshi, I; Yokomori, T, 2000)
" A regimen of sequential TMTX, FA and 5-fluorouracil (5-FU) has shown efficacy in patients with colorectal cancer."5.09Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO. ( Berdel, WE; Haboubi, N; Hohenberger, P; Kreuser, ED; Lochs, H; Szelényi, H; Thiel, E, 2000)
"To evaluate the safety and efficacy of a five-day regimen of oral 5-fluorouracil (5-FU) plus eniluracil (776C85) in patients with metastatic colorectal cancer (CRC)."5.09A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. ( Bonny, T; Bukowski, R; Burris, H; Hochster, H; Hohneker, J; Levin, J; Mani, S; O'Rourke, M; Schilsky, RL; Wall, JG, 2000)
"We evaluated economic implications of treatment with irinotecan, following a RCT which demonstrated significantly increased survival at 1 year with irinotecan (45%) compared to infusional 5-fluorouracil (5-FU) (32%) in patients with metastatic colorectal cancer."5.09Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure. ( Blijham, G; Jolain, B; Rougier, P; Schmitt, C; Van Cutsem, E, 1999)
"To determine the efficacy of fluorouracil (5-FU) plus eniluracil when administered to patients with previously untreated metastatic colorectal cancer."5.09Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. ( Beck, T; Bell, WN; Chevlen, EM; Hochster, H; Hohneker, J; Levin, J; Lokich, J; Mani, S; McGuirt, C; O'Rourke, MA; Schilsky, RL; Weaver, CH; White, R, 2000)
"In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the standard North Central Cancer Treatment Group/Mayo Clinic 5-day bolus 5FU/LV regimen."5.09Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. ( Bonetti, A; Boni, C; Cassidy, J; Cervantes, A; Cortes-Funes, H; de Braud, F; de Gramont, A; Figer, A; Freyer, G; Hendler, D; Hmissi, A; Homerin, M; Le Bail, N; Louvet, C; Morvan, F; Papamichael, D; Seymour, M; Wilson, C, 2000)
"To analyse patients' travel and time costs associated with 2 alternative drug therapies for advanced colorectal cancer: raltitrexed and fluorouracil plus folinic acid (leucovorin) [5FU + FA]."5.09Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid. ( Heyes, A; Palmer, MK; Sculpher, M, 2000)
"The aim of this study was to investigate the clinical pharmacokinetics of 5-fluorouracil (5-FU) and its major metabolite 5-fluoro-5,6-dihydrouracil (5-FDHU) in 20 colorectal cancer patients given two dose levels of 5-FU, 250 and 370 mg/m2, administered by i."5.09Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. ( Allegrini, G; Barsanti, G; Battistoni, M; Bocci, G; Conte, PF; Danesi, R; Del Tacca, M; Di Paolo, AD; Falcone, A; Innocenti, F; Melosi, A, 2000)
"The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer."5.09Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. ( Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB, 2000)
"The purpose of this study was to determine the efficacy of twice weekly hypo-fractionated radiation therapy (RT) plus continuous infusion 5-fluorouracil for unresectable or locally advanced colorectal cancer with synchronous metastases."5.09Avoidance of colostomy placement in advanced colorectal cancer with twice weekly hypofractionated radiation plus continuous infusion 5-fluorouracil. ( Breslin, T; Janjan, NA; Lenzi, R; Rich, TA; Skibber, J, 2000)
"In a randomized trial, the authors evaluated the possible adjuvant activity of intraportal chemotherapy (with 5-fluorouracil 500 mg/m2/day in continuous infusion for 7 days and mitomycin C 10 mg/m2 at day 7) administered after surgery to half of the patients who underwent a full resection for Dukes B2 or C colorectal cancer."5.09Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium). ( Beauduin, M; Brohée, D; Bury, J; Focan, C; Herman, ML; Lecomte, M; Vindevoghel, A, 2000)
"QUASAR is a large trial of adjuvant chemotherapy for colorectal cancer in which clinicians could choose to deliver a standard adjuvant cytotoxic chemotherapy regimen, 5-fluorouracil (5-FU) and L-folinic acid (L-FA), in either a once-weekly or a four-weekly schedule."5.09Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group. ( Barnwell, J; Gray, R; Kerr, DJ; McConkey, C, 2000)
"A phase II study was carried out to evaluate the efficacy and toxicity of a double biochemical modulation of 5-fluorouracil (5-FU) by methotrexate (MTX) and leucovorin (LV) in patients with advanced unresectable colorectal cancer."5.09Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer. ( Cizej, TE; Markovic, A; Plesnicar, A; Stabuc, B, 2000)
"The aim of this phase II study was to investigate the therapeutic value of second-line treatment with oxaliplatin, irinotecan (CPT-11) and mitomycin C (MMC) in patients with metastatic colorectal cancer pretreated with 5-fluorouracil (5-FU)-based chemotherapy."5.09Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer. ( Brodowicz, T; Hejna, M; Köstler, WJ; Raderer, M; Scheithauer, W; Tomek, S; Wiltschke, C; Zielinski, CC, 2000)
"Univariate and multivariate analyses were performed on data from 370 5-fluorouracil (5-FU)-resistant advanced colorectal cancer patients treated with oxaliplatin (Eloxatin)/5-FU+/-folinic acid (FA) to identify prognostic factors for oxaliplatin-based treatment."5.09Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients. ( Bleiberg, H; Bleuzen, P; Brienza, S; Cvitkovic, E; de Gramont, A; Ducreux, M; François, E; Gamelin, E; Lévi, F; Marty, M; Simon, J, 2000)
"The aim of this randomised trial was to evaluate the activity and toxicity of a biweekly regimen including 6S-leucovorin-modulated 5-fluorouracil (LFA-5-FU), combined with either irinotecan (CPT-11 + LFA 5-FU) or raltitrexed (Tomudex) (TOM + LFA-5-FU), in advanced colorectal cancer patients, and to make a preliminary comparison of both these experimental regimens with a biweekly administration of LFA-5-FU modulated by methotrexate (MTX + LFA-5-FU)."5.09Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial. ( Avallone, A; Biglietto, M; Cartenì, G; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lena, M; De Lucia, L; De Vita, F; Farris, A; Ianniello, GP; Leo, SS; Lorusso, V; Mancarella, S, 2000)
"Studies of bimonthly 48-hour regimens of high-dose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS)."5.09Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F; Molitor, JL; Tournigand, C, 2000)
"The purpose of this prospective study was to assess the efficacy, clinical benefit and safety of irinotecan (CPT-11) in patients with 5-fluorouracil-resistant metastatic colorectal cancer (CRC)."5.09Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy. ( Jirajarus, M; Ratanatharathorn, V; Sirachainan, E; Sirilerttrakul, S, 2000)
"Irinotecan is a topoisomerase I inhibitor that prolongs survival in patients with colorectal cancer refractory to fluorouracil (5-FU) and leucovorin (LV)."5.09Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. ( Alakl, M; Awad, L; Douillard, JY; Elfring, GL; Gruia, G; Locker, PK; Miller, LL; Pirotta, N; Saltz, LB, 2001)
"The aim of the study was to evaluate the efficacy, tolerability and quality of life in 5-fluorouracil (5-FU) pretreated colorectal cancer patients after combined 5-FU and Ginkgo biloba extract GBE 761 ONC (i."5.09Phase II study of combined 5-fluorouracil/ Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancer. ( Häring, B; Hauns, B; Köhler, S; Mross, K; Unger, C, 2001)
"Irinotecan (CPT11) has established activity in the treatment of advanced colorectal cancer without cross-resistance with established 5-fluorouracil/folinic acid-based therapy."5.09Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer. ( Adam, R; Bismuth, H; Castaing, D; Coeffic, D; Durrani, AK; Gil-Delgado, MA; Guinet, F; Khayat, D, 2001)
"We have recently evaluated the combination of raltitrexed, levofolinic acid (LFA) and 5-fluorouracil (5-FU) in advanced head and neck and colorectal cancer, and we have shown that this combination is well tolerated and has clinical activity."5.09Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours. ( Avallone, A; Caponigro, F; Comella, G; Comella, P; De Rosa, V; Ionna, F; Rivellini, F, 2001)
"Standard adjuvant chemotherapy for colorectal cancer consists of 5-fluorouracil with leucovorin or levamisole."5.09A United Kingdom coordinating committee on cancer research study of adjuvant chemotherapy for colorectal cancer: preliminary results. ( Kerr, DJ, 2001)
"Sixty eligible patients who had previously untreated, measurable, metastatic colorectal carcinoma were treated with oral eniluracil 50 mg on Days 1-7, 5-FU 20 mg/m(2) on Days 2-6, and LV 50 mg on Days 2-6."5.09Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma. ( Hollis, D; Mayer, RJ; Meropol, NJ; Niedzwiecki, D; Schilsky, RL, 2001)
"Standard therapy for advanced or metastatic colorectal cancer consists of 5-fluorouracil plus leucovorin (5-FU/LV) administered intravenously (i."5.09Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. ( Barker, C; Boyer, M; Cassidy, J; Findlay, M; Hieke, K; Jamieson, C; Osterwalder, B; Twelves, C; Weitzel, C, 2001)
"To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer."5.09Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. ( Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R, 2001)
"We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer."5.095-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001)
"A multicenter phase II trial was initiated in order to evaluate the weekly, high-dose 24-hour infusion of 5-fluorouracil (5-FU) plus folinic acid (FA) in patients with unresectable colorectal cancer hepatic metastases."5.09Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas. ( Gassel, HJ; Heinrich, S; Junginger, T; Köhne, CH; Lorenz, M; Mattes, E; Mueller, HH; Saeger, HD; Schramm, H; Staib-Sebler, E; Vetter, G, 2001)
" 29 patients with peritoneal carcinomatosis of colorectal origin without evidence of distant metastases underwent cytoreductive surgery and intra-operative HIPEC with mitomycin-C (MMC), followed by systemic chemotherapy with 5-fluorouracil (5-FU)/leucovorin."5.09Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. ( Beijnen, JH; Boot, H; de Bree, E; Kaag, MM; van Coevorden, F; van Slooten, GW; Witkamp, AJ; Zoetmulder, FA, 2001)
"This phase II study examined a regimen (FOLFOX7) of leucovorin (LV), high-dose intensity oxaliplatin, and 5-fluorouracil (5-FU), as second-line therapy for metastatic colorectal cancer."5.09High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F, 2001)
"Patients with isolated hepatic metastases from colorectal cancer were treated every three weeks with increasing doses of oxaliplatin (4 hours; starting dose 25 mg/m2, escalation in steps of 25 mg/m2) in combination with folinic acid (1 hour, 200 mg/m2) and 5-fluorouracil (2 hour, 600 mg/m2)."5.09Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer. ( Beckert, B; Beykirch, M; Braess, J; Goecke, E; Hiddemann, W; Kern, W; Lang, N; Schalhorn, A; Stein, J; Stemmler, J; Waggershauser, T, 2001)
"To identify the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of oxaliplatin (L-OHP) given on a weekly schedule including fixed doses of leucovorin (LV) and infusional 5-fluorouracil (5-FU), to define the toxicity profile of this regimen and to find preliminary evidence of its activity in pretreated patients with metastatic colorectal cancer (MCRC)."5.09Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. ( Manzione, L; Pizza, C; Rosati, G; Rossi, A; Tucci, A, 2001)
"Thirty-six patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding palliative chemotherapy with fluoropyrimidines leucovorin +/- irinotecan, participated in this study."5.09Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. ( Depisch, D; Kornek, GV; Lang, F; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Schuell, B; Ulrich-Pur, H, 2001)
"A multi-institutional study was performed to evaluate the appropriate duration of oral administration of Carmofur (1-hexylcarbamoyl-5-fluorouracil, HCFU), a 5-fluorouracil (5-FU) derivative, for postoperative adjuvant chemotherapy in patients with colorectal cancer undergoing curative operation."5.09Optimal duration of oral adjuvant chemotherapy with Carmofur in the colorectal cancer patients: the Kansai Carmofur Study Group trial III. ( Fujii, H; Kamigaki, T; Kuroda, Y; Nakamura, T; Ohno, M; Tabuchi, Y; Yamagishi, H, 2001)
"The primary objective of this trial was to determine the objective response of two regimens with CDDP administered every 2 weeks immediately before or after an 'optimal' 48-hour chronomodulated infusion of 5-fluorouracil (5-FU) modulated with leucovorin (LV) in metastatic colorectal cancer patients."5.095-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer. ( Allegrini, G; Bocci, G; Brunetti, I; Conte, P; Danesi, R; Del Tacca, M; Falcone, A; Lencioni, M; Masi, G; Pfanner, E, 2001)
"To evaluate the efficacy and safety of oxaliplatin (L-OHP) in combination with leucovorin (LV)-modulated bolus plus infusional 5-fluorouracil (5-FU; de Gramont schedule) every 2 weeks in chemotherapy-naive patients with advanced colorectal cancer (CRC)."5.09Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study. ( Agelaki, A; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malamos, N; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N, 2001)
"Thirty-three metastatic colorectal cancer patients were randomized to receive a 60-minute infusion of irinotecan before or after a 48-hour infusion of 5-FU modulated by LV."5.09Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. ( Allegrini, G; Comis, S; Conte, P; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Lencioni, M; Masi, G; Pfanner, E, 2001)
"A statistical analysis was performed on the patient data collected from two compassionate-use programmes using oxaliplatin (Eloxatin(R)) + 5-fluorouracil (5-FU) +/- folinic acid (FA), to identify predictive factors for oxaliplatin-based salvage treatment in patients with 5-FU-resistant advanced colorectal cancer (ACRC)."5.09Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. ( Bensmaïne, MA; Bleiberg, H; Brienza, S; Cvitkovic, E; de Gramont, A; Ducreux, M; François, E; Gamelin, E; Lévi, F; Marty, M, 2001)
" We measured DPD activities represented as DPD protein levels (units/mg protein) and the associated mRNA levels in tumorous and normal tissues from 40 colorectal cancer patients, and we studied the relation to 5-FU concentrations in the same samples after treatment with doxifluridine, a prodrug of 5-FU."5.09Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels. ( Kato, S; Onda, M; Tanaka, N; Tanaka-Nozaki, M, 2001)
"To compare the efficacy and safety of orally administered capecitabine (Xeloda; Roche Laboratories, Inc, Nutley, NJ), a novel fluoropyrimidine carbamate designed to mimic continuous fluorouracil (5-FU) infusion but with preferential activation at the tumor site, with that of intravenous (IV) 5-FU plus leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer."5.09Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. ( Allman, D; Bajetta, E; Boyer, M; Bugat, R; Cassidy, J; Findlay, M; Frings, S; Harper, P; Jahn, M; McKendrick, J; Osterwalder, B; Perez-Manga, G; Rosso, R; Rougier, P; Schmiegel, WH; Seitz, JF; Thompson, P; Twelves, C; Van Cutsem, E; Vieitez, JM; Weitzel, C, 2001)
"A weekly continuous 24-hour infusion therapy with 5-fluorouracil (5-FU) and calcium - folinic acid (CA-FA) was shown to be an effective first-line treatment in advanced metastatic colorectal cancer."5.09Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer. ( Drees, M; Fritze, D; Hartung, G; Hehlmann, R; Hofheinz, RD; Kreuser, ED; Kühnel, J; Queisser, W; Riedel, C; Rost, A; Wein, A, 2001)
"38 patients with metastatic colorectal cancer, who progressed while receiving or within six months after withholding systemic chemotherapy with oxaliplatin in combination with 5-fluorouracil/leucovorin or the specific thymidilate synthase inhibitor raltitrexed were enrolled in this study."5.09Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy. ( Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Pidlich, J; Raderer, M; Scheithauer, W; Ulrich-Pur, H, 2001)
"The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer."5.09Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001)
"Thirty-one patients with advanced colorectal cancer were treated with a regimen of epirubicin, cisplatin and continuous-infusion (c."5.09Epirubicin, cisplatin and continuous-infusion 5-fluorouracil (ECF regimen) in the treatment of advanced colorectal cancer. ( Caporale, A; Franchi, F; Gargano, L; Konstantatoy, E; Marcellini, M; Masciangelo, R; Menichetti, ET; Seminara, P, 2001)
"Capecitabine and oxaliplatin are both active anticancer agents in the treatment of patients with advanced colorectal cancer (ACRC)."5.09Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study. ( Carpi, A; Cherubini, R; Cognetti, F; Di Costanzo, E; Gasperoni, S; Moscetti, L; Paoloni, FP; Sdrobolini, A; Zeuli, M, 2001)
"Modulation of 5-fluorouracil (FUra) using leucovorin (LV) is a standard treatment approach in patients with metastatic colorectal cancer."5.08A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal cancer. ( Erlichman, C; Feld, R; Fine, S; Kaizer, L; Moore, MJ; Myers, R; Thiessen, JJ, 1995)
"A new modality of locoregional chemotherapy based on biochemical double modulation of 5-fluorouracil (FU) with both leucovorin (LV) and cisplatin (CDDP) against liver metastases of colorectal cancer was devised."5.08[A new modality of locoregional chemotherapy based on biochemical double modulation of 5-fluorouracil with both leucovorin and cisplatin against liver metastases of colorectal cancer]. ( Fukada, D; Kato, M; Kunieda, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H; Tsuji, K; Umemoto, T, 1995)
"The combination of 5-fluorouracil (5-FU) and folinic acid (FA) has demonstrated activity in colorectal cancer (CC)."5.085-Fluorouracil, folinic acid and cisplatin in advanced colorectal cancer: a pilot study. ( Bacoyiannis, C; Daliani, D; Katsikas, M; Kosmas, C; Kosmidis, P; Sakelaropoulos, N; Tentas, K; Tsavaris, N, 1995)
"A randomized early phase II study using l-leucovorin (l-LV) and 5-fluorouracil (5-FU) against gastric cancer and colorectal cancer was conducted on a multi-institutional basis in Japan."5.08[Clinical evaluation of leucovorin and 5-fluorouracil]. ( Sasaki, T, 1995)
"Between 1966 and 1983 we selected 209 patients with colorectal adenocarcinomas, stage B (14%) and C (86%) of Dukes, treated with convenient surgery in 100% of cases, 5-fluorouracil in 85% and postoperative radiotherapy with telecobalt in 46."5.08[Is radiotherapy necessary in the control of colorectal cancer?]. ( Molina Esquivel, J; Rodríguez del Rincón, E; Vargas Sandoval, G; Velázquez López, J, 1995)
"Modulation of 5-fluorouracil (5-FU) is currently being investigated in advanced colorectal cancer."5.08Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin. ( Astone, A; Barone, C; Cassano, A; Corsi, DC; Fontana, T; Noviello, MR; Pozzo, C, 1995)
"The aim of this study was to investigate the effects of adding interferon alfa-2b (IFN) to protracted venous infusion fluorouracil (PVI 5-FU) from the start of treatment in patients with advanced colorectal cancer."5.08Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. ( Ahmed, F; Cunningham, D; Findlay, M; Hickish, T; Hill, M; Middleton, G; Nicolson, V; Norman, A; Watson, M; Webb, A, 1995)
"We have conducted a retrospective study of high-dose folinic acid and 5-fluorouracil in 96 patients with advanced colorectal cancer."5.08High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients. ( Adams, M; Hanna, CL; Mason, MD; Maughan, TS; McKinna, FE; Morrey, D; Williams, LB, 1995)
"135 patients with locally advanced or metastatic colorectal cancer were entered into a phase III trial evaluating the efficacy of chemoimmunotherapy [recombinant interleukin 2 (rIL2)/5-fluorouracil (5-FU) and leucovorin (LV)] versus chemotherapy alone (5-FU/LV)."5.08A phase III study of recombinant interleukin-2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinoma. ( de Peuter, RA; Eremin, O; Franks, CR; Heys, SD; Oskam, R; Palmer, PA; Pein, F; Rainer, H; Ruggeri, EM, 1995)
"To compare the efficacy and toxicity profiles of a combination of fluorouracil (5-FU) with recombinant human interferon alfa-2a (Roferon-A; Hoffman La-Roche AG, Basel, Switzerland) versus the combination of 5-FU with leucovorin (LV) in the treatment of advanced colorectal cancer."5.08Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group. ( , 1995)
"A clinical trial was conducted in order to evaluate the anti-tumor effect and toxicity of a continuous infusion of 5-fluorouracil (5-FU) for metastatic colorectal cancer."5.08Clinical trial of continuous infusion of 5-fluorouracil using an ambulatory pump for metastatic colorectal cancer. ( Kondo, H; Ohkura, H; Saito, D; Shimada, Y; Shirao, K; Sugano, K; Yamao, T; Yokota, T; Yoshida, S, 1995)
"A multicentral cooperative study was conducted to evaluate the clinical efficacy and toxicity of l-Leucovorin (l-LV) and 5-fluorouracil (5-FU) in advanced colorectal cancer."5.08[A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)]. ( Abe, T; Kikkawa, N; Konishi, K; Maehara, Y; Ota, J; Sowa, M; Taguchi, T; Takashima, S; Yabushita, K; Yasutomi, M, 1995)
"Trimetrexate (TMQ), a non-classical folate antagonist, was studied in a randomized controlled trial in patients with advanced colorectal cancer and without prior chemotherapy."5.08A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: a Southwest Oncology Group study. ( Brown, TD; Fleming, TR; Goodman, PJ; Macdonald, JS; O'Rourke, T; Pugh, RP, 1995)
"These results indicate that suramin is inactive in patients with metastatic colorectal cancer pretreated with fluoropyrimidines."5.08Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study. ( Brunetti, I; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Pfanner, E, 1995)
"No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy."5.08Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. ( André, AM; Bertino, JR; Conti, JA; Grossano, DD; Kemeny, NE; Saltz, LB, 1995)
"A Phase II study of combination treatment with 5-fluorouracil (5-FU), leucovorin (LV), and interferon alpha-2a (IFN) in patients with previously untreated metastatic colorectal cancer was previously reported by the authors."5.085-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. ( Buter, J; de Vries, EG; Mulder, NH; Sinnige, HA; Sleijfer, DT; van der Graaf, WT; Verschueren, RC; Willemse, PH, 1995)
"A total of 56 consecutive patients with metastatic colorectal cancer received treatment with 5-fluorouracil (5-FU) given at 425 mg/m2 by rapid intravenous infusion, immediately preceded by leucovorin (LV) given at 20 mg/m2, with cycles being repeated every 4 weeks."5.085-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study. ( Dale, J; Fried, G; Haim, N; Stein, M; Tsalik, M, 1995)
"Between September 1990 and August 1994, 11 patients (pts) with liver metastases (mets) from colorectal cancer were treated with continuous hepatic arterial infusion chemotherapy of 5-fluorouracil (FU) plus leucovorin (LV)."5.08[Continuous intraarterial infusion of 5-fluorouracil plus leucovorin for liver metastases from colorectal cancer]. ( Ban, K; Higashi, H; Imanari, T; Ishihara, S; Kitazaki, M; Masuda, K; Matsumoto, M; Noma, M; Ota, M; Shida, H, 1995)
"From May 1988 to June 1992, 129 eligible patients suffering from measurable advanced colorectal cancer were enrolled in a randomized study comparing bolus fluorouracil plus leucovorin (FU-FA); continuous fluorouracil infusion (FU-cont); FUcont plus cyclophosphamide and mitomycin C (FUMIC)."5.08A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma. ( Bonnel, C; Caudry, M; Caudry, Y; Dujols, JP; Floquet, A; Marsault, C; Maton, O; Pujol, J; Quétin, P; Skawinski, P, 1995)
"A phase I and pharmacokinetic trial was performed between October 1993 and June 1994 to determine the maximum-tolerated dose of hepatic arterial infusion (HAI) of fluorouracil (5-FU) and intravenous (IV) leucovorin (folinic acid; FA) in patients with hepatic metastases from colorectal cancer."5.08Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil. ( Buckels, J; Budden, J; Doughty, J; Kerr, DJ; Ledermann, JA; McArdle, CS; Neoptolemos, J; Seymour, M; Taylor, I, 1995)
"We undertook a multicenter phase II trial of 5-fluorouracil (5FU) + 1-leucovorin (1-LV) in previously untreated patients with metastatic colorectal cancer to determine the response rate, response duration, time to progression, survival, and toxicity."5.08A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer. ( Erlichman, C; Fine, S; Gorg, C; Gustavsson, B; Hoffmann, W; Kerr, I; Preusser, P; Schmoll, HJ; Thuerlimann, B, 1996)
"This randomised clinical trial, involving patients with advanced colorectal cancer, was carried out to compare the effectiveness of accelerated folinic acid (FA) plus 5-fluorouracil (5-FU) with that of the conventional regimen of 5-FU alone."5.08Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care. ( Aquino, A; Botta, G; De Martino, A; Frediani, B; Lorenzi, M; Marsili, S; Marzocca, G; Palazzuoli, V; Petrioli, R; Tani, F, 1995)
"A joint study was performed by the Tokai HCFU study group, which included 41 institutions to study the usefulness of the concomitant therapy with Mitomycin C (MMC) and Carmofur (HCFU) as a postoperative adjuvant chemotherapy in patients with colorectal cancer who had curative resection."5.08Prospective adjuvant therapy with mitomycin C and carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group, the first study for colorectal cancer. ( Ito, K; Kato, T; Koike, A; Miura, K; Takagi, H; Yamaguchi, A, 1996)
"To determine the plasma pharmacokinetics and the maximum-tolerated dose (MTD) of intravenous (IV) azidothymidine (AZT) administered 90 to 120 minutes after fluorouracil (5-FU) and leucovorin and to preliminarily evaluate the antitumor activity of this combination in metastatic colorectal cancer."5.08Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. ( Brunetti, I; Conte, PF; Danesi, R; Dargenio, F; Del Tacca, M; Falcone, A; Nethersell, AB; Pfanner, E, 1996)
"Phase II studies of fluorouracil (5-FU) administered by protracted intravenous infusion have suggested an improved response rate and decreased toxicity profile when compared with 5-FU given by bolus injection in patients with metastatic colorectal cancer."5.08Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. ( Anderson, T; Benson, A; Haller, DG; Hansen, RM; Krzywda, B; Quebbeman, E; Ryan, L; Tormey, DC, 1996)
"We studied the effect of postoperative chemotherapy using 5-fluorouracil (5-FU) infusions and 1-hexylcarbamoyl-5-fluorouracil (HCFU) oral administration for curatively resected Stage II to IV colorectal cancer."5.08Postoperative chemotherapy for colorectal cancer by combining 5-fluorouracil infusion and 1-hexylcarbamoyl-5-fluorouracil administration after curative resection. ( Akiyoshi, T; Kakegawa, T; Maehara, Y; Ogawa, M; Sugimachi, K; Tomita, M, 1996)
"A phase II prospective trial was carried out to study the concept of 5-fluorouracil (5-FU) dose-intensity in patients with advanced colorectal cancer."5.08Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. ( Burtin, PC; Danquechin-Dorval, EM; Delva, RG; Dumesnil, YF; Gamelin, EC; Gesta, PH; Goudier, MJ; Larra, FG; Lortholary, AH; Maillart, PJ, 1996)
"We evaluated the role of low-dose alpha-2b interferon, added to chemotherapy, for advanced colorectal cancer; we randomized patients, to either a combination chemotherapy of 5-fluorouracil (5-FU) and high-dose folinic acid (HDFA) or the same regimen plus interferon."5.08Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2B interferon in advanced colorectal cancer. ( Di Lullo, L; Fabiani, F; Fanini, R; Lalli, A; Lombardo, M; Nuzzo, A; Peretti, G; Recchia, F; Torchio, P; Venturoni, L, 1996)
"A total of 26 patients with advanced colorectal cancer received 60 mg/m2 methotrexate i."5.08Multimodal biochemical modulation of 5-fluorouracil by leucovorin, methotrexate, and interferon alpha in patients with advanced colorectal cancer. ( Alessandroni, P; Casadei, V; Cascinu, S; Catalano, G; Del Ferro, E; Fedeli, A; Rossi, D, 1996)
"We undertook a randomized trial in patients with advanced colorectal cancer, comparing 5-fluorouracil and leucovorin versus combination of these agents with additional cisplatin."5.08[Evaluation of chemotherapy in the treatment of advanced colorectal cancer--pilot study of 5-FU by biochemical modulation]. ( Katsumata, K; Ohno, M; Shibata, K; Yamamoto, K; Yamashita, S, 1996)
"Despite its low antineoplastic activity 5-fluorouracil remains the most active compound for the treatment of patient with metastatic colorectal cancer."5.08[Progress in development of chemotherapy of colorectal carcinoma]. ( Köhne, CH, 1996)
"Methotrexate (MTX) has been described to modulate the activity of fluorouracil (5-FU) in patients with metastatic colorectal cancer."5.08Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study. ( Bleiberg, H; Blijham, G; Buset, M; Collette, L; Dalmark, M; de Greve, J; Lacave, A; Sahmoud, T; Selleslag, J; Wagener, T; Wils, J, 1996)
"To determine the effects of interferon alpha-2a (IFN alpha) on the efficacy and toxicity of fluorouracil (FUra) and leucovorin (LV) in patients with advanced colorectal cancer."5.08Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. ( Cunningham, D; Duffy, AM; Harper, PG; James, RD; Kerr, DJ; Ledermann, JA; McAdam, WA; Neoptolemos, JP; Nicholson, M; Perren, TJ; Seymour, MT; Slevin, ML; Stenning, SP; Stephens, RJ; Taylor, I, 1996)
"A phase II study was performed to evaluate the clinical and immunological effects of a regimen of fluorouracil (5-FU) and folinic acid (FA) combined with thymopentin (TP-5) and interleukin-2 (IL-2) in the treatment of patients with metastatic colorectal cancer."5.08Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: clinical and immunological effects. ( Ameglio, F; Di Lauro, L; Frasca, AM; Gandolfo, GM; Garaci, E; Lopez, M; Paoletti, G; Rasi, G; Santini, S; Vitelli, G, 1995)
"The primary objective of this study was to determine the response rate of patients with metastatic colorectal cancer to combined therapy with 5-fluorouracil (5-FU), leucovorin, and intravenous azidothymidine (AZT), a thymidine nucleoside analog."5.08Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer. ( Akerley, W; Beitz, J; Bigley, J; Browne, M; Clark, J; Cole, B; Cummings, F; Darnowski, J; Kennedy, T; Sikov, W; Wanebo, H; Weitberg, A, 1996)
"With the association of 5-fluorouracil (5-FU) and alpha-interferon (IFN), objective responses as high as 26 63% have been reported in untreated patients with advanced colorectal cancer."5.08A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. ( Acito, L; Bascioni, R; Bavosi, M; Carle, F; Cascinu, S; Cellerino, R; Del Papa, M; Francini, G; Giustini, L; Latini, L; Marcellini, M; Pancotti, A; Piga, A; Rossi, G, 1996)
"To evaluate ambulatory cancer chemotherapy, the clinical response, toxicities and survival time were analysed among 32 patients with non-curative or recurrent colorectal cancer who were treated by l-Leucovorin (l-LV) plus 5-fluorouracil for the past four years."5.08[Clinical study of ambulatory cancer chemotherapy for advanced colorectal cancer]. ( Kunii, Y; Ota, K; Takahashi, N, 1995)
"A phase I trial of 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN) was conducted in 15 advanced colorectal cancer patients refractory to a bolus regimen of 5-FU/LV."5.08A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. ( Cascinu, S; Catalano, G; Del Ferro, E; Ligi, M, 1996)
"To compare the efficacy and toxicity profiles of a combination of fluorouracil (5-FU) and recombinant human interferon alfa-2a ([IFN alpha 2a] Roferon-A; Hoffmann-LaRoche, Basel, Switzerland) versus 5-FU alone in the treatment of advanced colorectal cancer (ACC)."5.08Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. ( Buys, SS; Buyse, M; Einhorn, L; Figlin, R; Froimtchuk, MJ; Greco, FA; Man, A; Marshall, EM; Ritter, L; Schilsky, R; Schuchter, L; Schuller, J; Yap, AK; York, M, 1996)
"A joint study was performed by the Tokai HCFU study group, which included seven institutions, to examine the value of oral administration of Carmofur (HCFU), a 5-fluorouracil (5-FU) derivative, for postoperative adjuvant chemotherapy in patients with colorectal cancer undergoing curative resection."5.08Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: five-year follow-up. Tokai HCFU Study Group--third study on colorectal cancer. ( Baba, S; Ishii, M; Ito, K; Kato, T; Matsumoto, S; Miura, K; Takagi, H; Yamaguchi, A, 1996)
"5-Fluorouracil (5-FU) remains the most active therapeutic agent in advanced colorectal cancer."5.085-Fluorouracil continuous infusion in metastatic colorectal cancer. ( Ang, PT; Tan, EH, 1996)
"In a pilot study we treated 19 patients suffering from recurrent or locally advanced inoperable colorectal cancer, with concurrent hypofractionated radiotherapy (4-5 Gy/fraction, 2 fractions per week) and 5-fluorouracil bolus, 1 hour before RT at doses of 300 mg/m2."5.08Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study. ( Kapsoritakis, A; Kosma, L; Koukourakis, M; Mouder, N; Skarlatos, J; Yannakakis, D; Zambatis, C, 1996)
"Treatment using a combination of 5-fluorouracil (5-FU), interferon-alpha (IFN alpha-2a) and interleukin 2 (IL-2) has been shown to mediate disease regression in selected patients with advanced colorectal cancer."5.08Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer. ( Goey, SH; Gratama, JW; Mertelsmann, RH; Osterwalder, B; Primrose, JN; Stoter, G; Verweij, J; Ward, U, 1996)
" To evaluate these effects, 17 patients with advanced colorectal cancer took part in a randomised, parallel group study of rIL-2 with chemotherapy (5-fluorouracil and leucovorin) and chemotherapy alone."5.08The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerised assessments. ( Eremin, O; Heys, SD; Lolley, J; Walker, LG; Walker, MB; Wesnes, KP, 1996)
"This multicenter study compared the therapeutic ratio of a monthly schedule of low-dose leucovorin (LV) and fluorouracil (5-FU) bolus with a bimonthly schedule of high-dose LV and 5-FU bolus plus continuous infusion in patients with advanced colorectal cancer."5.08Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. ( Bedenne, L; Bosset, JF; Bouché, O; de Gramont, A; Etienne, PL; François, E; Guillot, T; Louvet, C; Milan, C; Morvan, F; Rougier, P, 1997)
"To compare the efficacy and toxicity of fluorouracil (FU) and racemic leucovorin (d,l-LV) versus FU combined with the l-isomer of leucovorin (l-LV) in the treatment of advanced colorectal cancer."5.08Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study. ( Burger, D; Depisch, D; Greiner, R; Karner, J; Kornek, G; Kovats, E; Marczell, A; Pidlich, J; Raderer, M; Rosen, H; Salem, G; Scheithauer, W; Schneeweiss, B, 1997)
"Although leucovorin (LV) + 5-fluorouracil (5-FU) is considered the treatment of choice for advanced colorectal cancer in most countries, the optimal schedule of this combination has not yet been established."5.08High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a 'GISCAD' phase III study. Italian Group for the Study of Digestive Tract Cancer. ( Arnoldi, E; Barni, S; Cascinu, S; Comella, G; Dallavalle, G; Duro, M; Fiorentini, G; Frontini, L; Gottardi, O; Labianca, R; Luporini, G; Martignoni, G; Oliani, C; Pancera, G; Pavanato, G; Piazza, E; Raina, A; Valsecchi, R; Zaniboni, A, 1997)
"Fourteen patients with 5-fluorouracil (5-FU) refractory, progressive colorectal cancer metastatic to liver and/or lung were treated with continuous oral trofosfamide, an alkylating agent structurally related to cyclophosphamide and ifosfamide."5.08Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil. ( Eberhardt, W; Harstrick, A; Klaassen, U; Korn, MW; Müller, C; Seeber, S; Strumberg, D; Wilke, H, 1997)
"The basic immunological indexes were investigated in patients with disseminated colorectal cancer after conduction of magnetothermia and chemotherapy using fluorouracil."5.08[Immunological monitoring of patients with disseminated colorectal cancer under thermochemotherapy]. ( Chernenko, OD; Iaremchuk, AIa; Kamenets, LIa; Kravchenko, AV, 1997)
"Diarrhea is one of the dose-limiting toxicities for administration of fluorouracil (5FU) in patients with colorectal cancer and can result in severe morbidity and mortality."5.08Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study. ( Ardizzoia, A; Barni, S; Cascinu, S; Catalano, G; Cazzaniga, M; Del Ferro, E; Ghiandoni, G; Labianca, R; Ligi, M; Luporini, G; Pessi, MA; Rocchi, MB; Ugolini, G; Zamparelli, G, 1997)
"A three-arm randomized phase III trial in advanced colorectal cancer patients was designed to test whether substitution of an equivalent dose of (1) l-leucovorin or (2) oral leucovorin would more effectively potentiate fluorouracil (5-FU) than standard intravenous (I."5.08Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. ( Goldberg, RM; Hatfield, AK; Kahn, M; Knost, JA; Krook, JE; Maillard, JA; Moertel, CG; O'Connell, MJ; Sargent, DJ; Schaefer, PL; Tirona, MT; Wiesenfeld, M, 1997)
"The aim of this phase I study was to establish the maximum tolerated dose (MTD) of 5-fluorouracil (5-FU), administered as a 5-day chronomodulated infusion in combination with 1-folinic acid (FA) to ambulatory metastatic colorectal cancer patients."5.08A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer. ( Aschelter, AM; Franchi, F; Gallà, DA; Garufi, C; Giunta, S; Lévi, F; Narduzzi, C; Nisticò, C; Pace, R; Silecchia, GF; Terzoli, E, 1997)
" To evaluate these effects, 17 patients with advanced colorectal cancer took part in a randomised, parallel group study of rIL-2 with chemotherapy (5-fluorouracil and leucovorin) versus chemotherapy alone."5.08The psychological and psychiatric effects of rIL-2 therapy: a controlled clinical trial. ( Eremin, O; Heys, SD; Lolley, J; Walker, LG; Walker, MB; Wesnes, K, 1997)
"To determine whether high-dose infusional fluorouracil (FU) is effectively modulated by leucovorin (LV), interferon (IFN) alpha-2b, or both when given to patients with metastatic colorectal cancer."5.08Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. ( Andreesen, R; Bade, J; Dörken, B; Harstick, A; Hecker, H; Hiddemann, W; Horster, A; Käufer, C; Klaasen, U; Köhne, CH; Ohl, U; Schmoll, HJ; Schöffski, P; Schott, G; Schubert, U; Westerhausen, M; Wilke, H, 1998)
"The purpose of this study was to compare the objective response rate, duration of remission, and survival of 5-fluorouracil (5-FU) versus those of 5-FU plus levamisole in metastatic colorectal cancer using the same dose and schedule of these agents as in the North Central Cancer Treatment Group and intergroup studies of adjuvant therapy."5.08Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. ( Bandealy, MT; Einhorn, LH; Gonin, R; Loehrer, PJ; Monaco, F, 1998)
" Patients with advanced colorectal cancer who participated in two international comparative studies of raltitrexed ('Tomudex') vs standard 5-fluorouracil (5-FU) plus leucovorin (LV) completed previously validated quality-of-life questionnaires (EORTC questionnaire, EuroQol and Rotterdam Symptom Check List) at various times during the studies."5.08Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials. ( Anderson, H; Palmer, MK, 1998)
"Although the efficacy of 5-fluorouracil (5-FU) modulated by leucovorin is well established for advanced colorectal cancer, the question of the most effective regimen and optimal dose of leucovorin remains unanswered."5.08A prospective randomized study comparing high- and low-dose leucovorin combined with same-dose 5-fluorouracil in advanced colorectal cancer. ( Blanc, F; Bons-Rosset, F; Fabbro-Peray, P; Gouze, C; Heran, B; Marçais, O; Perney, P; Ribard, D; Veyrac, M; Ychou, M, 1998)
"From February 1995 through October 1996, 25 patients with metastatic colorectal cancer showing a clinical resistance to 5-fluorouracil (5-FU) entered this study."5.08Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. ( Aapro, MS; Biffi, R; Brienza, S; De Pas, T; deBraud, F; Munzone, E; Nolè, F, 1998)
"A wide variety of fluorouracil (FU)-plus-leucovorin (LV) dose schedules are in clinical use for the treatment of advanced colorectal cancer."5.08The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK). ( Bacchi, M; Borner, MM; Castiglione, M; Fey, MF; Goldhirsch, A; Hanselmann, S; Herrmann, R; Leyvraz, S; Morant, R; Pagani, O; Pestalozzi, B; Weber, W, 1998)
"5-Fluorouracil and leucovorin combination is the most commonly applied chemotherapy treatment for colorectal cancer patients, both in the adjuvant setting and for advanced disease."5.08A phase II trial of carboplatin, methotrexate and fluorouracil in fluorouracil-pretreated colorectal cancer. ( Botto, F; Ghio, E; Neri, E; Pensa, F; Pronzato, P; Tognoni, A; Vaira, F; Vigani, A, 1998)
"The aim of this study was to evaluate the efficacy and tolerance of second-line continuous 5-fluorouracil (5FU) chemotherapy combined with folinic acid and mitomycin C in patients with advanced colorectal cancer who progressed on first-line chemotherapy."5.085-Fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma. ( Bardou, VJ; Bernardini, D; Capodano, G; Giovannini, M; Perrier, H; Seitz, JF, 1998)
"Patients with histologically confirmed advanced colorectal cancer were randomized to receive folinic acid (FA; 500 mg/mq in 2-hour intravenous infusion) and 5-fluorouracil (5FU; 600 mg/mq given as an intravenous bolus 1 hour after FA), beginning every week for 6 weeks, followed by a 2-week rest period, either without hydroxyurea (HU, arm A) or with HU (35 mg/kg per day) given orally in three administrations (every 8 hours) starting 6 hours after 5FU administration (arm B)."5.08High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research. ( Algeri, R; Angiona, S; Belsanti, V; Boni, C; Corgna, E; Di Costanzo, F; Figoli, F; Gasperoni, S; Luppi, G; Malacarne, P; Marzola, M; Passalacqua, R; Sdrobolini, A; Zironi, S, 1998)
"To compare raltitrexed (Tomudex; Zeneca Pharmaceuticals Ltd, Macclesfield, United Kingdom) a direct, specific thymidylate synthase (TS) inhibitor with fluorouracil (5-FU) plus high-dose leucovorin (LV) as first-line treatment for advanced colorectal cancer (ACC)."5.08Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. ( Cocconi, G; Cunningham, D; Francois, E; Gustavsson, B; Hietschold, SM; Kerr, D; Possinger, K; Van Cutsem, E; van Hazel, G, 1998)
"The objective of this multicenter study was to compare the efficacy and toxicity profiles of a combination of 5-fluorouracil (5-FU) given by bolus injection together with intravenous leucovorin (LV) versus high-dose 5-FU in continuous infusion (CI) in the treatment of advanced colorectal cancer."5.08Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. ( Antón-Torres, A; Aparicio, J; Aranda, E; Barneto, I; Carrato, A; Cervantes, A; Díaz-Rubio, E; García-Conde, J; López-Vega, JM; Massutí, T; Sastre, J; Tabernero, JM; Trés, A, 1998)
"We measured plasma total homocysteine (tHcy) in 14 patients (13 patients with colorectal cancer and 1 patient with breast cancer) during their first treatment with 5-fluorouracil (5-FU) plus leucovorin [LV (5-FULV)]."5.08Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients. ( Geisler, J; Geisler, SB; Lønning, PE; Refsum, H; Smaaland, R; Tveit, KM; Ueland, PM, 1998)
"Patients with proven metastatic colorectal cancer, which had progressed within 6 months of treatment with fluorouracil, were randomly assigned either 300-350 mg/m2 irinotecan every 3 weeks with supportive care or supportive care alone, in a 2:1 ratio."5.08Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. ( Awad, L; Cunningham, D; Heikkila, R; Herait, P; Hickish, TF; Jacques, C; James, RD; Johannesen, TB; Punt, CJ; Pyrhönen, S; Starkhammar, H; Topham, CA, 1998)
"In phase II trials, irinotecan is active in patients with advanced colorectal cancer, but the survival and clinical benefit of irinotecan compared with second-line fluorouracil by continuous infusion is not known."5.08Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. ( Awad, L; Bajetta, E; Bleiberg, H; Herait, P; Jacques, C; Labianca, R; Morant, R; Navarro, M; Niederle, N; Possinger, K; Rougier, P; Van Cutsem, E; Wils, J, 1998)
"Data from 12 metastatic colorectal cancer patients who were submitted to a pilot study with a multistep subcutaneous (sc) low dose recombinant interleukin-2 (rIL-2), 5-fluorouracil (5-FU) and leucovorin (LV) administration were compared with those from 13 historical controls who were comparable for the major prognostic indices."5.08A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study. ( Anselmi, L; Carpi, A; Ferrari, P; Nicolini, A; Sagripanti, A, 1998)
"The cumulative pharmacokinetic pattern of oxaliplatin, a new diamminecyclohexane platinum derivative, was studied in patients with metastatic colorectal cancer."5.08Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. ( Allain, P; Boisdron-Celle, M; Bouil, AL; Brienza, S; Cailleux, A; Cvitkovic, E; Delva, R; Gamelin, E; Krikorian, A; Larra, F; Robert, J; Turcant, A, 1997)
"We evaluated the pharmacokinetics of 5-fluorouracil (5-FU) combined with recombinant human interferon (IFN)-alpha 2a in 10 previously untreated patients with advanced colorectal carcinoma."5.08Pharmacokinetics of recombinant human interferon-alpha 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma. ( Kim, J; Koss-Twardy, SG; Passe, SM; Patel, IH; Pazdur, R; Satoh, H; Zhi, J, 1998)
"Raltitrexed (Tomudex) is currently licensed for first-line treatment of advanced colorectal cancer."5.08Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancer. ( Cunningham, D; Farrugia, DC; Norman, AR, 1998)
"This multicenter phase II study was designed to assess the efficacy of the alternating schedule of irinotecan (CPT-11) with bolus 5-fluorouracil (5-FU) and leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer (CRC)."5.08A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. ( Barone, C; Cognetti, F; Cote, C; Dirix, L; Filez, L; Garufi, C; Gruia, G; Humblet, Y; Pozzo, C; Starkhammar, H; Terzoli, E; Van Cutsem, E, 1998)
"FOLFOX2, a bimonthly regimen of high-dose leucovorin (LV), 48-hour continuous infusion of 5-fluorouracil (5-FU) (LV-5-FU) and oxaliplatin (100 mg/m2) produced a high response rate (46%; 95% confidence interval (95% CI): 31%-60%) in 5-FU pre-treated patients with metastatic colorectal cancer."5.08Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. ( André, T; de Gramont, A; Louvet, C; Raymond, E; Tournigand, C, 1998)
" 439 patients were entered into a phase III trial comparing a novel thymidylate synthase (TS) inhibitor Tomudex (raltitrexed, formerly ZD1694) with 5-FU and leucovorin (LV) for the treatment of advanced colorectal cancer."5.08Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. ( Kerr, D; Palmer, M; Seymour, L; Zalcberg, J, 1998)
"Cell ingrowth, hydroxyproline accumulation, and mRNA expression of collagen I were measured in two polytetrafluoroethylene grafts implanted subcutaneously at the time of colorectal cancer surgery to evaluate the influence of early postoperative chemotherapy on human wound healing."5.07The influence of early postoperative intraperitoneal chemotherapy on human wound healing. ( Gerdin, B; Glimelius, B; Graf, W; Hellsing, K; Ivarsson, M; Påhlman, L, 1994)
"To compare two commonly used schedules of fluorouracil (5FU) and leucovorin in the treatment of patients with advanced metastatic colorectal cancer."5.07Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. ( Buroker, TR; Gerstner, JB; Gesme, DH; Kardinal, CG; Krook, JE; Levitt, R; Mailliard, JA; O'Connell, MJ; Schaefer, PL; Wieand, HS, 1994)
"Eighty-one patients with metastatic or locally advanced colorectal cancer were treated at four oncological centers in Denmark with a regimen consisting of 5-fluorouracil 400 mg/m2 and leucovorin 20 mg/m2 for 5 consecutive days every 4 weeks."5.07Metastatic or locally advanced colorectal cancer treated with 5-fluorouracil and low dose leucovorin. ( Andersen, LJ; Brunsgaard, NH; Jensen, BB; Mejlholm, I, 1994)
"Twenty-one patients with advanced, pretreated colorectal cancer in disease progression were entered in a phase II study to investigate the use of 5-fluorouracil (5FU) + leucovorin with subcutaneous Interleukin-2 + alpha interferon (alpha-IFN)."5.07A phase II study of advanced colorectal cancer patients treated with combination 5-fluorouracil plus leucovorin and subcutaneous interleukin-2 plus alpha interferon. ( Amadori, D; Fedriga, R; Flamini, E; Maltoni, R; Milandri, C; Pezzi, L; Riccobon, A; Ridolfi, R; Santoni, A; Velotti, F, 1994)
"The disposition of 5-fluorouracil (FUra) was studied in 19 colorectal cancer patients during treatment with FUra and high-dose leucovorin (LV) with or without interferon alpha 2a (IFN-alpha)."5.07Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics. ( Joel, SP; Johnston, A; Patel, N; Seymour, MT; Slevin, ML, 1994)
"5-Fluorouracil (5-FU) activity for various carcinomas of adults has been enhanced through the synergistic effect of leucovorin."5.07Phase II study of 5-fluorouracil/leucovorin for pediatric patients with malignant solid tumors. ( Bowman, LC; Douglass, EC; Houghton, JA; Howlett, N; Kun, LE; Meyer, WH; Mounce, K; Poe, D; Pratt, CB, 1994)
"In a previous phase II trial, circadian (chronomodulated) delivery of fluorouracil (5-FU), folinic acid (FA; leucovorin), and oxaliplatin (1-OHP; a new platinum complex with no renal and minor hematologic toxic effects) produced an objective response rate of 58% in 93 patients with metastatic colorectal cancer."5.07Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. ( Chollet, P; Dogliotti, L; Faggiuolo, R; Focan, C; Garufi, C; Itzhaki, M; Lévi, FA; Perpoint, B; Vannetzel, JM; Zidani, R, 1994)
"Interferon alpha (IFN-alpha) enhances the activity of 5-fluorouracil (5-FU) in the treatment of advanced colorectal cancer although the mechanism is not understood."5.07The effect of 5-fluorouracil and alpha interferon and 5-fluorouracil and leucovorin on cellular anti-tumour immune responses in patients with advanced colorectal cancer. ( Nichols, PH; Primrose, JN; Ramsden, CW; Ward, U, 1994)
"Pharmacokinetics of total platinum, 5-fluorouracil, l-folinic and d-folinic acid, and 5-methyltetrahydrofolate were studied in plasma from nine patients with advanced colorectal cancer treated with oxaliplatin (20 mg/m2/day), 5-fluorouracil (600 mg/m2/day), and folinic acid (300 mg/m2/day)."5.07Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer. ( Bastian, G; Brienza, S; Comisso, M; Etienne, MC; Lévi, F; Massari, C; Metzger, G; Milano, G; Misset, JL; Touitou, Y, 1994)
"A total of 101 patients with advanced colorectal cancer in two consecutive Southern Italian Oncology Groups (GOIM) studies (8501 and 8801--arm A) were treated with a sequential combination of high dose methotrexate (HDMTX) and fluorouracil (FU)."5.07Sequential treatment with high-dose methotrexate and fluorouracil in advanced colorectal cancer. Experience of the Southern Italian Oncology Group (GOIM). ( Colucci, G; Giotta, F; Giuliani, F; Leo, S; Maiello, E; Pedicini, A; Pezzella, G; Prete, F; Romito, S; Valori, V, 1994)
"In an attempt to evaluate the feasibility of 5-fluorouracil (FU) treatment modulated by (R,S)-leucovorin (LV) and interferon alpha (IFN alpha) in patients with advanced colorectal cancer, we conducted a phase I trial with increasing doses of subcutaneous IFN alpha (3 x 1 x 10(6) U, 3 x 3 x 10(6) U, 3 x 3 x 10(6) U, 3 x 5 x 10(6) U and 3 x 10 x 10(6) U/week) and 500 mg/m2 LV i."5.07Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration. ( Djavanmard, MP; Gnant, MF; Jakesz, R; Locker, G; Mader, RM; Marosi, C; Rainer, H; Steger, GG, 1994)
"The management of patients with advanced colorectal cancer remains dependent on the optimal use of 5-Fluorouracil (5-FU)."5.07Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer. ( Carter, R; Cunningham, D; Evans, C; Findlay, M; Ford, H; Hill, A; Husband, J; Nicolson, M; Norman, A, 1994)
"Twenty-two patients with metastatic colorectal cancer entered a Phase I-II trial to assess the maximum tolerable dose of alpha-2B-interferon administered intramuscularly three times per week in combination with fixed doses of 5-fluorouracil (450 mg/m2 IV for 5 days, and, from day 28, weekly) and folinic acid (200 mg/m2 IV before 5-fluorouracil) and the efficacy of this combination."5.07Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients. ( Bertuccelli, M; Brunetti, I; Cianci, C; Conte, PF; Falcone, A; Ricci, S, 1994)
"A joint multicenter comparative study of carmofur (HCFU) alone or HCFU+dipyridamole (DP) concurrent administration was conducted by the Kinki Colorectal Cancer Chemotherapy Society."5.07[Some problems of TS measurement after administration of fluoropyrimidines in colorectal cancer. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma]. ( Fukuda, I; Hioki, K; Imaoka, S; Kameyama, M; Kikkawa, N; Mori, T; Nakamori, S; Oshima, A; Utsunomiya, J; Yasutomi, M, 1993)
"To increase the knowledge about the palliative effects of chemotherapy in patients with symptomatic advanced colorectal cancer, physician- and patient-rated "quality of life" was studied in a randomized multicenter trial comparing a regimen of methotrexate/5-fluorouracil (5-FU) followed by leucovorin rescue (MFL) with a regimen of 5-FU/leucovorin (FLV)."5.07Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. ( Glimelius, B; Graf, W; Hoffman, K; Påhlman, L; Sjödén, PO, 1994)
"Potentiation of the antitumor activity of 5-fluorouracil (5-FU) by folinic acid has been demonstrated in patients with colorectal adenocarcinoma."5.075-Fluorouracil combined with the [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma. A phase I-II study of two consecutive regimens. ( André, T; Goldschmidt, E; Grison, X; Hannoun, L; Lotz, JP; Machover, D; Marquet, J; Metzger, G; Richaud, J; Zittoun, J, 1993)
"A prospective, controlled randomized trial of hepatic arterial infusion of 5-fluorouracil (5-FU), adriamycin (ADM) and mitomycin C (MMC) [FAM group] versus 5-FU, epirubicin (EPIR) and MMC [FEM group] in patients with unresectable liver metastasis from colorectal cancer is reported."5.07[A randomized trial of intrahepatic infusion chemotherapy for unresectable colorectal liver metastases. Sendai Study Group]. ( Kunii, Y; Mashiko, H; Momono, S; Muto, I; Nakagawa, K; Ouchi, A; Shiiba, K; Wada, M; Yamamoto, K; Yamazaki, T, 1993)
"5-Fluorouracil (5-FU), when combined with leucovorin (LV) or interferon-alpha (IFN-alpha), may result in improved response rates compared with 5-FU alone in patients with advanced colorectal cancer."5.07Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study. ( Burghouts, JT; Croles, JJ; de Mulder, PH; Kamm, Y; Punt, CJ; van Liessum, PA, 1993)
" The purpose of this study was to compare its therapeutic effect with a standard fluorouracil (FU) regimen in patients with locally advanced or metastatic colorectal cancer."5.07Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. ( Amadori, D; Bajetta, E; Calabresi, F; Colleoni, M; Comella, G; Lorusso, V; Marangolo, M; Rosso, R; Scanni, A; Sobrero, A, 1993)
"25 patients with metastatic colorectal cancer were entered into a phase II trial of combination chemoimmunotherapy using a sequential regimen of 5-fluorouracil (5-FU) and leucovorin and high-dose recombinant human interleukin-2 (rIL-2)."5.07Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2. ( Landry, JG; Ritchey, JL; Rosenberg, SA; Shlasko, E; White, DE; Yang, JC, 1993)
"A prospectively randomized trial was performed to determine whether the combination of fluorouracil (FU) plus leucovorin (FU-LV) administered orally is more effective than equitoxic FU for patients with metastatic colorectal cancer."5.07A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. ( Brenckman, WD; Bukowski, RM; Clendennin, NJ; Collier, MA; Guaspari, A; Laufman, LR; McKinnis, RA; Sullivan, BA, 1993)
"Biochemical modulation of bolus fluorouracil (5-FU) by addition of leucovorin to the treatment regimen has increased response in patients with disseminated colorectal cancer from fewer than 20% to more than 40%."5.07Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer. ( Groshen, S; Jeffers, S; Leichman, CG; Leichman, L; Rosen, PJ; Spears, CP, 1993)
"Thirty-one patients with hepatic metastases from colorectal carcinoma were treated with carboplatin (CBDCA), 55 mg/m2, given in a 4-hour intra-arterial infusion daily for 5 days, and 5-fluorouracil, 900 mg/m2, given in a 20-hour intra-arterial infusion daily for 5 days."5.07Intra-arterial hepatic treatment with carboplatin (CBDCA) and 5-fluorouracil (5-FU) in metastases from colorectal carcinoma. ( Abuchaibe, O; Bilbao, I; Hidalgo, OF; Pardo, F; Rebollo, J; Tangco, E; Vieitez, JM, 1993)
" This prospective phase II study evaluates the efficacy and toxicity of hepatic arterial infusion of 5-Fluorouracil (5-FU) via an implantable Infusaid pump in previously untreated patients with localised but unresectable hepatic metastases from colorectal cancer."5.07Continuous hepatic artery infusion of 5-fluorouracil for metastatic colorectal cancer localised to the liver. ( Boyle, FM; Levi, JA; Smith, RC, 1993)
"A Nordic multicenter study in asymptomatic patients with advanced colorectal cancer compared initial chemotherapy with sequential methotrexate-5-FU with leucovorin rescue (MFL) for 6 months versus primary expectancy with chemotherapy only after the appearance of symptoms."5.07General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. A longitudinal study. ( Glimelius, B; Graf, W; Hoffman, K; Påhlman, L; Sjödén, PO; Wennberg, A, 1992)
"We have reported that 5-fluorouracil (5-FU) and folinic acid increased response rate and survival in patients with metastatic colorectal cancer."5.07Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. ( Erlichman, C; Fine, S; Gadalla, T; Steinberg, J; Wong, A, 1992)
"148 patients with advanced untreated colorectal cancer were randomised to receive a weekly bolus of 5-fluorouracil (5-FU) 600 mg/m2 alone, with or without leucovorin (LV) 500 mg/m2."5.07Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. ( Canobbio, L; Fassio, T; Gallo, L; Guglielmi, A; Nobile, MT; Rosso, R; Rubagotti, A; Sertoli, MR; Venturini, M; Vidili, MG, 1992)
"From January 31, 1986 to January 31, 1989, 184 eligible patients were enrolled in a randomized study of either infusional or bolus 5-fluorouracil (5-FU) for the treatment of metastatic measurable colorectal cancer."5.07Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer. ( Bogues, W; Cripps, IC; Fields, A; Maroun, J; McCormick, R; Pater, J; Shah, A; Temple, W; Weinerman, B; Wilson, K, 1992)
"Because of the different sites and mechanisms of biochemical interaction among 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN), we hypothesized that the concomitant use of IFN could increase the activity of the 5-FU/LV combination in colorectal cancer patients."5.07Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patients. ( Cascinu, S; Catalano, G; Fedeli, A; Fedeli, SL, 1992)
"15 untreated patients with advanced measurable colorectal cancer along with other 29 patients in progression after failing first line chemotherapy with fluoropyrimidines received 5-fluorouracil (5FU) 500 mg/m2 given as a weekly bolus at mid-infusion of leucovorin (LV), 500 mg/m2 administered intravenously over 2 h and interferon alpha 2b (IFN) 3 x 10(6) U given intramuscularly every other day."5.07Phase II study of 5-fluorouracil plus leucovorin and interferon alpha 2b in advanced colorectal cancer. ( Aschele, C; Bolli, E; Bruzzi, P; Gallo, L; Guglielmi, A; Mori, A; Nobile, MT; Parodi, GC; Sobrero, A; Tixi, L, 1992)
"A high rate of response to 5-fluorouracil (5FU) and alpha-interferon (alpha IFN) combination therapy has been reported in metastatic colorectal cancer patients."5.07Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study. ( Burghouts, JT; de Mulder, PH; Punt, CJ; Wagener, DJ, 1992)
"Thirty-eight patients with advanced colorectal adenocarcinoma were entered on a phase II trial of 5-fluorouracil (5-FU) in continuous infusion, using a portable pump."5.07Phase II trial of 7-day continuous 5-fluorouracil infusion in the treatment of advanced colorectal carcinoma. ( Ammarguellat, H; Benhamed, M; Ghosn, M; Goldberg, J; Kac, J; Laplaige, P; Piot, G; Rougier, P; Theodore, C; Tigaud, JM, 1992)
"One hundred sixty consecutive patients with histologically confirmed colorectal cancer (advanced disease) without prior chemotherapy were entered in a randomized trial comparing 5-fluorouracil (5-FU) 1,000 mg/m2 intravenously per day for 5 consecutive days in continuous infusion versus cisplatin (CP) 100 mg/m2 on day 1 plus 5-FU as described on days 2 to 6."5.07A prospective randomized trial of continuous infusion 5-fluorouracil (5-FU) versus 5-FU plus cisplatin in patients with advanced colorectal cancer. A trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.). ( Antón, A; Aranda, E; Belón, J; Carrato, A; Cruz-Hernández, J; Díaz-Rubio, E; Jimeno, J; Martin, M; Massuti, B; Sánchez, J, 1992)
"Treatment results in advanced colorectal cancer have improved during the last decade since the incorporation of agents like folinic acid, PALA, or interferon as active biomodulation of 5-fluorouracil (5-FU), the most potent drug in this disease."5.07A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation. ( Köhne-Wömpner, CH; Poliwoda, H; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, HJ, 1992)
"Patients with advanced colorectal cancer were randomized to receive either fluorouracil (5-FU) 370 mg/m2 IV days 1 to 5 followed by weekly applications of 5-FU 600 mg/m2 or the same doses of 5-FU preceded by folinic acid 200 mg/m2."5.07Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer--preliminary results of a randomized trial. ( Günther, E; Hinrichs, HF; Hirschmann, WD; Koniczek, KH; Natt, F; Sondern, W; Steinke, B; Wagner, T; Wander, HE; Werdier, D, 1992)
"Several reports on fluorouracil (5-FU) and alfa interferon (IFN-alpha) combination therapy in patients with advanced colorectal cancer have been published."5.07Fluorouracil continuous infusion plus alfa interferon plus oral folinic acid in advanced colorectal cancer. ( Burghouts, JT; de Mulder, PH; Punt, CJ; Wagener, DJ, 1992)
"In a clinical phase II study, 23 patients with progressive metastatic colorectal cancer and failure after first-line chemotherapy with fluorouracil (5-FU) and folinic acid (FA) were treated with a 5-day continuous infusion of recombinant interleukin-2 (IL-2), 3 x 10(6) cetus U/m2/d, followed after a rest period of 2 days by 5-FU, 600 mg/m2/d, and FA, 300 mg/m2/d over an additional 3 days."5.07Interleukin-2 followed by fluorouracil and folinic acid in refractory colorectal cancer--results of a clinical phase II study. ( Hiddemann, W; Koch, O; Musch, E; Ottensmeier, C; Rückle, H; Ruelfs, C; van de Loo, J, 1992)
"A total of 183 patients with advanced, but asymptomatic colorectal cancer were randomly allocated to receive either initial treatment with sequential methotrexate 250 mg/m2 during the first 2 hours, and fluorouracil (5-FU) 500 mg/m2 at hours 3 and 23 followed by leucovorin rescue initiated at hour 24 (MFL) for 12 courses or to primary expectancy with chemotherapy not considered until symptoms appeared."5.07Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. ( , 1992)
"One hundred eighty-one patients with measurable recurrent or metastatic colorectal cancer, who had not received prior chemotherapy, were randomized in a prospective controlled trial to receive 5-fluorouracil (5FU), 13."5.07Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). ( Bacchi, M; Bartolucci, R; Belsanti, V; Boni, C; Calabresi, F; Di Costanzo, F; Marzola, M; Sofra, M, 1992)
"The mechanisms of biochemical modulation of 5-fluorouracil (5-FU) cytotoxicity by folinic acid (FA) have been elucidated, and the clinical use of this combination has improved response rates and survival in patients with metastatic colorectal cancer."5.07A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma. ( Bauer, L; Budd, GT; Bukowski, RM; Gibson, V; Inoshita, G; Murthy, S; Prestifilippo, J; Sergi, JS; Yalavarthi, P, 1992)
"5-Fluorouracil (5-FU) remains the most effective chemotherapeutic agent in the management of patients with metastatic colorectal cancer."5.07Treatment of advanced colorectal cancer by 5-fluorouracil-leucovorin combination with or without allopurinol: a prospective randomized study. ( Chaitchik, S; Inbar, M; Merimsky, O, 1991)
"To report a new syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia after treatment with N-phosphonacetyl-L-aspartate (PALA) and fluorouracil for metastatic colorectal cancer."5.07A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) ( Costa, P; Kemeny, N; Kurtz, RC; Martin, D; Murray, M; Niedzwiecki, D; Seiter, K; Urmacher, C, 1991)
"Hepatic intra-arterial (HIA) infusion of floxuridine (FUDR) via an implanted pump has shown promise in the treatment of colorectal cancer metastasized to the liver."5.07Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. ( Chase, JL; Grobman, BJ; Hohn, DC; Lewis, BJ; Mulvihill, SJ; Rayner, AA; Roh, M; Stagg, RJ; Venook, AP; Warren, RS, 1991)
"Effectiveness, toxicity and complications of 5-fluorouracil (FU) and mitomycin-C (MMC) treatment were analyzed in 30 patients with metastatic colorectal cancer confined to the liver."5.07Phase II study of intra-arterial fluorouracil and mitomycin-C for liver metastases of colorectal cancer. ( Largiadèr, F; Metzger, U; Röthlin, M; Weder, W, 1991)
"A phase I study of 5-fluorouracil 600 mg/m2/week and folinic acid 500 mg/m2/week on day 1 and cisplatin administered weekly on day 2 was carried out on 30 patients with metastatic colorectal carcinoma of which 20 patients were pretreated with 5-fluorouracil."5.07A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma. ( Creaven, P; Gebbia, N; Gebbia, V; Palmeri, S; Petrelli, N; Rausa, L; Russo, A; Rustum, Y, 1991)
"Fourteen patients (group A) with unresectable metastasis to the liver from colorectal cancers (11 patients) and gastric cancers (3 patients) were treated with the combined application of hyperthermia and intra-hepato-arterial (IHA) chemotherapy with cisplatinum and 5-fluorouracil."5.07A phase II pilot study of the combined application of hyperthermia and intra-hepato-arterial chemotherapy using cisplatinum and 5-fluorouracil. ( Hamazoe, R; Hirooka, Y; Kaibara, N; Maeta, M; Murakami, A, 1991)
"In a previous study (J Clin Oncol 7:1407-1417, 1989), we identified two dosage administration schedules of fluorouracil (5FU) combined with leucovorin that were superior to single-agent 5FU for the treatment of advanced colorectal cancer."5.07Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. ( Gerstner, JB; Kardinal, CG; Krook, JE; Levitt, R; Mailliard, JA; O'Connell, MJ; Poon, MA; Tschetter, LK; Wieand, HS, 1991)
"One hundred eighty-four patients with advanced measurable colorectal cancer not previously treated with chemotherapy were entered into a prospective randomized clinical trial by the Mid-Atlantic Oncology Program (MAOP) to assess the value of weekly cisplatin (20 mg/m2) when added to a protracted schedule of 5-fluorouracil (5-FU) infusion (PIF) at 300 mg/m2/d for 10 weeks of every 12 weeks."5.07A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program study. ( Ahlgren, JD; Alt, DE; Cantrell, J; Fryer, JG; Gullo, JJ; Heim, WJ; Lokich, JJ; Wampler, GL, 1991)
"The importance of the interval between methotrexate (MTX) and fluorouracil (5-FU) was studied in 168 patients with previously untreated, measurable, advanced colorectal cancer."5.07The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. ( Bertino, JR; Capizzi, RL; Davis, CA; Durivage, HJ; Farber, LR; Katz, KH; Marsh, JC; Pasquale, DN; Richards, F; Rome, LS, 1991)
"Forty four patients who had documented progression of metastatic colorectal cancer while receiving 5-fluorouracil (5-FU) monotherapy were treated with continuous infusion 5-FU, 300 mg/mg2/day, plus weekly low-dose cisplatin, 20 mg/m2."5.07Protracted infusion of 5-FU with weekly low-dose cisplatin as second-line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy. ( Ahlgren, JD; Goldberg, R; Gullo, JJ; Muir, WA; Schacter, L; Sisk, R; Trocki, O, 1991)
"Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection."5.06Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. ( Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Martin, JK; Nagorney, DM; O'Connell, MJ; Rubin, J; Tschetter, LK; Wieand, HS, 1990)
"Protection by prolonged administration of allopurinol against high-dose 5-fluorouracil (5-FU) administered with folinic acid in 74 patients with colorectal cancer was investigated."5.06Folinic acid plus high-dose 5-fluorouracil with allopurinol protection in the treatment of advanced colorectal carcinoma. ( Bacoyannis, C; Kosmidis, P; Magoulas, D; Milonakis, N; Sarafidou, M; Tsavaris, N; Zamanis, N, 1990)
"Pursuant to a promising report suggesting that an allopurinol mouthwash could have a protective effect against 5-fluorouracil (5-FU)-induced stomatitis, the authors performed a randomized, placebo-controlled, double-blind, crossover study."5.06A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. ( Athmann, LM; Burnham, NL; Cianflone, SG; Cross, M; Dose, AM; Etzell, PS; Gainey, DK; Hagen, L; Loprinzi, CL; Therneau, TM, 1990)
"We have performed a prospective randomized controlled study of 5-fluorouracil (5FU) + leucovorin versus 5FU alone in patients with metastatic colorectal cancer."5.06Fluorouracil and leucovorin for metastatic colorectal cancer. ( Erlichman, C, 1990)
"A novel sequential administration schedule of PALA (N-phosphonoacetyl-L-aspartate) and thymidine to enhance the cytotoxic effect of 5-fluorouracil (5FU) was tested in 36 patients with advanced gastric cancer and 21 patients with advanced poorly differentiated (anaplastic) colorectal cancer."5.06A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer. ( Goldberg, RM; Krook, JE; Kugler, JW; Laurie, JA; Moertel, CG; O'Connell, MJ; Pfeifle, DM; Rubin, J; Wieand, HS; Windschitl, HE, 1990)
"A total of 21 untreated patients (5 males, 16 females; median age, 55 years; range, 28-72) with advanced measurable colorectal carcinoma were treated with an association of 5-fluorouracil (1000 mg/weekly) and alpha-2 interferon (three times a week s."5.06Alpha-2 interferon and 5-fluorouracil in advanced colorectal cancer. ( Aversa, SM; Daniele, O; Fiorentino, MV; Fornasiero, A; Ghiotto, C; Morandi, P, 1990)
"Four single-arm trials using methotrexate (M), 5-fluorouracil (5FU), and leucovorin (L) were sequentially performed in metastatic measurable colorectal cancer using different dosing and timing schedules for the three drugs."5.06Sequential methotrexate, 5-fluorouracil, and leucovorin in metastatic measurable colorectal cancer. Does it work? ( Cripps, C; Johnston, J; Maroun, J; Stewart, D; Weinerman, B, 1990)
"We conducted a phase II clinical trial of fluorouracil (5FU) and recombinant interferon alfa-2a (rIFN alpha-2a) in 52 previously untreated patients with bidimensionally measurable metastatic colorectal cancer."5.06Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma. ( Ajani, JA; Campos, L; DuBrow, R; Faintuch, J; Jackson, D; Patt, YZ; Pazdur, R; Quaraishi, M; Shepard, B; Winn, R, 1990)
"A prospective controlled randomized trial testing adjuvant postoperative combination chemotherapy (5-fluorouracil, lomustine (CCNU) and vincristine) versus no adjuvant therapy in patients operated on for Dukes' C colorectal cancer is reported."5.06Adjuvant chemotherapy with 5-fluorouracil, vincristine and CCNU for patients with Dukes' C colorectal cancer. The Swedish Gastrointestinal Tumour Adjuvant Therapy Group. ( Asklöf, G; Bergman, L; Domellöf, L; Hafström, L; Hansson, K; Kugelberg, C; Nilsson, T; Norryd, C; Rudenstam, CM; Wählby, L, 1990)
"We randomized 224 patients with resected Dukes' stage B2 or C colorectal cancer to either an untreated control group or to a group receiving 7 days of fluorouracil therapy (500 mg/m2 per day) by portal vein infusion."5.06Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group. ( Beart, RW; Fitzgibbons, RJ; Leigh, JE; Moertel, CG; van Heerden, JA; Wieand, HS; Windschitl, HE; Wolff, BG, 1990)
"The Mayo Clinic and the North Central Cancer Treatment Group (NCCTG) conducted a randomized clinical trial comparing five different combination chemotherapeutic regimens to single-agent 5-fluorouracil (5-FU), given by intravenous bolus technique (500 mg/m2 for 5 days) as a control, in the treatment of advanced colorectal cancer."5.06A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. ( O'Connell, MJ, 1989)
"Ninety-one patients with metastatic colorectal cancer were treated with continuous ambulatory 5-fluorouracil (5FU) infusion 250-300 mg/m2/day through a chronic indwelling central venous catheter."5.06Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: results in 91 patients. ( Anderson, T; Ausman, R; Beatty, P; Frick, J; Haas, C; Hansen, R; Quebbeman, E; Ritch, P; Schulte, W, 1989)
"A total of 249 patients with advanced, symptomatic colorectal cancer who received no previous cytostatic therapy were randomly allocated to receive either fluorouracil (5-FU), 600 mg/m2, for 2 days or the following regimen: sequential methotrexate, 250 mg/m2, during the first 2 hours and 5-FU, 500 mg/m2, at hours 3 and 23 followed by leucovorin rescue initiated at hour 24 (15 mg x 8) (MFL)."5.06Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial. ( , 1989)
"The effect of hepatic irradiation (RT) after intraarterial 5-fluorouracil (5-FU) was evaluated in 37 randomized patients with colorectal adenocarcinoma hepatic metastases."5.06Combined hepatic artery 5-fluorouracil and irradiation of liver metastases. A randomized study. ( Demets, D; Lee, JW; Ramirez, G; Stephenson, JA; Wiley, AL; Wirtanen, GW, 1989)
"5-Fluorouracil (5-FU) is an essential component of systemic chemotherapy for colorectal cancer (CRC) in the palliative and adjuvant settings."5.055-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. ( Buchler, T; Cervena, K; Veskrnova, V; Vodenkova, S; Vodicka, P; Vymetalkova, V, 2020)
"We included one randomised clinical trial with 61 participants (43 male and 18 female) with colorectal cancer with liver metastases: 22 received transarterial embolisation (TAE; hepatic artery embolisation), 19 received transarterial chemoembolisation (TACE; 5-fluorouracil hepatic artery infusion chemotherapy with degradable microspheres), and 20 received 'no active therapeutic intervention' as a control."5.05Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases. ( Bala, MM; Kleijnen, J; Mitus, JW; Pedziwiatr, M; Riemsma, RP; Storman, D; Swierz, MJ; Wolff, R, 2020)
"The clinical benefits of a combination of leucovorin and fluorouracil have been established in the treatment of colorectal cancer."5.05Efficacy and safety of high-dose vs low-dose leucovorin in patients with colorectal cancer: systematic review and meta-analysis. ( Chen, CY; Hsu, CY; Lin, YM; Tam, KW, 2020)
"The combination of oxaliplatin, irinotecan, fluorouracil (5-FU), and leucovorin (FOLFOXIRI) results in improved outcomes compared with standard chemotherapy when used in frontline to treat patients with metastatic colorectal cancer (mCRC)."5.01FOLFOXIRI plus biologics in advanced colorectal cancer. ( Gallego, I; García, G; García-Alfonso, P; Lloansí, A; Muñoz, A; Ortega, L; Sandoval, C; Torres, G, 2019)
"We performed the present systematic review and meta-analysis to evaluate the efficacy and safety for S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma (mCRC)."5.01Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis. ( Chen, J; Wang, J, 2019)
"5-Fluorouracil (5-Fu) is one of the most commonly prescribed antineoplastic agents against gastric and colorectal cancers."4.98Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis. ( Meng, F; Wang, Y; Xing, X; Zhang, L; Zhong, D, 2018)
"The clinical benefit of double-front-line therapy (including oxaliplatin or irinotecan or bevacizumab plus 5-fluorouracil (5FU) or capecitabine) compared to monotherapy (5FU or capecitabine) in elderly (> 70 years) patients with metastatic colorectal cancer (MCRC) is controversial."4.98Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients. ( Aparicio, T; Ghebriou, D; Guetz, GD; Landre, T; Maillard, E; Taleb, C; Zelek, L, 2018)
"5-Fluorouracil- and leucovorin-based chemotherapy regimens are the backbone of colorectal cancer treatment."4.98Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment? ( Bironzo, P; Di Maio, M; Scagliotti, GV; Tampellini, M, 2018)
"Nowadays, systemic chemotherapy with intravenous (IV) 5-fluorouracil (5-FU) remains the most commonly prescribed treatment for metastatic colorectal cancers (CRC), in combination with other cytotoxic drugs."4.98Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis. ( Deng, Y; Wu, Z, 2018)
"The last decade has seen the increasing use of biological medicines in combination with chemotherapy containing 5-fluorouracil/oxaliplatin or irinotecan for the treatment of metastatic colorectal cancer (mCRC)."4.98Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. ( Almeida, PHRF; Andrade, EIG; Cherchiglia, ML; da Silva, WC; de Araujo, VE; de Assis Acurcio, F; Dos Santos, JBR; Godman, B; Kurdi, A; Lima, EMEA; Silva, MRRD, 2018)
"The combination of fluorouracil, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-Bev) is an established and effective first-line chemotherapy regimen for metastatic colorectal cancer."4.95FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis. ( Barni, S; Ghidini, M; Passalacqua, R; Petrelli, F; Russo, A; Tomasello, G, 2017)
", folinic acid (FOL), fluorouracil (F) and oxaliplatin (OX), is a drug cocktail that is used to treat gastric and colorectal cancers."4.95Prognosis and treatment of FOLFOX therapy related interstitial pneumonia: a plea for multimodal immune modulating therapy in the respiratory insufficient patient. ( De Weerdt, A; Dendooven, A; Jorens, PG; Lammens, M; Pen, J; Snoeckx, A, 2017)
"Recent studies suggest that 5-fluorouracil (5-FU) dosing by use of pharmacokinetic (PK) parameters is superior to the traditional body surface area (BSA) method in colorectal cancer therapy."4.93Individual 5-Fluorouracil Dose Adjustment via Pharmacokinetic Monitoring Versus Conventional Body-Area-Surface Method: A Meta-Analysis. ( Han, Y; Lyu, Y; Tong, Q; Yang, P; Yang, R; Zhang, P; Zhang, Y; Zhou, H, 2016)
"The antiangiogenic monoclonal antibody aflibercept in association with fluorouracil and irinotecan improves the survival of patients with metastatic colorectal cancer (mCRC) treated previously with oxaliplatin-based therapy."4.93Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district. ( Ciuffreda, L; Fanchini, L; Mecca, C; Pinta, F; Ponzetti, A; Racca, P; Spadi, R; Zanini, M, 2016)
"This meta-analysis aims to evaluate chemotherapy with XELOX (capecitabine plus oxaliplatin) versus FOLFOX (fluorouracil plus oxaliplatin) as a treatment for metastatic colorectal cancer (mCRC) in terms of efficacy and safety."4.93XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis. ( Cheng, Y; Guo, Y; Ma, L; Xiong, BH; Zhang, T, 2016)
" Here, we carried out a network meta-analysis to assess the clinical efficacy and safety of CHIs combined with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) for advanced colorectal cancer (CRC)."4.93Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer. ( Ge, L; Mao, L; Shen, XP; Tian, JH; Wang, YF; Yang, KH; Zhang, J; Zhang, JH, 2016)
"Folate was identified as an essential micronutrient early in the twentieth century and anti-folate chemotherapy such as 5-fluorouracil (5-FU) has been central to the medical management of solid tumours including colorectal cancer for more than five decades."4.91How folate metabolism affects colorectal cancer development and treatment; a story of heterogeneity and pleiotropy. ( Jennings, BA; Willis, G, 2015)
"Capecitabine is a tumor-activated oral fluoropyrimidine used in breast and colorectal cancer."4.91Hypertriglyceridemia and hyperglycemia induced by capecitabine: a report of two cases and review of the literature. ( Han, GH; Huang, JX, 2015)
"The relative efficacy and safety of first-line metastatic colorectal cancer (mCRC) treatment regimens, capecitabine with irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI), are not well defined."4.91Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI). ( Cao, J; Ding, HH; Ji, ZY; Jiang, T; Jin, JH; Song, WF; Wang, JJ; Wang, LW; Wu, WD, 2015)
"The National Institute for Health and Care Excellence (NICE) invited the manufacturer of aflibercept (Sanofi) to submit clinical and cost-effectiveness evidence for aflibercept in combination with irinotecan and fluorouracil-based therapy [irinotecan/5-fluorouracil/folinic acid (FOLFIRI)] for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy, as part of the Institute's Single Technology Appraisal process."4.91The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of ( Duarte, A; Duffy, S; Rodriguez-Lopez, R; Simmonds, M; Spackman, E; Wade, R; Woolacott, N, 2015)
"Oxaliplatin and either capecitabine or infusional/bolus 5-fluorouracil (5FU)-based chemotherapy + bevacizumab (XELOX + B and FOLFOX + B) represent 2 of the approved first-line treatments for advanced colorectal cancer (CRC)."4.91Efficacy of oxaliplatin-based chemotherapy + bevacizumab as first-line treatment for advanced colorectal cancer: a systematic review and pooled analysis of published trials. ( Barni, S; Cabiddu, M; Coinu, A; Ghilardi, M; Petrelli, F; Zaniboni, A, 2015)
"The clinical benefit of first-line doublet chemotherapy (including oxaliplatin or irinotecan) compared to single-drug therapy (5FU) in elderly patients (>70 or >75 years old) with metastatic colorectal cancer (MCRC) is controversial."4.91Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis. ( Aparicio, T; Des Guetz, G; Landre, T; Mary, F; Nicolas, P; Taleb, C; Uzzan, B; Zelek, L, 2015)
"5-fluorouracil continues to be the cornerstone of treatment for colorectal cancer."4.90Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed. ( Avallone, A; Budillon, A; Di Gennaro, E; Iaffaioli, VR; Silvestro, L, 2014)
"An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer."4.90Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014)
"We tested candidate polymorphisms identified from a systematic literature search for associations with capecitabine toxicity in 927 patients with colorectal cancer in the Quick and Simple and Reliable trial (QUASAR2)."4.90Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. ( Afzal, S; Boige, V; Braun, M; Church, D; Domingo, E; Enghusen, H; Etienne-Grimaldi, MC; Garcia-Foncillas, J; Garmo, H; Glimelius, B; Gonzalez-Neira, A; Green, E; Gusella, M; Jensen, SA; Johnstone, E; Jones, A; Julier, P; Kerr, D; Kleibl, Z; Lacas, B; Laurent-Puig, P; Lecomte, T; Love, S; Martin, M; Martinez-Balibrea, E; McLeod, H; Midgley, R; Milano, G; Morel, A; Nicholson, G; Palles, C; Pignon, JP; Ribelles, N; Rosmarin, D; Sargent, D; Schwab, M; Scudder, C; Seymour, M; Sharma, R; Thompson, L; Tomlinson, I; Wadelius, M; Wang, H; Zanger, UM, 2014)
" All included patients who were treated for colorectal cancer, mainly with oxaliplatin in combination with 5-fluorouracil/leucovorin."4.90A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. ( Beijers, AJ; Mols, F; Vreugdenhil, G, 2014)
"Oxaliplatin, irinotecan and 5-fluorouracil in combination with or without targeted therapies are well-documented treatment options for first- and second-line treatments of metastatic colorectal cancer."4.90A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy. ( Jensen, BV; Larsen, FO; Nielsen, DL; Palshof, JA; Pfeiffer, P, 2014)
"While 5-fluorouracil used as single agent in patients with metastatic colorectal cancer has an objective response rate around 20%, the administration of combinations of irinotecan with 5-fluorouracil/folinic acid or oxaliplatin with 5-fluorouracil/folinic acid results in significantly increased response rates and improved survival."4.90FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy. ( Melichar, B; Mohelnikova-Duchonova, B; Soucek, P, 2014)
"Thymidylate synthetase is the major target of 5-fluorouracil (5-FU), which is widely used for the treatment of gastric cancer (GC) and colorectal cancer (CRC)."4.89An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens. ( Fang, JY; Wang, YC; Wang, ZH; Xue, HP, 2013)
"Irinotecan and infusional bolus 5-fluorouracil (5-FU)-based chemotherapy (FOLFIRI [5-fluorouracil, folinic acid, irinotecan]) + bevacizumab (FOLFIRI-B) is 1 of the cornerstones of first-line treatment of advanced colorectal cancer (CRC)."4.89FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. ( Barni, S; Beretta, GD; Borgonovo, K; Cabiddu, M; Ghilardi, M; Lonati, V; Maspero, F; Petrelli, F; Sauta, MG, 2013)
"This meta-analysis was performed to determine whether the addition of monoclonal antibodies (mAbs) of epidermal growth factor receptor (EGFR) to oxaliplatin-based chemotherapy treatment improves efficacy in KRAS wild-type metastatic colorectal cancer (mCRC), and whether infusional 5-fluorouracil (5-FU) and oxaliplatin is a preferred combination for EGFR mAbs."4.89Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody. ( Du, Z; He, X; Hu, Q; Li, M; Li, Q; Sang, Y; Tang, R; Wen, F; Zhang, P; Zhou, Y, 2013)
"Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based."4.89Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. ( Cool, M; Deboever, G; Hiltrop, N; Lambrecht, G, 2013)
"Irinotecan and infusional 5-fluorouracil-based chemotherapy (FOLFIRI) plus bevacizumab (FOLFIRI-B) is one of the most effective treatments of advanced colorectal cancer (CRC)."4.89FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials. ( Barni, S; Beretta, GD; Borgonovo, K; Cabiddu, M; Ghilardi, M; Petrelli, F; Squadroni, M; Stinco, S, 2013)
"The aim of this pooled-analysis is to evaluate the benefit of capecitabine (C) versus standard intravenous 5-Fluorouracil (5-FU) as monochemotherapy or combination therapy in advanced colorectal cancer (CRC) in terms of safety and efficacy."4.885-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials. ( Barni, S; Cabiddu, M; Petrelli, F, 2012)
"Many primary studies have considered the association of polymorphisms of folate metabolism and response to 5-fluorouracil (5-FU) and capecitabine in patients with colorectal cancer."4.88Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis. ( Jennings, BA; Kwok, CS; Loke, YK; Matthews, V; Wawruch, P; Willis, G, 2012)
"Bevacizumab has efficacy in first-line treatment of advanced colorectal cancer, but the current data are insufficient to support efficacy in all regimens, especially infusional fluorouracil regimens, like FOLFIRI and FOLFOX."4.88Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. ( da Costa Lima, AB; Macedo, LT; Sasse, AD, 2012)
"To evaluate the benefit and safety of fluorouracil implants on colorectal cancer."4.88[Fluorouracil implants for colorectal cancer: a systematic review and meta-analysis]. ( Chen, JR; Huang, Y; Li, YL; Nie, YL; Zhang, MM, 2012)
" In the USA, the approval of cetuximab has been recently expanded to include the first-line treatment of patients with KRAS mutation-negative (wild-type), EGFR-expressing, metastatic colorectal cancer (mCRC) when used in combination with FOLFIRI (irinotecan, fluorouracil, leucovorin [folinic acid])."4.88Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA. ( Lyseng-Williamson, KA, 2012)
"The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer."4.87Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011)
"The simultaneous administration of irinotecan, 5-fluorouracil, folinic acid and oxaliplatin (FOLFOXIRI) has been compared with standard 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) in randomized trials in metastatic colorectal cancer patients."4.87A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity. ( Chiriatti, A; Fiorentini, G; Francini, G; Montagnani, F; Turrisi, G, 2011)
"Colorectal cancer (CRC) treatment has evolved significantly over the last ten years with the use of active chemotherapeutic agents including fluoropyrimidines, oxaliplatin and irinotecan plus targeted monoclonal antibodies bevacizumab, cetuximab and panitumumab."4.87Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. ( Charles, KA; Chua, W; Clarke, SJ; Kho, PS; Moore, MM, 2011)
"We performed a computerized search using combinations of the following keywords: "metastatic colorectal cancer," "Xeloda," "chemotherapy," "capecitabine," or "5-fluorouracil."4.87Capecitabine-based chemotherapy for metastatic colorectal cancer. ( Fan, J; Ling, W; Ma, Y; Wang, H, 2011)
"The demonstrated efficacy of adding irinotecan, bevacizumab, or cetuximab to fluorouracil-based regimens in the treatment of patients with metastatic colorectal cancer led to several multicenter phase III trials investigating the efficacy of these agents in the adjuvant setting."4.87Adjuvant treatment of colon cancer: what is next? ( Van Loon, K; Venook, AP, 2011)
"We analyzed individual data on 6,284 patients from nine phase III trials of advanced colorectal cancer (aCRC) that used fluorouracil-based single-agent and combination chemotherapy."4.87Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. ( Blanke, CD; Bleyer, A; Bot, BM; de Gramont, A; Goldberg, RM; Kohne, CH; Sargent, DJ; Seymour, MT; Thomas, DM, 2011)
"For decades 5-fluorouracil (5-FU) has remained the treatment of choice in the adjuvant and palliative setting of colorectal cancer (CRC)."4.87DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens. ( Giaccone, G; Giovannetti, E; Hanauske, AR; Leon, LG; Peters, GJ; Smid, K; van Houte, BP, 2011)
"This meta-analysis was performed to evaluate the efficacy and safety of capecitabine plus oxaliplatin vs fluorouracil (FU) plus oxaliplatin as first line treatment for metastatic or advanced colorectal cancer."4.86Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner - meta-analysis of six randomized trials. ( Cao, Y; Gao, F; Liao, C; Liu, L; Mo, Z; Tan, A, 2010)
"We performed a meta-analysis to evaluate the efficacy and safety of Fluorouracil (FU)/Leucovorin (LV)/Oxaliplatin compared to FU/LV in treating advanced colorectal cancer."4.86A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer. ( Chen, ML; Dai, LH; Fang, CH; Liang, LS; Wang, XK, 2010)
"A meta-analysis of randomized controlled trials (RCT) was carried out to determine the efficacy and safety of capecitabine plus oxaliplatin (CAPOX) or fluorouracil plus oxaliplatin (FUOX) as first-line treatment for metastatic colorectal cancer (MCRC)."4.86Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis. ( Gao, P; Ma, B; Tian, JH; Yang, KH; Zhao, G, 2010)
", Nutley, NJ) is an orally administered fluoropyrimidine carbamate that serves as a prodrug of 5-fluorouracil (5-FU), an integral component of chemotherapy (CT) regimens for metastatic colorectal cancer (mCRC)."4.86Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer. ( Boehm, KA; Cartwright, T; McCollum, D, 2010)
"Capecitabine, an oral prodrug of 5-fluorouracil, is indicated for adjuvant treatment in patients with Dukes' C colon cancer and for subsequent lines in metastatic colorectal cancer."4.86Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer. ( Best, JH; Garrison, LP, 2010)
"5-Fluorouracil (5-FU) is a mainstay for treating colorectal cancer, alone or more frequently as part of combination therapies."4.86Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? ( Ciccolini, J; Dahan, L; Gross, E; Lacarelle, B; Mercier, C, 2010)
"Capecitabine is an oral fluoropyrimidine that is shown to have similar efficacy to 5-fluorouracil (5-FU) when used both alone and in combination with oxaliplatin in the treatment of colorectal cancer (CRC)."4.86Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer. ( Aliberti, C; Chiriatti, A; Fiorentini, G; Licitra, S; Montagnani, F, 2010)
"Literature searches from large publication databases (PubMed, ASCO, ASCO GI, ESMO) were performed to capture key data relevant to bevacizumab, irinotecan, and the treatment of colorectal cancer."4.86Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer. ( Heinemann, V; Hoff, PM, 2010)
"To compare clinical efficacy and toxicity of irinotecan combined with 5-fluorouracil and leucovorin with those of oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer."4.86Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis. ( Hou, SH; Li, YP; Liang, XB; Wang, LC; Yang, J; Zhang, X, 2010)
" For colorectal liver metastases (mCRC), in a salvage setting, response was 79% for (90)Y-RE combined with 5-fluorouracil/leucovorin (5-FU/LV), and 79% when combined with 5-FU/LV/oxaliplatin or 5-FU/LV/irinotecan, and in a first-line setting 91% and 91%, respectively."4.85Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. ( Lam, MG; Nijsen, JF; van den Bosch, MA; van der Tweel, I; van Het Schip, AD; Vente, MA; Wondergem, M; Zonnenberg, BA, 2009)
"Capecitabine (N -pentyloxycarbonyl-5-deoxy-5-fluorocytidine), an oral prodrug of 5-fluorouracil, has provided compelling efficacy data for the treatment of metastatic breast cancer and stage III or IV colorectal cancer, both as monotherapy and in combination regimens."4.85Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. ( Aprile, G; Mazzer, M; Moroso, S; Puglisi, F, 2009)
"For many years, 5-fluorouracil was the unique drug approved in the management of colorectal cancer."4.85[Colorectal cancers: prognostic and predictive factors of response to treatment]. ( Italiano, A; Sablin, MP; Spano, JP, 2009)
", the fluoropyrimidine 5-fluorouracil (5-FU) has remained the mainstay of therapeutic regimens used in the treatment of colorectal cancer and other human malignancies, with single-agent response rates of 20% to 25% in advanced disease stage."4.85Thymidylate synthase gene variations: predictive and prognostic markers. ( Lenz, HJ; Lurje, G; Manegold, PC; Ning, Y; Pohl, A; Zhang, W, 2009)
"Over the past decades, significant progress has been achieved in the cytotoxic treatment of colorectal cancer (CRC) by the use of fluoropyrimidines, irinotecan and oxaliplatin."4.85A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? ( Koopman, M; Nagtegaal, ID; Punt, CJ; van Krieken, JH; Venderbosch, S, 2009)
"Relevant studies were identified in PubMed, Ovid, Cochrane database and the American Society of Clinical Oncology abstracts using the following search terms: gemcitabine, fluorouracil, capecitabine and colorectal cancer."4.85Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512). ( Hoimes, C; Merl, M; Pham, T; Saif, MW, 2009)
" In this review, we summarized the current status of our knowledge about the effectiveness of curcumin when given in combination with current chemotherapeutics such as 5-fluorouracil, oxaliplatin, and gemcitabine in treatment of gastrointestinal cancers with particular reference to colorectal cancer."4.85Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview. ( Majumdar, AP; Patel, BB, 2009)
"Continuous-infusion 5-fluorouracil (5-FU)/leucovorin (LV) and oxaliplatin is a frequently used regimen in metastatic colorectal cancer."4.84Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer? ( Bennouna, J; Douillard, JY; Senellart, H, 2008)
"Six randomized phase II and III trials have investigated the role of oxaliplatin (OX) in combination with capecitabine (CAP) or infusional fluorouracil (FU) in metastatic colorectal cancer."4.84Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. ( Arkenau, HT; Arnold, D; Cassidy, J; Diaz-Rubio, E; Douillard, JY; Grothey, A; Hinke, A; Hochster, H; Martoni, A; Porschen, R; Schmiegel, W; Schmoll, HJ, 2008)
"The treatment of metastatic colorectal cancer (mCRC) has changed dramatically from the 1980s, when only fluorouracil (5-FU) was available for treatment and the median survival was at best 12 months, to a time when mCRC is considered more of a chronic disease in which the median survival is now reported in excess of 2 years."4.84First-line therapeutic strategies in metastatic colorectal cancer. ( Davies, JM; Goldberg, RM, 2008)
"5-fluorouracil (5FU)-based treatments remain the main chemotherapy for colorectal cancer."4.84Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer. ( Etienne-Grimaldi, MC; Formento, JL; Francoual, M; Milano, G, 2007)
"Based on improved safety and efficacy results, advanced colorectal cancer (CRC) treatment has recently shifted from intravenous bolus 5-fluorouracil (5-FU) monotherapy to standard combinations of prolonged intravenous 5-FU infusion with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI)."4.84Capecitabine plus oxaliplatin for the treatment of colorectal cancer. ( Carrato, A; Gallego-Plazas, J; Guillén-Ponce, C, 2008)
"Uncertainty exists about whether elderly patients benefit to the same extent as younger patients from combination therapy with irinotecan in the first-line treatment of metastatic colorectal cancer (CRC)."4.84Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. ( Douillard, JY; Folprecht, G; Hecker, H; Köhne, CH; Maughan, TS; Mitry, E; Rougier, P; Saltz, L; Schubert, U; Seymour, MT; Stephens, RJ; Van Cutsem, E, 2008)
"Capecitabine, an oral prodrug of fluorouracil (5FU), has shown efficacy in terms of progression-free and overall survival at least equivalent to standard folinic acid (leucovorin)-modulated intravenous 5FU bolus regimens in patients with metastatic colorectal cancer."4.84Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence. ( Avallone, A; Casaretti, R; Comella, P; Franco, L; Sandomenico, C, 2008)
"To evaluate three technologies for the management of advanced colorectal cancer: (1) first-line irinotecan combination [with 5-fluorouracil (5-FU)] or second-line monotherapy; (2) first- or second-line oxaliplatin combination (again, with 5-FU); and (3) raltitrexed, where 5-FU is inappropriate."4.84The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. ( Eggington, S; Hind, D; Ryan, A; Sutcliffe, P; Tappenden, P; Tumur, I, 2008)
"Modern chemotherapy combinations for metastatic colorectal cancer (mCRC) comprise infusional 5-fluorouracil (5-FU), leucovorin, and irinotecan or oxaliplatin."4.84Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer. ( Heinemann, V; Moosmann, N, 2008)
"In Western countries, efficacy of 5-fluorouracil (5-FU)+leucovorin (LV) as adjuvant chemotherapy for colorectal cancer has been already established."4.83[Adjuvant chemotherapy for colorectal cancer]. ( Akasu, T, 2006)
"We reviewed published studies reporting phase II and III clinical trials of dose-dense regimens for breast cancer and NHL, TAC (docetaxel, adriamycin, cyclophosphamide) chemotherapy for breast cancer, and infusional 5-fluorouracil-based regimens for colorectal cancer."4.83Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. ( Avritscher, EB; Bekele, BN; Cooksley, CD; Elting, LS; Jones, JA; Michelet, M, 2006)
"In a dozen years of development, irinotecan (CPT11) became one of major therapeutics in the taking care of the metastatic colorectal cancer (CCRM)."4.83[Irinotecan for the treatment of metastatic colorectal cancer]. ( Assenat, E; Duffour, J; Ychou, M, 2006)
"A combination of irinotecan (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is one of the standard treatments for advanced colorectal cancer patients."4.83[Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer]. ( Goto, A, 2006)
"An IFL regimen combining irinotecan, a bolus administration of 5-fluorouracil (5-FU) and leucovorin (LV) was associated with a significantly better response rate, progression-free survival and median overall survival, compared to 5-FU/LV against metastatic colorectal cancer."4.83[IFL]. ( Boku, N; Yamazaki, K; Yoshino, T, 2006)
" A phase III randomized trial, Xeloda in Adjuvant Colorectal Cancer Treatment, demonstrated that treatment with single-agent capecitabine was equivalent to bolus 5-fluorouracil with leucovorin with respect to disease-free survival and overall survival, with significantly less diarrhea, stomatitis, neutropenia, nausea and vomiting, and alopecia."4.83Capecitabine: a new adjuvant option for colorectal cancer. ( Berg, DT, 2006)
"Oxaliplatin, fluorouracil, and leucovorin are commonly used to treat advanced and resected colorectal cancer."4.83Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. ( Andre, T; Bleiberg, H; de Gramont, A; Goldberg, RM; Green, E; Rothenberg, ML; Sargent, DJ; Tabah-Fisch, I; Tournigand, C, 2006)
"Bevacizumab, a monoclonal antibody to vascular endothelial growth factor, was approved in 2004 for use in combination with intravenous 5-fluorouracil-based chemotherapy for the treatment of metastatic colorectal cancer."4.83Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer. ( Hochster, HS, 2006)
"The synergism between oxaliplatin and 5-fluorouracil (5FU)/leucovorin in the treatment of colorectal cancer raises the prospect of further clinically effective combinations."4.82New oxaliplatin-based combinations in the treatment of colorectal cancer. ( Cassidy, J; Hochster, H, 2003)
"5-Fluorouracil (5-FU) and irinotecan are now widely used for the treatment of advanced colorectal cancer."4.82Optimal use of the combination of irinotecan and 5-fluorouracil. ( Benson, AB; Goldberg, RM, 2003)
"Since its synthesis over 40 years ago, several studies including patients with colorectal cancer have shown that prolonged exposure to 5-fluorouracil (5-FU) is associated with better antitumor activity and decreased toxicity."4.82Practical considerations in the use of oral fluoropyrimidines. ( Hoff, PM, 2003)
"In patients with stage III colorectal cancer (CRC) who have undergone potentially curative resection, adjuvant treatment with 6 months' of 5-fluorouracil (5-FU) plus folinic acid (FA) is generally accepted as standard treatment and leads to a 5% to 10% improvement in absolute survival when compared with a no-chemotherapy control."4.82Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. ( Cascinu, S; Georgoulias, V; Kerr, D; Labianca, R; Maughan, T; Ychou, M, 2003)
"5-Fluorouracil (5-FU), used according to several types of administration and several modulations, remained the standard treatment of colorectal cancer for many years."4.82Colorectal cancer: integrating oxaliplatin. ( de Gramont, A; Louvet, C, 2003)
"During the last decade, considerable progress has been made in the development of 5-fluorouracil/leucovorin (5-FU/LV) regimens that optimize antitumor efficacy while minimizing toxicity in the management of colorectal cancer."4.82Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer. ( de Gramont, A; Kuebler, JP, 2003)
"Irinotecan (CPT-11, Camptosar) is one of the new generation of chemotherapeutic agents that has activity in advanced colorectal cancer."4.82Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule. ( Eisenberg, SG; Hwang, JJ; Marshall, JL, 2003)
"To evaluate the clinical and cost-effectiveness of capecitabine and tegafur with uracil (UFT/LV) as first-line treatments for patients with metastatic colorectal cancer, as compared with 5-fluorouracil/folinic acid (5-FU/FA) regimens."4.82Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. ( Brewer, N; Cowan, J; Kaltenthaler, E; Ward, S, 2003)
"5-fluorouracil (5-FU) plus leucovorin (LV) therapy is the most widely used regimen with a high evidence as the first-line treatment for advanced colorectal cancer (CRC), as well as CPT-11 as the second-line."4.82[Chemotherapy for colorectal carcinoma]. ( Enomoto, M; Higuchi, T; Sugihara, K; Uetake, H, 2003)
" Oral prodrugs of 5-FU, such as capecitabine and uracil, have been developed in order to mimic the protracted infusion schedule of 5-FU, and these drugs may change the daily practice of palliative chemotherapy for colorectal cancer in the coming years."4.82New developments in systemic chemotherapy in advanced colorectal cancer. ( Cats, A, 2003)
"Four phase III clinical trials comparing a fluorouracil-based regimen with the same regimen plus either CPT-11 or oxaliplatin in advanced colorectal cancer patients were reviewed."4.82Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11. ( Bleiberg, H; Buyse, M; Di Leo, A, 2004)
"Fluorouracil (FU)-leucovorin (LV), irinotecan, and oxaliplatin administered alone or in combination have proven effective in the treatment of advanced colorectal cancer (CRC)."4.82Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. ( Goldberg, RM; Grothey, A; Sargent, D; Schmoll, HJ, 2004)
"For advanced colorectal cancer (ACC), 5-fluorouracil (5-FU) based chemotherapy has been the standard for some decades."4.82Systemic treatment of advanced colorectal carcinoma. ( Punt, CJ; van Laarhoven, HW, 2004)
"Comparative trials of capecitabine (Xeloda) versus 5-FU/LV in metastatic colorectal cancer have shown that hand-foot syndrome (HFS) was the only clinical adverse event occurring more frequently with capecitabine."4.82Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). ( Hoff, P; Lassere, Y, 2004)
"Switching patients from intravenous 5-FU/LV to oral capecitabine (Xeloda) for the treatment of metastatic colorectal cancer is associated with a reduction in the need for hospitalisations to manage 5-FU-associated delivery and complications, with resulting healthcare savings."4.82Implementation of capecitabine (Xeloda) into a cancer centre: UK experience. ( Deery, P; Faithfull, S, 2004)
"The modulation of fluorouracil (FU) by folinic acid (leucovorin [LV]) has been shown to be effective in terms of tumor response rate in patients with advanced colorectal cancer, but a meta-analysis of nine trials previously published by our group failed to demonstrate a statistically significant survival difference between FU and FU-LV."4.82Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. ( Braud, AC; Buyse, M; Carlson, RW; Michiels, S; O'Connell, M; Piedbois, P; Pignon, JP; Sargent, P; Thirion, P, 2004)
" Although fluorouracil (5-FU) has been used for over 40 years, only in the last decade has its value been recognized in the treatment of advanced colorectal cancer."4.82Evidence-based update of chemotherapy options for metastatic colorectal cancer. ( Damjanovic, D; Findlay, MP; Thompson, P, 2004)
"Hand-foot syndrome is a localized cutaneous side effect associated with the administration of several chemotherapeutic agents, including the oralfluoropyrimidine capecitabine (Xeloda)."4.82Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. ( Blum, J; Scheithauer, W, 2004)
"New results presented at ASCO Conference in 2003 added further important data to our knowledge on successful use of irinotecan in colorectal cancer (CRC)."4.82[Recent results of irinotecan therapy in colorectal cancer]. ( Hitre, E; Láng, I, 2004)
"Variations of fluorouracil (5-FU) therapy have formed the backbone of chemotherapy for advanced colorectal cancer for many years."4.82Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics. ( Hwang, JJ, 2004)
"5-Fluorouracil (5-FU) plus leucovorin (LV) has been the mainstay of treatment for colorectal cancer (CRC), with infused schedules more widely adopted in Europe and bolus schedules preferred in North America."4.82Oral capecitabine: bridging the Atlantic divide in colon cancer treatment. ( Tejpar, S; Van Cutsem, E; Verslype, C, 2005)
"Fluorouracil (FU) has been the mainstay of treatment for metastatic colorectal cancer (mCRC) for many years."4.82Critical evaluation of current treatments in metastatic colorectal cancer. ( Venook, A, 2005)
"In 2002, the UK National Institute for Clinical Excellence (NICE) issued guidance on the use of irinotecan, oxaliplatin and raltitrexed in advanced colorectal cancer."4.82The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. ( Poston, GJ, 2005)
"Since the introduction of combined systemic chemotherapy with 5-folinic-acid (FA) and/or oxaliplatin or irinotecan, the median survival in patients with advanced colorectal cancer has increased to more than 20 months."4.82Indications and effect on survival of standard chemotherapy in advanced colorectal cancer. ( Kallinowski, B, 2005)
"Irinotecan is a cornerstone drug in the management of metastatic colorectal cancer, as demonstrated by several randomized studies proving a survival benefit for the first time."4.82Irinotecan-based regimens in the adjuvant therapy of colorectal cancer. ( Douillard, JY, 2005)
"In recent years, oxaliplatin-based chemotherapy protocols, particularly oxaliplatin in combination with infusional 5-fluorouracil/leucovorin (FOLFOX or FUFOX), have emerged as the standard of care in first- and second-line therapy of advanced-stage colorectal cancer."4.82Clinical management of oxaliplatin-associated neurotoxicity. ( Grothey, A, 2005)
" Of these, capecitabine is the most established, with registrations in most countries for breast and colorectal cancer."4.82Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer. ( Cassidy, J, 2005)
"Capecitabine is active against anthracycline- and taxane-pretreated metastatic breast cancer."4.82Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. ( Gauthier, AM; Hennessy, BT; Hortobagyi, G; Michaud, LB; Valero, V, 2005)
"Significant advances have been made in the treatment of advanced colorectal cancer over the past 5 years, namely due to the introduction of three novel cytotoxic agents-capecitabine (Xeloda), irinotecan (Camptosar), and oxaliplatin (Eloxatin)-and the recent approval of two biologic agents-bevacizumab (Avastin) and cetuximab (Erbitux)."4.82Current therapies for advanced colorectal cancer. ( Aggarwal, S; Chu, E, 2005)
"We examined the cardiotoxicity in 153 patients treated with capecitabine and oxaliplatin in two prospective trials for advanced colorectal cancer."4.82The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). ( Cunningham, D; Ng, M; Norman, AR, 2005)
"For the last four decades, fluorouracil (FU) has been the main treatment of choice in colorectal cancer (CRC) in both the advanced and adjuvant settings."4.82Role of genomic markers in colorectal cancer treatment. ( Allen, WL; Johnston, PG, 2005)
"For more than 40 years, 5-fluorouracil (5-FU) has been considered the most effective systemic agent for managing advanced colorectal cancer."4.82Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. ( Saif, MW, 2005)
"For several decades, 5-fluorouracil (5-FU) with or without leucovorin defined the standard of care for the treatment of metastatic colorectal cancer (CRC)."4.82Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. ( Hurwitz, H; Kabbinavar, F, 2005)
"For four decades, 5-fluorouracil was the only option available for patients with metastatic colorectal cancer."4.82Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy. ( Hoff, PM; Varadhachary, GR, 2005)
"The addition of oxaliplatin and irinotecan to the armamentarium for the treatment of colorectal cancer (CRC) has resulted in significant improvements in response rates and survival."4.82The role of bevacizumab as first-line therapy for colon cancer. ( Marshall, J, 2005)
"Recent trials have established the IFL combination (fluorouracil [5-FU], leucovorin, and irinotecan [CPT-11, Camptosar]) as a new standard first-line therapy for patients with metastatic colorectal cancer."4.81Targeting vascular endothelial growth factor in colorectal cancer. ( Berlin, JD, 2002)
"In the last 50 years, 5-fluorouracil-based therapy has been the mainstay of adjuvant and palliative treatment for colorectal cancer but response rates and median survival have been dismal despite the introduction of thymidylate synthase modulators such as leucovorin."4.81The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions. ( Schmoll, HJ, 2002)
"5-Fluorouracil (5-FU) has been utilized as part of standard chemotherapy for treatment of early-stage and metastatic colorectal cancer for more than 4 decades."4.81Oral fluoropyrimidine treatment of colorectal cancer. ( Eng, C; Kindler, HL; Schilsky, RL, 2001)
"The combination of capecitabine (Xeloda) and oxaliplatin (Eloxatin), or XELOX, is an effective and safe approach to the treatment of advanced colorectal cancer, with the potential advantage of convenience over standard combination regimens."4.81Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer? ( Twelves, C, 2002)
"For nearly 40 years, the medical treatment of colorectal cancer had been limited to the fluoropyrimidines until the recent development of irinotecan (CPT-11)."4.81Oxaliplatin: a new agent for colorectal cancer. ( Pelley, RJ, 2001)
"Randomized studies have tested a variety of strategies to improve the activity of 5-fluorouracil (5-FU) in colorectal cancer patients."4.81Biochemical modulation of 5-FU in systemic treatment of advanced colorectal cancer. ( Grem, JL, 2001)
"In this review, the clinical rationale and update of the present clinical status of irinotecan in the treatment of colorectal cancer and future prospects of irinotecan-based combinations are discussed."4.81Irinotecan in the treatment of colorectal cancer: clinical overview. ( Achterrath, W; Cao, S; Harstrick, A; Rustum, YM; Seeber, S; Vanhoefer, U, 2001)
"In colorectal cancer, leucovorin-modulated 5-fluorouracil (5-FU) has been the mainstay of both adjuvant treatment and treatment of metastatic disease for many years."4.81Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. ( Cunningham, D; James, RD, 2001)
"For several decades fluoropyrimidines, especially 5-fluorouracil (5-FU), have played a role in standard chemotherapy regimens for a range of solid tumours, including breast and colorectal cancers."4.81New options for outpatient chemotherapy--the role of oral fluoropyrimidines. ( Coleman, R; Cunningham, D, 2001)
"Oxaliplatin, a third-generation platinum analogue, is a novel compound with proven anti-tumor activity in colorectal cancer that has demonstrated synergy with 5-fluorouracil (5-FU) in human tumor xenograft models."4.81Integrating oxaliplatin into the management of colorectal cancer. ( Cassidy, J; Schmoll, HJ, 2001)
"Although 5-fluorouracil (5-FU) has been used to treat breast and colorectal cancers for several decades, bolus 5-FU has disappointing efficacy."4.81Capecitabine: a novel agent for the treatment of solid tumors. ( Johnston, PG; Kaye, S, 2001)
"Irinotecan (CPT-11) is a potent inhibitor of topoisomerase I, and has demonstrated antitumor activity against metastatic colorectal cancer."4.81[Standard therapy of CPT-11 for colorectal cancer]. ( Saitoh, S; Sakata, Y, 2001)
"Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) both have demonstrated single-agent activity in patients with colorectal cancer."4.81Capecitabine/irinotecan combination regimens in colorectal cancer. ( Kerr, DJ, 2002)
"Raltitrexed ('Tomudex') monotherapy is a conveniently administered alternative to 5-fluorouracil (5-FU) in the first-line treatment of advanced colorectal cancer (CRC), and has single-agent activity in a variety of advanced solid tumours."4.81Raltitrexed: current clinical status and future directions. ( Cervantes, A; Cunningham, D; Glimelius, B; Maroun, J; Van Cutsem, E, 2002)
"Although significant advances have been made in the treatment of advanced/metastatic colorectal cancer, 5-fluorouracil (5-FU) still forms the basis of chemotherapy."4.81Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer? ( Cassidy, J; Twelves, CJ, 2002)
"The administration of fluorouracil (5-FU) by continuous intravenous infusion (CI) is an alternative to the bolus administration of 5-FU in patients with advanced colorectal cancer."4.80Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. ( Benedetti, J; Brufman, G; Buyse, M; Fryer, J; Hansen, R; Isacson, R; Laplanche, A; Leichman, C; Levy, E; Lokich, J; Macdonald, J; Pater, J; Piedbois, P; Pignon, J; Rougier, P; Ryan, L; Weinerman, B; Zee, B, 1998)
"5-Fluorouracil (5-FU) remains the agent of choice for the treatment of colorectal cancer."4.80Biomodulation of Fluorouracil in colorectal cancer. ( Ardalan, B; Franceschi, D; Jaime, M; Luis, R, 1998)
"Oxaliplatin was first introduced to the clinical setting as a combination therapy with 5-fluorouracil/folinic acid (5-FU/FA) in an attempt to improve the response rate obtained with 5-FU/FA against colorectal cancer."4.80Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. ( Bleiberg, H; de Gramont, A, 1998)
" Synergistic effects with traditional therapy 5-fluorouracil/folinic acid have increased response rates significantly, improved time-sensitive response parameters, and facilitated the removal of previously unresectable hepatic metastases, thus changing the natural history of the disease."4.80Oxaliplatin for the treatment of advanced colorectal cancer: future directions. ( Bekradda, M; Cvitkovic, E; Ducreux, M; Louvet, C, 1998)
"The addition of leucovorin (LV) to 5-fluorouracil (5-FU) in advanced colorectal cancer has shown improved tumour response rates in many trials, but the optimal LV/5-FU regimen has yet to be determined."4.80A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). ( André, T; de Gramont, A; Krulik, M; Louvet, C; Tournigand, C, 1998)
"But fluorouracil (5-FU) and irinotecan (CPT-11 [Camptosar]) have shown activity in metastatic colorectal cancer and are approved for its treatment in the United States."4.80Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials. ( Erlichman, C; Goldberg, RM, 1998)
"Although 5-fluorouracil (5-FU) has been used to treat advanced colorectal cancer for 45 years, the drug has only a modest response rate and impact on survival."4.80Therapy for advanced colorectal cancer. ( Benson, AB, 1998)
"Salvage treatment with 5-fluorouracil (5-FU) with or without leucovorin may induce responses in patients with advanced colorectal cancer whose disease progresses after adjuvant therapy with the same drugs."4.80Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer? ( Goldberg, RM, 1998)
"Therapeutic options after failure of 5-fluorouracil (5-FU) for the treatment of colorectal cancer include regional treatments, different 5-FU-based regimens, and different chemotherapy regimens."4.80Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure. ( Henderson, CA, 1998)
"Fluorouracil (5-FU) continuous infusion is superior to 5-FU bolus in patients with advanced colorectal cancer, but the survival difference between the two treatments is small and, therefore, the difference in toxicity profile is crucial in choosing a treatment for individual patients."4.80Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. ( Benedetti, J; Brufman, G; Buyse, M; Fryer, J; Hansen, R; Isacson, R; Laplanche, A; Leichman, C; Lévy, E; Lokich, J; Macdonald, J; Pater, J; Piedbois, P; Pignon, JP; Quinaux, E; Rougier, P; Ryan, L; Thirion, P; Weinerman, B; Zee, B, 1998)
"The treatment of advanced colorectal cancer has been evaluated in a series of randomized trials, including infusional and modulated 5-fluorouracil (5-FU), and three meta-analyses encompassing trials of 5-FU plus leucovorin, continuous-infusion 5-FU, and intra-arterial fluoropyrimidines."4.80Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results. ( Benson, AB, 1998)
"5-Fluorouracil (5-FU) has been the mainstay of systemic therapy for colorectal cancer since its initial development 40 years ago."4.80Oral fluoropyrimidines in the treatment of colorectal cancer. ( Meropol, NJ, 1998)
" Chemotherapy with fluorouracil (5FU) plus leucovorin remains a standard in the treatment of patients with metastatic colorectal cancer."4.80[Irinotecan in combination for colon cancer]. ( André, T; de Gramond, A; Ducreux, M; Gil-Delgado, M; Khayat, D; Ychou, M, 1998)
"The final results of two very important randomized trials of irinotecan (Campto, Rhône-Poulenc Rorer, Antony, France) as second-line treatment for patients with advanced colorectal cancer are presented."4.80Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice. ( Cunningham, D, 1999)
"5-Fluorouracil (5-FU) has been available for over 40 years and has been used in a wide variety of different regimens for the treatment of advanced colorectal cancer, a malignancy with a poor prognosis that is common in industrialized countries."4.80Which 5-fluorouracil regimen?--the great debate. ( Harper, P; Labianca, R; Vincent, M, 1999)
"After nearly four decades of clinical experience with the fluoropyrimidines, 5-fluorouracil (5-FU) remains an integral part of chemotherapy for colorectal cancer."4.80Fluoropyrimidines: a critical evaluation. ( Brito, RA; Hoff, PM; Medgyesy, D; Pazdur, R; Ravandi-Kashani, F; Royce, ME; Zukowski, TH, 1999)
"For over four decades, 5-fluorouracil (5-FU) has been the mainstay of therapy for colorectal cancer and a major cytotoxic agent for treating gastrointestinal tumors and a variety of others, including breast and head and neck cancers."4.80Potential of Xeloda in colorectal cancer and other solid tumors. ( Cassidy, J, 1999)
"The evolution of and rationale for fluorouracil-based strategies in the treatment of metastatic colorectal cancer are discussed, and the role of the new oral fluoropyrimidines is described."4.80Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer. ( Ignoffo, RJ, 1999)
"For nearly four decades, 5-fluorouracil (5-FU) has been the mainstay of treatment for colorectal cancer."4.80Where do we stand with 5-fluorouracil? ( Büchele, T; Dempke, W; Grothey, A; Schmoll, HJ, 1999)
"For years, 5-fluorouracil (5-FU) was the only chemotherapeutic agent for the treatment of patients with advanced colorectal cancer."4.80New drugs in therapy of colorectal cancer: preclinical studies. ( Cao, S; Rustum, YM, 1999)
"Protracted intravenous infusions of fluorouracil (5-FU) in the treatment of colorectal cancer have been associated with a reduction in toxicity and enhanced clinical activity compared with bolus 5-FU schedules."4.80Oral fluoropoyrimidines. ( Brito, R; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, M, 1999)
"The combination of 5-fluorouracil (5-FU) and leucovorin has been the unofficial "standard" therapy for patients with colorectal cancer for over a decade."4.80The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status. ( Papamichael, D, 1999)
"Today, adjuvant 5-fluorouracil based therapy is known to significantly reduce the relapse rates and the risks of dying from resected colon cancer; chemotherapy approximately doubles overall survival of advanced colorectal cancer and second line treatment prolongs the survival of patients compared with best supportive care."4.80New directions in the treatment of colorectal cancer: a look to the future. ( Aapro, M; Glimelius, B; Kerr, D; Milano, G; Pritchard, DM; Rougier, P; Sobrero, A; Van Cutsem, E, 2000)
"The combination of 5-fluorouracil (5-FU) and leucovorin has been the unofficial "standard" therapy for patients with colorectal cancer for over a decade."4.80The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status. ( Papamichael, D, 2000)
" This review describes several oral fluoropyrimidine regimens with activity in colorectal cancer: capecitabine (Xeloda), tegafur, UFT, S-1, and eniluracil plus 5-FU."4.80Oral therapy for colorectal cancer: how to choose. ( Damjanov, N; Meropol, NJ, 2000)
"Fluorouracil has been the mainstay of treatment for colorectal cancer (CRC) for almost 40 years."4.80Progress in colorectal cancer chemotherapy: how far have we come, how far to go? ( Hoff, PM; Pazdur, R; Royce, ME, 2000)
"Oxaliplatin in combination with fluorouracil/folinic acid is an effective treatment option for patients with metastatic colorectal cancer, both as a first-line therapy and in patients refractory to previous chemotherapy."4.80Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. ( Clemett, D; Culy, CR; Wiseman, LR, 2000)
"For several years, fluorinated pyrimidines have been used in the treatment of advanced colorectal cancer, mainly in the form of intravenous injections of 5-fluorouracil (5-FU), alone or in combination with leucovorin."4.80[Fluorinated pyrimidines in oral treatment of advanced colorectal cancer]. ( Harboe, K; Lind, A; Ogreid, D; Todnem, K; Zotova, L, 2000)
"Irinotecan, also known as CPT-11, is a topoisomerase I inhibitor currently approved for use as a second-line agent in the treatment of advanced colorectal cancer."4.80The role of irinotecan in colorectal cancer. ( Saltz, LB, 1999)
" This hypothesis has been tested mostly in 5-fluorouracil (5-FU)-based regimens in colorectal cancer."4.80[Molecular markers as basis for chemotherapy?]. ( Brabender, J; Danenberg, PV; Lenz, HJ, 2000)
"Fluorouracil (5-FU) has remained the standard therapy for the treatment of advanced colorectal cancer for over 40 years."4.80Colorectal cancer: chemotherapy treatment overview. ( Dwivedy, S; Hoff, PM; Medgyesy, D; Pazdur, R; Royce, ME; Zukowski, TH, 2000)
" Phase II studies have shown that this agent has significant single-agent activity against both chemotherapy-naive and fluorouracil (5-FU)-refractory colorectal cancer."4.80Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer. ( Saltz, L, 2000)
"Two randomized phase III trials with irinotecan as second-line treatment of metastatic colorectal cancer have shown that irinotecan (CPT-11, Camptosar) significantly improves survival when compared with best supportive care or continuous infusion of fluorouracil (5-FU) after failure of 5-FU."4.80Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer. ( Douillard, JY, 2000)
" Although retreatment with fluorouracil (5-FU) is common, offering colorectal cancer patients a different chemotherapeutic agent as second-line therapy is a fairly recent strategy."4.80Second-line therapy in colorectal cancer. ( Berlin, J, 2000)
"No adequate second- or third-line therapy is available in the United States for patients with metastatic colorectal cancer and disease progression following treatment with fluorouracil (5-FU)-based therapy and an irinotecan (CPT-11, Camptosar)-containing regimen, or a combination of the two."4.80Oxaliplatin with 5-FU or as a single agent in advanced/metastatic colorectal cancer. ( Mitchell, EP, 2000)
"5-Fluorouracil (5-FU) is the most active single agent for treatment of advanced colorectal cancer, although objective responses occur in only 20% of patients, and there seems to be no impact on overall survival."4.79Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-alpha: an overview of clinical trials. ( Raderer, M; Scheithauer, W, 1995)
"We report a patient who developed multifocal cerebral demyelination with the use of 5-fluorouracil, levamisole, and leucovorin as adjuvant treatment for intestinal adenocarcinoma."4.79Cerebral demyelination with 5-fluorouracil and levamisole. ( Fassas, AB; Gattani, AM; Morgello, S, 1994)
"Even though fluorouracil (5FU) remains the standard treatment of advanced colorectal cancer, almost 90% of patients treated with 5FU alone do not achieve an objective response to chemotherapy."4.79Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project. ( , 1994)
"Possible prognostic variables for tumor response, time to progression (TTP), and survival in 141 patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy were analyzed."4.79Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy. ( Fountzilas, G; Gossios, K; Pavlidis, N; Skarlos, D; Svarna, E; Zisiadis, A, 1996)
"Since the late 1950s, 5-fluorouracil (5-FU) has remained the most effective chemotherapeutic agent in the treatment of advanced colorectal cancer, although response rates to 5-FU monotherapy are typically no more than 15%."4.79Role of chemotherapy for advanced colorectal cancer: new opportunities. ( Bleiberg, H, 1996)
" This demonstration was achieved using a 5-day infusion of 5-fluorouracil, leucovorin, and oxaliplatin in patients with colorectal cancer metastases."4.79Chronotherapy for gastrointestinal cancers. ( Lévi, F, 1996)
"CPT-11 (Campto, irinotecan) is a new topoisomerase I inhibitor and one of very few new cytotoxic agents to demonstrate clinical activity in colorectal cancer since the introduction of 5-fluorouracil (5-FU) into clinical practice almost 40 years ago."4.79CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. ( Khayat, D; Saltz, L; Shimada, Y, 1996)
"Several modifications to the administration schedule of 5-fluorouracil (5-FU) alone or in combination with other agents have been investigated in advanced colorectal cancer."4.79Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: a critical review of comparative studies. ( Facendola, G; Labianca, R; Luporini, G; Pessi, A; Pirovano, M, 1996)
"All of the published adjuvant studies for colorectal cancer in which 5-FU (either as a single agent or in combination with other cytotoxics or levamisole) was compared to a no-treatment control group were ranked according to the total planned dose of 5-FU (assuming a body weight of 70 kg or a body surface area of 1."4.79The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer. ( Siderov, J; Simes, J; Zalcberg, JR, 1996)
"We undertook a meta-analysis to assess the effects on recurrence and survival of administering fluorouracil (5-FU)-based chemotherapy by PVI after colorectal cancer surgery."4.79Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis Group. ( , 1997)
"5-fluorouracil (5-FU) is the best available drug for the treatment of advanced colorectal cancer."4.79High-dose infusional 5-FU in the treatment of advanced colorectal cancer: a summary of the European experience. ( Wils, JA, 1996)
"The rational of leucovorin modulation of 5-fluorouracil and the clinical results in colorectal cancer are reviewed with special emphasis on the monthly schedule of low dose leucovorin and 5FU bolus for 5 consecutive days (NCCTG-Mayo Clinic regimen) and the bimonthly schedule of high-dose leucovorin and 5FU bolus plus continuous infusion for two consecutive days (LV5FU2) which is now considered as a new standard."4.79[Modulation of 5-fluorouracil with folinic acid in advanced colorectal cancers. Groupe d'étude et de recherche sur les cancers de l'ovaire et digestifs (GERCOD)]. ( André, T; de Gramont, A; Krulik, M; Louvet, C; Molitor, JL; Raymond, E; Tournigand, C, 1997)
"Since the clinical introduction of 5-fluorouracil (5-FU) in 1958, improvements in the treatment of advanced colorectal cancer have been modest."4.79Chemotherapy of colorectal cancer: history and new themes. ( Bertino, JR, 1997)
"A variety of 5-fluorouracil (5-FU)- based chemotherapy regimens have been investigated in colorectal cancer patients in randomized trials over the past decade."4.79Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin. ( Grem, JL, 1997)
"In patients with metastatic colorectal cancer (CRC), conventional chemotherapy with 5-fluorouracil (5-FU) plus leucovorin provides an overall response rate of approximately 25% but has had little effect on survival."4.79Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer. ( Clark, JW, 1997)
"5-Fluorouracil (5-FU) is still the mainstay of chemotherapy in patients with metastatic colorectal cancer."4.78Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. ( Harstrick, A; Köhne-Wömpner, CH; Rustum, YM; Schmoll, HJ, 1992)
"A meta-analysis was performed on nine randomized clinical trials that compared fluorouracil (5-FU) with 5-FU plus intravenous (IV) leucovorin (LV) for the treatment of advanced colorectal cancer."4.78Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. ( , 1992)
"The systemic management of patients with colorectal cancer continues to center on the use of 5-fluorouracil (5-FU)."4.78Systemic therapy for colorectal cancer: an overview. ( Mayer, RJ, 1991)
"Three clinical trials have been conducted with fluorouracil (5-FU) and recombinant interferon alfa-2a (rIFN-alpha 2a) in the treatment of advanced colorectal carcinoma."4.78Clinical trials of fluorouracil with alpha-interferon in advanced colorectal carcinomas. ( Bready, B; Moore, DF; Pazdur, R, 1991)
"Seventy-five previously untreated patients with measurable advanced colorectal cancer were treated with 5 fluorouracil 1,000 mg/m2 as a 24-hour intravenous (i."4.78120-hour 5-fluorouracil (5-FU) continuous infusion (CI) plus BCNU in advanced colorectal cancer. ( Aguilo, J; Asencio, F; Candel, MT; Delgado, F; García-Reinoso, J; Martínez-Abad, M; Sánchez, JJ; Sanchis, C; Viciano, V; Villar-Grimalt, A, 1991)
" Studies show a definite therapeutic advantage for folinic acid/5-fluorouracil (5-FU) regimen compared with single agent 5-FU given intravenously in the management of advanced colorectal cancer."4.78Clinical trials with 5-fluorouracil, folinic acid and cisplatin in patients with gastrointestinal malignancies. ( Avvento, L; Madajewicz, S, 1990)
"Fluorouracil-based chemotherapy regimens have been utilized in metastatic colorectal cancer for more than 30 years."4.78Systemic therapy in metastatic colorectal cancer. ( Hansen, RM, 1990)
"To evaluate the safety and effectiveness of aflibercept in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) in Korean patients with metastatic colorectal cancer (mCRC) who progressed with oxaliplatin-containing regimen."4.31Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen. ( Ahn, MS; Bae, BN; Baik, SH; Beom, SH; Han, SW; Jeon, SY; Jo, HJ; Kang, MH; Kim, DH; Kim, HK; Kim, JG; Kim, JH; Kim, JS; Kim, JY; Lee, MA; Lee, S; Oh, J; Park, I; Park, YS; Shin, SH; Yoon, JA; Zang, DY, 2023)
"Safety and effectiveness of aflibercept with 5-fluorouracil/levofolinate/irinotecan have not been reported in Japanese patients with metastatic colorectal cancer (mCRC) in a real-world clinical setting."4.31Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance. ( Kazama, H; Terazawa, T; Uetake, H; Watanabe, J; Yamane, S; Yoshino, T, 2023)
"Using WES after a doublet chemotherapy regimen comprising irinotecan and 5-fluorouracil (n = 15), seven single nucleotide polymorphisms (SNPs) were identified as candidate biomarkers for irinotecan-associated toxicity of neutropenia."4.31Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity. ( Hamamoto, Y; Hazama, S; Iida, M; Ioka, T; Kanesada, K; Matsui, H; Nagano, H; Ogihara, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tsunedomi, R; Yoshida, S, 2023)
"5-Fluorouracil (5-FU) is a widely used chemotherapeutic agent for colorectal cancer (CRC) owing to its potent anticancer effects."4.315-Fluorouracil crystal-incorporated, pH-responsive, and release-modulating PLGA/Eudragit FS hybrid microparticles for local colorectal cancer-targeted chemotherapy. ( Bae, J; Hee Lee, E; Kim, H; Kim, J; Kim, MS; Kwak, D; Lee, J; Phyu Hlaing, S; Ryong Moon, H; Saparbayeva, A; Yoo, JW; Yoon, IS, 2023)
"5-Fluorouracil (5-FU) is one of the frequently used chemotherapeutic agents against colorectal cancer (CRC)."4.31microRNA-143 interferes the EGFR-stimulated glucose metabolism to re-sensitize 5-FU resistant colon cancer cells via targeting hexokinase 2. ( Chen, W; Chen, Y; Hui, T, 2023)
" However, the role of LOXL2 in the 5-fluorouracil (5-FU) resistance of colorectal cancer (CRC) remains unclear."4.31LOXL2 reduces 5-FU sensitivity through the Hedgehog/BCL2 signaling pathway in colorectal cancer. ( Chang, H; Lin, W; Mao, W; Peng, Q; Qiu, S; Qiu, Z, 2023)
"5-Fluorouracil (5-FU) represents the cornerstone for colorectal cancer therapy."4.31Enhancement of the antitumor effect of 5-fluorouracil with modulation in drug transporters expression using PI3K inhibitors in colorectal cancer cells. ( Abo-Elfadl, MT; Abo-Zeid, MAM; El-Daly, SM; Hussein, J, 2023)
"As EIF3D is oncogenic in colorectal cancer (CRC) and is associated with multidrug resistance, this study aims to investigate whether and how EIF3D regulates resistance to 5-fluorouracil (5-Fu) in CRC."4.31EIF3D promotes resistance to 5-fluorouracil in colorectal cancer through upregulating RUVBL1. ( Du, W; Li, C; Liang, Z; Lu, K; Yang, C, 2023)
"Capecitabine is a molecule of choice in the therapeutic arsenal of anticancer drugs used in Morocco for the treatment of breast cancer and colorectal cancer."4.31Assessment of patients' knowledge of their treatment with capecitabine at the National Institute of Oncology in Rabat. ( Bechar, H; Belahcen, MJ; Cherif Chefchaouni, A; Nouibi, C; Rahali, Y, 2023)
"5-Fluorouracil (5-Fu) is a first-line drug for colorectal cancer (CRC) therapy."4.31Thiol oxidative stress-dependent degradation of transglutaminase2 via protein S-glutathionylation sensitizes 5-fluorouracil therapy in 5-fluorouracil-resistant colorectal cancer cells. ( Chen, A; Chen, W; Chen, Z; Dai, W; Jiang, R; Li, X; Ling, Y; Ma, Y; Ni, M; Wu, J; Yao, Q; Zhou, Y, 2023)
"Chemoresistance to 5-fluorouracil (5-Fu)-based chemotherapy is one of the primary reasons for the failure of colorectal cancer (CRC) management."4.31STAT3 regulates 5-Fu resistance in human colorectal cancer cells by promoting Mcl-1-dependent cytoprotective autophagy. ( Sun, Z; Wang, X; Yue, Y; Zhang, Q, 2023)
" In this study, 5-fluorouracil (5FU) was loaded into ruthenium (Ru)-based nanocarrier (5FU-RuNPs) for the first time to eliminate the disadvantages of 5FU, and its cytotoxic and apoptotic effects on HCT116 colorectal cancer cells were compared with free 5FU."4.31The Novel 5-Fluorouracil Loaded Ruthenium-based Nanocarriers Enhanced Anticancer and Apoptotic Efficiency while Reducing Multidrug Resistance in Colorectal Cancer Cells. ( Bulut, H; Danişman-Kalindemirtaş, F; Kariper, İA; Özerkan, D, 2023)
"We evaluated the pharmacokinetics and pharmacodynamics/toxicodynamics of uracil-tegafur (UFT) after multiple administrations in colorectal cancer (CRC) model rats, and applied a pharmacometric approach to describe the time-course alterations of plasma 5-FU concentrations and tumor shrinkage."4.31A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model. ( Ito, Y; Kobuchi, S; Nakamura, T; Okamura, M; Tsuda, M, 2023)
"This study aims to evaluate the value of tissue inhibitors of MMPs-2 (TIMP-2) to indicate 5-Fluorouracil (5-Fu) resistance status in colorectal cancer."4.31TIMP-2 as a predictive biomarker in 5-Fu-resistant colorectal cancer. ( Hu, G; Li, Y; Lu, Z; Shen, L; Tao, F; Tao, K; Xu, C; Zhang, G; Zhu, R, 2023)
" 5-Fluorouracil (5FU) is widely used as the first-line treatment of colorectal cancer (CRC)."4.31Canonical Wnt Pathway Is Involved in Chemoresistance and Cell Cycle Arrest Induction in Colon Cancer Cell Line Spheroids. ( Castañeda-Patlán, MC; Macías-Silva, M; Moreno-Londoño, AP; Robles-Flores, M; Sarabia-Sánchez, MA, 2023)
" The use of the oral FP S-1 has been approved by the European Medicines Agency as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic CRC in whom it is not possible to continue treatment with another FP due to hand-foot syndrome (HFS) or cardiovascular toxicity (CVT)."4.31Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer. ( André, T; Bodoky, G; Cremolini, C; Heinemann, V; Maughan, T; McDermott, R; Osterlund, P; Pfeiffer, P; Punt, CJA; Teske, AJ; Van Cutsem, E, 2023)
"Encorafenib + cetuximab (E+C) is an effective therapeutic option in chemorefractory BRAFV600E metastatic colorectal cancer (mCRC)."4.31Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer. ( Altucci, L; Anderson, A; Ciardiello, D; Ciardiello, F; Coker, O; De Falco, V; Della Corte, CM; Famiglietti, V; Fowlkes, NW; Kanikarla, P; Kopetz, S; Lee, HM; Martinelli, E; Martini, G; Morris, V; Napolitano, S; Sorokin, A; Tabernero, J; Troiani, T; Villareal, OE; Woods, M, 2023)
"5-Fluorouracil (5-FU) is widely used for colorectal cancer (CRC) treatment; however, continuous treatment of CRC cells with 5-FU can result in acquired resistance, and the underlying mechanism of 5-FU resistance remains unclear."4.31Relationship between anticancer sensitivities and cellular respiration properties in 5-fluorouracil-resistant HCT116 human colorectal cancer cells. ( Kurasaka, C; Nishizawa, N; Ogino, Y; Sato, A; Uozumi, H, 2023)
"MicroRNA (miR)-19b is deregulated in colorectal cancer (CRC) and locally advanced rectal cancer (LARC), predicting worse outcome and disease progression in CRC patients, and acting as a promising prognostic marker of patient recurrence and pathological response to 5-fluorouracil (5-FU)-based neoadjuvant chemoradiotherapy in LARC."4.31Deregulation of the miR-19b/PPP2R5E Signaling Axis Shows High Functional Impact in Colorectal Cancer Cells. ( Caramés, C; Cristóbal, I; García-Foncillas, J; Luque, M; Madoz-Gúrpide, J; Rojo, F; Santos, A; Sanz-Álvarez, M, 2023)
"Fluorouracil infusion for 46±5h from the central venous(CV)port is required for mFOLFOX6, FOLFIRI, and FOLFOXIRI in patients with advanced colorectal cancer(CRC), followed by self-removal of the needle by patients."4.31[Educational Project of Self-Removal of the Intravenous Central Venous Access Port Guided by Patients with Advanced Colorectal Cancer Instructed by a Nurse in the University Hospital]. ( Beppu, N; Hirata, M; Ikeda, M; Ikeuchi, H; Kataoka, K; Kimura, K; Kuribayashi, M; Nishimura, Y; Nomura, K; Ohashi, E; Song, J; Takenaka, Y; Uchino, M; Yanagawa, T; Yarimizu, A, 2023)
"5-Fluorouracil (5-Fu) is the preferred drug in colorectal cancer treatment."4.31Atorvastatin calcium alleviates 5-fluorouracil-induced intestinal damage by inhibiting cellular senescence and significantly enhances its antitumor efficacy. ( Dai, Q; Ge, Y; He, S; Jia, H; Wang, X; Xia, J; Zhou, M, 2023)
"Immunosuppressive factors within the tumor microenvironment (TME), such as Transforming growth factor beta (TGF-β), constitute a crucial hindrance to immunotherapeutic approaches in colorectal cancer (CRC)."4.31Dual targeting of TGF-β and PD-L1 inhibits tumor growth in TGF-β/PD-L1-driven colorectal carcinoma. ( Anvari, K; Asgharzadeh, F; Avan, A; Batra, J; Ferns, GA; Fiuji, H; Gharib, M; Giovannetti, E; Hassanian, SM; Khalili-Tanha, G; Khalili-Tanha, N; Khazaei, M; Maftooh, M; Moghbeli, M; Mozafari, MR; Rahmani, F; Shahidsales, S; Shakour, N, 2023)
"Insensitivity and resistance to 5-fluorouracil (5FU) remain as major hurdles for effective and durable 5FU-based chemotherapy in colorectal cancer (CRC) patients."4.31Targeting PTGES/PGE2 axis enhances sensitivity of colorectal cancer cells to 5-fluorouracil. ( Cao, L; Geng, L; Geng, S; Ren, X; Zhan, H, 2023)
"To date, oxaliplatin and irinotecan are used in combination with 5-flourouracil (5-FU) for metastatic colorectal cancer."4.31Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells. ( Bock, F; Cappel, ML; Frerker, B; Hildebrandt, G; Klautke, G; Kriesen, S; Manda, K, 2023)
"This retrospective study included 289 patients with metastatic colorectal cancer treated with second-line folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors."4.31Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors. ( Chin, K; Fukuda, K; Fukuoka, S; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Shinozaki, E; Takahari, D; Wakatsuki, T; Yamaguchi, K; Yoshino, K, 2023)
"The gold standard drug for colorectal cancer (CRC) treatment, 5-Fluorouracil (5-FU), induces pharmacological tolerance in long-term management."4.31Dermatan Sulfate/Chitosan Nanoparticles Loaded with an Anti-Inflammatory Peptide Increase the Response of Human Colorectal Cancer Cells to 5-Fluorouracil. ( Barredo-Vacchelli, GR; Birocco, AM; Blachman, A; Calabrese, GC; Camperi, SA; Cenci, G; Curcio, S; Gianvincenzo, PD; Moya, S; Rodriguez, JA; Sosnik, A, 2023)
"In this study, we investigated the combined treatment of 5-fluorouracil (5-FU) and Anatolian propolis extract (PE) on colorectal cancer (CRC)using in vitro and in vivo studies."4.31Propolis Enhances 5-Fluorouracil Mediated Antitumor Efficacy and Reduces Side Effects in Colorectal Cancer: An in Vitro and in Vivo Study. ( Aydogdu, G; Durmus, E; Goren, AC; Guler, EM; Hekimoglu, ER; Kanimdan, E; Kocyigit, A; Oruc, HH; Ozman, Z; Yasar, O; Yenigun, VB, 2023)
"5-Fluorouracil (5-FU) is the first-line treatment for colorectal cancer (CRC) patients, but the development of acquired resistance to 5-FU remains a big challenge."4.31Targeting proteasomal deubiquitinases USP14 and UCHL5 with b-AP15 reduces 5-fluorouracil resistance in colorectal cancer cells. ( Chen, X; Ding, W; Jiang, LL; Liu, AC; Liu, BY; Liu, JB; Lou, EZ; Mao, Q; Meng, Y; Peng, GJ; Shi, XP; Tang, DL; Wang, JX; Wu, JZ; Zhang, HC; Zhou, H, 2023)
"To assess the cost-effectiveness of cetuximab in combination with chemotherapy fluorouracil, oxaliplatin, and leucovorin (FOLFOX) or fluorouracil, irinotecan and leucovorin (FOLFIRI) compared to standard chemotherapy alone as a first-line treatment for metastatic colorectal cancer (mCRC) with positive KRAS wild type patients in Indonesia."4.31Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting. ( Armansyah, A; Khoe, LC; Megraini, A; Nadjib, M; Nugraha, RR; Permanasari, VY; Putri, S; Saldi, SRF; Santatiwongchai, B; Sastroasmoro, S; Setiawan, E, 2023)
"5-Fluorouracil (5-FU) is a conventional and effective drug for colorectal cancer patients, and it is an important part of combined chemotherapy and adjuvant chemotherapy."4.31Peficitinib ameliorates 5-fluorouracil-induced intestinal damage by inhibiting aging, inflammatory factors and oxidative stress. ( Chen, C; Dai, Q; He, S; Jia, H; Wang, XB; Xia, J; Zhou, Y, 2023)
"Treatment with 5-fluorouracil (5-FU) based therapy is still used for colorectal cancer (CRC)."4.31Rebound increase in microRNA levels at the end of 5-FU-based therapy in colorectal cancer patients. ( Badr, D; Fouad, MA; Hussein, M; Salem, S; Shouman, S; Zekri, A, 2023)
"We found that ABCA2 polymorphism was significantly associated with systemic exposure to capecitabine and capecitabine-induced neutropenia in Japanese patients with CRC."4.31A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer. ( Fujita, KI; Ishida, H; Kubota, Y; Matsumoto, N; Murase, R; Shibata, Y; Shimada, K, 2023)
" Here, we designed a composite liposomal nano-carrier co-loading 5-Fluorouracil (5-FU) with all-trans retinoic acid (ATRA) to assess anticancer efficacy of the combined drugs in colorectal cancer (CRC)."4.31In vitro co-delivery of 5-fluorouracil and all-trans retinoic acid by PEGylated liposomes for colorectal cancer treatment. ( Afshar, S; Amini, R; Azarifar, Z; Najafi, R; Tanzadehpanah, H, 2023)
"The efficacy of fluorouracil + oxaliplatin + irinotecan with bevacizumab (FOLFOXIRI + BV) has been verified for metastatic colorectal cancer (mCRC)."4.12Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice. ( Aoyama, T; Kazama, K; Numata, M; Oshima, T; Rino, Y; Sato, M; Sato, S; Shiozawa, M; Sugano, N; Tamagawa, H; Uchiyama, M; Yukawa, N, 2022)
"To evaluate the efficacy and safety of apatinib combined with FOLFIRI in the first-line treatment of advanced metastatic colorectal cancer (mCRC) and explore potential factors of efficacy."4.12Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer. ( Liu, H; Rong, X; Wang, J; Wang, Y; Yu, H; Zhao, J, 2022)
"Acquired resistance of 5-fluorouracil (5-FU) remains a clinical challenge in colorectal cancer (CRC), and efforts to develop targeted agents to reduce resistance have not yielded success."4.12ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer. ( Cheng, Z; Dong, S; Hu, S; Li, L; Li, S; Liang, S; Luo, L; Xu, Q; Zhang, G; Zhang, W; Zhang, X; Zhong, M; Zhu, J, 2022)
"5-Fluorouracil (5-Fu) is the first-line chemotherapeutic option for colorectal cancer."4.12TIMP-2 regulates 5-Fu resistance via the ERK/MAPK signaling pathway in colorectal cancer. ( Chen, E; Huang, X; Luo, X; Meng, Q; Song, Z; Wang, D; Wang, Z; Xu, J; Zhang, G; Zhang, W; Zhou, W, 2022)
"Most patients affected with colorectal cancers (CRC) are treated with 5-fluorouracil (5-FU)-based chemotherapy but its efficacy is often hampered by resistance mechanisms linked to tumor heterogeneity."4.12CDX2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancer. ( Bersuder, E; Brigand, C; Chenard, MP; Delhorme, JB; Duluc, I; Freund, JN; Gross, I; Martin, E; Rohr, S; Terciolo, C; Vlami, O, 2022)
"Chemotherapy is used for recurrent and metastatic colorectal cancer, but the response rate of 5-fluorouracil (5-FU), the standard treatment for colorectal cancer, is low."4.12Effect of Thymidine Phosphorylase Gene Demethylation on Sensitivity to 5-Fluorouracil in Colorectal Cancer Cells. ( Akiyama, N; Eto, K; Koyama, M; Manome, Y; Osada, E, 2022)
"Our findings demonstrated that targeting RAS pathway using Valsartan interferes with cell-proliferation, induces apoptosis, reduces migration and synergistically interacts with 5-FU, supporting further studies on this new therapeutic approach for colorectal cancer."4.12Inhibition of angiotensin pathway via valsartan reduces tumor growth in models of colorectal cancer. ( Amerizadeh, F; Asgharzadeh, F; Avan, A; Ebrahimi, S; Fakhraei, M; Farshbaf, A; Ferns, GA; Giovannetti, E; Hassanian, SM; Khazaei, M; Mostafapour, A; Sabbaghzadeh, R, 2022)
"To compare the efficacy and safety of folinic acid, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab or aflibercept in metastatic colorectal cancer (mCRC) patients pretreated with oxaliplatin-based chemotherapy."4.12A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. ( Hong, JY; Jo, H; Kang, WK; Kim, H; Kim, ST; Lee, J; Lee, MS; Lee, YP; Lim, HY; Park, JO; Park, SH; Park, YS, 2022)
"The impact of activating transcription factor 4 (ATF4), differentially expressed in colorectal cancer (CRC), on 5-Fluorouracil (5-FU) chemoresistance has not been fully explained."4.12ATF4-mediated microRNA-145/HDAC4/p53 axis affects resistance of colorectal cancer cells to 5-fluorouracil by regulating autophagy. ( Chen, H; Hu, H; Ma, J; Xu, L; Zhang, Q; Zhao, L, 2022)
"The oral fluoropyrimidine S-1 has shown comparable efficacy to capecitabine in Asian and some Western studies on metastatic colorectal cancer."4.12Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer. ( Kwakman, JJM; Mol, L; Punt, CJA, 2022)
"The aim of this study was to improve the direct results of reconstructive surgery in patients operated on for complicated forms of colorectal cancer, by using 5-fluorouracil in the postoperative period."4.12The Effect of 5-Fluorouracil on the Adhesion Process in Patients Operated on for Colorectal Cancer. ( Irimbetov, S; Osombaev, M; Zhakipbekov, S, 2022)
"Clinically, 5-fluorouracil (5-Fu) is a first-line drug for the treatment of patients with colorectal cancer (CRC)."4.12Synergistic antitumor activity of 5-fluorouracil and atosiban against microsatellite stable colorectal cancer through restoring GATA3. ( Chen, M; Chen, Y; Guo, X; Li, J; Li, Z; Meng, F; Qiu, T; Wang, M; Wang, W; Xu, F; Yang, M; Zhang, H; Zhang, Q; Zhang, Y, 2022)
" 5-fluorouracil (5-FU) is commonly used for the treatment of colorectal cancer (CRC) in patients who receive concurrent chemoradiotherapy."4.12SPOCK1 silencing decreases 5-FU resistance through PRRX1 in colorectal cancer. ( Liu, XL; Qu, YL; Zhai, XF; Zhao, SY, 2022)
"Cancer patients treated with capecitabine and oxaliplatin (XELOX) often develop hand-foot syndrome (HFS) or palmar-plantar erythrodysesthesia."4.12Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome. ( Al-Tassan, NA; Cheadle, JP; Escott-Price, V; Houlston, RS; Kaplan, R; Kerr, DJ; Kerr, R; Madi, A; Maughan, TS; Palles, C; Watts, K; Wills, C, 2022)
" In this study, we aimed to determine the changes of autophagy in the cellular model of acquired chemoresistance of colorectal cancer cell lines HCT116 and SW620, induced by 5-fluorouracil (5-FU) or oxaliplatin (OxaPt) treatment, and determine the susceptible factors for autophagy inhibition."4.12Differential effects of 5-fluorouracil and oxaliplatin on autophagy in chemoresistant colorectal cancer cells. ( Jonusiene, V; Kukcinaviciute, E; Sasnauskiene, A; Starkuviene, V; Zitkute, V, 2022)
"To date, 5-fluorouracil-based chemotherapy is very important for locally advanced or metastatic colorectal cancer (CRC)."4.12Targeting DCLK1 overcomes 5-fluorouracil resistance in colorectal cancer through inhibiting CCAR1/β-catenin pathway-mediated cancer stemness. ( Cheng, J; Jin, M; Lin, Z; Ren, J; Wang, L; Wu, G; Yang, K; Yu, D; Zhang, D; Zhang, T; Zhao, L; Zhou, P, 2022)
"Surgically resected colorectal cancer specimens from 89 patients were decellularized to produce patient-derived scaffold, which were seeded with HT29 cells, cultured for 3 weeks, and treated with 5-fluorouracil."4.125-fluorouracil treatment of patient-derived scaffolds from colorectal cancer reveal clinically critical information. ( Bexe Lindskog, E; Holdfeldt, A; Landberg, G; Salerno, S; Ståhlberg, A, 2022)
" This study aims to investigate the role of the hypoxia-induced miR-675-5p in 5-Fluorouracil (5-FU) resistance on colorectal cancer (CRC) cells."4.12Mir-675-5p supports hypoxia-induced drug resistance in colorectal cancer cells. ( Alessandro, R; Barreca, MM; Conigliaro, A; Cordaro, A; Corrado, C; Zichittella, C, 2022)
"Five-fluorouracil, folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) regimen is used as the first-line treatment for metastatic colorectal cancer (mCRC)."4.12Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study. ( Gao, L; Liu, X; Ma, X; Ou, K; Wang, Q; Yang, L; Zhang, H, 2022)
"5-fluorouracil (5-FU) is a widely used drug for chemotherapy in colorectal cancer."4.12Investigation of ( Cagatay, P; Cevik, M; Ciftci, C; Deliorman, G; Karaalp, A; Koksal, UI; Namal, E; Sener, ND; Susleyici, B, 2022)
"5-Fluorouracil (5-FU) is a key component of chemotherapy for colorectal cancer (CRC)."4.12SHMT2-mediated mitochondrial serine metabolism drives 5-FU resistance by fueling nucleotide biosynthesis. ( Arcangeli, A; Caselli, A; Chiarugi, P; Cirri, P; Colantuoni, V; Leo, A; Lottini, T; Maddocks, ODK; Muccillo, L; Nesi, I; Paoli, P; Pardella, E; Parri, M; Pranzini, E; Raugei, G; Sabatino, L; Santi, A; Taddei, ML; Uribe, AH; Zhang, T, 2022)
" To identify functional phosphorylation sites involved in 5-fluorouracil (5-FU) resistance during its treatment of colorectal cancer cells, CRISPR-mediated cytosine base editor (CBE) and adenine base editor (ABE) are utilized for functional screens by mutating phosphorylated amino acids with two libraries specifically targeting 7779 and 10 149 phosphorylation sites."4.12Functional Phosphoproteomics in Cancer Chemoresistance Using CRISPR-Mediated Base Editors. ( Guo, J; Huang, S; Huang, X; Li, J; Li, M; Lin, J; Qiao, Y; Yu, W; Zhang, P; Zhao, Y, 2022)
"The drug, 5-fluorouracil (5FU) is a standard first-line treatment for colorectal cancer (CRC) patients."4.12Long-term resistance to 5-fluorouracil promotes epithelial-mesenchymal transition, apoptosis evasion, autophagy, and reduced proliferation rate in colon cancer cells. ( Arregui Ramos, DA; de-Freitas-Junior, JCM; Morgado-Díaz, JA; Sousa-Squiavinato, ACM; Tessmann, JW; Wagner, MS, 2022)
" Therefore, this study aimed to clarify the role of PYCR1 and its interaction with SLC25A10 in a chemotherapeutic agent 5-fluorouracil (5-FU)'s toxicity to colorectal cancer cells."4.12The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer. ( Mai, Z; Qiu, X; Song, Y; Xia, W; Yang, X; Ye, Y; Zhang, M; Zhou, B, 2022)
"a capecitabine and oxaliplatin drug combination regimen has shown a survival benefit in patients with advanced colorectal cancer, yet its administration represents an attractive option for low resource settings."4.12Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study. ( Begg, W; Kibudde, S, 2022)
"This cross-sectional study aims to elucidate the association between genetic variations in the DPYD gene and 5-fluorouracil toxicity among Jordanians with colorectal cancer (CRC)."4.12Pharmacogenetic Study of the Dihydropyridine Dehydrogenase Gene in Jordanian Patients with Colorectal Cancer. ( Almashagbah, NA; Bodoor, KG; Mahasneh, AA, 2022)
"5-Fluorouracil (5-FU), a known cardiotoxin, is the backbone for the treatment of colorectal cancer."4.12Managing life-threatening 5-fluorouracil cardiotoxicity. ( Boldig, K; Ganguly, A; Kadakia, M; Rohatgi, A, 2022)
" Topoisomerase-I inhibitor irinotecan is used clinically to treat colorectal cancer (CRC), often in combination with 5-fluorouracil (5FU)."4.12ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer. ( Bagby, SM; Cadogan, EB; Davis, SL; Diamond, JR; Durant, ST; Hartman, SJ; Hughes, GD; Leal, AD; Lieu, CH; Messersmith, WA; Pitts, TM; Schlaepfer, M; Simmons, DM; Tse, T; Yacob, BW, 2022)
"Despite the fact that 5-fluorouracil (5-FU) is the backbone for chemotherapy in colorectal cancer (CRC), the response rates in patients is limited to 50%."4.12Rewiring glucose metabolism improves 5-FU efficacy in p53-deficient/KRAS ( Burgering, BMT; Clevers, H; Drost, J; Gevers, S; Gulersonmez, MC; Ludikhuize, MC; Meerlo, M; Nguyen, NTB; Rodríguez Colman, MJ; Roudbari, SKS; Stigter, ECA, 2022)
"We experienced 2 cases of Stage Ⅳ colorectal cancer obtained long-term survival by chemotherapy with only capecitabine."4.12[Two Cases of Stage Ⅳ Colorectal Cancer with Long-Term Survival following Single-Agent Chemotherapy with Capecitabine-A Case Reports]. ( Ando, K; Chiku, T; Fukuyama, M; Hashiba, H; Sano, W; Shinoda, K; Suda, K, 2022)
"Recent evidence from randomized trials suggests that FOLFOXIRI (fluorouracil, oxaliplatin, and irinotecan) ± bevacizumab is associated with higher response rates, with the potential for conversion of unresectable to resectable disease in metastatic colorectal cancer (mCRC)."4.12Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience. ( Ahmed, S; Bhatti, T; Chalchal, H; Gill, D; Le, D; Moser, M; Shaw, J; Souied, O; Tan, KT; Zaidi, A, 2022)
"The aim of this study was to investigate the antitumor effects of quercetin and luteolin combined with 5-Fluorouracil (5-FU) in HT-29 human colorectal cancer cells."4.12Quercetin and Luteolin Improve the Anticancer Effects of 5-Fluorouracil in Human Colorectal Adenocarcinoma ( Ağca, CA; Aşkın, H; Erdoğan, MK, 2022)
"5-Fluorouracil (5-FU) and its prodrugs are the essential clinical drugs for colorectal cancer (CRC) treatment."4.02Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer. ( Cui, S; Guo, Z; Han, G; Liu, S; Liu, X; Luo, D; Lv, Y; Qu, X; Tian, X; Wan, S; Wang, W; Yang, S; Zhang, Y, 2021)
"Triplet chemotherapy with fluorouracil, folinic acid, oxaliplatin, and irinotecan plus bevacizumab (FOLFOXIRI-B) is an effective first-line treatment option for patients with metastatic colorectal cancer (mCRC)."4.02Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer. ( Bol, GM; Bond, MJ; Buffart, TE; Kessels, R; Koopman, M; Lemmens, VE; Mekenkamp, LJ; Scheerman, I; Valkenburg-van Iersel, LB; van Breeschoten, J; van Nassau, SC; Verheul, HM, 2021)
"Adjuvant chemotherapy with 5-fluorouracil (5-FU) does not improve survival of patients suffering from a form of colorectal cancer (CRC) characterized by high level of microsatellite instability (MSI-H)."4.02Casein Kinase-1-Alpha Inhibitor (D4476) Sensitizes Microsatellite Instable Colorectal Cancer Cells to 5-Fluorouracil via Authophagy Flux Inhibition. ( Behrouj, H; Dastghaib, S; Ghavami, S; Hudecki, J; Khazayel, S; Likus, W; Mokarram, P; Rezaie, S; Siri, M; Zamani, M; Łos, MJ, 2021)
"Although effective drugs have been developed, including 5-fluorouracil (5-FU), advanced colorectal cancer (CRC) shows low therapeutic sensitivity resulting from the development of 5-FU resistance."4.02Apigenin enhances apoptosis induction by 5-fluorouracil through regulation of thymidylate synthase in colorectal cancer cells. ( Choi, J; Hwang, S; Lim, W; Song, G; Song, J; Yang, C, 2021)
"5-Fluorouracil (5-FU) resistance has been long considered as an obstacle to the efficacy of chemotherapy in colorectal cancer (CRC)."4.02Syndecan-2, negatively regulated by miR-20b-5p, contributes to 5-fluorouracil resistance of colorectal cancer cells via the JNK/ERK signaling pathway. ( Hua, R; Li, X; Ni, Q; Tang, D; Wang, D; Yan, X; Zhang, Y; Zhu, J, 2021)
" In this context, tumor-associated macrophages (TAM) have been related to chemoresistance to 5-fluorouracil (5-FU), the first-line chemotherapeutic agent used in treating colorectal cancers."4.02Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer. ( Decaens, T; Gharzeddine, K; Laverriere, MH; Malier, M; Marsili, S; Millet, A; Roth, G; Thomas, F, 2021)
" p130Cas was inducible by 5-fluorouracil (5-FU) and FOLFIRI (folinic acid, 5-FU, irinotecan), and p130Cas and EREG were upregulated in distant metastases (GSE121418)."4.02p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy. ( Jung, A; Kirchner, T; Klauschen, F; Kumbrink, J; Li, P; Pók-Udvari, A, 2021)
"Currently, 5-Fluorouracil (5-FU) based chemotherapy is the primary option for colorectal cancer after surgery, whereas chemotherapy resistance related mortality is observed in a large proportion of patients."4.02Anemoside B4 sensitizes human colorectal cancer to fluorouracil-based chemotherapy through src-mediated cell apoptosis. ( Duan, XW; He, X; Hou, XL; Li, HQ; Liao, GB; Liu, W; Tang, J; Wang, JX; Yan, HZ; Yu, SY, 2021)
"We aimed to screen DPD level and the changes of plasma antioxidant capacity of colorectal cancer patients on 5-fluorouracil regimen."4.02Does dihydropyrimidine dehydrogenase level modify plasma antioxidant capacity in colorectal cancer patients treated with fluoropyrimidines? ( Angelov, M; Atanasova, L; Hristova-Avakumova, N; Kamenova, K; Minchev, V; Nikolov, R; Surcheva, S; Todorov, L, 2021)
"To evaluate the changes in left ventricular myocardial function in patients with colorectal cancer undergoing chemotherapy with mFOLFOX6 (oxaliplatin + 5-fluorouracil + calcium folinate) using three-dimensional speckle-tracking echocardiography (3D-STE)."4.02Use of spectral tracking technique to evaluate the changes in left ventricular function in patients undergoing chemotherapy for colorectal cancer. ( Dong, S; Feng, J; Guo, X; Huang, L; Liu, K; Lu, G; Qin, W; Wang, Z; Zhai, Z; Zhang, C, 2021)
"First-line regimens in the treatment of metastatic colorectal cancer (mCRC) combine a fluoropyrimidine with oxaliplatin (FOLFOX/XELOX) or irinotecan (FOLFIRI)."4.02Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens. ( Carneiro, BA; El-Deiry, WS; Marks, EI; Matera, R; Olszewski, AJ; Safran, H; Yakirevich, E, 2021)
"Chemotherapy regimens that include 5-fluorouracil (5-FU) are central to colorectal cancer treatment; however, risk/benefit concerns limit 5-FU's use, necessitating development of improved fluoropyrimidine (FP) drugs."4.02Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties. ( Brody, JR; Caudell, DL; D'Agostino, R; Deng, Z; Dominijanni, A; Ghiraldeli, LP; Gmeiner, WH; Haber, AO; Kiren, S; Mani, C; Palle, K; Pasche, BC; Smith, TL, 2021)
"FOLFOX is a combinational regimen of folinic acid (FnA, FOL), fluorouracil (5-Fu, F) and oxaliplatin (OxP, OX), and has been long considered as the standard treatment of colorectal cancer (CRC) and hepatocellular carcinoma (HCC)."4.02Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. ( Guo, J; Huang, L; Liu, Y; Sun, D; Yu, Z; Zou, Y, 2021)
" The present study aimed to evaluate the anticancer activity of MJ‑33 in fluorouracil (5FU)‑resistant colorectal cancer cells (HT‑29/5FUR) and to investigate the underlying molecular mechanisms."4.02Novel quinazolinone MJ‑33 induces AKT/mTOR‑mediated autophagy‑associated apoptosis in 5FU‑resistant colorectal cancer cells. ( Bau, DT; Chiang, JH; Ha, HA; Hour, MJ; Juan, YN; Lo, YH; Tsai, FJ; Yang, JS, 2021)
"5-Fluorouracil (5-FU) is one of the most frequently used pharmacological agents in the treatment of colorectal cancer (CRC)."4.02KHDRBS3 promotes multi-drug resistance and anchorage-independent growth in colorectal cancer. ( Harada, K; Hinoi, T; Honma, R; Maruyama, R; Naka, K; Ohdan, H; Sakamoto, N; Shimizu, W; Takakura, Y; Taniyama, D; Ukai, S; Yasui, W, 2021)
"To create a cost-effectiveness model to compare doublet therapy (encorafenib plus cetuximab) with standard chemotherapy (cetuximab plus irinotecan or cetuximab plus folinic acid, fluorouracil, and irinotecan) in treating patients with metastatic BRAF variant colorectal cancer."4.02Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer. ( Huntington, SF; Lacy, J; O'Hara, M; Patel, KK; Stein, S, 2021)
"5-Fluorouracil (5-FU) is an essential drug in systemic chemotherapy treatments for colorectal cancer (CRC)."4.02GABA-producing Lactobacillus plantarum inhibits metastatic properties and induces apoptosis of 5-FU-resistant colorectal cancer cells via GABA ( An, J; Ha, EM; Seok, H, 2021)
" Herein, mesoporous silica nanoparticles, a supported lipid bilayer and cetuximab were integrated to fabricate a hybrid nanoplatform for effectively encapsulating and selectively delivering 5-fluorouracil (5-FU) against colorectal cancer (CRC) cells."4.02Cetuximab functionalization strategy for combining active targeting and antimigration capacities of a hybrid composite nanoplatform applied to deliver 5-fluorouracil: toward colorectal cancer treatment. ( Chen, R; Gu, Q; Huang, Y; Li, J; Peng, C; Peng, W; Shao, G; Sheng, Y; Sun, Y; Tan, Y; Wang, L; Wang, Y; Yang, P; Zhang, Q; Zhou, J, 2021)
"Combination therapy of tegafur/uracil (UFT) and leucovorin (LV) is widely used to treat colorectal cancers."4.02Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/LV combination therapy after hepatectomy. ( Endo, Y; Hirashita, T; Inomata, M; Itoh, H; Iwao, M; Iwashita, Y; Masuda, T; Shiraiwa, K; Suzuki, Y; Tada, K; Tanaka, R; Uchida, H, 2021)
"The objectives were to describe treatment sequences for advanced colorectal cancer (CRC), use of second-line FOLFIRI (leucovorin, 5-fluorouracil, irinotecan) plus antiangiogenic drug (bevacizumab, ramucirumab, aflibercept beta) therapy, and the factors associated with the duration of antitumor drug treatment from second-line antiangiogenic therapy in Japan."4.02Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database. ( Cai, Z; Kagawa, Y; Makiyama, A; Piao, Y; Satake, H; Shinozaki, E; Tanizawa, Y, 2021)
"Recently the phase 3 BEACON trial showed that the combination of encorafenib, cetuximab, and binimetinib versus cetuximab and irinotecan/FOLFIRI improved overall survival in pre-treated patients with metastatic colorectal cancer (mCRC) with BRAF V600E mutation."4.02Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA. ( Ding, D; Hu, H; Huang, J; Li, S; Zhu, Y, 2021)
"We aim to compare the efficiency and toxicity of three different 5-fluorouracil (5-FU) administration types in 5-FU, leucovorin, and oxaliplatin (FOLFOX) combination treatment for adjuvant therapy in colorectal cancer (CRC)."4.02The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study. ( Açıkgöz, Ö; Akdeniz, N; Bilici, M; Dane, F; Demirci, A; Durnalı, AG; Erol, C; İnanç, M; Işıkdoğan, A; Kaplan, MA; Kaya, S; Koral, L; Küçüköner, M; Laçin, Ş; Ölmez, ÖF; Şahinli, H; Şendur, MAN; Türkmen, E; Uncu, D; Urakçı, Z, 2021)
" 5-fluorouracil (5FU) and albumin-bound PTX (Abraxane, ABX) for colorectal cancer treatment."4.02Albumin-stabilized layered double hydroxide nanoparticles synergized combination chemotherapy for colorectal cancer treatment. ( Han, FY; Li, L; Qian, Y; Sun, L; Wang, PY; Xu, ZP; Zhang, R, 2021)
" Loading of oxaliplatin (Ox) and 5-Fluorouracil (5-FU) into the thermogel were able to significantly decreased peritoneal carcinomatosis index (PCI) (-58%) and ascites (-70%) in a murine model of peritoneal metastases."4.02Combination of tumor cell anti-adhesion and anti-tumor effect to prevent recurrence after cytoreductive surgery in a mice model. ( Al Sabbagh, C; Boudy, V; Mignet, N; Pimpie, C; Pocard, M; Roy, P; Seguin, J, 2021)
"The administration schedule of capecitabine for the treatment of metastatic colorectal cancer (mCRC) in clinical trials has been 14 days of drug with 7 days off in a 21 day cycle (14/7)."4.02Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review. ( Akce, M; Alese, O; Bryson, E; Davis, C; Draper, A; El-Rayes, B; Goyal, S; Hall, K; Patel, U; Sakach, E; Shaib, W; Szabo, S; Watson, M; Wu, C, 2021)
" The present study investigated the mechanisms underlying the response and resistance to 5‑fluorouracil (5‑FU) in colorectal cancer (CRC) cell lines."4.02Inhibition of chaperone‑mediated autophagy reduces tumor growth and metastasis and promotes drug sensitivity in colorectal cancer. ( Xiang, L; Xiao, X; Xuan, Y; Zhao, S; Zheng, HC, 2021)
" This study aims to examine the combined effects of 5-fluorouracil (5FU) and propolis on colorectal cancer (CRC) in mouse models."4.02Co-administration of 5FU and propolis on AOM/DSS induced colorectal cancer in BALB-c mice. ( Alipour, M; Bandegi, AR; Pakdel, A; Sameni, HR; Semnani, V; Torabizadeh, N; Yosefi, S, 2021)
" Chemotherapy using 5-fluorouracil (5-FU) has been widely applied to treat colorectal cancer (CRC)."4.02Low curcumin concentration enhances the anticancer effect of 5-fluorouracil against colorectal cancer. ( Lin, J; Shao, Y; Song, F; Yang, X; Zheng, X, 2021)
"Combination therapy comprised of fluoropyrimidine plus irinotecan with an angiogenesis inhibitor is widely used as a second-line treatment for metastatic colorectal cancer (mCRC)."4.02Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor. ( Aoki, K; Hamano, T; Makishima, M; Oki, E; Sano, F; Yamanaka, T; Yamazaki, K; Yuki, S, 2021)
"5-Fluorouracil (5-FU) resistance is an urgent problem of colorectal cancer (CRC) chemotherapy that needs to be resolved."4.02LncRNA ENSG00000254615 Modulates Proliferation and 5-FU Resistance by Regulating p21 and Cyclin D1 in Colorectal Cancer. ( Deng, Y; Fu, Y; Huang, R; Li, J; Xie, X, 2021)
"5-Fluorouracil (5-FU)-based chemotherapy is the first-line treatment for colorectal cancer (CRC) but is hampered by chemoresistance."4.02The loss of SHMT2 mediates 5-fluorouracil chemoresistance in colorectal cancer by upregulating autophagy. ( Chen, C; Chen, J; Fan, G; Liu, X; Lu, H; Na, R; Peng, Z; Song, G; Tang, H; Wang, X; Wang, Y; Xiao, C; Yan, D; Zhuang, G, 2021)
"FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab is the preferred first-line treatment for right-sided metastatic colorectal cancer with RAS mutation."4.02Multiple stage IV colorectal cancers in a patient who received multidisciplinary treatment, including chemotherapy and Japanese Kampo medicine: A case report. ( Aomatsu, N; Ikeda, K; Kurihara, S; Maeda, K; Matsutani, S; Miyamoto, H; Nishii, T; Okada, T; Tachimori, A; Takeuchi, K; Tsujio, G; Uchima, Y, 2021)
"The efficacy of folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus ramucirumab (F-RAM) or aflibercept (F-AFL) as a second-line treatment in metastatic colorectal cancer (mCRC) is established."4.02Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2021)
"To evaluate the anti-cancer effects of OJe, its possible mechanisms of action were investigated in 5-fluorouracil (5-FU) resistant SNU-C5/5-FUR colorectal cancer cells."4.02Anti-cancer effects of the aqueous extract of Orostachys japonica A. Berger on 5-fluorouracil-resistant colorectal cancer via MAPK signalling pathways in vitro and in vivo. ( Kim, J; Kim, JW; Kim, SH; Mariappan, R; Moon, D; Yoon, SP, 2021)
" Although exposure measures have been implemented for the preparation and administration of the infusion pump(IP)used for continuous fluorouracil administration for 46-hour in FOLFOX and FOLFIRI therapies, which are standard chemotherapies for colorectal cancer, needle-removal procedures after the end of administration have not been investigated."4.02[Establishment of a Needle-Removal Method Considering Anticancer Drug Exposure after Continuous Administration of Fluorouracil Using an Infusion Pump]. ( Anami, S; Furihata, S; Ohno, R; Takamatsu, N; Yatsu, N, 2021)
"BACKGROUND The impact of therapeutic drug management (TDM) on reducing toxicity and improving efficacy in colorectal cancer (CRC) patients receiving fluorouracil-based chemotherapy is still unclear."4.02Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy. ( Chang, R; Chang, Y; Han, J; Qian, J; Shen, C; Zhao, H; Zhou, X, 2021)
"5-Fluorouracil (5-FU) is regarded as the first line treatment for colorectal cancer; however, its effectiveness is limited by drug resistance."4.02The combined effect of dichloroacetate and 3-bromopyruvate on glucose metabolism in colorectal cancer cell line, HT-29; the mitochondrial pathway apoptosis. ( Alboghobeish, S; Behmanesh, B; Khodayar, MJ; Mahdavinia, M; Nikravesh, H; Teimoori, A; Zeidooni, L, 2021)
"The present study aimed to investigate the influence of circular RNA nuclear receptor‑interacting protein 1 (circNRIP1) on the chemotherapeutic effect of 5‑fluorouracil (5‑FU) in colorectal cancer (CRC) and reveal its potential molecular mechanisms."4.02Knockdown of circNRIP1 sensitizes colorectal cancer to 5‑FU via sponging miR‑532‑3p. ( He, M; Li, R; Liu, F; Zhang, R; Zhang, Y, 2021)
"The study aimed to explore the efficacy of pharmacokinetic-based 5-fluorouracil dose management by plasma concentration test in advanced colorectal cancer treatment."3.96Pharmacokinetics-based Dose Management of 5-Fluorouracil Clinical Research in Advanced Colorectal Cancer Treatment. ( Deng, R; Guan, X; Shen, B; Shi, L; Wang, M; Yang, D; Zhu, W, 2020)
"For over 50 years, 5-Fluorouracil has played a critical role in the treatment of numerous malignancies, including colorectal cancer."3.96Optic neuritis induced by 5-fluorouracil chemotherapy: Case report and review of the literature. ( Gilbar, PJ; Grewal, GD; Holcombe, DJ; Raina, AJ, 2020)
"FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) is one of the main chemotherapy regimens for colorectal cancer (CRC), but only half of CRC patients respond to this regimen."3.96Qualitative transcriptional signature for predicting pathological response of colorectal cancer to FOLFOX therapy. ( Cheng, J; Guan, Q; Guo, Z; He, J; Li, Y; Wang, X; Yan, H; Zhao, W, 2020)
"5-fluorouracil (5-FU) is widely used in chemotherapy for colorectal cancer (CRC), but a high rate of chemoresistance reduces its effectiveness in clinical treatment."3.96FoxO3 reverses 5-fluorouracil resistance in human colorectal cancer cells by inhibiting the Nrf2/TR1 signaling pathway. ( Du, Q; He, B; Liu, C; Liu, X; Mi, Q; Peng, S; Qu, X; Wang, J; Yang, Y; Yao, Z; Zhang, X; Zhang, Y; Zhao, S; Zhao, Y; Zhu, Y; Zou, J, 2020)
" Normal adjacent gut epithelium tissue was collected during resection surgery from a cohort of 35 patients with stage II-III colorectal cancer (CRC) who were subsequently treated with capecitabine, XELOX or FOLFOX."3.96Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea. ( Bacon, O; Burke, JP; Carberry, S; Choudhry, A; Cremona, M; Doherty, G; Hennessy, BT; Lee, CS; Lindner, AU; McNamara, D; Oficjalska, K; Prehn, JHM; Resler, AJ; Ryan, EJ; Sheahan, K, 2020)
"The NCT00339183 trial demonstrated that adding panitumumab to fluorouracil, leucovorin and irinotecan (FOLFIRI) as a second-line therapy of wild-type RAS metastatic colorectal cancer (mCRC) increases the median progression-free survival (PFS)."3.96Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer. ( Li, J; Peng, L; Shi, Y; Tan, C; Wan, X, 2020)
"FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), a 5-fluorouracil (5-FU)-based chemotherapy regimen, is one of most common therapeutic regimens for colorectal cancer."3.96Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer. ( Chang, CW; Chen, MJ; Chen, YJ; Chiang Chiau, JS; Chuang, WH; Lee, HC; Li, LH; Liu, CY; Shih, SC; Tsai, TH; Wang, HY; Wang, TE, 2020)
"5-Fluorouracil-based therapy remains the main approach in colorectal cancer, even though there are still some drawbacks, such as chemoresistance."3.96Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo. ( Achim, M; Banciu, M; Casian, T; Dragos, N; Drotar, DM; Licarete, E; Luput, L; Muntean, D; Patras, L; Porfire, A; Rauca, VF; Sesarman, A; Stejerean, I; Toma, VA; Tomuta, I; Vlase, L, 2020)
"The standard first- and second- line chemotherapy backbone regimens for metastatic colorectal cancer (mCRC) are 5-fluorouracil (5-FU)/capecitabine-based with addition of irinotecan or oxaliplatin."3.96Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme. ( Carter, AM; Iveson, T; Mullamitha, S; Shiu, KK; Spooner, C; Stevens, D, 2020)
"The authors sought to forecast survival and enhance treatment decisions for patients with liver metastatic colorectal cancer by using on-treatment radiomics signature to predict tumor sensitiveness to irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) alone (F) or in combination with cetuximab (FC)."3.96Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway. ( Dercle, L; Eggleton, P; Lu, L; Piessevaux, H; Qian, M; Schwartz, LH; Tejpar, S; Zhao, B, 2020)
"5-Fluorouracil (5-Fu) is used as a conventional chemotherapy drug in chemotherapy for patients with advanced colorectal cancer, but many patients still suffer from treatment failure due to 5-Fu resistance."3.96CXCL-13 Regulates Resistance to 5-Fluorouracil in Colorectal Cancer. ( Cao, G; Chen, E; Huang, X; Jin, D; Ju, Z; Luo, X; Song, Z; Wang, F; Xu, J; Zhang, G; Zhang, W; Zhou, W, 2020)
"When the 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy regimen is used to treat colorectal cancer (CRC), chemotherapy-induced peripheral neuropathy (CIPN) caused by oxaliplatin can substantially affect quality of life (QOL) in the CRC patients."3.96Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study. ( Chen, JL; Chou, PL; Hsu, HT; Huang, YY; Juan, CH; Lin, PC; Wu, LM, 2020)
"Patients with RAS wild-type (WT) nonresectable metastatic colorectal cancer (mCRC) may receive either bevacizumab or an anti-epidermal growth factor receptor (EGFR) combined with first-line, 5-fluorouracil-based chemotherapy."3.96Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study). ( Baba-Hamed, N; Bignon-Bretagne, AL; Bouche, O; Buecher, B; Coriat, R; des Guetz, G; Dior, M; Doat, S; Galais, MP; Gornet, JM; Goujon, G; Granger, V; Henriques, J; Lievre, A; Locher, C; Manfredi, S; Metges, JP; Michel, P; Mineur, L; Obled, S; Palmieri, LJ; Pernot, S; Phelip, JM; Rousseau, B; Saban-Roche, L; Smith, D; Soularue, E; Tougeron, D; Trouilloud, I; Vernery, D; Vitellius, C, 2020)
" Casein kinase 2α (CK2α) is highly expressed in 5-fluorouracil (5FU)-resistant colorectal cancer (CRC) cells."3.96Casein Kinase 2α Enhances 5-Fluorouracil Resistance in Colorectal Cancer Cells by Inhibiting Endoplasmic Reticulum Stress. ( Han, YS; Kim, HJ; Lee, JH; Lee, SH, 2020)
"The aim of this study was to clarify the risk benefits of folinic acid, fluorouracil, and irinotecan (FOLFIRI) plus ramucirumab (F-RAM) as third-line and later-line treatment for metastatic colorectal cancer (mCRC)."3.96Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer. ( Kimura, M; Teramachi, H; Usami, E; Yoshimura, T, 2020)
" MTT assay, cell counting, cell death analysis, cell cycle analysis, and Western blotting were done on colorectal cancer cells with or without 5-fluorouracil resistance (SNU-C5 and SNU-C5/5-FUR)."3.96Yeast Extract Induces Apoptosis and Cell Cycle Arrest via Activating p38 Signal Pathway in Colorectal Cancer Cells. ( Kang, HK; Kim, J; Moon, D; Yoon, SP, 2020)
"Capecitabine is a prodrug of 5-fluorouracil (5-FU) used for the treatment of colorectal cancer, with a two-week course of administration."3.96Assessment of pharmacokinetic variations of capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model. ( Ito, Y; Kobuchi, S; Sakaeda, T; Sakai, S, 2020)
"5-Fluorouracil (5-FU) is a chemotherapeutic drug widely used to treat colorectal cancer."3.96Comparative lipidomics of 5-Fluorouracil-sensitive and -resistant colorectal cancer cells reveals altered sphingomyelin and ceramide controlled by acid sphingomyelinase (SMPD1). ( Akao, Y; Bandu, R; Jung, JH; Kim, KP; Komura, K; Lee, HM; Lee, KY; Lee, MY; Taniguchi, K, 2020)
"To analyse the results of fluorouracil (5-FU) plasma concentration monitoring in patients with advanced colorectal cancer after 5-FU treatment, and to provide a reference for the application prospect of 5-FU plasma concentration monitoring technology."3.96A retrospective analysis of plasma concentration monitoring of fluorouracil in patients with advanced colorectal cancer. ( Bi, Y; He, G; Li, X; Liu, Q; Ma, J; Yang, Q; Zhang, C; Zhang, J, 2020)
"This study aimed to evaluate the efficacy and the safety of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing neutropenia in metastatic colorectal cancer (mCRC) patients that received fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab (Bev) in clinical practice."3.96Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study. ( Chin, K; Kitagawa, Y; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Ota, Y; Shinozaki, E; Suenaga, M; Suzuki, T; Takahari, D; Wakatsuki, T; Yamaguchi, K, 2020)
"Cetuximab plus FOLFIRI (leucovorin, fluorouracil, and irinotecan) is the preferred first-line therapy for RAS and BRAF wild-type (RBWT) metastatic colorectal cancer (mCRC)."3.96Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study. ( Chen, H; Du, B; Hou, P; Jiang, T; Lai, J; Lin, M; Lin, X; Liu, Q; Wang, H; Wang, X; Yang, B; Zheng, J; Zhong, D, 2020)
"We studied the predictive value for response and toxicity of functional polymorphisms in genes involved in the oxaliplatin/fluorouracil pathway in colorectal cancer patients."3.96Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics? ( Anido, U; Barros, F; Bernárdez, B; Candamio, S; Carracedo, Á; Cruz, R; Duran, G; Giráldez, JM; Lamas, MJ; López-López, R; Simoes, AR, 2020)
"The combination of folinic acid, 5-fluorouracil, oxaliplatin and/or irinotecan (FOLFOXIRI) is the standard of care for metastatic colorectal cancer (CRC)."3.96Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment. ( Nowak-Sliwinska, P; Ramzy, GM; Rausch, M; Zoetemelk, M, 2020)
" Herein we revealed a previously unrecognized mechanism of 5-fluorouracil (5-FU) resistance contributed by high SphK2-upregulated dihydropyrimidine dehydrogenase (DPD) in colorectal cancer (CRC), which is evidenced from human CRC specimens, animal models, and cancer cell lines."3.96SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression. ( Cui, SX; Guo, ZK; Luo, DD; Miao, RR; Qu, XJ; Shi, WN; Sun, SY; Wan, SB; Wang, WY; Wu, SH; Yu, XF; Zhang, YH, 2020)
"5-Fluorouracil (5-FU) is one of the most effective drugs for the treatment of colorectal cancer (CRC)."3.96Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins. ( Cai, J; Li, W; Liu, Y; Ma, L; Xu, Y; Yang, Y; Zhang, Y, 2020)
"The purpose of this study was to investigate the effect of metformin or the combination of metformin and 5-FU on the growth and metastasis of colorectal cancer (CRC)."3.96Metformin Inhibited Proliferation and Metastasis of Colorectal Cancer and presented a Synergistic Effect on 5-FU. ( Sang, J; Sun, Q; Tang, R; Yang, M, 2020)
"High interindividual variability was reported with capecitabine toxicities among colorectal cancer (CRC) patients."3.96Genetic influence of ( Dubashi, B; Jayanthi, M; Shewade, DG; Sundaram, R; Varma, A, 2020)
"The AXEPT trial demonstrated that modified XELIRI (mXELIRI; capecitabine + irinotecan) was noninferior to standard treatment with FOLFIRI (fluorouracil + leucovorin + irinotecan), both ± bevacizumab, in the treatment of metastatic colorectal cancer (mCRC)."3.96Cost-effectiveness of Capecitabine + Irinotecan Versus Leucovorin + Fluorouracil + Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China. ( Li, Q; Liao, W; Wang, X; Wu, Q; Zhang, M; Zhang, P, 2020)
"To assess the efficacy and safety of cetuximab (CE) versus bevacizumab (BE) maintenance treatment after prior 8-cycle modified 5-fluorouracil, folinate, oxaliplatin, and irinotecan (FOLFOXIRI) plus CE induction therapy in treatment-naive KRAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC)."3.96Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer. ( Chen, B; Han, G; Huang, C; Ye, J; Yu, W; Zheng, D; Zhuang, J, 2020)
"Cancer stem cells (CSCs) from colorectal cancer (CRC), characterized by CD133 expression, have been associated with 5-fluorouracile (5-FU) chemoresistance."3.96MMR-proficient and MMR-deficient colorectal cancer cells: 5-Fluorouracil treatment response and correlation to CD133 and MGMT expression. ( Caba, O; Cabeza, L; Jimenez-Luna, C; Melguizo, C; Mesas, C; Oliver, JA; Ortiz, R; Perazzoli, G; Prados, J, 2020)
" The biomarkers identified by our approach accurately predict the drug responses of 114 colorectal cancer patients treated with 5-fluorouracil and 77 bladder cancer patients treated with cisplatin."3.96Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients. ( Ha, D; Han, SK; Kim, D; Kim, S; Kong, J; Lee, H; Shin, K, 2020)
" In this perspective, we recently developed a multipurpose thermosensitive hydrogel based on reversible thermogelling properties of poloxamers P407 and P188, a bioadhesive excipient and antineoplastic effect of 5-fluorouracil (5-FU) for the local treatment of colorectal cancer (CRC) in ectopic CT26 murine models."3.96Thermosensitive hydrogels for local delivery of 5-fluorouracil as neoadjuvant or adjuvant therapy in colorectal cancer. ( Agapova, E; Al Sabbagh, C; Boudy, V; Kramerich, D; Mignet, N; Seguin, J, 2020)
"In the treatment of metastatic colorectal cancer (mCRC), exposure to all three active cytotoxic agents, 5-fluorouracil/capecitabine, irinotecan and oxaliplatin, improves overall survival."3.96Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia. ( Ananda, S; Cooray, P; Delahunty, R; Desai, J; Gibbs, P; Johns, J; Kosmider, S; Lee, B; Lee, M; Mckendrick, J; Tie, J; Tran, B; Wong, HL; Wong, R, 2020)
"This study is an ancillary study from the PRODIGE-9 multicentre prospective study for which 491 patients with metastatic colorectal cancer (mCRC) treated by 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) and bevacizumab had been analysed."3.96Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. ( Aparicio, T; Barbier, E; Ben Abdelghani, M; Bennouna, J; Boige, V; Borel, C; Bouché, O; Desseigne, F; Dohan, A; Faroux, R; François, E; Gallix, B; Genet, D; Ghiringhelli, F; Guiu, B; Hoeffel, C; Jacquot, S; Jouve, JL; Khemissa-Akouz, F; Le Malicot, K; Lepage, C; Phelip, JM; Reinhold, C; Rinaldi, Y; Seitz, JF; Soyer, P; Suc, E; Taieb, J; Texereau, P, 2020)
"To investigate the influence of longan flower extract (LFE) on the sensitization of colorectal cancer (CRC) cells to 5-fluorouracil (5-FU) treatment, HT-29, Colo 320DM and SW480 cells were treated with LFE and 5-FU alone and in combination, and the cell viability was then assessed by trypan blue exclusion, the cell cycle by propidium iodide staining, the mitochondria membrane potential by rhodamine 123 staining, and the expression levels of associated genes by immunoblotting and quantitative real-time polymerase chain reaction."3.96Synergistic Effect of Combined Treatment with Longan Flower Extract and 5-Fluorouracil on Colorectal Cancer Cells. ( Chang, HL; Chang, HP; Chen, CH; Chen, SJ; Chou, JL; Chung, YC; Hsu, CP; Lin, CC, 2020)
"Despite new agent development and short-term benefits in patients with colorectal cancer (CRC), metastatic CRC cure rates have not improved due to high rates of 5-fluorouracil (5-FU)/leucovorin/oxaliplatin (FOLFOX)-resistance and a clinical therapeutic plateau."3.91ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells. ( Amin, S; Jaiswal, AS; Law, BK; Narayan, S; Ramisetti, S; Sharma, AK; Singh, P; Singh-Pillay, A, 2019)
"5-Fluorouracil (5-FU) is an important chemotherapeutic agent for the systemic treatment of colorectal cancer (CRC), but its effectiveness against CRC is limited by increased 5-FU resistance caused by the hypoxic tumor microenvironment."3.91Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer. ( Kim, CW; Kim, HG; Lee, DH; Lee, JS; Oh, ET; Park, HJ, 2019)
"This study investigated the potential of single nucleotide polymorphisms as predictors of survival in two cohorts comprising 417 metastatic colorectal cancer (mCRC) patients treated with the FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) regimen."3.91Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients. ( Allain, EP; Buonadonna, A; Cecchin, E; Couture, F; D'Andrea, M; De Mattia, E; Guillemette, C; Jonker, D; Labriet, A; Lévesque, É; Rouleau, M; Simonyan, D; Toffoli, G; Villeneuve, L, 2019)
"Clinically, one of the principal factors in the failure of advanced colorectal cancer (CRC) treatment is chemoresistance to 5-fluorouracil (5FU)-based chemotherapy."3.91miR-375-3p suppresses tumorigenesis and partially reverses chemoresistance by targeting YAP1 and SP1 in colorectal cancer cells. ( Chen, X; He, B; Liu, X; Pan, B; Pan, Y; Qin, J; Sun, H; Sun, L; Wang, S; Xu, M; Xu, T; Xu, X; Zeng, K, 2019)
"The first-line chemotherapy of colorectal cancer (CRC), besides surgery, comprises administration of 5-Fluorouracil (5FU)."3.91Ganoderma Lucidum induces oxidative DNA damage and enhances the effect of 5-Fluorouracil in colorectal cancer in vitro and in vivo. ( Cumova, A; Galanova, N; Horak, J; Hucl, T; Kostovcikova, K; Kozics, K; Macinga, P; Opattova, A; Rejhova, A; Sliva, D; Turnovcova, K; Vodenkova, S; Vodicka, P; Vodickova, L, 2019)
"The high-budding group demonstrated resistance to 5-fluorouracil-based chemotherapy, whereas the low-budding group exhibited significant survival benefits from adjuvant chemotherapy in stage III colorectal cancer."3.91Differential Survival Benefits of 5-Fluorouracil-Based Adjuvant Chemotherapy for Patients With Microsatellite-Stable Stage III Colorectal Cancer According to the Tumor Budding Status: A Retrospective Analysis. ( Hase, K; Kajiwara, Y; Mochizuki, S; Okamoto, K; Shinto, E; Ueno, H; Yamadera, M; Yamamoto, J, 2019)
"In the present study, we aimed to determine the efficacy of trabectedin (TRAB) combined with oxaliplatinum (OXA)+5-fluorouracil (5-FU) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (PDOX) mouse model."3.91Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model. ( Bouvet, M; Han, Q; Hoffman, RM; Singh, SR; Sun, YU; Tan, Y; Ye, J; Zhao, M; Zhu, G, 2019)
"To investigate the influence of organic cation transporter 3 (OCT3) expression on the effect of the combination regimen of 5-fluorouracil, folinic acid and oxaliplatin ((m)FOLFOX6) in colorectal cancer (CRC) patients."3.91Upregulated OCT3 has the potential to improve the survival of colorectal cancer patients treated with (m)FOLFOX6 adjuvant chemotherapy. ( Dong, D; Feng, S; Gu, J; Jiang, X; Li, T; Long, E; Tang, S; Wang, L, 2019)
"The aim of the present study was to determine the efficacy of trabectedin combined with FOLFIRI (irinotecan, leucovorin and 5-fluorouracil) on a colorectal cancer (CRC) patient-derived orthotopic xenograft (iPDOX) mouse model."3.91Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model. ( Bouvet, M; Clary, B; Han, Q; Hoffman, RM; Singh, SR; Sun, YU; Tan, Y; Ye, J; Zhao, M; Zhu, G, 2019)
"The current study suggests that the identification of predictive signatures of fluorouracil (5-FU) response for stage II and III colorectal cancer (CRC) could be confounded by chemotherapy-irrelevant low relapse risk."3.91Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit. ( Ao, L; Cai, H; Guo, Y; Guo, Z; Li, N; Song, K; Song, X; Wang, X; Zhao, W; Zheng, W, 2019)
"Selected SNPs in the adenosine pathway could affect the clinical outcomes of patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab."3.91Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. ( Battaglin, F; Berger, MD; Cao, S; Cremolini, C; Falcone, A; Heinemann, V; Lenz, HJ; Lo, JH; Loupakis, F; Millstein, J; Naseem, M; Puccini, A; Soni, S; Stintzing, S; Tokunaga, R; Zhang, W, 2019)
"Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU."3.91Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. ( Chakrabarti, S; Eiring, R; Finnes, H; Grothey, A; Halfdanarson, T; Hartgers, M; Lobo, R; Mitchell, J; Okano, A; Sara, J, 2019)
"5-Fluorouracil (5-FU) represents the backbone of systemic therapy regimens of colorectal cancer."3.915-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer. ( Abdel-Rahman, O, 2019)
"First-line adjuvant chemotherapy options for early-stage colorectal cancer (CRC) include CapeOx (capecitabine, intravenous oxaliplatin) and FOLFOX (intravenous 5-fluorouracil, leucovorin, oxaliplatin)."3.91Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer. ( Chambers, CR; Chu, MP; Dersch-Mills, D; Ghosh, S; Ha, V; Sawyer, MB; Wong, GG, 2019)
"Oral uracil-tegafur/leucovorin (UFT/LV) and intravenous 5-fluorouracil (FU)/LV are common adjuvant therapies for Stages II and III colorectal cancer."3.91Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan. ( Hsu, TC; Wang, CC, 2019)
"5-Fluorouracil (5-FU) has been established as the first-line chemotherapy for advanced colorectal cancer (CRC); however, acquired chemoresistance is often the cause of poor therapeutic response."3.91Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. ( Goel, A; Sakatani, A; Sonohara, F, 2019)
" By performing a series of experiments in chemoresistant colorectal cancer cell lines, we demonstrate that oligomeric proanthocyanidins (OPCs) from grape seed extracts can sensitize both acquired (HCT116-FOr cells) and innately chemoresistant (H716 cells) cancer cells to chemotherapeutic drugs, 5-fluorouracil (5FU) and oxaliplatin, by inhibiting adenosine triphosphate-binding cassette (ABC) transporter proteins."3.91Oligomeric proanthocyanidins (OPCs) from grape seed extract suppress the activity of ABC transporters in overcoming chemoresistance in colorectal cancer cells. ( Goel, A; Pasham, D; Ravindranathan, P, 2019)
"Oxaliplatin, combined with capecitabine (CAPOX) or infused 5-fluorouracil (FOLFOX), is standard of care in the adjuvant treatment of colorectal cancer (CRC)."3.91Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. ( Bono, P; Hänninen, UA; Karhunen, M; Lamminmäki, A; Osterlund, P; Soveri, LM, 2019)
"To evaluate the impact of sex on toxicity and efficacy outcomes among patients with metastatic colorectal cancer receiving first-line 5-fluorouracil-based regimens."3.91Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials. ( Abdel-Rahman, O, 2019)
" The studies observed patients with wild-type [Kirsten] rat sarcoma viral oncogene homolog ([K]RAS/RAS) metastatic colorectal cancer (mCRC), who had been treated with panitumumab in combination with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in the first line or with panitumumab combined with fluorouracil, leucovorin, and irinotecan (FOLFIRI) in the second line following fluoropyrimidine-based chemotherapy."3.91Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC. ( Bjorklof, K; Buchler, T; Csoszi, T; Demonty, G; Hebart, H; Kafatos, G; Kiehl, M; Koukakis, R; Kuhn, A; Tomasek, J, 2019)
" We sought to characterize the effects of 5 fluorouracil (5FU) chemotherapy on colon inflammation and functional measures in colorectal cancer (CRC) and to further determine whether gut microbiota can influence this response."3.91Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota. ( Bader, JE; Carson, JA; Carson, M; Chatzistamou, I; Enos, RT; Kubinak, JL; Murphy, EA; Nagarkatti, M; Pena, MM; Sougiannis, AT; VanderVeen, BN; Velazquez, KT; Walla, M, 2019)
"The efficacy of Fluorouracil (FU) in the treatment of colorectal cancer (CRC) is greatly limited by drug resistance."3.91ABHD5 blunts the sensitivity of colorectal cancer to fluorouracil via promoting autophagic uracil yield. ( Chen, Y; Hao, J; Li, F; Li, J; Liang, H; Luo, X; Ou, J; Peng, Y; Sun, W; Wang, L; Wu, S; Xie, G; Xie, X; Yang, W; Zha, L; Zhang, Y; Zhao, Y; Zhou, Q, 2019)
"Colorectal cancer is one of the primary causes of cancer-related deaths and 5-fluorouracil (5-FU) therapy remains the cornerstone of treatment in these patients."3.91RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer. ( Bachvarov, CH; Bogdanova, MK; Chaushev, BG; Conev, NV; Dimitrova, EG; Donev, IS; Georgiev, KD; Kalchev, KP; Kashlov, YK; Manev, RR; Petrov, DP; Popov, HB; Radanova, MA; Todorov, GN, 2019)
"5-Fluorouracil (5-FU) is an anticancer drug that is most frequently used to treat colorectal cancer (CRC) patients, but unfortunately it shows limited efficacy."3.91Tacalcitol increases the sensitivity of colorectal cancer cells to 5-fluorouracil by downregulating the thymidylate synthase. ( Klopotowska, D; Kutner, A; Milczarek, M; Rossowska, J; Stachowicz, M; Wietrzyk, J, 2019)
"Colorectal cancer (CRC) is still the third most common cancer in the world with a limited prognosis due to the chemoresistance of CRC cells to 5-fluorouracil (5-FU)-based chemotherapy."3.91Long non-coding RNA PCAT6 targets miR-204 to modulate the chemoresistance of colorectal cancer cells to 5-fluorouracil-based treatment through HMGA2 signaling. ( Fan, D; He, H; Lei, M; Liang, Y; Shen, L; Wu, H; Zhou, Q; Zou, Q, 2019)
"We used data of 7 treatment cycles of capecitabine in patients with metastatic colorectal cancer."3.91Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites. ( Aldaz, A; Bueno, L; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019)
"We enrolled patients administered adjuvant capecitabine plus oxaliplatin (CapeOX) for postoperative colorectal cancer (CRC) patients and metastatic CRC patients receiving CapeOX with/without bevacizumab."3.91Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil. ( Fujita, KI; Ishida, H; Ishikawa, F; Kubota, Y; Ohkuma, R; Sasaki, Y; Sekido, M; Shibanuma, M; Takahashi, T; Tsunoda, T, 2019)
"5-Fluorouracil (5-FU) remains the gold standard of first-line treatment for colorectal cancer (CRC)."3.91Establishment and Characterization of 5-Fluorouracil-Resistant Human Colorectal Cancer Stem-Like Cells: Tumor Dynamics under Selection Pressure. ( Bulanin, D; Francipane, MG; Lagasse, E, 2019)
" 5-Fluorouracil is a clinically approved drug which has limited response rate in the realm of colorectal cancer amelioration, hence our study aims to improve its efficacy by aiming the simultaneous delivery of 5-Flurouracil and apigenin which is naturally occurring flavone abundantly present in fruit and vegetables through a single liposome to combat and control colorectal cancer effectively in-vitro and in-vivo."3.91Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer. ( Banerjee, S; Mandal, M; Sen, K, 2019)
"Only 10%-20% of colorectal cancer (CRC) patients observe effective responses to 5-fluorouracil (5-FU) based chemo-treatment."3.91Epigenetically Down-Regulated Acetyltransferase PCAF Increases the Resistance of Colorectal Cancer to 5-Fluorouracil. ( Fang, X; Fang, Z; Hu, W; Jin, Y; Liu, T; Miao, QR; Wang, X, 2019)
"Although DNA-mismatch-repair-deficient (dMMR) status and aberrant expression of miRNAs are both critically implicated in the pathogenesis of resistance to 5-fluorouracil (5-FU) in colorectal cancer (CRC), whether these two factors regulate tumor response to 5-FU in a coordinated manner remains unknown."3.91MicroRNA-552 deficiency mediates 5-fluorouracil resistance by targeting SMAD2 signaling in DNA-mismatch-repair-deficient colorectal cancer. ( Dai, ZJ; Guan, HT; Liu, D; Ma, YG; Yan, CY; Zhao, P; Zhao, Y, 2019)
"Patients with advanced colorectal cancer often are treated with systemic cytotoxic therapy using fluorouracil (5-FU), oxaliplatin, irinotecan, and FOLFOX or FOLFIRI combination protocols."3.91In vivo effects of chemotherapy on oncogenic pathways in colorectal cancer. ( Elmasry, M; Horst, D; Kirchner, T; Schmidt, EM; Schulz, GB; Spartalis, C, 2019)
"The VELOUR study evaluated the efficacy and safety of adding aflibercept to FOLFIRI (fluorouracil, leucovorin, irinotecan) in second-line therapy for metastatic colorectal cancer (mCRC)."3.91Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis. ( Argilés Martínez, G; Carmona-Bayonas, A; Castañón López, C; Fernández Montes, A; Gallego Plazas, J; García Paredes, B; Gutiérrez Abad, D; Jiménez Fonseca, P; Juez Martel, I; Llorente Ayala, B; López Doldán, MC; López Flores, M; López López, C; López Muñoz, AM; Martínez de Castro, E; Páez López, D; Sánchez Cánovas, M; Tobeña Puyal, M, 2019)
" In the present study, the antitumor effects were investigated, and the possible underlying mechanisms of kaempferol combined with 5‑fluorouracil (5‑FU) in colorectal cancer cells were explored."3.91Synergistic effect of kaempferol and 5‑fluorouracil on the growth of colorectal cancer cells by regulating the PI3K/Akt signaling pathway. ( Chen, Y; Li, Q; Lin, J; Lin, S; Peng, J; Wei, L, 2019)
"We developed a molecular beacon targeting miR-141-3p, aberrantly increased in 5-fluorouracil-resistant colorectal cancer cells (R-CRCCs)."3.91Theragnosis by a miR-141-3p molecular beacon: simultaneous detection and sensitization of 5-fluorouracil resistant colorectal cancer cells through the activation of the TRIM13-associated apoptotic pathway. ( Heo, HJ; Jeong, SH; Jung, WY; Kim, S; Lee, YS; Moon, SU; Park, MG; Park, Y; Song, SK, 2019)
"5-fluorouracil in combination with the folate leucovorin is the cornerstone in treatment of colorectal cancer."3.91Folate pathway genes linked to mitochondrial biogenesis and respiration are associated with outcome of patients with stage III colorectal cancer. ( Carlsson, G; Gustavsson, B; Odin, E; Sondén, A; Wettergren, Y, 2019)
"To assess if CT texture analysis (TA) can serve as a biomarker of liver toxicity in patients with colorectal cancer treated with 5-fluorouracil (5-FU)-based chemotherapy."3.915-Fluorouracil induced liver toxicity in patients with colorectal cancer: role of computed tomography texture analysis as a potential biomarker. ( Alessandrino, F; Cruz, G; Meyerhardt, JA; Qin, L; Rosenthal, MH; Sahu, S; Shinagare, AB, 2019)
"5-Fluorouracil (5-FU)-based chemotherapy has always been the first-line treatment of colorectal cancer (CRC)."3.91The long non-coding RNA HOTAIRM1 suppresses cell progression via sponging endogenous miR-17-5p/ B-cell translocation gene 3 (BTG3) axis in 5-fluorouracil resistant colorectal cancer cells. ( Chen, J; Hou, J; Liu, C; Qin, A; Ren, T; Ren, W; Shan, F; Xiong, X, 2019)
"Precision medicine might be the response to the recent questioning of the use of metformin as an anticancer drug in colorectal cancer (CRC)."3.91A more physiological approach to lipid metabolism alterations in cancer: CRC-like organoids assessment. ( Cruz-Gil, S; Pape, K; Ramírez de Molina, A; Sánchez-Martínez, R; Schölch, S; Stange, D; Wagner-Reguero, S, 2019)
"5-Fluorouracil (5-FU) as a chemotherapeutic drug is used to treat colorectal cancer (CRC)."3.88The Effect of miR-200c Inhibition on Chemosensitivity (5- FluoroUracil) in Colorectal Cancer. ( Dermani, FK; Heydari, K; Najafi, R; Saidijam, M; Shabab, N; Sharifi, MR; Soleimani Asl, S, 2018)
"Our objective was to evaluate the benefit of re-exposing patients with refractory metastatic colorectal cancer (mCRC) to a combination of oxaliplatin, irinotecan and 5-fluorouracil treatment."3.88Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients. ( Artioli, M; Braghiroli, MI; Braghiroli, OFM; Costa, FP; Fernandes, GDS; Girardi, DDM; Gumz, BP; Hoff, PM; Paterlini, ACCR; Teixeira, MC, 2018)
" The objective of this exploratory study was to examine the association of low skeletal muscle, commonly known as sarcopenia, on the pharmacokinetics (PKs) of 5-fluorouracil (5FU) in patients receiving FOLFOX for colorectal cancer."3.88The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. ( Choi, SK; Deal, AM; McLeod, HL; Muss, HB; O'Neil, B; Patel, JN; Sanoff, HK; Shachar, SS; Walko, CM; Weinberg, MS; Williams, GR, 2018)
" The prognostic role of TOPO-1 and CES-2 in patients with metastatic colorectal cancer (mCRC) who underwent irinotecan chemotherapy was largely unknown."3.88Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer. ( Guisheng, L; Haixin, H; Li, H; Shaojun, C, 2018)
"To investigate expression of cell cycle-related and expression-elevated protein in tumor (CREPT) in colorectal cancer (CRC) and determine its prognostic value in response to 5-fluorouracil (5-FU)."3.88Overexpression of CREPT confers colorectal cancer sensitivity to fluorouracil. ( Chang, ZJ; Ding, LD; Jia, BQ; Kuang, YS; Li, J; Liu, HY; Liu, SH; Wang, XN; Wang, Y; Wang, YY; Yang, L; Zhu, BT, 2018)
"Regorafenib is a multi-kinase inhibitor, which was shown to be effective for patients with metastatic colorectal cancer refractory to standard therapies."3.88Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study. ( Gonoi, W; Hashimoto, M; Kondoh, C; Kuroyanagi, H; Matoba, S; Nishioka, Y; Ozaki, Y; Shindoh, J; Takano, T; Tanabe, Y, 2018)
"We describe a metastatic colorectal cancer patient, treated with first-line 5-fluorouracil, irinotecan, bevacizumab, and oxaliplatin (FIr-BFOx) therapy, with aggressive and resistant disease."3.88KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease. ( Alesse, E; Bruera, G; Calvisi, G; Cannita, K; Cocciolone, V; Cortellini, A; Dal Mas, A; Ficorella, C; Mastroiaco, V; Ricevuto, E; Tessitore, A; Zazzeroni, F, 2018)
" Furthermore, upregulating TFAP2C enhances spheroids formation ability, the fraction of SP cells, expression of stem cell factors and the mitochondrial potential, and reduces the apoptosis induced by 5-fluorouracil in colorectal cancer cells in vitro, and promotes stemness and chemoresistance of CRC cells in vivo; while silencing TFAP2C yields an opposite effect."3.88TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway. ( Chen, S; Ren, D; Sun, D; Tai, J; Wang, L; Wang, X; Yu, M, 2018)
" In this study, we investigated the effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma (CRC) cells and its mechanism."3.88The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism. ( Jiang, GS; Liu, GW; Liu, YH; Ren, WD, 2018)
"The aim of this study was to investigate the efficacy and safety of first-line panitumumab plus folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in patients with wild-type KRAS and wild-type NRAS metastatic colorectal cancer (mCRC)."3.88FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer. ( Geredeli, C; Yasar, N, 2018)
"Fluoropyrimidines, such as 5-fluorouracil (5-FU) and related prodrugs, are considered one of the most successful agents in the treatment of colorectal cancer, yet poor specificity and tumor cell resistance remain the major limiting bottlenecks."3.88DNA-based nanoscaffolds as vehicles for 5-fluoro-2'-deoxyuridine oligomers in colorectal cancer therapy. ( Aviñó, A; Eritja, R; Fàbrega, C; Jorge, AF; Pais, AACC, 2018)
"5-fluorouracil (5-FU) and oxaliplatin (OxaPt) are the main chemotherapeutics for colorectal cancer (CRC)."3.88Significance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT116. ( Dabkeviciene, D; Eidenaite, E; Jonusiene, V; Kukcinaviciute, E; Laurinavicius, A; Sasnauskiene, A, 2018)
"We aimed to evaluate the effect of potential regulatory variants in NLRC5 on overall survival and survival after 5-fluorouracil (5-FU)-based therapy of colorectal cancer (CRC) patients."3.88Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy. ( Catalano, C; da Silva Filho, MI; Försti, A; Hemminki, K; Jiraskova, K; Levy, M; Liska, V; Naccarati, A; Vodicka, P; Vodickova, L; Vycital, O; Vymetalkova, V; Weber, ANR, 2018)
"To investigate the effects of miR-519d on the 5-fluorouracil resistance in colorectal cancer cells and to explore the mechanism."3.88MiR-519d reduces the 5-fluorouracil resistance in colorectal cancer cells by down-regulating the expression of CCND1. ( Chi, YJ; Huang, R; Lin, JY, 2018)
"Chemotherapeutic 5-fluorouracil (5-FU) combined with oxaliplatin is often used as the standard treatment for colorectal cancer (CRC)."3.88Chrysin Attenuates Cell Viability of Human Colorectal Cancer Cells through Autophagy Induction Unlike 5-Fluorouracil/Oxaliplatin. ( Chen, CI; Chen, YJ; Cheng, KC; Chien, PH; Hsiang, YP; Hsu, YC; Lin, YM; Lu, CC; Pan, HL, 2018)
"The FIRE-3 [5-fluorouracil, folinic acid, and irinotecan (FOLFIRI) plus cetuximab versus FOLFIRI plus bevacizumab in first line treatment colorectal cancer (CRC)] study reported that first-line FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab resulted in similar progression-free survival (PFS) but improved overall survival (OS)."3.88Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry. ( Burge, M; Dean, AP; Eastgate, M; Gibbs, P; Kosmider, S; Lee, B; Lee, M; Lok, SW; Ma, B; Semira, C; Shapiro, J; Steel, SA; Torres, J; Wong, HL; Wong, R; Zimet, AS, 2018)
"BACKGROUND 5-Fluorouracil (5-FU)-based chemotherapy is a conventional therapeutic approach for the treatment of patients with colorectal cancer (CRC)."3.88miR-106a Reduces 5-Fluorouracil (5-FU) Sensitivity of Colorectal Cancer by Targeting Dual-Specificity Phosphatases 2 (DUSP2). ( Chen, X; Huo, Z; Liu, Z; Qin, Y; Tian, X, 2018)
"Capecitabine is a pro-drug of 5-fluorouracil (5-FU), and is an orally available chemotherapeutic used to treat colorectal cancer (CRC)."3.88Investigation into Enhancing Capecitabine Efficacy in Colorectal Cancer by Inhibiting Focal Adhesion Kinase Signaling. ( Baek, JH; Jeong, KY; Kim, HM; Lee, H; Park, MH; Sim, JJ, 2018)
"Curcumin, a well-studied component in turmeric, exhibits potent antitumor effects in colorectal cancer."3.88Turmeric extract, with absorbable curcumin, has potent anti-metastatic effect in vitro and in vivo. ( Fung, KP; Lau, CB; Li, M; Tsui, SK; Yue, GG, 2018)
" Median time from initial diagnosis of metastases to the start of regorafenib and treatment duration was 13."3.88Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial). ( Aranda, E; Benavides, M; Durán, G; Falcó, E; García-Alfonso, P; Gómez, A; López, R; López-Ladrón, A; Montagut, C; Muñoz, A; Rivera, F; Ruiz de Mena, I; Salgado, M; Sastre, J, 2018)
" Here, the role of PKM2 in the anticancer efficacy of 5-fluorouracil (5-FU) was evaluated in colorectal cancer (CRC)."3.88Enhancing 5-fluorouracil efficacy through suppression of PKM2 in colorectal cancer cells. ( Cao, Y; Jin, Y; Lin, Y; Pan, D; Wang, D; Zhang, Y; Zheng, C, 2018)
"The intent of this article is to evaluate the effect of oral cryotherapy on the prevention of oral mucositis and pain among patients with colorectal cancer undergoing fluorouracil-based chemotherapy."3.88Oral Cryotherapy: Prevention of Oral Mucositis and Pain Among Patients With Colorectal Cancer Undergoing Chemotherapy. ( Hsien Chan, CM; Idayu Mat Nawi, R; Lei Chui, P; Wan Ishak, WZ, 2018)
"To evaluate the safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (mFOLFOXIRI) for patients with advanced colorectal cancer (CRC)."3.88[Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer]. ( Cai, Y; Deng, R; Deng, Y; Hu, H; Li, J; Ling, J; Wu, Z; Yang, L; Zhang, J, 2018)
"The benefit of IFL (irinotecan, fluorouracil and leucovorin) regimen for metastatic colorectal cancer patients (mCRCs) with high levels of microsatellite instability (MSI-H) or loss of mismatch repair (dMMR) protein expression, is uncertain."3.88Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen. ( Bendardaf, R; Pyrhönen, S; Sharif-Askari, FS; Sharif-Askari, NS; Syrjänen, K, 2018)
" Interestingly, the panel also revealed that he had mismatch-repair(MMR)deficiency with MSH2 mutation, which is reported as a possible cause of resistance to 5-fluorouracil in colorectal cancer."3.88[A Case of Resistance to Systemic Therapy in Hypermutation of Colorectal Cancer]. ( Hotta, S; Ichikawa, H; Kameyama, H; Maruyama, S; Miura, K; Nagahashi, M; Nakano, M; Nogami, H; Shimada, Y; Tajima, Y; Takii, Y; Tanaka, K; Wakai, T; Yamada, S, 2018)
"More than half of patients with colorectal cancer will develop metastatic disease either evident at the time of initial diagnosis or during their course of disease."3.86Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. ( Arnold, D; Edelmann, T; Glockzin, G; Hildebrandt, B; Hollerbach, S; Illerhaus, G; Königsrainer, A; Richter, M; Schlitt, HJ; Schmoll, HJ; Stein, A; Wienke, A, 2012)
"Almost all colorectal cancer (CRC) cell lines are known to overexpress aspartate aminotransferase (GOT1), which potentially regulates the intracellular levels of reactive oxygen species (ROS) via the production of NADPH, and supports tumor growth."3.85Inhibition of GOT1 sensitizes colorectal cancer cells to 5-fluorouracil. ( Hong, C; Li, X; Zheng, J, 2017)
"Although 5-fluorouracil (5-FU) is known to interfere with the synthesis of ribonucleic acid and deoxyribonucleic acid, the mechanism underlying its therapeutic efficacy in colorectal cancer (CRC) has not been fully elucidated."3.855-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer. ( Cao, L; Du, C; Gu, J; Huang, D; Peng, Y; Wang, H; Yang, Y; Yao, Y; Zhao, Y; Zhu, WG, 2017)
"To evaluate whether the results of chemosensitivity testing were associated with prognosis of colorectal cancer patients after adjuvant 5-fluorouracil (FU)/ leucovorin chemotherapy."3.85Clinical Significance of 5-Fluorouracil Chemosensitivity Testing in Patients with Colorectal Cancer. ( Hong, KD; Ji, WB; Joung, SY; Kim, JS; Kim, YS; Lee, JH; Min, BW; Ryu, JS; Um, JW, 2017)
"5-Fluorouracil (5-FU) is the chemotherapeutic agent of first choice for the treatment ofcolorectal cancer, however, treatment-related liver toxicity remains a major concern."3.85Hepatoprotective Effect of Carboxymethyl Pachyman in Fluorouracil-Treated CT26-Bearing Mice. ( Gao, L; Huo, X; Li, C; Sun, G; Wang, C, 2017)
"5-Fluorouracil (5-FU) is a widely used chemotherapeutic drug in colorectal cancer."3.85Translational reprogramming of colorectal cancer cells induced by 5-fluorouracil through a miRNA-dependent mechanism. ( Auboeuf, D; Bash-Imam, Z; Catez, F; Dalla Venezia, N; David, A; Diaz, JJ; Dutertre, M; Lafôrets, F; Macari, F; Marcel, V; Mertani, HC; Pannequin, J; Pion, N; Polay Espinoza, M; Saurin, JC; Textoris, J; Thérizols, G; Vincent, A, 2017)
"The aim of this study was to evaluate the efficacy and safety of combining irinotecan, bevacizumab, and cetuximab/panitumumab as a 4th-line treatment in patients with metastatic colorectal cancer."3.85Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer. ( Colville-Ebeling, B; Jensen, BV; Larsen, FO; Markussen, A; Nielsen, D; Riis, LB, 2017)
"Cardiotoxicity is a rare but challenging complication of 5-fluorouracil (5-FU) therapy."3.85Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer. ( Franck, C; Malfertheiner, P; Venerito, M, 2017)
"Electronic Health Records at a UK oncology centre were included if they had (i) a diagnosis of metastatic breast cancer and received adjuvant epirubicin and cyclosphosphamide chemotherapy or (ii) colorectal cancer and received palliative oxaliplatin and infusional 5-fluorouracil chemotherapy, and (iii) were first diagnosed with cancer between January 2004 and February 2013."3.85Process mining routinely collected electronic health records to define real-life clinical pathways during chemotherapy. ( Baker, K; Dunwoodie, E; Hall, G; Johnson, O; Jones, RG; Leal, J; McGinley, P; Newsham, A; Price, CP; Twelves, C; Wolstenholme, J, 2017)
"Preclinical evidence demonstrates that mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway inhibition increases sensitivity to 5-fluorouracil (5-FU) in colorectal cancer (CRC) cell lines and xenografts."3.85MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. ( Chen, Y; Fakih, M; Gong, J; Pillai, R; Shirasawa, S; Yang, L, 2017)
" In this study, we chose human colorectal adenocarcinoma cell line HT-29 as the experimental model, and investigated the differential biological effects between 250 mGy single dose LDIR and 250 mGy intermittent LDIR pretreatments in high dose irradiation (HDIR) radiotherapy and 5-fluorouracil (5-FU) based chemotherapy."3.85Intermittent low dose irradiation enhances the effectiveness of radio- and chemo-therapy for human colorectal adenocarcinoma cell line HT-29. ( Li, Y; Wang, Y; Yang, L; Yin, D, 2017)
"Preoperative 5-fluorouracil- (5-FU-) based chemoradiotherapy is a standard treatment for locally advanced colorectal cancer (CRC)."3.85Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. ( Ai, YQ; Chen, ZT; Ju, YH; Li, WH; Li, YF; Liu, QY; Qin, JY; Wang, H; Xiong, W; Ye, Q, 2017)
"5-Fluorouracil (5-FU) has broadly been applied to treat colorectal cancer as one of the most effective chemotherapeutic agents."3.85Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model. ( Li, M; Liang, X; Liu, Z; Teng, N; Wang, X; Xie, W; Yang, Z; Zhang, Z, 2017)
" Our study focused on capecitabine during capecitabine plus oxaliplatin (XELOX) treatment as an adjuvant therapy for colorectal cancer."3.85Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer. ( Hama, T; Inoue, A; Kawakami, K; Kobayashi, K; Machida, Y; Suenaga, M; Sugisaki, T; Suzuki, K; Yamaguchi, K; Yamaguchi, T; Yokokawa, T, 2017)
"MicroRNAs (miRNAs) are increasingly involved in the development of drug resistance, including 5-fluorouracil (5-FU) resistance in colorectal cancer (CRC)."3.85Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway. ( Jia, L; Li, Y; Liu, B; Liu, Y; Pan, Y; Shan, Y; Zhao, L, 2017)
" 5-Fluorouracil (5-FU) is the first-line chemotherapeutic agent for colorectal cancer; however, most patients develop resistance to 5-FU through various mechanisms."3.85Synergistic antitumor effect of 3-bromopyruvate and 5-fluorouracil against human colorectal cancer through cell cycle arrest and induction of apoptosis. ( Chong, D; Huo, Q; Liu, F; Liu, H; Ma, L; Zhang, P; Zhang, Z; Zhao, S; Zheng, H, 2017)
"5-Fluorouracil (5-FU) resistance or multidrug resistance (MDR) has become a major obstacle in clinical treatment of cancers including colorectal cancer (CRC)."3.85Scutellaria barbata D. Don inhibits 5-fluorouracil resistance in colorectal cancer by regulating PI3K/AKT pathway. ( Feng, J; Jin, Y; Lai, Z; Li, Q; Lin, J; Peng, J; Wei, L; Yan, Z; Yang, H, 2017)
"We enrolled 103 consecutive patients with stage III and high-risk stage II colorectal cancer treated with mFOLFOX6 (n = 37) or oral fluorouracil and leucovorin (n = 66) after curative surgery."3.85Oxaliplatin-induced increase in splenic volume; irreversible change after adjuvant FOLFOX. ( Hara, K; Iwai, T; Koizumi, M; Ohta, K; Shinji, S; Takahashi, G; Takeda, K; Uchida, E; Yamada, T; Yokoyama, Y, 2017)
"The aim of this study was to explore the effects of single agent treatments and combination of Blu9931 and 5-fluorouracil (5-FU) on the biological characteristics of colorectal cancer cells and its mechanism."3.85Combination of FGFR4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells. ( Han, C; Jiang, D; Li, J; Wang, M; Wang, X; Ye, Y; Zhao, C, 2017)
"Colorectal cancer (CRC) is one of the leading causes of cancer mortality and 5-Fluorouracil (5-FU) is the most common chemotherapy agent of CRC."3.85Effect of AICAR and 5-Fluorouracil on X-ray Repair, Cross-Complementing Group 1 Expression, and Consequent Cytotoxicity Regulation in Human HCT-116 Colorectal Cancer Cells. ( Chang, SF; Chen, CN; Huang, WS; Lee, KC; Lin, CT; Liu, JL, 2017)
"A 32-year-old female with stage IV colorectal cancer and metastasis to the liver experienced cardiotoxic reactions after treatment with 5-fluorouracil and its oral prodrug capecitabine even at two-thirds the recommended dose."3.85Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses. ( Ardalan, B; Cioffi, JH; Estes, DJ; Florou, V, 2017)
"5-fluorouracil (5-FU) is one of the major components of many standard regimens for chemotherapy of colorectal cancer (CRC) and some other malignancies."3.85The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells. ( Eftekhar, E; Jaberi, H; Mansouri, A; Naghibalhossaini, F; Shefaghat, M; Tatar, M, 2017)
"Metastatic colorectal cancer (mCRC) combined with hyperbilirubinemia is typically considered a contraindication to irinotecan-based therapy, a proven first-line treatment of mCRC."3.85Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment. ( Chen, CW; Huang, CW; Huang, MY; Lu, CY; Ma, CJ; Tsai, HL; Wang, JY; Wu, JY; Yeh, YS, 2017)
"Metastatic colorectal cancer (mCRC) is a lethal disease and fluorouracil-leucovorin-irinotecan (FOLFIRI) plus bevacizumab (bev) is a standard approach."3.85Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab. ( Artaç, M; Börüban, MC; Bozcuk, H; Er, Z; Güler, T; Karaağaç, M; Korkmaz, L; Uysal, M, 2017)
" Our results showed that GLPs reactivated mutant p53 in colorectal cancer HT29 (p53R273H) and SW480 (p53R273H&P309S) cells while applied alone or together with 5-fluorouracil (5-FU)."3.85Restoration of the tumor-suppressor function to mutant p53 by Ganoderma lucidum polysaccharides in colorectal cancer cells. ( Cai, Y; Jiang, D; Jin, J; Wang, F; Wang, L; Zhang, R; Zhang, Z; Zhao, T, 2017)
"We analyzed the results of previously treated patients with metastatic colorectal cancer (mCRC) who received regorafenib plus FOLFIRI with the irinotecan dose escalation on the basis of uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping."3.85Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer. ( Cheng, TL; Hu, HM; Huang, CW; Ma, CJ; Tsai, HL; Wang, JY; Wu, IC; Yeh, YS, 2017)
" The upregulation of the Ca2+-permeable transient receptor potential channel 5 (TrpC5) activates the Wnt/β-catenin signaling pathway in 5-fluorouracil (5-Fu)-resistant human colorectal cancer (CRC) HCT-8 (HCT-8/5-Fu) cells."3.85Elevated expression of TrpC5 and GLUT1 is associated with chemoresistance in colorectal cancer. ( Hua, D; Lu, TX; Ning, K; Wang, T, 2017)
"To investigate the possibility of enhancing an anti-metastatic effect of 5-fluorouracil (5-FU) on colorectal cancer (CRC) cells by combining it with continuous calcium supplementation."3.85Synergistically Anti-metastatic Effect of 5-Flourouracil on Colorectal Cancer Cells via Calcium-mediated Focal Adhesion Kinase Proteolysis. ( Jeong, KY; Kim, HM; Park, M; Sim, JJ; Sundaramoorthy, P, 2017)
"5-Fluorouracil (5-FU) is a chemotherapeutic agent used in the treatment of colorectal cancer."3.855-Fluorouracil inhibits cell migration by induction of Sestrin2 in colon cancer cells. ( Ki, SH; Park, EY; Seo, K; Shin, SM, 2017)
"5-Fluorouracil (5-FU) is the most commonly used chemotherapeutic agent for colorectal cancer (CRC)."3.85FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10. ( Chen, C; Chen, J; Chen, L; Chen, Y; Chu, X; Dai, T; Geng, J; Huang, M; Liu, X; Mao, X; Ren, L; Wang, L; Wang, Q; Wang, R; Wang, Y; Xie, T; Xue, L; Yu, H; Zhang, K, 2017)
"We retrospectively investigated 156 patients with unresectable colorectal cancer who received oxaliplatin- or irinotecan-based first-line systemic chemotherapy with or without antibodies in our department between January 2007 and December 2015."3.85Characterization of Conversion Chemotherapy for Secondary Surgical Resection in Colorectal Cancer Patients with Lung Metastases. ( Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Murono, K; Nakajima, J; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Tanaka, T; Watanabe, T; Yasuda, K, 2017)
" A retrospective analysis of the cost of toxicity management was conducted on 243 metastatic colorectal cancer patients enrolled in a clinical trial and treated with standard of care FOLFIRI (5-fluorouracil combined with irinotecan)."3.85Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype. ( Buonadonna, A; Cecchin, E; De Mattia, E; Giodini, L; Innocenti, F; Montico, M; Roncato, R; Solfrini, V; Toffoli, G, 2017)
"Adding cetuximab to FOLFIRI (5-fluorouracil, leucovorin, irinotecan) significantly improved progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in patients with KRAS or RAS (KRAS/NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC) in the first-line CRYSTAL study."3.85Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy. ( Ando, M; Beier, F; Guenther, S; Ooki, A; Van Cutsem, E; von Hohnhorst, P; Yamaguchi, K, 2017)
"This retrospective study enrolled 131 patients with stage III colorectal cancer who underwent curative resection: 72 received 5-fluorouracil-based adjuvant chemotherapy (chemotherapy group) and 59 did not (surgery-alone group)."3.85Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer. ( Kameyama, H; Kobayashi, T; Kosugi, SI; Okamura, T; Shimada, Y; Tajima, Y; Wakai, T; Yagi, R, 2017)
" To test this phenomenon, we investigated the differential responses of three secondary colorectal cancer cell lines of different origins (HCT116, HT29, and SW620 cells) and four novel primary cell lines obtained from different colorectal cancer patients to 5-fluorouracil (5-FU) and oxaliplatin (L-OHP) and explored the differences in gene expression among the primary cell lines in response to exposure to cytotoxic drugs."3.85Heterogeneity in cancer cells: variation in drug response in different primary and secondary colorectal cancer cell lines in vitro. ( Arul, M; Cheah, SH; Roslani, AC, 2017)
"High-dose 5-fluorouracil (5-FU) containing chemotherapy occasionally causes hyperammonemia and can be lethal."3.85Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. ( Funakoshi, T; Horimatsu, T; Matsubara, K; Matsubara, T; Miyamoto, S; Muto, M; Nakagawa, S; Nishikawa, Y; Yanagita, M; Yonezawa, A, 2017)
" Hypoxia reduces sensitivity to 5-fluorouracil (5-FU)-chemotherapy for colorectal cancer (CRC)."3.85Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance. ( Adam, J; Bishop, CL; Bundy, JG; Feakins, R; Gammon, L; Jalaly, A; Jeffery, R; Lewis, A; Lowe, R; McDonald, S; Nijhuis, A; Parker, A; Propper, D; Silver, A; Soga, T; Suraweera, N; Thaha, MA; Thompson, H, 2017)
"To evaluate the efficiency and safety of hepatic artery infusion chemotherapy (HAIC) using raltitrexed or 5-fluorouracil for colorectal cancer (CRC) liver metastasis (CRCLM)."3.85Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis. ( Chen, H; Gao, S; Guo, JH; Li, XT; Wang, XD; Zhang, HY; Zhang, PJ; Zhu, X, 2017)
" Bevacizumab (Avastin), a monoclonal antibody against vascular endothelial growth factor (VEGF), is used in a combination with FOLFOX [FOL - Folinic acid; F - Fluorouracil (5-FU); OX - Oxaliplatin] as a first-line treatment for patients with metastatic colorectal cancer."3.83Posterior Reversible Encephalopathy Syndrome (PRES) Presenting as Status Epilepticus: A Case Report and Literature Review. ( Abbas, MK; Huynh, M; Sharma, P, 2016)
"The purpose of this study was to evaluate both in vitro and in vivo anticancer activities against colorectal cancer (CRC) of electrospun polylactide (PLA) nanofibers loaded with 5-fluorouracil (5-Flu) and oxaliplatin."3.83Antitumor activity of electrospun polylactide nanofibers loaded with 5-fluorouracil and oxaliplatin against colorectal cancer. ( Jing, X; Liu, S; Liu, T; Wang, X; Zhang, J, 2016)
" This study evaluates the cost-effectiveness of UGT1A1 genotyping in patients with metastatic colorectal cancer undergoing irinotecan-based chemotherapy compared to no testing from the perspective of the German statutory health insurance."3.83The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance. ( Butzke, B; Giessen-Jung, C; Heinemann, V; Oduncu, FS; Pfeufer, A; Rogowski, WH; Severin, F; Stollenwerk, B, 2016)
"We evaluated the usefulness of the in vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) for prediction of clinical response to fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer."3.83In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer. ( Kang, J; Kim, IK; Kwon, HY; Lee, KY; Sohn, SK, 2016)
"5-Fluorouracil (5-FU) is one among the anti-cancer agents in FOLFORINOX treatment along with oxaliplatin and irinotecan for the treatment of colorectal cancer."3.835-Fluorouracil enteric-coated nanoparticles for improved apoptotic activity and therapeutic index in treating colorectal cancer. ( Kuppusamy, G; Praveen, TK; Satish Kumar, MN; Tummala, S; Wadhwani, A, 2016)
"5-Fluorouracil (5-FU), a cell cycle-specific antimetabolite, is one of the most commonly used chemotherapeutic agents for colorectal cancer (CRC)."3.83Smad4 sensitizes colorectal cancer to 5-fluorouracil through cell cycle arrest by inhibiting the PI3K/Akt/CDC2/survivin cascade. ( Chen, X; Dou, L; Leng, C; Luo, X; Wu, C; Zhang, B; Zhang, Z, 2016)
"We investigated mechanisms of colorectal cancer (CRC) chemoresistance to first-line chemotherapy (capecitabine plus oxaliplatin (XELOX)) and identified two putative chemoresistant microRNAs, miR-1914* and -1915, that are downregulated in plasma samples from patients with chemoresistant CRC."3.83The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX. ( Cai, G; Cai, S; Hu, J; Xu, Y, 2016)
"Irinotecan (CPT-11)-induced neutropenia is associated with UDP-glucuronosyltransferase (UGT) 1A1*6 and *28 polymorphisms."3.83UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. ( Kusumi, T; Manabe, M; Miyata, Y; Mizunuma, N; Morita, Y; Taniguchi, F; Touyama, T, 2016)
"The purpose of this study was to characterize imaging biomarkers for the potential benefit of hypoxia-inducible factor-1 (HIF-1)α inhibition (by PX-12) during 5-fluorouracil (5-FU) chemotherapy in the treatment of colorectal cancer (CRC)."3.83Baseline [(18)F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model. ( De Bruycker, S; Pauwels, P; Staelens, S; Stroobants, S; Van den Wyngaert, T; Vangestel, C; Wouters, A; Wyffels, L, 2016)
" We investigated development of splenomegaly and its association with treatment outcome and genetic polymorphisms following adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in colorectal cancer (CRC) patients."3.83Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX. ( Bang, YJ; Cha, Y; Han, SW; Im, SA; Kim, MJ; Kim, SH; Kim, TY; Lee, DW; Lee, KH; Oh, DY, 2016)
"Oxaliplatin is frequently used as part of a chemotherapeutic regimen with 5-fluorouracil in the treatment of colorectal cancer (CRC)."3.83SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients. ( Balavarca, Y; Becker, N; Benner, A; Brenner, H; Burwinkel, B; Chang-Claude, J; Habermann, N; Hoffmeister, M; Jansen, L; Kap, EJ; Scherer, D; Seibold, P; Ulrich, A; Ulrich, CM; Zucknick, M, 2016)
"Adjuvant chemotherapy for colorectal cancer is mainly based on the combination of 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4)."3.83Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study. ( Balayssac, D; Buc, E; Déchelotte, P; Le Roy, B; Pereira, B; Pétorin, C; Pezet, D; Sauvanet, P; Tixier, L, 2016)
"5-Fluorouracil (5-FU) is widely used in chemotherapy for treatment of colorectal cancer."3.835-Fluorouracil induces apoptosis of colorectal cancer cells. ( He, C; Li, CY; Liu, T; Wang, L; Zhang, JT; Zhou, WL, 2016)
"To evaluate the safety and efficacy of the combination therapy of fluorouracil, leucovorin and irinotecan (FOLFIRI) and aflibercept in Asian patients with metastatic colorectal cancer (mCRC), who had progressed after oxaliplatin-based chemotherapy."3.83Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer. ( Chong, DQ; Choo, SP; Chua, C; Imperial, M; Manalo, M; Ng, M; Tan, IB; Teo, P; Yong, G, 2016)
" We applied ToxT analysis to adverse event data from two completed North Central Cancer Treatment Group (NCCTG/Alliance) trials: N9741 (NCT00003594), in which different combinations of oxaliplatin, 5-fluorouracil, and irinotecan were investigated for metastatic colorectal cancer, and 979254, in which survivors of breast cancer were given venlafaxine or placebo for control of hot flashes."3.83Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. ( Atherton, PJ; Grothey, A; Loprinzi, CL; Novotny, PJ; Sloan, JA; Thanarajasingam, G, 2016)
" The combination of epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan was originally designed for the treatment of metastatic colorectal cancer."3.83Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report. ( Chai, CY; Chien, TM; Huang, CN; Lin, CH; Lu, YM, 2016)
" Here we show that TruMBD4 plays an important role for enhancing 5-fluorouracil (5FU) sensitivity in MMR-deficient colorectal cancer cells."3.83Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status. ( Carethers, JM; Hamaya, Y; Iwaizumi, M; Kanaoka, S; Miyajima, H; Sugimoto, K; Suzuki, S; Tseng-Rogenski, S, 2016)
"Ten patients with histologically diagnosed peritoneal metastases of adenocarcinoma or pseudomyxoma peritonei underwent cytoreductive surgery and received HIPEC with 5-fluorouracil for 90 min, delivered via our modified system."3.83Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin. ( Cavazos, M; Cravioto-Villanueva, A; Esquivel, J; Luna-Perez, P; Martinez-Gomez, H; Montiel, H; Ramirez, ML; Solorzano, J, 2016)
"Multidrug resistance (MDR), a phenomenon that often occurs with drug treatment and is characterized by relapse or attenuation of drug efficacy, is almost unavoidable in colorectal cancer (CRC) patients receiving 5-fluorouracil (5-FU)-based chemotherapy."3.83miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1. ( Bian, Z; Feng, Y; Hu, Y; Huang, Z; Li, M; Liu, H; Yao, S; Yin, Y; You, Q, 2016)
"5-fluorouracil (5-Fu) is still recognized as the mainstay in colorectal cancer chemotherapy, but the response rate of 5-Fu in colorectal cancer is less than 50%."3.83B7-H3 upregulates BRCC3 expression, antagonizing DNA damage caused by 5-Fu. ( Hua, D; Jiang, B; Liu, F; Ning, K; Sun, ZZ; Tang, SC; Zhang, T; Zhu, R, 2016)
"A 69-year-old woman presented with arterial hypotension, pulmonary oedema and a severely depressed left ventricular ejection fraction (LVEF) of 25% only 3 days after having received her first treatment for colorectal cancer with 5-fluorouracil (5-FU)-based therapy."3.835-Fluorouracil-induced acute reversible heart failure not explained by coronary spasms, myocarditis or takotsubo: lessons from MRI. ( Dalsgaard, M; Fakhri, Y; Lav Madsen, P; Nielsen, D, 2016)
"A 54-year-old white male diagnosed with Stage IV colorectal cancer was treated with folinic acid, leucovorin, fluorouracil, oxaliplatin (FOLFOX) and bevacizumab."3.83When a good call leads to a bad connection: colovesical fistula in colorectal cancer treated with bevacizumab. ( Chen, J; Nadesan, S; Smalligan, RD, 2016)
" In this study, we investigated the effect of NNMT on 5-fluorouracil (5-FU) sensitivity of colorectal cancer (CRC) cells, and the underlying mechanisms."3.83Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway. ( Li, F; Li, G; Liu, H; Ruan, Z; Wang, X; Wang, Y; Xie, X; Yu, H; Zhang, J; Zhou, Y, 2016)
"To analyze the efficacy of last line sorafenib treatment in colorectal cancer patients."3.83Last line therapy with sorafenib in colorectal cancer: A retrospective analysis. ( Becker, M; Galle, PR; Martchenko, K; Möhler, M; Schimanski, CC; Schmidtmann, I; Thole, V; Thomaidis, T; Wehler, TC, 2016)
" In this study, we demonstrated that anisomycin, a JNK activator, stimulates nuclear export of GATA-6 in a colorectal cancer cell line, DLD-1."3.83Anisomycin-induced GATA-6 degradation accompanying a decrease of proliferation of colorectal cancer cell. ( Horyozaki, A; Maeda, M; Ushijima, H, 2016)
"Protein content of ABCC10 and ABCC11 was assessed in tumor tissue blocks of 140 colorectal cancer patients and associated with survival of patients with regard to 5-fluorouracil-based therapy."3.83Protein expression of ATP-binding cassette transporters ABCC10 and ABCC11 associates with survival of colorectal cancer patients. ( Bruha, J; Daum, O; Dubova, M; Krizkova, V; Liska, V; Skala, M; Soucek, P; Susova, S; Vycital, O, 2016)
"The development of chemoresistance to 5-fluorouracil (5-FU) is a major obstacle for sustained effective treatment of colorectal cancer (CRC), with the mechanisms being not fully understood."3.83Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine. ( Chen, X; Chen, Y; Hao, L; Hou, A; Li, Y; Liang, H; Luo, P; Miao, H; Ou, J; Ruan, Z; Shi, C; Wang, R; Zhang, X, 2016)
"Fluorouracil (5-FU) has been wildly used as a primary medication in the treatment of solid tumors including colorectal cancer."3.83Determining the optimal 5-FU therapeutic dosage in the treatment of colorectal cancer patients. ( Fang, L; Jiang, H; Jiang, Y; Lin, L; Yang, Y; Zhang, S; Zheng, J; Zheng, Y; Zhuang, X, 2016)
"5-fluorouracil (5-FU)-based chemotherapy is the main chemotherapeutic approach for colorectal cancer (CRC) treatment."3.83Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells. ( Cai, Z; Che, J; Chen, D; Chen, J; He, L; Huang, L; Iwamoto, A; Lan, P; Lin, M; Liu, H; Lou, Q; Qin, Q; Ren, D; Wang, H; Wang, J; Wang, L; Wen, C; Yang, X; Zhang, D, 2016)
"The two key aspects associated with the microsatellite instability (MSI) as genetic phenomenon in colorectal cancer (CRC) are better survival prognosis, and the varying response to 5-fluorouracil (5-FU)-based chemotherapy."3.83Microsatellite instability & survival in patients with stage II/III colorectal carcinoma. ( Branimir, Z; Daniela, B; Ivan, D; Jadranka, A; Petar, S; Srdjan, M; Velimir, M; Zoran, K, 2016)
"5-Fluorouracil (5FU) is still a major drug in combinations regimens for the treatment of colorectal cancer (CRC) both in the adjuvant and palliative setting."3.83Role of genomic factors beyond thymidylate synthase in the prediction of response to 5-fluorouracil. ( Leon, LG; Meijer, E; Peters, GJ; Smid, K; van Groeningen, CJ, 2016)
"The purpose of this study was to compare health-related quality of life (HRQoL) and costs associated with 2 adjuvant chemotherapy regimens [capecitabine-based therapy versus 5-fluorouracil/leucovorin (5-FU/LV)-based therapy] in stage III colorectal cancer patients."3.81Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients. ( Chen, HC; Chen, HH; Chen, WT; Chou, YH; Fang, CY; Hsu, HH; Huang, CC; Lee, HC; Lin, BW; Lin, JK; Lin, PC; Tan, EC; Ting, WC; Yang, MC; Yeh, CH, 2015)
"Different combinations of 5-fluorouracil (5-FU), oxaliplatin, irinotecan and other newly developed agents have been used to treat colorectal cancer."3.81Gene signatures of drug resistance predict patient survival in colorectal cancer. ( Tong, Y; Zheng, Y; Zhou, J, 2015)
" We simulated phase II trials by resampling patients from N9741, a randomized phase III trial of chemotherapy regimens for metastatic colorectal cancer, and compared the power of various end points to detect the superior therapy (FOLFOX [infusional fluorouracil, leucovorin, and oxaliplatin] had longer overall survival than both IROX [irinotecan plus oxaliplatin] and IFL [irinotecan and bolus fluorouracil plus leucovorin])."3.81Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials. ( Goldberg, RM; Gray, E; Karrison, TG; Sargent, DJ; Sharma, MR, 2015)
" Here, we showed that miR-22 inhibited autophagy and promoted apoptosis to increase the sensitivity of colorectal cancer (CRC) cells to 5-fluorouracil (5-FU) treatment both in vitro and in vivo."3.81MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells. ( Kong, J; Lai, M; Li, C; Tang, J; Wang, J; Wu, Y; Xu, E; Zhang, H, 2015)
" However, the molecular mechanism as to how miR-203 modulates the chemosensitivity to 5-fluorouracil (5-FU) in colorectal cancer is poorly known."3.81miR-203 enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer. ( Gao, F; Li, T; Zhang, XP, 2015)
" In the present study, we analyzed the cytotoxicity of LA on colorectal cancer (CRC) cells differing in their p53 status and investigated a putative synergistic effect with the anticancer drug 5-fluorouracil (5-FU)."3.81Lipoic acid induces p53-independent cell death in colorectal cancer cells and potentiates the cytotoxicity of 5-fluorouracil. ( Dörsam, B; Fahrer, J; Göder, A; Kaina, B; Seiwert, N, 2015)
"An aptamer (Apt) conjugated hyaluronan/chitosan nanoparticles (HACSNPs) were prepared as carrier for targeted delivery of 5-fluorouracil (5FU) to mucin1 (MUC1) overexpressing colorectal adenocarcinomas."3.81Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas. ( Atyabi, F; Dinarvand, R; Esfandyari-Manesh, M; Ghasemi, Z; Mottaghitalab, F; Sayari, E, 2015)
"The addition of bevacizumab to fluorouracil-based chemotherapy is a standard of care for previously untreated metastatic colorectal cancer."3.81First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. ( Ayer, T; Chen, Q; El-Rayes, BF; Flowers, CR; Goldstein, DA; Howard, DH; Lipscomb, J, 2015)
" This study evaluates the influence of common genetic variations within the VEGF pathway in the clinical outcomes of 172 metastatic colorectal cancer (mCRC) patients treated with first-line oxaliplatin/5-fluorouracil chemotherapy."3.81Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy. ( Baiget, M; Barnadas, A; Berenguer-Llergo, A; Páez, D; Paré-Brunet, L; Río, E; Salazar, J; Sebio, A, 2015)
"Thymidylate synthase (TYMS) is an important enzyme for 5-fluorouracil (5-FU) metabolism in metastatic colorectal cancer (mCRC) patients."3.81Thymidylate synthase expression in circulating tumor cells: a new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients. ( Abdallah, EA; Alves, VS; Araújo, DV; Buim, ME; Chinen, LT; Dettino, AL; Fanelli, MF; Gasparini Junior, JL; Machado Netto, MC; Mingues, NB; Ocea, LM; Rocha, BM; Romero, JV; Souza E Silva, V, 2015)
"We prospectively evaluated the feasibility of XELOX(oxaliplatin 130 mg/m/(2) on day 1 plus capecitabine 1,000 mg/m(2) twice daily on days 1 to 14 every 3 weeks) for adjuvant treatment in 15 patients with stage III/IV (Japanese classification) colorectal cancer and pathological curability A or B after D2-D3 lymph node dissection."3.81[A feasibility study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for Japanese patients with advanced colorectal cancer]. ( Higashino, K; Noura, S; Ohue, M; Sakai, D; Shingai, T; Sugimoto, N; Takeuchi, Y; Yagi, T; Yamamoto, S; Yano, M; Yoshinami, T, 2015)
"To explore the changes of anticancer efficiency of 5'-deoxy-5-fluorouridine (5'-DFUR) and 5-fluorouracil (5-Fu) in colorectal cancer cell line HT29 and LS174T cells after transfection of thymidine phosphorylase (TP) cDNA with a lentiviral vector."3.81[Transfection of thymidine phosphorylase cDNA with lentiviral vector enhances the anticancer effect of 5'-deoxy-5-fluorouridine on colorectal cancer cell lines HT29 and LS174T]. ( Liu, Q; Wang, Q; Ye, D; Zhang, J, 2015)
" Herein, we investigated an alginate-based 3D scaffold for screening of 5-fluorouracil (5-FU) or/and curcumin on malignancy of colorectal cancer cells (CRC)."3.81Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer. ( Buhrmann, C; Goel, A; Kraehe, P; Popper, B; Shakibaei, M; Shayan, P, 2015)
"Preoperative 5-fluorouracil (5-FU)-based chemoradiotherapy is a standard treatment for locally advanced colorectal cancer (CRC)."3.81Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells. ( Ai, YQ; Cui, JG; He, WJ; Hou, Y; Jiang, YX; Ju, YH; Li, WH; Li, YF; Liu, S; Liu, Y; Qin, JY; Wang, L; Wang, Y; Wu, XR; Xia, YX; Xiong, W, 2015)
"The purpose of this study is to evaluate the influence of germline polymorphisms of cytochrome P450 (CYP450) on objective response, progression-free survival (PFS) and overall suruvival (OS) in metastatic colorectal cancer (mCRC) receiving the combination chemotherapy of irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI)."3.81Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer. ( Cui, Y; Dong, N; Meng, F; Wang, M; Wu, Y; Zhang, S, 2015)
"500 mg/m(2) uracil was administered orally to 12 subjects with stages II-III colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects with stage IV metastasized CRC, all treated with CAP containing therapy."3.81Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients. ( Gelderblom, H; Guchelaar, HJ; Maring, JG; Opdam, F; van Kuilenburg, AB; van Staveren, MC, 2015)
" Overexpressing miR-197 could increase the sensitivity of colorectal cancer cells to 5-fluorouracil (5-FU)."3.81MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer. ( Bai, C; Chen, Y; Han, Q; Sun, Z; Zhao, L; Zhao, RC; Zhou, J; Zhou, N, 2015)
"There was performed a molecular genetic study of UGTlAl gene allelic variants polymorphism in patients with colorectal cancer who had had chemotherapy irinotecan-containing regimens FOLFIRI."3.81[The role of assessing UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity in the course of chemotherapy for colorectal cancer]. ( Abramova, NA; Dvadnenko, KV; Kit, OI; Vladimirova, LY; Vodolazhskiy, DI, 2015)
"This study aimed to investigate the association between methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and the prognosis of colorectal cancer (CRC) patients undergoing 5-fluorouracil (5-FU)-based chemotherapy in Taiwan."3.81Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and fluorouracil-based treatment in Taiwan colorectal cancer. ( Chang, LC; Chin, J; Hou, CF; Lin, TJ; Liu, WS; Su, SM; Wu, NC; Yang, JY, 2015)
"Colorectal cancer is commonly treated with 5-fluorouracil and 5-formyltetrahydrofolate (leucovorin)."3.81Expression of Folate Pathway Genes in Stage III Colorectal Cancer Correlates with Recurrence Status Following Adjuvant Bolus 5-FU-Based Chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Sondén, A; Wettergren, Y, 2015)
" This gene codifies for the target enzyme of 5-fluorouracil (5-FU), the basic treatment in colorectal cancer."3.81Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS. ( Balboa-Beltrán, E; Barros, F; Carracedo, A; Duran, G; Lamas, MJ, 2015)
" In addition, the effect of chemotherapeutics (5-fluorouracil and paclitaxel) released from the Fmoc-FF gel (with addition before and after gelation) on colorectal cancer cells were investigated using this methodology, demonstrating enhanced activity of these drugs compared to bulk control."3.81Dissolution and degradation of Fmoc-diphenylalanine self-assembled gels results in necrosis at high concentrations in vitro. ( Braet, F; Gloria, D; Su, Y; Thordarson, P; Truong, WT, 2015)
"Acquired drug resistance (ADR) can be developed in colorectal cancer cells after 5-fluorouracil (5-FU) treatment and diminish the effectiveness of chemotherapy."3.81Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles. ( Chen, L; Duan, W; He, L; Kong, L; She, X; Shigdar, S; Wang, T, 2015)
"We investigated the synergistic effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor plus radiation therapy, on the proliferation and survival of gastric cancer (GC) and colorectal cancer (CRC) cells."3.81Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor. ( Kang, WK; Kim, J; Lee, I; Lim, T, 2015)
"5-Fluorouracil (5-FU), a common chemotherapeutic agent used for the treatment of colorectal cancer (CRC), by itself has inadequate response rates; highlighting the need for novel and improved treatment regimens for these patients."3.81Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, Epithelial-to-mesenchymal transition and apoptosis in colorectal cancer. ( Buhrmann, C; Goel, A; Kraehe, P; Popper, B; Shakibaei, M; Shayan, P, 2015)
"5-Fluorouracil (5-Fu) has been widely used as a first-line drug for colorectal cancer (CRC) treatment but limited by drug resistance and severe toxicity."3.81Gypenosides Synergistically Enhances the Anti-Tumor Effect of 5-Fluorouracil on Colorectal Cancer In Vitro and In Vivo: A Role for Oxidative Stress-Mediated DNA Damage and p53 Activation. ( Fan, J; Kong, L; Liu, Q; Wang, P; Wang, X; Yang, Q; Yuan, W; Zhang, K, 2015)
"Systemic FOLFOX (folinic acid (leucovorin (LV)), 5-fluorouracil (5-FU), and oxaliplatin), FOLFIRI (LV, 5-FU, and irinotecan), or FOLFOXIRI (5-FU, leucovorin, oxaliplatin, and irinotecan) chemotherapy regimens and additional molecular-target treatments, including anti-vascular endothelial growth factor, anti-epidermal growth factor receptor, and anti-multi-kinase antibodies, have been recommended for unresectable recurrent colorectal cancers."3.81Hepatic artery infusion therapy is effective for chemotherapy-resistant liver metastatic colorectal cancer. ( Fujimoto, D; Goi, T; Kimura, Y; Koneri, K; Morikawa, M; Naruse, T; Yamaguchi, A, 2015)
"We have analyzed the association between disease-free survival (DFS) and obesity/body weight change during treatment in Korean stage III or high-risk stage II colorectal cancer patients treated with adjuvant 5-fluorouracil/ leucovorin/oxaliplatin."3.81Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients. ( Bang, YJ; Cha, Y; Han, SW; Im, SA; Jeong, SY; Kang, GH; Kim, TY; Lee, DW; Lee, KH; Oh, DY; Park, JW; Park, KJ; Ryoo, SB, 2015)
" Aflibercept is used for the treatment of metastatic colorectal cancer (mCRC) in association with irinotecan."3.81Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients. ( Beltjens, F; Bengrine, L; Ghiringhelli, F; Ladoire, S; Vincent, J, 2015)
" Here, we defined differentially expressed genes (DEGs) between pre-chemotherapy colorectal cancer (CRC) tissue samples of non-responders and responders for 5-fluorouracil and oxaliplatin-based therapy as clinically relevant drug resistance genes (CRG5-FU/L-OHP)."3.81Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues. ( Ao, L; Cai, H; Chi, P; Guan, Q; Guo, Y; Guo, Z; Li, M; Li, X; Lu, X; Tong, M; Yan, H; Zheng, W, 2015)
"12 patients with unresectable liver metastases from colorectal cancer were enrolled and received neoadjuvant FOLFIRI (5-fluorouracil, leucovorin, irinotecan) plus bevacizumab therapy."3.81Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging. ( Amato, DM; Avallone, A; Catalano, O; Filice, S; Fusco, R; Granata, V; Izzo, F; Nasti, G; Petrillo, A, 2015)
"The efficacy of 5-fluorouracil (5-FU)-based chemotherapy for colorectal cancer (CRC) widely varies among patients; therefore, it is difficult to accurately predict chemotherapeutic responses."3.81Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer. ( Bai, W; Wu, Y; Xi, Y; Zhang, P, 2015)
"Assessment of oxaliplatin-associated hepatotoxicity in patients receiving oxaliplatin, fluorouracil and leucovorin chemotherapy (FOLFOX) for colorectal cancer remains controversial."3.81Serum Type IV Collagen Concentration Correlates with Indocyanine Green Retention Rate and is an Indicator Of Hepatotoxicity In Patients Receiving FOLFOX for Colorectal Cancer. ( Fujino, S; Hosokawa, Y; Katsumata, K; Makino, H; Maruno, K; Mushiake, H; Sugiyama, Y; Watanabe, M, 2015)
"Assessment of oxaliplatin-associated hepatotoxicity in patients receiving oxaliplatin, fluorouracil and leucovorin chemotherapy (FOLFOX) for colorectal cancer remains controversial."3.81Serum Type IV Collagen Concentration Correlates with Indocyanine Green Retention Rate. ( Fujino, S; Hosokawa, Y; Katsumata, K; Makino, H; Maruno, K; Mushiake, H; Sugiyama, Y; Watanabe, M, 2015)
"Past reports have suggested that the addition of bevacizumab (BV) to oxaliplatin combined with 5-fluorouracil (5-FU) and folinic acid (leucovorin) (FOLFOX4) provides a limited survival benefit in metastatic colorectal cancer (mCRC)."3.80Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer. ( Matsusaka, S; Mizunuma, N; Shinozaki, E; Suenaga, M; Ueno, M; Yamaguchi, T, 2014)
"5-Fluorouracil (5-FU) is a cornerstone of chemotherapy for colorectal cancer (CRC), and the major targets of 5-FU are thymidylate synthase (TS), methylenetetrahydrofolate reductase (MTHFR), and reduced folate carrier 1 (RFC1)."3.80Polymorphisms of folate metabolism-related genes and survival of patients with colorectal cancer in the Korean population. ( Cho, YK; Chong, SY; Hong, SP; Hwang, SG; Jang, MJ; Jeon, YJ; Ji, YG; Kim, JW; Kim, NK; Oh, D, 2014)
"Despite the use of 5-fluorouracil (5-FU)-based adjuvant treatments, a large proportion of patients with high-risk stage II/III colorectal cancer will relapse."3.80AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. ( Arthur, K; Blayney, JK; Dunne, PD; Greer, S; Johnston, PG; Kalimutho, M; Longley, DB; Loughrey, M; McArt, DG; Ong, CW; Redmond, K; Salto-Tellez, M; Srivastava, S; Van Schaeybroeck, S; Wang, T, 2014)
"To evaluate the cost-effectiveness of the addition of bevacizumab to the irinotecan-fluorouracil (Douillard regimen-CPT-FUFA-) in first-line treatment of metastatic colorectal cancer in a single-institution population."3.80Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer. ( Albert-Mari, A; Jimenez-Torres, NV; Ruiz-Millo, O; Sendra-Garcia, A, 2014)
"TS mRNA expression levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer."3.80TS mRNA levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer. ( Guan, W; Hu, J; Liu, B; Qian, X; Shen, J; Wang, H; Wei, J; Xie, L; Yu, L; Zhang, Q, 2014)
" Here, we found that colorectal cancer (CRC) cells treated with oxaliplatin (OXA) and/or 5-fluorouracil (5-Fu) released high levels of high-mobility group box 1 (HMGB1) and heat shock protein 70 (HSP70)."3.80TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells. ( Ang, B; Cao, X; Fang, H; Huang, X; Li, N; Sun, Y; Wan, T; Wang, W; Wu, Y; Xu, X, 2014)
"Although FOLFOX (infusional fluorouracil/leucovorin plus oxaliplatin) is established as a standard chemotherapeutic regimen, the long term efficacy of adjuvant XELOX (oral capecitabine plus intravenous oxaliplatin) in Asian colorectal cancer (CRC) patients remains anecdotal."3.80Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis. ( Chiu, J; Chu, KW; Epstein, RJ; Leung, R; Poon, J; Tang, V; Wong, H; Yau, T, 2014)
" However, it is still unknown the association of GOLPH3 expression with the prognosis of colorectal cancer (CRC) patients who received 5-fluorouracil (5-FU)-based adjuvant chemotherapy."3.80GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy. ( Chen, L; Cui, M; Di, J; Dong, B; Ji, J; Jiang, B; Liu, M; Ma, Y; Su, X; Wang, Z; Xing, J; Yang, H; Yao, Z; Zhang, C; Zhang, N, 2014)
"This study compared the clinical responses of patients with metastatic colorectal cancer (mCRC) with 5-fluorouracil/leucovorin with irinotecan (FOLFIRI) plus bevacizumab therapy either with or without uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping and irinotecan dose escalation."3.80Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinote ( Chang, SF; Hu, HM; Huang, CM; Huang, CW; Huang, ML; Huang, MY; Lu, CY; Tsai, HL; Wang, JY; Yu, FJ, 2014)
"To explore genes of the killer-cell immunoglobulin-like receptor (KIR) and of the HLA ligand and their relationship with the outcome of metastatic colorectal cancer (mCRC) patients treated with first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI)."3.80Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. ( Buonadonna, A; Caggiari, L; Cecchin, E; D' Andrea, M; De Re, V; De Zorzi, M; Innocenti, F; Racanelli, V; Talamini, R; Toffoli, G; Zagonel, V, 2014)
"Patients with colorectal tumors with microsatellite instability (MSI) have better prognoses than patients with tumors without MSI, but have a poor response to 5-fluorouracil–based chemotherapy."3.80Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy. ( Arzouk, H; Bengrine-Lefèvre, L; Biard, DS; Bouvier, AM; Buhard, O; Chapusot, C; Collura, A; Coquelle, A; De Thonel, A; Delarue, P; Dorard, C; Duval, A; Fléjou, JF; Garrido, C; Gaub, MP; Guilloux, A; Iacopetta, B; Lacoste, C; Lagrange, A; Lefèvre, JH; Lepage, C; Loh, M; Marcion, G; Marisa, L; Mews, A; Milano, G; Parc, Y; Platell, C; Saget, A; Seigneuric, R; Selves, J; Senet, P; Soong, R; Svrcek, M; Taieb, A; Tournigand, C; Wanherdrick, K; Zeps, N, 2014)
" Decreases in the rates of ascites and jaundice were confirmed by ultrasound and bilirubin levels."3.80Whole-liver radiotherapy concurrent with chemotherapy as a palliative treatment for colorectal patients with massive and multiple liver metastases: a retrospective study. ( Lu, K; Qiao, WB; Sun, D; Yin, H; You, QS; Zhang, HY, 2014)
"To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping."3.80FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping. ( Chang, SF; Chen, CF; Hu, HM; Huang, ML; Wang, JY; Yeh, YS, 2014)
"Weekly cetuximab plus irinotecan-based regiments are standard first- and second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC)."3.80Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population. ( Bi, F; Cao, D; Chen, Y; Li, Q; Qiu, M, 2014)
"Patients with breast or colorectal cancer receiving capecitabine completed a symptom, temperature and dose diary twice a day using a mobile phone application."3.80A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homes. ( Brooks, C; Gibson, O; Grainger, L; Larsen, M; Love, SB; Shanyinde, M; Shearwood, V; Tarassenko, L; Waters, R; Weaver, A; Young, AM, 2014)
"Capecitabine is a safe chemotherapeutic agent with moderate activity for first-line treatment of older metastatic colorectal cancer patients with limited performance status."3.80First-line mono-chemotherapy in frail elderly patients with metastatic colorectal cancer. ( Alacacioglu, A; Barutca, S; Degirmenci, M; Dirican, A; Karabulut, B; Oktay, E; Uslu, R; Varol, U; Yildiz, I, 2014)
"We retrospectively investigated the relationship between IVS14+1 G > A genotype of the dihydropyrimidine dehydrogenase (DPD) gene with plasma concentration of 5-fluorouracil (5-FU) as well as adverse reactions in 80 patients with locally advanced or metastatic colorectal cancer."3.80The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: ( Cai, X; Fang, JM; Gu, HL; Hu, J; Song, WF; Wang, LW; Xue, P; Yang, HY, 2014)
"Data from the Czech national registry were analysed retrospectively to describe treatment outcomes for capecitabine and oxaliplatin (XELOX) regimen with bevacizumab versus 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimen with bevacizumab in the first-line therapy for metastatic colorectal cancer (mCRC)."3.80Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. ( Abrahamova, J; Benesova, V; Bortlicek, Z; Buchler, T; Dusek, L; Kiss, I; Kohoutek, M; Melichar, B; Obermannova, R; Pavlik, T; Usiakova, Z; Vyzula, R, 2014)
" The purpose of the present study was to investigate whether hypoxia-driven triple suicide gene TK/CD/UPRT expression enhances cytotoxicity to ganciclovir (GCV) and 5-fluorocytosine (5-FC), and sensitizes human colorectal cancer to radiation in vitro and in vivo."3.80Hypoxia-targeted triple suicide gene therapy radiosensitizes human colorectal cancer cells. ( Deng, X; Hsiao, HT; Li, GC; Ling, CC; Sun, X; Xing, L, 2014)
" This study evaluated the anti-proliferative effects of ginger and Gelam honey and its efficacy in enhancing the anti-cancer effects of 5-FU (5-fluorouracil) against a colorectal cancer cell line, HCT 116."3.80Gelam honey and ginger potentiate the anti cancer effect of 5-FU against HCT 116 colorectal cancer cells. ( Alias, E; Hakim, L; Makpol, S; Morad, NA; Ngah, WZ; Yusof, YA, 2014)
"The aim of this study was to investigate the antitumor effect of rapamycin, an inhibitor of mammalian target of rapamycin (mTOR) signaling, combined with 5-fluorouracil treatment on CT-26 colorectal adenocarcinoma cells implanted into BALB/c mice."3.80The synergistic effect of rapamycin combined with 5-fluorouracil in BALB/cByJNarl mice bearing CT-26 tumor cells. ( Chang, GR; Chao, TH; Chen, PL; Chen, WY; Mao, FC, 2014)
"Capecitabine, designed as a pro-drug to the cytotoxic agent 5-fluorouracil, is widely used in the management of colorectal cancer."3.80Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab. ( Buchner, P; Czejka, M; Farkouh, A; Georgopoulos, A; Gruenberger, B; Scheithauer, W; Schueller, J, 2014)
"Although 5-fluorouracil (5-FU) is an important drug for colorectal cancer (CRC) treatment, no useful biomarker is currently available to predict treatment response."3.80Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer. ( Fukui, T; Iida, T; Miyake, H; Miyoshi, N; Naitou, H; Ochiai, T; Ohno, K; Okumura, M; Sakamoto, M; Takahashi, M; Tokunaga, Y; Tsumura, H; Umeki, M, 2014)
"49 consecutive patients bearing unresectable metastatic colorectal cancer and who experienced failure to oxaliplatin- and irinotecan-based chemotherapy were treated with oxaliplatin (85 mg/m(2)), irinotecan (180 mg/m(2)), leucovorin (400 mg/m(2)), and fluorouracil (400 mg/m(2) bolus then 2,400 mg/m(2)) repeated every 2 weeks."3.80FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer. ( Chaix, M; Ghiringhelli, F; Lorgis, V; Vincent, J, 2014)
"The effectiveness of 5-fluorouracil (5-FU)-based adjuvant chemotherapy is reported in patients with colorectal cancer (CRC), but the usefulness of 5-FU metabolic enzymes as predictive biomarkers of the efficacy of this chemotherapy remains unclear."3.80Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis. ( Hasegawa, H; Ishii, Y; Kitagawa, Y; Okabayashi, K; Shigeta, K, 2014)
"To investigate the cost-effectiveness of panitumumab plus mFOLFOX6 (oxaliplatin, 5-fluorouracil and leucovorin) compared with bevacizumab plus mFOLFOX6 in first-line treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC)."3.80Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. ( Barber, B; de Liège, F; Graham, CN; Hechmati, G; Hjelmgren, J; Knox, H; Lanier, J, 2014)
" Therefore, we hypothesized that SNAI2 (Slug) may mediate 5-fluorouracil (5FU) chemotherapy resistance through inhibition of miR145 in colorectal cancer and thus represents a novel therapeutic target to enhance current colorectal cancer treatment strategies."3.80SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression. ( Camp, ER; Ethier, SP; Findlay, VJ; Hurst, K; Nogueira, LM; Quirk, D; Staveley O'Carroll, KF; Wang, C; Watson, DK, 2014)
"Recent observational studies showed that post-operative aspirin use reduces cancer relapse and death in the earliest stages of colorectal cancer."3.80Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients. ( Ali, R; Chan, ML; Chia, WK; Deng, YH; Ho, GF; Jian, X; Mehta, S; Segelov, E; Sharma, A; Soon, SS; Tan, CS; Toh, HC; Wee, HL, 2014)
"5-fluorouracil (5-FU) is the first line component used in colorectal cancer (CRC) therapy however even in combination with other chemotherapeutic drugs recurrence is common."3.80Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy. ( Brocardo, MG; Henderson, BR; Martino-Echarri, E, 2014)
"We tested the hypothesis that expression of microRNAs (miRNAs) in cancer tissue can predict effectiveness of bevacizumab added to capecitabine and oxaliplatin (CAPEOX) in patients with metastatic colorectal cancer (mCRC)."3.80Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab. ( Boisen, MK; Dehlendorff, C; Hansen, TF; Holländer, NH; Høgdall, EV; Jensen, BB; Jensen, BV; Johansen, JS; Keldsen, N; Larsen, JS; Linnemann, D; Nielsen, BS; Nielsen, SE; Osterlind, K; Pfeiffer, P; Qvortrup, C; Tarpgaard, LS, 2014)
"5-Fluorouracil (5-FU) and its pro-drug Capecitabine have been widely used in treating colorectal cancer."3.80Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients. ( Chong, SS; Choo, SP; Lee, CG; Ong, SJ; Ong, SY; Teo, YY; Wang, J; Wang, X; Zhao, M, 2014)
"The triplet combination of fluorouracil, oxaliplatin and irinotecan for metastatic colorectal cancer improves efficacy at the cost of increased toxicity."3.80Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis. ( Brunner, S; Camenisch Gross, U; Cathomas, R; Freyholdt, T; Mey, U; von Moos, R, 2014)
"Effectiveness and toxicity of transcatheter arterial injection of irinotecan-eluting beads (DEBIRI) with and without concurrent capecitabine in pre-treated patients with metastatic colorectal cancer (CRC)."3.80Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer. ( Akinwande, O; Hayes, D; Martin, RC; Miller, A; O'Hara, R; Tomalty, D, 2014)
" Food and Drug Administration in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer who have previously received an oxaliplatin-containing chemotherapy regimen."3.79Aflibercept. ( Berlin, J; Chan, E; Ciombor, KK, 2013)
"To identify changes in peripheral immune responses in patients with metastatic colorectal cancer (mCRC) treated with irinotecan/5-fluorouracil/leucovorin (IFL) alone or in combination with cetuximab (C-IFL)."3.79Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer. ( Amptoulach, S; Gritzapis, AD; Karadima, ML; Kosmas, C; Skopelitis, E; Tsavaris, N; Voutsas, IF; Xynos, ID, 2013)
" Herein, we examined the effectiveness of a combination treatment regimen of 5-fluorouracil (5-FU) and curcumin in colorectal cancer (CRC) cells."3.79Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and Src protein kinase signaling pathways. ( Busch, F; Goel, A; Lueders, C; Mobasheri, A; Shakibaei, M; Shayan, P, 2013)
"First-line chemotherapeutic treatment of colorectal cancer (CRC) typically comprises oral (capecitabine) or intravenous 5-fluorouracil (5-FU) plus leucovorin (LV), in combination with oxaliplatin (XELOX or FOLFOX, respectively), although debate exists regarding the best course of treatment by modality in clinical practice."3.79Comparative effectiveness of 5-fluorouracil with and without oxaliplatin in the treatment of colorectal cancer in clinical practice. ( Clingan, PR; Dawber, JP; Eckermann, S; Healey, E; Ranson, M; Stillfried, GE, 2013)
"The FFCD 2000-05 randomised trial included 410 patients with advanced colorectal cancer and compared a sequential arm S treated with 5-fluorouracil and leucovorin (LV5FU2) followed by FOLFOX (LV5FU2+oxaliplatin) and then FOLFIRI (LV5FU2+irinotecan) and a combination arm C that begins directly with FOLFOX followed by FOLFIRI."3.79Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial. ( Auby, D; Bouché, O; Ducreux, M; Etienne, PL; Michiels, S; Pénichoux, J; Pignon, JP; Rougier, P; Texereau, P, 2013)
" 5-fluorouracil (5-FU) has been a drug of choice for treatment of colorectal cancer (CRC)."3.79Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer. ( Kang, SB; Kim, DG; Kim, IH; Kim, SH; Kim, SL; Kim, SW; Lee, SO; Lee, ST; Trang, KT, 2013)
"We retrospectively analyzed ABCG2 expression levels in patients with metastatic colorectal cancer (CRC) to investigate the interaction between ABCG2 expression and the tumor response to oxaliplatin and 5-fluorouracil (FOLFOX)."3.79Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy--preliminary evidence. ( Chang, SC; Chen, WS; Li, AF; Lin, CC; Lin, HH; Lin, JK; Lin, PC; Yang, SH, 2013)
"We investigated the correlation between plasma ratio of dihydrouracil/uracil (UH2/Ura), a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase (DPD) activity, and 5-fluorouracil (5-FU) treatment efficacy in rats with colorectal cancer (CRC)."3.79Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013)
"We developed a pharmacokinetic/pharmacodynamic (PK/PD) model with the value of the plasma ratio of dihydrouracil (UH2)/uracil (Ura), which is a possible surrogate biomarker of hepatic dihydropyrimidine dehydrogenase activity, determined before 5-fluorouracil (5-FU) treatment to simulate the growth of tumors after 5-FU treatment in rats with colorectal cancer (CRC)."3.79Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Okada, K; Takada, K, 2013)
"To investigate the use of liposomal irinotecan (Irinophore C™) plus or minus 5-fluorouracil (5-FU) for the treatment of colorectal cancer."3.79Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil. ( Allen, TM; Anantha, M; Bally, MB; Dos Santos, N; Harasym, N; Hare, JI; Neijzen, RW; Waterhouse, DN; Webb, MS, 2013)
"To measure global gene expression in primary advanced colorectal cancer patients who have undergone fluorouracil, leucovorin and oxaliplatin (FOLFOX4) chemotherapy and screen valuable biomarkers to predict the effects of chemotherapy."3.79Identification of HOXB8 and KLK11 expression levels as potential biomarkers to predict the effects of FOLFOX4 chemotherapy. ( Chi, P; Li, S; Lu, X; Pan, J, 2013)
"There have been controversies in prognostic impact of mucinous histology on colorectal cancer, and its implication in patients treated with adjuvant 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is unclear."3.79Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy. ( Bae, JM; Bang, YJ; Cho, NY; Han, SW; Im, SA; Jeong, SY; Kang, GH; Kim, TY; Lee, DW; Lee, HJ; Lee, KH; Oh, DY; Park, JG; Park, KJ; Rhee, YY, 2013)
" Compared to SW480 and HCT116 colorectal cancer cells, P6C cells were highly resistant to Camptothecin and 5-fluorouracil, the commonly used chemotherapeutic agents to treat colorectal cancers."3.79Establishment of a human colorectal cancer cell line P6C with stem cell properties and resistance to chemotherapeutic drugs. ( Chen, Q; Du, L; Hao, JJ; Jin, HJ; Li, BW; Liu, HM; Rao, GH; Wang, J; Wang, MR; Wang, XH; Yang, YL, 2013)
"To report on the efficacy and safety of mitomycin-C-capecitabine (MIXE) regimen as salvage chemotherapy regimen for patients with refractory metastatic colorectal cancer."3.79Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study. ( Brennan, M; Garcon, MC; Kaley, K; Rodriguez, G; Saif, MW, 2013)
"This retrospective cohort study investigated the association between epidermal growth factor receptor (EGFR) polymorphisms and clinical outcomes in colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)-based chemotherapy."3.79Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy. ( Chiou, HY; Hsieh, LL; Lai, CY; Sung, FC; Tang, R; Wu, FY; Yeh, CC, 2013)
"The relationship between the plasma ratio of dihydrouracil/uracil (UH2/Ura) and hepatic dihydropyrimidine dehydrogenase (DPD) activity after repeated 5-fluorouracil (5-FU) treatment in rats with colorectal cancer (CRC) was investigated."3.79A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer. ( Imoto, K; Ito, Y; Kobuchi, S; Kuwano, S; Nishimura, A; Okada, K; Shibata, N; Takada, K, 2013)
"The efficacy and safety of bevacizumab(BV), combined with infusional 5-fluorouracil/leucovorin(5-FU/LV)plus irinotecan(FOLFIRI)as the second-line treatment for metastatic colorectal cancer(mCRC)after resection of the primary lesion, have not been fully clarified."3.79[Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion]. ( Abe, H; Abe, M; Hirata, T; Mafune, K; Minamimura, K; Umemura, A, 2013)
"Kirsten rat sarcoma virus (KRAS) wild-type status determined using a locked nucleic acid (LNA)-mediated quantitative polymerase chain reaction (qPCR) clamping assay (LNA assay) predicted response to therapy in the CRYSTAL (Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer) study."3.79Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay. ( Bray, C; Celik, I; Chang, SC; Denne, J; Green, G; Harbison, C; Horak, C; Khambata-Ford, S; Van Cutsem, E; Zhao, L, 2013)
"The aim of this study was to determine the feasibility of S-1 plus oxaliplatin (SOX) or capecitabine plus oxaliplatin (XELOX) as first-line therapy for patients with initially unresectable metastases from colorectal cancer."3.79Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Toyama, Y; Watanabe, K; Yanaga, K, 2013)
"To evaluate gemcitabine plus capecitabine as third-line or later-line therapy in patients with refractory advanced colorectal cancer (CRC) who maintain a good performance status (PS)."3.79Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: a retrospective study. ( Alonso, MÁ; Jorge, M; Mendez, JC; Montes, AF; Pellón, ML; Quintero, G; Ramos, M; Reboredo, M; Romero, C; Salgado, M; Valladares-Ayerbes, M; Varela, S, 2013)
" We report the detailed assessment of few cardiac parameter of toxicity in patients of advanced colorectal carcinoma subjected to two Schedules of high and low dose Folinic Acid, 5-Fluorouracil, bolus and continuous infusion."3.79Comparative cardiac toxicity in two treatment schedules of 5-FU/LV for colorectal carcinoma. ( Bano, N; Mateen, A; Najam, R, 2013)
"Mucinous colorectal cancer (CRC) exhibits distinct clinical and pathological features, including poorer response to fluorouracil (FU) compared with non-mucinous tumours."3.79Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil. ( Ardizzoni, A; Azzoni, C; Bottarelli, L; Campanini, N; Cascinu, S; Cunningham, D; Mandolesi, A; Negri, FV; Scartozzi, M; Silini, EM; Tinelli, C; Wotherspoon, A, 2013)
"In diabetic patients complicated with colorectal cancer (CRC), metformin treatment was reported to have diverse correlation with CRC-specific mortality."3.79Effects of metformin on CD133+ colorectal cancer cells in diabetic patients. ( Gao, F; Guan, M; Xue, Y; Zhang, Q; Zhang, Y; Zheng, Z, 2013)
"To evaluate efficacy, safety, and feasibility of maintenance therapy with capecitabine after fluoropyrimidines/oxaliplatin or fluoropyrimidines/irinotecan chemotherapy in patients with incurable colorectal cancer."3.79[Efficacy and tolerance of maintenance therapy in patients with incurable advanced colorectal cancer]. ( Jiang, W; Li, Y; Liu, J; Ma, D; Yang, D, 2013)
"We analyzed the clinical efficacy and safety of capecitabine plus oxaliplatin( XELOX) and bevacizumab( BV) as neoadjuvant chemotherapy, administered for the treatment of patients with resectable metastatic colorectal cancer between October 2009 and December 2012."3.79[Neoadjuvant chemotherapy with capecitabine plus oxaliplatin and bevacizumab for the treatment of patients with resectable metastatic colorectal cancer]. ( Egawa, T; Ito, Y; Kemmochi, T; Makino, H; Mihara, K; Mori, T; Nagashima, A; Ohkubo, Y; Yamamuro, W, 2013)
"Capecitabine is one of the most effective oral chemotherapeutic drugs for advanced or recurrent colorectal cancer and gastric cancer."3.79[Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy]. ( Amemori, K; Koike, C; Shigematsu, T; Shirai, M; Sunda, K; Takeda, K; Yamada, T; Yamagiwa, K, 2013)
" We hypothesized that gene expression levels and germline variations in CD133 will predict clinical outcome in patients with metastatic colorectal cancer (mCRC), treated in first-line setting with 5-fluorouracil, oxaliplatin and bevacizumab (BV), and we investigated whether there is a correlation with gene expression levels of CD133, vascular endothelial growth factor (VEGF) and its receptors."3.79Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. ( Danenberg, KD; El-Khoueiry, A; Hu-Lieskoven, S; Iqbal, S; Kahn, M; Lenz, HJ; Lurje, G; Ning, Y; Pohl, A; Shriki, J; Stebbing, J; Teo, JL; Winder, T; Yang, D; Zhang, W, 2013)
"The drug fluorouracil (5-FU) is a widely used antimetabolite chemotherapy in the treatment of colorectal cancer."3.79Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer. ( Ally, AA; Asano, JK; Brown, CJ; Chan, SY; Cheng, GS; Cheung, PY; Chittaranjan, S; Gill, S; Griffith, M; Griffith, OL; Hou, YC; Lee, A; Luk, M; Marra, MA; Miao, L; Moore, R; Morin, GB; Morin, RD; Mwenifumbo, JC; Novik, K; Owen, D; Paul, JE; Pugh, TJ; Severson, T; Tai, IT; Tang, MJ; Taylor, G, 2013)
" We have performed a genome-wide association study (GWAS) on 221 colorectal cancer (CRC) patients that had been treated with 5-fluorouracil (5-FU), either alone or in combination with oxaliplatin (FOLFOX)."3.79Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. ( Andreu, M; Baiget, M; Bessa, X; Brea-Fernández, A; Bujanda, L; Candamio, S; Carracedo, A; Castells, A; Castellví-Bel, S; Cazier, JB; Cortejoso, L; Crous-Bou, M; Durán, G; Fernandez-Rozadilla, C; Gallardo, E; García, MI; González, D; Gonzalo, V; Guinó, E; Jover, R; Lamas, MJ; Llor, X; López, R; López-Fernández, LA; Moreno, V; Páez, D; Palles, C; Paré, L; Reñé, JM; Rodrigo, L; Ruiz-Ponte, C; Tomlinson, I; Xicola, R, 2013)
"The aim of the study was to analyse the prevalence and characteristics of secondary diabetes induced by 5-fluorouracil (5-FU) based chemotherapy in non-diabetic patients with colorectal cancer (CRC)."3.79Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study. ( Fang, J; Feng, JP; Li, M; Lin, M; Luo, M; Xie, T; Ye, DW; Yuan, XL; Zhou, Y; Zhu, YM, 2013)
"We initiated this preclinical study in order to analyze the impact of sorafenib single treatment versus combination treatment in human colorectal cancer."3.79Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy. ( Berger, MR; Galle, PR; Gockel, I; Graf, C; Hainz, M; Hamdi, S; Maderer, A; Moehler, M; Schimanski, CC; Schmidtmann, I; Theobald, M; Wehler, TC, 2013)
"The prognostic impact of CpG island methylator phenotype (CIMP) and microsatellite instability (MSI) on the treatment outcome of colon cancer patients receiving adjuvant 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) is unclear."3.79Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. ( Bae, JM; Bang, YJ; Cho, NY; Han, SW; Im, SA; Jeong, SY; Kang, GH; Kim, TY; Lee, HJ; Lee, KH; Oh, DY; Park, JG; Park, KJ, 2013)
"Pharmacokinetics, biodistribution and antitumour activity of 5-fluorouracil (5-FU)-loaded polyhydroxybutyrate (PHB) and cellulose acetate phthalate (CAP) blend microspheres were investigated in chemically induced colorectal cancer in albino male Wistar rats and compared with pristine 5-FU given as a suspension."3.79Cytotoxicity and antitumour activity of 5-fluorouracil-loaded polyhydroxybutyrate and cellulose acetate phthalate blend microspheres. ( Aminabhavi, TM; Chaturvedi, K; Kulkarni, AR; Tripathi, SK, 2013)
"To investigate the hepatic dihydropyrimidine dehydrogenase (DPD) activity in colorectal cancer (CRC), which is critically important to create a patient-specific dosing regimen, we performed 5-FU pharmacokinetic studies in 1,2-dimethylhydrazine-induced CRC model rats (CRC rats)."3.79Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats. ( Imoto, K; Ito, Y; Kobuchi, S; Okada, K; Takada, K, 2013)
" The correlation of G1249A ABCC2 polymorphism with the development of colorectal cancer (CRC) and poor prognosis was evaluated in patients who were treated with fluorouracil/-leucovorin (FL) plus oxaliplatin (FOLFOX-4)."3.79Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy. ( Abdullah, S; Khoshzaban, A; Mirakhorli, M; Rahman, SA; Rozafzon, R; Vakili, M, 2013)
"Five prognostic factors had been previously identified in patients with metastatic colorectal cancer (MCRC) who received irinotecan-based second-line chemotherapy."3.79Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. ( Fukushima, H; Komatsu, Y; Muro, K; Naito, Y; Shitara, K; Takano, T; Yamazaki, K; Yasui, H; Yuki, S, 2013)
"Resistance to 5-fluorouracil (5FU) poses a constant challenge to the management of colorectal cancer (CRC)."3.79Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy. ( Chan, EC; Cheah, PY; Ho, HK; Koh, PK; Mal, M; Phua, LC, 2013)
"The goal of the present study was to compare the efficacy of the combination of cetuximab and irinotecan to the combination of oxaliplatin and fluoropyrimidines as second-line chemotherapy in patients with irinotecan-refractory and oxaliplatin-naïve metastatic colorectal cancer (mCRC) harboring wild-type KRAS."3.79Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. ( Baek, JY; Hong, YS; Kim, HJ; Kim, JC; Kim, JH; Kim, KP; Kim, SY; Kim, TW; Lee, JL; Lim, SB; Park, JH; Park, SJ; Yu, CS, 2013)
"5-Fluorouracil (5-FU), together with other drugs such as oxaliplatin, is one of the most important pharmacological agents in the treatment of colorectal cancer."3.78P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance. ( Arias-González, L; Callejas-Valera, JL; de la Cruz-Morcillo, MA; Galán-Moya, EM; García-Cano, J; García-Gil, E; Melgar-Rojas, P; Sánchez-Prieto, R; Valero, ML, 2012)
"FOLFOXIRI demonstrated higher efficacy compared to 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) as first-line treatment of metastatic colorectal cancer."3.78Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. ( Allegrini, G; Baldi, GG; Brunetti, IM; Cortesi, E; Cremolini, C; Cupini, S; Falcone, A; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Ricci, S; Salvatore, L; Tuzi, A; Vasile, E, 2012)
"No standard treatment exists for patients with metastatic colorectal cancer who have progressed after treatment with 5-fluorouracil (5-FU), oxaliplatin, irinotecan and an anti-EGFR antibody."3.78Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer. ( Boisen, MK; Fromm, AL; Jensen, BV; Larsen, FO, 2012)
"In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin."3.78Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012)
"The impact of thymidylate synthase (TYMS), methylenetetrahydrofolate reductase (MTHFR), and serine hydroxymethyltransferase 1 (SHMT1) gene polymorphisms and that of dihydropyrimidine dehydrogenase (DPD) enzyme activity, serum total homocysteine level, and estimated serum creatinine clearance on first-line 5-fluorouracil, leucovorin, irinotecan, and bevacizumab (FOLFIRI+bevacizumab) regimen efficacy in metastatic colorectal cancer patients was investigated."3.78Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab. ( Adleff, V; Budai, B; Hitre, E; Komlósi, V; Kralovánszky, J; Láng, I; Nagy, T; Pap, É; Réti, A, 2012)
"We assessed DNA repair efficiency over time, in vitro, in human colon adenocarcinoma HT-29 (wild-type KRAS) and HCT-116 (mutated KRAS) cell lines treated with Dbait in combination with 5-fluorouracil and/or camptothecin."3.78Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer. ( Berger, F; Biau, J; Bousquet, G; Devun, F; Dutreix, M; Herbette, A; Robine, S; Roulin, C; Sun, JS, 2012)
"004) of colorectal cancer patients receiving 5-fluorouracil based chemotherapy and significantly outperformed common uni- and multi-variate statistical approaches."3.78Clinical application of a systems model of apoptosis execution for the prediction of colorectal cancer therapy responses and personalisation of therapy. ( Concannon, CG; Dicker, P; Hector, S; Huber, HJ; Kay, EW; Kehoe, J; McCawley, N; McNamara, D; Murray, F; Prehn, JH; Rehm, M; Schmid, J, 2012)
"Oxaliplatin-based therapy, notably FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin), is a standard regimen approved globally for the treatment of metastatic colorectal cancer, and as adjuvant treatment of colon cancer."3.78Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. ( André, T; Brienza, S; de Gramont, A; Goldberg, RM; Gomi, K; Lee, PH; Mizunuma, N; Ohtsu, A; Rothenberg, ML; Shimada, Y; Sugihara, K, 2012)
" The aim of this study was to investigate the schedule-dependent effect of 5-fluorouracil (5-FU) and platinum derivatives (cisplatin or oxaliplatin) in colorectal cancer (CRC) cell lines, and to explore factors affecting it."3.78Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells. ( Fujita, M; Minegaki, T; Okumura, K; Takahashi, M; Takara, K; Yamamoto, K; Yokoyama, T, 2012)
"This exploratory retrospective study examined the effects of polymorphisms in transporter genes related to irinotecan pharmacokinetics and those in genes related to irinotecan pharmacodynamics on the efficacy of first-line combination chemotherapy with irinotecan, 5-fluorouracil, and folinic acid (leucovorin) (FOLFIRI) in Japanese patients with advanced colorectal cancer."3.78Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. ( Akiyama, Y; Fujita, K; Ishida, H; Kawara, K; Miwa, K; Saji, S; Sasaki, Y; Sunakawa, Y; Yamashita, K, 2012)
"The efficacy of bevacizumab combined with infusional 5-fluorouracil/leucovorin (5-FU/LV) plus irinotecan (FOLFIRI) as the second-line treatment for metastatic colorectal cancer (mCRC) has not been fully clarified, although bevacizumab combined with infusional 5-FU/LV plus oxaliplatin (FOLFOX) in the second-line setting has demonstrated a survival benefit."3.78Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV stud ( Baba, E; Bando, H; Boku, N; Esaki, T; Fukunaga, M; Hyodo, I; Kato, S; Katsumata, K; Miyake, Y; Moriwaki, T; Ozeki, M; Satoh, T; Takashima, A; Yamashita, K; Yamazaki, K; Yoshida, S, 2012)
"To assess the value for money of alternative chemotherapy strategies for managing advanced colorectal cancer using irinotecan or oxaliplatin, either in sequence or in combination with fluorouracil."3.78The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS). ( Asseburg, C; Bravo Vergel, Y; Manca, A; Meade, A; Parmar, M; Sculpher, MJ; Seymour, MT; Stephens, R, 2012)
"Patients with a diagnosis of breast or colorectal cancer and prescribed capecitabine were recruited from a UK teaching hospital."3.78Capecitabine non-adherence: exploration of magnitude, nature and contributing factors. ( Bhattacharya, D; Easthall, C; Small, M; Watson, S; Willoughby, KA, 2012)
" We investigated the clinical significance of miR-10b and its involvement in chemotherapeutic resistance to 5-fluorouracil (5-FU), which is a key component of common chemotherapy regimens in colorectal cancer."3.78MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells. ( Doki, Y; Ishii, H; Mimori, K; Mori, M; Nishida, N; Shibata, K; Sudo, T; Tanaka, F; Yamamoto, H; Yamashita, S, 2012)
" Breast cancer patients were receiving a 5-fluorouracil/epirubicin/cyclophosphamide (FEC) regimen (6 chemotherapy cycles), and colorectal cancer patients were receiving either an oxaliplatin/5-fluorouracil/folinic acid (FOLFOX) regimen (12 cycles) or a 5-fluorouracil/folinic acid (Mayo) regimen (6 cycles)."3.78Infections of Blastocystis hominis and microsporidia in cancer patients: are they opportunistic? ( Anita, ZB; Chandramathi, S; Kuppusamy, UR; Suresh, K, 2012)
" The aim of the present study was to analyse the possible predictive value of miRNA-126 in relation to first line capecitabine and oxaliplatin (XELOX) in patients with metastatic colorectal cancer (mCRC)."3.78The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. ( Hansen, TF; Jakobsen, A; Lindebjerg, J; Sørensen, FB, 2012)
"Human colorectal cancer cells, HT-29 and SW480, were cultured under hypoxic conditions and the sensitivity to 5-fluorouracil (FU), oxaliplatin, and SN-38 (active metabolite of irinotecan) was tested."3.78SN-38 overcomes chemoresistance of colorectal cancer cells induced by hypoxia, through HIF1alpha. ( Hiyoshi, M; Hongo, K; Kaneko, M; Kawai, K; Kitayama, J; Murono, K; Nirei, T; Sasaki, K; Sunami, E; Tada, N; Takahashi, K; Tsuno, NH, 2012)
" We analysed a cohort of 302 patients with colorectal cancer treated with 5-Fluorouracil (5-FU)."3.78Data-driven assessment of the association of polymorphisms in 5-Fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer. ( Afzal, S; Colding-Jørgensen, M; Jensen, SA; Mosekilde, E; Poulsen, HE; Rasmussen, CH; Sarac, SB; Thirstrup, S, 2012)
"Here we performed a systematic analysis of the immunohistochemical expression of the key proteins involved in apoptosome-dependent caspase activation (APAF1, Pro-caspases 9 and 3, SMAC, and XIAP) in a cohort of Stage II and III colorectal cancer patients from a Phase III trial of adjuvant 5-fluorouracil-based chemotherapy vs postoperative observation alone."3.78Apoptosome-dependent caspase activation proteins as prognostic markers in Stage II and III colorectal cancer. ( Concannon, CG; Conlon, S; Cummins, RJ; Dicker, P; Hector, S; Johnston, PG; Kay, EW; Prehn, JH; Schmid, J, 2012)
"Perifosine is a novel targeted oral Akt inhibitor currently in Phase III clinical development for treatment of colorectal cancer (CRC, in combination with capecitabine) and multiple myeloma (MM, in combination with bortezomib and dexamethasone)."3.78Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. ( Anderson, KC; Eng, C; Hideshima, T; Kolesar, J; Richardson, PG, 2012)
" Deficient mismatch repair, or microsatellite instability, is a potent marker for the ineffectiveness of 5-fluorouracil (5-FU) in colorectal cancer (CRC)."3.78FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer. ( Fujinaka, Y; Iimori, M; Kakeji, Y; Kitao, H; Maehara, Y; Morita, M; Nakanishi, R; Tokunaga, E; Yamashita, N, 2012)
" Here, we aimed to investigate the role of CQ in potentiating the effect of 5-fluorouracil (5-FU), the chemotherapeutic agent of first choice for the treatment of colorectal cancer, in an animal model of colon cancer."3.78Resistance of colon cancer to 5-fluorouracil may be overcome by combination with chloroquine, an in vivo study. ( Hiyoshi, M; Hongo, K; Kaneko, M; Kawai, K; Kitayama, J; Murono, K; Nirei, T; Sasaki, K; Sunami, E; Tada, N; Takahashi, K; Tsuno, NH, 2012)
" We aimed to assess the prognostic role of VEGF, bFGF, PDGF-AA, EGF, HGF, and E-selectin in patients with metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) chemotherapy protocol."3.78Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer. ( Berk, V; Elmalı, F; Er, O; Inanç, M; Karaca, H; Ozkan, M; Saraymen, R, 2012)
" It was analyzed in 12 colorectal cancer cells for associations with radiation or 5-fluorouracil susceptibility by Western blotting, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium Bromide assay, and small interfering RNA transfection."3.78Hydroxymethylglutaryl-coenzyme a synthase 2 expression is associated with chemoradiotherapy responses in colorectal cancer. ( Cho, MJ; Kim, DY; Kim, ES; Kim, JS; Kim, KH; Ku, JL; Yeo, SG; Yoo, BC, 2012)
"Capecitabine plus oxaliplatin combination (XELOX) is the first-line treatment in metastatic colorectal cancer."3.78Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment. ( Alì, G; Calabrese, R; Lenzi, P; Moretti, P; Orsucci, D; Petrozzi, L; Pizzanelli, C; Ricci, G; Siciliano, G, 2012)
"A combination of 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX) is a standard regimen for the chemotherapy of metastatic colorectal cancer."3.78Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study. ( Ando, T; Fukuoka, J; Horikawa, N; Hosokawa, A; Kajiura, S; Kobayashi, Y; Ogawa, K; Sugiyama, T; Suzuki, N; Tsukioka, Y; Ueda, A; Yabushita, K, 2012)
"Oxaliplatin is effective when used with 5-fluorouracil (5-FU) and leucovorin, or with capecitabine (COX) for the treatment of colorectal cancer."3.78Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo. ( Kobunai, T; Nakagawa, F; Nukatsuka, M; Saito, H; Sakamoto, K; Shiraishi, K; Takechi, T; Uchida, J, 2012)
"A colorectal cancer patient receiving chemotherapy (5-fluorouracil and oxaliplatin) plus bevacizumab developed acute, severe thrombocytopenia."3.78A rare hematological adverse event induced by bevacizumab: severe thrombocytopenia. ( Brezault, C; Chaussade, S; Coriat, R; Dhooge, M; Dior, M; Goldwasser, F; Mir, O; Perkins, G, 2012)
" In this retrospective study, we assessed the efficacy of palonosetron versus granisetron for the incidence of CINV induced by mFOLFOX6 and FOLFIRI in patients with advanced colorectal cancer."3.78[Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey]. ( Hayakawa, Y; Muro, K; Noma, H; Okamoto, H; Sato, Y; Tatematsu, M, 2012)
"Five patients with primary colorectal adenocarcinoma or anal squamous cell carcinoma were started on a 2-weeks-on, 1-week-off capecitabine dosing regimen in addition to other chemotherapeutic agents and/or radiation."3.78Capecitabine-induced chest pain relieved by diltiazem. ( Ambrosy, AP; Fisher, GA; Kunz, PL; Witteles, RM, 2012)
"We hypothesized that metachronous colorectal liver metastases (CLM) have different biology after failure of oxaliplatin (FOLFOX) compared to 5-fluorouracil (5-FU) or no chemotherapy for adjuvant treatment of colorectal cancer (CRC)."3.78Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. ( Aloia, TA; Andreou, A; Brouquet, A; Chen, SS; Curley, SA; Garrett, C; Kopetz, S; Maru, DM; Overman, MJ; Shindoh, J; Vauthey, JN; Zimmitti, G, 2012)
"Radiosensitization by vorinostat under hypoxia was studied in four colorectal carcinoma cell lines and in one colorectal carcinoma xenograft model by analysis of clonogenic survival and tumor growth delay, respectively."3.78Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma. ( Flatmark, K; Fleten, KG; Furre, T; Hektoen, HH; Kristian, A; Ree, AH; Saelen, MG, 2012)
"To evaluate effects of UDP-glucuronosyltransferase1A1 (UGT1A1) and thymidylate synthetase (TS) gene polymorphisms on irinotecan in metastatic colorectal cancer (mCRC)."3.78UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. ( Jiao, SC; Liu, ZY; Shen, L; Wang, JW; Wang, Y; Xu, JM; Xu, N, 2012)
" The aim of this study was to investigate the possible predictive value of the VEGF-A SNPs, in patients with metastatic colorectal cancer (mCRC) treated with first-line capecitabine and oxaliplatin (XELOX)."3.77The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer. ( Andersen, RF; Brandslund, I; Garm Spindler, KL; Hansen, TF; Jakobsen, A; Lindebjerg, J, 2011)
"The efficacy and safety of generic and brand name levofolinate injectable drugs were evaluated in 42 chemotherapy-naïve patients with colorectal cancer who received the combination chemotherapy of levofolinate, 5-fluorouracil, and oxaliplatin with or without bevacizumab."3.77Evaluation of efficacy and safety of generic levofolinate in patients who received colorectal cancer chemotherapy. ( Fujii, H; Iihara, H; Itoh, Y; Matsuura, K; Takahashi, T; Yasuda, K; Yoshida, K, 2011)
" We investigated associations between polymorphisms in both miRNA-containing genomic regions (primary and precursor miRNA) and in genes related to miRNA biogenesis with clinical outcome in metastatic colorectal cancer (mCRC) patients treated with 5-fluorouracil and irinotecan (CPT-11)."3.77Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. ( Aranda, E; Bandrés, E; Boni, V; Garcia-Foncillas, J; Gomez, MA; Maiello, E; Villa, JC; Zarate, R, 2011)
"The aim was to evaluate the association between plasma tissue inhibitor of metalloproteinase-1 (TIMP-1) and serum carcinoembryonic antigen (CEA) levels and outcome in patients with metastatic colorectal cancer (mCRC) receiving XELOX (combination chemotherapy with capecitabine and oxaliplatin) as first-line treatment."3.77Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer. ( Berglund, A; Brünner, N; Christensen, IJ; Frederiksen, C; Glimelius, B; Jensen, BV; Keldsen, N; Nielsen, HJ; Nielsen, SE; Pfeiffer, P; Qvortrup, C, 2011)
"5-Fluorouracil remains widely used in colorectal cancer treatment more than 40 years after its development."3.77Can localised (19)F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response? ( Griffiths, JR; Howe, FA; Ladroue, C; Lofts, F; McIntyre, DJ; Stubbs, M, 2011)
"The patients included were 145 who had colorectal or appendiceal carcinomatosis resected using cytoreductive surgery prior to treatment with hyperthermic intraperitoneal chemotherapy with mitomycin C as part of a multidrug regimen."3.77Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. ( Chang, D; Mahteme, H; Stuart, OA; Sugarbaker, PH; Van der Speeten, K, 2011)
" The authors of this report determined the frequency of reporting of time-to-event endpoints and tumor response outcomes in advanced colorectal cancer and examined the relation between the year of publication and the reported effectiveness of 5-fluorouracil or equivalent agents."3.77Reporting time-to-event endpoints and response rates in 4 decades of randomized controlled trials in advanced colorectal cancer. ( Arkenau, HT; Dobbins, T; Nordman, I; Ward, R, 2011)
"Patients with advanced colorectal cancer who received irinotecan combined with 5-fluorouracil plus l-leucovorin (FOLFIRI) as first-line therapy were divided into two groups: those with UGT1A1*1/*1 genotype and those with UGT1A1*1/*6 or *1/*28 genotype."3.77UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. ( Akiyama, Y; Ando, Y; Araki, K; Fujita, K; Hirose, T; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Miya, T; Mizuno, K; Nagashima, F; Narabayashi, M; Saji, S; Sasaki, Y; Sunakawa, Y; Yamamoto, W; Yamashita, K, 2011)
"Capecitabine plus oxaliplatin (CAPOX) is an established treatment option in colorectal cancer, but can be associated with severe toxicities."3.77Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. ( Baird, R; Barbachano, Y; Biondo, A; Chau, I; Chhaya, V; Cunningham, D; Karpathakis, A; McLachlan, J; Rahman, S, 2011)
"Irinotecan (CPT11) at 180 mg/m(2) with LV5FU2 for metastatic colorectal cancer (MCRC) has response rates (RRs) of 56 and 4% as first- and second-line treatments, respectively [1-2], and higher doses of CPT11 result in higher RRs."3.77Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients. ( Goubely, Y; Kirscher, S; Mineur, L; Molinari, N; Plat, F; Sabatier, R, 2011)
"Several long-standing chemotherapy regimens are available to treat metastatic colorectal cancer (mCRC) including: oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin (FOLFOX); and irinotecan plus 5-FU and leucovorin (FOLFIRI)."3.77Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics. ( Barber, B; Gregory, C; Long, SR; Song, X; Wang, PF; Zhao, Z, 2011)
"A total of 152 patients with metastatic colorectal cancer who were treated with oxaliplatin and continuous infusion 5-fluorouracil were genotyped for 21 polymorphisms in 13 cancer-related genes by PCR."3.77Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. ( El-Khouiery, A; Gordon, MA; Iqbal, S; Labonte, M; Ladner, RD; Lenz, HJ; Lurje, G; Nagashima, F; Sherrod, A; Wilson, P; Yang, D; Zhang, W, 2011)
" In the present study, we evaluated the characteristics of paclitaxel (PTX) and 5-fluorouracil (5-FU) penetration and their effects on tissue penetration using MCLs of human colorectal cancer cells (DLD-1 and HT-29) grown in Transwell inserts."3.77Penetration of paclitaxel and 5-fluorouracil in multicellular layers of human colorectal cancer cells. ( Choi, MS; Kim, SH; Kuh, HJ, 2011)
" The purpose of this pharmacogenetic trial was to study the relevance of thymidylate synthase (TS) genotyping and of the isoform 1A1 of uridine diphosphate glucuronosyltransferase (UGT1A1) in order to tailor a combination chemotherapy regimen of 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in metastatic colorectal cancer."3.77Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study. ( Chatelut, E; Delord, JP; Duret, A; Etienne, MC; Falandry, C; Freyer, G; Lledo, G; Merrouche, Y; Milano, G; Rebischung, C, 2011)
"We examined the feasibility of regimen selection for first-line irinotecan, 5-fluorouracil and leucovorin or oxaliplatin, 5-fluorouracil and leucovorin in Japanese patients with advanced colorectal cancer based on UDP-glucuronosyltransferase 1A1 genotype as well as physical status of patients related to diarrhea."3.77Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer. ( Akiyama, Y; Ando, Y; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Mizuno, K; Saji, S; Sasaki, Y; Sunakawa, Y; Yamashita, K, 2011)
"To examine cost and mortality among stage IV colorectal cancer (CRC) patients treated with 5-fluorouracil (5FU)/leucovorin/oxaliplatin (FOLFOX) or 5FU/leucovorin/irinotecan (FOLFIRI)."3.77A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer. ( Harley, C; Kulakodlu, M; Nelson, MA; Seal, B; Shetty, S, 2011)
"Hand-foot syndrome (HFS) is one of the most relevant dose-limiting adverse effects of capecitabine, an oral prodrug of 5-fluorouracil used in the standard treatment of breast and colorectal cancer."3.77A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome. ( Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J, 2011)
"There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)."3.77Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011)
"Combined chemotherapy with 5-fluorouracil and leucovorin (LV) has been widely used for the treatment of patients with colorectal cancer."3.77In vivo evidence for a significant role of folylpolyglutamate synthase in combined chemotherapy with oral fluoropyrimidine, UFT or S-1, and leucovorin. ( Fukushima, M; Kiniwa, M; Nakagawa, F; Saito, H; Sakamoto, E; Tsujimoto, H; Tsukioka, S; Uchida, J, 2011)
" In the present study, we aimed to investigate the antitumor effect of DCA combined with 5-Fluorouracil (5-FU) on colorectal cancer (CRC) cells."3.77Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. ( He, J; Li, J; Liang, H; Pan, F; Tong, J; Xie, G, 2011)
"The aim of this study was to evaluate the potential of fluorine-18 (F)-5-fluorouracil (F-5-FU) positron emission tomography/computed tomography (PET/CT) to show differences in 5-FU activity in metastatic colorectal cancer before and after treatment with bevacizumab."3.7718F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. ( Chin, FT; Conti, PS; Fisher, GA; Kunz, P; Quon, A; Subbarayan, M; Zissen, MH, 2011)
" We aimed to evaluate the effect of pretreatment serum metabolic profiles generated by (1)H NMR spectroscopy on toxicity in patients with inoperable colorectal cancer receiving single agent capecitabine."3.77Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine. ( Backshall, A; Clarke, SJ; Keun, HC; Sharma, R, 2011)
"When applying the topoisomerase inhibitor irinotecan (CPT) with the infusional fluorouracil/levofolinate (FOLFIRI) ± bevacizumab chemotherapy regimen in cases of advanced colorectal carcinoma, the international standard dose for CPT is 180 mg/m(2)."3.77Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma. ( Akutsu, N; Fujii, H; Hamamoto, Y; Miyamoto, J; Nagase, M; Nishi, T; Warita, E; Yamanaka, Y, 2011)
"Germline DNA was available from 568 previously untreated patients with advanced colorectal cancer participating in the CAIRO2 trial, assigned to capecitabine, oxaliplatin, and bevacizumab ± cetuximab."3.77Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. ( Beijnen, JH; Burylo, AM; Cats, A; de Boer, A; Deenen, MJ; Doodeman, VD; Guchelaar, HJ; Punt, CJ; Schellens, JH; Smits, PH; Tol, J; Vincent, A, 2011)
"Thymidylate synthase (TS) expression levels appear to be related to response to 5-fluorouracil-(5-FU)-based chemotherapy in colorectal cancer (CRC) patients."3.77Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil. ( Cianchi, F; Genuardi, M; Mazzei, T; Mini, E; Morganti, M; Napoli, C; Nobili, S; Papi, L; Putignano, AL; Tonelli, F; Valanzano, R; Vignoli, M, 2011)
"We have extensively assessed a biweekly regimen of irinotecan plus folinic acid and fluorouracil bolus (IRIFAFU) in metastatic colorectal cancer (MCRC)."3.77Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience. ( Barbato, E; Barberis, G; Comella, P; Condemi, G; Filippelli, G; Ionta, MT; Massidda, B; Natale, D; Palmeri, S; Putzu, C; Sandomenico, C; Tafuto, S; Vessia, G, 2011)
" It was motivated by an attempt to develop a model-based dose adaptation tool for clinical use in colorectal cancer patients receiving capecitabine, which induces severe hand-and-foot syndrome (HFS) toxicity in more than a half of the patients."3.77Empirical Bayes estimation of random effects of a mixed-effects proportional odds Markov model for ordinal data. ( Girard, P; Paule, I; Tod, M, 2011)
"The antivascular endothelial growth factor monoclonal antibody bevacizumab with infusional 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) is a standard first-line treatment option for metastatic colorectal cancer."3.77Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI. ( Boc, M; Ocvirk, J; Rebersek, M, 2011)
"The role of the calcium binding protein, Calbindin 2 (CALB2), in regulating the response of colorectal cancer (CRC) cells to 5-Fluorouracil (5-FU) was investigated."3.77Calbindin 2 (CALB2) regulates 5-fluorouracil sensitivity in colorectal cancer by modulating the intrinsic apoptotic pathway. ( Allen, WL; Johnston, L; Johnston, PG; Longley, DB; McCloskey, K; Proutski, I; Stevenson, L; Stewart, G; Wilson, PM, 2011)
" Here we show that ATP-binding cassette member B5 (ABCB5) identifies therapy-refractory tumor cells in colorectal cancer patients following fluorouracil (5-FU)-based chemoradiation therapy and provide evidence for a functional role of ABCB5 in colorectal cancer 5-FU resistance."3.77ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. ( Frank, MH; Frank, NY; Gasser, M; Gold, JS; Huang, Q; Ma, J; Murphy, GF; Saab, KR; Schanche, R; Schatton, T; Waaga-Gasser, AM; Wilson, BJ; Zhan, Q, 2011)
"Infusional fluorouracil/leucovorin (FU/LV) plus irinotecan (FOLFIRI) is one of the standard first-line options for patients with metastatic colorectal cancer (mCRC)."3.77A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. ( Baiget, M; del Rio, E; Marcuello, E; Páez, D; Paré, L; Salazar, J; Sebio, A, 2011)
"We studied patterns of DNA damage signaling and cell cycle response to clinically-relevant (bolus) and high doses of 5-fluorouracil (5-FU) in three colorectal cancer cell lines with differing MMR and TP53 status in an attempt to better understand how 5-FU exerts its cytotoxicity."3.77DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status. ( Adamsen, BL; De Angelis, PM; Kravik, KL, 2011)
"After resection of CRC and synchronous metastases, 53 (84%) out of 63 patients without chemotherapy, and 38 (83%) out of 46 that received 5-fluorouracil (5-FU) alone or with leucovorin (LV) developed recurrent tumors."3.77FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer. ( Kanazawa, T; Kawai, K; Kazama, S; Kitayama, J; Mori, K; Nagawa, H; Nozawa, H; Saito, S; Sunami, E; Yazawa, K, 2011)
"FOLFOX (a combination of leucovorin, fluorouracil and oxaliplatin) has achieved substantial success in the treatment of colorectal cancer (CRC) patients."3.77Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. ( Eshima, K; Horie, H; Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Konishi, T; Matsuda, K; Muto, T; Nozawa, K; Watanabe, T; Yamamoto, Y, 2011)
"Regimens containing bevacizumab and 5-fluorouracil have achieved substantial progress in the treatment of colorectal cancer."3.77Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients. ( Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Matsuda, K; Nozawa, K; Watanabe, T; Yamamoto, Y, 2011)
"XELOX (capecitabine + oxaliplatin) and FOLFOX 4 (5-FU + folinic acid + oxaliplatin) have shown similar improvements in survival in patients with metastatic colorectal cancer (MCRC)."3.77Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement. ( Chau, J; Chua, DT; Lee, AW; Lee, V; McGhee, SM; Ng, WT; Tse, VC, 2011)
"Injectable combination chemotherapy with 5-fluorouracil (5-FU)/Leucovorin (LV), oxaliplatin (OHP), and irinotecan (CPT-11) has been a standard treatment for advanced colorectal cancer (CRC)."3.77[Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer]. ( Matsueda, S; Sasaki, H; Tokunaga, Y, 2011)
"5-fluorouracil (5FU)-based chemotherapy is the standard treatment for advanced stage colorectal cancer (CRC) patients."3.77DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells. ( Carethers, JM; Iwaizumi, M; Tseng-Rogenski, S, 2011)
"For recurrent or metastatic colorectal cancer, a combination of leucovorin and fluorouracil with oxaliplatin (FOLFOX)is a standard first-line regimen."3.77[Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy]. ( Hasegawa, J; Hirota, M; Kim, Y; Nezu, R; Nishimura, J; Yoshida, Y, 2011)
"The purpose of this study was to investigate whether specific combinations of polymorphisms in 5-fluorouracil (5-FU) metabolism-related genes were associated with outcome in 5-FU-based adjuvant treatment of colorectal cancer."3.77The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer. ( Adleff, V; Afzal, S; Andersen, JT; Barile, C; Bertolaso, L; Brødbæk, K; Budai, B; Gusella, M; Hitre, E; Jensen, SA; Jimenez-Solem, E; Kralovánszky, J; Láng, I; Orosz, E; Padrini, R; Pasini, F; Petersen, M; Poulsen, HE; Vainer, B; Vogel, U, 2011)
"The aim of this study was to determine whether the relative mRNA expressions of the thymidylate synthase (TYMS) and the excision repair cross-complementing 1 (ERCC1) genes are associated with in vitro chemosensitivity to 5-fluorouracil (5-FU) and oxaliplatin in colorectal cancer, respectively."3.77Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer. ( Cho, YB; Choi, SH; Chun, HK; Chung, HJ; Kim, HC; Lee, WY; Yun, SH, 2011)
"It has been reported that thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), and excision repair cross-complementing-1 (ERCC-1) were useful markers to predict the efficacy of anti cancer agents including 5-fluorouracil (5-FU) and oxaliplatin for unresectable advanced colorectal cancer."3.77[The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer]. ( Haga, N; Ishibashi, K; Ishida, H; Ishiguro, T; Kumamoto, K; Kuwabara, K; Miura, I; Ohsawa, T; Okada, N, 2011)
" This study was performed to evaluate the efficacy and safety of Endostar plus leucovorin calcium/ 5-fluorouracil/oxaliplatin (FOLFOX4) in treating patients with advanced colorectal cancer."3.77Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients. ( Huang, XE; Li, CG; Li, Y; Qian, ZY; Xu, HX; Xu, X, 2011)
" Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29%)."3.77Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. ( Balaban, EP; Bull, J; Frenkel, EP; Graham, M; Periman, P; Perkins, S; Pruitt, B; Ross, M; Ruud, C; Sheehan, RG, 1994)
"Failure rate of colorectal cancer after surgical resection remains around 50% and adjuvant treatments are clearly required."3.77Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU. ( Nordlinger, B; Rougier, P, 1993)
"To investigate the mechanism of enhancing apoptosis-inducing effects of 5-fluorouracil on human colorectal adenocarcinoma cells by stable transfection of extrinsic Fas-associated death domain protein (FADD) gene, both in vitro and in vivo."3.76Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells. ( Jiang, Y; Luo, H; Yin, A; Zhang, X, 2010)
"A retrospective analysis was conducted to compare the tolerability and efficacy of single-agent capecitabine and 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) in the first-line treatment of patients aged > or =65 years with metastatic colorectal cancer (mCRC)."3.76Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis. ( Bodnar, L; Stec, R; Szczylik, C, 2010)
"Oxaliplatin-associated neuropathy remains a dose-limiting toxicity of the standard chemotherapy regimen of oxaliplatin and capecitabine for metastatic colorectal cancer."3.76Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? ( Cathomas, R; Köberle, D; Mayer, G; Mey, U; Räss, A; Ruhstaller, T; von Moos, R, 2010)
" We investigated whether p53 polymorphism and mutation were associated with in vitro sensitivity to 5-fluorouracil (5-FU) in patients with colorectal cancer."3.76Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer. ( Higashiguchi, T; Hotta, T; Iwahashi, M; Matsuda, K; Nasu, T; Oku, Y; Takifuji, K; Tominaga, T; Yamaue, H; Yokoyama, S, 2010)
"The purpose of the present study was to investigate polymorphisms related to the metabolism of fluoropyrimidine and oxaliplatin, thymidylate synthase (TS) and excision repair cross-complementing gene 1 (ERCC1) 118, in metastatic colorectal cancer patients treated with capecitabine and oxaliplatin (XELOX)."3.76EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. ( Andersen, RF; Jakobsen, A; Jensen, LH; Ploen, J; Spindler, KG, 2010)
" To test this we have addressed the hypothesis that histone deacetylase inhibitors SBHA and MS275 potentiate inhibitory effects of classical anti-colorectal cancer cytostatic, 5-fluorouracil (5-FU), on survival of colorectal cancer (CRC) cells in vitro."3.76MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells. ( Flis, K; Flis, S; Gnyszka, A; Spławiński, J, 2010)
"The in vitro chemosensitizing effect of triptolide (PG490) on the cytotoxicity of 5-fluorouracil (5-FU) was determined in three colorectal cancer (CRC) cell lines."3.76Triptolide simultaneously induces reactive oxygen species, inhibits NF-kappaB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines. ( Armesilla, AL; Cassidy, J; Darling, JL; Guo, X; Mathew, S; Wang, W; Xu, B, 2010)
" In this study, we investigated the expressions of FAK, Akt and NF-kappaB in human colorectal cancer (CRC), and the effects of FAK gene silencing on MCSs formation and 5-fluorouracil (5-FU) chemosensitivity in colon carcinoma MCSs culture cells."3.76The effect of focal adhesion kinase gene silencing on 5-fluorouracil chemosensitivity involves an Akt/NF-kappaB signaling pathway in colorectal carcinomas. ( Bian, Z; Chang, P; Chen, Y; Jiang, J; Li, J; Liang, H; Pan, F; Wang, Z; Xiang, L; Yang, L; Zou, L, 2010)
"To test prospectively the predictive value of germinal gene polymorphisms related to fluorouracil (FU) and oxaliplatin (Oxa) pharmacodynamics on toxicity and responsiveness of colorectal cancer (CRC) patients receiving FOLFOX therapy."3.76Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. ( André, T; Carola, E; Chibaudel, B; de Gramont, A; Etienne-Grimaldi, MC; Flesch, M; Formento, JL; Francoual, M; Lledo, G; Mabro, M; Maindrault-Goebel, F; Milano, G; Mineur, L, 2010)
"A 78-year-old male with stage III colorectal adenocarcinoma was prescribed with weekly iv 5-fluorouracil and folinic acid (FU/FA)."3.76Do 5-fluorouracil therapies alter CYP2C19 metaboliser status? ( Helsby, NA; Laking, GR; Lo, WY; Thompson, P, 2010)
"The purpose of our study was to estimate the out-of-pocket payment and cost-effectiveness of capecitabine plus oxaliplatin (XELOX) or XELOX plus bevacizumab from the perspective of patients with metastatic colorectal cancer (MCRC)."3.76Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan. ( Fukuda, T; Shiroiwa, T; Tsutani, K, 2010)
"Oxaliplatin and 5-fluorouracil (5-FU) currently form the backbone of conservative treatment in patients with metastatic colorectal cancer."3.76Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa. ( Borel Rinkes, IH; Cameron, K; de Bruijn, MT; Hoogwater, FJ; Kranenburg, O; Medema, JP; Raats, DA; van Houdt, WJ, 2010)
"To assess the potential of Lactobacillus acidophilus and Lactobacillus casei strains to increase the apoptosis of a colorectal cancer cell line in the presence of 5-fluorouracil (5-FU), LS513 colorectal cancer cells were treated for 48 h with increasing concentrations of these lactic acid bacteria (LAB) in the presence of 100 mu g/ml of 5-FU."3.76Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis. ( Baldwin, C; Lacroix, M; Luquet, FM; Millette, M; Oth, D; Ruiz, MT, 2010)
" Based on these data, we investigated whether patient's gender and TS polymorphism exert an interactive effect on the clinical evolution of patients with advanced colorectal cancer (CRC) subjected to 5 fluorouracil (5FU)-based adjuvant chemotherapy."3.76Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer. ( Fernández-Contreras, ME; Gamallo, C; García de Paredes, ML; Gisbert, JP; Guijarro, M; Hinojar-Gutiérrez, A; Rivas, N; Sánchez-Hernández, JJ, 2010)
"5-Fluorouracil has been the chemotherapy agent of first-choice for colorectal cancer for many years, but since there are no proven predictors of a patient's response to therapy, all patients receive similar treatment."3.76HnRNP K and PDI marked response to chemotherapy to human colorectal cancer cells. ( Chen, HQ; Chu, ZX; Huang, L; Ma, YL; Peng, JY; Qin, HL; Shen, TY; Zhang, M; Zhang, P; Zhou, YK, 2010)
"The aim was to evaluate the cost of capecitabine vs conventional combination chemotherapics such as 5-fluorouracil (5-FU) for the treatment of metastatic colorectal cancer (mCRC) in Italy."3.76Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients. ( Bianchessi, C; Bollina, R; Carteni, G; Cozzi, C; De Portu, S; Grimaldi, AM; Mantovani, LG; Ravaioli, A; Tamburini, E; Testa, TE, 2010)
"To explore the effect of PI3K p85alpha gene silencing on the 5-fluorouracil (5-FU)-induced apoptosis of colorectal cancer cells."3.76[PI3K p85alpha gene silencing by RNA interference promotes 5-fluorouracil-induced apoptosis of colorectal cancer LoVo cells]. ( Ma, YQ; Ni, L; Song, YG; Yang, H, 2010)
" 5-Fluorouracil (5-FU) is the drug of choice in managing colorectal cancer (CRC) patients."3.76Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance. ( Ardalan, B; Benitez, E; Nelson, G; Sarkar, M; Singhal, S; Subbarayan, PR, 2010)
" The SFK inhibitor saracatinib (AZD0530) is currently in phase II trials in patients including those with colorectal cancer (CRC), where links between SFK activity and poor prognosis are particularly striking."3.76Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters. ( Bönisch, H; Bryce, RA; Dive, C; Ghattas, M; Green, TP; Hickinson, DM; Morrow, CJ; Smith, C, 2010)
"A hospital based cross-sectional retrospective study was conducted to determine the frequency of hand foot syndrome (HFS) with Capecitabine as a single agent and in combination with Oxaliplatin."3.76High frequency of hand foot syndrome with capecitabine. ( Azman, N; Haron, M; Kamil, M; Khalid, I; Yosuff, N, 2010)
"Accurate description of current practice within advanced colorectal cancer (CRC) specialties were needed to inform an economic evaluation of the UGT1A1 pharmacogenetic test for irinotecan in the United Kingdom."3.76Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. ( Elliott, RA; Newman, WG; Payne, K; Shabaruddin, FH; Valle, JW, 2010)
"Oxaliplatin with 5-fluorouracil plus leucovorin (FOLFOX) has become the standard treatment in patients with colorectal cancer."3.76[Interstitial lung disease associated with combination chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin]. ( Jung, JJ; Kim, GB; Ko, JE; Ko, SH; Lee, YS; Park, S; Yoon, HS, 2010)
"Resistance to 5-fluorouracil (5-FU) represents a major contributor to cancer-related mortality in advanced colorectal cancer patients."3.76Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy. ( Auman, JT; Deal, AM; Hoskins, JM; Hudson, ML; Ibrahim, JG; McLeod, HL; Meyers, MO; Muhale, F; O'Neil, BH; Thorne, LB; Walko, CM; Watson, RG; Yu, J, 2010)
" As proof of principle, we used the approach to compare fluorouracil-resistant and -nonresistant human colorectal cancer cell lines."3.76Alternative expression analysis by RNA sequencing. ( Ally, A; Asano, JK; Chan, SY; Chittaranjan, S; Corbett, R; Delaney, A; Goya, R; Griffith, M; Griffith, OL; Hirst, M; Hou, YC; Jones, SJ; Li, HI; Marra, MA; McDonald, H; Morin, GB; Morin, RD; Morrissy, AS; Mwenifumbo, J; Pugh, TJ; Robertson, G; Tai, IT; Tang, MJ; Teague, K; Zeng, T; Zhao, Y, 2010)
"Although the 2009 edition of the Guidelines for Colorectal Cancer Therapy recommend capecitabine as a standard postoperative adjuvant chemotherapy for colorectal cancer therapy, a characteristic adverse event, hand-foot syndrome, develops at a high incidence, and appropriate management is necessary to continue therapy."3.76[Adverse events in patients treated with capecitabine as adjuvant chemotherapy after surgery for colorectal cancer--countermeasures against hand-foot syndrome]. ( Chiba, M; Fujimoto, H; Igawa, A; Iizawa, H; Ikeda, E; Inoue, K; Ishiyama, K; Kobayashi, Y; Matsuda, M; Mori, N; Saito, T; Sato, T; Sugawara, M; Suto, T; Suzuki, Y; Watanabe, T; Yabuki, H, 2010)
" In this study, we investigated antitumor effects of the combined therapy using DC vaccine and irinotecan plus infusional 5-fluorouracil and leucovorin (FOLFIRI) which have been clinically used for the treatment of colorectal cancer."3.76Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model. ( Kim, HJ; Kim, HS; Kim, SG; Kim, TG; Oh, ST; Park, HM; Park, JS; Sohn, HJ, 2010)
"Patients with locally advanced and metastatic colorectal cancer treated with capecitabine or 5-fluorouracil/leucovorin (5-FU/LV) as monotherapy or combination therapy with oxaliplatin from 2003-2006 were identified in the Thomson Reuters MarketScan® databases."3.76Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison. ( Cartwright, T; Chu, E; McKenna, EF; Schulman, KL, 2010)
"Combination of capecitabine and irinotecan (XELIRI regimen) is an active and well tolerated treatment for metastatic colorectal cancer (mCRC)."3.76Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. ( Alvarez-Suarez, S; García-Alfonso, P; Jerez-Gilarranz, Y; Khosravi, P; Martin, M; Muñoz-Martin, AJ; Riesco-Martinez, M, 2010)
"Infusional 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) plus bevacizumab chemotherapy is commonly implemented in the first-line treatment of metastatic colorectal cancer."3.76Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. ( Fakih, MG; Groman, A; Vaidyanathan, G; Wilding, G, 2010)
"The combination regimen of mitomycin-C/5-FU/leucovorin showed marginal activity and tolerable toxicity profiles in heavily pretreated metastatic colorectal cancer patients."3.76Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. ( Choi, IK; Choi, YJ; Kang, EJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2010)
"To find out whether SNPs in the transporter gene ATP-binding casette B1 (ABCB1) were related to adverse effects in colorectal cancer patients treated with 5-fluorouracil (5-FU) or capecitabine."3.76ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients. ( Alvarez, S; Barrueco, N; Cortejoso, L; García, MI; García-Alfonso, P; Gonzalez-Haba, E; Jiménez, JL; López-Fernández, LA; López-Lillo, C; Martín, ML; Muñóz-Fernández, MA; Sanjurjo, M, 2010)
"Data on patients with colorectal cancer who received FOLFOX (5-fluorouracil, leucovorin and oxaliplatin) treatment between June 2005 and June 2009 were retrieved from the prospective cohort database of the Outpatient Oncology Unit of the Kyoto University Hospital."3.76Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX. ( Chiba, T; Fukushima, M; Hazama, M; Ishiguro, H; Kanai, M; Kitano, T; Matsumoto, S; Mori, Y; Nagayama, S; Nishimura, T; Sakai, Y; Teramukai, S; Yanagihara, K; Yoshimura, K, 2010)
"This retrospective study evaluated the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil (5-FU) for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy."3.76Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis. ( Arai, Y; Aramaki, T; Boku, N; Inaba, Y; Kichikawa, K; Matsuoka, M; Nishiofuku, H; Otsuji, T; Sato, Y; Tanaka, T, 2010)
"We modelled a theoretical population treated with combined 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) for metastatic colorectal cancer."3.76Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer. ( Blasco, H; Bourgoin, H; Le Guellec, C; Le Louarn, A; Lecomte, T; Pichereau, S, 2010)
"Palmar-Plantar syndrome (PPS) is a common side effect of oral capecitabine--a chemotherapeutic agent used as an adjuvant treatment for colorectal cancer."3.76Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome. ( Begent, R; Gafson, AR; Goodkin, O, 2010)
"In progressive colorectal cancer these treatment results can be regarded as a significant change in the natural history of the disease."3.76Folinic acid (FA) plus 5-fluorouracil (FU) in progressive advanced colorectal cancer. ( Freund, M; Poliwoda, H; Preusser, P; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, H, 1988)
"The aim of this study is to evaluate if mismatch repair (MMR) defective colorectal cancer has a different response to adjuvant 5-fluorouracil (5-FU) chemotherapy in a cohort of patients prospectively followed during 5 years."3.75The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. ( Alenda, C; Andreu, M; Balaguer, F; Bessa, X; Bujanda, L; Castells, A; Clofent, J; Cubiella, J; Jover, R; Llor, X; Morillas, JD; Nicolás-Pérez, D; Payá, A; Pons, E; Reñé, JM; Sempere, L; Xicola, RM; Zapater, P, 2009)
"Patients with histologically proven, metastatic colorectal cancer receiving bevacizumab as first-line therapy in combination with irinotecan and 5-fluorouracil were eligible for our analysis."3.75Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. ( Berardi, R; Cascinu, S; Chiorrini, S; Galizia, E; Giampieri, R; Pierantoni, C; Scartozzi, M, 2009)
"5-Fluorouracil (5-FU)-based regimens remain a cornerstone in the treatment of colorectal cancer (CRC)."3.75Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes. ( Carlsson, G; Gustavsson, B; Kaiser, C; Lindskog, EB; Ma, D; Niyikiza, C; Odin, E; Wettergren, Y, 2009)
"Modifying the capecitabine dosing schedule from 14 days on, 7 days off (14/7) to 7 days on, 7 days off (7/7) may enable higher doses and improved antitumor efficacy in colorectal cancer xenografts."3.75In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models. ( Dugan, U; Heimbrook, D; Higgins, B; Kohles, J; Kolinsky, K; Packman, K; Shen, BQ; Zhang, YE; Zioncheck, TF, 2009)
"To investigate the synergistic effect of epidermal growth factor(EGF) and 5-fluorouracil for the treatment of human colorectal cancer in BALB/C nude mice subcutaneous xenografts model."3.75[Synergistic use of epidermal growth factor and 5-fluorouracil for the treatment of human colorectal cancer in BALB/C nude mice subcutaneous xenograft model]. ( Tao, KX; Wang, GB; Ye, L, 2009)
"We investigated the efficacy and toxicity of metronomic capecitabine administered at a fixed dose of 1,000 mg daily in three elderly or poor performance status patients with advanced colorectal cancer (CRC) and gastric cancer."3.75To widen the setting of cancer patients who could benefit from metronomic capecitabine. ( Biasco, G; Brandi, G; Di Cicilia, R; Maleddu, A; Nannini, M; Nobili, E; Pantaleo, MA, 2009)
"MSI in five reference loci, MMR enzymes (hMSH2, hMSH6, hMLH1 and hPMS2), thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) expression were assessed in paraffin embedded tumor specimens, and associated with outcome in 340 consecutive patients completely resected for colorectal cancer stages II-IV and subsequently receiving adjuvant 5-fluorouracil therapy."3.75Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression. ( Jensen, SA; Kruhøffer, M; Sørensen, JB; Vainer, B, 2009)
"The aim of this study was to determine whether the expression of the excision repair cross-complementing 1 (ERCC1), thymidylate synthase (TS) and glutathione S-transferase pi (GSTpi) predict clinical outcome in patients with advanced colorectal cancer treated with fluorouracil (5-FU)/oxaliplatin chemotherapy."3.75Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. ( Choi, HJ; Kim, DC; Kim, HJ; Kim, SH; Kwon, HC; Lee, DM; Lee, JH; Lee, S; Oh, SY; Park, KJ; Roh, MS, 2009)
"Capecitabine, an oral alternative to 5-fluorouracil (5-FU) in patients with colorectal cancer (CRC), has equal clinical efficacy and a favorable safety profile; however, its use may be limited because of unit cost concerns."3.75Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. ( Chu, E; Schulman, KL; Song, X; Zelt, S, 2009)
"In patients suffering from colorectal cancer liver metastases, 5-fluorouracil-based chemotherapy plus oxaliplatin ensures superior response rates at the cost of hepatic injury."3.75Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. ( Dorfmeister, M; Eipeldauer, S; Gruenberger, B; Gruenberger, T; Hacker, S; Herberger, B; Klinger, M; Koelblinger, C; Tamandl, D, 2009)
"A total of 76 patients with recurrent or metastatic colorectal cancer treated with capecitabine and oxaliplatin (XELOX) combination chemotherapy were enrolled in the present study."3.75Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin. ( Bae, SH; Chae, YS; Choi, GS; Jeon, SW; Jun, SH; Kang, BM; Kim, JG; Kum, Y; Lim, KH; Moon, JH; Park, IJ; Ryoo, HM; Sohn, SK, 2009)
"5-Fluorouracil (5FU) and oxaliplatin are standard therapy for metastatic colorectal cancer (CRC), but the development of chemoresistance is inevitable."3.75Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. ( Dallas, NA; Ellis, LM; Fan, F; Gaur, P; Gray, MJ; Kim, MP; Lim, SJ; Samuel, S; van Buren, G; Xia, L, 2009)
" Using this library, we identify a range of small RNA-encoding gene inserts that overcome resistance to 5-fluorouracil (5-FU)- or tumour necrosis factor alpha (TNF-alpha)- induced cell death in colorectal cancer cells."3.75RNA modulators of complex phenotypes in mammalian cells. ( Arndt, GM; Cairns, MJ; Cullen, L; Lai, A; Tran, N; Zhang, HP, 2009)
"Panaxadiol enhanced the anti-cancer effects of 5-FU on human colorectal cancer cells through the regulation of cell cycle transition and the induction of apoptotic cells."3.75Panaxadiol, a purified ginseng component, enhances the anti-cancer effects of 5-fluorouracil in human colorectal cancer cells. ( Li, XL; Mehendale, SR; Sun, S; Wang, CZ; Wang, Q; Yuan, CS, 2009)
"The purpose of this study was to assess retrospectively the sequential treatment of hepatic arterial infusion (HAI) chemotherapy followed by systemic therapy using oxaliplatin plus 5-fluorouracil (5-FU) and leucovorin, namely, FOLFOX, for patients with liver metastases from colorectal cancer."3.75Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer. ( Ozaki, T; Seki, H; Shiina, M, 2009)
" She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer."3.755 flourouracil-induced apical ballooning syndrome: a case report. ( Dentali, F; Gianni, M; Lonn, E, 2009)
"The correlations between adenomatous polyposis coli (APC) mutations and 5-fluorouracil (5-FU) adjuvant chemotherapy and colorectal cancer (CRC) patients' prognosis are not well known."3.75Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects. ( Chen, SP; Chen, YL; Chiu, SC; Harn, HJ; Kang, JC; Lin, PC; Lin, SZ; Pang, CY; Su, CC; Wu, CC, 2009)
"The purpose of this study was to investigate the association of methylation in the promoter regions of adenomatous polyposis coli (APC) and O(6)-methylguanine-DNA methyltransferase (MGMT) and the survival of Taiwanese colorectal cancer (CRC) subjects who received 5-fluorouracil (5-FU) adjuvant chemotherapy."3.75The association of methylation in the promoter of APC and MGMT and the prognosis of Taiwanese CRC patients. ( Chen, SP; Chen, YL; Chiu, SC; Harn, HJ; Kang, JC; Lin, PC; Lin, SZ; Pang, CY; Wu, CC, 2009)
"Stage II-III colorectal cancer patients treated with adjuvant FOLFOX or fluorouracil/leucovorin (5-FU/LV) at Roswell Park Cancer Institute between 2002 and 2006 were identified."3.75Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. ( Angitapalli, R; Fakih, MG; Kumar, PR; Litwin, AM; Lombardo, J; Mashtare, T; Nasser, E; Wilding, GE, 2009)
" Additionally, unsupervised clustering using the MMP/TIMP profile of N=25 colorectal cancer liver metastases was performed and the response to palliative 5-fluorouracil (5-FU)-based chemotherapy was assessed using radiological response criteria."3.75Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases. ( Brueckl, WM; Croner, RS; Dimmler, A; Dorlaque, L; Gentner, B; Hahn, EG; Hohenberger, W; Roedel, F; Wein, A; Wirtz, RM; Zeittraeger, I, 2009)
" demonstrated that irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine failure in advanced colorectal cancer."3.75Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer. ( Sobrero, A, 2009)
"The aim of this study was to determine the significance of three most common single-nucleotide polymorphisms (SNPs) of ABCB1 gene in the development of colorectal cancer and to estimate the influence of these SNPs to surviving patients' treatment combination adjuvant therapy 5-fluorouracil/leucovorin."3.75ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer. ( Balcerczak, E; Jamroziak, K; Mirowski, M; Panczyk, M; Pasz-Walczak, G; Piaskowski, S, 2009)
" We analyzed the influence of codon 751 Lys-->Gln polymorphism of XPD on its protein expression levels, clinico-pathological features, and outcome of 188 Chinese patients with metastatic colorectal carcinoma (CRC) that had been treated with first-line Oxaliplatin + Leucovorin + 5-Fluorouracil (FOLFOX-4) chemotherapy."3.75Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. ( Chen, PM; Chen, WS; Jiang, JK; Lai, JI; Lin, JK; Lin, TC; Tzeng, CH; Wang, HS; Wang, WS, 2009)
"We have tested several biomarkers [dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT), thymidine phosphorylase (TP), thymidylate synthase (TS) and excision cross-complementing gene (ERCC1)] for their prognostic and predictive value in relation to the outcome of chemotherapy in tumour tissues of 556 advanced colorectal cancer (ACC) patients who were randomised between sequential treatment and combination treatment in the CApecitabine, IRinotecan, Oxaliplatin (CAIRO) study."3.75Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. ( Koopman, M; Ligtenberg, MJ; Nagtegaal, I; Punt, CJ; Van Krieken, JH; van Tinteren, H; Venderbosch, S, 2009)
"A combination of oxaliplatin(L-OHP), folinic acid and 5-fluorouracil(5-FU)(mFOLFOX6)has been widely administered to treat advanced or recurrent colorectal cancer."3.75[Effect of withdrawal of 5-fluorouracil bolus administration on recovery from neutropenia in colorectal cancer patients treated with mFOLFOX6 chemotherapy-comparison with total dosage reduction]. ( Chihara, S; Demizu, M; Iwakawa, S; Kimura, F; Maeda, C; Nakanishi, Y; Oosawa, M; Ueda, H; Yano, K, 2009)
"We designed a study protocol in 2005 and 16 patients with metastatic colorectal cancer were treated accordingly in the first line setting with XELIRI regimen (capecitabin, irinotecan) + bevacizumab."3.75[Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer]. ( Kocák, I; Kocáková, I; Nemecek, R; Rehák, Z; Standara, M; Svoboda, M, 2009)
"We developed a longitudinal exposure-response tumor-growth inhibition (TGI) model of drug effect (and resistance) using phase II data of capecitabine (n = 34) and historical phase III data of fluorouracil (FU; n = 252) in colorectal cancer (CRC); and we developed a parametric survival model that related change in tumor size and patient characteristics to survival time using historical phase III data (n = 245)."3.75Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. ( Bruno, R; Claret, L; Fagerberg, J; Girard, P; Hoff, PM; Jorga, K; Van Cutsem, E; Zuideveld, KP, 2009)
"Bevacizumab was the first anti-angiogenic drug to be licensed in malignant disease, based on the results of a randomised trial in advanced colorectal cancer, in which the addition of bevacizumab to chemotherapy with irinotecan plus fluorouracil/leucovorin (IFL) significantly improved tumour response, progression-free survival (PFS) and overall survival (median 15."3.75Current perspective: bevacizumab in colorectal cancer--a time for reappraisal? ( Cunningham, D; Okines, A, 2009)
" We performed retrospective study that examined the efficacy of preventive treatment (granisetron+dexamethasone+domperidone) for delayed emesis induced by FOLFOX4 chemotherapy for advanced and recurrent colorectal cancer."3.75[Efficacy of preventive treatment for delayed emesis induced by FOLFOX4 chemotherapy]. ( Hama, T; Hatake, K; Imada, H; Kamisugi, K; Kawakami, K; Matsusaka, S; Mizunuma, N; Nakamoto, E; Shinozaki, E; Shirai, T; Shouji, D; Suenaga, M; Suzuki, W; Takahashi, G; Yokokawa, T, 2009)
" The aims of the present study were to compare, in vitro and in vivo, the antiangiogenic and antitumor activities of metronomic irinotecan (CPT-11), oxaliplatin (L-OHP) and 5-fluorouracil (5-FU) in colorectal cancer and to investigate the metronomic combination of these drugs."3.75Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. ( Alì, G; Allegrini, G; Bocci, G; Canu, B; Danesi, R; Del Tacca, M; Di Desidero, T; Emmenegger, U; Falcone, A; Fioravanti, A; Fontanini, G; Orlandi, P, 2009)
"We studied 150 surgically resected colorectal adenocarcinoma patients who received postoperative 5-Fluorouracil (5-FU) chemotherapy."3.75Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma. ( Bronner, MP; Chang, SJ; Cho, MY; Eom, M; Kim, IY; Kim, MD; Koh, SB; Ren, DN; Seong, SH; Yi, SY, 2009)
"In this study, we investigated the possible synergistic chemopreventive effects of American ginseng berry extract (AGBE) and 5-fluorouracil (5-FU) on human colorectal cancer cell lines, SW-480, HCT-116 and HT-29."3.75American ginseng berry enhances chemopreventive effect of 5-FU on human colorectal cancer cells. ( Du, W; He, TC; Li, XL; Mehendale, SR; Sun, S; Wang, CZ; Yuan, CS, 2009)
"To compare chemotherapy-related and total medical costs among patients with colorectal cancer (CRC) receiving capecitabine or 5-fluorouracil (5-FU) monotherapy after surgical resection."3.75Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer. ( Bendell, JC; Cartwright, T; Chu, E; Shi, N; Wei, W, 2009)
"To evaluate the efficacy and the safety of combined 5-Fluorouracil, irinotecan, bevacizumab and sirolimus in refractory advanced colorectal carcinoma."3.75Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study. ( Chauffert, B; Ghiringhelli, F; Guiu, B; Ladoire, S, 2009)
"Oxaliplatin is a platinum compound that is clinically effective for colorectal cancer (CRC), in combination with 5-fluorouracil (5-FU) and leucovorin (LV), and it is widely used for metastatic disease and for the adjuvant treatment of stage III CRC."3.75Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan. ( Akashi, K; Ariyama, H; Baba, E; Esaki, T; Kusaba, H; Mitsugi, K; Nakano, S; Shibata, Y; Takii, Y; Tsuchiya, T, 2009)
"5-Fluorouracil (5-FU) is considered to be the backbone of colorectal cancer (CRC) systemic therapy since the great majority of recommended regimens include its administration."3.75Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma. ( Garita, R; Michelin, OC; Okoshi, K; Paiva, BS; Paiva, CE, 2009)
"5-Fluorouracil(5FU) and oral analogues, such as capecitabine, remain one of the most useful agents for the treatment of colorectal adenocarcinoma."3.75APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling. ( Aly, E; Binnie, N; Collie-Duguid, ES; Gilbert, F; Loudon, M; MacDonald, G; McKinlay, A; Murray, GI; O'Kelly, T; Petty, RD; Samuel, LM; Semple, S; Wang, W, 2009)
"Tumor control, reflected in lower CEA, resulted in suppression of the acute phase response and generally in favorable effects on laboratory parameters indicative of risk factors of atherosclerosis, including lower homocysteine concentrations, and lower total and LDL cholesterol."3.75Serum homocysteine, cholesterol, retinol, alpha-tocopherol, glycosylated hemoglobin and inflammatory response during therapy with bevacizumab, oxaliplatin, 5-fluorouracil and leucovorin. ( Hyspler, R; Kalábová, H; Kasparová, M; Krcmová, L; Malírová, E; Melichar, B; Melicharová, K; Pecka, M; Solichová, D, 2009)
"Randomized, controlled trials (RCTs) in 220 patients with advanced colorectal cancer reported no significant differences in survival periods between folinic acid/5-fluorouracil/irinotecan (FOLFIRI) and folinic acid/5-fluorouracil/oxaliplatin (FOLFOX6) therapies, irrespective of the treatment sequence."3.75Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan. ( Akase, T; Arakawa, I; Harada, T; Inoue, T; Miyazaki, Y, 2009)
"Candidate predictive biomarkers for irinotecan and oxaliplatin were assessed in 1,628 patients in Fluorouracil, Oxaliplatin, CPT-11: Use and Sequencing (FOCUS), a large randomized trial of fluorouracil alone compared with fluorouracil and irinotecan and compared with fluorouracil and oxaliplatin in advanced colorectal cancer."3.74Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. ( Adlard, JW; Barrett, JH; Braun, MS; Daly, C; Elliott, F; Meade, AM; Parmar, MK; Quirke, P; Richman, SD; Selby, P; Seymour, MT; Stephens, RJ, 2008)
" A major obstacle in the treatment of colorectal cancer is relative insensitivity to the chemotherapeutic agent 5-Fluorouracil (5-FU)."3.74Single-cell transcription site activation predicts chemotherapy response in human colorectal tumors. ( Augenlicht, LH; Gandhi, SJ; Pestell, RG; Pezo, RC; Shirley, LA; Singer, RH, 2008)
"We describe the case of an HIV-positive 48-year-old male patient with metastatic colorectal cancer, treated with a bevacizumab, irinotecan, fluorouracil, and leucovorin regimen, with concomitant HAART."3.74Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer. ( Bearz, A; Berretta, M; Berretta, S; Fisichella, R; Lleshi, A; Nasti, G; Simonelli, C; Tirelli, U; Zanet, E, 2008)
" This study aimed to assess the range of gene copies per nucleus of thymidylate synthase (TYMS), thymidine phosphorylase (TP) and dihydrofolate reductase (DHFR) in colorectal cancer, and to evaluate its prognostic significance following adjuvant chemotherapy, since these enzymes are closely related to efficacy of 5-fluorouracil (5FU)."3.74Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer. ( Jensen, SA; Jørgensen, JT; Sørensen, JB; Vainer, B; Witton, CJ, 2008)
"We investigated the association between thymidylate synthase (TS) germline polymorphisms and response to 5-fluorouracil-based chemotherapy in 80 patients with liver-only metastatic colorectal cancer (MCRC)."3.74Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. ( Alessandroni, P; Baldi, G; Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Fornaro, L; Giordani, P; Giustini, L; Graziano, F; Loupakis, F; Magnani, M; Maltese, P; Masi, G; Ruzzo, A; Santini, D; Tonini, G; Vincenzi, B, 2008)
"Human colorectal cancer cells were treated, individually and in combination, with Rosco, taxol, 5-Fluorouracil (5-FU), doxorubicine or vinblastine."3.74Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells. ( Abaza, MS; Al-Attiyah, RJ; Bahman, AM, 2008)
"Although a variety of FOLFOX regimens (5-fluorouracil and L-leucovorin combined with oxaliplatin) are widely used for the treatment of advanced colorectal cancer, the neurotoxicity caused by oxaliplatin is often problematic."3.74Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study. ( Chiba, T; Fukushima, M; Ishiguro, H; Kanai, M; Kawamura, J; Kitano, T; Matsumoto, S; Miyamoto, S; Mori, Y; Nagayama, S; Nishimura, T; Nomura, A; Sakai, Y; Teramukai, S; Yanagihara, K, 2008)
" [Ann Oncol 2002;13:308-317] showed that four prognostic variables can be used to classify patients with metastatic colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)/leucovorin (LV) into three risk groups with different overall survival (OS)."3.74Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. ( Hurwitz, H; Irl, C; Kabbinavar, F; Zurlo, A, 2008)
"In this study, we investigated the efficacy and toxicity of fluorouracil(FU)+Leucovorin(LV)with oxaliplatin (FOLFOX)and irinotecan(FOLFIRI)for patients with advanced or metastatic colorectal cancer."3.74Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies. ( Adachi, K; Arimoto, Y; Kanamiya, Y; Nakamura, R; Nishio, K; Oba, H; Ohtani, H; Shintani, M; Yui, S, 2008)
"The modified irinotecan plus bolus 5-fluorouracil/L-leucovorin (IFL) regimen (irinotecan plus bolus 5-fluorouracil/L-leucovorin) used to be one of the standard treatments for metastatic colorectal cancer until approval of oxaliplatin in Japan."3.74Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan. ( Chin, K; Hatake, K; Matsusaka, S; Mizunuma, N; Muto, T; Oya, M; Shinozaki, E; Shouji, D; Suenaga, M; Yamaguchi, T, 2008)
"5-fluorouracil (5-FU) and oxaliplatin play important roles in chemotherapy for patients with colorectal cancer."3.74Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis. ( Azuma, M; Danenberg, KD; Danenberg, PV; Enomoto, M; Higuchi, T; Iida, S; Kobayashi, H; Lenz, HJ; Mori, R; Omori, A; Sugihara, K; Uetake, H; Yasuno, M, 2008)
"In patients with colorectal cancer (CRC), modulation of 5-fluorouracil (5-FU) by folinic acid (FA) improves response rate and overall survival compared with 5-FU alone."3.74Tissue levels of reduced folates in patients with colorectal carcinoma after infusion of folinic acid at various dose levels. ( Hentrich, M; Jauch, KW; Kuehl, M; Rauch, J; Schalhorn, A; Schlemmer, M, 2008)
"This retrospective study was performed to evaluate a survival benefit of the full administration of 5-fluorouracil (5-FU), irinotecan (CPT-11), and oxaliplatin (L-OHP) to patients with unresectable or recurrent colorectal cancer."3.74[The validity of full administration of 5-fluorouracil, irinotecan, and oxaliplatin to unresectable or recurrent colorectal cancer]. ( Inoue, N; Ishibashi, K; Ishida, H; Ishiguro, T; Matsuki, M; Mitsuhashi, T; Miyazaki, T; Okada, N; Okita, T; Sano, M; Yokoyama, M, 2008)
"We have evaluated the 5-fluorouracil sensitivity of cancer cells from colorectal cancer patients using the collagen gel droplet embedded drug sensitivity test under multiple drug concentrations and contact durations."3.74Evaluation of 5-fluorouracil applicability by the collagen gel droplet embedded drug sensitivity test with area under the curve analysis. ( Futagawa, S; Kitajima, M; Konishi, N; Nagaoka, I; Nishimura, K; Noguchi, H; Ochiai, T; Sato, G; Watanabe, T, 2007)
" To meet this demand, a nurse-/pharmacy-led clinic was established at the Beatson Oncology Centre in 2003 for the provision of oral capecitabine to metastatic colorectal cancer patients to provide a controlled and supportive environment."3.74A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: results of a prospective audit and retrospective survey of patient experiences. ( Branch, A; Cassidy, J; MacDonald, L; MacLeod, A; McDonald, A; Mohammed, N, 2007)
"The purpose of this study was to compare the activities of various enzymes, participating in the metabolism of 5-fluorouracil, between colorectal cancer and nontumor tissues and to investigate the association of the enzyme activities with clinicopathological backgrounds."3.74Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer. ( Fukushima, M; Matsusaka, S; Wakabayashi, I; Yamasaki, H, 2007)
"The aim of this study was to investigate the influence of combining thymidylate synthase (TS), X-ray cross complementing factor 1 (XRCC1) and uridine diphosphate glucoronosyltransferase (UGT1A1 *28) polymorphism genotypes in response rate and time to progression (TTP) in metastatic colorectal cancer patients treated with 5-fluorouracil (5-FU) plus irinotecan or oxaliplatin (OXA)."3.74Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxa ( Abad, A; Catot, S; Cirauqui, B; Manzano, JL; Martinez-Balibrea, E; Martinez-Cardus, A; Moran, T; Taron, M, 2007)
"Randomised trials have established the importance of oxaliplatin (O) and irinotecan (I) in advanced colorectal cancer (CRC)."3.74Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis. ( Adena, M; Damianovich, D; Tebbutt, NC, 2007)
"FOLFOX (oxaliplatin/leucovorin/5-fluorouracil) and FOLFIRI (irinotecan/leucovorin/5-fluorouracil) are important regimens for the treatment of advanced-stage colorectal cancer (CRC)."3.74Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool. ( Dranitsaris, G; Shah, A; Spirovski, B; Vincent, M, 2007)
"Capecitabine is an orally active fluoropyrimidine that has been approved for first-line treatment of metastatic colorectal cancer when fluoropyrimidines alone are indicated."3.74Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine. ( DeSimone, P; Sapp, CM, 2007)
"In patients with advanced colorectal cancer, leucovorin, fluorouracil, and irinotecan (FOLFIRI) is considered as one of the reference first-line treatments."3.74Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. ( Bareil, C; Bascoul-Mollevi, C; Bibeau, F; Chalbos, P; Conseiller, E; Copois, V; Del Rio, M; Fraslon, C; Granci, V; Kramar, A; Leblanc, B; Martineau, P; Molina, F; Pau, B; Salvetat, N; Ychou, M, 2007)
"This study explores the effect of 5-fluorouracil (5FU) exposure on mRNA levels of its target enzyme thymidylate synthase (TS) and the rate-limiting catabolic enzyme dihydropyrimidine dehydrogenase (DPD) in tumors of colorectal cancer patients."3.74Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer. ( Jansen, G; Mauritz, R; Peters, GJ; Pinedo, HM; Smid, K; van Groeningen, CJ, 2007)
" The aim of this study was to develop colon-specific compression coated systems of 5-fluorouracil (5-FU) for the treatment of colorectal cancer using xanthan gum, boswellia gum and hydroxypropyl methylcellulose (HPMC) as the coating materials."3.74Compression coated systems for colonic delivery of 5-fluorouracil. ( Bhinge, JR; Singh, A; Singh, S; Sinha, VR, 2007)
"The objective is to investigate whether polymorphisms with putative influence on fluorouracil/oxaliplatin activity are associated with clinical outcomes of patients with advanced colorectal cancer treated with first-line oxaliplatin, folinic acid, and fluorouracil palliative chemotherapy."3.74Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. ( Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Ficarelli, R; Floriani, I; Giordani, P; Giustini, L; Graziano, F; Loupakis, F; Magnani, M; Maltese, P; Masi, G; Mattioli, R; Rulli, E; Ruzzo, A; Santini, D; Schiavon, G; Silva, R; Tonini, G, 2007)
"Oxaliplatin in combination with infusional 5-fluorouracil/leucovorin (FOLFOX) have emerged as the standard of care in the therapy of advanced-stage colorectal cancer."3.74[Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions]. ( Akashi, T; Ando, H; Hanaoka, T; Itagaki, H; Kobayashi, Y; Muto, O; Ono, T; Onuki, M; Tanaka, Y, 2007)
"To evaluate the efficacy and safety of a regimen using Irinotecan, 5FU and Leucovorin for patients with advanced or recurrent colorectal cancer."3.74Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes. ( Iinuma, N; Ishizone, S; Koide, N; Maruta, F; Miyagawa, S; Nakayama, J; Yanagisawa, Y, 2007)
"Primary colorectal cancer tissue from 24 patients was investigated to evaluate the relationship between the mRNA expression level of several 5-fluorouracil (5-FU)-related metabolic enzymes (thymidylate synthase, TS; dihydropyrimidine dehydrogenase, DPD; and thymidine phosphorylase, TP) and chemosensitivity to two different 5-FU doses and duration (1: 5-FU concentration 1."3.74Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer. ( Abe, H; Endo, Y; Kurumi, Y; Mekata, E; Naitoh, H; Okumura, K; Shiomi, H; Tani, T, 2008)
"Over the past decade, new cytotoxic and biologic therapies beyond the old standard-of-care, biomodulated fluorouracil (5-FU), have become available for the treatment of metastatic colorectal cancer (mCRC)."3.74Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy. ( Grothey, A; Marshall, JL, 2007)
"The primary end point of the study was the analysis of associations between polymorphisms with putative influence on 5-fluorouracil/irinotecan activity and progression-free survival (PFS) of patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy."3.74Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. ( Alessandroni, P; Andreoni, F; Bisonni, R; Canestrari, E; Catalano, V; Falcone, A; Ficarelli, R; Fontana, A; Giustini, L; Graziano, F; Lippe, P; Loupakis, F; Magnani, M; Maltese, P; Mari, D; Menichetti, ET; Pizzagalli, F; Ruzzo, A; Santini, D; Schiavon, G; Testa, E; Tonini, G, 2008)
"Cetuximab (Erbitux) in combination with irinotecan is the most promising combination in heavily pretreated patients with advanced colorectal cancer."3.74Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. ( Iversen, A; Jensen, BV; Nielsen, D; Pfeiffer, P; Vejlø, C; Yilmaz, M, 2007)
"The oxaliplatin/fluorouracil/leucovorin (FOL-FOX regimen) is an effective and generally well-tolerated regimen in Western clinical studies of advanced colorectal cancer."3.74Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience. ( Fukuoka, M; Nakagawa, K; Okamoto, I; Ozaki, T; Satoh, T; Shimizu, T; Tamura, K, 2007)
"The objectives of the present study were to evaluate the efficacy and safety of an outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as the first-line treatment for patients with advanced colorectal cancer."3.74Outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as first-line treatment for patients with metastatic or recurrent colorectal cancer. ( Ahn, BM; Baek, JH; Chae, YS; Cho, YY; Choi, GS; Jun, SH; Kim, JG; Kim, SN; Lee, IT; Lee, SJ; Moon, JH; Sohn, SK, 2007)
"Capecitabine is a fluoropyrimidine-based drug that offers physicians a more convenient treatment for advanced colorectal cancer (CRC), with manageable toxicity and antitumor activity comparable to that of continuous-infusion therapies with 5-fluorouracil (5-FU)."3.74DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. ( Danenberg, KD; Danenberg, PV; Jakobsen, A; Kuramochi, H; Lindebjerg, J; Nielsen, JN; Shimizu, D; Vallböhmer, D; Yang, DY, 2007)
" 5-fluorouracil (5-FU) is still the most effective adjuvant therapy for patients with colorectal cancer."3.74Combination of ZD55-MnSOD therapy with 5-FU enhances antitumor efficacy in colorectal cancer. ( Liu, X; Qin, X; Wang, Y; Yao, L; Zhang, Y; Zhao, L, 2008)
"A combination of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) is one of the standard regimens for palliative and adjuvant chemotherapy for colorectal cancer."3.74Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer. ( Asaka, M; Doi, T; Fuse, N; Kojima, T; Muto, M; Ohtsu, A; Tahara, M; Takeuchi, S; Taku, K; Yoshida, S, 2007)
"Oxaliplatin, Irinotecan, 5-fluorouracil and leucovorin are commonly used to treat advanced colorectal cancer in Western countries."3.74Clinical outcomes of FOLFOX/FOLFIRI for the Japanese patients with far-advanced or recurrent colorectal cancer. ( Aso, M; Higashi, H; Imamura, S; Kakeji, Y; Katoh, H; Maehara, S; Maehara, Y; Makino, I; Saeki, H; Tanaka, J, 2007)
"We report a 59-year-old woman diagnosed with metastasic colorectal cancer who developed immune hemolytic anemia during FOLFOX chemotherapy (oxaliplatin/leucovorin/5-fluorouracil)."3.74Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature. ( Albiol, S; Cobo, F; De Celis, G; Latorre, X; Pereira, A; Pujadas, J, 2007)
"Short-term infusion of 5-fluorouracil with leucovorin in combination with irinotecan or oxaliplatin has been considered as standard treatment for metastatic colorectal cancer."3.74Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. ( Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T, 2007)
"FOLFOX-4 (folinic acid/5-fluorouracil/oxaliplatin) chemotherapy is used to treat patients with colorectal liver metastases."3.74The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study. ( Aithal, GP; Aloysius, MM; Beckingham, IJ; Bessell, EM; Lobo, DN; Neal, KR; Zaitoun, AM, 2007)
"A 59-year-old patient with a coexisting primary choroidal melanoma and colorectal cancer was treated with external beam radiation (EBR) of his choroidal melanoma and systemic chemotherapy with leukovorin/5 fluorouracil (FU) for treatment of his metastatic colorectal cancer."3.74Regression of radiation-induced macular edema after systemic bevacizumab. ( Bakri, SJ; Pulido, JS; Solano, JM, 2007)
"To investigate the mechanisms of drug resistance, a set of cell lines with different levels of sensitivity and possessing different mechanisms of resistance to 5-fluorouracil (5-FU) was established from a colorectal cancer cell line."3.74Swainsonine reduces 5-fluorouracil tolerance in the multistage resistance of colorectal cancer cell lines. ( Deguchi, K; Hamaguchi, J; Kamiyama, N; Kudo, T; Nakagawa, H; Nishimura, S; Oshima, T; Sato, Y; Sun, B; Takahashi, M; Todo, S, 2007)
" 5-fluorouracil (5-FU) or 5-FU plus oxaliplatin (FOLFOX) remains the backbone of colorectal cancer chemotherapeutics, but with limited success."3.74Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R. ( Majumdar, AP; Patel, BB; Qazi, S; Rishi, AK; Sengupta, R; Vachhani, H; Yu, Y, 2008)
"Colorectal cancer (CRC) cell lines displaying microsatellite instability (MSI) are resistant to 5-fluorouracil (5-FU) in vitro, which can be overcome by restoring DNA mismatch repair (MMR) competence."3.74Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases. ( Bendardaf, R; Korkeila, E; Lamlum, H; Pyrhönen, S; Ristamäki, R; Syrjänen, K, 2008)
" The aims of this study were to determine whether p53 mutation status and p53 and p33(ING1b) protein expression can predict which patients with Dukes' C colorectal cancer following curative surgical resection respond to adjuvant chemotherapy with 5-fluorouracil (5-FU)."3.74The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer. ( Ahmed, IA; Anderson, JJ; Angus, B; Challen, C; Kelly, SB; Lunec, J, 2008)
"Combination therapy with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin is widely used for the treatment of metastatic colorectal cancer."3.74Pharmacodynamic study of the Saltz regimen for metastatic colorectal cancer in a hemodialyzed patient. ( Akiyama, S; Gotoh, H; Gotoh, Y; Nakayama, H; Takami, H, 2007)
"The addition of bevacizumab to 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX) improved the time-to-progression (TTP) and overall survival (OS) in comparison to FOLFOX in the second-line treatment of metastatic colorectal cancer (MCRC)."3.745-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study. ( Bir, A; Fakih, MG; Lombardo, J; Tan, W; Wilding, GE, 2007)
"The clinical efficacy and safety of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer were studied retrospectively."3.74[Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer]. ( Hori, S; Hyodo, I; Iguchi, H; Imamine, S; Kajiwara, T; Kataoka, J; Moriwaki, T; Nasu, J; Nishina, T, 2007)
"In the phase III study AVF2107g, bevacizumab (BV) demonstrated a survival benefit when added to irinotecan, fluorouracil, and leucovorin (IFL) in first-line metastatic colorectal cancer (mCRC)."3.74Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. ( Goldberg, RM; Grothey, A; Hedrick, EE; Hurwitz, HI; Mass, RD; Ramanathan, RK; Sargent, DJ; Sarkar, S; Suzuki, S, 2008)
"The authors reported in a previous study that NK012, a 7-ethyl-10-hydroxy-camptothecin (SN-38)-releasing nano-system, exhibited high antitumor activity against human colorectal cancer xenografts."3.74Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil. ( Hamaguchi, T; Kano, Y; Kato, K; Koizumi, F; Matsumura, Y; Nakajima, TE; Shimada, Y; Shirao, K; Yamada, Y; Yasunaga, M, 2008)
"To compare efficacy and tolerability of weekly irinotecan combined with 5-fluorouracil (5-FU) bolus and folinic acid (FA) regimen (IFL) versus biweekly irinotecan with infusional 5-FU and FA (FOLFIRI) in patients (pts) with advanced stage colorectal cancer."3.74Retrospective comparison of two different schedules of irinotecan, 5-fluorouracil and folinic acid in previously untreated patients with advanced colorectal carcinoma: a single institution experience. ( Ariad, S; Gluzman, A; Lavrenkov, K; Man, S; Mermershtain, W; Rubinov, K, 2007)
"To evaluate the effect of thymidylate synthase (TYMS) and methylenetetrahydrofolate reductase (MTHFR) genotypes on toxicity in patients treated with capecitabine for advanced colorectal cancer and to determine the effect of these polymorphisms on the pretreatment levels of serum folate and plasma homocysteine."3.74Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. ( Clarke, SJ; Hoskins, JM; Liddle, C; London, R; Rivory, LP; Sharma, R; Zucknick, M, 2008)
"Low tumour expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) have been linked with improved outcome for colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)."3.74Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. ( Diasio, RB; Han, HC; Iacopetta, B; Joseph, D; Ng, SS; Salto-Tellez, M; Shah, N; Soo, RA; Soong, R; Tai, BC; Tan, WL; Zeps, N, 2008)
"Standard weekly cetuximab and irinotecan (CetIri) is an effective regimen in heavily pretreated patients with advanced colorectal cancer (ACRC)."3.74Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. ( Bjerregaard, J; Jensen, B; Nielsen, D; Pfeiffer, P; Qvortrup, C; Yilmaz, M, 2008)
"5-Fluorouracil (5-FU) is the most commonly used anticancer drug for colorectal cancer (CRC)."3.74Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy. ( Iinuma, H; Watanabe, T; Yamada, H, 2008)
"Oxaliplatin (L-OHP) in combination with infusional 5-fluorouracil/leucovorin (FOLFOX), has been established as a key drug for advanced colorectal cancer."3.74[Retrospective analysis of FOLFOX4 neurotoxicity for recovery from advanced colorectal cancer]. ( Chin, K; Hatake, K; Itimura, T; Kuboki, Y; Matsuda, M; Matsusaka, S; Mizunuma, N; Ogura, M; Suenaga, M; Syouji, D; Watanabe, C, 2008)
"The chemotherapy regimen suitable for advanced colorectal cancer patients previously treated with 5 fluorouracil (5FU); oxaliplatin and irinotecan remains an unresolved issue."3.74A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies. ( Borg, C; Chaigneau, L; Demarchi, MF; Legat, C; Limat, S; Nguyen, T; Pivot, X; Stein, U; Thiery-Vuillemin, A; Viel, E, 2008)
"Treatment-related safety data from three phase III clinical studies were analyzed by multivariate analysis: two comparing capecitabine with bolus FU/LV in metastatic colorectal cancer (MCRC) and one comparing capecitabine plus oxaliplatin (XELOX) with bolus FU/LV as adjuvant treatment for colon cancer."3.74Potential regional differences for the tolerability profiles of fluoropyrimidines. ( Allegra, C; Bertino, JR; Cassidy, J; Clarke, SJ; Cunningham, D; Douillard, JY; Gilberg, F; Gustavsson, BG; Haller, DG; Hoff, PM; Milano, G; O'Connell, M; Rothenberg, ML; Rustum, Y; Saltz, LB; Schmoll, HJ; Sirzén, F; Tabernero, J; Twelves, C; Van Cutsem, E, 2008)
"To evaluate 5-fluorouracil (5-FU) and 5-fluoro-5,6-dihydrouracil (5-FDHU) pharmacokinetics and disease-free survival (DFS) in colorectal cancer patients given 5-FU-based adjuvant chemotherapy within a nonrandomized, retrospective, pharmacokinetic study."3.745-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. ( Amatori, F; Bocci, G; Danesi, R; Del Tacca, M; Di Donato, S; Di Paolo, A; Falcone, A; Federici, F; Iannopollo, M; Lastella, M; Lencioni, M; Orlandini, C; Ricci, S, 2008)
"A combination of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) has become one of the global standard chemotherapy regimens for metastatic colorectal cancer."3.74Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer. ( Asaka, M; Doi, T; Fuse, N; Hamamoto, Y; Minashi, K; Muto, M; Ohtsu, A; Tahara, M; Yano, T; Yoshida, S, 2008)
"Capecitabine has demonstrated high efficacy as first-line treatment for metastatic colorectal cancer (mCRC)."3.74XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer. ( Argon, A; Aykan, NF; Basaran, M; Gumus, M; Guney, N; Saglam, S; Sakar, B; Tenekeci, AN; Ustaoglu, MA; Ustuner, Z, 2007)
"70 patients with advanced colorectal cancer were treated with irinotecan and 5-fluorouracil."3.74[Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients]. ( Bao, HY; Jiao, SC; Li, F; Li, J; Shen, L; Song, ST; Wang, JW; Wang, Y; Xu, JM; Xu, N; Yang, L; Zhang, JS, 2007)
"Oxaliplatin in combination with infusional 5-fluorouracil/Leucovorin (FOLFOX) has emerged as the treatment of choice for advanced-stage colorectal cancer."3.74[Reduction of oxaliplatin-related neurotoxicity by Gosha-jinki-gan]. ( Hibino, M; Imano, H; Nakamura, M; Shindo, Y; Tenma, K; Yoshino, K, 2008)
"This study evaluated the effects of oral capecitabine on the quality of life (QOL) of Brazilian patients with metastatic colorectal cancer who received capecitabine (1000 or 1250 mg/m2 twice a day on days 1-14, every 3 weeks) in a prospective, multicenter, open-label, noncomparative study."3.74Evaluation of quality of life in patients with metastatic colorectal cancer treated with capecitabine. ( Cabral, S; Federico, MH; Filho, Ude P; Franke, FA; Gampel, O; Perdicaris, MR; Ribeiro, Rde A; Segalla, JG; Skare, NG; Van Eyll, B, 2008)
"Although 5-fluorouracil (5-FU)-based chemotherapy is commonly used in patients with advanced colorectal cancer (CRC), little data exist on the tolerability and benefit of therapy in elderly patients."3.735-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study. ( Buroker, TR; Cha, SS; D'Andre, S; Goldberg, RM; Kugler, JW; O'Connell, MJ; Poon, MA; Sargent, DJ, 2005)
"Patients undergoing cytoreductive surgery and perioperative hyperthermic chemotherapy (mitomycin C, intraoperatively; 5-fluorouracil early post-operatively) for peritoneal carcinomatosis from colorectal cancer from 1996 to 2003 were evaluated retrospectively."3.73Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy. ( Ceranic, MS; Kecmanovic, DM; Kovacevic, PA; Pavlov, MJ; Sepetkovski, AV; Stamenkovic, AB, 2005)
", the Mayo-Clinic and AIO/Ardalan regimens, under real-life conditions in settings routinely used for chemotherapy administration in Germany (inpatient, day-clinic or office-based oncologists) and 2) to investigate the cost implications of the routine use of capecitabine, an oral alternative for the treatment of metastatic colorectal cancer."3.73Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds. ( Grothey, A; Hieke, K; Kleeberg, UR; Stauch, M, 2005)
"To determine whether the nonselective and relatively inexpensive nonsteroidal anti-inflammatory drug ibuprofen would be effective in inhibiting colorectal cancer and might improve mortality in a mouse model."3.73Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. ( Albert, A; Chang, AJ; Liu, TC; Sangha, S; Wolfe, MM; Yao, M; Zhou, W, 2005)
"To clarify the correlation between the expression level of thymidine phosphorylase (TP) and efficacy of doxifluridine (5'-DFUR) and 5-fluorouracil (5-FU), samples from 177 colorectal cancer patients who underwent curative resection were evaluated by immunohistochemical staining using a newly developed monoclonal antibody 1C6-203."3.73Thymidine phosphorylase expression and efficacy of adjuvant doxifluridine in advanced colorectal cancer patients. ( Hasegawa, R; Hasegawa, S; Koda, K; Miyazaki, M; Oda, K; Seike, K; Takiguchi, N, 2005)
"We examined Drg1 expression by immunohistochemistry in 131 patients with metastatic colorectal cancer enrolled in a clinical trial of adjuvant fluorouracil-based therapy from 1991 to 1995."3.73Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes. ( Cordon-Cardo, C; Drobnjak, M; Gonen, M; Hummer, A; Kemeny, N; Motwani, M; Schwartz, GK; Shah, MA, 2005)
"To investigate the prognostic value of thymidylate synthase (TS), topoisomerase-1 (Topo-1), and proliferating index Ki-67 in advanced colorectal cancer patients on irinotecan (CPT-11) in combination with fluorouracil treatment (5-Fu)."3.73[Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment]. ( Colucci, G; Giuliani, F; Maiello, E; Mangia, A; Montemurro, S; Paradiso, A; Simone, G; Xu, JM; Zhu, BD, 2005)
"Oxaliplatin-5-fluorouracil combinations have increased responses in first-line therapy up to 40% in advanced colorectal cancer."3.73FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer. ( Castells, A; Gallego, R; Gascón, P; Longarón, R; Marmol, M; Martin-Richard, M; Maurel, J; Molina, R; Nadal, C; Sanz, S, 2005)
"Although several evidences have demonstrated a synergistic activity of 5-fluorouracil with irinotecan and oxaliplatin, thus explaining the use of this drug combination in the first-line treatment of advanced colorectal cancer, the need for the reintroduction of 5-FU in the second-line setting is more questionable."3.73The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients. ( Barni, S; Berardi, R; Beretta, GD; Cascinu, S; Catalano, V; Gasparini, G; Graziano, F; Labianca, R; Scartozzi, M; Sobrero, A; Zaniboni, A, 2005)
" We examined TS expression in tumours from 86 patients with advanced colorectal cancer who received one of two chemotherapy regimes (either irinotecan alone or irinotecan and 5-flurouracil with folinic acid)."3.73Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer. ( Bendardaf, R; Elzagheid, A; Lamlum, H; Pyrhönen, S; Ristamäki, R, 2005)
"The aim of the study was to define the feasibility and efficacy of Xelox (capecitabine and oxaliplatin) administered through a new and original schedule in advanced pretreated colorectal cancer (CRC) patients."3.73Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. ( Caricato, M; Coppola, R; Di Seri, M; La Cesa, A; Rocci, L; Santini, D; Schiavon, G; Spalletta, B; Tonini, G; Vincenzi, B, 2005)
"The tumor-activated fluoropyrimidine capecitabine achieves response rates superior to those of bolus 5-fluorouracil/leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer (CRC), with favorable safety and fewer hospitalizations."3.73Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. ( Braud, Fd; Brunet, R; Butts, CA; Cassidy, J; Conroy, T; Diaz-Rubio, E; Figer, A; Grossmann, J; Schoffski, P; Sobrero, AF; Tabernero, JM; Twelves, CJ; Van Cutsem, EJ, 2005)
"We successfully treated four advanced colorectal cancers with irinotecan (CPT-11) plus 5-fluorouracil (5-FU) and l-leucovorin (l-LV) combination chemotherapy."3.73[Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy]. ( Aiba, M; Kamoshita, N; Makita, F; Morishita, Y; Nagashima, T; Ohwada, S; Takeyoshi, I; Tokiniwa, H, 2005)
"The present study aimed to prospectively investigate the influence of thymidylate synthase (TS) polymorphisms (5'-TSER, 3'-TSUTR) on the disease-free survival (DFS) and overall survival (OS) of patients with colorectal cancer (CRC) who were treated with adjuvant 5-fluorouracil (5-FU) therapy."3.73Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. ( Adleff, V; Budai, B; Czeglédi, F; Gyergyay, F; Hitre, E; Horváth, Z; Kásler, M; Kovács, T; Kralovánszky, J; Láng, I; Lövey, J; Orosz, Z, 2005)
"These results suggest that phospho-EGFR levels determine the sensitivity of colorectal cancer cells to gefitinib alone and that chemotherapy-mediated changes in phospho-EGFR levels determine the nature of interaction between gefitinib and chemotherapy."3.73Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. ( Galligan, L; Johnston, P; Karaiskou-McCaul, A; Kelly, D; Longley, D; Van Cutsem, E; Van Schaeybroeck, S, 2005)
"Fluorouracil-based chemotherapy, such as that with 5-fluorouracil (5-FU)/leucovorin, is standard as first-line chemotherapy for advanced colorectal cancer (CRC) in Japan."3.73In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer. ( Akiyama, T; Hirabayashi, Y; Hirai, T; Ikeda, M; Iki, K; Kubozoe, T; Matsumoto, H; Sadahira, Y; Tsunoda, T; Urakami, A; Yamamura, M; Yamashita, K, 2005)
"Irinotecan, in combination with 5-fluorouracil (5-FU) and a high dose of leucovorin (LV), known as FOLFIRI regimen, has shown activity in recurrent or metastatic colorectal cancer."3.73Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer. ( Byun, JH; Chang, SK; Choi, MG; Choi, SI; Hong, YS; Kang, JH; Lee, DS; Lee, KS; Lee, MA; Oh, ST; Shim, BY; Woo, IS, 2005)
"Some retrospective studies have shown a lack of benefit of 5-fluorouracil (5-FU) adjuvant chemotherapy in patients with mismatch repair (MMR) deficient colorectal cancer."3.73Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. ( Alenda, C; Andreu, M; Bessa, X; Bujanda, L; Castells, A; Clofent, J; Cubiella, J; Jover, R; Llor, X; Morillas, JD; Nicolás-Pérez, D; Payá, A; Piñol, V; Reñé, JM; Xicola, RM; Zapater, P, 2006)
"BALB/c nu/nu mice bearing LoVo and HT-29 (colon cancer), A-431 (vulval cancer), and KPL-4 and MAXF401 (breast cancer) human tumors were treated with erlotinib 100 mg/kg/day and/or capecitabine 359 or 90 mg/kg/day, by oral administration once daily for 14 days."3.73Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. ( Ouchi, KF; Sekiguchi, F; Tanaka, Y; Yanagisawa, M, 2006)
"To report 2 cases of severe hypertriglyceridemia associated with the use of oral capecitabine."3.73Capecitabine-induced severe hypertriglyceridemia: report of two cases. ( Babaoglu, MO; Guler, N; Kurt, M; Shorbagi, A; Yasar, U, 2006)
"The combination of irinotecan and a fluoro-pyrimidine is widely accepted as a treatment for advanced colorectal cancer."3.73in vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer. ( Eguchi, T; Hiro, J; Inoue, Y; Kusunoki, M; Miki, C; Tanaka, K; Toiyama, Y; Yoshiyama, S, 2006)
"(1) In patients with metastatic colorectal cancer initially treated with irinotecan combination therapy, second-line therapy with a combination of fluorouracil, folinic acid and oxaliplatin resulted in a median survival time of 21 months after the start of first-line chemotherapy, in one clinical trial."3.73Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation. ( , 2005)
"Resistance to apoptosis is one of the important determinants of resistance to 5-fluorouracil (5-FU) in colorectal cancer cells."3.73Overexpression of hRFI inhibits 5-fluorouracil-induced apoptosis in colorectal cancer cells via activation of NF-kappaB and upregulation of BCL-2 and BCL-XL. ( Kitayama, J; Konishi, T; Nagawa, H; Sasaki, S; Watanabe, T, 2006)
"The cost of chemotherapy has dramatically increased in advanced colorectal cancer patients, and the schedule of fluorouracil administration appears to be a determining factor."3.73Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer. ( Bracco-Nolin, CH; Chaigneau, L; Huchet, B; Legat-Fagnoni, C; Limat, S; Pivot, X; Stein, U; Woronoff-Lemsi, MC, 2006)
"We identified genes related to 5-fluorouracil (5-FU) sensitivity in colorectal cancer and utilized these genes for predicting the 5-FU sensitivity of liver metastases."3.73Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. ( Endo, I; Hayasizaki, Y; Ichikawa, Y; Ishikawa, T; Kunisaki, C; Matsuyama, R; Momiyama, N; Shimada, H; Shimizu, D; Suzuki, H; Togo, S, 2006)
"Hepatic arterial infusion chemotherapy with levofolinate (l-leucovorin) and fluorouracil regimen was performed using an implanted port system on unresectable hepatic metastasis patients with colorectal cancer."3.73[Method of levofolinate.5-FU administration by hepatic arterial infusion therapy for hepatic metastasis from colorectal cancer]. ( Fujino, H; Hata, K; Kitamura, N; Kobuchi, T; Maruhashi, K; Nakamura, T; Shimomatsuya, T; Shiraishi, S, 2006)
" In this study, we evaluated the correlation between sensitivity to 5-fluorouracil (5-FU) and the mRNA expression level of several 5-FU-related metabolic enzymes [thymidylate synthase, dihydropyrimidine dehydrogenase (DPD), thymidylate phosphorylase (TP), orotate phosphoribosyl transferase, and uridine phosphorylase] in primary colorectal cancer and synchronous liver metastases from ten patients to investigate how colorectal cancer acquires 5-FU resistance during liver metastases."3.73Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer. ( Endo, Y; Kaizuka, M; Kurumi, Y; Mekata, E; Okumura, K; Shiomi, H; Tani, T, 2006)
"The purpose of this study was to analyze the value of germline and tumor thymidylate synthase (TS) genotyping as a prognostic marker in a series of colorectal cancer patients receiving adjuvant fluorouracil (FU) -based treatment."3.73Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. ( Capellá, G; Cuatrecases, M; de Oca, J; Dotor, E; Figueras, A; Germà, JR; Guinó, E; Martínez-Iniesta, M; Molleví, DG; Moreno, V; Navarro, M; Pareja, L; Peinado, MA; Serrano, T; Vilardell, F; Villanueva, A, 2006)
"Several variables associated to thymidylate synthase (TS), the biological target of 5-fluorouracil (5FU) have been studied for their possible role as predictors of the clinical outcome and response to chemotherapy in colorectal cancer (CRC) patients."3.73Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil. ( Fernández-Contreras, ME; Gamallo, C; García de Paredes, ML; Gisbert, JP; Roda-Navarro, P; Sánchez-Hernández, JJ; Sánchez-Prudencio, S, 2006)
"We have previously shown that human colorectal cancer tissue is able to inactivate the anticancer drug paclitaxel through cytochrome P450 (CYP)2C8 and CYP3A4 metabolisms."3.73Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8. ( Agúndez, JA; García-Martín, E; Gutierrez-Martín, Y; Jover, R; Martínez, C; Pérez, G; Pizarro, RM, 2006)
" Blood samples were collected from 20 patients, who had received continuous intravenous infusion (CIV) of 5-FU (320 mg/m2/24 hr) after resection of colorectal cancer, and the FBAL level was determined by high performance liquid chromatography (HPLC), after derivatizing into o-phthalaldehyde (OPA) and detecting fluorescence."3.73Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients. ( Furuhata, T; Hata, F; Hirata, K; Katsuramaki, T; Kawakami, M; Kihara, C; Kimura, Y; Ohmura, T; Okita, K; Sasaki, K; Tsuruma, T; Yamaguchi, K, 2006)
"Pyrrolidinedithiocarbamate (PDTC) enhanced the activity of 5-fluorouracil (5-FU) in a colorectal cancer xenograft model."3.73Regional localisation of p53-independent apoptosis determines toxicity to 5-fluorouracil and pyrrolidinedithiocarbamate in the murine gut. ( Bach, SP; O'Dwyer, ST; Potten, CS; Watson, AJ; Williamson, SE, 2006)
"African-American patients with colorectal cancer were observed to have increased 5-fluorouracil (5-FU)-associated toxicity (leukopenia and anemia) and decreased overall survival compared with Caucasian patients."3.73Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. ( Desmond, RA; Diasio, RB; Fourie, J; Mattison, LK; Modak, A; Saif, MW, 2006)
"Bevacizumab (Avastin) in combination with intravenous 5-fluorouracil-based chemotherapy as first-line as well as second-line treatment of metastatic colorectal cancer improves survival."3.73Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. ( Gotlib, V; Khaled, S; Lapko, I; Mar, N; Saif, MW, 2006)
"To evaluate the regimen of 5-fluorouracil (5-FU) and mitomycin-C (MMC) in terms ofresponse rate and overall survival in advanced colorectal cancer."3.735-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer. ( Aphinives, P; Bhudhisawasdi, V; Sae-seow, O; Uttaravichien, T, 2006)
"We present two cases of multiple liver metastases from colorectal cancer, which did not respond to hepatic arterial infusion (HAI) using 5-fluorouracil (5-FU 1250 mg/body weekly) alone, but responded to HAI using 5-fluorouracil (5-FU 750 mg/body weekly) and l-leucovorin (l-LV 50 mg/body weekly) achieving a complete response (CR)."3.73[Two cases of multiple liver metastases from colorectal cancer which responded well to hepatic arterial infusion (HAI) using 5-fluorouracil and l-leucovorin]. ( Enomoto, M; Higuchi, T; Iida, S; Ishikawa, T; Kato, S; Sugihara, K; Uetake, H; Yasuno, M, 2006)
"The combination of irinotecan (CPT-11), bolus 5-fluorouracil (5-FU) and folinic acid (FA) (Saltz regimen) has recently been questioned as first-line chemotherapy for metastatic colorectal cancer after high early death rates due to gastrointestinal and thromboembolic events were reported in two US trials."3.72Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer. ( Adami, B; Baldus, M; Burg, H; Ehscheid, P; Galle, PR; Heike, M; Hoffmann, T; Hohl, H; Klein, O; Moehler, M; Schroeder, M; Schwindt, P; Zanke, C, 2003)
"The Mayo Clinic regimen of leucovorin 20 mg/m followed immediately by 5-fluorouracil 425 mg/m administered for 5 consecutive days every 4 weeks is commonly used in the treatment of colorectal cancer."3.72Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients. ( Bar-Sela, G; Beny, A; Haim, N; Tsalic, M; Visel, B, 2003)
"5-Fluorouracil (5-FU) is the major chemotherapeutic component for colorectal cancer (CRC) and other types of solid tumours."3.72Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. ( Cassidy, J; McLeod, HL; Wang, W, 2003)
"The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer."3.72Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003)
" Data from 40 patients receiving oxaliplatin combined with 5-fluorouracil and levofolinic acid as standard treatment for advanced colorectal cancer were analysed."3.72Population pharmacokinetics of oxaliplatin. ( Bugat, R; Canal, P; Chatelut, E; Delord, JP; Grégoire, N; Guimbaud, R; Lafont, T; Umlil, A, 2003)
" We investigated the combination effect of 5-fluorouracil (5-FU), a first-choice drug for the treatment of colorectal cancer and adenovirus-mediated transfer of caspase-8 in DLD-1 colon cancer cells."3.725-Fluorouracil efficiently enhanced apoptosis induced by adenovirus-mediated transfer of caspase-8 in DLD-1 colon cancer cells. ( Hamada, H; Kitayama, J; Nagawa, H; Shinoura, N; Uchida, H; Watanabe, T, 2003)
"The association oxaliplatin (OXA)-5-fluorouracil/folinic acid (FUFA) is currently a standard first-line treatment for advanced colorectal cancer."3.72Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status. ( Dubreuil, A; Etienne, MC; Fischel, JL; Formento, P; Lagrange, JL; Magné, N; Marcié, S; Milano, G, 2003)
"The aim of this study was to investigate the influence of low dosage (131)I-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody C50 ((131)I-C50) on tumor growth and the therapeutic efficacy of combination of low dosage (131)I-C50 with chemotherapy using 5-fluorouracil (5-FU) on human colorectal cancer xenografts in nude mice."3.72[Influence of combination of low dosage 131I-labeled anti-carcinoembryonic antigen antibody C50 and 5-fluorouracil on tumor growth of colorectal cancer xenografts in nude mice]. ( Cai, SR; He, YL; Lin, ZJ; Zhan, WH; Zheng, CX, 2003)
" To characterise the genomic changes that induce the development of resistance to fluoropyrimidines, we used comparative genomic hybridisation (CGH) to analyse and compare the parent DLD-1 human colorectal cancer cell line and two cell lines, DLD-1/5-FU and DLD-1/FdUrd, which were resistant to 5-fluorouracil (5-FU) and 5-fluoro-2'-deoxyuridine (FdUrd), respectively."3.72Chromosomal imbalances associated with acquired resistance to fluoropyrimidines in human colorectal cancer cells. ( Ayabe, H; Fukushima, M; Haseba, M; Hidaka, S; Nakagoe, T; Sawai, T; Tagawa, Y; Tsuji, T; Yamaguchi, H; Yano, H; Yasutake, T, 2003)
"Fluorouracil (5-FU) is widely used in the treatment of colorectal cancer."3.72Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. ( Batist, G; Cohen, V; Morin, I; Panet-Raymond, V; Rozen, R; Sabbaghian, N, 2003)
"Loss of DNA mismatch repair (MMR) occurs in 10-15% of sporadic colorectal cancer, is usually caused by hMLH1 hypermethylation, and has been shown to confer resistance to various chemotherapeutic reagents, including 5-fluorouracil (5-FU)."3.72Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. ( Arnold, CN; Boland, CR; Goel, A, 2003)
"To evaluate the therapeutic effects of hydroxycamptothecin (H) combined with leucovorin (L), fluorouracil (F) and cisplatin (P) on advanced cancer of gastric cardia and colorectal cancer."3.72[The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer]. ( Jin, ML; Li, J; Li, Y; Shen, L; Yang, BQ; Zhang, XD, 2003)
"To predict the sensitivity of colorectal cancer to 5-fluorouracil (5-FU), we compared the gene expression of surgically obtained colorectal cancer specimens with chemosensitivity to 5-FU as detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) assay."3.72Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. ( Fukushima, M; Hasegawa, H; Kitajima, M; Kubota, T; Nishibori, H; Takechi, T; Wada, N; Watanabe, M; Yoshinare, K, 2003)
"To determine the efficacy of the combination of oxaliplatin and capecitabine in patients with advanced colorectal cancer."3.72Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience. ( Cunningham, D; Gillbanks, A; Harper-Wynne, C; Hill, M; Norman, AR; Sumpter, K, 2003)
"The aim of this analysis is to evaluate the effect of 5-fluorouracil (5-FU) rechallenge on subsequent response and survival in patients with advanced colorectal cancer (CRC)."3.72Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials. ( Chau, I; Cunningham, D; Hill, M; Norman, AR; Ross, PJ; Yeoh, C, 2003)
"5-Fluorouracil (5-FU) has been used for more than 40 years in the treatment of neoplastic disease, and remains the standard first-line treatment for colorectal cancer in combination with irinotecan and leucovorin."3.72Quantitation of dihydropyrimidine dehydrogenase (DPD) mRNA expression levels in normal colon and colorectal cancer tumor paraffin-embedded tissue specimens. ( Bender, RA; Liu, JY; Sferruzza, AD; Zhou, W, 2003)
"Fifty-two consecutive patients with advanced colorectal cancer who developed persistent diarrhea following chemotherapy with 5-fluorouracil despite dose reduction were treated with amifostine 800, 500 or 150 mg/m(2)."3.72Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study. ( Kosmas, C; Koufos, C; Margaris, H; Papalambros, E; Papantoniou, N; Retalis, G; Rokana, S; Tsavaris, N; Vadiaka, M; Zografos, G; Zonios, D, 2003)
" In this study, we assessed whether or not the TSER genotype is an efficacious marker for tumor sensitivity to 5-fluorouracil (5-FU)-based oral adjuvant chemotherapy for colorectal cancer."3.72Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. ( Fukuoka, H; Haseba, M; Hidaka, S; Komatsu, H; Nakagoe, T; Nanashima, A; Sawai, T; Shibasaki, S; Shindou, H; Tagawa, Y; Tsuji, T; Yamaguchi, H; Yano, H; Yasutake, T; Yoshinaga, M, 2003)
"Hepatic intra-arterial infusion chemotherapy of 5-fluorouracil (5-FU) or fluorodeoxyuridine (FUDR) has been a treatment option for liver metastasis from colorectal cancer."3.72Pharmacokinetics of 5-fluorouracil following hepatic intra-arterial infusion in a VX2 hepatic metastasis model. ( Ishikawa, K; Makuuchi, H; Masuda, T; Murayama, C; Nakamura, T; Sadahiro, S; Suzuki, T; Tanaka, Y; Yasuda, S, 2003)
"Although the expression of thymidylate synthase (TS) in metastatic colorectal cancer (CRC) may be a better predictor of response to 5-fluorouracil chemotherapy than TS expression in primary CRC, this enzyme has not been well studied in tumor-draining regional lymph nodes."3.72Differential expression of thymidylate synthase in colorectal tumors and matched lymph nodes: impact on adjuvant treatment. ( Bilchik, AJ; Morton, DL; Saha, SS; Thompson, J; Trocha, SD; Wiese, D, 2003)
"The significance of hepatic arterial infusion chemotherapy for unresectable liver metastases from colorectal cancer was evaluated in 50 patients, who received either of the following regimens: 1 shot 5-FU + epirubicin + MMC (FAM group); hepatic arterial infusion of 5-FU for 2 hours + MMC (MF group); hepatic arterial infusion of 5-FU for 2 hours (5-FU group)."3.72[Validity of two-hour continuous hepatic arterial infusion chemotherapy with low-dose 5-FU for unresectable liver metastasis from colorectal cancer]. ( Hirakawa, K; Kosaka, K; Nishihara, T; Nishino, H; Ohira, M; Yamada, N, 2003)
"We herein report the result of a prospective study to investigate the efficacy of cimetidine administration in conjunction with chemotherapy for stage IV colorectal cancer."3.72[Effect of cimetidine with chemotherapy on stage IV colorectal cancer]. ( Fujimoto, T; Hashimoto, M; Ishibashi, K; Iwasaki, K; Ogawa, K; Umehara, A; Yokomizo, H; Yoshida, K; Yoshimatsu, K, 2003)
"In metastatic colorectal cancer the oral 5-fluorouracil (5FU) prodrug capecitabine is used with increasing frequency as an alternative to i."3.72In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength. ( Heerschap, A; Kamm, YJ; Klomp, DW; Punt, CJ; van Laarhoven, HW, 2003)
"The level of the enzyme thymidylate synthase (TS) is known to inversely correlate with the clinical activity of 5-fluorouracil (FU) in advanced colorectal cancer patients."3.72Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer. ( Aschele, C; Belvedere, O; Cataldi, P; Di Loreto, C; Guglielmi, A; Puglisi, F; Sobrero, A, 2004)
"5-Fluorouracil improves mortality in stage III colorectal cancer patients."3.72Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. ( Arnold, CA; Behling, CA; Boland, CR; Cabrera, BL; Carethers, JM; Doctolero, RT; Goel, A; Miyai, K; Nguyen, L; Smith, EJ; Tajima, A, 2004)
" For practical reasons and for the convenience of the patient, we used XELOX (Xeloda 2000 mg/m2 orally on days 1-14 and oxaliplatin 130 mg/m2 as a 30-min infusion on day 1) in patients with advanced colorectal cancer resistant to irinotecan and 5-fluorouracil."3.72Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. ( Hahn, P; Jensen, HA; Pfeiffer, P, 2003)
" In this study, digital karyotyping was used to search for genomic alterations in liver metastases that were clinically resistant to 5-fluorouracil (5-FU)."3.72Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. ( Bardelli, A; Choti, M; Diaz, LA; Donehower, R; Galizia, G; Iacobuzio-Donahue, C; Kinzler, KW; Lengauer, C; Parmigiani, G; Romans, K; Saha, S; Shih, IeM; Velculescu, VE; Vogelstein, B; Wang, TL, 2004)
"5-Fluorouracil, a widely used drug in cancer treatment, is known to have cardiotoxic effects: chest pain with ECG changes, arrhythmias, arterial hypertension or hypotension, myocardial infarction, cardiogenic shock and sudden death have been described in the literature."3.72Management of patients with persistent chest pain and ST-segment elevation during 5-fluorouracil treatment: report about two cases. ( Alberti, A; Corrada, E; Ferrari, S; Mafrici, A; Marenna, B, 2003)
"Preclinical in vitro and in vivo studies have demonstrated synergistic interactions between 5-fluorouracil (5-FU) and type I and II IFNs against human colorectal cancer cells."3.72Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. ( Barsoum, J; Choi, EA; Fraker, DL; Lei, H; Maron, DJ; Mick, R; Spitz, FR; Wilson, JM; Yu, QC, 2004)
"Microsatellite instability (MSI) is a characteristic feature of up to 15% of colorectal cancers (CRC) and is associated with better response to adjuvant chemotherapy with 5-fluorouracil (5-FU)."3.72Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer. ( Alessandro, R; Büttner, R; Gullotti, L; Hans, V; Houshdaran, F; Mathiak, M; Merkelbach-Bruse, S; Rüschoff, J; Sanguedolce, R, 2004)
"To elucidate mechanisms of resistance to chemotherapies currently used in the first-line treatment of advanced colorectal cancer, we have developed a panel of HCT116 p53 wild-type (p53(+/+)) and null (p53(-/-)) isogenic colorectal cancer cell lines resistant to the antimetabolite 5-fluorouracil (5-FU), topoisomerase I inhibitor irinotecan (CPT-11), and DNA-damaging agent oxaliplatin."3.72Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. ( Aroori, S; Boyer, J; Carey, PD; Johnston, PG; Longley, DB; McCulla, A; McLean, EG; Wilson, P, 2004)
"To evaluate the efficacy and safety of capecitabine as first-line therapy in patients with advanced and recurrent colorectal cancer."3.72[First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer]. ( Feng, FY; Fu, Q; Guan, ZZ; Huang, JJ; Liu, DG; Ruan, QL; Shi, D; Sun, SR; Wei, YQ; Wu, G; Wu, WQ; Wu, XD; Xiong, HH; Yang, CY; Yu, BM; Yu, SY; Zhang, P; Zhao, Y; Zheng, S; Zhuang, W; Zou, LQ, 2004)
"Expression of thymidylate synthase (TS) and the 5-fluorouracil (5-FU) metabolic enzymes, including dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyl transferase (OPRT), thymidine phosphorylase (TP), and uridine phosphorylase (UP), has been reported to be associated with the sensitivity to 5-FU-based chemotherapy in colorectal cancer."3.72Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis. ( Inokuchi, M; Shirota, Y; Sugihara, K; Tajima, M; Uetake, H; Yamada, H, 2004)
"5-Fluorouracil (5-FU) is the chemotherapeutic drug of choice for the treatment of metastatic colorectal cancer, but resistance to 5-FU remains a major obstacle to successful therapy."3.72Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. ( Beigi, M; Clausen, OP; de Angelis, PM; Fjell, B; Galteland, E; Haug, T; Kravik, KL; Reichelt, W; Stokke, T; Tunheim, SH, 2004)
"The aim of this study was to observe the effects of neoadjuvant therapy with irinotecan and 5-fluorouracil (5-FU)/folinic acid (FA) on the resection rate and survival of colorectal cancer patients with initially unresectable hepatic metastases."3.72Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. ( Barone, C; Basso, M; Cassano, A; Giuliante, F; Nuzzo, G; Pozzo, C; Quirino, M; Schinzari, G; Trigila, N; Vellone, M, 2004)
"One hundred and thirty-eight stage II and III colorectal cancer patients were included to evaluate the prognostic significance of genetic markers (including mutations of the p53, K-ras genes, and microsatellite instability) on the response to 5-fluorouracil (FU)-based post-operative adjuvant therapies (PAT)."3.72p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. ( Changchien, CR; Chen, HH; Chen, JS; Fan, CW; Hsieh, LL; Tang, R; Tsao, KC; Wang, JY; Wu, CM, 2004)
"Capecitabine is an oral prodrug of 5-fluorouracil and has been studied for the treatment of colorectal cancer."3.72Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands. ( Brouwers, JR; Jansman, FG; Postma, MJ; van Hartskamp, D; Willemse, PH, 2004)
"In this marker evaluation study, we tested whether distinct patterns of functional genomic polymorphisms in genes involved in drug metabolic pathways and DNA repair that predict clinical outcome to 5-fluorouracil (5-FU)/oxaliplatin chemotherapy in patients with advanced colorectal cancer could be identified."3.72A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. ( Groshen, S; Lenz, HJ; Park, DJ; Stoehlmacher, J; Yang, D; Zahedy, S; Zhang, W, 2004)
"The purpose of this study was to examine the relation between tumoral expression of dihydropyrimidine dehydrogenase (DPD), the rate limiting enzyme of the degradation pathway 5-fluorouracil (5-FU), and the efficacy of 5-FU based chemotherapy for colorectal cancer."3.72[Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer]. ( Hashimoto, D; Inokuma, S; Ishida, H; Nakada, H; Ohsawa, T; Shirakawa, K; Yamada, H; Yokoyama, M, 2004)
"Ten cases of advanced and metastatic colorectal cancer treated with irinotecan plus fluorouracil and l-leucovorin systemic chemotherapy (CPT-11/5-FU/l-LV) were investigated."3.72[Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer]. ( Hidaka, K; Matsukura, S; Samejima, R; Tanaka, M, 2004)
"High expression of thymidylate synthase (TS) is allegedly associated with the chemoresistance to 5-fluorouracil (5-FU) in colorectal cancers."3.72Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to ( Inada, K; Kamoshida, S; Maruta, M; Matsuoka, H; Matsuyama, A; Shimomura, R; Shiogama, K; Tsutsumi, Y, 2004)
"Seventy-five patients with advanced colorectal cancer and treated with CPT-11 and 5-fluorouracil, entered the study."3.72Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. ( Boisdron-Celle, M; Dumont, A; Gamelin, E; Guérin, O; Morel, A; Rouits, E, 2004)
"The goal of this study was to develop a simple and rapid in vitro drug resistance assay to ascertain the effectiveness of 5-fluorouracil (5-FU) for the individual therapy of colorectal cancer."3.72An in vitro short time-high dose drug exposure assay for predicting 5FU-resistance of colorectal cancer. ( Chan, CC; Chan, EC; Chen, SY; Fan, CW; Fan, HA; Hsu, SH; Hsu, YH, 2004)
"To determine whether deleted in colon cancer (DCC) protein expression in colorectal cancer (CRC) metastases could predict outcome to palliative fluorouracil (FU)-based chemotherapy and to assess whether it is similar to that observed in the corresponding primary tumors."3.72Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy. ( Aschele, C; Bandelloni, R; Casazza, S; Debernardis, D; Gallo, L; Lonardi, S; Monfardini, S, 2004)
"The efficacy of a concomitant oxaliplatin/bolus 5-fluorouracil/leucovorin regimen in 123 heavily pretreated patients with advanced colorectal cancer was evaluated."3.72Compassionate-use oxaliplatin with bolus 5-fluorouracil/leucovorin in heavily pretreated patients with advanced colorectal cancer. ( Amin-Zimmerman, F; Glisson, SD; Hargis, JB; Hicks, RM; Kosfeld, RE; LaRocca, RV; Leaton, KE, 2004)
"We retrospectively evaluated the relevance of thymidylate synthase (TS) expression in normal colonic mucosa as a predictive factor of toxicity in colorectal cancer patients receiving adjuvant fluorouracil (5-FU)-based chemotherapy."3.72Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy. ( Borzomati, D; Caricato, M; Coppola, R; Grilli, C; La Cesa, A; Perrone, G; Rabitti, C; Santini, D; Tonini, G; Verzì, A; Vincenzi, B, 2004)
"This study was conducted to evaluate the prognostic significance of thymidylate synthase (TS) expression in the tumor tissue of patients with metastatic colorectal cancer (CRC) who received protracted venous infusions of 5-fluorouracil (5-FU)."3.72Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil. ( Araake, M; Hamaguchi, T; Hosokawa, A; Morita, H; Muro, K; Orita, H; Shimada, Y; Shirao, K; Yamada, Y, 2004)
"The 5 fluorouracil hepato-arterial infusion (5-FU HAI) therapy has a good effect on the liver metastases of colorectal cancer."3.72[The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer]. ( Ebuchi, M; Hasegawa, K; Kato, K; Koide, A; Maruyama, M; Maruyama, S; Ohbu, M; Takashima, I, 2004)
"5-fluorouracil (5-FU) is a chemotherapeutic agent widely used in the treatment of solid malignancies, especially in colorectal cancer."3.72Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature. ( Aparicio, J; Calderero, V; Díaz, R; Guerrero, A; Pellín, L; Segura, A, 2004)
"We investigated the immune profile of patients with resected Dukes' stage C colorectal cancer (CRC), receiving adjuvant therapy with edrecolomab (Mo17-1A) or first-line 5-fluorouracil (5-FU)-based chemotherapy."3.72The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study. ( Gouveris, P; Katsoulas, HL; Kosmas, C; Kosmas, N; Papalambros, E; Papantoniou, N; Rokana, S; Skopeliti, M; Tsavaris, NB; Tsitsilonis, OE, 2004)
"A 60-year-old woman with a history of unresectable colon adenocarcinoma was treated by chemotherapy with a combination of oxaliplatin with leucovorin and fluorouracil."3.71Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer. ( Carrie, E; Gagnadoux, F; Lebeau, B; Monnier-Cholley, L; Roiron, C, 2002)
"Combined infusion of 5-FU and mitomycin C by hepatic artery catheter port is an effective treatment for liver metastases from colorectal cancer."3.71Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer. ( Jiang, HC; Liu, LX; Piao, DX; Qi, SY; Wu, LF; Zhang, WH; Zhu, AL, 2002)
"To verify whether fluorouracil (FU) clearance (CL) and volume of distribution (V(ss)) are better correlated with specific body compartments, such as body cell mass (BCM), total body water (TBW) or fat free mass (FFM), rather than with body surface area (BSA) or total body weight (BW)."3.71Relationships between body composition parameters and fluorouracil pharmacokinetics. ( Ferrari, M; Ferrazzi, E; Gusella, M; Padrini, R; Toso, S, 2002)
"We studied longitudinally inflammatory reactions and serum C-reactive protein (S-CRP) levels in 52 colorectal cancer patients treated with a median of six 3-weekly cycles of raltitrexed 1."3.71Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma. ( Elomaa, I; Joensuu, H; Orpana, A; Osterlund, P; Repo, H, 2002)
"The goal of this study was to ascertain the first cycle intolerability rate of the standard Mayo Clinic regimen, 5-fluorouracil (5-FU) 425 mg/m2 with low-dose folinic acid (FA) 20 mg/m2, as a rapid bolus intravenous injection (5-FU/FA) for 5 days every 4-5 weeks for advanced colorectal cancer chemotherapy."3.71Toxicity analysis of the 5-day bolus 5-fluorouracil/folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: a concern about dose. ( Ho, C; Stitt, L; Tomiak, A; Vincent, M; Whiston, F; Winquist, E, 2002)
"TS levels were measured immunohistochemically on archival specimens of colorectal cancer metastases from 124 patients homogeneously treated in a series of clinical trials at our institutions with: (A) leucovorin (LV)-modulated infusional 5-FU (n = 48); (B) LV-modulated bolus 5-FU (n = 41); (C) methotrexate (MTX)-modulated bolus 5-FU (n = 35)."3.71Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. ( Aschele, C; Bandelloni, R; Barni, S; Cascinu, S; Catalano, V; Debernardis, D; Drudi, G; Gallo, L; Giordani, P; Lonardi, S; Maley, F; Monfardini, S; Turci, D, 2002)
"We evaluated the effect of hepatic arterial infusion chemotherapy with levofolinate (l-LV) and 5-fluorouracil (5-FU) for multiple liver metastases from colorectal cancer."3.71[Evaluation of hepatic arterial infusion chemotherapy with levofolinate (l-LV) and 5-fluorouracil (5-FU) for multiple liver metastases from colorectal cancer]. ( Ebisui, C; Fujimoto, T; Fukuchi, N; Izawa, H; Kanai, T; Sakita, I; Soma, I; Yoshida, T, 2002)
"We administered interleukin (IL)-2 with mitomycin C (MMC) and 5-fluorouracil (5-FU) by hepatic arterial infusion for the treatment of liver recurrence from colorectal cancer."3.71[Hepatic arterial infusion of IL-2 and chemotherapy for unresectable liver metastasis from colorectal cancer]. ( Hazama, S; Iizuka, N; Matsuoka, K; Oka, M; Takano, N; Tangoku, A; Yoshimura, K, 2002)
"LSMs for 5-fluorouracil and 5-fluoro-5,6-dihydrouracil therapeutic monitoring have been developed in 80 patients with colorectal cancer (training set) given 5-fluorouracil, 370 mg/m(2) per day as an intravenous bolus, plus leucovorin, 100 mg/m(2) per day, for 5 days every 4 weeks."3.71Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. ( Amadori, D; Cionini, L; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Ibrahim, T; Mini, E; Vannozzi, F, 2002)
"Capecitabine (Xeloda) and irinotecan (CPT-11, Camptosar) exhibit single-agent activity in colorectal cancer, have nonoverlapping major toxicities, and exhibit a synergistic effect in tumor xenograft models."3.71Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials. ( Kerr, D, 2002)
" We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib."3.71Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002)
"Irinotecan (CPT-11), oxaliplatin (OXA) and different folinic acid(FA) modulated 5-fluorouracil (5-FU) regimens are active as first-and second-line chemotherapy of metastatic colorectal cancer."3.71Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens. ( Galle, PR; Heike, M; Hildner, K; Hoffmann, T; Moehler, M; Siebler, J, 2002)
"The clinical relevance of bax and bcl-2 protein expression has been investigated in 84 patients with recurrent or metastatic colorectal cancer submitted to a chemotherapy regimen including methotrexate and fluorouracil/leucovorin."3.71Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer. ( Costa, A; Daidone, MG; Dellapasqua, S; Lacava, J; Lena, MD; Leone, B; Paradiso, A; Simone, G; Vallejo, C, 2001)
"5-Fluorouracil (5-FU), in association with leucovorin (LV), is the most used chemotherapy agent in the treatment of colorectal cancer."3.71Effect of chemotherapy with 5-fluorouracil on intestinal permeability and absorption in patients with advanced colorectal cancer. ( Barletta, E; Carratù, R; Daniele, B; De Magistris, L; De Vivo, R; Delrio, P; Palaia, R; Pignata, S; Secondulfo, M; Tambaro, R, 2001)
"There has been no standard therapy for patients with metastatic colorectal cancer who have failed to first-line fluorouracil-based treatment."3.71Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer. ( Kang, YK; Kim, HC; Kim, JC; Kim, SH; Kim, TW; Kim, WK; Lee, JH; Lee, JS; Lee, KH; Yu, CS, 2001)
"Irinotecan (CPT-11) has shown considerable activity in colorectal cancer, and its combination with 5-fluorouracil (5-FU) represents an attractive approach."3.71A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer. ( Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kotsakis, A; Koukourakis, M; Kouroussis, C; Mavroudis, D; Romanos, J; Souglakos, J; Vardakis, N, 2001)
"In our institution, patients with multiple unresectable liver metastases from colorectal cancer have received 24-h continuous arterial infusion therapy of 5-fluorouracil (5-FU) 250 mg/body/day every 2 weeks for the past 11 years."3.71[Results and limitations of arterial infusion therapy for liver metastases from colorectal cancer]. ( Mori, T; Ohue, M; Takahashi, K; Yamaguchi, T, 2001)
"The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer."3.71A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001)
"The aim of this study is to clarify whether the expression of metallothionein (MT) is related with the malignant potential in primary colorectal cancer and/or synchronous liver metastasis."3.71Expression of metallothionein in colorectal cancers and synchronous liver metastases. ( Dhar, DK; Hishikawa, Y; Kimoto, T; Kohno, H; Koji, T; Kubota, H; Nagasue, N; Tachibana, M; Ueda, S, 2001)
"To identify the prognostically highest risk patients, DNA content and p53 nuclear or cytoplasmic accumulation, evaluated by monoclonal antibody DO7 and polyclonal antibody CM1, were determined in 94 surgically resected stage II (Dukes B2) colorectal cancers, treated or not with adjuvant 5-fluorouracil-based chemotherapy."3.71p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy. ( Benevolo, M; Brenna, A; Buglioni, S; Cosimelli, M; D'Agnano, I; D'Angelo, C; Mottolese, M; Perrone Donnorso, R; Vasselli, S; Zupi, G, 2001)
"High levels of thymidylate synthase (TS) expression have been associated with poor survival of colorectal cancer (CRC) patients to 5-fluorouracil (5-FU)-based chemotherapy."3.71A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. ( Elsaleh, H; Grieu, F; Iacopetta, B; Joseph, D, 2001)
"For patients with incurable stage IV colorectal cancer, minimally symptomatic primary tumours were left in situ and 5-fluorouracil-based chemotherapy was administered systemically."3.71Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer. ( Guillou, PJ; Guthrie, JA; O'Riordain, DS; Ride, E; Sarela, AI; Seymour, MT, 2001)
"Adjuvant chemotherapy with 5-fluorouracil (5-FU) and mitomycin C (MMC) has commonly been used after resection of colorectal cancer."3.71The potential clinical value of GML and the p53 gene as a predictor of chemosensitivity for colorectal cancer. ( Hashimoto, Y; Minami, K; Ueda, K; Watatani, M, 2001)
"We investigated whether the efficacy of peroral doxifluridine and hepatic arterial 5-FU infusion on synchronous liver metastasis of colorectal cancer could be predicted based on the expression of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) in the primary colorectal lesions."3.71[Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions]. ( Fujioka, M; Hashimoto, D; Hoshino, T; Inokuma, S; Ishida, H; Ishizuka, N; Matsumoto, Y; Miura, T; Murata, N; Nakada, H; Odaka, A; Ohsawa, T; Takeuchi, I; Yamada, H; Yokoyama, M, 2001)
"To test the hypotheses of whether the relative mRNA expression of the thymidylate synthase (TS) gene and the excision cross-complementing (ERCC1) gene are associated with response to and survival of fluorouracil (5-FU)/oxaliplatin chemotherapy in metastatic colorectal cancer."3.71ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. ( Brabender, J; Danenberg, KD; Danenberg, PV; Groshen, S; Lenz, HJ; Shirota, Y; Stoehlmacher, J; Tsao-Wei, DD; Uetake, H; Xiong, YP, 2001)
" Because increased DNA repair plays an important role in chemoresistance to platinum-based compounds, we assessed the aforementioned polymorphisms in 73 patients with metastatic colorectal cancer and determined their outcome to 5-fluorouracil/oxaliplatin."3.71A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. ( Groshen, S; Lenz, HJ; Park, DJ; Stoehlmacher, J; Tsao-Wei, DD; Zhang, W, 2001)
"The oral, tumour-selective fluoropyrimidine capecitabine represents a major new strategy for the treatment of colorectal cancer."3.71Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. ( Twelves, C, 2002)
"At increasing use of high-dose 5-fluorouracil-based chemotherapy for metastatic colorectal and gastric cancer complicated drug-induced colitis is observed more frequently."3.71[5-Fluorouracil-induced colitis--a review based upon consideration of 6 cases]. ( Hotz, J; Madisch, A; Marquard, F; Stolte, M; Wiedbrauck, F, 2002)
" thymidylate synthase (TS) and thymidine kinase (TK), in human colorectal cancers to compare their possible relationship with demographic and pathologic characteristics of the patients and their tumors, and moreover to evaluate their predictive significance regarding 5-fluorouracil (5-FU) sensitivity and the overall survival of patients, respectively."3.71Prognostic significance of the thymidylate biosynthetic enzymes in human colorectal tumors. ( Budai, B; Czeglédi, F; Hullán, L; Jeney, A; Katona, C; Kovács, T; Köves, I; Kralovánszky, J; Orosz, Z; Rahóty, P; Tóth, K, 2002)
"The aim of this study was to evaluate the objective tumor response rates and toxicities in elderly patients (older than 70 years) with advanced colorectal cancer treated with 5-fluorouracil (5-FU) as a first-line palliative chemotherapy regimen."3.71Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-year experience. ( Broisin, L; Ferrero, JM; François, E; Guardiola, E; Magné, N; Namer, M; Ramaïoli, A, 2002)
"The aim of this study was to assess in patients with advanced colorectal cancer which factors were associated with short-term survival (6 months or less) and progression to first-line 5-fluorouracil (5-FU) chemotherapy."3.71Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens. ( Cellerino, R; Lippe, P; Massacesi, C; Piga, A; Pistilli, B; Rocchi, MB; Valeri, M, 2002)
"The objective of this study was to investigate the possible prognostic factors in patients with metastatic colorectal cancer (CRC) treated with protracted venous infusion (PVI) of 5-fluorouracil (5-FU)."3.71Prognostic factors for patients with metastatic colorectal cancer receiving protracted venous infusion of 5-FU. ( Gotoh, M; Hamaguchi, T; Matsumura, Y; Mizuno, T; Muro, K; Namiki, Y; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2002)
"Since its introduction over 40 years ago, 5-fluorouracil (5-FU) has remained the only effective chemotherapy option available for the treatment of colorectal cancer (CRC)."3.71A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier. ( Jian, CH; Lee, YH; Lin, FH; Shieh, MJ; Wang, CY; Wong, JM, 2002)
"We investigated the relevance of mdm2 and p53 primary tumour expression to the clinical outcome of a consecutive series of advanced colorectal cancer patients treated with a 5-fluorouracil-based chemotherapy."3.71mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer. ( Costa, A; De Lena, M; Lacava, J; Leone, A; Paradiso, A; Ranieri, G; Silvestris, N; Simone, G; Vallejo, C, 2002)
" High DPD mRNA levels in liver metastasis and advanced colorectal cancer may have clinical importance for 5-fluorouracil-based chemosensitivity."3.71Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer. ( Ichikawa, W; Nihei, Z; Shirota, Y; Sugihara, K; Uetake, H; Yamada, H, 2002)
"Dynamic PET and [18F]fluorouracil (18F-FU) were used in patients with liver metastases from colorectal cancer to examine the pharmacokinetics of the drug up to 120 min after intravenous and intra-arterial injection of the same dose of fluorouracil (FU)."3.70Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma. ( Dimitrakopoulou-Strauss, A; Doll, J; Hohenberger, P; Irngartinger, G; Oberdorfer, F; Schlag, P; Strauss, LG; van Kaick, G, 1998)
"It has been observed previously that the pulmonary metastases of colorectal adenocarcinoma are less responsive to therapy with fluorouracil (FUra) as compared with other sites of metastasis (liver, local)."3.70Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. ( Banerjee, D; Bertino, JR; Danenberg, KD; Danenberg, PV; Fu, J; Gorlick, R; Jhanwar, S; Kemeny, N; Klimstra, D; Longo, GS; Metzger, R; Miles, JS; Salonga, D, 1998)
"5-Fluorouracil (FUra) modulated by leucovorin (LV) is active in the treatment of colorectal cancer."3.70Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. ( Cao, S; Rustum, YM; Troutt, AB, 1998)
" It is the first drug since fluorouracil to possess consistent antitumour activity against metastatic colorectal cancer."3.70A risk-benefit assessment of irinotecan in solid tumours. ( Rowinsky, EK; Siu, LL, 1998)
"Prior to the administration of 5-fluorouracil chemotherapy, the authors examined 14 colorectal carcinoma patients with unresectable liver metastases using a single PET scan and 18F-labeled fluorouracil (18F-FU)."3.7018F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. ( Dimitrakopoulou-Strauss, A; Gutzler, F; Moehler, M; Raeth, U; Strauss, LG; Stremmel, W, 1998)
"Spectral analysis could distinguish tumour kinetics from normal tissue kinetics in an individual [11C]-temozolomide study and demonstrated a markedly greater volume of distribution (VD) in glioma than in normal brain, although there was no appreciable difference in mean residence time."3.70Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. ( Brock, CS; Cunningham, VJ; Harte, RJ; Jones, T; Matthews, JC; Meikle, SR; Price, P; Wells, P, 1998)
"7% in patients with advanced colorectal cancer refractory to 5-fluorouracil [5-FU])."3.70Irinotecan: toward clinical end points in drug development. ( Pazdur, R, 1998)
"In all patients with advanced colorectal cancer, disease eventually progresses following fluorouracil (5-FU) therapy, with a worsening of disease-related symptoms and quality of life (QOL)."3.70Assessing the impact of chemotherapy on tumor-related symptoms in advanced colorectal cancer. ( Michael, M; Moore, MJ, 1998)
"The combination of oxaliplatin (LOHP)-5-fluorouracil (FU)-folinic acid (FA) has provided high response rates in pretreated patients with advanced colorectal cancer that is resistant to FU-FA."3.70Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. ( Etienne, MC; Fischel, JL; Formento, P; Milano, G, 1998)
"The purpose of this study was to investigate the side-effects experienced by patients with colorectal cancer receiving 5-fluorouracil + folinic acid chemotherapy."3.70Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. ( Dikken, C; Sitzia, J, 1998)
"We studied the effect of immunotherapy using recombinant interleukin-2 (rIL-2) in combination with a differentiating agent, sodium butyrate (NaBut), on experimental 5-fluorouracil (5-FU)-resistant liver metastasis from colorectal cancer in rats."3.70Interleukin-2/sodium butyrate treatment cures rats bearing liver tumors after acquired 5-fluorouracil resistance. ( Cordel, S; Douillard, JY; Dupas, B; Meflah, K, 1998)
"In an effort to improve the therapeutic selectivity of 5-fluorouracil (FUra) against colorectal cancer, S-1, a combination agent including a prodrug of FUra with two modulators, was recently developed by Taiho Pharmaceuticals Co."3.70Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model. ( Cao, S; Lu, K; Rustum, YM; Shirasaka, T; Slocum, HK; Tóth, K, 1999)
" The aim of this work was to investigate the role of p53 in the apoptosis of colorectal cancer cells in vitro, induced by 5-fluorouracil (5-FU) and hydroxy-camptothecin (HCPT)."3.70The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells. ( Li, N; Ou, Q; Shen, B; Wang, H; Yu, B; Zhang, H; Zheng, M, 1999)
"We have used chemo-immunotherapy with 5-fluorouracil (5-FU), thymosin alpha1 (T alpha1) and interleukin-2 (IL-2) to treat multiple liver metastases from colorectal cancer induced by DHD/K12 cells in syngeneic BDIX rats, comparing one and two cycles of treatment, and different treatment combinations."3.70Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery. ( Bernard, P; Garaci, E; Guarino, E; Pierimarchi, P; Rasi, G; Restuccia, A; Silecchia, G; Sinibaldi-Vallebona, P; Spaziani, E; Tuthill, C, 1999)
"Although treatment with 5-fluorouracil (5-FU) plus calcium folinate has been reported to prolong survival in patients with metastatic colorectal cancer, it can also cause significant toxicity, potentially, resulting in hospitalization."3.70Hospitalization for 5-FU toxicity in metastatic colorectal cancer: incidence and cost. ( Oster, G, 1999)
"The purpose of this work was to estimate the population pharmacokinetic parameters of 5-fluorouracil (5-FU) in patients with advanced colorectal cancer using circadian change kinetics."3.70Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer. ( Astre, C; Bressolle, F; Duffour, J; Gomeni, R; Joulia, JM; Pinguet, F; Ychou, M, 1999)
"The comparative saliva/plasma pharmacokinetics of 5-fluorouracil (5-FU) were investigated in 21 patients with metastatic colorectal cancer receiving high-dose folinic acid (LV (leucovorin) 200 mg/m2) followed by 5-FU bolus (400 mg/m2) and continuous infusion (600, 750, 900 or 1200 mg/m2) on days 1 and 2."3.70Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid. ( Astre, C; Bressolle, F; Duffour, J; Joulia, JM; Pinguet, F; Ychou, M, 1999)
"Diarrhea and oral mucositis are the most frequently reported gastrointestinal side effects caused by 5-fluorouracil (5-FU)."3.705-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. ( Fata, F; Kelsen, DP; Kemeny, N; Klimstra, D; O'Reilly, E; Ron, IG, 1999)
"In a recent multicentre, randomised, controlled, open-label study (Rougier and colleagues, Lancet 1998, 352, 1407-1412), irinotecan significantly increased survival without any deterioration in quality of life compared with best-estimated infusional 5-fluorouracil (5-FU) therapy in the setting of second-line treatment for metastatic colorectal cancer."3.70Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. ( Hickish, T; Iveson, TJ; Schmitt, C; Van Cutsem, E, 1999)
"The efficacy of oxaliplatin combined with high-dose 5-fluorouracil (5-FU) and folinic acid (FA) as an outpatient salvage treatment for patients with metastasized colorectal cancer was retrospectively analyzed in one center."3.70Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma. ( Galle, PR; Gödderz, W; Heike, M; Hofmann, MA; Kallen, KJ; Timm, A, 2000)
"5-fluorouracil (5-FU) is considered the standard antineoplastic drug of choice for metastatic colorectal cancer."3.70Changes in thymidylate synthase mRNA in blood leukocytes from patients with colorectal cancer after bolus administration of 5-fluorouracil. ( Ehrnrooth, E; Poulsen, JH; Sørensen, B; Sørensen, BS; von der Maase, H, 2000)
" In this study, we have determined the expression patterns of dUTPase in normal and neoplastic tissues and examined the association between dUTPase expression and response to 5-fluorouracil (5-FU)-based chemotherapy and overall survival in colorectal cancer."3.70dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer. ( Caradonna, SJ; Groshen, S; Ladner, RD; Lenz, HJ; Lynch, FJ; Sherrod, A; Stoehlmacher, J; Xiong, YP, 2000)
"The basis for current clinical trials in the treatment of colorectal cancer with the combination of irinotecan (CPT-11) and 5-fluorouracil (FUra) with or without leucovorin (LV) is their proven activity as single agents, their different mechanisms of action, and lack of CPT-11 cross-resistance to previous FUra/LV treatment."3.70Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. ( Cao, S; Rustum, YM, 2000)
"The addition of oxaliplatin (L-OHP) to a 5-fluorouracil (5-FU)/ leucovorin (FA) regimen was retrospectively evaluated in 35 consecutive advanced colorectal cancer patients after progression of disease."3.70Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. ( Aschelter, AM; Bertheault-Cvitkovic, F; Brienza, S; Caterino, M; Cosimelli, M; Garufi, C; Giannarelli, D; Giunta, S; Lévi, F; Nisticò, C; Pugliese, P; Terzoli, E, 2000)
"The authors describe the retrospective analysis of treatment by 5-fluorouracil and interferon-a aof 34 patients with advanced colorectal cancer."3.70Retrospective evaluation of 5-fluorouracil-interferon-a aTreatment of advanced colorectal cancer patients. ( András, C; Antal, L; Csiki, Z; Gál, I; Szegedi, G; Takács, I, 2000)
"Adjuvant 5-fluorouracil (5-FU)-based chemotherapy is standard treatment for stage C colorectal cancer (CRC)."3.70Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. ( Aaltonen, LA; Hemminki, A; Järvinen, H; Joensuu, H; Mecklin, JP, 2000)
"Thymidylate synthase (TS) expression in colorectal cancer metastases has been shown to predict for the clinical response to 5-fluorouracil."3.70Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. ( Aschele, C; Debernardis, D; Maley, F; Sobrero, A; Tunesi, G, 2000)
"Twenty-four patients with metastatic colorectal cancer were treated with recombinant IL-2 (rIL-2) by continuous intravenous infusion for 5 days (18 x 10(6) U/m2 per 24 h), followed by three injections of 5-fluorouracil (600 mg/m2) and folinic acid (25 mg/m2) at weekly intervals."3.69Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer. ( Broom, J; Eremin, O; Heys, SD; Simpson, WG; Whiting, PH, 1995)
"We observed leukoencephalopathy in 1 patient, and progressive dementia in another, during the administration of 5-fluorouracil (5-FU) and levamisole."3.69Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases. ( Dobranowski, J; Fawcet, SE; Figueredo, AT; Molloy, DW; Paulseth, JE, 1995)
"One hundred and seven previously untreated patients with measurable metastatic colorectal cancer who were treated with 5-fluorouracil (5FU) and leucovorin (LV) in two different maximum doses and schedules were retrospectively analyzed."3.69A comparative study with two administration schedules of leucovorin and 5-fluorouracil in advanced colorectal cancer. ( Bacoyannis, C; Basdanis, G; Foutzilas, G; Karvounis, N; Kosmidis, P; Markantonakis, P; Mylonakis, N; Sobolos, K; Tsavaris, N; Zisiadis, A, 1995)
"This study was designed to examine the optimal regimen of 5-fluorouracil (5-FU), uracil and degradable starch microspheres (DSM) to prevent the hepatic metastasis of colorectal cancer."3.69Inhibitory effect of simultaneous intraportal administration of 5-fluorouracil, uracil and degradable starch microspheres on experimental hepatic micrometastasis, is of colon cancer. ( Fujii, K; Hanaue, H; Kurosawa, T; Mitomi, T; Nakasaki, H; Tajima, T; Yasuda, S, 1994)
"The purpose of this study was to explore the mechanism of interaction between 5-FU and levamisole by investigating the effect of this combination on HLA class I gene expression in the colorectal cancer cell line WiDr."3.69Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line. ( AbdAlla, EE; Blair, GE; Johnston, D; Jones, RA; Sue-Ling, HM, 1995)
"To confirm our previous kinetic analysis of the mode of cell-killing action of 5-fluorouracil (5-FU), we carried out a flow cytometric analysis with human colorectal cancer DLD-1 cells."3.69Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells. ( Inaba, M; Mitsuhashi, J, 1994)
" We present herein the cases of three patients with multiple liver metastases from colorectal cancer in whom complete remission was achieved by treatment with an HAI of IL-2 in combination with mitomycin C (MMC) and 5-fluorouracil (5-FU)."3.69Complete remission of liver metastases from colorectal cancer by treatment with a hepatic artery infusion (HAI) of interleukin-2-based immunochemotherapy: reports of three cases. ( Akabane, Y; Koh, K; Kurooka, K; Nakajima, I; Ohnishi, H; Okuno, K; Shindo, K; Yasutomi, M, 1994)
"We studied the effect of combined chemo-immunotherapy, 5-FU followed by thymosin alpha 1 (T alpha 1) and interleukin-2 (IL-2) at low doses, on liver metastases from colorectal cancer, induced by splenic injection of DHD/K12 cells (1,2-dimethylhydrazine-induced colon adenocarcinoma) in syngeneic BDIX rats."3.69Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. ( Garaci, E; Pierimarchi, P; Rasi, G; Silecchia, G; Sinibaldi-Vallebona, P; Sivilia, M; Spaziani, E; Tremiterra, S, 1994)
"The purpose of the study was to evaluate the efficacy of long-term continuous administration of 5-fluorouracil (5-FU) in ambulatory patients with colorectal cancer."3.69[Treatment of advanced colorectal cancer with long-term continuous infusion of 5-fluorouracil]. ( Ando, J; Kotake, K; Koyama, Y; Nasu, J; Ogata, Y; Ozawa, I, 1994)
"From September 1989 to September 1992, 17 patients (pts) with non-curative or recurrent colorectal cancer were treated with 5-fluorouracil (FU) plus leucovorin (LV) systemic therapy."3.69[5-Fluorouracil plus low-dose leucovorin in the treatment of advanced colorectal cancer]. ( Ban, K; Imanari, T; Machida, T; Masuda, K; Matsumoto, M; Noda, Y; Shida, H; Takei, Y; Yamamoto, T, 1994)
"In 16 advanced colorectal cancer patients with 5-fluorouracil-associated diarrhea, we evaluated the role of bacterial pathogens in the development of this adverse effect."3.69Have enteric infections a role in 5-fluorouracil-associated diarrhea? ( Cascinu, S; Catalano, G, 1995)
"The optimal schedule for the administration of 5-fluorouracil (5-FU) in the management of advanced colorectal cancer remains to be determined."3.69Bioavailability of subcutaneous 5-fluorouracil: a case report. ( Carlin, W; Dunlop, DJ; Eatock, MM; Soukop, M; Watson, DG, 1996)
"Patients with colorectal cancer liver metastases were treated with fluorouracil (5FU) as a protracted venous infusion (300 mg/m2/d), with or without interferon-alpha 2b for two 10-week blocks separated by a 2-week break."3.69Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. ( Cronin, B; Cunningham, D; Findlay, M; Flower, M; Hickish, T; Husband, J; Iveson, A; Ott, R; Pratt, B; Young, H, 1996)
"Thirty-seven patients with advanced colorectal cancer were treated with fluorouracil (5-FU) and folinic acid (FA) (Jan 1990-Dec 1992)."3.69Advanced colorectal cancer treated with combined 5-fluorouracil and folinic acid: the experience within a surgical department. ( Carey, PD; Farrer, C; Gordon, A; Guillou, PJ; Monson, JR; Pearce, S; Sommers, SS, 1995)
"The pharmacokinetics after 20 min intravenous infusion or a 2 min bolus (push) injection of 5-fluorouracil (500 mg/m2) were studied in 14 colorectal cancer patients."3.69Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects. ( Carlsson, G; Glimelius, B; Graf, W; Gustavsson, B; Larsson, PA, 1996)
"Although intrahepatic infusion therapy with 5-fluorouracil for unresectable colorectal liver metastases may lead to improved overall survival for some patients, it is not clear why a response is not observed in others."3.69p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. ( Benhattar, J; Cerottini, JP; Givel, JC; Metthez, G; Saraga, E, 1996)
"The in vitro cytotoxicity of the combination of azidothymidine (AZT) and 5-fluorouracil (5-FU) against the human colorectal cancer cells SW-480, SW-620 and COLO-320DM was evaluated."3.69Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA-induced strand-breaks. ( Allegrini, G; Andreuccetti, M; Antonuzzo, A; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Malvaldi, G, 1996)
"We determined the chemosensitivity for cisplatin, mitomycin C, adriamycin, and 5-fluorouracil in vitro in 93 fresh human colorectal cancers using the MTT assay and performed chemotherapy according to results of the MTT assay."3.69Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MTT assay. ( Hotta, T; Ishimoto, K; Iwahashi, M; Murakami, K; Nakamori, M; Noguchi, K; Tani, M; Tanimura, H; Yamaue, H, 1996)
" In patients with colorectal cancer, the administration of adjuvant intraportal chemotherapy (with mitomycin and fluorouracil) has been reported to improve long-term survival in comparison with patients who are not given this treatment."3.69Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer. ( Bonistalli, L; Costantini, M; Messori, A; Tendi, E; Trallori, G, 1996)
" An audit of the total monthly costs of 'Tomudex' (raltitrexed; administered every 3 weeks), a drug recently introduced for the treatment of advanced colorectal cancer, and three 5-fluorouracil-based regimens [5-day daily bolus (Mayo); continuous ambulatory pump; 48-h continuous infusion (De Gramont)] was undertaken."3.69Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. ( Cunningham, D; Heron, J; Ross, P, 1996)
"In a series of 71 patients with advanced colorectal cancer treated with biochemically modulated 5-fluorouracil (5-FU) and methotrexate (MTX), we investigated the relationship between the proliferating-cell nuclear antigen (PCNA) (PC10) and p53 (Pab1801) primary-tumor immunohistochemical expression with respect to clinical response and long-term prognosis."3.69p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. ( Cuevas, MA; De Lena, M; Lacava, J; Leone, B; Machiavelli, M; Paradiso, A; Perez, J; Rabinovich, M; Rodriquez, R; Romero, A; Sapia, MG; Simone, G; Vallejo, C, 1996)
"Electroporation was applied in vitro and in vivo in the treatment of human colorectal cancer cell lines to study whether it can enhance the effect of bleomycin (BLM), 5-fluorouracil (5-FU) and cis-platinum (CDDP)."3.69Enhancing the effect of anticancer drugs against the colorectal cancer cell line with electroporation. ( Arita, D; Funato, T; Gamo, M; Kambe, M; Kanamaru, R; Kikuchi, H; Murakawa, Y; Tezuka, F, 1996)
"In this phase IB study, 24 patients with advanced colorectal cancer were treated with escalating doses of weekly chronomodulated 48 h infusions of 5-fluorouracil (5-FU) biochemically modulated by methotrexate 40 mg/m2 and (6S)-leucovorin 8 x 45 mg orally."3.69Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study. ( Kamm, YL; Punt, CJ; Wagener, DJ, 1997)
" A high incidence of colorectal adenocarcinomas with varied grades of cell differentiation can be induced by 1,2-dimethylhydrazine (DMH) in rats."3.69Preventive effect of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil on colonic carcinogenesis induced by 1,2-dimethylhydrazine in rats. ( Iwama, T; Kawachi, Y; Kudo, H; Murakami, S; Okayasu, I; Sagara, T; Sakamoto, S; Tsukada, K, 1997)
"The authors report a patient with colorectal carcinoma who developed neutropenic enterocolitis after treatment with 5-fluorouracil and leucovorin."3.69Neutropenic enterocolitis in a patient with colorectal carcinoma: unusual course after treatment with 5-fluorouracil and leucovorin--a case report. ( Blumgart, L; Kemeny, NE; Kronawitter, U, 1997)
"In the chemotherapy of colorectal cancers the most frequently given drug is 5-fluorouracil, which in certain cases reduces or delays the appearance of the local recurrence or metastasis."3.69[Determination of dihydropyrimidine dehydrogenase in the prediction of toxic side effects of 5-fluorouracil]. ( Fónyad, G; Jeney, A; Katona, C; Kralovánszky, J; Pandi, E; Rosta, A; Tóth, K, 1997)
"The aim of this study was to examine in detail the incidence and severity of hand-foot syndrome in advanced colorectal cancer patients receiving 5-fluorouracil (5-FU) and leucovorin (L-LV) chemotherapy."3.69Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. ( Barzacchi, C; Chiara, S; Di Somma, C; Meszaros, P; Nobile, MT; Rosso, R; Sanguineti, O; Vincenti, M, 1997)
"Use of chlorhexidine intraperitoneal therapy at the time of the operation for perforated colorectal cancer significantly decreases the frequency of gross tumor recurrence but not total recurrences."3.69Use of intraperitoneal 5-fluorouracil and chlorhexidine for prevention of recurrence of perforated colorectal carcinoma in a rat model. ( Ong, J; Stabile, B; Stamos, M; Stuntz, M; Wilmoth, G, 1997)
"5-Fluorouracil (5-FU) has been an accepted effective against colorectal cancer, but combination regimens resulted in a lesser effect than 5-FU alone."3.695-Fluorouracil + cisplatin + mitomycin C is a relatively most effective combination against xenograft lines of human colorectal cancer. ( Imamura, M; Kawabata, K; Nio, Y, 1997)
" In order to evaluate the HDRA with the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide end point for clinical use, chemosensitivity to mitomycin C, doxorubicin, 5-fluorouracil, and cisplatin of 107 advanced gastric and 109 advanced colorectal cancers was determined in vitro in a correlative clinical trial."3.69Clinical applications of the histoculture drug response assay. ( Furukawa, T; Hoffman, RM; Kubota, T, 1995)
"Multiple studies have shown that leucovorin-fluorouracil regimens are modestly superior to fluorouracil alone in the treatment of advanced colorectal cancer."3.69Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine. ( DeLap, RJ; Marshall, JL; Richmond, E, 1996)
"This study was conducted to investigate the activity and toxicity of 5fluorouracil folinic acid+mitomycin C combined with alpha 2b interferon in advanced colorectal cancer based upon recent studies suggesting a possible biochemical modulation of 5fluorouracil by interferon."3.68Mitomycin C, 5fluorouracil and folinic acid in combination with alpha 2b interferon for advanced colorectal cancer. ( Bascioni, R; Battelli, N; Battelli, T; Delprete, S; Manocchi, P; Mattioli, R; Mazzanti, P; Pilone, A; Rossini, S; Silva, RR, 1993)
"We studied the levamisole toxic effects in adjuvant therapy for colorectal cancer."3.68[Toxicity of levamisole in adjuvant chemotherapy for colorectal cancer]. ( Beerblock, K; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Navarro-Carola, E; Soubrane, D; Varette, C, 1993)
"Interferon (IFN) has been shown to enhance the cytotoxic effects of 5-fluorouracil (5FUra) in colorectal cancer, and clinical trials with this combination resulted in higher response rate with respect to 5FUra alone."3.68Cytokinetic effects of interferon in colorectal cancer tumors: implications in the design of the interferon/5-fluorouracil combinations. ( Acetoso, M; Bartolucci, M; Cascinu, S; Del Ferro, E; Fedeli, A; Foglietti, G; Grianti, C; Lungarotti, F; Olivieri, Q; Saba, V, 1993)
"5-Fluorouracil (5-FU) is the most widely used cytotoxic drug in oncology and the only one useful in the management of colorectal cancer - a leading cause of cancer death worldwide."3.68The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. ( Collins, DJ; Cunningham, D; Findlay, MP; Glaholm, J; Leach, MO; Mansi, JL; McCready, VR; Payne, GS, 1993)
"The efficacy of the protracted infusion of 5-fluorouracil (FU) 200 mg/m2/day admixed with leucovorin (LV) 20 mg/m2/day was assessed for the treatment of advanced colorectal and breast cancer patients."3.68Continuous intravenous infusion of leucovorin and 5-fluorouracil for the treatment of advanced colorectal and breast cancers. ( Chen, PM; Chiou, TJ; Hsieh, RK; Liu, JM; Tzeng, CH, 1993)
"A total of 77 patients with advanced colorectal cancer, including postoperative patients with liver, lung and peritoneal metastases, were treated with single or multiple injections of monoclonal antibody A7-neocarzinostatin (A7-NCS)."3.68Follow-up study of patients treated with monoclonal antibody-drug conjugate: report of 77 cases with colorectal cancer. ( Honda, M; Kitamura, K; Noguchi, A; Otsuji, E; Takahashi, T; Yamaguchi, T, 1993)
"In order to elucidate the effect of tumor vascularity on a various regimens concentration in tumor tissue, correlation among tegafur, 5-fluorouracil (5-FU), uracil concentrations in tissue and the microangiography were examined in 27 patients with colorectal cancer after preoperative administration of UFT (400 mg/day for 7 days)."3.68[Studies on tissue concentration of tegafur, 5-fluorouracil, uracil after UFT administration together with the study of microangiography of colorectal cancer]. ( Ishikawa, H; Kusano, H; Miyashita, K; Nakazaki, T; Ogawa, T; Shimizu, T; Shimoyama, T; Yasutake, T; Yoshida, A; Yoshida, K, 1993)
"Various factors, including thymidylate synthase, thymidine kinase, 5-fluorouracil phosphorylation and degradation pathways, folate concentrations, and the stability of ternary complex, which influence thymidylate synthase inhibition rate of fluoropyrimidines, were studied in 87 human adenocarcinoma tissues."3.68Ternary complex formation and reduced folate in surgical specimens of human adenocarcinoma tissues. ( Dohden, K; Ohmura, K; Watanabe, Y, 1993)
"Twenty-four patients with advanced or relapsed gastric or colorectal cancer were treated with a combination of 5-fluorouracil (5-FU), leucovorin (LV) and interferon-alpha (IFN-alpha)."3.68[Treatment of advanced gastric and colorectal cancer with 5-FU, leucovorin and interferon-alpha]. ( Ezaki, K; Hatanaka, T; Hobara, R; Iwase, K; Kawase, K; Nakano, H; Ohara, K; Okamoto, M; Ono, Y; Tsujimura, T, 1993)
"Forty-one patients with metastatic colorectal cancer were treated every four weeks with methotrexate 25 mg/m2 i."3.68Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination. ( Cascinu, S; Catalano, G; Fedeli, A; Luzi Fedeli, S, 1992)
" UFT (400 mg/day in terms of tegafur) was given preoperatively for 1-6 days in 6 patients with gastric cancer and 13 with colorectal cancer."3.68[Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT]. ( Inaba, S; Kawai, K; Kondo, Y; Ogino, A; Tsuchiya, K; Ueda, Y; Umeda, T, 1992)
" In a literature review of all published data of folinic acid and 5-fluorouracil intravenous bolus therapy in colorectal cancer with comparable dose intensity, an attempt was made to characterize the possible differences of the variations of schedules used."3.68The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer. ( Bokemeyer, C; Poliwoda, H; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, HJ, 1992)
"Twenty-four patients with advanced colorectal cancer received two cycles of combination chemotherapy consisting of mitomycin 10 mg/m2 for 5 days continuous infusion and allopurinol 300 mg x 3/day p."3.68Continuous 24-hour infusion of folinic acid does not increase the response rate of 5-fluorouracil but only the toxicity. ( Karvounis, N; Kosmidis, P; Tsavaris, N; Tzannou, I, 1992)
"The combination of folinic acid (FA) and 5-fluorouracil (5FU) is the most active systemic chemotherapy against advanced colorectal cancer."3.68High dose alpha-2b interferon + folinic acid in the modulation of 5-fluorouracil. A phase II study in advanced colorectal cancer with evidence of an unfavourable cost/benefit ratio. ( Dallavalle, G; Labianca, R; Luporini, A; Luporini, G; Pancera, G; Tedeschi, L, 1992)
"A cohort of 35 patients with advanced colorectal cancer, not previously exposed to chemotherapy, were included in a phase II study exploring the combination of interferon-alpha, 9 MU subcutaneously three times weekly, and 5-fluorouracil 750 mg/m2/day during 5 consecutive days in continuous intravenous infusion followed with weekly bolus injection of fluorouracil 750 mg/m2."3.68Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: activity in liver metastasis. ( Antón, A; Aranda, E; Blanco, E; Camps, C; Díaz Rubio, E; González Larriba, JL; Jimeno, J; Lízón, J; Massuti, B, 1992)
"Eighty-seven colorectal adenocarcinomas from untreated patients were investigated by short term tumor cultures to test in vitro sensitivity to 5-fluorouracil and mitomycin C."3.685-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures. ( Barone, C; Codacci-Pisanelli, G; Codacci-Pisanelli, M; Ferri, GM; Franchi, F; Garufi, C; Grieco, A; Pagani, V; Seminara, P, 1991)
"Because of conflicting reports of clinical synergy, we used the tetrazolium-based colorimetric (MTT) assay to test in vitro combination effects of methotrexate (MTX) plus 5-fluorouracil (FUra) in 4 schedules on 2 human non-small-cell lung cancer cell lines (adenocarcinoma, NC1-H23; bronchio-alveolar-cell carcinoma, NC1-H358), and 1 human colorectal adenocarcinoma cell line (SNU-C1)."3.68Schedule-dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines. ( Gazdar, AF; Kramer, BS; Perng, RP; Tsai, CM, 1991)
"Twenty-six patients with advanced colorectal cancer were treated with a combination based on multimodal biochemical modulation of 5-fluorouracil by means of high dose folinic acid, low-dose alpha-2b interferon and dipyridamole."3.68Fluorouracil, high-dose folinic acid, low-dose alpha-2b interferon and dipyridamole in the treatment of advanced colorectal cancer. A pilot study. ( Arcangeli, G; Bonera, F; Braga, M; Marini, G; Marpicati, P; Meriggi, F; Montini, E; Ragni, F; Simoncini, E; Zaniboni, A, 1991)
"18 patients with advanced colorectal cancer entered a phase I-II study of high-dose 48 h continuous infusion 5-fluorouracil (5-FU) for 6 weeks."3.68Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. ( Aranda, E; Barneto, I; Diaz-Rubio, E; Gonzalez-Larriba, J; Gonzalez-Mancha, R; Martin, M, 1990)
"Forty-five consecutive patients with advanced colorectal cancer were treated with 5-fluorouracil and high dose folinic acid."3.68[Fluorouracil and high-dose folinic acid in the treatment of advanced colorectal carcinoma]. ( Angelini, F; Carassai, A; Carpano, S; D'Aprile, M; Leggio, M; Lopez, M; Natali, M; Tonini, G; Vici, P, 1990)
"Twenty-nine evaluable patients with colorectal adenocarcinoma were treated in a phase I-II trial of combination chemotherapy with a 72-h continuous infusion of cisplatin (CDDP) and 5-fluorouracil (5-FU) with an infusion of VP-16 given at 24 and 48 h after the start of therapy."3.68A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal carcinoma. ( Browne, MJ; Calabresi, P; Clark, JW; Cummings, FJ; Curt, G; Posner, M; Slapak, CA; Urba, S; Weitberg, A; Wiemann, M, 1990)
"Intensive therapy with 5-fluorouracil (FU) and leucovorin (LV) has proved to be effective in the treatment of advanced colorectal cancer."3.68Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity. ( Anderson, I; Mortimer, JE, 1990)
"5-fluorouracil (5-FU) concentrations in peripheral blood, portal blood, normal and cancer tissues were evaluated in 26 patients with colorectal cancer after SF-SP administration (800 mg/day for 10 days)."3.68[Studies on 5-FU concentration and thymidine phosphorylase activity in tissues of patients with colorectal cancer after SF-SP administration]. ( Haruyama, K; Hase, S; Ishizawa, T; Katsura, Y; Niwa, K; Sameshima, T; Shimazu, H; Yamada, K; Yoshimura, A, 1990)
"Since there is no effective second line chemotherapy in colorectal cancer resistant to fluorouracil, this study was carried out to evaluate the therapeutic activity of the pineal hormone melatonin, which has appeared to have antineoplastic activity in some experimental conditions, in patients with metastatic colorectal carcinoma who did not respond to fluorouracil."3.68A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates. ( Archili, C; Barni, S; Crispino, S; Lissoni, P; Paolorossi, F; Tancini, G, 1990)
"Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical milieu at its site(s) of action."3.68Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. ( Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM, 1990)
"Thirty patients with advanced colorectal adenocarcinoma were treated by chemotherapy with an alternating regimen consisting of 5-fluorouracil (5-FU)-mitomycin C and 5-FU-dacarbazine at 3-week intervals."3.67Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study. ( Droz, JP; Herait, P; Kac, JL; Rougier, P; Theodore, C, 1989)
"Based on in vitro studies that have demonstrated synergy between recombinant alfa-2a-interferon (rIFN alpha-2a) and the fluoropyrimidine, fluorouracil (5FU), against two human colon cancer cell lines, a pilot clinical trial was initiated to determine the effects of the combination of 5FU and rIFN alpha-2a in patients with advanced, unresectable colorectal carcinoma."3.67Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. ( Goldman, M; Itri, L; Lyver, A; Rader, M; Schwartz, EL; Wadler, S; Weinberg, V; Wiernik, PH; Zimmerman, M, 1989)
"27 patients with advanced colorectal cancer were treated in a phase-II trial with high dose sequential methotrexate (MTX), 5-fluorouracil (5-FU), and folinic acid (FA)."3.67Sequential high dose methotrexate, 5-fluorouracil and folinic acid does not improve response rates in advanced colorectal cancer. ( Flechtner, H; Heim, ME; Queisser, W; Schuster, D; Worst, P, 1989)
"Two trials of leucovorin (LV) and 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer were done, both using a 3-day loading dose and then weekly doses to minimize toxicity."3.67Clinical experience with leucovorin and 5-fluorouracil. ( Brenckman, WD; Collier, M; Duch, DS; Ferone, R; Knick, VB; Laufman, LR; Morgan, ED; Mullin, R; Stydnicki, KA, 1989)
"Favorable results have been reported for the treatment of advanced colorectal cancer with the combination of 5-fluorouracil (5-FU) and leucovorin (LV)."3.67Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer. ( Peters, GJ; Pinedo, HM; van Groeningen, CJ, 1989)
"A total of 24 patients with advanced colorectal adenocarcinoma were entered into a phase I-II study of 5-fluorouracil (5-FU) and cisplatin, 21 of whom had previously received 5-FU."3.67Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma. ( Creaven, PJ; Herrera, L; Madejewicz, S; Mittelman, A; Petrelli, NJ; Plager, J; Rustum, Y; Soloman, J, 1989)
"Following the observation of antitumor activity for the combination of 5-fluorouracil (5-FU) and cisplatin in metastatic colorectal carcinoma, the combination of 5-FU and iproplatin was tested, also in colorectal carcinoma, in the hope of attaining equivalent activity without the nephrotoxicity observed with 5-FU/cisplatin."3.67Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma. ( Creaven, PJ; Herrera, L; Mittelman, A; Petrelli, NJ, 1989)
"The concentration of Tegafur, 5-FU and Uracil in tumor and normal tissue were measured in 47 colorectal cancer patients who had been administered UFT (400/mg) for seven days before operation."3.67[Pre- and post-operative adjuvant chemotherapy of colorectal cancer. Part 1. Drug concentration in tissues following UFT administration]. ( Eida, K; Fukuda, Y; Hirano, T; Ishii, T; Kotake, Y; Kusano, H; Nakagoe, T; Shimizu, T; Shimoyama, T; Tomita, M, 1988)
"An enhanced antineoplastic effect of 5-fluorouracil in patients with advanced colorectal cancer has been produced either by combination with folinic acid or administration by continuous infusion."3.67High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. ( Cady, J; De Gramont, A; Demuynck, B; Gonzalez-Canali, G; Grange, JD; Krulik, M; Lagadec, B; Loiseau, JP; Louvet, C; Maisani, JE, 1988)
"In metastatic colorectal cancer (mCRC), ETS gains relevance as an early available surrogate for patient survival."3.30Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306. ( D'Anastasi, M; Decker, T; Gesenhues, AB; Heinemann, V; Heintges, T; Hesse, N; Hofmann, FO; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Link, H; Modest, DP; Moehler, M; Scheithauer, W; Stintzing, S; von Weikersthal, LF, 2023)
" This Phase I/II study examined the toxicity and efficacy of high-dose pulsed AZD8931, an EGFR/HER2/HER3 inhibitor, combined with chemotherapy, in metastatic colorectal cancer (CRC)."3.30PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer. ( Barber, PR; Forsyth, S; Gao, F; Hackett, LD; Hartley, JA; Hochhauser, D; Lopes, A; Lowe, HL; Ng, TT; Pearce, S; Propper, DJ; Sarker, D; Saunders, MP; Spanswick, VJ; Weitsman, GE; White, L, 2023)
"In metastatic colorectal cancer (mCRC), the role of Trop-2 and Nectin-4 has been poorly investigated."3.30Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development. ( Bergamo, F; Conca, V; Cremolini, C; Di Donato, S; Fanotto, V; Fontanini, G; Germani, MM; Giordano, M; Latiano, TP; Lonardi, S; Masi, G; Moretto, R; Niccoli, C; Passardi, A; Pietrantonio, F; Prisciandaro, M; Proietti, A; Tamburini, E; Ugolini, C; Zaniboni, A, 2023)
"In clinical trials, the assessment of safety is traditionally focused on the overall rate of high-grade and serious adverse events (AEs)."3.30Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials. ( Boccaccino, A; Bustreo, S; Carullo, M; Clavarezza, M; Cremolini, C; Cupini, S; Daniel, F; Libertini, M; Lonardi, S; Morano, F; Niger, M; Palermo, F; Pietrantonio, F; Procaccio, L; Raimondi, A; Rossini, D; Santini, D; Tomasello, G; Zaniboni, A, 2023)
" Safety endpoints were rates of any grade and grade 3/4 adverse events during maintenance therapy."3.30Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212 ( Alig, AHS; Caca, K; Fruehauf, S; Goekkurt, E; Graeven, U; Haas, S; Heinemann, V; Heinrich, K; Held, S; Karthaus, M; König, AO; Kretzschmar, A; Kurreck, A; Modest, DP; Mueller, L; Sommerhäuser, G; Stahler, A; Stintzing, S; Trarbach, T; von Weikersthal, LF, 2023)
"The prognosis of mCRC (metastatic colorectal cancer) patients with RAS mutation is poor and capecitabine and oxaliplatin (CapeOx) plus bevacizumab has shown to be one of the standard therapeutic regimens as first line for these patients with objective response rate (ORR) of ~ 50% and median progression-free survival (mPFS) of 8-9 months."3.30Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study. ( Ding, K; Dong, C; Fang, X; Hu, H; Li, J; Liao, X; Sun, L; Wang, J; Weng, S; Xiao, Q; Xu, D; Yuan, Y; Zhang, S; Zhong, C, 2023)
"Main eligibility criteria are colorectal cancer, unresectable liver metastasis, no extra-hepatic metastases except pulmonary nodules if ≤3 and <10 mm, ECOG performance status 0 or 1."3.11Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. ( Audemar, F; De Baere, T; Ducreux, M; Gallois, C; Khemissa Akouz, F; Lapuyade, B; Lecaille, C; Lepage, C; Louafi, S; Mineur, L; Monterymard, C; Pellerin, O; Pernot, S; Simon, M; Smith, D; Taieb, J; Thirot-Bidault, A; Tougeron, D, 2022)
"Mebendazole was well tolerated and its addition to bevacizumab and FOLFOX4 enhanced tumor response to treatment which was translated by significant improvement of overall response rate 12 weeks after intervention [10 % (2) versus 65% (13) for control and mebendazole groups, respectively; p = 0."3.11Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer. ( El-Azab, GA; El-Ghoneimy, RA; Hegazy, SK; Mostafa, MF; Zakaria, F, 2022)
" Patient characteristics were evaluated with multiple regression analyses for survival outcomes, using the Cox proportional hazard model and linear regression analyses for the worst grade of adverse events."3.11Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years. ( Amagai, K; Bando, Y; Denda, T; Endo, S; Hatachi, Y; Hyodo, I; Ikezawa, K; Ishida, H; Kobayashi, K; Kuramochi, H; Morimoto, M; Moriwaki, T; Nakajima, G; Negoro, Y; Nishina, T; Sakai, Y; Sato, M; Shimada, M; Tsuji, A; Yamamoto, Y, 2022)
"This multicenter single-arm, phase II study evaluated the efficacy and safety of uninterrupted panitumumab usage combined with cytotoxic doublets for unresectable/metastatic colorectal cancer (mCRC)."3.11Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA. ( Akazawa, N; Ando, T; Hirata, K; Kagawa, Y; Kato, T; Maeda, H; Mishima, H; Nagasaka, T; Nagata, N; Oba, K; Sakamoto, J; Shiozawa, M; Watanabe, J; Yamada, T; Yokota, M, 2022)
"This study aimed to investigate the effect of the mFOLFOX6 regimen combined with SHR-1210 on immune function and prognosis in patients with microsatellite instability CRC."3.11Effects of mFOLFOX6 regimen combined with carrelizumab on immune function and prognosis in patients with microsatellite instability colorectal cancer. ( Lu, P; Sun, J; Wang, Y; Yao, N, 2022)
"44 patients with metastatic colorectal cancer were enrolled in this study."3.11Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study). ( Fukazawa, A; Hasegawa, S; Hirata, K; Koda, K; Kosugi, C; Kuramochi, H; Matsuda, A; Matsuoka, H; Ohta, R; Otsuka, T; Sakamoto, K; Sonoda, H; Takahashi, M; Watanabe, T; Yamada, T; Yoshida, H; Yoshida, Y, 2022)
"The outcomes of treatment of metastatic colorectal cancer (mCRC) is still unsatisfactory."3.11Triplet (FOLFOXIRI) Versus Doublet (FOLFOX or FOLFIRI) Regimen as First Line Treatment in Metastatic Colorectal Carcinoma, a Prospective Phase II, Randomized Controlled Trial. ( Hassan, MA; Khalil, KA; Mahmoud, IA; Musallam, HS, 2022)
" Patients exhibiting EWL had worse survival and higher frequencies of adverse events."3.11Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306). ( Algül, H; Decker, T; Erickson, NT; Gesenhues, AB; Heinemann, V; Heintges, T; Höffkes, HG; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Lerch, MM; Link, H; Liu, L; Michl, M; Modest, DP; Moehler, M; Ricard, I; Scheithauer, W; Stintzing, S; Theurich, S; von Weikersthal, LF, 2022)
"To overcome this problem, patients with colorectal cancer are treated with chemotherapy for a short time, followed by a less aggressive maintenance regimen of the chemotherapy drug 5-fluorouracil and the targeted therapy drug bevacizumab."3.01Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003. ( Cui, K; Gurary, EB; Kim, TW; Lerman, N; Taieb, J; Yoshino, T, 2021)
"The treatment of colorectal cancer (CRC) has evolved and become more personalized during the past several years."3.01Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review. ( Damato, A; Dottorini, L; Ghidini, A; Ghidini, M; Iaculli, A; Luciani, A; Petrelli, F; Tomasello, G, 2023)
"The incidence of chemotherapy-related adverse events in colorectal cancer patients with renal insufficiency has been compared to patients with normal renal function in only a few studies."3.01Feasibility and Safety of Adjuvant Chemotherapy for Resected Colorectal Cancer in Patients With Renal Insufficiency: A Pooled Analysis of Individual Patient Data from Five Japanese Large-scale Clinical Trials. ( Aoyama, T; Honda, M; Kanda, M; Kashiwabara, K; Maeda, H; Mayanagi, S; Muto, M; Oba, K; Sakamoto, J; Tanaka, K; Yamagishi, H; Yoshikawa, T, 2023)
"The meta-analysis aimed to assess the clinical efficacy of chemotherapeutic triplet-drug regimen combined with anti-EGFR antibody in patients with initially unresectable metastatic colorectal cancer (mCRC)."3.01Triplet-drug chemotherapy combined with anti-EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis. ( Dong, W; Jiang, T; Jiang, X; Li, H; Li, Y; Lv, Y; Tian, M; Xiao, J; Yin, Z; Zeng, J, 2023)
"Capecitabine (Cape) is an oral prodrug of the antimetabolite 5-fluorouracil."3.01Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer. ( Ali, A; Daily, KC; Dang, LH; George, TJ; Iqbal, A; Ivey, AM; Lee, JH; Ramnaraign, BH; Read, TE; Tan, SA; Terracina, KP; Wang, Y, 2021)
" In this phase II study, we prospectively analyzed the efficacy and safety of raltitrexed combined with S-1 (RS regimen) in the treatment of mCRC after the failure of conventional chemotherapy."3.01A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer. ( Chen, Z; Guo, W; Huang, M; Li, W; Qiu, L; Wang, C; Wang, Y; Yang, Y; Zhang, W; Zhang, X; Zhang, Z; Zhao, X; Zhu, X, 2021)
" Efficacy endpoints were progression-free survival (PFS), overall survival (OS) and overall response rate (ORR); safety endpoints were rates of any grade and grade 3/4 adverse events (AEs)."3.01Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study. ( Amatu, A; Antoniotti, C; Berenato, R; Clavarezza, M; Corallo, S; Di Bartolomeo, M; Di Maio, M; Fucà, G; Leone, AG; Lonardi, S; Morano, F; Murialdo, R; Pietrantonio, F; Raimondi, A; Ratti, M; Ritorto, G; Smiroldo, V; Tampellini, M; Zaniboni, A, 2021)
" The secondary endpoints were chronic cumulative neurotoxicity (EORTC QLQ-CIPN20), time to grade 2 neurotoxicity (NCI-CTCAE or the oxaliplatin-specific neuropathy scale), acute neurotoxicity (analog scale), rates of dose reduction or withdrawal due to OIPN, 3-year disease-free survival (DFS) and adverse events."2.94Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer. ( Chen, G; Deng, YH; Ding, PR; Fan, WH; Feng, F; Jin, Y; Li, YH; Liang, HL; Lu, ZH; Peng, JW; Ren, C; Shi, SM; Wang, DS; Wang, F; Wang, FH; Wang, W; Wang, ZQ; Xie, CB; Xu, RH; Zhang, JW, 2020)
"Chemotherapy in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy is under debate."2.94Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study). ( Fukunaga, M; Ide, Y; Ikumoto, T; Iwamoto, S; Kanazawa, A; Kato, T; Konishi, K; Kotaka, M; Kudo, T; Kurata, T; Sakai, D; Sano, Y; Satake, H; Satoh, T; Sugimoto, N; Tomita, N; Tsuji, A; Yamanaka, T, 2020)
" In 15 patients (40%) 21 serious adverse events related to debulking were reported."2.94Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer. ( Bakkerus, L; Buffart, TE; de Groot, JB; Gootjes, EC; Grunhagen, DJ; Haasbeek, CJA; Hendriks, MP; Labots, M; Meijerink, MR; Nuyttens, JJME; Ten Tije, AJ; Tuynman, JB; van de Ven, PM; van der Stok, EP; van Meerten, E; Verheul, HMW; Verhoef, C; Zonderhuis, BM, 2020)
"A total of 137 patients with advanced colorectal cancer were recruited."2.94The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer. ( Chang, L; Fu, X; Han, G; Han, Z; Hui, D; Jia, R; Li, Q; Li, Y; Liu, H; Liu, N; Zhang, H; Zhang, Y; Zhu, H, 2020)
"AtezoTRIBE is a prospective, open label, phase II, comparative trial in which initially unresectable and previously untreated mCRC patients, irrespective of microsatellite status, are randomized in a 1:2 ratio to receive up to 8 cycles of FOLFOXIRI/bevacizumab alone or in combination with atezolizumab, followed by maintenance with bevacizumab plus 5-fluoruracil/leucovorin with or without atezolizumab according to treatment arm until disease progression."2.94AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. ( Antoniotti, C; Aprile, G; Bergamo, F; Boccaccino, A; Boni, L; Borelli, B; Brunella, DS; Corallo, S; Cremolini, C; Falcone, A; Grassi, E; Lonardi, S; Marmorino, F; Morano, F; Moretto, R; Pietrantonio, F; Racca, P; Rossini, D; Salvatore, L; Tamberi, S; Tamburini, E; Tortora, G, 2020)
" with mCRC RAS/BRAF mutated, in first line will receive nivolumab in combination with FOLFOXIRI/bevacizumab every 2 weeks for 8 cycles followed by maintenance with bevacizumab plus nivolumab every 2 weeks."2.94Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018). ( Antonuzzo, L; Bergamo, F; Berselli, A; Bordonaro, R; Damato, A; Iachetta, F; Maiello, E; Nasti, G; Normanno, N; Pinto, C; Romagnani, A; Tonini, G; Zaniboni, A, 2020)
"gov, NCT01506167) that recruited patients with metastatic colorectal cancer scheduled to receive bevacizumab in combination with first-line chemotherapy as part of routine clinical practice."2.90ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. ( Baijal, S; Chau, I; Cunningham, D; Ellis, R; Harrison, M; Khakoo, S; Ograbek, A; Pedley, I; Raouf, S; Ross, P; Steward, W; Tahir, S, 2019)
" The studies demonstrated a significant benefit from the triplet at the price of an increased incidence of chemotherapy-related adverse events (AEs)."2.90Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. ( Allegrini, G; Aprile, G; Bergamo, F; Boccaccino, A; Boni, L; Borelli, B; Buonadonna, A; Cordio, S; Cremolini, C; Dell'Aquila, E; Falcone, A; Latiano, TP; Libertini, M; Lonardi, S; Marmorino, F; Masi, G; Moretto, R; Passardi, A; Pella, N; Randon, G; Ratti, M; Ricci, V; Ronzoni, M; Rossini, D; Tamburini, E; Urbano, F; Zucchelli, G, 2019)
" Overall, grade 3 adverse events, such as leukopenia and neutropenia, were observed in two of three patients (66."2.90Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial. ( Emoto, S; Hata, K; Hiyoshi, M; Ishihara, S; Ishimaru, K; Kaneko, M; Kawai, K; Muro, K; Murono, K; Nagata, H; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Shuno, Y; Tanaka, T, 2019)
"Simvastatin 80 mg tablets were taken orally once daily every day during the period of chemotherapy."2.90A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. ( Ahn, JB; Han, SW; Kang, WK; Kim, ST; Kim, TW; Kim, Y; Lee, J; Lim, HY; Park, JO; Park, YS, 2019)
"Metastatic colorectal cancer (mCRC) has low survival rates."2.90A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer. ( Beck, JT; Berlin, JD; Cubillo Gracian, A; Deming, DA; Elez Fernandez, E; Garcia-Alfonso, P; Gorbunova, V; Hofheinz, RD; Luo, Y; Mangel, L; Nechaeva, M; Ramanathan, RK; Sullivan, D; Torres, AH, 2019)
"Dose modification of chemotherapy for metastatic colorectal cancer (MCRC) is often needed, especially in second-line and later-line treatments due to adverse events of previous treatment and poor patient condition."2.90Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer. ( Aikawa, T; Akashi, K; Ariyama, H; Baba, E; Doi, Y; Esaki, T; Ito, M; Kobayashi, K; Kusaba, H; Makiyama, A; Mitsugi, K; Shimokawa, H; Takayoshi, K; Tsuchihashi, K; Uenomachi, M; Yoshihiro, T, 2019)
" As for the biomarkers, carcinoembryonic antigen and lactate dehydrogenase (LDH) smoothly declined immediately after the initial dosing in patients with a partial response or stable disease."2.90Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study). ( Hirata, K; Hotta, Y; Imasato, M; Ishibashi, K; Iwamoto, S; Maeda, H; Makiyama, A; Mishima, H; Morita, S; Morita, Y; Munemoto, Y; Nagasaka, T; Nagata, N; Sakamoto, J; Takemoto, H; Tanaka, C; Toyofuku, A; Yoshida, Y, 2019)
"Metastatic colorectal cancer (mCRC) is a heterogeneous disease where prognosis is dependent both on tumor biology and host factors."2.90Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. ( Dajani, O; Glimelius, B; Guren, TK; Hamfjord, J; Johansen, JS; Kure, EH; Lingjærde, OC; Pallisgaard, N; Pfeiffer, P; Sorbye, H; Spindler, KG; Tveit, KM, 2019)
" Treatment-emergent adverse events (TEAEs) were evaluated, and HRQL was assessed at baseline, cycle 3, and every other cycle using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-CR29, and EuroQol 5-Dimensions 3-Levels questionnaires (NCT01571284)."2.90Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). ( Aparicio, J; Bordonaro, R; Bury, D; Chau, I; Cicin, I; Di Bartolomeo, M; Drea, E; Fedyanin, MY; García-Alfonso, P; Heinemann, V; Karthaus, M; Kavan, P; Ko, YJ; Maiello, E; Martos, CF; Peeters, M; Picard, P; Riechelmann, RP; Sobrero, A; Srimuninnimit, V; Ter-Ovanesov, M; Yalcin, S, 2019)
"For stage II/Dukes B colorectal cancer (CRC), clinical biomarkers are urgently required to direct therapeutic options."2.87Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer. ( Gray, R; Handley, K; Hutchins, GGA; Kerr, D; Magill, L; Quirke, P; Seymour, M; Southward, K; Tinkler-Hundal, E; Treanor, D; Wright, A, 2018)
"Metastatic colorectal cancer frequently occurs in elderly patients."2.87Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. ( Aparicio, T; Baconnier, M; Bedenne, L; Bouché, O; El Hajbi, F; Etienne, PL; Faroux, R; François, E; Genet, D; Khemissa Akouz, F; Kirscher, S; Lavau-Denes, S; Lecomte, T; Locher, C; Maillard, E; Oden-Gangloff, A; Paillaud, E; Retornaz, F; Rinaldi, Y; Taieb, J, 2018)
"The actual resection rate of metastases was significantly associated with treatment setting (P = 0."2.87Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3. ( Becker, T; Bemelmans, M; Bruns, CJ; Denecke, T; Folprecht, G; Gebauer, B; Heinemann, V; Held, S; Lang, H; Modest, DP; Modest, HI; Neumann, UP; Pratschke, J; Rentsch, M; Ricard, I; Seehofer, D, 2018)
"Acne-like skin rash is a frequently occurring adverse event associated with drugs against the epidermal growth factor receptor."2.87EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity. ( Al-Batran, SE; Ettrich, TJ; Feustel, HP; Heeger, S; Hofheinz, RD; Homann, N; Kripp, M; Lorenzen, S; Merx, K; Ocvirk, J; Schatz, M; Schulte, N; Schulz, H; Tetyusheva, M; Trojan, J; Vlassak, S, 2018)
"The primary end point was the 10-month progression-free rate (PFR); secondary end points included progression-free and overall survival, response rate, rate of metastases resection, and adverse events."2.87Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. ( Antoniotti, C; Aprile, G; Bergamo, F; Boni, L; Cardellino, GG; Coltelli, L; Corsi, DC; Cremolini, C; Dell'Aquila, E; Di Fabio, F; Falcone, A; Fontanini, G; Gemma, D; Grande, R; Lonardi, S; Lupi, C; Mancini, ML; Marcucci, L; Marmorino, F; Masi, G; Mescoli, C; Ronzoni, M; Salvatore, L; Tonini, G; Zagonel, V, 2018)
" A prospective clinical trial was designed to evaluate the efficacy and safety of fluorouracil monotherapy combined with panitumumab administered to patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) intolerant to oxaliplatin and irinotecan."2.87A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial. ( Denda, T; Fukunaga, M; Kanda, M; Kataoka, M; Kim, HM; Mishima, H; Munemoto, Y; Nagata, N; Oba, K; Sakamoto, J; Takano, N; Takemoto, H; Tokunaga, Y, 2018)
" Patients were randomly assigned (1:1) to either BEVZ92 or reference bevacizumab (5 mg/kg on day 1 of each cycle every 2 weeks) in combination with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or fluorouracil, leucovorin, and irinotecan (FOLFIRI)."2.87Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. ( Abdalla, KC; Bondarenko, I; Del Campo García, A; Franke, F; Huerga, C; Melo Cruz, F; Mendonça Bariani, G; Millán, S; Ostwal, V; Paravisini, A; Peredpaya, S; Rahuman, SA; Ramesh, A; Roca, E; Romera, A; Shah, P; Shparyk, Y, 2018)
"From January 2011 to January 2016, 696 colorectal cancer patients were enrolled in this study: 341 patients were randomly assigned to the intraoperative chemotherapy, which consist of portal vein chemotherapy, intraluminal chemotherapy and intraperitoneal chemotherapy, plus surgery group, whereas 344 patients were randomized to the control group to undergo surgery alone."2.84Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: a randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC). ( Chen, G; Ding, PR; Fan, WH; Huang, JQ; Jiang, W; Ke, CF; Kong, LH; Lei, J; Li, C; Li, LR; Lin, JZ; Liu, Q; Lu, ZH; Pan, ZZ; Wan, DS; Wang, FL; Wu, XJ; Zhang, RX; Zhou, WH, 2017)
"Several predictors of metastatic colorectal cancer (mCRC) outcomes have been described."2.84Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients. ( Aparicio, T; Auby, D; Bachet, JB; Bouché, O; Boulat, O; Breysacher, G; Cretin, J; Faroux, R; Gargot, D; Gasmi, M; Genet, D; Jouve, JL; Khemissa, F; Lecomte, T; Lepère, C; Locher, C; Maillard, E; Mitry, E; Ramdani, M; Seitz, JF; Sobhani, I; Stefani, L; Teillet, L, 2017)
"Cetuximab-induced skin rash Gd3+ occurs in ≥16% patients (pts) (Heinemann et al."2.84Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care. ( Boller, E; Dingeldein, G; Ehscheidt, P; Flohr, T; Galle, PR; Geer, T; Göhler, T; Hebart, H; Heike, M; Indorf, M; Josten, KM; Karthaus, M; Lang, C; Moehler, M; Neise, M; Rudi, J; Schimanski, CC; Schmittel, A; Staib, F; Wierecky, J; Wörns, MA, 2017)
"One-hundred twenty-seven patients were randomly assigned to parsatuzumab, 400 mg, or placebo, in combination with mFOLFOX6 plus bevacizumab, 5 mg/kg."2.84Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. ( Anderson, M; Argiles, G; Braiteh, F; Chang, I; Chen, D; Funke, R; García-Carbonero, R; Gore, I; Hegde, P; Hurwitz, H; Jassem, J; McCall, B; Rhee, I; Rivera, F; Stroh, M; Tebbutt, N; van Cutsem, E; Wainberg, ZA; Wakshull, E; Ye, W, 2017)
"Doublet or triplet chemotherapy regimens in combination with anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (mAb), such as cetuximab or panitumumab, or the anti-vascular endothelial growth factor mAb bevacizumab, are the current recommended standard of care therapies for unresectable metastatic colorectal cancer (mCRC)."2.82Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives. ( Cremolini, C; Esser, R; Falcone, A; Folprecht, G; Martinelli, E; Mazard, T; Modest, DP; Tsuji, A, 2022)
"Aflibercept in combination with FOLFIRI chemotherapy is an established safe and efficacious regimen for the treatment of mCRC as second-line chemotherapy."2.82Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer. ( Chau, I; Lau, DK; Mencel, J, 2022)
"The treatment of colorectal cancer liver metastases has seen significant improvement in recent years and, for certain patients, the long-term survival and even cure are possible."2.82Chemotherapy in resectable or potentially resectable colon cancer with liver metastases. ( Naher, SK; Samoon, Z; Sjoquist, KM; Zalcberg, J, 2022)
"Many studies have determined colorectal cancer chemoresistance mechanisms such as drug efflux, cell cycle arrest, DNA damage repair, apoptosis, autophagy, vital enzymes, epigenetic, epithelial-mesenchymal transition, stem cells, and immune system suppression."2.82MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil. ( Gazouli, M; Lampropoulou, DI; Nemati, M; Pouya, FD; Rasmi, Y, 2022)
"Metastatic colorectal cancer (mCRC) frequently occurs in elderly patients."2.82Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). ( Adhoute, X; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Breysacher, G; Charneau, J; Chone, L; Cretin, J; Gargot, D; Gasmi, M; Jouve, JL; Khemissa, F; Lavau-Denes, S; Lecomte, T; Legoux, JL; Lepère, C; Locher, C; Maillard, E; Michel, P; Mitry, E; Phelip, JM; Provençal, J; Sobhani, I, 2016)
" A nonrandomized phase 1 dose-escalation study of ABT-751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab was conducted to define the maximum tolerated dose, dose-limiting toxicity (DLT), and pharmacokinetics in patients with advanced colorectal cancer."2.82Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer. ( Dasari, A; Donehower, RC; He, P; Hidalgo, M; Jimeno, A; Jin, R; Laheru, D; Messersmith, WA; Purcell, WT; Rudek, MA; Taylor, GE; Walker, R, 2016)
"Patients with liver-only metastatic colorectal cancer (mCRC) who are not candidates for potentially curative resection may become resectable with more aggressive chemotherapy regimens."2.82A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only. ( Bendell, JC; Boccia, R; Earwood, C; Gian, V; Lane, CM; Lipman, A; LoCicero, R; Meluch, A; Moskowitz, M; Peyton, JD; Waterhouse, D; Zakari, A, 2016)
" This study aimed to evaluate the drug safety and tolerability of continuous intravenous infusion (CIV) of endostar in combination with modified FOLFOX6 (mFOLFOX6) as an initial therapy in advanced colorectal cancer patients."2.80Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial. ( Cao, J; Chen, Z; Guo, W; Ji, D; Li, J; Li, W; Lv, F; Qiu, L; Wang, J; Xia, Z; Zhang, S; Zhang, W, 2015)
"Sleep disorders are prevalent in patients with advanced cancer."2.80Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer. ( Bjarnason, GA; Giacchetti, S; Innominato, PF; Lévi, F; Palesh, O; Spiegel, D; Ulusakarya, A, 2015)
"We assessed circulating tumor cells (CTCs) as a prognostic biomarker in patients treated with a 4-drug regimen."2.80Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. ( Ashcroft, L; Backen, A; Beech, J; Chau, I; Dive, C; Gollins, S; Hasan, J; Krebs, MG; Morris, K; Renehan, AG; Saunders, MP; Valle, JW, 2015)
" No difference in other treatment toxicity was observed between the two groups, and patients exhibited high compliance in dosing administration."2.80Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis. ( Aoyama, T; Kataoka, M; Kono, T; Matsuda, C; Mishima, H; Morita, S; Munemoto, Y; Nagata, N; Oshiro, M; Sakamoto, J, 2015)
" All patients experienced at least one grade 3 or higher adverse event: neutropenia (five patients, 83%), proteinuria (two patients; 33%) and anemia, thrombocytopenia and hypertension (one patient each, 17%)."2.80Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma. ( Gao, L; Gotoh, M; Nasroulah, F; Ohtsu, A; Yamazaki, K; Yoshino, T; Yoshizuka, N, 2015)
"Mucositis was the most common dose-limiting toxicity."2.80A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors. ( Evande, RE; Grem, JL; Kos, ME; Meza, JL; Schwarz, JK, 2015)
" Despite heterogeneity in response to aflibercept, no biomarkers for efficacy or adverse effects have been identified."2.80Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting. ( Chiron, M; Folprecht, G; Lambrechts, D; Margherini, E; Moisse, M; Pericay, C; Peuteman, G; Sagaert, X; Thienpont, B; Thuillier, V; Van Cutsem, E; Zalcberg, J; Zilocchi, C, 2015)
" Then the recovery time of bowel function, the incidence of adverse reactions and complications, and the pre- and post-chemotherapy routine blood tests and hepatorenal functions were compared."2.80[Safety evaluation of intraoperative peritoneal chemotherapy with Lobaplatin for advanced colorectal cancers]. ( Feng, L; Liu, Q; Liu, Y; Wu, X; Xia, D; Xu, L, 2015)
"Surgical excision of colorectal cancer at early clinical stages is highly effective, but 20-30% of patients relapse."2.79Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1. ( Artl, M; Balic, M; Böhm, G; Dandachi, N; Dietze, O; Filipits, M; Gnant, M; Graf, R; Greil, R; Heitzer, E; Hofbauer, F; Höfler, G; Lax, S; Resel, M; Samonigg, H; Schaberl-Moser, R; Weißenbacher, B; Wrba, F, 2014)
"Twenty-one Japanese colorectal cancer patients received intravenous FOLFIRI (bolus irinotecan, folinic acid, and fluorouracil followed by 46-hour fluorouracil infusion) followed by bevacizumab (5 mg/kg) in Cycle 1."2.79Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. ( Doi, T; Fuse, N; Hamamoto, Y; Hatake, K; Iwasaki, J; Matsumoto, H; Mizunuma, N; Motomura, S; Ohtsu, A; Suenaga, M; Yamaguchi, T; Yamanaka, Y, 2014)
"An IO dosing schedule had a significant benefit on both TTF and TTP versus CO dosing in this trial despite the very attenuated sample."2.79Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. ( Alberts, S; Ansari, R; Childs, BH; Chowhan, N; Grothey, A; Hainsworth, JD; Hart, L; Hochster, HS; Keaton, M; Ramanathan, RK; Rowland, K, 2014)
" The most frequent grade 3-4 adverse events included neutropenia (grade 3: 33."2.79An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer. ( Asmis, TR; Ayoub, JP; Ballal, S; Cervantes, A; Garcia-Carbonero, R; Maurel, J; Moore, MJ; Nasroulah, F; Rivera, F; Schwartz, JD; Tabernero, J, 2014)
"Advanced colorectal cancer is treated with a combination of cytotoxic drugs and targeted treatments."2.79Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. ( Adams, R; Butler, R; Fisher, D; Kaplan, R; Lowdell, C; Madi, A; Maughan, T; Meade, AM; Middleton, G; Pugh, C; Sizer, B; Sydes, B; Wasan, H; Wilson, R, 2014)
"Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years."2.79Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. ( Bowers, M; Bridgewater, J; Butler, R; Cunningham, D; Dixon, E; Falk, S; Finch-Jones, M; Garden, OJ; Hickish, T; Hornbuckle, J; Iveson, T; Little, L; Maughan, T; O'Reilly, D; Peterson, M; Primrose, J; Pugh, S; Rees, M; Siriwardena, A; Stanton, L; Valle, J, 2014)
"Over 50% of colorectal cancer (CRC) patients develop metastases."2.79FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. ( Aitouferoukh, S; Béchade, D; Bécouarn, Y; Beyssac, R; Brunet, R; Cany, L; Fonck, M; Lalet, C; Le Morvan, V; Mathoulin-Pélissier, S; Pulido, M; Robert, J; Texereau, P, 2014)
"The aim of this study was the evaluation of pharmacokinetic parameters, biomarkers, clinical outcome, and imaging parameters in metastatic colorectal cancer (mCRC) patients treated with FOLFIRI plus sunitinib."2.79FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data. ( Büchert, M; Burkholder, I; Jaehde, U; Kanefendt, F; Kuhlmann, J; Moritz, B; Mross, K; Scheulen, M; Sörgel, F; Strumberg, D, 2014)
"Pharmacokinetically guided (PK-guided) versus body surface area-based 5-fluorouracil (5-FU) dosing results in higher response rates and better tolerability."2.79A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy. ( Atluri, PM; Chay, CH; Deal, AM; Ibrahim, JG; Inzerillo, JJ; McLeod, HL; O'Neil, BH; Olajide, OA; Patel, JN; Sherrill, GB; Walko, CM, 2014)
"A total of 18 patients, 14 with colorectal cancer and 4 with pancreatic cancer, were included in this study."2.79Oxaliplatin and ototoxicity: is it really safe for hearing? ( Babacan, NA; Doğan, M; Kaçan, T; Kiliçkap, S; Koç, S; Seker, MM; Uysal, IO; Yüce, S, 2014)
" The most commonly reported adverse events in the FOLFOX6 cohorts included decreased appetite, neutropenia, diarrhea, peripheral neuropathy, and vomiting."2.78An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer. ( Adams, LM; Botbyl, J; Brady, J; Chau, I; Corrie, P; Digumarti, R; Laubscher, KH; Mallath, M; Midgley, RS, 2013)
" We evaluated the efficacy and safety of conatumumab (an agonistic monoclonal antibody against human death receptor 5) and ganitumab (a monoclonal antibody against the type 1 insulin-like growth factor receptor) combined with standard FOLFIRI chemotherapy as a second-line treatment in patients with mutant KRAS mCRC."2.78A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. ( Choo, SP; Chuah, BYS; Cohn, AL; Cottrell, S; Dubey, S; Galimi, F; Hei, YJ; Kopp, MV; Loberg, R; Maurel, J; McCaffery, I; Mitchell, EP; Nowara, E; Pan, Y; Sakaeva, DD; Sastre, J; Suzuki, S; Tabernero, J, 2013)
"We compared the results of stage IV colorectal cancer patients treated within a large Dutch phase III trial (CAIRO), in which standard chemotherapy and standard safety eligibility criteria were used, to patients treated outside the trial during the trial accrual period in a representative selection of 29 Dutch hospitals."2.78Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. ( Koopman, M; Mol, L; Ottevanger, PB; Punt, CJ; van Gils, CW, 2013)
"Fluorouracil dose was reduced to 2400 mg/m² after two of the first three patients reported grade 3-4 diarrhoea (in one case with febrile neutropenia)."2.78FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). ( Aprile, G; Bergamo, F; Bracarda, S; Cremolini, C; Falcone, A; Fontanini, G; Fornaro, L; Lonardi, S; Loupakis, F; Lupi, C; Masi, G; Morvillo, M; Salvatore, L; Schirripa, M; Sensi, E; Vivaldi, C; Zagonel, V; Zaniboni, A, 2013)
" We present the treatment rationale and protocol for an ongoing randomized multicenter placebo-controlled phase II study designed to evaluate the efficacy and safety of MetMAb combined with bevacizumab and mFOLFOX-6 (5-fluoruracil, leucovorin, and oxaliplatin)."2.78Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. ( Bendell, JC; Ervin, TJ; Gallinson, D; Hack, SP; Phan, SC; Saleh, MN; Singh, J; Vallone, M; Wallace, JA, 2013)
"A single-center colorectal cancer database was queried for c-stage II-III rectal cancer patients undergoing neoadjuvant chemoradiation followed by proctectomy between 1997 and 2007."2.78Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemoradiation: it means more than you think! ( Buta, M; de Campos-Lobato, LF; de Sousa, JB; Dietz, DW; Fazio, VW; Kalady, MF; Lavery, IC; Stocchi, L, 2013)
"Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-epidermal growth factor receptor (EGFR) therapy."2.78Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. ( Barugel, M; Bodoky, G; Burkes, R; Błasińska-Morawiec, M; Canon, JL; Cunningham, D; Douillard, JY; Humblet, Y; Jassem, J; Kocákova, I; Oliner, KS; Patterson, SD; Rivera, F; Rong, A; Rother, M; Ruff, P; Sidhu, R; Siena, S; Šmakal, M; Tabernero, J; Wiezorek, J; Williams, R, 2013)
"The study objectives were to evaluate the safety, tolerability, and preliminary efficacy of multiple doses of dulanermin in combination with modified FOLFOX6 and bevacizumab in previously untreated patients with locally advanced, recurrent, or metastatic colorectal cancer."2.78A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. ( Ashkenazi, A; Kapp, AV; Kozloff, MF; Messersmith, WA; Peddi, PF; Portera, CC; Royer-Joo, S; Wainberg, ZA, 2013)
" The severity of OPN was assessed according to the Common Toxicity Criteria for Adverse Events at baseline, every 2 weeks until the 8th cycle, and every 4 weeks thereafter until the 26th week."2.78Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy. ( Fukunaga, M; Hata, T; Kojima, H; Kono, T; Matsui, T; Mishima, H; Morita, S; Munemoto, Y; Nagata, N; Sakamoto, J; Shimada, M; Takemoto, H, 2013)
"Thirty-six metastatic colorectal cancer patients received every 2 weeks, as first- (17) or second-line (19) treatment a combined chronotherapy with CPT-11 (infused at day 1 from 2 to 8 a."2.78Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report ( Demolin, G; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N, 2013)
" This phase I study aimed to assess the maximal tolerated dose (MTD) of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer and to identify pharmacokinetic (PK) interactions and toxicities."2.78A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer. ( Copeman, M; Gibbs, P; Gouillou, M; Jefford, M; Lipton, L; Lynch, K; McArthur, G; Michael, M; Tebbutt, NC; Zalcberg, J, 2013)
"This prospective observational study assessed the efficacy of bevacizumab in combination with chemotherapy as preoperative treatment to downsize tumours for radical resection in patients with unresectable metastatic colorectal cancer (mCRC)."2.78Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma. ( Albiol, M; Alsina, M; Codina-Barreras, A; Figueras, J; Guardeño, R; Hernandez-Yagüe, X; Lopez-Ben, S; Queralt, B; Soriano, J, 2013)
" Patients were treated with cetuximab combined with either CAPIRI or CAPOX."2.78Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial. ( Giessen, C; Haas, M; Heinemann, V; Laubender, RP; Mansmann, U; Modest, DP; Schulz, C; Stintzing, S, 2013)
"Cediranib is a highly potent inhibitor of vascular endothelial growth factor (VEGF) signalling with activity against all three VEGF receptors."2.78Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. ( Cunningham, D; D'Haens, G; Douillard, JY; Robertson, J; Stone, AM; Van Cutsem, E; Wong, RP, 2013)
"This study evaluated the maximum tolerated dose (MTD) of sunitinib, a multitargeted tyrosine kinase inhibitor, combined with FOLFIRI (irinotecan 180 mg/m2 given over 90 min i."2.77A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. ( Aranda, E; Carrato, A; Chau, I; Countouriotis, AM; Cunningham, D; Guillen-Ponce, C; Iveson, TJ; Ramos, FJ; Ruiz-Garcia, A; Saunders, MP; Starling, N; Tabernero, J; Tursi, JM; Vázquez-Mazón, F; Wei, G, 2012)
"Cediranib is an oral, highly potent VEGF signaling inhibitor of all three VEGF receptors."2.77Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer. ( Boku, N; Mishima, H; Okamoto, W; Satoh, T; Shi, X; Shimamura, T; Yamaguchi, K; Yamazaki, K, 2012)
" We conducted a phase II trial to confirm the pharmacokinetic parameters from 3-Tesla dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) as surrogate biomarkers of BV + FOLFIRI regimen efficacy in colorectal cancer with liver metastases."2.77Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. ( Akiyoshi, K; Hamaguchi, T; Hirashima, Y; Horita, Y; Kato, K; Miyake, M; Nakajima, T; Okita, N; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Tateishi, U; Yamada, Y, 2012)
"Cediranib is an oral highly potent VEGF signalling inhibitor that inhibits all three VEGF receptors."2.77Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study. ( Amagai, K; Baba, H; Bando, H; Denda, T; Fukase, K; Hazama, S; Kato, T; Mishima, H; Muro, K; Shi, X; Skamoto, J; Yamaguchi, K, 2012)
"We randomly assigned 287 Stage III colorectal cancer patients after curative resection between 2002 and 2008 to receive 2 cycles of HAIC plus 4 cycles of systemic chemotherapy (combined therapy) or 6 cycles of systemic chemotherapy alone (monotherapy)."2.77Prophylactic adjuvant hepatic arterial infusion chemotherapy reduced hepatic metastases from Stage III colorectal cancer after curative resection. ( Bao, Y; Feng, WM; Huang, SX; Tang, CW; Tao, YL; Wang, Y; Zheng, YY, 2012)
"Up to 25% of patients with metastatic colorectal cancer (CRC) present with peritoneal carcinomatosis (PC) as the only site of metastases."2.77The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study. ( Bertrand, C; Ceelen, W; D'Hoore, A; Fieuws, S; Hompes, D; Kerger, J; Legendre, H; Peeters, M; Van Cutsem, E; Van der Speeten, K, 2012)
"KRAS p."2.77Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis. ( Brodowicz, T; Giessen, C; Heinemann, V; Knittelfelder, R; Laubender, RP; Modest, DP; Reinacher-Schick, A; Schmiegel, W; Stintzing, S; Tannapfel, A; Vrbanec, D; Zielinski, CC, 2012)
"Fifty-two patients with advanced colorectal cancer were enrolled in an ancillary pharmacogenetic study of the phase II CETUFTIRI trial."2.77Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. ( Bennouna, J; Chatelut, E; Douillard, JY; El Hannani, C; Etienne-Grimaldi, MC; Faroux, R; Formento, JL; Francois, E; Francoual, M; Hennebelle, I; Jacob, JH; Milano, G, 2012)
"Leucovorin Sodium (LV/Na) has a high solubility, and is stable when given with continuous infusion of 5-FU."2.77A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer. ( Bleiberg, H; D'Haens, G; Deleu, I; Efira, A; Humblet, Y; Paesmans, M; Peeters, M; Rezaei Kalantari, H; Vandebroek, A; Vergauwe, P, 2012)
"As part of a colorectal cancer long-term survivor study (LTS-01), long-term neurotoxicity was assessed in 353 patients on NSABP Protocol C-07 (cross-sectional sample)."2.77Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. ( Cecchini, RS; Ganz, PA; Kidwell, KM; Ko, CY; Kopec, JA; Land, SR; Wolmark, N; Yothers, G, 2012)
"Patients with metastatic colorectal cancer (mCRC) were randomized to XELOX plus bevacizumab using a standard triweekly cycle (Q3W) or a dose-dense biweekly cycle (Q2W) schedule."2.77A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard). ( Cartwright, T; Hu, S; Hurwitz, H; Kwok, A; McKenna, E; Mitchell, EP; Patt, YZ, 2012)
"The Maintenance in Colorectal Cancer trial was a phase III study to assess maintenance therapy with single-agent bevacizumab versus bevacizumab plus chemotherapy in patients with metastatic colorectal cancer."2.77Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. ( Abad, A; Aranda, E; Arrivi, A; Benavides, M; Díaz-Rubio, E; Fernández-Martos, C; Gallén, M; Gómez-España, A; González, E; Maestro, ML; Marcuello, E; Massuti, B; Rivera, F; Sastre, J; Tabernero, JM; Valladares, M; Vidaurreta, M, 2012)
" standard body-surface-area (BSA) dosing in a FOLFOX (folinic acid, fluorouracil, oxaliplatin) regimen in metastatic colorectal cancer (mCRC)."2.77Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ( Asevoaia, A; Boisdron-Celle, M; Capitain, O; Gamelin, E; Morel, A; Poirier, AL, 2012)
"In this multicenter phase Ib study, drozitumab was given in combination with the mFOLFOX6 regimen and bevacizumab in patients with previously untreated, locally advanced recurrent or metastatic colorectal cancer on day 1 of every 14-day cycle."2.77Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. ( Amler, LC; Baranda, JC; Bayraktar, S; Flores, AM; MacIntyre, J; Montero, A; Portera, C; Raja, R; Rocha Lima, CM; Royer-Joo, S; Stern, H; Wallmark, J, 2012)
"One hundred and twenty patients with colorectal cancer at Ruijin Hospital, Shanghai Jiaotong University School of Medicine were randomly assigned to the pure chemotherapy group (as the control group) and the QM + chemotherapy group (as the treatment group), 60 in each group."2.77[Effects of qisheng mixture on chemotherapy induced myelosuppression in patients with colorectal cancer]. ( Chen, JX; Shen, XH, 2012)
" We designed a pilot study in order to explore the optimal dosing period for indisetron during modified FOLFOX6 (mFOLFOX6)."2.77Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study. ( Asaka, M; Kato, K; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Muto, S; Nakatsumi, H; Oba, K; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2012)
" The most frequently observed adverse events reported with AZD6244 were acneiform dermatitis, diarrhoea, asthenia and peripheral oedema, compared with hand-foot syndrome, diarrhoea, nausea and abdominal pain with capecitabine."2.76A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. ( Adenis, A; Bennouna, J; Boer, K; Douillard, JY; Escudero, P; Kim, TY; Lang, I; Morris, CD; Pover, GM; Valladares-Ayerbes, M, 2011)
"The addition of cetuximab to chronotherapy allowed safe and effective therapeutic control of metastases, including their complete resection, despite previous failure of several treatment regimens."2.76Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. ( Adam, R; Bouchahda, M; Giacchetti, S; Gorden, L; Guettier, C; Hauteville, D; Innominato, PF; Karaboué, A; Lévi, F; Saffroy, R, 2011)
"8 or 45 μg/m(2) in combination with capecitabine-oxaliplatin (XELOX)."2.76Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies. ( Andretta, V; Bennicelli, E; Bordignon, C; Caprioni, F; Comandini, D; Fornarini, G; Guglielmi, A; Lambiase, A; Mammoliti, S; Mazzola, G; Pessino, A; Sciallero, S; Sobrero, AF, 2011)
"Peripheral sensory neurotoxicity is a frequent and potentially debilitating side effect of oxaliplatin treatment."2.76The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. ( Imholz, AL; Knijn, N; Koopman, M; Mol, L; Punt, CJ; Teerenstra, S; Tol, J; Valster, FA; Vincent, AD; Werter, MJ, 2011)
"Risk of recurrence was also significantly higher for KRAS mutant than KRAS wild-type tumors (28% [150 of 542] v 21% [219 of 1,041]; RR, 1."2.76Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. ( Beaumont, C; Chambers, P; Gray, R; Handley, K; Hutchins, G; Kerr, D; Magill, L; Quirke, P; Richman, S; Seymour, M; Southward, K; Stahlschmidt, J, 2011)
"Capecitabine and lapatinib were given orally at escalating doses, starting at capecitabine 1500 mg/m(2)/day on days 1-14 and lapatinib 1000 mg daily on days 1-21."2.76A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors. ( Alberti, D; Bowen, CJ; Dar, MM; Dennie, TW; Fleming, RA; Holen, KD; Loconte, N; Mulkerin, D; Oliver, K, 2011)
"Obesity is associated with an increased risk of development and recurrence of colorectal cancer."2.76Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. ( Derleyn, VA; Koopman, M; Mol, L; Muller, EW; Punt, CJ; Simkens, LH; Teerenstra, S; Ten Bokkel Huinink, D; Veldhuis, GJ, 2011)
"While the most frequent, surgery for colorectal cancer is avoided in patients with metastases to the regional lymph nodes (stage III) or distant ones (stage IV)."2.76[Results of adjuvant chemotherapy (XELOX) of advanced colorectal cancer]. ( Eropkin, PV; Kashnikov, VN; Panina, MV; Rybakov, EG, 2011)
"To evaluate the efficacy and safety of yiqi zhuyu decoction (YZD) combined with oxaliplatin plus 5-flurouracil/leucovorin (FOLFOX-4) in the patients with metastatic colorectal cancer (MCRC)."2.76Yiqi zhuyu decoction combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer. ( Cao, B; Deng, WL; Li, ST; Li, Z, 2011)
" Although skin toxicities are the most common adverse events associated with EGFR inhibitors, the differences in efficacy and safety between pre-emptive and reactive skin treatment according to KRAS tumor status has not been reported."2.76The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status. ( Iannotti, N; Lacouture, ME; Mitchell, EP; Pillai, MV; Piperdi, B; Shearer, H; Xu, F; Yassine, M, 2011)
"Patients with metastatic colorectal cancer received either FOLFOX-4 + bev or FOLFIRI + bev."2.75Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab. ( Chin, K; Fujiwara, Y; Hatake, K; Ichimura, T; Kobayashi, K; Konishi, F; Kuboki, Y; Matsueda, K; Matsusaka, S; Mizunuma, N; Ogura, M; Ozaka, M; Shinozaki, E; Suenaga, M, 2010)
"Patients suffering from advanced colorectal cancer can experience unintended weight loss and/or treatment-induced gastrointestinal toxicity."2.75Early supplementation of parenteral nutrition is capable of improving quality of life, chemotherapy-related toxicity and body composition in patients with advanced colorectal carcinoma undergoing palliative treatment: results from a prospective, randomize ( Essenbreis, M; Hasenberg, T; Herold, A; Post, S; Shang, E, 2010)
"This phase I dose-escalation study was designed to determine the maximum tolerated dose (MTD) and recommended dose of cetuximab administered on an every-second-week schedule to patients with metastatic colorectal cancer, on the basis of safety, pharmacokinetic and pharmacodynamic evaluation."2.75Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. ( Baselga, J; Cervantes, A; Ciardiello, F; Kisker, O; Liebscher, S; Macarulla, T; Martinelli, E; Ramos, FJ; Rivera, F; Rodriguez-Braun, E; Roselló, S; Tabernero, J; Vega-Villegas, ME, 2010)
"Patients with previously treated solid tumors received axitinib (starting dose 5 mg twice daily) combined with FOLFOX plus bevacizumab (1, 2, or 5 mg/kg, cohorts 1-3, respectively), FOLFIRI (cohort 4), or FOLFOX (cohort 5)."2.75A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. ( Abhyankar, V; Burgess, RE; Chen, Y; Infante, J; Kim, S; Robles, RL; Sharma, S; Tarazi, J; Tortorici, M; Trowbridge, RC, 2010)
"Stage IV colorectal cancer encompasses a broad patient population in which both curative and palliative management strategies may be used."2.75Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. ( Ashley, S; Brown, G; Chau, I; Cunningham, D; Gillbanks, A; Karanjia, N; Mudan, SS; Norman, AR; Watkins, DJ, 2010)
"Vorinostat doses were escalated in a standard 3 x 3 phase I design."2.75A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. ( Diasio, RB; Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Muindi, JR; Wang, K; Zwiebel, JA, 2010)
"Peritoneal carcinomatosis from colorectal cancer treated with chemotherapy alone results in median survival of 5 to 13 months, whereas CRS with HIPEC for early peritoneal carcinomatosis from colorectal cancer resulted in median survival of 48-63 months and 5 year survival of 51%."2.75Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases. ( Avital, I; Davis, JL; Kemp, CD; Ripley, RT; Steinberg, SM; Toomey, MA, 2010)
"Forty patients with metastatic colorectal cancer were enrolled."2.75Molecular markers in circulating tumour cells from metastatic colorectal cancer patients. ( Cortesi, E; Gazzaniga, P; Gradilone, A; Iacovelli, R; Naso, G; Nicolazzo, C; Petracca, A; Raimondi, C, 2010)
"As a project of the Kanagawa Colorectal Cancer Study Group, we performed this study to analyze the efficacy and the safety of modified FOLFIRI (irinotecan: 150 mg/m2) therapy for Japanese patients with metastatic colorectal cancer."2.75[Modified FOLFIRI (l-LV, 5-fluorouracil and irinotecan) therapy for Japanese patients with metastatic colorectal cancer]. ( Akaike, M; Imada, T; Masuda, M; Matsukawa, H; Ozawa, Y; Rino, Y; Shiozawa, M; Shiraishi, R; Suzuki, H; Takahashi, M; Tamura, I; Yamamoto, N; Yamamoto, Y; Yukawa, N, 2010)
"A total of 43 patients with advanced colorectal cancer were included."2.75[Influence of FOLFOX regimen on the immunologic function in patients with advanced colorectal cancer]. ( Duan, GL; Huang, CX; Jiang, YQ; Li, ZY; Wang, QQ, 2010)
" This study aims to achieve an improved disease free survival for patients after resection or resection combined with RFA of colorectal liver metastases by adding the angiogenesis inhibitor bevacizumab to an adjuvant regimen of CAPOX."2.75A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. ( Bergman, AM; Dalesio, O; Rinkes, IH; Schouten, SB; Snoeren, N; Tollenaar, RA; van der Sijp, JR; van Hillegersberg, R; Verheul, HM; Voest, EE, 2010)
"Liver metastasectomies were performed in 26% of all pts and in 39% of pts with LM."2.75"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. ( Antonucci, A; Baldi, PL; Bruera, G; Cannita, K; De Galitiis, F; Ficorella, C; Mancini, M; Marchetti, P; Ricevuto, E; Santomaggio, A; Tudini, M, 2010)
"Tetrathiomolybdate (TM) is an oral copper chelator under development as an anti-angiogenic agent."2.74A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. ( Brewer, GJ; Gartner, EM; Griffith, KA; Henja, GF; Merajver, SD; Pan, Q; Zalupski, MM, 2009)
"Twelve subjects with metastatic colorectal cancer within the liver failing first-line chemotherapy were treated in four cohorts with a single dose (3 x 10(6) to 1 x 10(8) particles) of NV1020, a multimutated, replication-competent HSV."2.74A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. ( Bhargava, A; Brody, L; Brown, K; Covey, A; Fong, Y; Getrajdman, G; Jarnagin, W; Karrasch, M; Kemeny, N; Kim, T; Mescheder, A; Schwartz, L, 2009)
"Simvastatin 40 mg tablet was given once daily per oral everyday during the period of chemotherapy without a rest."2.74Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. ( Ahn, JB; Byun, JH; Hong, YS; Im, SA; Jung, KH; Kang, WK; Kim, TW; Lee, J; Lee, N; Lim, HY; Oh, DY; Park, JO; Park, SH; Park, YS; Shin, DB; Shin, SJ, 2009)
" Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation."2.74Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009)
"Cediranib is a highly potent and selective inhibitor of the 3 vascular endothelial growth factor receptors and has a halflife suitable for once-daily oral dosing."2.74Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. ( Botwood, NA; Robertson, JD; Rothenberg, ML; Schmoll, HJ, 2009)
"Cediranib is a potent oral inhibitor of the tyrosine kinase activity associated with all subtypes of vascular endothelial growth factor receptor."2.74Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer. ( Chen, E; Gauthier, I; Jonker, D; MacLean, M; Powers, J; Seymour, L; Wells, J, 2009)
"All the patients with metastatic colorectal cancer treated with at least one line of chemotherapy for metastatic disease and progressed after I line chemotherapy were considered eligible and enrolled into the trial."2.74[Role of sequential chemotherapy in the treatment of metastatic colorectal cancer]. ( Carloni, F; Nicoletti, S; Ravaioli, A; Tamburini, E; Tassinari, D, 2009)
"Irinotecan therapy was associated with more grade 3 nausea, vomiting, diarrhea, and febrile neutropenia; FOLFOX4 was associated with more neutropenia and paresthesias."2.74Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. ( Alberts, SR; Fitch, TR; Goldberg, RM; Kim, GP; Mahoney, MR; Mathews, AP; Mitchell, E; Philip, PA; Pitot, HC; Rowland, KM; Sargent, DJ, 2009)
"Vorinostat was given orally twice daily for 1 week every 2 weeks."2.74A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. ( Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Pendyala, L; Ross, ME; Rustum, YM; Toth, K; Zwiebel, JA, 2009)
" Serious/grade 3-5 adverse events of interest for bevacizumab included bleeding (3%), gastrointestinal perforation (2%), arterial thromboembolism (1%), hypertension (5."2.74Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. ( Berry, S; Bridgewater, J; Canon, JL; Cunningham, D; DiBartolomeo, M; Georgoulias, V; Kretzschmar, A; Mazier, MA; Michael, M; Peeters, M; Rivera, F; Van Cutsem, E, 2009)
"Racial disparities in colorectal cancer (CRC) survival are documented, but there are few data on comparative response to chemotherapy."2.74Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. ( Goldberg, RM; Green, EM; McLeod, HL; Sanoff, HK; Sargent, DJ, 2009)
" Patients exhibited high compliance in dosing administration."2.74Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. ( Akhmadullina, LI; Barker, NP; Davidenko, IS; Firsov, I; Gertner, JM; Gotovkin, EA; Kopp, MV; Kulikov, EP; Moiseyenko, VM; Peterson, DE; Rakovskaya, GN; Rodionova, I; Sherman, NZ; Shinkarev, SA; Tuleneva, T; Woon, CW; Yarosh, A, 2009)
"Irinotecan is a chemotherapeutic agent used in the treatment of CRC and has demonstrated synergistic potential when used with radiation."2.74Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. ( Bower, GD; Briggs, GM; George, J; Goldstein, D; Olver, IN; Pavlakis, N; Price, D; Rossleigh, MA; Tapner, MJ; Taylor, DJ; van Hazel, GA, 2009)
"To compare the therapeutic effect and toxicity of chemotherapy, used alone or in combined with Shenqi Fuzheng Injection (SFI), for the treatment of advanced colorectal carcinoma (ACRC)."2.74[Effect of Shenqi Fuzheng injection combined with chemotherapy in treating advanced colorectal carcinoma]. ( Liang, QL; Pan, DC; Xie, JR, 2009)
" The primary toxicity outcome measure was toxicity-induced delay or dose reduction; the secondary outcome was Common Terminology Criteria of Adverse Events grade >or= 3 toxicity."2.74Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. ( Adlard, JW; Allan, JM; Braun, MS; Daly, CL; Meade, AM; Parmar, MK; Quirke, P; Richman, SD; Seymour, MT; Thompson, L, 2009)
"The treatment of peritoneal carcinomatosis is based on cytoreduction followed by hyperthermic intraperitoneal chemotherapy and combined with adjuvant chemotherapy."2.738-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. ( Boot, H; Bruin, S; van Slooten, G; van Tinteren, H; Verwaal, VJ, 2008)
"After 40 of the planned 74 patients had been randomly assigned, real-time adverse event monitoring led to early trial closure because of excess sequence-specific toxicity."2.73Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin. ( Anthoney, DA; Bradley, C; Brown, JM; Brown, S; Crawford, SM; Hennig, IM; Jackson, DP; Melcher, AM; Naik, JD; Seymour, MT; Szubert, A, 2008)
" Incidence of grade 3/4 treatment-related adverse events during the first 12 weeks of treatment were 59%, 36%, and 67% for mFOLFOX6, bFOL, and CapeOx, respectively, (TREE-1) and 59%, 51%, and 56% for the corresponding treatments plus bevacizumab (TREE-2; primary end point)."2.73Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. ( Abubakr, Y; Childs, BH; Cohn, AL; Fehrenbacher, L; Hainsworth, JD; Hart, LL; Hedrick, E; Hochster, HS; Ramanathan, RK; Saif, MW; Schwartzberg, L; Wong, L, 2008)
"Forty patients with colorectal cancer were included in this randomized prospective study."2.73Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer. ( Aydiner, A; Aykan, F; Can, G; Cevikbaş, A; Cinar, S; Deniz, G; Derin, D; Dişçi, R; Durna, Z; Guney, N; Gürer, U; Kürklü, E; Saglam, S; Sakar, B; Tanyeri, H; Taş, F; Topuz, E, 2008)
"There is strong evidence that colorectal cancer survival differs between socioeconomic groups."2.73No socioeconomic inequalities in colorectal cancer survival within a randomised clinical trial. ( Coleman, MP; Cooper, N; James, R; Lepage, C; Northover, JM; Nur, U; Parmar, MK; Rachet, B; Sydes, MR, 2008)
"Celecoxib was administered as 400 mg, twice daily starting on day 2 of cycle 1."2.73Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. ( Cao, S; Creaven, PJ; Durrani, FA; Iyer, RV; Javle, MM; Lawrence, DD; Noel, DC; Pendyala, L; Rustum, YM; Smith, PF, 2007)
"The aim of the present study was to investigate the safety and immunological responses of personalized peptide vaccination in combination with oral administration of a 5-fluorouracil derivative (TS-1) in advanced gastric or colorectal carcinoma patients."2.73Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. ( Fujiwara, T; Harada, M; Homma, S; Ikeda, Y; Ishihara, Y; Itoh, K; Maeda, Y; Mine, T; Sato, Y; Shomura, H; Tanaka, N; Todo, S; Tokunaga, N; Yamada, A, 2007)
"The R0 secondary resection rate of metastases was greater in the FOLFOXIRI arm (6% v 15%; P = ."2.73Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor ( Allegrini, G; Andreuccetti, M; Barbara, C; Benedetti, G; Brunetti, I; Chiara, S; Cortesi, E; Crinò, L; Evangelista, W; Falcone, A; Fanchini, L; Fioretto, L; Granetto, C; Masi, G; Orlandini, C; Pfanner, E; Picone, V; Porcile, G; Ricci, S; Vitello, S, 2007)
"To evaluate the efficacy and the toxicity of front line FOLFOX4 combined with bevacizumab in patients with metastatsic CRC (mCRC)."2.73Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. ( Agelaki, S; Androulakis, N; Chatzidakis, A; Christophylakis, C; Diamandidou, E; Emmanouilides, C; Georgoulias, V; Kalbakis, K; Kalykaki, A; Kotsakis, A; Mavroudis, D; Sfakiotaki, G; Souglakos, J; Touroutoglou, N; Vamvakas, L, 2007)
" The relation between adverse events on IROX to selected characteristics was analyzed."2.73Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. ( Alberts, SR; Ashley, AC; Campbell, ME; Findlay, BP; Fuchs, CS; Goldberg, RM; Grothey, A; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2007)
"We studied patients with advanced colorectal cancer, starting treatment with non-curative intent."2.73Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. ( Ferry, DR; Griffiths, GO; Gwyther, SJ; James, R; Ledermann, JA; Maraveyas, A; Maughan, TS; Meade, AM; Parmar, MK; Seymour, MT; Shepherd, S; Smith, DB; Stephens, RJ; Thompson, L; Topham, C, 2007)
"Patients diagnosed with colorectal cancer (n=150) were randomly allocated to receive monthly 5-FU and leucovorin bolus injections (the Mayo regimen) or a bimonthly 5-FU bolus plus continuous infusion (the simplified de Gramont regimen) for 24 weeks as postoperative adjuvant therapy."2.73Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. ( Elomaa, I; Joensuu, H; Korpela, R; Kouri, M; Ollus, A; Osterlund, P; Ruotsalainen, T; Saxelin, M; Valta, P, 2007)
"Sites of metastasis were as follows: liver (n = 10), lung (n = 8), skin (n = 1), and non-regional lymph nodes (n = 1)."2.73Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study. ( Chang, AY; Fong, FK; Hsin, KW; Lim, R; Lopes, G; Wong, J, 2007)
" Administration of TroVax alongside chemotherapy was safe and well tolerated with no SAEs attributed to the vaccine and no enhancement of chemo-related toxicity."2.73Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. ( Carroll, MW; Chikoti, P; Drury, N; Griffiths, R; Harrop, R; Hawkins, RE; Kingsman, SM; Naylor, S; Redchenko, I; Shingler, W; Steven, N, 2008)
" Three sequential skin biopsies were obtained in selected patients to assess the pharmacodynamic effects on EGFR signaling of FOLFIRI alone and with EKB-569."2.73Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with ( Abbas, R; Andreu, J; Baselga, J; Casado, E; Cortes-Funes, H; Folprecht, G; Köhne, CH; Lejeune, C; Marimón, I; Paz-Ares, L; Quinn, S; Rojo, F; Salazar, R; Tabernero, J; Ubbelohde, U; Zacharchuk, C, 2008)
"To evaluate the therapeutic efficacy and adverse reaction of Aidi Injection (ADI) combined with FOLFOX4 regimen for treatment of patients with advanced colorectal cancer, and controlled with those of FOLFOX4 regimen alone."2.73[Comparative study on treatment of advanced colorectal cancer by Aidi injection combined with FOLFOX4 regimen and by FOLFOX4 regimen alone]. ( Dong, L; Fu, SY; Li, HJ, 2007)
"Patients (n = 567) with metastatic colorectal cancer were randomly assigned to receive FLIRI or Lv5FU2-IRI."2.73A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. ( Albertsson, M; Balteskard, L; Berglund, A; Byström, P; Garmo, H; Glimelius, B; Heikkilä, R; Keldsen, N; Pfeiffer, P; Starkhammar, H; Sørbye, H; Tveit, K, 2008)
"The addition of cetuximab to capecitabine, oxaliplatin and bevacizumab in the first-line treatment of ACC appears to be safe and feasible."2.73A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. ( Antonini, NF; Cats, A; Creemers, GJ; Erdkamp, FL; Koopman, M; Mol, L; Punt, CJ; Rodenburg, CJ; Schrama, JG; Tol, J; Vos, AH, 2008)
"364 patients with histologically proven colorectal cancer and up to four liver metastases were randomly assigned to either six cycles of FOLFOX4 before and six cycles after surgery or to surgery alone (182 in perioperative chemotherapy group vs 182 in surgery group)."2.73Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. ( Bechstein, WO; Bethe, U; Collette, L; Finch-Jones, M; Glimelius, B; Gruenberger, T; Jaeck, D; Mirza, D; Nordlinger, B; Parks, RW; Poston, GJ; Praet, M; Primrose, JN; Rougier, P; Scheithauer, W; Schlag, PM; Sorbye, H; Van Cutsem, E; Walpole, ET, 2008)
"Patients with colorectal cancer (CRC) and liver metastases have a poor prognosis, but can benefit from perioperative chemotherapy and disease resection."2.73Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. ( Gruenberger, B; Gruenberger, T; Herbst, F; Scheithauer, W; Schueller, J; Tamandl, D; Zielinski, C, 2008)
"Individual FU dose adjustment based on pharmacokinetic monitoring resulted in significantly improved objective response rate, a trend to higher survival rate, and fewer grade 3/4 toxicities."2.73Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ( Boisdron-Celle, M; Delva, R; Dorval, E; Gamelin, E; Jacob, J; Merrouche, Y; Morel, A; Pezet, D; Piot, G; Raoul, JL, 2008)
"Gefitinib at a dose of 250 mg daily in combination with weekly 5-fluorouracil at 2,000 mg/m(2) or gefitinib at a dose of 500 mg daily with 5-fluorouracil at 1,600 mg/m(2) plus oxaliplatin has an acceptable safety profile."2.73Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO). ( Bokemeyer, C; Hartmann, JT; Höhler, T; Holtmann, M; Kröning, H; Pintoffl, JP, 2008)
"For metastatic colorectal cancer (mCRC) patients, it is recommended, as first-line treatment, chemotherapy (CT) based on doublet cytotoxic combinations of fluorouracil, leucovorin, and irinotecan (FOLFIRI) and fluorouracil, leucovorin, and oxaliplatin (FOLFOX)."2.72Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. ( Aranda Aguilar, E; Élez Fernández, E; Fernández Montes, A; García-Alfonso, P; González Astorga, B; González Flores, E; López Muñoz, AM; Salud Salvia, A; Salvà Ballabrera, F; Vera García, R, 2021)
"In patients with advanced colorectal cancer (ACRC), retrospective studies have shown that low expression levels of TS and DPD correlated with response to 5-FU."2.72Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. ( Dercksen, W; Giaccone, G; Noordhuis, P; Peters, GJ; Pinedo, HM; Smid, K; Smorenburg, CH; van Groeningen, CJ; van Riel, AM, 2006)
"Traditionally, metastatic colorectal cancer (MCRC) has been treated with intravenous (i."2.72A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. ( Gollins, S; Grieve, R; Samuel, L; Twelves, C, 2006)
"Losartan was used as a marker to assess CYP2C9 activity."2.72Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients. ( Babaoglu, MO; Boruban, C; Bozkurt, A; Coskun, U; Gunel, N; Gunes, A; Hassan, M; Rane, A; Sencan, O; Yasar, U; Zengil, H, 2006)
"Thalidomide was escalated individually to 600 mg po QD as tolerated."2.72The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; McCollum, AD; Michelini, A; Ryan, DP; Wu, B, 2006)
"Capecitabine was administered orally according to following schedule: 1/4 of dose at 8:00 a."2.72Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer. ( Gasparro, S; La Cesa, A; Santini, D; Schiavon, G; Tonini, G; Vincenzi, A; Vincenzi, B, 2006)
" This PK model could be useful in identifying predictors for PK and pharmacodynamic variability to individualize dosing."2.72Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. ( Brouwers, JR; Jansman, FG; Kho, Y; Neef, C; Prins, NH, 2006)
"Twenty-nine colorectal cancer patients with non-resectable hepatic metastases were consecutively enrolled for HAI alternating with systemic chemotherapy (HA + SC group)."2.72Hepatic arterial infusion alternating with systemic chemotherapy in patients with non-resectable hepatic metastases from colorectal cancer. ( Chang, HM; Ha, HK; Kim, HC; Kim, JC; Kim, JH; Kim, TW; Lee, KH; Lee, MG; Ryu, MH; Yu, CS, 2006)
"Patients with untreated advanced colorectal cancer were enrolled to this single arm phase II multi-center cooperative group trial of bevacizumab combined with IFL."2.72A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. ( Benson, AB; Catalano, PJ; Giantonio, BJ; Levy, DE; Meropol, NJ; O'dwyer, PJ, 2006)
" 5-FU pharmacokinetics was determined on day 2 of the first, third, and fifth cycles; type and the grade of adverse reactions were recorded on the next cycle."2.72Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer. ( Barile, C; Bononi, A; Crepaldi, G; Ferrari, M; Ferrazzi, E; Grigoletto, F; Gusella, M; Menon, D; Padrini, R; Scapoli, D; Stievano, L; Toso, S, 2006)
"Patients with metastatic colorectal cancer (MCC) usually receive FOLFOX-4, or other oxaliplatin (L-HOP)-based regimens, until the occurrence of progressive disease, with an increase in the incidence of neurotoxicity which is correlated to the cumulative dose of L-HOP."2.72FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. ( Cioppa, T; Civitelli, S; Francini, E; Francini, G; Intrivici, C; Lorenzi, M; Marsili, S; Nettuno, R; Paolelli, L; Petrioli, R; Roviello, F; Tanzini, G, 2006)
" A weekly 5 hour-administration of 5-FU (1500 mg) which was repeated for 8 weeks showed a comparable effect to a continuous infusion group with an identical total dosage of 5-FU."2.72[Prophylactic hepatic arterial infusion chemotherapy after curative surgery of colorectal liver metastases--the viewpoint from patients' quality of life]. ( Hoshino, H; Iwazawa, T; Kanoh, T; Kimura, Y; Matsushita, M; Miyazaki, S; Monden, T; Nakano, Y; Ohnishi, T; Shiozaki, K; Takemoto, H; Tono, T; Yano, H, 2006)
"Patients aged 70 or more, with stage IV colorectal cancer, ECOG performance status not worse than 2."2.71First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study. ( Daniele, B; De Maio, E; Gallo, C; Iaffaioli, RV; Manzione, L; Ottaiano, A; Perrone, F; Pignata, S; Rosati, G; Rossi, A; Tambaro, R, 2003)
"Postoperative complications were reported in 14 patients (13 occurring within 30 days after resection) and severe complications in 5 cases (including two deaths after extended resection)."2.71Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies. ( Gassel, HJ; Gog, C; Hohenberger, W; Jauch, KW; Lehmann, U; Lorenz, M; Müller, HH; Padberg, W; Proschek, D; Ridwelski, K; Staib-Sebler, E; Vestweber, KH; Zamzow, K, 2003)
"The objective of this study was to develop a population pharmacokinetic model and validate it using a Bayesian approach for predicting, a priori and a posteriori, the individual volume of distribution (V(d)) and clearance (Cl) of 5-fluorouracil (5-FU) given as short-term intravenous infusion in weekly and multiple doses."2.71A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer. ( Almenar-Cubells, D; Climente-Martí, M; Jiménez-Torres, NV; Merino-Sanjuán, M, 2003)
"Doxifluridine (5'-DFUR) is an intermediate of capecitabine approved in Europe and USA to treat metastatic colorectal cancer."2.71A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines. ( Koda, K; Kodaira, S; Miyazaki, M; Nakazato, H; Ogawa, K; Saito, N; Sarashina, H; Suwa, T; Suzuki, M; Watanabe, S, 2003)
"A prospective phase II study was performed to determine the feasibility, efficacy and safety of arterial hepatic infusion (HAI) using pirarubicin combined with intravenous chemotherapy."2.71Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer. ( Adenis, A; Baulieux, J; Colin, P; Couzigou, P; Douillard, JY; Ducreux, M; Fallik, D; Jacob, J; Mahjoubi, M; Mahjoubi, R; Rougier, P; Seitz, JF; Ychou, M, 2003)
"Thirteen patients had limited extrahepatic cancer."2.71A comparison between hepatic artery ligation and portal 5-Fu infusion versus 5-Fu intra arterial infusion for colorectal liver metastases. ( Blind, PJ; Gustavsson, B; Hafström, L; Lindnér, P; Naredi, P; Oman, M, 2003)
" A Bayesian methodology was used to assess individual pharmacokinetic parameters using the NONMEM computer program."2.71Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ( Bressolle, F; Debrigode, C; Duffour, J; Gourgou, S; Kramar, A; Pinguet, F; Ychou, M, 2003)
"Median survival in advanced colorectal cancer patients treated with 5-fluoro-uracil (5FU) and leucovorin (LV) is between 12 and 18 months."2.71[Long term survival in metastatic colorectal cancer treated with leucovorin and 5-fluoro-uracil chemotherapy]. ( André, T; Artru, P; Carola, E; de Gramont, A; Krulik, M; Louvet, C; Mabro, M; Molitor, JL; Perez, N; Tournigand, C, 2004)
"Weekly treatment at these doses is convenient and well-tolerated for the large majority of patients, and achieves DI comparable with the 5 days a month QUASAR schedule and other more toxic standard regimens."2.71Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection. ( Anthoney, DA; Crellin, AM; Messruther, J; Patel, K; Sebag-Montefiore, D; Seymour, MT, 2004)
"The purpose of our study was to determine the maximum-tolerated dose, dose-limiting toxicity, safety profile, and pharmacokinetics of the polyamine synthesis inhibitor SAM486A given in combination with 5-fluorouracil/leucovorin (5-FU/LV) in cancer patients."2.71Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer. ( Bootle, D; Bridgewater, J; Choi, L; de Bruijn, P; Eskens, FA; Ledermann, JA; Mueller, C; Planting, AS; Sklenar, I; Sparreboom, A; van Zuylen, L; Verweij, J, 2004)
"Topotecan has shown fewer side effects and higher efficacy when given as a continuous i."2.71Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer. ( Deckert, PM; Hütter, G; Keilholz, U; Szélenyi, H; Thiel, E, 2004)
"Colorectal peritoneal carcinomatosis (PC) is a frequent and very lethal event."2.71Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. ( Baton, O; Benhamou, E; Delperro, JR; Elias, D; Giovannini, M; Lasser, P; Pocard, M; Sideris, L, 2004)
"Peritoneal carcinomatosis in the absence of distant metastasis occurs in approximately 8 per cent of patients with colorectal cancer."2.71Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. ( van Ruth, S; van Tinteren, H; Verwaal, VJ; Zoetmulder, FA, 2004)
"Capecitabine is an oral fluoropyrimidine converted to fluourouracil (FU) preferentially in tumor tissue."2.71Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. ( Abbruzzese, JL; Carter, S; Hoff, PM; Lassere, Y; Pazdur, R; Polito, D; Samid, D, 2004)
" Pharmacokinetic studies were performed on cycle 1 and 2 to assess the best sequence and detect any interaction between the two drugs."2.71Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients. ( Adam, R; Bastian, G; Bismuth, H; Castaing, D; Gil-Delgado, MA; Guinet, F; Khayat, D; Rocher, MA; Spano, JP; Taillibert, S; Urien, S, 2004)
" In 10 of 19 patients who had not responded (SD, PD), three additional courses of chemotherapy were combined with sCMT (with 25 sCMT applications)."2.71Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study. ( Ahlers, O; Deja, M; Dräger, J; Felix, R; Hildebrandt, B; Kerner, T; Löffel, J; Riess, H; Stroszczynski, C; Wust, P, 2004)
"All patients had advanced/metastatic colorectal cancer."2.71Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin. ( Aslanis, V; Chatelut, E; Davis, T; Joel, SP; Locke, K; Papamichael, D; Richards, F; Seymour, MT; Slevin, ML, 2004)
" Pharmacokinetic analyses for both BAY 12-9566 and 5-fluorouracil were performed."2.71An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin. ( Agarwal, V; Chouinard, E; Goel, R; Hirte, H; Huan, S; Humphrey, R; Lathia, C; Matthews, S; Roach, J; Seymour, L; Stafford, S; Stewart, DJ; Walsh, W; Waterfield, B, 2005)
"As the number of active drugs for colorectal cancer increases, we continually revisit the question of how best to integrate them."2.71Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC). ( Babic, DR; Grbic, B; Jelic, SB; Matijasevic, MM; Popov, IP, 2004)
"Forty-seven patients with resectable metastases of colorectal cancer were prospectively enrolled onto this study."2.71Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. ( André, T; Artru, P; de Gramont, A; Gayet, B; Goebel, FM; Hebbar, M; Louvet, C; Parc, R; Paye, F; Perez, N; Taïeb, J; Tournigand, C, 2005)
"Among 13 patients with advanced colorectal cancer, 10 required dose reductions of irinotecan and 5-FU because of dehydration, diarrhoea, and neutropenia, seven of whom required hospitalisation, three with neutropenic fever."2.71A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. ( Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML, 2005)
"Patients (n=38) with colorectal cancer received IFN-alpha 5 MU/m(2) SC on days 1-6; on days 2-6, LV 200 mg/m(2) IV was given with 5-FU at initial doses of 370-425 mg/m(2)/h."2.71A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel. ( Ernst, A; Grem, JL; Grogan, L; Grollman, F; Ismail, AS; Kao, V; Kirsch, IR; Parr, A; Quinn, MG; Wright, MA, 2005)
" This study was performed to determine the efficacy and safety of irinotecan (CPT-11) in combination with fluorouracil (FU) administered as a 48-hour continuous infusion twice a month in elderly patients."2.71Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study. ( Abad, A; Antón, A; Aranda, E; Carrato, A; Díaz-Rubio, E; Gil, S; Maestu, I; Marcuello, E; Masutti, B; Maurel, J; Navarro, M; Sastre, J; Valladares, M; Vicent, JM, 2005)
"To explore the efficacy and safety of CPT-11 combined with fluoropyrimidine in treatment for advanced or metastatic colorectal carcinoma."2.71[Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma]. ( Wu, WQ; Yu, BM, 2005)
"Isolated hepatic metastases of colorectal cancer constitute a frequent and serious therapeutic problem that has led to the evaluation of hepatic arterial infusion (HAI) of different drugs."2.71Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. ( Boige, V; Delperro, JR; Ducreux, M; Elias, D; Gamelin, E; Husseini, F; Jacob, JH; Laplanche, A; Lasser, P; Luboinski, M; Quenet, F; Viret, F; Ychou, M, 2005)
" We therefore reanalyzed a pharmacokinetic study in order to develop a limited sampling schedule."2.71Pharmacokinetics of bolus 5-fluorouracil: relationship between dose, plasma concentrations, area-under-the-curve and toxicity. ( Codacci-Pisanelli, G; Lankelma, J; Peters, GJ; Pinedo, HM; Van Gennip, AH; Van Groeningen, CJ; Van Kuilenburg, AB, 2005)
"In patients with metastatic colorectal cancer that have previously received treatment with 5-FU based chemotherapy, treatment with SIR-spheres has demonstrated encouraging activity."2.71A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. ( Bailey, W; Dowling, R; Gibbs, P; Liechtenstein, M; Lim, L; Little, A; Shapiro, JD; Smith, D; Yip, D, 2005)
" Studies of bimonthly regimens of high-dose leucovorin (LV) and 5-fluorouracil (5-FU) by continuous infusion combined with oxaliplatin (L-OHP) have shown encouraging response rates in patients not responding to a bimonthly LV/5-FU regimen."2.70Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. ( Atanackovic, D; Corovic, A; Gruber, Y; Hegewisch-Becker, S; Hossfeld, DK; Nierhaus, A; Pichlmeier, U, 2002)
"Capecitabine (Xeloda; CAP) is a recently developed oral antineoplastic prodrug of 5-fluorouracil (5-FU) with enhanced tumor selectivity."2.70Metabolism of capecitabine, an oral fluorouracil prodrug: (19)F NMR studies in animal models and human urine. ( Desmoulin, F; Gilard, V; Malet-Martino, M; Martino, R, 2002)
"Forty-two gastric cancer patients at T(3)II-T(4)III( B) stages and 96 patients with colorectal cancer at B to D stages admitted from January 1996 to October 1998 were randomly divided into control group (group I, 65 cases) receiving intraperitoneal thermochemotherapy, and group II (73 cases) receiving both intraperitoneal thermochemotherapy and intraperitoneal IL-2 immunotherapy."2.70Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection. ( Fu, QG; Guo, RX; Meng, FD; Shen, XD, 2002)
"Most colorectal cancers metastatic to the liver are resistant to chemotherapy and are not amenable to surgical resection."2.70Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil. ( Bilchik, AJ; Chawla, SP; Chung, MH; Foshag, LJ; Ramming, KP; Rose, DM; Stern, SS; Wood, TF, 2001)
" A phase II clinical trial of this combination using a continuous dosing schedule was carried out in patients with metastatic colorectal cancer."2.70Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer. ( Benson, AB; Catalano, P; Cornfeld, MJ; Graham, DL; Huang, J; Marsh, JC; O'Dwyer, PJ, 2002)
" We investigated the therapeutic and adverse drug reaction of intensive chemotherapy using cisplatin (CDDP), 5-FU and dl-leucovorin (LV) (PFL-therapy), which may be producing dual biochemical modulation effect of 5-FU for advanced colorectal carcinoma."2.70Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer. ( Arai, T; Fukahara, T; Ishikawa, T; Iwai, T; Kuwabara, H; Maruyama, S; Murase, N; Okabe, S; Ootsukasa, S; Tanami, H; Udagawa, M; Yamashita, H, 2002)
"Patients with advanced colorectal cancer who had received prior therapy were eligible for the trial."2.70Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer. ( Lange, LM; Shields, AF; Zalupski, MM, 2001)
" Therefore, we performed a study of PVI 5FU in 61 patients with advanced colorectal cancer to assess the variability (inter- and intra-subject) in 5FU Css associated with PVI 5FU (300 mg m(-2)day(-1)) and to attempt to correlate pharmacodynamic end-points (anti-tumour activity, toxicity) with 5FU Css as a prelude to 'exposure-guided' 5FU administration."2.705-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer. ( Aird, R; Bowman, A; Jodrell, DI; Knowles, G; McLean, C; Stewart, M; Wall, L, 2001)
"Irinotecan (CPT-11) is an active drug in the treatment of patients with advanced colorectal carcinoma."2.70Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study. ( Aschelter, AM; Comis, S; D'Attino, RM; Dogliotti, L; Garufi, C; Nisticó, C; Perrone, M; Pugliese, P; Tampellini, M; Terzoli, E, 2001)
"Treatment with fluorouracil (with or without folinic acid or levamisole) at outpatient clinic or at home."2.70Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial. ( Borras, JM; Espinas, JA; Germa, JR; Martinez, M; Mendez, E; Navarro, M; Ponton, JL; Sanchez-Hernandez, A, 2001)
" The effect of food on the oral bioavailability of UFT (2 x 100 mg capsules; dose in terms of FT) and leucovorin (2 x 15 mg tablets) was evaluated in a single-dose, randomized, two-way crossover study."2.70Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients. ( Alberts, D; Brooks, D; Damle, B; Ferreira, I; Kaul, S; Pazdur, R; Ravandi, F; Sonnichsen, D; Stewart, D, 2001)
"164 patients with advanced colorectal cancer were enrolled in this randomised, placebo-controlled, double-blind, multicenter phase III study."2.70Double-blind randomised placebo-controlled phase III study of an E. coli extract plus 5-fluorouracil versus 5-fluorouracil in patients with advanced colorectal cancer. ( Clemm, C; Clevert, HD; Häring, B; Hockertz, S; Kalousek, MB; Kruse, A; Schneider, B; Thumann, A; Unger, C; Weber, B, 2001)
" The severity of adverse events was associated with increased 5-FU/5-FDHU AUC ratio and reduced 5-FU CL, while 5-FU and 5-FDHU pharmacokinetics were not related to DPD activity."2.70Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients. ( Allegrini, G; Bocci, G; Cionini, L; Conte, PF; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G; Mini, E; Vannozzi, F, 2001)
"Gemcitabine was administered as a 30-minute intravenous infusion weekly for 3 weeks followed by a 1-week break."2.70Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. ( Bertucci, D; Kindler, HL; Ratain, MJ; Schilsky, RL; Vogelzang, NJ, 2002)
"In palliative first-line treatment of colorectal cancer, the secondary resection of distant metastases after downstaging has constantly gained in importance."2.70Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. ( Baum, U; Becker, D; Bernatik, T; Brueckl, WM; Hahn, EG; Hänsler, J; Hohenberger, W; Köckerling, F; Martus, P; Ott, R; Reck, T; Riedel, C; Schneider, T; Wein, A, 2001)
"Trimetrexate (TMTX) is a biochemical modulator of 5-fluorouracil (5-FU) and leucovorin (LV)."2.70Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study. ( Croles, JJ; Douma, J; Hammershaimb, L; Keizer, HJ; Lochs, H; Muller, EW; Punt, CJ; Schüller, J; Skovsgaard, T; Ten Napel, CH; Zhang, J, 2002)
"Furthermore, presence of lung metastases, a primary rectal cancer and presence of lymph node metastases all predicted a better outcome in the multivariate setting."2.70Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. ( Aranda, E; Baron, B; Blijham, G; Cunningham, D; Di Costanzo, F; Glimelius, B; Hecker, H; Köhne, CH; Micheel, S; Palmer, M; Pignatti, F; Rougier, P; Scheithauer, W; Schöffski, P; Wils, J, 2002)
"Patients with one to three potentially resectable metastases were randomized preoperatively to receive no further therapy (control arm, 56 patients) or postoperative hepatic arterial floxuridine combined with intravenous continuous-infusion fluorouracil (chemotherapy arm, 53 patients)."2.70Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. ( Adak, S; Benson, AB; Gray, B; Kemeny, MM; Lipsitz, S; Macdonald, JS; O'Dwyer, PJ; Sigurdson, ER; Smith, T, 2002)
" As a result, both the host tolerance and antitumor efficacy of 5-fluorouracil (5-FU) and oxaliplatin (L-OHP), like 30 other anticancer drugs, vary largely according to the dosing time in laboratory rodents."2.70Chronotherapy of colorectal cancer. ( Giacchetti, S, 2002)
" Eight episodes of grade 3 or 4 stomatitis were observed, and were responsible for dosage modifications of MTX and 5-FU."2.69Double modulation of 5-fluorouracil by methotrexate and high-dose L-leucovorin in advanced colorectal cancer. ( Acuña, JM; Acuña, LA; Amato, S; Barbieri, MR; Cuevas, MA; DeLena, M; Dominguez, ME; Lacava, JA; Langhi, MJ; Leone, BA; Lorusso, V; Machiavelli, MR; Ortiz, EH; Perez, JE; Rodriguez, R; Romero, AO; Sabatini, CL; Salvadori, MA; Vallejo, CT, 1998)
"Diarrhea was experienced by six of 10 patients, and only three patients were able to receive six weekly chemotherapy treatments without dose reduction or delay."2.69Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. ( Blumenson, LE; Creaven, PJ; Meropol, NJ, 1998)
"Capecitabine (Ro 09-1978) is a novel oral fluoropyrimidine carbamate that was rationally designed to generate 5-fluorouracil (5-FU) selectively in tumors."2.69Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. ( Allman, D; Banken, L; Cassidy, J; Dirix, L; Osterwalder, B; Reigner, B; Roos, B; Twelves, C; Utoh, M; Verweij, J; Weidekamm, E, 1998)
"Only patients with colorectal cancer who had evidence of unresectable metastases confined to the liver were eligible."2.69Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. ( Bernath, AM; Bolton, JS; Burch, P; Colon-Otero, G; Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Nagorney, DM; O'Connell, MJ; Schroeder, G, 1998)
"The 24 patients with advanced colorectal cancer were divided into 2 groups randomly and both were treated with 5-FU 250 mg/day by continuous hepatic arterial infusion for three weeks."2.69[Method of preventing hepatic artery occlusion during continuous intrahepatic arterial infusion chemotherapy of 5-FU]. ( Ishida, H; Ishikawa, K; Itoh, I; Iwase, H; Kameya, T; Makuuchi, H; Mukai, M; Ohtaki, M; Sadahiro, S; Suzuki, T; Tajima, T; Tokunaga, N; Yasuda, S, 1998)
"203 patients with measurable advanced colorectal cancer were randomised to bolus 5-FU either as an injection for 2-4 min or as a short-term infusion lasting 10-20 min."2.69Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. ( Berglund, A; Brunsgaard, N; Gadeberg, C; Glimelius, B; Graf, W; Gustavsson, B; Hansen, P; Jakobsen, A; Kjaer, M; Lindberg, B; Lorentz, T; Påhlman, L; Sandberg, E; Sellström, H, 1998)
" Four episodes of grade 2 stomatitis were observed, causing dosage modifications."2.69Biomodulation with sequential intravenous IFN-alpha2b and 5-fluorouracil as second-line treatment in patients with advanced colorectal cancer. ( Amato, S; Barbieri, MR; Domínguez, ME; Lacava, JA; Langhi, MJ; Leone, BA; Machiavelli, MR; Marrone, N; Ortiz, EH; Pérez, JE; Rodríguez, R; Romero Acuña, JM; Romero Acuña, LA; Romero, AO; Vallejo, CT, 1998)
"The cases with esophageal cancer, stomach cancer, pancreatic cancer, hepatocellular carcinoma or colonic cancer co-existing with their inoperable lesion(s) were considered in this chemotherapy."2.69[Biochemical modulation of 5-FU--effect of low dose CDDP]. ( Denno, R; Hirata, K; Kimura, H; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Tsuji, A; Yamamitsu, S, 1999)
"The potential for site of metastasis as a predictive variable for response to chemotherapy and survival was examined, in addition to other clinical parameters."2.69Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma. ( Assersohn, L; Benepal, T; Cunningham, D; Norman, A; Oates, J; Ross, PJ, 1999)
"Nonresectable colorectal cancer metastases in the liver respond to chemotherapy in 20-25% only."2.69Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. ( Bangard, M; Bangard, N; Bender, H; Biersack, HJ; Metten, N; Mezger, J; Schomburg, A, 1999)
" The levels of free platin decreased triphasically, with a mean terminal half-life of 27."2.69Oxaliplatin pharmacokinetics during a four-hour infusion. ( Böttger, B; Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Schleyer, E, 1999)
"All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)."2.69Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999)
"A total of 99 patients with advanced colorectal cancer were treated with carboplatin (80 mg/m2, day 1-7), 5-FU (750 mg/m2, day 1-5), leucovorin (100 mg/m2, day 1-5) every 4 weeks."2.69The role of stable disease in objective response assessment and its impact on survival in advanced colorectal cancer: is "stable disease" a homogenous response category? ( Jelić, S; Nikolić-Tomasević, Z; Popov, I; Radosavljević, D, 1999)
"16 patients with advanced colorectal cancer were treated with 650 mg/m2/d fluorouracil as 5 day continuous infusion and randomized to receive either 20 mg/m2 or 100 mg/m2 calcium folinate as short infusion twice daily."2.69Pharmacokinetic and pharmacodynamic comparison of two doses of calcium folinate combined with continuous fluorouracil infusion in patients with advanced colorectal cancer. ( Jaehde, U; Kreuser, ED; Schunack, W; Streit, M; Stremetzne, S, 1999)
"Twelve colorectal cancer patients with small volume disease metastatic to the liver (all lesions < or = 2."2.69Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study. ( Angerstein, C; Becker, H; Becker, W; Béhé, M; Behr, TM; Blumenthal, RD; Fayyazi, A; Goldenberg, DM; Hiddemann, W; Liersch, T; Ringe, B; Salib, AL; Sharkey, RM; Wörmann, B, 1999)
"Twenty-two colorectal cancer patients (infusion group) in Dukes' C stage were given hepatic arterial infusion of 5-FU (500 mg/body for 1 hr per week, repeated 50 times) and peroral UFT-E (2."2.69[Clinical trial of prophylactic hepatic arterial chemotherapy for liver metastases in patients with Dukes' C colorectal cancer]. ( Fujioka, M; Idezuki, Y; Inokuma, S; Ishida, H; Kamano, T; Kishi, T; Kondo, K; Matsumoto, Y; Miura, T; Murata, N; Nakada, H; Odaka, A; Shimomura, K; Suzuki, T; Takeuchi, I; Yamada, H, 1999)
" Also, groups receiving a dosage of 15 g or greater of 5-FU showed prolonged survival rates."2.69[Cooperative study of intraarterial preventive chemotherapy after resection of hepatic metastasis from colorectal cancer]. ( Hamada, H; Ishizaki, A; Itou, Y; Kassai, S; Katsuki, Y; Kimura, J; Kino, S; Kusano, M; Nakasaki, H; Suzuki, K; Suzuki, S; Tsuji, Y; Tsujita, K; Watanabe, M; Yamamoto, Y, 1999)
" To predict 5-FU catabolic deficiencies and toxic side effects, we conducted a prospective study of patients treated for advanced colorectal cancer by high-dose 5-FU."2.69Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. ( Boisdron-Celle, M; Delva, R; Gamelin, E; Genevieve, F; Guérin-Meyer, V; Ifrah, N; Larra, F; Lortholary, A; Robert, J, 1999)
"Recent advances in the management of colorectal cancer have improved the quality of life and the survival of patients treated with chemotherapy."2.69[Bimonthly 5-fluorouracil in elderly patients with metastatic colorectal cancer. Study of 50 patients]. ( Carola, E; de Gramont, A; Gilles-Amar, V; Krulik, M; Louvet, C; Mabro, M; Maindrault-Goebel, F, 1999)
"Six of 40 patients with metastatic colorectal cancer obtained an objective response (15%; 95% confidence interval, 6-30%)."2.69Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer. ( Avallone, A; Blackie, R; Budillon, A; Caponigro, F; Cartenì, G; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lucia, L; De Vita, F; Gravina, A; McLeod, H; Morsman, J, 1999)
" Four patients who suffered from PMC-related side effects of grade 1-2 wanted to decrease their dosage of UFT and/or 5-FU."2.69[Usefulness of pharmacokinetic modulating chemotherapy (PMC) for the postoperative adjuvant therapy of colorectal carcinoma: a preliminary report]. ( Izumi, S; Nakagawa, J; Nishihara, M; Onoda, Y; Shimizu, N; Shiota, K; Suzuka, I, 1999)
"Five patients, two with gastric cancer and three with colorectal cancer, who had metastatic tumor nodules in their livers were studied dynamically in vivo after 5-FU injection."2.69Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy. ( Presant, CA; Shani, J; Waluch, V; Weitz, I; Wiseman, CL; Wolf, W, 2000)
"In primary colorectal tumors, the concentration of 5-FU was on average 3."2.69Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. ( Banken, L; Cassidy, J; Dumont, E; Durston, S; Mori, K; Reigner, B; Roos, B; Schüller, J; Utoh, M; Weidekamm, E, 2000)
"Pharmacokinetic modulating chemotherapy (PMC) is a new therapeutic concept in combination with continuous 5-fluorouracil (5-FU) infusion and UFT."2.69Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. ( Kusunoki, M; Noda, M; Yamamura, T; Yanagi, H; Yoshikawa, R, 2000)
"A pharmacokinetic population approach was used to analyze the data from 21 patients with colorectal cancer."2.69Dose and time dependencies of 5-fluorouracil pharmacokinetics. ( Boisdron-Celle, M; Bugat, R; Canal, P; Chatelut, E; Erdociain, E; Féty-Deporte, R; Gamelin, E; Guimbaud, R; Lafont, T; McLeod, HL; Terret, C, 2000)
"Out of 213 consecutive cases of colorectal cancer patients, 39 patients had liver metastasis (31 synchronous metastases and 8 metachronous metastases)."2.68[Experience in intra-hepatic-arterial chemotherapy and hepatic resection for metastatic colorectal cancer]. ( Ariga, T; Kinoshita, H; Maruyama, T; Ooshima, I; Ozaki, M; Shimada, H; Shouko, T; Takeda, A; Yoshimura, S, 1995)
"Cimetidine has demonstrated a survival benefit in a randomized trial as adjuvant therapy for gastric cancer."2.68A randomized trial of cimetidine with 5-fluorouracil and folinic acid in metastatic colorectal cancer. ( Adams, WJ; Clingan, PR; Legge, J; Links, M; Morris, DL; O'Baugh, J; Phadke, K; Ross, WB, 1995)
" As a result, the extent of toxicity of cancer chemotherapy varies by 50% or more according to dosing time in mice or rats."2.68[Chrono-chemotherapy and dose intensity]. ( Lévi, F, 1995)
"These findings suggest that colorectal cancer with aneuploidy and a DI above 1."2.68Prophylactic portal infusion chemotherapy as adjuvant therapy for the prevention of metachronous liver metastasis in colorectal cancer. ( Hoshino, K; Kaibara, N; Kimura, O; Kurayoshi, K; Makino, M; Sugezawa, A, 1995)
" Dosing decisions in older patients are difficult and must integrate assessments of organ function, comorbidities, overall physical status, and goals of treatment, in an effort to ensure the best possible outcome for these patients."2.68Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. ( Arcangeli, G; Douglass, HO; Driscoll, DL; Meropol, NJ; Petrelli, NJ; Stein, BN, 1995)
"There were 51 patients with colorectal cancer and 130 patients with appendiceal cancer."2.68Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. ( Jablonski, KA; Sugarbaker, PH, 1995)
"Site of metastases included liver (n = 16), lung (n = 7), abdomen (n = 2), pelvic recurrences (n = 2), cutaneous (n = 1)."2.68Cytarabine and cisplatin as salvage therapy in patients with metastatic colorectal cancer who failed 5-fluorouracil + folinic acid regimen. French Northern Oncology Group. ( Adenis, A; Bonneterre, J; Carlier, D; Darloy, F; Demaille, A; Pion, JM, 1995)
"Thirty-five patients with metastatic colorectal cancer were treated; 15 (41%) had received previous therapy, 22 (63%) had W."2.68A phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer. ( Adam, R; Bismuth, H; Caussanel, JP; Jasmin, C; Lévi, F; Metzger, G; Misset, JL; Smolensky, M; Soussan, A, 1995)
"The purpose of this study was to evaluate a potential pharmacokinetic (PK) interaction between fluorouracil (5-FU) and the biomodulating agent interferon alpha (IFN-alpha) in patients with metastatic colorectal carcinoma."2.68Pharmacokinetic interaction of 5-fluorouracil and interferon alpha-2b with or without folinic acid. ( b1p6uller, J; Czejka, M, 1995)
" Patients who received Tomudex spent a substantially shorter time in hospital for dosing and had significantly lower rates of grade 3 and 4 toxicities such as leucopenia and mucositis."2.68'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group. ( Cunningham, D; Harper, P; Kerr, D; Olver, I; Perez-Manga, G; Rath, U; Seitz, JF; Svensson, C; Van Cutsem, E; Zalcberg, JR, 1995)
" These results show that there is no pharmacokinetic advantage to the use of 6S-LV rather than 6R,S-LV as a modulator of 5-FU."2.68A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma. ( Berghorn, E; Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, YM, 1995)
"Metastatic colorectal cancer is generally incurable."2.68Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer. ( Abbruzzese, JL; Brown, BW; Gross, HM; Jones, DV; Levin, B; Levy, LB; Pendergrass, KB; Pugh, RP; Wade, JL; Winn, RJ, 1995)
" The dosage was as follows: group A received FA i."2.68Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. ( Archimandritis, A; Bacoyiannis, C; Giannopoulos, A; Kalahanis, N; Karatzas, G; Kosmas, C; Kosmidis, P; Papachristodoulou, A; Papadimas, V; Polyzos, A; Sakelaropoulos, N; Tsavaris, N, 1996)
"To determine the most effective dose of leucovorin (folinic acid [FA]) within a weekly bolus fluorouracil (FU) schedule, we conducted a randomized multicenter trial to compare therapeutic effects and toxicity of high-dose FA versus low-dose FA combined with FU at equal doses in both treatment groups."2.68Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. ( Bernhard, G; Bernhard, H; Heike, M; Jäger, E; Klein, O; Knuth, A; Lautz, D; Meyer zum Büschenfelde, KH; Michaelis, J, 1996)
"5-Fluorouracil (5-FU) was measured in hair samples to assess patient exposure to 5-FU, and its potential usefulness is discussed as an index of compliance with postoperative adjuvant chemotherapy."2.68Measurement of 5-fluorouracil in scalp hair: a possible index of patient compliance with oral adjuvant chemotherapy. ( Fujii, M; Hamano, K; Kato, T; Kodaira, S; Kotake, K; Masuike, T; Nakashima, M; Oka, H; Uematsu, T; Yasutomi, M, 1996)
"Sixty-eight patients with advanced colorectal cancer received every 2 weeks hydroxyurea per os 1."2.68Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. ( Beerblock, K; Bennamoun, M; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Mal, F; Moreau, S; Soubrane, D; Varette, C; Zylberait, D, 1996)
"Forty-six patients with colorectal cancer were studied for the effects of intraportal chemotherapy in terms of the administered dose of 5-FU."2.68[The effect of intraportal chemotherapy in terms of administered dose of 5-FU]. ( Akaishi, O; Hanai, A; Kikuchi, K; Matsuzaki, H; Miyake, H; Oikawa, H; Ozasa, T; Seo, K; Tanaka, K; Tsukikawa, S; Yamaguchi, S; Yamamura, T, 1996)
"Ukrain is a new effective drug in the therapy of colorectal cancer."2.68Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer. ( Korsh, OB; Kravchenco, OB; Susak, YM; Yaremchuk, OY; Yatsyk, IM; Zemskov, VS, 1996)
"Residual metastases were surgically removed in 13 patients (26%)."2.68Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. ( Adam, R; Bertheault-Cvitkovic, F; Bismuth, H; Brienza, S; Brummer, PD; Ithzaki, M; Jami, A; Kunstlinger, F; Lévi, F; Misset, JL, 1996)
"Grade 4 leukopenia was observed in 1 case and grade 3 to 4 thrombocytopenia was observed in two cases, respectively."2.68The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD). ( Antón-Torres, A; Aranda, E; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Massutí, T, 1996)
"Chemotherapy pretreated patients with colorectal cancer seem to have a substantial survival benefit with this salvage protocol."2.68High-dose infusional 5-fluorouracil combination therapy of metastatic gastric and colorectal cancer. ( Hausamen, TU; Loeffler, TM, 1996)
"Colorectal carcinoma is one of the most common neoplasms in Western societies, being second only to lung cancer as a cause of death from malignancy."2.68First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer. ( Beuzeboc, P; Deffontaines, D; Diéras, V; Dorval, T; Garcia-Giralt, E; Jouve, M; Palangie, T; Pouillart, P; Scholl, S, 1996)
"These studies demonstrate that the present dose and schedule of AZT in combination with 5-FU + LV has significant activity in metastatic colorectal cancer and that the combination of 5-FU + LV with AZT increases the amount of DNA damage."2.68Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand break ( Allegrini, G; Andreuccetti, M; Antonuzzo, A; Brunetti, I; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Lencioni, M; Malvaldi, G; Pfanner, E, 1997)
"Doxifluridine (5-dFUR) is a fluoropyrimidine derivative, which is preferentially converted to 5-fluorouracil (5-FU) within tumour tissues."2.68Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens. ( Artale, S; Bajetta, E; Bignami, P; Buzzoni, R; Del Vecchio, M; Di Bartolomeo, M; Magnani, E; Somma, L; Zunino, F, 1997)
"The response rate was 56."2.68[Current status of low-dose CDDP. 5-FU therapy for solid malignant tumors--nationwide questionnaire survey]. ( Aiba, K; Araki, H; Chung, Y; Hirata, K; Saji, S; Sasaki, K; Shirasaka, T; Sowa, M; Tanaka, M; Toge, T; Wada, H; Yamamitsu, S; Yasumoto, K, 1997)
"5-Fluorouracil (5-FU) was delivered via a surgically placed hepatic artery catheter."2.68A phase II study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal liver metastases. ( Buckles, J; Budden, J; Gallagher, HJ; Howell, JD; Kerr, DJ; Ledermann, JA; McArdle, CS; Taylor, I, 1997)
"Two hundred patients with advanced colorectal cancer received PVI 5-FU 300 mg/m2/day for a maximum of 24 weeks and were randomised to PVI 5-FU alone or PVI 5-FU + MMC 10 mg/m2 (7 mg/m2 from June 1995) 6 weekly for 4 courses."2.68A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. ( Cunningham, D; Iveson, T; Massey, A; Norman, A; Oates, J; Padhani, A; Popescu, R; Prendiville, J; Ross, P; Watson, M; Webb, A, 1997)
"Trimetrexate (TMTX) is a dihydrofolate reductase inhibitor, which, like methotrexate (MTX), has been shown to potentiate fluorouracil (FU) cytotoxicity by increasing phosphoribosylpyrophosphate (PRPP) levels."2.67Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. ( André, M; Bertino, JR; Conti, JA; Goker, E; Kemeny, N; Ragusa, K; Seiter, K; Tong, W, 1994)
" There was an improvement in survival with increased 5-FU dosage (500 mg m-2) [relative hazard (RH) = 0."2.67Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK? ( Canney, PA; Cassidy, J; Jodrell, DI; Kaye, SB; Murray, LS; Reed, NS, 1994)
" Drug concentrations in both peritoneal and plasma compartments followed a first-order model with similar half-life value of 1."2.67Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma. ( Dobbie, JW; el Eini, DI; Kerr, DJ; McArdle, CS; O'Gorman, P; Vinké, BJ; Warren, H; Watson, D; Wotherspoon, HA, 1994)
"Second-line therapy of patients with colorectal cancer metastatic to the liver is unsatisfactory."2.67Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. ( Bakal, CW; Cynamon, J; Haynes, H; Kaleya, R; Martinelli, DJ; Rozenblit, A; Wadler, S; Wiernik, PH, 1994)
"Eight patients with advanced colorectal cancer received 5-FU (initial dose of 500 mg/m2/day) and FA (20 mg/m2/day) as a continuous intravenous infusion over 5 consecutive days."2.67Chronotherapy with 5-fluorouracil and folinic acid in advanced colorectal carcinoma. Results of a chronopharmacologic phase I trial. ( Adler, S; Eibl-Eibesfeldt, B; Emmerich, B; Hallek, M; Lang, S; Langenmayer, I; Rump, W, 1994)
"Sixteen patients with metastatic colorectal cancer have been treated with a regimen involving an 120 h continuous infusion of rIL-2, 18 x 10(6) iu m-2 day followed by three injections of 5FU 600 mg m-2 at weekly intervals."2.67A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer. ( Franks, CR; Hamblin, TJ; Oskam, R; Palmer, P; Sadullah, S; Stevenson, J; Williamson, P, 1993)
" The pharmacokinetic interaction between alpha-IF and LV may play a role in the activity of this regimen."2.67Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin. ( Buter, J; de Vries, EG; Mulder, NH; Roenhorst, HW; Sinnige, HA; Sleijfer, DT; Uges, DR; Verschueren, RC; Willemse, PH, 1993)
"In patients with colorectal cancer, we have done a multicentre, randomised controlled trial comparing five-year survival after intraportal infusion of fluorouracil (1 g per day) plus heparin (10,000 U per day) (130 patients) or heparin alone (123) during curative resection and for 7 days thereafter, or after resection alone (145)."2.67Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. ( Fielding, LP; Fry, JS; Grace, RH; Hittinger, R, 1992)
"One patient with metastatic colon cancer who received 5-FU at 540 mg/m2 achieved a partial response."2.67Phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte-macrophage colony-stimulating factor. ( Moore, DF; Pazdur, R, 1992)
"Twenty-nine patients with advanced cancer (75% colon or pancreatic cancer) were treated."2.67A phase I trial of fluorouracil, leucovorin, and recombinant interferon alpha-2b in patients with advanced malignancy. ( Alberts, DS; Hersh, EM; Marcus, SG; Modiano, MR; Taylor, CW; Woodson, ME, 1992)
"Seventeen patients with colorectal cancer who failed local chemotherapy received 5-FU as a 4-hour infusion, preceded by a bolus of FA and IFN."2.67A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma. ( Boese-Landgraf, J; Boewer, C; Hilgenfeld, RU; Hoksch, B; Knauf, WU; Kreuser, ED; Matthias, M; Oldenkott, B; Schalhorn, A; Zeitz, M, 1992)
"In a prospective randomized multicentre trial 139 patients with metastatic colorectal carcinoma (70 men, 69 women; age 35-81 years) were given palliative treatment with fluorouracil (400 mg/m2 daily for 5 days) alone or combined with folic acid (100 mg/m2 before each dose of fluorouracil)."2.67[Fluorouracil as monotherapy or combined with folinic acid in the treatment of metastasizing colorectal carcinoma]. ( Aulbert, E; Burghardt, F; Hausamen, TU; Korsten, FW; Lindemann, W; Löffler, TM; Planker, M; Reis, HE; Schröder, M; Strohmeyer, G, 1992)
"The possibility of a deleterious effect of the unnatural stereoisomer on the modulation of 5-FU led us to carry out a phase I-II study of 5-FU combined with the (6S)-stereoisomer of folinic acid given in high doses for treatment of patients with advanced colorectal carcinoma."2.67Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study. ( Goldschmidt, E; Grison, X; Guillot, T; Hannoun, L; Lotz, JP; Machover, D; Marquet, J; Metzger, G; Richaud, J; Zittoun, J, 1992)
" in 15' x 5 days) every 4 weeks (Arm A), or to 5-FU alone at the same dosage (Arm B)."2.67Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer). ( Aitini, E; Barni, S; Beretta, A; Beretta, GD; Cesana, B; Comella, G; Cozzaglio, L; Cristoni, M; Labianca, R; Pancera, G, 1991)
"Phase II studies in metastatic colorectal cancer in 345 patients have demonstrated an average response rate of 36% (range 15-59%) and a prospective randomized study performed by the Mid-Atlantic Oncology Program (MAOP) has confirmed a higher response rate with 5FU infusion compared with a bolus schedule."2.675-Fluorouracil by protracted venous infusion: a review of recent clinical studies. ( Hansen, RM, 1991)
"Ninety-six patients with colorectal cancer (stage B2-C) were randomized to the control arm or to receive adjuvant chemotherapy with folinic acid, FU and MMC."2.675-Fluorouracil (FU) with folinic acid (FA) and mitomycin C (MMC) in the adjuvant treatment of colorectal carcinoma. Part I. Evaluation of toxicity. ( Astone, A; Barone, C; Cassano, A; Coco, C; Franchi, F; Netri, G; Pozzo, C; Ratto, C; Ricevuto, E; Sofo, L, 1991)
"After curative resection of colorectal cancer, immediate short-term postoperative intraportal adjuvant chemotherapy reduces the relative risk of recurrence and death in the non-transfused patient significantly, when compared to transfused patients without chemotherapy."2.67[Following curative resection of colorectal cancer, portal chemotherapy especially benefits non-transfused patients]. ( Berres, M; Harder, F; Jäggi, P; Laffer, U; Metzger, U, 1990)
"In 28 patients with advanced colorectal cancer, in progression under FA-5FU, we continued treatment with FA-5FU plus DIP."2.67Multimodal biochemical modulation of 5-fluorouracil activity in advanced colorectal cancer with allopurinol, folinic acid and dipyridamol. ( Antonopoulos, A; Bacoyannis, C; Beldecos, D; Karvounis, N; Kosmidis, P; Mylonacis, N; Tsavaris, N; Valilis, P; Zamanis, N; Zinelis, A, 1990)
"5-Fluorouracil (5-FU) has been the treatment of choice for colorectal carcinoma with an overall response rate of about 20%."2.67A phase I-II study on the toxicity and therapeutic efficacy of 5-fluorouracil in combination with leucovorin and cisplatinum in patients with advanced colorectal carcinoma. ( Borsellino, N; Gebbia, N; Gebbia, V; Palmeri, S; Rausa, L; Russo, A; Rustum, Y, 1990)
"Among 13 patients with colorectal cancer, 4 partial responses were observed."2.67Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination. ( Comis, RL; Cornfeld, MJ; O'Dwyer, PJ; Peter, R, 1990)
"Thirty one gastric cancer pts."2.67[High-dose leucovorin and 5-fluorouracil in advanced gastric and colorectal cancer. High-Dose Leucovorin and 5-FU Study Group]. ( Akazawa, S; Matsuoka, T; Mukaiyama, T; Ogawa, M; Ota, K; Sakai, Y; Sakata, Y; Sasaki, T; Wakui, A; Yoshino, M, 1990)
"Metastatic colorectal cancer (mCRC) is one of the most common and deadly cancers worldwide."2.66Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis. ( Dong, Y; Fan, Q; Lv, W; Wang, J; Xiang, Z; Xu, Y, 2020)
" In addition, grade 3 and 4 adverse events are found to be higher in panitumumab group than those in control group (RR = 1."2.66The efficacy and safety of panitumumab supplementation for colorectal cancer: A meta-analysis of randomized controlled studies. ( Chen, S; Chen, X; Tan, C; Wang, C, 2020)
"Pharmacological treatment of colorectal carcinoma currently proceeds through the administration of a combination of different chemotherapeutic agents."2.66The p38 MAPK Signaling Activation in Colorectal Cancer upon Therapeutic Treatments. ( Bossi, G; Fratantonio, D; Piastra, V; Pranteda, A; Stramucci, L, 2020)
" The use of polymers tailors the desorption profile, improving drug bioavailability and enhancing the local treatment of CRC via oral administration."2.66Recent Advances in Polymer Nanomaterials for Drug Delivery of Adjuvants in Colorectal Cancer Treatment: A Scientific-Technological Analysis and Review. ( Castro, C; Martinez, E; Naranjo, T; Osorio, M, 2020)
"Colorectal cancer is one of the most frequent cancers in the world and between 50% and 60% of patients will develop colorectal liver metastases (CRLM) during the disease."2.66The actual management of colorectal liver metastases. ( Dorcaratto, D; Garcés-Albir, M; Huerta Álvaro, M; Muñoz-Forner, E; Pérez-Santiago, L; Roselló Keranën, S; Sabater, L, 2020)
"5-Fluorouracil (5-FU) has become one of the most widely employed antimetabolite chemotherapeutic agents in recent decades."2.66Recent Advances in Designing 5-Fluorouracil Delivery Systems: A Stepping Stone in the Safe Treatment of Colorectal Cancer. ( Entezar-Almahdi, E; Farjadian, F; Mohammadi-Samani, S; Tayebi, L, 2020)
" However, the optimal protocol for neoadjuvant therapy has not been determined yet, and it remains a source of controversy about whether systemic chemotherapy combined with cetuximab can increase the surgical resection rate and obtain more clinical benefits."2.66Potentially Resectable mCRC-treated with Cetuximab Combined with Chemotherapy. ( Hong, L; Kong, Y; Xu, X, 2020)
"Thirty-two patients with untreated advanced colorectal carcinoma received high-dose methotrexate pretreatment followed sequentially by 5-fluorouracil (5-FU)."2.66High-dose methotrexate and 5-fluorouracil in patients with advanced colorectal carcinoma. A randomized study of two pretreatment intervals. ( Ajani, JA; Bedikian, AY; Kanojia, MD, 1989)
"Indications and contraindications for treatment of colorectal carcinomas with chemotherapeutic agents are described."2.66[Chemotherapy of inoperable colorectal cancer]. ( Herrmann, R, 1988)
"Sixty patients with advanced colorectal cancer were randomized between cisplatin (60 mg/mq i."2.66Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study. ( Cesana, B; Clerici, M; Labianca, R; Luporini, G; Montinari, F; Pancera, G, 1988)
"5-Fluorouracil (5-FU) has been commonly prescribed for patients with CRC, but resistance to 5-FU is one of the main reasons for failure in the treatment of this condition."2.61The role of microRNAs in 5-FU resistance of colorectal cancer: Possible mechanisms. ( Aghaee-Bakhtiari, SH; Avan, A; Ferns, GA; Khazaei, M; Marjaneh, RM, 2019)
"Among 2636 patients with stage III colon cancer treated with FOLFOX, MMR status was available for 2501."2.58Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. ( Alberts, SR; Folprecht, G; Goldberg, RM; Julie, C; Laurent-Puig, P; Le Malicot, K; Meyers, JP; Mini, E; Sargent, DJ; Shi, Q; Sinicrope, FA; Smyrk, TC; Tabernero, J; Taieb, J; Van Laethem, JL; Zaanan, A; Zawadi, A, 2018)
" We calculated the incidence of "any-grade" and "severe" toxicity for haematological and non-haematological adverse events of each group."2.58A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients. ( Baratelli, C; Brizzi, MP; Di Maio, M; Scagliotti, GV; Sonetto, C; Tampellini, M; Zichi, C, 2018)
"Treatment with eniluracil with oral 5-FU was associated with inferior PFS and OS among participants treated with palliative intent for CRC, and eniluracil is no longer being developed."2.55Oral versus intravenous fluoropyrimidines for colorectal cancer. ( Chionh, F; Lau, D; Price, T; Tebbutt, N; Yeung, Y, 2017)
" The present systematic review and meta-analysis evaluated the efficacy and safety data of bevacizumab combined with first-line fluoropyrimidine monochemotherapy for these complex patients."2.55Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. ( Antonuzzo, L; Aprile, G; Barni, S; Maiello, E; Masi, G; Petrelli, F; Pinto, C; Porcu, L; Scartozzi, M; Torri, V, 2017)
"5-fluorouracil is a chemotherapeutic agent that plays an important role in the treatment of various cancers including head and neck and gastrointestinal malignancies."2.53Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review. ( Mahipal, A; Markey, KR; Saneeymehri, SS, 2016)
"The survival improvement in metastatic colorectal cancer, achieved with more intensive chemotherapy regimens, has recently led clinicians to question the optimal duration of therapies and to consider the role of maintenance."2.53Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy. ( Aprile, G; Bonotto, M; Fasola, G; Fontanella, C; Giuliani, F; Lutrino, SE; Rihawi, K, 2016)
"The management of metastatic colorectal cancer substantially improved over the last 10 years and median overall survival of patients might exceed 30 months."2.53Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. ( Lenz, HJ; Schirripa, M; Sunakawa, Y, 2016)
"To compare the efficacy and safety of two chemotherapeutic regimens, irinotecan monotherapy or irinotecan in combination with fluoropyrimidines, for patients with advanced CRC when administered in the first or second-line settings."2.53Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. ( Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N, 2016)
"Colorectal cancer is one of the most frequent solid tumors in the western world, with low survival rates in patients with metastatic disease."2.53Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer. ( Bekaii-Saab, T; Stintzing, S; Sunakawa, Y, 2016)
"Pharmacokinetic guided dosing of 5-fluorouracil chemotherapies to bring plasma 5-fluorouracil into a desired therapeutic range may lead to fewer side effects and better patient outcomes."2.53Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review. ( Clarke, A; Connock, M; Court, R; Freeman, K; Gurung, T; Saunders, MP; Sutcliffe, P; Taylor-Phillips, S; Uthman, OA, 2016)
"The objective of the treatment of colorectal cancer patients with unresectable liver metastases should be clearly defined at the outset."2.53Unresectable liver metastases in colorectal cancer: review of current strategies. ( Pellerin, O; Pernot, S; Pointet, AL; Sueur, B; Taieb, J; Voron, T, 2016)
" The risk of mortality, therapeutic efficacy, and adverse effect were meta-analyzed."2.53Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis. ( Chen, K; Gong, Y; Shen, Y; Zhang, Q; Zhou, T, 2016)
"Fluoropyrimidines, the mainstay agents for the treatment of colorectal cancer, alone or as a part of combination therapies, cause severe adverse reactions in about 10%-30% of patients."2.52Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. ( Berenato, R; Bernardi, FF; Bossi, I; Caporale, M; Cheli, S; Clementi, E; de Braud, F; Di Bartolomeo, M; Falvella, FS; Maggi, C; Martinetti, A; Niger, M; Pietrantonio, F; Ricchini, F; Sottotetti, E, 2015)
" Herein, we critically discuss the current data on the efficacy and safety profile of bevacizumab in combination with fluoropyrimidine-based chemotherapy for first-line and maintenance treatment of metastatic CRC and briefly comment on existing controversies and future perspectives."2.52Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer. ( Grapsa, D; Saif, MW; Syrigos, K, 2015)
"5-Fluorouracil (5-FU) is a chemotherapy used in colorectal, head and neck (H&N) and other cancers."2.52Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion. ( Clarke, A; Connock, M; Court, R; Cummins, E; Freeman, K; Gurung, T; Saunders, M; Sutcliffe, P; Taylor-Phillips, S, 2015)
"Based on the individual genomic profile, the oncologists will have new possibilities, based on the individual genetic profile, to make treatment decisions for their patients and to redefine scheduling and dosage of FluOx-based therapy."2.52Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy. ( Berretta, M; De Lucia, L; De Monaco, A; Del Pup, L; Di Francia, R; Di Martino, S; Di Paolo, M; Lleshi, A, 2015)
"Colorectal cancer is the third most common cancer, with recent advances in the management of unresectable metastatic lesions."2.50Options for metastatic colorectal cancer beyond the second line of treatment. ( Foubert, F; Matysiak-Budnik, T; Touchefeu, Y, 2014)
"Metastatic colorectal cancer remains a lethal disease with a poor prognosis in the majority of patients."2.50Methods of overcoming treatment resistance in colorectal cancer. ( Alameddine, R; Mukherji, D; Shamseddine, A; Temraz, S, 2014)
" Seven electronic databases were searched for randomized controlled trials (RCTs) of FOLFOX4 combined with HMs compared to FOLFOX4 alone."2.50FOLFOX 4 combined with herbal medicine for advanced colorectal cancer: a systematic review. ( Chen, M; May, BH; Xue, CC; Zhang, AL; Zhou, IW, 2014)
"The management of metastatic colorectal cancer remains a significant clinical challenge to oncologists worldwide."2.50Sequencing of treatment in metastatic colorectal cancer: where to fit the target. ( Mukherji, D; Shamseddine, A; Temraz, S, 2014)
"Chemotherapy-induced diarrhea (CID) is a common and often severe side effect experienced by colorectal cancer (CRC) patients during their treatment."2.50Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. ( Doherty, GA; Lee, CS; Ryan, EJ, 2014)
"The treatment of metastatic colorectal cancer (mCRC) has evolved considerably in the last decade, currently allowing most mCRC patients to live more than two years."2.50Role of cetuximab in first-line treatment of metastatic colorectal cancer. ( Aguado, C; Díaz-Rubio, E; García-Paredes, B; Sastre, J; Sotelo, MJ, 2014)
"Capecitabine has previously been compared to 5-fluorouracil-either as a monotherapy or in combination with oxaliplatin, irinotecan, or biological drugs-and has been found to have comparable efficacy and safety profiles."2.50Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? ( Aguado, C; Díaz-Rubio, E; García-Paredes, B; Sastre, J; Sotelo, MJ, 2014)
"Colorectal cancer is the third most common cancer worldwide."2.50Use of microRNAs in directing therapy and evaluating treatment response in colorectal cancer. ( Andreoli, SC; de Andrade, RV; de Carvalho, GP; Garicochea, B; Gasparini, NJ; Pogue, RE, 2014)
"Survival of patients with metastatic colorectal cancer (mCRC) has been significantly improved with the introduction of the monoclonal antibodies targeting the vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR)."2.50Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. ( Kirstein, MM; Kubicka, S; Lange, A; Manns, MP; Prenzler, A; Vogel, A, 2014)
" With a more capillary use of this new class of agents comes the recognition of diverse adverse events related to disturbance of critical biological pathways involved in physiological functions."2.49Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer. ( Cipriani, G; Fioretto, L; Marinozzi, C; Pino, MS; Ribecco, AS, 2013)
"Capecitabine is an orally administered prodrug that converts preferentially to 5-FU within tumors, resulting in enhanced concentrations of 5-FU in tumor tissue."2.49Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy. ( Endo, A; Nakashima, R; Takahashi, N; Tanabe, K; Yoshida, Y, 2013)
"Microsatellite instability is the consequence of a deficient mismatch repair system."2.49Role of microsatellite instability in the management of colorectal cancers. ( Buecher, B; Cacheux, W; Dieumegard, B; Lièvre, A; Mitry, E; Rouleau, E, 2013)
"What are the colorectal cancer prognostic factors which would guide the chemotherapy? TNM classification, number of examined lymph nodes, MSI status, and presence or not of a perforation or a perinervous, lymphatic or venous invasion is recognized prognostic factors."2.48[Is there alternative to FOLFOX adjuvant chemotherapy for stage III colorectal cancer patients?]. ( Brezault, C; Chaussade, S; Coriat, R; Esch, A; Perkins, G, 2012)
"Liver metastasis from colorectal cancer has become a common disease associated with the increase of primary colorectal cancer in Japan."2.48Chemotherapy and molecular-targeted treatment for unresectable hepatic metastases: a Japanese perspective. ( Shimada, Y, 2012)
"Metastatic colorectal cancer has evolved from a paradigm that was previously centered upon the use of systemic chemotherapy to one of multimodality therapy."2.47Surgical therapies in metastatic colorectal cancer with a potential for cure. ( Chua, TC; Esquivel, J; Koong, HN; Liauw, W, 2011)
"Capecitabine is a prodrug of 5-fluorouracil, more easily administered by mouth; its transformation in 5-fluorouracil is performed in the liver."2.47Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report. ( Bagli, L; Drudi, F; Fantini, M; Gianni, L; Nicoletti, S; Possenti, C; Ravaioli, A; Sintini, M; Tamburini, E; Tassinari, D, 2011)
"Recently its role in colorectal cancer has become more established in both the metastatic and adjuvant setting."2.47XELOX in colorectal cancer: a convenient option for the future? ( Cassidy, J; Lindsay, CR, 2011)
"Colorectal cancer is the second leading cause of cancer-related deaths in the world."2.47Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. ( Crea, F; Danesi, R; Landini, I; Mini, E; Napoli, C; Nobili, S; Paolicchi, E; Perrone, G, 2011)
"Patients with surgically resected colorectal cancer with high risk of recurrence."2.46Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer. ( Des Guetz, G; Morere, JF; Nicolas, P; Perret, G; Uzzan, B, 2010)
"Capecitabine is an orally administered fluoropyrimidine carbamate that is absorbed intact from the gastrointestinal tract and becomes metabolically activated to 5-FU within the tumor."2.46Evolution of capecitabine dosing in colorectal cancer. ( Sun, W, 2010)
"Chemotherapy for colorectal cancer (CRC) was representative of the cancer unable to expect achieving response in previous times."2.46[Transition of chemotherapy for metastatic colorectal cancer and recent advances]. ( Muro, K, 2010)
"The prognosis of metastatic colorectal cancer remains poor despite advances made in recent years, particularly with new treatments directed towards molecular targets."2.46Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. ( Díaz-Rubio, E; García-Foncillas, J, 2010)
"This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer based on the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process."2.46Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer. ( Pandor, A; Rees, A; Stevenson, M; Whyte, S, 2010)
"Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration."2.46Update on capecitabine alone and in combination regimens in colorectal cancer patients. ( Azzariti, A; Cinieri, S; Colucci, G; De Vita, F; Lorusso, V; Maiello, E; Millaku, A; Numico, G; Petriella, D; Pisconti, S; Russo, A; Santini, D; Silvestris, N; Tommasi, S, 2010)
"Risk factors for colorectal cancer are mainly dietary and genetic."2.46Colorectal cancer treatment. ( Landau, D; Qureshi, A; Ross, P; Verma, A, 2010)
"A form of non-alcoholic steatohepatitis (NASH) related to chemotherapy and otherwise known as chemotherapy-associated steatohepatitis (CASH) is closely linked to irinotecan-based therapy and is associated with inferior outcomes following hepatic surgery mainly due to hepatic insufficiency and poor regeneration."2.45Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. ( Khan, AZ; Makuuchi, M; Morris-Stiff, G, 2009)
"Liver metastases from colorectal cancer (CRC) have a poor prognosis."2.45Treatment of colorectal liver metastases: a review. ( Hendlisz, A; Van den Eynde, M, 2009)
"The median age at diagnosis of colorectal cancer is during the seventh decade, and the incidence of the disease increases continuously with age."2.45Chemotherapy for colorectal cancer in the elderly: Whom to treat and what to use. ( Belda, C; Casado, E; Castro, JD; Feliu, J; González-Barón, M; Sereno, M, 2009)
"Chemotherapy is widely used in colorectal cancer that has relapsed or failed to respond to first-line treatment."2.45Second-line chemotherapy in advanced and metastatic CRC. ( Bonfill Cosp, X; López, JJ; Martin-Richard, M; Roqué I Figuls, M; Solà, I, 2009)
"Chemotherapy options of metastatic colorectal cancer (mCRC) have been progressed rapidly in the last years."2.45[The development of the first line treatment of metastatic colorectal cancer (mCRC)]. ( Landherr, L; Nagykálnai, T, 2009)
"Large randomized trials of metastatic colorectal cancer have demonstrated significant clinical benefit with bevacizumab (inhibiting the vascular endothelial growth factor VEGF) and inhibitors of epidermal growth factor receptor (EGFR), namely cetuximab and the panitumumab."2.45[Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis]. ( Assenat, E; Ychou, M, 2009)
"The development of chemoresistance in colorectal cancer (CRC) cells was usually thought to be inevitable as a result of continuing exposure to chemotherapeutic drugs."2.44Expression of CD44 is regulated by ELF3 in 5-FU treated colorectal cancer cells. ( Du, B; Fan, X; Guo, Y; Li, F; Liu, S; Qiu, F; Xi, X; Yu, Q; Zhu, Y, 2024)
" Many drugs have been used for the treatment of this disease, but there is little information about how predictive factors can be used to aid treatment response and anticipate toxic effects related to anticancer treatment in colorectal cancer."2.44Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. ( Pantano, F; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B, 2008)
"Data on colorectal cancer in HIV-positive patients are limited."2.44FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature. ( Bearz, A; Berretta, M; Berretta, S; Del Ben, C; Di Benedetto, F; Martellotta, F; Simonelli, C; Spina, M; Tirelli, U, 2008)
"The CTS plays a role in cancer processes and their treatments through the downregulation of malignant growth and the generation of large and predictable 24 hour changes in toxicity and efficacy of anti-cancer drugs."2.44Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. ( Altinok, A; Clairambault, J; Goldbeter, A; Lévi, F, 2008)
"Resectability of liver-limited colorectal cancer metastases should be considered as an endpoint for all patients."2.44Regional chemotherapy for liver-limited metastatic colorectal cancer. ( Healey-Bird, BR; Kemeny, NE; Power, DG, 2008)
" In addition to demonstrated survival benefits, the convenient dosing schedule and lack of interactions should ensure the successful integration of this novel agent into clinical practice."2.44Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. ( Krämer, I; Lipp, HP, 2007)
"Capecitabine is an oral prodrug of 5-fluorouracil."2.44Capecitabine in the treatment of colorectal cancer. ( Cassidy, J; Kelly, C, 2007)
"Gemcitabine is a well-tolerated anti-tumour drug with broad-spectrum activity."2.44[Gemcitabine and digestive carcinomas]. ( André, T; Blanchard, P; Huguet, F, 2007)
"Colorectal cancers have been the first cancers to benefit from an efficient anti-angiogenic treatment, represented by bevacizumab, which has been approved for first-line metastatic treatment in combination with reference chemotherapies and which is under study in the adjuvant setting."2.44[Angiogenesis targeting in gastro-intestinal cancers]. ( Meric, JB, 2007)
"The role of surgery in advanced colorectal cancer in the elderly is restricted to the relief of bowel obstruction and where appropriate resection of hepatic metastasis."2.44Treatment of advanced colorectal cancer in the elderly. ( Audisio, RA; Bruce, C; Köhne, CH, 2007)
"There are 3 450 new cases of colorectal cancer in Norway annually."2.44[Palliative chemotherapy and radiotherapy for metastatic colorectal cancer]. ( Balteskard, L; Braendengen, M; Sørbye, H, 2008)
"Metastatic colorectal cancer (CRC) is most frequently seen in the liver."2.44Advances in neoadjuvant therapy for colorectal cancer with liver metastases. ( Barone, C; Kemeny, NE; Pozzo, C, 2008)
"Advances in the medical treatment of colorectal cancer patients have resulted in considerable improvements through the introduction of new cytotoxic drugs."2.44[Antibody treatment in colorectal cancer--what the surgeon needs to know]. ( Bueter, M; Fein, M; Gasser, M; Illert, B; Meyer, D; Reimer, P; Thalheimer, A; Thiede, A; Waaga-Gasser, AM, 2008)
" Although patients can take the drug orally in the convenience of their own home, the key to successful management of capecitabine is the clinician's awareness of its severe, but low in incidence, adverse effects, and the patients' education, emphasizing compliance with the treatment plan, prevention and timely recognition of its toxicities."2.44Capecitabine: an overview of the side effects and their management. ( Katirtzoglou, NA; Saif, MW; Syrigos, KN, 2008)
"Advances in systemic therapy for colorectal cancer have dramatically improved prognosis."2.44The role of molecular markers in predicting response to therapy in patients with colorectal cancer. ( Benson, AB; Mulcahy, MF; Shankaran, V; Wisinski, KB, 2008)
"Colorectal cancer is the fourth most common noncutaneous malignancy in the United States and the second most frequent cause of cancer-related death."2.44Systemic treatment of colorectal cancer. ( Mayer, RJ; Wolpin, BM, 2008)
"The outcome of patients with advanced colorectal cancer has significantly improved in the past decade because of the development of new treatment strategies."2.44Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group. ( Antonini, N; Koopman, M; Mol, L; Punt, C; Simkens, L; Tol, J; van Krieken, H, 2008)
"Chemotherapy for advanced colorectal cancer is much improved in this decade."2.43[Second-line chemotherapy for advanced colorectal cancer]. ( Enomoto, M; Higuchi, T; Iida, S; Sugihara, K; Tsunozaki, H; Uetake, H; Yasuno, M, 2005)
"For instance, in patients with colorectal cancer, higher enzyme activity of topoisomerase-I seems to be predictive of a better response to irinotecan."2.43Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. ( Lentz, F; Pons, G; Rey, E; Tran, A; Tréluyer, JM, 2005)
"Irinotecan was first developed in patients refractory to fluorouracil."2.43Benefit-risk assessment of irinotecan in advanced colorectal cancer. ( Glimelius, B, 2005)
"Since colorectal cancer is the second most prevalent cancer worldwide, its treatment remains a major challenge for researchers, gastroenterologists and oncologists."2.43New chemotherapeutic strategies in colorectal cancer. ( Galle, PR; Moehler, M; Teufel, A, 2005)
"Overall survival in metastatic colorectal cancer improves with the availability of multiple effective chemotherapeutic agents."2.43Management of advanced colorectal cancer in older patients. ( Lichtman, SM, 2005)
"Capecitabine has significantly less serious toxicity than 5-FU when used alone or in combination with other cytotoxic agents."2.43Capecitabine: effective oral fluoropyrimidine chemotherapy. ( Coutsouvelis, J; McKendrick, J, 2005)
"Worldwide, colorectal cancer is a common cancer and a major cause of morbidity and mortality."2.43Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer. ( Jefford, M; Khamly, K; Michael, M; Zalcberg, J, 2005)
"Colorectal cancer is a frequently occurring malignancy in the western world."2.43[Chemotherapy of patients with colorectal carcinoma]. ( Punt, CJ, 2005)
"If almost all colorectal cancers (CRC) correspond to the same histopathological type (adenocarcinoma), molecular biology allowed the identification of two different molecular mechanisms of colorectal carcinogenesis: chromosomal instability characterized by recurrent allelic losses on chromosomes 17, 5, 18, 8 and 22 that contribute to the inactivation of tumor suppressor genes, and genetic instability characterized by the instability of microsatellite loci due to an alteration of DNA mismatch repair leading to the accumulation of mutations in genes involved in the control of cell cycle and apoptosis."2.43[Molecular biology in clinical cancer research: the example of digestive cancers]. ( Laurent-Puig, P; Lièvre, A, 2005)
"Colorectal cancer is one of the most common cancers affecting men and women in the United States."2.43Advanced colorectal cancer: current treatment and nursing management with economic considerations. ( Fung, A; Viale, PH; Zitella, L, 2005)
"For the treatment of metastatic colorectal cancer, improved response rates and prolonged survival have been reported when irinotecan or oxaliplatin was added to 5-FU/FA; a further increase in efficacy was shown when bevacizumab, an antibody to vascular endothelial growth factor, was added to chemotherapy."2.43Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting. ( Folprecht, G; Köhne, CH, 2005)
"Irinotecan was developed for gastrointestinal cancer."2.43[Recent progress of chemotherapy for colorectal cancer]. ( Ishiguro, A; Munakata, M; Saitoh, S; Sakata, Y; Shitara, K, 2005)
"A patient with metastatic colorectal cancer should today be expected to have a median survival of 18-20 months compared to that of 11-14 months only a few years ago."2.43Chemotherapy for colorectal cancer. ( Goyle, S; Maraveyas, A, 2005)
"Advanced colorectal cancer is a common disease with an high mortality rate."2.43Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience. ( Aquino, A; Bonmassar, E; Correale, P; Cusi, MG; Del Vecchio, MT; Francini, G; Giorgi, G; Micheli, L; Nencini, C; Torino, F, 2006)
"About 50% of patients with colorectal cancer (CCR) are destined to develop hepatic metastases during the course of the disease."2.43Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. ( Biasco, G; Brandi, G; Derenzini, E; Ercolani, G; Grazi, G; Pantaleo, MA; Ravaioli, M, 2006)
"Capecitabine is an oral fluoropyrimidine which is converted to 5-fluorouracil primarily in tumor tissue, and has the advantages of ease-of-administration, acceptable toxicity and significant antineoplastic activity."2.43Capecitabine in the treatment of colorectal cancer. ( Cassidy, J; O'Neill, VJ, 2005)
"The modern treatment of colorectal cancer."2.43[The modern treatment of colorectal cancer. Present and future]. ( András, C; Farczádi, E; Szántó, J, 2006)
"Colorectal cancer is the second leading cause of cancer-related deaths in the Western world."2.43Predicting the outcome of chemotherapy for colorectal cancer. ( Allen, WL; Coyle, VM; Johnston, PG, 2006)
"In the USA, colorectal cancer is the fourth most prevalent cancer and is the second leading cause of cancer death after lung cancer."2.43First- and second-line therapy of metastatic colorectal cancer. ( Grothey, A; Terstriep, S, 2006)
"As the treatment for metastatic colorectal cancer, capecitabine showed at least comparable efficacy with a favorable safety profile to bolus 5-FU/LV."2.43[Capecitabine]. ( Shimamura, T; Tada, M; Yamaguchi, K, 2006)
"In stage II colon cancer, treatment strategies are more debated."2.43[Adjuvant treatment of colorectal cancer]. ( Afchain, P; André, T; de Gramont, A; Segura, C, 2006)
"5-Fluorouracil has been the mainstay of therapy for the last four decades."2.43Surgical adjuvant therapy for colorectal cancer: current approaches and future directions. ( Monga, DK; O'Connell, MJ, 2006)
"Chemotherapy for colorectal cancer is now improving rapidly due to new drugs like oxaliplatin and molecular targeting drugs."2.43[S-1 as a single agent for colorectal cancer]. ( Eguchi, T; Shirao, K, 2006)
"However, genotyping of cancer patients with reduced or normal DPD activity showed that only 17% of those patients had a molecular basis for their deficient phenotype, which emphasized the complex nature of the molecular mechanisms controlling polymorphic DPD activity in vivo,suggesting that it is difficult to identify DPD deficiency by genotyping."2.43[Dihydropyrimidine dehydrogenase activity and its genetic aberrations]. ( Ogura, K, 2006)
"Colorectal carcinoma is one of the most common cancers in Hungary, responsible for about 5000 deaths each year."2.43[Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma]. ( Gyôrffy, B; Tegze, B; Tulassay, Z, 2006)
"Metastatic colorectal cancer has a poor prognosis, and the majority of patients are left with palliative measures."2.42Palliative treatment of patients with colorectal cancer. ( Glimelius, B, 2003)
"Half of the patients with colorectal cancer present with liver metastases at some point in their illness."2.42Hepatic resection after down-staging of unresectable hepatic colorectal metastases. ( Adam, R; Azoulay, D; Bismuth, H; Castaing, D; Huguet, E; Kunstlinger, F; Levi, F, 2003)
"The chemotherapy of metastatic colorectal cancer (CRC) has undergone a succession of refinements."2.42Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. ( Carnaghi, C; Comella, P; Díaz-Rubio, E; Douillard, JY; Santoro, A; Sobrero, A; Van Cutsem, E, 2003)
" The use of irinotecan together with raltitrexed is also being investigated, as is its combination with oxaliplatin."2.42Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers. ( Ducreux, M; Köhne, CH; Schwartz, GK; Vanhoefer, U, 2003)
"In untreated metastatic gastric cancer, median survival is 3-4 months."2.42Current treatments and future perspectives in colorectal and gastric cancer. ( Van Cutsem, E; Wilke, HJ, 2003)
"Colorectal cancer is a leading cause of cancer death world-wide."2.42Review article: colorectal cancer chemotherapy. ( Gill, S; Goldberg, RM; Thomas, RR, 2003)
" DPD-inhibiting oral fluoropyrimidines showing promise in early clinical studies included UFT (the 5-FU prodrug, tegafur, plus the DPD substrate, uracil), eniluracil (an irreversible DPD inhibitor that improves the oral bioavailability of 5-FU) and S-1 (tegafur plus a reversible DPD inhibitor, 5-chloro-2,4-dihydroxypyridine, and oxonic acid)."2.42Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer. ( Schmoll, HJ, 2003)
"Systemic therapy for metastatic colorectal cancer is evolving rapidly after many years without significant change."2.42Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents. ( O'Neil, BH, 2003)
"Fluorouracil has been the mainstay of treatment in this setting for the past few decades."2.42First-line treatment strategies to improve survival in patients with advanced colorectal cancer. ( Gill, S; Goldberg, RM, 2004)
"The treatment of colorectal cancer has evolved dramatically over the last 15 years."2.42Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy. ( Grann, VR; Matasar, MJ; Neugut, AI; Sundararajan, V, 2004)
"New targets in the treatment of colorectal cancer are the EGF and VEGF receptor."2.42The role of new agents in the treatment of colorectal cancer. ( Folprecht, G; Köhne, CH, 2004)
"Patients with a partial DPD deficiency have an increased risk of developing grade IV neutropenia."2.42Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. ( van Kuilenburg, AB, 2004)
"Adjuvant therapy for colorectal cancer has been one of the most important contributions of medical oncology to the health of the population, saving more lives annually than more effective therapy for less common cancers, such as Hodgkin's disease."2.42Adjuvant therapy for rectal cancer in the elderly. ( Cohen, SM; Neugut, AI, 2004)
"5-fluorouracil (5-FU) has been a pivotal and a single active agent in the treatment of colorectal cancer."2.42[Chemotherapy]. ( Aiba, K, 2004)
"The medical treatment of colorectal cancer (CRC) has rapidly evolved in recent years with the introduction of novel cytotoxic drugs into clinical practice such as irinotecan, oxaliplatin, and capecitabine."2.42Oxaliplatin plus oral fluoropyrimidines in colorectal cancer. ( Goetz, MP; Grothey, A, 2004)
"Survival in patients with advanced colorectal cancer is on a positive trajectory."2.42Current strategies in previously untreated advanced colorectal cancer. ( Goldberg, RM; Penland, SK, 2004)
"Patients with colorectal cancer commonly succumb to the sequelae of hepatic metastases."2.42Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. ( Barber, FD; Kurzrock, R; Mavligit, G, 2004)
"capecitabine) are a convenient alternative but have to prove a comparable efficacy to infusional 5-FU."2.42[New therapy options in colorectal carcinoma]. ( Folprecht, G; Köhne, CH, 2004)
"Colorectal cancer is a leading cause of cancer death worldwide."2.42Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. ( Gill, S; Goldberg, RM, 2004)
"In Westernised countries, colorectal cancer (CRC) is second only to lung cancer as a cause of death from malignancy, with only 60% of patients alive at 5 years."2.42Which drug combination for colorectal cancer? ( Doggrell, SA, 2004)
"Colorectal Cancer is one of the leading causes for cancer related death in the industrialized world."2.42[Colorectal cancer: current treatment options]. ( Andre, N; Graeven, U; Schmiegel, W, 2004)
"Colorectal cancer is the second leading cause of cancer death in the USA and fluoropyrimidines have been the mainstay of treatment for over 40 years."2.42Capecitabine: the new generation of fluoropyrimidines in colorectal cancer. ( Iqbal, S; Lenz, HJ, 2004)
"Metastatic colorectal cancer has long been considered as a short-term, poor prognosis, chemoresistant disease."2.41Therapeutic advances in the management of metastatic colorectal cancer. ( Descos, L; Freyer, G; Kraft, D; Ligneau, B; Trillet-Lenoir, V, 2001)
"Colorectal cancer is one of the most common tumors worldwide."2.41The role of genomic instabilities in affecting treatment responses of colorectal cancer. ( Bazzoli, F; Ricciardiello, L, 2002)
"Many patients who develop metastases are offered systemic chemotherapy to try to extend survival and maintain or improve quality of life."2.41Chemotherapy for metastatic colorectal cancer. ( , 2002)
"Adjuvant therapy for colorectal cancer includes chemotherapy, radiotherapy and immunotherapy."2.41Adjuvant therapy of colorectal cancer: the next step forward. ( Kumar, D; Prabhudesai, AG, 2002)
"Colorectal cancer is the second most common cause of cancer-related mortality in Europe and North America."2.41Chemotherapy in colorectal cancer: new options and new challenges. ( Chau, I; Cunningham, D, 2002)
" The safety of capecitabine and optimal dosing schedules have been explored in phase I/II studies, resulting in the evaluation of the intermittent schedule (1250 mg/m2 twice daily for 14 days, every 3 weeks) in most subsequent clinical trials."2.41Capecitabine (Xeloda): from the laboratory to the patient's home. ( Pentheroudakis, G; Twelves, C, 2002)
"Metastatic colorectal cancer is a major cause of cancer-related mortality."2.41Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer. ( Goldberg, RM; Hobday, TJ, 2002)
"Adjuvant radiation therapy for rectal cancer is not widely used in Japan, while chemotherapy is considered the adjuvant treatment of choice."2.41[Progress in adjuvant therapy for colorectal cancer]. ( Kakeji, Y; Kohnoe, S; Maehara, Y, 2002)
"Capecitabine (Xeloda) is an oral prodrug that is enzymatically converted to fluorouracil (5-FU) within cancer cells."2.41Current status of capecitabine in the treatment of colorectal cancer. ( Rothenberg, ML, 2002)
"Progression of colorectal cancer can occur primarily isolated in the liver."2.41Relevance of locoregional chemotherapy in patients with liver metastases from colorectal primaries. ( Gog, C; Heinrich, S; Lorenz, M; Müller, HH; Petrowsky, H; Staib-Sebler, E; Vetter, G, 2000)
"Capecitabine (Xeloda)(R) was developed as a tumour-selective fluoropyrimidine carbamate to achieve higher intratumoural 5-FU level and lower toxicity than 5-FU."2.41Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer. ( Di Costanzo, F; Gasperoni, S; Sdrobolini, A, 2000)
"Survival, disease progression, quality of life, and toxicity."2.41Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. ( Simmonds, PC, 2000)
"In advanced colorectal cancer, liver metastases are a major problem."2.41Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver. ( Giaccone, G; Pinedo, HM; van Groeningen, CJ; van Riel, JM, 2000)
"Treatment of advanced colorectal cancer has progressed substantially."2.41Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. ( Burzykowski, T; Buyse, M; Carlson, RW; Molenberghs, G; Piedbois, P; Thirion, P, 2000)
" Fluorodeoxyuridine (FUDR) or 5-fluorouracil (5-FU) was used as the agent and a total dosage of 10-20 g was administered for 6-12 months in most studies."2.41[The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer]. ( Monden, T; Tono, T, 2000)
"Capecitabine (Xeloda) is a new, orally administered, enzyme-activated fluoropyrimidine carbamate designed to generate high levels of fluorouracil (5-FU) in tumor cells."2.41Pharmacology and clinical status of capecitabine. ( Schilsky, RL, 2000)
"Among colorectal cancer patients with recurrent or metastatic sites, survival was significantly prolonged for a group undergoing LV/5-FU therapy based on biochemical modulation compared with a group receiving no chemotherapy (best supportive care)."2.41[Progress in chemotherapy for colorectal cancer]. ( Maeda, Y; Sasaki, T, 2000)
"A significant number of patients with colorectal cancer will present with hepatic metastases as their only site of metastatic disease."2.41Intrahepatic therapy for resected hepatic metastases from colorectal carcinoma. ( Alberts, SR, 2000)
"The mainstay of chemotherapy in colorectal cancer patients for the past 40 years has been fluorouracil (5-FU)."2.41Efficacy of oxaliplatin in the treatment of colorectal cancer. ( Rothenberg, ML, 2000)
" Phase I studies have been completed showing the tolerability of two dosing schedules, including (1) a chronic schedule with twice-daily administration of eniluracil plus oral fluorouracil (5-FU) (10:1 ratio) for 28 days, and (2) a schedule of eniluracil administered daily on days 1-7 with oral 5-FU once daily on days 2-6."2.41Oral eniluracil/5-FU for advanced colon and breast carcinomas. ( Benson, AB, 2001)
"Capecitabine is a novel oral fluoropyrimidine carbamate that is preferentially converted to the cytotoxic moiety fluorouracil (5-fluorouracil; 5-FU) in target tumour tissue through a series of 3 metabolic steps."2.41Clinical pharmacokinetics of capecitabine. ( Blesch, K; Reigner, B; Weidekamm, E, 2001)
"Colorectal cancer is usually diagnosed in patients around 70 years of age."2.41Chemotherapy in elderly patients with colorectal cancer. ( Aapro, M; Bokemeyer, C; Bontke, N; Grothey, A; Köhne, CH, 2001)
"Metastatic colorectal cancer remains incurable with available systemic therapeutic options."2.41Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer. ( Grivicich, I; Mans, DR; Peters, GJ; Schwartsmann, G, 2001)
"Unusual aspect of the development of oxaliplatin was that substantial evidence of its activity was gathered when used in combination with protracted infusion of 5FU combined with leucovorin, preceeding the formal demonstration of its single activity in this disease."2.41[Oxaliplatin in combination with 5-fluoro-uracil and folinic acid as treatment of metastatic colorectal cancer]. ( André, T; Gramont, AD; Louvet, C; Maindrault-Goebel, F, 2001)
" The dosage and administration is referred to the weekly method developed at RPMI."2.41[Levofolinate and fluorouracil combination therapy]. ( Murakami, M; Takeuchi, S, 2001)
"Capecitabine is an oral fluoropyrimidine that was developed in response to the clinical need for new therapeutic options offering improved efficacy, tolerability, and convenience for patients."2.41The evolution of fluoropyrimidine therapy: from intravenous to oral. ( Cassidy, J; Hoff, PM; Schmoll, HJ, 2001)
"Metastatic colorectal cancer has traditionally been treated with i."2.41Answering patients' needs: oral alternatives to intravenous therapy. ( Borner, M; Maroun, J; Scheithauer, W; Twelves, C; Wilke, H, 2001)
" Since 5-FU seems to have dual, mechanisms of cell kill; DNA and RNA directed cytotoxicity, it is important to know how to maximize or improve therapeutic ratio by dosing or scheduling 5-FU administration, even modulating 5-FU with other agents."2.41[5-fluorouracil]. ( Aiba, K, 2001)
"Colorectal cancer is still a majorhealth and social problem."2.41Disease management considerations: disease management considerations. ( Beretta, GD; Labianca, RF; Pessi, MA, 2001)
"Capecitabine is an orally administered fluoropyrimidine which is selectively activated in tumour tissue to the active moiety fluorouracil and is cytotoxic through inhibition of DNA synthesis."2.41Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. ( Goa, KL; McGavin, JK, 2001)
"Capecitabine is a fluoropyrimidine carbamate that was rationally designed as an oral drug capable of mimicking continuous infusion 5-fluorouracil (5-FU) and delivering 5-FU preferentially to tumour tissue."2.41Rational development of capecitabine. ( Venturini, M, 2002)
"Colorectal cancer is the second leading cause of cancer death and it is clear that patients with metastatic disease have better quality of life and survival when given treatment."2.41New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. ( Holen, KD; Saltz, LB, 2001)
"The treatment of advanced colorectal cancer has long been a dilemma for clinicians."2.41Randomized clinical trials in advanced and metastatic colorectal carcinoma. ( Dangelica, MI; Nissan, A; Shoup, MC, 2002)
"Targeted treatment of colorectal cancer based on TS quantitation has thus been hypothesized similar to the use of hormone receptor in breast cancer."2.41Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. ( Aschele, C; Lonardi, S; Monfardini, S, 2002)
"Capecitabine is a synthetic oral fluoropyrimidine carbamate that is sequentially activated in a three-step process, which results in the preferential production of 5-fluorouracil in tumours, rather than in the normal surrounding tissue."2.41Capecitabine: fulfilling the promise of oral chemotherapy. ( Hwang, JJ; Marshall, JL, 2002)
"Colorectal cancer is the third leading cause of cancer mortality for men and women in the United States."2.40Experimental chemotherapeutic agents for the treatment of colorectal carcinoma. ( O'Reilly, S; Rowinsky, EK, 1997)
"Approximately 50% of patients with colorectal cancer develop locally recurrent or distant metastatic disease during the course of their illness and eventually die."2.40Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview. ( Borud, K; Isacoff, WH, 1997)
" Optimal dosing and administration strategies remain to be determined."2.40A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. ( Machover, D, 1997)
"Patients with advanced colorectal cancer can only benefit from these important advances, however, if a truly multidisciplinary approach to patient care is adopted which requires integration of the roles of the surgeon, medical oncologist and radiotherapist."2.40The need for a multidisciplinary approach in the treatment of advanced colorectal cancer: a critical review from a medical oncologist and surgeon. ( Neoptolemos, JP; Rougier, P, 1997)
"Colorectal cancer is one of the most frequent cancers in western countries."2.40[Colorectal cancer: a controllable disease]. ( Bleiberg, H; Gerard, B, 1997)
"Trimetrexate is a nonclassical antifolate that has demonstrated antitumor activity against a number of malignancies, including those resistant to the classical antifolate methotrexate."2.40Trimetrexate: review and current clinical experience in advanced colorectal cancer. ( Blanke, CD; Messenger, M; Taplin, SC, 1997)
"Over the last 40 years the treatment of colorectal cancer has not achieved the same progress as treatment for other types of tumors."2.40Beyond 5-fluorouracil monochemotherapy in colorectal cancer--it is time. ( Franchi, F; Satta, F, 1997)
" A North American study (study 10) was originally set up to compare two raltitrexed dosage arms (3."2.40Mature results from three large controlled studies with raltitrexed ('Tomudex'). ( Cunningham, D, 1998)
"In human colorectal cancer cell lines and various animal tumour model systems 5-fluoro-2'-deoxyuridine (FdUrd) is more effective than 5-fluorouracil (5-FU)."2.40Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer. ( Ackland, SP; Peters, GJ; Rustum, YM; van Groeningen, CJ; van Laar, JA, 1998)
"Colorectal cancer is the second leading cause of cancer death in western countries."2.40[Adjuvant therapy of colorectal carcinoma--1998 status]. ( Borner, M; Maurer, C, 1998)
"Colorectal cancer is one of the most frequent cancers in the western world."2.405-Fluorouracil in colorectal cancer: rationale and clinical results of frequently used schedules. ( Kamm, YJ; Punt, CJ; Rietjens, IM; Wagener, DJ, 1998)
"Eniluracil is a potent inactivator of dihydropyrimidine dehydrogenase (DPD), which is the first enzyme in the degradative pathway of systemically administered 5-fluorouracil (5-FU)."2.40Clinical development of eniluracil: current status. ( Hohneker, JA, 1998)
"Irinotecan (CPT11) is a synthetic camptothecin-derived DNA topoisomerase I inhibitor."2.40[Irinotecan: various administration schedules, study of drug combinations, phase I experience]. ( Armand, JP; Boige, V; Raymond, E, 1998)
"Irinotecan or CPT11 is a topoisomerase 1 inhibitor."2.40[Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials]. ( Peeters, M; Van Cutsem, E, 1998)
"Irinotecan treated patients lived for significantly longer than those on 5FU: median time of survival was 10."2.40[Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials]. ( Ducreux, M; Mitry, E; Rougier, P, 1998)
"Capecitabine was converted to 5'-DFUR by either human carboxyestelase or cytidine deaminase, which were mainly localized in human liver."2.40[Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine]. ( Saeki, T; Takashima, S, 1999)
"This article describes two cases of colorectal cancer in adolescents and reviews the literature regarding this rare condition."2.40Colorectal cancer in adolescents. ( Renaut, AJ; Shankar, A; Taylor, I; Whelan, J, 1999)
"5-fluorouracil has been the major chemotherapeutic agent for the treatment of colorectal carcinoma for the past four decades."2.40A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer. ( Adjei, AA, 1999)
"Tegafur/uracil has been commercially available in Japan since 1983 and examined extensively in various tumours."2.40Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil. ( Hoff, PM; Lassere, Y; Pazdur, R, 1999)
" Low dose and either continuous infusion or repetitive dosing of leucovorin, as well as the effect of treatment sequence and intervals between drugs, require additional investigation."2.39Preclinical and clinical aspects of biomodulation of 5-fluorouracil. ( Allegra, CJ; Grogan, L; Sotos, GA, 1994)
"Fifty per cent of patients with colorectal cancer develop hepatic metastases but only a minority are candidates for potentially curative surgical resection."2.39Hepatic artery chemotherapy for colorectal liver metastases. ( Jorgensen, JO; McCall, JL; Morris, DL, 1995)
"Colorectal cancer is the second most common cancer in the Western world, and yet the survival after potentially curative excisional surgery has improved little over the last half century."2.39Adjuvant chemotherapy for colorectal cancer. ( Leicester, RJ; Mansi, JL; Rayter, Z, 1995)
"The current EORTC study for colorectal cancer investigates the role of the combination of short time regional and long term systemic chemotherapy."2.39Colorectal carcinoma: current problems and future perspectives. ( Schmoll, HJ, 1994)
"Survival from colorectal cancer has not improved over the last four decades despite advances in surgery and anaesthesia."2.39Adjuvant therapy for colorectal cancer--is there a place for a Northern Ireland study? ( Houston, RF; Moorehead, RJ; Wilson, RH, 1994)
"Chemotherapy for advanced colorectal cancer is reviewed stressing the historical development of combination chemotherapy and the application of a new idea called biochemical modulation based upon a preclinical biochemical and molecular pharmacological rationale."2.39[Recent advance in chemotherapy for advanced colorectal cancer]. ( Aiba, K, 1996)
" In many countries patients with CRC do not receive chemotherapy because some clinicians perceive that the benefits of such treatment do not compensate for the potential negative effects on patient quality of life in terms of toxicity and inconvenient dosage schedules."2.39Colorectal cancer--an undertreated disease. ( Kemeny, N, 1996)
"5-Fluorouracil (5-FU) has been studied over the past two decades in five prospective randomized trials comparing bolus with infusional schedules."2.39Infusional 5-FU for advanced colorectal cancer. ( Lokich, J, 1995)
"Colorectal cancer is a common cancer and a common cause of death."2.39Colorectal cancer: the challenge. ( Bleiberg, H, 1996)
"The treatment of advanced colorectal cancer has improved in recent years."2.38Recent advances in the treatment of advanced colorectal cancer. ( Ahlgren, JD; Anderson, N; Kemeny, N; Lokich, JJ, 1993)
"Advanced colorectal cancer belongs to the most chemotherapy-resistant human malignancies."2.38Chemotherapy of colorectal cancer. ( Blijham, GH, 1991)
"The substantial recurrence rate of colorectal cancer following potentially curative resection has fuelled the search for effective adjuvant therapy."2.38Adjuvant therapy of colorectal cancer: an overview. ( Green, M; Wirth, A; Zalcberg, JR, 1991)
"In the case of multi-site metastases, outside of trials, the decision to employ chemotherapy must be taken on an individual basis."2.38[Therapy of advanced colorectal cancer]. ( Schalhorn, A, 1991)
"Oxaliplatin utilized in colorectal neoplasms treatment could induce acute peripheral neuropathy (APN) which is a dreadful and frequent adverse event."1.91Incidence and risk factors associated with development of oxalipatin-induced acute peripheral neuropathy in colorectal cancer patients. ( Ben Ayed, W; Ben Mahmoud, IT; Ben Said, A; Berguiga, S; Cherif, I; Hamdi, A; Houij, R; Limayem, I, 2023)
"Xenografted patient-derived colon cancer tissues with MSI also show variable patterns of HDAC2 expression in mice."1.91The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil. ( Brachetti, C; Brenner, W; Kiweler, N; Krämer, OH; Linnebacher, M; Matschos, S; Mullins, C; Nguyen, A; Piée-Staffa, A; Roos, WP; Schneider, G; Schwarz, H, 2023)
"Moreover, E2 fraction potentialized colorectal cancer cells to 5-FU treatment."1.91Anti-tumoral Effect of ( Borie, N; Chazee, L; Devarenne-Charpentier, E; El Btaouri, H; Hammami, M; Martiny, L; Remy, S; Renault, JH; Toumi, I; Yatouji, S, 2023)
"5-Fluorouracil (5-FU) is an essential component of systemic chemotherapy for CRC."1.91 ( Amor, D; Belaid, I; Ben Ahmed, S; Ben Rejeb, N; Bouslama, A; Chouchane, S; Khalij, Y; Omezzine, A, 2023)
"Of patients with colon cancer treated with an initial lower 5-FU dose, 18% had a therapeutic 5-FU blood level."1.91Initiating Treatment with Low Fluorouracil Dose and Titrating According to Blood Levels in Patients Treated with a 46-Hour Continuous Infusion. ( Baranseh, J; Khatib, AW; Selub, SM; Shai, A; Uryvaey, A, 2023)
"Colorectal cancer is the fourth most common cancer worldwide and the third most frequently diagnosed form of cancer associated with high mortality rates."1.91Folic-Acid-Conjugated Thermoresponsive Polymeric Particles for Targeted Delivery of 5-Fluorouracil to CRC Cells. ( Car, H; Lazny, R; Markiewicz, KH; Milewska, S; Misztalewska-Turkowicz, I; Niemirowicz-Laskowska, K; Sawicka, D; Siemiaszko, G; Szymczuk, D; Wilczewska, AZ, 2023)
" We utilized an in vitro dataset of cancer cell lines treated with 5FU and used the reported area under the dose-response curve values to determine the therapeutic response to 5FU treatment."1.91New Transcriptomic Biomarkers of 5-Fluorouracil Resistance. ( Fekete, JT; Győrffy, B, 2023)
"Three datasets of colorectal cancer patients (GSE28691, GSE81006, and GSE77932) from the Gene Expression Omnibus (GEO) database were analyzed and volcano plots for DEGs were generated using the GEO2R tool."1.91Gamma-Aminobutyric Acid Type A Receptor Subunit Pi is a potential chemoresistance regulator in colorectal cancer. ( Chen, C; Chen, J; Feng, Y; Huang, Z; Jin, L; Wang, T; Wu, T; Yao, S; Zhen, Q, 2023)
"Colorectal cancer has risen to the third occurring cancer in the world."1.91The Gut Microbiota Metabolite Urolithin B Prevents Colorectal Carcinogenesis by Remodeling Microbiota and PD-L1/HLA-B. ( Chen, J; Chen, Q; Jin, S; Song, H; Song, X; Wang, L; Wang, Z; Xing, W; Yang, H; Zhao, W, 2023)
"Body surface area (BSA)-based dosing of 5-fluorouracil (5-FU) results in marked inter-individual variability in drug levels, whereas determination of plasma 5-FU concentration and area under the curve (AUC) is a more precise dosing method but has not been integrated into clinical routine."1.91Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy-results of a prospective, multicenter German observational study. ( Burkholder, I; Frank-Gleich, S; Fries, S; Hebart, H; Hofheinz, RD; Hutzschenreuter, U; Kollendt, M; Lamberti, C; Lathan, B; Li, M; Lorentz, C; Lück, A; Mindt, S; Sandner, R; Sick, C; Stein, W; Stosiek, C; Tesch, H; Zingerle, M; Zöller, T, 2023)
"Colorectal cancer (CRC) is the third most common cancer in the world, but current chemotherapy options are limited due to adverse effects and low oral bioavailability of drugs."1.91Development and cytotoxicity evaluation of multiple nanoemulsions for oral co-delivery of 5-fluorouracil and short chain triglycerides for colorectal cancer. ( Barreto, T; Branco, PC; Fukumori, C; Ishida, K; Lopes, LB, 2023)
"Blastocystis is an enteric protozoan parasite with extensive genetic variation and unclear pathogenicity."1.91Blastocystis sp. reduces the efficacy of 5-fluorouracil as a colorectal cancer chemotherapeutic treatment. ( Govind, SK; Jayalakshmi, P; Kumarasamy, V; Kuppusamy, UR, 2023)
"To evaluate the association of age with treatment-related adverse events and survival in patients with mCRC and explore the potential underlying factors."1.91Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer. ( Delgado, MG; Gomez, MF; Hubbard, JM; Ji, R; Kim, RD; Knepper, TC; Laber, DA; Meng, L; Permuth, JB; Thapa, R; Wang, X; Xie, H, 2023)
"Chemoresistance mechanisms of colorectal cancer remain largely elusive."1.91Proteomic Profiling of Chemotherapy Responses in FOLFOX-Resistant Colorectal Cancer Cells. ( Chen, JY; Islam Khan, MZ; Law, HK; Tam, SY; Tam, TY; Yan, HY; Yip, JH, 2023)
"Four databases were compared for colorectal cancer (CRC) cases and stage IV CRC cases: American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange Biopharma Collaborative (GENIE-BPC), The Cancer Genome Atlas (TCGA), SEER-Medicare, and MarketScan Commercial and Medicare Supplemental claims databases."1.91Evaluation and Comparison of Real-World Databases for Conducting Research in Patients With Colorectal Cancer. ( Amonkar, MM; Bortnichak, EA; Liu, X; McDonald, AC; Shao, C; Wang, CY; Zhou, W, 2023)
"BRAF V600E mutant-metastatic colorectal cancer (mCRC) is characterized by its short survival time."1.91Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China. ( Chang, W; Fu, J; Lin, Q; Lv, Y; Tang, W; Wang, G; Xu, J; Xu, Y; Zhang, T; Zheng, X; Zhu, Z, 2023)
"RNA sequencing of primary colorectal cancer specimens vs adjacent liver tissue vs synchronous and asynchronous liver metastases."1.91Interrogating colorectal cancer metastasis to liver: a search for clinically viable compounds and mechanistic insights in colorectal cancer Patient Derived Organoids. ( Blandino, G; Canu, V; Caricato, M; Cioce, M; Crescenzi, A; Diodoro, MG; Donzelli, S; Fanciulli, M; Fazio, VM; Fumagalli, MR; Goeman, F; Grazi, GL; La Porta, C; Levrero, M; Morrone, A; Orlandi, G; Palcau, AC; Pulito, C; Rutigliano, D; Sacconi, A; Strano, S; Verri, M; Zapperi, S, 2023)
"Conventional therapy for colorectal cancer often involves the use of 5-fluorouracil as a chemotherapeutic agent."1.91In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells. ( Dehelean, C; Ilia, I; Ionita, I; Macasoi, I; Pinzaru, I; Susan, M; Susan, R, 2023)
" We investigated whether plasma angiogenesis factors could predict the efficacy of biologics combined with chemotherapy in first-line (1L) treatment in patients with RAS wild-type mCRC and the dynamics of plasma angiogenesis factors at progression during 1L treatment."1.91Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study. ( Abe, Y; Asano, C; Bando, H; Denda, T; Esaki, T; Kagawa, Y; Kato, T; Kawakami, H; Matsuhashi, N; Nishina, T; Nomura, S; Satake, H; Shiozawa, M; Sunakawa, Y; Takahashi, N; Takashima, A; Taniguchi, H; Yamazaki, K; Yasui, H; Yoshino, T; Yuki, S, 2023)
" Using cell models of colorectal and pancreatic cancers, we show that cotreatment with Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone, AcB), a natural flavone from Achyrocline bogotensis, allows for four-fold reduction in 5-Fu dosage without loss of efficacy."1.91Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone) synergizes with 5-fluorouracil allowing for dose reduction and reduced off-target toxicity in the treatment of colonic and pancreatic cancers. ( Cartwright, BM; Corso, JN; Krishnan, K; Lightner, J; Palau, VE; Torrenegra, RD; Whitted, C, 2023)
" Number of cycles, dose delays for any cause, and dose reductions for adverse events (AEs) were comparable between age classes."1.91Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study. ( Anchisi, S; Bohanes, P; Derigs, HG; Geffriaud-Ricouard, C; Grünberger, B; Gueldner, M; Hofheinz, RD; Piringer, G; Scholten, F; Schwarz, L; Thaler, J; von Moos, R, 2023)
"Silencing HCG11 inhibited colon cancer cell proliferation, migration, invasion and glucose metabolism and sensitized CRC cells to 5-FU."1.72LncRNA HCG11 promotes 5-FU resistance of colon cancer cells through reprogramming glucose metabolism by targeting the miR-144-3p-PDK4 axis. ( Cui, Z; Deng, MH; Han, QL; Wang, Q, 2022)
"To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC)."1.72Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study. ( Aprile, G; Avallone, A; Bilancia, D; Brugnatelli, S; Carlomagno, C; Cicero, G; Cinausero, M; Colombo, A; Corsi, D; Dell'Aquila, E; Pinto, C; Rapisardi, S; Reggiardo, G; Rosati, G, 2022)
"Metformin is an old, inexpensive, and relatively safe anti-diabetic medication that can decrease the risk of several types of cancer in patients with diabetes."1.72The Emerging Role of Metformin in the Prevention and Treatment of Colorectal Cancer: A Game Changer for the Management of Colorectal Cancer. ( Ala, M, 2022)
"Cardiotoxicity is a severe side effect for colorectal cancer (CRC) patients undergoing fluoropyrimidine-based chemotherapy."1.72Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy. ( Chen, L; Chou, C; Li, C; Ngorsuraches, S; Qian, J, 2022)
"Combining colorectal resection with HAI pump implantation is a safe surgical approach for management of unresectable CRLM."1.72Combined Primary Resection with Hepatic Artery Infusion Pump Implantation Is Safe for Unresectable Colorectal Liver Metastases. ( Allen, PJ; Creasy, JM; Lan, B; Lidsky, ME; Mantyh, CR; Migaly, J; Moore, C; Sharib, J; Thacker, JKM; Turley, MC; Zani, S, 2022)
"5-Fluorouracil is an anticancer drug with a short biological half-life."1.72The development of a novel oral 5-Fluorouracil in-situ gelling nanosuspension to potentiate the anticancer activity against colorectal cancer cells. ( Abdullah, S; Aldahlawi, A; El Hadad, S, 2022)
"During the development of colorectal cancer, tumor cells will generate some cancer stem cells with self-renewal ability because they adapt to the environment."1.72BIX-01294 enhances the effect of chemotherapy on colorectal cancer by inhibiting the expression of stemness genes. ( Han, Y; Hua, Z; Jiang, Y; Liu, S; Nie, S; Shu, X; Wang, X; Xu, G; Xu, S; Yang, H; Zhou, C, 2022)
"The incidence of colorectal cancer (CRC) in individuals of fertile age is increasing."1.72Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer. ( Berglund, Å; Eberhard, J; Falk, P; Guren, MG; Hofsli, E; Österlund, P; Severin, M; Sorbye, H; Tandberg, A, 2022)
"Fifteen percent of colorectal cancer (CRC) cells exhibit a mucin hypersecretory phenotype, which is suggested to provide resistance to immune surveillance and chemotherapy."1.72Reversing chemorefraction in colorectal cancer cells by controlling mucin secretion. ( Alonso-Marañón, J; Cantero-Recasens, G; Espinosa, L; Garrido, M; Iglesias, M; Lobo-Jarne, T; Malhotra, V, 2022)
" Based on the T helper 17(Th17)/regulatory T cell(Treg) balance, the present study explored the possible mechanism of AR-CR combined with 5-fluorouracil(5-FU) on the tumor growth of orthotopic xenograft model mice of colorectal carcinoma."1.72[Effect of Astragali Radix-Curcumae Rhizoma compatibility combined with 5-fluorouracil on Th17/Treg balance and tumor-related mRNA and protein expression in orthotopic xenograft model mice of CT26.WT colorectal carcinoma]. ( Guan, HQ; Guo, WH; Liang, L; Liang, Y; Liu, TT; Qi, ZC; Tang, DC; Yu, QH, 2022)
" The efficacy and adverse effects of maintenance treatment were compared between the two groups."1.72Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer. ( Cha, Y; Huang, W; Tian, Y; Xiong, H; Yuan, X; Zhang, H, 2022)
" Common Terminology Criteria for Adverse Events v4."1.72Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study. ( Alyami, M; Bakrin, N; Bardet, SM; Dumont, F; Durand Fontanier, S; Eveno, C; Gagniere, J; Glehen, O; Hübner, M; Pache, B; Pocard, M; Quenet, F; Sgarbura, O; Taibi, A; Teixeira Farinha, H; Thibaudeau, E, 2022)
"Most of Stage II/III colorectal cancer (CRC) patients can be cured by surgery alone, and only certain CRC patients benefit from adjuvant chemotherapy."1.72A retrospective analysis using deep-learning models for prediction of survival outcome and benefit of adjuvant chemotherapy in stage II/III colorectal cancer. ( Jonnagaddala, J; Li, X; Xu, XS; Yang, S; Zhang, H, 2022)
"Chemotherapy resistance of colorectal cancer stem cells (CRC-SCs) has become a major challenge in clinical treatment of cancer."1.72Methionine restriction enhances the chemotherapeutic sensitivity of colorectal cancer stem cells by miR-320d/c-Myc axis. ( Liu, C; Wang, JL; Wu, DZ; Xin, L; Yuan, YW, 2022)
"But its role in the development of colorectal cancer (CRC) cancer remains unknown."1.72FAM98A promotes resistance to 5-fluorouracil in colorectal cancer by suppressing ferroptosis. ( Deng, H; He, Z; Li, G; Mou, T; Shi, J; Sui, C; Sun, K; Wang, T; Wang, Y; Xu, Z; Yang, J; Zhang, P; Zhuang, B, 2022)
"It revealed a peritoneal recurrence in the pouch of Douglas."1.72[A Case Report for Peritoneal Recurrences by Laparoscopic Surgery after Colorectal Cancer Resection]. ( Arakawa, A; Ii, Y; Irie, T; Kawaguchi, M; Kawai, M; Kobari, A; Kojima, Y; Momose, H; Sakamoto, K; Sugimoto, K; Terao, Y; Tomiki, Y; Tsukamoto, R, 2022)
" The most frequent grade 3/4 adverse events were: asthenia (21."1.72Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen. ( Alonso de Castro, B; Cameselle García, S; Carmona Campos, M; Cousillas Castiñeiras, A; De la Cámara Gómez, JC; Fernández-Montes, A; Gómez-Randulfe Rodríguez, MI; González Villarroel, P; Martínez-Lago, N; Méndez Méndez, JC; Romero Reinoso, C; Salgado Fernández, M; Vidal Insua, Y, 2022)
"Colorectal cancer is one of the most commonly diagnosed malignancies globally and nearly half of these patients develop metastatic colorectal cancer (mCRC)."1.72Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy. ( Liu, JY; Liu, X; Long, YX; Qiu, M; Zhou, YW, 2022)
"However, its role and mechanism in colorectal cancer (CRC) remained unknown."1.72circEXOC6B interacting with RRAGB, an mTORC1 activator, inhibits the progression of colorectal cancer by antagonizing the HIF1A-RRAGB-mTORC1 positive feedback loop. ( Chen, L; Chen, Y; Dai, P; Li, X; Lin, W; Long, H; Lu, Y; Wang, H; Wang, J; Yuan, Q, 2022)
"Chemoresistance is a main obstacle for colorectal cancer treatment."1.72Stabilizing and upregulating Axin with tankyrase inhibitor reverses 5-fluorouracil chemoresistance and proliferation by targeting the WNT/caveolin-1 axis in colorectal cancer cells. ( Li, J; Liu, J; Liu, K; Luo, F, 2022)
"5-Fluorouracil (5-FU) has long been used as a standard first-line treatment for CRC patients."1.72Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer. ( Duan, T; Feng, J; Huang, X; Jin, W; Ke, K; Mei, R; Mou, Y; Shou, L; Sui, X; Sun, X; Wu, Q; Xie, T; Yu, S; Zhang, R; Zhu, Q, 2022)
" Treatment regimens, body surface area, dosage, number of treatment courses, and adverse events( AEs) were evaluated."1.72[Comparative Safety Assessment of Ramucirumab plus FOLFIRI and Bevacizumab plus FOLFIRI in Second- and Later-Line Treatment in Japanese Patients with Metastatic Colorectal Carcinoma]. ( Iwai, M; Kimura, M; Usami, E; Yoshimura, T, 2022)
" Data from experiments for 48 h showed that Bru, alone or in combination with 5-FU, is capable of causing an increase in the percentage of apoptotic cells in HT-29 cells compared to those of Erio alone or in combination with 5-FU."1.72Potential cancer treatment effects of brusatol or eriodictyol combined with 5-fluorouracil (5-FU) in colorectal cancer cell. ( Alper, M; Ardıl, B, 2022)
"More and more patients with advanced colorectal cancer (CRC) have benefited from surgical resection or ablation following neoadjuvant chemoradiotherapy (nCRT), but nCRT may be ineffective and have potential risks to some patients."1.72Kif4A mediates resistance to neoadjuvant chemoradiotherapy in patients with advanced colorectal cancer via regulating DNA damage response. ( Ding, C; Dong, Z; Gong, B; Jin, S; Liu, S; Xie, W; Xu, C; Xu, L; Zhang, R; Zhao, Y; Zheng, Y, 2022)
"Grade ≥ 3 neutropenia was significantly more common in patients with than without osteopenia (p = 0."1.72Impact of osteopenia and neutropenia in patients with colorectal cancer treated with FOLFOXIRI: a retrospective cohort study. ( Kashihara, H; Nakao, T; Nishi, M; Shimada, M; Takasu, C; Tokunaga, T; Wada, Y; Yamashita, S; Yoshikawa, K; Yoshimoto, T, 2022)
" However, during CRC treatment, long-term use of traditional chemotherapeutic drugs will reduce the sensitivity of chemotherapy."1.72A serum metabolomics study based on LC-MS: Chemosensitization effects of Rauvolfia vomitoria Afzel. combined with 5- fluorouracil on colorectal cancer mice. ( Kong, WR; Wang, JF; Wang, N; Wang, SQ; Wang, ZF; You, YL, 2022)
" Treatment was started with 30 mg of prednisolone, and the dosage was gradually decreased."1.72[A Case of Unilateral Interstitial Lung Disease in a Patient Treated with Oxaliplatin, 5-Fluorouracil, and Leucovorin]. ( Aisaki, K; Aoki, K; Doumoto, Y; Funatsu, K; Hosaka, M; Kimura, T; Kobori, S; Minoshima, K; Ushiku, H; Wakabayashi, M; Yoshida, H, 2022)
"On day 2 of re-treatment, serous retinal detachment recurred and treatment was discontinued."1.72[A Case of Serous Retinal Detachment after Encorafenib, Binimetinib, and Cetuximab Treatment for BRAF V600E Mutant Colorectal Cancer]. ( Ajihara, T; Fukuya, Y; Hanada, M; Koike, T; Kono, T; Miyata, R; Naritomi, T; Shiozawa, S; Yoshimatsu, K, 2022)
" By combining high content light microscopy imaging and processing with rapid multiwell plate bioprinting, dose-response profiles are generated from CRC spheroids challenged with oxaliplatin (OX) and fluorouracil (5FU), as well as radiotherapy."1.72A rapid high throughput bioprinted colorectal cancer spheroid platform for ( Alibhai, D; Bayley, H; Chambers, AC; Collard, TJ; Johnson, PA; Menegatti, S; Perriman, AW; Williams, AC, 2022)
"Case 2: A 72-year-old man underwent sigmoid colon cancer resection with duodenal infiltration."1.72[Cases of Advanced Colorectal Cancer with Nephrotic Syndrome after FOLFIRI plus Ramucirumab Administration]. ( Fujimura, T; Nakura, M; Nojima, K; Sasaki, S; Takenaka, S; Takeshita, M; Watanabe, T; Yamazaki, H, 2022)
"A total of 48 consecutive patients with colorectal cancer (CRC) with hepatic metastasis were retrospectively reviewed, and factors such as metastatic tumor vascular microenvironment, chemotherapy response and hepatic resection, were analyzed."1.62Tumor Vascular Microenvironment of Colorectal Hepatic Metastasis and Chemotherapy Response. ( Ichikawa, D; Iino, H; Okamoto, H; Shiba, S; Sudoh, M, 2021)
"The outbreak of coronavirus disease 2019 (COVID-19) has affected the treatment of cancer patients, with particular regard to the management of both chemotherapy and side effects."1.62NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study. ( Caputo, V; Cicero, G; De Luca, R; Ferrera, G; Mistretta, O; Paci, R; Rosati, G; Volpe, C, 2021)
" Doctors should be aware of the sex difference in the incidence of early DLTs, adjust the CAPOX dosage and provide supportive care for female CRC patients."1.62Women are predisposed to early dose-limiting toxicities during adjuvant CAPOX for colorectal cancer. ( Abe, S; Anzai, H; Emoto, S; Ishihara, S; Kawai, K; Kishikawa, J; Murono, K; Nagai, Y; Nozawa, H; Ozawa, T; Sasaki, K; Sonoda, H; Yokoyama, Y, 2021)
"Among patients with colorectal cancer (CRC) treated with oxaliplatin (L-OHP)-based chemotherapy, delayed chemotherapy-induced nausea and vomiting (CINV) have not been well controlled."1.62Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk. ( Fukunaga, M; Hayashi, T; Kogawa, T; Matsui, R; Mizuki, F; Nishimura, J; Satoh, T; Shimokawa, M; Tsuji, Y, 2021)
"Regorafenib, which has been approved as a salvage line for metastatic colorectal cancer, features many adverse events, and there are few cases in which the approved dose can be administered."1.62[A Case of Long-Term Survival after Administration of Regorafenib for Stage Ⅳ Colorectal Cancer]. ( Koike, T; Kono, T; Miyano, Y; Oyama, K; Shiozawa, S; Yokokawa, H; Yoshimatsu, K, 2021)
"Fatty liver is a side effect of chemotherapy that limits the ability to treat colorectal cancer (CRC) patients in the most effective way."1.62Alterations in hepatic fatty acids reveal depletion of total polyunsaturated fatty acids following irinotecan plus 5-fluorouracil treatment in an animal model of colorectal cancer. ( Bathe, O; Jacobs, R; Mazurak, VC; Monirujjaman, M; Nelson, R; Pant, A, 2021)
"Colorectal cancer is one of the most common cancers in the world."1.62Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report. ( Akkuş, E; Gürbüz, M; Utkan, G, 2021)
"The enterocyte subtype of colorectal cancer (CRC) responds favorably to oxaliplatin-based adjuvant treatment for stage III CRC."1.62Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer. ( Barzi, A; Berger, MD; Cao, S; Lenz, HJ; Matsusaka, S; Miyamoto, Y; Okazaki, S; Schirripa, M; Suenaga, M; Yamaguchi, T; Yamamoto, N; Zhang, W, 2021)
"Individuals with Stages II and III colorectal cancer who underwent major resection from 2014 to 2015 were identified."1.62Addressing the variation in adjuvant chemotherapy treatment for colorectal cancer: Can a regional intervention promote national change? ( Birch, RJ; Brown, V; Dent, J; Dewdney, A; Morris, EJA; Quirke, P; Rossington, HL; Seligmann, JF; Swinson, D; Taylor, JC, 2021)
"All breast and colorectal cancer patients enrolled in the POG program between July 1, 2012 and November 30, 2016 were eligible for inclusion."1.62Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancer. ( Abadi, S; Chia, S; Guenter, J; Jones, M; Laskin, J; Lim, H; Marra, M; Rebic, N; Renouf, DJ; Woods, R, 2021)
"5-Fluorouracil is an antineoplastic agent generally used to treat various types of solid tumors."1.62Case report on 5-fluorouracil induced cerebrovascular accident. ( Ashok, AM; Babu, CM; Karthikeyan, K; Madhu, CS; Shaji, S, 2021)
"The distinct features among BRAF mutant colorectal cancers make these tumor groups hard to treat for oncologists."1.62The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study. ( Artac, M; Ates, O; Beypinar, I; Demir, H; Eren, T; Ergun, Y; Korkmaz, M; Sakalar, T; Sakin, A; Taskoylu, BY; Turhal, S, 2021)
"A considerable proportion of metastatic colorectal cancer patients who received active chemotherapy in this population-based study received only one line of therapy."1.62Real-world patterns of chemotherapy administration and attrition among patients with metastatic colorectal cancer. ( Abdel-Rahman, O; Koski, S; Mulder, K, 2021)
"Colorectal cancer is a major health problem with a significant impact on the patients' quality of life."1.625-FU inhibits migration and invasion of CRC cells through PI3K/AKT pathway regulated by MARCH1. ( Dai, J; Jia, X; Liu, C; Wang, N; Wu, Y; Yang, L; Zhang, R, 2021)
"In patients with metastatic colorectal cancer (mCRC) receiving highly active first-line combination treatments, early tumor shrinkage (ETS) and depth of response (DoR) are associated with survival, but their influence on outcomes during maintenance therapy is unknown."1.62Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. ( Antista, M; Antoniotti, C; Bergamo, F; Calareso, G; Clavarezza, M; Corallo, S; Cremolini, C; de Braud, F; Di Bartolomeo, M; Greco, FG; Lonardi, S; Manca, P; Morano, F; Murialdo, R; Pagani, F; Palermo, F; Pietrantonio, F; Prisciandaro, M; Racca, P; Raimondi, A; Randon, G; Rimassa, L; Smiroldo, V; Tampellini, M; Tomasello, G; Vaiani, M; Zaniboni, A, 2021)
" Although the survival benefits when combined with chemotherapy have been determined, there are no studies comparing the two agents with chemotherapy in the second-line treatment."1.62The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience. ( Almuradova, E; Çakar, B; Doğanavşargil, B; Gürsoy, P; Harman, M; Karabulut, B; Karateke, M; Sezak, M, 2021)
"The use of sodium levofolinate (Na-Lev) is safe in combination with continuous infusion 5-fluorouracil in patients with gastrointestinal tumors treated with the FOLFIRI regimen."1.62Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination with 5-Fluorouracil in the FOLFIRI Regimen. ( Bartolini, G; Crudi, L; Donati, C; Foca, F; Frassineti, GL; Masini, C; Matteucci, L; Monti, M; Pagan, F; Passardi, A; Rapposelli, I; Ruscelli, S; Sbaffi, S; Sullo, F; Valgiusti, M, 2021)
"Oesophageal cancer is categorised among the most fatal cancers across the world with a mortality ranking of sixth position."1.62Rare presentation of subglottic soft-tissue swelling following FOLFOX therapy in a patient with metastatic oesophageal cancer. ( Govero, AB; Kukhon, FR; Sanghavi, DK; Yarrarapu, SNS, 2021)
"42 L/h/kg after intravenous administration, oral bioavailability of 13."1.62Targeting thymidine phosphorylase inhibition in human colorectal cancer xenografts. ( Altenhofen, S; Basso, LA; Bizarro, CV; Bonan, CD; Borsoi, AF; da Silva Dadda, A; de Sousa, JT; de Souza, APD; Freitas, DDN; Freitas, RDS; Machado, P; Nabinger, DD; Perelló, MA; Picada, JN; Rodrigues-Junior, VS; Roth, CD; Silva, RBM; Sperotto, NDM, 2021)
"It is used to treat metastatic colorectal carcinoma."1.62A rare presentation of panitumumab-involved interstitial lung disease: Spontaneous pneumomediastinum. ( Ates, UC; Comert, B; Ergun, B; Gezer, S; Ugur, L; Yakar, N, 2021)
"Emerging data show a rise in colorectal cancer (CRC) incidence in young men and women that is often chemoresistant."1.62Mice with dysfunctional TGF-β signaling develop altered intestinal microbiome and colorectal cancer resistant to 5FU. ( Hopson, LM; Jogunoori, W; Lin, P; Mazumder, R; Miller, L; Mishra, L; Nguyen, BN; Obias, V; Rao, S; Singleton, SS; Wang, Z; White, J; Yang, X; Yao, M, 2021)
"Colorectal cancer is the second most common malignant tumor in China."1.62[Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil/leucovorin for colorectal cancer]. ( , 2021)
"Drug resistance in colorectal cancer is a great challenge in clinic."1.62MicroRNA-29b-3p promotes 5-fluorouracil resistance via suppressing TRAF5-mediated necroptosis in human colorectal cancer. ( Fang, Y; Liu, P; Shen, X; Wang, W; Wu, S; Zhang, H; Zhou, Y, 2021)
"Zotarolimus is a semi-synthetic derivative of rapamycin and an inhibitor of mammalian target of rapamycin (mTOR) signaling."1.62Anti-Cancer Effects of Zotarolimus Combined with 5-Fluorouracil Treatment in HCT-116 Colorectal Cancer-Bearing BALB/c Nude Mice. ( Chang, GR; Chen, CH; Kuo, CY; Liao, HJ; Lin, TC; Lin, WL; Tsai, MY; Wang, YC, 2021)
" Although curcumin is known to have anti-tumor, hepatoprotective, and hypoglycemic-like actions, its low water solubility, oral absorption, and bioavailability impede its therapeutic uses."1.62Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids. ( Abugomaa, A; Ayame, H; Elbadawy, M; Hayashi, K; Hayashi, SM; Hazama, S; Ishihara, Y; Kaneda, M; Nagano, H; Nakajima, M; Sasaki, K; Shibutani, M; Shinohara, Y; Suzuki, N; Takenouchi, H; Tsunedomi, R; Usui, T; Yamawaki, H, 2021)
"Metastatic colorectal cancer patients treated with aflibercept beyond second-line therapy were included."1.56Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study. ( Artru, P; Auclin, E; Auvray, M; Coriat, R; Hammel, P; Hautefeuille, V; Lecaille, C; Lecomte, T; Locher, C; Moulin, V; Pernot, S; Sickersen, G; Taieb, J; Tougeron, D; Vernerey, D, 2020)
"Although the colorectal cancer (CRC) mortality rates are decreasing in virtue of CRC screening and improved therapeutic methods, CRC is still a leading cause of cancer deaths."1.56Ferritin Light Chain (FTL) competes with long noncoding RNA Linc00467 for miR-133b binding site to regulate chemoresistance and metastasis of colorectal cancer. ( Chen, H; Huang, L; Li, Z; Liu, J; Shen, R; Shi, H; Tao, J; Wang, T; Zhang, Y, 2020)
"Over 50% of colorectal cancer patients develop resistance after a transient response to therapy."1.56Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis. ( Cao, Y; Li, Q; Liu, Y; Zhang, Y; Zhou, J, 2020)
"In metastatic colorectal cancer (MCRC), mucinous histology has been associated with poor response rate and prognosis."1.56Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients. ( Alessandroni, P; Bergamo, F; Borelli, B; Catalano, V; Cremolini, C; Falcone, A; Giordani, P; Graziano, F; Intini, R; Lonardi, S; Mattioli, R; Negri, F; Rocchi, MBL; Rossini, D; Santini, D; Sarti, D; Stragliotto, S; Vincenzi, B; Zagonel, V, 2020)
"Truncating mutations in adenomatous polyposis coli (APC) are well-described events in CRC carcinogenesis."1.56APC truncating mutations in Middle Eastern Population: Tankyrase inhibitor is an effective strategy to sensitize APC mutant CRC To 5-FU chemotherapy. ( Abduljabbar, A; Ahmed, SO; Al-Dayel, F; Al-Kuraya, KS; Al-Sanea, N; Ashari, LH; Begum, R; Concepcion, RMJA; Kumar Parvathareddy, S; Melosantos, R; Padmaja Divya, S; Pratheeshkumar, P; Siraj, AK, 2020)
"5-Fluorouracil (5-FU) is a typical CRC treatment."1.56BET inhibitor bromosporine enhances 5-FU effect in colorectal cancer cells. ( Cheng, X; Huang, Z; Jin, W; Long, D, 2020)
"Untreated colorectal tumors contain a population of quiescent/slow cycling cells with stem cell features (quiescent cancer stem cells, QCSCs) characterized by a predetermined mesenchymal-like chemoresistant phenotype."1.56A pre-existing population of ZEB2 ( Baiocchi, M; Boe, A; Careccia, S; Ciardi, A; Colace, L; Contavalli, P; D'Andrea, V; De Angelis, ML; De Maria, R; Francescangeli, F; Giuliani, A; Guardiola, O; Haas, TL; La Torre, F; Medema, J; Minchiotti, G; Pagliuca, A; Salaris, F; Signore, M; Tcheremenskaia, O; Zeuner, A, 2020)
"The chemotherapeutic efficacy in colorectal cancer (CRC) is limited due to the inter-individual variability in drug response and the development of tumour resistance."1.56Expression quantitative trait loci in ABC transporters are associated with survival in 5-FU treated colorectal cancer patients. ( Bartu, L; Bendova, P; Buchler, T; Hughes, DJ; Kral, J; Kumar, R; Levy, M; Naccarati, A; Pardini, B; Rosa, F; Soucek, P; Susova, S; Vodicka, P; Vodickova, L; Vymetalkova, V, 2020)
" A modified FOLFOXIRI regimen is also widely used to reduce adverse events."1.56Efficacy and Safety of Modified FOLFOXIRI+α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience. ( Adachi, T; Eguchi, S; Enjoji, T; Hidaka, M; Inoue, Y; Ito, S; Kanetaka, K; Kobayashi, K; Kosaka, T; Kuba, S; Okada, S; Takatsuki, M; Tetsuo, H; Torashima, Y; Yamaguchi, S; Yamanouchi, K, 2020)
" Physiological information of treatment response derived via diffuse reflectance spectroscopy (DRS) from murine primary CRC tumors provide a better understanding for the development of new drugs and dosing strategies in CRC."1.56Diffuse reflectance spectroscopy to monitor murine colorectal tumor progression and therapeutic response. ( Bullard, EA; Fahr, MJ; Greening, GJ; Hale, LN; Muldoon, TJ; Mundo, AI; Rajaram, N, 2020)
"TUSC3 gene plays an oncogenic role in colorectal cancer (CRC), however, the role of TUSC3 in drug resistance of CRC is still unclear."1.56TUSC3 induces drug resistance and cellular stemness via Hedgehog signaling pathway in colorectal cancer. ( Cai, R; Deng, R; Ding, Y; Lin, J; Lu, X; Luo, Y; Ren, Y; Wang, Z; Yin, M; Zhu, Y, 2020)
"Some metastatic colorectal cancer (mCRC) patients receive conversion surgery (CS), including metastasectomy after palliative chemotherapy."1.56Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases. ( Chang, W; Cho, JY; Cho, S; Jheon, S; Kang, SB; Kim, DW; Kim, JH; Kim, JW; Kim, K; Kim, SA; Lee, KW; Oh, HK; Suh, KJ, 2020)
"FOLFOX therapy has been used for gastric cancer in Japan since 2017."1.56[Clinical Efficacy of mFOLFOX6 for Advanced Gastric Cancer]. ( Cho, H; Funasaka, C; Kanemasa, Y; Omuro, Y; Shimoyama, T, 2020)
"Developing new drugs for killing colorectal cancer (CRC) cells is urgently needed."1.56Toosendanin-induced apoptosis in colorectal cancer cells is associated with the κ-opioid receptor/β-catenin signaling axis. ( Chen, J; Chen, S; He, L; Huang, L; Li, W; Liu, H; Liu, R; Wang, F; Wang, H; Wen, C; Yang, X; Yu, WK; Zhou, Q, 2020)
"Thirty metastatic colorectal cancer patients without RAS and BRAF mutations were prospectively enrolled and treated with cytotoxic agents and EGFR blockade as first-line therapy."1.56Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy. ( Iwai, T; Koizumi, M; Kuriyama, S; Matsuda, A; Ohta, R; Shinji, S; Takahashi, G; Takeda, K; Ueda, K; Yamada, T; Yokoyama, Y; Yoshida, H, 2020)
"Cutaneous metastases from colorectal cancer are extremely rare and generally appear several years after diagnosis or resection of the primary colorectal tumor."1.56Cutaneous metastasis of ascending colon cancer harboring a BRAF V600E mutation: A rare case report. ( Cheng, Q; Liao, L; Pei, F; Ye, S; Zhu, G, 2020)
" Chemotherapy-induced side effects were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE Version 5."1.56Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. ( Abdhaghighi, MJ; Jalali, H; Janbabaei, G; Negarandeh, R; Nosrati, A; Saghafi, F; Salehifar, E, 2020)
"Treatment options for locally advanced rectal cancer have continued to consist largely of chemotherapy, chemoradiation, and/or surgical resection."1.56Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series. ( Cho, M; Damle, N; Dayyani, F; Demisse, R; Eng, C; Fakih, M; Gholami, S; Gong, J; Halabi, W; Ji, J; Kim, E; Liu, J; Louie, R; McKenny, M; Monjazeb, A; Oesterich, L; Tam, K, 2020)
"The overexpression of CTCF promoted colorectal cancer cell proliferation and tumor growth, while the opposite effects were observed in CTCF knockdown cells."1.56CTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axis. ( Cai, J; Ding, J; Fang, Y; He, C; He, J; Lai, Q; Li, A; Li, Q; Lin, S; Liu, S; Liu, Y; Wang, X; Wu, C; Yan, Q; Zhang, Y; Zhong, Q, 2020)
"Fifty patients with metastatic colorectal cancer were prospectively followed-up during the first 4 cycles of fluoropyrimidine-based treatment to assess AEs."1.56Association of C677T and A1298C ( Chinchilla, R; Ramos-Esquivel, A; Valle, M, 2020)
" We weekly applied the orofacial section of the Acute and Chronic Neuropathy Questionnaire of Common Toxicity Criteria for Adverse Events of the National Cancer Institute of the United States of America (Oxaliplatin-specific neurotoxicity scale)."1.56FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study. ( Costa, BA; da Rocha Filho, DR; de Albuquerque Ribeiro Gondinho, P; de Barros Silva, PG; Gifoni, MAC; Junior, RCPL; Lima, MVA; Lisboa, MRP; Vale, ML, 2020)
"Eighteen cases of stage IV CAC (7 ulcerative colitis, 11 Crohn disease) and 18 CRC were identified."1.56Systemic Chemotherapy for Metastatic Colitis-Associated Cancer Has a Worse Outcome Than Sporadic Colorectal Cancer: Matched Case Cohort Analysis. ( Bates, DDB; Capanu, M; Chatila, W; Chou, J; Hersch, J; Kelsen, D; Paroder, V; Schultz, N; Tang, L; Yaeger, R, 2020)
" Whether a patient who experienced a major cardiac side effect from 5-FU can be safely rechallenged with this drug is a clinical dilemma."1.565-Fluorouracil Rechallenge After Cardiotoxicity. ( Almnajam, M; Desai, A; Kim, AS; Mohammed, T; Patel, KN, 2020)
"Glycine has been shown to protect livers from CTx-induced injury and oxidative stress, and it reduces platelet aggregation and improves microperfusion."1.56Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury: A Colorectal Cancer Liver Metastasis Treatment Model in Rats. ( Bausys, A; Feldbacher, N; Hoefler, G; Kolb-Lenz, D; Leber, B; Maneikyte, J; Schemmer, P; Stiegler, P; Strupas, K, 2020)
"Patients with PM from colorectal cancer and PCI >20 that were treated with CRS and HIPEC experience a one year longer and doubled overall survival compared with open-close/debulking patients."1.56Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. ( Artursson, S; Birgisson, H; Cashin, P; Enblad, M; Ghanipour, L; Graf, W, 2020)
"The study includes the total of 60 colorectal cancer metastases operated patients, divided into two groups of 30 patients: the group of patients who were treated with "bevacizumab plus FOLFOX IV" protocol as a neoadjuvant therapy - prior to liver metastases surgery and the control group, patients with the liver resection done without previous neoadjuvant chemotherapy."1.56Molecular mechanisms of liver damage during neoadjuvant treatment for hepatic metastases of colorectal cancer. ( Gmijovic, M; Pecic, V; Stojanovic, M, 2020)
"At the time of disease progression, FOLFIRI cetuximab regimen was reintroduced resulting in stabilization of disease and he continued with capecitabine cetuximab therapy until disease progression in October 2016."1.56Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report. ( Antonuzzo, L; Castiglione, F; Di Costanzo, F; Lastraioli, E; Lavacchi, D; Messerini, L; Palmieri, VE, 2020)
" Although several biomarkers predicted different toxic effects, they cannot be considered as risk factors for severe toxicity."1.56Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma. ( Cañadas-Garre, M; Carrasco-Campos, MI; Pérez-Ramírez, C; Puerta-García, E; Segura-Pérez, A; Urbano-Pérez, D, 2020)
"In half of all CRC patients, colorectal cancer liver metastases (CRLM) can be observed."1.56Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer. ( Alawi, M; David, K; Ewald, F; Fischer, L; Indenbirken, D; Izbicki, JR; Jücker, M; Juhl, H; Molloy, MP; Nashan, B; Omidi, M; Sauter, G; Schlüter, H; Simon, R; Smit, DJ; Spohn, M; Voß, H; Wurlitzer, M, 2020)
"However, the effect of tazemetostat on colorectal cancer (CRC) and 5-FU sensitivity remains unclear."1.56Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer. ( Liu, P; Shen, L; Tan, X; Tong, JS; Yao, H; Zhang, Z, 2020)
"However, to date, the role of KHSRP in colorectal cancer (CRC) progression has not been reported."1.56Inhibition of KHSRP sensitizes colorectal cancer to 5-fluoruracil through miR-501-5p-mediated ERRFI1 mRNA degradation. ( Cai, W; Li, P; Pan, R; Sun, J; Yu, C; Zheng, M, 2020)
"The central role of CD44v6 in colorectal cancer has been previously reported."1.51Downregulation of CD44v6 Enhances Chemosensitivity by Promoting Apoptosis and Inhibiting Autophagy in Colorectal Cancer HT29 Cells. ( Bhandari, A; Liu, HG; Lv, L; Pan, XX; Sun, YH; Wang, OC; Wang, QX; Ye, DR; Zhang, XH, 2019)
"Treatment of B/U liver metastases from CRC with conversion chemotherapy using mFLOX regimen followed by surgical resection was associated with a high R0 resection rate and favorable survival outcomes."1.51Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings. ( Amor Divino, PH; Bonadio, RC; Capareli, FC; Hoff, PM; Kruger, JAP; Lima, KCA; Obando, JSM; Recchimuzzi, DZ; Saragiotto, DF, 2019)
" Older age was associated with a higher probability of serious adverse events (OR (odds ratio) 0."1.51Impact of age on toxicity and efficacy of 5-FU-based combination chemotherapy among patients with metastatic colorectal cancer; a pooled analysis of five randomized trials. ( Abdel-Rahman, O; Karachiwala, H, 2019)
"Colorectal cancer is the third leading cause of cancer death worldwide."1.51In-Vivo Retention of 5-Fluorouracil Using ( Albert, MS; Davenport, E; Davenport, K; Fox, MS; Li, T; Shepelytskyi, Y, 2019)
"Platinum was readily detectable in skin biopsies more than 60 months post-completion of FOLFOX."1.51Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy. ( Cao, Y; Chang, Q; Chen, EX; Hedley, D; Ornatsky, O; Zhang, W, 2019)
"Studies of patients treated with bevacizumab and other vascular epithelial growth factor (VEGF) inhibitors have reported that hypertension adverse events (AEs) are associated with improved overall survival (OS) or progression-free survival (PFS)."1.51Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab. ( Hopkins, AM; Karapetis, CS; Lim, HH; Rowland, A; Sorich, MJ; Yuen, HY, 2019)
"For the quantification of circulating tumor cells in the peripheral blood, we used the maintrac method."1.51Insulin enhancement of the antitumor activity of chemotherapeutic agents in colorectal cancer is linked with downregulating PIK3CA and GRB2. ( Agrawal, AK; Agrawal, S; Banach, J; Gamian, A; Makuch, S; Pielka, E; Pizon, M; Wietrzyk, J; Woźniak, M; Ziółkowski, P; Łuc, M, 2019)
"Chemotherapy is currently used to treat colorectal cancer (CRC), the most common cancer worldwide."1.51Identification of bioactive compounds in Lactobacillus paracasei subsp. paracasei NTU 101-fermented reconstituted skimmed milk and their anti-cancer effect in combination with 5-fluorouracil on colorectal cancer cells. ( Chang, CY; Pan, TM, 2019)
" Within multivariable logistic regression analysis, patients with an ECOG score of 0 have a lower probability of serious adverse events (OR 0."1.51ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials. ( Abdel-Rahman, O, 2019)
"HER2-positve patients with stage II colorectal cancer can benefit from 5-fluorouracial based adjuvant chemotherapy, especially for patients with pMMR status."1.51HER2 as a potential biomarker guiding adjuvant chemotherapy in stage II colorectal cancer. ( Cai, S; Feng, Y; Huang, D; Li, Y; Peng, J, 2019)
"Irinotecan (CPT-11) is a drug used against a wide range of tumor types."1.51Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer. ( Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019)
" Severe adverse events were equivalent across age groups."1.51Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study. ( Bernard, MA; Coutureau, J; Droz, C; Duc, S; Forrier-Réglat, A; Gérard, S; Gouverneur, A; Grelaud, A; Jové, J; Lassalle, R; Noize, P; Ravaud, A; Rouyer, M; Smith, D, 2019)
"Here, we have analyzed STK17A in colorectal cancer and demonstrated decreased expression of STK17A in primary tumors, which is further reduced in metastatic lesions, indicating a potential role in regulating the metastatic cascade."1.51Serine Threonine Kinase 17A Maintains the Epithelial State in Colorectal Cancer Cells. ( Bilotta, AJ; Chen, X; Revetta, FL; Short, SP; Thompson, JJ; Washington, MK; Williams, CS, 2019)
" Through univariate and multivariate logistic regression analyses, factors predicting the development of serious adverse events, fatal adverse events, and toxicity-related hospitalizations were determined."1.51Predictors of toxicity-related hospitalization in four randomized studies of 5-fluorouracil-based chemotherapy in metastatic colorectal cancer. ( Abdel-Rahman, O; Ahmed, O, 2019)
"In human colorectal cancer tissue specimens, a strong correlation of FOXM1 and TYMS staining was observed."1.51FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression. ( Harada-Shoji, N; Kenny, LM; Lam, EW; Magnani, L; Mauri, F; Szydlo, RM; Varghese, V; Yao, S, 2019)
"Although hepatectomy for metastatic colorectal cancer (mCRC) prolongs survival in up to 40% of people, recurrence rates approach 70%."1.51Repeat hepatectomy with systemic chemotherapy might improve survival of recurrent liver metastasis from colorectal cancer-a retrospective observational study. ( Hanai, T; Hayashi, T; Ikeda, Y; Kato, Y; Katsuno, H; Koide, Y; Maeda, K; Masumori, K; Matsuoka, H; Morise, Z; Nakajima, S; Sugioka, A; Tanahashi, Y; Tanaka, C; Uyama, I, 2019)
" Neurological adverse effects were assessed by CTC v2."1.51Effect of diabetes on neurological adverse effects and chemotherapy induced peripheral neuropathy in advanced colorectal cancer patients treated with different FOLFOX regimens. ( Bano, N; Ikram, R, 2019)
" To test this hypothesis, we analyzed CEA and CA19-9 serum levels in patients with advanced colorectal cancer who received cetuximab in combination with chemotherapy."1.51The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer. ( Dai, G; Gou, M; Jia, J; Qian, N; Yang, F; Zhang, P, 2019)
"Aiming to address the issue of poor bioavailability of most anti-tumor medicines against colorectal cancer, we developed a targeted anticancer nanocarrier using biocarriers able to both bind and easily release their load in a controlled manner."1.51Poly(3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer. ( Costache, M; Galateanu, B; Georgiana Nitu, S; Ginghina, O; Hudita, A; Iovu, H; Negrei, C; Radu, IC; Shtilman, M; Tanasa, EV; Tsatsakis, A; Velonia, K; Zaharia, C, 2019)
"Korean female patients with colorectal cancer who received 5-FU chemotherapy experienced more frequent adverse drug reactions including alopecia and leukopenia than male patients."1.51Sex-Dependent Adverse Drug Reactions to 5-Fluorouracil in Colorectal Cancer. ( Jung, J; Kim, KS; Kim, SY; Lee, E; Lee, S; Lim, H; Moon, A; Oh, S, 2019)
"To overcome the problem of overlooking colorectal tumors, a new and highly sensitive modality of colonoscopy is needed."1.51Epidermal growth factor receptor-targeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models. ( Fujimoto, S; Kida, Y; Kitamura, S; Miyamoto, H; Miyamoto, Y; Muguruma, N; Nakagawa, T; Nakamura, F; Okada, Y; Okamoto, K; Sato, Y; Takayama, T; Tanaka, K, 2019)
"5-Fluorouracil (5-FU) is a chemotherapeutic drug used to treat cancer, including CRC."1.51Enhancement of chemosensitivity in 5-fluorouracil-resistant colon cancer cells with carcinoembryonic antigen-specific RNA aptamer. ( Lee, JH; Lee, SW, 2019)
"Peritoneal carcinomatosis (PC) from colorectal cancer is associated with poor prognosis."1.51Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study. ( Burnett, A; Cloutier, AS; Dubé, P; Gervais, MK; Lecompte, MA; Sideris, L; Trabulsi, N; Trilling, B, 2019)
"Cancer stem cells (CSCs) residing in colorectal cancer tissues have tumorigenic capacity and contribute to chemotherapeutic resistance and disease relapse."1.51Combination of 5-fluorouracil and thymoquinone targets stem cell gene signature in colorectal cancer cells. ( Agaimy, A; Ballout, F; Çapci, A; Chanvorachote, P; El-Baba, C; Erlenbach-Wuensch, K; Gali-Muhtasib, H; Geppert, CI; Hartmann, A; Huebner, K; Klein, V; Muenzner, JK; Ndreshkjana, B; Roehe, AV; Schneider-Stock, R; Steinmann, S; Tsogoeva, SB, 2019)
"Irinotecan (CPT-11) is a drug used against a wide variety of tumors, which can cause severe toxicity, possibly leading to the delay or suspension of the cycle, with the consequent impact on the prognosis of survival."1.51Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters. ( Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019)
"Sarcopenia was defined as SMI ≤38."1.51Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer. ( Block, C; Gorsuch, K; Gupta, D; Hill, D; Vashi, PG; Wan, L, 2019)
"Our study included 90 cases of colorectal cancer liver metastasis resected after preoperative chemotherapy."1.51Sinusoidal Obstruction Syndrome and Postoperative Complications Resulting from Preoperative Chemotherapy for Colorectal Cancer Liver Metastasis. ( Akagi, Y; Akiba, J; Fujita, F; Fukahori, M; Goto, Y; Hisaka, T; Ishikawa, H; Kawahara, R; Kinugasa, T; Miwa, K; Mizobe, T; Naito, Y; Nakashima, O; Nomura, Y; Okuda, K; Sakai, H; Tanaka, H; Tanigawa, M; Yano, H; Yasunaga, M, 2019)
"Chemotherapy-induced interstitial lung disease in colorectal cancer patients is rare but represents a life-threatening adverse reaction."1.48Interstitial lung disease following FOLFOX + FOLFIRI and bevacizumab therapy associated with leucovorin: A case report. ( Aizawa, K; Furukawa, T; Kozakai, H; Mitsuboshi, S; Nagai, K; Yamada, H, 2018)
"Forty patients with metastatic colorectal cancer receiving FOLFOX4 chemotherapy with or without bevacizumab and 40 healthy volunteers were included in the study."1.48Changes of reduced glutathione and glutathione S-transferase levels in colorectal cancer patients undergoing treatment. ( Aleknavicius, E; Baltruskeviciene, E; Didziapetriene, J; Kazbariene, B; Krikstaponiene, A; Stratilatovas, E; Suziedelis, K; Venceviciene, L, 2018)
"Melatonin has antitumor activity via several mechanisms including its anti-proliferative and pro-apoptotic effects."1.48Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro. ( Bejarano, I; Espino, J; Pariente, JA; Pariente, R; Rodríguez, AB, 2018)
"Among 496 consecutive M1c colorectal cancer patients, R0 resection was achieved for 94 patients (19%)."1.48Long-Term Outcomes After R0 Resection of Synchronous Peritoneal Metastasis from Colorectal Cancer Without Cytoreductive Surgery or Hyperthermic Intraperitoneal Chemotherapy. ( Kanemitsu, Y; Ochiai, H; Shida, D; Tsukamoto, S, 2018)
"Significant inter-individual variation in the sensitivity to 5-fluorouracil (5-FU) represents a major therapeutic hindrance either by impairing drug response or inducing adverse drug reactions (ADRs)."1.48DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer. ( Ahmed, MU; Apu, MNH; Chowdhury, SM; Hasnat, A; Islam, MR; Islam, MS; Nahar, Z; Nahid, NA; Shabnaz, S, 2018)
"Two cohorts of metastatic colorectal cancer (CRC) were analyzed: a nonrandomized exploratory cohort of 184 patients treated at a single institution from 2003 to 2010 and a confirmatory cohort of 200 patients from a multi-institutional randomized trial (NO16966)."1.48The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. ( Ferrarotto, R; George, B; Hobbs, B; Hoff, PM; Kopetz, S; Loyer, EM; Machado, KK; Mazard, T; Overman, MJ; Qiao, W; Raghav, K; Saltz, LB; Vauthey, JN, 2018)
"Early disease progression in the chemotherapy to LR interval occurred in approximately 15% of patients and was associated with extremely poor survival."1.48Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? ( Carnaghi, C; Cimino, M; Darwish, SS; Del Fabbro, D; Donadon, M; Personeni, N; Procopio, F; Rimassa, L; Santoro, A; Torzilli, G; Vigano, L, 2018)
"non-mutated) metastatic colorectal cancer, not eligible for liver resection at baseline, from the UK National Health Service and Personal Social Services perspective."1.48Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England. ( Crathorne, L; Hoyle, M; Huxley, N; Napier, M; Snowsill, T; Tikhonova, IA; Varley-Campbell, J, 2018)
"However, its role in colorectal cancer (CRC) remains poorly understood."1.48β‑arrestin2 promotes 5‑FU‑induced apoptosis via the NF‑κB pathway in colorectal cancer. ( Gao, F; He, X; Liu, F; Liu, Y; Ren, W; Wang, T; Zhang, Q; Zhang, Y; Zhou, J, 2018)
"Successful treatment of colorectal cancer (CRC) is greatly impeded by metastasis and chemoresistance, particularly to 5-fluoruracil (5-Fu), one of the staples of clinical intervention in advanced CRC."1.48GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer. ( Feng, C; Li, X; Liu, L; Lou, Y; Sun, Y; Wang, Y; Zhan, L; Zhang, L; Zhang, Y, 2018)
"In patients with metastatic colorectal cancer, combination treatment with several anti-cancer drugs is employed and improves overall survival in some patients."1.48Hedgehog Signals Mediate Anti-Cancer Drug Resistance in Three-Dimensional Primary Colorectal Cancer Organoid Culture. ( Elbadawy, M; Hazama, S; Kaneda, M; Nagano, H; Nakajima, M; Ohama, T; Sakurai, M; Sasaki, K; Sato, K; Suzuki, N; Takenouchi, H; Tsunedomi, R; Umata, K; Usui, T; Yamawaki, H, 2018)
" Dosage was more often reduced in patients receiving FOLFOX based therapy."1.48Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects. ( Evert, M; Fest, P; Fichtner-Feigl, S; Gerken, M; Herr, W; Klinkhammer-Schalke, M; Munker, S; Ott, C; Reng, M; Schlitt, HJ; Schnoy, E; Stroszczynski, C; Teufel, A; Vogelhuber, M; Wiggermann, P, 2018)
" Pretreatment with the pan-caspase inhibitor, z-VAD-FMK, attenuated the caspase-dependent apoptosis induced by circularly permuted tumor necrosis factor-related apoptosis-inducing ligand alone or combined with 5-fluorouracil."1.48Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480. ( Liang, X; Sun, T; Yang, S; Zhao, R; Zhu, T, 2018)
"Colorectal carcinoma is a common malignant tumor occurring in the alimentary system."1.48Beta-elemene increases chemosensitivity to 5-fluorouracil through down-regulating microRNA-191 expression in colorectal carcinoma cells. ( Guo, Z; Liu, Z; Wang, J; Yue, H, 2018)
"HCT116 colorectal cancer cells were treated with cobimetinib, and MTT assay, colony formation assay, and flow cytometry were used to evaluate cell viability, cell cycle, and apoptosis, respectively."1.48Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells. ( Gong, S; Peng, R; Xu, D; Zhu, J; Zou, F, 2018)
"5-Fluorouracil (5-FU) is a cornerstone of chemotherapy for CRC and the major targets of 5-FU are folate-metabolizing enzymes."1.48The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer. ( Al-Ramadhani, H; Al-Yacoub, S; Kadi, T; Tantawi, DA; Yousef, AM; Zawiah, M, 2018)
"Its influence on colorectal cancer (CRC), however, has never been evaluated."1.48Overcoming stemness and chemoresistance in colorectal cancer through miR-195-5p-modulated inhibition of notch signaling. ( Chen, Y; Hu, H; Huang, Q; Jin, Y; Wang, G; Wang, M, 2018)
"Colorectal cancer is one of the most common malignancies both in men and women."1.48A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo. ( Chen, CQ; Ding, HW; Li, DD; Ren, TS; Wang, J; Wu, Q; Zhao, CH; Zhao, QC, 2018)
"While early stage colorectal cancer can be removed by surgery, patients with advanced disease are treated by chemotherapy, with 5-Fluorouracil (5-FU) as a main ingredient."1.48Functional significance of Hippo/YAP signaling for drug resistance in colorectal cancer. ( Gu, D; Liu, B; Song, R; Xie, J; Yu, B; Zhang, L; Zhang, X, 2018)
"Here, we show that colorectal cancers (CRCs) display negligible expression of OTC and, in subset of cases, ASS1 proteins."1.48Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes. ( Al-Aqbi, SS; Alexandrou, C; Andreadi, C; Blades, M; Boyle, W; Brown, K; Cheng, PN; Higgins, JA; Howells, LM; Karmokar, A; Luo, JL; Moore, DA; Murray, GI; Rufini, A; Thomas, A; Viskaduraki, M, 2018)
"Crocin was able to ameliorate the severe inflammation with mucosal ulcers and high-grade dysplastic crypts as detected by inflammation score, crypt loss, pathological changes and histology scores."1.48Crocin synergistically enhances the antiproliferative activity of 5-flurouracil through Wnt/PI3K pathway in a mouse model of colitis-associated colorectal cancer. ( Amerizadeh, F; Avan, A; Boroumand, N; Ferns, GA; Fiuji, H; Ghayour-Mobarhan, M; Hassanian, SM; Khazaei, M; Moradi-Marjaneh, R; Nosrati-Tirkani, A; Rahmani, F; Rezaei, N, 2018)
"The use of circulating tumor cells (CTCs) as indicators of treatment response in metastatic colorectal cancer (mCRC) needs to be clarified."1.48Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients. ( de Miguel-Pérez, D; Delgado-Ramirez, M; Delgado-Ureña, M; Exposito-Hernandez, J; García-Puche, JL; Garrido-Navas, MC; Ilyine, H; Lorente, JA; Ortega, FG; Rodriguez-Martínez, A; Serrano, MJ, 2018)
"Background Early relapse in colorectal cancer (CRC) after curative resection is mainly attributed to the key determinants such as tumor histology, stage, lymphovascular invasion, and the response to chemotherapy."1.48Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy. ( Ajaj, AR; Al-Hiary, R; Al-Yacoub, S; Kadi, T; Majdalawi, K; Mukred, R; Tantawi, D; Yousef, AM; Yousef, M; Zawiah, M, 2018)
"Colorectal cancer is one of the most frequently diagnosed cancers worldwide."1.48The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer. ( An, C; Li, H; Mushtaq, N; Shi, Y; Ullah, S; Xu, J; Yang, F; Yuan, L; Zhang, S, 2018)
"Chemotherapy-induced oral mucositis impairs the quality of life."1.48Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study. ( Dote, S; Hira, D; Itakura, S; Kamei, K; Kobayashi, Y; Noda, S; Terada, T, 2018)
"Isoliquiritigenin (ISL) is a natural flavonoid that exhibits anticancer properties in various carcinoma cell types."1.48Isoliquiritigenin-mediated p62/SQSTM1 induction regulates apoptotic potential through attenuation of caspase-8 activation in colorectal cancer cells. ( Jin, H; Lee, SH; Seo, GS, 2018)
"Curcumin has been reported to be an effective compound in the reversal of MDR in colorectal cancer cells."1.48Nrf2 is a key factor in the reversal effect of curcumin on multidrug resistance in the HCT‑8/5‑Fu human colorectal cancer cell line. ( Chen, YY; He, LJ; Jia, YW; Liu, DF; Liu, XP; Miao, DD; Shen, J; Ye, HZ; Zhang, C; Zhang, SP; Zhu, YB, 2018)
"First-line chemotherapy for metastatic colorectal cancer (mCRC) is effective and feasible in selected older patients."1.48Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study. ( Dehlendorff, C; Johansen, JS; Lund, CM; Nielsen, DL; Rønholt, F; Vistisen, KK, 2018)
"Systemic EGFRi may increase dry eye signs as well as decrease CEBD and CNFD."1.48Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial. ( Adán, A; Castellà, C; Eixarch, A; Reguart, N; Saint-Jean, A; Sainz-de-la-Maza, M; Sánchez-Dalmau, B, 2018)
"A total of 80 cases of colorectal cancer tissues were examined by immunohistochemistry for MTA3 protein expression."1.46MTA3 regulates malignant progression of colorectal cancer through Wnt signaling pathway. ( Feng, M; Gao, T; Jiao, T; Li, Y; Liu, M; Sun, M; Zhang, Y; Zhou, H, 2017)
" Potential correlation between treatment modalities (regimen, dosage and route of administration of L-OHP, and injection timing for dexamethasone administration) and HSRs was assessed."1.46Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer. ( Ando, Y; Hayashi, T; Ikeda, Y; Ito, K; Kawada, K; Kumazawa, S; Maeda, K; Matsuoka, H; Murai, S; Ohta, H; Shiouchi, H; Yamada, S; Yasuda, K, 2017)
"Right-sided colorectal cancer (RSCRC) were associated with reduced overall response rate (ORR) (4."1.46The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. ( Antoniotti, C; Cascinu, S; Cremolini, C; Demurtas, L; Falcone, A; Gelsomino, F; Giampieri, R; Loretelli, C; Mandolesi, A; Masi, G; Meriggi, F; Pusceddu, V; Puzzoni, M; Scartozzi, M; Zaniboni, A; Ziranu, P, 2017)
"We screened international colorectal cancer therapeutic guidelines and determined distinct functional tumor behaviors (proliferation, metastasis, and angiogenesis) and differential sensitivities to standard therapy."1.46Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts. ( Carvalho, T; Ferreira, MG; Figueiredo, N; Fior, R; Gomes, A; Mendes, RV; Póvoa, V, 2017)
"Metastatic colorectal cancer (mCRC) patients with mutant KRAS or NRAS are ineligible for anti-epidermal growth factor receptor (anti-EGFR) therapy, as RAS mutations activate downstream pathways independently of EGFR and induce primary resistance."1.46Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. ( Amar, Y; Berger, F; Bieche, I; Cacheux, W; Canet, J; Cartier, A; de Koning, L; Guimbaud, R; Guyetant, S; Lecomte, T; Lièvre, A; Mariani, O; Ouine, B; Selves, J, 2017)
"5-fluorouracil (5-FU) is a specific anti-cancer agent that is generally used to treat gastrointestinal, colorectal, and breast cancer."1.46Preparation and Bioactivity Assessment of Chitosan-1-Acetic Acid-5-Flurouracil Conjugates as Cancer Prodrugs. ( Haj, NQ; Hussain, KS; Mohammed, MO, 2017)
"Collectively, SGK1 promotes colorectal cancer development via regulation of CRC cell proliferation, migration and survival."1.46Therapeutic inhibition of SGK1 suppresses colorectal cancer. ( An, Y; Chen, T; Fu, W; Huang, Q; Jiao, G; Lan, C; Li, Y; Liang, X; Long, X; Wang, K; Xiao, J; Xu, B; Xu, J; Zhou, J, 2017)
"Surgical resection combined with adjuvant chemotherapy is considered as the gold-standard treatment for advanced colorectal cancer patients."1.46Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment. ( Chen, L; Huang, L; Lin, X; Xie, Y; Zheng, Q, 2017)
"We describe 4 cases of locally advanced colorectal cancer resected successfully after neoadjuvant chemotherapy(NAC) conducted between April 2015 and August 2016."1.46[Four Cases of Locally Advanced Colorectal Cancer Resected after Neoadjuvant Chemotherapy with mFOLFOX6 plus Bevacizumab]. ( Doi, Y; Kameda, Y; Masuda, M; Matsuura, H; Rino, Y; Sugano, N; Suzuki, Y; Takata, K; Yamaoku, K; Yoneyama, K, 2017)
"Peritoneal carcinomatosis (PC) from colorectal cancers (CRC) either at initial presentation or at subsequent recurrence presents a significant treatment challenge."1.46Peritoneal Carcinomatosis in Colorectal Cancers - Management Perspective Needs a Change. ( Bhamre, R; Bhandare, M; Engineer, R; Ostwal, V; Pai, V; Patil, P; Saklani, A, 2017)
"In patients with colorectal cancer (CRC), the BRAF V600E mutation has been reported to be associated with several clinicopathological features and poor survival."1.46BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status. ( Han, HS; Hwang, DY; Hwang, TS; Jang, MH; Kim, S; Kim, WS; Kim, WY; Lim, SD, 2017)
"Forty-seven cases of stage III colorectal cancer who received adjuvant chemotherapy with oxaliplatin after curative surgery between January 2010 and August 2014 were retrospectively reviewed."1.46Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy. ( Horiuchi, T; Kimura, M; Maeda, T; Shirai, Y; Tanishima, H; Tominaga, T, 2017)
"Cetuximab has activity against colorectal cancers."1.46Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer. ( Hazama, S; Iida, M; Inoue, Y; Kanekiyo, S; Nagano, H; Sakamoto, K; Suzuki, N; Takeda, S; Tokuhisa, Y; Tokumitsu, Y; Tomochika, S; Tsunedomi, R; Ueno, T; Yoshino, S, 2017)
"Aberrantly expressed BORIS relates to colorectal cancer, but its function in colorectal cancer cells remains unclear."1.46Brother of Regulator of Imprinted Sites (BORIS) suppresses apoptosis in colorectal cancer. ( Fang, J; Fang, M; Ren, J; Song, Y; Wang, X; Zhang, Y, 2017)
"A historical cohort of 112 RAS mutated colorectal cancer patients treated with FOLFOX6 alone served as control group."1.46IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients. ( Barone, C; Basso, M; Berenato, R; Bossi, I; Capoluongo, E; Caporale, M; Danesi, R; de Braud, F; Del Re, M; Di Salvatore, M; Guarino, D; Martinetti, A; Mennitto, A; Mennitto, R; Orlandi, A; Pietrantonio, F; Rossi, E; Santonocito, C; Schinzari, G, 2017)
"Both patients presented with colorectal cancer with synchronous liver metastasis."1.46A New Technique of Radiofrequency-assisted Ultrasound-guided Needle-localized Laparoscopic Resection of Disappearing Colorectal Liver Metastases. ( Aydin, N; Berber, E; Dural, C; Okoh, AK; Taskin, HE; Yazici, P; Yigitbas, H, 2017)
"The CONCERT study (observational cohort study of patients with metastatic colorectal cancer initiating chemotherapy in combination with bevacizumab) aimed to describe patient characteristics, bevacizumab use, its efficacy in terms of progression-free survival (PFS) and overall survival (OS), and its safety in patients with metastatic colorectal cancer (mCRC) treated in daily medical practice."1.46Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT). ( André, T; Asselain, B; Bennouna, J; Ducreux, M; Phelip, JM, 2017)
"Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab."1.46Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. ( Bibeau, F; Del Rio, M; Emile, JF; Gongora, C; Martineau, P; Mollevi, C; Robert, J; Roger, P; Selves, J; Tubiana-Mathieu, N; Vie, N; Ychou, M, 2017)
"These findings suggest the potential roles of HM781-36B as the treatment for EGFR-overexpressing colon cancer, singly or in combination with chemotherapeutic agents."1.43Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells. ( Kang, MH; Kim, JH; Kim, JW; Lee, HS; Lee, JS; Lee, KW; Moon, SU; Sung, JH, 2016)
"Colorectal cancer is the third most common cancer diagnosed in the USA each year."1.43Systemic capillary leak syndrome in a patient receiving adjuvant oxaliplatin for locally advanced colon cancer. ( Anderson, BJ; Peterson, LL, 2016)
"Metastatic liver disease from colorectal cancer is a significant clinical problem."1.43The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis. ( Denys, A; Devun, F; Dutreix, M; Herath, NI; Herbette, A; Lienafa, MC; Sun, JS, 2016)
"The location of the colorectal cancer was classified into 4 regions (the right‑ and left-sided colon, rectosigmoid and rectum) and was compared with gene expression."1.43Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis. ( Fukushima, M; Nukatsuka, M; Shimamoto, Y; Takechi, T, 2016)
"Patients with metastatic colorectal cancer (mCRC) with BRAF mutation (BRAF MT) generally have a poorer prognosis."1.43BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education? ( Amitesh, R; Beeke, C; Karapetis, C; Lo, L; Maddern, G; Moore, J; Padbury, R; Price, TJ; Roder, D; Townsend, AR, 2016)
"Capecitabine is an oral fluoropyrimidine, and administration of oxaliplatin does not necessarily require the insertion of a central venous access device (CVAD)."1.43Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer. ( André, T; Bonnet, I; Bouché, O; Boucher, E; Chibaudel, B; Dauba, J; Faroux, R; Garcia, ML; Guering-Meyer, V; Hug de Larauze, M; Lapeyre-Prost, A; Lièvre, A; Malka, D; Obled, S; Taieb, J; Ychou, M, 2016)
" The primary objective was to investigate the incidence of adverse drug reactions, particularly those of interest for bevacizumab."1.43Bevacizumab safety in Japanese patients with colorectal cancer. ( Doi, T; Hatake, K; Ishihara, Y; Shirao, K; Takahashi, Y; Uetake, H, 2016)
"Of them, 315 node-negative stage II colorectal cancer cases were enrolled."1.43Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial. ( Doki, Y; Fukunaga, M; Ikeda, M; Kato, T; Matsuura, N; Miyake, Y; Mizushima, T; Monden, M; Mori, M; Murata, K; Nakamura, Y; Nezu, R; Noura, S; Ohnishi, T; Ohtsuka, M; Ohue, M; Sekimoto, M; Takemasa, I; Yamamoto, H, 2016)
"Targeting cancer stem cells (CSCs) in colorectal cancer (CRC) remains a difficult problem, as the regulation of CSCs in CRC is poorly understood."1.43KCTD12 Regulates Colorectal Cancer Cell Stemness through the ERK Pathway. ( Duan, T; Huang, H; Kang, T; Li, L; Wang, F; Wang, S; Wang, X; Wu, Y; Zhang, M; Zhang, RH, 2016)
"Capecitabine is a chemotherapeutic agent used in the treatment of metastatic colon cancer and metastatic breast cancer."1.43Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy. ( Aladağ, E; Karakulak, UN; Maharjan, N; Övünç, K, 2016)
"5-Fluorouracil (5FU) was able to stimulate the activation of SMAD3 and the transcription of specific genes such as ACVRL1, FN1 and TGFB1."1.43The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells. ( Bianco, MR; Bugarin, C; Cerrito, MG; Gaipa, G; Garanzini, C; Giovannoni, R; Giuffrè, MR; Grassilli, E; Lavitrano, M; Leone, BE; Leoni, S; Papa, M; Pettinato, M; Romano, G; Santi, L; Savarese, L, 2016)
"Here we will show that, in a colorectal cancer patient cohort, both poor and ultra-rapid metabolizers have significantly increased the risk of developing severe toxicity (grade3-4)."1.43Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort. ( Borro, M; Botticelli, A; Gentile, G; La Torre, M; Lionetto, L; Marchetti, L; Marchetti, P; Mazzotti, E; Mazzuca, F; Simmaco, M, 2016)
"Using a tissue microarray of 89 colorectal cancer cases, we found that SIRT4 was significantly downregulated in colorectal cancer tissues compared with that noted in the corresponding normal tissue (P<0."1.43Clinical and therapeutic significance of sirtuin-4 expression in colorectal cancer. ( Chen, X; Cheng, J; Huang, G; Liu, C; Liu, X; Peng, Z; Yu, F; Yuan, C, 2016)
"Studies of human colorectal cancer cells where the VEGF gene has been deleted suggest an intracellular role of VEGF as a cell survival factor."1.43Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells. ( Bhattacharya, R; Boulbes, D; Ellis, LM; Fan, F; Ling, X; McManus, M; Wang, R; Ye, XC, 2016)
"Despite being the standard anti-colorectal cancer drug, 5-fluorouracil (5-FU) exhibits only limited therapeutic benefits."1.43Paricalcitol Enhances the Chemopreventive Efficacy of 5-Fluorouracil on an Intermediate-Term Model of Azoxymethane-Induced Colorectal Tumors in Rats. ( Ahmad, J; El-Shemi, AG; Idris, S; Kensara, OA; Mohamed, AM; Refaat, B, 2016)
" We evaluated treatment-related adverse events (AEs), progression-free survival (PFS) and overall survival (OS)."1.43Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer. ( Abdullah, NM; Sharial, MM; Yusof, MM; Zaatar, A, 2016)
"4% experienced grade 3/4 adverse events."1.43Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort. ( Becouarn, Y; Fourrier-Réglat, A; Grelaud, A; Guimbaud, R; Jové, J; Moore, N; Noize, P; Ravaud, A; Robinson, P; Rouyer, M; Smith, D; Tubiana-Mathieu, N, 2016)
"Patients who underwent metastasectomy or those with Eastern Cooperative Oncology Group performance status (ECOG-PS) ≤1 had longer PFS and OS independent of the type of chemotherapy regimen."1.43Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. ( Artaç, M; Avcı, N; Çabuk, D; Coşkun, HŞ; Dane, F; Doruk, H; Faruk Aykan, N; Karaağaç, M; Karabulut, B; Karabulut, S; Korkmaz, L; Turhal, NS, 2016)
" We found that cetuximab, in combination with chemotherapy, fostered ICD in CRC cells, which we measured via the endoplasmic reticulum (ER) stress response and an increase in phagocytosis by dendritic cells."1.43The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. ( Bardelli, A; Bonaldi, T; Cancelliere, C; Conte, A; Cuomo, A; Di Fiore, PP; Magni, E; Penna, G; Pozzi, C; Ravenda, PS; Rescigno, M; Sigismund, S; Silvola, A; Spadoni, I; Zampino, MG, 2016)
"First-line use of EGFRI in metastatic colorectal cancer is not cost effective at its current pricing relative to Bev."1.43Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. ( Berry, SR; Chan, KK; Giotis, A; Ko, YJ; Lien, K; Mittmann, N; Riesco-Martínez, MC; Wong, WW, 2016)
"Treatment with lenalidomide reduced tumor vessel density (p = 0."1.43Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. ( Aglietta, M; Bertotti, A; Bussolino, F; Gammaitoni, L; Giraudo, E; Giraudo, L; Grignani, G; Leone, F; Leuci, V; Luraghi, P; Maione, F; Mesiano, G; Migliardi, G; Rotolo, R; Sangiolo, D; Sassi, F; Todorovic, M; Trusolino, L, 2016)
"The human colorectal cancer cell lines HCT116, SW480, DLD1, and KM12SM were engineered to stably express a green fluorescent molecule fused to the degron of ornithine decarboxylase, resulting in an accumulation of the fluorescence in LPACs."1.43Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity. ( Carethers, JM; Doki, Y; Fukusumi, T; Hata, T; Ikenaga, M; Kano, Y; Kato, T; Kawai, K; Kitahara, T; Miyo, M; Mizushima, T; Mori, M; Munakata, K; Murata, K; Nishikawa, S; Nishimura, J; Takahashi, Y; Takemasa, I; Tanaka, S; Uemura, M; Yamamoto, H, 2016)
"Among the advanced colorectal cancer patients who received treatment with FOLFOX or FOLFIRI at Koyama Memorial Hospital, patients older than 65 years of age were selected in order to assess the effectiveness of aprepitant as an antiemetic supportive therapy."1.43[Study of the Efficacy of Aprepitant in FOLFOX/FOLFIRI for Elderly Patients with Advanced Colorectal Cancer]. ( Hanaka, J; Nakayama, H; Takahashi, M; Terashima, T, 2016)
"However, the expression of tmTNF-α in colorectal cancer (CRC) and its association with clinical outcome in CRC have remained unclear."1.43Molecular correlates and prognostic value of tmTNF-α expression in colorectal cancer of 5-Fluorouracil-Based Adjuvant Therapy. ( Huang, K; Li, N; Li, X; Liu, C; Ma, J; Ming, L; Ren, H; Sun, X; Wang, S; Xu, M, 2016)
"Cachexia affects the majority of cancer patients, with currently no effective treatments."1.43Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. ( Barreto, R; Bonetto, A; Gao, H; Liu, Y; Waning, DL; Zimmers, TA, 2016)
" In particular, oxaliplatin(L-OHP), one such platinum-based chemotherapeutic drug, has a synergistic effect in combination with 5-FU and Leucovorin for the treatment of advanced colorectal cancer."1.43[The Molecular Aspect of the Antitumor Effect of Oxaliplatin in Combination with 5-FU]. ( Akiyama, S; Edahiro, K; Iimori, M; Kakeji, Y; Kanaji, S; Kataoka, Y; Kitao, H; Kiyonari, S; Maehara, Y; Nakanishi, R; Niimi, S; Oki, E; Saeki, H; Tokunaga, E, 2016)
"Most colorectal cancer (CRC) cell lines are identified to overexpress phosphoserine phosphatase (PSPH), which regulates the intracellular synthesis of serine and glycine, and supports tumor growth."1.43Inhibition of phosphoserine phosphatase enhances the anticancer efficacy of 5-fluorouracil in colorectal cancer. ( Li, X; Xun, Z; Yang, Y, 2016)
" This relationship favors new treatment strategies with white blood cell growth factors or chemotherapy dosing based on muscle value."1.43Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer. ( Ammari, S; Antoun, S; Bayar, MA; Chemama, S; Elias, D; Goéré, D; Lanoy, E; Raynard, B; Stoclin, A, 2016)
"Data were validated in the rectal cancer cohort treated in the neoadjuvant setting."1.43Calnexin, an ER stress-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer. ( Bacon, O; Carberry, S; Concannon, CG; Fay, J; Hector, S; Kay, EW; Lindner, AU; McCawley, N; McNamara, DA; Murphy, ÁC; Prehn, JH; Ryan, D, 2016)
"The treatment of metastatic colorectal cancer (mCRC) has changed substantially in the last 2 decades, but to the authors' knowledge, the effect of age and comorbidities on chemotherapy use has not been well studied to date."1.43Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer. ( Cohen, SJ; Dotan, E; Hall, MJ; Li, T; Vijayvergia, N; Wong, YN, 2016)
"Primary cultures of colorectal cancer cells from a patient's tumors were studied using the flow cytometry and cytological methods."1.43Primary cultures of human colon cancer as a model to study cancer stem cells. ( Bajenova, O; Danilova, A; Koshkin, S; O'Brien, SJ; Petrov, N; Raskin, G; Tolkunova, E; Tomilin, A, 2016)
" A strong antitumorigenic effect of FOXK1-shRNA was enhanced when combined with 5-FU treatment."1.43Knockdown of FOXK1 alone or in combination with apoptosis-inducing 5-FU inhibits cell growth in colorectal cancer. ( Ba, Y; Chen, Y; Li, A; Liu, S; Liu, X; Nan, Q; Peng, Y; Tang, W; Wang, J; Wu, M; Wu, Y; Xie, R; Zhang, P; Zhao, J, 2016)
"Andrographolide is a natural diterpenoid from Andrographis paniculata which has anti-bacterial, anti-antiviral and anti-inflammation activities."1.43Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression. ( Fu, Z; Gao, J; Gu, Y; Guo, W; Li, L; Liu, W; Shu, Y; Sun, Y; Wang, W; Xu, Q, 2016)
"PSB-603 alters cellular metabolism in colorectal cancer cells and increases their sensitivity to chemotherapy."1.43The A ( Coates, JL; Failla, LM; Heath, JK; Hollande, F; Mølck, C; Pascussi, JM; Ryall, J; Stewart, G, 2016)
"Capecitabine is an oral 5-fluorouracil (5-FU) pro-drug commonly used to treat colorectal carcinoma and other tumours."1.42A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. ( Carracedo, A; Castells, A; Castellvi-Bel, S; Domingo, E; Fernández-Rozadilla, C; Freeman-Mills, L; Gonzalez-Neira, A; Howarth, K; Johnstone, E; Jones, A; Julier, P; Kaur, K; Kerr, D; Kerr, R; Love, S; Martin, M; Pagnamenta, A; Palles, C; Pita, G; Rosmarin, D; Ruiz-Ponte, C; Scudder, C; Taylor, J; Tomlinson, I; Wang, H, 2015)
" By exclusion the pseudo-obstruction was attributed to a toxic oxaliplatin-induced autonomic neuropathy which slowly improved during months of follow-up."1.42A case of delayed oxaliplatin-induced pseudo-obstruction: an atypical presentation of oxaliplatin neurotoxicity. ( Bleecker, JD; Pauwels, W; Vandamme, M, 2015)
"Patients with KRAS wild-type metastatic colorectal cancer in the CORECT registry who initiated treatment with bevacizumab between 2008 and 2012 were enrolled."1.42Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data. ( Bortlíček, Z; Kubáčková, K; Linke, Z; Pikus, T; Pokorná, P; Prausová, J; Vyzula, R, 2015)
"INK-128 inhibited colorectal cancer cell growth and survival, and induced both apoptotic and non-apoptotic cancer cell death."1.42The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent. ( Chen, MB; Cui, JF; Li, C; Liu, CY; Liu, F; Lu, PH; Zhang, QD; Zou, J, 2015)
"Knockdown of CRY2 increased colorectal cancer sensitivity to oxaliplatin in colorectal cancer cells."1.42Circadian Clock Gene CRY2 Degradation Is Involved in Chemoresistance of Colorectal Cancer. ( Deng, Y; Fang, L; Hsiao, CD; Lee, MH; Tung, JY; Wang, J; Wang, L; Wang, P; Yang, Z; Zhou, J, 2015)
"The KRAS gene frequently mutates in colorectal cancer (CRC)."1.42KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer. ( Cai, Y; Chen, D; Deng, Y; Dou, R; Fu, X; Kim, GP; Tan, S; Wang, J; Wang, L; Zhu, J, 2015)
"Using the Tet-OFF system and a human colorectal cancer cell line, DLD-1, we first constructed an in vitro system in which TS expression is dynamically controllable."1.42Dynamic modulation of thymidylate synthase gene expression and fluorouracil sensitivity in human colorectal cancer cells. ( Fukushima, M; Hattori, H; Kawabata, R; Maehara, Y; Nakao, S; Oda, S; Taguchi, K; Uchida, J; Wakasa, K; Yamanaka, T, 2015)
"Colorectal cancer is common."1.42Growth inhibitory effect of polyunsaturated fatty acids (PUFAs) on colon cancer cells via their growth inhibitory metabolites and fatty acid composition changes. ( Das, UN; Ni, X; Shen, S; Yu, H; Zhang, C, 2015)
"Metastasis of colorectal cancer (CRC) in an adrenal gland develops in 1."1.42[Epinephros metastasis of colorectal cancer complicated by tumor thrombosis of inferior vena cava]. ( Andreĭtseva, OI; Gritsiuta, AI; Kalinin, DV; Kharazov, AF; Vishnevskiĭ, AV; Zhavoronkova, OI, 2015)
"The role of MCTs in the survival of colorectal cancer (CRC) cells is scarce and poorly understood."1.42Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells. ( Amorim, R; Baltazar, F; Miranda-Gonçalves, V; Moyer, MP; Pereira, H; Pinheiro, C; Preto, A, 2015)
"Colon cancer in pregnancy is uncommon."1.42Chemotherapeutic treatment of colorectal cancer in pregnancy: case report. ( Al-Khatani, K; Al-Mohaisen, F; Makoshi, Z; Perrott, C, 2015)
" Most grade ≥ 3 adverse events (AEs) were reported during the initial cycles of treatment."1.42Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program. ( Díaz de Corcuera, I; García de la Torre, M; Pérez Hoyos, MT; Salgado Fernández, M; Vidal Arbués, A, 2015)
" The remission rate, control rate and time to disease progression were compared among patients receiving cetuximab combined with different chemotherapy regimens in different periods."1.42[Clinical efficacy observation of cetuximab combined with chemotherapy in the treatment of metastatic colorectal carcinoma]. ( Bai, L; Han, C; Jiao, S; Li, J; Su, D; Wang, Y; Zhang, T, 2015)
"Chemotherapy-induced toxic liver injury is a relevant issue in the clinical management of patients affected with metastatic colorectal cancer (mCRC)."1.42Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience. ( Fausti, V; Gallo, P; Imperatori, M; Picardi, A; Santini, D; Spalato Ceruso, M; Tonini, G; Vespasiani Gentilucci, U; Vincenzi, B, 2015)
"However, the role of KLF8 in colorectal cancer remains unknown."1.42Suppression of KLF8 induces cell differentiation and sensitizes colorectal cancer to 5-fluorouracil. ( Bai, Y; Chen, C; Chen, Y; Cheng, T; Liu, S; Luo, X; Peng, Y; Shi, X; Wang, J; Wu, Y; Yan, Q; Zhang, M; Zhang, W; Zhang, Y; Zhao, J, 2015)
"Most liver metastases from colorectal cancer (CRC) are unresectable at diagnosis."1.42Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial. ( Artru, P; Chalabreysse, P; Desramé, J; Lledo, G; Marsot, J; Mithieux, F; Pellerin, O; Pernot, S; Taieb, J; Watkin, E, 2015)
"Importantly, studies of colorectal cancer specimens indicate that the expression of miR-587 and PPP2R1B positively and inversely correlates with chemoresistance, respectively, in colorectal cancer."1.42MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer. ( Talmon, G; Wang, J; Zhang, Y, 2015)
"For different stages of colorectal cancer, expression of VMP1 had a negative correlation with the malignancy of the cancer."1.42Downregulation of VMP1 confers aggressive properties to colorectal cancer. ( Cai, YJ; Che, XH; Chen, F; Guo, XZ; Liu, XJ; Wei, XN; Xiao, WZ; Ye, XL; You, QH; Yu, MH; Yuan, H, 2015)
"However, the potential role of GA in colorectal cancer and its ability to overcome the chemotherapeutic resistance in CRC cells have not been well studied."1.42Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells. ( Chen, J; Huang, L; Iwamoto, A; Li, W; Lin, M; Liu, H; Lu, B; Rutnam, ZJ; Wang, Z; Wen, C; Yang, X, 2015)
"The diagnosis and treatment of colorectal cancer is one of the main diseases of gastrointestinal surgeons."1.42[Gastrointestinal surgeons should master the adjuvant therapy of colorectal cancer]. ( Chen, P; Gu, J, 2015)
"Its role in tumorigenesis is more controversial and both the presence and the absence of autophagy have been implicated."1.42Autophagy is upregulated during colorectal carcinogenesis, and in DNA microsatellite stable carcinomas. ( Benincasa, M; Magnani, G; Mancini, S; Mariani, F; Palumbo, C; Pedroni, M; Roncucci, L; Sena, P, 2015)
"Because the serum concentration of 5-FU fluctuates and displays various patterns, the dosage should not be based on body surface area."1.42Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer. ( Higashida, M; Hirai, T; Kubota, H; Matsumoto, H; Murakami, H; Okumura, H; Tohyama, K; Tsuruta, A, 2015)
"We present 2 patients with metastatic colorectal cancer who had progressed despite treatment with first-line FOLFOX and second-line FOLFIRI combination chemotherapy regimens."1.42Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. ( El-Deiry, WS; Marks, EI; Scicchitano, A; Tan, C; Yang, Z; Zhang, J; Zhou, L, 2015)
"The optimal cutoff affecting recurrence was 276×10(9)/L."1.42[Impact of platelet count on prognosis of stage II-III colorectal cancer receiving adjuvant chemotherapy]. ( Cai, Z; Guan, H; Hong, C; Liang, Z; Luo, D; Luo, P; Tan, Z; Wei, Y; Yang, Z; Zeng, Z, 2015)
"The SCAN colorectal cancer systemic therapy workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy for colorectal cancer in Singapore."1.42Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer. ( , 2015)
"Approximately 20% of the patients with colorectal cancer have distant metastasis during diagnosis."1.42Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients. ( Albayrak, D; Cicin, I; Erdogan, B; Hacibekiroglu, I; Kodaz, H; Tozkir, H; Turkmen, E; Uzunoglu, S, 2015)
"Berberine is an alkaloid isolated from the Chinese herbal medicine Huanglian, and has long been used as an antibiotic."1.40Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. ( Cai, Y; Huang, P; Jiang, W; Luo, R; Shi, Y; Sun, Y; Xia, Q, 2014)
"Gefitinib was cytostatic."1.40Gefitinib enhances the effects of combined radiotherapy and 5-fluorouracil in a colorectal cancer cell line. ( Aristei, C; Calzuola, M; Cecchini, D; Contavalli, P; Falzetti, F; Marini, V; Palumbo, I; Piattoni, S; Valentini, V; Vecchio, FM, 2014)
"The HT-29 colorectal cancer cell line was cultured and exposed with 5-FU in three stages based on Bolus protocol."1.40Down-regulation of BAX gene during carcinogenesis and acquisition of resistance to 5-FU in colorectal cancer. ( Bandehpour, M; Karbasi, A; Kazemi, B; Manoochehri, M, 2014)
"We enrolled 234 patients with Stage III colorectal cancer who underwent curative resection."1.40Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status. ( Fukazawa, S; Hase, K; Hashiguchi, Y; Kubo, T; Naito, Y; Okamoto, K; Shikina, A; Shinto, E; Ueno, H; Yamamoto, J, 2014)
"According to treatment, ORR, metastasectomies, PFS and OS were significantly favourable in triplet CT plus targeted agent compared to triplet, respectively: 80%, 40%, 13 months, not reached; 28%, 6%, 8 months, 11 months."1.40Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype. ( Bruera, G; Cannita, K; Ficorella, C; Giordano, AV; Ricevuto, E; Vicentini, R, 2014)
"Human colorectal cancer specimens (n=94) and human colorectal cancer cell lines HRT18 and HT115 were used."1.40Death associated protein 1 is correlated with the clinical outcome of patients with colorectal cancer and has a role in the regulation of cell death. ( Davies, ML; Hargest, R; Ji, J; Ji, K; Jia, Y; Jiang, WG; Ruge, F; Toms, AM; Ye, L, 2014)
"We found that oxaliplatin resistance in colorectal cancer cells depends on the DNA methylation-associated inactivation of the BRCA1 interactor SRBC gene."1.40Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. ( Abad, A; Carmona, FJ; Cassingena, A; Elez, E; Esteller, M; Martínez-Balibrea, E; Martinez-Cardús, A; Moutinho, C; Musulen, E; Navarro-Pérez, V; Salazar, R; Santos, C; Sartore-Bianchi, A; Siena, S; Tabernero, J, 2014)
"Cinnamaldehyde is an active monomer isolated from the stem bark of Cinnamomum cassia, a traditional oriental medicinal herb, which is known to possess marked antitumor effects in vitro and in vivo."1.40Cinnamaldehyde/chemotherapeutic agents interaction and drug-metabolizing genes in colorectal cancer. ( Liu, SL; Qi, MH; Yu, C; Zou, X, 2014)
"Cardiac toxicity an uncommon but serious side-effect of some fluoropyrimides."1.40Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. ( Ferry, D; Fournier, M; Gebski, V; Gordon, S; Karapetis, CS; Price, TJ; Ransom, D; Simes, RJ; Tebbutt, N; Wilson, K; Yip, D, 2014)
"In the clinic, predicting metastasis and chemoresistance takes high priority, but has not been well established."1.40Predicting distant metastasis and chemoresistance using plasma miRNAs. ( Chen, J; Chen, Y; Hu, T; Wang, W; Zhang, Y, 2014)
"Patients with stage IV colorectal cancer and peritoneal carcinomatosis are increasingly treated with curative intent and perioperative systemic chemotherapy combined with targeted therapy."1.40Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. ( Elias, D; Eveno, C; Gayat, E; Glehen, O; Goéré, D; Passot, G; Pocard, M; Soyer, P, 2014)
"Ninety-two metastatic colorectal cancer patients treated with first-line 5-fluoropyrimidine (5-FU), leucovorin, and oxaliplatin (FOLFOX), capecitabine, and oxaliplatin (XELOX) and sixty-two patients receiving 5-FU, leucovorin, and irinotecan (FOLFIRI) were reviewed."1.40Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. ( Cai, S; Li, W; Sun, M; Yu, Q; Zhang, W; Zhang, Z; Zhao, J; Zhu, D, 2014)
"Despite curative surgery for colorectal cancer, some patients experience tumor recurrence."1.40Comparison of clinicopathological characteristics and prognosis between early and late recurrence after curative surgery for colorectal cancer. ( Chang, SC; Chen, WS; Chiou, SH; Jiang, JK; Lan, YT; Lin, CC; Lin, JK; Lin, TC; Wang, HS; Yang, SH, 2014)
"We found that S100P expression of colorectal cancer tissue was significantly higher than that of normal colorectal mucosal tissues."1.40Overexpression of S100P promotes colorectal cancer metastasis and decreases chemosensitivity to 5-FU in vitro. ( Chen, L; Dong, L; Jiang, L; Jin, R; Li, G; Lin, F; Ni, W; Wang, F; Wu, J; Yin, X, 2014)
"Unresectable metastatic colorectal cancer with very slow tumour growth rate does not necessarily require for strong short-interval chemotherapy."1.40Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer. ( Akiba, T; Enomoto, H; Kawahara, H; Tomoda, M; Watanabe, K; Yanaga, K, 2014)
"Twelve to 13% of patients with colorectal cancer (CRC) develop peritoneal carcinomatosis (PC), the majority of whom present with unresectable disease."1.40A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer. ( Aalbers, A; Boot, H; Hompes, D; Prevoo, W; van Tinteren, H; van Velthuysen, ML; Verwaal, V; Vogel, W, 2014)
"5-Fluorouracil (5-FU) is a first line chemotherapeutic medication used in the treatment of gallbladder cancer; however, the efficacy is below satisfactory."1.40Icariin-mediated inhibition of NF-κB activity enhances the in vitro and in vivo antitumour effect of 5-fluorouracil in colorectal cancer. ( Cai, GX; Cai, SJ; Gu, WL; Guan, ZQ; Li, DW; Li, XX; Peng, JJ; Shi, DB; Xu, Y; Zheng, HT, 2014)
"0144) adverse effects in stage II/III patients."1.40Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens. ( Beachler, C; El-Deiry, WS; Harvey, HA; Kline, CL; Mackley, HB; McKenna, K; Messaris, E; Poritz, L; Schiccitano, A; Sheikh, H; Sivik, J; Staveley-O'Carroll, K; Stewart, D; Zhu, J, 2014)
"The incidence of colorectal cancer has been increasing every year in Korea."1.40FOLFIRI as second-line chemotherapy after failure of FOLFOX4 in advanced colorectal cancer: a Korean single-center experience. ( Kim, JH; Kim, SE; Ku, KH; Moon, W; Park, MI; Park, SJ; Song, SE, 2014)
"Surgery is the standard treatment for colorectal cancer (CRC), and adjuvant chemotherapy has been shown to be effective in stage III but less so in stage II."1.40Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines. ( Artells, R; Cordeiro, A; Diaz, T; Ferrer, G; Hernandez, R; Monzo, M; Moreno, I; Navarro, A; Tapia, G; Tejero, R, 2014)
"A total of 102 metastatic colorectal cancer patients treated with a oxaliplatin (XELOX) ±Bevacizumab combination were retrospectively evaluated."1.40Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy. ( Berk, V; Bozkurt, O; Duran, AO; Inanc, M; Karaca, H; Ozaslan, E; Ozkan, M, 2014)
"We have planned a multicentre prospective study to examine the relative impact of the efficacy and adverse events of cetuximab plus first-line chemotherapy on the quality of life in Japanese patients with KRAS wild-type unresectable colorectal cancer."1.40A prospective observational study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK Trial. ( Ando, M; Fujii, H; Ooki, A; Sakamoto, J; Sato, A; Yamaguchi, K, 2014)
"A 67-year-old man diagnosed with colorectal cancer in 2008 presented in April 2011 to Appalachian Regional Healthcare Cancer Center with obstructive jaundice and weight loss."1.40Safety and efficacy of FOLFOX followed by cetuximab for metastatic colorectal cancer with severe liver dysfunction. ( Craig, J; Elsoueidi, R; Mourad, H; Richa, EM, 2014)
"A primary challenge in identifying replicable pharmacogenomic markers from clinical genomewide association study (GWAS) trials in oncology is the difficulty in performing a second large clinical trial with the same drugs and dosage regimen."1.40Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses. ( Alba, E; Alonso, R; de la Torre-Montero, JC; Dolan, ME; González-Neira, A; Lopez-Fernandez, LA; Martín, M; Pita, G; Wheeler, HE, 2014)
"Biological characteristics of colorectal cancer liver metastases (CRCLM) are increasingly recognized as major determinants of patient outcome."1.40Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver. ( Christophi, C; Lau, LF; Lee, ST; Muralidharan, V; Scott, AM; Williams, DS, 2014)
"Hepatic resection of metastatic colorectal cancer (CRC) has become the treatment of choice for patients after resection of the primary CRC."1.40Extracapsular lymph node involvement is associated with colorectal liver metastases and impact outcome after hepatectomy for colorectal metastases. ( Araki, K; Asao, T; Fujii, T; Kubo, N; Kuwano, H; Suzuki, H; Tsukagoshi, M; Tsutsumi, S; Wada, S; Watanabe, A, 2014)
"The formation of liver metastases in colorectal cancer patients is the primary cause of patient death."1.40Suppression of colorectal cancer liver metastasis by apolipoprotein(a) kringle V in a nude mouse model through the induction of apoptosis in tumor-associated endothelial cells. ( Ahn, JH; Hong, SW; Kim, JS; Kim, SJ; Lee, HJ; Yu, HK, 2014)
"Patients with inoperable tumors due to metastasis at the time of diagnosis who were treated with oxaliplatin or irinotecan as the first-line treatment were included in this study."1.40Prognostic factors for metastatic colorectal cancer after first-line chemotherapy with FOLFOX-4 or FOLFIRI regimen. ( Choi, PR; Kim, JH; Kim, SE; Lee, GW; Moon, W; Park, MI; Park, SJ, 2014)
"Long-term OS after CRS and HIPEC for colorectal cancer is associated with CC and neoadjuvant therapy containing bevacizumab."1.40Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. ( Ceelen, W; Pattyn, P; Putte, DV; Van Nieuwenhove, Y, 2014)
"The treatment of colorectal cancer (CRC) might be improved by the identification of a signalling pathway that could be targeted with novel therapeutics."1.40Role of SLC6A6 in promoting the survival and multidrug resistance of colorectal cancer. ( Matsumura, Y; Yasunaga, M, 2014)
"Patients with colorectal cancer who received adjuvant CAPOX from January 2005 to August 2011 were reviewed."1.40Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer. ( Altaf, R; Kristensen, B; Lund Brixen, A; Nielsen, SE, 2014)
"Adjuvant chemotherapy use in stage II colorectal cancer (CRC) is debated."1.40The role of adjuvant chemotherapy in stage II colorectal cancer patients. ( Chang, SC; Chang, YY; Chen, WS; Jiang, JK; Lan, YT; Lin, CC; Lin, HH; Lin, JK; Lin, TC; Wang, HS; Yang, SH, 2014)
"We enrolled 36 patients with colorectal cancer, treated with adjuvant mFOLFOX6 or XELOX chemotherapy, and 22 healthy volunteers."1.40The impact of oxaliplatin-based chemotherapy for colorectal cancer on the autonomous nervous system. ( Basdanis, G; Dermitzakis, EV; Eleftheraki, A; Fountzilas, G; Georgiadis, G; Kimiskidis, VK; Konstantis, A; Lazaridis, G; Tsiptsios, I, 2014)
"Diarrhea is a common toxicity of chemotherapy, but the practice of reporting only severe grades (≥ 3) in clinical trials results in misleading conclusions of significance."1.40Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy. ( Aprile, G; Barsevick, A; Bonaventura, A; Elting, LS; Grunberg, SM; Keefe, DM; Koczwara, B; Nguyen, HT; Selva-Nayagam, S; Sonis, ST, 2014)
"Colorectal cancer metastasis is a major cause of mortality worldwide, which may only be controlled with novel methods limiting tumor dissemination and chemoresistance."1.40Unbiased proteomic and transcript analyses reveal that stathmin-1 silencing inhibits colorectal cancer metastasis and sensitizes to 5-fluorouracil treatment. ( Chung, MC; Lim, TK; Tan, HT; Tan, XF; Wu, W, 2014)
"Sampling of saliva is a quick, noninvasive, safe and painless process that gives information about patients Ura and UH₂ levels prior to chemotherapeutical treatment."1.40Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2014)
" The comparison revealed no significant differences in response rate, progression-free survival, overall survival, and the frequency of overall adverse events after the start of second-line chemotherapy, although the frequency of anemia(Bgrade 3, p=0."1.40[The efficacy and safety of FOLFIRI or combined FOLFIRI and bevacizumab treatment as second-line chemotherapy for metastatic colorectal cancer patients aged 75 years and older]. ( Baba, H; Chika, N; Haga, N; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Okada, N; Sano, M; Tajima, Y, 2014)
"To estimate the incremental cost per life-year gained (LYG) of aflibercept in combination with FOLFIRI as second-line treatment in metastatic colorectal cancer (mCRC) patients previously treated with oxaliplatin."1.40[Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer]. ( Abad, A; Echave, M; Frías, C; Giménez, E; Joulain, F; Lamas, MJ; Naoshy, S; Oyagüez, I; Pericay, C; Rubio, M, 2014)
" OBJECTIVE response rates (ORRs), progression-free survival (PFS), overall survival (OS) and adverse events were recorded, and the relationships between various clinical factors and PFS or OS were evaluated by Cox proportional hazards models."1.40Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer. ( Chen, L; Ju, HX; Liu, BX; Liu, LY; Luo, C; Xu, Q; Yang, YS; Ying, JE; Zhao, YZ; Zhong, HJ; Zhu, LM, 2014)
"The aim of this retrospectively study was to evaluate the clinical efficacy of Aidi injection (ADI) combined with FOLFOX4 chemothreapy regimen in the treatment of advanced colorectal carcinoma."1.40Aidi injection combined with FOLFOX4 chemotherapy regimen in the treatment of advanced colorectal carcinoma. ( Li, Y; Nan, H; Wang, T; Wang, Y; Zhang, C; Zhang, X, 2014)
"Mechanistic studies in a colorectal cancer mouse model revealed that FOLFIRI-like therapy including the drugs CPT11 and 5-fluorouracil (5FU) damaged host immunocompetence in a manner that limits treatment outcomes."1.40Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes. ( Baniyash, M; Biton, M; Goldshtein, A; Hubert, A; Ish-Shalom, E; Kanterman, J; Lasry, A; Sade-Feldman, M, 2014)
"Unlike metastatic colorectal cancer (CRC) there are to date few reports concerning the predictive value of molecular biomarkers on the clinical outcome in stage II/III CRC patients receiving adjuvant chemotherapy."1.40Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial. ( Bauer, S; Formentini, A; Galle, PR; Hoffman, A; Kittner, JM; Kornmann, M; Link, KH; Maderer, A; Moehler, M; Neumann, W; Rey, JW; Schad, A; Schwarz, M; Thomaidis, T; Trautmann, M; Weinmann, A, 2014)
" A randomized trial showed increased OS and decreased toxicity with PK-guided compared with BSA-based 5-FU dosing in patients with mCRC."1.40Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer. ( Ayer, T; Chen, Q; El-Rayes, BF; Flowers, CR; Goldstein, DA; Harvey, RD; Howard, DH; Lipscomb, J, 2014)
"We examined Sdc-1 shedding in colorectal cancer by enzyme-linked immunosorbent assay (ELISA), Dot blot, reverse transcription-PCR (RT-PCR), immunohistochemistry and so on, its impact on chemotherapeutic sensitivity by collagen gel droplet embedded culture-drug sensitivity test (CD-DST) and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), and potential mechanisms of action by Dot blot, western blot and immunofluorescence."1.40Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer. ( Ba, Y; Chen, Y; Deng, T; He, Y; Li, W; Liu, R; Ren, L; Wang, X; Ying, G; Zhou, L; Zuo, D, 2014)
"In practice, patients with metastatic colorectal cancer in treatment failure or relapse after first-line therapy should not expect too much from the addition of aflibercept or bevacizumab to a second-line protocol."1.40Aflibercept. Metastatic colorectal cancer: at least as poorly tolerated as bevacizumab. ( , 2014)
"To assess the frequency and severity of gastrointestinal adverse effects in advanced colorectal carcinoma patients treated with four different schedules of FOLFOX."1.40Gastrointestinal adverse effects in advanced colorectal carcinoma patients treated with different schedules of FOLFOX. ( Bano, N; Mateen, A; Najam, R; Qazi, F, 2014)
" Radiofrequency ablation (RFA) is a safe and effective technique for treatment of isolated liver metastasis."1.40Safety and efficacy of radiofrequency ablation with aflibercept and FOLFIRI in a patient with metastatic colorectal cancer. ( Agarwal, A; Butler-Bowen, H; Daly, KP; Saif, MW, 2014)
"Participants were 91 colorectal cancer patients treated with OXA-based chemotherapy."1.40Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. ( Alberti, P; Argyriou, AA; Bergamo, F; Briani, C; Bruna, J; Cacciavillani, M; Campagnolo, M; Cavaletti, G; Cazzaniga, M; Cortinovis, D; Frigeni, B; Izquierdo, C; Kalofonos, HP; Velasco, R, 2014)
"All unresectable metastatic colorectal cancer patients who began receiving bevacizumab at participating facilities from 2006 to 2011 were retrospectively analyze to determine the safety and efficacy."1.40Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer. ( Asao, T; Fujii, T; Kato, T; Kuwano, H; Morita, H; Suto, T; Tsutsumi, S; Yajima, R; Yamaguchi, S, 2014)
"When co-cultured with colorectal cancer cells in the presence of 5-FC, HB1."1.39Suppression of the growth of human colorectal cancer cells by therapeutic stem cells expressing cytosine deaminase and interferon-β via their tumor-tropic effect in cellular and xenograft mouse models. ( Choi, KC; Choi, KJ; Kang, NH; Kim, SU; Lee, HR; Park, MA; Yi, BR, 2013)
" All patients were genotyped for MTHFR 1298A>C and 677C>T polymorphisms and analysed in both cohorts separately for the association between the MTHFR genotype and incidence of grade 3-4 overall toxicity and specific adverse events, as well as efficacy parameters."1.39MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer. ( Gelderblom, H; Guchelaar, HJ; Punt, CJ; van Huis-Tanja, LH, 2013)
" The use of combined neoadjuvant chemotherapy is safe before hepatic resection."1.39Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment. ( Baranyai, ZS; Besznyák, I; Bursics, A; Dede, K; Jakab, F; Landherr, L; Mersich, T; Salamon, F; Zaránd, A, 2013)
"Patients with metastatic colorectal cancer (n = 543) from an international phase 3 trial comparing FOLFOX2 with chronoFLO4 were categorized into 4 subgroups according to the occurrence of FWL or other clinically relevant toxicities during the initial 2 courses of chemotherapy."1.39Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. ( Bjarnason, GA; Carvalho, C; Focan, C; Garufi, C; Giacchetti, S; Iacobelli, S; Innominato, PF; Karaboué, A; Lévi, F; Moreau, T; Poncet, A; Smaaland, R; Spiegel, D; Tampellini, M; Tumolo, S, 2013)
" The frequency of grade 3 and 4 adverse effects were comparatively assessed in each treatment arm."1.39Comparative assessment of skin and subcutaneous toxicity in patients of advanced colorectal carcinoma treated with different schedules of FOLFOX. ( Bano, N; Mateen, A; Najam, R, 2013)
"The genome expression profiles of colorectal cancer tissues were examined using DNA microarray analysis, and differential gene expression was identified using a significance analysis of the microarray."1.39Establishment of a predictive genetic model for estimating chemotherapy sensitivity of colorectal cancer with synchronous liver metastasis. ( Chi, P; Huang, S; Huang, Y; Li, S; Lin, H; Lu, X; Pan, J; Shen, S; Xu, Z, 2013)
"5-fluorouracil (5-FU) has been widely used since the 1980s, and it remains the backbone of many chemotherapeutic combination regimens."1.39DMET™ (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity. ( Amadori, A; Boldrin, E; Rumiato, E; Saggioro, D, 2013)
" Clinical data demonstrated that there was higher correlation between DPD activity and toxic effects of 5-FU (p<0."1.39Evaluation of clinical value of single nucleotide polymorphisms of dihydropyrimidine dehydrogenase gene to predict 5-fluorouracil toxicity in 60 colorectal cancer patients in China. ( Lu, Z; Sun, B; Zhang, X, 2013)
" Grade 3/4 adverse events were: neutropenia (54."1.39Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer. ( Maruyama, S; Takii, Y, 2013)
"In 5-fluorouracil (5-FU)-treated patients, the tumour overexpression of SOX9 correlated with markedly poorer survival (HR=8."1.39Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients. ( Candy, PA; Colley, SM; Davidson, JA; Leedman, PJ; Phillips, MR; Redfern, AD; Stuart, LM; Wood, BA; Zeps, N, 2013)
"Thyroid function in colorectal cancer patients receiving fluoropyrimidine-based chemotherapy with or without bevacizumab was evaluated at baseline and monthly."1.39Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kiyota, N; Minami, H; Mukohara, T; Tomioka, H, 2013)
" Pharmacogenotyping is therefore recommended to guide dosing of 5-FU and prevent neutropenia."1.39Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients. ( Bannur, Z; Fijeraid, H; Hamzah, S; Hasbullani, Z; Hashim, H; Md Nor, A; Ngow, H; Ramasamy, P; Salleh, MZ; Shia, JK; Sood, S; Teh, LK; Zailani, M; Zakaria, ZA, 2013)
"As oxaliplatin is a standard agent in colorectal cancer therapy today, all clinicians and pathologists should be aware of such non-neoplastic lesions as one of the rare differential diagnoses of metastatic liver tumor, to prevent overtreatment."1.39Oxaliplatin-induced liver injury mimicking metastatic tumor on images: a case report. ( Endo, Y; Fujisawa, M; Kai, K; Matsukawa, A; Matsumoto, Y; Nobuhisa, T; Notohara, K; Sato, S; Uchino, K; Watanabe, T, 2013)
"Silencing of PI3K p85α in colorectal cancer cells increased disruption of mitochondrial membrane potential and enhanced 5-FU-induced apoptosis."1.39The effects of silencing of PI3K p85α on 5-FU-induced colorectal cancer cells apoptosis. ( Sun, Y; Tian, H; Wang, L; Yang, H, 2013)
"A total of 250 White metastatic colorectal cancer patients homogenously treated with a first-line FOLFIRI regimen were genotyped for a panel of variants in five transporter genes."1.39Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. ( Buonadonna, A; Cecchin, E; Corona, G; D'Andrea, M; De Mattia, E; Dreussi, E; Polesel, J; Toffoli, G; Zagonel, V, 2013)
"MC was found in 12."1.39Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma. ( de Hingh, IH; de Wilt, JH; Hugen, N; Lemmens, VE; Nagtegaal, ID; Pruijt, JF; Radema, SA; Verhoeven, RH, 2013)
"Metastatectomy in colorectal cancer (CRC) is now a standard of care with improved survival reported."1.39Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy. ( Beeke, C; Bishnoi, S; Karapetis, CS; Maddern, G; Padbury, R; Padman, S; Price, TJ; Townsend, AR, 2013)
"Elderly patients with metastatic colorectal cancer (mCRC) differ from the general population and are underrepresented in clinical trials."1.39Oxaliplapin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients. ( Aprile, G; Bearz, A; Berretta, M; Borsatti, E; Canzonieri, V; Ferrari, L; Fiorica, F; Fisichella, R; Foltran, L; Lestuzzi, C; Lleshi, A; Lutrino, S; Nasti, G; Talamini, R; Tirelli, U; Urbani, M, 2013)
"When treating colorectal cancer with chemotherapy, it is important to elucidate how the prognosis can be improved while maintaining the quality of life( QOL)."1.39[Protocol for the administration of modified FOLFOX6 (mFOLFOX6) in patients with unresectable/recurrent colorectal cancer]. ( Hagino, S; Iwata, K; Kiriyama, M; Kurata, T; Makita, N; Tsuneda, A, 2013)
"Colorectal cancer is the fourth most common cancer worldwide and the second leading cause of cancer-related death."1.39Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases. ( Bi, F; Chen, Q; Ge, XJ; Tang, QL; Xia, HW; Zhang, YC, 2013)
"Patients with advanced colorectal cancer (CRC) who have received oxaliplatin, 5-fluoropyrimidine, and irinotecan chemotherapy (with or without bevacizumab) and antiepidermal growth factor receptor therapy (if KRAS is wild type) have no further standard treatment options."1.39Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. ( Beeke, C; Bishnoi, S; Broadbridge, V; Jain, K; Karapetis, CS; Luke, C; Padbury, R; Price, TJ; Townsend, AR, 2013)
" Combined quantification of U and UH(2) with 5-FU and 5-FUH(2) may provide a pre-therapeutic assessment of DPD activity and further guide drug dosing during therapy."1.39LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients. ( Amstutz, U; Büchel, B; Bühr, C; Largiadèr, CR; Rhyn, P; Schürch, S, 2013)
" Another option is to use desensitization protocols that induce a temporary state of tolerance by gradually administering small quantities of the antineoplastic drug until the therapeutic dosage is reached."1.39Effectiveness of oxaliplatin desensitization protocols. ( Aguilella-Vizcaíno, MJ; Calleja-Hernández, MÁ; Cortés-Funes Castro, H; Cortijo-Cascajares, S; García-Escobar, I; Herreros-de-Tejada, A; Nacle-López, I, 2013)
"Gastric and colorectal cancers are among the most common cancers worldwide and cause serious cancer mortality."1.39Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers. ( He, C; Hu, X; Huang, X; Kuang, Y; Li, L; Mo, L; Rong, R; Shi, Q; Shu, X; Su, X; Sui, X; Tao, Q, 2013)
"These results suggest that HR + RFA after effective chemotherapy is a safe procedure with low local recurrence at the RFA site and is a potentially effective treatment option for patients with initially unresectable CRLM."1.39Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence. ( Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Kikuchi, K; Kuroki, H; Mima, K; Miyamoto, Y; Nakagawa, S; Okabe, H; Sakamoto, Y; Watanabe, M, 2013)
"Periodontitis has been observed infrequently in bevacizumab-containing chemotherapy in clinical practice."1.39A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients. ( Akiyoshi, K; Hamaguchi, T; Hosokawa, A; Iwasa, S; Kato, K; Nakajima, TE; Nishitani, H; Ogawa, K; Shimada, Y; Sugiyama, T; Ueno, T; Yamada, Y, 2013)
"Patients with colorectal cancer (CRC) and liver metastases benefit from perioperative chemotherapy and liver resection."1.39Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection. ( Asghar, U; Barbachano, Y; Chau, I; Constantinidou, A; Cunningham, D; Khan, A; Mudan, S; Rao, S; Shurmahi, F, 2013)
"Major postoperative complications were independently associated with major (≥ 3 segments) resections (57%) and perioperative blood transfusion."1.39Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. ( Allen, PJ; Bao, F; D'Angelica, MI; DeMatteo, RP; Fong, Y; Gönen, M; Jarnagin, WR; Kemeny, N; Kingham, TP; Park, JO; Shia, J; Wolf, PS, 2013)
"Combined resection of colorectal cancer with surgery for synchronous liver metastases (LM) still remains controversial because of the possible higher morbidity rate, the necessity of an adequate abdominal approach for both resections and the impact on oncological results."1.39Laparoscopic resection of colorectal cancer facilitates simultaneous surgery of synchronous liver metastases. ( Belghiti, J; Bretagnol, F; Farges, O; Hatwell, C; Panis, Y, 2013)
" Gimeracil, a DPD inhibitor, was checked whether it could reverse the reduced bioavailability of 5-FU."1.39The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil. ( Cao, D; Chen, X; Ding, J; Dong, H; Du, Y; Ge, J; Li, LH; Liu, JY; Luo, WX; Men, HT; Tan, BX; Tang, J; Zhao, F, 2013)
"Peritoneal carcinomatosis (PC), considered to have a dismal prognosis, is exclusively sub-classified into stage IVB, even though other metastases to a sole organ are sub-classified into stage IVA, which is considered to be associated with better survival."1.39Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy? ( Baba, H; Haga, N; Hatano, S; Ishibashi, K; Ishida, H; Kumagai, Y; Kumamoto, K; Matsuzawa, T; Okada, N, 2013)
"Capecitabine is a member of the fluoropyrimidine family of chemotherapeutic agents that selectively delivers 5-fluorouracil (5-FU) to tumors."1.38Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm. ( Rather, A; Shah, A; Shah, NR, 2012)
"Seventy-four metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study."1.38PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. ( Crucitti, P; Falcone, A; Frezza, AM; Galluzzo, S; Graziano, F; Loupakis, F; Muda, AO; Perrone, G; Rabitti, C; Rizzo, S; Russo, A; Ruzzo, AM; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B; Zoccoli, A, 2012)
" However, many toxic effects are evaluated on a categorical scale."1.38Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation. ( Freyer, G; Girard, P; Hénin, E; Paule, I; Tod, M; You, B, 2012)
" We investigated whether there might be a discrepancy between the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) and the Neurotoxicity Criteria of Debiopharm (DEB-NTC), the commonly used oxaliplatin-specific scales, in the evaluation of peripheral neurotoxicity."1.38Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer. ( Inoue, N; Ishibashi, K; Ishida, H; Kishino, T; Kumamoto, K; Okada, N; Sano, M, 2012)
"Population-based studies of adverse events are scarce."1.38Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. ( Cen, P; Du, XL; Liu, C, 2012)
"HCT116 colorectal or PPC1 prostate cancer cells were treated with quercetin and the drugs."1.38Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells. ( Fadlalla, K; Katkoori, V; Manne, U; Mosley, L; Samuel, T; Turner, T, 2012)
"Fifty seven metastatic colorectal cancer patients were prospectively included and 40 tumors were analyzed."1.38Absence of transcriptomic signature of response to chemotherapy in metastatic colorectal carcinoma patients. ( Brunet, R; Evrard, S; Kauffmann, A; Laroche-Clary, A; Laurand-Quancard, A; Le Morvan, V; Robert, J; Smith, D, 2012)
", Salt Lake City, UT) that measures plasma 5-FU concentration and reports an AUC in mg · h/L has been developed to optimize therapy using pharmacokinetic (PK) dosing."1.38Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. ( Grier, CE; Hamilton, SA; Haregewoin, A; Kaldate, RR; McLeod, HL, 2012)
"Patients with colorectal cancer treated with oxaliplatin based chemotherapy (FOLFOX or XELOX) were retrospectively divided into two groups according to the use of GM1."1.38The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study. ( Chen, XF; Guo, RH; Li, J; Røe, OD; Shu, YQ; Wang, R; Wu, T; Yin, YM; Zhu, LJ, 2012)
"Colorectal carcinoma is rare in the paediatric population but is increasing in incidence."1.38Metastatic paediatric colorectal carcinoma. ( Kennedy, MJ; Larkin, JO; McCormick, P; Mehigan, B; Muldoon, C; Woods, R, 2012)
" Our findings suggest that it is necessary to manage drug dosage for Japanese patients while considering their renal function, and to actively monitor for any side effects."1.38[Side effect analyses in consideration of renal functions for capecitabine-administered patients]. ( Iwai, M; Kimura, M; Yasuda, T; Yoshimura, T, 2012)
"Predictors of the response of colorectal cancer to chemotherapy remain poorly understood."1.38Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer. ( Goto, T; Hibi, K; Kigawa, G; Kitamura, Y; Nemoto, H; Saito, M; Sakuraba, K; Sanada, Y; Shinmura, K; Shirahata, A; Yokomizo, K, 2012)
"A total of 18 colorectal cancer patients who received bevacizumab combined with chemotherapy were included."1.38Evaluating coagulation disorders in the use of bevacizumab for metastatic colorectal cancer by thrombelastography. ( Akay, OM; Bal, C; Gulbas, Z; Keskin, M; Kuş, E; Ustuner, Z, 2012)
"The efficacy and tolerability of bevacizumab every 2 or 4 weeks using the same dosage in combination with biweekly FOLFIRI were retrospectively evaluated in metastatic colorectal cancer (mCRC) patients in the first-line and second-line therapy."1.38Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. ( Alkis, N; Benekli, M; Berk, V; Buyukberber, S; Ciltas, A; Coskun, U; Dane, F; Dikilitas, M; Dogu, GG; Durnali, AG; Kaplan, MA; Karaca, H; Ozkan, M; Sevinc, A; Yetisyigit, T; Yildiz, R, 2012)
"The 5-FU concentrations in colorectal cancer tissue, liver, lung, and blood were(73."1.38[Comparison of targeting distribution of two kinds of fluorouracil magnetic albumin microspheres in colorectal neoplasm nude mice in vivo under magnetic field]. ( Gu, J; Jiang, T; Kong, X; Liu, JG; Liu, ZC, 2012)
"Metastatic colorectal cancer (CRC) is predominantly a disease of the elderly, therefore the current standards should be evaluated in this population."1.38Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). ( Doornebal, J; Koopman, M; Lemmens, W; Punt, CJ; Teerenstra, S; Venderbosch, S, 2012)
"Human colorectal cancer cell lines HCT116 and DLD-1 were treated with a panel of small interfering RNAs directed against the PI3K/AKT/mTOR and Ras pathways; proliferation, apoptosis, and protein expression were assessed."1.38Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer. ( Elliott, VA; Evers, BM; Gao, T; Mustain, WC; Rychahou, PG; Valentino, JD; Wang, C; Zaytseva, YY, 2012)
" We also observed bioavailability of ursolic acid in the serum and tissue of animals."1.38Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine. ( Aggarwal, BB; Baladandayuthapani, V; Deorukhkar, A; Diagaradjane, P; Guha, S; Kannappan, R; Krishnan, S; Prasad, S; Reuter, S; Sung, B; Wei, C; Yadav, VR, 2012)
" Gastro-intestinal adverse events graded according to the WHO criteria were recorded after the first cycle."1.38Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. ( Bocci, G; Ciccolini, J; Danesi, R; Di Paolo, A; Iliadis, A; Lacarelle, B; Marouani, H; Woloch, C, 2012)
"Ellagic acid has been demonstrated to inhibit the growth of several types of cancer cells."1.38Effects of ellagic acid on chemosensitivity to 5-fluorouracil in colorectal carcinoma cells. ( Chang, HP; Chen, CH; Chou, JL; Chung, YC; Hou, YC; Hsu, CP; Kao, TY; Tsai, YW, 2012)
"Metastatic colorectal cancer is the second leading cause of cancer death in the United States."1.38Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer. ( de Braud, F; Díaz-Rubio, E; Pietrantonio, F, 2012)
"The grades of neurosensory adverse events (NSAEs) induced by FOLFOX4 treatment were compared between Asian and Western colorectal cancer patients and correlated with cumulative oxaliplatin doses."1.38Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. ( André, T; Brienza, S; Goldberg, RM; Gomi, K; Gramont, A; Lee, PH; Mizunuma, N; Ohtsu, A; Rothenberg, ML; Shimada, Y; Sugihara, K, 2012)
"Hyporexia/anorexia is a relevant clinical problem affecting the quality of life of many cancer patients."1.37Steroids, cancer and vertebral fractures: a dreaded combination. ( Uña Cidón, E, 2011)
"The authors report two cases of young patients who developed clubbing and hypertrophic osteoarthropathy in one case or lung diffusion disorder in the second, after a long-term use of bevacizumab plus chemotherapy in a palliative setting of metastatic colorectal cancer."1.37Clubbing and hypertrophic osteoarthropathy in two patients taking long-term bevacizumab for metastatic colorectal cancer. ( Audrain, O; Boucher, E; Kerjouan, M; Le Roux, C; Pracht, M; Raoul, JL, 2011)
"Gastric cancer is the third most common cancer worldwide and the second leading cause of cancer deaths."1.37Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer. ( Abou-Alfa, GK; Al-Olayan, A; Kelsen, D; Lowery, M; Naghy, M; Power, D; Saliba, T; Shah, MA; Shamseddine, A; Smyth, E, 2011)
"Twenty-four colorectal and 24 breast cancer patients participated in this study."1.37Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. ( Braun, M; Jaehde, U; Ko, YD; Kuhn, W; Mey, UJ; Ringsdorf, S; Schmidt-Wolf, I; Schwindt, PF; Simons, S, 2011)
"Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease."1.37Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin. ( Peters, GJ; Schneiders, FL; van den Berg, HP; van der Vliet, HJ; Verheul, HM, 2011)
"Patients with CIMP-positive colorectal tumors do not benefit from 5-FU-based adjuvant chemotherapy."1.375-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. ( Alenda, C; Andreu, M; Balaguer, F; Bessa, X; Boland, CR; Bujanda, L; Castells, A; Clofent, J; Cubiella, J; Goel, A; Jover, R; Llor, X; Morillas, JD; Nguyen, TP; Nicolás-Pérez, D; Payá, A; Pérez-Carbonell, L; Reñé, JM; Rojas, E; Xicola, RM; Zapater, P, 2011)
"Patients with metastatic colorectal cancers have poor outcomes."1.37Changing management and survival in patients with stage IV colorectal cancer. ( Ng, S; O'bichere, A; Platell, C; Tebbutt, N, 2011)
" The incidences of grade 3 or 4 adverse events and grade 2 or greater histopathological sinusoidal injury were significantly higher in the SVI ≥ +30% than in the SVI < +30% group."1.37Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy. ( Arai, T; Kobayashi, S; Koike, J; Koizumi, S; Makizumi, R; Miura, K; Miyajima, N; Nakano, H; Otsubo, T; Sakurai, J; Shimamura, T; Yamada, K, 2011)
" Adverse events were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events."1.37Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study. ( Asaka, M; Hatanaka, K; Hosokawa, A; Iwanaga, I; Kato, T; Komatsu, Y; Kusumi, T; Miyagishima, T; Nakamura, M; Sakata, Y; Sogabe, S; Yuki, S, 2011)
"Interstitial lung disease in patients with colorectal cancer during chemotherapy combined with bevacizumab is rare."1.37Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients. ( Furushima, K; Ishihara, T; Katou, Y; Tanai, C; Tanaka, Y; Usui, K, 2011)
"In metastatic colorectal cancer patients treated with mFolfox-6, the combination of haplotype XPD Lys751Gln-GSTP1 105Val seems to predict the risk of progression."1.37Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. ( Balboa, E; Barros, F; Bernardez, B; Carracedo, A; Duran, G; Gallardo, E; Lamas, MJ; Lopez, R; Touris, M; Vidal, Y, 2011)
"We report two cases of advanced colorectal cancer which showed splenomegaly after administration of oxaliplatin-based chemotherapy."1.37[Two cases of advanced colorectal cancer which demonstrated the reversibility of oxaliplatin-mediated increase in splenic volume]. ( Furuse, J; Hanai, C; Hosokawa, Y; Kawase, T; Kitagawa, N; Konno, T; Motoori, S; Nishimura, H; Saisho, H, 2011)
"FOLFOX plus bevacizumab therapy can be given safely to hemodialytic patients with no reduction in the dose of oxaliplatin if hemodialysis is performed soon after the administration of oxaliplatin and the dosing interval is extended to 3 weeks."1.37Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. ( Chiba, T; Ezoe, Y; Horimatsu, T; Mashimo, Y; Miyamoto, S; Morita, S; Muto, M, 2011)
" The drug combination elevated the plasma level of PHT in a patient on chemotherapy with capecitabine for colorectal cancer."1.37[A case of toxicity caused by drug interaction between capecitabine and phenytoin in patient with colorectal cancer]. ( Fukui, E; Kawahara, K; Sakurai, M; Ueda, R; Yamada, R, 2011)
"Here, we report on 2 patients with colorectal cancer and severe liver dysfunction secondary to hepatic metastases."1.37Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction. ( Bubenzer, J; do O, N; Fuchs, R; Luedde, T; Roderburg, C; Spannbauer, M; Tischendorf, JJ; Trautwein, C, 2011)
"About 50% of patients with primary colorectal cancer (CRC) will develop liver metastases (CLM)."1.37Type IV collagen as a tumour marker for colorectal liver metastases. ( Hafström, L; Naredi, P; Nyström, H; Sund, M, 2011)
"For the metastatic colorectal cancer LLD population with K-ras wild-type genotype, mean overall survival estimates were 37."1.37Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. ( Asseburg, C; Frank, M; Griebsch, I; Hartmann, JT; Köhne, CH; Mittendorf, T; Mohr, A; Osowski, U; Schulten, J, 2011)
"However, its role in colorectal cancer (CRC) pathobiology and clinical relevance remains unknown."1.37Overexpression of neurone glial-related cell adhesion molecule is an independent predictor of poor prognosis in advanced colorectal cancer. ( Chan, JY; Ong, CW; Salto-Tellez, M, 2011)
"Metastatic colorectal cancer has a low cure rate."1.37Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer. ( Afonso, S; Afonso, V; Stefano, E; Viani, G, 2011)
"The prognosis of patients with advanced colorectal cancer with icterus is dismally poor, and adequate chemotherapy for these patients has not been established yet."1.37FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases. ( Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yokota, T, 2011)
"Especially ischemic colitis can rapidly develop into bowel perforation, so an emergency operation often is needed."1.37[A case of severe bevacizumab-induced ischemic pancolitis, treated with conservative management]. ( Chun, SH; Kim, SW; Lee, H; Lee, HM; Lee, HN; Lee, MA; Lim, Y; Won, HS, 2011)
"Tissues of 82 patients treated for colorectal cancer (CRC) were analyzed using antibodies against AIF, p53, DR4, DR5, cleaved caspase-3 and the TUNEL method to detect apoptosis; whereas staining of Ki-67 was used as a proliferation marker."1.37Expression of p53 and DR5 in normal and malignant tissues of colorectal cancer: correlation with advanced stages. ( Akil, H; Jauberteau, MO; Labrousse, F; Mathonnet, M; Nouaille, M; Perraud, A; Petit, D, 2011)
"Acriflavine was active in cell spheroids, indicating good drug penetration and activity against hypoxic cells."1.37Novel activity of acriflavine against colorectal cancer tumor cells. ( Fayad, W; Felth, J; Fryknäs, M; Glimelius, B; Graf, W; Gullbo, J; Hassan, S; Larsson, R; Laryea, D; Linder, S; Mahteme, H; Nygren, P; Påhlman, L; Rickardson, L, 2011)
"A total of 27 patients with metastatic colorectal cancer received the FOLFOX (n=17) or FOLFIRI (n=10) chemotherapeutic regimen."1.37Impact of chemotherapy for colorectal cancer on regulatory T-cells and tumor immunity. ( Hazama, S; Kamei, R; Kan, S; Maeda, K; Maeda, N; Maeda, Y; Oka, M; Shindo, Y; Tokuno, K; Watanabe, Y; Yoshimura, K; Yoshino, S, 2011)
"XELOX for unresectable advanced colorectal cancer has been approved in Japan."1.37[Our experience of the treatment with XELOX±Bevacizumab for unresectable advanced colorectal cancer]. ( Amano, R; Fuyuhiro, Y; Hirakawa, K; Ishikawa, T; Kashiwagi, S; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Nagahara, H; Nakata, B; Noda, E; Ohira, M; Tanaka, H; Yamada, N; Yashiro, M, 2011)
"The subject was 28 patients of colorectal cancer with synchronous unresectable liver metastasis who received mFOLFOX6 as a first-line treatment from 2005 to 2010."1.37[Therapeutic effect of mFOLFOX6 for synchronous unresectable liver metastases from colorectal cancer]. ( Amano, K; Chikatani, K; Haga, N; Hatano, S; Ishibashi, K; Ishida, H; Ishiguro, T; Iwama, T; Kumamoto, K; Kuwabara, K; Ohsawa, T; Okada, N; Sobajima, J; Tajima, Y, 2011)
"Cumulative risks of recurrence were 10."1.37[Recurrance of disappearing colorectal liver metastases after mFOLFOX6 regimen]. ( Haga, N; Ishibashi, K; Ishida, H; Kumamoto, K; Okada, N; Ono, T, 2011)
"The outcomes and management of colorectal cancer (CRC) hepatic metastasis have undergone many evolutionary changes."1.37Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment. ( Chan, KM; Chen, JS; Chiang, JM; Lee, CF; Lee, WC; Wang, JY; Yu, MC, 2011)
"Nu/Nu mice were injected IP with HT-29 colorectal cancer cells."1.36Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo. ( Al-Kasspooles, MF; Broward, M; Cohen, MS; Henry, D; Roby, KF; Williamson, SK, 2010)
"Capecitabine is an oral fluoropyrimidine that was designed to allow selective activation in tumour tissues, thus reducing toxicity."1.36Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer. ( Ahmad, A; Gounaris, I, 2010)
"Here we adapted an orthotopic colorectal cancer model, in which HT-29 colorectal cancer cells form tumors in the rectal lining and metastasize to the para-aortic lymph nodes with high frequency."1.36Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging. ( Prewett, M; Steiner, P; Surguladze, D; Tonra, JR, 2010)
" Cardiotoxicity causing angina, arrhythmia and infarction are serious adverse events associated with these agents."1.36[Cardiotoxicity induced by 5-fluorouracil or capecitabine]. ( Baeksgaard, L; Jensen, SA; Petersen, LN; Reiter, L; Sørensen, JB, 2010)
"From April, 2007 to February, 2009, 23 colorectal cancer patients were treated with Bevacizumab."1.36[Evaluation of bevacizumab for advanced colorectal cancer]. ( Hoshino, S; Matsuo, K; Naito, M; Nakano, M; Noda, N; Shinohara, T; Tanaka, S; Yamashita, Y; Yamauchi, Y, 2010)
"Eniluracil is a potent inactivator of dihydropyrimidine dehydrogenase (uracil reductase), the enzyme that rapidly catabolizes 5-fluorouracil (5-FU)."1.36A possible cause and remedy for the clinical failure of 5-fluorouracil plus eniluracil. ( Cao, S; Spector, T, 2010)
" Adverse events resulting from its use include gastrointestinal perforation, wound-healing complications, hemorrhage, and arterial thromboembolism."1.36Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer. ( Gamboa, EO; Haller, N; Rehmus, EH, 2010)
"Histological response of colorectal cancer liver metastases to chemotherapy may be graded based on the extent of tumor regression."1.36Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. ( Dorfmeister, M; Eipeldauer, S; Gruenberger, B; Gruenberger, T; Hacker, S; Herberger, B; Kaczirek, K; Klinger, M; Tamandl, D, 2010)
"Capecitabine is an anticancer agent, prodrug of 5 fluorouracil (5-FU) administered orally and with a narrow therapeutic index."1.36[Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency]. ( Bontemps, H; Coursier, S; Emptoz, J; Guillermet, A; Martelet, S; Villier, C, 2010)
"Colorectal cancer is the most common form of malignancy in Taiwan and the third leading cause of death from cancer, preceded only by lung and hepatic cancers."1.36rTSbeta as a novel 5-fluorouracil resistance marker of colorectal cancer: a preliminary study. ( Chow, KC; Lin, YL, 2010)
"Chemotherapy-induced interstitial lung disease (ILD) in colorectal cancer (CRC) patients is rarely reported, but its clinical features remain to be clarified."1.36Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. ( Doi, T; Fuse, N; Joh, T; Minashi, K; Ohtsu, A; Shimura, T; Tahara, M; Yoshino, T, 2010)
"In patients with stage IV colorectal cancer, liver metastases exhibit a better histological response than primary tumors to OCFL neoadjuvant chemotherapy."1.36Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. ( Andres, A; Gervaz, P; Majno, P; Mentha, G; Morel, P; Roth, A; Rubbia-Brandt, L, 2010)
"Capecitabine is an oral fluoropyrimidine which is transformed to 5-Fluorouracil inside tumor cells, where it achieves high drug concentrations."1.36Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect? ( Emiliani, A; Losanno, T; Manna, G; Seminara, P, 2010)
"The risk of venous thromboembolism has been reported to increase when receiving bevacizumab."1.36Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab. ( Doi, T; Fuse, N; Ikematsu, H; Kaneko, K; Koike, K; Kojima, T; Minashi, K; Mochizuki, S; Ohtsu, A; Tahara, M; Yano, T; Yoshino, T, 2010)
"We compared clinical outcome and pharmacokinetic (pK) parameters of a new pharmacokinetically-guided dosing strategy in two groups of patients (age < or >65 years) with metastatic colorectal cancer (mCRC)."1.36Clinical impact of intesified 5-Fluorouracil-based chemotherapy using a prospective pharmacokinetically-guided dosing approach: comparative study in elderly and non-elderly patients with metastatic colorectal cancer. ( Abderrahim, AG; Bressolle, F; Duffour, J; Pinguet, F; Poujol, S; Roca, L; Ychou, M, 2010)
"42%; P = ."1.36Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. ( Abdalla, EK; Capussotti, L; Contreras, CM; Curley, SA; Kishi, Y; Kopetz, S; Maru, DM; Motta, M; Ravarino, N; Ribero, D; Risio, M; Vauthey, JN; Zorzi, D, 2010)
"However, the role of CSCs in colorectal cancer metastasis is unclear."1.36A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. ( Cheung, LW; Chow, AK; Chu, AC; Lam, CS; Lan, HY; Lan, XR; Law, WL; Ng, L; Pang, R; Poon, JT; Poon, RT; Tan, VP; Wong, BC; Yau, TC, 2010)
"However, economic burden of colorectal cancer is considerable."1.36Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer. ( Ajima, H; Fujita, K; Ishida, H; Kawara, K; Miwa, K; Mizuno, K; Nakayama, H; Ogata, H; Sasaki, Y; Sunakawa, Y; Takahashi, H; Yamashita, K, 2010)
"Colorectal cancer is (CRC) one of the commonest cancers and its therapy is still based on few drugs."1.365-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency. ( Bodmer, WF; Bracht, K; Liu, Y; Nicholls, AM, 2010)
"5-Fluorouracil/leucovorin-treated CRC patients achieved a significantly longer progression-free survival when presenting with SI-positive tumours before therapy (median 12."1.36Cellular senescence predicts treatment outcome in metastasised colorectal cancer. ( Dörken, B; Gröne, J; Haugstetter, AM; Lenze, D; Loddenkemper, C; Petersen, I; Schmitt, CA; Standfuss, C, 2010)
"Colorectal cancer is one of the leading malignancies in the world."1.36Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer. ( Fu, ZX; Shen, W; Tu, JK; Wang, XH, 2010)
"Capecitabine levels were quantified by a simple reversed-phase HPLC system with an external standard method."1.36A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes. ( Czejka, M; Ettlinger, D; Farkouh, A; Georgopoulos, A; Scheithauer, W; Schueller, J, 2010)
" A protocol-defined prohibitive adverse event occurred in 4 patients (6%), including 2 treatment-associated deaths."1.36Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. ( Chen, HX; Christos, P; Hamilton, A; Horvath, L; Kindler, HL; Matulich, D; Ocean, AJ; Polite, B; Sparano, JA, 2010)
"We report two cases of venous thrombosis confirmed during the bevacizumab combination chemotherapy for colorectal cancer."1.36[Two cases of venous thrombosis confirmed during the bevacizumab combination chemotherapy for colorectal cancer]. ( Hosokawa, T; Iwao, Y; Koshiishi, H; Koshinaga, T; Matsuyama, T; Nishida, K; Okamura, T; Sakamoto, K; Tokita, H, 2010)
"Fifty patients with unresectable colorectal cancer treated with mFOLFOX6 therapy were enrolled in this study."1.36[The expression of thymidylate synthase (TS) and excision repair complementing-1 (ERCC-1) protein in patients with unresectable colorectal cancer treated with mFOLFOX6 therapy]. ( Haga, N; Ishibashi, K; Ishida, H; Ishiguro, T; Itoyama, S; Kumamoto, K; Kuwabara, K; Miura, I; Mori, T; Ohsawa, T; Okada, N; Tamaru, J; Yamada, H; Yokoyama, M, 2010)
"Recent advances in chemotherapy for colorectal cancer prolonged survival."1.36[Roles of hepatectomy for colorectal liver metastases with necrotic foci caused by prior anti-cancer therapies]. ( Inoue, T; Ishikawa, H; Ko, S; Kunishige, T; Mukogawa, T; Nakamoto, T; Nishiwada, T; Watanabe, A, 2010)
"5-Fluorouracil (5-FU) is a standard chemotherapeutic drug to treat CRC."1.35Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry. ( Au, TC; Chan, AT; Chan, CM; Chan, WH; Cheuk, W; Hui, EP; Lam, MY; Ma, BB; Wong, CS; Wong, MC; Wong, VW, 2008)
" The setting of dosage was differed in two hospitals."1.35[Comparative survey on current status and the differences of treatment using modified FOLFOX6 regimen in patients with colorectal cancer in two general hospitals]. ( Anami, S; Fujii, C; Fukunaga, M; Furukawa, H; Kitada, N; Morimoto, S; Morita, S; Takara, K; Watari, M; Yamasaki, H; Yokoyama, T, 2008)
"Liver metastases (n = 93) along with primary tumors (n = 48) were analyzed for K-Ras mutations (codons 12 and 13), p53 mutations (exons 4-9), p53 polymorphism (codon 72), thymidylate synthase (TS) polymorphism (28-bp repeats including G>C mutation), methylenetetrahydrofolate reductase polymorphism (677C>T, 1298A>C), thymidylate synthase (TS) activity, dihydropyrimidine dehydrogenase activity, folylpolyglutamate synthase activity, and p53 protein expression."1.35K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. ( Benchimol, D; Chazal, M; Delpero, JR; Etienne-Grimaldi, MC; Formento, JL; Formento, P; François, E; Francoual, M; Laurent-Puig, P; Letoublon, C; Milano, G; Pezet, D; Renée, N; Seitz, JF, 2008)
" Pharmacokinetic analysis was performed on plasma samples collected at the first cycle of treatment."1.35A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. ( Antonuzzo, A; Bocci, G; Bursi, S; Chiara, S; Del Tacca, M; Di Paolo, A; Falcone, A; Fornaro, L; Loupakis, F; Masi, G; Pfanner, E; Vasile, E, 2009)
"Capecitabine is a chemotherapeutic prodrug that is metabolised to 5-fluorouracil."1.35Coronary spasm induced by capecitabine mimicks ST elevation myocardial infarction. ( Curzen, NP; Ferchow, L; Hobson, A; Scott, PA, 2008)
"In patients with metastatic colorectal cancer (mCRC), several prognostic factors such as performance status (PS), number of metastatic sites, carcinoembryonic antigen (CEA), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) have been reported."1.35Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer. ( Asaka, M; Boku, N; Fukutomi, A; Hironaka, S; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T, 2008)
"CRP was associated with disease progression and factors reflecting nutritional depletion such as serum albumin, lymphocyte count and body weight loss ratio."1.35Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. ( Inoue, Y; Koike, Y; Kusunoki, M; Miki, C; Okugawa, Y; Tanaka, K; Toiyama, Y; Yokoe, T, 2008)
"Hepatic metastasis from colorectal cancer (mCRC) is best treated with a multidisciplinary approach."1.35Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases. ( Campbell, ML; Landry, CS; Martin, RC; McMasters, KM; Scoggins, CR; Slomiany, BA; Woodall, CE, 2009)
"Of 55 patients with colorectal cancer, 20 had no metastasis and the other 35 had distant metastasis."1.35Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer. ( Akagi, Y; Hattori, S; Kage, M; Kawahara, A; Kuwano, M; Mizobe, T; Ono, M; Shirouzu, K; Yanagawa, T, 2009)
"Patients with colorectal cancer that had recurred, following surgery and adjuvant chemotherapy and underwent a second operation were included in the present study."1.35Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy. ( Agrogiannis, G; Arapogiannis, G; Gouveris, P; Kavantzas, N; Kopterides, P; Kosmas, C; Kyriakou, V; Lazaris, A; Papathomas, T; Patsouris, E; Tsavaris, N; Zorzos, H, 2009)
" In addition, relative dose intensity (RDI), therapeutic efficacy, and adverse events in the patients who were given the regimen, we compared between the groups."1.35[Efficacy and safety of modified FOLFOX6 regimen in aged patients with nonresectable colorectal cancer]. ( Inoue, N; Ishibashi, K; Ishida, H; Ishiguro, T; Kuwabara, K; Matsuki, M; Miyazaki, T; Okada, N; Sano, M; Yokoyama, M, 2008)
"The increased MMP-7 levels at disease progression support the hypothesis that this protease could play a role in acquired resistance by degrading IGFBP-3."1.35Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer. ( Augé, JM; Carcereny, E; Codony-Servat, J; Gallego, R; García-Albéniz, X; Gascón, P; Longarón, R; Maurel, J; Oliveras, A; Tosca, M, 2009)
"The subjects were 13 colorectal cancer patients who had undergone resection of the primary tumor, and showed multiple, unresectable liver metastases and severe liver dysfunction."1.35[Combination of hepatic arterial infusion therapy and FOLFOX for colorectal cancer with multiple unresectable liver metastases causing severe liver dysfunction]. ( Iizawa, H; Ikeda, E; Ishiyama, K; Mori, N; Saito, K; Sakurai, N; Sato, T; Suto, T; Takano, N, 2009)
"Mitomycin was the most frequently active agent for the superficial part."1.35In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA). ( Ahn, KD; Cho, YB; Choi, SH; Chun, HK; Kim, HC; Lee, JM; Lee, WY; Shin, HJ; Song, SY; Yun, SH, 2009)
" Prospective trials are required to assess whether dosing adjustments based on neutropaenia may improve chemotherapy efficacy."1.35Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. ( Inaba, Y; Matsuo, K; Muro, K; Najima, M; Sato, Y; Shitara, K; Takahari, D; Ura, T; Yamaura, H; Yokota, T, 2009)
" Moreover, in combination with 5-fluorouracil modulated by folinic acid (5FU-FA) or with Raltitrexed (RTX), both commonly used in the treatment of this disease, it showed a clear schedule-dependent synergistic antiproliferative interaction as demonstrated by calculating combination indexes."1.35Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. ( Avallone, A; Bruzzese, F; Budillon, A; Delrio, P; Di Gennaro, E; Leone, A; Pepe, S; Subbarayan, PR, 2009)
"Taste disorders are frequent occurrences among those patients under the FOLFOX-FOLFIRI regimen for colorectal cancer."1.35[Development of taste disorders following FOLFOX-FOLFIRI therapy and its effects on the QOL of patients with colorectal cancer]. ( Adachi, M; Iida, A; Mori, K; Sakakibara, T; Sugawara, S; Sugiura, M; Takimoto, N; Yamamura, K, 2009)
"Hepatocellular carcinoma was the second most frequent malignancy to be observed--23 patients (18."1.35[Advanced hepatic resection for malignancy]. ( Kotel'nikov, AG; Patiutko, IuI; Pylev, AL; Sagaĭdak, IV, 2009)
"Using HCT-116 human colorectal cancer cells, we compared the efficacy of WG and RG."1.35Asian ginseng enhances the anti-proliferative effect of 5-fluorouracil on human colorectal cancer: comparison between white and red ginseng. ( Aung, HH; Fishbein, AB; Li, XL; Mehendale, SR; Sun, S; Wang, CZ; Yuan, CS, 2009)
" Coadministration of S-1 changed the pharmacokinetic behavior of CPT-11 and its metabolites."1.35Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer. ( Hamada, A; Saito, H; Sasaki, Y; Tazoe, K; Yokoo, K, 2009)
" Grade 3 or 4 hematological toxicities were leukocytopenia in four patients, and neutropenia in 12 patients, while non-hematological toxicities such as nausea, anorexia and sensory neuropathy occurred in only one patient each adverse event."1.35The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer. ( Hattori, M; Honda, I; Kato, N; Kobayashi, D; Matsushita, H; Okochi, O; Tsuboi, K, 2009)
"1236G>A), which was observed five- out of eight-times in patients with severe adverse effects."1.35Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. ( Aebi, S; Amstutz, U; Farese, S; Largiadèr, CR, 2009)
"Radiation bystander effects induce genomic instability; however, the mechanism driving this instability is unknown."1.35Radiation and chemotherapy bystander effects induce early genomic instability events: telomere shortening and bridge formation coupled with mitochondrial dysfunction. ( Gorman, S; Howe, O; Hyland, J; Lyng, F; Mulcahy, H; O'Donoghue, D; O'Sullivan, J; Sheahan, K; Tosetto, M, 2009)
"Seventy-six metastatic colorectal cancer patients receiving cetuximab plus FOLFIRI or FOLFOX-4 chemotherapy were enrolled."1.35Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. ( Chang, YT; Chen, CW; Chu, KS; Lin, SR; Lu, CY; Tsai, HL; Wang, HM; Wang, JY; Yeh, YS; Yen, LC, 2009)
"Rapamycin suppressed advanced stage colorectal cancer, even with oral administration."1.35Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1. ( Candinas, D; Egger, B; Hunt, KK; Laemmle, A; Roh, V; Strehlen, M; Stroka, D; Trochsler, M; Vorburger, SA; Wagner, M, 2009)
"Genomic instability in colorectal cancer is categorized into two distinct classes: chromosome instability (CIN) and microsatellite instability (MSI)."1.35Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells. ( Furumai, R; Goodman, BK; Jardim, MJ; Wakeman, T; Wang, Q; Wang, XF, 2009)
"To understand the mechanisms of the effects of combination treatments, we established animal models showing antitumor activity of bevacizumab as a monotherapy and in combination with capecitabine or capecitabine and oxaliplatin and measured thymidine phosphorylase (TP) and vascular endothelial growth factor (VEGF) levels."1.35Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models. ( Fujimoto-Ouchi, K; Mori, K; Yamashita, Y; Yanagisawa, M; Yorozu, K, 2009)
" The CPT-11 dosage was 150 mg/m(2)."1.35[Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI]. ( Fukuoka, T; Hatano, N; Imamura, Y; Morita, Y; Usui, H; Yokoyama, S, 2009)
"We measured health utility scores of colorectal cancer (CRC) patients from a societal perspective in Japan."1.35Health utility scores of colorectal cancer based on societal preference in Japan. ( Fukuda, T; Shiroiwa, T; Tsutani, K, 2009)
" Chemotherapy was administered via the penil vein, using the same dosing scheme and duration as the second group."1.35Effect of early preoperative 5-fluorouracil on the integrity of colonic anastomoses in rats. ( Berber, I; Kara, M; Koyuturk, M; Krand, O; Ozel, L; Ozel, MS; Ozkan, KS; Tellioglu, G; Toros, AB, 2009)
"Although colorectal cancer screening is cost-effective, it requires a considerable net investment by governments or insurance companies."1.35Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. ( Habbema, JD; Kuipers, EJ; Lansdorp-Vogelaar, I; van Ballegooijen, M; Zauber, AG, 2009)
"5-Fluorouracil (5-FU) is an antimetabolite that acts during the S phase of the cell cycle."1.35Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma? ( Rajebi, MR; Saif, MW; Shahrokni, A, 2009)
"We retrospectively investigated the frequency and severity of adverse events in 124 patients with colorectal cancer who were treated by mFOLFOX6 regimen from August, 2005 to December, 2006."1.35[Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen]. ( Boku, N; Kato, T; Kimura, H; Kudou, Y; Matsunaga, Y; Motokawa, S; Muramatsu, T; Nagata, N; Nakagaki, S; Ohashi, Y; Shino, M; Yamazaki, K; Yoshida, T, 2009)
"To explore the potential markers of colorectal cancer metastasis and the influence of 5-FU on differentially expressed proteins by using proteomic technology, and to elucidate the mechanism of colorectal cancer metastasis."1.35[Proteomic research of biomarker of colorectal cancer metastasis]. ( Chen, HQ; Chu, ZX; Huang, L; Ma, YL; Peng, JY; Qin, HL; Shen, TY; Zhang, M; Zhang, P; Zhou, YK, 2009)
"NAC by FOLFOX for liver metastasis of colorectal cancer showed a high reduction rate, and there was a little influence to hepatectomy indicating that FOLFOX could be an effective therapy."1.35[Results of neo-adjuvant chemotherapy by FOLFOX and FOLFIRI for colorectal liver metastasis]. ( Amano, R; Hirakawa, K; Inoue, T; Ishikawa, T; Kubo, N; Maeda, K; Muguruma, K; Nakata, B; Noda, E; Ohira, M; Onoda, N; Sawada, T; Tanaka, H; Yamada, N; Yashiro, M, 2009)
"These patients can also be affected by superior vena cava syndrome causing dyspnea followed by trunk or extremity swelling."1.35Treatment of superior vena cava (SVC) syndrome and inferior vena cava (IVC) thrombosis in a patient with colorectal cancer: combination of SVC stenting and IVC filter placement to palliate symptoms and pave the way for port implantation. ( Kickuth, R; Sauter, A; Schmidt, F; Triller, J, 2008)
"The present study supports the toxic effect of 5-FU on the myocardium, which is largely schedule-dependent, whereas a low but finite risk of such toxicity has been observed with oral capecitabine."1.35Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. ( Kallistratos, MS; Karabelis, A; Kopterides, P; Kosmas, C; Mylonakis, N; Skopelitis, H; Syrios, J; Tsavaris, N, 2008)
" Both coated and uncoated pellets were orally administered to the rats at a dosage equivalent to 15mg/kg."1.35Study on colon-specific pectin/ethylcellulose film-coated 5-fluorouracil pellets in rats. ( Cao, DY; Du, Q; Fan, LF; He, W; Xiang, B, 2008)
" Administration of 30 mg/kg CS-706 from Day 7 combined with a single intravenous treatment of 10 mg/kg cisplatin on Day 7 completely regressed the tumors in all tumor-bearing mice examined, whereas only in 1 of 10 mice tumor was regressed with cisplatin treatment."1.35CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents. ( Fujiwara, K; Hanai, M; Inoue, S; Ishida, S; Kimura, T; Kurakata, S; Senzaki, M; Yada, A, 2008)
"Capecitabine was administered at a fixed dose of 2000 mg daily without interruptions."1.35Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors. ( Battistelli, S; Civitelli, S; Fiaschi, AI; Francini, E; Francini, G; Lorenzi, M; Marsili, S; Pascucci, A; Petrioli, R; Roviello, F; Tanzini, G, 2008)
"Early relapse in colorectal cancer (CRC) patients is attributed mainly to the higher malignant entity (such as an unfavorable genotype, deeper tumor invasion, lymph node metastasis and advance cancer stage) and poor response to chemotherapy."1.35ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. ( Cheng, TL; Fang, WY; Huang, MY; Lee, SC; Lin, SR; Wang, JY, 2008)
"Neoadjuvant chemotherapy for metastatic colorectal cancer may render some unresectable patients resectable, affording these patients the possibility of prolonged survival."1.35[A successfully resected case of colorectal cancer with multiple liver metastases treated with FOLFIRI after failure of mFOLFOX6]. ( Fukuda, H; Hirokawa, S; Nagata, T; Sawada, S; Tazawa, K; Tsukada, K; Uotani, H; Yamagishi, F, 2008)
" Although this patient could accept it relatively safely without any severe side effect, the optimal dosage and the timing of hemodialysis for inoperable metastatic colorectal cancer patients should be determined by a further study using more cases."1.35[Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer]. ( Ehara, K; Hasebe, S; Hashimoto, M; Hayashi, M; Igarashi, M; Ito, T; Katori, H; Kinoshita, Y; Matoba, S; Matsuda, M; Mine, S; Moriyama, J; Sato, M; Sawada, T; Toda, S; Tsutsumi, K; Udagawa, H; Ueno, M; Watanabe, G; Yokoyama, T, 2008)
"When chemotherapy is conducted to treat colorectal carcinoma, especially when 5-FU is included in the regimen, anti-APRIL therapy might be an important assistant treatment to counter the impact of APRIL caused by antitumor drugs."1.35[Expression of APRIL in colorectal carcinoma tissues and effects of chemotherapeutic agents on APRIL expression in colorectal carcinoma SW480 cells]. ( Feng, ZY; Guo, YW; Li, YW; Wen, ZF; Zheng, FP, 2008)
"Capecitabine is a drug that requires the consecutive action of three enzymes: carboxylesterase 2 (CES 2), cytidine deaminase (CDD), and thymidine phosphorylase (TP) for transformation into 5-fluorouracil (5FU)."1.35A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression. ( Alba, E; Carabantes, F; Dueñas, R; González, E; López-Siles, J; Márquez, A; Ribelles, N; Sánchez, A; Sánchez, MJ; Sánchez-Rovira, P; Sevilla, I, 2008)
" We observed adverse events, time to treatment failure, response rate, reason to discontinue treatment, and dose intensity."1.35[Safety and efficacy analysis of FOLFOX4 regimen in elderly compared to younger colorectal cancer patients]. ( Chin, K; Hatake, K; Ichimura, T; Kuboki, Y; Matsuda, M; Matsuzaka, S; Mizunuma, N; Ogura, M; Shinozaki, E; Suenaga, M, 2008)
"5-Fluorouracil (5-FU) is a chemotherapeutic agent for the treatment of colorectal cancer that interferes with the growth of cancer cells."1.34Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells. ( Aung, HH; He, TC; Luo, X; Mehendale, S; Ni, M; Song, WX; Wang, CZ; Xie, JT; Yuan, CS; Zhang, B, 2007)
"Ninety-six resections for colorectal cancer hepatic metastases performed from July 2001 to July 2003 (93% > or =2 segments) were reviewed."1.34Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes. ( Cattral, MS; Chan, EK; Dixon, E; Gallinger, S; Grant, DR; Greig, PD; Sahajpal, A; Taylor, BR; Vollmer, CM; Wei, A, 2007)
"About 20% of patients with colorectal cancer have synchronous un-resectable liver metastases."1.34Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? ( Amisano, M; Bouzari, H; Capussotti, L; Massucco, P; Muratore, A; Sperti, E; Zorzi, D, 2007)
"The number of elderly patients with colorectal cancer is increasing in Japan."1.34[Chemotherapy for elderly patients with colorectal cancer]. ( Kuboki, Y; Mizunuma, N, 2007)
"We showed in colorectal cancer cell lines that the expression of MV-H/F, but also of RSV-F, as well as VSV-G can synergistically enhance p53-independent clinically relevant chemotherapy (FOLFOX) over most of the cytotoxic dose range."1.34Mechanistic analysis and comparison of viral fusogenic membrane proteins for their synergistic effects on chemotherapy. ( Grunwald, T; Hoffmann, D; Kuate, S; Wildner, O, 2007)
" Adverse drug reactions to 5-FU-based chemotherapy have been reported to be in part the result of polymorphisms in the thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) genes."1.34Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. ( Cho, HJ; Kang, WK; Kim, JW; Lee, SY; Park, YS, 2007)
"A case of colorectal cancer in a 60-year-old man became resectable after downstaging was achieved with mFOLFOX 6 for multiple liver metastases from colorectal cancer."1.34[A case of liver failure associated with liver damage due to mFOLFOX 6 after resection for multiple liver metastases from colorectal cancer]. ( Abe, T; Aoki, T; Ishizaki, T; Katsumata, K; Koyanagi, Y; Tsuchida, A; Wada, T, 2007)
"Malignant cells from the recurrences displayed a statistical significant increase, concerning the levels of topoisomerase I, by comparison with the primary tumors (P=0."1.34Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy. ( Delladetsima, J; Gouveris, P; Kyriakou, V; Lazaris, AC; Nonni, A; Papathomas, TG; Patsouris, ES; Tsavaris, N, 2007)
" In the man, the capecitabine dosage was reduced and metoprolol was prescribed, while in the woman the capecitabine was stopped."1.34[Myocardial ischaemia as a result of treatment with capecitabine]. ( Liem, AH; Planting, AS; van Halteren, HK, 2007)
"8% (3/38) and was accompanied by severe Gr 4 toxic symptoms (neutropenia, mucositis, diarrhea)."1.34[Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer]. ( Adleff, V; Budai, B; Hitre, E; Komlósi, V; Kralovánszky, J; Pap, E; Réti, A, 2007)
" In May 2002, we devised a new regimen by intermittent dosage of 5-FU (-->S-1), CDDP and paclitaxel utilizing the difference of cell cycle between normal and cancer cells, and thirteen patients with advanced colorectal cancer (Stage IV) were treated with this regimen."1.34[The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamamitsu, S, 2007)
"All patients died from neoplastic disease progression despite further chemotherapy at 6, 17 and 31 months following the diagnosis of NRH."1.34Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? ( Canon, JL; Ceratti, A; Gigot, JF; Horsmans, Y; Hubert, C; Humblet, Y; Machiels, JP; Rahier, J; Sempoux, C, 2007)
"Familial Mediterranean Fever is a chronic hereditary disease which is relatively prevalent in the Middle East and is associated with recurrent episodes of serosal, synovial or cutaneous inflammations."1.34Adjuvant chemotherapy with 5-fluorouracil in a patient with colorectal cancer and Familial Mediterranean Fever. ( Brenner, B; Purim, O; Sulkes, A, 2007)
"In human colorectal cancer model CXF280, antitumor activity of the combination at two-thirds of the maximum tolerated dose (MTD) was superior to that of each monotherapy at MTD."1.34Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts. ( Kondoh, K; Mori, K; Sawada, N, 2007)
"Liver metastasis is an important prognostic factor in colorectal cancer."1.34Benefit of FOLFOX to unresectable liver metastases secondary from colorectal carcinoma in an oncologic emergency. ( Higuchi, R; Koda, K; Kosugi, C; Sugimoto, M; Suzuki, M; Takenoue, T; Tezuka, T; Watayo, Y; Yagawa, Y; Yamamoto, S; Yamazaki, M; Yasuda, H, 2007)
"At our hospital, 232 patients with colorectal cancer underwent outpatient home chemotherapy by placing a CV-port and using a portable disposable pump for continuous infusion of 5-FU between 1998 and 2005."1.34Central venous access port-related complications in outpatient chemotherapy for colorectal cancer. ( Inaba, Y; Muro, K; Najima, M; Nishiofuku, H; Sato, Y; Shimamoto, H; Ura, T; Yamaura, H, 2007)
"In advanced colorectal cancer (ACC), FOLFOX4 has been accepted as a standard chemotherapeutic regimen."1.34UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen. ( Brugnatelli, S; Corazza, GR; Gattoni, E; Luchena, G; Riccardi, A; Sagrada, P; Scalamogna, R; Tinelli, C; Tronconi, MC, 2007)
"Patients with mucinous colorectal cancer generally have worse prognoses than those with the nonmucinous variety."1.33Unfavourable expression of pharmacologic markers in mucinous colorectal cancer. ( Carvalho, LP; Fleshman, JW; Glasgow, SC; McLeod, HL; Shannon, WD; Yu, J, 2005)
"Advanced colorectal cancer specimens (n=97) were prepared for immunohistochemical staining using monoclonal antibodies against TP, p53, vascular endothelial growth factor (VEGF), factor VIII, CD68 and thymidylate synthase (TS)."1.33Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma. ( Koike, M; Matsumoto, H; Mori, T; Shimizu, S; Takahashi, K; Takizawa, T; Toi, M; Yamaguchi, T; Yasuno, M, 2005)
"The therapeutic efficacy of G207, a replication-competent herpes simplex virus, for malignancies is increased when combined with certain chemotherapies, but the mechanism is unclear and the interaction between G207 and surgical resection has not been extensively studied."1.33Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models. ( Cohen, JB; Glorioso, JC; Kuroki, S; Nakano, K; Tanaka, M; Todo, T; Yamaguchi, K; Zhao, G, 2005)
"Colorectal cancer patients with central venous catheters (CVC) for pharmacokinetic modulating chemotherapy (PMC) have a substantial risk of venous thromboembolism (VTE)."1.33Venous thromboembolism in colorectal cancer patients with central venous catheters for 5-FU infusion-based pharmacokinetic modulating chemotherapy. ( Fujiwara, Y; Gega, M; Hashimoto-Tamaoki, T; Higasa, S; Ikeuchi, H; Inoue, T; Nakano, H; Noda, M; Oshima, T; Sakaki, T; Shoji, Y; Tsukamoto, K; Yamamura, T; Yanagi, H; Yoshikawa, R, 2005)
"Although colorectal cancer has the third highest cancer mortality rate, the treatment remains far from optimized with patients showing variable responses to standard treatment."1.33Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer. ( Kidd, EA; Li, X; McLeod, HL; Shannon, WD; Watson, MA; Yu, J, 2005)
"Twenty-three patients with colorectal cancer and isolated liver metastases were enrolled in this trial."1.33Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver. ( Brener, J; Chaitchik, S; Czerniak, A; Hayat, H; Schachter, P; Shimonov, M, 2005)
"An HCT-8 colorectal cancer cell line was used and a high concentration of 5-Fluorouracid (5-FU) was introduced at the beginning to induce drug resistance, then the concentration of 5-FU was increased in gradients."1.33Modulation of multidrug resistance by andrographolid in a HCT-8/5-FU multidrug-resistant colorectal cancer cell line. ( Bu, LM; Han, Y; Ji, X; Liu, CY; Wang, ZH, 2005)
"Drug treatment of colorectal cancer has made impressive progress during the past 10 years."1.33[Systemic therapy for colorectal cancer]. ( Jäger, D; Knuth, A; Pestalozzi, BC, 2005)
"To predict the sensitivity of colorectal cancer to 5-FU, mRNA is extracted from surgically obtained cancer specimens and expression of thymidylate synthetase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), uridine phosphorylase (UP), es-nucleoside transporter (NT), and E2F1 are detected by real-time reverse transcription polymerase chain reaction (RT-PCR) (TaqMan)."1.33Real-time RT-PCR (TaqMan) of tumor mRNA to predict sensitivity of specimens to 5-fluorouracil. ( Kubota, T, 2005)
"Severe steatohepatitis can be associated with preoperative administration of irinotecan or oxaliplatin, especially in the obese."1.33Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. ( Fernandez, FG; Goodwin, JW; Hawkins, WG; Linehan, DC; Ritter, J; Strasberg, SM, 2005)
"Fifty-eight cases of colorectal cancer in stage B2 and C following radical resections were divided into two groups: SMI+IPC group (36 cases) and IPC group (22 cases)."1.33[Clinical research of intraperitoneal chemotherapy plus Shenmai Injection in treating advanced colorectal cancer]. ( Guo, YB; Shen, XH; Yuan, JM; Zheng, L; Zhu, WR, 2005)
"Gene expression profiling of 3 colorectal cancer cell lines (DLD-1, HT-29 and NUGC-3) and the corresponding 5-FU-resistant sublines (DLD-1/FU, HT-29/FU and NUGC-3/5FU/L) showed 81 genes that were differentially expressed."1.33Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays. ( Danenberg, PV; Hayasizaki, Y; Ichikawa, Y; Ishikawa, T; Okazaki, Y; Shimada, H; Shimizu, D; Togo, S, 2005)
" In this study, we investigated the anticancer activity of BGC9331 either alone or combined with 5-fluorouracil (5-FU), MTA (multi-target antifolate), oxali-platin and SN-38, the active metabolite of the topoisomerase I inhibitor CPT-11."1.33Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen ( André, T; Coudray, AM; De Gramont, A; Faivre, S; Gespach, C; Kornprobst, M; Larsen, AK; Louvet, C; Raymond, E; Tournigand, C, 2005)
"Metastatic/advanced colorectal cancer is considered a resistant disease and oncologic emergencies secondary to advanced disease may be regarded with a nihilistic attitude."1.33Oncologic emergencies secondary to advanced colorectal cancer successfully treated with oxaliplatin/5-fluorouracil/leucovorin: report of three cases. ( Anselmi, E; Bertè, R; Bidin, L; Cavanna, L; Civardi, G; Lazzaro, A; Moroni, CF; Palladino, MA; Rodinò, C; Vallisa, D, 2005)
" We introduce a test statistic to select genes with significant dose-response expression in a monotonic fashion based on a permutation procedure."1.33Analysis of dose-response effects on gene expression data with comparison of two microarray platforms. ( Coombes, KR; Hamilton, SR; Hu, J; Kapoor, M; Zhang, W, 2005)
"However, standard treatment for Dukes C colorectal cancer patients currently involves the administration of 5-fluorouracil (5-FU)-based adjuvant chemotherapy after surgery."1.33SMAD4 levels and response to 5-fluorouracil in colorectal cancer. ( Aaltonen, LA; Alazzouzi, H; Alhopuro, P; Arango, D; Dávalos, V; Hemminki, A; Järvinen, H; Mecklin, JP; Salovaara, R; Sammalkorpi, H; Schwartz, S, 2005)
"Irinotecan (CPT11) is a prodrug activated in humans mainly by carboxylesterase 2 (CES2) generating the SN38 metabolite responsible for the drug efficacy and toxicity."1.33Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. ( Biason, P; Buonadonna, A; Cattarossi, G; Cecchin, E; Colussi, A; Corona, G; Frustaci, S; Masier, S; Toffoli, G, 2005)
"Capecitabine is an oral prodrug to 5-fluorouracil (5-FU)."1.33Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma. ( Hoeffding, LD; Jakobsen, A; Lindebjerg, J; Nielsen, JN, 2005)
"We developed a method to assess the similarity of pharmacokinetic data between ethnically different populations."1.33Overlap coefficient for assessing the similarity of pharmacokinetic data between ethnically different populations. ( Fukushima, A; Matsuyama, Y; Mizuno, S; Ohashi, Y; Yamaguchi, T, 2005)
"The type of genomic instability could influence the prognosis of CRC, in particular in stages II and III."1.33Microsatellite instability and colorectal cancer prognosis. ( Barana, D; Benatti, P; Di Gregorio, C; Gafà, R; Guerzoni, L; Lanza, G; Losi, L; Maestri, I; Maffei, S; Marino, M; Menigatti, M; Oliani, C; Pedroni, M; Ponti, G; Ponz de Leon, M; Roncari, B; Roncucci, L; Rossi, G; Santini, A; Scarselli, A, 2005)
"The subjects were 31 patients with colorectal cancer who underwent surgical excision between December 2003 and July 2004 at our department."1.33The relationship between 5-fluorouracil sensitivity and single nucleotide polymorphisms of the orotate phosphoribosyl transferase gene in colorectal cancer. ( Hata, M; Kamano, T; Kitajima, M; Maeda, T; Ochiai, T; Sakamoto, K; Takita, N, 2006)
"Capecitabine was approved for funding in the province of British Columbia in the spring of 2002 as an oral chemotherapeutic option for metastatic CRC."1.33Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis. ( Gill, S; Ho, C; Ng, K; O'Reilly, S, 2005)
"Celecoxib was initiated in the diet at 100 ppm (equivalent to 20 mg/kg/d p."1.33Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. ( Blanquicett, C; Buchsbaum, DJ; Carpenter, MD; Chhieng, DC; Diasio, RB; Eloubeidi, M; Johnson, MR; Russo, S; Saif, MW; Sellers, JC; Vickers, SM, 2005)
"The treatment of metastatic colorectal cancer by chemotherapy alone was considered palliative and without the potential to cure patients unless patients were rendered resectable."1.33Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases. ( Kemeny, NE; Leonard, GD, 2006)
"Colorectal cancer is the second most common malignant tumour in Germany with an unfavorable prognosis especially in a locally advanced or metastasizing stage."1.33[Adjuvant and palliative chemotherapy of colorectal cancer in Germany outside controlled trials]. ( Bogdanow, M; Gorschlüter, M; Lamberti, C; Lundin, S; Sauerbruch, T; Schmidt-Wolf, IG, 2006)
"To study the effect of angiogenesis inhibitor YH-16 in combination with 5-FU on liver metastasis of colorectal cancer."1.33[Inhibitory effect of angiogenesis inhibitor YH-16 in combination with 5-FU on liver metastasis of colorectal cancer]. ( Chen, G; Lin, SX; Lu, ZH; Ren, JQ; Tang, SX; Wan, DS; Wang, GQ; Ye, YL; Zhou, ZW, 2006)
"Microsatellite instability is a recognised pathway of colorectal carcinogenesis responsible for about 15% of all sporadic colorectal cancers."1.335-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer. ( Kaufman, A; Ramanathan, P; Robinson, BG; Schnitzler, M; Warusavitarne, J, 2006)
" A reduction in irinotecan dosage or use of an alternative agent may be warranted in patients with risk factors for toxicity."1.33Individualizing chemotherapeutic treatment of colorectal cancer. ( Crews, KR, 2006)
"In recent years, chemotherapy for colorectal cancer has advanced rapidly."1.33[Outpatient based colorectal cancer treatment--the current status, challenges and future outlook]. ( Akazai, Y; Kimura, H; Nitta, Y, 2006)
"(1) The prognosis for metastatic colorectal cancer is grim."1.33Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice. ( , 2006)
" Our data suggest that GSTT1-null is associated with a greater probability of developing toxicity to 5-Fu/CPT-11/Lv treatments, indicating a potential application of this genetic analysis in predicting adverse effects of this regimen."1.33Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients. ( Aranda, E; Bandres, E; De la Haba, J; Garcia, F; García-Foncillas, J; Gómez, A; Huarriz, M; Morales, R; Romero, RZ, 2006)
"Experimentally, we studied a diploid colorectal cancer line heterozygous at TS to mimic three common TS genotypes of cancers."1.33Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy. ( Brody, JR; Gallmeier, E; Hucl, T; Kern, SE; Murphy, KM; Winter, JM, 2006)
"Fifty five patients with advanced colorectal cancer were treated by FOLFIRI or FOLFOX regimen from April 2005 to June 2006."1.33[Present status of home therapy cancer patients using an infusor]. ( Chiba, H; Honda, K; Kondo, H; Makino, K; Mizushima, T; Ohura, K; Sumiyoshi, T; Tamura, F; Tanaka, S; Tsuji, Y; Tsushima, T; Yoshizaki, N, 2006)
"Chemotherapy for colorectal cancer has changed greatly."1.33[The future of chemotherapy at home--from outpatient chemotherapy to chemotherapy at home]. ( Takahashi, K, 2006)
"Human colorectal cancer cells (SW48) are characterized by the hypermethylation of proapoptotic genes."1.33The synergistic effect of 5-aza-2'-deoxycytidine and 5-fluorouracil on drug-resistant tumors. ( Iida, S; Kato, K; Morita, S; Sugihara, K; Takagi, Y; Uetake, H, 2006)
"Patients with unresectable distant metastasis are not suitable candidates for surgical resection and intraoperative radiation therapy, whereas those with resectable metastasis are potential candidates."1.32Indicators for surgical resection and intraoperative radiation therapy for pelvic recurrence of colorectal cancer. ( Hashiguchi, Y; Kato, S; Kazumoto, T; Nishimura, Y; Sakamoto, H; Sakura, M; Sekine, T; Tanaka, Y, 2003)
"The younger patients with colorectal cancer had more mucin-producing (14."1.32Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age. ( Cheng, AL; Huang, KC; Jeng, YM; Liang, JT; Wang, SM; Wu, MS, 2003)
"Median time to disease progression was 9."1.32Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. ( Aparicio, J; Calderero, V; Díaz, R; Gironés, R; López-Tendero, P; Pérez-Fidalgo, JA; Segura, A; Yuste, AL, 2003)
"Liver metastasis from colorectal cancer remains an oncological challenge."1.32Quality of life in patients with colorectal metastasis and intrahepatic chemotherapy. ( Blair, SL; Chu, DZ; Cullinane, C; Dean, G; Grant, M; Schwarz, RE; Wagman, L, 2003)
"Drugs pharmacokinetic control is a usual practice in case of flat continuous infusions."1.32[Modeling 5-FU clearance during a chronomodulated infusion]. ( Chevalier, V; Chevrier, R; Chollet, P; Cure, H; Kwiatkowski, F; Richard, D, 2003)
"Capecitabine is an orally available fluoropyrimidine and is finally converted to 5-FU selectively in tumor tissues."1.32Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889. ( Eda, H; Endo, M; Hattori, K; Ishikawa, T; Ishitsuka, H; Miwa, M; Miyazaki-Nose, T; Shimma, N; Tanimura, H; Ura, M; Yamada-Okabe, H, 2003)
"These data in a heavily pretreated patient population confirm that oxaliplatin is safe when used as a single agent or with a variety of FU-based regimens as salvage therapy in patients with advanced colorectal cancer."1.32Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. ( Clark, JW; Gococo, KO; Haller, DG; Kardinal, CG; Kemeny, NE; Lenz, HJ; Mitchell, EP; Ramanathan, RK, 2003)
"3R allele in colorectal cancer was subdivided into around half by the SNP, indicating its commonness among Japanese."1.32Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. ( Kawakami, K; Watanabe, G, 2003)
"5 patients with colorectal cancer with multiple liver metastases underwent resection of primary lesions."1.32[Evaluation of hepatic arterial infusion chemotherapy with low-dose leucovorin and 5-FU from reservoir for multiple liver metastases by colorectal cancer]. ( Abe, N; Ishii, Y; Itou, T; Nakayama, K; Takahashi, M, 2003)
"We performed radiofrequency ablation (RFA) therapy combined with intrahepatic arterial infusion chemotherapy for 7 patients with liver metastasis from colorectal cancer."1.32[Radiofrequency ablation therapy combined with intrahepatic arterial infusion chemotherapy for liver metastasis of colorectal cancer]. ( Fuchimoto, S; Inagaki, M; Miyoshi, K; Oosaki, T; Otsuka, S; Sakata, T; Takahashi, M, 2003)
"Hemoptysis was negligible until he died 8 months later."1.32[Clinical benefit of bronchial arterial infusion chemotherapy to pulmonary metastasis from colorectal cancer--report of two cases]. ( Ishigaki, T; Kitai, T; Kojima, N; Miki, A; Nishikawa, S; Nomura, A; Todo, G; Ukikusa, M, 2003)
"Among 182 patients with stage II-III colorectal cancers, 89 patients (adjuvant chemotherapy group) received oral 5-FU based-adjuvant chemotherapy, and 93 patients (surgery alone group) did not receive 5-FU."1.32Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone. ( Hidaka, S; Nagayasu, T; Nakagoe, T; Sawai, T; Tagawa, Y; Takeshita, H; Tsuji, T; Yamaguchi, H; Yasutake, T, 2004)
"Patients with liver metastases of colorectal cancer were treated with 5-FU (500/600 mg/m)+folinic acid with or without trimetrexate."1.3219F-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil. ( Heerschap, A; Kamm, YJ; van den Bergh, EJ; Wagener, DJ, 2004)
"Patients with stage III/IV colorectal cancer were treated by bolus intravenous (I."1.32Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer. ( Chabner, BA; Charlat, O; Clark, JW; Kelly, P; Kreconus, E; Nesbitt, S; Puchalski, TA; Ryan, DP; Stanton, VP; Supko, JG; Zhu, AX, 2004)
"Four patients had primary liver cancers."1.32A longterm follow-up study of thymidylate synthase as a predictor for survival of patients with liver tumours receiving hepatic arterial infusion chemotherapy. ( Danenberg, K; Danenberg, P; Formentini, A; Hillenbrand, A; Kornmann, M; Salonga, D; Sander, S; Staib, L, 2004)
"Catheter-related deep venous thrombosis is a complication that can occur in patients receiving chemotherapy."1.32Upper extremity deep venous thrombosis in patients with 5-fluorouracil-containing adjuvant chemotherapy--three case reports and a review. ( Albertsson, M; Tham, J, 2004)
"Colon and rectal cancer are in France a challenging problem in public health, reaching the second place in cancer related deaths."1.32[Colorectal cancer: what should be the management of primary tumour?]. ( Delpero, JR; Lelong, B; Moutardier, V, 2004)
"The expression of the FasL gene in colorectal cancer cells is related to immune evasion to escape from being killed by immune cells, showing stronger drug-resistance, and it facilitates hepatic metastasis."1.32Influence of FasL gene expression on hepatic metastasis of colorectal carcinoma. ( An, P; Cai, HY; Li, SY; Wei, JC; Yu, B; Zuo, FY, 2004)
"The deleted in colorectal cancer (DCC) gene predicts a poor outcome for patients with colorectal carcinoma."1.32Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients. ( Gal, R; Klein, B; Koren, R; Sadikov, E; Sulkes, J, 2004)
" We have examined the effect of this CDO alone and in combination with a range of common chemotherapeutic agents in colorectal cancer cell lines."1.32The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines. ( Liu, WM; Propper, DJ; Scott, KA; Shahin, S, 2004)
"In patients with liver metastases from colorectal cancer, survival can be increased by hepatic resection."1.32Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy. ( Carlo, WF; Fong, Y; Gonen, M; Hummer, AJ; Jarnagin, W; Kemeny, N; Schwartz, L; Sullivan, D, 2004)
"We evaluated the cytotoxic effect of ZD0473 administered alone or in combination with 5-Fluorouracil (5FU) or SN38 in a panel of sensitive and 5FU-resistant colorectal cell lines (HT29/HT29-5FUR and LoVo/LoVo-5FUR)."1.32Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines. ( Abad, A; Martinez-Balibrea, E; Plasencia, C; Taron, M, 2004)
"The study included 32 colorectal cancer patients; apoptosis was determined by annexin-V binding and light-scatter morphology before and after drug infusion."1.32Fluorouracil induces apoptosis and surface molecule modulation of peripheral blood leukocytes. ( Drucker, L; Kimhi, O; Lahav, M; Lishner, M; Neumann, A; Radnay, J; Shapira, J; Shapiro, H; Yarkoni, S, 2004)
"Sigmoid colon cancer and hepatocellular cancer (S5, S6, S8) were diagnosed before surgery."1.32[The use of radio frequency ablation (RFA) for colorectal liver metastases in one patient]. ( Hamada, H; Katsuki, Y; Takada, J; Tsuji, Y, 2004)
"Objective responses in colorectal cancer patients were: 1st-line MdG (22 assessable): PR=36%, NC=32%, PD=32%."1.31A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. ( Cheeseman, SL; Chester, JD; Dent, JT; Joel, SP; Richards, FJ; Seymour, MT; Wilson, G, 2002)
" In order to evaluate the clinical relevance of SMAD4 deletion, gene copy alterations were determined by copy dosage using real-time quantitative PCR in 202 colorectal tumour biopsies from a previous randomised study of adjuvant chemotherapy."1.31SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer. ( Boulay, JL; Herrmann, R; Laffer, U; Lagrange, M; Lowy, A; Mild, G; Reuter, J; Rochlitz, C; Terracciano, L, 2002)
"5-Fluorouracil (5-FU) is a widely used for colorectal carcinoma."1.31Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis. ( Ikeguchi, M; Kaibara, N; Makino, M, 2002)
"Cerivastatin may allow successful 5FU therapy in chemoresistant patients."1.31Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. ( Cassidy, J; Collie-Duguid, E; Wang, W, 2002)
"Tissue specimens were obtained from colorectal cancer patients and in vitro chemosensitivity was tested using fluorescein diacetate assay (FDA) or histoculture drug response assay (HDRA)."1.31Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. ( Gen, T; Isshi, K; Katuyama, T; Kuroda, T; Maekawa, Y; Nakamura, Y; Sakuyama, T, 2002)
"The pharmacokinetic parameters obtained for (-)-fTHF following the administration of (-)-fTHF only were: terminal half-life, 1."1.31Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid. ( Braess, J; Ehninger, G; Hiddemann, W; Kern, W; Rudolph, KL; Schleyer, E; Unterhalt, M, 2000)
" In this study, the pharmacokinetic parameters of 5-FU are monitored in six patients, who received two chemotherapeutic courses of 2,600 mg/m2 BSA 5FU over 24 h, one course with 700 mg/m2 BSA amifostine prior to the 5-FU infusion and the other without."1.31Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma. ( Fuhlroth, J; Martens-Lobenhoffer, J; Ridwelski, K, 2000)
" Forty-seven patients (35%+/-8%) experienced significant toxicity and were unable to receive the second cycle as scheduled: 76% required dose reduction, 11% discontinued therapy (including two toxic deaths), 11% discontinued therapy during the first cycle, and 2% required dose delay."1.31Standard dose (Mayo regimen) 5-fluorouracil and low dose folinic acid: prohibitive toxicity? ( Griffeth, S; Keith, B; Kocha, W; Sawyer, M; Stitt, L; Taylor, M; Tomiak, A; Vincent, M; Whiston, F; Winquist, E, 2000)
"We investigated the effects of 2'-deoxyinosine (d-Ino), a modulator yielding thymidine phosphorylase activity, on cellular pharmacology of 5-fluorouracil (FUra) in various human colorectal cell lines and its antitumoral activity when combined with FUra in human xenografts."1.31Enhanced antitumor activity of 5-fluorouracil in combination with 2'-deoxyinosine in human colorectal cell lines and human colon tumor xenografts. ( Aubert, C; Catalin, J; Ciccolini, J; Cuq, P; Evrard, A; Formento, P; Milano, G; Peillard, L; Pelegrin, A, 2000)
"Data on 45 patients with colorectal cancer were analyzed."1.31Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. ( Hinoshita, E; Kinukawa, N; Kuwano, M; Maehara, Y; Sugimachi, K; Taguchi, K; Tsuneyoshi, M; Uchiumi, T, 2000)
"A total of 35 patients with primary colorectal cancer who underwent surgical treatment were examined by chemosensitivity test with the viable tumor samples using Histoculture Drug Response Assay (HDRA)."1.31[Clinical significance of serum p53 antibody detection in a chemosensitivity assay in cases of human colorectal cancer]. ( Imaseki, H; Isono, K; Iwasaki, K; Kondo, S; Kouno, T; Makino, H; Nakajima, K; Natsume, T; Ochiai, T; Okazumi, S; Shimada, H; Suzuki, T; Takayama, W; Takeda, A, 2000)
"Pretreatment with eniluracil (5-ethynyluracil) prevents catabolism of FU."1.31Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics. ( Alauddin, MM; Bading, JR; Conti, PS; Fissekis, JD; Joung, J; Shahinian, AH; Spector, T, 2000)
"As there is no information on UDG in colorectal cancer, this study characterized UDG activity and protein expression in a panel of 20 colorectal tumors and 6 colorectal cell lines."1.31Analysis of uracil DNA glycosylase in human colorectal cancer. ( Dusseau, C; Keenan, RA; Krokan, HE; McLeod, HL; Murray, GI; O'Kelly, T, 2001)
"In other two groups (gastric and colorectal cancer patients) side effects of chemotherapy caused relatively less QL deterioration."1.31Quality of life in cancer patients treated by chemotherapy. ( Herman, ZS; Machalski, M; Scieszka, M; Zielinski, M, 2000)
"Colorectal carcinoma is one of the most common malignancies in the western world, and although fluorouracil (5-FU) has been used in its treatment for almost 40 years, new agents with significant activity have been introduced recently."1.31The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. ( Antoine, EC; Bastian, G; Gil-Delgado, M; Khayat, D; Nizri, D, 2001)
"The subjects were 24 colorectal cancer patients."1.31A pharmacological study of the weekday-on/weekend-off oral UFT schedule in colorectal cancer patients. ( Iwase, H; Kameya, T; Makuuchi, H; Sadahiro, S; Suzuki, T; Tajima, T, 2001)
"Fluoropyrimidine therapy for elderly colorectal cancer patients remains controversial."1.31[Tumoral levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in elderly colorectal cancer patients]. ( Fujioka, M; Hashimoto, D; Hoshino, T; Idezuki, Y; Inokuma, S; Ishida, H; Murata, N; Nakada, H; Ohsawa, T; Takeuchi, I, 2001)
"Treating elderly patients with colorectal cancer is a challenging task for which many aspects have to be taken into account."1.31[Chemotherapy of colorectal cancer--which therapy is justified for elderly patients?]. ( Bokemeyer, C; Honecker, F; Kolb, G; Wedding, U, 2001)
"Phase I and II trials were performed in colorectal cancer to define the optimal dose and schedule of capecitabine."1.31Xeloda in colorectal cancer. ( Cassidy, J, 2001)
" This is the first report of non-invasive monitoring of toxic 5-FU metabolites in normal human tissues."1.31Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment. ( Griffiths, JR; Howe, FA; Lofts, F; McIntyre, DJ; McSheehy, PM; Nicholson, G; Noordhuis, P; Peters, GJ; Price, NM; Rodrigues, LM; Smid, K; Stubbs, M; Wadsworth, P, 2001)
" Pharmacodynamic changes were thus observed as a result of electrostatic treatment during chemotherapy."1.31Pharmacodynamics induced by direct electric current for the treatment of 5-fluorouracil resistant tumor: an animal experiment. ( Akiyama, S; Ando, H; Hibi, K; Hidemura, K; Ito, K; Kasai, Y; Nakao, A; Wong, L, 2001)
"(1) The reference treatment for colorectal cancer is surgery."1.31Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage. ( , 2001)
"Carbamazepine levels were 4."1.31[Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study]. ( Adelsberger, H; Eckel, F; Erdmann, J; Lersch, C; Quasthoff, S; Schmelz, R, 2002)
"Patients were treated for colorectal cancer and received chemotherapy consisting of leucovorin 20 mg m(-2) plus 5-fluorouracil 425 mg m(-2)."1.31Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. ( De Vries, EG; Groen, HJ; Haasjes, J; Maring, JG; Piersma, H; Uges, DR; Van Gennip, AH; van Kuilenburg, AB, 2002)
"It has previously been shown that colorectal cancer patients who are homozygous for the triple tandem repeats (L/L) have significantly higher thymidylate synthase mRNA expression than those homozygous for the double repeat variant (S/S)."1.31Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer. ( Groshen, S; Lenz, HJ; Park, DJ; Stoehlmacher, J; Tsao-Wei, D; Zhang, W, 2002)
"Only 63."1.31[Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms]. ( Grothey, A; Kellermann, L; Schmoll, HJ, 2002)
"In conclusion, many efforts to overcome colorectal cancer will soon open new therapeutic windows."1.31[Recent advances in the diagnosis and treatment of colorectal cancers]. ( Mimori, K; Mori, M, 2002)
" The mean total dosage was 6."1.30[Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine]. ( Baba, H; Kohnoe, S; Matsuoka, H; Morita, M; Saito, T; Seo, Y; Taketomi, A; Tomoda, H, 1997)
"The purpose of our study was to develop a pharmacokinetic model to quantify the intracellular 5-fluorouracil (5-FU) concentration in liver metastases, which is expected to be closely correlated to therapy response."1.30Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. ( Bellemann, ME; Brix, G; Dimitrakopoulou-Strauss, A; Haberkorn, U; Kissel, J; Lorenz, WJ; Port, R; Strauss, LG, 1997)
"Forty-six disseminated colorectal cancer patients had measurable tumor biopsies for polymerase chain reaction (PCR)-based determination of TS mRNA pretreatment."1.30Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. ( Baranda, J; Boswell, W; Danenberg, K; Danenberg, PV; Groshen, S; Leichman, CG; Leichman, L; Lenz, HJ; Metzger, R; Tan, M, 1997)
" There seemed to be no correlation with the total dosage of 5-FU or the number of administrations."1.30[Complication due to arterial infusion chemotherapy for liver metastasis from colorectal cancer]. ( Hamada, H; Hashimoto, M; Katsuki, Y; Kawata, S; Kon, H; Sasaki, R; Tomita, I; Tsuji, Y; Yasuda, T, 1997)
" Gastrimmune immunisation may be a therapeutic option for the treatment of colorectal cancer in combination with 5-FU/leucovorin."1.30Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model. ( Clarke, PA; Grimes, S; Hardcastle, JD; Justin, TA; Michael, D; Morris, TM; Robinson, G; Watson, SA, 1998)
"When tegafur was injected, the concentration of 5-FU in cancer tissue or lymphnodes was significantly higher than in normal tissue."1.30[Concentrations of 5-fluorouracil (5-FU) in serum and tissues at venous injection of tegafur or 5-FU--clinical study on colorectal cancer]. ( Inamura, Y; Kanemitsu, T; Kojima, T; Miyashita, A; Naruse, T; Owa, Y; Suzumura, K, 1998)
" Participation by both the oncology care team and patients is crucial for effective side effect management."1.30Managing the side effects of chemotherapy for colorectal cancer. ( Berg, D, 1998)
"Forty-four advanced colorectal cancer patients (15 women and 29 men; median age 63, range, 27-78 years) receiving a standard FU-folinic acid protocol were included."1.30Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data. ( Chazal, M; Cheradame, S; Cure, H; Etienne, MC; Formento, JL; Formento, P; François, E; Francoual, M; Letoublon, C; Milano, G; Mousseau, M; Pezet, D; Richelme, H; Seitz, JF, 1997)
" Details are presented here on the methodology of NMRS data acquisition and on their pharmacokinetic analysis."1.30Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies. ( Presant, CA; Waluch, V; Wolf, W, 1998)
"5-Fluorouracil (5-FU) is a commonly used anticancer agent for the treatment of gastrointestinal, head and neck, and breast tumours."1.30Autoregulation of 5-fluorouracil metabolism. ( Cassidy, J; Hardy, SC; Hawksworth, GM; Lock, RE; McLeod, HL; Sludden, J, 1998)
"The human colorectal cancer cell line C170HM2 readily forms liver metastases in vivo."1.30A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2. ( Jackman, AL; Morris, TM; Page, MJ; Rohlff, C; Skelton, L; Watson, SA, 1999)
"Twenty-one paired pharmacokinetic studies were completed on patients with colorectal, gastric, and hepatocellular cancer, utilizing positron emission tomography (PET), which allowed the acquisition of tumor, normal tissue, and plasma pharmacokinetic data and tumor blood flow (TBF) measurements."1.30Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. ( Brady, F; Brown, G; Harte, RJ; Jones, T; Luthra, SJ; Matthews, JC; O'Reilly, SM; Osman, S; Price, PM; Tilsley, DW, 1999)
"A total of 22 patients with primary colorectal cancer who underwent surgical treatment were examined for chemosensitivity with iable tumor samples using the Histoculture Drug Response Assay (HDRA)."1.30Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer. ( Hayashi, H; Imaseki, H; Isono, K; Nakajima, K; Ochiai, T; Shimada, H; Suzuki, T; Takayama, W; Takeda, A, 1999)
"Capecitabine (Xeloda) is a rationally designed oral, tumor-selective fluoropyrimidine carbamate aimed at preferential conversion to 5-fluorouracil (5-FU) within the tumor."1.30Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ( Banken, L; Cassidy, J; Glynne-Jones, R; Goggin, T; Reigner, B; Roos, B; Schüller, J; Twelves, C; Utoh, M; Weidekamm, E, 1999)
"We measured the chemosensitivity of colorectal cancer to 5-FU by MTT assay using specimens from colonoscopy, and compared this with the histopathological effects."1.30[Comparative study of histopathological effects of preoperative chemotherapy using UFT and in vitro MTT assay of colonoscopy specimens from patients with colorectal cancer]. ( Fujii, M; Imai, S; Mochizuki, F, 1999)
" The dose-response behaviors of 5-FU and FdUMP[10] toward H630 and H630-10 (human colorectal tumor) cells were first investigated separately."1.30Positive interaction between 5-FU and FdUMP[10] in the inhibition of human colorectal tumor cell proliferation. ( Anderson, J; Gmeiner, WH; Kolar, C; Kolath, J; Lawson, TA; Liu, J; Talmadge, J, 1999)
"The surgical treatment of colorectal cancer (CRC) in elderly patients (age 70 years or older) has improved, but data on adjuvant and palliative chemotherapy tolerability and benefits in this growing population remain scarce."1.30Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. ( Cunningham, D; Norman, A; Parikh, B; Popescu, RA; Ross, PJ, 1999)
"5-Fluorouracil (5-FU) is an antimetabolite frequently used in the treatment of cancer."1.29Dermatological toxicity from chemotherapy containing 5-fluorouracil. ( Campanella, GA; Carrieri, G; Colucci, G; Leo, S; Tatulli, C; Taveri, R, 1994)
" Low drug dosages (relative to the sensitivity of in vivo NMR) or rapid drug elimination create the additional problem of data sparsity where a pharmacokinetic model cannot be fitted individually."1.29Pharmacokinetic analysis of sparse in vivo NMR spectroscopy data using relative parameters and the population approach. ( Bachert, P; Port, RE; Schlemmer, HP, 1994)
"Two cases of hepatic metastasis of colorectal cancer were treated effectively by intrahepatic-arterial infusion immunotherapy using OK-432 (2 KE/week or 2 weeks), recombinant IL-2 (35 x 10(4) JRU or 40 x 10(4) JRU/week or 2 weeks), MMC (4 mg/week or 2 weeks) and 5-FU (250 mg/day during admission, 250 mg/week or 2 weeks during outpatient treatment)."1.29[Two cases of hepatic metastasis of colorectal cancer treated effectively by intrahepatic arterial infusion immunotherapy using OK-432, rIL-2, MMC and 5-FU]. ( Akiyama, T; Kiriyama, M; Kita, I; Kosaka, T; Kurosaka, Y; Matsushita, M; Takashima, S; Tomita, F, 1994)
" Tumor xenografts composed of CD-expressing cells can selectively generate tumor levels of > 400 microM 5FUra when the host mouse is dosed with nontoxic levels of 5FCyt."1.29Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. ( Austin, EA; Davis, ST; Good, SS; Huber, BE; Richards, CA, 1994)
" Eighty per cent reduction of leucovorin dosage leads to a significant decrease in grade 2 and grade 3 haematological and gastrointestinal toxicity."1.29Local and systemic toxicity of intra-hepatic-arterial 5-FU and high-dose or low-dose leucovorin for liver metastases of colorectal cancer. ( Klotz, HP; Largiadèr, F; Weder, W, 1994)
" Preoperative regimens of HCFU 240 mg/m2/day, given by 14-day oral dosage or HCFU 240 mg/m2/day and DP (Dipyridamole) 300 mg/body/day, both 14-day oral dosage were used."1.29[TS inhibition rate and flow cytometric analysis of DNA content in preoperative chemotherapy with biochemical modulator]. ( Sakuyama, T; Takahashi, N, 1994)
"Fifty-three patients with advanced colorectal cancer were given single oral doses of 5'-DFUR, 400 mg/body, preoperatively to assess the pharmacokinetics of 5'-DFUR in the patients with colorectal cancer and to investigate schedules for 5'-DFUR treatment."1.29[Study on the relationship between concentrations of 5-FU and PyNPase activity in tumor tissue during oral 5'-DFUR treatment in patients with advanced colorectal cancer]. ( Hanyu, F; Hayashi, T; Igarashi, T; Suzuki, M; Watanabe, K; Yoshida, K, 1994)
"The outlook for patients with advanced colorectal cancer remains poor."1.29Pharmacokinetics of 5-fluorouracil in colorectal cancer patients receiving interferon. ( Patel, N; Perren, T; Pittman, K; Primrose, J; Selby, P; Slevin, M; Ward, U, 1993)
"Five cases of colorectal cancer with unresectable liver metastases treated from April 1992 to April 1993 in Osaka National Hospital were summarized in this paper."1.29[Continuous intra-hepatic-arterial infusion of low dose 5-fluorouracil for colorectal cancer patients with unresectable liver metastases]. ( Imamura, H; Kanoh, T; Kikkawa, N; Miyazaki, M; Nakayama, T; Tamaki, Y; Taniguchi, K; Tohno, K; Utsunomiya, T, 1993)
"Since 1980, 89 patients with colorectal cancer showed liver metastasis."1.29[Efficacy of hepatic arterial and intraportal infusion chemotherapy for liver metastasis of colorectal cancer]. ( Akaike, M; Okamoto, T; Sugimasa, Y; Takemiya, S, 1993)
" Rats were dosed p."1.295-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. ( Baccanari, DP; Cao, S; Davis, ST; Joyner, SS; Rustum, YM; Spector, T, 1995)
" Pharmacokinetic evaluation demonstrated that ILP at 21 mg/mL maximally elevated total lung FUDR and 5-fluorouracil levels (508."1.29Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival. ( Burt, ME; Ellis, JL; Lenert, JT; Nawata, S; Ng, B; Port, JL, 1996)
"There were 43 colorectal and 104 appendiceal cancer patients."1.29Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy. ( Chang, D; Koslowe, P; Sugarbaker, PH, 1996)
"The goals of this study of a hepatic arterial infusion (HAI) regimen of alternating floxuridine and 5-fluorouracil were to evaluate the treatment-related toxic effects, the antitumor response rate, and patient survival."1.29Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity. ( Chase, JL; Curley, SA; Davidson, BS; DuBrow, RA; Hohn, DC; Izzo, F; Patt, Y, 1996)
"Twenty-two patients with colorectal cancer and synchronous unresectable hepatic metastases were treated by resection the primary tumour with concurrent insertion of an Infusaid infusaport system for regional chemoperfusion (hepatic arterial 20, portal venous 2)."1.29Primary resection and synchronous regional hepatic chemotherapy or cryotherapy for colorectal cancer with liver metastases. ( Clingan, PR; Dasappa, V; King, DW; King, J; Morris, DL; Ross, WB, 1996)
"Body weight was diminished significantly in rats receiving chemotherapy."1.29Combined preoperative irradiation and direct postoperative 5-fluorouracil without negative effects on early anastomotic healing in the rat colon. ( Biert, J; de Man, B; Hendriks, T; Hoogenhout, J; Wobbes, T, 1996)
"Thirty patients with advanced colorectal cancer were treated preoperatively by combined regional radiofrequency hyperthermia and 5-FU."1.28[Preoperative regional radiofrequency thermochemotherapy of colorectal cancer: clinical and pathological studies]. ( Wu, GR, 1992)
"Hepatectomy has been performed as a treatment for hepatocellular carcinoma (HCC) and metastatic liver carcinoma."1.28[Intermittent intra-arterial chemotherapy using subcutaneously implanted reservoir for hepatocellular carcinoma and liver metastasis of colorectal carcinoma]. ( Hanawa, S; Hasebe, Y; Kuramoto, S; Maeda, T; Nakazaki, H; Suzuki, Y; Watanabe, M; Yanagita, K; Yoshio, T, 1992)
"The benefits from medical treatment in colorectal cancer are limited."1.28Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acid. ( Bajetta, E; Colleoni, M; de Braud, F; Nelli, P; Nolè, F; Zilembo, N, 1992)
" The 5-FU concentration was a determinant factor affecting modification of the effects of the drug combination from antagonism (with low 5-FU concentrations) to synergism (high 5-FU concentrations) (P less than 0."1.28[Cytotoxic effects of the combination of a new nitrosourea, fotemustine, combined with 5-fluorouracil and folinic acid depend on the sequence of their administration]. ( Berille, J; Berlion, M; Bizzari, JP; Fischel, JL; Formento, P; Gioanni, J; Milano, G, 1992)
"Thirty-five patients with advanced colorectal cancer received 5-FU (500 mg/m2) at 1 to 48 hours prior to surgery."1.28Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin. ( Laurensse, E; Meijer, S; Peters, GJ; Pinedo, HM; Smid, K; van der Wilt, CL; van Groeningen, CJ, 1992)
"Two groups of patients with colorectal cancer and remote metastases in the liver are presented: one received surgical treatment alone, the other combined therapy."1.28[A combined method for treating metastases of colorectal carcinoma to the liver]. ( Dimitrov, V; Dudunkov, Z; Kurtev, P; Kurteva, G; Ralchev, K, 1991)
"Chemotherapy for colorectal cancer with liver metastases following surgical operation for primary tumor should be selected following surgical intervention."1.28[Continuous infusion chemotherapy using an infusional port in colorectal cancer with liver metastases]. ( Ishida, Y; Kojima, N; Kusumoto, S; Nakayoshi, A; Oka, H, 1991)
"With colorectal cancer, the therapeutic outcome for multiple hepatic metastasis extending to the bilateral lobe, even when various chemotherapies are administered, is extremely poor."1.28[Intra-arterial infusion chemotherapy using an implantable reservoir in the treatment of hepatic metastases in colorectal cancer]. ( Gotohda, H; Katoh, M; Kinami, Y; Kumaki, T; Saitoh, H; Takashima, S; Takegawa, S; Tomita, F, 1991)
"Seventeen patients with colorectal cancer metastatic to the liver underwent hepatic resection."1.28Hepatic recurrence not prevented with low-dosage long-term intraportal 5-FU infusion after resection of colorectal liver metastasis. ( Furusawa, M; Kakeji, Y; Maehara, Y; Sugimachi, K; Tomoda, H; Tsujitani, S; Watanabe, A, 1991)
"5-Fluorouracil (5-FU) was delivered in a dose-intensive schedule to 23 patients with metastatic or unresectable colorectal carcinoma."1.28A dose-intensive regimen of 5-fluorouracil for the treatment of metastatic colorectal carcinoma. ( Baker, L; Brodfuehrer, J; Kraut, M; Poplin, EA; Vaitkevicius, V, 1991)
"Twenty-five patients with pretreated advanced colorectal carcinoma were subjected to second-line chemotherapy with sequential high-dose methotrexate and 5-fluorouracil."1.28Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil. ( Airoma, G; Bianco, AR; Caponigro, F; Gridelli, C; Incoronato, P; Palmieri, G; Pepe, R, 1991)
" The dosage of raIFN-2a could not be further escalated above 12 x 10(6) IU."1.285-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study. ( Gebbia, V; Palmeri, S; Rausa, L, 1990)
"The cases were comprised of 9 gastric cancers, 6 colorectal cancers, 1 appendiceal carcinoma, and 1 malignant tumor of retroperitoneum, all of which were observed to have peritoneal dissemination during surgical operations."1.28[Evaluation of intraperitoneal cancer chemotherapy using an implantable reservoir in patients with peritonitis carcinomatosa]. ( Katsuki, Y; Nishimura, A; Tsuji, Y; Yasuda, T, 1990)
"These two cases showed no recurrent liver cancers."1.28[Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases]. ( Houjo, K; Kawano, N; Moriya, Y; Sugihara, K, 1990)
" This was deemed due to the small dosage and a short duration of 5'-DFUR."1.28[A study on preoperative administration of doxifluridine in carcinoma of the colon and rectum]. ( Harada, T; Hirano, M; Kikkawa, H; Masuda, S; Matsu, T; Saito, H; Sakatoku, M; Tatsuzawa, T, 1990)
"Out of 40 patients with colorectal cancer, 34 received leucovorin 50 mg and 6 received 200 mg."1.28Sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic gastrointestinal cancer. ( Carlsson, G; Glimelius, B; Graf, W; Gustavsson, BG; Påhlman, L; Spears, PC, 1990)
"Excisions of metastatic liver cancer were performed in 36 patients and 23 had nonresectable metastatic liver cancer."1.28[Results of intra-arterial infusion chemotherapy of colorectal cancer in patients with metastatic liver cancer]. ( Hojo, K; Moriya, Y; Sawada, T, 1989)
"Excisions of metastatic liver cancer were performed in 36 patients and 23 had nonresectable metastatic liver cancer."1.28[Complications of intra-arterial infusion chemotherapy in patients with colorectal cancer with liver metastasis, with special reference to IA-5-FU induced sclerosing cholangitis]. ( Hojo, K; Moriya, Y; Sawada, T, 1989)
"Lipiodol-ADM was injected for hepatocellular carcinoma every 2 months and MMC-5-FU was injected for liver metastasis of colorectal carcinoma every one or two weeks."1.28[Usefulness of subcutaneously implanted reservoir for postoperative therapy in hepatocellular carcinoma and liver metastases of colorectal carcinoma]. ( Adachi, W; Hanasaki, K; Horigome, N; Iida, F; Kajikawa, S; Kinosita, T; Kuroda, T; Sodeyama, H, 1989)
"Seven patients with metastatic colorectal cancer have been treated with a regimen involving an 120-hour continuous infusion of rIL-2, 3 x 10(6) mu/m2."1.28A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma. ( Franks, CR; Hamblin, TJ; Inzani, V; Palmer, P; Sadullah, S; Stevenson, FK; van der Plas, J; Williamson, P, 1989)
" 5-fluorouracil (5-FU) with a daily dosage of 1 g/m2/day was given continuously for 5 consecutive days at 3-week intervals."1.28Intrahepatic 5-FU retreatment of liver metastases of colorectal cancer that were progressive under previous systemic chemotherapy. ( Herrmann, R; Hohenberger, P; Räth, U; Schlag, P, 1989)
"Fluorouracil (Adrucil) has been used for more than 20 years to treat metastatic colorectal carcinoma and has provided significant palliation of symptoms to some patients."1.28Treatment of metastatic colorectal carcinoma. Recent advances in use of fluorouracil. ( Joseph, RR; Treat, J, 1989)
"Mitomycin C was given to 9 patients as a third-line regimen with resulting 5 NC for 2-4 months."1.27[Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C]. ( Farroukh, R; Gerlach, D; Hoffmann, W; Kress, M; Migeod, F; Seeber, S, 1988)
" At these dosage levels, diarrhea was not a limiting toxicity."1.27High-dose folinic acid and 5-fluorouracil in the treatment of advanced colon cancer. ( Arnold, DJ; Balcueva, EP; Dimitrov, NV; Scholnik, AP; Schwenke, P; Suhrland, LG; Walker, WS, 1988)

Research

Studies (6,297)

TimeframeStudies, this research(%)All Research%
pre-1990103 (1.64)18.7374
1990's943 (14.98)18.2507
2000's2030 (32.24)29.6817
2010's2399 (38.10)24.3611
2020's822 (13.05)2.80

Authors

AuthorsStudies
Nakagawa, Y2
Iinuma, M1
Naoe, T1
Nozawa, Y1
Akao, Y3
Ahlskog, JK1
Dumelin, CE1
Trüssel, S1
Mårlind, J1
Neri, D1
Lu, S2
Obianom, ON1
Ai, Y1
Narayan, S1
Ramisetti, S1
Jaiswal, AS1
Law, BK2
Singh-Pillay, A1
Singh, P1
Amin, S1
Sharma, AK1
Han, X3
Peng, B1
Xiao, BB1
Yang, CR1
Wang, WZ1
Wang, FC1
Li, HY1
Yuan, XL4
Shi, R1
Liao, J2
Wang, H27
Li, J44
Xu, X11
Leong, SW1
Chia, SL1
Abas, F1
Yusoff, K1
Liu, ZY2
Tang, ML1
Ning, JF1
Hao, YP1
Zhou, L10
Sun, X11
Yang, J9
Cao, C1
Luo, D3
Lan, S1
Luo, M4
Shan, H1
Ma, X4
Liu, Y31
Yu, S5
Zhong, X1
Li, R5
Wu, WC1
Liu, YM1
Liao, YH1
Hsu, KC2
Lien, ST1
Chen, IC1
Lai, MJ1
Li, YH12
Pan, SL1
Chen, MC1
Liou, JP1
Ma, K1
Zhang, M11
Wu, X11
Yang, P6
Yin, C1
Chang, CK1
Chiu, PF1
Yang, HY2
Juang, YP1
Lai, YH1
Lin, TS1
Hsu, LC1
Yu, LC1
Liang, PH1
Zhang, Y61
Yang, S7
Tian, X2
Lv, Y3
Guo, Z9
Liu, X22
Han, G4
Liu, S15
Wang, W24
Cui, S2
Qu, X4
Wan, S1
Fakhr, E1
Zare, F1
Azadmanesh, K1
Teimoori-Toolabi, L1
Okamoto, H3
Shiba, S1
Iino, H1
Sudoh, M1
Ichikawa, D1
De Luca, R1
Volpe, C1
Mistretta, O1
Paci, R1
Ferrera, G1
Caputo, V1
Rosati, G18
Cicero, G4
Zhang, W54
Sun, R2
Hu, R1
Li, Q21
Wu, W5
Cao, X2
Zhou, J12
Pei, J1
Yuan, P1
Mosca, L1
Pagano, M1
Borzacchiello, L1
Mele, L1
Russo, A13
Russo, G1
Cacciapuoti, G1
Porcelli, M1
van Nassau, SC1
Bond, MJ1
Scheerman, I1
van Breeschoten, J1
Kessels, R1
Valkenburg-van Iersel, LB1
Verheul, HM3
Buffart, TE4
Mekenkamp, LJ1
Lemmens, VE3
Koopman, M27
Bol, GM1
Stahler, A14
Heinemann, V69
Schuster, V1
Heinrich, K9
Kurreck, A10
Gießen-Jung, C2
Fischer von Weikersthal, L16
Kaiser, F12
Decker, T22
Held, S22
Graeven, U26
Schwaner, I5
Denzlinger, C5
Schenk, M3
Neumann, J6
Kirchner, T25
Jung, A26
Kumbrink, J2
Stintzing, S65
Modest, DP46
Nozawa, H11
Kawai, K14
Sasaki, K19
Murono, K8
Emoto, S4
Yokoyama, Y3
Abe, S3
Kishikawa, J1
Nagai, Y2
Sonoda, H5
Anzai, H1
Ozawa, T1
Ishihara, S9
Lin, LW1
Lai, PS1
Chen, YY2
Chen, CY2
Siri, M1
Behrouj, H1
Dastghaib, S1
Zamani, M1
Likus, W1
Rezaie, S1
Hudecki, J1
Khazayel, S1
Łos, MJ1
Mokarram, P1
Ghavami, S1
Cui, Z1
Wang, Q13
Deng, MH1
Han, QL1
Giuliani, J4
Mantoan, B1
Bonetti, A8
Yang, C5
Song, J2
Hwang, S1
Choi, J3
Song, G4
Lim, W1
Li, G11
Fang, S3
Shao, X1
Li, Y42
Tong, Q4
Kong, B2
Chen, L22
Wang, Y45
Yu, H11
Xie, X7
Zhang, J24
Pan, R3
Lu, M4
Zhang, Q15
Lin, Z6
Qin, Y2
Wang, Z25
Gong, S2
Lin, H6
Chong, S1
Lu, L4
Liao, W3
Lu, X8
Hua, R1
Yan, X2
Tang, D2
Li, X29
Ni, Q1
Wang, D10
Zhu, J8
Othman, MS1
Al-Bagawi, AH1
Obeidat, ST1
Fareid, MA1
Habotta, OA1
Moneim, AEA1
Xu, H6
Wong, CC3
Li, W17
Zhou, Y14
Wang, L36
Liu, L16
Yu, J11
Malier, M2
Gharzeddine, K2
Laverriere, MH2
Marsili, S7
Thomas, F2
Decaens, T2
Roth, G3
Millet, A2
Fuel, M1
Mesas, C2
Martínez, R1
Ortiz, R2
Quiñonero, F1
Prados, J2
Porres, JM1
Melguizo, C2
Fernández, J1
Silván, B1
Entrialgo-Cadierno, R1
Villar, CJ1
Capasso, R1
Uranga, JA1
Lombó, F1
Abalo, R1
Shimokawa, M4
Hayashi, T9
Nishimura, J7
Satoh, T16
Fukunaga, M18
Matsui, R1
Tsuji, Y25
Mizuki, F1
Kogawa, T1
Kono, T10
Yokokawa, H1
Miyano, Y1
Oyama, K1
Yoshimatsu, K12
Koike, T2
Shiozawa, S4
Claramunt García, R1
Muñoz Cid, CL1
Sánchez Ruiz, A2
Marín Pozo, JF1
Wein, A11
Stoehr, R1
Kersting, S1
Siebler, J7
Merkel, S2
Busse, D1
Wolff, K1
Ostermeier, N1
Neufert, C1
Vitali, F1
Eckstein, M1
Roth, JP1
Anhut, P1
Schreiner, W1
Uder, M1
Hartmann, A2
Neurath, MF2
Grützmann, R1
Aggarwal, N1
Quaglia, A1
McPhail, MJW1
Monahan, KJ1
Rossini, D16
Boccaccino, A11
Sbrana, A1
Daniel, F4
Borelli, B10
Raimondi, A9
Santini, D26
Conca, V6
Tomasello, G18
Caponnetto, S3
Marmorino, F15
Zaniboni, A42
Buonadonna, A19
Masi, G50
Lonardi, S51
Pietrantonio, F33
Falcone, A84
Antonuzzo, A6
Cremolini, C55
Yamamoto, S4
Nagashima, K8
Kawakami, T1
Mitani, S3
Komoda, M2
Izawa, N4
Kawakami, K10
Yamamoto, Y11
Makiyama, A13
Yamazaki, K35
Masuishi, T5
Esaki, T19
Nakajima, TE5
Okuda, H4
Moriwaki, T9
Boku, N25
Corsi, D5
Avallone, A24
Brugnatelli, S2
Dell'Aquila, E8
Cinausero, M1
Aprile, G22
Carlomagno, C6
Colombo, A3
Rapisardi, S3
Pinto, C7
Reggiardo, G6
Bilancia, D4
Sofocleous, CT1
D'Angelica, MI9
Monirujjaman, M1
Pant, A1
Nelson, R1
Bathe, O1
Jacobs, R1
Mazurak, VC1
Ala, M1
Kadono, T1
Okuyama, Y6
Nakatsugawa, Y1
Yamada, S10
Nishimura, T4
Fujii, H11
Tomatsuri, N1
Sato, H4
Kimura, H7
Urata, Y1
Huang, B4
Zhao, X3
Cui, D1
Yuan, W4
Yang, L18
Kazama, K1
Shiozawa, M7
Numata, M2
Sugano, N4
Sato, S5
Uchiyama, M1
Sato, M6
Aoyama, T7
Tamagawa, H6
Oshima, T4
Yukawa, N3
Rino, Y4
Kim, TW35
Taieb, J31
Gurary, EB1
Lerman, N1
Cui, K2
Yoshino, T29
Peng, C4
Yan, J1
Chen, P4
Jiang, C5
Sang, S1
Yuan, Y9
Hong, Y3
Yao, M6
Li, C12
Chou, C1
Ngorsuraches, S1
Qian, J3
Oneda, E2
Turley, MC1
Moore, C2
Creasy, JM3
Sharib, J1
Lan, B1
Thacker, JKM1
Migaly, J1
Zani, S3
Allen, PJ7
Mantyh, CR1
Lidsky, ME5
Raghavan, R1
Koyande, N1
Beher, R1
Chetlangia, N1
Ramadwar, M2
Pawade, S1
Thorat, R2
van Hengel, J1
Sklyarova, T1
van Roy, F1
Dalal, SN2
Li, P2
Pók-Udvari, A1
Klauschen, F1
Folprecht, G29
Martinelli, E10
Mazard, T3
Tsuji, A18
Esser, R3
Peng, L6
Jiang, J5
Chen, HN1
Huang, Z11
Qin, S4
Jin, P2
Li, B4
Shi, J4
Xie, N2
Deng, LW1
Liou, YC1
Nice, EC2
Huang, C4
Wei, Y10
He, X9
Tang, J4
Yan, HZ1
Wang, JX2
Li, HQ1
Duan, XW1
Yu, SY3
Hou, XL1
Liao, GB1
Liu, W11
Kim, SA2
Park, H1
Kim, KJ2
Kim, JW12
Sung, JH3
Nam, M1
Lee, JH15
Jung, EH1
Suh, KJ2
Lee, JY3
Kim, SH12
Lee, JO2
Kim, YJ4
Kim, JH26
Bang, SM4
Lee, JS14
Lee, KW12
Buisman, FE2
Filipe, WF1
Galjart, B1
Grünhagen, DJ3
Homs, MYV1
Moelker, A1
Verhoef, C6
Groot Koerkamp, B1
Lee, J14
Koom, WS1
Byun, HK1
Yang, G2
Kim, MS4
Park, EJ1
Ahn, JB15
Beom, SH3
Kim, HS10
Shin, SJ15
Kim, K4
Chang, JS1
Bedon, L1
Cecchin, E12
Fabbiani, E1
Dal Bo, M1
Polano, M1
Toffoli, G13
Patel, A2
Spychalski, P1
Antoszewska, M1
Regula, J1
Kobiela, J1
Ben Mahmoud, IT1
Ben Said, A1
Berguiga, S1
Houij, R1
Cherif, I1
Hamdi, A1
Ben Ayed, W1
Limayem, I1
Baxter, NN1
Kennedy, EB1
Bergsland, E4
Berlin, J11
George, TJ4
Gill, S10
Gold, PJ3
Hantel, A1
Jones, L1
Lieu, C2
Mahmoud, N1
Morris, AM1
Ruiz-Garcia, E1
You, YN1
Meyerhardt, JA17
Élez, E10
Gómez-España, MA2
Grávalos, C9
García-Alfonso, P20
Ortiz-Morales, MJ2
Losa, F11
Díaz, IA1
Graña, B3
Toledano-Fonseca, M2
Valladares-Ayerbes, M10
Polo, E3
Salgado, M8
Martínez de Castro, E2
Safont, MJ11
Salud, A13
Ruiz-Casado, A4
Tabernero, J41
Riesco, MDC1
Rodriguez-Ariza, A2
Aranda, E41
Peng, SH1
Mbarak, HS1
Ma, C2
Shang, QL1
Chen, Z11
Bian, DJ1
Xiao, EH1
Manzoor, S1
Saber-Ayad, M1
Maghazachi, AA1
Hamid, Q1
Muhammad, JS1
Kim, HJ8
An, J5
Ha, EM5
Sakai, S2
Kobuchi, S7
Ito, Y12
Sakaeda, T5
Nixon, AB5
Sibley, AB2
Hatch, AJ1
Mulkey, F1
Starr, MD2
Brady, JC2
Niedzwiecki, D13
Venook, AP13
Baez-Diaz, L1
Lenz, HJ73
O'Neil, BH14
Innocenti, F12
O'Reilly, EM5
Owzar, K2
Hurwitz, HI14
Abdullah, S2
El Hadad, S1
Aldahlawi, A1
Zhang, L17
Wu, H5
Xiao, X2
Chu, F1
Hwang, J2
Park, A1
Kim, C2
Yu, D4
Byun, H1
Ku, M1
Kim, TI3
Jeong, KS1
Kim, KY2
Lee, H5
Jiang, Z4
Hou, Z3
Yu, Z3
Liang, Z5
Chen, S8
Jiang, Y8
Yang, H11
Hua, Z1
Han, Y10
Zhou, C5
Xu, S3
Nie, S1
Xu, G3
Shu, X3
Wang, X55
Lau, DK1
Mencel, J1
Chau, I23
Ychou, M30
Rivoire, M4
Thezenas, S5
Guimbaud, R12
Ghiringhelli, F13
Mercier-Blas, A1
Mineur, L19
Francois, E26
Khemissa, F4
Chauvenet, M1
Kianmanesh, R1
Fonck, M2
Houyau, P1
Aparicio, T17
Galais, MP4
Audemar, F2
Assenat, E5
Lopez-Crapez, E1
Jouffroy, C1
Adenis, A15
Adam, R28
Bouché, O28
Rong, X1
Liu, H14
Zhao, J13
Wang, J43
Fernández Montes, A5
Vivancos, A1
Martínez, N1
González, P1
Covela, M1
de la Cámara, J2
Cousillas, A1
Méndez, JC4
Dong, S4
Liang, S2
Cheng, Z1
Zhang, X25
Luo, L2
Li, L16
Li, S7
Xu, Q6
Zhong, M2
Zhang, G8
Hu, S3
Therizols, G2
Bash-Imam, Z2
Panthu, B1
Machon, C1
Vincent, A3
Ripoll, J1
Nait-Slimane, S1
Chalabi-Dchar, M1
Gaucherot, A1
Garcia, M1
Laforêts, F2
Marcel, V2
Boubaker-Vitre, J1
Monet, MA1
Bouclier, C1
Vanbelle, C1
Souahlia, G1
Berthel, E1
Albaret, MA1
Mertani, HC3
Prudhomme, M1
Bertrand, M1
David, A4
Saurin, JC2
Bouvet, P1
Rivals, E1
Ohlmann, T1
Guitton, J1
Dalla Venezia, N2
Pannequin, J3
Catez, F2
Diaz, JJ3
Luo, X10
Xu, J20
Chen, E7
Meng, Q2
Huang, X11
Zhou, W9
Song, Z4
Pernot, S9
Pellerin, O5
Monterymard, C2
Smith, D14
Lapuyade, B1
Gallois, C2
Khemissa Akouz, F3
De Baere, T8
Tougeron, D8
Thirot-Bidault, A1
Simon, M1
Lecaille, C7
Louafi, S1
Lepage, C8
Ducreux, M52
Arbag, HC1
Sumbul, HE1
Buyuksimsek, M1
Ogul, A1
Yetisir, AE1
Koseci, T1
Bozkurt Duman, B1
Tohumcuoglu, M1
Kesen, O1
Cil, T1
Kagawa, Y9
Inoue, A2
Nishizawa, Y3
Ohta, T1
Hata, T13
Naito, A4
Komatsu, H2
Miyazaki, Y2
Tomokuni, A2
Motoori, M1
Fujitani, K6
Kato, T35
Takeda, Y7
Murata, K9
Delhorme, JB1
Bersuder, E1
Terciolo, C1
Vlami, O1
Chenard, MP2
Martin, E2
Rohr, S1
Brigand, C1
Duluc, I1
Freund, JN1
Gross, I2
Zhang, WL1
Deng, YX1
Hou, ZL1
Zhang, LJ1
Lin, JZ2
Pan, ZZ9
Lu, ZH8
Peng, JH1
Qin, BD1
Ye, CY1
Wang, MM1
Yuan, LY1
Dai, WP1
Sun, L7
Liu, K5
Qin, WX1
Jiao, XD1
Li, XN1
Zang, YS1
Asgharzadeh, F5
Naghibzadeh, N1
Hashemzehi, M2
Mostafapour, A3
Hassanian, SM9
Avan, A10
Khazaei, M9
Koyama, M2
Osada, E1
Akiyama, N1
Eto, K1
Manome, Y2
McCleary, NJ4
Zhang, S15
Ou, FS4
Bainter, TM1
Polite, BN2
Hochster, HS11
Atkins, JN2
Goldberg, RM61
Ng, K4
Mayer, RJ17
Blanke, CD12
Fuchs, CS22
Yazici, O2
Ucar, G1
Sütcüoglu, O2
Turhal, NS3
Yildiz, B1
Karamouzis, M1
Yavuz, S1
Karadurmuş, N1
Zengin, N4
Geva, R2
Abali, H2
Falk, P1
Severin, M1
Berglund, Å12
Guren, MG1
Hofsli, E2
Österlund, P13
Tandberg, A1
Eberhard, J1
Sorbye, H12
Cantero-Recasens, G1
Alonso-Marañón, J1
Lobo-Jarne, T1
Garrido, M1
Iglesias, M1
Espinosa, L1
Malhotra, V1
Liu, Z12
Weng, S2
Guo, C2
Dang, Q1
Lu, T1
Sun, Z5
Khin, NY1
De Silva, M1
Clarke, S10
Pavlakis, N4
Rogan, CM1
Ho-Shon, K1
Lane, RJ1
Tsai, HL15
Chen, YC5
Yin, TC3
Su, WC5
Chen, PJ3
Chang, TK5
Li, CC3
Huang, CW13
Wang, JY25
Guo, WH1
Qi, ZC1
Guan, HQ1
Liu, TT1
Liang, L4
Yu, QH1
Liang, Y5
Tang, DC1
De Francia, S1
Berchialla, P1
Armando, T1
Storto, S1
Allegra, S1
Sciannameo, V1
Soave, G1
Sprio, AE1
Racca, S1
Caiaffa, MR1
Ciuffreda, L4
Mussa, MV1
Samoon, Z1
Naher, SK1
Sjoquist, KM1
Zalcberg, J9
Matsumura, M2
Hasegawa, K14
Oba, M4
Yamaguchi, K24
Uetake, H19
Morita, S27
Takahashi, K36
Unno, M2
Shimada, Y38
Muro, K51
Matsuhashi, N3
Mori, M13
Baba, H39
Shimada, M9
Mise, Y4
Kawaguchi, Y2
Kagimura, T2
Ishigure, K2
Saiura, A3
Sugihara, K23
Kokudo, N5
Pouya, FD1
Gazouli, M2
Rasmi, Y2
Lampropoulou, DI1
Nemati, M1
Watanabe, G6
Inoue, Y12
Takahashi, Y10
Kishi, Y3
Suyama, K2
Takayama, T8
Noie, T1
Nishioka, Y4
Akamatsu, N2
Arita, J1
Huang, W1
Zhang, H17
Tian, Y6
Cha, Y4
Xiong, H3
Yuan, X3
Fasihi, K1
Amerizadeh, F4
Sabbaghzadeh, R3
Heydari, M1
Rahmani, F5
Rasouli, E1
Ferns, GA8
Rezayi, M1
Matsumura, K1
Yamamura, K2
Miyamoto, H7
Hara, Y1
Oda, E1
Akahoshi, S1
Yoshida, K14
Yuki, H1
Motohara, T2
Sakamoto, K14
Komohara, Y1
Beppu, T12
Ge, P1
Reyila, A1
Li, XY2
Liu, SY1
Jiang, YX2
Yang, YJ1
Li, XL7
Bian, Y1
Liu, D5
Coker, OO1
Liu, C13
Kang, W2
To, KF2
Sung, JJ2
Ebrahimi, S1
Fakhraei, M1
Farshbaf, A1
Giovannetti, E5
Jo, H1
Lee, MS1
Lee, YP1
Kim, H9
Hong, JY1
Park, SH9
Park, JO8
Park, YS21
Lim, HY7
Kang, WK9
Kim, ST7
Yao, H2
Qiu, S5
Chen, J30
Gao, Q2
Chen, X20
Xi, C1
Huang, D6
Zhang, F4
Gao, S6
Ren, G1
Tao, X2
Li, M15
Chen, W7
Suzuki, K8
Matsuo, K10
Kikuchi, Y2
Koda, K8
Tanaka, K14
Liu, J22
Yang, X10
Jiang, Q1
Ji, F2
Xu, Y17
Fan, X3
Zhou, Z4
Fu, C4
Gao, Y6
Derksen, JWG1
Smit, KC1
May, AM2
Punt, CJA10
Liang, YH1
Liang, JT5
Lin, BR1
Huang, J4
Hung, JS1
Lai, SL1
Chen, TC1
Tsai, JH1
Cheng, YM3
Tsao, TH1
Hsu, WL1
Chen, KH1
Yeh, KH6
Li, Z16
Lin, G1
Bekaii-Saab, TS3
Zhao, L11
Chen, H13
Ma, J7
Hu, H16
Xu, L5
Matsubara, Y1
Ogata, T1
Nakazawa, T1
Kato, K26
Nozawa, K4
Narita, Y4
Honda, K4
Bando, H10
Taniguchi, H11
Kadowaki, S5
Ando, M10
Tajika, M2
Taibi, A6
Sgarbura, O1
Hübner, M1
Bardet, SM4
Alyami, M1
Bakrin, N1
Durand Fontanier, S4
Eveno, C4
Gagniere, J1
Pache, B1
Pocard, M12
Quenet, F4
Teixeira Farinha, H1
Thibaudeau, E1
Dumont, F5
Glehen, O2
Jonnagaddala, J1
Xu, XS1
Kwakman, JJM1
Mol, L11
Kim, JG6
Baik, SH3
Shin, SH2
Park, I1
Lee, MA5
Lee, S6
Jeon, SY1
Han, SW13
Kang, MH3
Oh, J1
Kim, JS11
Kim, JY3
Ahn, MS1
Zang, DY5
Bae, BN1
Jo, HJ1
Kim, HK3
Yoon, JA1
Kim, DH2
Zhakipbekov, S1
Osombaev, M1
Irimbetov, S1
Watanabe, M23
Katsumata, K6
Sumi, T1
Ishizaki, T2
Enomoto, M5
Shigoka, M1
Wada, T2
Kuwabara, H4
Mazaki, J1
Kasahara, K1
Tago, T1
Udo, R1
Nagakawa, Y1
Kawachi, S1
Tsuchida, A3
Kato, A2
Miyoshi, N4
Ohtsuru, T1
Sakai, D7
Hasegawa, J4
Nakata, K3
Imasato, M4
Ikenaga, M6
Kudo, T5
Tei, M1
Uemura, M6
Takahashi, H5
Mizushima, T12
Yamamoto, H10
Doki, Y10
Eguchi, H3
Ulaş Kahya, B1
Özdemir, N3
Wu, Z6
Gong, Z1
Xia, Y1
Du, L2
Gao, X6
Fan, Z2
Qian, Q1
Ding, Z1
Guo, S2
Wang, M12
Guo, X5
Yang, M3
Meng, F3
Chen, Y34
Chen, M5
Qiu, T1
Xu, F4
Hanna, CR2
Lemmon, E1
Hall, PS1
Ennis, H1
Morris, E1
McLoone, P1
Boyd, KA4
Jones, RJ3
Chauvin, A1
Bergeron, D1
Vencic, J1
Lévesque, D1
Paquette, B1
Scott, MS1
Boisvert, FM1
Lipsyc-Sharf, M1
Yurgelun, MB1
Rubinson, DA1
Schrag, D7
Dakhil, SR4
Stella, PJ2
Weckstein, DJ1
Wender, DB2
Faggen, M1
Zemla, TJ1
Heying, EN1
Schuetz, SR1
Noble, S1
Bekaii-Saab, T4
Satake, H6
Shinozaki, E20
Tanizawa, Y3
Jin, L7
Cai, Z6
Hegazy, SK1
El-Azab, GA1
Zakaria, F1
Mostafa, MF1
El-Ghoneimy, RA1
Wang, JL2
Wu, DZ1
Yuan, YW1
Xin, L1
Sugarbaker, PH10
Du, J3
Li, H18
Guo, H1
Xiong, B1
Song, FX1
Chen, HL1
Wang, XJ2
Jin, ZX1
Han, TY1
Zhang, DK1
He, Z3
Sui, C1
Zhang, P13
Wang, T13
Mou, T1
Sun, K3
Xu, Z2
Deng, H1
Zhuang, B1
Ii, Y1
Irie, T2
Kobari, A1
Kawaguchi, M1
Momose, H1
Tsukamoto, R1
Kawai, M3
Sugimoto, K2
Kojima, Y1
Arakawa, A1
Terao, Y1
Tomiki, Y1
Kitazume, Y1
Kawazoe, H3
Uozumi, R1
Yoshizawa, T1
Iihara, H3
Takahashi, M20
Arai, T10
Murachi, Y1
Sato, Y21
Mikami, T1
Hashiguchi, K1
Yamazaki, T2
Fujita, Y2
Hosokawa, Y4
Morozumi, I1
Tsuchiya, M2
Yokoyama, A1
Hashimoto, H3
Yamaguchi, M1
Gong, P1
Zhao, Y17
Qu, YL1
Liu, XL1
Zhao, SY1
Zhai, XF1
Watts, K2
Wills, C2
Madi, A8
Palles, C5
Maughan, TS15
Kaplan, R7
Al-Tassan, NA2
Kerr, R3
Kerr, DJ27
Houlston, RS2
Escott-Price, V2
Cheadle, JP4
Nishina, T20
Sakai, Y8
Ishida, H44
Amagai, K2
Endo, S2
Negoro, Y3
Kuramochi, H10
Denda, T22
Hatachi, Y1
Ikezawa, K1
Nakajima, G3
Bando, Y1
Morimoto, M1
Kobayashi, K14
Hyodo, I18
Yang, Y20
Yuan, H3
Tian, M2
Nie, Y3
Niu, J1
Wang, G14
Song, Y6
van Dijk, E1
van Werkhoven, E3
Asher, R1
Mooi, JK1
Espinoza, D2
van Essen, HF1
van Tinteren, H9
van Grieken, NCT1
Tebbutt, NC19
Ylstra, B2
Zitkute, V3
Kukcinaviciute, E4
Jonusiene, V5
Starkuviene, V1
Sasnauskiene, A5
Walker, BS1
Billingsley, KG1
Sutton, TL1
Kolbeck, KJ1
Korngold, EK1
Nabavizadeh, N1
Dewey, EN1
Herzig, DO1
Lopez, CD4
Mayo, SC2
Jin, M1
Zhou, P1
Ren, J3
Cheng, J4
Yang, K1
Wu, G2
Zhang, T13
Zhang, D3
Salerno, S1
Ståhlberg, A1
Holdfeldt, A1
Bexe Lindskog, E1
Landberg, G1
Wang, WY2
Zhou, H5
Zhang, YH3
Germani, MM6
Allegrini, G27
Maddalena, G1
Randon, G6
Antoniotti, C25
Passardi, A13
Zichittella, C1
Barreca, MM1
Cordaro, A1
Corrado, C1
Alessandro, R2
Conigliaro, A1
Kiweler, N1
Schwarz, H1
Nguyen, A1
Matschos, S1
Mullins, C1
Piée-Staffa, A1
Brachetti, C1
Roos, WP1
Schneider, G1
Linnebacher, M3
Brenner, W1
Krämer, OH1
Guan, M3
Huo, C1
Yu, C3
Hu, B3
Cai, J6
Maruyama, K1
Tominaga, T6
Nonaka, T1
Moriyama, M1
Oyama, S1
Ishii, M4
Sawai, T6
Nagayasu, T3
Chou, J2
Kaller, M3
Jaeckel, S1
Rokavec, M2
Hermeking, H3
Fischer, LE2
von Weikersthal, LF16
Kiani, A17
Al-Batran, SE11
Heintges, T15
Lerchenmüller, C8
Kahl, C15
Seipelt, G10
Kullmann, F16
Stauch, M13
Scheithauer, W49
Giessen-Jung, C5
Uhlig, J4
Peuser, B2
Weiss, L2
Guo, J5
Huang, L15
Zhang, B9
Ma, Y7
Zhao, F3
Wang, B3
Jin, H3
Zhou, F2
Guan, J2
Zhao, Q5
Liu, Q14
Martínez-Lago, N1
Cameselle García, S1
Alonso de Castro, B1
Gómez-Randulfe Rodríguez, MI1
Carmona Campos, M1
González Villarroel, P2
Salgado Fernández, M4
De la Cámara Gómez, JC1
Romero Reinoso, C2
Cousillas Castiñeiras, A1
Méndez Méndez, JC3
Vidal Insua, Y1
Fernández-Montes, A1
Moretto, R10
Elliott, A1
Intini, R2
Sartore-Bianchi, A6
Rasola, C1
Scartozzi, M12
Salati, M1
Pella, N7
Calegari, MA2
Carullo, M3
Corti, F1
Mauri, G2
Fassan, M4
Brodskiy, P1
Shields, A1
Korn, M1
Tang, Y3
Nan, N1
Gui, C1
Zhou, X7
Jiang, W5
Prisciandaro, M6
Pagani, F3
Bozzarelli, S2
Tampellini, M17
Fanchini, L3
Murialdo, R4
Clavarezza, M6
Berenato, R4
Ratti, M4
Petrelli, F15
Antonuzzo, L8
Giordano, M7
Rossi, A7
Di Bartolomeo, M18
Di Maio, M10
Morano, F14
Arai, H3
Millstein, J4
Battaglin, F6
Kawanishi, N2
Jayachandran, P3
Soni, S7
Zhou, YW2
Long, YX1
Liu, JY5
Qiu, M4
Watanabe, J4
Maeda, H4
Nagasaka, T6
Yokota, M2
Hirata, K17
Akazawa, N3
Yamada, T15
Ando, T3
Mishima, H37
Sakamoto, J29
Oba, K17
Nagata, N15
Lin, W3
Yuan, Q1
Lu, Y4
Dai, P2
Long, H2
Xiao, Y1
Loupakis, F50
Mancao, C2
Liu, T11
Shen, L17
Luo, F1
Porretto, CM1
Aparicio, J16
Virgili Manrique, AC1
Capdevila, J2
Muñoz Boza, F1
Galván, P1
Richart, P1
Oliveres, H1
Páez, D9
Hernando, J1
Serrano, S1
Vera, R6
Hernandez-Yagüe, X2
Gallego, RÁ1
Riesco-Martinez, MC2
García de Albeniz, X1
Maurel, J15
Ke, K1
Jin, W3
Zhu, Q3
Mei, R1
Zhang, R12
Shou, L1
Feng, J7
Duan, T2
Mou, Y1
Xie, T4
Wu, Q8
Sui, X3
Hiraide, T1
Morita, Y7
Horikawa, M1
Sugiyama, E1
Sato, T14
Kahyo, T1
Furuhashi, S1
Takeda, M2
Kikuchi, H3
Hiramatsu, Y1
Sakaguchi, T1
Konno, H2
Setou, M1
Takeuchi, H1
Iwai, M2
Kimura, M7
Usami, E3
Yoshimura, T5
Maftooh, M3
Nasiri, SN1
Moradi-Marjaneh, R2
Shahidsales, S2
Joudi-Mashhad, M1
Ghayour-Mobarhan, M3
Sawicka, D3
Hryniewicka, A1
Gohal, S1
Sadowska, A2
Pryczynicz, A1
Guzińska-Ustymowicz, K2
Sokołowska, E2
Morzycki, JW1
Car, H3
Sun, J2
Yao, N1
Lu, P1
Judge, SJ2
Cho, M4
Gholami, S4
Torregrosa, C1
Vaflard, P1
Perret, A1
Tournigand, C34
Randrian, V1
Doat, S4
Neuzillet, C1
Moulin, V3
Stouvenot, M1
Darbas, T1
Auberger, B1
Godet, T1
Jaffrelot, M1
Lambert, A1
Dubreuil, O2
Gluszak, C1
Bernard-Tessier, A1
Turpin, A2
Palmieri, LJ2
Goujon, G3
Lecomte, T17
Sefrioui, D3
Locher, C10
Grados, L1
Gignoux, P1
Trager, S1
Nassif, E1
Saint, A1
Hammel, P3
Bureau, M1
Perrier, M1
Botsen, D1
Bourgeois, V1
Auclin, E2
Iimura, Y2
Furukawa, N1
Ishibashi, M1
Ahiko, Y1
Tanabe, T3
Aikou, S1
Shida, D5
Nojima, M1
Kuroda, S1
Chrabaszcz, S1
Rajeev, R1
Witmer, HDD1
Dhiman, A1
Klooster, B1
Gamblin, TC1
Banerjee, A1
Johnston, FM1
Turaga, KK1
Guo, Y10
Prosperi, M1
Braithwaite, D1
Wang, F20
Kibbe, W1
Wagner, L1
Bian, J1
Minchev, V1
Hristova-Avakumova, N1
Kamenova, K1
Atanasova, L1
Angelov, M1
Todorov, L1
Surcheva, S1
Nikolov, R1
Xia, M1
Zhang, Z15
Tan, Y5
Li, E1
Fang, M2
Zhu, Y10
Hu, Z3
Ardıl, B1
Alper, M1
Arnold, D22
Eggers, E1
Reichert, D1
Becker, L1
Thiebach, L1
Ito, T4
Takashima, A12
Yukami, H1
Tsuda, M8
Suto, T5
Sugimoto, N5
Ojima, H5
Takii, Y5
Yasui, H12
Goto, M5
Saruta, M1
Otsu, S3
Shinozaki, K6
Fujiwara, T4
Tamura, T7
Baba, E12
Ueno, H4
Ou, K1
Gao, L7
Cevik, M1
Namal, E2
Sener, ND1
Koksal, UI1
Cagatay, P1
Deliorman, G1
Ciftci, C1
Karaalp, A1
Susleyici, B1
Gong, B1
Xie, W2
Zheng, Y5
Jin, S2
Ding, C2
Xu, C5
Dong, Z1
Sommerhäuser, G7
Dechow, T1
Karthaus, M17
Fuchs, M3
König, A2
Roderburg, C2
Hoyer, I1
Quante, M1
Fruehauf, S6
Müller, L4
Reinacher-Schick, A13
Ettrich, TJ3
Wang, S11
Cao, J10
Pei, L1
Nakao, T1
Yoshikawa, K2
Tokunaga, T2
Nishi, M1
Kashihara, H1
Takasu, C2
Wada, Y2
Yoshimoto, T1
Yamashita, S4
Yao, F1
Xie, Z1
Strickler, JH5
Cubillo, A4
Matrana, M1
Kozloff, M4
Lowe, T1
Blaney, M1
Sahtout, M1
Naumovski, L1
Wainberg, ZA6
He, MM2
Xiao, J3
Zhang, YQ1
Fang, WJ4
Hu, XH2
Ma, ZG1
Yao, YC1
Zhuang, ZX1
Zhou, FX1
Ying, JE2
Zou, QF1
Guo, ZQ1
Wu, XY3
Jin, Y11
Mai, ZJ1
Wang, ZQ7
Qiu, H2
Shi, SM2
Chen, SZ1
Luo, HY5
Zhang, DS4
Wang, FH8
Xu, RH14
Diab, R1
Rakhshan, A1
Kaddah, A1
Abdollahimajd, F1
Mirzaei, HR1
Terazawa, T3
Ohta, K4
Noura, S5
Kawakami, H4
Hasegawa, H11
Yanagihara, K4
Shingai, T3
Kotaka, M7
Hiraki, M2
Konishi, K5
Nakae, S1
Kurokawa, Y3
Shimokawa, T1
Tsujinaka, T4
Pan, H4
Pan, J4
Wu, J8
Kasper, S6
Moosmann, N8
Keitel, V1
Jacobasch, L1
Fischer V Weikersthal, L1
Sent, D1
Junghanß, C1
Lorenzen, S2
Kaczirek, K5
Hofmann, FO3
D'Anastasi, M2
Gesenhues, AB3
Hesse, N3
Moehler, M25
Link, H5
Holch, JW10
Pranzini, E1
Pardella, E1
Muccillo, L1
Leo, A1
Nesi, I1
Santi, A1
Parri, M1
Uribe, AH1
Lottini, T1
Sabatino, L1
Caselli, A1
Arcangeli, A1
Raugei, G1
Colantuoni, V1
Cirri, P1
Chiarugi, P1
Maddocks, ODK1
Paoli, P1
Taddei, ML1
Yu, W6
Bao, X1
Ciardiello, D2
Chiarazzo, C1
Famiglietti, V2
Damato, A4
Zampino, MG6
Castellano, G1
Gervaso, L1
Bordonaro, R11
Zichi, C3
De Vita, F15
Parisi, A2
Giampieri, R7
Berardi, R5
Lavacchi, D2
Tamburini, E13
Maiorano, BA1
Parrella, P2
Latiano, TP7
Normanno, N9
De Stefano, A3
Martini, G2
Napolitano, S3
Troiani, T9
Ciardiello, F16
Maiello, E27
Martínez, E2
Osorio, M3
Finkielstein, C1
Ortíz, I1
Peresin, MS1
Castro, C3
Zheng, H7
McCombs, JS1
Barzi, A4
Toumi, I1
Yatouji, S1
Borie, N1
Remy, S1
Renault, JH1
Chazee, L1
Hammami, M1
Martiny, L1
Devarenne-Charpentier, E1
El Btaouri, H1
Islam, MM1
Mirza, SP1
Lin, J10
Huang, S9
Qiao, Y1
Gathirua-Mwangi, W1
Yang, T3
Khan, T1
Wu, Y19
Afable, M1
Sousa-Squiavinato, ACM1
Arregui Ramos, DA1
Wagner, MS1
Tessmann, JW1
de-Freitas-Junior, JCM1
Morgado-Díaz, JA1
Hendrych, M1
Říhová, K1
Adamová, B1
Hradil, V1
Stiborek, M1
Vlček, P2
Hermanová, M1
Vašíčková, J1
Beneš, P1
Šmarda, J1
Kanický, V1
Preisler, J1
Navrátilová, J1
Zhou, B3
Mai, Z1
Ye, Y3
Xia, W1
Qiu, X2
Hamze, K1
Abdallah, RH1
Younis, NK1
Fardoun, M1
Darwiche, N1
Kobeissy, F1
Iratni, R1
Bouhadir, K1
Eid, AH1
Robles, J1
Pintado-Berninches, L1
Boukich, I1
Escudero, B1
de Los Rios, V1
Bartolomé, RA1
Jaén, M1
Martín-Regalado, Á1
Fernandez-Aceñero, MJ1
Imbaud, JI1
Casal, JI1
Khalij, Y1
Belaid, I1
Chouchane, S1
Amor, D1
Omezzine, A1
Ben Rejeb, N1
Ben Ahmed, S2
Bouslama, A1
Fang, Q1
Zheng, X5
Monzer, A1
Wakimian, K1
Ballout, F2
Al Bitar, S1
Yehya, A1
Kanso, M1
Saheb, N1
Tawil, A1
Doughan, S1
Hussein, M3
Mukherji, D3
Faraj, W1
Gali-Muhtasib, H2
Abou-Kheir, W1
Kibudde, S1
Begg, W1
Almashagbah, NA1
Mahasneh, AA1
Bodoor, KG1
Wang, ZF1
Kong, WR1
Wang, N5
You, YL1
Wang, JF1
Wang, SQ1
Miarons, M1
Riera, P1
García-Gil, S1
Gutiérrez-Nicolás, F2
Matsuoka, H12
Ohta, R2
Yoshida, Y15
Watanabe, T21
Kosugi, C4
Fukazawa, A3
Matsuda, A3
Yoshida, H6
Hasegawa, S14
Otsuka, T2
Sakita, JY1
Elias-Oliveira, J1
Carlos, D1
de Souza Santos, E1
Almeida, LY1
Malta, TM1
Brunaldi, MO1
Albuquerque, S1
Araújo Silva, CL1
Andrade, MV1
Bonato, VLD1
Garcia, SB1
Cunha, FQ1
Cebinelli, GCM1
Martins, RB1
Matthews, J1
Colli, L1
Martin, FL1
Uyemura, SA1
Kannen, V1
Ko, HM1
Jee, W1
Park, DI1
Kim, KI1
Jung, JH2
Jang, HJ1
Wijler, LA1
Dijk, FJ1
Quirindongo, H1
Raats, DAE1
Dorresteijn, B1
Furber, MJW1
Kranenburg, O5
van Dijk, M1
Okamoto, K7
Boldig, K1
Ganguly, A1
Kadakia, M1
Rohatgi, A1
Yang, D25
Yang, SB1
Sang, R1
Deng, F1
Engel, A1
Goldys, E1
Deng, W2
Khatib, AW1
Selub, SM1
Uryvaey, A1
Baranseh, J1
Shai, A1
Kimura, T4
Wakabayashi, M1
Kobori, S1
Aoki, K2
Minoshima, K1
Doumoto, Y1
Hosaka, M1
Ushiku, H1
Aisaki, K1
Funatsu, K1
Sakamoto, S2
Tagai, N1
Kurebayashi, H1
Sawai, K1
Morikawa, M2
Koneri, K2
Tamaki, M1
Murakami, M5
Hirono, Y1
Goi, T2
Miyata, R1
Hanada, M1
Ajihara, T1
Naritomi, T1
Fukuya, Y1
Rendón, JP1
Cañas, AI1
Correa, E1
Bedoya-Betancur, V1
Naranjo, TW1
Yamane, S1
Kazama, H1
Kanesada, K1
Tsunedomi, R5
Hazama, S14
Ogihara, H1
Hamamoto, Y9
Shindo, Y3
Matsui, H1
Tokumitsu, Y2
Yoshida, S9
Iida, M2
Suzuki, N8
Takeda, S3
Ioka, T1
Nagano, H10
Khalil, KA1
Musallam, HS1
Hassan, MA1
Mahmoud, IA1
Kumar, A1
Singh, AK1
Singh, H2
Thareja, S1
Kumar, P1
Davis, SL1
Hartman, SJ1
Bagby, SM1
Schlaepfer, M1
Yacob, BW1
Tse, T1
Simmons, DM1
Diamond, JR1
Lieu, CH1
Leal, AD1
Cadogan, EB1
Hughes, GD1
Durant, ST1
Messersmith, WA5
Pitts, TM1
Jurczyk, M1
Midro, A1
Król, M1
Olesiak, W1
Stąpor, D1
Gil, A2
Gil, K1
Ludikhuize, MC1
Gevers, S1
Nguyen, NTB1
Meerlo, M1
Roudbari, SKS1
Gulersonmez, MC1
Stigter, ECA1
Drost, J1
Clevers, H3
Burgering, BMT1
Rodríguez Colman, MJ1
Johnson, PA1
Menegatti, S1
Chambers, AC1
Alibhai, D1
Collard, TJ1
Williams, AC1
Bayley, H1
Perriman, AW1
Bruckner, HW2
Bassali, F1
Dusowitz, E1
Gurell, D1
Book, A1
De Jager, R1
Chang, C1
Cao, D6
Liu, XM2
Zhu, WT2
Jia, ML1
Li, YT1
Liu, ZQ2
Yan, PK2
Fulgenzi, CAM1
Vetere, G1
Citarella, F1
Spagnoletti, A1
Nappo, F1
Tong, G1
Parseghian, CM1
Woods, M2
Lee, HM5
Alshenaifi, J1
Willis, J1
Nunez, S1
Raghav, KP2
Morris, VK2
Shen, JP3
Eluri, M1
Sorokin, A2
Kanikarla, P2
Vilar, E2
Rehn, M1
Ang, A1
Kopetz, S15
Propper, DJ3
Gao, F7
Saunders, MP17
Sarker, D1
Hartley, JA1
Spanswick, VJ1
Lowe, HL1
Hackett, LD1
Ng, TT1
Barber, PR1
Weitsman, GE1
Pearce, S2
White, L1
Lopes, A1
Forsyth, S1
Hochhauser, D2
Sarradin, V1
Betrian, S1
Chaltiel, L1
Brac De La Perriere, C1
Delord, JP5
LaCourse, KD3
Zepeda-Rivera, M3
Kempchinsky, AG3
Baryiames, A3
Minot, SS3
Johnston, CD3
Bullman, S3
Beck, A3
Fehrenbach, U3
Mueller, L5
Koenig, AO3
V Weikersthal, LF3
Goekkurt, E6
Haas, S4
Alig, AHS6
Trarbach, T14
Perrin, ML3
Yardin, C3
To, YH3
Degeling, K3
McCoy, M3
Wong, R11
Jones, I3
Dunn, C4
Hong, W5
Loft, M3
Gibbs, P22
Tie, J6
Okamoto, W5
Sakai, K3
Shitara, K13
Nakano, Y7
Hara, H4
Miura, Y3
Hironaka, S8
Misumi, T3
Nishio, K6
Shah, MA4
Grothey, A36
Cervantes, A29
Oh, SC4
Fakih, M9
Wu, C12
Chiu, VK2
Tomasek, J5
Bendell, J5
Fontaine, M2
Hitron, M2
Xu, B7
Van Cutsem, E93
Bae, J2
Kwak, D2
Kim, J6
Phyu Hlaing, S2
Saparbayeva, A2
Hee Lee, E2
Yoon, IS2
Ryong Moon, H2
Yoo, JW2
Erol, C3
Sendur Mehmet, AN2
Bilgetekin, I2
Garbioglu, DB2
Hamdard, J3
Akbas, S2
Hizal, M2
Arslan, C2
Sevinc, A4
Kucukarda, A3
Erdem, D2
Kahraman, S2
Cakir, E2
Demirkiran, A2
On, S2
Dogan, I2
Erdogan, AP2
Koca, S2
Kubilay, P2
Eren, OO2
Cilbir, E2
Celik, E2
Araz, M3
Ozyukseler, DT2
Yildirim, ME2
Bahceci, A2
Taskaynatan, H2
Oyman, A2
Deniz, GI2
Menekse, S2
Kut, E2
Gulmez, A2
Sakin, A5
Nayir, E2
Acar, R2
Sen, E2
Inal, A3
Turhal, S3
Kaya, AO4
Paydas, S2
Tastekin, D2
Hacibekiroglu, I3
Cincin, I2
Bilici, A4
Mandel, NM2
Dede, DS2
Akinci, MB2
Oksuzoglu, B3
Uncu, D4
Yalcin, B2
Artac, M6
Soueidy, C1
Skaff, S1
Stephan, F1
Kattan, J1
Hui, T1
Qiu, Z1
Mao, W1
Peng, Q1
Chang, H1
El-Daly, SM1
Abo-Elfadl, MT1
Hussein, J1
Abo-Zeid, MAM1
Lu, K4
Du, W3
Sahin, IH1
Imanirad, I1
Felder, SI1
Kim, RD3
Xie, H2
Vale, N1
Pereira, M1
Santos, J1
Moura, C1
Marques, L1
Duarte, D1
Nouibi, C1
Cherif Chefchaouni, A1
Bechar, H1
Belahcen, MJ1
Rahali, Y1
Okuno, K8
Kandimalla, R2
Mendiola, M1
Balaguer, F5
Bujanda, L6
Fernandez-Martos, C10
Feliu, J9
Tokunaga, M1
Kinugasa, Y2
Goel, A16
Milewska, S1
Siemiaszko, G1
Wilczewska, AZ1
Misztalewska-Turkowicz, I1
Markiewicz, KH1
Szymczuk, D1
Lazny, R1
Niemirowicz-Laskowska, K1
Fekete, JT1
Győrffy, B2
Fan, R1
Yin, Z2
Huang, Y10
Yuan, F1
Yin, A2
Tang, G2
Pu, R1
Yin, S1
Zhen, Q1
Wu, T6
Yao, S5
Feng, Y10
Chen, C8
Rodríguez, R4
Alés Díaz, I1
García-Ortiz, MV1
Rivera, F38
Tabernero, JM5
Riesco, MC1
Yusefi, M2
Shameli, K2
Lee-Kiun, MS1
Teow, SY2
Moeini, H1
Ali, RR1
Kia, P1
Jie, CJ1
Abdullah, NH1
Janssens, K1
Vanhoutte, G1
Lybaert, W1
Demey, W1
Decaestecker, J2
Hendrickx, K1
Rezaei Kalantari, H2
Zwaenepoel, K1
Pauwels, P2
Fransen, E1
Op de Beeck, K1
Van Camp, G1
Rolfo, C2
Peeters, M24
Raga, MG1
Pérez, IP1
Veiga, RC1
Sosa, MM1
Aguilera, MJS1
Rodríguez, PL1
Bonastre, MTT1
Urtasun, JA1
Abad, LP1
Hernández, IB1
Li, F7
Gu, NN1
Shen, H1
Han, CL1
Li, KY1
Yan, RY1
Mi, ZK1
Nakura, M1
Nojima, K1
Yamazaki, H1
Takenaka, S1
Takeshita, M1
Sasaki, S3
Fujimura, T1
Suda, K2
Chiku, T1
Fukuyama, M1
Shinoda, K1
Hashiba, H1
Sano, W1
Ando, K2
Ni, M2
Chen, A1
Dai, W1
Jiang, R1
Ling, Y2
Yao, Q2
Kocak, MZ1
Er, M1
Ugrakli, M1
Hendem, E1
Eryilmaz, MK1
Proietti, A1
Niccoli, C1
Fanotto, V1
Di Donato, S8
Bergamo, F25
Fontanini, G14
Ugolini, C3
Kaneko, J2
Isogai, J2
Hayashi, K7
Takatsuno, Y1
Okamoto, S2
Hayakawa, T1
Maejima, K1
Iwamoto, K2
Hyuga, S1
Ohashi, T1
Nakahara, Y2
Furukawa, K4
Moon, J2
Asaoka, T2
Shibasaki, Y1
Yokobori, T1
Sohda, M1
Shioi, I1
Ozawa, N1
Komine, C1
Suga, K1
Nakazawa, N1
Osone, K1
Shiraishi, T4
Okada, T5
Sano, A1
Sakai, M1
Ogawa, H2
Kaira, K2
Shirabe, K6
Saeki, H9
Godlewska, K1
Zapora, E1
Chen, Q7
Song, H1
Xing, W1
Song, X5
Zhao, W3
Ghidini, M4
Dottorini, L2
Iaculli, A1
Ghidini, A4
Luciani, A2
Yue, Y1
Ogawa, T2
Kawamoto, S1
Yamamoto, K7
Atarashi, M1
Terashima, T2
Kurogi, N1
Yan, Q3
Lai, Q3
Fang, Y4
Tan, J2
Li, A6
Danişman-Kalindemirtaş, F1
Özerkan, D1
Kariper, İA1
Bulut, H1
Brockmueller, A2
Samuel, SM1
Mazurakova, A1
Büsselberg, D1
Kubatka, P1
Shakibaei, M8
Su, Y2
Choi, HS1
Choi, JH3
Jang, YS1
Seo, JW1
Okamura, M2
Nakamura, T11
Peng, S3
Xie, Y2
Shen, D1
Zhu, M2
Huang, M3
Luo, Y6
Gan, Y2
Wang, R8
Han, S1
Rong, P1
Gong, W2
Chai, R1
Wan, Z1
Zheng, B3
Hu, X5
Chen, B4
Dai, Q3
Yu, P1
Tu, S1
Girisa, S1
Kunnumakkara, AB3
Jakubauskas, M1
Jakubauskiene, L1
Leber, B2
Horvath, A1
Strupas, K3
Stiegler, P2
Schemmer, P3
Zhu, R2
Hu, G2
Tao, K1
Tao, F1
Lu, Z4
Beechinor, RJ1
Abidalhassan, MF1
Small, DF1
Hoang, HK1
Lamba, R1
Loehfelm, TW1
Foster, CC1
Koontz, MZ1
Kim, EJ1
Mindt, S1
Lück, A1
Hutzschenreuter, U1
Kollendt, M1
Lathan, B1
Zöller, T1
Frank-Gleich, S1
Lorentz, C1
Lamberti, C3
Sick, C1
Zingerle, M1
Tesch, H1
Stein, W1
Hebart, H4
Stosiek, C1
Sandner, R1
Fries, S1
Burkholder, I3
Hofheinz, RD13
Moreno-Londoño, AP1
Castañeda-Patlán, MC1
Sarabia-Sánchez, MA1
Macías-Silva, M1
Robles-Flores, M1
Bré, J1
Dickson, AL1
Read, OJ1
McKissock, FG1
Mullen, P1
Tang, P1
Zickuhr, GM1
Czekster, CM1
Harrison, DJ2
Yuwono, KA1
Hutajulu, SH1
Gofir, A1
Nugroho, DB1
Maughan, T9
McDermott, R2
Bodoky, G14
André, T58
Teske, AJ1
Pfeiffer, P25
Seitz, R1
Catteau, A1
Salvatore, L21
McGregor, K2
Leonetti, S1
Papiani, G1
Bensi, M1
Murgioni, S3
Ross, DT1
Boquet, I1
Nielsen, TJ1
Galon, J1
Varga, MG1
Schweitzer, BL1
Zheng, Z4
Han, J4
Guo, G1
Guo, P2
Li, D5
Yan, Y2
Niu, W2
Meng, Z2
Yu, B5
Kang, S1
Lee, MW1
Song, IC1
Lee, HJ8
Yun, HJ1
Jo, DY1
Kwon, JH2
Lee, KH11
Ryu, H1
De Falco, V1
Della Corte, CM1
Anderson, A1
Fowlkes, NW1
Villareal, OE1
Coker, O1
Morris, V3
Altucci, L1
Song, M1
Di, M1
Pan, Q3
Du, Y6
Xiang, T1
He, J7
Weng, D1
Xia, JC1
Kurasaka, C1
Nishizawa, N1
Uozumi, H1
Ogino, Y2
Sato, A14
Sun, Y12
Ni, X2
Fu, Z2
Liu, R5
Zhang, CY1
Ohori, H4
Yuasa, Y2
Miwa, K11
Oki, E15
Naitoh, T1
Komatsu, Y19
Hihara, M1
Soeda, J1
Akagi, K1
Ochiai, A3
Tsuchihara, K3
Kauffels, A1
Nowack, H1
Bohnenberger, H2
Spitzner, M3
Sprenger, T1
Ghadimi, M1
Sperling, J2
Yeku, OO1
Longo, DL1
Jahedi, M1
Meshkini, A1
Källberg, J1
Harrison, A1
March, V1
Bērziņa, S1
Nemazanyy, I1
Kepp, O1
Kroemer, G1
Mouillet-Richard, S1
Laurent-Puig, P19
Taly, V1
Xiao, W2
Sun, S9
Bian, Z5
Liu, M5
You, X1
Santos, A1
Cristóbal, I5
Caramés, C3
Luque, M1
Sanz-Álvarez, M1
Madoz-Gúrpide, J4
Rojo, F6
García-Foncillas, J11
Mao, C1
Ji, D2
Ding, Y6
Song, W2
Song, L1
Feng, X3
Xu, N5
Fukumori, C1
Branco, PC1
Barreto, T1
Ishida, K4
Lopes, LB1
Zaidi, MY1
Nussbaum, DP1
Hsu, SD3
Uronis, HE3
Rea, CG1
Borgonovo, K4
Dognini, G2
Parati, MC2
Petrò, D1
Ghilardi, M6
Kataoka, K4
Takeuchi, J1
Ito, K9
Beppu, N2
Ceelen, W6
Kanemitsu, Y9
Ajioka, Y1
Endo, I5
Ikeda, M9
Kuribayashi, M1
Nomura, K1
Yarimizu, A1
Hirata, M1
Ohashi, E1
Kimura, K4
Takenaka, Y1
Yanagawa, T2
Nishimura, Y2
Uchino, M1
Ikeuchi, H4
Situ, Y1
Thakur, A1
Chorawala, MR1
Patel, RS1
Dote, S2
Shiwaku, E1
Kohno, E1
Fujii, R2
Mashimo, K2
Morimoto, N2
Yoshino, M3
Odaira, N1
Ikesue, H1
Hirabatake, M1
Takagi, M2
Nishiuma, S1
Shimato, A1
Itakura, S2
Shigemori, M1
Watanabe, H4
Hayasaka, D1
Nakao, M2
Tasaka, M1
Goto, E2
Kataoka, N1
Yokomizo, A1
Kobayashi, A2
Nakata, Y2
Miyake, M2
Hayashi, Y2
Hirata, T2
Azuma, K1
Makihara, K1
Fukui, R1
Tokutome, A1
Yagisawa, K1
Honda, S2
Meguro, Y1
Suzuki, S7
Yamaguchi, D1
Miyata, H1
Kobayashi, Y11
Yousef, AM3
Zeineddine, FA1
Zeineddine, MA1
Tidwell, RS1
Beaty, KA1
Scofield, LC1
Rafeeq, S1
Hornstein, N1
Lano, E1
Eng, C15
Matamoros, A1
Foo, WC1
Uppal, A1
Scally, C1
Mansfield, P1
Taggart, M1
Overman, MJ7
Fournier, K1
Huang, MY8
Huang, YJ1
Cheng, TL4
Jhang, WY1
Ke, CC1
Chen, YT3
Kuo, SH1
Lin, IL1
Huang, YH1
Chuang, CH1
Niger, M5
Bustreo, S2
Procaccio, L1
Cupini, S12
Libertini, M3
Palermo, F4
Kumarasamy, V1
Kuppusamy, UR2
Jayalakshmi, P1
Govind, SK1
Imai, K7
Xia, J2
He, S5
Jia, H2
Ge, Y1
Zhou, M3
Khalili-Tanha, G2
Fiuji, H3
Gharib, M1
Moghbeli, M1
Khalili-Tanha, N1
Shakour, N1
Anvari, K1
Mozafari, MR1
Batra, J1
Chung, J1
Chang, J1
Parise, RA1
Chu, E24
Schmitz, JC3
Valizadeh, M1
Babaei, E1
Sharifi, R1
Yazdanbod, A1
Tan, T1
Mayanagi, S1
Kanda, M3
Honda, M4
Kashiwabara, K1
Muto, M5
Yamagishi, H3
Yoshikawa, T4
Satake, M2
Tanaka, H5
Higashida, M3
Fujiwara, Y7
Ueno, T3
Eucker, J1
Pihusch, R1
Müller, C3
Burkart, C1
Kasper-Virchow, S1
Krammer-Steiner, B1
Prager, GW1
Geng, S1
Zhan, H1
Cao, L3
Geng, L3
Ren, X1
Meng, L1
Thapa, R1
Delgado, MG1
Gomez, MF1
Ji, R1
Knepper, TC1
Hubbard, JM1
Permuth, JB1
Laber, DA1
Tam, SY1
Islam Khan, MZ1
Chen, JY1
Yip, JH1
Yan, HY1
Tam, TY1
Law, HK1
Wei, PL1
Huang, CY1
Chang, TC2
Lin, JC1
Lee, CC1
Prince, GMSH1
Makondi, PT1
Chui, AW1
Chang, YJ1
Frerker, B1
Bock, F1
Cappel, ML1
Kriesen, S1
Klautke, G2
Hildebrandt, G1
Manda, K1
Fukuda, K4
Osumi, H5
Yoshino, K2
Nakayama, I4
Fukuoka, S1
Ogura, M10
Wakatsuki, T8
Ooki, A6
Takahari, D14
Chin, K10
Hsiao, KC1
Ruan, SY1
Chen, SM1
Lai, TY1
Chan, RH1
Zhang, YM1
Chu, CA1
Cheng, HC1
Tsai, HW1
Tu, YF1
Chang, TT1
Chow, NH1
Chiang, CW1
Wang, CY3
Shao, C1
McDonald, AC1
Amonkar, MM1
Bortnichak, EA1
König, AO2
Caca, K1
Kretzschmar, A5
Nichetti, F2
Wasan, HS4
Meade, AM11
Díaz-Rubio, E41
Fisher, D9
Pang, Y2
Hu, J13
Ballhausen, A1
Meyer-Knees, JW1
Chang, W8
Fu, J3
Lin, Q4
Zhu, Z2
Tang, W5
Cioce, M1
Fumagalli, MR1
Donzelli, S1
Goeman, F1
Canu, V1
Rutigliano, D1
Orlandi, G1
Sacconi, A1
Pulito, C1
Palcau, AC1
Fanciulli, M1
Morrone, A1
Diodoro, MG2
Caricato, M5
Crescenzi, A1
Verri, M1
Fazio, VM1
Zapperi, S1
Levrero, M1
Strano, S1
Grazi, GL2
La Porta, C1
Blandino, G1
Fang, X2
Zhong, C2
Xiao, Q2
Xu, D3
Liao, X1
Dong, C2
Ding, K3
Blachman, A1
Birocco, AM1
Curcio, S1
Camperi, SA1
Gianvincenzo, PD1
Rodriguez, JA1
Barredo-Vacchelli, GR1
Cenci, G1
Sosnik, A1
Moya, S1
Calabrese, GC1
Katipally, RR1
Martinez, CA1
Pugh, SA1
Bridgewater, JA1
Primrose, JN8
Domingo, E4
Talamonti, MS1
Posner, MC1
Weichselbaum, RR1
Pitroda, SP1
Zhao, R3
Ren, L7
Ye, Q4
Cui, Y5
He, G3
Feng, Q2
Zhu, D4
Zhou, G1
Liang, F4
Ye, F1
Fan, J5
Abbasi, S1
Rivand, H1
Eshaghi, F1
Moosavi, MA1
Amanpour, S1
McDermott, MF1
Rahmati, M1
Lee, K3
Cho, S2
Kang, DU1
Park, S4
Kang, Y2
Choe, G1
Moon, KC1
Lee, KS4
Park, JH7
Hong, C3
Nateghi, R1
Pourakpour, F1
Jahromi, SAF1
Khani, A1
Kim, HR4
Choi, DH1
Han, CH1
Kwak, JT1
Han, B2
Ho, DJ1
Kang, GH9
Chun, SY1
Jeong, WK1
Park, P1
Kocyigit, A1
Guler, EM1
Durmus, E1
Yenigun, VB1
Kanimdan, E1
Ozman, Z1
Yasar, O1
Goren, AC1
Hekimoglu, ER1
Oruc, HH1
Aydogdu, G1
Susan, M1
Macasoi, I1
Pinzaru, I1
Dehelean, C1
Ilia, I1
Susan, R1
Ionita, I1
Teng, P1
Fei, B2
Ling, F1
Ding, W1
Wu, JZ1
Liu, AC1
Jiang, LL1
Zhang, HC1
Meng, Y1
Liu, BY2
Peng, GJ1
Lou, EZ1
Mao, Q1
Tang, DL1
Liu, JB1
Shi, XP1
Putri, S1
Saldi, SRF1
Khoe, LC2
Setiawan, E1
Megraini, A1
Santatiwongchai, B1
Nugraha, RR1
Permanasari, VY1
Nadjib, M1
Sastroasmoro, S2
Armansyah, A2
Marisi, G2
Azzali, I1
Rebuzzi, F1
Bartolini, G2
Urbini, M1
Canale, M1
Molinari, C1
Matteucci, L2
Sullo, FG1
Debonis, SA1
Gallio, C1
Gallo, G1
Frassineti, GL9
Ulivi, P1
Wang, XB1
Wang, XW1
Jiang, YH1
Ye, W4
Shao, CF1
Xie, JJ1
Hashimoto, T2
Mizusawa, J3
Kataoka, T2
Fukuda, H3
Tsukamoto, S4
Hamaguchi, T22
Alzahrani, SM1
Al Doghaither, HA1
Al-Ghafari, AB1
Pushparaj, PN1
Verheij, FS2
Kuhlmann, KFD3
Silliman, DR2
Soares, KC2
Kingham, TP7
Balachandran, VP4
Drebin, JA3
Wei, AC2
Jarnagin, WR10
Cercek, A7
Kok, NFM4
Kemeny, NE21
Yuki, S11
Sunakawa, Y18
Takahashi, N6
Asano, C1
Abe, Y1
Nomura, S1
Raunkilde, L1
Hansen, TF9
Havelund, BM1
Thomsen, CB1
Rafaelsen, SR1
Lindebjerg, J7
Jensen, LH4
Juřica, J1
Šuverová, P1
Goněc, R1
Synek, S1
Turjap, M1
Badr, D1
Fouad, MA1
Salem, S1
Zekri, A1
Shouman, S1
Shibata, Y4
Matsumoto, N1
Murase, R1
Kubota, Y3
Shimada, K12
Fujita, KI2
La, X2
Tian, J1
Xi, Y4
Bai, W2
An, L2
Jamialahmadi, H1
Nazari, SE1
TanzadehPanah, H2
Saburi, E1
Khojasteh-Leylakoohi, F1
Alaei, M1
Mirahmadi, M1
Babaei, F1
Asghari, SZ1
Mansouri, S1
Binabaj, MM1
Al-Asady, AM1
Soleimani, A1
Mehraban, S1
Ghorbani, E1
Ryzhikov, M1
Cartwright, BM1
Corso, JN1
Lightner, J1
Whitted, C1
Torrenegra, RD1
Krishnan, K1
Palau, VE1
Ghalambor, T1
Cavnar, MJ1
Merkow, RP1
Dominguez-Rosado, I1
Karanicolas, PJ1
Rocha, FG1
Fields, RC1
Patel, RA1
Kennecke, HF1
Koerkamp, BG1
Yopp, AC1
Petrowsky, H3
Mahalingam, D1
Kemeny, N32
D'Angelica, M5
Piringer, G1
Thaler, J6
Anchisi, S2
Geffriaud-Ricouard, C1
Gueldner, M1
Scholten, F1
Derigs, HG1
Bohanes, P4
Grünberger, B1
Schwarz, L1
von Moos, R5
Qin, W2
Zhou, R2
Mihara, Y1
Hirasaki, M1
Horita, Y5
Fujino, T2
Fukushima, H2
Kamakura, Y1
Uranishi, K1
Hirano, Y1
Ryozawa, S1
Yasuda, M1
Makino, Y1
Shibazaki, S1
Silveira, MJ1
Martins, C1
Cruz, T1
Castro, F1
Amorim-Costa, Â1
Chester, K1
Oliveira, MJ1
Sarmento, B1
Brañes, A1
Karanicolas, P1
Qiu, F2
Yu, Q4
Xi, X1
Du, B2
Jasinevicius, A1
Vaitiekaite, G1
Aleksandraviciute, B1
Eidenaite, E2
Sudeikis, L1
Azarifar, Z1
Amini, R2
Afshar, S1
Najafi, R5
Malka, D15
Verret, B1
Faron, M4
Caramella, C2
Edeline, J1
Bengrine-Lefevre, L7
Dupont-Bierre, E1
Goéré, D15
Dartigues, P4
Lacroix, L2
Boige, V26
Gelli, M4
Pignon, JP15
Ghelardi, F1
De Grandis, MC1
Barsotti, G1
Formica, V6
Boscolo, G2
Cinieri, S7
Ambrosini, M1
Piva, VM1
Dong, W2
Jiang, T5
Zeng, J3
Jiang, X4
Taniguchi, SH1
Komine, K1
Takenaga, N1
Kawamura, Y2
Kasahara, Y1
Ouchi, K1
Imai, H1
Saijo, K1
Shirota, H1
Ishioka, C5
Lian, J1
Okumura, S2
Goumard, C1
Gayet, B3
Fuks, D1
Scatton, O1
Lyskjær, I2
Kronborg, CS1
Rasmussen, MH4
Sørensen, BS2
Demuth, C1
Rosenkilde, M1
Johansen, AFB2
Knudsen, M2
Vang, S1
Krag, SRP1
Spindler, KG3
Andersen, CL4
Pooresmaeil, M1
Behzadi Nia, S1
Namazi, H1
Pentheroudakis, G8
Mavroeidis, L1
Papadopoulou, K1
Koliou, GA2
Bamia, C1
Chatzopoulos, K1
Samantas, E7
Mauri, D1
Efstratiou, I2
Pectasides, D8
Makatsoris, T5
Bafaloukos, D6
Papakostas, P7
Papatsibas, G1
Bombolaki, I1
Chrisafi, S1
Kourea, HP1
Petraki, K1
Kafiri, G1
Fountzilas, G18
Kotoula, V4
Ariyoshi, N1
Miyauchi, H2
Ohira, G1
Kaneya, N1
Arai, K7
Yamazaki, S3
Matsubara, H4
Suzuki, T20
Ishii, I1
Fu, S2
Gao, W1
Lei, Y1
Shao, J1
Xie, K1
Maletzki, C1
Bock, S1
Fruh, P1
Macius, K1
Witt, A1
Prall, F1
Almeida Junior, JC1
Helal-Neto, E1
Pinto, SR1
Dos Santos, SN1
Bernardes, ES1
Al-Qahtani, M1
Nigro, F1
Alencar, LMR1
Ricci-Junior, E1
Santos-Oliveira, R1
Shindoh, J4
Kinowaki, K1
Gonoi, W3
Tani, K1
Matoba, S3
Kuroyanagi, H2
Hashimoto, M7
Munemoto, Y7
Nakamura, M15
Kuroda, H2
Minagawa, N1
Touyama, T5
Takahashi, T24
Kurosawa, S2
Miura, T10
Khakoo, S1
Pedley, I1
Ellis, R3
Steward, W3
Harrison, M4
Baijal, S1
Tahir, S1
Ross, P5
Raouf, S4
Ograbek, A1
Cunningham, D93
Wang, QX1
Lv, L2
Ye, DR1
Sun, YH1
Pan, XX1
Bhandari, A2
Zhang, XH1
Wang, OC1
Liu, HG1
Bonadio, RC1
Amor Divino, PH1
Obando, JSM1
Lima, KCA1
Recchimuzzi, DZ1
Kruger, JAP1
Saragiotto, DF2
Capareli, FC2
Hoff, PM34
Conradi, LC1
Metzger, AL1
Kisly, M1
Middel, P1
Gaedcke, J3
Ghadimi, MB1
Liersch, T5
Rüschoff, J2
Beißbarth, T2
Grade, M2
Kim, HG1
Kim, CW3
Lee, DH1
Oh, ET1
Park, HJ2
Abdel-Rahman, O10
Karachiwala, H1
Ottaiano, A5
Scala, S1
Napolitano, M1
Capozzi, M1
Rachiglio, AM4
Roma, C2
Trotta, AM1
D'Alterio, C1
Portella, L1
Romano, C4
Cassata, A5
Casaretti, R13
Silvestro, L2
Nappi, A3
Tafuto, S8
Tamburini, M1
Picone, C1
Petrillo, A6
Izzo, F8
Palaia, R4
Albino, V2
Amore, A1
Belli, A1
Pace, U1
Di Marzo, M1
Chiodini, P1
Botti, G4
De Feo, G2
Delrio, P7
Nasti, G11
Chen, N1
Kong, Y2
Geng, Q1
Labriet, A2
Lévesque, É3
De Mattia, E7
Villeneuve, L2
Rouleau, M1
Jonker, D6
Couture, F6
Simonyan, D2
Allain, EP1
D'Andrea, M7
Guillemette, C3
Geissler, M4
Wilson, R3
Price, T12
Tracy, M1
Burdon, P2
Oshiro, H1
Tome, Y1
Kiyuna, T1
Yoon, SN2
Lwin, TM1
Han, Q4
Miyake, K1
Higuchi, T6
Sugisawa, N1
Katsuya, Y1
Zang, Z1
Razmjooei, S1
Bouvet, M3
Clary, B2
Singh, SR3
Kanaya, F1
Nishida, K3
Hoffman, RM4
Morine, Y1
Ikemoto, T1
Iwahashi, S1
Saito, YU1
Higashijima, J3
Imura, S1
Shepelytskyi, Y1
Fox, MS1
Davenport, K1
Li, T4
Albert, MS1
Davenport, E1
Cao, Y6
Chang, Q1
Ornatsky, O1
Hedley, D2
Chen, EX2
Tang, X1
Che, G1
Yu, Y8
He, L8
Wang, ZH3
Liu, JM2
Li, CY3
Lv, H3
Lv, SW1
Zhao, N1
Ma, H2
Lo Dico, R3
Kaci, R2
Naneix, AL2
Malgras, B1
Mathonnet, M6
Xu, M4
Pan, B1
Qin, J1
Xu, T2
Zeng, K1
Pan, Y5
He, B3
Sun, H3
Nohria, A1
Mohammadpour, S1
Goodarzi, HR1
Jafarinia, M1
Porhoseingholi, MA1
Nazemalhosseini-Mojarad, E1
Opattova, A2
Horak, J1
Vodenkova, S2
Kostovcikova, K1
Cumova, A1
Macinga, P1
Galanova, N1
Rejhova, A1
Vodickova, L3
Kozics, K1
Turnovcova, K1
Hucl, T3
Sliva, D1
Vodicka, P8
Yamadera, M1
Shinto, E2
Kajiwara, Y1
Mochizuki, S2
Hase, K2
Yamamoto, J4
Zucchelli, G5
Urbano, F2
Ronzoni, M14
Ricci, V7
Cordio, S7
Boni, L12
Dho, SH1
Cho, EH1
Lee, SY2
Jung, SH3
Kim, LK1
Lim, JC1
Rao, S6
Peri, S1
Hoffmann, J1
Cai, KQ1
Harris, B1
Rhodes, M1
Connolly, DC1
Testa, JR1
Wiest, DL1
Allard, MA2
Beghdadi, N1
Kitano, Y1
Kokudo, T1
Yamashita, YI1
Sa Cunha, A2
Vibert, E2
Elias, D19
Cherqui, D2
Ooft, SN1
Weeber, F1
Dijkstra, KK1
McLean, CM1
Kaing, S1
Schipper, L1
Hoes, L1
Vis, DJ1
van de Haar, J1
Prevoo, W2
Snaebjornsson, P3
van der Velden, D1
Klein, M1
Chalabi, M2
Boot, H7
van Leerdam, M1
Bloemendal, HJ1
Beerepoot, LV1
Wessels, L1
Cuppen, E1
Voest, EE3
Hou, L1
Zhu, L6
Hou, Y3
Zou, H1
Gu, Y5
Weng, X1
Gaiddon, C1
Meng, X1
Matsumoto, H14
Ishihara, Y4
Masumoto, S1
Kawamoto, K1
Takayanagi, K1
Sawazaki, S1
Ju, M1
Morita, J1
Komori, K3
Maezawa, Y1
Amano, S1
Mushiake, H3
Masuda, M3
Kassentoft, CG1
Laursen, MB1
Madsen, AH1
Iversen, LH1
Sunesen, KG1
Kong, XX1
Zhou, JJ2
Song, YM2
Huang, XF1
Li, GH1
Ying, XJ2
Dai, XY1
Jiang, K2
Fu, DL1
He, JJ1
Wang, JW4
Sun, LF1
Xu, JY1
Li, JS1
Yan, M3
Ding, KF2
Auvray, M1
Artru, P18
Hautefeuille, V3
Sickersen, G1
Coriat, R9
Vernerey, D2
Deng, R3
Shi, L3
Zhu, W2
Guan, X3
Shen, B3
Shi, H3
Tao, J1
Shen, R1
Sanchez-Vazquez, B1
Lee, JB1
Strimaite, M1
Buanz, A1
Bailey, R1
Gershkovich, P1
Pasparakis, G1
Williams, GR2
Lim, HH1
Hopkins, AM1
Rowland, A1
Yuen, HY1
Karapetis, CS7
Sorich, MJ1
Catalano, V12
Vincenzi, B15
Negri, F1
Giordani, P5
Alessandroni, P4
Stragliotto, S1
Sarti, D1
Rocchi, MBL1
Zagonel, V13
Mattioli, R7
Graziano, F13
Tai, CC1
Chen, WS14
Jiang, JK11
Yang, SH10
Wang, HS10
Chang, SC8
Lan, YT5
Lin, CC7
Lin, HH3
Huang, SC1
Cheng, HH1
Chao, Y1
Teng, HW5
Stramucci, L2
Pranteda, A2
Stravato, A1
Amoreo, CA2
Pennetti, A1
Bartolazzi, A1
Milella, M2
Bossi, G2
Siraj, AK1
Kumar Parvathareddy, S1
Pratheeshkumar, P1
Padmaja Divya, S1
Ahmed, SO1
Melosantos, R1
Begum, R1
Concepcion, RMJA1
Al-Sanea, N1
Ashari, LH1
Abduljabbar, A1
Al-Dayel, F1
Al-Kuraya, KS1
Zhu, G3
Zhao, M6
Sun, YU2
Ye, J3
Kim, HB1
Lim, HJ1
Park, SG1
Cheng, X2
Long, D1
Nakajima, Y4
Kajiwara, A1
Sakaki, M1
Otoyama, Y1
Nishihara, S1
Usami, T1
Nakatani, S1
Wong, WWL1
Zargar, M1
Berry, SR2
Ko, YJ4
Riesco-Martínez, M2
Chan, KKW2
Agrawal, S2
Woźniak, M1
Łuc, M1
Makuch, S1
Pielka, E1
Agrawal, AK1
Wietrzyk, J3
Banach, J1
Gamian, A1
Pizon, M1
Ziółkowski, P1
Wang, DS2
Chen, G14
Peng, JW3
Deng, YH2
Zhang, JW2
Liang, HL2
Feng, F2
Xie, CB1
Ren, C2
Fan, WH2
Ding, PR4
Paccard, C1
Chiron, M2
Chang, CY2
Pan, TM2
Gu, J8
Dong, D2
Long, E1
Tang, S2
Feng, S2
Raina, AJ1
Gilbar, PJ1
Grewal, GD1
Holcombe, DJ1
Lobefaro, R1
Antista, M3
Mosconi, S3
Rimassa, L8
Longarini, R3
Farina, G1
Gori, S3
Corallo, S8
Guarini, V1
Martinetti, A4
Macagno, M1
Barault, L1
Perrone, F6
Tamborini, E1
Milione, M4
Di Nicolantonio, F1
Fucà, G3
de Braud, F19
Igarashi, H1
Nosho, K1
Ishigami, K1
Koide, H1
Mitsuhashi, K1
Okita, K3
Takemasa, I8
Nakase, H1
Park, GB1
Jeong, JY1
Kim, D2
Buchler, T9
Cervena, K1
Veskrnova, V2
Vymetalkova, V5
Zhou, T3
Zheng, JH1
Lin, SR7
Tseng, FJ1
Tsai, MJ1
Lue, SI1
Chia, YC1
Woon, M1
Fu, YS1
Weng, CF1
Guan, Q2
Yan, H2
Jiang, B5
Yan, D3
Ge, H1
Liu, F11
Ai, FY1
Zhang, DC1
Tian, L1
Yang, ZY1
Liu, SJ1
Islam, SMA1
Dey, A1
Patel, R4
Smalley, T1
Acevedo-Duncan, M1
Yao, Z3
Zhao, S3
Mi, Q1
Zou, J3
Du, Q2
de Boer, NL2
Brandt-Kerkhof, ARM3
Madsen, EVE3
Diepeveen, M1
van Meerten, E5
van Eerden, RAG1
de Man, FM1
Bouamar, R1
Koolen, SLW1
de Hingh, IHJT4
Bakkers, C4
Rovers, KP4
Creemers, GM5
Deenen, MJ3
Kranenburg, OW1
Constantinides, A1
Mathijssen, RHJ1
Burger, JWA4
Kitazawa, M1
Hatta, T1
Sasaki, Y18
Fukui, K1
Ogawa, K10
Fukuda, E1
Goshima, N1
Okita, N3
Yamada, Y32
Nakagama, H1
Natsume, T2
Horimoto, K1
Moritani, K1
Katayama, H1
Chen, RM1
Chiou, YS1
Chong, QY1
Poh, HM1
Tan, TZ1
Zhang, MY1
Ma, L9
Zhu, T2
Pandey, V1
Kumar, AP1
Lobie, PE1
Lindner, AU2
Resler, AJ1
Carberry, S3
Oficjalska, K1
Bacon, O3
Lee, CS2
Choudhry, A1
Burke, JP1
Sheahan, K3
Cremona, M1
Hennessy, BT2
McNamara, D2
Doherty, G1
Ryan, EJ2
Prehn, JHM2
Iveson, T10
Kerr, RS2
Robles-Zurita, J1
Briggs, AH1
Cassidy, J51
Hollander, NH5
Haydon, A2
Glimelius, B52
Harkin, A4
Allan, K2
McQueen, J2
Pearson, S1
Waterston, A2
Medley, L2
Wilson, C3
Essapen, S3
Dhadda, AS2
Falk, S9
Rees, C3
Olesen, RK2
Propper, D4
Bridgewater, J13
Azzabi, A2
Farrugia, D2
Webb, A9
Hickish, T12
Weaver, A3
Gollins, S7
Wasan, H9
Paul, J3
Ma, CJ9
Yeh, YS8
Chang, YT2
Sveen, A1
Dienstmann, R2
Wirapati, P2
Neureiter, D3
Al-Batran, S1
Aderka, D2
Tejpar, S14
Okuyama, H1
Nogami, W1
Tona, Y1
Tanaka, Y9
Lu, W1
Fu, D1
Kong, X2
Hwang, M1
Kennecke, H3
Berry, S5
Maroun, J11
Kavan, P2
Aucoin, N1
Poulin-Costello, M1
Gillesby, B1
Ron, DA1
Labandeira, CM1
Manrique, MCA1
Núñez, MÁ1
Cid, NG1
Mata, JG1
Montes, AF2
Sheng, W1
Dong, M3
Hu, M2
Guan, K1
Hendricks, A1
Rosenstiel, P1
Hinz, S1
Burmeister, G1
Röcken, C3
Boersch, K1
Schafmayer, C1
Becker, T3
Franke, A1
Forster, M1
Shi, Y8
Wan, X2
Tan, C3
Francescangeli, F1
Contavalli, P2
De Angelis, ML1
Careccia, S1
Signore, M2
Haas, TL1
Salaris, F1
Baiocchi, M1
Boe, A1
Giuliani, A1
Tcheremenskaia, O1
Pagliuca, A1
Guardiola, O1
Minchiotti, G1
Colace, L1
Ciardi, A1
D'Andrea, V1
La Torre, F1
Medema, J1
De Maria, R3
Zeuner, A1
von Einem, JC8
Michl, M5
Rosa, F3
Susova, S3
Bendova, P2
Levy, M3
Kral, J1
Bartu, L1
Hughes, DJ1
Soucek, P4
Naccarati, A5
Kumar, R2
Pardini, B4
Tamjidifar, R2
Akbari, M2
Tarzi, S2
Sadeghzadeh, M1
Abolghasemi, M1
Poursaei, E1
Shomali, N2
Mahdavi, F1
Dyhl-Polk, A1
Vaage-Nilsen, M1
Schou, M1
Vistisen, KK2
Lund, CM2
Kümler, T1
Appel, JM1
Nielsen, DL3
Liu, XY2
Zheng, CB1
Gou, LS1
Qi, X3
Zeng, X3
Chang, CW1
Lee, HC2
Li, LH2
Chiang Chiau, JS1
Wang, TE1
Chuang, WH1
Chen, MJ3
Wang, HY1
Shih, SC1
Liu, CY4
Tsai, TH1
Chen, YJ2
Chouliaras, K1
Russell, G1
Levine, E2
Howerton, R1
Votanopoulos, K1
Clark, C1
Shen, P4
Luput, L1
Sesarman, A1
Porfire, A1
Achim, M1
Muntean, D1
Casian, T1
Patras, L1
Rauca, VF1
Drotar, DM1
Stejerean, I1
Tomuta, I1
Vlase, L1
Dragos, N1
Toma, VA1
Licarete, E1
Banciu, M1
Milczarek, M2
Chodyński, M1
Pietraszek, A1
Stachowicz-Suhs, M1
Yasuda, K5
Sakaki, T2
Kutner, A2
Sueur, B2
Zaanan, A4
de la Fouchardiére, C4
Des Guetz, G9
Touchefeu, Y3
Ferru, A1
Evrard, C1
Chautard, R1
Gentilhomme, L1
Henriques, J2
Cohen, R1
Chiang, TY1
Hsu, HC5
Jane, SW1
Chen, SC3
Dent, P1
Booth, L1
Roberts, JL1
Poklepovic, A1
Hancock, JF1
Mansoori, B2
Mohammadi, A1
Abedi-Gaballu, F1
Abbaspour, S1
Ghasabi, M1
Yekta, R1
Shirjang, S1
Dehghan, G1
Hamblin, MR1
Baradaran, B2
Carter, AM1
Shiu, KK2
Spooner, C1
Stevens, D1
Mullamitha, S1
Dercle, L1
Schwartz, LH3
Qian, M1
Eggleton, P1
Zhao, B2
Piessevaux, H2
Cao, G4
Ju, Z1
Jin, D1
Hsu, HT1
Wu, LM1
Lin, PC7
Juan, CH1
Huang, YY1
Chou, PL1
Chen, JL1
Holma, R2
Laatikainen, R1
Orell, H1
Joensuu, H6
Peuhkuri, K2
Poussa, T4
Korpela, R4
Rousseau, B1
Granger, V1
Gornet, JM1
Lievre, A10
Bignon-Bretagne, AL1
Metges, JP2
Baba-Hamed, N1
Michel, P7
Obled, S2
Vitellius, C1
Saban-Roche, L1
Buecher, B2
Trouilloud, I1
Dior, M2
Manfredi, S4
Soularue, E1
Phelip, JM8
Vernery, D1
Scherr, AL1
Jassowicz, A1
Pató, A1
Elssner, C1
Ismail, L1
Schmitt, N1
Hoffmeister, P1
Neukirch, L1
Gdynia, G1
Goeppert, B1
Schulze-Bergkamen, H4
Jäger, D4
Köhler, BC1
Gao, P4
Ding, H2
Fang, L4
Labianca, R31
Galli, F3
Rulli, E4
Cardellino, GG3
Mambrini, A2
Banzi, M1
Pusceddu, V2
Zampino, M1
Marchetti, P9
Sobrero, A34
Elnahry, AG1
Elnahry, GA1
Wei, L5
Wen, J1
Wu, D1
Mata, E1
González, E8
Juez, I2
Alonso, V7
Iranzo, P1
Martínez, NP1
López, C2
Cabrera, JM1
González, B1
Escudero, P14
Pericay, C9
Hashimoto, Y2
Miyazaki, M11
Aisu, N7
Kajitani, R2
Munechika, T1
Matsumoto, Y8
Shimaoka, H1
Komono, A2
Sakamoto, R1
Yoshimatsu, G2
Yoshimura, F2
Kiyomi, F1
Fan, Q1
Lv, W1
Dong, Y4
Xiang, Z1
Xu, R3
Zhu, B1
Lin, X4
Ma, D7
Cai, X4
Fang, W2
Fang, H3
Ye, ML1
Zhang, YP1
Li, WJ1
Li, MT1
Wang, HZ1
Yin, JW1
Hu, Q2
Wei, WH1
Chang, Y2
Yamaguchi, S9
Ito, S1
Torashima, Y1
Okada, S3
Enjoji, T1
Tetsuo, H1
Kuba, S1
Kosaka, T2
Adachi, T2
Hidaka, M1
Yamanouchi, K1
Kanetaka, K1
Takatsuki, M2
Eguchi, S3
Luo, DD2
Wan, SB2
Qu, XJ2
Di Maggio, G1
Giuliani, F15
Pisconti, S8
Rinaldi, A4
Febbraro, A3
Aieta, M2
Rizzi, D5
Colucci, G19
Ma, S1
Lin, T1
Zhao, G4
Inaba, Y16
Aramaki, T4
Sone, M2
Nishiofuku, H6
Tanaka, T19
Matsueda, K4
Arai, Y12
Pothuraju, R1
Rachagani, S1
Krishn, SR1
Chaudhary, S1
Nimmakayala, RK1
Siddiqui, JA1
Ganguly, K1
Lakshmanan, I1
Cox, JL1
Mallya, K1
Kaur, S1
Batra, SK1
Han, YS2
Lee, SH8
Teramachi, H2
Mundo, AI1
Greening, GJ1
Fahr, MJ1
Hale, LN1
Bullard, EA1
Rajaram, N1
Muldoon, TJ1
Ren, TJ1
Hou, JF1
Shan, FX1
Clarke, SJ11
Burge, M6
Feeney, K1
Jones, K1
Marx, G1
Molloy, MP2
Reece, WHH1
Segelov, E4
Das, S1
Allen, A1
Lv, X1
Fukuzaki, T2
Okimura, S1
Taniguchi, Y1
Fukata, T1
Nishida, H1
Takayama, O1
Yoshioka, S1
Hojo, S1
Ohigashi, H1
Tokuno, K2
Harada, E1
Hamano, K3
Sakamoto, T2
Murakami, K3
Katsura, Y2
Omura, Y1
Masuzawa, T1
Takeno, A1
Moon, D2
Kang, HK1
Yoon, SP2
Ma, R2
Cao, H2
Bendell, JC13
Sauri, T1
Gracián, AC1
Alvarez, R3
López-López, C2
Miron, ML1
Montagut, C5
Vivas, CS1
Bessudo, A1
Plezia, P1
Moons, V1
Andel, J1
Bennouna, J17
van der Westhuizen, A1
Samuel, L3
Rossomanno, S1
Boetsch, C1
Lahr, A1
Franjkovic, I1
Heil, F1
Lechner, K1
Krieter, O2
Hurwitz, H9
Swierz, MJ1
Storman, D1
Riemsma, RP1
Wolff, R2
Mitus, JW1
Pedziwiatr, M1
Kleijnen, J2
Bala, MM1
Glynne-Jones, R4
Denecke, T2
Pratschke, J5
Lang, H4
Bemelmans, M2
Rentsch, M2
Seehofer, D3
Bruns, CJ2
Gebauer, B2
Neumann, UP4
Ricard, I6
Wang, C9
Zhao, C2
Peng, Y6
Feng, Z1
Huang, H5
Nakamoto, Y1
Noda, M4
Mikami, R1
Tokunaga, Y5
Okumoto, T1
Kawamura, T2
Fujiwara, H2
Doi, S1
Tomita, N6
Mao, J1
Du, P2
Yang, HT1
Wang, SY1
Cheng, ZB1
Buhrmann, C5
Popper, B4
Majeed, M1
Aggarwal, BB4
Hua, L1
Feng, C2
Mo, Q1
Wei, M1
Shen, Y4
Taniguchi, K4
Lee, MY2
Bandu, R1
Komura, K1
Lee, KY2
Kim, KP12
Sastre, J24
Orden, V1
Martínez, A1
Bando, I2
Balbín, M1
Bellosillo, B1
Palanca, S1
Peligros Gomez, MI1
Mediero, B1
Llovet, P1
Moral, VM1
Viéitez, JM5
Calle, SG1
Quintero, G5
Das, M2
Yang, Q3
Bi, Y1
Zhang, C12
Shi, X4
Horst, D2
Berger, MD12
Ning, Y14
Cao, S26
Miyamoto, Y17
Suenaga, M28
Schirripa, M24
Hanna, DL4
Puccini, A4
Tokunaga, R5
Naseem, M4
Piastra, V1
Fratantonio, D1
Chang, CC2
Chao, KC1
Huang, CJ2
Hung, CS1
Wang, YC3
Innominato, PF8
Ballesta, A1
Huang, Q7
Focan, C23
Chollet, P8
Karaboué, A8
Giacchetti, S16
Bouchahda, M6
Garufi, C20
Lévi, FA4
Maltseva, D1
Raygorodskaya, M1
Knyazev, E1
Zgoda, V1
Tikhonova, O1
Zaidi, S1
Nikulin, S1
Baranova, A1
Turchinovich, A1
Rodin, S1
Tonevitsky, A1
Rezvani, H1
Mortazavizadeh, SM1
Allahyari, A1
Nekuee, A1
Najafi, SN1
Vahidfar, M1
Ghadyani, M1
Khosravi, A1
Qarib, S1
Sadeghi, A1
Esfandbod, M1
Rajaeinejad, M1
Rezvani, A1
Hajiqolami, A1
Payandeh, M2
Shazad, B1
Anjidani, N1
Meskinimood, S1
Alikhasi, A1
Karbalaeian, M1
Salari, S1
Ren, Y1
Cai, R1
Yin, M1
Kitagawa, Y6
Ota, Y2
Kim, S13
Choung, S1
Sun, RX1
Ung, N1
Hashemi, N1
Fong, EJ1
Lau, R1
Spiller, E1
Gasho, J1
Foo, J1
Mumenthaler, SM2
Tantawy, MA1
El-Sherbeeny, NA1
Helmi, N1
Alazragi, R1
Salem, N1
Elaidy, SM1
Oh, HK1
Cho, JY1
Kim, DW3
Kang, SB3
Jheon, S1
Okuno, M2
Hatano, E5
Toda, R1
Nishino, H3
Nakamura, K6
Ishii, T3
Seo, S4
Taura, K3
Yasuchika, K3
Yazawa, T3
Zaima, M3
Kanazawa, A7
Terajima, H3
Kaihara, S2
Adachi, Y7
Inoue, N5
Furumoto, K2
Manaka, D4
Tokuka, A1
Furuyama, H2
Doi, K3
Hirose, T3
Horimatsu, T6
Matsumoto, S13
Uemoto, S3
Wu, P1
Zhu, H5
Zhuang, Y1
Gu, N1
Zheng, J7
Yang, B1
Zhong, D2
Lin, M5
Lai, J1
Hou, P1
Funasaka, C1
Kanemasa, Y1
Shimoyama, T4
Cho, H1
Omuro, Y2
Wen, C3
Zhou, Q6
Yu, WK1
Okazaki, S9
Ishikawa, T10
Takahashi, G4
Iwai, T6
Takeda, K6
Ueda, K2
Kuriyama, S3
Koizumi, M3
Shinji, S2
Roseweir, AK2
Hoorn, ST1
Powell, AG1
Aherne, S1
Roxburgh, CS1
McMillan, DC3
Horgan, PG3
Ryan, E1
Vermeulen, L2
Graham, J4
Sansom, O2
Church, DN2
Tomlinson, I7
Saunders, M5
Iveson, TJ5
Edwards, J2
Chun, YJ1
Kim, SG2
Cho, SH5
Baek, JY6
Hong, S3
Chu, CW1
Jung, M3
Naranjo, T1
Iwamoto, S8
Ide, Y2
Ikumoto, T1
Sano, Y1
Kurata, T2
Yamanaka, T8
Duran, G6
Cruz, R1
Simoes, AR1
Barros, F3
Giráldez, JM1
Bernárdez, B2
Anido, U1
Candamio, S5
López-López, R2
Carracedo, Á5
Lamas, MJ5
Kratz, JD1
LoConte, NK2
Martens, UM1
Riera-Knorrenschild, J1
Greeve, J1
Florschütz, A1
Wessendorf, S1
Ettrich, T1
Kanzler, S3
Nörenberg, D2
Seidensticker, M1
Buechner-Steudel, P1
Atzpodien, J2
Seufferlein, T7
Tannapfel, A8
Reinacher-Schick, AC2
Scarabel, L1
Garziera, M1
Fortuna, S1
Asaro, F1
Geremia, S1
Sadahiro, S9
Okada, K9
Saito, G1
Miyakita, H1
Ogimi, T1
Chan, LF1
Kamei, Y2
Xie, P1
Mo, JL1
Liu, JH8
Tan, LM1
Zhou, HH1
Liao, L1
Cheng, Q1
Pei, F1
Ye, S1
Komori, A3
Ura, T14
Gootjes, EC1
van der Stok, EP2
Bakkerus, L1
Labots, M1
Zonderhuis, BM1
Tuynman, JB3
Meijerink, MR1
van de Ven, PM1
Haasbeek, CJA1
Ten Tije, AJ4
de Groot, JB1
Hendriks, MP1
Nuyttens, JJME1
Verheul, HMW3
Danielewicz, I1
Argilés, G3
Borg, C8
Van de Wouw, AJ1
Fedyanin, M1
Stroyakovskiy, D1
Kroening, H1
Kanehisa, A1
Egorov, A1
Aubel, P1
Amellal, N1
Moiseenko, V1
Cai, Y6
Deng, Y8
Raoul, JL7
Dahan, L7
Jouve, JL5
Zoetemelk, M2
Ramzy, GM1
Rausch, M2
Nowak-Sliwinska, P2
Nomura, Y3
Hashiguchi, Y3
Shibasaki, M1
Sakamoto, H2
Yamagata, S1
Aoyanagi, N1
Kaneko, H2
Koyama, H1
Miyagawa, S2
Tsushima, T4
Tsuda, T2
Hosokawa, A10
Tokunaga, S12
Shimokawa, H3
Ozaki, Y2
Koh, Y1
Kishimoto, J1
Blondy, S3
David, V1
Verdier, M2
Perraud, A4
Christou, N3
Fujiwara, D1
Hoshida, T1
Noda, A1
Takeda, T1
Tsubaki, M3
Nishida, S2
Sakaguchi, K1
Negarandeh, R1
Salehifar, E1
Saghafi, F1
Jalali, H1
Janbabaei, G1
Abdhaghighi, MJ1
Nosrati, A1
Shi, WN1
Wu, SH1
Miao, RR1
Sun, SY1
Guo, ZK1
Yu, XF1
Cui, SX1
Parakrama, R1
Fogel, E1
Chandy, C1
Augustine, T1
Coffey, M1
Tesfa, L1
Goel, S1
Maitra, R1
Belfiore, A1
Centonze, G1
Morelli, L2
Urbani, L3
Brich, S1
Cillo, U2
Cattaneo, L1
Shuwen, H1
Yuefen, P1
Jiamin, X1
Quan, Q2
Haihong, L1
Yizhen, J1
Wei, W4
Kong, N1
Konishi, T5
Yoshidome, H3
Shimizu, H3
Yoshitomi, H2
Takayashiki, T2
Kuboki, S2
Takano, S4
Ohtsuka, M5
de la Cámara Gómez, J2
Pellón Augusto, ML1
Covela Rua, M2
Quintero Aldana, G2
Reboredo López, M2
Valladares Ayerbes, M1
Jorge Fernández, M2
Ramos Vázquez, M1
Henry, M1
Delavari, N1
Webber, J1
Kobayashi, M6
Sato, R1
Komura, T1
Ichikawa, H3
Hirashima, T2
Otake, S1
Abe, T4
Kakita, T1
Oikawa, M1
Tsuchiya, T2
Nilsson, S1
Stein, A6
Kranich, AL1
Mann, J5
Papadimitriou, K1
Theile, S1
Amberg, S1
Bokemeyer, C16
Kashiwa, M1
Matsushita, R1
Dey, DK1
Chang, SN2
Vadlamudi, Y1
Park, JG4
Kang, SC1
Ritorto, G3
Adamo, V3
Peverelli, G1
Gürbüz, M1
Akkuş, E1
Utkan, G1
Xiang, L4
Ni, T1
Jin, F1
Deng, J2
Shintaro, I1
Demisse, R1
Damle, N1
Kim, E1
Gong, J5
Oesterich, L1
McKenny, M1
Ji, J4
Louie, R1
Tam, K1
Halabi, W1
Monjazeb, A1
Dayyani, F1
Schulz, C6
Haas, M4
Fraccaroli, A1
Elshenawy, MA1
Badran, A1
Aljubran, A1
Alzahrani, A1
Rauf, MS1
Eldali, A1
Bazarbashi, S1
Amrane, K1
le Pennec, R1
Schick, U1
Abgral, R1
Jácome, AA1
Kee, B3
Fogelman, D2
Dasari, A3
Shureiqi, I3
Raghav, K3
Johnson, B1
Overman, M2
Rogers, J1
Ahmed, SU1
Mehdizadeh, A1
Rothschild, N1
van Erning, FN1
Nienhuijs, SW3
Simkens, GAAM2
Hemmer, PHJ3
Lemmens, VEPP1
Tanis, PJ5
Fu, X3
Chang, L1
Hui, D1
Jia, R1
Liu, N1
Han, Z2
He, C6
Lin, S2
Ding, J3
Zhong, Q1
Chen, HX3
Ao, L4
Tamberi, S1
Tortora, G3
Brunella, DS1
Grassi, E1
Racca, P5
Chung, HH1
Lee, CT1
Hu, JM1
Chou, YC1
Lin, YW2
Shih, YL1
Helderman, RFCPA1
Löke, DR1
Verhoeff, J1
Rodermond, HM2
van Bochove, GGW1
Boon, M1
van Kesteren, S1
Garcia Vallejo, JJ1
Kok, HP1
Franken, NAP1
Crezee, J1
Oei, AL1
Ramos-Esquivel, A2
Chinchilla, R1
Valle, M2
Kuwata, GO1
Ikeda, K3
Maeda, T7
Yamashita, K13
Naito, K4
Yasumoto, K4
Takimoto, R4
Kamigaki, T6
Goto, S4
Sakata, N1
Kodama, S2
Matsusaka, S21
Yamamoto, N7
Yamaguchi, T36
Meiler, J1
Knipp, H1
Höhler, T5
Reimer, P4
Steinmetz, T1
Berger, W1
Linden, G1
Reis, H1
Markus, P1
Paul, A1
Dechêne, A1
Schumacher, B1
Kostbade, K1
Virchow, I1
Ting, S1
Worm, K1
Schmid, KW1
Herold, T1
Wiesweg, M1
Schuler, M1
Barbier, E3
Legoux, JL5
Bojesen, RD1
Friis, M1
Gögenur, I1
de Albuquerque Ribeiro Gondinho, P1
de Barros Silva, PG1
Lisboa, MRP1
Costa, BA1
da Rocha Filho, DR1
Gifoni, MAC1
Lima, MVA1
Junior, RCPL1
Vale, ML1
Pérez-Santiago, L1
Dorcaratto, D1
Garcés-Albir, M1
Muñoz-Forner, E1
Huerta Álvaro, M1
Roselló Keranën, S1
Sabater, L1
Napier, KJ1
Reed, SA1
Wong, TZ1
Kim, CY1
Wildman-Tobriner, B1
Nakane, M1
Gallego, J6
Yaeger, R3
Paroder, V1
Bates, DDB1
Capanu, M8
Tang, L3
Chatila, W1
Schultz, N1
Hersch, J1
Kelsen, D3
Jahangirian, H1
Umakoshi, H1
Saleh, B1
Rafiee-Moghaddam, R1
Webster, TJ1
Entezar-Almahdi, E1
Mohammadi-Samani, S1
Tayebi, L1
Farjadian, F1
Bian, X1
Wu, JL1
Qian, Y2
Gou, H3
Yat Luk, ST1
Chan, LS1
Shirasawa, S2
Po, A1
Citarella, A1
Catanzaro, G1
Besharat, ZM1
Trocchianesi, S1
Gianno, F1
Sabato, C1
Moretti, M1
De Smaele, E1
Vacca, A1
Fiori, ME1
Ferretti, E1
Taylor, JC1
Swinson, D2
Seligmann, JF3
Birch, RJ1
Dewdney, A2
Brown, V1
Dent, J1
Rossington, HL1
Quirke, P10
Morris, EJA1
Vaghari-Tabari, M1
Majidinia, M1
Moein, S1
Qujeq, D1
Asemi, Z1
Alemi, F1
Mohamadzadeh, R1
Targhazeh, N1
Safa, A1
Yousefi, B1
Wang, JH3
Wu, CC3
Sung, YC2
Chen, TL1
Wang, HM3
Tang, HC1
Chen, JB1
Ke, TW2
Tsai, CS1
Huang, HY1
Sharma, P2
Shimura, T4
Banwait, JK1
Guenter, J1
Abadi, S1
Lim, H3
Chia, S1
Woods, R2
Jones, M2
Rebic, N1
Renouf, DJ2
Laskin, J1
Marra, M1
Sang, J2
Tang, R10
Sun, Q2
Hsu, WH2
Yu, FJ3
Desai, A1
Mohammed, T1
Patel, KN1
Almnajam, M1
Kim, AS1
Cui, J2
Mercier, F1
Kerioui, M1
Desmée, S1
Guedj, J1
Bruno, R4
Iachetta, F1
Tonini, G32
Romagnani, A1
Berselli, A1
Boilève, A1
De Cuyper, A1
Larive, A1
Mahjoubi, L1
Najdawi, M1
Tazdait, M2
Tselikas, L2
Smolenschi, C2
Maneikyte, J1
Bausys, A1
Feldbacher, N1
Hoefler, G2
Kolb-Lenz, D1
Birgisson, H1
Enblad, M1
Artursson, S1
Ghanipour, L1
Cashin, P1
Graf, W13
El-Hout, S1
Lopez, L1
Schaeverbeke, T1
Richez, C1
Kostine, M1
Truchetet, ME1
Gmijovic, M1
Pecic, V1
Stojanovic, M1
Rashidi, G1
Rezaeepoor, M1
Mohammadi, C1
Solgi, G1
Lastraioli, E1
Palmieri, VE1
Castiglione, F1
Messerini, L1
Di Costanzo, F12
Matsuda, C6
Ueda, S4
Kusaba, H6
Okamura, S2
Shirakawa, T2
Yamashita, H8
Karthikeyan, K1
Babu, CM1
Shaji, S1
Ashok, AM1
Madhu, CS1
Selfridge, JE1
Gorityala, S1
Du, Z2
Wang, JM1
Hao, Y1
Cioffi, G1
Conlon, RA1
Barnholtz-Sloan, JS1
Saltzman, J1
Krishnamurthi, SS1
Vinayak, S1
Veigl, M1
Bajor, DL1
Markowitz, SD1
Meropol, NJ20
Eads, JR1
Shibata, S4
Miyatani, Y1
Beypinar, I1
Demir, H1
Taskoylu, BY1
Sakalar, T1
Ergun, Y1
Korkmaz, M1
Ates, O2
Eren, T1
Froelich, MF1
Petersen, EL1
Sommer, WH2
Yin, T1
Luo, C2
Yu, L3
Lapeyre-Prost, A2
Sigrand, J1
Le Malicot, K5
Mary, F2
Caroli-Bosc, FX1
Marthey, L1
Desrame, J6
Perkhofer, L1
Hoffmann, T3
Hebart, HF1
Herrmann, T3
Hannig, CV1
Büchner-Steudel, P1
Güthle, M1
Hermann, PC1
Berger, AW1
Patil, SA1
Etheridge, AS1
Howell, SD1
Plummer, SJ1
Casey, G2
Bertagnolli, MM3
McLeod, HL20
Auman, JT2
Furukawa, Y2
Kubo, M1
Parker, JS1
Ratain, MJ2
Yonesaka, K3
Kondoh, C2
Yamaguchi, H6
Varma, A1
Jayanthi, M1
Dubashi, B1
Shewade, DG1
Sundaram, R1
Srouji, RM1
Narayan, RR1
Boerner, T1
Seier, K1
Gonen, M7
Wei, A2
Fea, E2
Grande, R2
Zheng, D1
Zhuang, J2
Hu, D2
Peng, X2
Arici, S2
Sengiz Erhan, S1
Atci, MM1
Cekin, R1
Saka, B1
Köse, E1
Saydam, T1
Geredeli, C3
Cihan, S3
Nagourney, RA1
Evans, S1
Tran, PH2
Nagourney, AJ1
Kennedy, SA1
Morrissey, ME1
Dunne, MR1
O'Connell, F1
Butler, CT1
Cathcart, MC1
Buckley, AM1
Mehigan, BJ1
Larkin, JO2
McCormick, P2
Kennedy, BN1
O'Sullivan, J2
Shan, S3
Stack, A1
Khanal, R1
Denlinger, CS2
Ermacora, P1
Malla, SB1
Fisher, DJ1
Blake, A1
Hassanieh, S1
Redmond, KL1
Richman, SD6
Youdell, M1
Walker, SM1
Logan, GE1
Chatzipli, A1
Amirkhah, R1
Humphries, MP1
Craig, SG1
McDermott, U3
Seymour, MT29
Morton, DG1
West, NP1
Salto-Tellez, M7
Kennedy, RD1
Johnston, PG21
Koelzer, VH1
Campo, L1
Kaplan, RS5
Longley, DB13
Lawler, M1
Brown, LC1
Dunne, PD3
Puerta-García, E1
Urbano-Pérez, D1
Carrasco-Campos, MI1
Pérez-Ramírez, C1
Segura-Pérez, A1
Cañadas-Garre, M1
Koski, S4
Mulder, K1
Kamiyama, H2
Ishibashi, K27
Dai, J1
Jia, X1
Oliver, JA1
Jimenez-Luna, C1
Cabeza, L1
Perazzoli, G1
Caba, O1
Nasu, J4
Matsumoto, T2
Moriyama, I1
Miguchi, M1
Yoshida, R1
Nozaka, K1
Tanioka, H4
Kurisu, Y1
Tsuchihashi, K3
Inukai, M4
Kikuchi, T2
Taflin, H1
Odin, E6
Carlsson, G13
Tell, R1
Gustavsson, B16
Wettergren, Y7
Voß, H1
Wurlitzer, M1
Smit, DJ1
Ewald, F1
Alawi, M1
Spohn, M1
Indenbirken, D1
Omidi, M1
David, K1
Juhl, H1
Simon, R2
Sauter, G1
Fischer, L1
Izbicki, JR1
Nashan, B1
Schlüter, H1
Jücker, M1
Lin, PM1
Huang, CI1
Tai, TS1
Chen, JH1
Chen, CI2
Su, YC1
Kong, J2
Han, SK1
Ha, D1
Shin, K1
Patel, S2
Pandey, D1
Saklani, A3
Miller-Phillips, L2
Yuan, Z3
Huang, R4
Tang, Q4
Ren, T2
Shen, Z1
Hui, F1
Middleton, G8
Nippgen, J3
Burris, H2
Nassar, A1
Loriau, J1
Penna, C3
Brouquet, A3
Benoist, S3
Connell, LC2
Hong, L1
Al Sabbagh, C3
Seguin, J2
Agapova, E2
Kramerich, D1
Boudy, V3
Mignet, N3
Bang, YH1
Hong, YS19
Han, HS3
Kim, SY13
Eun, CK1
Kim, JE2
Alexander, PG1
Pennel, KAF1
van Wyk, HC1
Powell, AGMT1
Kelly, C2
Hay, J1
Roxburgh, CSD1
Zhu, C1
Guo, T1
Zhai, Z2
Lu, G2
Tian, S1
Jensen, BV14
Punt, C2
Garcia-Carbonero, R10
Benavides, M12
Le, DT1
Farooqui, MZH1
Marinello, P1
Diaz, LA2
King, BH1
Baumgartner, JM1
Kelly, KJ1
Marmor, RA1
Lowy, AM1
Veerapong, J1
Deng, X2
Hou, J2
Deng, Q2
Zhong, Z2
Marks, EI2
Matera, R1
Olszewski, AJ1
Yakirevich, E1
El-Deiry, WS9
Safran, H1
Carneiro, BA1
Feng, M2
Dos Santos, AM1
Meneguin, AB1
Akhter, DT1
Fletcher, N1
Houston, ZH1
Bell, C1
Thurecht, KJ1
Gremião, MPD1
Tan, X5
Liu, P5
Tong, JS1
Manca, P1
Smiroldo, V2
Greco, FG1
Vaiani, M2
Calareso, G1
Talbot, H1
Saada, S1
Battu, S4
Jauberteau, MO3
Lalloué, F1
Schmoll, HJ46
Kamiimabeppu, D1
Gürsoy, P1
Çakar, B2
Almuradova, E1
Karateke, M1
Doğanavşargil, B1
Sezak, M1
Harman, M1
Karabulut, B4
Bhattacharya, S1
Gmeiner, WH4
Dominijanni, A1
Haber, AO1
Ghiraldeli, LP1
Caudell, DL1
D'Agostino, R1
Pasche, BC1
Smith, TL1
Deng, Z1
Kiren, S1
Mani, C1
Palle, K1
Brody, JR3
Cheng, L3
Ni, P1
Ni, S1
Yao, X2
Cen, X1
Koch, J1
Mönch, D1
Maaß, A1
Gromoll, C1
Hehr, T1
Leibold, T1
Schlitt, HJ4
Dahlke, MH1
Renner, P1
Dupertuis, YM1
Boulens, N1
Angibaud, E1
Briod, AS1
Viglione, A1
Allémann, E1
Delie, F1
Pichard, C1
Sun, D3
Zou, Y1
Gu, X2
Ha, HA1
Chiang, JH1
Tsai, FJ1
Bau, DT1
Juan, YN1
Lo, YH1
Hour, MJ1
Yang, JS1
Watanabe, D1
Kiyama, S1
Kobayashi, R2
Suzuki, A1
Ukai, S1
Sakamoto, N3
Taniyama, D1
Harada, K2
Honma, R1
Maruyama, R1
Naka, K1
Hinoi, T1
Takakura, Y2
Shimizu, W2
Ohdan, H3
Yasui, W2
Azar, MRMH1
Aghazadeh, H1
Mohammed, HN1
Sara, MRS1
Hosseini, A1
Mansouri, M1
Sarand, SP1
Marofi, F1
Shotorbani, SS1
Patel, KK1
Stein, S1
Lacy, J1
O'Hara, M1
Huntington, SF1
Khosravi, N1
Shahgoli, VK1
Amini, M1
Safaei, S1
Mokhtarzadeh, A1
Derakhshani, A1
Baghbanzadeh, A1
Hsieh, AC1
Wei, X2
Gao, WQ1
Faruk, M1
Ibrahim, S2
Aminu, SM1
Adamu, A1
Abdullahi, A1
Suleiman, AM1
Rafindadi, AH1
Mohammed, A1
Iliyasu, Y1
Idoko, J1
Saidu, R1
Randawa, AJ1
Musa, HS1
Ntekim, A1
Shah, KZ1
Abubakar, S1
Adoke, KU1
Manko, M1
Awasum, CA1
Park, SM1
Choi, SB1
Lee, YS4
Lee, IK2
Ii, T1
Rikiyama, N1
Noguchi, A2
Aoki, Y1
Sato, J2
Kikuchi, D1
Yamanami, H1
Inui, M1
Zenitani, S1
Wada, R1
Mikamori, M1
Kishi, K2
Akamatsu, H2
Nakatsukasa, R1
Hayashi, N6
Urabe, S1
Nakagawa, T3
Michiura, T1
Yamabe, K1
Chen, YQ1
Lin, CY1
Yuan, ZW1
Li, ZH1
Hewitt, DB1
Pawlik, TM1
Cloyd, JM1
Köstek, O2
Housein, Z1
Kareem, TS1
Salihi, A1
Ivey, AM1
Ali, A1
Daily, KC1
Ramnaraign, BH1
Tan, SA1
Terracina, KP1
Read, TE1
Dang, LH1
Iqbal, A1
Nicoletti, M1
Lonati, V2
Cabiddu, M5
Seok, H1
Chen, R4
Peng, W3
Gu, Q1
Sheng, Y1
Shao, G1
Yu, IS1
Loree, JM1
Shiraiwa, K1
Suzuki, Y4
Uchida, H2
Iwashita, Y1
Tanaka, R5
Iwao, M1
Tada, K1
Hirashita, T1
Masuda, T5
Endo, Y5
Inomata, M4
Itoh, H1
Piao, Y1
Zhu, X3
Qiu, L2
Guo, W4
Ding, D1
Gholamzadeh Khoei, S1
Saidijam, M2
Jalali, A1
Akdeniz, N1
Kaplan, MA3
İnanç, M6
Kaya, S2
Dane, F5
Küçüköner, M1
Demirci, A1
Bilici, M1
Durnalı, AG3
Koral, L1
Şendur, MAN2
Türkmen, E2
Ölmez, ÖF1
Açıkgöz, Ö1
Laçin, Ş1
Şahinli, H1
Urakçı, Z1
Işıkdoğan, A3
Lin, SM1
Huang, SH1
Xu, ZB1
Lu, XR1
Xu, DB1
Chi, P5
Nindra, U1
Shahnam, A1
Mahon, KL1
Yan, Z3
Lv, M1
Ma, W1
Kuhn, E1
González Astorga, B1
Salvà Ballabrera, F1
Aranda Aguilar, E1
Élez Fernández, E2
González Flores, E2
Vera García, R1
López Muñoz, AM2
Salud Salvia, A1
Han, FY1
Wang, PY1
Xu, ZP1
Villard, C1
Habib, M1
Nordenvall, C1
Nilsson, PJ1
Jorns, C1
Sparrelid, E1
Sun, LT1
Zhang, LY1
Shan, FY1
Shen, MH1
Ruan, SM1
Kang, J2
Verdina, A1
Di Segni, M1
Sperduti, I4
Buglioni, S2
Mottolese, M4
Di Rocco, G1
Soddu, S1
McCann, C1
Matveeva, A1
McAllister, K1
Van Schaeybroeck, S7
Sessler, T1
Fichtner, M1
Rehm, M2
Noepel-Duennebacke, S1
Juette, H1
Schulmann, K4
Porschen, R12
Stoehlmacher, J11
Hegewisch-Becker, S8
Raulf, A1
Fontana, E2
Nyamundanda, G1
Sadanandam, A1
Zhao, K1
Ye, Z1
Xing, C2
Pimpie, C1
Roy, P1
Bellyei, S1
Boronkai, Á1
Pozsgai, E1
Fodor, D1
Mangel, L2
Bryson, E1
Sakach, E1
Patel, U1
Watson, M5
Hall, K1
Draper, A1
Davis, C1
Goyal, S1
Alese, O1
Akce, M1
Shaib, W2
El-Rayes, B2
Szabo, S1
Xuan, Y1
Zheng, HC1
Monti, M1
Donati, C1
Foca, F1
Pagan, F1
Rapposelli, I1
Ruscelli, S2
Valgiusti, M1
Sullo, F1
Sbaffi, S1
Crudi, L1
Masini, C1
Bhatti, T1
Moser, M1
Tan, KT1
Chalchal, H3
Souied, O1
Le, D1
Shaw, J1
Zaidi, A1
Gill, D1
Ahmed, S1
Komori, T2
Paku, M1
Kim, HM5
Sameni, HR1
Yosefi, S1
Alipour, M1
Pakdel, A1
Torabizadeh, N1
Semnani, V1
Bandegi, AR1
Christenson, ES1
Gizzi, A1
Egleston, M1
Seamon, KJ1
DePasquale, M1
Orris, B1
Park, BH2
Stivers, JT1
Kang, YH1
Lee, NH1
Seo, CS1
Son, CG1
Song, F1
Shao, Y2
Cheng, K1
Li, ZP1
Luo, DY1
Shen, YL1
Bi, F7
Gou, HF1
Yarrarapu, SNS1
Govero, AB1
Kukhon, FR1
Sanghavi, DK1
Jin, G1
She, Z1
Deng, S1
Ramos, H1
Soares, MIL1
Silva, J1
Raimundo, L1
Calheiros, J1
Gomes, C1
Reis, F1
Monteiro, FA1
Nunes, C1
Reis, S1
Bosco, B1
Piazza, S1
Domingues, L1
Chlapek, P1
Fabian, P1
Rajado, AT1
Carvalho, ATP1
Veselska, R1
Inga, A1
Pinho E Melo, TMVD1
Saraiva, L1
Su, K1
Hu, C2
Du, X2
Xing, B1
Sano, F1
Makishima, M1
Hamano, T1
Deligonul, A1
Aksoy, S2
Tezcan, G1
Tunca, B1
Kanat, O1
Cubukcu, E1
Yilmazlar, T1
Ozturk, E1
Egeli, U1
Cecener, G1
Alemdar, A1
Evrensel, T1
Akabane, S1
Kochi, M5
Taguchi, K3
Nakashima, I1
Sato, K5
Hattori, M3
Egi, H1
Sentani, K1
Wang, K6
Gu, C1
Deyme, L1
Barbolosi, D1
Mbatchi, LC1
Tubiana-Mathieu, N6
Evrard, A6
Gattacceca, F1
Lou, Y2
Sreekumar, R1
Al-Saihati, H1
Emaduddin, M1
Moutasim, K1
Mellone, M1
Kilic, S1
Cetin, M1
Erdemir, S1
Navio, MS1
Lopez, MA1
Curtis, N1
Yagci, T1
Price, BD1
Berx, G1
Thomas, GJ1
Tulchinsky, E1
Mirnezami, A1
Sayan, AE1
Fu, Y1
Chou, JF4
Chatila, WK1
Sanchez-Vega, F1
Sperotto, NDM1
Silva, RBM1
Perelló, MA1
Borsoi, AF1
da Silva Dadda, A1
Roth, CD1
Freitas, RDS1
de Souza, APD1
Freitas, DDN1
Picada, JN1
de Sousa, JT1
Nabinger, DD1
Altenhofen, S1
Bonan, CD1
Rodrigues-Junior, VS1
Bizarro, CV1
Basso, LA1
Machado, P1
Fujisawa, A1
Takahara, H1
Kondo, Y3
Akagami, M1
Yokoyama, T5
Takahara, N1
Na, R1
Xiao, C1
Lu, H2
Tang, H2
Zhuang, G1
Fan, G1
Peng, Z2
Yakar, N1
Ergun, B1
Ugur, L1
Ates, UC1
Gezer, S1
Comert, B1
Aomatsu, N1
Maeda, K10
Uchima, Y1
Matsutani, S1
Tsujio, G1
Kurihara, S1
Nishii, T1
Tachimori, A1
Takeuchi, K1
Thijs, AMJ2
Kusters, M2
Versteeg, KS1
Aalbers, AGJ2
Wiezer, MJ2
Boerma, D2
Los, M2
de Reuver, PR2
Bremers, AJA2
Kruijff, S2
de Groot, DJA2
Witkamp, AJ3
van Grevenstein, WMU2
Nederend, J2
Lahaye, MJ2
Fijneman, RJA2
van 't Erve, I2
Dijkgraaf, MGW2
Marshall, J7
de Gramont, A61
Chuang, KH1
Jie, Y1
Hernández, C1
Moreno, G1
Herrera-R, A1
Cardona-G, W1
Adams, J2
Casali, A2
Campbell, K1
Hopson, LM1
Singleton, SS1
Jogunoori, W1
Mazumder, R1
Obias, V1
Lin, P1
Nguyen, BN1
Miller, L1
White, J1
Mishra, L1
Karthika, C1
Hari, B1
Rahman, MH1
Akter, R1
Najda, A1
Albadrani, GM1
Sayed, AA1
Akhtar, MF1
Abdel-Daim, MM1
Saoudi Gonzalez, N1
Salvà, F1
Ros, J1
Baraibar, I1
Marmolejo, D1
Valdivia, A1
Cuadra-Urteaga, JL1
Mulet, N1
Nakayama, Y1
Kawamura, H1
Takano, Y3
Takiguchi, K1
Kamiga, T1
Muto, A1
Shiraso, S1
Yamashita, N3
Iwao, T1
Kono, K1
Konno, S1
Liu, G3
Lai, D1
Zhao, H7
Ackland, S2
Sjoquist, K2
Chinchilla-Monge, R1
Abbas, J1
Poma, AM1
Granetto, C10
Frassoldati, A1
Bertolini, AS1
Machover, D7
Almohamad, W1
Castagné, V1
Desterke, C2
Gomez, L1
Gaston-Mathé, Y2
Boucheix, C1
Goldschmidt, E4
Chaudhary, N1
Choudhary, BS1
Shah, SG1
Khapare, N1
Dwivedi, N1
Gaikwad, A1
Joshi, N1
Raichanna, J1
Basu, S1
Gurjar, M1
P K, S1
Gera, P1
Patil, P2
Gota, V1
Dhar, SK1
Gupta, S3
Wu, S3
Shen, X3
Herting, CJ1
Farren, MR1
Tong, Y3
O'Neil, B2
Noonan, A1
McQuinn, C1
Mace, TA1
El-Rayes, BF8
Shahda, S1
Lesinski, GB1
Kristin, E1
Endarti, D1
Taroeno-Hariadi, KW1
Trijayanti, C1
Akalovich, S1
Portyanko, A1
Pundik, A1
Mezheyeuski, A1
Doroshenko, T1
Hudita, A2
Radu, IC2
Galateanu, B2
Ginghina, O2
Herman, H1
Balta, C1
Rosu, M1
Zaharia, C2
Costache, M2
Tanasa, E1
Velonia, K2
Tsatsakis, A2
Hermenean, A1
Kang, SI1
Robling, KR1
Abada, PB1
Hozak, RR3
Siegel, R1
Fill, JA1
Wijayawardana, S1
Walgren, RA1
Giles, B1
Jones, A3
Pitts, KR1
Drove, N1
Mariappan, R1
Furihata, S1
Yatsu, N1
Ohno, R1
Takamatsu, N1
Anami, S2
Kerr, D14
Gray, V1
West, H1
Park, HE1
Yoo, SY1
Cho, NY4
Bae, JM7
Lee, HS4
Park, KJ7
Kim, TY17
Gamoh, M4
Iwanaga, I3
Sakashita, A1
Kotake, M3
Takahashi, S4
Erdoğan, MK1
Ağca, CA1
Aşkın, H1
Westphalen, CB3
Schlieker, L1
Jelas, I3
Iwasa, S9
Bai, L3
Shen, C1
Chang, R2
Easaw, J1
Chang, GR2
Kuo, CY1
Tsai, MY1
Lin, WL1
Lin, TC13
Liao, HJ1
Chen, CH3
Nikravesh, H1
Khodayar, MJ1
Behmanesh, B1
Mahdavinia, M1
Teimoori, A1
Alboghobeish, S1
Zeidooni, L1
Wei, B2
Porzio, G3
Cannita, K7
Venditti, O2
Filippi, R1
Ribelli, M1
Nigro, O1
Gelsomino, F2
Spallanzani, A1
Zurlo, V1
Leo, S8
Claudia, F1
Lombardi, P2
Keränen, SR1
Aimar, G1
Depetris, I1
Morelli, C1
De Tursi, M2
Tinari, N2
Di Pietro, FR1
De Galitiis, F4
Zanaletti, N1
Vitale, P1
Garajova, I1
Spinelli, GP1
Zoratto, F2
Roberto, M2
Ierino, D1
D'Orazio, C1
Ficorella, C9
Cortellini, A2
Peixoto, RD1
Coutinho, AK2
Weschenfelder, RF1
Prolla, G1
Rocha, D1
Andrade, AC2
Rego, JF1
Fernandes, GDS2
Crosara, M1
Costa E Silva, M1
Riechelmann, RP4
Garza-Treviño, EN1
Martínez-Rodríguez, HG1
Delgado-González, P1
Solís-Coronado, O1
Ortíz-Lopez, R2
Soto-Domínguez, A1
Treviño, VM1
Padilla-Rivas, GR1
Islas-Cisneros, JF1
Quiroz-Reyes, AG1
Said-Fernández, SL1
He, M1
Yoshida, T6
You, J1
Chen, D7
Siu, HWD1
Tebbutt, N11
Chantrill, L1
Karapetis, C5
Steer, C1
Wilson, K8
Bailey, L1
Yip, S2
Cuff, J1
Thavaneswaran, S1
Briscoe, K1
Srivastav, R1
Shannon, J1
Caird, S1
Francesconi, A1
Wuttke, M1
Ladwa, R1
Elbadawy, M2
Ayame, H1
Abugomaa, A1
Shibutani, M2
Hayashi, SM1
Takenouchi, H2
Nakajima, M2
Shinohara, Y2
Kaneda, M2
Yamawaki, H2
Usui, T2
Leone, AG1
Amatu, A1
Wincenciak, J1
Erickson, NT1
Lerch, MM3
Höffkes, HG2
Theurich, S1
Algül, H1
Beca, JM1
Dai, WF1
Pataky, RE1
Tran, D1
Dvorani, E1
Isaranuwatchai, W1
Peacock, S1
Alvi, R1
Cheung, WY1
Earle, CC7
Gavura, S1
Yoon, YS1
Roh, SA3
Cho, DH3
Kim, MB1
Kim, JC8
Yang, YF1
Wang, GY1
He, JL1
Wu, FP1
Zhang, YN1
Yamauchi, S3
Groshen, S13
Jiao, T2
Gao, T2
Sun, M3
Gopez, RF1
West, JD3
Hanna, D1
Ruers, T2
Van Coevorden, F3
Punt, CJ55
Pierie, JE1
Borel-Rinkes, I1
Ledermann, JA9
Poston, G6
Bechstein, W3
Lentz, MA2
Mauer, M5
Nordlinger, B18
Fan, L1
Niu, Y1
Mian, W1
Xie, M1
Mei, Q4
Ohta, H2
Murai, S1
Shiouchi, H1
Ando, Y7
Kumazawa, S1
Ikeda, Y5
Kawada, K3
Ye, M1
He, Y4
Zhong, J1
Xue, ZX1
Cai, ZZ1
Heydari, K1
Sharifi, MR1
Dermani, FK1
Soleimani Asl, S1
Shabab, N1
Xue, H1
Gu, L1
García-González, AP1
Ritter, AD1
Shrestha, S1
Andersen, EC1
Yilmaz, LS1
Walhout, AJM1
Scott, TA1
Quintaneiro, LM1
Norvaisas, P1
Lui, PP1
Wilson, MP1
Leung, KY1
Herrera-Dominguez, L1
Sudiwala, S1
Pessia, A1
Clayton, PT1
Bryson, K1
Velagapudi, V1
Mills, PB1
Typas, A1
Greene, NDE1
Cabreiro, F1
Kim, SB1
Park, SJ8
Hong, SP2
Cheon, JH1
Kim, WH1
Lim, A1
Le Sourd, S1
Senellart, H4
Luet, D1
Douane, F1
Perret, C1
Bouvier, A1
Métairie, S1
Cauchin, E1
Rougier, P51
Matysiak-Budnik, T2
Leal, F1
Ferreira, FP1
Sasse, AD3
Tang, M2
Du, C2
Hou, T1
Tu, B1
Cao, Z1
Jiang, L2
Liu, B6
Luo, J1
Zhu, WG2
Lim, KH2
Lee, HY1
Park, SB1
Song, SY2
Kwon, Y1
Park, M3
Jang, M1
Yun, S1
Kim, WK3
Paik, S2
Min, B1
Vehling-Kaiser, U15
Jagenburg, A2
Yabasin, IB1
Yu, JC1
Wen, Q3
Yao, Y3
Khorrami, S1
Zavaran Hosseini, A1
Mowla, SJ2
Soleimani, M1
Rakhshani, N1
Malekzadeh, R1
Ji, WB1
Um, JW1
Ryu, JS2
Hong, KD1
Min, BW1
Joung, SY1
Kim, YS3
Saber, A1
Alipour, B1
Faghfoori, Z1
Mousavi Jam, A1
Yari Khosroushahi, A1
Huo, X1
Sun, G3
Dabkeviciene, D3
Kirveliene, V1
Mao, H3
Dai, G2
Yu, X4
Polay Espinoza, M1
Pion, N1
Macari, F1
Textoris, J1
Auboeuf, D1
Dutertre, M1
Chiou, GY1
Yang, TW1
Huang, CC4
Tang, CY1
Yen, JY1
Tsai, MC1
Chen, HY1
Fadhilah, N1
Jong, YJ1
Larsen, FO6
Markussen, A2
Nielsen, D5
Colville-Ebeling, B1
Riis, LB1
Franck, C1
Malfertheiner, P1
Venerito, M1
Passalacqua, R3
Barni, S23
Baker, K1
Dunwoodie, E1
Jones, RG1
Newsham, A1
Johnson, O1
Price, CP1
Wolstenholme, J1
Leal, J1
McGinley, P1
Twelves, C21
Hall, G1
Pillai, R1
Jeong, KY3
Kim, IU1
Sim, JJ3
Yin, D1
Gopez, R1
Akihito, T1
Ichikawa, W13
DePaolo, RW2
Butler, SJ1
Richardson, L1
Farias, N1
Morrison, J1
Coomber, BL1
Gharib, AF1
Shalaby, SM1
Raafat, N1
Fawzy, WMS1
Abdel Hakim, NH1
Crispin, A1
Schalhorn, A12
Quietzsch, D2
Kruger, S1
von Einem, J1
Valsuani, C1
Duwe, G1
Knitter, S1
Pesthy, S1
Beierle, AS1
Bahra, M2
Schmelzle, M1
Schmuck, RB1
Lohneis, P1
Raschzok, N1
Öllinger, R1
Sinn, M1
Struecker, B1
Sauer, IM1
Andreou, A3
Huang, WW1
Hsieh, KP1
Huang, RY1
Yang, YH1
Xing, X2
Shen, Q1
Tan, S2
Demurtas, L1
Puzzoni, M2
Ziranu, P1
Mandolesi, A2
Loretelli, C1
Meriggi, F3
Cascinu, S27
Fruth, B1
Greene, C1
Schilsky, RL13
El-Khoueiry, AB2
Watson, P1
Benson, AB20
Mulkerin, DL2
Blanke, C4
Carrato, A22
Abad, A24
Massuti, B17
Longo-Muñoz, F1
Manzano, JL12
Gómez, A7
García-Paredes, B3
Dueñas, R6
Yang, Z9
Fukushima, M18
Iizuka, K1
Jin, C1
Hong, M1
Eshima, K2
Xiong, W2
Ai, YQ2
Li, YF4
Chen, ZT1
Qin, JY2
Liu, QY1
Ju, YH2
Li, WH2
Miaris, N1
Sgouros, J4
Gerolympou, M1
Spyropoulos, B1
Drakopoulos, D1
Gkoura, S1
Res, H1
Zhao, Z7
Teng, N1
Liang, X4
Ishii, F1
Yamauchi, Y3
Kojima, D2
Mera, T2
Kato, D1
Hamada, Y1
Nimura, S1
Oumrani, S1
Guillaumot, MA1
Brieau, B1
Oudjit, A1
Léandri, C1
Brezault, C7
Chaussade, S7
Sobhani, N1
Generali, D1
Roviello, G2
Mitsuboshi, S1
Kozakai, H1
Yamada, H11
Nagai, K2
Furukawa, T3
Aizawa, K1
AlShamaileh, H1
Xiang, D1
Yin, W1
Barrero, RA1
Zhang, PZ1
Kong, L3
Zhou, SF1
Shigdar, S2
Duan, W4
Leone, F5
Iaffaioli, RV5
Corsi, DC6
Ferraú, F3
Urushibara, S1
Tsubota, T1
Asai, R1
Azumi, J1
Ashida, K1
Shiota, G1
Ye, R1
Niu, B1
Hutchins, GGA1
Treanor, D1
Wright, A1
Handley, K2
Magill, L2
Tinkler-Hundal, E1
Southward, K2
Seymour, M9
Gray, R7
Richardson, C1
Hernandez Borrero, LJ1
Chionh, F2
Lau, D1
Yeung, Y1
Yokokawa, T3
Sugisaki, T1
Machida, Y1
Hama, T4
Shan, Y1
Jia, L1
Gonzaga-López, A1
Muñoz-Rodriguez, J1
Guo, B2
Xiao, N1
Yu, K1
Zheng, S4
Baltruskeviciene, E1
Kazbariene, B1
Aleknavicius, E1
Krikstaponiene, A1
Venceviciene, L1
Suziedelis, K1
Stratilatovas, E1
Didziapetriene, J1
Choi, YR1
Hur, BY1
Han, JK2
Ruff, P10
Lakomy, R5
Prausova, J13
van Hazel, GA11
Moiseyenko, VM6
Soussan-Lazard, K2
Dochy, E2
Magherini, E3
Macarulla, T6
Papamichael, D8
Kamel, KM1
Khalil, IA1
Rateb, ME1
Elgendy, H1
Elhawary, S1
Chong, D1
Huo, Q1
Lévi, F37
Saffroy, R2
Hebbar, M15
Innominato, P4
Carvalho, C5
Milano, G30
Lemoine, A4
Pariente, R1
Bejarano, I1
Rodríguez, AB1
Pariente, JA1
Espino, J1
Persia, FA1
Rinaldini, E1
Carrión, A1
Hapon, MB1
Gamarra-Luques, C1
Vu, T1
Yuan, G1
Datta, PK2
Fior, R1
Póvoa, V1
Mendes, RV1
Carvalho, T1
Gomes, A1
Figueiredo, N1
Ferreira, MG1
Kaiga, T1
Funada, T1
Taketani, A1
Andriana, BB1
Matsuyoshi, H1
Caraglia, M5
Mi, H1
Peter, CCK1
Fu, H1
Lai, Z2
Peng, J5
Zhang, RX3
Lei, J1
Li, LR2
Huang, JQ1
Kong, LH2
Wang, FL2
Ke, CF1
Zhou, WH1
Wan, DS7
Wu, XJ5
De Weerdt, A1
Dendooven, A1
Snoeckx, A1
Pen, J1
Lammens, M1
Jorens, PG1
Hara, K1
Uchida, E1
Braghiroli, MI2
Artioli, M1
Paterlini, ACCR1
Teixeira, MC1
Gumz, BP1
Girardi, DDM1
Braghiroli, OFM1
Costa, FP1
Miller, CL1
Taylor, MS1
Qadan, M1
Deshpande, V1
Worthington, S1
Smalley, R1
Collura, C1
Ryan, DP11
Allen, JN1
Blaszkowsky, LS1
Clark, JW15
Murphy, JE1
Parikh, AR1
Berger, D1
Tanabe, KK1
Lillemoe, KD1
Ferrone, CR1
Marques, RP1
Duarte, GS1
Sterrantino, C1
Pais, HL1
Quintela, A1
Martins, AP1
Costa, J1
Devarasetty, M1
Skardal, A1
Cowdrick, K1
Marini, F1
Soker, S1
Payette, E1
Sarker, S1
Daniele, B5
Ferrari, D1
Cavanna, L3
Sozzi, P1
Germano, D1
Codecà, C1
Lieto, E2
Auricchio, A1
Cardella, F1
Mabilia, A1
Basile, N1
Castellano, P1
Orditura, M6
Galizia, G3
Chan, K1
Qi, Y2
Ning, F1
Wu, M2
Cai, S5
Esposito Abate, R1
Lambiase, M4
Forgione, L1
Cardone, C2
Iannaccone, A1
Sacco, A1
Biglietto, M4
Yuan, YF1
Lin, HC1
Li, BK1
Sun, P1
Yan, SM1
Zhang, YZ1
An, JH1
Liu, YX1
Wu, XC1
Han, SS1
Ren, XQ1
Qin, CJ1
Shi, Q4
Alberts, SR15
Meyers, JP1
Smyrk, TC2
Julie, C3
Zawadi, A1
Mini, E11
Van Laethem, JL5
Sargent, DJ28
Sinicrope, FA5
Moussallem, T1
Lim, C1
Osseis, M2
Esposito, F2
Lahat, E1
Fuentes, L1
Salloum, C1
Azoulay, D9
Ouine, B1
Canet, J1
Cartier, A1
Amar, Y1
Cacheux, W3
Mariani, O1
Selves, J5
Guyetant, S1
Bieche, I2
Berger, F2
de Koning, L1
Wei, Q2
Gao, J3
Que, K1
Que, G1
Maillard, E5
Kirscher, S3
Etienne, PL10
Faroux, R12
El Hajbi, F2
Rinaldi, Y4
Lavau-Denes, S4
Baconnier, M2
Oden-Gangloff, A2
Genet, D6
Paillaud, E3
Retornaz, F2
Bedenne, L12
Schneiderova, M2
Gaetano, CD1
Jiraskova, K2
Veskrna, K1
Landi, S1
Jiang, D2
Han, C2
de Camargo, MR1
Gorgulho, CM1
Rodrigues, CP1
Penitenti, M1
Frederico, JCL1
Rodrigues, MAM1
Kaneno, R1
Kajitani, T1
Arita, S2
Oda, H1
Ochiai, H4
Siena, S11
Koukakis, R8
Demonty, G5
Bubalo, JS1
Herrington, JD1
Takemoto, M1
Willman, P1
Edwards, MS1
Williams, C1
Fisher, A1
Palumbo, A1
Prenen, H6
Köhne, CH49
Nasir, SN1
Abu, N1
Ab Mutalib, NS1
Ishak, M1
Sagap, I1
Mazlan, L1
Rose, IM1
Jamal, R1
Cen, C1
Ai, X1
Lin, C2
Tang, YC1
Zhi, Q2
Wu, MY2
Gong, FR2
Shen, M1
Tao, M2
Gu, DM1
Xu, MD2
Mohammed, MO1
Hussain, KS1
Haj, NQ1
Lee, KC1
Lin, CT1
Chang, SF3
Chen, CN1
Liu, JL1
Huang, WS1
Codony-Servat, J3
Cuatrecasas, M2
Asensio, E1
Montironi, C1
Martínez-Cardús, A6
Marín-Aguilera, M1
Horndler, C3
Martínez-Balibrea, E10
Rubini, M1
Jares, P2
Reig, O1
Victoria, I1
Gaba, L1
Martín-Richard, M4
Méndez, M4
Castells, A13
Prat, A1
Rosell, R5
García-Albéniz, X3
Camps, J1
Nahid, NA1
Apu, MNH1
Islam, MR1
Shabnaz, S1
Chowdhury, SM1
Ahmed, MU1
Nahar, Z1
Islam, MS2
Hasnat, A1
Virgone-Carlotta, A1
Lemasson, M1
Monnier, S1
Dehoux, T1
Delanoë-Ayari, H1
Rivière, C1
Rieu, JP1
Han, L1
Deal, AM3
Shachar, SS1
Walko, CM5
Patel, JN2
Weinberg, MS1
Choi, SK1
Muss, HB1
Sanoff, HK5
Pak, LM1
Boucher, T1
DeMatteo, RP5
Acharya, G1
Cruz Carreras, MT1
Rice, TW1
Lan, C1
Jiao, G1
Fu, W1
Long, X1
An, Y1
Chen, T1
Zheng, Q1
Cioffi, JH1
Estes, DJ1
Florou, V1
Ardalan, B10
Kamal, T1
Sarfraz, M1
Arafat, M1
Mikov, M1
Rahman, N1
Modest, HI1
Su, M1
Qin, B2
Grem, JL15
Mulcahy, MF3
Catalano, PJ5
Kauh, JS1
Hall, MJ2
Saltzman, JN1
Zangmeister, J1
Chiorean, EG1
Cheema, PS1
O'Dwyer, PJ19
Karimi Dermani, F1
Jalili-Nik, M1
Soltani, A1
Moussavi, S1
Cohn, AL11
Obermannova, R5
Ciuleanu, TE8
Portnoy, DC3
Siegel, RW1
Konrad, RJ1
Ouyang, H1
Melemed, SA1
Ferry, D3
Nasroulah, F7
Velut, G1
Kourie, RH1
Amouyal, G1
Sapoval, M1
Pointet, AL2
Landi, B5
Zaimi, Y1
Lepère, C5
Sönnichsen, R1
Hennig, L1
Blaschke, V1
Winter, K1
Körfer, J1
Hähnel, S1
Monecke, A1
Wittekind, C1
Jansen-Winkeln, B1
Thieme, R1
Gockel, I2
Grosser, K1
Weimann, A2
Kubick, C1
Wiechmann, V1
Aigner, A1
Bechmann, I1
Lordick, F9
Kallendrusch, S1
Gu, K1
Castro-Rojas, CA1
Esparza-Mota, AR1
Hernandez-Cabrera, F1
Romero-Diaz, VJ1
Gonzalez-Guerrero, JF1
Maldonado-Garza, H1
Garcia-Gonzalez, IS1
Buenaventura-Cisneros, S1
Sanchez-Lopez, JY1
Camacho-Morales, A1
Barboza-Quintana, O1
Rojas-Martinez, A1
Shaojun, C1
Haixin, H1
Guisheng, L1
Jo, YK2
Park, NY1
Shin, JH1
Jo, DS1
Bae, JE1
Choi, ES1
Maeng, S1
Jeon, HB1
Chang, JW1
Emi, Y12
Ogata, Y12
Akagi, Y10
Sakamoto, Y8
Maehara, Y22
Kuriyama, A1
Endo, K3
Shimodaira, H3
Linnekamp, JF1
Hooff, SRV1
Prasetyanti, PR1
Buikhuisen, JY1
Fessler, E1
Ramesh, P1
Lee, KAST1
Bochove, GGW1
de Jong, JH1
Cameron, K2
Leersum, RV1
Franitza, M1
Nürnberg, P1
Mangiapane, LR1
Stassi, G2
Medema, JP3
Fan, H2
Shida, T1
Yoshioka, T3
Ono, Y2
Inoue, T7
Torén, W1
Ansari, D1
Andersson, B1
Spelt, L1
Andersson, R2
Zeppola, T1
Stellato, M1
Chiara, S12
Tomcikova, D1
Ferrarotto, R2
George, B1
Qiao, W1
Machado, KK1
Saltz, LB15
Vauthey, JN10
Hobbs, B1
Loyer, EM3
Cotte, AK1
Aires, V1
Fredon, M1
Limagne, E2
Derangère, V2
Thibaudin, M2
Humblin, E1
Scagliarini, A1
de Barros, JP1
Hillon, P1
Delmas, D2
Trojan, J1
Ocvirk, J6
Schulz, H1
Homann, N1
Feustel, HP1
Schatz, M3
Kripp, M1
Schulte, N1
Tetyusheva, M1
Heeger, S2
Vlassak, S1
Merx, K1
Hu, F2
Buggin, F1
Lutrino, ES1
Lucchetti, J1
Arnoldi, E3
Zou, C2
Naghibalhossaini, F2
Shefaghat, M1
Mansouri, A1
Jaberi, H1
Tatar, M1
Eftekhar, E2
Osada, S2
Gotoh, A1
Yokoi, R1
Tsuchiya, H1
Sakuratani, T1
Okumura, N1
Hayashi, H8
Mukai, T1
Hermunen, K3
Lantto, E1
Haglund, C2
Ding, F1
Bai, G1
Doi, Y2
Yamaoku, K1
Takata, K1
Matsuura, H1
Yoneyama, K1
Kameda, Y2
Kuang, YS1
Ding, LD1
Liu, SH2
Zhu, BT1
Wang, XN2
Liu, HY2
Chang, ZJ1
Wang, YY1
Jia, BQ1
Tanabe, Y1
Takano, T3
Tessitore, A1
Bruera, G5
Mastroiaco, V1
Cocciolone, V1
Dal Mas, A1
Calvisi, G1
Zazzeroni, F1
Ricevuto, E7
Alesse, E1
Ünal, E2
Karaosmanoğlu, AD1
Ozmen, MN1
Akata, D1
Karcaaltincaba, M1
Tai, J1
Yu, M4
Ren, D3
Mescoli, C2
Coltelli, L1
Lupi, C5
Gemma, D2
Di Fabio, F3
Mancini, ML2
Marcucci, L4
Baratelli, C4
Brizzi, MP5
Sonetto, C2
Scagliotti, GV5
Wen, S2
Shen, J4
Pu, J1
Liang, H7
Schelhaas, S1
Wachsmuth, L1
Hermann, S1
Rieder, N1
Heller, A1
Heinzmann, K1
Honess, DJ1
Smith, DM1
Fricke, IB1
Just, N1
Doblas, S1
Sinkus, R1
Döring, C1
Schäfers, KP1
Griffiths, JR3
Faber, C1
Schneider, R1
Aboagye, EO2
Jacobs, AH1
Lledo, G18
Vigano, L3
Darwish, SS1
Cimino, M1
Carnaghi, C5
Donadon, M2
Procopio, F1
Personeni, N3
Del Fabbro, D1
Santoro, A6
Torzilli, G1
Reiser, MF1
Baumann, AB1
Tikhonova, IA1
Huxley, N1
Snowsill, T1
Crathorne, L1
Varley-Campbell, J1
Napier, M1
Hoyle, M2
Takemoto, H8
Takano, N3
Kataoka, M3
Gao, G1
Qian, X2
Nakayama, G4
Sakisaka, H1
Cashin, PH2
Mahteme, H5
Syk, I2
Frödin, JE6
Mennitto, A2
Pellegrinelli, A3
Mazzaferro, V1
Murcia, O2
Jover, R9
Egoavil, C2
Perez-Carbonell, L3
Juárez, M2
Hernández-Illán, E2
Rojas, E2
Alenda, C5
Andreu, M8
Llor, X8
Boland, CR6
Duo, Y1
Bi, J1
Mei, L1
Bao, S1
Shan, A1
Price, TJ20
Liu, GW1
Liu, YH1
Jiang, GS1
Ren, WD1
Yasar, N2
Pastorino, A1
Iaffaioli, V1
Fasola, G4
Zilocchi, C2
Scudder, C3
Briggs, A1
Berardi, G1
De Man, M1
Laurent, S3
Smeets, P3
Tomassini, F1
Ariotti, R1
Hoorens, A1
van Dorpe, J1
Varin, O1
Geboes, K4
Troisi, RI1
Tamura, A2
Uesugi, N2
Osakabe, M1
Eizuka, M1
Hasegawa, Y2
Nitta, H2
Otsuka, K2
Sasaki, A1
Ehara, S2
Sugai, T2
Ren, W2
Jorge, AF1
Aviñó, A1
Pais, AACC1
Eritja, R1
Fàbrega, C1
Zhan, L1
Moran, M2
Zeger, G1
Astrow, SH2
Laurinavicius, A1
Sakurai, M2
Umata, K1
Ohama, T1
Jonker, DJ2
Tang, PA2
Welch, SA1
Cripps, MC1
Asmis, T2
Tomiak, A4
Alcindor, T3
Goffin, JR1
Korpanty, GJ1
Feilotter, H1
Tsao, MS1
Theis, A1
Tu, D4
Seymour, L4
Spagnoletti, G1
Li Bergolis, V1
Piscazzi, A2
Giannelli, F1
Condelli, V1
Sisinni, L1
Bove, G1
Storto, G1
Landriscina, M3
Landre, T3
Taleb, C2
Ghebriou, D1
Guetz, GD1
Zelek, L4
Munker, S1
Gerken, M1
Fest, P1
Ott, C1
Schnoy, E1
Fichtner-Feigl, S1
Wiggermann, P1
Vogelhuber, M1
Herr, W1
Stroszczynski, C4
Evert, M1
Reng, M1
Klinkhammer-Schalke, M1
Teufel, A4
Jiang, S2
Song, C1
Miao, D2
Lv, J2
Zhu, JH1
Yao, XQ1
Sun, T1
Tucci, M1
Claret, L3
Pentafragka, C1
Karovic, S1
Maitland, ML1
Bironzo, P1
Xie, C3
Peng, P1
Zang, A2
Odisio, BC1
Simoneau, E1
Holmes, AA1
Conrad, CH1
Nie, J3
Guo, M1
Han, W4
Yue, H1
Yang, F4
Xia, E1
Wang, O1
Catalano, C1
da Silva Filho, MI1
Liska, V3
Vycital, O3
Hemminki, K2
Weber, ANR1
Försti, A2
Lin, JY1
Chi, YJ1
Chen, EY2
Haller, DG14
Dragovich, T1
Robles, C1
Mattek, N1
Sanborn, RE1
Abbas, MK1
Huynh, M1
Zou, F1
Peng, R1
Gajjar, KK1
Vora, HH1
Kobawala, TP1
Trivedi, TI1
Ghosh, NR1
Zawiah, M2
Al-Yacoub, S2
Kadi, T2
Tantawi, DA1
Al-Ramadhani, H1
Orlandi, A3
Fenizia, F3
Soto Parra, H1
Frassinetti, GL1
Repetto, L2
Barone, C21
Jiao, N2
Shu, Y4
McSkane, M1
Lin, YM2
Hsiang, YP1
Hsu, YC1
Cheng, KC1
Chien, PH1
Pan, HL1
Lu, CC1
Ivanova, A2
O'Reilly, S5
Kasbari, SS1
Moore, DT1
Zamboni, W2
Grogan, W1
Leonard, G2
Ryan, T1
Olowokure, OO1
Fernando, NH3
McCaffrey, J1
Horgan, AM1
Sherrill, GB2
Yacoub, GH1
Yan, P1
Dietrich, D4
Brauchli, P4
Klingbiel, D1
Fiocca, R1
Delorenzi, M2
Bosman, F2
Roth, AD8
Sánchez-Gundín, J2
Fernández-Carballido, AM2
Martínez-Valdivieso, L1
Barreda-Hernández, D2
Torres-Suárez, AI2
El-Fatatry, BM1
Ibrahim, OM1
Hussien, FZ1
Mostafa, TM1
Huang, SZ1
Liu, WY1
Shen, AL1
Liu, LY2
Harty, G1
Jarrett, J1
Jofre-Bonet, M1
Song, K1
Cai, H5
Zheng, W5
Li, N8
Semira, C2
Lee, B3
Lee, M4
Kosmider, S3
Shapiro, J4
Ma, B7
Dean, AP1
Zimet, AS1
Steel, SA1
Lok, SW1
Torres, J1
Eastgate, M1
Wong, HL4
Berger, AK1
Lücke, S1
Abel, U2
Haag, GM1
Grüllich, C1
Stange, A1
Dietrich, M1
Apostolidis, L1
Freitag, A1
Trierweiler, C1
von Gall, C1
Ose, J1
Giesel, F1
Weber, TF1
Haberkorn, U6
Álvarez-Gallego, R1
Muñoz, M1
Pond, G1
Perea, S3
Sánchez, G3
Martin, M9
Rodríguez-Pascual, J2
Garralda, E2
Vega, E2
de Vicente, E2
Quijano, Y2
Muñoz, C1
Ugidos, L1
Toledo, RA2
Hidalgo, M8
Karavasilis, V3
Aravantinos, G6
Kalogeropoulou, L1
Souglakos, I1
Kentepozidis, N3
Koumakis, G1
Zarkavelis, G1
Laschos, K1
Petraki, C1
Tikas, I1
Poulios, C1
Voutsina, A3
Goudopoulou, A1
Vrettou, E2
Kalogera-Fountzila, A1
Yazdi, M1
Shayan, P4
Huo, Z1
Canon, JL8
Akin, S1
Kas Guner, C1
Sturrock, M1
Miller, IS1
Kang, G1
Hannis Arba'ie, N1
O'Farrell, AC1
Barat, A1
Marston, G1
Coletta, PL1
Byrne, AT1
Prehn, JH5
Guillén-Ponce, C4
Alcaide, J2
López, R7
Méndez Ureña, M2
García, T3
Martín-Valadés, JI1
Falcó, E4
Navalón, M3
Ma García Tapiador, A1
Ma López Muñoz, A1
Barrajón, E1
Reboredo, M5
García Teijido, P1
Viudez, A3
Cárdenas, N1
Bencardino, K2
Park, MH2
Baek, JH5
Li, DD1
Zhao, CH1
Ding, HW1
Ren, TS1
Chen, CQ1
Zhao, QC1
Song, R1
Gu, D1
Xie, J2
Ren, F1
Li, K1
Benhaim, L7
Deschamps, F3
Anwar, A1
Uddin, N1
Siddiqui, BS1
Siddiqui, RA1
Begum, S1
Choudhary, MI1
Eckstrom, J1
Bartels, T1
Abraham, I1
Patel, H2
Elquza, E1
Scott, AJ1
Malangone, S1
Hollings, J1
McBride, A1
Graham, CN3
Christodoulopoulou, A1
Knox, HN2
Sabatelli, L1
Hechmati, G4
Garawin, T1
Shui, L1
Wu, YS1
Shui, P1
Hubert, C2
Lucidi, V2
Weerts, J4
Dili, A1
Demetter, P1
Massart, B1
Komuta, M1
Navez, J1
Reding, R1
Gigot, JF3
Sempoux, C3
Yue, GG1
Tsui, SK1
Fung, KP1
Lau, CB1
Oweira, H1
Giryes, A1
Mannhart, M1
Decker, M1
Grisoni, ML1
Liebaert, F1
Montestruc, F1
Thiébaut, R1
Alexandrou, C1
Al-Aqbi, SS1
Higgins, JA2
Boyle, W1
Karmokar, A2
Andreadi, C1
Luo, JL1
Moore, DA1
Viskaduraki, M1
Blades, M1
Murray, GI3
Howells, LM4
Thomas, A4
Brown, K5
Cheng, PN1
Rufini, A1
Zhou, S1
SekharKathera, C1
Janardhan, A1
Edick, AM1
Zhang, A1
Pan, F3
Colley, JP1
Maynard, J1
Humphreys, V1
Adams, RA5
Idziaszczyk, S2
Harris, R2
Lim, R6
Ba, Y5
Bai, Y3
Fan, N1
Wei, V1
Shi, D2
Muñoz, A5
López-Ladrón, A2
Ruiz de Mena, I1
Rezaei, N1
Boroumand, N1
Nosrati-Tirkani, A1
Takada, S1
Sagawa, T3
Fujikawa, K3
Tahatsu, K1
Fukai, Y1
Hashishita, H1
Endo, M3
Lin, Y2
Pan, D1
Zheng, C1
Krajewska, JB1
Bartoszek, A1
Fichna, J1
Rodríguez-Soler, M1
Giner-Calabuig, M1
Alustiza, M1
Castillejo, A1
Barberá, V1
Mangas-Sanjuan, C1
Yuste, A1
Clofent, J4
Zapater, P4
Delgado-Ureña, M1
Ortega, FG1
de Miguel-Pérez, D1
Rodriguez-Martínez, A1
García-Puche, JL1
Ilyine, H1
Lorente, JA1
Exposito-Hernandez, J1
Garrido-Navas, MC1
Delgado-Ramirez, M1
Serrano, MJ1
Marjaneh, RM1
Aghaee-Bakhtiari, SH1
Yousef, M1
Majdalawi, K1
Al-Hiary, R1
Tantawi, D1
Mukred, R1
Ajaj, AR1
Hsiang, J1
Stephens, C1
Takagane, A2
Tani, S2
Eto, T1
Fujii, M11
Yuan, L1
Mushtaq, N1
Ullah, S1
An, C1
Field, K1
Nott, L1
Tran, B2
Richardson, G1
Zimet, A1
Lipton, L2
Tamjid, B1
Johns, J2
Harold, M1
Idayu Mat Nawi, R1
Lei Chui, P1
Wan Ishak, WZ1
Hsien Chan, CM1
Kusano, M4
Okabayashi, K5
Nakamori, S2
Asahara, T1
Ohashi, Y8
Saji, S13
Romera, A1
Peredpaya, S1
Shparyk, Y2
Bondarenko, I5
Mendonça Bariani, G1
Abdalla, KC2
Roca, E1
Franke, F1
Melo Cruz, F1
Ramesh, A1
Ostwal, V2
Shah, P1
Rahuman, SA1
Paravisini, A1
Huerga, C1
Del Campo García, A1
Millán, S1
Ling, J1
Feng, L2
Fang, G1
Hong, D1
Kamei, K1
Hira, D1
Noda, S2
Terada, T1
Lo, JH2
Sales, MVC1
Suemoto, CK1
Apolinario, D1
Serrao, V1
Andrade, CS1
Conceição, DM1
Amaro, E1
de Melo, BAR1
Weldon Gilcrease, G1
Stenehjem, DD1
Wade, ML1
Weis, J1
Whisenant, J2
Boucher, KM1
Thorne, K1
Orgain, N1
Garrido-Laguna, I1
Sharma, S3
Zeynali-Moghaddam, S1
Mohammadian, M1
Kheradmand, F1
Fathi-Azarbayjani, A1
Esna-Ashari, O1
Malekinejad, H1
Ruan, H2
Wu, L2
Cheng, Y5
Seo, GS3
Tong, J2
Ciuleanu, T3
O'Connor, J1
Wijayawardana, SR1
Chu, JN1
Ostvar, S1
Torchia, JA1
Reynolds, KL1
Tramontano, A1
Gainor, JF1
Chung, DC1
Hur, C1
He, LJ1
Ye, HZ1
Liu, DF1
Zhu, YB1
Miao, DD1
Zhang, SP1
Jia, YW1
Liu, XP1
Dehlendorff, C3
Rønholt, F1
Johansen, JS6
Nagata, H2
Ishimaru, K1
Kaneko, M6
Hiyoshi, M4
Otani, K3
Shuno, Y2
Nishikawa, T4
Hata, K5
Freiberg-Richter, J2
Peveling Genannt Reddemann, C1
Schuch, G3
Hu, YB1
Yan, C1
Mu, L1
Mi, YL1
Tao, DD1
Wu, YQ1
Gong, JP1
Qin, JC1
Chakrabarti, S1
Sara, J1
Lobo, R1
Eiring, R1
Finnes, H1
Mitchell, J2
Hartgers, M1
Okano, A1
Halfdanarson, T1
Bendardaf, R8
Sharif-Askari, FS2
Sharif-Askari, NS2
Syrjänen, K5
Pyrhönen, S12
Rhoades, K1
Smith, B1
Honaker, MD1
Hiret, S2
Bertaut, A2
Deplanque, G3
Borel, C2
Conroy, T12
Seitz, JF20
Stanbury, T1
Denis, MG1
Xi, J1
Lin, HY1
Kuo, WT1
Hsu, CW2
Han, D1
Yang, R2
Limaiem, F1
Bouraoui, S1
Li, XW1
Qiu, SJ1
Kaplan, DL1
Lan, P5
Saint-Jean, A1
Reguart, N1
Eixarch, A1
Adán, A1
Castellà, C1
Sánchez-Dalmau, B1
Sainz-de-la-Maza, M1
Kim, Y3
da Silva, WC1
de Araujo, VE1
Lima, EMEA1
Dos Santos, JBR1
Silva, MRRD1
Almeida, PHRF1
de Assis Acurcio, F1
Godman, B1
Kurdi, A1
Cherchiglia, ML1
Andrade, EIG1
Gorbunova, V2
Beck, JT1
Nechaeva, M1
Cubillo Gracian, A1
Deming, DA1
Ramanathan, RK17
Torres, AH1
Sullivan, D3
Berlin, JD5
Jing, C1
Yang, JW1
Zhang, QH1
Akagi, J1
Wong, GG1
Ha, V1
Chu, MP1
Dersch-Mills, D1
Ghosh, S1
Chambers, CR1
Sawyer, MB1
Tan, BR2
Reeves, JA1
Somer, B1
Scappaticci, F1
Palma, JF1
Price, R1
Lee, JJ4
Nicholas, A1
Sommer, N1
Hsu, TC1
Wang, CC1
Wu, B4
Uchiumi, F1
Tanuma, SI1
Grigaitis, P1
Dapkunas, J1
Wasserman, I1
Lee, LH1
Ogino, S4
Marco, MR1
Datta, J1
Sadot, E1
Szeglin, B1
Guillem, JG1
Paty, PB2
Weiser, MR1
Nash, GM1
Saltz, L12
Barlas, A1
Manova-Todorova, K1
Uppada, SPB1
Elghouayel, AE1
Ntiamoah, P1
Glickman, JN1
Hamada, T1
Kosumi, K1
Inamura, K1
Chan, AT4
Nishihara, R1
Ganesh, K1
Dhawan, P1
Sawyers, CL1
Garcia-Aguilar, J1
Giannakis, M1
Shia, J4
Smith, JJ1
Sakatani, A1
Sonohara, F1
Kearney, MR1
Vaccaro, GM1
Strother, J1
Burt, A1
Todd, K1
Donovan, J1
Kampa-Schittenhelm, KM1
Yehia, R1
Saleh, S1
El Abhar, H1
Saad, AS1
Schaalan, M1
Ravindranathan, P1
Pasham, D1
Yoshihiro, T1
Uenomachi, M1
Ito, M2
Mitsugi, K5
Aikawa, T1
Takayoshi, K1
Ariyama, H4
Akashi, K4
Oyaga-Iriarte, E3
Insausti, A3
Sayar, O3
Aldaz, A3
Yasuno, M11
Ishiguro, M3
Mizunuma, N26
Miyata, G1
Shiomi, A1
Bachet, JB5
Douillard, JY34
Youssof, AME1
Alanazi, FK1
Salem-Bekhit, MM1
Shakeel, F2
Haq, N1
Sui, Y1
Weng, W1
Cai, G2
Gouverneur, A1
Coutureau, J1
Jové, J2
Rouyer, M2
Grelaud, A2
Duc, S1
Gérard, S1
Ravaud, A3
Droz, C1
Bernard, MA1
Lassalle, R1
Forrier-Réglat, A1
Noize, P2
Soveri, LM2
Lamminmäki, A1
Hänninen, UA1
Karhunen, M1
Bono, P2
Sahin, T1
Dizdar, O1
Bilgin, B1
Demir, M1
Bozbulut, UB1
Kilickap, S4
Yalcin, S4
Komarzynski, S1
Ulusakarya, A2
Haydar, M1
Bossevot-Desmaris, R1
Mocquery, M1
Plessis, V1
Short, SP1
Thompson, JJ1
Bilotta, AJ1
Revetta, FL1
Washington, MK2
Williams, CS1
Ge, XX1
Chen, K7
Shou, LM1
Wang, WJ2
Dost Gunay, FS1
Kırmızı, BA1
Ensari, A1
İcli, F3
Akbulut, H3
Ahmed, O1
Kiehl, M1
Csoszi, T1
Kafatos, G1
Kuhn, A1
Bjorklof, K1
Yan, L2
Yu, HH1
Liu, YS3
Wang, YS1
Zhao, WH1
Martínez Lago, N1
González Villaroel, P1
Luz Pellón Augusto, M1
Graña Suárez, B1
García Gómez, J1
Umemura, K1
Ishido, K1
Kudo, D1
Kimura, N2
Morohashi, H2
Hakamada, K2
Tajima, Y10
Hotta, S1
Nakano, M3
Kameyama, H2
Miura, K4
Nagahashi, M1
Nogami, H1
Maruyama, S10
Wakai, T3
Unson, S1
Kongsaden, C1
Wonganan, P1
Chibaudel, B14
Auby, D6
Louvet, C51
Lebrun-Ly, V2
Dauba, J2
Garcia, ML4
Hamed, NB1
Meurisse, A1
Larsen, AK7
Tijeras-Raballand, A1
Bonnetain, F9
Madurantakam Royam, M1
Kumarasamy, C1
Baxi, S1
Gupta, A1
Ramesh, N1
Kodiveri Muthukaliannan, G1
Jayaraj, R1
Varghese, V1
Magnani, L1
Harada-Shoji, N1
Mauri, F1
Szydlo, RM1
Lam, EW1
Kenny, LM1
Casagrande, M2
Delfanti, S1
Sensi, E6
Rezkallah, KNM1
Ahmed, A1
Kozma, K1
Lacas, B2
Gasmi, M5
Texereau, P5
Gargot, D5
Lombard-Bohas, C2
Azzedine, A3
Denis, B2
Geoffroy, P2
Borget, I2
Roca-Lema, D1
Martinez-Iglesias, O1
Fernández de Ana Portela, C1
Rodríguez-Blanco, A1
Díaz-Díaz, A1
Casas-Pais, A1
Prego, C1
Figueroa, A1
He, K1
Guo, Q1
Huang, K2
Ding, Q1
Xiang, G1
Morise, Z2
Tanaka, C5
Masumori, K2
Koide, Y3
Katsuno, H2
Tanahashi, Y1
Nakajima, S2
Hanai, T2
Kato, Y2
Sugioka, A2
Uyama, I1
Bano, N5
Ikram, R1
Wei, F1
Deng, SC1
Wei, JC2
Chen, ZP1
Li, WL1
Chen, HC5
Jia, J3
Gou, M1
Qian, N1
Sougiannis, AT1
VanderVeen, BN1
Enos, RT1
Velazquez, KT1
Bader, JE1
Carson, M1
Chatzistamou, I1
Walla, M1
Pena, MM1
Kubinak, JL1
Nagarkatti, M1
Carson, JA1
Murphy, EA1
Strowitzki, MJ1
Radhakrishnan, P2
Pavicevic, S1
Scheer, J1
Kimmer, G1
Ritter, AS1
Tuffs, C1
Volz, C1
Vondran, F1
Harnoss, JM1
Klose, J1
Schmidt, T2
Schneider, M6
Kazlauskas, A1
Darinskas, A1
Meškys, R1
Tamašauskas, A1
Urbonavičius, J1
Santos, C3
Azuara, D1
Valladares, M7
Robles-Díaz, L1
Bugés, C1
Navarro, V1
Capellá, G3
Salazar, R7
Zhong, F1
Guo, L1
Ou, J2
Yang, W1
Hao, J2
Zha, L1
Xie, G2
Sun, W5
Salhia, B1
Weisenberger, DJ1
Liang, G1
Rizzo, A1
Palloni, A1
Frega, G1
Abbati, F1
De Lorenzo, S1
Brocchi, S1
Brandi, G5
Delahunty, R1
Mckendrick, J6
Cooray, P1
Ananda, S1
Desai, J2
Torres, G1
García, G1
Gallego, I1
Ortega, L1
Sandoval, C1
Lloansí, A1
Ying, K1
Chong, Y1
Bing, D1
Yanyan, S1
Xuefeng, Y1
Ke, L1
Huijberts, S1
Cuyle, PJ1
Gollerkeri, A1
Christy-Bittel, J1
Maharry, K1
Sandor, V2
Schellens, JHM1
Kumar, B1
Murali, A1
Bharath, AB1
Giri, S1
Oh, HJ1
Wen, X1
Jung, S1
Iovu, H1
Tanasa, EV1
Georgiana Nitu, S1
Negrei, C1
Shtilman, M1
Mimaki, S1
Kawamoto, Y2
Yamashita, R1
Ohtsu, A17
Conev, NV1
Dimitrova, EG1
Bogdanova, MK1
Kashlov, YK1
Chaushev, BG1
Radanova, MA1
Petrov, DP1
Georgiev, KD1
Bachvarov, CH1
Todorov, GN1
Kalchev, KP1
Popov, HB1
Manev, RR1
Donev, IS1
Rossowska, J1
Klopotowska, D1
Stachowicz, M1
Demircan, NC1
Gökyer, A1
Sunal, BS1
Hacıoğlu, MB1
Eslame, H1
Solak, S1
Yılmaz, E1
Uzunoğlu, S2
Tunçbilek, N1
Çiçin, I3
Erdoğan, B2
Lima-Fernandes, E1
Murison, A1
da Silva Medina, T1
Ma, A1
Leung, C1
Luciani, GM1
Haynes, J1
Pollett, A1
Zeller, C1
Duan, S1
Kreso, A1
Barsyte-Lovejoy, D1
Wouters, BG1
Jin, J2
Carvalho, DD1
Lupien, M1
Arrowsmith, CH1
O'Brien, CA1
Lee, E1
Oh, S2
Jung, J1
Kim, KS2
Moon, A1
Zou, Q1
He, H2
Lei, M1
Fan, D1
Yun, CW1
Bueno, L1
Paralta Branco, F1
Brito, CB1
Luz, G1
Teixeira, JA1
Sekido, M1
Ohkuma, R1
Tsunoda, T4
Ishikawa, F1
Shibanuma, M1
Muguruma, N1
Fujimoto, S1
Okada, Y2
Kida, Y1
Nakamura, F1
Kitamura, S1
Peng, H1
Hosseini, SA1
Zand, H1
Cheraghpour, M1
Nørgaard, HH1
Hermann, HK1
Larsen, PN1
Hogdall, E1
Ambrož, M1
Lněničková, K1
Matoušková, P1
Skálová, L1
Boušová, I1
Francipane, MG1
Bulanin, D1
Lagasse, E1
Saeinasab, M1
Bahrami, AR1
González, J1
Marchese, FP1
Martinez, D1
Matin, MM1
Huarte, M1
Sen, K1
Banerjee, S1
Mandal, M1
Khan, N1
Jajeh, F1
Eberhardt, EL1
Miller, DD1
Albrecht, DM1
Van Doorn, R1
Hruby, MD1
Maresh, ME1
Clipson, L1
Mukhtar, H1
Halberg, RB1
Hotta, Y1
Toyofuku, A1
Ayez, N2
Sluiter, NR1
van der Vliet, HJ2
Wassenaar, ECE1
Hunting, CB1
Been, LB1
van Ginkel, RJ1
Fehrmann, RSN1
de Wilt, JHW1
Radema, SA2
Herbschleb, KH1
Haj Mohammad, N1
van Duyn, EB1
Mastboom, WJB1
Mekenkamp, LJM1
van Laarhoven, HWM1
Zwinderman, AH1
Bouma, JM1
Lee, SW3
Zemla, T1
Kabbarah, O1
Hu, W1
Fang, Z3
Miao, QR1
Hamfjord, J3
Guren, TK3
Dajani, O2
Lingjærde, OC1
Tveit, KM16
Kure, EH7
Pallisgaard, N2
Lee, DW5
Kim, HP1
Lyu, J1
Han, H2
Jang, H2
Bang, D2
Won, JK1
Jeong, SY5
Ichimura, T3
Colin, DJ1
Dormond, O1
Zhao, P1
Ma, YG1
Dai, ZJ1
Yan, CY1
Guan, HT1
Burnett, A1
Lecompte, MA1
Trabulsi, N1
Dubé, P1
Gervais, MK1
Trilling, B1
Cloutier, AS1
Sideris, L2
Ndreshkjana, B1
Çapci, A1
Klein, V1
Chanvorachote, P1
Muenzner, JK1
Huebner, K1
Steinmann, S3
Erlenbach-Wuensch, K1
Geppert, CI1
Agaimy, A1
El-Baba, C1
Roehe, AV1
Tsogoeva, SB1
Schneider-Stock, R1
Dohan, A1
Gallix, B1
Guiu, B4
Reinhold, C1
Soyer, P2
Jacquot, S1
Ben Abdelghani, M2
Khemissa-Akouz, F1
Desseigne, F6
Suc, E1
Hoeffel, C1
Spartalis, C1
Schmidt, EM1
Elmasry, M1
Schulz, GB1
Zheng, R1
Ouyang, X1
Iwuji, COO1
Irving, GRB1
Barber, S1
Walter, H2
Sidat, Z1
Griffin-Teall, N1
Singh, R1
Foreman, N1
Patel, SR2
Morgan, B4
Steward, WP4
Gescher, A1
Thomas, AL3
López López, C1
Argilés Martínez, G1
Páez López, D1
García Paredes, B1
Gutiérrez Abad, D2
Castañón López, C1
Jiménez Fonseca, P1
Gallego Plazas, J1
López Doldán, MC1
Sánchez Cánovas, M1
Tobeña Puyal, M1
Llorente Ayala, B1
Juez Martel, I2
López Flores, M1
Carmona-Bayonas, A1
Kuranaga, Y1
Tahara, T1
Shibata, T1
Nagasaka, M1
Funasaka, K1
Ohmiya, N1
Chen, SJ3
Chung, YC2
Chang, HL1
Chang, HP2
Chou, JL2
Hsu, CP4
Olejniczak-Kęder, A1
Szaryńska, M1
Wrońska, A1
Siedlecka-Kroplewska, K1
Kmieć, Z1
Moon, SU3
Park, Y1
Park, MG1
Song, SK1
Jeong, SH1
Heo, HJ1
Jung, WY1
Pintova, S1
Dharmupari, S1
Moshier, E1
Zubizarreta, N1
Ang, C2
Holcombe, RF2
Matikas, A2
Souglakos, J17
Katsaounis, P1
Kotsakis, A3
Kouroupakis, P1
Pantazopoulos, N1
Nikolaidi, A1
Messaritakis, I1
Tzovara, I1
Hatzidaki, D3
Prinarakis, E1
Georgoulias, V22
Dumont, A2
de Rosny, C1
Kieu, TL1
Perrey, S1
Berger, H1
Fluckiger, A1
Muller, T1
Pais de Barros, JP1
Pichon, L1
Hichami, A1
Thomas, C1
Rébé, C2
Rialland, M1
Vashi, PG1
Gorsuch, K1
Wan, L1
Hill, D1
Block, C1
Gupta, D1
Srimuninnimit, V3
Fedyanin, MY1
Martos, CF1
Ter-Ovanesov, M1
Picard, P1
Bury, D1
Drea, E1
Sondén, A2
Gupta, R1
Bhatt, LK1
Momin, M1
Alessandrino, F1
Qin, L1
Cruz, G1
Sahu, S1
Rosenthal, MH1
Shinagare, AB1
Chen, SH1
Yeh, YM1
Chen, LT2
Hsu, CY1
Tam, KW1
Shan, F1
Xiong, X1
Qin, A2
Liang, JY1
Xing, BC1
Kusumoto, T3
Katayose, Y1
Zheng, L2
Van den Eynde, M4
Berkhout, M1
Cai, W1
Zheng, M2
Liu, RX1
Chan, KW1
Tan, H1
Horvath, P1
Beckert, S1
Königsrainer, A2
Nadalin, S1
Königsrainer, I1
Cruz-Gil, S1
Sánchez-Martínez, R1
Wagner-Reguero, S1
Stange, D1
Schölch, S1
Pape, K1
Ramírez de Molina, A2
Neitzel, C1
Seiwert, N2
Göder, A2
Diehl, E1
Weber, C1
Nagel, G1
Stroh, S1
Rasenberger, B1
Christmann, M1
Fahrer, J2
Sahin, S1
Secmeler, S1
Can, O1
Demir, C1
Matsuda, E1
Ibe, H1
Oguma, E1
Naitoh, K1
Makita, K1
Hisaka, T1
Ishikawa, H7
Sakai, H1
Kawahara, R1
Goto, Y1
Yasunaga, M3
Kinugasa, T1
Fujita, F5
Mizobe, T2
Fukahori, M1
Nakashima, O1
Tanigawa, M1
Naito, Y3
Akiba, J1
Yano, H6
Okuda, K1
Sanderson, SM1
Dai, Z1
Reid, MA1
Cooper, DE1
Richie, JP1
Ciccarella, A1
Calcagnotto, A1
Mikhael, PG1
Mentch, SJ1
Ables, G1
Kirsch, DG1
Hsu, DS1
Nichenametla, SN1
Locasale, JW1
Masada, T1
Tatsumoto, S1
Marugami, N2
Otsuji, T6
Kanno, M1
Koyama, F2
Sho, M2
Kichikawa, K5
Yi, BR1
Park, MA1
Lee, HR1
Kang, NH1
Choi, KJ1
Kim, SU1
Choi, KC1
van Huis-Tanja, LH1
Gelderblom, H9
Guchelaar, HJ9
Dede, K3
Mersich, T2
Besznyák, I2
Zaránd, A1
Salamon, F1
Baranyai, ZS1
Landherr, L3
Jakab, F2
Bursics, A3
Ciombor, KK1
Chan, E6
Xynos, ID1
Karadima, ML1
Voutsas, IF2
Amptoulach, S1
Skopelitis, E2
Kosmas, C13
Gritzapis, AD2
Tsavaris, N19
Mobasheri, A1
Lueders, C1
Busch, F1
Brady, J1
Corrie, P1
Digumarti, R1
Adams, LM1
Botbyl, J1
Laubscher, KH1
Midgley, RS4
Mallath, M1
Thornton, M1
Aslam, MA1
Tweedle, EM1
Campbell, F1
Jackson, R1
Costello, E1
Rooney, PS1
Vlatković, N1
Boyd, MT1
Robinson, SM4
Manas, DM3
Mann, DA4
White, SA4
Teillet, L2
Subtil, F1
Le Brun-Ly, V1
Cretin, J3
Breysacher, G4
Charneau, J2
Stefani, L2
Ramdani, M2
Mitry, E19
van den Broek, MA1
Vreuls, CP1
Winstanley, A1
Jansen, RL3
van Bijnen, AA1
Dello, SA1
Bemelmans, MH1
Dejong, CH1
Driessen, A1
Olde Damink, SW1
Schmiegel, W17
Kubicka, S6
Freier, W3
Dietrich, G2
Geißler, M1
Pohl, M1
Hinke, A8
Giessen, C10
Laubender, RP9
Mansmann, UR1
Funke, V1
Lehmann-Koch, J1
Bickeböller, M1
Benner, A2
Tagscherer, KE2
Grund, K1
Pfeifer, M1
Herpel, E1
Schirmacher, P1
Chang-Claude, J3
Brenner, H2
Hoffmeister, M2
Roth, W2
Healey, E1
Stillfried, GE1
Eckermann, S1
Dawber, JP1
Clingan, PR9
Ranson, M2
Vañó-Galván, S2
Longo, F2
Grillo, E1
Jaén, P2
Pénichoux, J1
Michiels, S3
Schultheis, B1
Kuhlmann, J2
Ehrenberg, R2
Hacker, UT2
Kornacker, M1
Boix, O1
Lettieri, J1
Krauss, J1
Fischer, R2
Hamann, S2
Strumberg, D5
Mross, KB1
Cordwell, C1
Reece, W1
Cui, L2
Jensen, NF2
Tarpgaard, LS5
Qvortrup, C8
Rømer, MU2
Stenvang, J1
Hansen, TP1
Christensen, LL1
Hansen, F4
Brünner, N5
Ørntoft, TF1
Kim, SL1
Trang, KT1
Kim, IH1
Lee, SO1
Lee, ST3
Kim, DG1
Kim, SW2
Nowara, E1
Chuah, BYS1
Kopp, MV2
Sakaeva, DD1
Mitchell, EP7
Dubey, S1
Hei, YJ2
Galimi, F2
McCaffery, I1
Loberg, R1
Cottrell, S1
Choo, SP5
Kerscher, AG2
Chua, TC6
Gasser, M3
Maeder, U2
Kunzmann, V2
Isbert, C1
Germer, CT4
Pelz, JO2
van Gils, CW1
Ottevanger, PB2
Craven, O3
Hughes, CA1
Burton, A1
Molassiotis, A3
Gladkov, O1
Davidenko, I1
Vladimirova, L1
Cheporov, S1
Burdaeva, O1
Bulavina, I1
Potter, V1
Chang, YL1
Lokker, NA1
Weiswald, LB2
Richon, S1
Massonnet, G1
Guinebretière, JM1
Vacher, S1
Laurendeau, I1
Cottu, P1
Marangoni, E1
Nemati, F2
Validire, P1
Bellet, D1
Dangles-Marie, V2
Berindan-Neagoe, I1
Braicu, C1
Pileczki, V1
Cojocneanu Petric, R1
Miron, N1
Balacescu, O1
Iancu, D1
Shelton, JW1
Waxweiler, TV1
Landry, J2
Gao, H2
Shu, HK1
Piccirillo, MC2
Giordano, P1
Lastoria, S3
Caracò, C2
de Lutio di Castelguidone, E2
Daniele, G2
Aloj, L2
Romano, G2
Lin, JK17
Li, AF2
Brodowicz, T6
Radosavljevic, D2
Shacham-Shmueli, E5
Vrbanec, D4
Plate, S2
Mrsic-Krmpotic, Z2
Dank, M1
Purkalne, G2
Messinger, D3
Zielinski, CC7
Nakai, T1
Kitaguchi, H1
Yamasaki, M1
Truant, S3
Desauw, C1
Sergent-Baudson, G1
Cattan, S1
Piessen, G1
Pruvot, FR5
Moreau, LC1
Rajan, R1
Thirlwell, MP2
Koch, S2
Boxberger, F3
Harich, HD1
Hohenberger, W10
Dörje, F1
Ye, LC2
Liu, TS1
Zhu, DX2
Zai, SY1
Ye, QH1
Qin, XY1
Arnheim, K2
Hochster, H9
Alberts, S3
Imoto, K4
Kuwano, S3
Takada, K7
Magge, D2
Zureikat, AH2
Bartlett, DL2
Holtzman, MP1
Choudry, HA1
Beumer, JH1
Pingpank, JF1
Holleran, JL3
Strychor, S1
Cunningham, DE1
Jones, HL1
Zeh, HJ1
Sym, SJ2
Bae, KS2
Chang, HM4
Lee, JL9
Kang, YK6
Shin, JG2
Xia, Q1
Luo, R1
Huang, P1
Infante, JR2
Reid, TR2
Edenfield, WJ1
Cescon, TP1
Hamm, JT2
Malik, IA1
Rado, TA1
McGee, PJ1
Richards, DA3
Tarazi, J3
Rosbrook, B2
Cartwright, TH2
de Amuriza-Chicharro, N1
Gastalver-Martín, C1
Cortijo-Cascajares, S2
Ferrari-Piquero, JM1
Vasilaki, A1
Mathers, J1
Burt, AD1
Oakley, F3
Negandhi, AA1
Hyde, A1
Dicks, E1
Pollett, W1
Younghusband, BH1
Parfrey, P1
Green, RC1
Savas, S1
Hare, JI1
Neijzen, RW1
Anantha, M1
Dos Santos, N1
Harasym, N1
Webb, MS1
Allen, TM1
Bally, MB1
Waterhouse, DN1
Moreau, T3
Bjarnason, GA6
Smaaland, R5
Iacobelli, S7
Tumolo, S6
Poncet, A1
Spiegel, D2
Bulusu, A1
Pang, H4
Wong, NS3
Honeycutt, W2
Amara, A1
Mertens, J2
De Bruyne, S2
Van Damme, N2
Troisi, R2
Goethals, I1
Van de Wiele, C2
Zhang, GQ1
Wen, XY1
Li, JY1
Wu, LL1
Jiao, SC3
Xue, HP1
Fang, JY2
Gupta, M1
Han, K1
Joshi, A1
Sarapa, N1
Powell, B1
Rhee, YY1
Oh, DY7
Im, SA8
Bang, YJ7
Al-Tonbary, Y1
Darwish, A1
El-Hussein, A1
Fouda, A1
Fornaro, L11
Vivaldi, C2
Bracarda, S1
Morvillo, M2
Osawa, G3
Yokomizo, H8
Okayama, S2
Sagawa, M2
Naritaka, Y3
Shionome, Y1
Lin, WH1
Shiao, HY1
Hsieh, HP1
Hsu, JT1
Ouchi, T1
Najam, R4
Mateen, A4
Huang, XE4
You, SX1
Lu, YY2
Bennamoun, M5
Mabro, M16
Brusquant, D4
Ji, JH1
Kang, HJ5
Shim, BY4
Caparello, C1
Funel, N1
Pollina, L2
Vasile, E7
Lindsay, CR2
Roxburgh, P1
Shen, S2
Uygun, K1
Oven Ustaalioglu, BB1
Yildiz, R4
Temiz, S1
Seker, M1
Aksu, G1
Cabuk, D2
Gumus, M2
Brown, SR1
Richman, S3
Gwyther, S1
Lowe, C1
Wadsley, J1
Maisey, N1
Hill, M12
Dawson, L1
O'Callaghan, A1
Benstead, K1
Chambers, P3
Oliver, A1
Marshall, H1
Napp, V1
Green, E5
Yothers, G4
O'Connell, M4
Twelves, CJ3
Rao, GH1
Liu, HM1
Li, BW1
Hao, JJ1
Yang, YL1
Wang, MR1
Wang, XH2
Jin, HJ1
Karaayvaz, M1
Zhai, H1
Ju, J2
Saif, MW15
Kaley, K1
Brennan, M1
Garcon, MC1
Rodriguez, G1
Gerger, A4
Labonte, MJ5
El-Khoueiry, R2
Rumiato, E1
Boldrin, E1
Amadori, A1
Saggioro, D1
de la Cueva, A1
Alvarez-Ayerza, N1
Ramos, MA1
Cebrián, A1
Del Pulgar, TG1
Lacal, JC1
Maspero, F1
Sauta, MG1
Beretta, GD11
Derenzini, E3
Pietrabissa, A2
Pinna, AD1
Ercolani, G2
Pantaleo, MA3
Di Girolamo, S1
de Rosa, F1
Biasco, G6
García Alfonso, P3
Muñoz Martin, A1
Alvarez Suarez, S1
Blanco Codeidido, M1
Mondejar Solis, R1
Tapia Rico, G1
López Martín, P1
Ryan, EM1
Hanly, A1
Morrin, MM1
McNamara, DA3
Boers-Sonderen, MJ1
Desar, IM1
van Herpen, CM1
Sun, B2
Tseng, KC2
Hsu, CL1
Yang, TS9
Chen, JS8
Tang, RP1
Lim, B1
Scicchitano, A3
Beachler, C3
Gusani, N1
Sarwani, N2
Staveley-O'Carroll, K2
Ashkenazi, A2
Portera, C2
Lamparella, NE1
Saroya, BS1
Sarwani, NE1
Lai, CY3
Sung, FC3
Hsieh, LL4
Chiou, HY2
Wu, FY2
Yeh, CC3
Kim, HO1
Lee, SJ4
Oh, SJ1
Moon, DH1
Su, T2
Jensen, SA14
Ervin, TJ1
Gallinson, D1
Singh, J2
Wallace, JA1
Saleh, MN1
Vallone, M1
Phan, SC2
Hack, SP3
de Campos-Lobato, LF1
Stocchi, L1
de Sousa, JB1
Buta, M1
Lavery, IC1
Fazio, VW1
Dietz, DW2
Kalady, MF1
Tezuka, T2
Hamada, C1
Ooshiro, M3
Kawasaki, S1
Wen, F1
Sang, Y1
Nishimura, A5
Shibata, N1
Nielsen, BS2
Jakobsen, A18
Sørensen, FB4
Dréanic, J2
Maillet, M2
Dhooge, M3
Mir, O4
Goldwasser, F5
Misumi, N1
Goto, T2
Miyoshi, T1
Hiraike, M1
Shirasawa, H1
Saito, O1
Nishino, T1
Oudo, M1
Field, KM1
Shapiro, JD2
McKendrick, JJ3
Ruzzo, A6
Lucchesi, S1
Abe, H4
Mafune, K1
Minamimura, K1
Abe, M1
Umemura, A1
Boisen, MK4
Larsen, JS2
Østerlind, K1
Hansen, J1
Nielsen, SE5
Keldsen, N7
Jensen, BB3
Di Biasi, B1
Prochilo, T2
Sabatini, T1
Siegel, CL1
Reidy-Lagunes, D1
Bai, CH1
Candy, PA1
Phillips, MR1
Redfern, AD1
Colley, SM1
Davidson, JA1
Stuart, LM1
Wood, BA1
Zeps, N3
Leedman, PJ1
Chayahara, N3
Mukohara, T1
Kiyota, N1
Tomioka, H1
Funakoshi, Y1
Minami, H1
Ke, J1
Yuan, R1
Ueno, M4
Palumbo, I1
Piattoni, S1
Valentini, V3
Marini, V1
Calzuola, M1
Vecchio, FM2
Cecchini, D1
Falzetti, F1
Aristei, C1
Christensen, Rd1
Andersen, RF4
Johnsson, A3
Turner, LD1
Harrison, JD1
Hardingham, JE3
Lee, CK5
Townsend, AR8
Wrin, JW3
Weickhardt, A3
Simes, RJ5
Murone, C3
Terrazzino, S1
Cargnin, S1
Del Re, M3
Danesi, R24
Canonico, PL1
Genazzani, AA1
Roesler, B1
Bielfeld, C1
Emons, G1
Wolff, HA1
Rave-Fränk, M1
Kramer, F1
Beissbarth, T1
Kitz, J1
Wienands, J1
Ghadimi, BM1
Ebner, R1
Ried, T1
Teh, LK1
Hamzah, S1
Hashim, H1
Bannur, Z1
Zakaria, ZA1
Hasbullani, Z1
Shia, JK1
Fijeraid, H1
Md Nor, A1
Zailani, M1
Ramasamy, P1
Ngow, H1
Sood, S1
Salleh, MZ1
Foubert, F1
Uchino, K3
Fujisawa, M1
Nobuhisa, T1
Kai, K1
Notohara, K1
Matsukawa, A1
Hoehler, T2
von Wichert, G1
Schimanski, C1
Moehler, MH1
Hochhaus, A6
Hallek, M2
Hofheinz, R4
Sulzyc-Bielicka, V4
Bielicki, D4
Binczak-Kuleta, A1
Kaczmarczyk, M1
Pioch, W1
Machoy-Mokrzynska, A1
Ciechanowicz, A1
Gołębiewska, M1
Drozdzik, M1
Denne, J1
Horak, C1
Green, G1
Khambata-Ford, S1
Bray, C1
Celik, I4
Harbison, C1
Vilaça, N1
Amorim, R2
Machado, AF1
Parpot, P1
Pereira, MF1
Sardo, M1
Rocha, J1
Fonseca, AM1
Neves, IC1
Baltazar, F2
Tian, H1
Koçer, M1
Nazıroğlu, M1
Lin, CH3
Huang, CM2
Chai, CY2
Thalheimer, A2
Korb, D1
Bönicke, L1
Wiegering, A2
Mühling, B2
Riedel, SS1
Beilhack, A1
Brändlein, S1
Otto, C2
Kondo, K5
Sugiyama, Y10
Maindrault-Goebel, F12
Vidaurreta, M2
López, MR1
Gallen, M4
Rubio, ED1
Polesel, J2
Corona, G4
Dreussi, E1
Louie, SG1
Ely, B1
Albain, KS1
Gotay, C1
Coleman, D1
Raghavan, D1
Shields, AF5
Watanabe, K8
Kawahara, H4
Enomoto, H2
Toyama, Y1
Akiba, T2
Yanaga, K2
Pellón, ML1
Romero, C2
Jorge, M5
Ramos, M2
Varela, S1
Alonso, MÁ1
Oliner, KS7
Burkes, R4
Barugel, M3
Humblet, Y11
Jassem, J5
Kocákova, I6
Błasińska-Morawiec, M3
Šmakal, M3
Rother, M3
Williams, R2
Rong, A2
Wiezorek, J2
Sidhu, R4
Patterson, SD2
Lang, I11
Marcuello, E20
Lorusso, V16
Shin, DB7
Osborne, S1
Andre, N3
Waterkamp, D2
Nasyrov, AR2
Pirtskhalava, TL2
Korovina, IaV2
Ando, H3
Kanekiyo, S2
Hinoda, Y2
Okayama, N1
Oka, M4
Joulain, F4
Proskorovsky, I1
Allegra, C5
Iqbal, SU2
Akiyama, Y7
Aoki, T6
Hagiwara, K1
Hironaka, K1
Teranishi, F1
Osuka, F1
Takeuchi, M5
Nakajima, T8
Hugen, N1
Verhoeven, RH1
de Hingh, IH4
Pruijt, JF1
Nagtegaal, ID4
de Wilt, JH2
Grande, C2
París Bouzas, L1
Villanueva, MJ1
Campos, B1
Gallardo, E3
Alvarez, E2
Casal, J1
Mel, JR1
Temraz, S2
Alameddine, R1
Shamseddine, A3
Peddi, PF1
Kapp, AV1
Royer-Joo, S2
Portera, CC1
Kozloff, MF2
Hashash, JG1
Proksell, S1
Regueiro, MD1
Hutchinson, L1
Behringer, D1
Wolff, T1
Zimber, J1
Kettner, E2
Pflüger, KH2
Kirsch, A1
Di Gennaro, E4
Iaffaioli, VR2
Budillon, A7
Jang, MJ1
Jeon, YJ1
Chong, SY1
Hwang, SG1
Oh, D1
Cho, YK1
Ji, YG1
Kim, NK7
Padman, S1
Padbury, R3
Beeke, C3
Bishnoi, S2
Maddern, G2
Berretta, M9
Urbani, M1
Bearz, A7
Lutrino, S1
Foltran, L1
Ferrari, L2
Talamini, R4
Fiorica, F1
Lleshi, A5
Canzonieri, V1
Lestuzzi, C1
Borsatti, E1
Fisichella, R3
Tirelli, U7
Cereda, V2
di Bari, MG1
Grenga, I3
Tesauro, M2
Raffaele, P1
Ferroni, P2
Guadagni, F4
Roselli, M7
Ma, BB2
Chan, SL1
Ho, WM2
Lau, W1
Mo, F1
Hui, EP2
Chan, C1
Poon, A2
Dattatray, RD1
Wong, SC1
King, AD1
Ahuja, A1
Kjersem, JB4
Ikdahl, T7
Lingjaerde, OC1
Guren, T5
Poston, GJ6
Schlag, PM7
Bechstein, WO9
Walpole, ET3
Finch-Jones, M4
Jaeck, D5
Mirza, D3
Parks, RW3
Tanis, E3
Gruenberger, T20
Matsui, T2
Kojima, H2
Manoochehri, M1
Karbasi, A1
Bandehpour, M1
Kazemi, B1
Schwartzberg, L3
Yee, L1
Dreisbach, L1
Haddad, V1
Sabin, A1
Negri, FV2
Azzoni, C1
Bottarelli, L1
Campanini, N1
Wotherspoon, A3
Tinelli, C3
Silini, EM1
Ardizzoni, A2
Fukuchi, M2
Okada, N20
Yokoyama, M11
Chika, N5
Hatano, S7
Matsuzawa, T3
Kumamoto, K12
Kumagai, Y5
Mochiki, E2
Dai, S1
Ribecco, AS1
Pino, MS2
Cipriani, G1
Marinozzi, C1
Fioretto, L3
Michelucci, A1
Pfanner, E12
Brunetti, I11
Simi, P1
Ferry, DR3
Chevalier, S2
Allegra, CJ10
Hristova, NR1
Fassl, A1
Kopitz, J1
Spencer, SK1
Pommier, AJ1
Morgan, SR1
Barry, ST1
Robertson, JD3
Jürgensmeier, JM2
Nakajima, A2
Arimoto, A1
McArt, DG1
Blayney, JK2
Kalimutho, M1
Greer, S1
Srivastava, S1
Ong, CW3
Arthur, K1
Loughrey, M1
Redmond, K1
McCall, S1
Rushing, C1
Cohn, A5
Starodub, A1
Arrowood, C1
Haley, S1
Meadows, KL1
Morse, MA4
Blobe, GC3
Zafar, SY1
Deng, T2
Liu, XJ2
Xu, JM7
Bai, YX1
Ruiz-Millo, O1
Albert-Mari, A1
Sendra-Garcia, A1
Jimenez-Torres, NV2
Swieboda-Sadlej, A2
Pastorelli, D2
Bloom, J1
Ricart, AD1
Sobrero, AF8
Swiderek, E1
Kalas, W1
Wysokinska, E1
Pawlak, A1
Rak, J1
Strzadala, L1
Carter, HE1
Zannino, D3
John Simes, R1
Schofield, DJ1
Howard, K1
Zalcberg, JR11
Yi, JH1
Choi, JS2
Choi, GH1
Min, BS4
Kuwabara, K10
Yoshida, M5
Sakata, Y8
Shikina, A1
Kubo, T1
Fukazawa, S1
Giordano, AV2
Vicentini, R2
Uslu, R3
Yilmaz, U3
Buyukunal, E1
Buyukberber, S6
Camci, C1
Sencan, O2
Ozdener, F1
Cevik, D1
Shang, J1
Xue, G1
Jia, Y1
Ye, L2
Ji, K1
Toms, AM1
Davies, ML1
Ruge, F1
Hargest, R1
Jiang, WG1
Moutinho, C1
Navarro-Pérez, V1
Musulen, E2
Carmona, FJ1
Cassingena, A1
Esteller, M1
Liu, SL1
Qi, MH1
Zou, X1
Domagala, P3
Safranow, K3
Domagala, W3
Xue, Y2
Xie, L1
Wei, J3
Guan, W1
Shiomi, H4
Haraguchi, N3
Isohashi, F1
Yoshioka, Y2
Ransom, D1
Fournier, M1
Gebski, V5
Yip, D3
Gordon, S1
Heitzer, E1
Artl, M1
Filipits, M2
Resel, M1
Graf, R1
Weißenbacher, B1
Lax, S2
Gnant, M2
Wrba, F5
Greil, R7
Dietze, O2
Hofbauer, F1
Böhm, G1
Höfler, G1
Samonigg, H5
Schaberl-Moser, R1
Balic, M1
Dandachi, N1
Endo, A1
Nakashima, R1
Tanabe, K1
Hu, T1
Correale, P5
Botta, C2
Rotundo, MS1
Guglielmo, A1
Conca, R3
Licchetta, A2
Pastina, P2
Bestoso, E2
Ciliberto, D1
Cusi, MG4
Fioravanti, A3
Guidelli, GM1
Bianco, MT1
Misso, G2
Martino, E1
Tassone, P2
Mantovani, G1
Ridolfi, R2
Pirtoli, L1
Tagliaferri, P3
Kim, DY3
Paek, TY1
Oh, SY4
Kim, YB2
Choi, ZS1
Suh, KW3
Pörneczi, B1
Mester, G1
Fekete, A1
Kőszegi, G1
Passot, G1
Gayat, E2
Machida, N5
Sasaki, T11
Yachi, Y1
Onuma, H1
May, BH1
Zhou, IW1
Xue, CC1
Zhang, AL1
Bar, J1
Spencer, S1
Morgan, S1
Brooks, L1
Robertson, J3
Goss, GD1
Chiou, SH2
Hotko, Y4
Strickland, AH5
Wilson, G6
Roman, L4
Ang, B1
Wan, T1
Zemelka, T1
Schlichting, M4
Heighway, J1
Eggleton, SP1
Dobi, E1
Jary, M3
Monnien, F1
Curtit, E1
Nguyen, T3
Lakkis, Z3
Heyd, B2
Fratte, S1
Cléau, D1
Lamfichekh, N1
Nerich, V2
Demarchi, M1
Chiu, J1
Tang, V1
Leung, R1
Wong, H2
Chu, KW1
Poon, J1
Epstein, RJ1
Yau, T2
Dong, L2
Yin, X1
Lin, F3
Ni, W1
Jin, R2
Fuse, N7
Yamanaka, Y3
Motomura, S2
Doi, T11
Hatake, K13
Iwasaki, J1
Bae, S1
Singh, K1
Shimizu, T5
Murata, S1
Takebayashi, K1
Miyake, T2
Mekata, E3
Naka, S1
Tani, T4
Iyama, KI1
Kakeji, Y11
Samura, H5
Matsumoto, A3
Yano, Y2
Nakayama, M2
Shimakawa, T1
Katsube, T1
Kemmochi, T1
Egawa, T1
Mihara, K1
Ohkubo, Y1
Mori, T24
Nagashima, A1
Makino, H4
Yamamuro, W1
Tsuneda, A1
Makita, N1
Hagino, S1
Iwata, K1
Kiriyama, M2
Tomoda, M1
Andoh, H2
Ledermann, J2
Ruers, TJ2
Huh, JW3
Lee, WY5
Park, YA1
Cho, YB5
Yun, SH5
Kim, HC9
Chun, HK5
Baroudi, O1
Baroudi, T1
Omrane, I1
Moussa, A1
Mezlini, A1
Ayari, H1
Guermazi, S1
Bahloul, A1
Bouzaienne, H1
Uhrhammer, N1
Bignon, YJ1
El-Gaaied, AB1
Bougatef, K1
Bichard, D1
Limat, S3
Lorgis, V3
Vincent, J6
Berthou, J1
Orry, D1
Ortega-Deballon, P1
Facy, O1
Rat, P1
Ladoire, S6
Hompes, D2
Aalbers, A1
van Velthuysen, ML1
Vogel, W1
Verwaal, V1
Shi, DB1
Li, XX1
Zheng, HT1
Li, DW1
Cai, GX1
Peng, JJ1
Gu, WL1
Guan, ZQ1
Cai, SJ1
Di, J1
Cui, M1
Xing, J1
Zhang, N1
Dong, B1
Su, X2
Thiébaut, A1
Samson, S1
Ricordeau, P1
Guillemot, D1
Engelmann, BE1
Loft, A1
Kjær, A1
Nielsen, HJ3
Gerds, TA1
Benzon, EV1
Christensen, IJ4
Hansson, SH1
Kristensen, MH1
Löfgren, J1
Markova, E1
Sloth, C1
Højgaard, L1
Nagashima, M1
Moriyama, A1
Sugishita, Y1
Kadoya, K1
Kitahara, T2
Takagi, R1
Urita, T1
Oshiro, T1
Okazumi, S3
Katoh, R1
Yoshita, H1
Ueda, A4
Kajiura, S2
Kato, H2
Kawabe, H1
Tomizawa, G1
Horikawa, N2
Yabuhita, K1
Note, M1
Sugiyama, T3
Xia, HW1
Ge, XJ1
Zhang, YC1
Tang, QL1
Kline, CL2
Schiccitano, A1
Sheikh, H1
Harvey, HA1
Mackley, HB1
McKenna, K1
Poritz, L1
Messaris, E1
Stewart, D3
Sivik, J2
Shi, M4
Lu, CY5
Hu, HM3
Huang, ML3
Deng, G1
Zhang, K5
Park, MI3
Moon, W2
Kim, SE2
Ku, KH1
Song, SE1
Lei, H2
Zhong, Y2
Naeim, A2
Ward, PR1
Wang, HJ2
Dichmann, R2
Liem, AK2
Chan, D3
Hu, EH2
Tchekmedyian, NS2
Hecht, JR9
Tamura, S1
Kubo, N4
Ijichi, K1
De Re, V1
Caggiari, L1
De Zorzi, M1
Racanelli, V1
D' Andrea, M1
Yilmaz, M4
Turkington, RC1
Allen, WL7
Stevenson, L4
McLaughlin, K1
Diaz, T2
Tejero, R1
Moreno, I3
Ferrer, G1
Cordeiro, A1
Artells, R2
Navarro, A2
Hernandez, R2
Tapia, G1
Monzo, M3
Spindler, KL1
Ploen, J3
Nishitani, H3
Akiyoshi, K4
Abrams, TA1
Meyer, G1
Moloney, J1
Collura, A3
Lagrange, A3
Svrcek, M3
Marisa, L3
Buhard, O3
Guilloux, A1
Wanherdrick, K2
Dorard, C2
Taieb, A1
Saget, A2
Loh, M2
Soong, R4
Platell, C2
Mews, A1
Iacopetta, B13
De Thonel, A2
Seigneuric, R1
Marcion, G1
Chapusot, C1
Bouvier, AM1
Gaub, MP4
Senet, P1
Delarue, P1
Arzouk, H1
Lacoste, C1
Coquelle, A2
Lefèvre, JH3
Parc, Y2
Biard, DS1
Fléjou, JF3
Garrido, C2
Duval, A3
Barrios, CH1
del Giglio, A2
Dutra, C1
Forones, NM1
Correa, M1
Portella, Mdo S1
Passos, VQ1
Chinen, RN1
van Eyll, B3
López-Ríos, F2
Plaza, C1
García, E1
Hernando, O1
Rubio, C1
Duran, AO4
Karaca, H7
Berk, V8
Bozkurt, O4
Ozaslan, E4
Ozkan, M9
Haller, D2
Cartwright, T8
McKenna, E3
Herbertson, RA1
Lee, FT1
Chappell, B1
Cavicchiolo, T1
Saunder, T1
O'Keefe, GJ1
Murphy, R1
Hopkins, W1
Scott, FE1
Scott, AM3
Uehara, K3
Mashita, N1
Kobayashi, D2
Fujii, T5
Sugimoto, H2
Koike, M4
Nomoto, S1
Fujiwara, M4
Kodera, Y4
Munakata, K2
Ozaki, M3
Konno, M1
Raab, HR2
Weitz, J5
Hartmann, JT8
Stoehlmacher-Williams, J2
Ockert, D2
Jaeger, D1
Steger, U1
Suedhoff, T1
Rentsch, A1
Elsoueidi, R1
Craig, J1
Mourad, H1
Richa, EM1
Rambach, L1
Lee, AM1
Diasio, RB8
Rosmarin, D2
Church, D1
Johnstone, E3
Love, S2
Julier, P2
Nicholson, G2
Gonzalez-Neira, A4
Sargent, D4
McLeod, H5
Zanger, UM1
Schwab, M1
Braun, M2
Thompson, L3
Ribelles, N3
Afzal, S6
Enghusen, H1
Etienne-Grimaldi, MC13
Wadelius, M2
Garmo, H3
Gusella, M6
Sharma, R5
Kleibl, Z2
Morel, A9
Midgley, R5
Wheeler, HE1
Pita, G3
de la Torre-Montero, JC1
Alonso, R1
Lopez-Fernandez, LA4
Alba, E2
Dolan, ME1
Lau, LF1
Williams, DS2
Christophi, C1
Muralidharan, V1
Dirican, A3
Kucukzeybek, Y2
Alacacioglu, A3
Varol, U4
Aksun, S1
Bayoglu, IV2
Demir, L2
Coban, E2
Sutcu, R1
Tarhan, MO2
Calderaro, J1
Zafrani, ES1
Hart, L1
Rowland, K2
Ansari, R3
Chowhan, N2
Keaton, M1
Hainsworth, JD7
Childs, BH2
Chirica, M1
Tranchard, H1
Balladur, P1
Afchain, P3
Paye, F3
Rahbari, NN2
Reissfelder, C2
Büchler, MW2
Koch, M1
Jennings, BA2
Willis, G2
Suzuki, H5
Asao, T4
Tsutsumi, S4
Wada, S1
Araki, K4
Watanabe, A4
Tsukagoshi, M1
Kuwano, H7
Morganti, AG2
Mignogna, S2
Caravatta, L2
Deodato, F2
Macchia, G2
Plantamura, NM1
Massaccesi, M1
Picardi, V2
Cilla, S2
Shigaki, H1
Murata, A3
Sugihara, H1
Etoh, K1
Ishimoto, T1
Iwatsuki, M2
Baba, Y6
Iwagami, S1
Yoshida, N1
Rong, Z1
Martel, G1
Vandenbroucke-Menu, F1
Lapointe, R1
Yin, H1
Qiao, WB1
Zhang, HY2
You, QS1
Chen, CF2
DʼAngelica, MI1
Correa-Gallego, C1
Gewirtz, AN1
Fong, Y13
Pagnamenta, A1
Kaur, K1
Howarth, K1
Freeman-Mills, L1
Fernández-Rozadilla, C2
Ruiz-Ponte, C2
Castellvi-Bel, S2
Taylor, J1
Slavicek, L1
Pavlik, T4
Bortlicek, Z5
Melichar, B7
Vyzula, R6
Finek, J3
Majek, O1
Dusek, L5
Chung, M1
Cho, MS1
Baek, SJ1
Hur, H1
Ayoub, JP1
Moore, MJ9
Asmis, TR1
Schwartz, JD1
Ballal, S1
Flis, S3
Gnyszka, A2
Flis, K2
Stec, R2
Bodnar, L2
Smoter, M1
Korniluk, J1
Kuchar, A1
Młot, B1
Szczylik, C3
Smith, DL1
Sequeira, M1
Bates, RC1
Proia, DA1
Schwartzberg, LS4
Go, WY2
Miyake, Y5
Goto, A6
Shirao, K16
Ahn, JH2
Yu, HK1
Hong, SW1
Kim, SJ1
Adams, R3
Pugh, C1
Sydes, B1
Sizer, B1
Lowdell, C1
Butler, R2
Yamagiwa, K1
Shigematsu, T1
Shirai, M1
Amemori, K1
Sunda, K1
Koike, C1
Primrose, J2
Valle, J4
O'Reilly, D1
Siriwardena, A1
Hornbuckle, J1
Peterson, M1
Rees, M1
Stanton, L1
Dixon, E4
Little, L1
Bowers, M1
Pugh, S1
Garden, OJ2
Kasliwal, MK1
Tan, LA1
O'Toole, JE1
Beijers, AJ2
Mols, F2
Vreugdenhil, G5
Palshof, JA1
van den Berg, MW1
Sloothaak, DA1
Dijkgraaf, MG1
van der Zaag, ES1
Bemelman, WA1
Bosker, RJ1
Fockens, P1
ter Borg, F1
van Hooft, JE1
Doherty, GA1
Barbazán, J1
Muinelo-Romay, L1
Vieito, M1
Díaz-López, A1
Cano, A1
Gómez-Tato, A1
Casares de Cal, Mde L1
Abal, M1
Vamvakas, L9
Karampeazis, A2
Kakolyris, S12
Christophylakis, C2
Boukovinas, I3
Polyzos, A8
Choi, PR1
Lee, GW1
Van Nieuwenhove, Y1
Putte, DV1
Pattyn, P2
Bolonesi, RM1
Rogers, JE1
Bécouarn, Y7
Cany, L2
Pulido, M1
Beyssac, R1
Le Morvan, V2
Béchade, D1
Brunet, R6
Aitouferoukh, S1
Lalet, C1
Mathoulin-Pélissier, S1
Robert, J6
García-Girón, C7
Cirera, L3
Bustos, IA1
Sotelo, MJ2
Aguado, C2
Feng, QY1
Chen, JW1
Chang, WJ1
Love, SB2
Larsen, M1
Shanyinde, M1
Waters, R1
Grainger, L1
Shearwood, V1
Brooks, C1
Gibson, O1
Young, AM1
Tarassenko, L1
Han, GH1
Huang, JX1
Matsumura, Y4
Hu, AP1
Li, SL1
Grande, E1
Afonso, R1
Reina, JJ5
Campos, JM5
Martínez, V1
Angeles, C1
Mross, K4
Scheulen, M2
Kanefendt, F2
Sörgel, F1
Jaehde, U6
Moritz, B3
Büchert, M2
Mahamat, A2
Chazal, M6
Olschwang, S2
Formento, JL10
Formento, P10
Sudaka, A1
Abderrahim-Ferkoune, A2
Benchimol, D3
Houry, S2
Faucheron, JL2
Letoublon, C8
Gilly, FN2
Delpero, JR8
Lasser, P6
Pradere, B2
Pezet, D12
Penault-Llorca, F1
Daher Abdi, Z1
Prémaud, A1
Urien, S2
Sauvage, FL1
Martin, J1
Leobon, S1
Marquet, P1
Rousseau, A1
Okoshi, K2
Yamada, M1
Arao, T1
Matsumoto, K1
Togashi, Y1
Hirashima, Y6
Okita, NT5
Honma, Y3
Nakagawa, K7
Hoshino, S5
Naito, M6
Tanimura, S3
Mogi, A2
Tamura, K2
Yamashita, Y8
Yildiz, I1
Oktay, E1
Degirmenci, M1
Barutca, S3
Fang, JM1
Xue, P1
Song, WF2
Gu, HL1
Wang, LW3
McRee, AJ1
Davies, JM2
Sanoff, HG1
Bernard, S2
Dees, EC1
Keller, K1
Fu, L1
Wang, E2
Alonso-Espinaco, V1
Marmol, M2
Ortego, J1
Gallego, R3
Lozano, JJ1
Marshall, JL10
Lou, H1
Lou, F1
Gong, L1
Jing, X1
Baldane, S1
Dikilitas, M4
Er, O4
Skovlund, E3
Kersten, C3
Dalsgaard, AM1
Yilmaz, MK2
Fokstuen, T6
Usiakova, Z1
Kiss, I4
Kohoutek, M2
Benesova, V1
Abrahamova, J2
Zulato, E1
De Paoli, A1
Griguolo, G1
Esposito, G1
De Salvo, GL1
Rugge, M1
Nardin, M1
Di Grazia, L1
Indraccolo, S1
Hsiao, HT1
Xing, L1
Ling, CC1
Li, GC1
Xie, S1
Xu, W2
Qin, Z1
Rincón, R2
Manso, R3
Aguilera, O1
Cartenì, G6
Montesarchio, V3
Tatangelo, F4
Serra, O1
Casado, E7
Bosch, C4
Bohn, U2
Pérez-Carrión, R4
Carmona, A2
Martínez-Marín, V1
Park, JM1
Saito, N3
Takiguchi, N3
Ohue, M8
Akaike, M4
Kubo, Y1
Moriya, Y9
Liu, HC1
Yen, LC3
Chang, JY1
Huang, JJ2
Hakim, L1
Alias, E1
Makpol, S1
Ngah, WZ1
Morad, NA1
Yusof, YA1
Kang, KA1
Piao, MJ1
Kim, KC1
Yao, CW1
Cha, JW1
Maeng, YH1
Chang, WY1
Moon, PG1
Baek, MC1
Hyun, JW1
Sabino, FD1
Campos, CF1
Caetano, CE1
Trotte, MN1
Oliveira, AV1
Marques, RG1
Chao, TH1
Chen, WY1
Chen, PL1
Mao, FC1
Schreiber, V1
Kitzmueller, M1
Poxhofer, M1
Gintersdorfer, S1
Neudorfer, C1
Lichtneckert, M1
Dittrich, C3
Czejka, M5
Farkouh, A3
Buchner, P1
Georgopoulos, A2
Schueller, J5
Gruenberger, B11
Vargas, GM1
Parmar, AD1
Sheffield, KM1
Tamirisa, NP1
Brown, KM1
Riall, TS1
Ochiai, T13
Umeki, M2
Miyake, H2
Iida, T1
Okumura, M1
Ohno, K2
Sakamoto, M1
Tsumura, H1
Naitou, H1
Fukui, T2
del Puerto-Nevado, L1
Erten, C1
Somali, I1
Can, A1
Akyol, M1
Yildiz, Y1
Koyuncu, B1
Ward, P1
Koca, D2
Ünal, OÜ1
Öztop, I1
Andreoli, SC1
Gasparini, NJ1
de Carvalho, GP1
Garicochea, B1
Pogue, RE1
de Andrade, RV1
Dutton, SJ1
Kenealy, N1
Sharma, RA2
Chaix, M1
Altaf, R1
Lund Brixen, A1
Kristensen, B1
Chang, YY1
Schütte, K1
Ehninger, G2
Dermitzakis, EV1
Kimiskidis, VK1
Eleftheraki, A1
Lazaridis, G1
Konstantis, A1
Basdanis, G6
Tsiptsios, I1
Georgiadis, G1
Nam, JK1
Park, JK2
Min, do S1
Kuh, HJ3
Subbiah, IM1
Blackmon, SH1
Correa, AM1
Vaporciyan, AA1
Swisher, SG1
Keefe, DM1
Elting, LS2
Nguyen, HT1
Grunberg, SM1
Bonaventura, A1
Selva-Nayagam, S1
Barsevick, A1
Koczwara, B1
Sonis, ST1
Mei, Z1
Cui, A1
Tan, XF1
Tan, HT1
Lim, TK1
Chung, MC1
Landsman-Blumberg, PB1
Carter, GC1
Johnson, BH1
Sedgley, R1
Nicol, SJ2
Shankaran, V3
Cainap, C1
Qin, Q2
Ricker, JL1
Fischer, J1
McKee, MD1
Carlson, DM1
Volz, NB1
El-Khoueiry, RE1
Li, JE1
Kardosh, A1
Scherer, SJ1
Hielscher, J2
Scholz, M2
Müller, S2
Niederle, N5
Rost, A2
Lindig, RU1
Rossius, L2
Sclafani, F1
Williams, M2
Singer, RA1
Lerner, A1
Chen, HH3
Chen, WT2
Fang, CY2
Chou, YH1
Lin, BW1
Yeh, CH2
Hsu, HH1
Ting, WC1
Yang, MC2
Tan, EC2
Tejani, MA1
ter Veer, A1
Milne, D1
Ottesen, R1
Skibber, J3
Weiser, M2
Wilkinson, N1
Cohen, SJ3
Sameshima, S2
Ina, K4
Yin, Y6
Guo, R1
Ibrahim, JG2
Olajide, OA1
Atluri, PM1
Inzerillo, JJ1
Chay, CH1
Ikeya, T1
Sugano, K5
Nagahara, H2
Ohtani, H2
Hirakawa, K5
Miyamae, Y1
Igarashi, T2
Hirai, K2
Tsukagoshi, H1
Yoshinari, D1
Sunose, Y1
Takeyoshi, I3
Danno, K2
Miyazaki, S2
Kubota, M1
Kawada, J1
Fukui, A1
Iwase, K3
Okagawa, Y2
Hisai, H1
Koshiba, Y1
Wada, H3
Miyazaki, E1
Kanari, Y1
Kawano, Y3
Iyama, S3
Miyanishi, K3
Kobune, M2
Kato, J3
Haga, N9
Sano, M5
Mohelnikova-Duchonova, B2
Frías, C1
Echave, M1
Oyagüez, I1
Rubio, M1
Giménez, E1
Naoshy, S1
Kalikaki, A1
Politaki, H1
Apostolaki, S1
Papadimitraki, E1
Georgoulia, N1
Tzardi, M2
Mavroudis, D12
Dedić Plavetić, N1
Rakušić, Z1
Ozretić, D1
Simetić, L1
Krpan, AM1
Bišof, V1
Luccchetti, J1
Smyth, EC1
Nardecchia, A1
Słomian, G1
Świętochowska, E1
Malinowska-Borowska, J1
Kasperczyk, S1
Rogalska, A1
Nowak, P1
Chiang, HC1
Hsiao, KH1
Kuo, ML1
Shigeta, K3
Ishii, Y5
Zhu, LM1
Zhao, YZ1
Ju, HX1
Liu, BX1
Yang, YS1
Zhong, HJ1
Yao, L2
Xia, L3
Pan, L2
Silvestris, N6
Simone, G6
Partipilo, G1
Scarpi, E2
Brunetti, AE1
Paradiso, A6
Mangia, A3
Nan, H1
Parikh, N1
Jiang, ZQ1
Maru, D4
Elvin, P1
Gallick, G1
Kanterman, J1
Sade-Feldman, M1
Biton, M1
Ish-Shalom, E1
Lasry, A1
Goldshtein, A1
Hubert, A1
Baniyash, M1
Ramcharan, KS1
Lip, GY1
Stonelake, PS1
Blann, AD1
Luo, H2
Ding, P1
Pan, Z1
Wan, D1
Hjelmgren, J2
de Liège, F1
Lanier, J1
Knox, H1
Barber, B5
Findlay, VJ1
Nogueira, LM1
Hurst, K1
Quirk, D1
Ethier, SP1
Staveley O'Carroll, KF1
Watson, DK1
Camp, ER1
Soon, SS1
Chia, WK1
Chan, ML1
Ho, GF1
Jian, X1
Tan, CS1
Sharma, A2
Mehta, S1
Ali, R1
Toh, HC2
Wee, HL1
Ress, AL1
Stiegelbauer, V1
Schwarzenbacher, D1
Deutsch, A1
Perakis, S1
Ling, H1
Ivan, C1
Calin, GA1
Rinner, B1
Pichler, M2
Quinaux, E5
Ni, J1
Luo, Z1
Thomaidis, T2
Maderer, A2
Formentini, A4
Bauer, S1
Trautmann, M1
Schwarz, M1
Neumann, W1
Kittner, JM1
Schad, A2
Link, KH8
Rey, JW1
Weinmann, A1
Hoffman, A1
Galle, PR13
Kornmann, M8
Jackson, CG1
Sharples, K1
Thompson, PI1
O'Donnell, A1
Robinson, BA3
Perez, DJ1
Isaacs, R3
Deva, S1
Hinder, VA1
Findlay, MP5
Okabe, H8
Hirashima, K1
Imamura, Y3
Chikamoto, A4
Nakayama, N2
Nagaraju, GP1
Alese, OB1
Diaz, R4
Martino-Echarri, E1
Henderson, BR1
Brocardo, MG1
Goldstein, DA4
Ayer, T2
Howard, DH2
Lipscomb, J2
Harvey, RD1
Flowers, CR3
Petersen, V1
Schulze, M3
Seraphin, J1
Hoeffkes, HG1
Valdix, AR1
Schroeder, J1
Herrenberger, J1
Leutgeb, B1
Kutscheidt, A1
Lunardi, G1
Inno, A2
Magarotto, R1
Duranti, S1
Messa, MG1
Mucchino, C1
Cirillo, M2
Zuo, D1
Ying, G1
Wu, DW1
Chang, SW1
Chen, TH1
Kirstein, MM1
Lange, A1
Prenzler, A1
Manns, MP1
Vogel, A2
Linnemann, D1
Osterlind, K1
Høgdall, EV1
Chen, HM1
Cortesi, E12
Spadi, R3
Amoroso, D4
Boni, C4
Qazi, F2
van Kuilenburg, AB9
Meijer, J1
Hennekam, RC1
Vijzelaar, R1
Sharma, MR1
Gray, E1
Karrison, TG1
di Gaetano, C1
Novotny, J4
Matullo, G1
Ueno, S2
Kuramoto, M1
Kabashima, A1
Takahashi, I2
Natsugoe, S3
Agarwal, A2
Daly, KP1
Butler-Bowen, H1
Ong, SJ1
Ong, SY3
Chong, SS1
Teo, YY1
Lee, CG1
Dutel, JL1
Khalil, A3
Hadengue, A1
Dalban, C1
Brucker, P1
Flesch, M10
Carola, E18
Martin, P1
Vaillant, E1
Fernandez-Plana, J1
Saigi, E3
Tjan-Heijnen, VC1
Faber, CG1
van de Poll-Franse, LV1
Fu, Q2
Luo, S2
Chung, IJ4
Lee, JW4
Jo, SJ2
Brunner, S1
Mey, U2
Camenisch Gross, U1
Freyholdt, T1
Cathomas, R3
Amaraneni, A1
Seth, A1
Itawi, EA1
Chandana, SR1
Bensch, F1
van Rooijen, JM1
Schröder, CP1
Reyners, AK1
Sebagh, M3
Baillie, G1
Faitot, F1
Vitadello, F1
Xu, E1
Lai, M1
Kameoka, S4
Mochizuki, I1
Vishwanath, RL2
Bhargava, P2
Nöpel-Dünnebacke, S1
Stadler, ZK1
Cao, R1
Hu, L2
Wang, CZ7
Anderson, S1
Yuan, CS7
Zhang, XP1
Van Buskirk, M2
Thurston, K2
Cade, DN2
Rahman, A1
Akinwande, O1
Miller, A1
Hayes, D1
O'Hara, R1
Tomalty, D2
Martin, RC4
Vandamme, M1
Pauwels, W1
Bleecker, JD1
Kim, MK2
Di Caro, G1
Wong, J2
Shalapour, S1
Wan, J2
Sanchez-Lopez, E1
Wu, LW1
Fearon, E1
Grivennikov, SI1
Karin, M1
Dörsam, B1
Kaina, B1
Ding, HH1
Wu, WD1
Ji, ZY1
Jin, JH1
Wang, JJ2
Mudan, S3
Lasserre, S1
Hermann, F1
Yokoyama, S4
Ieda, J1
Mitani, Y1
Takifuji, K4
Hotta, T6
Matsuda, K5
Shively, JE2
Yamaue, H5
Kong, S1
Miao, R1
Sheng, H1
Yüce, S1
Seker, MM1
Koç, S1
Uysal, IO1
Kaçan, T1
Doğan, M2
Babacan, NA1
Lv, F1
Xia, Z2
Ohishi, T2
Ohnuma, H1
Hirakawa, M2
Osuga, T1
Murase, K1
Mizuguchi, T2
Furuhata, T4
Petrelli, N5
Roth, A6
Gibson, F1
Briani, C3
Argyriou, AA3
Izquierdo, C1
Velasco, R3
Campagnolo, M1
Alberti, P3
Frigeni, B1
Cacciavillani, M2
Cortinovis, D5
Cazzaniga, M6
Bruna, J3
Cavaletti, G3
Kalofonos, HP9
Carlsen, AL1
Heegaard, NH1
Oldenhuis, CN1
Loos, WJ1
Esteves, B1
van Doorn, L2
Cotreau, MM1
Strahs, AL1
den Hollander, MW1
Gietema, JA1
de Vries, EG5
Eskens, FA3
Kubáčková, K2
Pikus, T1
Linke, Z2
Pokorná, P1
Custodio, AB1
Mo, JS1
Alam, KJ1
Kang, IH1
Park, WC1
Choi, SC1
Moon, HB1
Yun, KJ1
Chae, SC1
Koeberle, D2
Betticher, DC1
Baertschi, D1
Matter, K1
Winterhalder, R1
Borner, M8
Moosmann, P1
Kollar, A1
Saletti, P4
Frueh, M1
Kueng, M1
Popescu, RA2
Schacher, S1
Hess, V1
Herrmann, R21
Melezínek, I1
Beier, F5
Stroh, C3
van Krieken, JH7
Nygren, P6
Talmon, G3
Wade, R1
Duarte, A1
Simmonds, M1
Rodriguez-Lopez, R1
Duffy, S1
Woolacott, N1
Spackman, E1
Qiao, Z1
Qian, W1
Ying, J1
Tsujii, M1
Kondo, J1
Kato, M6
Akasaka, T1
Shiraishi, E1
Hiyama, S2
Tsujii, Y1
Maekawa, A1
Kawai, S1
Fujinaga, T1
Araki, M1
Shinzaki, S1
Watabe, K1
Nishida, T1
Iijima, H1
Takehara, T1
Kwak, EL1
Heiskala, M1
de La Bourdonnaye, G1
Mita, M1
Kon, M1
Sakaguchi, Y1
Ihaya, T1
Choi, DR1
Kim, BC1
Choi, YK1
Kim, JB1
Song, HH1
Tao, L1
Yang, JK1
Zhao, AG1
Zhu, YJ1
Ciarlo, A2
Bertolini, A4
Verusio, C2
Aitini, E3
Iacovelli, R3
Dotti, KF3
Maggi, C3
Bajetta, E12
Toden, S2
Okugawa, Y4
Jascur, T1
Wodarz, D1
Komarova, NL1
Ghasemi, Z1
Dinarvand, R1
Mottaghitalab, F1
Esfandyari-Manesh, M1
Sayari, E1
Atyabi, F1
Nipp, RD1
Marton, E1
Liegl-Atzwanger, B1
Knittelfelder, R3
Lindner, E1
Streubel, B1
Linot, B1
Palesh, O1
Krebs, MG1
Renehan, AG1
Backen, A1
Hasan, J1
Valle, JW3
Morris, K1
Beech, J1
Ashcroft, L1
Dive, C2
Kozak, MM1
von Eyben, R1
Pai, J1
Vossler, SR1
Limaye, M1
Anderson, EM1
Shaffer, JL1
Longacre, T1
Pai, RK1
Koong, AC1
Chang, DT1
Baba, K1
Oshita, A1
Kohyama, M1
Inoue, S3
Kuroo, Y1
Nakamura, H2
Tazaki, T1
Sasaki, M1
Daimaru, Y1
Nakamitsu, A1
Cui, JF1
Chen, MB2
Zhang, QD1
Lu, PH1
Marks, E1
Rizvi, SM1
Martelli, S1
Piacentini, P1
Malik, H1
Khan, AZ2
Berry, DP5
Cameron, IC1
Pope, I1
Sherlock, D2
Helmy, S1
Byrne, B1
Thompson, M1
Pulfer, A1
Davidson, B1
Paré-Brunet, L1
Sebio, A3
Salazar, J5
Berenguer-Llergo, A1
Río, E1
Barnadas, A6
Baiget, M9
Vitello, S3
D'Amico, M2
Abdallah, EA1
Fanelli, MF1
Buim, ME1
Machado Netto, MC1
Gasparini Junior, JL1
Souza E Silva, V1
Dettino, AL1
Mingues, NB1
Romero, JV1
Ocea, LM1
Rocha, BM1
Alves, VS1
Araújo, DV1
Chinen, LT1
Nanni, O1
Tassinari, D5
Turci, D6
Fontana, A5
Mucciarini, C1
Ragazzini, A1
Amadori, D10
Bruhn, MA1
Mann, KP1
Simes, J4
Van Hazel, G4
Robinson, B3
Yoshinami, T1
Yagi, T1
Takeuchi, Y4
Higashino, K1
Yano, M1
Nukatsuka, M3
Nakagawa, F5
Saito, H5
Sakata, M1
Uchida, J6
Takechi, T5
Kotasek, D1
Burris, HA2
Stephenson, J2
Warner, DJ1
Goldstein, D9
Pilat, N1
Grünberger, T1
Längle, F2
Mittlböck, M1
Perisanidis, B1
Kappel, S1
Wolf, B1
Starlinger, P2
Kührer, I1
Mühlbacher, F1
Kandioler, D1
Neumann, JH1
Falvella, FS2
Cheli, S2
Mazzali, C1
Gariboldi, M1
Pierotti, MA1
Sottotetti, E2
Mennitto, R2
Bossi, I3
Clementi, E2
Lin, L3
You, H1
Pei, Y1
Zhang, ZY1
Rateesh, S1
Shekar, K1
Naidoo, R1
Mittal, D1
Bhaskar, B1
Matono, K1
Tsuda, H1
Ushijima, M1
Uchida, S2
Shirouzu, K6
Dhelens, C1
Bonadona, A1
Chapuis, C1
Potton, L1
Bedouch, P1
Schwebel, C1
Ramos-Díaz, R1
Nazco-Casariego, GJ1
González-Perera, I1
Pérez-Pérez, JA1
Coinu, A1
Benson, A3
Guillén Ponce, C1
Macpherson, IR1
Wagner, A1
Luigi Garosi, V1
Grunert, J1
Fakih, MG8
Maglinte, GA2
Esposito, C1
Saneeymehri, SS1
Markey, KR1
Mahipal, A1
Ucar, M1
Elmali, F2
Tung, JY1
Hsiao, CD1
Wang, P2
Lee, MH1
Rubino, L1
Villa, E1
Tronconi, MC2
Gerardi, C1
Floriani, I5
Destro, A1
Raschioni, C1
Simkens, LH4
May, A1
Creemers, GJ5
Loosveld, OJ2
de Jongh, FE1
Erdkamp, FL5
Erjavec, Z3
van der Torren, AM1
Tol, J8
Braun, HJ1
Nieboer, P1
van der Hoeven, JJ1
Haasjes, JG1
Wals, J4
Cats, A7
Derleyn, VA2
Honkoop, AH3
Utsumi, H1
Nara, S1
Esaki, M1
Lutrino, SE2
Llimpe, FR1
Pisa, FE1
Kim, GP4
Dou, R1
Stremitzer, S3
Stift, J1
Tamandl, D8
Irving, GR1
Iwuji, CO1
Li, BL1
Hu, XL1
Zhao, XH1
Sun, HG1
Zhou, CY1
Ye, D1
Simms, L1
Wakasa, K1
Kawabata, R1
Nakao, S1
Hattori, H1
Oda, S2
Chow, AK2
Cheng, NS1
Lam, CS2
Ng, L2
Wong, SK1
Wan, TM1
Man, JH1
Cheung, AH1
Yau, TC2
Poon, JT2
Law, WL3
Pang, RW1
Ikeda, J1
Nishisaki, H2
Kraehe, P2
Webber, EM1
Kauffman, TL1
O'Connor, E1
Goddard, KA1
Schoellhammer, HF1
Goldner, B1
Merchant, SJ1
Kessler, J1
Gagandeep, S1
Das, UN1
Bencsikova, B1
Halamkova, J1
Ostrizkova, L1
Valik, D1
Zdrazilova-Dubska, L1
Iwayama, Y1
Tsuruma, T2
Toyota, N1
Torigoe, T1
Sato, N1
Yokogawa, T1
Oguchi, K1
Kazuno, H2
Tanaka, N5
Osada, A1
Caporale, M2
Ricchini, F1
Bernardi, FF1
Kunieda, K6
Kurachi, K2
Srinivas, US1
Dyczkowski, J1
Mansour, WY1
Borgmann, K1
Dobbelstein, M1
Vishnevskiĭ, AV1
Andreĭtseva, OI1
Kharazov, AF1
Gritsiuta, AI1
Kalinin, DV1
Zhavoronkova, OI1
Liu, RL1
Deng, YZ1
Li, WD1
Yoshioka, R1
Okura, N1
Amankwatia, EB1
Chakravarty, P1
Carey, FA1
Weidlich, S1
Steele, RJ1
Munro, AJ1
Wolf, CR1
Smith, G1
Wu, XR1
Cui, JG1
Xia, YX1
He, WJ1
Yasui, M3
Ohno, Y1
Sekimoto, M5
Nezu, R4
Tokka, A1
Liao, D1
Bai, M1
Dong, N1
You, Q2
Muhammand, S1
Tanaka, S9
Sasaki, E1
Hibi, K4
Sakuyama, T3
Sekikawa, T1
Nishina, H1
Klinkhardt, U1
Duecker, K1
Huiskens, J1
van Gulik, TM1
van Lienden, KP1
Engelbrecht, MR1
Meijer, GA2
van Grieken, NC1
Schriek, J1
Keijser, A1
Molenaar, IQ1
de Jong, KP1
Dejong, KH1
Kazemier, G1
Ruers, TM1
Karlberg, M1
Vistisen, K1
Lindh, B1
Bjerregaard, JK1
Terwey, JH2
Papaxoinis, G4
Gourgioti, G2
Raptou, G2
Scopa, CD2
Azvolinsky, A1
van Staveren, MC1
Opdam, F1
Maring, JG2
Scudellari, M1
Yang, IP1
Wu, JY3
Kuo, CH2
Tseng, FY1
James, MI1
Iwuji, C1
Irving, G1
Griffin-Teal, N1
Greaves, P1
Dennison, A1
Metcalfe, M1
Garcea, G2
Lloyd, DM1
Rothbarth, J1
Eggermont, AM1
Dakhil, S2
Saleh, M1
Piperdi, B2
Cline-Burkhardt, M1
Oshiro, M2
Roselló, S2
Laffranchi, B1
Jego, V1
von Richter, O1
Hamaya, Y2
Guarinos, C1
Tseng-Rogenski, SS1
Iwaizumi, M3
Das, R1
Carethers, JM8
Li, ZJ1
Li, LF1
Wu, WK2
Chan, RL1
Liu, YW1
Ren, SX1
Chan, KM2
Cho, CH1
Volovat, SR1
Volovat, C1
Negru, SM1
Danciu, M1
Scripcariu, V1
Pinheiro, C1
Miranda-Gonçalves, V1
Pereira, H1
Moyer, MP1
Preto, A1
Kocak, I2
Petruzelka, L1
Oberg, AL1
Sueyoshi, S2
Higashi, H4
Matsuda, H1
Ayadi, M2
Bouygues, A1
Ouaret, D1
Ferrand, N1
Chouaib, S1
Thiery, JP1
Muchardt, C1
Sabbah, M1
Lam, JY1
McConnell, YJ2
Rivard, JD1
Temple, WJ2
Mack, LA2
Zhou, N1
Bai, C1
Zhao, RC1
Frontini, L6
Rota, S1
Pepe, A1
Signoriello, S1
De Placido, S3
Makoshi, Z1
Perrott, C1
Al-Khatani, K1
Al-Mohaisen, F1
Anderson, BJ1
Peterson, LL1
Kroep, JR1
Polee, M1
van Groeningen, CJ18
Beeker, A1
Erdkamp, F1
Weijl, N1
van Bochove, A3
Kapiteijn, E1
Stiggelbout, AM1
Nortier, HW1
Pérez Hoyos, MT1
Díaz de Corcuera, I1
Vidal Arbués, A1
García de la Torre, M1
Choueiri, MB1
Gross, AM1
Huang, JK1
Ideker, T1
Fanta, P1
Kit, OI1
Vladimirova, LY1
Vodolazhskiy, DI1
Abramova, NA1
Dvadnenko, KV1
Poschau, M1
Dickreuter, E1
Singh-Müller, J1
Zscheppang, K1
Eke, I1
Cordes, N1
Butzke, B1
Oduncu, FS1
Severin, F1
Pfeufer, A1
Stollenwerk, B1
Rogowski, WH1
Uzzan, B4
Nicolas, P4
Su, D1
Jiao, S1
Giommoni, E2
Latiano, T1
Pavese, I2
Azzarello, D1
Pastina, I1
Mogavero, S1
Angelini, V1
Pazzagli, M1
Wu, NC1
Su, SM1
Lin, TJ1
Chin, J1
Hou, CF1
Yang, JY1
Liu, WS1
Chang, LC1
Imperatori, M1
Picardi, A3
Vespasiani Gentilucci, U1
Gallo, P1
Fausti, V1
Spalato Ceruso, M1
Gotoh, M4
Yoshizuka, N1
Ozaka, M3
Weickhardt, AJ1
Parry, MM1
Asadi, K1
Mariadason, JM1
Liu, JW2
Gao, YJ1
Chen, YM2
Cheng, T1
Mithieux, F1
Marsot, J1
Watkin, E1
Chalabreysse, P1
Scoggins, CR3
Schreeder, M2
Rilling, WS1
Laing, CJ1
Tatum, CM1
Kelly, LR1
Garcia-Monaco, RD1
Sharma, VR1
Crocenzi, TS1
Strasberg, SM3
Ota, M3
Tatsumi, K1
Suwa, H1
Shoichi, F1
Ichikawa, Y5
Kunisaki, C2
Yajima, R1
Morita, H2
Ikenishi, M1
Ueda, M2
Kuroda, A1
Tsukazaki, H1
Konishi, Y1
Matsuda, T3
Figoni, W1
Ohtori, T1
Matsuyama, K1
Satoh, H2
Sawada, Y1
Nakatsuka, E1
Chan, MT1
Kemmerling, R1
Folwaczny, M1
Balboa-Beltrán, E1
Truong, WT1
Gloria, D1
Braet, F1
Thordarson, P1
González-Alonso, P1
De Divitiis, C1
Barretta, ML1
O'Connell, D1
Varghese, B1
Yip, J2
Dolatshahi Pirooz, S1
Li, GM1
Ellen Martin, S1
Machida, K1
Liang, C1
Yeh, CT2
Adebayo, BO1
Lin, YC2
Deng, L1
Rao, YK1
Lee, WH1
Wu, AT1
Hsiao, M2
Wu, CH1
Wang, LS1
Tzeng, YM1
Patyutko, YI1
Kotelnikov, AG1
Mamontov, KG1
Podluzhny, DV1
Ponomarenko, AA1
Kos, ME1
Evande, RE1
Meza, JL1
Schwarz, JK1
She, X1
O'Donovan, TR1
Rajendran, S1
O'Sullivan, GC1
McKenna, SL1
Thomsen, M1
Indrebø, G1
Lingjærde, O1
Möhler, M3
D'Haens, G4
Latini, L2
Staines, H1
Oum'Hamed, Z1
Dressler, H1
Studeny, M1
Chan, DL1
Šišić, I1
Pojskić, B1
Mekić Abazović, A1
Kovčin, V1
Lim, T1
Lee, I2
Kleist, B1
Kempa, M1
Meurer, T1
Poetsch, M1
Deschoemaeker, S1
Di Conza, G1
Lilla, S1
Martín-Pérez, R1
Mennerich, D1
Boon, L1
Hendrikx, S1
Maddocks, OD1
Marx, C1
Myllyharju, J1
Kietzmann, T1
Vousden, KH1
Zanivan, S1
Mazzone, M1
Skoupá, J1
Jandová, P1
Garde-Noguera, J1
Gil-Raga, M1
Evgenyeva, E1
García, JA1
Llombart-Cussac, A1
Camps-Herrero, C1
Lyu, Y1
Deniz, K1
Ágoston, EI1
Baranyai, Z1
Kulka, J1
Harsányi, L1
Szász, AM1
Guo, XZ1
Ye, XL1
Xiao, WZ1
Wei, XN1
You, QH1
Che, XH1
Cai, YJ1
Chen, F1
Yu, MH1
Atanackovic, D2
Hildebrandt, B6
Stübs, P1
Brugger, W1
Hapke, G1
Steffens, CC2
Illerhaus, G2
Bluemner, E1
Stöhlmacher, J1
Xun, C1
Qi, L1
Tie-Ning, Z1
Ning, L1
Zhi-Xiao, C1
Li-Wei, W1
Sadanaga, N4
Mezi, S1
He, P2
Jung, AS1
Emile, JF2
Aust, D1
Lutz, MP6
Schlag, P11
Fisseler, A1
Ponzetti, A1
Pinta, F1
Mecca, C2
Zanini, M1
Goto, R1
Kurihara, M3
Lambrechts, D2
Thienpont, B1
Thuillier, V1
Sagaert, X1
Moisse, M1
Peuteman, G1
Margherini, E1
Lerchenmüller, CA1
Killing, B1
Depenbusch, R1
Lange, T1
Quidde, J1
Lemire, M1
Zaidi, SH1
Zanke, BW1
Gallinger, S4
Hudson, TJ1
Cleary, SP1
To, KK1
Leung, WW1
Ng, SS2
Fiore, D1
Proto, MC1
Pisanti, S1
Picardi, P1
Pagano Zottola, AC1
Butini, S1
Gemma, S1
Casagni, A1
Laezza, C1
Vitale, M1
Ligresti, A1
Di Marzo, V1
Zisterer, DM1
Nathwani, S1
Williams, DC1
Campiani, G1
Gazzerro, P1
Bifulco, M1
Lu, B1
Rutnam, ZJ1
Iwamoto, A3
Isaakidou, A1
Karantanos, T1
Sioziou, A1
Theodoropoulos, GE1
Pektasides, D1
Fontanella, C1
Bonotto, M1
Rihawi, K1
Li, PL1
Wang, LL1
Du, LT1
Yang, YM1
Wang, CX1
Naruse, T2
Kimura, Y8
Fujimoto, D1
Yamaguchi, A3
Soda, H1
Kono, E1
Park, JW1
Ryoo, SB1
Fujii, A1
Adhoute, X1
Provençal, J1
Chone, L1
Sobhani, I2
Beltjens, F1
Bengrine, L1
Kumekawa, Y1
Loriot, MA4
Lafargue, JP1
Moon, HH1
Ku, JL3
Xia, D1
Tibiche, C1
Zaman, N1
Trifiro, M1
O'Connor-McCourt, M1
Sena, P1
Mariani, F1
Mancini, S1
Benincasa, M1
Magnani, G1
Pedroni, M2
Palumbo, C1
Roncucci, L2
Okumura, H2
Murakami, H3
Kubota, H3
Tsuruta, A2
Tohyama, K1
Hirai, T4
Lim, SH1
Hwang, IG1
Grapsa, D1
Syrigos, K4
Kwon, HY1
Kim, IK1
Sohn, SK4
Tong, M2
Azadeh, P1
Mortazavi, N1
Tahmasebi, A1
Hosseini Kamal, F1
Novin, K1
Polverari, RS1
Ottone, A2
Alabiso, I3
Bitossi, R2
Forti, L3
Bertona, E1
Alabiso, O3
Aglietta, M6
Berruti, A2
Zeichner, SB1
Bartnik, CM1
Neustadter, E1
Freeman, K2
Connock, M2
Cummins, E1
Gurung, T2
Taylor-Phillips, S2
Court, R2
Clarke, A2
Sutcliffe, P3
Yuan, J1
Sun, DC1
Wang, ZK1
Dai, GH2
Min, J1
Tao, D1
Xie, D2
Granata, V2
Fusco, R1
Catalano, O2
Filice, S1
Amato, DM1
Ajavon, Y1
Castaing, D10
Kunstlinger, F6
Afshar, M1
Maki, C1
Hosomi, M1
Nishihara, M2
Katsumata, T1
Houssany, S1
Renner, J1
Boutonnet, M1
Peigne, V1
Soler, C1
Dong, J2
Rollin, J1
Payancé, A1
Gouilleux-Gruart, V2
Boisdron-Celle, M14
Azzopardi, N2
Gruel, Y1
Paintaud, G3
Gamelin, E23
Watier, H2
Uboha, N1
Peng, K1
Xie, R2
Shahriari-Ahmadi, A1
Fahimi, A1
Sadeghi, M1
Rudek, MA2
Laheru, D2
Walker, R1
Taylor, GE1
Jimeno, A4
Donehower, RC4
Purcell, WT1
Tummala, S1
Kuppusamy, G1
Satish Kumar, MN1
Praveen, TK1
Wadhwani, A1
Di Francia, R1
De Lucia, L9
Di Paolo, M1
Di Martino, S1
Del Pup, L1
De Monaco, A1
Herath, NI1
Devun, F2
Lienafa, MC1
Herbette, A2
Denys, A1
Sun, JS2
Dutreix, M2
Thomas, SA1
Tomeh, N1
Theard, S1
Hu, Y4
Gu, B1
Leng, C1
Dou, L1
Bonin, S1
Donada, M1
Bussolati, G1
Nardon, E1
Annaratone, L1
Chiaravalli, AM1
Capella, C1
Stanta, G1
Laurent, M1
Bastuji-Garin, S1
Culine, S2
Caillet, P1
Audureau, E1
Carvahlo-Verlinde, M1
Reinald, N1
LeThuaut, A1
Canouï-Poitrine, F1
Jiang, CF1
Li, DM1
Ge, X1
Shi, ZM1
Zhen, L1
Liu, LZ1
Jiang, BH1
Shimamoto, Y2
Sakoda, M1
Chiarotto, JA1
Dranitsaris, G2
Cohen, SA1
Wirtz, R1
Gkakou, C1
Kalogeras, KT2
Grady, WM1
Guan, H1
Zeng, Z1
Luo, P2
Tan, Z1
Mitchell, E5
Kröning, H4
Le-Guennec, S1
Andria, M2
Miyata, Y2
Kusumi, T2
Taniguchi, F1
Manabe, M1
Lo, L1
Amitesh, R1
Roder, D1
Moore, J2
De Bruycker, S1
Vangestel, C2
Van den Wyngaert, T1
Wyffels, L2
Wouters, A1
Staelens, S2
Stroobants, S2
Chatelut, E7
Quesada, JL1
Roblin, X1
Mendoza, C1
Buc, E3
Lin, GN1
Liu, PP1
Liu, DY1
Xiao, JJ1
Xia, ZJ1
Ye, X1
Bhattacharya, R2
Boulbes, DR1
Fan, F4
Ellis, LM6
Spång, N1
Torkzad, M1
Hug de Larauze, M2
Guering-Meyer, V1
Boucher, E6
Bonnet, I1
Andoh, M1
Yatabe, Y2
Kinoshita, T1
Hendlisz, A6
Delaunoit, T5
Varea, R1
Chao, G1
Wallin, J1
Hua, D4
Kim, MJ1
Meulendijks, D1
Henricks, LM1
Amstutz, U3
Froehlich, TK1
Largiadèr, CR4
Beijnen, JH4
de Boer, A2
Schellens, JH2
Maindrault-Gœbel, F1
Dupuis, O4
Arbaud, C1
Wang, YW1
Yeh, CG1
Cellini, F1
Padula, GD1
Buwenge, M1
Di Lullo, L3
Gambacorta, MA1
Balducci, M1
Mattiucci, GC1
Autorino, R1
Boucher, TM1
Fong, YC1
Ohnishi, T6
Nakamura, Y4
Matsuura, N1
Monden, M3
Rogowski, W2
Kap, EJ2
Seibold, P1
Scherer, D1
Habermann, N1
Balavarca, Y1
Jansen, L1
Zucknick, M2
Becker, N1
Ulrich, A2
Ulrich, CM2
Burwinkel, B1
Elvas, F1
Pak, K1
Vermeulen, P1
Gray, B3
Miyamato, Y1
Parekh, A2
Flanagan, L1
Meyer, M1
Fay, J2
Curry, S1
Duessmann, H1
John, K1
Boland, KC1
Kay, EW5
Bantel, H1
Zhang, RH1
Kang, T1
Casadei Gardini, A1
Carloni, S1
Maltoni, P1
Dorizzi, RM1
Cortesi, P1
Giannini, MB1
Lucchesi, A1
Cavalcanti, E1
Maiolino, P1
Bianco, F1
Aprea, P1
De Bellis, M1
Pecori, B1
Gallo, C3
Leone, A3
Romano, GM1
Le Roy, B1
Tixier, L1
Pereira, B1
Sauvanet, P1
Pétorin, C1
Déchelotte, P1
Balayssac, D1
Barbara, C4
Zheng, P1
Qin, X2
Xiong, BH1
Volk, AM1
Fritzmann, J1
Weber, GF1
Wulaningsih, W1
Wardhana, A1
Watkins, J1
Yoshuantari, N1
Repana, D1
Van Hemelrijck, M1
Karakulak, UN1
Aladağ, E1
Maharjan, N1
Övünç, K1
Fujimoto, T6
Maruno, K2
Fujino, S2
Dos Santos, LV2
Faria, TM1
Lima, AB1
de Moraes, ED1
Cruz, MR1
Lima, JP2
Kodaz, H1
Tozkir, H1
Albayrak, D1
Sharma, NK1
Ricke, J1
Perez, D1
Ferguson, T1
Rodríguez, J7
Wolf, I1
Ganju, V4
Walpole, E1
Tichler, T1
Powell, A1
Eliadis, P1
Price, D4
Moeslein, F1
Bower, G3
Zakari, A1
Peyton, JD1
Boccia, R1
Moskowitz, M1
Gian, V1
Lipman, A1
Waterhouse, D2
LoCicero, R1
Earwood, C1
Lane, CM2
Meluch, A1
Tran, HM1
Tovar-Camargo, OA1
Lin, DR1
Serrablo, A1
Paliogiannis, P1
Pulighe, F1
Moro, SS1
Borrego-Estella, V1
Attene, F1
Scognamillo, F1
Santi, L1
Bianco, MR1
Giuffrè, MR1
Pettinato, M1
Bugarin, C1
Garanzini, C1
Savarese, L1
Leoni, S1
Cerrito, MG1
Leone, BE1
Gaipa, G1
Grassilli, E1
Papa, M1
Lavitrano, M1
Giovannoni, R1
Shan, Z1
Jin, Z1
Mazzuca, F2
Borro, M2
Botticelli, A2
Mazzotti, E1
Marchetti, L1
Gentile, G2
La Torre, M2
Lionetto, L2
Simmaco, M2
Tai, WC1
Wong, WY1
Lee, MM1
Chan, BD1
Lu, C2
Hsiao, WL1
Zhang, JT1
Zhou, WL1
Huang, G1
Yu, F2
Yuan, C1
Ye, XC1
Ling, X1
McManus, M1
Boulbes, D1
Yoshii, Y1
Yoshimoto, M1
Kiyono, Y1
Zhang, MR1
Fujibayashi, Y1
Saga, T1
Franken, MD1
van Oijen, MG1
Bordonaro, AR1
Rachiglio, M1
Modoni, G1
He, EY1
Hawkins, NJ1
Mak, G1
Roncolato, F1
Liauw, W2
Clingan, P6
Chin, M1
Ward, RL1
El-Shemi, AG1
Refaat, B1
Kensara, OA1
Mohamed, AM1
Idris, S1
Ahmad, J1
Kim, N1
Cho, SB1
Park, YL1
Park, SY1
Myung, E1
Yu, HM1
Son, YA1
Myung, DS1
Lee, WS2
Joo, YE1
Yusof, MM1
Abdullah, NM1
Sharial, MM1
Zaatar, A2
Xiao, L1
Shroff, R1
Shaw, K1
Mills, GB1
Wolff, RA4
Hamilton, S1
Meric-Bernstam, F1
Abbruzzese, J3
Morris, J3
Quan, C1
Mao, Y2
Li, ZZ1
Zhang, ZC1
Qiu, MZ3
Shao, JY1
Malkomes, P1
Lunger, I1
Luetticke, A1
Oppermann, E1
Haetscher, N1
Serve, H1
Holzer, K1
Rieger, MA1
Tsuruta, M1
Endo, T2
Kondo, T1
Umehara, M1
Umehara, Y1
Nishikawa, S3
Tokura, T1
Matsuzaka, M1
Morita, T2
Chong, DQ1
Manalo, M1
Imperial, M1
Teo, P1
Yong, G1
Ng, M2
Tan, IB1
Chua, C1
Thanarajasingam, G1
Atherton, PJ1
Novotny, PJ2
Loprinzi, CL4
Sloan, JA2
Fourrier-Réglat, A1
Robinson, P1
Moore, N1
Lu, YM1
Chien, TM1
Huang, CN1
Lopez Lopez, R1
Roh, JK6
Chistyakov, V1
Ackland, SP8
Kopp, M1
Udovitsa, D1
Hall, M2
Tseng-Rogenski, S2
Miyajima, H1
Kanaoka, S1
Kosmacek, EA1
Chatterjee, A1
Oberley-Deegan, RE1
Vishnubalaji, R1
Hamam, R1
Yue, S1
Al-Obeed, O1
Kassem, M1
Liu, FF1
Aldahmash, A1
Alajez, NM1
Lin, WR1
Chiang, JM6
Liang, KH1
Lim, SN1
Lai, MW1
Tsou, YK1
Hsieh, TY1
Hsu, CK1
Coşkun, HŞ1
Korkmaz, L2
Karaağaç, M2
Karabulut, S1
Faruk Aykan, N1
Doruk, H1
Avcı, N1
Pozzi, C1
Cuomo, A1
Spadoni, I1
Magni, E3
Silvola, A1
Conte, A1
Sigismund, S1
Ravenda, PS1
Bonaldi, T1
Cancelliere, C1
Di Fiore, PP1
Bardelli, A2
Penna, G1
Rescigno, M1
Cravioto-Villanueva, A1
Cavazos, M1
Luna-Perez, P2
Martinez-Gomez, H1
Ramirez, ML1
Solorzano, J1
Montiel, H1
Esquivel, J4
Osawa, H1
Mittmann, N1
Giotis, A1
Lien, K1
Wong, WW1
Chan, KK1
Leuci, V1
Maione, F1
Rotolo, R1
Giraudo, E1
Sassi, F1
Migliardi, G1
Todorovic, M1
Gammaitoni, L1
Mesiano, G1
Giraudo, L1
Luraghi, P1
Bussolino, F1
Grignani, G1
Trusolino, L1
Bertotti, A1
Sangiolo, D1
McCulloch, M1
Ly, H1
Broffman, M1
See, C1
Clemons, J1
Cabart, M1
Frénel, JS1
Campion, L1
Ramée, JF1
Lu, J2
Fang, F2
Miyo, M1
Kano, Y2
Fukusumi, T1
Sun, ZZ1
Ning, K2
Tang, SC1
Nagase, M4
Eguchi Nakajima, T1
Taira, K1
Funai, S1
Okuno, T3
Kurimoto, T1
Okabe, M1
Seki, N3
Taku, K4
Tamura, F2
Nakashima, K1
Popanda, O1
Basso, M5
Dadduzio, V1
Ardito, F2
Strippoli, A1
Vellone, M3
Rossi, S1
Cerchiaro, E1
Cassano, A10
Giuliante, F4
Hanaka, J1
Nakayama, H3
Pan, W1
Ren, H1
Ming, L1
Lerchenmueller, C1
Mueller, S1
Cortejoso, L3
García-González, X1
García, MI3
Sanjurjo, M2
Fakhri, Y1
Dalsgaard, M1
Lav Madsen, P1
Sawaki, A1
Okajima, M2
Yamaguchi, Y2
Wilhelm, M1
Miller, MC2
Link, K1
Holdenrieder, S2
Bertsch, T1
Stoetzer, OJ1
Suttmann, I1
Braess, J4
Birkmann, J1
Roessler, M1
Kraff, S1
Salamone, SJ1
Barreto, R1
Waning, DL1
Zimmers, TA1
Bonetto, A1
Huynh, N1
Shulkes, A1
Baldwin, G1
Miranda, VC1
Faria, LD1
Bariani, G1
Alex, A1
Bezerra Neto, JE1
Sabbaga, J1
Lobo Dos Santos, JF1
Song, N1
Pogue-Geile, KL1
Gavin, PG1
Kim, SR1
Johnson, NL1
Lipchik, C1
Petrelli, NJ7
O'Connell, MJ24
Wolmark, N3
Pilancı, KN1
Saglam, S3
Okyar, A1
Yucel, S1
Pala-Kara, Z1
Ordu, C1
Ciftci, R1
Iner-Koksal, U1
Kaytan-Saglam, E1
Boye, K1
Jacob, H1
Frikstad, KA1
Nesland, JM1
Maelandsmo, GM1
Dahl, O8
Nesbakken, A1
Flatmark, K3
Chung, SS1
Oliva, B1
Dwabe, S1
Vadgama, JV1
Ju, HQ1
Lu, YX1
Chen, DL1
Tian, T1
Mo, HY1
Wei, XL1
Liao, JW1
Zeng, ZL1
Pelicano, H1
Aguilar, M1
Jia, WH1
Alzoubi, S1
Brody, L2
Rahman, S2
Mahul-Mellier, AL1
Mercado, N1
El-Bahrawy, M1
Silver, A2
Boobis, A1
Bell, JD1
Hajji, N1
Furushima, K2
Koike, J3
Yonemura, Y2
Kitao, H2
Kiyonari, S1
Iimori, M2
Niimi, S1
Kataoka, Y1
Akiyama, S5
Edahiro, K1
Nakanishi, R3
Tokunaga, E3
Kanaji, S1
Smalligan, RD1
Nadesan, S1
Hamidou, Z1
Garcia-Larnicol, ML1
Ruan, Z2
Yi, H1
Huo, W1
Kim, YC1
Wang, SM4
Ge, L1
Wang, YF1
Tian, JH2
Mao, L1
Zhang, JH1
Shen, XP1
Yang, KH2
Lv, WH1
Li, XD1
Zhang, MQ1
Martchenko, K1
Schmidtmann, I2
Thole, V1
Becker, M1
Wehler, TC2
Schimanski, CC6
Xun, Z1
Chemama, S1
Bayar, MA1
Lanoy, E1
Ammari, S1
Stoclin, A1
Raynard, B3
Antoun, S2
Ikezawa, N1
Shoji, H1
Daibo, K1
Sehdev, A1
Cramer, HM1
Ibrahim, AA1
Younger, AE1
Kiyomatsu, T2
Ryan, D2
Murphy, ÁC1
Hector, S3
McCawley, N2
Concannon, CG3
Vijayvergia, N1
Wong, YN1
Dotan, E2
Weyrech, J1
Dagois, S1
Sheng, YH1
Hasnain, SZ1
Tong, H1
Clarke, DT1
Lourie, R1
Oancea, I1
Wong, KY1
Lumley, JW1
Florin, TH1
Sutton, P1
Hooper, JD1
McMillan, NA1
McGuckin, MA1
Sasse, C1
Vossen, S1
Van Sant, C1
Ball, HA1
Keating, A1
Krivoshik, A1
Ushijima, H1
Horyozaki, A1
Maeda, M1
Mao, X2
Xue, L2
Chu, X2
Stanisavljević, L1
Myklebust, MP2
Leh, S2
Koshkin, S1
Danilova, A1
Raskin, G1
Petrov, N1
Bajenova, O1
O'Brien, SJ1
Tomilin, A1
Tolkunova, E1
Uthman, OA1
Hu, YL1
Feng, YY1
Bian, ZH1
Zhou, LY1
Fei, BJ1
Wang, YG1
Huang, ZH2
Azzariti, A2
Porcelli, L1
Brunetti, O1
Longo, V1
Nardulli, P1
Signorile, M1
Calabrese, A1
Quatrale, AE1
Krizkova, V1
Dubova, M1
Bruha, J2
Skala, M1
Daum, O1
Ho, C3
Winquist, E3
Rayson, D1
Stitt, L3
Tokmakejian, S1
Vincent, MD2
Schmitz, R5
Valls, AF1
Yerbes, R1
von Richter, S1
Kahlert, C1
Loges, S1
Ruiz de Almodovar, C1
Dhir, M1
Novak, S1
Euvrard, R1
Chevriaux, A1
Boidot, R1
Végran, F1
Bonnefoy, N1
Apetoh, L1
Liao, Z1
Ørum-Madsen, MS1
Nordgaard, C1
Noer, J1
Moreira, JM1
Hao, L1
Hou, A1
Shi, C1
Miao, H1
Gonçalves-Ribeiro, S1
Díaz-Maroto, NG1
Berdiel-Acer, M1
Soriano, A1
Guardiola, J1
Martínez-Villacampa, M4
Villanueva, A2
Molleví, DG2
Hoshiba, T1
Tanaka, M5
Veelenturf, S1
Binkhorst, L1
Bins, S1
Mathijssen, R1
Nan, Q1
Portnoy, D1
Ronga, P1
Paolicchi, E4
De Gregorio, V1
Crea, F4
Zhuang, R1
Cayre, A1
Jacquin, M1
Arbez-Gindre, F1
Fein, F1
Gned, D1
Bertaggia, C1
Veltri, A1
Ji, Q1
Jiang, H2
Zhuang, X1
Chen, CW2
Paschall, AV1
Redd, PS1
Heaton, CM1
Lee, JR1
Nayak-Kapoor, A1
Ahn, SJ2
Bhandare, M1
Pai, V1
Bhamre, R1
Engineer, R1
Hokuto, D1
Nomi, T1
Yamato, I1
Yasuda, S6
Obara, S1
Kawaguchi, C1
Kanehiro, H1
Porcu, L1
Torri, V3
Chong, LC1
Mølck, C1
Ryall, J1
Failla, LM1
Coates, JL1
Pascussi, JM1
Heath, JK1
Stewart, G4
Hollande, F1
Safwat, MA1
Soliman, GM1
Sayed, D1
Attia, MA1
Che, J1
Lou, Q1
Uysal, M1
Er, Z1
Güler, T1
Börüban, MC1
Bozcuk, H1
Díez de Corcuera, I1
García García, T1
Kunicka, T1
Prochazka, P1
Krus, I1
Protivova, M1
Hlavac, V1
Novak, P1
Pitule, P1
Moore, M5
Zbuk, K1
Jeyakumar, A1
Chan, T1
Spratlin, J1
Rothenstein, J1
Kudrik, F1
Kauh, J2
Kambhampati, SR1
Ramdas, N1
Binder, P1
Strevel, E1
Voron, T1
Srdjan, M1
Jadranka, A1
Ivan, D1
Branimir, Z1
Daniela, B1
Petar, S1
Velimir, M1
Zoran, K1
Zou, ZW1
Chen, HJ1
Yu, JL1
Lin, XH1
Nagayama, S4
Hida, K1
Matsuo, T2
Tada, M3
Nishitai, R1
Mitsuyoshi, A1
Yoshimura, K6
Niimi, M2
Sánchez Cendra, C1
Yun, Q1
Wang, SS1
Yang, JP1
Yang, LL1
Fu, SZ1
Wu, JB1
Letocha, H3
Fernebro, E4
Boedigheimer, M1
Twomey, B1
Fattouh, K1
Collet-Benzaquen, D1
Provensal, AM1
Castillo, C2
Combemale, P1
de la Fouchardière, A1
Cheng, AL5
Cornelio, G1
Guan, Z1
Masood, N1
Doval, DC1
Oh, ST3
Gorospe, C1
Sirachainan, E2
Hill, A3
Chatterjee, S1
Kaiho, T2
Kobayashi, S2
Maruyama, T3
Boulat, O1
He, F1
Ji, Z1
Yao, J1
Huang, A1
Onesti, CE1
Romiti, A2
Petremolo, A1
Occhipinti, M1
Falcone, R1
de la Varga, LU1
Pascual, JR1
Sarno, F1
Prieto, SH1
Lopéz-Casas, PP1
Schade, H1
Davis, L2
Kabos, P1
Gong, Y2
Zhao, T1
Ålgars, A3
Sundström, J1
Lintunen, M1
Jokilehto, T1
Kytölä, S1
Kaare, M1
Vainionpää, R1
Orpana, A2
Ristimäki, A1
Carpen, O1
Ristamäki, R8
Mehta, AM1
Huitema, AD1
Burger, JW1
Brandt-Kerkhof, AR1
van den Heuvel, SF1
Verwaal, VJ6
Peters, GJ23
Smid, K12
Meijer, E1
Leon, LG2
Badran, MM1
Mady, MM1
Ghannam, MM1
Jang, MH1
Hwang, DY2
Kim, WY1
Lim, SD1
Kim, WS2
Hwang, TS1
Yamakawa, T1
Yamatsuji, T1
Yoshimitsu, M1
Toyota, K1
Yamano, T2
Tanishima, H1
Shirai, Y2
Horiuchi, T1
Wu, IC2
Takemura, H1
Minamoto, T2
Däster, S2
Amatruda, N1
Calabrese, D1
Ivanek, R1
Turrini, E1
Droeser, RA1
Zajac, P1
Fimognari, C1
Spagnoli, GC1
Iezzi, G2
Mele, V2
Muraro, MG2
Moretto R, R1
Pilati, P2
Benahim, E1
Smith, CG2
Elliott, F3
Brown, S2
Cheadle, J1
Lu, TX1
Sundaramoorthy, P1
Sánchez-Velázquez, P1
Töpel, I1
Piso, P2
Seo, K3
Ki, SH1
Park, EY1
Shin, SM1
Bertocchi, P1
Aroldi, F1
Pinter, T3
Klippel, Z1
Cesas, A1
Croitoru, A1
Kurteva, G5
Salek, T1
Reiner, M1
Morrow, PK1
Choi, MR1
Whittaker, S1
Parikh, A1
Atreya, C1
Korn, WM1
Lin, YK2
Liang, Q1
Sun, HQ1
She, F1
Jiang, G1
Geng, J1
Dai, T1
Nakajima, J1
Stevenson, HL1
Prats, MM1
Sasatomi, E1
Copija, A1
Waniczek, D1
Witkoś, A1
Walkiewicz, K1
Nowakowska-Zajdel, E1
Roncato, R1
Montico, M1
Giodini, L1
Solfrini, V1
Tomochika, S1
Tokuhisa, Y1
Yoshino, S2
Lee, YC1
Su, CY1
Lin, YF1
Lin, CM2
Chen, CL1
McQuade, RM1
Stojanovska, V1
Bornstein, JC1
Nurgali, K1
Guenther, S1
von Hohnhorst, P1
Fang, J2
Yagi, R1
Okamura, T6
Kobayashi, T7
Kosugi, SI1
Gea, S1
López-Martínez, N1
Arul, M1
Roslani, AC1
Cheah, SH1
Mocellin, S3
Baretta, Z1
Roqué I Figuls, M2
Solà, I2
Hallum, S1
Bonfill Cosp, X2
Di Salvatore, M1
Rossi, E1
Guarino, D1
Santonocito, C1
Schinzari, G5
Capoluongo, E1
Bommer, UA1
Vine, KL2
Puri, P1
Engel, M1
Belfiore, L1
Fildes, K1
Batterham, M1
Lochhead, A1
Aghmesheh, M1
Yigitbas, H1
Yazici, P1
Taskin, HE1
Okoh, AK1
Dural, C1
Aydin, N1
Berber, E1
Ju, H1
Jie, K1
Scevola, G1
Loreni, G1
Rastelli, M1
Sposato, S1
Ramponi, S1
Miele, V1
Shi, W2
Zeng, Q1
Yang, QL1
Staib, F1
Göhler, T1
Heike, M7
Neise, M1
Rudi, J4
Geer, T1
Dingeldein, G1
Lang, C1
Ehscheidt, P1
Flohr, T1
Josten, KM1
Schmittel, A1
Wierecky, J1
Boller, E1
Indorf, M1
Wörns, MA1
Nishikawa, Y2
Funakoshi, T1
Miyamoto, S6
Matsubara, T1
Yanagita, M1
Nakagawa, S3
Yonezawa, A1
Matsubara, K1
Nijhuis, A1
Thompson, H1
Adam, J1
Parker, A1
Gammon, L1
Lewis, A1
Bundy, JG1
Soga, T1
Jalaly, A1
Jeffery, R1
Suraweera, N1
McDonald, S1
Thaha, MA1
Feakins, R1
Lowe, R1
Bishop, CL1
Hart, LL4
Firdaus, I2
Mace, JR1
McFarlane, JJ1
Catenacci, D1
Hsu, JJ1
Shames, DS1
Koeppen, H1
Park, SR1
Nam, BH1
Oh, HS1
Park, YI1
Song, EK1
Lee, KT1
Kang, JH4
Itabashi, M1
Hamano, M1
Hirai, E1
Okuyama, R1
Araida, T1
Wood, G1
Grenader, T1
Nash, S1
Gore, I2
Braiteh, F1
Funke, R1
Anderson, M1
McCall, B1
Stroh, M1
Wakshull, E1
Hegde, P1
Chang, I1
Rhee, I1
Asselain, B1
Matthes, N1
Koospal, M1
Quenzer, A1
Peter, S1
Del Rio, M4
Mollevi, C1
Bibeau, F4
Vie, N2
Roger, P1
Gongora, C3
Martineau, P4
Guo, JH1
Zhang, PJ1
Li, XT1
Wang, XD1
Webster, PJ1
Littlejohns, AT1
Gaunt, HJ1
Prasad, KR1
Beech, DJ1
Burke, DA1
Braun, MS3
Daly, C1
Adlard, JW3
Barrett, JH2
Selby, P3
Stephens, RJ6
Parmar, MK4
Bruin, S1
van Slooten, G1
Marti, P1
Merrouche, Y5
Tigaud, JM3
Rebischung, C4
Schiavon, G9
Pantano, F1
Ghebremichael, M1
Ardavanis, A1
Ziras, N7
Athanasiadis, A3
Varthalitis, I4
Amarantidis, K1
Tsousis, S3
Vardakis, N8
Rothenberg, ML12
Cox, JV3
Butts, C4
Navarro, M10
Goel, R3
Siu, LL3
Laguerre, S1
Besnard, T1
Renée, N7
Martínez C, J1
Jarufe C, N1
González D, R1
Alvarez Z, M1
Wong, CS1
Wong, VW1
Chan, CM1
Wong, MC1
Lam, MY1
Au, TC1
Chan, WH1
Cheuk, W1
Di Benedetto, F2
Simonelli, C3
Martellotta, F2
Del Ben, C1
Berretta, S5
Spina, M3
Pezo, RC1
Gandhi, SJ1
Shirley, LA1
Pestell, RG2
Augenlicht, LH1
Singer, RH1
Kweekel, DM4
Van der Straaten, T4
Antonini, NF9
Müller, CI1
Arkenau, H1
Hahn, SA1
Schmoll, SH1
de Liguori Carino, N1
van Leeuwen, BL1
Ghaneh, P1
Wu, A1
Audisio, RA2
Zanet, E2
Ishikawa, M1
Miyauchi, T1
Kashiwagi, Y1
Backus, HH3
Wouters, D3
Vainer, B6
Witton, CJ1
Jørgensen, JT1
Sørensen, JB10
Hickmann, L1
Vick, B1
Urbanik, T1
Berger, MR2
Weber, A1
Hennig, IM1
Naik, JD1
Szubert, A1
Anthoney, DA2
Jackson, DP1
Melcher, AM1
Crawford, SM1
Bradley, C3
Brown, JM1
Paré, L6
del Rio, E6
Altés, A5
Hata, F3
Yamamitsu, S5
Shirasaka, T11
Ben Fredj, R1
Gross, E2
Hassine, H1
Saguem, S1
Sharma, RI1
Smith, TA1
Mizuno, H1
Sugiura, T1
Udatsu, Y1
Okazawa, M1
Sugimura, K1
Kusumoto, H1
Kishimoto, T2
Izukura, M1
Kitada, N1
Morimoto, S2
Yamasaki, H2
Fujii, C1
Furukawa, H2
Takara, K2
Watari, M1
Wong, L3
Fehrenbacher, L5
Abubakr, Y1
Hedrick, E1
Altinok, A1
Clairambault, J1
Goldbeter, A1
Gibson, TB3
Grothey, E1
Power, DG3
Healey-Bird, BR1
Comandone, A1
Granetti, C1
Oliva, C1
Zuradelli, M2
Mari, E2
Pressiani, T1
Frustaci, S5
Lombardi, D1
Fratino, L1
Bonanno, S1
Spartà, D1
Palmucci, S1
Francoual, M8
Kaufman, HL1
Singh, D1
Garett, C1
Cripps, C3
von Mehren, M1
Dalfen, R1
Heim, WJ2
Conry, RM1
Urba, WJ1
Caterini, J1
Kim-Schulze, S1
Debenedette, M1
Salha, D1
Vogel, T1
Elias, I1
Berinstein, NL1
Kornprat, P1
Schöllnast, H1
Cerwenka, H1
Werkgartner, G1
Bernhardt, G1
Mischinger, HJ1
Laffer, U11
Metzger, U9
Aeberhard, P5
Lorenz, M19
Harder, F2
Maibach, R1
Zuber, M1
Grouls, V1
Kamisugi, K2
Imada, H3
Shoji, D1
Nakamoto, E2
Hirata, Y2
Nawano, K1
Ogawa, M5
Molloy, D1
Smith, LN1
Aitchison, T1
Brake, R1
Starnes, C1
Radinsky, R1
Borges, L1
Gartner, EM1
Griffith, KA1
Brewer, GJ1
Henja, GF1
Merajver, SD1
Zalupski, MM7
Massutti, B2
Constenla, M1
Cámara, JC1
Comella, P24
Massidda, B8
Filippelli, G5
Farris, A11
Natale, D7
Barberis, G2
Maiorino, L9
Palmeri, S16
Cannone, M2
Condemi, G2
Cubiella, J3
Sempere, L1
Xicola, RM3
Reñé, JM4
Bessa, X4
Morillas, JD3
Nicolás-Pérez, D3
Pons, E1
Payá, A3
Canestrari, E5
Maltese, P4
Bisonni, R4
Baldi, G3
Giustini, L5
Magnani, M5
Kanate, AS1
Auber, ML1
Higa, GM1
Granci, V2
Kramar, A5
Boissière-Michot, F1
Thirion, A1
Topuz, E1
Derin, D1
Can, G1
Kürklü, E1
Cinar, S1
Aykan, F1
Cevikbaş, A1
Dişçi, R1
Durna, Z1
Sakar, B2
Tanyeri, H1
Deniz, G1
Gürer, U1
Taş, F1
Guney, N2
Aydiner, A1
Croghan, G1
Bukowski, R2
Rudek, M1
Messersmith, W1
Erlichman, C12
Pelley, R1
Donehower, R2
Boni, J1
Abbas, R2
Martins, P1
Zacharchuk, C2
McBride, D1
Sakai, T4
Maekawa, T1
Mikami, K1
Shirakusa, T1
Kabbinavar, FF5
Wallace, JF1
Holmgren, E3
Yi, J3
Cella, D1
Yost, KJ1
Abaza, MS1
Bahman, AM1
Al-Attiyah, RJ1
Kanai, M3
Mori, Y3
Kawamura, J1
Nomura, A2
Kitano, T3
Ishiguro, H3
Teramukai, S3
Chiba, T5
Sessa, C1
Cavalli, F1
Fields, AL2
Bleiberg, H27
Portier, G3
Nitti, D5
O'Callaghan, C1
Langer, B3
Martignoni, G5
Lazorthes, F2
Nortier, JW6
Sedano, L2
Cortés, A1
Lopatriello, S1
Donati, S1
Fornasiero, A3
Smergo, A1
Lalli, A3
Iacono, C1
Lucenti, A1
D'Alonzo, L1
Negrini, C1
Caponigro, F6
Lacombe, D1
Bauer, J2
Govaerts, AS1
Marréaud, S1
Milano, A2
Anthoney, A3
Wong, AO2
Koralewski, PM1
Miller, WH1
Habboubi, N1
Garay, C1
Olivatto, LO1
Booth, C1
Patiutko, IuI2
Poliakov, AN1
Sagaĭdak, IV2
Kotel'nikov, AG2
Garg, A1
Tisdale, AW1
Haidari, E1
Kokkoli, E1
Bursi, S4
Di Paolo, A12
Bocci, G9
Del Tacca, M16
Galizia, E2
Chiorrini, S1
Pierantoni, C1
Scott, PA1
Ferchow, L1
Hobson, A1
Curzen, NP1
Onozawa, Y4
Fukutomi, A3
Asaka, M6
Recchia, F4
Candeloro, G1
Necozione, S1
Bratta, M1
Bisegna, R1
Rea, S2
Kabbinavar, F7
Irl, C1
Zurlo, A1
Sirohi, B1
Pluzanska, A1
Utracka-Hutka, B1
Zaluski, J2
Koralewski, P3
Mainwaring, P3
Chan, RT2
Tabah-Fisch, I4
Conti, JA6
Kendall, TJ1
Bateman, A1
Armstrong, TA1
Papa-Adams, A1
Packham, G1
Benyon, RC1
Iredale, JP1
Arimoto, Y1
Kanamiya, Y1
Oba, H1
Adachi, K1
Shintani, M1
Nakamura, R1
Yui, S1
Buzzoni, R5
Ferrario, E4
Mariani, L3
Bajetta, R2
Gevorgyan, A1
Venturino, P1
Galassi, M1
Koike, Y1
Miki, C4
Yokoe, T1
Toiyama, Y4
Kusunoki, M7
Yan, TD3
Morris, DL16
Ito, I1
Mukai, M7
Ninomiya, H4
Kishima, K1
Tsuchiya, K4
Tajima, T10
Oida, Y1
Makuuchi, H12
Veerasarn, V1
Boonnuch, W1
Chinswangwatanakul, V1
Lohsiriwat, D1
Mahamadsolaeh, P1
Flamen, P2
Vanderlinden, B2
Delatte, P2
Ghanem, G1
Ameye, L1
Fisher, GA6
Kuo, T2
Ramsey, M1
Schwartz, E1
Rouse, RV1
Cho, CD3
Halsey, J3
Sikic, BI4
Fujita, K7
Nagashima, F5
Yamamoto, W4
Endo, H3
Mizuno, K4
Matsunaga, M1
Miya, T4
Narabayashi, M3
Kawara, K7
Dintinjana, RD1
Guina, T1
Krznarić, Z1
Radić, M1
Dintinjana, M1
Campbell, ML1
Landry, CS1
Slomiany, BA1
Woodall, CE1
McMasters, KM1
Vente, MA1
Wondergem, M1
van der Tweel, I1
van den Bosch, MA1
Zonnenberg, BA1
Lam, MG1
van Het Schip, AD1
Nijsen, JF1
Campbell, ME2
Morton, RF7
Williamson, SK8
Findlay, BP7
Pitot, HC9
Michael, M12
Smith, R1
Godwood, A1
Oliver, S1
Perboni, S1
Bowers, C1
Kojima, S2
Asakawa, A1
Inui, A1
Shouji, D2
Oya, M1
Muto, T3
Arkenau, HT5
Martoni, A4
Kim, T2
Bhargava, A1
Schwartz, L3
Covey, A1
Karrasch, M1
Getrajdman, G1
Mescheder, A1
Jarnagin, W6
Kobayashi, H1
Iida, S4
Azuma, M2
Mori, R2
Omori, A1
Danenberg, KD15
Danenberg, PV18
Vakhabova, JV1
Semenov, NN1
Dobrova, NV1
Lichinitser, MR1
Nobili, S6
Checcacci, D1
Filippelli, F1
Del Buono, S1
Mazzocchi, V1
Mazzei, T5
Siewczynski, R1
Hacker, U1
Honda, T1
Matsubara, J2
Shimoda, T2
Nur, U1
Rachet, B1
Sydes, MR1
Cooper, N1
Northover, JM1
James, R3
Coleman, MP1
Kuefler, P1
Hyman, W1
Berger, M1
Richards, D3
Vukelja, S1
Nugent, JE1
Ruxer, RL1
Boehm, KA4
Asmar, L3
Schlemmer, M1
Kuehl, M1
Rauch, J1
Jauch, KW3
Hentrich, M2
Lee, JT1
Lee, MG2
Lee, HW1
Lee, YJ2
Lee, YL1
Yoo, J1
Ahn, BC1
Ha, JH1
Kaiser, C2
Lindskog, EB1
Niyikiza, C1
Ota, K5
Kurita, S1
Nishimura, M1
Ariyoshi, Y5
Oyama, A1
Hoshino, A1
Amo, H1
Kawahara, A1
Hattori, S1
Ono, M2
Kuwano, M2
Kage, M1
Brown, TJ1
Ng, R1
Jennens, R1
Cinc, E1
Pho, M1
Fox, RM1
Sarkar, S3
Rosen, O2
Small, RM1
Lubezky, N2
Shmueli, E1
Figer, A13
Nakache, R2
Klausner, JM1
Ben-Haim, M2
Chang, PM1
Tzeng, CH8
Chen, PM11
Wang, WS8
Mandalà, M2
Isa, L2
Fornarini, G3
Marangolo, M5
Baki, M1
Idelevich, E2
Greif, F2
Mavor, E1
Miller, R1
Kashtan, H1
Susmalian, S1
Ariche, A1
Brenner, B3
Baruch, NB1
Dinerman, M1
Shani, A2
Hénin, E2
You, B2
VanCutsem, E1
Zuideveld, KP2
Sirzen, F4
Dartois, C1
Freyer, G7
Tod, M3
Girard, P4
Puthillath, A1
Mashtare, T2
Wilding, G3
Khushalani, N1
Steinbrenner, L1
Ross, ME2
Romano, K1
Wisniewski, M1
Fernández-Contreras, ME4
Sánchez-Hernández, JJ3
Herráez, B1
Domínguez, I1
Lozano, M1
García De Paredes, ML5
Gamallo, C4
Lazaris, A1
Gouveris, P4
Kavantzas, N1
Kopterides, P2
Papathomas, T1
Agrogiannis, G1
Arapogiannis, G1
Zorzos, H1
Kyriakou, V2
Patsouris, E2
Morris-Stiff, G1
Makuuchi, M3
Pozzo, C10
Uchida, K3
Ishiguro, T10
Miyazaki, T7
Matsuki, M2
Okita, T1
Mitsuhashi, T1
Carcereny, E1
Longarón, R2
Oliveras, A1
Tosca, M1
Augé, JM1
Gascón, P2
Gunnlaugsson, A1
Anderson, H3
Kjellén, E1
Byström, P5
Berglund, K1
Ekelund, M1
Påhlman, L16
Holm, T1
Chaves, M2
Queralt, B4
Gómez-España, A6
González-Flores, E4
Sanchez-Rovira, P2
Maestu, I6
Makhson, A2
Donea, S1
Ludwig, H3
Loos, AH2
Zubel, A4
Aguilar, G1
Palencia, S1
Newton, E1
Abo, A1
Gade, TP1
Buchanan, IM1
Motley, MW1
Mazaheri, Y1
Spees, WM1
Koutcher, JA1
Belaguli, N1
Berger, DH1
Kolinsky, K3
Shen, BQ1
Zhang, YE2
Kohles, J1
Dugan, U2
Zioncheck, TF1
Heimbrook, D3
Packman, K3
Higgins, B3
Ince, W1
Novotny, WF4
Wang, GB1
Tao, KX1
Moreira, LR1
Schenka, AA1
Latuff Filho, P1
Nascimento, H1
Passos Lima, CS1
Silva Trevisan, MA1
Vassallo, J1
Postma, C1
Eijk, PP1
Carvalho, B1
Mori, N2
Ishiyama, K2
Sakurai, N1
Saito, K2
Iizawa, H3
Ikeda, E3
Nannini, M1
Nobili, E2
Di Cicilia, R2
Maleddu, A1
Sprinzl, MF1
Abdelfattah, M1
Adami, B3
Godderz, W2
Majer, K1
Flieger, D2
Bidard, FC2
Kruhøffer, M1
Costantino, CL1
Eshleman, JR1
Gallmeier, E2
van der Heijden, MS1
Winter, JM2
Wikiewicz, AK1
Yeo, CJ1
Kern, SE3
Kay, E3
Kenny, S1
Kortman, GA1
Mekenkamp, L1
Ligtenberg, MJ2
Hoogerbrugge, N1
Rätz Bravo, AE1
Hofer, S1
Krähenbühl, S1
Ludwig, C2
Mattera, L1
Escaffit, F1
Pillaire, MJ1
Tyteca, S1
Hoffmann, JS1
Gourraud, PA1
Chevillard-Briet, M1
Cazaux, C1
Trouche, D1
Jung, KH3
Lee, N1
Byun, JH3
Choi, SH2
Shin, HJ1
Ahn, KD1
Lee, JM1
Kwon, HC3
Lee, DM1
Roh, MS3
Kim, DC1
Choi, HJ2
Tumeh, JW1
Shenoy, PJ1
Moore, SG1
Flowers, C1
Yamamori, M3
Kadowaki, Y1
Miki, I2
Okumura, K4
Azuma, T1
Kasuga, M1
Hirai, M1
Gil-Bazo, I1
Schulman, KL2
Zelt, S1
Rodenburg, CJ4
Schrama, JG2
Vos, AH3
Sinnige, HA6
Richel, DJ3
Dijkstra, JR1
Vink-Börger, ME1
Dalesio, O3
Klinger, M4
Eipeldauer, S3
Hacker, S3
Herberger, B5
Dorfmeister, M2
Koelblinger, C1
Bhushan, S1
Kozuch, P1
Malamud, S1
Wasserman, C1
Homel, P1
Mirzoyev, T1
Grossbard, M1
Botwood, NA1
Maniadakis, N2
Fragoulakis, V2
Costantino, E1
Maddalena, F1
Calise, S1
Tirino, V1
Fersini, A1
Ambrosi, A1
Neri, V1
Yokota, T4
Yamaura, H4
Najima, M2
Chae, YS3
Moon, JH3
Ryoo, HM2
Bae, SH2
Kum, Y1
Jeon, SW1
Kang, BM1
Park, IJ1
Choi, GS3
Jun, SH3
Liao, C2
Tan, A1
Mo, Z1
Gauthier, I1
MacLean, M1
Wells, J1
Powers, J1
Haviland, D1
Dematteo, R3
Kitano, S2
Hirohashi, S1
Takahashi, A1
Sakaguchi, H1
Matsuoka, M4
Takahama, J1
Higashiura, W1
Dallas, NA1
Gray, MJ1
Gaur, P1
van Buren, G1
Samuel, S1
Kim, MP1
Lim, SJ1
Popov, I2
Milicević, M2
Radosević-Jelić, Lj2
Ricci, S12
Brunetti, IM6
Ferraldeschi, R1
Naso, G2
Filipponi, F2
Goletti, O2
Andreuccetti, M9
Mazzer, M1
Moroso, S1
Puglisi, F4
Kawabata, Y2
Nakagawa, A2
Uchikoshi, H1
Tamiya, Y1
Chun, YS1
Laurent, A2
Bruzzese, F2
Pepe, S2
Subbarayan, PR5
Lai, A1
Cairns, MJ1
Tran, N1
Zhang, HP1
Cullen, L1
Arndt, GM1
Keller, A1
Kardinal, C2
Cohen, A2
Schulz, J3
Eisenberg, P2
Forster, J1
Wissel, P1
Maeda, S2
Hikiba, Y1
Nakagawa, H3
Hayakawa, Y2
Shibata, W1
Yanai, A1
Ogura, K2
Omata, M1
Mehendale, SR3
Strauss, LG11
Hoffend, J1
Koczan, D1
Dimitrakopoulou-Strauss, A7
Giusti, RM2
Cohen, MH3
Keegan, P3
Pazdur, R28
Milla, P1
Airoldi, M1
Weber, G1
Drescher, A1
Cattel, L2
Richter, SN1
Nadai, M1
Palumbo, M1
Palù, G1
Takimoto, N1
Sugawara, S1
Iida, A2
Sakakibara, T1
Mori, K10
Sugiura, M1
Adachi, M1
Otsuka, S3
Inagaki, M3
Nishie, M2
Hamano, R2
Tokunaga, N6
Tsunemitsu, Y2
Miyoshi, K3
Oosaki, T2
Iwagaki, H1
Seki, H2
Ozaki, T3
Shiina, M2
Ginés, A3
Plasencia, C3
Neamati, N1
Gianni, M1
Dentali, F1
Lonn, E1
Chen, SP2
Lin, SZ2
Kang, JC2
Su, CC1
Chen, YL2
Chiu, SC2
Pang, CY2
Harn, HJ2
Angitapalli, R1
Litwin, AM1
Kumar, PR1
Nasser, E1
Lombardo, J2
Wilding, GE2
Gentner, B1
Croner, RS1
Zeittraeger, I1
Wirtz, RM1
Roedel, F1
Dimmler, A1
Dorlaque, L1
Hahn, EG7
Brueckl, WM3
Spłwiński, J1
Gómez Portilla, A1
Cendoya, I1
Olabarría, I1
Martínez de Lecea, C1
Gómez Martínez de Lecea, C1
Muriel, J1
Magrach, L1
Romero, E1
Lirola, A1
Guede, N1
Moraza, N1
Fernández, E1
Kvadatze, M1
Valdovinos, M1
Larrabide, I1
Ruiz de Alegría, N1
Fernández, JL1
Rua, O1
Ulibarrena, MA1
Hitre, E9
Chang Chien, CR1
Schischmanoff, O1
Morere, JF3
Sereno, M1
Castro, JD1
Belda, C1
González-Barón, M4
Chen, ML1
Fang, CH1
Liang, LS1
Dai, LH1
Wang, XK1
Carloni, F1
Nicoletti, S2
Ravaioli, A7
Sablin, MP1
Italiano, A1
Spano, JP2
Aussilhou, B1
Dokmak, S1
Faivre, S4
Paradis, V1
Vilgrain, V1
Belghiti, J3
Biason, P3
Pylev, AL1
Husseini, F4
Cals, L2
López, JJ1
Mahoney, MR4
Rowland, KM2
Philip, PA3
Mathews, AP1
Fitch, TR2
Jackson, NA1
Barrueco, J3
Soufi-Mahjoubi, R2
Meyerhardt, J1
Pendyala, L2
Fetterly, G2
Toth, K4
Zwiebel, JA2
Espinoza-Delgado, I2
Litwin, A2
Rustum, YM26
Egorin, MJ3
Humeniuk, R1
Mishra, PJ1
Bertino, JR12
Banerjee, D2
Lurje, G3
Manegold, PC1
Pohl, A2
Frigo, AC1
Bolzonella, C1
Marinelli, R1
Barile, C4
Bononi, A2
Crepaldi, G2
Menon, D2
Stievano, L2
Toso, S3
Pasini, F4
Ferrazzi, E3
Padrini, R5
Skof, E1
Rebersek, M2
Hlebanja, Z1
Shimizu, Y2
Teitelbaum, UR1
DiBartolomeo, M1
Mazier, MA1
Fishbein, AB1
Aung, HH3
Panczyk, M1
Balcerczak, E1
Piaskowski, S1
Jamroziak, K1
Pasz-Walczak, G1
Mirowski, M1
Yokoo, K1
Hamada, A1
Tazoe, K1
Lai, JI1
Petrini, I2
Pohlmann, PR1
Mernaugh, RL1
Goff, LW1
Copur, MS3
Norvell, M1
Obermiller, A1
Polansky, M1
Ross, AC1
Floristan, U1
Feltes, RA1
Sendagorta, E1
Feito-Rodriguez, M1
Ramírez-Marín, P1
Vidaurrázaga, C1
Casado-Jiménez, M1
Bathe, OF2
Ernst, S2
Sutherland, FR1
Bigam, D2
Holland, D1
Porter, GA1
Koppel, J1
Dowden, S2
Venderbosch, S3
Nagtegaal, I1
Matsushita, H1
Tsuboi, K4
Honda, I1
Kato, N1
Okochi, O2
Ueda, H1
Demizu, M1
Oosawa, M1
Chihara, S1
Nakanishi, Y1
Maeda, C2
Yano, K1
Kimura, F2
Iwakawa, S1
Vogel, U2
Matsen, JP1
Andersen, PK1
Poulsen, HE5
Buyse, M23
Perez-Staub, N4
Moreno, C1
Medina, J1
Pérez-García, B1
García-López, JL1
Fidlerova, J1
Kleiblova, P1
Kormunda, S1
Bilek, M1
Bouskova, K1
Sevcik, J1
Knudsen, AR1
Kannerup, AS1
Mortensen, FV1
Nielsen, DT1
Shiroiwa, T3
Fukuda, T3
Tsutani, K3
Svoboda, M1
Nemecek, R1
Rehák, Z1
Standara, M1
Farese, S1
Aebi, S2
Walther, A1
Swanton, C1
Gorman, S1
Tosetto, M1
Lyng, F1
Howe, O1
O'Donoghue, D1
Hyland, J1
Mulcahy, H1
Thelen, A1
Riess, H6
Jonas, S1
Schmeding, M1
Bova, R1
Neuhaus, P2
Chu, KS1
Wagner, M2
Roh, V1
Strehlen, M1
Laemmle, A1
Stroka, D1
Egger, B1
Trochsler, M1
Hunt, KK1
Candinas, D1
Vorburger, SA1
Kwok-Keung Choi, C1
Jardim, MJ1
Furumai, R1
Wakeman, T1
Goodman, BK1
Wang, XF1
Spiro, H1
Yanagisawa, M2
Fujimoto-Ouchi, K1
Yorozu, K1
Nagykálnai, T2
Fujimoto, Y1
Akasu, T3
Fujita, S2
Pasquali, S1
Keese, M2
Yagublu, V2
Schwenke, K1
Post, S2
Bastiaens, P1
Cui, F1
Chen, JZ2
Wan, C1
Luo, RC4
Hatano, N1
Fukuoka, T1
Usui, H1
Zhou, JF2
Bai, CM2
Cheng, YJ1
Jia, N1
Shao, YJ2
Bjerregaard, B2
Mejer, J1
Diagaradjane, P2
Anand, P1
Harikumar, KB1
Kuzhuvelil, HB1
Deorukhkar, A2
Gelovani, J1
Guha, S2
Krishnan, S2
Teng, KY1
Ruan, DY1
Chen, XQ2
He, YJ3
Spoto, C2
Gasparro, S2
Rizzo, S2
Zobel, BB1
Valeri, S1
Coppola, R4
Gapski, J1
Young, S1
Green, EM2
Peterson, DE1
Barker, NP1
Akhmadullina, LI1
Rodionova, I1
Sherman, NZ1
Davidenko, IS1
Rakovskaya, GN1
Gotovkin, EA1
Shinkarev, SA1
Kulikov, EP1
Gertner, JM1
Firsov, I1
Tuleneva, T1
Yarosh, A1
Woon, CW1
Jorga, K1
Fagerberg, J1
Ishizuka, M1
Takagi, K3
Kubota, K1
Fukumitsu, H1
Yazawa, N1
Hoshikawa, T1
Hirakawa, H1
Ogoshi, K1
Okines, A1
Kuebler, JP3
Olver, IN1
Tapner, MJ1
Bower, GD1
Briggs, GM1
Rossleigh, MA1
Taylor, DJ1
George, J1
Suzuki, W1
Shirai, T1
Luo, W2
Liao, WJ4
Huang, YT2
Xie, JT2
Tong, R1
McEntee, E1
Palmirotta, R2
Savonarola, A2
Ludovici, G2
Del Monte, G2
Sugimoto, S1
Katano, K1
Yoshimura, H1
Kidani, A1
Takeda, H1
Makino, M4
Ozaki, N1
Ikeguchi, M2
Fernández-Peralta, AM1
Daimiel, L1
Nejda, N1
Iglesias, D1
Medina Arana, V1
González-Aguilera, JJ1
Schmidt, C1
Chua, W2
Dhillon, H2
Mitchell, P2
Liang, QL1
Pan, DC1
Xie, JR1
Merl, M1
Hoimes, C1
Pham, T1
Canu, B2
Alì, G2
Orlandi, P2
Di Desidero, T2
Emmenegger, U1
Kuboki, Y5
Konishi, F2
Fournier, P1
Romano, O2
Cohen, MS1
Al-Kasspooles, MF1
Henry, D1
Broward, M1
Roby, KF1
Brearley, SG1
Swindell, R4
Caputo, G1
Novello, G1
Manzione, L10
Ren, DN1
Kim, IY1
Koh, SB1
Chang, SJ1
Eom, M1
Yi, SY1
Seong, SH1
Kim, MD1
Bronner, MP1
Cho, MY1
He, TC3
Ozel, L1
Ozel, MS1
Toros, AB1
Kara, M1
Ozkan, KS1
Tellioglu, G1
Krand, O1
Koyuturk, M1
Berber, I1
Kouroussis, Ch3
Kalbakis, K10
Massara, MC1
Portarena, I1
Fiaschetti, V1
Del Vecchio Blanco, G1
Sileri, P1
Tosetto, L1
Skoulidis, F1
Pallone, F1
Tsunoda, A1
Yasuda, N1
Nakao, K1
Narita, K1
Matsui, N1
Triboulet, JP1
Shi, N1
Muñoz-Martin, A2
Mendez-Ureña, M1
Quiben-Pereira, R1
Perez-Manga, G7
Dy, GK2
Hobday, TJ3
Nelson, G2
Windschitl, HE4
Nikcevich, DA1
Chauffert, B4
Köberle, D2
Ruhstaller, T3
Mayer, G1
Räss, A1
Boostrom, SY1
Nagorney, DM5
Donohue, JH2
Harmsen, S1
Thomsen, K1
Que, F1
Kendrick, M1
Reid-Lombardo, KM1
Ji, X2
Wan, F1
Zhong, B1
Tucker, S1
Shi, YX1
Xiang, XJ3
Lansdorp-Vogelaar, I1
van Ballegooijen, M1
Zauber, AG1
Habbema, JD1
Kuipers, EJ1
Samalin, E2
Boyer-Gestin, C1
Portales, F2
Vaillant, JN1
Colin, P4
Yim, KL1
Park, CM1
Yun, HR1
Heo, JS1
Iwahashi, M2
Higashiguchi, T2
Oku, Y2
Nasu, T1
Townsend, A1
Shahrokni, A1
Rajebi, MR1
Bambury, R1
McCaffrey, JA1
Réti, A3
Pap, E3
Adleff, V6
Jeney, A3
Kralovánszky, J8
Budai, B7
Köppler, H1
Heymanns, J1
Thomalla, J1
Kleboth, K1
Weide, R1
Gounaris, I1
Ahmad, A2
Matsunaga, Y1
Motokawa, S1
Nakagaki, S1
Muramatsu, T1
Kudou, Y1
Shino, M1
Mammano, E1
Tessari, E1
Lise, M3
Spławiński, J1
Nakano, S5
Daly, CL2
Allan, JM1
Hoshino, H2
Tomimaru, Y1
Ishii, H2
Tibbe, A1
Terstappen, LW1
Taylor, G2
Hasenberg, T1
Essenbreis, M1
Herold, A1
Shang, E1
Mathew, S1
Armesilla, AL2
Darling, JL2
Chang, P1
Zou, L1
Brearley, S1
Wardley, A1
Farrell, C1
Todd, C2
Luker, K1
Kockler, L2
Ma, YL2
Peng, JY2
Shen, TY2
Chen, HQ2
Zhou, YK2
Chu, ZX2
Qin, HL2
Paiva, CE1
Paiva, BS1
Garita, R1
Michelin, OC1
Rodriguez-Braun, E1
Ramos, FJ2
Vega-Villegas, ME2
Liebscher, S1
Kisker, O2
Baselga, J2
Abhyankar, V1
Burgess, RE1
Infante, J1
Trowbridge, RC1
Tortorici, M1
Robles, RL1
Frilling, A1
Konopke, R1
Parisi, F1
Sala-Vila, A1
Folkes, J1
Calder, PC1
Kim, YH4
Chang, DK2
Rhee, PL1
Kim, DS1
Yun, H1
Godai, TI1
Suda, T2
Tsuchida, K1
Sekiguchi, H1
Sekiyama, A1
Yoshihara, M1
Matsukuma, S1
Sakuma, Y1
Tsuchiya, E1
Miyagi, Y1
Dohn, LH1
Petty, RD1
Samuel, LM1
MacDonald, G1
O'Kelly, T2
Loudon, M1
Binnie, N1
Aly, E1
McKinlay, A1
Gilbert, F1
Semple, S1
Collie-Duguid, ES1
Morris, JS2
Glover, KY1
Adinin, R1
Valero, V2
Yan, S1
Tran, HT1
Abbruzzese, JL10
Heymach, JV1
Kaibori, M1
Ishizaki, M1
Matsui, K1
Saito, T4
Yoshioka, K1
Kwon, AH1
Uen, YH1
Wu, DC1
Surguladze, D1
Steiner, P2
Prewett, M1
Tonra, JR1
Petrioli, R6
Bargagli, G2
Lazzi, S1
Pascucci, A3
Francini, E4
Bellan, C1
Martellucci, I1
Fiaschi, AI2
Lorenzi, B1
Francini, G9
Kalábová, H1
Krcmová, L1
Kasparová, M1
Malírová, E2
Melicharová, K1
Pecka, M1
Hyspler, R1
Solichová, D1
Hokama, N1
Kubota, S4
Amano, R2
Yamada, N4
Noda, E2
Muguruma, K2
Yashiro, M2
Onoda, N1
Sawada, T5
Nakata, B3
Ohira, M3
Tamaru, J2
Kikuoka, S1
Takeuchi, I6
Ishida, F1
Ozawa, F1
Moriguchi, M2
Iwakawa, K1
Iwagak, H1
Kaneko, T2
Shimizu, K4
Mishima, T1
Koshiishi, H2
Matsuyama, T2
Goto, H1
Kakimoto, Y1
Minami, T2
Maruyama, M6
Takahashi, E1
Koshiishi, Y1
Matsumoto, R1
Kuroda, T4
Mamiya, Y1
Kon, A1
Sobajima, J3
Ohsawa, T11
Inokuma, S6
An, X1
Gasparini, G4
Azzarello, G1
Basso, U1
Pessa, S2
Lo Re, G3
De Paoli, P1
Jun, L1
Haiping, Z1
Beibei, Y1
Wagman, L2
Weiland, TL1
Lai, LL1
Schwarz, RE2
Molina, R2
Dentchev, T1
Bolton, JS3
Bin, Q1
de Haas, RJ2
Wicherts, DA2
Flores, E1
Paule, B4
Baeksgaard, L1
Petersen, LN1
Reiter, L1
Wilson, PM5
El-Khoueiry, A3
Iqbal, S5
Fazzone, W1
Cole, S1
Kornacki, M1
Ladner, RD5
Montagnani, F2
Chiriatti, A3
Turrisi, G1
Fiorentini, G4
Kopper, L1
Tímár, J2
Kim, LG1
Kong, HH1
Low, LY1
Choi, EY1
Na, YS1
Noda, N1
Shinohara, T2
Kitai, T3
Kawashima, M1
Mashima, S1
Shimahara, Y2
Fujimura, K1
Mune, D1
Ohnishi, C1
Fujisaki, E1
Hatahara, K1
Sukawa, Y1
Fujii, K2
Nishimura, S3
Yonezawa, K1
Shinomura, Y1
Watkins, DJ1
Mudan, SS1
Karanjia, N1
Brown, G4
Ashley, S1
Norman, AR20
Gillbanks, A2
Sawayama, H2
Toyama, E2
Takamori, H5
Kim, NS1
Park, JY1
Kang, BW2
Perret, G1
Wang, BS1
Li, JQ1
Spector, T5
Gamboa, EO1
Rehmus, EH1
Haller, N1
Newton, K1
Hill, J1
Harada, T2
Akase, T1
Arakawa, I1
Albrecht, H1
Konturek, PC1
Reulbach, U1
Maennlein, G1
Meyer, T1
Garm Spindler, KL1
Brandslund, I1
Boer, K1
Pover, GM1
Morris, CD1
Hu, XT1
Shi, QL1
Zhang, FB1
Patel, BB2
Majumdar, AP2
Cappellani, A1
Cacopardo, B1
Nunnari, G1
Izzi, I1
Lanzafame, M1
Basile, F1
Schiantarelli C, C1
Garlassi, E1
Ridolfo, A1
Guella, L1
Helsby, NA1
Lo, WY1
Thompson, P4
Laking, GR1
Fredriksson, LA1
Berglund, M1
Kohnke, H1
Sørbye, H8
Seront, E1
Marot, L1
Coche, E1
Gala, JL1
Ferrari, G1
Gemignani, F1
Macaluso, C1
Vanhoefer, U9
Frieling, T1
Lehnert, L1
Zarate, R3
Bandres, E4
Patiño-Garcia, A1
Ponz-Sarvise, M1
Ramirez, N1
Bitarte, N2
Chopitea, A1
Gacía-Foncillas, J1
Coursier, S1
Martelet, S1
Guillermet, A1
Emptoz, J1
Villier, C1
Bontemps, H1
Bao, HY3
Zhang, XC2
Shi, GM2
Yu, LF2
Mou, HB1
Deshaies, I1
Dromain, C3
Yuuki, S1
Miyagishima, T3
Kudo, M2
Tateyama, M2
Kunieda, Y1
Wakahama, O1
Maleux, G2
Vaninbroukx, J1
Heye, S1
Oyen, R1
Lin, YL1
Chow, KC1
Komori, H2
Horino, K2
Imsung, C1
Ootao, R1
Iyama, K1
Minashi, K3
Tahara, M5
Joh, T4
Ohrling, K1
Edler, D2
Hallström, M2
Ragnhammar, P5
Yoshioka, A2
Takahashi, R1
Matsuda, F1
Higuchi, M1
Iwatsubo, S1
Shirakawa, A1
Mishima, K1
Iwasaki, K4
Ma, SH1
Chen, GG1
Lai, PB1
de Bruijn, MT2
Raats, DA2
Hoogwater, FJ1
van Houdt, WJ1
Borel Rinkes, IH1
Matsuura, K1
Itoh, Y1
Baldwin, C1
Millette, M1
Oth, D1
Ruiz, MT1
Luquet, FM1
Lacroix, M1
Taura, M1
Fukuda, R1
Suico, MA1
Eguma, A1
Koga, T1
Shuto, T1
Morino-Koga, S1
Kai, H1
Guijarro, M1
Gisbert, JP2
Rivas, N1
Hinojar-Gutiérrez, A1
McCollum, D1
Baumgaertner, I1
Pillai, M1
Gollard, R1
Heim, W3
Swan, F1
Dreiling, L1
Mo, M1
Malik, I2
Boccia, RV1
Cosgriff, TM2
Headley, DL1
Badarinath, S2
Best, JH1
Garrison, LP1
Tondulli, L1
Mendiboure, J2
Castaing, M3
Barrois, M1
Trégouët, DA2
Le Corre, D1
Miran, I1
Mulot, C1
Beaune, P3
Kinoshita, K1
Akira, C1
Watanebe, M1
Uña Cidón, E1
Gorden, L1
Hauteville, D2
Guettier, C2
Lu, GC1
Li, DC1
Gervaz, P3
Rubbia-Brandt, L3
Andres, A3
Majno, P1
Morel, P2
Mentha, G4
Wu, Wy1
Durando, X3
Farges, MC1
Abrial, C1
Petorin-Lesens, C1
Gillet, B1
Vasson, MP1
Thivat, E2
Madroñal, C1
Bolaños, M3
Gil, M1
Llombart, A1
Castro-Carpeño, J1
Takamoto, T1
Sano, K1
Maruyama, Y1
Inoue, K3
Ogata, S1
Takemura, T1
Morelli, MF2
Santomaggio, A2
Tudini, M2
Mancini, M3
Pelliccione, M1
Calista, F1
Guglielmi, F1
Martella, F1
Lanfiuti Baldi, P1
Gebbia, N11
Seminara, P4
Losanno, T1
Emiliani, A1
Manna, G1
De Portu, S1
Mantovani, LG1
Bollina, R1
Cozzi, C1
Grimaldi, AM1
Testa, TE1
Bianchessi, C1
Xing, PY1
Feng, FY3
Shi, YK1
Pessaux, P1
Panaro, F1
Casnedi, S2
Zeca, I1
Marzano, E1
Bachellier, P2
Koizumi, W3
Takiuchi, H5
Muindi, JR2
Nagasaki, E1
Takahara, A1
Koido, S1
Sagawa, Y1
Aiba, K7
Tajiri, H1
Yagita, H1
Homma, S2
Bergougnoux, L1
Kojima, T3
Ikematsu, H1
Yano, T2
Kaneko, K1
Koike, K1
Hosoda, K1
Aoki, M1
Kido, H1
Natsu, K1
Tamura, H1
Kojima, M2
Amemiya, T1
Kamoshida, T1
Yasutome, M1
Joo, EH1
Rha, SY5
Kang, HY1
Koong, HN1
Ripley, RT1
Davis, JL1
Kemp, CD1
Steinberg, SM3
Toomey, MA1
Avital, I1
Ni, L1
Ma, YQ1
Song, YG1
Ramos, Y1
Gonzalez, M1
Fernandez, A1
Mezentsev, D1
Reis, I1
Duncan, R1
Podolsky, L2
Lima, M1
Ganjei-Azar, P1
Pracht, M1
Le Roux, C1
Kerjouan, M1
Audrain, O1
Gebski, VJ1
Cummins, MM2
Broad, A2
Forgeson, G1
Stockler, MR1
Chua, Y1
Widmer, L1
Uhlmann, C1
Simcock, M1
Lanz, D2
Popescu, R4
Zhuang, L1
Bai, J1
Tang, C2
Duanmu, Z1
Sarkar, M1
Benitez, E1
Singhal, S1
Chen, MH2
de Bock, CE1
Garg, MB2
Scott, N1
Sakoff, JA2
Scorgie, FE2
Lincz, LF2
Smyth, E1
Abou-Alfa, GK1
Lowery, M1
Al-Olayan, A1
Naghy, M1
Power, D1
Saliba, T1
Morrow, CJ1
Ghattas, M1
Smith, C1
Bönisch, H1
Bryce, RA1
Hickinson, DM1
Green, TP1
Simons, S1
Ringsdorf, S1
Mey, UJ1
Schwindt, PF1
Ko, YD1
Schmidt-Wolf, I1
Kuhn, W1
Napoli, C3
Landini, I2
Morganti, M2
Cianchi, F2
Valanzano, R2
Tonelli, F2
Cortesini, C1
Kataoka, H1
Mabuchi, M1
Mizoshita, T1
Kubota, E1
Tanida, S1
Kamiya, T1
Duffour, J6
Roca, L2
Bressolle, F4
Abderrahim, AG1
Poujol, S2
Pinguet, F5
Lambert, B1
Vannoote, J1
De Keukeleire, K1
Verslype, C5
Defreyne, L1
Paesmans, M2
Gasa, F1
Terui, K1
Awatsu, A1
Sugishita, H1
Watanabe, S2
Tanaka, A2
Morioka, J1
Suemaru, K1
Watanabe, Y4
Kawachi, K1
Araki, H3
Zorzi, D2
Contreras, CM1
Maru, DM3
Ribero, D2
Motta, M1
Ravarino, N1
Risio, M1
Curley, SA7
Abdalla, EK5
Capussotti, L7
Schneiders, FL1
van den Berg, HP1
Pang, R1
Chu, AC1
Cheung, LW1
Lan, XR1
Lan, HY2
Tan, VP1
Poon, RT1
Wong, BC1
Kyula, JN1
Doherty, J1
Fenning, CS1
Hsieh, YY2
Hsu, YN1
Chau, GY1
King, KL1
Boni, V2
Villa, JC1
Gomez, MA2
Ajima, H1
Ogata, H1
Beslija, S1
Koza, I1
Pápai, Z2
Faluhelyi, Z1
Wenczl, M1
Gazzaniga, P1
Gradilone, A1
Petracca, A1
Nicolazzo, C1
Raimondi, C1
Bartucci, M1
Svensson, S1
Ricci-Vitiani, L2
Dattilo, R1
Biffoni, M1
Ferla, R1
Surmacz, E1
Bracht, K1
Nicholls, AM1
Bodmer, WF1
Guastadisegni, C1
Colafranceschi, M1
Ottini, L1
Dogliotti, E1
Haugstetter, AM1
Loddenkemper, C1
Lenze, D1
Gröne, J1
Standfuss, C1
Petersen, I1
Dörken, B4
Schmitt, CA1
Layos, L1
Moreno, V3
Astier, A1
Kamil, M1
Haron, M1
Yosuff, N1
Khalid, I1
Azman, N1
Lubner, SJ1
Holen, KD4
Schelman, W1
Thomas, JP1
Jumonville, A1
Eickhoff, JC1
Frederiksen, C1
Takemura, M1
Morimura, K1
Osugi, H1
Kishida, S1
Shiraishi, R1
Matsukawa, H1
Tamura, I1
Ozawa, Y1
Imada, T1
Agata, T1
Noro, T1
Shiota, M1
Ozeki, S1
Hatta, K1
Ota, H2
Tang, JT1
Tanoue, Y1
Tizzano, E1
Shabaruddin, FH1
Elliott, RA1
Newman, WG1
Payne, K1
Waddell, T1
Soe, W1
Allen, J1
Bentley, D1
Lloyd, A1
Taylor, MB1
Gong, C1
Shi, S1
Qian, Z1
Bester, L1
Akther, J1
Jung, JJ1
Kim, GB1
Yoon, HS1
Ko, SH1
Ko, JE1
Marshall, MB1
Del Monte, F1
Kimata, T1
Sakamoto, E3
Kawachi, A1
Kuroki, A1
Kawade, Y1
Tokui, K1
Oyama, T1
Uchida, T1
Kondoh, M1
Kho, PS1
Moore, MM1
Charles, KA1
Watson, RG1
Muhale, F1
Thorne, LB1
Hoskins, JM2
Meyers, MO1
Hudson, ML1
Siquini, W1
Stortoni, P1
Marmorale, C1
Fianchini, A1
Mladkova, J1
Sanda, M1
Matouskova, E1
Selicharova, I1
Bergin, P1
Hanning, F1
Findlay, M7
Damianovich, D2
McKeage, MJ1
Stathopoulos, GP2
Batziou, C1
Trafalis, D1
Koutantos, J1
Batzios, S1
Stathopoulos, J1
Legakis, J1
Armakolas, A1
Mizuno, T2
Oriuchi, N1
Baxevanis, CN1
McIntyre, DJ2
Howe, FA2
Ladroue, C1
Lofts, F5
Stubbs, M2
Jaitner, S1
Schäffauer, AJ1
Dietmaier, W1
Griffith, M2
Griffith, OL2
Mwenifumbo, J1
Goya, R1
Morrissy, AS1
Morin, RD2
Corbett, R1
Tang, MJ3
Hou, YC3
Pugh, TJ2
Robertson, G1
Chittaranjan, S2
Ally, A1
Asano, JK2
Chan, SY2
Li, HI1
McDonald, H1
Teague, K1
Zeng, T1
Delaney, A1
Hirst, M1
Morin, GB2
Jones, SJ1
Tai, IT4
Marra, MA2
Yabuki, H2
Chiba, M1
Igawa, A1
Fujimoto, H2
Sugawara, M1
Matsuda, M5
Mikalauskas, S1
Mikalauskiene, L1
Bruns, H1
Nickkholgh, A1
Hoffmann, K1
Longerich, T1
Mammoliti, S1
Andretta, V1
Bennicelli, E1
Caprioni, F1
Comandini, D1
Guglielmi, A11
Pessino, A1
Sciallero, S1
Mazzola, G1
Lambiase, A2
Bordignon, C1
Van der Speeten, K2
Stuart, OA1
Chang, D3
Khattak, A1
Frago, R1
Kreisler, E1
Biondo, S1
Dominguez, J1
Escalante, E1
Spigel, DR1
Greco, FA4
Shipley, D1
Vazquez, ER1
Clark, BL1
Wu, XN1
Zhao, YB1
Ding, L1
Ai, B1
Zhou, MZ1
Yanagisawa, Y2
Shen, W1
Tu, JK1
Fu, ZX2
Huang, CX1
Li, ZY1
Jiang, YQ1
Duan, GL1
Wang, QQ1
Stutchbury, TK1
Locke, JM1
Chrisp, JS1
Bremner, JB1
Park, HM1
Park, JS1
Sohn, HJ1
Kim, TG1
Nordman, I1
Dobbins, T1
Ward, R1
Chalermchai, T1
Tantiphlachiva, K1
Suwanrusme, H1
Voravud, N1
Sriuranpong, V1
Ciccolini, J8
Lacarelle, B3
Mercier, C3
McKenna, EF1
Licitra, S1
Aliberti, C1
Tzekova, V1
Collins, S1
Gansert, J2
Wolf, M1
Kong, D1
Song, T1
Ru, T1
Fantini, M1
Gianni, L2
Possenti, C1
Drudi, F1
Sintini, M1
Bagli, L1
Chung, H1
Chaudhry, J1
Lopez, CG1
Ling, W1
Snoeren, N1
Bergman, AM1
Tollenaar, RA1
van der Sijp, JR1
Schouten, SB1
Rinkes, IH2
van Hillegersberg, R1
Oh, M1
Francheschi, D1
Livingstone, A1
Lombardo, Y1
Scopelliti, A1
Cammareri, P1
Todaro, M1
Iovino, F1
Gulotta, G1
Dieli, F1
Di Battista, M2
Morselli-Labate, AM1
Paragona, M1
Corbelli, J1
Macchini, M1
Prandoni, P1
Baldi, PL1
Antonucci, A1
Torsello, A1
Ettorre, GM1
Zeuli, M5
Campanella, C1
Vennarecci, G1
Cognetti, F9
Chang, MH1
Si, Y1
Woo, IS2
Ciacio, O1
Muñoz-Martin, AJ1
Alvarez-Suarez, S1
Jerez-Gilarranz, Y1
Khosravi, P1
Mariani, P3
Boisseau, A1
Sastre, X1
Cucherousset, J1
Lagorce, C1
Schischmanoff, PO2
Vourli, G1
Xanthakis, I3
Papadimitriou, C1
Samelis, G2
Syrigos, KN3
Xiros, N1
Stavropoulos, M2
Kosmidis, P10
Christodoulou, C1
Linardou, H1
Skondra, M1
Economopoulos, T3
Whyte, S1
Pandor, A1
Stevenson, M1
Rees, A1
Pander, J1
Wessels, JAM1
Vrdoljak, E1
Omrčen, T1
Boban, M1
Hrabar, A1
Tsai, PC1
Chuang, SC2
Hou, MF2
Baird, R1
Biondo, A1
Chhaya, V1
McLachlan, J1
Karpathakis, A1
Barbachano, Y4
Knijn, N1
Werter, MJ2
Imholz, AL1
Valster, FA1
Vincent, AD1
Teerenstra, S5
Vaidyanathan, G1
Groman, A2
Nicolella, D1
Dapretto, E1
Valeri, N1
Gasparini, P1
Braconi, C1
Paone, A1
Lovat, F1
Fabbri, M1
Sumani, KM1
Alder, H1
Patel, T2
Nuovo, GJ1
Fishel, R1
Croce, CM1
Hasbak, P1
Mortensen, J1
Matsunoki, A1
Ramiscal, JA1
Jatoi, A1
Sabatier, R1
Plat, F1
Goubely, Y1
Molinari, N1
Fuccio, L1
Cennamo, V1
Lu, SX1
Chay, WY1
Tan, SH2
Lo, YL1
Ng, HC1
Koo, WH3
Kang, EJ1
Choi, YJ3
Park, KH2
Choi, IK1
Seo, JH2
Shin, SW2
Madajewicz, S5
Waterhouse, DM1
Ritch, PS1
Khan, MQ1
Higby, DJ1
Leichman, CG14
Malik, SK1
Hentschel, P2
Gill, JF1
George, T1
Stasi, I1
Fabbri, MA1
Puglisi, M1
Trenta, P1
Crinò, L2
Ababneh, Y1
Verpoort, K1
Schmidt, B1
Musch, R1
Soeling, U1
Maintz, C1
Fahlke, J2
Gregory, C1
Wang, PF1
Long, SR1
Tommasi, S2
Numico, G1
Petriella, D1
Millaku, A1
Gonzalez-Haba, E1
López-Lillo, C1
Barrueco, N1
Alvarez, S1
Jiménez, JL1
Martín, ML1
Muñóz-Fernández, MA1
Hazama, M1
Ho, YF1
Lu, WC1
Chen, RR1
Molina-Garrido, MJ1
Liang, XB1
Hou, SH1
Li, YP2
Wang, LC1
Mishima, Y3
Terui, Y2
Jithesh, PV3
Oliver, GR1
Proutski, I4
Proutski, V1
Harkin, P1
Kadota, K1
Huang, CL1
Yokomise, H1
Haba, R1
Utsunomiya, S1
Kawai, H1
Gordon, MA2
El-Khouiery, A1
Labonte, M1
Wilson, P3
Sherrod, A3
Stojadinovic, A1
Doerfer, J1
Fasol, U1
Arends, J1
Hense, J1
Scheulen, ME1
Nguyen, TP1
Ettlinger, D1
De Marchis, ML1
Schirru, M1
Park, KS1
Chung, HC3
Kitazono, M1
Yamamoto, M4
Morikita, T1
Prasad, RB1
Lorenzo Bermejo, J1
Kim, YK1
Hirota, M2
Kawano, K1
Izumi, H1
Kohno, K1
Samaras, P1
Breitenstein, S1
Haile, SR1
Stenner-Liewen, F1
Heinrich, S4
Feilchenfeldt, J1
Renner, C1
Knuth, A5
Pestalozzi, BC5
Clavien, PA2
Krieger, PM1
Faybik, P1
Fleischmann, E1
Maresch, J1
Ocean, AJ1
Polite, B1
Christos, P1
Horvath, L2
Hamilton, A1
Matulich, D1
Sparano, JA1
Kindler, HL4
Jacene, H1
Kulesza, P1
Laheru, DA2
Kahn, Y1
Spira, A1
Dancey, J2
Iacobuzio-Donahue, C2
Carducci, M1
Camacho, LH1
Garcia, S1
Panchal, AM1
Lim, J1
Hong, DS1
Ng, C1
Madoff, DC1
Gayed, I1
Kurzrock, R2
Kumamoto, T2
Nojiri, K2
Matsuyama, R2
Akiyama, H1
Katsumoto, Y1
Aritake, N1
Endoh, A1
Hosokawa, T1
Tokita, H1
Iwao, Y1
Koshinaga, T1
Miura, I2
Itoyama, S2
Kanoh, T4
Tono, T9
Tsukao, Y1
Inatome, J1
Kagara, N1
Monden, T6
Imaoka, S2
Kagawa, S1
Takeuchi, D1
Ko, S1
Mukogawa, T1
Nishiwada, T1
Nakamoto, T1
Kunishige, T1
Aoyagi, H1
Katsuta, E1
Someno, Y1
Saguchi, M1
Takahata, T1
Hamada, S1
Maejima, S1
Otsuka, Y1
Shiokawa, H1
Kurihara, A2
Funahashi, K1
Shimada, H8
Choi, MS1
Ng, S1
O'bichere, A1
Daniele, S1
Frezza, AM4
Berti, P2
Vespasiani, U2
Zhou, MQ1
Chai, H1
Tian, R1
Nakano, H4
Sakurai, J1
Koizumi, S2
Shimamura, T3
Makizumi, R1
Yamada, K3
Miyajima, N2
Otsubo, T1
Kidera, Y1
Okamoto, I2
Fumita, S1
Makimura, C1
Kiyota, H1
Tsurutani, J1
Yoshinaga, M2
Fujiwara, K3
Yamazoe, Y1
Moriyama, K1
Chiba, Y1
Seki, A1
Hori, S2
Nishioka, M1
Kurita, N1
Iwata, T1
Miyatani, T1
Fridlyand, J1
Kaiser, LD1
Fyfe, G2
Cushman, S1
Aklilu, M1
Ashton, J1
Duret, A1
Etienne, MC9
Falandry, C2
Saffery, C1
Khan, A2
Strimpakos, AS1
Thomas, J1
Compton, S1
Chua, YJ1
Hass, HG2
Dietzfelbinger, H2
Oruzio, D2
Klein, S2
Zellmann, K2
Abenhardt, W2
Puchtler, G2
Kappauf, H2
Mittermüller, J2
Haberl, C2
Franchina, T1
Minciullo, PL1
Pace, E1
Colonese, F1
Ricciardi, GR1
Saitta, S1
Ferraro, M1
Spatari, G1
Gangemi, S1
Sogabe, S2
Hatanaka, K1
Usui, K1
Katou, Y1
Tanai, C1
Ishihara, T1
Nelson, MA1
Shetty, S1
Kulakodlu, M1
Harley, C1
Seal, B1
Shah, NR1
Shah, A4
Rather, A1
Caronia, D1
de la Torre, J1
García-Sáenz, JA1
Alonso, MR1
Moreno, LT1
Benítez, J1
Iguchi, T1
Idani, H1
Asami, S2
Kanazawa, S1
Perrocheau, G1
Dominguez, S2
Florentin, V1
Urasinska, E1
Tan, WL2
Bhattacharya, B1
Balasubramanian, I1
Akram, M1
Thakkar, B1
Soo, RA2
Fichtner, I1
Tsukioka, S1
Tsujimoto, H2
Kiniwa, M1
Hutchins, G1
Beaumont, C1
Stahlschmidt, J1
Ibrahim, T2
Amatori, F3
Mercatali, L1
Ravaioli, E1
Flamini, E2
Sacanna, E1
Bertolini, F1
Malavasi, N1
Scarabelli, L1
Fiocchi, F1
Bagni, B1
Del Giovane, C1
Gerunda, GE1
Depenni, R1
Zironi, S3
Pettorelli, E1
Luppi, G3
Conte, PF9
Klaver, YL3
Cabebe, EC1
Frumento, P3
Zhi, J2
Major, P2
Burns, I1
Rittweger, K2
Abt, M1
Zissen, MH1
Kunz, P1
Subbarayan, M1
Chin, FT1
Conti, PS3
Quon, A1
Backshall, A1
Keun, HC1
Hoff, P3
Saini, JP1
Gilberg, F3
Meguro, E1
Shibata, H1
Hoshino, Y2
Nishi, T2
Warita, E2
Miyamoto, J1
Akutsu, N1
Xiao, H1
Yokoyama, H2
Okuda, N1
Iwata, N1
Ohashi, N2
Nakao, A4
Yoon, CJ1
Shin, DY1
Lee, YG1
Choi, SY1
Kang, SG1
Cooper, A1
Garrett, CR1
Starling, N2
Vázquez-Mazón, F1
Countouriotis, AM1
Ruiz-Garcia, A1
Wei, G1
Tursi, JM2
Seki, K1
Senzaki, K1
Tsuduki, Y1
Ioroi, T1
Yamauchi, H1
Shiraishi, Y1
Nakata, I1
Nishiguchi, K2
Matsubayashi, T1
Takakubo, Y1
Okamura, N1
Muhale, FA1
Wetmore, BA1
Thomas, RS1
Balboa, E1
Touris, M1
Vidal, Y1
Germond, C1
Berg, W2
Chen, BL2
Jalava, T2
Lebwohl, D3
Meinhardt, G3
Laurent, D3
Lin, E3
Jäger, E4
Lloyd-Salvant, K1
Pendergrass, K1
Vogel, UB1
Andersen, JT2
Broedbaek, K1
Petersen, M2
Jimenez-Solem, E2
Bertolaso, L2
Boston, EA1
Gaffney, EA1
Lopez, M9
Copetti, M1
Tuveri, G1
Xavier, CP1
Lima, CF1
Rohde, M1
Pereira-Wilson, C1
Rodriguez, NA1
Ascaso, FJ1
Pichereau, S1
Le Louarn, A1
Blasco, H1
Le Guellec, C1
Bourgoin, H1
Burylo, AM1
Doodeman, VD1
Smits, PH1
Motoori, S1
Kawase, T1
Nishimura, H1
Konno, T1
Hanai, C1
Kitagawa, N1
Saisho, H1
Furuse, J1
Mashimo, Y1
Ezoe, Y1
Nowacki, MP1
Shchepotin, I1
Perrone, G3
Ruzzo, AM1
Crucitti, P1
Galluzzo, S1
Zoccoli, A1
Rabitti, C2
Muda, AO1
Hofmann, G1
Langsenlehner, U1
Langsenlehner, T1
Glehr, M1
Absenger, G2
Szkandera, J1
Fuerst, F1
Krippl, P1
Renner, W1
Hinrichs, J1
Tan, TH1
Dowling, R2
Lichtenstein, M1
Kakefuda, R1
Tajima, N1
Sowa, Y2
Vignoli, M1
Putignano, AL1
Papi, L1
Genuardi, M1
Almagro, BM1
Steyls, MC1
Navarro, NL1
Domínguez, EG1
Acosta, EH1
Pérez, MA1
Ceballos, EH1
Van Loon, K1
Hesketh, PJ2
Sanz-Altamira, P1
Bushey, J1
Hesketh, AM1
Kawahara, K2
Ueda, R1
Fukui, E1
Yamada, R2
Thompson, LC1
Brewster, AE1
Shepherd, SF1
O'Mahony, MS1
Parmar, M2
Langley, RE1
Garant, A1
Des Groseilliers, S1
Martin, L1
Ferland, É1
Vuong, T1
Saridaki, Z2
Hongo, K3
Tanaka, J2
Tsuno, NH3
Sunami, E5
Kitayama, J7
Nagawa, H6
Nishibori, N1
Itoh, M1
Kashiwagi, M1
Arimochi, H1
Morita, K1
Yao, W1
Xiong, Y1
Nie, L1
do O, N1
Fuchs, R2
Bubenzer, J1
Spannbauer, M1
Luedde, T1
Trautwein, C1
Tischendorf, JJ1
Baraniskin, A1
Munding, J1
Meier, D1
Putzu, C2
Sandomenico, C3
Vessia, G1
Ionta, MT1
Barbato, E1
Dennie, TW1
Fleming, RA1
Bowen, CJ1
Dar, MM1
Alberti, D1
Oliver, K1
Loconte, N1
Mulkerin, D1
Paule, I2
Boc, M1
Khelwatty, SA1
Seddon, AM1
Modjtahedi, H1
Huang, SM1
Chien, CC1
Lee, CL1
Wu, HH1
Nyström, H1
Naredi, P3
Hafström, L7
Sund, M1
Johnston, L1
McCloskey, K1
Heun, JM1
Branda, ME1
Asseburg, C2
Frank, M1
Griebsch, I2
Mohr, A1
Osowski, U1
Schulten, J1
Mittendorf, T1
Hwang, WL1
Yang, MH1
Tsai, ML1
Su, SH1
Wang, HW1
Hewish, M1
Wilson, RH5
Kenny, SL3
Mitchell, JK1
Jasani, B1
James, MD1
Kennedy, MJ3
Claes, B1
Hodgkinson, E1
Pope, M1
Rogers, P1
Bessell, EM2
Bot, BM1
Thomas, DM1
Bleyer, A1
Chua, A1
Shivasami, A1
Wilson, BJ1
Schatton, T1
Zhan, Q1
Saab, KR1
Schanche, R1
Waaga-Gasser, AM2
Gold, JS1
Murphy, GF1
Frank, MH1
Frank, NY1
Ross, JS1
Brown, C1
Ransom, DT1
Jeffrey, GM1
Buck, M1
Lowenthal, RM1
Boland, A1
Galluccio, N1
Manzoni, M1
Danova, M2
O'Connor, JP1
Rose, CJ1
Jackson, A1
Watson, Y1
Cheung, S1
Maders, F1
Whitcher, BJ1
Roberts, C1
Buonaccorsi, GA1
Thompson, G1
Clamp, AR1
Jayson, GC1
Parker, GJ1
Adamsen, BL1
Kravik, KL2
De Angelis, PM2
Saito, S2
Kanazawa, T3
Kazama, S2
Yazawa, K3
Larsen, O1
Kobunai, T3
Iinuma, H3
Horie, H1
Urick, ME1
Chung, EJ1
Shield, WP1
Gerber, N1
White, A1
Sowers, A1
Thetford, A1
Camphausen, K1
Citrin, DE1
Zalinski, S1
Mariette, C1
Farges, O2
Henriksen, T1
Farias, IL1
Farias, JG1
Rossato, L1
Araújo, MC1
Chiesa, J1
Morsh, V1
Schetinger, MR1
Chan, JY1
Qureshi, A1
Verma, A1
Landau, D1
Gallant, JN1
Allen, JE1
Smith, CD1
Dicker, DT1
Dolloff, NG1
Navaraj, A1
Ankerst, DP1
Farr, GH1
Maples, WJ1
Rubin, J7
Fuloria, J1
Steen, PD1
Tse, VC1
Ng, WT1
Lee, V1
Lee, AW1
Chua, DT1
Chau, J1
McGhee, SM1
Kuwahara, A1
Kadoyama, K1
Inokuma, T1
Takemoto, Y1
Fujishima, Y1
Holt, K1
Geh, JI1
Ma, YT1
Almeida da Cruz, L1
Ferrari, CL1
Riechelmann, RS1
de Andrade, DP1
Lima, AD1
Afonso, S2
Viani, G1
Afonso, V1
Stefano, E1
Rocha, JA1
Butera, A2
Di Lucca, G1
De Pauli, F1
Parra, HS1
Bethke, A1
Kühne, K1
Platzek, I1
Sasaki, H1
Matsueda, S1
Mizota, A1
Kondo, C2
Nomura, M1
Mehta, SS1
Hessissen, M1
Saint-Aubert, B1
Lee, HN1
Lim, Y1
Won, HS1
Chun, SH1
Tateishi, U1
Kambe, M2
Gamo, M2
Kanamaru, R2
van Houte, BP1
Hanauske, AR2
Giaccone, G5
Winder, T2
Trillet-Lenoir, V3
Kraemer, S1
Veldhuis, GJ1
Ten Bokkel Huinink, D1
Muller, EW2
Horinouchi, Y1
Sakurada, T1
Tajima, S1
Nishisako, H1
Teraoka, K1
Kujime, T1
Kawazoe, K1
Minakuchi, K1
Akil, H1
Nouaille, M1
Petit, D1
Labrousse, F1
Choi, S2
Eropkin, PV1
Rybakov, EG1
Kashnikov, VN1
Panina, MV1
Polysalov, VN1
Rutkin, IO1
Krotova, OA1
Tlostanova, MS1
Jacques, N1
Vimond, N1
Pierga, JY2
Guichard, P1
Cvitkovic, F2
Farace, F1
Cao, B1
Li, ST1
Deng, WL1
Min, BH1
Lee, EJ1
Yu, HS1
Park, CK1
Kim, KM1
Fukase, K1
Skamoto, J1
Suzuki, C1
Blomqvist, L1
Sundin, A1
Jacobsson, H1
Kishino, T1
Rai, K1
Tsushima, M1
Kudo, K1
Mizuta, M1
Yonei, T1
Yamadori, I1
Kiura, K1
Ishiguro, S2
Hiramatsu, K1
Nishio, H1
Takeuchi, E1
Ebata, T1
Nagino, M1
Mohammed, TA1
Dennie, T1
de la Cruz-Morcillo, MA1
Valero, ML1
Callejas-Valera, JL1
Arias-González, L1
Melgar-Rojas, P1
Galán-Moya, EM1
García-Gil, E1
García-Cano, J1
Sánchez-Prieto, R1
Shumaker, GC1
Khandelwal, P1
Smith, DA1
Neubauer, MA1
Mehta, N1
Watkins, DL1
Yassine, MR1
Pathak, P1
Saam, J1
Critchfield, GC1
Hamilton, SA2
Roa, BB1
Wenstrup, RJ1
Kaldate, RR2
Kuniyoshi, R1
Kummar, S2
Rose, M1
Wadler, S14
O'Rourke, M2
Brenckman, W1
Tilton, R1
Cheng, YC1
Sehgal, R1
Lembersky, BC2
Rajasenan, KK1
Crandall, TL1
Balaban, EP2
Pinkerton, RA1
Kane, P1
Schmotzer, A2
Zeh, H1
Potter, DM1
Teixeira, L1
Nitzkorski, JR1
Farma, JM1
Watson, JC2
Siripurapu, V1
Zhu, F2
Matteotti, RS1
Sigurdson, ER4
Mayerle, J1
Bangerter, M1
Sieber, M1
Teschendorf, C1
Aubele, P1
Okumura, T1
Ohde, Y1
Kondo, H4
Yusuf, SW1
Wang, JP1
Wu, PH1
Opdam, FL1
Swen, JJ1
Wessels, JA1
Vijayaraghavan, A1
Efrusy, MB1
Göke, B1
Santas, CC1
Abbas, M2
Baldi, GG1
Tuzi, A1
Hassan, S1
Laryea, D1
Felth, J1
Fryknäs, M1
Fayad, W1
Linder, S1
Rickardson, L1
Gullbo, J1
Larsson, R1
Rubie, C1
Frick, VO1
Ghadjar, P1
Justinger, C1
Graeber, S1
Kollmar, O1
Schilling, MK1
Kawase, Y1
Takami, Y1
Mizuno, A1
Uno, Y1
Sasada, Y1
Takamura, S1
Kozaki, K1
Bonnefoy, M1
Brødbæk, K1
Orosz, E1
Lam, VW1
Spiro, C1
Laurence, JM1
Johnston, E1
Hollands, MJ1
Pleass, HC1
Richardson, AJ1
Farrar, WL1
Sheikh, HS1
Gingrich, R1
Finnberg, NK1
Mohapatra, P1
Preet, R1
Choudhuri, M1
Choudhuri, T1
Kundu, CN1
Fromm, AL1
Sun, AM1
Wang, LH1
He, MR1
Kumar, RV1
Sinha, VR2
Jego, G1
Joly, AL1
Gobbo, J1
Penard-Lacronique, V1
Zouali, H1
Tubacher, E1
Kirzin, S1
Tiret, E1
Muratore, A3
Zimmitti, G2
Mellano, A1
Ternant, D1
Piller, F1
Vignault-Desvignes, C1
Guan, ZZ3
Liang, J3
Qin, SK2
Qi, C1
Decosta, L1
Egashira, A1
Toyama, T1
Ohga, T1
Kohakura, F1
Niwa, K2
Kohnoe, S6
Nemunaitis, J2
Vukelja, SJ2
Hagenstad, C1
Campos, LT1
Hermann, RC2
Sportelli, P1
Gardner, L1
Gormley, JA1
Hegarty, SM1
O'Grady, A1
Stevenson, MR1
Burden, RE1
Barrett, HL1
Scott, CJ1
Johnston, JA1
Olwill, SA1
Yoneda, A1
Matsuo, M1
Kajiyama, M1
Kishikawa, H1
Pilgrim, CH1
Brettingham-Moore, K1
Pham, A1
Murray, W1
Link, E1
Smith, M1
Usatoff, V1
Evans, PM1
Banting, S1
Thomson, BN1
Phillips, WA1
Lacouture, ME1
Shearer, H1
Iannotti, N1
Pillai, MV1
Yassine, M1
Viret, F3
Crapez-Lopez, E1
Bleuse, JP1
McMahon, J1
Cen, P1
Du, XL1
Ahmad, MZ2
Akhter, S2
Anwar, M2
Singh, A3
Ahmad, I1
Ain, MR1
Jain, GK1
Khar, RK1
Ahmad, FJ2
Coyle, VM2
Carson, G1
Tatematsu, M2
Ishikawa, K4
Noma, H2
Komlósi, V2
Nagy, T2
Bienvenu, B1
Harker, WG1
Birchfield, G1
Tokaz, LK1
Barrera, D1
Conkling, PR1
O'Rourke, MA2
Reidy, D1
Solit, D1
Vakiani, E1
Scales, A1
Zhan, F1
Sano, T1
Rho, JK1
Bousquet, G1
Biau, J1
Roulin, C1
Robine, S1
Rahman, M1
Chan, AP1
Schmid, J2
Kehoe, J1
Dicker, P2
Murray, F1
Huber, HJ1
Tsuji, S1
Midorikawa, Y1
Yagi, K1
Aburatani, H1
Lee, PH3
Brienza, S17
Gomi, K2
Chung, HJ1
Esch, A1
Perkins, G2
Danenberg, K4
Goeb, R1
Staib, L4
Kron, M1
Henne-Bruns, D3
Danenberg, P2
Fujita, M5
Minegaki, T1
Franko, J1
Goldman, CD1
Pockaj, BA2
Nelson, GD1
Pelletier, E1
Bhosle, M1
Klingman, D1
Bradley, WD1
Lee, RJ1
Schostack, K1
Simcox, ME1
Lestini, B1
Bollag, G1
Su, F1
Smith, DH1
Nygård, SB1
Nielsen, KV1
Mbatchi, L1
Tibbitts, J1
Ries, P1
Norguet, E1
Iliadis, A3
Ouafik, L1
Bellot, GL1
Tan, WH1
Tay, LL1
Koh, D1
Kan, S1
Maeda, Y5
Kamei, R1
Maeda, N1
Tominaga, H1
Kashiwagi, S1
Fuyuhiro, Y1
Ishibashi, H1
Sako, S1
Mizumoto, A1
Hirano, M2
Ichinose, M1
Takao, N1
Matsuda, N1
Togawa, T1
Ozamto, Y1
Chang-Yun, L1
Elnemr, A1
Xiao-Jun, Y1
Chikatani, K1
Amano, K2
Iwama, T5
Ono, T2
Honjou, H1
Onouchi, T1
Yakabi, K1
Manceau, G1
Blons, H1
Shi, Z1
Bai, R1
Zhu, YL1
Wang, RF1
Lee, CF1
Yu, MC1
Lee, WC1
Kato, S6
Ozeki, M1
Hossain, AM2
Stoffregen, C1
Nicol, S1
Samuel, T1
Fadlalla, K1
Mosley, L1
Katkoori, V1
Turner, T1
Manne, U1
Munakata, M4
Yanai, T2
Stoll, C1
Kemper, K1
Rodermond, H1
Colak, S1
Grandela, C1
Hu-Lieskoven, S1
Kahn, M2
Teo, JL1
Shriki, J1
Stebbing, J1
Martínez de Prado, P2
Arrivi, A3
Lacasta, A1
Llanos, M1
Antón, A9
Miano, ST1
Marzocca, G2
Tabuse, K1
Nakatani, Y1
Fukiage, O1
Makrantonakis, P1
Xynogalos, S1
Christophyllakis, Ch1
Mwenifumbo, JC1
Cheung, PY1
Paul, JE1
Ally, AA1
Miao, L1
Lee, A1
Severson, T1
Cheng, GS1
Novik, K1
Moore, R1
Luk, M1
Owen, D2
Brown, CJ1
Qing, H1
Che, Y1
Ferrero, A1
Langella, S1
Russolillo, N1
Vigano', L1
Lo Tesoriere, R1
Tsai, WS1
Hsieh, PS3
Yeh, CY3
Changchien, CR5
Gaya, A1
Tse, V1
Manca, A1
Bravo Vergel, Y1
Meade, A1
Stephens, R1
Sculpher, MJ1
Broadbridge, V1
Jain, K1
Luke, C1
Atreya, CE1
Ducker, GS1
Feldman, ME1
Bergsland, EK1
Warren, RS4
Shokat, KM1
Biondani, P1
Marchianò, A1
Jin, CH1
Wang, AH1
Chen, JM1
Li, RX1
Wang, GP3
Xing, LQ1
Burtness, B1
Mintzer, D1
Ruth, K1
Tuttle, H1
Sylvester, J1
Xu, HX2
Li, CG2
Tang, JH1
Bhattacharya, D1
Easthall, C1
Willoughby, KA1
Small, M1
Watson, S1
Cazier, JB1
Crous-Bou, M1
Guinó, E3
González, D1
Gonzalo, V1
Rodrigo, L1
Brea-Fernández, A1
Xicola, R1
Xia, H1
Collette, L3
Nishida, N1
Mimori, K2
Sudo, T1
Tanaka, F2
Shibata, K3
Feng, WM1
Tang, CW1
Huang, SX1
Zheng, YY1
Bao, Y1
Tao, YL1
Laroche-Clary, A1
Kauffmann, A1
Laurand-Quancard, A1
Evrard, S1
Chandramathi, S1
Suresh, K1
Anita, ZB1
Welch, S1
Krzyzanowska, MK1
Knox, J1
Feld, R3
MacKay, H1
Petronis, J1
Fujishima, H2
Hong, X1
Lou, C1
Yoshizaki, K1
Fujii, S2
Nakajima, K3
Sugito, M1
Haregewoin, A1
Grier, CE1
Tojima, Y1
Suzumura, K2
Naganuma, T1
Kwok, CS2
Matthews, V1
Wawruch, P1
Loke, YK1
Assy, N1
Basher, W1
Chetver, L1
Shnaider, J1
Zidan, J1
Qian, ZY1
D'Hoore, A1
Fieuws, S1
Bertrand, C1
Legendre, H2
Kerger, J1
Chen, XF1
Yin, YM1
Røe, OD1
Zhu, LJ1
Guo, RH1
Shu, YQ1
Weber, T1
Roitman, M1
Tada, N2
Nirei, T2
Lechuga, MJ3
Hirohashi, T1
Shibata, A1
Hashigaki, S2
Lee, KA1
Nam, YS1
Oh, YH1
Macedo, LT1
da Costa Lima, AB1
Hori, N1
Murakoshi, K1
Yokote, N1
Park, LC1
Kang, MJ2
Gil-Calle, S2
Cabrera, E1
Gómez, MJ1
Guasch, I3
Etxeberría, A1
Alfaro, J1
Sarac, SB1
Rasmussen, CH1
Thirstrup, S1
Colding-Jørgensen, M1
Mosekilde, E1
Büchel, B1
Rhyn, P1
Schürch, S1
Bühr, C1
Brittain, EH1
Fay, MP1
Follmann, DA1
Tarver, K1
Conibear, J1
Sigurdsson, F1
Kure, E1
Birkemeyer, E1
Starkhammar, H7
Erdal, AB1
Christoffersen, T1
Conlon, S1
Cummins, RJ1
Hennebelle, I2
El Hannani, C1
Jacob, JH3
Coudert, B5
Mormont, MC2
Waterhouse, J2
Richardson, PG1
Kolesar, J1
Hideshima, T1
Anderson, KC1
Ng, SL1
Burns, WI1
Snyder, RD1
Newnham, GM1
McLachlan, SA1
Liew, D1
Dowling, AJ1
Fujinaka, Y1
Morita, M3
Dexiang, Z1
Haifu, W1
Yunshi, Z1
Qinghai, Y1
Shenyong, Z1
Bo, X1
Xiangou, P1
Haohao, L1
Lechi, Y1
Tianshu, L1
Jia, F1
Xinyu, Q1
Jianmin, X1
Metzger, T1
Tatum, C1
Sharma, V1
Mizutani, N1
Lawal, TO1
Farris, AB1
Subramanian, RM1
Arii, S1
Nie, YL1
Zhang, MM1
Li, YL1
Chen, JR1
Márquez, E1
Rodríguez, E1
Pascual, J1
Alejandro, LM1
Behrendt, CE1
Openshaw, H1
Qiu, W2
Xiang, J3
Wei, H2
Sui, A2
Muldoon, C1
Mehigan, B1
Vandebroek, A1
Deleu, I1
Vergauwe, P2
Efira, A1
Kidwell, KM1
Ganz, PA1
Land, SR1
Ko, CY1
Cecchini, RS1
Kopec, JA1
Bleichrodt, RP2
Apollinari, S1
Abbruzzese, A2
Sperlongano, P1
Fukasawa, T1
Tabe, Y1
Kigure, W2
Saraymen, R1
Yasuda, T6
Shinmura, K1
Yokomizo, K1
Sakuraba, K1
Kitamura, Y1
Shirahata, A1
Saito, M1
Kigawa, G1
Nemoto, H1
Sanada, Y1
Feng, JP1
Zhu, YM1
Ye, DW1
Yeo, SG1
Kim, KH1
Cho, MJ1
Kim, ES1
Yoo, BC1
Ferdinande, L1
Libbrecht, L1
Ida, S1
Ogasawara, N1
Esumi, H1
Kwok, A1
Patt, YZ5
Barroso, E1
Nuzzo, G4
Laurent, C1
Ijzermans, JN1
Figueras, J3
Mirza, DF2
Isoniemi, H1
Herrera, J1
Sousa, FC1
Pardo, F2
Popescu, I1
Bauer, KM1
Lambert, PA1
Hummon, AB1
Cetin, B2
Ozturk, SC1
Benekli, M5
Coskun, U5
Goyer, P1
Hajjam, ME1
Maestro, ML1
Karaca, B1
Sezgin, C1
Gulec, SA1
Pennington, K1
Wheeler, J1
Barot, TC1
Suthar, RR1
Schwartzentruber, D1
Kapaun, C1
Wollenberg, A1
Farid, M1
Chowbay, B1
Ramasamy, S1
Orsucci, D1
Pizzanelli, C1
Calabrese, R1
Ricci, G1
Lenzi, P1
Petrozzi, L1
Moretti, P1
Siciliano, G1
Yin, XG1
Xu, JF2
Cheng, LZ1
Lee, EK1
Revil, C1
Ngoh, CA1
Lister, J1
Kwon, JM1
Lee, NS1
Bae, EJ1
Treska, V1
Safranek, J1
Lysak, D1
Mirka, H1
Skalicky, T1
Slauf, F1
Hes, O1
Shi, MM1
Dellas, K1
Reese, T1
Richter, M2
Dunst, J2
Capitain, O2
Asevoaia, A1
Poirier, AL2
Takanashi, K1
Katsuki, S1
Fujita, T1
Waga, E1
Shimodate, Y1
Someya, T1
Ustuner, Z2
Akay, OM1
Keskin, M1
Kuş, E1
Bal, C1
Gulbas, Z1
Ku, GY1
Haaland, BA1
de Lima Lopes, G1
Guo, ST1
Jiang, CC1
Guo, XY1
Yang, RH1
Tseng, HY1
Thorne, RF1
Zhang, XD2
Mochinaga, S1
Okahashi, T1
Koga, S2
Yakabe, T1
Sumi, K1
Kitahara, K2
Noshiro, H1
Kimura, S1
Fujito, H1
Hisa, A1
Alkis, N2
Ciltas, A1
Yetisyigit, T2
Dogu, GG1
Liu, ZC1
Liu, JG1
Dugué, PA1
Eleftheraki, AG1
Nikitas, N1
Papandreou, CN1
Timotheadou, E2
Koutras, A2
Klouvas, G1
Tsukioka, Y1
Yabushita, K3
Fukuoka, J1
Shiraishi, K1
Murakawa, Y2
Gafson, AR1
Goodkin, O1
Begent, R1
Doornebal, J1
Lemmens, W1
Corrie, PG1
Bulusu, R1
Wilson, CB1
Armstrong, G1
Bond, S1
Hardy, R1
Lao-Sirieix, S1
Parashar, D1
Blesing, C1
Moody, AM1
McAdam, K2
Osborne, M1
Mo, Y1
Patel, K2
Yerram, SR1
Azad, NA1
Julien, S1
Merino-Trigo, A1
Landron, S1
Bigot, L1
Lantuas, D1
Morgand, L1
Pham, E1
Gonin, P1
Job, B1
Dessen, P1
Bruno, A1
Pierré, A1
De Thé, H1
Soliman, H1
Nunes, M1
Lardier, G1
Calvet, L1
Demers, B1
Prévost, G2
Vrignaud, P1
Roman-Roman, S1
Duchamp, O1
Berthet, C1
Valentino, JD1
Elliott, VA1
Zaytseva, YY1
Rychahou, PG1
Mustain, WC1
Evers, BM1
Prasad, S1
Yadav, VR1
Sung, B1
Reuter, S1
Kannappan, R1
Wei, C1
Baladandayuthapani, V1
Glockzin, G2
von Breitenbuch, P1
Zhang, HX1
Xu, LX1
Zhang, ZQ1
Yuan, KT1
Xue, CL1
Yu, HL1
Shi, HP1
Salut, A3
León, AI1
Sevilla, I3
Esteban, B1
García-Rico, E1
Murias, A1
Cortés-Funes, H5
Nacle-López, I1
García-Escobar, I1
Aguilella-Vizcaíno, MJ1
Herreros-de-Tejada, A1
Cortés-Funes Castro, H1
Calleja-Hernández, MÁ1
Bollet, MA1
Servois, V1
Zefkili, S1
Farkhondeh, F2
Baranger, B1
Turkington, R1
Zanusso, C1
Errante, D2
Garassino, MC1
Ishiyama, A1
Eguchi, T3
Uchida, N1
Hosouchi, Y1
Yashuda, N1
Harris, DR1
Mims, A1
Bunz, F2
Wienke, A1
Edelmann, T1
Hollerbach, S1
Kitamura, H1
Koike, S2
Nakazawa, K1
Matsumura, H1
Yokoi, K2
Arai, M1
Nishizuka, SS1
Kume, K1
Endo, F1
Katagiri, H1
Noda, H1
Iwaya, T1
Itabashi, T1
Maesawa, C1
Tamura, G1
Koeda, K1
Wakabayashi, G1
Jin, HR1
Liao, Y1
Huang, WH1
Li, SP1
Hamada, M1
Okigami, M1
Morimoto, Y1
Matsushita, K2
Kawamura, M1
Hashimoto, K1
Saigusa, S1
Araki, T1
Mohri, Y1
Mizoguchi, A1
Rong, R1
Mo, L1
Kuang, Y1
Tao, Q1
Dong, Q1
Nichols, LL1
Pettersson, K1
Holmberg, C1
Sporrong, SK1
Ambrosy, AP1
Kunz, PL1
Witteles, RM1
Mima, K1
Kuroki, H1
Kikuchi, K3
Moiseyenko, V1
Polikoff, J2
Tellier, A1
Castan, R1
Jiang, WQ1
Fu, FF1
Li, YX1
Wang, WB1
Wang, HH1
Jiang, HP1
Teng, LS1
Honoré, C1
Tzanis, D1
Park, C1
Fajardo, AD1
Tan, B1
Reddy, R2
Fleshman, J1
Lacunza, E1
Canzoneri, R1
Rabassa, ME1
Zwenger, A1
Segal-Eiras, A1
Croce, MV1
Abba, MC1
Koski, SL1
Barker, P1
Mookerjee, B1
Koynov, KD1
Pike, L1
Fielding, A1
Wu, XL1
Zhang, LW1
Chen, SS2
Garrett, C1
Aloia, TA2
Wernroth, L1
Johansson, B1
Larsson, A1
Woloch, C1
Marouani, H1
Hamdi, S1
Graf, C1
Hainz, M1
Theobald, M1
Adler, K1
Trojan, D1
Bombled, M1
Méchighel, P1
Muleris, M1
de Reynies, A1
Florent, JC1
Mahuteau-Betzer, F1
Faussat, AM1
Lieberman, R1
Tezcan, H1
Roach, N1
Mun, Y1
Fish, S1
Flick, ED1
Dalal, D1
Saelen, MG1
Ree, AH2
Kristian, A1
Fleten, KG1
Furre, T1
Hektoen, HH1
Uguen, T1
Leconte, B1
Desgrippes, R1
Tchoundeu, B1
Bretagne, JF1
Baños, A1
Constantinidou, A1
Shurmahi, F1
Asghar, U1
Rossi, L1
Veltri, E1
Zullo, A1
Colonna, M1
Di Seri, M4
Giannarelli, D7
Ruco, L1
Barucca, V1
Adua, D1
Tomao, S1
Gencer, D1
Wolf, PS1
Bao, F1
Tzeng, CW1
Lyseng-Williamson, KA1
Kao, TY1
Tsai, YW1
Rocha Lima, CM1
Bayraktar, S1
Flores, AM1
MacIntyre, J1
Montero, A1
Baranda, JC1
Wallmark, J1
Raja, R1
Stern, H1
Amler, LC1
Ying, HY1
Yang, XD1
Ning, XH1
Chaturvedi, K1
Tripathi, SK1
Kulkarni, AR1
Aminabhavi, TM1
Mackey, HM1
Yauch, RL1
Graham, RA1
Bray, GL1
Low, JA1
King, TM1
Chang, MC1
Hatwell, C1
Bretagnol, F1
Panis, Y2
Demolin, G2
Kreutz, F6
Graas, MP4
Longrée, L5
Matus, G1
Moeneclaey, N5
Focan-Henrard, D7
Sairanen, U1
Blom, M1
Rautio, M1
Saxelin, M2
Chachad, S1
Purandare, S1
Malhotra, G1
Naidu, R1
Tran, TH1
Rui, H1
Knudsen, ES1
Elsaleh, H6
Fluge, Ø1
Vonen, B2
Myrvold, HE1
Deboever, G1
Hiltrop, N1
Cool, M1
Lambrecht, G1
Odejide, O1
Szymonifka, J1
Hezel, A1
Bates, DO1
Symonds, KE1
Varey, AH1
Ramani, P1
Giantonio, BJ3
Harper, SJ1
Lucchetta, M1
Gouillou, M1
Jefford, M2
McArthur, G1
Copeman, M1
Lynch, K1
Lee, SS2
Curran, D1
Sartorius, U1
Van Praagh, I1
Belliere, A1
Mouret-Reynier, MA1
Kwiatkowski, F3
Mahammedi, H1
Dillies, AF1
Chevrier, R2
Francis, WP1
Ho, T1
Satram-Hoang, S1
Lee, L1
Guduru, SR1
Gunuganti, AR1
Reyes, C1
Kamata, H1
Koisumi, J1
Lopez-Ben, S1
Alsina, M1
Soriano, J1
Albiol, M1
Guardeño, R1
Codina-Barreras, A1
Yu, DS1
Solvang, H1
Androulakis, N11
Kabouraki, E1
Asayama, M1
Chen, JX1
Shen, XH2
Pox, C1
Anai, H1
Rouleau, E1
Dieumegard, B1
Addeo, R1
Heberer, M1
Cesare Spagnoli, G1
Tatsushima, Y1
Egashira, N1
Narishige, Y1
Fukui, S1
Kawashiri, T1
Oishi, R1
Rana, SV1
Voboril, Z1
Krajina, A1
Weiner, P1
Nová, M1
Ryska, A1
Dvorák, J1
Kim, G2
Jung, EJ1
Ryu, CG1
Mirakhorli, M1
Rahman, SA1
Vakili, M1
Rozafzon, R1
Khoshzaban, A1
Uemoto, J1
Onodera, K1
Bonnet, S1
Mansmann, U1
Matsui, S2
Murao, S1
Phua, LC1
Mal, M1
Koh, PK1
Cheah, PY1
Chan, EC2
Ho, HK1
Mummy, D1
Koepl, L1
Blough, D1
Yim, YM1
Yu, E1
Ramsey, S1
Tran, G1
Kerr, A1
Stokes, L1
Lim, SB1
Yu, CS5
Winograd, E1
Papoulas, M1
Lahat, G1
Klausner, J1
Wong, RP1
Stone, AM1
Nohejlová Medková, A1
Kupec, M1
Bláha, M1
Dong, H1
Men, HT1
Luo, WX1
Ge, J1
Tan, BX1
Li, XR1
Chen, DJ1
Wu, JH1
Dalzell, JR1
Abu-Arafeh, A1
Campbell, RT1
Gramont, A1
Kii, T1
Kawabe, S2
Kuwakado, S1
Asaishi, K1
Miyamoto, T1
Higuchi, K1
Ichanté, JL1
Montoto-Grillot, C2
Staszewska-Skurczynska, M1
De la Cruz, JA1
Williams, JA1
Korytowsky, B1
Christensen, JG1
Lichinitser, M3
Suresh, AV1
Manikhas, G1
Warner, D1
Jain, R1
Nakatsumi, H1
Muto, S1
Uebayashi, M1
Meguro, T1
Bélanger, AS1
Harvey, M1
Nishimaki, T1
Harputluoğlu, H1
Budakoğlu, B1
Öztürk, MA1
Köş, T1
Dong, X1
Cui, B1
Stinco, S1
Squadroni, M1
Ligneau, B1
Kraft, D1
Descos, L1
Maroun, JA3
Norum, J2
Balteskard, L4
Edna, TH1
Laino, R1
Wählby, L2
Rønning, G1
Crucitta, E2
Del Gaizo, F1
Lannelli, A1
Mancarella, S6
Buzzi, F4
De Cataldis, G3
Bonino, F1
Conte, P6
Ricciardiello, L1
Bazzoli, F1
Itoh, S1
Takamatsu, M1
Horimi, T3
Nan, L1
Lindsey, JR1
Lai, MD1
Gagnadoux, F1
Roiron, C1
Carrie, E1
Monnier-Cholley, L1
Lebeau, B1
Petak, I1
Stewart, C1
Turner, PK1
Ashley, J1
Tillman, DM1
Douglas, L1
Tan, M3
Billups, C1
Mihalik, R1
Weir, A1
Tauer, K1
Shope, S1
Houghton, JA2
Liu, LX1
Zhang, WH1
Jiang, HC1
Zhu, AL1
Wu, LF1
Qi, SY1
Piao, DX1
Kelsen, DP3
Ilson, D1
O'Reilly, E3
Zaknoen, S1
Baum, C1
Statkevich, P1
Hollywood, E1
Cheeseman, SL1
Joel, SP3
Chester, JD2
Dent, JT2
Richards, FJ2
Gruber, Y1
Corovic, A1
Pichlmeier, U2
Nierhaus, A1
Hossfeld, DK2
de las Peñas, R1
Vicent, JM5
Garcerá, S2
Llorca, C3
Yuste, AL4
Farrés, J1
Baldwin, J1
Skillings, JR2
Davidson, N2
Harper, P6
Thompson, S1
Maniero, A1
Benner, SE1
Carmichael, J5
Popiela, T3
Radstone, D1
Oza, A3
Skovsgaard, T4
Munier, S1
Martin, C4
Ferrari, M2
Ohta, M1
Mashino, K1
Inoue, H1
Bogenrieder, T1
Weitzel, C3
Schölmerich, J3
Landthaler, M1
Stolz, W1
Gennatas, K2
Vadiaka, M5
Paliaros, P1
Dimitrakopoulos, A2
Diamantis, T1
Tsipras, H2
Papastratis, G4
Sugitani, M2
Nishimura, K5
Noguchi, H5
Suda, S1
Elomaa, I4
Repo, H1
Boulay, JL3
Mild, G3
Lowy, A3
Reuter, J2
Lagrange, M1
Terracciano, L4
Rochlitz, C4
Huang, KC3
Lai, HS1
Hsu, CH2
Chang, KJ2
Prabhudesai, AG1
Kumar, D1
Nagy, A1
Monson, J1
Moylan, E1
Jones, D1
Dethling, J1
Colman, J1
Coward, L1
MacGregor, S1
Kliche, KO1
Kubsch, K1
Raida, M1
Masri-Zada, R1
Höffken, K2
Lepille, D1
Marre, A1
Mignot, L1
Hua, A1
Méry-Mignard, D3
Kornek, GV6
Raderer, M8
Schüll, B3
Schmid, K2
Huber, H1
Lauria, R1
De Laurentiis, M1
Arpino, G1
Massarelli, E1
Ferrara, C1
Vernaglia Lombardi, A1
Costanzo, R1
Catalano, G15
Bianco, AR4
Calvo, E3
Cortés, J2
González-Cao, M1
Aramendía, JM1
Fernández-Hidalgo, O2
Martín-Algarra, S2
Salgado, JE1
Martínez-Monge, R2
de Irala, J2
Brugarolas, A2
Desmoulin, F1
Gilard, V1
Malet-Martino, M1
Martino, R1
Bachmann, F1
Glatz, K1
Yamamura, T10
Yabe, K1
Oka, H5
Kouzuma, T1
Wakayama, T1
Sugiura, A1
Hagiwara, M1
Ohdate, K1
Okamura, R2
Miyahara, T1
Moriyama, Y1
Gunji, A1
Mikami, Y3
Yamamura, M3
Kubozoe, T2
Urakami, A3
Kimoto, M1
Kaibara, N4
Reid, T2
Galanis, E2
Sze, D2
Wein, LM1
Andrews, J2
Randlev, B1
Heise, C1
Uprichard, M1
Hatfield, M2
Rome, L1
Kirn, D2
Fraker, DL2
Soulen, M1
Xila, V1
Rokana, S4
Margaris, E1
Zografos, G3
Kouraklis, G1
Givel, JC3
Aellen, S1
Moubayed, H1
Michetti, P1
Dorta, G1
Miyanari, N2
Collie-Duguid, E1
Hartung, G2
Samel, S1
Emig, M1
Pilz, L2
Willeke, F1
Hehlmann, R3
Queisser, W3
Leonard, P2
Fu, QG1
Meng, FD1
Shen, XD1
Guo, RX1
Mainwaring, CJ1
Naylor, E1
Jerwood, S1
Hall, V1
Page, A1
James, CM1
Fisher, MD3
D'Orazio, AI1
Gambill, BD2
Fishman, AD1
Bilchik, AJ3
Wood, TF1
Chawla, SP1
Rose, DM1
Chung, MH1
Stern, SS1
Foshag, LJ1
Ramming, KP1
Chansky, K2
Macdonald, JS12
Doukas, MA1
Budd, GT2
Giguere, JK1
Rose, MG1
Farrell, MP2
Shirota, Y5
Nihei, Z3
Hirayama, R3
Marsh, S1
Pintilie, M1
Jolivet, J3
Fields, A2
Lee, IM1
Rebollo, J2
Vincent, M4
Whiston, F2
Chico, IM1
Marsh, JC3
Catalano, P2
Graham, DL1
Cornfeld, MJ2
Kjaer, M6
Linné, T1
Boussard, B4
Oulid-Aïssa, D1
De Rosa, V3
Fiore, F2
Lapenta, L1
Comella, G14
Aschele, C14
Debernardis, D4
Bandelloni, R2
Drudi, G1
Gallo, L6
Maley, F3
Monfardini, S3
Violette, S1
Festor, E1
Pandrea-Vasile, I1
Mitchell, V1
Adida, C1
Dussaulx, E1
Lacorte, JM1
Chambaz, J1
Lacasa, M1
Lesuffleur, T2
Ishida, Y2
Omura, K2
Kotake, K6
Koyama, Y4
Shida, S2
Kanazawa, K1
Miyata, M1
Nagamachi, Y1
Iwasaki, Y6
Omoto, R1
Tamakuma, S1
Kitajima, M7
Kodaira, S8
Cuq, P4
Giacometti, S3
Pelegrin, A2
Aubert, C5
Cano, JP2
Kouroussis, C5
Papadouris, S1
Agelaki, S6
Panopoulos, C1
Sarra, E2
Fina, F1
Bezulier, K1
Roussel, M1
Romain, S1
Martin, PM1
Maung, K2
Lee, D1
DeGrendele, HC1
Schilsky, R3
Jain, VK1
Copur, S1
Johnson, L1
Salman, HS1
Cynamon, J2
Jagust, M1
Bakal, C1
Rozenblit, A2
Kaleya, R2
Negassa, A1
Hamada, H8
Yasuda, D2
Takada, J3
Katsuki, Y11
Ebuchi, M5
Nagahama, T4
Takashima, I3
Natui, S1
Nakazaki, H3
Hasebe, Y2
Takita, W1
Seo, A1
Takata, M1
Teramoto, T2
Hirano, K1
Soma, I1
Kanai, T1
Fukuchi, N1
Izawa, H1
Ebisui, C1
Sakita, I2
Iizuka, N1
Matsuoka, K2
Tangoku, A1
Natsui, S1
Isshi, K1
Gen, T1
Katuyama, T1
Maekawa, Y1
Vannozzi, F3
Cionini, L2
Lieberman, G2
Griffing, S2
Harsley, SR1
Dooley, MJ1
Summerhayes, M1
Rothmann, M2
Chi, GY1
Temple, R1
Tsou, HH1
Ayers, GD2
Ohta, S1
Katsu, K1
Honma, S1
Barnett, KT1
Malafa, MP1
Altuntas, F1
Akbulut, KG1
Ozturk, G1
Cindoruk, M1
Zanke, C2
Hohl, H2
Burg, H1
Ehscheid, P1
Schwindt, P1
Schroeder, M2
Klein, O3
Baldus, M1
Sekine, T1
Kazumoto, T1
Sakura, M1
Madsen, EL1
Sandberg, E4
Poulsen, JP1
Jeng, YM1
Wu, MS1
Schwinnen, I1
Staib-Sebler, E6
Gog, C4
El-Ganainy, A1
Gutt, C1
Müller, HH8
Hildner, K1
Wils, J13
Blijham, GH6
Wagener, T2
De Greve, J3
Kok, TC1
Couvreur, ML2
Genicot, B2
Baron, B4
Kargman, S1
Lam, EC1
Kelly, CR1
Luk, P1
Kwong, E1
Evans, JF1
Wolfe, MM2
Riedel, C5
Brückl, W2
Ott, R3
Hanke, B3
Baum, U2
Fuchs, F1
Günther, K1
Reck, T2
Papadopoulos, T1
McArdle, CS13
Taylor, I8
Sherlock, DJ1
Buckels, J2
Mayer, D1
Cain, D2
Janciauskiene, R1
Juozaityte, E1
Pavalkis, D1
Min, YJ1
Tsalic, M1
Bar-Sela, G2
Beny, A1
Visel, B1
Haim, N3
James, RD6
Topham, C4
McArdle, C1
Stoeltzing, O1
Reinmuth, N1
Parry, GC1
Parikh, AA1
McCarty, MF1
Bucana, CD1
Mazar, AP1
Pauler, DK1
McCoy, S1
Moinpour, C1
Tambaro, R2
De Maio, E1
Pignata, S2
Cristaudo, A1
Vanni, B4
Bria, E3
Aschelter, AM6
Santucci, B1
Terzoli, E9
Rao, MS1
Segura, A2
López-Tendero, P1
Gironés, R1
Pérez-Fidalgo, JA1
Calderero, V2
Blair, SL1
Grant, M1
Chu, DZ2
Cullinane, C1
Dean, G1
Okabe, S7
Tanami, H1
Fukahara, T1
Udagawa, M3
Ootsukasa, S2
Murase, N5
Gieschke, R1
Burger, HU3
Reigner, B5
Blesch, KS1
Steimer, JL1
Proschek, D1
Ridwelski, K7
Gassel, HJ5
Lehmann, U1
Vestweber, KH1
Padberg, W1
Zamzow, K1
Grinev, MV1
Umlil, A1
Grégoire, N1
Lafont, T2
Canal, P3
Bugat, R9
Piedbois, P16
Hosie, KB1
Gilbert, JA1
Downes, M2
Lakin, G1
Pemberton, G1
Timms, K1
Young, A2
Stanley, A1
Selke, B1
Lebrun, T1
Comte, S1
Kovats, E2
Schneeweiss, B3
Lang, F3
Lenauer, A3
Depisch, D5
Rooney, PH1
Taron, M3
Shinoura, N1
Magné, N5
Fischel, JL3
Dubreuil, A1
Marcié, S1
Lagrange, JL2
Alimonti, A3
Satta, F2
Burattini, E1
Zoffoli, V1
Vecchione, A2
Zheng, CX1
Zhan, WH1
Cai, SR1
He, YL1
Lin, ZJ1
Hidaka, S4
Yasutake, T5
Haseba, M2
Tsuji, T6
Nakagoe, T6
Ayabe, H2
Tagawa, Y4
Gutzler, F2
Boehme, M1
Raeth, U2
Stremmel, W3
Carrasco, J1
Esteban, E1
Fra, J1
Muñiz, I1
Sala, M1
Buesa, JM1
Jiménez Lacave, A1
Seshimo, A2
Huguet, E1
Bismuth, H11
Cohen, V1
Panet-Raymond, V1
Sabbaghian, N1
Morin, I1
Batist, G2
Rozen, R1
Colarusso, D2
Meyer, L1
Climente-Martí, M1
Merino-Sanjuán, M1
Almenar-Cubells, D1
Becerra, CR1
Frenkel, EP2
Ashfaq, R1
Gaynor, RB1
Brooks, A1
Morris, D1
Dahm, F1
Selzner, N1
Selzner, M1
Oza, AM1
Bigelow, RH1
Garay, CA2
Burger, BG1
Le Bail, N4
Fusai, G1
Davidson, BR2
Ambo, T1
Sarashina, H1
Suwa, T1
Suzuki, M3
Nakazato, H2
Arnold, CN2
Fallik, D1
Jacob, J3
Baulieux, J1
Couzigou, P1
Mahjoubi, R1
Mahjoubi, M1
Gilles-Amar, V4
Krulik, M16
Oman, M1
Blind, PJ1
Lindnér, P2
Saini, A2
Tait, D5
Jodrell, D3
Ross, PJ13
Oates, J10
Reardon, DA1
Friedman, HS1
Powell, JB1
Gilbert, M1
Yung, WK1
Schwartz, GK4
Wilke, HJ7
Debrigode, C2
Gourgou, S2
Klump, B1
Nehls, O1
Okech, T1
Hsieh, CJ1
Gaco, V1
Gittinger, FS1
Sarbia, M1
Borchard, F1
Greschniok, A1
Gruenagel, HH1
Gregor, M1
Yang, BQ1
Jin, ML1
Bading, JR3
Yoo, PB2
Fissekis, JD2
Alauddin, MM2
D'Argenio, DZ1
Yoshinare, K2
Kubota, T4
Wada, N1
Nishibori, H1
Salvador, J1
Pica, JM1
Rueda, A1
Lorenzo, A1
de la Puente, CG1
Borrega, P1
Moreno-Nogueira, JA1
Chevalier, V2
Richard, D1
Cure, H4
Busquier, I2
Galán, A3
Bouzid, K1
Khalfallah, S1
Tujakowski, J1
Piko, B1
Padrik, P1
Serafy, M1
Pshevloutsky, EM1
Chachoua, A1
Speyer, J1
Escalon, J1
Zeleniuch-Jacquotte, A1
Muggia, F1
Miwa, M1
Eda, H1
Ura, M1
Tanimura, H3
Miyazaki-Nose, T1
Hattori, K1
Shimma, N1
Yamada-Okabe, H1
Ishitsuka, H1
Ribic, CM1
Thibodeau, SN1
French, AJ1
Hamilton, SR3
Gryfe, R1
Shepherd, LE1
Redston, M1
Bamias, A4
Pavlidis, N4
Man, S4
Lavrenkov, K5
Gluzman, A3
Geffen, DB2
Cohen, Y3
Yan, DB1
Pivot, X3
Thyss, A2
Demard, F1
Gococo, KO1
Kardinal, CG3
Sumimura, J1
Yoshidome, K1
Tsuji, K2
Oota, F1
Tsuboyama, N1
Nagai, I1
Park, DJ6
La Cesa, A4
Van Rijnsoever, M1
Joseph, D3
McCaul, K2
Ferns, H1
Hwang, YH1
Suh, CK1
Park, SP1
Sumpter, K3
Harper-Wynne, C1
Thomas, RJ1
Garcia-Vargas, J1
Barceló, R3
Rubio, I1
Mañé, JM1
Ferreiro, J1
López-Vivanco, G1
Yeoh, C1
Cassinello, J2
Marcos, F2
Pujol, E3
Colmenarejo, A2
González del Val, R1
Valero, J1
Oruezábal, MJ1
Guillem, V1
García, I1
Arcediano, A2
Marfà, X2
Hills, R1
Stowe, R1
Nardoni, C1
Gamucci, T4
Gabriele, A3
Ferraresi, V3
Tewes, M1
Schleucher, N1
Achterrath, W3
Frings, S2
Seeber, S6
Harstrick, A9
Alfonso, R1
Macías, JA1
Manrique, I1
Flores, L1
Sferruzza, AD1
Bender, RA1
Schöffski, P11
Voigtmann, R2
Lutz, M1
Kleeberg, C1
Souchon, R1
El-Serafi, M2
Weiss, U1
Burkhard, O1
Rückle, H2
Lichnitser, M1
Langenbuch, T2
Gambardella, A3
Zonios, D1
Papalambros, E4
Papantoniou, N2
Margaris, H2
Retalis, G1
Koufos, C2
Keller, R1
Fischbach, W1
Ferretti, G4
Di Cosimo, S1
Asche, C1
Romeyer, F1
Mukherjee, J1
Skillings, J1
Letarte, J1
Koike, A2
Takagi, H4
Baba, S3
Mai, M1
Ganem, G2
Valleur, P1
Aziza, T1
Fagniez, PL1
Auroux, J1
Kobeiter, H1
Tayar, C1
Braud, AC2
Haddad, E2
Piolot, A1
Giannakakis, T1
Karadima, D1
Shindou, H1
Fukuoka, H1
Shibasaki, S1
Nanashima, A1
Diasio, R1
Thomas, RR2
Jantscheff, P1
Glatz-Krieger, K1
Grunert, F1
Micheel, B1
Brümmer, J1
Schramm, H4
Hauss, J2
Schäfer, H1
Berger, G3
Reszka, R1
Pohlen, U1
Lucas, S1
Buhr, HJ1
Taguchi, S1
Adab, F1
Thomas, G1
Wadd, NJ1
Rea, D1
Philips, R1
Bozzino, J1
MacMillan, C1
Counsell, R1
McDonald, A2
Stewart, J2
Robinson, A1
Davies, S1
Murayama, C2
Kulke, MH5
Enzinger, PC7
Stuart, K2
Catarius, KJ1
Winkelmann, J1
Stickel, F1
Jüngert, B1
Brueckl, V1
Schirner, I1
Männlein, G1
Hegewald, J1
Mühldorfer, S1
Bittorf, B1
Belloc, J1
Etienney, I1
Montembault, S1
Vayre, L1
Ezenfis, J1
Ohtsukasa, S2
Hwang, JJ3
Eisenberg, SG1
Trocha, SD1
Saha, SS1
Wiese, D1
Thompson, J1
Morton, DL1
Imanishi, T1
Kuroda, Y3
Kabeshima, Y1
Nagao, M1
Takasaka, H2
Nishikawa, N1
Nishimura, G2
Shimoyama, S1
Katayanagi, S4
Tsukuda, K2
Ota, T2
Shimizu, N4
Akazawa, S5
Yamashina, T1
Murakami, T1
Nakazima, T1
Sakurai, T1
Stippel, DL1
Töx, U1
Gossmann, A1
Beckurts, KT1
Hölscher, AH1
Nakayama, K1
Itou, T1
Abe, N1
Kirsch, IR2
Ward, S1
Kaltenthaler, E2
Cowan, J2
Brewer, N1
Lüftner, D1
Jozereau, D1
Possinger, K3
Zappalà, AM1
Fuchimoto, S1
Sakata, T1
Shirakawa, K2
Nakada, H6
Odaka, A3
Hoshino, T3
Murata, N4
Hashimoto, D5
Watayo, T1
Nakata, H1
Kito, A1
Kunihiro, O1
Togo, S3
Kosaka, K1
Nishihara, T1
Umehara, A4
La Grotta, G1
Infante, L1
Passera, R1
Arpicco, S1
Brusa, P1
Bumma, C1
Hsuen Lim, E1
Seng Cheong Lim, R1
Seng Wu, T1
Loong Kong, H1
van Laarhoven, HW3
Klomp, DW2
Kamm, YJ3
Heerschap, A3
Lamlum, H6
Achille, E1
Flesh, M1
Couteau, C2
Fenández-Martos, C1
Huarte, L1
Balcells, M5
Wong, JY1
Williams, LE1
Liu, A1
Yamauchi, DM1
Wilczynski, S1
Ikle, DN1
Wu, AM1
Yazaki, PJ1
Doroshow, JH4
Raubitschek, AA1
Belvedere, O2
Di Loreto, C1
Cataldi, P1
Braendengen, M2
Øgreid, D2
Lewis, NL2
Diz, P1
García López, MJ1
España, P2
de la Torre, A1
Martínez del Prado, P1
Duarte, I1
Arizcun, A1
Cruz, JJ1
Köves, I2
Orosz, Z3
Hajnal, A1
Miki, A1
Ukikusa, M1
Kojima, N2
Ishigaki, T1
Todo, G1
Honecker, F2
Artale, S2
Pinotti, G2
Carreca, I1
Bonaglia, L1
Marini, G4
Iannelli, A1
Beretta, E2
Ma, T1
Zhu, ZG1
Ji, YB1
Yu, YY1
Yin, HR1
Lin, YZ1
Zhang, ZL1
Zou, WG1
Luo, CX1
Li, BH1
Sun, LY1
Qian, QJ1
Hansson, J1
Skarlos, D4
Janinis, J2
Kouvatseas, G2
Economopulos, T1
Takeshita, H2
Perez, N2
Molitor, JL5
Ibrahim, A1
Hirschfeld, S1
Griebel, DJ1
Williams, GA1
Ruth, SV1
Zoetmulder, FA4
Smith, EJ1
Behling, CA1
Nguyen, L1
Tajima, A1
Doctolero, RT1
Cabrera, BL1
Arnold, CA1
Miyai, K1
Matasar, MJ1
Sundararajan, V1
Grann, VR1
Neugut, AI2
Hahn, P1
Jensen, HA1
Wang, TL1
Romans, K1
Saha, S1
Choti, M1
Parmigiani, G1
Shih, IeM1
Kinzler, KW3
Vogelstein, B3
Lengauer, C1
Velculescu, VE1
Mafrici, A1
Alberti, A1
Corrada, E1
Ferrari, S1
Marenna, B1
Choi, EA1
Maron, DJ1
Mick, R1
Barsoum, J1
Yu, QC1
Wilson, JM1
Spitz, FR1
Allen, MJ2
Ford, HE3
Cremonesi, M1
Rezzani, C1
Mary, C1
Emura, T2
Murakami, Y3
Kitazato, K1
Merkelbach-Bruse, S1
Hans, V1
Mathiak, M1
Sanguedolce, R1
Büttner, R2
Houshdaran, F1
Gullotti, L1
van den Bergh, EJ1
Wagener, DJ7
Bertino, J1
Kelsen, DK1
Tong, W3
Welch, M1
Endres, S1
Dimery, I1
Lewis, KG1
Lewis, MD1
Robinson-Bostom, L1
Pan, TD1
Zhu, AX5
Puchalski, TA1
Stanton, VP1
Nesbitt, S1
Charlat, O1
Kelly, P1
Kreconus, E1
Chabner, BA1
Supko, JG2
Bukowski, RM3
Dufour, P6
Lokich, J7
Schoelmerich, J1
Collan, Y2
Di Leo, A3
Masutti, B2
Ribera, F1
Pronk, L1
Crellin, AM1
Sebag-Montefiore, D1
Messruther, J1
Francis, DL1
Visvikis, D1
Costa, DC1
Croasdale, I1
Arulampalam, TH1
Luthra, SK1
Ell, PJ1
van Zuylen, L1
Sparreboom, A1
de Bruijn, P1
Sklenar, I1
Planting, AS3
Choi, L1
Bootle, D1
Mueller, C1
Verweij, J5
Boyer, J1
McLean, EG1
Aroori, S1
McCulla, A1
Carey, PD2
Azem, F1
Amit, A1
Merimsky, O2
Lessing, JB1
Machiavelli, MR3
Salum, G1
Pérez, JE4
Ortiz, EH3
Romero, AO3
Bologna, F1
Vallejo, CT4
Lacava, JA3
Dominguez, ME3
Leone, BA4
Tsamandas, AC1
Kardamakis, D1
Ravazoula, P1
Zolota, V1
Salakou, S1
Tepetes, K1
Kalogeropoulou, C1
Tsota, I1
Kourelis, T1
Karavias, D1
Bonikos, DS1
Petsas, T1
Liu, DG1
Yu, BM2
Wu, WQ2
Wei, YQ1
Zou, LQ1
Wu, XD1
Zhuang, W1
Xiong, HH1
Yang, CY1
Sun, SR1
Ruan, QL1
Inokuchi, M1
Tajima, M1
Hillenbrand, A1
Sander, S1
Salonga, D4
Fjell, B1
Haug, T1
Tunheim, SH1
Reichelt, W1
Beigi, M1
Clausen, OP1
Galteland, E1
Stokke, T1
Tham, J1
Albertsson, M4
Takemiya, S2
Nishisho, I5
Lelong, B1
Moutardier, V1
Baust, JG1
Gage, AA1
Clarke, D1
Baust, JM1
Van Buskirk, R1
Kikuchi, I1
Miyanaga, O1
Harada, M3
Hütter, G1
Szélenyi, H2
Deckert, PM1
Keilholz, U1
Thiel, E3
Delperro, JR2
Benhamou, E1
Baton, O1
Giovannini, M4
Cohen, SM1
Li, SY1
An, P1
Zuo, FY1
Cai, HY1
Toffolatti, L1
Pei, Z1
Qian, C2
Gal, R1
Sadikov, E1
Sulkes, J1
Klein, B1
Koren, R1
Messinese, S1
Piccolomini, A1
Ceciarini, F1
Micheli, L3
Nencini, C3
Neri, A1
Vuolo, G1
Guarnieri, A1
Prete, SD1
Giorgi, G3
Nattam, S1
Ansari, RH2
Kasza, K1
Wade-Oliver, K1
Vokes, EE1
Quirino, M3
Trigila, N3
Ceyhan, C2
Meydan, N2
Tekten, T2
Onbasili, AO1
Ozturk, B3
Unal, S1
Bayrak, I1
Chen, VM1
Thrift, KM1
Morel-Kopp, MC1
Jackson, D3
Ward, CM1
Flower, RL1
van Ruth, S1
Oechsle, K1
Reis, HE2
Haag, C1
Batran, SA1
Büchele, T2
Kanz, L1
Lassere, Y3
Carter, S1
Samid, D1
Polito, D1
Debraud, F2
Grossmann, J2
Sawada, N2
Gil-Delgado, MA2
Bastian, G3
Guinet, F2
Taillibert, S1
Rocher, MA1
Khayat, D5
Goessl, C1
Grozdanovic, Z1
Kumada, T2
Sone, Y4
Toyoda, H2
Kiriyama, S2
Tanikawa, M1
Hisanaga, Y1
Kuzuya, T1
Nonogaki, K1
Shimizu, J2
Yamauti, T1
Kawase, N1
Fan, CW2
Tsao, KC1
Wu, CM1
Novotny, W2
Hainsworth, J1
Baron, A1
Ferrara, N1
Rogers, B1
Ross, R1
Jansman, FG3
Postma, MJ1
van Hartskamp, D1
Willemse, PH5
Brouwers, JR3
Zito, A1
Montemurro, S3
Hsieh, RK4
Chao, TY1
Dräger, J1
Kerner, T1
Deja, M1
Löffel, J1
Ahlers, O1
Felix, R1
Wust, P2
Awad, L6
Rixe, O1
Favre, R2
Merad, L1
Laadem, A2
Juin, P1
Bereder, JM1
Bernardini, D2
Herait, P6
Noordhuis, P6
Holwerda, U1
Van der Wilt, CL5
Meijer, S4
Pinedo, HM15
Zappalà, AR2
Pugliese, P4
Cappellini, GA1
Perrone, M3
Liu, WM1
Scott, KA1
Shahin, S1
Goetz, MP3
Zahedy, S1
Penland, SK1
Venook, A3
Blackwell, K1
Snyder, S1
Dewhirst, M1
Greenberg, C1
Simizu, M1
Matsukura, S1
Samejima, R1
Hidaka, K1
Richards, F2
Davis, T1
Aslanis, V1
Locke, K1
Slevin, ML5
Fackler-Schwalbe, I1
Schwalbe, B1
Epple, M1
Becker, A1
Prügl, L1
Gassel, WD1
Stoffels, D1
Südhoff, T1
Kaçar, S1
Kahya, M1
Gürkan, A1
Karaca, C1
Varilsüha, C1
Uslu, A1
Sutherland, F1
Walley, B1
Ruether, D1
Barber, FD1
Mavligit, G1
Mahyar-Roemer, M1
Fritzsche, C1
Wagner, S1
Laue, M1
Roemer, K1
Kuehr, T1
Rapoport, BL1
Jacobs, C1
Slevin, M2
Payne, S1
Kamoshida, S1
Shiogama, K1
Matsuyama, A1
Shimomura, R1
Inada, K1
Maruta, M1
Tsutsumi, Y1
Hill, ME5
Shellito, P2
Onbasili, A1
Kadikoylu, G1
Bolaman, Z1
Carlo, WF1
Hummer, AJ1
Price, N2
Oberfield, RA1
Sampson, E1
Heatley, GJ1
Johata, K1
Sahara, M1
Naka, T1
Ochiai, M1
Tsubota, YT1
Liljefors, M2
Nilsson, B2
Ullenhag, G1
Mellstedt, H2
Ruotsalainen, T2
Ollus, A2
Ikonen, M1
Whitehead, RP2
Benedetti, JK2
Williamson, S1
Gaynor, ER1
Balcerzak, SP2
Polemonivi, N1
O'Leary, E1
Lloyd, TD1
Dennison, AR1
Rouits, E1
Guérin, O1
Tada, T1
Kazama, Y1
Hecker, H5
Cho, EK2
Oh, JH2
Tucci, A2
Pizza, C2
Faithfull, S1
Deery, P1
Gerbrecht, BM1
Kangas, T1
Kim, TM1
Yu, SJ1
Joh, YH1
Heo, DS2
Burger, C1
Rühl, A1
Irngartinger, G2
Ferraz, JM1
Zinzindohoué, F1
Berger, A1
Cugnenc, PH1
Jian, R1
Zhou, ZW3
Fan, HA1
Hsu, SH1
Chan, CC1
Chen, SY1
Hsu, YH1
Casazza, S2
Thirion, P5
Carlson, RW2
Sargent, P1
Waters, JS3
Katopodis, R1
Oates, JR3
Calviello, G1
Di Nicuolo, F1
Serini, S1
Piccioni, E1
Boninsegna, A1
Maggiano, N1
Ranelletti, FO1
Palozza, P1
Jiménez De Ayala, B1
Velasco, A1
Majano, PL1
Palacios, J1
Damjanovic, D1
Grossi, F5
Delvart, V2
Pascal, G2
Valeanu, A1
Ghémard, O1
César, A1
Menoyo, A2
LaRocca, RV1
Glisson, SD1
Hargis, JB1
Kosfeld, RE1
Leaton, KE1
Hicks, RM1
Amin-Zimmerman, F1
Parvez, T1
Mahrous, AR1
Fawazi, A1
Cobo, M1
Carabantes, F2
Villar, E1
Graupera, J1
Manzano, H2
Batiste-Alentorn, E2
Acusa, A1
Vélez de Mendizabal, E1
Antón, I1
Dixon, MR1
Stamos, MJ1
Saggio, G1
Nuzzo, A2
Lullo, LD1
Cesta, A2
Thomas, SP1
Salim, M2
Schaefer, PL3
Mailliard, JA7
Blum, J1
Senzer, NN1
Grouleff, P1
Rogers, T1
Kelley, SK1
Ramies, DA1
Lum, BL1
Eiseman, JL1
Brown-Proctor, C1
Kinahan, PE1
Collins, JM2
Anderson, LW1
Joseph, E1
Hamburger, DR1
Pan, SS1
Mathis, CA1
Klecker, RW1
Kimhi, O1
Drucker, L1
Neumann, A1
Shapiro, H1
Shapira, J1
Yarkoni, S1
Lahav, M1
Radnay, J1
Lishner, M1
Sharieff, W1
Medinger, M1
Steinbild, S1
Blackwell, A1
Anderson, J3
Moroz, P1
Cardaci, G1
Chouinard, E1
Stewart, DJ1
Huan, S1
Hirte, H1
Stafford, S1
Waterfield, B1
Roach, J1
Lathia, C1
Agarwal, V1
Humphrey, R1
Walsh, W1
Matthews, S1
Borzomati, D1
Grilli, C1
Verzì, A1
Shirane, M1
Hiro, J3
Yanagi, H4
Araake, M1
Orita, H1
Cerri, E3
Masutani, S2
Nakayama, T3
Imamura, H2
Tatsuta, M2
Tomotsu, K1
Ueda, Y2
Tagi, T1
Shiozaki, A1
Tamai, H1
Sonoyama, T1
Ashikawa, K1
Katayama, M1
Hanai, A3
Takizawa, K1
Koide, A1
Ohbu, M1
Tokuoka, M1
Kashiwazaki, M1
Hasuike, Y10
Masuda, N1
Hirao, M1
Sawamura, T4
Gory-Delabaere, G1
Bosquet, L1
Bosset, JF3
Monges, G1
Matsushita, M4
Iwazawa, T3
Okamura, J2
Gurtler, J1
Kennedy, P1
Brandt, DS1
Wertheim, M1
Shumaker, G1
Hallman, D1
Burger, B1
Mauritz, R2
Schwabe, W1
Haeusler, P1
Behnke, D1
Doggrell, SA1
Kuhfahl, J1
Steinbrecher, C1
Wagner, T2
Wagner, H1
Fritze, D2
Schulte, F1
Kreuser, ED8
Stahl, M5
Schweers, K1
Köster, W2
Wilke, H12
Popov, IP2
Jelic, SB1
Matijasevic, MM1
Grbic, B1
Babic, DR1
Bourgeon, A3
Hadj Tahar, A1
Gnad-Vogt, U1
Saussele, S1
Kreil, S1
Presicci, PF1
Veronesi, G1
D'Aiuto, M1
Spaggiari, L1
Glasgow, SC1
Carvalho, LP1
Shannon, WD2
Fleshman, JW1
Papadopoulou-Zekeridou, P1
Alexandridis, E1
Delithanasis, I1
Zekeridis, T1
Lagra, F1
Krokidis, X1
Lazaridis, N1
Christopoulou, A1
Emmanouilides, C2
Pegram, M1
Robinson, R1
Hecht, R1
Isacoff, W1
Goebel, FM1
Parc, R1
Reddy, GK4
Gibson, AD1
D'Andre, S1
Cha, SS2
Buroker, TR2
Kugler, JW2
Poon, MA5
Borner, MM5
Bernhard, J1
Wernli, M2
Rauch, D1
Honegger, H2
Tsunozaki, H1
Krook, J1
Fuchs, C2
Ishizu, K2
Benedetti, J3
Kecmanovic, DM1
Pavlov, MJ1
Ceranic, MS1
Sepetkovski, AV1
Kovacevic, PA1
Stamenkovic, AB1
Kleeberg, UR3
Hieke, K3
Guerrero, A1
Pellín, L1
Toi, M1
Takizawa, T1
Shimizu, S1
Carlini, LE1
Bever, J1
Andria, ML1
Hill, T1
Gold, P1
Rogatko, A1
Blanchard, RL1
Tsavaris, NB1
Katsoulas, HL1
Kosmas, N1
Skopeliti, M1
Tsitsilonis, OE1
Pohl, G1
Rudas, M1
Grill, R1
Pirker, R1
Hausmaninger, H2
Kubista, E1
Jakesz, R4
Ozer, H1
Lentz, F1
Tran, A1
Rey, E1
Pons, G1
Tréluyer, JM1
Nielsen, JN4
Gyldenkerne, N1
Lindeberg, J1
McCleod, M1
Mass, R1
Perrou, B1
Nelson, B1
Bruzzi, P3
Sangha, S1
Albert, A1
Chang, AJ1
Liu, TC1
Kanou, Y1
Ooshima, H1
Kawase, J1
Kudou, J1
Mizuno, Y1
Nakano, K1
Todo, T1
Kuroki, S1
Cohen, JB1
Glorioso, JC1
Dirix, L5
Van Belle, S2
Gonzalez Baron, M2
Morant, R5
Joosens, E2
Gruia, G5
Sibaud, D1
Seike, K1
Oda, K1
Hasegawa, R1
Yoshikawa, R3
Gega, M1
Tsukamoto, K1
Shoji, Y1
Higasa, S1
Hashimoto-Tamaoki, T2
Artandi, M1
Rosales, AM1
Landi, E1
Schattner, M1
Akhurst, T2
Lim, DH1
Park, BB1
Ji, SH1
Park, KW1
Jung, CW1
Im, YH1
Park, K1
Mattek, NC1
Deloughery, TG1
Koop, DR1
Blum, HE1
Freeman, S1
Post, L1
McCormick, F1
Sze, DY1
Guallar, JL1
Kidd, EA1
Watson, MA1
Seium, Y1
Stupp, R2
Philippe, M1
Allal, A1
Trembleau, C1
Sahin, M1
Erikoglu, M1
Ozer, S1
Tekin, A1
Boz, S1
Gölcük, M1
Avunduk, MC1
Aköz, M1
Lima, AP1
Massacesi, C3
Marcucci, F1
Cappelletti, C1
Imperatori, L1
Pilone, A2
Rocchi, M1
Laici, G1
Bonsignori, M1
Lippe, P3
Dimopoulos, M1
Chalkidou, S1
Karina, M1
Bacoyiannis, C4
Samelis, GF1
Kalfarentzos, F1
Chong, G3
Llosa, F1
Yubero, A2
Sanz-Lacalle, JJ1
Lopez-Gómez, L2
Gómez-Reina, MJ1
Jankilevich, G1
Kallinowski, B1
Hambleton, J2
Mass, RD2
Hummer, A1
Drobnjak, M1
Motwani, M1
Cordon-Cardo, C1
Veronese, ML1
Giantonio, B1
Shults, J1
Ismail, AS1
Quinn, MG2
Wright, MA2
Ernst, A1
Kao, V1
Grogan, L2
Parr, A1
Grollman, F1
Ng, CV1
Shimonov, M1
Hayat, H1
Chaitchik, S3
Brener, J1
Schachter, P1
Czerniak, A1
Gauthier, AM1
Michaud, LB1
Hortobagyi, G1
Lucia, LD1
Cataldis, GD1
Bu, LM1
Gil, S1
Ebisawa, Y1
Tomita, I3
Chisato, N1
Kamiya, K1
Asama, T1
Ayabe, T1
Ashida, T1
Kohgo, Y1
Kasai, S2
Fernandez, FG1
Ritter, J1
Goodwin, JW2
Linehan, DC2
Hawkins, WG2
Pessi, MA5
Milesi, L1
Bazan, V2
Agnese, V2
Rodolico, V1
Corsale, S1
Calò, V1
Valerio, MR2
Latteri, MA1
Vieni, S1
Grassi, N1
Dardanoni, G1
Tomasino, RM1
Gebbia, V10
Paoletti, G7
Borsellino, N5
Pezzella, G4
Romito, S4
Yildirim, Y1
Akcali, Z1
Ozyilkan, O1
Tyagi, P3
Lopez, T1
Encarnacion, C1
Biquet, JF1
Materne, R1
Delforge, M1
Rea, DW1
Ten Bokkel Huinink, WW4
Groenewegen, G1
Smit, JM2
Steven, N2
Bakker, JM1
Semiond, D1
Caruso, M2
Agostara, B1
Misino, A1
Durini, E1
Cramarossa, A1
Di Bisceglie, M1
Chiarenza, M1
Guida, T1
Leonardi, V1
Carrozza, F1
Nettis, G1
Valdesi, M1
Fortunato, S2
Brunetti, C1
Reichardt, P1
Rückle-Lanz, H2
Frickhofen, N1
Mergenthaler, HG1
Anak, O1
Storojeva, I1
Heinimann, K1
Ballabeni, P1
Aggarwal, S1
Lichtman, SM1
Coutsouvelis, J1
Dong, PD1
Zhang, LH1
Ji, JF1
Inokuchi, K2
Takeuchi, T1
Muneoka, K1
Yokoyama, N1
Hatakeyama, K1
Arnaud, JP4
Debois, M2
Ollier, JC1
Grobost, O2
Lacourt, J1
Guimares dos Santos, J1
Mackiewickz, R1
Morin, T1
Baila, L1
Zhu, BD1
Nadal, C1
Sanz, S1
Kuroiwa, T1
Khamly, K1
Zhu, WR1
Guo, YB1
Yuan, JM1
Paty, P1
Morse, M1
Blumgart, L3
Laplanche, A4
Luboinski, M2
Shimizu, D5
Hayasizaki, Y2
Okazaki, Y1
Coudray, AM2
Kornprobst, M1
Raymond, E10
Gespach, C2
Arii, K1
Sung, JY1
Han, SH1
Codacci-Pisanelli, G3
Lankelma, J2
Van Gennip, AH4
Bertè, R1
Bidin, L2
Civardi, G1
Anselmi, E1
Lazzaro, A1
Moroni, CF1
Palladino, MA1
Rodinò, C1
Vallisa, D1
Rosales, J1
Leong, LA1
Kawashima, K1
Satoh, S1
Ikai, I1
Katoh, K1
Nakasato, T1
Satoh, C1
Ohtsuka, K1
Cai, Q1
Zhang, ZR1
Tsang, KY1
Del Vecchio, MT2
Placa, ML1
Intrivici, C2
Aquino, A3
Ferrari, F1
Bonmassar, E2
Elzagheid, A2
Kapoor, M1
Coombes, KR1
Spalletta, B2
Rocci, L1
Pan, CX1
Loehrer, P1
Seitz, D1
Helft, P1
Juliar, B1
Pletcher, W1
Vinson, J1
Sweeney, C1
Dickson, JL1
Butts, CA1
Braud, Fd1
Van Cutsem, EJ1
Wade Iii, JL1
Bearden Iii, JD1
Borchard, E1
Gil, J2
Tsao-Wei, DD4
Yun, J2
Gordon, M1
Press, OA1
Rhodes, K1
Tóvári, J1
Gilly, R1
Rásó, E1
Paku, S1
Bereczky, B1
Varga, N1
Vágó, A1
Bakouboula, B1
Morel, O1
Douchet, MP1
Chauvin, M1
Niv, Y1
Madden, M1
Goldberg, P1
Geddes, C1
Van der Merwe, L1
Wakelee, HA1
Advani, RH1
Ford, JM1
Watabe, S1
Kamano, T4
Mok, T1
Yeo, W1
Lai, P1
Koh, J1
Wong, YY1
King, A1
Leow, CK1
Giampaolo, MA1
Mansueto, G1
Buccilli, A1
Ciccarese, M1
Weihrauch, MR1
Ansén, S1
Jurkiewicz, E1
Geisen, C1
Anderson, KS1
Gracien, E1
Schmidt, M1
Wittig, B1
Diehl, V1
Wolf, J1
Bohlen, H1
Nadler, LM1
Jansen, AJ1
Coenen, JL1
de Graaf, JC1
Smit, WM1
Sleijfer, DT5
Kamoshita, N2
Makita, F1
Aiba, M1
Tokiniwa, H1
Nagashima, T1
Ohwada, S2
Morishita, Y2
García Palomo, A1
Alonso López, C1
León Carbonero, A1
Adróver Cebrián, E1
Barceló Galíndez, R1
Arroyo Yustos, M1
Alvarez Gallego, J1
Czeglédi, F2
Horváth, Z1
Gyergyay, F1
Lövey, J1
Kovács, T2
Kásler, M1
Reed, E1
Viguier, J1
Miquel, C1
Giraudeau, B1
Sabourin, JC1
Sarasin, A1
Praz, F1
Alhopuro, P1
Alazzouzi, H1
Sammalkorpi, H1
Dávalos, V1
Salovaara, R1
Hemminki, A2
Järvinen, H2
Mecklin, JP2
Schwartz, S1
Aaltonen, LA2
Arango, D1
Brennan, DD1
Farrelly, C1
Cooney, R1
Norris, S1
McEniff, N1
Massari, D1
Trobonjac, Z1
Rukavina, D1
Radosević-Stasić, B1
Cantor, M1
Brahmandam, M1
Namgyal, C1
Kawasaki, T3
Kinsella, K2
Michelini, AL1
Loda, M2
Chang, DZ1
Leonard, GD2
Fioravanti, S1
Harold, N1
Schuler, B1
Hillner, BE1
Llorca Ferrándiz, C1
Esquerdo Galiana, G1
Cervera Grau, JM1
Briceño García, HC1
Calduch Broseta, JV1
Del Pino Cuadrado, J1
Rio, ED1
Guichard, SM1
Mayer, I1
Jodrell, DI5
Matin, K2
Jacobs, SA1
Richards, T1
Wong, MK1
Earle, M1
Evans, T1
Troetschel, M1
Ferri, W1
Friedland, D1
Pinkerton, R1
Volkin, R1
Wieand, S2
Masier, S1
Cattarossi, G1
Colussi, A1
Galligan, L2
Allen, W1
Wilson, T1
Wakui, K3
Komatsu, N3
Nakasaki, H5
Nogué, M1
Arcusa, A1
de Mendizábal, EV1
de Olaguer, JP1
Boleda, M1
Vicente, P2
Hoeffding, LD1
Palazzo, S1
Iannace, C1
Ianniello, GP2
Pistillucci, G1
Gemini, M1
Persico, G1
Choi, IS1
Tsao-Wei, D2
Sones, E1
Mallik, N1
Lim, L1
Little, A1
Bailey, W1
Liechtenstein, M1
Horvath, WL1
Sternfeld, WC1
Levitt, R4
Nair, S2
Viale, PH1
Fung, A1
Zitella, L1
Karaiskou-McCaul, A1
Kelly, D1
Longley, D1
Johnston, P1
Nisticò, C4
Hirabayashi, Y2
Iki, K2
Akiyama, T2
Sadahira, Y1
Gattuso, D1
Morabito, A1
Longo, R1
Torino, F2
Sarmiento, R1
Vitale, S1
Smorenburg, CH1
van Riel, AM1
Dercksen, W1
Yuen, J1
Sargeant, AM1
Abdi, E3
Shepherd, L1
Mizuno, S1
Fukushima, A1
Matsuyama, Y1
Ferrari, V1
Valcamonico, F1
Amoroso, V1
Simoncini, E2
Vassalli, L1
Marpicati, P2
Rangoni, G1
Grisanti, S1
Pasinetti, N1
Yonemitsu, K1
Sugihara, S1
Tsuruta, Y1
Teshima, K1
Ehrsson, H1
Mortensen, JP2
Baltesgard, L1
Wallin, I1
Choi, MG1
Chang, SK1
Choi, SI1
Lee, DS1
Piñol, V1
Gordon, MS1
Nolting, A1
Pollert, P1
Schulthess, G1
Kolyvanos Naumann, U1
Käser, L1
Vetter, W1
Bhatnagar, A2
Harper, PG2
Coleman, R2
Coxon, F1
Redfern, CH1
Jones, JJ1
Hawkins, R1
Northfelt, D1
Sreedharan, S1
Valone, F1
Tonachella, R1
Tropea, F1
Verri, C1
Gionfra, T2
Modugno, G1
Gallo Curcio, C1
Krakamp, B3
Troidl, H1
Xiao, JX1
Han, M1
Chen, LH1
Bai, PS1
Kates, TJ1
Mazumdar, M1
Yeung, H1
Riedel, ER1
Burt, BM1
Larson, SM1
Amano, M3
Niinobu, T1
Itani, Y1
Higaki, N1
Hayashida, H1
Sakon, M1
Shiba, Y1
Umekita, N5
Noda, K1
Kitamura, M2
Mackay, HJ1
Billingsley, K1
Smith, A1
Yeung, R1
Pond, GR1
Croitoru, M1
Swanson, PE1
Krishnamurthi, S1
Rigatos, SK1
Stathopoulos, JG1
Xynotroulas, JP1
Dimou, E1
López Vivanco, G1
GarcíaGirón, C1
Alonso, M1
Castañón, C1
Centelles, M1
Pallis, A3
Xenidis, N1
Milaki, G1
Benatti, P1
Gafà, R1
Barana, D1
Marino, M1
Scarselli, A1
Maestri, I1
Guerzoni, L1
Menigatti, M1
Roncari, B1
Maffei, S1
Rossi, G2
Ponti, G1
Santini, A1
Losi, L1
Di Gregorio, C1
Oliani, C2
Ponz de Leon, M1
Lanza, G1
Takita, N1
Hata, M1
Ohtsuka, T1
Liu, XF1
Koga, Y1
Kitajima, Y2
Nakafusa, Y2
Ha, CW1
Miyazaki, K2
Cedermark, B1
Bentzen, SM1
Grönberg, H1
Hultborn, R1
Kubala, E1
Pipková, R1
Hladíková, J1
Kodach, LL1
Bos, CL1
Durán, N1
Peppelenbosch, MP1
Ferreira, CV1
Hardwick, JC1
Grieve, R1
Ishiguro, A2
Saitoh, S2
Becker, K2
Macdonald, J3
John, W1
Vincent, JM1
Perez-Enguix, D1
Taylor, JR2
Hollis, DR3
Sutherland, S2
Blanquicett, C2
Buchsbaum, DJ1
Eloubeidi, M1
Vickers, SM1
Chhieng, DC1
Carpenter, MD1
Sellers, JC1
Russo, S1
Johnson, MR1
Ouchi, KF1
Sekiguchi, F1
Viti, M1
Bhatnagar, P1
Young, E1
Padang, R1
Barbado, M1
Preisser, L1
Verriele, V1
Lorimier, G1
Kurt, M1
Babaoglu, MO2
Yasar, U2
Shorbagi, A1
Guler, N1
Yoshiyama, S1
Vallböhmer, D3
Cho, HK1
Lee, ES1
Shim, CK1
Chung, SJ1
Kim, DD1
Varadhachary, GR1
Sumiyoshi, T2
Yoshizaki, N2
Kuroiwa, G1
Chirivella, I2
Tsukada, A2
Watanabe, E2
Nagaoka, I3
Futagawa, S3
Koppe, MJ1
Boerman, OC1
Oyen, WJ2
Gunes, A1
Boruban, C1
Gunel, N1
Bozkurt, A1
Rane, A1
Hassan, M1
Zengil, H1
Nisi, E1
Bottomley, A2
McCollum, AD1
Michelini, A3
Martinez, J1
Chacon, M1
Korbenfeld, E1
Bella, S1
Senna, S1
Richardet, E1
Coppola, F1
Bas, C1
Hidalgo, J1
Escobar, E1
Reale, M1
Smilovich, AM1
Wasserman, E1
Lønborg, JT1
Bracco-Nolin, CH1
Legat-Fagnoni, C1
Chaigneau, L2
Stein, U2
Huchet, B1
Woronoff-Lemsi, MC1
Momiyama, N1
Goyle, S1
Maraveyas, A2
Toftbagen, C1
Shimomatsuya, T1
Kobuchi, T1
Kitamura, N1
Shiraishi, S1
Fujino, H1
Maruhashi, K1
Alliot, C1
Hospers, GA1
Schaapveld, M1
de Jong, RS3
de Gooyer, DJ1
Slee, PH1
Gerrits, CJ1
Mulder, NH5
Vincenzi, A1
Naughton, MJ1
Weeks, JC1
Herndon, JE1
Kalykaki, A3
Samonis, G3
Lundin, S2
Bogdanow, M2
Gorschlüter, M1
Schmidt-Wolf, IG1
Sauerbruch, T2
Kaizuka, M1
Kurumi, Y2
Stoller, R1
Auber, M1
Potter, D1
Cai, C1
Kiefer, G1
Ceelen, WP1
Ooyama, A1
Toda, E1
Sugimoto, Y2
Oka, T1
Shimizu, M1
Varette, C3
Grazi, G1
Ravaioli, M1
Rivory, L1
Beale, P4
Ong, S1
De Castro, J1
de Mon, MA1
Okita, A1
Doihara, H1
Suda, M1
Nakano, T1
Suzuki, E1
Andou, A1
Wang, GQ2
Ren, JQ1
Tang, SX1
Ye, YL1
Lin, SX1
O'Neill, VJ1
Warusavitarne, J1
Ramanathan, P1
Kaufman, A1
Robinson, BG1
Schnitzler, M1
Miyakura, S1
Takasaki, K1
Dotor, E1
Cuatrecases, M1
Martínez-Iniesta, M1
Vilardell, F1
Pareja, L1
Figueras, A1
Serrano, T1
de Oca, J1
Peinado, MA1
Germà, JR2
Morese, R1
Cianci, G1
Di Rocco, ZC1
Sánchez-Prudencio, S1
Roda-Navarro, P1
Lockhart, AC2
Cropp, GF1
Donnelly, E1
Schumaker, RD1
Schaaf, LJ2
Hande, KR1
Fleischer, AC1
Hannah, AL1
Jones, JA1
Avritscher, EB1
Cooksley, CD1
Michelet, M1
Bekele, BN1
András, C2
Farczádi, E1
Szántó, J2
Vincitore, M1
Sheehan, S1
Plantade, A1
Kho, Y1
Prins, NH1
Neef, C1
Alvarez, JV1
López, MJ1
Segovia, F1
Filipovich, E1
Castro, IG1
Madary, A1
Hewes, JC1
Riddy, D1
Morris, RW1
Woodrooffe, AJ1
Fuller, B1
Crews, KR1
Potamianou, A1
Tselepatiotis, E1
Christofillakis, C1
Akazai, Y1
Nitta, Y1
Sturm, I1
Rau, B1
Hauptmann, S1
Daniel, PT1
Gupta, N1
Saleem, A1
Kötz, B1
Osman, S2
Phillips, R1
Vernon, C1
Jones, T3
Hoskin, PJ1
Price, PM3
Crozier, JE1
McKee, RF1
Angerson, WJ1
Anderson, JH5
Pagenstecher, C1
Friedrichs, N1
Ryu, MH3
Ha, HK1
La Mura, N1
Malaguarnera, M2
Fulvi, A1
Shehu, I1
Melloni, G1
Doglioni, C1
Bandiera, A1
Carretta, A1
Ciriaco, P1
Arrigoni, G1
Zannini, P1
Guida, C1
Marone, P1
Cascini, LG1
Morrica, B1
Parisi, V2
Beaven, AW1
García-Martín, E1
Pizarro, RM1
Martínez, C1
Gutierrez-Martín, Y1
Pérez, G2
Agúndez, JA1
Lin, EH1
Crane, CC1
Feig, B1
Delcos, M1
Vadhan, SR1
Ross, A1
Brown, T2
Rodriguez-Bigas, MA1
Janjan, N1
Di Renzo, N1
Mallamaci, R1
Verderame, F1
Callari, A1
Tirrito, ML2
Valenza, R1
Tralongo, P1
Kawakami, M1
Kihara, C1
Ohmura, T1
Katsuramaki, T1
Terstriep, S1
Murr, R1
Ogino, K1
Hiroyoshi, M1
Fujita, H1
Itoh, T1
Toyama, H1
Kawai, Y1
Makita, D1
Tsunemi, K1
Moritomo, H1
Sculli, CM1
Gorzegno, G1
Magnino, A2
Sperti, E3
Miraglia, S1
Harris, A1
Dogliotti, L4
Tsuruoka, Y1
Ward, SE1
Marples, M1
Orr, B1
Bach, SP1
Williamson, SE1
O'Dwyer, ST1
Potten, CS1
Watson, AJ1
Shalan, N1
Pasetto, LM1
De Pangher, V1
Giusto, M1
Medici, M1
Gaion, F1
Sandri, P1
Galligioni, E2
Bonura, S1
Boccalon, M1
Mousseau, M4
Cassan, P2
Leduc, B1
Berger, C1
Dunant, A1
Fournet, J1
Suto, K1
Li, KM1
Rivory, LP2
Hoskins, J1
Mooney, M1
Boron, M1
Vena, D1
Mosby, K1
Grochow, L1
Jaffe, C1
Rubinstein, L1
Zwiebel, J1
Kremer, A2
Stieber, P1
Wilkowski, R1
Nagel, D1
Seidel, D1
Nakata, E1
Takai, Y1
Nemoto, K1
Ogawa, Y1
Nomiya, T1
Milas, L1
Romero, RZ1
Morales, R1
Garcia, F1
Huarriz, M1
De la Haba, J1
Segura, C1
Douma, J3
Akkermans-Vogelaar, JM1
Levy, DE1
Bjarnason, G2
Anciaux, N1
Gorlia, T1
Monga, DK1
Patiyil, S1
Scholtens, D1
Betensky, RA1
Biedrzycki, BA1
Berg, DT1
Nagaya, M2
Tsukikawa, S4
Yanagi, Y1
Isogai, A3
Dhami, M1
Godfrey, T1
Kovatich, AJ1
Lund, KA1
Schwarting, R1
Virzí, V1
Mitchell, PL1
Friedlander, M2
White, S1
Thomson, JA1
Scapoli, D1
Grigoletto, F1
Popat, S1
Zhao, D1
Hearle, N1
Chandler, I1
Aherne, W1
Houlston, R1
Faggiuolo, R3
Gerbino, A1
Ortega, C1
Ferraris, R1
Mattison, LK1
Fourie, J1
Desmond, RA1
Modak, A1
Rijpkema, M1
Kamm, YL2
Barentsz, JO1
Song, WX1
Mehendale, S1
Lee, C1
Eckhoff, L1
Schønnemann, K1
Aabo, K2
Ojima, E1
Murphy, KM1
Read, JA1
Beale, PJ1
Volker, DH1
Smith, N1
Childs, A1
Yoo, PS1
Lopez-Soler, RI1
Longo, WE1
Cha, CH1
Wolpin, BM3
Blaszkowsky, L2
Merritt, J1
Robbins, J1
Schupp, J1
Fellague-Chebra, R1
Postel Vinay, S1
Fey, L1
Lainé-Cessac, P1
Boldrini, L1
Lastella, M2
Giostra, E2
Audard, V1
Sartoretti, P1
Dousset, B1
Majno, PE2
Soubrane, O1
Terris, B1
Canale, ML1
Camerini, A1
Stroppa, S1
Porta, RP1
Caravelli, P1
Mariani, M1
Balbarini, A1
Sahajpal, A1
Vollmer, CM1
Chan, EK1
Cattral, MS1
Taylor, BR1
Grant, DR1
Greig, PD1
Charnsangavej, C1
Rosen, LS3
Davis, ID2
Gutheil, J2
Schnell, FM2
Cesano, A2
Gayko, U2
Chen, MG2
Saric, J1
Aloia, T1
Plasse, M1
Karam, V1
Gotlib, V1
Khaled, S1
Lapko, I1
Mar, N1
Rouquie, D1
Ciuchendea, R1
Qi, R1
Bo, L1
Kotsakis, AP1
Gioulbasanis, J1
Tsetis, D2
Sfakiotaki, G2
Chatzidaki, D1
Rosa, DD1
Ismael, GF1
de Azambuja, E1
Braga, S1
Cardoso, F1
Benizri, E1
Di Pietrantonio, D1
Menegon, P1
Sun, YJ1
Guo, YW2
Tang, XC1
Tang, LN1
Klumpen, HJ1
Westermann, AM1
Zoetekouw, L1
Van Lenthe, H3
Bakker, PJ3
Martoni, AA1
Lelli, G1
Rojas Llimpe, FL1
Gentile, AL2
Mutri, V1
Ballardini, P1
Giaquinta, S1
Piana, E2
Ramani, VS1
Gollins, SW1
Bouzari, H1
Amisano, M1
Massucco, P1
Chao, TC1
Tiu, CM1
de Geus-Oei, LF1
Leer, JW1
Corstens, FH1
da Silva, RG1
Tumber, A1
Collins, LS1
Petersen, KD1
Thougaard, A1
Christiansen, SJ1
Dejligbjerg, M1
Jensen, PB1
Sehested, M1
Ritchie, JW1
Chalbos, P2
Bressole, F1
Gennatas, C2
Michalaki, V1
Mouratidou, D1
Andreadis, C1
Pafiti, A1
Zhou, ZT1
Konishi, N1
Sato, G1
Di Leonardo, G1
D'Argento, E2
Kecmanovic, D1
Tomasevic, Z1
Borojevic, N1
Micev, MT1
Kezic, I1
Paolelli, L1
Civitelli, S2
Cioppa, T1
Roviello, F2
Nettuno, R1
Tanzini, G2
Lorenzi, M3
Ciaparrone, M2
Zannoni, G2
La Torre, G1
Fukuyama, R1
Ng, KP1
Cicek, M1
Kelleher, C1
Niculaita, R1
Sizemore, N1
MacLeod, A1
Branch, A1
Mohammed, N1
MacDonald, L1
Wakabayashi, I1
Kasai, M1
Muto, O2
Okada, R1
Mitobe, S1
Sakuraba, H1
Ikami, I1
Wollert, J1
Salgado, J1
Zabalegui, N1
Gil, C1
Monreal, I1
Aphinives, P1
Bhudhisawasdi, V1
Sae-seow, O1
Uttaravichien, T1
Baize, N1
Gerard, B3
Caroli-Bosc, F1
Berthier, F1
Pector, JC2
Hattori, T4
Kokubu, T1
Mine, T2
Itoh, K2
Shiozaki, H1
Shiozaki, K2
Ohtani, T1
Ohsawa, G1
Gonda, T1
Tegze, B1
Tulassay, Z1
Eder, JP1
Stewart, CF1
D'Amato, F1
Bartel, C1
Henry, A1
Poethig, M1
Masson, E1
Wiedenmann, B1
Milner, AD1
Bolling, C1
Rakhit, A2
Fettner, S1
Brennscheidt, U2
Feyereislova, A2
Doyle, DP1
Engelking, C1
Moran, T1
Cirauqui, B1
Catot, S1
Adena, M1
Krämer, I1
Lipp, HP1
Javle, MM1
Durrani, FA1
Lawrence, DD1
Smith, PF1
Creaven, PJ7
Noel, DC1
Iyer, RV1
Futamura, Y1
Hibi, S1
Nagaoka, M1
Yuasa, S1
Nagao, S1
Gelibter, AJ2
Di Segni, S1
Nuzzo, C2
Wan, de S1
Chen, YB1
Spirovski, B1
Sapp, CM1
DeSimone, P2
Molina, F2
Bascoul-Mollevi, C2
Copois, V2
Bareil, C1
Salvetat, N1
Fraslon, C2
Conseiller, E2
Leblanc, B1
Pau, B1
Jansen, G1
Singh, S1
Bhinge, JR1
Aupérin, A1
Clavero-Fabri, MC1
Stremsdoerfer, N1
Nasca, S1
Queuniet, AM1
Lahans, T1
Neri, B1
Pantaleo, P1
Grifoni, R1
Paoletti, C1
Rotella, V1
Pantalone, D1
Taddei, A1
Mercatelli, A1
Tonelli, P1
Blanshard, K1
Shannon, JA1
Sorscher, SM1
Hoffmann, D1
Grunwald, T1
Kuate, S1
Wildner, O1
Cho, BC1
Jeung, HC2
Kourousis, C1
Heuer, T1
Nusch, A1
Ficarelli, R2
Silva, R1
Chiou, TJ4
Yen, CC3
Gootenberg, J1
Cho, HJ1
Tan, L2
Luo, SQ2
Manza, SG1
Rusin, B1
Ferris, AM1
Vaishampayan, U1
Heilbrun, LK1
Venkatramanamoorthy, R1
Tominaga, S2
Itagaki, H1
Onuki, M1
Akashi, T1
Hanaoka, T1
Minami, K2
Kameda, A1
Tsutani, Y1
Miyahara, E1
Noso, Y1
Almond, J1
Ralston, S1
Schwartz, MA1
Korkeila, E3
Maruta, F1
Iinuma, N1
Ishizone, S1
Koide, N1
Nakayama, J1
Giovannini, I1
Shomura, H1
Yamada, A1
Todo, S2
Kokuba, Y1
Ozawa, H2
Hatate, K1
Onosato, W1
Ihara, A2
Chiba, H1
Makino, K1
Ohura, K1
Benedetti, G1
Evangelista, W1
Picone, V1
Porcile, G1
Orlandini, C2
Parks, R1
Blumgart, LH2
Enzinger, P1
Lawrence, C1
Malik, Z1
Doci, R2
Rosati, R1
Pedicini, V1
Gullo, G1
Abbadessa, G1
Morenghi, E1
Marcon, I1
Garassino, I1
Skopelitis, H2
Papadoniou, N1
Adoniou, E1
Gryniatsos, J1
Felekouras, E1
Zacharakis, M1
Sigala, F1
Terashima, M1
Bijelic, L1
Brooks, AJ1
Begg, EJ1
Chapman, BA1
Fitzharris, BM1
Shapiro, S1
Hughes, G1
Al-Obaidi, MJ1
Ramesh, S1
Smith, J1
Ahmad, R1
Dawson, C1
Riddle, P1
Sekhar, M1
Offterdinger, M1
Tischer, C1
Girod, A1
Lommerse, PH1
Magdeburg, R1
Bastiaens, PI1
Naitoh, H1
Posey, J1
Tchekmedyian, S1
Hu, E1
Amado, RG1
Xiao, BX1
Zeng, WS1
Zou, ZP1
Xu, AM1
Diamandidou, E1
Touroutoglou, N1
Chatzidakis, A1
Hiraoka, K1
Logg, CR1
Tai, CK1
Haga, K1
Lawson, GW1
Kasahara, N1
Andreoni, F2
Mari, D1
Pizzagalli, F1
Testa, E1
Menichetti, ET2
Sowa, M3
Fukunaga, Y1
Tsujitani, S2
Mitachi, Y1
Iyevleva, AG1
Buslov, KG1
Togo, AV1
Matsko, DE1
Filimonenko, VP1
Imyanitov, EN1
McWilliams, RR1
Morlan, BW1
Krook, JE10
Ames, MM1
Ashley, AC1
Iversen, A1
Vejlø, C1
Koyanagi, Y2
Fukuoka, M1
Laus, G1
Martignetti, A1
Zorzino, L2
Lorizzo, K1
Santoro, L2
Boselli, S1
De Ruvo, N1
Drigo, A1
Cho, YY1
Ahn, BM1
Kim, SN1
Lee, IT1
Haines, IE1
Lazaris, AC1
Papathomas, TG1
Nonni, A1
Delladetsima, J1
Patsouris, ES1
Sauter, A1
Triller, J1
Schmidt, F1
Kickuth, R1
Yang, DY1
Tan, MC1
Siegel, BA1
Tesselaar, ME1
Slee, PHTJ1
Gwyther, SJ1
Smith, DB1
Shepherd, S1
Griffiths, GO1
van Halteren, HK2
Liem, AH1
Kallistratos, MS1
Syrios, J1
Mylonakis, N3
Karabelis, A1
Cardot, JM2
Yao, YF1
Zhang, HG2
Zhang, YJ1
Song, SP1
Chu, DT2
Pollera, CF1
Signorelli, C1
Gasperoni, S4
Takeuchi, S2
Abrahantes, JC1
Burzykowski, T3
Maehara, S1
Makino, I1
Imamura, S1
Aso, M1
Katoh, H1
Cobo, F1
De Celis, G1
Pereira, A1
Latorre, X1
Pujadas, J1
Albiol, S1
Vénat-Bouvet, L1
Saint-Marcoux, F1
Lagarde, C1
Peyronnet, P1
Harrop, R2
Drury, N2
Shingler, W2
Chikoti, P2
Redchenko, I2
Carroll, MW2
Kingsman, SM2
Naylor, S2
Melcher, A1
Nicholls, J1
Wassan, H1
Habib, N1
Kulig, J2
Richter, P1
Klek, S1
Sticca, RP1
Inui, N1
Evans, TR1
Somanath, S1
Schatzlein, A1
Takagi, Y2
Horsmans, Y1
Rahier, J1
Machiels, JP1
Ceratti, A1
He, W1
Cao, DY1
Xiang, B1
Fan, LF1
Abadie-Lacourtoisie, S1
Xiong, JP1
Zhong, LX1
Tao, QS1
Tang, XM1
Prezerakos, P1
Hasuike, N1
Ono, H2
Purim, O1
Sulkes, A3
Lee, FC1
Liebmann, JE1
Diamandidis, D1
Eckhardt, SG1
Javle, M1
Justice, GR1
Keiser, W1
Salvatore, JR1
Bexon, A1
Cai, RG1
Wu, F1
Senesse, P1
Kondoh, K1
Thomsen Lønborg, J1
Vilmar, A1
Mård, D1
Astrup Jensen, S1
Aloysius, MM1
Zaitoun, AM1
Beckingham, IJ1
Neal, KR1
Aithal, GP1
Lobo, DN1
Celio, L1
Denaro, A1
Dotti, K1
Mancin, M1
Pusceddu, S1
Solano, JM1
Bakri, SJ1
Pulido, JS1
Oestreicher, P1
Avninder, S1
Agrawal, U1
Saxena, S1
Blanchard, P1
Huguet, F1
Ray-Coquard, I1
Bachelot, T1
Saba, C1
Confavreux, C1
Brantus, JF1
Rustam, F1
Ghesquière, H1
Sebban, C1
Biron, P1
Guastalla, JP1
Blay, JY1
Li, YM1
Jin, X1
Fanciullino, R1
Piccerelle, P1
Hiraoka, T1
Higuchi, S1
Matsuzaka, S2
Niitsu, Y1
Hamaguchi, J1
Kamiyama, N1
Deguchi, K1
Valta, P1
Kouri, M2
Astone, A3
Terraz, S1
Allal, AS1
Tappenden, P2
Jones, R1
Paisley, S1
Carroll, C1
Yaman, E2
Uner, A2
Polat, M1
Yamac, D1
Afroza, A1
Hasan, S1
Rukunuzzaman, M1
Hussain, SA1
Amin, R1
Ogreid, D3
Wanderås, EH1
Wentzel-Larsen, T1
Sengupta, R1
Qazi, S1
Vachhani, H1
Rishi, AK1
Château, Y1
Koo, DH1
Hamberg, P1
De Jong, FA1
Brandsma, D1
Sleijfer, S1
Moreno-Solórzano, I1
Ibeas-Rollan, R1
Monzó-Planella, M1
Moreno-Solórzano, J1
Martínez-Ródenas, F1
Pou-Sanchis, E1
Hernández-Borlan, R1
Navarro-Vigo, M2
Ortigosa-Rodríguez, S1
Gel-Moreno, B1
Chang, AY1
Lopes, G1
Hsin, KW1
Fong, FK1
O'Dwyer, P2
Issa, JP1
Wierzbicki, R1
Jeffery, M1
Ahmed, IA1
Kelly, SB1
Anderson, JJ1
Angus, B1
Challen, C1
Lunec, J1
Takami, H1
Gotoh, H1
Gotoh, Y1
Vega, ME1
Meric, JB1
Buechele, T1
Bir, A1
Tan, W1
Fettner, SH1
Folkvord, S1
Seierstad, T1
Røe, K1
Rasmussen, H1
Bruce, C1
Sugimoto, M1
Yasuda, H1
Yamazaki, M6
Takenoue, T1
Higuchi, R1
Watayo, Y1
Yagawa, Y1
Carroll, K1
Miller, LL4
Elfring, GL4
Soulié, P3
Valera, JS1
Senzaki, M1
Ishida, S1
Yada, A1
Hanai, M1
Kurakata, S1
Moon, YW1
Yoo, NC1
Noh, SH1
Min, JS1
Kim, BS1
Kamnerdsupaphon, P1
Lorvidhaya, V1
Chitapanarux, I1
Tonusin, A1
Sukthomya, V1
Battistelli, S1
Armbrust, T1
Sobotta, M1
Füzesi, L1
Grabbe, E1
Ramadori, G1
Shimamoto, H1
Wilson, KS1
Fitzgerald, CA1
Barnett, JB1
Khoo, KE1
Salvagni, S1
Pucci, F1
Crocicchio, F1
Griffiths, R1
Hawkins, RE2
Cha, SH1
Braumann, D2
Janssens, J1
Späth-Schwalbe, E1
Van Den Brande, J1
Bethe, U2
Kajiwara, T1
Kataoka, J1
Imamine, S1
Iguchi, H1
Taucher, S1
Steger, GG2
Tausch, C1
Wette, V1
Schippinger, W1
Kwasny, W1
Reiner, G1
Dubsky, P1
Poestlberger, S1
Tschmelitsch, J1
Barnwell, J2
McConkey, C2
Hills, RK1
Williams, NS1
Schiel, X1
Scheidt, B1
Reitmeier, M1
Hoffmann, U1
Lutz, L1
Choi, CK1
Tung, SY1
Lui, L1
Siu, S1
Au, GK1
Ho, JW1
Oussoultzoglou, E1
Rosso, E1
Chenard-Neu, MP1
Mehta, NN1
Ravikumar, R1
Coldham, CA1
Buckels, JA1
Hubscher, SG1
Bramhall, SR1
Wigmore, SJ1
Mayer, AD1
Paz-Ares, L1
Quinn, S1
Lejeune, C1
Marimón, I1
Andreu, J1
Ubbelohde, U1
Hedrick, EE1
Scalamogna, R1
Sagrada, P1
Gattoni, E1
Riccardi, A2
Luchena, G1
Corazza, GR1
Oguz, M1
B, DY1
Nagatsuka, R1
Kawabe, Y1
Fuchimoto, M1
Oka, Y1
Imai, S5
Koizumi, F1
Li, HJ1
Fu, SY1
Ibeas, R1
Gel, B1
Martinez, F1
Moreno, J1
Bovio, H1
Colomer, R1
Tveit, K2
Heikkilä, R2
Denis, V1
Bec, N1
Robert, B1
Larroque, C1
Rubinov, K1
Mermershtain, W3
Ariad, S1
London, R1
Liddle, C1
Shah, N1
Tai, BC1
Han, HC1
Fang, WY1
Lee, SC1
Kandutsch, S1
Berdah, JF1
Chamorey, E2
Lesbats, G1
Teissier, E1
Codoul, JF1
Badetti, JL1
Hébert, C1
Mari, V1
Thürmann, PA1
Gallego-Plazas, J1
Rothenberg, M1
Rosen, L1
Englisch-Fritz, C1
Bjerregaard, J1
Jensen, B1
Shastri, K1
Pilaro, AM1
Cordoba-Rodriguez, R1
Koti, K1
Men, AY1
Hughes, M1
Weiss, KD1
Dell'Orto, P1
Sonzogni, A1
Fazio, N1
Monfardini, L1
Chiappa, A1
Biffi, R2
Underhill, C1
Gorbounova, VA1
Biakhov, MY1
Bazin, IS1
Granov, DA1
Blatter, J1
Zuckerman, DS1
Itimura, T1
Syouji, D1
Watanabe, C1
Tazawa, K1
Sawada, S1
Nagata, T1
Uotani, H1
Hirokawa, S1
Yamagishi, F1
Tsukada, K2
Torresi, U1
Humar, B1
Schubert, U2
Praet, M1
Seya, T1
Kanazawa, Y1
Ohaki, Y1
Tajiri, T1
Cohen, DJ1
Viel, E1
Demarchi, MF1
Legat, C1
Thiery-Vuillemin, A1
Wei, WQ1
Liu, DZ1
Zeng, HY1
Yang, LX1
Zielinski, C2
Herbst, F1
Toda, S1
Moriyama, J1
Ehara, K1
Mine, S1
Kinoshita, Y1
Tsutsumi, K1
Udagawa, H1
Katori, H1
Hayashi, M1
Igarashi, M1
Hasebe, S1
Illert, B1
Bueter, M1
Thiede, A1
Fein, M1
Meyer, D1
Katirtzoglou, NA1
Efficace, F1
Coens, C1
Fricker, J1
Wisinski, KB1
Wen, ZF1
Zheng, FP1
Li, YW1
Feng, ZY1
Cevik, OM1
Punzengruber, R1
Riemann, J1
Wöll, E1
Arnheim, KE1
Delva, R3
Dorval, E1
Piot, G2
Gustavsson, BG2
Rustum, Y5
White, RR1
Munoz, JA1
Raggio, G1
Lencioni, M5
Federici, F1
Iannopollo, M1
Bujko, K1
Bujko, M1
Franco, L1
Cheetham, S1
Mesak, F1
Hind, D1
Tumur, I1
Eggington, S1
Ryan, A1
Di Fiore, F1
López-Siles, J1
Sánchez, A1
Sánchez, MJ1
Márquez, A1
Basaran, M1
Argon, A1
Ustaoglu, MA1
Tenekeci, AN1
Aykan, NF2
Zhang, JS1
Song, ST1
Tenma, K1
Imano, H1
Hibino, M1
Pintoffl, JP1
Holtmann, M1
Ide, T1
Ohtaka, K1
Mitsuno, M1
Zamboni, S1
Mallano, A1
Flego, M1
Ascione, A1
Dupuis, ML1
Gellini, M1
Barca, S1
Cianfriglia, M1
Simkens, L1
Antonini, N1
van Krieken, H1
Segalla, JG1
Federico, MH1
Skare, NG1
Franke, FA1
Perdicaris, MR1
Filho, Ude P1
Gampel, O1
Cabral, S1
Ribeiro, Rde A1
Bernard, SA1
Braich, T1
Evars, JP1
Hrushesky, WJ2
Duffy, A1
Huitzil-Melendez, FD1
Adams, WJ2
Kaizer, L1
Myers, R1
Thiessen, JJ1
Fine, S4
Kühl, M1
Rossion, I2
Koch, B1
Encke, A4
Sotos, GA1
Seiter, K5
Goker, E1
André, M1
Ragusa, K1
Ivarsson, M1
Gerdin, B1
Hellsing, K1
Bermann, A1
Franchi, F7
Simpson, WG1
Heys, SD5
Whiting, PH1
Eremin, O5
Broom, J1
Rinck, G1
Van den Bos, TG1
de Haes, HJ1
Schadé, E1
Veenhof, CH3
Kraimps, JL1
Thomas, E1
Margerit, D1
Ingrand, P1
Bretaudeau, B1
Barthes, JN1
Daban, A1
Barbier, J1
Fernandez-Trigo, V1
Shamsa, F1
Vidal-Jové, J1
Kern, DH1
Miya, K3
Fukada, D3
Umemoto, T3
Takao, H3
Hanada, H1
Maeshiro, T3
Yamada, F2
Awane, Y3
Kikkawa, N15
Tamaki, Y4
Yagyu, T4
Shin, E7
Kohashi, S1
Shiroto, H1
Kondo, M1
Ikuta, K1
Uchino, J1
Ariga, T2
Ooshima, I1
Kinoshita, H2
Takeda, A4
Yoshimura, S2
Shouko, T1
Tentas, K1
Katsikas, M1
Sakelaropoulos, N2
Daliani, D1
Figueredo, AT1
Fawcet, SE1
Molloy, DW1
Dobranowski, J1
Paulseth, JE1
Links, M1
Phadke, K2
O'Baugh, J1
Legge, J1
Ross, WB4
Van den Hout, BM1
Taal, BG4
Gortzak, E1
Schwartz, EL4
Ferguson, JE1
Hulse, P1
Lorigan, P1
Jayson, G1
Scarffe, JH1
Foutzilas, G1
Markantonakis, P1
Bacoyannis, C3
Zisiadis, A2
Karvounis, N3
Sobolos, K1
Marinelli, A1
Cloos, J1
van de Velde, CJ1
Kimura, O1
Kurayoshi, K1
Hoshino, K1
Sugezawa, A1
Molina Esquivel, J1
Vargas Sandoval, G1
Rodríguez del Rincón, E1
Velázquez López, J1
Fontana, T1
Noviello, MR1
Hanaue, H1
Mitomi, T3
Kurosawa, T1
Oo, TY1
Maoleekoonpairoj, S1
Norman, A7
Nicolson, V1
Ahmed, F2
Hanna, CL1
McKinna, FE1
Williams, LB1
Morrey, D1
Adams, M1
Mason, MD1
Käufer, C2
Rauschecker, H1
Andreesen, R2
Ohl, U2
Lange, HJ1
Klaassen, U3
Stenram, U1
Wieand, HS7
Gerstner, JB3
Gesme, DH1
Zissiadis, A1
Zamagni, C1
Cricca, A2
Pannuti, F2
Ruggeri, EM1
Pein, F1
Rainer, H2
Oskam, R2
de Peuter, RA1
Palmer, PA1
Franks, CR5
Flores, MR1
Tatulli, C1
Taveri, R1
Campanella, GA1
Carrieri, G1
Reynolds, T1
AbdAlla, EE1
Blair, GE1
Jones, RA1
Sue-Ling, HM1
Johnston, D1
Taguchi, T5
Ogawa, N1
Marshall, ME1
Tangen, CM2
Berenberg, JL1
Dorval, ED1
Regimbeau, C1
Picon, L1
Bérard, H1
Ambiru, S2
Ito, H2
Hayashi, S3
Nakajima, N2
Hiddemann, W8
Schüller, J6
Weiss, J1
Lohrmann, HP1
Schmitz-Hübner, U1
Bodenstein, H1
Schöber, C4
Grem, J2
Yamao, T1
Saito, D1
Ohkura, H1
Fleming, TR4
Muggia, FM2
Meyers, FJ1
Weiss, GR1
Mangalik, A1
Kumai, K1
Barberi-Heyob, M1
Merlin, JL1
Vigneron, M1
Vaughn, D1
Treat, J3
McCall, JL1
Jorgensen, JO1
Rayter, Z1
Leicester, RJ1
Mansi, JL3
Ota, J1
Takashima, S4
Yasutomi, M10
Takada, O1
Hasebe, K1
Tsugawa, K1
Tsuji, M1
Demachi, H1
Brown, TD1
Goodman, PJ1
Pugh, RP2
O'Rourke, T1
Otani, Y1
Tsuji, R1
Hiki, Y1
Shinohara, K1
Stein, BN1
Douglass, HO2
Driscoll, DL1
Arcangeli, G2
Cianci, C4
Andersen, LJ1
Brunsgaard, NH1
Mejlholm, I1
Weiber, S1
Jiborn, H1
Zederfeldt, B1
André, AM1
Grossano, DD1
Maltoni, R1
Riccobon, A1
Fedriga, R1
Milandri, C2
Pezzi, L1
Velotti, F1
Santoni, A1
Riesener, KP2
Winkeltau, G2
Klemm, M1
Schumpelick, V2
Buter, J2
van der Graaf, WT1
Verschueren, RC3
Fried, G1
Tsalik, M1
Stein, M1
Dale, J1
Shida, H2
Ban, K2
Matsumoto, M6
Noma, M1
Kitazaki, M1
Masuda, K2
Imanari, T2
Hisikawa, E1
Yaguchi, H1
Arima, H1
Hachisu, T1
Kashiwabara, H1
Jablonski, KA1
Port, RE2
Schlemmer, HP2
Bachert, P2
Inaba, M2
Mitsuhashi, J2
Lévy, E4
Vaillant, JC1
Garcia, P1
Tusquets, I1
Font, A1
Fabregat, X1
Leichman, L6
Caudry, M1
Bonnel, C1
Floquet, A1
Marsault, C1
Quétin, P1
Pujol, J1
Maton, O1
Dujols, JP1
Caudry, Y1
Skawinski, P1
Carlier, D1
Darloy, F1
Pion, JM2
Bonneterre, J2
Demaille, A1
Warren, HW3
O'Gorman, P2
Kane, E2
Cooke, TG4
Patel, N2
Johnston, A1
Murray, LS1
Reed, NS1
Canney, PA1
Kaye, SB2
Wotherspoon, HA1
Warren, H2
Watson, D1
Vinké, BJ1
Dobbie, JW1
el Eini, DI1
Pratt, CB2
Meyer, WH1
Howlett, N1
Douglass, EC1
Bowman, LC1
Poe, D1
Mounce, K1
Kun, LE1
Zidani, R5
Vannetzel, JM2
Perpoint, B4
Itzhaki, M3
Misuta, K1
Masui, H2
Ike, H1
Ohki, S3
Cho, G1
Takatsuka, Y3
Aratake, T1
Kawase, A1
Kirita, T1
Higaki, T1
Oishi, H1
Kono, S1
Tomita, F2
Kurosaka, Y1
Kita, I1
Haruta, A1
Umeno, T1
Toriya, H1
Jyozaki, H1
Ikeda, S1
Nichols, PH1
Ward, U3
Ramsden, CW1
Engarås, B1
Holmberg, SB1
Jönsson, PE1
Tidebrant, G1
Buer, J1
Kirchner, H1
Schomburg, A2
Schüler, A1
Manns, M1
Lopez-Hänninen, E1
Duensing, S1
Poliwoda, H4
Sips, JH1
van Tellingen, O1
Nooijen, WJ1
Rodenhuis, S2
Ten Bokkel Huinink, WJ1
Semmler, W2
Hohenberger, P8
Lorenz, WJ2
van Kaick, G4
Villar-Grimalt, A3
Belón, J2
Jimeno, JM1
Candel, MT3
Colajori, E1
Ono, K1
Saijo, N2
Begos, DG1
Ballantyne, GH1
Ashikaga, K2
Kimura, C1
Stein, TA1
Burns, GP1
Bailey, B1
Citron, ML1
Fassas, AB1
Gattani, AM1
Morgello, S1
Castoldi, MC1
Dellafiore, L1
Pancera, G8
Ohnishi, H1
Nakajima, I1
Akabane, Y1
Kurooka, K2
Koh, K2
Shindo, K3
Huber, BE3
Austin, EA3
Richards, CA2
Davis, ST3
Good, SS2
Metzger, G7
Massari, C1
Comisso, M1
Touitou, Y2
Misset, JL10
Sewell, GJ1
Allsopp, M1
Collinson, MP1
Tyrrell, C1
Prentice, AJ1
Copplestone, JA1
Pedicini, A1
Valori, V1
Giotta, F2
Prete, F1
Bergström, R1
Martinelli, DJ1
Bakal, CW1
Haynes, H1
Wiernik, PH4
Egeli, R3
Arma, S3
Barras, JP1
Martinoli, S3
Müller, W3
Castiglione, M3
Schroeder, R1
Mader, RM1
Djavanmard, MP1
Gnant, MF1
Locker, G1
Marosi, C2
Moertel, CG8
Carl, J1
Brunsgaard, N2
Nørgaard-Pedersen, B1
Silva, RR2
Battelli, N1
Manocchi, P1
Rossini, S1
Delprete, S1
Mazzanti, P1
Bascioni, R2
Battelli, T1
Foa, P1
Giaccon, G1
Luporini, G8
Kerr, I2
Hoffman, W1
Gorg, C2
Preusser, P3
Senn, HJ1
Grison, X3
Zittoun, J3
Lotz, JP7
Richaud, J3
Hannoun, L3
Marquet, J3
Guillot, T3
Kohne-Wompner, CH3
Hagiwara, A1
Weh, HJ4
Dierlamm, J1
Siegmund, R2
Illiger, HJ2
Hilgenfeld, U1
Steinke, B3
Nicolson, M1
Ford, H1
Husband, J2
Evans, C1
Carter, R1
Bertuccelli, M2
Muttini, MP1
Dargenio, F2
Klotz, HP2
Weder, W3
Largiadèr, F3
Navarro-Carola, E1
Demuynck, B3
Beerblock, K4
Soubrane, D2
Grangé, JD3
Rasi, G3
Silecchia, G2
Sinibaldi-Vallebona, P2
Spaziani, E2
Pierimarchi, P2
Sivilia, M1
Tremiterra, S1
Garaci, E3
Adler, S1
Lang, S1
Langenmayer, I1
Eibl-Eibesfeldt, B1
Rump, W1
Emmerich, B1
Rosso, R10
Cartei, G2
Cartei, F1
Overgaard, M1
Bertelsen, K1
Dalmark, M2
Gadeberg, CC1
von der Maase, H2
Overgaard, J1
Sell, A1
Del Ferro, E4
Fedeli, A5
Grianti, C1
Foglietti, G1
Olivieri, Q1
Acetoso, M1
Bartolucci, M1
Saba, V1
Lungarotti, F1
Kameyama, M2
Utsunomiya, J2
Oshima, A2
Hioki, K3
Fukuda, I2
Hamblin, TJ2
Sadullah, S2
Williamson, P2
Stevenson, J1
Palmer, P2
Mori, A2
Bertoglio, S1
Bolli, E2
Tixi, L4
Chase, JL3
Hohn, DC3
Koster, RH1
Weissman, DE1
Graham, M1
Perkins, S1
Sheehan, RG1
Ross, M1
Bull, J1
Pruitt, B1
Periman, P1
Ruud, C1
Ando, J1
Ozawa, I1
de Takats, PG1
Poole, CJ1
Hoffman, K3
Sjödén, PO3
Hoekman, K1
Priest, DG1
Bunni, MA1
Hanyu, F1
Takei, Y1
Noda, Y2
Machida, T1
Yamamoto, T1
Di Tora, P2
Mannella, E2
Casaldi, V1
Civalleri, D3
Morandi, GB1
Da Pian, PP2
Padovani, A1
Callopoli, A2
Fischkoff, S1
Martin, K1
Dimitrakopoulou, A2
Clorius, JH1
Ostertag, H1
Heim, M1
Oberdorfer, F4
Helus, F1
Boese-Landgraf, J4
Häring, R1
Weber, B2
Hopfenmüller, W1
Hager, K1
Pittman, K1
Perren, T1
Jordan, E1
Robson, ME1
Binder, RA1
Hamilton, JM3
Arbuck, SG4
Beveridge, RA1
Kales, AN1
Miller, JA1
Leach, MO1
Collins, DJ1
Payne, GS1
Glaholm, J1
McCready, VR1
Tohno, K1
Utsunomiya, T1
Oikawa, H2
Matsuzaki, H4
Akaishi, O3
Ozasa, T3
Katayama, K1
Shinohara, M1
Mukaijo, T1
Nakatsuka, A1
Kido, C3
Shiiba, K1
Ouchi, A1
Kunii, Y2
Momono, S1
Muto, I1
Mashiko, H1
Wada, M1
Sugimasa, Y1
Okamoto, T2
Burghouts, JT3
Croles, JJ2
van Liessum, PA1
de Mulder, PH3
Kamm, Y1
Colleoni, M2
Scanni, A1
Calabresi, F2
Lehner, B1
Frohmüller, S2
Uges, DR2
Roenhorst, HW1
Yang, JC1
Shlasko, E1
Ritchey, JL1
Landry, JG1
White, DE1
Rosenberg, SA1
Knick, VC1
Tibbels, S1
Kitamura, K1
Otsuji, E1
Laufman, LR3
Collier, MA1
Sullivan, BA1
McKinnis, RA1
Clendennin, NJ1
Guaspari, A1
Brenckman, WD3
Meyer, S2
Vermorken, JB1
Nieweg, MB1
Cuesta, M1
Spears, CP1
Rosen, PJ1
Jeffers, S1
Lokich, JJ2
Anderson, N2
Ahlgren, JD3
Kusano, H2
Miyashita, K2
Nakazaki, T1
Yoshida, A1
Dohden, K1
Ohmura, K1
Kok, RM1
Hidalgo, OF1
Bilbao, I1
Tangco, E1
Abuchaibe, O1
Sartor, O1
Inaba, H1
Weiner, LM3
Hudes, GR2
Kitson, J1
Walczak, J2
Watts, P1
Litwin, S2
Sigurdson, E1
Lincer, R1
Botet, J3
Chapman, D1
Costa, P3
Degardin, M1
Horner, D1
Brockmann, WP1
Wiegel, T1
Sommer, K1
Hübener, KH1
Tsujimura, T1
Ezaki, K1
Kawase, K1
Hatanaka, T1
Ohara, K2
Hobara, R1
Okamoto, M1
Boyle, FM1
Smith, RC1
Levi, JA1
Poorter, RL2
Taat, CW1
Spiers, EM1
Potts, RC1
Sharpe, SY1
Newman, EL1
Lavelle-Jones, M1
Beck, JS1
Cuschieri, A1
Bajard, F1
Fety, R1
Bumann, D1
Crone-Münzebrock, W2
Carl, U1
Baccanari, DP2
Joyner, SS1
Neoptolemos, J1
Doughty, J1
Budden, J2
Soussan, A1
Caussanel, JP2
Jasmin, C3
Smolensky, M1
Bovo, G1
Brivio, F1
Brenna, A2
Fumagalli, L1
Perego, P1
Brivio, O1
Uggeri, F1
Lavorato, F1
Bratina, G1
b1p6uller, J1
Rowley, S1
Lindauer, M1
Gebert, JF1
Moebius, U1
Herfarth, C2
Schackert, HK1
Hoffmann, W2
Thuerlimann, B1
Rath, U3
Olver, I1
Svensson, C2
Frediani, B1
Palazzuoli, V1
Botta, G1
Tani, F1
De Martino, A1
Eatock, MM1
Carlin, W1
Dunlop, DJ1
Soukop, M2
Watson, DG2
Brett, MC1
Pickard, M1
Green, B1
Howel-Evans, A1
Kinsella, A1
Carlson, R1
Allen-Mersh, T1
Chang, A1
Sondak, V1
Kemeny, M1
Gossios, K2
Svarna, E1
Rodriguez-Bigas, M1
Blumenson, LE2
Frank, C3
Berghorn, E1
Matei, D1
Hagag, N1
Avvento, L2
Burns, P1
Fiore, J1
Lipera, W1
Zarrabi, H1
Young, H1
Iveson, A1
Cronin, B1
Pratt, B1
Flower, M1
Nethersell, AB1
Smyth, JF1
Hardcastle, JD2
Denton, G1
Alderson, D1
Grace, RH2
Yosef, HM1
Nordle, O1
Lauri, H1
Wählby, S1
Jones, DV2
Winn, RJ1
Brown, BW2
Levy, LB1
Wade, JL1
Gross, HM1
Pendergrass, KB1
Levin, B3
Vermeulen, PB1
Dirix, LY1
Pelgrims, G1
Van Oosterom, AT1
Dorta, J1
Blanco, E2
Cruz-Hernandez, JJ1
Gonzalez-Mancha, R2
García-Conde, J3
Hansen, RM4
Ryan, L3
Anderson, T3
Krzywda, B1
Quebbeman, E3
Tormey, DC1
Bécouarn, YH1
Brunet, RC1
Rouhier, ML2
Bussières, EJ1
Avril, AR1
Richaud, PM1
Dilhuydy, JM1
Sugimachi, K5
Kakegawa, T1
Tomita, M2
Akiyoshi, T1
Gamelin, EC1
Danquechin-Dorval, EM1
Dumesnil, YF1
Maillart, PJ1
Goudier, MJ1
Burtin, PC1
Delva, RG1
Lortholary, AH1
Gesta, PH1
Larra, FG1
Farrer, C1
Gordon, A1
Sommers, SS1
Monson, JR2
Guillou, PJ3
Anand, A2
Anand, N1
Lombardo, M1
Fabiani, F1
Fanini, R1
Venturoni, L1
Torchio, P1
Peretti, G1
Larsson, PA1
Vaughn, DJ2
Takeda, I1
Sugiyama, K1
Osada, T1
Ooki, H1
Samori, T1
Kanno, H1
Yoden, Y1
Ohashi, S1
Iwanaga, T1
Nomura, H1
Giannopoulos, A1
Papadimas, V1
Kalahanis, N1
Karatzas, G1
Archimandritis, A1
Papachristodoulou, A1
Houston, RF1
Moorehead, RJ1
Rossi, D1
Casadei, V1
Ohno, M2
Toge, T2
Tanemura, H1
Oshita, H1
Benhattar, J1
Cerottini, JP1
Saraga, E1
Metthez, G1
Doughty, JC1
Stewart, IS1
Reid, AW1
Blijham, G4
Buset, M1
Lacave, A1
Selleslag, J1
Sahmoud, T1
Bernhard, H1
Bernhard, G1
Lautz, D1
Michaelis, J1
Meyer zum Büschenfelde, KH2
Perren, TJ1
McAdam, WA1
Neoptolemos, JP2
Nicholson, M1
Duffy, AM1
Stenning, SP1
Perrier, H2
Uematsu, T1
Nakashima, M1
Masuike, T1
Gustafson, P1
Di Lauro, L3
Santini, S1
Gandolfo, GM1
Vitelli, G1
Frasca, AM1
Ameglio, F2
Malvaldi, G2
Li, XM1
Mormont, C1
Babu, KG1
Rasheshyam, D1
Lalitha, N1
Clark, J1
Sikov, W2
Cummings, F2
Browne, M1
Akerley, W2
Wanebo, H1
Weitberg, A2
Kennedy, T1
Cole, B1
Bigley, J1
Beitz, J2
Darnowski, J1
Port, JL1
Ng, B1
Ellis, JL1
Nawata, S1
Lenert, JT1
Burt, ME1
Ang, PT2
Moreau, S2
Mal, F2
Zylberait, D1
Porte, H1
De Moulins, H1
Gambiez, L2
Wurtz, A1
Quandalle, P2
Dayan, A1
Beauchemin, M1
Chahla, D1
Mamo, A1
Bertrand, R1
Testa, A1
Majello, E1
Cannata, G1
Mastrandrea, G1
Feo, M1
Bajardi, G1
Piga, A3
Marcellini, M2
Bavosi, M1
Acito, L1
Pancotti, A1
Del Papa, M1
Carle, F1
Cellerino, R2
Kubo, R2
Koslowe, P1
Vinci, M2
Vaghi, M1
Pirovano, M2
Facendola, G2
Blomgren, H2
Taketomi, A2
Seo, Y2
Tomoda, H3
Kosaka, A3
Hojyo, M1
Watabiki, Y2
Ohara, M3
Shikata, A3
Hoshiya, Y2
Yorozuya, K1
Yabata, E1
Endou, M1
Harmantas, A1
Rotstein, LE1
Kido, Y1
Tomikawa, M1
Shiraishi, M1
Davidson, BS1
DuBrow, RA2
Patt, Y1
Ligi, M2
Blesing, CH1
Borden, EC1
Figlin, R1
York, M1
Einhorn, L1
Marshall, EM1
Buys, SS1
Froimtchuk, MJ1
Schuchter, L1
Ritter, L1
Man, A2
Yap, AK1
Nakamori, M1
Noguchi, K1
Tani, M1
Ishimoto, K1
Dreyfus, B1
Olivier, JP1
Dumas, F1
Duclos, B1
Olivares, R1
Leszler, A1
Bergerat, JP2
Audhuy, B1
Thill, L1
Oberling, F1
Antón-Torres, A3
Massutí, T3
Barneto, I3
Barón, JM1
Hilgenfeld, RU3
Streit, M2
Susak, YM1
Zemskov, VS1
Yaremchuk, OY1
Kravchenco, OB1
Yatsyk, IM1
Korsh, OB1
Ron, IG2
Lotan, A1
Inbar, MJ1
Bertheault-Cvitkovic, F3
Jami, A2
Ithzaki, M1
Brummer, PD1
Dasappa, V1
King, J2
King, DW1
Tan, EH1
Ruffin, WK1
Skarlatos, J1
Kosma, L1
Koukourakis, M2
Zambatis, C1
Kapsoritakis, A1
Mouder, N1
Yannakakis, D1
Messori, A2
Bonistalli, L1
Costantini, M1
Trallori, G1
Tendi, E1
Heron, J1
Pessi, A1
Rabinovich, M1
Vallejo, C3
Machiavelli, M2
Romero, A2
Perez, J1
Lacava, J3
Cuevas, MA3
Rodriquez, R1
Leone, B2
Sapia, MG1
De Lena, M3
Goey, SH1
Gratama, JW1
Mertelsmann, RH1
Osterwalder, B7
Stoter, G1
Hanyu, N1
Yin, MB1
Gonen, O1
Murphy-Boesch, J1
Li, CW1
Padavic-Shaller, K1
Negendank, WG1
Brown, TR1
Mariani, G1
Di Sacco, S1
Bonini, R1
Di Luca, L1
Buralli, S1
Bonora, D1
Baranowska-Kortylewicz, J1
Adelstein, SJ1
Kassis, AI1
Oliver, I1
Schneider, HJ1
Sampson, SA1
Andreyev, HJ2
Tilsed, JV1
Clarke, PA2
Biert, J1
Wobbes, T1
Hoogenhout, J1
de Man, B1
Hendriks, T1
Walker, LG2
Wesnes, KP1
Walker, MB2
Lolley, J2
Fenton-Lee, D1
Milan, C1
Morvan, F4
Kornek, G2
Marczell, A2
Salem, G1
Karner, J1
Burger, D1
Greiner, R1
Pidlich, J2
Rosen, H2
Morgan, G1
Clinton, S1
Hardcastle, A1
Aherne, GW1
Lucchi, E1
Cady, J2
Siderov, J1
Olsen, JA1
Revhaug, A1
Prendiville, J3
Gottardi, O1
Duro, M1
Pavanato, G1
Raina, A1
Piazza, E2
Dallavalle, G2
Valsecchi, R1
Keuning, JJ1
Presant, CA3
Wolf, W3
Waluch, V3
Eberhardt, W1
Korn, MW1
Arita, D1
Funato, T1
Tezuka, F1
Kievit, E1
Schlüper, HM1
Haisma, HJ1
Boven, E1
Rafique, M1
Adachi, W2
Kajikawa, S2
Sugenoya, A1
Amano, J1
Nonami, T1
Kurokawa, T1
Taniguch, K1
Harada, A1
Earlam, S1
Glover, C3
Davies, M1
Fordy, C2
Allen-Mersh, TG3
Cremona, F1
Ruffolo, F1
Wattanatorn, W1
Kendle, KE1
Hoque, A1
Lozano, R1
Pozdur, R1
Chase, J1
Carrasco, H1
Chuang, V1
Delpassand, ES1
Ellis, L1
Curley, S1
Roh, M2
Hageboutros, A1
Greene, F1
LaCreta, FP1
Brennan, J1
Loeffler, TM1
Hausamen, TU2
Wils, JA2
Garcia-Giralt, E2
Beuzeboc, P2
Deffontaines, D2
Diéras, V2
Dorval, T2
Jouve, M2
Palangie, T2
Scholl, S2
Pouillart, P2
Kawachi, Y1
Sagara, T1
Murakami, S1
Kudo, H1
Okayasu, I1
Howell, JD3
Gallagher, H1
Maguire, R1
Iaremchuk, AIa1
Kravchenko, AV1
Kamenets, LIa1
Chernenko, OD1
Fan, FS2
Hsu, H2
Schroeder, G2
Knost, JA2
Ghosh, C1
Kirschling, RJ1
Minsky, BD1
Rowinsky, EK2
Rocchi, MB2
Zamparelli, G1
Ardizzoia, A1
Ugolini, G1
Ghiandoni, G1
Gunderson, LL2
Nelson, H2
Martenson, JA1
Cha, S3
Haddock, MG2
Devine, RM2
Fieck, JM2
Wolff, BG3
Dozois, RR2
Kronawitter, U1
Kissel, J2
Brix, G2
Bellemann, ME2
Port, R1
Somma, L1
Del Vecchio, M1
Zunino, F3
Bignami, P1
Magnani, E1
Isacoff, WH1
Borud, K1
Katona, C2
Rosta, A1
Fónyad, G1
Pandi, E1
Nobile, MT5
Barzacchi, C1
Sanguineti, O2
Vincenti, M2
Di Somma, C1
Meszaros, P1
Stuntz, M1
Wilmoth, G1
Ong, J1
Stabile, B1
Stamos, M1
Cvitkovic, E10
Grandi, AM1
Morandi, E1
Zanzi, P1
Bulgheroni, P1
Guasti, L1
Venco, A1
Esposito, M1
De Cian, F1
Balletto, N2
Vannozzi, MO1
Mondini, G1
Carrabetta, S1
Bocchio, MM1
Cantore, M2
Rabbi, C1
Cavazzini, G1
Bertani, M1
Pulica, C1
Campo, S1
Pari, F1
Bezzi, A1
Zamagni, D1
Amadori, M1
Smerieri, F1
Pillasch, J3
Metzger, R5
Butzer, U1
Leder, GH2
Weindel, M1
Safi, F3
Beger, HG5
Baranda, J1
Boswell, W1
Murad, A1
de Andrade, CA1
Delfino, C1
Arikian, S1
Doyle, J1
Sinha, N1
Chung, Y1
Harrison, J1
Berkery, R1
Chinery, R1
Brockman, JA1
Peeler, MO1
Shyr, Y1
Beauchamp, RD1
Coffey, RJ1
Hatfield, AK1
Maillard, JA1
Wiesenfeld, M1
Tirona, MT1
Omodei Zorini, C1
Buckles, J1
Gallagher, HJ1
Morimoto, O1
Miya, A1
Satomi, T1
Hashizume, R1
Arifuku, T1
Nagaoka, S1
Shuto, K1
Takayama, W3
Fukunaga, T1
Aoyama, H1
Shinoto, K1
Imazeki, H1
Isono, K3
Hosoki, T2
Oshima, I1
Ioku, T1
Iwashita, C1
Shoko, T1
Kon, H1
Sasaki, R1
Kawata, S1
Pace, R1
Giunta, S3
Gallà, DA1
Silecchia, GF1
Narduzzi, C1
Kawabata, K1
Nio, Y2
Imamura, M1
Padhani, A1
Massey, A2
Messenger, M1
Taplin, SC1
Pignon, J1
Hansen, R3
Zee, B2
Weinerman, B4
Pater, J3
Leichman, C2
Fryer, J2
Brufman, G2
Isacson, R2
Drews, M1
Szmeja, J1
Paszkowski, J1
Wierzbicki, T1
Załuski, J1
Fundowicz, D1
Wesnes, K1
Gordon, D1
Caroti, C3
Ciferri, E1
Verdi, E1
Klaasen, U1
Westerhausen, M1
Schott, G1
Harstick, A1
Bade, J1
Horster, A1
Paillot, B2
Rekacewicz, C1
Laplaige, P2
Grandjouan, S1
Fabri, MC1
Sabatini, CL1
Barbieri, MR2
Salvadori, MA1
Acuña, LA1
Acuña, JM1
Langhi, MJ2
Amato, S2
DeLena, M1
Vignoud, J1
Watson, SA2
Michael, D1
Justin, TA1
Grimes, S1
Morris, TM2
Robinson, G1
Guichard, S1
Ahnen, DJ1
Feigl, P1
Quan, G1
Fenoglio-Preiser, C1
Lovato, LC1
Bunn, PA1
Stemmerman, G1
Wells, JD1
Meyskens, FL1
Doll, J1
Kanemitsu, T1
Miyashita, A1
Inamura, Y1
Owa, Y1
Gorlick, R2
Miles, JS1
Longo, GS1
Klimstra, D2
Jhanwar, S1
Troutt, AB1
Bandealy, MT1
Gonin, R1
Loehrer, PJ1
Monaco, F1
Einhorn, LH2
Allman, D3
Weidekamm, E4
Roos, B3
Banken, L3
Utoh, M3
Palmer, MK2
John, WJ1
Foon, KA1
Luis, R1
Jaime, M1
Franceschi, D1
Stroomer, AE1
Pajkos, G3
Szentpétery, L1
Kristó, K1
Izsó, J2
Bekradda, M3
Hata, Y1
Kawasaki, R1
Awatani, T1
Leccia, JR1
Pierrefite, V1
Lebouil, A1
Turcant, A2
Cailleux, A2
Krikorian, A2
Larra, F3
Allain, P2
Fabbro-Peray, P1
Perney, P1
Marçais, O1
Gouze, C1
Ribard, D1
Bons-Rosset, F1
Heran, B1
Veyrac, M2
Blanc, F1
Munzone, E1
Nolè, F2
De Pas, T1
Aapro, MS1
Van Daele, D1
Gil, T1
Fernez, B1
Bulusu, VR1
van Laar, JA1
Maurer, C1
Gabel, M1
Kolozsvary, A1
Khil, M1
Freytag, S1
Bacchi, M3
Weber, W2
Fey, MF1
Pagani, O1
Leyvraz, S1
Pestalozzi, B1
Hanselmann, S2
Goldhirsch, A2
Naoe, Y1
Rietjens, IM1
Bernath, AM1
Fitzgibbons, RJ3
Burch, P1
Colon-Otero, G1
Peppercorn, PD1
Reznek, RH1
Gupta, RK1
Pronzato, P1
Botto, F1
Ghio, E1
Pensa, F1
Tognoni, A1
Vaira, F1
Vigani, A1
Neri, E1
Capodano, G1
Bardou, VJ1
Pádi, E1
Meikle, SR1
Matthews, JC3
Brock, CS1
Wells, P1
Harte, RJ3
Cunningham, VJ1
Price, P1
Kujime, J1
Yamagami, H2
Kimura, J3
Ohira, S2
Iwase, H2
Kameya, T2
Itoh, I1
Ohtaki, M2
Nishishou, I2
Sai, H1
Nagao, N1
O'Reilly, SM2
Malacarne, P2
Belsanti, V2
Marzola, M3
Corgna, E1
Sdrobolini, A3
Figoli, F2
Algeri, R2
Angiona, S1
Gadeberg, C1
Hansen, P1
Lindberg, B1
Sellström, H1
Lorentz, T1
Romero Acuña, LA1
Romero Acuña, JM1
Marrone, N1
Glenn, D1
Casillas, S1
Jones, SC1
Milsom, JW1
Kasperk, R1
Cocconi, G1
Hietschold, SM1
Trés, A1
López-Vega, JM1
Lionetto, R2
Gozza, A1
Barzacchi, MC1
Geisler, J1
Geisler, SB1
Lønning, PE1
Refsum, H1
Ueland, PM1
Conley, BA1
Fietkau, R2
Hocking, RA1
Tong, A1
Ognoskie, N1
Meyer, W1
Henderson, CA1
Berg, D1
Davies, MM1
Hickish, TF1
Johannesen, TB1
Topham, CA1
Jacques, C2
Nicolini, A1
Carpi, A2
Ferrari, P1
Sagripanti, A1
Anselmi, L1
Fink, D1
Gordon, R1
Fink, JL1
Howell, SB2
Cheradame, S1
Richelme, H1
Bouil, AL1
Richmond, E1
DeLap, RJ1
Hale, HL1
Husband, JE1
Koss-Twardy, SG1
Passe, SM1
Patel, IH1
Hohneker, JA1
Dikken, C1
Sitzia, J1
Cordel, S1
Dupas, B1
Meflah, K1
Yonekura, R1
Ohshimo, H1
Kumagai, K1
Masuo, K1
Yamagata, K1
Ajani, JA4
Dumas, P1
Fairweather, J1
Stewart, JM1
Millward, MJ1
Farrugia, DC2
Rau, HG1
Stieger, R2
Filez, L1
Cote, C2
Rodriguez-Coria, DF1
Arroyo, B1
Gonzalez-Macouzet, J1
Stubbs, RS1
Alwan, MH1
Booth, MW1
Sludden, J1
Hardy, SC1
Lock, RE1
Hawksworth, GM1
Mattes, P2
Junginger, T2
Saeger, HD2
Armand, JP2
Gil-Delgado, M2
de Gramond, A1
Hejna, M2
Valencak, J1
Weinländer, G1
Fiebiger, W2
Miholic, J1
Palmer, M2
Yamane, N1
Blom, MJ1
Mul, EP1
Slocum, HK1
Leder, G2
Pillasch, AF1
Sunelaitis, E2
Pressmar, J1
DeVore, RF1
Rivkin, SE1
Geyer, CE1
Sandbach, J1
Wolf, DL1
Mohrland, JS1
Von Hoff, DD1
Rohlff, C1
Skelton, L1
Jackman, AL2
Page, MJ1
Saeki, T2
Mukaiya, M1
Oikawa, I1
Denno, R1
Nutting, C1
Folkes, A1
Assersohn, L1
Benepal, T1
Alexopoulos, CG1
Symann, M1
Cholet, P1
Fillet, G1
Van Groeningen, C1
Panagos, G1
Unger, C3
Blanc, C1
Bender, H1
Bangard, N1
Metten, N1
Bangard, M1
Mezger, J1
Biersack, HJ1
Kern, W3
Böttger, B1
Kaufmann, CC1
Schleyer, E2
Zaers, J1
Stevenson, JP2
Groener, MG1
van Ineveld, BM1
Byttebier, G1
van Hout, BA1
Rutten, FF1
Boussen, H1
Kallel, N1
Khomsi, F1
Jerbi, G1
Dhouib, R1
Ben Safta, Z1
Ben Abdesselem, M1
el May, M1
Gammoudi, A1
Benna, F1
Hamza, H1
Dziri, C1
Najah, N1
Zaouche, A1
Rahal, K1
Ben Ayed, F1
Tilsley, DW1
Luthra, SJ1
Brady, F1
Guillemin, F1
Arican, A1
Cay, F1
Dinçol, D1
Karaoğuz, H1
Demirkazik, A1
Rao, BN1
Merchant, TE1
Avery, L1
Cain, A1
Bodner, S1
Poquette, C1
Lizón, J2
Sánchez, B1
Frau, A1
Gorostidi, B1
Goedkoop, R1
Ou, Q1
Shankar, A1
Renaut, AJ1
Whelan, J1
Lippert, H1
Rotarski, M1
Letourneau, Y2
Llory, JF2
Le Rol, A2
Mitoro, A2
Tsujinoue, H2
Toyokawa, Y1
Nakatani, T2
Fukui, H2
Lobelle, JP1
Dallemagne, B2
Jehaes, C2
Markiewicz, S2
Miller, M1
Imaseki, H2
Rödel, C1
Asato, Y1
Yoshimi, F1
Amemiya, R1
Goya, T1
Galli, C1
Petrasch, S1
Dörr, T1
Kemmeries, G1
Kaneda, K1
Goggin, T1
Kakisaka, A1
Minami, M1
Goto, J1
Isizaki, A1
Kino, S2
Guarino, E1
Restuccia, A1
Bernard, P1
Tuthill, C1
Brito, RA1
Medgyesy, D3
Zukowski, TH2
Royce, ME4
Ravandi-Kashani, F1
Rudroff, C1
Altendorf-Hoffmann, A1
Stangl, R2
Scheele, J2
Alafaci, E1
Reynes, M1
Oster, G1
Ollendorf, D1
Joulia, JM2
Astre, C2
Gomeni, R1
Decker-Baumann, C1
Buhl, K2
von Herbay, A1
Dueck, M1
Moser, R1
Mlineritsch, B1
Schmidt, H1
Pecherstorfer, M1
Fridrik, M1
Kopf, C1
Nitsche, D1
Kaider, A1
Jacobson, JR1
Modiano, M2
Daniels, JR1
Fletcher, WS1
Cavaliere, F1
Di Filippo, F1
Cosimelli, M4
Aloe, L1
Arcuri, E1
Anzà, M2
Morace, E1
Botti, C1
Natoli, S1
Tedesco, M1
Cavaliere, R1
Jelić, S1
Nikolić-Tomasević, Z1
Vian, L1
Mochizuki, F1
Skradis, A1
Kolar, C3
Kolath, J2
Lawson, T1
Talmadge, J2
Stremetzne, S1
Schunack, W1
McGarry, W1
Bready, B3
Belt, RJ1
Winn, R3
Fata, F1
Koehne, CH1
Gravina, A2
Faranda, A1
Comis, S3
O'Byrne, KJ1
Braybrooke, JP1
Bates, NP1
Taylor, MA1
Madigan, D1
Ganesan, TS1
Talbot, DC1
Harris, AL1
Baldelli, AM1
Giuliodori, L1
Agostinelli, R2
Adjei, AA1
Behr, TM1
Salib, AL1
Béhé, M1
Angerstein, C1
Blumenthal, RD1
Fayyazi, A1
Sharkey, RM1
Ringe, B1
Becker, H1
Wörmann, B1
Goldenberg, DM1
Becker, W1
Bensmaine, MA3
Lucas, V1
Dupont-André, G1
Lawson, TA2
Fujioka, M3
Kishi, T1
Shimomura, K1
Idezuki, Y2
Ishizaki, A1
Kassai, S1
Tsujita, K1
Itou, Y1
Ukei, T1
Touno, T1
Oozato, H1
Oohata, K1
Tukamoto, H2
Yoneyama, Y2
Takanishi, K1
Matsumoto, J1
Ohzato, H3
Aihara, T1
Kan, K1
Imamoto, H1
Guérin-Meyer, V1
Lortholary, A1
Genevieve, F1
Ifrah, N1
Antonelli, G1
Tunesi, G2
Baldo, C1
Parikh, B1
Taketani, S2
Oyaizu, H1
Ikebukuro, K2
Ikehara, S2
Ofner, D1
Bern, M1
Coco, F1
Ignoffo, RJ1
Dempke, W1
Royce, M1
Brito, R1
Makower, D1
Cohen, AM2
Brennan, MF1
Turnbull, AD1
Stockman, J1
Bertheaut-Cvitkovic, F1
Larregain-Fournier, D1
Walter, S1
Marty, M5
Ségal, V1
Morsman, J1
Blackie, R1
Skarlos, DV1
Sgouros, I1
Florou, S1
Suzuka, I1
Izumi, S1
Onoda, Y1
Shiota, K1
Nakagawa, J1
Wiseman, CL1
Weitz, I1
Shani, J1
Pospisil, M1
Vannucci, L1
Horvath, O1
Fiserova, A1
Krausova, K1
Bezouska, K1
Mosca, F1
Bichisao, E1
Silingardi, V1
Sansoni, E1
Izrael, V4
Rudolph, KL1
Unterhalt, M1
Gwilt, P1
Tempero, M2
Connolly, M1
Martens-Lobenhoffer, J1
Fuhlroth, J1
Boulanger, N1
Schmitt, C3
Denimal, F1
Karoui, M1
Dewailly, V1
Kocha, W3
Taylor, M1
Keith, B1
Sawyer, M1
Griffeth, S1
Tansik, RL1
Porter, DJ1
Lampert, S2
Reingruber, B1
Vetter, G2
Dalley, D1
Kallen, KJ1
Hofmann, MA1
Timm, A1
Haba, A1
Pritchard, DM1
Aapro, M2
Okamoto, R1
Takeda, N1
Takayasu, Y1
Nakao, N1
Kubota, A1
Karasek, P1
Jandik, P1
Alakl, M2
Novellino, PS1
Trejo, YG1
Beviacqua, M1
Bordenave, RH1
Rumi, LS1
Smail, A1
Cailliez, V1
Ehrnrooth, E1
Sørensen, B1
Poulsen, JH1
Dumont, E1
Durston, S1
Levy-Piedbois, C1
Durand-Zaleski, I1
Juhel, H1
Bellanger, A1
Papagianopoulos, P1
Ride, E2
Turner, J1
Wardle, J1
Evans, V1
Kay, S1
McArdle, RJ1
Wendling, JL1
Burki, F1
Mignard, D2
Johnson, M1
Peillard, L1
Catalin, J1
Toki, J1
Schallhorn, A1
Hochmuth, K1
Eida, K2
Nogawa, T1
Kunisaki, T1
Tobinaga, K1
Furukawa, M1
Ino, M1
Arima, S1
Tachikawa, D1
Futami, K1
Yokomori, T1
Iesato, H1
Ohya, T2
Nagaoka, H1
Okabe, T1
Lochs, H2
Haboubi, N1
Berdel, WE3
Wall, JG1
Mani, S3
Bonny, T1
Levin, J3
Hohneker, J2
Hinoshita, E1
Uchiumi, T1
Kinukawa, N1
Tsuneyoshi, M1
Ravandi, F2
Rytting, ME1
Osmon, C1
Braud, EL1
Roach, RW1
Edwards, K1
Jolain, B1
Damjanov, N1
Takasaki, M1
Kouno, T1
Kondo, S1
Kawasaki, H1
Matsunaga, T1
Nakagawa, N1
Yabana, T1
Yasojima, T1
Pelosi, E1
Masaneo, I1
Clara, R1
Valetto, MR1
Bellò, M1
Zanon, C1
Chiappino, I1
Grosso, M1
Mussa, A1
Bisi, G1
Csonka, C1
Gergely, M1
Lynch, FJ1
Xiong, YP2
Caradonna, SJ1
Beck, T1
Chevlen, EM1
Weaver, CH1
Bell, WN2
White, R1
McGuirt, C1
Canaparo, R1
Casale, F1
Muntoni, E1
Zara, GP1
Della Pepa, C1
Berno, E1
Pons, N1
Fornari, G1
Eandi, M1
Cwikiel, M1
Kinhult, S1
Eskilsson, J1
Vanhöfer, U1
Homerin, M1
Hmissi, A1
Hendler, D1
Toh, Y2
Nakashima, H1
Droz, JP3
Sculpher, M1
Heyes, A1
Di Paolo, AD1
Melosi, A1
Battistoni, M1
Barsanti, G1
Bleuzen, P2
Bogdan, A1
Lellouch, J1
Lim, GC1
Rampal, KG1
Fuad, I1
Lim, AK1
Simmonds, PC1
van Riel, JM4
Molenberghs, G1
Shahinian, AH2
Paff, MT1
Hsia, DW1
Fridman, MKh1
Kondrat'ev, VB1
Manikhas, GM1
Kozlov, AV1
Nicum, S2
Kennedy, AS1
Harrison, GH1
Mansfield, CM1
Zhou, XJ1
Balcer-Kubiczek, EK1
Caterino, M1
Bissett, D1
Locker, PK2
Pirotta, N2
Tsujii, T1
Terret, C1
Erdociain, E1
Féty-Deporte, R1
Scott, RJ1
Spigelman, AD1
Janjan, NA1
Breslin, T1
Lenzi, R1
Rich, TA1
Csiki, Z1
Gál, I1
Takács, I1
Antal, L1
Szegedi, G1
Bury, J1
Beauduin, M1
Herman, ML1
Vindevoghel, A1
Brohée, D2
Lecomte, M1
Joung, J1
Cigolari, S1
Pedicini, T1
Arcangeli, V1
Panzini, I2
Sartori, S1
Stabuc, B1
Markovic, A1
Plesnicar, A1
Cizej, TE1
Fizazi, K1
Köstler, WJ1
Tomek, S1
Wiltschke, C1
Culy, CR1
Clemett, D1
Wiseman, LR1
Kanoh, Y1
Yasue, A1
Kinuta, M1
Matsuda, I1
Asakura, T1
Shirata, Y1
Kurisu, S1
Taira, Y1
Fujimori, A1
Simon, J1
Croockewit, A1
Schellens, J1
van Bronswijk, H1
Lekkerkerker, JF1
Koopmans, PP2
Leo, SS1
Todnem, K1
Harboe, K1
Zotova, L1
Lind, A1
McCann, J1
Lo Bello, L1
Pistone, G1
Restuccia, S1
Vinci, E1
Mazzoleni, G1
Waters, J1
Shatari, T1
Giuliani, R1
Lanfranco, C1
Gilles, V2
Ratanatharathorn, V1
Jirajarus, M1
Sirilerttrakul, S1
Konovalova, NP1
Volkova, LM1
Codacci-Pisanelli, D1
Dusseau, C1
Keenan, RA1
Krokan, HE1
Benoit, R1
Chalmet, P1
Pelley, RJ1
Hauns, B1
Häring, B2
Köhler, S1
Trippoli, S1
Brabender, J2
Dwivedy, S1
Kłek, S1
Wachol, D1
Bock, PR1
Hanisch, J1
Goldberg, R2
Manalo, J1
Bregman, D1
Albers, SH1
Cazemier, M1
Bleichrodt, R1
van den Berg, FG1
Watine, J1
Soulage, C1
Furuyama, JI1
Bras-Gonçalves, RA1
Poirson-Bichat, F1
De Pinieux, G1
Pandrea, I1
Arvelo, F1
Ronco, G1
Villa, P1
Dutrillaux, B1
Poupon, MF1
Coeffic, D1
Durrani, AK1
Lange, LM1
Stewart, M2
Aird, R1
Knowles, G1
Bowman, A1
Wall, L1
McLean, C1
Di Constanzo, F1
Pensel, RA1
Marsh, J1
Lena, MD1
Dellapasqua, S1
Daidone, MG1
Costa, A2
D'Attino, RM1
Rivellini, F2
Secondulfo, M1
De Vivo, R1
De Magistris, L1
Barletta, E1
Carratù, R1
Witte, RS1
Cnaan, A1
Mansour, EG1
Barylak, E1
Harris, JE1
Schutt, AJ1
Scieszka, M1
Zielinski, M1
Machalski, M1
Herman, ZS1
Ionna, F1
Hollis, D1
Blesch, K1
Boyer, M3
Barker, C1
Jamieson, C1
Borras, JM1
Sanchez-Hernandez, A1
Martinez, M1
Mendez, E1
Ponton, JL1
Espinas, JA1
Damle, B1
Kaul, S1
Sonnichsen, D1
Ferreira, I1
Brooks, D1
Alberts, D1
Zaninelli, M1
Leone, R1
Franceschi, T1
Fraccon, AP1
Sabbioni, R1
Cetto, GL1
Sich, D1
Dukers, DF2
Vos, W2
Bloemena, E2
Happich, K1
Martus, P2
Parsch, H1
Himmler, B1
Cox, J2
Kuperminc, M1
Walde, D1
Weaver, C1
Harrison, E1
Rosty, C2
Recaldin, E1
Testore, P1
Moiseenko, VM1
Semenova, AI1
Orlova, RV1
Capadano, M1
Lynch, J1
Goertzen, T1
McCowan, T1
Brand, R1
Manola, J1
Valone, FH2
Ryan, LM1
Hines, JD3
Mueller, HH1
Mattes, E1
de Bree, E1
Kaag, MM1
van Slooten, GW1
Romanos, J1
Antoine, EC1
Nizri, D1
Kruse, A1
Thumann, A1
Schneider, B1
Clemm, C1
Clevert, HD1
Hockertz, S1
Kalousek, MB1
Sengoku, H1
Kihara, A1
Okano, M1
Porta, C1
Accurso, S1
Girino, M1
Bontke, N1
Dentico, P1
Angelelli, B1
Scicolone, S1
Grumett, SA1
Archer, VR1
Mulholland, P1
Blewitt, L1
Beckert, B1
Lang, N1
Stemmler, J1
Beykirch, M1
Stein, J1
Goecke, E1
Waggershauser, T1
Schuell, B1
Ulrich-Pur, H2
Penz, M1
Wedding, U1
Kolb, G1
Valls, C1
Rafecas, A1
Fabregat, J1
Ramos, E1
Jaurrieta, E1
Blot, F1
El Otmany, A1
Tabuchi, Y1
Krieger, G1
Traynor, K1
Höpfner, M1
Maaser, K1
Barthel, B1
von Lampe, B1
Hanski, C1
Riecken, EO1
Zeitz, M2
Scherübl, H1
Malamos, N1
Agelaki, A1
Araki, Y1
Isomoto, H1
Cyjon, A1
Neuman-Levin, M1
Rakowsky, E1
Belinky, A1
Atar, E1
Hardoff, R1
Grivicich, I1
Mans, DR1
Schwartsmann, G1
De Giorgi, U1
Giovanis, P2
Guadagni, S1
Fujioka, A1
Virkkunen, P1
Hishikawa, Y1
Kohno, H1
Kimoto, T1
Dhar, DK1
Tachibana, M1
Koji, T1
Nagasue, N1
D'Agnano, I1
Vasselli, S1
Perrone Donnorso, R1
D'Angelo, C1
Benevolo, M1
Zupi, G2
Tanaka-Nozaki, M1
Onda, M1
Grieu, F1
Gramont, AD1
Sarela, AI1
Guthrie, JA1
O'Riordain, DS1
El-Malt, M1
van den Broecke, C1
Cuvelier, C1
De Neve, W1
de Hemptinne, B1
Hwang, PM1
Rago, C1
Chan, TA1
Murphy, MP1
Kelso, GF1
Smith, RA1
Kaye, S1
McSheehy, PM1
Rodrigues, LM1
Wadsworth, P1
Price, NM1
Müller, H1
Nakchbandi, W1
Chatzissavvidis, I1
Valek, V2
Hidemura, K1
Kasai, Y1
Burke, D1
Carnochan, P1
Jahn, M1
Schmiegel, WH2
Labianca, RF1
Drees, M1
Kühnel, J1
Gedlicka, C1
Watatani, M1
Takamatsu, S1
Toukairin, H1
Kure, N1
Ishizuka, N1
Amaya, K1
Terada, I1
Nishijima, K1
Gnanasampanthan, G1
Wong, NA2
Brett, L1
Leitch, A1
Dunlop, MG1
Lessells, AM1
Gansauge, F1
McGavin, JK1
Goa, KL1
Sasson, AR1
Bertucci, D1
Vogelzang, NJ1
Gargano, L1
Caporale, A1
Konstantatoy, E1
Masciangelo, R1
Adler, G1
Eckel, F1
Schmelz, R1
Adelsberger, H1
Erdmann, J1
Quasthoff, S1
Lersch, C1
Mitchell, F1
Calvert, AH1
Judson, IR1
de Wit, R1
Greim, G1
van der Born, K1
Wanders, J1
de Boer, RF1
Fumoleau, P1
Deng, YC1
Zhen, YS1
Xue, YC1
Nicolaides, C1
Dimopoulos, MA1
Giannoulis, E1
Dervenis, C1
Androulakis, I1
Kandilis, K1
Manziuk, LV1
Artamonova, EV1
Sholokhov, VN1
Strygina, EA1
Marková, J1
Boudný, J1
Kala, Z1
Hanke, I1
Ostrízek, T1
Leypold, J1
Venturini, M2
Köckerling, F1
Hänsler, J1
Bernatik, T1
Becker, D1
Schneider, T1
Di Costanzo, E1
Paoloni, FP1
Moscetti, L1
Cherubini, R1
Abushullaih, S1
Saad, ED1
Munsell, M1
Madisch, A1
Wiedbrauck, F1
Marquard, F1
Stolte, M1
Hotz, J1
Shultz, J1
Kasimis, B1
Fleagle, J1
Carlin, D1
Hammershaimb, L3
Keizer, HJ1
Ten Napel, CH1
Niezgodzki, G1
Chipponi, J1
Eaton, D1
Imaeda, Y1
Umemoto, S1
Specchia, M1
Martini, M1
Pignatti, F1
Micheel, S1
Romel, L1
Vargas-Chanes, D1
Kemeny, MM2
Adak, S1
Smith, T1
Lipsitz, S1
West, WH1
Wong, A2
Colwell, B1
White, RL1
Yates, BB1
McGuirt, PV1
Hargreaves, D1
Nguyen-Van-Tam, J1
Ng, T1
Rahóty, P1
Hullán, L1
Magnusson, I1
Castiglione-Gertsch, M1
Chung, T1
Dangelica, MI1
Shoup, MC1
Nissan, A1
Haruyama, K2
Broisin, L1
Guardiola, E1
Ramaïoli, A1
Ferrero, JM1
Namer, M1
Pistilli, B1
Valeri, M1
Namiki, Y1
Ensminger, WD2
Dizon, DS1
Haasjes, J1
Piersma, H1
Groen, HJ1
Potter, JD1
Demedts, I1
Tomlinson, SK1
Melin, SA1
Higgs, V1
White, DR1
Savage, P1
Case, D1
Blackstock, AW1
Lin, FH1
Lee, YH1
Jian, CH1
Wong, JM1
Shieh, MJ1
Pasquini, E1
Cruciani, G1
Oliverio, G1
Zumaglini, F1
Nicolini, M1
Kourousis, Ch1
Athanasiadis, N1
Burger, U1
Garin, A1
McKendric, J1
Ranieri, G1
Kellermann, L1
Morris, RG1
McCondochie, A1
Bader, S1
Del Prete, S1
Benjamin, I1
Maisey, NR1
Croockewit, AJ1
de Boer, JE1
van Loenhout, JW1
Adimi, P1
Wennberg, A2
Schilling, A1
Gewiese, B1
Fobbe, F1
Stiller, D1
Gallkowski, U1
Wolf, KJ1
Wu, GR1
Kuramoto, S1
Hanawa, S1
Yanagita, K1
Yoshio, T1
Ohe, Y1
Ohmori, T1
Fielding, LP1
Hittinger, R1
Fry, JS1
Garten, L1
Stenning, S1
Hill, GJ1
Holmberg, A1
Steinberg, J1
Gadalla, T1
Platz, D1
Buggisch, P1
Eckardt, N1
Drescher, S1
Müllerleile, U1
Sertoli, MR2
Rubagotti, A2
Vidili, MG2
Canobbio, L2
Fassio, T2
Luzi Fedeli, S2
Fowler, WC1
Eisenberg, BL1
Hoffman, JP1
Rausa, L4
Inaba, S1
Ogino, A1
Umeda, T1
Moore, DF3
Cripps, IC1
McCormick, R1
Temple, W1
Bogues, W1
Zilembo, N1
Nelli, P1
Reid, I1
Sharpe, I1
Maxwell, W1
McDevitt, J1
Tanner, WA1
Fedeli, SL1
Kleeberg, U1
Middeke, H1
Korsten, FW2
Trux, FA1
Schmieder, A1
Evers, C1
Ismail Ali, A1
Simadibrata, R1
Aziz Rani, A1
Chudahman, M1
Dharmika, D1
Berlion, M1
Berille, J1
Gioanni, J1
Bizzari, JP1
Parodi, GC1
Nanninga, AG1
de Vries, GE1
Okuyama, K1
Awano, T1
Tohnosu, N1
Nakaichi, H1
Funami, Y1
Amano, H1
Hottenrott, C4
Maier, P1
Reimann, M1
Inglis, R2
Eschwege, F1
Ammarguellat, H1
Ghosn, M2
Benhamed, M1
Theodore, C2
Kac, J1
Goldberg, J1
Jimeno, J2
Sánchez, J1
Cruz-Hernández, J1
Matthias, M3
Hoksch, B2
Boewer, C2
Oldenkott, B2
Lenk, H1
Wiener, N1
Dixon, DO1
Freedman, LS1
Spiegelhalter, DJ1
Greenhouse, JB1
Günther, E1
Hirschmann, WD1
Sondern, W1
Koniczek, KH1
Wander, HE1
Natt, F1
Hinrichs, HF1
Werdier, D1
Younes, A2
Taylor, CW1
Modiano, MR1
Woodson, ME1
Marcus, SG1
Alberts, DS1
Hersh, EM1
Knauf, WU1
Ruelfs, C1
Ottensmeier, C1
Musch, E1
Koch, O1
van de Loo, J1
Laurensse, E1
Boarman, D1
Balis, FM1
Murphy, RF1
McAtee, N1
Bussières, E1
Lagarde, P1
Martin, D2
Wiseberg, J1
McCulloch, W1
Tzannou, I1
Posner, M2
Martin, A1
Slapak, CA2
Cummings, FJ2
Robert, NJ1
Arigoni, M1
Barras, J2
Schweizer, W2
Gazit, Z1
Weiss, DW1
Shouval, D1
Yechezkeli, M1
Schirrmacher, V1
Notter, M1
Walter, J1
Kedar, E1
Guaraldi, M1
Covizzi, M1
Tedeschi, L1
Luporini, A1
Park, KG1
Murray, JB1
Hayes, PD1
Ashby, JA1
Bartolucci, R2
Sofra, M1
Löffler, TM1
Planker, M1
Burghardt, F1
Aulbert, E1
Lindemann, W1
Schröder, M1
Strohmeyer, G1
Díaz Rubio, E1
Camps, C1
González Larriba, JL1
Tohma, H1
Shikama, T1
Steger, G1
Bellmunt, J1
Albanell, J1
Gallego, OS1
Inoshita, G1
Yalavarthi, P1
Murthy, S1
Gibson, V1
Sergi, JS1
Bauer, L1
Prestifilippo, J1
Itzakhi, M1
Lecouturier, S1
Descorps-Declère, A1
Tsuchiya, S3
Iijima, N2
Aso, K2
Nishiyama, K2
Amano, T2
Murayama, N2
Kuusela, P1
Beretta, A1
Cesana, B2
Cozzaglio, L2
Cristoni, M1
Sofo, L1
Netri, G1
Ratto, C1
Coco, C1
Codacci-Pisanelli, M1
Ferri, GM1
Grieco, A1
Pagani, V1
Daponte, A1
Parziale, A1
Iervolino, V1
Santillo, G1
Zarrilli, D1
Inbar, M1
Ahmann, FR1
Garewal, HS1
Urmacher, C1
Kurtz, RC1
Murray, M1
Stagg, RJ1
Lewis, BJ1
Mulvihill, SJ1
Grobman, BJ1
Rayner, AA1
Maybaum, J1
Burton, EC1
Shelton, DA1
Jing, HW1
Dusenbury, CE1
Stetson, PL1
Cheson, BD1
Durante, F1
Porcellana, M1
Cavaliere, P1
Anfossi, A1
Pilati, PL1
Altendorf-Hofmann, A1
Gall, FP1
Tsekova, V1
Koĭnov, K1
Velikova, M1
Dudunkov, Z1
Dimitrov, V1
Kurtev, P1
Ralchev, K1
Tsai, CM1
Gazdar, AF2
Perng, RP1
Kramer, BS2
Baur, M1
Schlappack, O1
Havelec, L1
Mader, R1
Tohyama, N2
Gandolfo, G1
Naglieri, E1
Cornia, E1
Del Bufalo, D1
Röthlin, M1
Kusumoto, S1
Nakayoshi, A1
Takegawa, S1
Kumaki, T1
Katoh, M1
Gotohda, H1
Saitoh, H1
Kinami, Y1
Kurosawa, H1
Fukano, M2
Tokitoh, T1
Lembersky, B1
Atkins, M1
Kirkwood, J1
Creaven, P1
Montini, E1
Bonera, F1
Braga, M1
Ragni, F1
Hamazoe, R2
Murakami, A1
Hirooka, Y1
Maeta, M2
Brunner, K2
Hojo, K3
Furusawa, M1
Tschetter, LK3
Delgado, F1
García-Reinoso, J1
Sanchis, C1
Viciano, V1
Asencio, F1
Martínez-Abad, M1
Aguilo, J1
Sánchez, JJ1
Pastor, MC1
Carles, J1
Oller, B1
Armengol, M1
Salva, A1
Ribas, M1
Cantrell, J1
Wampler, GL1
Gullo, JJ2
Fryer, JG1
Alt, DE1
Poplin, EA1
Kraut, M1
Baker, L1
Brodfuehrer, J1
Vaitkevicius, V2
Schiessel, R2
Karall, M1
Ernst, F1
Sebesta, C1
Hentschel, E1
Wirth, A1
Green, M1
Nott, D1
Jenkins, S1
Katz, KH1
Davis, CA1
Durivage, HJ1
Rome, LS1
Capizzi, RL1
Farber, LR1
Pasquale, DN1
Furue, H1
Trocki, O1
Muir, WA1
Sisk, R1
Schacter, L1
Palmieri, G2
Gridelli, C2
Airoma, G2
Pepe, R1
Incoronato, P2
Kozatsani-Halvidi, D1
Tsaroucha, E1
Bulger, KN1
Slavik, M1
Rabinovich, MG1
Bianco, A1
Alvarez, LA1
Faradji, A2
Bohbot, A2
Damonte, J2
Eber, M1
Laustriat, D1
Goetz, J2
Wiesel, ML2
Follea, G2
Piemont, Y1
Schimpfle, B1
Wolff, H1
Mai, C1
Lüning, M1
Gerard, A1
Willems, G1
Delvaux, G1
Depadt, G1
Chua, L1
Tian, EM1
Sridhar, K1
Benedetto, P1
Legaspi, A1
Waldman, S1
Morrell, L1
Danhauser-Riedl, S1
Steinhauser, G1
Rastetter, J1
Heim, ME3
Klee, M1
Rieche, K1
Edler, L1
Tsubono, M1
Morimoto, H1
Tseng, CC1
Tobe, T1
Yasui, K1
Berres, M1
Jäggi, P1
Schiller, JH1
Bittner, G1
Kakuta, T2
Sakurai, H1
Yoshimatsu, A1
Fukunaga, J1
Kitahama, H1
Okuyama, A1
Seki, T1
Tsurui, K1
Saka, M1
Sasagawa, M1
Hishinuma, S1
Noto, T1
Mizutani, K1
Gotoh, K1
Tsukui, M1
Ohtani, Y1
Kawano, N1
Houjo, K1
Iijima, K1
Hamahata, Y1
McBee, P1
Petraiuolo, W1
Katoh, A2
Mazy, V1
Jacquet, N1
Demoulin, JC1
Sakatoku, M1
Kikkawa, H1
Matsu, T1
Tatsuzawa, T1
Masuda, S1
Balestrino, M1
Bisogno, A1
Martin, JK1
Gonzalez-Larriba, J1
Schumacher, K1
Roscher, R2
Bittner, R1
Franklin, HR1
McVie, JG1
Spears, PC1
Wagman, LD1
Leong, L1
Terz, JJ1
Hill, LR1
Beatty, JD1
Kokal, WA1
Riihimaki, DU1
Natali, M1
D'Aprile, M1
Leggio, M1
Vici, P1
Carpano, S1
Angelini, F1
Carassai, A1
Milonakis, N1
Sarafidou, M1
Zamanis, N2
Magoulas, D1
Knöpfle, G1
Leidig, P1
Cianflone, SG1
Dose, AM2
Etzell, PS1
Burnham, NL1
Therneau, TM1
Hagen, L1
Gainey, DK1
Cross, M1
Athmann, LM1
Sznol, M1
Friedman, MA2
Zinelis, A1
Beldecos, D1
Mylonacis, N1
Valilis, P1
Antonopoulos, A1
Hunt, TM1
Flowerdew, AD1
Birch, SJ1
Williams, JD1
Mullee, MA1
Pfeifle, DM1
Laurie, JA3
Daniele, O1
Ghiotto, C1
Aversa, SM1
Morandi, P1
Fiorentino, MV1
North, ML1
Johnston, J1
Theve, T1
Browne, MJ1
Curt, G1
Calabresi, P1
Wiemann, M1
Urba, S1
Mortimer, JE1
Anderson, I1
Shepard, B1
DuBrow, R1
Campos, L1
Quaraishi, M1
Faintuch, J1
Sammarco, P1
Adams, L1
Derby, S2
Murray, P1
Houston, C1
Peter, R1
Comis, RL2
Goldberg, JA2
Wilmott, N1
McKillop, JH2
Onodera, H1
Somers, SS1
Hase, S1
Yoshimura, A1
Sameshima, T1
Ishizawa, T1
Shimazu, H1
Matsuoka, T1
Wakui, A1
Mukaiyama, T1
Obrist, R1
Obrecht, JP1
Haegele, P1
Tagnon, A1
Duez, N1
Domellöf, L1
Rudenstam, CM1
Norryd, C1
Bergman, L1
Nilsson, T1
Hansson, K1
Asklöf, G1
Kugelberg, C1
Colella, G1
Casciarri, G1
Gennari, L1
Colla, G1
Goldman, M2
Lyver, A2
Lissoni, P1
Paolorossi, F1
Crispino, S1
Archili, C1
Tancini, G1
Hölting, T1
Schwarz, V2
May, D1
Wandl, U2
Becher, R2
Schmidt, CG1
McMaster, ML1
Johnson, DH1
Beart, RW1
Leigh, JE2
van Heerden, JA1
Willmott, N1
Bates, CD1
Amino, K1
Mieno, K1
Miura, S1
Satoi, Y1
Ohtaki, K1
Aoki, H1
Shikata, J1
Paul, AR1
Wereldsma, JC1
Bruggink, ED1
Meijer, WS1
Roukema, JA1
van Putten, WL1
Birsic, W1
D'Oro, L1
Charoensiri, S1
Olafsdottir, M1
Schneider, A1
Martin, DS1
Colofiore, J1
Sawyer, RC1
Salvia, B1
Cullinan, SA1
Everson, LK2
Namba, M1
Muto, K1
Ikeguchi, S1
Kac, JL1
Marks, HG1
Marks, V1
Kremer, B1
Teshima, Y1
Yamagata, M1
Sakabe, T1
Maruyama, J1
Morikawa, E1
Hida, J1
Ko, K1
Bär, HU1
Mennigen, R2
Barkun, J1
Klauke, H1
Lumbroso, J1
Sidibe, S1
Bitter, R1
Schumacher, KA1
Gaus, W1
Didolkar, MS1
Kirkowa-Reimann, M1
Runhaar, EA1
Verwey, J1
Neyt, JP1
Horigome, N1
Hanasaki, K1
Kinosita, T1
Sodeyama, H1
Iida, F1
Mitsugi, O1
Sugahara, K1
Rader, M1
Zimmerman, M1
Itri, L1
Weinberg, V1
Weeks, A1
Raber, MN1
Gravel, D1
Chun, HG1
Zelkowitz, RS1
Posner, MR1
Weitberg, AB1
de Quay, N1
Cuttat, JF1
Tevaearai, H1
Chapuis, G1
Albe, X1
Vassilakos, P1
Houvenaeghel, G1
Guerinel, G1
Carcassonne, Y1
Ausman, R1
Frick, J1
Ritch, P1
Schulte, W1
Haas, C1
Beatty, P1
Abdi, EA1
Hanson, J1
Harbora, DE1
Young, DG1
McPherson, TA1
Miser, AW1
Ahlquist, DA1
Kanojia, MD1
Bedikian, AY1
Inzani, V1
Stevenson, FK1
van der Plas, J1
Herrera, L3
Russell, D1
Stablein, DM1
Schinella, R1
Green, MD1
Schuster, D1
Flechtner, H1
Worst, P1
LoRusso, P1
Redman, BG1
Kinzie, J1
Hryniuk, WM1
Pratesi, G1
Manzotti, C1
Tortoreto, M1
Prosperi, E1
Köhler, L1
Fuchshuber, P1
Eypasch, E1
McCormack, GW1
Malliard, J1
Arisawa, Y1
Takabayashi, T1
Abe, O1
Okubo, Y1
Maruyama, H1
Imajo, M1
Yaegashi, K1
Adelstein, DJ2
Spiess, JL2
Giroski, P1
Carter, SG2
Stydnicki, KA2
Morgan, ED2
Collier, M2
Knick, VB2
Duch, DS2
Mullin, R2
Ferone, R2
Wittlinger, PS1
Drakes, T1
Eisenberg, PD1
Malec, M1
Hannigan, JF1
Fan, S1
Liang, CL1
Wiley, AL1
Wirtanen, GW1
Stephenson, JA1
Ramirez, G1
Demets, D1
Joseph, RR1
Madejewicz, S1
Plager, J1
Soloman, J1
Mittelman, A2
Quentmeier, A1
Reichman, B1
Vinciguerra, V1
Michaelson, R1
Rosenbluth, R1
Deonarine, S1
Greene, RF1
Cagnazzo, P1
Cardi, G1
Ricciuti, FP1
Frati, L1
Marchei, P1
Dobbs, BR1
Edwards, IR1
Perrier, DG1
Muhrer, KH1
Schwemmle, K1
Nishiyama, M1
Takagami, S1
Kirihara, Y1
Hirabayashi, N1
Nosoh, Y1
Niimoto, M1
Farley, PC1
McFaden, KH1
Clerici, M1
Montinari, F1
Freund, M1
Bruckner, H1
Stablein, D1
Kurschel, E1
Kloke, O1
Weinhardt, O1
Khan, H1
Bergner, S1
Fiore, JJ1
Zarrabi, MH1
Hirano, T1
Fukuda, Y1
Kotake, Y1
Migeod, F1
Gerlach, D1
Kress, M1
Farroukh, R1
Harding, MJ1
Ferguson, JC1
Ball, AS1
Mann, CV1
Clifton, MA1
Baker, WN1
Goode, AW1
Scholnik, AP1
Arnold, DJ1
Walker, WS1
Schwenke, P1
Suhrland, LG1
Balcueva, EP1
Dimitrov, NV1
Lagadec, B1
Maisani, JE1
Loiseau, JP1
Gonzalez-Canali, G1
Trey, JE1

Clinical Trials (429)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized, Open, Multicenter Phase III Study With Capecitabine Plus Bevacizumab Versus Capecitabine Plus Irinotecan Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer[NCT01249638]Phase 3516 participants (Anticipated)Interventional2010-12-31Recruiting
A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer Who Have Not [NCT04456699]Phase 3335 participants (Actual)Interventional2020-08-19Completed
Targeted Therapy With or Without Dose Intensified Radiotherapy for Oligo-progressive Disease in Oncogene-addicted Lung Tumours[NCT03256981]Phase 2/Phase 3113 participants (Actual)Interventional2017-11-27Active, not recruiting
Precision Radiation for OligoMetastatIc and MetaStatic DiseasE (PROMISE)-004: Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression[NCT03808662]Phase 2107 participants (Actual)Interventional2019-01-16Active, not recruiting
Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial): A Randomized Phase II Trial[NCT02756793]90 participants (Actual)Interventional2016-10-31Active, not recruiting
TRAP - Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.[NCT03644303]84 participants (Anticipated)Interventional2018-08-13Recruiting
Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver[NCT02885753]Phase 3348 participants (Anticipated)Interventional2016-12-31Recruiting
Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT): A Single-arm Study[NCT03727763]Phase 230 participants (Anticipated)Interventional2018-10-08Recruiting
BOND-3: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer[NCT02292758]Phase 236 participants (Actual)Interventional2014-12-12Completed
Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer[NCT03925662]Phase 340 participants (Anticipated)Interventional2019-04-01Recruiting
A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST- LINE TREATMENT FOR METASTATIC COLORECTAL CANCER[NCT00719797]Phase 3509 participants (Actual)Interventional2008-07-31Completed
FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB FOLLOWED BY REINTRODUCTION OF FOLFOXIRI PLUS BEVACIZUMAB AT PROGRESSION Versus FOLFOX PLUS BEVACIZUMAB FOLLOWED BY FOLFIRI PLUS BEVACIZUMAB AT PROGRESSION IN FIRST- AND SECOND-LINE TREATMENT OF UNRESECTABLE METASTATIC[NCT02339116]Phase 3654 participants (Anticipated)Interventional2015-02-26Active, not recruiting
Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer.[NCT00433927]Phase 3568 participants (Anticipated)Interventional2007-01-31Active, not recruiting
Prospective, Randomized, Open, Multicenter Phase II Trial to Investigate the Efficacy of Trifluridine/Tipiracil Plus Panitumumab Versus Trifluridine/Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer: FIRE-8; AIO-KRK/YMO-05[NCT05007132]Phase 2153 participants (Anticipated)Interventional2021-12-17Recruiting
Phase 2 Study Comparing Efficacy and Safety of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab[NCT03368859]Phase 270 participants (Actual)Interventional2018-03-20Terminated (stopped due to Study may continue)
[NCT01384994]Phase 2111 participants (Anticipated)Interventional2011-08-31Recruiting
AZD8931, an Inhibitor of EGFR, ERBB2 and ERBB3 Signalling, in Combination With FOLFIRI: a Phase I/II Study to Determine the Importance of Schedule and Activity in Colorectal Cancer[NCT01862003]Phase 224 participants (Actual)Interventional2014-05-31Completed
Randomized Phase II Study for Evaluation of Efficacy and Safety of Maintenance Treatment With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction Treatment With mFOLFOX6 Plus Panitumumab and Re-induction With mFOLFOX6 Plus Panitumumab in Case[NCT01991873]Phase 2387 participants (Actual)Interventional2014-04-30Completed
Acute Kidney Injury in Cancer Patients Receiving Anti-Vascular Endothelial Growth Factor Monoclonal Antibody vs Immune Checkpoint Inhibitors: a Retrospective Real-world Study[NCT06119347]1,581 participants (Actual)Observational2020-01-01Completed
Molecular Profiling of Colorectal Cancer: A Translational Research Study With a Next Generation Sequencing Panel.[NCT04863768]300 participants (Anticipated)Observational2006-01-01Recruiting
A Phase 2 Randomized Study Comparing the Efficacy and Safety of mFOLFOX6+Panitumumab Combination Therapy and 5-FU/LV+Panitumumab Combination Therapy in the Patients With Chemotherapy-Naive Unresectable Advanced Recurrent Colorectal Carcinoma of KRAS Wild-[NCT02337946]Phase 2164 participants (Actual)Interventional2014-10-16Completed
An Observational Study of Avastin® (Bevacizumab) in Combination With Chemotherapy for Treatment of First-line Metastatic Colorectal Adenocarcinoma[NCT01506167]719 participants (Actual)Observational2012-07-06Completed
A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colore[NCT00819780]Phase 2285 participants (Actual)Interventional2009-04-24Completed
A Single Arm Multicentre Phase II Study of Panitumumab in Combination With Irinotecan/5-fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer[NCT00508404]Phase 2154 participants (Actual)Interventional2007-05-09Completed
A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic C[NCT00364013]Phase 31,183 participants (Actual)Interventional2006-08-01Completed
Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors[NCT06077591]40 participants (Anticipated)Interventional2024-02-01Not yet recruiting
MicroOrganoSphere Drug Screen to Lead Care (MODEL) Precision Oncology Pilot Trial in Colorectal Cancer (CRC)[NCT05189171]180 participants (Anticipated)Observational2022-10-25Recruiting
Randomized Controlled Trial Comparing Conventional and Fast Track Multi-Discipline Treatment Interventions for Colorectal Cancer[NCT01080547]Phase 3374 participants (Actual)Interventional2010-03-31Completed
A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy Wit[NCT01183780]Phase 31,072 participants (Actual)Interventional2010-12-02Completed
The Effect of Monosialotetrahexosylganglioside (GM1) in Prevention of Oxaliplatin Induced Neurotoxicity in Colorectal Cancer Patients Who Received Oxaliplatin-based Adjuvant Chemotherapy: A Multi-center, Randomized, Placebo-controlled Trial[NCT02251977]Phase 3196 participants (Actual)Interventional2014-09-30Completed
Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326]Phase 221 participants (Anticipated)Interventional2021-12-01Recruiting
Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347]Phase 118 participants (Anticipated)Interventional2021-01-01Recruiting
Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975]Phase 235 participants (Anticipated)Interventional2022-05-02Recruiting
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to UGT1A1 Genotyping Versus Regorafenib Monotherapy in Patients With Previously Treated Metastatic Colorectal Cancer: A Prospective, Randomized, Controlled Study[NCT03880877]Phase 2153 participants (Anticipated)Interventional2019-02-26Recruiting
A Randomized, Multicenter Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Chemotherapy to the Efficacy of Chemotherapy Alone in Patients With Previously Treated Metastatic Colorectal Cancer[NCT00339183]Phase 31,186 participants (Actual)Interventional2006-06-30Completed
An Open-label, Randomized, Controlled, Multicenter Phase III Trial to Compare Cetuximab in Combination With FOLFOX-4 Versus FOLFOX-4 Alone in the First Line Treatment of Metastatic Colorectal Cancer in Chinese Subjects With RAS Wild-type Status[NCT01228734]Phase 3553 participants (Actual)Interventional2010-09-09Completed
Follow-up and Registration Study of Anlotinib Combined With Adjuvant Chemotherapy in the Treatment of Locally Advanced Gastrointestinal Tumors[NCT05742620]100 participants (Anticipated)Interventional2023-06-20Not yet recruiting
An Australian Translational Study to Evaluate the Prognostic Role of Inflammatory Markers in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab (Avastin™)[NCT01588990]Phase 4128 participants (Actual)Interventional2012-06-26Completed
TACE Associated With Systemic Chemotherapy Versus Systemic Chemotherapy in Patients Who Failed With First Line Chemotherapy[NCT03783559]Phase 3168 participants (Actual)Interventional2016-01-31Active, not recruiting
Phase III, Randomized Clinical Trial to Evaluate FOLFOX + Bevacizumab Versus FOLFOXIRI + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells.[NCT01640405]Phase 3350 participants (Actual)Interventional2012-07-31Completed
Randomized Phase II Study to Explore the Influence of BRAF and PIK3K Status on the Efficacy of FOLFIRI Plus Bevacizumab or Cetuximab, as First Line Therapy of Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells[NCT01640444]Phase 2240 participants (Actual)Interventional2012-07-31Completed
A Phase III, Randomized, Two-armed, Triple Blinded, Parallel, Active Controlled Non-Inferiority Clinical Trial of Stivant (AryoGen Trastuzumab) Efficacy and Safety in Comparison to Avastin in Metastatic Colorectal Cancer[NCT03288987]Phase 3126 participants (Actual)Interventional2016-10-04Completed
Safety and Efficacy of mFOLFOX6+ Bevacizumab+PD-1 Monoclonal Antibody Treatment Combinations in Patients With Local Advanced Microsatellite Stability Colorectal Cancer --an Open Label, Multicenter, Prospective Phase Ⅱ Study (BASKETII)[NCT04895137]Phase 242 participants (Anticipated)Interventional2021-05-01Recruiting
An Open-label, Randomised, Non-comparative Phase 2 Study Evaluating S 95005 (TAS-102) Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Metastatic COlorectal Cancer Who Are Non-eligible for Intensive Therapy (TASCO1 [NCT02743221]Phase 2154 participants (Actual)Interventional2016-04-29Completed
Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study[NCT01839877]Phase 258 participants (Actual)Interventional2013-05-31Completed
An Investigator Initiated Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor (KPT-330), An Oral Selective Inhibitor Of Nuclear Export (SINE), In Patients With Metastatic Colorectal Cancer[NCT02384850]Phase 110 participants (Actual)Interventional2015-03-31Terminated
A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer[NCT01311050]46 participants (Anticipated)Observational2009-01-31Recruiting
Randomized Phase II Study of FOLFOXIRI Plus Bevacizumab Plus Atezolizumab Versus FOLFOXIRI Plus Bevacizumab as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients.[NCT03721653]Phase 2218 participants (Actual)Interventional2018-11-30Completed
Bi-weekly Cetuximab Combined With FOLFOX-6 as First-line Treatment in Metastatic Colorectal Cancer Patients With Wild-type K-ras Status[NCT01051167]Phase 259 participants (Actual)Interventional2009-02-28Completed
Study of Avastin in Combination With Chemotherapy for the First Line Treatment of RAS Mutant Unresectable Colorectal Liver-limited Metastases[NCT01972490]Phase 4241 participants (Actual)Interventional2013-10-31Completed
Determination of the UGT1A1 Polymorphism as Guidance for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Treated With First-Line Bevacizumab and FOLFIRI (PURE FIST)[NCT02256800]213 participants (Actual)Interventional2014-08-13Completed
Phase II Study on NIVolumab in Combination With FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced COloRectal Cancer RASm/BRAFm Patients[NCT04072198]Phase 270 participants (Anticipated)Interventional2019-09-26Recruiting
Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer[NCT02181556]Phase 241 participants (Actual)Interventional2014-10-31Completed
TRICC-C: A Multicenter, Randomized, Phase II Trial: BIBF 1120 vs. Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)[NCT01362361]Phase 254 participants (Actual)Interventional2011-06-30Completed
Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer: a Prospective Phase II Study[NCT06148402]Phase 230 participants (Anticipated)Interventional2024-01-31Recruiting
An Open-label, Multiple-site, Phase I/II Dose Cohort Trial of [6R] 5,10-Methylene Tetrahydrofolate (Modufolin®) in Combination With a Fixed Dose of 5-Fluorouracil (5-FU) Alone or Together With a Fixed Dose of Oxaliplatin or Irinotecan in Patients With Sta[NCT02244632]Phase 1/Phase 2105 participants (Actual)Interventional2014-09-30Completed
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)[NCT06141369]21 participants (Anticipated)Interventional2023-12-01Not yet recruiting
Efficacy and Safety of Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin in pMMR/MSS Locally Advanced Middle and Low Rectal Cancer: An Open, Multi-center, Prospective, Single-arm Phase II Clinical Study[NCT06056804]Phase 220 participants (Anticipated)Interventional2023-12-01Not yet recruiting
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)[NCT02563002]Phase 3307 participants (Actual)Interventional2015-11-30Completed
Combination of Sintilimab,Celecoxib and Regorafenib in Mismatch Repair (MMR) Proficient Refractory Advanced Colorectal Cancer Without Liver Metastasis:a Single Arm Phase II SINCERE Study.[NCT05933980]Phase 233 participants (Anticipated)Interventional2023-08-20Not yet recruiting
Multi-center, Non-interventional, Prospective Registry Study on the Treatment of Solid Tumors With Mismatch Repair Deficiency or Microsatellite Instability[NCT06004713]190 participants (Anticipated)Observational2023-10-07Recruiting
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin[NCT05504252]Phase 280 participants (Anticipated)Interventional2022-10-05Recruiting
A Phase II Clinical Study of Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer Failed of Standard Chemotherapy[NCT02618356]Phase 282 participants (Anticipated)Interventional2015-12-25Recruiting
Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination With 5FU/or in FOLFIRI Regimen[NCT04680104]64 participants (Actual)Observational2015-11-03Completed
Phase 4 Study to Characterize and Evaluate Markers of Chemoresistance in Patients With Metastatic Colorectal Cancer[NCT00559676]Phase 4200 participants (Anticipated)Interventional2005-03-31Completed
A Randomized Phase II Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer[NCT01312857]Phase 275 participants (Actual)Interventional2011-03-31Active, not recruiting
Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superio[NCT02758951]Phase 2/Phase 3358 participants (Anticipated)Interventional2017-06-01Recruiting
Association of the C677T and A1298C MTHFR Polymorphisms With Chemotherapy Effectiveness Among Patients With Metastatic Colorectal Cancer[NCT03852290]65 participants (Anticipated)Observational2019-01-16Active, not recruiting
The Effect and Safety on Unresectable CRLM From RFA in Combination With Second-line Chemotherapy and Bevacizumab Compared With the Combination of Second-line Chemotherapy and Bevacizumab: a Randomized and Controlled Clinical Trial[NCT03686254]Phase 2/Phase 3160 participants (Anticipated)Interventional2018-07-16Recruiting
Phase III Randomized Controlled Trial and Economic Evaluation of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer (SABR-COMET-3)[NCT03862911]330 participants (Anticipated)Interventional2019-11-01Recruiting
A Randomized Phase II Study of the Administration of Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy for Patients With Squamous Cell Carcinoma of the Anal Canal (BISQUIT)[NCT03870607]Phase 275 participants (Anticipated)Interventional2019-03-13Recruiting
A Prospective, Multicenter, Open-label, Phase II Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Canc[NCT04659382]Phase 252 participants (Anticipated)Interventional2020-10-07Recruiting
A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU/ Leucovorin With Bevacizumab, or Cetuximab (C225), or With the Combination of Bevacizumab and Cetuximab for Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum[NCT00265850]Phase 32,334 participants (Actual)Interventional2005-11-30Completed
The Molecular Mechanism of RAS Wild-type Metastatic Colorectal Cancer (mCRC) Resistance to Anti Epidermal Growth Factor Receptor (EGFR) Antibody[NCT04466267]40 participants (Actual)Observational2017-03-01Completed
An Open Label Randomized, Multi-Centre Exploratory Phase II Study to Evaluate the Efficacy and Safety of the Combination of Panitumumab With FOLFOX 4 Chemotherapy or Panitumumab With FOLFIRI Chemotherapy in Subjects With Wild- Type KRAS Colorectal Cancer [NCT00885885]Phase 280 participants (Actual)Interventional2009-05-31Completed
A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxalipla[NCT00561470]Phase 31,226 participants (Actual)Interventional2007-11-30Completed
Protocol for Evaluation of Oncological Treatment in Patients With CRLM Using Zebra Fish Avatars-may This Model Improve Resection Rates and Survival in Patients With Upfront Non-resectable Metastatic Disease?[NCT05289076]Phase 1/Phase 240 participants (Anticipated)Interventional2022-05-17Recruiting
A Prospective,Single-center,Randomized,Controlled Phase III Clinical Study Comparing Efficacy and Safety of Intraoperative Chemotherapy With 5-Fluorouracil Plus Curative Resection Versus Surgery Alone for Patients With Colorectal Cancer[NCT01465451]Phase 3695 participants (Actual)Interventional2011-03-31Active, not recruiting
Construction and Evaluation of the Early Identification and Individualized Treatment for Oxaliplatin-induced Portal Hypertension[NCT04524676]25 participants (Anticipated)Interventional2020-08-31Not yet recruiting
Surgery Outcome Treated by Neo-adjuvant Chemotherapy FOLFOXIRI Regimen in Colorectal Cancer With Liver-limited Synchronous Metastases[NCT05362825]89 participants (Anticipated)Observational2022-02-18Recruiting
Diagnostic Value of Intraoperative Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases During Staging Laparoscopy for Gastric Adenocarcinoma: a Prospective, Multicentric Study.[NCT05687617]Phase 230 participants (Anticipated)Interventional2022-12-15Recruiting
A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer[NCT00079274]Phase 33,397 participants (Actual)Interventional2004-02-29Completed
Multicenter Study Investigating Utilization of Pharmacokinetic-Guided 5-Fluorouracil in Patients Receiving mFOLFOX6 With or Without Bevacizumab[NCT01164215]Phase 176 participants (Actual)Interventional2010-02-28Completed
Phase II Randomized Controlled Trial Of Dendritic Cell + Cytokine-Induced Killer Cell Immunotherapy With S-1 Versus S-1 Alone As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma Patients[NCT05955157]Phase 2/Phase 352 participants (Anticipated)Interventional2023-01-03Recruiting
Efficacy and Safety of Crisaborole Ointment, a Phosphodiesterase 4 (PDE4) Inhibitor, for the Topical Treatment of Cetuximab-Related Skin Toxicity Among Metastatic Colorectal Cancer Patients:A Prospective, Single-arm, Phase II Clinical Trial[NCT06118047]Phase 233 participants (Anticipated)Interventional2023-08-01Recruiting
Randomized Phase II Study of First-Line FOLFOX Plus Panitumumab Versus 5FU Plus Panitumumab in RAS And BRAF Wild-Type Metastatic Colorectal Cancer Elderly Patients[NCT02904031]Phase 2180 participants (Anticipated)Interventional2016-07-31Active, not recruiting
Induction Chemotherapy With Folfoxiri Plus Cetuximab and Maintenance With Cetuximab or Bevacizumab Therapy in Unresectable Kras Wild-type Metastatic Colorectal Cancer Patients[NCT02295930]Phase 2143 participants (Actual)Interventional2011-10-31Completed
A Randomized Phase II Study of Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients With Metastatic Colorectal Cancer.[NCT01622543]Phase 2109 participants (Actual)Interventional2012-10-26Completed
Genetic Variants and the Efficacy or Severe Adverse Reactions of CPT-11 Based Regimens in mCRC[NCT01282658]200 participants (Anticipated)Observational2010-11-30Recruiting
Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients[NCT05298670]Phase 280 participants (Anticipated)Interventional2022-02-01Recruiting
Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients: a Prospective, Randomized, Sham-controlled, Double-blinded and Multicenter Study[NCT05798884]150 participants (Anticipated)Interventional2023-05-31Not yet recruiting
Develop and Evaluate the Effectiveness of a Self-Care Smartphone Application on the Self-Efficacy, and Resilience Among Newly Diagnosed Breast Cancer Patients Undergoing Treatment[NCT05576545]73 participants (Actual)Interventional2020-09-18Completed
Phase-II, Randomized, Multicentre Pilot Study to Evaluate the Safety and Efficacy of the Treatment With mFOLFOX-6 Plus Cetuximab Versus Initial Treatment With mFOLFOX-6 Plus Cetuximab (for 8 Cycles), Followed by Maintenance With Cetuximab Alone as First-l[NCT01161316]Phase 2194 participants (Actual)Interventional2010-08-31Completed
Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases - A Randomized Phase II/III Trial[NCT02494973]Phase 2/Phase 3104 participants (Actual)Interventional2015-05-26Suspended (stopped due to Recruitment too slow)
A Multinational, Randomized, Double-Blind Study of Aflibercept Versus Placebo With Irinotecan/ 5-FU Combination (FOLFIRI) in Patients With Metastatic Colorectal Cancer (MCRC) After Failure of an Oxaliplatin Based Regimen[NCT01661270]Phase 3332 participants (Actual)Interventional2012-07-31Completed
Phase II Study of Regorafenib as Single Agent for the Treatment of Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab[NCT02175654]Phase 215 participants (Actual)Interventional2014-06-30Terminated (stopped due to The trial was prematurely closed due to lack of accrual)
Open Label Randomized Bioequivalence Study to Evaluate the Pharmacokinetic and Safety Profile of Bevacizumab Biosimilar (BEVZ92) vs Bevacizumab (AVASTIN®), Both With FOLFOX or FOLFIRI, in First-line Treatment for mCRC Patients[NCT02069704]Phase 1142 participants (Actual)Interventional2014-10-29Completed
A Phase I/II Study of RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma[NCT01047293]Phase 1/Phase 247 participants (Actual)Interventional2010-05-31Completed
Phase II, Multicentric Randomized Trial, Evaluating the Efficacy of Fluoropyrimidine-based Standard Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receivi[NCT01442649]Phase 2133 participants (Actual)Interventional2010-12-31Completed
Steam (Sequencing Triplet With Avastin and Maintenance): FOLFOXIRI/Bevacizumab Regimens (Concurrent and Sequential) vs. FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer[NCT01765582]Phase 2280 participants (Actual)Interventional2013-01-23Terminated
The Possible Protective Effect of Pentoxifylline Against Chemotherapy Induced Toxicities in Patients With Colorectal Cancer[NCT05590117]Early Phase 148 participants (Anticipated)Interventional2022-10-11Enrolling by invitation
Multidom Remote Monitoring of Patient With Advanced Pancreatic Cancer Treated With Florinox Using the PiCaDo Domomedecine Plateform[NCT04263948]42 participants (Anticipated)Interventional2021-06-01Recruiting
A Multicenter Randomized Dble-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin and 5-FU/LV Combination in First-Line Treatment of Patients With Metastatic Colorectal Carcinoma(MCRC)[NCT00272051]Phase 3620 participants Interventional2002-07-31Completed
A Multicenter, Randomized Double-blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-line Treatment of Patients With Metastatic Colorectal Cancer Treated With Oxaliplatin / 5-FU/LV[NCT00305188]Phase 3879 participants (Actual)Interventional2005-12-31Completed
PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-Line Treatment of Subjects With Metastatic Colorectal Cancer[NCT00115765]Phase 31,053 participants (Actual)Interventional2005-06-01Completed
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Pat[NCT00384176]Phase 2/Phase 31,814 participants (Actual)Interventional2006-08-30Completed
Phase II Randomized Study of Maintenance Treatment With Bevacizumab or Bevacizumab Plus Metronomic Chemotherapy After First-line Induction FOLFOXIRI Plus Bevacizumab for Metastatic Colorectal Cancer Patients[NCT02271464]Phase 2232 participants (Actual)Interventional2012-03-31Completed
Open Label Phase II Study of FOLFIRI + Panitumumab Using Ultra-selection Technology With Next Generation High Sensitivity Genotyping of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS G[NCT01704703]Phase 272 participants (Actual)Interventional2012-10-31Completed
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafe[NCT02928224]Phase 3702 participants (Actual)Interventional2016-10-13Completed
5-Fluorouracil/Folinate/Oxaliplatin (Eloxatin) (FLOX Regimen), Given Continuously or Intermittently, in Combination With Cetuximab (Erbitux), in First-line Treatment of Metastatic Colorectal Cancer. A Phase III Multicenter Trial.[NCT00145314]Phase 3571 participants (Actual)Interventional2005-05-31Completed
Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma[NCT01900717]Phase 2102 participants (Actual)Interventional2011-07-31Completed
Multicenter Phase III Randomized Study of FOLFIRI Plus Bevacizumab Following or Not by a Maintenance Therapy With Bevacizumab in Patients With Non-Pretreated Metastatic Colorectal Cancer[NCT00952029]Phase 2/Phase 3492 participants (Actual)Interventional2010-03-31Completed
Risk Stratification of Hepatocarcinogenesis Using a Deep Learning Based Clinical, Biological and Ultrasound Model in High-risk Patients[NCT04802954]400 participants (Anticipated)Interventional2021-09-01Recruiting
CMAB009 Plus Irinotecan Versus Irinotecan-only as Second-line Treatment After Fluoropyrimidine and Oxaliplatin Failure in KRAS Wild-type Metastatic Colorectal Cancer Patients: Prospective, Open-label, Randomized, Phase II/III Trial[NCT01550055]Phase 2/Phase 3512 participants (Actual)Interventional2009-05-31Completed
A Phase I/IIa Study Combining Curcumin (Curcumin C3-Complex, Sabinsa) With Standard Care FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer.[NCT01490996]Phase 1/Phase 241 participants (Actual)Interventional2012-02-29Completed
Genistein Combined With FOLFOX or FOLFOX-Avastin for Treatment of Metastatic Colorectal Cancer: Phase I/II Pilot Study[NCT01985763]Phase 1/Phase 213 participants (Actual)Interventional2013-11-30Completed
A Open Label, Non Randomized, Phase Two Trial in Metastatic Colorectal Cancer (mCRC) With the Combination of m FOLFIRI Plus Aflibercept as First Line Treatment: MINOAS Trial[NCT02624726]Phase 231 participants (Actual)Interventional2016-01-31Active, not recruiting
A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen[NCT01571284]Phase 3781 participants (Actual)Interventional2012-05-30Completed
A Non-interventional Uncontrolled Multicenter Study to Investigate the Emergence of RAS Resistance Mutations in RAS Wild Type mCRC Patients Receiving First Line Cetuximab Treatment[NCT03401957]120 participants (Anticipated)Observational [Patient Registry]2018-01-31Recruiting
Randomized Phase II Study of mFOLFOX6 + Bevacizumab or mFOLFOX6 + Cetuximab in Liver Only Metastasis From KRAS Wild Type Colorectal Cancer[NCT01836653]Phase 2122 participants (Actual)Interventional2013-05-31Completed
The Predictive Value of Cytokines on Response to Preoperative Chemoradiotherapy in Patients With Rectal Cancer[NCT02077296]34 participants (Actual)Observational2014-03-31Completed
An Open-Label, Pharmacokinetic Study of the Safety and Tolerability of Pazopanib in Combination With FOLFOX 6 or CapeOx in Subjects With Colorectal Cancer[NCT00387387]Phase 150 participants (Actual)Interventional2006-10-20Completed
Randomized Study of Classic vs Simplified Leucovorin Calcium and Fluorouracil With or Without Irinotecan in Patients Aged At Least 75 Years With Advanced Colorectal Cancer[NCT00303771]Phase 3282 participants (Actual)Interventional2003-06-30Completed
Randomized Trial of Treatment Strategy for Chemotherapy in Colorectal Cancer, FFCD 2000-05[NCT00126256]Phase 3570 participants (Anticipated)Interventional2002-02-28Completed
An Uncontrolled, Open-label, Phase II Study in Subjects With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First Line Chemotherapy With mFOLFOX6 (Oxaliplatin/ Folinic Acid/5-fluorouracil [5-FU]) in Combination With Regorafenib[NCT01289821]Phase 254 participants (Actual)Interventional2011-02-28Completed
Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination With FOLFIRI Versus Placebo With FOLFIRI as Second-Line Therapy in Patients With Metastatic Colorectal Cancer[NCT01298570]Phase 2181 participants (Actual)Interventional2011-04-07Completed
Phase I, Open-label, Non-placebo Controlled Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRI as First or Second Line Therapy in Patients With Metastatic Colorectal.[NCT00934882]Phase 145 participants (Actual)Interventional2009-08-31Completed
Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With RAS-mutated Metastatic Colorectal Cancer: a Dose-escalation, Phase I/II Trial[NCT03828799]Phase 1/Phase 213 participants (Actual)Interventional2019-05-17Active, not recruiting
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study[NCT05277766]Phase 145 participants (Anticipated)Interventional2022-11-21Recruiting
Phase 2b, DB, Randomized Study Evaluating Efficacy & Safety of Sorafenib Compared With Placebo When Administered in Combination With Modified FOLFOX6 for the Treatment of Metastatic CRC Subjects Previously Untreated for Stage IV Disease[NCT00865709]Phase 2198 participants (Actual)Interventional2009-03-31Completed
Study of Cetuximab in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer[NCT01564810]Phase 4150 participants (Anticipated)Interventional2006-09-30Recruiting
A Randomized Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Combinations With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer Preceded By A Phase 1 Portion[NCT00460603]Phase 1/Phase 2187 participants (Actual)Interventional2006-01-31Completed
Phase II Study of Oxaliplatin, Capecitabine and Bevacizumab in the Treatment of Metastatic Colorectal Cancer[NCT00416494]Phase 250 participants (Actual)Interventional2003-09-30Completed
A Single Arm, Open Label, Exploratory Study of Pemetrexed and S-1 in Combination With Bevacizumab in Patients Who Have Progressed After Standard Second Line Therapy[NCT03843853]Phase 20 participants (Actual)Interventional2019-05-01Withdrawn (stopped due to cooperation terminated)
A Single Arm, Open Label, Exploratory Study of Pemetrexed and TAS-102 in Combination With Bevacizumab in Patients Who Have Progressed After Standard Second Line Therapy[NCT04683965]Phase 227 participants (Anticipated)Interventional2021-01-01Active, not recruiting
A Randomised Clinical Trial of Treatment for Fluorouracil-Resistant Advanced Colorectal Cancer Comparing Standard Single-Agent Irinotecan Versus Irinotecan Plus Panitumumab and Versus Irinotecan Plus Ciclosporin [Panitumumab, Irinotecan & Ciclosporin in C[NCT00389870]Phase 31,198 participants (Actual)Interventional2006-12-31Completed
Low-dose Versus Standard-dose Capecitabine Adjuvant Chemotherapy for Chinese Elderly Patients With Stage II/III Colorectal Cancer: A Randomized, Phase 3 Non-inferiority Study[NCT02316535]Phase 3710 participants (Anticipated)Interventional2014-11-30Recruiting
Discovery and Validate of Multi-genetic Biomarkers for Capecitabine in Chinese Colorectal Patients[NCT03030508]300 participants (Anticipated)Observational2016-01-31Enrolling by invitation
XELOX III. Capecitabine (Xeloda) in Combination With Oxaliplatin (Eloxatin) as First-line Treatment of Patients With Advanced or Metastatic Colorectal Cancer. A Randomized Phase II Study[NCT00212615]Phase 2/Phase 3116 participants (Actual)Interventional2004-02-29Completed
Avastin and Chemotherapy Followed by Avastin Alone or in Combination With Tarceva for the Treatment of Metastatic Colorectal Cancer.[NCT00598156]Phase 3249 participants (Actual)Interventional2007-06-30Completed
Randomized, Multicenter, Phase III Study, to Evaluate the Efficacy and Safety of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy After Initial Chemotherapy Treatment With Capecitabine, Oxaliplatin and Bevacizumab in Meta[NCT00335595]Phase 3480 participants (Actual)Interventional2006-07-31Completed
Development of a Prospective Clinicobiological Database in Metastatic Digestive Cancers[NCT03978078]200 participants (Anticipated)Interventional2016-09-12Recruiting
Tempus CRC Surveillance Study: A Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Colorectal Cancer (CRC) Using Comprehensive Next-Generation Sequencing (NGS)Assays[NCT05234177]160 participants (Anticipated)Observational2022-06-21Recruiting
A Phase II Clinical Trial Study on Apatinib and XELOX Combination Regimen in the First-line Treatment of End-stage Colorectal Cancer Patients[NCT02829385]Phase 253 participants (Anticipated)Interventional2016-06-30Recruiting
Predictive Impact of RAS Mutations in Circulating Tumor DNA for Efficacy of Anti-EGFR Reintroduction Treatment in Patients With Metastatic Colorectal Cancer[NCT03259009]73 participants (Anticipated)Observational [Patient Registry]2017-10-01Not yet recruiting
The Oncopanel Pilot (TOP) Study[NCT02171286]432 participants (Actual)Observational2014-10-31Completed
A Randomised, Open-label Phase III Study to Assess Efficacy and Safety of Bevacizumab in Combination With Capecitabine as First-line Treatment for Elderly Patients With Metastatic Colorectal Cancer[NCT00484939]Phase 3280 participants (Actual)Interventional2007-07-31Completed
Temozolomide Plus Bevacizumab Chemotherapy in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status (KPS<70)[NCT02898012]Phase 270 participants (Actual)Interventional2010-10-31Completed
Observational Study of the Impact of Circulating T Regulatory Cells (Tregs) on Clinical Outcome of Metastatic Colorectal Cancer (MCRC) Patients Treated With Standard Fluorouracil/Irinotecan/Bevacizumab First Line Therapy[NCT01533740]31 participants (Actual)Observational2012-03-31Completed
Pre- and Post-Operative Chemotherapy With Oxaliplatin 5FU/LV Versus Surgery Alone in Resectable Liver Metastases From Colorectal Origin - Phase III Study[NCT00006479]Phase 30 participants Interventional2000-09-30Active, not recruiting
Simultaneous RESEction of Colorectal Cancer With Synchronous Liver MeTastases (RESECT): A Feasibility Study[NCT02954913]41 participants (Actual)Interventional2017-02-14Completed
Peri-operative Chemotherapy VS Postoperative Chemotherapy for the Treatment of Colon Cancer With Resectable Liver Metastasis: a Prospective Randomized Clinical Trial[NCT02912052]Phase 3240 participants (Anticipated)Interventional2016-10-31Not yet recruiting
A Prospective Study Evaluating Diagnostic Accuracy, Outcome, and Economic Impact of Abbreviated Gadoxetate-enhanced MRI of the Liver in Patients With Metastatic Colorectal Carcinoma[NCT05314400]300 participants (Anticipated)Interventional2022-07-01Recruiting
Stereotactic Body Radiotherapy (SBRT) for the Treatment of OligoMetastasis in Breast Cancer Patients (STOMP): A Prospective Feasibility Trial[NCT03295916]Early Phase 130 participants (Anticipated)Interventional2018-01-01Recruiting
A Phase 1b/2 Study of AMG 655 in Combination With Modified FOLFOX6 and Bevacizumab for the First-Line Treatment of Subjects With Metastatic Colorectal Cancer[NCT00625651]Phase 1/Phase 2202 participants (Actual)Interventional2007-10-31Completed
FOLFOXIRI Plus Bevacizumab as First-line Treatment for BRAF V600E Mutant Metastatic Colorectal Cancer: a Prospective Evaluation[NCT01437618]15 participants (Actual)Observational2009-06-30Completed
A Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Dasatinib for Patients With Advanced Solid Tumors With Expanded Cohort of Patients With Previously Untreated Metastatic Colorectal Cancer.[NCT00920868]Phase 122 participants (Actual)Interventional2009-05-31Completed
Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer: An Open, Multi-centered, Randomize Controlled Phase 3 Trial.[NCT03970694]Phase 349 participants (Actual)Interventional2019-05-11Terminated (stopped due to Significant differences in conversion rate as well as R0 resection rate between the two groups.)
A Randomized, Open-label Phase II Study Evaluating the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab as First-line Therapy in Subjects With Metastatic Colorectal Cancer.[NCT00439517]Phase 2302 participants (Actual)Interventional2007-02-28Completed
Epidemiological and Molecular Colorectal Cancer Registry[NCT02781337]2,100 participants (Anticipated)Observational [Patient Registry]2012-05-31Recruiting
LARCID: Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea[NCT00582426]Phase 3139 participants (Actual)Interventional2008-04-30Completed
Phase I Trial of Oral Capecitabine Combined With 131I-huA33 in Patients With Metastatic Colorectal Cancer[NCT00291486]Phase 119 participants (Actual)Interventional2003-10-31Completed
Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC II-IV, With a 5-FU-based Standard Radiochemotherapy Followed by Total Mesorectal Excision.[NCT03034473]200 participants (Actual)Interventional2011-08-31Active, not recruiting
Open, Randomized, Multicenter, Randomized Phase II Trial Comparing the Combination of Cetuximab With Oxaliplatin/5-FU/FA Versus the Combination of Cetuximab With Irinotecan/5-FU/FA as Neoadjuvant Treatment in Patients With Non-Resectable Colorectal Liver [NCT00153998]Phase 2135 participants (Actual)Interventional2004-11-30Completed
Age, Body Mass Index and Tumor Sidedness in Metastatic Colorectal Cancer Patients as Predictive Factors for Systemic Therapy Outcome[NCT04543019]50 participants (Anticipated)Observational2020-12-31Not yet recruiting
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621]Phase 2135 participants (Actual)Interventional2019-03-25Completed
A Phase II Study of the Rate of Conversion to Complete Resection in Patients With Initially Inoperable Hepatic-Only Metastases From Colorectal Cancer After Treatment With Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Bes[NCT00492999]Phase 264 participants (Anticipated)Interventional2007-05-31Active, not recruiting
A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver[NCT03366155]Phase 240 participants (Anticipated)Interventional2019-06-24Recruiting
Biomarker-Panel Guided Maintenance Treatment With Cetuximab Monotherapy Versus Continuation After First Line Induction Therapy of Metastatic Colorectal Cancer (mCRC) : a Multicenter, Prospective, Randomized Controlled Trial[NCT02942706]Phase 2/Phase 3200 participants (Anticipated)Interventional2021-11-30Not yet recruiting
A Multicenter Study of Prognosis and the Efficacy Comparison of Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Patients(Clinical Risk Score≥3) of Resectable Colorectal Liver Metastasis[NCT03031444]Phase 2/Phase 3135 participants (Actual)Interventional2016-01-31Completed
Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641]Phase 2100 participants (Anticipated)Interventional2019-01-28Recruiting
Double-blind, Phase II Study to Assess the Effectiveness of Lycopene vs Placebo to Reduce Skin Toxicity in Patients With Colorectal Carcinoma Treated With Panitumumab[NCT03167268]Phase 228 participants (Actual)Interventional2016-08-03Active, not recruiting
The Effectiveness of Topical Oral Vitamin D Gel in Prevention of Radiation-induced Oral Mucositis[NCT04308161]Phase 245 participants (Anticipated)Interventional2019-11-02Recruiting
The Effectiveness of Melatonin in Prevention of Radiation-induced Oral Mucositis[NCT03833570]Phase 240 participants (Actual)Interventional2018-01-12Completed
A Multicenter Phase II Study of the Capecitabine, Oxaliplatin and Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer[NCT01024504]Phase 246 participants (Anticipated)Interventional2006-03-31Completed
BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis[NCT02399410]Phase 260 participants (Actual)Interventional2015-12-31Active, not recruiting
Phase II Study Evaluating the Efficacy and Tolerance to Chemotherapy With 5-fluorouracil, Folinic Acid, Irinotecan and Bevacizumab as First-line Treatment in Patients With Metastatic Colorectal Cancer[NCT00467142]Phase 262 participants (Actual)Interventional2007-01-23Completed
Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (≥75 Years)[NCT00812864]Phase 420 participants (Actual)Interventional2009-01-31Completed
A Sequential Phase I Study Of The Combination Of Everolimus (Rad001) With 5-Fu/Lv (De Gramont), Folfox6, And Folfox6/Panitumumab In Patients With Refractory Solid Malignancies[NCT00610948]Phase 174 participants (Actual)Interventional2008-03-31Completed
Open Labeled, Multicenter Phase I/II Study Evaluating the Dose Escalation/Safety of Cetuximab and Oxaliplatin/5-FU/FA/Irinotecan as First-Line Treatment of Metastatic Colorectal Cancer[NCT00422773]Phase 1/Phase 221 participants (Anticipated)Interventional2007-01-31Completed
Evaluation of Individual Peripheral Blood Circulating Tumor Cells Combined With Tumor Marker Detection of Efficacy of Chemotherapy in Patients With Advanced Colorectal Cancer: A Observational Clinical Trial[NCT02948985]100 participants (Anticipated)Observational [Patient Registry]2017-01-31Not yet recruiting
Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer[NCT00284258]Phase 2/Phase 3426 participants (Actual)Interventional2006-01-31Completed
A Clinical Proof-of-concept Study Evaluating Efficacy and Safety of ZL-2306 (Niraparib) Combined With Brivanib or Toripalimab in Patients With Metastatic, Recurrent, and Persistent Cervical Cancer[NCT04395612]Phase 238 participants (Anticipated)Interventional2020-05-08Recruiting
Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies[NCT02648711]Phase 141 participants (Actual)Interventional2015-10-31Terminated (stopped due to Company decision)
Assessment of Histopathological Response to Combination Chemotherapy With Oxaliplatin, Irinotecan, Fluorouracil and Bevacizumab in Patients With Peritoneal Metastasis From Colorectal Cancer[NCT02591667]Phase 230 participants (Anticipated)Interventional2016-03-31Recruiting
Phase I Trial of Intraperitoneal Oxaliplatin in Combination With Intravenous FOLFIRI (5-fluorouracil, Leucovorin and Irinotecan) for Peritoneal Carcinomatosis From Colorectal and Appendiceal Cancer[NCT02833753]Phase 114 participants (Actual)Interventional2016-07-31Completed
Essai De Phase III De Chimiotherapie Par FOLFOX 4 Ou Par Une Succession FOLFOX 7 - FOLFIRI Chez Des Patients Ayant Des Metastases Resecables D'Origine Colorectale - MIROX[NCT00268398]Phase 3284 participants (Actual)Interventional2002-07-31Completed
A Randomized Phase III Study of SOX vs. COX in Patients With Advanced Colorectal Cancer[NCT00677443]Phase 3344 participants (Actual)Interventional2008-06-30Completed
Randomised Comparative Study Of Folfox6m Plus Sir-Spheres® Microspheres Versus Folfox6m Alone As First Line Treatment In Patients With Nonresectable Liver Metastases From Primary Colorectal Carcinoma[NCT00724503]530 participants (Actual)Interventional2006-08-31Completed
Phase II Study of Irinotecan Plus Capecitabine as the First-line or Second-line Treatment for Advanced Colorectal Cancer Patients[NCT01322152]Phase 252 participants (Actual)Interventional2011-03-31Completed
A Multicentre Randomised Phase II Study to Assess the Safety and Resectability in Patients With Initially Unresectable Liver Metastases Secondary to Colorectal Cancer Receiving First-line Treatment Either With mFOLFOX-6 Plus Bevacizumab or FOLFOXIRI Plus [NCT00778102]Phase 280 participants (Actual)Interventional2008-10-31Completed
Comparison of High Tone Therapy and TENS Therapy in Chemotherapy-induced Polyneuropathy[NCT03978585]51 participants (Actual)Interventional2019-09-03Completed
A Phase 1b, Open-Label, Dose-Escalation Study of Tivozanib (AV-951) Plus FOLFOX6 in Subjects With Advanced Colorectal Cancer and Other Gastrointestinal Cancers[NCT00660153]Phase 130 participants (Actual)Interventional2008-06-30Completed
Bevacizumab Maintenance Versus no Maintenance After Stop of First-line Chemotherapy in Patients With Metastatic Colorectal Cancer. A Randomized Multicenter Phase III Non-inferiority Trial[NCT00544700]Phase 3265 participants (Actual)Interventional2007-11-26Terminated (stopped due to Data collection is completed. As no changes in the endpoints were expected in the future, no further data is needed.)
Open-label Phase 1b Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer Who Have Progressed Following Chemotherapy for Advanced or Metastatic Disease[NCT00719199]Phase 121 participants (Actual)Interventional2009-01-31Terminated (stopped due to Sponsor will discontinue further development of EMD 1201081)
A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice[NCT01460745]60 participants (Actual)Observational2011-11-30Completed
Study of Blood Components as Probable Prognostic and Predictive Markers of Response to Treatment in Advanced Colon and Rectal Cancers[NCT02979470]100 participants (Anticipated)Observational [Patient Registry]2016-09-30Recruiting
SEQUENTIAL TREATMENT STRATEGY FOR METASTATIC COLORECTAL CANCER: A PHASE III PROSPECTIVE RANDOMIZED MULTICENTER STUDY OF CHEMOTHERAPY (CT) WITH OR WITHOUT BEVACIZUMAB AS FIRST-LINE THERAPY FOLLOWED BY TWO PHASE III RANDOMIZED STUDIES OF CT ALONE OR CT PLUS[NCT01878422]Phase 3350 participants (Anticipated)Interventional2007-11-30Completed
An Open-Label, Dose-Finding Study to Evaluate the Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer[NCT00101894]Phase 1119 participants (Actual)Interventional2004-12-31Completed
Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3, Multicentre, Randomised Controlled Trial (CAN)[NCT02958111]Phase 3406 participants (Actual)Interventional2017-01-31Active, not recruiting
Maintenance Treatment With Capecitabine and Bevacizumab Versus Observation After Induction Treatment With Chemotherapy and Bevacizumab as First-line Treatment in Patients With Advanced Colorectal Carcinoma[NCT00442637]Phase 3635 participants (Anticipated)Interventional2007-01-31Active, not recruiting
Capecitabine Metronomic Chemotherapy Versus Conventional Chemotherapy as Maintenance Treatment in Metastatic Colorectal Cancer[NCT02893540]Phase 2/Phase 3250 participants (Anticipated)Interventional2016-09-30Recruiting
Maintenance Treatment With Capecitabine Plus Cetuximab After First-line 5-Fluorouracil-based Chemotherapy Plus Cetuximab for Patients With RAS Wild-type Metastatic Colorectal Cancer: a Single Arm, Open-label, Multi-center Clinical Trial[NCT02717923]Phase 250 participants (Anticipated)Interventional2014-01-31Recruiting
Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Responders After Induction Therapy in Metastatic Colorectal Cancer[NCT03158610]Phase 2/Phase 320 participants (Actual)Interventional2018-01-29Terminated (stopped due to Difficult to enrollment patient)
Apatinib Versus Bevacizumab in Combination With Second-line FOLFIRI in Patients With Metastatic Colorectal Cancer That Progressed During or After First-line Bevacizumab Plus an Oxaliplatin-based Regimen: A Randomised Phase 2 Trial[NCT03271255]Phase 280 participants (Anticipated)Interventional2018-05-23Recruiting
TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.[NCT04392479]Phase 3202 participants (Anticipated)Interventional2020-09-02Active, not recruiting
The Biomarkers Identification for Apatinib and Bevacizumab in the Second-line Therapy for Colorectal Cancer: A Randomised Controlled Trial[NCT03743428]40 participants (Anticipated)Interventional2020-10-22Suspended (stopped due to Too slow speed for recruiting.)
Study Evaluating the Safety and Efficacy of FOLFOX Plus Apatinib or FOLFIRI Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer[NCT03193814]Phase 250 participants (Anticipated)Interventional2019-12-01Not yet recruiting
Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases CAIRO5 a Randomized Phase 3 Study of the Dutch Colorectal Cancer Group (DCCG)[NCT02162563]Phase 3564 participants (Anticipated)Interventional2014-07-31Recruiting
A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI With Either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Tumors[NCT00418938]Phase 2266 participants (Actual)Interventional2006-11-01Completed
Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)[NCT05913674]Phase 225 participants (Anticipated)Interventional2023-07-31Not yet recruiting
Open-label, Efficacy and Safety Study of Bevacizumab (Avastin®) in Combination With XELOX (Oxaliplatin Plus Xeloda®) for the First-line Treatment of Patients With Metastatic Cancer of the Colon or Rectum - 'OBELIX'[NCT00577031]Phase 4205 participants (Actual)Interventional2008-02-29Completed
A Phase I Clinical Trial of Sequential Pralatrexate Followed by a 48-hour Infusion of 5- Fluorouracil Given Every Other Week in Adult Patients With Solid Tumors[NCT01206465]Phase 129 participants (Actual)Interventional2010-09-14Completed
An Open Label, Single-arm, Phase II Study to Evaluate the Efficacy and the Feasibility of Bevacizumab (Avastin) Based on a FOLFOXIRI Regimen Until Progression in Patients With Previously Untreated Metastatic Colorectal Carcinoma(OPAL-Study)[NCT00940303]Phase 297 participants (Actual)Interventional2009-06-30Completed
Randomized Three Arm Phase III Trial on Induction Treatment With a Fluoropyrimidine-, Oxaliplatin- and Bevacizumab-based Chemotherapy for 24 Weeks Followed by Maintenance Treatment With a Fluoropyrimidine and Bevacizumab vs. Bevacizumab Alone vs. no Maint[NCT00973609]Phase 3853 participants (Actual)Interventional2009-08-31Completed
Chemotherapy With FOLFIRI Plus Bevacizumab (AvastinR) in Patients With Metastatic Colorectal Cancer Bearing Genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*1/UGT1A1*28: Prospective, Phase II, Multicenter Study[NCT00628810]Phase 286 participants (Actual)Interventional2007-01-31Completed
Optimal Control of Liver Metastases With Intravenous Cetuximab and Hepatic Artery Infusion of Three-drug Chemotherapy in Patients With Liver-only Metastases From Colorectal Cancer. A European Multicenter Phase II Trial[NCT00852228]Phase 260 participants (Anticipated)Interventional2008-07-31Active, not recruiting
Phase 2 Study to Improve Tolerance of Chemotherapy Involving Cetuximab and Multidrug FOLFIRI, With Pharmacokinetic and Pharmacogenetic Studies, in Patients With Metastatic Colorectal Cancer[NCT00559741]Phase 280 participants (Anticipated)Interventional2005-10-31Completed
A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.[NCT01524094]Phase 349 participants (Actual)Interventional2003-06-30Completed
The Identification, Validation and Implementation of Molecular Markers to Predict Response to Fluorouracil-based Adjuvant Chemotherapy in Stage III Colorectal Cancer Patients - Prospective Clinical Observational Study[NCT03127111]300 participants (Anticipated)Observational2022-12-01Not yet recruiting
Randomized Phase 3 Study on the Optimization of Bevacizumab With mFOLFOX/mOXXEL in the Treatment of Patients With Metastatic Colorectal Cancer[NCT01718873]Phase 3230 participants (Actual)Interventional2012-05-31Completed
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) as First-line Treatment for Metastatic Colorectal Cancer[NCT01219920]Phase 3244 participants (Actual)Interventional2001-11-30Completed
Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study[NCT01721954]Phase 3209 participants (Actual)Interventional2013-05-01Completed
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only[NCT01226719]Phase 215 participants (Actual)Interventional2010-12-31Completed
Maintenance Treatment With Capecitabine Versus Observation After First Line Chemotherapy in Patients With Metastatic Colorectal Cancer: a Randomized Phase II Study[NCT02027363]Phase 2245 participants (Anticipated)Interventional2010-01-31Active, not recruiting
Maintenance Treatment With S-1 Versus Observation After First-line Chemotherapy in Patients With Advanced Gastric Cancer: a Randomized Phase II Study[NCT03701373]Phase 2200 participants (Anticipated)Interventional2016-01-01Recruiting
Assessment of Targeted Therapy Against Colorectal Cancer (ATTACC) Screening Protocol[NCT01196130]1,275 participants (Actual)Observational2010-08-31Completed
Randomized, Multinational, Study Of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer[NCT00851084]Phase 2268 participants (Actual)Interventional2009-02-28Completed
A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin With 5-FU Plus LV for the Treatment of Patients With Stages II and III Carcinoma of the Colon[NCT00004931]Phase 32,472 participants (Anticipated)Interventional2000-02-29Completed
An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of 5 FU/FA and Oxaliplatin (Modified FOLFOX 6) in Combination With Ramucirumab or IMC-18F1 or Without Investigational Therapy as Second Line Therapy in Patients With M[NCT01111604]Phase 2158 participants (Actual)Interventional2010-08-31Completed
[NCT00594529]Phase 227 participants (Anticipated)Interventional2008-01-31Recruiting
"Living Donor Liver Transplantation (LDLT) in Non Resectable Colo-rectal Cancer Liver Metastasis. The LIVERMORE Trial (LIVing Donor livEr tRansplant Modena cOloRectal mEtastasis) [Original Title in Italian: Trapianto di Fegato da Donatore Vivente Per Meta[NCT05186116]25 participants (Anticipated)Interventional2022-01-01Recruiting
Open-label, Multicenter, Phase II Study Of First-line Biweekly Irinotecan, Oxaliplatin And Infusional 5-FU/LV (FOLFOXIRI) In Combination With Bevacizumab In Patients With Metastatic Colorectal Cancer[NCT01163396]Phase 257 participants (Actual)Interventional2007-07-31Completed
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Pegfilgrastim Admininstered to Subjects With Newly Diagnosed, Locally-advanced or Metastatic Colorectal Cancer Treated With Bevacizumab & Either 5-fluorouracil, Oxaliplatin, Leucovorin (FOLF[NCT00911170]Phase 3847 participants (Actual)Interventional2009-11-03Completed
TACTIC: a Phase II Study of TAS-102 Monotherapy and Thalidomide Plus TAS-102 as Third-line Therapy and Beyond in Patients With Advanced Colorectal Carcinoma[NCT05266820]Phase 2120 participants (Anticipated)Interventional2021-10-01Recruiting
Randomized, Double-Blind, Phase II Study of FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment for Patients With Metastatic Colorectal Cancer[NCT01418222]Phase 2194 participants (Actual)Interventional2011-09-14Completed
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer[NCT01399684]Phase 2127 participants (Actual)Interventional2011-11-30Completed
Risk of Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy[NCT04941625]150 participants (Anticipated)Observational2018-02-23Recruiting
Pilot Phase II Study of Safety and Immunogenicity of an ALVAC-CEA/B7.1 Vaccine Administered With Chemotherapy, Alone or in Combination With Tetanus Toxoid, as Compared to Chemotherapy Alone, in Patients With Metastatic Colorectal Adenocarcinoma[NCT00027833]Phase 20 participants Interventional2001-12-31Active, not recruiting
Comparison of Showerpatch Versus Other Measures to Protect Intravenous Catheter Entry Site During Bathing Activities[NCT02324868]18 participants (Actual)Interventional2016-01-31Terminated (stopped due to logistic problems)
A Phase III, Multicenter, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab) in Combination With Standard Chemotherapy in Subjects With Metastatic Colorectal Cancer[NCT00109070]Phase 30 participants Interventional2000-09-30Completed
A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab), a Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, in Combination With 5-[NCT00109226]Phase 20 participants Interventional2000-08-31Completed
Phase I Study of PS-341 (VELCADE) in Combination With 5FU/LV Plus Oxaliplatin in Patients With Advanced Colorectal Cancer[NCT00098982]Phase 116 participants (Actual)Interventional2004-09-30Completed
A Multicenter, Open-Label, Randomized, Two-Arm Study of Irinotecan (CPT-11) Versus the Combination of Oxaliplatin + Irinotecan (CPT-11) as Second-Line Treatment of Metastatic Colorectal Carcinoma[NCT00012389]Phase 30 participants Interventional2000-12-31Completed
A Study of ZD1839 (Iressa) in Combination With Oxaliplatin, 5-Fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Malignancies (Phase I) and Advanced Colorectal Cancers (Phase II)[NCT00025142]Phase 20 participants Interventional2001-07-31Completed
Radioembolization With Yttrium-90 Microspheres for Intermediate or Advanced HCC (Hepatocellular Carcinoma) Not Eligible to Curative Approach. A Phase II-b Study.[NCT00910572]Phase 260 participants (Anticipated)Interventional2007-07-31Completed
Transarterial Radioembolization Versus Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma[NCT02729506]Phase 4150 participants (Anticipated)Interventional2016-01-31Recruiting
A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum[NCT00003594]Phase 31,691 participants (Actual)Interventional1998-10-31Completed
A Phase I Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety, Efficacy and Pharmacokinetics Profiles of TSB-9-W1 in Pre-treated Patients With Metastatic Colorectal Cancer (mCRC).[NCT02249650]Phase 121 participants (Actual)Interventional2017-07-10Completed
Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxal[NCT01434147]Phase 225 participants (Actual)Interventional2011-10-31Completed
Open, Randomized, Controlled, Multicenter Phase II Study Comparing 5-FU/FA Plus Oxaliplatin (FOLFOX-4) Plus Cetuximab Versus 5-FU/FA Plus Oxaliplatin (FOLFOX-4) as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal [NCT00125034]Phase 2344 participants (Actual)Interventional2005-07-31Completed
A Three-Arm Randomised Controlled Trial Comparing Either Continuous Chemotherapy Plus Cetuximab or Intermittent Chemotherapy With Standard Continuous Palliative Combination Chemotherapy With Oxaliplatin and a Fluoropyrimidine in First Line Treatment of Me[NCT00182715]Phase 32,421 participants (Anticipated)Interventional2005-03-31Active, not recruiting
Cetuximab Added to Capecitabine, Oxaliplatin and Bevacizumab in Patients With Previously Untreated Advanced Colorectal Carcinoma, a Randomised Phase III Study[NCT00208546]Phase 3750 participants (Actual)Interventional2005-06-30Completed
Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI[NCT01858649]Phase 260 participants (Actual)Interventional2013-05-31Completed
A Phase I, Open-Label, Dose-Seeking Study of AZD2171 Given Daily Orally in Combination With Selected Standard Chemotherapy Regimens (CT) in Patients With Advanced Incurable Non-Small Cell Lung Cancer (NSCLC) or Colorectal Cancer[NCT00343408]Phase 131 participants (Actual)Interventional2005-11-29Completed
A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin In Patients With Unresectable Hepatic Metastases From Colorectal Cancer[NCT00008294]Phase 10 participants Interventional2000-08-31Completed
The Influence of Two Different Hepatectomy Methods on Transection Speed and Chemokine Release From the Liver[NCT01785212]40 participants (Actual)Interventional2013-03-31Completed
A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639]Phase 28 participants (Actual)Interventional2012-04-30Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.)
Role of Circulating Tumour DNA (ctDNA) Testing in Assessing for Alterations of Primary Anti-Epidermal Growth Factor Receptor (EGFR) Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients[NCT05051592]40 participants (Anticipated)Observational2021-03-26Recruiting
A Randomized Phase II Study to Evaluate the Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma[NCT02014831]Phase 20 participants (Actual)Interventional2016-02-29Withdrawn (stopped due to Industry decline to supply study drug)
Biomarker-Panel Enriched Maintenance Treatment With Cetuximab Monotherapy Versus Continuation After Induction Treatment With Chemotherapy + Cetuximab in Metastatic Colorectal Cancer (mCRC)[NCT02978313]Phase 2/Phase 3500 participants (Anticipated)Interventional2016-11-30Not yet recruiting
Open, Randomized, Controlled, Multicenter Phase III Study Comparing 5FU/ FA Plus Irinotecan Plus Cetuximab Versus 5FU/FA Plus Irinotecan as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer[NCT00154102]Phase 31,221 participants (Actual)Interventional2004-05-31Completed
Exploration of New Biologic Factors' Predictive Value , Especially Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab[NCT01405430]63 participants (Actual)Interventional2010-05-31Completed
Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer[NCT01268943]Phase 118 participants (Actual)Interventional2010-11-30Completed
Phase 2 Study of Neoadjuvant 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma[NCT00168155]Phase 270 participants Interventional2002-01-31Completed
Phase II-III Study of an Optimized LV-5FU-Oxaliplatin Strategy in Metastatic Colorectal Cancer. Optimox2 Study. C02-2[NCT00274872]Phase 2/Phase 3600 participants (Anticipated)Interventional2004-01-31Active, not recruiting
Phase II Study Evaluating the Interest of the Re-introduction of Pemetrexed and Platinum (Cisplatin or Carboplatin) With Prolonged Angiogenic Blocking by Bevacizumab in Non Squamous Non Small Cell Lung Cancer of Advanced Stage.[NCT01705184]Phase 2120 participants (Actual)Interventional2012-12-31Completed
Fluorouracil, Oxaliplatin and Irinotecan: Use and Sequencing: A Randomized Trial to Assess the Role of Irinotecan and Oxaliplatin in Advanced Colorectal Cancer[NCT00008060]Phase 30 participants Interventional2000-05-31Completed
A Randomized, Controlled Study of Standardized Patient Coaching Versus Patient Management According to Local Practice for Patients With Hormone Receptor Positive HER2 Negative Metastatic Breast Cancer Treated With Abemaciclib[NCT04030728]212 participants (Anticipated)Observational2020-03-31Not yet recruiting
Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer[NCT02117466]Phase 1/Phase 285 participants (Actual)Interventional2014-04-30Terminated (stopped due to Primary endpoint could no longer be reached.)
Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors[NCT01858662]Phase 24 participants (Actual)Interventional2014-01-31Terminated (stopped due to due to poor recrutment)
Value of Contrast Enhanced Intraoperative Ultrasound Compared to Preoperative CEUS, CT and MRT in the Treatment of Colorectal Liver Metastases.[NCT01522209]59 participants (Actual)Interventional2011-12-31Completed
A Phase II Trial Evaluating Multiple Metastasectomy Combined With Hepatic Artery Infusion Of Floxuridine (FUDR) And Dexamethasone (DXM), Alternating With Systemic Oxaliplatin (OXAL) And Capecitabine (CAPCIT) For Colorectal Carcinoma Metastatic To The Live[NCT00026234]Phase 275 participants (Actual)Interventional2002-02-28Completed
Chemotherapy Administered Every 2 Weeks With or Without a Single Injection of Pegfilgrastim as First or Second-Line Treatment in Subjects With Locally Advanced or Metastatic Colon Cancer[NCT00094809]Phase 2252 participants (Actual)Interventional2003-02-01Completed
Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases[NCT01095523]Phase 20 participants (Actual)Interventional2010-01-14Withdrawn
Oxaliplatin, Irinotecan, and Capecitabine as a Combination Regimen for First-Line Treatment of Advanced or Metastatic Colorectal Cancer[NCT00217711]Phase 1/Phase 223 participants (Actual)Interventional2005-05-31Completed
A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062]Phase 1120 participants (Actual)Interventional2013-03-31Completed
Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma[NCT02289547]Phase 3184 participants (Anticipated)Interventional2015-05-31Recruiting
A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618]Phase 241 participants (Actual)Interventional2014-07-05Completed
NGR005: Pilot Study of NGR-hTNF Administered at Low and High Doses in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer[NCT00675012]Phase 224 participants (Actual)Interventional2007-12-31Completed
A Randomized Phase II Study of Modified FOLFOX6 (Infusional 5-Fluorouracil/Leucovorin, Oxaliplatin) and Bevacizumab With or Without Cetuximab in Patients With Metastatic Colorectal Cancer[NCT00193219]Phase 236 participants (Actual)Interventional2005-07-31Completed
Phase II Trial of FOLFOXIRI Plus Panitumumab as First-Line Treatment for Kras and Braf Wild-Type Metastatic Colorectal Cancer[NCT01358812]Phase 237 participants (Actual)Interventional2010-03-31Completed
Randomized Phase III Study Post Radical Resection of Liver Metastasis of Colorectal Cancer: Bevacizumab in Combination With XELOX as Adjuvant Chemotherapy vs XELOX Alone[NCT00394992]Phase 379 participants (Actual)Interventional2006-12-31Terminated (stopped due to Data from the C08 study and Avant study)
Polymorphism Interaction to Predict Bevacizumab Efficacy in Advanced Breast Cancer Patients: an Exploratory Retrospective Analysis[NCT01935102]169 participants (Actual)Observational2012-12-31Completed
A Phase II, Randomised Controlled Trial to Evaluate the Efficacy and Safety of Moisturising Creams With or Without Palm-oil-derived Vitamin E Concentrate in Addition to Urea-based Cream or Urea-based Cream Alone in Capecitabine-associated Palmar-Plantar E[NCT05939726]90 participants (Anticipated)Interventional2023-05-16Recruiting
"Evaluation of the Restorative Efficacy of the Cosmetic Product Onco-Repair vs. Placebo on Grade 2 Hand Foot Syndrome Induced by Targeted Therapies or Conventional Chemotherapy. Randomized, Multicentre, Double Blind, Controlled Study Versus Placebo."[NCT03612011]Phase 372 participants (Actual)Interventional2018-07-12Completed
A Multicenter, Randomized Phase II Trial of Avastin Plus Gemcitabine Plus 5FU/Folinic Acid (A + FFG) vs. Avastin Plus Oxaliplatin Plus 5FU/Folinic Acid (A + FOLFOX 4) as Therapy for Patients With Metastatic Colorectal Cancer[NCT00192075]Phase 284 participants (Actual)Interventional2003-06-30Completed
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer[NCT00100841]Phase 266 participants (Actual)Interventional2004-11-30Completed
Phase II Study of Oxaliplatin, Capecitabine, Cetuximab, and Bevacizumab in the Treatment of Metastatic Colorectal Cancer[NCT00290615]Phase 230 participants (Actual)Interventional2006-01-31Completed
Phase II Clinical Trial of Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Patients With Previously Untreated Unresectable Liver-only Metastases From Colorectal Cancer[NCT01022541]Phase 247 participants (Actual)Interventional2006-06-30Completed
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum[NCT00056446]Phase 3855 participants (Actual)Interventional2003-01-31Completed
A Randomized, Double-blind, Placebo-controlled, Phase Lll Study in Patients With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First-line Chemotherapy With Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo[NCT00056459]Phase 31,168 participants (Actual)Interventional2003-02-28Completed
Drug Treatment for Bowel Cancer: Making the Best Choices When a Milder Treatment is Needed[NCT00070213]Phase 3460 participants (Actual)Interventional2003-09-30Completed
Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Metastatic Colorectal Cancer[NCT03530267]Phase 2124 participants (Actual)Interventional2018-09-28Active, not recruiting
A Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced or Metastatic Colorectal Cancer[NCT00536809]Phase 112 participants (Actual)Interventional2007-09-26Completed
Comparison of Hepatectomy and Local Ablation for Resectable Synchronous and Metachronous Colorectal Liver Metastasis (HELARC) ------ a Randomized Controlled Multicenter Clinical Study[NCT02886104]548 participants (Anticipated)Interventional2016-08-31Recruiting
Phase II Randomized Study of First-Line Therapy Comprising Bevacizumab and Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil (FOLFIRI) Versus Bevacizumab and Irinotecan Hydrochloride and Capecitabine (XELIRI) in Patients With Unresectable Met[NCT00423696]Phase 2145 participants (Actual)Interventional2006-03-23Completed
Multi Center, Open Label, Single Arm Trial Evaluating Panitumumab in Combination With FOLFIRI Therapy Following First Line FOLFOX and Bevacizumab Treatment of Metastatic Colorectal Cancer[NCT00411450]Phase 2116 participants (Actual)Interventional2006-11-30Completed
First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial[NCT00003287]Phase 3554 participants (Anticipated)Interventional1998-03-31Completed
A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma[NCT04000737]Phase 2125 participants (Anticipated)Interventional2020-01-10Recruiting
Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246]Phase 266 participants (Anticipated)Interventional2022-12-08Active, not recruiting
A Randomized Placebo-Controlled Study of Perifosine in Combination With Single Agent Chemotherapy for Metastatic Cancer Patients[NCT00398879]Phase 2381 participants (Actual)Interventional2005-08-31Completed
A Phase 2, Open-label, Randomized Clinical Trial of Skin Toxicity Treatment in Subjects Receiving Second-line FOLFIRI or Irinotecan Only Chemotherapy Concomitantly With Panitumumab[NCT00332163]Phase 295 participants (Actual)Interventional2006-04-30Completed
Intravital Microscopy (IVM) in Human Solid Tumors[NCT03823144]50 participants (Anticipated)Interventional2019-02-28Recruiting
Intravital Microscopy (IVM) in Patients With Peritoneal Carcinomatosis (PC)[NCT03517852]30 participants (Actual)Interventional2018-08-15Active, not recruiting
Circulating Tumor DNA (ctDNA) as a Assisted Diagnosis, Early Intervention and Prognostic Marker for Peritoneal Metastases From Colorectal Cancer: A Prospective, Open-label, Randomized Controlled Study[NCT04752930]138 participants (Anticipated)Interventional2020-08-24Recruiting
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin With 5-FU/LV Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer[NCT00612586]Phase 2117 participants (Actual)Interventional2008-02-29Completed
A Randomized Phase III Study of Irinotecan Plus 5-fluorouracil Plus Leucovorin and Bevacizumab (FOLFIRI+Avastin) Versus Irinotecan Plus Capecitabine and Bevacizumab (XELIRI+Avastin) as 1st Line Treatment of Locally Advanced or Metastatic Colorectal Cancer[NCT00469443]Phase 3330 participants (Anticipated)Interventional2006-12-31Completed
Phase II Study of the Combination of Cetuximab, Capecitabine, and Oxaliplatin With Out Without Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer[NCT00321100]Phase 223 participants (Actual)Interventional2006-04-12Terminated (stopped due to Enrollment closed 10/15/2008 based on data about KRAS.)
A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer[NCT00483834]Phase 250 participants (Actual)Interventional2006-12-31Completed
METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin[NCT03388190]Phase 280 participants (Actual)Interventional2018-05-29Active, not recruiting
Phase II Stereotactic Body Radiotherapy (SBRT) and Stereotactic Hypofractionated Radiotherapy (SHRT) for Oligometastatic Prostate Cancer[NCT01859221]39 participants (Actual)Interventional2013-05-31Completed
A Phase II Study Of Sunitinib In Combination With Irinotecan, L-leucovorin, And 5-Fluorouracil In Patients With Unresectable Or Metastatic Colorectal Cancer[NCT00668863]Phase 271 participants (Actual)Interventional2008-05-31Completed
Surveillance of Metabolic Parameters in Patients Who Will Receive Chemotherapy After Surgical Resection of Colorectal Cancer: KBSMC Colon Cancer Cohort[NCT02700555]23 participants (Actual)Observational [Patient Registry]2016-02-29Terminated (stopped due to The patient's study enrollment was too low.)
Clinical Study of Dynamic Contrast-enhanced Magnetic Resonance Imaging Combined With IVIM-DWI for Early Prediction of Chemosensitivity in Liver Metastasis of Breast Cance[NCT05550090]40 participants (Anticipated)Observational2022-09-16Recruiting
Phase II Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer[NCT00159432]Phase 263 participants (Actual)Interventional2005-02-28Completed
Efficacy and Safety of Second-line Combination Chemotherapy With Avastin in Patients With Metastatic Colorectal Cancer Who Have Received First-line Chemotherapy Plus Avastin[NCT00862342]Phase 278 participants (Actual)Interventional2009-01-31Completed
The Effect of ATP-Binding Cassette C2 (ABCC2) Transporter Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin -Based Chemotherapy[NCT05494320]120 participants (Anticipated)Observational2021-08-15Recruiting
FOLFOX and Bevacizumab With or Without Irinotecan in First-line Treatment for Metastatic Colorectal Cancer. A Randomized Phase II Study[NCT01321957]Phase 2250 participants (Actual)Interventional2011-05-31Completed
Perioperative FOLFOXIRI and Bevacizumab Compared With Postoperative FOLFOX in Patients With Resectable Liver Metastases From Colorectal Cancer (PERIMAX). A Randomized, Multidisciplinary DGAV(CAO-V/CALGP)/AIO Phase II Trial[NCT01540435]Phase 20 participants (Actual)Interventional2012-09-30Withdrawn (stopped due to insufficient recruitment)
Retrospective Validation for Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy With S-1[NCT01905969]500 participants (Anticipated)Observational2012-10-31Active, not recruiting
A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer Who Have Failed First-Line Therapy[NCT02045030]Phase 214 participants (Actual)Interventional2014-01-31Terminated (stopped due to Drug (Aflibercept) no longuer available for the study)
Feasibility of Switching Fluoropyrimidine Due to Cardiotoxicity in Patients With Solid Tumors: A Retrospective, International and Non-interventional Study[NCT04260269]200 participants (Anticipated)Observational2018-06-01Enrolling by invitation
Chemotherapy-Related Changes in Neurocognitive Function and Symptoms in Colorectal Cancer Patients: A Pilot Study[NCT03683004]40 participants (Actual)Observational2018-01-22Completed
A Dose-escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Aflibercept in Combination With Intravenous Irinotecan/5-fluorouracil/Isovorin (FOLFIRI) Administered Every 2 Weeks in Patients With Metastatic Colorectal Cancer[NCT00921661]Phase 116 participants (Actual)Interventional2009-06-30Completed
A Multicenter, Randomised, Double-Blind, Phase 3 Study Of Sunitinib In Metastatic Colorectal Cancer Patients Receiving Irinotecan, 5-Fluorouracil And Leucovorin (FOLFIRI) As First Line Treatment[NCT00457691]Phase 3768 participants (Actual)Interventional2007-06-30Completed
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma[NCT00752570]Phase 2144 participants (Actual)Interventional2008-11-30Completed
Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients: An Open-label, Single-arm, Multicenter Phase II Study[NCT03053167]Phase 2100 participants (Anticipated)Interventional2016-12-31Recruiting
A Phase II Trial of 5-Fluorouracil Plus 776C85 in Patients With Advanced Resistant Colorectal Cancer[NCT00003254]Phase 275 participants (Actual)Interventional1998-04-30Completed
Candidate Gene Polymorphisms and Response to Rituximab-CHOP in Patients With Diffuse Large Cell Lymphoma[NCT00590941]52 participants (Actual)Interventional2005-02-28Completed
Usefulness of Extracorporeal Removal of sFlt-1 in Women With Severe Preeclampsia at Less Than 26 Weeks' Gestation[NCT02286284]Phase 22 participants (Actual)Interventional2015-03-31Terminated (stopped due to Safety of patients : CSI recommandation and promotor decision)
Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial.[NCT03289728]1,756 participants (Anticipated)Interventional2018-04-04Recruiting
Effect of Short-duration Preoperative Neoadjuvant Therapy With FOLFOX Based Therapy on Morbidity After Liver Resection for Colorectal Cancer Metastases[NCT00537823]Phase 29 participants (Actual)Interventional2007-06-30Terminated (stopped due to Poor accrual.)
Phase Ib Study of the Safety and Pharmacokinetics of Chemoembolization With Irinotecan-Eluting Beads for the Treatment of Hepatic Metastases[NCT01336985]Phase 15 participants (Actual)Interventional2011-03-28Terminated
A Phase II Trial of Eloxatin in Combination With 5-Fluorouracil and Leucovorin in Patients With Advanced Colorectal Carcinoma[NCT00004102]Phase 20 participants Interventional1999-01-31Completed
Clinical Significance of Genetic Markers in Colon Cancer[NCT00014079]675 participants (Actual)Observational1997-09-30Completed
The Predictive Value of Guangzhou Panel for Recurrence in Early-stage Colorectal Cancer[NCT03923335]287 participants (Anticipated)Observational2019-04-30Not yet recruiting
Multicenter, Phase II Study of Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly[NCT02992886]Phase 268 participants (Actual)Interventional2016-09-30Completed
A Prospective, Randomized, Active-Control, Multi-Center Study Assessing Overall Survival Using Chemotherapy With or Without Impedance-Based Radiofrequency Ablation for Subjects With Colorectal Cancer and Incurable Metastatic Liver Disease, Failing at Leas[NCT00510627]Phase 40 participants (Actual)Interventional2007-08-31Withdrawn (stopped due to Boston Scientific has decided to close the Study.)
A Phase II Study to Assess Efficacy and Safety of Capecitabine and Irinotecan Plus Bevacizumab Followed by Capecitabine and Oxaliplatin Plus Bevacizumab or the Reverse Sequence in Patients With Metastatic Colorectal Cancer[NCT02119026]Phase 2120 participants (Actual)Interventional2011-02-28Completed
Vitro 3D Drug Sensitivity Detection of Micro Tumor (PTC) Combined With Tumor Whole Exon (WES) Sequencing Technology to Guide Postoperative Adjuvant Treatment Strategy and Prognosis of Colorectal Cancer[NCT05424692]200 participants (Anticipated)Interventional2021-09-01Recruiting
A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330]Phase 260 participants (Actual)Interventional2007-02-28Completed
Multicenter Phase II Trial of Oxaliplatin and Docetaxel for Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck[NCT00557206]Phase 235 participants (Actual)Interventional2005-04-30Terminated (stopped due to Funding was terminated)
Efficacy and Safety of Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma[NCT04059562]Phase 228 participants (Anticipated)Interventional2021-10-28Active, not recruiting
Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529]Phase 228 participants (Anticipated)Interventional2021-03-01Recruiting
Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer[NCT00714077]570 participants (Anticipated)Observational2008-04-30Recruiting
A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer[NCT00531245]Phase 1/Phase 277 participants (Anticipated)Interventional2006-08-31Completed
Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian and Primary Peritoneal Carcinoma[NCT00868192]Phase 238 participants (Actual)Interventional2008-05-31Completed
Medical and Economical Evaluation of Contrast-enhanced Ultrasound Imaging for the Early Estimate of Bevacizumab Effect on Colorectal Cancer Liver Metastases[NCT00489697]200 participants (Anticipated)Interventional2007-01-31Completed
The Effects of Exercise Training on Tumor Vascularity and Response to Neoadjuvant Therapy in Operable Breast Cancer: A Phase I-II Study[NCT00405678]Phase 1/Phase 223 participants (Actual)Interventional2006-09-30Completed
Phase I Study Evaluating the Safety of Bevacizumab in Women With a History of Breast Cancer Suffering From Moderate to Severe Upper Extremity Lymphedema[NCT00318513]Phase 135 participants InterventionalNot yet recruiting
Angiogenesis Inhibitors and Hypertension: Clinical Aspects[NCT00511511]80 participants (Anticipated)Observational2007-08-31Completed
A Pilot Study to Evaluate the Effects of Antiangiogenic Factor as an Adjunct Treatment After Photoangiolysis in Patients With Bilateral Recurrent Respiratory Papillomatosis of the Vocal Fold[NCT01020747]Phase 120 participants (Actual)Interventional2009-11-30Completed
A Phase II Safety and Tolerability Study of Avastin When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain[NCT00476827]Phase 216 participants (Actual)Interventional2007-05-31Terminated (stopped due to Slow accrual)
A Prospective, Phase II Trial of Intravenous Bevacizumab (Avastin) for the Prevention of Recurrent Malignant Ascites[NCT00908219]Phase 20 participants (Actual)Interventional2009-07-31Withdrawn (stopped due to Accrual closed by sponsor due to lack of accrual and study progress)
Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study[NCT00462423]Phase 250 participants (Actual)Interventional2007-04-30Completed
Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer[NCT01152710]Phase 257 participants (Actual)Interventional2004-06-30Completed
Retrospective Analysis of Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer[NCT01025349]Phase 220 participants (Actual)Interventional2005-01-31Completed
A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficienc[NCT02784067]Phase 40 participants (Actual)Interventional2016-05-31Withdrawn (stopped due to Clinical Trial Material)
A Phase II Study of Picoplatin as Second-Line Therapy for Subjects With Resistant or Refractory Small Cell Lung Cancer[NCT00116610]Phase 275 participants Interventional2005-06-30Completed
A Phase I Open-Label Study of Picoplatin in Combination With 5-Fluorouracil and Leucovorin as Initial Therapy in Subjects With Metastatic Colorectal Cancer[NCT00478946]Phase 1/Phase 243 participants (Anticipated)Interventional2006-04-30Active, not recruiting
Phase 3 Study of Enteral Nutrition Rich in Eicosapentaenoic Acid in Patients Receiving Chemotherapy for Gastric Cancer or Colorectal Cancer[NCT01048463]Phase 390 participants (Anticipated)Interventional2009-12-31Recruiting
A Randomized Phase II Trial Of Capecitabine And Different Schedules Of Irinotecan As First Line Treatment For Advanced Or Metastatic Colorectal Cancer[NCT00030797]Phase 275 participants (Actual)Interventional2001-02-28Completed
A Phase II Study of Oral Xeloda (Capecitabine) in Combination With Intravenous Irinotecan for Patients With Locally Advanced and/or Metastatic Colorectal Cancer[NCT00022698]Phase 267 participants (Actual)Interventional2001-05-31Completed
Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma[NCT01525069]Phase 127 participants (Actual)Interventional2012-04-03Terminated (stopped due to Equipment that was used in the study was discontinued)
A Randomized Crossover Trial Comparing Oral Capecitabine and Intravenous Fluorouracil + Folinic Acid (Nordic FU/FA Regimen) for Patient Preference in Colorectal Cancer[NCT00212589]Phase 360 participants Interventional2002-12-31Completed
Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients[NCT01584544]Phase 124 participants (Actual)Interventional2011-01-31Completed
CPT-11 in Combination With Weekly 24 Hour Infusion 5-FU Plus Folinic Acid Relative to Weekly 24 Hour Infusion 5-FU Plus Folinic Acid Alone in Patients With Advanced Colorectal Cancer[NCT00004885]Phase 3430 participants (Actual)Interventional1999-07-31Completed
Standardization of Laparoscopic Surgery for Right Hemi Colon Cancer (SLRC)[NCT02942238]582 participants (Anticipated)Interventional2017-01-31Not yet recruiting
Chemotherapy Intra-Arterial Hepatic With Oxaliplatin Combined With Leucovorin Calcium and Fluorouracil IV[NCT00006050]Phase 20 participants Interventional1999-04-04Completed
A Phase II, Randomized, Open-label, Controlled, Dose-elevation, Multicenter Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Patients With Previously Untreated Metastatic Colorectal [NCT00040391]Phase 20 participants Interventional2002-06-30Terminated
Estudo Randomizado de Fase II Com Capecitabina Versus 5-Fluorouracil/Leucovorin em Bolus Associados à Radioterapia no Tratamento Neoadjuvante de câncer de Reto Localmente avançado: INCAGI004.[NCT03428529]Phase 2/Phase 363 participants (Actual)Interventional2011-01-12Completed
A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum (Per 04/99 Amendment) Old Title: A Phase II Study of Patients With Unresectable Metastatic Adenocarcinoma of the Colon or Rectum Confined to the Liver[NCT00003834]Phase 244 participants (Actual)Interventional1999-03-31Completed
A Phase III Study of Immediate Versus Delayed Chemotherapy for Asymptomatic Advanced Colorectal Cancer[NCT00002570]Phase 367 participants (Actual)Interventional1994-07-15Completed
A Randomized Study Of Continuous FOLFOX4 vs. FOLFOX4 in a Stop-and-Go Fashion in 1st Line Advanced Colorectal Cancer[NCT01023633]Phase 4300 participants (Anticipated)Interventional2009-10-31Recruiting
PHASE III STUDY OF HEPATIC ARTERY FLOXURIDINE (FUDR), LEUCOVORIN (LV), AND DEXAMETHASONE (DEX) VERSUS SYSTEMIC 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) AS TREATMENT FOR HEPATIC METASTASES FROM COLORECTAL CANCER[NCT00002716]Phase 3135 participants (Actual)Interventional1996-01-31Completed
A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268]Phase 1/Phase 2100 participants (Anticipated)Interventional2021-11-30Not yet recruiting
A Phase 1/Phase 2 Study for the Prevention of Oral Mucositis (SPOM)[NCT05338398]Phase 1/Phase 2100 participants (Anticipated)Interventional2022-04-15Enrolling by invitation
Phase I Study of Multiple Ascending Dose, to Investigate the Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy[NCT05308732]Phase 136 participants (Anticipated)Interventional2021-05-11Recruiting
A Phase II Study of OSI-774 (Tarceva) in Combination With Oxaliplatin and Capecitabine in Previously Treated Patients With Stage IV Colorectal Cancer[NCT00123851]Phase 232 participants Interventional2003-03-31Completed
A Phase II Trial of Neoadjuvant Capecitabine, Oxaliplatin, and Bevacizumab for Resectable Colorectal Metastases in the Liver[NCT00118105]Phase 20 participants (Actual)Interventional2006-11-30Withdrawn (stopped due to Budget Constraints)
A Multicenter Study of the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin®) Plus 5-Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancers That Have Progressed After Standard Chemotherapy[NCT00066846]Phase 20 participants Interventional2003-08-31Completed
A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916]Phase 242 participants (Actual)Interventional2015-07-31Completed
A Randomised Study of Sequential Versus Combination Chemotherapy in Patients With Previously Untreated Advanced Colorectal Carcinoma[NCT00312000]Phase 3820 participants (Actual)Interventional2003-01-31Completed
Phase II Trial of Fluorouracil (5-FU), Leucovorin (LV), Irinotecan (CPT-11) and Bevacizumab (Anti-VEGF) in Previously Untreated Patients With Advanced Colorectal Cancer[NCT00006786]Phase 20 participants Interventional2000-11-30Completed
Harnessing Chronomodulation to Enhance Osteogenesis - A Pilot Randomized Controlled Trial -[NCT03911336]Phase 40 participants (Actual)Interventional2023-01-01Withdrawn (stopped due to Decided not to proceed)
The Kinetics of Endocannabinoids in Patients With Chemotherapy Induced Peripheral Neuropathy by Using a Portable Metered-Dose Cannabis Inhaler[NCT04376437]40 participants (Anticipated)Interventional2022-03-15Not yet recruiting
A Phase I Study Of ZD1839 (Iressa) In Combination With Irinotecan, Leucovorin, And 5-Fluorouracil In Previously Untreated, Stage IV Colorectal Cancer[NCT00026364]Phase 122 participants (Actual)Interventional2001-11-30Completed
A Phase II Of An Optimized LV-5FU-Oxaliplatin Strategy With Celebrex In Metastatic Colorectal Cancer, Optimox2-Celecoxib Study[NCT00072553]Phase 20 participants Interventional2003-09-30Active, not recruiting
A Phase II Study of Perioperative QBECO Site Specific Immunomodulator (Qu Biologics®) in Patients With Metastatic Colorectal Adenocarcinoma Within the Liver Undergoing Resection[NCT05677113]Phase 2115 participants (Anticipated)Interventional2023-08-30Recruiting
Construction and Evaluation of the Early Identification for Oxaliplatin Induced Portal Hypertension[NCT04524650]370 participants (Anticipated)Observational2020-08-31Not yet recruiting
Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449]Phase 3338 participants (Actual)Interventional2012-12-31Completed
Coala-T-CBD Study: A Study of the Effect of Hemp-CBD on the Severity and Duration of Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Neurotoxic Chemotherapy for Non-Metastatic Breast, Uterine, Pancreatic, and Colorectal Cancer and All Sta[NCT04398446]Phase 256 participants (Actual)Interventional2020-05-27Active, not recruiting
mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or Stage IIIC Colorectal Cancer: A Randomized Controlled Clinical Research[NCT05200299]Phase 2100 participants (Anticipated)Interventional2022-02-01Recruiting
A Clinical Trial of the Safety and Efficacy of ABX-EGF in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil in Subjects With Metastatic Colorectal Cancer[NCT00111761]Phase 243 participants (Actual)Interventional2002-07-31Completed
Phase II Trial Of Irinotecan + 5-Fluorouracil + Leucovorin + Oxaliplatin As First-Line Treatment For Metastatic Colorectal Cancer[NCT00080951]Phase 214 participants (Actual)Interventional2004-03-31Completed
Randomized Phase II Study Evaluating Three Chemotherapies: [Irinotecan + Oxaliplatin (Irinox)], [Irinotecan + LV5FU2] and [Oxaliplatin + LV5FU2] as First Intention Treatment in Subjects With Metastatic Colorectal Cancer[NCT00066274]Phase 20 participants Interventional2002-07-23Completed
The Influence of Probiotics on Vancomycin-Resistant Enterococcus[NCT00591474]8 participants (Actual)Interventional2007-12-31Terminated (stopped due to Participant lost to followup)
A Double-blind Placebo-controlled Evaluation of Ropivacaine Efficacy by Local Per and Post Hepatectomy Infiltrations for Adult Pain Management[NCT01194843]85 participants (Actual)Interventional2009-03-31Completed
Irinotecan Combined With Infusional 5-FU/Folinic Acid or Capecitabine and the Role of Celecoxib in Patients With Metastatic Colorectal Cancer[NCT00064181]Phase 386 participants (Actual)Interventional2003-05-31Completed
A UKCCCR Study of Adjuvant Chemotherapy for Colorectal Cancer[NCT00005586]Phase 32,500 participants (Anticipated)Interventional1997-10-31Completed
Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. A Proof-of-concept Study[NCT04189055]Phase 272 participants (Anticipated)Interventional2020-01-07Recruiting
FOcUs on Colorectal CAncer oUtcomes: Long-Term Study[NCT03965325]300 participants (Anticipated)Observational2019-06-07Recruiting
[NCT02748772]Phase 3148 participants (Anticipated)Interventional2016-01-31Recruiting
Long-term Evaluation of the Quality of Life After Major Hepatic Resection for Malignant and Benign Diseases.[NCT00681499]198 participants (Actual)Observational2008-02-29Completed
A Phase I Trial of ZD1694 (TOMUDEX® (Registered Trademark)), an Inhibitor of Thymidylate Synthase, in Pediatric Patients With Advanced Neoplastic Disease[NCT00001341]Phase 160 participants Interventional1993-09-30Completed
A Randomized, Controlled Phase II Clinical Trial of Fruquintinib Combined With Raltitrexed Versus Fruquintinib Monotherapy in Patients With Advanced Colorectal Cancer Who Had Failed Second-line or Above Standard Chemotherapy[NCT04582981]Phase 2136 participants (Anticipated)Interventional2020-09-28Recruiting
The Optimisation of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer[NCT00943137]Phase 255 participants (Anticipated)Interventional2009-06-30Active, not recruiting
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the HIV-1 DNA Vaccine VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade Env) With the Plasmid Cytokine Adjuvant VRC-ADJDNA004-IL2-VP (IL-2/Ig)[NCT00069030]Phase 170 participants (Actual)Interventional2003-12-31Completed
Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II.[NCT03562897]Phase 240 participants (Actual)Interventional2018-10-25Completed
A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer[NCT01396707]Phase 255 participants (Actual)Interventional2011-06-30Completed
Short-term Effects of Laparoscopic-assisted Small-incision Surgery Versus Conventional Laparotomy in Treatment of Resectable Colorectal Liver Metastasis[NCT02350166]Phase 340 participants (Anticipated)Interventional2013-11-30Recruiting
A Prospective Random Assignment Trial to Study Operative Debulking and Systemic Chemotherapy With or Without Intra-and Peri-Operative Intraperitoneal Chemotherapy for Subjects With Peritoneal Carcinomatosis From Low Grade Gastrointestinal Adenocarcinoma[NCT00052962]Phase 330 participants (Actual)Interventional2003-01-31Completed
A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase[NCT00248404]Phase 1/Phase 2155 participants (Anticipated)Interventional2005-09-30Completed
Phase 2 Prospective Randomized Double Blind Trial Comparing Metastasectomy Plus Sulindac Versus Metastasectomy Alone in Patients With Stage IV Colorectal Cancer[NCT01856322]Phase 23 participants (Actual)Interventional2013-04-30Terminated (stopped due to The trial was prematurely closed due to lack of accrual.)
A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).[NCT05927857]Phase 1/Phase 245 participants (Anticipated)Interventional2023-09-01Not yet recruiting
Randomized Phase II Trial of Fluorouracil and Folinic Acid With or Without Liposomal Irinotecan (ONIVYDE) for Patients With Metastatic Biliary Tract Cancer Which Progressed Following Gemcitabine Plus Cisplatin[NCT03524508]Phase 2178 participants (Actual)Interventional2018-09-04Completed
Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma[NCT00379262]Phase 3803 participants (Actual)Interventional2006-09-30Completed
A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas[NCT00763516]8 participants (Actual)Interventional2009-02-28Completed
A Study Using Photon/Proton Beam Radiation Therapy and Chemotherapy for Unresectable Carcinoma of the Pancreas[NCT00685763]13 participants (Actual)Interventional2008-03-31Completed
A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome[NCT01291628]10 participants (Anticipated)Interventional2012-01-31Not yet recruiting
Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320]Phase 2200 participants (Actual)Interventional2015-10-05Active, not recruiting
A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases[NCT01042691]Phase 110 participants (Actual)Interventional2003-05-31Completed
Aromatase Inhibitors Plus Metronomic Capecitabine in Treatment of Patients With Recurrent or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer[NCT04942899]Phase 270 participants (Anticipated)Interventional2023-08-30Not yet recruiting
A Phase I-II Study of Capecitabine and Oxaliplatin in Chemotherapy-Naive and Thymidylate Synthase Inhibitor Pretreated Advanced or Metastatic Colorectal Cancer[NCT00004187]Phase 1/Phase 20 participants Interventional1999-06-30Completed
A Phase I Study of Capecitabine In Patients With Solid Tumors[NCT00697502]Phase 123 participants (Actual)Interventional2007-05-31Completed
The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma.[NCT00674167]Phase 221 participants (Actual)Interventional2007-05-31Active, not recruiting
Prospective, Randomized Study Aiming to Assess the Benefit of Autohypnosis Learning in the Care of Patients Treated by Adjuvant Chemotherapy for Colorectal or Breast Cancer.[NCT03429296]120 participants (Actual)Interventional2018-05-23Completed
A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer[NCT01045538]Phase 1/Phase 245 participants (Actual)Interventional2010-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Disease Control Rate (DCR)

Disease control is defined as maintaining Complete Response (CR) or Partial Response (PR) or Stable Disease (SD) as the tumor assessment result during the defined time window. DCR (percentage) is defined as number of patients with success of disease control divided by total number of patients in the analysis population multiplied by 100, excluding patients who refuse treatment before the initiation of any treatment. CR: Disappearance of all evidence of disease, PR: Regression of measurable disease and no new sites, PD: Any new lesion or increase by ≥50% of previously involved sites from nadir, SD: Neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD taking as reference the MSD (NCT02292758)
Timeframe: Up to 2 years

Interventionpercentage of participants (Number)
Arm I (Irinotecan, Cetuximab, Bevacizumab)68.4
Arm II (Irinotecan, Cetuximab, Placebo)52.9

Duration of Response (DOR)

The distribution of DOR by treatment group will be estimated using the method of Kaplan-Meier. Six and 12 month durable response (i.e. maintaining CR or PR without progressive disease [PD]) rates by treatment group with confidence intervals will be estimated based on Kaplan-Meier curves. The HR with confidence interval will be estimated based on stratified Cox models (stratified by levels of stratification factors), without and with adjusting for baseline clinical/pathological factors.CR: Disappearance of all evidence of disease, PR: Regression of measurable disease and no new sites, PD: Any new lesion or increase by ≥50% of previously involved sites from nadir (NCT02292758)
Timeframe: From the date of first tumor assessment with the response status being CR or PR to the date of 1st documented progressive disease, assessed up to 12 months

Interventionmonths (Median)
Arm I (Irinotecan, Cetuximab, Bevacizumab)9.2
Arm II (Irinotecan, Cetuximab, Placebo)9.7

Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Events

The number of participants who experienced at least one grade 3 or higher adverse events assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. (NCT02292758)
Timeframe: Up to 30 days from last dose of study treatment

InterventionParticipants (Count of Participants)
Arm I (Irinotecan, Cetuximab, Bevacizumab)9
Arm II (Irinotecan, Cetuximab, Placebo)6

Overall Response Rate (ORR)

The response rate (percentage) is the percent of participants whose best response was Complete Response (CR) or Partial Response (PR) as defined by RECIST 1.1 criteria. Percentage of successes will be estimated by 100 times the number of successes divided by the total number of evaluable patients. Response rates (including complete and partial response) will be tested using Fisher's exact test. CR: Disappearance of all evidence of disease, PR: Regression of measurable disease and no new sites (NCT02292758)
Timeframe: Up to 2 years

Interventionpercentage of participants (Number)
Arm I (Irinotecan, Cetuximab, Bevacizumab)36.8
Arm II (Irinotecan, Cetuximab, Placebo)11.8

Overall Survival (OS)

The distribution of OS by group will be estimated using the method of Kaplan-Meier. Median OS by treatment group with confidence intervals will be estimated based on Kaplan-Meier curves. The HR with confidence interval will be estimated based on stratified Cox models (stratified by levels of stratification factors), without and with adjusting for baseline clinical/pathological factors. (NCT02292758)
Timeframe: From randomization to the date of death due to any cause, assessed up to 24 months

Interventionmonths (Median)
Arm I (Irinotecan, Cetuximab, Bevacizumab)19.7
Arm II (Irinotecan, Cetuximab, Placebo)10.2

Percentage of Participants With Treatment Failure at 6 Months

TTF is defined as the time from the date of randomization to the date of treatment discontinuation due to PD, death, or severe AE. The distribution of TTF by treatment group will be estimated using the method of Kaplan-Meier. Six month event-free rates by treatment group with confidence intervals will be estimated based on Kaplan-Meier curves. The HR with confidence interval will be estimated based on stratified Cox models (stratified by levels of stratification factors), without and with adjusting for baseline clinical/pathological factors. PD: Any new lesion or increase by ≥50% of previously involved sites from nadir (NCT02292758)
Timeframe: assessed at 6 months

Interventionpercentage of participants (Number)
Arm I (Irinotecan, Cetuximab, Bevacizumab)72.7
Arm II (Irinotecan, Cetuximab, Placebo)38.4

Progression-Free Survival (PFS)

The distribution of PFS by group will be estimated using the method of Kaplan-Meier. Median by treatment group with confidence intervals will be estimated based on Kaplan-Meier curves. The hazard ratio (HR) with confidence interval will be estimated based on stratified Cox models (stratified by levels of stratification factors), without and with adjusting for baseline clinical/pathological factors. Progression (PD) is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. PD: Any new lesion or increase by ≥50% of previously involved sites from nadir). (NCT02292758)
Timeframe: From the date of randomization to the date of 1st documented disease progression or death due to any cause, whichever occurs first, assessed up to 24 months

Interventionmonths (Median)
Arm I (Irinotecan, Cetuximab, Bevacizumab)9.7
Arm II (Irinotecan, Cetuximab, Placebo)5.5

12-month, 18-month, and 24-month Overall Survival (OS) Rates

The distribution of OS by group will be estimated using the method of Kaplan-Meier. Twelve, 18- and 24-month survival rates by treatment group with confidence intervals will be estimated based on Kaplan-Meier curves. The HR with confidence interval will be estimated based on stratified Cox models (stratified by levels of stratification factors), without and with adjusting for baseline clinical/pathological factors. (NCT02292758)
Timeframe: From randomization to the date of death due to any cause, assessed up to 24 months

,
Interventionpercentage of participants (Number)
12-month OS rate18-month OS rate24-month OS rate
Arm I (Irinotecan, Cetuximab, Bevacizumab)77.256.114.0
Arm II (Irinotecan, Cetuximab, Placebo)47.111.85.9

6-month and 12-month Progression-free Survival (PFS) Rates

The distribution of PFS by group will be estimated using the method of Kaplan-Meier. Six and 12 month PFS rates by treatment group with confidence intervals will be estimated based on Kaplan-Meier curves. The hazard ratio (HR) with confidence interval will be estimated based on stratified Cox models (stratified by levels of stratification factors), without and with adjusting for baseline clinical/pathological factors. Progression (PD) is defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. PD: Any new lesion or increase by ≥50% of previously involved sites from nadir). (NCT02292758)
Timeframe: From the date of randomization to the date of 1st documented disease progression or death due to any cause, whichever occurs first, assessed up to 24 months

,
Interventionpercentage of participants (Number)
6-month PFS rate12-month PFS rate
Arm I (Irinotecan, Cetuximab, Bevacizumab)76.527.5
Arm II (Irinotecan, Cetuximab, Placebo)41.217.6

Relative Dose Intensity (RDI)

RDI is defined as the total dose of protocol therapy a patient actually received (i.e., summation of actually received dose at each cycle) divided by the total planned dose (i.e., summation of planned dose level at each cycle) multiplied by 100. Separate RDIs will be calculated for irinotecan and cetuximab. Agent-specific RDI will be summarized by medians, and min and max values, all of which will be compared between the two treatment groups by the Wilcoxon Rank sum test. (NCT02292758)
Timeframe: Up to 2 years

,
Interventionpercentage of dose received (Median)
CetuximabIrinotecan
Arm I (Irinotecan, Cetuximab, Bevacizumab)98.589
Arm II (Irinotecan, Cetuximab, Placebo)95.590

Objective Response Rate (ORR)

ORR is defined as the proportion of participants with a complete response (CR) or partial response (PR) as determined by a investigator assessment based on Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1. (NCT03368859)
Timeframe: From randomization up to 30 days after last dose of study drug; median time on follow-up was 25.6 (0.3 - 64.4) and 37.6 (0.3 - 66.3) weeks in ABT-165 plus FOLFIRI and Bevacizumab plus FOLFIRI, respectively

Interventionpercentage of participants (Number)
ABT-165 Plus FOLFIRI5.6
Bevacizumab Plus FOLFIRI14.7

Overall Survival (OS)

OS is defined as the time from randomization until death from any cause. (NCT03368859)
Timeframe: Follow up continued until the first occurrence of radiographic progression, death from any cause or termination of the study; median follow-up time was 25.6(0.3-64.4) and 37.6(0.3-66.3) weeks in ABT-165 plus FOLFIRI and Bevacizumab + FOLFIRI, respectively

InterventionMonths (Median)
ABT-165 Plus FOLFIRI7.95
Bevacizumab Plus FOLFIRINA

Progression Free Survival (PFS)

PFS is defined as the time from randomization until the first occurrence of radiographic progression determined by investigator assessment or death from any cause. (NCT03368859)
Timeframe: Follow up continued until the first occurrence of radiographic progression, death from any cause or termination of the study; median follow-up time was 25.6(0.3-64.4) and 37.6(0.3-66.3) weeks in ABT-165 plus FOLFIRI and Bevacizumab + FOLFIRI, respectively

InterventionMonths (Median)
ABT-165 Plus FOLFIRI3.78
Bevacizumab Plus FOLFIRI7.36

Overall Survival (OS)

OS was defined as the time from the day of randomization (Day 0) until death by all causes. (NCT02337946)
Timeframe: Up to approximately 31 months

Interventionmonths (Median)
Group ANA
Group BNA

Percentage of Participants With Adverse Events

Safety population was defined as all participants who received at least one dose of protocol treatment after randomization. (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)

Interventionpercentage of participants (Number)
Group A100
Group B100

Percentage of Participants With Grade 2 or Higher Peripheral Neuropathy

"Peripheral neuropathy was defined as events classified with a preferred term (PT) of peripheral neuropathy according to Standardized MedDRA Queries." (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)

Interventionpercentage of participants (Number)
Group A30.4
Group B3.7

Progression-Free Survival (PFS)

The PFS is the period from the date of randomization (Day 0) until the date of judgment of progression from the date of randomization, or until death by all causes, whichever comes first. The presence/absence of progressive disease (PD) was determined based on imaging, consideration of clinical PD, or survival research results. PD based on response evaluation criteria in solid tumors (RECIST) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT02337946)
Timeframe: Up to approximately 31 months

Interventionmonths (Median)
Group A9.1
Group B9.3

Progression-Free Survival Rate (PFS Rate) at 9 Months After Randomization

PFS rate was defined as the gross percentage of participants who survived with no evidence of progression from the day of randomization (Day 0) until 9 months after Day 0. The presence/absence of progressive disease (PD) was determined based on imaging, consideration of clinical PD, or survival research results. PD based on response evaluation criteria in solid tumors (RECIST) is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT02337946)
Timeframe: Up to 9 months after randomization

Interventionpercentage of participants (Number)
Group A46.4
Group B47.4

Response Rate (RR)

RR was defined as the percentage of participants who had shown complete response (CR) or partial response (PR) as the best overall response in accordance with the RECIST 1.1 criteria after randomization. The best overall response was CR, followed by PR, stable disease (SD), progressive disease (PD), and not evaluable (NE). CR: disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to <10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters as the best overall response after randomization., SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). (NCT02337946)
Timeframe: Up to approximately 31 months

Interventionpercentage of participants (Number)
Group A80.4
Group B87.7

Time to Treatment Failure (TTF)

TTF was defined as the time from the day of randomization (Day 0) until the day of protocol treatment discontinuation determination, the day of PD decision during protocol treatment, or death from any cause, whichever came the earliest. (NCT02337946)
Timeframe: Up to approximately 31 months

Interventionmonths (Median)
Group A8.1
Group B6.1

Percentage of Participants With Adverse Events by Severity Graded Using the Common Terminology Criteria for Adverse Events (CTCAE) Grade

An AE is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)

,
Interventionpercentage of participants (Number)
Grade 1Grade 2Grade 3, 4 and 5
Group A019.680.4
Group B027.872.2

Percentage of Participants With Grade 3 or Higher Skin Toxicity

"Skin toxicity was defined as events classified with an system organ class of Skin and subcutaneous tissue disorders or a preferred term of paronychia." (NCT02337946)
Timeframe: Up to 28 days after discontinuation of study drug or start of subsequent therapy (data cut off: 31 August 2017; Overall study completion date)

,
Interventionpercentage of participants (Number)
Skin and subcutaneous tissue disordersParonychia
Group A17.97.1
Group B18.59.3

Duration of Response

For participants with a confirmed objective response, the time from first confirmed objective response to radiologic disease progression per modified RECIST 1.0 criteria or death. For participants who responded and have not progressed or died, duration of response was censored at their last evaluable disease assessment date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Interventionmonths (Median)
Panitumumab Plus mFOLFOX610.0
Bevacizumab Plus mFOLFOX69.0

Overall Survival

Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Interventionmonths (Median)
Panitumumab Plus mFOLFOX6NA
Bevacizumab Plus mFOLFOX625.4

Overall Survival in Participants With Wild-type RAS

Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Interventionmonths (Median)
Panitumumab Plus mFOLFOX6NA
Bevacizumab Plus mFOLFOX629.0

Overall Survival in Participants With Wild-type RAS / BRAF

Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Interventionmonths (Median)
Panitumumab Plus mFOLFOX6NA
Bevacizumab Plus mFOLFOX629.0

Percentage of Participants With an Objective Response

Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Interventionpercentage of participants (Number)
Panitumumab Plus mFOLFOX657.75
Bevacizumab Plus mFOLFOX653.52

Percentage of Participants With an Objective Response for Participants With Wild-type RAS

"Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met.~Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions." (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Interventionpercentage of participants (Number)
Panitumumab Plus mFOLFOX663.64
Bevacizumab Plus mFOLFOX660.49

Percentage of Participants With an Objective Response for Participants With Wild-type RAS / BRAF

Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Interventionpercentage of participants (Number)
Panitumumab Plus mFOLFOX663.64
Bevacizumab Plus mFOLFOX661.54

Progression-free Survival (PFS)

PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Interventionmonths (Median)
Panitumumab Plus mFOLFOX610.9
Bevacizumab Plus mFOLFOX610.1

Progression-free Survival (PFS) in Participants With Wild-type RAS / V-raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Interventionmonths (Median)
Panitumumab Plus mFOLFOX613.1
Bevacizumab Plus mFOLFOX69.7

Progression-free Survival (PFS) in Participants With Wild-type Rat Sarcoma Viral Oncogene Homolog (RAS)

PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Interventionmonths (Median)
Panitumumab Plus mFOLFOX613.0
Bevacizumab Plus mFOLFOX69.5

Resection Rate

The resection rate was defined as the percentage of participants with a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Interventionpercentage of participants (Number)
Panitumumab Plus mFOLFOX612.68
Bevacizumab Plus mFOLFOX611.19

Time to Disease Progression

Time to progression (TTP) is defined as the time from randomization to the date of radiologic disease progression per modified RECIST 1.0 criteria. Participants not meeting criteria for disease progression by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Interventionmonths (Median)
Panitumumab Plus mFOLFOX611.0
Bevacizumab Plus mFOLFOX611.1

Time to Initial Objective Response

For participants with a confirmed objective response, the time from randomization to the date of first confirmed objective response. Assessments are based on the investigator's review of scans using a modified-RECIST v1.0. An objective response is defined as a best tumor response of complete or partial response. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. (NCT00819780)
Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Interventionmonths (Median)
Panitumumab Plus mFOLFOX61.8
Bevacizumab Plus mFOLFOX61.9

Number of Participants With Adverse Events (AEs)

Severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) v3.0, with the exception of some dermatology/skin adverse events that were graded using CTCAE v3.0 with modifications. Fatal adverse events are classified as grade 5. Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard. Treatment-related AEs were those that the investigator considered a reasonable possibility that might have been caused by study drug. (NCT00819780)
Timeframe: The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus mFOLFOX arm and 7.3 months for Bevacizumab Plus mFOLFOX6 arm.

,
Interventionparticipants (Number)
Any adverse event (AE)AE with worst grade of 3AE with worst grade of 4AE with worst grade of 5Serious adverse event (SAE)AE leading to discontinuation of study drugAny treatment-related adverse event (TRAE)Treatment-related AE with worst grade of 3Treatment-related AE with worst grade of 4Treatment-related AE with worst grade of 5Serious treatment-related adverse eventTRAE leading to discontinuation of study drug
Bevacizumab Plus mFOLFOX6139782895337136772522829
Panitumumab Plus mFOLFOX6139883176134138922433728

Disease Control Rate

"The percentage of participants whose best response was either a complete or partial response or stable disease, based on modified RECIST v1.0 criteria as assessed by the Investigator.~Stable diease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD of target lesions and no progression of existing non-target lesions and no new lesions, or, the persistence of 1 or more non-target lesions not qualifying for either CR or PD if no target lesions were identified at Baseline." (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks

Interventionpercentage of participants (Number)
Wild-type KRAS90.59
Mutant KRAS89.66

Duration of Response

Duration of response was calculated only for those participants who had a confirmed complete or partial response, and is defined as the time from first confirmed response to first observed progression. For participants who responded and did not progress by the analysis data cut-off date, duration of response was censored at their last evaluable disease assessment date. Duration of response was analyzed using the Kaplan-Meier method. (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.

Interventionmonths (Median)
Wild-type KRAS13.0
Mutant KRAS7.4

Duration of Stable Disease

Duration of stable disease was calculated only for participants with a best response of stable disease and is defined as the time from enrollment to first observed PD. For participants who did not progress by the analysis data cut-off date, duration of SD was censored at their last evaluable disease assessment date. Duration of stable disease was estimated using Kaplan-Meier methods. (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.

Interventionmonths (Median)
Wild-type KRAS5.9
Mutant KRAS6.1

Objective Response by 17 Weeks

The percentage of participants with a best response of complete response or partial response by Week 17. Disease assessments are based on investigator review of scans using modified RECIST V1.0 criteria. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Participants with no post-baseline assessment were considered non-responders. (NCT00508404)
Timeframe: Up to Week 17

Interventionpercentage of participants (Number)
Wild-type KRAS49.41
Mutant KRAS34.48

Objective Response Rate

"Objective response rate is defined as the percentage of participants with a best response of complete response or partial response. Disease assessments are based on investigator review of scans using modified Response Evaluation Criteria in Solid Tumors (RECIST) V1.0 criteria. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Participants with no post-baseline assessment were considered non-responders.~Complete Response (CR): disappearance of all target and non-target lesions and no new lesions.~Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions." (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks

Interventionpercentage of participants (Number)
Wild-type KRAS56.47
Mutant KRAS37.93

Progression-free Survival

Progression-free survival is the time from the date of enrollment to the date of first observed progression or death, whichever comes first. Participants who were alive and did not progress by the analysis data cut-off date were censored at the last evaluable disease assessment date. Progression-free survival was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.

Interventionmonths (Median)
Wild-type KRAS8.9
Mutant KRAS7.2

Resection Rate

The percentage of participants who underwent a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.

Interventionpercentage of participants (Number)
Wild-type KRAS15.12
Mutant KRAS6.78

Time to Disease Progression

Time to progression is the time from the enrollment date to the date of first observed progression. For participants who had not progressed by the analysis data cutoff date, time to progressive disease was censored at their last evaluable disease assessment date. Time to disease progression was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.

Interventionmonths (Median)
Wild-type KRAS11.2
Mutant KRAS7.3

Time to Disease Relapse Following Surgical Intervention

Calculated only for those participants who underwent surgical intervention, and defined as the time from the date of first post-intervention radiographic disease assessment to the date of first observed PD. Participants with no post-intervention disease assessment had their time to relapse set to zero and censored in the analysis. Participants that had evidence of progression / recurrence at their first post-intervention disease assessment had a time to relapse of zero. For participants who had not progressed by the analysis data cut-off date, time to relapse was censored at the date of their last evaluable disease assessment. Time to relapse was analyzed using Kaplan-Meier metjhods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.

Interventionmonths (Median)
Wild-type KRASNA
Mutant KRASNA

Time to Initial Objective Response

Time to response is the time from the date of enrollment to the date of first confirmed complete or partial response. Participants with a best response of stable disease at the analysis data cut-off date were censored at their last assessment of SD and participants with all other categories of best response were censored at the maximum observed time to a first confirmed response among all responders. Time to initial objective response was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: Tumor response was assessed at Week 8 and every 8 weeks to Week 48 and 3 monthly thereafter until disease progression; median follow-up time was 34 weeks.

Interventionmonths (Median)
Wild-type KRAS3.8
Mutant KRASNA

Time to Treatment Failure

Time to treatment failure is defined as the time from enrollment to the date the decision was made to end the treatment phase for any reason. For participants who remained in the treatment phase at the analysis data cut-off date, time to treatment failure was censored at the date of their last on-study assessment. Time to treatment failure was analyzed using Kaplan-Meier methods. (NCT00508404)
Timeframe: From enrollment until the data cut-off date of 18 June 2009; median follow-up time was 34 weeks.

Interventionmonths (Median)
Wild-type KRAS6.9
Mutant KRAS5.8

Duration of Response

Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.

Interventionmonths (Median)
Wild-type KRAS - FOLFOX + Panitumumab11.1
Wild-type KRAS - FOLFOX8.8
Mutant KRAS - FOLFOX + Panitumumab7.4
Mutant KRAS - FOLFOX8.0

Overall Survival

The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 28 August 2009. Maximum time on follow-up was 153 weeks.

Interventionmonths (Median)
Wild-type KRAS - FOLFOX + Panitumumab23.9
Wild-type KRAS - FOLFOX19.7
Mutant KRAS - FOLFOX + Panitumumab15.5
Mutant KRAS - FOLFOX19.3

Percentage of Participants With an Objective Response

Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.

Interventionpercentage of participants (Number)
Wild-type KRAS - FOLFOX + Panitumumab55.21
Wild-type KRAS - FOLFOX47.68
Mutant KRAS - FOLFOX + Panitumumab39.53
Mutant KRAS - FOLFOX40.28

Progression-free Survival

Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 30 September 2008. Maximum follow-up time was 109 weeks.

Interventionmonths (Median)
Wild-type KRAS - FOLFOX + Panitumumab9.6
Wild-type KRAS - FOLFOX8.0
Mutant KRAS - FOLFOX + Panitumumab7.3
Mutant KRAS - FOLFOX8.8

Time to Progression

Time to progression was defined as time from randomization date to date of disease progression per the modified RECIST criteria. (NCT00364013)
Timeframe: From randomization until the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.

Interventionmonths (Median)
Wild-type KRAS - FOLFOX + Panitumumab10.8
Wild-type KRAS - FOLFOX9.2
Mutant KRAS - FOLFOX + Panitumumab7.5
Mutant KRAS - FOLFOX9.0

Number of Participants With Adverse Events (AEs)

"A serious adverse event (SAE) is defined as an AE that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: Is there a reasonable possibility that the event may have been caused by the study treatment?" (NCT00364013)
Timeframe: From randomization until the data cut-off date of 28 August 2009; Maximum time on follow-up was 153 weeks.

,
Interventionparticipants (Number)
Any adverse eventSerious adverse eventLeading to discontinuation of any study drugTreatment-related adverse event (TRAE)Serious treatment-related adverse eventTRAE leading to discontinuation of any study drug
FOLFOX + Panitumumab583262136581162117
FOLFOX Alone579198845658963

Change From Baseline in European Organisation for Research and Treatment of Cancer [EORTC] QLQ-C30 Global Health Status

The EORTC QLQ-C30 (v. 3.0) is a self-administered, cancer-specific questionnaire with multidimensional scales assessing 15 domains (5 functional domains, 9 symptoms, and global health status). A linear transformation was applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptom scales, higher scores represent a greater degree of symptoms. Maximum improvement is the best post-baseline change. (NCT01183780)
Timeframe: Baseline Up to 171 Weeks

Interventionunits on a scale (Mean)
Ramucirumab + FOLFIRI4.0
Placebo + FOLFIRI6.6

Change From Baseline in EuroQol- 5D (EQ-5D)

The EQ-5D is a generic, multidimensional, health status instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a 3-level scale (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). A negative change indicated a worsening of the participant's health status. (NCT01183780)
Timeframe: Baseline and 30-Day Follow-Up (FU) up to 171 Weeks

Interventionunits on a scale (Mean)
Ramucirumab + FOLFIRI-0.097
Placebo + FOLFIRI-0.103

Overall Survival (OS)

OS was defined as the time in months from the date of randomization to the date of death from any cause. For participants not known to have died as of the cut-off date, OS was censored at the last known date alive. (NCT01183780)
Timeframe: Randomization to Date of Death from Any Cause Up to 39.36 Months

Interventionmonths (Median)
Ramucirumab + FOLFIRI13.3
Placebo + FOLFIRI11.7

Percentage of Participants Achieving an Objective Response (Objective Response Rate)

The objective response rate is equal to the proportion of participants achieving a best overall response of partial response or complete response (PR + CR). Response was defined using RECIST, v. 1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm and normalization of tumor marker level of non-target lesions; PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameter. (NCT01183780)
Timeframe: Randomization until Disease Progression Up to 38.01 Months

Interventionpercentage of participants (Number)
Ramucirumab + FOLFIRI13.4
Placebo + FOLFIRI12.5

Progression-free Survival (PFS) Time

PFS was defined as the time from the date of randomization until the date of objectively determined progressive disease (PD) [according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v). 1.1] or death due to any cause, whichever was first. PD is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Participants who died without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress or were lost to follow-up were censored at the day of their last radiographic tumor assessment. (NCT01183780)
Timeframe: Randomization to Measured PD or Date of Death from Any Cause Up to 38.01 Months

Interventionmonths (Median)
Ramucirumab + FOLFIRI5.7
Placebo + FOLFIRI4.5

Observed Maximum Concentration (Cmax) and Observed Minimum Concentration (Cmin) of Ramucirumab

(NCT01183780)
Timeframe: Preinfusion and 1 hour postinfusion in Cycles 3, 5, 9, 13, and 17

Interventionmicrograms/milliliter (ug/mL) (Geometric Mean)
Cmin Dose 3 (n=248)Cmin Dose 5 (n=154)Cmin Dose 9 (n=27)Cmin Dose 13 (n=11)Cmin Dose 17 (n=5)Cmax Dose 3 (n=88)Cmax Dose 5 (n=51)Cmax Dose 9 (n=18)Cmax Dose 13 (n=12)Cmax Dose 17 (n=7)
Ramucirumab + FOLFIRI46.365.177.975.972.0221.0243.0262.0307.0253.0

Percentage of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies

Blood samples were tested to determine if a participant reacted to ramucirumab by producing anti-ramucirumab antibodies. Samples were identified as treatment emergent anti-drug antibody (TE ADA) if the post-treatment sample had an increase of at least 4 fold in titer from pre-treatment values. If the pre-treatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence. The percentage of participants with TE ADA was calculated as: (the number of participants with TE ADA / total number of participants with at least 1 post-treatment immunogenicity sample analyzed)*100. (NCT01183780)
Timeframe: Cycles 1, 3, 5, and 30-Day FU

,
Interventionpercentage of participants (Number)
Immunogenicity Any Time During Study (n=516, 512)Immunogenicity Post-Treatment (n=477, 473)
Placebo + FOLFIRI5.53.8
Ramucirumab + FOLFIRI5.63.1

Duration of Response

"Calculated only for those participants with an objective response as the time from the first objective response (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified-RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.~Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions." (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months

Interventionmonths (Median)
Wild-type KRAS - Panitumumab Plus FOLFIRI7.6
Wild-type KRAS - FOLFIRI Alone6.6
Mutant KRAS - Panitumumab Plus FOLFIRI6.0
Mutant KRAS - FOLFIRI Alone7.4

Overall Survival

Overall survival was defined as the time from randomization to the date of death. Participants who had not died by the analysis data cutoff date had their time of death censored at their last contact date. (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months

Interventionmonths (Median)
Wild-type KRAS - Panitumumab Plus FOLFIRI14.5
Wild-type KRAS - FOLFIRI Alone12.5
Mutant KRAS - Panitumumab Plus FOLFIRI11.8
Mutant KRAS - FOLFIRI Alone11.1

Percentage of Participants With an Objective Response

Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on study, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders. (NCT00339183)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 April 2009. Maximum time on follow-up was 33 months.

Interventionpercentage of participants (Number)
Wild-type KRAS - Panitumumab Plus FOLFIRI35.35
Wild-type KRAS - FOLFIRI Alone9.82
Mutant KRAS - Panitumumab Plus FOLFIRI13.36
Mutant KRAS - FOLFIRI Alone13.92

Progression-free Survival (PFS)

"Progression-free survival was defined as the time from randomization to first disease progression per modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria or death, based on independent central radiological assessment. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date.~Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions." (NCT00339183)
Timeframe: From randomization until the data cut-off date of 8 April 2008. Maximum follow-up time was 17 months.

Interventionmonths (Median)
Wild-type KRAS - Panitumumab Plus FOLFIRI5.9
Wild-type KRAS - FOLFIRI Alone3.9
Mutant KRAS - Panitumumab Plus FOLFIRI5.0
Mutant KRAS - FOLFIRI Alone4.9

Time to Disease Progression

"Time to progression was defined as the time from the randomization date to the date of first observed disease progression per the modified RECIST criteria. Participants not meeting these criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date.~Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions." (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months

Interventionmonths (Median)
Wild-type KRAS - Panitumumab Plus FOLFIRI7.3
Wild-type KRAS - FOLFIRI Alone5.3
Mutant KRAS - Panitumumab Plus FOLFIRI5.5
Mutant KRAS - FOLFIRI Alone5.5

Number of Participants With Adverse Events (AEs)

"A serious adverse event (SAE) is defined by regulatory authorities as one that • is fatal • is life threatening (places the subject at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: Is there a reasonable possibility that the event may have been caused by the study treatment?" (NCT00339183)
Timeframe: From randomization until the data cut-off date of 30 April 2009. Maximum follow-up time was 33 months.

,
Interventionparticipants (Number)
Any adverse eventSerious adverse eventLeading to discontinuation of any study drugTreatment-related adverse event (TRAE)Serious treatment-related adverse eventTRAE leading to discontinuation of any study drug
FOLFIRI Alone573175645429034
Panitumumab Plus FOLFIRI58423212357712497

Best Overall Response Rate (ORR)

The Best ORR was defined as the percentage of subjects having achieved complete response (CR) or partial response (PR) according to RECIST version 1.0 as determined by the IRC. CR: defined as disappearance of all target and all non-target lesions and no new lesions. PR: defined as at least a 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters, no progression of non-target lesions and no new lesions. (NCT01228734)
Timeframe: Baseline up to 333 weeks

Interventionpercentage of subjects (Number)
Cetuximab + FOLFOX-466.3
FOLFOX-440.5

Overall Survival (OS) Time

OS was defined as the time (in months) from randomization to death. For subjects who were still alive at the analysis data cut-off date or who lost to follow-up, survival was censored at the last recorded date that the subject was known to be alive. (NCT01228734)
Timeframe: Baseline up to 333 weeks

Interventionmonths (Median)
Cetuximab + FOLFOX-420.8
FOLFOX-416.5

Progression Free Survival (PFS) Time

PFS was defined as the duration (in months) from randomization until the first progressive disease (PD) observation as assessed by the Independent Review Committee (IRC) according to Response Evaluation Criteria for Solid Tumors (RECIST) version 1.0, or death due to any cause when death occurred within 90 days of randomization or the last tumor assessment, whichever was later. PD was defined as at least a 20% increase in the sum of longest diameter (LD) of the target lesions, taking as references the smallest sum LD since the treatment started (including baseline), or appearance of one or more new lesions, and/or unequivocal progression of existing non-target lesions. (NCT01228734)
Timeframe: Baseline up to 333 weeks

Interventionmonths (Median)
Cetuximab + FOLFOX-49.2
FOLFOX-47.4

Time to Treatment Failure (TTF)

TTF was defined as time from randomization to date of the first occurrence of radiologically confirmed PD as determined by IRC, Clinical PD according to the Investigator's assessment (if radiological confirmation of PD by IRC was unavailable), discontinuation of treatment due to progression or adverse event, start of new anticancer therapy, withdrawal of consent, or death within 90 days of last tumor assessment or randomization. Subjects without event were censored on the date of last tumor assessment. (NCT01228734)
Timeframe: Baseline up to 333 weeks

Interventionmonths (Median)
Cetuximab + FOLFOX-49.2
FOLFOX-45.6

Number of Subjects With Curative Surgery of Liver Metastases

The number of subjects who underwent liver metastatic surgery after start of treatment and the outcome of surgery with respect to residual tumor after surgery (R0, R1, R2, not evaluable) were summarized. In case of resection of more than one metastasis, the worst outcome of surgery defined the overall status of a subject. R0 = No residual tumor after resection (all lesions resected completely); R1 = Metastases not resected completely with microscopic residual lesions; and R2 = Metastases not resected completely with macroscopic residual lesions. (NCT01228734)
Timeframe: Baseline up to 333 weeks

,
Interventionsubjects (Number)
Subjects with liver surgerySubjects with liver surgery outcome: R0Subjects with liver surgery outcome: R1Subjects with liver surgery outcome: R2Subjects not evaluable
Cetuximab + FOLFOX-497100
FOLFOX-462200

Association Between Longitudinal NLR (Longitudinal NLR ≤5 Versus NLR >5) and OS as Assessed by Hazard Ratio

NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. Longitudinal NLR was assessed by treating the NLR measurements taken over the time-course of treatment as a time-dependent covariate. OS was defined as the time from the start of initial treatment to the date of death, regardless of the cause of death. The association between longitudinal NLR (longitudinal NLR ≤5 vs NLR >5) and OS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to death or end of study (up to 4 years)

Interventionhazard ratio (Number)
Bevacizumab: Phase A and Phase B2.2

Association Between Longitudinal NLR (Longitudinal NLR ≤5 Versus NLR >5) and PFS as Assessed by Hazard Ratio

NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. Longitudinal NLR was assessed by treating the NLR measurements taken over the time-course of treatment as a time-dependent covariate. PFS was defined as time from the start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as: an unequivocal and clinically meaningful increase in size of known tumors, appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. The association between longitudinal NLR (longitudinal NLR ≤5 vs N>5) and PFS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)

Interventionhazard ratio (Number)
Bevacizumab: Phase A and Phase B1.3

Association Between Neutrophil to Lymphocyte Ratio (NLR) [NLR ≤5 Versus NLR >5] and Progression-Free Survival (PFS) as Assessed by Hazard Ratio

NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. PFS was defined as the time from the start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (carcinoembryonic antigen [CEA]) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. The association between NLR (NLR less than or equal to [≤] 5 vs greater than [>] 5) and PFS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)

Interventionhazard ratio (Number)
Bevacizumab: Phase A and Phase B1.4

Association Between NLR (NLR ≤5 Versus NLR >5) and OS as Assessed by Hazard Ratio

NLR was calculated from the laboratory values as the ratio of Neutrophils to Lymphocytes. OS was defined as the time from the start of initial treatment to the date of death, regardless of the cause of death. The association between NLR (NLR ≤ 5 vs > 5) and OS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)

Interventionhazard ratio (Number)
Bevacizumab: Phase A and Phase B1.6

Association Between NLR Normalization (First NLR Post-Baseline ≤5 Versus NLR >5) and PFS as Assessed by Hazard Ratio

NLR was calculated from laboratory values as ratio of Neutrophils to Lymphocytes. NLR normalization was assessed by adding first post-baseline measurement of NLR to the primary model. This is equivalent to testing whether first change in NLR is significantly associated with outcome. PFS was defined as time from start of initial treatment to documentation of first disease progression or death from any cause. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was defined as: an unequivocal and clinically meaningful increase in size of known tumors, appearance of ≥1 new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration.The association between NLR normalization (first NLR post-baseline ≤5 vs >5) and PFS was reported as hazard ratio. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)

Interventionhazard ratio (Number)
Bevacizumab: Phase A and Phase B0.9

Duration of Disease Control (DDC) as Assessed by the Investigator Based on Routine Clinical Practice: Overall

DDC was defined as PFS + PFS-B. In cases where a participant did not enter Phase B, then DDC was defined as PFS. PFS was defined as time from start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. PFS-B was time from start of Phase B treatment to documentation of second disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate DDC. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)

Interventionmonths (Median)
Bevacizumab: Phase A and Phase B14.0

OS: Phase B

Overall Survival in Phase B was defined as the time from the start of treatment in Phase B to death due to any cause. Kaplan-Meier methodology was used to estimate OS. (NCT01588990)
Timeframe: From the start of Phase B treatment death or end of study (up to 4 years)

Interventionmonths (Median)
Bevacizumab: Phase B14.9

Overall Survival (OS) From the Start of Treatment to Study Completion: Overall

OS was defined as the time from the start of initial treatment to the date of death, regardless of the cause of death. Kaplan-Meier methodology was used to estimate OS. (NCT01588990)
Timeframe: Baseline until death or end of study (up to 4 years)

Interventionmonths (Median)
Bevacizumab: Phase A and Phase B25.0

Percentage of Participants Who Underwent Liver Resection: Overall

The results include percentage of participants who underwent potentially curative liver resection. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)

Interventionpercentage of participants (Number)
Bevacizumab: Phase A and Phase B1.6

PFS Until First Disease Progression as Assessed by the Investigator Based on Routine Clinical Practice: Phase A

PFS until first progression was defined as the time from the start of initial treatment to documentation of first disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate PFS. (NCT01588990)
Timeframe: Baseline up to first disease progression, death or end of study (up to 4 years)

Interventionmonths (Median)
Bevacizumab: Phase A9.2

PFS Until Second Disease Progression as Assessed by the Investigator Based on Routine Clinical Practice: Phase B

PFS in Phase B (PFS-B) was defined as the time from the start of Phase B treatment to documentation of second disease progression or death from any cause, whichever occurred first. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate PFS. (NCT01588990)
Timeframe: From the start of Phase B treatment to disease progression, death or end of study (up to 4 years)

Interventionmonths (Median)
Bevacizumab: Phase B6.7

Survival Beyond First Disease Progression: Overall

Survival beyond first progression was defined as the time from the date of first disease progression to death due to any cause. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate survival beyond first disease progression. (NCT01588990)
Timeframe: Baseline until death or end of study (up to 4 years)

Interventionmonths (Median)
Bevacizumab: Phase A and Phase B12.6

Time to Failure of Strategy (TFS): Overall

TFS was defined as time from the start of initial treatment to documentation of first disease progression without entering Phase B, or second disease progression having entered Phase B. Disease progression was determined according to standard practice based on radiological, biochemical (CEA) or clinical factors. Determination of disease progression was to be unequivocal and was defined as any of the following: an unequivocal and clinically meaningful increase in the size of known tumors, the appearance of one or more new lesions, death due to disease without prior objective documentation of progression, elevated CEA accompanied by other radiological or clinical evidence of progression, or symptomatic deterioration. Kaplan-Meier methodology was used to estimate TFS. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)

Interventionmonths (Median)
Bevacizumab: Phase A and Phase B14.8

AQoL-8D Global Utility Score: Phase B

AQoL-8D provides a global utility score and consists of 8 separately scored dimensions including Independent Living, Life Satisfaction, Mental Health, Coping, Relationships, Self Worth, Pain, and Senses. Each of the 8 scales is calculated based on the answers to 3 questions. Each question is given an answer dependent utility score (0 [worst] to 1 [best]) and then these scores are combined using a multiplicative model to get the normalized scale score value, each scale ranging between 0.0 (representing death) and 1.0 (representing full health). (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]

Interventionunits on a scale (Mean)
Phase B BaselinePhase B Visit 2 (up to 4 years)Phase B Visit 3 (up to 4 years)Phase B Visit 4 (up to 4 years)Phase B Visit 5 (up to 4 years)Phase B Visit 6 (up to 4 years)Phase B Visit 7 (up to 4 years)Phase B Visit 8 (up to 4 years)Phase B Visit 9 (up to 4 years)Phase B Visit 10 (up to 4 years)Phase B Visit 11 (up to 4 years)Phase B Visit 12 (up to 4 years)Phase B Visit 13 (up to 4 years)Phase B Visit 14 (up to 4 years)Phase B Visit 15 (up to 4 years)Phase B Visit 16 (up to 4 years)Phase B Visit 17 (up to 4 years)Phase B Visit 18 (up to 4 years)Phase B Visit 19 (up to 4 years)Phase B Visit 20 (up to 4 years)Phase B Visit 21 (up to 4 years)Phase B Visit 22 (up to 4 years)Phase B Visit 23 (up to 4 years)Phase B Visit 24 (up to 4 years)Phase B EOT Visit (up to 4 years)Survival Follow-Up 1 (up to 4 years)Survival Follow-Up 2 (up to 4 years)Survival Follow-Up 3 (up to 4 years)Survival Follow-Up 4 (up to 4 years)Survival Follow-Up 6 (up to 4 years)
Bevacizumab: Phase B0.7360.7730.8130.8780.8080.8090.8250.9100.8190.8560.7300.9600.9650.9580.9670.9420.9270.9310.8660.8870.9400.9190.9370.9500.7080.7880.7910.9890.9810.875

Assessment of Quality of Life - Eight Dimensions (AQoL-8D) Global Utility Score: Phase A

AQoL-8D provides a global utility score and comprised of 35 questions from which 8 dimensions (Independent Living, Life Satisfaction, Mental Health, Coping, Relationships, Self Worth, Pain, and Senses) are derived. Each of the 8 scales is calculated based on the answers to 3 questions. Each question is given an answer dependent utility score (0 [worst] to 1 [best]) and then these scores are combined using a multiplicative model to get the normalized scale score value, each scale ranging between 0.0 (representing death) and 1.0 (representing full health). (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]

Interventionunits on a scale (Mean)
Phase A BaselinePhase A Visit 2 (Weeks 8-9)Phase A Visit 3 (Weeks 16-17)Phase A Visit 4 (Weeks 24-25)Phase A Visit 5 (Weeks 32-33)Phase A Visit 6 (Weeks 40-41)Phase A Visit 7 (Weeks 48-49)Phase A Visit 8 (Weeks 56-57)Phase A Visit 9 (Weeks 64-65)Phase A Visit 10 (Weeks 72-73)Phase A Visit 11 (Weeks 80-81)Phase A Visit 12 (Weeks 88-89)Phase A Visit 13 (Weeks 96-97)Phase A Visit 14 (Weeks 104-105)Phase A Visit 15 (Weeks 112-113)Phase A Visit 16 (Weeks 120-121)Phase A Visit 17 (Weeks 128-129)Phase A Visit 18 (Weeks 136-137)Phase A Visit 19 (Weeks 144-145)Phase A Visit 20 (Weeks 152-153)Phase A Visit 21 (Weeks 160-161)Phase A Visit 22 (Weeks 168-169)Phase A Visit 23 (Weeks 176-177)Phase A EOT Visit (up to 4 years)Survival Follow-Up 1 (up to 4 years)Survival Follow-Up 2 (up to 4 years)Survival Follow-Up 3 (up to 4 years)Survival Follow-Up 4 (up to 4 years)Survival Follow-Up 5 (up to 4 years)Survival Follow-Up 6 (up to 4 years)Survival Follow-Up 7 (up to 4 years)
Bevacizumab: Phase A0.7470.7600.7670.7960.8000.8310.8180.8510.8220.8270.8390.8560.8310.8150.8710.8690.8590.8800.9150.8640.8060.8110.7090.7390.7180.7920.6960.6200.8000.8100.874

European Quality of Life 5-Dimension (EuroQol-5D) Utility Score: Phase A

"EQ-5D is a standardized generic preference based health related quality of life instrument. It records how one's health is today and consists of a descriptive system. The descriptive system is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem[s] and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects' health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life." (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, end of treatment (EOT) (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]

Interventionunits on a scale (Mean)
Phase A BaselinePhase A Visit 2 (Weeks 8-9)Phase A Visit 3 (Weeks 16-17)Phase A Visit 4 (Weeks 24-25)Phase A Visit 5 (Weeks 32-33)Phase A Visit 6 (Weeks 40-41)Phase A Visit 7 (Weeks 48-49)Phase A Visit 8 (Weeks 56-57)Phase A Visit 9 (Weeks 64-65)Phase A Visit 10 (Weeks 72-73)Phase A Visit 11 (Weeks 80-81)Phase A Visit 12 (Weeks 88-89)Phase A Visit 13 (Weeks 96-97)Phase A Visit 14 (Weeks 104-105)Phase A Visit 15 (Weeks 112-113)Phase A Visit 16 (Weeks 120-121)Phase A Visit 17 (Weeks 128-129)Phase A Visit 18 (Weeks 136-137)Phase A Visit 19 (Weeks 144-145)Phase A Visit 20 (Weeks 152-153)Phase A Visit 21 (Weeks 160-161)Phase A Visit 22 (Weeks 168-169)Phase A Visit 23 (Weeks 176-177)Phase A EOT Visit (up to 4 years)Survival Follow-Up 1 (up to 4 years)Survival Follow-Up 2 (up to 4 years)Survival Follow-Up 3 (up to 4 years)Survival Follow-Up 4 (up to 4 years)Survival Follow-Up 5 (up to 4 years)Survival Follow-Up 6 (up to 4 years)Survival Follow-Up 7 (up to 4 years)
Bevacizumab: Phase A0.8300.8570.8650.8530.8690.8920.8720.8810.8940.8430.8980.9150.8440.8990.8780.8990.8730.9090.9470.8520.9330.8130.9000.8170.7680.9010.8190.8431.0000.8350.816

EuroQol-5D Utility Score: Phase B

"EQ-5D is a standardized generic preference based health related quality of life instrument. It records how one's health is today and consists of a descriptive system. The descriptive system is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each dimension on the EQ-5D involves a 3-point response scale which indicates the level of impairment (level 1 = no problem; level 2 = some or moderate problem[s] and level 3 = unable, or extreme problems). Level of problem reported in each EQ-5D dimension determines a unique health state which is converted into a weighted health state index by applying scores from EQ-5D preference weights elicited from general population samples. This generates a unique description of the subjects' health status, which is valued between 0 (representing death) and 1 (representing perfect health). Higher the score, the better the quality of life." (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]

Interventionunits on a scale (Mean)
Phase B BaselinePhase B Visit 2 (up to 4 years)Phase B Visit 3 (up to 4 years)Phase B Visit 4 (up to 4 years)Phase B Visit 5 (up to 4 years)Phase B Visit 6 (up to 4 years)Phase B Visit 7 (up to 4 years)Phase B Visit 8 (up to 4 years)Phase B Visit 9 (up to 4 years)Phase B Visit 10 (up to 4 years)Phase B Visit 11 (up to 4 years)Phase B Visit 12 (up to 4 years)Phase B Visit 13 (up to 4 years)Phase B Visit 14 (up to 4 years)Phase B Visit 15 (up to 4 years)Phase B Visit 16 (up to 4 years)Phase B Visit 17 (up to 4 years)Phase B Visit 18 (up to 4 years)Phase B Visit 19 (up to 4 years)Phase B Visit 20 (up to 4 years)Phase B Visit 21 (up to 4 years)Phase B Visit 22 (up to 4 years)Phase B Visit 23 (up to 4 years)Phase B Visit 24 (up to 4 years)Phase B EOT Visit (up to 4 years)Survival Follow-Up 1 (up to 4 years)Survival Follow-Up 2 (up to 4 years)Survival Follow-Up 3 (up to 4 years)Survival Follow-Up 4 (up to 4 years)Survival Follow-Up 6 (up to 4 years)
Bevacizumab: Phase B0.8140.8590.8940.8970.8660.8370.8760.8740.9080.8110.8060.8441.0001.0000.8440.8330.8440.8330.8270.8160.8440.8440.8270.8440.8090.7400.7720.8270.8271.000

FACT-C Score: Phase B

FACT-C is one part of the FACIT Measurement System, which comprehensively assesses the health-related QoL of cancer participants and participants with other chronic illnesses. It is composed of 27 items of the general version of the FACT-C as a general core QoL measure and has a disease-specific subscale containing 9 colorectal cancer-specific items. It consists of total 36 items, summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range from 0 to 28, emotional well-being (6 items) range from 0 to 24, colorectal cancer subscale (9 items) range from 0 to 36; higher subscale score=better QoL. All single-item measures range from 0='Not at all' to 4='Very much'. Total possible score range: 0 to 144. High scale score represents a better QoL. (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]

Interventionunits on a scale (Mean)
Phase B BaselinePhase B Visit 2 (up to 4 years)Phase B Visit 3 (up to 4 years)Phase B Visit 4 (up to 4 years)Phase B Visit 5 (up to 4 years)Phase B Visit 6 (up to 4 years)Phase B Visit 7 (up to 4 years)Phase B Visit 8 (up to 4 years)Phase B Visit 9 (up to 4 years)Phase B Visit 10 (up to 4 years)Phase B Visit 11 (up to 4 years)Phase B Visit 12 (up to 4 years)Phase B Visit 13 (up to 4 years)Phase B Visit 14 (up to 4 years)Phase B Visit 15 (up to 4 years)Phase B Visit 16 (up to 4 years)Phase B Visit 17 (up to 4 years)Phase B Visit 18 (up to 4 years)Phase B Visit 19 (up to 4 years)Phase B Visit 20 (up to 4 years)Phase B Visit 21 (up to 4 years)Phase B Visit 22 (up to 4 years)Phase B Visit 23 (up to 4 years)Phase B Visit 24 (up to 4 years)Phase B EOT Visit (up to 4 years)Survival Follow-Up 1 (up to 4 years)Survival Follow-Up 2 (up to 4 years)Survival Follow-Up 3 (up to 4 years)Survival Follow-Up 4 (up to 4 years)Survival Follow-Up 6 (up to 4 years)
Bevacizumab: Phase B103.47108.71108.19114.89110.60111.28114.78120.39108.08110.50109.33125.00119.00117.00126.00123.00127.00126.00127.00126.00123.00124.00126.00130.00101.6798.72102.50126.33125.00124.67

Functional Assessment of Cancer Therapy-Colorectal (FACT-C) Score: Phase A

FACT-C is one part of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System, which comprehensively assesses the health-related QoL of cancer participants and participants with other chronic illnesses. It is composed of 27 items of the general version of the FACT-C as a general core QoL measure and has a disease-specific subscale containing 9 colorectal cancer-specific items. It consists of total 36 items, summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range from 0 to 28, emotional well-being (6 items) range from 0 to 24, colorectal cancer subscale (9 items) range from 0 to 36; higher subscale score=better QoL. All single-item measures range from 0='Not at all' to 4='Very much'. Total possible score range: 0 to 144. High scale score represents a better QoL. (NCT01588990)
Timeframe: Baseline, every 8-9 weeks thereafter, EOT (30 days after disease progression [up to 4 years]), survival follow-up 12-weekly visits (up to 4 years) [Detailed time points are presented in the category titles]

Interventionunits on a scale (Mean)
Phase A BaselinePhase A Visit 2 (Weeks 8-9)Phase A Visit 3 (Weeks 16-17)Phase A Visit 4 (Weeks 24-25)Phase A Visit 5 (Weeks 32-33)Phase A Visit 6 (Weeks 40-41)Phase A Visit 7 (Weeks 48-49)Phase A Visit 8 (Weeks 56-57)Phase A Visit 9 (Weeks 64-65)Phase A Visit 10 (Weeks 72-73)Phase A Visit 11 (Weeks 80-81)Phase A Visit 12 (Weeks 88-89)Phase A Visit 13 (Weeks 96-97)Phase A Visit 14 (Weeks 104-105)Phase A Visit 15 (Weeks 112-113)Phase A Visit 16 (Weeks 120-121)Phase A Visit 17 (Weeks 128-129)Phase A Visit 18 (Weeks 136-137)Phase A Visit 19 (Weeks 144-145)Phase A Visit 20 (Weeks 152-153)Phase A Visit 21 (Weeks 160-161)Phase A Visit 22 (Weeks 168-169)Phase A Visit 23 (Weeks 176-177)Phase A EOT Visit (up to 4 years)Survival Follow-Up 1 (up to 4 years)Survival Follow-Up 2 (up to 4 years)Survival Follow-Up 3 (up to 4 years)Survival Follow-Up 4 (up to 4 years)Survival Follow-Up 5 (up to 4 years)Survival Follow-Up 6 (up to 4 years)Survival Follow-Up 7 (up to 4 years)
Bevacizumab: Phase A103.84103.33106.34109.66109.39111.30111.40113.51113.92115.11114.00115.99113.54112.36119.48116.38113.69112.94117.55115.86106.00112.00105.00103.94102.89104.00105.50109.00119.00103.61115.00

Percentage of Participants With Confirmed Complete or Partial Response as Assessed by the Investigator Based on Routine Clinical Practice: Overall

Percentage of participants with best overall response of confirmed complete response or partial response based on the investigator assessment of the response as per routine clinical practice was reported. The confirmation of response must be no less than 4 weeks after initial assessment. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)

Interventionpercentage of participants (Number)
Complete responsePartial response
Bevacizumab: Phase A and Phase B3.18.6

Percentage of Participants With Confirmed Complete or Partial Response as Assessed by the Investigator Based on Routine Clinical Practice: Phase A

Percentage of participants with best overall response of confirmed complete response or partial response based on the investigator assessment of the response as per routine clinical practice was reported. The confirmation of response must be no less than 4 weeks after initial assessment. (NCT01588990)
Timeframe: Baseline up to disease progression, death or end of study (up to 4 years)

Interventionpercentage of participants (Number)
Complete responsePartial response
Bevacizumab: Phase A3.18.6

Percentage of Participants With Confirmed Complete or Partial Response as Assessed by the Investigator Based on Routine Clinical Practice: Phase B

Percentage of participants with best overall response of confirmed complete response or partial response based on the investigator assessment of the response as per routine clinical practice was reported. The confirmation of response must be no less than 4 weeks after initial assessment. (NCT01588990)
Timeframe: From the start of Phase B treatment to disease progression, death or end of study (up to 4 years)

Interventionpercentage of participants (Number)
Complete responsePartial response
Bevacizumab: Phase B00

Incidence of the Adverse Events

Safety was assessed on the basis of reports of adverse events, laboratory-test results, and vital sign measurements. Adverse events were categorized According to the Common Toxicity Criteria of the National Cancer Institute, version 5.0, in which a grade of 1 indicates mild adverse events, a grade of 2 moderate adverse events, a grade of 3 serious adverse events, and a grade of 4 life-threatening adverse events (NCT03288987)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)76
Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)44

Number of Positive Anti-drug Antibody (ADA) Samples Among Patients (Immunogenicity)

Anti-drug antibody assessment (NCT03288987)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)1
Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)1

Objective Response Rate

Tumor response was defined as partial and complete responses, according to the RECIST criteria ( version 1.1). The definitions were as follows: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), decrease of at least 30% in the lesion that has the largest diameter; Objective Response Rate (ORR) = CR + PR. (NCT03288987)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)17
Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)5

Overall Survival (OS)

Overall survival OS was defined as the time from date of randomization to date of death due to any cause (NCT03288987)
Timeframe: Up to 12 months

InterventionParticipants (Count of Participants)
Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)30
Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)17

Progression Free Survival (PFS)

PFS is defined as the time from the date of randomization to the first date of documentation progression (per investigator assessment) or death as a result of any cause. (NCT03288987)
Timeframe: PFS was measured from the start of chemotherapy to the date of disease progression or to the date of death if no progression whichever came first, assessed up to 12 months

InterventionDay (Median)
Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)232
Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)210

Time to Treatment Failure

"Time to treatment failure was defined as the time from the date of randomization to the date of each of the following,~The treatment modalities did not destroy or modify the cancer cells,~The tumor either became larger (disease progression) or stayed the same size after treatment,~Death due to any cause,~Discontinuation of treatment" (NCT03288987)
Timeframe: Up to 12 months

InterventionDay (Median)
Bevacizumab + FOLFIRI-3 (AryoGen Pharmed Bevacizumab)73
Bevacizumab + FOLFIRI-3 (Roche Bevacizumab)73

Disease Control Rate (DCR)

DCR was the proportion of patients with confirmed CR, PR or stable disease (SD) as best overall response. SD defined as neither sufficient decrease to qualify for PR nor sufficient increase to qualify for PD. (NCT02743221)
Timeframe: Baseline and every 8 weeks (maximum follow-up duration: 17.9 months)

InterventionParticipants (Count of Participants)
Trifluridine/Tipiracil + Bevacizumab66
Capecitabine + Bevacizumab59

Duration of Response (DR)

The DR was calculated among patients with CR or PR as the time (months) from the first documentation of response to the first documentation of objective tumor progression or death due to any cause, whichever occurred first. (NCT02743221)
Timeframe: Baseline and every 8 weeks (maximum follow-up duration: 16.6 months)

Interventionmonths (Median)
Trifluridine/Tipiracil + Bevacizumab7.9
Capecitabine + Bevacizumab9.9

Overall Response Rate (ORR)

As per RECIST v1.1, Complete Response (CR) was disappearance of all target lesions; Partial Response (PR) was at least 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. The ORR was the proportion of patients who presented CR or PR with confirmation at subsequent time point or at least 4 weeks later. (NCT02743221)
Timeframe: Baseline and every 8 weeks (maximum follow-up duration: 17.9 months)

InterventionParticipants (Count of Participants)
Trifluridine/Tipiracil + Bevacizumab26
Capecitabine + Bevacizumab23

Overall Survival (OS)

The OS was defined as the time from the date of randomisation to the date of death. If death was not confirmed, or patient was alive at study cut-off date, survival time was censored at the date of last follow-up or at the study cut-off date, whichever was earlier. (NCT02743221)
Timeframe: Baseline up to death or study cut-off (maximum follow-up duration: 19.9 months)

Interventionmonths (Median)
Trifluridine/Tipiracil + Bevacizumab18.0
Capecitabine + Bevacizumab16.2

Progression Free Survival (PFS)

The progression free survival (PFS), defined as the time from the date of randomisation until the date of the investigator-assessed radiological disease progression or death due to any cause according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Progressive disease (PD) was defined at least a 20% increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) and an absolute increase of at least 5 mm in the sum of lesions or the appearance of new lesions. (NCT02743221)
Timeframe: Baseline and every 8 weeks (maximum follow-up duration: 17.9 months)

Interventionmonths (Median)
Trifluridine/Tipiracil + Bevacizumab9.2
Capecitabine + Bevacizumab7.8

Number of Patients Still Alive at End of Study (Overall Survival)

"Secondary objectives are to determine the efficacy and tolerability of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer by~- Overall survival (OS)~Overall survial is defined as length of time from start of treatment that patients are still alive. For this time-to-event variables the Kaplan-Meier method was intended to be used" (NCT02384850)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Selinexor 40 mg+ mFOLFOX60
Selinexor 20mg + mFOLFOX62

Overall Response Rate

"Secondary objectives are to determine the efficacy and tolerability of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer by~- Overall response rate (RR) (acc. to RECIST v1.1)~Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed byCT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT02384850)
Timeframe: 2 years

InterventionParticipants (Count of Participants)
Selinexor 40 mg+ mFOLFOX60
Selinexor 20mg + mFOLFOX61

Progression Free Survival (PFS)

"Secondary objectives are to determine the efficacy and tolerability of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer by~- Progression free survival (PFS) The disease status was measured by CT/MRI and evaluated according to RECIST 1.1 criteria every 8 weeks during treatment, at End of Treatment and every 3 weeks during Follow-up to determine time until patient has Progressive Disease (PD). PD is defined according to RECIST v1.1 at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression." (NCT02384850)
Timeframe: 2 years

Interventionmonths (Mean)
Selinexor 40 mg+ mFOLFOX6NA
Selinexor 20mg + mFOLFOX6NA

Number of Patients Experiencing Adverse Events

"Secondary objectives are to determine the efficacy and tolerability of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer by~- Toxicity (acc. to NCI Common Terminology Criteria for Adverse Events (CTC AE) v4.03)" (NCT02384850)
Timeframe: treatment start to up to 30 days after last dose

,
InterventionParticipants (Count of Participants)
Patients with AEs of any CTCAE GradePatients with AEs of at least CTCAE Grade 3Patients with Selinexor related AEs of any GradePatients with Selinexor related AEs of at least Grade 3Patients with chemotherapy related AEs of any GradePatients with chemotherapy related AEs of at least Grade 3Patients with AEs leading to discontinuationPatients with at least 1 SAEPatients with at least 1 SAE related to SelinexorPatients with at least 1 SAE related to chemotherapy
Selinexor 20mg + mFOLFOX66645632313
Selinexor 40 mg+ mFOLFOX64444442211

Numbers of Patients With Dose Limiting Toxicities

"Primary objective is the determination of the maximum tolerated dose (MTD) of selinexor in combination with mFOLFOX6 in patients with metastatic colorectal cancer.~Criteria to assess MTD was the experience of AEs > grade 3, discontinuation from study treatment due to adverse events or withdrawal of consent by the patients." (NCT02384850)
Timeframe: 28 days of treatment

,
InterventionParticipants (Count of Participants)
Discontinuation due to Adverse eventsDiscontinuation due to Withdrawal of ConsentDiscontinuation due to Progressive Disease
Selinexor 20mg + mFOLFOX6222
Selinexor 40 mg+ mFOLFOX6220

Overall Survival

Overall survival is defined as the time from the date of the patient's inclusion to the patient's death (all causes). For alive patients the date of the latest news is taken into account (NCT02181556)
Timeframe: Up to 2 years after the end of the treatment

InterventionMonths (Median)
FOLFIRI + Aflibercept18.63

Progression-free Survival

"The progression-free survival is the time from inclusion to the first radiological progression or death (all causes). For patients alive without progression date of last news will be considered.~Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions compared the little sum of diameters observed durin the study (NADIR), or a measurable increase in a non-target lesion, or the appearance of new lesions" (NCT02181556)
Timeframe: up to 12 months

InterventionMonths (Median)
FOLFIRI + Aflibercept8.16

Rate of Patients Alive and Progression-free 6 Months After Inclusion.

"Progression was evaluated by CT scan, according to RECIST criteria (version 1.1) definition by the investigator. Death was also considered as an event (all causes).~Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions compared the little sum of diameters observed during the study (NADIR), or a measurable increase in a non-target lesion, or the appearance of new lesions" (NCT02181556)
Timeframe: 6 months

InterventionNb of patients alive without progression (Number)
FOLFIRI + Aflibercept22

Number of Participants Who Discontinued Study Treatment Due to an AE

An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who discontinued study treatment due to an AE was presented for the first course study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months

InterventionParticipants (Count of Participants)
Pembrolizumab21
Standard of Care (SOC)20

Number of Participants Who Experienced an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. An AE could be any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Any worsening (i.e., any clinically significant adverse change infrequency and/or intensity) of a preexisting condition that was temporally associated with the use of study treatment, was also an AE. The number of participants who experienced at least one AE was presented for the first course study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months

InterventionParticipants (Count of Participants)
Pembrolizumab149
Standard of Care (SOC)142

Overall Response Rate (ORR) Per RECIST1.1 as Assessed by Central Imaging Vendor

ORR was defined as the percentage of the participants who experienced a Complete Response (CR; disappearance of all target lesions) or a Partial Response (PR; at least a 30% decrease in the sum of diameters of target lesions) and was assessed using RECIST 1.1 as assessed by the central imaging vendor. The percentage of participants who experienced a CR or PR was presented for the first course of study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months

InterventionPercentage of Participants (Number)
Pembrolizumab45.1
Standard of Care (SOC)33.1

Overall Survival (OS)

OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of analysis were censored at the date of last known contact. HR and associated 95% CIs from a Cox proportional hazard model with Efron's method of tie handling and with a single treatment covariate was presented for the first course study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months

InterventionMonths (Median)
PembrolizumabNA
Standard of Care (SOC)36.7

Progression-Free Survival (PFS) Per RECIST1.1 As Assessed by Central Imaging Vendor

PFS was defined as the time from randomization to the first documented disease progression (PD) per RECIST 1.1 based on blinded central imaging vendor review or death due to any cause, whichever occurs first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum had to demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. Hazards ratio (HR) and associated 95% confidence intervals (CIs) from a Cox proportional hazard model with Efron's method of tie handling and with a single treatment covariate was presented for the first course study treatment per protocol. (NCT02563002)
Timeframe: Up to approximately 59 months

InterventionMonths (Median)
Pembrolizumab16.5
Standard of Care (SOC)8.2

Overall Survival

Survival time will be defined as the time from registration to death. Time to event distributions will be estimated using the Kaplan-Meier method. Overall Survival (OS) will be compared between Arm A and Arm B. (NCT00265850)
Timeframe: Up to 5 years post-treatment

Interventionmonths (Median)
Arm A: FOLFOX or FOLFIRI + Bevacizumab29.0
Arm B: FOLFOX or FOLFIRI + Cetuximab30.0

Progression-free Survival (PFS)

PFS will be measured from study entry until first documented progression or death from any cause. Time to event distributions will be estimated using the Kaplan-Meier method. PFS will be compared between Arm A and Arm B. (NCT00265850)
Timeframe: Up to 5 years post-treatment

Interventionmonths (Median)
Arm A: FOLFOX or FOLFIRI + Bevacizumab10.6
Arm B: FOLFOX or FOLFIRI + Cetuximab10.5

Overall Objective Response Rate (ORR) Based on the Tumor Assessment by the Independent Review Committee (IRC) as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria

"The overall ORR was the percentage of evaluable participants who achieved complete response [CR] or partial response [PR] according to RECIST criteria version 1.0.~CR reflected the disappearance of all tumor lesions (with no new tumors)~PR reflected a pre-defined reduction in tumor burden~Tumors were assessed by the IRC using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 06 May 2010 (approximately 30 months)

Interventionpercentage of participants (Number)
Placebo/FOLFIRI11.1
Aflibercept/FOLFIRI19.8

Overall Survival (OS)

"Overall Survival was the time interval from the date of randomization to the date of death due to any cause. Once disease progression was documented, participants were followed every 2 months for survival status, until death or until the study cutoff date, whichever came first. The final data cutoff date for the analysis of OS was the date when 863 deaths had occurred (07 February 2011).~OS was estimated using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years)

Interventionmonths (Median)
Placebo/FOLFIRI12.06
Aflibercept/FOLFIRI13.50

Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)

"PFS was the time interval from the date of randomization to the date of progression, or death from any cause if it occurs before tumor progression is documented. To evaluate disease progression, copies of all tumor imaging sets were systematically collected and assessed by the IRC.~PFS was analyzed using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model.~The analysis for PFS was performed as planned when 561 deaths (OS events) had occurred." (NCT00561470)
Timeframe: From the date of the first randomization until the occurrence of 561 OS events, 06 May 2010 (approximately 30 months)

Interventionmonths (Median)
Placebo/FOLFIRI4.67
Aflibercept/FOLFIRI6.90

Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay

Serum samples for immunogenicity assessment were analyzed using a bridging immunoassay to detect ADA. Positive samples in the ADA assay were further analyzed in the NAb assay using a validated, non-quantitative ligand binding assay. (NCT00561470)
Timeframe: Baseline, every other treatment cycle, 30 days and 90 days after the last infusion of aflibercept/placebo

,
Interventionparticipants (Number)
At least one positive sample in the ADA assayAt least one positive sample in the NAb assay
Aflibercept/FOLFIRI81
Placebo/FOLFIRI182

Number of Participants With Adverse Events (AE)

"All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 30 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization.~The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported." (NCT00561470)
Timeframe: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized

,
Interventionparticipants (Number)
Treatment-Emergent Adverse Event (TEAE)Serious TEAETEAE leading to DeathTEAE causing permanent treatment discontinuation
Aflibercept/FOLFIRI60629437164
Placebo/FOLFIRI5921982973

Disease-free Survival (Arms A and D: Mutant KRAS Patients)

"A secondary endpoint for this study was to investigate the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years

Interventionpercentage of participants (Number)
Mutant KRAS Arm A67.1
Mutant KRAS Arm D65.0

Disease-free Survival (Arms A and D: Wild-type KRAS Patients)

"The primary endpoint for this study was to compare the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years

Interventionpercentage of participants (Number)
Wild-type KRAS Arm A74.6
Wild-type KRAS Arm D71.5

Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Mutant KRAS Patients)

Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event-free rates (percentage) are report below for mutant KRAS patients. (NCT00079274)
Timeframe: Up to 3 years

Interventionpercentage of participants (Number)
Mutant KRAS Arm A87.9
Mutant KRAS Arm D82.7

Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Wild-type KRAS Patients)

Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event free rates (percentage) are reported below for Wild-type KRAS Patients. (NCT00079274)
Timeframe: Up to 3 years

Interventionpercentage of participants (Number)
Wild-type KRAS Arm A87.3
Wild-type KRAS Arm D85.6

Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Mutant KRAS Patients)

The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years

Interventionpercentage of patients (Number)
Mutant KRAS Arm A55.6
Mutant KRAS Arm D72.3

Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Wild-type KRAS Patients)

The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years

Interventionpercentage of patients (Number)
Wild-type KRAS Arm A51.1
Wild-type KRAS Arm D73.3

Changes in CEA Levels

Changes in CEA level from baseline to week 28 during treatment. (NCT01622543)
Timeframe: Baseline and at 28 weeks

Interventionng/mL (Mean)
Folfox Plus Bevacizumab and Reolysin-14209.4
Folfox Plus Bevacizumab-1107.99

Objective Response Rate

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective Response Rate =Proportion of (CR + PR) observed over all randomized patients. (NCT01622543)
Timeframe: 19 months

InterventionParticipants (Count of Participants)
Folfox Plus Bevacizumab and Reolysin27
Folfox Plus Bevacizumab18

Overall Survival

Time from randomization to death from any cause or censored at the time of last known alive (NCT01622543)
Timeframe: From date of randomization to death from any cause or censored at the time of last known alive, assessed up to 49 months

InterventionMonths (Median)
Folfox Plus Bevacizumab and Reolysin19.3
Folfox Plus Bevacizumab20.0

Progression Free Survival

Time from the day of randomization until the first observation of objective disease relapse or progression, or the appearance of new lesions or death due to any cause. If a patient had not relapsed/progressed or died, PFS was censored on the date of last disease assessment defined as the earliest test date of target lesion or non-target lesions (if patient had no target lesions). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01622543)
Timeframe: 19 months

InterventionMonths (Median)
Folfox Plus Bevacizumab and Reolysin7.33
Folfox Plus Bevacizumab9.13

Overall Survival (OS)

OS was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the earliest between the last date of the participants was known to be alive and the study cut-off date. Analysis was performed by Kaplan-Meier method. (NCT01661270)
Timeframe: 31.6 months

Interventionmonths (Median)
Placebo11.93
Aflibercept14.59

Percentage of Participants With Objective Response

Objective response rate was defined as the proportion of participants with confirmed complete response (CR) or confirmed partial response (PR), as assessed by Investigators and the IRC according to RECIST 1.0 criteria, relative to the total number of participants in the relevant analysis population. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions. (NCT01661270)
Timeframe: 26.6 months

Interventionpercentage of participants (Number)
Placebo3.7
Aflibercept18.4

Progression-free Survival (PFS)

PFS was defined as the time interval from the date of randomization to the date of first observation of either tumor progression or death due to any cause. Tumor assessment was performed by Independent Review Committee (IRC) as per response evaluation criteria in solid tumors (RECIST) version 1.0. Progression was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study or absolute increase and at least 5 mm, progression of existing non-target lesions, or presence of new lesions. PFS was calculated by Kaplan-Meier estimates. (NCT01661270)
Timeframe: 26.7 months

Interventionmonths (Median)
Placebo5.59
Aflibercept6.93

Area Under the Concentration-versus-time Curve (AUC) at Cycle 1 (AUC0-336h) of BEVZ92 and Avastin®

"To compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin®, both administered in combination with FOLFOX (any) or FOLFIRI, by means of comparing the truncated AUC calculated from start of the first infusion until start of the second infusion (i.e. at Cycle 1; AUC0-336h)~For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% confidence interval (CI) of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 80-125%." (NCT02069704)
Timeframe: AUC0-336 hrs: 0 to 336 hours after start of the first infusion

Interventionng.h/mL (Geometric Least Squares Mean)
Bevacizumab Biosimilar (BEVZ92)16500000
Avastin® (Bevacizumab, Ref. Product).16600000

AUC at Steady State (AUCss) of BEVZ92 and Avastin®

"To compare the PK profile of BEVZ92 and Avastin®, both administered in combination with FOLFOX (any) or FOLFIRI, by means of comparing the truncated area under the concentration-versus-time curve calculated over a dosage interval at steady state (i.e. at Cycle 7; AUCss).~For the PK similarity assessments, regulatory guidelines on bioequivalence were followed whereby two treatments are judged not to be different from one another if the 90% CI of the ratio of a log-transformed exposure measure (AUC) falls completely within the range 80-125%." (NCT02069704)
Timeframe: AUCss: 0 to 336 hours after the administration of Cycle 7 infusion (Week 13).

Interventionng.h/mL (Geometric Least Squares Mean)
Bevacizumab Biosimilar (BEVZ92)35900000
Avastin® (Bevacizumab, Ref. Product).35700000

Cmax,sd of BEVZ92 and Avastin®

Secondary PK endpoints included the Cmax calculated at Cycle 1 (Cmax,sd ) (NCT02069704)
Timeframe: Cmax, sd: 0 to 336 hours after start of the first infusion.

Interventionng/mL (Geometric Least Squares Mean)
Bevacizumab Biosimilar (BEVZ92)120000
Avastin® (Bevacizumab, Ref. Product).123000

Cmax,ss of BEVZ92 and Avastin®

Secondary PK endpoints included the Cmax calculated at Cycle 7 (Cmax, ss ) (NCT02069704)
Timeframe: Cmax, ss: 0 to 336 hours post-dose after the administration of Cycle 7 infusion (Week 13)

Interventionng/mL (Geometric Least Squares Mean)
Bevacizumab Biosimilar (BEVZ92)195000
Avastin® (Bevacizumab, Ref. Product).200000

Ctrough,sd of BEVZ92 and Avastin®

Secondary PK endpoints included the Ctrough calculated at Cycle 1 (Ctrough,sd ) (NCT02069704)
Timeframe: Ctrough, sd: 0 to 336 hours after start of the first infusion.

Interventionng/mL (Geometric Least Squares Mean)
Bevacizumab Biosimilar (BEVZ92)344
Avastin® (Bevacizumab, Ref. Product).349

Ctrough,ss of BEVZ92 and Avastin®

Secondary PK endpoints included the Ctrough calculated at Cycle 7 (Ctrough,ss) (NCT02069704)
Timeframe: Ctrough, ss: 0 to 336 hours after the administration of the Cycle 7 infusion.

Interventionng/mL (Geometric Least Squares Mean)
Bevacizumab Biosimilar (BEVZ92)69600
Avastin® (Bevacizumab, Ref. Product).69300

Elimination Half-life (t1/2) of BEVZ92 and Avastin®

Secondary PK endpoints included the t1/2 calculated at Cycle 7 (NCT02069704)
Timeframe: t1/2: 0 to 336 hours after the administration of the Cycle 7 infusion.

Interventionh (Geometric Least Squares Mean)
Bevacizumab Biosimilar (BEVZ92)294
Avastin® (Bevacizumab, Ref. Product).289

Elimination Rate Constant (Kel) of BEVZ92 and Avastin®

Secondary PK endpoints included the Kel calculated at Cycle 7 (Ctrough,ss) (NCT02069704)
Timeframe: Kel: 0 to 336 hours after the administration of the Cycle 7 infusion.

Interventionl/h (Geometric Least Squares Mean)
Bevacizumab Biosimilar (BEVZ92)0.00236
Avastin® (Bevacizumab, Ref. Product).0.00240

Progression-free Survival (PFS) of BEVZ92 and Avastin®

"Compare PFS between the randomized treatment arms. Progression-free survival (PFS) was defined as the time from the randomization date to the date of disease progression using RECIST v1.1, or death. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions plus 5 mm absolute increase, and/or unequivocal progression of known non-target lesion, and/or the appearance of new lesions." (NCT02069704)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 weeks.

Interventionmonths (Median)
Bevacizumab Biosimilar (BEVZ92)10.8
Avastin® (Bevacizumab, Ref. Product)11.1

Volume of Distribution (Vd) of BEVZ92 and Avastin®

Secondary PK endpoints included the Vd calculated at Cycle 7 (NCT02069704)
Timeframe: Vd: 0 to 336 hours after the administration of the Cycle 7 infusion.

InterventionL (Geometric Least Squares Mean)
Bevacizumab Biosimilar (BEVZ92)4.06
Avastin® (Bevacizumab, Ref. Product).3.86

Anti-Drug Antibody (ADA) of BEVZ92 and Avastin®

Immunogenicity profile by means of measurement of ADA developed de novo (seroconversion) after cycle 5, cycle 8, and 12 months after first drug administration (pre-dose). (NCT02069704)
Timeframe: At baseline, and on Day 1 (pre-dose) of Cycles: 1, 5 and 8, and 12 months after first drug administration

,
Interventionparticipants (Number)
SeroconversionNo seroconversion
Avastin® (Bevacizumab, Ref. Product)071
Bevacizumab Biosimilar (BEVZ92)267

Objective Response Rate (ORR) of BEVZ92 and Avastin®

"To compare efficacy in terms of ORR between arms. Clinical and radiological tumor assessments were performed according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 using computed tomography (CT) or magnetic resonance imaging (MRI) scans.~Objective response (OR) is defined as a best overall response of partial response (PR) or complete response (CR) as defined by RECIST v1.1. All participants who did not meet the criteria for CR or PR by the end of the study were considered non-responders." (NCT02069704)
Timeframe: Every four weeks. Up to 48 weeks

,
InterventionParticipants (Count of Participants)
ORR (CR+PR)Stable diseaseProgressive diseaseunevaluable
Avastin® (Bevacizumab, Ref. Product)402524
Bevacizumab Biosimilar (BEVZ92)352745

Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Reported With BEVZ92 and Avastin®

Compare the safety profile by means of the frequency and severity of TEAEs and SAEs reported in each treatment arm. (NCT02069704)
Timeframe: From first study dose and up to 30 days after the end of study treatment for each patient, for an average of 11 months

,
Interventionparticipants (Number)
Any TEAE (any causality)Any grade>=3 TEAEAny TEAE leading to discontinuationAny treatment-related TEAEAny grade >=3 treatment-related TEAEAny serious TEAEAny bleeding event
Avastin® (Bevacizumab, Ref. Product)7149670702119
Bevacizumab Biosimilar (BEVZ92)66441363631914

Evaluate Safety of the Combination at a Daily Dosing of 2.5mg RAD001, 5 mg RAD001 or 10 mg RAD001 (Phase 1 Part)

Number of patients who experienced a Dose Limiting Toxicity (DLT). DLT will be assessed in the first 28 days of dosing. Patients need to get dosed with 2 rounds/sessions of all chemotherapy agents in the first 28 days in order to be evaluable for DLT assessment. The primary endpoint is safety as summarized by dose limiting toxicity (DLT). (NCT01047293)
Timeframe: December 2011

Interventionparticipants (Number)
ARM 1 RAD001 5 mg QOD0
ARM 2 5mg RAD001 QD1
ARM 3 10mg RAD001 QD1

Progression Free Survival at Six Months

(NCT01047293)
Timeframe: 6 months

Interventionpercentage of participants (Number)
All Patients87

Overall Survival (OS)

OS was defined as the time from the date of randomization to the date of death from any cause. (NCT01765582)
Timeframe: Randomization until death due to any cause (up to approximately 3 years)

Interventionmonths (Median)
Arm A: Concurrent FOLFOXIRI + Bevacizumab33.97
Arm B: Sequential FOLFOXIRI + Bevacizumab28.32
Arm C: FOLFOX + Bevacizumab30.65
Arms A + B: Pooled FOLFOXIRI + Bevacizumab28.32

Percentage of Participants With Adverse Events

An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT01765582)
Timeframe: Randomization up to approximately 3 years

InterventionPercentage of participants (Number)
Arm A: Concurrent FOLFOXIRI + Bevacizumab100
Arm B: Sequential FOLFOXIRI + Bevacizumab98.9
Arm C: FOLFOX + Bevacizumab100
Arms A + B: Pooled FOLFOXIRI + Bevacizumab99.4

Percentage of Participants With Overall Response During First-Line Therapy (ORR1)

ORR1 was the percentage of participants with complete response (CR) or partial response (PR) during first-line therapy as assessed by investigator according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v.1.1). CR was defined as disappearance of all extranodal target lesions and all pathological lymph nodes had to have decreased to <10 millimeter (mm) in short axis. PR was defined as at least a 30% decrease in the sum of longest diameters of target lesions, taking as reference the baseline sum diameters. ORR1 = CR + PR (NCT01765582)
Timeframe: Randomization up to disease progression during first-line therapy or death, whichever occurs first (up to approximately 3 years)

InterventionPercentage of participants (Number)
Arm A: Concurrent FOLFOXIRI + Bevacizumab72.0
Arm B: Sequential FOLFOXIRI + Bevacizumab72.8
Arm C: FOLFOX + Bevacizumab62.1
Arms A + B: Pooled FOLFOXIRI + Bevacizumab72.4

Progression-Free Survival During First-Line Therapy (PFS1)

PFS1 was defined as time from randomization to the first occurrence of disease progression during first-line therapy, as assessed by the Investigator using RECIST v1.1, or death from any cause, whichever occurs first. Disease progression was defined as sum of longest diameters increased by at least 20% from the smallest value on study. The sum of longest diameters must also demonstrate an absolute increase of at least 5 mm. (NCT01765582)
Timeframe: Randomization up to disease progression during first-line therapy or death, whichever occurs first (up to approximately 3 years)

Interventionmonths (Median)
Arm A: Concurrent FOLFOXIRI + Bevacizumab11.86
Arm B: Sequential FOLFOXIRI + Bevacizumab11.37
Arm C: FOLFOX + Bevacizumab9.46
Arms A + B: Pooled FOLFOXIRI + Bevacizumab11.70

Proportion of Participants Considered by the Investigator to be Unresectable on Study Enrollment Who Subsequently Underwent Attempted Curative Resections of Metastases

The proportion of participants considered by the investigator to be unresectable at study enrollment who subsequently underwent attempted curative resections of metastases was calculated as follows: number of participants considered by the investigator to be unresectable at study enrollment who subsequently underwent attempted curative resections of metastases divided by total number of participants in each arm. This outcome represents a measure of the rate of conversion from unresectable to resectable disease. (NCT01765582)
Timeframe: Randomization up to approximately 3 years

InterventionProportion of participants (Number)
Arm A: Concurrent FOLFOXIRI + Bevacizumab0.24
Arm B: Sequential FOLFOXIRI + Bevacizumab0.17
Arm C: FOLFOX + Bevacizumab0.14
Arms A + B: Pooled FOLFOXIRI + Bevacizumab0.21

Proportion of Participants Who Underwent Liver Metastases Resections

Reported here is the proportion of participants who underwent liver metastases resections calculated as follows: number of participants who underwent liver metastases resections divided by total number of participants in each arm. (NCT01765582)
Timeframe: Randomization up to approximately 3 years

InterventionProportion of participants (Number)
Arm A: Concurrent FOLFOXIRI + Bevacizumab0.17
Arm B: Sequential FOLFOXIRI + Bevacizumab0.10
Arm C: FOLFOX + Bevacizumab0.08
Arms A + B: Pooled FOLFOXIRI + Bevacizumab0.14

Time to PFS2

Time to PFS2 was defined as time from randomization to the first occurrence of disease progression after reinduction of second-line therapy, as assessed by the Investigator using RECIST v1.1, or death from any cause, whichever occurs first. Disease progression was defined as sum of longest diameters increased by at least 20% from the smallest value on study. The sum of longest diameters must also demonstrate an absolute increase of at least 5mm. (NCT01765582)
Timeframe: Randomization up to disease progression during second-line therapy or death, whichever occurs first (up to approximately 3 years)

Interventionmonths (Median)
Arm A: Concurrent FOLFOXIRI + Bevacizumab18.76
Arm B: Sequential FOLFOXIRI + Bevacizumab13.17
Arm C: FOLFOX + Bevacizumab14.75
Arms A + B: Pooled FOLFOXIRI + Bevacizumab15.08

Objective Tumor Response Rate (Irinotecan)

Best overall response of complete or partial response within irinotecan stratum (NCT00115765)
Timeframe: Overall Study

InterventionParticipant (Number)
Irinotecan and Bevacizumab Plus Panitumumab49
Irinotecan and Bevacizumab Without Panitumumab46

Objective Tumor Response Rate (Mutant KRAS)

Best overall response of complete or partial response in participants treated with irinotecan and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study

InterventionParticipant (Number)
Irinotecan and Bevacizumab Plus Panitumumab14
Irinotecan and Bevacizumab Without Panitumumab15

Objective Tumor Response Rate (Oxaliplatin)

Best overall response of complete or partial response within oxaliplatin stratum (NCT00115765)
Timeframe: Overall study

InterventionParticipant (Number)
Oxaliplatin and Bevacizumab Plus Panitumumab190
Oxaliplatin and Bevacizumab Without Panitumumab196

Objective Tumor Response Rate (Wild-type KRAS)

Best overall response of complete or partial response in participants treated with irinotecan and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study

InterventionParticipant (Number)
Irinotecan and Bevacizumab Plus Panitumumab31
Irinotecan and Bevacizumab Without Panitumumab28

Objective Tumor Response Through Week 12 (Irinotecan)

Objective tumor response (complete or partial) rate through week 12 based on central review in the Irinotecan stratum (NCT00115765)
Timeframe: Overall Study

InterventionParticipant (Number)
Irinotecan and Bevacizumab Plus Panitumumab29
Irinotecan and Bevacizumab Without Panitumumab27

Overall Survival (Irinotecan)

Incidence of mortality from any cause in groups treated with Irinotecan. Incidence is provided in lieu of the median time to death since the median or its measure of dispersion was not estimable for at least one treatment arm. (NCT00115765)
Timeframe: Overall study

InterventionParticipant (Number)
Irinotecan and Bevacizumab Plus Panitumumab26
Irinotecan and Bevacizumab Without Panitumumab18

Overall Survival (Mutant KRAS)

Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median. (NCT00115765)
Timeframe: Overall Study

InterventionParticipant (Number)
Oxaliplatin and Bevacizumab Plus Panitumumab47
Oxaliplatin and Bevacizumab Without Panitumumab45

Overall Survival (Oxaliplatin)

Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin (NCT00115765)
Timeframe: Overall study

InterventionMonth (Median)
Oxaliplatin and Bevacizumab Plus Panitumumab19.4
Oxaliplatin and Bevacizumab Without Panitumumab24.5

Overall Survival (Wild-type KRAS)

Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median (NCT00115765)
Timeframe: Overall Study

InterventionParticipant (Number)
Oxaliplatin and Bevacizumab Plus Panitumumab71
Oxaliplatin and Bevacizumab Without Panitumumab46

Progression-free Survival (Irinotecan)

Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression (NCT00115765)
Timeframe: Overall Study

InterventionMonth (Median)
Irinotecan and Bevacizumab Plus Panitumumab10.1
Irinotecan and Bevacizumab Without Panitumumab11.7

Progression-free Survival (Mutant KRAS)

Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study

InterventionMonth (Median)
Oxaliplatin and Bevacizumab Plus Panitumumab10.4
Oxaliplatin and Bevacizumab Without Panitumumab11.0

Progression-Free Survival (Oxaliplatin)

Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression (NCT00115765)
Timeframe: Overall study

InterventionMonth (Median)
Oxaliplatin and Bevacizumab Plus Panitumumab10.0
Oxaliplatin and Bevacizumab Without Panitumumab11.4

Progression-free Survival (Wild-type KRAS)

Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study

InterventionMonth (Median)
Oxaliplatin and Bevacizumab Plus Panitumumab9.8
Oxaliplatin and Bevacizumab Without Panitumumab11.5

Time to Progression (Irinotecan)

Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the irinotecan stratum (NCT00115765)
Timeframe: Overall Study

InterventionMonth (Median)
Irinotecan and Bevacizumab Plus Panitumumab11.1
Irinotecan and Bevacizumab Without Panitumumab11.9

Time to Progression (Oxaliplatin)

Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the oxaliplatin stratum (NCT00115765)
Timeframe: Overall Study

InterventionMonth (Median)
Oxaliplatin and Bevacizumab Plus Panitumumab10.8
Oxaliplatin and Bevacizumab Without Panitumumab11.4

Time to Treatment Failure (Irinotecan)

Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the irinotecan stratum (NCT00115765)
Timeframe: Overall Study

InterventionMonth (Median)
Irinotecan and Bevacizumab Plus Panitumumab6.6
Irinotecan and Bevacizumab Without Panitumumab6.0

Time to Treatment Failure (Oxaliplatin)

Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the oxaliplatin stratum. (NCT00115765)
Timeframe: Overall study

InterventionMonth (Median)
Oxaliplatin and Bevacizumab Plus Panitumumab5.7
Oxaliplatin and Bevacizumab Without Panitumumab5.9

Duration of Response

Duration of Response is calculated as the time from the first recording of CR/PR until the patient progresses, regardless of whether the patient was still taking study medication. Only confirmed responses are included in the calculation. For patients who had not progressed, the end date used in the calculation of duration of response is the data cut-off date of 15th November 2009. (NCT00384176)
Timeframe: Up until data cut-off date of 15/11/2007

InterventionMonths (Median)
Cediranib 20 mg8.6
Bevacizumab 5 mg/kg9.6

Objective Response Rate

"Objective response rate is Complete Response (CR) + Partial Response (PR) as defined below:~CR = Disappearance of all target lesions. PR = At least a 30% decrease in the sum of longest diameters (LDs) of target lesions, taking as reference the baseline sum of LDs." (NCT00384176)
Timeframe: Up until data cut-off

InterventionParticipants (Number)
Cediranib 20 mg328
Bevacizumab 5 mg/kg337

Overall Survival

Number of months from randomisation to the date of death from any cause (NCT00384176)
Timeframe: Randomisation until data cut-off

InterventionMonths (Median)
Cediranib 20 mg22.8
Bevacizumab 5 mg/kg21.3

Percentage Change in Tumour Size

Percentage change in tumour size from baseline to first RECIST assessment (Week 8) ((Week 8 - baseline)/baseline)*100 (NCT00384176)
Timeframe: Baseline to Week 8

InterventionPercentage change in tumour size (Mean)
Cediranib 20 mg-23.2
Bevacizumab 5 mg/kg-22.1

Progression Free Survival

Progression is defined as the number of months from randomisation until progressive disease based on RECIST (progression of target lesions, clear progression of existing non-target lesions or the appearance of one or more new lesions) or death in the absence of progression. (NCT00384176)
Timeframe: Baseline then at Weeks 8, 16, 24 and then every 12 weeks until progression

InterventionMonths (Median)
Cediranib 20 mg9.9
Bevacizumab 5 mg/kg10.3

Time to Worsening of Health Related Quality of Life (QOL) Based on the FACT Colorectal Symptom Index (FCSI)

Time to worsening of symptoms, as measured by the FACT colorectal symptom index (FCSI), will be defined as the time when a sustained clinically important deterioration in the total score from the FCSI has been recorded. (NCT00384176)
Timeframe: Baseline through to data cut-off

InterventionDays (Median)
Cediranib 20 mg170
Bevacizumab 5 mg/kg245

(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per BICR

DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to PD or death due to underlying disease (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Doublet Arm6.06
Phase 3:Control ArmNA

(Phase 3) Comparison of Duration of Response (DOR) in Doublet Arm vs Control Arm Per Investigator

DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to PD or death due to underlying disease (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Doublet Arm5.70
Phase 3:Control Arm5.75

(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per BICR

DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to PD or death due to underlying disease (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Triplet Arm4.80
Phase 3:Control ArmNA

(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Control Arm Per Investigator

DOR was defined as the time from first radiographic evidence of response to the earliest documented disease progression (PD) or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to PD or death due to underlying disease (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Triplet Arm4.80
Phase 3:Control Arm5.75

(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by BICR

DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to PD or death due to underlying disease (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)

InterventionMonths (Median)
Phase 3: Triplet Arm4.80
Phase 3:Doublet Arm6.06

(Phase 3) Comparison of Duration of Response (DOR) in Triplet Arm vs Doublet Arm by Investigator

DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to PD or death due to underlying disease (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)

InterventionMonths (Median)
Phase 3: Triplet Arm4.80
Phase 3:Doublet Arm5.70

(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per BICR

ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)

InterventionPercentage of participants (Number)
Phase 3: Doublet Arm20.4
Phase 3:Control Arm1.9

(Phase 3) Comparison of Objective Response Rate (ORR) in Doublet Arm vs Control Arm Per Investigator

ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)

InterventionPercentage of participants (Number)
Phase 3: Doublet Arm15.9
Phase 3:Control Arm3.7

(Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Control Arm Per Investigator

ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)

InterventionPercentage of participants (Number)
Phase 3: Triplet Arm26.1
Phase 3:Control Arm3.7

(Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per BICR

ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)

InterventionPercentage of participants (Number)
Phase 3: Triplet Arm26.1
Phase 3: Doublet Arm20.4

(Phase 3) Comparison of Objective Response Rate (ORR) in Triplet Arm vs Doublet Arm Per Investigator

ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)

InterventionPercentage of participants (Number)
Phase 3: Triplet Arm26.1
Phase 3: Doublet Arm15.9

(Phase 3) Comparison of Progression-Free Survival (PFS) in Doublet Arm vs Control Arm Per BICR

PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Doublet Arm4.21
Phase 3:Control Arm1.51

(Phase 3) Comparison of Progression-Free Survival (PFS) in Doublet Arm vs Control Arm Per Investigator

PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Doublet Arm4.27
Phase 3:Control Arm1.58

(Phase 3) Comparison of Progression-Free Survival (PFS) in Triplet Arm vs Control Arm Per BICR

PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Triplet Arm4.30
Phase 3:Control Arm1.51

(Phase 3) Comparison of Progression-free Survival (PFS) in Triplet Arm vs Control Arm Per Investigator

PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Triplet Arm4.47
Phase 3:Control Arm1.58

(Phase 3) Comparison of Progression-Free Survival (PFS) in Triplet Arm vs Doublet Arm Per BICR

PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)

InterventionMonths (Median)
Phase 3: Triplet Arm4.30
Phase 3: Doublet Arm4.21

(Phase 3) Comparison of Progression-Free Survival (PFS) in Triplet Arm vs Doublet Arm Per Investigator

PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)

InterventionMonths (Median)
Phase 3: Triplet Arm4.47
Phase 3: Doublet Arm4.27

(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per BICR

Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Doublet Arm1.48
Phase 3:Control Arm1.45

(Phase 3) Comparison of Time to Response in Doublet Arm vs Control Arm Per Investigator

Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 268 weeks for doublet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Doublet Arm1.48
Phase 3:Control Arm2.63

(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per BICR

Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Triplet Arm1.43
Phase 3:Control Arm1.45

(Phase 3) Comparison of Time to Response in Triplet Arm vs Control Arm Per Investigator

Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Triplet Arm1.48
Phase 3:Control Arm2.63

(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per BICR

Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)

InterventionMonths (Median)
Phase 3: Triplet Arm1.43
Phase 3:Doublet Arm1.48

(Phase 3) Comparison of Time to Response in Triplet Arm vs Doublet Arm Per Investigator

Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 277.4 weeks for triplet arm and 268 weeks for doublet arm)

InterventionMonths (Median)
Phase 3: Triplet Arm1.48
Phase 3:Doublet Arm1.48

(Phase 3) Evaluation of the Model-Based Clearance (CL) for Cetuximab

The reported cross-arm CL/F value is a fixed-effect parameter determined from a population PK analysis. The analysis included pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register. (NCT02928224)
Timeframe: 2 and 6 hours post-dose on Day 1 of Cycle 1, Predose and 2 hours post-dose on Day 1 of Cycle 2 (each cycle of 28 days)

InterventionLiter/hour (Geometric Mean)
Pharmacokinetic Population of Encorafenib0.0154

(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Binimetinib

The reported cross-arm CL/F value is a fixed-effect parameter determined from a population PK analysis. The analysis included pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register. (NCT02928224)
Timeframe: 2 and 6 hours post-dose on Day 1 of Cycle 1, Predose and 2 hours post-dose on Day 1 of Cycle 2 (each cycle of 28 days)

InterventionLiter/hour (Geometric Mean)
Pharmacokinetic Population of Encorafenib19.0

(Phase 3) Evaluation of the Model-Based Oral Clearance (CL/F) for Encorafenib

The reported cross-arm CL/F value is a fixed-effect parameter determined from a population PK analysis. The analysis included pooled data from participants enrolled in multiple studies including those who were not enrolled in this study. The NCTID include: NCT01719380, NCT01543698, and NCT01436656. An additional study ARRAY-162-105 is not required to register. (NCT02928224)
Timeframe: 2 and 6 hours post-dose on Day 1 of Cycle 1, Predose and 2 hours post-dose on Day 1 of Cycle 2 (each cycle of 28 days)

InterventionLiter/hour (Geometric Mean)
Pharmacokinetic Population of Encorafenib16.4

(Phase 3) Objective Response Rate (ORR) by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST), v1.1 of Triplet Arm vs. Control Arm

ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of complete response (CR) or partial response (PR), where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 millimeter [mm] short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: Duration of Phase 3, approximately 6 months (up to 28 days per cycle)

InterventionPercentage of participants (Number)
Phase 3: Triplet Arm26.1
Phase 3:Control Arm1.9

(Phase 3) Overall Survival (OS) in Doublet Arm vs. Control Arm

OS was defined as the time from randomization to death due to any cause. (NCT02928224)
Timeframe: From randomization to death due to any cause until 204 deaths were observed (maximum treatment exposure of 89.7 weeks for doublet arm and 52.4 weeks for control arm)

InterventionMonths (Median)
Phase 3: Doublet Arm9.40
Phase 3:Control Arm5.88

(Phase 3) Overall Survival (OS) in Triplet Arm vs. Doublet Arm

OS was defined as the time from randomization to death due to any cause. (NCT02928224)
Timeframe: From randomization to death due to any cause until 204 deaths were observed (maximum treatment exposure of 89.7 weeks for doublet arm and 89.1 weeks for triplet arm)

InterventionMonths (Median)
Phase 3: Triplet Arm9.82
Phase 3: Doublet Arm9.40

(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Final Analysis

OS was defined as the time from randomization to death due to any cause. (NCT02928224)
Timeframe: From randomization to death due to any cause (maximum treatment exposure of 277.4 weeks for triplet arm and 108 weeks for control arm)

InterventionMonths (Median)
Phase 3: Triplet Arm9.82
Phase 3:Control Arm5.88

(Phase 3) Overall Survival (OS) of Triplet Arm vs. Control Arm - Interim Analysis

OS was defined as the time from randomization to death due to any cause. (NCT02928224)
Timeframe: From randomization to death due to any cause until 204 deaths were observed (maximum treatment exposure of 89.1 weeks for triplet arm and 52.4 weeks for control arm)

InterventionMonths (Median)
Phase 3: Triplet Arm9.03
Phase 3: Control Arm5.42

(Safety Lead-in) Duration of Response (DOR) by BICR

DOR was defined as the time from first radiographic evidence of response to the earliest documented PD or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to the earliest documented PD or death due to underlying disease (maximum treatment exposure of 280 weeks)

InterventionMonths (Median)
Combined Safety Lead-in8.15

(Safety Lead-in) Duration of Response (DOR) by Investigator

DOR was defined as the time from first radiographic evidence of response to the earliest documented disease progression (PD) or death due to underlying disease. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From time of response to the earliest documented PD or death due to underlying disease (maximum treatment exposure of 280 weeks)

InterventionMonths (Median)
Combined Safety Lead-in6.47

(Safety Lead-in) Evaluation of the Steady-State Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for a Metabolite of Binimetinib

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter (Geometric Mean)
Combined Safety Lead-in3.41

(Safety Lead-in) Evaluation of the Steady-State Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Binimetinib

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter (Geometric Mean)
Combined Safety Lead-in55.3

(Safety Lead-in) Evaluation of the Steady-State Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Cetuximab

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter (Geometric Mean)
Combined Safety Lead-in55400

(Safety Lead-in) Evaluation of the Steady-State Concentration Measured Just Before the Next Dose of Study Drug (Ctrough) for Encorafenib

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter (Geometric Mean)
Combined Safety Lead-in18.9

(Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Interim Analysis

An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants with dose interruptions, dose modifications and dose discontinuations due to AEs were reported in this outcome measure. (NCT02928224)
Timeframe: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)

InterventionParticipants (Count of Participants)
Combined Safety Lead-in26

(Safety Lead-in) Number of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants reporting AEs were reported in this outcome measure. (NCT02928224)
Timeframe: Duration of safety lead-in, approximately 6 months (up to 28 days per cycle)

InterventionParticipants (Count of Participants)
Combined Safety Lead-in37

(Safety Lead-in) Number of Participants With Dose-Limiting Toxicities (DLTs)

(NCT02928224)
Timeframe: Cycle 1 (up to 28 days)

InterventionParticipants (Count of Participants)
Combined Safety Lead-in (CSLI)5

(Safety Lead-in) Objective Response Rate (ORR) by BICR

ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (maximum treatment exposure of 280 weeks)

InterventionPercentage of participants (Number)
Combined Safety Lead-in41.7

(Safety Lead-in) Objective Response Rate (ORR) by Investigator

ORR per RECIST, v1.1, was defined as the percentage of participants achieving an overall best response of CR or PR, where CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (<10 mm short axis), and PR: at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesions and/or maintenance of tumor marker level above the normal limits. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (maximum treatment exposure of 280 weeks)

InterventionPercentage of participants (Number)
Combined Safety Lead-in52.8

(Safety Lead-in) Progression-Free Survival (PFS) by BICR

PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 280 weeks)

InterventionMonths (Median)
Combined Safety Lead-in5.59

(Safety Lead-in) Progression-Free Survival (PFS) by Investigator

PFS was defined as the time from first dose to the earliest documented PD or death due to any cause. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. (NCT02928224)
Timeframe: From first dose to the earliest documented PD or death due to any cause (maximum treatment exposure of 280 weeks)

InterventionMonths (Median)
Combined Safety Lead-in8.08

(Safety Lead-in) Time to Response by BICR

Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 280 weeks)

InterventionMonths (Median)
Combined Safety Lead-in1.45

(Safety Lead-in) Time to Response by Investigator

Time to response was defined as the time from first dose to first radiographic evidence of response. (NCT02928224)
Timeframe: From first dose to first radiographic evidence of response (maximum treatment exposure of 280 weeks)

InterventionMonths (Median)
Combined Safety Lead-in1.45

Phase 3: Number of Participants With Clinically Notable Shifts in Urinalysis Laboratory Parameters

Clinically notable shifts was defined as worsening by at least 2 grades or to >= Grade 3 based on CTCAE version 4.03 where Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life threatening and Grade 5: death. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)

InterventionParticipants (Count of Participants)
Phase 3: Triplet Arm8
Phase 3: Doublet Arm8
Phase 3: Control Arm5

(Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Participants (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

The EORTC QLQ-C30 questionnaire consisted of 30 questions generating 5 functional scores (physical, role, cognitive, emotional, & social); a global health (GH) status/global quality of life scale score; 3 symptom scale scores (fatigue, pain, & nausea & vomiting); & 6 standalone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, & diarrhea) & perceived financial burden. All items were graded by severity experienced during previous week & used 4-point-scale (1: not at all, 2: a little, 3: quite a bit, 4: very much). The scores were converted to health-related quality of life (HRQoL) scale ranging from 0-100. Higher scores indicating higher response levels (i.e., higher functioning, higher symptom severity). (NCT02928224)
Timeframe: Baseline, Cycle(C)1 Day(D)1 , C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3:Control Arm62.8-3.4-1.9-0.21.4-2.2-4.51.70.0-4.82.133.34.20.0-15.5-24.6

(Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Participants (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

The EORTC QLQ-C30 questionnaire consisted of 30 questions generating 5 functional scores (physical, role, cognitive, emotional, & social); a global health (GH) status/global quality of life scale score; 3 symptom scale scores (fatigue, pain, & nausea & vomiting); & 6 standalone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, & diarrhea) & perceived financial burden. All items were graded by severity experienced during previous week & used 4-point-scale (1: not at all, 2: a little, 3: quite a bit, 4: very much). The scores were converted to health-related quality of life (HRQoL) scale ranging from 0-100. Higher scores indicating higher response levels (i.e., higher functioning, higher symptom severity). (NCT02928224)
Timeframe: Baseline, Cycle(C)1 Day(D)1 , C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at Cycle 14 Day 1Change at Cycle 15 Day 1Change at Cycle 16 Day 1Change at Cycle 17 Day 1Change at Cycle 18 Day 1Change at Cycle 19 Day 1Change at Cycle 20 Day 1Change at Cycle 21 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3: Triplet Arm62.8-2.4-1.60.70.2-1.1-4.0-2.5-2.6-5.8-3.3-5.20.00.0-1.23.6-16.7-27.8-16.70.0-250.0-14.1-17.4

(Phase 3) Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for Cancer Participants (QLQ-C30) Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

The EORTC QLQ-C30 questionnaire consisted of 30 questions generating 5 functional scores (physical, role, cognitive, emotional, & social); a global health (GH) status/global quality of life scale score; 3 symptom scale scores (fatigue, pain, & nausea & vomiting); & 6 standalone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, & diarrhea) & perceived financial burden. All items were graded by severity experienced during previous week & used 4-point-scale (1: not at all, 2: a little, 3: quite a bit, 4: very much). The scores were converted to health-related quality of life (HRQoL) scale ranging from 0-100. Higher scores indicating higher response levels (i.e., higher functioning, higher symptom severity). (NCT02928224)
Timeframe: Baseline, Cycle(C)1 Day(D)1 , C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at Cycle 14 Day 1Change at Cycle 15 Day 1Change at Cycle 16 Day 1Change at Cycle 17 Day 1Change at Cycle 18 Day 1Change at Cycle 19 Day 1Change at Cycle 20 Day 1Change at Cycle 21 Day 1Change at Cycle 22 Day 1Change at Cycle 23 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3:Doublet Arm60.7-4.33.83.54.24.35.64.34.2-5.6-2.83.9-4.6-3.2-6.02.8-5.6-2.8-8.3-8.3-8-16.7-16.70.0-13.1-10.4

(Phase 3) Change From Baseline in the EuroQol-5D-5L Visual Analog Scale (EQ-5D-5L VAS) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

The EQ-5D-5L contains 1 item for each of 5 dimensions of health-related QoL (i.e., mobility, self-care, usual activities, pain or discomfort and anxiety or depression). Response options for each item varied from having no problems to moderate problems or extreme problems. The EQ-5D-5L (v4.0) is a standardized measure of health utility that provides a single index value for one's health status. The EQ-5D-5L is frequently used for economic evaluations of health care and has been recognized as a valid and reliable instrument for this purpose. The EQ visual analog scale (VAS) is a score that is directly reported by the participant and ranges from 0 to 100 (higher is better quality health). (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3:Control Arm68.3-2.1-2.4-1.4-0.42.5-3.62.4-2.8-8.1-1.84.01.5-2.0-12.7-11.0

(Phase 3) Change From Baseline in the EuroQol-5D-5L Visual Analog Scale (EQ-5D-5L VAS) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

The EQ-5D-5L contains 1 item for each of 5 dimensions of health-related QoL (i.e., mobility, self-care, usual activities, pain or discomfort and anxiety or depression). Response options for each item varied from having no problems to moderate problems or extreme problems. The EQ-5D-5L (v4.0) is a standardized measure of health utility that provides a single index value for one's health status. The EQ-5D-5L is frequently used for economic evaluations of health care and has been recognized as a valid and reliable instrument for this purpose. The EQ visual analog scale (VAS) is a score that is directly reported by the participant and ranges from 0 to 100 (higher is better quality health). (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at Cycle 14 Day 1Change at Cycle 15 Day 1Change at Cycle 16 Day 1Change at Cycle 17 Day 1Change at Cycle 18 Day 1Change at Cycle 19 Day 1Change at Cycle 20 Day 1Change at Cycle 21 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3: Triplet Arm69.00.81.43.04.03.31.31.44.10.30.20.2-4.0-3.0-4.0-3.4-10.4-18.37.08.08.08.0-8.5-11.1

(Phase 3) Change From Baseline in the EuroQol-5D-5L Visual Analog Scale (EQ-5D-5L VAS) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

The EQ-5D-5L contains 1 item for each of 5 dimensions of health-related QoL (i.e., mobility, self-care, usual activities, pain or discomfort and anxiety or depression). Response options for each item varied from having no problems to moderate problems or extreme problems. The EQ-5D-5L (v4.0) is a standardized measure of health utility that provides a single index value for one's health status. The EQ-5D-5L is frequently used for economic evaluations of health care and has been recognized as a valid and reliable instrument for this purpose. The EQ visual analog scale (VAS) is a score that is directly reported by the participant and ranges from 0 to 100 (higher is better quality health). (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at Cycle 14 Day 1Change at Cycle 15 Day 1Change at Cycle 16 Day 1Change at Cycle 17 Day 1Change at Cycle 18 Day 1Change at Cycle 19 Day 1Change at Cycle 20 Day 1Change at Cycle 21 Day 1Change at Cycle 22 Day 1Change at Cycle 23 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3:Doublet Arm66.5-0.91.94.25.65.12.93.62.0-4.0-8.1-0.1-0.6-4.1-0.44.23.31.7-3.3-5.52.0-5.0-5.0-5.0-8.0-5.9

(Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

FACT-C= Functional Assessment of Chronic Illness Therapy (FACIT), which assessed HRQoL of cancer participants & participants with other chronic illnesses. It consists of total 36 items (27 items of general version of FACT-C and disease-specific subscale containing 9 CRC-specific items), summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range:0-28, emotional well-being (6 items) range: 0-24, colorectal cancer subscale (9 items) range: 0-36; higher subscale score= better QoL. All single-item measures range: 0= 'Not at all' to 4= 'Very much'. Table summarizes functional well-being subscale, individual questions are linearly scaled & combined to form functional well-being subscale score (range 0-28). High score represents better QoL. (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3:Control Arm16.8-1.4-0.9-0.7-1.8-1.6-1.9-0.5-2.1-2.60.5-4.5-4.5-8.0-3.1-4.2

(Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

FACT-C= Functional Assessment of Chronic Illness Therapy (FACIT), which assessed HRQoL of cancer participants & participants with other chronic illnesses. It consists of total 36 items (27 items of general version of FACT-C and disease-specific subscale containing 9 CRC-specific items), summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range:0-28, emotional well-being (6 items) range: 0-24, colorectal cancer subscale (9 items) range: 0-36; higher subscale score= better QoL. All single-item measures range: 0= 'Not at all' to 4= 'Very much'. Table summarizes functional well-being subscale, individual questions are linearly scaled & combined to form functional well-being subscale score (range 0-28). High score represents better QoL. (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at Cycle 14 Day 1Change at Cycle 15 Day 1Change at Cycle 16 Day 1Change at Cycle 17 Day 1Change at Cycle 18 Day 1Change at Cycle 19 Day 1Change at Cycle 20 Day 1Change at Cycle 21 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3: Triplet Arm16.3-0.2-0.3-0.20.40.70.70.50.9-1.9-1.7-1.5-1.5-2.0-2.4-2.3-4.2-6.7-5.0-7.0-6.0-9.0-2.4-3.5

(Phase 3) Change From Baseline in the Functional Assessment of Cancer Therapy-Colon Cancer (FACT-C) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

FACT-C= Functional Assessment of Chronic Illness Therapy (FACIT), which assessed HRQoL of cancer participants & participants with other chronic illnesses. It consists of total 36 items (27 items of general version of FACT-C and disease-specific subscale containing 9 CRC-specific items), summarized to 5 subscales: physical well-being (7 items), functional well-being (7 items), social/family well-being (7 items); all 3 subscales range:0-28, emotional well-being (6 items) range: 0-24, colorectal cancer subscale (9 items) range: 0-36; higher subscale score= better QoL. All single-item measures range: 0= 'Not at all' to 4= 'Very much'. Table summarizes functional well-being subscale, individual questions are linearly scaled & combined to form functional well-being subscale score (range 0-28). High score represents better QoL. (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at Cycle 14 Day 1Change at Cycle 15 Day 1Change at Cycle 16 Day 1Change at Cycle 17 Day 1Change at Cycle 18 Day 1Change at Cycle 19 Day 1Change at Cycle 20 Day 1Change at Cycle 21 Day 1Change at Cycle 22 Day 1Change at Cycle 23 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3:Doublet Arm16.2-0.9-0.6-0.2-0.1-0.20.6-0.10.2-0.8-1.3-0.5-1.1-3.2-4.0-1.5-0.7-0.7-3.0-6.0-5.0-5.0-12.0-9.0-2.2-0.8

(Phase 3) Change From Baseline in the Participant Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

"The PGIC is a measure of participant's perceptions of change in their symptoms over time that can be used as an anchoring method to determine the minimal clinically important difference for other participant reported outcome (PROs). For this assessment, participants answered the following question: Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse." (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3:Control Arm3.90.0-0.3-0.5-0.5-0.7-0.8-1.1-1.0-1.0-0.30.0-0.5-1.00.40.7

(Phase 3) Change From Baseline in the Participant Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

"The PGIC is a measure of participant's perceptions of change in their symptoms over time that can be used as an anchoring method to determine the minimal clinically important difference for other participant reported outcome (PROs). For this assessment, participants answered the following question: Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse." (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at Cycle 14 Day 1Change at Cycle 15 Day 1Change at Cycle 16 Day 1Change at Cycle 17 Day 1Change at Cycle 18 Day 1Change at Cycle 19 Day 1Change at Cycle 20 Day 1Change at Cycle 21 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3: Triplet Arm3.8-0.1-0.7-0.9-0.9-0.9-0.8-1.1-1.2-0.8-0.5-0.9-0.9-1.3-1.1-1.2-2.0-1.3-2.0-3.0-3.0-3.00.3-0.1

(Phase 3) Change From Baseline in the Participant Global Impression of Change (PGIC) in Triplet Arm vs Control Arm, Doublet Arm vs Control, and Triplet vs Doublet

"The PGIC is a measure of participant's perceptions of change in their symptoms over time that can be used as an anchoring method to determine the minimal clinically important difference for other participant reported outcome (PROs). For this assessment, participants answered the following question: Since starting treatment, my colorectal cancer symptoms are: (1) very much improved, (2) much improved, (3) minimally improved, (4) no change, (5) minimally worse, (6) much worse or (7) very much worse." (NCT02928224)
Timeframe: Baseline,Cycle (C)1 Day (D)1, C2 D1, C3 D1, C4 D1, C5 D1, C6 D1, C7 D1, C8 D1, C9 D1, C10 D1, C11 D1, C12 D1, C13 D1, C14 D1, C15 D1, C16 D1, C17 D1, C18 D1, C19 D1, C20 D1, C21 D1, C22 D1, C23 D1, End of Treatment, 30 Day Follow Up(each cycle of 28 days)

InterventionUnits on a scale (Mean)
BaselineChange at Cycle 1 Day 1Change at Cycle 2 Day 1Change at Cycle 3 Day 1Change at Cycle 4 Day 1Change at Cycle 5 Day 1Change at Cycle 6 Day 1Change at Cycle 7 Day 1Change at Cycle 8 Day 1Change at Cycle 9 Day 1Change at Cycle 10 Day 1Change at Cycle 11 Day 1Change at Cycle 12 Day 1Change at Cycle 13 Day 1Change at Cycle 14 Day 1Change at Cycle 15 Day 1Change at Cycle 16 Day 1Change at Cycle 17 Day 1Change at Cycle 18 Day 1Change at Cycle 19 Day 1Change at Cycle 20 Day 1Change at Cycle 21 Day 1Change at Cycle 22 Day 1Change at Cycle 23 Day 1Change at End of TreatmentChange at 30 Day Follow Up
Phase 3:Doublet Arm3.80.1-0.8-1.2-1.1-1.1-1.2-1.0-1.1-0.9-0.6-1.1-0.8-0.9-1.5-1.6-0.7-1.0-1.0-0.5-2.0-2.0-2.0-2.00.10.5

(Safety Lead-in) Evaluation of the Area Under the Concentration-Time Curve From Zero to the Last Measurable Time Point (AUClast) for Binimetinib

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter *hour (Geometric Mean)
Cycle 1Cycle 2
Combined Safety Lead-in19601540

(Safety Lead-in) Evaluation of the Area Under the Concentration-Time Curve From Zero to the Last Measurable Time Point (AUClast) for Cetuximab

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter *hour (Geometric Mean)
Cycle 1Cycle 2
Combined Safety Lead-in841000970000

(Safety Lead-in) Evaluation of the Area Under the Concentration-Time Curve From Zero to the Last Measurable Time Point (AUClast) for Encorafenib

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter *hour (Geometric Mean)
Cycle 1Cycle 2
Combined Safety Lead-in113006660

(Safety Lead-in) Evaluation of the Area Under the Concentration-time Curve From Zero to the Last Measurable Time Point (AUClast) for Metabolite of Binimetinib (AR00426032)

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter *hour (Geometric Mean)
Cycle 1Cycle 2
Combined Safety Lead-in20670.0

(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Binimetinib

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter (Geometric Mean)
Cycle 1Cycle 2
Combined Safety Lead-in654524

(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Cetuximab

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter (Geometric Mean)
Cycle 1Cycle 2
Combined Safety Lead-in195000199000

(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Encorafenib

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter (Geometric Mean)
Cycle 1Cycle 2
Combined Safety Lead-in33602490

(Safety Lead-in) Evaluation of the Maximum Concentration (Cmax) for Metabolite of Binimetinib (AR00426032)

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionNanogram/milliliter (Geometric Mean)
Cycle 1Cycle 2
Combined Safety Lead-in59.920.5

(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Binimetinib

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionHours (Median)
Cycle 1Cycle 2
Combined Safety Lead-in1.981.04

(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Cetuximab

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionHours (Median)
Cycle 1Cycle 2
Combined Safety Lead-in3.773.05

(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Encorafenib

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionHours (Median)
Cycle 1Cycle 2
Combined Safety Lead-in2.002.00

(Safety Lead-in) Evaluation of the Time of Maximum Observed Concentration (Tmax) for Metabolite of Binimetinib (AR00426032)

(NCT02928224)
Timeframe: Predose and 1, 2, 4 and 6 hours post-dose on Day 1 of Cycles 1 and 2 (each cycle of 28 days)

InterventionHours (Median)
Cycle 1Cycle 2
Combined Safety Lead-in2.001.58

(Safety Lead-in) Incidence of Dose Interruptions, Dose Modifications and Discontinuations Due to Adverse Events (AEs) - Final Analysis

An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. Number of participants according to incidence of dose interruptions, dose modifications and dose discontinuations due to AEs were reported in this outcome measure. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (maximum treatment exposure of 280 weeks)

InterventionParticipants (Count of Participants)
Dose interruptionsDose modificationsDiscontinuation due to AEs
Combined Safety Lead-in30168

Phase 3: Number of Participants With Clinically Notable Shifts in Hematology and Coagulation Laboratory Parameters

Clinically notable shifts was defined as worsening by at least 2 grades or to more than or equal to (>=) Grade 3 based on Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 where Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life threatening and Grade 5: death. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)

,,
InterventionParticipants (Count of Participants)
Activated Partial Thromboplastin Time - HyperHemoglobin - HyperHemoglobin - HypoLeukocytes - HyperLeukocytes - HypoLymphocytes - HyperLymphocytes - HypoNeutrophils - HypoPlatelets - HypoProthrombin Intl. Normalized Ratio - Hyper
Phase 3: Doublet Arm903009347852
Phase 3: Triplet Arm9097021225413
Phase 3:Control Arm40170514576542

Phase 3: Number of Participants With Clinically Notable Shifts in Serum Chemistry Laboratory Parameters

Clinically notable shifts was defined as worsening by at least 2 grades or to >= Grade 3 based on CTCAE version 4.03 where Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life threatening and Grade 5: death. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)

,,
InterventionParticipants (Count of Participants)
Alanine Aminotransferase - HyperAlbumin - HypoAlkaline Phosphatase - HyperAspartate Aminotransferase - HyperBilirubin - HyperCalcium - HyperCalcium - HypoCreatine Kinase - HyperCreatinine - HyperGlucose - HyperGlucose - HypoMagnesium - HyperMagnesium - HypoPotassium - HyperPotassium - HypoSodium - HyperSodium - HypoTroponin I - HyperUrate - Hyper
Phase 3: Control Arm10171891207364129592501
Phase 3: Doublet Arm7161271308111160141071402
Phase 3: Triplet Arm115013111111518458401114511004

Phase 3: Number of Participants With Newly Occurring Clinically Notable Electrocardiogram (ECG) Values

Newly occurring clinically notable changes was defined as participants not meeting the criterion at baseline and meeting criterion post-baseline. The criterion included: heart rate- decrease from baseline > 25% and to a value < 50 and increase from baseline > 25% and to a value > 100. QT interval- new > 450 (millisecond) msec, new > 480 msec, new > 500 msec, increase from baseline > 30 msec and increase from baseline > 60 msec. QTcF- new > 450 msec, new > 480 msec, new > 500 msec, increase from baseline > 30 msec and increase from baseline > 60 msec. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)

,,
InterventionParticipants (Count of Participants)
Heart Rate - Decrease from baseline > 25% and to a value < 50Heart Rate - Increase from baseline > 25% and to a value > 100QT Interval - New > 450 millisecond (msec)QT Interval - New > 480 msecQT Interval - New > 500 msecQT Interval - increase from baseline > 30 msecQT Interval - increase from baseline > 60 msecQTcF - New > 450 msecQTcF - New > 480 msecQTcF - New > 500 msecQTcF - increase from baseline > 30 msecQTcF - increase from baseline > 60 msec
Phase 3: Control Arm02872032102352245
Phase 3: Doublet Arm42430759921511867520
Phase 3: Triplet Arm1271743972239915912

Phase 3: Number of Participants With Newly Occurring Clinically Notable Vital Sign Abnormalities

Newly occurring clinically notable changes was defined as participants not meeting the criterion at baseline and meeting criterion post-baseline. The criterion included: low/high systolic blood pressure (SBP): <= 90 millimeters of mercury (mmHg) with decrease from baseline of >= 20mmHg or >= 160mmHg with increase from baseline of >= 20mmHg, low or high diastolic blood pressure (DBP): <= 50mmHg with decrease from baseline of >= 15mmHg or >= 100mmHg with increase from baseline of >= 15mmHg, low or high pulse: <= 50 beats/min with decrease from baseline of >= 15 beats/min or >= 120 beats/min with increase from baseline of >= 15 beats/min, low or high temperature: <= 36 degree Celsius (deg C) or >= 37.5 deg C. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)

,,
InterventionParticipants (Count of Participants)
Diastolic Blood Pressure - HighDiastolic Blood Pressure - LowPulse Rate - HighPulse Rate - LowSystolic Blood Pressure - HighSystolic Blood Pressure - LowTemperature - HighTemperature - Low
Phase 3: Control Arm752035102555
Phase 3: Doublet Arm62714413282384
Phase 3: Triplet Arm82123319373393

Phase 3: Number of Participants With Shift in Visual Acuity Logarithm of the Minimum Angle of Resolution (LogMAR) Score

Visual acuity was measured using the Snellen visual acuity conversion chart. This was determined by establishing the smallest optotypes that could be identified correctly by the participant at a given observation distance. Snellen visual acuity was reported as a Snellen fraction (m/M) in which the numerator (m) indicated the test distance and the denominator (M) indicated the distance at which the gap of the equivalent Landolt ring subtends 1 minute of arc. The LogMAR score was calculated as - log(m/M). The maximum increase in score of <= 0, 0 to < 0.1, 0.1 to < 0.2, 0.2 to < 0.3 and >=0.3 relative to baseline in LogMAR were reported in this endpoint. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)

,,
InterventionParticipants (Count of Participants)
Baseline <=0 to >0-<0.1Baseline <=0 to 0.1-<0.2Baseline <=0 to 0.2-<0.3Baseline <=0 to >=0.3Baseline <=0 to missing scoreBaseline >0-<0.1 to <=0Baseline >0-<0.1 to 0.1-<0.2Baseline >0-<0.1 to 0.2-<0.3Baseline >0-<0.1 to >=0.3Baseline >0-<0.1 to missing scoreBaseline 0.1-<0.2 to <=0Baseline 0.1-<0.2 to >0-<0.1Baseline 0.2-<0.3 to <=0Baseline 0.2-<0.3 to >0-<0.1Baseline 0.2-<0.3 to 0.1-<0.2Baseline 0.2-<0.3 to missing scoreBaseline >=0.3 to <=0Baseline >=0.3 to >0-<0.1Baseline >=0.3 to 0.1-<0.2Baseline >=0.3 to 0.2-<0.3Baseline >=0.3 to missing scoreBaseline 0.1-<0.2 to 0.2-<0.3Baseline 0.1-<0.2 to missing score
Phase 3: Control Arm000012900003000000500001307
Phase 3: Doublet Arm83018662102510001420101939
Phase 3: Triplet Arm33154691774335113319412100

Phase 3: Number of Participants With Shifts in Left Ventricular Ejection Fraction (LVEF) From Baseline to Maximum Grade On-treatment

Left ventricular ejection fraction (LVEF) abnormalities were defined according to CTCAE version 4.03 where Grade 0: Non-missing value below Grade 2, Grade 2: LVEF between 40% and 50% or absolute change from baseline between -10% and < -20%, Grade 3: LVEF between 20% and 39% or absolute change from baseline <= -20%, Grade 4: LVEF lower than 20%. Categories with at least 1 non-zero data values showing any shift in Grade from baseline to 1 day after dose 1 (post-baseline) were reported. Participants whose grade category was unchanged (e.g. Grade 0 to Grade 0) were not reported. (NCT02928224)
Timeframe: From start of study treatment until 30 days post last dose of study treatment (for triplet arm: maximum treatment exposure of 277.4 weeks; for doublet arm: maximum treatment exposure of 268 weeks; for Control arm: maximum treatment exposure of 108 weeks)

,,
InterventionParticipants (Count of Participants)
Baseline Grade 0 to Grade 2 post baselineBaseline Grade 0 to Grade 3 post baselineBaseline Grade 0 to missing gradeBaseline Grade 2 to missing gradeBaseline missing grade to Grade 0 post baseline
Phase 3: Control Arm0018620
Phase 3: Doublet Arm0120530
Phase 3: Triplet Arm2711701

Number of Participants With an Overall Response Rate (ORR)

Number of participants with an ORR - the portion of patients with a tumor size reduction of a predefined amount for a minimum time period (NCT01985763)
Timeframe: up to 50 months

InterventionParticipants (Count of Participants)
Genistein6

Number of Participants With Best Overall Response Rate (ORR)

The number of participants with best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria. (NCT01985763)
Timeframe: up to 50 months

InterventionParticipants (Count of Participants)
Genistein8

Overall Survival (OS)

Overall Survival - Number of months still living since baseline (NCT01985763)
Timeframe: up to 50 months

Interventionmonths (Median)
Genistein36.5

Percent Change in Tumor Size

Percent change in tumor size after cycle 6. Each cycle is 21 days. (NCT01985763)
Timeframe: end of Cycle 6

InterventionPercent change (Median)
Genistein-43.0

Progression Free Survival (PFS)

Patients monitored for progression. Progression-free survival (PFS) is the length of time during and after the treatment that a patient lives with the disease but it does not get worse. (NCT01985763)
Timeframe: up to 50 months

Interventionmonths (Median)
Genistein11.5

Best Overall Response Rate RECIST Criteria

"Best Overall Response Rate (ORR) as measured by radiologic RECIST criteria. The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.~SD - target lesion SD, non target lesions Non-PD, and no new lesions. PR - target lesion CR, non target lesions Incomplete response/SD and no new lesions; or target lesion PR, non target lesions Non-PD, and no new lesions.~PD - target lesions PD, non target lesions Any, can have new lesions; or target lesions Any, non target lesions PD, can have new lesions; or target lesions Any, non target lesions Any, have new lesions." (NCT01985763)
Timeframe: up to 50 months

InterventionParticipants (Count of Participants)
PRSDPDNot evaluable
Genistein6322

Number of Adverse Events

Number of adverse events to assess tolerability of genistein treatment. Evaluation of side effects conducted every 14 days before each chemotherapy/genistein cycle. (NCT01985763)
Timeframe: up to 6 months

Interventionevents (Number)
Grade 1Grade 2Grade 3Grade 4
Genistein250119240

Percent of Patients With Progression Free Survival (PFS) at 6 Months and 12 Months

"Patients monitored for progression during the study period and 1 year following.~Progression-free survival (PFS) is the length of time during and after the treatment that a patient lives with the disease but it does not get worse." (NCT01985763)
Timeframe: 6 month and 12 month

Interventionpercentage of participants (Number)
6 months12 months
Genistein6938

Response Rate RECIST Criteria

"Response Rate (RR) as measured by radiologic RECIST criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.~Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).~Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study." (NCT01985763)
Timeframe: end of Cycle 6

InterventionParticipants (Count of Participants)
PRSDPDNot evaluable
Genistein8122

Creatinine Clearance of Aflibercept Plus FOLFIRI

Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance was calculated using the Cockroft-Gault or Modification of Diet in Renal Disease (MDRD). (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionmL/min (Mean)
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)71.4

Number of Participants With Proteinuria Grade >=2

Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria grade >=2 (graded as per NCI CTCAE Version 4.03), where Grade>=2 represents moderate to life-threatening/disabling event. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

Interventionparticipants (Number)
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)182

Change From Baseline in HRQL EORTC QLQ-C30 Score: Symptom Scales

EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)

Interventionunits on a scale (Mean)
Fatigue - BaselineFatigue - Change at Cycle 3Fatigue - Change at Cycle 5Fatigue - Change at Cycle 7Fatigue - Change at Cycle 9Fatigue - Change at Cycle 11Fatigue - Change at Cycle 13Fatigue - Change at Cycle 15Fatigue - Change at Cycle 17Fatigue - Change at Cycle 19Fatigue - Change at Cycle 21Fatigue - Change at Cycle 23Fatigue - Change at Cycle 25Fatigue - Change at Cycle 27Fatigue - Change at Cycle 29Fatigue - Change at Cycle 31Fatigue - Change at Cycle 33Fatigue - Change at Cycle 35Fatigue - Change at EOTNausea and Vomiting - BaselineNausea and Vomiting - Change at Cycle 3Nausea and Vomiting - Change at Cycle 5Nausea and Vomiting - Change at Cycle 7Nausea and Vomiting - Change at Cycle 9Nausea and Vomiting - Change at Cycle 11Nausea and Vomiting - Change at Cycle 13Nausea and Vomiting - Change at Cycle 15Nausea and Vomiting - Change at Cycle 17Nausea and Vomiting - Change at Cycle 19Nausea and Vomiting - Change at Cycle 21Nausea and Vomiting - Change at Cycle 23Nausea and Vomiting - Change at Cycle 25Nausea and Vomiting - Change at Cycle 27Nausea and Vomiting - Change at Cycle 29Nausea and Vomiting - Change at Cycle 31Nausea and Vomiting - Change at Cycle 33Nausea and Vomiting - Change at Cycle 35Nausea and Vomiting - Change at EOTPain - BaselinePain - Change at Cycle 3Pain - Change at Cycle 5Pain - Change at Cycle 7Pain - Change at Cycle 9Pain - Change at Cycle 11Pain - Change at Cycle 13Pain - Change at Cycle 15Pain - Change at Cycle 17Pain - Change at Cycle 19Pain - Change at Cycle 21Pain - Change at Cycle 23Pain - Change at Cycle 25Pain - Change at Cycle 27Pain - Change at Cycle 29Pain - Change at Cycle 31Pain - Change at Cycle 33Pain - Change at Cycle 35Pain - Change at EOTDyspnoea - BaselineDyspnoea - Change at Cycle 3Dyspnoea - Change at Cycle 5Dyspnoea - Change at Cycle 7Dyspnoea - Change at Cycle 9Dyspnoea - Change at Cycle 11Dyspnoea - Change at Cycle 13Dyspnoea - Change at Cycle 15Dyspnoea - Change at Cycle 17Dyspnoea - Change at Cycle 19Dyspnoea - Change at Cycle 21Dyspnoea - Change at Cycle 23Dyspnoea - Change at Cycle 25Dyspnoea - Change at Cycle 27Dyspnoea - Change at Cycle 29Dyspnoea - Change at Cycle 31Dyspnoea - Change at Cycle 33Dyspnoea - Change at Cycle 35Dyspnoea - Change at EOTInsomnia - BaselineInsomnia - Change at Cycle 3Insomnia - Change at Cycle 5Insomnia - Change at Cycle 7Insomnia - Change at Cycle 9Insomnia - Change at Cycle 11Insomnia - Change at Cycle 13Insomnia - Change at Cycle 15Insomnia - Change at Cycle 17Insomnia - Change at Cycle 19Insomnia - Change at Cycle 21Insomnia - Change at Cycle 23Insomnia - Change at Cycle 25Insomnia - Change at Cycle 27Insomnia - Change at Cycle 29Insomnia - Change at Cycle 31Insomnia - Change at Cycle 33Insomnia - Change at Cycle 35Insomnia - Change at EOTAppetite loss - BaselineAppetite loss - Change at Cycle 3Appetite loss - Change at Cycle 5Appetite loss - Change at Cycle 7Appetite loss - Change at Cycle 9Appetite loss - Change at Cycle 11Appetite loss - Change at Cycle 13Appetite loss - Change at Cycle 15Appetite loss - Change at Cycle 17Appetite loss - Change at Cycle 19Appetite loss - Change at Cycle 21Appetite loss - Change at Cycle 23Appetite loss - Change at Cycle 25Appetite loss - Change at Cycle 27Appetite loss - Change at Cycle 29Appetite loss - Change at Cycle 31Appetite loss - Change at Cycle 33Appetite loss - Change at Cycle 35Appetite loss - Change at EOTConstipation - BaselineConstipation - Change at Cycle 3Constipation - Change at Cycle 5Constipation - Change at Cycle 7Constipation - Change at Cycle 9Constipation - Change at Cycle 11Constipation - Change at Cycle 13Constipation - Change at Cycle 15Constipation - Change at Cycle 17Constipation - Change at Cycle 19Constipation - Change at Cycle 21Constipation - Change at Cycle 23Constipation - Change at Cycle 25Constipation - Change at Cycle 27Constipation - Change at Cycle 29Constipation - Change at Cycle 31Constipation - Change at Cycle 33Constipation - Change at Cycle 35Constipation - Change at EOTDiarrhoea - BaselineDiarrhoea - Change at Cycle 3Diarrhoea - Change at Cycle 5Diarrhoea - Change at Cycle 7Diarrhoea - Change at Cycle 9Diarrhoea - Change at Cycle 11Diarrhoea - Change at Cycle 13Diarrhoea - Change at Cycle 15Diarrhoea - Change at Cycle 17Diarrhoea - Change at Cycle 19Diarrhoea - Change at Cycle 21Diarrhoea - Change at Cycle 23Diarrhoea - Change at Cycle 25Diarrhoea - Change at Cycle 27Diarrhoea - Change at Cycle 29Diarrhoea - Change at Cycle 31Diarrhoea - Change at Cycle 33Diarrhoea - Change at Cycle 35Diarrhoea - Change at EOTFinancial difficulties - BaselineFinancial difficulties - Change at Cycle 3Financial difficulties - Change at Cycle 5Financial difficulties - Change at Cycle 7Financial difficulties - Change at Cycle 9Financial difficulties - Change at Cycle 11Financial difficulties - Change at Cycle 13Financial difficulties - Change at Cycle 15Financial difficulties - Change at Cycle 17Financial difficulties - Change at Cycle 19Financial difficulties - Change at Cycle 21Financial difficulties - Change at Cycle 23Financial difficulties - Change at Cycle 25Financial difficulties - Change at Cycle 27Financial difficulties - Change at Cycle 29Financial difficulties - Change at Cycle 31Financial difficulties - Change at Cycle 33Financial difficulties - Change at Cycle 35Financial difficulties - Change at EOT
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)29.167.358.409.547.8911.308.337.416.708.9310.3910.807.669.6611.6714.0715.1514.4412.315.886.686.986.616.208.976.826.853.456.563.997.874.027.251.6713.333.033.336.6420.472.682.523.002.726.645.167.269.398.747.258.335.755.074.1710.007.586.6710.8513.453.635.756.986.898.196.363.585.166.783.794.041.233.03-1.7516.6716.6716.676.5324.150.37-0.08-2.37-0.242.560.65-2.19-1.921.640.74-0.93-0.00-1.52-3.33-4.44-6.06-3.335.3117.389.109.029.849.9814.5310.6710.748.919.8413.0412.3811.4915.9415.0015.5615.1516.6712.0312.712.423.772.635.354.424.584.925.438.336.069.265.751.456.6722.2212.1210.003.7810.3711.7210.8514.6311.4415.4611.2611.0210.3415.2514.0718.5210.3413.6416.6720.0018.1830.007.3120.12-1.83-1.32-0.99-0.493.301.11-0.270.771.674.442.94-4.60-2.900.00-2.22-3.030.002.97

Change From Baseline in HRQL EQ-5D-3L Quality of Life: Single Index Utility Score

EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems & severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)

Interventionunits on a scale (Mean)
BaselineChange at Cycle 3Change at Cycle 5Change at Cycle 7Change at Cycle 9Change at Cycle 11Change at Cycle 13Change at Cycle 15Change at Cycle 17Change at Cycle 19Change at Cycle 21Change at Cycle 23Change at Cycle 25Change at Cycle 27Change at Cycle 29Change at Cycle 31Change at Cycle 33Change at Cycle 35Change at EOT
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)0.77-0.02-0.03-0.04-0.05-0.07-0.05-0.06-0.05-0.05-0.09-0.14-0.08-0.08-0.08-0.120.02-0.05-0.11

Change From Baseline in HRQL EQ-5D-3L VAS Score

EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and VAS. EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems & severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. The VAS recorded the respondent's self-rated health on a vertical visual analogue scale. The VAS 'thermometer' has endpoints of 100 (Best imaginable health state) at the top and 0 (Worst imaginable health state) at the bottom. This information can be used as a quantitative measure of health outcome as judged by the individual respondents. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)

Interventionunits on a scale (Mean)
BaselineChange at Cycle 3Change at Cycle 5Change at Cycle 7Change at Cycle 9Change at Cycle 11Change at Cycle 13Change at Cycle 15Change at Cycle 17Change at Cycle 19Change at Cycle 21Change at Cycle 23Change at Cycle 25Change at Cycle 27Change at Cycle 29Change at Cycle 31Change at Cycle 33Change at Cycle 35Change at EOT
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)72.81-1.85-2.15-2.20-2.74-3.10-2.36-1.05-1.91-3.06-2.13-5.77-7.28-4.94-8.80-6.69-7.90-8.88-6.67

Mean Change From Baseline in Health Related Quality of Life (HRQL) European Organization for Research and Treatment for Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30 Score): Global Health Status

EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent).EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at the end of treatment (EOT) (within 30 days of last treatment) (maximum exposure: 214 weeks)

Interventionunits on a scale (Mean)
BaselineChange at Cycle 3Change at Cycle 5Change at Cycle 7Change at Cycle 9Change at Cycle 11Change at Cycle 13Change at Cycle 15Change at Cycle 17Change at Cycle 19Change at Cycle 21Change at Cycle 23Change at Cycle 25Change at Cycle 27Change at Cycle 29Change at Cycle 31Change at Cycle 33Change at Cycle 35Change at EOT
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)68.61-3.34-4.70-3.63-3.97-5.85-2.26-3.05-1.18-2.36-5.56-6.86-8.05-10.14-8.33-9.44-11.36-5.83-8.82

Mean Change From Baseline in HRQL EORTC QLQ-C30 Score: Functional Scales

EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28).Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)

Interventionunits on a scale (Mean)
Physical - BaselinePhysical - Change at Cycle 3Physical - Change at Cycle 5Physical - Change at Cycle 7Physical - Change at Cycle 9Physical - Change at Cycle 11Physical - Change at Cycle 13Physical - Change at Cycle 15Physical - Change at Cycle 17Physical - Change at Cycle 19Physical - Change at Cycle 21Physical - Change at Cycle 23Physical - Change at Cycle 25Physical - Change at Cycle 27Physical - Change at Cycle 29Physical - Change at Cycle 31Physical - Change at Cycle 33Physical - Change at Cycle 35Physical - Change at EOTRole - BaselineRole - Change at Cycle 3Role - Change at Cycle 5Role - Change at Cycle 7Role - Change at Cycle 9Role - Change at Cycle 11Role - Change at Cycle 13Role - Change at Cycle 15Role - Change at Cycle 17Role - Change at Cycle 19Role - Change at Cycle 21Role - Change at Cycle 23Role - Change at Cycle 25Role - Change at Cycle 27Role - Change at Cycle 29Role - Change at Cycle 31Role - Change at Cycle 33Role - Change at Cycle 35Role - Change at EOTEmotional - BaselineEmotional - Change at Cycle 3Emotional - Change at Cycle 5Emotional - Change at Cycle 7Emotional - Change at Cycle 9Emotional - Change at Cycle 11Emotional - Change at Cycle 13Emotional - Change at Cycle 15Emotional - Change at Cycle 17Emotional - Change at Cycle 19Emotional - Change at Cycle 21Emotional - Change at Cycle 23Emotional - Change at Cycle 25Emotional - Change at Cycle 27Emotional - Change at Cycle 29Emotional - Change at Cycle 31Emotional - Change at Cycle 33Emotional - Change at Cycle 35Emotional - Change at EOTCognitive - BaselineCognitive - Change at Cycle 3Cognitive - Change at Cycle 5Cognitive - Change at Cycle 7Cognitive - Change at Cycle 9Cognitive - Change at Cycle 11Cognitive - Change at Cycle 13Cognitive - Change at Cycle 15Cognitive - Change at Cycle 17Cognitive - Change at Cycle 19Cognitive - Change at Cycle 21Cognitive - Change at Cycle 23Cognitive - Change at Cycle 25Cognitive - Change at Cycle 27Cognitive - Change at Cycle 29Cognitive - Change at Cycle 31Cognitive - Change at Cycle 33Cognitive - Change at Cycle 35Cognitive- Change at EOTSocial - BaselineSocial - Change at Cycle 3Social - Change at Cycle 5Social - Change at Cycle 7Social - Change at Cycle 9Social - Change at Cycle 11Social - Change at Cycle 13Social - Change at Cycle 15Social - Change at Cycle 17Social - Change at Cycle 19Social - Change at Cycle 21Social - Change at Cycle 23Social - Change at Cycle 25Social - Change at Cycle 27Social - Change at Cycle 29Social - Change at Cycle 31Social - Change at Cycle 33Social - Change at Cycle 35Social - Change at EOT
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)81.79-3.73-3.95-4.62-4.36-6.99-4.99-3.54-5.10-5.68-5.70-7.87-5.75-6.59-7.67-9.33-5.45-10.00-11.1679.91-6.26-5.66-6.68-6.55-8.76-7.36-7.18-9.58-9.84-9.78-10.65-10.92-10.14-10.83-14.44-15.15-15.00-12.1178.961.140.741.581.690.080.932.512.911.390.061.754.981.572.641.300.25-0.00-2.8786.90-1.77-1.87-1.99-2.18-4.27-2.83-2.28-3.45-5.00-5.56-5.71-6.90-5.80-6.67-5.56-10.61-11.67-4.9880.57-2.05-2.86-4.78-4.56-7.09-5.56-6.18-5.56-5.28-5.56-7.62-4.60-2.17-5.00-7.78-1.52-1.67-9.01

Number of Participants With Abnormal Electrolytes Parameters

Abnormal electrolytes parameters included: hyponatremia, hypernatremia, hypocalcemia, hypercalcemia, hypokalemia, and hyperkalemia. Number of participants with each of these parameters were analyzed by grades ( All Grades and Grades 3-4 as per NCI CTCAE Version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
Hyponatremia: All GradesHyponatremia: Grades 3-4Hypernatremia: All GradesHypernatremia: Grades 3-4Hypocalcemia: All GradesHypocalcemia: Grades 3-4Hypercalcemia: All GradesHypercalcemia: Grades 3-4Hypokalemia: All GradesHypokalemia: Grades 3-4Hyperkalemia: All GradesHyperkalemia: Grades 3-4
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)1813275121355221211616610

Number of Participants With Abnormal Hematological Parameters

Abnormal hematological parameters included: anaemia, thrombocytopenia, leukopenia and neutropenia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4 as per NCI CTCAE (Version 4.03), where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
Anaemia: All GradesAnaemia: Grades 3-4Thrombocytopenia: All GradesThrombocytopenia: Grades 3-4Leukopenia: All GradesLeukopenia: Grades 3-4Neutropenia: All GradesNeutropenia: Grades 3-4
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)535142931353272450227

Number of Participants With Abnormal Non-Gradable Biochemistry Parameters

Non-gradeable biochemistry parameters included; chloride, urea, total protein, blood urea nitrogen (BUN) and lactate dehydrogenase (LDH). Number of participants with upper limit of normal ranges (ULN) for each of these parameters were reported. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
ChlorideChloride>ULNBUNBUN>ULNUREAUREA>ULNLDHLDH>ULNTotal proteinsTotal proteins>ULN
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)1352174183602507942316277

Number of Participants With Abnormal Renal and Liver Function Parameters

Renal and liver function parameters included: creatinine, hyperbilirubinemia, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
Creatinine: All GradesCreatinine: Grades 3-4Hyperbilirubinemia: All GradesHyperbilirubinemia: Grades 3-4AST: All GradesAST: Grades 3-4ALT: All GradesALT: Grades 3-4Alkaline phosphatase: All GradesAlkaline phosphatase: Grades 3-4
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)16121309342122701046523

Number of Participants With Cycle Delay and/or Dose Modification

A theoretical cycle is a 2 week period i.e. 14 days. A cycle is delayed if duration of previous cycle is greater than 14+2 days ; dose modification includes dose reduction and dose omission. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
No delay and no dose modificationAny delay and/or dose modificationDelay onlyDelay and Aflibercept modifiedDelay and FOLFIRI modifiedDelay and Aflibercept and Folfiri modifiedOnly Aflibercept modifiedOnly FOLFIRI modifiedBoth Aflibercept and FOLFIRI modified
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)11966016339308975435

Number of Participants With International Normalized Ratio (INR)

The INR is a derived measure of the prothrombin time. The INR is the ratio of a participant's prothrombin time to a normal control sample. Normal range (without anti coagulation therapy): 0.8-1.2; Targeted range (with anti coagulation therapy) 2.0-3.0. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
INR<1.5INR>=1.5 to <3INR>=3 to <5INR>=5
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)106022

Number of Participants With Other Abnormal Biochemistry Parameters

Other abnormal biochemistry parameters included: hypoglycemia, hyperglycemia and hypoalbuminemia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE Version 4.03, where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
Hypoglycemia: All GradesHypoglycemia: Grades 3-4Hyperglycemia: All GradesHyperglycemia: Grades 3-4Hypoalbuminemia: All GradesHypoalbuminemia: Grades 3-4
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)906403302416

Number of Participants With Proteinuria (Grade>=2) Concomitant With Hematuria and /or Hypertension

Proteinuria is defined as the presence of excess proteins in the urine (assessed either by spot sample, dipstick/ urine protein or 24 hour urine collection). Hematuria is defined as the presence of blood in urine (positive dipstick for RBC or reported AE). Number of participants with proteinuria grade >=2 (graded as per NCI CTCAE Version 4.03), where Grade>=2 represents moderate to life-threatening/disabling event. Hypertension (high blood pressure) is defined as having a blood pressure reading of more than 140/90 mmHg over a number of weeks. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
Proteinuria with hematuriaProteinuria with hypertensionProteinuria with hematuria and hypertension
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)7243

Number of Participants With Proteinuria Events

Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria were analyzed by grades (Grades 1, 2, 3 ,4) as per NCI CTCAE Version 4.03 where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
Grade 1Grade 2Grade 3Grade 4
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)286123545

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. A serious AE (SAE): Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Version 4.03 was used to assess severity (Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling) of AEs. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
Any TEAE (All Grades)Any TEAEs (Grades 3-4)Any serious TEAEAny serious related TEAEAny TEAE leading to deathAny TEAE (permanent treatment discontinuation)Any TEAE (premature treatment discontinuation)
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)76960927215947208104

Number of Participants With Urinary Protein-Creatinine Ratio (UPCR)

Urinary protein creatinine ratio (UPCR) corresponds to the ratio of the urinary protein and urinary creatinine concentration (expressed in mg/dL). This ratio provides an accurate quantification of 24-hours urinary protein excretion. There is a high correlation between morning UPCR and 24-hour proteinuria in participants with normal or reduced renal functions. Normal ratio is < or = 1. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)

InterventionParticipants (Count of Participants)
UPCR<=1UPCR>=1 to <=2UPCR>=2 to <=3UPCR>3
Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin)265512427

Disease Control (DC)

DC was defined as the proportion of participants who had a best response rating of CR, PR, or stable disease (SD) according to RECIST criteria that was achieved during treatment or within 30 days after termination of study treatment. CR and PR were confirmed not earlier than 4 weeks following the initial detection of response. A minimum of 8 weeks (allowing a minus 7-day time window) between start of study treatment and the first follow-up tumor assessment with SD as response was required to assign SD as best overall response. (NCT01289821)
Timeframe: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks

InterventionProportion of participants (Number)
Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)0.8537

Duration of Response (DOR)

DOR was defined as the time from the date of first documented objective response of PR or CR, whichever was noted earlier, to first subsequent disease progression or death (if death occurred before progression was documented). DOR was defined for responders only (that is, subjects with CR or PR). DOR for subjects without disease progression or death before progression was right censored at the date of their last tumor assessment. (NCT01289821)
Timeframe: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks

InterventionDays (Median)
Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)257

Duration of Stable Disease (DOSD)

DOSD was only evaluated in participants failing to achieve a best response of CR or PR, but who achieved SD. DOSR was defined as the time (in days) from date of start of study treatment to the date at which disease progression or death (if death occurred before progression was first documented). The date the tumor scan was performed was used for this calculation. DOSD for participants without disease progression or death before progression at the time of analysis were censored at the date of their last tumor assessment. (NCT01289821)
Timeframe: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks

InterventionDays (Median)
Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)231

Objective Response (OR)

OR was defined as the best tumor response (confirmed complete response [CR] or partial response [PR]) observed by MRI or CT scan assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria, version 1.1. CR and PR were confirmed not earlier than 4 weeks following the initial detection of response. CR = Disappearance of all clinical and radiological evidence of tumor (both target and no-target). Any pathological lymph nodes (whether target or non target) must have a reduction in short axis to < 10 mm. PR = At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum, no unequivocal progression of existing nontarget lesions and no appearance of new lesions. (NCT01289821)
Timeframe: From start of treatment until 30 days after termination of study medication, an average of 47 weeks. Assessed every 8 weeks.

InterventionProportion of participants (Number)
Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)0.4390

Overall Survival (OS)

OS was calculated as the time from first date of receiving study treatment to date of death due to any cause. Participants alive at the time of analysis were censored at their last date of follow-up. (NCT01289821)
Timeframe: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks

InterventionDays (Median)
Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)772

Progression-free Survival (PFS)

PFS was defined as time from the date of start of study treatment to the date of first observed disease progression (radiological according to central assessment or clinical), or death due to any cause, if death occurred before progression was documented. PFS for participants without disease progression or death at the date of database cutoff were right-censored at the last date of tumor assessment. Participants who had no tumor evaluation after baseline and no clinical progression post baseline and who did not die were censored at Day 1 in the analysis. PD = At least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non target lesions or the appearance of one or more new lesions will also constitute PD. (NCT01289821)
Timeframe: From start of treatment until 30 days after the last dose of study treatment, assessed by every 8 weeks

InterventionDays (Median)
Regorafenib + Oxaliplatin/Folinic Acid/5-FU (mFOLFOX6)258

Overall Survival (OS)

To compare overall survival (OS) between ARM A and ARM B. OS is defined as the time from randomization until death as a result of any cause. (NCT01298570)
Timeframe: 5.5 years

InterventionMonths (Median)
Arm A13.8
Arm B11.7

Progression Free Survival (PFS)

To compare PFS between regorafenib + FOLFIRI chemotherapy (ARM A) versus placebo + FOLFIRI (ARM B) in patients failing one prior oxaliplatin-containing regimen for metastatic colorectal cancer. PFS is defined as the time from randomization until metastatic colorectal cancer (mCRC) progression or death as a result of any cause. Radiographic response will be measured by RECIST, Response Evaluation Criteria In Solid Tumors Criteria, indicating if subject experienced a Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), no response or less response than Partial or Progressive; or Progressive Disease (PD), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01298570)
Timeframe: 5.5 years

InterventionMonths (Median)
Arm A6.1
Arm B5.3

Drug Metabolism

To compare the pharmacokinetic (PK) profile of FOLFIRI between a subset of patients receiving regorafenib (ARM A) and patients receiving placebo (Arm B). The Area Under the Curve (AUC) levels of the irinotecan metabolite SN-38 were compared. (NCT01298570)
Timeframe: 28 days

,
InterventionAUC/dose=(ng/mL*h)/(mg/m^2) (Median)
Cycle 1Cycle 2
Arm A0.680.59
Arm B0.630.72

Percentage of Patients With Severe Adverse Events

Toxicity Assessments were made according to NCI CTCAE v. 4.0 . Severe events (grades 3-4) that occurred in a higher percentage of regorafenib treated participants as compared to placebo are reported below. (NCT01298570)
Timeframe: 3 years

,
Interventionpercentage of participants (Number)
neutropeniadiarrheahypophosphatemiahypertensionelevated lipase
Arm A41151488
Arm B305023

Duration of Response

Duration of Response was defined as the time from date of first response (Complete Response (CR) or Partial Response (PR)) to the date when Progressive Disease (PD) was first documented or to the date of death, whichever occurred first according to Response Evaluation Criteria in Solid Tumors (RECIST). Subjects still having CR or PR and alive at the time of analysis were censored at their last date of tumor evaluation. CR was defined as disappearance of tumor lesions, PR as a decrease of at least 30% and PD as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks

Interventionmonths (Number)
Sorafenib (Nexavar, BAY43-9006) + mFOLFOX67.5
Matching Placebo + mFOLFOX66.7

Overall Response

Overall response of a subject was defined as the best tumor response (Complete Response (CR) or Partial Response (PR)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.

Interventionparticipants (Number)
Sorafenib (Nexavar, BAY43-9006) + mFOLFOX645
Matching Placebo + mFOLFOX661

Overall Survival (OS)

Overall Survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact. (NCT00865709)
Timeframe: From randomization of the first subject until 33 months later.

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6535
Matching Placebo + mFOLFOX6552

Progression-Free Survival (PFS)

Progression-free Survival (PFS) was defined as the time from date of randomization to disease progression or death due to any cause, whichever occurred first. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation. Disease progression was defined as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.

InterventionMonths (Median)
Sorafenib (Nexavar, BAY43-9006) + mFOLFOX69.1
Matching Placebo + mFOLFOX68.7

Time to Progression (TTP)

Time to progression (TTP) was defined as the time from date of randomization to disease progression. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation. Disease progression was defined as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.

InterventionMonths (Median)
Sorafenib (Nexavar, BAY43-9006) + mFOLFOX69.2
Matching Placebo + mFOLFOX69.0

Duration of Response (DR): Phase 2

Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cancer. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response. CR: disappearance of all lesions and no appearance of new lesions. PR: >=30% decrease in sum of LD of target lesions taking as reference the baseline sum LD, without progression of nontarget lesions and no appearance of new lesions. Progression: >=20% increase in sum of LD of target lesions taking as references the smallest sum LD recorded since treatment start, unequivocal progression of existing nontarget lesions, or appearance of new lesions, occurrence of pleural effusion/ascites, substantiated by cytologic investigation. (NCT00460603)
Timeframe: Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)

Interventiondays (Median)
Phase 2: Axitinib + FOLFOX434.0
Phase 2: Bevacizumab + FOLFOXNA
Phase 2: Axitinib + Bevacizumab + FOLFOX343.0

Overall Survival (OS): Phase 2

Time in days from randomization date to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death). (NCT00460603)
Timeframe: Every 3 months after discontinuation of study treatment until death due to any cause or 1 year after randomization of the last participant

Interventiondays (Median)
Phase 2: Axitinib + FOLFOX552.0
Phase 2: Bevacizumab + FOLFOX659.0
Phase 2: Axitinib + Bevacizumab + FOLFOX601.0

Percentage of Participants With Objective Response: Phase 2

Percentage of participants with objective response (OR) based assessment of confirmed complete response(CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed CR defined as disappearance of all lesions and no appearance of new lesions. Confirmed PR defined as >=30 percent (%) decrease in sum of the longest dimensions (LD) of the target lesions taking as reference the baseline sum LD , without progression of nontarget lesions and no appearance of new lesions. Confirmed responses are those that persist on repeat imaging study >=4 weeks after initial documentation of response. (NCT00460603)
Timeframe: Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)

InterventionPercentage of participants (Number)
Phase 2: Axitinib + FOLFOX28.6
Phase 2: Bevacizumab + FOLFOX48.8
Phase 2: Axitinib + Bevacizumab + FOLFOX39.0

Progression-Free Survival (PFS): Phase 2

"Time in days from date of randomization to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was Death). Progression: >=20% increase in sum of LD of target lesions taking as references the smallest sum LD recorded since treatment start, unequivocal progression of existing nontarget lesions, or appearance of new lesions, occurrence of pleural effusion/ascites, substantiated by cytologic investigation." (NCT00460603)
Timeframe: Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)

Interventiondays (Median)
Phase 2: Axitinib + FOLFOX336
Phase 2: Bevacizumab + FOLFOX485
Phase 2: Axitinib + Bevacizumab + FOLFOX381

Time to Treatment Failure (TTF): Phase 2

TTF is defined as the time from the randomization to the date of the first documentation of PD, symptomatic deterioration, death due to any cause, or treatment discontinuation due to adverse event, refusal or other reasons. Progression: >=20% increase in sum of LD of target lesions taking as references the smallest sum LD recorded since treatment start, unequivocal progression of existing nontarget lesions, or appearance of new lesions, occurrence of pleural effusion/ascites, substantiated by cytologic investigation. (NCT00460603)
Timeframe: Baseline (Phase 2) until disease progression, assessed every 6 weeks up to Week 148 (Phase 2) or follow-up (every 6 weeks after last dose of study drug until progression or start of alternate therapy)

Interventiondays (Median)
Phase 2: Axitinib + FOLFOX187.0
Phase 2: Bevacizumab + FOLFOX241.0
Phase 2: Axitinib + Bevacizumab + FOLFOX238.0

Apparent Oral Clearance (CL/F) For Axitinib: Phase 1

Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. CL/F for axitinib (AG-013736) in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1

,,
InterventionLiter per hour (L/hr) (Geometric Mean)
Cycle 1 Day 8Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)30.0130.08
Phase 1: Axitinib + FOLFIRI (Cohort 4)47.1033.33
Phase 1: Axitinib + FOLFOX (Cohort 5)28.4928.90

Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For 5-Fluorouracil: Phase 1

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. AUClast for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 5-FU dose. (NCT00460603)
Timeframe: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

,,
Interventionng*hr/mL (Geometric Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)39212.0345087.71
Phase 1: Axitinib + FOLFIRI (Cohort 4)40955.2936533.84
Phase 1: Axitinib + FOLFOX (Cohort 5)52164.2895123.13

Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Axitinib: Phase 1

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). Pharmacokinetic (PK) parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. AUClast for axitinib in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. Results were normalized to axitinib 5 mg dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6 and 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1

,,
Interventionnanogram hour per milliliter (ng*hr/mL) (Geometric Mean)
Cycle 1 Day 8Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)119.0295.70
Phase 1: Axitinib + FOLFIRI (Cohort 4)106.76143.68
Phase 1: Axitinib + FOLFOX (Cohort 5)97.05117.47

Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Bevacizumab: Phase 1

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. AUClast for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. The bevacizumab pharmacokinetic parameters were normalized to 1 mg/kg dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

Interventionng*hr/mL (Geometric Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)3394758.833554899.52

Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Irinotecan: Phase 1

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). AUClast for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 irinotecan dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

Interventionng*hr/mL (Geometric Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + FOLFIRI (Cohort 4)12081.5811496.32

Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Oxaliplatin: Phase 1

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast). PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. AUClast for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 oxaliplatin dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

,
Interventionng*hr/mL (Geometric Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)4814.875231.71
Phase 1: Axitinib + FOLFOX (Cohort 5)4308.715303.66

Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For 5-Fluorouracil: Phase 1

AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. AUC (0 - ∞) for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 5-FU dose. (NCT00460603)
Timeframe: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

,,
Interventionng*hr/mL (Geometric Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)36314.1438983.80
Phase 1: Axitinib + FOLFIRI (Cohort 4)41460.5036776.79
Phase 1: Axitinib + FOLFOX (Cohort 5)52430.1596632.41

Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Axitinib: Phase 1

AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. AUC (t - ∞] for axitinib in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. Results were normalized to axitinib 5 mg dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1

,,
Interventionng*hr/mL (Geometric Mean)
Cycle 1 Day 8Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)190.51224.46
Phase 1: Axitinib + FOLFIRI (Cohort 4)113.20168.07
Phase 1: Axitinib + FOLFOX (Cohort 5)205.41178.46

Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Bevacizumab: Phase 1

AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. AUC (0 - ∞) for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. The bevacizumab pharmacokinetic parameters were normalized to 1 mg/kg dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

Interventionng*hr/mL (Geometric Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)4987528.965114888.84

Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Irinotecan: Phase 1

AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). AUC (0 - ∞) for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 irinotecan dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

Interventionng*hr/mL (Geometric Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + FOLFIRI (Cohort 4)13055.8812459.89

Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] For Oxaliplatin: Phase 1

AUC (0 - ∞)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - ∞). It was obtained from AUC (0 - t) plus AUC (t - ∞). PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. AUC (0 - ∞) for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 oxaliplatin dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

,
Interventionng*hr/mL (Geometric Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)5955.706744.06
Phase 1: Axitinib + FOLFOX (Cohort 5)5137.316430.67

Change From Baseline in M.D. Anderson Symptom Assessment Inventory - Diarrhea (MDASI-D) Symptom Severity and Interference Subscale Scores at Day 1 of Cycle 2 Through Day 1 Cycle 42 and Follow-up: Phase 2

"PROs included assessment of symptom severity and interference which were measured using M.D. Anderson Symptom Assessment Inventory-Diarrhea (MDASI-D), 20-item questionnaire which assesses the severity of 14 symptoms over the past 24 hours, as well as symptoms interference with 6 areas of function (e.g., walking, work, mood), when the symptom was at its worst. Each item is scored from 0 to 10, with '0' indicating that the symptom was either not present or did not interfere with their activities, and '10' indicating that the symptom was as bad as you can imagine or interfered completely with their life. The 2 subscales, symptom severity score and symptom interference score were average of respective items and ranged from 0 to 10, higher score indicating greater severity or interference of symptoms." (NCT00460603)
Timeframe: Cycle 1 Day 1 (baseline), every 2 weeks for the first 2 months (Cycle 2 Day 1 [C2D1], Cycle 3 Day 1, and Cycle 4 Day 1) then monthly thereafter starting Cycle 6 Day 1, and 28 days after the last dose

,,
Interventionunits on scale (Mean)
Severity Scale: Baseline (n=41,43,40)Severity Scale: C2D1 (n=37,37,37)Severity Scale: C3D1 (n=32,38,32)Severity Scale: C4D1 (n=23,37,30)Severity Scale: C5D1 (n=23,34,29)Severity Scale: C6D1 (n=15,38,26)Severity Scale: C7D1 (n=12,30,22)Severity Scale: C8D1 (n=17,29,22)Severity Scale: C9D1 (n=11,24,21)Severity Scale: C10D1 (n=14,27,21)Severity Scale: C11D1 (n=10,20,19)Severity Scale: C12D1 (n=11,23,16)Severity Scale: C13D1 (n=8,13,12)Severity Scale: C14D1 (n=8,17,14)Severity Scale: C15D1 (n=7,11,9)Severity Scale: C16D1 (n=7,17,14)Severity Scale: C17D1 (n=5,11,6)Severity Scale: C18D1 (n=6,14,9)Severity Scale: C19D1 (n=4,8,16)Severity Scale: C20D1 (n=5,14,8)Severity Scale: C21D1 (n=4,5,5)Severity Scale: C22D1 (n=3,11,8)Severity Scale: C23D1 (n=4,5,3)Severity Scale: C24D1 (n=5,11,7)Severity Scale: C25D1 (n=4,5,5)Severity Scale: C26D1 (n=4,6,7)Severity Scale: C27D1 (n=4,3,4)Severity Scale: C28D1 (n=4,5,7)Severity Scale: C29D1 (n=2,3,4)Severity Scale: C30D1 (n=3,6,3)Severity Scale: C31D1 (n=1,1,3)Severity Scale: C32D1 (n=2,4,4)Severity Scale: C33D1 (n=0,0,2)Severity Scale: C34D1 (n=2,4,3)Severity Scale: C35D1 (n=0,0,1)Severity Scale: C36D1 (n=2,3,2)Severity Scale: C37D1 (n=0,1,0)Severity Scale: C38D1 (n=2,2,1)Severity Scale: C39D1 (n=0,1,0)Severity Scale: C40D1 (n=2,2,2)Severity Scale: C42D1 (n=2,2,1)Severity Scale: Follow_Up (n=4,15,14)Interference Scale: Baseline (n=41,43,40)Interference Scale: C2D1 (n=37,37,36)Interference Scale: C3D1 (n=31,38,30)Interference Scale: C4D1 (n=23,36,30)Interference Scale: C5D1 (n=23,34,29)Interference Scale: C6D1 (n=15,38,26)Interference Scale: C7D1 (n=12,30,22)Interference Scale: C8D1 (n=17,29,22)Interference Scale: C9D1 (n=11,24,21)Interference Scale: C10D1 (n=14,27,21)Interference Scale: C11D1 (n=10,20,19)Interference Scale: C12D1 (n=10,23,16)Interference Scale: C13D1 (n=8,13,12)Interference Scale: C14D1 (n=8,17,14)Interference Scale: C15D1 (n=7,11,9)Interference Scale: C16D1 (n=7,17,14)Interference Scale: C17D1 (n=5,11,6)Interference Scale: C18D1 (n=6,14,9)Interference Scale: C19D1 (n=4,8,6)Interference Scale: C20D1 (n=5,14,8)Interference Scale: C21D1 (n=4,5,5)Interference Scale: C22D1 (n=3,11,8)Interference Scale: C23D1 (n=4,5,3)Interference Scale: C24D1 (n=5,11,7)Interference Scale: C25D1 (n=4,5,5)Interference Scale: C26D1 (n=4,6,7)Interference Scale: C27D1 (n=4,3,4)Interference Scale: C28D1 (n=4,5,7)Interference Scale: C29D1 (n=2,3,4)Interference Scale: C30D1 (n=3,6,3)Interference Scale: C31D1 (n=1,1,3)Interference Scale: C32D1 (n=2,4,4)Interference Scale: C33D1 (n=0,0,2)Interference Scale: C34D1 (n=2,4,3)Interference Scale: C35D1 (n=0,0,1)Interference Scale: C36D1 (n=2,3,2)Interference Scale: C37D1 (n=0,1,0)Interference Scale: C38D1 (n=2,2,1)Interference Scale: C39D1 (n=0,1,0)Interference Scale: C40D1 (n=2,2,2)Interference Scale: C42D1 (n=2,2,1)Interference Scale: Follow Up (n=4,15,14)
Phase 2: Axitinib + Bevacizumab + FOLFOX2.180.800.630.640.600.960.260.420.760.770.570.380.73-0.050.710.050.720.610.81-0.061.200.091.05-0.20-0.30-0.130.34-0.43-0.090.641.551.290.890.430.79-0.18NA0.86NA0.430.000.292.470.781.091.151.190.990.550.480.750.990.840.380.310.290.70-0.011.171.001.040.351.830.831.280.550.900.331.630.191.331.062.332.171.921.111.671.33NA-0.17NA0.250.000.91
Phase 2: Axitinib + FOLFOX1.620.630.680.880.720.700.280.28-0.150.280.150.32-0.090.030.28-0.30-0.200.02-0.18-0.06-0.250.570.300.910.25-0.05-0.210.123.001.05-0.500.11NA0.04NA0.29NA0.13NA0.180.181.292.500.460.600.920.650.320.430.01-0.14-0.180.420.03-0.50-0.10-0.52-0.02-0.900.060.040.27-0.040.440.212.000.000.330.040.713.250.940.000.08NA0.17NA0.17NA0.08NA0.420.251.33
Phase 2: Bevacizumab + FOLFOX2.200.04-0.22-0.40-0.340.09-0.16-0.13-0.030.06-0.050.470.100.380.420.110.210.310.340.150.270.810.640.37-0.030.460.070.74-0.140.45-0.640.80NA0.75NA1.240.861.680.861.291.25-0.002.79-0.08-0.57-0.54-0.59-0.18-0.59-0.10-0.390.15-0.510.17-0.310.150.27-0.48-0.290.040.54-0.08-0.970.741.130.300.100.670.110.97-0.561.08-0.171.50NA1.25NA1.890.832.250.502.502.58-0.21

Clearance (CL) For 5-Fluorouracil: Phase 1

CL is a quantitative measure of the rate at which a drug substance is removed from the body. PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. CL for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

,,
InterventionL/hr (Geometric Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)147.43137.34
Phase 1: Axitinib + FOLFIRI (Cohort 4)128.28144.62
Phase 1: Axitinib + FOLFOX (Cohort 5)99.3653.92

Clearance (CL) For Bevacizumab: Phase 1

CL is a quantitative measure of the rate at which a drug substance is removed from the body. PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. CL for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

InterventionL/hr (Geometric Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)0.010.02

Clearance (CL) For Irinotecan: Phase 1

CL is a quantitative measure of the rate at which a drug substance is removed from the body. CL for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

InterventionL/hr (Geometric Mean)
Cycle 1 Day 8Cycle 2 Day 1
Phase 1: Axitinib + FOLFIRI (Cohort 4)26.0927.34

Clearance (CL) For Oxaliplatin: Phase 1

CL is a quantitative measure of the rate at which a drug substance is removed from the body. PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. CL for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

,
InterventionL/hr (Geometric Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)27.5124.29
Phase 1: Axitinib + FOLFOX (Cohort 5)30.7424.56

Maximum Observed Plasma Concentration (Cmax) For 5-Fluorouracil: Phase 1

PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. Cmax for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 5-FU dose. (NCT00460603)
Timeframe: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

,,
Interventionng/mL (Geometric Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)16160.8516249.77
Phase 1: Axitinib + FOLFIRI (Cohort 4)34436.9439730.46
Phase 1: Axitinib + FOLFOX (Cohort 5)19622.7434180.87

Maximum Observed Plasma Concentration (Cmax) For Axitinib: Phase 1

PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3.Cmax for axitinib (AG-013736) in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. Results were normalized to axitinib 5 mg dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1

,,
Interventionng/mL (Geometric Mean)
Cycle 1 Day 8Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)35.5727.51
Phase 1: Axitinib + FOLFIRI (Cohort 4)27.1442.48
Phase 1: Axitinib + FOLFOX (Cohort 5)24.2332.62

Maximum Observed Plasma Concentration (Cmax) For Bevacizumab: Phase 1

PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. Cmax for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. The bevacizumab pharmacokinetic parameters were normalized to 1 mg/kg dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

Interventionng/mL (Geometric Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)26460.0526850.12

Maximum Observed Plasma Concentration (Cmax) For Irinotecan: Phase 1

Cmax for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 irinotecan dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

Interventionng/mL (Geometric Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + FOLFIRI (Cohort 4)1910.251788.69

Maximum Observed Plasma Concentration (Cmax) For Oxaliplatin: Phase 1

PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. Cmax for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. Results were normalized to Cycle 1 Day 1 oxaliplatin dose. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

,
Interventionng/mL (Geometric Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)278.81318.99
Phase 1: Axitinib + FOLFOX (Cohort 5)265.05374.03

Plasma Decay Half-Life (t1/2) For 5-Fluorouracil: Phase 1

Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of 5-FU were combined for Cohorts 1, 2, and 3. t1/2 for 5-FU in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Pre-5-FU bolus, 5 min (post-5-FU bolus), 0.25, 0.5, 0.75, 2, 4, 6, 22, 34-46 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

,,
Interventionhours (Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)0.260.25
Phase 1: Axitinib + FOLFIRI (Cohort 4)0.190.14
Phase 1: Axitinib + FOLFOX (Cohort 5)0.390.24

Plasma Decay Half-Life (t1/2) For Axitinib: Phase 1

Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of axitinib (AG-013736) were combined for Cohorts 1, 2, and 3. t1/2 for axitinib in absence of bevacizumab + FOLFOX was estimated from Cycle 1 Day 8 data and in presence of bevacizumab + FOLFOX was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6, 8 hours postdose on Cycle 1 Day 8, Cycle 2 Day 1

,,
Interventionhours (Mean)
Cycle 1 Day 8Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)3.266.12
Phase 1: Axitinib + FOLFIRI (Cohort 4)2.233.09
Phase 1: Axitinib + FOLFOX (Cohort 5)3.471.73

Plasma Decay Half-Life (t1/2) For Bevacizumab: Phase 1

Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of bevacizumab were combined for Cohorts 1, 2, and 3. t1/2 for bevacizumab in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

Interventionhours (Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)205.97210.22

Plasma Decay Half-Life (t1/2) For Irinotecan: Phase 1

Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. t1/2 for irinotecan in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Predose, 1, 2, 2.5, 4, 6, 8, 24 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

Interventionhours (Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + FOLFIRI (Cohort 4)6.456.75

Plasma Decay Half-Life (t1/2) For Oxaliplatin: Phase 1

Plasma decay half-life (t1/2) is the time measured for the plasma concentration to decrease by one half. PK parameters of oxaliplatin, assessed by estimating total platinum in plasma ultrafiltrate, were combined for Cohorts 1, 2, and 3. t1/2 for oxaliplatin in absence of axitinib was estimated from Cycle 1 Day 1 data and in presence of axitinib was estimated from Cycle 2 Day 1 data. (NCT00460603)
Timeframe: Predose, 1, 2, 2.25, 2.5, 4, 6, 8, 24, 36-48 hours postdose on Cycle 1 Day 1, Cycle 2 Day 1

,
Interventionhours (Mean)
Cycle 1 Day 1Cycle 2 Day 1
Phase 1: Axitinib + Bevacizumab + FOLFOX (Cohort 1-3)20.6323.30
Phase 1: Axitinib + FOLFOX (Cohort 5)18.3819.86

Disease Free Survival

"Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.~Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions." (NCT00416494)
Timeframe: From time of treatment until documented progression or death from any cause, whichever came first, assesed up to 60 months.

Interventionmonths (Median)
Initial Cohort10.1
Second Cohort10.4

Overall Survival

Average months of survival of participants after receiving study drug. (NCT00416494)
Timeframe: From time of treatment until death from any cause, assesed up to 60 months.

Interventionmonths (Median)
Initial Cohort19.6
Second Cohort24.8

Response Rate (Percentage of Participants With Partial or Complete Response)

"Restaging scans occurred every 9 weeks from time of study drug initiation until disease progression.~Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.~The definitions were:~Complete response (CR)- Disappearance of all target lesions Partial response (PD)- At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Stable disease (SD)- Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started Progressive disease (PD) - At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions" (NCT00416494)
Timeframe: After all subjects were evaluated for restaging which occured every 9 weeks from drug initiation until disease progression, assesed up to 24 months.

Interventionpercentage of participants with response (Number)
Initial Cohort63
Second Cohort42

Safety and Tolerability

Number of participants with adverse events (NCT00416494)
Timeframe: After all participants went off study drug regimine.

Interventionparticipants with adverse event (Number)
Initial Cohort19
Second Cohort29

Time to Progression

"Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.~Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions." (NCT00416494)
Timeframe: From time of treatment until documented progression, assesed up to 60 months.

Interventionmonths (Median)
Initial Cohort10.1
Second Cohort10.4

Duration of Follow-up

Duration of follow-up is defined as the time in days from randomization until disease progression or death, or time to censoring for overall survival. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)

InterventionDays (Mean)
Bevacizumab + Capecitabine540.5
Capecitabine479.2

Duration of Response

Duration of response was defined as the time in months from the first confirmed complete response (CR) or partial response (PR) until disease progression or death from any cause, whichever occurred first. CR was defined as the disappearance of all target (TL) and non-target lesions (non-TL). PR was defined as ≥ 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD, or the persistence of 1 or more non-TLs. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)

InterventionMonths (Median)
Bevacizumab + Capecitabine9.7
Capecitabine9.4

Overall Survival

Overall survival was defined as the time in months from randomization to death from any cause. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)

InterventionMonths (Median)
Bevacizumab + Capecitabine20.7
Capecitabine17.0

Percentage of Participants Requiring Additional Treatment for Malignancy

Reported is the percentage of participants requiring additional treatment for malignancy in the survival follow-up period. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)

InterventionPercentage of participants (Number)
Bevacizumab + Capecitabine50.7
Capecitabine49.3

Progression-free Survival

Progression-free survival was defined as the time in months from the date of randomization to the date of disease progression or death from any cause, whichever occurred first. All measurable lesions (maximum of 5 per organ and 10 in total, those with the longest diameter and suitability for accurate repeated measurements) were identified as target lesions (TL). A sum of the longest diameter for all TLs was calculated and reported as the baseline sum longest diameter (SLD). All other lesions were identified as non-TLs and recorded at baseline. PD was defined as ≥ 20% increase in the sum of the longest diameter of TLs, taking as reference the smallest SLD recorded since treatment started, the unequivocal progression of existing non-TLs, or the appearance of 1 or more new lesions. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)

InterventionMonths (Median)
Bevacizumab + Capecitabine9.1
Capecitabine5.1

Time to Response

Time to response was defined as the time in months from the date of first study treatment to the date of the first documentation of complete response (CR) or partial response (PR), whichever occurred first. CR was defined as the disappearance of all target (TL) and non-target lesions (non-TL). PR was defined as ≥ 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD, or the persistence of 1 or more non-TLs. Participants who did not have a confirmed response were censored at the date of the last evaluable tumor assessment, or if that was unavailable, at the date of the first dose of study medication. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)

InterventionMonths (Median)
Bevacizumab + CapecitabineNA
CapecitabineNA

Best Overall Response (BOR)

BOR was defined as the best response (complete response [CR], partial response [PR], stable disease [SD], progressive disease [PD], not evaluable [NE], or not assessed [NA]) recorded from the start of study treatment until disease progression (PD) or death. CR was defined as the disappearance of all target (TL) and non-target lesions (non-TL). PR was defined as ≥ 30% decrease in the sum of the longest diameter (SLD) of TLs, taking as reference the baseline SLD, or the persistence of 1 or more non-TLs. For TLs, SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SLD since treatment started. For non-TLs, SD was defined as the persistence of 1 or more lesions. PD was defined as ≥ 20% increase in the sum of the longest diameter of TLs, taking as reference the smallest SLD recorded since treatment started, the unequivocal progression of existing non-TLs, or the appearance of 1 or more new lesions. (NCT00484939)
Timeframe: Baseline to the end of the study (up to 5 years 8 months)

,
InterventionPercentage of participants (Number)
Complete ResponsePartial ResponseStable DiseaseProgressive DiseaseNot assessed
Bevacizumab + Capecitabine2.917.154.310.015.7
Capecitabine1.48.648.621.420.0

Eastern Cooperative Oncology Group (ECOG) Performance Status

The ECOG performance status is a scale used to quantify cancer patients' general well-being and activities of daily life. The scale ranges from 0 to 5, with 0 denoting perfect health and 5 indicating death. The 6 categories are 0=Asymptomatic (Fully active, able to carry on all predisease activities without restriction), 1=Symptomatic but completely ambulatory (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature), 2=Symptomatic, < 50% in bed during the day (Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours), 3=Symptomatic, > 50% in bed, but not bedbound (Capable of only limited self-care, confined to bed or chair 50% or more of waking hours), 4=Bedbound (Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair), 5=Death. Reported is the percentage of participants in each of the 6 ECOG performance status categories. (NCT00484939)
Timeframe: Baseline to the Safety Follow-up which occurred 28 days after the last dose of treatment (up to 5 years 8 months).

,
InterventionPercentage of participants (Number)
Week 7 ECOG = 0 (n=117,110)Week 7 ECOG = 1Week 7 ECOG = 2Week 7 ECOG = 3Week 7 ECOG = 4Week 7 ECOG = 5Week 16 ECOG = 0 (n=88,77)Week 16 ECOG = 1Week 16 ECOG = 2Week 16 ECOG = 3Week 16 ECOG = 4Week 16 ECOG = 5Week 25 ECOG = 0 (n=66,42)Week 25 ECOG = 1Week 25 ECOG = 2Week 25 ECOG = 3Week 25 ECOG = 4Week 25 ECOG = 5Week 34 ECOG = 0 (n=48,24)Week 34 ECOG = 1Week 34 ECOG = 2Week 34 ECOG = 3Week 34 ECOG = 4Week 34 ECOG = 5Safety Follow-up ECOG = 0 (n=89,82)Safety Follow-up ECOG = 1Safety Follow-up ECOG = 2Safety Follow-up ECOG = 3Safety Follow-up ECOG = 4Safety Follow-up ECOG = 5
Bevacizumab + Capecitabine50.447.01.70.90.00.050.045.53.41.10.00.043.948.56.11.50.00.039.658.30.02.10.00.033.747.212.46.70.00.0
Capecitabine34.558.25.51.80.00.036.451.911.70.00.00.045.245.29.50.00.00.033.358.38.30.00.00.032.945.114.64.91.21.2

Best Overall Response (BOR)

"BOR defined as percentage of subjects, whose BOR was either (confirmed) complete response (CR) or partial response (PR), relative to the number of subjects belonging to the study population of interest. CR defined as Disappearance of all target lesions plus disappearance of all non-target lesions & without appearance of any new lesions; confirmed minimum 4 weeks later. PR defined as At least 30% reduction in the SOLD of target lesions plus no significant change in non-target lesions to qualify for either CR or PD without appearance of new lesions; confirmed minimum 4 weeks later" (NCT00439517)
Timeframe: Evaluations were performed every 8 weeks until disease progression, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009

Interventionpercentage of participants (Number)
UFOX + Cetuximab37.5
FOLFOX4 + Cetuximab51.3

Overall Survival (OS)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00439517)
Timeframe: Time from randomization to death or last known to be alive, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009

Interventionmonths (Median)
UFOX + Cetuximab12.9
FOLFOX4 + Cetuximab15.5

Overall Survival (OS)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00439517)
Timeframe: Time from randomization to death or last known to be alive, reported between day of first patient randomised, Feb 2007, until cut off date, 31 Aug 2011

Interventionmonths (Median)
UFOX + Cetuximab16.8
FOLFOX4 + Cetuximab18.4

Progression-free Survival (PFS)

Duration from randomization until progression or death due to any cause. Only deaths within 12 weeks of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment. Response and progression were assessed by the Investigators using response evaluation criteria in solid tumors (RECIST) 1.0 criteria (NCT00439517)
Timeframe: Time from randomization to disease progression, death, or last tumor assessment reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009

Interventionmonths (Median)
UFOX + Cetuximab6.6
FOLFOX4 + Cetuximab8.2

Safety - Number of Patients Experiencing Any Adverse Event

Please refer to Adverse Events section for details of individual serious adverse events and other adverse events (NCT00439517)
Timeframe: Time from first dose up to 30 days after last dose of study treatment, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009

Interventionparticipants (Number)
UFOX + Cetuximab151
FOLFOX4 + Cetuximab149

QOL EuroQuol-5D (EQ-5D) Health Outcome Questionnaire

The EQ-5D questionnaire is a measure of health status that provides a simple descriptive profile and a single index value. The optional part of the questionnaire was not applied. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items are combined to generate health profiles. These profiles were converted to a continuous single index score using a one to one matching. The lowest possible score is -0.59 and the highest is 1.00, higher scores on the EQ-5D represent a better QOL. (NCT00439517)
Timeframe: at baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. All cycles were 4 weeks long unless dosing delays

,
Interventionscores on a scale (Least Squares Mean)
BaselineCycle 3Cycle 6
FOLFOX4 + Cetuximab0.7340.7580.771
UFOX + Cetuximab0.7470.7820.758

QOL Therapy Preference Questionnaire (TPQ)

TPQ was used to investigate which features of chemotherapy treatment are the most relevant in ensuring patient satisfaction. The most essential characteristics of a cancer medication are shown at baseline and at cycle 3, along with percentage of subjects selecting that characteristic. (NCT00439517)
Timeframe: at baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. All cycles were 4 weeks long unless dosing delays

,
Interventionpercentage of participants (Number)
Baseline: Does not increase your risk of infectionBaseline: Does not interfere with daily activitiesBaseline: Does not make you vomitBaseline: Does not give you diarrheaCycle 3: Does not increase your risk of infectionCycle 3: Does not interfere with daily activitiesCycle 3: Does not make you vomitCycle 3: Does not give you diarrhea
FOLFOX4 + Cetuximab16151451511104
UFOX + Cetuximab1817491510415

Quality of Life (QOL) Functional Assessment of Cancer Therapy-Colorectal (FACT-C)

"All of the single-item measures of the FACT-C are assessed on ordinal response categories ranging from 0=Not at all to 4=Very much. For scoring purposes the response scores are reversed on negatively phrased questions. The principle for scoring the sub-scales is the same in all cases: subscale score = (Sum of items × Number of items in the subscale) / numbers of items answered. The lowest possible total score is 0 and the highest is 136. A high scale score represents a high QOL." (NCT00439517)
Timeframe: At baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. Cycles were 4 weeks long unless dosing delays

,
Interventionscores on a scale (Least Squares Mean)
BaselineCycle 3Cycle 6
FOLFOX4 + Cetuximab96.4595.8994.70
UFOX + Cetuximab98.2295.4194.75

Treatment Impact on Social Daily Living and Health Care Resource Utilization

Non-protocol medical care visits and consultations (NCT00439517)
Timeframe: From randomisation until final visit, reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009

,
Interventionvisits or consultations (Number)
Emergency room visitHospital oupatient clinic visitPractice visitHome visitGeneral Practitioner consultationSpecialist consultationNurse consultationOther consultation
FOLFOX4 + Cetuximab26351591301248412318
UFOX + Cetuximab3440711565621519

Change From Baseline in Quality of Life Measured by the Functional Assessment of Chronic Illness Therapy-Diarrhea (FACIT-D)

Quality of life (QoL) is evaluated using FACIT-D scale. FACIT-D is composed of 38 items, whose responses range from 0 to 4. The total FACIT-D score may range from 0 to 152. The 38 items compose five subscales, each evaluating a different component of the (QOL). For calculating the subscale score, some items are computed in a reverse fashion, so that higher FACIT-D scores indicate a better (QoL). Descriptive statistics (mean, standard deviation, median, minimum and maximum) are used to summarize FACIT-D scores (total and subscales) by study group at each time point. (NCT00582426)
Timeframe: Baseline to Day 168

InterventionUnits on a scale (Mean)
Octreotide Long Acting Release0.5
Standard Treatment3.4

Number of Episodes of Diarrhea by Patient

Number of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis. (NCT00582426)
Timeframe: 6 months overall

InterventionEpisodes/patients/day (Mean)
Octreotide Long Acting Release21.6
Standard Treatment20.4

Percentage of Participants Developing Diarrhea (Grade 1 to 4)

The percentage of patients developing diarrhea (incidence of grade 1 to 4) during treatment, considering only the worst grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 0=None, 1 = Increase of <4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse. (NCT00582426)
Timeframe: 6 month overall

InterventionPercentage of Participants (Number)
Octreotide Long Acting Release76.1
Standard Treatment78.9

Percentage of Participants Who Need Chemotherapy Dose Reduction Due to Diarrhea

For patient, chemotherapy dose reduction due to diarrhea as counted each time it occurred. Chemotherapy dose reduction because of other adverse events related to chemotherapy was not considered. (NCT00582426)
Timeframe: 6 months overall

InterventionPercentage of participants (Number)
Octreotide Long Acting Release26.9
Standard Treatment11.3

Percentage of Participants Who Need Intravenous Hydration for Control of Diarrhea

(NCT00582426)
Timeframe: 6 months overall

InterventionPercentage of Participants (Number)
Octreotide Long Acting Release4.5
Standard Treatment7.0

Percentage of Participants Who Need Opioids for Control of Diarrhea

(NCT00582426)
Timeframe: 6 months overall

InterventionPercentage of Participants (Number)
Octreotide Long Acting Release1.5
Standard Treatment1.4

Percentage of Patients Hospitalized Due to Diarrhea

(NCT00582426)
Timeframe: 6 months overall

InterventionPercentage of patients (Number)
Octreotide Long Acting Release6
Standard Treatment4.2

Number of Episodes of Diarrhea by Patient by Cycle

Mean number of episodes of diarrhea is evaluated by patient diaries recorded by cycle. (cycle 1 to cycle 7.) (NCT00582426)
Timeframe: at each cycle (28 days per cycle)

,
InterventionEpisodes/patient/cycle (Mean)
Cycle 1 (n=20, 18)Cycle 2 (n=36,38)Cycle 3 (n=33,39)Cycle 4 (n=24, 27)Cycle 5 (n=20,29)Cycle 6 (n=22, 22)Cycle 7 (n= 16, 20)
Octreotide Long Acting Release2.68.26.98.68.16.14.8
Standard Treatment2.25.96.77.175.86.6

Percentage of Episodes by Grade

Grade (severity)of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis by considering only worse grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 1 = Increase of <4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence;or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse. (NCT00582426)
Timeframe: 6 months overall

,
InterventionPercentage of Episodes (Number)
Grade 1Grade 2Grade 3Grade 4
Octreotide Long Acting Release65.423.311.30
Standard Treatment66.927.25.90

Percentage of Participants With Complete or Partial Response at Response Evaluation Criteria in Solid Tumors (RECIST)

Lesions that can be accurately measured in at least one dimension (longest diameter (LD) to be recorded) as > 20 mm with conventional techniques (CT, MRI) or as > 10 mm with spiral CT scan. All measurable lesions up to maximum of 5 lesions per organ and 10 lesions in total representative of all involved organs should be identified as target lesions and recorded and measured at baseline. Complete Response is defined as Disappearance of all target lesions. Partial Response is defined at least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. (NCT00582426)
Timeframe: Day 56, Day 84, Day 112, Day 140, Day 168

,
InterventionPercentage of Participants (Number)
Day 56 (N=11,2)Day 84 (N=5,3)Day 112 (N=1,1)Day 140 (N=9,1)Day 168 (N=2,1)
Octreotide Long Acting Release45.560.010044.4100
Standard Treatment0.01000.0100100

Percentage of Patients by Grade of Diarrhea

Grade (severity) of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis by considering only worse grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 0 = None, 1 = Increase of <4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse. (NCT00582426)
Timeframe: 6 months overall

,
InterventionPercentage of Participants (Number)
Grade 1Grade 2Grade 3Grade 4
Octreotide Long Acting Release41.225.533.30
Standard Treatment26.851.821.40

Mean Total Tumor Dose of 131I-huA33

"Gamma camera imaging were performed on four occasions (1-4 hours, Day 1, Day 2 or 3, and Day 4 or 5) following completion of the initial infusion and 7+2 days post-therapy infusion in week 2, and again in week 3 or 4 and week 5 following the therapy infusion.~Dosimetry analysis was performed on the series of gamma camera whole-body planar images.~Tumor radioactivity content after the initial infusion was estimated from the geometric mean of anterior and posterior regions of interest counts. The counts for each organ were corrected for background using regions of interest drawn adjacent to each tumor. Resultant counts were converted to activity using a camera sensitivity factor calculated from a gamma camera standard of known activity which was scanned at the same time." (NCT00291486)
Timeframe: 5 weeks

InterventionGy (Mean)
All Patients13.83
Cohorts 2 and 3; 30 mCi 131I-huA3313.15
Cohorts 4 and 5: 40 mCi 131I-huA3314.89

Number of Patients With Dose-Limiting Toxicities (DLT)

"Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE v3.0). DLT was defined as any of the following related events:~Any grade 2 or greater allergic reaction related to huA33. Any grade ≥ 3 non-haematological toxicity related to 131I-huA33 or capecitabine.~These toxicities included palmar plantar erythema, but skin rash thought to be related to huA33 protein was not a DLT as previous studies have shown no relation of this toxicity to dose of huA33 or radioiodine dose.~Capecitabine cardiotoxicity grade ≥ 3 - including vasospasm, acute coronary syndrome and arrhythmia, necessitated the cessation of study drug in the affected patient but were not considered DLT as these are recognized as idiosyncratic in nature and not known to be related to capecitabine dose.~Any grade ≥ 4 neutropenia ≥ 7 days in duration or any thrombocytopenia with a platelet count < 10 x 10^9/L." (NCT00291486)
Timeframe: 7 weeks

InterventionParticipants (Count of Participants)
Cohort 10
Cohort 22
Cohort 30
Cohort 40
Cohort 50

Biodistribution of 131I-huA33 Measured by Whole Body Clearance and Normal Organ Clearance Reported as Mean Biological Half-life (T1/2 Biological) After Initial 131I-huA33 Infusion

T1/2 biological is the clearance of the isotope from the whole body. Following the initial 131I-huA33 infusion, gamma camera scans were acquired over a 1 week period (1-4 hours, Day 1, Day 2 or 3, and Day 4 or 5). Whole body clearance, or biological half time, T1/2 biological, was calculated from the whole body anterior and posterior planar images. A region of interest (ROI) was calculated to encompass the whole body, and for each ROI at each time point, the mean counts per pixel per minute was normalised to imaging time point Day 1. (NCT00291486)
Timeframe: 1 week

Interventionhours (Mean)
Whole Body Clearance (T1/2 biologic)Normal Organ Clearance in the Liver (T1/2 biological - liver)Normal Organ Clearance in the kidney (T1/2 biological - kidney)
Cohorts 1-5219.5662.29104.89

Impact of Capecitabine on 131I-huA33 Clearance (CL) as Measured by Initial and Therapy Dose Clearance (CL)

"Blood samples for pharmacokinetics (PK) were drawn in week 0 immediately pre-initial 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post-initial 131I-huA33 infusion, Day 1, Day 2 or Day 3, Day 4 or Day 5. In week 1, PK samples were collected immediately pre-therapy 131I-huA33 infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post-therapy 13II-huA33 infusion, then weekly until 4 weeks post therapy.~Pharmacokinetic calculations were performed on serum 131I-huA33 data using a curve fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain View, CA)." (NCT00291486)
Timeframe: 5 weeks

,,
Interventionml/hr (Mean)
Initial dose CLTherapy dose CL
Cohort 5; 1250 mg/m2/Day Capecitabine34.6535.53
Cohorts 1 and 2; 1500 mg/m2/Day Capecitabine34.8826.88
Cohorts 3 and 4; 1000 mg/m2/Day Capecitabine40.5439.41

Mean Specific Absorbed Dose of 131I-huA33 for Normal Organs Calculated From the Initial Infusion

"Gamma camera imaging with anterior and posterior whole body scans using conjugate view methodology were performed on four occasions (1-4 hours, Day 1, Day 2 or 3, and Day 4 or 5) following completion of the intravenous initial infusion.~Dosimetric analysis was performed on the series of gamma camera whole-body planar images acquired in all patients following the first infusion.~Organ radioactivity content was estimated from the geometric mean of anterior and posterior regions of interest counts. The counts for each organ were corrected for background using regions of interest drawn adjacent to each organ where whole body thickness was comparable." (NCT00291486)
Timeframe: 1 week

InterventioncGy/MBq (Mean)
LiverSpleenKidneyLungRed Marrow
Cohorts 1-50.120.180.140.090.056

Pharmacokinetics (PK) of 131I-huA33 as Measured by Area Under the Serum Concentration Curve Extrapolated to Infinite Time (AUC)

"Blood samples for pharmacokinetics (PK) were drawn in week 0 immediately pre-initial 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post-initial 131I-huA33 infusion, Day 1, Day 2 or Day 3, Day 4 or Day 5. In week 1, PK samples were collected immediately pre-therapy 131I-huA33 infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post-therapy 131I-huA33 infusion, then weekly until 4 weeks post therapy.~Pharmacokinetic calculations were performed on serum 131I-huA33 data using a curve fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain View, CA)." (NCT00291486)
Timeframe: 5 weeks

Interventionmcg.hr/mL (Mean)
AUC after initial 131I-huA33 infusionAUC after therapy 131I-huA33 infusion
Cohorts 1-5130.43592.46

Pharmacokinetics (PK) of 131I-huA33 as Measured by Clearance (CL)

"Blood samples for pharmacokinetics (PK) were drawn in week 0 immediately pre-initial 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post-initial 131I-huA33 infusion, Day 1, Day 2 or Day 3, Day 4 or Day 5. In week 1, PK samples were collected immediately pre-therapy 131I-huA33 infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post-therapy 13II-huA33 infusion, then weekly until 4 weeks post therapy.~Pharmacokinetic calculations were performed on serum 131I-huA33 data using a curve fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain View, CA)." (NCT00291486)
Timeframe: 5 weeks

InterventionmL/hr (Mean)
CL after initial 131I-huA33 infusionCL after therapy 131I-huA33 infusion
Cohorts 1-536.7232.60

Pharmacokinetics (PK) of 131I-huA33 as Measured by Maximum Serum Concentration (Cmax)

"Blood samples for pharmacokinetics (PK) were drawn in week 0 immediately pre-initial 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post-initial 131I-huA33 infusion, Day 1, Day 2 or Day 3, Day 4 or Day 5. In week 1, PK samples were collected immediately pre-therapy 131I-huA33 infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post-therapy 131I-huA33 infusion, then weekly until 4 weeks post therapy.~Pharmacokinetic calculations were performed on serum 131I-huA33 data using a curve fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain View, CA)." (NCT00291486)
Timeframe: 5 weeks

Interventionmcg/mL (Mean)
Cmax after initial 131I-huA33 infusionCmax after therapy 131I-huA33 infusion
Cohorts 1-51.535.52

Pharmacokinetics (PK) of 131I-huA33 as Measured by T½α and T½β (Half Lives of the Initial and Terminal Phases of Disposition, Respectively)

"Blood samples for pharmacokinetics (PK) were drawn in week 0 immediately pre-initial 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post-initial 131I-huA33 infusion, Day 1, Day 2 or Day 3, Day 4 or Day 5. In week 1, PK samples were collected immediately pre-therapy 131I-huA33 infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post-therapy 131I-huA33 infusion, then weekly until 4 weeks post therapy.~Pharmacokinetic calculations were performed on serum 131I-huA33 data using a curve fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain View, CA)." (NCT00291486)
Timeframe: 5 weeks

Interventionhours (Mean)
T½α after initial 131I-huA33 infusionT½α after therapy 131I-huA33 infusionT½β after initial 131I-huA33 infusionT½β after therapy 131I-huA33 infusion
Cohorts 1-515.7828.63100.24152.60

Pharmacokinetics (PK) of 131I-huA33 as Measured by the Volume of the Central Compartment (V1)

"Blood samples for pharmacokinetics (PK) were drawn in week 0 immediately pre-initial 131I-huA33 infusion; then 5 minutes, 60 minutes and 2 hours post-initial 131I-huA33 infusion, Day 1, Day 2 or Day 3, Day 4 or Day 5. In week 1, PK samples were collected immediately pre-therapy 131I-huA33 infusion, 5 minutes, 24 ± 2 hours and approximately 7 days post-therapy 131I-huA33 infusion, then weekly until 4 weeks post therapy.~Pharmacokinetic calculations were performed on serum 131I-huA33 data using a curve fitting Program (WinNonLin version 5.2; Pharsight Co., Mountain View, CA)." (NCT00291486)
Timeframe: 5 weeks

InterventionmL (Mean)
V1 after initial 131I-huA33 infusionV1 after therapy 131I-huA33 infusion
Cohorts 1-53204.263363.69

Number of Patients With Human Anti-human Antibodies (HAHA) to 131I-huA33

Serum samples for human anti-human antibody (HAHA) assessment were collected prior to each 131I-huA33 infusion, at weekly intervals during weeks 0-7, then alternate weeks until the end-of-study visit. Measurement of immune responses to huA33 in patients serum was performed using a BIAcore 2000 biosensor (Biacore AB, Uppsala, Sweden). (NCT00291486)
Timeframe: 13 weeks

InterventionParticipants (Count of Participants)
Pre-treatment72460703Pre-treatment72460704Pre-treatment72460705Pre-treatment72460706Pre-treatment72460702Week 172460703Week 172460704Week 172460705Week 172460706Week 172460702Week 272460703Week 272460704Week 272460705Week 272460706Week 272460702Week 372460703Week 372460704Week 372460705Week 372460706Week 372460702Week 472460703Week 472460704Week 472460702Week 472460705Week 472460706Week 572460703Week 572460704Week 572460705Week 572460702Week 572460706Week 672460703Week 672460704Week 672460706Week 672460702Week 672460705Week 872460702Week 872460703Week 872460704Week 872460705Week 872460706Week 10-1172460703Week 10-1172460704Week 10-1172460705Week 10-1172460706Week 10-1172460702Week 12-1372460703Week 12-1372460704Week 12-1372460705Week 12-1372460706Week 12-1372460702
Negative HAHAPositive HAHA
Cohort 20
Cohort 40
Cohort 50
Cohort 26
Cohort 33
Cohort 43
Cohort 54
Cohort 41
Cohort 32
Cohort 42
Cohort 30
Cohort 52
Cohort 51
Cohort 13
Cohort 10
Cohort 24
Cohort 23
Cohort 31
Cohort 53
Cohort 12

Median Duration of Response

Duration of response is defined as the delay between response (complete or partial) and disease progression according to RECIST V1.0. Therefore, this criterion can only be assessed in in subjects who have responded. Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.). Progression is defined as a 20% increase in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD, or appearance of one or several new lesions (RECIST V1.0) Radiologic assessment was carried out every four cycles (8 weeks) with centralized external secondary review. (NCT00467142)
Timeframe: 24 months

Interventionmonths (Median)
Folfiri and Bevacizumab9.5

Percentage of Participants in Objective Response (Partial or Complete Responses)

Objective response defined as complete or partial responses according to RECIST v1.0. Complete response is defined as the disappearance of all target lesions and partial response is defined as at least a 30% decrease in the sum of the longest diameters (SLD) of target lesions, taking as reference the baseline SLD (RECIST V1.0.).Radiologic assessment was carried out every four cycles (8 weeks) with centralized external secondary review. (NCT00467142)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Folfiri and Bevacizumab47.5

Percentage of Participants With Overall Response

Tumour Response Rate per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT: Complete Response (CR) - Disappearance of all target lesions which is confirmed if determined by two observations not less than 4 weeks apart; Partial Response (PR) - >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00724503)
Timeframe: Through study completion, up to 60 months

Interventionpercentage of participants (Number)
B: FOLFOX + SIR-Spheres76.4
A: FOLFOX Alone68.1

Progression-Free Survival (PFS) at Any Site

PFS defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as an increase in the sum of the longest diameters of ≥ 20% and an absolute increase in the sum of the longest diameters of ≥ 5 mm, or the appearance of a new lesion. (NCT00724503)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

InterventionMonths (Median)
mFOLFOX6 Plus SIRT10.7
mFOLFOX6 Alone10.2

Overall Survival (OS)

OS was defined as the time from randomization to death from any cause. For participants without an event of death, OS was censored at the last-known alive date. OS was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (prior to each cycle, and within 7 days prior to surgery; at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)

Interventionmonths (Median)
Bevacizumab + mFOLFOX-632.2
Bevacizumab + FOLFOXIRINA

Percentage of Participants Experiencing Death or Disease Progression

PD was defined, using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, as at least a 20% increase in the sum of the longest diameter of target lesions, or the appearance of one or more new lesions. The percentage of participants experiencing PD or death was calculated as [number of participants with event divided by the number of participants analyzed] multiplied by 100. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX-689.7
Bevacizumab + FOLFOXIRI68.3

Percentage of Participants Experiencing Relapse Following Curative Resection

Among participants with curative resection (complete resection [R0] or microscopic residual tumor [R1]), relapse was defined as the first new occurrence of cancer or death. The percentage of participants who experienced relapse was calculated as [number of participants with a relapse event divided by the number of participants initially classified as R0 or R1 following resective surgery] multiplied by 100. (NCT00778102)
Timeframe: Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX-676.9
Bevacizumab + FOLFOXIRI57.1

Percentage of Participants Who Died

(NCT00778102)
Timeframe: Up to 5 years (prior to each cycle, and within 7 days prior to surgery; at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX-648.7
Bevacizumab + FOLFOXIRI19.5

Percentage of Participants With a Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.0

Using RECIST version 1.0, participants were considered to have achieved CR upon the disappearance of all target and non-target lesions. Participants who achieved PR demonstrated at least a 30% decrease in the sum of the largest diameter of target lesions, taking as reference the Screening sum largest diameter. Responses were confirmed by repeat assessments no less than 4 weeks after criteria for response were first met. The collective percentage of participants with confirmed best overall response of CR or PR was calculated as [number of participants meeting RECIST criteria for CR or PR divided by the number of participants analyzed] multiplied by 100. Associated 95% confidence intervals were calculated for one-sample binomial using the Clopper-Pearson method. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX-661.5
Bevacizumab + FOLFOXIRI80.5

Percentage of Participants With Complete or Major Histopathological Response

At the time of resective surgery, participants were evaluated for histopathological response as defined through pathologist review of the resected metastatic lesions, including assessment of margin status and tumor cell viability. Histopathological response classification was based upon the percentage of viable tumor cells, as described previously. The collective percentage of participants assessed as having a complete or major response was calculated as [number of participants with complete or major response divided by the number of participants who completed the assessment] multiplied by 100. Associated 95% confidence intervals were calculated for one-sample binomial using the Clopper-Pearson method. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; and at time of/after surgery)

Interventionpercentage of participants (Number)
Bevacizumab + mFOLFOX-657.1
Bevacizumab + FOLFOXIRI52.4

Progression-Free Survival (PFS)

PFS was defined, using RECIST version 1.0, as the time from randomization to the date of first documented PD or death from any cause. PD was defined as at least a 20% increase in the sum of the longest diameter of target lesions, or the appearance of one or more new lesions. For participants without documented PD or death, PFS was censored at the time of last tumor assessment. PFS was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)

Interventionmonths (Median)
Bevacizumab + mFOLFOX-611.5
Bevacizumab + FOLFOXIRI18.6

Relapse-Free Survival (RFS)

RFS was defined as the time from curative resection (complete resection [R0] or microscopic residual tumor [R1]) to the date of first diagnosis of relapse. For participants with curative resection and without relapse, RFS was censored at the last known relapse-free assessment. RFS was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)

Interventionmonths (Median)
Bevacizumab + mFOLFOX-68.1
Bevacizumab + FOLFOXIRI17.1

Time to Resection

Time to resection was defined as the time from randomization to the date of first resective surgery. For participants who did not undergo resective surgery, time to resection was censored at Day 1. Time to resection was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (at Screening; prior to each cycle, and within 7 days prior to surgery; and at time of surgery)

Interventionmonths (Median)
Bevacizumab + mFOLFOX-64.4
Bevacizumab + FOLFOXIRI4.3

Time to Response

Time to response according to RECIST version 1.0 was defined as the time from randomization to the date of first documented CR or PR. Participants were considered to have achieved CR upon the disappearance of all target and non-target lesions. Participants who achieved PR demonstrated at least a 30% decrease in the sum of the largest diameter of target lesions, taking as reference the Screening sum largest diameter. Responses were confirmed by repeat assessments no less than 4 weeks after criteria for response were first met. For participants who did not complete a confirmatory tumor assessment, time to response was censored at the date of last tumor assessment, or if unavailable, at the date of first dose. Time to response was estimated by Kaplan-Meier analysis. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; 4 and 12 weeks after surgery; and at the end of Cycles 4 and 8 if assessed as R0 or R1, or every 6 weeks until progression or resectability if assessed as R2)

Interventionmonths (Median)
Bevacizumab + mFOLFOX-63.1
Bevacizumab + FOLFOXIRI3.1

Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor

Following resective surgery, participants were evaluated for complete resection (R0) or the presence of microscopic (R1) or macroscopic (R2) residual tumor. The percentage of participants within each residual tumor classification was calculated as [number of participants with R0, R1, and/or R2 divided by the total number of participants] multiplied by 100. Associated 95% confidence intervals were calculated for one-sample binomial using the Clopper-Pearson method. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; and at time of/after surgery)

,
Interventionpercentage of participants (Number)
R0, R1, or R2R0 or R1R0
Bevacizumab + FOLFOXIRI61.051.248.8
Bevacizumab + mFOLFOX-648.733.323.1

Percentage of Participants With Complications Related to First Resective Surgery

Complications related to the first resective surgery were evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0, and classified according to severity. The NCI-CTCAE severity classification criteria are as follows: Grade 5 equals (=) resulting in death; Grade 4 = life-threatening; Grade 3 = severe; Grade 2 = moderate; and Grade 1 = mild. The percentage of participants experiencing a given adverse event (AE) by severity grade was calculated as [number of participants with an AE divided by the number of participants who underwent first resective surgery] multiplied by 100. (NCT00778102)
Timeframe: Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)

,
Interventionpercentage of participants (Number)
Any complication, TotalAny complication, Grade 1Any complication, Grade 2Any complication, Grade 3Any complication, Grade 4Any complication, Grade 5Bleeding, TotalBleeding, Grade 1Bleeding, Grade 2Bleeding, Grade 3Cardiovascular, TotalCardiovascular, Grade 2Cardiovascular, Grade 3Cardiovascular, Grade 4Infections, TotalInfections, Grade 1Infections, Grade 2Infections, Grade 3Infections, Grade 4Liver insufficiency, TotalLiver insufficiency, Grade 5Neural disorder, TotalNeural disorder, Grade 2Noninfected perihepatic fluid collections, TotalNoninfected perihepatic fluid collections, Grade 2Other complication, TotalOther complication, Grade 1Other complication, Grade 2Other complication, Grade 3Other complication, Grade 4Pulmonary, TotalPulmonary, Grade 3Renal impairment, TotalRenal impairment, Grade 2Renal impairment, Grade 4Wound healing, TotalWound healing, Grade 1Wound healing, Grade 3Wound healing, Grade 4
Bevacizumab + FOLFOXIRI52.04.012.024.012.008.004.04.04.04.00032.012.0016.04.000004.04.028.08.08.012.004.04.04.04.0012.004.08.0
Bevacizumab + mFOLFOX-673.715.836.810.5010.515.85.35.35.310.505.35.326.310.55.35.35.310.510.55.35.30052.626.321.105.35.35.310.55.35.35.35.300

Percentage of Participants With Complications Related to Second Resective Surgery

Complications related to the second resective surgery were evaluated using the NCI-CTCAE version 3.0, and classified according to severity. The NCI-CTCAE severity classification criteria are as follows: Grade 5 = resulting in death; Grade 4 = life-threatening; Grade 3 = severe; Grade 2 = moderate; and Grade 1 = mild. The percentage of participants experiencing a given AE by severity grade was calculated as [number of participants with an AE divided by the number of participants who underwent second resective surgery] multiplied by 100. (NCT00778102)
Timeframe: Up to 5 years (at time of surgery; 48 hours and 4 and 12 weeks after surgery; within 4 weeks after completion of treatment; every 3 to 6 months for 1 year; then annually)

,
Interventionpercentage of participants (Number)
Any complication, TotalAny complication, Grade 1Any complication, Grade 2Any complication, Grade 3Any complication, Grade 3aBleeding, TotalBleeding, Grade 1Bleeding, Grade 2
Bevacizumab + FOLFOXIRI66.733.3033.3033.333.30
Bevacizumab + mFOLFOX-6100.0066.7033.333.3033.3

Percentage of Participants With Histopathological Response

At the time of resective surgery, participants were evaluated for histopathological response as defined through pathologist review of the resected metastatic lesions, including assessment of margin status and tumor cell viability. Histopathological response classification was based upon the percentage of viable tumor cells, where 'Complete response' was considered for those with 0 percent (%) viable tumor cells, 'Major response' for those with 1% to 49% viable tumor cells, 'Minor response' for 50% to 99% viable tumor cells, and 'No response' for 100% viable tumor cells. The response could not be determined in some cases and was documented as 'Unknown.' The percentage of participants within each response category was calculated as [number of participants with a given response divided by the number of participants who completed the assessment] multiplied by 100. (NCT00778102)
Timeframe: Up to 5 years (at Screening; every 6 weeks, and within 4 weeks prior to surgery; and at time of/after surgery)

,
Interventionpercentage of participants (Number)
Complete responseMajor responseMinor responseNo responseUnknown
Bevacizumab + FOLFOXIRI4.847.633.3014.3
Bevacizumab + mFOLFOX-6057.128.6014.3

Disease Control

Disease control is defined as incidence of objective response or stable disease on study up to starting a new anti-tumor therapy. (NCT00418938)
Timeframe: From randomization up to 65 months.

,
Intervention% of participants (Number)
Wild-type KRAS (n=91,91)Mutant KRAS (n=36,32)
Bevacizumab Plus FOLFIRI79.5266.67
Panitumumab Plus FOLFIRI72.4152.94

Duration of Response

Duration of response is defined as time from first confirmed objective response to disease progression per modified RECIST version 1.0 (by central assessment). (NCT00418938)
Timeframe: From randomization up to 65 months.

,
Interventionmonths (Median)
Wild-type KRAS (n=91,91)Mutant KRAS (n=36,32)
Bevacizumab Plus FOLFIRI8.915.2
Panitumumab Plus FOLFIRI12.710.2

Objective Response Rate

Objective response rate is defined as incidence of either a confirmed complete response (CR) or partial response (PR) on study up to starting a new anti-tumor therapy and will be based on modified RECIST version 1.0 (responder) by central assessment. (NCT00418938)
Timeframe: From randomization up to 65 months.

,
Intervention% of patients (Number)
Wild-type KRAS (n=91,91)Mutant KRAS (n=36,32)
Bevacizumab Plus FOLFIRI19.283.33
Panitumumab Plus FOLFIRI32.1811.76

Overall Survival

Overall survival is defined as time from the date of randomization to the date of death due to any cause. Subjects who have not died or are lost to follow-up at the analysis cutoff date will be censored at their last contact date. (NCT00418938)
Timeframe: From randomization up to 65 months.

,
Interventionmonths (Median)
Wild-type KRAS (n=91,91)Mutant KRAS (n=36,32)
Bevacizumab Plus FOLFIRI21.413.5
Panitumumab Plus FOLFIRI18.08.7

Progression-free Survival (PFS)

Progression-free survival is defined as time from the date of randomization to the date of first progression per modified RECIST version 1.0 (based on central review of the radiographic scans), or death within 60 days after the last evaluable tumor assessment or randomization date (whichever is later). (NCT00418938)
Timeframe: From randomization up to 65 months.

,
Interventionmonths (Median)
Wild-type KRAS (n=91,91)Mutant KRAS (n=36,32)
Bevacizumab Plus FOLFIRI9.26.4
Panitumumab Plus FOLFIRI7.73.7

Time to Progression

Time to progression is defined as time from the date of randomization to the date of radiographic disease progression per modified RECIST version 1.0 (per central assessment). (NCT00418938)
Timeframe: From randomization up to 65 months.

,
Interventionmonths (Median)
Wild-type KRASMutant KRAS
Bevacizumab Plus FOLFIRI9.47.4
Panitumumab Plus FOLFIRI11.14.5

Time to Response

Time to response is defined as time from the date of randomization to the date of first confirmed objective response (NCT00418938)
Timeframe: From randomization up to 65 months.

,
Interventionmonths (Median)
Wild-type KRAS (n=91,91)Mutant KRAS (n=36,32)
Bevacizumab Plus FOLFIRI3.71.8
Panitumumab Plus FOLFIRI2.12.2

Duration of Overall Response Among Participants Whose Best Response Was CR or PR During First Line Treatment - Time to Event

For participants with a best overall response of CR or PR, the duration of overall response was measured from the time that the criteria for CR or PR (whichever occurred first) was met until the first date that progressive disease was objectively documented or until the date of death due to underlying cancer, whichever occurred first. Data for participants who did not have an event or who were alive without an objectively documented progressive disease were censored at the date of last adequate tumor assessment. Median duration of overall response was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years

Interventionmonths (Median)
Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab8.52

Duration of Stable Response

For participants with a best overall response of CR, PR, or SD during first line treatment, the duration of stable response was measured from the time that the criteria for CR, PR, or SD (whichever occurred first) was met until the first date that progressive disease was objectively documented or until the date of death due to underlying cancer, whichever occurred first. Data for participants who did not have an event or who were alive without an objectively documented progressive disease were censored at the date of last adequate tumor assessment. Median duration of stable response was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years

Interventionmonths (Median)
Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab10.39

Overall Survival: Percentage of Participants That Died Due to Any Cause

Overall survival was defined as the time from the date of the first day of treatment until the date of death from any cause. If a participant was not known to have died, survival was censored at the last date the participant was known to be alive. (NCT00577031)
Timeframe: Baseline, Day 1 of every cycle to end-of-treatment, every 3 months during longer-term follow-up, or to death due to any cause up to 5 years

Interventionpercentage of participants (Number)
Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab50.76

Overall Survival: Time to Event

Overall survival was defined as the time from the date of the first day of treatment until the date of death from any cause. If a participant was not known to have died, survival was censored at the last date the participant was known to be alive. Median overall survival was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, Day 1 of every cycle to end-of-treatment, every 3 months during longer-term follow-up, or to death due to any cause up to 5 years

Interventionmonths (Median)
Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab23.15

Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Among Participants in the ITT Population Who Had at Least 1 Post-Baseline Assessment

The percentage of participants with a best overall response of CR or PR according to RECIST. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than [<]10 millimeters [mm]). No new lesions. PR was defined as a greater than or equal to (≥) 30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years

Interventionpercentage of participants (Number)
Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab58.79

Percentage of Participants With a Best Overall Response of CR or PR During First Line Treatment

CR and PR were defined using RECIST v1.0 criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis <10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. Short axis was used in sum for target nodes, while longest diameter was used in sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years

Interventionpercentage of participants (Number)
Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab54.64

Percentage of Participants With a CR or PR Among Participants in the ITT Population

CR and PR were defined using RECIST v1.0. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis <10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years

Interventionpercentage of participants (Number)
Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab49.24

Percentage of Participants With a Stable Response During First Line Treatment

Stable response defined as participants with a best overall response of CR, PR, or stable disease (SD), defined using RECIST v1.0 criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis <10 mm). No new lesions. PR was defined as a ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD defined as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since the treatment started. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years

Interventionpercentage of participants (Number)
Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab52.63

Percentage of Participants With Treatment Failure

Treatment-failure was defined as discontinuation of treatment for any reason, including the following qualifying events: death due to any cause, adverse event, insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent). (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years

Interventionpercentage of participants (Number)
Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab82.74

PFS: Time to Event

PFS was defined as the time period in months from the start of study treatment to the first observation of disease progression or death from any cause, whichever occurred first. Data for participants with no tumor assessments after baseline but who were still alive at the time of the clinical cutoff were censored at Day 1. Participants who underwent surgery after experiencing a sufficient shrinkage of the tumor, had any relapse, new occurrence of colorectal cancer, or who died were all considered as having had an event. Participants who underwent surgery without any such event were censored at the date of the last tumor assessment that documented that neither a relapse nor a new colorectal cancer had occurred. Median PFS was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline and Day 1 of every cycle until disease progression or death up to 5 years

Interventionmonths (Median)
Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab9.70

Progression-Free Survival (PFS): Percentage of Participants With Progressive Disease or Death

PFS was defined as the time period in months from the start of study treatment to the first observation of disease progression or death from any cause, whichever occurred first. Data for participants with no tumor assessments after baseline but who were still alive at the time of the clinical cutoff were censored at Day 1. Participants who underwent surgery after experiencing a sufficient shrinkage of the tumor, had any relapse, new occurrence of colorectal cancer, or who died were all considered as having had an event. Participants who underwent surgery without any such event were censored at the date of the last tumor assessment that documented neither a relapse nor a new colorectal cancer had occurred. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20 percent (%) increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00577031)
Timeframe: Baseline and Day 1 of every cycle until disease progression or death up to 5 years

Interventionpercentage of participants (Number)
Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab50.25

Time to CR or PR Overall Response - Time to Event

Time to overall response (CR or PR) was calculated as the time between the date of start of treatment until first documented response (CR or PR defined per RECIST v1.0). Participants who did not achieve CR or PR were censored at the date of progression, death, or at last adequate tumor assessment date. Median time to CR or PR overall response was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years

Interventionmonths (Median)
Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab3.93

Time to Treatment Failure

Time to treatment-failure was defined as the time from the first day of treatment to discontinuation of treatment for any reason, including: death due to any cause, adverse event, insufficient therapeutic response (progression of disease), failure to return (lost to follow-up), refusing treatment (participant non-compliance), being unwilling to cooperate and withdrawing consent (participant withdrew consent). For participants who did not experience a qualifying event, their data were censored at the earlier of either the date of last tumour assessment or the date of the last intake of study medication. Median time to treatment-failure was estimated using the Kaplan-Meier method. (NCT00577031)
Timeframe: Baseline, every 3 weeks (every cycle) to disease progression or death up to 5 years

Interventionmonths (Median)
Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab6.69

European Quality of Life 5 Dimension (EQ-5D) Raw-Index Score

"Quality of life (QoL) assessments were used to derive pre-specified QoL scores according to the QoL manual EQ-5D-3 Level (3L) user guide for instrument version 4.0. The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single index value. The visual analog scale (VAS) component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. The overall health score absolute changes were calculated for each participant as follows: (score at the end of treatment minus score at baseline). EQ-5D health states were converted into EQ-5D-3L raw index value by applying the scoring algorithm based on the European EQ-net VAS set. The raw index was chosen instead of rescaled index, since the questionnaire was used in order to obtain a quality of life assessment. The raw index scores ranged from 0 (worst health state) to 100 (best health state)." (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles), at end-of-treatment up to 5 years

Interventionunits on a scale (Mean)
BaselineLast visitAbsolute change from baseline
Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab80.2474.94-5.30

Percentage of Participants Undergoing Surgical Intervention With Residual Disease Status Post-surgery

The percentage of participants who underwent surgery during the study period with an evaluation of their disease status after surgery. The surgery during the study period was described by reason: curative, palliative, biopsy, other, or unknown. Residual disease status after surgery was described as: no residual disease due to radical surgery, presence of residual disease, unknown or not applicable. (NCT00577031)
Timeframe: At surgery, at least 6 to 8 weeks after last dose of bevacizumab up to 5 years

Interventionpercentage of participants (Number)
Curative, no residual diseaseCurative, residual diseaseCurative, unknownCurative, not applicablePalliative, no residual diseasePalliative, residual diseasePalliative, unknownPalliative, not applicableBiopsy, residual diseaseBiopsy, not applicableUnknown, unknownUnknown, not applicableOther, residual diseaseOther, not applicable
Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab55.7713.463.857.693.857.693.851.921.921.921.923.851.923.85

Percentage of Participants With Best Overall Response of CR or PR by Kirsten Rat Sarcoma Viral Oncogene Homolog (K-Ras)/V-Raf Murine Sarcoma Viral Oncogene Homolog B (B-Raf) Mutation Status

"The percentage of participants with a best overall response of CR or PR according to RECIST. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis <10 mm). No new lesions. PR was defined as ≥30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.~The K-Ras and/or the B-Raf gene mutation status of participants was evaluated by the central laboratory using tumor samples. Wild-type participants did not have a mutation in either gene." (NCT00577031)
Timeframe: Baseline, every 9 weeks (every 3 cycles) until end of treatment, disease progression, or withdrawal up to 5 years

Interventionpercentage of participants (Number)
Wild-type (n=18)Gene mutation (n=15)
Bevucizamab+Oxaliplatin+Capecitabine/Bevacizumab88.8966.67

5-FU Plasma Levels

Pharmacokinetics of 5-FU - Cmax plasma levels (NCT01206465)
Timeframe: 22, 23, 45 & 46 hours during the 48 hour infusion

Interventionmg/m^2 (Mean)
22 Hours1147
23 Hours1159
45 Hours1123
46 Hours1113

Pharmacokinetics of PDX- AUClast

Plasma concentrations versus time (at all time points) (NCT01206465)
Timeframe: Pre-treatment, end of infusion, at 15, 30, and 60 min, and then at 2, 4, 6, 8, 12, 22, 23, 24, 45, and 46 hours for PDX.

Interventionng/ml *hr (Mean)
75 mg/m^212,818
94 mg/m^216300
118 mg/m^215680
148 mg/m^223570
185 mg/m^242121

Recommended Dose of PDX Given With a Fixed Dose of 5-FU

Recommended dose of PDX given in combination with a fixed dose of 5-FU administered as a 48-hour infusion given every other weekMaximum tolerated dose will have been exceeded when 2 patients entered at a given dose level experience specified dose-limiting toxicities in the initial cycle (NCT01206465)
Timeframe: During the initial course (day 1 & 15 of a 4 week schedule)

Interventionmg per meter square (Number)
Treatment (Enzyme Inhibitor Therapy)148

Time to Disease Progression

Time to disease progression in all Participants (NCT01206465)
Timeframe: restaging imaging done after each two 4-week course until time of progression (longest time to progression = 588 days)

Interventiondays (Median)
Treatment (Enzyme Inhibitor Therapy)112

Number of Patients Experiencing Grade 3-4 Toxicity While Receiving the Combination of PDX and 5-FU

Participants remained on study as long as they did not progress, and wished to continue on study (no limit on number of cycles) (NCT01206465)
Timeframe: "., From the time the subject signs the consent form and ending 4 weeks following the final chemotherapy, an average of 3 years"

Interventionparticipants (Number)
gr 3-4 neutropeniagr 3-4 thrombocytopeniagr 3-4 anemiagr 3-4 diarrheagr 3-4 mucositisgr 3-4 dehydrationgr 3-4 fatigue
Treatment (Enzyme Inhibitor Therapy)4041511

Polymorphisms in Methylenetetrahydrofolate Reductase and Thymidylate Synthase

Number of Participants with Polymorphisms in Methylenetetrahydrofolate Reductase and Thymidylate Synthase (NCT01206465)
Timeframe: Prior to the first dose of protocol therapy

,,
Interventionpercentage of patients (Number)
SLC19A1 80G>Agamma glutamyl hydrolase (GGH) 401C>Tgamma glutamyl hydrolase (GGH) 452C>Tfolyl polyglutamate synthase (FPGS) rs10760502A>Gfolyl polyglutamate synthase (FPGS) rs1544105C>Tmethylene tetrahydrofolate reductase (MTHFR 677C>Tmethylene tetrahydrofolate reductase MTHFR 1298A>Cthymidylate synthase 28-bp tandem repeats (2 or 3)
Heterozygous40.737.011.14.055.625.933.348.2
Homozygous Variant7.47.40018.518.514.837.0
Wild Type51.955.688.996.025.955.651.914.8

Disease Control Rate

Disease control rate was calculated by adding complete and partial responses and stable disease. (NCT01718873)
Timeframe: At weeks 12 and 24 from randomization and every 3 months thereafter, assessed up to 90 months

InterventionParticipants (Count of Participants)
Bevacizumab Before Chemotherapy107
Bevacizumab With Chemotherapy103

Objective Response Rate

"Objective response rate (ORR), according to Response Evaluation Criteria in Solid Tumors (RECIST),version 1.1, was the primary end point and was defined as the number of complete plus partial responses divided by the number of enrolled patients.~Per RECIST v 1.1 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT01718873)
Timeframe: Objective response was assessed by computed tomographic scan or other appropriate imaging at weeks 12 and 24 from randomization, and every 3 months thereafter, assessed up to 90 months.

Interventionparticipants (Number)
Bevacizumab Before Chemotherapy65
Bevacizumab With Chemotherapy66

Overall Survival

Overall survival was defined as the time from randomization to the date of death. Patients alive at the time of the final analysis were censored on the date of the last follow-up information available. (NCT01718873)
Timeframe: assessed up to 90 months

Interventionmonths (Median)
Bevacizumab Before Chemotherapy29.8
Bevacizumab With Chemotherapy24.1

Progression-free Survival (PFS)

"Progression-free survival was defined as the time from randomization to the date of progression or death, whichever occurred first. Patients without progression were censored on the date of the last follow-up visit.~Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions." (NCT01718873)
Timeframe: assessed up to 90 months

Interventionmonths (Median)
Bevacizumab Before Chemotherapy11.7
Bevacizumab With Chemotherapy10.5

Toxic Effects

Toxic effects were scored according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0. For the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE), version 4.0 scale score range from 1 to 4. A high score, that is 3 and 4, represents a high level of toxicity, whereas the minimum values, that is 1 and 2, represents a mild/modest level of toxicity. (NCT01718873)
Timeframe: up to 4 weeks after the end of the treatment

InterventionParticipants (Count of Participants)
Bevacizumab Before Chemotherapy108
Bevacizumab With Chemotherapy113

Overall Survival (OS)

OS defined as the time interval between the date of randomization and the date of death from any cause. (NCT01721954)
Timeframe: From date of randomization until the date of death from any cause assessed up 3 yrs 8 months

Interventionmonths (Median)
mFOLFOX6 Plus SIRT25.9
mFOLFOX6 Alone25.0

Progression-free Survival

PFS defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as an increase in the sum of the longest diameters of ≥ 20% and an absolute increase in the sum of the longest diameters of ≥ 5 mm, or the appearance of a new lesion. (NCT01721954)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years 8 months.

Interventionmonths (Median)
mFOLFOX6 Plus SIRT11.8
mFOLFOX6 Alone11.2

Overall Response Rate (ORR)

The Percentage of Patients Who Experience an Objective Benefit From Treatment. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT01226719)
Timeframe: 18 months

Interventionpercentage of evaluable participants (Number)
FOLFOXIRI+Panitumumab Regimen75

Overall Survival (OS)

The Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death (NCT01226719)
Timeframe: 18 months

Interventionmonths (Median)
FOLFOXIRI+Panitumumab RegimenNA

Progression-free Survival (PFS)

The Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT01226719)
Timeframe: 18 months

Interventionmonths (Median)
FOLFOXIRI+Panitumumab Regimen13.3

R0 Resection Rate

To determine the rate of complete (R0) resection for patients treated with this regimen. (NCT01226719)
Timeframe: 18 months

Interventionpercentage of patients with surgery (Number)
FOLFOXIRI+Panitumumab Regimen100

To Determine the Acute Toxicity Produced by This Regimen.

The analyses of safety will be based on the frequency of adverse events and their severity for patients who received at least one dose of study treatment. (NCT01226719)
Timeframe: 18 months

Interventionparticipants (Number)
RashDiarrheaFatigueNauseaMucositisPeripheral neuropathyVomitingAnorexiaCold sensitivityConstipationDehydrationLeukopeniaAnemiaHypokalemiaHypomagnesemiaNail changesNeutropeniaTaste alterationThrombocytopeniaWeight lossAbdominal painAlopeciaDepressionDizzinessInsomniaAlkaline phosphatase increasedALT increasedAnxietyAST increasedAstheniaBack painBlood bicarbonate increasedDecreased ejection fractionDry mouthDysesthesiaDyspepsiaEdemaEpistaxisFlashersHand-foot syndromeHematocheziaHemorrhoidsHyperpigmentationHypertensionHypoalbuminemiaHyponatremiaInfection - otherInfusion related reactionMemory lossOral infectionParaphasiaPruritusSpeech impairmentSwollen tongue
FOLFOXIRI+Panitumumab Regimen1298876544444333333332222211111111111111111111111111111

Overall Objective Response Rate (ORR)

"Summary of overall objective response rate based on tumor assessment by the Independent Review Committee (IRC) as per Response Evaluation Criteria in Solid Tumours (RECIST) criteria. ORR was defined as the proportion of patients with confirmed Complete Response (CR) or confirmed Partial Response (PR) relative to the total number of patients in the analysis population.~Per RECIST v 1.0 target lesions evaluation and assessed by tumor imaging: Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): >=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.~The study was not powered for comparison of ORR between the two arms (non-comparative, open-label study)." (NCT00851084)
Timeframe: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)

Interventionpercentage of participants (Number)
mFOLFOX6 Only45.9
mFOLFOX6 + Aflibercept49.1

Overall Survival (OS)

"Overall survival was defined as the time from the date of randomization to the date of death due to any cause. In absence of confirmation of death, survival time was censored at the earliest between the last date the patient was known to be alive and the study cutoff date.~The study was not powered for comparison of OS between the two arms (non-comparative, open-label study)." (NCT00851084)
Timeframe: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)

Interventionmonths (Median)
mFOLFOX6 Only22.31
mFOLFOX6 + Aflibercept19.45

Progression Free Survival (PFS)

"PFS was defined as the time from the date of randomization to the date of tumor progression or death from any cause, whichever occurred first. PFS was based on tumor assessment by the Independent Review Committee (IRC). PFS was estimated from Kaplan-Meier Curves.~The study was not powered for comparison of PFS between the two arms (non-comparative, open-label study).~Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions." (NCT00851084)
Timeframe: From the date of the first randomization until the study data cut-off date, 14 April 2011 (approximately 26 months)

InterventionMonths (Median)
mFOLFOX6 Only8.77
mFOLFOX6 + Aflibercept8.48

Progression Free Survival (PFS) Rate at 12 Months

PFS rate at 12 months was defined as the percentage of patients alive without disease progression at 12 months after randomization. The primary efficacy analysis was based on assessment by the Independent Review Committee (IRC). The study was not powered for comparison of PFS rate at 12 months between the two arms (non-comparative, open-label study). Progression was defined using Response Evaluation Criteria In Solid Tumors (RECIST v1.0), as at least a 20 percent increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non target-lesions. (NCT00851084)
Timeframe: 12 months

Interventionpercentage of participants (Number)
mFOLFOX6 Only21.2
mFOLFOX6 + Aflibercept25.8

Immunogenicity of Intravenous (IV) Aflibercept

The antidrug antibody (ADA) assay was evaluated for participants receiving aflibercept. (NCT00851084)
Timeframe: Any time post baseline and 90 days after the last infusion of aflibercept, according to baseline status

,
Interventionparticipants (Number)
ADA Negative post-baselineADA Positive (drug specific) post-baselineADA Negative 90 days after last doseADA Positive 90 days after last dose
Negative or Missing1057450
Positive1211

Number of Participants With Treatment-emergent Adverse Events (TEAE)

Summary of treatment-emergent adverse events in the safety population. The National Cancer Institute Common Terminology Criteria for Adverse Event (NCI-CTCAE), version 3.0 was used in this study to grade the severity of AEs. (NCT00851084)
Timeframe: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized

,
Interventionparticipants (Number)
Treatment Emergent Adverse Event (TEAE)Grade 3-4 TEAETreatment emergent Serious Adverse Event (SAE)TEAE leading to deathPremature treatment discontinuationPermanent treatment discontinuation
mFOLFOX6 + Aflibercept1191085583437
mFOLFOX6 Only11587322NA26

Duration of Response (DoR)

DoR was measured from the time measurement criteria are first met for Complete Response or Partial Response or until the first date that the criteria for disease progression or death from any cause. whichever is first recorded. As defined according to RECIST v1.1, CR is the disappearance of all non-nodal target lesions, and PR is the short axes of any target lymph nodes reduced to < 10 mm and at least a 30% decrease in the sum of the diameters of target lesions including the short axes of any target lymph nodes.) (NCT01111604)
Timeframe: Criteria First Met for CR or PR until Disease Progression or Death from Any Cause (Up to 95 Weeks)

InterventionWeeks (Median)
mFOLFOX-635.6
mFOLFOX-6 + RamucirumabNA
mFOLFOX-6 + IcrucumabNA

Number of Participants With Serum Ramucirumab Antibody Assessment

A sample will be considered positive for anti-Ramucirumab antibodies if it exhibits a post-baseline antibody level exceeding the normal anti-Ramucirumab antibody level seen in healthy untreated individuals. (NCT01111604)
Timeframe: 31 Weeks

InterventionParticipants (Count of Participants)
mFOLFOX-6 + Ramucirumab0

Overall Survival (OS)

Overall survival is defined as the time from baseline to the date of death from any cause. If the participant is alive at the end of the follow-up period or is lost to follow-up, OS will be censored on the last date the participant is known to be alive. (NCT01111604)
Timeframe: Baseline Until Death from Any Cause (Up to 163 Weeks)

InterventionWeeks (Median)
mFOLFOX-653.6
mFOLFOX-6 + Ramucirumab41.7
mFOLFOX-6 + Icrucumab42.0

Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

The ORR is the percentage of participants with Complete Response (CR, the disappearance of target lesions and any pathological lymph nodes [target or non-target] taking as reference the baseline sum of diameters in response to treatment) or Partial Response (PR, at least a 30% decrease in the sum of diameter of target lesions, taking as reference the baseline sum diameters in response to treatment) according to RECIST v1.1 from the start of the treatment until disease progression. (NCT01111604)
Timeframe: Baseline until Disease Progression (Up to 95 Weeks)

Interventionpercentage of participants (Number)
mFOLFOX-614
mFOLFOX-6 + Ramucirumab3.8
mFOLFOX-6 + Icrucumab3.8

Pharmacokinetics (PK): Maximum Concentration (Cmax) at Cycle 5

Maximum concentration (1 hour post end of infusion, Cmax) is the concentration measured in serum. (NCT01111604)
Timeframe: Cycle 5, 1 Hour Post End of Infusion

Interventionmicrogram/milliliter (µg/mL) (Geometric Mean)
mFOLFOX-6 + RamucirumabNA
mFOLFOX-6 + Icrucumab201

Pharmacokinetics (PK): Trough Serum Concentrations (Ctrough) at Cycle 5

Trough (prior to infusion, Ctrough) concentrations measured in serum. (NCT01111604)
Timeframe: Cycle 5, Prior to Infusion

Interventionµg/mL (Geometric Mean)
mFOLFOX-6 + Ramucirumab53.6
mFOLFOX-6 + Icrucumab146

Progression-Free Survival (PFS)

PFS is defined as the time from baseline until the date of disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1), or death from any cause, whichever was first. Participants who die without a reported prior progression will be considered to have progressed on the day of their death. Participants who did not progress, are lost to follow-up, or have missed two or more scheduled tumor assessments will be censored at the day of their last radiographic tumor assessment, if there are no post-baseline tumor measurements for a randomized and treated participant, the participant will be censored at the date of randomization. If death or progressive disease (PD) occurs after 2 or more missing radiographic visits, censoring will occur at the date of the last radiographic visit prior to the last visit. (NCT01111604)
Timeframe: Baseline until Disease Progression or Death from Any Cause (Up to 95 Weeks)

InterventionWeeks (Median)
mFOLFOX-618.4
mFOLFOX-6 + Ramucirumab21.4
mFOLFOX-6 + Icrucumab15.9

Number of Participants With Adverse Events

A summary of serious AEs (SAEs) and all other non-serious AEs regardless of causality, is located in the Reported Adverse Events module. (NCT01111604)
Timeframe: Baseline up to 165 weeks

,,
InterventionParticipants (Count of Participants)
Any TEAEAny SAEAny Grade ≥3 AEAny AE leading to discontinuation (any drug)
mFOLFOX-64911306
mFOLFOX-6 + Icrucumab52123111
mFOLFOX-6 + Ramucirumab52183718

Overall Survival

Median time from randomization to date of death caclulated using the Kaplan-Meier method. Participants were censored on the date of last contact (i.e., the date the participant was last known to be alive) if they were not known to have died. (NCT00911170)
Timeframe: From randomization to the data cut-off date of 8 June 2012. Median time on study was 11.6 months and the maximum was 27.6 months.

Interventionmonths (Median)
Placebo24.6
Pegfilgrastim21.8

Percentage of Participants With an Objective Response

The percentage of participants with a complete response (CR) or partial response (PR) defined by the RECIST v1.1 criteria at any time during the study. Response was be determined by the investigator's assessment of radiographic scans. CR: Disappearance of all non-nodal target lesions and the disappearance of all non-nodal non-target lesions, and no new lesions. All nodal lesions must have reduction of short axis to < 10 mm. PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters and no new lesions and/or unequivocal progression of existing non-target lesions, or, the disappearance of all non-nodal target lesions with persistence of one or more non-target lesion(s). (NCT00911170)
Timeframe: From randomization to the data cut-off date of 8 June 2012. Median time on study was 11.6 months and the maximum was 27.6 months.

Interventionpercentage of participants (Number)
Placebo56.7
Pegfilgrastim58.1

Percentage of Participants With Grade 3/4 Febrile Neutropenia Across the First 4 Cycles of Chemotherapy

Grade 3/4 febrile neutropenia (FN) is defined as: • A temperature ≥ 38.0°C (≥ 100.4°F) and absolute neutrophil count (ANC) < 1.0 × 10^9/L, where ANC was measured the same day or within ± 1 calendar day of a temperature ≥ 38.0°C (≥ 100.4°F), or • An ANC < 1.0 × 10^9/L in combination with: - documented sepsis or infection, OR - neutropenia-related hospitalization where ANC was measured the same day or within ± 1 calendar day. Participants monitored their oral temperatures and maintained diaries to record their temperature twice per day: once in the morning and once in the evening, as well as whenever they suspect they had fever throughout the first 4 cycles of chemotherapy treatment. (NCT00911170)
Timeframe: Approximately 2 months duration (Daily for 4 cycles of treatment; 2 weeks per cycle)

Interventionpercentage of participants (Number)
Placebo5.7
Pegfilgrastim2.4

Percentage of Participants With Grade 3/4 Neutropenia Across the First 4 Cycles of Chemotherapy

Grade 3/4 severe neutropenia is defined as neutropenia with absolute neutrophil count (ANC) <1.0 x 10^9/L. (NCT00911170)
Timeframe: Approximately 2 months duration (Daily for 4 cycles of treatment; 2 weeks per cycle)

Interventionpercentage of participants (Number)
Placebo17.0
Pegfilgrastim3.6

Percentage of Participants With Grade 4 Febrile Neutropenia Across the First 4 Cycles of Chemotherapy

"Grade 4 febrile neutropenia (FN) is defined as:~A temperature ≥ 38.0ºC (≥ 100.4ºF) and absolute neutrophil count (ANC) < 0.5 × 10^9/L, where ANC is measured the same day or within +/- 1 calendar day of a temperature ≥ 38.0ºC (≥ 100.4ºF), or~An ANC <0.5 × 10^9/L in combination with:~Documented sepsis or infection, OR~Neutropenia-related hospitalization where ANC is measured the same day or within +/- 1 calendar day." (NCT00911170)
Timeframe: Approximately 2 months duration (Daily for 4 cycles of treatment; 2 weeks per cycle)

Interventionpercentage of participants (Number)
Placebo3.5
Pegfilgrastim2.4

Percentage of Participants With Grade 4 Neutropenia Across the First 4 Cycles of Chemotherapy

Grade 4 severe neutropenia is defined as neutropenia with absolute neutrophil count (ANC) <0.5 x 10^9/L. (NCT00911170)
Timeframe: Approximately 2 months duration (Daily for 4 cycles of treatment; 2 weeks per cycle)

Interventionpercentage of participants (Number)
Placebo8.3
Pegfilgrastim2.4

Progression Free Survival

Time from randomization to date of radiological disease progression or death from any cause, whichever event occurs first, calculated using the Kaplan-Meier method. Participants without either event by the analysis data cutoff date were censored on the date of their last evaluable disease assessment. Disease progression based on the investigator's assessment of radiographic scans using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Clinical progression without radiological assessment was not be considered a disease progression in this analysis. Progression defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. (NCT00911170)
Timeframe: From randomization to the data cut-off date of 8 June 2012. Median time on study was 11.6 months and the maximum was 27.6 months.

Interventionmonths (Median)
Placebo10.1
Pegfilgrastim9.7

Time to Progression

Time from randomization to date of radiological disease progression calculated using the Kaplan-Meier method. Participants without progression were censored on the date of their last radiographic tumor assessment. Disease progression based on the investigator's assessment of scans using the RECIST v1.1. Clinical progression without radiological assessment was not considered a disease progression. Progression defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. (NCT00911170)
Timeframe: From randomization to the data cut-off date of 8 June 2012. Median time on study was 11.6 months and the maximum was 27.6 months.

Interventionmonths (Median)
Placebo11.1
Pegfilgrastim10.8

Number of Participants With Adverse Events (AEs)

A serious adverse event (SAE) is defined as an adverse event that - is fatal; - is life threatening (places the participant at immediate risk of death); - requires inpatient hospitalization or prolongation of existing hospitalization; - results in persistent or significant disability/incapacity; - is a congenital anomaly/birth defect; - other significant medical hazard. AEs were assessed for severity according to National Cancer Institute, Common Terminology Criteria for Adverse Events, Version 3.0, based on this general guideline: Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. (NCT00911170)
Timeframe: Approximately 8 weeks (4 treatment cycles)

,
Interventionparticipants (Number)
Any adverse eventWorst Grade of > 2Worst Grade of > 3Worst Grade of > 4Serious adverse eventsSevere adverse eventsLife-threatening adverse eventsFatal adverse eventsLeading to discontinuation of IPLeading to discontinuation from study treatment
Pegfilgrastim3442401153168106271038
Placebo3552541194555103431119

Best Overall Response Rate - Independent Review Committee (IRC)

The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified World Health Organisation (WHO) criteria) as assessed by an IRC. (NCT00125034)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 4 August 2006

Interventionpercentage of participants (Number)
Cetuximab Plus FOLFOX-445.6
FOLFOX-4 Alone35.7

Best Overall Response Rate (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population)

The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria) as assessed by an IRC. (NCT00125034)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 1 Mar 2007

Interventionpercentage of participants (Number)
Cetuximab Plus FOLFOX-457.3
FOLFOX-4 Alone34.0

Best Overall Response Rate (KRAS Mutant Population)

The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria) as assessed by an IRC. (NCT00125034)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 1 Mar 2007

Interventionpercentage of participants (Number)
Cetuximab Plus FOLFOX-433.8
FOLFOX-4 Alone52.5

Disease Control Rate (Cut Off Date 4 August 2006)

The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments as assessed by IRC (based on modified WHO criteria). (NCT00125034)
Timeframe: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 4 August 2006

Interventionpercentage of participants (Number)
Cetuximab Plus FOLFOX-485.2
FOLFOX-4 Alone81.0

Duration of Response

"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria." (NCT00125034)
Timeframe: Time from first assessment of Complete Response or Partial Response to disease progression,death or last tumor assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 01 Mar 2007

Interventionmonths (Median)
Cetuximab Plus FOLFOX-49.0
FOLFOX-4 Alone5.7

Overall Survival Time

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00125034)
Timeframe: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008

Interventionmonths (Median)
Cetuximab Plus FOLFOX-418.3
FOLFOX-4 Alone18.0

Overall Survival Time (KRAS Mutant Population)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00125034)
Timeframe: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008

Interventionmonths (Median)
Cetuximab Plus FOLFOX-413.4
FOLFOX-4 Alone17.5

Overall Survival Time (KRAS Wild-Type Population)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00125034)
Timeframe: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008

Interventionmonths (Median)
Cetuximab Plus FOLFOX-422.8
FOLFOX-4 Alone18.5

Participants With No Residual Tumor After Metastatic Surgery

No residual tumor after on-study surgery for metastases. (NCT00125034)
Timeframe: Time from first dose up to 30 days after the last dose of study treatment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 November 2008

Interventionparticipants (Number)
Cetuximab Plus FOLFOX-48
FOLFOX-4 Alone4

Progression-free Survival Time

"Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00125034)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 01 Mar 2007

Interventionmonths (Median)
Cetuximab Plus FOLFOX-47.2
FOLFOX-4 Alone7.2

Progression-free Survival Time (KRAS Mutant Population)

"Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00125034)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008

Interventionmonths (Median)
Cetuximab Plus FOLFOX-45.5
FOLFOX-4 Alone8.6

Progression-free Survival Time (KRAS Wild-Type Population)

"Duration from randomization until radiological progression as assessed by an IRC (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00125034)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 27 Jul 2005, until cut-off date 30 Nov 2008

Interventionmonths (Median)
Cetuximab Plus FOLFOX-48.3
FOLFOX-4 Alone7.2

Safety - Number of Patients Experiencing Any Adverse Event

Please refer to Adverse Events section for further details (NCT00125034)
Timeframe: time from first dose up to 30 after last dose of study treatment, reported between day of first patient dose of study treatment, 27 Jul 2005, until cut-off date 30 Nov 2008

Interventionparticipants (Number)
Cetuximab Plus FOLFOX-4170
FOLFOX-4 Alone165

Best Overall Response Rate - Independent Review Committee (IRC) Assessments

The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

Interventionpercentage of participants (Number)
Cetuximab Plus FOLFIRI46.9
FOLFIRI Alone38.7

Best Overall Response Rate (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments

The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

Interventionpercentage of participants (Number)
Cetuximab Plus FOLFIRI31.3
FOLFIRI Alone36.1

Best Overall Response Rate (KRAS Wild-Type Population) - Independent Review Committee (IRC) Assessments

The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

Interventionpercentage participants (Number)
Cetuximab Plus FOLFIRI57.3
FOLFIRI Alone39.7

Disease Control Rate - Independent Review Committee (IRC) Assessments

The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria). (NCT00154102)
Timeframe: Evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

Interventionpercentage of participants (Number)
Cetuximab Plus FOLFIRI84.3
FOLFIRI Alone85.5

Duration of Response - Independent Review Committee (IRC) Assessments

"Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).~Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria." (NCT00154102)
Timeframe: Time from first assessment of complete response or partial response to disease progression, death or last tumor assessment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

Interventionmonths (Median)
Cetuximab Plus FOLFIRI9.6
FOLFIRI Alone7.7

Overall Survival Time (KRAS Mutant Population)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later. (NCT00154102)
Timeframe: Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009

Interventionmonths (Median)
Cetuximab Plus FOLFIRI16.2
FOLFIRI Alone16.7

Overall Survival Time (KRAS Wild-Type Population)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later. (NCT00154102)
Timeframe: Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009

Interventionmonths (Median)
Cetuximab Plus FOLFIRI23.5
FOLFIRI Alone20.0

Overall Survival Time (OS)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later. (NCT00154102)
Timeframe: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009

Interventionmonths (Median)
Cetuximab Plus FOLFIRI19.9
FOLFIRI Alone18.6

Participants With No Residual Tumor After Metastatic Surgery

Participants with no residual tumor after on-study surgery for metastases (NCT00154102)
Timeframe: time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007

InterventionParticipants (Number)
Cetuximab Plus FOLFIRI29
FOLFIRI Alone10

Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments

"Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00154102)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

Interventionmonths (Median)
Cetuximab Plus FOLFIRI8.9
FOLFIRI Alone8.0

Progression-free Survival Time (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) - Independent Review Committee (IRC) Assessments

"Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00154102)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

Interventionmonths (Median)
Cetuximab Plus FOLFIRI9.9
FOLFIRI Alone8.4

Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments

"Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause.~Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment." (NCT00154102)
Timeframe: Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

Interventionmonths (Median)
Cetuximab Plus FOLFIRI7.4
FOLFIRI Alone7.7

Safety - Number of Patients Experiencing Any Adverse Event

Please refer to Adverse Events section for further details (NCT00154102)
Timeframe: time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007

Interventionparticipants (Number)
Cetuximab Plus FOLFIRI599
FOLFIRI Alone597

Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status

Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL. (NCT00154102)
Timeframe: at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

,
Interventionscores on a scale (Least Squares Mean)
At baselineAt week 8At week 16At week 24At week 32At week 40
Cetuximab Plus FOLFIRI58.8859.0260.7761.8359.6863.43
FOLFIRI Alone60.3361.8363.2964.0665.0764.02

Quality of Life Assessment (EORTC QLQ-C30) Social Functioning

Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning. (NCT00154102)
Timeframe: at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006

,
Interventionscores on a scale (Least Squares Mean)
At baselineAt week 8At week 16At week 24At week 32At week 40
Cetuximab Plus FOLFIRI75.2174.1473.7276.3174.0476.58
FOLFIRI Alone77.2876.7176.6777.9875.6478.07

Dose Related Toxicity

dose related toxicity is defined as follows:1. WBC damage >= grade 3; granular cell decrease >= grade 3; hemoglobin >= grade 2; platelet >= grade 2;SGPT/SGOT elevation >= grade 2; ALP >= grade 2; GGT >= grade 2; Tbil >= grade 2;renal function damage: BUN/Cr elevation >= grade 2;Non-gradular cell decreased fever >= grade 2;nausea/vomiting >= grade 2; fatigue >= grade 3; weight loss >= grade 3;gastritis >= grade 3; dairrea >= grade 3; abdominal pain >= grade 3; pancreatitis >= grade 2; upper gastrointestinal bleeding >= grade 2;other toxic reaction >= grade 3;KPS < 50 during the treatment (NCT01268943)
Timeframe: up to 9 weeks

Interventionevent (Number)
1000mg1
1200mg0
1400mg0
1500mg3

Antibiotic Use Due to Febrile Neutropenia

Antibiotic use during any of the first 4 cycles of treatment due to febrile neutropenia. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)

InterventionParticipants (Number)
Pegfilgrastim (Neulasta)2
Placebo8

Dose Delay or Reduction Due to Neutropenia

Dose delay or reduction in chemotherapy doses due to neutropenia (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)

InterventionParticipants (Number)
Pegfilgrastim (Neulasta)5
Placebo26

Dose Delay or Reduction for Any Reason

Dose delay or reduction in chemotherapy dose during the first 4 cycles for any reason (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)

InterventionParticipants (Number)
Pegfilgrastim (Neulasta)41
Placebo53

Febrile Neutropenia

Febrile neutropenia, Defined as a temperature ≥ 38.2 °C on a given day, with an ANC < 1.0 x 10^9/L recorded on the same day or the next day, during any of the first 4 cycles of treatment. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)

InterventionParticipants (Number)
Pegfilgrastim (Neulasta)3
Placebo10

Grade 3 or 4 Neutropenia

Grade 3 or 4 neutropenia, defined as an absolute neutrophil count (ANC) < 1 x 10^9/L, in any of the first four cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)

InterventionParticipants (Number)
Pegfilgrastim (Neulasta)16
Placebo51

Grade 4 Neutropenia

Grade 4 neutropenia, defined as an absolute neutrophil count (ANC) <0.5 x 10^9/L, in any of the first four cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)

InterventionParticipants (Number)
Pegfilgrastim (Neulasta)13
Placebo17

Hospitalization Due to a Neutropenia-Related Event

Hospitalization because of a neutropenia-related event during the first 4 cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of neutropenia (8 weeks)

InterventionParticipants (Number)
Pegfilgrastim (Neulasta)7
Placebo9

Objective Tumor Response

Objective tumor response (complete or partial) at the end of treatment, defined as a reduction of at least 50% in the area of all measurable lesions (partial response) or disappearance of all measurable or evaluable disease without the development of new lesions (complete response) on computed tomographic (CT) or other scanning. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)

InterventionParticipants (Number)
Pegfilgrastim (Neulasta)34
Placebo37

Progression-Free Survival

Kaplan-Meier estimate of the median time to disease progression or death (NCT00094809)
Timeframe: Up to 24 months after first four cycles of treatment

InterventionDays (Median)
Pegfilgrastim (Neulasta)318
Placebo322

Survival

Death from any cause through the end of the follow-up period (NCT00094809)
Timeframe: Up to 24 months after first four cycles of treatment

InterventionParticipants (Number)
Pegfilgrastim (Neulasta)47
Placebo49

Number of Patients With Adverse Events as a Measure of Safety With FOLFOX6 Combined With Bevacizumab and Cetuximab

The toxicity assessments were made according to the common terminology criteria for adverse events (CTCAE version 3.0) of the National Cancer Institute. Number of participants with Grade 1 to 5 adverse events are reported here. (NCT00193219)
Timeframe: 18 months

InterventionParticipants (Count of Participants)
Bevacizumab/Cetuximab/FOLFOX31

Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00193219)
Timeframe: 18 months

Interventionpercentage of patients (Number)
Bevacizumab/Cetuximab/FOLFOX55

Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death

Measured from the date of first treatment until the date of death from any cause (NCT00193219)
Timeframe: 36 months

Interventionmonths (Median)
Bevacizumab/Cetuximab/FOLFOX25.7

Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease

Progression Free Survival (PFS) is defined as the interval between the start date of treatment and the date of occurrence of progressive disease or death. (NCT00193219)
Timeframe: 18 months

Interventionmonths (Median)
Bevacizumab/Cetuximab/FOLFOX9

Duration of Response

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. (NCT00192075)
Timeframe: date of first response until the first date of documented progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A+FFG12.7
A + FOLFOX 47.9

Duration of Response - A+FOLFOX4 - Avastin Subgroup

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. (NCT00192075)
Timeframe: date of first response until the first date of documented progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A + FOLFOX 4 - Avastin Subgroup5.2

Overall Survival

Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact. (NCT00192075)
Timeframe: randomization to the date of death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A+FFG20.6
A + FOLFOX 419.7

Progression-Free Survival

Defined as the time from randomization to the first observation of disease progression, or death due to any cause. (NCT00192075)
Timeframe: randomization to the first date of progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A+FFG8.6
A + FOLFOX 49.5

Progression-Free Survival - Avastin Subgroup

Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause. (NCT00192075)
Timeframe: randomization to the first date of progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A+FFG - Avastin Subgroup13.7
A + FOLFOX 4 - Avastin Subgroup11.5

Time to Progressive Disease

Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00192075)
Timeframe: randomization to the date of first documented disease progression or death due to disease under study, whichever comes first (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A+FFG8.6
A + FOLFOX 49.7

Time to Progressive Disease - Avastin Subgroup

Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00192075)
Timeframe: randomization to the date of first documented disease progression or death due to disease under study, whichever comes first (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A+FFG - Avastin Subgroup13.7
A + FOLFOX 4 - Avastin Subgroup13.8

Survival at 12 Months and 24 Months - Avastin Subgroup

Percentage of participants who were alive at 12 months and 24 months. (NCT00192075)
Timeframe: randomization to the date of death from any cause (up to 24 months)

,
Interventionpercentage of participants alive (Number)
12-Month Survival24-Month Survival
A + FOLFOX 4 - Avastin Subgroup83.366.7
A+FFG - Avastin Subgroup75.650.4

Toxicity - Avastin Subgroup

Includes all Grade 3-4 hematologic toxicities and all non-hematologic toxicities with either >=1 Grade 4 or >=2 Grade 3 adverse events (NCT00192075)
Timeframe: every cycle (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

,
Interventionparticipants (Number)
Neutropenia (Grade 3)Neutropenia (Grade 4)Thrombocytopenia (Grade 3)Thrombocytopenia (Grade 4)Leukopenia (Grade 3)Leukopenia (Grade 4)Anemia (Grade 3)Anemia (Grade 4)Febrile neutropenia (Grade 3)Febrile neutropenia (Grade 4)Diarrhea (Grade 3)Diarrhea (Grade 4)Small intestinal obstruction (Grade 3)Small intestinal obstruction (Grade 4)Fatigue (Grade 3)Fatigue (Grade 4)Cerebral infarction (Grade 3)Cerebral infarction (Grade 4)Hyperglycemia (Grade 3)Hyperglycemia (Grade 4)Dehydration (Grade 3)Dehydration (Grade 4)Deep vein thrombosis (Grade 3)Deep vein thrombosis (Grade 4)Myocardial infarction (Grade 3)Myocardial infarction (Grade 4)Subdural hematoma (Grade 3)Subdural hematoma (Grade 4)Perirectal abscess (Grade 3)Perirectal abscess (Grade 4)Hypoxia (Grade 3)Hypoxia (Grade 4)
A + FOLFOX 4 - Avastin Subgroup51000000100110200000102002000000
A+FFG - Avastin Subgrouup35103100001010000000000000001000

Tumor Response - Avastin Subgroup

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. (NCT00192075)
Timeframe: baseline to measured progressive disease (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

,
Interventionparticipants (Number)
Complete Response (CR)Partial Response (PR)Overall Response Rate (CR+PR)Stable Disease (SD)Disease Control Rate (CR+PR+SD)Progressive DiseaseUnknown
A + FOLFOX 4 - Avastin Subgroup18981710
A+FFG - Avastin Subgroup000111161

Tumor Response by Response Evaluation Criteria In Solid Tumors (RECIST)

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. (NCT00192075)
Timeframe: baseline to measured progressive disease (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

,
Interventionparticipants (Number)
Complete Response (CR)Partial Response (PR)Overall Response Rate (CR+PR)Stable Disease (SD)Disease Control Rate (CR+PR+SD)Progressive DiseaseUnknown
A + FOLFOX 421517163372
A+FFG1342125143

Progression Free Survival Rate

(NCT00100841)
Timeframe: From randomization to the first documented disease progression

Interventionmonths (Median)
Treatment (Combination Chemotherapy)9.6

Severe Adverse Event (SAE) Rate

The primary objective is to evaluate safety in all treated patients specifically the rate of serious adverse events which were defined as grade 5 events, grade 4 hemorrhage or thrombosis or bowel perforation (NCT00100841)
Timeframe: The duration of the study

Interventionparticipants (Number)
Grade 5 DeathGrade 4 venous thrombosis
Treatment (Combination Chemotherapy)22

Overall Survival

Average months of survival of participants after receiving study drug. (NCT00290615)
Timeframe: From time of treatment until death from any cause, assesed up to 60 months.

Interventionmonths (Median)
Capecitabine, Oxaliplatin, Bevacizumab, Cetuximab18.8

Progression-free Survival

"Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.~Progressive disease is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.~This is the average number of months participants survived without showing progressive disease." (NCT00290615)
Timeframe: From time of treatment until documented progression or death from any cause, whichever came first, assesed up to 60 months.

Interventionmonths (Median)
Capecitabine, Oxaliplatin, Bevacizumab, Cetuximab10.3

Response Rate (Percentage of Participants With Partial or Complete Response)

"Restaging scans occurred every 9 weeks from time of study drug initiation until disease progression.~Disease assessment was performed and recorded according to the Response Evaluation Criteria in Solid Tumors (RECIST v.1.0) Guidelines.~The definitions were:~Complete response (CR)- Disappearance of all target lesions Partial response (PD)- At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Stable disease (SD)- Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started Progressive disease (PD) - At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions" (NCT00290615)
Timeframe: After all subjects were evaluated for restaging which occured every 9 weeks from drug initiation until disease progression, assesed up to 24 months.

Interventionpercentage of participants with response (Number)
Capecitabine, Oxaliplatin, Bevacizumab, Cetuximab43

Safety and Tolerability

Number of participants with adverse events (NCT00290615)
Timeframe: After all participants went off study drug regimine.

Interventionparticipants with adverse event (Number)
Capecitabine, Oxaliplatin, Bevacizumab, Cetuximab30

Overall Response in Phase II

The overall response is defined as the number of participants whose tumor response was classified as a complete response (CR; disappearance of all target lesions) or partial response (PR; 30% decrease in the sum of the longest diameter of target lesions) per Response Evaluation Criteria in Solid Tumors. Response was measured for participants in Phase II only. To determine response, radiographic images were taken at baseline, 8 weeks, and every 8 weeks thereafter until the participant withdrew from the study. (NCT00536809)
Timeframe: Baseline to response (up to 135 days)

Interventionparticipants (Number)
Lap. 1000 mg/Oxaliplatin 130 mg/m^2/Capecitabine 1500 mg/m^22

Best Response During Second-Line Treatment

"Objective response rate is defined as the percentage of participants with a best response of complete response or partial response based on investigator review of scans using modified RECIST criteria. A complete or partial response was confirmed no less than 4 weeks after the criteria for response were first met. Participants with no post-baseline radiographic tumor assessment(s) were considered non-responders.~CR: disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the size of target lesions with no progression of non-target lesions (defined as a ≥ 25% increase in lesion size) and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or PD and no new lesions." (NCT00411450)
Timeframe: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.

Interventionpercentage of participants (Number)
Wild-type KRAS23
Mutant KRAS16

Duration of Response

Duration of response is defined as the time from the date of first response to the date of first progression of disease during second-line treatment (as evaluated by the investigator) or death (if the death was due to disease progression but not detected earlier) in the subset of participants who responded (CR or PR, as evaluated by the investigator). Duration of response was analyzed using Kaplan-Meier methods; participants who responded but did not progress while on study were censored at the date of last tumor assessment. (NCT00411450)
Timeframe: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.

Interventionweeks (Median)
Wild-type KRAS29
Mutant KRAS23

Overall Survival

Overall survival is defined as as the number of days from Study Day 1 to the date of death due to any cause. Overall survival was analyzed using the Kaplan-Meier method; participants who were lost to follow-up or who had not died at the end of the study (52 weeks after the last participant was enrolled) were censored at the date of last contact. (NCT00411450)
Timeframe: From Study Day 1 until the data cut-off date of 2 January 2009; median follow-up time was 39 weeks, with a maximum of 93 weeks.

Interventionweeks (Median)
Wild-type KRAS50
Mutant KRAS31

Progression-free Survival Time

Progression-free survival time was defined as the time from Study Day 1 to the date of disease progression (based on investigator assessment) or the date of death due to any cause. Participants who terminated from the study early (eg, prior to disease progression due to fully withdrawn informed consent) were censored at their last tumor assessment. (NCT00411450)
Timeframe: From Study Day 1 until the data cut-off date of 2 January 2009; median follow-up time was 39 weeks, with a maximum of 93 weeks.

Interventionweeks (Median)
Wild-type KRAS26
Mutant KRAS19

Time to Progression

Time to progression is defined as the time from study Day 1 to the date of observed disease progression. Time to progression was analyzed using Kaplan-Meier methods; participants who did not have disease progression were censored at the date of last evaluable tumor assessment. (NCT00411450)
Timeframe: From Study Day 1 until the data cut-off date of 2 January 2009; median follow-up time was 39 weeks, with a maximum of 93 weeks.

Interventionweeks (Median)
Wild-type KRAS26
Mutant KRAS17

Time to Response

Time to response of second-line treatment is defined as the time from study Day 1 to the date of first documentation of CR or PR, calculated for those participants with an objective tumor response of CR or PR. (NCT00411450)
Timeframe: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.

Interventionweeks (Median)
Wild-type KRAS9.1
Mutant KRAS9.3

Time to Treatment Failure

Time to failure of second-line treatment is defined as the time from study Day 1 to the date of the earliest of the following events: end of second-line therapy due to any reason except for complete response and curative surgery; progressive disease; or death due to any cause. Time to treatment failure was analyzed using Kaplan-Meier methods; participants who did not discontinue second-line treatment or discontinue due to complete response or curative surgery, who were still alive, and who did not have disease progression were censored at the date of the last contact. (NCT00411450)
Timeframe: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.

Interventionweeks (Median)
Wild-type KRAS19
Mutant KRAS15

Disease Control Rate at Weeks 17 and 25

The percentage of participants whose best response was either a complete or partial response or stable disease, based on modified RECIST criteria as assessed by the investigator. Stable diease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD of target lesions and no progression of existing non-target lesions and no new lesions, or, the persistence of 1 or more non-target lesions not qualifying for either CR or PD if no target lesions were identified at Baseline. (NCT00411450)
Timeframe: Week 17 and Week 25

,
Interventionpercentage of participants (Number)
Week 17Week 25
Mutant KRAS5858
Wild-type KRAS6464

Number of Participants Who Developed Antibodies to Panitumumab

The immunogenicity of panitumumab was evaluated using 2 different screening immunoassays for the detection of anti-panitumumab antibodies: an acid dissociation bridging enzyme-linked immunosorbent assay (ELISA; detecting high-affinity antibodies) and a Biacore® biosensor immunoassay (detecting both high and low-affinity antibodies). When either of the 2 screening assays yielded a positive result, that particular sample was subjected to an in vitro bioassay for the detection of neutralizing antibodies. (NCT00411450)
Timeframe: Prior to first dose and 28 days after the last dose of second-line treatment

Interventionparticipants (Number)
Binding antibody positiveNeutralizing antibody positive
Panitumumab Plus FOLFIRI10

Number of Participants With Adverse Events

The severity of adverse events (AEs) was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, except for panitumumab related skin toxicities, where Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. The relationship of each adverse event to the panitumumab and/or FOLFIRI regimen was assessed by the investigator. A serious adverse event was defined as an adverse event that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. (NCT00411450)
Timeframe: From the first dose date to 30 days after the last dose date. The median time frame is 4.5 months.

Interventionparticipants (Number)
Any adverse eventGrade 3 or higher adverse eventPanitumumab-related adverse eventsChemotherapy-related adverse events≥ grade 3 panitumumab-related adverse events≥ grade 3 chemotherapy-related adverse eventsSerious adverse eventsSerious panitumumab-related adverse eventsSerious chemotherapy-related adverse eventsLife-threatening adverse eventsEnded second-line treatment due to adverse eventsEnded panitumumab due to adverse eventsEnded FOLFIRI due to adverse eventsDeath due to adverse eventsPanitumumab infusion reactionsDeaths during study
Panitumumab Plus FOLFIRI115941071125665461524181820288271

Number of Participants With Grade 4 Laboratory Toxicities

Laboratory toxicities were graded according to CTCAE version 3. (NCT00411450)
Timeframe: From the first dose date to 30 days after the last dose date. The median time frame is 4.5 months.

Interventionparticipants (Number)
AnemiaNeutropeniaHypomagnesaemiaHypokalemiaHypocalcaemiaHyperbilirubinaemia
Panitumumab Plus FOLFIRI148131

Objective Response Rate at Weeks 17 and 25

Objective response rate is defined as the percentage of participants with a best response of complete response or partial response. Disease assessments were based on investigator review of scans using modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria. A complete or partial response was confirmed no less than 4 weeks after the criteria for response were first met. Participants with no radiographic tumor assessment(s) at Week 17 or 25 were considered non-responders. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions (defined as a ≥ 25% increase in lesion size) and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions. (NCT00411450)
Timeframe: Week 17 and Week 25

,
Interventionpercentage of participants (Number)
Week 17Week 25
Mutant KRAS1414
Wild-type KRAS2022

Progression-free Survival Rate at Weeks 17 and 25

"The progression-free survival rate is defined as the Kaplan-Meier (KM) estimator of progression-free survival at Week 17 and Week 25 reported as the probability of being event (disease progression or death)-free. Tumor assessments were evaluated by the investigator according to modified RECIST criteria.~PD: At least a 20% increase in the size of target lesions since the treatment started or at least a 25% increase in the size of non-target lesions and the lesion(s) measure ≥ 10 mm, or the appearance of any new lesions. Participants who withdraw from the study prior to completion of Week 17 or 25 radiographic tumor assessments were censored at the last evaluable tumor assessment." (NCT00411450)
Timeframe: Week 17 and Week 25

,
Interventionpercent probability (Number)
Week 17Week 25
Mutant KRAS5541
Wild-type KRAS6752

Best Overall Response Rate

Best overall response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) while on study. Tumor response was assessed by CT scan or MRI of the abdomen, pelvis, and all other sites of disease. Disease assessments were performed by central review according to the modified RECIST criteria. CR: Disappearance of all target and non-target lesions and no new lesions. PR: Either the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or PD (≥ 25% increase in lesion size) and no new lesions, or, at least a 30% decrease in the size of target lesions with no progression of existing non-target lesions, and no new lesions. (NCT00332163)
Timeframe: Response was assessed at Weeks 9 and 13 and then every 8 weeks for the Q2W regimen, or at Weeks 10, 14, 22 and then every 9 weeks for the Q3W regimen until the end of treatment; median treatment duration was 13 and 17 weeks in each group respectively.

Interventionpercentage of participants (Number)
Pre-emptive Skin Treatment15
Reactive Skin Treatment11

Overall Survival

Overall Survival is defined as the time from the date of randomization to the date of death. Participants who did not die while on study or who were lost-to-follow-up were censored at their last contact date. Overall survival was analyzed using all data regardless of whether it was collected during second- or third-line treatment. (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.

Interventionmonths (Median)
Pre-emptive Skin Treatment11.2
Reactive Skin Treatment13.6

Percentage of Participants With Any Grade 2 or Higher Skin Toxicity of Any Type During the 6-week Skin Treatment Period

"The percentage of participants who developed at least 1 incidence of ≥ grade 2 skin toxicities of any type during the 6-week skin treatment period. Analysis of this endpoint was based on adverse event data associated with the Skin and Subcutaneous Tissue Disorders system organ class. Adverse events were graded according to the National Cancer Institute (NCI) CTCAE version 3.0." (NCT00332163)
Timeframe: 6 weeks

Interventionpercentage of participants (Number)
Pre-emptive Skin Treatment40
Reactive Skin Treatment62

Percentage of Participants With Panitumumab Dose Reductions Due to the Specific Skin Toxicities of Interest

(NCT00332163)
Timeframe: 6 weeks

Interventionpercentage of participants (Number)
Pre-emptive Skin Treatment6
Reactive Skin Treatment11

Percentage of Participants With Specific Grade 2 or Higher Skin Toxicities During the 6-week Skin Treatment Period

Skin toxicities were assessed by the study clinician and graded according to the modified Common Toxicity Criteria for Adverse Events (CTCAE) v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks

Interventionpercentage of participants (Number)
Pre-emptive Skin Treatment29
Reactive Skin Treatment62

Progression-free Survival

Defined as the time from the date of randomization to the first date of observed disease progression or death due to any cause (whichever comes first). Participants who were alive and had not progressed while on study were censored at the date of last progression-free tumor assessment. (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.

Interventionmonths (Median)
Pre-emptive Skin Treatment4.7
Reactive Skin Treatment4.1

Rate of Disease Control at First Scheduled Assessment

Tumor response was assessed by CT scan or MRI of the abdomen, pelvis, and all other sites of disease. Disease assessments were performed by central review according to the modified response evaluation criteria in solid tumors (RECIST). Disease control rate is defined as the percentage of participants with a CR, PR or stable disease (SD) at the Week 9/10 assessment visit and a corresponding response (CR or PR) confirmed at the Week 13/14 assessment visit for the Q2W/Q3W regimens. SD: Neither sufficient shrinkage or increase in target lesions to qualify for PR or PD, with no progression of non-target lesions and no new lesions. (NCT00332163)
Timeframe: Week 9 with confirmed response at Week 13 for the FOLFIRI and panitumumab Q2W regimen or at Week 10 with confirmed response at Week 14 for the irinotecan and panitumumab Q3W regimen.

Interventionpercentage of participants (Number)
Pre-emptive Skin Treatment63
Reactive Skin Treatment64

Response Rate at First Scheduled Assessment

Tumor response was assessed by computed tomography (CT) scan or magnetic resonance imaging (MRI) of the abdomen, pelvis, and all other sites of disease. Disease assessments were performed by central review according to the modified response evaluation criteria in solid tumors (RECIST). Response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) at the Week 9/10 assessment visit and a corresponding CR or PR confirmed at the Week 13/14 assessment visit for the Q2W/Q3W regimens. CR: Disappearance of all target and non-target lesions and no new lesions. PR: Either the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease (PD; ≥ 25% increase in lesion size) and no new lesions, or, at least a 30% decrease in the size of target lesions with no progression of existing non-target lesions, and no new lesions. (NCT00332163)
Timeframe: Week 9 with confirmed response at Week 13 for the FOLFIRI and panitumumab Q2W regimen or at Week 10 with confirmed response at Week 14 for the irinotecan and panitumumab Q3W regimen.

Interventionpercentage of participants (Number)
Pre-emptive Skin Treatment6
Reactive Skin Treatment6

Time to First Most Severe Specific Grade 2 or Higher Skin Toxicities of Interest

Time to the first most severe grade ≥ 2 of all the specific skin-related toxicities of interest was defined as the time from the first dose of panitumumab to the date of the first occurrence of the most severe specific ≥ grade 2 skin toxicity of interest during the 6-week skin treatment period. Participants who did not experience any specific skin-related toxicity of grade ≥ 2 were censored at their last skin toxicity assessment during the 6-week skin toxicity assessment period. Skin toxicities were assessed by the study clinician and graded according to the modified CTCAE v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks

Interventionweeks (Median)
Pre-emptive Skin TreatmentNA
Reactive Skin Treatment2.7

Time to First Occurrence of Specific Grade 2 or Higher Skin Toxicities of Interest

The time to the first occurrence of specific grade 2 or higher skin toxicities of interest was defined as the time from the first dose of panitumumab to the date of first occurrence of specific ≥ grade 2 skin toxicities of interest. Participants who did not experience specific skin-related toxicities were censored at their last skin toxicity assessment during the skin toxicity assessment period. Skin toxicities were assessed by the study clinician and graded according to the modified CTCAE v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks

Interventionweeks (Median)
Pre-emptive Skin TreatmentNA
Reactive Skin Treatment2.1

Time to Progression

"Time from the date of randomization to the date of observed disease progression or death due to disease progression. Participants who did not have documented disease progression were censored at the date of last tumor assessment; participants who died for reasons other than disease progression while on study were censored at the date of death. PD: At least a 20% increase in the size of target lesions, recorded since the treatment started, or at least a 25% increase in size of non-target lesions and the lesion(s) measure > 10 mm in one dimension, or the appearance of one or more new lesions.~Time to progression was analyzed using the Kaplan-Meier method. This analysis excludes any data collected during follow-up for participants who began third-line treatment." (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.

Interventionmonths (Median)
Pre-emptive Skin Treatment4.9
Reactive Skin Treatment4.1

Time to Treatment Failure

Time-to-treatment failure is defined as the time from the date of randomization to the first date of any of the following events: discontinuation of study therapy due to any reason (except for complete response and curative surgery), progression of disease, or death due to any cause. Participants who did not discontinue, who were still alive, and who did not have disease progression were censored at the date of last contact. Time to treatment failure was analyzed using the Kaplan-Meier method. (NCT00332163)
Timeframe: From randomization until the end of study; median time on study was 31 weeks and 41 weeks in each treatment group respectively with a maximum time on study of 97 weeks.

Interventionmonths (Median)
Pre-emptive Skin Treatment3.1
Reactive Skin Treatment4.2

Change From Baseline in Overall Dermatologic Quality of Life Index (DLQI) Score

Skin-related quality of life was assessed using the DLQI. The DLQI questionnaire asks participants to evaluate the degree that their skin condition has affected their quality of life in the last week. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much); The DLQI score is calculated by summing the scores for all questions, resulting in a maximum of 30 and a minimum of 0; higher scores indicate a more impaired quality of life. (NCT00332163)
Timeframe: Baseline and Weeks 2, 3, 4, 5, 6 and 7

,
Interventionunits on a scale (Mean)
Baseline (n=46, 44)Change from Baseline to Week 2 (n=42, 41)Change from Baseline to Week 3 (n=44, 42)Change from Baseline to Week 4 (n=42, 42)Change from Baseline to Week 5 (n=44, 42)Change from Baseline to Week 6 (n=42, 38)Change from Baseline to Week 7 (n=40, 40)
Pre-emptive Skin Treatment0.30.71.31.71.31.62.0
Reactive Skin Treatment0.11.64.23.82.72.32.6

Most Severe Specific Grade 2 or Higher Skin Toxicities of Interest

The percentage of participants with a most severe grade of 2, 3 or 4 specific skin toxicity of interest reported during the 6-week skin treatment period. Skin toxicities were assessed by the study clinician and graded according to the modified CTCAE v.3.0 Dermatology Toxicity Grading criteria, on a scale from Grade 1 (mild) to 4 (life-threatening). The specific skin toxicities of interest were pruritus, acneiform dermatitis, skin desquamation (also described as skin exfoliation), exfoliative dermatitis, paronychia, nail disorder, skin fissures, skin laceration, pruritic rash, pustular rash, skin infection, skin ulceration, and local infection. (NCT00332163)
Timeframe: 6 weeks

,
Interventionpercentage of participants (Number)
Grade 2Grade 3Grade 4
Pre-emptive Skin Treatment2360
Reactive Skin Treatment40210

Overall Survival (OS)

OS was the duration from enrollment to death due to any cause. For participants who are alive, OS is censored at the last contact. (NCT00612586)
Timeframe: Randomization up to 22.8 months

Interventionmonths (Median)
Enzastaurin + 5-FU/LV + BevNA
Placebo + 5FU/LV + BevNA

Overall Survival (OS) From Start of First Line Therapy

OS was the duration from first line therapy to death due to any cause. For participants who are alive, OS is censored at the last contact. (NCT00612586)
Timeframe: Start of first line therapy (approximately 3 months prior to randomization) to date of death from any cause up to 27 months post randomization

Interventionmonths (Median)
Enzastaurin + 5-FU/LV + Bev20.0
Placebo + 5FU/LV + BevNA

PFS From Start of First Line Therapy

PFS was defined as the time from first line therapy to the first observation of disease progression or death due to any cause. Progressive disease was determined using a modified version of RECIST Assessment and was defined as at least a 20% increase in sum of longest diameter of target lesions. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00612586)
Timeframe: Start of first line therapy to measured progressive disease or death up to 24 months

Interventionmonths (Median)
Enzastaurin + 5-FU/LV + Bev8.9
Placebo + 5FU/LV + Bev11.3

Progression Free Survival (PFS)

PFS was defined as the time from randomization to the first observation of disease progression or death due to any cause. Progressive disease was determined using a modified version of Response Evaluation Criteria in Solid Tumor (RECIST) Assessment and was defined as at least a 20% increase in sum of longest diameter of target lesions. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00612586)
Timeframe: Randomization to measured progressive disease or death up to 17.2 months

Interventionmonths (Median)
Enzastaurin + 5-FU/LV + Bev5.8
Placebo + 5FU/LV + Bev8.1

Number of Participants With Adverse Events (AEs)

A summary of serious and all other non-serious AEs is located in the Reported Adverse Event module. (NCT00612586)
Timeframe: Randomization up to 17.2 months

,
InterventionParticipants (Count of Participants)
Serious AEsOther Non-Serious AEs
Enzastaurin + 5-FU/LV + Bev1553
Placebo + 5FU/LV +Bev1152

Overall Survival

Follow-up for survival to be done at 3 month intervals for 2 years, then 6 month intervals for up to 5 years from study registration (NCT00321100)
Timeframe: From dose of first study drug to last timepoint known to be alive (median follow-up for all patients was 25.9 months)

Interventionmonths (Median)
Cetuximab, Oxaliplatin, Capecitabine, Bevacizumab18
Cetuximab, Oxaliplatin, Capecitabine42.5

Time to Progression (TTP)

"Per Response Evaluation Criteria In Solid Tumors (RECISTv1.0) assessed by CT, MRI, x-ray scan:~Complete response (CR): Disappearance of all lesions Partial response (PR): >=30% decrease in the sum of the longest diameter of target lesions (SoL); from baseline SoL Stable disease (SD): Neither PR, PD, or CR Progressive disease (PD): >=20% increase in the SoL; from smallest SoL. Or appearance of new lesion" (NCT00321100)
Timeframe: every 6-9 weeks; from dose of first study drug to event

Interventionmonths (Median)
Cetuximab, Oxaliplatin, Capecitabine, Bevacizumab8.7
Cetuximab, Oxaliplatin, Capecitabine14.4

Objective Response Rate (ORR)

"Objective response rate calculated by the proportion of overall response: CR+PR. Patients were categorized by one of the following (1-4 per RECISTv1.0 criteria on CT, MRI, x-ray; 4-9 considered failure to respond/disease progression):~complete response (CR): Disappearance of all lesions~partial response (PR): >=30% decrease in the sum of the longest diameter of target lesions (SoL); from baseline SoL~stable disease (SD): Neither PR, PD, or CR~progressive disease (PD): >=20% increase in the SoL; from smallest SoL. Or appearance of new lesion~early death from malignant disease~early death from toxicity~early death from other cause~9) unknown (not assessable, insufficient data)" (NCT00321100)
Timeframe: every 6-9 weeks; from date of first study drug dose until off treatment date (median of 8 cycles; range <1-19)

,
InterventionParticipants (Count of Participants)
Overall responseComplete responsePartial responseStable disease
Cetuximab, Oxaliplatin, Capecitabine8173
Cetuximab, Oxaliplatin, Capecitabine, Bevacizumab4137

Apparent Oral Clearance (CL/F) of Sunitinib

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. (NCT00668863)
Timeframe: Cycle 1 Day 15

InterventionL/hour (Mean)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI32.9

Clearance of Irinotecan

CL is calculated as dose divided by AUC 0-∞ (NCT00668863)
Timeframe: Cycle 1 Day 15

InterventionL/hour (Mean)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI23.0

Duration of Response (DR)

DR is defined as the time from the first objective documentation of complete or partial response that is subsequently confirmed to the first documentation of disease progression or to death due to any cause, whichever occurs first. The definition of censorship is the same as PFS. (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)

Interventionweeks (Median)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI28.3

Percentage of Participants Who Presented Objective Response: Objective Response Rate (ORR)

ORR is defined as the percentage of participants with best overall response of either a confirmed complete (CR) or partial response (PR) relative to the number of participants in FAS. Based on the response evaluation criteria in solid tumors (RECIST), CR is defined as the disappearance of all target lesions and PR is defined as a greater than or equal to 30% decrease in the sum of the longest dimensions of the target lesion. (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)

Interventionpercentage of participants (Median)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI36.6

Plasma Concentration at Steady State (Css) of 5-FU

Concentration at 22 hour post start of 5-FU infusion were to be used as Css if 5-FU concentrations suggested steady state at 22 hours time point. (NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionng/mL (Mean)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI650

Progression-Free Survival (PFS)

"PFS is defined as the time from the date of enrollment to the date of the first documentation of objective tumor progression or death due to any cause, whichever occurs first.~PFS data was censored on the day following the date of the last tumor assessment documenting absence of progressive disease for patients who 1) were given anti-tumor treatment other than the study treatment prior to observing objective tumor progression; 2) were removed from the study prior to documentation of objective tumor progression; and 3) were ongoing at the time of the analysis." (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)

Interventionweeks (Median)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI28.9

Terminal Phase Elimination Half-life (t1/2) of Irinotecan

Terminal phase half-life of irinotecan was calculated as ln 2/ kel. (NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionhours (Mean)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI5.36

Volume of Distribution at Steady State (Vss) of Irinotecan

Vss was calculated using following equation: CL x mean residence time (MRT), where MRT = the area under the first moment curve from zero time to infinity (AUMC 0-∞)/AUC 0-∞- (infusion time/2), AUMC 0-∞ = the area under the first moment curve from zero time to time t (AUMC t)+ ((t x Ct*)/ kel) + (Ct* / kel^2), AUMC t is calculated using the linear trapezoidal method. (NCT00668863)
Timeframe: Cycle 1 Day 15

InterventionL (Mean)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI160

Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours Postdose (AUC 0-24) of Sunitinib

AUC 0-24 was determined using the Linear/Log trapezoidal method. (NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionng.h/mL (Mean)
Sunitinib AUC 0-24SU012662 AUC 0-24Total (sunitinib + SU0122662) AUC 0-24
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI11613461507

Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC Last) and Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC ∞) of Irinotecan

"AUC last of irinotecan and its metabolite SN-38 were calculated using the Linear/Log trapezoidal method.~AUC∞ of irinotecan was calculated using following equation; AUC last+(C*t/kel), where Ct* is the estimated concentration at the time of the last quantifiable concentration, kel is terminal phase rate constant that is estimated as the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm (ln) transformed concentration-time profile." (NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionng.h/mL (Mean)
Irinotecan AUC lastIrinotecan AUC ∞SN-38 AUC last
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI1310013800274

Maximum Observed Plasma Concentration (Cmax) and Predose Concentration (Ctrough) of Sunitinib.

Plasma concentrations were assessed at predose, 2, 4, 6, 8, and 24 hours postdose and Cmax and Ctrough of sunitinib, its metabolite SU012662, and the total (sunitinib + SU0122662) were determined. (NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionng/mL (Mean)
Sunitinib CmaxSunitinib CtroughSU012662 CmaxSU012662 CtroughTotal (sunitinib + SU0122662) CmaxTotal (sunitinib + SU0122662) Ctrough
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI54.341.815.811.370.053.1

Maximum Observed Plasma Concentration (Cmax) of Irinotecan

Plasma samples were assessed at prior to initiation of irinotecan (and l-leucovorin) infusion, 1, 2 (predose for 5-FU bolus), 4, 8, and 24 hours after initiation of irinotecan infusion, and Cmax of irinotecan and its metabolite SN-38 were determined. (NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionng/mL (Mean)
Irinotecan CmaxSN-38 Cmax
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI196325.1

Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Grade 3 or Higher Adverse Events According to Common Terminology Criteria (CTCAE).

Any untoward medical occurrence in a patient who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events (TEAE): those which occurred or worsened after baseline. An adverse event resulting in any of the following outcomes, or deemed to be significant for any other reason, was considered to be a serious adverse event (SAE): death; initial or prolonged inpatient hospitalization; a life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)

InterventionParticipants (Number)
Treatment emergent adverse eventsSerious adverse eventsCTCAE grade 3 or 4 adverse eventsCTCAE grade 5 adverse events
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI7132701

Time to Reach Maximum Plasma Concentration (Tmax) of Irinotecan

(NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionhours (Mean)
Irinotecan tmaxSN-38 tmax
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI24

Time to Reach Maximum Plasma Concentration (Tmax) of Sunitinib

(NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionhours (Mean)
Sunitinib TmaxSU012662 TmaxTotal (sunitinib + SU0122662) Tmax
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI646

Median Time for Progression Free Survival

Progression-free survival was measured from the start of treatment until the time the subject is first recorded as having disease progression (progression = 20% increase in sum of longest diameters of target measurable lesions over smallest sum observed or baseline, progression of non-measurable disease in the opinion of treating physician, appearance of new lesion/site, death due to disease), or death due to any cause. If a subject has not progressed or died, progression-free survival was censored at the time of last follow-up or the start of another treatment, whichever came first. (NCT00159432)
Timeframe: Up to 6 years

InterventionMonths (Median)
Oxaliplatin Followed by Bevacizumab, With Capecitabine15.8

Number of Participants With Grade 3 or Higher Toxicity

Summary of grade 3 (per CTCAE v3.0) or higher toxicities which generally is described as a severe adverse reaction or symptom. (NCT00159432)
Timeframe: Baseline, every 2 weeks of each cycle, and at end of treatment, up to 18 months.

InterventionParticipants (Number)
Oxaliplatin Followed by Bevacizumab, With Capecitabine51

Duration of Response (DR)

DR was defined as the time from the first objective documentation of CR or PR that was subsequently confirmed to the first documentation of disease progression or to death due to any cause, whichever occurred first. (NCT00457691)
Timeframe: Day 28 of Cycle 1 up to 30 months

InterventionWeeks (Median)
FOLFIRI + Sunitinib30.1
FOLFIRI + Placebo39.0

Number of Participants With Overall Confirmed Objective Response

Objective disease response: participants with a confirmed complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as the disappearance of all target lesions. PR was defined as a greater than or equal to 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. (NCT00457691)
Timeframe: Day 28 of Cycle 1 up to 30 months

InterventionParticipants (Number)
FOLFIRI + Sunitinib124
FOLFIRI + Placebo128

Overall Survival (OS)

OS was defined as the time from randomization to the date of death due to any cause. OS data were censored on the day following the date of the last contact at which the patient was known to be alive. (NCT00457691)
Timeframe: Baseline up to 30 months

InterventionWeeks (Median)
FOLFIRI + Sunitinib87.9
FOLFIRI + Placebo85.9

Progression-free Survival (PFS)

PFS defined as time from date of randomization to date of first documentation of objective tumour progression or death due to any cause, whichever occurred first. (NCT00457691)
Timeframe: First dose of study treatment up to 30 months

InterventionWeeks (Median)
FOLFIRI + Sunitinib33.6
FOLFIRI + Placebo36.6

Change From Baseline in European Quality of Life (EuroQol) EQ-5D Self-Report Questionnaire

"EQ-5D: participant-rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problem); 3 indicates worst health state (eg, confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain. Score is transformed and results in total score range -1.11 to 1.000; higher score indicates better health state." (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal

,
InterventionScores on a scale (Mean)
Cycle 2, Day 1Cycle 3, Day 1Cycle 5, Day 1Cycle 7, Day 1Cycle 9, Day 1Cycle 11, Day 1
FOLFIRI + Placebo0.040.040.030.050.050.09
FOLFIRI + Sunitinib0.020.020.020.030.000.01

Change From Baseline in EuroQol (EQ) Visual Analog Scale (VAS) (EQ-VAS)

EQ-5D: participant-rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal

,
InterventionScores on a scale (Mean)
Cycle 2, Day 1Cycle 3, Day 1Cycle 5, Day 1Cycle 7, Day 1Cycle 9, Day 1Cycle 11, Day 1
FOLFIRI + Placebo3.34.36.64.34.09.0
FOLFIRI + Sunitinib1.01.71.83.8-0.9-1.6

Change From Baseline in MDASI-GI Symptom Interference Score

Symptom Interference score is comprised of the sum 6 function items from MDASI core (general activity, walking, work, mood, relations with other people, and enjoyment of life). Participant asked to rate how much symptoms have interfered in past 24 hours; each item rated from 0 to 10, with 0=did not interfere and 10=interfered completely; lower scores indicated better outcome (range: 0 to 60). (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal

,
Interventionscores on a scale (Mean)
Cycle 2, Day 1Cycle 3, Day 1Cycle 5, Day 1Cycle 7, Day 1Cycle 9, Day 1Cycle 11, Day 1
FOLFIRI + Placebo-1.3-1.7-1.2-0.2-1.7-1.0
FOLFIRI + Sunitinib0.0-0.10.2-0.52.13.1

Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Assessment Inventory of Gastrointestinal Symptoms (MDASI-GI) Symptom Intensity Score

Symptom Intensity score is comprised of the sum of 13 MDASI core items (ie, pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness or tingling). Participant asked to rate severity of each symptom at their worst in past 24 hours; each item rated from 0 to 10, with 0=symptom not present and 10=as bad as you can imagine; lower scores indicated better outcome (range: 0 to 130). (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until end of treatment (EOT)/withdrawal

,
InterventionScores on a scale (Mean)
Cycle 2, Day 1Cycle 3, Day 1Cycle 5, Day 1Cycle 7, Day 1Cycle 9, Day 1Cycle 11, Day 1
FOLFIRI + Placebo0.40.91.82.71.2-2.7
FOLFIRI + Sunitinib1.70.81.00.70.85.0

All-cause Mortality

(NCT00537823)
Timeframe: 30 days following surgery

Interventionparticipants (Number)
Arm 1 - Wildtype0
Arm 2 K-Ras 12/13 Codon Mutation0

Change in Tumor Size From Pretreatment to Preoperative CT Scan

-Compare total longest diameter from baseline to preoperative CT scan. (NCT00537823)
Timeframe: Completion of neoadjuvant therapy (approximately 8 weeks)

Interventionpercentage of change of longest diameter (Median)
Arm 1 - Wildtype-23.8
Arm 2 K-Ras 12/13 Codon Mutation-14.3

Effect of Preoperative Chemotherapy on Tumor Size

Number of participants whose tumor size decreased from baseline to completion of preoperative chemotherapy. (NCT00537823)
Timeframe: Upon completion of neoadjuvant chemotherapy (approximately 2 months)

Interventionparticipants (Number)
Arm 1 - Wildtype4
Arm 2 K-Ras 12/13 Codon Mutation2

Major Postoperative Complication Rate

Fraction of patients with any complication grades IV and V (NCT00537823)
Timeframe: 30 days following surgery

Interventionpercentage of participants (Number)
Arm 1 - Wildtype25
Arm 2 K-Ras 12/13 Codon Mutation0

Postoperative Complication Rate

Fraction of patients with any grade of complication I-V (NCT00537823)
Timeframe: 30 days following surgery

Interventionpercentage of participants (Number)
Arm 1 - Wildtype25
Arm 2 K-Ras 12/13 Codon Mutation0

Histologic Hepatic Toxicity at Surgery

(NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)

,
Interventionparticipants (Number)
Not reported on pathology reportMildAborted surgeryNone
Arm 1 - Wildtype1111
Arm 2 K-Ras 12/13 Codon Mutation0001

Nonalcoholic Steatohepatitis Score (0-3)

"NASH Scoring~Steatosis **<5% = 0~**5-33%=1~**>33-66%=2~**>66%=3~Lobular inflammation~**No foci=0~**<2 foci per x 200 field=1~**2-4 foci per x 200 field=2~**>4 foci per x 200 field=3~Hepatocellular ballooning **None=0 **Few balloon cells = 1 **Many cells/prominent ballooning=2" (NCT00537823)
Timeframe: Time of surgery (approximately 11-16 weeks)

,
Interventionparticipants (Number)
Not reported on pathology reportAborted surgeryScore 0
Arm 1 - Wildtype310
Arm 2 K-Ras 12/13 Codon Mutation001

Postoperative Recurrence Patterns

Liver only vs distant disease (NCT00537823)
Timeframe: Up to 5 years

,
Interventionparticipants (Number)
Liver onlyDistant disease
Arm 1 - Wildtype01
Arm 2 K-Ras 12/13 Codon Mutation00

Duration of Response

"Duration of overall response was measured from the time that measurement criteria are met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the onset of progression. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date).~Missing onset of progression data because of refusal or because of death was replaced.~If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements." (NCT02119026)
Timeframe: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD

Interventiondays (Median)
A: XELIRI + BEV Followed by XELOX + BEV244.0
B: XELOX + BEV Followed by XELIRI + BEV315

Efficacy Duration of Disease Control by Tumor Assessment (CT/MRI/Clinical Examination)

The primary variable was duration of disease control (DDC) and was defined as the sum of progression free survival intervals during first line and second line treatment (= time from the beginning of first line treatment until onset of progression during second line treatment). Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). (NCT02119026)
Timeframe: screening, every 8 to 9 weeks until progression, at end of treatment (other than progression), every 3 months until progression, death or up to 24 months (whatever comes first)

Interventiondays (Median)
A: XELIRI + BEV Followed by XELOX + BEV373.00
B: XELOX + BEV Followed by XELIRI + BEV370.00

First Line Progression Free Survival (PFS)

The first line PFS was defined as the progression free survival interval during first line treatment. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). Missing onset of progression data because of refusal or because of death was replaced. If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements. (NCT02119026)
Timeframe: at progression of disease (PD) in first line therapy or at 28 days safety follow-up in cases without PD

Interventiondays (Median)
A: XELIRI + BEV Followed by XELOX + BEV241
B: XELOX + BEV Followed by XELIRI + BEV280

Overall Response Rate (Number of Participants With Response)

The rate of overall response was measured as the response rate from randomization until the day of documented complete response (CR) or partial response (PR) (whichever status is recorded first). (NCT02119026)
Timeframe: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD

InterventionParticipants (Count of Participants)
A: XELIRI + BEV Followed by XELOX + BEV32
B: XELOX + BEV Followed by XELIRI + BEV36

Overall Survival of XELIRI Plus Bevacizumab and XELOX Plus Bevacizumab

Overall survival was measured as the time from the randomization date to the date of death. Patients without death date were censored at the date of the last tumor assessment (exception: availability of validated information about a later exitus date or a prolonged survival - in such a case the date of the follow-up assessment was either defined as the exitus date or replaced the last tumor assessment date) or the date of refusal. (NCT02119026)
Timeframe: date of death or date of last tumor assessment (28d safety f-u) in patients without death

Interventiondays (Median)
A: XELIRI + BEV Followed by XELOX + BEV593.0
B: XELOX + BEV Followed by XELIRI + BEV643

Second Line PFS

"The second line PFS was defined as the progression free survival interval during second line treatment. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). Missing onset of progression data because of refusal or because of death was replaced.~If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements." (NCT02119026)
Timeframe: at progression of disease (PD) in second line therapy or at 28 days safety follow-up in cases without PD

Interventiondays (Median)
A: XELIRI + BEV Followed by XELOX + BEV129
B: XELOX + BEV Followed by XELIRI + BEV155

Time to Response

Time to overall response was measured from the time of randomization until the day of documented complete response (CR) or partial response (PR) (whichever status is recorded first). Patients without response were censored at the date of the last tumor assessment, the date of death or the date of refusal. (NCT02119026)
Timeframe: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD

Interventiondays (Median)
A: XELIRI + BEV Followed by XELOX + BEV185.0
B: XELOX + BEV Followed by XELIRI + BEV178.0

Tumour Assessments (Based on RECIST Criteria) in 1st-line

Best response in first line was based on the tumor assessments (based on RECIST criteria) for target lesions and assessed by CT scans, MRI scans, X-ray, bone scan and clinical examination: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter (sum LD) of target lesions; Progressive Disease (PD), >= 20% increase in the sum of the LD of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. (NCT02119026)
Timeframe: Baseline, every 8-9 weeks, 28d Safety follow-up

,
Interventionparticipants (Number)
Progressive Disease (PD)Stable Disease (SD)Partial Response (PR)Complete Response (CR)
A: XELIRI + BEV Followed by XELOX + BEV421262
B: XELOX + BEV Followed by XELIRI + BEV123300

Tumour Assessments (Based on RECIST Criteria) in 2nd-line

Best response in second line was based on the tumor assessments (based on RECIST criteria) for target lesions and assessed by CT scans, MRI scans, X-ray, bone scan and clinical examination: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter (sum LD) of target lesions; Progressive Disease (PD), >= 20% increase in the sum of the LD of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. (NCT02119026)
Timeframe: Baseline, every 8-9 weeks, 28d Safety follow-up

,
Interventionparticipants (Number)
Progressive Disease (PD)Stable Disease (SD)Partial Response (PR)Complete Response (CR)Not available (NA)
A: XELIRI + BEV Followed by XELOX + BEV711608
B: XELOX + BEV Followed by XELIRI + BEV813201

Median Progression-Free Survival (PFS)

Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date

Interventionsurvival time in months (Median)
1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin6.97

Median Survival

Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date

Interventionsurvival time in months (Median)
1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti10.51

Response Rate

The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year

Interventionpercentage of participants (Number)
1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti41.7

To Assess the Safety and Tolerability of the Combination of Bevacizumab, Oxaliplatin and Capecitabine in Patients With Previously Untreated Metastatic Esophagogastric Adenocarcinoma

Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days

Interventionparticipants (Number)
1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti56

Overall Response Rate

"Overall response rate = complete response + partial response~Complete response = disappearance of all target and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart.~Partial response = at least a 30% decrease in the sum of the longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be non unequivocal progression of non-target lesions and no new lesions." (NCT00868192)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Pemetrexed and Bevacizumab41

Overall Survival (OS)

OS = observed length of time from entry into the study to death or date of last contact (NCT00868192)
Timeframe: 12 months

Interventionpercentage of participants (Number)
Pemetrexed and Bevacizumab79

Overall Survival (OS)

OS = observed length of time from entry into the study to death or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)

Interventionmonths (Median)
Pemetrexed and Bevacizumab25.7

Progression-free Survival (PFS)

PFS = Period from study entry until disease progression, death, or date of last contact (NCT00868192)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Pemetrexed and Bevacizumab56

Progression-free Survival (PFS)

PFS = Period from study entry until disease progression, death, or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)

Interventionmonths (Median)
Pemetrexed and Bevacizumab7.9

CA-125 Response

A CA-125 response was defined as at least a 50% reduction in CA-125 levels from a pretreatment sample following guidelines described by the Gynecological Cancer Intergroup. (NCT00868192)
Timeframe: 6 months

Interventionparticipants (Number)
50% CA-125 response75% CA-125 responseNo CA-125 response
Pemetrexed and Bevacizumab1782

Distribution of Overall Survival (OS)

OS = observed length of time from entry into the study to death or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)

Interventionmonths (Median)
Platinum-free interval of <6 monthsPlatinum-free interval of 6-12 monthsPlatinum-free interval of >12 months
Pemetrexed and Bevacizumab16.724.928.0

Distribution of Progression-free Survival (PFS)

PFS = Period from study entry until disease progression, death, or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)

Interventionmonths (Median)
Platinum-free interval of <6 monthsPlatinum-free interval of 6-12 monthsPlatinum-free interval of >12 months
Pemetrexed and Bevacizumab6.74.716.8

Frequency of Clinical Response

As measured by RECIST criteria (NCT00868192)
Timeframe: 6 months

Interventionparticipants (Number)
Complete responsePartial responseStable diseaseProgressive disease
Pemetrexed and Bevacizumab014182

Toxicity Associated With Bevacizumab and Pemetrexed

Detailed serious adverse events and other adverse events are shown in the adverse event module of the results. (NCT00868192)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Grade 3/4 hematologic toxicityMost common non-hematologic toxicity - fatigueGrade 3 renal toxicityGastrointestinal toxicitySubsequently developed hematologic malignancies
Pemetrexed and Bevacizumab53946916

The Primary Activity Variable Was the Recurrence of Recurrent Respiratory Papillomatosis (RRP) in Bevacizumab Treated and the Un-treated Vocal Fold in the Same Patient During and at the End of the 6-month Treatment Period.

Prior to each treatment,the area of reappearance of disease was measured and the % change from baseline was calculated. The change was then added to the % change from the previous treatment to generate a cumulative total % change of reappearance of RRP from baseline. The additive nature of this parameter resulted in % greater than 100% if the area of vocal fold affected by the RRP increased over the baseline measurement. (NCT01020747)
Timeframe: 6 months

Interventiontotal percentage change (Mean)
Bevacizumab Treated Vocal Fold85.3
Untreated Vocal Fold225.3

Objective Response Rate (RR) in Patients With Measurable Lesions Time to Objective Response

The objective response rate is defined as the percentage of patients showing complete or partial response. (NCT00462423)
Timeframe: The median duration of follow-up for surviving patients was 41.6 months.

InterventionPercentage of participants (Number)
Single Arm, Open Label36

Overall Survival (OS)

The duration of overall survival was defined as the number of months between the start date of protocol treatment and the date of death (irrespective of cause), and was right-censored at the date of last contact for patients who were alive as of the data cutoff. (NCT00462423)
Timeframe: April 2007 through December 2010

Interventionmonths (Median)
Single Arm, Open Label16.8

Progression-free Survival

Median time of progression-free survival from first treatment according to RECIST 1.0 (NCT00462423)
Timeframe: From start of treatment to disease progressin; median duration of follow-up for surviving patients was 41.6 months.

InterventionMonths (Median)
Single Arm, Open Label7.63

Progression-free Survival (PFS) at 4 Months

Progression-free survival at 4 months from first treatment as determined by RECIST 1.0 (NCT00462423)
Timeframe: 4 months.

Interventionpercentage of patients (Number)
Single Arm, Open Label75

Duration of Overall Complete Response

The duration of overall complete response was assessed from the time that measurement criteria were met for complete response until the first date that recurrent or progressive disease was objectively documented. Participants without observed progressive disease after an objective complete response were censored at the date of the last tumor assessment. (NCT00022698)
Timeframe: Approximately 43 Months

Interventionmonths (Number)
Cohort 1, Initial Regimen: (Capecitabine + Irinotecan)12.45
Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)12.68

Duration of Overall Response

Duration of overall response was assessed from the time that measurement criteria were first met for CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease was documented. It was analyzed for responders only. Participants without observed progressive disease after an objective response were censored at the date of the last tumor assessment. (NCT00022698)
Timeframe: Approximately 43 Months

Interventionmonths (Median)
Cohort 1, Initial Regimen: (Capecitabine + Irinotecan)7.0
Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)7.7

Overall Survival

Overall Survival is defined as the time from start of treatment to the date of death. Participants who did not die were censored at the last date the participant was known to be alive. (NCT00022698)
Timeframe: Approximately 43 Months

Interventionmonths (Median)
Cohort 1, Initial Regimen: (Capecitabine + Irinotecan)22.9
Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)20.5

Percentage of Participants With One-year Survival

Survival was measured as the time from start of treatment to the date of death or till one year whichever occurred first. (NCT00022698)
Timeframe: Up to Month 12

Interventionpercentage of participants (Number)
Cohort 1, Initial Regimen: (Capecitabine + Irinotecan)67
Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)71

Time to Disease Progression

Time to disease progression was assessed as the time from start of treatment to the time the participant was first recorded as having disease progression or died due to causes other than disease progression. If a participant never progressed while being followed, he/she was censored at the date of the last tumor assessment or the date of the last dose if no post-baseline tumor measurement was available. (NCT00022698)
Timeframe: Approximately 43 Months

Interventionmonths (Median)
Cohort 1, Initial Regimen: (Capecitabine + Irinotecan)6.1
Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)7.6

Time To Objective Response

The time to objective response is defined as the time from start of treatment to the date of first objective response. Participants who never responded during study were censored at the last tumor assessment or the date of last dose, whichever was later, or at the date of death if occurring prior to response. (NCT00022698)
Timeframe: Approximately 43 Months

Interventionmonths (Median)
Cohort 1, Initial Regimen: (Capecitabine + Irinotecan)5.5
Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)4.3

Time to Treatment Failure

Time to treatment failure was assessed as the time from start of treatment to the time the participant was withdrawn due to any of the reasons such as adverse events, progressive disease, insufficient therapeutic response, death, failure to return, or refused treatment, did not cooperate or withdrew consent. (NCT00022698)
Timeframe: Approximately 43 Months

Interventionmonths (Median)
Cohort 1, Initial Regimen: (Capecitabine + Irinotecan)5.8
Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)7.3

Number of Participants With Any Adverse Events, Serious Adverse Events and Deaths

An adverse event (AEs) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. A serious adverse event is defined as any event which was fatal (resulted in death), life-threatening (with immediate risk of death), resulted in a new or prolongation of a current hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, considered medically significant by the investigator, required intervention to prevent one or more of the outcomes listed above. (NCT00022698)
Timeframe: Approximately 43 Months

,,
InterventionNumber of participants (Number)
Any AEsSAEsDeaths During StudyDeaths During Follow-up
Cohort 1, Initial Regimen: (Capecitabine + Irinotecan)1510013
Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)5225323
Total Participants (Cohort 1 + Cohort 2)6735336

Tumor Response Rate Based on Tumor Measurement as Per Response Evaluation Criteria In Solid Tumors Version 1.0 (RECIST 1.0)

Objective Response Rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST 1.0). CR is defined as the disappearance of all target and non-target lesions and normalization of tumor marker level. PR is defined as a greater than or equal to (>/=) 30% decrease in the sum of the longest diameter (LD) of the target lesions, taking as reference the baseline sum of LD. Participants who did not have a post-baseline tumor measurement were considered non-responders in the assessment of ORR. (NCT00022698)
Timeframe: Approximately 43 Months

,
Interventionpercentage of participants (Number)
CRPR
Cohort 1, Initial Regimen:(Capecitabine + Irinotecan)740
Cohort 2, Amended Regimen: (Capecitabine + Irinotecan)242

Number of Participants Experienced Dose Limited Toxicity

Dose related toxicity is defined as follows:1. luecopenia > grade 2; granular cell decrease > grade 2; anemia > grade 1; platelet > grade 1;SGPT/SGOT elevation > grade 1; ALP > grade 1; GGT > grade 1; Tbil > grade 1;renal function damag > grade 2;Non-gradular cell decreased fever > grade 1;nausea/vomiting > grade 1; fatigue > grade 2; weight loss > grade 2;gastritis > grade 2; dairrea > grade 2; abdominal pain > grade 2; upper gastrointestinal bleeding > grade 1;other toxic reaction > grade 2;KPS < 50 during the treatment (NCT01584544)
Timeframe: up to 7 weeks from start of the treatment

Interventionparticipants (Number)
1000mg0
1200mg1
1350mg1
1500mg0
1650mg1

Number of Participants Who Died (Part 2)

The number of participants in Part 2 who died during the study. (NCT00111761)
Timeframe: From enrollment until last contact. Maximum follow-up was 16 months.

Interventionparticipants (Number)
Panitumumab With FOLFIRI6

Number of Participants With an Objective Tumor Response (Part 2)

Objective tumor response (complete or partial) in Part 2 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease. (NCT00111761)
Timeframe: Until disease progression (median 47 weeks)

InterventionParticipants (Number)
Panitumumab With FOLFIRI8

Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 1)

The number of participants with grade 3 or grade 4 diarrhea in Part 1 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC). (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first

InterventionParticipants (Number)
Panitumumab With IFL11

Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 2)

The number of participants with grade 3 or grade 4 diarrhea in Part 2 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC). (NCT00111761)
Timeframe: Until disease progression (median 47 weeks)

InterventionParticipants (Number)
Panitumumab With FOLFIRI6

Number of Participants With Objective Tumor Response (Part 1)

Objective tumor response (complete or partial) in Part 1 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease. (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first

InterventionParticipants (Number)
Panitumumab With IFL9

Progression-free Survival Time (Part 1)

Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 1 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until disease progression or death. Maximum follow-up time was 25 months.

Interventionweeks (Median)
Panitumumab With IFL24.3

Progression-free Survival Time (Part 2)

Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 2 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until disease progression or death. Maximum follow-up time was 16 months.

Interventionweeks (Median)
Panitumumab With FOLFIRI41.1

Survival Time (Part 1)

Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date. (NCT00111761)
Timeframe: From enrollment until death. Maximum follow-up time was 25 months.

Interventionweeks (Median)
Panitumumab With IFL73.1

Survival Time (Part 2)

Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date. (NCT00111761)
Timeframe: From enrollment until death. Maximum follow-up time was 16 months.

Interventionweeks (Median)
Panitumumab With IFL73.1

Time to Disease Progression (Part 1)

Kaplan-Meier estimate of the median time from the first dose of study drug to disease progression or death if due to disease progression (whichever comes first) in Part 1 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until disease progression or death. Maximum follow-up time was 25 months.

Interventionweeks (Median)
Panitumumab With IFL35.0

Time to Disease Progression (Part 2)

Kaplan-Meier estimate of median time from the first dose of study drug to first observed disease progression or death if the death was due to disease progression (whichever comes first) in Part 2 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until death or diease progression. Maximum follow-up time was 16 months.

Interventionweeks (Median)
Panitumumab With FOLFIRI47.3

Time to Initial Objective Tumor Response (Part 1)

Median time to first observed objective tumor response (complete or partial) among responders in Part 1 of the study. (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first

Interventionweeks (Median)
Panitumumab With IFL5.9

Time to Treatment Failure (Part 1)

Kaplan-Meier estimate of the median time from the date of first dose of panitumumab or chemotherapy to the date the decision was made to end treatment for any reason in Part 1 of the study. (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first

InterventionWeeks (Median)
Panitumumab With IFL24.3

Number of Participants With an Adverse Event

Here is the number of participants with an adverse event. For a detailed list of adverse events see the adverse event module. (NCT00052962)
Timeframe: 2003-2008

InterventionParticipants (Number)
Arm 1 Surgery + Post op Chemotherapy7
Arm 2 Surgery + CHPP6

Cumulative Incidence of grade3+ Bowel Perforation, Grade 3+ Bleeding (Ocurring Withing 1 Years) and grade4+ Nonhematologic Acute Adverse Events (Limited to Within 90 Days of Treatment Start)

(NCT00685763)
Timeframe: 1 year following the completion of radiation therapy

Interventionparticipants (Number)
Proton Radiation and Chemotherapy0

Reviews

865 reviews available for fluorouracil and Colorectal Cancer

ArticleYear
Antiproliferative and palliative activity of flavonoids in colorectal cancer.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 143

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe

2021
Systematic review and meta-analysis of tumour microsatellite-instability status as a predictor of response to fluorouracil-based adjuvant chemotherapy in colorectal cancer.
    International journal of colorectal disease, 2022, Volume: 37, Issue:1

    Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Microsatellite Instability; Micr

2022
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
    ESMO open, 2021, Volume: 6, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Feb

2021
Intra-Arterial Therapy for Unresectable Colorectal Liver Metastases: Which and When? A Commentary on "Intra-Arterial Therapy for Unresectable Colorectal Liver Metastases: A Meta-Analysis".
    Journal of vascular and interventional radiology : JVIR, 2021, Volume: 32, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery;

2021
Adjuvant treatment of colon cancer with microsatellite instability - the state of the art.
    Critical reviews in oncology/hematology, 2022, Volume: 169

    Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms; DNA Mismatch Repair; Fluorouracil;

2022
Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives.
    Cancer treatment reviews, 2022, Volume: 102

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C

2022
Adjuvant intra-arterial chemotherapy for patients with resected colorectal liver metastases: a systematic review and meta-analysis.
    HPB : the official journal of the International Hepato Pancreato Biliary Association, 2022, Volume: 24, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro

2022
Proton pump inhibitors and colorectal cancer: A systematic review.
    World journal of gastroenterology, 2021, Nov-28, Volume: 27, Issue:44

    Topics: Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Proton Pump Inhibitors

2021
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 03-10, Volume: 40, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Colonic Neo

2022
Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer.
    Expert opinion on drug safety, 2022, Volume: 21, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2022
Chemotherapy in resectable or potentially resectable colon cancer with liver metastases.
    Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorecta

2022
MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil.
    Molecular biology reports, 2022, Volume: 49, Issue:6

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Reg

2022
Efficacy and safety of aflibercept plus chemotherapy in metastatic colorectal cancer: A systematic review and PRISMA-Compliant single-arm Meta-Analysis of noncomparative clinical studies and randomized controlled trials.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci

2022
Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 166

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Fluorouracil; Hu

2022
After thirty years of experience with early postoperative intraperitoneal 5-fluorouracil now saying goodbye.
    Surgical oncology, 2022, Volume: 42

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Cyt

2022
Comparison between diagnostic performance of intestinal Fusobacterium nucleatum, Bacteroides fragilis and Escherichia coli in 5-fluorouracil resistance to colorectal cancer: A meta‑analysis.
    Cancer treatment and research communications, 2022, Volume: 32

    Topics: Bacteroides fragilis; Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum;

2022
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 170

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase II

2022
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 170

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase II

2022
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 170

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase II

2022
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 170

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials, Phase II

2022
Formulation of two lipid-based membrane-core nanoparticles for FOLFOX combination therapy.
    Nature protocols, 2022, Volume: 17, Issue:8

    Topics: Animals; Carcinoma, Hepatocellular; Colorectal Neoplasms; Fluorodeoxyuridylate; Fluorouracil; Lipids

2022
A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials.
    American journal of clinical oncology, 2022, 08-01, Volume: 45, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neopla

2022
Leukocytoclastic vasculitis presenting clinically as bullous pyoderma gangrenosum following leucovorin, fluorouracil and oxaliplatin chemotherapy: a rare case report and literature review.
    Anti-cancer drugs, 2022, 10-01, Volume: 33, Issue:9

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouraci

2022
Efficacy of various adjuvant chemotherapy methods in preventing liver metastasis from potentially curative colorectal cancer: A systematic review network meta-analysis of randomized clinical trials.
    Cancer medicine, 2023, Volume: 12, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C

2023
Versatile use of Carmofur: A comprehensive review of its chemistry and pharmacology.
    Drug development research, 2022, Volume: 83, Issue:7

    Topics: Antineoplastic Agents; Brain Neoplasms; Child; Colorectal Neoplasms; COVID-19; Fluorouracil; Humans

2022
Efficacy and safety of high doses of irinotecan in patients with metastatic colorectal cancer treated with the FOLFIRI regimen based on the UGT1A1 genotype: A systematic review.
    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2022, 07-17, Volume: 46, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Ge

2022
The efficacy of irinotecan supplementation for colorectal cancer: A meta-analysis of randomized controlled studies.
    Medicine, 2022, Oct-14, Volume: 101, Issue:41

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dietary Suppleme

2022
Regulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer.
    Medical oncology (Northwood, London, England), 2022, Oct-29, Volume: 40, Issue:1

    Topics: Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Signal Transduction; Thymidyl

2022
Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review.
    Current oncology reports, 2023, Volume: 25, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Fluorou

2023
Curcumin, calebin A and chemosensitization: How are they linked to colorectal cancer?
    Life sciences, 2023, Apr-01, Volume: 318

    Topics: Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Curcumin; Cytostatic Agents; Drug Resistance, Neo

2023
Recurrent Reversible Stroke-Like Encephalopathy After 5-Fluorouracil (5-FU) Chemotherapy: A Case Report and Literature Review.
    The American journal of case reports, 2023, Apr-04, Volume: 24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cerebral Infarction; Colorectal Neoplasms; Fluoroura

2023
Hepatic artery infusion for unresectable colorectal cancer liver metastases: Palliation and conversion.
    Surgery, 2023, Volume: 174, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery;

2023
A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety.
    Critical reviews in oncology/hematology, 2023, Volume: 188

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2023
Feasibility and Safety of Adjuvant Chemotherapy for Resected Colorectal Cancer in Patients With Renal Insufficiency: A Pooled Analysis of Individual Patient Data from Five Japanese Large-scale Clinical Trials.
    Anticancer research, 2023, Volume: 43, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; East A

2023
Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer.
    Future oncology (London, England), 2023, Volume: 19, Issue:23

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Camptothecin; Clinical Tria

2023
5‑Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review).
    Oncology reports, 2023, Volume: 50, Issue:4

    Topics: Capecitabine; Cell Division; Cell Membrane; Colorectal Neoplasms; Fluorouracil; Humans

2023
High vs. low-dose leucovorin in regimens with fluorouracil in colorectal cancer therapy.
    Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti, 2023,Summer, Volume: 72, Issue:3

    Topics: Colorectal Neoplasms; Cytostatic Agents; Drug-Related Side Effects and Adverse Reactions; Fluorourac

2023
Triplet-drug chemotherapy combined with anti-EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis.
    World journal of surgical oncology, 2023, Nov-18, Volume: 21, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase II as Topic; Colon

2023
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future.
    Pharmacology & therapeutics, 2020, Volume: 206

    Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans; Prodrugs

2020
FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms.
    Cancer medicine, 2020, Volume: 9, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Cycle Proteins; Colorectal N

2020
Maintenance treatment in metastatic colorectal cancer: in search of the best strategy.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Ca

2020
Response to: Optic neuritis induced by 5-fluorouracil chemotherapy: case report and review of the literature.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:3

    Topics: Colorectal Neoplasms; Fluorouracil; Humans; Magnetic Resonance Imaging; Optic Neuritis

2020
Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis.
    Current pharmaceutical design, 2020, Volume: 26, Issue:26

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colo

2020
Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
    The Cochrane database of systematic reviews, 2020, 03-12, Volume: 3

    Topics: Antimetabolites, Antineoplastic; Chemoembolization, Therapeutic; Colorectal Neoplasms; Embolization,

2020
The efficacy and safety of panitumumab supplementation for colorectal cancer: A meta-analysis of randomized controlled studies.
    Medicine, 2020, Volume: 99, Issue:11

    Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neo

2020
The p38 MAPK Signaling Activation in Colorectal Cancer upon Therapeutic Treatments.
    International journal of molecular sciences, 2020, Apr-16, Volume: 21, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Colorectal Neoplasms; Fluorouracil; Humans; Oxaliplatin; p38 Mitog

2020
Recent Advances in Polymer Nanomaterials for Drug Delivery of Adjuvants in Colorectal Cancer Treatment: A Scientific-Technological Analysis and Review.
    Molecules (Basel, Switzerland), 2020, May-12, Volume: 25, Issue:10

    Topics: Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Humans; Nanostructures; Polymers

2020
Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update.
    Cellular oncology (Dordrecht), 2020, Volume: 43, Issue:6

    Topics: Animals; Autophagy; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Pharmacog

2020
5-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes.
    Cancer science, 2020, Volume: 111, Issue:9

    Topics: Antimetabolites, Antineoplastic; Biomarkers; Colorectal Neoplasms; Drug Resistance, Neoplasm; Energy

2020
Undiagnosed Case of Signet Ring Cell Colorectal Carcinoma: A Case Report and Review of the Literature.
    Clinical colorectal cancer, 2020, Volume: 19, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant;

2020
MicroRNAs and Apoptosis in Colorectal Cancer.
    International journal of molecular sciences, 2020, Jul-28, Volume: 21, Issue:15

    Topics: Apoptosis; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; MicroRNAs; RNA, Ne

2020
The actual management of colorectal liver metastases.
    Minerva chirurgica, 2020, Volume: 75, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Electroporation;

2020
Controversies in the treatment of RAS wild-type metastatic colorectal cancer.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:4

    Topics: Advisory Committees; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colo

2021
Recent Advances in Designing 5-Fluorouracil Delivery Systems: A Stepping Stone in the Safe Treatment of Colorectal Cancer.
    International journal of nanomedicine, 2020, Volume: 15

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biological

2020
MicroRNAs and colorectal cancer chemoresistance: New solution for old problem.
    Life sciences, 2020, Oct-15, Volume: 259

    Topics: ATP-Binding Cassette Transporters; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Drug R

2020
Oxaliplatin-induced Immune Thrombocytopenia: A Case Report and Literature Review.
    Clinical colorectal cancer, 2021, Volume: 20, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colorectal Neopla

2021
Efficacy and Safety of Bevacizumab Plus Oxaliplatin- or Irinotecan-Based Doublet Backbone Chemotherapy as the First-Line Treatment of Metastatic Colorectal Cancer: A Systematic Review and Meta-analysis.
    Drug safety, 2021, Volume: 44, Issue:1

    Topics: Bevacizumab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Oxaliplatin

2021
Intraarterial Chemotherapy for Liver Metastases.
    Surgical oncology clinics of North America, 2021, Volume: 30, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hep

2021
Potentially Resectable mCRC-treated with Cetuximab Combined with Chemotherapy.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2020, Volume: 30, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms;

2020
Current Perspectives on the Role of Nrf2 in 5-Fluorouracil Resistance in Colorectal Cancer.
    Anti-cancer agents in medicinal chemistry, 2021, Volume: 21, Issue:17

    Topics: Antimetabolites, Antineoplastic; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm

2021
Review of systemic chemotherapy in unresectable colorectal peritoneal carcinomatosis.
    Asia-Pacific journal of clinical oncology, 2022, Volume: 18, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Peritone

2022
Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:8

    Topics: Age Factors; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined

2021
Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2021, Volume: 32, Issue:8

    Topics: Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Mutation; Proto-Oncogene Proteins

2021
[A Case of Liver Metastasis of Colorectal Cancer in a Hemodialysis Patient, Underwent Liver Resection and Chemotherapy after Colorectal Resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colon, Sigmoid; Colorectal Neoplasms; Fluorouracil;

2021
Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone.
    Cancer treatment reviews, 2021, Volume: 98

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Fluorou

2021
Multiple strategies with the synergistic approach for addressing colorectal cancer.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 140

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette

2021
Up-to-date role of aflibercept in the treatment of colorectal cancer.
    Expert opinion on biological therapy, 2021, Volume: 21, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2021
[FOLFIRI plus Ramucirumab Treatment for Metastatic Colorectal Cancer-Narrative Review of Real-World Evidence in Japan].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2021
The efficacy and safety of bevacizumab combined with FOLFOX regimen in the treatment of advanced colorectal cancer: A systematic review and meta-analysis.
    Medicine, 2021, Jul-30, Volume: 100, Issue:30

    Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2021
Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2022, Volume: 34, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; British Columbia; Camptothecin; Cohort

2022
Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis.
    Medicine, 2017, Volume: 96, Issue:12

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neopla

2017
[Cetuximab in association with an oxaliplatin-based chemotherapy as first-line treatment of metastatic colorectal cancer.]
    Recenti progressi in medicina, 2017, Volume: 108, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Fluorouracil; Human

2017
FOLFOXIRI Regimen for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Clinical colorectal cancer, 2017, Volume: 16, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Sur

2017
FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.
    JAMA oncology, 2017, Jul-13, Volume: 3, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu

2017
Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2017, Volume: 43, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Chemical and D

2017
Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis.
    Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:1

    Topics: Administration, Oral; Antineoplastic Agents; Colorectal Neoplasms; Databases, Bibliographic; Disease

2018
Oral versus intravenous fluoropyrimidines for colorectal cancer.
    The Cochrane database of systematic reviews, 2017, Jul-28, Volume: 7

    Topics: Administration, Oral; Adult; Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuva

2017
Combination adjuvant chemotherapy with targeted drugs for treatment of colorectal cancer: A network meta-analysis.
    Journal of cellular biochemistry, 2018, Volume: 119, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Campt

2018
The paradigm of tumor shrinkage and rapid liver remnant hypertrophy for conversion of initially unresectable colorectal liver metastasis: a case report and literature review.
    World journal of surgical oncology, 2017, Aug-03, Volume: 15, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Carcinoma; C

2017
Prognosis and treatment of FOLFOX therapy related interstitial pneumonia: a plea for multimodal immune modulating therapy in the respiratory insufficient patient.
    BMC cancer, 2017, Aug-29, Volume: 17, Issue:1

    Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms;

2017
Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis.
    Critical reviews in oncology/hematology, 2017, Volume: 118

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2017
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
    JAMA oncology, 2018, Mar-01, Volume: 4, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brai

2018
Current status and future prospective of Curcumin as a potential therapeutic agent in the treatment of colorectal cancer.
    Journal of cellular physiology, 2018, Volume: 233, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Curcumin; Fluorouraci

2018
Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2018, Volume: 26, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal

2018
Efficacy and safety of FOLFIRI and biotherapy versus FOLFIRI alone for metastatic colorectal cancer patients: A meta-analysis.
    Medicine, 2017, Volume: 96, Issue:48

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Camptothecin; Colorectal Neoplas

2017
Hepatobiliary phase liver MR imaging findings after Oxaliplatin-based chemotherapy in cancer patients.
    Abdominal radiology (New York), 2018, Volume: 43, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical and Dru

2018
A systematic review of the safety profile of the different combinations of fluoropyrimidines and oxaliplatin in the treatment of colorectal cancer patients.
    Critical reviews in oncology/hematology, 2018, Volume: 122

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F

2018
[Metastatic colorectal cancer: To stop or not to stop?]
    Bulletin du cancer, 2018, Volume: 105, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo

2018
FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Medicine, 2018, Volume: 97, Issue:10

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; C

2018
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
    British journal of cancer, 2018, Volume: 118, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin;

2018
Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients.
    International journal of colorectal disease, 2018, Volume: 33, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasm

2018
Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment?
    Future oncology (London, England), 2018, Volume: 14, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Hypoxia; Colorectal Neoplasms; Disea

2018
Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy.
    Journal of cancer research and clinical oncology, 2018, Volume: 144, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2018
New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer.
    International journal of medical sciences, 2018, Volume: 15, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum

2018
Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 48, Issue:5

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin;

2018
New Trends in Liposome-based Drug Delivery in Colorectal Cancer.
    Mini reviews in medicinal chemistry, 2019, Volume: 19, Issue:1

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Colon; Colorectal Neoplasms; Drug Delivery

2019
The role of microRNAs in 5-FU resistance of colorectal cancer: Possible mechanisms.
    Journal of cellular physiology, 2019, Volume: 234, Issue:3

    Topics: Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplasti

2019
Recent advances in understanding colorectal cancer.
    F1000Research, 2018, Volume: 7

    Topics: Antibodies; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Microsatellite Instability;

2018
Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
    Current treatment options in oncology, 2018, 11-27, Volume: 19, Issue:12

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Fluorour

2018
Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2018, Volume: 32, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brazil; Cetuximab; Colorectal Neoplasms

2018
Current Evidence on miRNAs as Potential Theranostic Markers for Detecting Chemoresistance in Colorectal Cancer: A Systematic Review and Meta-Analysis of Preclinical and Clinical Studies.
    Molecular diagnosis & therapy, 2019, Volume: 23, Issue:1

    Topics: Biomarkers, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; MicroRNAs;

2019
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3.
    International journal of cancer, 2019, 10-15, Volume: 145, Issue:8

    Topics: AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarke

2019
FOLFOXIRI plus biologics in advanced colorectal cancer.
    Expert opinion on biological therapy, 2019, Volume: 19, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm

2019
Efficacy and safety assessment of S-1-based regimens comparing to intravenous fluorouracil-based ones in Asian patients with metastatic colorectal carcinoma: A system review and meta-analysis.
    Medicine, 2019, Volume: 98, Issue:23

    Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian Peop

2019
Efficacy and safety of high-dose vs low-dose leucovorin in patients with colorectal cancer: systematic review and meta-analysis.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2020, Volume: 22, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorect

2020
[Oxaliplatin in colorectal carcinoma: from palliation to cure].
    Onkologie, 2004, Volume: 27 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co

2004
New oxaliplatin-based combinations in the treatment of colorectal cancer.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2003, Volume: 5 Suppl 3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boro

2003
The evolving role of oxaliplatin in the management of colorectal cancer.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2003, Volume: 5 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2003
OncoSurge: a strategy for long-term survival in metastatic colorectal cancer.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2003, Volume: 5 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

2003
An integrated analysis of the association between Ts gene polymorphisms and clinical outcome in gastric and colorectal cancer patients treated with 5-FU-based regimens.
    Molecular biology reports, 2013, Volume: 40, Issue:7

    Topics: Alleles; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2013
Adenocarcinoma of the colon in children: case series and mini-review of the literature.
    Hematology/oncology and stem cell therapy, 2013, Volume: 6, Issue:1

    Topics: Abdomen; Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Barium Sulfate;

2013
FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials.
    Clinical colorectal cancer, 2013, Volume: 12, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2013
Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
    Onkologie, 2013, Volume: 36, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2013
Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.
    Cancer science, 2013, Volume: 104, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2013
Chemotherapeutic options for colorectal cancer patients with cardiovascular diseases.
    Reviews on recent clinical trials, 2013, Volume: 8, Issue:2

    Topics: Antineoplastic Agents; Cardiovascular Diseases; Colorectal Neoplasms; Fluorouracil; Global Health; H

2013
DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.
    Pharmacogenomics, 2013, Volume: 14, Issue:11

    Topics: Alleles; Alternative Splicing; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug-Relate

2013
Options for metastatic colorectal cancer beyond the second line of treatment.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2014
Methods of overcoming treatment resistance in colorectal cancer.
    Critical reviews in oncology/hematology, 2014, Volume: 89, Issue:2

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

2014
Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.
    Expert opinion on drug safety, 2014, Volume: 13, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Enzyme Inhibito

2014
Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer.
    Expert review of anticancer therapy, 2013, Volume: 13, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; M

2013
Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy.
    International heart journal, 2013, Volume: 54, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Cardiomyopathies; Colorectal Neoplasm

2013
FOLFOX 4 combined with herbal medicine for advanced colorectal cancer: a systematic review.
    Phytotherapy research : PTR, 2014, Volume: 28, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

2014
Raltitrexed-based chemotherapy for advanced colorectal cancer.
    Clinics and research in hepatology and gastroenterology, 2014, Volume: 38, Issue:2

    Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Chemical and Drug Induce

2014
Capecitabine plus irinotecan versus 5-FU/leucovorin plus irinotecan in the treatment of colorectal cancer: a meta-analysis.
    Clinical colorectal cancer, 2014, Volume: 13, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De

2014
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-01, Volume: 32, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; D

2014
How folate metabolism affects colorectal cancer development and treatment; a story of heterogeneity and pleiotropy.
    Cancer letters, 2015, Jan-28, Volume: 356, Issue:2 Pt A

    Topics: Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Folic Acid; Folic Acid Antagonists;

2015
Sequencing of treatment in metastatic colorectal cancer: where to fit the target.
    World journal of gastroenterology, 2014, Feb-28, Volume: 20, Issue:8

    Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anti

2014
A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

2014
A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.
    Cancer treatment reviews, 2014, Volume: 40, Issue:6

    Topics: Alanine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth

2014
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
    World journal of gastroenterology, 2014, Apr-14, Volume: 20, Issue:14

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas

2014
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
    World journal of gastroenterology, 2014, Apr-14, Volume: 20, Issue:14

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas

2014
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
    World journal of gastroenterology, 2014, Apr-14, Volume: 20, Issue:14

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas

2014
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
    World journal of gastroenterology, 2014, Apr-14, Volume: 20, Issue:14

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas

2014
Role of cetuximab in first-line treatment of metastatic colorectal cancer.
    World journal of gastroenterology, 2014, Apr-21, Volume: 20, Issue:15

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

2014
Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.
    World journal of gastroenterology, 2014, Apr-21, Volume: 20, Issue:15

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Dise

2014
Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
    Clinical colorectal cancer, 2014, Volume: 13, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2014
Hypertriglyceridemia and hyperglycemia induced by capecitabine: a report of two cases and review of the literature.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2015, Volume: 21, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Capecitabine; Colorectal Neopl

2015
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
    Angiogenesis, 2014, Volume: 17, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2014
Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?
    World journal of gastroenterology, 2014, May-28, Volume: 20, Issue:20

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine

2014
Use of microRNAs in directing therapy and evaluating treatment response in colorectal cancer.
    Einstein (Sao Paulo, Brazil), 2014, Volume: 12, Issue:2

    Topics: Antineoplastic Agents; Capecitabine; Chemoradiotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidin

2014
A simple technique to estimate best- and worst-case survival in patients with metastatic colorectal cancer treated with chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu

2014
FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.
    World journal of gastroenterology, 2014, Aug-14, Volume: 20, Issue:30

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biotransformation; Camptothecin;

2014
Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.
    The oncologist, 2014, Volume: 19, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2014
Oxaliplatin-induced Lhermitte sign. A case report and review of literature.
    Clinical colorectal cancer, 2014, Volume: 13, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F

2014
Diagnosis and management of DNA mismatch repair-deficient colorectal cancer.
    Hematology/oncology clinics of North America, 2015, Volume: 29, Issue:1

    Topics: Adenoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; C

2015
Meta-analysis comparing the safety and efficacy of metastatic colorectal cancer treatment regimens, capecitabine plus irinotecan (CAPIRI) and 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI).
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De

2015
A review of the evolution of systemic chemotherapy in the management of colorectal cancer.
    Clinical colorectal cancer, 2015, Volume: 14, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug D

2015
The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of
    PharmacoEconomics, 2015, Volume: 33, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Ana

2015
[Molecular pathology of colorectal cancer].
    Der Pathologe, 2015, Volume: 36, Issue:2

    Topics: Adenocarcinoma; Algorithms; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Colorectal

2015
Efficacy of oxaliplatin-based chemotherapy + bevacizumab as first-line treatment for advanced colorectal cancer: a systematic review and pooled analysis of published trials.
    American journal of clinical oncology, 2015, Volume: 38, Issue:2

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape

2015
Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Cardiotoxicity; Chest Pain; Co

2016
Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy.
    BMC cancer, 2015, Mar-21, Volume: 15

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Microsatellite Instabil

2015
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase.
    International journal of molecular sciences, 2015, Apr-21, Volume: 16, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP);

2015
Microsatellite instability testing and its role in the management of colorectal cancer.
    Current treatment options in oncology, 2015, Volume: 16, Issue:7

    Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo

2015
Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
    International journal of colorectal disease, 2015, Volume: 30, Issue:10

    Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2015
MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer.
    Cell proliferation, 2015, Volume: 48, Issue:5

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Therapy, Combinat

2015
[Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
    Bulletin du cancer, 2015, Volume: 102, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Camptoth

2015
Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; C

2015
Individual 5-Fluorouracil Dose Adjustment via Pharmacokinetic Monitoring Versus Conventional Body-Area-Surface Method: A Meta-Analysis.
    Therapeutic drug monitoring, 2016, Volume: 38, Issue:1

    Topics: Antimetabolites, Antineoplastic; Body Surface Area; Colorectal Neoplasms; Dose-Response Relationship

2016
Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district.
    Tumori, 2016, Nov-11, Volume: 102, Issue:Suppl. 2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cam

2016
Maintenance Therapy in Colorectal Cancer: Moving the Artillery Down While Keeping an Eye on the Enemy.
    Clinical colorectal cancer, 2016, Volume: 15, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin;

2016
Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer.
    Expert review of anticancer therapy, 2015, Volume: 15, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal

2015
Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.
    Clinical colorectal cancer, 2016, Volume: 15, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bev

2016
Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion.
    Health technology assessment (Winchester, England), 2015, Volume: 19, Issue:91

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Mo

2015
TAS-102: a novel antimetabolite for the 21st century.
    Future oncology (London, England), 2016, Volume: 12, Issue:2

    Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto

2016
Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy.
    European review for medical and pharmacological sciences, 2015, Volume: 19, Issue:22

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou

2015
Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colonic Neopla

2016
Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer.
    Critical reviews in oncology/hematology, 2016, Volume: 100

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colore

2016
XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis.
    Cancer investigation, 2016, Volume: 34, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chi-Square Distribution; Colorectal Ne

2016
Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases.
    BMC cancer, 2016, Feb-10, Volume: 16

    Topics: Bevacizumab; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hepatic Veno-Occlusive D

2016
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.
    The Cochrane database of systematic reviews, 2016, Feb-12, Volume: 2

    Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combine

2016
Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.
    Cancer treatment reviews, 2016, Volume: 45

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Campt

2016
Chinese Herbal Medicine and Fluorouracil-Based Chemotherapy for Colorectal Cancer: A Quality-Adjusted Meta-Analysis of Randomized Controlled Trials.
    Integrative cancer therapies, 2016, Volume: 15, Issue:3

    Topics: Colorectal Neoplasms; Complementary Therapies; Drugs, Chinese Herbal; Fluorouracil; Humans; Phytothe

2016
Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.
    Pharmacogenomics, 2016, Volume: 17, Issue:7

    Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; DNA Repair; DNA-Binding Proteins; Endonuc

2016
Mitomycin-C+fluoropyrimidines in heavily pretreated metastatic colorectal cancer: a systematic review and evidence synthesis.
    Anti-cancer drugs, 2016, Volume: 27, Issue:6

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorecta

2016
Liver Metastases in Colorectal Cancer.
    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2016, Volume: 35

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit

2016
Network meta-analysis of Chinese herb injections combined with FOLFOX chemotherapy in the treatment of advanced colorectal cancer.
    Journal of clinical pharmacy and therapeutics, 2016, Volume: 41, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Colorectal Neoplasms; Drugs, Chinese

2016
Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
    Discovery medicine, 2016, Volume: 21, Issue:117

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, T

2016
Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review.
    BMC cancer, 2016, 07-25, Volume: 16

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans;

2016
Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Clinical colorectal cancer, 2017, Volume: 16, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasm

2017
Selective internal radiation therapy for liver metastases from colorectal cancer.
    Cancer treatment reviews, 2016, Volume: 50

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Surv

2016
Unresectable liver metastases in colorectal cancer: review of current strategies.
    Minerva chirurgica, 2016, Volume: 71, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols

2016
Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis.
    Medicine, 2016, Volume: 95, Issue:46

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu

2016
Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded).
    Bulletin du cancer, 2017, Volume: 104, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization; Colorectal Neoplasms;

2017
Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients.
    International journal of molecular sciences, 2017, Jan-06, Volume: 18, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Colon; Colorectal Neoplasms; DNA Mismatch Repair; Fluorour

2017
Colorectal Cancer Chemotherapy: The Evolution of Treatment and New Approaches.
    Current medicinal chemistry, 2017, Volume: 24, Issue:15

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Coordination Complexes; DNA Damage; Drug Ther

2017
Second-line systemic therapy for metastatic colorectal cancer.
    The Cochrane database of systematic reviews, 2017, 01-27, Volume: 1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co

2017
Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer.
    Nature clinical practice. Oncology, 2008, Volume: 5, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De

2008
[Current therapeutic options for liver metastasis].
    Revista medica de Chile, 2008, Volume: 136, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Catheter Ablation; Colorect

2008
FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature.
    Cancer investigation, 2008, Volume: 26, Issue:6

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highl

2008
Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer?
    Clinical colorectal cancer, 2008, Volume: 7, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F

2008
Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.
    Philosophical transactions. Series A, Mathematical, physical, and engineering sciences, 2008, Oct-13, Volume: 366, Issue:1880

    Topics: Animals; Antineoplastic Agents; Biological Clocks; Cell Cycle; Circadian Rhythm; Colorectal Neoplasm

2008
Regional chemotherapy for liver-limited metastatic colorectal cancer.
    Clinical colorectal cancer, 2008, Volume: 7, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo

2008
[Molecular targets for colon cancer. VEGF, EGFR - and what else?].
    Der Pathologe, 2008, Volume: 29 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capec

2008
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
    European radiology, 2009, Volume: 19, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colore

2009
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
    European radiology, 2009, Volume: 19, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colore

2009
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
    European radiology, 2009, Volume: 19, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colore

2009
Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.
    European radiology, 2009, Volume: 19, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colore

2009
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-20, Volume: 26, Issue:36

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

2008
[Colorectal carcinoma--primary treatment in case of advanced metastization].
    Onkologie, 2008, Volume: 31 Suppl 5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Le

2008
Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.
    Journal of hepato-biliary-pancreatic surgery, 2009, Volume: 16, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit

2009
MicroRNA and colorectal cancer.
    World journal of surgery, 2009, Volume: 33, Issue:4

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; CpG Islands; Down-Regulation; Fluorouracil; G

2009
First-line therapeutic strategies in metastatic colorectal cancer.
    Oncology (Williston Park, N.Y.), 2008, Nov-30, Volume: 22, Issue:13

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2008
Treatment of colorectal liver metastases: a review.
    Reviews on recent clinical trials, 2009, Volume: 4, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasm

2009
Role of pharmacogenetics as predictive biomarkers of response and/or toxicity in the treatment of colorectal cancer.
    Clinical colorectal cancer, 2009, Volume: 8, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms

2009
Capecitabine plus oxaliplatin vs fluorouracil plus oxaliplatin as first line treatment for metastatic colorectal caner - meta-analysis of six randomized trials.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2010, Volume: 12, Issue:1

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl

2010
The role of targeted therapy in the treatment of advanced colorectal cancer.
    Current treatment options in oncology, 2008, Volume: 9, Issue:4-6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
    Acta chirurgica Iugoslavica, 2008, Volume: 55, Issue:4

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2008
Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
    Anti-cancer drugs, 2009, Volume: 20, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C

2009
Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases.
    The Lancet. Oncology, 2009, Volume: 10, Issue:3

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Fatty Liver; Fluorouracil; Humans; Liver; Liver Neoplas

2009
The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.
    Revista espanola de enfermedades digestivas, 2009, Volume: 101, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant

2009
Microsatellite instability: a predictive marker in metastatic colorectal cancer?
    Targeted oncology, 2009, Volume: 4, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Clinical Trials as

2009
Chemotherapy for colorectal cancer in the elderly: Whom to treat and what to use.
    Cancer treatment reviews, 2009, Volume: 35, Issue:3

    Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2009
A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
    Surgical oncology, 2010, Volume: 19, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2010
[Colorectal cancers: prognostic and predictive factors of response to treatment].
    Bulletin du cancer, 2009, Volume: 96, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetu

2009
Second-line chemotherapy in advanced and metastatic CRC.
    The Cochrane database of systematic reviews, 2009, Apr-15, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop

2009
Thymidylate synthase gene variations: predictive and prognostic markers.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:5

    Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Fluorouracil; Gene Express

2009
What's new in ... colorectal cancer. Meaningful progress in therapy options.
    JAAPA : official journal of the American Academy of Physician Assistants, 2009, Volume: 22, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop

2009
A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned?
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:11

    Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; DNA Mismatch

2009
Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2010, Volume: 12, Issue:7

    Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Dru

2010
Genetic prognostic and predictive markers in colorectal cancer.
    Nature reviews. Cancer, 2009, Volume: 9, Issue:7

    Topics: beta Catenin; Biomarkers, Tumor; Camptothecin; Capecitabine; Chromosomes, Human, Pair 18; Colorectal

2009
[Chemotherapy of elderly patients with colorectal cancer].
    Magyar onkologia, 2009, Volume: 53, Issue:2

    Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant

2009
Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer.
    The Cochrane database of systematic reviews, 2009, Jul-08, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

2009
A novel K-ras mutation in colorectal cancer. A case report and literature review.
    Anticancer research, 2009, Volume: 29, Issue:8

    Topics: Adenocarcinoma, Mucinous; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineop

2009
Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512).
    Expert opinion on investigational drugs, 2009, Volume: 18, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Cli

2009
Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer.
    World journal of gastroenterology, 2009, Aug-21, Volume: 15, Issue:31

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2009
KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?
    European journal of cancer care, 2010, Volume: 19, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2010
Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer.
    Cancer treatment reviews, 2009, Volume: 35, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy,

2009
Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144.
    Clinical colorectal cancer, 2009, Volume: 8, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother

2009
Chemotherapy, which drugs and when.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45 Suppl 1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; C

2009
[The development of the first line treatment of metastatic colorectal cancer (mCRC)].
    Magyar onkologia, 2009, Volume: 53, Issue:3

    Topics: Administration, Oral; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Human

2009
Selective internal radiation therapy for liver metastases from colorectal cancer.
    The Cochrane database of systematic reviews, 2009, Oct-07, Issue:4

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Floxuridine; Fluor

2009
[Pathological diagnosis for individualized therapy of colorectal cancer].
    Der Pathologe, 2010, Volume: 31, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2010
[Chemotherapy for colorectal cancer].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2009, Volume: 54, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cetux

2009
[Impact of mutational status of KRAS in the care of patients with colorectal cancer metastasis].
    Bulletin du cancer, 2009, Volume: 96 Suppl

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2009
[Expression of dihydropyrimidine dehydrogenase in primary colorectal cancer and liver metastasis--a relationship between mRNA levels in cancer cells and protein levels in cancerous tissue and effect of 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Enzyme-Li

2009
Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2011, Volume: 13, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans

2011
A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2011, Volume: 13, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2011
Duration of adjuvant chemotherapy for patients with non-metastatic colorectal cancer.
    The Cochrane database of systematic reviews, 2010, Jan-20, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Color

2010
Evolution of capecitabine dosing in colorectal cancer.
    Clinical colorectal cancer, 2010, Volume: 9, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabi

2010
Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview.
    Nutrition and cancer, 2009, Volume: 61, Issue:6

    Topics: Adenoma; Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combine

2009
Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
    American journal of clinical oncology, 2010, Volume: 33, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin;

2010
Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer.
    Expert review of pharmacoeconomics & outcomes research, 2010, Volume: 10, Issue:2

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cost Sa

2010
Surgical therapies in metastatic colorectal cancer with a potential for cure.
    American journal of clinical oncology, 2011, Volume: 34, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N

2011
Meta-analysis of chemotherapy with irinotecan or oxaliplatin-involved regimen for untreated metastatic advanced colorectal cancer.
    Oncology research, 2010, Volume: 18, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progress

2010
[Transition of chemotherapy for metastatic colorectal cancer and recent advances].
    Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2010
Microsatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival data.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:15

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans;

2010
[Recent developments of pharmacogenomics in the treatment of colorectal cancers].
    Annales pharmaceutiques francaises, 2010, Volume: 68, Issue:4

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Biotr

2010
Meta-analysis: perioperative regional liver chemotherapy for improving survival and preventing liver metastases in patients with colorectal carcinoma.
    Journal of digestive diseases, 2010, Volume: 11, Issue:4

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hepa

2010
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.
    Transactions of the American Clinical and Climatological Association, 2010, Volume: 121

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2010
Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2010, Volume: 12, Issue:8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop

2010
Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer.
    Critical reviews in oncology/hematology, 2011, Volume: 79, Issue:3

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Ch

2011
Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope?
    Clinical colorectal cancer, 2010, Volume: 9, Issue:4

    Topics: Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Colorectal Neoplasms; Dihydropyrimidin

2010
Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
    Clinical colorectal cancer, 2010, Volume: 9, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De

2010
Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2011, Volume: 17, Issue:3

    Topics: Adenocarcinoma; Age Factors; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Cap

2011
Capecitabine-based chemotherapy for metastatic colorectal cancer.
    Journal of cancer research and clinical oncology, 2011, Volume: 137, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De

2011
Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection.
    Critical reviews in oncology/hematology, 2011, Volume: 79, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Camptothecin; Chemotherapy, Adju

2011
Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
    Health technology assessment (Winchester, England), 2010, Volume: 14, Issue:Suppl. 2

    Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetab

2010
Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
    Oncology, 2010, Volume: 79, Issue:1-2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2010
Update on capecitabine alone and in combination regimens in colorectal cancer patients.
    Cancer treatment reviews, 2010, Volume: 36 Suppl 3

    Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, An

2010
Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
    Chinese medical journal, 2010, Volume: 123, Issue:22

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop

2010
Chemotherapy of metastatic colorectal cancer.
    Prescrire international, 2010, Volume: 19, Issue:109

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neo

2010
XELOX in colorectal cancer: a convenient option for the future?
    Expert review of gastroenterology & hepatology, 2011, Volume: 5, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials

2011
Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:12

    Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Huma

2011
5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F

2012
Adjuvant treatment of colon cancer: what is next?
    Current opinion in oncology, 2011, Volume: 23, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2011
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-10, Volume: 29, Issue:20

    Topics: Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo

2011
Biomarker-based selection of therapy for colorectal cancer.
    Biomarkers in medicine, 2011, Volume: 5, Issue:3

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers; Capecitabine; Colorectal Neoplasms; Deoxy

2011
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined

2011
Colorectal cancer treatment.
    BMJ clinical evidence, 2010, Apr-27, Volume: 2010

    Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Intestinal Ob

2010
Common side effects and interactions of colorectal cancer therapeutic agents.
    The Journal of practical nursing, 2011,Spring, Volume: 61, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2011
Evolution of systemic therapy for metastatic colorectal cancer.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2011, Volume: 13, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2011
Unilateral hand-foot syndrome: does it take sides? Case report and literature review.
    Clinical colorectal cancer, 2012, Volume: 11, Issue:1

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Ha

2012
Bevacizumab in metastatic colorectal cancer and carcino-embryonic antigen kinetics: case report and review of literature.
    Anti-cancer drugs, 2011, Volume: 22 Suppl 2

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biom

2011
DNA copy number profiles correlate with outcome in colorectal cancer patients treated with fluoropyrimidine/antifolate-based regimens.
    Current drug metabolism, 2011, Volume: 12, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop

2011
[State of art of the radiofrequency ablation of colorectal liver metastases].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Catheter Ablation; Colorec

2011
Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.
    Cancer treatment reviews, 2012, Volume: 38, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2012
A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases.
    Annals of surgical oncology, 2012, Volume: 19, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2012
Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies.
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2011, Volume: 14, Issue:6

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neopl

2011
Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Nov-01, Volume: 29, Issue:31

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2011
[Neoadjuvant therapy concepts for liver metastases].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2011, Volume: 82, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2011
[Is there alternative to FOLFOX adjuvant chemotherapy for stage III colorectal cancer patients?].
    Presse medicale (Paris, France : 1983), 2012, Volume: 41, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Choice Behav

2012
Oxaliplatin: a review of approved uses.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:1

    Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Therapy, Combination;

2012
Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer.
    Scandinavian journal of gastroenterology, 2012, Volume: 47, Issue:3

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Clinical Trials as Topic; Colorectal Neoplas

2012
Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives.
    Scandinavian journal of gastroenterology, 2012, Volume: 47, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Campt

2012
[Chemotherapy for advanced colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 3

    Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Molecul

2011
[A review of FOLFOXIRI chemotherapy for the 1st line treatment of metastatic colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2011
[Current view and possibilities of chemotherapy sensitivity and resistance assays and metabolic enzyme analysis in individualized chemotherapy for the patients with colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 3

    Topics: Aged; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouracil; Humans; Male; Mi

2011
[FOLFOX-related hypersensitivity reactions: clinical presentation and management].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Hypersensitivity; Fluorou

2011
A preclinical and clinical review of aflibercept for the management of cancer.
    Cancer treatment reviews, 2012, Volume: 38, Issue:5

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemother

2012
Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis.
    Pharmacogenetics and genomics, 2012, Volume: 22, Issue:4

    Topics: Capecitabine; Colorectal Neoplasms; Databases, Genetic; Deoxycytidine; Fluorouracil; Folic Acid; Gen

2012
Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
    Clinical colorectal cancer, 2012, Volume: 11, Issue:3

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hu

2012
Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups.
    BMC cancer, 2012, Mar-13, Volume: 12

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2012
[Fluorouracil implants for colorectal cancer: a systematic review and meta-analysis].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2012, Volume: 15, Issue:4

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans; Randomized Controlled Trials as T

2012
Chemotherapy and molecular-targeted treatment for unresectable hepatic metastases: a Japanese perspective.
    Journal of hepato-biliary-pancreatic sciences, 2012, Volume: 19, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2012
Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2012
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Circadian Clocks; Colorectal Ne

2012
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
    BMC cancer, 2012, Aug-16, Volume: 12

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2012
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
    BMC cancer, 2012, Aug-16, Volume: 12

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2012
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
    BMC cancer, 2012, Aug-16, Volume: 12

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2012
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
    BMC cancer, 2012, Aug-16, Volume: 12

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2012
Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.
    Oncology, 2012, Volume: 83, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2012
Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice.
    Journal of Zhejiang University. Science. B, 2012, Volume: 13, Issue:9

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms

2012
Colorectal liver metastases.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2013, Volume: 17, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablati

2013
Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.
    Molecular diagnosis & therapy, 2012, Volume: 16, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2012
Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis.
    World journal of gastroenterology, 2012, Oct-14, Volume: 18, Issue:38

    Topics: Adult; Aged; Anaphylaxis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Col

2012
Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
    Clinical colorectal cancer, 2013, Volume: 12, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cardiovascular Agents; Colorectal Neoplasms;

2013
Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer.
    Surgery today, 2013, Volume: 43, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo

2013
[Colorectal carcinoma: what's new?].
    Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:49

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectomy; Col

2012
Role of microsatellite instability in the management of colorectal cancers.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Volume: 45, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Colore

2013
Oncological management of unresectable liver metastases.
    Digestive diseases (Basel, Switzerland), 2012, Volume: 30 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2012
[Modified FOLFOX6(mFOLFOX6)in metastatic colorectal carcinoma patients with poor performance status].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans;

2012
FOLFIRI + bevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2013
Therapeutic advances in the management of metastatic colorectal cancer.
    Expert review of anticancer therapy, 2001, Volume: 1, Issue:2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colo

2001
The role of genomic instabilities in affecting treatment responses of colorectal cancer.
    Digestive diseases (Basel, Switzerland), 2002, Volume: 20, Issue:1

    Topics: Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Hum

2002
Chemotherapy for metastatic colorectal cancer.
    Drug and therapeutics bulletin, 2002, Volume: 40, Issue:7

    Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoplas

2002
Targeting vascular endothelial growth factor in colorectal cancer.
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:8 Suppl 7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2002
Adjuvant therapy of colorectal cancer: the next step forward.
    Current medical research and opinion, 2002, Volume: 18, Issue:5

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Fluo

2002
[Review of comparative studies of postoperative adjuvant chemotherapy after curatively resected colorectal cancer in Japan].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A

2002
Regional therapy of hepatic metastases.
    Hematology/oncology clinics of North America, 2002, Volume: 16, Issue:4

    Topics: Antineoplastic Agents; Catheter Ablation; Colorectal Neoplasms; Cryosurgery; Embolization, Therapeut

2002
Chemotherapy in colorectal cancer: new options and new challenges.
    British medical bulletin, 2002, Volume: 64

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms

2002
The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
    Seminars in oncology, 2002, Volume: 29, Issue:5 Suppl 15

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop

2002
Recommendation for irinotecan, 5-fluorouracil, and leucovorin as first-line therapy for colorectal cancer.
    Clinical colorectal cancer, 2001, Volume: 1, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N

2001
Irinotecan/5-FU/leucovorin, oxaliplatin/5-FU/leucovorin, and oxaliplatin/irinotecan are each effective in the treatment of 5-FU-resistant advanced colorectal cancer.
    Clinical colorectal cancer, 2001, Volume: 1, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II

2001
Review of the role of CPT-11 in the treatment of colorectal cancer.
    Clinical colorectal cancer, 2001, Volume: 1, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N

2001
Oral fluoropyrimidine treatment of colorectal cancer.
    Clinical colorectal cancer, 2001, Volume: 1, Issue:2

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials

2001
Advances in the treatment of metastatic colorectal cancer.
    Clinical colorectal cancer, 2001, Volume: 1, Issue:1

    Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cancer Vaccines;

2001
Thymidylate synthase: a critical target for cancer chemotherapy.
    Clinical colorectal cancer, 2002, Volume: 1, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

2002
Adjuvant therapy of colon cancer: a review.
    Clinical colorectal cancer, 2002, Volume: 1, Issue:4

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy,

2002
Thymidylate synthase pharmacogenetics in colorectal cancer.
    Clinical colorectal cancer, 2001, Volume: 1, Issue:3

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Huma

2001
Capecitabine (Xeloda): from the laboratory to the patient's home.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:1

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, P

2002
Lack of benefit of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer with microsatellite instability.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:3

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Genetic

2002
Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2002
[Progress in adjuvant therapy for colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A

2002
Current status of capecitabine in the treatment of colorectal cancer.
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:12 Suppl N

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherap

2002
Can capecitabine replace 5-FU/leucovorin in combination with oxaliplatin for the treatment of advanced colorectal cancer?
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:12 Suppl N

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials

2002
Complications of hepatic artery infusion: a review of 4580 reported cases.
    International journal of gastrointestinal cancer, 2001, Volume: 30, Issue:3

    Topics: Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Bone Marrow Diseases; Catheters, Indwe

2001
[The role of the regional (intra-arterial) chemotherapy in the treatment of hepatic metastases of colorectal cancer].
    Medicina (Kaunas, Lithuania), 2003, Volume: 39, Issue:1

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

2003
The combination of capecitabine and oxaliplatin in metastatic colorectal cancer.
    Clinical colorectal cancer, 2003, Volume: 2, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic

2003
Predictive markers for colorectal cancer: current status and future prospects.
    Clinical colorectal cancer, 2003, Volume: 2, Issue:4

    Topics: Antineoplastic Agents; Base Pair Mismatch; Biomarkers; Colorectal Neoplasms; Drug Resistance, Neopla

2003
Contribution of meta-analyses to the evaluation of treatments for advanced colorectal cancer.
    Expert review of anticancer therapy, 2002, Volume: 2, Issue:4

    Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Data Interp

2002
[Economic assessment of adjuvant and palliative chemotherapy in colorectal cancer: a review].
    Bulletin du cancer, 2003, Volume: 90, Issue:2

    Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Fra

2003
Palliative treatment of patients with colorectal cancer.
    Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society, 2003, Volume: 92, Issue:1

    Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Disease Progression; Enzyme Inh

2003
[Chemotherapy for colorectal cancers].
    Journal de chirurgie, 2003, Volume: 140, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl

2003
Arterial chemotherapy as adjuvant and palliative treatment of hepatic colorectal metastases: an update.
    Surgical oncology clinics of North America, 2003, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Flox

2003
Hepatic resection after down-staging of unresectable hepatic colorectal metastases.
    Surgical oncology clinics of North America, 2003, Volume: 12, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Liver Neop

2003
Management of colorectal liver metastases.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2003, Volume: 5, Issue:1

    Topics: Antimetabolites, Antineoplastic; Balloon Occlusion; Catheter Ablation; Colorectal Neoplasms; Combine

2003
Irinotecan: promising activity in the treatment of malignant glioma.
    Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:5 Suppl 5

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined

2003
Optimal use of the combination of irinotecan and 5-fluorouracil.
    Seminars in oncology, 2003, Volume: 30, Issue:3 Suppl 6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N

2003
Practical considerations in the use of oral fluoropyrimidines.
    Seminars in oncology, 2003, Volume: 30, Issue:3 Suppl 6

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Color

2003
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14 Suppl 2

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col

2003
Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonography, Computed Tomog

2003
Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antine

2003
Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm

2003
Current treatments and future perspectives in colorectal and gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo

2003
[Oral fluoropyrimidines in the treatment of colorectal carcinoma].
    Deutsche medizinische Wochenschrift (1946), 2003, Jun-13, Volume: 128 Suppl 2

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2003
Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.
    International journal of colorectal disease, 2004, Volume: 19, Issue:1

    Topics: Antimetabolites, Antineoplastic; Carcinoma; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 18

2004
Tailoring chemotherapy in advanced colorectal cancer.
    Current opinion in pharmacology, 2003, Volume: 3, Issue:4

    Topics: Animals; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NAD

2003
Campto effective and flexible chemotherapy for advanced colorectal cancer.
    International journal of palliative nursing, 2003, Volume: 9, Issue:7

    Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2003
Colorectal cancer: integrating oxaliplatin.
    Current treatment options in oncology, 2003, Volume: 4, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; C

2003
[Therapeutic strategies in colorectal cancer].
    Deutsche medizinische Wochenschrift (1946), 2003, Sep-12, Volume: 128, Issue:37

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Color

2003
Current and ongoing trials with irinotecan in the United States.
    Seminars in oncology, 2003, Volume: 30, Issue:4 Suppl 12

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cap

2003
Alternative schedules with irinotecan.
    Seminars in oncology, 2003, Volume: 30, Issue:4 Suppl 12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N

2003
Induction therapy in patients with metastatic colorectal cancer.
    Seminars in oncology, 2003, Volume: 30, Issue:4 Suppl 12

    Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Inf

2003
Review article: colorectal cancer chemotherapy.
    Alimentary pharmacology & therapeutics, 2003, Oct-01, Volume: 18, Issue:7

    Topics: Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Ne

2003
[Controversy of treatment for advanced colorectal cancer--intermedisine].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Cl

2003
Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.
    Seminars in oncology, 2003, Volume: 30, Issue:4 Suppl 15

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl

2003
Pharmacogenomics in colorectal cancer.
    Seminars in oncology, 2003, Volume: 30, Issue:4 Suppl 15

    Topics: Antimetabolites, Antineoplastic; Cisplatin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP)

2003
Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer.
    Anti-cancer drugs, 2003, Volume: 14, Issue:9

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2003
Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule.
    Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:9 Suppl 8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N

2003
[Polymorphism in colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genetic Predisposition to D

2003
[Immunohistologic evaluation of TS, DPD, and p53 protein expression in patients with colorectal cancer having liver and pulmonary metastases].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Liver Neoplasms; Lun

2003
[Adjuvant chemotherapy for colorectal cancer: Its efficacy and problems].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co

2003
[Molecular biological analysis of 5-fluorouracil sensitivity in colorectal neoplasm].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Resi

2003
[Response marker to 5-FU after curative surgery in colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, N

2003
[Application and problems in hepatic arterial infusion chemotherapy].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hep

2003
[Home chemotherapy and outpatient treatment for metastatic colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms;

2003
[Doxifluridine for treatment of colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Floxuridine; Flu

2003
[Intravenous continuous infusion of fluorouracil for treatment of metastatic colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2003
[5-fluorouracil and leucovorin therapy for advanced colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N

2003
[Irinotecan plus fluorouracil and leucovorin for advanced colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N

2003
[Effect of systemic chemotherapy by 5-FU with low dose CDDP (in the hospital) and UFT with low dose CDDP (in outpatient clinic) in unresectable recurrent colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Ne

2003
[Present status of chemotherapy for colorectal cancer in countries outside of Japan].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb

2003
[Toxicities associated with chemotherapy in colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Clinical Trials a

2003
[Complications of hepatic artery chemotherapy for liver metastases in colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Cholangitis, Sclerosing

2003
[Adjuvant chemotherapy for colorectal carcinoma after curative resection].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2003
[Long-term prognosis for colorectal carcinoma treated with adjuvant immunochemotherapy].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Antimetabolites, Antineoplastic; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Cytokin

2003
[Guidance and informed consent in colon cancer therapy].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colorectal Neoplasms; Fluor

2003
[Treatment for recurrent colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

2003
Successful treatment of radiofrequency-induced biliary lesions by interventional endoscopic retrograde cholangiography (ERC).
    Surgical endoscopy, 2003, Volume: 17, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Carcinoma, Hepatocellula

2003
[Treatment of metastatic liver carcinoma: chemotherapy and immunotherapy].
    Nihon Geka Gakkai zasshi, 2003, Volume: 104, Issue:10

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colo

2003
Systemic therapy for colorectal cancer: focus on newer chemotherapy and novel agents.
    Seminars in radiation oncology, 2003, Volume: 13, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant;

2003
Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2003, Volume: 7, Issue:32

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analysis; Deoxycyt

2003
[Chemotherapy for colorectal carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administrat

2003
A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Dec-01, Volume: 9, Issue:16 Pt 1

    Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal Neopla

2003
Integrating oxaliplatin and capecitabine in adjuvant therapy of high-risk colorectal cancer.
    Clinical colorectal cancer, 2003, Volume: 3, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trial

2003
Development of new agents for the treatment of advanced colorectal cancer.
    Clinical colorectal cancer, 2003, Volume: 3, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I

2003
[Palliative therapy of colorectal cancer].
    Onkologie, 2003, Volume: 26 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Dise

2003
[Chemotherapy of advanced colorectal carcinoma: treatment options for elderly patients].
    Onkologie, 2003, Volume: 26 Suppl 7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Top

2003
First-line treatment strategies to improve survival in patients with advanced colorectal cancer.
    Drugs, 2004, Volume: 64, Issue:1

    Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; H

2004
New developments in systemic chemotherapy in advanced colorectal cancer.
    Scandinavian journal of gastroenterology. Supplement, 2003, Issue:239

    Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2003
Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy.
    Drugs & aging, 2004, Volume: 21, Issue:2

    Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy

2004
The role of new agents in the treatment of colorectal cancer.
    Oncology, 2004, Volume: 66, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2004
Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clini

2004
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-01, Volume: 22, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C

2004
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-01, Volume: 22, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C

2004
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-01, Volume: 22, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C

2004
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-01, Volume: 22, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C

2004
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-01, Volume: 22, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C

2004
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-01, Volume: 22, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C

2004
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-01, Volume: 22, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C

2004
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-01, Volume: 22, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C

2004
Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-01, Volume: 22, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C

2004
Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    European journal of cancer (Oxford, England : 1990), 2004, Volume: 40, Issue:7

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; D

2004
[Oral 5-FU and digestive cancers].
    Gastroenterologie clinique et biologique, 2004, Volume: 28, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

2004
Adjuvant therapy for rectal cancer in the elderly.
    Drugs & aging, 2004, Volume: 21, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cli

2004
[Hepatic arterial infusion chemotherapy for colorectal liver metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Ad

2004
[Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C

2004
Systemic treatment of advanced colorectal carcinoma.
    European journal of gastroenterology & hepatology, 2004, Volume: 16, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2004
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Therapy, Co

2004
Current approaches to first-line treatment of advanced colorectal cancer.
    Clinical colorectal cancer, 2004, Volume: 4 Suppl 1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe

2004
Oxaliplatin plus oral fluoropyrimidines in colorectal cancer.
    Clinical colorectal cancer, 2004, Volume: 4 Suppl 1

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2004
Progress in the development of novel treatments for colorectal cancer.
    Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2004
Current strategies in previously untreated advanced colorectal cancer.
    Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; C

2004
Current status of adjuvant therapy for colorectal cancer.
    Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant;

2004
Defining the role of hepatic arterial infusion chemotherapy in metastatic colorectal cancer.
    Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:6

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Floxuridine; Fluorour

2004
Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview.
    Cancer treatment reviews, 2004, Volume: 30, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flo

2004
[New therapy options in colorectal carcinoma].
    Therapeutische Umschau. Revue therapeutique, 2004, Volume: 61, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
[Surgery of liver metastasis from colorectal cancer following irinotecan and 5FU-folinic acid].
    Annales de chirurgie, 2004, Volume: 129 Spec No 2

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Huma

2004
Developments in combination chemotherapy for colorectal cancer.
    Expert review of anticancer therapy, 2004, Volume: 4, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy,

2004
Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2004, Volume: 54 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C

2004
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:9

    Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms;

2004
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:9

    Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms;

2004
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:9

    Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms;

2004
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:9

    Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms;

2004
Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2004, Volume: 8 Suppl 1

    Topics: Activities of Daily Living; Algorithms; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitab

2004
Implementation of capecitabine (Xeloda) into a cancer centre: UK experience.
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2004, Volume: 8 Suppl 1

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Cancer Care Facilities; Cap

2004
Implications of capecitabine (Xeloda) for cancer nursing practice.
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2004, Volume: 8 Suppl 1

    Topics: Administration, Oral; Ambulatory Care; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabi

2004
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Sep-15, Volume: 22, Issue:18

    Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovori

2004
Evidence-based update of chemotherapy options for metastatic colorectal cancer.
    ANZ journal of surgery, 2004, Volume: 74, Issue:9

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Campt

2004
[Advances in palliative and adjuvant chemotherapy of colon cancer].
    Deutsche medizinische Wochenschrift (1946), 2004, Oct-01, Volume: 129, Issue:40

    Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deo

2004
Meta-analysis of new treatment strategies for metastatic colorectal cancer.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2004, Volume: 14, Issue:10

    Topics: Alkyl and Aryl Transferases; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neop

2004
Strategies for palliative care in advanced colorectal cancer.
    Digestive surgery, 2004, Volume: 21, Issue:5-6

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Huma

2004
Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
    Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:9

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine

2004
Pharmacogenomics and colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Repair; Fluorouracil; Gene

2004
Current perspectives in the treatment of metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15 Suppl 4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clini

2004
Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?
    Clinical colorectal cancer, 2004, Volume: 4 Suppl 2

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant

2004
[Adjuvant and palliative anticancer treatment of colon carcinoma in 2004].
    Praxis, 2004, Sep-29, Volume: 93, Issue:40

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop

2004
Which drug combination for colorectal cancer?
    Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:12

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Campt

2004
[Colorectal cancer: current treatment options].
    Zeitschrift fur Gastroenterologie, 2004, Volume: 42, Issue:12

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Colo

2004
Capecitabine: the new generation of fluoropyrimidines in colorectal cancer.
    Expert review of anticancer therapy, 2004, Volume: 4, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clini

2004
[Recent results of irinotecan therapy in colorectal cancer].
    Magyar onkologia, 2004, Volume: 48, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antine

2004
Chemotherapy in metastatic colorectal cancer.
    Techniques in coloproctology, 2004, Volume: 8 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neop

2004
[Second-line chemotherapy for advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administrat

2005
Irinotecan and 5-FU/ leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics.
    Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2004
Systemic therapy for colorectal cancer.
    The New England journal of medicine, 2005, Feb-03, Volume: 352, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2005
Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can).
    Seminars in oncology, 2005, Volume: 32, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Clinical Trials a

2005
Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
    Seminars in oncology, 2005, Volume: 32, Issue:1

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2005
Adjuvant therapy of colon cancer.
    Seminars in oncology, 2005, Volume: 32, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy

2005
Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.
    Seminars in oncology, 2005, Volume: 32, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Campt

2005
Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer.
    Seminars in oncology, 2005, Volume: 32, Issue:1

    Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluor

2005
Perspectives in the treatment of colorectal cancer.
    Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 15

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug

2004
Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
    American journal of pharmacogenomics : genomics-related research in drug development and clinical practice, 2005, Volume: 5, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2005
[Surgical treatment of hepatic metastases of colorectal neoplasms].
    Il Giornale di chirurgia, 2004, Volume: 25, Issue:10

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv

2004
[Colon cancer: molecular markers].
    Deutsche medizinische Wochenschrift (1946), 2005, Apr-08, Volume: 130, Issue:14

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin;

2005
Critical evaluation of current treatments in metastatic colorectal cancer.
    The oncologist, 2005, Volume: 10, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2005
The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2005, Volume: 31, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2005
New combinations in metastatic colorectal cancer: what are our expectations?
    The oncologist, 2005, Volume: 10, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2005
Benefit-risk assessment of irinotecan in advanced colorectal cancer.
    Drug safety, 2005, Volume: 28, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col

2005
Indications and effect on survival of standard chemotherapy in advanced colorectal cancer.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2005, Volume: 165

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl

2005
New chemotherapeutic strategies in colorectal cancer.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2005, Volume: 165

    Topics: Administration, Oral; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neop

2005
Irinotecan-based regimens in the adjuvant therapy of colorectal cancer.
    Clinical colorectal cancer, 2005, Volume: 5 Suppl 1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2005
Clinical management of oxaliplatin-associated neurotoxicity.
    Clinical colorectal cancer, 2005, Volume: 5 Suppl 1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou

2005
Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer.
    Clinical colorectal cancer, 2005, Volume: 5 Suppl 1

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycyti

2005
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:8

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clinical Trials, Phase

2005
The development of clinical research in CRC.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F

2005
Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16 Suppl 4

    Topics: Colorectal Neoplasms; Fluorouracil; Mutation; Predictive Value of Tests; Prognosis; Proto-Oncogene P

2005
Current therapies for advanced colorectal cancer.
    Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2005
Management of advanced colorectal cancer in older patients.
    Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:5

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neo

2005
Capecitabine: effective oral fluoropyrimidine chemotherapy.
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy,

2005
(Neo-)adjuvant treatments in colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2005
The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC).
    European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinic

2005
Role of genomic markers in colorectal cancer treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jul-10, Volume: 23, Issue:20

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Fluorouracil; Gene Exp

2005
Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer.
    Expert opinion on investigational drugs, 2005, Volume: 14, Issue:6

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Drug Delivery System

2005
[Chemotherapy of patients with colorectal carcinoma].
    Nederlands tijdschrift voor geneeskunde, 2005, Jun-25, Volume: 149, Issue:26

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop

2005
Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:2

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2005
Biologic behavior of microsatellite-unstable colorectal cancer and treatment with 5-fluorouracil.
    The Israel Medical Association journal : IMAJ, 2005, Volume: 7, Issue:8

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Microsatellite Repeats;

2005
The treatment of colorectal carcinoma: standard chemotherapy and beyond.
    Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:9

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2004
Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX.
    Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clini

2005
[5-Fluorouracil-induced small bowel toxicity in a patient with colorectal cancer].
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2005, Volume: 7, Issue:8

    Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Ileitis

2005
Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study.
    British journal of cancer, 2005, Oct-17, Volume: 93, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2005
[Molecular biology in clinical cancer research: the example of digestive cancers].
    Revue d'epidemiologie et de sante publique, 2005, Volume: 53, Issue:3

    Topics: Adenocarcinoma; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agen

2005
Advanced colorectal cancer: current treatment and nursing management with economic considerations.
    Clinical journal of oncology nursing, 2005, Volume: 9, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Campt

2005
Metastatic colorectal cancer: is there one standard approach?
    Oncology (Williston Park, N.Y.), 2005, Volume: 19, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2005
Elderly patients with advanced colorectal cancer: which therapy is the safest?
    Expert opinion on drug safety, 2005, Volume: 4, Issue:6

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorecta

2005
A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer.
    British journal of cancer, 2005, Nov-28, Volume: 93, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

2005
Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
    Nature clinical practice. Oncology, 2005, Volume: 2, Issue:11

    Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptot

2005
[Drug therapy of patients with metastatic colorectal cancer].
    Ugeskrift for laeger, 2005, Nov-07, Volume: 167, Issue:45

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents,

2005
Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer.
    Oncology, 2005, Volume: 69 Suppl 3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2005
Managing patients treated with bevacizumab combination therapy.
    Oncology, 2005, Volume: 69 Suppl 3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2005
The future development of bevacizumab in colorectal cancer.
    Oncology, 2005, Volume: 69 Suppl 3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2005
Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.
    Clinical colorectal cancer, 2005, Volume: 5 Suppl 2

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bioma

2005
[Recent progress of chemotherapy for colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N

2005
Capecitabine/Oxaliplatin combinations in advanced colorectal cancer: summary of recent randomized studies.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F

2005
Front-line therapy for advanced colorectal cancer: emphasis on chemotherapy.
    Seminars in oncology, 2005, Volume: 32, Issue:6 Suppl 9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De

2005
The role of bevacizumab as first-line therapy for colon cancer.
    Seminars in oncology, 2005, Volume: 32, Issue:6 Suppl 9

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2005
Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies.
    Annals of surgery, 2006, Volume: 243, Issue:2

    Topics: Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hum

2006
Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe?
    Cancer investigation, 2006, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Col

2006
Chemotherapy for colorectal cancer.
    Digestive surgery, 2005, Volume: 22, Issue:6

    Topics: Antimetabolites, Antineoplastic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neop

2005
Chemo-immunotherapy of colorectal carcinoma: preclinical rationale and clinical experience.
    Investigational new drugs, 2006, Volume: 24, Issue:2

    Topics: Adjuvants, Immunologic; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cancer Vaccines; Cis

2006
Polymorphisms in the thymidylate synthase gene predict response to 5-fluorouracil therapy in colorectal cancer.
    Clinical colorectal cancer, 2006, Volume: 5, Issue:5

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Polymorphism, Genetic;

2006
Use of hyperthermic intraperitoneal chemotherapy (HIPEC) in management of peritoneal carcinomatosis from colorectal origin.
    Surgical technology international, 2005, Volume: 14

    Topics: Antineoplastic Agents; Appendiceal Neoplasms; Carcinoma; Colorectal Neoplasms; Combined Modality The

2005
[Adjuvant chemotherapy for colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug C

2006
Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties.
    Cancer treatment reviews, 2006, Volume: 32, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Chemotherapy, Adjuv

2006
Capecitabine in the treatment of colorectal cancer.
    Future oncology (London, England), 2005, Volume: 1, Issue:2

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Fo

2005
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2006
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2006
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2006
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2006
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2006
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2006
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2006
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2006
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms

2006
[The modern treatment of colorectal cancer. Present and future].
    Orvosi hetilap, 2006, Mar-05, Volume: 147, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, A

2006
Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow.
    Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:5

    Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2006
Predicting the outcome of chemotherapy for colorectal cancer.
    Current opinion in pharmacology, 2006, Volume: 6, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bioma

2006
First- and second-line therapy of metastatic colorectal cancer.
    Expert review of anticancer therapy, 2006, Volume: 6, Issue:6

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug A

2006
[Irinotecan for the treatment of metastatic colorectal cancer].
    Bulletin du cancer, 2006, Volume: 93, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe

2006
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
    British journal of cancer, 2006, Jul-03, Volume: 95, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Ana

2006
Biological agents versus chemotherapy in the treatment of colorectal cancer.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2006
[Capecitabine].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:7

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clini

2006
[Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Cli

2006
[IFL].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit

2006
[Adjuvant treatment of colorectal cancer].
    Bulletin du cancer, 2006, Volume: 93, Issue:7

    Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capeci

2006
Surgical adjuvant therapy for colorectal cancer: current approaches and future directions.
    Annals of surgical oncology, 2006, Volume: 13, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trial

2006
[S-1 as a single agent for colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1

    Topics: Administration, Oral; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2006
Metastatic colorectal cancer: Therapeutic options.
    Current treatment options in oncology, 2006, Volume: 7, Issue:5

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2006
[Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:8

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Dihydrouracil Dehydrogenase

2006
Capecitabine: a new adjuvant option for colorectal cancer.
    Clinical journal of oncology nursing, 2006, Volume: 10, Issue:4

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Cause of Death; Colorectal Neop

2006
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Sep-01, Volume: 24, Issue:25

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptot

2006
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Sep-01, Volume: 24, Issue:25

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptot

2006
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Sep-01, Volume: 24, Issue:25

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptot

2006
Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Sep-01, Volume: 24, Issue:25

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptot

2006
Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
    Clinical colorectal cancer, 2006, Volume: 6, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2006
Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
    Clinical colorectal cancer, 2006, Volume: 6, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2006
Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
    Clinical colorectal cancer, 2006, Volume: 6, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2006
Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
    Clinical colorectal cancer, 2006, Volume: 6, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2006
Update on capecitabine in colorectal cancer.
    The oncologist, 2006, Volume: 11, Issue:9

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxy

2006
Methyl-group metabolism and the response of colorectal cancer to 5-fluorouracil.
    Critical reviews in oncogenesis, 2006, Volume: 12, Issue:1-2

    Topics: Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); DNA Methylation; Fluorouracil; Folic Acid;

2006
Bevacizumab in combination with 5-fluorouracil-based chemotherapy in the second-line treatment of metastatic colorectal cancer.
    Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2006
Bevacizumab in older patients and patients with poorer performance status.
    Seminars in oncology, 2006, Volume: 33, Issue:5 Suppl 10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2006
Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer.
    Seminars in oncology, 2006, Volume: 33, Issue:5 Suppl 10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2006
[Request for a compassionate use of biotherapies in oncology].
    Bulletin du cancer, 2006, Volume: 93, Issue:11

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2006
[Present status and prospect of irinotecan application in adjuvant therapy for colorectal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2006, Volume: 28, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo

2006
[Colorectal liver metastases. Neoadjuvant chemotherapy: aspects of medical and surgical oncology].
    Der Internist, 2007, Volume: 48, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diseas

2007
[Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma].
    Magyar onkologia, 2006, Volume: 50, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2006
Oral capecitabine (Xeloda) in cancer treatment.
    The Nurse practitioner, 2007, Volume: 32, Issue:2

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2007
[Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2006, Volume: 28, Issue:9

    Topics: Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols;

2006
Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
    Journal of clinical pharmacy and therapeutics, 2007, Volume: 32, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites,

2007
Biological therapy update in colorectal cancer.
    Expert opinion on biological therapy, 2007, Volume: 7, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2007
Oxaliplatin in the treatment of colorectal cancer.
    Expert opinion on drug metabolism & toxicology, 2007, Volume: 3, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou

2007
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb

2008
Capecitabine in the treatment of colorectal cancer.
    Expert review of anticancer therapy, 2007, Volume: 7, Issue:6

    Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplas

2007
[Surgery and chemotherapy for colorectal cancer: current status and perspective].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2007, Volume: 104, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colectomy; Col

2007
Systemic chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
    Cancer treatment and research, 2007, Volume: 134

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Clinical Trials as Topic; C

2007
[Pre-operative chemotherapy for patients with hepatic metastases from colorectal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo

2007
Presurgical chemotherapy in patients being considered for liver resection.
    The oncologist, 2007, Volume: 12, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Fluorouraci

2007
[Gemcitabine and digestive carcinomas].
    Bulletin du cancer, 2007, Volume: 94 Spec No Actualites

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl

2007
[Are antiangiogenic antibodies universal for solid tumor?].
    Bulletin du cancer, 2007, Volume: 94 Spec No

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2007
The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.
    European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:17

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2007
Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature.
    Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:5

    Topics: Adult; Antiemetics; Antineoplastic Agents, Phytogenic; Ataxia; Camptothecin; Capecitabine; Central N

2008
[Angiogenesis targeting in gastro-intestinal cancers].
    Bulletin du cancer, 2007, Volume: 94, Issue:7 Suppl

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2007
Treatment of advanced colorectal cancer in the elderly.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2007, Volume: 33 Suppl 2

    Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents;

2007
Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer.
    Pharmacogenomics, 2007, Volume: 8, Issue:11

    Topics: Antimetabolites, Antineoplastic; Biotransformation; Clinical Trials as Topic; Colorectal Neoplasms;

2007
[Progress of chemotherapy in colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2007
The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
    Best practice & research. Clinical gastroenterology, 2007, Volume: 21, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Com

2007
[Palliative chemotherapy and radiotherapy for metastatic colorectal cancer].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2008, Jan-17, Volume: 128, Issue:2

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant

2008
Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
    Expert review of anticancer therapy, 2008, Volume: 8, Issue:2

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials,

2008
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer.
    Clinical colorectal cancer, 2008, Volume: 7, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N

2008
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
    Clinical colorectal cancer, 2008, Volume: 7, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans

2008
Advances in neoadjuvant therapy for colorectal cancer with liver metastases.
    Cancer treatment reviews, 2008, Volume: 34, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N

2008
Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin;

2008
Exploring alternative individualized treatment strategies in colorectal cancer.
    Clinical colorectal cancer, 2007, Volume: 7 Suppl 1

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biological Therapy; Chemotherapy, Adjuvant; Colorecta

2007
Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
    Clinical colorectal cancer, 2007, Volume: 7 Suppl 1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop

2007
Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer.
    Clinical colorectal cancer, 2007, Volume: 7 Suppl 1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2007
[Antibody treatment in colorectal cancer--what the surgeon needs to know].
    Zentralblatt fur Chirurgie, 2008, Volume: 133, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites,

2008
Capecitabine: an overview of the side effects and their management.
    Anti-cancer drugs, 2008, Volume: 19, Issue:5

    Topics: Administration, Oral; Age Factors; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine;

2008
The role of molecular markers in predicting response to therapy in patients with colorectal cancer.
    Molecular diagnosis & therapy, 2008, Volume: 12, Issue:2

    Topics: Algorithms; Antibody-Dependent Cell Cytotoxicity; Biomarkers, Tumor; Chromosomes, Human, Pair 18; Cl

2008
Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence.
    Drugs, 2008, Volume: 68, Issue:7

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2008
The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Health technology assessment (Winchester, England), 2008, Volume: 12, Issue:15

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Ana

2008
Systemic treatment of colorectal cancer.
    Gastroenterology, 2008, Volume: 134, Issue:5

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; ErbB Receptors;

2008
Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group.
    Clinical colorectal cancer, 2008, Volume: 7, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Clinical colorectal cancer, 2008, Volume: 7, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2008
[Pharmacology of regional chemotherapy of colorectal liver metastases].
    Zentralblatt fur Chirurgie, 1995, Volume: 120, Issue:10

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Dose

1995
[Results of resection and adjuvant therapy of liver metastases of primary colorectal tumors--a review of the literature].
    Zentralblatt fur Chirurgie, 1995, Volume: 120, Issue:10

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regiona

1995
Preclinical and clinical aspects of biomodulation of 5-fluorouracil.
    Cancer treatment reviews, 1994, Volume: 20, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Colorectal Neopla

1994
Prolonged infusion of fluorinated pyrimidines in gastrointestinal malignancies: a review of recent clinical trials.
    Cancer investigation, 1994, Volume: 12, Issue:2

    Topics: Carcinoma, Squamous Cell; Circadian Rhythm; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasm

1994
[Chemotherapy and radiochemotherapy of colorectal cancers: adjuvant and palliative therapeutic procedures].
    Leber, Magen, Darm, 1994, Volume: 24, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Color

1994
5-fluorouracil modulation in the chemotherapy of colorectal cancer.
    The Italian journal of gastroenterology, 1994, Volume: 26, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Interfer

1994
[What is the value of arterial chemotherapy in treatment of colorectal liver metastases].
    Langenbecks Archiv fur Chirurgie, 1994, Volume: 379, Issue:6

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Floxu

1994
Biochemical modulation as an approach to reversal of antimetabolite resistance.
    Cancer treatment and research, 1994, Volume: 73

    Topics: Antimetabolites, Antineoplastic; Aspartic Acid; Clinical Trials as Topic; Colorectal Neoplasms; Drug

1994
[Adjuvant and palliative regional therapy of liver metastases in colorectal tumors].
    Deutsche medizinische Wochenschrift (1946), 1995, May-12, Volume: 120, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Region

1995
Metastatic colorectal cancer: advances in biochemical modulation and new drug development.
    Seminars in oncology, 1995, Volume: 22, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Colorectal Neoplasms; Diar

1995
Update on regional treatments for hepatobiliary malignancies.
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular;

1995
[Combined chemotherapy with 5-FU+cis-platin or UFT+cisplatin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Colorectal Neop

1995
[Biomodulation of 5-fluorouracil by interferon].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:8

    Topics: Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Drug Synergism; Drug Therapy, Combination;

1995
Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-alpha: an overview of clinical trials.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:6

    Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Fluor

1995
The role of interferons in the treatment of colorectal cancer.
    Journal of chemotherapy (Florence, Italy), 1993, Volume: 5, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug

1993
Cancers of the large bowel and hepatobiliary tract.
    Cancer chemotherapy and biological response modifiers, 1994, Volume: 15

    Topics: Carcinoma, Hepatocellular; Colorectal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Pancreatic N

1994
Hepatic artery chemotherapy for colorectal liver metastases.
    The Australian and New Zealand journal of surgery, 1995, Volume: 65, Issue:6

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infu

1995
Adjuvant chemotherapy for colorectal cancer.
    Annals of the Royal College of Surgeons of England, 1995, Volume: 77, Issue:2

    Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Levamisole; Neoplasm Staging; Pr

1995
[Treatment of metastases of colorectal cancers].
    La Revue du praticien, 1994, Dec-15, Volume: 44, Issue:20

    Topics: Colorectal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Recurrence, Local

1994
Cytokine-based biotherapy of gastrointestinal tumors.
    The Clinical investigator, 1994, Volume: 72, Issue:7

    Topics: Clinical Trials as Topic; Colorectal Neoplasms; Cytokines; Drug Synergism; Fluorouracil; Gastrointes

1994
Cerebral demyelination with 5-fluorouracil and levamisole.
    Cancer investigation, 1994, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Colorec

1994
The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer.
    British journal of cancer, 1994, Volume: 70, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1994
Current approaches to metastatic colorectal cancer.
    Seminars in oncology, 1994, Volume: 21, Issue:4 Suppl 7

    Topics: Adjuvants, Pharmaceutic; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedul

1994
Chemotherapy for colorectal cancer.
    The New England journal of medicine, 1994, Apr-21, Volume: 330, Issue:16

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine

1994
Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. Advanced Colorectal Cancer Meta-Analysis Project.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu

1994
Biochemical modulation of fluoropyrimidines: the "GISCAD" studies. GISCAD (Italian Group for the Study of Digestive Tract Cancer).
    Advances in experimental medicine and biology, 1993, Volume: 339

    Topics: Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Digestive System

1993
[Targeting therapy of gastric and colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:6

    Topics: Colorectal Neoplasms; Drug Delivery Systems; Fat Emulsions, Intravenous; Fluorouracil; Humans; Infus

1994
Systemic treatment of colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin

1994
Colorectal carcinoma: current problems and future perspectives.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Region

1994
[Problems of randomized controlled study on surgical adjuvant chemotherapy for colorectal cancer in Japan].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co

1993
Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review.
    Cancer investigation, 1994, Volume: 12, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta

1994
Hepatic arterial chemotherapy for metastatic colorectal carcinoma.
    British journal of cancer, 1994, Volume: 69, Issue:2

    Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial;

1994
Folate metabolites as modulators of antitumor drug activity.
    Advances in experimental medicine and biology, 1993, Volume: 338

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Transport; Biotransformation; Cell Line;

1993
What can we learn from a meta-analysis of trials testing the modulation of 5-FU by leucovorin? Advanced Colorectal Meta-analysis Project.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

1993
Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4 Suppl 2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N

1993
Recent advances in the treatment of advanced colorectal cancer.
    Cancer, 1993, Jan-01, Volume: 71, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Drug Administra

1993
Systemic treatment of colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Dr

1993
Unexpected fatal toxicity related to low-dose leucovorin with 5-fluorouracil treatment in metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:2

    Topics: Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Pneumonia, Staphylococcal; Sto

1993
Thymidylate synthase inhibition, a dead end?
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:12

    Topics: Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Therapy, Combination; Fluorou

1995
Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.
    Journal of the National Cancer Institute, 1996, Mar-06, Volume: 88, Issue:5

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Health Care Costs;

1996
Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy.
    Medical and pediatric oncology, 1996, Volume: 26, Issue:5

    Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fl

1996
Biochemical modulation of fluoropyrimidines: is there an optimal (6R,S) leucovorin dose and schedule?
    Journal of the National Cancer Institute, 1996, Apr-03, Volume: 88, Issue:7

    Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neoplasms; Floxuridine; Fluo

1996
Role of chemotherapy for advanced colorectal cancer: new opportunities.
    Seminars in oncology, 1996, Volume: 23, Issue:1 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

1996
Cancers of the large bowel and hepatobiliary tract.
    Cancer chemotherapy and biological response modifiers, 1996, Volume: 16

    Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as

1996
Adjuvant therapy for colorectal cancer--is there a place for a Northern Ireland study?
    The Ulster medical journal, 1994, Volume: 63, Issue:1

    Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colore

1994
[Recent advance in chemotherapy for advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl

1996
[Progress of adjuvant chemotherapy in colon cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin

1996
[Immunotherapy of colorectal cancers].
    Gastroenterologie clinique et biologique, 1996, Volume: 20, Issue:1

    Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; BCG Vaccine; Colore

1996
Combining 5-fluorouracil with interferon-alpha in the treatment of advanced colorectal cancer: optimism followed by disappointment.
    Anti-cancer drugs, 1996, Volume: 7, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as

1996
Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:7

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluor

1996
Biochemical and molecular studies of human methenyltetrahydrofolate synthetase.
    Stem cells (Dayton, Ohio), 1996, Volume: 14, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Carbon-Nitrogen Ligases; Colorectal Neoplasms; Drug Therap

1996
New concepts for the development and use of antifolates.
    Stem cells (Dayton, Ohio), 1996, Volume: 14, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Therapy, Combination; Fluoroura

1996
[Diagnosis and therapy for metastatic liver cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Basement Membrane; Colorectal Neoplasms; Co

1996
How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.
    Medical oncology (Northwood, London, England), 1995, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asp

1995
Intraarterial infusion chemotherapy for unresectable hepatic metastases from colorectal cancer.
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery;

1996
Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature.
    Cancer, 1996, Oct-15, Volume: 78, Issue:8

    Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms;

1996
Intra-hepatic arterial drug delivery.
    Journal of drug targeting, 1996, Volume: 3, Issue:5

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Col

1996
Chronotherapy for gastrointestinal cancers.
    Current opinion in oncology, 1996, Volume: 8, Issue:4

    Topics: Antineoplastic Agents; Chronotherapy; Clinical Trials as Topic; Colorectal Neoplasms; Drug Delivery

1996
Current treatment modalities in advanced colorectal carcinoma.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1996, Volume: 142

    Topics: Colorectal Neoplasms; Fluorouracil; Humans; Interferons; Methotrexate; Prognosis; Quality of Life

1996
Colorectal cancer--an undertreated disease.
    Anti-cancer drugs, 1996, Volume: 7, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv

1996
Hepatic arterial infusion for metastatic colorectal cancer: the price of "success".
    The American journal of gastroenterology, 1996, Volume: 91, Issue:11

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Hu

1996
Infusional 5-FU for advanced colorectal cancer.
    The Journal of infusional chemotherapy, 1995,Fall, Volume: 5, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neop

1995
CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Col

1996
Colorectal cancer: the challenge.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A Suppl 5

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Therapy, Combina

1996
Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: a critical review of comparative studies.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A Suppl 5

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Huma

1996
Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A Suppl 5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chronotherapy; Colorectal Neoplasms; Drug Ad

1996
[Sequential methotrexate and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:14

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr

1996
Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1

    Topics: Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Relationship, Drug;

1997
Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA Damage; DNA, Neoplasm; Drug Resistance; F

1997
The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv

1996
Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. Liver Infusion Meta-analysis Group.
    Journal of the National Cancer Institute, 1997, Apr-02, Volume: 89, Issue:7

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

1997
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: the Royal Marsden Hospital experience.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Esophageal Neoplasms; Fluorouracil; Gastroint

1997
Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:6

    Topics: Antidotes; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Fr

1997
Pre- and/or post-operative immunochemotherapy for advanced digestive cancer.
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colorectal Neopla

1997
The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
    The Journal of infusional chemotherapy, 1996,Fall, Volume: 6, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Clin

1996
The French experience with infusional 5-fluorouracil in advanced colorectal cancer.
    The Journal of infusional chemotherapy, 1996,Summer, Volume: 6, Issue:3

    Topics: Antidotes; Antimetabolites, Antineoplastic; Chronotherapy; Colorectal Neoplasms; Dose-Response Relat

1996
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience.
    The Journal of infusional chemotherapy, 1996,Summer, Volume: 6, Issue:3

    Topics: Ambulatory Care; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Clinical Trials as Topic;

1996
High-dose infusional 5-FU in the treatment of advanced colorectal cancer: a summary of the European experience.
    The Journal of infusional chemotherapy, 1996,Summer, Volume: 6, Issue:3

    Topics: Antidotes; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Res

1996
[Prognostic factors of advanced colorectal cancers].
    La Revue du praticien, 1997, Jun-15, Volume: 47, Issue:12 Spec No

    Topics: Colorectal Neoplasms; Fluorouracil; Genes, p53; Humans; Prognosis

1997
[First line chemotherapy of advanced colorectal cancers].
    La Revue du praticien, 1997, Jun-15, Volume: 47, Issue:12 Spec No

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans

1997
The role of adjuvant radiation therapy in the treatment of colorectal cancer.
    Hematology/oncology clinics of North America, 1997, Volume: 11, Issue:4

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms

1997
The role of adjuvant chemotherapy in the treatment of colorectal cancer.
    Hematology/oncology clinics of North America, 1997, Volume: 11, Issue:4

    Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc

1997
Experimental chemotherapeutic agents for the treatment of colorectal carcinoma.
    Hematology/oncology clinics of North America, 1997, Volume: 11, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as

1997
Colorectal cancer--is there an alternative to 5-FU?
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:4

    Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorect

1997
Chemotherapy for the treatment of patients with metastatic colorectal cancer: an overview.
    World journal of surgery, 1997, Volume: 21, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Flox

1997
[Oxaliplatin: the first DACH platinum in clinical practice].
    Bulletin du cancer, 1997, Volume: 84, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female;

1997
[Chemotherapy of advanced colorectal cancers].
    Annales de chirurgie, 1997, Volume: 51, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chronotherapy; Colorectal Neoplasms; Drug Ad

1997
A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma.
    Cancer, 1997, Oct-01, Volume: 80, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

1997
[Modulation of 5-fluorouracil with folinic acid in advanced colorectal cancers. Groupe d'étude et de recherche sur les cancers de l'ovaire et digestifs (GERCOD)].
    La Revue de medecine interne, 1997, Volume: 18 Suppl 4

    Topics: Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin

1997
The need for a multidisciplinary approach in the treatment of advanced colorectal cancer: a critical review from a medical oncologist and surgeon.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1997, Volume: 23, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Col

1997
[Colorectal cancer: a controllable disease].
    Revue medicale de Bruxelles, 1997, Volume: 18, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv

1997
Chemotherapy of colorectal cancer: history and new themes.
    Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 18

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal

1997
Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin.
    Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 18

    Topics: Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Drug

1997
Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 18

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherap

1997
Biomodulation of 5-fluorouracil with antifolates.
    Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 18

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as

1997
Trimetrexate: review and current clinical experience in advanced colorectal cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:5 Suppl 18

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as

1997
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous;

1998
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous;

1998
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous;

1998
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous;

1998
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous;

1998
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous;

1998
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous;

1998
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous;

1998
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous;

1998
Beyond 5-fluorouracil monochemotherapy in colorectal cancer--it is time.
    Journal of chemotherapy (Florence, Italy), 1997, Volume: 9, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as

1997
Mature results from three large controlled studies with raltitrexed ('Tomudex').
    British journal of cancer, 1998, Volume: 77 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials,

1998
Interferon use in solid tumors.
    Cancer treatment and research, 1998, Volume: 94

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Smal

1998
Biomodulation of Fluorouracil in colorectal cancer.
    Cancer investigation, 1998, Volume: 16, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clin

1998
Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer.
    Seminars in oncology, 1998, Volume: 25, Issue:2 Suppl 5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo

1998
Oxaliplatin for the treatment of advanced colorectal cancer: future directions.
    Seminars in oncology, 1998, Volume: 25, Issue:2 Suppl 5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Col

1998
Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:3

    Topics: Antimetabolites, Antineoplastic; Cell Division; Clinical Trials as Topic; Colorectal Neoplasms; Flox

1998
[Adjuvant therapy of colorectal carcinoma--1998 status].
    Schweizerische medizinische Wochenschrift, 1998, May-16, Volume: 128, Issue:20

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Dose

1998
5-Fluorouracil in colorectal cancer: rationale and clinical results of frequently used schedules.
    Anti-cancer drugs, 1998, Volume: 9, Issue:5

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; H

1998
New drugs in the treatment of colorectal carcinoma.
    Cancer, 1998, Aug-15, Volume: 83, Issue:4

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Campt

1998
A review of GERCOD trials of bimonthly leucovorin plus 5-fluorouracil 48-h continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:5

    Topics: Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, I

1998
Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:8 Suppl 6

    Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorec

1998
[Multidisciplinary treatment for colorectal liver metastases].
    Nihon Geka Gakkai zasshi, 1998, Volume: 99, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu

1998
National Cancer Institute Clinical Trials Program in Colorectal Cancer.
    Cancer chemotherapy and pharmacology, 1998, Volume: 42 Suppl

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplas

1998
[What's new in adjuvant therapy of colorectal cancers?].
    Annales de chirurgie, 1998, Volume: 52, Issue:6

    Topics: Adjuvants, Immunologic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe

1998
Therapy for advanced colorectal cancer.
    Seminars in oncology, 1998, Volume: 25, Issue:5 Suppl 11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo

1998
Is repeated treatment with a 5-fluorouracil-based regimen useful in colorectal cancer?
    Seminars in oncology, 1998, Volume: 25, Issue:5 Suppl 11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Floxuridine; Flu

1998
Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure.
    Seminars in oncology, 1998, Volume: 25, Issue:5 Suppl 11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N

1998
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:11

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma

1998
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:11

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma

1998
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:11

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma

1998
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:11

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma

1998
Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:10 Suppl 7

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

1998
Clinical development of eniluracil: current status.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:10 Suppl 7

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

1998
Oral fluoropyrimidines in the treatment of colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:10

    Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit

1998
[Irinotecan: various administration schedules, study of drug combinations, phase I experience].
    Bulletin du cancer, 1998, Volume: Spec No

    Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc

1998
[Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
    Bulletin du cancer, 1998, Volume: Spec No

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cam

1998
[Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
    Bulletin du cancer, 1998, Volume: Spec No

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothec

1998
[Irinotecan in combination for colon cancer].
    Bulletin du cancer, 1998, Volume: Spec No

    Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; C

1998
Basic research supported developments of chemotherapy in nonresectable isolated colorectal liver metastases to a protocol of hepatic artery infusion using mitoxantrone, 5-FU + folinic acid and mitomycin C.
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug

1999
[Leucovorin and 5-FU for advanced gastrointestinal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials,

1999
[Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:4

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trial

1999
Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.
    Seminars in oncology, 1999, Volume: 26, Issue:1 Suppl 5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, P

1999
Chemotherapy of advanced colorectal cancer.
    Cancer treatment and research, 1998, Volume: 98

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms;

1998
Recent insights into the molecular basis of intrinsic resistance of colorectal cancer: new challenges for systemic therapeutic approaches.
    Cancer treatment and research, 1998, Volume: 98

    Topics: Antimetabolites, Antineoplastic; Cell Death; Colorectal Neoplasms; Combined Modality Therapy; Drug R

1998
Colorectal cancer in adolescents.
    Annals of the Royal College of Surgeons of England, 1999, Volume: 81, Issue:2

    Topics: Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colon; Colore

1999
Which 5-fluorouracil regimen?--the great debate.
    Anti-cancer drugs, 1999, Volume: 10, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms;

1999
Regional IL-2-based immunochemotherapy of colorectal liver metastases.
    Hepato-gastroenterology, 1999, Volume: 46 Suppl 1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cance

1999
Fluoropyrimidines: a critical evaluation.
    Oncology, 1999, Volume: 57 Suppl 1

    Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neopla

1999
Potential of Xeloda in colorectal cancer and other solid tumors.
    Oncology, 1999, Volume: 57 Suppl 1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

1999
Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art.
    Critical reviews in oncology/hematology, 1999, Volume: 30, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Monitoring; Fluorouracil; Head and Neck

1999
Clinical implications of 5-FU modulation.
    Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:7 Suppl 3

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; DNA, Neoplasm; Drug Combina

1999
Schedule dependency of 5-fluorouracil.
    Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:7 Suppl 3

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Cell Cycle; Clinical Trials as Topic; Colorec

1999
Advanced colorectal cancer: which regimes should we recommend?
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:8

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as

1999
A review of the pharmacology and clinical activity of new chemotherapy agents for the treatment of colorectal cancer.
    British journal of clinical pharmacology, 1999, Volume: 48, Issue:3

    Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Glutamates;

1999
[The efficacy and limitation of hepatic arterial infusion chemotherapy for colorectal liver metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Administration, Oral; Chemoembolization, Therapeutic; Colorectal Neoplasms; Combined Modality Therap

1999
In situ standardised AgNOR analysis: a simplified method for routine use to determine prognosis and chemotherapy efficiency in colorectal adenocarcinoma.
    Micron (Oxford, England : 1993), 2000, Volume: 31, Issue:2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Nuclear

2000
Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1999, Dec-01, Volume: 56, Issue:23

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

1999
Where do we stand with 5-fluorouracil?
    Seminars in oncology, 1999, Volume: 26, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Chro

1999
Drug resistance in colon cancer.
    Seminars in oncology, 1999, Volume: 26, Issue:6

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Cycle; Colorectal Neoplasms; Drug Resistance, Neoplas

1999
New drugs in therapy of colorectal cancer: preclinical studies.
    Seminars in oncology, 1999, Volume: 26, Issue:6

    Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydro

1999
Oral fluoropoyrimidines.
    Seminars in oncology, 1999, Volume: 26, Issue:6

    Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydro

1999
Oxaliplatin: a new therapeutic option in colorectal cancer.
    Seminars in oncology, 1999, Volume: 26, Issue:6

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothec

1999
Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer.
    Seminars in oncology, 1999, Volume: 26, Issue:6

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical T

1999
Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

1999
The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
    The oncologist, 1999, Volume: 4, Issue:6

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Prodrugs; Thym

1999
Raltitrexed (Tomudex) in combination treatment for colorectal cancer: new perspectives.
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35 Suppl 1

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother

1999
[Pharmacokinetic monitoring].
    Bulletin du cancer, 2000, Volume: 87, Issue:1

    Topics: Antineoplastic Agents; Body Mass Index; Camptothecin; Colorectal Neoplasms; Drug Interactions; Drug

2000
[Adjuvant intra-arterial chemotherapy after curative resection of liver metastasis from colorectal cancer. Results of a pilot study in 30 patients].
    Chirurgie; memoires de l'Academie de chirurgie, 1999, Volume: 124, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; F

1999
New possibilities in chemotherapy for colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10 Suppl 6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Color

1999
[Improvements in palliative treatment of colorectal carcinoma].
    Deutsche medizinische Wochenschrift (1946), 2000, Feb-04, Volume: 125, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou

2000
Relevance of locoregional chemotherapy in patients with liver metastases from colorectal primaries.
    Swiss surgery = Schweizer Chirurgie = Chirurgie suisse = Chirurgia svizzera, 2000, Volume: 6, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Follow-Up Studies;

2000
Tegafur/uracil + calcium folinate in colorectal cancer: double modulation of fluorouracil.
    Drugs, 1999, Volume: 58 Suppl 3

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as To

1999
New directions in the treatment of colorectal cancer: a look to the future.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:5

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality The

2000
[New combination therapies for gastrointestinal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal

2000
[Adjuvant chemotherapy for colorectal carcinoma].
    Der Internist, 2000, Volume: 41, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, A

2000
The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status.
    Stem cells (Dayton, Ohio), 2000, Volume: 18, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

2000
Adjuvant therapy of colorectal cancer.
    Hospital practice (1995), 2000, May-15, Volume: 35, Issue:5

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chemotherapy, Cancer,

2000
Oral therapy for colorectal cancer: how to choose.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:6

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Availabilit

2000
Recent meta-analyses in colorectal cancer.
    Current opinion in oncology, 2000, Volume: 12, Issue:4

    Topics: Adjuvants, Immunologic; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Follow-Up Stud

2000
Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer.
    Critical reviews in oncology/hematology, 2000, Volume: 35, Issue:2

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical

2000
[Infusiontherapy with 5-fluorouracil ("infusional" 5-FU) in solid tumors].
    Medizinische Klinik (Munich, Germany : 1983), 2000, Volume: 95 Suppl 1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C

2000
[State of the treatment for gastrointestinal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II a

2000
Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group.
    BMJ (Clinical research ed.), 2000, Sep-02, Volume: 321, Issue:7260

    Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Databases, Bibliographic; Disease Progr

2000
Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver.
    Oncology, 2000, Volume: 59, Issue:2

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Hu

2000
Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer.
    Lancet (London, England), 2000, Jul-29, Volume: 356, Issue:9227

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

2000
[The role of prophylactic hepatic arterial infusion chemotherapy after potentially curative resection of hepatic metastases from colorectal cancer].
    Nihon Geka Gakkai zasshi, 2000, Volume: 101, Issue:8

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatectomy; Hepat

2000
Chemotherapy for colorectal cancer.
    Journal of the Royal Society of Medicine, 2000, Volume: 93, Issue:8

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms

2000
Oral fluoropyrimidines in the treatment of colorectal cancer.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2000, Volume: 12, Issue:4

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour

2000
[Colon carcinoma. Consensus of therapeutic strategies].
    Der Internist, 2000, Volume: 41, Issue:9

    Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Che

2000
Pharmacology and clinical status of capecitabine.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:9

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal

2000
Progress in colorectal cancer chemotherapy: how far have we come, how far to go?
    Drugs & aging, 2000, Volume: 17, Issue:3

    Topics: Camptothecin; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Fluoroura

2000
Current treatment options for advanced colorectal cancer.
    Seminars in oncology, 2000, Volume: 27, Issue:5 Suppl 10

    Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; H

2000
Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy.
    Seminars in oncology, 2000, Volume: 27, Issue:5 Suppl 10

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Folic Acid Antagonists; Humans;

2000
Chronotherapy with 5-fluorouracil and other drugs in gastrointestinal malignancies. Chronotherapy Group of the European Organization for Research and Treatment of Cancer.
    Seminars in oncology, 2000, Volume: 27, Issue:5 Suppl 10

    Topics: Animals; Antineoplastic Agents; Chronobiology Phenomena; Chronotherapy; Clinical Trials as Topic; Co

2000
Trimetrexate as a biochemical modulator of 5-fluorouracil and leucovorin in colorectal cancer.
    Seminars in oncology, 2000, Volume: 27, Issue:5 Suppl 10

    Topics: Antidotes; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colorectal Neoplasms; Fluorour

2000
Oxaliplatin in colorectal cancer: an overview.
    Seminars in oncology, 2000, Volume: 27, Issue:5 Suppl 10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Col

2000
Oral fluoropyrimidines in colorectal cancer.
    Seminars in oncology, 2000, Volume: 27, Issue:5 Suppl 10

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycyti

2000
Combination chemotherapy and colorectal cancer.
    Seminars in oncology, 2000, Volume: 27, Issue:5 Suppl 10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2000
Rational development of capecitabine.
    Seminars in oncology, 2000, Volume: 27, Issue:5 Suppl 10

    Topics: Animals; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxyc

2000
ABC of colorectal cancer: adjuvant therapy.
    BMJ (Clinical research ed.), 2000, Nov-11, Volume: 321, Issue:7270

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro

2000
Treatment of colorectal cancer.
    Annales chirurgiae et gynaecologiae, 2000, Volume: 89, Issue:3

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Colorectal Ne

2000
Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
    Drugs, 2000, Volume: 60, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; C

2000
Oral fluoropyrimidines in cancer treatment.
    Cancer investigation, 2000, Volume: 18, Issue:8

    Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colo

2000
[Fluorinated pyrimidines in oral treatment of advanced colorectal cancer].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2000, Sep-30, Volume: 120, Issue:23

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine

2000
The role of irinotecan in colorectal cancer.
    Current oncology reports, 1999, Volume: 1, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col

1999
5-fluorouracil alone versus 5-fluorouracil plus folinic acid in the treatment of colorectal carcinoma: meta-analysis.
    International journal of clinical pharmacology and therapeutics, 2000, Volume: 38, Issue:12

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

2000
The changing face of chemotherapy in colorectal cancer.
    British journal of cancer, 2001, Jan-05, Volume: 84, Issue:1

    Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans;

2001
[Hepatic arterial infusion chemotherapy for liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fema

2000
[Progress in chemotherapy for colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Tria

2000
[Recent advances is surgical adjuvant chemotherapy for colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A

2000
Therapeutic approaches to metastasis confined to the liver.
    Current oncology reports, 2001, Volume: 3, Issue:2

    Topics: Antimetabolites, Antineoplastic; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Colorectal

2001
Determinants of prognosis and response to therapy in colorectal cancer.
    Current oncology reports, 2001, Volume: 3, Issue:2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl

2001
Oxaliplatin: a new agent for colorectal cancer.
    Current oncology reports, 2001, Volume: 3, Issue:2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl

2001
[Molecular markers as basis for chemotherapy?].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2000, Volume: 71, Issue:12

    Topics: Biomarkers, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Gene Expression Re

2000
Role of oral chemotherapy in colorectal cancer.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:11A

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine

2000
Colorectal cancer: chemotherapy treatment overview.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cl

2000
Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trial

2000
Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Prot

2000
Second-line therapy in colorectal cancer.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Co

2000
Safety of oxaliplatin in the treatment of colorectal cancer.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials,

2000
Oxaliplatin with 5-FU or as a single agent in advanced/metastatic colorectal cancer.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2000
Oxaliplatin in colorectal cancer: current studies.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neop

2000
Intrahepatic therapy for resected hepatic metastases from colorectal carcinoma.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as

2000
Novel combinations with oxaliplatin.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Cli

2000
Efficacy of oxaliplatin in the treatment of colorectal cancer.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Cl

2000
Biochemical modulation of 5-FU in systemic treatment of advanced colorectal cancer.
    Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:1 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Synergism; Fluorouracil;

2001
Capecitabine in colorectal cancer.
    Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:1 Suppl 2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine;

2001
Oral eniluracil/5-FU for advanced colon and breast carcinomas.
    Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:1 Suppl 2

    Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplas

2001
Irinotecan in the treatment of colorectal cancer: clinical overview.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-01, Volume: 19, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli

2001
Irinotecan in the treatment of colorectal cancer: clinical overview.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-01, Volume: 19, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli

2001
Irinotecan in the treatment of colorectal cancer: clinical overview.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-01, Volume: 19, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli

2001
Irinotecan in the treatment of colorectal cancer: clinical overview.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-01, Volume: 19, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli

2001
Irinotecan in the treatment of colorectal cancer: clinical overview.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-01, Volume: 19, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli

2001
Irinotecan in the treatment of colorectal cancer: clinical overview.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-01, Volume: 19, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli

2001
Irinotecan in the treatment of colorectal cancer: clinical overview.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-01, Volume: 19, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli

2001
Irinotecan in the treatment of colorectal cancer: clinical overview.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-01, Volume: 19, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli

2001
Irinotecan in the treatment of colorectal cancer: clinical overview.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Mar-01, Volume: 19, Issue:5

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli

2001
Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer.
    British journal of cancer, 2001, Mar-02, Volume: 84, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Interfer

2001
Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:1

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neopla

2001
Clinical pharmacokinetics of capecitabine.
    Clinical pharmacokinetics, 2001, Volume: 40, Issue:2

    Topics: Antacids; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Doceta

2001
Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:7

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine

2001
[Multidisciplinary treatment for liver metastasis using cytokines].
    Nihon Geka Gakkai zasshi, 2001, Volume: 102, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2001
Chemotherapy in elderly patients with colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:4

    Topics: Aged; Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Geriatric

2001
A systematic overview of chemotherapy effects in colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2001, Volume: 40, Issue:2-3

    Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colo

2001
[New chemotherapies for colorectal cancer treatment].
    Gastroenterologie clinique et biologique, 2001, Volume: 25, Issue:4 Suppl

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop

2001
Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy.
    Anti-cancer drugs, 2001, Volume: 12, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo

2001
Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2001, Volume: 34, Issue:9

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe

2001
New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
    Cancer treatment reviews, 2001, Volume: 27, Issue:4

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2001
[Oxaliplatin: a first DACH-platinum in oncology].
    Bulletin du cancer, 2001, Volume: 88 Spec No

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as T

2001
[Oxaliplatin in combination with 5-fluoro-uracil and folinic acid as treatment of metastatic colorectal cancer].
    Bulletin du cancer, 2001, Volume: 88 Spec No

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Clinical Trials, Phase II as Topic; C

2001
[Preclinical studies of oxaliplatin in combination chemotherapy].
    Bulletin du cancer, 2001, Volume: 88 Spec No

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under

2001
[Levofolinate and fluorouracil combination therapy].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2001, Volume: 118, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Colorectal Neopl

2001
The evolution of fluoropyrimidine therapy: from intravenous to oral.
    The oncologist, 2001, Volume: 6 Suppl 4

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Color

2001
Answering patients' needs: oral alternatives to intravenous therapy.
    The oncologist, 2001, Volume: 6 Suppl 4

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Color

2001
Optimizing the use of irinotecan in colorectal cancer.
    The oncologist, 2001, Volume: 6 Suppl 4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe

2001
Integrating oxaliplatin into the management of colorectal cancer.
    The oncologist, 2001, Volume: 6 Suppl 4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

2001
Capecitabine: a novel agent for the treatment of solid tumors.
    Anti-cancer drugs, 2001, Volume: 12, Issue:8

    Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; D

2001
[Standard therapy of CPT-11 for colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:10

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cli

2001
[5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:10

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

2001
Cancers of the large bowel and hepatobiliary tract.
    Cancer chemotherapy and biological response modifiers, 2001, Volume: 19

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl

2001
Oral versus intravenous fluoropyrimidines for advanced colorectal cancer: by either route, it's all the same.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2001
Disease management considerations: disease management considerations.
    Drugs, 2001, Volume: 61, Issue:12

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans;

2001
[New therapeutic options in chemotherapy of advanced colorectal cancer].
    Medizinische Klinik (Munich, Germany : 1983), 2001, Oct-15, Volume: 96, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Clinical Tria

2001
Therapy of disseminated colorectal cancer: the emerging role of intratumoral molecular biology.
    The European journal of surgery. Supplement. : = Acta chirurgica. Supplement, 2001, Issue:586

    Topics: Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Oxidoreductases; Thy

2001
Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer.
    Drugs, 2001, Volume: 61, Issue:15

    Topics: Absorption; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecit

2001
Hepatic artery infusional chemotherapy for colorectal liver metastases.
    Cancer treatment and research, 2001, Volume: 109

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Equipm

2001
[Chemotherapy of colorectal carcinoma].
    Der Internist, 2001, Volume: 42, Issue:12

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemo

2001
Rational development of capecitabine.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38 Suppl 2

    Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase

2002
[The new chemotherapy of colorectal cancers].
    Presse medicale (Paris, France : 1983), 2002, Jan-26, Volume: 31, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe

2002
[Evidence for and practical use of arterial infusion chemotherapy for liver metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

2002
Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-15, Volume: 20, Issue:6

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Incidence; Logi

2002
Prediction of the response of colorectal cancer to systemic therapy.
    The Lancet. Oncology, 2002, Volume: 3, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Capecitabine; Chemothe

2002
New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.
    The Lancet. Oncology, 2001, Volume: 2, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop

2001
Randomized clinical trials in advanced and metastatic colorectal carcinoma.
    Surgical oncology clinics of North America, 2002, Volume: 11, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Evidence-Based Medicine; Fluorouracil; Humans

2002
Intrahepatic arterial infusion of chemotherapy: pharmacologic principles.
    Seminars in oncology, 2002, Volume: 29, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Fl

2002
Intrahepatic arterial infusion of chemotherapy: clinical results.
    Seminars in oncology, 2002, Volume: 29, Issue:2

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Floxuridine; Fluor

2002
The treatment of advanced colorectal cancer: where are we now and where do we go?
    Best practice & research. Clinical gastroenterology, 2002, Volume: 16, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

2002
Capecitabine/irinotecan combination regimens in colorectal cancer.
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:4 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic

2002
Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer.
    Cancer treatment reviews, 2002, Volume: 28, Issue:1

    Topics: Colorectal Neoplasms; Cytological Techniques; Drug Resistance, Neoplasm; Floxuridine; Fluorouracil;

2002
Capecitabine: fulfilling the promise of oral chemotherapy.
    Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:6

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2002
Raltitrexed: current clinical status and future directions.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as

2002
Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?
    British journal of cancer, 2002, Jun-05, Volume: 86, Issue:11

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clini

2002
[Systemic chemotherapy for advanced colorectal cancer with liver metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:6

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusi

2002
[Oral fluoropyrimidines registered for the treatment of metastatic colorectal carcinoma: a possible gain].
    Nederlands tijdschrift voor geneeskunde, 2002, Jun-15, Volume: 146, Issue:24

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl

2002
Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.
    Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisp

1992
Is hepatic infusion of chemotherapy effective treatment for liver metastases? No!
    Important advances in oncology, 1992

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Forecasting; Humans; Infusio

1992
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:6

    Topics: Colorectal Neoplasms; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; M

1992
[Systemic chemotherapy in metastatic colorectal adenocarcinomas].
    Gastroenterologie clinique et biologique, 1992, Volume: 16, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Fem

1992
The value of adjuvant therapy after radical surgery for colorectal cancer.
    Annals of medicine, 1992, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore

1992
[Biochemical modulation of 5-FU with interferon].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Admini

1992
[High-dose leucovorin and 5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Fluorodeoxyur

1992
[Advances in the treatment of advanced colorectal cancer].
    Revista clinica espanola, 1990, Volume: 186, Issue:6

    Topics: Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dr

1990
[Current status of adjuvant therapy in patients with colorectal cancer: report and commentary on the Consensus Conference, 16-18 April 1990, National Cancer Institute, Bethesda, Maryland].
    Wiener klinische Wochenschrift, 1991, Volume: 103, Issue:4

    Topics: Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Staging; Palliative

1991
Chemotherapy of colorectal cancer.
    Anti-cancer drugs, 1991, Volume: 2, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1991
Modulation of fluoropyrimidines by leucovorin: rationale and status.
    Journal of surgical oncology. Supplement, 1991, Volume: 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

1991
Developments of the fluoropyrimidines as inhibitors of thymidylate synthetase: pharmacologic and clinical aspects.
    Journal of surgical oncology. Supplement, 1991, Volume: 2

    Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Drug Synergism; Floxuridine; Fluorouracil; Hum

1991
5-Fluorouracil (5FU) with or without folinic acid (LV) in human colorectal cancer? Multivariate meta-analysis of the literature.
    Medical oncology and tumor pharmacotherapy, 1991, Volume: 8, Issue:4

    Topics: Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Leucovorin; Meta-Analysis as

1991
[5-Fluorouracil (5-FU)/leucovorin in comparison to other current chemotherapy protocols in metastasizing colorectal carcinoma].
    Wiener klinische Wochenschrift, 1991, Volume: 103, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorou

1991
Sequential methotrexate/5-fluorouracil in advanced colorectal cancer treatment.
    Journal of surgical oncology. Supplement, 1991, Volume: 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

1991
Chemotherapy for patients not benefitting from 5-fluorouracil therapy.
    Journal of surgical oncology. Supplement, 1991, Volume: 2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou

1991
[The biochemical modulation of 5-fluorouracil by leucovorin].
    Schweizerische medizinische Wochenschrift, 1991, Aug-17, Volume: 121, Issue:33

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Clinical Trials as Topic; Colorec

1991
Systemic therapy for colorectal cancer: an overview.
    Seminars in oncology, 1991, Volume: 18, Issue:5 Suppl 7

    Topics: Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans

1991
Clinical trials of fluorouracil with alpha-interferon in advanced colorectal carcinomas.
    Seminars in oncology, 1991, Volume: 18, Issue:5 Suppl 7

    Topics: Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Follow-Up Studies; Humans;

1991
120-hour 5-fluorouracil (5-FU) continuous infusion (CI) plus BCNU in advanced colorectal cancer.
    American journal of clinical oncology, 1991, Volume: 14, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carmustine; Colorectal Neopl

1991
Adjuvant therapy of colorectal cancer: an overview.
    The Australian and New Zealand journal of surgery, 1991, Volume: 61, Issue:1

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Leucov

1991
Role of adjuvant therapy in colorectal cancer.
    Advances in internal medicine, 1991, Volume: 36

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Colorectal Neopl

1991
[Experimental models for hepatic metastases from colorectal tumors].
    Annales de chirurgie, 1991, Volume: 45, Issue:3

    Topics: Animals; Azoxymethane; Colectomy; Colorectal Neoplasms; Cyclosporins; Disease Models, Animal; Fluoro

1991
[Therapy of advanced colorectal cancer].
    Fortschritte der Medizin, 1991, Mar-20, Volume: 109, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu

1991
Biochemical modulation of 5-fluorouracil.
    Cancer treatment reviews, 1990, Volume: 17 Suppl A

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

1990
[Intra-arterial and intravenous chemotherapy in the treatment of hepatic metastases of colorectal origin: review of the literature and preliminary results].
    Revue medicale de Liege, 1990, Volume: 45, Issue:3

    Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery

1990
Clinical trials with 5-fluorouracil, folinic acid and cisplatin in patients with gastrointestinal malignancies.
    Journal of chemotherapy (Florence, Italy), 1990, Volume: 2 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Evaluation; Fl

1990
Clinical trial with 5-fluorouracil and leucovorin.
    Journal of chemotherapy (Florence, Italy), 1990, Volume: 2 Suppl 1

    Topics: Adenocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Drug Evaluation; Drug Therapy, Combination;

1990
5-Fluorouracil plus levamisole: effective adjuvant treatment for colon cancer.
    Important advances in oncology, 1990

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemistry, Clinical; Colonic Neoplas

1990
Biochemical rationale for the 5-fluorouracil leucovorin combination and update of clinical experience.
    Journal of chemotherapy (Florence, Italy), 1990, Volume: 2 Suppl 1

    Topics: Animals; Clinical Trials as Topic; Colorectal Neoplasms; Drug Synergism; Drug Therapy, Combination;

1990
Consensus panel considers adjuvant therapy for colon and rectal cancer, identifies levamisole--fluorouracil as standard in colon cancer.
    Clinical pharmacy, 1990, Volume: 9, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu

1990
Systemic therapy in metastatic colorectal cancer.
    Archives of internal medicine, 1990, Volume: 150, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Comb

1990
Management of colorectal cancer.
    Comprehensive therapy, 1990, Volume: 16, Issue:11

    Topics: Adenocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hu

1990
Modulation of 5-fluorouracil efficacy.
    Cancer treatment reviews, 1990, Volume: 17, Issue:2-3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Fluorouracil;

1990
Treatment of advanced colorectal cancer.
    Hematology/oncology clinics of North America, 1989, Volume: 3, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation;

1989
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dru

1989
[Chemotherapy of colorectal cancer].
    Zeitschrift fur Gastroenterologie, 1989, Volume: 27, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo

1989
Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer.
    Cancer, 1989, Mar-15, Volume: 63, Issue:6 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo

1989
5-Fluorouracil by protracted venous infusion. A review of current progress.
    Oncology, 1989, Volume: 46, Issue:4

    Topics: Catheterization; Colorectal Neoplasms; Fluorouracil; Forecasting; Humans; Infusions, Intravenous

1989
Low-dose continuous infusion 5-fluorouracil and cisplatin: phase II evaluation in advanced colorectal carcinoma.
    American journal of clinical oncology, 1989, Volume: 12, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N

1989
5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment?
    British journal of cancer, 1989, Volume: 60, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo

1989
Cytostatic drug therapy in disseminated colorectal cancer.
    Scandinavian journal of gastroenterology. Supplement, 1988, Volume: 149

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Col

1988
[Therapy concepts in colorectal liver metastases. What is proven, what is open to discussion?].
    Leber, Magen, Darm, 1988, Volume: 18, Issue:6

    Topics: Colorectal Neoplasms; Combined Modality Therapy; Floxuridine; Fluorouracil; Hepatectomy; Humans; Inf

1988
Adjuvant cytotoxic chemotherapy for colorectal cancer: the present position.
    The Australian and New Zealand journal of surgery, 1988, Volume: 58, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine

1988
Colorectal cancer. Are adjuvant therapies beneficial?
    Postgraduate medicine, 1988, Nov-01, Volume: 84, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant

1988
Folinic acid (FA) plus 5-fluorouracil (FU) in progressive advanced colorectal cancer.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1988, Volume: 42, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo

1988
Preclinical and clinical biochemical modulation of 5-fluorouracil by leucovorin and uridine.
    The science reports of the research institutes, Tohoku University. Ser. C, Medicine. Tohoku Daigaku, 1988, Volume: 35, Issue:1-4

    Topics: Animals; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Mice; Tumor Cells, Cultured; Uridin

1988

Trials

1873 trials available for fluorouracil and Colorectal Cancer

ArticleYear
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial).
    European journal of cancer (Oxford, England : 1990), 2021, Volume: 157

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec

2021
A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPA
    Oncology, 2022, Volume: 100, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuxi

2022
Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003.
    Future oncology (London, England), 2021, Volume: 17, Issue:36

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum

2021
Machine Learning Application in a Phase I Clinical Trial Allows for the Identification of Clinical-Biomolecular Markers Significantly Associated With Toxicity.
    Clinical pharmacology and therapeutics, 2022, Volume: 111, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Colorectal Neo

2022
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
    British journal of cancer, 2022, Volume: 126, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Colorectal Neoplasms; Fluo

2022
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.
    British journal of cancer, 2022, Volume: 126, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo

2022
Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2022, Volume: 54, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hep

2022
Cetuximab and vemurafenib plus FOLFIRI (5-fluorouracil/leucovorin/irinotecan) for BRAF V600E-mutated advanced colorectal cancer (IMPROVEMENT): An open-label, single-arm, phase II trial.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 163

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluor

2022
A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study.
    Langenbeck's archives of surgery, 2022, Volume: 407, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Disease-Free Surviv

2022
A multicenter phase II trial evaluating the efficacy of bevacizumab plus mFOLFOX6 for R0 surgical resection in advanced colorectal liver metastases harboring mutant-type KRAS: NEXTO-mt trial.
    HPB : the official journal of the International Hepato Pancreato Biliary Association, 2022, Volume: 24, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum

2022
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore

2023
A Phase II Study of Dose-reductive XELOX Plus Bevacizumab in Elderly or Vulnerable Patients With Metastatic Colorectal Cancer (MCSGO-1202).
    Anticancer research, 2022, Volume: 42, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasm

2022
Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.
    The oncologist, 2022, 04-05, Volume: 27, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo

2022
Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer.
    Life sciences, 2022, Jun-15, Volume: 299

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carc

2022
Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years.
    Japanese journal of clinical oncology, 2022, 07-08, Volume: 52, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neopla

2022
Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX.
    International journal of cancer, 2022, 10-01, Volume: 151, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chromosome Deletion; Chromosomes; Colon

2022
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
    British journal of cancer, 2022, Volume: 127, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic

2022
Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 Trial.
    Clinical colorectal cancer, 2022, Volume: 21, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bevacizumab; Camptothecin; Cetuximab;

2022
Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA.
    International journal of cancer, 2022, Dec-15, Volume: 151, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell-Free Nucleic Acids; Colonic Neopl

2022
[The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab].
    Recenti progressi in medicina, 2022, Volume: 113, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms;

2022
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022, Volume: 24, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circulating Tu

2022
Effects of mFOLFOX6 regimen combined with carrelizumab on immune function and prognosis in patients with microsatellite instability colorectal cancer.
    Cellular and molecular biology (Noisy-le-Grand, France), 2022, Feb-04, Volume: 67, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla

2022
Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC s
    BMC gastroenterology, 2022, Jul-14, Volume: 22, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trial

2022
Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line tre
    BMC cancer, 2022, Jul-27, Volume: 22, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bev

2022
Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study.
    Future oncology (London, England), 2022, Volume: 18, Issue:27

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co

2022
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study).
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 10-03, Volume: 28, Issue:19

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Bevacizumab; C

2022
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 173

    Topics: Aged; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co

2022
The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results.
    The oncologist, 2023, 07-05, Volume: 28, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Frail Elde

2023
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314).
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 173

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

2022
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.
    European radiology, 2023, Volume: 33, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neopla

2023
Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study).
    International journal of clinical oncology, 2022, Volume: 27, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum

2022
Triplet (FOLFOXIRI) Versus Doublet (FOLFOX or FOLFIRI) Regimen as First Line Treatment in Metastatic Colorectal Carcinoma, a Prospective Phase II, Randomized Controlled Trial.
    Asian Pacific journal of cancer prevention : APJCP, 2022, Oct-01, Volume: 23, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu

2022
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
    British journal of cancer, 2023, Volume: 128, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors;

2023
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci

2023
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci

2023
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci

2023
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci

2023
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci

2023
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci

2023
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci

2023
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci

2023
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 178

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci

2023
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR).
    ESMO open, 2022, Volume: 7, Issue:6

    Topics: Bevacizumab; Biomarkers; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; F-Box-WD Re

2022
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR).
    ESMO open, 2022, Volume: 7, Issue:6

    Topics: Bevacizumab; Biomarkers; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; F-Box-WD Re

2022
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR).
    ESMO open, 2022, Volume: 7, Issue:6

    Topics: Bevacizumab; Biomarkers; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; F-Box-WD Re

2022
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR).
    ESMO open, 2022, Volume: 7, Issue:6

    Topics: Bevacizumab; Biomarkers; Colonic Neoplasms; Colorectal Neoplasms; Disease-Free Survival; F-Box-WD Re

2022
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
    Clinical colorectal cancer, 2023, Volume: 22, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms;

2023
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
    Clinical colorectal cancer, 2023, Volume: 22, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms;

2023
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
    Clinical colorectal cancer, 2023, Volume: 22, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms;

2023
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
    Clinical colorectal cancer, 2023, Volume: 22, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms;

2023
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
    Journal of cancer research and therapeutics, 2022, Volume: 18, Issue:12 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore

2022
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
    Journal of cancer research and therapeutics, 2022, Volume: 18, Issue:12 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore

2022
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
    Journal of cancer research and therapeutics, 2022, Volume: 18, Issue:12 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore

2022
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
    Journal of cancer research and therapeutics, 2022, Volume: 18, Issue:12 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore

2022
Tumor Response-speed Heterogeneity as a Novel Prognostic Factor in Patients With Metastatic Colorectal Cancer.
    American journal of clinical oncology, 2023, 02-01, Volume: 46, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci

2023
NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 05-01, Volume: 29, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Colonic Neoplasms; Colorect

2023
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.
    British journal of cancer, 2023, Volume: 128, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore

2023
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 06-13, Volume: 29, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore

2023
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    JAMA, 2023, 04-18, Volume: 329, Issue:15

    Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2023
Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials.
    ESMO open, 2023, Volume: 8, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorourac

2023
Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial.
    JAMA network open, 2023, 06-01, Volume: 6, Issue:6

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Appendiceal Neoplasms; Colorectal

2023
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 189

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore

2023
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 09-01, Volume: 41, Issue:25

    Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; C

2023
Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212
    ESMO open, 2023, Volume: 8, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Female; Flu

2023
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 190

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms;

2023
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 190

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci

2023
Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study.
    BMC cancer, 2023, Jul-18, Volume: 23, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; C

2023
Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial.
    JAMA oncology, 2023, 09-01, Volume: 9, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans;

2023
Preoperative chemotherapy prior to primary tumour resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: The RECUT multicenter randomised controlled trial.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 191

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu

2023
Prospective validation of VEGF and eNOS polymorphisms as predictors of first-line bevacizumab efficacy in patients with metastatic colorectal cancer.
    Scientific reports, 2023, 08-09, Volume: 13, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum

2023
Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study.
    Acta oncologica (Stockholm, Sweden), 2023, Volume: 62, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin;

2023
Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 195

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Fluorouracil; Human

2023
A randomized controlled, open-label early phase II trial comparing incidence of FOLFIRI.3-induced diarrhoea between Hangeshashinto and oral alkalization in Japanese patients with colorectal cancer.
    Journal of clinical pharmacy and therapeutics, 2019, Volume: 44, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Campto

2019
SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 119

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2019
ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2019
Cetuximab, irinotecan and fluorouracile in fiRst-line treatment of immunologically-selected advanced colorectal cancer patients: the CIFRA study protocol.
    BMC cancer, 2019, Sep-09, Volume: 19, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Fluorouracil; Human

2019
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2019
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2019
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2019
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2019
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2019
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2019
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2019
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2019
Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2019
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 12-01, Volume: 30, Issue:12

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2019
Fast-track multidisciplinary treatment versus conventional treatment for colorectal cancer: a multicenter, open-label randomized controlled study.
    BMC cancer, 2019, Oct-23, Volume: 19, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorect

2019
Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer.
    American journal of clinical oncology, 2020, Volume: 43, Issue:1

    Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuxim

2020
Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
    Cancer medicine, 2020, Volume: 9, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Disease-F

2020
Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 02-01, Volume: 26, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colore

2020
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 03-01, Volume: 26, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin;

2020
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 03-01, Volume: 26, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin;

2020
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 03-01, Volume: 26, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin;

2020
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 03-01, Volume: 26, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin;

2020
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 03-01, Volume: 26, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin;

2020
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 03-01, Volume: 26, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin;

2020
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 03-01, Volume: 26, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin;

2020
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 03-01, Volume: 26, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin;

2020
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 03-01, Volume: 26, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin;

2020
A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study).
    Japanese journal of clinical oncology, 2020, Jan-24, Volume: 50, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Com

2020
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
    Health technology assessment (Winchester, England), 2019, Volume: 23, Issue:64

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Capecitabine; Chemotherapy, Adjuvan

2019
Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
    Trials, 2019, Dec-19, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinic

2019
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 11-01, Volume: 30, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin;

2019
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo

2020
Consumption of Lactose, Other FODMAPs and Diarrhoea during Adjuvant 5-Fluorouracil Chemotherapy for Colorectal Cancer.
    Nutrients, 2020, Feb-04, Volume: 12, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Diet Records; Diet, Ca

2020
Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial.
    BMJ open, 2020, 02-12, Volume: 10, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot

2020
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    JAMA oncology, 2020, 04-01, Volume: 6, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C

2020
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    JAMA oncology, 2020, 04-01, Volume: 6, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C

2020
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    JAMA oncology, 2020, 04-01, Volume: 6, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C

2020
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
    JAMA oncology, 2020, 04-01, Volume: 6, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C

2020
Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer.
    Medical science monitor : international medical journal of experimental and clinical research, 2020, Feb-16, Volume: 26

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2020
Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802).
    Clinical colorectal cancer, 2020, Volume: 19, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal N

2020
The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT].
    PloS one, 2020, Volume: 15, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark

2020
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).
    The oncologist, 2020, Volume: 25, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2020
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306.
    Annals of surgical oncology, 2020, Volume: 27, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorect

2020
Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial.
    International journal of clinical oncology, 2020, Volume: 25, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neop

2020
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
    Clinical colorectal cancer, 2020, Volume: 19, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu

2020
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
    Clinical colorectal cancer, 2020, Volume: 19, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu

2020
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
    Clinical colorectal cancer, 2020, Volume: 19, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu

2020
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
    Clinical colorectal cancer, 2020, Volume: 19, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu

2020
Sex-dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial.
    Cancer medicine, 2020, Volume: 9, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

2020
Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-blind, Noninferiority Clinical Trial.
    Clinical therapeutics, 2020, Volume: 42, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biosimilar Pharmaceuticals

2020
Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-RAS status for unresectable colorectal liver metastasis (BECK study): Long-term results of survival.
    Journal of hepato-biliary-pancreatic sciences, 2020, Volume: 27, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neop

2020
A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
    Clinical colorectal cancer, 2020, Volume: 19, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic An

2020
Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).
    International journal of clinical oncology, 2020, Volume: 25, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecit

2020
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panit
    Journal of cancer research and clinical oncology, 2020, Volume: 146, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2020
Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial.
    Oncology, 2020, Volume: 98, Issue:9

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2020
Phase I Study of Alternate-Day Administration of S-1, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer.
    The oncologist, 2020, Volume: 25, Issue:11

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo

2020
Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer.
    The oncologist, 2020, Volume: 25, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Cytoreduction Sur

2020
Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Flu

2020
Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study.
    British journal of cancer, 2020, Volume: 123, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Colorec

2020
A Multicenter Phase 2 Trial to Evaluate the Efficacy of mFOLFOX6 + Cetuximab as Induction Chemotherapy to Achieve R0 Surgical Resection for Advanced Colorectal Liver Metastases (NEXTO Trial).
    Annals of surgical oncology, 2020, Volume: 27, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Combined Modality T

2020
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 135

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom

2020
Immune characterization of metastatic colorectal cancer patients post reovirus administration.
    BMC cancer, 2020, Jun-18, Volume: 20, Issue:1

    Topics: Adult; Antigen-Presenting Cells; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy

2020
First-line panitumumab plus capecitabine for the treatment of older patients with wild-type RAS metastatic colorectal cancer. The phase II, PANEL study.
    Journal of geriatric oncology, 2020, Volume: 11, Issue:8

    Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorect

2020
Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial.
    International journal of clinical oncology, 2020, Volume: 25, Issue:10

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cy

2020
Selinexor (KPT-330), an Oral Selective Inhibitor of Nuclear Export (SINE) Compound, in Combination with FOLFOX in Patients with Metastatic Colorectal Cancer (mCRC) - Final Results of the Phase I Trial SENTINEL.
    Current cancer drug targets, 2020, Volume: 20, Issue:10

    Topics: Active Transport, Cell Nucleus; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neo

2020
Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
    Clinical therapeutics, 2020, Volume: 42, Issue:7

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothec

2020
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: A pre-specified secondary analysis of the Valentino study.
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 135

    Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarke

2020
Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
    Anti-cancer drugs, 2020, Volume: 31, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorect

2020
Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer.
    World journal of surgical oncology, 2020, Jul-08, Volume: 18, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N

2020
The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer.
    Recent patents on anti-cancer drug discovery, 2020, Volume: 15, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Double-B

2020
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
    BMC cancer, 2020, Jul-22, Volume: 20, Issue:1

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological

2020
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
    BMC cancer, 2020, Jul-22, Volume: 20, Issue:1

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological

2020
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
    BMC cancer, 2020, Jul-22, Volume: 20, Issue:1

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological

2020
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
    BMC cancer, 2020, Jul-22, Volume: 20, Issue:1

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological

2020
Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial.
    Clinical colorectal cancer, 2020, Volume: 19, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Drug A

2020
Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2020, Volume: 52, Issue:10

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combine

2020
Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 09-20, Volume: 38, Issue:27

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal

2020
Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 138

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2020
Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment.
    Journal of pharmacokinetics and pharmacodynamics, 2020, Volume: 47, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop

2020
Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
    BMC cancer, 2020, Aug-31, Volume: 20, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy

2020
Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.
    Medicine, 2020, Sep-04, Volume: 99, Issue:36

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic C

2020
5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against
    Cancer research, 2020, 11-01, Volume: 80, Issue:21

    Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzeneacetamides; Class I Phosphati

2020
Impact of Size and Location of Metastases on Early Tumor Shrinkage and Depth of Response in Patients With Metastatic Colorectal Cancer: Subgroup Findings of the Randomized, Open-Label Phase 3 Trial FIRE-3/AIO KRK-0306.
    Clinical colorectal cancer, 2020, Volume: 19, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorect

2020
Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).
    Clinical colorectal cancer, 2020, Volume: 19, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2020
Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111).
    International journal of cancer, 2021, 03-15, Volume: 148, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2021
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 01-01, Volume: 27, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biologi

2021
Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG
    Targeted oncology, 2020, Volume: 15, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptot

2020
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy-a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 139

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin;

2020
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
    British journal of cancer, 2021, Volume: 124, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasm

2021
Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study.
    International journal of clinical oncology, 2021, Volume: 26, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Surv

2021
A phase II study of FOLFOXIRI plus bevacizumab as initial chemotherapy for patients with untreated metastatic colorectal cancer: TRICC1414 (BeTRI).
    International journal of clinical oncology, 2021, Volume: 26, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N

2021
Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin.
    Cancer chemotherapy and pharmacology, 2021, Volume: 87, Issue:1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomark

2021
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
    British journal of cancer, 2021, Volume: 124, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C

2021
Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer.
    The oncologist, 2021, Volume: 26, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disea

2021
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
    The New England journal of medicine, 2020, 12-03, Volume: 383, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunologi

2020
Remodeling the homeostasis of pro- and anti-angiogenic factors by Shenmai injection to normalize tumor vasculature for enhanced cancer chemotherapy.
    Journal of ethnopharmacology, 2021, Apr-24, Volume: 270

    Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antineoplastic Combined Chemotherapy Protocols; Colo

2021
Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer.
    The oncologist, 2021, Volume: 26, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F

2021
A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer.
    Asia-Pacific journal of clinical oncology, 2021, Volume: 17, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2021
Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial.
    The British journal of surgery, 2021, 04-30, Volume: 108, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeuti

2021
Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT).
    The oncologist, 2021, Volume: 26, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal

2021
[Capecitabine and Oxaliplatin(CAPOX)plus Bevacizumab as Second-Line Chemotherapy for Metastatic Colorectal Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Colorectal

2021
Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study.
    The oncologist, 2021, Volume: 26, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum

2021
Population pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimen.
    Cancer chemotherapy and pharmacology, 2021, Volume: 88, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2021
A Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Therapy With or Without Panitumumab After Hepatic Resection of KRAS Wild-type Colorectal Cancer.
    Annals of surgery, 2021, 08-01, Volume: 274, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; C

2021
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
    JAMA surgery, 2021, 08-01, Volume: 156, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cap

2021
A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab.
    Oncology research, 2021, Sep-07, Volume: 28, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2021
A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186.
    Cancer immunology, immunotherapy : CII, 2021, Volume: 70, Issue:11

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biom

2021
Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study.
    Current medical research and opinion, 2021, Volume: 37, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci

2021
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III
    European journal of cancer (Oxford, England : 1990), 2021, Volume: 154

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec

2021
Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer.
    Cancer science, 2021, Volume: 112, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2021
MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG).
    BMC cancer, 2021, Aug-18, Volume: 21, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Colorectal

2021
Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study.
    ESMO open, 2021, Volume: 6, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu

2021
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
    International journal of cancer, 2022, 01-01, Volume: 150, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorect

2022
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 77

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Proteins;

2017
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.
    International journal of cancer, 2017, 07-15, Volume: 141, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo

2017
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
    Journal of the National Cancer Institute, 2017, 09-01, Volume: 109, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuva

2017
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
    Journal of the National Cancer Institute, 2017, 09-01, Volume: 109, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuva

2017
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
    Journal of the National Cancer Institute, 2017, 09-01, Volume: 109, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuva

2017
Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial.
    Journal of the National Cancer Institute, 2017, 09-01, Volume: 109, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuva

2017
Feasibility of Modified FOLFOX in Elderly Patients Aged ≥80 Years with Metastatic Gastric Cancer or Colorectal Cancer.
    Oncology, 2017, Volume: 93, Issue:2

    Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2017
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 79

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorect

2017
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer.
    Anti-cancer drugs, 2017, Volume: 28, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm

2017
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
    BMC cancer, 2017, Jun-09, Volume: 17, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Dis

2017
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    JAMA, 2017, 06-20, Volume: 317, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi

2017
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    JAMA, 2017, 06-20, Volume: 317, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi

2017
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    JAMA, 2017, 06-20, Volume: 317, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi

2017
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    JAMA, 2017, 06-20, Volume: 317, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi

2017
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    JAMA, 2017, 06-20, Volume: 317, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi

2017
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    JAMA, 2017, 06-20, Volume: 317, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi

2017
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    JAMA, 2017, 06-20, Volume: 317, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi

2017
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    JAMA, 2017, 06-20, Volume: 317, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi

2017
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    JAMA, 2017, 06-20, Volume: 317, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi

2017
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 81

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2017
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 83

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2017
A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer.
    Medicine, 2017, Volume: 96, Issue:30

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer.
    Histopathology, 2018, Volume: 72, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; Humans; Image Interp

2018
Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
    Journal of geriatric oncology, 2018, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combin

2018
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
    British journal of cancer, 2017, Sep-26, Volume: 117, Issue:7

    Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arylamine

2017
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 84

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu

2017
Safety of intraoperative chemotherapy with 5-FU for colorectal cancer patients receiving curative resection: a randomized, multicenter, prospective, phase III IOCCRC trial (IOCCRC).
    Journal of cancer research and clinical oncology, 2017, Volume: 143, Issue:12

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Intraoperative Care; In

2017
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial.
    British journal of cancer, 2017, Oct-10, Volume: 117, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc

2017
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 01-01, Volume: 29, Issue:1

    Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplas

2018
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Nov-01, Volume: 28, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colore

2017
Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 01-01, Volume: 29, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2018
Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials.
    Journal of cancer research and clinical oncology, 2018, Volume: 144, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2018
Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2018, Volume: 26, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepit

2018
Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
    Journal of surgical oncology, 2018, Volume: 117, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deo

2018
Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 88

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C

2018
Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOG-ACRIN Cancer Research Group (E4203).
    Cancer, 2018, 02-15, Volume: 124, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec

2018
Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 03-01, Volume: 29, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immun

2018
Thymidylate synthase gene variants as predictors of clinical response and toxicity to fluoropyrimidine-based chemotherapy for colorectal cancer.
    Drug metabolism and personalized therapy, 2017, 12-20, Volume: 32, Issue:4

    Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colorectal

2017
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 03-01, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva

2018
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 04-01, Volume: 29, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N

2018
EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 04-01, Volume: 29, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuxi

2018
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.
    BMC cancer, 2018, 01-25, Volume: 18, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2018
Can carcinoembryonic antigen replace computed tomography in response evaluation of metastatic colorectal cancer?
    Acta oncologica (Stockholm, Sweden), 2018, Volume: 57, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Ca

2018
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
    JAMA oncology, 2018, Apr-01, Volume: 4, Issue:4

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2018
Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial.
    European journal of radiology, 2018, Volume: 100

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothec

2018
A phase II trial to evaluate the efficacy of panitumumab combined with fluorouracil-based chemotherapy for metastatic colorectal cancer: the PF trial.
    Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorect

2018
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.
    Clinical colorectal cancer, 2018, Volume: 17, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizum

2018
Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2018, Volume: 44, Issue:7

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal N

2018
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
    Clinical colorectal cancer, 2018, Volume: 17, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cohort Studies; Colore

2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
    The Lancet. Oncology, 2018, Volume: 19, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2018
A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.
    Clinical colorectal cancer, 2018, Volume: 17, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Canada; Colorectal Neoplas

2018
Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study.
    Cancer chemotherapy and pharmacology, 2018, Volume: 82, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2018
UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy.
    Cancer chemotherapy and pharmacology, 2018, Volume: 82, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2018
Geriatric analysis from PRODIGE 20 randomized phase II trial evaluating bevacizumab + chemotherapy versus chemotherapy alone in older patients with untreated metastatic colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 97

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin;

2018
A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer.
    American journal of clinical oncology, 2018, Volume: 41, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2018
Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC.
    Future oncology (London, England), 2018, Volume: 14, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neo

2018
Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study.
    Clinical colorectal cancer, 2018, Volume: 17, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Body Height; Camptothecin;

2018
Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.
    Cancer, 2018, 08-01, Volume: 124, Issue:15

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dou

2018
Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 99

    Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacologica

2018
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
    International journal of colorectal disease, 2018, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L

2018
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
    International journal of colorectal disease, 2018, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L

2018
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
    International journal of colorectal disease, 2018, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L

2018
Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
    International journal of colorectal disease, 2018, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Egypt; Fluorouracil; Humans; L

2018
Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.
    British journal of cancer, 2018, Volume: 119, Issue:2

    Topics: Adult; Aged; Camptothecin; Cetuximab; Colorectal Neoplasms; Female; Fluorodeoxyglucose F18; Fluorour

2018
Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer.
    American journal of clinical oncology, 2019, Volume: 42, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Che

2019
AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2018, Volume: 17, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorect

2018
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK cli
    British journal of cancer, 2018, Volume: 119, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2018
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK cli
    British journal of cancer, 2018, Volume: 119, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2018
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK cli
    British journal of cancer, 2018, Volume: 119, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2018
Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK cli
    British journal of cancer, 2018, Volume: 119, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2018
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 101

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Diseas

2018
Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
    BMC cancer, 2018, Aug-06, Volume: 18, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase I as

2018
A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US.
    Journal of medical economics, 2018, Volume: 21, Issue:11

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy

2018
Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 01-01, Volume: 25, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu

2019
Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 102

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Clinical Decision-Making; C

2018
Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: a randomized Phase III study.
    Future oncology (London, England), 2018, Volume: 14, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Campto

2018
A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundatio
    Journal of cancer research and therapeutics, 2018, Volume: 14, Issue:Supplement

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla

2018
Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
    The lancet. Gastroenterology & hepatology, 2018, Volume: 3, Issue:12

    Topics: Adult; Aged; Antibodies; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy

2018
Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer.
    Investigational new drugs, 2019, Volume: 37, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec

2019
Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 01-01, Volume: 30, Issue:1

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers,

2019
Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial.
    Cancer chemotherapy and pharmacology, 2019, Volume: 83, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecit

2019
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 01-01, Volume: 37, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasm

2019
Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
    JAMA oncology, 2019, 01-01, Volume: 5, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark

2019
A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Cancer research and treatment, 2019, Volume: 51, Issue:3

    Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy

2019
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer.
    British journal of cancer, 2019, Volume: 120, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Beva

2019
Hydrogen gas restores exhausted CD8+ T cells in patients with advanced colorectal cancer to improve prognosis.
    Oncology reports, 2019, Volume: 41, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; CD8-Positive

2019
Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    The oncologist, 2019, Volume: 24, Issue:7

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neo

2019
Tumor calcification as a prognostic factor in cetuximab plus chemotherapy-treated patients with metastatic colorectal cancer.
    Anti-cancer drugs, 2019, Volume: 30, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Cetuxima

2019
A Phase II Study Alternating Erlotinib With Second-line mFOLFOX6 or FOLFIRI for Metastatic Colorectal Cancer.
    Anticancer research, 2019, Volume: 39, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2019
L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways.
    Toxicology and applied pharmacology, 2019, 02-15, Volume: 365

    Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants;

2019
Efficacy and safety of ramucirumab plus modified FOLFIRI for metastatic colorectal cancer.
    International journal of clinical oncology, 2019, Volume: 24, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2019
mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival.
    International journal of clinical oncology, 2019, Volume: 24, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fema

2019
Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase II study.
    International journal of oncology, 2019, Volume: 54, Issue:4

    Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr

2019
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 109

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine;

2019
Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial.
    Expert review of pharmacoeconomics & outcomes research, 2019, Volume: 19, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2019
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 05-01, Volume: 30, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2019
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 06-10, Volume: 37, Issue:17

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab;

2019
Intrahepatic Oxaliplatin and Systemic 5-FU +/- Cetuximab in Chemo-Naïve Patients with Liver Metastases from Colorectal Cancer.
    Oncology, 2019, Volume: 96, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neopl

2019
Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study).
    Medical oncology (Northwood, London, England), 2019, Apr-24, Volume: 36, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2019
Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, random
    BMC cancer, 2019, 04-25, Volume: 19, Issue:1

    Topics: Adult; Bevacizumab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Cytored

2019
Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 08-01, Volume: 37, Issue:22

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms;

2019
Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 07-01, Volume: 30, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell-Free Nucleic Acids; Clinical

2019
CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial.
    Cancer communications (London, England), 2019, 05-24, Volume: 39, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy

2019
Curcumin Combined with FOLFOX Chemotherapy Is Safe and Tolerable in Patients with Metastatic Colorectal Cancer in a Randomized Phase IIa Trial.
    The Journal of nutrition, 2019, 07-01, Volume: 149, Issue:7

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cu

2019
Genistein combined with FOLFOX or FOLFOX-Bevacizumab for the treatment of metastatic colorectal cancer: phase I/II pilot study.
    Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Colorectal Neopla

2019
MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer.
    Targeted oncology, 2019, Volume: 14, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2019
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
    Clinical colorectal cancer, 2019, Volume: 18, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2019
Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial).
    British journal of cancer, 2019, Volume: 121, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuxim

2019
Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab.
    Drugs in R&D, 2019, Volume: 19, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2019
Selective TACE with irinotecan-loaded 40 μm microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study.
    BMC cancer, 2019, Aug-01, Volume: 19, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camp

2019
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
    Investigational new drugs, 2013, Volume: 31, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2013
Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-10, Volume: 31, Issue:11

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols;

2013
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2013
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2013
An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT].
    BMC cancer, 2013, Mar-15, Volume: 13

    Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2013
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2013
Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands.
    Acta oncologica (Stockholm, Sweden), 2013, Volume: 52, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2013
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, May-01, Volume: 19, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2013
Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial.
    British journal of cancer, 2013, Apr-30, Volume: 108, Issue:8

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2013
FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2013
Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jun-01, Volume: 31, Issue:16

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia

2013
A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer.
    Annals of surgical oncology, 2013, Volume: 20, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoembryonic Antigen; C

2013
A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine;

2013
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.
    Cancer, 2013, 07-15, Volume: 119, Issue:14

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axit

2013
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.
    Cancer medicine, 2013, Volume: 2, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimeta

2013
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:8

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C

2013
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin

2013
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin

2013
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin

2013
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin

2013
Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study.
    Journal of chemotherapy (Florence, Italy), 2013, Volume: 25, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl

2013
Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:1

    Topics: Ablation Techniques; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineop

2013
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:8

    Topics: Aged; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

2013
Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II Trials.
    Onkologie, 2013, Volume: 36, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2013
Capecitabine, irinotecan (CAPIRI) and sunitinib in metastatic colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2013, Volume: 52, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Studies; Colorect

2013
3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dideoxynucleoside

2013
Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer.
    Clinical colorectal cancer, 2013, Volume: 12, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2013
Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemoradiation: it means more than you think!
    Annals of surgical oncology, 2013, Volume: 20, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Col

2013
Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study.
    Investigational new drugs, 2013, Volume: 31, Issue:5

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2013
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimeta

2013
MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.
    British journal of cancer, 2013, Sep-03, Volume: 109, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop

2013
Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab.
    Cancer medicine, 2013, Volume: 2, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop

2013
Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205.
    British journal of cancer, 2013, Sep-17, Volume: 109, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2013
Effects of 5-fluorouracil on oxidative stress and calcium levels in the blood of patients with newly diagnosed colorectal cancer.
    Biological trace element research, 2013, Volume: 155, Issue:3

    Topics: Antimetabolites, Antineoplastic; Calcium; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male;

2013
A phase II clinical study of mFOLFOX6 plus bevacizumab as first-line therapy for Japanese advanced/recurrent colorectal cancer patients.
    Japanese journal of clinical oncology, 2013, Volume: 43, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2013
Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
    Clinical colorectal cancer, 2013, Volume: 12, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2013
Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030).
    British journal of cancer, 2013, Oct-01, Volume: 109, Issue:7

    Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Colorectal Neopl

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2013
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:11

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2013
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:11

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2013
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:11

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2013
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:11

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2013
[Effectiveness of combined systemic and regional chemotherapy in treating patients with metastatic colorectal cancer after extrahepatic progression of the disease].
    Voprosy onkologii, 2013, Volume: 59, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Reg

2013
UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.
    Cancer science, 2013, Volume: 104, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2013
Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer.
    British journal of cancer, 2013, Oct-01, Volume: 109, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2013
FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplas

2013
Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer.
    Journal of geriatric oncology, 2013, Volume: 4, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine;

2013
A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
    Clinical colorectal cancer, 2013, Volume: 12, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2013
Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial.
    BMC cancer, 2013, Oct-04, Volume: 13

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2013
Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha.
    Cancer, 2013, Dec-01, Volume: 119, Issue:23

    Topics: Adult; Aged; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal

2013
Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.
    Molecular oncology, 2014, Volume: 8, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co

2014
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo

2013
Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:6

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2013
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer: A randomized phase 1b/2 trial.
    Cancer, 2013, Dec-15, Volume: 119, Issue:24

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2013
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:1

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2014
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2014
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2014
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2014
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2014
Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.
    British journal of cancer, 2013, Nov-26, Volume: 109, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Proteins; Capecitabine; Colorectal

2013
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:2

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2014
Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2013
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
    Clinical colorectal cancer, 2013, Volume: 12, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2013
Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).
    Anti-cancer drugs, 2014, Volume: 25, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2014
The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe

2014
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2013
Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.
    Oncology, 2013, Volume: 85, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2013
Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients.
    BioMed research international, 2013, Volume: 2013

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2013
Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1.
    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2014, Volume: 27, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Chemotherapy, Adjuvant; Colo

2014
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2014, Volume: 37, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2014
Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer.
    Journal of surgical oncology, 2014, Volume: 109, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colore

2014
Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:3

    Topics: Adiponectin; Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemo

2014
Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.
    Clinical colorectal cancer, 2014, Volume: 13, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo

2014
Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2014
FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study.
    Clinical colorectal cancer, 2014, Volume: 13, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2014
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.
    BMC cancer, 2013, Dec-27, Volume: 13

    Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-2; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2013
Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.
    Journal of clinical pharmacology, 2014, Volume: 54, Issue:5

    Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto

2014
Hyperthermic intraperitoneal chemotherapy using a combination of mitomycin C,5-fluorouracil, and oxaliplatin in patients at high risk of colorectal peritoneal metastasis: A Phase I clinical study.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2014, Volume: 40, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Colorectal Neo

2014
Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.
    Anticancer research, 2014, Volume: 34, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2014
Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.
    The oncologist, 2014, Volume: 19, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2014
A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.
    Journal of geriatric oncology, 2013, Volume: 4, Issue:4

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites

2013
Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.
    PloS one, 2014, Volume: 9, Issue:2

    Topics: Adipokines; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin

2014
Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study.
    Anticancer research, 2014, Volume: 34, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2014
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-01, Volume: 32, Issue:10

    Topics: Adult; Aged; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2014
Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer.
    American journal of clinical oncology, 2016, Volume: 39, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2016
Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial.
    British journal of cancer, 2014, Mar-18, Volume: 110, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Catheterization, Central Venous; Cohor

2014
Targeted chemoradiation in metastatic colorectal cancer: a phase I trial of 131I-huA33 with concurrent capecitabine.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014, Volume: 55, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antimetabolites, Antineoplasti

2014
The impact of dose/time modification in irinotecan- and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2014
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:5

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2014
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:5

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2014
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:5

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2014
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:5

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2014
Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
FOLFIRI-bevacizumab and concurrent low-dose radiotherapy in metastatic colorectal cancer: preliminary results of a phase I-II study.
    Journal of chemotherapy (Florence, Italy), 2014, Volume: 26, Issue:6

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2014
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
    Annals of surgery, 2015, Volume: 261, Issue:2

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap

2015
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
    Annals of surgery, 2015, Volume: 261, Issue:2

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap

2015
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
    Annals of surgery, 2015, Volume: 261, Issue:2

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap

2015
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
    Annals of surgery, 2015, Volume: 261, Issue:2

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherap

2015
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.
    The oncologist, 2014, Volume: 19, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2014
Mitomycin C and high-dose 5-fluorouracil with folinic acid as a therapeutic option for heavily pretreated patients with metastatic colorectal cancer: prospective phase II trial.
    The oncologist, 2014, Volume: 19, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; D

2014
PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Jul-20, Volume: 32, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo

2014
Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study.
    Anticancer research, 2014, Volume: 34, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2014
Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients.
    Anticancer research, 2014, Volume: 34, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2014
Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:6

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab;

2014
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:6

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2014
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2014
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2014
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2014
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2014
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2014
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2014
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2014
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2014
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2014
Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research G
    BMC cancer, 2014, Apr-22, Volume: 14

    Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2014
FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms.
    BMC research notes, 2014, Apr-23, Volume: 7

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
    Oncology research, 2013, Volume: 21, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2013
Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2014
FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data.
    International journal of clinical pharmacology and therapeutics, 2014, Volume: 52, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm

2014
Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer.
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo

2014
A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohor

2014
FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.
    BMC cancer, 2014, May-19, Volume: 14

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetu

2014
Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2014
First-line bevacizumab and capecitabine-oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study.
    British journal of cancer, 2014, Jul-15, Volume: 111, Issue:2

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic

2014
Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final r
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:13

    Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy

2014
Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis.
    Journal of geriatric oncology, 2014, Oct-01, Volume: 5, Issue:4

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal

2014
FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-on
    BMC cancer, 2014, Jul-09, Volume: 14

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combine

2014
Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer.
    BMC cancer, 2014, Jul-19, Volume: 14

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cet

2014
Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.
    Clinical colorectal cancer, 2014, Volume: 13, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2014
Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.
    The pharmacogenomics journal, 2015, Volume: 15, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2014
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2014
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2014
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2014
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2014
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2014
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2014
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2014
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2014
Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2014, Volume: 12, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms;

2014
A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl

2015
Effects of cytokine-induced killer cell treatment in colorectal cancer patients: a retrospective study.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2014, Volume: 68, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cytokine-I

2014
A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy.
    The oncologist, 2014, Volume: 19, Issue:9

    Topics: Adult; Area Under Curve; Body Surface Area; Colorectal Neoplasms; Dose-Response Relationship, Drug;

2014
Association between chemotherapy and plasma adipokines in patients with colorectal cancer.
    Pharmacological reports : PR, 2014, Volume: 66, Issue:5

    Topics: Adipokines; Adipose Tissue; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colo

2014
Effectiveness of a novel herbal agent MB-6 as a potential adjunct to 5-fluoracil-based chemotherapy in colorectal cancer.
    Nutrition research (New York, N.Y.), 2014, Volume: 34, Issue:7

    Topics: Aged; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; An

2014
Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; China; Colorectal Neoplas

2014
Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:17

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2014
Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study.
    BMC cancer, 2014, Oct-02, Volume: 14

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2014
A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study).
    The oncologist, 2014, Volume: 19, Issue:11

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia

2014
Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer.
    Cell death and differentiation, 2015, Volume: 22, Issue:5

    Topics: Amino Acid Substitution; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female;

2015
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Should the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Jan-20, Volume: 33, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camp

2015
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2015
Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study).
    BMC cancer, 2014, Nov-22, Volume: 14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2014
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
    BMC cancer, 2014, Nov-26, Volume: 14

    Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Administ

2014
A phase I study of UGT1A1 *28/*6 genotype-directed dosing of irinotecan (CPT-11) in Korean patients with metastatic colorectal cancer receiving FOLFIRI.
    Oncology, 2015, Volume: 88, Issue:3

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorect

2015
A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808).
    Annals of surgical oncology, 2015, Volume: 22, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothecin; Colorecta

2015
Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy.
    Zeitschrift fur Gastroenterologie, 2014, Volume: 52, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarke

2014
A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer.
    Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevaci

2015
Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study.
    BMC cancer, 2014, Dec-01, Volume: 14

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Colorectal Neoplasms; Fluo

2014
Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients.
    BMC cancer, 2014, Dec-19, Volume: 14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal

2014
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2015
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2015
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2015
Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2015
Oxaliplatin and ototoxicity: is it really safe for hearing?
    Turkish journal of medical sciences, 2014, Volume: 44, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Co

2014
Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

2015
A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv

2015
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:3

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2015
Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer.
    British journal of cancer, 2015, Feb-17, Volume: 112, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2015
A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.
    Clinical colorectal cancer, 2015, Volume: 14, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

2015
Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2015
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Mar-01, Volume: 33, Issue:7

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biom

2015
Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:4

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2015
Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.
    International journal of clinical oncology, 2015, Volume: 20, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Double-Blind Method; Dru

2015
Phase II study on hepatic arterial infusion chemotherapy using percutaneous catheter placement techniques for liver metastases from colorectal cancer (JFMC28 study).
    Asia-Pacific journal of clinical oncology, 2015, Volume: 11, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

2015
A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2015
Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2015
FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Clinical colorectal cancer, 2015, Volume: 14, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Codon; Colorectal Neoplasms; Female

2015
Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer.
    Sleep medicine, 2015, Volume: 16, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal Neoplasms; Fe

2015
Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer.
    Clinical colorectal cancer, 2015, Volume: 14, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine

2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2015
Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2015
Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc

2015
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
    British journal of cancer, 2015, Mar-17, Volume: 112, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2015
Randomized phase II study of 5-fluorouracil hepatic arterial infusion with or without antineoplastons as an adjuvant therapy after hepatectomy for liver metastases from colorectal cancer.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzeneacetam

2015
Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2015
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Class I Phosphat

2015
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
    Clinical colorectal cancer, 2015, Volume: 14, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms;

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Lancet (London, England), 2015, May-09, Volume: 385, Issue:9980

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study.
    Anticancer research, 2015, Volume: 35, Issue:4

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Co

2015
Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:7

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2015
Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): study protocol for a randomised control trial.
    Trials, 2015, Mar-24, Volume: 16

    Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc

2015
Endostar combined with irinotecan/calcium folinate/5-fluorouracil (FOLFIRI) for treating advanced colorectal cancer: A clinical study.
    Journal of chemotherapy (Florence, Italy), 2015, Volume: 27, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blin
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2015
Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802).
    BMC cancer, 2015, Mar-25, Volume: 15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2015
Prognostic value of HLA class I expression in patients with colorectal cancer.
    World journal of surgical oncology, 2015, Feb-12, Volume: 13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2015
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2015
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:10

    Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Capecitabine; Colorectal Ne

2015
Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).
    Journal of hepato-biliary-pancreatic sciences, 2015, Volume: 22, Issue:8

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr

2015
A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.
    Investigational new drugs, 2015, Volume: 33, Issue:4

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2015
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:10

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Codon;

2015
Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).
    BMC cancer, 2015, May-06, Volume: 15

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Ca

2015
Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group.
    Clinical colorectal cancer, 2015, Volume: 14, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Disease-Free

2015
Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2015
Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or
    BMC cancer, 2015, May-10, Volume: 15

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Fem

2015
Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy.
    Cancer letters, 2015, Aug-10, Volume: 364, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Colorectal Neoplasms; Curcumin;

2015
SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2015, Volume: 14, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2015
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal

2015
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.
    British journal of cancer, 2015, Jun-09, Volume: 112, Issue:12

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2015
The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis.
    Journal of chemotherapy (Florence, Italy), 2016, Volume: 28, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2016
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
    International journal of clinical oncology, 2016, Volume: 21, Issue:1

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co

2016
Randomised study of tegafur-uracil plus leucovorin versus capecitabine as first-line therapy in elderly patients with advanced colorectal cancer--TLC study.
    Journal of geriatric oncology, 2015, Volume: 6, Issue:4

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto

2015
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
    World journal of gastroenterology, 2015, Jun-21, Volume: 21, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc

2015
Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma.
    Anticancer research, 2015, Volume: 35, Issue:7

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2015
Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
    Drug design, development and therapy, 2015, Volume: 9

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemo

2015
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
    British journal of cancer, 2015, Jun-30, Volume: 113, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biom

2015
Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis.
    Cancer, 2015, Oct-15, Volume: 121, Issue:20

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co

2015
The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
    Hepato-gastroenterology, 2014, Volume: 61, Issue:132

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvan

2014
S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N

2015
[HEMIHEPATECTOMY FOR RESECTABLE HEPATIC METASTASIS FROM COLORECTAL CANCER WITH POOR PROGNOSIS].
    Voprosy onkologii, 2015, Volume: 61, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2015
A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors.
    Cancer, 2015, Nov-01, Volume: 121, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung;

2015
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-10, Volume: 33, Issue:32

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C

2015
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva

2015
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
    British journal of cancer, 2015, Sep-15, Volume: 113, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2015
A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
    International journal of clinical oncology, 2016, Volume: 21, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Be

2016
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptoth

2015
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptoth

2015
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptoth

2015
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptoth

2015
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, 12-15, Volume: 21, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2015
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, 12-15, Volume: 21, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2015
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, 12-15, Volume: 21, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2015
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, 12-15, Volume: 21, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2015
Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:17

    Topics: Adult; Aged; Antigens, CD; Antigens, CD20; Antigens, Differentiation, Myelomonocytic; Antineoplastic

2015
Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
    BMC cancer, 2015, Sep-09, Volume: 15

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva

2015
Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.
    British journal of cancer, 2015, Sep-29, Volume: 113, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc

2015
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc

2015
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc

2015
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc

2015
Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc

2015
Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
    BMC cancer, 2015, Oct-14, Volume: 15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuxi

2015
Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).
    International journal of clinical oncology, 2016, Volume: 21, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2016
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2016
High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin;

2015
[Safety evaluation of intraoperative peritoneal chemotherapy with Lobaplatin for advanced colorectal cancers].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2015, Volume: 18, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cyclobu

2015
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer.
    British journal of cancer, 2015, Nov-17, Volume: 113, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci

2015
Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neo

2016
Q-TWiST analysis of panitumumab plus FOLFOX4 versus FOLFOX4 alone in patients with previously untreated wild-type RAS metastatic colorectal cancer.
    Current medical research and opinion, 2016, Volume: 32, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2016
Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab.
    Pharmacogenomics, 2015, Volume: 16, Issue:18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Disea

2015
Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.
    Journal of clinical pharmacology, 2016, Volume: 56, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2016
Evaluation of resectability after neoadjuvant chemotherapy for primary non-resectable colorectal liver metastases: A multicenter study.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2016, Volume: 42, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Co

2016
Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
    Clinical colorectal cancer, 2016, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cape

2016
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing A
    Targeted oncology, 2016, Volume: 11, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2016
High Resectability Rate of Initially Unresectable Colorectal Liver Metastases After UGT1A1-Adapted High-Dose Irinotecan Combined with LV5FU2 and Cetuximab: A Multicenter Phase II Study (ERBIFORT).
    Annals of surgical oncology, 2016, Volume: 23, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neo

2016
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 53

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu

2016
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 53

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu

2016
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 53

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu

2016
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 53

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu

2016
Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.
    British journal of cancer, 2016, Feb-16, Volume: 114, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2016
[Efficacy evaluation of heat-sensitive moxibustion for chemotherapy symptoms of large intestine cancer].
    Zhongguo zhen jiu = Chinese acupuncture & moxibustion, 2015, Volume: 35, Issue:10

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2015
PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.
    Cancer medicine, 2016, Volume: 5, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2016
Low-dose radiotherapy and concurrent FOLFIRI-bevacizumab: a Phase II study.
    Future oncology (London, England), 2016, Volume: 12, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemoradioth

2016
Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 07-01, Volume: 22, Issue:13

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined

2016
Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial.
    Oncotarget, 2016, Mar-01, Volume: 7, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2016
A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
    BMC cancer, 2016, Feb-08, Volume: 16

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2016
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:5

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2016
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:5

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2016
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:5

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2016
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:5

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2016
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 05-20, Volume: 34, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color

2016
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 05-20, Volume: 34, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color

2016
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 05-20, Volume: 34, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color

2016
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 05-20, Volume: 34, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color

2016
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 05-20, Volume: 34, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color

2016
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 05-20, Volume: 34, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color

2016
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 05-20, Volume: 34, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color

2016
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 05-20, Volume: 34, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color

2016
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 05-20, Volume: 34, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Color

2016
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only.
    The oncologist, 2016, Volume: 21, Issue:3

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neo

2016
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2016
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2016
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2016
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2016
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2016
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2016
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2016
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2016
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2016
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Class I Phosphatidylinositol 3-Kinases; C

2016
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Colorectal Neoplasms; CpG Islands; DNA Methylatio

2016
Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
    International journal of cancer, 2016, Aug-15, Volume: 139, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2016
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv

2016
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N

2016
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:8

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2016
Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-
    BMJ open, 2016, 06-02, Volume: 6, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabi

2016
Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice.
    Clinical colorectal cancer, 2016, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colorectal Neoplasms;

2016
Phase 2 Trial of Metformin Combined With 5-Fluorouracil in Patients With Refractory Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2016, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv

2016
Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial.
    JAMA oncology, 2016, Sep-01, Volume: 2, Issue:9

    Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Class I Phosphatidylinositol 3-Kinases;

2016
Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study.
    Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2016
Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy.
    Cancer medicine, 2016, Volume: 5, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva

2016
Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial.
    PloS one, 2016, Volume: 11, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2016
Clinical effects of bevacizumab targeted treatment on advanced colorectal cancer with liver metastasis.
    European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum

2016
Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV Study.
    Clinical pharmacokinetics, 2017, Volume: 56, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2017
BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Oct-15, Volume: 22, Issue:20

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tu

2016
LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2016, Volume: 55, Issue:12

    Topics: AC133 Antigen; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Co

2016
Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen.
    Cancer research, 2016, 09-15, Volume: 76, Issue:18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Disease-Free Surv

2016
TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.
    Oncotarget, 2016, Sep-13, Volume: 7, Issue:37

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cell Line, Tumor; Cell Movemen

2016
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:11

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2016
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C

2016
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C

2016
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C

2016
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C

2016
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
    Cancer science, 2016, Volume: 107, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Antibodies, Monoclonal; Antineoplastic Combined Chemotherap

2016
Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:12

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2016
Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers.
    International journal of clinical oncology, 2017, Volume: 22, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2017
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
    Clinical colorectal cancer, 2017, Volume: 16, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cetuximab; Co

2017
Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
    Anticancer research, 2016, Volume: 36, Issue:10

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvan

2016
Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 74

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2017
Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
    Oncotarget, 2017, May-23, Volume: 8, Issue:21

    Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptothecin;

2017
Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Drug design, development and therapy, 2016, Volume: 10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot

2016
Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 03-01, Volume: 28, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2017
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306).
    International journal of cancer, 2017, Apr-15, Volume: 140, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; C

2017
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-V
    Clinical colorectal cancer, 2017, Volume: 16, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2017
Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy.
    International journal of clinical oncology, 2017, Volume: 22, Issue:3

    Topics: Aged; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Haplotypes; Humans; Male; Methy

2017
Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Journal of medical economics, 2017, Volume: 20, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bev

2017
Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody.
    Oncology, 2017, Volume: 92, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Ca

2017
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
    Journal of cancer research and clinical oncology, 2017, Volume: 143, Issue:6

    Topics: Adenocarcinoma; Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Ant

2017
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.
    The oncologist, 2017, Volume: 22, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2017
Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab.
    Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:3

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Ag

2017
Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
    Anti-cancer drugs, 2017, Volume: 28, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuxi

2017
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
    The oncologist, 2017, Volume: 22, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Mono

2017
mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design
    Clinical colorectal cancer, 2017, Volume: 16, Issue:2

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diseas

2017
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Annals of surgical oncology, 2008, Volume: 15, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R

2008
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Annals of surgical oncology, 2008, Volume: 15, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R

2008
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Annals of surgical oncology, 2008, Volume: 15, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R

2008
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Annals of surgical oncology, 2008, Volume: 15, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R

2008
High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: a new way to allow resection of liver metastases?
    Oncology, 2008, Volume: 74, Issue:1-2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos

2008
Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.
    Oncology, 2008, Volume: 74, Issue:1-2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2008
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci

2008
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study.
    British journal of cancer, 2008, Jul-22, Volume: 99, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De

2008
Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group.
    International journal of colorectal disease, 2008, Volume: 23, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; DNA, Neoplasm; Drug The

2008
Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-10, Volume: 26, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Chemotherapy, Ad

2008
Efficacy of a continuous venous infusion of fluorouracil and daily divided dose cisplatin as adjuvant therapy in resectable colorectal cancer: a prospective randomized trial.
    Surgery today, 2008, Volume: 38, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colo

2008
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-20, Volume: 26, Issue:21

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2008
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2008
Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-01, Volume: 14, Issue:15

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; Camptothecin; Carcinoembryonic A

2008
Adjuvant perioperative portal vein or peripheral intravenous chemotherapy for potentially curative colorectal cancer: long-term results of a randomized controlled trial.
    International journal of colorectal disease, 2008, Volume: 23, Issue:12

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C

2008
Cytotoxic chemotherapy for incurable colorectal cancer: living with a PICC-line.
    Journal of clinical nursing, 2008, Volume: 17, Issue:18

    Topics: Activities of Daily Living; Adult; Aged; Antimetabolites, Antineoplastic; Catheterization, Central V

2008
A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer.
    Investigational new drugs, 2009, Volume: 27, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols

2009
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia

2009
Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.
    Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2009
Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:15

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor;

2008
Effect of oral administration of kefir on serum proinflammatory cytokines on 5-FU induced oral mucositis in patients with colorectal cancer.
    Investigational new drugs, 2008, Volume: 26, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cultured M

2008
A phase I study of EKB-569 in combination with capecitabine in patients with advanced colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Sep-01, Volume: 14, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Aminoquinolines; Aniline Compounds; Antineoplastic Combined Chemothe

2008
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
    The oncologist, 2008, Volume: 13, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
    The oncologist, 2008, Volume: 13, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
    The oncologist, 2008, Volume: 13, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
    The oncologist, 2008, Volume: 13, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-20, Volume: 26, Issue:30

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2008
GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group.
    British journal of cancer, 2008, Oct-21, Volume: 99, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp

2008
An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acid

2009
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-01, Volume: 26, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci

2008
Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer.
    American journal of clinical oncology, 2008, Volume: 31, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone

2008
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Diseas

2009
[Phase I study of CPT-11 and continuous 5-FU / l-leucovorin combination therapy(modified AIO regimen)in patients with metastatic colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined M

2008
Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cohort Stud

2009
Preoperative chemoradiation for locally advanced rectal cancer with capecitabine 2,000 mg/m2/day.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2008, Volume: 91, Issue:10

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neopl

2008
A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Nov-01, Volume: 14, Issue:21

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2008
Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).
    Biological & pharmaceutical bulletin, 2008, Volume: 31, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin

2008
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-10, Volume: 26, Issue:35

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Colorectal Neoplasms; Di

2008
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-10, Volume: 26, Issue:35

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Colorectal Neoplasms; Di

2008
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-10, Volume: 26, Issue:35

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Colorectal Neoplasms; Di

2008
Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Dec-10, Volume: 26, Issue:35

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Colorectal Neoplasms; Di

2008
Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer.
    Investigational new drugs, 2009, Volume: 27, Issue:3

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorec

2009
A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2009, Volume: 17, Issue:2

    Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin;

2009
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
    Journal of chemotherapy (Florence, Italy), 2008, Volume: 20, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2008
No socioeconomic inequalities in colorectal cancer survival within a randomised clinical trial.
    British journal of cancer, 2008, Dec-02, Volume: 99, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Thera

2008
Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Clinical colorectal cancer, 2008, Volume: 7, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2008
Combination therapy with mitomycin C (NSC-26980), 5-fluorouracil (NSC-19893), and cytosine arabinoside (NSC-63878) for advanced cancer in man.
    Cancer chemotherapy reports, 1972, Volume: 56, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Colorectal

1972
A pilot human evaluation of a formulation of irinotecan and hyaluronic acid in 5-fluorouracil-refractory metastatic colorectal cancer patients.
    Chemotherapy, 2009, Volume: 55, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Carriers; F

2009
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-10, Volume: 27, Issue:2

    Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant

2009
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-10, Volume: 27, Issue:2

    Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant

2009
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-10, Volume: 27, Issue:2

    Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant

2009
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-10, Volume: 27, Issue:2

    Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant

2009
Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

2009
Phase II study of UFT with leucovorin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastases of colorectal cancer.
    Chemotherapy, 2009, Volume: 55, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dih

2009
A dynamic model of hand-and-foot syndrome in patients receiving capecitabine.
    Clinical pharmacology and therapeutics, 2009, Volume: 85, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluoroura

2009
A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer.
    Critical reviews in oncology/hematology, 2009, Volume: 71, Issue:3

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2009
Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Codon;

2009
Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
    BMC cancer, 2008, Dec-23, Volume: 8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2008
Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorecta

2009
Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.
    Critical reviews in oncology/hematology, 2009, Volume: 70, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

2009
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Feb-10, Volume: 27, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
    The oncologist, 2009, Volume: 14, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo

2009
DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplas

2009
Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients.
    World journal of gastroenterology, 2009, Jan-28, Volume: 15, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2009
Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.
    British journal of cancer, 2009, Jan-27, Volume: 100, Issue:2

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2009
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
    British journal of cancer, 2009, Jan-27, Volume: 100, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 8

2009
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2009
Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
    American journal of clinical oncology, 2009, Volume: 32, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptot

2009
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
    The New England journal of medicine, 2009, Feb-05, Volume: 360, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer.
    Clinical colorectal cancer, 2009, Volume: 8, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin

2009
Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.
    Clinical colorectal cancer, 2009, Volume: 8, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2009
XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis.
    Current medical research and opinion, 2009, Volume: 25, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorect

2009
Phase I study of cediranib in combination with oxaliplatin and infusional 5-Fluorouracil in patients with advanced colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-15, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2009
Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2009
Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Apr-20, Volume: 27, Issue:12

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy

2009
FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer.
    The oncologist, 2009, Volume: 14, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2009
Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
    Anti-cancer drugs, 2009, Volume: 20, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chemotherapy

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Apr-02, Volume: 360, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
[Role of sequential chemotherapy in the treatment of metastatic colorectal cancer].
    Recenti progressi in medicina, 2009, Volume: 100, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr

2009
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
    BMC cancer, 2009, Apr-14, Volume: 9

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2009
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jun-10, Volume: 27, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2009
Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study.
    Cancer, 2009, Jun-15, Volume: 115, Issue:12

    Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2009
A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, May-01, Volume: 15, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorec

2009
Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer.
    British journal of cancer, 2009, May-19, Volume: 100, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2009
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
    BMC cancer, 2009, Apr-22, Volume: 9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplas

2009
A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603.
    Japanese journal of clinical oncology, 2009, Volume: 39, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Dis

2009
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer.
    British journal of cancer, 2009, Jun-02, Volume: 100, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal

2009
A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases.
    BMC cancer, 2009, May-20, Volume: 9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neopl

2009
FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols

2009
Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials.
    British journal of cancer, 2009, Jul-07, Volume: 101, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cost-Benefit Ana

2009
Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array.
    British journal of cancer, 2009, Jul-21, Volume: 101, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated

2009
Effects of bevacizumab on plasma concentration of irinotecan and its metabolites in advanced colorectal cancer patients receiving FOLFIRI with bevacizumab as second-line chemotherapy.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2010
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com

2009
[Clinical research of bevacizumab in combination with irinotecan, fluorouracil and leucovorin for advanced metastatic colorectal cancer].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2009, Volume: 12, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2009
[Efficacy and safety of combination of irinotecan and capecitabine in patients with metastatic colorectal cancer after failure of chemotherapy with oxaliplatin].
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2009, Volume: 31, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal

2009
A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2010
Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial.
    Cancer, 2009, Oct-15, Volume: 115, Issue:20

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2009
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.
    Oncology, 2009, Volume: 77, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-01, Volume: 27, Issue:25

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Black or African Ame

2009
Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-10, Volume: 27, Issue:26

    Topics: Abdominal Pain; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea

2009
Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-01, Volume: 27, Issue:25

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Australia; Brachytherapy; Camptothecin; Chemotherapy,

2009
Dynamic monitoring the TCR CDR3 spectratypes in patients with metastatic CRC treated with a combination of bevacizumab, irinotecan, fluorouracil, and leucovorin.
    Cancer immunology, immunotherapy : CII, 2010, Volume: 59, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2010
Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients.
    Journal of experimental & clinical cancer research : CR, 2009, Aug-07, Volume: 28

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Le

2009
[Effect of Shenqi Fuzheng injection combined with chemotherapy in treating advanced colorectal carcinoma].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2009, Volume: 29, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drugs, Chinese Herbal; Fluorou

2009
Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies

2010
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine;

2010
Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG).
    Critical reviews in oncology/hematology, 2010, Volume: 76, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2010
Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
    Oncology, 2009, Volume: 77, Issue:3-4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal

2009
Preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy: a placebo-controlled double-blind randomized phase II study (the GONE Study).
    Japanese journal of clinical oncology, 2009, Volume: 39, Issue:12

    Topics: Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child;

2009
Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group.
    British journal of cancer, 2009, Oct-06, Volume: 101, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci

2009
A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ca

2010
Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.
    Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Ne

2010
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-01, Volume: 27, Issue:34

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2009
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-01, Volume: 27, Issue:34

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2009
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-01, Volume: 27, Issue:34

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2009
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-01, Volume: 27, Issue:34

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2009
Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-20, Volume: 27, Issue:33

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2009
KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-10, Volume: 27, Issue:35

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tu

2009
Early supplementation of parenteral nutrition is capable of improving quality of life, chemotherapy-related toxicity and body composition in patients with advanced colorectal carcinoma undergoing palliative treatment: results from a prospective, randomize
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2010, Volume: 12, Issue:10 Online

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body W

2010
Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-20, Volume: 27, Issue:36

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neopla

2009
Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer.
    British journal of cancer, 2010, Jan-05, Volume: 102, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl

2010
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:7

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2010
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Ant

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jan-20, Volume: 28, Issue:3

    Topics: Adult; Aged; Angiogenesis Inducing Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized

2010
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
    Anti-cancer drugs, 2010, Volume: 21, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin

2010
Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-10, Volume: 28, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl

2010
Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-10, Volume: 28, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cat

2010
A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

2010
Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status.
    British journal of cancer, 2010, Jan-19, Volume: 102, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2010
Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study.
    International journal of clinical oncology, 2010, Volume: 15, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium; Colorectal Neoplasms; Drug Administration S

2010
Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial.
    Medical science monitor : international medical journal of experimental and clinical research, 2010, Volume: 16, Issue:2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2010
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens.
    Investigational new drugs, 2011, Volume: 29, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Capecitabine; Colorectal Neop

2011
Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.
    The pharmacogenomics journal, 2011, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe

2011
Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Onkologie, 2010, Volume: 33, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Ch

2010
Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
    British journal of cancer, 2010, Mar-16, Volume: 102, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma;

2010
Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplas

2011
Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies.
    Clinical drug investigation, 2010, Volume: 30, Issue:4

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothec

2010
Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?
    Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe

2010
Comparison of the levogyre and dextro-levogyre forms of leucovorin in a phase III trial of bimonthly LV5FU2 versus monthly 5-fluorouracil and high-dose leucovorin for patients with stage II and III colon cancer (GERCOR C96.1).
    Clinical colorectal cancer, 2010, Volume: 9, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemot

2010
A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
    Clinical colorectal cancer, 2010, Volume: 9, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2010
A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Clinical colorectal cancer, 2010, Volume: 9, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2010
Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-20, Volume: 28, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2010
Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2011
[Efficacy and toxicity analysis of XELOX and FOLFOX4 regimens as adjuvant chemotherapy for stage III colorectal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C

2010
[Short-term therapeutic effect and safety of endostar combined with XELIRI regimen in the treatment of advanced colorectal cancer].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2010, Volume: 30, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal

2010
Dietary methionine restriction with FOLFOX regimen as first line therapy of metastatic colorectal cancer: a feasibility study.
    Oncology, 2010, Volume: 78, Issue:3-4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diet; Disease Progressio

2010
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer.
    British journal of cancer, 2010, May-11, Volume: 102, Issue:10

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2010
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.
    Oncology reports, 2010, Volume: 23, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos

2010
[Assessment of the protective effect of calcium-magnesium infusion and glutathione on oxaliplatin-induced neurotoxicity].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:3

    Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Calcium Gl

2010
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:10

    Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jul-15, Volume: 16, Issue:14

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla

2010
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
    International journal of cancer, 2011, Feb-01, Volume: 128, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Coloni

2011
Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2011
Plasma disposition of capecitabine and its metabolites 5'DFCR and 5'DFUR in a standard and dose-intensified monotherapy regimen.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:3

    Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Capecitabine; Colorectal Neoplasms; Cross-O

2011
Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.
    Trials, 2010, May-25, Volume: 11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy

2010
A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jun-01, Volume: 16, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Colorecta

2010
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-01, Volume: 28, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2010
Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: a phase I trial (SAKK 41/03).
    Onkologie, 2010, Volume: 33, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De

2010
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-10, Volume: 28, Issue:23

    Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Emboliza

2010
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial.
    World journal of gastroenterology, 2010, Jul-07, Volume: 16, Issue:25

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
Molecular markers in circulating tumour cells from metastatic colorectal cancer patients.
    Journal of cellular and molecular medicine, 2010, Volume: 14, Issue:8

    Topics: AC133 Antigen; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antigens, CD; Antineoplastic

2010
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
    British journal of cancer, 2010, Aug-10, Volume: 103, Issue:4

    Topics: Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms

2010
A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.
    Clinical colorectal cancer, 2010, Volume: 9, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2010
[Modified FOLFIRI (l-LV, 5-fluorouracil and irinotecan) therapy for Japanese patients with metastatic colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplas

2010
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci

2011
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci

2011
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci

2011
Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci

2011
Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics.
    Transactions of the American Clinical and Climatological Association, 2010, Volume: 121

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2010
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2010
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2010
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2010
Treatment of colorectal cancer with and without bevacizumab: a phase III study.
    Oncology, 2010, Volume: 78, Issue:5-6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Ant

2010
A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv

2011
Multicentre phase II study of XELOX with bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer: an ASCA study.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2011
Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients.
    Investigational new drugs, 2012, Volume: 30, Issue:1

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera

2012
Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2011
Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
    Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:7

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2010
[Efficacy and safety of bevacizumab plus capecitabine for metastatic colorectal cancer].
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2010, Volume: 32, Issue:4

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2010
[Influence of FOLFOX regimen on the immunologic function in patients with advanced colorectal cancer].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2010, Volume: 13, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2010
Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
    Asia-Pacific journal of clinical oncology, 2010, Volume: 6, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Col

2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2010
A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment.
    BMC cancer, 2010, Oct-11, Volume: 10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2010
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.
    BMC cancer, 2010, Oct-19, Volume: 10

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2010
Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2011
Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX.
    Anticancer research, 2010, Volume: 30, Issue:10

    Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Co

2010
Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
    Anticancer research, 2010, Volume: 30, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2010
Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2011
Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer.
    Anti-cancer drugs, 2011, Volume: 22, Issue:2

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu

2011
Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy.
    Pharmacogenetics and genomics, 2011, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta

2011
Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies.
    Investigational new drugs, 2012, Volume: 30, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2012
The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2011
Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2011
Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Dec-20, Volume: 28, Issue:36

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2010
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
    Journal of cancer research and clinical oncology, 2011, Volume: 137, Issue:6

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; De

2011
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
    Journal of cancer research and clinical oncology, 2011, Volume: 137, Issue:6

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; De

2011
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
    Journal of cancer research and clinical oncology, 2011, Volume: 137, Issue:6

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; De

2011
The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study.
    Journal of cancer research and clinical oncology, 2011, Volume: 137, Issue:6

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; De

2011
Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy.
    Asia-Pacific journal of clinical oncology, 2010, Volume: 6, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Gluconate; Capecita

2010
Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer.
    Investigational new drugs, 2012, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B

2012
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.
    Journal of the National Cancer Institute, 2011, Jan-05, Volume: 103, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2011
Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study.
    Onkologie, 2010, Volume: 33, Issue:12

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr

2010
Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
    Anti-cancer drugs, 2011, Volume: 22, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone M

2011
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
    Investigational new drugs, 2012, Volume: 30, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment
    International journal of clinical pharmacology and therapeutics, 2011, Volume: 49, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm

2011
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
    Investigational new drugs, 2012, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplas

2012
A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience.
    Surgery today, 2011, Volume: 41, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2011
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.
    Clinical colorectal cancer, 2010, Volume: 9, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2010
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2011
Normalization of T cell receptor repertoire diversity in patients with advanced colorectal cancer who responded to chemotherapy.
    Cancer science, 2011, Volume: 102, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Cont

2011
The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen.
    International journal of clinical oncology, 2011, Volume: 16, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drugs

2011
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.
    Anticancer research, 2011, Volume: 31, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2011
A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2011
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-10, Volume: 29, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2011
Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal

2011
Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
    Oncology, 2010, Volume: 79, Issue:3-4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Cos

2010
Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Apr-01, Volume: 29, Issue:10

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy,

2011
Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer.
    Journal of clinical pharmacology, 2012, Volume: 52, Issue:3

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2012
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.
    British journal of cancer, 2011, Mar-29, Volume: 104, Issue:7

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2011
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.
    Investigational new drugs, 2012, Volume: 30, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2012
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
    British journal of cancer, 2011, Apr-12, Volume: 104, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2011
A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:5

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizuma

2011
Phase II study of FOLFOX4 with "wait and go" strategy as first-line treatment for metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2011
[Immune enhancing effect of modified sijunzi decoction on patients with colorectal cancer undergoing chemotherapy].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2011, Volume: 31, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drugs, Chinese Herbal; Female;

2011
Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study.
    International journal of clinical oncology, 2011, Volume: 16, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla

2011
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2012
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, May-20, Volume: 29, Issue:15

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Che

2011
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, May-20, Volume: 29, Issue:15

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Che

2011
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
    Oncology, 2010, Volume: 79, Issue:5-6

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2010
[Phase I / II study of XELOX plus bevacizumab in Japanese patients with metastatic colorectal cancer(JO19380)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2011
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, May-20, Volume: 29, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2011
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, May-20, Volume: 29, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2011
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, May-20, Volume: 29, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2011
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, May-20, Volume: 29, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2011
Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.
    Anticancer research, 2011, Volume: 31, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2011
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
    Lancet (London, England), 2011, May-21, Volume: 377, Issue:9779

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2011
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
    Lancet (London, England), 2011, May-21, Volume: 377, Issue:9779

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2011
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
    Lancet (London, England), 2011, May-21, Volume: 377, Issue:9779

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2011
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
    Lancet (London, England), 2011, May-21, Volume: 377, Issue:9779

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2011
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal

2012
A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
    Clinical colorectal cancer, 2011, Mar-01, Volume: 10, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dis

2011
Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer.
    Investigational new drugs, 2012, Volume: 30, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort St

2012
Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741.
    The oncologist, 2011, Volume: 16, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ant

2011
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
    Lancet (London, England), 2011, Jun-18, Volume: 377, Issue:9783

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2011
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
    Lancet (London, England), 2011, Jun-18, Volume: 377, Issue:9783

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2011
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
    Lancet (London, England), 2011, Jun-18, Volume: 377, Issue:9783

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2011
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
    Lancet (London, England), 2011, Jun-18, Volume: 377, Issue:9783

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2011
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
    The Lancet. Oncology, 2011, Volume: 12, Issue:7

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Disease Progress

2011
Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-01, Volume: 29, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2011
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined

2011
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.
    British journal of cancer, 2011, Jun-28, Volume: 105, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore

2011
Oxidative damage to guanine nucleosides following combination chemotherapy with 5-fluorouracil and oxaliplatin.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, H

2012
Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.
    Clinical colorectal cancer, 2011, Volume: 10, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2011
Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52.
    Clinical colorectal cancer, 2012, Volume: 11, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2012
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.
    British journal of cancer, 2011, Jul-12, Volume: 105, Issue:2

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2011
Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study.
    Investigational new drugs, 2012, Volume: 30, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2012
Neoadjuvant treatment of colorectal liver metastases is associated with altered contrast enhancement on computed tomography.
    Cancer imaging : the official publication of the International Cancer Imaging Society, 2011, Jun-29, Volume: 11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2011
Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
    International journal of cancer, 2012, May-15, Volume: 130, Issue:10

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2012
Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer.
    International journal of clinical oncology, 2012, Volume: 17, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia

2012
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
    Clinical colorectal cancer, 2012, Volume: 11, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2012
Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cam

2011
[Results of adjuvant chemotherapy (XELOX) of advanced colorectal cancer].
    Voprosy onkologii, 2011, Volume: 57, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci

2011
[Chemotherapy in patients with non-resectable colorectal cancer metastases to the liver: systemic or regional?].
    Voprosy onkologii, 2011, Volume: 57, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2011
Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:4

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2012
Yiqi zhuyu decoction combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer.
    Chinese journal of integrative medicine, 2011, Volume: 17, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease

2011
Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta

2012
The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2012
Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study.
    Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl

2011
An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
    Clinical colorectal cancer, 2011, Volume: 10, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antine

2011
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.
    Clinical colorectal cancer, 2011, Volume: 10, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2011
Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963).
    Chronobiology international, 2011, Volume: 28, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Clock

2011
A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
    Clinical colorectal cancer, 2011, Volume: 10, Issue:2

    Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl

2011
A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer.
    Clinical colorectal cancer, 2011, Volume: 10, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop

2011
Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study.
    The oncologist, 2011, Volume: 16, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2011
A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
    BMC cancer, 2011, Aug-23, Volume: 11

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2011
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2011, Volume: 12, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorec

2011
Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients.
    Cancer biology & therapy, 2011, Oct-01, Volume: 12, Issue:7

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area U

2011
Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:5

    Topics: Adenocarcinoma; Aged; Algorithms; Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Colorect

2012
Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Oct-01, Volume: 17, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2011
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.
    Chinese journal of cancer, 2011, Volume: 30, Issue:10

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2011
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorect

2012
A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience.
    Surgery today, 2011, Volume: 41, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2011
Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Nov-20, Volume: 29, Issue:33

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore

2011
The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study.
    British journal of cancer, 2011, Nov-08, Volume: 105, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2011
The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
    Clinical colorectal cancer, 2011, Volume: 10, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2011
Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial.
    International journal of clinical oncology, 2012, Volume: 17, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2012
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.
    The oncologist, 2011, Volume: 16, Issue:11

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2011
A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2012
Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2012
Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.
    Clinical colorectal cancer, 2012, Volume: 11, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2012
Fast track multi-discipline treatment (FTMDT trial) versus conventional treatment in colorectal cancer--the design of a prospective randomized controlled study.
    BMC cancer, 2011, Nov-24, Volume: 11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Protocols; Colorectal Neoplas

2011
Response prediction in metastasised colorectal cancer using intratumoural thymidylate synthase: results of a randomised multicentre trial.
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male

2012
A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer.
    Investigational new drugs, 2012, Volume: 30, Issue:5

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jan-20, Volume: 30, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2012
FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study).
    Japanese journal of clinical oncology, 2012, Volume: 42, Issue:2

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2012
Multi-center phase II study of FLOX for advanced colorectal cancer patients in Japan: SWIFT 3 study.
    Anticancer research, 2011, Volume: 31, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu

2011
A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer.
    Cancer, 2012, Sep-01, Volume: 118, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2012
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2012
Phase III aflibercept-chemotherapy combination trial shows benefit in previously treated metastatic colorectal cancer patients.
    Oncology (Williston Park, N.Y.), 2011, Nov-15, Volume: 25, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

2011
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
    The oncologist, 2012, Volume: 17, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop

2012
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC).
    British journal of cancer, 2012, Jan-31, Volume: 106, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2012
Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer.
    The Journal of international medical research, 2011, Volume: 39, Issue:6

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal N

2011
A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study.
    Journal of gastrointestinal cancer, 2012, Volume: 43, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2012
A clinical study on safety and efficacy of Aidi injection combined with chemotherapy.
    Asian Pacific journal of cancer prevention : APJCP, 2011, Volume: 12, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal

2011
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983).
    Annals of surgery, 2012, Volume: 255, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fem

2012
Prophylactic adjuvant hepatic arterial infusion chemotherapy reduced hepatic metastases from Stage III colorectal cancer after curative resection.
    Hepato-gastroenterology, 2012, Volume: 59, Issue:116

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2012
A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2012
Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients.
    Advances in therapy, 2012, Volume: 29, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Fr

2012
First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.
    The oncologist, 2012, Volume: 17, Issue:3

    Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant

2012
Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study.
    International journal of clinical oncology, 2013, Volume: 18, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap

2013
First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: a phase II study.
    Journal of clinical gastroenterology, 2012, Volume: 46, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine;

2012
The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
    Annals of surgical oncology, 2012, Volume: 19, Issue:7

    Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy,

2012
Phase I study of sunitinib plus modified FOLFOX6 in Japanese patients with treatment-naive colorectal cancer.
    Anticancer research, 2012, Volume: 32, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu

2012
Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors.
    Clinical colorectal cancer, 2012, Volume: 11, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diabe

2012
Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.
    Anti-cancer drugs, 2012, Volume: 23, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-20, Volume: 30, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-20, Volume: 30, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-20, Volume: 30, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-20, Volume: 30, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-20, Volume: 30, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-20, Volume: 30, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-20, Volume: 30, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-20, Volume: 30, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-20, Volume: 30, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-20, Volume: 30, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-20, Volume: 30, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-20, Volume: 30, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-20, Volume: 30, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-20, Volume: 30, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-20, Volume: 30, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-20, Volume: 30, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan.
    British journal of clinical pharmacology, 2012, Volume: 73, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2012
Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer.
    International journal of cancer, 2012, Dec-01, Volume: 131, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Colorectal Neoplasms;

2012
A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.
    Oncology, 2012, Volume: 82, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2012
Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2012, Volume: 16, Issue:8

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic

2012
Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable fo
    British journal of cancer, 2012, May-22, Volume: 106, Issue:11

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B

2012
First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.
    Cancer science, 2012, Volume: 103, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothe

2012
Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer.
    Pathology oncology research : POR, 2012, Volume: 18, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2012
A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.
    Acta gastro-enterologica Belgica, 2012, Volume: 75, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ant

2012
Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01.
    Cancer, 2012, Nov-15, Volume: 118, Issue:22

    Topics: Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin;

2012
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2012, Volume: 35, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Case

2012
Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.
    British journal of cancer, 2012, Jun-05, Volume: 106, Issue:12

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2012
A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).
    The oncologist, 2012, Volume: 17, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2012
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
    The oncologist, 2012, Volume: 17, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2012
Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial.
    American journal of clinical oncology, 2013, Volume: 36, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Chemoradio

2013
Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu
    International journal of cancer, 2013, Jan-01, Volume: 132, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2013
Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under C

2012
Clinical and cost effectiveness of bevacizumab + FOLFIRI combination versus FOLFIRI alone as first-line treatment of metastatic colorectal cancer in South Korea.
    Clinical therapeutics, 2012, Volume: 34, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2012
Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).
    The pharmacogenomics journal, 2013, Volume: 13, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2013
Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study.
    Radiation oncology (London, England), 2012, Jun-09, Volume: 7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap

2012
Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.
    Clinical colorectal cancer, 2012, Volume: 11, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

2012
Usefulness of the preoperative administration of tegafur suppositories as alternative adjuvant chemotherapy for patients with resectable stage II or III colorectal cancer: a KODK4 multicenter randomized control trial.
    Oncology, 2012, Volume: 83, Issue:1

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Surv

2012
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Circadian Clocks; Colorectal Ne

2012
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.
    BMC cancer, 2012, Jun-29, Volume: 12

    Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antibodies, Monoclonal, Humanized; Antineoplast

2012
Safety verification trials of mFOLFIRI and sequential IRIS + bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients.
    Oncology, 2012, Volume: 83, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia

2012
Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy.
    Investigational new drugs, 2013, Volume: 31, Issue:1

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineopla

2013
A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications.
    British journal of cancer, 2012, Aug-07, Volume: 107, Issue:4

    Topics: Adolescent; Adult; Aged; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diseas

2012
A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2012, Volume: 14, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2012
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore

2012
Randomized phase II study of capecitabine with or without oxaliplatin as first-line treatment for elderly or fragile patients with metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group CO06-01.
    American journal of clinical oncology, 2013, Volume: 36, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Capecitabine;

2013
Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2012
The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801).
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2012
Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
    Oncology, 2012, Volume: 83, Issue:3

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2012
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
    BMC cancer, 2012, Aug-16, Volume: 12

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2012
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
    BMC cancer, 2012, Aug-16, Volume: 12

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2012
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
    BMC cancer, 2012, Aug-16, Volume: 12

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2012
Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
    BMC cancer, 2012, Aug-16, Volume: 12

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2012
Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI.
    Journal of vascular and interventional radiology : JVIR, 2012, Volume: 23, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin

2012
Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
    British journal of cancer, 2012, Sep-25, Volume: 107, Issue:7

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-01, Volume: 30, Issue:28

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-10, Volume: 30, Issue:29

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2012
Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Oct-10, Volume: 30, Issue:29

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2012
Evaluation of predictive markers for patients with advanced colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; C-

2012
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study.
    BMC cancer, 2012, Sep-29, Volume: 12

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2012
Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer.
    British journal of cancer, 2012, Nov-06, Volume: 107, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Surv

2012
Phase Ib study of drozitumab combined with first-line mFOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
    Cancer investigation, 2012, Volume: 30, Issue:10

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
    The Lancet. Oncology, 2012, Volume: 13, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2012
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
    The Lancet. Oncology, 2012, Volume: 13, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2012
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
    The Lancet. Oncology, 2012, Volume: 13, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2012
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
    The Lancet. Oncology, 2012, Volume: 13, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2012
A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Jan-01, Volume: 19, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2013
Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer.
    Journal of clinical gastroenterology, 2013, Volume: 47, Issue:1

    Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Breath Tests; Carcinoma; Chemotherapy, Adj

2013
Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:2

    Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Breast Neoplasms; Capeci

2013
Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer.
    British journal of cancer, 2012, Nov-06, Volume: 107, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Combined Mo

2012
XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2013
Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report
    Pathologie-biologie, 2013, Volume: 61, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2013
A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides;

2013
A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
    American journal of clinical oncology, 2014, Volume: 37, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2013
Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2013
Effect of portal vein chemotherapy on liver metastasis after surgical resection of colorectal cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:9

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Catheters, Indwelling; Colorectal Neoplasms; Fluoro

2012
Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab.
    BMC cancer, 2012, Nov-20, Volume: 12

    Topics: 3' Untranslated Regions; Adult; Aged; Alleles; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2012
A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.
    British journal of cancer, 2012, Dec-04, Volume: 107, Issue:12

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2012
Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
    PloS one, 2012, Volume: 7, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2012
A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
    Investigational new drugs, 2013, Volume: 31, Issue:4

    Topics: Administration, Intravenous; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

2013
[Effects of qisheng mixture on chemotherapy induced myelosuppression in patients with colorectal cancer].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2012, Volume: 32, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2012
Transcatheter arterial chemoembolization using cisplatin powder mixed with degradable starch microspheres for colorectal liver metastases after FOLFOX failure: results of a phase I/II study.
    Journal of vascular and interventional radiology : JVIR, 2013, Volume: 24, Issue:1

    Topics: Absorbable Implants; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Peripher

2013
Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial.
    Acta oncologica (Stockholm, Sweden), 2013, Volume: 52, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camp

2013
Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
    Asia-Pacific journal of clinical oncology, 2013, Volume: 9, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Capecitabine; Colorectal Neoplasms; Cost-

2013
Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction.
    Journal of surgical oncology, 2013, Volume: 107, Issue:6

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Chemoth

2013
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer.
    British journal of cancer, 2013, Feb-19, Volume: 108, Issue:3

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2013
Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer.
    Cancer investigation, 2013, Volume: 31, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2013
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2013
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-01, Volume: 31, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2013
A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.
    British journal of cancer, 2013, Feb-19, Volume: 108, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camp

2013
Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study.
    Chemotherapy, 2012, Volume: 58, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bridged

2012
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.
    The Journal of pharmacology and experimental therapeutics, 2013, Volume: 345, Issue:1

    Topics: 3' Untranslated Regions; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2013
Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701).
    Oncology, 2013, Volume: 84, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2013
Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.
    Oncology, 2013, Volume: 84, Issue:4

    Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy;

2013
Ralitrexed (Tomudex) or Nordic-FLv regimen in metastatic colorectal cancer: a randomized phase II study focusing on quality of life, patients' preferences and health economics.
    Journal of chemotherapy (Florence, Italy), 2002, Volume: 14, Issue:3

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne

2002
Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptot

2002
Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2002
A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:7

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biopsy, Needle; Colorectal Neoplasms; Dose-Res

2002
Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2002
Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
    Oncology, 2002, Volume: 63, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin;

2002
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-01, Volume: 20, Issue:17

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2002
Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-01, Volume: 20, Issue:17

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2002
Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer.
    Medical science monitor : international medical journal of experimental and clinical research, 2002, Volume: 8, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Etoposide; Fluorouracil; Human

2002
High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection.
    International journal of cancer, 2002, Oct-20, Volume: 101, Issue:6

    Topics: Adult; Aged; Colon; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; L

2002
Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study.
    Lancet (London, England), 2002, Aug-31, Volume: 360, Issue:9334

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplasti

2002
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.
    Journal of cancer research and clinical oncology, 2002, Volume: 128, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Ne

2002
Biweekly chemotherapy with oxaliplatin, irinotecan, infusional Fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2002
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2002
Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:10

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col

2002
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.
    Oncology, 2002, Volume: 63, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2002
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
    Oncology, 2002, Volume: 63, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2002
Metabolism of capecitabine, an oral fluorouracil prodrug: (19)F NMR studies in animal models and human urine.
    Drug metabolism and disposition: the biological fate of chemicals, 2002, Volume: 30, Issue:11

    Topics: Animals; Antimetabolites, Antineoplastic; Bile; Biotransformation; Capecitabine; Colorectal Neoplasm

2002
[Final results of a randomized clinical trial of adjuvant intraportal chemotherapy for colorectal cancer: Intraportal Chemotherapy for Colorectal Cancer Group].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2002
Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.
    Cancer research, 2002, Nov-01, Volume: 62, Issue:21

    Topics: Adenoviruses, Human; Adult; Aged; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols;

2002
Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer.
    Journal of chemotherapy (Florence, Italy), 2002, Volume: 14, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease

2002
Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
    Anti-cancer drugs, 2002, Volume: 13, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2002
Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.
    British journal of cancer, 2002, Nov-18, Volume: 87, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia

2002
Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection.
    World journal of gastroenterology, 2002, Volume: 8, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2002
Systemic irinotecan or regional floxuridine chemotherapy prolongs survival after hepatic cryosurgery in patients with metastatic colon cancer refractory to 5-fluorouracil.
    Clinical colorectal cancer, 2001, Volume: 1, Issue:1

    Topics: Antimetabolites, Antineoplastic; Camptothecin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regiona

2001
Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: a Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer.
    Investigational new drugs, 2002, Volume: 20, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Protocols; Colorectal Ne

2002
Oxaliplatin combinations as first-line therapy in advanced colorectal cancer.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos

2002
N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Re

2002
The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:2

    Topics: Adult; Aged; Camptothecin; Canada; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Admi

2002
Irinotecan in 5-fluorouracil-refractory colorectal cancer.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:2

    Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administrati

2002
Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2002
Intravenous versus intrahepatic arterial 5-fluorouracil/leucovorin for treatment of colorectal cancer metastases.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Hepatic

2002
Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2002
Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Nee

2002
Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptotheci

2002
[Neo-adjuvant chemotherapy with carmofur for colorectal cancer--a multi-institutional randomized controlled study].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche

2002
Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC).
    American journal of clinical oncology, 2002, Volume: 25, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2002
Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2002
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jan-01, Volume: 21, Issue:1

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera

2003
Dose-effect relationship of bolus 5-fluorouracil in the treatment of advanced colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2002, Volume: 41, Issue:6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neoplasms; Dose-Response

2002
High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group.
    European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Di

2003
Neoadjuvant treatment with weekly high-dose 5-Fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer.
    Oncology, 2003, Volume: 64, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy,

2003
Biweekly bolus 5-fluorouracil and leucovorin plus oxaliplatin in pretreated patients with advanced colorectal cancer: a dose-finding study.
    Anti-cancer drugs, 2003, Volume: 14, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F

2003
Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial.
    Lancet (London, England), 2003, Feb-01, Volume: 361, Issue:9355

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Sch

2003
Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin.
    American journal of clinical oncology, 2003, Volume: 26, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Floxuridine; Fluorouraci

2003
Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2003, Feb-08, Volume: 361, Issue:9356

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi

2003
First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study.
    Journal of clinical gastroenterology, 2003, Volume: 36, Issue:3

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto

2003
Skin testing and hypersensitivity reactions to oxaliplatin.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Hy

2003
Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer.
    Journal of medical and dental sciences, 2002, Volume: 49, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisp

2002
Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
    British journal of clinical pharmacology, 2003, Volume: 55, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2003
Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
    Zentralblatt fur Chirurgie, 2003, Volume: 128, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

2003
Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Apr-01, Volume: 21, Issue:7

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci

2003
[Interferon-alpha in adjuvant treatment of colorectal carcinoma].
    Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress, 2002, Volume: 119

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin

2002
Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study.
    Chemotherapy, 2003, Volume: 49, Issue:1-2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorec

2003
Irinotecan in the treatment of advanced colorectal cancer in patients pretreated with Fluorouracil-based chemotherapy: a study to determine recommendable therapeutic dosage.
    American journal of clinical oncology, 2003, Volume: 26, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Enzy

2003
PET-FDG as predictor of therapy response in patients with colorectal carcinoma.
    The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), 2003, Volume: 47, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorodeoxyglucose F18; Fluoro

2003
Subcutaneous granulocyte-macrophage colony-stimulating factor in mucositis induced by an adjuvant 5-fluorouracil plus leucovorin regimen. A phase II study and review of the literature.
    Oncology, 2003, Volume: 64, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2003
A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer.
    Journal of pharmaceutical sciences, 2003, Volume: 92, Issue:6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Bayes Theorem; Colorectal Neoplasms;

2003
Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study.
    International journal of cancer, 2003, Jul-20, Volume: 105, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms;

2003
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jun-01, Volume: 21, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2003
Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer.
    Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2003
A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines.
    International journal of oncology, 2003, Volume: 23, Issue:1

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorect

2003
Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col

2003
Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer.
    American journal of clinical oncology, 2003, Volume: 26, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2003
A comparison between hepatic artery ligation and portal 5-Fu infusion versus 5-Fu intra arterial infusion for colorectal liver metastases.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2003, Volume: 29, Issue:5

    Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined M

2003
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer.
    British journal of cancer, 2003, Jun-16, Volume: 88, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2003
Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
    Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neoplasms

2003
A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:4

    Topics: Adolescent; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogen

2003
Multicenter phase II trial evaluating a three-weekly schedule of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:7

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Campto

2003
A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2003
Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jul-15, Volume: 21, Issue:14

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2003
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
    The New England journal of medicine, 2003, Jul-17, Volume: 349, Issue:3

    Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant; C

2003
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
    The New England journal of medicine, 2003, Jul-17, Volume: 349, Issue:3

    Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant; C

2003
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
    The New England journal of medicine, 2003, Jul-17, Volume: 349, Issue:3

    Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant; C

2003
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
    The New England journal of medicine, 2003, Jul-17, Volume: 349, Issue:3

    Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant; C

2003
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
    The New England journal of medicine, 2003, Jul-17, Volume: 349, Issue:3

    Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant; C

2003
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
    The New England journal of medicine, 2003, Jul-17, Volume: 349, Issue:3

    Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant; C

2003
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
    The New England journal of medicine, 2003, Jul-17, Volume: 349, Issue:3

    Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant; C

2003
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
    The New England journal of medicine, 2003, Jul-17, Volume: 349, Issue:3

    Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant; C

2003
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
    The New England journal of medicine, 2003, Jul-17, Volume: 349, Issue:3

    Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant; C

2003
Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
    Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Squar

2003
Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study.
    Chemotherapy, 2003, Volume: 49, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2003
Lessons learned from raltitrexed--quality assurance, patient education and intensive supportive drugs to optimise tolerability.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2003, Volume: 15, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Health Edu

2003
Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
    Clinical colorectal cancer, 2003, Volume: 3, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2003
Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2003
Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal

2003
5-fluorouracil as a protracted continuous infusion plus irinotecan (CPT-11) in patients with advanced colorectal cancer treated with fluoropyrimidine-based regimens as first line.
    Anti-cancer drugs, 2003, Volume: 14, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2003
Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastroint
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Oct-15, Volume: 21, Issue:20

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sch

2003
Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma.
    British journal of cancer, 2003, Sep-15, Volume: 89, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2003
Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up.
    International journal of colorectal disease, 2004, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Administration, Oral; Aged; Antimetabolites, Antineoplastic;

2004
Multimodal therapy with intravenous biweekly leucovorin, 5-fluorouracil and irinotecan combined with hepatic arterial infusion pirarubicin in non-resectable hepatic metastases from colorectal cancer (a European Association for Research in Oncology trial).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com

2003
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasm

2003
[Interim analysis of a prospective, randomized multi-center study by the "Liver Metastases" Study Group: adjuvant intra-arterial chemotherapy after curative liver resection of colorectal metastases].
    Langenbecks Archiv fur Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress, 1998, Volume: 115, Issue:Suppl I

    Topics: Adult; Aged; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Combined Modality Therapy; Fem

1998
Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer.
    British journal of cancer, 2003, Oct-06, Volume: 89, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi

2003
A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer.
    Cancer investigation, 2003, Volume: 21, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2003
Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly.
    British journal of cancer, 2003, Oct-20, Volume: 89, Issue:8

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Anti

2003
A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients.
    British journal of cancer, 2003, Nov-17, Volume: 89, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Colorectal

2003
Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer.
    Farmaco (Societa chimica italiana : 1989), 2003, Volume: 58, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chronotherapy; Colorectal Neoplasm

2003
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-15, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2004
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2004
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2004
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2004
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2004
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2004
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2004
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2004
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2004
Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.
    Methods and findings in experimental and clinical pharmacology, 2003, Volume: 25, Issue:8

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Alopecia; Camptothecin; Chemotherapy, Adjuvant; Colorectal

2003
Randomized comparative study of surgical adjuvant chemotherapy using 5-fluorouracil and dl-leucovorin with CDDP, 5-FU and dl-leucovorin for advanced colorectal cancer.
    Journal of gastroenterology and hepatology, 2004, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2004
A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Dec-01, Volume: 9, Issue:16 Pt 1

    Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal Neopla

2003
Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi

2004
A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil.
    Clinical colorectal cancer, 2003, Volume: 3, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Drug Administrat

2003
Randomized trial comparing the addition of oxaliplatin or irinotecan to high-dose leucovorin and 5-Fluorouracil intravenous bolus every two weeks in metastatic colorectal carcinoma: Southern Italy Cooperative Oncology Group 0103.
    Clinical colorectal cancer, 2003, Volume: 3, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admi

2003
Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma.
    Cancer, 2004, Jan-15, Volume: 100, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma;

2004
Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study.
    British journal of cancer, 2004, Jan-26, Volume: 90, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C

2004
A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.
    Cancer investigation, 2003, Volume: 21, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcin

2003
[Long term survival in metastatic colorectal cancer treated with leucovorin and 5-fluoro-uracil chemotherapy].
    La Revue de medecine interne, 2004, Volume: 25, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu

2004
Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial.
    Cancer, 2004, Feb-01, Volume: 100, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecitabine; Carcinoma

2004
FDA drug approval summaries: oxaliplatin.
    The oncologist, 2004, Volume: 9, Issue:1

    Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Disease Progression; Drug Approval; Drug

2004
Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.
    Journal of surgical oncology, 2004, Volume: 85, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Carcinoma; Cecum

2004
Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2003, Volume: 42, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2003
The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-15, Volume: 22, Issue:8

    Topics: Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colorectal Neoplas

2004
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Mar-01, Volume: 10, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch

2004
Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer.
    Anti-cancer drugs, 2004, Volume: 15, Issue:3

    Topics: Adult; Aged; Colorectal Neoplasms; Confidence Intervals; Drug Administration Schedule; Female; Fluor

2004
Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma.
    Clinical colorectal cancer, 2004, Volume: 3, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Circadian Rhythm; Colorectal Neoplasms; Fluorouracil; Humans;

2004
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
    British journal of cancer, 2004, Mar-22, Volume: 90, Issue:6

    Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb

2004
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
    British journal of cancer, 2004, Mar-22, Volume: 90, Issue:6

    Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb

2004
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
    British journal of cancer, 2004, Mar-22, Volume: 90, Issue:6

    Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb

2004
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
    British journal of cancer, 2004, Mar-22, Volume: 90, Issue:6

    Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb

2004
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
    British journal of cancer, 2004, Mar-22, Volume: 90, Issue:6

    Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb

2004
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
    British journal of cancer, 2004, Mar-22, Volume: 90, Issue:6

    Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb

2004
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
    British journal of cancer, 2004, Mar-22, Volume: 90, Issue:6

    Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb

2004
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
    British journal of cancer, 2004, Mar-22, Volume: 90, Issue:6

    Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb

2004
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials.
    British journal of cancer, 2004, Mar-22, Volume: 90, Issue:6

    Topics: Administration, Oral; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Comb

2004
Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorecta

2004
Weekly 5-fluorouracil and leucovorin: achieving lower toxicity with higher dose-intensity in adjuvant chemotherapy after colorectal cancer resection.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2004
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Mar-15, Volume: 10, Issue:6

    Topics: Adult; Aged; Amidines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Coloni

2004
Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma.
    American journal of clinical oncology, 2004, Volume: 27, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu

2004
A phase II Japanese study of a modified capecitabine regimen for advanced or metastatic colorectal cancer.
    Anti-cancer drugs, 2004, Volume: 15, Issue:2

    Topics: Administration, Oral; Adult; Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease Progre

2004
Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
    International journal of clinical oncology, 2004, Volume: 9, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2004
Phase I/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5-FU-pretreated patients with colorectal cancer.
    Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Dru

2004
Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials.
    Annals of surgical oncology, 2004, Volume: 11, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colorectal

2004
Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients.
    Oncology, 2004, Volume: 66, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.
    British journal of cancer, 2004, May-04, Volume: 90, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl

2004
A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2004
Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy.
    The British journal of surgery, 2004, Volume: 91, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colo

2004
Phase I study of the combination of oxaliplatin, irinotecan and continuous infusion 5-fluorouracil in digestive tumors.
    Anti-cancer drugs, 2004, Volume: 15, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos

2004
Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil.
    Anti-cancer drugs, 2004, Volume: 15, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jun-01, Volume: 22, Issue:11

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dis

2004
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jun-01, Volume: 22, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2004
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jun-01, Volume: 22, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2004
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jun-01, Volume: 22, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2004
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jun-01, Volume: 22, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2004
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jun-01, Volume: 22, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2004
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jun-01, Volume: 22, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2004
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jun-01, Volume: 22, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2004
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jun-01, Volume: 22, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2004
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jun-01, Volume: 22, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2004
Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients.
    American journal of clinical oncology, 2004, Volume: 27, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2004, Jun-03, Volume: 350, Issue:23

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.
    International journal of cancer, 2004, Aug-20, Volume: 111, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; DNA Topoisomeras

2004
Oxaliplatin added to simplified bimonthly low-dose leucovorin and 5-FU for pretreated advanced colorectal cancer is effective and not affected by different previous 5-FU regimens.
    Cancer investigation, 2004, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv

2004
Whole-body hyperthermia in the scope of von Ardenne's systemic cancer multistep therapy (sCMT) combined with chemotherapy in patients with metastatic colorectal cancer: a phase I/II study.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2004, Volume: 20, Issue:3

    Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth

2004
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea;

2004
5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:7

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore

2004
High-dose chronomodulated infusion of 5-fluorouracil (5-FU) and folinic acid (FA) (FF5-16) in advanced colorectal cancer patients.
    Journal of cancer research and clinical oncology, 2004, Volume: 130, Issue:8

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Child

2004
Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma.
    Cancer, 2004, Jul-01, Volume: 101, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2004
Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin.
    Clinical pharmacology and therapeutics, 2004, Volume: 76, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colorectal Neoplasms;

2004
The toxicity rates of two different regimens of irinotecan.
    Hepato-gastroenterology, 2003, Volume: 50 Suppl 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos

2003
Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
    BMC cancer, 2004, Jul-10, Volume: 4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of

2004
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
    BMC cancer, 2004, Jul-16, Volume: 4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms;

2004
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
    BMC cancer, 2004, Jul-20, Volume: 4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother

2004
Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer.
    British journal of cancer, 2004, Aug-31, Volume: 91, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2004
A new perspective on cardiotoxicity of 5-fluorouracil. A novel research tool 'cardiac ultrasonic integrated backscatter analysis' indicates transient, subclinical myocardial dysfunction due to high-dose leucovorin and infusional 5-fluorouracil regimen.
    Chemotherapy, 2004, Volume: 50, Issue:3

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Therapy, Combin

2004
Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne

2004
Prolonged cytostatic tumor dormancy induced by serial exchange of chemotherapy in colorectal carcinoma.
    Nagoya journal of medical science, 2004, Volume: 67, Issue:1-2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Clinical

2004
Bevacizumab improves the efficacy of 5-fluorouracil/leucovorin in patients with advanced colorectal cancer.
    Clinical colorectal cancer, 2004, Volume: 4, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2004
Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
    International journal of oncology, 2004, Volume: 25, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, Neoplasm; Ant

2004
Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2004, Volume: 2, Issue:8

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dietary Fiber; Dietary Supplemen

2004
A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.
    Investigational new drugs, 2004, Volume: 22, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Do

2004
First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer.
    Oncology, 2004, Volume: 66, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2004
A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Oncology, 2004, Volume: 66, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia

2004
Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
    Japanese journal of clinical oncology, 2004, Volume: 34, Issue:7

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C

2004
Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2004, Volume: 45, Issue:9

    Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survi

2004
[Comparing the effect of adjuvant chemotherapy by portal vein infusion with intraluminal chemotherapy for colorectal cancer].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 2004, Aug-07, Volume: 42, Issue:15

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional

2004
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
    British journal of cancer, 2004, Oct-18, Volume: 91, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2004
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil.
    British journal of cancer, 2004, Oct-18, Volume: 91, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv

2004
Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy.
    Medical oncology (Northwood, London, England), 2004, Volume: 21, Issue:3

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Confidence Intervals

2004
Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer.
    Medical oncology (Northwood, London, England), 2004, Volume: 21, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cam

2004
Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according
    Anti-cancer drugs, 2004, Volume: 15, Issue:9

    Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Confidence Intervals; Drug Administration Schedule;

2004
Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX.
    British journal of cancer, 2004, Oct-18, Volume: 91, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2004
Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
    Cancer, 2004, Nov-15, Volume: 101, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2004
Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Oct-01, Volume: 10, Issue:19

    Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protoc

2004
Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?
    Clinical colorectal cancer, 2004, Volume: 4 Suppl 2

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant

2004
Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
    Journal of surgical oncology, 2004, Nov-01, Volume: 88, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap

2004
An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
    Investigational new drugs, 2005, Volume: 23, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Canada;

2005
Gene expression profiles of colorectal carcinoma in response to neo-adjuvant chemotherapy.
    International journal of oncology, 2004, Volume: 25, Issue:6

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr

2004
Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
    International journal of clinical oncology, 2004, Volume: 9, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2004
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2004
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2004
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2004
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2004
Irinotecan combined with bolus 5-fluorouracil and folinic acid for metastatic colorectal cancer: is this really a dangerous treatment?
    Journal of chemotherapy (Florence, Italy), 2004, Volume: 16, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2004
Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Dec-01, Volume: 22, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2004
Second-line treatment of advanced colorectal cancer with a weekly simultaneous 24-hour infusion of 5-fluorouracil and sodium-folinate: a multicentre phase II trial.
    Onkologie, 2004, Volume: 27, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2004
Application of adjuvant chemotherapy in colorectal cancer -- a survey in the region of Essen, Germany.
    Onkologie, 2005, Volume: 28, Issue:1

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Germany;

2005
Mayo regimen plus three different second-line chemotherapy regimens in sequential therapy in patients with advanced colorectal cancer (ACRC).
    Journal of experimental & clinical cancer research : CR, 2004, Volume: 23, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen

2004
Bevacizumab for advanced colorectal cancer.
    Issues in emerging health technologies, 2004, Issue:63

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Clinic

2004
Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
    Anti-cancer drugs, 2005, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2005
Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer.
    Techniques in coloproctology, 2004, Volume: 8 Suppl 1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Colorectal Neoplasms;

2004
Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-20, Volume: 23, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com

2005
A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma Southern Italy Cooperative Oncology Group trial 0108.
    Critical reviews in oncology/hematology, 2005, Volume: 53, Issue:2

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto

2005
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capec

2005
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathet

2005
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathet

2005
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathet

2005
Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathet

2005
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2005
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Feb-01, Volume: 11, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2005
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Feb-01, Volume: 11, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2005
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Feb-01, Volume: 11, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2005
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Feb-01, Volume: 11, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2005
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-01, Volume: 23, Issue:16

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2005
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-01, Volume: 23, Issue:16

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2005
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-01, Volume: 23, Issue:16

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2005
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-01, Volume: 23, Issue:16

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2005
[Trial of outpatient anti-cancer chemotherapy with infusion of 5-FU and cisplatin for advanced gastric and colorectal cancers].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:2

    Topics: Adenocarcinoma; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; C

2005
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study.
    British journal of cancer, 2005, Mar-28, Volume: 92, Issue:6

    Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Mid

2005
Irinotecan combined or alternated with bolus 5-fluorouracil and folinic acid versus the Mayo Clinic regimen in the first-line therapy of advanced colorectal cancer.
    Oncology reports, 2005, Volume: 13, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Campto

2005
Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
    Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col

2005
A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer.
    Prostaglandins & other lipid mediators, 2005, Volume: 75, Issue:1-4

    Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Cyc

2005
Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin.
    Cancer gene therapy, 2005, Volume: 12, Issue:8

    Topics: Adenoviridae; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neop

2005
Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer.
    Clinical colorectal cancer, 2005, Volume: 4, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi

2005
Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos

2005
Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology G
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2005
Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience.
    European journal of cancer care, 2005, Volume: 14, Issue:2

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cross-Over Studie

2005
High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:7

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols;

2005
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2005
Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:8

    Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorecta

2005
Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, May-01, Volume: 23, Issue:13

    Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecit

2005
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-01, Volume: 23, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2005
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-01, Volume: 23, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2005
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-01, Volume: 23, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2005
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-01, Volume: 23, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2005
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
    British journal of cancer, 2005, May-23, Volume: 92, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl

2005
A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel.
    Oncology reports, 2005, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Color

2005
Biweekly oxaliplatin combined with oral capecitabine (OXXEL regimen) as first-line treatment of metastatic colorectal cancer patients: a Southern Italy Cooperative Oncology Group phase II study.
    Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast

2005
Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, May-20, Volume: 23, Issue:15

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2005
Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, May-20, Volume: 23, Issue:15

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2005
Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer.
    Journal of chemotherapy (Florence, Italy), 2005, Volume: 17, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2005
FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16 Suppl 4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Celecoxib; Col

2005
Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:1

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour

2005
Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci

2005
[Irinotecan combined with fluoropyrimidine in treatment for advanced/metastatic colorectal carcinoma].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 2005, May-01, Volume: 43, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal

2005
[Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study].
    Pathologie-biologie, 2005, Volume: 53, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chronob

2005
[Feasibility survey (Phase I-II) of a four drugs combination (5-fluorouracil, folinic acid, carboplatin and irinotecan) delivered using a chronomodulated infusion in the treatment of advanced colorectal cancer].
    Pathologie-biologie, 2005, Volume: 53, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronobiolog

2005
A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecit

2005
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-01, Volume: 23, Issue:22

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2005
Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-01, Volume: 23, Issue:22

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2005
A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer.
    Oncology reports, 2005, Volume: 14, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore

2005
Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
    Cancer, 2005, Jul-15, Volume: 104, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2005
[Problems of case accumulation in a clinical trial of hepatic arterial infusion after resection of hepatic metastases: A summary of the study design and questionnaire survey of the participating centers in study no. 29-0003 of the Japanese Foundation for
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administ

2005
[Pharmacokinetic modulating chemotherapy highly effective for colorectal carcinoma metastases to multiple organs].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chronothe

2005
Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.
    The Lancet. Oncology, 2005, Volume: 6, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer,

2005
Randomized controlled trial to evaluate laparoscopic surgery for colorectal cancer: Japan Clinical Oncology Group Study JCOG 0404.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas

2005
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-01, Volume: 23, Issue:22

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2005
Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-01, Volume: 23, Issue:22

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2005
Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer.
    Oncology reports, 2005, Volume: 14, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Alkaline Phosphatase; Antineoplastic Combined

2005
Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2005
Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2005
Pharmacokinetics of bolus 5-fluorouracil: relationship between dose, plasma concentrations, area-under-the-curve and toxicity.
    Journal of chemotherapy (Florence, Italy), 2005, Volume: 17, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neoplasms; Dose-Response

2005
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-10, Volume: 23, Issue:35

    Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen;

2005
A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
    Oncology, 2005, Volume: 69, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neo

2005
Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
    British journal of cancer, 2005, Sep-05, Volume: 93, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal

2005
Assessment of infusional 5-fluorouracil schedule and dose intensity: a Southwest Oncology Group and Eastern Cooperative Oncology Group study.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; D

2005
Double-blind randomised trial comparing 5-fluorouracil plus leucovorin to placebo for metastatic colorectal carcinoma.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2005, Volume: 7, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Colorectal Neoplasms; Doubl

2005
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2005
Correlation between expression of orotate phosphoribosyl transferase and 5-fluorouracil sensitivity, as measured by apoptosis index in colorectal cancer tissue.
    International journal of gastrointestinal cancer, 2005, Volume: 35, Issue:3

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Apoptosis; Biological Assay; Colorectal

2005
Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group.
    Medical oncology (Northwood, London, England), 2005, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2005
Activity and toxicity of oxaliplatin and bolus fluorouracil plus leucovorin in pretreated colorectal cancer patients: a phase II study.
    Journal of experimental & clinical cancer research : CR, 2005, Volume: 24, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; D

2005
Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-15, Volume: 11, Issue:16

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen;

2005
Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2005, Volume: 7, Issue:6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Color

2005
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-15, Volume: 11, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Campt

2005
Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
    BMC cancer, 2005, Sep-16, Volume: 5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials a

2005
Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy?
    Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free

2006
Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptot

2005
A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer.
    American journal of clinical oncology, 2005, Volume: 28, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2005
Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:15

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2005
Modulation of 5-fluorouracil as adjuvant systemic chemotherapy in colorectal cancer: the IGCS-COL multicentre, randomised, phase III study.
    British journal of cancer, 2005, Oct-17, Volume: 93, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2005
A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy.
    BMC cancer, 2005, Oct-15, Volume: 5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Colorectal Neoplasms; Disease-Free Survival; D

2005
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2005
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2005
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2005
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2005
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2005
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2005
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2005
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2005
Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2005
Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:5

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2006
Combined therapy with weekly irinotecan, infusional 5-fluorouracil and the selective COX-2 inhibitor rofecoxib is a safe and effective second-line treatment in metastatic colorectal cancer.
    The oncologist, 2005, Volume: 10, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Flu

2005
Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dih

2006
An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
    Oncology, 2005, Volume: 69, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia

2005
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic A

2006
Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2006
Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:3

    Topics: Adult; Aged; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antineoplastic Combined Chemotherap

2006
A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases.
    American journal of clinical oncology, 2005, Volume: 28, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bio

2005
Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
    American journal of clinical oncology, 2005, Volume: 28, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers,

2005
Irinotecan (CPT-11) combined with bolus 5-fluorouracil/leucovorin (Saltz regimen) as first-line chemotherapy of patients with advanced colorectal cancer.
    Anti-cancer drugs, 2006, Volume: 17, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2006
Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial.
    Oncology, 2005, Volume: 69, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2005
Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
    Acta oncologica (Stockholm, Sweden), 2005, Volume: 44, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2005
A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combi

2006
Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Die

2005
FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2005
Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:4

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Age

2005
Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer.
    Annals of surgical oncology, 2006, Volume: 13, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined M

2006
Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer.
    Journal of cancer research and clinical oncology, 2006, Volume: 132, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Creatini

2006
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-20, Volume: 24, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2006
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-20, Volume: 24, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2006
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-20, Volume: 24, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2006
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-20, Volume: 24, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2006
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-20, Volume: 24, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2006
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-20, Volume: 24, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2006
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-20, Volume: 24, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2006
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-20, Volume: 24, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2006
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jan-20, Volume: 24, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2006
Inhibitory effect of 5-fluorouracil on cytochrome P450 2C9 activity in cancer patients.
    Basic & clinical pharmacology & toxicology, 2006, Volume: 98, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylases; Colo

2006
The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer.
    American journal of clinical oncology, 2006, Volume: 29, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col

2006
Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
    American journal of clinical oncology, 2006, Volume: 29, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia

2006
Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Dr

2006
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
    BMC cancer, 2006, Feb-24, Volume: 6

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemot

2006
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Mar-20, Volume: 24, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy.
    Investigational new drugs, 2006, Volume: 24, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug R

2006
Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study).
    Cancer investigation, 2006, Volume: 24, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineo

2006
A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer.
    British journal of cancer, 2006, Apr-10, Volume: 94, Issue:7

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytid

2006
XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.
    British journal of cancer, 2006, Apr-10, Volume: 94, Issue:7

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine;

2006
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study.
    Oncology reports, 2006, Volume: 15, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2006
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
    American journal of clinical oncology, 2006, Volume: 29, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin

2006
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Apr-20, Volume: 24, Issue:12

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

2006
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
    British journal of cancer, 2006, May-08, Volume: 94, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2006
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
    British journal of cancer, 2006, May-08, Volume: 94, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2006
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
    British journal of cancer, 2006, May-08, Volume: 94, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2006
A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients.
    British journal of cancer, 2006, May-08, Volume: 94, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2006
Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer.
    Therapeutic drug monitoring, 2006, Volume: 28, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Creatinine; Drug Administratio

2006
Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.
    Clinical colorectal cancer, 2006, Volume: 5, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2006
Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan.
    Oncology, 2006, Volume: 70, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytid

2006
Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.
    Investigational new drugs, 2006, Volume: 24, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colorectal Ne

2006
Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, May-15, Volume: 12, Issue:10

    Topics: Administration, Inhalation; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carbon Diox

2006
Hepatic arterial infusion alternating with systemic chemotherapy in patients with non-resectable hepatic metastases from colorectal cancer.
    Journal of gastroenterology and hepatology, 2006, Volume: 21, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He

2006
FOLFOX2 regimen in the treatment of advanced colorectal cancer: a comparison between elderly and young patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:10

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorec

2006
Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study.
    British journal of cancer, 2006, Jun-19, Volume: 94, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2006
Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?
    American journal of clinical oncology, 2006, Volume: 29, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combi

2006
FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neo

2006
Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 7

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2006
[Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2006, Volume: 26, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2006
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2006
The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients.
    British journal of cancer, 2006, Jul-03, Volume: 95, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Datab

2006
The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-01, Volume: 24, Issue:19

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2006
Randomised trial comparing three different schedules of infusional 5FU and raltitrexed alone as first-line therapy in metastatic colorectal cancer. Final results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 trial.
    Oncology, 2006, Volume: 70, Issue:3

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy,

2006
Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jul-01, Volume: 12, Issue:13

    Topics: Adult; Aged; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Gen

2006
Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-20, Volume: 24, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2006
Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-20, Volume: 24, Issue:21

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo

2006
Nucleosomes in colorectal cancer patients during radiochemotherapy.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2006, Volume: 27, Issue:5

    Topics: Aged; Biomarkers, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Huma

2006
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci

2006
A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2006
Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Can
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-01, Volume: 24, Issue:22

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chronotherapy; Color

2006
Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Can
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-01, Volume: 24, Issue:22

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chronotherapy; Color

2006
Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Can
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-01, Volume: 24, Issue:22

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chronotherapy; Color

2006
Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Can
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-01, Volume: 24, Issue:22

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chronotherapy; Color

2006
Repeated hepatic intra-arterial chemotherapy based on results of anticancer drug sensitivity test in patients with synchronous hepatic metastases from colorectal cancer.
    Surgery, 2006, Volume: 140, Issue:3

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Relati

2006
Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer.
    Anti-cancer drugs, 2006, Volume: 17, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2006
Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Sep-01, Volume: 24, Issue:25

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2006
Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth

2007
Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Chemotherapy, Adj

2006
A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:12

    Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fe

2006
Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:16

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col

2006
Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2007, Volume: 15, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Biomarkers; Body Composition; Campt

2007
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.
    Clinical colorectal cancer, 2006, Volume: 6, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2006
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas

2007
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas

2007
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas

2007
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Diseas

2007
Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-20, Volume: 24, Issue:33

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Administr

2006
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2006
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2006
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2006
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2006
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2006
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2006
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2006
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2006
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2006
Peritoneal carcinomatosis of colorectal origin.
    Gastroenterologie clinique et biologique, 2006, Volume: 30, Issue:10

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Chemotherapy, Adjuvant; Co

2006
Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2007
Comparison of two kinds of intraperitoneal chemotherapy following complete cytoreductive surgery of colorectal peritoneal carcinomatosis.
    Annals of surgical oncology, 2007, Volume: 14, Issue:2

    Topics: Adult; Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Parente

2007
Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial).
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:18

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2006
Weekly fluorouracil at 425 mg/m(2) plus low-dose folinic acid for 24 weeks as adjuvant treatment for colorectal cancer: assessment of toxicity and delivery.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dose-Response Relation

2006
Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

2007
Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp

2007
A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma.
    Journal of chemotherapy (Florence, Italy), 2006, Volume: 18, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ca

2006
Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial.
    British journal of cancer, 2007, Jan-15, Volume: 96, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Ce

2007
FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer.
    Oncology, 2006, Volume: 70, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2006
[Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:13

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop

2006
Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
    Onkologie, 2006, Volume: 29, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Respo

2006
[Prophylactic hepatic arterial infusion chemotherapy after curative surgery of colorectal liver metastases--the viewpoint from patients' quality of life].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:12

    Topics: Angiography; Catheterization; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions,

2006
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2007
A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc

2007
Phase 1b dose escalation study of erlotinib in combination with infusional 5-Fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jan-15, Volume: 13, Issue:2 Pt 1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorec

2007
Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Feb-01, Volume: 13, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celeco

2007
[A phase I study of modified FOLFOX 6 therapy for advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

2007
The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
    Chemotherapy, 2007, Volume: 53, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female;

2007
Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
    Oncology, 2006, Volume: 71, Issue:1-2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2006
Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study.
    British journal of cancer, 2007, Apr-10, Volume: 96, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colorec

2007
Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Mar-20, Volume: 25, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Austral

2007
The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2008
Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
    Digestive diseases (Basel, Switzerland), 2007, Volume: 25, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camp

2007
A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
    Onkologie, 2007, Volume: 30, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2007
Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
    The oncologist, 2007, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Dis

2007
FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer.
    The oncologist, 2007, Volume: 12, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2007
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

2008
A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb

2008
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Apr-20, Volume: 25, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2007
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Apr-20, Volume: 25, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2007
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Apr-20, Volume: 25, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2007
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Apr-20, Volume: 25, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2007
Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients.
    Cancer science, 2007, Volume: 98, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cell Survival; Colorec

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nor
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2007
The efficacy of hybrid chemotherapy with intravenous oxaliplatin and folinic acid and intra-hepatic infusion of 5-fluorouracil in patients with colorectal liver metastases: a phase II study.
    Investigational new drugs, 2007, Volume: 25, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Catheterization;

2007
Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study.
    Chemotherapy, 2007, Volume: 53, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl

2007
Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
    Clinical colorectal cancer, 2007, Volume: 6, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols;

2007
Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine.
    Clinical colorectal cancer, 2007, Volume: 6, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxyc

2007
Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study.
    BMC cancer, 2007, May-30, Volume: 7

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2007
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-20, Volume: 25, Issue:27

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore

2007
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Tri
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-20, Volume: 25, Issue:27

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore

2007
Continuous infusion of 5-fluorouracil with versus without low-dose, consecutive administration of cisplatin in advanced colorectal cancer. A prospective randomized phase II study.
    Journal of experimental & clinical cancer research : CR, 2007, Volume: 26, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Diseas

2007
Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer.
    Clinical colorectal cancer, 2007, Volume: 6, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl

2007
Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma.
    Clinical colorectal cancer, 2007, Volume: 6, Issue:7

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2007
Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.
    Cancer, 2007, Aug-01, Volume: 110, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2007
First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer.
    Cancer, 2007, Aug-15, Volume: 110, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla

2007
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
    Lancet (London, England), 2007, Jul-14, Volume: 370, Issue:9582

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci

2007
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
    Lancet (London, England), 2007, Jul-14, Volume: 370, Issue:9582

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci

2007
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
    Lancet (London, England), 2007, Jul-14, Volume: 370, Issue:9582

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci

2007
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
    Lancet (London, England), 2007, Jul-14, Volume: 370, Issue:9582

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci

2007
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
    Lancet (London, England), 2007, Jul-14, Volume: 370, Issue:9582

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin

2007
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
    Lancet (London, England), 2007, Jul-14, Volume: 370, Issue:9582

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin

2007
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
    Lancet (London, England), 2007, Jul-14, Volume: 370, Issue:9582

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin

2007
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.
    Lancet (London, England), 2007, Jul-14, Volume: 370, Issue:9582

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin

2007
Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients.
    Clinical pharmacology and therapeutics, 2008, Volume: 83, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve;

2008
[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2007
A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.
    Current medical research and opinion, 2007, Volume: 23, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2007
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2007
Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Aug-01, Volume: 13, Issue:15 Pt 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colorectal Neoplasms;

2007
Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.
    Cancer immunology, immunotherapy : CII, 2008, Volume: 57, Issue:3

    Topics: Adult; Aged; Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Antineoplastic Combined Chemo

2008
Evaluation of adjuvant chemotherapy irinotecan + 5-fluorouracil + leucovorine in advanced colorectal cancer.
    Acta chirurgica Belgica, 2007, Volume: 107, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2007
Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-10, Volume: 25, Issue:23

    Topics: Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female;

2007
A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
    Anti-cancer drugs, 2007, Volume: 18, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2007
Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece.
    Current medical research and opinion, 2007, Volume: 23, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost of Illness;

2007
Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results.
    American journal of clinical oncology, 2007, Volume: 30, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal

2007
[10-hydroxy-camptothecin plus fluorouracil/leucovorin for the treatment of patients with advanced colorectal cancer].
    Zhonghua yi xue za zhi, 2007, Jun-05, Volume: 87, Issue:21

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos

2007
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2007
Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptotheci

2007
A Phase II trial of oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX4) as first-line chemotherapy in advanced colorectal cancer: a China single-center experience.
    Cancer investigation, 2007, Volume: 25, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Colorectal Neopl

2007
Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study.
    British journal of cancer, 2007, Oct-22, Volume: 97, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2007
Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases.
    British journal of cancer, 2007, Oct-22, Volume: 97, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2007
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2008
Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer.
    Medical oncology (Northwood, London, England), 2007, Volume: 24, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2007
Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2007
A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.
    Clinical pharmacokinetics, 2007, Volume: 46, Issue:11

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve;

2007
A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer.
    Journal of Korean medical science, 2007, Volume: 22 Suppl

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antin

2007
Two Doses of oxaliplatin with capecitabine (XELOX) in metastatic colorectal cancer.
    Clinical colorectal cancer, 2007, Volume: 6, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2007
Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study.
    Clinical colorectal cancer, 2007, Volume: 6, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Deoxyc

2007
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2007
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2007
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2007
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2007
Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.
    Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2008
FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study.
    Cancer, 2007, Dec-15, Volume: 110, Issue:12

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Stud

2007
An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer.
    Surgery, 2007, Volume: 142, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Combined Modalit

2007
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecita

2008
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Nov-20, Volume: 25, Issue:33

    Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb

2007
Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols;

2008
FOLFIRI chemotherapy for metastatic colorectal cancer patients.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2007, Volume: 90, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2007
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.
    British journal of cancer, 2008, Jan-15, Volume: 98, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; E

2008
Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.
    Cancer immunology, immunotherapy : CII, 2008, Volume: 57, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Colorectal Neop

2008
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemot

2008
Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.
    World journal of gastroenterology, 2007, Dec-14, Volume: 13, Issue:46

    Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal

2007
The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
    Breast cancer research and treatment, 2008, Volume: 112, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan

2008
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal

2007
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal

2007
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal

2007
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal

2007
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal

2007
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal

2007
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal

2007
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal

2007
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal

2007
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal

2007
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal

2007
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal

2007
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal

2007
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal

2007
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal

2007
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.
    Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604

    Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal

2007
Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma--a dual-centre phase II study: the MAC-6.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2008, Volume: 20, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal

2008
Effect of preoperative chemotherapy on liver resection for colorectal liver metastases.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2008, Volume: 34, Issue:7

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2008
Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jan-01, Volume: 14, Issue:1

    Topics: Adult; Aged; Aminoquinolines; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Cam

2008
[Comparative study on treatment of advanced colorectal cancer by Aidi injection combined with FOLFOX4 regimen and by FOLFOX4 regimen alone].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2007, Volume: 27, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2007
Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008, Volume: 10, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Ne

2008
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin;

2008
Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2008, Volume: 34, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2008
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2008
Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2008
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
    Clinical colorectal cancer, 2008, Volume: 7, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans

2008
Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer.
    Clinical colorectal cancer, 2008, Volume: 7, Issue:1

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasm

2008
Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2008
[A feasibility study of oxaliplatin (L-OHP) in combination with infusional 5-FU/l-LV (FOLFOX4 regimen) for advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

2008
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Mar-01, Volume: 14, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C

2008
Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?
    Cancer chemotherapy and pharmacology, 2008, Volume: 63, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2008
A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
    Oncology, 2007, Volume: 73, Issue:1-2

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplast

2007
Perioperative chemotherapy for resectable hepatic metastases.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Fluorou

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
    Lancet (London, England), 2008, Mar-22, Volume: 371, Issue:9617

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2008
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2008
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2008
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2008
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanize

2008
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F

2008
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F

2008
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F

2008
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F

2008
Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases.
    BMC cancer, 2008, Apr-25, Volume: 8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore

2008
Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:8

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2008
Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-01, Volume: 26, Issue:13

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Surface Area; Colorec

2008
Pharmacogenetic approach for capecitabine or 5-fluorouracil selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:9

    Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl

2008
Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).
    Onkologie, 2008, Volume: 31, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Respo

2008
A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer.
    Clinical colorectal cancer, 2008, Volume: 7, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2008
A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal cancer.
    Cancer chemotherapy and pharmacology, 1995, Volume: 37, Issue:1-2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1995
Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Digestive System

1994
The influence of early postoperative intraperitoneal chemotherapy on human wound healing.
    The Journal of surgical research, 1994, Volume: 57, Issue:3

    Topics: Adult; Aged; Biocompatible Materials; Collagen; Colorectal Neoplasms; Combined Modality Therapy; Dou

1994
Survival after systemic therapy for metastatic colorectal cancer.
    Lancet (London, England), 1995, Feb-04, Volume: 345, Issue:8945

    Topics: Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous; Palliative Care; Prospective Stu

1995
Trials in palliative care.
    BMJ (Clinical research ed.), 1995, Mar-04, Volume: 310, Issue:6979

    Topics: Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Neoplasms; Palliative Care; Randomized Contr

1995
Colorectal carcinoma.
    The European journal of surgery = Acta chirurgica, 1995, Volume: 161, Issue:6

    Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Intraoperative Period; Postopera

1995
[A new modality of locoregional chemotherapy based on biochemical double modulation of 5-fluorouracil with both leucovorin and cisplatin against liver metastases of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administ

1995
[Preventive chemotherapy for residual liver after resection of hepatic metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Hu

1995
[Study of hepatic arterial infusion chemotherapy for prophylaxis of liver metastases of colorectal cancer after hepatic resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

1995
[Evaluation of prophylactic hepatic arterial infusion chemotherapy after hepatectomy for metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Su

1995
[Assessment of serial carcinoembryonic antigen (CEA): monitor to evaluate efficacy of continuous intrahepatic chemotherapy for nonresectable liver metastases of colorectal carcinomas].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic

1995
[The study of chemotherapy via the reservoir to colo-rectal cancer patients with liver metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1995
[Experience in intra-hepatic-arterial chemotherapy and hepatic resection for metastatic colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr

1995
5-Fluorouracil, folinic acid and cisplatin in advanced colorectal cancer: a pilot study.
    Anti-cancer drugs, 1995, Volume: 6, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Colorectal Neopla

1995
A randomized trial of cimetidine with 5-fluorouracil and folinic acid in metastatic colorectal cancer.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1995, Volume: 21, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant

1995
[Clinical evaluation of leucovorin and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

1995
[Chrono-chemotherapy and dose intensity].
    Bulletin du cancer, 1995, Volume: 82 Suppl 1

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronobiology

1995
Prophylactic portal infusion chemotherapy as adjuvant therapy for the prevention of metachronous liver metastasis in colorectal cancer.
    Surgery today, 1995, Volume: 25, Issue:3

    Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; H

1995
[Is radiotherapy necessary in the control of colorectal cancer?].
    Ginecologia y obstetricia de Mexico, 1995, Volume: 63

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Cobalt Radioisotopes; Colectomy; Colonic

1995
Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin.
    Journal of cancer research and clinical oncology, 1995, Volume: 121, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N

1995
Combination 5-fluorouracil (5-FU) and alpha interferon (IFN) in metastatic colorectal cancer.
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22 Suppl 3

    Topics: Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Inter

1995
Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:9

    Topics: Adolescent; Adult; Aged; Alopecia; Chi-Square Distribution; Colorectal Neoplasms; Combined Modality

1995
High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer: poor response rate in unselected patients.
    British journal of cancer, 1995, Volume: 72, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

1995
Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Canc
    Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

1995
Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche

1994
Failure to increase 5-fluorouracil activity with interferon-alpha 2a in the treatment of advanced colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:1

    Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Interferon alpha-2; Interferon-alph

1995
A phase III study of recombinant interleukin-2, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinoma.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:1

    Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Interleukin-2; Leucovorin; Male; Mi

1995
Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorect

1995
[Early phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Administr

1995
Treatment of advanced colorectal carcinoma with 5-fluorouracil, leucovorin and Roferon-A: a Southwest Oncology Study Group Study.
    Cancer biotherapy, 1994,Winter, Volume: 9, Issue:4

    Topics: Adult; Aged; Colorectal Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Interfer

1994
[Treatment of acute chemically induced diarrhea by inhibition of enkephalinase. Results of a pilot study].
    Gastroenterologie clinique et biologique, 1995, Volume: 19, Issue:1

    Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Diarrhe

1995
[Intraportal infusion of 5-FU and lipiodol-aclarubicin after hepatic resection for colorectal liver metastasis].
    Nihon Geka Gakkai zasshi, 1995, Volume: 96, Issue:3

    Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therape

1995
Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla

1995
Clinical trial of continuous infusion of 5-fluorouracil using an ambulatory pump for metastatic colorectal cancer.
    Japanese journal of clinical oncology, 1995, Volume: 25, Issue:2

    Topics: Adult; Aged; Catheters, Indwelling; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusion Pum

1995
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chem

1995
[Late phase II trial of high-dose l-leucovorin and 5-fluorouracil in advanced colorectal carcinoma. l-Leucovorin and 5-FU Study Group (Japan Eastern Group)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche

1995
[A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:7

    Topics: Adult; Aged; Anorexia; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorou

1995
[Biochemically modulated chemotherapy with high-dose L-leucovorin and 5-fluorouracil for multiple liver metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:7

    Topics: Adenocarcinoma; Aged; Anorexia; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Live

1995
A randomized trial of two schedules of trimetrexate versus 5-fluorouracil in advanced colorectal cancer: a Southwest Oncology Group study.
    Anti-cancer drugs, 1995, Volume: 6, Issue:2

    Topics: Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle

1995
[Effect of prophylactic intra-arterial infusion of anticancer drugs on post hepatic resection for hepatic metastasis of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21 Suppl 4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

1994
[Home therapy approach in cancer patients-chemotherapy (case 2-2)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Home Infusion Th

1994
Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial.
    Cancer, 1995, Jan-01, Volume: 75, Issue:1

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; F

1995
Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study.
    Cancer, 1995, Jan-15, Volume: 75, Issue:2

    Topics: Adult; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Male; Middle Aged; Neo

1995
Metastatic or locally advanced colorectal cancer treated with 5-fluorouracil and low dose leucovorin.
    Acta oncologica (Stockholm, Sweden), 1994, Volume: 33, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Co

1994
The AXIS colorectal cancer trial: randomization of over 2000 patients. The AXIS Steering Group.
    The British journal of surgery, 1994, Volume: 81, Issue:11

    Topics: Aged; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Male

1994
Experimental colonic healing in relation to timing of 5-fluorouracil therapy.
    The British journal of surgery, 1994, Volume: 81, Issue:11

    Topics: Animals; Colon; Colorectal Neoplasms; Fluorouracil; Male; Rats; Rats, Wistar; Time Factors; Wound He

1994
Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.
    Cancer, 1995, Feb-01, Volume: 75, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1995
A phase II study of advanced colorectal cancer patients treated with combination 5-fluorouracil plus leucovorin and subcutaneous interleukin-2 plus alpha interferon.
    Journal of chemotherapy (Florence, Italy), 1994, Volume: 6, Issue:4

    Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fem

1994
5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration.
    Cancer, 1995, Mar-01, Volume: 75, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

1995
5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study.
    Cancer chemotherapy and pharmacology, 1995, Volume: 35, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

1995
[Continuous intraarterial infusion of 5-fluorouracil plus leucovorin for liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche

1995
[Pharmacokinetic study of UFT in cancer patients receiving maintenance dialysis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

1995
Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy.
    Annals of surgery, 1995, Volume: 221, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Appendicea

1995
Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial.
    Cancer, 1995, Mar-15, Volume: 75, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr

1995
A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma.
    American journal of clinical oncology, 1995, Volume: 18, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C

1995
Cytarabine and cisplatin as salvage therapy in patients with metastatic colorectal cancer who failed 5-fluorouracil + folinic acid regimen. French Northern Oncology Group.
    American journal of clinical oncology, 1995, Volume: 18, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Cytara

1995
A phase II study of regional 5-fluorouracil infusion with intravenous folinic acid for colorectal liver metastases.
    British journal of cancer, 1994, Volume: 70, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

1994
Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics.
    British journal of cancer, 1994, Volume: 70, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Fluid Compartments; Colorectal Neo

1994
Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?
    British journal of cancer, 1994, Volume: 70, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1994
Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma.
    British journal of cancer, 1994, Volume: 70, Issue:4

    Topics: Colorectal Neoplasms; Dextrins; Dialysis Solutions; Drug Administration Schedule; Drug Stability; Fe

1994
Phase II study of 5-fluorouracil/leucovorin for pediatric patients with malignant solid tumors.
    Cancer, 1994, Nov-01, Volume: 74, Issue:9

    Topics: Adolescent; Carcinoma; Child; Child, Preschool; Colorectal Neoplasms; Drug Administration Schedule;

1994
Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.
    Journal of the National Cancer Institute, 1994, Nov-02, Volume: 86, Issue:21

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Colo

1994
[A study of regional chemotherapy: hepatic arterial infusion for metastatic liver tumors].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Fluorouracil; Hepat

1994
[Evaluation of prophylactic intra-hepatic-arterial infusion chemotherapy after resection of hepatic metastases from colorectal primaries].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:13

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Do

1994
[Intraarterial infusion combination therapy with LV and 5-FU in hepatic metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

1994
[Hepatic arterial infusion after hepatectomy for liver metastases of colorectal carcinoma to prevent residual hepatic recurrence].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Floxuridine; Flu

1994
[The significance of portal infusion chemotherapy for prevention of recurrence in residual liver after hepatectomy for metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He

1994
[A study of preoperative administration of 5'-DFUR in patients with colo-rectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:14

    Topics: Administration, Oral; Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans

1994
The effect of 5-fluorouracil and alpha interferon and 5-fluorouracil and leucovorin on cellular anti-tumour immune responses in patients with advanced colorectal cancer.
    British journal of cancer, 1994, Volume: 70, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

1994
Treatment of liver metastases from colorectal cancer with hepatic artery occlusion, intraportal 5-fluorouracil infusion, and oral allopurinol. A randomized clinical trial.
    Cancer, 1994, Nov-15, Volume: 74, Issue:10

    Topics: Administration, Oral; Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Colo

1994
Phase II study with iododoxorubicin in measurable advanced colorectal adenocarcinoma. Effective rescue using weekly high-dose 5-fluorouracil (WFU). Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD), Work Group of SEOM (Spanish Medical Onc
    Tumori, 1994, Apr-30, Volume: 80, Issue:2

    Topics: Adenocarcinoma; Aged; Colorectal Neoplasms; Doxorubicin; Female; Fluorouracil; Humans; Male; Middle

1994
Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer.
    Journal of the National Cancer Institute, 1994, Jul-20, Volume: 86, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

1994
[The usefulness of pre- and immediately postoperative chemotherapy in colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:8

    Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy,

1994
Spontaneous or imposed circadian changes in plasma concentrations of 5-fluorouracil coadministered with folinic acid and oxaliplatin: relationship with mucosal toxicity in patients with cancer.
    Clinical pharmacology and therapeutics, 1994, Volume: 56, Issue:2

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm;

1994
Sequential treatment with high-dose methotrexate and fluorouracil in advanced colorectal cancer. Experience of the Southern Italian Oncology Group (GOIM).
    Journal of chemotherapy (Florence, Italy), 1994, Volume: 6, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1994
Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma.
    Cancer, 1994, Sep-15, Volume: 74, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Colorec

1994
[Status of portal perfusion in colorectal cancer. Swiss Study Group for Clinical Cancer Research].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 1994, Volume: 65, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N

1994
Double modulation of 5-fluorouracil by high-dose leucovorin and interferon alpha 2b in advanced colorectal cancer: a phase I and a phase II study of weekly administration.
    Journal of cancer research and clinical oncology, 1994, Volume: 120, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

1994
Estimated treatment responses in metastatic colorectal carcinoma based on longitudinal carcinoembryonic antigen series.
    Scandinavian journal of clinical and laboratory investigation, 1993, Volume: 53, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Ne

1993
Experience with 5FU + L-leucovorin.
    Advances in experimental medicine and biology, 1993, Volume: 339

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

1993
5-Fluorouracil combined with the pure [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study of two consecutive regimens.
    Advances in experimental medicine and biology, 1993, Volume: 339

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1993
5-Fluorouracil modulation in colorectal carcinoma experience of German investigators.
    Advances in experimental medicine and biology, 1993, Volume: 339

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Germany; Humans; Immunologic Factors; Int

1993
Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1994
Continuous-infusion 5-fluorouracil in metastatic colorectal cancer patients pretreated with bolus 5-fluorouracil: clinical evidence of incomplete cross-resistance.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:3

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Drug Resistance; Fluorouracil; Humans; Infusions

1994
Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients.
    American journal of clinical oncology, 1994, Volume: 17, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Drug Administ

1994
Chronotherapy with 5-fluorouracil and folinic acid in advanced colorectal carcinoma. Results of a chronopharmacologic phase I trial.
    Cancer, 1994, Jun-15, Volume: 73, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Colorectal Neoplasms;

1994
Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Female;

1994
A randomized feasibility study evaluating the effect of radiotherapy alone or combined with 5-fluorouracil in the treatment of locally recurrent or inoperable colorectal carcinoma.
    Acta oncologica (Stockholm, Sweden), 1993, Volume: 32, Issue:5

    Topics: Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Middl

1993
Local and systemic toxicity of intra-hepato-arterial chemotherapy for treatment of unresectable liver metastases of colorectal cancer with 5-Fluorouracil and high dose Leucovorin.
    Helvetica chirurgica acta, 1993, Volume: 60, Issue:1-2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Colore

1993
[Some problems of TS measurement after administration of fluoropyrimidines in colorectal cancer. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:14

    Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Dipyridamole; Female; Fluorouracil; Humans

1993
A phase-III study of recombinant interleukin 2 and 5-fluorouracil chemotherapy in patients with metastatic colorectal cancer.
    British journal of cancer, 1993, Volume: 68, Issue:6

    Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capillary Permeabi

1993
Adjuvant hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases.
    American journal of surgery, 1993, Volume: 166, Issue:6

    Topics: Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Humans

1993
Re: "Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: activity in liver metastasis".
    Cancer investigation, 1994, Volume: 12, Issue:1

    Topics: Colorectal Neoplasms; Fluorouracil; Humans; Interferon Type I; Liver Neoplasms; Recombinant Proteins

1994
Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review.
    Cancer investigation, 1994, Volume: 12, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta

1994
Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group.
    Cancer, 1994, Feb-01, Volume: 73, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1994
Bolus vs. continuous hepatic arterial infusion of cisplatin plus intravenous 5-fluorouracil chemotherapy for unresectable colorectal metastases.
    Diseases of the colon and rectum, 1994, Volume: 37, Issue:2 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Female; Fluorouraci

1994
Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4 Suppl 2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N

1993
5-Fluorouracil combined with the [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma. A phase I-II study of two consecutive regimens.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4 Suppl 2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

1993
Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

1993
[Intermittent hepatic arterial infusion of high-dose 5-FU for liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:11

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intra-A

1993
[A randomized trial of intrahepatic infusion chemotherapy for unresectable colorectal liver metastases. Sendai Study Group].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubicin; Epir

1993
Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study.
    Cancer, 1993, Oct-01, Volume: 72, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

1993
Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans;

1993
Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Feasibi

1993
Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin and interleukin-2.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; H

1993
A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:10

    Topics: Adenocarcinoma; Aged; Colorectal Neoplasms; Double-Blind Method; Drug Administration Schedule; Femal

1993
Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer.
    Journal of the National Cancer Institute, 1993, Jan-06, Volume: 85, Issue:1

    Topics: Adjuvants, Pharmaceutic; Adult; Aged; Aged, 80 and over; Carcinoembryonic Antigen; Colorectal Neopla

1993
Intra-arterial hepatic treatment with carboplatin (CBDCA) and 5-fluorouracil (5-FU) in metastases from colorectal carcinoma.
    American journal of clinical oncology, 1993, Volume: 16, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino

1993
Combination chemotherapy with tauromustine (TCNU), 5-fluorouracil and leucovorin in advanced colorectal carcinoma: a dose-finding study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

1993
A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases.
    Cancer, 1993, Mar-15, Volume: 71, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

1993
[The chemoradiotherapy of advanced colorectal carcinoma--the results and toxicity in a pilot study with 44 patients].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1993, Volume: 169, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

1993
Continuous hepatic artery infusion of 5-fluorouracil for metastatic colorectal cancer localised to the liver.
    Australian and New Zealand journal of medicine, 1993, Volume: 23, Issue:1

    Topics: Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Inf

1993
Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. The Nordic Gastrointestina
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

1993
Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

1995
A phase I-II trial of five-day continuous intravenous infusion of 5-fluorouracil delivered at circadian rhythm modulated rate in patients with metastatic colorectal cancer.
    The Journal of infusional chemotherapy, 1995, Volume: 5, Issue:3 Suppl 1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Circadian Rhythm; Colorectal Neoplasms; Disease-Free S

1995
Pharmacokinetic interaction of 5-fluorouracil and interferon alpha-2b with or without folinic acid.
    Medical oncology (Northwood, London, England), 1995, Volume: 12, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

1995
A phase II trial of 5-fluorouracil and 1-leucovorin in patients with metastatic colorectal cancer.
    American journal of clinical oncology, 1996, Volume: 19, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fe

1996
'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dr

1995
Treatment of advanced colorectal cancer with high-dose intensity folinic acid and 5-fluorouracil plus supportive care.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:12

    Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration S

1995
A phase II and pharmacokinetic study of 6S-leucovorin plus 5-fluorouracil in patient with colorectal carcinoma.
    Investigational new drugs, 1995, Volume: 13, Issue:2

    Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Cohort Studies; Colorectal Neopl

1995
Prospective adjuvant therapy with mitomycin C and carmofur (HCFU) for colorectal cancer, 10-year follow-up: Tokai HCFU Study Group, the first study for colorectal cancer.
    Journal of surgical oncology, 1996, Volume: 62, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

1996
Preclinical and clinical evaluation of 5-fluorouracil biochemical modulation with folinic acid and hydroxyurea for patients with colorectal carcinoma.
    Cancer, 1995, Oct-15, Volume: 76, Issue:8

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; H

1995
Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore

1996
Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:9

    Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged;

1995
Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer.
    Cancer, 1995, Nov-15, Volume: 76, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1995
5-fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer.
    Cancer, 1995, Aug-01, Volume: 76, Issue:3

    Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc

1995
A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
    Cancer, 1995, Aug-15, Volume: 76, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla

1995
Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer.
    Journal of the National Cancer Institute, 1996, May-15, Volume: 88, Issue:10

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Colorectal Neoplasms; Disease-Fre

1996
High dose folinic acid and 5-fluorouracil bolus and continuous infusion for patients with advanced colorectal cancer.
    Cancer, 1995, Oct-01, Volume: 76, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1995
Postoperative chemotherapy for colorectal cancer by combining 5-fluorouracil infusion and 1-hexylcarbamoyl-5-fluorouracil administration after curative resection.
    Cancer, 1996, Jan-01, Volume: 77, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad

1996
Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU.
    Cancer, 1996, Feb-01, Volume: 77, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Therapy, Combination; Femal

1996
Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2B interferon in advanced colorectal cancer.
    American journal of clinical oncology, 1996, Volume: 19, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1996
[Comparative study of the combined effect of HCFU and dipyridamole (DP) in colorectal carcinoma--TS inhibition rate. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dipyridamole; Dru

1996
Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
    Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Che

1996
Multimodal biochemical modulation of 5-fluorouracil by leucovorin, methotrexate, and interferon alpha in patients with advanced colorectal cancer.
    Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

1996
[Evaluation of chemotherapy in the treatment of advanced colorectal cancer--pilot study of 5-FU by biochemical modulation].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:4

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplas

1996
[Effect of leucovorin and 5-FU for advanced colorectal cancer patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

1996
[Progress in development of chemotherapy of colorectal carcinoma].
    Medizinische Klinik (Munich, Germany : 1983), 1996, Apr-12, Volume: 91 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Dr

1996
Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Europe; Female; Fluorour

1996
Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1996
Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

1996
Measurement of 5-fluorouracil in scalp hair: a possible index of patient compliance with oral adjuvant chemotherapy.
    European journal of clinical pharmacology, 1996, Volume: 50, Issue:1-2

    Topics: Animals; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Mod

1996
A Bayesian analysis of bivariate survival data from a multicentre cancer clinical trial.
    Statistics in medicine, 1995, Dec-15, Volume: 14, Issue:23

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Cisplatin; Colorectal Neoplasms; Dose

1995
Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: clinical and immunological effects.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1995
Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer.
    Journal of cancer research and clinical oncology, 1996, Volume: 122, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Adm

1996
A report of infusional 5-fluorouracil and subcutaneous alpha-2A-interferon in the treatment of advanced colorectal carcinoma.
    Annals of the Academy of Medicine, Singapore, 1996, Volume: 25, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Drug Ther

1996
Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer.
    The Journal of infusional chemotherapy, 1996,Spring, Volume: 6, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

1996
A pilot study of adjuvant hepatic arterial infusion chemotherapy, associating 5-fluorouracil and leucovorin, after resection of colorectal cancer liver metastases.
    Surgical oncology, 1995, Volume: 4, Issue:6

    Topics: Aged; Antidotes; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fema

1995
Subcutaneous low-dose interleukin-2 and intravenous 5-fluorouracil plus high-dose levofolinic acid as salvage treatment for metastatic colorectal carcinoma.
    Anti-cancer drugs, 1996, Volume: 7, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationsh

1996
A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer.
    British journal of cancer, 1996, Volume: 74, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1996
Sequential methotrexate and 5-fluorouracil as second-line chemotherapy for advanced colorectal cancer patients pretreated with 5-fluorouracil and leucovorin: a GISCAD study.
    Journal of chemotherapy (Florence, Italy), 1996, Volume: 8, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1996
[Clinical study of ambulatory cancer chemotherapy for advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22 Suppl 4

    Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Col

1995
[Continuous hepatic arterial infusion chemotherapy with low-dose CDDP plus 5-FU for liver metastases from colorectal carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug A

1996
[Clinical evaluation of hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Doxorubicin;

1996
[Evaluation of prophylactic hepatic arterial infusion chemotherapy after hepatectomy for metastases from colorectal cancer--the second report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Hepatectomy; Hepatic Artery; Human

1996
[The preventive effect of weekly high-dose 5-FU infusion (WHF) after resection of hepatic metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11

    Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; H

1996
[The effect of intraportal chemotherapy in terms of administered dose of 5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusion Pumps, Implantabl

1996
Hypocalcemia associated with 5-fluorouracil and low dose leucovorin in patients with advanced colorectal or gastric carcinomas.
    Cancer, 1996, Oct-15, Volume: 78, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Calcium; Colorectal Neoplasms; Fem

1996
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
    Cytotechnology, 1996, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Col

1996
A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma.
    Anti-cancer drugs, 1996, Volume: 7, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Colorectal Neopl

1996
Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1996
5-Fluorouracil versus 5-fluorouracil plus alpha-interferon as treatment of metastatic colorectal carcinoma. A randomized study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore

1996
Outpatient weekly high-dose continuous-infusion 5-fluorouracil plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla

1996
Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: five-year follow-up. Tokai HCFU Study Group--third study on colorectal cancer.
    Journal of surgical oncology, 1996, Volume: 63, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplas

1996
Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer.
    Drugs under experimental and clinical research, 1996, Volume: 22, Issue:3-5

    Topics: Alkaloids; Antimetabolites, Antineoplastic; Antineoplastic Agents; Berberine Alkaloids; Biopsy; Colo

1996
Advanced colorectal carcinoma: redefining the role of oral ftorafur.
    Anti-cancer drugs, 1996, Volume: 7, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

1996
Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:11

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidotes; Antineoplastic Combined Chemotherapy Protocols;

1996
5-Fluorouracil continuous infusion in metastatic colorectal cancer.
    Annals of the Academy of Medicine, Singapore, 1996, Volume: 25, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal N

1996
Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study.
    International journal of colorectal disease, 1996, Volume: 11, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modalit

1996
Clinical application of biochemical modulation in cancer chemotherapy: biochemical modulation for 5-FU.
    Oncology, 1997, Volume: 54 Suppl 1

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug

1997
Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.
    British journal of cancer, 1996, Volume: 74, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antibody Formation; Antimetabolites, Antineoplastic; Antineoplastic Age

1996
Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

1996
The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerised assessments.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:13

    Topics: Aged; Antimetabolites, Antineoplastic; Cognition Disorders; Colorectal Neoplasms; Combined Modality

1996
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore

1997
Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure l-isomer of leucovorin for the treatment of advanced colorectal cancer: a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:3

    Topics: Adult; Aged; Agranulocytosis; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dise

1997
Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    Cancer, 1997, Mar-15, Volume: 79, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1997
Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    Cancer, 1997, Mar-15, Volume: 79, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige

1997
Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

1997
High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a 'GISCAD' phase III study. Italian Group for the Study of Digestive Tract Cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

1997
Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil.
    Anti-cancer drugs, 1997, Volume: 8, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Colorectal Neoplasm

1997
Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hum

1997
Adjuvant therapy for resectable colorectal carcinoma with 5-fluorouracil portal vein infusion.
    Journal of chemotherapy (Florence, Italy), 1997, Volume: 9, Issue:2

    Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorourac

1997
Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore

1997
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
    Investigational new drugs, 1997, Volume: 15, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Colorectal Neoplasms; Drug Interactions

1997
The EORTC GI group experience with high-dose infusional 5-FU in colorectal cancer.
    The Journal of infusional chemotherapy, 1996,Summer, Volume: 6, Issue:3

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

1996
The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
    The Journal of infusional chemotherapy, 1996,Summer, Volume: 6, Issue:3

    Topics: Administration, Oral; Adult; Aged; Anemia; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Co

1996
The French experience with infusional 5-fluorouracil in advanced colorectal cancer.
    The Journal of infusional chemotherapy, 1996,Summer, Volume: 6, Issue:3

    Topics: Antidotes; Antimetabolites, Antineoplastic; Chronotherapy; Colorectal Neoplasms; Dose-Response Relat

1996
High-dose infusional 5-fluorouracil combination therapy of metastatic gastric and colorectal cancer.
    The Journal of infusional chemotherapy, 1996,Summer, Volume: 6, Issue:3

    Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc

1996
First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
    The Journal of infusional chemotherapy, 1996,Summer, Volume: 6, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carbop

1996
Infusion pumps for systemic and intra-arterial chemotherapy of colorectal liver metastases.
    Annals of the Royal College of Surgeons of England, 1997, Volume: 79, Issue:4

    Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cost Savings; E

1997
[Immunological monitoring of patients with disseminated colorectal cancer under thermochemotherapy].
    Klinichna khirurhiia, 1997, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hot

1997
Factors predictive of response and survival in patients with metastatic colorectal cancer in Taiwan.
    Japanese journal of clinical oncology, 1997, Volume: 27, Issue:3

    Topics: Adjuvants, Immunologic; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasm

1997
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

1997
Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1997, Volume: 5, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chi-Square Distribution; Colorectal

1997
Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand break
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Damage; DNA,

1997
Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents

1997
Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy.
    Lancet (London, England), 1997, Sep-06, Volume: 350, Issue:9079

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal Neoplasms; Fe

1997
[Effects of adjuvant hyaluronidase in tumors refractory to chemotherapy. Review of the literature and pharmacokinetics of cisplatin after regional administration in animals and humans].
    Il Giornale di chirurgia, 1997, Volume: 18, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma 256, Walker; Chemotherapy

1997
Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy.
    Cancer letters, 1997, Sep-16, Volume: 118, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomar

1997
Intermittent hepatic arterial infusion of high-dose 5FU on a weekly schedule for liver metastases from colorectal cancer.
    Cancer chemotherapy and pharmacology, 1997, Volume: 40, Issue:6

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; H

1997
UFT plus leucovorin vs 5-FU plus leucovorin for metastatic colorectal cancer.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:9 Suppl 10

    Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug C

1997
5-FU or UFT combined with leucovorin for previously untreated metastatic colorectal Ca.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:9 Suppl 10

    Topics: Adult; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combina

1997
[Current status of low-dose CDDP. 5-FU therapy for solid malignant tumors--nationwide questionnaire survey].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administration

1997
9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.
    Cancer, 1997, Nov-01, Volume: 80, Issue:9

    Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Resist

1997
Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:11

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

1997
A phase II study of regional 2-weekly 5-fluorouracil infusion with intravenous folinic acid in the treatment of colorectal liver metastases.
    British journal of cancer, 1997, Volume: 76, Issue:10

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; In

1997
A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Re

1997
A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cath

1997
[Combined treatment of large bowel cancer].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1997, Volume: 50 Suppl 1 Pt 1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

1997
The psychological and psychiatric effects of rIL-2 therapy: a controlled clinical trial.
    Psycho-oncology, 1997, Volume: 6, Issue:4

    Topics: Antimetabolites, Antineoplastic; Cognition Disorders; Colorectal Neoplasms; Combined Modality Therap

1997
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study.
    British journal of cancer, 1998, Volume: 77, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr

1998
Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Drug Admini

1998
5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:11

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil;

1997
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Fe

1997
Double modulation of 5-fluorouracil by methotrexate and high-dose L-leucovorin in advanced colorectal cancer.
    American journal of clinical oncology, 1998, Volume: 21, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

1998
[Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD].
    La Revue de medecine interne, 1997, Volume: 18, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hum

1997
Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
    Cancer research, 1998, Mar-15, Volume: 58, Issue:6

    Topics: Cell Division; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Ge

1998
Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin.
    American journal of clinical oncology, 1998, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Female

1998
Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protoc

1998
Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:4

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Capecitabine

1998
Measuring quality of life: impact of chemotherapy for advanced colorectal cancer. Experience from two recent large phase III trials.
    British journal of cancer, 1998, Volume: 77 Suppl 2

    Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Enzyme I

1998
[The evaluation of weekly hepatic arterial infusion of high-dose 5-FU for liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Female; F

1998
Determination of unbound platinum after oxaliplatin administration: comparison of currently available methods and influence of various parameters.
    Anti-cancer drugs, 1998, Volume: 9, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou

1998
A prospective randomized study comparing high- and low-dose leucovorin combined with same-dose 5-fluorouracil in advanced colorectal cancer.
    American journal of clinical oncology, 1998, Volume: 21, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationsh

1998
Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil.
    American journal of clinical oncology, 1998, Volume: 21, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche

1998
Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer.
    Anti-cancer drugs, 1998, Volume: 9, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasm

1998
The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK).
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta

1998
Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv

1998
A phase II trial of carboplatin, methotrexate and fluorouracil in fluorouracil-pretreated colorectal cancer.
    Journal of chemotherapy (Florence, Italy), 1998, Volume: 10, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colorectal Neoplasms; Drug Admini

1998
5-Fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma.
    Journal of chemotherapy (Florence, Italy), 1998, Volume: 10, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1998
[Method of preventing hepatic artery occlusion during continuous intrahepatic arterial infusion chemotherapy of 5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:9

    Topics: Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Colorectal N

1998
[Clinical evaluation of intermittent hepatic arterial infusion therapy for metastatic liver tumor of gastric and colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:9

    Topics: Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; C

1998
High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research.
    American journal of clinical oncology, 1998, Volume: 21, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1998
Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; Female; F

1998
Biomodulation with sequential intravenous IFN-alpha2b and 5-fluorouracil as second-line treatment in patients with advanced colorectal cancer.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 1998, Volume: 18, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Femal

1998
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

1998
Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:7

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Fe

1998
Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.
    Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe

1998
Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorecta

1998
[Adjuvant radio-chemotherapy is effective in the treatment of Dukes B and C rectal cancer: results of a randomized controlled Norwegian trial].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1998, Volume: 174, Issue:9

    Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Norway; Radiotherapy, Adjuvant

1998
Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases.
    British journal of cancer, 1998, Volume: 78, Issue:8

    Topics: Colorectal Neoplasms; Drug Resistance, Neoplasm; Floxuridine; Fluorouracil; Hepatic Artery; Humans;

1998
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
    Lancet (London, England), 1998, Oct-31, Volume: 352, Issue:9138

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Color

1998
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
    Lancet (London, England), 1998, Oct-31, Volume: 352, Issue:9138

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phy

1998
A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1998, Volume: 52, Issue:7-8

    Topics: Aged; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Inte

1998
Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl

1997
Pharmacokinetics of recombinant human interferon-alpha 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma.
    Anti-cancer drugs, 1998, Volume: 9, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Drug A

1998
Anticancer effects of preoperative chemotherapy on colorectal carcinoma.
    Digestive surgery, 1998, Volume: 15, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant;

1998
Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluor

1998
Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen)
    Annals of surgery, 1998, Volume: 228, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

1998
A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

1998
Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1998
[Multicenter phase II study of the Liver Metastases Study Group of weekly intra-arterial 24-hour high dose therapy with 5-FU and folinic acid (FA) in liver metastases of colorectal tumors].
    Langenbecks Archiv fur Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress, 1998, Volume: 115

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

1998
[Intra-arterial (5-FU/FA and FUDR) versus systemic chemotherapy (5-FU/FA) of non-resectable colorectal liver metastases].
    Langenbecks Archiv fur Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress, 1998, Volume: 115

    Topics: Adult; Aged; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; F

1998
5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Colorectal Neopl

1998
Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:12

    Topics: Adult; Age Factors; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neop

1998
S-phase accumulation precedes apoptosis induced by preoperative treatment with 5-fluorouracil in human colorectal carcinoma cells.
    Cancer, 1999, Jan-15, Volume: 85, Issue:2

    Topics: Apoptosis; Colorectal Neoplasms; DNA, Neoplasm; Female; Flow Cytometry; Fluorouracil; Humans; Immuno

1999
Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

1999
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Cancer, 1999, Feb-15, Volume: 85, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic;

1999
[Biochemical modulation of 5-FU--effect of low dose CDDP].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin

1999
Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma.
    British journal of cancer, 1999, Volume: 79, Issue:11-12

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Ag

1999
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Color

1999
Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer.
    Hybridoma, 1999, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Aged; Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Feasibility St

1999
A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group.
    Seminars in oncology, 1999, Volume: 26, Issue:1 Suppl 5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplas

1999
Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
    Seminars in oncology, 1999, Volume: 26, Issue:1 Suppl 5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplas

1999
Oxaliplatin pharmacokinetics during a four-hour infusion.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Colorectal Neopl

1999
A simplified regimen of weekly high dose 5-fluorouracil and leucovorin as a 24-hour infusion in patients with advanced colorectal carcinoma.
    Cancer, 1999, May-01, Volume: 85, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

1999
An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer.
    Anti-cancer drugs, 1999, Volume: 10, Issue:3

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Cost-Benefit Analysis; Costs and Cost Analysis; Fluorou

1999
[Adjuvant chemotherapy after curative surgery for non-metastatic colorectal carcinomas (2-year results of 52 cases)].
    La Tunisie medicale, 1999, Volume: 77, Issue:2

    Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colo

1999
Phase II study of cisplatin and dacarbazine for metastatic colorectal carcinoma resistant to 5-fluorouracil.
    Oncology, 1999, Volume: 56, Issue:4

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined C

1999
A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer.
    British journal of cancer, 1999, Volume: 80, Issue:5-6

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

1999
High-dose therapy with combined 5-fluorouracil and folinic acid with and without amifostine in the treatment of patients with metastatic colorectal carcinoma.
    International journal of colorectal disease, 1999, Volume: 14, Issue:2

    Topics: Amifostine; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Therapy, Combinat

1999
A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy.
    Cancer, 1999, Jun-15, Volume: 85, Issue:12

    Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplas

1999
Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.
    Anti-cancer drugs, 1999, Volume: 10, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Clocks; Colonic Neoplasms; C

1999
[Treatment for advanced colorectal carcinoma with 5-fluorouracil plus low-dose leucovorin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone

1999
Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II study.
    Cancer chemotherapy and pharmacology, 1999, Volume: 44, Issue:2

    Topics: Adult; Aged; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Hu

1999
[Irinotecan in the second-line therapy of metastatic colorectal carcinoma].
    Zeitschrift fur Gastroenterologie, 1999, Volume: 37, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplas

1999
[Peripheral 5-FU blood concentration after high-dose injection into the hepatic artery: potential preventive effect on extrahepatic metastatic foci].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:8

    Topics: Adult; Aged; Area Under Curve; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; Hepatic Arte

1999
Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases.
    Langenbeck's archives of surgery, 1999, Volume: 384, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

1999
Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal Neoplasms; Co

1999
Impact of uracil/tegafur plus oral calcium folinate on resource utilization.
    Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:7 Suppl 3

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour

1999
Using preoperative UFT to predict sensitivity to fluoropyrimidines in colorectal cancer.
    Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:7 Suppl 3

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy,

1999
Reduction of chemotherapy-induced side-effects by parenteral glutamine supplementation in patients with metastatic colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1999
Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Interactions

1999
Intra-arterial 5-fluorouracil and intravenous folinic acid in the treatment of liver metastases from colorectal cancer.
    The European journal of surgery = Acta chirurgica, 1999, Volume: 165, Issue:7

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore

1999
Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucovorin for patients with metastatic colorectal carcinoma: A Southwest Oncology Group pilot trial.
    Cancer, 1999, Sep-01, Volume: 86, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Cisplat

1999
The role of stable disease in objective response assessment and its impact on survival in advanced colorectal cancer: is "stable disease" a homogenous response category?
    Neoplasma, 1999, Volume: 46, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colorectal

1999
Pharmacokinetic and pharmacodynamic comparison of two doses of calcium folinate combined with continuous fluorouracil infusion in patients with advanced colorectal cancer.
    Pharmacy world & science : PWS, 1999, Volume: 21, Issue:4

    Topics: Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ch

1999
Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Aci

1999
Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant

1999
A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1999
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1999
Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:10 Suppl

    Topics: Adult; Aged; Animals; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan;

1999
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1999
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1999
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1999
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1999
[Clinical trial of prophylactic hepatic arterial chemotherapy for liver metastases in patients with Dukes' C colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Adm

1999
[Cooperative study of intraarterial preventive chemotherapy after resection of hepatic metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

1999
[Evaluation of the non-effective cases of irresectable multiple liver metastasis of colorectal cancer receiving hepatic arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorou

1999
[Efficacy of intra-arterial chemotherapy on life prolongation in patients with hepatic metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Modality T

1999
[Efficacy and side effect of continuous intra-arterial infusion of high-dose 5-FU for liver metastases of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Femal

1999
[The efficacy and limitation of hepatic arterial infusion chemotherapy for colorectal liver metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Administration, Oral; Chemoembolization, Therapeutic; Colorectal Neoplasms; Combined Modality Therap

1999
Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Chi-Square Distribution; Chromatogra

1999
Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Neoplasm

1999
[Bimonthly 5-fluorouracil in elderly patients with metastatic colorectal cancer. Study of 50 patients].
    La Revue de medecine interne, 1999, Volume: 20, Issue:10

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression;

1999
A dose-escalation phase II clinical trial of infusional mitomycin C for 7 days in patients with advanced measurable colorectal cancer refractory or resistant to 5-fluorouracil.
    Cancer investigation, 1999, Volume: 17, Issue:8

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dis

1999
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.
    The New England journal of medicine, 1999, Dec-30, Volume: 341, Issue:27

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C

1999
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:1

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Co

2000
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:1

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Co

2000
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:1

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Co

2000
Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:1

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Co

2000
Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:11

    Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe

1999
Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Colorectal Ne

1999
Irinotecan (CPT-11) in patients with advanced colorectal cancer previously treated with 5-fluorouracil-based chemotherapy.
    Critical reviews in oncology/hematology, 1999, Volume: 32, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Color

1999
[Usefulness of pharmacokinetic modulating chemotherapy (PMC) for the postoperative adjuvant therapy of colorectal carcinoma: a preliminary report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:14

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla

1999
Enhancement of fluorouracil uptake in human colorectal and gastric cancers by interferon or by high-dose methotrexate: An in vivo human study using noninvasive (19)F-magnetic resonance spectroscopy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Relationship, Drug

2000
Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials.
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35 Suppl 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

1999
High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2000, Volume: 8, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic C

2000
Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv

1999
CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

1999
Pharmacokinetics of levamisole in cancer patients treated with 5-fluorouracil.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:3

    Topics: Adjuvants, Immunologic; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Colorectal Neop

2000
Chronotherapy with 5-fluorouracil, folinic acid and carboplatin for metastatic colorectal cancer; an interesting therapeutic index in a phase II trial.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chronot

2000
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxyc

2000
Selective augmentations of intratumoral 5-fluorouracil concentration by local immunotherapy with OK-432 and fibrinogen.
    Diseases of the colon and rectum, 2000, Volume: 43, Issue:3

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Colon; Colorec

2000
Limited but definite efficacy of prophylactic hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases: A randomized study.
    Cancer, 2000, Apr-01, Volume: 88, Issue:7

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Diseas

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Cisplatin containing chemotherapy influences HLA-DR expression on monocytes from cancer patients.
    Journal of experimental & clinical cancer research : CR, 1999, Volume: 18, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorecta

1999
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressur

2000
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressur

2000
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressur

2000
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressur

2000
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressur

2000
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressur

2000
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressur

2000
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressur

2000
Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Chromatography, High Pressur

2000
Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2000
Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2000
Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv

2000
A patient preference study comparing raltitrexed ('Tomudex') and bolus or infusional 5-fluorouracil regimens in advanced colorectal cancer: influence of side-effects and administration attributes.
    European journal of cancer care, 1999, Volume: 8, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; In

1999
Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study.
    American journal of clinical oncology, 2000, Volume: 23, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug R

2000
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:4

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Admi

2000
Phase II study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer.
    Journal of chemotherapy (Florence, Italy), 2000, Volume: 12, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Sch

2000
[Regional chemotherapy of the liver after resection of liver metastases in colorectal carcinoma].
    Zeitschrift fur Gastroenterologie, 2000, Volume: 38, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin

2000
Preoperative UFT administration for patients with advanced colorectal cancer--increased uptake of 5-fluorouracil by tumor tissue is a prognostic factor.
    Anti-cancer drugs, 2000, Volume: 11, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Ne

2000
[The effect of combination chemotherapy to adapted to chronotherapy with 5-fluorouracil, leucovorin, mitomycin C and cisplatin in patients with gastric or colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administ

2000
Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO.
    Oncology, 2000, Volume: 58, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone M

2000
A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Ne

2000
Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer.
    Anti-cancer drugs, 1999, Volume: 10, Issue:6

    Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms

1999
Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer after 5-FU failure.
    Anti-cancer drugs, 1999, Volume: 10, Issue:6

    Topics: Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; C

1999
Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27 Suppl 2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2000
Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:15

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
    British journal of cancer, 2000, Volume: 83, Issue:4

    Topics: Adult; Aged; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cam

2000
Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid.
    PharmacoEconomics, 2000, Volume: 17, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

2000
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neo

2000
Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Colorectal Neoplasms;

2000
Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases.
    Cancer, 2000, Sep-15, Volume: 89, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe

2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2000
Dose and time dependencies of 5-fluorouracil pharmacokinetics.
    Clinical pharmacology and therapeutics, 2000, Volume: 68, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Dr

2000
Avoidance of colostomy placement in advanced colorectal cancer with twice weekly hypofractionated radiation plus continuous infusion 5-fluorouracil.
    Journal of pain and symptom management, 2000, Volume: 20, Issue:4

    Topics: Colorectal Neoplasms; Colostomy; Contraindications; Dose Fractionation, Radiation; Drug Administrati

2000
Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium).
    Anti-cancer drugs, 2000, Volume: 11, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2000
Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly versus four-weekly schedules--less pain, same gain. QUASAR Colorectal Cancer Study Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin

2000
5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomised phase II study of the Southern Italy Oncology Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2000
Can mitomycin C represent a valid partner for 5-fluorouracil in second-line chemotherapy of colorectal cancer?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:8

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2000
Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer.
    Neoplasma, 2000, Volume: 47, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

2000
Phase II study of second-line oxaliplatin, irinotecan and mitomycin C in patients with advanced or metastatic colorectal cancer.
    Anti-cancer drugs, 2000, Volume: 11, Issue:8

    Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothec

2000
[Evaluation of hepatic resection following hepatic arterial infusion chemotherapy for colorectal liver metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Moda

2000
[Indication for hepatic resection after hepatic arterial infusion chemotherapy for multiple liver metastases of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:12

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorourac

2000
[Arterial infusion chemotherapy for liver metastases from colorectal cancer--therapeutic effects of different protocols].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:12

    Topics: Antineoplastic Agents; Cisplatin; Colorectal Neoplasms; Doxorubicin; Drug Administration Schedule; E

2000
Prevention of hepatic artery occlusion during continuous infusion of fluorouracil using liposteroid.
    AJR. American journal of roentgenology, 2000, Volume: 175, Issue:6

    Topics: Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Colorectal Neoplasms; Dexamethasone; F

2000
Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:18

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; C

2000
Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2000
Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:11

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore

2000
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C

2000
Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2000, Volume: 83, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2000
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
    The oncologist, 2001, Volume: 6, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother

2001
Phase II study of combined 5-fluorouracil/ Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancer.
    Phytotherapy research : PTR, 2001, Volume: 15, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

2001
Double-blind pilot-study on the efficacy of enzyme therapy in advanced colorectal cancer.
    Przeglad lekarski, 2000, Volume: 57 Suppl 5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chymotrypsin; Colorectal Neo

2000
Hepatic arterial 5-fluorouracil in patients with liver metastases of colorectal cancer: single-centre experience in 145 patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluor

2000
Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer.
    American journal of clinical oncology, 2001, Volume: 24, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2001
Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer.
    American journal of clinical oncology, 2001, Volume: 24, Issue:1

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dox

2001
5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer.
    British journal of cancer, 2001, Mar-02, Volume: 84, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Endpoint Determination; Female;

2001
Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I study.
    Cancer, 2001, Feb-15, Volume: 91, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Colorectal

2001
Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
    Oncology, 2001, Volume: 60, Issue:2

    Topics: Actuarial Analysis; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antin

2001
Comparison of 5-fluorouracil alone, 5-fluorouracil with levamisole, and 5-fluorouracil with hepatic irradiation in the treatment of patients with residual, nonmeasurable, intra-abdominal metastasis after undergoing resection for colorectal carcinoma.
    Cancer, 2001, Mar-01, Volume: 91, Issue:5

    Topics: Abdominal Neoplasms; Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined

2001
Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.
    Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2001
A United Kingdom coordinating committee on cancer research study of adjuvant chemotherapy for colorectal cancer: preliminary results.
    Seminars in oncology, 2001, Volume: 28, Issue:1 Suppl 1

    Topics: Adjuvants, Immunologic; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Ne

2001
Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
    Cancer, 2001, Apr-01, Volume: 91, Issue:7

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti

2001
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2001
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2001
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2001
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2001
Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial.
    BMJ (Clinical research ed.), 2001, Apr-07, Volume: 322, Issue:7290

    Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluor

2001
Effect of food on the oral bioavailability of UFT and leucovorin in cancer patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Apr-15, Volume: 19, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap

2001
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
    British journal of cancer, 2001, Apr-20, Volume: 84, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Conjunctivitis; D

2001
Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, May-01, Volume: 19, Issue:9

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Ar

2001
Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cance
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, May-01, Volume: 19, Issue:9

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Aspartic Acid; Colorectal Neoplasms; Female; Fluo

2001
Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2001
Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:8

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemothera

2001
High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:8

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug

2001
Double-blind randomised placebo-controlled phase III study of an E. coli extract plus 5-fluorouracil versus 5-fluorouracil in patients with advanced colorectal cancer.
    Arzneimittel-Forschung, 2001, Volume: 51, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blood Cell Count; Color

2001
Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi

2001
Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colorectal Neoplasms;

2001
Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Dose-Response

2001
Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2001
Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy.
    Cancer, 2001, Jul-01, Volume: 92, Issue:1

    Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Ne

2001
Optimal duration of oral adjuvant chemotherapy with Carmofur in the colorectal cancer patients: the Kansai Carmofur Study Group trial III.
    International journal of oncology, 2001, Volume: 19, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplas

2001
5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancer.
    Oncology, 2001, Volume: 61, Issue:1

    Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorect

2001
Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study.
    Oncology, 2001, Volume: 61, Issue:1

    Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

2001
Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Aug-01, Volume: 19, Issue:15

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2001
Liver metastases from colorectal cancer: regional intra-arterial treatment following failure of systemic chemotherapy.
    British journal of cancer, 2001, Aug-17, Volume: 85, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug R

2001
Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients.
    British journal of cancer, 2001, Aug-17, Volume: 85, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi

2001
Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:9

    Topics: Antimetabolites, Antineoplastic; Colon; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Do

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Phase II study of a weekly 24-hour infusion with 5-fluorouracil and simultaneous sodium-folinic acid in the first-line treatment of metastatic colorectal cancer.
    Onkologie, 2001, Volume: 24, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

2001
Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp

2001
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:9

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chromatography, High Pressure

2001
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
    British journal of cancer, 2001, Nov-02, Volume: 85, Issue:9

    Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols

2001
Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival.
    Cancer, 2001, Dec-01, Volume: 92, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2001
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-15, Volume: 20, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplasti

2002
Epirubicin, cisplatin and continuous-infusion 5-fluorouracil (ECF regimen) in the treatment of advanced colorectal cancer.
    Chemotherapy, 2001, Volume: 47, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Diseas

2001
Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:1

    Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Deoxyuridine; Enzyme Inhib

2002
P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
    International journal of cancer, 2002, Feb-01, Volume: 97, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Cell D

2002
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2002
Protracted hepatic arterial infusion with low-dose cisplatin plus 5-fluorouracil for unresectable liver metastases from colorectal cancer.
    Surgery, 2002, Volume: 131, Issue:1 Suppl

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Colorectal Neoplasms; Femal

2002
A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
    American journal of clinical oncology, 2002, Volume: 25, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2002
Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study.
    American journal of clinical oncology, 2002, Volume: 25, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2002
Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluo

2001
Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorecta

2001
Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience.
    Cancer investigation, 2002, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil

2002
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
    BMC cancer, 2002, Volume: 2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2002
A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorect

2002
Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2002
Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Female; F

2002
Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-01, Volume: 20, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chrono

2002
Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells.
    British journal of cancer, 2002, Jan-21, Volume: 86, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antig

2002
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:2

    Topics: Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour

2002
Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial.
    Gene therapy, 2001, Volume: 8, Issue:21

    Topics: Adenoviridae; Adenovirus E1B Proteins; Aged; Antibodies, Viral; Antineoplastic Combined Chemotherapy

2001
Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-15, Volume: 20, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

2002
Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-15, Volume: 20, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla

2002
Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Apr-01, Volume: 20, Issue:7

    Topics: Adjuvants, Immunologic; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic

2002
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Apr-01, Volume: 20, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2002
Effect of a 3-hour interval between methotrexate and 5-fluorouracil in the treatment of metastatic colorectal cancer.
    Japanese journal of clinical oncology, 2002, Volume: 32, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

2002
Chronotherapy of colorectal cancer.
    Chronobiology international, 2002, Volume: 19, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbop

2002
Pharmaco-economic comparative evaluation of combination chronotherapy vs. standard chemotherapy for colorectal cancer.
    Chronobiology international, 2002, Volume: 19, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal Neoplasms; Costs and Cost

2002
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study.
    BMC cancer, 2002, May-02, Volume: 2

    Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols;

2002
Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, May-15, Volume: 20, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2002
Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-01, Volume: 20, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia

2002
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine;

2002
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine;

2002
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine;

2002
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine;

2002
Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA Mutationa

2002
A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer.
    Oncology, 2002, Volume: 62, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2002
Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients.
    British journal of cancer, 2002, Jun-17, Volume: 86, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2002
Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer.
    British journal of cancer, 2002, Jun-05, Volume: 86, Issue:11

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col

2002
Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials.
    Acta oncologica (Stockholm, Sweden), 2002, Volume: 41, Issue:2

    Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit

2002
General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. A longitudinal study.
    Acta oncologica (Stockholm, Sweden), 1992, Volume: 31, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Colorectal Neo

1992
Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma.
    Lancet (London, England), 1992, Aug-29, Volume: 340, Issue:8818

    Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Follow-Up Studies; Hepar

1992
Intraperitoneal 5-fluorouracil in the management of colorectal liver cancer.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1992, Volume: 18, Issue:2

    Topics: Adult; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusion Pumps, Implantable; Liver Neopla

1992
Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:11

    Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotr

1992
Phase II trial of 5-fluorouracil and recombinant interferon alfa-2B in metastatic colorectal carcinoma.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Ev

1992
Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:11

    Topics: Adult; Aged; Colorectal Neoplasms; Conjunctivitis; Diarrhea; Drug Administration Schedule; Female; F

1992
Cisplatinum in combination with 5-fluorouracil and citrovorum factor in the treatment of advanced colorectal carcinoma.
    Cancer investigation, 1992, Volume: 10, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug A

1992
Phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte-macrophage colony-stimulating factor.
    American journal of clinical oncology, 1992, Volume: 15, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan

1992
Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer.
    American journal of clinical oncology, 1992, Volume: 15, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intra

1992
A phase 2 trial of recombinant interleukin-2 and 5-fluorouracil in patients with metastatic colorectal carcinoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1992, Volume: 18, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

1992
Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Interactions; Fema

1992
Sequential methotrexate and 5-fluorouracil (FU) vs. FU alone in metastatic colorectal cancer. Results of a randomized multicenter trial. The Association of Medical Oncology (AIO) of the German Cancer Society.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

1992
Phase II study of 5-fluorouracil plus leucovorin and interferon alpha 2b in advanced colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:4-5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Dr

1992
A phase I-II study of 14-days continuous infusion of 5-fluorouracil with weekly bolus leucovorin in metastatic colorectal carcinoma.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:4-5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

1992
Continuous regional treatment with fluoropyrimidines for metastases from colorectal carcinomas: influence of modulation with leucovorin.
    Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 3

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Floxuridine; Fluorouracil; Hepatic Arter

1992
Is hepatic infusion of chemotherapy effective treatment for liver metastases? No!
    Important advances in oncology, 1992

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluorouracil; Forecasting; Humans; Infusio

1992
Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study.
    Cancer chemotherapy and pharmacology, 1992, Volume: 29, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Drug Evaluation; Drug Therapy, Combination; Fluor

1992
Phase II trial of 7-day continuous 5-fluorouracil infusion in the treatment of advanced colorectal carcinoma.
    Oncology, 1992, Volume: 49, Issue:1

    Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule;

1992
A prospective randomized trial of continuous infusion 5-fluorouracil (5-FU) versus 5-FU plus cisplatin in patients with advanced colorectal cancer. A trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.).
    American journal of clinical oncology, 1992, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N

1992
A phase II trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
    Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Ne

1992
Bayesian subset analysis in a colorectal cancer clinical trial.
    Statistics in medicine, 1992, Jan-15, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Colorectal Neoplasms; Dose-Response R

1992
Application of Bayesian statistics to decision making during a clinical trial.
    Statistics in medicine, 1992, Jan-15, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Cisplatin; Colorectal Neoplasms; Comb

1992
Description of the statistical aspects of a study for advanced colorectal cancer patients.
    Statistics in medicine, 1992, Jan-15, Volume: 11, Issue:1

    Topics: Bayes Theorem; Cisplatin; Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationshi

1992
A 3-day schedule of 5-fluorouracil and folinic acid in metastatic progressive colorectal cancer and its impact in terms of palliation.
    Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 3

    Topics: Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leuco

1992
Fluorouracil versus folinic acid/fluorouracil in advanced colorectal cancer--preliminary results of a randomized trial.
    Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 3

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Liver

1992
Alfa-2A interferon and 5-fluorouracil for advanced colorectal carcinoma: the Memorial Sloan-Kettering experience.
    Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation;

1992
Modulation of fluorouracil with recombinant alfa interferon: M. D. Anderson Clinical trial.
    Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Fluorouracil;

1992
A phase I trial of fluorouracil, leucovorin, and recombinant interferon alpha-2b in patients with advanced malignancy.
    Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1992
A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
    Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 3

    Topics: Adult; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluatio

1992
Fluorouracil continuous infusion plus alfa interferon plus oral folinic acid in advanced colorectal cancer.
    Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 3

    Topics: Administration, Oral; Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule; Drug Evaluati

1992
Interleukin-2 followed by fluorouracil and folinic acid in refractory colorectal cancer--results of a clinical phase II study.
    Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation;

1992
The value of adjuvant therapy after radical surgery for colorectal cancer.
    Annals of medicine, 1992, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore

1992
Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1992
A phase II trial of continuous infusion cisplatin and 5-fluorouracil with oral calcium leucovorin in colorectal carcinoma.
    American journal of clinical oncology, 1992, Volume: 15, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colore

1992
[Final evaluation of the randomized multicenter study SAKK 40/81: adjuvant portal chemotherapy of curatively resected colorectal cancer].
    Helvetica chirurgica acta, 1992, Volume: 58, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu

1992
Randomized clinical trial with a weekly regimen of 5-FU vs 5-FU + intermediate-dose folinic acid in the treatment of advanced colo-rectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3, Issue:1

    Topics: Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combi

1992
Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicity.
    Cancer immunology, immunotherapy : CII, 1992, Volume: 35, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cytotoxicity, Immunologic; Dru

1992
A phase I study of regional 5-fluorouracil and systemic folinic acid for patients with colorectal liver metastases.
    British journal of cancer, 1992, Volume: 65, Issue:6

    Topics: Aged; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Evaluation; Female; Fluorouracil;

1992
Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research (GOIRC).
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3, Issue:5

    Topics: Adult; Aged; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; D

1992
[Fluorouracil as monotherapy or combined with folinic acid in the treatment of metastasizing colorectal carcinoma].
    Deutsche medizinische Wochenschrift (1946), 1992, Jun-26, Volume: 117, Issue:26

    Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Therapy, Combination; Female; Fluorouraci

1992
[Chemotherapy for advanced and recurrent cancer patients--the effect of combination chemotherapy using cisplatin, peplomycin, mitomycin C, adriamycin, and 5-fluorouracil].
    Nihon Gan Chiryo Gakkai shi, 1990, Aug-20, Volume: 25, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Colorectal Neopla

1990
A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma.
    Cancer, 1992, Feb-15, Volume: 69, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1992
A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer.
    Cancer, 1992, Feb-15, Volume: 69, Issue:4

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Colo

1992
Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa).
    Diseases of the colon and rectum, 1992, Volume: 35, Issue:2

    Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemothera

1992
Fluorouracil combined with the pure (6S)-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I-II study.
    Journal of the National Cancer Institute, 1992, Mar-04, Volume: 84, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1992
Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma.
    Journal of surgical oncology, 1992, Volume: 49, Issue:2

    Topics: Adult; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Bio

1992
Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer).
    Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C

1991
5-Fluorouracil by protracted venous infusion: a review of recent clinical studies.
    Cancer investigation, 1991, Volume: 9, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Drug Evaluat

1991
5-Fluorouracil (FU) with folinic acid (FA) and mitomycin C (MMC) in the adjuvant treatment of colorectal carcinoma. Part I. Evaluation of toxicity.
    Medical oncology and tumor pharmacotherapy, 1991, Volume: 8, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug E

1991
Treatment of advanced colorectal cancer by 5-fluorouracil-leucovorin combination with or without allopurinol: a prospective randomized study.
    Anti-cancer drugs, 1991, Volume: 2, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Colorec

1991
A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin. A Southwest Oncology Group study.
    Investigational new drugs, 1991, Volume: 9, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N

1991
A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA)
    Annals of internal medicine, 1991, Dec-15, Volume: 115, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Aspartic Acid; Colorectal Neoplasms;

1991
Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer.
    Journal of the National Cancer Institute, 1991, Mar-20, Volume: 83, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Female; Floxu

1991
Two consecutive clinical trials on cisplatin (CDDP), hepatic arterial infusion (HAI), and i.v. 5-fluorouracil (5-FU) chemotherapy for unresectable colorectal liver metastases: an alternative to FUdR-based regimens?
    Journal of surgical oncology. Supplement, 1991, Volume: 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Floxuridine;

1991
[5-Fluorouracil (5-FU)/leucovorin in comparison to other current chemotherapy protocols in metastasizing colorectal carcinoma].
    Wiener klinische Wochenschrift, 1991, Volume: 103, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorou

1991
Thymopentin and interleukin-2 in combination with 5-fluorouracil and leucovorin in metastatic colorectal adenocarcinoma: preliminary results.
    Journal of surgical oncology. Supplement, 1991, Volume: 2

    Topics: Adenocarcinoma; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Femal

1991
Preliminary report of high dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research.
    Journal of surgical oncology. Supplement, 1991, Volume: 2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr

1991
Phase II study of intra-arterial fluorouracil and mitomycin-C for liver metastases of colorectal cancer.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1991, Volume: 121

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl

1991
Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1991
A phase I study of cisplatinum plus 5-fluorouracil in modulation with citrovorum factor in metastatic colorectal carcinoma.
    Journal of chemotherapy (Florence, Italy), 1991, Volume: 3, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colorectal Neopla

1991
A phase II pilot study of the combined application of hyperthermia and intra-hepato-arterial chemotherapy using cisplatinum and 5-fluorouracil.
    Journal of surgical oncology, 1991, Volume: 48, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Modality T

1991
[Chemotherapy of colorectal cancer. Screening systems--value of special cytostatic drug combinations].
    Fortschritte der Medizin, 1991, Aug-30, Volume: 109, Issue:25

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Evaluation; Fl

1991
Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu

1991
Sequential combination of methotrexate (MTX), 5-fluorouracil (FU), and high-dose folinic acid (FA) in advanced colorectal cancer: double biochemical modulation?
    American journal of clinical oncology, 1991, Volume: 14, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1991
A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program study.
    Cancer, 1991, Jan-01, Volume: 67, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Synergis

1991
Treatment of patients with advanced colorectal cancer with cisplatin, 5-fluorouracil, and leucovorin.
    Cancer, 1991, Mar-01, Volume: 67, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N

1991
The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche

1991
Protracted infusion of 5-FU with weekly low-dose cisplatin as second-line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy.
    Cancer investigation, 1991, Volume: 9, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug A

1991
Role of adjuvant therapy in colorectal cancer.
    Advances in internal medicine, 1991, Volume: 36

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Colorectal Neopl

1991
Phase I evaluation of spirogermanium and 5-fluorouracil in colorectal carcinoma.
    Investigational new drugs, 1991, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorec

1991
Advanced colorectal carcinoma. A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone.
    American journal of clinical oncology, 1991, Volume: 14, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

1991
A randomized study of on-line plasma perfusion over protein A-sepharose and 5-fluorouracil chemotherapy in patients with metastatic colorectal carcinoma.
    The International journal of artificial organs, 1991, Volume: 14, Issue:2

    Topics: Chromatography, Gel; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans;

1991
Hepatic artery ligation with and without portal infusion of 5-FU. A randomized study in patients with unresectable liver metastases from colorectal carcinoma. The E.O.R.T.C. Gastrointestinal Cancer Cooperative Group (G.I. Group).
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1991, Volume: 17, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil;

1991
A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:4

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms;

1991
Tumor necrosis factor in advanced colorectal cancer: a phase II study. A trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer Society.
    Onkologie, 1990, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Adult; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule

1990
[Following curative resection of colorectal cancer, portal chemotherapy especially benefits non-transfused patients].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 1990, Volume: 61, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Colorectal Neoplasms; Combined Mo

1990
'AXIS': a new type of cancer trial.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1990, Volume: 2, Issue:3

    Topics: Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusions, Intravenous; Pelvi

1990
Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial.
    Archives of surgery (Chicago, Ill. : 1960), 1990, Volume: 125, Issue:8

    Topics: Adenocarcinoma; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Infusion Pump

1990
Cancer chronotherapy: a drug delivery challenge.
    Progress in clinical and biological research, 1990, Volume: 341A

    Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Circadian Rhythm; Colorectal Neoplasms; Drug

1990
A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

1990
Folinic acid plus high-dose 5-fluorouracil with allopurinol protection in the treatment of advanced colorectal carcinoma.
    European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:10

    Topics: Aged; Allopurinol; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination

1990
A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis.
    Cancer, 1990, Apr-15, Volume: 65, Issue:8

    Topics: Allopurinol; Colorectal Neoplasms; Consumer Behavior; Double-Blind Method; Fluorouracil; Humans; Leu

1990
Multimodal biochemical modulation of 5-fluorouracil activity in advanced colorectal cancer with allopurinol, folinic acid and dipyridamol.
    Journal of chemotherapy (Florence, Italy), 1990, Volume: 2, Issue:2

    Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Ne

1990
Fluorouracil and leucovorin for metastatic colorectal cancer.
    Journal of chemotherapy (Florence, Italy), 1990, Volume: 2 Suppl 1

    Topics: Colorectal Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leucovorin; Male; Ran

1990
A phase I-II study on the toxicity and therapeutic efficacy of 5-fluorouracil in combination with leucovorin and cisplatinum in patients with advanced colorectal carcinoma.
    Journal of chemotherapy (Florence, Italy), 1990, Volume: 2 Suppl 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co

1990
Biochemical rationale for the 5-fluorouracil leucovorin combination and update of clinical experience.
    Journal of chemotherapy (Florence, Italy), 1990, Volume: 2 Suppl 1

    Topics: Animals; Clinical Trials as Topic; Colorectal Neoplasms; Drug Synergism; Drug Therapy, Combination;

1990
Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases.
    The British journal of surgery, 1990, Volume: 77, Issue:7

    Topics: Adolescent; Adult; Aged; Colorectal Neoplasms; Embolization, Therapeutic; Female; Fluorouracil; Hepa

1990
A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer.
    Cancer, 1990, Sep-01, Volume: 66, Issue:5

    Topics: Adult; Aged; Aspartic Acid; Clinical Trials as Topic; Colorectal Neoplasms; Drug Evaluation; Drug Sy

1990
Alpha-2 interferon and 5-fluorouracil in advanced colorectal cancer.
    Tumori, 1990, Aug-31, Volume: 76, Issue:4

    Topics: Adult; Aged; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule

1990
A randomized study of combined 5-fluorouracil and plasma perfusion over protein A-sepharose in human advanced colorectal carcinoma.
    Biotherapy (Dordrecht, Netherlands), 1990, Volume: 2, Issue:1

    Topics: Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Liver Ne

1990
A randomized controlled trial of oral 5-FU versus placebo in colorectal cancer: results of 10 years observation time.
    The British journal of surgery, 1990, Volume: 77, Issue:9

    Topics: Colorectal Neoplasms; Fluorouracil; Humans; Time Factors

1990
Sequential methotrexate, 5-fluorouracil, and leucovorin in metastatic measurable colorectal cancer. Does it work?
    Cancer investigation, 1990, Volume: 8, Issue:3-4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Dr

1990
Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:12

    Topics: Colorectal Neoplasms; Female; Fluorouracil; Humans; Interferon alpha-2; Interferon-alpha; Male; Midd

1990
Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity.
    Cancer, 1990, Dec-15, Volume: 66, Issue:12

    Topics: Adult; Aged; Colorectal Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Infusion

1990
Phase I trial of 5-fluorouracil, leucovorin, and cisplatin in combination.
    Cancer chemotherapy and pharmacology, 1990, Volume: 27, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Moda

1990
Regional chemotherapy for colorectal liver metastases: a phase II evaluation of targeted hepatic arterial 5-fluorouracil for colorectal liver metastases.
    The British journal of surgery, 1990, Volume: 77, Issue:11

    Topics: Adult; Aged; Albumins; Angiotensin II; Colorectal Neoplasms; Drug Evaluation; Fluorouracil; Hepatic

1990
[High-dose leucovorin and 5-fluorouracil in advanced gastric and colorectal cancer. High-Dose Leucovorin and 5-FU Study Group].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

1990
Randomized phase II study of a combination of cisplatin (DDP), 5-fluorouracil (5-FU), and allopurinol (HPP) versus 5-FU in advanced colorectal carcinoma. An EORTC Gastrointestinal Tract Cancer Cooperative Group study.
    Cancer investigation, 1990, Volume: 8, Issue:5

    Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neop

1990
Adjuvant chemotherapy with 5-fluorouracil, vincristine and CCNU for patients with Dukes' C colorectal cancer. The Swedish Gastrointestinal Tumour Adjuvant Therapy Group.
    The British journal of surgery, 1990, Volume: 77, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fem

1990
Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group.
    Archives of surgery (Chicago, Ill. : 1960), 1990, Volume: 125, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Combined Modality Therapy; Fem

1990
Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I).
    Cancer, 1990, Feb-01, Volume: 65, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Central Venou

1990
Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma.
    Seminars in oncology, 1990, Volume: 17, Issue:1 Suppl 1

    Topics: Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Drug Synergism; Drug Therapy, Combination

1990
A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study.
    Cancer, 1989, Mar-15, Volume: 63, Issue:6 Suppl

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms

1989
A controlled clinical trial including folinic acid at two distinct dose levels in combination with 5-fluorouracil (5FU) for the treatment of advanced colorectal cancer: experience of the Mayo Clinic and North Central Cancer Treatment Group.
    Advances in experimental medicine and biology, 1988, Volume: 244

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Dose

1988
Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison of two regimens.
    European journal of cancer & clinical oncology, 1989, Volume: 25, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1989
[Intra-portal chemoprevention and therapy of liver metastases].
    Zeitschrift fur Gastroenterologie. Verhandlungsband, 1989, Volume: 24

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Comb

1989
[Is there a primary indication for regional therapy of liver metastases of gastrointestinal tumors?].
    Zeitschrift fur Gastroenterologie. Verhandlungsband, 1989, Volume: 24

    Topics: Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hu

1989
[Can the occurrence of extrahepatic metastases in regional chemotherapy of the liver be prevented by adding systemic chemotherapy? A randomized multicenter study].
    Zeitschrift fur Gastroenterologie. Verhandlungsband, 1989, Volume: 24

    Topics: Adenocarcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusion Pumps

1989
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dru

1989
[Chemotherapy of colorectal cancer].
    Zeitschrift fur Gastroenterologie, 1989, Volume: 27, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo

1989
[Mitomycin C plus HCFU adjuvant chemotherapy for noncuratively resected cases of colorectal carcinoma. (Second report): 5-year survival rate. Cooperative Study Group of Kyushu and Chugoku for HCFU Adjuvant Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:3 Pt 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu

1989
[Randomized controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:6

    Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials

1989
[Effects of prophylactic intraportal chemotherapy on liver function, blood profile and survival in patients with colo-rectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap

1989
[Initial results of adjuvant portal liver infusion following radical surgery of colorectal cancer (Swiss Study Group for Epidemiologic and Clinical Cancer Research Study 40/81)].
    Helvetica chirurgica acta, 1989, Volume: 56, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fem

1989
Value of in vivo tissue testing in predicting the clinical response to regional perfusion chemotherapy in colorectal cancer patients with liver metastases.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1989, Volume: 165, Issue:7

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colorect

1989
[Regional chemotherapy of liver metastases in colorectal carcinoma. Intra-arterial vs intravenous plus intra-arterial therapy].
    Deutsche medizinische Wochenschrift (1946), 1989, Sep-29, Volume: 114, Issue:39

    Topics: Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Evaluation Studies as Topic; Female; F

1989
Prevention of extrahepatic disease during intraarterial floxuridine of colorectal liver metastases by simultaneous systemic 5-fluorouracil treatment? A prospective multicenter study.
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Inju

1989
[European topic: liver surgery II--regional chemotherapy].
    Langenbecks Archiv fur Chirurgie. Supplement II, Verhandlungen der Deutschen Gesellschaft fur Chirurgie. Deutsche Gesellschaft fur Chirurgie. Kongress, 1989

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flo

1989
Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer.
    Cancer, 1989, Mar-15, Volume: 63, Issue:6 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo

1989
Continuous systemic 5-fluorouracil infusion in advanced colorectal cancer: results in 91 patients.
    Journal of surgical oncology, 1989, Volume: 40, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Colorectal Neoplasms; Female; Fluorouracil

1989
Adjuvant chemoimmuno- and immunotherapy in Dukes' stage B2 and C colorectal carcinoma: a 7-year follow-up analysis.
    Journal of surgical oncology, 1989, Volume: 40, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Clinical T

1989
Cancer control research in the North Central Cancer Treatment Group (NCCTG).
    Progress in clinical and biological research, 1989, Volume: 293

    Topics: Allopurinol; Anorexia; Antineoplastic Agents; Cachexia; Clinical Trials as Topic; Colorectal Neoplas

1989
High-dose methotrexate and 5-fluorouracil in patients with advanced colorectal carcinoma. A randomized study of two pretreatment intervals.
    American journal of clinical oncology, 1989, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blood; Clinical Trials as Topic; Col

1989
Improvements in fluorouracil chemotherapy?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug

1989
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:10

    Topics: Aged; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administration Schedule; Drug Interaction

1989
Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced symptomatic colorectal carcinoma: a randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Ne

1989
5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment?
    British journal of cancer, 1989, Volume: 60, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo

1989
Correlation of dose intensity and prognosis in adjuvant chemotherapy: an extended controversy.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1989, Volume: 115

    Topics: Adjuvants, Pharmaceutic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorecta

1989
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Humans; Levamisole; Lymp

1989
Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1989
Combined hepatic artery 5-fluorouracil and irradiation of liver metastases. A randomized study.
    Cancer, 1989, Nov-01, Volume: 64, Issue:9

    Topics: Adenocarcinoma; Blood Chemical Analysis; Colorectal Neoplasms; Combined Modality Therapy; Female; Fl

1989
Cytostatic drug therapy in disseminated colorectal cancer.
    Scandinavian journal of gastroenterology. Supplement, 1988, Volume: 149

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Col

1988
The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer.
    European journal of clinical pharmacology, 1988, Volume: 34, Issue:5

    Topics: Adult; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Half-Life; Humans; Infusions,

1988
[Chemotherapy of inoperable colorectal cancer].
    Wiener medizinische Wochenschrift (1946), 1988, Jul-15, Volume: 138, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo

1988
Postoperative adjuvant therapy.
    Scandinavian journal of gastroenterology. Supplement, 1988, Volume: 149

    Topics: Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans

1988
Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: a randomized study.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co

1988
Folinic acid (FA) plus 5-fluorouracil (FU) in progressive advanced colorectal cancer.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1988, Volume: 42, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo

1988
The Roswell Park Memorial Institute and Gastrointestinal Tumor Study Group phase III experience with the modulation of 5-fluorouracil by leucovorin in metastatic colorectal adenocarcinoma.
    Advances in experimental medicine and biology, 1988, Volume: 244

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal

1988
5-Fluorouracil (FUra) and folinic acid (FA) therapy in patients with colorectal cancer.
    Advances in experimental medicine and biology, 1988, Volume: 244

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug

1988
Clinical experience with CF-FUra.
    Advances in experimental medicine and biology, 1988, Volume: 244

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi

1988
A randomized trial of 5-fluorouracil alone versus 5-fluorouracil and high dose leucovorin in untreated advanced colorectal cancer patients.
    Advances in experimental medicine and biology, 1988, Volume: 244

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Ne

1988
5-Fluorouracil and 5-formyltetrahydrofolate in advanced malignancies.
    Advances in experimental medicine and biology, 1988, Volume: 244

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colorect

1988
Clinical experience with 5-FU/DDP +/- OHDW combination chemotherapy in patients with advanced colorectal carcinoma.
    Advances in experimental medicine and biology, 1988, Volume: 244

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Colorectal Neop

1988
5-Fluorouracil and folinic acid: summary of clinical experience.
    Advances in experimental medicine and biology, 1988, Volume: 244

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colorect

1988

Other Studies

3584 other studies available for fluorouracil and Colorectal Cancer

ArticleYear
Characterized mechanism of alpha-mangostin-induced cell death: caspase-independent apoptosis with release of endonuclease-G from mitochondria and increased miR-143 expression in human colorectal cancer DLD-1 cells.
    Bioorganic & medicinal chemistry, 2007, Aug-15, Volume: 15, Issue:16

    Topics: Apoptosis; Caspases; Cell Line, Tumor; Colorectal Neoplasms; Endodeoxyribonucleases; Fluorouracil; H

2007
In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives.
    Bioorganic & medicinal chemistry letters, 2009, Aug-15, Volume: 19, Issue:16

    Topics: Acetamides; Animals; Antigens, Neoplasm; Antineoplastic Agents; Carbonic Anhydrase Inhibitors; Carbo

2009
Novel cinnamaldehyde-based aspirin derivatives for the treatment of colorectal cancer.
    Bioorganic & medicinal chemistry letters, 2018, 09-15, Volume: 28, Issue:17

    Topics: Acrolein; Animals; Antineoplastic Agents; Apoptosis; Aspirin; Cell Cycle Checkpoints; Cell Line, Tum

2018
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
    European journal of medicinal chemistry, 2019, Jan-01, Volume: 161

    Topics: Adamantane; Antineoplastic Agents; Aza Compounds; Cell Proliferation; Cell Survival; Colorectal Neop

2019
Synthesis and evaluation of chalcone analogues containing a 4-oxoquinazolin-2-yl group as potential anti-tumor agents.
    European journal of medicinal chemistry, 2019, Jan-15, Volume: 162

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chalcones;

2019
Synthesis and in-vitro anti-cancer evaluations of multi-methoxylated asymmetrical diarylpentanoids as intrinsic apoptosis inducer against colorectal cancer.
    Bioorganic & medicinal chemistry letters, 2020, 04-15, Volume: 30, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Dose-R

2020
Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
    European journal of medicinal chemistry, 2020, May-01, Volume: 193

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Colorectal Neoplasms; Docetaxel

2020
Discovery of 4-(3,5-dimethoxy-4-(((4-methoxyphenethyl)amino)methyl)phenoxy)-N-phenylaniline as a novel c-myc inhibitor against colorectal cancer in vitro and in vivo.
    European journal of medicinal chemistry, 2020, Jul-15, Volume: 198

    Topics: Amino Acid Sequence; Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor;

2020
Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells.
    European journal of medicinal chemistry, 2020, Oct-01, Volume: 203

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, T

2020
Discovery of a potent β-catenin destabilizer for overcoming the resistance of 5-fluorouracil in colorectal cancer.
    Bioorganic & medicinal chemistry, 2021, 01-15, Volume: 30

    Topics: Alkaloids; Antineoplastic Agents; beta Catenin; Cell Survival; Colorectal Neoplasms; Dose-Response R

2021
Targeting Colorectal Cancer with Conjugates of a Glucose Transporter Inhibitor and 5-Fluorouracil.
    Journal of medicinal chemistry, 2021, 04-22, Volume: 64, Issue:8

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Disease Model

2021
Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
    European journal of medicinal chemistry, 2021, Dec-05, Volume: 225

    Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Cells, Cultured; Colorectal Neoplasms; Dos

2021
LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 143

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms;

2021
Tumor Vascular Microenvironment of Colorectal Hepatic Metastasis and Chemotherapy Response.
    Anticancer research, 2021, Volume: 41, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Camp

2021
NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study.
    European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:16

    Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms

2021
Cabazitaxel suppresses colorectal cancer cell growth via enhancing the p53 antitumor pathway.
    FEBS open bio, 2021, Volume: 11, Issue:11

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Screening Assay

2021
S-Adenosylmethionine Increases the Sensitivity of Human Colorectal Cancer Cells to 5-Fluorouracil by Inhibiting P-Glycoprotein Expression and NF-κB Activation.
    International journal of molecular sciences, 2021, Aug-27, Volume: 22, Issue:17

    Topics: Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1;

2021
Trends in Use and Perceptions About Triplet Chemotherapy Plus Bevacizumab for Metastatic Colorectal Cancer.
    JAMA network open, 2021, 09-01, Volume: 4, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Cross-Secti

2021
Women are predisposed to early dose-limiting toxicities during adjuvant CAPOX for colorectal cancer.
    International journal of clinical practice, 2021, Volume: 75, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neo

2021
Expression of astrocyte-elevated gene-1 indicates prognostic value of fluoropyrimidine-based adjuvant chemotherapy in resectable stage III colorectal cancer.
    Pathology international, 2021, Volume: 71, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

2021
Casein Kinase-1-Alpha Inhibitor (D4476) Sensitizes Microsatellite Instable Colorectal Cancer Cells to 5-Fluorouracil via Authophagy Flux Inhibition.
    Archivum immunologiae et therapiae experimentalis, 2021, Sep-18, Volume: 69, Issue:1

    Topics: Apoptosis; Casein Kinase Ialpha; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm;

2021
LncRNA HCG11 promotes 5-FU resistance of colon cancer cells through reprogramming glucose metabolism by targeting the miR-144-3p-PDK4 axis.
    Cancer biomarkers : section A of Disease markers, 2022, Volume: 34, Issue:1

    Topics: Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Glucose; Humans; MicroRNAs;

2022
Cost-effectiveness of maintenance therapy after first-line treatment in metastatic colorectal cancer.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; Cost-B

2022
Apigenin enhances apoptosis induction by 5-fluorouracil through regulation of thymidylate synthase in colorectal cancer cells.
    Redox biology, 2021, Volume: 47

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apigenin; Apoptosis; Colorectal Neoplasms; Drug Resi

2021
Curcumin Reverses NNMT-Induced 5-Fluorouracil Resistance via Increasing ROS and Cell Cycle Arrest in Colorectal Cancer Cells.
    Biomolecules, 2021, 08-31, Volume: 11, Issue:9

    Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplas

2021
Epigenetic induction of lipocalin 2 expression drives acquired resistance to 5-fluorouracil in colorectal cancer through integrin β3/SRC pathway.
    Oncogene, 2021, Volume: 40, Issue:45

    Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; Epigene

2021
Syndecan-2, negatively regulated by miR-20b-5p, contributes to 5-fluorouracil resistance of colorectal cancer cells via the JNK/ERK signaling pathway.
    Acta biochimica et biophysica Sinica, 2021, Nov-10, Volume: 53, Issue:11

    Topics: Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; Base Pairin

2021
Antitumor Activity of Zinc Nanoparticles Synthesized with Berberine on Human Epithelial Colorectal Adenocarcinoma (Caco-2) Cells through Acting on Cox-2/NF-kB and p53 Pathways.
    Anti-cancer agents in medicinal chemistry, 2022, Volume: 22, Issue:10

    Topics: Adenocarcinoma; Animals; Apoptosis; bcl-2-Associated X Protein; Berberine; Caco-2 Cells; Caspase 3;

2022
RING-finger protein 6 promotes colorectal tumorigenesis by transcriptionally activating SF3B2.
    Oncogene, 2021, Volume: 40, Issue:47

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinogenesis; Case-Control

2021
Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer.
    Cancer research, 2021, 12-01, Volume: 81, Issue:23

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Colorect

2021
Antioxidant and antiproliferative potential of ethanolic extracts from Moringa oleifera, Tropaeolum tuberosum and Annona cherimola in colorrectal cancer cells.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 143

    Topics: Annona; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined

2021
Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.
    BMC cancer, 2021, Oct-16, Volume: 21, Issue:1

    Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Ph

2021
[A Case of Long-Term Survival after Administration of Regorafenib for Stage Ⅳ Colorectal Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouraci

2021
Bevacizumab and aflibercept in second-line metastatic colorectal cancer: 12 years of experience.
    European journal of clinical pharmacology, 2022, Volume: 78, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Flu

2022
Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer.
    BMC cancer, 2021, Oct-29, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angiogenesis Inhibitors; Antineoplastic Agents

2021
Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study.
    Journal of geriatric oncology, 2022, Volume: 13, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Colorectal Neopl

2022
Alterations in hepatic fatty acids reveal depletion of total polyunsaturated fatty acids following irinotecan plus 5-fluorouracil treatment in an animal model of colorectal cancer.
    Prostaglandins, leukotrienes, and essential fatty acids, 2021, Volume: 174

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2021
The Emerging Role of Metformin in the Prevention and Treatment of Colorectal Cancer: A Game Changer for the Management of Colorectal Cancer.
    Current diabetes reviews, 2022, Volume: 18, Issue:8

    Topics: Adenoma; Colorectal Neoplasms; Fluorouracil; Humans; Hypoglycemic Agents; Incidence; Metformin

2022
[A case of pembrolizumab responding to recurrent small bowel mucinous adenocarcinoma with Peutz-Jeghers syndrome].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2021, Volume: 118, Issue:11

    Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pr

2021
Twist and Vimentin protein expression in colorectal cancer tissues and their relationship with oxaliplatin-based postoperative adjuvant chemotherapy.
    Panminerva medica, 2022, Volume: 64, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro

2022
Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice.
    International journal of colorectal disease, 2022, Volume: 37, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu

2022
Sanguisorba officinalis L. suppresses 5-fluorouracil-sensitive and-resistant colorectal cancer growth and metastasis via inhibition of the Wnt/β-catenin pathway.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2022, Volume: 94

    Topics: Animals; beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Ep

2022
Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy.
    Cardiovascular toxicology, 2022, Volume: 22, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Colorectal Neoplasms; Decision

2022
Combined Primary Resection with Hepatic Artery Infusion Pump Implantation Is Safe for Unresectable Colorectal Liver Metastases.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2022, Volume: 26, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery;

2022
Plakophilin3 loss leads to increased adenoma formation and rectal prolapse in APC
    Biochemical and biophysical research communications, 2022, 01-01, Volume: 586

    Topics: Adenoma; Animals; Antimetabolites, Antineoplastic; Colon; Colorectal Neoplasms; Disease Progression;

2022
p130Cas Is Correlated with EREG Expression and a Prognostic Factor Depending on Colorectal Cancer Stage and Localization Reducing FOLFIRI Efficacy.
    International journal of molecular sciences, 2021, Nov-16, Volume: 22, Issue:22

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Atlases as Topic; Breast Neoplasms; Camptothe

2021
Redox-sensitive cyclophilin A elicits chemoresistance through realigning cellular oxidative status in colorectal cancer.
    Cell reports, 2021, 11-30, Volume: 37, Issue:9

    Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Cell

2021
Anemoside B4 sensitizes human colorectal cancer to fluorouracil-based chemotherapy through src-mediated cell apoptosis.
    Aging, 2021, 12-10, Volume: 13, Issue:23

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspase 9; Colorectal Neoplasms; Drug Resistanc

2021
Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer.
    Scientific reports, 2021, 12-10, Volume: 11, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Combined Chemotherapy Protocols; Biomar

2021
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2022, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2022
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2022, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2022
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2022, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2022
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2022, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2022
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2022, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2022
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2022, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2022
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2022, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2022
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2022, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2022
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2022, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2022
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2022, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2022
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2022, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2022
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2022, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2022
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2022, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2022
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2022, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2022
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2022, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2022
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2022, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2022
Incidence and risk factors associated with development of oxalipatin-induced acute peripheral neuropathy in colorectal cancer patients.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou

2023
Neoadjuvant intra-arterial versus intravenous chemotherapy in colorectal cancer.
    Medicine, 2021, Dec-23, Volume: 100, Issue:51

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2021
MLH1 mediates cytoprotective nucleophagy to resist 5-Fluorouracil-induced cell death in colorectal carcinoma.
    Neoplasia (New York, N.Y.), 2022, Volume: 24, Issue:2

    Topics: Autophagy; Cell Death; Cell Line, Tumor; Colorectal Neoplasms; Cytoprotection; DNA Damage; Fluoroura

2022
Lactobacillus plantarum-derived metabolites sensitize the tumor-suppressive effects of butyrate by regulating the functional expression of SMCT1 in 5-FU-resistant colorectal cancer cells.
    Journal of microbiology (Seoul, Korea), 2022, Volume: 60, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Butyrates; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluoro

2022
Assessment of Drug-drug Interaction and Optimization in Capecitabine and Irinotecan Combination Regimen using a Physiologically Based Pharmacokinetic Model.
    Journal of pharmaceutical sciences, 2022, Volume: 111, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboxylesteras

2022
Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 07-01, Volume: 28, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Cetuximab; Colonic Neoplasm

2022
The development of a novel oral 5-Fluorouracil in-situ gelling nanosuspension to potentiate the anticancer activity against colorectal cancer cells.
    International journal of pharmaceutics, 2022, Feb-05, Volume: 613

    Topics: Colorectal Neoplasms; Delayed-Action Preparations; Drug Liberation; Fluorouracil; Gels; Humans

2022
Induction of lncRNA NORAD accounts for hypoxia-induced chemoresistance and vasculogenic mimicry in colorectal cancer by sponging the miR-495-3p/ hypoxia-inducible factor-1α (HIF-1α).
    Bioengineered, 2022, Volume: 13, Issue:1

    Topics: Adult; Aged; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms

2022
Suppression of DYRK1A/B Drives Endoplasmic Reticulum Stress-mediated Autophagic Cell Death Through Metabolic Reprogramming in Colorectal Cancer Cells.
    Anticancer research, 2022, Volume: 42, Issue:1

    Topics: Animals; Apoptosis; Autophagic Cell Death; Autophagy; Cell Line, Tumor; Cell Proliferation; Cellular

2022
Circular RNA protein tyrosine kinase 2 (circPTK2) promotes colorectal cancer proliferation, migration, invasion and chemoresistance.
    Bioengineered, 2022, Volume: 13, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neop

2022
BIX-01294 enhances the effect of chemotherapy on colorectal cancer by inhibiting the expression of stemness genes.
    Biochemical and biophysical research communications, 2022, 01-29, Volume: 590

    Topics: Animals; Azepines; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorecta

2022
Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer.
    Investigational new drugs, 2022, Volume: 40, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2022
Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022, Volume: 24, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clone Cells; Colonic Neoplasms; Colorectal Neoplasms

2022
ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer.
    Journal of experimental & clinical cancer research : CR, 2022, Jan-08, Volume: 41, Issue:1

    Topics: Animals; beta Catenin; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Fluorouracil;

2022
Alteration of ribosome function upon 5-fluorouracil treatment favors cancer cell drug-tolerance.
    Nature communications, 2022, 01-10, Volume: 13, Issue:1

    Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; DNA Replicat

2022
TIMP-2 regulates 5-Fu resistance via the ERK/MAPK signaling pathway in colorectal cancer.
    Aging, 2022, 01-12, Volume: 14, Issue:1

    Topics: Aged; Animals; Butadienes; Cell Survival; Colorectal Neoplasms; Cytokines; Drug Resistance, Neoplasm

2022
Panitumumab Associated Acute Pancreatitis.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:5

    Topics: Acute Disease; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colonic

2022
[A Long-Survival Case of Lower Rectal Cancer with Unresectable Liver Metastases Treated with FOLFOXIRI plus Bevacizumab(BEV)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fem

2021
CDX2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancer.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 147

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CDX2 Transcription Factor; Cell Lin

2022
[Prognostic factors affecting the success of conversion chemotherapy in patients with unresectable liver metastases from initially colorectal cancer].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2022, Jan-25, Volume: 25, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Colorectal Neopl

2022
Angiotensin II Receptor Antagonist, Valsartan, Has Beneficial Effect in Lung Metastasis of Colorectal Cancer Treated with Fluorouracil.
    Journal of gastrointestinal cancer, 2023, Volume: 54, Issue:1

    Topics: Angiotensin Receptor Antagonists; Animals; Colorectal Neoplasms; Fluorouracil; Humans; Lung Neoplasm

2023
Effect of Thymidine Phosphorylase Gene Demethylation on Sensitivity to 5-Fluorouracil in Colorectal Cancer Cells.
    Anticancer research, 2022, Volume: 42, Issue:2

    Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Decitabine;

2022
Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis.
    Journal of geriatric oncology, 2022, Volume: 13, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore

2022
Metastatic colorectal cancer in both sides of Aegean sea: practice patterns and outcome.
    Current medical research and opinion, 2022, Volume: 38, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms; Fluoro

2022
Sex hormones and sperm parameters after adjuvant oxaliplatin-based treatment for colorectal cancer.
    Cancer treatment and research communications, 2022, Volume: 31

    Topics: Colorectal Neoplasms; Female; Fluorouracil; Follicle Stimulating Hormone; Gonadal Steroid Hormones;

2022
Reversing chemorefraction in colorectal cancer cells by controlling mucin secretion.
    eLife, 2022, 02-08, Volume: 11

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene

2022
Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer.
    Nature communications, 2022, 02-10, Volume: 13, Issue:1

    Topics: B7-H1 Antigen; Biomarkers, Tumor; CD8 Antigens; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro

2022
Liver Isolation Oxaliplatin (LIOX): Long Term Survival from a New Locoregional Technique for Chemorefractory Patients with Colorectal Liver Metastases.
    Annals of surgical oncology, 2022, Volume: 29, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

2022
Comparison of
    Oncology research, 2022, May-04, Volume: 29, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neopla

2022
[Effect of Astragali Radix-Curcumae Rhizoma compatibility combined with 5-fluorouracil on Th17/Treg balance and tumor-related mRNA and protein expression in orthotopic xenograft model mice of CT26.WT colorectal carcinoma].
    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2022, Volume: 47, Issue:1

    Topics: Animals; Colorectal Neoplasms; Drugs, Chinese Herbal; Fluorouracil; Heterografts; Humans; Male; Mice

2022
Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?
    European journal of clinical pharmacology, 2022, Volume: 78, Issue:6

    Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug-Related

2022
Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer.
    Journal of clinical pharmacy and therapeutics, 2022, Volume: 47, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoembryonic Antigen;

2022
The therapeutic potential of γ-Al
    Tissue & cell, 2022, Volume: 76

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Nanoparticles; Sulfhydryl Compounds; S

2022
Highly Advanced Colorectal Liver Metastases Successfully Treated With Fluorouracil Plus Leucovorin Monotherapy and Microwave Ablation.
    Anticancer research, 2022, Volume: 42, Issue:3

    Topics: Ablation Techniques; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, A

2022
Squalene epoxidase drives cancer cell proliferation and promotes gut dysbiosis to accelerate colorectal carcinogenesis.
    Gut, 2022, Volume: 71, Issue:11

    Topics: Animals; Azoxymethane; Bile Acids and Salts; Carcinogenesis; Cell Proliferation; Cholesterol; Colore

2022
Inhibition of angiotensin pathway via valsartan reduces tumor growth in models of colorectal cancer.
    Toxicology and applied pharmacology, 2022, 04-01, Volume: 440

    Topics: Angiotensins; Animals; Colorectal Neoplasms; Fluorouracil; Matrix Metalloproteinase 2; Mice; Valsart

2022
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2022, Volume: 34, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore

2022
Choline deficiency-related multi-omics characteristics are susceptible factors for chemotherapy-induced thrombocytopenia.
    Pharmacological research, 2022, Volume: 178

    Topics: Antineoplastic Agents; Choline; Choline Deficiency; Colorectal Neoplasms; Fluorouracil; Humans; Leuk

2022
[Prehepatectomy Chemotherapy Using Circadian Chrono-HAI for Liver Metastases from Colorectal Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2022, Volume: 49, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery;

2022
Up-regulated FNDC1 accelerates stemness and chemoradiation resistance in colorectal cancer cells.
    Biochemical and biophysical research communications, 2022, 04-30, Volume: 602

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Neoplasm Proteins; Neoplastic Stem Cel

2022
Circular RNA sterile alpha motif domain containing 4A contributes to cell 5-fluorouracil resistance in colorectal cancer by regulating the miR-545-3p/6-phosphofructo-2-kinase/fructose-2,6-bisphosphataseisotype 3 axis.
    Anti-cancer drugs, 2022, 07-01, Volume: 33, Issue:6

    Topics: Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Fructose; Humans; MicroRNAs; Phosphofructoki

2022
Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2022, Volume: 121, Issue:10

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms

2022
Circ_0014130 is involved in the drug sensitivity of colorectal cancer through miR-197-3p/PFKFB3 axis.
    Journal of gastroenterology and hepatology, 2022, Volume: 37, Issue:5

    Topics: Cell Proliferation; Colorectal Neoplasms; Drug Resistance; Fluorouracil; Humans; MicroRNAs; Phosphof

2022
Cases in the management of metastatic colorectal cancer: regorafenib as second-line therapy after FOLFOXIRI plus bevacizumab in a patient with a
    Clinical advances in hematology & oncology : H&O, 2021, Volume: 19 Suppl 20, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu

2021
Measures to mitigate treatment-related toxicities in third-line metastatic colorectal cancer.
    Clinical advances in hematology & oncology : H&O, 2021, Volume: 19 Suppl 24, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

2021
ATF4-mediated microRNA-145/HDAC4/p53 axis affects resistance of colorectal cancer cells to 5-fluorouracil by regulating autophagy.
    Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:5

    Topics: Activating Transcription Factor 4; Animals; Autophagy; Cell Line, Tumor; Colorectal Neoplasms; Drug

2022
Feasibility and Safety of Oxaliplatin-Based Pressurized Intraperitoneal Aerosol Chemotherapy With or Without Intraoperative Intravenous 5-Fluorouracil and Leucovorin for Colorectal Peritoneal Metastases: A Multicenter Comparative Cohort Study.
    Annals of surgical oncology, 2022, Volume: 29, Issue:8

    Topics: Aerosols; Cohort Studies; Colorectal Neoplasms; Feasibility Studies; Fluorouracil; Humans; Leucovori

2022
A retrospective analysis using deep-learning models for prediction of survival outcome and benefit of adjuvant chemotherapy in stage II/III colorectal cancer.
    Journal of cancer research and clinical oncology, 2022, Volume: 148, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Artificial Intelligence; Biomarkers, Tumor; Chemothe

2022
[Tumor-associated macrophages: New targets to thwart 5-FU chemoresistance in colorectal cancers?]
    Medecine sciences : M/S, 2022, Volume: 38, Issue:3

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fl

2022
Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2022, Volume: 21, Issue:3

    Topics: Capecitabine; Cardiotoxicity; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hand-Foot Syndr

2022
Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore

2023
The Effect of 5-Fluorouracil on the Adhesion Process in Patients Operated on for Colorectal Cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2022, Mar-01, Volume: 23, Issue:3

    Topics: Colorectal Neoplasms; Fluorouracil; Humans; Postoperative Complications; Quality of Life; Tissue Adh

2022
Nucleic Acid Metabolizing Enzyme Levels Predict Chemotherapy Effects in Advanced and Recurrent Colorectal Cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2022, Mar-01, Volume: 23, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (N

2022
Can Systemic Control Be Achieved in the Treatment of Oligometastatic Hepatocellular Cancer With Hepatic Artery Infusion Fluorouracil, Leucovorin, and Oxaliplatin Treatment?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 06-10, Volume: 40, Issue:17

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colorectal Neoplasms; Flu

2022
Acoustic Bioprinting of Patient-Derived Organoids for Predicting Cancer Therapy Responses.
    Advanced healthcare materials, 2022, Volume: 11, Issue:13

    Topics: Acoustics; Bioprinting; Colorectal Neoplasms; Fluorouracil; Humans; Organoids

2022
Synergistic antitumor activity of 5-fluorouracil and atosiban against microsatellite stable colorectal cancer through restoring GATA3.
    Biochemical pharmacology, 2022, Volume: 199

    Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; GATA3 Tr

2022
Cancer Trial Impact: Understanding Implementation of the Short Course Oncology Treatment (SCOT) Trial Findings in colorectal cancer at a National Level.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2022, Volume: 34, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neo

2022
Downregulation of KRAB zinc finger proteins in 5-fluorouracil resistant colorectal cancer cells.
    BMC cancer, 2022, Apr-04, Volume: 22, Issue:1

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Fluorouracil; Hu

2022
Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer.
    Advances in therapy, 2022, Volume: 39, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chem

2022
Methionine restriction enhances the chemotherapeutic sensitivity of colorectal cancer stem cells by miR-320d/c-Myc axis.
    Molecular and cellular biochemistry, 2022, Volume: 477, Issue:7

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluo

2022
Kaempferol Can Reverse the 5-Fu Resistance of Colorectal Cancer Cells by Inhibiting PKM2-Mediated Glycolysis.
    International journal of molecular sciences, 2022, Mar-24, Volume: 23, Issue:7

    Topics: Carrier Proteins; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Drug Resistance, Neopla

2022
Discoidin domain receptor 1a (DDR1a) confers 5-fluorouracil cytotoxicity in LoVo cell via PI3K/AKT/Bcl-2 pathway.
    Bioengineered, 2022, Volume: 13, Issue:4

    Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Discoidin Domain Receptor 1; Discoidin Domain Rec

2022
FAM98A promotes resistance to 5-fluorouracil in colorectal cancer by suppressing ferroptosis.
    Archives of biochemistry and biophysics, 2022, 06-15, Volume: 722

    Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Ferroptosis;

2022
[A Case Report for Peritoneal Recurrences by Laparoscopic Surgery after Colorectal Cancer Resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2022, Volume: 49, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neo

2022
Proton pump inhibitors affect capecitabine efficacy in patients with stage II-III colorectal cancer: a multicenter retrospective study.
    Scientific reports, 2022, 04-21, Volume: 12, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neo

2022
Clinical Efficacy of Bevacizumab Plus XELOX Chemotherapy in Colorectal Cancer and Application Value of Mindfulness-Based Stress Reduction Intervention.
    Alternative therapies in health and medicine, 2022, Volume: 28, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deo

2022
SPOCK1 silencing decreases 5-FU resistance through PRRX1 in colorectal cancer.
    Pathology, research and practice, 2022, Volume: 234

    Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Exp

2022
Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.
    International journal of cancer, 2022, 09-15, Volume: 151, Issue:6

    Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Colorectal Ne

2022
Targeting the miR-34a/LRPPRC/MDR1 axis collapse the chemoresistance in P53 inactive colorectal cancer.
    Cell death and differentiation, 2022, Volume: 29, Issue:11

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Reg

2022
Differential effects of 5-fluorouracil and oxaliplatin on autophagy in chemoresistant colorectal cancer cells.
    Journal of cellular biochemistry, 2022, Volume: 123, Issue:6

    Topics: Apoptosis; Autophagy; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouraci

2022
Hepatic arterial infusion pump chemotherapy combined with systemic therapy for patients with advanced colorectal liver metastases: Outcomes in a newly established program.
    Journal of surgical oncology, 2022, Volume: 126, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hep

2022
Targeting DCLK1 overcomes 5-fluorouracil resistance in colorectal cancer through inhibiting CCAR1/β-catenin pathway-mediated cancer stemness.
    Clinical and translational medicine, 2022, Volume: 12, Issue:5

    Topics: Apoptosis Regulatory Proteins; beta Catenin; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Colo

2022
5-fluorouracil treatment of patient-derived scaffolds from colorectal cancer reveal clinically critical information.
    Journal of translational medicine, 2022, 05-13, Volume: 20, Issue:1

    Topics: Colorectal Neoplasms; Fluorouracil; HT29 Cells; Humans; Neoplasm Recurrence, Local; Tumor Microenvir

2022
Mir-675-5p supports hypoxia-induced drug resistance in colorectal cancer cells.
    BMC cancer, 2022, May-20, Volume: 22, Issue:1

    Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouraci

2022
The epigenetic modifier HDAC2 and the checkpoint kinase ATM determine the responses of microsatellite instable colorectal cancer cells to 5-fluorouracil.
    Cell biology and toxicology, 2023, Volume: 39, Issue:5

    Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Colonic Neoplasms; Colorectal Neoplasms; DNA; Epige

2023
RASSF4 inhibits cell proliferation and increases drug sensitivity in colorectal cancer through YAP/Bcl-2 pathway.
    Journal of cellular and molecular medicine, 2022, Volume: 26, Issue:12

    Topics: Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; DNA-Bind

2022
Efficacy of risk-stratified indicators for adjuvant chemotherapy with fluorouracil and oxaliplatin after hepatectomy for colorectal cancer liver metastasis.
    International journal of colorectal disease, 2022, Volume: 37, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female

2022
AP4 suppresses DNA damage, chromosomal instability and senescence via inducing MDC1/Mediator of DNA damage Checkpoint 1 and repressing MIR22HG/miR-22-3p.
    Molecular cancer, 2022, 05-27, Volume: 21, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Cycle Proteins; Chromosomal Instability; Colorec

2022
Colorectal Cancer Patient-Derived 2D and 3D Models Efficiently Recapitulate Inter- and Intratumoral Heterogeneity.
    Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022, Volume: 9, Issue:22

    Topics: Carcinogenesis; Colorectal Neoplasms; Fluorouracil; Humans; Organoids

2022
Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen.
    PloS one, 2022, Volume: 17, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Ne

2022
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
    British journal of cancer, 2022, Volume: 127, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore

2022
Blockage of PD-L1 by FERMT3-mediated Wnt/β-catenin signalling regulates chemoresistance and immune evasion of colorectal cancer cells.
    Clinical and experimental pharmacology & physiology, 2022, Volume: 49, Issue:9

    Topics: B7-H1 Antigen; beta Catenin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluo

2022
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial.
    International journal of cancer, 2022, 11-15, Volume: 151, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans;

2022
Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy.
    Future oncology (London, England), 2022, Volume: 18, Issue:22

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore

2022
circEXOC6B interacting with RRAGB, an mTORC1 activator, inhibits the progression of colorectal cancer by antagonizing the HIF1A-RRAGB-mTORC1 positive feedback loop.
    Molecular cancer, 2022, 06-23, Volume: 21, Issue:1

    Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Feedback; Fluorouracil; Gene Expression

2022
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 172

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neopla

2022
Stabilizing and upregulating Axin with tankyrase inhibitor reverses 5-fluorouracil chemoresistance and proliferation by targeting the WNT/caveolin-1 axis in colorectal cancer cells.
    Cancer gene therapy, 2022, Volume: 29, Issue:11

    Topics: Animals; Apoptosis; Axin Protein; beta Catenin; Caveolin 1; Cell Line, Tumor; Cell Proliferation; Co

2022
Extracellular vesicles derived from Lactobacillus plantarum restore chemosensitivity through the PDK2-mediated glucose metabolic pathway in 5-FU-resistant colorectal cancer cells.
    Journal of microbiology (Seoul, Korea), 2022, Volume: 60, Issue:7

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Extracellular Vesicles; Fluoroura

2022
Identification of Genes Related to 5-Fluorouracil Based Chemotherapy for Colorectal Cancer.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Reg

2022
Saturated Fatty Acids in Cell Membrane Lipids Induce Resistance to 5-Fluorouracil in Colorectal Cancer Cells.
    Anticancer research, 2022, Volume: 42, Issue:7

    Topics: Colorectal Neoplasms; Fatty Acids; Fatty Acids, Monounsaturated; Fluorouracil; Humans; Membrane Lipi

2022
[Comparative Safety Assessment of Ramucirumab plus FOLFIRI and Bevacizumab plus FOLFIRI in Second- and Later-Line Treatment in Japanese Patients with Metastatic Colorectal Carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2022, Volume: 49, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2022
Inhibition of the Wnt/b-catenin pathway using PNU-74654 reduces tumor growth in in vitro and in vivo models of colorectal cancer.
    Tissue & cell, 2022, Volume: 77

    Topics: Animals; Apoptosis; Benzamides; beta Catenin; Catenins; Cell Line, Tumor; Cell Movement; Cell Prolif

2022
Establishment of In Vitro and In Vivo Anticolorectal Cancer Efficacy of Lithocholic Acid-Based Imidazolium Salts.
    International journal of molecular sciences, 2022, Jun-24, Volume: 23, Issue:13

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Hum

2022
Genomic Predictors of Recurrence Patterns After Complete Resection of Colorectal Liver Metastases and Adjuvant Hepatic Artery Infusion Chemotherapy by Narayan et al.
    Annals of surgical oncology, 2022, Volume: 29, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro

2022
Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-

2022
FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study.
    International journal of cancer, 2022, Dec-01, Volume: 151, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fem

2022
Simulating Colorectal Cancer Trials Using Real-World Data.
    JCO clinical cancer informatics, 2022, Volume: 6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorectal Neop

2022
Does dihydropyrimidine dehydrogenase level modify plasma antioxidant capacity in colorectal cancer patients treated with fluoropyrimidines?
    Folia medica, 2021, Oct-31, Volume: 63, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antioxidants; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NA

2021
METTL3 antagonizes 5‑FU chemotherapy and confers drug resistance in colorectal carcinoma.
    International journal of oncology, 2022, Volume: 61, Issue:3

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance,

2022
Potential cancer treatment effects of brusatol or eriodictyol combined with 5-fluorouracil (5-FU) in colorectal cancer cell.
    Naunyn-Schmiedeberg's archives of pharmacology, 2022, Volume: 395, Issue:9

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Synergism; Flavanones; F

2022
Treatment of Metastatic Colorectal Carcinoma with Bevacizumab in First-Line and beyond First Progression: The KORALLE Non-Interventional Cohort Study.
    Oncology research and treatment, 2022, Volume: 45, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cohort Studies; Colorectal Neopl

2022
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon a
    International journal of clinical oncology, 2022, Volume: 27, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colonic Neoplasms; Colorecta

2022
Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
    BMC cancer, 2022, Jul-21, Volume: 22, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab;

2022
Investigation of
    Personalized medicine, 2022, Volume: 19, Issue:5

    Topics: Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genotype; Humans; Methylenet

2022
Kif4A mediates resistance to neoadjuvant chemoradiotherapy in patients with advanced colorectal cancer via regulating DNA damage response.
    Acta biochimica et biophysica Sinica, 2022, 05-25, Volume: 54, Issue:7

    Topics: Cisplatin; Colorectal Neoplasms; DNA Damage; Fluorouracil; Humans; Kinesins; Neoadjuvant Therapy

2022
Knockdown of circ_0004585 enhances the chemosensitivity of colorectal cancer cells to 5-fluorouracil via the miR-874-3p/CCND1 axis.
    Histology and histopathology, 2023, Volume: 38, Issue:1

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cyclin D1; Fluorouracil; Humans

2023
Impact of osteopenia and neutropenia in patients with colorectal cancer treated with FOLFOXIRI: a retrospective cohort study.
    International journal of clinical oncology, 2022, Volume: 27, Issue:9

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Diseases, M

2022
LINC02418 upregulates EPHA2 by competitively sponging miR-372-3p to promote 5-Fu/DDP chemoresistance in colorectal cancer.
    Carcinogenesis, 2022, 10-22, Volume: 43, Issue:9

    Topics: Cisplatin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation

2022
Development and validation of a cancer-associated fibroblast-derived lncRNA signature for predicting clinical outcomes in colorectal cancer.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Adenocarcinoma; Breast Neoplasms; Cancer-Associated Fibroblasts; Colorectal Neoplasms; Female; Fluor

2022
SHMT2-mediated mitochondrial serine metabolism drives 5-FU resistance by fueling nucleotide biosynthesis.
    Cell reports, 2022, 08-16, Volume: 40, Issue:7

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Mitochondri

2022
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM).
    ESMO open, 2022, Volume: 7, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci

2022
5-Fluorouracil drug delivery system based on bacterial nanocellulose for colorectal cancer treatment: Mathematical and in vitro evaluation.
    International journal of biological macromolecules, 2022, Nov-01, Volume: 220

    Topics: Antineoplastic Agents; Biocompatible Materials; Colorectal Neoplasms; Delayed-Action Preparations; D

2022
Provider imaging practices and outcomes of advanced colorectal cancer.
    Cancer treatment and research communications, 2022, Volume: 32

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2022
Anti-tumoral Effect of
    Anti-cancer agents in medicinal chemistry, 2023, Volume: 23, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Fluoro

2023
Functional Phosphoproteomics in Cancer Chemoresistance Using CRISPR-Mediated Base Editors.
    Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022, Volume: 9, Issue:30

    Topics: Adenine; Amino Acids; Clustered Regularly Interspaced Short Palindromic Repeats; Colorectal Neoplasm

2022
Real-world overall survival of patients receiving cetuximab in later lines of treatment for metastatic colorectal cancer.
    Future oncology (London, England), 2022, Volume: 18, Issue:29

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Colorect

2022
Long-term resistance to 5-fluorouracil promotes epithelial-mesenchymal transition, apoptosis evasion, autophagy, and reduced proliferation rate in colon cancer cells.
    European journal of pharmacology, 2022, Oct-15, Volume: 933

    Topics: Apoptosis; Autophagy; Cadherins; Cell Line, Tumor; Cell Proliferation; Claudin-3; Colonic Neoplasms;

2022
Disulfiram increases the efficacy of 5-fluorouracil in organotypic cultures of colorectal carcinoma.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 153

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Copper; Disulfiram; Fluorouracil; Humans; Spheroids, Cellula

2022
The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer.
    Human cell, 2022, Volume: 35, Issue:6

    Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Deferoxamine;

2022
2-Nucleobase-substituted 4,6-Diaminotriazine Analogs: Synthesis and Anti-cancer Activity in 5-Fluorouracil-sensitive and Resistant Colorectal Cancer Cells.
    Current medicinal chemistry, 2023, Volume: 30, Issue:26

    Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil;

2023
A prognostic six-gene expression risk-score derived from proteomic profiling of the metastatic colorectal cancer secretome.
    The journal of pathology. Clinical research, 2022, Volume: 8, Issue:6

    Topics: Biomarkers, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Gene Expression Profiling;

2022
    Journal of chemotherapy (Florence, Italy), 2023, Volume: 35, Issue:5

    Topics: 5' Untranslated Regions; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydr

2023
Targeting mitochondrial tyrosyl-tRNA synthetase YARS2 suppresses colorectal cancer progression.
    Cancer biology & therapy, 2022, 12-31, Volume: 23, Issue:1

    Topics: Adenosine Triphosphate; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Mutation; Reac

2022
Novel therapeutic diiminoquinone exhibits anticancer effects on human colorectal cancer cells in two-dimensional and three-dimensional
    World journal of gastroenterology, 2022, Sep-07, Volume: 28, Issue:33

    Topics: Catenins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci

2022
Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study.
    The Pan African medical journal, 2022, Volume: 42

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colorectal N

2022
Pharmacogenetic Study of the Dihydropyridine Dehydrogenase Gene in Jordanian Patients with Colorectal Cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2022, Sep-01, Volume: 23, Issue:9

    Topics: Colorectal Neoplasms; Cross-Sectional Studies; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Hum

2022
A serum metabolomics study based on LC-MS: Chemosensitization effects of Rauvolfia vomitoria Afzel. combined with 5- fluorouracil on colorectal cancer mice.
    Journal of pharmaceutical and biomedical analysis, 2022, Nov-30, Volume: 221

    Topics: Animals; Cell Line, Tumor; Chromatography, Liquid; Colorectal Neoplasms; Fatty Acids; Fluorouracil;

2022
Mast cell-T cell axis alters development of colitis-dependent and colitis-independent colorectal tumours: potential for therapeutically targeting via mast cell inhibition.
    Journal for immunotherapy of cancer, 2022, Volume: 10, Issue:10

    Topics: Animals; Colitis; Colorectal Neoplasms; Fluorouracil; Humans; Mast Cells; Mice

2022
The Antitumor Effect of Timosaponin A3 through c-Myc Inhibition in Colorectal Cancer Cells and Combined Treatment Effect with 5-FU or Doxorubicin.
    International journal of molecular sciences, 2022, Oct-07, Volume: 23, Issue:19

    Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms;

2022
    Oncotarget, 2022, 10-08, Volume: 13

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Caspase 3; Cholecalciferol; Colorectal Neop

2022
Adjuvant Capecitabine and Oxaliplatin for Elderly Patients with Colorectal Cancer.
    Oncology, 2022, Volume: 100, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorect

2022
Managing life-threatening 5-fluorouracil cardiotoxicity.
    BMJ case reports, 2022, Oct-17, Volume: 15, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Camptothecin; Cardiotoxici

2022
Lipid-polymer nanocarrier platform enables X-ray induced photodynamic therapy against human colorectal cancer cells.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 155

    Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Folic Acid; Humans; Lip

2022
Initiating Treatment with Low Fluorouracil Dose and Titrating According to Blood Levels in Patients Treated with a 46-Hour Continuous Infusion.
    Chemotherapy, 2023, Volume: 68, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluor

2023
[A Case of Unilateral Interstitial Lung Disease in a Patient Treated with Oxaliplatin, 5-Fluorouracil, and Leucovorin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2022, Volume: 49, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Le

2022
[A Case of BRAF V600E-Mutant Colorectal Cancer Treated Effectively by Encorafenib, Binimetinib, and Cetuximab Triple Therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2022, Volume: 49, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms;

2022
[A Case of Serous Retinal Detachment after Encorafenib, Binimetinib, and Cetuximab Treatment for BRAF V600E Mutant Colorectal Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2022, Volume: 49, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms;

2022
Evaluation of the Effects of Genistein In Vitro as a Chemopreventive Agent for Colorectal Cancer-Strategy to Improve Its Efficiency When Administered Orally.
    Molecules (Basel, Switzerland), 2022, Oct-19, Volume: 27, Issue:20

    Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Genistein; Humans; Reactive Oxygen

2022
Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance.
    International journal of clinical oncology, 2023, Volume: 28, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Coloni

2023
Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity.
    Cancer medicine, 2023, Volume: 12, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2023
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer.
    BMC cancer, 2022, Oct-29, Volume: 22, Issue:1

    Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Cell Line, Tumor; Colorectal Neopla

2022
Modulating the activity of fluoropyrimidines against colorectal cancer by Vitamin D and its analogs.
    Folia medica Cracoviensia, 2022, Sep-15, Volume: 62, Issue:3

    Topics: Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Vitamin D

2022
Rewiring glucose metabolism improves 5-FU efficacy in p53-deficient/KRAS
    Communications biology, 2022, 10-31, Volume: 5, Issue:1

    Topics: Colorectal Neoplasms; Fluorouracil; Glucose; Humans; Proto-Oncogene Proteins p21(ras); Tumor Suppres

2022
A rapid high throughput bioprinted colorectal cancer spheroid platform for
    Biofabrication, 2022, Nov-02, Volume: 15, Issue:1

    Topics: Bioprinting; Cell Line; Colorectal Neoplasms; Fluorouracil; Humans; Oxaliplatin; Spheroids, Cellular

2022
Actionable tests and treatments for patients with gastrointestinal cancers and historically short median survival times.
    PloS one, 2022, Volume: 17, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neo

2022
Letter re: "Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer".
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 177

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Fluorouracil; Hu

2022
Rapamycin Liposomes Combined with 5-Fluorouracil Inhibits Angiogenesis and Tumor Growth of APC
    International journal of nanomedicine, 2022, Volume: 17

    Topics: Animals; Azoxymethane; Colitis; Colorectal Neoplasms; Dextran Sulfate; Disease Models, Animal; Fluor

2022
Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a subanalysis of the TRIBE and TRIBE2 trials.
    ESMO open, 2022, Volume: 7, Issue:6

    Topics: Bevacizumab; Bone Neoplasms; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hu

2022
The
    International journal of clinical pharmacology and therapeutics, 2023, Volume: 61, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Genotype; Humans

2023
Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 01-20, Volume: 41, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Drug Resistance, Ne

2023
5-fluorouracil with oxaliplatin and/or irinotecan for advanced sinonasal intestinal-type adenocarcinoma (ITAC).
    Bulletin du cancer, 2023, Volume: 110, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms;

2023
The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
    Cell reports, 2022, 11-15, Volume: 41, Issue:7

    Topics: Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; Humans; Microbiota

2022
The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
    Cell reports, 2022, 11-15, Volume: 41, Issue:7

    Topics: Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; Humans; Microbiota

2022
The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
    Cell reports, 2022, 11-15, Volume: 41, Issue:7

    Topics: Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; Humans; Microbiota

2022
The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
    Cell reports, 2022, 11-15, Volume: 41, Issue:7

    Topics: Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; Humans; Microbiota

2022
The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
    Cell reports, 2022, 11-15, Volume: 41, Issue:7

    Topics: Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; Humans; Microbiota

2022
The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
    Cell reports, 2022, 11-15, Volume: 41, Issue:7

    Topics: Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; Humans; Microbiota

2022
The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
    Cell reports, 2022, 11-15, Volume: 41, Issue:7

    Topics: Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; Humans; Microbiota

2022
The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
    Cell reports, 2022, 11-15, Volume: 41, Issue:7

    Topics: Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; Humans; Microbiota

2022
The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
    Cell reports, 2022, 11-15, Volume: 41, Issue:7

    Topics: Colorectal Neoplasms; Escherichia coli; Fluorouracil; Fusobacterium nucleatum; Humans; Microbiota

2022
Effect of 5-Fluoro-Uracile + Oxaliplatin chemotherapy on the histological response of PEritoneal and hePatIc corectal metasTases in a mOuse model: PEPITO experimental study.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2023, Volume: 49, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Liver N

2023
Effect of 5-Fluoro-Uracile + Oxaliplatin chemotherapy on the histological response of PEritoneal and hePatIc corectal metasTases in a mOuse model: PEPITO experimental study.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2023, Volume: 49, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Liver N

2023
Effect of 5-Fluoro-Uracile + Oxaliplatin chemotherapy on the histological response of PEritoneal and hePatIc corectal metasTases in a mOuse model: PEPITO experimental study.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2023, Volume: 49, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Liver N

2023
Effect of 5-Fluoro-Uracile + Oxaliplatin chemotherapy on the histological response of PEritoneal and hePatIc corectal metasTases in a mOuse model: PEPITO experimental study.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2023, Volume: 49, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Liver N

2023
Real-world adjuvant chemotherapy treatment patterns and outcomes over time for resected stage II and III colorectal cancer.
    Asia-Pacific journal of clinical oncology, 2023, Volume: 19, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colorectal Neopla

2023
Real-world adjuvant chemotherapy treatment patterns and outcomes over time for resected stage II and III colorectal cancer.
    Asia-Pacific journal of clinical oncology, 2023, Volume: 19, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colorectal Neopla

2023
Real-world adjuvant chemotherapy treatment patterns and outcomes over time for resected stage II and III colorectal cancer.
    Asia-Pacific journal of clinical oncology, 2023, Volume: 19, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colorectal Neopla

2023
Real-world adjuvant chemotherapy treatment patterns and outcomes over time for resected stage II and III colorectal cancer.
    Asia-Pacific journal of clinical oncology, 2023, Volume: 19, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colorectal Neopla

2023
5-Fluorouracil crystal-incorporated, pH-responsive, and release-modulating PLGA/Eudragit FS hybrid microparticles for local colorectal cancer-targeted chemotherapy.
    International journal of pharmaceutics, 2023, Jan-05, Volume: 630

    Topics: Animals; Colorectal Neoplasms; Drug Carriers; Drug Delivery Systems; Fluorouracil; Hydrogen-Ion Conc

2023
5-Fluorouracil crystal-incorporated, pH-responsive, and release-modulating PLGA/Eudragit FS hybrid microparticles for local colorectal cancer-targeted chemotherapy.
    International journal of pharmaceutics, 2023, Jan-05, Volume: 630

    Topics: Animals; Colorectal Neoplasms; Drug Carriers; Drug Delivery Systems; Fluorouracil; Hydrogen-Ion Conc

2023
5-Fluorouracil crystal-incorporated, pH-responsive, and release-modulating PLGA/Eudragit FS hybrid microparticles for local colorectal cancer-targeted chemotherapy.
    International journal of pharmaceutics, 2023, Jan-05, Volume: 630

    Topics: Animals; Colorectal Neoplasms; Drug Carriers; Drug Delivery Systems; Fluorouracil; Hydrogen-Ion Conc

2023
5-Fluorouracil crystal-incorporated, pH-responsive, and release-modulating PLGA/Eudragit FS hybrid microparticles for local colorectal cancer-targeted chemotherapy.
    International journal of pharmaceutics, 2023, Jan-05, Volume: 630

    Topics: Animals; Colorectal Neoplasms; Drug Carriers; Drug Delivery Systems; Fluorouracil; Hydrogen-Ion Conc

2023
Cetuximab severe cutaneous toxicity… a gateway for bacteremia: case report.
    Anti-cancer drugs, 2023, 01-01, Volume: 34, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Cellulitis; Cetu

2023
microRNA-143 interferes the EGFR-stimulated glucose metabolism to re-sensitize 5-FU resistant colon cancer cells via targeting hexokinase 2.
    Journal of chemotherapy (Florence, Italy), 2023, Volume: 35, Issue:6

    Topics: Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Neoplas

2023
LOXL2 reduces 5-FU sensitivity through the Hedgehog/BCL2 signaling pathway in colorectal cancer.
    Experimental biology and medicine (Maywood, N.J.), 2023, Volume: 248, Issue:6

    Topics: Amino Acid Oxidoreductases; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colorectal

2023
Enhancement of the antitumor effect of 5-fluorouracil with modulation in drug transporters expression using PI3K inhibitors in colorectal cancer cells.
    Life sciences, 2023, Feb-15, Volume: 315

    Topics: Apoptosis; ATP-Binding Cassette Transporters; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Co

2023
EIF3D promotes resistance to 5-fluorouracil in colorectal cancer through upregulating RUVBL1.
    Journal of clinical laboratory analysis, 2023, Volume: 37, Issue:2

    Topics: Animals; Apoptosis; ATPases Associated with Diverse Cellular Activities; bcl-2-Associated X Protein;

2023
Prediction of Drug Synergism between Peptides and Antineoplastic Drugs Paclitaxel, 5-Fluorouracil, and Doxorubicin Using In Silico Approaches.
    International journal of molecular sciences, 2022, Dec-21, Volume: 24, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal

2022
Assessment of patients' knowledge of their treatment with capecitabine at the National Institute of Oncology in Rabat.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neoplasms

2023
Circ-ERBB2 knockdown sensitized colorectal cancer cells to 5-FU via miR-181a-5p/PTEN/Akt pathway.
    Journal of biochemical and molecular toxicology, 2023, Volume: 37, Issue:4

    Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Humans; MicroRNAs; Proto-O

2023
A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer.
    Molecular cancer, 2023, 01-20, Volume: 22, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin

2023
Folic-Acid-Conjugated Thermoresponsive Polymeric Particles for Targeted Delivery of 5-Fluorouracil to CRC Cells.
    International journal of molecular sciences, 2023, Jan-10, Volume: 24, Issue:2

    Topics: Colorectal Neoplasms; Drug Carriers; Drug Delivery Systems; Fluorouracil; Folic Acid; Humans; Nanopa

2023
New Transcriptomic Biomarkers of 5-Fluorouracil Resistance.
    International journal of molecular sciences, 2023, Jan-12, Volume: 24, Issue:2

    Topics: Biomarkers; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Membrane Proteins

2023
Glochodpurnoid B from
    Molecules (Basel, Switzerland), 2023, Jan-04, Volume: 28, Issue:2

    Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Endoplasmic Reticulum Stress; Fluorouracil; Human

2023
Gamma-Aminobutyric Acid Type A Receptor Subunit Pi is a potential chemoresistance regulator in colorectal cancer.
    Molecular biology reports, 2023, Volume: 50, Issue:4

    Topics: Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplasti

2023
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 159

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circulating MicroRNA; Colonic Neoplasm

2023
Chitosan coated magnetic cellulose nanowhisker as a drug delivery system for potential colorectal cancer treatment.
    International journal of biological macromolecules, 2023, Apr-01, Volume: 233

    Topics: Cellulose; Chitosan; Colorectal Neoplasms; Drug Delivery Systems; Drug Liberation; Fluorouracil; Hum

2023
Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023, Volume: 25, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore

2023
[Hydroxysafflor yellow A inhibits proliferation, migration, and chemoresistance of colorectal cancer cells through Akt/mTOR-autophagy pathway].
    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2023, Volume: 48, Issue:2

    Topics: Autophagy; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fl

2023
[Cases of Advanced Colorectal Cancer with Nephrotic Syndrome after FOLFIRI plus Ramucirumab Administration].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2022, Volume: 49, Issue:13

    Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorec

2022
[Two Cases of Stage Ⅳ Colorectal Cancer with Long-Term Survival following Single-Agent Chemotherapy with Capecitabine-A Case Reports].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2022, Volume: 49, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuv

2022
Thiol oxidative stress-dependent degradation of transglutaminase2 via protein S-glutathionylation sensitizes 5-fluorouracil therapy in 5-fluorouracil-resistant colorectal cancer cells.
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2023, Volume: 67

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Drug Re

2023
Could the concomitant use of beta blockers with bevacizumab improve survival in metastatic colon cancer?
    European journal of clinical pharmacology, 2023, Volume: 79, Issue:4

    Topics: Adrenergic beta-Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Ne

2023
[A Case of Liver Metastasis of Colorectal Cancer Successfully Treated with Hepatic Arterial Infusion Chemotherapy after Systemic Chemotherapy Was Difficult to Administer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2023, Volume: 50, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery;

2023
[FOLFIRI plus RAM Therapy in Later Line of Unresectable Colorectal Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2023, Volume: 50, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu

2023
Association of High LAT1 Expression with Poor Prognosis and Recurrence in Colorectal Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy.
    International journal of molecular sciences, 2023, Jan-30, Volume: 24, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro

2023
Beneficial Proapoptotic Effect of Heterobasidion Annosum Extract in Colorectal Cancer Xenograft Mouse Model.
    Molecules (Basel, Switzerland), 2023, Jan-31, Volume: 28, Issue:3

    Topics: Animals; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Ki-67 Antigen; Mic

2023
The Gut Microbiota Metabolite Urolithin B Prevents Colorectal Carcinogenesis by Remodeling Microbiota and PD-L1/HLA-B.
    Oxidative medicine and cellular longevity, 2023, Volume: 2023

    Topics: Animals; B7-H1 Antigen; Carcinogenesis; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Gastr

2023
STAT3 regulates 5-Fu resistance in human colorectal cancer cells by promoting Mcl-1-dependent cytoprotective autophagy.
    Cancer science, 2023, Volume: 114, Issue:6

    Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, N

2023
[Two Cases of Transfusion-Free Hepatectomy Following Chemotherapy for H3 Grade of Simultaneous Liver Metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2023, Volume: 50, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Femal

2023
METTL14-dependent maturation of pri-miR-17 regulates mitochondrial homeostasis and induces chemoresistance in colorectal cancer.
    Cell death & disease, 2023, 02-21, Volume: 14, Issue:2

    Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil;

2023
The Novel 5-Fluorouracil Loaded Ruthenium-based Nanocarriers Enhanced Anticancer and Apoptotic Efficiency while Reducing Multidrug Resistance in Colorectal Cancer Cells.
    Journal of fluorescence, 2023, Volume: 33, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line

2023
7
    Marine drugs, 2023, Jan-24, Volume: 21, Issue:2

    Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Heterograf

2023
A Pharmacokinetic-Pharmacodynamic Model Predicts Uracil-tegafur Effect on Tumor Shrinkage and Myelosuppression in a Colorectal Cancer Rat Model.
    Anticancer research, 2023, Volume: 43, Issue:3

    Topics: Administration, Oral; Animals; Colorectal Neoplasms; Fluorouracil; Rats; Tegafur; Uracil

2023
Fasting-mimicking diet synergizes with ferroptosis against quiescent, chemotherapy-resistant cells.
    EBioMedicine, 2023, Volume: 90

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fasting; Ferropto

2023
Curcumol Reduces Aerobic Glycolysis and Overcomes Chemoresistance by Inducing Cdh1-Mediated Skp2 Ubiquitination.
    The American journal of Chinese medicine, 2023, Volume: 51, Issue:3

    Topics: Antigens, CD; Cadherins; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorour

2023
Loss of exosomal miR-200b-3p from hypoxia cancer-associated fibroblasts promotes tumorigenesis and reduces sensitivity to 5-Flourouracil in colorectal cancer via upregulation of ZEB1 and E2F3.
    Cancer gene therapy, 2023, Volume: 30, Issue:6

    Topics: Cancer-Associated Fibroblasts; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Cell Transforma

2023
Resveratrol Modulates Chemosensitisation to 5-FU via β1-Integrin/HIF-1α Axis in CRC Tumor Microenvironment.
    International journal of molecular sciences, 2023, Mar-05, Volume: 24, Issue:5

    Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil;

2023
Probiotic Supplementation Attenuates Chemotherapy-Induced Intestinal Mucositis in an Experimental Colorectal Cancer Liver Metastasis Rat Model.
    Nutrients, 2023, Feb-23, Volume: 15, Issue:5

    Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Diarrhea; Fluorouracil; Male; Mucositis; Probi

2023
TIMP-2 as a predictive biomarker in 5-Fu-resistant colorectal cancer.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:10

    Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers; Cell Line, Tumor; Colorectal Neoplasms; Drug R

2023
A Case of Heavily Pretreated HER2+ Colorectal Liver Metastases Responsive to Hepatic Arterial Infusion Chemotherapy.
    Clinical colorectal cancer, 2023, Volume: 22, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery;

2023
Drug monitoring detects under- and overdosing in patients receiving 5-fluorouracil-containing chemotherapy-results of a prospective, multicenter German observational study.
    ESMO open, 2023, Volume: 8, Issue:2

    Topics: Colorectal Neoplasms; Drug Monitoring; Fluorouracil; Germany; Humans; Prospective Studies

2023
Canonical Wnt Pathway Is Involved in Chemoresistance and Cell Cycle Arrest Induction in Colon Cancer Cell Line Spheroids.
    International journal of molecular sciences, 2023, Mar-09, Volume: 24, Issue:6

    Topics: beta Catenin; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Colonic Neopl

2023
The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent.
    Cancer chemotherapy and pharmacology, 2023, Volume: 91, Issue:5

    Topics: Antimetabolites; Colorectal Neoplasms; DNA; Enzyme Inhibitors; Fluorodeoxyuridylate; Fluorouracil; H

2023
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer.
    ESMO open, 2023, Volume: 8, Issue:2

    Topics: Capecitabine; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hand-Foot Syndrome; Humans; Imm

2023
Effect of intra-operative chemotherapy with 5-fluorouracil and leucovorin on the survival of patients with colorectal cancer after radical surgery: a retrospective cohort study.
    Chinese medical journal, 2023, Apr-05, Volume: 136, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

2023
Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAF
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Factors; Cetuximab; Colonic

2023
Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 06-13, Volume: 29, Issue:12

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms;

2023
Alarmin IL-33 orchestrates antitumoral T cell responses to enhance sensitivity to 5-fluorouracil in colorectal cancer.
    Theranostics, 2023, Volume: 13, Issue:5

    Topics: Alarmins; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; I

2023
Relationship between anticancer sensitivities and cellular respiration properties in 5-fluorouracil-resistant HCT116 human colorectal cancer cells.
    FEBS open bio, 2023, Volume: 13, Issue:6

    Topics: Adenosine Triphosphate; Cell Respiration; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluoroura

2023
In vivo self-assembled small RNA targets H19 lncRNA for the treatment of colorectal cancer.
    Journal of controlled release : official journal of the Controlled Release Society, 2023, Volume: 358

    Topics: Animals; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Humans; Lung Neoplasms; Mice; Micro

2023
Hepatic arterial infusion with nanoliposomal irinotecan leads to significant regression of tumor size of colorectal liver metastases in a CC531 rat model.
    Clinical & experimental metastasis, 2023, Volume: 40, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Colonic N

2023
Combination Therapy, Including Bevacizumab, for Advanced Colorectal Cancer.
    The New England journal of medicine, 2023, May-04, Volume: 388, Issue:18

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neop

2023
Tumor tropic delivery of FU.FA@NSs using mesenchymal stem cells for synergistic chemo-photodynamic therapy of colorectal cancer.
    Colloids and surfaces. B, Biointerfaces, 2023, Volume: 226

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Humans; Hydrogen Peroxi

2023
Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer.
    Cell death & disease, 2023, 05-05, Volume: 14, Issue:5

    Topics: Colorectal Neoplasms; Fluorouracil; Humans; Secretome

2023
SNHG15 promotes chemoresistance and glycolysis in colorectal cancer.
    Pathology, research and practice, 2023, Volume: 246

    Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil;

2023
Knockdown of hnRNPAB reduces the stem cell properties and enhances the chemosensitivity of human colorectal cancer stem cells.
    Oncology reports, 2023, Volume: 49, Issue:6

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fl

2023
Deregulation of the miR-19b/PPP2R5E Signaling Axis Shows High Functional Impact in Colorectal Cancer Cells.
    International journal of molecular sciences, 2023, Apr-24, Volume: 24, Issue:9

    Topics: Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Disease Progression; Fluorouracil; Gene

2023
Development and cytotoxicity evaluation of multiple nanoemulsions for oral co-delivery of 5-fluorouracil and short chain triglycerides for colorectal cancer.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2023, Aug-01, Volume: 187

    Topics: Colorectal Neoplasms; Emulsions; Fluorouracil; Humans; Surface-Active Agents; Triglycerides; Viscosi

2023
Oxaliplatin in Adjuvant Colorectal Cancer: Is There a Role in Older Patients?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 06-20, Volume: 41, Issue:18

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorect

2023
Correlation between recurrence-free survival and overall survival after upfront surgery for resected colorectal liver metastases.
    The British journal of surgery, 2023, 06-12, Volume: 110, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diseas

2023
[Educational Project of Self-Removal of the Intravenous Central Venous Access Port Guided by Patients with Advanced Colorectal Cancer Instructed by a Nurse in the University Hospital].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2023, Volume: 50, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheterization, Central Venous;

2023
Protein Kinase D1 Correlates with Less Lymph Node Metastasis Risk, Enhanced 5-FU Sensitivity, and Better Prognosis in Colorectal Cancer.
    The Tohoku journal of experimental medicine, 2023, Aug-11, Volume: 260, Issue:4

    Topics: Colorectal Neoplasms; Fluorouracil; Humans; Lymphatic Metastasis; Prognosis; Protein Kinases

2023
Liver cirrhosis following oxaliplatin-based adjuvant chemotherapy for rectal cancer.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Chemotherapy, Adjuva

2023
Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study.
    International journal of clinical oncology, 2023, Volume: 28, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colonic N

2023
XPF-ERCC1 Blocker Improves the Therapeutic Efficacy of 5-FU- and Oxaliplatin-Based Chemoradiotherapy in Colorectal Cancer.
    Cells, 2023, May-25, Volume: 12, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Colorectal Neoplasms; DN

2023
Blastocystis sp. reduces the efficacy of 5-fluorouracil as a colorectal cancer chemotherapeutic treatment.
    Experimental parasitology, 2023, Volume: 251

    Topics: Animals; Blastocystis; Colorectal Neoplasms; Cysts; Fluorouracil; Humans; Male; Rats; Rats, Wistar

2023
Initially unresectable colorectal liver metastases: the best therapeutic regimens.
    The Lancet. Oncology, 2023, Volume: 24, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hum

2023
Atorvastatin calcium alleviates 5-fluorouracil-induced intestinal damage by inhibiting cellular senescence and significantly enhances its antitumor efficacy.
    International immunopharmacology, 2023, Volume: 121

    Topics: Animals; Atorvastatin; Cellular Senescence; Colorectal Neoplasms; Endothelial Cells; Fluorouracil; H

2023
Dual targeting of TGF-β and PD-L1 inhibits tumor growth in TGF-β/PD-L1-driven colorectal carcinoma.
    Life sciences, 2023, Sep-01, Volume: 328

    Topics: B7-H1 Antigen; Colorectal Neoplasms; Fluorouracil; Humans; Transforming Growth Factor beta; Tumor Mi

2023
Scutellaria baicalensis enhances 5-fluorouracil-based chemotherapy via inhibition of proliferative signaling pathways.
    Cell communication and signaling : CCS, 2023, 06-19, Volume: 21, Issue:1

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Humans; Mice; Scu

2023
Restoration of miR-650 leads to down-regulation of KISS1, a possible route involved in overcoming 5-FU resistance and induction of apoptosis in CRC cells in-vitro.
    Molecular biology reports, 2023, Volume: 50, Issue:8

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Down-Regulation; Drug Resista

2023
CX43 down-regulation promotes cell aggressiveness and 5-fluorouracil-resistance by attenuating cell stiffness in colorectal carcinoma.
    Cancer biology & therapy, 2023, 12-31, Volume: 24, Issue:1

    Topics: Cell Communication; Colorectal Neoplasms; Connexin 43; Connexins; Down-Regulation; Fluorouracil; Gap

2023
Poor Prognosis in Patients With Stage III Colorectal Cancer Receiving Adjuvant FOLFOX/CAPOX Therapy Is Predicted by the Presence of Many Poorly Differentiated Clusters.
    Anticancer research, 2023, Volume: 43, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Neoplasm

2023
Targeting PTGES/PGE2 axis enhances sensitivity of colorectal cancer cells to 5-fluorouracil.
    Biochemistry and cell biology = Biochimie et biologie cellulaire, 2023, Dec-01, Volume: 101, Issue:6

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Dinoprostone; Drug Resistance, Neoplasm; Fluorouracil; Human

2023
Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer.
    JAMA network open, 2023, 06-01, Volume: 6, Issue:6

    Topics: Abdominal Pain; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Human

2023
Proteomic Profiling of Chemotherapy Responses in FOLFOX-Resistant Colorectal Cancer Cells.
    International journal of molecular sciences, 2023, Jun-08, Volume: 24, Issue:12

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Proteomics;

2023
PCTAIRE Protein Kinase 1 (PCTK1) Suppresses Proliferation, Stemness, and Chemoresistance in Colorectal Cancer through the BMPR1B-Smad1/5/8 Signaling Pathway.
    International journal of molecular sciences, 2023, Jun-11, Volume: 24, Issue:12

    Topics: Bone Morphogenetic Protein Receptors, Type I; Cell Line, Tumor; Cell Proliferation; Colorectal Neopl

2023
Radiosensitizing Effects of Irinotecan versus Oxaliplatin Alone and in Combination with 5-Fluorouracil on Human Colorectal Cancer Cells.
    International journal of molecular sciences, 2023, Jun-20, Volume: 24, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2023
Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors.
    BMC cancer, 2023, Jul-06, Volume: 23, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm

2023
The B56γ3-containing protein phosphatase 2A attenuates p70S6K-mediated negative feedback loop to enhance AKT-facilitated epithelial-mesenchymal transition in colorectal cancer.
    Cell communication and signaling : CCS, 2023, 07-10, Volume: 21, Issue:1

    Topics: Colorectal Neoplasms; Epithelial-Mesenchymal Transition; Feedback; Fluorouracil; Humans; Phosphatidy

2023
Evaluation and Comparison of Real-World Databases for Conducting Research in Patients With Colorectal Cancer.
    JCO clinical cancer informatics, 2023, Volume: 7

    Topics: Aged; Benchmarking; Colorectal Neoplasms; Databases, Factual; Female; Fluorouracil; Humans; Male; Me

2023
Engineered multitargeting exosomes carrying miR-323a-3p for CRC therapy.
    International journal of biological macromolecules, 2023, Aug-30, Volume: 247

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB

2023
Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2023, Volume: 49, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colonic Neoplasms; Colorecta

2023
Flashback Foreword: Bevacizumab and FOLFOX4 for Colorectal Cancer and Bevacizumab Versus Placebo Plus Oxaliplatin-Based Chemotherapy in Metastatic Colorectal Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 07-20, Volume: 41, Issue:21

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms

2023
Interrogating colorectal cancer metastasis to liver: a search for clinically viable compounds and mechanistic insights in colorectal cancer Patient Derived Organoids.
    Journal of experimental & clinical cancer research : CR, 2023, Jul-17, Volume: 42, Issue:1

    Topics: Colorectal Neoplasms; Fluorouracil; Humans; Interleukin-6; Liver Neoplasms; Organoids; Pentoxifyllin

2023
Dermatan Sulfate/Chitosan Nanoparticles Loaded with an Anti-Inflammatory Peptide Increase the Response of Human Colorectal Cancer Cells to 5-Fluorouracil.
    Macromolecular bioscience, 2023, Volume: 23, Issue:11

    Topics: Anti-Inflammatory Agents; Cell Line, Tumor; Chitosan; Colorectal Neoplasms; Dermatan Sulfate; Fluoro

2023
Inhibition of IRE1 RNase activity modulates tumor cell progression and enhances the response to chemotherapy in colorectal cancer.
    Medical oncology (Northwood, London, England), 2023, Jul-22, Volume: 40, Issue:9

    Topics: Animals; Apoptosis; Colorectal Neoplasms; Endoribonucleases; Fluorouracil; Mice; Mice, Inbred BALB C

2023
CRISPR/Cas9-mediated inactivation of miR-34a and miR-34b/c in HCT116 colorectal cancer cells: comprehensive characterization after exposure to 5-FU reveals EMT and autophagy as key processes regulated by miR-34.
    Cell death and differentiation, 2023, Volume: 30, Issue:8

    Topics: Autophagy; Cell Line, Tumor; Colorectal Neoplasms; CRISPR-Cas Systems; Fluorouracil; Gene Expression

2023
PAIP 2020: Microsatellite instability prediction in colorectal cancer.
    Medical image analysis, 2023, Volume: 89

    Topics: Artificial Intelligence; Colorectal Neoplasms; Fluorouracil; Humans; Microsatellite Instability; Pro

2023
Propolis Enhances 5-Fluorouracil Mediated Antitumor Efficacy and Reduces Side Effects in Colorectal Cancer: An in Vitro and in Vivo Study.
    Chemistry & biodiversity, 2023, Volume: 20, Issue:9

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; F

2023
In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells.
    Current oncology (Toronto, Ont.), 2023, 06-27, Volume: 30, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Agents; Aspirin; bcl-2-Associated X Protein; Caspases; Colorectal Neo

2023
Acetylation of aldehyde dehydrogenase ALDH1L2 regulates cellular redox balance and the chemosensitivity of colorectal cancer to 5-fluorouracil.
    The Journal of biological chemistry, 2023, Volume: 299, Issue:9

    Topics: Acetylation; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Re

2023
Targeting proteasomal deubiquitinases USP14 and UCHL5 with b-AP15 reduces 5-fluorouracil resistance in colorectal cancer cells.
    Acta pharmacologica Sinica, 2023, Volume: 44, Issue:12

    Topics: Animals; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil;

2023
Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting.
    BMC cancer, 2023, Aug-08, Volume: 23, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Col

2023
Peficitinib ameliorates 5-fluorouracil-induced intestinal damage by inhibiting aging, inflammatory factors and oxidative stress.
    International immunopharmacology, 2023, Volume: 123

    Topics: Animals; Cellular Senescence; Colorectal Neoplasms; Fluorouracil; Humans; Intestinal Mucosa; Mice; M

2023
SIRT1 promotes the progression and chemoresistance of colorectal cancer through the p53/miR-101/KPNA3 axis.
    Cancer biology & therapy, 2023, 12-31, Volume: 24, Issue:1

    Topics: alpha Karyopherins; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neo

2023
Combined Hepatic Arterial Infusion Pump and Systemic Chemotherapy in the Modern Era for Chemotherapy-Naive Patients with Unresectable Colorectal Liver Metastases.
    Annals of surgical oncology, 2023, Volume: 30, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery;

2023
Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study.
    Cancer medicine, 2023, Volume: 12, Issue:18

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Prod

2023
ASO Visual Abstract: Combined Hepatic Artery Infusion Pump and Systemic Chemotherapy in the Modern Era for Chemotherapy-Naive Patients with Unresectable Colorectal Liver Metastases.
    Annals of surgical oncology, 2023, Volume: 30, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery;

2023
Rebound increase in microRNA levels at the end of 5-FU-based therapy in colorectal cancer patients.
    Scientific reports, 2023, 08-30, Volume: 13, Issue:1

    Topics: Circulating MicroRNA; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; MicroRNAs

2023
A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer.
    Cancer chemotherapy and pharmacology, 2023, Volume: 92, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Capecitabine; Col

2023
Tumor-associated macrophages confer colorectal cancer 5-fluorouracil resistance by promoting MRP1 membrane translocation via an intercellular CXCL17/CXCL22-CCR4-ATF6-GRP78 axis.
    Cell death & disease, 2023, 09-01, Volume: 14, Issue:9

    Topics: Activating Transcription Factor 6; Chemokines, CXC; Colorectal Neoplasms; Endoplasmic Reticulum Chap

2023
Targeting transforming growth factor beta (TGF-β) using Pirfenidone, a potential repurposing therapeutic strategy in colorectal cancer.
    Scientific reports, 2023, 09-01, Volume: 13, Issue:1

    Topics: Cadherins; Colorectal Neoplasms; Fluorouracil; Humans; Pyridones; Tumor Microenvironment

2023
Vactosertib potently improves anti-tumor properties of 5-FU for colon cancer.
    Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2023, Volume: 31, Issue:2

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; F

2023
Achyrocline B (3,5 dihydroxy-6,7,8-trimethoxyflavone) synergizes with 5-fluorouracil allowing for dose reduction and reduced off-target toxicity in the treatment of colonic and pancreatic cancers.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023, Volume: 167

    Topics: Achyrocline; Animals; Carcinoma; Colonic Neoplasms; Colorectal Neoplasms; Drug Tapering; Fluorouraci

2023
ASO Visual Abstract: Current Practices in Hepatic Artery Infusion (HAI) Chemotherapy-An International Survey of the HAI Consortium Research Network.
    Annals of surgical oncology, 2023, Volume: 30, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery;

2023
Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study.
    Journal of geriatric oncology, 2023, Volume: 14, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms;

2023
LIMK1 m
    Cancer letters, 2023, 11-01, Volume: 576

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Flu

2023
PTEN-induced kinase 1 gene single-nucleotide variants as biomarkers in adjuvant chemotherapy for colorectal cancer: a retrospective study.
    BMC gastroenterology, 2023, Oct-02, Volume: 23, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Chemotherapy, Adjuvan

2023
scFv biofunctionalized nanoparticles to effective and safe targeting of CEA-expressing colorectal cancer cells.
    Journal of nanobiotechnology, 2023, Oct-02, Volume: 21, Issue:1

    Topics: Carcinoembryonic Antigen; Colorectal Neoplasms; Fluorouracil; Humans; Nanoparticles; Single-Chain An

2023
Adjuvant Hepatic Artery Infusion Chemotherapy: Still Swimming in Dark Water?
    Annals of surgical oncology, 2024, Volume: 31, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C

2024
Expression of CD44 is regulated by ELF3 in 5-FU treated colorectal cancer cells.
    Gene, 2024, Jan-20, Volume: 892

    Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; DNA-Binding Proteins; Drug Resistance, Neoplasm;

2024
The role of p62 in cell death and survival of 5-fluorouracil and oxaliplatin-resistant colorectal cancer cells.
    Journal of cellular biochemistry, 2023, Volume: 124, Issue:11

    Topics: Apoptosis; Cell Death; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorourac

2023
Does statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer? A single-center observational study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023, Oct-28, Volume: 31, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neo

2023
In vitro co-delivery of 5-fluorouracil and all-trans retinoic acid by PEGylated liposomes for colorectal cancer treatment.
    Molecular biology reports, 2023, Volume: 50, Issue:12

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Lipopolysaccharides; Liposomes; Polyet

2023
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 195

    Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Col

2023
FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma.
    Anticancer research, 2023, Volume: 43, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Colorectal Neoplasms; Fluorou

2023
Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling.
    Journal for immunotherapy of cancer, 2019, 08-08, Volume: 7, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; CCAAT-Enhancer-Binding Protein-beta; Cell L

2019
Laparoscopic versus open two-stage hepatectomy for bilobar colorectal liver metastases: A bi-institutional, propensity score-matched study.
    Surgery, 2019, Volume: 166, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot

2019
Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer.
    Scientific reports, 2019, 08-08, Volume: 9, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2019
Green encapsulation of LDH(Zn/Al)-5-Fu with carboxymethyl cellulose biopolymer; new nanovehicle for oral colorectal cancer treatment.
    International journal of biological macromolecules, 2019, Oct-15, Volume: 139

    Topics: Administration, Oral; Capsules; Carboxymethylcellulose Sodium; Colorectal Neoplasms; Drug Carriers;

2019
Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Aged; Alternative Splicing; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antineoplastic Co

2019
MCT1 relieves osimertinib-induced CRC suppression by promoting autophagy through the LKB1/AMPK signaling.
    Cell death & disease, 2019, 08-13, Volume: 10, Issue:8

    Topics: Acrylamides; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Aniline Compounds;

2019
NSG mice as hosts for oncological precision medicine.
    Laboratory investigation; a journal of technical methods and pathology, 2020, Volume: 100, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Huma

2020
Colorectal Adenocarcinoma: Imaging using 5-Fluoracil Nanoparticles Labeled with Technetium 99 Metastable.
    Current pharmaceutical design, 2019, Volume: 25, Issue:30

    Topics: Adenocarcinoma; Colorectal Neoplasms; Fluorouracil; Humans; Nanoparticles; Radiopharmaceuticals; Tec

2019
Dynamic Changes in Normal Liver Parenchymal Volume During Chemotherapy for Colorectal Cancer: Liver Atrophy as an Alternate Marker of Chemotherapy-Associated Liver Injury.
    Annals of surgical oncology, 2019, Volume: 26, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrophy; Bevacizumab

2019
Downregulation of CD44v6 Enhances Chemosensitivity by Promoting Apoptosis and Inhibiting Autophagy in Colorectal Cancer HT29 Cells.
    Annals of clinical and laboratory science, 2019, Volume: 49, Issue:4

    Topics: Apoptosis; Autophagy; Beclin-1; Cell Proliferation; Colorectal Neoplasms; Down-Regulation; Fluoroura

2019
Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings.
    Journal of global oncology, 2019, Volume: 5

    Topics: Adult; Aged; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Middle Aged; N

2019
Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer.
    BMC cancer, 2019, Sep-05, Volume: 19, Issue:1

    Topics: Afatinib; Antibodies, Monoclonal, Humanized; Caco-2 Cells; Cell Survival; Colorectal Neoplasms; Drug

2019
Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer.
    International journal of molecular sciences, 2019, Sep-05, Volume: 20, Issue:18

    Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm;

2019
Impact of age on toxicity and efficacy of 5-FU-based combination chemotherapy among patients with metastatic colorectal cancer; a pooled analysis of five randomized trials.
    International journal of colorectal disease, 2019, Volume: 34, Issue:10

    Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2019
CAC1 knockdown reverses drug resistance through the downregulation of P-gp and MRP-1 expression in colorectal cancer.
    PloS one, 2019, Volume: 14, Issue:9

    Topics: Adult; Aged; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily

2019
Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients.
    Scientific reports, 2019, 09-10, Volume: 9, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2019
Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatinum in a Patient-derived Orthotopic Xenograft Mouse Model.
    Anticancer research, 2019, Volume: 39, Issue:9

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sul

2019
Clinical Impact of FOLFOXIRI Aiming for Conversion Surgery in Unresectable Multiple Colorectal Liver Metastasis.
    Anticancer research, 2019, Volume: 39, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit

2019
In-Vivo Retention of 5-Fluorouracil Using
    Scientific reports, 2019, 09-13, Volume: 9, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Fluor

2019
Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy.
    Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colorectal Neoplasms; Female; F

2019
miR-133b suppresses colorectal cancer cell stemness and chemoresistance by targeting methyltransferase DOT1L.
    Experimental cell research, 2019, 12-01, Volume: 385, Issue:1

    Topics: Cell Line; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Down-Regulation; Drug Resista

2019
Bacterial Biofilm Bioinspired Persistent Luminescence Nanoparticles with Gut-Oriented Drug Delivery for Colorectal Cancer Imaging and Chemotherapy.
    ACS applied materials & interfaces, 2019, Oct-09, Volume: 11, Issue:40

    Topics: Animals; Biofilms; Cell Line; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Diagnostic Imag

2019
Evaluation of a new histological grading system for assessing the response to chemotherapy of peritoneal metastases from colorectal cancer: A mouse model study.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2020, Volume: 46, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Models, Anima

2020
miR-375-3p suppresses tumorigenesis and partially reverses chemoresistance by targeting YAP1 and SP1 in colorectal cancer cells.
    Aging, 2019, 09-22, Volume: 11, Issue:18

    Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carcinogenesis; Cell Line, Tumor; Cell

2019
The clinical conundrum of managing 5-fluorouracil-induced vasospasm in colorectal carcinoma.
    Cancer, 2019, 12-15, Volume: 125, Issue:24

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Neop

2019
EMAST status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for Stage II/III colorectal cancer.
    Journal of cellular physiology, 2020, Volume: 235, Issue:4

    Topics: Aged; Chemotherapy, Adjuvant; Colon; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorourac

2020
Ganoderma Lucidum induces oxidative DNA damage and enhances the effect of 5-Fluorouracil in colorectal cancer in vitro and in vivo.
    Mutation research. Genetic toxicology and environmental mutagenesis, 2019, Volume: 845

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Division; Cell Line, Tumor; Colorecta

2019
Differential Survival Benefits of 5-Fluorouracil-Based Adjuvant Chemotherapy for Patients With Microsatellite-Stable Stage III Colorectal Cancer According to the Tumor Budding Status: A Retrospective Analysis.
    Diseases of the colon and rectum, 2019, Volume: 62, Issue:11

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Fema

2019
A novel therapeutic anti‑CD55 monoclonal antibody inhibits the proliferation and metastasis of colorectal cancer cells.
    Oncology reports, 2019, Volume: 42, Issue:6

    Topics: Antibodies, Monoclonal; CD55 Antigens; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Comp

2019
RPL22L1 induction in colorectal cancer is associated with poor prognosis and 5-FU resistance.
    PloS one, 2019, Volume: 14, Issue:10

    Topics: Animals; Cell Proliferation; Colorectal Neoplasms; DNA Modification Methylases; DNA Repair Enzymes;

2019
Multicentre study of perioperative
    BJS open, 2019, Volume: 3, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast

2019
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
    Science translational medicine, 2019, 10-09, Volume: 11, Issue:513

    Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan;

2019
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
    Science translational medicine, 2019, 10-09, Volume: 11, Issue:513

    Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan;

2019
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
    Science translational medicine, 2019, 10-09, Volume: 11, Issue:513

    Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan;

2019
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.
    Science translational medicine, 2019, 10-09, Volume: 11, Issue:513

    Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Female; Fluorouracil; Humans; Irinotecan;

2019
Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway.
    Oncogene, 2020, Volume: 39, Issue:2

    Topics: Animals; Apoptosis; Base Sequence; Colorectal Neoplasms; Dichloroacetic Acid; Drug Resistance, Neopl

2020
[Effectiveness of Allergy Regimen for Allergic Reactions to Oxaliplatin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Hypersensitivity; Fluorou

2019
[A Case Altered Consciousness Due to 5-Fluorouracil-Induced Hyperammonemia in a Patient with Recurrent Colorectal Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Consciousn

2019
Validation of computational determination of microsatellite status using whole exome sequencing data from colorectal cancer patients.
    BMC cancer, 2019, Oct-21, Volume: 19, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neopl

2019
Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study.
    Clinical colorectal cancer, 2020, Volume: 19, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc

2020
Pharmacokinetics-based Dose Management of 5-Fluorouracil Clinical Research in Advanced Colorectal Cancer Treatment.
    Mini reviews in medicinal chemistry, 2020, Volume: 20, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Dose-Response

2020
Ferritin Light Chain (FTL) competes with long noncoding RNA Linc00467 for miR-133b binding site to regulate chemoresistance and metastasis of colorectal cancer.
    Carcinogenesis, 2020, 06-17, Volume: 41, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Apoferritins; Apoptosis; Binding Sites; Biomarkers, Tumor;

2020
Solid lipid nanoparticles self-assembled from spray dried microparticles.
    International journal of pharmaceutics, 2019, Dec-15, Volume: 572

    Topics: Administration, Oral; Aerosols; Caco-2 Cells; Cell Survival; Colorectal Neoplasms; Delayed-Action Pr

2019
Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis.
    Cancer research, 2020, 02-01, Volume: 80, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Evolution; Clinical Trials, Phase III as

2020
Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab.
    Targeted oncology, 2019, Volume: 14, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col

2019
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients.
    Journal of cancer research and clinical oncology, 2020, Volume: 146, Issue:2

    Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto

2020
MKK3 sustains cell proliferation and survival through p38DELTA MAPK activation in colorectal cancer.
    Cell death & disease, 2019, 11-06, Volume: 10, Issue:11

    Topics: Autophagy; Cell Proliferation; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Ge

2019
Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients.
    Pharmacogenomics, 2019, Volume: 20, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Carboxylic Ester Hydrolases; Colorectal Neoplasms; Disease-Free Surv

2019
APC truncating mutations in Middle Eastern Population: Tankyrase inhibitor is an effective strategy to sensitize APC mutant CRC To 5-FU chemotherapy.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 121

    Topics: Adenomatous Polyposis Coli; Aged; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neop

2020
Combination of Trabectedin With Oxaliplatinum and 5-Fluorouracil Arrests a Primary Colorectal Cancer in a Patient-derived Orthotopic Xenograft Mouse Model.
    Anticancer research, 2019, Volume: 39, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Cell Proliferation;

2019
Evaluation and Clinical Significance of Jagged-1-activated Notch Signaling by APEX1 in Colorectal Cancer.
    Anticancer research, 2019, Volume: 39, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Co

2019
BET inhibitor bromosporine enhances 5-FU effect in colorectal cancer cells.
    Biochemical and biophysical research communications, 2020, 01-22, Volume: 521, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carbamates; Cell Cycle; Cell Cyc

2020
[Primary appendiceal signet ring cell carcinoma:a case report].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2019, Volume: 116, Issue:11

    Topics: Appendiceal Neoplasms; Carcinoma, Signet Ring Cell; Colorectal Neoplasms; Female; Fluorouracil; Huma

2019
Cost-effectiveness analysis of selective first-line use of biologics for unresectable
    Current oncology (Toronto, Ont.), 2019, Volume: 26, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Produ

2019
Insulin enhancement of the antitumor activity of chemotherapeutic agents in colorectal cancer is linked with downregulating PIK3CA and GRB2.
    Scientific reports, 2019, 11-12, Volume: 9, Issue:1

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Caco-2 Cells; Cell Line, Tumor; Class I Phosphati

2019
Identification of bioactive compounds in Lactobacillus paracasei subsp. paracasei NTU 101-fermented reconstituted skimmed milk and their anti-cancer effect in combination with 5-fluorouracil on colorectal cancer cells.
    Food & function, 2019, Dec-11, Volume: 10, Issue:12

    Topics: Antineoplastic Agents; Autophagy-Related Protein 5; Cell Line, Tumor; Cell Survival; Colorectal Neop

2019
ECOG performance score 0 versus 1: impact on efficacy and safety of first-line 5-FU-based chemotherapy among patients with metastatic colorectal cancer included in five randomized trials.
    International journal of colorectal disease, 2019, Volume: 34, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne

2019
Upregulated OCT3 has the potential to improve the survival of colorectal cancer patients treated with (m)FOLFOX6 adjuvant chemotherapy.
    International journal of colorectal disease, 2019, Volume: 34, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; China; Colorect

2019
Optic neuritis induced by 5-fluorouracil chemotherapy: Case report and review of the literature.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:2

    Topics: Administration, Intravenous; Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Glucocortico

2020
PRDM14 promotes malignant phenotype and correlates with poor prognosis in colorectal cancer.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:7

    Topics: Adenocarcinoma; Adenoma; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation;

2020
Modified TLR-mediated downregulation of miR-125b-5p enhances CD248 (endosialin)-induced metastasis and drug resistance in colorectal cancer cells.
    Molecular carcinogenesis, 2020, Volume: 59, Issue:2

    Topics: Antigens, CD; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement;

2020
LncRNA HAND2-AS1 inhibits 5-fluorouracil resistance by modulating miR-20a/PDCD4 axis in colorectal cancer.
    Cellular signalling, 2020, Volume: 66

    Topics: Adenocarcinoma; Animals; Apoptosis Regulatory Proteins; Cell Line, Tumor; Colorectal Neoplasms; Drug

2020
Clerodane Diterpene Ameliorates Inflammatory Bowel Disease and Potentiates Cell Apoptosis of Colorectal Cancer.
    Biomolecules, 2019, 11-21, Volume: 9, Issue:12

    Topics: Animals; Apoptosis; Azoxymethane; Biomarkers, Tumor; Caco-2 Cells; Cell Cycle; Cell Proliferation; C

2019
Qualitative transcriptional signature for predicting pathological response of colorectal cancer to FOLFOX therapy.
    Cancer science, 2020, Volume: 111, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Evaluation Studies as Topic; F

2020
Knockdown of TMEM45A overcomes multidrug resistance and epithelial-mesenchymal transition in human colorectal cancer cells through inhibition of TGF-β signalling pathway.
    Clinical and experimental pharmacology & physiology, 2020, Volume: 47, Issue:3

    Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship,

2020
LncRNA NEAT1 knockdown attenuates autophagy to elevate 5-FU sensitivity in colorectal cancer via targeting miR-34a.
    Cancer medicine, 2020, Volume: 9, Issue:3

    Topics: 3' Untranslated Regions; Apoptosis; Autophagy; Autophagy-Related Proteins; Cell Proliferation; Cell

2020
Atypical Protein Kinase-C inhibitors exhibit a synergistic effect in facilitating DNA damaging effect of 5-fluorouracil in colorectal cancer cells.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 121

    Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; DNA Damage; DNA Fragmentation; DNA

2020
Combination of Trabectedin With Irinotecan, Leucovorin and 5-Fluorouracil Arrests Primary Colorectal Cancer in an Imageable Patient-derived Orthotopic Xenograft Mouse Model.
    Anticancer research, 2019, Volume: 39, Issue:12

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Colorectal Neopl

2019
FoxO3 reverses 5-fluorouracil resistance in human colorectal cancer cells by inhibiting the Nrf2/TR1 signaling pathway.
    Cancer letters, 2020, 02-01, Volume: 470

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Auranofin; Cell Line, Tumor; Colorectal Neo

2020
Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial.
    BMJ open, 2019, 12-08, Volume: 9, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Colorectal Neopla

2019
Promotion of the Warburg effect is associated with poor benefit from adjuvant chemotherapy in colorectal cancer.
    Cancer science, 2020, Volume: 111, Issue:2

    Topics: Adult; Aged; Antioxidants; Carbohydrate Metabolism; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fe

2020
Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK.
    International journal of molecular sciences, 2019, Dec-09, Volume: 20, Issue:24

    Topics: Animals; Caco-2 Cells; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neo

2019
Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea.
    Journal of molecular medicine (Berlin, Germany), 2020, Volume: 98, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2020
Predictive modeling in colorectal cancer: time to move beyond consensus molecular subtypes.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 11-01, Volume: 30, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Cetuxi

2019
Characterization of CD44-positive Cancer Stem-like Cells in COLO 201 Cells.
    Anticancer research, 2020, Volume: 40, Issue:1

    Topics: Animals; Biomarkers; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Cell Transformation, Neopla

2020
A retrospective observational study to estimate the attrition of patients across lines of systemic treatment for metastatic colorectal cancer in Canada.
    Current oncology (Toronto, Ont.), 2019, Volume: 26, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2019
Cooperation of SRPK2, Numb and p53 in the malignant biology and chemosensitivity of colorectal cancer.
    Bioscience reports, 2020, 01-31, Volume: 40, Issue:1

    Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Colorectal Neoplasms; Disease Progre

2020
Relaxin-FOLFOX-IL-12 triple combination therapy engages memory response and achieves long-term survival in colorectal cancer liver metastasis.
    Journal of controlled release : official journal of the Controlled Release Society, 2020, 03-10, Volume: 319

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Interle

2020
Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy.
    BMC medical genetics, 2020, 01-03, Volume: 21, Issue:1

    Topics: Adenomatous Polyposis Coli Protein; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bev

2020
Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer.
    Advances in therapy, 2020, Volume: 37, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot

2020
A pre-existing population of ZEB2
    Journal of experimental & clinical cancer research : CR, 2020, Jan-08, Volume: 39, Issue:1

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epit

2020
Expression quantitative trait loci in ABC transporters are associated with survival in 5-FU treated colorectal cancer patients.
    Mutagenesis, 2020, 07-11, Volume: 35, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Case-Contro

2020
Prognostic and Diagnostic Values of miR-506 and SPON 1 in Colorectal Cancer with Clinicopathological Considerations.
    Journal of gastrointestinal cancer, 2021, Volume: 52, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Chemotherap

2021
Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2020, Volume: 59, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardio

2020
SPZ1 promotes deregulation of Bim to boost apoptosis resistance in colorectal cancer.
    Clinical science (London, England : 1979), 2020, 01-31, Volume: 134, Issue:2

    Topics: Animals; Apoptosis; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Bcl-2-Like Protein

2020
Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer.
    International journal of molecular sciences, 2020, Jan-08, Volume: 21, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Colorectal Neo

2020
Hepatic arterial infusion chemotherapy for colorectal liver metastases revisited.
    HPB : the official journal of the International Hepato Pancreato Biliary Association, 2020, Volume: 22, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery;

2020
Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo.
    Cancer science, 2020, Volume: 111, Issue:4

    Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Carcinoma; Cell Line, Tumor; Cell Proliferation; Col

2020
Synthesis, CYP24A1-Dependent Metabolism and Antiproliferative Potential against Colorectal Cancer Cells of 1,25-Dihydroxyvitamin D
    International journal of molecular sciences, 2020, Jan-18, Volume: 21, Issue:2

    Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Drug Synergism; Epit

2020
Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study.
    International journal of cancer, 2020, 07-01, Volume: 147, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorect

2020
EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020, Volume: 28, Issue:10

    Topics: Acneiform Eruptions; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols;

2020
(Curcumin+sildenafil) enhances the efficacy of 5FU and anti-PD1 therapies in vivo.
    Journal of cellular physiology, 2020, Volume: 235, Issue:10

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line,

2020
Hyaluronic acid-decorated liposomal nanoparticles for targeted delivery of 5-fluorouracil into HT-29 colorectal cancer cells.
    Journal of cellular physiology, 2020, Volume: 235, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Colorectal Neoplasms; Dr

2020
Review of metastatic colorectal cancer treatment pathways and early clinical experience of trifluridine/tipiracil in the UK named patient programme.
    BMC cancer, 2020, Feb-03, Volume: 20, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr

2020
Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway.
    Journal of the National Cancer Institute, 2020, 09-01, Volume: 112, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Cetu

2020
CXCL-13 Regulates Resistance to 5-Fluorouracil in Colorectal Cancer.
    Cancer research and treatment, 2020, Volume: 52, Issue:2

    Topics: Aged; Animals; Chemokine CXCL13; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorourac

2020
Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study.
    Medicine, 2020, Volume: 99, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cross-Sectional Studies; Femal

2020
Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
    The oncologist, 2020, Volume: 25, Issue:2

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neop

2020
Knockdown of Atg7 Induces Nuclear-LC3 Dependent Apoptosis and Augments Chemotherapy in Colorectal Cancer Cells.
    International journal of molecular sciences, 2020, Feb-07, Volume: 21, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 7; Beclin-1;

2020
Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
    International journal of colorectal disease, 2020, Volume: 35, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Sur

2020
5-Nitrouracil stabilizes the plasma concentration values of 5-FU in colorectal cancer patients receiving capecitabine.
    Scientific reports, 2020, 02-17, Volume: 10, Issue:1

    Topics: Adult; Antimetabolites, Antineoplastic; Biotransformation; Capecitabine; Colorectal Neoplasms; Femal

2020
Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China.
    BMC cancer, 2020, Feb-18, Volume: 20, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizu

2020
MicroRNA-375-3p enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer.
    Cancer science, 2020, Volume: 111, Issue:5

    Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neop

2020
Efficacy and Safety of Modified FOLFOXIRI+α in the Treatment of Advanced and Recurrent Colorectal Cancer: A Single-center Experience.
    Internal medicine (Tokyo, Japan), 2020, May-15, Volume: 59, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N

2020
S1PR2 inhibitors potently reverse 5-FU resistance by downregulating DPD expression in colorectal cancer.
    Pharmacological research, 2020, Volume: 155

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Dihydrouracil Dehy

2020
Nanocomplexes loaded with miR-128-3p for enhancing chemotherapy effect of colorectal cancer through dual-targeting silence the activity of PI3K/AKT and MEK/ERK pathway.
    Drug delivery, 2020, Volume: 27, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Male; MAP Kina

2020
Hepatic Arterial Infusion Chemotherapy of 5-Fluorouracil for Patients with Unresectable Liver Metastases from Colorectal Cancer Refractory to Standard Systemic Chemotherapy: A Multicenter Retrospective Study.
    Oncology, 2020, Volume: 98, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2020
Adjuvant therapy for colorectal cancer in 2020: has anything changed this millennium?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:4

    Topics: Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxaliplatin

2020
Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance.
    Molecular cancer, 2020, 02-25, Volume: 19, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Biomarkers, Tumor;

2020
Casein Kinase 2α Enhances 5-Fluorouracil Resistance in Colorectal Cancer Cells by Inhibiting Endoplasmic Reticulum Stress.
    Anticancer research, 2020, Volume: 40, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Casein Kinase II; Cell Line, Tumor; Colorectal Neopl

2020
Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer.
    Anticancer research, 2020, Volume: 40, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2020
Diffuse reflectance spectroscopy to monitor murine colorectal tumor progression and therapeutic response.
    Journal of biomedical optics, 2020, Volume: 25, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Disease Models, A

2020
CircDDX17 reduces 5-fluorouracil resistance and hinders tumorigenesis in colorectal cancer by regulating miR-31-5p/KANK1 axis.
    European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Carcinogenesis; Cell

2020
Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
    Clinical colorectal cancer, 2020, Volume: 19, Issue:2

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Prot

2020
Predicting the effect of 5-fluorouracil-based adjuvant chemotherapy on colorectal cancer recurrence: A model using gene expression profiles.
    Cancer medicine, 2020, Volume: 9, Issue:9

    Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplas

2020
[A Case of Nephrotic Syndrome Induced by FOLFIRI plus Ramucirumab for Metastatic Descending Colon Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2019
[Questionnaire Survey on Adjuvant Chemotherapy for Colorectal Cancer in Yamaguchi Prefecture].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro

2019
[Experience of Using Aflibercept Beta and FOLFIRI Chemotherapy for Metastatic Colorectal Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:13

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2019
Yeast Extract Induces Apoptosis and Cell Cycle Arrest via Activating p38 Signal Pathway in Colorectal Cancer Cells.
    Annals of clinical and laboratory science, 2020, Volume: 50, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Prol

2020
IRX5 prompts genomic instability in colorectal cancer cells.
    Journal of cellular biochemistry, 2020, Volume: 121, Issue:11

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Biomarkers, Tumo

2020
FOLFOXIRI reintroduction in metastatic colorectal cancer.
    The Lancet. Oncology, 2020, Volume: 21, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu

2020
Prodigiosin impairs autophagosome-lysosome fusion that sensitizes colorectal cancer cells to 5-fluorouracil-induced cell death.
    Cancer letters, 2020, 07-01, Volume: 481

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagosomes; Autophagy; Caco-2 Cells; Cell Death; Cell

2020
Assessment of pharmacokinetic variations of capecitabine after multiple administration in rats: a physiologically based pharmacokinetic model.
    Cancer chemotherapy and pharmacology, 2020, Volume: 85, Issue:5

    Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Capecitabine; Carboxylesteras

2020
Prognostic value of carbohydrate antigen125 and carcino embryonic antigen expression in patients with colorectal carcinoma and its guiding significance for chemotherapy.
    Medicine, 2020, Volume: 99, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Cape

2020
Calebin A Potentiates the Effect of 5-FU and TNF-β (Lymphotoxin α) against Human Colorectal Cancer Cells: Potential Role of NF-κB.
    International journal of molecular sciences, 2020, Mar-31, Volume: 21, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Line; Cell Proliferation; Cell Survival; C

2020
Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
    BMC gastroenterology, 2020, Apr-07, Volume: 20, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo

2020
Comparative lipidomics of 5-Fluorouracil-sensitive and -resistant colorectal cancer cells reveals altered sphingomyelin and ceramide controlled by acid sphingomyelinase (SMPD1).
    Scientific reports, 2020, 04-09, Volume: 10, Issue:1

    Topics: Cell Line, Tumor; Ceramides; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Fluor

2020
Nano Codelivery of Oxaliplatin and Folinic Acid Achieves Synergistic Chemo-Immunotherapy with 5-Fluorouracil for Colorectal Cancer and Liver Metastasis.
    ACS nano, 2020, 04-28, Volume: 14, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans;

2020
A retrospective analysis of plasma concentration monitoring of fluorouracil in patients with advanced colorectal cancer.
    European journal of hospital pharmacy : science and practice, 2020, Volume: 27, Issue:e1

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne

2020
Characterization of a p53/miR-34a/CSF1R/STAT3 Feedback Loop in Colorectal Cancer.
    Cellular and molecular gastroenterology and hepatology, 2020, Volume: 10, Issue:2

    Topics: Cell Line, Tumor; Colectomy; Colon; Colorectal Neoplasms; CpG Islands; DNA Methylation; Drug Resista

2020
A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials.
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 131

    Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Campt

2020
Association between aberrant dynein cytoplasmic 1 light intermediate chain 1 expression levels, mucins and chemosensitivity in colorectal cancer.
    Molecular medicine reports, 2020, Volume: 22, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Cytoplasmic Dyneins; F

2020
Knockdown of the α5 laminin chain affects differentiation of colorectal cancer cells and their sensitivity to chemotherapy.
    Biochimie, 2020, Volume: 174

    Topics: Antimetabolites, Antineoplastic; Cell Dedifferentiation; Colorectal Neoplasms; Fluorouracil; Gene Kn

2020
TUSC3 induces drug resistance and cellular stemness via Hedgehog signaling pathway in colorectal cancer.
    Carcinogenesis, 2020, 12-31, Volume: 41, Issue:12

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Prolifer

2020
Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study.
    BMC cancer, 2020, Apr-28, Volume: 20, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fema

2020
Comparison of Cell and Organoid-Level Analysis of Patient-Derived 3D Organoids to Evaluate Tumor Cell Growth Dynamics and Drug Response.
    SLAS discovery : advancing life sciences R & D, 2020, Volume: 25, Issue:7

    Topics: Anthracyclines; Cell Proliferation; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Fluorour

2020
Synthetic antiprotozoal thiazolide drug induced apoptosis in colorectal cancer cells: implications of IL-6/JAK2/STAT3 and p53/caspases-dependent signaling pathways based on molecular docking and in vitro study.
    Molecular and cellular biochemistry, 2020, Volume: 469, Issue:1-2

    Topics: Antineoplastic Agents; Antiprotozoal Agents; Apoptosis; Caspases; Cell Cycle; Cell Survival; Colorec

2020
Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases.
    Journal of cancer research and clinical oncology, 2020, Volume: 146, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2020
Combined Therapeutic Effects of
    International journal of nanomedicine, 2020, Volume: 15

    Topics: Animals; Antimetabolites, Antineoplastic; Blood Circulation; Cell Line, Tumor; Cell Survival; Cetuxi

2020
Cetuximab Maintenance Therapy in Patients with Unresectable Wild-Type RAS and BRAF Metastatic Colorectal Cancer: A Single-Institute Prospective Study.
    Advances in therapy, 2020, Volume: 37, Issue:6

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neopl

2020
[Clinical Efficacy of mFOLFOX6 for Advanced Gastric Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Japan; L

2020
Toosendanin-induced apoptosis in colorectal cancer cells is associated with the κ-opioid receptor/β-catenin signaling axis.
    Biochemical pharmacology, 2020, Volume: 177

    Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; A

2020
[Perioperative Chemotherapies for Patients with Colorectal Liver Metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Combined Modality

2020
Emerging RAS, BRAF, and EGFR mutations in cell-free DNA of metastatic colorectal patients are associated with both primary and secondary resistance to first-line anti-EGFR therapy.
    International journal of clinical oncology, 2020, Volume: 25, Issue:8

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell-Free Nucleic Acids; Ce

2020
Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer.
    The journal of pathology. Clinical research, 2020, Volume: 6, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms;

2020
Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?
    Journal of chemotherapy (Florence, Italy), 2020, Volume: 32, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2020
Defining Early Multidisciplinary Goals: NEXTO Trial in High-Risk Colorectal Cancer with Liver Metastases.
    Annals of surgical oncology, 2020, Volume: 27, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase II as Topic; Color

2020
Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy.
    Scientific reports, 2020, 05-29, Volume: 10, Issue:1

    Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Binding Si

2020
Cutaneous metastasis of ascending colon cancer harboring a BRAF V600E mutation: A rare case report.
    Medicine, 2020, May-22, Volume: 99, Issue:21

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms;

2020
TRIBE2 results and toxicity.
    The Lancet. Oncology, 2020, Volume: 21, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu

2020
TRIBE2 results and toxicity.
    The Lancet. Oncology, 2020, Volume: 21, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu

2020
Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment.
    Molecules (Basel, Switzerland), 2020, Jun-04, Volume: 25, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Colorectal Neoplasms;

2020
[Three Cases of Augmented Chemotherapy-Induced Peripheral Neuropathy after Changing from mFOLFOX6 to FOLFIRI Therapy in Patients with Colorectal Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2020
Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients.
    BMC cancer, 2020, Jun-16, Volume: 20, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cross-Sect

2020
SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression.
    Oncogene, 2020, Volume: 39, Issue:29

    Topics: Animals; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Fluoro

2020
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials.
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 135

    Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizu

2020
Impact of preoperative chemotherapy on the histological response of patients with peritoneal metastases from colorectal cancer according to peritoneal regression grading score (PRGS) and TRG.
    Surgical oncology, 2020, Volume: 33

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Agents, Immunological; Antineoplastic Combi

2020
Effects of postoperative adjuvant chemotherapy and palliative chemotherapy on the gut microbiome in colorectal cancer.
    Microbial pathogenesis, 2020, Volume: 149

    Topics: Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Gastrointestinal Microbiom

2020
5-Fluorouracil induced dysregulation of the microbiome-gut-brain axis manifesting as depressive like behaviors in rats.
    Biochimica et biophysica acta. Molecular basis of disease, 2020, 10-01, Volume: 1866, Issue:10

    Topics: Animals; Antimetabolites, Antineoplastic; Behavior, Animal; Colorectal Neoplasms; Depression; Diseas

2020
Splenic enlargement induced by preoperative chemotherapy is a useful indicator for predicting liver regeneration after resection for colorectal liver metastases.
    World journal of surgical oncology, 2020, Jun-23, Volume: 18, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hepatect

2020
Enalapril overcomes chemoresistance and potentiates antitumor efficacy of 5-FU in colorectal cancer by suppressing proliferation, angiogenesis, and NF-κB/STAT3-regulated proteins.
    Cell death & disease, 2020, 06-24, Volume: 11, Issue:6

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Color

2020
Synergistic therapy with tangeretin and 5-fluorouracil accelerates the ROS/JNK mediated apoptotic pathway in human colorectal cancer cell.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2020, Volume: 143

    Topics: Apoptosis; Cell Survival; Colorectal Neoplasms; DNA Fragmentation; Down-Regulation; Drug Synergism;

2020
Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:2

    Topics: Acneiform Eruptions; Adenocarcinoma; Administration, Topical; Aloe; Antineoplastic Agents; Antineopl

2021
DJ‑1 is a new prognostic marker and predicts chemotherapy efficacy in colorectal cancer.
    Oncology reports, 2020, Volume: 44, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers,

2020
Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2020, Volume: 18, Issue:7

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;

2020
EGFR inhibition in colorectal cancer with liver metastasis.
    Clinical advances in hematology & oncology : H&O, 2020, Volume: 18, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; ErbB Receptors; Female; Fluoro

2020
Complete Metabolic Response Assessed by FDG PET/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic Colorectal Cancer.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo

2020
FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival.
    Clinical colorectal cancer, 2020, Volume: 19, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2020
Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases.
    JAMA oncology, 2020, 08-01, Volume: 6, Issue:8

    Topics: Aged; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Flu

2020
CTCF promotes colorectal cancer cell proliferation and chemotherapy resistance to 5-FU via the P53-Hedgehog axis.
    Aging, 2020, 07-20, Volume: 12, Issue:16

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; CCCTC-Binding Factor; Cell Proliferation; Color

2020
[The development of a general drug resistance score model based on MIC
    Yi chuan = Hereditas, 2020, Jun-20, Volume: 42, Issue:6

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Reg

2020
NKX6.1 Represses Tumorigenesis, Metastasis, and Chemoresistance in Colorectal Cancer.
    International journal of molecular sciences, 2020, Jul-19, Volume: 21, Issue:14

    Topics: Animals; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Transformation, Ne

2020
The Temperature-Dependent Effectiveness of Platinum-Based Drugs Mitomycin-C and 5-FU during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Cell Lines.
    Cells, 2020, 07-25, Volume: 9, Issue:8

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms

2020
Association of C677T and A1298C
    Anticancer research, 2020, Volume: 40, Issue:8

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne

2020
Involvement of Corticotropin-releasing Hormone-related Peptides in Cellular Stress Caused by Anticancer Drugs in Colorectal Cancer.
    Anticancer research, 2020, Volume: 40, Issue:8

    Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Corticotropin-Releasing Hormone; Fluo

2020
Changes in Immunological Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemoimmunotherapy.
    Anticancer research, 2020, Volume: 40, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorec

2020
Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer.
    Pharmacogenetics and genomics, 2021, Volume: 31, Issue:1

    Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; CDX2 Transcription Factor; Col

2021
Age is an individual risk factor for not being referred to adjuvant chemotherapy in patients resected for UICC III colorectal cancer: a nationwide cohort study.
    Acta oncologica (Stockholm, Sweden), 2020, Volume: 59, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; Colorectal N

2020
FLOX (5-fluorouracil + leucovorin + oxaliplatin) chemotherapy for colorectal cancer leads to long-term orofacial neurotoxicity: a STROBE-guided longitudinal prospective study.
    International journal of clinical oncology, 2020, Volume: 25, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2020
Implementation of a Hepatic Artery Infusion Program: Initial Patient Selection and Perioperative Outcomes of Concurrent Hepatic Artery Infusion and Systemic Chemotherapy for Colorectal Liver Metastases.
    Annals of surgical oncology, 2020, Volume: 27, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery;

2020
Portal Vein Thrombosis in Metastatic Colorectal Cancer During FOLFIRI-bevacizumab Chemotherapy Successfully Treated with Apixaban.
    Internal medicine (Tokyo, Japan), 2021, Jan-01, Volume: 60, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasm

2021
Systemic Chemotherapy for Metastatic Colitis-Associated Cancer Has a Worse Outcome Than Sporadic Colorectal Cancer: Matched Case Cohort Analysis.
    Clinical colorectal cancer, 2020, Volume: 19, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-C

2020
The Potential Anticancer Activity of 5-Fluorouracil Loaded in Cellulose Fibers Isolated from Rice Straw.
    International journal of nanomedicine, 2020, Volume: 15

    Topics: Antimetabolites, Antineoplastic; Cell Line; Cell Line, Tumor; Cellulose; Colorectal Neoplasms; Drug

2020
ASO Author Reflections: Implementation of a New Hepatic Artery Infusion Program for Colorectal Liver Metastases is Safe, Feasible, and Effective.
    Annals of surgical oncology, 2020, Volume: 27, Issue:13

    Topics: Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplas

2020
In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
    Gastroenterology, 2020, Volume: 159, Issue:6

    Topics: Animals; Colon; Colorectal Neoplasms; DNA Demethylation; Drug Resistance, Neoplasm; Female; Fluorour

2020
Hedgehog-GLI signalling promotes chemoresistance through the regulation of ABC transporters in colorectal cancer cells.
    Scientific reports, 2020, 08-19, Volume: 10, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; Cell Line, Tumor; Colorectal Ne

2020
Addressing the variation in adjuvant chemotherapy treatment for colorectal cancer: Can a regional intervention promote national change?
    International journal of cancer, 2021, 02-15, Volume: 148, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot

2021
Andrographis-mediated chemosensitization through activation of ferroptosis and suppression of β-catenin/Wnt-signaling pathways in colorectal cancer.
    Carcinogenesis, 2020, 10-15, Volume: 41, Issue:10

    Topics: Andrographis; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco

2020
Microsatellite instability and sensitivity to fluoropyrimidine and oxaliplatin containing first-line chemotherapy in metastatic colorectal cancer.
    European journal of hospital pharmacy : science and practice, 2020, Volume: 27, Issue:5

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F

2020
Evaluating genomic biomarkers associated with resistance or sensitivity to chemotherapy in patients with advanced breast and colorectal cancer.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Colore

2021
Metformin Inhibited Proliferation and Metastasis of Colorectal Cancer and presented a Synergistic Effect on 5-FU.
    BioMed research international, 2020, Volume: 2020

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colo

2020
Prognostic Value of EGFR Expression for Patients With Stage III Colorectal Cancer Receiving Fluoropyrimidine Metronomic Maintenance Therapy After Radical Resection and Adjuvant Oxaliplatin-Based Chemotherapy.
    Oncology research, 2021, Sep-07, Volume: 28, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Capeci

2021
5-Fluorouracil Rechallenge After Cardiotoxicity.
    The American journal of case reports, 2020, Aug-29, Volume: 21

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Col

2020
Circ_0007031 enhances tumor progression and promotes 5-fluorouracil resistance in colorectal cancer through regulating miR-133b/ABCC5 axis.
    Cancer biomarkers : section A of Disease markers, 2020, Volume: 29, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluoroura

2020
Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases.
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 138

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N

2020
Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury: A Colorectal Cancer Liver Metastasis Treatment Model in Rats.
    Nutrients, 2020, Aug-28, Volume: 12, Issue:9

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2020
Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2020, Volume: 46, Issue:12

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Administration, Intravenous; Adolescent; Adult; Aged; Aged

2020
Rapidly progressive interstitial lung disease under FOLFOX treatment for colorectal cancer associated with systemic sclerosis: two case reports.
    Rheumatology (Oxford, England), 2021, 02-01, Volume: 60, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu

2021
Molecular mechanisms of liver damage during neoadjuvant treatment for hepatic metastases of colorectal cancer.
    Annali italiani di chirurgia, 2020, Volume: 91

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hum

2020
Inhibition of semaphorin 4D enhances chemosensitivity by increasing 5-fluorouracile-induced apoptosis in colorectal cancer cells.
    Molecular biology reports, 2020, Volume: 47, Issue:9

    Topics: Antigens, CD; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorour

2020
Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report.
    Anti-cancer drugs, 2020, Volume: 31, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab;

2020
Case report on 5-fluorouracil induced cerebrovascular accident.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:4

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal N

2021
Hyperammonemia with impaired consciousness caused by continuous 5-fluorouracil infusion for colorectal cancer: A case report.
    International journal of clinical pharmacology and therapeutics, 2020, Volume: 58, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Consciousness; Female; F

2020
The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study.
    Journal of gastrointestinal cancer, 2021, Volume: 52, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Femal

2021
Anti-tumor effect of single-chain antibody to Reg3a in colorectal cancer.
    Experimental cell research, 2020, 11-01, Volume: 396, Issue:1

    Topics: Animals; Antineoplastic Agents, Immunological; Apoptosis; Binding Sites; Cell Line, Tumor; Cell Move

2020
Genetic influence of
    Drug metabolism and personalized therapy, 2020, 09-23, Volume: 35, Issue:4

    Topics: Administration, Oral; Capecitabine; Chromatography, Liquid; Colorectal Neoplasms; Dihydrouracil Dehy

2020
Extrahepatic recurrence rates in patients receiving adjuvant hepatic artery infusion and systemic chemotherapy after complete resection of colorectal liver metastases.
    Journal of surgical oncology, 2020, Volume: 122, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot

2020
Cost-effectiveness of Capecitabine + Irinotecan Versus Leucovorin + Fluorouracil + Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China.
    Clinical therapeutics, 2020, Volume: 42, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; China; Colorectal Neoplas

2020
Cetuximab versus bevacizumab maintenance following prior 8-cycle modified FOLFOXIRI plus cetuximab in Asian postmenopausal women with treatment-naive KRAS and BRAF wild-type metastatic colorectal cancer.
    The Journal of international medical research, 2020, Volume: 48, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neo

2020
Antitumor effects of curcumin on the proliferation, migration and apoptosis of human colorectal carcinoma HCT‑116 cells.
    Oncology reports, 2020, Volume: 44, Issue:5

    Topics: Animals; Apoptosis; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Curcumin; Fluorouracil;

2020
The conversion of RAS status in metastatic colorectal cancer patients after first-line biological agent treatment.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2021, Volume: 23, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Factors; Cetuximab; Colorect

2021
Colorectal cancer cells from patients treated with FOLFOX or CAPOX are resistant to oxaliplatin.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021, Volume: 47, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Colorectal Neoplasms; Drug

2021
Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors.
    BMC cancer, 2020, Oct-02, Volume: 20, Issue:1

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiopoietin-2; Antineoplastic Combined Chemothera

2020
Inhibitory effect of bound polyphenol from foxtail millet bran on miR-149 methylation increases the chemosensitivity of human colorectal cancer HCT-8/Fu cells.
    Molecular and cellular biochemistry, 2021, Volume: 476, Issue:2

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Proliferation; Colorectal Neoplasms; D

2021
In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 01-01, Volume: 27, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biological Assay; Bi

2021
Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma.
    Surgical oncology, 2020, Volume: 35

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subf

2020
Real-world patterns of chemotherapy administration and attrition among patients with metastatic colorectal cancer.
    International journal of colorectal disease, 2021, Volume: 36, Issue:3

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F

2021
5-FU inhibits migration and invasion of CRC cells through PI3K/AKT pathway regulated by MARCH1.
    Cell biology international, 2021, Volume: 45, Issue:2

    Topics: Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Epithelial-Mesenchymal Transition; Female; Fl

2021
MMR-proficient and MMR-deficient colorectal cancer cells: 5-Fluorouracil treatment response and correlation to CD133 and MGMT expression.
    Journal of biosciences, 2020, Volume: 45

    Topics: AC133 Antigen; Colorectal Neoplasms; DNA Methylation; DNA Mismatch Repair; DNA Modification Methylas

2020
Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer.
    Clinical & experimental metastasis, 2020, Volume: 37, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Extracellular Matrix; Extracel

2020
Synergistic Antiproliferative Effect of Ribociclib (LEE011) and 5-Fluorouracil on Human Colorectal Cancer.
    Anticancer research, 2020, Volume: 40, Issue:11

    Topics: Aminopyridines; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; C

2020
Lactobacillus-derived metabolites enhance the antitumor activity of 5-FU and inhibit metastatic behavior in 5-FU-resistant colorectal cancer cells by regulating claudin-1 expression.
    Journal of microbiology (Seoul, Korea), 2020, Volume: 58, Issue:11

    Topics: Antimetabolites, Antineoplastic; Claudin-1; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Th

2020
Network-based machine learning in colorectal and bladder organoid models predicts anti-cancer drug efficacy in patients.
    Nature communications, 2020, 10-30, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Drug De

2020
Results from the PROPHYLOCHIP-PRODIGE 15 trial.
    The Lancet. Oncology, 2020, Volume: 21, Issue:11

    Topics: Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Peritoneal Neoplasms; Retrospective Studies

2020
LncRNA NEAT1 remodels chromatin to promote the 5-Fu resistance by maintaining colorectal cancer stemness.
    Cell death & disease, 2020, 11-09, Volume: 11, Issue:11

    Topics: Cell Line, Tumor; Cell Proliferation; Chromatin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fe

2020
Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post hoc analysis (WJOG4407GSS2).
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021, Volume: 29, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fema

2021
What is the Best Therapeutic Strategy for Metachronous Resectable Colorectal Liver Metastases After Adjuvant Oxaliplatin-Based Chemotherapy? A Multidisciplinary Inter-Group Survey.
    World journal of surgery, 2021, Volume: 45, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro

2021
Thermosensitive hydrogels for local delivery of 5-fluorouracil as neoadjuvant or adjuvant therapy in colorectal cancer.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2020, Volume: 157

    Topics: Alginates; Animals; Antineoplastic Agents; Cell Line, Tumor; Chemotherapy, Adjuvant; Colorectal Neop

2020
Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice.
    Clinical colorectal cancer, 2021, Volume: 20, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B

2021
The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer.
    British journal of cancer, 2021, Volume: 124, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cohort S

2021
HIF1α promotes tumor chemoresistance via recruiting GDF15-producing TAMs in colorectal cancer.
    Experimental cell research, 2021, 01-15, Volume: 398, Issue:2

    Topics: Antimetabolites, Antineoplastic; Cells, Cultured; Colorectal Neoplasms; Drug Resistance, Neoplasm; F

2021
Use of spectral tracking technique to evaluate the changes in left ventricular function in patients undergoing chemotherapy for colorectal cancer.
    The international journal of cardiovascular imaging, 2021, Volume: 37, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomechanical Phenomena; Cardiotoxicity; Colo

2021
Identification of Two Subgroups of FOLFOX Resistance Patterns and Prediction of FOLFOX Response in Colorectal Cancer Patients.
    Cancer investigation, 2021, Volume: 39, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fem

2021
Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    PloS one, 2020, Volume: 15, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Comb

2020
Predictive value of clinical toxicities of chemotherapy with fluoropyrimidines and oxaliplatin in colorectal cancer by DPYD and GSTP1 gene polymorphisms.
    World journal of surgical oncology, 2020, Dec-06, Volume: 18, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluoroura

2020
Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens.
    American journal of clinical oncology, 2021, 02-01, Volume: 44, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine

2021
Epigenetically regulated gene expression profiles reveal four molecular subtypes with prognostic and therapeutic implications in colorectal cancer.
    Briefings in bioinformatics, 2021, 07-20, Volume: 22, Issue:4

    Topics: Biomarkers, Tumor; Cetuximab; Colorectal Neoplasms; DNA Methylation; DNA, Neoplasm; Epigenesis, Gene

2021
Understanding the role of colon-specific microparticles based on retrograded starch/pectin in the delivery of chitosan nanoparticles along the gastrointestinal tract.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2021, Volume: 158

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Chitosan; Colon; Colo

2021
Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer.
    Cell death & disease, 2020, 12-12, Volume: 11, Issue:12

    Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Biphenyl Compounds; Cell Line, Tumor;

2020
Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2021, Volume: 144

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Flu

2021
Overexpression of sortilin is associated with 5-FU resistance and poor prognosis in colorectal cancer.
    Journal of cellular and molecular medicine, 2021, Volume: 25, Issue:1

    Topics: Adaptor Proteins, Vesicular Transport; Aged; Aged, 80 and over; Animals; Cell Line, Tumor; Colorecta

2021
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
    The oncologist, 2021, Volume: 26, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu

2021
Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy.
    Cancer medicine, 2021, Volume: 10, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2021
The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience.
    Journal of chemotherapy (Florence, Italy), 2021, Volume: 33, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot

2021
Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer.
    Recent patents on anti-cancer drug discovery, 2021, Volume: 16, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Delayed-Acti

2021
Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties.
    Molecular cancer therapeutics, 2021, Volume: 20, Issue:3

    Topics: Animals; Colorectal Neoplasms; Fluorouracil; Humans; Mice; Mice, Nude; Polymers

2021
Three dimensional cultivation increases chemo- and radioresistance of colorectal cancer cell lines.
    PloS one, 2021, Volume: 16, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Col

2021
Antitumor Effect of 5-Fluorouracil-Loaded Liposomes Containing n-3 Polyunsaturated Fatty Acids in Two Different Colorectal Cancer Cell Lines.
    AAPS PharmSciTech, 2021, Jan-06, Volume: 22, Issue:1

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasm

2021
Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma.
    Molecular cancer, 2021, 01-06, Volume: 20, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Hepatocellular; C

2021
Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study.
    BMC cancer, 2021, Jan-07, Volume: 21, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cetuximab; Col

2021
Novel quinazolinone MJ‑33 induces AKT/mTOR‑mediated autophagy‑associated apoptosis in 5FU‑resistant colorectal cancer cells.
    Oncology reports, 2021, Volume: 45, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Survival; Colorectal Neop

2021
Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI Plus Bevacizumab or Aflibercept.
    Anticancer research, 2021, Volume: 41, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi

2021
KHDRBS3 promotes multi-drug resistance and anchorage-independent growth in colorectal cancer.
    Cancer science, 2021, Volume: 112, Issue:3

    Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor;

2021
miR-193a-5p as a promising therapeutic candidate in colorectal cancer by reducing 5-FU and Oxaliplatin chemoresistance by targeting CXCR4.
    International immunopharmacology, 2021, Volume: 92

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Col

2021
Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer.
    JAMA network open, 2021, 01-04, Volume: 4, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carbamates; Cetuximab; Colorectal Neoplasms; Cost-Be

2021
Suppression of Nanog inhibited cell migration and increased the sensitivity of colorectal cancer cells to 5-fluorouracil.
    European journal of pharmacology, 2021, Mar-05, Volume: 894

    Topics: Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; C

2021
Patient-derived organoids in cellulosic sponge model chemotherapy response of metastatic colorectal cancer.
    Clinical and translational medicine, 2021, Volume: 11, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Culture Techniques; Cells, Cultured; Collagen; Colorectal Neopl

2021
Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.
    PloS one, 2021, Volume: 16, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Animals; Annexin A5; Antineoplastic Combined Chemotherapy Prot

2021
Predictive value of KRAS mutation and excision repair cross-complementing 1 (ERCC1) protein overexpression in patients with colorectal cancer administered FOLFOX regimen.
    Asian journal of surgery, 2021, Volume: 44, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Repair; DNA-Binding Protei

2021
[Two Cases of Resectable Liver Metastasis from Colorectal Cancer with Pathological Complete Response after Neoadjuvant Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Flu

2020
[Case Series of the TAS-102 plus Bevacizumab(Bev)Combination Therapy in Unresectable Advanced Colorectal Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Drug Combinations

2020
[Laparoscopic Abdominoperineal Resection Following Intensive Chemotherapy for Stage Ⅳ Rectal Cancer with Unresectable Metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum

2020
Delivery of Rapamycin by Liposomes Synergistically Enhances the Chemotherapy Effect of 5-Fluorouracil on Colorectal Cancer.
    International journal of nanomedicine, 2021, Volume: 16

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colo

2021
Who Will Benefit? Using Radiomics to Predict Response to Oxaliplatin-Based Chemotherapy in Patients with Colorectal Liver Metastases.
    Annals of surgical oncology, 2021, Volume: 28, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Liver Ne

2021
Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer.
    American journal of clinical oncology, 2020, 12-01, Volume: 43, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2020
In Reply: Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer.
    American journal of clinical oncology, 2020, 12-01, Volume: 43, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2020
Co-delivery of 5-fluorouracil and miRNA-34a mimics by host-guest self-assembly nanocarriers for efficacious targeted therapy in colorectal cancer patient-derived tumor xenografts.
    Theranostics, 2021, Volume: 11, Issue:5

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Combi

2021
In vitro anticancer activity of hydrogen sulfide and nitric oxide alongside nickel nanoparticle and novel mutations in their genes in CRC patients.
    Scientific reports, 2021, 01-28, Volume: 11, Issue:1

    Topics: Alleles; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; DNA Mutationa

2021
Lactobacillus Kefiri LKF01 (Kefibios
    Nutrients, 2021, Jan-27, Volume: 13, Issue:2

    Topics: Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Diarrhea; Endpoint Determination; F

2021
GABA-producing Lactobacillus plantarum inhibits metastatic properties and induces apoptosis of 5-FU-resistant colorectal cancer cells via GABA
    Journal of microbiology (Seoul, Korea), 2021, Volume: 59, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; gam

2021
Cetuximab functionalization strategy for combining active targeting and antimigration capacities of a hybrid composite nanoplatform applied to deliver 5-fluorouracil: toward colorectal cancer treatment.
    Biomaterials science, 2021, Mar-21, Volume: 9, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Nano

2021
FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left-Sided RAS/BRAF Wild-Type Colorectal Cancer: Which "Side" Are You On?
    The oncologist, 2021, Volume: 26, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu

2021
Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.
    The pharmacogenomics journal, 2021, Volume: 21, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bio

2021
Simultaneous quantification method for 5-FU, uracil, and tegafur using UPLC-MS/MS and clinical application in monitoring UFT/LV combination therapy after hepatectomy.
    Scientific reports, 2021, 02-04, Volume: 11, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Calibration; Chroma

2021
Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database.
    PloS one, 2021, Volume: 16, Issue:2

    Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort

2021
Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA.
    Advances in therapy, 2021, Volume: 38, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carbamates; Cetuximab; Colorectal Ne

2021
Impact of PIN1 Inhibition on Tumor Progression and Chemotherapy Sensitivity in Colorectal Cancer.
    Journal of gastrointestinal cancer, 2022, Volume: 53, Issue:2

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Gene Expression

2022
The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study.
    International journal of colorectal disease, 2021, Volume: 36, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

2021
[Construction of artificial neural network model for predicting the efficacy of first-line FOLFOX chemotherapy for metastatic colorectal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2021, Feb-23, Volume: 43, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci

2021
PTPN6 promotes chemosensitivity of colorectal cancer cells via inhibiting the SP1/MAPK signalling pathway.
    Cell biochemistry and function, 2021, Volume: 39, Issue:3

    Topics: Caco-2 Cells; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; HT29 Cell

2021
Bilateral adrenal haematoma complicated by adrenal insufficiency in a patient treated with bevacizumab.
    BMJ case reports, 2021, Feb-22, Volume: 14, Issue:2

    Topics: Adrenal Insufficiency; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neopl

2021
Albumin-stabilized layered double hydroxide nanoparticles synergized combination chemotherapy for colorectal cancer treatment.
    Nanomedicine : nanotechnology, biology, and medicine, 2021, Volume: 34

    Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorec

2021
Conversion therapy in patients with colorectal liver metastases.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021, Volume: 47, Issue:8

    Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineopl

2021
Jiedu Sangen decoction inhibits chemoresistance to 5-fluorouracil of colorectal cancer cells by suppressing glycolysis via PI3K/AKT/HIF-1α signaling pathway.
    Chinese journal of natural medicines, 2021, Volume: 19, Issue:2

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Fluorourac

2021
HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancer.
    Oncology reports, 2021, Volume: 45, Issue:3

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Carrier Proteins; Cell Line, Tumor; Cell Survival; Chemoth

2021
Development of a protein signature to enable clinical positioning of IAP inhibitors in colorectal cancer.
    The FEBS journal, 2021, Volume: 288, Issue:18

    Topics: Alkaline Phosphatase; Antineoplastic Agents; Apoptosis; Caspase 8; Cell Line, Tumor; Colorectal Neop

2021
Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and witho
    Journal of cancer research and clinical oncology, 2021, Volume: 147, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Biomarkers, Tumor; Clini

2021
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study.
    ESMO open, 2021, Volume: 6, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Consensus; Fluor

2021
Exosome-Mediated Transfer of circ_0000338 Enhances 5-Fluorouracil Resistance in Colorectal Cancer through Regulating MicroRNA 217 (miR-217) and miR-485-3p.
    Molecular and cellular biology, 2021, 04-22, Volume: 41, Issue:5

    Topics: Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Colorectal Neoplasms; Drug Resistance, Neop

2021
Combination of tumor cell anti-adhesion and anti-tumor effect to prevent recurrence after cytoreductive surgery in a mice model.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2021, Volume: 169

    Topics: Animals; Antineoplastic Agents; Biological Availability; Colorectal Neoplasms; Combined Modality The

2021
Effective chemotherapy and targeted therapy supplemented with stereotactic radiotherapy of a patient with metastatic colon cancer following renal transplantation: a case report.
    Journal of medical case reports, 2021, Mar-20, Volume: 15, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Diabetes Mell

2021
Safety and Efficacy of 7 Days on/7 Days off Versus 14 Days on/7 Days off Schedules of Capecitabine in Patients with Metastatic Colorectal Cancer: A Retrospective Review.
    Clinical colorectal cancer, 2021, Volume: 20, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci

2021
Inhibition of chaperone‑mediated autophagy reduces tumor growth and metastasis and promotes drug sensitivity in colorectal cancer.
    Molecular medicine reports, 2021, Volume: 23, Issue:5

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Chaperone-Mediated Autophagy; Colorectal Neoplasms;

2021
Prospective Observational Study Comparing Calcium and Sodium Levofolinate in Combination with 5-Fluorouracil in the FOLFIRI Regimen.
    The oncologist, 2021, Volume: 26, Issue:8

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Calcium; Camptothecin; Colorectal Neopla

2021
Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience.
    Journal of gastrointestinal cancer, 2022, Volume: 53, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colorecta

2022
Co-administration of 5FU and propolis on AOM/DSS induced colorectal cancer in BALB-c mice.
    Life sciences, 2021, Jul-01, Volume: 276

    Topics: Animals; Anti-Infective Agents; Antimetabolites, Antineoplastic; Azoxymethane; Carcinogens; Colorect

2021
Inhibition of Human Uracil DNA Glycosylase Sensitizes a Large Fraction of Colorectal Cancer Cells to 5-Fluorodeoxyuridine and Raltitrexed but Not Fluorouracil.
    Molecular pharmacology, 2021, Volume: 99, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Screening Assays, An

2021
    Molecules (Basel, Switzerland), 2021, Mar-25, Volume: 26, Issue:7

    Topics: Colorectal Neoplasms; Coptis chinensis; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Fluorourac

2021
Low curcumin concentration enhances the anticancer effect of 5-fluorouracil against colorectal cancer.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2021, Volume: 85

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Curcumin; Down-Regul

2021
Andrographis overcomes 5-fluorouracil-associated chemoresistance through inhibition of DKK1 in colorectal cancer.
    Carcinogenesis, 2021, 06-21, Volume: 42, Issue:6

    Topics: Andrographis; Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Prolifera

2021
Rare presentation of subglottic soft-tissue swelling following FOLFOX therapy in a patient with metastatic oesophageal cancer.
    BMJ case reports, 2021, Apr-13, Volume: 14, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Esophageal Neoplasms; Fluorour

2021
Prophylactic Administration of Recombinant Human Thrombopoietin in the Secondary Prevention of Thrombocytopenia Induced by XELOX Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer.
    American journal of therapeutics, 2021, Apr-07, Volume: 28, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neo

2021
A selective p53 activator and anticancer agent to improve colorectal cancer therapy.
    Cell reports, 2021, 04-13, Volume: 35, Issue:2

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycl

2021
Sec62 promotes stemness and chemoresistance of human colorectal cancer through activating Wnt/β-catenin pathway.
    Journal of experimental & clinical cancer research : CR, 2021, Apr-15, Volume: 40, Issue:1

    Topics: Animals; beta Catenin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fl

2021
Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor.
    Clinical colorectal cancer, 2021, Volume: 20, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin;

2021
    Genetic testing and molecular biomarkers, 2021, Volume: 25, Issue:4

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Bi

2021
Tumor budding as a predictive marker for 5-fluorouracil response in adjuvant-treated stage III colorectal cancer.
    International journal of clinical oncology, 2021, Volume: 26, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms;

2021
Tenacissoside G synergistically potentiates inhibitory effects of 5-fluorouracil to human colorectal cancer.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2021, Volume: 86

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Lin

2021
Vanillin downregulates NNMT and attenuates NNMT‑related resistance to 5‑fluorouracil via ROS‑induced cell apoptosis in colorectal cancer cells.
    Oncology reports, 2021, Volume: 45, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzaldehydes; Cell Line, Tumor; Colorect

2021
A438079 affects colorectal cancer cell proliferation, migration, apoptosis, and pyroptosis by inhibiting the P2X7 receptor.
    Biochemical and biophysical research communications, 2021, 06-18, Volume: 558

    Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Movement; Cell Prolifera

2021
The ZEB2-dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer.
    Molecular oncology, 2021, Volume: 15, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; DNA

2021
LncRNA ENSG00000254615 Modulates Proliferation and 5-FU Resistance by Regulating p21 and Cyclin D1 in Colorectal Cancer.
    Cancer investigation, 2021, Volume: 39, Issue:9

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms

2021
Targeting thymidine phosphorylase inhibition in human colorectal cancer xenografts.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 139

    Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line,

2021
The loss of SHMT2 mediates 5-fluorouracil chemoresistance in colorectal cancer by upregulating autophagy.
    Oncogene, 2021, Volume: 40, Issue:23

    Topics: Animals; Antimalarials; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Line, Tumor; Cel

2021
A rare presentation of panitumumab-involved interstitial lung disease: Spontaneous pneumomediastinum.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

2021
Multiple stage IV colorectal cancers in a patient who received multidisciplinary treatment, including chemotherapy and Japanese Kampo medicine: A case report.
    Neuropeptides, 2021, Volume: 88

    Topics: Adenocarcinoma; Aged; Bevacizumab; Colorectal Neoplasms; Drug Therapy; Fluorouracil; Humans; Japan;

2021
Pulsatilla Decoction Combined with 5-Fluorouracil Triggers Immunogenic Cell Death in Colorectal Cancer Cells.
    Cancer biotherapy & radiopharmaceuticals, 2022, Volume: 37, Issue:10

    Topics: Adenosine Triphosphate; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplas

2022
Stability of calcium levofolinate, 5-fluorouracil and oxaliplatin (FOLFOX) mixture.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium; Colorectal Neoplasms; Fluorouracil; Humans;

2022
New Hybrids Based on Curcumin and Resveratrol: Synthesis, Cytotoxicity and Antiproliferative Activity against Colorectal Cancer Cells.
    Molecules (Basel, Switzerland), 2021, May-01, Volume: 26, Issue:9

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; CHO

2021
Sensitive High-Throughput Assays for Tumour Burden Reveal the Response of a
    International journal of molecular sciences, 2021, May-12, Volume: 22, Issue:10

    Topics: Animals; Animals, Genetically Modified; Antineoplastic Agents; Colorectal Neoplasms; Drosophila mela

2021
Mice with dysfunctional TGF-β signaling develop altered intestinal microbiome and colorectal cancer resistant to 5FU.
    Biochimica et biophysica acta. Molecular basis of disease, 2021, 10-01, Volume: 1867, Issue:10

    Topics: Animals; Antineoplastic Agents; Azoxymethane; Colon; Colorectal Neoplasms; Dextran Sulfate; Female;

2021
Risk-benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer.
    Anticancer research, 2021, Volume: 41, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camp

2021
Benefit of intensive chemotherapy for elderly patients aged 80 years or older with metastatic colorectal cancer: a state-wide multicenter cohort study.
    International journal of clinical oncology, 2021, Volume: 26, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal

2021
Demethylzeylasteral Exerts Antitumor Effects
    Anti-cancer agents in medicinal chemistry, 2022, Volume: 22, Issue:5

    Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Huma

2022
Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group.
    Clinical colorectal cancer, 2021, Volume: 20, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum

2021
C677T and A1298C MTHFR gene polymorphisms and response to fluoropyrimidine-based chemotherapy in Mestizo patients with metastatic colorectal cancer.
    Pharmacogenetics and genomics, 2021, 12-01, Volume: 31, Issue:9

    Topics: Case-Control Studies; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Genetic Predisposition

2021
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study.
    European journal of cancer (Oxford, England : 1990), 2021, Volume: 153

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal N

2021
Pharmacologic modulation of 5-fluorouracil by folinic acid and high-dose pyridoxine for treatment of patients with digestive tract carcinomas.
    Scientific reports, 2021, 06-16, Volume: 11, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2021
Lipocalin 2 expression promotes tumor progression and therapy resistance by inhibiting ferroptosis in colorectal cancer.
    International journal of cancer, 2021, 10-01, Volume: 149, Issue:7

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Prolifer

2021
[Chinese expert consensus on the clinical application of the Chinese modified triplet combination with irinotecan, oxaliplatin and continuous infusional 5-fluorouracil/leucovorin for colorectal cancer].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2021, Jun-25, Volume: 24, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplasms; Consensus

2021
MicroRNA-29b-3p promotes 5-fluorouracil resistance via suppressing TRAF5-mediated necroptosis in human colorectal cancer.
    European journal of histochemistry : EJH, 2021, Jun-22, Volume: 65, Issue:2

    Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expre

2021
Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia.
    Asian Pacific journal of cancer prevention : APJCP, 2021, Jun-01, Volume: 22, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Cos

2021
5-FU resistant colorectal cancer cells possess improved invasiveness and β
    Experimental oncology, 2021, Volume: 43, Issue:2

    Topics: Antineoplastic Agents; Cell Adhesion; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil;

2021
A Bioactive Compound from
    Molecules (Basel, Switzerland), 2021, Jun-24, Volume: 26, Issue:13

    Topics: Cell Death; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; F

2021
Bioinspired silk fibroin nano-delivery systems protect against 5-FU induced gastrointestinal mucositis in a mouse model and display antitumor effects on HT-29 colorectal cancer cells
    Nanotoxicology, 2021, Volume: 15, Issue:7

    Topics: Colorectal Neoplasms; Fibroins; Fluorouracil; HT29 Cells; Humans; Mucositis

2021
Prognostic Implications of Chemotherapy-Induced Neutropenia in Stage III Colorectal Cancer.
    The Journal of surgical research, 2021, Volume: 267

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Color

2021
Anti-cancer effects of the aqueous extract of Orostachys japonica A. Berger on 5-fluorouracil-resistant colorectal cancer via MAPK signalling pathways in vitro and in vivo.
    Journal of ethnopharmacology, 2021, Nov-15, Volume: 280

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Crassulaceae;

2021
[Establishment of a Needle-Removal Method Considering Anticancer Drug Exposure after Continuous Administration of Fluorouracil Using an Infusion Pump].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop

2021
Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.
    International journal of cancer, 2021, 11-01, Volume: 149, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Color

2021
Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX.
    Scientific reports, 2021, 07-16, Volume: 11, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms;

2021
Quercetin and Luteolin Improve the Anticancer Effects of 5-Fluorouracil in Human Colorectal Adenocarcinoma
    Nutrition and cancer, 2022, Volume: 74, Issue:2

    Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Luteolin; Q

2022
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
    International journal of cancer, 2021, 12-01, Volume: 149, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B

2021
Clinical Benefit of Therapeutic Drug Monitoring in Colorectal Cancer Patients Who Received Fluorouracil-Based Chemotherapy.
    Medical science monitor : international medical journal of experimental and clinical research, 2021, Jul-31, Volume: 27

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Cu

2021
Risk of arterial and venous thromboembolic events among patients with colorectal carcinoma: a real-world, population-based study.
    Future oncology (London, England), 2021, Volume: 17, Issue:30

    Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Humans; Logistic Models; Male;

2021
Low-Molecular-Weight Fucoidan as Complementary Therapy of Fluoropyrimidine-Based Chemotherapy in Colorectal Cancer.
    International journal of molecular sciences, 2021, Jul-27, Volume: 22, Issue:15

    Topics: Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Colorectal Neoplasms; Epithelial-Mesen

2021
Anti-Cancer Effects of Zotarolimus Combined with 5-Fluorouracil Treatment in HCT-116 Colorectal Cancer-Bearing BALB/c Nude Mice.
    Molecules (Basel, Switzerland), 2021, Aug-02, Volume: 26, Issue:15

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Colorectal N

2021
The combined effect of dichloroacetate and 3-bromopyruvate on glucose metabolism in colorectal cancer cell line, HT-29; the mitochondrial pathway apoptosis.
    BMC cancer, 2021, Aug-07, Volume: 21, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Co

2021
Downregulation of miRNA-14669 Reverses Vincristine Resistance in Colorectal Cancer Cells through PI3K/AKT Signaling Pathway.
    Recent patents on anti-cancer drug discovery, 2022, Volume: 17, Issue:2

    Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Fluor

2022
Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.
    Clinical colorectal cancer, 2021, Volume: 20, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Case-Control Studies; Colorectal Neopla

2021
Fluorouracil Bolus Use in Infusional Regimens Among Oncologists-A Survey by Brazilian Group of Gastrointestinal Tumors.
    JCO global oncology, 2021, Volume: 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brazil; Colorectal Neoplasms; Cross-Sectional Studie

2021
Chemosensitivity analysis and study of gene resistance on tumors and cancer stem cell isolates from patients with colorectal cancer.
    Molecular medicine reports, 2021, Volume: 24, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Biomarkers, Tumor; CD24 Antigen; Colorectal Neoplasms; Drug Resistance,

2021
Knockdown of circNRIP1 sensitizes colorectal cancer to 5‑FU via sponging miR‑532‑3p.
    Oncology reports, 2021, Volume: 46, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proli

2021
Primary Tumor-Related Complications Among Patients With Unresectable Stage IV Colorectal Cancer in the Era of Targeted Therapy: A Competing Risk Regression Analysis.
    Diseases of the colon and rectum, 2021, 09-01, Volume: 64, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neoplasms;

2021
Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 142

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Cycle; Cell Proliferation; Cell Surv

2021
Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices.
    Cancer treatment and research communications, 2021, Volume: 28

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Top

2021
Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer.
    Anticancer research, 2017, Volume: 37, Issue:3

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2017
Inhibition of GOT1 sensitizes colorectal cancer cells to 5-fluorouracil.
    Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:4

    Topics: Antimetabolites, Antineoplastic; Aspartate Aminotransferase, Cytoplasmic; Cell Line, Tumor; Cell Pro

2017
MTA3 regulates malignant progression of colorectal cancer through Wnt signaling pathway.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2017, Volume: 39, Issue:3

    Topics: Adult; Aged; Apoptosis; Carcinogenesis; Cell Proliferation; Colorectal Neoplasms; Cyclin D1; Cyclin

2017
An apple oligogalactan enhances the growth inhibitory effect of 5-fluorouracil on colorectal cancer.
    European journal of pharmacology, 2017, Jun-05, Volume: 804

    Topics: Animals; Apoptosis; Carcinogenesis; Cell Proliferation; Colorectal Neoplasms; Down-Regulation; Drug

2017
Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
    Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:5

    Topics: Aged; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast

2017
High expression of atonal homolog 8 predicts a poor clinical outcome in patients with colorectal cancer and contributes to tumor progression.
    Oncology reports, 2017, Volume: 37, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Cell

2017
The Effect of miR-200c Inhibition on Chemosensitivity (5- FluoroUracil) in Colorectal Cancer.
    Pathology oncology research : POR, 2018, Volume: 24, Issue:1

    Topics: Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Cadherins; Cell Proliferation; Colorectal

2018
Down-regulation of long non-coding RNA RP11-708H21.4 is associated with poor prognosis for colorectal cancer and promotes tumorigenesis through regulating AKT/mTOR pathway.
    Oncotarget, 2017, Apr-25, Volume: 8, Issue:17

    Topics: Adult; Aged; Animals; Apoptosis; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Movement;

2017
Bacterial Metabolism Affects the C. elegans Response to Cancer Chemotherapeutics.
    Cell, 2017, 04-20, Volume: 169, Issue:3

    Topics: Animals; Antineoplastic Agents; Caenorhabditis elegans; Camptothecin; Colorectal Neoplasms; Comamona

2017
Host-Microbe Co-metabolism Dictates Cancer Drug Efficacy in C. elegans.
    Cell, 2017, 04-20, Volume: 169, Issue:3

    Topics: Animals; Antineoplastic Agents; Autophagy; Caenorhabditis elegans; Cell Death; Colorectal Neoplasms;

2017
Postoperative adjuvant chemotherapy is associated with a lower incidence of colorectal adenomas in patients with previous colorectal cancer.
    Gastrointestinal endoscopy, 2018, Volume: 87, Issue:3

    Topics: Adenoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonoscopy; Colorectal Neop

2018
Hepatic Arterial Infusion Chemotherapy for Unresectable Liver Metastases of Colorectal Cancer: A Multicenter Retrospective Study.
    Clinical colorectal cancer, 2017, Volume: 16, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2017
Downregulation of SIRT7 by 5-fluorouracil induces radiosensitivity in human colorectal cancer.
    Theranostics, 2017, Volume: 7, Issue:5

    Topics: Animals; Antimetabolites, Antineoplastic; ATPases Associated with Diverse Cellular Activities; Color

2017
Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype.
    Oncotarget, 2017, Jun-13, Volume: 8, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva

2017
Cisatracurium-induced proliferation impairment and death of colorectal cancer cells, HCT116 is mediated by p53 dependent intrinsic apoptotic pathway in vitro.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 91

    Topics: Apoptosis; Atracurium; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; Fluorouraci

2017
5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer.
    Cancer letters, 2017, 08-01, Volume: 400

    Topics: Acetylation; Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chromatin; Colorect

2017
MicroRNA-146a induces immune suppression and drug-resistant colorectal cancer cells.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2017, Volume: 39, Issue:5

    Topics: Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Proliferation; Colorectal Neoplasms; Drug Resi

2017
Clinical Significance of 5-Fluorouracil Chemosensitivity Testing in Patients with Colorectal Cancer.
    Anticancer research, 2017, Volume: 37, Issue:5

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto

2017
Secretion metabolites of probiotic yeast, Pichia kudriavzevii AS-12, induces apoptosis pathways in human colorectal cancer cell lines.
    Nutrition research (New York, N.Y.), 2017, Volume: 41

    Topics: Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; Caco-2 Cells; Caspase 3; Caspas

2017
Hepatoprotective Effect of Carboxymethyl Pachyman in Fluorouracil-Treated CT26-Bearing Mice.
    Molecules (Basel, Switzerland), 2017, May-06, Volume: 22, Issue:5

    Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Apopto

2017
Effect of mTHPC-mediated photodynamic therapy on 5-fluorouracil resistant human colorectal cancer cells.
    Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2017, Jul-01, Volume: 16, Issue:7

    Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Dose-Response Relati

2017
Anti-angiogenic therapy with contrast-enhanced ultrasound in colorectal cancer patients with liver metastasis.
    Medicine, 2017, Volume: 96, Issue:20

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Area Under Cur

2017
Translational reprogramming of colorectal cancer cells induced by 5-fluorouracil through a miRNA-dependent mechanism.
    Oncotarget, 2017, Jul-11, Volume: 8, Issue:28

    Topics: Cellular Reprogramming; Colonic Neoplasms; Colorectal Neoplasms; DNA-Binding Proteins; Drug Resistan

2017
Musashi-1 promotes a cancer stem cell lineage and chemoresistance in colorectal cancer cells.
    Scientific reports, 2017, 05-19, Volume: 7, Issue:1

    Topics: Biomarkers; Cell Line, Tumor; Cell Lineage; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluores

2017
Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer.
    Oncology, 2017, Volume: 93, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2017
Safe administration of S-1 after 5-fluorouracil-induced cardiotoxicity in a patient with colorectal cancer.
    BMJ case reports, 2017, May-22, Volume: 2017

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicit

2017
Process mining routinely collected electronic health records to define real-life clinical pathways during chemotherapy.
    International journal of medical informatics, 2017, Volume: 103

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Cost-Benefit

2017
MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines.
    Anticancer research, 2017, Volume: 37, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cel

2017
Enhancing 5-Fluorouracil Efficacy in a Primary Colorectal Cancer by Long-lasting Calcium Supplementation.
    Anticancer research, 2017, Volume: 37, Issue:6

    Topics: Animals; Antimetabolites, Antineoplastic; Calcium Compounds; Colorectal Neoplasms; Fluorouracil; Foc

2017
Intermittent low dose irradiation enhances the effectiveness of radio- and chemo-therapy for human colorectal adenocarcinoma cell line HT-29.
    Oncology reports, 2017, Volume: 38, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Ataxia Telangiectasia Mutated Proteins; Benzothiazo

2017
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.
    International journal of cancer, 2017, 09-15, Volume: 141, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phas

2017
Characterization of cancer stem cell drug resistance in the human colorectal cancer cell lines HCT116 and SW480.
    Biochemical and biophysical research communications, 2017, 08-12, Volume: 490, Issue:1

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Neoplastic

2017
Assessment of neutralizing interleukin-4 effect on CD133 gene expression in colon cancer cell line.
    Cytokine, 2017, Volume: 97

    Topics: AC133 Antigen; Antibodies, Neutralizing; Antineoplastic Agents; Apoptosis; Caco-2 Cells; Cell Prolif

2017
Role of cyclooxygenase-2 inhibitors in the survival outcome of colorectal cancer patients: A population-based cohort study.
    The Kaohsiung journal of medical sciences, 2017, Volume: 33, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorect

2017
A colon targeted drug delivery system based on alginate modificated graphene oxide for colorectal liver metastasis.
    Materials science & engineering. C, Materials for biological applications, 2017, Oct-01, Volume: 79

    Topics: Alginates; Animals; Colon; Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Glucuronic Aci

2017
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
    British journal of cancer, 2017, Jul-25, Volume: 117, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms;

2017
AQP9-induced cell cycle arrest is associated with RAS activation and improves chemotherapy treatment efficacy in colorectal cancer.
    Cell death & disease, 2017, 06-22, Volume: 8, Issue:6

    Topics: Amino Acid Motifs; Animals; Antineoplastic Agents; Aquaporins; Cell Cycle Checkpoints; Cell Line, Tu

2017
Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
    Drug design, development and therapy, 2017, Volume: 11

    Topics: Activation, Metabolic; Administration, Oral; Animals; Antimetabolites, Antineoplastic; Colorectal Ne

2017
Microarray Analysis of Circular RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells.
    BioMed research international, 2017, Volume: 2017

    Topics: Chemoradiotherapy; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Re

2017
Posterior Reversible Encephalopathy Syndrome During Treatment with Aflibercept, 5-Fluorouracil, Leucovorin, and Irinotecan for Metastatic Colorectal Cancer.
    Journal of gastrointestinal cancer, 2019, Volume: 50, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Colorectal Neoplasms; Female; Fluoro

2019
Elevated Expression of ERCC6 Confers Resistance to 5-Fluorouracil and Is Associated with Poor Patient Survival in Colorectal Cancer.
    DNA and cell biology, 2017, Volume: 36, Issue:9

    Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA Helicases; DNA Repair Enzymes; D

2017
Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model.
    Basic & clinical pharmacology & toxicology, 2017, Volume: 121, Issue:6

    Topics: Animals; Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Carnosine; Cell Proliferation; Colorect

2017
Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated αβ T-cells.
    Anticancer research, 2017, Volume: 37, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasm

2017
Tumour growth increased following antiangiogenic interruption: the challenge of tumour evaluation.
    Anti-cancer drugs, 2017, Volume: 28, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; F

2017
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy.
    EBioMedicine, 2017, Volume: 22

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Organopl

2017
Interstitial lung disease following FOLFOX + FOLFIRI and bevacizumab therapy associated with leucovorin: A case report.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018, Volume: 24, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasm

2018
Aptamer-mediated survivin RNAi enables 5-fluorouracil to eliminate colorectal cancer stem cells.
    Scientific reports, 2017, 07-19, Volume: 7, Issue:1

    Topics: Animals; Apoptosis; Aptamers, Nucleotide; Base Sequence; Cell Line, Tumor; Colorectal Neoplasms; Dow

2017
WNT/β-Catenin Signaling Inhibitor IC-2 Suppresses Sphere Formation and Sensitizes Colorectal Cancer Cells to 5-Fluorouracil.
    Anticancer research, 2017, Volume: 37, Issue:8

    Topics: beta Catenin; Cell Proliferation; Colorectal Neoplasms; Fluorouracil; Gene Expression Regulation, Ne

2017
Small-molecule CB002 restores p53 pathway signaling and represses colorectal cancer cell growth.
    Cell cycle (Georgetown, Tex.), 2017, Sep-17, Volume: 16, Issue:18

    Topics: Aniline Compounds; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplas

2017
Self-Reported Adherence to Capecitabine on XELOX Treatment as Adjuvant Therapy for Colorectal Cancer.
    Oncology research, 2017, Nov-02, Volume: 25, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot

2017
Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway.
    Molecular carcinogenesis, 2017, Volume: 56, Issue:12

    Topics: 3' Untranslated Regions; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cel

2017
Necrotising fasciitis in a patient treated with FOLFIRI-aflibercept for colorectal cancer: a case report.
    Annals of the Royal College of Surgeons of England, 2017, Volume: 99, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co

2017
Changes of reduced glutathione and glutathione S-transferase levels in colorectal cancer patients undergoing treatment.
    Tumori, 2018, Volume: 104, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Case-Co

2018
Therapeutic response assessment using 3D ultrasound for hepatic metastasis from colorectal cancer: Application of a personalized, 3D-printed tumor model using CT images.
    PloS one, 2017, Volume: 12, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl

2017
Chitosan-Coated Cinnamon/Oregano-Loaded Solid Lipid Nanoparticles to Augment 5-Fluorouracil Cytotoxicity for Colorectal Cancer: Extract Standardization, Nanoparticle Optimization, and Cytotoxicity Evaluation.
    Journal of agricultural and food chemistry, 2017, Sep-13, Volume: 65, Issue:36

    Topics: Antineoplastic Agents; Cell Survival; Chitosan; Cinnamomum zeylanicum; Colorectal Neoplasms; Drug Ca

2017
Synergistic antitumor effect of 3-bromopyruvate and 5-fluorouracil against human colorectal cancer through cell cycle arrest and induction of apoptosis.
    Anti-cancer drugs, 2017, Volume: 28, Issue:8

    Topics: Adenosine Triphosphate; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cyc

2017
Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro.
    Molecular and cellular biochemistry, 2018, Volume: 440, Issue:1-2

    Topics: Adenocarcinoma; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Melatonin

2018
Evaluation of cytotoxic and antitumoral properties of Tessaria absinthioides (Hook & Arn) DC, "pájaro bobo", aqueous extract.
    Medicina, 2017, Volume: 77, Issue:4

    Topics: Animals; Antineoplastic Agents, Phytogenic; Asteraceae; Cell Line, Tumor; Colorectal Neoplasms; Dise

2017
STRAP Promotes Stemness of Human Colorectal Cancer via Epigenetic Regulation of the NOTCH Pathway.
    Cancer research, 2017, 10-15, Volume: 77, Issue:20

    Topics: Animals; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Epigenesis, Genetic; Fluorouracil; HCT11

2017
Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts.
    Proceedings of the National Academy of Sciences of the United States of America, 2017, 09-26, Volume: 114, Issue:39

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female;

2017
Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy.
    World journal of surgical oncology, 2017, Aug-24, Volume: 15, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2017
Raman endoscopy for monitoring the anticancer drug treatment of colorectal tumors in live mice.
    The Analyst, 2017, Sep-25, Volume: 142, Issue:19

    Topics: Animals; Antineoplastic Agents; Cisplatin; Colorectal Neoplasms; Docetaxel; Endoscopy; Fluorouracil;

2017
FOLFOXIRI in metastatic colorectal cancer: A criticism from its native land.
    Cancer letters, 2017, 11-01, Volume: 408

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Sur

2017
Bifidobacterium Infantis Ameliorates Chemotherapy-Induced Intestinal Mucositis Via Regulating T Cell Immunity in Colorectal Cancer Rats.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 42, Issue:6

    Topics: Animals; Antineoplastic Agents; Bifidobacterium longum subspecies infantis; Cell Line; Colorectal Ne

2017
Scutellaria barbata D. Don inhibits 5-fluorouracil resistance in colorectal cancer by regulating PI3K/AKT pathway.
    Oncology reports, 2017, Volume: 38, Issue:4

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neo

2017
Oxaliplatin-induced increase in splenic volume; irreversible change after adjuvant FOLFOX.
    Journal of surgical oncology, 2017, Volume: 116, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms;

2017
Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients.
    Journal of gastrointestinal cancer, 2018, Volume: 49, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febr

2018
Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2017, Volume: 21, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2017
Bioengineered Submucosal Organoids for In Vitro Modeling of Colorectal Cancer.
    Tissue engineering. Part A, 2017, Volume: 23, Issue:19-20

    Topics: Acinar Cells; Animals; Bioengineering; Cell Line, Tumor; Collagen; Colorectal Neoplasms; Drug Resist

2017
Impact of travel distance on access to treatment and survival in patients with metastatic colorectal cancer prescribed bevacizumab plus chemotherapy.
    Canadian journal of rural medicine : the official journal of the Society of Rural Physicians of Canada = Journal canadien de la medecine rurale : le journal officiel de la Societe de medecine rurale du Canada, 2017,Fall, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitab

2017
Fluorescence-Guided Surgery in the Combined Treatment of Peritoneal Carcinomatosis from Colorectal Cancer: Preliminary Results and Considerations.
    World journal of surgery, 2018, Volume: 42, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Coloring Agents; Co

2018
Participation of CCL1 in Snail-Positive Fibroblasts in Colorectal Cancer Contribute to 5-Fluorouracil/Paclitaxel Chemoresistance.
    Cancer research and treatment, 2018, Volume: 50, Issue:3

    Topics: 3T3 Cells; Animals; Cancer-Associated Fibroblasts; Cell Line, Tumor; Chemokine CCL1; Coculture Techn

2018
Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases.
    Chinese journal of cancer, 2017, Oct-02, Volume: 36, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuxim

2017
XRCC2-Deficient Cells are Highly Sensitive to 5-Fluorouracil in Colorectal Cancer.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 43, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Checkpoint Kinase

2017
Early small bowel perforation due to aflibercept.
    Drug discoveries & therapeutics, 2017, Nov-22, Volume: 11, Issue:5

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2017
Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
    British journal of cancer, 2017, Dec-05, Volume: 117, Issue:12

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothe

2017
Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
    Chinese journal of cancer, 2017, Oct-16, Volume: 36, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2017
Downregulation of miR-874-3p promotes chemotherapeutic resistance in colorectal cancer via inactivation of the Hippo signaling pathway.
    Oncology reports, 2017, Volume: 38, Issue:6

    Topics: Aged; Apoptosis; Cell Proliferation; Colorectal Neoplasms; DNA-Binding Proteins; Drug Resistance, Ne

2017
MicroRNA-binding site polymorphisms in genes involved in colorectal cancer etiopathogenesis and their impact on disease prognosis.
    Mutagenesis, 2017, 10-17, Volume: 32, Issue:5

    Topics: 3' Untranslated Regions; Adenomatous Polyposis Coli Protein; Aged; Antimetabolites, Antineoplastic;

2017
Combination of FGFR4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells.
    International journal of oncology, 2017, Volume: 51, Issue:5

    Topics: Acrylamides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Colorect

2017
Low Concentration of 5-Fluorouracil Increases the Effectiveness of Tumor RNA to Activate Murine Dendritic Cells.
    Cancer biotherapy & radiopharmaceuticals, 2017, Volume: 32, Issue:8

    Topics: Animals; Antigen Presentation; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Cancer Vaccines;

2017
Anti-Epidermal Growth Factor Receptor Antibody Readministration in Chemorefractory Metastatic Colorectal Cancer.
    Anticancer research, 2017, Volume: 37, Issue:11

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C

2017
Long-Term Outcomes After R0 Resection of Synchronous Peritoneal Metastasis from Colorectal Cancer Without Cytoreductive Surgery or Hyperthermic Intraperitoneal Chemotherapy.
    Annals of surgical oncology, 2018, Volume: 25, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2018
Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
    Clinical colorectal cancer, 2018, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemother

2018
LOC285629 regulates cell proliferation and motility in colorectal cancer cells.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2018, Volume: 20, Issue:6

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Cell Proliferation; Colorectal Neoplasms;

2018
Hedyotis diffusa Willd inhibits proliferation and induces apoptosis of 5‑FU resistant colorectal cancer cells by regulating the PI3K/AKT signaling pathway.
    Molecular medicine reports, 2018, Volume: 17, Issue:1

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Cell Survival; Colorect

2018
The long non-coding RNA ENST00000547547 reduces 5-fluorouracil resistance of colorectal cancer cells via competitive binding to microRNA-31.
    Oncology reports, 2018, Volume: 39, Issue:1

    Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Down-Regulation; Drug Res

2018
Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo.
    International journal of oncology, 2018, Volume: 52, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Co

2018
Preparation and Bioactivity Assessment of Chitosan-1-Acetic Acid-5-Flurouracil Conjugates as Cancer Prodrugs.
    Molecules (Basel, Switzerland), 2017, Nov-08, Volume: 22, Issue:11

    Topics: Acetic Acid; Animals; Antineoplastic Agents; Cell Line, Tumor; Chitosan; Colorectal Neoplasms; Fluor

2017
Effect of AICAR and 5-Fluorouracil on X-ray Repair, Cross-Complementing Group 1 Expression, and Consequent Cytotoxicity Regulation in Human HCT-116 Colorectal Cancer Cells.
    International journal of molecular sciences, 2017, Nov-08, Volume: 18, Issue:11

    Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Apoptosis;

2017
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
    British journal of cancer, 2017, Dec-05, Volume: 117, Issue:12

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2017
DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
    Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bangladesh; Colorectal Neoplasms; Dihydrouracil Dehydr

2018
In-depth phenotypic characterization of multicellular tumor spheroids: Effects of 5-Fluorouracil.
    PloS one, 2017, Volume: 12, Issue:11

    Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Spher

2017
Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients.
    Cancer genetics, 2017, Volume: 218-219

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2017
The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer.
    Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:2

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizuma

2018
5-FU-induced leukoencephalopathy with reversible lesion of splenium of corpus callosum in a patient with colorectal cancer.
    BMJ case reports, 2017, Nov-21, Volume: 2017

    Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Corpus Callosum; Fluorouracil; Humans;

2017
Therapeutic inhibition of SGK1 suppresses colorectal cancer.
    Experimental & molecular medicine, 2017, 11-24, Volume: 49, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colo

2017
Effect of dendritic cell-cytokine-induced killer cells in patients with advanced colorectal cancer combined with first-line treatment.
    World journal of surgical oncology, 2017, Nov-28, Volume: 15, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Ch

2017
Treatment of advanced colorectal cancer in a patient with cardiotoxic reactions to 5-fluorouracil and capecitabine using suboptimal doses.
    BMJ case reports, 2017, Nov-27, Volume: 2017

    Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Colorectal Neoplasms; Dose-Res

2017
Cross-linked guar gum and sodium borate based microspheres as colon-targeted anticancer drug delivery systems for 5-fluorouracil.
    Pakistan journal of pharmaceutical sciences, 2017, Volume: 30, Issue:6(Suppleme

    Topics: Administration, Oral; Antineoplastic Agents; Borates; Colorectal Neoplasms; Delayed-Action Preparati

2017
Andrographolide enhanced 5-fluorouracil-induced antitumor effect in colorectal cancer via inhibition of c-MET pathway.
    Drug design, development and therapy, 2017, Volume: 11

    Topics: Antineoplastic Agents; Cell Proliferation; Colorectal Neoplasms; Diterpenes; Dose-Response Relations

2017
miR-200c as a Predictive Biomarker for 5-Fluorouracil Chemosensitivity in Colorectal Cancer.
    Journal of gastrointestinal cancer, 2018, Volume: 49, Issue:1

    Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Colorectal Neoplasms; Drug Res

2018
5-FU or mitomycin C hepatic arterial infusion after failure of arterial oxaliplatin in patients with colorectal cancer unresectable liver metastases.
    Clinics and research in hepatology and gastroenterology, 2018, Volume: 42, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; H

2018
Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma.
    Clinical colorectal cancer, 2018, Volume: 17, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Colorectal Neopl

2018
Insulin-like growth factor 1 inhibits autophagy of human colorectal carcinoma drug-resistant cells via the protein kinase B/mammalian target of rapamycin signaling pathway.
    Molecular medicine reports, 2018, Volume: 17, Issue:2

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Line, Tumor; Colorectal Neoplasms; Drug

2018
Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer.
    Cancer biology & therapy, 2018, 03-04, Volume: 19, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboxylesterase; Colorectal Neoplasms; DNA Topoisom

2018
Up-regulation of UVRAG by HDAC1 Inhibition Attenuates 5FU-induced Cell Death in HCT116 Colorectal Cancer Cells.
    Anticancer research, 2018, Volume: 38, Issue:1

    Topics: Antimetabolites, Antineoplastic; Cell Death; Colorectal Neoplasms; DNA Damage; Epigenesis, Genetic;

2018
Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer.
    Anticancer research, 2018, Volume: 38, Issue:1

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; B

2018
Apical Lymph Nodes in the Distant Metastases and Prognosis of Patients with Stage III Colorectal Cancer with Adequate Lymph Node Retrieval Following FOLFOX Adjuvant Chemotherapy.
    Pathology oncology research : POR, 2019, Volume: 25, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe

2019
Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models.
    Cell death and differentiation, 2018, Volume: 25, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Differentiation; Cell Proliferati

2018
[Economic Evaluation of mFOLFOX6-based First-line Regimens for Unresectable Advanced or Recurrent Colorectal Cancer Using Clinical Decision Analysis].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2018, Volume: 138, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2018
Thymidylate synthase: a predictive biomarker in resected colorectal liver metastases receiving 5-FU treatment.
    Future oncology (London, England), 2018, Volume: 14, Issue:4

    Topics: Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression Regulation, Neoplasti

2018
The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.
    Journal of the National Cancer Institute, 2018, 08-01, Volume: 110, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemica

2018
Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance.
    Nature communications, 2018, 01-22, Volume: 9, Issue:1

    Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Animals; Caspases; CD8-Positive T-Lymphocytes; Cell D

2018
PIK3R3 promotes chemotherapeutic sensitivity of colorectal cancer through PIK3R3/NF-kB/TP pathway.
    Cancer biology & therapy, 2018, 03-04, Volume: 19, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Datasets as Topic; Diseas

2018
Loss of ABCB4 attenuates the caspase-dependent apoptosis regulating resistance to 5-Fu in colorectal cancer.
    Bioscience reports, 2018, 02-28, Volume: 38, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cas

2018
The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells.
    Acta medica Iranica, 2017, Volume: 55, Issue:12

    Topics: Caco-2 Cells; Camptothecin; Colorectal Neoplasms; Fluorouracil; Genotype; HCT116 Cells; HT29 Cells;

2017
Effective Timing of Surgical Resection of Colorectal Cancer Liver Metastases During Chemotherapy.
    Anticancer research, 2018, Volume: 38, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Cadherins; Cell Line, Tumor; Colorectal Neoplasms; E2F1 Tr

2018
Knockdown of aquaporin-5 sensitizes colorectal cancer cells to 5-fluorouracil via inhibition of the Wnt-β-catenin signaling pathway.
    Biochemistry and cell biology = Biochimie et biologie cellulaire, 2018, Volume: 96, Issue:5

    Topics: Aquaporin 5; beta Catenin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Knock

2018
[Four Cases of Locally Advanced Colorectal Cancer Resected after Neoadjuvant Chemotherapy with mFOLFOX6 plus Bevacizumab].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Flu

2017
Overexpression of CREPT confers colorectal cancer sensitivity to fluorouracil.
    World journal of gastroenterology, 2018, Jan-28, Volume: 24, Issue:4

    Topics: Adenoma; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinogenesis; Cell Cycle;

2018
Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study.
    BMC cancer, 2018, 02-05, Volume: 18, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2018
KRAS and 2 rare PI3KCA mutations coexisting in a metastatic colorectal cancer patient with aggressive and resistant disease.
    Human pathology, 2018, Volume: 74

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neopl

2018
TFAP2C promotes stemness and chemotherapeutic resistance in colorectal cancer via inactivating hippo signaling pathway.
    Journal of experimental & clinical cancer research : CR, 2018, Feb-13, Volume: 37, Issue:1

    Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Ge

2018
Nucleoside diphosphate kinase 2 confers acquired 5-fluorouracil resistance in colorectal cancer cells.
    Artificial cells, nanomedicine, and biotechnology, 2018, Volume: 46, Issue:sup1

    Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; Fluor

2018
Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018, Volume: 59, Issue:7

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Artifacts; Biological Transport; Cell Trans

2018
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery?
    Annals of surgical oncology, 2018, Volume: 25, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Cont

2018
Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
    PharmacoEconomics, 2018, Volume: 36, Issue:7

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cet

2018
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 06-15, Volume: 24, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Colorectal Neoplasms; CpG Islands; DNA M

2018
Targeted delivery of anti-miR-155 by functionalized mesoporous silica nanoparticles for colorectal cancer therapy.
    International journal of nanomedicine, 2018, Volume: 13

    Topics: Animals; Antagomirs; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Drug D

2018
Modified XELIRI (capecitabine plus irinotecan) for metastatic colorectal cancer.
    The Lancet. Oncology, 2018, Volume: 19, Issue:5

    Topics: Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leu

2018
Prognostic Impact of R0 Resection and Targeted Therapy for Colorectal Cancer with Synchronous Peritoneal Metastasis.
    Annals of surgical oncology, 2018, Volume: 25, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab;

2018
The reversal effect of Ginsenoside Rh2 on drug resistance in human colorectal carcinoma cells and its mechanism.
    Human cell, 2018, Volume: 31, Issue:3

    Topics: ATP Binding Cassette Transporter, Subfamily B; Carcinoma; Cell Cycle; Cell Movement; Cell Proliferat

2018
FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.
    World journal of surgical oncology, 2018, Mar-27, Volume: 16, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2018
Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2018, Volume: 44, Issue:7

    Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizu

2018
Correlation between CT morphologic appearance and histologic findings in colorectal liver metastasis after preoperative chemotherapy.
    Abdominal radiology (New York), 2018, Volume: 43, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2018
β‑arrestin2 promotes 5‑FU‑induced apoptosis via the NF‑κB pathway in colorectal cancer.
    Oncology reports, 2018, Volume: 39, Issue:6

    Topics: Aged; Aged, 80 and over; Antimetabolites; beta-Arrestin 2; Cell Line, Tumor; Cell Proliferation; Cel

2018
DNA-based nanoscaffolds as vehicles for 5-fluoro-2'-deoxyuridine oligomers in colorectal cancer therapy.
    Nanoscale, 2018, Apr-19, Volume: 10, Issue:15

    Topics: Cell Line, Tumor; Cholesterol; Colorectal Neoplasms; Deoxyuridine; DNA; Drug Resistance, Neoplasm; F

2018
GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 101

    Topics: Base Sequence; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene

2018
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
    Clinical colorectal cancer, 2018, Volume: 17, Issue:3

    Topics: Activin Receptors, Type II; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2018
Significance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT116.
    Journal of cellular biochemistry, 2018, Volume: 119, Issue:7

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Drug Resistance, Neopl

2018
Hedgehog Signals Mediate Anti-Cancer Drug Resistance in Three-Dimensional Primary Colorectal Cancer Organoid Culture.
    International journal of molecular sciences, 2018, Apr-06, Volume: 19, Issue:4

    Topics: Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; HCT116 Cells; Hedgehog

2018
Cyclin-dependent kinase 1 targeting improves sensitivity to radiation in BRAF V600E colorectal carcinoma cells.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2018, Volume: 40, Issue:4

    Topics: CDC2 Protein Kinase; Cell Line, Tumor; Chemoradiotherapy; Colorectal Neoplasms; Fluorouracil; HCT116

2018
Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects.
    BMC cancer, 2018, 04-23, Volume: 18, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2018
Ubiquitin-Specific Peptidase 22 Contributes to Colorectal Cancer Stemness and Chemoresistance via Wnt/β-Catenin Pathway.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 46, Issue:4

    Topics: AC133 Antigen; Animals; beta Catenin; Caco-2 Cells; Cell Line, Tumor; Colorectal Neoplasms; Drug Res

2018
Knockdown of long non‑coding RNA PVT1 reverses multidrug resistance in colorectal cancer cells.
    Molecular medicine reports, 2018, Volume: 17, Issue:6

    Topics: Adult; Aged; Biomarkers; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female;

2018
Effects of Recombinant Circularly Permuted Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) (Recombinant Mutant Human TRAIL) in Combination with 5-Fluorouracil in Human Colorectal Cancer Cell Lines HCT116 and SW480.
    Medical science monitor : international medical journal of experimental and clinical research, 2018, Apr-26, Volume: 24

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Caspase Inhibitors; Caspases; Cell

2018
FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report.
    BMC cancer, 2018, 04-26, Volume: 18, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Colorectal Neoplasms; Fatal Outcom

2018
Fast-Track Two-Stage Hepatectomy Using a Hybrid Interventional Radiology/Operating Suite as Alternative Option to Associated Liver Partition and Portal Vein Ligation for Staged Hepatectomy Procedure.
    Journal of the American College of Surgeons, 2018, Volume: 227, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Embolization

2018
DNA methylation-mediated repression of miR-181a/135a/302c expression promotes the microsatellite-unstable colorectal cancer development and 5-FU resistance via targeting PLAG1.
    Journal of genetics and genomics = Yi chuan xue bao, 2018, 04-20, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; DNA Methylation; DNA-Binding Proteins

2018
Anticancer and Antimigration Effects of a Combinatorial Treatment of 5-Fluorouracil and Lactobacillus paracasei subsp. paracasei NTU 101 Fermented Skim Milk Extracts on Colorectal Cancer Cells.
    Journal of agricultural and food chemistry, 2018, Jun-06, Volume: 66, Issue:22

    Topics: Animals; Antineoplastic Agents; Cell Line; Cell Movement; Cell Survival; Colorectal Neoplasms; Combi

2018
Beta-elemene increases chemosensitivity to 5-fluorouracil through down-regulating microRNA-191 expression in colorectal carcinoma cells.
    Journal of cellular biochemistry, 2018, Volume: 119, Issue:8

    Topics: beta Catenin; Colorectal Neoplasms; Down-Regulation; Fluorouracil; Gene Expression Regulation, Neopl

2018
Dihydroartemisinin potentiates antitumor activity of 5-fluorouracil against a resistant colorectal cancer cell line.
    Biochemical and biophysical research communications, 2018, 06-27, Volume: 501, Issue:3

    Topics: Antimalarials; Antimetabolites, Antineoplastic; Apoptosis; Artemisinins; Colorectal Neoplasms; Drug

2018
Short article: Influence of regulatory NLRC5 variants on colorectal cancer survival and 5-fluorouracil-based chemotherapy.
    European journal of gastroenterology & hepatology, 2018, Volume: 30, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2018
MiR-519d reduces the 5-fluorouracil resistance in colorectal cancer cells by down-regulating the expression of CCND1.
    European review for medical and pharmacological sciences, 2018, Volume: 22, Issue:9

    Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Cyclin D1; Down-Regulation;

2018
Posterior Reversible Encephalopathy Syndrome (PRES) Presenting as Status Epilepticus: A Case Report and Literature Review.
    Connecticut medicine, 2016, Volume: 80, Issue:8

    Topics: Antihypertensive Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy

2016
Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2018, Volume: 16, Issue:5S

    Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tu

2018
Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 47, Issue:2

    Topics: Apoptosis; Azetidines; Cell Line, Tumor; Colorectal Neoplasms; Cyclin D1; Cyclin-Dependent Kinase In

2018
Deciphering the potential value of 5-fluorouracil metabolic enzymes in predicting prognosis and treatment response of colorectal cancer patients.
    The International journal of biological markers, 2018, Volume: 33, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Colorectal Neoplasms; Dihydrouracil Dehydrogenase

2018
The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer.
    Cancer chemotherapy and pharmacology, 2018, Volume: 82, Issue:2

    Topics: 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; Adult; Aged; Antineoplastic Combined Chem

2018
How should BRAF V600E-mutated colorectal cancer be treated?
    Clinical advances in hematology & oncology : H&O, 2018, Volume: 16, Issue:5

    Topics: Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin;

2018
Overcoming stemness and chemoresistance in colorectal cancer through miR-195-5p-modulated inhibition of notch signaling.
    International journal of biological macromolecules, 2018, Oct-01, Volume: 117

    Topics: Animals; Base Sequence; Cell Line, Tumor; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Ne

2018
Upregulation of HOXA10 Protein Expression Predicts Poor Prognosis for Colorectal Cancer.
    Genetic testing and molecular biomarkers, 2018, Volume: 22, Issue:6

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Chemotherapy, Adjuvant; Colorectal Neopl

2018
Chrysin Attenuates Cell Viability of Human Colorectal Cancer Cells through Autophagy Induction Unlike 5-Fluorouracil/Oxaliplatin.
    International journal of molecular sciences, 2018, Jun-14, Volume: 19, Issue:6

    Topics: Antineoplastic Agents; Autophagy; Cell Survival; Colorectal Neoplasms; Flavonoids; Fluorouracil; HCT

2018
Patrinia scabiosaefolia Inhibits Growth of 5-FU-Resistant Colorectal Carcinoma Cells via Induction of Apoptosis and Suppression of AKT Pathway.
    Chinese journal of integrative medicine, 2019, Volume: 25, Issue:2

    Topics: Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorect

2019
Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work.
    Applied health economics and health policy, 2018, Volume: 16, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Cost-

2018
Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019, Volume: 33, Issue:1

    Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fe

2019
Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry.
    Clinical colorectal cancer, 2018, Volume: 17, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorect

2018
Resveratrol Chemosensitizes TNF-β-Induced Survival of 5-FU-Treated Colorectal Cancer Cells.
    Nutrients, 2018, Jul-12, Volume: 10, Issue:7

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Ce

2018
miR-106a Reduces 5-Fluorouracil (5-FU) Sensitivity of Colorectal Cancer by Targeting Dual-Specificity Phosphatases 2 (DUSP2).
    Medical science monitor : international medical journal of experimental and clinical research, 2018, Jul-16, Volume: 24

    Topics: 3' Untranslated Regions; Cell Line, Tumor; Cell Proliferation; Cell Survival; China; Colorectal Neop

2018
Investigation of the relationship among fatigue, self-efficacy and quality of life during chemotherapy in patients with breast, lung or gastrointestinal cancer.
    European journal of cancer care, 2019, Volume: 28, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2019
Anti-angiogenic drug scheduling optimisation with application to colorectal cancer.
    Scientific reports, 2018, 07-25, Volume: 8, Issue:1

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Prolifera

2018
Toxicity of oxaliplatin rechallenge in metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 10-01, Volume: 29, Issue:10

    Topics: Colorectal Neoplasms; Fluorouracil; Humans; Organoplatinum Compounds; Oxaliplatin

2018
Investigation into Enhancing Capecitabine Efficacy in Colorectal Cancer by Inhibiting Focal Adhesion Kinase Signaling.
    Anticancer research, 2018, Volume: 38, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Calcium Compounds; Capecitabine; Cell Line,

2018
A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5-Fluorouracil by reversing Notch and epithelial-mesenchymal transition in vitro and in vivo.
    Cell proliferation, 2018, Volume: 51, Issue:5

    Topics: A549 Cells; ADAM17 Protein; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Movement; Ce

2018
Functional significance of Hippo/YAP signaling for drug resistance in colorectal cancer.
    Molecular carcinogenesis, 2018, Volume: 57, Issue:11

    Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Cycle Proteins; Cell Line, Tumor;

2018
Bcl-2-associated athanogene 3(BAG3) is associated with tumor cell proliferation, migration, invasion and chemoresistance in colorectal cancer.
    BMC cancer, 2018, Aug-06, Volume: 18, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Aged; Antimetabolites, Antineoplastic; Apoptosis Regulatory Pr

2018
A natural flavonoid lawsonaringenin induces cell cycle arrest and apoptosis in HT-29 colorectal cancer cells by targeting multiple signalling pathways.
    Molecular biology reports, 2018, Volume: 45, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Prolife

2018
A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2019, Volume: 27, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2019
Impact of biological agents on the prevalence of chemotherapy associated liver injury (CALI): Multicentric study of patients operated for colorectal liver metastases.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2018, Volume: 44, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2018
Turmeric extract, with absorbable curcumin, has potent anti-metastatic effect in vitro and in vivo.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2018, Jul-15, Volume: 46

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Curcuma; Curcumin; Fluoroura

2018
Impact of Time to Start Systemic Therapy on the Outcomes of Patients with Metastatic Colorectal Cancer Treated with First Line FOLFOX Chemotherapy; a Patient-Level Pooled Analysis of Two Clinical Trials.
    Expert review of gastroenterology & hepatology, 2018, Volume: 12, Issue:10

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevaciz

2018
ZBTB7 evokes 5-fluorouracil resistance in colorectal cancer through the NF‑κB signaling pathway.
    International journal of oncology, 2018, Volume: 53, Issue:5

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; DNA-Binding Protei

2018
Sensitivity of Colorectal Cancer to Arginine Deprivation Therapy is Shaped by Differential Expression of Urea Cycle Enzymes.
    Scientific reports, 2018, 08-14, Volume: 8, Issue:1

    Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Arginase; Arginine; Argininosuccinate

2018
Wnt pathway is involved in 5-FU drug resistance of colorectal cancer cells.
    Experimental & molecular medicine, 2018, 08-14, Volume: 50, Issue:8

    Topics: Acetylation; Animals; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Colorectal Neoplasms; DN

2018
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    The oncologist, 2018, Volume: 23, Issue:11

    Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2018
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    The oncologist, 2018, Volume: 23, Issue:11

    Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2018
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    The oncologist, 2018, Volume: 23, Issue:11

    Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2018
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    The oncologist, 2018, Volume: 23, Issue:11

    Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2018
Crocin synergistically enhances the antiproliferative activity of 5-flurouracil through Wnt/PI3K pathway in a mouse model of colitis-associated colorectal cancer.
    Journal of cellular biochemistry, 2018, Volume: 119, Issue:12

    Topics: Animals; Antioxidants; Carotenoids; Cell Proliferation; Colitis; Colorectal Neoplasms; Dextran Sulfa

2018
Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy
    Asian Pacific journal of cancer prevention : APJCP, 2018, Aug-24, Volume: 19, Issue:8

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cetuximab;

2018
Enhancing 5-fluorouracil efficacy through suppression of PKM2 in colorectal cancer cells.
    Cancer chemotherapy and pharmacology, 2018, Volume: 82, Issue:6

    Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Antimetabolites, Antineoplastic; Cell Prolif

2018
Impact of diabetes comorbidity on the efficacy and safety of FOLFOX first-line chemotherapy among patients with metastatic colorectal cancer: a pooled analysis of two phase-III studies.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019, Volume: 21, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Colorecta

2019
Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
    PloS one, 2018, Volume: 13, Issue:9

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; CpG Islands;

2018
Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients.
    Journal of translational medicine, 2018, 09-06, Volume: 16, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Female; Fluo

2018
Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy.
    Drug metabolism and personalized therapy, 2018, 12-19, Volume: 33, Issue:4

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dihydrouracil Dehydro

2018
Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2018, Volume: 17, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cetuximab; Colorectal Neoplasms; Female;

2018
The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 108

    Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Biodiversity; Cell Line, Tumor; Colorectal Ne

2018
Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?
    Internal medicine journal, 2019, Volume: 49, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemoth

2019
Oral Cryotherapy: Prevention of Oral Mucositis and Pain Among Patients With Colorectal Cancer Undergoing Chemotherapy.
    Clinical journal of oncology nursing, 2018, 10-01, Volume: 22, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Antifungal Agents; Antineoplastic Agents; Co

2018
Safety evaluation of simultaneous resection of colorectal primary tumor and liver metastasis after neoadjuvant therapy: A propensity score matching analysis.
    American journal of surgery, 2019, Volume: 218, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2019
[Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2018, Sep-25, Volume: 21, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2018
ANRIL promotes chemoresistance via disturbing expression of ABCC1 by regulating the expression of Let-7a in colorectal cancer.
    Bioscience reports, 2018, 12-21, Volume: 38, Issue:6

    Topics: Apoptosis; Carcinogenesis; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Drug Resistance,

2018
Colorectal cancer combination therapy using drug and gene co-delivered, targeted poly(ethylene glycol)-ε-poly(caprolactone) nanocarriers.
    Drug design, development and therapy, 2018, Volume: 12

    Topics: Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Carriers; Dr

2018
Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study.
    BMC cancer, 2018, Oct-05, Volume: 18, Issue:1

    Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2018
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:1

    Topics: 5'-Nucleotidase; Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Bevacizumab; Bi

2019
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:1

    Topics: 5'-Nucleotidase; Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Bevacizumab; Bi

2019
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:1

    Topics: 5'-Nucleotidase; Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Bevacizumab; Bi

2019
Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:1

    Topics: 5'-Nucleotidase; Adenosine; Antineoplastic Combined Chemotherapy Protocols; Apyrase; Bevacizumab; Bi

2019
Effects of Adjuvant Chemotherapy on Cognitive Function of Patients With Early-stage Colorectal Cancer.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adjuvant;

2019
A molecular basis for the synergy between 17‑allylamino‑17‑demethoxy geldanamycin with Capecitabine and Irinotecan in human colorectal cancer cells through VEFG and MMP-9 gene expression.
    Gene, 2019, Feb-05, Volume: 684

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Camptothecin; Capecitabine; Colonic N

2019
Nuclear factor I/B promotes colorectal cancer cell proliferation, epithelial-mesenchymal transition and 5-fluorouracil resistance.
    Cancer science, 2019, Volume: 110, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms

2019
A new chalcone derivative, 3-phenyl-1-(2,4,6-tris(methoxymethoxy)phenyl)prop-2-yn-1-one), inhibits phorbol ester-induced metastatic activity of colorectal cancer cells through upregulation of heme oxygenase-1.
    European journal of pharmacology, 2018, Dec-15, Volume: 841

    Topics: Cell Movement; Cell Proliferation; Chalcone; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor

2018
MiR-30-5p suppresses cell chemoresistance and stemness in colorectal cancer through USP22/Wnt/β-catenin signaling axis.
    Journal of cellular and molecular medicine, 2019, Volume: 23, Issue:1

    Topics: beta Catenin; Caco-2 Cells; Cell Line; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; D

2019
Isoliquiritigenin-mediated p62/SQSTM1 induction regulates apoptotic potential through attenuation of caspase-8 activation in colorectal cancer cells.
    European journal of pharmacology, 2018, Dec-15, Volume: 841

    Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 8; Cell Line, Tumor; Cell Survival; Chalcones; Co

2018
Cost-effectiveness of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
    Cancer, 2019, 01-15, Volume: 125, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy

2019
Nrf2 is a key factor in the reversal effect of curcumin on multidrug resistance in the HCT‑8/5‑Fu human colorectal cancer cell line.
    Molecular medicine reports, 2018, Volume: 18, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation;

2018
Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study.
    Acta oncologica (Stockholm, Sweden), 2018, Volume: 57, Issue:11

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr

2018
Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance.
    Oncogene, 2019, Volume: 38, Issue:11

    Topics: Animals; Antineoplastic Agents; Cell Dedifferentiation; Cell Proliferation; Cells, Cultured; Colorec

2019
Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiotox

2019
Patients with hMLH1 or/and hMSH2-deficient Metastatic Colorectal Cancer Are Associated with Reduced Levels of Vascular Endothelial Growth Factor-1 Expression and Higher Response Rate to Irinotecan-based Regimen.
    Anticancer research, 2018, Volume: 38, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2018
Neoadjuvant Capecitabine Results in Similar Total Lymph Node Harvests as 5-Fluorouracil but an Increased Number of Lymph Nodes Containing Adenocarcinoma on Resection.
    The American surgeon, 2018, Jul-01, Volume: 84, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Colorectal

2018
HER2 as a potential biomarker guiding adjuvant chemotherapy in stage II colorectal cancer.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2019, Volume: 45, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplas

2019
Chemotherapy-induced
    Bioscience reports, 2018, 12-21, Volume: 38, Issue:6

    Topics: Animals; Apoptosis; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Disease Progression; Dr

2018
Laparoscopic repair of bevacizumab-induced vesicovaginal fistula in metastatic colon cancer - a video vignette.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2019, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cecal Neo

2019
Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy.
    Cell death & disease, 2018, 11-19, Volume: 9, Issue:12

    Topics: Aged; Autophagy; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neopla

2018
Chemotherapy-induced liver injury in metastatic colorectal cancer: about 48 cases.
    The Pan African medical journal, 2018, Volume: 30

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury;

2018
Overexpression of miR-215-3p sensitizes colorectal cancer to 5-fluorouracil induced apoptosis through regulating CXCR1.
    European review for medical and pharmacological sciences, 2018, Volume: 22, Issue:21

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Dose-Response Relationshi

2018
A Biodegradable Stent with Surface Functionalization of Combined-Therapy Drugs for Colorectal Cancer.
    Advanced healthcare materials, 2018, Volume: 7, Issue:24

    Topics: Absorbable Implants; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, T

2018
5-Fluorouracil-related Cardiotoxicity; Findings From Five Randomized Studies of 5-Fluorouracil-based Regimens in Metastatic Colorectal Cancer.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cardiotoxicity; Cardiovascular Diseases

2019
Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial.
    Journal francais d'ophtalmologie, 2018, Volume: 41, Issue:10

    Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplasti

2018
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 106

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembry

2019
MEK inhibitor enhanced the antitumor effect of oxaliplatin and 5‑fluorouracil in MEK1 Q56P‑mutant colorectal cancer cells.
    Molecular medicine reports, 2019, Volume: 19, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Butadienes; Cell Line, Tumor; Cell Survival; C

2019
Autophagy facilitates anticancer effect of 5-fluorouracil in HCT-116 cells.
    Journal of cancer research and therapeutics, 2018, Volume: 14, Issue:Supplement

    Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Beclin-1; Cell Prolif

2018
Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Drug Interaction

2019
Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan.
    Journal of comparative effectiveness research, 2019, Volume: 8, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe

2019
[The inhibition of angiogenic pathway in second line treatment of metastatic colorectal cancer.]
    Recenti progressi in medicina, 2018, Volume: 109, Issue:11

    Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Campt

2018
Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
    Genomics, 2019, Volume: 111, Issue:6

    Topics: Acrylamides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Color

2019
Exogenous interleukin-1α signaling negatively impacts acquired chemoresistance and alters cell adhesion molecule expression pattern in colorectal carcinoma cells HCT116.
    Cytokine, 2019, Volume: 114

    Topics: Apoptosis; Cell Adhesion Molecules; Cell Cycle Checkpoints; Cell Shape; Colorectal Neoplasms; Down-R

2019
SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 03-15, Volume: 25, Issue:6

    Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherap

2019
Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells.
    Carcinogenesis, 2019, 05-14, Volume: 40, Issue:3

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; D

2019
Oligomeric proanthocyanidins (OPCs) from grape seed extract suppress the activity of ABC transporters in overcoming chemoresistance in colorectal cancer cells.
    Carcinogenesis, 2019, 05-14, Volume: 40, Issue:3

    Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Colorectal Neoplasms; Drug Resist

2019
Population pharmacokinetic model of irinotecan and its metabolites in patients with metastatic colorectal cancer.
    European journal of clinical pharmacology, 2019, Volume: 75, Issue:4

    Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2019
Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
    International journal of cancer, 2019, 07-15, Volume: 145, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinica

2019
Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
    International journal of cancer, 2019, 07-15, Volume: 145, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinica

2019
Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
    International journal of cancer, 2019, 07-15, Volume: 145, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinica

2019
Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials.
    International journal of cancer, 2019, 07-15, Volume: 145, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinica

2019
Bacterial Ghosts Carrying 5-Fluorouracil: A Novel Biological Carrier for Targeting Colorectal Cancer.
    AAPS PharmSciTech, 2019, Jan-07, Volume: 20, Issue:2

    Topics: Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Membrane; Cell Wall; Colorectal Neoplasms; Drug

2019
Cost-effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients.
    Pharmacogenomics, 2019, Volume: 20, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal N

2019
Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer.
    Journal of experimental & clinical cancer research : CR, 2019, 01-10, Volume: 38, Issue:1

    Topics: Adult; Aged; Animals; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Cell Line, Tumor; Cell

2019
Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:1

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Cetuximab; Cohort Studies;

2019
Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy.
    Acta oncologica (Stockholm, Sweden), 2019, Volume: 58, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother

2019
The frequency and predictors of persistent amenorrhea in premenopausal women with colorectal cancer who received adjuvant chemotherapy.
    Anti-cancer drugs, 2019, Volume: 30, Issue:3

    Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorecta

2019
Home-Based e-Health Platform for Multidimensional Telemonitoring of Symptoms, Body Weight, Sleep, and Circadian Activity: Relevance for Chronomodulated Administration of Irinotecan, Fluorouracil-Leucovorin, and Oxaliplatin at Home-Results From a Pilot Stu
    JCO clinical cancer informatics, 2018, Volume: 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Circadian Rhythm; Colorect

2018
Serine Threonine Kinase 17A Maintains the Epithelial State in Colorectal Cancer Cells.
    Molecular cancer research : MCR, 2019, Volume: 17, Issue:4

    Topics: Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Epithelial Cel

2019
Values of applying white blood cell counts in the prognostic evaluation of resectable colorectal cancer.
    Molecular medicine reports, 2019, Volume: 19, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Basophils; Capecitabine; Chemotherapy,

2019
Tumor-associated Macrophages and Neuroendocrine Differentiation Decrease the Efficacy of Bevacizumab Plus Chemotherapy in Patients With Advanced Colorectal Cancer.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Differe

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile

2019
Predictors of toxicity-related hospitalization in four randomized studies of 5-fluorouracil-based chemotherapy in metastatic colorectal cancer.
    International journal of colorectal disease, 2019, Volume: 34, Issue:4

    Topics: Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; Hospitalization; Humans; Logistic Models

2019
Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC.
    Advances in therapy, 2019, Volume: 36, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C

2019
Esculetin enhances the inhibitory effect of 5-Fluorouracil on the proliferation, migration and epithelial-mesenchymal transition of colorectal cancer.
    Cancer biomarkers : section A of Disease markers, 2019, Volume: 24, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell

2019
Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers.
    Cancer medicine, 2019, Volume: 8, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmaco

2019
[A Case of Complete Pathological Response of Unresectable Synchronous Colorectal Hepatic Metastasis with Icterus after FOLFOX plus Panitumumab Therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:13

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatecto

2018
[A Case of Resistance to Systemic Therapy in Hypermutation of Colorectal Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:13

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Le

2018
Cepharanthine combined with 5-fluorouracil inhibits the growth of p53-mutant human colorectal cancer cells.
    Journal of Asian natural products research, 2020, Volume: 22, Issue:4

    Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzylisoquinolines; Cell Line,

2020
FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression.
    Scientific reports, 2019, 02-06, Volume: 9, Issue:1

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Co

2019
A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome.
    BMJ case reports, 2019, Feb-09, Volume: 12, Issue:2

    Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged, 80 and over; Antineoplastic Agents, Immunological; An

2019
(-)-Epigallocatechin Gallate (EGCG) Enhances the Sensitivity of Colorectal Cancer Cells to 5-FU by Inhibiting GRP78/NF-κB/miR-155-5p/MDR1 Pathway.
    Journal of agricultural and food chemistry, 2019, Mar-06, Volume: 67, Issue:9

    Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Catechin; Colorectal Neoplasms; DNA Damage

2019
    International journal of medical sciences, 2019, Volume: 16, Issue:2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bio

2019
SSRP1 promotes colorectal cancer progression and is negatively regulated by miR-28-5p.
    Journal of cellular and molecular medicine, 2019, Volume: 23, Issue:5

    Topics: Aged; Animals; Apoptosis; Cell Movement; Cell Proliferation; Cisplatin; Colorectal Neoplasms; Diseas

2019
Repeat hepatectomy with systemic chemotherapy might improve survival of recurrent liver metastasis from colorectal cancer-a retrospective observational study.
    World journal of surgical oncology, 2019, Feb-15, Volume: 17, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2019
Effect of diabetes on neurological adverse effects and chemotherapy induced peripheral neuropathy in advanced colorectal cancer patients treated with different FOLFOX regimens.
    Pakistan journal of pharmaceutical sciences, 2019, Volume: 32, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2019
PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways.
    Cancer letters, 2019, 05-28, Volume: 450

    Topics: Animals; B7-H1 Antigen; Cisplatin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; HC

2019
The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer.
    Disease markers, 2019, Volume: 2019

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9

2019
Impact of 5 fluorouracil chemotherapy on gut inflammation, functional parameters, and gut microbiota.
    Brain, behavior, and immunity, 2019, Volume: 80

    Topics: Animals; Azoxymethane; Colitis; Colon; Colonic Neoplasms; Colorectal Neoplasms; Dextran Sulfate; Dis

2019
High hepatic expression of PDK4 improves survival upon multimodal treatment of colorectal liver metastases.
    British journal of cancer, 2019, Volume: 120, Issue:7

    Topics: Aged; Animals; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Down-Regulati

2019
Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
    BMC cancer, 2019, Mar-04, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Caco-2 Cells; Cell Line,

2019
PAR2 Inhibition Enhanced the Sensitivity of Colorectal Cancer Cells to 5-FU and Reduced EMT Signaling.
    Oncology research, 2019, Jul-12, Volume: 27, Issue:7

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Colorectal Neo

2019
Down-regulation of miR-543 expression increases the sensitivity of colorectal cancer cells to 5-Fluorouracil through the PTEN/PI3K/AKT pathway.
    Bioscience reports, 2019, 03-29, Volume: 39, Issue:3

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Colorect

2019
ABHD5 blunts the sensitivity of colorectal cancer to fluorouracil via promoting autophagic uracil yield.
    Nature communications, 2019, 03-06, Volume: 10, Issue:1

    Topics: 1-Acylglycerol-3-Phosphate O-Acyltransferase; Animals; Antimetabolites, Antineoplastic; Autophagy; B

2019
Quality of life in non-metastasic colorectal cancer patients in FOLFOX or XELOX therapy.
    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2019, 03-01, Volume: 43, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2019
Cysteine-rich intestinal protein 1 suppresses apoptosis and chemosensitivity to 5-fluorouracil in colorectal cancer through ubiquitin-mediated Fas degradation.
    Journal of experimental & clinical cancer research : CR, 2019, Mar-08, Volume: 38, Issue:1

    Topics: Animals; Apoptosis; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Dr

2019
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone.
    Anti-cancer drugs, 2019, Volume: 30, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2019
Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia.
    Internal medicine journal, 2020, Volume: 50, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Bevacizum

2020
Effect of FOLFOX6 chemotherapy on serum VEGF expression in advanced colorectal cancer patients.
    Revista da Associacao Medica Brasileira (1992), 2019, Volume: 65, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl

2019
Guar gum modified upconversion nanocomposites for colorectal cancer treatment through enzyme-responsive drug release and NIR-triggered photodynamic therapy.
    Nanotechnology, 2019, Aug-02, Volume: 30, Issue:31

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Delayed-Action Preparations; Fluorouracil; Ga

2019
p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    British journal of cancer, 2019, Volume: 120, Issue:8

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col

2019
Poly(3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer.
    Drug delivery, 2019, Volume: 26, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biological Availability; Cell Survival; Colorectal

2019
Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
    BMC cancer, 2019, Mar-21, Volume: 19, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Clo

2019
Cloning, expression of the truncation of recombinant peroxidase derived from millet bran and its reversal effects on 5-Fu resistance in colorectal cancer.
    International journal of biological macromolecules, 2019, Jul-01, Volume: 132

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cloning, Molecular; Colorectal Neoplasms; Drug Resi

2019
RIPK3 expression as a potential predictive and prognostic marker in metastatic colon cancer.
    Clinical and investigative medicine. Medecine clinique et experimentale, 2019, 03-23, Volume: 42, Issue:1

    Topics: Apoptosis; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Prognosis; R

2019
Tacalcitol increases the sensitivity of colorectal cancer cells to 5-fluorouracil by downregulating the thymidylate synthase.
    The Journal of steroid biochemistry and molecular biology, 2019, Volume: 190

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydroxycholecalciferols; Down-Regulation; D

2019
Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2019, Volume: 21, Issue:11

    Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2019
Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells.
    Nature communications, 2019, 03-29, Volume: 10, Issue:1

    Topics: Animals; Cell Differentiation; Cell Proliferation; Cell Self Renewal; Colorectal Neoplasms; Enhancer

2019
Sex-Dependent Adverse Drug Reactions to 5-Fluorouracil in Colorectal Cancer.
    Biological & pharmaceutical bulletin, 2019, Volume: 42, Issue:4

    Topics: Aged; Animals; Antimetabolites, Antineoplastic; Asian People; Cell Line, Tumor; Cell Survival; Color

2019
Long non-coding RNA PCAT6 targets miR-204 to modulate the chemoresistance of colorectal cancer cells to 5-fluorouracil-based treatment through HMGA2 signaling.
    Cancer medicine, 2019, Volume: 8, Issue:5

    Topics: Adult; Aged; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm;

2019
Cytoplasmic E-Cadherin Expression Is Associated With Higher Tumour Level of VEGFA, Lower Response Rate to Irinotecan-based Treatment and Poorer Prognosis in Patients With Metastatic Colorectal Cancer.
    Anticancer research, 2019, Volume: 39, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomar

2019
PGC-1α Controls Mitochondrial Biogenesis in Drug-Resistant Colorectal Cancer Cells by Regulating Endoplasmic Reticulum Stress.
    International journal of molecular sciences, 2019, Apr-05, Volume: 20, Issue:7

    Topics: Antioxidants; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Cytoprotection; Drug Resistance, Ne

2019
Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites.
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2019, Volume: 22, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Data Mining; Fluor

2019
Central venous catheter misplaced in the epidural space.
    BMJ case reports, 2019, Apr-08, Volume: 12, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Catheterization, Central Venous; Centra

2019
Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
    Cancer chemotherapy and pharmacology, 2019, Volume: 83, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Cu

2019
Epidermal growth factor receptor-targeted molecular imaging of colorectal tumors: Detection and treatment evaluation of tumors in animal models.
    Cancer science, 2019, Volume: 110, Issue:6

    Topics: Animals; Antineoplastic Agents; Azoxymethane; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms;

2019
ROS/JNK/c-Jun axis is involved in oridonin-induced caspase-dependent apoptosis in human colorectal cancer cells.
    Biochemical and biophysical research communications, 2019, 06-04, Volume: 513, Issue:3

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Colore

2019
The Influence of Curcumin on the Downregulation of MYC, Insulin and IGF-1 Receptors: A possible Mechanism Underlying the Anti-Growth and Anti-Migration in Chemoresistant Colorectal Cancer Cells.
    Medicina (Kaunas, Lithuania), 2019, Apr-03, Volume: 55, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement;

2019
Antiproliferative Effects of Hop-derived Prenylflavonoids and Their Influence on the Efficacy of Oxaliplatine, 5-fluorouracil and Irinotecan in Human ColorectalC Cells.
    Nutrients, 2019, Apr-19, Volume: 11, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Beer; Caco-2 Cells; Caspases

2019
Establishment and Characterization of 5-Fluorouracil-Resistant Human Colorectal Cancer Stem-Like Cells: Tumor Dynamics under Selection Pressure.
    International journal of molecular sciences, 2019, Apr-12, Volume: 20, Issue:8

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers; Cell Cycle; Cell Line, Tumor; Color

2019
SNHG15 is a bifunctional MYC-regulated noncoding locus encoding a lncRNA that promotes cell proliferation, invasion and drug resistance in colorectal cancer by interacting with AIF.
    Journal of experimental & clinical cancer research : CR, 2019, 04-24, Volume: 38, Issue:1

    Topics: Animals; Apoptosis Inducing Factor; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; CRIS

2019
Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer.
    Colloids and surfaces. B, Biointerfaces, 2019, Aug-01, Volume: 180

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2019
Fisetin and 5-fluorouracil: Effective combination for PIK3CA-mutant colorectal cancer.
    International journal of cancer, 2019, 12-01, Volume: 145, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell

2019
Enhancement of chemosensitivity in 5-fluorouracil-resistant colon cancer cells with carcinoembryonic antigen-specific RNA aptamer.
    Molecular biology reports, 2019, Volume: 46, Issue:4

    Topics: Animals; Aptamers, Nucleotide; Biomarkers, Pharmacological; Carcinoembryonic Antigen; Cell Adhesion;

2019
Epigenetically Down-Regulated Acetyltransferase PCAF Increases the Resistance of Colorectal Cancer to 5-Fluorouracil.
    Neoplasia (New York, N.Y.), 2019, Volume: 21, Issue:6

    Topics: Acetylation; Animals; Apoptosis; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Cyclin D1;

2019
Association of pathway mutation with survival after recurrence in colorectal cancer patients treated with adjuvant fluoropyrimidine and oxaliplatin chemotherapy.
    BMC cancer, 2019, May-06, Volume: 19, Issue:1

    Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T

2019
Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2019
Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma.
    Scientific reports, 2019, 05-08, Volume: 9, Issue:1

    Topics: Antimetabolites, Antineoplastic; Cell Culture Techniques; Coculture Techniques; Colorectal Neoplasms

2019
MicroRNA-552 deficiency mediates 5-fluorouracil resistance by targeting SMAD2 signaling in DNA-mismatch-repair-deficient colorectal cancer.
    Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:2

    Topics: Animals; Colorectal Neoplasms; Disease Models, Animal; DNA Mismatch Repair; Fluorouracil; Humans; Mi

2019
Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
    World journal of surgical oncology, 2019, May-15, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma;

2019
Evaluating Immunotherapy in Nonmetastatic Colorectal Cancer.
    Oncology (Williston Park, N.Y.), 2019, 05-14, Volume: 33, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Che

2019
Combination of 5-fluorouracil and thymoquinone targets stem cell gene signature in colorectal cancer cells.
    Cell death & disease, 2019, 05-16, Volume: 10, Issue:6

    Topics: AC133 Antigen; Animals; Benzoquinones; beta Catenin; Cell Adhesion; Chick Embryo; Colorectal Neoplas

2019
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
    Gut, 2020, Volume: 69, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2020
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
    Gut, 2020, Volume: 69, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2020
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
    Gut, 2020, Volume: 69, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2020
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
    Gut, 2020, Volume: 69, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2020
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
    Gut, 2020, Volume: 69, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2020
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
    Gut, 2020, Volume: 69, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2020
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
    Gut, 2020, Volume: 69, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2020
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
    Gut, 2020, Volume: 69, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2020
Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
    Gut, 2020, Volume: 69, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2020
Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters.
    Journal of pharmacological sciences, 2019, Volume: 140, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea;

2019
In vivo effects of chemotherapy on oncogenic pathways in colorectal cancer.
    Cancer science, 2019, Volume: 110, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cell Proliferation; Colorec

2019
Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis.
    The oncologist, 2019, Volume: 24, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2019
Induced miR-31 by 5-fluorouracil exposure contributes to the resistance in colorectal tumors.
    Cancer science, 2019, Volume: 110, Issue:8

    Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Down-Regulation; Drug Resis

2019
Synergistic Effect of Combined Treatment with Longan Flower Extract and 5-Fluorouracil on Colorectal Cancer Cells.
    Nutrition and cancer, 2020, Volume: 72, Issue:2

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell S

2020
Effects of 5-FU and anti-EGFR antibody in combination with ASA on the spherical culture system of HCT116 and HT29 colorectal cancer cell lines.
    International journal of oncology, 2019, Volume: 55, Issue:1

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Autophagy; Cell Cyc

2019
Synergistic effect of kaempferol and 5‑fluorouracil on the growth of colorectal cancer cells by regulating the PI3K/Akt signaling pathway.
    Molecular medicine reports, 2019, Volume: 20, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Drug Synergism; Fluorour

2019
Theragnosis by a miR-141-3p molecular beacon: simultaneous detection and sensitization of 5-fluorouracil resistant colorectal cancer cells through the activation of the TRIM13-associated apoptotic pathway.
    Chemical communications (Cambridge, England), 2019, Jul-04, Volume: 55, Issue:52

    Topics: Antagomirs; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; DNA-Binding Proteins; Drug Resistance

2019
Docosahexaenoic acid inhibits both NLRP3 inflammasome assembly and JNK-mediated mature IL-1β secretion in 5-fluorouracil-treated MDSC: implication in cancer treatment.
    Cell death & disease, 2019, 06-19, Volume: 10, Issue:7

    Topics: Animals; Antineoplastic Agents; beta-Arrestin 2; Caspase 1; Cell Line, Tumor; Colorectal Neoplasms;

2019
Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer.
    PloS one, 2019, Volume: 14, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2019
Folate pathway genes linked to mitochondrial biogenesis and respiration are associated with outcome of patients with stage III colorectal cancer.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2019, Volume: 41, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2019
Potent antitumor activity of Laccaic acid and Phenethyl isothiocyanate combination in colorectal cancer via dual inhibition of DNA methyltransferase-1 and Histone deacetylase-1.
    Toxicology and applied pharmacology, 2019, 08-15, Volume: 377

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis;

2019
5-Fluorouracil induced liver toxicity in patients with colorectal cancer: role of computed tomography texture analysis as a potential biomarker.
    Abdominal radiology (New York), 2019, Volume: 44, Issue:9

    Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers; Chemical and Drug Induced Liver Injury; Colorecta

2019
Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol.
    BMC cancer, 2019, Jun-28, Volume: 19, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemo

2019
The long non-coding RNA HOTAIRM1 suppresses cell progression via sponging endogenous miR-17-5p/ B-cell translocation gene 3 (BTG3) axis in 5-fluorouracil resistant colorectal cancer cells.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 117

    Topics: Animals; Base Sequence; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Colorectal Neoplasms;

2019
Nomogram predicted disease free survival for colorectal liver metastasis patients with preoperative chemotherapy followed by hepatic resection.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2019, Volume: 45, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine

2019
Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 10-15, Volume: 25, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Chemotherapy,

2019
IPO5 promotes the proliferation and tumourigenicity of colorectal cancer cells by mediating RASAL2 nuclear transportation.
    Journal of experimental & clinical cancer research : CR, 2019, Jul-09, Volume: 38, Issue:1

    Topics: Active Transport, Cell Nucleus; Adult; Aged; Animals; beta Karyopherins; Carrier Proteins; Cell Line

2019
Inhibition of KHSRP sensitizes colorectal cancer to 5-fluoruracil through miR-501-5p-mediated ERRFI1 mRNA degradation.
    Journal of cellular physiology, 2020, Volume: 235, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Animals; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluo

2020
Exosomal transfer of p-STAT3 promotes acquired 5-FU resistance in colorectal cancer cells.
    Journal of experimental & clinical cancer research : CR, 2019, Jul-19, Volume: 38, Issue:1

    Topics: Animals; Apoptosis; Biomarkers, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Exosomes; Fl

2019
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection for concurrent peritoneal and hepatic metastases of gastrointestinal and gynecological primary tumors.
    Journal of visceral surgery, 2019, Volume: 156, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com

2019
A more physiological approach to lipid metabolism alterations in cancer: CRC-like organoids assessment.
    PloS one, 2019, Volume: 14, Issue:7

    Topics: Animals; Antineoplastic Agents; Coenzyme A Ligases; Colorectal Neoplasms; Down-Regulation; Fluoroura

2019
Lipoic Acid Synergizes with Antineoplastic Drugs in Colorectal Cancer by Targeting p53 for Proteasomal Degradation.
    Cells, 2019, 07-30, Volume: 8, Issue:8

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Do

2019
Efficacy and tolerability of adjuvant therapy in ≥70-year-old patients with T3N0M0 colorectal cancer: An observational study.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy,

2020
Prognostic Factors for Colorectal Cancer Patients Treated With Combination of Immune-cell Therapy and First-line Chemotherapy: A Retrospective Study.
    Anticancer research, 2019, Volume: 39, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecit

2019
Sinusoidal Obstruction Syndrome and Postoperative Complications Resulting from Preoperative Chemotherapy for Colorectal Cancer Liver Metastasis.
    Anticancer research, 2019, Volume: 39, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Dise

2019
Dietary methionine influences therapy in mouse cancer models and alters human metabolism.
    Nature, 2019, Volume: 572, Issue:7769

    Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Diet; Disease Models, Animal; Female; Fluorouracil;

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Canada; Colorectal Neoplasms; Drug-

2019
Suppression of the growth of human colorectal cancer cells by therapeutic stem cells expressing cytosine deaminase and interferon-β via their tumor-tropic effect in cellular and xenograft mouse models.
    Molecular oncology, 2013, Volume: 7, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Engineering; Cell Line; Cell Line, Tumor; Colon; Colo

2013
MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer.
    Pharmacogenetics and genomics, 2013, Volume: 23, Issue:4

    Topics: Aged; Biomarkers, Pharmacological; Capecitabine; Clinical Trials, Phase III as Topic; Colorectal Neo

2013
Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment.
    Pathology oncology research : POR, 2013, Volume: 19, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Analysis of Variance; Angiogenesis Inhibitors;

2013
Aflibercept.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Apr-15, Volume: 19, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Cl

2013
Chemotherapy ± cetuximab modulates peripheral immune responses in metastatic colorectal cancer.
    Oncology, 2013, Volume: 84, Issue:5

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2013
Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and Src protein kinase signaling pathways.
    PloS one, 2013, Volume: 8, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Colorectal Neoplasms; Curcumi

2013
The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer.
    International journal of cancer, 2013, Sep-15, Volume: 133, Issue:6

    Topics: Adult; Aged; Apoptosis; Biomarkers, Tumor; Colorectal Neoplasms; Endoplasmic Reticulum Chaperone BiP

2013
An experimental study to identify the potential role of pharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury.
    HPB : the official journal of the International Hepato Pancreato Biliary Association, 2013, Volume: 15, Issue:8

    Topics: Adenosine Triphosphatases; Animals; Antineoplastic Combined Chemotherapy Protocols; Cation Transport

2013
Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
    Annals of surgical oncology, 2013, Volume: 20, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biom

2013
Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial.
    Cancer science, 2013, Volume: 104, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II

2013
The PEA-15/PED protein regulates cellular survival and invasiveness in colorectal carcinomas.
    Cancer letters, 2013, Jul-28, Volume: 335, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; A

2013
Comparative effectiveness of 5-fluorouracil with and without oxaliplatin in the treatment of colorectal cancer in clinical practice.
    Anticancer research, 2013, Volume: 33, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu

2013
[Panitumumab-induced trichomegaly].
    Medicina clinica, 2013, Apr-20, Volume: 140, Issue:8

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin

2013
Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr

2013
Elevated serum IL-22 levels correlate with chemoresistant condition of colorectal cancer.
    Clinical immunology (Orlando, Fla.), 2013, Volume: 147, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell

2013
High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.
    Molecular oncology, 2013, Volume: 7, Issue:3

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Line

2013
Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer.
    Cancer letters, 2013, Jul-28, Volume: 335, Issue:2

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Apoptosis; Caspas

2013
Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades.
    British journal of cancer, 2013, Apr-16, Volume: 108, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort S

2013
Is a nurse-led telephone intervention a viable alternative to nurse-led home care and standard care for patients receiving oral capecitabine? Results from a large prospective audit in patients with colorectal cancer.
    European journal of cancer care, 2013, Volume: 22, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Analysis of Variance; Antimetabolites, Antineoplast

2013
A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation.
    British journal of cancer, 2013, Apr-30, Volume: 108, Issue:8

    Topics: Animals; Camptothecin; Cell Line, Tumor; Cell Movement; Cell Survival; Colorectal Neoplasms; Drug Sc

2013
5-Fluorouracil potentiates the anti-cancer effect of oxaliplatin on Colo320 colorectal adenocarcinoma cells.
    Journal of gastrointestinal and liver diseases : JGLD, 2013, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Color

2013
In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells.
    International journal of radiation oncology, biology, physics, 2013, Jul-01, Volume: 86, Issue:3

    Topics: Animals; Antineoplastic Agents; Benzimidazoles; Camptothecin; Chemoradiotherapy; Colorectal Neoplasm

2013
Expression of ABCG2 associated with tumor response in metastatic colorectal cancer patients receiving first-line FOLFOX therapy--preliminary evidence.
    The International journal of biological markers, 2013, Jun-28, Volume: 28, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette

2013
Unresectable colorectal liver metastases: the safety and efficacy of conversion therapy using hepatic arterial infusion immunochemotherapy with 5-fluorouracil and polyethylene glycol-interferon α-2a.
    World journal of surgery, 2013, Volume: 37, Issue:8

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival;

2013
High-dose FOLFIRI, surgery, and radiofrequency ablation for patients with unresectable liver metastases from colorectal cancer.
    Anticancer research, 2013, Volume: 33, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Abla

2013
Response to chemotherapy in metastatic colorectal cancer after exposure to oxaliplatin in the adjuvant setting.
    Anticancer research, 2013, Volume: 33, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2013
Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptot

2013
Pre-therapeutic assessment of plasma dihydrouracil/uracil ratio for predicting the pharmacokinetic parameters of 5-fluorouracil and tumor growth in a rat model of colorectal cancer.
    Biological & pharmaceutical bulletin, 2013, Volume: 36, Issue:6

    Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP);

2013
Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer.
    Journal of pharmaceutical sciences, 2013, Volume: 102, Issue:6

    Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colon; Colorectal Neoplasms; Dihydroura

2013
The impact of glycemic levels in patients with colon cancer.
    Clinical advances in hematology & oncology : H&O, 2013, Volume: 11, Issue:2

    Topics: Antineoplastic Agents; Blood Glucose; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diet; Fluorourac

2013
Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo.
    Journal of natural medicines, 2014, Volume: 68, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro

2014
[Secondary necrotizing fasciitis associated with panitumumab].
    Medicina clinica, 2013, Nov-16, Volume: 141, Issue:10

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Causal

2013
Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.
    Journal of hepatology, 2013, Volume: 59, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Cell Cycle; Colorectal Neopla

2013
MTHFR Glu429Ala and ERCC5 His46His polymorphisms are associated with prognosis in colorectal cancer patients: analysis of two independent cohorts from Newfoundland.
    PloS one, 2013, Volume: 8, Issue:4

    Topics: Adult; Aged; Amino Acid Substitution; Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Ne

2013
Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.
    PloS one, 2013, Volume: 8, Issue:4

    Topics: Animals; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Disease Models, Animal; Drug Combinat

2013
Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer.
    Cancer, 2013, Jul-15, Volume: 119, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi

2013
Standardized added metabolic activity (SAM) IN ¹⁸F-FDG PET assessment of treatment response in colorectal liver metastases.
    European journal of nuclear medicine and molecular imaging, 2013, Volume: 40, Issue:8

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2013
[Changes of lymphocyte subsets before and after chemotherapy in colorectal carcinoma patients].
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2013, Volume: 35, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Camp

2013
Identification of HOXB8 and KLK11 expression levels as potential biomarkers to predict the effects of FOLFOX4 chemotherapy.
    Future oncology (London, England), 2013, Volume: 9, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Colorectal Neopla

2013
Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jun-10, Volume: 31, Issue:17

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2013
Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy.
    British journal of cancer, 2013, May-28, Volume: 108, Issue:10

    Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto

2013
Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:1

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic

2013
A novel aurora-A inhibitor, BPR1K0609S1, sensitizes colorectal tumor cells to 5-fluorofracil (5-FU) treatment.
    International journal of biological sciences, 2013, Volume: 9, Issue:4

    Topics: Animals; Aurora Kinase A; Aurora Kinases; Colorectal Neoplasms; Enzyme Inhibitors; Female; Fluoroura

2013
Comparative assessment of skin and subcutaneous toxicity in patients of advanced colorectal carcinoma treated with different schedules of FOLFOX.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2013
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.
    British journal of cancer, 2013, Jun-25, Volume: 108, Issue:12

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2013
How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?
    Future oncology (London, England), 2013, Volume: 9, Issue:6

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cet

2013
Establishment of a predictive genetic model for estimating chemotherapy sensitivity of colorectal cancer with synchronous liver metastasis.
    Cancer biotherapy & radiopharmaceuticals, 2013, Volume: 28, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2013
XELIRI plus bevacizumab compared with FOLFIRI plus bevacizumab as first-line setting in patients with metastatic colorectal cancer: experiences at two-institutions.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2013
Will PICCOLO affect metastatic colorectal cancer therapy?
    The Lancet. Oncology, 2013, Volume: 14, Issue:8

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

2013
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jul-10, Volume: 31, Issue:20

    Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine

2013
Establishment of a human colorectal cancer cell line P6C with stem cell properties and resistance to chemotherapeutic drugs.
    Acta pharmacologica Sinica, 2013, Volume: 34, Issue:6

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Design; D

2013
miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer.
    Cell death & disease, 2013, Jun-06, Volume: 4

    Topics: 3' Untranslated Regions; Animals; Antimetabolites, Antineoplastic; Apoptosis; Base Sequence; Binding

2013
Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study.
    Anticancer research, 2013, Volume: 33, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2013
Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.
    The pharmacogenomics journal, 2014, Volume: 14, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival;

2014
DMET™ (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:2

    Topics: 5' Untranslated Regions; Antimetabolites, Antineoplastic; Carbohydrate Sulfotransferases; Colorectal

2013
Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis;

2013
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases.
    Clinical colorectal cancer, 2013, Volume: 12, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherap

2013
Unusual ischemic complication of bevacizumab treatment for metastatic colorectal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Oct-20, Volume: 31, Issue:30

    Topics: Abdominal Pain; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2013
Evaluation of clinical value of single nucleotide polymorphisms of dihydropyrimidine dehydrogenase gene to predict 5-fluorouracil toxicity in 60 colorectal cancer patients in China.
    International journal of medical sciences, 2013, Volume: 10, Issue:7

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Base Sequence; China; Colorectal Neoplasms; Dihydroura

2013
Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer.
    International journal of colorectal disease, 2013, Volume: 28, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neop

2013
FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer.
    Cancer biology & therapy, 2013, Volume: 14, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2013
Contradictory KRAS mutation test results in a patient with metastatic colon cancer: a clinical dilemma in the era of personalized medicine.
    Cancer biology & therapy, 2013, Volume: 14, Issue:8

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

2013
Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy.
    Annals of surgical oncology, 2013, Volume: 20 Suppl 3

    Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Dr

2013
Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review.
    British journal of cancer, 2013, Jun-25, Volume: 108, Issue:12

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2013
Nuclear orphan receptor NR4A2 confers chemoresistance and predicts unfavorable prognosis of colorectal carcinoma patients who received postoperative chemotherapy.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:16

    Topics: Adenoma; Adenomatous Polyposis Coli; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biom

2013
On 5-fluorouracil therapy of colorectal cancer.
    Danish medical journal, 2013, Volume: 60, Issue:7

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combine

2013
A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
    Biopharmaceutics & drug disposition, 2013, Volume: 34, Issue:7

    Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Dihydrouracil Deh

2013
Visualising and quantifying angiogenesis in metastatic colorectal cancer : A comparison of methods and their predictive value for chemotherapy response.
    Cellular oncology (Dordrecht), 2013, Volume: 36, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cape

2013
Prognostic value of the Glasgow Prognostic Score in metastatic colorectal cancer in the era of anti-EGFR therapies.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:3

    Topics: Aged; Albumins; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic A

2013
[Risk factors for hyperammonemia during mFOLFOX6 treatment].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:4

    Topics: Aged; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Flu

2013
Financial incentives in cancer care and impact on prescribing practice.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Aug-10, Volume: 31, Issue:23

    Topics: Aged; Antineoplastic Agents; Australia; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Pres

2013
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum

2013
[Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:5

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2013
Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer.
    Clinical colorectal cancer, 2013, Volume: 12, Issue:3

    Topics: Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorecta

2013
Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer.
    Chemotherapy, 2013, Volume: 59, Issue:2

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2013
Tumor site- and stage-specific associations between allelic variants of glutathione S-transferase and DNA-repair genes and overall survival in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Alleles; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cohort Studies; Colorectal Neoplasms; D

2013
Notch-induced transcription factors are predictive of survival and 5-fluorouracil response in colorectal cancer patients.
    British journal of cancer, 2013, Aug-20, Volume: 109, Issue:4

    Topics: Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Ca

2013
Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines.
    Oncology reports, 2013, Volume: 30, Issue:4

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2013
Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer.
    Annals of surgical oncology, 2014, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cell Proli

2014
Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer.
    Asia-Pacific journal of clinical oncology, 2014, Volume: 10, Issue:4

    Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic

2014
Gefitinib enhances the effects of combined radiotherapy and 5-fluorouracil in a colorectal cancer cell line.
    International journal of colorectal disease, 2014, Volume: 29, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemoradiotherapy; Colorectal Neop

2014
Bilateral optic disc oedema and associated optic neuropathy in the setting of FOLFOX chemotherapy.
    BMC ophthalmology, 2013, Aug-08, Volume: 13, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

2013
STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo.
    International journal of cancer, 2014, Feb-15, Volume: 134, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Chemorad

2014
Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.
    Therapeutic drug monitoring, 2013, Volume: 35, Issue:5

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug-Rela

2013
Oxaliplatin-induced liver injury mimicking metastatic tumor on images: a case report.
    Japanese journal of clinical oncology, 2013, Volume: 43, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diagno

2013
Thymidylate synthase gene polymorphism and survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Genetic testing and molecular biomarkers, 2013, Volume: 17, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Flu

2013
Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.
    Clinical colorectal cancer, 2013, Volume: 12, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2013
Potentiation of 5-fluorouracil encapsulated in zeolites as drug delivery systems for in vitro models of colorectal carcinoma.
    Colloids and surfaces. B, Biointerfaces, 2013, Dec-01, Volume: 112

    Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Carrier

2013
The effects of silencing of PI3K p85α on 5-FU-induced colorectal cancer cells apoptosis.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:4

    Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Cell Li

2013
Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
    Journal of surgical oncology, 2013, Volume: 108, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms;

2013
Noninvasive visualization of tumor growth in a human colorectal liver metastases xenograft model using bioluminescence in vivo imaging.
    The Journal of surgical research, 2013, Volume: 185, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Models, Animal; Disease Prog

2013
A 5-fluorouracil-loaded polydioxanone weft-knitted stent for the treatment of colorectal cancer.
    Biomaterials, 2013, Volume: 34, Issue:37

    Topics: Animals; Antimetabolites, Antineoplastic; Colon; Colorectal Neoplasms; Drug-Eluting Stents; Fluorour

2013
Platinum-sensitivity in metastatic colorectal cancer: towards a definition.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:18

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease

2013
Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.
    Pharmacogenetics and genomics, 2013, Volume: 23, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Camptothecin; Col

2013
Feasibility study of oxaliplatin with oral S-1 or capecitabine as first-line therapy for patients with metastases from colorectal cancer.
    Anticancer research, 2013, Volume: 33, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2013
Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: a retrospective study.
    Anticancer research, 2013, Volume: 33, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2013
Beyond exon 2--the developing story of RAS mutations in colorectal cancer.
    The New England journal of medicine, 2013, Sep-12, Volume: 369, Issue:11

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; ErbB R

2013
Comparative cardiac toxicity in two treatment schedules of 5-FU/LV for colorectal carcinoma.
    Pakistan journal of pharmaceutical sciences, 2013, Volume: 26, Issue:5

    Topics: Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Pressure; Carcino

2013
[Aflibercept (Zaltrap(®)) approved in metastatic colorectal cancer].
    Bulletin du cancer, 2013, Volume: 100, Issue:10

    Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinic

2013
Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different.
    Expert opinion on biological therapy, 2013, Volume: 13, Issue:11

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2013
Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:11

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms;

2013
Crohn's disease with worsening symptoms.
    Gastroenterology, 2013, Volume: 145, Issue:5

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Colectomy; Colorectal Neoplasms; Combined Mo

2013
Gastrointestinal cancer: AVEX: opportunities in elderly patients with mCRC.
    Nature reviews. Clinical oncology, 2013, Volume: 10, Issue:11

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; B

2013
Polymorphisms of folate metabolism-related genes and survival of patients with colorectal cancer in the Korean population.
    Gene, 2014, Jan-10, Volume: 533, Issue:2

    Topics: Aged; Asian People; Colorectal Neoplasms; Female; Fluorouracil; Folic Acid; Humans; Male; Metabolic

2014
Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy.
    Acta oncologica (Stockholm, Sweden), 2013, Volume: 52, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2013
Oxaliplapin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients.
    Anti-cancer agents in medicinal chemistry, 2013, Volume: 13, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Ne

2013
The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome.
    British journal of cancer, 2013, Oct-29, Volume: 109, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemical and Drug Induced

2013
Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B).
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimeta

2013
Down-regulation of BAX gene during carcinogenesis and acquisition of resistance to 5-FU in colorectal cancer.
    Pathology oncology research : POR, 2014, Volume: 20, Issue:2

    Topics: Apoptosis; bcl-2-Associated X Protein; BH3 Interacting Domain Death Agonist Protein; Carcinogenesis;

2014
Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil.
    Anticancer research, 2013, Volume: 33, Issue:10

    Topics: Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Case-Control Stu

2013
Oxaliplatin-based chemotherapy in patients aged 75 years or older with metastatic colorectal cancer.
    Anticancer research, 2013, Volume: 33, Issue:10

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2013
Over-expression of the ATP5J gene correlates with cell migration and 5-fluorouracil sensitivity in colorectal cancer.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Colorecta

2013
Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:12

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under

2013
Lgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2013, Volume: 67, Issue:8

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport

2013
Notch1-dependent regulation of p27 determines cell fate in colorectal cancer.
    International journal of oncology, 2013, Volume: 43, Issue:6

    Topics: Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Colorectal Neop

2013
Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease?
    World journal of surgery, 2014, Volume: 38, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2014
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jan-01, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Biomarkers, Tumor; Cell L

2014
Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma.
    Gut, 2014, Volume: 63, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2014
Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2014, Volume: 20, Issue:5

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2014
Role of cyclin polymorphisms in predicting outcome of 5-fluorouracil-based chemotherapy in colorectal cancer: one piece in a complex puzzle.
    Pharmacogenomics, 2013, Volume: 14, Issue:14

    Topics: Colorectal Neoplasms; Cyclin D; Fluorouracil; Humans; Polymorphism, Single Nucleotide

2013
The interplay between epigenetic silencing, oncogenic KRas and HIF-1 regulatory pathways in control of BNIP3 expression in human colorectal cancer cells.
    Biochemical and biophysical research communications, 2013, Nov-29, Volume: 441, Issue:4

    Topics: Antimetabolites, Antineoplastic; Cell Hypoxia; Colorectal Neoplasms; DNA Methylation; Drug Resistanc

2013
Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia.
    Oncology, 2013, Volume: 85, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2013
C-reactive protein is a negative independent factor in patients with stage IV colorectal cancer undergoing oxaliplatin-based chemotherapy.
    Anticancer research, 2013, Volume: 33, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2013
A small cog in a big wheel: PIK3CA mutations in colorectal cancer.
    Journal of the National Cancer Institute, 2013, Dec-04, Volume: 105, Issue:23

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuv

2013
Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
    Japanese journal of clinical oncology, 2014, Volume: 44, Issue:1

    Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers

2014
Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype.
    International journal of oncology, 2014, Volume: 44, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2014
MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells.
    Journal of cellular biochemistry, 2014, Volume: 115, Issue:4

    Topics: Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptotic Protease-Activating Factor 1; B

2014
Death associated protein 1 is correlated with the clinical outcome of patients with colorectal cancer and has a role in the regulation of cell death.
    Oncology reports, 2014, Volume: 31, Issue:1

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Mo

2014
Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Capecitabine; Cell Line,

2014
Cinnamaldehyde/chemotherapeutic agents interaction and drug-metabolizing genes in colorectal cancer.
    Molecular medicine reports, 2014, Volume: 9, Issue:2

    Topics: Acrolein; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cinnamomum aromaticum; Colo

2014
Thymidylate synthase expression and p21(WAF1)/p53 phenotype of colon cancers identify patients who may benefit from 5-fluorouracil based therapy.
    Cellular oncology (Dordrecht), 2014, Volume: 37, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Cohort Studies;

2014
Effects of metformin on CD133+ colorectal cancer cells in diabetic patients.
    PloS one, 2013, Volume: 8, Issue:11

    Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Agents; Apoptosis; beta

2013
TS mRNA levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer.
    Cancer chemotherapy and pharmacology, 2014, Volume: 73, Issue:2

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouracil;

2014
Impact of stereotactic body radiotherapy on colorectal cancer with distant metastases.
    Oncology reports, 2014, Volume: 31, Issue:2

    Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2014
Carcinoembryonic antigen expression level as a predictive factor for response to 5-fluorouracil in colorectal cancer.
    Molecular biology reports, 2014, Volume: 41, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Cell Line, Tumor; CHO Cells; Cis

2014
Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci

2014
Predicting distant metastasis and chemoresistance using plasma miRNAs.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:1

    Topics: Antineoplastic Agents; Case-Control Studies; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female

2014
[Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].
    Magyar sebeszet, 2013, Volume: 66, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2013
Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
    Annals of surgical oncology, 2014, Volume: 21, Issue:6

    Topics: Abdominal Abscess; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combin

2014
Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cass

2014
Comparison of clinicopathological characteristics and prognosis between early and late recurrence after curative surgery for colorectal cancer.
    American journal of surgery, 2014, Volume: 207, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl

2014
TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells.
    Cellular & molecular immunology, 2014, Volume: 11, Issue:2

    Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cell Differe

2014
[Efficacy and tolerance of maintenance therapy in patients with incurable advanced colorectal cancer].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2013, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De

2013
Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 14, Issue:11

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2014
Overexpression of S100P promotes colorectal cancer metastasis and decreases chemosensitivity to 5-FU in vitro.
    Molecular and cellular biochemistry, 2014, Volume: 389, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Calcium-Binding Proteins; Cell Line, Tumor; Cell

2014
Loss of Smad4 in colorectal cancer induces resistance to 5-fluorouracil through activating Akt pathway.
    British journal of cancer, 2014, Feb-18, Volume: 110, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Cell Cycle Proteins; Cell L

2014
Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2014, Volume: 40, Issue:5

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplas

2014
[Assessment of host status in patients treated with mFOLFOX6 adjuvant chemotherapy after colorectal cancer surgery].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chemotherapy, Adjuvant

2013
[Neoadjuvant chemotherapy with capecitabine plus oxaliplatin and bevacizumab for the treatment of patients with resectable metastatic colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2013
[Protocol for the administration of modified FOLFOX6 (mFOLFOX6) in patients with unresectable/recurrent colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2013
Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
    Anticancer research, 2014, Volume: 34, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytid

2014
Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Prognostic factors associated with primary cancer in curatively resected stage IV colorectal cancer.
    Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2014
Thymidylate synthase polymorphism in sporadic colorectal and gastric cancer in Tunisian population: a predictive role in 5-fluorouracil based chemotherapy treatment.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:2

    Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Case-Contr

2014
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
    Annals of surgical oncology, 2014, Volume: 21, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2014
A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2014, Volume: 16, Issue:8

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Icariin-mediated inhibition of NF-κB activity enhances the in vitro and in vivo antitumour effect of 5-fluorouracil in colorectal cancer.
    Cell biochemistry and biophysics, 2014, Volume: 69, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Drug Synergism;

2014
GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy.
    Journal of translational medicine, 2014, Jan-21, Volume: 12

    Topics: Aged; Cell Death; Cell Line, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survi

2014
Elderly patients with colorectal cancer: treatment modalities and survival in France. National data from the ThInDiT cohort study.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cohort Studies; Colorectal N

2014
Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:6

    Topics: Aged; Analgesics, Opioid; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dela

2014
Predictive value of optimal morphologic response to first-line chemotherapy in patients with colorectal liver metastases.
    Digestion, 2014, Volume: 89, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized;

2014
Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Drug Resist

2013
Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
    Clinical colorectal cancer, 2014, Volume: 13, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2014
Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinote
    Translational research : the journal of laboratory and clinical medicine, 2014, Volume: 164, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Knockdown of astrocyte elevated gene-1 inhibits tumor growth and modifies microRNAs expression profiles in human colorectal cancer cells.
    Biochemical and biophysical research communications, 2014, Feb-14, Volume: 444, Issue:3

    Topics: Base Sequence; Cell Adhesion Molecules; Cell Line, Tumor; Colorectal Neoplasms; DNA Primers; Fluorou

2014
FOLFIRI as second-line chemotherapy after failure of FOLFOX4 in advanced colorectal cancer: a Korean single-center experience.
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2014, Jan-25, Volume: 63, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2014
Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Ce

2014
How we treat metastatic colon cancer in older adults.
    Journal of geriatric oncology, 2013, Volume: 4, Issue:4

    Topics: Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; An

2013
Interstitial pneumonia during bevacizumab-based chemotherapy for colorectal cancer.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:3

    Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Ch

2014
Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr

2014
Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.
    Cell death & disease, 2014, Feb-06, Volume: 5

    Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplas

2014
Role of miR-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines.
    Journal of surgical oncology, 2014, Volume: 109, Issue:7

    Topics: Aged; Cell Line, Tumor; Colorectal Neoplasms; Disease-Free Survival; Epithelial-Mesenchymal Transiti

2014
The feasibility of a short bevacizumab infusion in patients with metastatic colorectal cancer.
    Anticancer research, 2014, Volume: 34, Issue:2

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2014
Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antin

2014
Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy.
    Gastroenterology, 2014, Volume: 146, Issue:2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarke

2014
Haematologic parameters in metastatic colorectal cancer patients treated with capecitabine combination therapy.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
A prospective observational study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK Trial.
    Japanese journal of clinical oncology, 2014, Volume: 44, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biom

2014
SCGB2A1 is a novel prognostic marker for colorectal cancer associated with chemoresistance and radioresistance.
    International journal of oncology, 2014, Volume: 44, Issue:5

    Topics: Aged; Analysis of Variance; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Drug Resi

2014
Safety and efficacy of FOLFOX followed by cetuximab for metastatic colorectal cancer with severe liver dysfunction.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2014, Volume: 12, Issue:2

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bilirubin;

2014
Prognostic value of chemotherapy-induced hematological toxicity in metastatic colorectal cancer patients.
    World journal of gastroenterology, 2014, Feb-14, Volume: 20, Issue:6

    Topics: Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Databases, Factual; Female; Fluorou

2014
Genetic biomarkers for Fluorouracil toxicity prediction: the long road to clinical utility.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-01, Volume: 32, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; D

2014
Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses.
    Pharmacogenetics and genomics, 2014, Volume: 24, Issue:5

    Topics: Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Femal

2014
Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver.
    Annals of surgical oncology, 2014, Volume: 21, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2014
Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antibodies, Mono

2014
Hepatocellular carcinoma and nodular regenerative hyperplasia after chemotherapy for metastatic colorectal carcinoma.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Colorectal Neoplasms; Drug Therapy; Fluorouracil;

2014
Impact of preoperative and postoperative FOLFOX chemotherapies in patients with resectable colorectal liver metastasis.
    Journal of gastrointestinal cancer, 2014, Volume: 45, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore

2014
Adjuvant therapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy.
    BMC cancer, 2014, Mar-11, Volume: 14

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2014
Extracapsular lymph node involvement is associated with colorectal liver metastases and impact outcome after hepatectomy for colorectal metastases.
    World journal of surgery, 2014, Volume: 38, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2014
Evaluation of the necessity of primary tumor resection for synchronous metastatic colorectal cancer.
    Surgery today, 2014, Volume: 44, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Digestive

2014
Impact of peri-operative bevacizumab on survival in patients with resected colorectal liver metastases: an analysis of the LiverMetSurvey.
    HPB : the official journal of the International Hepato Pancreato Biliary Association, 2014, Volume: 16, Issue:4

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera

2014
Whole-liver radiotherapy concurrent with chemotherapy as a palliative treatment for colorectal patients with massive and multiple liver metastases: a retrospective study.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Ascites; Bilirubin; Colorectal Neoplasms; Combined Modality T

2014
FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping.
    Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2014, Volume: 23, Issue:5

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2014
A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
    Gut, 2015, Volume: 64, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms;

2015
Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry.
    BMC gastroenterology, 2014, Mar-25, Volume: 14

    Topics: Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined

2014
Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
    Journal of surgical oncology, 2014, Volume: 110, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Dis

2014
DNA methyltransferase inhibitors improve the effect of chemotherapeutic agents in SW48 and HT-29 colorectal cancer cells.
    PloS one, 2014, Volume: 9, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Cell Cycle; Cell Line, Tumor

2014
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
    Investigational new drugs, 2014, Volume: 32, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Survival

2014
Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia

2014
Suppression of colorectal cancer liver metastasis by apolipoprotein(a) kringle V in a nude mouse model through the induction of apoptosis in tumor-associated endothelial cells.
    PloS one, 2014, Volume: 9, Issue:4

    Topics: Animals; Apolipoproteins A; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Endoplasmic Reticulum

2014
[Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40 Suppl 2

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine

2013
Intradural tumor recurrence after resection of extradural metastasis: a rare but potential complication of intraoperative durotomy.
    Journal of neurosurgery. Spine, 2014, Volume: 20, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Colorectal Neoplasms; C

2014
Bridge-to-surgery stent placement versus emergency surgery for acute malignant colonic obstruction.
    The British journal of surgery, 2014, Volume: 101, Issue:7

    Topics: Aged; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protocols; Colonic Diseases; Color

2014
A multimarker panel for circulating tumor cells detection predicts patient outcome and therapy response in metastatic colorectal cancer.
    International journal of cancer, 2014, Dec-01, Volume: 135, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2014
Prognostic factors for metastatic colorectal cancer after first-line chemotherapy with FOLFOX-4 or FOLFIRI regimen.
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2014, Volume: 63, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2014
Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
    Annals of surgical oncology, 2014, Volume: 21, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Region

2014
A case report--treatment of metastatic colorectal cancer in a patient on hemodialysis.
    Journal of gastrointestinal cancer, 2014, Volume: 45 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2014
A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homes.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2014, Volume: 22, Issue:10

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Cell Phone; Colorectal

2014
Role of SLC6A6 in promoting the survival and multidrug resistance of colorectal cancer.
    Scientific reports, 2014, Apr-30, Volume: 4

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters;

2014
Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study.
    British journal of cancer, 2014, May-27, Volume: 110, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor;

2014
Overcoming the challenges of primary tumor management in patients with metastatic colorectal cancer unresectable for cure and an asymptomatic primary tumor.
    Diseases of the colon and rectum, 2014, Volume: 57, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Colonos

2014
Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.
    Oncotarget, 2014, May-15, Volume: 5, Issue:9

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients.
    International journal of clinical oncology, 2015, Volume: 20, Issue:2

    Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined

2015
First-line mono-chemotherapy in frail elderly patients with metastatic colorectal cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:7

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Color

2014
The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer:
    European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pr

2014
Decreased ARID1A expression facilitates cell proliferation and inhibits 5-fluorouracil-induced apoptosis in colorectal carcinoma.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:8

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Color

2014
RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore

2014
Maintenance therapy for colorectal cancer.
    Oncology (Williston Park, N.Y.), 2014, Volume: 28, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape

2014
Use of metformin alone is not associated with survival outcomes of colorectal cancer cell but AMPK activator AICAR sensitizes anticancer effect of 5-fluorouracil through AMPK activation.
    PloS one, 2014, Volume: 9, Issue:5

    Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis

2014
The predictive and prognostic value of the Glasgow Prognostic Score in metastatic colorectal carcinoma patients receiving bevacizumab.
    Anti-cancer drugs, 2014, Volume: 25, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2014
Antitumor activity of electrospun polylactide nanofibers loaded with 5-fluorouracil and oxaliplatin against colorectal cancer.
    Drug delivery, 2016, Volume: 23, Issue:3

    Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Drug Delivery Systems; Fluorouracil; Humans; M

2016
Positive effects of oral β-glucan on mucositis and leukopenia in colorectal cancer patients receiving adjuvant FOLFOX-4 combination chemotherapy.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; b

2014
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis.
    BMC cancer, 2014, May-07, Volume: 14

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab.
    British journal of cancer, 2014, Jul-08, Volume: 111, Issue:1

    Topics: Adult; Aged; AMP-Activated Protein Kinases; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humaniz

2014
miR-200 family in CRC primary tumors and metastases.
    Journal of surgical oncology, 2014, Volume: 110, Issue:4

    Topics: Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; MicroRNAs

2014
Hypoxia-targeted triple suicide gene therapy radiosensitizes human colorectal cancer cells.
    Oncology reports, 2014, Volume: 32, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Chemoradiotherapy; Colorectal Neopla

2014
Deregulation of miR-200b, miR-200c and miR-429 indicates its potential relevant role in patients with colorectal cancer liver metastasis.
    Journal of surgical oncology, 2014, Volume: 110, Issue:4

    Topics: Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; MicroRNAs

2014
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:9

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

2014
Beclin 1 and UVRAG confer protection from radiation-induced DNA damage and maintain centrosome stability in colorectal cancer cells.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Cell Lin

2014
Decreasing relapse in colorectal cancer patients treated with cetuximab by using the activating KRAS detection chip.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:10

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo

2014
Gelam honey and ginger potentiate the anti cancer effect of 5-FU against HCT 116 colorectal cancer cells.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; Biological Factors; Cell Line, Tumor; Cell Proliferation; Cell Sur

2014
Epigenetic alterations are involved in the overexpression of glutathione S-transferase π-1 in human colorectal cancers.
    International journal of oncology, 2014, Volume: 45, Issue:3

    Topics: Caco-2 Cells; Cell Line, Tumor; Colorectal Neoplasms; DNA Methylation; Epigenesis, Genetic; Fluorour

2014
Effects of TachoSil and 5-fluorouracil on colonic anastomotic healing.
    The Journal of surgical research, 2014, Volume: 192, Issue:2

    Topics: Anastomosis, Surgical; Animals; Antimetabolites; Colon; Colorectal Neoplasms; Drug Combinations; Fib

2014
The synergistic effect of rapamycin combined with 5-fluorouracil in BALB/cByJNarl mice bearing CT-26 tumor cells.
    Anticancer research, 2014, Volume: 34, Issue:7

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell

2014
Impact of co-administered drugs on drug monitoring of capecitabine in patients with advanced colorectal cancer.
    Anticancer research, 2014, Volume: 34, Issue:7

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antineoplastic Combined Chemotherapy Protocols; Capecitabin

2014
Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
    Anticancer research, 2014, Volume: 34, Issue:7

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape

2014
Impact of liver-directed therapy in colorectal cancer liver metastases.
    The Journal of surgical research, 2014, Volume: 191, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Catheter Ablation; Colorec

2014
Impact of 5-fluorouracil metabolizing enzymes on chemotherapy in patients with resectable colorectal cancer.
    Oncology reports, 2014, Volume: 32, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe

2014
Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation.
    Biochimica et biophysica acta, 2014, Volume: 1842, Issue:9

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Comb

2014
Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2014
FOLFOX7 regimen in the first-line treatment of metastatic colorectal cancer.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2014, Volume: 25, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2014
FOLFIRINOX bevacizumab is a promising therapy for chemorefractory metastatic colorectal cancer.
    Oncology, 2014, Volume: 87, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2014
Incidence of cold-induced peripheral neuropathy and dose modification of adjuvant oxaliplatin-based chemotherapy for patients with colorectal cancer.
    Oncology, 2014, Volume: 87, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cold Temperatu

2014
The role of adjuvant chemotherapy in stage II colorectal cancer patients.
    International journal of colorectal disease, 2014, Volume: 29, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2014
The impact of oxaliplatin-based chemotherapy for colorectal cancer on the autonomous nervous system.
    European journal of neurology, 2014, Volume: 21, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autonomic Nervou

2014
Differential protein expression and novel biomarkers related to 5-FU resistance in a 3D colorectal adenocarcinoma model.
    Oncology reports, 2014, Volume: 32, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Chr

2014
Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma.
    Oncotarget, 2014, Aug-30, Volume: 5, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant;

2014
Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:4

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Austr

2014
Interleukin 22 protects colorectal cancer cells from chemotherapy by activating the STAT3 pathway and inducing autocrine expression of interleukin 8.
    Clinical immunology (Orlando, Fla.), 2014, Volume: 154, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autocrine Communication; Cell

2014
Unbiased proteomic and transcript analyses reveal that stathmin-1 silencing inhibits colorectal cancer metastasis and sensitizes to 5-fluorouracil treatment.
    Molecular cancer research : MCR, 2014, Volume: 12, Issue:12

    Topics: Antimetabolites, Antineoplastic; Cell Proliferation; Colorectal Neoplasms; Epithelial-Mesenchymal Tr

2014
Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.
    Clinical colorectal cancer, 2014, Volume: 13, Issue:3

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2014
Cetuximab or bevacizumab in metastatic colorectal cancer?
    The Lancet. Oncology, 2014, Volume: 15, Issue:10

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2014
Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.
    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2015, Volume: 24, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci

2015
Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid;

2014
Capecitabine: toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Prescrire international, 2014, Volume: 23, Issue:150

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Hu

2014
Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2015
[Retrospective analysis of the bevacizumab and CapeOX combination in untreated metastatic/recurrent colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2014
[Tolerability of XELOX in postoperative adjuvant chemotherapy for colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C

2014
Successful treatment with entecavir for reactivation of hepatitis B virus following systemic chemotherapy in a hepatitis B surface antigen-negative patient with colorectal cancer.
    Internal medicine (Tokyo, Japan), 2014, Volume: 53, Issue:16

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Colorectal Neoplasms; Fluoro

2014
[The efficacy and safety of FOLFIRI or combined FOLFIRI and bevacizumab treatment as second-line chemotherapy for metastatic colorectal cancer patients aged 75 years and older].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:7

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2014
[Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer].
    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2014, Jul-01, Volume: 38, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Ana

2014
KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2014
UGT1A1*28 polymorphisms: a potential pharmacological biomarker of irinotecan-based chemotherapies in colorectal cancer.
    Pharmacogenomics, 2014, Volume: 15, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm

2014
A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI.
    BMC cancer, 2014, Aug-20, Volume: 14

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2014
Fatal outcome of posterior "reversible" encephalopathy syndrome in metastatic colorectal carcinoma after irinotecan and fluoropyrimidine chemotherapy regimen.
    World journal of surgical oncology, 2014, Aug-20, Volume: 12

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2014
Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizuma

2014
Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis.
    World journal of surgery, 2014, Volume: 38, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Col

2014
Efficacy and safety of bevacizumab in Chinese patients with metastatic colorectal cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:16

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2014
Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.
    BMC gastroenterology, 2014, Aug-29, Volume: 14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colo

2014
Gene signatures of drug resistance predict patient survival in colorectal cancer.
    The pharmacogenomics journal, 2015, Volume: 15, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; C

2015
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
    International journal of molecular sciences, 2014, Sep-05, Volume: 15, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa

2014
Aidi injection combined with FOLFOX4 chemotherapy regimen in the treatment of advanced colorectal carcinoma.
    Journal of cancer research and therapeutics, 2014, Volume: 10 Suppl 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug-Related Side

2014
Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.
    BMC cancer, 2014, Sep-10, Volume: 14

    Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Fluorouracil; Focal Adhesion Kinase 1; He

2014
Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes.
    Cancer research, 2014, Nov-01, Volume: 74, Issue:21

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Differentiati

2014
Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer.
    British journal of cancer, 2014, Oct-28, Volume: 111, Issue:9

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera

2014
Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:16

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2014
SNAI2 modulates colorectal cancer 5-fluorouracil sensitivity through miR145 repression.
    Molecular cancer therapeutics, 2014, Volume: 13, Issue:11

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition

2014
Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients.
    PloS one, 2014, Volume: 9, Issue:9

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Aspirin; Capecitabin

2014
Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer.
    Oncotarget, 2014, Sep-30, Volume: 5, Issue:18

    Topics: AC133 Antigen; Adenocarcinoma; Antigens, CD; Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Pro

2014
Knockdown of β3GnT8 reverses 5-fluorouracil resistance in human colorectal cancer cells via inhibition the biosynthesis of polylactosamine-type N-glycans.
    International journal of oncology, 2014, Volume: 45, Issue:6

    Topics: Amino Sugars; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance

2014
Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.
    Journal of experimental & clinical cancer research : CR, 2014, Oct-02, Volume: 33

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo

2014
Carcinoembryonic antigen half-life is an early predictor of therapeutic effects in induction chemotherapy for liver metastases from colorectal cancer.
    Anticancer research, 2014, Volume: 34, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Ant

2014
HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy.
    Oncotarget, 2014, Oct-30, Volume: 5, Issue:20

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Colorectal Neoplasms;

2014
Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy.
    Oncotarget, 2014, Oct-30, Volume: 5, Issue:20

    Topics: Adenomatous Polyposis Coli; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr

2014
Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer.
    Clinical colorectal cancer, 2014, Volume: 13, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2014
Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study.
    Acta oncologica (Stockholm, Sweden), 2015, Volume: 54, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop

2015
Pharmacokinetics of oxaliplatin in a hemodialyzed patient: chemotherapy dose adjustment and timing of dialysis.
    Clinical colorectal cancer, 2014, Volume: 13, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response

2014
Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer.
    British journal of cancer, 2014, Nov-11, Volume: 111, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Wester

2014
Aflibercept. Metastatic colorectal cancer: at least as poorly tolerated as bevacizumab.
    Prescrire international, 2014, Volume: 23, Issue:152

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2014
Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.
    PloS one, 2014, Volume: 9, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2014
Reduced-intensity FOLFOXIRI in Treating Refractory Metastatic Colorectal Cancer: A Pilot Study.
    American journal of clinical oncology, 2017, Volume: 40, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2017
Gastrointestinal adverse effects in advanced colorectal carcinoma patients treated with different schedules of FOLFOX.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:19

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2014
Frequent intragenic rearrangements of DPYD in colorectal tumours.
    The pharmacogenomics journal, 2015, Volume: 15, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neopl

2015
Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Jan-01, Volume: 33, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Cl

2015
Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients.
    Carcinogenesis, 2015, Volume: 36, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Fema

2015
Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study).
    Anticancer research, 2014, Volume: 34, Issue:11

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Safety and efficacy of radiofrequency ablation with aflibercept and FOLFIRI in a patient with metastatic colorectal cancer.
    Anticancer research, 2014, Volume: 34, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Colorectal Neoplasms; Comb

2014
Effect of Smad3/4 on chemotherapeutic drug sensitivity in colorectal cancer cells.
    Oncology reports, 2015, Volume: 33, Issue:1

    Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Cell Survival; Colorectal Neoplasm

2015
Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients.
    PloS one, 2014, Volume: 9, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2014
Can grade 2 neutropenia predict the risk of grade 3 neutropenia in metastatic colorectal cancer patients treated with chemotherapy?
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2015
Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
    Acta oncologica (Stockholm, Sweden), 2015, Volume: 54, Issue:4

    Topics: Aged; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C

2015
[Function of death associated protein kinase(DAPK) in colorectal cancer chemoresistance].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2014, Volume: 17, Issue:11

    Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Prol

2014
Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.
    Oncology research and treatment, 2014, Volume: 37, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal

2014
A 21-year-old patient with a HER2-positive colorectal cancer.
    Gastroenterology, 2015, Volume: 148, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor

2015
Comparison of complete pathologic response and hepatic injuries between hepatic arterial infusion and systemic administration of oxaliplatin in patients with colorectal liver metastases.
    Annals of surgical oncology, 2015, Volume: 22, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot

2015
MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells.
    Cancer letters, 2015, Jan-28, Volume: 356, Issue:2 Pt B

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins;

2015
Natural products and chemotherapeutic agents on cancer: prevention vs. treatment.
    The American journal of Chinese medicine, 2014, Volume: 42, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biological Availability; Biologic

2014
miR-203 enhances chemosensitivity to 5-fluorouracil by targeting thymidylate synthase in colorectal cancer.
    Oncology reports, 2015, Volume: 33, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Down-Reg

2015
FOLFOXIRI and bevacizumab in metastatic colorectal cancer.
    The Lancet. Oncology, 2014, Volume: 15, Issue:13

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2014
Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer.
    Anticancer research, 2014, Volume: 34, Issue:12

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptot

2014
A case of delayed oxaliplatin-induced pseudo-obstruction: an atypical presentation of oxaliplatin neurotoxicity.
    Acta clinica Belgica, 2015, Volume: 70, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colecto

2015
Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis.
    Immunity, 2014, Dec-18, Volume: 41, Issue:6

    Topics: Aberrant Crypt Foci; Animals; Antibodies, Blocking; Antineoplastic Combined Chemotherapy Protocols;

2014
Lipoic acid induces p53-independent cell death in colorectal cancer cells and potentiates the cytotoxicity of 5-fluorouracil.
    Archives of toxicology, 2015, Volume: 89, Issue:10

    Topics: Antimetabolites, Antineoplastic; Caco-2 Cells; Caspases; Cell Death; Cell Survival; Colorectal Neopl

2015
CEACAM1 and hollow spheroid formation modulate the chemosensitivity of colorectal cancer to 5-fluorouracil.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:2

    Topics: Aged; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Cell Adhesion Molecules; Cell Line,

2015
Upregulation of CD147 promotes cell invasion, epithelial-to-mesenchymal transition and activates MAPK/ERK signaling pathway in colorectal cancer.
    International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:11

    Topics: Basigin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epithelial-Mesenchymal T

2014
Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study.
    Journal of the peripheral nervous system : JPNS, 2014, Volume: 19, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Co

2014
Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data.
    Future oncology (London, England), 2015, Volume: 11, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2015
Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.
    PloS one, 2015, Volume: 10, Issue:1

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2015
MicroRNA 196B regulates FAS-mediated apoptosis in colorectal cancer cells.
    Oncotarget, 2015, Feb-20, Volume: 6, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Caco-2 Cells; Case-Control Studies; Caspase 3; Cas

2015
Always look at the bright side of drugs?
    Acta oncologica (Stockholm, Sweden), 2015, Volume: 54, Issue:2

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2015
MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer.
    The Journal of biological chemistry, 2015, Mar-06, Volume: 290, Issue:10

    Topics: Animals; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Flu

2015
Inhibition of STAT3/cyclinD1 pathway promotes chemotherapeutic sensitivity of colorectal caner.
    Biochemical and biophysical research communications, 2015, Feb-20, Volume: 457, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Colon; Colorectal Neoplasms; Cyclin D1; Drug Resistance, Neop

2015
The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells.
    International journal of oncology, 2015, Volume: 46, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Cell Culture Techniques; Cell Li

2015
Weichang'an and 5-fluorouracil suppresses colorectal cancer in a mouse model.
    World journal of gastroenterology, 2015, Jan-28, Volume: 21, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined

2015
Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer.
    Carcinogenesis, 2015, Volume: 36, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Color

2015
Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas.
    Carbohydrate polymers, 2015, May-05, Volume: 121

    Topics: Adenocarcinoma; Animals; Aptamers, Nucleotide; Chitosan; CHO Cells; Colorectal Neoplasms; Cricetinae

2015
Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
    The oncologist, 2015, Volume: 20, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2015
FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin;

2015
Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
    Journal of clinical pathology, 2015, Volume: 68, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor;

2015
Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis.
    World journal of gastroenterology, 2015, Feb-14, Volume: 21, Issue:6

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2015
First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Apr-01, Volume: 33, Issue:10

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo

2015
The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent.
    Cancer biology & therapy, 2015, Volume: 16, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoxazoles; Cadherins; Carrier Proteins; Cell Line, Tum

2015
A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases.
    Cancer biology & therapy, 2015, Volume: 16, Issue:3

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Campt

2015
Thromboembolic disease in advanced colorectal cancer treated with chemotherapy and bevacizumab: a case of real "pan-thrombosis".
    Tumori, 2015, Mar-20, Volume: 101, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2015
Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:4

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2015
Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy.
    The pharmacogenomics journal, 2015, Volume: 15, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; G

2015
Thymidylate synthase expression in circulating tumor cells: a new tool to predict 5-fluorouracil resistance in metastatic colorectal cancer patients.
    International journal of cancer, 2015, Sep-15, Volume: 137, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistan

2015
[A feasibility study of adjuvant therapy with capecitabine plus oxaliplatin (XELOX) for Japanese patients with advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C

2015
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.
    Anticancer research, 2015, Volume: 35, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal

2015
Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells.
    Cancer research and treatment, 2016, Volume: 48, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasm

2016
Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 Research Group study.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cohort Studies; Colorectal Neo

2015
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
    British journal of clinical pharmacology, 2015, Volume: 80, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dih

2015
Overexpression of DHX32 contributes to the growth and metastasis of colorectal cancer.
    Scientific reports, 2015, Mar-18, Volume: 5

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Carbonic Anhydrase IX; Carbonic Anhydrases; Ce

2015
Use of extracorporeal membrane oxygenation for mechanical circulatory support in a patient with 5-fluorouracil induced acute heart failure.
    Circulation. Heart failure, 2015, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Cardiotoxicity; Colorectal Neoplasms; Extrac

2015
Lethal 5-fluorouracil toxicity in a colorectal patient with severe dihydropyrimidine dehydrogenase (DPD) deficiency.
    International journal of colorectal disease, 2016, Volume: 31, Issue:3

    Topics: Colorectal Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Fatal Outcome; Female; Fluorouraci

2016
Validation of a fast and low-cost alkaline lysis method for gDNA extraction in a pharmacogenetic context.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:5

    Topics: Alkalies; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); DNA, Neoplasm; Fluorouracil; Gen

2015
Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Journal of medical economics, 2015, Volume: 18, Issue:8

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neopla

2015
[Incidence and management of adverse events in FOLFOX plus bevacizumab therapy for colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 2

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

2015
Analyses of multiple factors for determination of "selected patients" who should receive rechallenge treatment in metastatic colorectal cancer: a retrospective study from Turkey.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Colore

2015
Circadian Clock Gene CRY2 Degradation Is Involved in Chemoresistance of Colorectal Cancer.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cell Line, Tumor; Colorectal Ne

2015
Bevacizumab and postoperative wound complications in patients with liver metastases of colorectal cancer.
    Anticancer research, 2015, Volume: 35, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Colorectal Neoplasms; Female; Fluoroura

2015
KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer.
    Molecular oncology, 2015, Volume: 9, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort S

2015
[Transfection of thymidine phosphorylase cDNA with lentiviral vector enhances the anticancer effect of 5'-deoxy-5-fluorouridine on colorectal cancer cell lines HT29 and LS174T].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2015, Volume: 37, Issue:1

    Topics: Antineoplastic Agents; Cell Line; Cell Line, Tumor; Colorectal Neoplasms; DNA, Complementary; Floxur

2015
Dynamic modulation of thymidylate synthase gene expression and fluorouracil sensitivity in human colorectal cancer cells.
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Colorectal Neoplasms;

2015
Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26(+) cancer stem cells in colorectal carcinoma.
    Molecular cancer, 2015, Apr-11, Volume: 14

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell

2015
Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer.
    BMC cancer, 2015, Apr-10, Volume: 15

    Topics: Alginates; Animals; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Curcumin; Drug Synergism; F

2015
Colorectal liver metastases: making the unresectable resectable using irreversible electroporation for microscopic positive margins - a case report.
    BMC cancer, 2015, Apr-12, Volume: 15

    Topics: Ablation Techniques; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neo

2015
Growth inhibitory effect of polyunsaturated fatty acids (PUFAs) on colon cancer cells via their growth inhibitory metabolites and fatty acid composition changes.
    PloS one, 2015, Volume: 10, Issue:4

    Topics: Antimetabolites, Antineoplastic; Arachidonate 5-Lipoxygenase; Cell Line, Tumor; Colorectal Neoplasms

2015
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view.
    BMC gastroenterology, 2015, Mar-24, Volume: 15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2015
Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA.
    International journal of oncology, 2015, Volume: 46, Issue:6

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA, Neoplasm; Drug Combinations; Equilibrati

2015
5-Fluorouracil sensitizes colorectal tumor cells towards double stranded DNA breaks by interfering with homologous recombination repair.
    Oncotarget, 2015, May-20, Volume: 6, Issue:14

    Topics: Antineoplastic Agents; Cell Line, Tumor; Chemoradiotherapy; Colorectal Neoplasms; DNA Breaks, Double

2015
[Epinephros metastasis of colorectal cancer complicated by tumor thrombosis of inferior vena cava].
    Khirurgiia, 2015, Issue:1

    Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Agents; Capecitabine; Colecto

2015
Tumor suppressor miR-145 reverses drug resistance by directly targeting DNA damage-related gene RAD18 in colorectal cancer.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:7

    Topics: Aged; Animals; Apoptosis; Colorectal Neoplasms; DNA Damage; DNA Repair; DNA-Binding Proteins; Drug R

2015
Radiological Morphology of Colorectal Liver Metastases after Preoperative Chemotherapy Predicts Tumor Viability and Postoperative Outcomes.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2015, Volume: 19, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Bevacizumab; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy

2015
MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms.
    British journal of cancer, 2015, Apr-28, Volume: 112, Issue:9

    Topics: Adenoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Colorectal Neoplas

2015
Microarray Analysis of Long Non-coding RNA Expression Profile Associated with 5-Fluorouracil-Based Chemoradiation Resistance in Colorectal Cancer Cells.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:8

    Topics: Antineoplastic Agents; Chemoradiotherapy; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluoroura

2015
Elevated microRNA-23a Expression Enhances the Chemoresistance of Colorectal Cancer Cells with Microsatellite Instability to 5-Fluorouracil by Directly Targeting ABCF1.
    Current protein & peptide science, 2015, Volume: 16, Issue:4

    Topics: Apoptosis; ATP-Binding Cassette Transporters; Base Sequence; Cell Line, Tumor; Cell Survival; Colore

2015
miRNA-497 Enhances the Sensitivity of Colorectal Cancer Cells to Neoadjuvant Chemotherapeutic Drug.
    Current protein & peptide science, 2015, Volume: 16, Issue:4

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms

2015
Genetic polymorphisms in cytochrome P450 and clinical outcomes of FOLFIRI chemotherapy in patients with metastatic colorectal cancer.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cyt

2015
Colorectal cancer stem cell and chemoresistant colorectal cancer cell phenotypes and increased sensitivity to Notch pathway inhibitor.
    Molecular medicine reports, 2015, Volume: 12, Issue:2

    Topics: AC133 Antigen; Amyloid Precursor Protein Secretases; Animals; Antigens, CD; Antineoplastic Agents; C

2015
Colorectal cancer: to stack or sequence therapy?
    Journal of the National Cancer Institute, 2015, Volume: 107, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2015
Influence of metastatic disease on the usefulness of uracil pharmacokinetics as a screening tool for DPD activity in colorectal cancer patients.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape

2015
Drug development: Mix and match.
    Nature, 2015, May-14, Volume: 521, Issue:7551

    Topics: Antineoplastic Agents; Cancer Vaccines; Colorectal Neoplasms; Drug Approval; Fluorouracil; Genes, ra

2015
Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:2

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarke

2015
The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adju

2015
Comparing the effectiveness of capecitabine versus 5-fluorouracil/leucovorin therapy for elderly Taiwanese stage III colorectal cancer patients based on quality-of-life measures (QLQ-C30 and QLQ-CR38) and a new cost assessment tool.
    Health and quality of life outcomes, 2015, May-19, Volume: 13

    Topics: Administration, Intravenous; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antimetabol

2015
Efficacy of Adjuvant 5-Fluorouracil Therapy for Patients with EMAST-Positive Stage II/III Colorectal Cancer.
    PloS one, 2015, Volume: 10, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal

2015
Vascular-targeted TNFα improves tumor blood vessel function and enhances antitumor immunity and chemotherapy in colorectal cancer.
    Journal of controlled release : official journal of the Controlled Release Society, 2015, Jul-28, Volume: 210

    Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow; Cell Line; Cell Line, Tumor; Cell-Penetrating

2015
Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells.
    Cancer letters, 2015, Aug-28, Volume: 365, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; C

2015
Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry.
    Anticancer research, 2015, Volume: 35, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2015
MiR-320e is a novel prognostic biomarker in colorectal cancer.
    British journal of cancer, 2015, Jun-30, Volume: 113, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2015
Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors.
    Oncotarget, 2015, Jul-30, Volume: 6, Issue:21

    Topics: Antineoplastic Agents; Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Camptothecin; Cel

2015
Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
    American journal of surgery, 2015, Volume: 210, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2015
MicroRNA-197 influences 5-fluorouracil resistance via thymidylate synthase in colorectal cancer.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015, Volume: 17, Issue:11

    Topics: Antimetabolites, Antineoplastic; Blotting, Western; Cell Line, Tumor; Colorectal Neoplasms; Drug Res

2015
Time required to start multicentre clinical trials within the Italian Medicine Agency programme of support for independent research.
    Journal of medical ethics, 2015, Volume: 41, Issue:10

    Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Breas

2015
Chemotherapeutic treatment of colorectal cancer in pregnancy: case report.
    Journal of medical case reports, 2015, Jun-13, Volume: 9

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female;

2015
Systemic capillary leak syndrome in a patient receiving adjuvant oxaliplatin for locally advanced colon cancer.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2016, Volume: 22, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Colorectal Neoplasms; Fluor

2016
Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program.
    Expert opinion on drug safety, 2015, Volume: 14, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl

2015
ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer.
    PloS one, 2015, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2015
[The role of assessing UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity in the course of chemotherapy for colorectal cancer].
    Voprosy onkologii, 2015, Volume: 61, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos

2015
EGFR and β1-integrin targeting differentially affect colorectal carcinoma cell radiosensitivity and invasion.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2015, Volume: 116, Issue:3

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; ErbB R

2015
The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.
    Acta oncologica (Stockholm, Sweden), 2016, Volume: 55, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasm

2016
[Clinical efficacy observation of cetuximab combined with chemotherapy in the treatment of metastatic colorectal carcinoma].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2015, Volume: 18, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Ne

2015
Methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and fluorouracil-based treatment in Taiwan colorectal cancer.
    Anti-cancer drugs, 2015, Volume: 26, Issue:8

    Topics: Aged; Antineoplastic Agents; Asian People; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Hum

2015
Liver toxicity in colorectal cancer patients treated with first-line FOLFIRI-containing regimen: a single institution experience.
    Expert review of anticancer therapy, 2015, Volume: 15, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemic

2015
Relationship between DNA repair gene XPD751 single-nucleotide polymorphisms and prognosis of colorectal cancer.
    Genetics and molecular research : GMR, 2015, May-22, Volume: 14, Issue:2

    Topics: Adult; Aged; Colorectal Neoplasms; Disease Progression; DNA Repair; Female; Fluorouracil; Genotype;

2015
Suppression of KLF8 induces cell differentiation and sensitizes colorectal cancer to 5-fluorouracil.
    Oncology reports, 2015, Volume: 34, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Differentiation; Cell Transformat

2015
Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial.
    Clinics and research in hepatology and gastroenterology, 2015, Volume: 39, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Che

2015
Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer.
    Hepato-gastroenterology, 2014, Volume: 61, Issue:131

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2014
Expression of Folate Pathway Genes in Stage III Colorectal Cancer Correlates with Recurrence Status Following Adjuvant Bolus 5-FU-Based Chemotherapy.
    Molecular medicine (Cambridge, Mass.), 2015, Jul-17, Volume: 21

    Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival;

2015
A Study on Drug Interaction between Warfarin and Capecitabine with Special Reference to the Co-Administered Term or the Discontinuation Term of Capecitabine.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Colorectal Neo

2015
Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2015
Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS.
    Mayo Clinic proceedings, 2015, Volume: 90, Issue:9

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Fluorouracil; Gene Frequency; Genet

2015
Decreased expression of PinX1 protein predicts poor prognosis of colorectal cancer patients receiving 5-FU adjuvant chemotherapy.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2015, Volume: 73

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Cycle Prote

2015
Dissolution and degradation of Fmoc-diphenylalanine self-assembled gels results in necrosis at high concentrations in vitro.
    Biomaterials science, 2015, Volume: 3, Issue:2

    Topics: Animals; Cell Survival; Colorectal Neoplasms; Dipeptides; Fluorenes; Fluorouracil; Humans; Hydrogels

2015
Clinical Usefulness of 5-FU Metabolic Enzymes as Predictive Markers of Response to Chemotherapy in Colorectal Cancer.
    World journal of surgery, 2016, Volume: 40, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Female; Flu

2016
[Late complete response after long remission from treatment with FOLFIRI-aflibercept for metastatic colorectal cancer after progression to FOLFOX-bevacizumab].
    Recenti progressi in medicina, 2015, Volume: 106, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptot

2015
Truncating mutation in the autophagy gene UVRAG confers oncogenic properties and chemosensitivity in colorectal cancers.
    Nature communications, 2015, Aug-03, Volume: 6

    Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Autophagy; Carcinogenesis; Cell Line, Tumor;

2015
4-Acetylantroquinonol B inhibits colorectal cancer tumorigenesis and suppresses cancer stem-like phenotype.
    Toxicology and applied pharmacology, 2015, Oct-15, Volume: 288, Issue:2

    Topics: 4-Butyrolactone; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pr

2015
Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles.
    Nanoscale, 2015, Sep-07, Volume: 7, Issue:33

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Biocompatible Materials; Cell Line, Tumor;

2015
MicroRNA-587 antagonizes 5-FU-induced apoptosis and confers drug resistance by regulating PPP2R1B expression in colorectal cancer.
    Cell death & disease, 2015, 08-06, Volume: 6

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Drug Resistance, Neoplasm

2015
Lithium Modulates Autophagy in Esophageal and Colorectal Cancer Cells and Enhances the Efficacy of Therapeutic Agents In Vitro and In Vivo.
    PloS one, 2015, Volume: 10, Issue:8

    Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; E

2015
AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.
    The pharmacogenomics journal, 2016, Volume: 16, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clinical Trials, Pha

2016
Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?
    The oncologist, 2015, Volume: 20, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2015
Therapeutic efficacy and toxicity of bolus application of chemotherapy protocol in the treatment of metastatic colorectal cancer.
    Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina, 2015, Volume: 12, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; H

2015
Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor.
    International journal of radiation oncology, biology, physics, 2015, Oct-01, Volume: 93, Issue:2

    Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Chemoradiotherapy; Colorectal Neoplasms; Combined

2015
Correlation between DPYD gene variation and KRAS wild type status in colorectal cancer.
    Journal of clinical pathology, 2016, Volume: 69, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil

2016
PHD1 regulates p53-mediated colorectal cancer chemoresistance.
    EMBO molecular medicine, 2015, Volume: 7, Issue:10

    Topics: Animals; Antineoplastic Agents; Cell Line; Chemoradiotherapy; Colorectal Neoplasms; Drug Resistance,

2015
[Cost-effectiveness Analysis of Panitumumab Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 for First-line Treatment of Patients with Wild-type RAS Metastatic Colorectal Cancer--Czech Republic Model Adaptation].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2015, Volume: 28, Issue:4

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neop

2015
High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016, Volume: 18, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomark

2016
Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, Epithelial-to-mesenchymal transition and apoptosis in colorectal cancer.
    Biochemical pharmacology, 2015, Nov-01, Volume: 98, Issue:1

    Topics: Alginates; Antimetabolites; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Pro

2015
Predictive Significance of VEGF and HIF-1α Expression in Patients with Metastatic Colorectal Cancer Receiving Chemotherapy Combinations with Bevacizumab.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:14

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2015
[Occurrence, intratumoral heterogeneity, prognostic and predictive potential of microsatellite instability following surgical resection of primary colorectal carcinomas and corresponding liver metastases].
    Orvosi hetilap, 2015, Sep-06, Volume: 156, Issue:36

    Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bi

2015
Downregulation of VMP1 confers aggressive properties to colorectal cancer.
    Oncology reports, 2015, Volume: 34, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colore

2015
Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo.
    Journal of experimental & clinical cancer research : CR, 2015, Sep-04, Volume: 34

    Topics: Adamantane; Animals; Antineoplastic Agents; Cell Proliferation; Cisplatin; Colorectal Neoplasms; Fem

2015
Maintenance therapy for metastatic colorectal cancer.
    The Lancet. Oncology, 2015, Volume: 16, Issue:13

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine;

2015
Gypenosides Synergistically Enhances the Anti-Tumor Effect of 5-Fluorouracil on Colorectal Cancer In Vitro and In Vivo: A Role for Oxidative Stress-Mediated DNA Damage and p53 Activation.
    PloS one, 2015, Volume: 10, Issue:9

    Topics: Animals; Caco-2 Cells; Cell Proliferation; Colorectal Neoplasms; DNA Damage; Fluorouracil; Gynostemm

2015
The effect of 5-fluorouracil/leucovorin chemotherapy on CpG methylation, or the confounding role of leukocyte heterogeneity: An illustration.
    Genomics, 2015, Volume: 106, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; CpG Islands; DNA

2015
Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
    Experimental cell research, 2015, Nov-01, Volume: 338, Issue:2

    Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette

2015
Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells.
    Cancer biology & therapy, 2016, 08-02, Volume: 17, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor;

2016
Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells.
    International journal of oncology, 2015, Volume: 47, Issue:5

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neo

2015
Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer.
    Cancer biomarkers : section A of Disease markers, 2015, Volume: 15, Issue:6

    Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Combined Chemotherapy Pr

2015
MicroRNA-218 is a prognostic indicator in colorectal cancer and enhances 5-fluorouracil-induced apoptosis by targeting BIRC5.
    Carcinogenesis, 2015, Volume: 36, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Base Sequence; Binding S

2015
Hepatic artery infusion therapy is effective for chemotherapy-resistant liver metastatic colorectal cancer.
    World journal of surgical oncology, 2015, Oct-09, Volume: 13

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colo

2015
Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients.
    BMC cancer, 2015, Oct-14, Volume: 15

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chemothera

2015
Clinical Usefulness of 5-FU Metabolic Enzymes as Predictive Markers of Response to Chemotherapy in Colorectal Cancer.
    World journal of surgery, 2016, Volume: 40, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Female; Flu

2016
Fluorouracil, leucovorin and irinotecan associated with aflibercept can induce microscopic colitis in metastatic colorectal cancer patients.
    Investigational new drugs, 2015, Volume: 33, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colitis, Microscopic; Colorecta

2015
Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
    BMC cancer, 2015, Oct-21, Volume: 15

    Topics: Adult; Aged; Antibodies, Anti-Idiotypic; Bevacizumab; Colorectal Neoplasms; Disease-Free Survival; D

2015
Correlation between the promoter methylation status of ATP-binding cassette sub-family G member 2 and drug sensitivity in colorectal cancer cell lines.
    Oncology reports, 2016, Volume: 35, Issue:1

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Caco-2 C

2016
[Gastrointestinal surgeons should master the adjuvant therapy of colorectal cancer].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2015, Volume: 18, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro

2015
Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    JAMA oncology, 2016, Volume: 2, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor;

2016
Autophagy is upregulated during colorectal carcinogenesis, and in DNA microsatellite stable carcinomas.
    Oncology reports, 2015, Volume: 34, Issue:6

    Topics: Apoptosis; Autophagy; Bevacizumab; Carcinogenesis; Chloroquine; Colorectal Neoplasms; Fluorouracil;

2015
Fluctuation in Plasma 5-Fluorouracil Concentration During Continuous 5-Fluorouracil Infusion for Colorectal Cancer.
    Anticancer research, 2015, Volume: 35, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2015
In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer.
    Cancer research and treatment, 2016, Volume: 48, Issue:3

    Topics: Adenocarcinoma; Adenosine Triphosphate; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Anti

2016
Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues.
    Oncotarget, 2015, Dec-01, Volume: 6, Issue:38

    Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug

2015
Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer.
    Chemotherapy, 2016, Volume: 61, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab;

2016
Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy.
    Chronobiology international, 2015, Volume: 32, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circad

2015
Periostin expression in intra-tumoral stromal cells is prognostic and predictive for colorectal carcinoma via creating a cancer-supportive niche.
    Oncotarget, 2016, Jan-05, Volume: 7, Issue:1

    Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cell Adhesion Molecules; Cell Lin

2016
Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy.
    Cancer biology & therapy, 2015, Volume: 16, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Cell Line, Tumor; Colorec

2015
[Prognostic Factors of Stage 3 Colorectal Cancer in 433 Patients].
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2015, Volume: 37, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neo

2015
Absence of DAB2IP promotes cancer stem cell like signatures and indicates poor survival outcome in colorectal cancer.
    Scientific reports, 2015, Nov-13, Volume: 5

    Topics: Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Colorectal Neoplasms; Epithelial-Mesenchyma

2015
Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging.
    PloS one, 2015, Volume: 10, Issue:11

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2015
[Influence of the Site of Port Insertion on the Flow Velocity of 5-FU Continuous Intravenous Injection by Using a Compression-Type Portable Continuous Infuser for Colorectal Cancer Patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2015
[Septic shock and Tissierella praeacuta].
    Medecine et maladies infectieuses, 2016, Volume: 46, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholecystectomy; Cholecystitis

2016
[Association between RIPK4 relative copy number and prognosis of colorectal cancer patient after oxaliplatin-based chemotherapy].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2015, Volume: 18, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Color

2015
Prevalence of Oxaliplatin-induced Chronic Neuropathy and Influencing Factors in Patients with Colorectal Cancer in Iran.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:17

    Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Cape

2015
5-Fluorouracil enteric-coated nanoparticles for improved apoptotic activity and therapeutic index in treating colorectal cancer.
    Drug delivery, 2016, Volume: 23, Issue:8

    Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Del

2016
The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cholesterol; Colorectal Neoplasms; Disease Models,

2016
Fluorouracil-induced Hyperammonemia in a Patient with Colorectal Cancer.
    Anticancer research, 2015, Volume: 35, Issue:12

    Topics: Adult; Colorectal Neoplasms; Fluorouracil; Humans; Hyperammonemia; Male

2015
Down-regulation of SNX1 predicts poor prognosis and contributes to drug resistance in colorectal cancer.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Colorec

2016
Smad4 sensitizes colorectal cancer to 5-fluorouracil through cell cycle arrest by inhibiting the PI3K/Akt/CDC2/survivin cascade.
    Oncology reports, 2016, Volume: 35, Issue:3

    Topics: Animals; Apoptosis; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Proliferation; Chromones; Colo

2016
A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:6

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemoth

2016
Chronological Age and Risk of Chemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or III Colorectal Cancer Patients Given Adjuvant-modified FOLFOX6.
    American journal of clinical oncology, 2018, Volume: 41, Issue:1

    Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort St

2018
MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1.
    Oncotarget, 2016, Jan-19, Volume: 7, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Movement; Cell Prolifer

2016
Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: A large-scale population analysis.
    International journal of molecular medicine, 2016, Volume: 37, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA-

2016
Maintenance treatment in metastatic colorectal cancer.
    The Lancet. Oncology, 2015, Volume: 16, Issue:16

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine;

2015
Maintenance treatment in metastatic colorectal cancer.
    The Lancet. Oncology, 2015, Volume: 16, Issue:16

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine;

2015
Maintenance treatment in metastatic colorectal cancer - Authors' reply.
    The Lancet. Oncology, 2015, Volume: 16, Issue:16

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine;

2015
FOLFOX chemotherapy can safely be given to neutropenic patients with early-stage colorectal cancer for higher dose intensity and fewer visits.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropeni

2016
The Plasma microRNA miR-1914* and -1915 Suppresses Chemoresistant in Colorectal Cancer Patients by Down-regulating NFIX.
    Current molecular medicine, 2016, Volume: 16, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Cell Line; Cell Li

2016
[Impact of platelet count on prognosis of stage II-III colorectal cancer receiving adjuvant chemotherapy].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2015, Volume: 18, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorecta

2015
UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer.
    International journal of clinical oncology, 2016, Volume: 21, Issue:4

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomark

2016
BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?
    Molecular diagnosis & therapy, 2016, Volume: 20, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Australia; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabin

2016
Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:10

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NAD

2015
Roles of genetic variants in the PI3K/PTEN pathways in susceptibility to colorectal carcinoma and clinical outcomes treated with FOLFOX regimen.
    International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:10

    Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Class I

2015
Baseline [(18)F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model.
    Molecular imaging and biology, 2016, Volume: 18, Issue:4

    Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Colorectal Neoplasms; Female; Fluorine Radioisotopes;

2016
Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy.
    Chinese journal of cancer, 2016, Jan-06, Volume: 35

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

2016
A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling.
    Stem cells translational medicine, 2016, Volume: 5, Issue:3

    Topics: ADAM Proteins; ADAM17 Protein; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms

2016
Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer.
    Clinical colorectal cancer, 2016, Volume: 15, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Centra

2016
A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer.
    Japanese journal of clinical oncology, 2016, Volume: 46, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

2016
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer.
    Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; C

2015
Bevacizumab safety in Japanese patients with colorectal cancer.
    Japanese journal of clinical oncology, 2016, Volume: 46, Issue:3

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2016
B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:7

    Topics: Antimetabolites, Antineoplastic; Apoptosis; B7 Antigens; Biomarkers, Tumor; Blotting, Western; Cell

2016
Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX.
    Cancer research and treatment, 2016, Volume: 48, Issue:3

    Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Co

2016
Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.
    International journal of cancer, 2016, Jun-01, Volume: 138, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fl

2016
Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy.
    Journal of surgical oncology, 2016, Volume: 113, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ch

2016
Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 07-01, Volume: 22, Issue:13

    Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Dise

2016
E2F1/TS Immunophenotype and Survival of Patients with Colorectal Cancer Treated with 5FU-Based Adjuvant Therapy.
    Pathology oncology research : POR, 2016, Volume: 22, Issue:3

    Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; E2F1 Transcription Factor; Fema

2016
SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients.
    International journal of cancer, 2016, Jun-15, Volume: 138, Issue:12

    Topics: Adenosine Triphosphatases; Aged; Aged, 80 and over; Alcohol Oxidoreductases; Antineoplastic Combined

2016
Early Prediction of Tumor Response to Treatment: Preclinical Validation of 99mTc-Duramycin.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016, Volume: 57, Issue:5

    Topics: Animals; Bacteriocins; Biological Transport; Cell Line, Tumor; Colorectal Neoplasms; Female; Fluorou

2016
Low levels of Caspase-3 predict favourable response to 5FU-based chemotherapy in advanced colorectal cancer: Caspase-3 inhibition as a therapeutic approach.
    Cell death & disease, 2016, Feb-04, Volume: 7

    Topics: Antimetabolites, Antineoplastic; Caspase 3; Cell Proliferation; Colorectal Neoplasms; Female; Fluoro

2016
miR-450b-5p Suppresses Stemness and the Development of Chemoresistance by Targeting SOX2 in Colorectal Cancer.
    DNA and cell biology, 2016, Volume: 35, Issue:5

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Down-Regulatio

2016
The hypoxia-mimetic agent CoCl₂ induces chemotherapy resistance in LOVO colorectal cancer cells.
    Molecular medicine reports, 2016, Volume: 13, Issue:3

    Topics: bcl-2-Associated X Protein; bcl-Associated Death Protein; Cell Hypoxia; Cell Line, Tumor; Cell Proli

2016
KCTD12 Regulates Colorectal Cancer Cell Stemness through the ERK Pathway.
    Scientific reports, 2016, Feb-05, Volume: 6

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Colorectal

2016
Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study.
    PloS one, 2016, Volume: 11, Issue:2

    Topics: Adenosine Triphosphatases; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols;

2016
Efficacy of continued cetuximab for unresectable metastatic colorectal cancer after disease progression during first-line cetuximab-based chemotherapy: a retrospective cohort study.
    Oncotarget, 2016, Mar-08, Volume: 7, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cohort Studies; Colorectal

2016
Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy.
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2016, Volume: 44, Issue:1

    Topics: Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Coronary Vasospasm; Fluorouracil; Humans;

2016
Hepatic Arterial Infusion Chemotherapy for Life Threatening Patients due to Liver Metastases from Colorectal Cancer with Cetuximab.
    Hepato-gastroenterology, 2015, Volume: 62, Issue:139

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal N

2015
Serum Type IV Collagen Concentration Correlates with Indocyanine Green Retention Rate and is an Indicator Of Hepatotoxicity In Patients Receiving FOLFOX for Colorectal Cancer.
    Hepato-gastroenterology, 2015, Volume: 62, Issue:139

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemical and Drug Induced Liver In

2015
Timing of adjuvant chemotherapy in colorectal cancer.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2016, Volume: 18, Issue:9

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brazil; Chemotherapy, Adjuvant;

2016
Serum Type IV Collagen Concentration Correlates with Indocyanine Green Retention Rate.
    Hepato-gastroenterology, 2015, Volume: 62, Issue:140

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cohort

2015
Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients.
    Hepato-gastroenterology, 2015, Volume: 62, Issue:140

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2015
Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer.
    Oncotarget, 2016, Mar-29, Volume: 7, Issue:13

    Topics: Animals; Antineoplastic Agents; Catechin; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, N

2016
Impact of novel histopathological factors on the outcomes of liver surgery for colorectal cancer metastases.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2016, Volume: 42, Issue:9

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; C

2016
The TGF-β pathway is activated by 5-fluorouracil treatment in drug resistant colorectal carcinoma cells.
    Oncotarget, 2016, Apr-19, Volume: 7, Issue:16

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm;

2016
High expression of Zinc-finger protein X-linked promotes tumor growth and predicts a poor outcome for stage II/III colorectal cancer patients.
    Oncotarget, 2016, Apr-12, Volume: 7, Issue:15

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Caco-2 Cells; Cell Cycle Checkpoints; Cell Line

2016
Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort.
    Oncotarget, 2016, Apr-12, Volume: 7, Issue:15

    Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Dihydrouracil Dehydrogenas

2016
Mechanistic study of the anti-cancer effect of Gynostemma pentaphyllum saponins in the Apc(Min/+) mouse model.
    Proteomics, 2016, Volume: 16, Issue:10

    Topics: Adenomatous Polyposis Coli Protein; Animals; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms

2016
5-Fluorouracil induces apoptosis of colorectal cancer cells.
    Genetics and molecular research : GMR, 2016, Mar-04, Volume: 15, Issue:1

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Colorectal Neoplasms; Fluorouracil;

2016
Clinical and therapeutic significance of sirtuin-4 expression in colorectal cancer.
    Oncology reports, 2016, Volume: 35, Issue:5

    Topics: Aged; Animals; Antimetabolites, Antineoplastic; Cell Survival; Colorectal Neoplasms; Drug Resistance

2016
Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells.
    Cancer research, 2016, 05-15, Volume: 76, Issue:10

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Colorectal Neopla

2016
(64)Cu-ATSM therapy targets regions with activated DNA repair and enrichment of CD133(+) cells in an HT-29 tumor model: Sensitization with a nucleic acid antimetabolite.
    Cancer letters, 2016, 06-28, Volume: 376, Issue:1

    Topics: AC133 Antigen; Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Colorectal Neoplasms; C

2016
Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making.
    American journal of clinical oncology, 2016, Volume: 39, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clin

2016
The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
    The oncologist, 2016, Volume: 21, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col

2016
Paricalcitol Enhances the Chemopreventive Efficacy of 5-Fluorouracil on an Intermediate-Term Model of Azoxymethane-Induced Colorectal Tumors in Rats.
    Cancer prevention research (Philadelphia, Pa.), 2016, Volume: 9, Issue:6

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azoxymethane; Blotting, Western; Carcinogen

2016
Effect of Recepteur d'Origine Nantais expression on chemosensitivity and tumor cell behavior in colorectal cancer.
    Oncology reports, 2016, Volume: 35, Issue:6

    Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Lymphangiogenesis; Neovascu

2016
Safety and Management of Toxicity Related to Aflibercept in Combination with Fluorouracil, Leucovorin and Irinotecan in Malaysian Patients with Metastatic Colorectal Cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2016, Volume: 17, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal Neoplasms; Di

2016
LncRNA-UCA1 enhances cell proliferation and 5-fluorouracil resistance in colorectal cancer by inhibiting miR-204-5p.
    Scientific reports, 2016, Apr-05, Volume: 6

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Cyclic AMP Response

2016
Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response.
    Oncotarget, 2016, May-10, Volume: 7, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Asian People; Camptothecin; Cetuximab; Colorecta

2016
Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells.
    Annals of surgical oncology, 2016, Volume: 23, Issue:9

    Topics: AC133 Antigen; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colon; Colorect

2016
Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer.
    Anticancer research, 2016, Volume: 36, Issue:4

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorect

2016
Safety and efficacy of aflibercept in combination with fluorouracil, leucovorin and irinotecan in the treatment of Asian patients with metastatic colorectal cancer.
    Asia-Pacific journal of clinical oncology, 2016, Volume: 12, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2016
Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254.
    The Lancet. Oncology, 2016, Volume: 17, Issue:5

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Combined Chemotherapy Protocols

2016
Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort.
    Journal of geriatric oncology, 2016, Volume: 7, Issue:3

    Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizu

2016
Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report.
    Journal of medical case reports, 2016, Apr-18, Volume: 10

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorect

2016
Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status.
    Cancer biology & therapy, 2016, 07-02, Volume: 17, Issue:7

    Topics: Colorectal Neoplasms; DNA Mismatch Repair; Endodeoxyribonucleases; Fluorouracil; Frameshift Mutation

2016
MnTnBuOE-2-PyP protects normal colorectal fibroblasts from radiation damage and simultaneously enhances radio/chemotherapeutic killing of colorectal cancer cells.
    Oncotarget, 2016, Jun-07, Volume: 7, Issue:23

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Senesc

2016
MicroRNA-320 suppresses colorectal cancer by targeting SOX4, FOXM1, and FOXQ1.
    Oncotarget, 2016, Jun-14, Volume: 7, Issue:24

    Topics: 3' Untranslated Regions; Animals; Antimetabolites, Antineoplastic; Cell Movement; Cell Proliferation

2016
GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
    Medicine, 2016, Volume: 95, Issue:17

    Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2016
Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study.
    Journal of gastrointestinal cancer, 2016, Volume: 47, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasm

2016
The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.
    Nature medicine, 2016, Volume: 22, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

2016
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin.
    Surgery today, 2016, Volume: 46, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy;

2016
Full-length LGR5-positive cells have chemoresistant characteristics in colorectal cancer.
    British journal of cancer, 2016, 05-24, Volume: 114, Issue:11

    Topics: Adenocarcinoma; Alternative Splicing; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Ce

2016
Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer.
    Journal of oncology practice, 2016, Volume: 12, Issue:6

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co

2016
Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.
    Journal of translational medicine, 2016, 05-05, Volume: 14, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ce

2016
[KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
    Bulletin du cancer, 2016, Volume: 103, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2016
Anti-tumor and immunomodulatory activities of an exopolysaccharide from Rhizopus nigricans on CT26 tumor-bearing mice.
    International immunopharmacology, 2016, Volume: 36

    Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Dru

2016
Cancer Stem-like Properties in Colorectal Cancer Cells with Low Proteasome Activity.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Nov-01, Volume: 22, Issue:21

    Topics: Animals; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistan

2016
miR-139-5p sensitizes colorectal cancer cells to 5-fluorouracil by targeting NOTCH-1.
    Pathology, research and practice, 2016, Volume: 212, Issue:7

    Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Neoplasm; Fluor

2016
B7-H3 upregulates BRCC3 expression, antagonizing DNA damage caused by 5-Fu.
    Oncology reports, 2016, Volume: 36, Issue:1

    Topics: B7 Antigens; Cell Line, Tumor; Colorectal Neoplasms; Deubiquitinating Enzymes; DNA Damage; DNA Repai

2016
Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F

2016
Reply to 'Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients' by C. Cremolini et al.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F

2016
Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab.
    Medicine, 2016, Volume: 95, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2016
Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:7

    Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Campt

2016
Incompatibility between irinotecan and fluorouracil injections.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2016, Jun-01, Volume: 73, Issue:11

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplas

2016
[Study of the Efficacy of Aprepitant in FOLFOX/FOLFIRI for Elderly Patients with Advanced Colorectal Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Camptothecin; C

2016
Combination Therapy of Lactobacillus plantarum Supernatant and 5-Fluouracil Increases Chemosensitivity in Colorectal Cancer Cells.
    Journal of microbiology and biotechnology, 2016, Aug-28, Volume: 26, Issue:8

    Topics: AC133 Antigen; Aldehyde Dehydrogenase 1 Family; Antigens, CD; Antineoplastic Agents; Apoptosis; Axin

2016
MicroRNA-874 inhibits growth, induces apoptosis and reverses chemoresistance in colorectal cancer by targeting X-linked inhibitor of apoptosis protein.
    Oncology reports, 2016, Volume: 36, Issue:1

    Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Down-Regulation; Female; Fluo

2016
Molecular correlates and prognostic value of tmTNF-α expression in colorectal cancer of 5-Fluorouracil-Based Adjuvant Therapy.
    Cancer biology & therapy, 2016, 06-02, Volume: 17, Issue:6

    Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Prognosis; Signal

2016
Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.
    Pharmacogenomics, 2016, Volume: 17, Issue:9

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

2016
5-Fluorouracil-induced acute reversible heart failure not explained by coronary spasms, myocarditis or takotsubo: lessons from MRI.
    BMJ case reports, 2016, Jun-01, Volume: 2016

    Topics: Aged; Colorectal Neoplasms; Coronary Angiography; Diagnosis, Differential; Echocardiography; Female;

2016
Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs.
    Oncotarget, 2016, Jul-12, Volume: 7, Issue:28

    Topics: Activin Receptors, Type II; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Compositio

2016
Up-regulation of stem cell markers by P21-activated kinase 1 contributes to 5-fluorouracil resistance of colorectal cancer.
    Cancer biology & therapy, 2016, 08-02, Volume: 17, Issue:8

    Topics: Animals; Carcinogenesis; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorour

2016
Combination treatment with flavonoid morin and telomerase inhibitor MST‑312 reduces cancer stem cell traits by targeting STAT3 and telomerase.
    International journal of oncology, 2016, Volume: 49, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Colorectal Ne

2016
Redox Regulation of Stem-like Cells Though the CD44v-xCT Axis in Colorectal Cancer: Mechanisms and Therapeutic Implications.
    Theranostics, 2016, Volume: 6, Issue:8

    Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents; Cell Line; Colorectal Neoplasms; Flu

2016
Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer.
    Oncotarget, 2016, Jul-12, Volume: 7, Issue:28

    Topics: Acetylation; Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism;

2016
Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05).
    Targeted oncology, 2016, Volume: 11, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Female

2016
[The Molecular Aspect of the Antitumor Effect of Oxaliplatin in Combination with 5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Gene Expression

2016
When a good call leads to a bad connection: colovesical fistula in colorectal cancer treated with bevacizumab.
    Hospital practice (1995), 2016, Volume: 44, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neo

2016
Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway.
    Oncotarget, 2016, Jul-19, Volume: 7, Issue:29

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Drug Resista

2016
Transforming Growth Factor β Mediates Drug Resistance by Regulating the Expression of Pyruvate Dehydrogenase Kinase 4 in Colorectal Cancer.
    The Journal of biological chemistry, 2016, 08-12, Volume: 291, Issue:33

    Topics: Animals; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expre

2016
Last line therapy with sorafenib in colorectal cancer: A retrospective analysis.
    World journal of gastroenterology, 2016, Jun-21, Volume: 22, Issue:23

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2016
Inhibition of phosphoserine phosphatase enhances the anticancer efficacy of 5-fluorouracil in colorectal cancer.
    Biochemical and biophysical research communications, 2016, 09-02, Volume: 477, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Enzy

2016
Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer.
    Annals of surgical oncology, 2016, Volume: 23, Issue:12

    Topics: Administration, Intravenous; Adult; Antineoplastic Combined Chemotherapy Protocols; Body Composition

2016
Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer.
    Anticancer research, 2016, Volume: 36, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chem

2016
Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer.
    Anticancer research, 2016, Volume: 36, Issue:7

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2016
Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study.
    Oncology, 2016, Volume: 91, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bevacizumab; C

2016
Calnexin, an ER stress-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer.
    Journal of translational medicine, 2016, 07-01, Volume: 14, Issue:1

    Topics: Biomarkers, Tumor; Calnexin; Cell Death; Cell Survival; Clone Cells; Colorectal Neoplasms; Endoplasm

2016
Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.
    Cancer, 2016, Oct-15, Volume: 122, Issue:20

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc

2016
Epidural analgesia combined with a comprehensive physiotherapy program after Cytoreductive Surgery and HIPEC is associated with enhanced post-operative recovery and reduces intensive care unit stay: A retrospective study of 124 patients.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2016, Volume: 42, Issue:12

    Topics: Analgesia, Epidural; Analgesia, Patient-Controlled; Antineoplastic Combined Chemotherapy Protocols;

2016
MUC13 protects colorectal cancer cells from death by activating the NF-κB pathway and is a potential therapeutic target.
    Oncogene, 2017, 02-02, Volume: 36, Issue:5

    Topics: Animals; Antigens, Surface; Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Cell Line, Tu

2017
Anisomycin-induced GATA-6 degradation accompanying a decrease of proliferation of colorectal cancer cell.
    Biochemical and biophysical research communications, 2016, 09-09, Volume: 478, Issue:1

    Topics: Anisomycin; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor;

2016
MicroRNA-149 Increases the Sensitivity of Colorectal Cancer Cells to 5-Fluorouracil by Targeting Forkhead Box Transcription Factor FOXM1.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2016, Volume: 39, Issue:2

    Topics: 3' Untranslated Regions; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto

2016
Primary cultures of human colon cancer as a model to study cancer stem cells.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:9

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Camptothecin; Cell Line, Tumor; Colonic Neoplasms

2016
ABCG2 is required for self-renewal and chemoresistance of CD133-positive human colorectal cancer cells.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:9

    Topics: AC133 Antigen; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; ATP Binding Cassette Transpo

2016
Glucose deprivation induces chemoresistance in colorectal cancer cells by increasing ATF4 expression.
    World journal of gastroenterology, 2016, Jul-21, Volume: 22, Issue:27

    Topics: Activating Transcription Factor 4; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Bi

2016
Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.
    World journal of gastroenterology, 2016, Jul-21, Volume: 22, Issue:27

    Topics: Adult; Aged; Angiogenesis Inhibitors; Angiopoietin-2; Antineoplastic Combined Chemotherapy Protocols

2016
Protein expression of ATP-binding cassette transporters ABCC10 and ABCC11 associates with survival of colorectal cancer patients.
    Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:3

    Topics: Aged; Antimetabolites, Antineoplastic; ATP-Binding Cassette Transporters; Colorectal Neoplasms; Dise

2016
Pretreatment Serum Folate Levels and Toxicity/Efficacy in Colorectal Cancer Patients Treated With 5-Fluorouracil and Folinic Acid.
    Clinical colorectal cancer, 2016, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; F

2016
TAM receptors Tyro3 and Mer as novel targets in colorectal cancer.
    Oncotarget, 2016, 08-30, Volume: 7, Issue:35

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Axl Receptor Tyrosine Kina

2016
Robotic-Assisted Placement of an Hepatic Artery Infusion Pump and Catheter for Regional Chemotherapy of the Liver.
    Annals of surgical oncology, 2016, Volume: 23, Issue:Suppl 5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Flu

2016
Role of γ-glutamyl cyclotransferase as a therapeutic target for colorectal cancer based on the lentivirus-mediated system.
    Anti-cancer drugs, 2016, Volume: 27, Issue:10

    Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Disease Progression; Fluorouracil; gamma-Glutamyl

2016
Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine.
    Cancer letters, 2016, 10-28, Volume: 381, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Colorectal Neoplasms; Drug Resistanc

2016
Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells.
    Oncotarget, 2016, Sep-13, Volume: 7, Issue:37

    Topics: Antineoplastic Agents; Apoptosis; Cancer-Associated Fibroblasts; Cell Line, Tumor; Colorectal Neopla

2016
Decellularized matrices as in vitro models of extracellular matrix in tumor tissues at different malignant levels: Mechanism of 5-fluorouracil resistance in colorectal tumor cells.
    Biochimica et biophysica acta, 2016, Volume: 1863, Issue:11

    Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; Cell Proliferation;

2016
Capecitabine and the Risk of Fingerprint Loss.
    JAMA oncology, 2017, Jan-01, Volume: 3, Issue:1

    Topics: Capecitabine; Carcinoma, Hepatocellular; Colorectal Neoplasms; Dermatoglyphics; Female; Fluorouracil

2017
The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients treated with targeted agents.
    Recenti progressi in medicina, 2016, Volume: 107, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou

2016
Knockdown of FOXK1 alone or in combination with apoptosis-inducing 5-FU inhibits cell growth in colorectal cancer.
    Oncology reports, 2016, Volume: 36, Issue:4

    Topics: Animals; Apoptosis; Carcinogenesis; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Fluorourac

2016
FOLFIRI plus cetuximab in patients with liver-limited or non-liver-limited RAS wild-type metastatic colorectal cancer: A retrospective subgroup analysis of the CRYSTAL study.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2016, Volume: 42, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuxi

2016
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
    Oncology, 2016, Volume: 91, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2016
Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2016, Volume: 39, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine

2016
Complete Response to Aflibercept-FOLFIRI in One Patient With Colorectal Cancer Refractory to Bevacizumab-FOLFOX: A Possible Autocrine Vascular Endothelial Growth Factor Receptor 2-Related Mechanism.
    Clinical colorectal cancer, 2016, Volume: 15, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin;

2016
Changes in hepatic perfusion assessed by dynamic contrast enhanced MRI, associated with morphologic evaluation, in patients with liver metastases from colorectal cancer treated with first-line chemotherapy.
    La Radiologia medica, 2016, Volume: 121, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Colorectal Neo

2016
Response to 'Comment on 'The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome''.
    British journal of cancer, 2016, 10-11, Volume: 115, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Veno-Occ

2016
Glucose-regulated protein 78 contributes to the proliferation and tumorigenesis of human colorectal carcinoma via AKT and ERK pathways.
    Oncology reports, 2016, Volume: 36, Issue:5

    Topics: Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Co

2016
Determining the optimal 5-FU therapeutic dosage in the treatment of colorectal cancer patients.
    Oncotarget, 2016, Dec-06, Volume: 7, Issue:49

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neoplasms; Dihydrouracil

2016
Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment.
    Chemotherapy, 2017, Volume: 62, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bili

2017
CD133+CD24lo defines a 5-Fluorouracil-resistant colon cancer stem cell-like phenotype.
    Oncotarget, 2016, Nov-29, Volume: 7, Issue:48

    Topics: AC133 Antigen; Aldehyde Dehydrogenase; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CD24 Anti

2016
Bevacizumab in colorectal cancer: it should have worked.
    The Lancet. Oncology, 2016, Volume: 17, Issue:11

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bev

2016
Prediction of the therapeutic response after FOLFOX and FOLFIRI treatment for patients with liver metastasis from colorectal cancer using computerized CT texture analysis.
    European journal of radiology, 2016, Volume: 85, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2016
Peritoneal Carcinomatosis in Colorectal Cancers - Management Perspective Needs a Change.
    Clinical colorectal cancer, 2017, Volume: 16, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Combined Modalit

2017
The prognosis of liver resection for patients with four or more colorectal liver metastases has not improved in the era of modern chemotherapy.
    Journal of surgical oncology, 2016, Volume: 114, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2016
Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression.
    Biochemical pharmacology, 2016, Dec-01, Volume: 121

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Cell

2016
The A
    Cancer letters, 2016, 12-01, Volume: 383, Issue:1

    Topics: Adenosine A2 Receptor Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

2016
Gold nanoparticles enhance 5-fluorouracil anticancer efficacy against colorectal cancer cells.
    International journal of pharmaceutics, 2016, Nov-20, Volume: 513, Issue:1-2

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Drug Delivery Systems; Drug Libera

2016
Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells.
    Cancer letters, 2016, 12-28, Volume: 383, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; CD

2016
Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet Count, CRP, and Albumin Levels in Metastatic Colorectal Cancer Patients Treated with FOLFIRI-Bevacizumab.
    Journal of gastrointestinal cancer, 2017, Volume: 48, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemot

2017
Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017, Volume: 19, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2017
Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma.
    BMC cancer, 2016, 10-12, Volume: 16, Issue:1

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; CpG Islands; DNA Met

2016
Microsatellite instability & survival in patients with stage II/III colorectal carcinoma.
    The Indian journal of medical research, 2016, Volume: 143, Issue:Supplement

    Topics: Adult; Aged; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; H

2016
Gap junction composed of connexin43 modulates 5‑fluorouracil, oxaliplatin and irinotecan resistance on colorectal cancers.
    Molecular medicine reports, 2016, Volume: 14, Issue:5

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Connexin

2016
Interstitial lung disease caused by oxaliplatin. An uncommon but not unknown complication.
    Archivos de bronconeumologia, 2017, Volume: 53, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne

2017
Use of 5-Fluorouracil Loaded Micelles and Cisplatin in Thermosensitive Chitosan Hydrogel as an Efficient Therapy against Colorectal Peritoneal Carcinomatosis.
    Macromolecular bioscience, 2017, Volume: 17, Issue:4

    Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmac

2017
Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer.
    British journal of cancer, 2016, Nov-08, Volume: 115, Issue:10

    Topics: Amphiregulin; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tu

2016
Putting a brake on stress signaling: miR-625-3p as a biomarker for choice of therapy in colorectal cancer.
    Epigenomics, 2016, Volume: 8, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal

2016
Necrotizing Infundibular Crystalline Folliculitis (NICF) Induced by Anti-Tumoral Therapies: Report of 2 Cases.
    The American Journal of dermatopathology, 2017, Volume: 39, Issue:10

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorecta

2017
[Difference analysis of chemotherapy efficacy among different primary tumor sites in metastatic colorectal cancer].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2016, Oct-25, Volume: 19, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colon, Sigmoid; Colon, Transvers

2016
Anti-EGFR antibody sensitizes colorectal cancer stem-like cells to Fluorouracil-induced apoptosis by affecting autophagy.
    Oncotarget, 2016, Dec-06, Volume: 7, Issue:49

    Topics: AC133 Antigen; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cetuximab; Colo

2016
Gankyrin sustains PI3K/GSK-3β/β-catenin signal activation and promotes colorectal cancer aggressiveness and progression.
    Oncotarget, 2016, Dec-06, Volume: 7, Issue:49

    Topics: Animals; Antimetabolites, Antineoplastic; beta Catenin; Cell Movement; Cell Proliferation; Colorecta

2016
Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer.
    Oncotarget, 2016, Dec-06, Volume: 7, Issue:49

    Topics: Animals; Antineoplastic Agents; Caco-2 Cells; Cell Proliferation; Colorectal Neoplasms; Drug Resista

2016
53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway.
    Journal of cancer research and clinical oncology, 2017, Volume: 143, Issue:3

    Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Cell Proliferation; Checkpoint Kinase 2; Colorectal

2017
5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.
    Anti-cancer drugs, 2017, Volume: 28, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2017
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
    World journal of surgical oncology, 2016, Nov-16, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Capecitabine; Chemo

2016
Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer.
    Oncology (Williston Park, N.Y.), 2016, Nov-15, Volume: 30, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Male; Mi

2016
Restoration of the tumor-suppressor function to mutant p53 by Ganoderma lucidum polysaccharides in colorectal cancer cells.
    Oncology reports, 2017, Volume: 37, Issue:1

    Topics: Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Fluoro

2017
EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
    International journal of cancer, 2017, 02-15, Volume: 140, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chem

2017
Standard Clinical Protocol for Bidirectional Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Systemic Leucovorin, 5-Fluorouracil, and Heated Intraperitoneal Oxaliplatin in a Chloride-Containing Carrier Solution.
    Annals of surgical oncology, 2017, Volume: 24, Issue:4

    Topics: Administration, Intravenous; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Chloride

2017
Role of genomic factors beyond thymidylate synthase in the prediction of response to 5-fluorouracil.
    Nucleosides, nucleotides & nucleic acids, 2016, Volume: 35, Issue:10-12

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chromosomes, Human, Pair 12; Colorectal Neoplasms; Com

2016
Preparation and characterization of polymeric nanoparticles surface modified with chitosan for target treatment of colorectal cancer.
    International journal of biological macromolecules, 2017, Volume: 95

    Topics: Chitosan; Colorectal Neoplasms; Drug Liberation; Fluorouracil; HT29 Cells; Humans; Kinetics; Nanopar

2017
BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status.
    Journal of Korean medical science, 2017, Volume: 32, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; ErbB Receptors; F

2017
Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017, Volume: 25, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chronic Disease

2017
Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer.
    Oncology research, 2017, May-24, Volume: 25, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2017
Prognostic and predictive significance of long interspersed nucleotide element-1 methylation in advanced-stage colorectal cancer.
    BMC cancer, 2016, 12-12, Volume: 16, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Cell Line, Tumor; Colorectal Neo

2016
Induction of hypoxia and necrosis in multicellular tumor spheroids is associated with resistance to chemotherapy treatment.
    Oncotarget, 2017, Jan-03, Volume: 8, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Hypoxia; Colorectal Neoplasms; Drug Resistance, Neopl

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C

2017
[Aflibercept: focus on tolerability.]
    Recenti progressi in medicina, 2016, Volume: 107, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2016
Elevated expression of TrpC5 and GLUT1 is associated with chemoresistance in colorectal cancer.
    Oncology reports, 2017, Volume: 37, Issue:2

    Topics: Aged; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene

2017
Synergistically Anti-metastatic Effect of 5-Flourouracil on Colorectal Cancer Cells via Calcium-mediated Focal Adhesion Kinase Proteolysis.
    Anticancer research, 2017, Volume: 37, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Calcium Compounds; Cell Death; Ce

2017
"
    World journal of gastroenterology, 2016, Dec-14, Volume: 22, Issue:46

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cecal

2016
5-Fluorouracil inhibits cell migration by induction of Sestrin2 in colon cancer cells.
    Archives of pharmacal research, 2017, Volume: 40, Issue:2

    Topics: Antimetabolites, Antineoplastic; Antioxidants; Benzothiazoles; Cell Movement; Colorectal Neoplasms;

2017
Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
    Journal of chemotherapy (Florence, Italy), 2017, Volume: 29, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorec

2017
Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2017, Volume: 15, Issue:1

    Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic

2017
Epigenomics alternations and dynamic transcriptional changes in responses to 5-fluorouracil stimulation reveal mechanisms of acquired drug resistance of colorectal cancer cells.
    The pharmacogenomics journal, 2018, Volume: 18, Issue:1

    Topics: Cell Line, Tumor; Colorectal Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Gene

2018
WNT5A Promoter Methylation Is Associated with Better Responses and Longer Progression-Free Survival in Colorectal Cancer Patients Treated with 5-Fluorouracil-Based Chemotherapy.
    Genetic testing and molecular biomarkers, 2017, Volume: 21, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Biomarkers, Tumor; Cell L

2017
FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10.
    Oncotarget, 2017, Jan-31, Volume: 8, Issue:5

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Binding Sites; Colorectal Neoplasms; Dose-Respo

2017
Characterization of Conversion Chemotherapy for Secondary Surgical Resection in Colorectal Cancer Patients with Lung Metastases.
    Oncology, 2017, Volume: 92, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot

2017
Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
    BMC cancer, 2017, 01-07, Volume: 17, Issue:1

    Topics: Actins; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protoco

2017
Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.
    Clinical pharmacology and therapeutics, 2017, Volume: 102, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Ana

2017
Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer.
    Cancer science, 2017, Volume: 108, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2017
Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
    Oncotarget, 2017, Feb-14, Volume: 8, Issue:7

    Topics: Acid Phosphatase; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; B

2017
FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer: A necessity?
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 73

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2017
Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy.
    Clinical colorectal cancer, 2017, Volume: 16, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuxi

2017
Brother of Regulator of Imprinted Sites (BORIS) suppresses apoptosis in colorectal cancer.
    Scientific reports, 2017, 01-18, Volume: 7

    Topics: Aged; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplas

2017
Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer.
    Japanese journal of clinical oncology, 2017, Apr-01, Volume: 47, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female;

2017
Heterogeneity in cancer cells: variation in drug response in different primary and secondary colorectal cancer cell lines in vitro.
    In vitro cellular & developmental biology. Animal, 2017, Volume: 53, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Pharmacological; Cell Cycle;

2017
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.
    Oncotarget, 2017, Mar-07, Volume: 8, Issue:10

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cohort S

2017
Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin.
    Cell communication and signaling : CCS, 2017, Feb-01, Volume: 15, Issue:1

    Topics: Biomarkers, Tumor; Carcinogenesis; Cell Death; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluo

2017
A New Technique of Radiofrequency-assisted Ultrasound-guided Needle-localized Laparoscopic Resection of Disappearing Colorectal Liver Metastases.
    Surgical laparoscopy, endoscopy & percutaneous techniques, 2017, Volume: 27, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Catheter Ablation

2017
microRNA-577 suppresses tumor growth and enhances chemosensitivity in colorectal cancer.
    Journal of biochemical and molecular toxicology, 2017, Volume: 31, Issue:6

    Topics: Adult; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; China; Colorectal

2017
Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization.
    Medical oncology (Northwood, London, England), 2017, Volume: 34, Issue:3

    Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2017
CXCL12/CXCR4 axis induced miR-125b promotes invasion and confers 5-fluorouracil resistance through enhancing autophagy in colorectal cancer.
    Scientific reports, 2017, 02-08, Volume: 7

    Topics: Adenomatous Polyposis Coli Protein; Animals; Apoptosis; Autophagy; Base Sequence; Cell Line, Tumor;

2017
Rechallenge and maintenance therapy using cetuximab and chemotherapy administered to a patient with metastatic colorectal cancer.
    BMC cancer, 2017, 02-14, Volume: 17, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cetuximab; Colorectal Neop

2017
Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia.
    Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:3

    Topics: Aged; Ammonia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; beta

2017
Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance.
    Human molecular genetics, 2017, 04-15, Volume: 26, Issue:8

    Topics: Amino Acids; Apoptosis; Cell Hypoxia; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil;

2017
Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
    The oncologist, 2017, Volume: 22, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne

2017
Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
    Clinical colorectal cancer, 2017, Volume: 16, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot

2017
Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
    Neoplasia (New York, N.Y.), 2017, Volume: 19, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; C

2017
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 76

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2017
The extracellular domain of E cadherin linked to invasiveness in colorectal cancer: a new resistance and relapses monitoring serum-bio marker?
    Journal of cancer research and clinical oncology, 2017, Volume: 143, Issue:7

    Topics: Adult; Aged; Antigens, CD; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cadherins; C

2017
Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis.
    World journal of gastroenterology, 2017, Feb-28, Volume: 23, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; He

2017
AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells.
    Cell cycle (Georgetown, Tex.), 2017, Volume: 16, Issue:22

    Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Colorectal Neoplasms; DNA Breaks, Double-Stranded; Fluo

2017
Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jun-01, Volume: 26, Issue:16

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2008
Hepatic arterial infusion chemotherapy for metastases from colorectal cancer: is it really the end of an era?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jun-01, Volume: 26, Issue:16

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal Neoplasms; Floxuridine; Fluoroura

2008
Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
    Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2008
Nonparametric estimation of mean residual functions.
    Lifetime data analysis, 2009, Volume: 15, Issue:1

    Topics: Algorithms; Analysis of Variance; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as

2009
Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2008, Jul-01, Volume: 870, Issue:1

    Topics: Capecitabine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Cytidine Deaminase; Deoxyc

2008
Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry.
    Oncology reports, 2008, Volume: 20, Issue:1

    Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationship,

2008
Single-cell transcription site activation predicts chemotherapy response in human colorectal tumors.
    Cancer research, 2008, Jul-01, Volume: 68, Issue:13

    Topics: Adenosine Triphosphatases; Algorithms; Antineoplastic Agents; bcl-2 Homologous Antagonist-Killer Pro

2008
Liver resection for colorectal liver metastases in older patients.
    Critical reviews in oncology/hematology, 2008, Volume: 67, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col

2008
Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer.
    Onkologie, 2008, Volume: 31, Issue:7

    Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Acti

2008
Clinical implications of thymidylate synthetase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activity levels in colorectal carcinoma following radical resection and administration of adjuvant 5-FU chemotherapy.
    BMC cancer, 2008, Jul-02, Volume: 8

    Topics: Aged; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Therapy; Enzyme Activation; Fem

2008
Functional inactivity and mutations of p53 differentially affect sensitivity to 5-fluorouracil and antifolate inhibitors of thymidylate synthase (TS) by altering TS levels in colorectal cancer cells.
    Nucleosides, nucleotides & nucleic acids, 2008, Volume: 27, Issue:6

    Topics: Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Folic Acid Antagonists; Gene Expression Regula

2008
Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:6

    Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy,

2008
Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
    World journal of gastroenterology, 2008, Jun-28, Volume: 14, Issue:24

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; bcl-X Protein; Camptothecin; Cell Line, Tumor; Cel

2008
Methylenetetrahydrofolate reductase gene polymorphisms: genomic predictors of clinical response to fluoropyrimidine-based chemotherapy in females.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-10, Volume: 26, Issue:20

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Colorectal

2008
The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
    Pathologie-biologie, 2009, Volume: 57, Issue:6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers; Chromatography, High Pressure Liquid; Colo

2009
Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2008, Volume: 49, Issue:8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biological Transpo

2008
[Efficacy of 5-FU hepatic arterial infusion with l-leucovorin for patients with unresectable colorectal liver metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Hum

2008
[Comparative survey on current status and the differences of treatment using modified FOLFOX6 regimen in patients with colorectal cancer in two general hospitals].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2008
Combined chemotherapy of hydroxycampothecin with oxaliplatin as an adjuvant treatment for human colorectal cancer.
    The Tohoku journal of experimental medicine, 2008, Volume: 215, Issue:3

    Topics: Adjuvants, Pharmaceutic; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apopt

2008
Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
    Clinical colorectal cancer, 2008, Volume: 7, Issue:4

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2008
Highlights from: The 44th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL; May 30-June 3, 2008.
    Clinical colorectal cancer, 2008, Volume: 7, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2008
FOLFOX2 in the treatment of advanced colorectal cancer: a comparison between elderly and middle aged patients.
    Journal of chemotherapy (Florence, Italy), 2008, Volume: 20, Issue:4

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr

2008
K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-01, Volume: 14, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Genes, ras; Humans; Leuc

2008
Management of colorectal liver metastases after complete response to neoadjuvant chemotherapy. A case of computertomography-guided wire marking of the liver tumor.
    International journal of colorectal disease, 2009, Volume: 24, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2009
[The prevention of diarrhea while under capecitabine therapy].
    Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:34-35

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Fluoro

2008
[Preparation of a brochure for patients undergoing FOLFIRI chemotherapy based on survey of adverse reactions].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Con

2008
Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models.
    Molecular cancer research : MCR, 2008, Volume: 6, Issue:8

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizum

2008
The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:3

    Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplas

2009
Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy.
    British journal of cancer, 2008, Sep-02, Volume: 99, Issue:5

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Haplotypes; H

2008
Priorities and uncertainties of administering chemotherapy in a pregnant woman with newly diagnosed colorectal cancer.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2009, Volume: 15, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; H

2009
KRAS status predicts response to cetuximab for metastatic colorectal cancer.
    ONS connect, 2008, Volume: 23, Issue:8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2008
Expression of beta-F1-ATPase and mitochondrial transcription factor A and the change in mitochondrial DNA content in colorectal cancer: clinical data analysis and evidence from an in vitro study.
    International journal of colorectal disease, 2008, Volume: 23, Issue:12

    Topics: Blotting, Western; Cell Hypoxia; Colorectal Neoplasms; DNA-Binding Proteins; DNA, Mitochondrial; Fem

2008
Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer.
    Cancer biotherapy & radiopharmaceuticals, 2008, Volume: 23, Issue:4

    Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined M

2008
Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells.
    World journal of gastroenterology, 2008, Sep-07, Volume: 14, Issue:33

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms

2008
Safety and efficacy of modified FOLFOX6 for treatment of metastatic or locally advanced colorectal cancer. A single-institution outcome study.
    Chemotherapy, 2008, Volume: 54, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2008
Commentary 2008: 25 or 50 years later?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-20, Volume: 26, Issue:30

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colorectal Neopl

2008
Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.
    British journal of cancer, 2008, Oct-07, Volume: 99, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2008
The CAP-CR study: direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:17

    Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capec

2008
Bevacizumab in advanced colorectal cancer: a challenge to the current paradigm.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-01, Volume: 26, Issue:28

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
[The combined treatment of colorectal cancer with liver metastases].
    Khirurgiia, 2008, Issue:7

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

2008
Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide.
    International journal of pharmaceutics, 2009, Jan-21, Volume: 366, Issue:1-2

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Drug Delivery Systems; Endoc

2009
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptotheci

2009
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:2

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla

2009
Coronary spasm induced by capecitabine mimicks ST elevation myocardial infarction.
    Emergency medicine journal : EMJ, 2008, Volume: 25, Issue:10

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chest Pain; Colorectal Neoplasms; Coronary Vaso

2008
Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
    Japanese journal of clinical oncology, 2008, Volume: 38, Issue:10

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2008
Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.
    Oncology, 2008, Volume: 75, Issue:3-4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
The desmoplastic reaction surrounding hepatic colorectal adenocarcinoma metastases aids tumor growth and survival via alphav integrin ligation.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Oct-15, Volume: 14, Issue:20

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Adhesion; Cell Proliferation; Colla

2008
Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl

2008
Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer.
    Journal of surgical oncology, 2008, Dec-01, Volume: 98, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; C-Reactive Prote

2008
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care?
    Annals of surgery, 2008, Volume: 248, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Femal

2008
Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage II colorectal cancer.
    Oncology reports, 2008, Volume: 20, Issue:5

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore

2008
Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.
    Physics in medicine and biology, 2008, Nov-21, Volume: 53, Issue:22

    Topics: Aged; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Embolization, Therapeutic; Fluorode

2008
Effects of nutritional support in patients with colorectal cancer during chemotherapy.
    Collegium antropologicum, 2008, Volume: 32, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Body Mass Index; Camptothecin; Color

2008
Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
    Annals of surgical oncology, 2009, Volume: 16, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2009
What is the standard chemotherapy for colorectal cancer patients with resectable liver metastases?
    Nature clinical practice. Oncology, 2009, Volume: 6, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin

2009
[Is it possible to individualize prescription of medical treatment in colorectal cancer? The clinician point of view].
    Bulletin du cancer, 2008, Volume: 95, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetu

2008
[The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer].
    Bulletin du cancer, 2008, Volume: 95, Issue:10

    Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Cyclin D1; Dihydrouracil Dehydrogenase (N

2008
Growth hormone releasing peptide 2 reverses anorexia associated with chemotherapy with 5-fluoruracil in colon cancer cell-bearing mice.
    World journal of gastroenterology, 2008, Nov-07, Volume: 14, Issue:41

    Topics: Animals; Anorexia; Antimetabolites, Antineoplastic; Appetite Stimulants; Body Weight; Cachexia; Cell

2008
Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan.
    Journal of gastroenterology, 2008, Volume: 43, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Dose-Response Re

2008
Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
    International journal of oncology, 2008, Volume: 33, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; DNA-Binding Protein

2008
Clinical study of combined use of tomudex (raltitrexed) and xeloda (capecitabine) as first-line treatment for patients with metastasizing colorectal cancer.
    Bulletin of experimental biology and medicine, 2008, Volume: 145, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dis

2008
Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer.
    Oncology, 2009, Volume: 76, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neoplasm

2009
Tissue levels of reduced folates in patients with colorectal carcinoma after infusion of folinic acid at various dose levels.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Dec-01, Volume: 14, Issue:23

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorou

2008
In vitro antiproliferative characteristics of flavonoids and diazepam on SNU-C4 colorectal adenocarcinoma cells.
    Journal of natural medicines, 2009, Volume: 63, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apigenin; Cell Line, Tumor; Cell Pro

2009
Molecular determinants of efficacy for 5-FU-based treatments in advanced colorectal cancer: mRNA expression for 18 chemotherapy-related genes.
    International journal of cancer, 2009, Mar-01, Volume: 124, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil

2009
Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer.
    Journal of clinical pathology, 2009, Volume: 62, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colo

2009
Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy.
    Journal of surgical oncology, 2009, Feb-01, Volume: 99, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2009
ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma.
    Cancer science, 2009, Volume: 100, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Codon; Colorectal Neoplasms; DNA-Bindi

2009
[Report from the 44th Congress of the American Society of Clinical Oncology].
    Magyar onkologia, 2008, Volume: 52, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms

2008
Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients.
    International journal of oncology, 2009, Volume: 34, Issue:1

    Topics: 3' Untranslated Regions; 5' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, A

2009
Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:2

    Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, A

2009
A dilemma in geriatric oncology: malignant bowel obstruction in an 81-year-old man.
    Cancer treatment reviews, 2008, Volume: 34 Suppl 2

    Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col

2008
Recurrent disease four years after surgery and adjuvant chemotherapy.
    Cancer treatment reviews, 2008, Volume: 34 Suppl 2

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla

2008
[Efficacy and safety of modified FOLFOX6 regimen in aged patients with nonresectable colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Fem

2008
[The validity of full administration of 5-fluorouracil, irinotecan, and oxaliplatin to unresectable or recurrent colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2008
Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer.
    Endocrine-related cancer, 2009, Volume: 16, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptoth

2009
rNAPc2 inhibits colorectal cancer in mice through tissue factor.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jan-01, Volume: 15, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cell Line, Tumor; C

2009
Imaging intratumoral convection: pressure-dependent enhancement in chemotherapeutic delivery to solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jan-01, Volume: 15, Issue:1

    Topics: Animals; Antineoplastic Agents; Collagenases; Colorectal Neoplasms; Convection; Energy Metabolism; E

2009
In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizum

2009
[Synergistic use of epidermal growth factor and 5-fluorouracil for the treatment of human colorectal cancer in BALB/C nude mice subcutaneous xenograft model].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2009, Volume: 12, Issue:1

    Topics: Animals; Caco-2 Cells; Cell Line, Tumor; Colorectal Neoplasms; Epidermal Growth Factor; Fluorouracil

2009
Correlation between thymidylate synthase protein expression and gene polymorphism with clinicopathological parameters in colorectal carcinoma.
    International journal of surgical pathology, 2009, Volume: 17, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Colorectal Neoplasms; Fema

2009
[Combination of hepatic arterial infusion therapy and FOLFOX for colorectal cancer with multiple unresectable liver metastases causing severe liver dysfunction].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury;

2009
To widen the setting of cancer patients who could benefit from metronomic capecitabine.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:1

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxyc

2009
Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression.
    BMC cancer, 2009, Jan-20, Volume: 9

    Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); DNA Mismatch Repa

2009
Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence.
    Cancer research, 2009, Feb-01, Volume: 69, Issue:3

    Topics: Alleles; Antimetabolites, Antineoplastic; Base Sequence; Cell Line, Tumor; Colorectal Neoplasms; Flu

2009
Fatal drug-drug interaction of brivudine and capecitabine.
    Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Aged, 80 and over; Antimetabolites, Antineoplastic; Antivir

2009
The p400/Tip60 ratio is critical for colorectal cancer cell proliferation through DNA damage response pathways.
    Oncogene, 2009, Mar-26, Volume: 28, Issue:12

    Topics: Apoptosis; Cell Proliferation; Colorectal Neoplasms; DNA Damage; DNA Helicases; DNA-Binding Proteins

2009
In vitro chemosensitivity based on depth of invasion in advanced colorectal cancer using ATP-based chemotherapy response assay (ATP-CRA).
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2009, Volume: 35, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug Screening Assays, Antit

2009
Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    American journal of clinical oncology, 2009, Volume: 32, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colo

2009
A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
    American journal of clinical oncology, 2009, Volume: 32, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neoplasms;

2009
Unresectable liver metastases from colorectal cancer and hepatic arterial infusion chemotherapy: how, when and to whom?
    Cardiovascular and interventional radiology, 2009, Volume: 32, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cathet

2009
Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer.
    Cancer, 2009, Apr-01, Volume: 115, Issue:7

    Topics: Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fees, Pharmaceutical; Female; Fluorouracil;

2009
Targeted therapy for advanced colorectal cancer--more is not always better.
    The New England journal of medicine, 2009, Feb-05, Volume: 360, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2009
Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2009, Volume: 35, Issue:5

    Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells.
    Cancer letters, 2009, Jun-28, Volume: 279, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Camptothecin; Carcinoma; Colorectal Neopl

2009
Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:10

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla

2009
Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

2009
Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
    Journal of surgical oncology, 2009, Oct-01, Volume: 100, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig

2009
Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
    Journal of surgical oncology, 2009, Oct-01, Volume: 100, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig

2009
Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
    Journal of surgical oncology, 2009, Oct-01, Volume: 100, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig

2009
Surgery after neoadjuvant chemotherapy for colorectal liver metastases is safe and feasible in elderly patients.
    Journal of surgical oncology, 2009, Oct-01, Volume: 100, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig

2009
Early detection of therapeutic response to hepatic arterial infusion chemotherapy of liver metastases from colorectal cancer using diffusion-weighted MR imaging.
    Cardiovascular and interventional radiology, 2009, Volume: 32, Issue:4

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Catheters, Indwelling; Colorectal Neoplasm

2009
Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition.
    Cancer research, 2009, Mar-01, Volume: 69, Issue:5

    Topics: AC133 Antigen; Animals; Antigens, CD; Apoptosis; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fl

2009
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
    Annals of surgery, 2009, Volume: 249, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl

2009
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
    Annals of surgery, 2009, Volume: 249, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl

2009
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
    Annals of surgery, 2009, Volume: 249, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl

2009
Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
    Annals of surgery, 2009, Volume: 249, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl

2009
The CAIRO and FOCUS studies: which lesson is to be learned?
    The oncologist, 2009, Volume: 14, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2009
[The optimal volume of medicinal solution in the portable disposable infusion pump (SUREFUSER A) for FOLFOX6, FOLFIRI therapy of colorectal cancer patients].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2009, Volume: 129, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disposable Equip

2009
Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed.
    Cancer biology & therapy, 2009, Volume: 8, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Colorectal

2009
RNA modulators of complex phenotypes in mammalian cells.
    PloS one, 2009, Volume: 4, Issue:3

    Topics: Antimetabolites, Antineoplastic; Blotting, Western; Cell Death; Colorectal Neoplasms; Drug Resistanc

2009
Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Apr-01, Volume: 15, Issue:7

    Topics: Angiogenesis Inducing Agents; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Cell L

2009
Panaxadiol, a purified ginseng component, enhances the anti-cancer effects of 5-fluorouracil in human colorectal cancer cells.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:6

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Proliferation; Cell Survival; Colorec

2009
Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kinetics.
    European journal of nuclear medicine and molecular imaging, 2009, Volume: 36, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Dis

2009
Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colo

2009
[Development of taste disorders following FOLFOX-FOLFIRI therapy and its effects on the QOL of patients with colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl

2009
[A case of resection of synchronous multiple liver metastases from colorectal cancer after FOLFOX chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; L

2009
Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer.
    Cardiovascular and interventional radiology, 2009, Volume: 32, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Colorectal Neoplasms; D

2009
Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
    International journal of cancer, 2009, Jun-15, Volume: 124, Issue:12

    Topics: Adenocarcinoma; Adenosine Triphosphatases; Adult; Aged; Aged, 80 and over; Antineoplastic Combined C

2009
5 flourouracil-induced apical ballooning syndrome: a case report.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2009, Volume: 20, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Coronary Disease; Female; Fluorouracil;

2009
Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
    American journal of clinical oncology, 2009, Volume: 32, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chromatography, High

2009
The association of methylation in the promoter of APC and MGMT and the prognosis of Taiwanese CRC patients.
    Genetic testing and molecular biomarkers, 2009, Volume: 13, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA Methylation

2009
Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.
    Oncology, 2009, Volume: 76, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2009
Differences in the gene expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in primary colorectal tumors and their synchronous liver metastases.
    Anticancer research, 2009, Volume: 29, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression Profilin

2009
Novel regimens of capecitabine alone and combined with irinotecan and bevacizumab in colorectal cancer xenografts.
    Anticancer research, 2009, Volume: 29, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe

2009
Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide.
    Anticancer research, 2009, Volume: 29, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; BALB 3T3 Cells; Cell Cycle; Cell

2009
Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab.
    Annals of surgical oncology, 2009, Volume: 16, Issue:6

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant

2009
Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, May-20, Volume: 27, Issue:15

    Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Camptothecin; C

2009
[Advanced hepatic resection for malignancy].
    Khirurgiia, 2009, Issue:2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatoce

2009
Epigenetic reversal of acquired resistance to 5-fluorouracil treatment.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:5

    Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Base Sequence; Cell Line, Tumor; Colorectal N

2009
Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progress

2009
Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as To

2009
Asian ginseng enhances the anti-proliferative effect of 5-fluorouracil on human colorectal cancer: comparison between white and red ginseng.
    Archives of pharmacal research, 2009, Volume: 32, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe

2009
ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer.
    International journal of colorectal disease, 2009, Volume: 24, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP B

2009
Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:2

    Topics: Adenocarcinoma; Animals; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fas-Associated Death Dom

2010
Effects of oral administration of S-1 on the pharmacokinetics of SN-38, irinotecan active metabolite, in patients with advanced colorectal cancer.
    Therapeutic drug monitoring, 2009, Volume: 31, Issue:3

    Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; D

2009
Very low prevalence of XPD K751Q polymorphism and its association with XPD expression and outcomes of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.
    Cancer science, 2009, Volume: 100, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma; Colorectal Neo

2009
Chemotherapy and immunotherapy in metastatic colorectal cancer.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2009
Chemotherapy and immunotherapy in metastatic colorectal cancer.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2009
Chemotherapy and immunotherapy in metastatic colorectal cancer.
    The New England journal of medicine, 2009, May-14, Volume: 360, Issue:20

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2009
Subacute cutaneous lupus erythematosus induced by capecitabine.
    Clinical and experimental dermatology, 2009, Volume: 34, Issue:7

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Drug Erupt

2009
Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Clini

2009
The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi

2009
[Effect of withdrawal of 5-fluorouracil bolus administration on recovery from neutropenia in colorectal cancer patients treated with mFOLFOX6 chemotherapy-comparison with total dosage reduction].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationsh

2009
MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:10

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Denmark; Disease-Free

2009
Perforating dermatosis in a patient receiving bevacizumab.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2009, Volume: 23, Issue:8

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A

2009
Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy.
    Neoplasma, 2009, Volume: 56, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2009
Deriving the intrahepatic arteriovenous shunt rate from CT images and biochemical data instead of from arterial perfusion scintigraphy in hepatic arterial infusion chemotherapy.
    Cardiovascular and interventional radiology, 2009, Volume: 32, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Catheters, Indwelling; Colorectal Neoplasm

2009
Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy.
    Acta radiologica (Stockholm, Sweden : 1987), 2009, Volume: 50, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Abla

2009
Molecular markers of chemotherapy in advanced colorectal cancer: back to square one.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:11

    Topics: Antineoplastic Agents; Colorectal Neoplasms; DNA Mismatch Repair; Drug Resistance, Neoplasm; Fluorou

2009
[Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2009, Volume: 22, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2009
Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment.
    Pharmacogenomics, 2009, Volume: 10, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch

2009
Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
    Japanese journal of clinical oncology, 2009, Volume: 39, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2009
Radiation and chemotherapy bystander effects induce early genomic instability events: telomere shortening and bridge formation coupled with mitochondrial dysfunction.
    Mutation research, 2009, Oct-02, Volume: 669, Issue:1-2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bystander Effect; Colorectal Neoplasms; Combin

2009
Nonresponse to pre-operative chemotherapy does not preclude long-term survival after liver resection in patients with colorectal liver metastases.
    Surgery, 2009, Volume: 146, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Ne

2009
Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jul-01, Volume: 15, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Cetuximab, chemotherapy and KRAS status in mCRC.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2009
Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2009, Volume: 13, Issue:10

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Mice;

2009
Reduced ATR or Chk1 expression leads to chromosome instability and chemosensitization of mismatch repair-deficient colorectal cancer cells.
    Molecular biology of the cell, 2009, Volume: 20, Issue:17

    Topics: Animals; Antimetabolites, Antineoplastic; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Protein

2009
Cetuximab for metastatic colorectal cancer.
    The New England journal of medicine, 2009, Jul-02, Volume: 361, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2009
Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models.
    Oncology reports, 2009, Volume: 22, Issue:2

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe

2009
Long-term results of hepatectomy after hepatic arterial infusion chemotherapy for initially unresectable hepatic colorectal metastases.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2009, Volume: 13, Issue:9

    Topics: Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Female; Fluorou

2009
Fluorescence lifetime imaging microscopy of chemotherapy-induced apoptosis resistance in a syngenic mouse tumor model.
    International journal of cancer, 2010, Jan-01, Volume: 126, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Base Sequence; Caspase 3; Colorectal Neoplasms; Disease M

2010
Current role of bevacizumab in colorectal cancer.
    Clinical advances in hematology & oncology : H&O, 2009, Volume: 7, Issue:6

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2009
[Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:7

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch

2009
Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model.
    International journal of cancer, 2009, Nov-01, Volume: 125, Issue:9

    Topics: Animals; Antineoplastic Agents; Apoptosis; Capecitabine; Cell Line, Tumor; Cell Proliferation; Color

2009
[Impact of adjuvant chemotherapy duration on 3-year disease-free survival of colorectal carcinoma patients after radical resection].
    Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:7

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Age Factors; Aged; Antineoplastic Combined Chemothe

2009
Health utility scores of colorectal cancer based on societal preference in Japan.
    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2009, Volume: 18, Issue:8

    Topics: Adaptation, Psychological; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols;

2009
A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:2

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antineoplastic Combined Che

2010
Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-01, Volume: 27, Issue:25

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials,

2009
Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.
    Annals of surgery, 2009, Volume: 250, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; CA-19-9 Antigen; Camptothe

2009
Efficacy of 5-FU/LV plus CPT-11 as first-line adjuvant chemotherapy for stage IIIa colorectal cancer.
    Oncology reports, 2009, Volume: 22, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo

2009
Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:14

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2009
Radioembolization of liver metastases in patients with colorectal cancer: a nonsurgical treatment with combined modality potential.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-01, Volume: 27, Issue:25

    Topics: Antimetabolites, Antineoplastic; Brachytherapy; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo

2009
[Efficacy of preventive treatment for delayed emesis induced by FOLFOX4 chemotherapy].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2009, Volume: 129, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dexamethasone; Do

2009
Methylnaltrexone, a peripherally acting opioid receptor antagonist, enhances tumoricidal effects of 5-Fu on human carcinoma cells.
    Anticancer research, 2009, Volume: 29, Issue:8

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell C

2009
Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy.
    International journal of colorectal disease, 2010, Volume: 25, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2010
Metastatic colorectal cancer: is surgery necessary?
    Journal of the National Cancer Institute, 2009, Aug-19, Volume: 101, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant;

2009
Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.
    British journal of cancer, 2009, Sep-15, Volume: 101, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA-Binding Prote

2009
Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.
    Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:2

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Anemia; Antimetabolites, Antineoplastic; Antineoplast

2010
Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer.
    European journal of pharmacology, 2009, Oct-01, Volume: 619, Issue:1-3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell L

2009
Combination intraperitoneal chemotherapy is superior to mitomycin C or oxaliplatin for colorectal carcinomatosis in vivo.
    Annals of surgical oncology, 2010, Volume: 17, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe

2010
Clinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK.
    European journal of cancer care, 2010, Volume: 19, Issue:4

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neopla

2010
Colorectal cancer: Irinotecan therapy-following a trail of breadcrumbs?
    Nature reviews. Gastroenterology & hepatology, 2009, Volume: 6, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop

2009
Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma.
    Journal of surgical oncology, 2009, Dec-01, Volume: 100, Issue:7

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomark

2009
American ginseng berry enhances chemopreventive effect of 5-FU on human colorectal cancer cells.
    Oncology reports, 2009, Volume: 22, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Prolif

2009
Effect of early preoperative 5-fluorouracil on the integrity of colonic anastomoses in rats.
    World journal of gastroenterology, 2009, Sep-07, Volume: 15, Issue:33

    Topics: Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Body Weight; Colon; Colorectal Neop

2009
Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
    Cancer biomarkers : section A of Disease markers, 2009, Volume: 5, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo

2009
Long-term outcome of unresectable metastatic colorectal cancer: does "adjuvant" chemotherapy play a role after resection?
    Annals of surgery, 2009, Volume: 250, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C

2009
Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer.
    Oncology, 2009, Volume: 77, Issue:3-4

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fl

2009
Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: a pilot study.
    World journal of gastroenterology, 2009, Sep-14, Volume: 15, Issue:34

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2009
Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy?
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2010, Volume: 18, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore

2010
Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2009, Volume: 13, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo

2009
Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.
    Journal of the National Cancer Institute, 2009, Oct-21, Volume: 101, Issue:20

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonosco

2009
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.
    BMC cancer, 2009, Sep-28, Volume: 9

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2009
Stop and go: yes or no?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-01, Volume: 27, Issue:34

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

2009
Chemotherapy: Optimizing irinotecan regimens for colorectal cancer.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10

    Topics: Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl

2009
Relationship of polymorphism of the tandem repeat sequence in the thymidylate synthase gene and the survival of stage III colorectal cancer patients receiving adjuvant 5-flurouracil-based chemotherapy.
    Journal of surgical oncology, 2010, Jan-01, Volume: 101, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv

2010
Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer.
    International journal of cancer, 2010, Apr-01, Volume: 126, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; bcl-2-Associated X

2010
Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?
    Clinical colorectal cancer, 2009, Volume: 8, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F

2009
Trichomegaly of the eyelashes after colorectal cancer treatment with the epidermal growth factor receptor inhibitor cetuximab.
    Clinical colorectal cancer, 2009, Volume: 8, Issue:4

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; C

2009
Enhanced 5-fluorouracil cytotoxicity in high cyclooxygenase-2 expressing colorectal cancer cells and xenografts induced by non-steroidal anti-inflammatory drugs via downregulation of dihydropyrimidine dehydrogenase.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Pro

2010
The impact of new treatment options for advanced colorectal cancer on routine care: results of a retrospective analysis of 206 consecutive patients treated in a community-based oncology group practice in Germany.
    European journal of cancer care, 2010, Volume: 19, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci

2010
Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2010, Volume: 16, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit

2010
[Revision of the informed consent form for patients based on investigation of adverse events of mFOLFOX6 regimen].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2009
Hepatic arterial infusion for unresectable colorectal liver metastases combined or not with systemic chemotherapy.
    Anticancer research, 2009, Volume: 29, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; D

2009
EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorecta

2010
MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells.
    European journal of pharmacology, 2010, Feb-10, Volume: 627, Issue:1-3

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colo

2010
Oxaliplatin-induced allergic reaction in patients with colorectal cancer in Japan.
    International journal of clinical oncology, 2009, Volume: 14, Issue:5

    Topics: Adult; Aged; Anti-Allergic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

2009
Epithelial-mesenchymal transition with expression of SNAI1-induced chemoresistance in colorectal cancer.
    Biochemical and biophysical research communications, 2009, Dec-18, Volume: 390, Issue:3

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epithelium; Fluoro

2009
Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2010
Triptolide simultaneously induces reactive oxygen species, inhibits NF-kappaB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines.
    Cancer letters, 2010, May-28, Volume: 291, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Sur

2010
The effect of focal adhesion kinase gene silencing on 5-fluorouracil chemosensitivity involves an Akt/NF-kappaB signaling pathway in colorectal carcinomas.
    International journal of cancer, 2010, Jul-01, Volume: 127, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Base Sequence; Blotting, Western; Cell Line, Tumor

2010
[Proteomic research of biomarker of colorectal cancer metastasis].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2009, Volume: 12, Issue:6

    Topics: Biomarkers, Tumor; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis

2009
Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma.
    Cancer science, 2010, Volume: 101, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2010
Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma.
    Journal of gastrointestinal cancer, 2009, Volume: 40, Issue:3-4

    Topics: Acute Coronary Syndrome; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2009
Improved first-line chemotherapy: a better chance for surgery?
    The Lancet. Oncology, 2010, Volume: 11, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2010
The effect of three lipid emulsions differing in fatty acid composition on growth, apoptosis and cell cycle arrest in the HT-29 colorectal cancer cell line.
    Clinical nutrition (Edinburgh, Scotland), 2010, Volume: 29, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Count; Cell Cycle; Cell Survival; C

2010
The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2010
Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.
    BMC cancer, 2009, Dec-02, Volume: 9

    Topics: Aged; Alleles; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Codon; Colorectal N

2009
Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2010
APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling.
    BMC cancer, 2009, Dec-11, Volume: 9

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Biomarkers, Tumor; Colorectal Neoplasms; Drug Resistan

2009
[Hepatic resection after neoadjuvant therapy for initially unresectable colorectal liver metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:13

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Femal

2009
Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Annals of surgery, 2010, Volume: 251, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2010
Methods for evaluating effects of an irinotecan + 5-fluorouracil/leucovorin (IFL) regimen in an orthotopic metastatic colorectal cancer model utilizing in vivo bioluminescence imaging.
    Methods in molecular biology (Clifton, N.J.), 2010, Volume: 602

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined

2010
Serum homocysteine, cholesterol, retinol, alpha-tocopherol, glycosylated hemoglobin and inflammatory response during therapy with bevacizumab, oxaliplatin, 5-fluorouracil and leucovorin.
    Anticancer research, 2009, Volume: 29, Issue:11

    Topics: Adult; Aged; alpha-Tocopherol; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla

2009
[The prognosis of patients with an allergic reaction in the treatment of mFOLFOX6 therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2009
[Results of neo-adjuvant chemotherapy by FOLFOX and FOLFIRI for colorectal liver metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2009
[Hepatic metastatectomy of colorectal cancer following mFOLFOX6 treatment--analysis of 7 cases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2009
[Switching to direct intrahepatic arterial infusion of 5-FU after a progression of liver metastases from colorectal carcinoma treated with systemic infusion of FOLFOX].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

2009
[A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant

2009
[A curative resection with the combination of portal vein branch embolization and systemic chemotherapy in a patient with synchronous multiple and bilobar colorectal liver metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C

2009
[Two resected cases of pulmonary metastasis from post operative colorectal cancer after preoperative chemotherapy with FOLFOX].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu

2009
[Chemotherapy with bevacizumab (BV)+modified FOLFOX6 for unresectable colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla

2009
[Clinical features of hypersensitivity reactions to oxaliplatin among Chinese colorectal cancer patients].
    Chinese journal of cancer, 2010, Volume: 29, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Anaphylaxis; Anti-Allergic Agents

2010
Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients.
    Swiss medical weekly, 2009, Dec-12, Volume: 139, Issue:49-50

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2009
Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases.
    Annals of surgical oncology, 2010, Volume: 17, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Ca

2010
[Cardiotoxicity induced by 5-fluorouracil or capecitabine].
    Ugeskrift for laeger, 2010, Jan-04, Volume: 172, Issue:1

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; He

2010
[Validation study of KRAS mutation in colorectal cancer].
    Magyar onkologia, 2009, Volume: 53, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2009
Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.
    British journal of clinical pharmacology, 2010, Volume: 69, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2010
CD133 expression predicts for non-response to chemotherapy in colorectal cancer.
    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2010, Volume: 23, Issue:3

    Topics: AC133 Antigen; Adenocarcinoma; Antigens, CD; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Che

2010
Genome-wide identification of chemosensitive single nucleotide polymorphism markers in colorectal cancers.
    Cancer science, 2010, Volume: 101, Issue:4

    Topics: Aged; Antineoplastic Agents; Biomarkers; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasm

2010
[Evaluation of bevacizumab for advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:1

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant

2010
[Chemotherapy for elderly colorectal cancer patients in a regional hospital--problems in regional cancer care].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2010
[Pulmonary embolism during palliative chemotherapy including cetuximab for metastatic colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop

2010
Treatment results of FOLFOX chemotherapy before surgery for lymph node metastasis of advanced colorectal cancer with synchronous liver metastasis: the status of LN metastasis and vessel invasions at the primary site in patients who responded to FOLFOX.
    International journal of clinical oncology, 2010, Volume: 15, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Col

2010
MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
    Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:8

    Topics: Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cape

2010
[Effect of delayed-release 5-fluorouracil implants on colorectal cancer].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2010, Volume: 13, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Delayed-Action Preparations; Female;

2010
A possible cause and remedy for the clinical failure of 5-fluorouracil plus eniluracil.
    Clinical colorectal cancer, 2010, Volume: 9, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relatio

2010
Fournier's gangrene as a possible side effect of bevacizumab therapy for resected colorectal cancer.
    Clinical colorectal cancer, 2010, Volume: 9, Issue:1

    Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
5-FU and mismatch repair deficient colorectal cancer: is it time to consider a change in practice?
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2010, Volume: 12, Issue:7

    Topics: Antimetabolites, Antineoplastic; Base Pair Mismatch; Colorectal Neoplasms; DNA, Neoplasm; Fluorourac

2010
Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan.
    Clinical therapeutics, 2009, Volume: 31 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Costs and Cost A

2009
The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer.
    The pharmacogenomics journal, 2011, Volume: 11, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2011
[Silencing of Adrm1 by RNA interference suppresses proliferation of colorectal cancer cells].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:11

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colore

2009
Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection.
    Current HIV research, 2010, Volume: 8, Issue:3

    Topics: Adult; Anti-HIV Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antir

2010
Do 5-fluorouracil therapies alter CYP2C19 metaboliser status?
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites; Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylase

2010
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
    Annals of surgical oncology, 2010, Volume: 17, Issue:8

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla

2010
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
    Annals of surgical oncology, 2010, Volume: 17, Issue:8

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla

2010
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
    Annals of surgical oncology, 2010, Volume: 17, Issue:8

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla

2010
Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
    Annals of surgical oncology, 2010, Volume: 17, Issue:8

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla

2010
Prognostic value of perineural invasion in patients with stage II colorectal cancer.
    Annals of surgical oncology, 2010, Volume: 17, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms;

2010
Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
    Cancer treatment reviews, 2010, Volume: 36 Suppl 1

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemot

2010
Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan.
    International journal of clinical oncology, 2010, Volume: 15, Issue:3

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla

2010
Chemotherapy-associated peripheral sensory neuropathy assessed using in vivo corneal confocal microscopy.
    Archives of neurology, 2010, Volume: 67, Issue:3

    Topics: Aged; Capecitabine; Carcinoma; Colorectal Neoplasms; Cornea; Deoxycytidine; Fluorouracil; Humans; Ma

2010
[Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
    Gastroenterologie clinique et biologique, 2010, Volume: 34, Issue:3

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycyti

2010
Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases.
    Annals of surgery, 2010, Volume: 251, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2010
Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy.
    Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:6

    Topics: Aneurysm; Angiogenesis Inhibitors; Angiomyolipoma; Antibodies, Monoclonal; Antibodies, Monoclonal, H

2010
rTSbeta as a novel 5-fluorouracil resistance marker of colorectal cancer: a preliminary study.
    Annals of the Academy of Medicine, Singapore, 2010, Volume: 39, Issue:2

    Topics: Biomarkers; Cell Line, Tumor; Colorectal Neoplasms; Cytological Techniques; Drug Resistance, Neoplas

2010
Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients.
    International journal of clinical oncology, 2010, Volume: 15, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2010
Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2010
Re: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.
    Journal of the National Cancer Institute, 2010, Apr-21, Volume: 102, Issue:8

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2010
Mismatch repair protein expression is an independent prognostic factor in sporadic colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Analysis of Variance; Antineoplastic Combined Che

2010
Associations between glutathione S-transferase pi Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy.
    Cancer epidemiology, 2010, Volume: 34, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2010
[Analysis of a case of oxaliplatin - induced persistence sensory neuropathy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl

2010
Role of local liver therapy for hepatic metastases from colorectal cancer.
    Clinical advances in hematology & oncology : H&O, 2009, Volume: 7, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Colorectal Neoplasms; Fluorouraci

2009
Therapeutic effect of alpha-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice.
    Gene therapy, 2010, Volume: 17, Issue:7

    Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; BH3 Interacting Domain Death Agonist Protein; Ca

2010
Oncogenic KRAS sensitises colorectal tumour cells to chemotherapy by p53-dependent induction of Noxa.
    British journal of cancer, 2010, Apr-13, Volume: 102, Issue:8

    Topics: Animals; Apoptosis; Cell Cycle; Colorectal Neoplasms; Fluorouracil; Genes, p53; Genes, ras; HCT116 C

2010
Evaluation of efficacy and safety of generic levofolinate in patients who received colorectal cancer chemotherapy.
    Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:2

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2011
Probiotic Lactobacillus acidophilus and L. casei mix sensitize colorectal tumoral cells to 5-fluorouracil-induced apoptosis.
    Nutrition and cancer, 2010, Volume: 62, Issue:3

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Cell Line, Tumor; Colorectal Neoplasms; Cycli

2010
TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis.
    Cancer science, 2010, Volume: 101, Issue:7

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line; Cell L

2010
[Optimal volume of medicinal solution in the portable disposable infusion pump (SUREFUSER A) for FOLFOX6, FOLFIRI therapy of colorectal cancer patients (2nd report)-influence of temperature on outflow speed of the medicinal solution].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2010, Volume: 130, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disposable Equip

2010
Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer.
    Oncology reports, 2010, Volume: 23, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2010
Chemotherapy-free intervals in patients with metastatic colorectal cancer: a tale of two cities?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jun-01, Volume: 28, Issue:16

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free S

2010
FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases.
    Anticancer research, 2010, Volume: 30, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2010
Steroids, cancer and vertebral fractures: a dreaded combination.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2011, Volume: 17, Issue:3

    Topics: Adrenal Cortex Hormones; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabin

2011
Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.
    Annals of surgical oncology, 2010, Volume: 17, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2010
HnRNP K and PDI marked response to chemotherapy to human colorectal cancer cells.
    Electrophoresis, 2010, Volume: 31, Issue:10

    Topics: Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Electrophoresi

2010
Recovery of liver function after the cessation of preoperative chemotherapy for colorectal liver metastasis.
    Annals of surgical oncology, 2010, Volume: 17, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit

2010
Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
    Cardiology, 2010, Volume: 116, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Col

2010
Cost analysis of capecitabine vs 5-fluorouracil-based treatment for metastatic colorectal cancer patients.
    Journal of chemotherapy (Florence, Italy), 2010, Volume: 22, Issue:2

    Topics: Age Factors; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cost-Benefit Analy

2010
Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2010, Volume: 36, Issue:6

    Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents;

2010
Combined treatment with dendritic cells and 5-fluorouracil elicits augmented NK cell-mediated antitumor activity through the tumor necrosis factor-alpha pathway.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2010, Volume: 33, Issue:5

    Topics: Animals; Antibodies, Blocking; Antigen Presentation; Antigens, Neoplasm; Cancer Vaccines; Cell Extra

2010
Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
In defense of hepatic arterial infusion for hepatic metastases of colorectal cancer.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2010, Volume: 8, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv

2010
[Investigation of FOLFIRI/FOLFOX (+/-bevacizumab) therapy for patients with metastatic colorectal cancer in our hospital].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:5

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2010
Economic and patient-reported outcomes of outpatient home-based versus inpatient hospital-based chemotherapy for patients with colorectal cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011, Volume: 19, Issue:7

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C

2011
Microsatellite instability and adjuvant fluorouracil chemotherapy: a mismatch?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Resistance, Neop

2010
[PI3K p85alpha gene silencing by RNA interference promotes 5-fluorouracil-induced apoptosis of colorectal cancer LoVo cells].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2010, Volume: 30, Issue:5

    Topics: Apoptosis; Cell Line, Tumor; Class Ia Phosphatidylinositol 3-Kinase; Colorectal Neoplasms; Fluoroura

2010
Clubbing and hypertrophic osteoarthropathy in two patients taking long-term bevacizumab for metastatic colorectal cancer.
    Journal of gastrointestinal cancer, 2011, Volume: 42, Issue:3

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizuma

2011
Strategic options on behalf of patients with metastatic colorectal cancer: mass tumor murder versus serial tumor killing.
    Onkologie, 2010, Volume: 33, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase I

2010
Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance.
    Anticancer research, 2010, Volume: 30, Issue:4

    Topics: Colorectal Neoplasms; Drug Resistance, Neoplasm; Enzyme Induction; Fluorouracil; HT29 Cells; Humans;

2010
Arsenic trioxide suppresses thymidylate synthase in 5-FU-resistant colorectal cancer cell line HT29 In Vitro re-sensitizing cells to 5-FU.
    Anticancer research, 2010, Volume: 30, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Blotting, Western; Col

2010
VEGF -460T → C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma.
    The pharmacogenomics journal, 2011, Volume: 11, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Female; Fluo

2011
Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo.
    The pharmacogenomics journal, 2011, Volume: 11, Issue:4

    Topics: Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Neoplasms; D

2011
Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer.
    Journal of gastrointestinal cancer, 2011, Volume: 42, Issue:1

    Topics: Adenocarcinoma; Adenoma, Villous; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin

2011
Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.
    Cancer research, 2010, Jul-15, Volume: 70, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Cisplatin; Colorectal Neoplasms; DNA

2010
Treatment considerations in elderly colorectal cancer patients.
    Clinical advances in hematology & oncology : H&O, 2010, Volume: 8, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms;

2010
Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011, Volume: 19, Issue:7

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Confidence In

2011
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
    International journal of cancer, 2011, Apr-15, Volume: 128, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuv

2011
Metastatic colorectal cancer with severe liver dysfunction successfully treated using FOLFOX therapy.
    Journal of gastrointestinal cancer, 2011, Volume: 42, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Fluoroura

2011
Clinical impact of intesified 5-Fluorouracil-based chemotherapy using a prospective pharmacokinetically-guided dosing approach: comparative study in elderly and non-elderly patients with metastatic colorectal cancer.
    Journal of chemotherapy (Florence, Italy), 2010, Volume: 22, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neopla

2010
[Bevacizumab in combination with mFOLFOX6 or FOLFIRI for previously treated metastatic colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:6

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2010
[Nephrotoxicity induced by repeated cycles of oxaliplatin in a Japanese colorectal cancer patient with moderate renal impairment].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Colorectal Neoplasms; Creatine;

2010
Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases.
    Annals of surgical oncology, 2010, Volume: 17, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2010
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
    Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ato

2011
A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer.
    Cell stem cell, 2010, Jun-04, Volume: 6, Issue:6

    Topics: Animals; Apoptosis; Biomarkers, Tumor; Carcinoma; Cell Migration Assays; Cell Transformation, Neopla

2010
Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jul-01, Volume: 16, Issue:13

    Topics: ADAM Proteins; ADAM17 Protein; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Pro

2010
Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
    International journal of colorectal disease, 2010, Volume: 25, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl

2010
Special report: laboratory testing to allow area under the curve (AUC)-targeted 5-fluorouracil dosing for patients administered chemotherapy for cancer.
    Technology Evaluation Center Assessment Program. Executive summary, 2010, Volume: 24, Issue:10

    Topics: Antimetabolites, Antineoplastic; Area Under Curve; Chemotherapy, Adjuvant; Clinical Trials as Topic;

2010
Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan.
    The pharmacogenomics journal, 2011, Volume: 11, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Pr

2011
Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Costs and Cost A

2010
Obesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fluorouracil in colorectal tumor stem cells.
    Endocrine-related cancer, 2010, Volume: 17, Issue:3

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Adhesion; Cel

2010
5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.
    British journal of cancer, 2010, Jul-27, Volume: 103, Issue:3

    Topics: Antimetabolites, Antineoplastic; Biocompatible Materials; Cell Line, Tumor; Collagen; Colorectal Neo

2010
Cellular senescence predicts treatment outcome in metastasised colorectal cancer.
    British journal of cancer, 2010, Aug-10, Volume: 103, Issue:4

    Topics: Cellular Senescence; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin;

2010
High frequency of hand foot syndrome with capecitabine.
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2010, Volume: 20, Issue:6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Cross-Sectional St

2010
Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore

2011
miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:8

    Topics: Binding Sites; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neopl

2010
[Selection of anticancer drug for poorly-differentiated adenocarcinoma of colorectum from the level of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase activities in cancer tissue].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cell Differentiation; Colorectal Neoplasms; Dihydrourac

2010
[HAI chemotherapy for liver metastases of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluor

2010
Primary site resection is superior for incurable metastatic colorectal cancer.
    World journal of gastroenterology, 2010, Jul-28, Volume: 16, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2010
Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy.
    British journal of clinical pharmacology, 2010, Volume: 70, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Neoplasm

2010
Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.
    British journal of cancer, 2010, Jul-27, Volume: 103, Issue:3

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin;

2010
5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice.
    BMC cancer, 2010, Aug-02, Volume: 10

    Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Delivery Systems; Female; Fluor

2010
Successful right hepatectomy after four treatments of yttrium-90 microspheres (SIR-Spheres) and concomitant FOLFOX as bridging therapy to resection of colorectal liver metastases.
    Anticancer research, 2010, Volume: 30, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro

2010
[Interstitial lung disease associated with combination chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2010, Volume: 55, Issue:5

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F

2010
Multi-modality therapy for metastatic colorectal cancer-ready for prime time?
    The American surgeon, 2010, Volume: 76, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Appendicitis; Colectomy; Colonoscopy

2010
[Performance of a portable continuous infusion pump (SUREFUSER A) in continuous infusion of 5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Colorectal Neoplasms; Female;

2010
Amplification of thymidylate synthetase in metastatic colorectal cancer patients pretreated with 5-fluorouracil-based chemotherapy.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistan

2010
The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2011, Volume: 43, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Femal

2011
Phenotyping breast cancer cell lines EM-G3, HCC1937, MCF7 and MDA-MB-231 using 2-D electrophoresis and affinity chromatography for glutathione-binding proteins.
    BMC cancer, 2010, Aug-23, Volume: 10

    Topics: Adult; Aged; Alcohol Oxidoreductases; Antineoplastic Combined Chemotherapy Protocols; Blotting, West

2010
Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability.
    BMC cancer, 2010, Aug-23, Volume: 10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Cisplatin; C

2010
S-1 for advanced colorectal cancer: do we need another oral fluorouracil prodrug?
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Com

2010
Can localised (19)F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response?
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carbon Dioxide; Colon; Colorectal N

2011
[mRNA quantification. The next challenge in routine diagnostics].
    Der Pathologe, 2010, Volume: 31 Suppl 2

    Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor

2010
[Microsatellite instability. A new predictive marker (?)].
    Der Pathologe, 2010, Volume: 31 Suppl 2

    Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemothera

2010
Alternative expression analysis by RNA sequencing.
    Nature methods, 2010, Volume: 7, Issue:10

    Topics: Alternative Splicing; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Datab

2010
[Adverse events in patients treated with capecitabine as adjuvant chemotherapy after surgery for colorectal cancer--countermeasures against hand-foot syndrome].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycyt

2010
Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.
    Annals of surgical oncology, 2011, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot

2011
Dietary glycine protects from chemotherapy-induced hepatotoxicity.
    Amino acids, 2011, Volume: 40, Issue:4

    Topics: Animals; Antineoplastic Agents; Camptothecin; Chemical and Drug Induced Liver Injury; Colorectal Neo

2011
Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:1

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ap

2011
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomised phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, P

2010
Outcomes in the management of obstructive unresectable stage IV colorectal cancer.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2010, Volume: 36, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2010
Medical oncology: A novel low-toxicity regimen for advanced colorectal cancer?
    Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:10

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2010
Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer.
    Oncology reports, 2010, Volume: 24, Issue:5

    Topics: Adenocarcinoma; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal

2010
Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles.
    Anti-cancer drugs, 2011, Volume: 22, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; beta-Cyclodextrins; Breast Neoplasms; Cell

2011
Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model.
    Vaccine, 2010, Nov-16, Volume: 28, Issue:49

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Carcinoembry

2010
Reporting time-to-event endpoints and response rates in 4 decades of randomized controlled trials in advanced colorectal cancer.
    Cancer, 2011, Feb-15, Volume: 117, Issue:4

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Outcom

2011
Patients with locally advanced and metastatic colorectal cancer treated with capecitabine versus 5-fluorouracil as monotherapy or combination therapy with oxaliplatin: a cost comparison.
    Clinical colorectal cancer, 2010, Volume: 9, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neop

2010
EGFR antibodies in colorectal cancer: where do they belong?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2010
Treatment of colorectal cancer with unresectable synchronous liver-only metastases with combined therapeutic modalities.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2011, Volume: 15, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Colorectal Neoplasms; Combi

2011
Cyclin E and histone H3 levels are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner.
    Cancer biology & therapy, 2010, Dec-01, Volume: 10, Issue:11

    Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Cell Cycle; Colorectal Neopla

2010
A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer.
    British journal of cancer, 2010, Nov-09, Volume: 103, Issue:10

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2010
5-Fluorouracil/Leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma: a clinical experience.
    Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials,

2011
Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice.
    Gastroenterology, 2011, Volume: 140, Issue:1

    Topics: AC133 Antigen; Adenomatous Polyposis Coli; Aged; Aged, 80 and over; Animals; Antigens, CD; Antineopl

2011
Venous thromboembolism and port-related thrombosis in metastatic colorectal cancer patients: a monocenter experience.
    Pathophysiology of haemostasis and thrombosis, 2010, Volume: 37, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2010
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:2

    Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Camptotheci

2011
Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.
    British journal of cancer, 2010, Nov-09, Volume: 103, Issue:10

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2010
Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2011
Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases.
    Annals of surgical oncology, 2011, Volume: 18, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Com

2011
Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer.
    British journal of cancer, 2010, Nov-09, Volume: 103, Issue:10

    Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Antineoplastic Agent

2010
Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction.
    British journal of cancer, 2011, Jan-04, Volume: 104, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2011
[Choice of surgical strategy for colorectal liver metastases depending on clinical and pathological response to neoadjuvant chemo- and targeted therapy].
    Orvosi hetilap, 2010, Nov-21, Volume: 151, Issue:47

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2010
Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer.
    Oncology, 2010, Volume: 79, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo

2010
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2).
    Proceedings of the National Academy of Sciences of the United States of America, 2010, Dec-07, Volume: 107, Issue:49

    Topics: Base Pair Mismatch; Colorectal Neoplasms; Down-Regulation; Drug Resistance; Fluorouracil; Gene Expre

2010
Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer.
    Cancer science, 2011, Volume: 102, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biomarkers; Chromosomes, Human, Pair 18; Color

2011
Bevacizumab-induced nasal septal perforation: incidence of symptomatic, confirmed event(s) in colorectal cancer patients.
    Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo

2011
Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan?: A monocentric institution safety analysis of 46 patients.
    Clinics and research in hepatology and gastroenterology, 2011, Volume: 35, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorectal Neopl

2011
Bevacizumab-based therapy and complication risk after colonic stent placement: is it time for a warning?
    Gastrointestinal endoscopy, 2010, Volume: 72, Issue:6

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2010
Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma.
    Asia-Pacific journal of clinical oncology, 2010, Volume: 6, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F

2010
Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.
    Journal of the National Cancer Institute, 2011, Jan-05, Volume: 103, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Sur

2011
Treatment patterns and metastasectomy among mCRC patients receiving chemotherapy and biologics.
    Current medical research and opinion, 2011, Volume: 27, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biologic

2011
ABCB1 gene polymorphisms are associated with adverse reactions in fluoropyrimidine-treated colorectal cancer patients.
    Pharmacogenomics, 2010, Volume: 11, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Ca

2010
Safety of 10 min infusion of bevacizumab in combination with 5FU-based chemotherapy in non-selected metastatic colorectal cancer patients.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2011, Volume: 43, Issue:3

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabo

2011
Oxaliplatin-free interval as a risk factor for hypersensitivity reaction among colorectal cancer patients treated with FOLFOX.
    Oncology, 2010, Volume: 79, Issue:1-2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

2010
Comment on 'capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer'.
    British journal of cancer, 2011, Jan-04, Volume: 104, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2011
Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:3

    Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu

2011
Generalized pairwise comparisons of prioritized outcomes in the two-sample problem.
    Statistics in medicine, 2010, Dec-30, Volume: 29, Issue:30

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aptamers, Nucleotide; Colorectal Neoplasms; Disease-

2010
The colorectal cancer disease-specific transcriptome may facilitate the discovery of more biologically and clinically relevant information.
    BMC cancer, 2010, Dec-20, Volume: 10

    Topics: Antimetabolites, Antineoplastic; Biopsy; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neopl

2010
Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
    International journal of oncology, 2011, Volume: 38, Issue:2

    Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Prolifera

2011
Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.
    Pharmacogenomics, 2011, Volume: 12, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2011
Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin.
    BMC cancer, 2010, Dec-22, Volume: 10

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Ch

2010
5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.
    Gastroenterology, 2011, Volume: 140, Issue:4

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cohort Studies; Co

2011
A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes.
    Anticancer research, 2010, Volume: 30, Issue:12

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Calibration; Capeci

2010
Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.
    International journal of colorectal disease, 2011, Volume: 26, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2011
5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes.
    British journal of clinical pharmacology, 2011, Volume: 72, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Czech Republic; Disease-Free Survival; Ferred

2011
Clinical usefulness of mitochondrial transcription factor A expression as a predictive marker in colorectal cancer patients treated with FOLFOX.
    Cancer science, 2011, Volume: 102, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2011
Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
    Annals of surgical oncology, 2011, Volume: 18, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorectal Neoplasms; F

2011
Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing.
    Annals of surgical oncology, 2011, Volume: 18, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2011
Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma.
    Clinical colorectal cancer, 2010, Volume: 9, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2010
Hepatic arterial infusion of 5-fluorouracil for patients with liver metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis.
    Clinical colorectal cancer, 2010, Volume: 9, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up

2010
Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases.
    Clinical colorectal cancer, 2010, Volume: 9, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2010
[Prehepatectomy chemotherapy using hepatic artery infusion plus systemic chemotherapy for liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2010
[The efficacy of cetuximab for metastatic colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast

2010
[Two cases of venous thrombosis confirmed during the bevacizumab combination chemotherapy for colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Aged; Angiogenesis Inducing Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antin

2010
[The expression of thymidylate synthase (TS) and excision repair complementing-1 (ERCC-1) protein in patients with unresectable colorectal cancer treated with mFOLFOX6 therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Colorect

2010
[Adjuvant chemotherapy with FOLFOX4 regimen after curative resection of liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms;

2010
[Two-stage hepatectomy combined with converting chemotherapy achieved a successful treatment for initially unresectable multiple bilobar colorectal liver metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2010
[Roles of hepatectomy for colorectal liver metastases with necrotic foci caused by prior anti-cancer therapies].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla

2010
[A case of unresectable multiple hepatic metastases from colorectal cancer successfully treated with IRIS (S-1, CPT-11) therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch

2010
[Hepatic arterial infusion chemotherapy with oxaliplatin in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co

2010
Penetration of paclitaxel and 5-fluorouracil in multicellular layers of human colorectal cancer cells.
    Oncology reports, 2011, Volume: 25, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Carcinoma; Cell Line, Tumor

2011
Changing management and survival in patients with stage IV colorectal cancer.
    Diseases of the colon and rectum, 2011, Volume: 54, Issue:2

    Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Antineoplastic Agents; Australia; Camptothecin; Capecit

2011
The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012, Volume: 20, Issue:1

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape

2012
miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.
    Acta biochimica et biophysica Sinica, 2011, Volume: 43, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Carrier Proteins; Cell Line, Tumor; Colorectal Neoplasms; Dru

2011
Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy.
    International journal of clinical oncology, 2011, Volume: 16, Issue:3

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb

2011
High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.
    International journal of clinical oncology, 2011, Volume: 16, Issue:3

    Topics: Adenocarcinoma; Anti-Allergic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies

2011
Transcatheter arterial chemoembolization with docetaxel-loaded microspheres controls heavily pretreated unresectable liver metastases from colorectal cancer: a case study.
    International journal of clinical oncology, 2011, Volume: 16, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolizati

2011
Analysis of tumor burden versus progression-free survival for Phase II decision making.
    Contemporary clinical trials, 2011, Volume: 32, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites,

2011
Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
    Anticancer research, 2011, Volume: 31, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2011
R1 resection for aggressive or advanced colorectal liver metastases is justified in combination with effective prehepatectomy chemotherapy.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2011, Volume: 37, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot

2011
Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives.
    Journal of cellular physiology, 2011, Volume: 226, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2011
Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo

2011
Interstitial lung disease during chemotherapy combined with oxaliplatin and/or bevacizumab in advanced colorectal cancer patients.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:4

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Alveolitis, Extrinsic Allergic; Antibodies, Monoclona

2011
Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal

2011
A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer.
    Journal of medical economics, 2011, Volume: 14, Issue:2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

2011
Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2012, Volume: 18, Issue:1

    Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Coronary Vasospasm; Defi

2012
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-01, Volume: 17, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Breas

2011
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
    Asia-Pacific journal of clinical oncology, 2011, Volume: 7, Issue:1

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineo

2011
Hepatic arterial infusion chemotherapy prior to standard systemic chemotherapy in patients with highly advanced unresectable liver metastases from colorectal cancer: a report of three patients.
    Acta medica Okayama, 2011, Volume: 65, Issue:1

    Topics: Angiography; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Campto

2011
Expression of p21WAF1 in Astler-Coller stage B2 colorectal cancer is associated with survival benefit from 5FU-based adjuvant chemotherapy.
    Virchows Archiv : an international journal of pathology, 2011, Volume: 458, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms;

2011
Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer.
    Cancer biology & therapy, 2011, Mar-15, Volume: 11, Issue:6

    Topics: Animals; Apoptosis; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; Mice; Pyr

2011
In vivo evidence for a significant role of folylpolyglutamate synthase in combined chemotherapy with oral fluoropyrimidine, UFT or S-1, and leucovorin.
    Oncology reports, 2011, Volume: 25, Issue:5

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Col

2011
Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy after early failure of adjuvant systemic chemotherapy.
    Journal of surgical oncology, 2011, Volume: 103, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Combined Modalit

2011
Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer.
    Journal of biomedicine & biotechnology, 2011, Volume: 2011

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Cy

2011
The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen.
    Expert opinion on drug safety, 2011, Volume: 10, Issue:3

    Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotr

2011
18F-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases.
    Nuclear medicine communications, 2011, Volume: 32, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo

2011
Pharmacometabonomic profiling as a predictor of toxicity in patients with inoperable colorectal cancer treated with capecitabine.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-01, Volume: 17, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Capeci

2011
Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma.
    International journal of clinical oncology, 2011, Volume: 16, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2011
Efficacy and safety of hepatic arterial infusion of fluorouracil with leucovorin as salvage treatment for refractory liver metastases from colorectal cancer.
    The Korean journal of internal medicine, 2011, Volume: 26, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2011
Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
    Cancer, 2011, Oct-01, Volume: 117, Issue:19

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2011
Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer.
    International journal of medical sciences, 2011, Mar-10, Volume: 8, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2011
Systems pharmacology assessment of the 5-fluorouracil pathway.
    Pharmacogenomics, 2011, Volume: 12, Issue:3

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorou

2011
Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer.
    Pharmacogenomics, 2011, Volume: 12, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmaco

2011
Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jun-01, Volume: 17, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluor

2011
The influence of toxicity constraints in models of chemotherapeutic protocol escalation.
    Mathematical medicine and biology : a journal of the IMA, 2011, Volume: 28, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Protocols; Cell Cycle; Colorectal Neoplasms; Drug Administrati

2011
Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:6

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspases; Cell Line, Tumor; Colorectal Neoplasms; Fluoro

2011
Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-20, Volume: 29, Issue:18

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2011
Cost-effectiveness of UGT1A1*28 genotyping in preventing severe neutropenia following FOLFIRI therapy in colorectal cancer.
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2010, Volume: 13, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Ana

2010
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, May-15, Volume: 17, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Biomar

2011
[Two cases of advanced colorectal cancer which demonstrated the reversibility of oxaliplatin-mediated increase in splenic volume].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:4

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2011
Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2011
PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.
    Journal of cellular physiology, 2012, Volume: 227, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth

2012
Single nucleotide polymorphisms of integrin alpha-2 and beta-3 genes are not associated with relapse-free and overall survival in colorectal cancer patients.
    Anticancer research, 2011, Volume: 31, Issue:4

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA, Neoplasm; Female

2011
Radioembolization in combination with systemic chemotherapy as first-line therapy for liver metastases from colorectal cancer.
    Journal of vascular and interventional radiology : JVIR, 2011, Volume: 22, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Brachytherapy; Chemotherapy,

2011
Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo.
    International journal of oncology, 2011, Volume: 39, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorecta

2011
Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil.
    Pharmacological research, 2011, Volume: 64, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; Female; F

2011
Occurrence of subacute cutaneous lupus erythematosus after treatment with systemic fluorouracil.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-10, Volume: 29, Issue:20

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Female; Fluorouracil; Heart Diseases; Humans; Lupus Ery

2011
Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012, Volume: 20, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms

2012
[A case of toxicity caused by drug interaction between capecitabine and phenytoin in patient with colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:5

    Topics: Adult; Anticonvulsants; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycy

2011
Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2011, Volume: 23, Issue:7

    Topics: Adenocarcinoma; Anastomotic Leak; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth

2011
How do we apply adjuvant FOLFOX to Japanese patients with curatively resected colorectal cancer?
    Asia-Pacific journal of clinical oncology, 2011, Volume: 7, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Chemotherapy, Adjuvant; C

2011
Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle.
    Journal of the National Cancer Institute, 2011, Jun-08, Volume: 103, Issue:11

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Colorectal Neoplasms,

2011
Do we need oncology trials tailored for the elderly or frail?
    Lancet (London, England), 2011, May-21, Volume: 377, Issue:9779

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Ne

2011
CD133(-) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the β1-integrin signaling.
    The Journal of surgical research, 2012, Jun-15, Volume: 175, Issue:2

    Topics: AC133 Antigen; Adenocarcinoma; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers,

2012
5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemothe

2012
In vitro cytotoxic effect of ethanol extract prepared from sporophyll of Undaria pinnatifida on human colorectal cancer cells.
    Phytotherapy research : PTR, 2012, Volume: 26, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Survival; Colorectal Neoplasms; Cul

2012
Attenuated expression of HRH4 in colorectal carcinomas: a potential influence on tumor growth and progression.
    BMC cancer, 2011, May-24, Volume: 11

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell

2011
Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction.
    Clinical colorectal cancer, 2011, Mar-01, Volume: 10, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Camptothecin; Colorectal Neoplasms;

2011
Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
    Clinical colorectal cancer, 2011, Mar-01, Volume: 10, Issue:1

    Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Colorectal Neoplasms; Deoxycytidin

2011
Efficacy and tolerability of biweekly bevacizumab, irinotecan, folinic acid and fluorouracil intravenous bolus (BIFF Regimen) in patients with metastatic colorectal cancer: the southern Italy cooperative oncology group experience.
    Clinical colorectal cancer, 2011, Mar-01, Volume: 10, Issue:1

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant

2011
Empirical Bayes estimation of random effects of a mixed-effects proportional odds Markov model for ordinal data.
    Computer methods and programs in biomedicine, 2011, Volume: 104, Issue:3

    Topics: Antineoplastic Agents; Bayes Theorem; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Empirical R

2011
Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
    Anticancer research, 2011, Volume: 31, Issue:5

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant

2011
Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members.
    International journal of oncology, 2011, Volume: 39, Issue:2

    Topics: Afatinib; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neopla

2011
A predicted protein, KIAA0247, is a cell cycle modulator in colorectal cancer cells under 5-FU treatment.
    Journal of translational medicine, 2011, May-28, Volume: 9

    Topics: Aged; Cell Cycle; Cell Division; Colon; Colorectal Neoplasms; Complement System Proteins; Cyclins; F

2011
Type IV collagen as a tumour marker for colorectal liver metastases.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2011, Volume: 37, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2011
Calbindin 2 (CALB2) regulates 5-fluorouracil sensitivity in colorectal cancer by modulating the intrinsic apoptotic pathway.
    PloS one, 2011, Volume: 6, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Caspase 3; Caspase 7; Caspase 9; Cell Survival;

2011
Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Clinical therapeutics, 2011, Volume: 33, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2011
SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells.
    Gastroenterology, 2011, Volume: 141, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies; Antigens, CD; Antimetabolites, Antineoplastic;

2011
First-line treatment of advanced colorectal cancer.
    Lancet (London, England), 2011, Jun-18, Volume: 377, Issue:9783

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2011
ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients.
    Cancer research, 2011, Aug-01, Volume: 71, Issue:15

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamil

2011
A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.
    British journal of cancer, 2011, Jun-28, Volume: 105, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2011
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.
    BMC cancer, 2011, Jun-14, Volume: 11

    Topics: Adenocarcinoma; Aged; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla

2011
DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6.
    British journal of cancer, 2011, Jun-28, Volume: 105, Issue:1

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2011
DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status.
    International journal of oncology, 2011, Volume: 39, Issue:3

    Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Colorectal Neo

2011
FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer.
    Oncology, 2011, Volume: 80, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2011
Regarding 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
    Oncology, 2011, Volume: 80, Issue:1-2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2011
Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
    Oncology, 2011, Volume: 80, Issue:1-2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2011
Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2011, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colo

2011
Enhancement of 5-fluorouracil-induced in vitro and in vivo radiosensitization with MEK inhibition.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Aug-01, Volume: 17, Issue:15

    Topics: Animals; Benzimidazoles; Cell Line, Tumor; Colorectal Neoplasms; Cytoprotection; DNA Repair; Drug Th

2011
Can the CIMP status be used to stratify the colorectal cancer patients who respond to adjuvant chemotherapy?
    Journal of surgical oncology, 2011, Volume: 104, Issue:7

    Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cp

2011
Management of patients with synchronous liver metastases of colorectal cancer. Clinical practice guidelines. Guidelines of the French society of gastrointestinal surgery (SFCD) and of the association of hepatobiliary surgery and liver transplantation (ACH
    Journal of visceral surgery, 2011, Volume: 148, Issue:3

    Topics: Adenocarcinoma; Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2011
Correlation between TBARS levels and glycolytic enzymes: the importance to the initial evaluation of clinical outcome of colorectal cancer patients.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2011, Volume: 65, Issue:6

    Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bioma

2011
Overexpression of neurone glial-related cell adhesion molecule is an independent predictor of poor prognosis in advanced colorectal cancer.
    Cancer science, 2011, Volume: 102, Issue:10

    Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Adhesion Molecules; Colorectal Neoplasms; Female; F

2011
Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer.
    Cancer biology & therapy, 2011, Aug-01, Volume: 12, Issue:3

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C

2011
Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
    Diseases of the colon and rectum, 2011, Volume: 54, Issue:8

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb

2011
Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.
    BMC cancer, 2011, Jul-09, Volume: 11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl

2011
Effects of bolus injection of 5-fluorouracil on steady-state plasma concentrations of 5-fluorouracil in Japanese patients with advanced colorectal cancer.
    International journal of medical sciences, 2011, Volume: 8, Issue:5

    Topics: Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neoplasms; Fluorouracil; Humans; Japan

2011
Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.
    Anti-cancer drugs, 2011, Volume: 22 Suppl 2

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto

2011
Bevacizumab in combination with irinotecan, 5-fluorouracil and leucovorin given as first-line treatment of metastatic colorectal cancer.
    Anti-cancer drugs, 2011, Volume: 22 Suppl 2

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2011
[Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:7

    Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2011
FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:7

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2011
Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis.
    Annals of surgery, 2011, Volume: 254, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; C

2011
Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients.
    Surgery today, 2011, Volume: 41, Issue:8

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Anti

2011
[A case of severe bevacizumab-induced ischemic pancolitis, treated with conservative management].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2011, Volume: 58, Issue:1

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2011
Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Sep-01, Volume: 17, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized;

2011
[Hypertension as a predictive factor of effect of bevacizumab in treatment of colorectal cancer].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2011, Volume: 131, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop

2011
Expression of p53 and DR5 in normal and malignant tissues of colorectal cancer: correlation with advanced stages.
    Oncology reports, 2011, Volume: 26, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Colorectal Neoplasms; Female; Fluor

2011
Resistance of colorectal cancer cells to radiation and 5-FU is associated with MELK expression.
    Biochemical and biophysical research communications, 2011, Aug-26, Volume: 412, Issue:2

    Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm;

2011
Dose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adaptation, Physiological; Algorithms; Antimetabolites, Antineoplastic; Bayes Theorem; Capecitabine;

2012
[End results of combined treatment in metastatic colorectal cancer].
    Voprosy onkologii, 2011, Volume: 57, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoembolization, Therapeutic; Chemot

2011
DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells.
    Cancer biology & therapy, 2011, Oct-15, Volume: 12, Issue:8

    Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal

2011
The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.
    BMC cancer, 2011, Aug-10, Volume: 11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2011
[Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2011
Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer.
    International journal of clinical oncology, 2012, Volume: 17, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co

2012
A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomark

2011
Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:10

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2011
P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance.
    Oncogene, 2012, Mar-01, Volume: 31, Issue:9

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Autophagy; Cell

2012
Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.
    Clinical colorectal cancer, 2011, Volume: 10, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies;

2011
Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.
    Clinical colorectal cancer, 2011, Volume: 10, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve;

2011
Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.
    Cancer, 2011, Sep-01, Volume: 117, Issue:17

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant

2011
Outcome and natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection.
    Annals of surgical oncology, 2012, Volume: 19, Issue:2

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2012
Prognostic significance of thymidylate synthase expression in the adjuvant chemotherapy after resection for pulmonary metastases from colorectal cancer.
    Anticancer research, 2011, Volume: 31, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil;

2011
Chemotherapy for older patients with colorectal cancer.
    Lancet (London, England), 2011, Aug-27, Volume: 378, Issue:9793

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Cardiovascular Diseases; Colorectal Neoplasms;

2011
SNPs and haplotypes in DPYD and outcome of capecitabine--Letter.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Sep-01, Volume: 17, Issue:17

    Topics: Carcinoma; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug-Related Sid

2011
SNPs and Haplotypes in DPYD and Outcome of Capecitabine-Letter.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Sep-01, Volume: 17, Issue:17

    Topics: Carcinoma; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug-Related Sid

2011
Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
    International journal of cancer, 2012, Jul-15, Volume: 131, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2012
Sequential chemotherapy for colorectal cancer.
    The Lancet. Oncology, 2011, Volume: 12, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorour

2011
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
    Clinical colorectal cancer, 2012, Volume: 11, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2012
Novel activity of acriflavine against colorectal cancer tumor cells.
    Cancer science, 2011, Volume: 102, Issue:12

    Topics: Acriflavine; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Topoisomerases, Type I; DNA T

2011
Effect of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in colorectal liver metastases.
    World journal of gastroenterology, 2011, Jul-14, Volume: 17, Issue:26

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Proliferation;

2011
[Cetuximab-associated skin ulceration in patient with metastatic colorectal cancer: a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:9

    Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combine

2011
Revisiting the frontiers of pharmacogenomics of colon cancer.
    Pharmacogenomics, 2011, Volume: 12, Issue:9

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmaco

2011
The association of polymorphisms in 5-fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.
    Pharmacogenomics, 2011, Volume: 12, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Cohort Studies; Colorectal Neoplasms; Dihydr

2011
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2012
5-fluorouracil increases the chemopreventive potentials of resveratrol through DNA damage and MAPK signaling pathway in human colorectal cancer cells.
    Oncology research, 2011, Volume: 19, Issue:7

    Topics: Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Movement; Cell

2011
Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:2

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2012
[Lentivirus-mediated RNA interference suppresses APRIL expression and enhances chemosensitivity in colorectal cancer cells].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2011, Volume: 31, Issue:9

    Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance,

2011
Tailoring of drug delivery of 5-fluorouracil to the colon via a mixed film coated unit system.
    Acta pharmaceutica (Zagreb, Croatia), 2011, Sep-01, Volume: 61, Issue:3

    Topics: Antimetabolites, Antineoplastic; Cellulose; Colon; Colorectal Neoplasms; Delayed-Action Preparations

2011
Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis.
    Nature medicine, 2011, Sep-25, Volume: 17, Issue:10

    Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Colorectal Neoplasms; DNA Primers; Fluor

2011
Chemotherapy between the first and second stages of a two-stage hepatectomy for colorectal liver metastases: should we routinely recommend it?
    Annals of surgical oncology, 2012, Volume: 19, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Sur

2012
Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
    Genetics and molecular research : GMR, 2011, Oct-03, Volume: 10, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2011
[FOLFOX as adjuvant chemotherapy after curative resection of distant metastatic lesions in patients with colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2011
[Four cases of locally advanced colorectal cancer resected successfully after preoperative chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2011
mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury.
    HPB : the official journal of the International Hepato Pancreato Biliary Association, 2011, Volume: 13, Issue:11

    Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Dihydrouracil D

2011
Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.
    Cancer, 2012, Jun-01, Volume: 118, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva

2012
Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Beva

2012
Feasibility of Assam Bora rice starch as a compression coat of 5-fluorouracil core tablet for colorectal cancer.
    Current drug delivery, 2012, Volume: 9, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Cellulose; Colorectal Neoplasms; Drug Carriers; Fluorourac

2012
A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:1

    Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; C

2012
[Induced nausea and vomiting induced by mFOLFOX6 and FOLFIRI with advanced colorectal cancer: a retrospective survey].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2011, Volume: 131, Issue:11

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin;

2011
Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab.
    Pharmacogenetics and genomics, 2012, Volume: 22, Issue:1

    Topics: 3' Untranslated Regions; 5' Untranslated Regions; Alleles; Antibodies, Monoclonal, Humanized; Antine

2012
Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgery.
    Oncology, 2011, Volume: 81, Issue:3-4

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2011
Efficacy of oxaliplatin-based chemotherapy in curatively resected colorectal cancer with liver metastasis.
    Oncology, 2011, Volume: 81, Issue:3-4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2011
Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer.
    Journal of gastroenterology, 2012, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tu

2012
A peptide of SPARC interferes with the interaction between caspase8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivo.
    PloS one, 2011, Volume: 6, Issue:11

    Topics: Animals; Apoptosis; Blotting, Western; Breast Neoplasms; Caspase 8; Caspase Inhibitors; Colorectal N

2011
Clinical application of a systems model of apoptosis execution for the prediction of colorectal cancer therapy responses and personalisation of therapy.
    Gut, 2012, Volume: 61, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers; Caspases; Chemotherapy, Adjuvant; Colo

2012
Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis.
    British journal of cancer, 2012, Jan-03, Volume: 106, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

2012
Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.
    Clinical colorectal cancer, 2012, Volume: 11, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Australia; Canada; Clinical Trials as Topic; C

2012
The central vein access port and catheter in outpatient chemotherapy for colorectal cancer: a retrospective study of 101 patients.
    Surgery today, 2012, Volume: 42, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cathet

2012
Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
    Anticancer research, 2011, Volume: 31, Issue:11

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carc

2011
Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2012, Feb-14, Volume: 45, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplas

2012
Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe.
    Current medical research and opinion, 2012, Volume: 28, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combin

2012
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Cancer research, 2012, Feb-01, Volume: 72, Issue:3

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe

2012
Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Feb-01, Volume: 30, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2012
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin;

2012
Impact of chemotherapy for colorectal cancer on regulatory T-cells and tumor immunity.
    Anticancer research, 2011, Volume: 31, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-L

2011
Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer.
    Drug metabolism and pharmacokinetics, 2012, Volume: 27, Issue:3

    Topics: 3' Flanking Region; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Color

2012
[Our experience of the treatment with XELOX±Bevacizumab for unresectable advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2011
Treatment results of peritonectomy combined with perioperative chemotherapy for colorectal cancer-patients with peritoneal carcinomatosis.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neo

2011
[Therapeutic effect of mFOLFOX6 for synchronous unresectable liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2011
[Recurrance of disappearing colorectal liver metastases after mFOLFOX6 regimen].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2011
[The clinical outcome of mFOLFOX6 treatment for colorectal cancer patients who underwent resection of liver metastasis -comparison between synchronous and metachronous liver metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2011
[Prediction of the efficacy of modified FOLFOX6 therapy according to the mRNA levels of thymidylate synthase (TS), excision repair cross-complementing-1 and -2( ERCC-1 and ERCC-2) and methylenetetrahydrofolate dehydrogenase( MTHFD) in the primary lesion o
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2011
[The Relationship between the efficacy of mFOLFOX6 treatment and the expression of TS, DPD, TP, and ERCC-1 in unresectable colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2011
Prediction of response to anticancer treatment as simple as the resolution of ordinary differential equations?
    Gut, 2012, Volume: 61, Issue:5

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Decision Support Techniques; Femal

2012
Induced pluripotent stem cell-related genes influence biological behavior and 5-fluorouracil sensitivity of colorectal cancer cells.
    Journal of Zhejiang University. Science. B, 2012, Volume: 13, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Colorectal Neoplasms; Female; Fluorour

2012
Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment.
    World journal of surgical oncology, 2011, Dec-30, Volume: 9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot

2011
Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV stud
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort

2012
Dual-mode interaction between quercetin and DNA-damaging drugs in cancer cells.
    Anticancer research, 2012, Volume: 32, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; bcl-2-Associated X Protein;

2012
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 3

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents,

2011
[Safety and efficacy of FOLFOX and FOLFIRI in elderly patients with colorectal cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2011, Volume: 69 Suppl 3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorourac

2011
Targeting colorectal cancer stem cells with inducible caspase-9.
    Apoptosis : an international journal on programmed cell death, 2012, Volume: 17, Issue:5

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Caspase 3; Caspa

2012
Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.
    The pharmacogenomics journal, 2013, Volume: 13, Issue:2

    Topics: AC133 Antigen; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antigens, CD; Beva

2013
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
    Cancer investigation, 2012, Volume: 30, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineop

2012
Management of obstructive colorectal cancer: evaluation of preoperative bowel decompression using ileus tube drainage.
    Surgery today, 2012, Volume: 42, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colorectal

2012
Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer.
    The pharmacogenomics journal, 2013, Volume: 13, Issue:2

    Topics: Alternative Splicing; Cell Line, Tumor; Colorectal Neoplasms; Down-Regulation; Drug Resistance, Neop

2013
PAK1-dependent MAPK pathway activation is required for colorectal cancer cell proliferation.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012, Volume: 33, Issue:4

    Topics: Animals; Anthracenes; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line,

2012
Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2012, Volume: 16, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chi-Square Distributi

2012
Impact of chemotherapy-related prognostic factors on long-term survival in patients with stage III colorectal cancer after curative resection.
    International journal of clinical oncology, 2013, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Ther

2013
The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS).
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2012, Volume: 15, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop

2012
Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy.
    American journal of clinical oncology, 2013, Volume: 36, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Fluorou

2013
Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
    Investigational new drugs, 2012, Volume: 30, Issue:6

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; C

2012
Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:4

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape

2012
Capecitabine non-adherence: exploration of magnitude, nature and contributing factors.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2012, Volume: 18, Issue:3

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorec

2012
Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration.
    The pharmacogenomics journal, 2013, Volume: 13, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmaco

2013
Loss of E-cadherin promotes the growth, invasion and drug resistance of colorectal cancer cells and is associated with liver metastasis.
    Molecular biology reports, 2012, Volume: 39, Issue:6

    Topics: Active Transport, Cell Nucleus; Antimetabolites, Antineoplastic; beta Catenin; Cadherins; Cell Adhes

2012
Identification of Nkx2-3 and TGFB1I1 expression levels as potential biomarkers to predict the effects of FOLFOX4 chemotherapy.
    Cancer biology & therapy, 2012, Volume: 13, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Cell

2012
Epidermal growth factor receptor R521K polymorphism shows favorable outcomes in KRAS wild-type colorectal cancer patients treated with cetuximab-based chemotherapy.
    Cancer science, 2012, Volume: 103, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2012
MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells.
    Annals of surgical oncology, 2012, Volume: 19, Issue:9

    Topics: Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Protein

2012
Absence of transcriptomic signature of response to chemotherapy in metastatic colorectal carcinoma patients.
    Pharmacogenomics, 2012, Volume: 13, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Camptothec

2012
Infections of Blastocystis hominis and microsporidia in cancer patients: are they opportunistic?
    Transactions of the Royal Society of Tropical Medicine and Hygiene, 2012, Volume: 106, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blastocystis hominis; Breast Neoplasms; Col

2012
STAT5a-targeting miRNA enhances chemosensitivity to cisplatin and 5-fluorouracil in human colorectal cancer cells.
    Molecular medicine reports, 2012, Volume: 5, Issue:5

    Topics: Annexin A5; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin;

2012
Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patients.
    International journal of clinical oncology, 2013, Volume: 18, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2013
Differences in tissue degeneration between preoperative chemotherapy and preoperative chemoradiotherapy for colorectal cancer.
    International journal of colorectal disease, 2012, Volume: 27, Issue:8

    Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Colorect

2012
Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6.
    The oncologist, 2012, Volume: 17, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Co

2012
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:5

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2012
Clinical observation of Endostar® combined with chemotherapy in advanced colorectal cancer patients.
    Asian Pacific journal of cancer prevention : APJCP, 2011, Volume: 12, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Ad

2011
The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer.
    BMC cancer, 2012, Mar-08, Volume: 12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort

2012
The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2012, Volume: 66, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2012
SN-38 overcomes chemoresistance of colorectal cancer cells induced by hypoxia, through HIF1alpha.
    Anticancer research, 2012, Volume: 32, Issue:3

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Cell Division; Cell Hypoxia; Colorectal

2012
A case of therapy-related acute myeloid leukemia following 5-fluorouracil chemotherapy.
    The Korean journal of internal medicine, 2012, Volume: 27, Issue:1

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone

2012
Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer.
    International journal of clinical oncology, 2013, Volume: 18, Issue:3

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2013
Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer.
    World journal of gastroenterology, 2012, Mar-14, Volume: 18, Issue:10

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che

2012
Data-driven assessment of the association of polymorphisms in 5-Fluorouracil metabolism genes with outcome in adjuvant treatment of colorectal cancer.
    Basic & clinical pharmacology & toxicology, 2012, Volume: 111, Issue:3

    Topics: Adjuvants, Pharmaceutic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc

2012
LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.
    Biomedical chromatography : BMC, 2013, Volume: 27, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Chromatography, Liquid; Colorectal Neoplasms; Drug Monitoring

2013
A valid formulation of the analysis of noninferiority trials under random effects meta-analysis.
    Biostatistics (Oxford, England), 2012, Volume: 13, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal N

2012
Dose-modified XELIRI chemotherapy for metastatic colorectal cancer--a retrospective study of 78 patients.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2012, Volume: 24, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De

2012
Apoptosome-dependent caspase activation proteins as prognostic markers in Stage II and III colorectal cancer.
    British journal of cancer, 2012, Apr-24, Volume: 106, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosomes; Caspases; Chemotherapy

2012
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
    Expert opinion on drug metabolism & toxicology, 2012, Volume: 8, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Ca

2012
X-ACT: an important step on an unfinished journey.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:7

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycy

2012
A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
    Asia-Pacific journal of clinical oncology, 2012, Volume: 8, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin

2012
FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
    Annals of surgical oncology, 2012, Volume: 19, Issue:11

    Topics: Adaptor Proteins, Signal Transducing; Aged; Antimetabolites, Antineoplastic; Basic-Leucine Zipper Tr

2012
Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases.
    Annals of surgical oncology, 2012, Volume: 19, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9

2012
Oxaliplatin-induced hepatoportal sclerosis, portal hypertension, and variceal bleeding successfully treated with transjugular intrahepatic portosystemic shunt.
    Clinical colorectal cancer, 2012, Volume: 11, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo

2012
Fate of metastatic foci after chemotherapy and usefulness of contrast-enhanced intraoperative ultrasonography to detect minute hepatic lesions.
    Journal of hepato-biliary-pancreatic sciences, 2012, Volume: 19, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colo

2012
Inadvertent severe acute kidney injury and oxaliplatin.
    International urology and nephrology, 2013, Volume: 45, Issue:1

    Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorecta

2013
Predicting acute and persistent neuropathy associated with oxaliplatin.
    American journal of clinical oncology, 2013, Volume: 36, Issue:4

    Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cohort

2013
Metastatic paediatric colorectal carcinoma.
    Irish medical journal, 2012, Volume: 105, Issue:3

    Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevac

2012
Resistance of colon cancer to 5-fluorouracil may be overcome by combination with chloroquine, an in vivo study.
    Anti-cancer drugs, 2012, Volume: 23, Issue:7

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis;

2012
Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2012, Volume: 38, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colo

2012
Prediction of genetic polymorphisms of DNA repair genes XRCC1 and XRCC3 in the survival of colorectal cancer receiving chemotherapy in the Chinese population.
    Hepato-gastroenterology, 2012, Volume: 59, Issue:116

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms

2012
Central venous port system-related complications in outpatient chemotherapy for colorectal cancer.
    Hepato-gastroenterology, 2012, Volume: 59, Issue:116

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2012
Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:5

    Topics: Angiogenesis Inducing Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cap

2012
[Side effect analyses in consideration of renal functions for capecitabine-administered patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycy

2012
Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer.
    Anticancer research, 2012, Volume: 32, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fl

2012
Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2013, Volume: 15, Issue:1

    Topics: Aged; Analysis of Variance; Antimetabolites, Antineoplastic; C-Peptide; Colorectal Neoplasms; Diabet

2013
Hydroxymethylglutaryl-coenzyme a synthase 2 expression is associated with chemoradiotherapy responses in colorectal cancer.
    Diseases of the colon and rectum, 2012, Volume: 55, Issue:6

    Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Chemoradiot

2012
Feasibility and short-term outcome of adjuvant FOLFOX after resection of colorectal liver metastases.
    Journal of hepato-biliary-pancreatic sciences, 2013, Volume: 20, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

2013
KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer.
    British journal of cancer, 2012, Jul-10, Volume: 107, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Class I Phosphatidyl

2012
Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases.
    Annals of surgical oncology, 2012, Volume: 19, Issue:9

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap

2012
Comparative label-free LC-MS/MS analysis of colorectal adenocarcinoma and metastatic cells treated with 5-fluorouracil.
    Proteomics, 2012, Volume: 12, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antioxidants; Cell Adhesion; Cell Line, Tumor; Chro

2012
Prognostic factors for overall survival in patients with metastatic colorectal carcinoma treated with vascular endothelial growth factor-targeting agents.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2012
Complete calcification of colorectal liver metastases on imaging after chemotherapy does not indicate sterilization of disease.
    Journal of visceral surgery, 2012, Volume: 149, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Camptothecin; Colo

2012
Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
    American journal of clinical oncology, 2013, Volume: 36, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorecta

2013
Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment.
    Neuromuscular disorders : NMD, 2012, Volume: 22, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiomyopathies; Colo

2012
Adenovirus KH901 promotes 5-FU antitumor efficacy and S phase in LoVo cells.
    Frontiers in bioscience (Elite edition), 2012, 06-01, Volume: 4, Issue:7

    Topics: Adenoviridae; Antimetabolites, Antineoplastic; bcl-2-Associated X Protein; Blotting, Western; Cell L

2012
A complex oncosurgical approach to increasing the resectability of colorectal cancer metastases - a case report.
    Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2014, Volume: 158, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Emboliza

2014
[A case of advanced primary colorectal carcinoma accompanied by liver metastasis in which ileus developed due to marked fibrosis with cicatricial formation in primary colorectal cancer treated by chemotherapy including bevacizumab].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2012, Volume: 109, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carc

2012
Evaluating coagulation disorders in the use of bevacizumab for metastatic colorectal cancer by thrombelastography.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bloo

2012
MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer.
    Oncogene, 2013, Apr-11, Volume: 32, Issue:15

    Topics: 3' Untranslated Regions; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin;

2013
Effects of reduced dose intensity of modified FOLFOX6 in patients with metastatic or recurrent colorectal cancer.
    Oncology research, 2011, Volume: 19, Issue:10-11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu

2011
Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:11

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2012
[Comparison of targeting distribution of two kinds of fluorouracil magnetic albumin microspheres in colorectal neoplasm nude mice in vivo under magnetic field].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2012, Volume: 15, Issue:6

    Topics: Animals; Colorectal Neoplasms; Fluorouracil; Humans; Magnetics; Mice; Mice, Nude; Microspheres; Tiss

2012
Preventive effect of traditional Japanese medicine on neurotoxicity of FOLFOX for metastatic colorectal cancer: a multicenter retrospective study.
    Anticancer research, 2012, Volume: 32, Issue:7

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2012
Efficacy of combination chemotherapy using oral fluoropyrimidine S-1 with oxaliplatin (SOX) against colorectal cancer in vivo.
    Anticancer research, 2012, Volume: 32, Issue:7

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycy

2012
Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome.
    BMJ case reports, 2010, Nov-09, Volume: 2010

    Topics: 2-Propanol; Acetates; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Camphor; Capecita

2010
[A case of colorectal neuroendocrine carcinoma effectively treated with bevacizumab+levofolinate+5-FU chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:7

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2012
Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: a retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG).
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic;

2012
Conditionally replicative adenovirus-based mda-7/IL-24 expression enhances sensitivity of colon cancer cells to 5-fluorouracil and doxorubicin.
    Journal of gastroenterology, 2013, Volume: 48, Issue:2

    Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apopto

2013
A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing.
    Oncotarget, 2012, Volume: 3, Issue:7

    Topics: Animals; Antibodies, Monoclonal; Antibody Specificity; Colorectal Neoplasms; Dose-Response Relations

2012
Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Oct-01, Volume: 18, Issue:19

    Topics: Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Camptot

2012
Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer.
    Surgery, 2012, Volume: 152, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Cell Cy

2012
Ursolic acid inhibits growth and metastasis of human colorectal cancer in an orthotopic nude mouse model by targeting multiple cell signaling pathways: chemosensitization with capecitabine.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Sep-15, Volume: 18, Issue:18

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis;

2012
Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
    Journal of surgical oncology, 2013, Volume: 107, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2013
A rare hematological adverse event induced by bevacizumab: severe thrombocytopenia.
    The American journal of medicine, 2012, Volume: 125, Issue:8

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera

2012
N-3 PUFAs have antiproliferative and apoptotic effects on human colorectal cancer stem-like cells in vitro.
    The Journal of nutritional biochemistry, 2013, Volume: 24, Issue:5

    Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferat

2013
Effectiveness of oxaliplatin desensitization protocols.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:3

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape

2013
New strategy in hepatic metastatic colorectal cancer: tomotherapy and capecitabine followed by hepatic surgical resection.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:5

    Topics: Antineoplastic Agents; Capecitabine; Carcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Fluorou

2012
Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Oct-01, Volume: 18, Issue:19

    Topics: Biomarkers, Pharmacological; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Galanin;

2012
A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.
    The pharmacogenomics journal, 2013, Volume: 13, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2013
Genetic disruption of USP9X sensitizes colorectal cancer cells to 5-fluorouracil.
    Cancer biology & therapy, 2012, Volume: 13, Issue:13

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; F

2012
[Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptot

2012
A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: contrast-enhanced ultrasonography and histological examination.
    Journal of surgical oncology, 2013, Volume: 107, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2013
Molecular marker identification for relapse prediction in 5-FU-based adjuvant chemotherapy in gastric and colorectal cancers.
    PloS one, 2012, Volume: 7, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor

2012
The antitumor natural compound falcarindiol promotes cancer cell death by inducing endoplasmic reticulum stress.
    Cell death & disease, 2012, Aug-23, Volume: 3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Diyne

2012
In vivo real-time imaging of chemotherapy response on the liver metastatic tumor microenvironment using multiphoton microscopy.
    Oncology reports, 2012, Volume: 28, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal

2012
Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers.
    The Journal of pathology, 2013, Volume: 229, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Autophagy-Related Protein 12; Autoph

2013
[Expressions of orotate phosphoribosyltransferase in colorectal carcinoma and its correlations with toxicities of chemotherapy].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2012, Volume: 32, Issue:8

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; In

2012
Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden -- a clinical practice model approach.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:7

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cap

2012
Capecitabine-induced chest pain relieved by diltiazem.
    The American journal of cardiology, 2012, Dec-01, Volume: 110, Issue:11

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Anus Neoplasms; Calcium Channel Blockers; Cap

2012
Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence.
    International journal of clinical oncology, 2013, Volume: 18, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap

2013
Ovarian metastasis is associated with retroperitoneal lymph node relapses in women treated for colorectal peritoneal carcinomatosis.
    Annals of surgical oncology, 2013, Volume: 20, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2013
The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
    Angiogenesis, 2013, Volume: 16, Issue:1

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Anti

2013
Inhibition of monocarboxylate transporter 2 induces senescence-associated mitochondrial dysfunction and suppresses progression of colorectal malignancies in vivo.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:11

    Topics: Animals; Autophagy; Biomarkers, Tumor; Cell Cycle; Cell Nucleus; Cell Proliferation; Cell Transforma

2012
Delayed repeated intraperitoneal chemotherapy after cytoreductive surgery for colorectal and appendiceal carcinomatosis.
    Diseases of the colon and rectum, 2012, Volume: 55, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Colorectal Neopl

2012
RHBDD2: a 5-fluorouracil responsive gene overexpressed in the advanced stages of colorectal cancer.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012, Volume: 33, Issue:6

    Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Case-Control Studies; Colon;

2012
[Relationship between single nucleotide polymorphism in repair gene XPD751 and prognosis in colorectal carcinoma patients].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi

2012
Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
    Annals of surgery, 2012, Volume: 256, Issue:4

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto

2012
Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity.
    Current topics in medicinal chemistry, 2012, Volume: 12, Issue:15

    Topics: Aged; Biomarkers; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Huma

2012
Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy.
    International journal of colorectal disease, 2013, Volume: 28, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cel

2013
Predicting 5-fluorouracil toxicity in colorectal cancer patients from peripheral blood cell telomere length: a multivariate analysis.
    British journal of cancer, 2012, Oct-23, Volume: 107, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colo

2012
Assam Bora rice starch based biocompatible mucoadhesive microsphere for targeted delivery of 5-fluorouracil in colorectal cancer.
    Molecular pharmaceutics, 2012, Nov-05, Volume: 9, Issue:11

    Topics: Adhesiveness; Animals; Antimetabolites, Antineoplastic; Coated Materials, Biocompatible; Colorectal

2012
Extensive characterization of sphere models established from colorectal cancer cell lines.
    Cellular and molecular life sciences : CMLS, 2013, Volume: 70, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; C

2013
A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients.
    International journal of clinical oncology, 2013, Volume: 18, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2013
Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg.
    American journal of therapeutics, 2012, Volume: 19, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2012
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
    The oncologist, 2012, Volume: 17, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combin

2012
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma.
    Radiation oncology (London, England), 2012, Sep-27, Volume: 7

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycy

2012
First description of an uterine perforation potentially imputable to treatment with bevacizumab.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:8

    Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2012
Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
    Clinical colorectal cancer, 2013, Volume: 12, Issue:1

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2013
Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice.
    Future oncology (London, England), 2012, Volume: 8, Issue:9

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva

2012
Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
    International journal of cancer, 2013, May-01, Volume: 132, Issue:9

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2013
Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
    Journal of the American College of Surgeons, 2013, Volume: 216, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopla

2013
Effects of ellagic acid on chemosensitivity to 5-fluorouracil in colorectal carcinoma cells.
    Anticancer research, 2012, Volume: 32, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X

2012
S-1 in colorectal cancer: a new standard of care?
    The Lancet. Oncology, 2012, Volume: 13, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; D

2012
Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer.
    The oncologist, 2012, Volume: 17, Issue:11

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape

2012
Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases.
    Chinese medical journal, 2012, Volume: 125, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Car

2012
Cytotoxicity and antitumour activity of 5-fluorouracil-loaded polyhydroxybutyrate and cellulose acetate phthalate blend microspheres.
    Journal of microencapsulation, 2013, Volume: 30, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cellulose; Colorectal Neoplasms; Drug Ca

2013
Laparoscopic resection of colorectal cancer facilitates simultaneous surgery of synchronous liver metastases.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2013, Volume: 15, Issue:1

    Topics: Adult; Aged; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Ad

2013
[Chronotherapy with 5-fluorouracil folinic acid and oxaliplatin delivered over 48 hours every second week in colorectal cancer. The CHC-Liège experience (Belgium)].
    Pathologie-biologie, 2013, Volume: 61, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal N

2013
High and low dose folinic acid, 5-fluorouracil bolus and continuous infusion for poor-prognosis patients with advanced colorectal carcinoma.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

2012
Safety and effectiveness of oxaliplatin-based chemotherapy regimens in adults 75 years and older with colorectal cancer.
    Clinical colorectal cancer, 2013, Volume: 12, Issue:1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combi

2013
Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Nov-15, Volume: 18, Issue:22

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2012
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:6

    Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecita

2012
Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors.
    Oncology, 2013, Volume: 84, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2013
HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy.
    Journal of surgical oncology, 2013, Volume: 107, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2013
Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer.
    Journal of gastrointestinal cancer, 2013, Volume: 44, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Ne

2013
Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer.
    British journal of cancer, 2012, Dec-04, Volume: 107, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell L

2012
Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Feb-20, Volume: 31, Issue:6

    Topics: Alleles; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor;

2013
Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:5

    Topics: Age Factors; Aged; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, A

2013
Pharmacokinetics of 5-fluorouracil and increased hepatic dihydropyrimidine dehydrogenase activity levels in 1,2-dimethylhydrazine-induced colorectal cancer model rats.
    European journal of drug metabolism and pharmacokinetics, 2013, Volume: 38, Issue:3

    Topics: 1,2-Dimethylhydrazine; Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil

2013
CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines.
    Stem cells translational medicine, 2012, Volume: 1, Issue:8

    Topics: AC133 Antigen; Activated-Leukocyte Cell Adhesion Molecule; Aldehyde Dehydrogenase 1 Family; Animals;

2012
Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2013, Volume: 67, Issue:1

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calci

2013
Importance of methanogenic flora in intestinal toxicity during 5-fluorouracil therapy for colon cancer.
    Journal of clinical gastroenterology, 2013, Volume: 47, Issue:1

    Topics: Antimetabolites, Antineoplastic; Carcinoma; Colon; Colorectal Neoplasms; Female; Fluorouracil; Human

2013
Hepatic arterial infusion of irinotecan, 5-Fluorouracil and leucovorin in patients with liver metastases from colorectal carcinoma.
    Anticancer research, 2012, Volume: 32, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2012
Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer.
    Yonsei medical journal, 2013, Jan-01, Volume: 54, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumo

2013
Multidrug resistance protein 2 genetic polymorphism and colorectal cancer recurrence in patients receiving adjuvant FOLFOX-4 chemotherapy.
    Molecular medicine reports, 2013, Volume: 7, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Femal

2013
Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy.
    Annals of surgery, 2013, Volume: 257, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother

2013
UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil.
    World journal of gastroenterology, 2012, Dec-07, Volume: 18, Issue:45

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic;

2012
Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
    Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2013
CEA fluctuation during a single fluorouracil-based chemotherapy cycle for metastatic colorectal cancer.
    Anticancer research, 2013, Volume: 33, Issue:1

    Topics: Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil

2013
[Two cases of long-term survival of metastatic colorectal cancer following treatment with polysaccharide K and mFOLFOX6 therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therap

2012
[Predictive value of Köhne's index on the efficacy of FOLFIRI regimen in the treatment of unresectable liver metastatsis of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2012
Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:3

    Topics: Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms

2013
Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer.
    Clinical colorectal cancer, 2013, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2013
Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.
    Cancer science, 2013, Volume: 104, Issue:4

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camp

2013
Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2013, Volume: 17, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antibodies, Monoclonal, Humanized; Antineoplastic

2013
[Cost analysis of XELOX and FOLFOX-4 chemotherapy regimens for colorectal carcinoma].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2012, Volume: 25, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colore

2012
The upregulation of dihydropyrimidine dehydrogenase in liver is involved in acquired resistance to 5-fluorouracil.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:7

    Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Proliferation; Colorectal Neoplasm

2013
Association between polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln genes and prognosis of colorectal cancer in a Chinese population.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Colorectal Neoplasms; DNA-Binding Prot

2012
Cardiotoxicity with 5-fluorouracil based agents: rechallenge cannot currently be safely advised.
    The American journal of cardiology, 2013, Feb-01, Volume: 111, Issue:3

    Topics: Chest Pain; Colorectal Neoplasms; Deoxycytidine; Diltiazem; Female; Fluorouracil; Humans; Male

2013
Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies.
    Cancer medicine, 2012, Volume: 1, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Colorectal Neoplasms; Female; Fl

2012
Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.
    Digestion, 2013, Volume: 87, Issue:1

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2013
Pilot study of the early start of chemotherapy after resection of primary colorectal cancer with distant metastases (Pearl Star 01).
    World journal of surgical oncology, 2013, Feb-07, Volume: 11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colectom

2013
Should isolated peritoneal carcinomatosis from colorectal cancer be sub-classified into stage IVB in era of modern chemotherapy?
    Techniques in coloproctology, 2013, Volume: 17, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2013
Association between MTHFR polymorphisms and overall survival of colorectal cancer patients in Northeast China.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:1

    Topics: Aged; Asian People; Chemotherapy, Adjuvant; China; Colorectal Neoplasms; Female; Fluorouracil; Follo

2013
New studies highlight benefit of Xeloda in new combination treatments for colorectal cancer.
    Expert review of anticancer therapy, 2002, Volume: 2, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Clinical Tria

2002
ERBITUX as a single agent and in combination in colorectal carcinoma.
    Expert review of anticancer therapy, 2002, Volume: 2, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2002
Capecitabine in the management of colorectal cancer.
    Expert review of anticancer therapy, 2001, Volume: 1, Issue:3

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxy

2001
Colorectal cancer. A novel approach to adjuvant chemotherapy with fluoropyrimidines.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2002, Volume: 34, Issue:6

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans;

2002
Another NICE mess.
    The Lancet. Oncology, 2002, Volume: 3, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2002
[Preliminary clinical evaluation of low-dose cisplatin and continuous infusion of 5-FU (LFP) chemotherapy after weekly high-dose 5-FU therapy for the treatment of liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dose-Response

2002
[The prevention of negative side effects in homeochemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:7

    Topics: Abdominal Pain; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neop

2002
Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
    Molecular medicine (Cambridge, Mass.), 2002, Volume: 8, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms;

2002
Increased sensitivity of colorectal cancer cell lines with microsatellite instability to 5-fluorouracil in vitro.
    Chinese medical journal, 2002, Volume: 115, Issue:7

    Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Base Pair Mismatch; Carrier P

2002
Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer.
    American journal of clinical oncology, 2002, Volume: 25, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne

2002
Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer.
    World journal of gastroenterology, 2002, Volume: 8, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2002
A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer.
    British journal of cancer, 2002, Aug-12, Volume: 87, Issue:4

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2002
FDA evaluating oxaliplatin for advanced colorectal cancer treatment.
    Journal of the National Cancer Institute, 2002, Aug-21, Volume: 94, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug

2002
A biological perspective on the selection of stage II colorectal cancer patients for adjuvant chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials

2002
Relationships between body composition parameters and fluorouracil pharmacokinetics.
    British journal of clinical pharmacology, 2002, Volume: 54, Issue:2

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; Body Surface Area; Body

2002
Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo.
    International journal of cancer, 2002, Sep-20, Volume: 101, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cisplatin; Color

2002
Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma?
    Dermatology (Basel, Switzerland), 2002, Volume: 205, Issue:2

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Colorectal Neoplasms

2002
Chronomodulated chemotherapy in advanced colorectal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-15, Volume: 20, Issue:18

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Clinical Trials as To

2002
[Study of cut-off values for orotate phosphoribosyl transferase (OPRT) in colorectal cancer using maximal chi 2 values].
    Nihon Geka Gakkai zasshi, 2002, Volume: 103, Issue:8

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Fluorouraci

2002
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
    British journal of cancer, 2002, Sep-09, Volume: 87, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2002
SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer.
    British journal of cancer, 2002, Sep-09, Volume: 87, Issue:6

    Topics: Antimetabolites, Antineoplastic; Biomarkers; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosome

2002
DCR3 locus is a predictive marker for 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer.
    International journal of cancer, 2002, Nov-20, Volume: 102, Issue:3

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Chromosomes, Human, Pair 20; Colorect

2002
Gender differences in the dihydropyrimidine dehydrogenase expression of colorectal cancers.
    Cancer letters, 2002, Dec-15, Volume: 188, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil

2002
Thymidine phosphorylase and dihydropyrimidine dehydrogenase activity in colorectal carcinoma and patients prognosis.
    Langenbeck's archives of surgery, 2002, Volume: 387, Issue:5-6

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplas

2002
[Colorectal cancer: curative treatment and surveillance].
    Revue medicale de la Suisse romande, 2002, Volume: 122, Issue:9

    Topics: Colonoscopy; Colorectal Neoplasms; Fluorouracil; Humans; Immunosuppressive Agents; Neoadjuvant Thera

2002
Evaluation of aggressively treated patients with unresectable multiple liver metastases from colorectal cancer.
    Diseases of the colon and rectum, 2002, Volume: 45, Issue:11

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Thera

2002
[Therapy of colorectal carcinoma in internal medicine].
    Praxis, 2002, Oct-23, Volume: 91, Issue:43

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co

2002
Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines.
    FEBS letters, 2002, Nov-20, Volume: 531, Issue:3

    Topics: Antimetabolites, Antineoplastic; Base Sequence; Colorectal Neoplasms; DNA; DNA Primers; Drug Resista

2002
Superior venocaval obstruction secondary to central venous catheter-related thromboses in two patients with metastatic colorectal carcinoma receiving weekly 5-flurouracil. Should adjusted-dose warfarin be used as thromboprophylaxis?
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2002, Volume: 13, Issue:8

    Topics: Aged; Anticoagulants; Antineoplastic Agents; Catheterization, Central Venous; Colorectal Neoplasms;

2002
Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
    Clinical colorectal cancer, 2001, Volume: 1, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorou

2001
25th European Society for Medical Oncology Congress. Hamburg, Germany. October 13-17, 2000.
    Clinical colorectal cancer, 2001, Volume: 1, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy

2001
First-line capecitabine is as effective as 5-fluorouracil/leucovorin in treating advanced colorectal cancer.
    Clinical colorectal cancer, 2001, Volume: 1, Issue:1

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials, Phase III as T

2001
Clinical colorectal cancer: thymidylate synthase as a molecular biomarker.
    Clinical colorectal cancer, 2001, Volume: 1, Issue:3

    Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Immu

2001
Capecitabine combinations in the treatment of advanced colorectal cancer.
    Clinical colorectal cancer, 2001, Volume: 1, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic

2001
Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites.
    Clinical colorectal cancer, 2001, Volume: 1, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Fluorourac

2001
Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2003, Jan-05, Volume: 783, Issue:1

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Chromatography, High Pressure Liquid; Colorectal Neop

2003
Oxaliplatin: a welcome addition to our therapeutic armamentarium.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro

2002
Toxicity analysis of the 5-day bolus 5-fluorouracil/folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: a concern about dose.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2002
Irinotecan/5-fluorouracil/leucovorin in advanced colorectal cancer: Oncologic Drugs Advisory committee summary.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe

2002
Postmarketing re-evaluation of irinotecan plus 5-fluorouracil/leucovorin for first-line treatment of metastatic colorectal cancer.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe

2002
Lessons learned from the Saltz and Mayo Clinic regimens.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N

2002
Inhibiting 5-fluorouracil breakdown: a broken down approach to 5-fluorouracil modulation.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Syne

2002
Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B

2002
Reg IV, a new member of the regenerating gene family, is overexpressed in colorectal carcinomas.
    International journal of cancer, 2003, Jan-10, Volume: 103, Issue:2

    Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Northern; Ca

2003
Clinical colorectal cancer: oral chemotherapy comes of age.
    Clinical colorectal cancer, 2001, Volume: 1, Issue:2

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl

2001
Functional polymorphism of the thymidylate synthase gene in colorectal cancer accompanied by frequent loss of heterozygosity.
    Japanese journal of cancer research : Gann, 2002, Volume: 93, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Humans; Loss of Heterozy

2002
Combination of thymidine phosphorylase gene transfer and deoxyinosine treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivo.
    Molecular cancer therapeutics, 2001, Volume: 1, Issue:2

    Topics: Animals; Apoptosis; Cell Division; Colorectal Neoplasms; Combined Modality Therapy; Drug Synergism;

2001
[Gleaning from the American Oncology Congress. A new standard in colorectal carcinoma].
    MMW Fortschritte der Medizin, 2002, Oct-10, Volume: 144, Issue:41

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

2002
Transmission of apoptosis in human colorectal tumor cells exposed to capecitabine, Xeloda, is mediated via Fas.
    Molecular cancer therapeutics, 2002, Volume: 1, Issue:11

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Bystander Effect; Capecitabine; Cell Division; Cell Memb

2002
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2002
Systemic chemotherapy for metastatic colorectal cancer: reasons to combine.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2002
[Resection made possible following hepatic arterial infusion in 2 cases of hepatic metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:12

    Topics: Aged; Aged, 80 and over; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; Hepat

2002
[5-FU pharmacokinetic study of 5-FU hepato-arterial infusion with oral UFT].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:12

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2002
[Hepatectomy and intraarterial infusion chemotherapy for liver metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:12

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Infusions,

2002
[Evaluation of hepatic arterial infusion chemotherapy with levofolinate (l-LV) and 5-fluorouracil (5-FU) for multiple liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

2002
[Hepatic arterial infusion of IL-2 and chemotherapy for unresectable liver metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:12

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colectomy; Colorectal Neoplasms; Female; F

2002
[Pharmacological study on levofolinate in intraperitoneal leucovorin-5-FU chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu

2002
Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU.
    International journal of clinical oncology, 2002, Volume: 7, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Survival; Clinical Enzyme Test

2002
Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
    Clinical pharmacology and therapeutics, 2002, Volume: 72, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Chemotherapy, Adjuva

2002
Variability in administration of 5-fluorouracil and folinic acid in standard treatment regimens for advanced colorectal cancer.
    Internal medicine journal, 2002, Volume: 32, Issue:12

    Topics: Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neoplasms; Fluorouracil; Humans; Infus

2002
Choice of chemotherapy regimen for advanced colorectal cancer.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2002, Volume: 14, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Health Care Surv

2002
Design and analysis of non-inferiority mortality trials in oncology.
    Statistics in medicine, 2003, Jan-30, Volume: 22, Issue:2

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Confidence Intervals; Controlle

2003
Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:12 Suppl N

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cl

2002
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity.
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:12 Suppl N

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Celecoxib; Colorectal Neoplasms;

2002
[Chemotherapy improves prognosis in colorectal carcinoma. Soon oral therapy at home?].
    MMW Fortschritte der Medizin, 2002, Nov-14, Volume: 144, Issue:46

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials,

2002
[Effectiveness of chemotherapy for outpatients with gastric or colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29 Suppl 3

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplati

2002
[Rules to carry out hepatic arterial infusion chemotherapy at home for patients with liver metastasis of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Fluorouracil; Hepat

2002
Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
    Cytokine, 2002, Nov-24, Volume: 20, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2002
Safety and efficacy of outpatient treatment with CPT-11 plus bolus folinic acid/5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer.
    Anti-cancer drugs, 2003, Volume: 14, Issue:1

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorect

2003
Indicators for surgical resection and intraoperative radiation therapy for pelvic recurrence of colorectal cancer.
    Diseases of the colon and rectum, 2003, Volume: 46, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2003
Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age.
    The British journal of surgery, 2003, Volume: 90, Issue:2

    Topics: Adolescent; Adult; Age Factors; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal

2003
Technical complications of continuous intra-arterial chemotherapy with 5-fluorodeoxyuridine and 5-fluorouracil for colorectal liver metastases.
    Surgery, 2003, Volume: 133, Issue:1

    Topics: Antimetabolites, Antineoplastic; Catheterization; Colorectal Neoplasms; Disease-Free Survival; Femal

2003
Weekly oxaliplatin, high-dose folinic acid and 24h-5-fluorouracil (FUFOX) as salvage therapy in metastatic colorectal cancer patients pretreated with irinotecan and folinic acid/5-fluorouracil regimens.
    Zeitschrift fur Gastroenterologie, 2002, Volume: 40, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cam

2002
Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
    Cancer research, 2003, Feb-01, Volume: 63, Issue:3

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; be

2003
Oxaliplatin (Eloxatin) for advanced colon cancer.
    The Medical letter on drugs and therapeutics, 2003, Jan-20, Volume: 45, Issue:1148

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseas

2003
Hepatic artery infusion for liver metastases from colorectal cancer.
    Lancet (London, England), 2003, Feb-01, Volume: 361, Issue:9355

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe

2003
Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients.
    American journal of clinical oncology, 2003, Volume: 26, Issue:1

    Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouraci

2003
Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice.
    International journal of cancer, 2003, Apr-20, Volume: 104, Issue:4

    Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Division; Cell Survival; Colorectal Neoplasms; End

2003
Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines.
    International journal of cancer, 2003, Apr-20, Volume: 104, Issue:4

    Topics: Active Transport, Cell Nucleus; Apoptosis; Colorectal Neoplasms; Disulfiram; DNA; Drug Synergism; Fl

2003
Pattern mixture models for longitudinal quality of life studies in advanced stage disease.
    Statistics in medicine, 2003, Mar-15, Volume: 22, Issue:5

    Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as T

2003
Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-01, Volume: 21, Issue:5

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2003
Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy.
    Clinical colorectal cancer, 2003, Volume: 2, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Female; Flu

2003
Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer.
    Clinical colorectal cancer, 2003, Volume: 2, Issue:4

    Topics: Antidiarrheals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Tri

2003
Quality of life in patients with colorectal metastasis and intrahepatic chemotherapy.
    Annals of surgical oncology, 2003, Volume: 10, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2003
[Cytoreductive surgery as an alternative to palliative operations in oncology (the model of treatment of stage IV colorectal cancer)].
    Vestnik khirurgii imeni I. I. Grekova, 2002, Volume: 161, Issue:6

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Combined Che

2002
Population pharmacokinetics of oxaliplatin.
    Cancer chemotherapy and pharmacology, 2003, Volume: 51, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2003
A pilot study of adjuvant intraperitoneal 5-fluorouracil using 4% icodextrin as a novel carrier solution.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2003, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Co

2003
Chromosomal imbalance maps of human 5FU-resistant colorectal cancer cell lines: implications in the analysis of 5FU-acquired resistance mechanisms.
    International journal of oncology, 2003, Volume: 22, Issue:5

    Topics: Antimetabolites, Antineoplastic; Cell Survival; Chromosome Aberrations; Colorectal Neoplasms; Drug R

2003
5-Fluorouracil efficiently enhanced apoptosis induced by adenovirus-mediated transfer of caspase-8 in DLD-1 colon cancer cells.
    The journal of gene medicine, 2003, Volume: 5, Issue:4

    Topics: Adenoviridae; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Caspase 8; Caspase 9; Caspases;

2003
Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status.
    Oncology, 2003, Volume: 64, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A

2003
Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:5

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bacitracin; Camptothecin; Colo

2003
[Influence of combination of low dosage 131I-labeled anti-carcinoembryonic antigen antibody C50 and 5-fluorouracil on tumor growth of colorectal cancer xenografts in nude mice].
    Ai zheng = Aizheng = Chinese journal of cancer, 2003, Volume: 22, Issue:4

    Topics: Animals; Antibodies; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal Neoplasms

2003
Chromosomal imbalances associated with acquired resistance to fluoropyrimidines in human colorectal cancer cells.
    European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:7

    Topics: Antimetabolites, Antineoplastic; Chromosome Aberrations; Colorectal Neoplasms; DNA, Neoplasm; Drug R

2003
Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma.
    International journal of clinical oncology, 2003, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Biopsy, Needle; Cell Division; Co

2003
Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Alleles; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deo

2003
5-fluorouracil, folinic acid and oxaliplatin administered via hepatic arterial infusion as regional second-line therapy for advanced colorectal cancer.
    Oncology, 2003, Volume: 64, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo

2003
Hepatic artery chemotherapy and colorectal liver metastases.
    Lancet (London, England), 2003, May-17, Volume: 361, Issue:9370

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Floxuridine; Fluor

2003
Hepatic artery chemotherapy and colorectal liver mestastases.
    Lancet (London, England), 2003, May-17, Volume: 361, Issue:9370

    Topics: Antineoplastic Agents; Catheters, Indwelling; Colorectal Neoplasms; Controlled Clinical Trials as To

2003
Oxaliplatin for colorectal cancer in the United States: better late than never.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jun-01, Volume: 21, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Approval; Europe; Fluorou

2003
Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines.
    International journal of cancer, 2003, Aug-10, Volume: 106, Issue:1

    Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Azacitidine; Base Pair Mismat

2003
[The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2003, Volume: 25, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Cisplatin; Colore

2003
Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats.
    Cancer research, 2003, Jul-01, Volume: 63, Issue:13

    Topics: Adenocarcinoma; Animals; Colorectal Neoplasms; Disease Models, Animal; Female; Fluorine Radioisotope

2003
Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens.
    Cancer science, 2003, Volume: 94, Issue:7

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA Primers; Female; Fluorouracil; Gene Expre

2003
[Modeling 5-FU clearance during a chronomodulated infusion].
    Pathologie-biologie, 2003, Volume: 51, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Chronothe

2003
Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889.
    International journal of cancer, 2003, Sep-20, Volume: 106, Issue:5

    Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Capecitabine; Cell Division; Colorectal

2003
Chemotherapy with irinothecan, 5-fluorouracil and folinic acid in the first-line management of advanced colorectal carcinoma: retrospective study.
    Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Fr

2003
Hepatic cryotherapy and regional chemotherapy with or without resection for liver metastases from colorectal carcinoma: how many are too many?
    Cancer, 2003, Jul-15, Volume: 98, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Moda

2003
Impact of platinum complexes on dihydropyrimidine dehydrogenase activity in 5-fluorouracil-treated patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dihydr

2003
Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Aug-01, Volume: 21, Issue:15

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2003
[A case report of complete remission of liver metastases from colorectal cancer treated with continuous hepatic arterial infusion].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modal

2003
Cancer chronotherapy: principles, applications, and perspectives.
    Cancer, 2003, Aug-15, Volume: 98, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronobiology Pheno

2003
CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-01, Volume: 9, Issue:8

    Topics: Aged; Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Neoplasms; CpG Islands; DNA Methyl

2003
Multifocal inflammatory leukoencephalopathy: use of thallium-201 SPECT and proton MRS.
    Journal of Korean medical science, 2003, Volume: 18, Issue:4

    Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Aspartic Acid; Axons; Biopsy; Brain; Brain

2003
Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2003, Volume: 15, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci

2003
Onycholysis associated with capecitabine in combination with irinotecan in two patients with colorectal cancer.
    Journal of the National Cancer Institute, 2003, Aug-20, Volume: 95, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De

2003
Validation of the role of angiogenesis as a chemotherapeutic target.
    Clinical colorectal cancer, 2003, Volume: 3, Issue:2

    Topics: Adaptation, Physiological; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal,

2003
Adding a humanized antibody to vascular endothelial growth factor (Bevacizumab, Avastin) to chemotherapy improves survival in metastatic colorectal cancer.
    Clinical colorectal cancer, 2003, Volume: 3, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2003
Capecitabine in combination with irinotecan or oxaliplatin in advanced colorectal cancer.
    Clinical colorectal cancer, 2003, Volume: 3, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De

2003
Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials.
    Clinical colorectal cancer, 2003, Volume: 3, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore

2003
Anything in modulation?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo

2003
Quantitation of dihydropyrimidine dehydrogenase (DPD) mRNA expression levels in normal colon and colorectal cancer tumor paraffin-embedded tissue specimens.
    Anti-cancer drugs, 2003, Volume: 14, Issue:7

    Topics: Antineoplastic Agents; Colon; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil

2003
Another study of how to give fluorouracil?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Oct-15, Volume: 21, Issue:20

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo

2003
Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study.
    Journal of pain and symptom management, 2003, Volume: 26, Issue:3

    Topics: Aged; Aged, 80 and over; Amifostine; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea

2003
Bevacizumab, bleeding, thrombosis, and warfarin.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Sep-15, Volume: 21, Issue:18

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antineoplastic Combined C

2003
Can colorectal cancer patients with thymidylate synthase-overexpressing liver metastases have an overall survival advantage with hepatic arterial infusion alone?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Sep-15, Volume: 21, Issue:18

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Floxuridine; Fluorouraci

2003
A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
    PharmacoEconomics, 2003, Volume: 21, Issue:14

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Canada; Clinical Trials, Phase III as T

2003
Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Sep-01, Volume: 9, Issue:10 Pt 1

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuva

2003
Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Oct-01, Volume: 21, Issue:19

    Topics: Adenocarcinoma; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antigens, Neoplasm; Antineo

2003
[Liposome encapsulation of cystostatic drugs and starch microspheres improve tumor targeting in locoregional therapy. An animal experiment study of CC 531 liver tumor].
    Langenbecks Archiv fur Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress, 1998, Volume: 115, Issue:Suppl I

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Delivery System

1998
Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene.
    Cancer research, 2003, Sep-15, Volume: 63, Issue:18

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasm

2003
Pharmacokinetics of 5-fluorouracil following hepatic intra-arterial infusion in a VX2 hepatic metastasis model.
    Japanese journal of clinical oncology, 2003, Volume: 33, Issue:8

    Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Models, Animal; Drug Adminis

2003
Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.
    Anti-cancer drugs, 2003, Volume: 14, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia

2003
Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs.
    Journal of cancer research and clinical oncology, 2003, Volume: 129, Issue:12

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcin

2003
Capecitabine in colorectal, breast, and other solid tumors: novel therapeutic approaches. Selected abstracts from ASCO 2003.
    Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:8 Suppl 8

    Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deox

2003
Differential expression of thymidylate synthase in colorectal tumors and matched lymph nodes: impact on adjuvant treatment.
    The American surgeon, 2003, Volume: 69, Issue:10

    Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluorouracil

2003
[Evaluation of hepatic arterial infusion chemotherapy with low-dose leucovorin and 5-FU from reservoir for multiple liver metastases by colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colorectal Neoplasms; D

2003
Microsatellite instability in colon cancer.
    The New England journal of medicine, 2003, Oct-30, Volume: 349, Issue:18

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans;

2003
Catheter occlusion by calcium carbonate: a well-known problem persists in spite of better knowledge.
    Onkologie, 2003, Volume: 26, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium Carbonate; Catheterization, Central Venous;

2003
[Radiofrequency ablation therapy combined with intrahepatic arterial infusion chemotherapy for liver metastasis of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Cisplati

2003
[Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dihydrouracil Deh

2003
[Concentration of 5-FU after hepatic artery infusion chemotherapy for liver metastases of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule;

2003
[Relationship between effectiveness of hepatic artery injection chemotherapy and serum VEGF].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoembryonic Antigen; Chemoembo

2003
[Efficacy of circadian chronotherapy via hepatic arterial infusion].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colorectal Neoplasms; Female; F

2003
[Validity of two-hour continuous hepatic arterial infusion chemotherapy with low-dose 5-FU for unresectable liver metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

2003
[Effect of cimetidine with chemotherapy on stage IV colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Colorectal

2003
Oxaliplatin/fluorouracil/leucovorin in advanced colorectal carcinoma: an asian experience.
    The Annals of pharmacotherapy, 2003, Volume: 37, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Colorectal Neoplasms; Fem

2003
In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength.
    Cancer research, 2003, Nov-15, Volume: 63, Issue:22

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fl

2003
CD44 variant 6 expression predicts response to treatment in advanced colorectal cancer.
    Oncology reports, 2004, Volume: 11, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2004
Scheduling of fluorouracil: a forget-me-not in the jungle of doublets.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

2004
Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Cell Cycle Proteins; Colorectal Neoplasms; DNA-Binding Pro

2004
[A new systemic combination chemotherapy to be provided at home for patients with unresectable recurrent colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administration

2003
Heterozygote deficiency in thymidylate synthase enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patients.
    International journal of cancer, 2004, Mar-01, Volume: 108, Issue:6

    Topics: 3' Untranslated Regions; Aged; Case-Control Studies; Colorectal Neoplasms; Diet; DNA; Electrophoresi

2004
[Clinical benefit of bronchial arterial infusion chemotherapy to pulmonary metastasis from colorectal cancer--report of two cases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Cisplatin; Colorectal Neoplasms;

2003
Correlation of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase with sensitivity of gastrointestinal cancer cells to 5-fluorouracil and 5-fluoro-2'-deoxyuridine.
    World journal of gastroenterology, 2004, Jan-15, Volume: 10, Issue:2

    Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; Dihydrouracil Dehydrogenase

2004
An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy.
    Cell research, 2003, Volume: 13, Issue:6

    Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cu

2003
Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone.
    Cancer letters, 2004, Feb-10, Volume: 204, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, T

2004
First-line hepatic infusion of pirarubicin in patients with isolated liver metastases: is it really promising?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N

2004
Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer.
    Gastroenterology, 2004, Volume: 126, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Neoplasms; Female; Fluorouracil; G

2004
Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2003, Volume: 42, Issue:8

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

2003
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients.
    Proceedings of the National Academy of Sciences of the United States of America, 2004, Mar-02, Volume: 101, Issue:9

    Topics: Chromosomes, Human, Pair 18; Colorectal Neoplasms; DNA, Neoplasm; Drug Resistance, Neoplasm; Electro

2004
Management of patients with persistent chest pain and ST-segment elevation during 5-fluorouracil treatment: report about two cases.
    Italian heart journal : official journal of the Italian Federation of Cardiology, 2003, Volume: 4, Issue:12

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antimetabolites, Antineoplas

2003
Combined 5-fluorouracil/systemic interferon-beta gene therapy results in long-term survival in mice with established colorectal liver metastases.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Feb-15, Volume: 10, Issue:4

    Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Colorectal Neop

2004
Gilbert's syndrome and fluorouracil toxicity in colorectal cancer patients: which correlation?
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2004, Volume: 6, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drug-Related Side Effects an

2004
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
    International journal of molecular medicine, 2004, Volume: 13, Issue:4

    Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C

2004
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
    International journal of molecular medicine, 2004, Volume: 13, Issue:4

    Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C

2004
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
    International journal of molecular medicine, 2004, Volume: 13, Issue:4

    Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C

2004
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells.
    International journal of molecular medicine, 2004, Volume: 13, Issue:4

    Topics: Animals; Antimetabolites; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplasms; C

2004
Associations between polymorphisms in the thymidylate synthase gene, the expression of thymidylate synthase mRNA and the microsatellite instability phenotype of colorectal cancer.
    Oncology reports, 2004, Volume: 11, Issue:4

    Topics: 5' Untranslated Regions; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Chemotherapy, Adjuvant;

2004
19F-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil.
    Anti-cancer drugs, 2004, Volume: 15, Issue:3

    Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorine Radioisotopes; Fluorouracil; Humans; Liver Neopl

2004
Inflammation of actinic keratoses during capecitabine therapy.
    Archives of dermatology, 2004, Volume: 140, Issue:3

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxyc

2004
Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.
    Clinical colorectal cancer, 2004, Volume: 3, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Dihydrouracil Dehydroge

2004
Response to chemotherapy (irinotecan plus 5-fluorouracil) in colorectal carcinoma can be predicted by tumour DNA content.
    Oncology, 2004, Volume: 66, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colore

2004
Assessment of recurrent colorectal cancer following 5-fluorouracil chemotherapy using both 18FDG and 18FLT PET.
    European journal of nuclear medicine and molecular imaging, 2004, Volume: 31, Issue:6

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Dideoxynucleosides; Fluorodeoxyglucose F18; Fluorouraci

2004
Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Mar-15, Volume: 10, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Flu

2004
Successful transfer of frozen-thawed embryos obtained after subtotal colectomy for colorectal cancer and before fluorouracil-based chemotherapy.
    Gynecologic oncology, 2004, Volume: 93, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Combined Mod

2004
The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2004, Volume: 180, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv

2004
[First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2004, Volume: 26, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fem

2004
Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis.
    Cancer chemotherapy and pharmacology, 2004, Volume: 53, Issue:5

    Topics: Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression Regulation,

2004
A longterm follow-up study of thymidylate synthase as a predictor for survival of patients with liver tumours receiving hepatic arterial infusion chemotherapy.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2004, Volume: 30, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Epirubicin; Femal

2004
Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil.
    International journal of oncology, 2004, Volume: 24, Issue:5

    Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm;

2004
Upper extremity deep venous thrombosis in patients with 5-fluorouracil-containing adjuvant chemotherapy--three case reports and a review.
    Acta oncologica (Stockholm, Sweden), 2004, Volume: 43, Issue:1

    Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2004
[Colorectal cancer: what should be the management of primary tumour?].
    La Revue du praticien, 2004, Jan-31, Volume: 54, Issue:2

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colon; Colonoscopy; Colorectal Neoplasms; D

2004
Cryosurgery--a putative approach to molecular-based optimization.
    Cryobiology, 2004, Volume: 48, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Caspase Inhibitors; Caspases; Cell Death; Cell Line, Tumor; Cell S

2004
Influence of FasL gene expression on hepatic metastasis of colorectal carcinoma.
    Hepatobiliary & pancreatic diseases international : HBPD INT, 2004, Volume: 3, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cell Division; Cell Line, Tumor;

2004
Combination of Targeting Gene-ViroTherapy with 5-FU enhances antitumor efficacy in malignant colorectal carcinoma.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2004, Volume: 24, Issue:4

    Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Cell Line; Ce

2004
Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
    Diseases of the colon and rectum, 2004, Volume: 47, Issue:7

    Topics: Adjuvants, Immunologic; Aged; Antimetabolites, Antineoplastic; Carcinoma; Cell Adhesion Molecules; C

2004
Mature results of adjuvant colon cancer trials from the fluorouracil-only era.
    Journal of the National Cancer Institute, 2004, May-19, Volume: 96, Issue:10

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms

2004
Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2004
Influence of high-dose leucovorin and 5-fluorouracil chemotherapy regimen on P wave duration and dispersion.
    Journal of clinical pharmacy and therapeutics, 2004, Volume: 29, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Carcinoma; Colorectal Neoplas

2004
An immediate hemolytic reaction induced by repeated administration of oxaliplatin.
    Transfusion, 2004, Volume: 44, Issue:6

    Topics: Adenocarcinoma; Anemia, Hemolytic, Autoimmune; Antibody Specificity; Antigens; Antineoplastic Agents

2004
PET concerns in bevacizumab treatment.
    Nature medicine, 2004, Volume: 10, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizu

2004
p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy.
    Cancer letters, 2004, Jul-08, Volume: 210, Issue:1

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA, Neoplasm; Female

2004
Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands.
    Clinical therapeutics, 2004, Volume: 26, Issue:4

    Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit

2004
The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines.
    European journal of biochemistry, 2004, Volume: 271, Issue:13

    Topics: Base Sequence; Camptothecin; Cell Division; Cell Line, Tumor; Colorectal Neoplasms; Cyclin-Dependent

2004
Bevacizumab targeted therapy: validation of angiogenesis as a key target for advanced colorectal cancer.
    Clinical colorectal cancer, 2004, Volume: 4, Issue:1

    Topics: Androgen Antagonists; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb

2004
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
    British journal of cancer, 2004, Jul-19, Volume: 91, Issue:2

    Topics: Acyltransferases; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bi

2004
[Thymidylate synthase and dihydropyrimidine dehydrogenase gene expressions in colorectal cancer using the Danenberg tumor profile method].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:6

    Topics: Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Gene Expression Profiling; H

2004
[Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dihydrouracil Deh

2004
[Retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin

2004
[Occlusion of central venous port catheters after simultaneous 24 h infusions of 5-FU and calcium-folinic acid in patients with gastrointestinal cancer].
    Wiener medizinische Wochenschrift (1946), 2004, Volume: 154, Issue:9-10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Carbonate; Catheterization, Central Ve

2004
Mitochondrial p53 levels parallel total p53 levels independent of stress response in human colorectal carcinoma and glioblastoma cells.
    Oncogene, 2004, Aug-19, Volume: 23, Issue:37

    Topics: Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Doxorubicin; Flow Cytome

2004
New treatments for colon cancer.
    BMJ (Clinical research ed.), 2004, Jul-17, Volume: 329, Issue:7458

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cetux

2004
Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to
    Pathology international, 2004, Volume: 54, Issue:8

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2004
Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy.
    Journal of surgical oncology, 2004, Aug-01, Volume: 87, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo

2004
Hepatic artery infusion chemotherapy for metastatic colorectal cancer to the liver at the lahey clinic: comparison between two methods of treatment, surgical versus percutaneous catheter placement.
    American journal of clinical oncology, 2004, Volume: 27, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brachial Artery; Catheterization, Peripheral; Colorect

2004
Increased expression of thymidine phosphorylase in tumor tissue in proportion to TP-expression in primary normal tissue.
    Oncology reports, 2004, Volume: 12, Issue:3

    Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Colon; Colorectal Neoplasms; Enzyme-Linked Immuno

2004
Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
    Investigational new drugs, 2004, Volume: 22, Issue:4

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Intera

2004
Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
    Investigational new drugs, 2004, Volume: 22, Issue:4

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Intera

2004
Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
    Investigational new drugs, 2004, Volume: 22, Issue:4

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Intera

2004
Antiproliferative effects of ZD0473 (AMD473) in combination with 5-fluorouracil or SN38 in human colorectal cancer cell lines.
    Investigational new drugs, 2004, Volume: 22, Issue:4

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; DNA Damage; Drug Intera

2004
Two-stage liver resection and chemotherapy for bilobar colorectal liver metastases.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2004, Volume: 30, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

2004
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Aug-01, Volume: 10, Issue:15

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base

2004
Chemotherapy and survival in colorectal cancer patients with and without microsatellite instability: can MSI be a prognostic marker?
    Gastroenterology, 2004, Volume: 127, Issue:2

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Microsatellite Repeats;

2004
Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer.
    Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:6

    Topics: Administration, Oral; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dihydrouracil

2004
[A new systemic combination chemotherapy to be provided at home for patients with unresectable recurrent colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:1 Suppl

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasm

2003
Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-01, Volume: 10, Issue:17

    Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal

2004
An in vitro short time-high dose drug exposure assay for predicting 5FU-resistance of colorectal cancer.
    Cancer letters, 2004, Oct-28, Volume: 214, Issue:2

    Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Biological Assay; Cell Survival; Colorectal

2004
Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Sep-15, Volume: 22, Issue:18

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molecules; Colorectal Neo

2004
Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5-fluorouracil.
    Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:1

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Docosahexaenoic Acids; Dose-Respon

2005
Thymidylate synthase expression pattern is a prognostic factor in patients of colorectal cancer treated with 5-fluorouracil.
    International journal of oncology, 2004, Volume: 25, Issue:4

    Topics: Aged; Cell Nucleus; Colorectal Neoplasms; Female; Fluorescent Antibody Technique; Fluorouracil; Huma

2004
Roles of infusional high-dose 5-fluorouracil with leucovorin in advanced colorectal cancer.
    Clinical colorectal cancer, 2004, Volume: 4, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N

2004
Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast

2004
Single nucleotide polymorphism in the 5' tandem repeat sequences of thymidylate synthase gene predicts for response to fluorouracil-based chemotherapy in advanced colorectal cancer patients.
    International journal of cancer, 2004, Dec-10, Volume: 112, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2004
Compassionate-use oxaliplatin with bolus 5-fluorouracil/leucovorin in heavily pretreated patients with advanced colorectal cancer.
    Southern medical journal, 2004, Volume: 97, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fema

2004
Bevacizumab proves active in wide range of cancers.
    Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Distribution of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil in mice bearing colorectal cancer xenografts: rationale for therapeutic use and as a positron emission tomography probe for thymidylate synthase.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Oct-01, Volume: 10, Issue:19

    Topics: Animals; Arabinofuranosyluracil; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; HT29 Cel

2004
Fluorouracil induces apoptosis and surface molecule modulation of peripheral blood leukocytes.
    Clinical and laboratory haematology, 2004, Volume: 26, Issue:5

    Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Blood Cells; CD18 Antigens; Cell Adhesion Molecules;

2004
Bevacizumab in colorectal cancer.
    The New England journal of medicine, 2004, Oct-14, Volume: 351, Issue:16

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2004
Thymidylate synthase expression in normal colonic mucosa: a predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy.
    Oncology, 2004, Volume: 67, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva

2004
Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil.
    International journal of clinical oncology, 2004, Volume: 9, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluorouracil

2004
[Two cases of resection of synchronous bilobar multiple liver metastases from colorectal cancer after hepatic arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Infu

2004
[Two case reports of complete regression of liver metastases from colorectal cancer after locoregional immunochemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colorect

2004
[Evaluation of hepatic artery infusion chemotherapy for liver metastasis of colorectal cancer using a side-hole catheter].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Catheterization; Catheterization, Peripheral;

2004
[The 5-fluorouracil hepato-arterial infusion with oral UFT therapy for the hepatic and extra hepatic metastases of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dr

2004
[Host immunity in colorectal cancer patients treated with low-dose Leucovorin plus 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu

2004
[Evaluation of prophylactic hepatic arterial infusion chemotherapy after curative hepatectomy for metastatic colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Humans; Infusions, Intra-Art

2004
[The use of radio frequency ablation (RFA) for colorectal liver metastases in one patient].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Catheter Ablation; Colorectal Neoplasms; Fluorouracil; Hepatitis B; Humans; Infusions, Intra-Arteria

2004
[Clinical practice guideline: 2003 update of Standards, Options et Recommendations for first line palliative chemotherapy in patients with metastatic colorectal cancer (summary report)].
    Bulletin du cancer, 2004, Volume: 91, Issue:10

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

2004
Re: Verwaal VJ, van Tinteren H, Ruth SV, et al.: Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004; 85:61-67.
    Journal of surgical oncology, 2004, Dec-15, Volume: 88, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Color

2004
Adjuvant hepatic arterial infusion after curative resection of colorectal liver metastases using removable intra-arterial catheters with shape-memory alloy.
    Journal of surgical oncology, 2004, Dec-15, Volume: 88, Issue:4

    Topics: Adult; Aged; Alloys; Antimetabolites, Antineoplastic; Catheters, Indwelling; Chemotherapy, Adjuvant;

2004
Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
    Annals of surgery, 2004, Volume: 240, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Contraindication

2004
Comparison of mRNA expression levels determined with TaqMan and competitive template RT-PCR.
    Nucleosides, nucleotides & nucleic acids, 2004, Volume: 23, Issue:8-9

    Topics: Actins; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); F

2004
Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.
    Pharmacogenetics, 2004, Volume: 14, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluor

2004
Long-term survival after salvage surgery for colorectal lung metastases.
    The Annals of thoracic surgery, 2005, Volume: 79, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C

2005
[Successes in late solid tumors. New therapy offer].
    MMW Fortschritte der Medizin, 2004, Nov-18, Volume: 146, Issue:47

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop

2004
[The present and future of home care chemotherapy for patients with advanced and recurrent colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

2004
Unfavourable expression of pharmacologic markers in mucinous colorectal cancer.
    British journal of cancer, 2005, Jan-31, Volume: 92, Issue:2

    Topics: Adenocarcinoma, Mucinous; Aged; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease-Free

2005
Adjuvant chemotherapy in colorectal cancer.
    Techniques in coloproctology, 2004, Volume: 8 Suppl 1

    Topics: Adult; Age Distribution; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colectomy; Colorectal

2004
The development of the FOLFOX regimens as a treatment standard of advanced colorectal cancer.
    Clinical colorectal cancer, 2005, Volume: 4, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Ne

2005
Evolution of FOLFOX regimens in the treatment of advanced colorectal cancer.
    Clinical colorectal cancer, 2005, Volume: 4, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Co

2005
The addition of bevacizumab to FOLFOX4 prolongs survival in relapsed colorectal cancer: interim data from the ECOG 3200 trial.
    Clinical colorectal cancer, 2005, Volume: 4, Issue:5

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera

2005
5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study.
    Clinical colorectal cancer, 2005, Volume: 4, Issue:5

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chi-Square Distribution; Clinical Trials a

2005
[Colorectal carcinoma--approval of eloxatine in adjuvant therapy--better chances for recovery].
    Krankenpflege Journal, 2004, Volume: 42, Issue:7-10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A

2004
Estimation of the time of pulmonary metastasis in colorectal cancer patients with isolated synchronous liver metastasis.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:1

    Topics: Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hep

2005
Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma.
    Cancer, 2005, Mar-15, Volume: 103, Issue:6

    Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Dose-Response Relatio

2005
Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2005, Volume: 31, Issue:2

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C

2005
Health economic analysis of fluoropyrimidine-based therapies of colorectal cancer from the perspective of statutory sickness funds.
    Zeitschrift fur Gastroenterologie, 2005, Volume: 43, Issue:2

    Topics: Administration, Oral; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Capecitabine;

2005
Lethal toxicity after 5-fluorouracil chemotherapy and its possible relationship to dihydropyrimidine dehydrogenase deficiency: a case report and review of the literature.
    Journal of chemotherapy (Florence, Italy), 2004, Volume: 16, Issue:6

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Deficiency Diseases; Dihydropyrimidine Dehydr

2004
Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma.
    Oncology reports, 2005, Volume: 13, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoma;

2005
The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study.
    Oncology, 2004, Volume: 67, Issue:5-6

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytoto

2004
Costs of treatment of colorectal cancer in different settings in Germany.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2004, Volume: 5, Issue:3

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Costs and

2004
Hepatic arterial infusion after liver resection.
    The New England journal of medicine, 2005, Feb-17, Volume: 352, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Dex

2005
Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-20, Volume: 23, Issue:6

    Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Austria; Bio

2005
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-01, Volume: 23, Issue:7

    Topics: Colorectal Neoplasms; Disease Progression; Drug Screening Assays, Antitumor; Female; Fluorouracil; H

2005
Bevacizumab plus fluorouracil: the value of being part of a developing story.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-01, Volume: 23, Issue:16

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2005
Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Feb-15, Volume: 11, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line,

2005
Enhanced efficacy of conditionally replicating herpes simplex virus (G207) combined with 5-fluorouracil and surgical resection in peritoneal cancer dissemination models.
    The journal of gene medicine, 2005, Volume: 7, Issue:5

    Topics: Animals; Antibodies, Viral; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality

2005
Thymidine phosphorylase expression and efficacy of adjuvant doxifluridine in advanced colorectal cancer patients.
    Oncology reports, 2005, Volume: 13, Issue:4

    Topics: Administration, Oral; Aged; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Differenti

2005
Venous thromboembolism in colorectal cancer patients with central venous catheters for 5-FU infusion-based pharmacokinetic modulating chemotherapy.
    Oncology reports, 2005, Volume: 13, Issue:4

    Topics: Adult; Aged; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Agents; Catheterization

2005
An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-20, Volume: 23, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoro

2005
Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Apr-01, Volume: 11, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cluster Analysis; Colorectal Neopla

2005
Determination of operation time in colorectal diseases: preoperative chemotherapy application.
    The Journal of surgical research, 2005, Volume: 124, Issue:2

    Topics: Abdominal Wall; Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Th

2005
Therapy for colorectal cancer.
    The New England journal of medicine, 2005, Apr-28, Volume: 352, Issue:17

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms

2005
Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, May-01, Volume: 11, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle Proteins; Colorectal

2005
Hypersensitivity reactions to oxaliplatin in two asian patients.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:6

    Topics: Adult; Anti-Allergic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2005
Combined systemic chronotherapy and hepatic artery infusion for the treatment of metastatic colorectal cancer confined to the liver.
    Chemotherapy, 2005, Volume: 51, Issue:2-3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Chronotherapy; Colo

2005
Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2005
Modulation of multidrug resistance by andrographolid in a HCT-8/5-FU multidrug-resistant colorectal cancer cell line.
    Chinese journal of digestive diseases, 2005, Volume: 6, Issue:2

    Topics: Adenocarcinoma; Andrographis; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Mu

2005
[Systemic therapy for colorectal cancer].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2005, Volume: 76, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com

2005
Real-time RT-PCR (TaqMan) of tumor mRNA to predict sensitivity of specimens to 5-fluorouracil.
    Methods in molecular medicine, 2005, Volume: 111

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Cycle Proteins; Cell Membrane; Colorect

2005
[Improving longevity in advanced intestinal cancer].
    Krankenpflege Journal, 2005, Volume: 43, Issue:1-3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2005
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
    Journal of the American College of Surgeons, 2005, Volume: 200, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch

2005
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
    Journal of the American College of Surgeons, 2005, Volume: 200, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch

2005
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
    Journal of the American College of Surgeons, 2005, Volume: 200, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch

2005
Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
    Journal of the American College of Surgeons, 2005, Volume: 200, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch

2005
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16 Suppl 4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore

2005
Controversy in folinic acid administration after fluorouracil.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-01, Volume: 23, Issue:16

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

2005
Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
    Oncology reports, 2005, Volume: 14, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA, N

2005
[Expression of metabolic enzymes of fluoropyrimidines in primary colorectal cancer and its clinical significance].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2005, Jun-18, Volume: 37, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorec

2005
[Prognostic value of thymidylate synthase, topoisomerase-1 and Ki-67 in advanced colorectal cancer patients on irinotecan and fluorouracil treatment].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2005, Volume: 27, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Ne

2005
Slow evolution of liver metastasis from colon cancer.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2005, Volume: 37, Issue:8

    Topics: Antimetabolites, Antineoplastic; Carcinoma; Colectomy; Colorectal Neoplasms; Disease-Free Survival;

2005
FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jul-01, Volume: 11, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2005
Feasibility study of ambulatory continuous infusion of 5-fluorouracil followed by cisplatin through hepatic artery for metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:1

    Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2006
[Clinical research of intraperitoneal chemotherapy plus Shenmai Injection in treating advanced colorectal cancer].
    Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, 2005, Volume: 3, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorecta

2005
Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays.
    International journal of oncology, 2005, Volume: 27, Issue:2

    Topics: Antimetabolites, Antineoplastic; Bone Morphogenetic Proteins; Cell Line, Tumor; Cell Proliferation;

2005
Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen
    International journal of oncology, 2005, Volume: 27, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Camptothecin; Caspase 3; Caspase Inhibitors; Cas

2005
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
    Oncology, 2005, Volume: 68, Issue:2-3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Campto

2005
Oncologic emergencies secondary to advanced colorectal cancer successfully treated with oxaliplatin/5-fluorouracil/leucovorin: report of three cases.
    Journal of chemotherapy (Florence, Italy), 2005, Volume: 17, Issue:3

    Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female;

2005
Chemotherapy for metastatic colorectal cancer.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2005, Volume: 3, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop

2005
[Combined chemotherapy with oral leucovorin (LV) + tegafur/uracil (UFT) and hepatic arterial infusion (HAI) therapy for liver metastasis of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:7

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dr

2005
[A case of cerebral infarction caused by disseminated intravascular coagulation during hepatic arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cerebral Infarction; Colorectal Neoplasms; Dis

2005
Lectin-mediated cytotoxicity and specificity of 5-fluorouracil conjugated with peanut agglutinin (5-Fu-PNA) in vitro.
    Journal of drug targeting, 2005, Volume: 13, Issue:4

    Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Dose-Respons

2005
Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer.
    Oncology reports, 2005, Volume: 14, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2005
Analysis of dose-response effects on gene expression data with comparison of two microarray platforms.
    Bioinformatics (Oxford, England), 2005, Sep-01, Volume: 21, Issue:17

    Topics: Algorithms; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Dose-Response Relationshi

2005
Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients.
    Oncology, 2005, Volume: 69, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chronothera

2005
Adjuvant therapy: new treatment options with oxaliplatin-based chemotherapy.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro

2005
Recent data with oxaliplatin-containing regimens in the adjuvant treatment of colorectal cancer.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co

2005
Adjuvant irinotecan regimens in combination with infusional 5-fluorouracil/leucovorin fail to improve outcomes in surgically resected colorectal cancer.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trial

2005
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:2

    Topics: Administration, Oral; Adult; Age Factors; Aged; Analysis of Variance; Antineoplastic Combined Chemot

2005
Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2005
Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models.
    Cancer research, 2005, Aug-15, Volume: 65, Issue:16

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor;

2005
[Reversible cardiogenic shock under 5-fluorouracil treatment].
    Annales de cardiologie et d'angeiologie, 2005, Volume: 54, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Car

2005
Assessing the clinical significance of drug interactions with fluorouracil in patients with colorectal cancer.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2005, Sep-01, Volume: 62, Issue:17

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Drug Interactions; Drug-Related Side Effects and Advers

2005
[Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:8

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla

2005
Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Pharmacogenetics and genomics, 2005, Volume: 15, Issue:10

    Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers

2005
ERCC1 and clinical resistance to platinum-based therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17

    Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; DNA Repair; DNA-Binding Proteins; Drug Resista

2005
ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17

    Topics: Antineoplastic Combined Chemotherapy Protocols; Codon; Colorectal Neoplasms; DNA Repair; DNA-Binding

2005
SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17

    Topics: Allelic Imbalance; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Chrom

2005
Abdominal rash after transarterial chemoembolization via the right inferior phrenic artery.
    Journal of vascular and interventional radiology : JVIR, 2005, Volume: 16, Issue:9

    Topics: Abdomen; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Arteries; Chemoembolization,

2005
SMS 201-995 enhances S-phase block induced by 5-fluorouracil in a human colorectal cancer cell line.
    Anti-cancer drugs, 2005, Volume: 16, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neopl

2005
Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Con: Pumpin' FU (or, avoiding that oral fixation).
    Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Color

2005
[Healing for more patients].
    Krankenpflege Journal, 2005, Volume: 43, Issue:4-6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemo

2005
Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
    Cancer, 2005, Nov-01, Volume: 104, Issue:9

    Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Colorecta

2005
Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2005, Nov-05, Volume: 826, Issue:1-2

    Topics: Animals; Capecitabine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Deoxycytidine; Dr

2005
Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboxylestera

2005
Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer.
    Cancer research, 2005, Oct-01, Volume: 65, Issue:19

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neopla

2005
Recurrence and 5-FU sensitivity of stage III/Dukes' C colorectal cancer with occult neoplastic cells in lymph node sinuses.
    Oncology reports, 2005, Volume: 14, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Dihydrourac

2005
Recurrence and 5-FU sensitivity of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses.
    Oncology reports, 2005, Volume: 14, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Dihydrourac

2005
Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2005, Volume: 113, Issue:9

    Topics: Adenocarcinoma; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Immunohisto

2005
Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer.
    Journal of Korean medical science, 2005, Volume: 20, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colo

2005
ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
    Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; DNA-Binding Proteins; Endonucleases; Female; F

2003
Prognostic factors in patients with colorectal cancer receiving adjuvant chemotherapy or chemoradiotherapy: a pooled analysis of two randomized studies.
    International journal of gastrointestinal cancer, 2005, Volume: 36, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorourac

2005
Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-15, Volume: 11, Issue:20

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Dose-Response Relation

2005
In vitro detection of cross-resistant and non-cross-resistant agents with fluorouracil for patients with colorectal cancer.
    International journal of clinical oncology, 2005, Volume: 10, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin

2005
First-line treatment options for patients with metastatic colorectal cancer.
    Nature clinical practice. Oncology, 2004, Volume: 1, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo

2004
Overlap coefficient for assessing the similarity of pharmacokinetic data between ethnically different populations.
    Clinical trials (London, England), 2005, Volume: 2, Issue:2

    Topics: Clinical Trials as Topic; Colorectal Neoplasms; Confidence Intervals; Cross-Cultural Comparison; Dat

2005
[A clinical study of hepatic arterial infusion chemotherapy with low-dose CDDP and 5-FU for liver metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorecta

2005
Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer.
    The Korean journal of internal medicine, 2005, Volume: 20, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2005
Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
    Gut, 2006, Volume: 55, Issue:6

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Base Pair Mismatch; Chemotherapy, Adjuvant

2006
[Colorectal carcinoma].
    Praxis, 2005, Nov-02, Volume: 94, Issue:44

    Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2005
Treatment of advanced colorectal and gastric cancer with 5-fluorouracil and calcium n-methyltetrahydrofolate.
    Journal of chemotherapy (Florence, Italy), 1989, Volume: 1, Issue:4 Suppl

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; F

1989
Perfusion chemotherapy for colorectal liver metastases: a randomized study comparing FUDR against 5-FU/BCNU.
    Journal of chemotherapy (Florence, Italy), 1989, Volume: 1, Issue:4 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colorectal Neoplasms; Floxuridine; Fluor

1989
[Expression of dihydropyrimidine dehydrogenase in human colorectal carcinoma and its clinical implications].
    Zhonghua yi xue za zhi, 2005, Aug-10, Volume: 85, Issue:30

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dihydrouracil Deh

2005
Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Diges

2005
[Radiofrequency ablation (RFA) in colorectal cancer with hepatic metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Colorectal Neoplasm

2005
[Chemotherapy for liver metastasis of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineo

2005
[A case report of recurrence of liver metastases from colorectal cancer, which seemed to have vanished for a time by intra-aortic chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Combined

2005
[Hepatic arterial infusion (HAI) chemotherapy achieved a complete response (CR) for multiple liver metastases of colorectal cancer--two case reports].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C

2005
Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.
    IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:12

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizum

2005
Microsatellite instability and colorectal cancer prognosis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-01, Volume: 11, Issue:23

    Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Mucinous; Antimetabolites, Ant

2005
The relationship between 5-fluorouracil sensitivity and single nucleotide polymorphisms of the orotate phosphoribosyl transferase gene in colorectal cancer.
    Oncology reports, 2006, Volume: 15, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Female; Fluo

2006
Methylation-induced silencing of ASC and the effect of expressed ASC on p53-mediated chemosensitivity in colorectal cancer.
    Oncogene, 2006, Mar-16, Volume: 25, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; CARD Signaling Adaptor Proteins; Colorectal Neoplasms; CpG Islands

2006
[Irinotecan in combination with 5-fluorouracil and leucovorin in the treatment of metastatic colorectal cancer].
    Casopis lekaru ceskych, 2005, Volume: 144, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Colorectal Neo

2005
Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells.
    Carcinogenesis, 2006, Volume: 27, Issue:3

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Down-Regulation; Drug Interactions

2006
Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:4

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Capecitabine; Cohort Stud

2005
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-15, Volume: 11, Issue:24 Pt 1

    Topics: 5'-Nucleotidase; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabi

2005
Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-20, Volume: 23, Issue:36

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N

2005
Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models.
    Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Capecit

2006
Unresectable hepatic colorectal metastases: need for new surgical strategies.
    Annals of surgical oncology, 2006, Volume: 13, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modalit

2006
Irinotecan with bolus and infusional 5-flurouracil and folinic acid for patients with advanced or metastatic colorectal cancer previously treated with 5-flurouracil: a possible alternative to single-agent irinotecan in a 'real-life' setting.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2005, Volume: 17, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2005
Longterm results and prognostic indicators after cryotherapy and hepatic arterial chemotherapy with or without resection for colorectal liver metastases in 224 patients: longterm survival can be achieved in patients with multiple bilateral liver metastase
    Journal of the American College of Surgeons, 2006, Volume: 202, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cryotherapy; Female; Fluorouracil; Foll

2006
Tumor quantification of several fluoropyrimidines resistance gene expression with a unique quantitative RT-PCR method. Implications for pretherapeutic determination of tumor resistance phenotype.
    Cancer letters, 2006, Oct-28, Volume: 242, Issue:2

    Topics: Antimetabolites, Antineoplastic; Biopsy; Carcinoma; Colorectal Neoplasms; DNA Primers; DNA, Compleme

2006
Capecitabine-induced severe hypertriglyceridemia: report of two cases.
    The Annals of pharmacotherapy, 2006, Volume: 40, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycy

2006
in vitro synergistic antitumor activity of a combination of 5-fluorouracil and irinotecan in human colon cancer.
    International journal of oncology, 2006, Volume: 28, Issue:2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Pr

2006
Molecular factors of 5-fluorouracil metabolism in colorectal cancer: analysis of primary tumor and lymph node metastasis.
    International journal of oncology, 2006, Volume: 28, Issue:2

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydr

2006
Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.
    Prescrire international, 2005, Volume: 14, Issue:80

    Topics: Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; C

2005
Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire international, 2005, Volume: 14, Issue:80

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials

2005
Overexpression of hRFI inhibits 5-fluorouracil-induced apoptosis in colorectal cancer cells via activation of NF-kappaB and upregulation of BCL-2 and BCL-XL.
    Oncogene, 2006, May-25, Volume: 25, Issue:22

    Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Carrier Proteins; Colorectal Neoplasms; C

2006
[Clinical administration of oxaliplatin for patients previously treated for refractory advanced or recurrent colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:1

    Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr

2006
Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy.
    International journal of cancer, 2006, Jun-15, Volume: 118, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Ad

2006
On prejudice and facts and choices.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2006
[Chemotherapy and MSI status].
    Gastroenterologie clinique et biologique, 2005, Volume: 29, Issue:10

    Topics: Antimetabolites, Antineoplastic; Chromosomal Instability; Colorectal Neoplasms; Fluorouracil; Humans

2005
An integrated psychological strategy for advanced colorectal cancer patients.
    Health and quality of life outcomes, 2006, Feb-06, Volume: 4

    Topics: Adaptation, Psychological; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Col

2006
Benefits and risks of palliative capecitabine based therapy to elderly patients with advanced colorectal cancer: Danish single centre experiences.
    Acta oncologica (Stockholm, Sweden), 2006, Volume: 45, Issue:1

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorect

2006
Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
    The European journal of health economics : HEPAC : health economics in prevention and care, 2006, Volume: 7, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admin

2006
Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases.
    Diseases of the colon and rectum, 2006, Volume: 49, Issue:3

    Topics: Acetates; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms;

2006
Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response.
    International journal of cancer, 2006, Jul-15, Volume: 119, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Cytokines; Dihydrour

2006
Reader comments on the cost of cancer care.
    Clinical journal of oncology nursing, 2006, Volume: 10, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop

2006
[Reflexion on a good strategy of use of oxaliplatine with 5-fluorouracil and its derivatives in patients with advanced colorectal cancer].
    Bulletin du cancer, 2006, Feb-01, Volume: 93 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N

2006
[Method of levofolinate.5-FU administration by hepatic arterial infusion therapy for hepatic metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarr

2006
Capecitabine and mitomycin C in patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F

2006
[Adjuvant and palliative chemotherapy of colorectal cancer in Germany outside controlled trials].
    Deutsche medizinische Wochenschrift (1946), 2006, Mar-10, Volume: 131, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot

2006
Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
    Oncology reports, 2006, Volume: 15, Issue:4

    Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Colorec

2006
Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA Mutational An

2006
Thymidine phosphorylase and dihydropyrimidine dehydrogenase expression levels in tumor and normal tissue specimens of T3 human colorectal carcinoma.
    Surgery today, 2006, Volume: 36, Issue:4

    Topics: 5'-Nucleotidase; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; CD3 Complex; Colorectal

2006
[Inhibitory effect of angiogenesis inhibitor YH-16 in combination with 5-FU on liver metastasis of colorectal cancer].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2006, Volume: 9, Issue:2

    Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Colorectal Neoplasms; Drug Therapy, Combination;

2006
5-fluorouracil (5FU) treatment does not influence invasion and metastasis in microsatellite unstable (MSI-H) colorectal cancer.
    International journal of colorectal disease, 2006, Volume: 21, Issue:7

    Topics: Animals; Cell Count; Cell Survival; Colorectal Neoplasms; Disease Models, Animal; Flow Cytometry; Fl

2006
5-fluorouracil-related gene expression levels in primary colorectal cancer and corresponding liver metastasis.
    International journal of cancer, 2006, Aug-01, Volume: 119, Issue:3

    Topics: Aged; Aged, 80 and over; Colon; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fl

2006
Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Apr-01, Volume: 24, Issue:10

    Topics: Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Genotype; Haplotype

2006
Long-term survival and tumor 5-FU sensitivity in patients with stage IV colorectal cancer and peritoneal dissemination.
    Oncology reports, 2006, Volume: 15, Issue:5

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Huma

2006
Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil.
    International journal of oncology, 2006, Volume: 28, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorour

2006
Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy).
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C

2006
Southwest Oncology Group 0408: Phase II trial of neoadjuvant capecitabine/oxaliplatin/bevacizumab for resectable colorectal metastases in the liver.
    Clinical colorectal cancer, 2006, Volume: 5, Issue:6

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capec

2006
A prospective study of isolated human hepatocyte function following liver resection for colorectal liver metastases: the effects of prior exposure to chemotherapy.
    Journal of hepatology, 2006, Volume: 45, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Therapy, Comb

2006
Individualizing chemotherapeutic treatment of colorectal cancer.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2006, May-01, Volume: 63, Issue:9 Suppl 2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bilirubin; Biomark

2006
In response to: 'On prejudice and facts and choices', an editorial by Kohne and Folprecht.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Choice Behavior; Clinical T

2006
[Outpatient based colorectal cancer treatment--the current status, challenges and future outlook].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:5

    Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms;

2006
Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy.
    BMC cancer, 2006, May-10, Volume: 6

    Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Colorectal Neopl

2006
Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer.
    Gut, 2006, Volume: 55, Issue:6

    Topics: Antimetabolites, Antineoplastic; Base Pair Mismatch; Colorectal Neoplasms; DNA Repair; DNA, Neoplasm

2006
The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer.
    British journal of cancer, 2006, Jun-19, Volume: 94, Issue:12

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; C-Reactive Protein; Chemotherapy, Adjuvant; C

2006
Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer.
    International journal of colorectal disease, 2007, Volume: 22, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Disease-Free Survi

2007
Prognostic factors and analysis of microsatellite instability in resected pulmonary metastases from colorectal carcinoma.
    The Annals of thoracic surgery, 2006, Volume: 81, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemother

2006
Neoadjuvant therapy with bevacizumab.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-01, Volume: 24, Issue:16

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2006
Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8.
    Pharmacogenomics, 2006, Volume: 7, Issue:4

    Topics: Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Base Sequence; Caco-2 Cells; Cell

2006
Plasma level of a 5-fluorouracil metabolite, fluoro-beta-alanine correlates with dihydropyrimidine dehydrogenase activity of peripheral blood mononuclear cells in 5-fluorouracil treated patients.
    Journal of experimental & clinical cancer research : CR, 2006, Volume: 25, Issue:1

    Topics: Aged; Alanine; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Combined Modality Therapy

2006
Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice.
    Prescrire international, 2006, Volume: 15, Issue:83

    Topics: Antibodies, Monoclonal; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil;

2006
[Clinical study of 5-Fluorouracil and l-Leucovorin therapy for 56 patients with advanced recurrent colorectal carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2006
Adaptive design: estimation and inference with censored data in a semiparametric model.
    Biostatistics (Oxford, England), 2007, Volume: 8, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Computer Simulation; Confidenc

2007
Prognostic impact of orotate phosphoribosyl transferase activity in resectable colorectal cancers treated by 5-fluorouracil-based adjuvant chemotherapy.
    Journal of surgical oncology, 2006, Jul-01, Volume: 94, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal

2006
Regional localisation of p53-independent apoptosis determines toxicity to 5-fluorouracil and pyrrolidinedithiocarbamate in the murine gut.
    British journal of cancer, 2006, Jul-03, Volume: 95, Issue:1

    Topics: Animals; Antioxidants; Apoptosis; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Admin

2006
Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients.
    British journal of clinical pharmacology, 2007, Volume: 63, Issue:1

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Deoxyuridine; Fe

2007
Turning point for colorectal cancer clinical trials.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-20, Volume: 24, Issue:21

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cross-Over Studi

2006
Progress with biological agents in metastatic colorectal cancer leads to many challenges.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-20, Volume: 24, Issue:21

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2006
S-1, an oral fluoropyrimidine, enhances radiation response of DLD-1/FU human colon cancer xenografts resistant to 5-FU.
    Oncology reports, 2006, Volume: 16, Issue:3

    Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neoplas

2006
Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients.
    Oncology reports, 2006, Volume: 16, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2006
A computationally simple bivariate survival estimator for efficacy and safety.
    Lifetime data analysis, 2006, Volume: 12, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biometry; Clinical Trials, Ph

2006
Case-based discussion for the management of metastatic colorectal cancer.
    ONS news, 2006, Volume: 21, Issue:8 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Monitoring;

2006
Thymidine phosphorylase and capecitabine: a predictive marker for therapy selection?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Sep-01, Volume: 24, Issue:25

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Clinical Trials as

2006
Highlights from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2006.
    Clinical colorectal cancer, 2006, Volume: 6, Issue:2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2006
Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity.
    Clinical colorectal cancer, 2006, Volume: 6, Issue:2

    Topics: Amines; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cyclohexanecarboxylic

2006
Outcome of metastatic colorectal cancer: analysis of a consecutive series of 229 patients. The impact of a multidisciplinary approach.
    Diseases of the colon and rectum, 2006, Volume: 49, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

2006
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Sep-15, Volume: 12, Issue:18

    Topics: Adult; Aged; Anemia; Black or African American; Breath Tests; Carbon Dioxide; Colorectal Neoplasms;

2006
Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil.
    NMR in biomedicine, 2007, Volume: 20, Issue:2

    Topics: Adult; Aged; Colorectal Neoplasms; Contrast Media; Female; Fluorouracil; Gadolinium DTPA; Humans; Im

2007
Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:1

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Adhesion; Cell Proliferation; Cell Shape;

2007
Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?
    Annals of surgical oncology, 2006, Volume: 13, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA-Binding Prote

2006
The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines.
    Oncology reports, 2006, Volume: 16, Issue:5

    Topics: Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Cycle; Cell Growth Processes; Cell Line, Tumor;

2006
Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy.
    Cancer research, 2006, Oct-01, Volume: 66, Issue:19

    Topics: 5' Untranslated Regions; Alleles; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal Neop

2006
Do all patients with metastatic colorectal cancer need chemotherapy until disease progression?
    Clinical colorectal cancer, 2006, Volume: 6, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease

2006
Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma.
    Clinical colorectal cancer, 2006, Volume: 6, Issue:3

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites,

2006
Is thymidylate synthase a reliable predictor for response and survival during hepatic arterial infusion for hepatic metastases from colorectal cancer?
    British journal of cancer, 2006, Nov-06, Volume: 95, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Genotype; Hepati

2006
Identification of a novel mutation in the dihydropyrimidine dehydrogenase gene in a patient with a lethal outcome following 5-fluorouracil administration and the determination of its frequency in a population of 500 patients with colorectal carcinoma.
    Clinical biochemistry, 2007, Volume: 40, Issue:1-2

    Topics: Adenine; Aged; Alleles; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); DNA Mutational Ana

2007
Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
    Gut, 2006, Volume: 55, Issue:11

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans;

2006
Thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer and normal mucosa in patients.
    Pharmacogenetics and genomics, 2006, Volume: 16, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Caco-2 Cells; Capecitabine; Carcino

2006
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot

2007
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot

2007
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot

2007
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot

2007
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot

2007
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot

2007
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot

2007
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot

2007
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot

2007
A case of acute myocardial infarction during 5-fluorouracil infusion.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2006, Volume: 7, Issue:11

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Coronary Angiography; Creatine Kinase, MB For

2006
Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes.
    Journal of surgical oncology, 2007, Jan-01, Volume: 95, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cohort Studies

2007
Portal thrombosis and steatosis after preoperative chemotherapy with FOLFIRI-bevacizumab for colorectal liver metastases.
    World journal of gastroenterology, 2006, Oct-28, Volume: 12, Issue:40

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2006
Benefits and risks of neoadjuvant therapy for liver metastases.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatectomy; Hum

2006
Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colo

2006
Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colo

2006
Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colo

2006
Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colo

2006
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response.
    Anti-cancer drugs, 2006, Volume: 17, Issue:10

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2006
Suppression of colorectal tumor growth by regulated survivin targeting.
    Journal of molecular medicine (Berlin, Germany), 2006, Volume: 84, Issue:12

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Caspases; Cell Line; Cel

2006
OPTIMOX1 in advanced colorectal cancer: lack of evidence for a stop-and-go strategy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-10, Volume: 24, Issue:32

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Data Interpretation, Statistic

2006
The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil.
    International journal of cancer, 2007, Feb-01, Volume: 120, Issue:3

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dihydrouracil D

2007
Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer.
    Chinese medical journal, 2006, Nov-05, Volume: 119, Issue:21

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2006
Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin.
    European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast

2007
Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?
    Annals of surgical oncology, 2007, Volume: 14, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Combined Modality T

2007
Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?
    Annals of surgical oncology, 2007, Volume: 14, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Combined Modality T

2007
Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?
    Annals of surgical oncology, 2007, Volume: 14, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Combined Modality T

2007
Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy?
    Annals of surgical oncology, 2007, Volume: 14, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colorectal Neoplasms; Combined Modality T

2007
FDG-PET in colorectal cancer.
    Cancer imaging : the official publication of the International Cancer Imaging Society, 2006, Oct-31, Volume: 6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Clinic

2006
Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer.
    Journal of the American College of Surgeons, 2006, Volume: 203, Issue:6

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2006
Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
    Gut, 2006, Volume: 55, Issue:12

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans;

2006
Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer.
    Gut, 2006, Volume: 55, Issue:12

    Topics: Antimetabolites, Antineoplastic; Base Pair Mismatch; Colorectal Neoplasms; DNA Repair; DNA, Neoplasm

2006
The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:2

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relati

2007
Evaluation of 5-fluorouracil applicability by the collagen gel droplet embedded drug sensitivity test with area under the curve analysis.
    Anti-cancer drugs, 2007, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neoplasms; Drug

2007
Incomplete operative removal of colorectal liver metastases followed by chemotherapy decreases survival in comparison to chemotherapy alone.
    Journal of experimental & clinical cancer research : CR, 2006, Volume: 25, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort St

2006
Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Oncology, 2006, Volume: 70, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplas

2006
Role of IKK and oscillatory NFkappaB kinetics in MMP-9 gene expression and chemoresistance to 5-fluorouracil in RKO colorectal cancer cells.
    Molecular carcinogenesis, 2007, Volume: 46, Issue:5

    Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorourac

2007
A nurse-/pharmacy-led capecitabine clinic for colorectal cancer: results of a prospective audit and retrospective survey of patient experiences.
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2007, Volume: 11, Issue:3

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cancer Care Faciliti

2007
Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer.
    Chemotherapy, 2007, Volume: 53, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluor

2007
Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
    Oncology reports, 2007, Volume: 17, Issue:2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Color

2007
5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2006, Volume: 89, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administrat

2006
Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases.
    Gastroenterologie clinique et biologique, 2006, Volume: 30, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fem

2006
[A phase I study of combination-therapy using personalized peptide vaccine and UFT/UZEL for advanced or recurrent colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:12

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines;

2006
[Two cases of multiple liver metastases from colorectal cancer which responded well to hepatic arterial infusion (HAI) using 5-fluorouracil and l-leucovorin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne

2006
[Hepatic arterial infusion of low-dose leucovorin/5-FU chemotherapy for unresectable hepatic metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Hepatic Artery;

2006
[The relationship between plasma level of VEGF or soluble Flt-1 and efficacy of hepatic arterial chemotherapy in patients with liver metastasis of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic

2006
Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: the NO16966 trial.
    Clinical colorectal cancer, 2006, Volume: 6, Issue:4

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2006
Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count.
    Clinical colorectal cancer, 2006, Volume: 6, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Col

2006
Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxa
    Oncology reports, 2007, Volume: 17, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; DNA-Bindin

2007
Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis.
    British journal of cancer, 2007, Feb-26, Volume: 96, Issue:4

    Topics: Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia

2007
Old age: biologic versus chronologic.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Feb-20, Volume: 25, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy;

2007
Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool.
    Clinical colorectal cancer, 2007, Volume: 6, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2007
Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine.
    Clinical colorectal cancer, 2007, Volume: 6, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Erythema;

2007
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Mar-01, Volume: 25, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fl

2007
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer.
    International journal of cancer, 2007, Jun-15, Volume: 120, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neopl

2007
Compression coated systems for colonic delivery of 5-fluorouracil.
    The Journal of pharmacy and pharmacology, 2007, Volume: 59, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Boswellia; Chemistry, Pharmaceutical; Colon; Colorectal Ne

2007
Integrating Chinese and conventional medicine in colorectal cancer treatment.
    Integrative cancer therapies, 2007, Volume: 6, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidin

2007
[Chemotherapy for elderly patients with colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:3

    Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combine

2007
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
    Virchows Archiv : an international journal of pathology, 2007, Volume: 450, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2007
Mechanistic analysis and comparison of viral fusogenic membrane proteins for their synergistic effects on chemotherapy.
    Cancer biology & therapy, 2007, Volume: 6, Issue:4

    Topics: Animals; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line,

2007
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Apr-01, Volume: 25, Issue:10

    Topics: 5' Untranslated Regions; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neo

2007
Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
    Therapeutic drug monitoring, 2007, Volume: 29, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Colorectal Neoplasms; Dihydrouracil Dehy

2007
[Construction of lentivirus producing PLC-gamma1 siRNA and its effect on apoptosis of human colorectal carcinomas cell lines].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2007, Volume: 27, Issue:3

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Colorectal Neoplasm

2007
[Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcium; Colorectal Neoplas

2007
[Clinical administration of FOLFOX regimens for patients with unresectable advanced or recurrent colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; C

2007
The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer.
    British journal of cancer, 2007, May-07, Volume: 96, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F

2007
Thymidylate synthase expression in primary colorectal tumours is correlated with its expression in metastases.
    Scandinavian journal of gastroenterology, 2007, Volume: 42, Issue:4

    Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluorouracil; Huma

2007
Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.
    Scandinavian journal of gastroenterology, 2007, Volume: 42, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemo

2007
Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2007, Volume: 11, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore

2007
Size matters. What can we learn from a small randomized trial?
    Onkologie, 2007, Volume: 30, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Data Interpretat

2007
[Outpatient chemotherapy of an advanced or metastatic colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 2

    Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms;

2006
[Present status of home therapy cancer patients using an infusor].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 2

    Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms;

2006
[The future of chemotherapy at home--from outpatient chemotherapy to chemotherapy at home].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 2

    Topics: Ambulatory Care; Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Camptot

2006
Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents.
    Journal of the American College of Surgeons, 2007, Volume: 204, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chi-Square Distribution; Color

2007
The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
    Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:1 Suppl 1

    Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2007
[Comparisons of standard treatments for colorectal cancer between Japan and Western Countries].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo

2007
Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer.
    Annals of surgical oncology, 2007, Volume: 14, Issue:8

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma; Chemothe

2007
Two cases of severe liver injury possibly related to 5-fluorouracil and calcium folinate.
    Internal medicine journal, 2007, Volume: 37, Issue:5

    Topics: Acute Disease; Aged; Antineoplastic Agents; Cholestasis, Intrahepatic; Colorectal Neoplasms; Fluorou

2007
Acute myeloid leukaemia secondary to treatment with capecitabine for metastatic colorectal cancer.
    European journal of haematology, 2007, Volume: 78, Issue:6

    Topics: Acute Disease; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F

2007
Quantitative imaging of apoptosis commitment in colorectal tumor cells.
    Differentiation; research in biological diversity, 2007, Volume: 75, Issue:9

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Cell Line, Tumor; Colorectal Neoplasms; DNA D

2007
Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:4

    Topics: Aged; Antimetabolites; Collagen; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; F

2008
Antitumour effects on human colorectal carcinomas cells by stable silencing of phospholipase C-gamma 1 with lentivirus-delivered siRNA.
    Chinese medical journal, 2007, May-05, Volume: 120, Issue:9

    Topics: Apoptosis; Cell Adhesion; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Laminin; Len

2007
Optimizing palliative treatment of metastatic colorectal cancer in the era of biologic therapy.
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Colorectal N

2007
Therapeutic efficacy of replication-competent retrovirus vector-mediated suicide gene therapy in a multifocal colorectal cancer metastasis model.
    Cancer research, 2007, Jun-01, Volume: 67, Issue:11

    Topics: Animals; Colorectal Neoplasms; Cytosine Deaminase; Disease Models, Animal; Female; Flucytosine; Fluo

2007
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.
    The pharmacogenomics journal, 2008, Volume: 8, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis

2008
Measurement of DPD and TS transcripts aimed to predict clinical benefit from fluoropyrimidines: confirmation of the trend in Russian colorectal cancer series and caution regarding the gene referees.
    Onkologie, 2007, Volume: 30, Issue:6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Artifa

2007
Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil.
    Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2007
[A case of liver failure associated with liver damage due to mFOLFOX 6 after resection for multiple liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin

2007
Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience.
    International journal of clinical oncology, 2007, Volume: 12, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2007
Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
    Anti-cancer drugs, 2007, Volume: 18, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Ce

2007
Cetuximab/targeted chemotherapy in an HIV-positive patient with metastatic colorectal cancer in the HAART era: a case report.
    Journal of chemotherapy (Florence, Italy), 2007, Volume: 19, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2007
Outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as first-line treatment for patients with metastatic or recurrent colorectal cancer.
    Journal of Korean medical science, 2007, Volume: 22, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Femal

2007
Questions about the role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jul-01, Volume: 25, Issue:19

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cryotherapy; Data Interpretati

2007
Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy.
    Journal of cancer research and clinical oncology, 2007, Volume: 133, Issue:12

    Topics: Age Factors; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA Topoisomerases, Type I; Female; Fluor

2007
Treatment of superior vena cava (SVC) syndrome and inferior vena cava (IVC) thrombosis in a patient with colorectal cancer: combination of SVC stenting and IVC filter placement to palliate symptoms and pave the way for port implantation.
    Cardiovascular and interventional radiology, 2008, Volume: 31 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Catheterization, Peripheral; Colorectal Neoplasms; C

2008
DPD is a molecular determinant of capecitabine efficacy in colorectal cancer.
    International journal of oncology, 2007, Volume: 31, Issue:2

    Topics: Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dihydrouracil Dehydr

2007
Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2007, Volume: 11, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo

2007
Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?
    Lancet (London, England), 2007, Jul-14, Volume: 370, Issue:9582

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; C

2007
Combination of ZD55-MnSOD therapy with 5-FU enhances antitumor efficacy in colorectal cancer.
    Journal of cancer research and clinical oncology, 2008, Volume: 134, Issue:2

    Topics: Adenoviridae; Adenovirus E1B Proteins; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting

2008
[Myocardial ischaemia as a result of treatment with capecitabine].
    Nederlands tijdschrift voor geneeskunde, 2007, Jun-30, Volume: 151, Issue:26

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fl

2007
Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
    Journal of cancer research and clinical oncology, 2008, Volume: 134, Issue:1

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorec

2008
Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2007
[Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Magyar onkologia, 2007, Volume: 51, Issue:2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv

2007
Clinical outcomes of FOLFOX/FOLFIRI for the Japanese patients with far-advanced or recurrent colorectal cancer.
    Fukuoka igaku zasshi = Hukuoka acta medica, 2007, Volume: 98, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian Peopl

2007
Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature.
    Anti-cancer drugs, 2007, Volume: 18, Issue:8

    Topics: Adenocarcinoma; Anemia, Hemolytic, Autoimmune; Antidotes; Antimetabolites, Antineoplastic; Antineopl

2007
Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered.
    Anti-cancer drugs, 2007, Volume: 18, Issue:8

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch

2007
Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin?
    The pharmacogenomics journal, 2008, Volume: 8, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Cohor

2008
[The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8

    Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplas

2007
In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines.
    British journal of cancer, 2007, Sep-17, Volume: 97, Issue:6

    Topics: Blotting, Western; Carcinoembryonic Antigen; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplas

2007
The synergistic effect of 5-aza-2'-deoxycytidine and 5-fluorouracil on drug-resistant tumors.
    Oncology, 2006, Volume: 71, Issue:5-6

    Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Calcium-Calmodulin-Dependent Protein

2006
Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?
    Liver international : official journal of the International Association for the Study of the Liver, 2007, Volume: 27, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Chemot

2007
Study on colon-specific pectin/ethylcellulose film-coated 5-fluorouracil pellets in rats.
    International journal of pharmaceutics, 2008, Feb-04, Volume: 348, Issue:1-2

    Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Area Under Curve; Biological Availab

2008
The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer.
    The pharmacogenomics journal, 2008, Volume: 8, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Gastr

2008
Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-20, Volume: 25, Issue:27

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Colorectal N

2007
Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2007, Volume: 28, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Pai

2007
Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia

2007
Adjuvant chemotherapy with 5-fluorouracil in a patient with colorectal cancer and Familial Mediterranean Fever.
    Anti-cancer drugs, 2007, Volume: 18, Issue:6

    Topics: Adenocarcinoma; Amyloidosis, Familial; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryo

2007
Enhancement of capecitabine efficacy by oxaliplatin in human colorectal and gastric cancer xenografts.
    Oncology reports, 2007, Volume: 18, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycy

2007
Prognosis of small bowel adenocarcinoma treated with Mayo or Xelox regimen: a matched case-control study from a database of 581 patients with colorectal cancer.
    Oncology reports, 2007, Volume: 18, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Cont

2007
The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study.
    Virchows Archiv : an international journal of pathology, 2007, Volume: 451, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms;

2007
Regression of radiation-induced macular edema after systemic bevacizumab.
    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2007, Volume: 42, Issue:5

    Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetab

2007
Sequencing therapies: the role of targeted agents in metastatic colorectal cancer.
    ONS connect, 2007, Volume: 22, Issue:8 Suppl

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials

2007
Isolated splenic metastasis from colorectal mucinous carcinoma.
    International journal of gastrointestinal cancer, 2006, Volume: 37, Issue:2-3

    Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Co

2006
DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.
    Medical oncology (Northwood, London, England), 2007, Volume: 24, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Di

2007
In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation.
    British journal of cancer, 2007, Oct-08, Volume: 97, Issue:7

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Proliferation; Colorectal Neop

2007
[Drug information brochure for patients undergoing FOLFOX 4 chemotherapy based on survey of adverse reactions].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Information

2007
[A case of resection of synchronous multiple liver metastases from colorectal cancer after hepatic infusion chemotherapy and systemic chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined

2007
Swainsonine reduces 5-fluorouracil tolerance in the multistage resistance of colorectal cancer cell lines.
    Molecular cancer, 2007, Sep-21, Volume: 6

    Topics: Animals; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Tole

2007
Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
    Annals of surgical oncology, 2008, Volume: 15, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Feasibility Studi

2008
Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score.
    Annals of surgical oncology, 2008, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2008
Carcinoma-rectum in an 11 years old boy.
    Mymensingh medical journal : MMJ, 2007, Volume: 16, Issue:2 Suppl

    Topics: Child; Colorectal Neoplasms; Fluorouracil; Humans; Laparotomy; Leucovorin; Male

2007
Curcumin enhances the effects of 5-fluorouracil and oxaliplatin in mediating growth inhibition of colon cancer cells by modulating EGFR and IGF-1R.
    International journal of cancer, 2008, Jan-15, Volume: 122, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; C

2008
Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.
    Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B

2008
Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Oct-15, Volume: 13, Issue:20

    Topics: Aged; Antineoplastic Agents; Colorectal Neoplasms; CpG Islands; DNA Methylation; Female; Fluorouraci

2007
The predictive value of p53 and p33(ING1b) in patients with Dukes'C colorectal cancer.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2008, Volume: 10, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cohort Stud

2008
Pharmacodynamic study of the Saltz regimen for metastatic colorectal cancer in a hemodialyzed patient.
    Chemotherapy, 2007, Volume: 53, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diabetes M

2007
Comments on final report of the AIO Colorectal Cancer Group Study: fluorouracil/oxaliplatin versus capecitabine/oxaliplatin.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Nov-01, Volume: 25, Issue:31

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F

2007
Capecitabine plus oxaliplatin in metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Nov-01, Volume: 25, Issue:31

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; F

2007
5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a single-institute study.
    Oncology, 2007, Volume: 72, Issue:1-2

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2007
Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2008, Volume: 86, Issue:3

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; HT29 Cells; Hu

2008
Benefit of FOLFOX to unresectable liver metastases secondary from colorectal carcinoma in an oncologic emergency.
    Hepato-gastroenterology, 2007, Volume: 54, Issue:78

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonoscopy; Colorecta

2007
Progression-free survival is a surrogate for survival in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Nov-20, Volume: 25, Issue:33

    Topics: Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Leucovorin

2007
CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents.
    International journal of cancer, 2008, Mar-15, Volume: 122, Issue:6

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin

2008
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
    Anti-cancer drugs, 2008, Volume: 19, Issue:1

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxyc

2008
Chemotherapy-induced suppression to adenoma or complete suppression of the primary in patients with stage IV colorectal cancer: report of four cases.
    European journal of gastroenterology & hepatology, 2007, Volume: 19, Issue:11

    Topics: Adenocarcinoma; Adenoma; Aged; Antineoplastic Agents; Colon; Colonic Polyps; Colonoscopy; Colorectal

2007
Central venous access port-related complications in outpatient chemotherapy for colorectal cancer.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:12

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter

2007
Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience.
    Cancer investigation, 2007, Volume: 25, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydropyrimi

2007
Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases.
    Onkologie, 2007, Volume: 30, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant

2007
CAIRO and FOCUS.
    Lancet (London, England), 2007, Dec-08, Volume: 370, Issue:9603

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

2007
[Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2007
Adjuvant chemotherapy of colorectal cancer.
    Lancet (London, England), 2007, Dec-15, Volume: 370, Issue:9604

    Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Su

2007
Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer.
    Oncology reports, 2008, Volume: 19, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Colorectal Neoplasms; Drug

2008
Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.
    Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.
    Annals of surgery, 2008, Volume: 247, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution;

2008
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jan-10, Volume: 26, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jan-10, Volume: 26, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jan-10, Volume: 26, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jan-10, Volume: 26, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2008
UFT as maintenance therapy in patients with advanced colorectal cancer responsive to the FOLFOX4 regimen.
    Oncology, 2007, Volume: 72, Issue:5-6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi

2007
Xelox (capecitabine plus oxaliplatin) as neoadjuvant chemotherapy of unresectable liver metastases in colorectal cancer patients.
    Neoplasma, 2008, Volume: 55, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C

2008
[Results of hepatic arterial infusion chemotherapy with 5-FU and leucovorin for unresectable liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:1

    Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusio

2008
Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
    International journal of cancer, 2008, May-01, Volume: 122, Issue:9

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined

2008
Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
    Oncology, 2007, Volume: 72, Issue:5-6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deo

2007
Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells.
    Molecular cancer, 2008, Jan-25, Volume: 7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; C

2008
Retrospective comparison of two different schedules of irinotecan, 5-fluorouracil and folinic acid in previously untreated patients with advanced colorectal carcinoma: a single institution experience.
    Journal of chemotherapy (Florence, Italy), 2007, Volume: 19, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Admi

2007
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-01, Volume: 26, Issue:4

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2008
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Feb-01, Volume: 14, Issue:3

    Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabi

2008
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore

2008
ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study.
    BMC cancer, 2008, Feb-12, Volume: 8

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Chemotherapy, Adjuvant; Colectomy; Color

2008
[Chemotherapy in patients with colorectal carcinoma: applicability of data from clinical trials for the individual patient].
    Zentralblatt fur Chirurgie, 2008, Volume: 133, Issue:1

    Topics: Age Factors; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Mod

2008
Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:6

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2008
Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Oncology reports, 2008, Volume: 19, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy,

2008
Role of palifermin in fluorouracil-based therapy for metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-10, Volume: 26, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fibroblast Growth Factor 7; Fl

2008
Systemic therapy for metastatic colorectal cancer: current questions.
    Cancer, 2008, May-01, Volume: 112, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Capecitabine; Clinical Trial

2008
[Retrospective analysis of FOLFOX4 neurotoxicity for recovery from advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

2008
[A successfully resected case of colorectal cancer with multiple liver metastases treated with FOLFIRI after failure of mFOLFOX6].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colonoscopy; Colore

2008
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antine

2008
Correlation between clinical pathologic factors and activity of 5-FU-metabolizing enzymes in colorectal cancer.
    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2008, Volume: 75, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasm

2008
A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
    American journal of clinical oncology, 2008, Volume: 31, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Ad

2008
[Evaluation of efficacy and influence factors of transarterial interventional therapy in patients with liver metastasis from malignancy of alimentary tract].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, T

2007
Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms;

2008
[Modified FOLFOX6 in a patient on hemodialysis with metastatic colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Humans;

2008
Sequential vs combination colorectal cancer therapy sparks debate.
    British journal of hospital medicine (London, England : 2005), 2008, Volume: 69, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Color

2008
[Expression of APRIL in colorectal carcinoma tissues and effects of chemotherapeutic agents on APRIL expression in colorectal carcinoma SW480 cells].
    Ai zheng = Aizheng = Chinese journal of cancer, 2008, Volume: 27, Issue:4

    Topics: Adult; Aged; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male;

2008
CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells.
    International journal of oncology, 2008, Volume: 32, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation;

2008
[Therapy of colorectal carcinoma. To combine saves lives].
    MMW Fortschritte der Medizin, 2004, Jan-15, Volume: 146, Issue:1-2

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine;

2004
Will we ever be ready for blood level-guided therapy?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-01, Volume: 26, Issue:13

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Body Surface Area; Colorectal Neoplasms; Drug Admin

2008
Potential regional differences for the tolerability profiles of fluoropyrimidines.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-01, Volume: 26, Issue:13

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Cape

2008
Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-01, Volume: 26, Issue:13

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Color

2008
Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-01, Volume: 26, Issue:13

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Color

2008
Chemotherapy in elderly patients with colorectal cancer.
    The oncologist, 2008, Volume: 13, Issue:4

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr

2008
Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases.
    Journal of surgical oncology, 2008, Jun-01, Volume: 97, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co

2008
5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, May-01, Volume: 14, Issue:9

    Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorect

2008
Adjuvant chemotherapy for rectal cancer.
    Lancet (London, England), 2008, May-03, Volume: 371, Issue:9623

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease-Free Survival

2008
SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response.
    British journal of cancer, 2008, Jun-03, Volume: 98, Issue:11

    Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; Cell Proliferation; Colorectal Neopl

2008
Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer.
    International journal of clinical oncology, 2008, Volume: 13, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru

2008
[Non-resectable metastases from colorectal cancers].
    Gastroenterologie clinique et biologique, 2008, Volume: 32, Issue:5 Pt 2

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C

2008
A carboxylesterase 2 gene polymorphism as predictor of capecitabine on response and time to progression.
    Current drug metabolism, 2008, Volume: 9, Issue:4

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carboxylesterase; Colorectal Neopla

2008
XELOX followed by XELIRI or the reverse sequence in advanced colorectal cancer.
    Oncology, 2007, Volume: 73, Issue:5-6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal

2007
[Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:12

    Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian Peop

2007
[Safety and efficacy analysis of FOLFOX4 regimen in elderly compared to younger colorectal cancer patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

2008
[Reduction of oxaliplatin-related neurotoxicity by Gosha-jinki-gan].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2008
Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.
    Oncology reports, 2008, Volume: 19, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2008
Genetic construction, expression, and characterization of a single chain anti-CEA antibody fused to cytosine deaminase from yeast.
    International journal of oncology, 2008, Volume: 32, Issue:6

    Topics: Amino Acid Sequence; Antibodies, Monoclonal; Apoptosis; Blotting, Western; Carcinoembryonic Antigen;

2008
Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
    Medical oncology (Northwood, London, England), 2009, Volume: 26, Issue:1

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant

2009
Evaluation of quality of life in patients with metastatic colorectal cancer treated with capecitabine.
    Clinical colorectal cancer, 2008, Volume: 7, Issue:2

    Topics: Antimetabolites, Antineoplastic; Brazil; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female;

2008
Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
    Clinical colorectal cancer, 2008, Volume: 7, Issue:2

    Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl

2008
Cimetidine and colorectal cancer--old drug, new use?
    Nature medicine, 1995, Volume: 1, Issue:12

    Topics: Antimetabolites, Antineoplastic; Cimetidine; Colorectal Neoplasms; Drug Synergism; Fluorouracil; For

1995
Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer.
    Clinical and experimental immunology, 1995, Volume: 99, Issue:2

    Topics: Acute-Phase Proteins; Biomarkers, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Fluorourac

1995
Prognostic implications of chemoresistance-sensitivity assays for colorectal and appendiceal cancer.
    American journal of clinical oncology, 1995, Volume: 18, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Appendiceal Neoplasms; Cell Survival; Colorectal Neoplasms; Dose

1995
Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases.
    Cancer investigation, 1995, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Chemoth

1995
Long-term survival in two cases of colorectal carcinoma following a new chemotherapy regimen and subsequent metastasectomy.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1995, Volume: 21, Issue:5

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms;

1995
Chemotherapy for colorectal carcinoma: observations regarding recent clinical trials using biochemical modulation.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Drug

1995
Continuous infusion of 5-fluorouracil with alpha 2b interferon for advanced colorectal carcinoma.
    British journal of cancer, 1995, Volume: 72, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1995
A comparative study with two administration schedules of leucovorin and 5-fluorouracil in advanced colorectal cancer.
    Journal of chemotherapy (Florence, Italy), 1995, Volume: 7, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1995
The effect of different routes of administration of 5-fluorouracil on thymidylate synthase inhibition in the rat.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:5

    Topics: Administration, Topical; Animals; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Fl

1995
Inhibitory effect of simultaneous intraportal administration of 5-fluorouracil, uracil and degradable starch microspheres on experimental hepatic micrometastasis, is of colon cancer.
    The Tokai journal of experimental and clinical medicine, 1994, Volume: 19, Issue:1-2

    Topics: Animals; Colorectal Neoplasms; Fluorouracil; Infusions, Intravenous; Liver Neoplasms; Male; Mice; Mi

1994
Chemotherapy of colorectal cancer.
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22 Suppl 3

    Topics: Colorectal Neoplasms; Fluorouracil; Humans

1995
Re: Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line.
    Journal of the National Cancer Institute, 1995, Aug-02, Volume: 87, Issue:15

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Synergism; Fluor

1995
A new complication of chemotherapy administered via permanent indwelling central venous catheter.
    Cancer, 1995, Apr-15, Volume: 75, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Carbonate; Catheterization, Cen

1995
Dermatological toxicity from chemotherapy containing 5-fluorouracil.
    Journal of chemotherapy (Florence, Italy), 1994, Volume: 6, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

1994
Dutch trial casts doubt on colorectal adjuvant therapy.
    Journal of the National Cancer Institute, 1995, Apr-05, Volume: 87, Issue:7

    Topics: Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorectal Neoplasms; Drug Therapy, Combination; E

1995
Mechanism of synergy of levamisole and fluorouracil: induction of human leukocyte antigen class I in a colorectal cancer cell line.
    Journal of the National Cancer Institute, 1995, Apr-05, Volume: 87, Issue:7

    Topics: beta 2-Microglobulin; Blotting, Northern; Colorectal Neoplasms; DNA Probes; Drug Synergism; Drug The

1995
Chemotherapy for colorectal carcinoma: one small step forward, one step backward.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:6

    Topics: Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Survival Rate

1995
Addition of heparin in 5-fluorouracil solution for portal vein infusion has no influence on its stability under clinically relevant conditions.
    Anti-cancer drugs, 1995, Volume: 6, Issue:1

    Topics: Carcinoma; Catheterization, Peripheral; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Stability

1995
[Home therapy approach in cancer patients-chemotherapy (case 2-3)--intra-arterial infusion cancer chemotherapy for hepatic metastasis of colorectal cancer--case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21 Suppl 4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic

1994
[Surgical therapy of liver metastases. Therapeutic procedures, results and prognostic factors].
    Langenbecks Archiv fur Chirurgie, 1994, Volume: 379, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Chem

1994
Pharmacokinetic analysis of sparse in vivo NMR spectroscopy data using relative parameters and the population approach.
    European journal of clinical pharmacology, 1994, Volume: 47, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Data Interpretation, Statistical; Female; Fluorou

1994
Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells.
    Oncology research, 1994, Volume: 6, Issue:7

    Topics: Cell Cycle; Cell Survival; Colorectal Neoplasms; DNA, Neoplasm; DNA, Ribosomal; Dose-Response Relati

1994
Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors.
    Cancer research, 1995, Apr-01, Volume: 55, Issue:7

    Topics: Actins; Adult; Aged; Base Sequence; Colorectal Neoplasms; Female; Fluorouracil; Gene Expression Regu

1995
[Two cases of hepatic metastasis of colorectal cancer treated effectively by intrahepatic arterial infusion immunotherapy using OK-432, rIL-2, MMC and 5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:13

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sch

1994
[The potentiation of toxic effects by the combined administration of 5-fluorouracil and folinic acid salts].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1994, Volume: 170, Issue:10

    Topics: Clinical Trials as Topic; Colorectal Neoplasms; Drug Synergism; Drug Therapy, Combination; Fluoroura

1994
The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid.
    Cancer chemotherapy and pharmacology, 1994, Volume: 35, Issue:2

    Topics: Ascites; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Fluorouracil; Humans; Injection

1994
Management of advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N

1994
Drug monitoring of 5-fluorouracil: in vivo 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma.
    Magnetic resonance imaging, 1994, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; H

1994
Regional chemotherapy for colorectal liver metastases: thirty years without patient benefit.
    Journal of surgical oncology, 1994, Volume: 56, Issue:3

    Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Incidence; Infusions, Intra

1994
5-Fluorouracil pharmacokinetics in patients with metastatic colorectal carcinoma after high-dose leucovorin.
    Cancer investigation, 1994, Volume: 12, Issue:4

    Topics: Aged; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluorouraci

1994
[The evolution of the liver metastases from colorectal carcinoma treated with hepatic intra-arterial chemotherapy. The echographic and CT aspects].
    La Radiologia medica, 1994, Volume: 87, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Floxuridine; Fluoro

1994
Complete remission of liver metastases from colorectal cancer by treatment with a hepatic artery infusion (HAI) of interleukin-2-based immunochemotherapy: reports of three cases.
    Surgery today, 1994, Volume: 24, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu

1994
Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase.
    Proceedings of the National Academy of Sciences of the United States of America, 1994, Aug-16, Volume: 91, Issue:17

    Topics: Animals; Biotransformation; Cell Division; Cell Survival; Chromatography, High Pressure Liquid; Colo

1994
Stability studies on admixtures of 5-fluorouracil with carboplatin and 5-fluorouracil with heparin for administration in continuous infusion regimens.
    Journal of clinical pharmacy and therapeutics, 1994, Volume: 19, Issue:2

    Topics: Carboplatin; Chromatography, High Pressure Liquid; Colorectal Neoplasms; Drug Evaluation; Drug Stabi

1994
5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
    Cancer research, 1994, Mar-15, Volume: 54, Issue:6

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic A

1994
Mitomycin C, 5fluorouracil and folinic acid in combination with alpha 2b interferon for advanced colorectal cancer.
    Tumori, 1993, Dec-31, Volume: 79, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Sche

1993
Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. A multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO).
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1994
Local and systemic toxicity of intra-hepatic-arterial 5-FU and high-dose or low-dose leucovorin for liver metastases of colorectal cancer.
    Surgical oncology, 1994, Volume: 3, Issue:1

    Topics: Aged; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial;

1994
[Toxicity of levamisole in adjuvant chemotherapy for colorectal cancer].
    La Revue de medecine interne, 1993, Volume: 14, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N

1993
Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats.
    International journal of cancer, 1994, Jun-01, Volume: 57, Issue:5

    Topics: Animals; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Cytotoxicity, Immunologic; Fluo

1994
Adjuvant 5-fluorouracil plus levamisole in colon cancer: the plot thickens?
    British journal of cancer, 1994, Volume: 69, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorecta

1994
[TS inhibition rate and flow cytometric analysis of DNA content in preoperative chemotherapy with biochemical modulator].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21 Suppl 1

    Topics: Administration, Oral; Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dipyridamole; DNA,

1994
Cytokinetic effects of interferon in colorectal cancer tumors: implications in the design of the interferon/5-fluorouracil combinations.
    Cancer research, 1993, Nov-15, Volume: 53, Issue:22

    Topics: Adult; Aged; Cell Cycle; Colorectal Neoplasms; Drug Interactions; Flow Cytometry; Fluorouracil; Huma

1993
[Weekly hepatic arterial infusion of high-dose 5-FU for liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:15

    Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouraci

1993
Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil.
    Cancer chemotherapy and pharmacology, 1993, Volume: 33, Issue:2

    Topics: Aged; Colorectal Neoplasms; Drug Resistance; Female; Fluorouracil; Humans; Infusions, Intravenous; I

1993
[Treatment of liver metastases of colorectal tumors using intra-arterial fluorouracil to the liver, administered with a completely implantable access system and a portable infusion pump].
    Nederlands tijdschrift voor geneeskunde, 1993, Dec-11, Volume: 137, Issue:50

    Topics: Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps; Infusions, Intra-Arteria

1993
[Treatment of advanced colorectal cancer with long-term continuous infusion of 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:1

    Topics: Aged; Ambulatory Care; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hum

1994
Potentiation of 5-fluorouracil induced inhibition of thymidylate synthase in human colon tumors by leucovorin is dose dependent.
    Advances in experimental medicine and biology, 1993, Volume: 338

    Topics: Binding Sites; Colonic Neoplasms; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Syner

1993
[Study on the relationship between concentrations of 5-FU and PyNPase activity in tumor tissue during oral 5'-DFUR treatment in patients with advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Fema

1994
[5-Fluorouracil plus low-dose leucovorin in the treatment of advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

1994
Fluorouracil and leucovorin: there is a choice.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

1993
Response to "More is not always better: a case for low-dose leucovorin".
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

1993
Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1993, Volume: 34, Issue:7

    Topics: Colorectal Neoplasms; Female; Fluorine Radioisotopes; Fluorouracil; Humans; Liver; Liver Neoplasms;

1993
[Are there prognostic parameters for predicting the success of regional chemotherapy in nonresectable liver metastases of colorectal cancer?].
    Zentralblatt fur Chirurgie, 1993, Volume: 118, Issue:5

    Topics: Adult; Aged; Biomarkers, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouraci

1993
Pharmacokinetics of 5-fluorouracil in colorectal cancer patients receiving interferon.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:6

    Topics: Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Drug Synergism; Fluorouracil; Humans;

1993
The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

1993
[Continuous intra-hepatic-arterial infusion of low dose 5-fluorouracil for colorectal cancer patients with unresectable liver metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:11

    Topics: Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusion Pum

1993
[Arterial infusion chemotherapy of 5-FU and leucovorin for patients with liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1993
[Intra-arterial chemotherapy with 5-FU (weekly high dose 5-FU HAI) for the prevention of tumor recurrence in residual liver after hepatic resection of metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:11

    Topics: Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hepatectomy; Humans;

1993
[Efficacy of hepatic arterial and intraportal infusion chemotherapy for liver metastasis of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colorectal

1993
Perfusion of colorectal liver metastases and uptake of fluorouracil assessed by H2(15)O and [18F]uracil positron emission tomography (PET).
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:12

    Topics: Colorectal Neoplasms; Fluorine Radioisotopes; Fluorouracil; Humans; Liver Neoplasms; Oxygen Radioiso

1993
Continuous intravenous infusion of leucovorin and 5-fluorouracil for the treatment of advanced colorectal and breast cancers.
    Zhonghua yi xue za zhi = Chinese medical journal; Free China ed, 1993, Volume: 52, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms;

1993
In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase.
    Cancer research, 1993, Oct-01, Volume: 53, Issue:19

    Topics: Animals; Cell Division; Colorectal Neoplasms; Cytosine Deaminase; Female; Flucytosine; Fluorouracil;

1993
Follow-up study of patients treated with monoclonal antibody-drug conjugate: report of 77 cases with colorectal cancer.
    Japanese journal of cancer research : Gann, 1993, Volume: 84, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco

1993
[The treatment of liver metastases of colorectal tumors using intra-arterial fluorouracil via hepatic artery, administered with a completely implantable access system and a portable infusion pump].
    Nederlands tijdschrift voor geneeskunde, 1993, Oct-02, Volume: 137, Issue:40

    Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps; Inf

1993
[Studies on tissue concentration of tegafur, 5-fluorouracil, uracil after UFT administration together with the study of microangiography of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:1

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pr

1993
Ternary complex formation and reduced folate in surgical specimens of human adenocarcinoma tissues.
    Cancer, 1993, Jan-15, Volume: 71, Issue:2

    Topics: Adenocarcinoma; Colorectal Neoplasms; Culture Techniques; Fluorouracil; Folic Acid; Humans; Leucovor

1993
Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma.
    Cancer chemotherapy and pharmacology, 1993, Volume: 31, Issue:4

    Topics: Adult; Aged; Animals; Colorectal Neoplasms; Female; Fluorodeoxyuridylate; Fluorouracil; Gas Chromato

1993
More is not always better: a case for low-dose leucovorin.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

1993
[Antitumor activity of BOF-A2, a new 5-fluorouracil derivative, against human cancers xenografted in nude mice by intermittent administration].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:2

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols

1993
Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.
    Cancer immunology, immunotherapy : CII, 1993, Volume: 36, Issue:3

    Topics: Adenocarcinoma; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols

1993
A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase.
    Molecular pharmacology, 1993, Volume: 43, Issue:3

    Topics: Amino Acid Sequence; Animals; Base Sequence; Cloning, Molecular; Colorectal Neoplasms; Cytosine Deam

1993
[Treatment of advanced gastric and colorectal cancer with 5-FU, leucovorin and interferon-alpha].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

1993
Intermittent continuous intravenous infusion of 5-fluorouracil; a useful approach in disseminated colorectal cancer?
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:5

    Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middl

1993
Response of soluble IL-2 receptor levels to repeated cycles of IL-2 immunotherapy/chemotherapy.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:6

    Topics: Colorectal Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; Interleukin-2; Leukocy

1993
Regional hepatic arterial chemotherapy for colorectal cancer metastatic to the liver: the controversy continues.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:5

    Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps; Infusions,

1993
Marked fluctuations in drug plasma concentrations caused by use of portable pumps for fluorouracil continuous infusion.
    Journal of the National Cancer Institute, 1993, Jun-16, Volume: 85, Issue:12

    Topics: Ambulatory Care; Colorectal Neoplasms; Fluorouracil; Head and Neck Neoplasms; Humans; Infusion Pumps

1993
[Follow up of liver metastases using computed tomography in colorectal cancer treated with interferon-alpha and 5-fluorouracil].
    Rontgenpraxis; Zeitschrift fur radiologische Technik, 1993, Volume: 46, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Follow-U

1993
Have enteric infections a role in 5-fluorouracil-associated diarrhea?
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1995, Volume: 3, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bacterial Infections; Colorectal Neoplasms; Diarrhea;

1995
5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
    Cancer research, 1995, Dec-15, Volume: 55, Issue:24

    Topics: Animals; Carcinoma; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Synergism; Enzyme

1995
Pre-operative interleukin-2 immunotherapy induces eosinophilic infiltration in colorectal neoplastic stroma.
    Pathologica, 1995, Volume: 87, Issue:2

    Topics: Adult; Antineoplastic Agents; Carcinoma; Chemotaxis, Leukocyte; Chemotherapy, Adjuvant; Colorectal N

1995
Cytosine deaminase gene as a potential tool for the genetic therapy of colorectal cancer.
    Journal of surgical oncology, 1996, Volume: 61, Issue:1

    Topics: Base Sequence; Cell Death; Cloning, Molecular; Colorectal Neoplasms; Cytosine Deaminase; Escherichia

1996
Adjuvant treatment for colorectal cancer.
    BMJ (Clinical research ed.), 1996, Feb-17, Volume: 312, Issue:7028

    Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc

1996
Bioavailability of subcutaneous 5-fluorouracil: a case report.
    Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:1

    Topics: Antidotes; Antimetabolites, Antineoplastic; Biological Availability; Carcinoma; Colorectal Neoplasms

1996
p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1996, Volume: 22, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluoroura

1996
Role of fluoropyrimidine Schedule and (6R,S)leucovorin dose in a preclinical animal model of colorectal carcinoma.
    Journal of the National Cancer Institute, 1996, Apr-03, Volume: 88, Issue:7

    Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Female

1996
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Body Weight; Colorectal Neoplasms; Deoxygluc

1996
Advanced colorectal cancer treated with combined 5-fluorouracil and folinic acid: the experience within a surgical department.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1995, Volume: 21, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fema

1995
Re: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer.
    Journal of the National Cancer Institute, 1996, Jun-19, Volume: 88, Issue:12

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Hu

1996
Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects.
    Acta oncologica (Stockholm, Sweden), 1996, Volume: 35, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Infusions

1996
[The clinical evaluation of hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer employing an implanted port system].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 1996, Volume: 93, Issue:1

    Topics: Aged; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantabl

1996
[Estimation of pathways of 5-fluorouracil anabolism in human cancer cells in vitro and in vivo].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:6

    Topics: Animals; Colorectal Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Lung Neoplasms; Mice; Mice,

1996
p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas.
    International journal of cancer, 1996, Jun-21, Volume: 69, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neo

1996
Response to regional chemotherapy in patients with variant hepatic arterial anatomy.
    The British journal of surgery, 1996, Volume: 83, Issue:5

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusio

1996
Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA-induced strand-breaks.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Death; Colorectal Neoplasms; DNA Damage; DNA, N

1996
[Rhythmic component of twelve hours].
    Pathologie-biologie, 1996, Volume: 44, Issue:3

    Topics: Adult; Animals; Antimetabolites; Antimetabolites, Antineoplastic; Bone Marrow Cells; Buthionine Sulf

1996
Adjuvant treatment of colorectal cancer in The Netherlands: a commentary.
    The Netherlands journal of medicine, 1996, Volume: 49, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluoro

1996
Canities--reversal with chemotherapy.
    The Journal of the Association of Physicians of India, 1995, Volume: 43, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasm

1995
Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival.
    The Annals of thoracic surgery, 1996, Volume: 62, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Chromatography,

1996
Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy.
    Cancer treatment and research, 1996, Volume: 81

    Topics: Appendiceal Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans

1996
[Locoregional therapy for liver metastases of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11

    Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasm

1996
[Hepatic intra-arterial 5-fluorouracil and CDDP administration in patients with colorectal cancer metastasis to the liver].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorecta

1996
[Indication of prophylactic hepatic arterial-infusion chemotherapy after hepatic resection for liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11

    Topics: Colorectal Neoplasms; Doxorubicin; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Humans; Infusi

1996
Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity.
    American journal of surgery, 1996, Volume: 172, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliar

1996
Interferons as biochemical modulators.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:10

    Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Synergism; Fl

1996
Clinical evaluation of chemosensitivity testing for patients with colorectal cancer using MTT assay.
    Diseases of the colon and rectum, 1996, Volume: 39, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Colorectal Neoplasms; Doxorubicin; Drug Screening Ass

1996
5-Fluorouracil in colorectal cancer, a never ending story.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

1996
Primary resection and synchronous regional hepatic chemotherapy or cryotherapy for colorectal cancer with liver metastases.
    International journal of colorectal disease, 1996, Volume: 11, Issue:1

    Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Cryosurgery;

1996
Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer.
    Journal of clinical gastroenterology, 1996, Volume: 23, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Cost-B

1996
Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A Suppl 5

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colorectal N

1996
Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation.
    Oncology, 1997, Volume: 54 Suppl 1

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms;

1997
p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis.
    International journal of cancer, 1996, Dec-20, Volume: 69, Issue:6

    Topics: Adult; Aged; Colorectal Neoplasms; Disease Progression; Drug Therapy, Combination; Female; Fluoroura

1996
[Clinical study of home hepatic arterial infusion chemotherapy for liver metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23 Suppl 3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disposable Eq

1996
Major upper gastrointestinal haemorrhage associated with hepatic arterial chemoperfusion.
    The Australian and New Zealand journal of surgery, 1996, Volume: 66, Issue:12

    Topics: Aged; Aged, 80 and over; Colorectal Neoplasms; Duodenal Ulcer; Female; Fluorouracil; Gastrointestina

1996
Simultaneous 3D NMR spectroscopy of proton-decoupled fluorine and phosphorus in human liver during 5-fluorouracil chemotherapy.
    Magnetic resonance in medicine, 1997, Volume: 37, Issue:2

    Topics: Absorption; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fl

1997
Biochemical modulation by 5-fluorouracil and 1-folinic acid of tumor uptake of intra-arterial 5-[123I]iodo-2'deoxyuridine in patients with liver metastases from colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 1996, Volume: 35, Issue:7

    Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Feasibility Studies; Fluorouracil; Huma

1996
Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas.
    British journal of cancer, 1997, Volume: 75, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemot

1997
Combined preoperative irradiation and direct postoperative 5-fluorouracil without negative effects on early anastomotic healing in the rat colon.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1996, Volume: 41, Issue:3

    Topics: Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Body Weight; Colon; Colorectal Neop

1996
Role of portal vein chemotherapy following failure of previous treatment for advanced colorectal hepatic metastases.
    The British journal of surgery, 1997, Volume: 84, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions,

1997
Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.
    British journal of cancer, 1997, Volume: 75, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluorouracil

1997
Role of interferon as a modulator of fluoropyrimidines: reply to a recent editorial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Interfer

1997
5-Fluorouracil-based treatment of patients with advanced colorectal carcinoma outside clinical trials: importance of limited toxicity.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Antidotes; Antineoplastic Agents; Colorectal Neoplasms; Drug Therapy, Combination; Fluorouracil; Hum

1997
5-Fluorouracil revisited: a new perspective for treatment planning.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans

1997
Enhancing the effect of anticancer drugs against the colorectal cancer cell line with electroporation.
    The Tohoku journal of experimental medicine, 1996, Volume: 180, Issue:2

    Topics: Animals; Antineoplastic Agents; Bleomycin; Cell Division; Cisplatin; Colorectal Neoplasms; Electropo

1996
Determination of tumor-related factors of influence on the uptake of the monoclonal antibody 323/A3 in experimental human ovarian cancer.
    International journal of cancer, 1997, Apr-10, Volume: 71, Issue:2

    Topics: Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Ce

1997
Adverse effects of intraportal chemotherapy on natural killer cell activity in colorectal cancer patients.
    Journal of surgical oncology, 1997, Volume: 64, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CD56 Antigen; Chemotherapy, Adjuvant; Colorect

1997
Regional adjuvant chemotherapy after partial hepatectomy for metastatic colorectal carcinoma.
    Seminars in oncology, 1997, Volume: 24, Issue:2 Suppl 6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Chemotherapy, Ad

1997
High-performance liquid chromatographic assay of 5-fluorouracil in human erythrocytes, plasma and whole blood.
    Journal of chromatography. B, Biomedical sciences and applications, 1997, Apr-25, Volume: 692, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Erythrocytes; Fluorouracil; Humans; Reproduci

1997
[Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:8

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Flo

1997
Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study.
    Anti-cancer drugs, 1997, Volume: 8, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Clinical Trials, Phase I as

1997
Preventive effect of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil on colonic carcinogenesis induced by 1,2-dimethylhydrazine in rats.
    Cancer detection and prevention, 1997, Volume: 21, Issue:4

    Topics: 1,2-Dimethylhydrazine; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Differentiatio

1997
Locally advanced primary colorectal cancer: IOERT and EBRT +/-5-FU.
    Frontiers of radiation therapy and oncology, 1997, Volume: 31

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Huma

1997
Locally recurrent colorectal cancer: IOERT and EBRT +/-5-FU and maximal resection.
    Frontiers of radiation therapy and oncology, 1997, Volume: 31

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Femal

1997
Neutropenic enterocolitis in a patient with colorectal carcinoma: unusual course after treatment with 5-fluorouracil and leucovorin--a case report.
    Cancer, 1997, Aug-15, Volume: 80, Issue:4

    Topics: Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Enterocolitis; Fluorouracil; Human

1997
Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma.
    Cancer research, 1997, Aug-15, Volume: 57, Issue:16

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorine Radioisotopes;

1997
[Determination of dihydropyrimidine dehydrogenase in the prediction of toxic side effects of 5-fluorouracil].
    Orvosi hetilap, 1997, Jul-20, Volume: 138, Issue:29

    Topics: Adjuvants, Pharmaceutic; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydro

1997
Should patients with advanced colorectal cancer be treated with chemotherapy?
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:6

    Topics: Antimetabolites, Antineoplastic; Clinical Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Di

1997
Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:6

    Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc

1997
Use of intraperitoneal 5-fluorouracil and chlorhexidine for prevention of recurrence of perforated colorectal carcinoma in a rat model.
    Diseases of the colon and rectum, 1997, Volume: 40, Issue:9

    Topics: Animals; Anti-Infective Agents, Local; Antimetabolites, Antineoplastic; Chlorhexidine; Colorectal Ne

1997
Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:7

    Topics: Adult; Aged; Antidotes; Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Fluorouracil; Follow

1997
[Combined intra-arterial locoregional and systemic treatment of nonresectable hepatic metastases of colorectal carcinoma].
    Il Giornale di chirurgia, 1997, Volume: 18, Issue:4

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic

1997
Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:10

    Topics: Actins; Aged; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration

1997
A pharmacoeconomic comparison of UFT and 5-FU chemotherapy for colorectal cancer in South America.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:9 Suppl 10

    Topics: Argentina; Brazil; Chemotherapy, Adjuvant; Colorectal Neoplasms; Costs and Cost Analysis; Drug Combi

1997
Chronotherapy with 5-fluorouracil, oxaliplatin, and folinic acid in colorectal cancer.
    Lancet (London, England), 1997, Nov-01, Volume: 350, Issue:9087

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Colo

1997
Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta.
    Nature medicine, 1997, Volume: 3, Issue:11

    Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; CCAAT-Enhancer-Binding Proteins; Col

1997
First line protracted venous infusion fluorouracil with CisDDP or carboplatine in advanced colorectal cancer.
    La Clinica terapeutica, 1997, Volume: 148, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy;

1997
[Hepatic arterial chemotherapy for liver cancer over a period of 8 years].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Epirubicin; Female;

1997
[Continuous hepatic arterial infusion of fluorouracil with leucovorin for liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12

    Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antidotes; Colorectal Neoplasms; Drug Administ

1997
[Evaluation of CTA for arterial infusion chemotherapy for liver metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubicin; Fluorouracil; Hep

1997
[A new two-part therapy for multiple bilobar liver metastases of colorectal cancer--treatment of one lobe with partial hepatectomy and the other with arterial chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Moda

1997
[Hepatectomy and intra-arterial infusion chemotherapy for hepatic metastasis of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorourac

1997
[Combination hepatic intra-arterial 5-fluorouracil and CDDP administration with oral regimen in patients with colorectal cancer metastasis to the liver].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Ne

1997
[Complication due to arterial infusion chemotherapy for liver metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Choles

1997
A pilot study of multimodality therapy for initially unresectable liver metastases from colorectal carcinoma: hepatic resection after hepatic arterial infusion chemotherapy and portal embolization.
    Japanese journal of clinical oncology, 1997, Volume: 27, Issue:5

    Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modal

1997
5-Fluorouracil + cisplatin + mitomycin C is a relatively most effective combination against xenograft lines of human colorectal cancer.
    Anti-cancer drugs, 1997, Volume: 8, Issue:8

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisp

1997
Previous intravenous chemotherapy does not alter response rate or survival time of patients with hepatic metastases from colorectal cancer treated by hepatic artery chemotherapy.
    The Australian and New Zealand journal of surgery, 1997, Volume: 67, Issue:11

    Topics: Antidotes; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal Neoplasms; Fluorour

1997
Can antioxidants enhance chemotherapy?
    Gastroenterology, 1998, Volume: 114, Issue:2

    Topics: Antioxidants; Apoptosis; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug

1998
Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer model.
    International journal of cancer, 1998, Mar-16, Volume: 75, Issue:6

    Topics: Animals; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colore

1998
Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.
    Biochemical pharmacology, 1998, Mar-01, Volume: 55, Issue:5

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplas

1998
Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1998, Volume: 39, Issue:3

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorine Radioisotopes; Fluorodeoxyglucose F1

1998
[Concentrations of 5-fluorouracil (5-FU) in serum and tissues at venous injection of tegafur or 5-FU--clinical study on colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:4

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; H

1998
Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Colo

1998
5-Fluorouracil and mitomycin-C in colorectal cancer: unacceptable conclusion.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Mitomyci

1998
Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer.
    Cancer research, 1998, Apr-15, Volume: 58, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Female; Flu

1998
No circadian variation of dihydropyrimidine dehydrogenase, uridine phosphorylase, beta-alanine, and 5-fluorouracil during continuous infusion of 5-fluorouracil.
    Advances in experimental medicine and biology, 1998, Volume: 431

    Topics: Antimetabolites, Antineoplastic; beta-Alanine; Circadian Rhythm; Colorectal Neoplasms; Dihydrouracil

1998
[Combined therapy of metastatic liver neoplasms: intrahepatic chemoembolization and systemic chemotherapy].
    Orvosi hetilap, 1998, Apr-26, Volume: 139, Issue:17

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

1998
A clinically applicable assay for tumoral thymidylate synthase combining reverse transcriptase-PCR and high-performance liquid chromatography.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Colorectal Neopl

1998
A risk-benefit assessment of irinotecan in solid tumours.
    Drug safety, 1998, Volume: 18, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe

1998
Irinotecan and 5-fluorouracil in colorectal cancer: time for a pause?
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Clinical Trials, Phase II

1998
Selective in vivo radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells transduced with the E. coli cytosine deaminase (CD) gene.
    International journal of radiation oncology, biology, physics, 1998, Jul-01, Volume: 41, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Cytosine

1998
Mechanisms for 5-fluorouracil resistance in human colon cancer DLD-1 cells.
    Biological & pharmaceutical bulletin, 1998, Volume: 21, Issue:6

    Topics: Antimetabolites, Antineoplastic; Cell Count; Colorectal Neoplasms; Drug Resistance, Neoplasm; Floxur

1998
Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer.
    British journal of cancer, 1998, Volume: 77, Issue:11

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fatty Liver; Female; Fluorouraci

1998
Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1998, Volume: 39, Issue:7

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorine Radioisotopes; Fluorouracil; Humans;

1998
18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil.
    Cancer, 1998, Jul-15, Volume: 83, Issue:2

    Topics: Aged; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Drug Interactions

1998
[Low-dose leucovorin and interferon-alpha as modulators of 5-fluorouracil for adjuvant chemotherapy of colorectal cancer].
    Orvosi hetilap, 1998, Jun-28, Volume: 139, Issue:26

    Topics: Adjuvants, Pharmaceutic; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Dose-Response Rel

1998
Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study.
    Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:3

    Topics: Acridines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Colorectal Neoplasms;

1998
[Intra-arterial preventive chemotherapy for residual liver after resection of hepatic metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:9

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorou

1998
[Efficacy of combination therapy (hepatectomy and prophylactic arterial chemoinfusion) for liver metastases of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:9

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Drug Administratio

1998
[Preoperative CEA level predicts outcomes of hepatic resection for liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Neoplasms; Comb

1998
Sources of error in tissue and tumor measurements of 5-[18F]fluorouracil.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1998, Volume: 39, Issue:8

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Feasibility Studies; Fluorine Ra

1998
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:4

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcino

1998
5-Fluorouracil and mitomycin-C in colorectal cancer: unacceptable conclusion.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Mitomyci

1998
Irinotecan: toward clinical end points in drug development.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:8 Suppl 6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, P

1998
Thymidylate synthase as a predictor of response.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:8 Suppl 6

    Topics: Actins; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical T

1998
US pivotal studies of irinotecan in colorectal carcinoma.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:8 Suppl 6

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic;

1998
Assessing the impact of chemotherapy on tumor-related symptoms in advanced colorectal cancer.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:8 Suppl 6

    Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Colorectal Neop

1998
Radiologically placed hepatic artery catheter allows selection of patients with high-volume liver metastases for regional chemotherapy.
    Australasian radiology, 1998, Volume: 42, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Catheterization, Peripheral;

1998
Vasopressin selectively increases 5-fluorouracil uptake by colorectal liver metastases following hepatic artery bolus infusion.
    The Journal of surgical research, 1998, Jul-01, Volume: 77, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Models, Animal; Dose-Respons

1998
[Adjuvant regional arterial port chemotherapy after resection of colorectal liver metastases].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 1998, Volume: 69, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwellin

1998
[Continuous intravenous infusional 5-FU compared with bolus administration in metastatic colorectal carcinoma].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1998, Volume: 174, Issue:9

    Topics: Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, I

1998
Patterns of serum CEA fall after hepatic arterial chemotherapy as sole therapy and combined with cryotherapy for colorectal metastases.
    The Australian and New Zealand journal of surgery, 1998, Volume: 68, Issue:10

    Topics: Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal Neoplasms; Combined Modality T

1998
Improved survival in patients with advanced colorectal carcinoma failing 5-fluorouracil who received irinotecan hydrochloride and have high intratumor C-fos expression.
    American journal of clinical oncology, 1998, Volume: 21, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans

1998
Managing the side effects of chemotherapy for colorectal cancer.
    Seminars in oncology, 1998, Volume: 25, Issue:5 Suppl 11

    Topics: Antineoplastic Agents; Camptothecin; Colorectal Neoplasms; Drugs, Investigational; Fluorouracil; Hum

1998
High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:10

    Topics: Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinoteca

1998
Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Synergism; Fluorouracil;

1998
Irinotecan may extend survival in people with metastatic colorectal cancer.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:10

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, P

1998
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:10

    Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antineoplastic Agents; Carboplatin; Carrier Pr

1997
Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Chemotherapy, Adjuvant; Colonic Neoplasms; Col

1997
Clinical applications of the histoculture drug response assay.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:3

    Topics: Antineoplastic Agents; Cell Culture Techniques; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorecta

1995
5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:8

    Topics: Animals; Body Weight; Colorectal Neoplasms; Female; Fluorouracil; Leucovorin; Metabolic Clearance Ra

1995
Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:9

    Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as

1996
CT of calcified liver metastases in colorectal carcinoma.
    Clinical radiology, 1998, Volume: 53, Issue:10

    Topics: Antimetabolites, Antineoplastic; Calcinosis; Colorectal Neoplasms; Fluorouracil; Humans; Liver Disea

1998
Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer.
    Journal of clinical nursing, 1998, Volume: 7, Issue:4

    Topics: Adenocarcinoma; Aged; Alopecia; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Di

1998
Interleukin-2/sodium butyrate treatment cures rats bearing liver tumors after acquired 5-fluorouracil resistance.
    International journal of cancer, 1998, Dec-09, Volume: 78, Issue:6

    Topics: Animals; Butyrates; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Interleukin-2; Li

1998
Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil.
    Anti-cancer drugs, 1998, Volume: 9, Issue:9

    Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms;

1998
Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma.
    Investigational new drugs, 1998, Volume: 16, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms; Drug Administration Schedule;

1998
Second line treatment options in advanced colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Resistance, Multiple; Dru

1998
Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies.
    NMR in biomedicine, 1998, Volume: 11, Issue:7

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Half-

1998
The natural history of liver metastases from colorectal cancer.
    Archives of medical research, 1998,Winter, Volume: 29, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1998
Hepatic cryotherapy and subsequent hepatic arterial chemotherapy for colorectal metastases to the liver.
    HPB surgery : a world journal of hepatic, pancreatic and biliary surgery, 1998, Volume: 11, Issue:2

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Cryosurgery; Femal

1998
Autoregulation of 5-fluorouracil metabolism.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:10

    Topics: Animals; Antidotes; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Hemostas

1998
Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients.
    British journal of cancer, 1999, Volume: 79, Issue:3-4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

1999
Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Colorectal Neoplasms; Disease Models, Animal; Drug Combin

1999
A novel, orally administered nucleoside analogue, OGT 719, inhibits the liver invasive growth of a human colorectal tumor, C170HM2.
    Cancer research, 1999, Mar-15, Volume: 59, Issue:6

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Asialoglycoprotein Receptor; Cell Membrane; Co

1999
The use of raltitrexed (tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1999, Volume: 11, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Enzyme Inhibitors; Female; Fluorouracil; Huma

1999
Noninvasive determination of the arterial input function of an anticancer drug from dynamic PET scans using the population approach.
    Medical physics, 1999, Volume: 26, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Aorta; Colorectal Neoplasms; Female; Fluorine Ra

1999
Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Aspartic Acid; Co

1999
Quality of life in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Interferon a

1999
Treatment of colorectal carcinoma in adolescents and young adults with surgery, 5-fluorouracil/leucovorin/interferon-alpha 2a and radiation therapy.
    Medical and pediatric oncology, 1999, Volume: 32, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant

1999
The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells.
    Journal of cancer research and clinical oncology, 1999, Volume: 125, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Camptothecin; Colorectal Neoplasms

1999
Electrochemotherapy against colorectal carcinoma: comparison of in vitro cytotoxicity of 5-fluorouracil, cisplatin and bleomycin.
    International journal of oncology, 1999, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bleomycin; Cell Membrane Permeability; Cisplatin; Co

1999
Second line therapies move to the forefront in colorectal cancer.
    Journal of the National Cancer Institute, 1999, Jun-16, Volume: 91, Issue:12

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, C

1999
Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer.
    Journal of surgical oncology, 1999, Volume: 71, Issue:2

    Topics: Adenocarcinoma; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cispla

1999
[Efficacy and toxicity spectrum of continuous infusion of 5-fluorouracil compared with bolus administration in advanced colorectal tumors].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1999, Volume: 175, Issue:6

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intravenous;

1999
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Ne

1999
Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery.
    Cancer immunology, immunotherapy : CII, 1999, Volume: 48, Issue:4

    Topics: Animals; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Colorectal Neoplasms; Fluorouracil; Injec

1999
Hospitalization for 5-FU toxicity in metastatic colorectal cancer: incidence and cost.
    Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:7 Suppl 3

    Topics: Antimetabolites, Antineoplastic; Cohort Studies; Colorectal Neoplasms; Cost of Illness; Drug Hyperse

1999
Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 1999, Volume: 44, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Bayes Theorem; Body Fluid Compartments; Circadian Rhythm; Col

1999
Plasma and salivary pharmacokinetics of 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer receiving 5-FU bolus plus continuous infusion with high-dose folinic acid.
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:2

    Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil;

1999
Adjuvant regional chemotherapy after hepatic resection for colorectal metastases.
    The British journal of surgery, 1999, Volume: 86, Issue:8

    Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Co

1999
The integrated treatment of peritoneal carcinomatosis. A preliminary experience.
    Journal of experimental & clinical cancer research : CR, 1999, Volume: 18, Issue:2

    Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Carcinoma; Chemotherapy, Adjuvant; Chemotherapy, Cance

1999
Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase.
    British journal of cancer, 1999, Volume: 80, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Agents; Cell Survival; Cloning, Molecular; Colorectal Neoplasms; DNA,

1999
[Comparative study of histopathological effects of preoperative chemotherapy using UFT and in vitro MTT assay of colonoscopy specimens from patients with colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colonoscopy; Colorectal Neoplasms; Drug Administrati

1999
Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5-FU.
    Nucleosides & nucleotides, 1999, Volume: 18, Issue:8

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biotransformation; Body Weight; Chromatogr

1999
5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma.
    Cancer, 1999, Oct-01, Volume: 86, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Female

1999
Positive interaction between 5-FU and FdUMP[10] in the inhibition of human colorectal tumor cell proliferation.
    Antisense & nucleic acid drug development, 1999, Volume: 9, Issue:5

    Topics: Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms; Drug Synergism; Fluorodeoxyuri

1999
[Intraarterial infusion therapy for unresectable liver metastasis of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; Fe

1999
[Complete responses in patients with unresectable liver metastases from colorectal cancer with weekly high-dose 5-FU plus one-shot CDDP HAI].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administ

1999
[Management after hepatectomy of colorectal cancer metastases to the liver--intrahepatic arterial infusion chemotherapy and repeated hepatectomy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1999
[Complications related to hepatic arterial infusion chemotherapy for liver metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwellin

1999
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

1999
Apoptosis of colorectal adenocarcinoma induced by 5-FU and/or IFN-gamma through caspase 3 and caspase 8.
    International journal of oncology, 1999, Volume: 15, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Blotting,

1999
[Hemodynamics at hepatoarterial infusion of 5-FU in a chronic renal failure patient maintained by hemodialysis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:14

    Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; I

1999
Cancer immunomodulation by carbohydrate ligands for the lymphocyte receptor NKR-P1.
    International journal of oncology, 2000, Volume: 16, Issue:2

    Topics: Animals; Antigens, Surface; Antimetabolites, Antineoplastic; Azoxymethane; Carcinogens; Colorectal N

2000
Impact of the simultaneous administration of the (+)- and (-)-forms of formyl-tetrahydrofolic acid on plasma and intracellular pharmacokinetics of (-)-tetrahydrofolic acid.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Interactions; Female; Fluor

2000
Influence of the administration of amifostine on the pharmacokinetics of 5-fluorouracil in patients with metastatic colorectal carcinoma.
    International journal of clinical pharmacology and therapeutics, 2000, Volume: 38, Issue:1

    Topics: Aged; Amifostine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; C

2000
Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU.
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cos

1999
Standard dose (Mayo regimen) 5-fluorouracil and low dose folinic acid: prohibitive toxicity?
    American journal of clinical oncology, 2000, Volume: 23, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administ

2000
alpha-fluoro-beta-alanine: effects on the antitumor activity and toxicity of 5-fluorouracil.
    Biochemical pharmacology, 2000, Apr-15, Volume: 59, Issue:8

    Topics: Animals; Antimetabolites, Antineoplastic; beta-Alanine; Colonic Neoplasms; Colorectal Neoplasms; Dru

2000
Weekly oxaliplatin, high-dose infusional 5-fluorouracil and folinic acid as palliative third-line therapy of advanced colorectal carcinoma.
    Zeitschrift fur Gastroenterologie, 2000, Volume: 38, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv

2000
[Evaluation of hepatic toxicity following high-dose 5-FU arterial infusion chemotherapy: analysis of 42 cases of colorectal liver metastases].
    Nihon Igaku Hoshasen Gakkai zasshi. Nippon acta radiologica, 2000, Volume: 60, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Atrophy; Chemical and Drug Induced Liver Injury; Color

2000
Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization.
    Annals of surgery, 2000, Volume: 231, Issue:4

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

2000
Changes in thymidylate synthase mRNA in blood leukocytes from patients with colorectal cancer after bolus administration of 5-fluorouracil.
    Acta oncologica (Stockholm, Sweden), 2000, Volume: 39, Issue:1

    Topics: Adult; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Injectio

2000
Hepatic arterial chemotherapy: still on trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:8

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-

2000
Enhanced antitumor activity of 5-fluorouracil in combination with 2'-deoxyinosine in human colorectal cell lines and human colon tumor xenografts.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:4

    Topics: Analysis of Variance; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Divis

2000
Recent advances in colorectal chemotherapy: oral fluorinated pyrimidines, oxaliplatin and irinotecan.
    Journal of gastroenterology, 2000, Volume: 35 Suppl 12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C

2000
Morphological change, loss of deltapsi(m) and activation of caspases upon apoptosis of colorectal adenocarcinoma induced by 5-FU.
    Cancer letters, 2000, May-29, Volume: 153, Issue:1-2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Caspases; Cell Nucleus; Colorectal Neopl

2000
Theoretical considerations and in vitro concentration response studies with two human colorectal carcinoma cell lines. The rational experimental base for clinical studies in regional chemotherapy.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:4

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

2000
Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer.
    The New England journal of medicine, 2000, May-18, Volume: 342, Issue:20

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Data Interpret

2000
5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma.
    Cancer, 2000, May-15, Volume: 88, Issue:10

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Intestinal Di

2000
[Thymidylate synthase activity after preoperative administration of 5-FU in patients with gastric or colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administ

2000
Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:6

    Topics: Adenocarcinoma; Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic;

2000
Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells.
    International journal of oncology, 2000, Volume: 17, Issue:2

    Topics: Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms; Drug Resistance, Neoplasm; Dru

2000
[Clinical significance of serum p53 antibody detection in a chemosensitivity assay in cases of human colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:6

    Topics: Antineoplastic Agents; Autoantibodies; Cisplatin; Colorectal Neoplasms; Drug Screening Assays, Antit

2000
[Weekly low-dose CPT-11 and HCFU for advanced colorectal cancer on an outpatient treatment basis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:6

    Topics: Adenocarcinoma; Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Pr

2000
Technetium-99m labelled macroaggregated albumin arterial catheter perfusion scintigraphy: prediction of gastrointestinal toxicity in hepatic arterial chemotherapy.
    European journal of nuclear medicine, 2000, Volume: 27, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Catheterization, Peripheral; Colorectal Neopl

2000
[The role of interval surgery and irradiation in the treatment of primarily non-resectable rectal cancers].
    Orvosi hetilap, 2000, Jun-04, Volume: 141, Issue:23

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female;

2000
dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer.
    Cancer research, 2000, Jul-01, Volume: 60, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Cell Survival; Cells, Cultured; Colon; Colonic Neoplasms; Colorectal

2000
Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose.
    Cancer research, 2000, Jul-15, Volume: 60, Issue:14

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined

2000
Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy.
    British journal of clinical pharmacology, 2000, Volume: 50, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cis

2000
5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma.
    Cancer, 2000, Aug-01, Volume: 89, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Endothelium, Vascular; Fluorouracil;

2000
Adjuvant chemotherapy for colorectal cancer: a Malaysian experience.
    The Medical journal of Malaysia, 1997, Volume: 52, Issue:2

    Topics: Adolescent; Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans;

1997
Chemotherapy for advanced colorectal cancer.
    BMJ (Clinical research ed.), 2000, Sep-02, Volume: 321, Issue:7260

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Costs; Fluorourac

2000
Validation of fluorouracil metabolite analysis in excised tumor. Lability of anabolites.
    Biochemical pharmacology, 2000, Oct-01, Volume: 60, Issue:7

    Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Models, Animal; Female; Fluo

2000
[Apropos the article by M. V. Grinev and F. Kh. Abdusamatov "Cytoreductive surgery in the treatment of stage-4 colorectal cancer--is it justified?"].
    Voprosy onkologii, 2000, Volume: 46, Issue:3

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans;

2000
Survival of colorectal cancer cell lines treated with paclitaxel, radiation, and 5-FU: effect of TP53 or hMLH1 deficiency.
    International journal of cancer, 2000, Aug-20, Volume: 90, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytog

2000
Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:15

    Topics: Antimetabolites, Antineoplastic; Blotting, Western; Cell Division; Colorectal Neoplasms; DNA, Neopla

2000
Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients.
    Anti-cancer drugs, 2000, Volume: 11, Issue:6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chronotherapy; Colorectal Neoplasms; Drug Resistance;

2000
Moving beyond fluorouracil for colorectal cancer.
    The New England journal of medicine, 2000, Sep-28, Volume: 343, Issue:13

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col

2000
Electrochemotherapy for colorectal cancer with commonly used chemotherapeutic agents in a mouse model.
    Digestive diseases and sciences, 2000, Volume: 45, Issue:8

    Topics: Animals; Antineoplastic Agents; Bleomycin; Cisplatin; Colorectal Neoplasms; Disease Models, Animal;

2000
Tumour site, sex, and survival in colorectal cancer.
    Lancet (London, England), 2000, Sep-02, Volume: 356, Issue:9232

    Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fl

2000
Tumour site, sex, and survival in colorectal cancer.
    Lancet (London, England), 2000, Sep-02, Volume: 356, Issue:9232

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans;

2000
Retrospective evaluation of 5-fluorouracil-interferon-a aTreatment of advanced colorectal cancer patients.
    Pathology oncology research : POR, 2000, Volume: 6, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2000
Blocking catabolism with eniluracil enhances PET studies of 5-[18F]fluorouracil pharmacokinetics.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2000, Volume: 41, Issue:10

    Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Enzyme Inhibitors; Female; Fluorine

2000
'Hold the Mayo': solid facts or pulp fiction?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:8

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv

2000
Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.
    Gastroenterology, 2000, Volume: 119, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch;

2000
Future treatment options with capecitabine.
    Seminars in oncology, 2000, Volume: 27, Issue:5 Suppl 10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neop

2000
Role of BAX in the apoptotic response to anticancer agents.
    Science (New York, N.Y.), 2000, Nov-03, Volume: 290, Issue:5493

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; A

2000
Adjuvant chemotherapy.
    Lancet (London, England), 2000, Oct-07, Volume: 356, Issue:9237

    Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasm

2000
[Case report--efficacy of short-term intraarterial 5-fluorouracil for liver metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Dr

2000
[Thymidylate synthase and dihydropyrimidine dehydrogenase activity in a metastatic liver tumor from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:12

    Topics: Antimetabolites, Antineoplastic; Colon; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Fl

2000
[Continuous hepatic arterial infusion of 5-fluorouracil with leucovorin for unresectable liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:12

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug

2000
[Efficacy of combination therapy for multiple liver metastases of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:12

    Topics: Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal Neoplasms; Combined Modality T

2000
[Three cases in which CR was obtained in residual metastatic lesions by intrahepatic arterial infusion after resection of hepatic metastases from colorectal carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Drug Adminis

2000
[Complications related to arterial infusion chemotherapy in patients with hepatic metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:12

    Topics: Adult; Aged; Arterial Occlusive Diseases; Biliary Fistula; Colorectal Neoplasms; Common Bile Duct; E

2000
Surrogate endpoints for new colorectal cancer drugs.
    Lancet (London, England), 2000, Nov-18, Volume: 356, Issue:9243

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Floxuridine; Fluorouracil; Hum

2000
A novel weekday-on/weekend-off UFT schedule.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:10 Suppl 9

    Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy

2000
Can we predict response to 5-FU?
    Journal of the National Cancer Institute, 2000, Dec-20, Volume: 92, Issue:24

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Genes, p5

2000
[Effect of Ruboxyl (nitroxyl derivative of daunorubicin) on hepatic metastases of colorectal carcinoma].
    Voprosy onkologii, 2000, Volume: 46, Issue:4

    Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Daunoru

2000
Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neoplasm

2000
Analysis of uracil DNA glycosylase in human colorectal cancer.
    International journal of oncology, 2001, Volume: 18, Issue:2

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA Glycosylases; Dr

2001
[Anaphylactoid shock due to folinic acid during treatment of metastatic colorectal cancer].
    Gastroenterologie clinique et biologique, 2000, Volume: 24, Issue:12

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anaphylaxis; Antimetabolites, Antineoplastic; Colorectal Ne

2000
Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2001, Volume: 21, Issue:1

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Hu

2001
[The prospects of the outpatient clinic or home anti-cancer chemotherapy for unresectable recurrence of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27 Suppl 3

    Topics: Ambulatory Care Facilities; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Ne

2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2001, Jan-25, Volume: 344, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Cost-Benefit Ana

2001
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2001, Jan-25, Volume: 344, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2001
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2001, Jan-25, Volume: 344, Issue:4

    Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrh

2001
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
    The New England journal of medicine, 2001, Jan-25, Volume: 344, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Data Interpretat

2001
[Ambulatory chemotherapy schedule for metastatic colorectal cancer].
    Presse medicale (Paris, France : 1983), 2001, Jan-13, Volume: 30, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

2001
Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
    Cancer research, 2001, Feb-01, Volume: 61, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo

2001
Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis.
    Gastroenterology, 2001, Volume: 120, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis;

2001
Expression of apoptosis-related markers and clinical outcome in patients with advanced colorectal cancer.
    British journal of cancer, 2001, Mar-02, Volume: 84, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Biomarkers, T

2001
Effect of chemotherapy with 5-fluorouracil on intestinal permeability and absorption in patients with advanced colorectal cancer.
    Journal of clinical gastroenterology, 2001, Volume: 32, Issue:3

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Intestinal Absorption;

2001
Quality of life in cancer patients treated by chemotherapy.
    Neoplasma, 2000, Volume: 47, Issue:6

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An

2000
Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal cancer.
    Seminars in oncology, 2001, Volume: 28, Issue:1 Suppl 1

    Topics: Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody

2001
Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer.
    Journal of Korean medical science, 2001, Volume: 16, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv

2001
Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl

2001
5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Biomark

2001
CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Carcinoembryonic Antigen; Colorectal

2001
Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival.
    International journal of cancer, 2001, May-20, Volume: 95, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluor

2001
[The potential of capecitabine (Xeloda) in the treatment of disseminated solid tumors].
    Voprosy onkologii, 2001, Volume: 47, Issue:1

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colorectal Neoplasms; Deoxycytidine

2001
[Oral cytostatic drug in colorectal carcinoma. Selective tumor therapy at home].
    MMW Fortschritte der Medizin, 2001, Mar-29, Volume: 143, Issue:13

    Topics: Administration, Oral; Ambulatory Care; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neo

2001
A dose-finding study of irinotecan (CPT-11) plus a four-day continuous 5-fluorouracil infusion in advanced colorectal cancer.
    Oncology, 2001, Volume: 60, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fem

2001
The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
    Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:4

    Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Colorectal Neoplasms; Drug Administra

2001
Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer.
    International journal of colorectal disease, 2001, Volume: 16, Issue:2

    Topics: Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colectomy; Colorec

2001
[Correlation between 5-fluorouracil (5-FU) sensitivity as measured by collagen gel droplet embedded culture drug sensitivity test (CD-DST) and expression of orotate phosphoribosyl transferase (OPRT), thymidylate synthase (TS), and dihydropyrimidine dehydr
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:5

    Topics: Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Dru

2001
Sequential intrahepatic and systemic fluoropyrimidine-based chemotherapy for metastatic colorectal cancer confined to the liver. A phase II study.
    Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Surv

2001
A pharmacological study of the weekday-on/weekend-off oral UFT schedule in colorectal cancer patients.
    Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; D

2001
[Results and limitations of arterial infusion therapy for liver metastases from colorectal cancer].
    Nihon Geka Gakkai zasshi, 2001, Volume: 102, Issue:5

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans;

2001
The role of mitomycin C in the treatment of patients with advanced colorectal cancer resistant to 5-fluorouracil-folinic acid chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:4

    Topics: Antibiotics, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans;

2001
[Tumoral levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in elderly colorectal cancer patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:6

    Topics: Age Factors; Aged; Aged, 80 and over; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NADP); Enzy

2001
[Chemotherapy of colorectal cancer--which therapy is justified for elderly patients?].
    Onkologie, 2001, Volume: 24, Issue:1

    Topics: Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colorec

2001
The microsatellite instability phenotype in human colorectal carcinoma: relationship to sex, age, and tumor site.
    Gastroenterology, 2001, Volume: 121, Issue:1

    Topics: Adult; Age Factors; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; Fluorouracil; Humans

2001
Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases.
    The British journal of surgery, 2001, Volume: 88, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chemotherapy, Adjuva

2001
[Irinotecan plus fluorouracil and folinic acid in metastatic colorectal cancer].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2001, Volume: 177, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe

2001
Researchers urge caution with standard regimen for metastatic colorectal cancer.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2001, Jul-01, Volume: 58, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2001
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
    The New England journal of medicine, 2001, Jul-12, Volume: 345, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Colorectal Neoplasms;

2001
Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer.
    The New England journal of medicine, 2001, Jul-12, Volume: 345, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2001
Xeloda in colorectal cancer.
    International journal of clinical practice, 2001, Volume: 55, Issue:5

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Color

2001
Growth inhibition and apoptosis induced by P2Y2 receptors in human colorectal carcinoma cells: involvement of intracellular calcium and cyclic adenosine monophosphate.
    International journal of colorectal disease, 2001, Volume: 16, Issue:3

    Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Apoptosis; Calcium; Cell Division; Colorect

2001
Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:6

    Topics: Adult; Aged; Cell Cycle Proteins; Colorectal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasm

2001
Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer.
    The Kurume medical journal, 2001, Volume: 48, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dihydrouracil Dehydrogenase (NAD

2001
Targeted drug delivery to chemoresistant cells: folic acid derivatization of FdUMP[10] enhances cytotoxicity toward 5-FU-resistant human colorectal tumor cells.
    The Journal of organic chemistry, 2001, Aug-24, Volume: 66, Issue:17

    Topics: Antineoplastic Agents; Carrier Proteins; Colorectal Neoplasms; Drug Delivery Systems; Drug Resistanc

2001
Intra-arterial hepatic chemotherapy (IAHC) for liver metastases from colorectal cancer: need of guidelines for catheter positioning, port management, and anti-coagulant therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:7

    Topics: Antimetabolites, Antineoplastic; Catheters, Indwelling; Colorectal Neoplasms; Fluorouracil; Hepatic

2001
Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:13

    Topics: Animals; Blotting, Western; Colorectal Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Humans; M

2001
A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer.
    Oncology, 2001, Volume: 61, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2001
Expression of metallothionein in colorectal cancers and synchronous liver metastases.
    Oncology, 2001, Volume: 61, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla

2001
p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy.
    American journal of clinical pathology, 2001, Volume: 116, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cell Nucleus; Chemotherapy, Adjuvant; Colorectal Neopla

2001
A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil.
    British journal of cancer, 2001, Sep-14, Volume: 85, Issue:6

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; DNA Primers; DNA, Neoplasm; Enhancer Elements

2001
Non-operative management of the primary tumour in patients with incurable stage IV colorectal cancer.
    The British journal of surgery, 2001, Volume: 88, Issue:10

    Topics: Abdominal Pain; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop

2001
Healing of experimental colonic anastomoses: effects of combined preoperative high-dose radiotherapy and intraperitoneal 5-fluorouracil.
    International journal of cancer, 2001, Oct-20, Volume: 96, Issue:5

    Topics: Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Body Weight; Colon; Colonic Disease

2001
Thymidine phosphorylase (TP) activation: convenience through innovation.
    The oncologist, 2001, Volume: 6 Suppl 4

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Colorectal Neoplasms; Deoxy

2001
Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells.
    Nature medicine, 2001, Volume: 7, Issue:10

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Colorectal Neoplasms; Ferredoxin-NADP Red

2001
Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment.
    Acta oncologica (Stockholm, Sweden), 2001, Volume: 40, Issue:5

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biological Availability; Bone Marrow; Carb

2001
Intra-arterial infusion of 5-fluorouracil plus granulocyte-macrophage colony-stimulating factor (GM-CSF) and chemoembolization with melphalan in the treatment of disseminated colorectal liver metastases.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2001, Volume: 27, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Colorectal Neoplasms

2001
Pharmacodynamics induced by direct electric current for the treatment of 5-fluorouracil resistant tumor: an animal experiment.
    International journal of colorectal disease, 2001, Volume: 16, Issue:5

    Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Resistance, Neoplasm; Electric

2001
Correlation between tumour blood flow and fluorouracil distribution in a hypovascular liver metastasis model.
    Clinical & experimental metastasis, 2000, Volume: 18, Issue:7

    Topics: Animals; Antimetabolites, Antineoplastic; Antipyrine; Calibration; Colorectal Neoplasms; Fluorouraci

2000
The potential clinical value of GML and the p53 gene as a predictor of chemosensitivity for colorectal cancer.
    International journal of clinical oncology, 2001, Volume: 6, Issue:2

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Cycle Proteins

2001
[Adjuvant short-term continuous hepatoarterial infusion of 5-FU for advanced colorectal cancer using a removable hepatoarterial catheter].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:11

    Topics: Adenocarcinoma; Aged; Animals; Antimetabolites, Antineoplastic; Catheterization; Chemotherapy, Adjuv

2001
[Effect of peroral doxifluridine plus hepatic arterial infusion for synchronous liver metastasis of colorectal cancer--correlation with the expression of thymidine phosphorylase and dihydropyrimidine dehydrogenase in primary colorectal cancer lesions].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dihydrouracil Dehydrogen

2001
[Four cases of multiple liver metastasis of colorectal cancer treated with hepatic resection after chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms;

2001
Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage.
    Prescrire international, 2001, Volume: 10, Issue:52

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as

2001
Adjuvant chemotherapy for colorectal cancer.
    British journal of cancer, 2001, Nov-16, Volume: 85, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co

2001
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Dec-01, Volume: 19, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; California; Colorect

2001
Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.
    The Journal of pathology, 2001, Volume: 195, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Biomarkers, Tumor; Chemotherapy, Adjuva

2001
Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma.
    British journal of cancer, 2001, Dec-14, Volume: 85, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Cell Differentiation; Cell Nucleus; Co

2001
A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.
    Cancer research, 2001, Dec-15, Volume: 61, Issue:24

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Codon; Colorectal Ne

2001
[The advantages and disadvantages of administering anti-cancer chemotherapy at home].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Fluorouracil; Home

2001
Toxicity of irinotecan in patients with colorectal cancer.
    The New England journal of medicine, 2001, 11-01, Volume: 345, Issue:18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Hu

2001
[Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].
    Deutsche medizinische Wochenschrift (1946), 2002, Jan-18, Volume: 127, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

2002
Activity of boanmycin against colorectal cancer.
    World journal of gastroenterology, 2001, Volume: 7, Issue:1

    Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bleomycin; Colorectal Neoplas

2001
Idiosyncratic reaction after oxaliplatin: circumvention by use of a continuous infusional administration schedule.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:11

    Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colo

2001
[Combination therapy including mutamycin (mitomycin C) in the treatment of advanced colorectal and gastric cancer].
    Voprosy onkologii, 2001, Volume: 47, Issue:6

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An

2001
[Personal experience with intra-arterial locoregional chemotherapy of liver metastases from colorectal carcinoma].
    Vnitrni lekarstvi, 2001, Volume: 47, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Doxorubicin; Female

2001
Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38 Suppl 2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2002
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Feb-15, Volume: 20, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardiovascular Diseases; Colorectal Ne

2002
[5-Fluorouracil-induced colitis--a review based upon consideration of 6 cases].
    Zeitschrift fur Gastroenterologie, 2002, Volume: 40, Issue:2

    Topics: Aged; Colitis; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule;

2002
Cimetidine in colorectal cancer--are the effects immunological or adhesion-mediated?
    British journal of cancer, 2002, Jan-21, Volume: 86, Issue:2

    Topics: Antimetabolites, Antineoplastic; Cell Adhesion; Chemotherapy, Adjuvant; Cimetidine; Colorectal Neopl

2002
Predictive value of thymidylate synthase expression in resected metastases of colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva

2002
Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.
    Journal of chemotherapy (Florence, Italy), 2002, Volume: 14, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplas

2002
Vive la difference: sex and fluorouracil toxicity.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-15, Volume: 20, Issue:6

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Sex Facto

2002
Capecitabine monotherapy in metastatic colorectal cancer.
    The Lancet. Oncology, 2001, Volume: 2, Issue:7

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Hu

2001
Prognostic significance of the thymidylate biosynthetic enzymes in human colorectal tumors.
    Oncology, 2002, Volume: 62, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Female; Fluor

2002
Thymidylate synthase levels: prognostic, predictive, or both?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Apr-01, Volume: 20, Issue:7

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor;

2002
Echogenicity of liver metastases from colorectal carcinoma is an independent prognostic factor in patients treated with regional chemotherapy.
    Cancer, 2002, Mar-15, Volume: 94, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Female; Flox

2002
Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-year experience.
    American journal of clinical oncology, 2002, Volume: 25, Issue:2

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil

2002
Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens.
    American journal of clinical oncology, 2002, Volume: 25, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2002
Prognostic factors for patients with metastatic colorectal cancer receiving protracted venous infusion of 5-FU.
    American journal of clinical oncology, 2002, Volume: 25, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Colorectal Neoplasms; Female; Fluorouracil; Humans

2002
Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene.
    British journal of cancer, 2002, Apr-08, Volume: 86, Issue:7

    Topics: Aged; Alleles; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Colorectal Neo

2002
Thymidylate synthase polymorphism and survival of colorectal cancer patients treated with 5-fluorouracil.
    British journal of cancer, 2002, Apr-22, Volume: 86, Issue:8

    Topics: Colorectal Neoplasms; Fluorouracil; Genetic Predisposition to Disease; Polymorphism, Genetic; Progno

2002
[Initial results of randomized studies of metastatic colorectal carcinoma urge careful and controlled use of CPT-11].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2002, Volume: 178, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of Death; Colorectal Neoplasms;

2002
Predictive values of sex and tumour site for survival benefit from 5FU in colorectal cancer.
    British journal of cancer, 2002, May-06, Volume: 86, Issue:9

    Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Female; Fluorouracil; Humans; Male; Neoplasm

2002
A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier.
    Biomaterials, 2002, Volume: 23, Issue:9

    Topics: Aluminum Silicates; Antimetabolites, Antineoplastic; Bentonite; Cations; Chromatography, Ion Exchang

2002
Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer.
    International journal of colorectal disease, 2002, Volume: 17, Issue:1

    Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorour

2002
[Patient preference for oral chemotherapy].
    Krankenpflege Journal, 2002, Volume: 40, Issue:1-2

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2002
[Capsule instead of infusion--new oral chemotherapy option].
    Krankenpflege Journal, 2002, Volume: 40, Issue:1-2

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2002
mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer.
    Oncology, 2002, Volume: 62, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Femal

2002
[Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms].
    Medizinische Klinik (Munich, Germany : 1983), 2002, May-15, Volume: 97, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Chemothe

2002
Cyclin D1 overexpression in colorectal carcinoma in vivo is dependent on beta-catenin protein dysregulation, but not k-ras mutation.
    The Journal of pathology, 2002, Volume: 197, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; beta Catenin; Biomarkers, Tumor; Cell Division; Colore

2002
Is the NICE process flawed?
    Lancet (London, England), 2002, Jun-15, Volume: 359, Issue:9323

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Liver Ne

2002
[Treatment for patients with liver metastasis from colorectal cancer--expansion of hepatic arterial infusion therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:6

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver

2002
Baseline quality of life predicts survival in patients with advanced colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Cohort Studies; Colorec

2002
[Recent advances in the diagnosis and treatment of colorectal cancers].
    Nihon Geka Gakkai zasshi, 2002, Volume: 103, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Colorectal Neoplasms; Feces; Fluoro

2002
Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer.
    Annals of surgical oncology, 2002, Volume: 9, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers; Colorectal Neoplasms; Dihydrouracil Dehydrogenase

2002
Liver tumors: follow-up with P-31 MR spectroscopy after local chemotherapy and chemoembolization.
    Radiology, 1992, Volume: 182, Issue:3

    Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Fluorouraci

1992
[Preoperative regional radiofrequency thermochemotherapy of colorectal cancer: clinical and pathological studies].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 1992, Volume: 30, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diathermy; F

1992
[Intermittent intra-arterial chemotherapy using subcutaneously implanted reservoir for hepatocellular carcinoma and liver metastasis of colorectal carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:10 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C

1992
In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.
    Cancer chemotherapy and pharmacology, 1992, Volume: 30, Issue:6

    Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Survival; Colony-Forming Units Assay; Colorecta

1992
Intraportal 5-fluorouracil for colorectal cancer: the AXIS trial.
    Lancet (London, England), 1992, Oct-17, Volume: 340, Issue:8825

    Topics: Adenocarcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans

1992
Adjuvant treatment with 5-fluorouracil for colorectal cancer.
    Lancet (London, England), 1992, Nov-28, Volume: 340, Issue:8831

    Topics: Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Research Design

1992
Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination.
    Journal of chemotherapy (Florence, Italy), 1992, Volume: 4, Issue:1

    Topics: Adenocarcinoma; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl

1992
Hepatic resection following systemic chemotherapy for metastatic colorectal carcinoma.
    Journal of surgical oncology, 1992, Volume: 51, Issue:2

    Topics: Aged; Antineoplastic Agents; Aspartic Acid; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy;

1992
[Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:13

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour

1992
Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acid.
    Tumori, 1992, Aug-31, Volume: 78, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Resistance;

1992
Chemotherapy for colorectal carcinoma.
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:8 Suppl

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvant; Colorectal Neopl

1992
[Cytotoxic effects of the combination of a new nitrosourea, fotemustine, combined with 5-fluorouracil and folinic acid depend on the sequence of their administration].
    Bulletin du cancer, 1992, Volume: 79, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Colorectal Neoplasms; Dose-Response R

1992
[Signification of liver metastases of colorectal cancer with special reference to recurrence in the residual liver after hepatic resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:10 Suppl

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubi

1992
[Advance of chemotherapy and radiotherapy in colorectal cancers].
    Pathologie-biologie, 1992, Volume: 39, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Flu

1992
[Adjuvant treatment of rectal carcinoma: also a step forward?].
    Nederlands tijdschrift voor geneeskunde, 1992, Mar-14, Volume: 136, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal

1992
On some applications of Bayesian methods in cancer clinical trials.
    Statistics in medicine, 1992, Jan-15, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Clinical Trials as Topic; Colorectal

1992
The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer.
    Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 3

    Topics: Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fluorouracil

1992
Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin.
    Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 3

    Topics: Adult; Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Thym

1992
Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations.
    Seminars in oncology, 1992, Volume: 19, Issue:2 Suppl 3

    Topics: Colonic Neoplasms; Colorectal Neoplasms; Drug Administration Schedule; Drug Interactions; Fluorourac

1992
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

1992
Sequential methotrexate and fluorouracil in colon cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

1992
Continuous 24-hour infusion of folinic acid does not increase the response rate of 5-fluorouracil but only the toxicity.
    Oncology, 1992, Volume: 49, Issue:2

    Topics: Adult; Aged; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fema

1992
Best treatment for colorectal cancer and confirmatory trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1992, Volume: 3, Issue:3

    Topics: Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Randomized Control

1992
Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
    Cancer immunology, immunotherapy : CII, 1992, Volume: 35, Issue:2

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm

1992
High dose alpha-2b interferon + folinic acid in the modulation of 5-fluorouracil. A phase II study in advanced colorectal cancer with evidence of an unfavourable cost/benefit ratio.
    Tumori, 1992, Feb-29, Volume: 78, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Fluorou

1992
[Adjuvant therapeutic possibilities in carcinoma of colon and rectum].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1992, Jun-23, Volume: 81, Issue:26

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Colectomy;

1992
Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: activity in liver metastasis.
    Cancer investigation, 1992, Volume: 10, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluorouracil; Hu

1992
[Antineoplastic chemotherapy in digestive tumors].
    Medicina clinica, 1991, Sep-21, Volume: 97, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubicin; Fluorouracil; Hum

1991
Multiple confirmatory trials. How can additional studies be of value?
    Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo

1991
5-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures.
    Medical oncology and tumor pharmacotherapy, 1991, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA, Neoplasm;

1991
Treatment of advanced colorectal cancer with mitoxantrone, high dose folinic acid and fluorouracil.
    Tumori, 1991, Oct-31, Volume: 77, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

1991
Divergent patterns of incorporation of bromodeoxyuridine and iododeoxyuridine in human colorectal tumor cell lines.
    Biochemical pharmacology, 1991, Jun-21, Volume: 42, Issue:1

    Topics: Bromodeoxyuridine; Cell Division; Colorectal Neoplasms; DNA, Neoplasm; Floxuridine; Fluorouracil; Ga

1991
Clinical trials referral resource. Treatment of advanced colorectal cancer.
    Oncology (Williston Park, N.Y.), 1991, Volume: 5, Issue:4

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clinical Trial

1991
Colorectal metastases to the liver: present results and future strategies.
    Journal of surgical oncology. Supplement, 1991, Volume: 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Fem

1991
[Regional chemotherapy of diffuse liver metastases of colorectal cancer].
    Zentralblatt fur Chirurgie, 1991, Volume: 116, Issue:21

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

1991
[The adjuvant chemotherapy of patients with colorectal carcinoma (preliminary report)].
    Khirurgiia, 1991, Volume: 44, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adju

1991
[A combined method for treating metastases of colorectal carcinoma to the liver].
    Khirurgiia, 1991, Volume: 44, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Colorectal

1991
Schedule-dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines.
    International journal of cancer, 1991, Feb-01, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols;

1991
[Hepatic arterial infusion of high dose 5-FU in weekly schedule for liver metastases from colorectal cancer employing a newly developed pump "Koken Infusor"].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:10

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Evaluation Studies as Topic; Female; Fluorouraci

1991
[Five-hour hepatic arterial infusion of high-dose 5-FU on weekly schedule for liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:11

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Drug Evaluation; Fluorouracil; Humans; Infusions

1991
Therapeutic potential of differentiating agents in colon cancer treatment.
    Journal of surgical oncology. Supplement, 1991, Volume: 2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Survival; Col

1991
[Continuous infusion chemotherapy using an infusional port in colorectal cancer with liver metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:11

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colo

1991
[Intra-arterial infusion chemotherapy using an implantable reservoir in the treatment of hepatic metastases in colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Colorectal Neop

1991
[Effects and complications of continuous hepatic arterial infusion chemotherapy using implantable reservoir for liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Catheterization; Colorectal Neoplasms; Drug Administ

1991
Mechanisms of relapse for colorectal cancer: implications for intraperitoneal chemotherapy.
    Journal of surgical oncology. Supplement, 1991, Volume: 2

    Topics: Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusi

1991
Fluorouracil, high-dose folinic acid, low-dose alpha-2b interferon and dipyridamole in the treatment of advanced colorectal cancer. A pilot study.
    Journal of chemotherapy (Florence, Italy), 1991, Volume: 3, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dipyridamole; Fem

1991
Rational basis for the metabolic modulation of 5-fluorouracil by leucovorin and interferon alpha.
    British journal of haematology, 1991, Volume: 79 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Survival; Clinical Trials as Topic;

1991
Fluorouracil and recombinant interferon alfa-2a in advanced gastrointestinal neoplasms.
    British journal of haematology, 1991, Volume: 79 Suppl 1

    Topics: Colorectal Neoplasms; Combined Modality Therapy; Drug Evaluation; Fluorouracil; Humans; Interferon a

1991
Adjuvant hepatic intra-arterial chemotherapy after potentially curative hepatectomy for liver metastases from colorectal cancer: a pilot study.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1991, Volume: 17, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

1991
Hepatic recurrence not prevented with low-dosage long-term intraportal 5-FU infusion after resection of colorectal liver metastasis.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1991, Volume: 17, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop

1991
[Is there a reliable adjuvant (intraoperative) chemotherapy of colorectal cancer?].
    Langenbecks Archiv fur Chirurgie. Supplement II, Verhandlungen der Deutschen Gesellschaft fur Chirurgie. Deutsche Gesellschaft fur Chirurgie. Kongress, 1990

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combin

1990
A dose-intensive regimen of 5-fluorouracil for the treatment of metastatic colorectal carcinoma.
    Cancer, 1991, Jan-15, Volume: 67, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorour

1991
[Treatment of colorectal cancer with antineoplastic agents. Too early to introduce routine adjuvant therapy].
    Lakartidningen, 1991, Jan-23, Volume: 88, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Levamiso

1991
Colorectal liver metastases.
    The British journal of surgery, 1991, Volume: 78, Issue:1

    Topics: Colorectal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Microspheres

1991
[Systemic chemotherapy of colorectal cancer--recent approaches].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Combined Modality T

1991
5-Fluorouracil dose intensity increase in 5-fluorouracil and leucovorin combination: results of a phase II study.
    Journal of chemotherapy (Florence, Italy), 1991, Volume: 3, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relationship, Dr

1991
Second-line chemotherapy of advanced colorectal cancer with sequential high-dose methotrexate and 5-fluorouracil.
    Journal of chemotherapy (Florence, Italy), 1991, Volume: 3, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Rel

1991
Therapeutic doses of dipyridamole failed to potentiate 5-fluorouracil tumor activity.
    Journal of chemotherapy (Florence, Italy), 1991, Volume: 3, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dipyridamole; Female; Fluorour

1991
[Adjuvant chemotherapy in colonic carcinoma?].
    Deutsche medizinische Wochenschrift (1946), 1991, May-10, Volume: 116, Issue:19

    Topics: Adjuvants, Immunologic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colon

1991
[Value of CEA determination in follow-up of patients with liver metastasis of colorectal cancers with loco-regional chemotherapy].
    Zentralblatt fur Chirurgie, 1991, Volume: 116, Issue:1

    Topics: Adult; Aged; Biomarkers, Tumor; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil

1991
What is the value of methotrexate in the treatment of advanced colorectal cancer?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Fluorouracil; Human

1991
[Colorectal carcinogenesis, tumor progression and chemoresistance].
    Gastroenterologie clinique et biologique, 1990, Volume: 14, Issue:12 ( Pt 2)

    Topics: Camptothecin; Cell Transformation, Neoplastic; Colorectal Neoplasms; Drug Resistance; Fluorouracil;

1990
5-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study.
    Journal of chemotherapy (Florence, Italy), 1990, Volume: 2, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Fluorouracil; Human

1990
Stimulation of clonal growth of human colorectal tumor cells by IL-3 and GM-CSF. Modulation of 5-FU cytotoxicity by GM-CSF.
    Onkologie, 1990, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Cell Division; Cell Line; Cell Survival; Colorectal Neoplasms; Combined Modality The

1990
Chemosensitivity correlation between the primary tumors and simultaneous metastatic lymph nodes of patients evaluated by DNA synthesis inhibition assay.
    Cancer, 1990, Mar-15, Volume: 65, Issue:6

    Topics: Breast Neoplasms; Carbazilquinone; Cisplatin; Colorectal Neoplasms; DNA, Neoplasm; Doxorubicin; Drug

1990
[Treatment of liver metastases from colorectal cancer--major hepatic resection and continuous hepatic arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:4 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorubicin; Fluorouracil; Hep

1990
Anti-proliferative effects of tumor necrosis factor, gamma interferon and 5-fluorouracil on human colorectal carcinoma cell lines.
    International journal of cancer, 1990, Jul-15, Volume: 46, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Division; Cell Line; Colorectal Neop

1990
[Evaluation of intraperitoneal cancer chemotherapy using an implantable reservoir in patients with peritonitis carcinomatosa].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:8 Pt 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Colorectal Ne

1990
[A study of low-dose intermittent intra-arterial infusion chemotherapy for liver metastasis in colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:8 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

1990
[Clinical evaluation and problem of intra-arterial infusion chemotherapy of liver metastasis from digestive organ cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:8 Pt 2

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusion Pumps, Implantabl

1990
[Hepatic arterial infusion chemotherapy using implantable reservoir in colorectal liver metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:8 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Doxorubicin; Fluoro

1990
[Results of prophylactic intra-arterial infusion chemotherapy after hepatic resection in colorectal metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:8 Pt 2

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorour

1990
[Continuous hepatic arterial infusion chemotherapy using implantable reservoir in liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:8 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Neoplasms; Drug

1990
Inhibition of liver metastases in nude mice by the combined action of 5-fluorouracil and interferon.
    Anti-cancer drugs, 1990, Volume: 1, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response Relatio

1990
[A study on preoperative administration of doxifluridine in carcinoma of the colon and rectum].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Administration, Oral; Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Lymph

1990
Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:6

    Topics: Aged; Colorectal Neoplasms; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Hum

1990
Modification of 5-fluorouracil activity by high-dose methotrexate or leucovorin in advanced colorectal carcinoma.
    European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Ne

1990
Regional chemotherapy in liver metastases of colorectal carcinoma: monitoring with arterial computed tomography.
    Cancer investigation, 1990, Volume: 8, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Doxorub

1990
5-Fluorouracil plus tauromustine in advanced colorectal cancer: unexpected negative results.
    European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1990
Sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic gastrointestinal cancer.
    European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1990
[Fluorouracil and high-dose folinic acid in the treatment of advanced colorectal carcinoma].
    La Clinica terapeutica, 1990, Jul-15, Volume: 134, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1990
[Primary and metastatic liver tumors--evaluation of tumor regression and response with regional cytostatic drug therapy by sonography and fine needle puncture histology].
    Leber, Magen, Darm, 1990, Volume: 20, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Hepatocellular; Carmustin

1990
[Is levamisole combined with fluorouracil efficient in colorectal cancer?].
    Lakartidningen, 1990, Sep-12, Volume: 87, Issue:37

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Levamiso

1990
A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal carcinoma.
    American journal of clinical oncology, 1990, Volume: 13, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N

1990
Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity.
    Cancer chemotherapy and pharmacology, 1990, Volume: 26, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms

1990
Paradoxical effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer.
    British journal of cancer, 1990, Volume: 62, Issue:6

    Topics: Aged; Colorectal Neoplasms; Female; Fluorouracil; Humans; Interleukin-2; Killer Cells, Lymphokine-Ac

1990
[Studies on 5-FU concentration and thymidine phosphorylase activity in tissues of patients with colorectal cancer after SF-SP administration].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:12

    Topics: Colorectal Neoplasms; Combined Modality Therapy; Delayed-Action Preparations; Fluorouracil; Humans;

1990
Effectiveness and low toxicity of hepatic artery infusion with fluorouracil and mitomycin for metastatic colorectal cancer confined to the liver. The Swiss Group for Clinical and Epidemiological Cancer Research (SAKK).
    Annals of oncology : official journal of the European Society for Medical Oncology, 1990, Volume: 1, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1990
A feasibility study of high-dose cisplatin and 5-fluorouracil with glutathione protection in the treatment of advanced colorectal cancer.
    Tumori, 1990, Dec-31, Volume: 76, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Adminis

1990
Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.
    Cancer research, 1990, Apr-01, Volume: 50, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

1990
A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates.
    Tumori, 1990, Feb-28, Volume: 76, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Drug Resistance; Female; Fluorouracil; Fol

1990
Hepatic arterial infusion (HAI) chemotherapy for liver metastases of colorectal cancer using 5-FU.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1990, Volume: 16, Issue:2

    Topics: Colorectal Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps; Infusions, Intra

1990
[Cardiac side effects of 5-fluorouracil].
    Deutsche medizinische Wochenschrift (1946), 1990, Apr-20, Volume: 115, Issue:16

    Topics: Aged; Arrhythmias, Cardiac; Colorectal Neoplasms; Electrocardiography; Female; Fluorouracil; Heart;

1990
An evaluation of combination 5-fluorouracil and spirogermanium in the treatment of advanced colorectal carcinoma.
    Investigational new drugs, 1990, Volume: 8, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoroura

1990
The pharmacokinetics of 5-fluorouracil administered by arterial infusion in advanced colorectal hepatic metastases.
    British journal of cancer, 1990, Volume: 61, Issue:6

    Topics: Colorectal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplas

1990
[Evaluation of reservoir inserted for the prevention of liver metastasis of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:8 Pt 2

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Hepatectomy; Humans; Infusion Pump

1990
Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspa

1990
[Antitumor activity and metabolism of BOF-A2, a new 5-fluorouracil derivative, with human cancers xenografted in nude mice].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:9

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Colorectal Neoplasms; Fluorouracil; Humans; Li

1990
Biochemical modulation of 5-fluorouracil by PALA.
    Cancer investigation, 1990, Volume: 8, Issue:2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colo

1990
5-Fluorouracil and levamisole in colorectal carcinoma.
    Cancer investigation, 1990, Volume: 8, Issue:2

    Topics: Adjuvants, Immunologic; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Levam

1990
The combined effect of interferon and 5-FU on tumor-cell metastasis in the nude mouse.
    Diseases of the colon and rectum, 1989, Volume: 32, Issue:4

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluor

1989
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
    Cancer research, 1989, Aug-15, Volume: 49, Issue:16

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid

1989
[Clinical use of magnetic resonance spectroscopy and positron emission tomography in oncology].
    Zeitschrift fur Gastroenterologie. Verhandlungsband, 1989, Volume: 24

    Topics: Colorectal Neoplasms; Energy Metabolism; Fluorouracil; Humans; Liver Neoplasms; Magnetic Resonance S

1989
[Intra-arterial chemotherapy of local recurrences of gastrointestinal tumors].
    Zeitschrift fur Gastroenterologie. Verhandlungsband, 1989, Volume: 24

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colorectal Neopla

1989
[Plasma and tissue concentration of tegafur by a new soft capsule type suppository in colorectal carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:1

    Topics: Aged; Aged, 80 and over; Capsules; Colorectal Neoplasms; Female; Fluorouracil; Humans; Lymph Nodes;

1989
Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study.
    Oncology, 1989, Volume: 46, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1989
[Locoregional chemotherapy of liver tumors].
    Zentralblatt fur Chirurgie, 1989, Volume: 114, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

1989
[Availability of intermittent chemotherapy by reservoir in liver metastasis of colo-rectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Evaluation Studie

1989
[Results of intra-arterial infusion chemotherapy of colorectal cancer in patients with metastatic liver cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Catheterization; Colorectal Neoplasms; Combined Moda

1989
[Study of long-survival cases with liver metastasis of colorectal cancer by hepatic arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colorectal Neoplasms; Doxo

1989
[Complications of intra-arterial infusion chemotherapy in patients with colorectal cancer with liver metastasis, with special reference to IA-5-FU induced sclerosing cholangitis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Cholangitis, Sclerosin

1989
Intra-arterial hepatic chemotherapy for metastatic liver from colo-rectal carcinoma origin.
    Selective cancer therapeutics, 1989, Volume: 5, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery

1989
Regional chemotherapy for hepatic metastases from colorectal carcinoma.
    Maryland medical journal (Baltimore, Md. : 1985), 1989, Volume: 38, Issue:10

    Topics: Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms

1989
Treatment of liver metastases from colorectal cancer with continuous high dose intra-arterial floxuridine (FUDR) and systemic fluorouracil: a phase II study.
    European journal of cancer & clinical oncology, 1989, Volume: 25, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation;

1989
[Usefulness of subcutaneously implanted reservoir for postoperative therapy in hepatocellular carcinoma and liver metastases of colorectal carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colorectal Neoplasms; Com

1989
[The study of transcatheter arterial chemo-lipiodol administration in liver metastasis of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality

1989
Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Fluorouracil; Human

1989
Phase I trial of semustine plus weekly fluorouracil and high-dose leucovorin calcium in patients with advanced colorectal cancer.
    Journal of the National Cancer Institute, 1989, Dec-06, Volume: 81, Issue:23

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluatio

1989
A phase I/II trial of 5-fluorouracil and etoposide in metastatic colorectal carcinoma.
    American journal of clinical oncology, 1989, Volume: 12, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1989
[Synchronous hepatic metastases of colorectal adenocarcinoma: what is the course? Apropos of 36 cases].
    Helvetica chirurgica acta, 1989, Volume: 56, Issue:4

    Topics: Adenocarcinoma; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusions, In

1989
[Early adjuvant intraportal chemotherapy with 5-fluorouracil after hepatic resection of colorectal metastasis: a preliminary clinical and pharmacokinetic study].
    Bulletin du cancer, 1989, Volume: 76, Issue:10

    Topics: Adult; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Hepatectomy; Humans; I

1989
A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma.
    Cancer treatment reviews, 1989, Volume: 16 Suppl A

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Female;

1989
Sequential high dose methotrexate, 5-fluorouracil and folinic acid does not improve response rates in advanced colorectal cancer.
    Onkologie, 1989, Volume: 12, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

1989
Effects of 5-FU and cis-DDP combination on human colorectal tumor xenografts.
    Tumori, 1989, Feb-28, Volume: 75, Issue:1

    Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Fem

1989
Treatment with 5-FU, VCR and BCNU in tumor bearing nude mice.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1989, Volume: 165, Issue:7

    Topics: Adenocarcinoma; Animals; Carmustine; Colorectal Neoplasms; Female; Fluorouracil; Humans; Mice; Mice,

1989
Bolus fluorouracil for metastatic colorectal carcinoma?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:9

    Topics: Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Neoplasm Metastasis; Progn

1989
[Hepatic arterial infusion chemotherapy using totally implantable reservoir in liver metastases in colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Carcinoemb

1989
[Portal vein infusion therapy of the prevention of liver metastasis from colorectal carcinomas].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:8 Pt 2

    Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouraci

1989
Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokinetics.
    Cancer, 1989, Mar-15, Volume: 63, Issue:6 Suppl

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

1989
Clinical experience with leucovorin and 5-fluorouracil.
    Cancer, 1989, Mar-15, Volume: 63, Issue:6 Suppl

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige

1989
Lack of effectiveness of combined 5-fluorouracil and leucovorin in patients with 5-fluorouracil-resistant advanced colorectal cancer.
    European journal of cancer & clinical oncology, 1989, Volume: 25, Issue:1

    Topics: Adult; Aged; Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms;

1989
Phase II evaluation of 5-fluorouracil, folinic acid and cisplatin in advanced-stage colorectal adenocarcinoma.
    Oncology, 1989, Volume: 46, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N

1989
Treatment of metastatic colorectal adenocarcinoma with fluorouracil and high-dose leucovorin: a pilot study.
    Zhonghua yi xue za zhi = Chinese medical journal; Free China ed, 1989, Volume: 43, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F

1989
Intrahepatic 5-FU retreatment of liver metastases of colorectal cancer that were progressive under previous systemic chemotherapy.
    American journal of clinical oncology, 1989, Volume: 12, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Cause of Death; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Art

1989
Treatment of metastatic colorectal carcinoma. Recent advances in use of fluorouracil.
    Postgraduate medicine, 1989, Nov-01, Volume: 86, Issue:6

    Topics: Adenocarcinoma; Colorectal Neoplasms; Fluorouracil; Humans; Infusion Pumps; Leucovorin

1989
Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma.
    Cancer chemotherapy and pharmacology, 1989, Volume: 23, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

1989
Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma.
    Cancer chemotherapy and pharmacology, 1989, Volume: 23, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Color

1989
Assessment of serial carcinoembryonic antigen: determinations to monitor the therapeutic progress and prognosis of metastatic liver disease treated by regional chemotherapy.
    Journal of surgical oncology, 1989, Volume: 40, Issue:2

    Topics: Adult; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Cancer, Regional Perfusion; Cohort

1989
Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma. Differences in survival in two patient groups with similar response rates.
    Cancer, 1989, Mar-15, Volume: 63, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug A

1989
Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines.
    Journal of the National Cancer Institute, 1988, Dec-07, Volume: 80, Issue:19

    Topics: Carcinoma; Cell Survival; Colorectal Neoplasms; Drug Synergism; Floxuridine; Fluorouracil; Humans; L

1988
[Rationale and current results of loco-regional chemotherapy in hepatic metastases of colorectal carcinoma].
    La Clinica terapeutica, 1987, Jun-15, Volume: 121, Issue:5

    Topics: Antineoplastic Agents; Carmustine; Cisplatin; Colorectal Neoplasms; Doxorubicin; Floxuridine; Fluoro

1987
The antiproliferative effects of fluoropyrimidine derivatives against human tumor xenografts in a subrenal capsule assay.
    The Japanese journal of surgery, 1988, Volume: 18, Issue:6

    Topics: Animals; Antineoplastic Agents; Body Weight; Cell Division; Colorectal Neoplasms; Floxuridine; Fluor

1988
[Pre- and post-operative adjuvant chemotherapy of colorectal cancer. Part 1. Drug concentration in tissues following UFT administration].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Postoper

1988
[Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C].
    Onkologie, 1988, Volume: 11 Suppl 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dipyridamole; Dos

1988
A phase II study of sequential methotrexate and 5-fluorouracil in colorectal carcinoma.
    Medical oncology and tumor pharmacotherapy, 1988, Volume: 5, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administrati

1988
Regional injection of 5-fluorouracil and starch microspheres in colorectal cancer.
    Acta chirurgica Scandinavica, 1988, Volume: 154, Issue:9

    Topics: Adenocarcinoma; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Fluorouracil; Humans

1988
High-dose folinic acid and 5-fluorouracil in the treatment of advanced colon cancer.
    American journal of clinical oncology, 1988, Volume: 11, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bloo

1988
High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige

1988
High-dose weekly oral leucovorin and 5-fluorouracil in previously untreated patients with advanced colorectal carcinoma: a phase I study.
    Advances in experimental medicine and biology, 1988, Volume: 244

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation;

1988
Role of dose, schedule and route of administration of 5-formyltetra-hydrofolate: preclinical and clinical investigations.
    Advances in experimental medicine and biology, 1988, Volume: 244

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms;

1988
Another effective chemotherapy combination for colorectal cancer.
    Oncology (Williston Park, N.Y.), 1988, Volume: 2, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovor

1988